FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Zheng, X
   Zhang, W
   Hu, XT
AF Zheng, Xia
   Zhang, Wang
   Hu, Xiaotong
TI Different concentrations of lipopolysaccharide regulate barrier function
   through the PI3K/Akt signalling pathway in human pulmonary microvascular
   endothelial cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY;
   VE-CADHERIN; PERMEABILITY; MIGRATION; SEPSIS; PHOSPHORYLATION;
   PROLIFERATION; EXPRESSION
AB Lipopolysaccharide (LPS) can lead to vascular endothelial barrier dysfunction, which often results in acute lung injury and acute respiratory distress syndrome. However, the effects of different concentrations of LPS on human pulmonary microvascular endothelial barrier function and the involvement of the phosphatidylinositol-3-kinase-serine/threonine kinase (PI3K/Akt) pathway in this process remain unclear. Human pulmonary microvascular endothelial cells (HPMECs) were stimulated with different doses of LPS, and barrier function was examined by determining cell monolayer permeability, cell migration, and the expression of intercellular junction proteins (VE-Cadherin, Claudin-5, and Connexin-43). LY294002 was used to inhibit PI3K to verify the role of the PI3K/Akt pathway in the regulation of barrier function in HPMECs stimulated by LPS. Low doses of LPS increased HPMEC migration, up-regulated VE-Cadherin and Claudin-5 expression, down-regulated Connexin-43 expression, and promoted Akt phosphorylation, which could collectively decrease monolayer permeability. In contrast, high doses of LPS suppressed HPMEC migration, down-regulated the expression of VE-Cadherin and Claudin-5, up-regulated Connexin-43 expression, and reduced Akt phosphorylation, which could collectively increase monolayer permeability. LPS has a biphasic effect on HPMEC barrier function through the PI3K/Akt pathway, and this effect is concentration-dependent.
C1 [Zheng, Xia; Zhang, Wang] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Crit Care Med, Hangzhou 310003, Zhejiang, China.
C1 [Hu, Xiaotong] Zhejiang Univ, Affiliated Hosp 1, Coll Med, State Key Lab Diag & Treatment Infect Dis,Collabo, Hangzhou 310003, Zhejiang, China.
C3 Zhejiang University; Zhejiang University
RP Zheng, X (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Crit Care Med, Hangzhou 310003, Zhejiang, Peoples R China.
EM zxicu@zju.edu.cn
FU Young science foundation of National Natural Science Foundation of China
   [81101445]; Zhejiang Provincial Natural Science Foundation [LY16H150002]
FX The work was supported by Young science foundation of National Natural
   Science Foundation of China (81101445) and Zhejiang Provincial Natural
   Science Foundation (LY16H150002).
CR Akizuki R, 2017, BBA-MOL CELL RES, V1864, P293, DOI 10.1016/j.bbamcr.2016.11.018
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Camire RB, 2014, J PHARMACOL EXP THER, V351, P654, DOI 10.1124/jpet.114.218339
   Chichger H, 2015, FASEB J, V29, P868, DOI 10.1096/fj.14-257212
   Edens HA, 2003, CURR OPIN HEMATOL, V10, P25, DOI 10.1097/00062752-200301000-00005
   Garrett JP, 2017, MOL BIOL CELL, V28, P85, DOI 10.1091/mbc.E16-08-0616
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Guo CR, 2016, MOL MED, V22, DOI 10.2119/molmed.2015.00240
   Herwig MC, 2013, PATHOBIOLOGY, V80, P245, DOI 10.1159/000347062
   Huang LY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160875
   Jian ZC, 2016, PHARMAZIE, V71, P588, DOI 10.1691/ph.2016.6576
   Kandasamy K, 2015, AM J PHYSIOL-LUNG C, V309, pL584, DOI 10.1152/ajplung.00211.2014
   Keck T, 2002, GASTROENTEROLOGY, V122, P188, DOI 10.1053/gast.2002.30348
   Kim DI, 2012, J CLIN IMMUNOL, V32, P340, DOI 10.1007/s10875-011-9628-1
   Laakkonen JP, 2017, ANGIOGENESIS, V20, P109, DOI 10.1007/s10456-016-9532-7
   Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65
   Liu H, 2015, INT IMMUNOPHARMACOL, V29, P937, DOI 10.1016/j.intimp.2015.10.010
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Lv JW, 2017, MICROVASC RES, V109, P45, DOI 10.1016/j.mvr.2016.10.001
   Matsuda N, 2006, J PHARMACOL EXP THER, V319, P1348, DOI 10.1124/jpet.106.109785
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   O'Donnell JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100931
   PATTERSON CE, 1992, J APPL PHYSIOL, V72, P865, DOI 10.1152/jappl.1992.72.3.865
   Qi D, 2017, INT J MOL MED, V40, P1803, DOI 10.3892/ijmm.2017.3176
   Qi D, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.265
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Reddy NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129676
   Sarmiento D, 2014, INT J BIOCHEM CELL B, V55, P11, DOI 10.1016/j.biocel.2014.08.001
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Sun HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040844
   Sun YL, 2016, EXP CELL RES, V347, P274, DOI 10.1016/j.yexcr.2016.07.009
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Xu H, 2013, INFLAMMATION, V36, P216, DOI 10.1007/s10753-012-9537-3
   Zhang J, 2015, AM J PHYSIOL-LUNG C, V309, pL1323, DOI 10.1152/ajplung.00016.2015
   Zhang LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044590
   Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106328
   Zhu MY, 2013, CIRC J, V77, P772, DOI 10.1253/circj.CJ-12-0310
NR 41
TC 49
Z9 53
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 2
PY 2018
VL 8
AR 9963
DI 10.1038/s41598-018-28089-3
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GL2MG
UT WOS:000436955000018
PM 29967433
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Lee, JY
   Alexeyev, M
   Kozhukhar, N
   Pastukh, V
   White, R
   Stevens, T
AF Lee, Ji Young
   Alexeyev, Mikhail F.
   Kozhukhar, Natalia
   Pastukh, Viktoriya
   White, Roderica
   Stevens, Troy
TI Carbonic anhydrase IX is a critical determinant of pulmonary
   microvascular endothelial cell pH regulation and angiogenesis during
   acidosis
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE heterogeneity; Matrigel; network formation; pulmonary circulation; SLC-0111 
ID PSEUDOMONAS-AERUGINOSA INFECTION; INTRACELLULAR PH; CA-IX; LUNG-CANCER;
   BICARBONATE TRANSPORTERS; CATALYTIC DOMAIN; LACTIC-ACIDOSIS;
   ISCHEMIC-STROKE; HYPOXIA; EXPRESSION
AB Carbonic anhydrase IX (CA IX) is highly expressed in rapidly proliferating and highly glycolytic cells, where it serves to enhance acid-regulatory capacity. Pulmonary microvascular endothelial cells (PMVECs) actively utilize aerobic glycolysis and acidify media, whereas pulmonary arterial endothelial cells (PAECs) primarily rely on oxidative phosphorylation and minimally change media pH. Therefore, we hypothesized that CA IX is critical to PMVEC angiogenesis because of its important role in regulating pH. To test this hypothesis, PMVECs and PAECs were isolated from Sprague-Dawley rats. CA IX knockout PMVECs were generated using the CRISPR-Cas9 technique. During serum-stimulated growth, mild acidosis (pH 6.8) did not affect cell counts of PMVECs, but it decreased PAEC cell number. Severe acidosis (pH 6.2) decreased cell counts of PMVECs and elicited an even more pronounced reduction of PAECs. PMVECs had a higher CA IX expression compared with PAECs. CA activity was higher in PMVECs compared with PAECs, and enzyme activity was dependent on the type IX isoform. Pharmacological inhibition and genetic ablation of CA IX caused profound dysregulation of extra-and intracellular pH in PMVECs. Matrigel assays revealed impaired angiogenesis of CA IX knockout PMVECs in acidosis. Lastly, pharmacological CA IX inhibition caused profound cell death in PMVECs, whereas genetic CA IX ablation had little effect on PMVEC cell death in acidosis. Thus CA IX controls PMVEC pH necessary for angiogenesis during acidosis. CA IX may contribute to lung vascular repair during acute lung injury that is accompanied by acidosis within the microenvironment.
C1 [Lee, Ji Young; Alexeyev, Mikhail; Kozhukhar, Natalya; Pastukh, Viktoriya; Stevens, Troy] Univ S Alabama, Dept Physiol & Cell Biol, Mobile, AL 36688, United States.
C1 [Lee, Ji Young; Stevens, Troy] Univ S Alabama, Dept Internal Med, Mobile, AL 36688, United States.
C1 [Lee, Ji Young] Univ S Alabama, Div Pulm & Crit Care Med, Mobile, AL 36688, United States.
C1 [Lee, Ji Young; Alexeyev, Mikhail; Kozhukhar, Natalya; Pastukh, Viktoriya; Stevens, Troy] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688, United States.
C1 [White, Roderica] Univ S Alabama, Ctr Hlth Communities, Mobile, AL 36688, United States.
C3 University of South Alabama; University of South Alabama; University of
   South Alabama; University of South Alabama; University of South Alabama
RP Stevens, T (corresponding author), Univ S Alabama, Coll Med, Ctr Lung Biol, Mobile, AL 36688 USA.
EM tstevens@southalabama.edu
OI Lee, Ji Young/0000-0002-8005-2446
FU National Heart, Lung, and Blood Institute [HL-66299, HL-60024]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants HL-66299 and HL-60024 (T. Stevens).
CR Allyn J, 2016, J CRIT CARE, V31, P243, DOI 10.1016/j.jcrc.2015.09.025
   Alterio V, 2009, P NATL ACAD SCI USA, V106, P16233, DOI 10.1073/pnas.0908301106
   Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Balczon R, 2017, FASEB J, V31, P2785, DOI 10.1096/fj.201601042RR
   Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086
   Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413
   Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820
   Chen AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027586
   Chen LQ, 2015, LEUKEMIA LYMPHOMA, V56, P1432, DOI 10.3109/10428194.2014.933218
   Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470
   Cotroneo E, 2015, CIRC RES, V116, P1680, DOI 10.1161/CIRCRESAHA.116.305265
   De Simone G, 2010, BBA-PROTEINS PROTEOM, V1804, P404, DOI 10.1016/j.bbapap.2009.07.027
   Dong L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020278
   Dong LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061991
   Edye ME, 2013, J BIOL CHEM, V288, P30485, DOI 10.1074/jbc.M113.478941
   Faes S, 2016, ONCOTARGET, V7, P86026, DOI 10.18632/oncotarget.13323
   Fan YY, 2014, J CEREBR BLOOD F MET, V34, P275, DOI 10.1038/jcbfm.2013.193
   Frost SC, 2013, CARBONIC ANHYDRASE M
   Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255
   Giatromanolaki A, 2001, CANCER RES, V61, P7992
   Gillies RJ, 2015, CANCER J, V21, P88, DOI 10.1097/PPO.0000000000000102
   GUNNERSON KJ, 2006, CRIT CARE, V10
   Gut MO, 2002, GASTROENTEROLOGY, V123, P1889, DOI 10.1053/gast.2002.37052
   Hilvo M, 2008, J BIOL CHEM, V283, P27799, DOI 10.1074/jbc.M800938200
   Huang YZ, 2004, CELL, V118, P665, DOI 10.1016/j.cell.2004.09.004
   Ihnatko R, 2006, INT J ONCOL, V29, P1025
   Ilie M, 2010, BRIT J CANCER, V102, P1627, DOI 10.1038/sj.bjc.6605690
   Inserte J, 2011, ANTIOXID REDOX SIGN, V14, P923, DOI 10.1089/ars.2010.3312
   Kaluz S, 2009, BBA-REV CANCER, V1795, P162, DOI 10.1016/j.bbcan.2009.01.001
   Kellum J A, 2004, Crit Care Resusc, V6, P197
   Kimmoun A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0896-7
   Kopacek J, 2005, BBA-GENE STRUCT EXPR, V1729, P41, DOI 10.1016/j.bbaexp.2005.03.003
   Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099
   Lee JY, 2017, PULM CIRC, V7, P777, DOI 10.1177/2045893217731295
   Loncaster JA, 2001, CANCER RES, V61, P6394
   Luong-Player A, 2014, AM J CLIN PATHOL, V141, P219, DOI 10.1309/AJCPVJDS28KNYZLD
   Martinez D, 2006, J IMMUNOL, V176, P1163, DOI 10.4049/jimmunol.176.2.1163
   Morgan PE, 2007, AM J PHYSIOL-CELL PH, V293, pC738, DOI 10.1152/ajpcell.00157.2007
   Nakamura J, 2011, AM J PATHOL, V178, P515, DOI 10.1016/j.ajpath.2010.10.010
   O'Croinin DF, 2008, CRIT CARE MED, V36, P2128, DOI 10.1097/CCM.0b013e31817d1b59
   OOSTERWIJK E, 1986, INT J CANCER, V38, P489, DOI 10.1002/ijc.2910380406
   Pan PW, 2012, TRANSGENIC RES, V21, P163, DOI 10.1007/s11248-011-9520-z
   Parra-Bonilla G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075984
   Parra-Bonilla G, 2010, AM J PHYSIOL-LUNG C, V299, pL513, DOI 10.1152/ajplung.00274.2009
   Pezzulo AA, 2012, NATURE, V487, P109, DOI 10.1038/nature11130
   Rafajova M, 2004, INT J ONCOL, V24, P995
   RHEE KH, 1993, CHEST, V104, P913, DOI 10.1378/chest.104.3.913
   ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296
   Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500
   Siebels M, 2011, WORLD J UROL, V29, P121, DOI 10.1007/s00345-010-0570-2
   Simi L, 2006, LUNG CANCER, V52, P59, DOI 10.1016/j.lungcan.2005.11.017
   Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119
   Svastova E, 2012, J BIOL CHEM, V287, P3392, DOI 10.1074/jbc.M111.286062
   Torres IM, 2018, AM J PHYSIOL-LUNG C, V314, pL225, DOI 10.1152/ajplung.00338.2017
   Torres IM, 2017, AM J PHYSIOL-LUNG C, V313, pL126, DOI 10.1152/ajplung.00524.2016
   Verdegem D, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-19
   Wahl ML, 2002, ENDOTHELIUM-J ENDOTH, V9, P205, DOI 10.1080/10623320213633
   Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026
   Zhao L, 2015, NATURE, V524, P356, DOI 10.1038/nature14620
NR 59
TC 14
Z9 14
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2018
VL 315
IS 1
BP L41
EP L51
DI 10.1152/ajplung.00446.2017
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA GP5XZ
UT WOS:000440952000004
PM 29631360
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Li, HB
   Shi, HJ
   Ma, N
   Zi, PP
   Liu, QL
   Sun, RQ
AF Li, Hongbin
   Shi, Huijuan
   Ma, Ning
   Zi, Panpan
   Liu, Qilong
   Sun, Rongqing
TI BML-111 alleviates acute lung injury through regulating the expression
   of lncRNA MALAT1
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE ALI/ARDS; MALAT1; BML-111; Cell apoptosis; Inflammation 
ID LIPOXIN RECEPTOR AGONIST; NF-KAPPA-B; GENE-EXPRESSION; AUTOPHAGY;
   PROTECTS
AB BML-111 is a lipoxin receptor agonist that plays a vital role on inflammation. MALAT1 is reported to mediate lung injury. ALI rat model was established using the method of venous cannula. Pulmonary microvascular endothelial cells (PMVEC) of rats were isolated using immunomagnetic separation method. Hematoxylin-eosin (HE) staining was performed to observe the lung injury degree. Real-time PCR and western blot were performed to detect the genes expression. ELIAS was used to determine the level of TNF-alpha and IL-6. RNA pull-down and RIP were carried out to affirm the relationship between MALAT1 and TLR4. The lung injury score and lung wet/dry weight ratio was significantly increased in ALI rats, while BML-111 treatment significantly decreased it, the HE staining directly revealed the lung injury. The expression of MALAT1 was decreased, while TLR4 was increased in ALI rats, BML-111 stimulation significantly reversed it. MALAT1 targets TLR4 to regulate its expression. TLR4 regulated the inflammation and cell apoptosis of PMVEC via NF-kappa B and p38 MAPK signaling pathway. The down-regulated MALAT1 mediates the mechanism of ALI by regulating of NF-icB and p38 MAPK signaling pathways via TLR4, while BML-111 stimulation significantly alleviated the ALI by regulating the expression of MALAT1.
C1 [Li, Hongbin; Shi, Huijuan; Ma, Ning; Zi, Panpan; Liu, Qilong; Sun, Rongqing] Zhengzhou Univ, Affiliated Hosp 1, Dept Crit Care Med, 1 Jianshe East Rd, Zhengzhou 450052, Henan, China.
C3 Zhengzhou University
RP Sun, RQ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Crit Care Med, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM rongqing.sun@126.com
CR Bucher M, 2002, INTENS CARE MED, V28, P642, DOI 10.1007/s00134-002-1264-z
   Charron CE, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00188-2017
   Chun SY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112282
   Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3
   Gong J, 2012, RESUSCITATION, V83, P907, DOI 10.1016/j.resuscitation.2011.12.035
   Guo D, 2017, CELL PHYSIOL BIOCHEM, V43, P182, DOI 10.1159/000480337
   Hermier D, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0220-4
   Hu QD, 2017, PROSTAG OTH LIPID M, V131, P75, DOI 10.1016/j.prostaglandins.2017.08.008
   Huang GJ, 2014, J AGR FOOD CHEM, V62, P5321, DOI 10.1021/jf405113g
   Huang H, 2017, CELL MOL BIOL, V63, P58, DOI 10.14715/cmb/2017.63.8.13
   Jin Y, 2017, EUR REV MED PHARMACO, V21, P3176
   Li HB, 2013, J SURG RES, V183, P710, DOI 10.1016/j.jss.2013.03.007
   Li HB, 2014, SHOCK, V41, P311, DOI 10.1097/SHK.0000000000000104
   Li Ning, 2016, BMC Physiology, V16, P7, DOI 10.1186/s12899-016-0027-y
   Liu JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.466
   Liu J, 2017, ONCOTARGET, V8, P75272, DOI 10.18632/oncotarget.20775
   Novoselova E G, 2017, Dokl Biol Sci, V476, P203, DOI 10.1134/S0012496617050015
   Puthanveetil P, 2015, J CELL MOL MED, V19, P1418, DOI 10.1111/jcmm.12576
   Sabzi Feridoun, 2015, Indian Heart J, V67, P480, DOI 10.1016/j.ihj.2015.05.022
   Shin Na-Rae, 2017, Lab Anim Res, V33, P209, DOI 10.5625/lar.2017.33.3.209
   Tamura DY, 1998, SURGERY, V124, P403, DOI 10.1067/msy.1998.90483
   Tang M, 2016, J SURG RES, V200, P619, DOI 10.1016/j.jss.2015.09.005
   Wang Y, 2017, ONCOTARGET, V8, P59417, DOI 10.18632/oncotarget.19727
   Wu SH, 2016, INFLAMMATION, V39, P611, DOI 10.1007/s10753-015-0286-y
   Yan D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071114
   Yu SY, 2017, INT J CARDIOL, V247, P25, DOI 10.1016/j.ijcard.2017.04.011
   Zhang A, 2013, CELL RES, V23, P340, DOI 10.1038/cr.2012.164
   Zhang XJ, 2017, J NEUROSCI, V37, P1797, DOI 10.1523/JNEUROSCI.3389-16.2017
   Zhou Y, 2018, BIOCHEM BIOPH RES CO, V495, P526, DOI 10.1016/j.bbrc.2017.10.170
NR 29
TC 36
Z9 37
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUL 1
PY 2018
VL 649
BP 15
EP 21
DI 10.1016/j.abb.2018.04.016
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GJ0AG
UT WOS:000434906100002
PM 29704485
DA 2023-08-21
ER

PT J
AU Mitra, S
   Exline, M
   Habyarimana, F
   Gavrilin, MA
   Baker, PJ
   Masters, SL
   Wewers, MD
   Sarkar, A
AF Mitra, Srabani
   Exline, Matthew
   Habyarimana, Fabien
   Gavrilin, Mikhail A.
   Baker, Paul J.
   Masters, Seth L.
   Wewers, Mark D.
   Sarkar, Anasuya
TI Microparticulate Caspase 1 Regulates Gasdermin D and Pulmonary Vascular
   Endothelial Cell Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
ID MEMBRANE MICROPARTICLES; GASTROINTESTINAL-TRACT; PYROPTOSIS; PORE;
   INTERLEUKIN-1-BETA; SECRETION; APOPTOSIS; RELEASE; GSDMD; MACROPHAGES
AB Lung endothelial cell apoptosis and injury occur throughout all stages of acute lung injury/acute respiratory distress syndrome and impact disease progression. Caspases 1, 4, and 5 are essential for completion of the apoptotic program known as pyroptosis that also involves proinflammatory cytokines. Because gasdermin D (GSDMD) mediates pyroptotic death and is essential for pore formation, we hypothesized that it might direct caspase 1-encapsulated microparticle (MP) release and mediate endothelial cell death. Our present work provides evidence that GSDMD is released by LPS-stimulated THP-1 monocytic cells, where it is packaged into microparticles together with active caspase 1. Furthermore, only MP released from stimulated monocytic cells that contain both cleaved GSDMD and active caspase 1 induce endothelial cell apoptosis. MPs pretreated with caspase 1 inhibitor Y-VAD or pan-caspase inhibitor Z-VAD do not contain cleaved GSDMD. MPs from caspase 1-knockout cells are also deficient in p30 active GSDMD, further confirming that caspase 1 regulates GSDMD function. Although control MPs contained cleaved GSDMD without caspase 1, these fractions were unable to induce cell death, suggesting that encapsulation of both caspase 1 and GSDMD is essential for cell death induction. Release of microparticulate active caspase 1 was abrogated in GSDMD knockout cells, although cytosolic caspase 1 activation was not impaired. Last, higher concentrations of microparticulate GSDMD were detected in the plasma of septic patients with acute respiratory distress syndrome than in that of healthy donors. Taken together, these findings suggest that GSDMD regulates the release of microparticulate active caspase 1 from monocytes essential for induction of cell death and thereby may play a critical role in sepsis-induced endothelial cell injury.
C1 [Mitra, Srabani; Sarkar, Anasuya] Ohio State Univ, Dept Physiol & Cell Biol, 473 West 12th Ave, Columbus, OH 43210, United States.
C1 [Mitra, Srabani; Exline, Matthew; Habyarimana, Fabien; Gavrilin, Mikhail A.; Wewers, Mark D.; Sarkar, Anasuya] Ohio State Univ, Dept Internal Med, 473 West 12th Ave, Columbus, OH 43210, United States.
C1 [Baker, Paul J.; Masters, Seth L.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.
C1 [Baker, Paul J.; Masters, Seth L.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University of Melbourne; Walter & Eliza
   Hall Institute
RP Sarkar, A (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 473 West 12th Ave, Columbus, OH 43210 USA.; Sarkar, A (corresponding author), Ohio State Univ, Dept Internal Med, 473 West 12th Ave, Columbus, OH 43210 USA.
EM anasuya.sarkar@osumc.edu
RI Wewers, Mark/AAB-6202-2021; Masters, Seth L/N-2886-2013; Gavrilin,
   Mikhail A/D-2469-2009
OI Masters, Seth L/0000-0003-4763-576X; Baker, Paul J./0000-0002-3642-2366;
   Gavrilin, Mikhail/0000-0003-2003-768X
FU National Institutes of Health (NIH) [R01HL24325, R01GM108928]
FX Supported by National Institutes of Health (NIH) grants R01HL24325
   (A.S.) and R01GM108928 (A.S. and M.D.W.).
CR Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126
   Chen X, 2016, CELL RES, V26, P1007, DOI 10.1038/cr.2016.100
   Diamant M, 2004, EUR J CLIN INVEST, V34, P392, DOI 10.1111/j.1365-2362.2004.01355.x
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Distler JHW, 2005, APOPTOSIS, V10, P731, DOI 10.1007/s10495-005-2941-5
   Distler JHW, 2006, AUTOIMMUNITY, V39, P683, DOI 10.1080/08916930601061538
   Exline MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090968
   Gurcel L, 2006, CELL, V126, P1135, DOI 10.1016/j.cell.2006.07.033
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Huber LC, 2007, APOPTOSIS, V12, P363, DOI 10.1007/s10495-006-0622-7
   Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Lin HY, 2015, EXP DERMATOL, V24, P897, DOI 10.1111/exd.12797
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Man SM, 2015, CELL RES, V25, P1183, DOI 10.1038/cr.2015.124
   Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E
   Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004
   McKechnie NM, 2006, EXP EYE RES, V83, P304, DOI 10.1016/j.exer.2005.11.028
   Mitra S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145607
   Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913
   Rowe SJ, 2002, J IMMUNOL, V169, P6401, DOI 10.4049/jimmunol.169.11.6401
   Russo HM, 2016, J IMMUNOL, V197, P1353, DOI 10.4049/jimmunol.1600699
   Saeki N, 2000, MAMM GENOME, V11, P718, DOI 10.1007/s003350010138
   Sarkar A, 2006, AM J RESP CRIT CARE, V174, P1003, DOI 10.1164/rccm.200604-546OC
   Sarkar A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007140
   Sborgi L, 2016, EMBO J, V35, P1766, DOI 10.15252/embj.201694696
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003
   Watanabe JJ, 2003, J BIOL CHEM, V278, P33161, DOI 10.1074/jbc.M305321200
   Wewers MD, 2004, P NATL ACAD SCI USA, V101, P10241, DOI 10.1073/pnas.0403971101
NR 33
TC 54
Z9 60
U1 1
U2 15
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUL
PY 2018
VL 59
IS 1
BP 56
EP 64
DI 10.1165/rcmb.2017-0393OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA GL3MN
UT WOS:000437040100011
PM 29365280
OA Green Published
DA 2023-08-21
ER

PT J
AU Oita, RC
   Camp, SM
   Ma, WL
   Ceco, E
   Harbeck, M
   Singleton, P
   Messana, J
   Sun, XG
   Wang, T
   Garcia, JGN
AF Oita, Radu C.
   Camp, Sara M.
   Ma, Wenli
   Ceco, Ermelinda
   Harbeck, Mark
   Singleton, Patrick A.
   Messana, Joe
   Sun, Xiaoguang
   Wang, Ting
   Garcia, Joe G. N.
TI Novel Mechanism for Nicotinamide Phosphoribosyltransferase Inhibition of
   TNF-alpha-mediated Apoptosis in Human Lung Endothelial Cells
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE apoptosis; nicotinamide phosphoribosyltransferase; NAD(+); ALI/ARDS 
ID COLONY-ENHANCING FACTOR; RESPIRATORY-DISTRESS-SYNDROME; OXIDATIVE
   STRESS; ADIPOSE-TISSUE; VISFATIN; INJURY; ACTIVATION; EXPRESSION;
   INCREASES; FAT
AB Nicotinamide phosphoribosyltransferase (NAMPT) exists as both intracellular NAMPT and extracellular NAMPT (eNAMPT) proteins. eNAMPT is secreted into the blood and functions as a cytokine/enzyme (cytozyme) that activates NF-kappa B signaling via ligation of Toll-like receptor 4 (TLR4), further serving as a biomarker for inflammatory lung disorders such as acute respiratory distress syndrome. In contrast, intracellular NAMPT is involved in nicotinamide mononucleotide synthesis and has been implicated in the regulation of cellular apoptosis, although the exact mechanisms for this regulation are poorly understood. We examined the role of NAMPT in TNF-alpha-induced human lung endothelial cell (EC) apoptosis and demonstrated that reduced NAMPT expression (siRNA) increases EC susceptibility to TNF-alpha-induced apoptosis as reflected by PARP-1 cleavage and caspase-3 activation. In contrast, overexpression of NAMPT served to reduce degrees of TNF-alpha-induced EC apoptosis. Inhibition of nicotinamide mononucleotide synthesis by FK866 (a selective NAMPT enzymatic inhibitor) failed to alter TNF-alpha-induced human lung EC apoptosis, suggesting that NAMPT-dependent NAD(+) generation is unlikely to be involved in regulation of TNF-alpha-induced EC apoptosis. We next confirmed that TNF-alpha-induced EC apoptosis is attributable to NAMPT secretion into the EC culture media and subsequent eNAMPT ligation of TLR4 on the EC membrane surface. Silencing of NAMPT expression, direct neutralization of secreted eNAMPT by an NAMPT-specific polyclonal antibody (preventing TLR4 ligation), or direct TLR4 antagonism all served to significantly increase EC susceptibility to TNF-alpha-induced EC apoptosis. Together, these studies provide novel insights into NAMPT contributions to lung inflammatory events and to novel mechanisms of EC apoptosis regulation.
C1 [Oita, Radu C.; Camp, Sara M.; Ma, Wenli; Messana, Joe; Sun, Xiaoguang; Wang, Ting; Garcia, Joe G. N.] Univ Arizona, Univ Arizona Hlth Sci, Div Pulm Allergy Crit Care & Sleep Med, 1295 N Martin Ave,Suite A274, Tucson, AZ 85721, United States.
C1 [Ceco, Ermelinda; Harbeck, Mark] Univ Illinois, Inst Personalized Resp Med, Chicago, IL, United States.
C1 [Singleton, Patrick] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637, United States.
C3 University of Arizona; University of Arizona Health Sciences; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital; University of Chicago
RP Garcia, JGN (corresponding author), Univ Arizona, Univ Arizona Hlth Sci, Div Pulm Allergy Crit Care & Sleep Med, 1295 N Martin Ave,Suite A274, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
RI SUN, XIAOGUANG/ACA-5558-2022
FU NIH [R01-HL094394, P01-HL058064, P01-HL126609, P01-HL134610]
FX Supported by NIH grants R01-HL094394, P01-HL058064, P01-HL126609, and
   P01-HL134610 (J.G.N.G.).
CR Adya R, 2008, DIABETES CARE, V31, P758, DOI 10.2337/dc07-1544
   Adya R, 2009, ATHEROSCLEROSIS, V205, P113, DOI 10.1016/j.atherosclerosis.2008.11.024
   Adyshev DM, 2014, AM J RESP CELL MOL, V50, P409, DOI 10.1165/rcmb.2013-0292OC
   Bajwa EK, 2007, CRIT CARE MED, V35, P1290, DOI 10.1097/01.CCM.0000260243.22758.4F
   Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Cagnetta A, 2015, CLIN CANCER RES, V21, P3934, DOI 10.1158/1078-0432.CCR-14-3023
   Camp SM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13135
   Cheng Q, 2011, J MOL ENDOCRINOL, V47, P13, DOI 10.1530/JME-10-0106
   Curat CA, 2006, DIABETOLOGIA, V49, P744, DOI 10.1007/s00125-006-0173-z
   Del Nagro C, 2014, J BIOL CHEM, V289, P35182, DOI 10.1074/jbc.M114.580159
   Evans L, 2011, ARTHRITIS RHEUM-US, V63, P1866, DOI 10.1002/art.30338
   Frank MG, 2015, BRAIN BEHAV IMMUN, V48, P1, DOI 10.1016/j.bbi.2015.03.010
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   Gao W, 2011, RESP PHYSIOL NEUROBI, V178, P235, DOI 10.1016/j.resp.2011.06.016
   Garten A, 2010, BIOCHEM BIOPH RES CO, V391, P376, DOI 10.1016/j.bbrc.2009.11.066
   Ginet V, 2014, AUTOPHAGY, V10, P603, DOI 10.4161/auto.27722
   Gomez R, 2011, NAT REV RHEUMATOL, V7, P528, DOI 10.1038/nrrheum.2011.107
   Gosset M, 2008, ARTHRITIS RHEUM-US, V58, P1399, DOI 10.1002/art.23431
   Hallschmid M, 2009, DIABETES, V58, P637, DOI 10.2337/db08-1176
   Hasmann M, 2003, CANCER RES, V63, P7436
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Hsu CP, 2009, CIRC RES, V105, P481, DOI 10.1161/CIRCRESAHA.109.203703
   Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI 10.1172/JCI19930
   Kim HJ, 2010, DIABETES, V59, pA661
   Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017
   Laiguillon MC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4467
   Lee KA, 2011, CHEST, V140, P382, DOI 10.1378/chest.10-3100
   Li HL, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-15
   Li Y, 2013, BIOCHEM BIOPH RES CO, V434, P117, DOI 10.1016/j.bbrc.2013.02.132
   Li Y, 2011, J BONE MINER RES, V26, P2656, DOI 10.1002/jbmr.480
   Li YK, 2008, J BIOL CHEM, V283, P34833, DOI 10.1074/jbc.M805866200
   Lim SY, 2008, J CELL MOL MED, V12, P1395, DOI 10.1111/j.1582-4934.2008.00332.x
   Linz-McGillem LA, 2004, STEM CELLS DEV, V13, P496, DOI 10.1089/1547328042417282
   Liu P, 2009, CELL BIOL INT, V33, P19, DOI 10.1016/j.cellbi.2008.10.015
   Ma Y, 2010, DIABETES RES CLIN PR, V90, P60, DOI 10.1016/j.diabres.2010.06.010
   Mamali I, 2012, PEPTIDES, V33, P120, DOI 10.1016/j.peptides.2011.11.007
   Moschen AR, 2011, HEPATOLOGY, V54, P675, DOI 10.1002/hep.24416
   Oita RC, 2010, PFLUG ARCH EUR J PHY, V459, P619, DOI 10.1007/s00424-009-0752-1
   Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297
   Rongvaux A, 2008, J IMMUNOL, V181, P4685, DOI 10.4049/jimmunol.181.7.4685
   SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431
   Sun XG, 2014, AM J RESP CELL MOL, V51, P660, DOI 10.1165/rcmb.2014-0117OC
   Sun Y, 2012, INT J MOL MED, V30, P622, DOI 10.3892/ijmm.2012.1032
   Wang P, 2009, CARDIOVASC RES, V81, P370, DOI 10.1093/cvr/cvn288
   Xie H, 2007, CALCIFIED TISSUE INT, V80, P201, DOI 10.1007/s00223-006-0155-7
   Ye SQ, 2005, MICROVASC RES, V70, P142, DOI 10.1016/j.mvr.2005.08.003
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
   Zhang LQ, 2008, FEBS LETT, V582, P1802, DOI 10.1016/j.febslet.2008.04.061
NR 50
TC 29
Z9 29
U1 0
U2 12
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUL
PY 2018
VL 59
IS 1
BP 36
EP 44
DI 10.1165/rcmb.2017-0155OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA GL3MN
UT WOS:000437040100009
PM 29337590
OA Green Published
DA 2023-08-21
ER

PT J
AU Otulakowski, G
   Engelberts, D
   Post, M
   Masterson, C
   Kavanagh, BP
AF Otulakowski, Gail
   Engelberts, Doreen
   Post, Martin
   Masterson, Claire
   Kavanagh, Brian P.
TI Mechanical Ventilation Induces Desensitization of Lung Axl Tyrosine
   Kinase Receptors
SO ANESTHESIOLOGY
LA English
DT Article
ID TAM RECEPTORS; INJURY; GAS6; STIMULATION; HYPERCAPNIA; EXPRESSION;
   STRETCH; TARGET; LIGAND; CELLS
AB Background: Lower tidal volumes are increasingly used in acute respiratory distress syndrome, but mortality has changed little in the last 20 yr. Therefore, in addition to ventilator settings, it is important to target molecular mediators of injury. Sepsis and other inflammatory states increase circulating concentrations of Gas6, a ligand for the antiinflammatory receptor Axl, and of a soluble decoy form of Axl. We investigated the effects of lung stretch on Axl signaling.
   Methods: We used a mouse model of early injury from high tidal volume and assessed the effects of inhibiting Axl on in vivo lung injury (using an antagonist R428, n=4/group). We further determined the effects of stretch on Axl activation using in vitro lung endothelial cells.
   Results: High tidal volume caused mild injury (compliance decreased 6%) as intended, and shedding of the Axl receptor (soluble Axl in bronchoalveolar fluid increased 77%). The Axl antagonist R428 blocked the principal downstream Axl target (suppressor of cytokine signaling 3 [SOCS3]) but did not worsen lung physiology or inflammation. Cyclic stretch in vitro caused Axl to become insensitive to activation by its agonist, Gas6. Finally, in vitro Axl responses were rescued by blocking stretch-activated calcium channels (using guanidinium chloride [GdCl3]), and the calcium ionophore ionomycin replicated the effect of stretch.
   Conclusions: These data suggest that lung endothelial cell overdistention activates ion channels, and the resultant influx of Ca2+ inactivates Axl. Downstream inactivation of Axl by stretch was not anticipated; preventing this would be required to exploit Axl receptors in reducing lung injury.
C1 [Otulakowski, Gail; Engelberts, Doreen; Post, Martin; Masterson, Claire; Kavanagh, Brian P.] Univ Toronto, Translat Med, Toronto, ON, Canada.
C1 [Kavanagh, Brian P.] Univ Toronto, Hosp Sick Children, Dept Crit Care Med, Toronto, ON, Canada.
C1 [Kavanagh, Brian P.] Univ Toronto, Hosp Sick Children, Dept Anesthesia, Toronto, ON, Canada.
C1 [Kavanagh, Brian P.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto; Hospital for Sick Children
   (SickKids); University of Toronto; Hospital for Sick Children
   (SickKids); University of Toronto
RP Kavanagh, BP (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM brian.kavanagh@utoronto.ca
RI kavanagh, brian/HTQ-4160-2023
OI Masterson, Claire/0000-0002-9863-5324
FU Canadian Institutes of Health Research (Ottawa, Canada) [311394]
FX Supported by a Canadian Institutes of Health Research (Ottawa, Canada)
   Operating Grant (311394) to Dr. Kavanagh. Dr. Kavanagh holds the Dr.
   Geoffrey Barker Chair in Critical Care Research. Dr. Post holds a Canada
   Research Chair (Tier I) in Fetal, Neonatal and Maternal Health.
CR Avanzi GC, 1998, BLOOD, V91, P2334, DOI 10.1182/blood.V91.7.2334.2334_2334_2340
   Bellani G, 2011, AM J RESP CRIT CARE, V183, P1193, DOI 10.1164/rccm.201008-1318OC
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Curley GF, 2016, CHEST, V150, P1109, DOI 10.1016/j.chest.2016.07.019
   D'Arcangelo D, 2006, CARDIOVASC RES, V71, P754, DOI 10.1016/j.cardiores.2006.06.002
   Delos Santos RC, 2015, CELL SIGNAL, V27, P1963, DOI 10.1016/j.cellsig.2015.07.004
   Ekman C, 2010, CRIT CARE, V14, DOI 10.1186/cc9233
   Ekman C, 2010, CLIN BIOCHEM, V43, P873, DOI 10.1016/j.clinbiochem.2010.04.006
   Fujimori T, 2015, MUCOSAL IMMUNOL, V8, P1021, DOI 10.1038/mi.2014.129
   Gattinoni L, 2016, INTENS CARE MED, V42, P663, DOI 10.1007/s00134-015-4200-8
   Gruber RC, 2014, J NEUROSCI, V34, P16320, DOI 10.1523/JNEUROSCI.2449-14.2014
   Happonen KE, 2016, J BIOL CHEM, V291, P10586, DOI 10.1074/jbc.M115.699058
   Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004
   Hecquet CM, 2010, ADV EXP MED BIOL, V661, P155, DOI 10.1007/978-1-60761-500-2_10
   Henderson WR, 2017, AM J RESP CRIT CARE, V196, P822, DOI 10.1164/rccm.201612-2495CI
   Laurance S, 2014, J THROMB HAEMOST, V12, P395, DOI 10.1111/jth.12481
   Lee IJ, 2015, CLIN IMMUNOL, V158, P231, DOI 10.1016/j.clim.2015.01.012
   Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076
   Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212
   Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Morty RE, 2014, AM J PHYSIOL-LUNG C, V307, pL817, DOI 10.1152/ajplung.00254.2014
   O'Gara B, 2015, SEMIN RESP CRIT CARE, V36, P823, DOI 10.1055/s-0035-1564889
   Otulakowski G, 2017, THORAX, V72, P538, DOI 10.1136/thoraxjnl-2016-209501
   Otulakowski G, 2014, J PHYSIOL-LONDON, V592, P4507, DOI 10.1113/jphysiol.2014.277616
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Rodriguez-Palacios A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8577
   Rose F, 2002, AM J PHYSIOL-LUNG C, V282, pL207, DOI 10.1152/ajplung.00156.2001
   Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034
   Rothlin CV, 2015, ANNU REV IMMUNOL, V33, P355, DOI 10.1146/annurev-immunol-032414-112103
   Schwingshackl A, 2016, AM J PHYSIOL-LUNG C, V311, pL639, DOI 10.1152/ajplung.00458.2015
   Standiford TJ, 2016, TRANSL RES, V167, P183, DOI 10.1016/j.trsl.2015.04.015
   Tong LS, 2017, J CEREBR BLOOD F MET, V37, P1971, DOI 10.1177/0271678X16658490
   Tsou WI, 2014, J BIOL CHEM, V289, P25750, DOI 10.1074/jbc.M114.569020
   Tsuchida S, 2006, AM J RESP CRIT CARE, V174, P279, DOI 10.1164/rccm.200506-1006OC
   van den Brand BT, 2013, ARTHRITIS RHEUM-US, V65, P671, DOI 10.1002/art.37786
   van der Meer JHM, 2014, BLOOD, V123, P2460, DOI 10.1182/blood-2013-09-528752
   Wang T, 2017, AM J PHYSIOL-LUNG C, V312, pL452, DOI 10.1152/ajplung.00231.2016
   Wung BS, 1996, AM J PHYSIOL-HEART C, V270, pH1462, DOI 10.1152/ajpheart.1996.270.4.H1462
   Xiaoming J, 2008, CHEST, V133, P853, DOI DOI 10.1378/CHEST.07-1121.RISK
   Zheng SS, 2015, J IMMUNOL, V194, P1928, DOI 10.4049/jimmunol.1401933
NR 43
TC 5
Z9 5
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUL
PY 2018
VL 129
IS 1
BP 143
EP 153
DI 10.1097/ALN.0000000000002140
PG 11
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA GJ7JU
UT WOS:000435563800018
PM 29474201
OA Bronze
DA 2023-08-21
ER

PT J
AU Ying, LH
   Alvira, CM
   Cornfield, DN
AF Ying, Lihua
   Alvira, Cristina M.
   Cornfield, David N.
TI Developmental differences in focal adhesion kinase expression modulate
   pulmonary endothelial barrier function in response to inflammation
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY-DISTRESS; CAPILLARY LEAK SYNDROME; ACUTE LUNG INJURY;
   SPHINGOSINE 1-PHOSPHATE; ADHERENS JUNCTIONS; KAPPA-B; ENDOTOXIN; CELLS;
   PHOSPHORYLATION; PERMEABILITY
AB Compromised pulmonary endothelial cell (PEC) barrier function characterizes acute respiratory distress syndrome (ARDS), a cause of substantial morbidity and mortality. Survival from ARDS is greater in children compared with adults. Whether developmental differences intrinsic to PEC barrier function contribute to this survival advantage remains unknown. To test the hypothesis that PEC barrier function is more well-preserved in neonatal lungs compared with adult lungs in response to inflammation, we induced lung injury in neonatal and adult mice with systemic lipopolysaccharide (LPS). We assessed PEC barrier function in vivo and in vitro, evaluated changes in the expression of focal adhesion kinase 1 (FAK1) and phosphorylation in response to LPS, and determined the effect of FAK silencing and overexpression on PEC barrier function. We found that LPS induced a greater increase in lung permeability and PEC barrier disruption in the adult mice, despite similar degrees of inflammation and apoptosis. Although baseline expression was similar, LPS increased FAK1 expression in neonatal PEC but increased FAK1 phosphorylation and decreased FAK1 expression in adult PEC. Pharmacologic inhibition of FAK1 accentuated LPS-induced barrier disruption most in adult PEC. Finally, in response to LPS, FAK silencing markedly impaired neonatal PEC barrier function, whereas FAK overexpression preserved adult PEC barrier function. Thus, developmental differences in FAK expression during inflammatory injury serve to preserve neonatal pulmonary endothelial barrier function compared with that of adults and suggest that intrinsic differences in the immature versus pulmonary endothelium, especially relative to FAK1 phosphorylation, may contribute to the improved outcomes of children with ARDS.
C1 [Ying, Lihua; Cornfield, David N.] Stanford Univ, Dept Pediat, Sch Med, Div Pulm Med, Stanford, CA 94305, United States.
C1 [Alvira, Cristina M.] Stanford Univ, Dept Pediat, Sch Med, Div Crit Care Med, Stanford, CA 94305, United States.
C3 Stanford University; Stanford University
RP Cornfield, DN (corresponding author), Stanford Univ, Sch Med, Ctr Excellence Pulm Biol, 770 Welch Rd,Suite 350, Stanford, CA 94305 USA.
EM cornfield@stanford.edu
OI Alvira, Cristina/0000-0002-6921-0001
FU National Heart, Lung, and Blood Institute [HL-060784, HL-0706280,
   HL-122918]; Burroughs Wellcome Fund Preterm Birth Initiative; Stanford
   Child Health Research Institute Tashia; John Morgridge Faculty Scholar
   Award
FX This work has been supported by National Heart, Lung, and Blood
   Institute Grants HL-060784 (D. N. Cornfield), HL-0706280 (D. N.
   Cornfield), and HL-122918 (C. M. Alvira). Further support for this work
   derived from the Burroughs Wellcome Fund Preterm Birth Initiative and
   the Stanford Child Health Research Institute Tashia and John Morgridge
   Faculty Scholar Award.
CR ABMAN SH, 1991, AM J PHYSIOL, V260, pL280, DOI 10.1152/ajplung.1991.260.4.L280
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195
   Alvira CM, 2007, AM J RESP CRIT CARE, V175, P805, DOI 10.1164/rccm.200608-1162OC
   ASHBAUGH DG, 1967, LANCET, V2, P319
   AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247
   Bannerman DD, 1999, LAB INVEST, V79, P1181
   Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371
   Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Farley KS, 2009, AM J PHYSIOL-LUNG C, V296, pL480, DOI 10.1152/ajplung.90201.2008
   FOLKESSON HG, 1991, J APPL PHYSIOL, V71, P1106, DOI 10.1152/jappl.1991.71.3.1106
   Frey EA, 1998, MICROB PATHOGENESIS, V24, P101, DOI 10.1006/mpat.1997.0178
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gozin A, 1998, FREE RADICAL BIO MED, V25, P1021, DOI 10.1016/S0891-5849(98)00134-8
   Guignabert C, 2009, AM J PHYSIOL-LUNG C, V297, pL1082, DOI 10.1152/ajplung.00199.2009
   Harju K, 2001, PEDIATR RES, V49, P81, DOI 10.1203/00006450-200101000-00018
   Hsu P, 2015, PEDIATRICS, V135, pE730, DOI 10.1542/peds.2014-2268
   Iosef C, 2012, AM J PHYSIOL-LUNG C, V302, pL1023, DOI 10.1152/ajplung.00230.2011
   Jiao H, 2013, J IMMUNOL, V191, P6191, DOI 10.4049/jimmunol.1300873
   Komarova YA, 2017, CIRC RES, V120, P179, DOI 10.1161/CIRCRESAHA.116.306534
   Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503
   MEYRICK BO, 1986, AM J PATHOL, V122, P140
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Munshi N, 2002, J IMMUNOL, V168, P5860, DOI 10.4049/jimmunol.168.11.5860
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Quasney MW, 2015, PEDIATR CRIT CARE ME, V16, pS118, DOI 10.1097/PCC.0000000000000438
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Schmidt TT, 2013, AM J PHYSIOL-LUNG C, V305, pL291, DOI 10.1152/ajplung.00094.2013
   Skelly CL, 2007, P NATL ACAD SCI USA, V104, P12474, DOI 10.1073/pnas.0705429104
   Sonntag J, 1998, ANN THORAC SURG, V65, P525, DOI 10.1016/S0003-4975(97)01340-4
   Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419
   Stiller B, 2001, INTENS CARE MED, V27, P193, DOI 10.1007/s001340000704
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Timmerman I, 2012, MOL BIOL CELL, V23, P4212, DOI 10.1091/mbc.E12-01-0038
   TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WEIBEL ER, 1973, PHYSIOL REV, V53, P419, DOI 10.1152/physrev.1973.53.2.419
   Xie ZH, 2012, BLOOD, V119, P4321, DOI 10.1182/blood-2011-08-375816
NR 41
TC 12
Z9 12
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2018
VL 315
IS 1
BP L66
EP L77
DI 10.1152/ajplung.00363.2017
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA GP5XZ
UT WOS:000440952000007
PM 29597831
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Shah, T
   Qin, SS
   Vashi, M
   Predescu, DN
   Jeganathan, N
   Bardita, C
   Ganesh, B
   diBartolo, S
   Fogg, LF
   Balk, RA
   Predescu, SA
AF Shah, Trushil
   Qin, Shanshan
   Vashi, Mona
   Predescu, Dan N.
   Jeganathan, Niranjan
   Bardita, Cristina
   Ganesh, Balaji
   diBartolo, Salvatore
   Fogg, Louis F.
   Balk, Robert A.
   Predescu, Sanda A.
TI Alk5/Runx1 signaling mediated by extracellular vesicles promotes
   vascular repair in acute respiratory distress syndrome
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE ALI/ARDS; Circulatory extracellular vesicles; Runx1 isoforms; Alk5; Endothelial damage 
ID MESENCHYMAL STEM-CELLS; ACUTE LUNG INJURY; STROMAL CELLS; GROWTH-FACTOR;
   NANOPARTICLE TRACKING; INTERNATIONAL SOCIETY; MICROPARTICLES;
   PROLIFERATION; MICROVESICLES; RECOVERY
AB Background: Pulmonary endothelial cells' (ECs) injury and apoptotic death are necessary and sufficient for the pathogenesis of the acute respiratory distress syndrome (ARDS), regardless of epithelial damage. Interaction of dysfunctional ECs with circulatory extracellular vesicles (EVs) holds therapeutic promise in ARDS. However, the presence in the blood of long-term ARDS survivors of EVs with a distinct phenotype compared to the EVs of non-surviving patients is not reported. With a multidisciplinary translational approach, we studied EVs from the blood of 33 patients with moderate-to-severe ARDS.
   Results: The EVs were isolated from the blood of ARDS and control subjects. Immunoblotting and magnetic beads immunoisolation complemented by standardized flow cytometry and nanoparticles tracking analyses identified in the ARDS patients a subset of EVs with mesenchymal stem cell (MSC) origin (CD73(+)CD105(+)Cd34(-)CD45(-)). These EVs have 4.7-fold greater counts compared to controls and comprise the transforming growth factor-beta receptor I (T beta RI)/Alk5 and the Runx1 transcription factor. Time course analyses showed that the expression pattern of two Runx1 isoforms is critical for ARDS outcome: the p52 isoform shows a continuous expression, while the p66 is short-lived. A high ratio Runx1p66/p52 provided a survival advantage, regardless of age, sex, disease severity or length of stay in the intensive care unit. Moreover, the Runx1p66 isoform is transiently expressed by cultured human bone marrow-derived MSCs, it is released in the EVs recoverable from the conditioned media and stimulates the proliferation of lipopolysaccharide (LPS)-treated ECs. The findings are consistent with a causal effect of Runx1p66 expression on EC proliferation. Furthermore, morphological and functional assays showed that the EVs bearing the Runx1p66 enhanced junctional integrity of LPS-injured ECs and decreased lung histological severity in the LPS-treated mice.
   Conclusions: The expression pattern of Runx1 isoforms might be a reliable circulatory biomarker of ARDS activity and a novel determinant of the molecular mechanism for lung vascular/tissue repair and recovery after severe injury.
C1 [Qin, Shanshan; Vashi, Mona; Predescu, Dan N.; Jeganathan, Niranjan; diBartolo, Salvatore; Balk, Robert A.; Predescu, Sanda A.] Rush Univ, Med Ctr, Dept Internal Med Pulm Crit Care & Sleep Med, 1750W Harrison St 1535 JS, Chicago, IL 60612, United States.
C1 [Fogg, Louis F.] Rush Med Coll, Coll Nursing, Chicago, IL 60612, United States.
C1 [Ganesh, Balaji] Univ Illinois, Chicago, IL, United States.
C1 [Shah, Trushil] Univ Texas Southwestern Med Ctr Dallas, Pulm & Crit Care Med, Dallas, TX 75390, United States.
C1 [Bardita, Cristina] Univ Alabama Birmingham, Pulm Allergy & Crit Care Med, Birmingham, AL, United States.
C3 Rush University; Rush University; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Alabama System; University of Alabama
   Birmingham
RP Predescu, SA (corresponding author), Rush Univ, Med Ctr, Dept Internal Med Pulm Crit Care & Sleep Med, 1750W Harrison St 1535 JS, Chicago, IL 60612 USA.
EM Sanda_Predescu@rush.edu
RI shah, trushil/K-6113-2019
OI shah, trushil/0000-0003-0204-1503
FU National Heart, Lung, and Blood Institute [R01 HL127022]
FX This work was supported in part by National Heart, Lung, and Blood
   Institute, Grant R01 HL127022.
CR [Anonymous], 2012, JAMA, DOI DOI 10.1001/JAMA.2012.5669
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Bardita C, 2015, J CELL SCI, V128, P1528, DOI 10.1242/jcs.163030
   Bardita C, 2013, APOPTOSIS, V18, P57, DOI 10.1007/s10495-012-0762-x
   Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782
   Belema-Bedada F, 2008, CELL STEM CELL, V2, P566, DOI 10.1016/j.stem.2008.03.003
   Bern MM, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0165-2
   Chen J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/985814
   Cochi SE, 2016, ANN AM THORAC SOC, V13, P1742, DOI 10.1513/AnnalsATS.201512-841OC
   Cohen J, 1988, STAT POWER ANAL BEHA
   David S, 2011, AM J PHYSIOL-LUNG C, V300, pL851, DOI 10.1152/ajplung.00459.2010
   Enjeti AK, 2016, THROMB RES, V145, P18, DOI 10.1016/j.thromres.2016.06.029
   Fang XH, 2015, J IMMUNOL, V195, P875, DOI 10.4049/jimmunol.1500244
   Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738
   Garcia BA, 2005, J PROTEOME RES, V4, P1516, DOI 10.1021/pr0500760
   Gardiner C, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.19671
   GIL J, 1982, ANN NY ACAD SCI, V384, P31, DOI 10.1111/j.1749-6632.1982.tb21359.x
   Gotts JE, 2011, CRIT CARE CLIN, V27, P719, DOI 10.1016/j.ccc.2011.04.004
   Guervilly C, 2011, CRIT CARE, V15, DOI 10.1186/cc9978
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hall JB, 2011, NEW ENGL J MED, V364, P1358, DOI 10.1056/NEJMe1101057
   Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8
   Herridge MS, 2011, CRIT CARE CLIN, V27, P685, DOI 10.1016/j.ccc.2011.04.003
   Iwatsuki K, 2005, ONCOGENE, V24, P1129, DOI 10.1038/sj.onc.1208287
   Jeganathan N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0543-1
   Kanada M, 2015, P NATL ACAD SCI USA, V112, pE1433, DOI 10.1073/pnas.1418401112
   Kim W, 2014, P NATL ACAD SCI USA, V111, P16389, DOI 10.1073/pnas.1407097111
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Lacroix R, 2013, J THROMB HAEMOST, V11, P1190, DOI 10.1111/jth.12207
   Lahm T, 2007, SHOCK, V28, P4, DOI 10.1097/shk.0b013e31804d1998
   Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036
   Leroyer AS, 2008, J AM COLL CARDIOL, V52, P1302, DOI 10.1016/j.jacc.2008.07.032
   Lindoso Rafael Soares, 2017, Stem Cell Investig, V4, P75, DOI 10.21037/sci.2017.08.08
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054
   Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Martin TR, 2011, CRIT CARE CLIN, V27, P735, DOI 10.1016/j.ccc.2011.05.013
   Martinez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149119
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456
   Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Morel O, 2006, ARTERIOSCL THROM VAS, V26, P2594, DOI 10.1161/01.ATV.0000246775.14471.26
   Nguyen DC, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1463778
   Occhetta P, 2018, P NATL ACAD SCI USA, V115, P4625, DOI 10.1073/pnas.1720658115
   Patel M, 2017, AM J PATHOL, V187, P528, DOI 10.1016/j.ajpath.2016.11.012
   Patel M, 2013, J BIOL CHEM, V288, P25701, DOI 10.1074/jbc.M113.502674
   Peired AJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4798639
   Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041
   Rich JT, 2010, OTOLARYNG HEAD NECK, V143, P331, DOI 10.1016/j.otohns.2010.05.007
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shah T, 2016, AM J RESP CRIT CARE, V193
   Shaver CM, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1700-7
   Shaver CM, 2014, CLIN CHEST MED, V35, P639, DOI 10.1016/j.ccm.2014.08.004
   Sinclair KA, 2016, STEM CELLS, V34, P2548, DOI 10.1002/stem.2419
   Tanaka T, 1996, MOL CELL BIOL, V16, P3967
   Tang XJ, 2017, AM J RESP CELL MOL, V57, P174, DOI 10.1165/rcmb.2016-0319OC
   Vasina EM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.94
   Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360
   Wu CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174327
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
   Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 63
TC 26
Z9 28
U1 0
U2 8
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD JUN 22
PY 2018
VL 7
AR 19
DI 10.1186/s40169-018-0197-2
PG 18
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GK5BC
UT WOS:000436185100001
PM 29931538
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Li, XY
   Yu, YF
   Gorshkov, B
   Haigh, S
   Bordan, Z
   Weintraub, D
   Rudic, RD
   Chakraborty, T
   Barman, SA
   Verin, AD
   Su, YC
   Lucas, R
   Stepp, DW
   Chen, F
   Fulton, DJR
AF Li, Xueyi
   Yu, Yanfang
   Gorshkov, Boris A.
   Haigh, Stephen
   Bordan, Zsuzsanna
   Weintraub, Daniel
   Rudic, Radu Daniel
   Chakraborty, Trinad
   Barman, Scott A.
   Verin, Alexander D.
   Su, Yunchao
   Lucas, Rudolf
   Stepp, David W.
   Chen, Feng
   Fulton, David J. R.
TI Hsp70 Suppresses Mitochondrial Reactive Oxygen Species and Preserves
   Pulmonary Microvascular Barrier Integrity Following Exposure to
   Bacterial Toxins
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE pneumolysin; ECs/HPMECs/HUVECs/MPVECs; ROS; mitochondria; Hsp70 
ID HEAT-SHOCK PROTEINS; ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME;
   KINASE-C-ALPHA; OXIDATIVE STRESS; ENDOTHELIAL-CELLS;
   STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL PNEUMONIA; MOLECULAR CHAPERONES;
   STRUCTURAL BASIS
AB Pneumonia is a leading cause of death in children and the elderly worldwide, accounting for 15% of all deaths of children under 5 years old. Streptococcus pneumoniae is a common and aggressive cause of pneumonia and can also contribute to meningitis and sepsis. Despite the widespread use of antibiotics, mortality rates for pneumonia remain unacceptably high in part due to the release of bacterial toxins. Pneumolysin (PLY) is a cholesterol-dependent toxin that is produced by Streptococcus, and it is both necessary and sufficient for the development of the extensive pulmonary permeability edema that underlies acute lung injury. The mechanisms by which PLY disrupts the pulmonary endothelial barrier are not fully understood. Previously, we found that reactive oxygen species (ROS) contribute to the barrier destructive effects of PLY and identified an unexpected but potent role of Hsp70 in suppressing ROS production. The ability of Hsp70 to influence PLY-induced barrier dysfunction is not yet described, and the goal of the current study was to identify whether Hsp70 upregulation is an effective strategy to protect the lung microvascular endothelial barrier from G(+) bacterial toxins. Overexpression of Hsp70 via adenovirus-mediated gene transfer attenuated PLY-induced increases in permeability in human lung microvascular endothelial cells (HLMVEC) with no evidence of cytotoxicity. To adopt a more translational approach, we employed a pharmacological approach using geranylgeranylacetone (GGA) to acutely upregulate endogenous Hsp70 expression. Following acute treatment (6 h) with GGA, HLMVECs exposed to PLY displayed improved cell viability and enhanced endothelial barrier function as measured by both Electric Cell-substrate Impedance Sensing (ECIS) and transwell permeability assays compared to control treated cells. PLY promoted increased mitochondrial ROS, decreased mitochondrial oxygen consumption, and increased caspase 3 cleavage and cell death, which were collectively improved in cells pretreated with GGA. In mice, IP pretreatment with GGA 24 h prior to IT administration of PLY resulted in significantly less Evans Blue Dye extravasation compared to vehicle, indicating preserved endothelial barrier integrity and suggesting that the acute upregulation of Hsp70 may be an effective therapeutic approach in the treatment of lung injury associated with pneumonia.
C1 [Li, Xueyi; Yu, Yanfang; Gorshkov, Boris; Haigh, Stephen; Bordan, Zsuzsanna; Weintraub, Daniel; Verin, Alexander D.; Lucas, Rudolf; Chen, Feng; Fulton, David J. R.] Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30904, United States.
C1 [Yu, Yanfang; Chen, Feng] Nanjing Med Univ, Dept Forens Med Nanjing, Nanjing, Jiangsu, China.
C1 [Rudic, Radu Daniel; Barman, Scott A.; Su, Yunchao; Lucas, Rudolf; Stepp, David W.; Fulton, David J. R.] Augusta Univ, Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA, United States.
C1 [Chakraborty, Trinad] Justus Liebig Univ Giessen, Inst Med Microbiol, Giessen, Germany.
C3 University System of Georgia; Augusta University; Nanjing Medical
   University; University System of Georgia; Augusta University; Justus
   Liebig University Giessen
RP Chen, F; Fulton, DJR (corresponding author), Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30904 USA.; Chen, F (corresponding author), Nanjing Med Univ, Dept Forens Med Nanjing, Nanjing, Jiangsu, Peoples R China.; Fulton, DJR (corresponding author), Augusta Univ, Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA USA.
EM fchen@njmu.edu.cn; dfulton@augusta.edu
RI Rudic, Dan/HSH-5268-2023; Stepp, David W/F-4250-2011; Chen,
   Feng/E-1133-2011; Lucas, Rudolf/ABA-3011-2020
OI Rudic, Dan/0000-0001-9122-3127; Chen, Feng/0000-0003-3508-8834; Li,
   Xueyi/0000-0003-2358-5171; Barman, Scott/0000-0001-9085-5122; Verin,
   Alexander/0000-0003-0627-7185
FU NIH [P01 HL101902-01A1, R01HL124773, R01HL125926]; Vice President for
   Research at Augusta University; ADA [1-16-IBS-196]; German Research
   Foundation (DFG) [SFB TR-84]
FX This work was supported by NIH grants P01 HL101902-01A1 (AV and DF),
   R01HL124773 (SB and DF), R01HL125926 (DS and DF), extramural Success
   Award from the Vice President for Research at Augusta University (to
   RL), ADA grant #1-16-IBS-196 (to AV, RL, and DF), as well as by SFB
   grant TR-84 "Innate Immunity of the Lung" from the German Research
   Foundation (DFG) (to TC). RL is a Mercator Fellow of the DFG.
CR Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Bermpohl D, 2005, J CLIN INVEST, V115, P1607, DOI 10.1172/JCI23223
   Boyd AR, 2011, AGING DIS, V2, P487
   Braun JS, 2007, INFECT IMMUN, V75, P4245, DOI 10.1128/IAI.00031-07
   Braun JS, 2002, J CLIN INVEST, V109, P19
   Brocchieri L, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-19
   Caja S, 2017, REDOX BIOL, V12, P821, DOI 10.1016/j.redox.2017.04.021
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Chen CA, 2010, NATURE, V468, P1115, DOI 10.1038/nature09599
   Chen F, 2017, BIOCHEM PHARMACOL, V127, P34, DOI 10.1016/j.bcp.2016.12.014
   Chen F, 2015, FREE RADICAL BIO MED, V89, P793, DOI 10.1016/j.freeradbiomed.2015.09.019
   Chen F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099823
   Chen F, 2012, ARTERIOSCL THROM VAS, V32, P2989, DOI 10.1161/ATVBAHA.112.300361
   Chen F, 2011, ANTIOXID REDOX SIGN, V14, P2107, DOI 10.1089/ars.2010.3669
   Cheng KT, 2017, J CLIN INVEST, V127, P4124, DOI 10.1172/JCI94495
   Chong KY, 1998, J MOL CELL CARDIOL, V30, P599, DOI 10.1006/jmcc.1997.0623
   Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039
   Deocaris CC, 2006, CELL STRESS CHAPERON, V11, P116, DOI 10.1379/CSC-144R.1
   Dessing MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007993
   Di A, 2016, CELL CALCIUM, V60, P163, DOI 10.1016/j.ceca.2016.02.002
   Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033
   Dikalov SI, 2013, AM J PHYSIOL-HEART C, V305, pH1417, DOI 10.1152/ajpheart.00089.2013
   Doughan AK, 2008, CIRC RES, V102, P488, DOI 10.1161/CIRCRESAHA.107.162800
   Dreyfuss D, 2005, CLIN CHEST MED, V26, P105, DOI 10.1016/j.ccm.2004.10.014
   Feldman C, 2002, RESP MED, V96, P580, DOI 10.1053/rmed.2002.1316
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Garcia-Suarez MD, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-3
   Gilbert RJC, 2000, INT J MED MICROBIOL, V290, P389
   Gilbert RJC, 2010, ADV EXP MED BIOL, V677, P56
   Gonzales JN, 2014, AM J PHYSIOL-LUNG C, V306, pL497, DOI 10.1152/ajplung.00086.2013
   Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199
   Hirota K, 2000, BIOCHEM BIOPH RES CO, V275, P825, DOI 10.1006/bbrc.2000.3392
   Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124
   Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kang QX, 2016, J SURG RES, V202, P87, DOI 10.1016/j.jss.2015.12.034
   KOLLER M, 1993, ZBL BAKT-INT J MED M, V278, P365
   Kondrikov D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129343
   Kroller-Schon S, 2014, ANTIOXID REDOX SIGN, V20, P247, DOI 10.1089/ars.2012.4953
   Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001
   Kwon IS, 2017, TOXICON, V129, P100, DOI 10.1016/j.toxicon.2017.02.017
   Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009
   Leu JIJ, 2017, ONCOTARGET, V8, P45656, DOI 10.18632/oncotarget.17321
   Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199
   Li P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122753
   Li XY, 2017, CAN J PHYSIOL PHARM, V95, P247, DOI 10.1139/cjpp-2016-0515
   Lucas R, 2013, TOXINS, V5, P1244, DOI 10.3390/toxins5071244
   Lucas R, 2012, AM J RESP CELL MOL, V47, P445, DOI 10.1165/rcmb.2011-0332OC
   Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321
   Madrigal-Matute J, 2012, CARDIOVASC RES, V95, P116, DOI 10.1093/cvr/cvs158
   Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100
   Martner A, 2008, INFECT IMMUN, V76, P4079, DOI 10.1128/IAI.01747-07
   Matthay MA, 2017, LANCET RESP MED, V5, P524, DOI 10.1016/S2213-2600(17)30188-1
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McCallister C, 2015, BIOCHEM BIOPH RES CO, V467, P835, DOI 10.1016/j.bbrc.2015.10.057
   Mikhed Y, 2015, INT J MOL SCI, V16, P15918, DOI 10.3390/ijms160715918
   Nazarewicz RR, 2013, AM J PHYSIOL-HEART C, V305, pH1131, DOI 10.1152/ajpheart.00063.2013
   Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000
   Nollen EAA, 2002, J CELL SCI, V115, P2809
   Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Otaka M, 2007, BIOCHEM BIOPH RES CO, V353, P399, DOI 10.1016/j.bbrc.2006.12.031
   Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458
   Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201
   Radons J, 2016, CELL STRESS CHAPERON, V21, P379, DOI 10.1007/s12192-016-0676-6
   RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665
   Sharma K, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014654
   Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175
   Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100
   Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033
   TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1
   Tyc J, 2015, MBIO, V6, DOI 10.1128/mBio.02425-14
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   Wang LL, 2012, J APPL PHYSIOL, V113, P1669, DOI 10.1152/japplphysiol.00658.2012
   Weycker D, 2010, VACCINE, V28, P4955, DOI 10.1016/j.vaccine.2010.05.030
   Wippel C, 2011, J INFECT DIS, V204, P930, DOI 10.1093/infdis/jir434
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Xiong CL, 2010, VASC PHARMACOL, V52, P207, DOI 10.1016/j.vph.2009.12.010
   Zhou A, 2012, INT J MOL MED, V29, P1025, DOI 10.3892/ijmm.2012.946
   Zhou CX, 2017, AM J TRANSL RES, V9, P386
   Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3
NR 81
TC 28
Z9 34
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 12
PY 2018
VL 9
AR 1309
DI 10.3389/fimmu.2018.01309
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GJ0WM
UT WOS:000434975200001
PM 29951058
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Geng, P
   Ma, T
   Xing, J
   Jiang, L
   Sun, H
   Zhu, B
   Zhang, H
   Xiao, H
   Wang, J
   Zhang, J
AF Geng, P.
   Ma, T.
   Xing, J.
   Jiang, L.
   Sun, H.
   Zhu, B.
   Zhang, H.
   Xiao, H.
   Wang, J.
   Zhang, J.
TI Dexamethasone ameliorates H2S-induced acute lung injury by increasing
   claudin-5 expression via the PI3K pathway
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Article
DE ALI/ARDS; claudin-5; hydrogen sulfide; dexamethasone; PI3K 
ID PULMONARY ENDOTHELIAL BARRIER; BLOOD-BRAIN-BARRIER; NF-KAPPA-B;
   HYDROGEN-SULFIDE; SIGNALING PATHWAYS; UP-REGULATION; P38 MAPK;
   DYSFUNCTION; INHIBITION; FOXO1
AB Acute lung injury (ALI) is a major outcome of exposure to high levels of hydrogen sulfide (H2S). Dexamethasone (DXM) has been used to treat ALI. However, the mechanisms involved in H2S-induced ALI and the protective mechanisms of DXM in treating ALI are still nebulous. To explore the mechanisms involved, we evaluated the role of claudin-5 in the protective effect of DXM against H2S-induced ALI. Sprague-Dawley rats were exposed to H2S to establish the ALI model. In parallel with the animal model, a cell model was also established by incubating human umbilical vein endothelial cells (HUVECs) with NaHS. Lung hematoxylin-eosin staining, electron microscope assay, and wet/dry ratio were used to identify whether the ALI was successfully induced by H2S, and changes in claudin-5 expression were detected in both rats and HUVECs. Our results revealed that claudin-5 was markedly decreased after H2S exposure and that DXM significantly attenuated the H2S-induced downregulation of claudin-5 in both rats and HUVECs. In the animal experiment, p-Akt and p-FoxO(1) presented a similar tendency as claudin-5, but their levels decreased 6 h prior to the levels of claudin-5. In a further investigation, the DXM-induced protective effect on ALI and rescue effect on downregulation of claudin-5 were both blocked by LY294002. The current study demonstrated that claudin-5 was involved in the development of H2S-induced ALI and that DXM exerted protective effects through increasing claudin-5 expression by activating the phosphatidylinositol 3-kinase pathway. Therefore, claudin-5 might represent a novel pharmacological target for treating ALI induced by H2S and other hazardous gases.
C1 [Geng, P.; Ma, T.; Xing, J.; Jiang, L.; Sun, H.; Zhang, J.] Nanjing Med Univ, Affiliated Hosp 1, Dept Emergency Med, 300 Guangzhou Rd, Nanjing, Jiangsu, China.
C1 [Zhu, B.; Zhang, H.] Jiangsu Prov Ctr Dis Prevent & Control, Dept Occupat Dis Prophylact Therapeut Inst, Nanjing, Jiangsu, China.
C1 [Xiao, H.; Wang, J.] Nanjing Med Univ, Key Lab Modern Toxicol NJMU, Minist Educ, Dept Toxicol,Sch Publ Hlth, Nanjing, Jiangsu, China.
C3 Nanjing Medical University; Nanjing Medical University
RP Zhang, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Emergency Med, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China.; Wang, J (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Toxicol, Nanjing 211166, Jiangsu, Peoples R China.
EM wangjun@njmu.edu.cn; zhangjsojz@163.com
CR Adachi T, 2012, ARCH BIOCHEM BIOPHYS, V520, P30, DOI 10.1016/j.abb.2012.01.014
   Al-Harbi NO, 2016, IMMUNOL INVEST, V45, P349, DOI 10.3109/08820139.2016.1157814
   Asif MJ, 2012, RESP CARE, V57, P307, DOI 10.4187/respcare.01038
   BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321
   Chen H, 2008, J BIOL CHEM, V283, P29228, DOI 10.1074/jbc.M802906200
   Chen WG, 2014, AM J RESP CELL MOL, V50, P328, DOI 10.1165/rcmb.2013-0058OC
   Crossland H, 2010, J PHYSIOL-LONDON, V588, P1333, DOI 10.1113/jphysiol.2009.183699
   Dalmasso AP, 2014, J BIOL CHEM, V289, P838, DOI 10.1074/jbc.M113.455766
   Dorman DC, 2000, NEUROTOXICOL TERATOL, V22, P71, DOI 10.1016/S0892-0362(99)00055-0
   Eghbal MA, 2004, TOXICOLOGY, V203, P69, DOI 10.1016/j.tox.2004.05.020
   Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038
   Gavard J, 2008, NAT CELL BIOL, V10, P883, DOI 10.1038/ncb0808-883
   Gross CM, 2014, J CELL PHYSIOL, V229, P1802, DOI 10.1002/jcp.24633
   Guo RM, 2013, INT J MOL MED, V31, P644, DOI 10.3892/ijmm.2013.1246
   He Dai-Kun, 2011, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V29, P289
   Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC
   Jiang L, 2015, INHAL TOXICOL, V27, P613, DOI 10.3109/08958378.2015.1048909
   Kaarteenaho R, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-59
   Keil JM, 2013, INVEST OPHTH VIS SCI, V54, P4007, DOI 10.1167/iovs.13-11980
   Li QR, 2009, J CELL MOL MED, V13, P4061, DOI 10.1111/j.1582-4934.2009.00975.x
   Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028
   Mokra D, 2013, ADV EXP MED BIOL, V756, P189, DOI 10.1007/978-94-007-4549-0_24
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Oesterhelweg L, 2008, INT J LEGAL MED, V122, P101, DOI 10.1007/s00414-007-0172-8
   Overgaard CE, 2011, ANTIOXID REDOX SIGN, V15, P1179, DOI 10.1089/ars.2011.3893
   Sadowska GB, 2010, AM J PHYSIOL-HEART C, V298, pH179, DOI 10.1152/ajpheart.00828.2009
   Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033
   Soma T, 2004, EXP CELL RES, V300, P202, DOI 10.1016/j.yexcr.2004.07.012
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Wang JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096899
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje
   Xia XM, 2010, WORLD J GASTROENTERO, V16, P2994, DOI 10.3748/wjg.v16.i24.2994
   Zhang HL, 2007, J IMMUNOL, V179, P4153, DOI 10.4049/jimmunol.179.6.4153
NR 34
TC 10
Z9 14
U1 1
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD JUN
PY 2018
VL 37
IS 6
BP 626
EP 635
DI 10.1177/0960327117721961
PG 10
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA GF6IV
UT WOS:000432071400008
PM 28741371
DA 2023-08-21
ER

PT J
AU Song, NP
   Li, P
   Jiang, YT
   Sun, H
   Cui, J
   Zhao, GY
   Li, D
   Guo, Y
   Chen, YH
   Gao, JM
   Sun, SH
   Zhou, YS
AF Song, Nianping
   Li, Pei
   Jiang, Yuting
   Sun, Hong
   Cui, Jing
   Zhao, Guangyu
   Li, Dan
   Guo, Yan
   Chen, Yuehong
   Gao, Jimin
   Sun, Shihui
   Zhou, Yusen
TI C5a receptor1 inhibition alleviates influenza virus-induced acute lung
   injury
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE complement; C5aR1 inhibition; ALI/ARDS; influenza; immune response 
ID RESPIRATORY-DISTRESS-SYNDROME; TUMOR-NECROSIS-FACTOR; CD8(+) T-CELLS;
   GENE-EXPRESSION; H5N1 VIRUS; ENDOTHELIAL-CELLS; IMMUNE-RESPONSES;
   IFN-GAMMA; TNF-ALPHA; INFECTION
AB Influenza A virus is an important human pathogen that causes 3 to 5 million severe cases of influenza worldwide each year. An aberrant innate immune response, particularly hypercytokinemia, is thought to play an important role in the disease, although the pathogenesis of severe influenza virus infection remains unclear and no specific and efficacious immunotherapy is available. This study reports dysregulated complement activation in mice after infection with A/Puerto Rico/8/34 (PR8). C5aR1-deficient mice and mice treated with an anti-C5aR1 antibody were used as models to study the C5a-C5aR1 axis during acute lung injury (ALI) induced by influenza virus infection. The results showed that blocking the C5a-C5aR1 axis alleviated ALI by inhibiting endothelial cell activation and dampening the host immune response (i.e., reduced TNF-alpha, IL-beta, IL-6, IP-10, MCP-1, IL-12p70, and IFN-gamma concentrations in plasma), particularly CM-mediated immunopathology. Furthermore, blockade of the C5a-C5aR1 axis inhibited viral replication in lung tissue. Taken together, the results indicate that the C5a-C5aR1 axis plays an important role in the outcome of All induced by influenza virus infection and that regulation of complement activation, particularly the C5aR1 inhibition, is a promising intervention and adjunctive treatment.
C1 [Song, Nianping; Gao, Jimin; Zhou, Yusen] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou 325035, Zhejiang, China.
C1 [Song, Nianping; Li, Pei; Jiang, Yuting; Zhao, Guangyu; Li, Dan; Guo, Yan; Chen, Yuehong; Sun, Shihui; Zhou, Yusen] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, China.
C1 [Sun, Hong; Cui, Jing] North China Univ Sci & Technol, Dept Basic Med Sci, Tangshan 063210, China.
C3 Wenzhou Medical University; Beijing Institute of Microbiology &
   Epidemiology; North China University of Science & Technology
RP Sun, SH; Zhou, YS (corresponding author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.; Zhou, YS (corresponding author), Sch Lab Med & Life Sci, Wenzhou 325035, Zhejiang, Peoples R China.
EM sunsh01@163.com; yszhou@bmi.ac.cn
RI Jiang, Yuting/HLW-3078-2023; Gao, Jimin/IVV-3983-2023
FU National Key Plan for Scientific Research and Development of China
   [2016YFD0500306]; National Nature Science Foundation of China [81371805,
   81571983]; Program of National Ministry of Science and Technology
   [2014ZX09J14105-04B]; National Project of Infectious Diseases
   [2017-ZX10304402-003]; State Key Laboratory of Pathogen and Biosecurity
   [SKLPBS1509]
FX This work was supported by grants from the National Key Plan for
   Scientific Research and Development of China (2016YFD0500306), the
   National Nature Science Foundation of China (81371805 and 81571983), the
   Program of National Ministry of Science and Technology
   (2014ZX09J14105-04B), the National Project of Infectious Diseases
   (2017-ZX10304402-003) and by funding from the State Key Laboratory of
   Pathogen and Biosecurity (SKLPBS1509).
CR Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2
   Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166
   Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355
   Chen GJ, 2011, LAB INVEST, V91, P472, DOI 10.1038/labinvest.2010.183
   Clancy R M, 1985, Prog Biochem Pharmacol, V20, P120
   Cohen ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020597
   Dawson TC, 2000, AM J PATHOL, V156, P1951, DOI 10.1016/S0002-9440(10)65068-7
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   DeBerge MP, 2014, J IMMUNOL, V192, P5839, DOI 10.4049/jimmunol.1302729
   DeBerge MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079340
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006
   Herold S, 2015, EUR RESPIR J, V45, P1463, DOI 10.1183/09031936.00186214
   Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065
   Hsu MH, 1999, BLOOD, V93, P3241, DOI 10.1182/blood.V93.10.3241.410k02_3241_3249
   Hu R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.274
   Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665
   Jacob A, 2010, J NEUROIMMUNOL, V221, P46, DOI 10.1016/j.jneuroim.2010.02.011
   Kang MC, 2016, J VIROL, V90, P2273, DOI 10.1128/JVI.02768-15
   Karsten CM, 2012, IMMUNOBIOLOGY, V217, P1067, DOI 10.1016/j.imbio.2012.07.015
   Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495
   Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4
   Lalli PN, 2007, J IMMUNOL, V179, P5793, DOI 10.4049/jimmunol.179.9.5793
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Liu AN, 1999, AM J RESP CELL MOL, V20, P849, DOI 10.1165/ajrcmb.20.5.3585
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Ng HH, 2012, EXP MOL PATHOL, V92, P287, DOI 10.1016/j.yexmp.2012.03.003
   Nyakoe NK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-7
   Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v
   Patel SN, 2008, J EXP MED, V205, P1133, DOI 10.1084/jem.20072248
   Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115
   Perrone LA, 2010, J INFECT DIS, V202, P1161, DOI 10.1086/656365
   Pollara J, 2011, CYTOM PART A, V79A, P603, DOI 10.1002/cyto.a.21084
   Ramana CV, 2015, AM J PHYSIOL-LUNG C, V308, pL650, DOI 10.1152/ajplung.00360.2014
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   SCHINDLER R, 1990, BLOOD, V76, P1631
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Song DL, 2017, MOL VIS, V23, P210
   Stoermer KA, 2011, VIROLOGY, V411, P362, DOI 10.1016/j.virol.2010.12.045
   Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001
   Sun SH, 2015, CLIN INFECT DIS, V60, P586, DOI 10.1093/cid/ciu887
   Sun SH, 2013, AM J RESP CELL MOL, V49, P221, DOI 10.1165/rcmb.2012-0428OC
   Sun SH, 2011, AM J RESP CELL MOL, V45, P834, DOI 10.1165/rcmb.2010-0444OC
   Teijaro JR, 2014, P NATL ACAD SCI USA, V111, P3799, DOI 10.1073/pnas.1400593111
   Toapanta FR, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-112
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044
   Weaver DJ, 2010, EUR J IMMUNOL, V40, P710, DOI 10.1002/eji.200939333
   WELLS MA, 1981, J IMMUNOL, V126, P1036
   Williams T. J., 2001, NOVART FDN SYMP, V234, P141
   Williams TJ, 2001, NOVART FDN SYMP, V234, P136
   Xu LM, 2004, J IMMUNOL, V173, P721, DOI 10.4049/jimmunol.173.2.721
   Zeng H, 2012, J VIROL, V86, P667, DOI 10.1128/JVI.06348-11
   Zhao GY, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-9
NR 60
TC 16
Z9 18
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2018
VL 59
BP 12
EP 20
DI 10.1016/j.intimp.2018.03.029
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA GH9QR
UT WOS:000434004500002
PM 29621732
DA 2023-08-21
ER

PT J
AU Zhang, XL
   Zhuang, R
   Wu, HY
   Chen, J
   Wang, FY
   Li, GP
   Wu, CY
AF Zhang, Xiaolong
   Zhuang, Rong
   Wu, Haiya
   Chen, Jie
   Wang, Fangyan
   Li, Guoping
   Wu, Chengyun
TI A novel role of endocan in alleviating LPS-induced acute lung injury
SO LIFE SCIENCES
LA English
DT Article
DE Endocan; LPS; ALI/ARDS; apoptosis; Mitochondrial UPR; Cellular bioenergetics 
ID CELL SPECIFIC MOLECULE-1; VEGF-A; EXPRESSION; ACTIVATION; ENDOTOXIN;
   RESPONSES; BINDING; MARKER; TARGET; ESM-1
AB Aims: Endotoxin induced acute lung injury (ALI) is a critical complication of some clinical illnesses. Endothelial cell dysfunction and excessive pro-inflammation cytokine release are pivotal to the injury of alveolar-capillary membrane which is the typical characteristic of endotoxic lung injury. As a potential marker of endothelial cells, endocan plays an important role in many endothelial-dependent pathophysiological diseases. We speculated that endocan have anti-inflammatory property in ALI. Here, we investigated the role of endocan in LPS-induced ALI. Materials and methods: Mice were randomly divided into 4 groups. LPS were used to construct ALI mice model by aerosolization for 20 min. Endocan was intraperitoneal injected at 30 min before LPS exposure. Levels of TNF-alpha, IFN-gamma, IL-1 beta, IL-6 and MPO activities were detected by indicated ELISA. Cell apoptotic rate was determined by Annexin V/PI kit, ROS level and MPTP were detected by DCFH-DA and JC-1 kit, respectively. Seahorse XF96 was applied to evaluate the alteration of OCR and ECAR. Western blot and qRT-PCR were used to detect indicated molecules.
   Key findings: Endocan effectively decreased TNF-alpha, IFN-gamma, IL-1 beta, and IL-6 levels as well as relieved pulmonary epithelium cell apoptosis caused by LPS exposure. Endocan significantly reversed LPS induced UPRmt and promoted cell metabolism reprogramming which were crucial for the protective characteristic of endocan in ALI mice model.
   Significance: The above findings suggested endocan could significantly suppress inflammatory response in ALI model through attenuating UPRmt associated apoptosis and switch cellular bioenergetics, indicating endocan could be considered as a promising compound against LPS induced ALI.
C1 [Zhang, Xiaolong; Zhuang, Rong; Wu, Haiya; Chen, Jie] Wenzhou Med Univ, Dept Anesthesiol Crit Care & Pain Med, Affiliated Hosp 2, 109 Xueyuan Western Rd, Wenzhou 325027, Zhejiang, China.
C1 [Zhang, Xiaolong; Zhuang, Rong; Wu, Haiya; Chen, Jie; Wu, Chengyun] Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan Western Rd, Wenzhou 325027, Zhejiang, China.
C1 [Wang, Fangyan] Wenzhou Med Univ, Dept Pathophysiol, Wenzhou 325027, Zhejiang, China.
C1 [Li, Guoping] Tongde Hosp Zhejiang Prov, Dept Resp Med, Hangzhou, Zhejiang, China.
C1 [Wu, Chengyun] Wenzhou Med Univ, Dept Resp Med, Affiliated Hosp 2, Wenzhou 325027, China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University
RP Wu, CY (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan Western Rd, Wenzhou 325027, Zhejiang, Peoples R China.; Li, GP (corresponding author), Tongde Hosp Zhejiang Prov, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China.; Wu, CY (corresponding author), Wenzhou Med Univ, Dept Resp Med, Affiliated Hosp 2, Wenzhou 325027, Peoples R China.
EM wzmclgp@163.com; wcy857516126@163.com
FU National Natural Science Foundation of China [30772088]; Wenzhou
   Municipal Science and Technology Bureau [Y20140670]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30772088, C.Y.), and the Wenzhou Municipal Science
   and Technology Bureau (Y20140670, X.Z.).
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Altmann C, 2012, AM J PHYSIOL-RENAL, V302, pF421, DOI 10.1152/ajprenal.00559.2010
   Bechard D, 2001, J IMMUNOL, V167, P3099, DOI 10.4049/jimmunol.167.6.3099
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033
   Gray KD, 2003, AM J SURG, V186, P526, DOI 10.1016/j.amjsurg.2003.07.010
   Han X, 2016, EXP THER MED, V11, P788, DOI 10.3892/etm.2016.2988
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535
   Jin SW, 2007, ANESTH ANALG, V104, P369, DOI 10.1213/01.ane.0000252414.00363.c4
   Kang YH, 2012, CELL SIGNAL, V24, P1940, DOI 10.1016/j.cellsig.2012.06.004
   Kechagia M, 2016, INT J CHRONIC OBSTR, V11, P3179, DOI 10.2147/COPD.S118692
   Lee W, 2014, J CELL PHYSIOL, V229, P620, DOI 10.1002/jcp.24485
   Lin YF, 2016, MOL CELL, V61, P677, DOI 10.1016/j.molcel.2016.02.004
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Maurage CA, 2009, J NEUROPATH EXP NEUR, V68, P633, DOI 10.1097/NEN.0b013e3181a52a7f
   Mikkelsen ME, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.07.077
   Obi AT, 2016, J VASC RES, V53, P186, DOI 10.1159/000447299
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Perey L, 2001, BRIT J CANCER, V85, P1713, DOI 10.1054/bjoc.2001.2177
   Rath E, 2012, INFLAMM BOWEL DIS, V18, P1364, DOI 10.1002/ibd.21944
   Rennel E, 2007, EXP CELL RES, V313, P1285, DOI 10.1016/j.yexcr.2007.01.021
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sarrazin S, 2006, BBA-REV CANCER, V1765, P25, DOI 10.1016/j.bbcan.2005.08.004
   Sarrazin S, 2010, GLYCOBIOLOGY, V20, P1380, DOI 10.1093/glycob/cwq100
   Scherpereel A, 2006, CRIT CARE MED, V34, P532, DOI 10.1097/01.CCM.0000198525.82124.74
   Shin JW, 2008, BLOOD, V112, P2318, DOI 10.1182/blood-2008-05-156331
   Tissier S, 2004, SHOCK, V21, P352, DOI 10.1097/00024382-200404000-00010
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Xiong J. X., 2004, J CLIN EXP PATHOL, V20, P187
   Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601
   Zhang SM, 2012, BIOTECH HISTOCHEM, V87, P172, DOI 10.3109/10520295.2011.577754
   Zhao WY, 2014, TUMOR BIOL, V35, P10043, DOI 10.1007/s13277-014-2287-0
   Zuo L, 2008, WORLD J GASTROENTERO, V14, P4562, DOI 10.3748/wjg.14.4562
NR 34
TC 17
Z9 20
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUN 1
PY 2018
VL 202
BP 89
EP 97
DI 10.1016/j.lfs.2018.04.005
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GH6MS
UT WOS:000433559000011
PM 29627442
DA 2023-08-21
ER

PT J
AU Soni, D
   Wang, DM
   Regmi, SC
   Mittal, M
   Vogel, SM
   Schluter, D
   Tiruppathi, C
AF Soni, Dheeraj
   Wang, Dong-Mei
   Regmi, Sushil C.
   Mittal, Manish
   Vogel, Stephen M.
   Schlueter, Dirk
   Tiruppathi, Chinnaswamy
TI Deubiquitinase function of A20 maintains and repairs endothelial barrier
   after lung vascular injury
SO CELL DEATH DISCOVERY
LA English
DT Article
ID NF-KAPPA-B; RESPIRATORY-DISTRESS-SYNDROME; MODIFYING ENZYME A20;
   IN-VIVO; LEUKOCYTE EXTRAVASATION; VE-CADHERIN; RESTRICTS UBIQUITINATION;
   ADHERENS JUNCTIONS; PROTECTS CELLS; CA2+ ENTRY
AB Vascular endothelial cadherin (VE-cad) expression at endothelial adherens junctions (AJs) regulates vascular homeostasis. Here we show that endothelial A20 is required for VE-cad expression at AJs to maintain and repair the injured endothelial barrier. In endothelial cell (EC)-restricted Tnfaip3 (A20) knockout (A20(Delta EC))mice, LPS challenge caused uncontrolled lung vascular leak and persistent sequestration of polymorphonuclear neutrophil (PMNs). Importantly, A20(Delta EC) mice exhibited drastically reduced VE-cad expression in lungs compared with wild-type counterparts. Endothelial expression of wild-type A20 but not the deubiquitinase-inactive A20 mutant (A20(C103A)) prevented VE-cad ubiquitination, restored VE-cad expression, and suppressed lung vascular leak in A20(Delta EC) mice. Interestingly, IRAK-Mmediated nuclear factor-kappa B (NE-kappa B) signaling downstream of TLR4 was required for A20 expression in ECs. interleukin-1 receptor-associated kinase M (IRAK-M) knockdown suppressed basal and LPS-induced A20 expression in ECs. Further, in vivo silencing of IRAK-M in mouse lung vascular ECs through the CRISPR-Cas9 system prevented expression of A20 and VE-cad while augmenting lung vascular leak. These results suggest that targeting of endothelial A20 is a potential therapeutic strategy to restore endothelial barrier integrity in the setting of acute lung injury.
C1 [Soni, Dheeraj; Wang, Dong-Mei; Regmi, Sushil C.; Mittal, Manish; Vogel, Stephen M.; Tiruppathi, Chinnaswamy] Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60607, United States.
C1 [Soni, Dheeraj; Wang, Dong-Mei; Regmi, Sushil C.; Mittal, Manish; Vogel, Stephen M.; Tiruppathi, Chinnaswamy] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60607, United States.
C1 [Schlueter, Dirk] Otto von Guericke Univ, Inst Med Microbiol & Hosp Hyg, Magdeburg, Germany.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   Otto von Guericke University
RP Tiruppathi, C (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60607 USA.; Tiruppathi, C (corresponding author), Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60607 USA.
EM tiruc@uic.edu
RI Soni, Dheeraj/P-5496-2017
OI Soni, Dheeraj/0000-0002-5555-2051
FU National Institutes of Health [R01HL128359, R01GM117028, R01HL122157]
FX This work was supported by National Institutes of Health Grants
   R01HL128359, R01GM117028, and R01HL122157.
CR Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110
   BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229
   Coornaert B, 2009, J BIOL CHEM, V284, P8217, DOI 10.1074/jbc.R800032200
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Deng JC, 2006, J CLIN INVEST, V116, P2532, DOI 10.1172/JCI28054
   Duong BH, 2015, IMMUNITY, V42, P55, DOI 10.1016/j.immuni.2014.12.031
   Frye M, 2015, J EXP MED, V212, P2267, DOI 10.1084/jem.20150718
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Gong HX, 2014, J EXP MED, V211, P579, DOI 10.1084/jem.20131190
   Gotsch U, 1997, J CELL SCI, V110, P583
   Herwig MC, 2013, PATHOBIOLOGY, V80, P245, DOI 10.1159/000347062
   Hovelmeyer N, 2011, EUR J IMMUNOL, V41, P595, DOI 10.1002/eji.201041313
   Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4
   Just S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39796
   Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9
   Komander D, 2008, BIOCHEM J, V409, P77, DOI 10.1042/BJ20071399
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lin SC, 2008, J MOL BIOL, V376, P526, DOI 10.1016/j.jmb.2007.11.092
   Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mittal M, 2017, CIRC RES, V121, P1081, DOI 10.1161/CIRCRESAHA.117.311747
   Onizawa M, 2015, NAT IMMUNOL, V16, P618, DOI 10.1038/ni.3172
   OPIPARI AW, 1992, J BIOL CHEM, V267, P12424
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Paria BC, 2003, J BIOL CHEM, V278, P37195, DOI 10.1074/jbc.M304287200
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Schlegel N, 2009, CRIT CARE MED, V37, P1735, DOI 10.1097/CCM.0b013e31819deb6a
   Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304
   Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Soni D, 2017, AM J PHYSIOL-LUNG C, V312, pL1003, DOI 10.1152/ajplung.00008.2017
   Sundivakkam PC, 2013, J BIOL CHEM, V288, P17030, DOI 10.1074/jbc.M112.411272
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919
   Tiruppathi C, 2014, NAT IMMUNOL, V15, P239, DOI 10.1038/ni.2823
   Vereecke L, 2010, J EXP MED, V207, P1513, DOI 10.1084/jem.20092474
   Vestweber D, 2014, SEMIN IMMUNOPATHOL, V36, P177, DOI 10.1007/s00281-014-0419-7
   Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794
   Wertz IE, 2015, NATURE, V528, P370, DOI 10.1038/nature16165
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Zhou H, 2013, EMBO J, V32, P583, DOI 10.1038/emboj.2013.2
   Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407
NR 48
TC 17
Z9 17
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD MAY 16
PY 2018
VL 4
AR 60
DI 10.1038/s41420-018-0056-3
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HR4WB
UT WOS:000463147000001
PM 29796309
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Yang, JX
   Ruan, F
   Zheng, ZJ
AF Yang, Jianxin
   Ruan, Feng
   Zheng, Zhongjun
TI Ripasudil Attenuates Lipopolysaccharide (LPS)-Mediated Apoptosis and
   Inflammation in Pulmonary Microvascular Endothelial Cells via ROCK2/eNOS
   Signaling
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE ALI/ARDS; apoptosis; Inflammation; Rho/RhoA 
ID RHOA/ROCK PATHWAY; INHIBITOR; ACTIVATION; K-115
AB Background: Microvascular endothelial inflammation and apoptosis are responsible for septic acute lung injury (ALI). Ripasudil is a novel Rho/Rho kinase (ROCK) inhibitor which shows therapeutic effects on several vascular diseases. The aim of this study was to investigate the protective effects and correlated molecular mechanisms of ripasudil on lipopolysaccharide- induced inflammation and apoptosis of pulmonary microvascular endothelial cells (PMVECs).
   Material/Methods: Cultured PMVECs were exposed to lipopolysaccharide (LPS). Ripasudil at various concentrations was used to treat the cells. Several cells were also co-administrated with the endothelial nitric oxide synthase (eNOS) inhibitor P-Nitro-L-arginine methyl ester hydrochloride (L-NAME). Cell viability was assessed by MTT assay. Terminal dUTP transferase nick-end labeling (TUNEL) assay was used to detect the apoptosis. The colorimetric method was used to measure the activity of eNOS and ROCK2. Protein phosphorylation and expression were assessed by Western blotting.
   Results: Ripasudil attenuated the LPS-induced inflammation and apoptosis in PMVECs, which was reversed by L-NAME. Ripasudil suppressed ROCK2 activity and further increased the eNOS activity. Ripasudil treatment increased the phosphorylation of eNOS, increased the expression level of Bcl2, and decreased the expression level of active caspase3 in LPS-treated PMVECs. Moreover, the ripasudil treatment also inhibited the nuclear translocation of NF-kappa B and further suppressed the levels of interleukin (IL) 6 and tumor necrosis factor (TNF) alpha. The co-treatment with L-NAME, however, impaired the anti-apoptotic and anti-inflammatory effects of ripasudil on PMVECs without affecting ROCK2.
   Conclusions: The novel ROCK2 inhibitor ripasudil suppressed LPS-induced apoptosis and inflammation in PMVECs by regulating the ROCK2/eNOS signaling pathway.
C1 [Yang, Jianxin; Ruan, Feng; Zheng, Zhongjun] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Emergency, Hangzhou, Zhejiang, China.
C3 Zhejiang University
RP Ruan, F (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Emergency, Hangzhou, Zhejiang, Peoples R China.
EM 20918166@zju.edu.cn
RI yang, jian/HIK-0188-2022
CR Bai XL, 2017, ONCOTARGET, V8, P103985, DOI 10.18632/oncotarget.21944
   Bell M, 2017, NEURAL REGEN RES, V12, P572, DOI 10.4103/1673-5374.205091
   Chung HH, 2010, BRIT J PHARMACOL, V160, P971, DOI 10.1111/j.1476-5381.2010.00740.x
   Cicek FA, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-51
   Crestani S, 2017, AM J HYPERTENS, V30, P389, DOI 10.1093/ajh/hpw201
   Deng HF, 2017, LIFE SCI, V191, P115, DOI 10.1016/j.lfs.2017.10.018
   Dharwal V, 2018, BIOCHEM PHARMACOL, V150, P24, DOI 10.1016/j.bcp.2018.01.027
   Ediriweera MK, 2016, J ETHNOPHARMACOL, V189, P165, DOI 10.1016/j.jep.2016.05.047
   Feng YB, 2016, J MED CHEM, V59, P2269, DOI 10.1021/acs.jmedchem.5b00683
   Hamacher J, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01644
   Huang Y, 2014, ASIAN PAC J TROP MED, V7, P884, DOI 10.1016/S1995-7645(14)60154-1
   Isobe T, 2014, CURR EYE RES, V39, P813, DOI 10.3109/02713683.2013.874444
   Janeczko M, 2017, YEAST, V34, P253, DOI 10.1002/yea.3230
   Kim JE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102228
   Liu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146051
   Lv JW, 2017, MICROVASC RES, V109, P45, DOI 10.1016/j.mvr.2016.10.001
   Menden H, 2015, J BIOL CHEM, V290, P5449, DOI 10.1074/jbc.M114.600692
   Uchida T, 2017, INVEST OPHTH VIS SCI, V58, P5584, DOI 10.1167/iovs.17-22679
   Wang YX, 2013, INT J MOL MED, V32, P568, DOI 10.3892/ijmm.2013.1420
   Yu JB, 2016, SCI REP-UK, V6, DOI 10.1038/srep36530
   Yuan QH, 2018, PULM PHARMACOL THER, V48, P144, DOI 10.1016/j.pupt.2017.11.007
   Zhu WX, 2017, MOL MED REP, V16, P9361, DOI 10.3892/mmr.2017.7824
NR 22
TC 20
Z9 22
U1 2
U2 15
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAY 16
PY 2018
VL 24
BP 3212
EP 3219
DI 10.12659/MSM.910184
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GF8XP
UT WOS:000432259800002
PM 29766980
OA Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Huang, WC
   Huang, MC
   Ouyang, H
   Peng, JW
   Liang, J
AF Huang, Weichen
   Huang, Mingcheng
   Ouyang, Hui
   Peng, Jingwen
   Liang, Jiang
TI Oridonin inhibits vascular inflammation by blocking NF-kappa B and MAPK
   activation
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE oridonin; ECs/HPMECs/HUVECs/MPVECs; vascular inflammation 
ID ENDOTHELIAL-CELLS; EXPRESSION; ATHEROSCLEROSIS; ADHESION; PATHWAY;
   DISEASE; DYSFUNCTION; PROTEIN-1
AB Oridonin, an active diterpenoid compound isolated from the plant Rabdosia Rrubescens, has various pharmacological activities, including antioxidant, anti-tumor capacities and anti-inflammation. In the present study, we explore the role of oridonin in regulating endothelial inflammation and its underlying mechanism. Endothelial cell-monocyte interaction was detected by Leukocyte-endothelium Adhesion Assay. The protein expression was measured by Western blot. NF-kappa B p65 translocation was measured by immunofluorescence. Acute lung inflammation model was used to evaluate leukocyte infiltration in vivo. The endothelial-leukocyte adhesion and the leukocyte transmigration were profoundly reduced by oridonin. Oridonin dramatically inhibited the expression of TNF-alpha-induced endothelial adhesion molecules (intercellular adhesion molecule-1 (ICAM-1); vascular cell adhesion molecule-1 (VCAM-1) and E-selectin) and the pro-inflammatory cytokine (IL-6, IL-8 and monocyte chemoattractant protein-1(MCP-1)). Oridonin suppressed the penetration of the leukocyte in the acute lung injury mice model. Furthermore, Oridonin also suppressed the TNF-alpha-activated MAPK and Nuclear factor kappa B (NF-kappa B) activation. Our results suggest that oridonin has the anti-inflammatory properties in endothelial cells, at least in part, through the suppression of MAPK and NF-kappa B activation, which may have a potential therapeutic use for inflammatory vascular diseases.
C1 [Huang, Weichen] Guiyang Coll Tradit Chinese Med, Affiliated Hosp 2, Dept Orthoped 1, Guiyang, Guizhou, China.
C1 [Huang, Mingcheng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Guangdong, China.
C1 [Ouyang, Hui] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Gastroenterol, Shenzhen, Guandong, China.
C1 [Peng, Jingwen] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rehabil Med, Guangzhou, Guandong, China.
C1 [Liang, Jiang] Guiyang Coll Tradit Chinese Med, Collaborat Innovat Ctr Miao Med, Guiyang, Guizhou, China.
C3 Guizhou University of Traditional Chinese Medicine; Sun Yat Sen
   University; Sun Yat Sen University; Sun Yat Sen University; Guizhou
   University of Traditional Chinese Medicine
RP Huang, WC (corresponding author), Guiyang Coll Tradit Chinese Med, Affiliated Hosp 2, Dept Orthoped 1, Guiyang, Guizhou, Peoples R China.; Liang, J (corresponding author), Guiyang Coll Tradit Chinese Med, Collaborat Innovat Ctr Miao Med, Guiyang, Guizhou, Peoples R China.
EM huangweichen1573@sina.com; liangjiang1573@hotmail.com
RI huang, mingcheng/AAB-4543-2022
FU National Natural Science Foundation of China (Less Developed regions)
   [81560817]; Guizhou Provinceial Science and Technology Funds, China
   [[2013]2074]; Research Foundation for Young Scholars of Education Bureau
   of guizhou Province [[2015]438]; State Key Program for Basic Research of
   Guizhou Province [[2015]2002]
FX This work was supported by National Natural Science Foundation of China
   (Less Developed regions) (Grant No. 81560817).; the Guizhou Provinceial
   Science and Technology Funds, China (Grant No. [2013]2074); the Research
   Foundation for Young Scholars of Education Bureau of guizhou Province
   (Grant No. [2015]438); Project supported by the State Key Program for
   Basic Research of Guizhou Province (Grant No. [2015]2002).
CR Aird WC, 2007, CURR DRUG TARGETS, V8, P501, DOI 10.2174/138945007780362782
   Al-Amran FG, 2014, PHARMACOLOGY, V93, P296, DOI 10.1159/000363657
   Bao RF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-217
   Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2
   Chen M, 2002, CIRCULATION, V106, P2707, DOI 10.1161/01.CIR.0000038706.30661.86
   Cines DB, 1998, BLOOD, V91, P3527
   Cook-Mills JM, 2011, ANTIOXID REDOX SIGN, V15, P1607, DOI 10.1089/ars.2010.3522
   Gareus R, 2008, CELL METAB, V8, P372, DOI 10.1016/j.cmet.2008.08.016
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Guo Y, 2012, CANCER BIOL THER, V13, P1244, DOI 10.4161/cbt.21460
   Han QB, 2004, CHEM PHARM BULL, V52, P767, DOI 10.1248/cpb.52.767
   Harrison D, 2003, AM J CARDIOL, V91, p7A
   Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0
   Hoefen RJ, 2002, VASC PHARMACOL, V38, P271, DOI 10.1016/S1537-1891(02)00251-3
   Kempe S, 2005, NUCLEIC ACIDS RES, V33, P5308, DOI 10.1093/nar/gki836
   Khan F, 2010, NAT REV RHEUMATOL, V6, P253, DOI 10.1038/nrrheum.2010.44
   Ku CM, 2013, FOOD CHEM, V141, P1104, DOI 10.1016/j.foodchem.2013.04.044
   Kuo LM, 2014, MOLECULES, V19, P3327, DOI 10.3390/molecules19033327
   Liang CJ, 2011, FREE RADICAL BIO MED, V51, P1337, DOI 10.1016/j.freeradbiomed.2011.06.023
   Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368
   Molestina RE, 2000, INFECT IMMUN, V68, P4282, DOI 10.1128/IAI.68.7.4282-4288.2000
   Nizamutdinova IT, 2007, INT IMMUNOPHARMACOL, V7, P343, DOI 10.1016/j.intimp.2006.11.004
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753
   Robinson April, 2014, Nurse Pract, V39, P10, DOI 10.1097/01.NPR.0000450384.22603.87
   Roifman I, 2009, CLIN GASTROENTEROL H, V7, P175, DOI 10.1016/j.cgh.2008.10.021
   Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tian Y, 2009, AM J PHYSIOL-CELL PH, V296, pC256, DOI 10.1152/ajpcell.00325.2008
NR 29
TC 51
Z9 59
U1 0
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAY 5
PY 2018
VL 826
BP 133
EP 139
DI 10.1016/j.ejphar.2018.02.044
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GA3UL
UT WOS:000428255000016
PM 29518395
DA 2023-08-21
ER

PT J
AU Gross, CM
   Kellner, M
   Wang, T
   Lu, Q
   Sun, XT
   Zemskov, EA
   Noonepalle, S
   Kangath, A
   Kumar, S
   Gonzalez-Garay, M
   Desai, AA
   Aggarwal, S
   Gorshkov, B
   Klinger, C
   Verin, AD
   Catravas, JD
   Jacobson, JR
   Yuan, JXJ
   Rafikov, R
   Garcia, JGN
   Black, SM
AF Gross, Christine M.
   Kellner, Manuela
   Wang, Ting
   Lu, Qing
   Sun, Xutong
   Zemskov, Evgeny A.
   Noonepalle, Satish Kumar
   Kangath, Archana
   Kumar, Sanjiv
   Gonzalez-Garay, Manuel
   Desai, Ankit A.
   Aggarwal, Saurabh
   Gorshkov, Boris A.
   Klinger, Christina
   Verin, Alexander D.
   Catravas, John D.
   Jacobson, Jeffrey R.
   Yuan, Jason X-J.
   Rafikov, Ruslan
   Garcia, Joe G. N.
   Black, Stephen M.
TI LPS-induced Acute Lung Injury Involves NF-kappa B-mediated
   Downregulation of SOX18
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; RESPIRATORY-DISTRESS-SYNDROME; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; DNA METHYLATION; CLAUDIN-5 GENE; ALPHA; KINASE;
   PHOSPHORYLATION; TRANSCRIPTION
AB One of the early events in the progression of LPS-mediated acute lung injury in mice is the disruption of the pulmonary endothelial barrier resulting in lung edema. However, the molecular mechanisms by which the endothelial barrier becomes compromised remain unresolved. The SRY (sex-determining region on the Y chromosome)-related high-mobility group box (Sox) group F family member, SOX18, is a barrier-protective protein through its ability to increase the expression of the tight junction protein CLDN5. Thus, the purpose of this study was to determine if downregulation of the SOX18-CLDN5 axis plays a role in the pulmonary endothelial barrier disruption associated with LPS exposure. Our data indicate that both SOX18 and CLDN5 expression is decreased in two models of in vivo LPS exposure (intraperitoneal, intratracheal). A similar downregulation was observed in cultured human lung microvascular endothelial cells (HLMVECs) exposed to LPS. SOX18 overexpression in HLMVECs or in the mouse lung attenuated the LPS-mediated vascular barrier disruption. Conversely, reduced CLDN5 expression (siRNA) reduced the HLMVEC barrier-protective effects of SOX18 overexpression. The mechanism by which LPS decreases SOX18 expression was identified as transcriptional repression through binding of NF-kappa B (p65) to a SOX18 promoter sequence located between -1,082 and -1,073 bp with peroxynitrite contributing to LPS-mediated NF-kappa B activation. We conclude that NF-kappa B-dependent decreases in the SOX18-CLDN5 axis are essentially involved in the disruption of human endothelial cell barrier integrity associated with LPS-mediated acute lung injury.
C1 [Gross, Christine M.; Kumar, Sanjiv; Gorshkov, Boris; Verin, Alexander D.] Augusta Univ, Vasc Biol Ctr, Augusta, GA, United States.
C1 [Kellner, Manuela; Wang, Ting; Lu, Qing; Sun, Xutong; Zemskov, Evgeny A.; Noonepalle, Satish; Kangath, Archana; Gonzalez-Garay, Manuel; Desai, Ankit A.; Klinger, Christina; Yuan, Jason X-J; Rafikov, Ruslan; Garcia, Joe G. N.; Black, Stephen M.] Univ Arizona Hlth Sci, Dept Med, Tucson, AZ 85724, United States.
C1 [Aggarwal, Saurabh] Univ Alabama Birmingham, Sch Med, Dept Anesthesiol & Perioperat Med, Birmingham, AL, United States.
C1 [Catravas, John D.] Old Dominion Univ, Frank Reidy Res Ctr Bioelect, Norfolk, VA, United States.
C1 [Jacobson, Jeffrey R.] Univ Illinois, Coll Med, Dept Med, Chicago, IL, United States.
C3 University System of Georgia; Augusta University; University of Arizona;
   University of Arizona Health Sciences; University of Alabama System;
   University of Alabama Birmingham; Old Dominion University; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital
RP Black, SM (corresponding author), Univ Arizona Hlth Sci, Div Translat & Regenerat Med, Steele Childrens Res Ctr, Off 7341A,1501N Campbell Ave POB 245002, Tucson, AZ 85724 USA.
EM steveblack@e-mail.arizona.edu
RI Garcia, Joe GN/E-8862-2010; Noonepalle, Satish/ABD-6753-2021; Rafikov,
   Ruslan/AAG-9352-2019
OI Gonzalez-Garay, Manuel/0000-0003-3412-0353; Lu,
   Qing/0000-0002-1000-3884; Desai, Ankit/0000-0001-6427-616X; Rafikov,
   Ruslan/0000-0001-5950-4076; Noonepalle, Satish
   kumar/0000-0002-0346-3882; Black, Stephen M./0000-0002-4524-6544; Verin,
   Alexander/0000-0003-0627-7185
FU National Institutes of Health (NIH) [HL60190, HL67841, HL101902,
   P01HL134610, HL126609, HL115014, HL096887, HL132918]; American Heart
   Association National Office [14SDG20480354]
FX Supported in part by grants HL60190 (S.M.B.), HL67841 (S.M.B.), HL101902
   (S.M.B.), P01HL134610 (S.M.B.), HL126609 (J.G.N.G.), HL115014
   (J.X.-J.Y.), HL096887 (J.R.J.), and HL132918 (R.R.), all from the
   National Institutes of Health (NIH), and by a Scientist Development
   Grant (14SDG20480354 [R.R.]) from the American Heart Association
   National Office.
CR Aggarwal S, 2014, AM J RESP CELL MOL, V50, P614, DOI 10.1165/rcmb.2013-0193OC
   Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106
   Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001
   Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016
   Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7
   Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3
   Basilio J, 2013, BIOCHEM BIOPH RES CO, V442, P221, DOI 10.1016/j.bbrc.2013.11.030
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Catravas JD, 2010, VASC PHARMACOL, V52, P175, DOI 10.1016/j.vph.2009.12.009
   Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7
   Choy MK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-519
   Di Ruscio A, 2013, NATURE, V503, P371, DOI 10.1038/nature12598
   Fontijn RD, 2008, AM J PHYSIOL-HEART C, V294, pH891, DOI 10.1152/ajpheart.01248.2007
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Gross CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119918
   Gross CM, 2014, J CELL PHYSIOL, V229, P1802, DOI 10.1002/jcp.24633
   Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Irrthum A, 2003, AM J HUM GENET, V72, P1470, DOI 10.1086/375614
   Ishizaki T, 2003, EXP CELL RES, V290, P275, DOI 10.1016/S0014-4827(03)00354-9
   Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200
   Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7
   Kouba DJ, 1999, J IMMUNOL, V162, P4226
   Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541
   Liu Y, 2012, ONCOGENE, V31, P1143, DOI 10.1038/onc.2011.308
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Ma J, 2014, J CELL PHYSIOL, V229, P916, DOI 10.1002/jcp.24523
   Matute-Bello G, 2001, AM J PATHOL, V158, P153, DOI 10.1016/S0002-9440(10)63953-3
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Pennisi D, 2000, NAT GENET, V24, P434, DOI 10.1038/74301
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   Rafikov R, 2014, J BIOL CHEM, V289, P4710, DOI 10.1074/jbc.M114.547596
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6
   Sharma S, 2010, VASC PHARMACOL, V52, P182, DOI 10.1016/j.vph.2009.11.010
   Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50
   Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200
   Yakovlev VA, 2007, BIOCHEMISTRY-US, V46, P11671, DOI 10.1021/bi701107z
   Yamamoto M, 2008, AM J PATHOL, V172, P521, DOI 10.2353/ajpath.2008.070076
   Yuan L, 2012, J BIOL CHEM, V287, P6582, DOI 10.1074/jbc.M111.300236
   Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X
NR 49
TC 54
Z9 58
U1 0
U2 12
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2018
VL 58
IS 5
BP 614
EP 624
DI 10.1165/rcmb.2016-0390OC
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA GE4PN
UT WOS:000431198400015
PM 29115856
OA Green Published
DA 2023-08-21
ER

PT J
AU Karki, P
   Birukova, AA
AF Karki, Pratap
   Birukova, Anna A.
TI Substrate stiffness-dependent exacerbation of endothelial permeability
   and inflammation: mechanisms and potential implications in ALI and PH
   (2017 Grover Conference Series)
SO PULMONARY CIRCULATION
LA English
DT Article
DE substrate stiffness; ALI/ARDS; pulmonary hypertension; permeability; Inflammation 
ID ATOMIC-FORCE MICROSCOPY; FLUID SHEAR-STRESS; ACUTE LUNG INJURY;
   RHO-KINASE; PULMONARY-HYPERTENSION; EXTRACELLULAR-MATRIX; BARRIER
   DYSFUNCTION; STIFFENING PROMOTES; CELL-STIFFNESS; VE-CADHERIN
AB The maintenance of endothelial barrier integrity is absolutely essential to prevent the vascular leak associated with pneumonia, pulmonary edema resulting from inhalation of toxins, acute elevation to high altitude, traumatic and septic lung injury, acute lung injury (ALI), and its life-threatening complication, acute respiratory distress syndrome (ARDS). In addition to the long-known edemagenic and inflammatory agonists, emerging evidences suggest that factors of endothelial cell (EC) mechanical microenvironment such as blood flow, mechanical strain of the vessel, or extracellular matrix stiffness also play an essential role in the control of endothelial permeability and inflammation. Recent studies from our group and others have demonstrated that substrate stiffening causes endothelial barrier disruption and renders EC more susceptible to agonist-induced cytoskeletal rearrangement and inflammation. Further in vivo studies have provided direct evidence that proinflammatory stimuli increase lung microvascular stiffness which in turn exacerbates endothelial permeability and inflammation and perpetuates a vicious circle of lung inflammation. Accumulating evidence suggests a key role for RhoA GTPases signaling in stiffness-dependent mechanotransduction mechanisms defining EC permeability and inflammatory responses. Vascular stiffening is also known to be a key contributor to other cardiovascular diseases such as arterial pulmonary hypertension (PH), although the precise role of stiffness in the development and progression of PH remains to be elucidated. This review summarizes the current understanding of stiffness-dependent regulation of pulmonary EC permeability and inflammation, and discusses potential implication of pulmonary vascular stiffness alterations at macro- and microscale in development and modulation of ALI and PH.
C1 [Karki, Pratap; Birukova, Anna A.] Univ Maryland Hosp, Dept Med, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21201, United States.
C3 University System of Maryland; University of Maryland Baltimore
RP Birukova, AA (corresponding author), Univ Maryland, Dept Med, Sch Med, 20 Penn St,HSF-2,Room 143, Baltimore, MD 21201 USA.
EM abirukova@som.umaryland.edu
FU NHLBI [HL107920, HL130431]; NIGMS [GM114171]
FX This work has been supported by NHLBI grants HL107920 and HL130431, and
   NIGMS grant GM114171.
CR Alcaide P, 2008, BLOOD, V112, P2770, DOI 10.1182/blood-2008-03-147181
   Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Beckers CML, 2015, VASC PHARMACOL, V70, P45, DOI 10.1016/j.vph.2015.03.017
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2013, MOL BIOL CELL, V24, P2678, DOI 10.1091/mbc.E13-02-0098
   Birukova AA, 2013, MICROVASC RES, V87, P50, DOI 10.1016/j.mvr.2012.12.006
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Bordeleau F, 2017, P NATL ACAD SCI USA, V114, P492, DOI 10.1073/pnas.1613855114
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   Byfield FJ, 2009, J BIOMECH, V42, P1114, DOI 10.1016/j.jbiomech.2009.02.012
   Califano JP, 2009, IEEE ENG MED BIO, P3343, DOI 10.1109/IEMBS.2009.5333194
   Califano JP, 2010, CELL MOL BIOENG, V3, P68, DOI 10.1007/s12195-010-0102-6
   Cameron JD, 2007, CLIN EXP PHARMACOL P, V34, P677, DOI 10.1111/j.1440-1681.2007.04659.x
   Chan W, 2011, SEX HEALTH, V8, P474, DOI 10.1071/SH10160
   Chao MCM, 2010, RESP PHYSIOL NEUROBI, V173, P179, DOI 10.1016/j.resp.2010.08.005
   Chouinard JA, 2008, EXP CELL RES, V314, P3007, DOI 10.1016/j.yexcr.2008.07.020
   ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Ding YH, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601426
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Doggrell SA, 2005, EXPERT OPIN INV DRUG, V14, P1157, DOI 10.1517/13543784.14.9.1157
   Eguiluz RCA, 2017, BIOMATERIALS, V140, P45, DOI 10.1016/j.biomaterials.2017.06.010
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867
   Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007
   Fukumoto Y, 2005, HEART, V91, P391, DOI 10.1136/hrt.2003.029470
   Guilluy C, 2011, NAT CELL BIOL, V13, P722, DOI 10.1038/ncb2254
   Hagiwara S, 2007, LUNG, V185, P31, DOI 10.1007/s00408-006-0085-1
   Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004
   Hinz Boris, 2009, Curr Rheumatol Rep, V11, P120
   Huang XW, 2012, AM J RESP CELL MOL, V47, P340, DOI 10.1165/rcmb.2012-0050OC
   Huynh J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002761
   Janmey PA, 2011, J CELL SCI, V124, P9, DOI 10.1242/jcs.071001
   Kaess BM, 2012, JAMA-J AM MED ASSOC, V308, P875, DOI 10.1001/2012.jama.10503
   Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245
   Kohn JC, 2015, BIOPHYS J, V108, P471, DOI 10.1016/j.bpj.2014.12.023
   Krishnan R, 2011, AM J PHYSIOL-CELL PH, V300, pC146, DOI 10.1152/ajpcell.00195.2010
   Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112
   Lee SY, 2011, INT J NANOMED, V6, P179, DOI 10.2147/IJN.S12760
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Li Min, 2013, Cardiovasc Eng Technol, V4, P26
   Li M, 2009, J VASC RES, V46, P561, DOI 10.1159/000226224
   Liu F, 2010, J CELL BIOL, V190, P693, DOI 10.1083/jcb.201004082
   Mambetsariev I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092670
   Mammoto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2774
   Maruthamuthu V, 2011, P NATL ACAD SCI USA, V108, P4708, DOI 10.1073/pnas.1011123108
   Matsumoto T, 2002, PHYSIOL MEAS, V23, P635, DOI 10.1088/0967-3334/23/4/304
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Meng FY, 2015, AM J RESP CELL MOL, V52, P152, DOI 10.1165/rcmb.2013-0468OC
   Nakasaki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9574
   Nohria A, 2006, CIRC RES, V99, P1426, DOI 10.1161/01.RES.0000251668.39526.c7
   Nourshargh S, 2010, NAT REV MOL CELL BIO, V11, P366, DOI 10.1038/nrm2889
   Oakes PW, 2014, CURR OPIN CELL BIOL, V30, P68, DOI 10.1016/j.ceb.2014.06.003
   Okamoto T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06463-x
   Orr AW, 2005, J CELL BIOL, V169, P191, DOI 10.1083/jcb.200410073
   Peled N, 2009, J RHEUMATOL, V36, P970, DOI 10.3899/jrheum.081088
   Peyton SR, 2007, CELL BIOCHEM BIOPHYS, V47, P300, DOI 10.1007/s12013-007-0004-y
   Reinhart-King CA, 2005, BIOPHYS J, V89, P676, DOI 10.1529/biophysj.104.054320
   Reinhart-King CA, 2008, BIOPHYS J, V95, P6044, DOI 10.1529/biophysj.107.127662
   Roca-Cusachs P, 2012, J CELL SCI, V125, P3025, DOI 10.1242/jcs.095794
   Ross TD, 2013, CURR OPIN CELL BIOL, V25, P613, DOI 10.1016/j.ceb.2013.05.006
   Sato M, 2000, J BIOMECH, V33, P127, DOI 10.1016/S0021-9290(99)00178-5
   Schaefer A, 2015, J CELL SCI, V128, P2221, DOI 10.1242/jcs.163055
   Schaefer A, 2014, J CELL SCI, V127, P4470, DOI 10.1242/jcs.154708
   Scott HA, 2016, INTEGR BIOL-UK, V8, P869, DOI 10.1039/c6ib00084c
   Stroka KM, 2011, CELL MOL BIOENG, V4, P9, DOI 10.1007/s12195-010-0142-y
   Tan W, 2014, PULM CIRC, V4, P560, DOI 10.1086/677370
   Tan Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102195
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Thenappan T, 2016, ANN AM THORAC SOC, V13, P276, DOI 10.1513/AnnalsATS.201509-599FR
   Turowski P, 2008, J CELL SCI, V121, P29, DOI 10.1242/jcs.022681
   Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639
   Urbano RL, 2017, BIOPHYS J, V113, P645, DOI 10.1016/j.bpj.2017.06.033
   van Geemen D, 2014, ARTERIOSCL THROM VAS, V34, P2059, DOI 10.1161/ATVBAHA.114.304180
   VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295
   Wang N, 2002, AM J PHYSIOL-CELL PH, V282, pC606, DOI 10.1152/ajpcell.00269.2001
   Wang Q, 2002, ANTIOXID REDOX SIGN, V4, P39, DOI 10.1089/152308602753625843
   Wang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep11097
   Wang Zhijie, 2011, Pulm Circ, V1, P212, DOI 10.4103/2045-8932.83453
   Watson WH, 2016, REDOX BIOL, V8, P305, DOI 10.1016/j.redox.2016.02.005
   Wu J, 2014, CIRC RES, V114, P616, DOI 10.1161/CIRCRESAHA.114.302157
   Wu TH, 2013, TRANSL RES, V162, P45, DOI 10.1016/j.trsl.2013.03.005
   Wygrecka M, 2008, THROMB HAEMOSTASIS, V99, P494, DOI 10.1160/TH07-11-0666
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Yeh YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046889
   Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041
NR 89
TC 20
Z9 20
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD MAY 1
PY 2018
VL 8
IS 2
AR 2045894018773044
DI 10.1177/2045894018773044
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA GF6ZI
UT WOS:000432116900001
PM 29714090
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Lu, Q
   Gottlieb, E
   Rounds, S
AF Lu, Qing
   Gottlieb, Eric
   Rounds, Sharon
TI Effects of cigarette smoke on pulmonary endothelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Review
DE ALI/ARDS; cigarette smoke; emphysema; ECs/HPMECs/HUVECs/MPVECs; pulmonary hypertension 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; FOCAL ADHESION KINASE;
   NITRIC-OXIDE SYNTHASE; UNFOLDED-PROTEIN-RESPONSE; BARRIER DYSFUNCTION;
   INCREASED PERMEABILITY; VASCULAR DYSFUNCTION; INDUCED INFLAMMATION;
   AIRWAY INFLAMMATION
AB Cigarette smoking is the leading cause of preventable disease and death in the United States. Cardiovascular comorbidities associated with both active and secondhand cigarette smoking indicate the vascular toxicity of smoke exposure. Growing evidence supports the injurious effect of cigarette smoke on pulmonary endothelial cells and the roles of endothelial cell injury in development of acute respiratory distress syndrome (ARDS), emphysema, and pulmonary hypertension. This review summarizes results from studies of humans, preclinical animal models, and cultured endothelial cells that document toxicities of cigarette smoke exposure on pulmonary endothelial cell functions, including barrier dysfunction, endothelial activation and inflammation, apoptosis, and vasoactive mediator production. The discussion is focused on effects of cigarette smoke-induced endothelial injury in the development of ARDS, emphysema, and vascular remodeling in chronic obstructive pulmonary disease.
C1 [Lu, Qing; Rounds, Sharon] Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI, United States.
C1 [Lu, Qing; Gottlieb, Eric; Rounds, Sharon] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University
RP Lu, Q (corresponding author), Providence VA Med Ctr, Vasc Res Lab, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM Qing_Lu@brown.edu
RI Rounds, Sharon/AAF-7380-2020
OI Gottlieb, Eric/0000-0003-2181-6263; Lu, Qing/0000-0002-4088-6200
FU National Heart, Lung, and Blood Institute [R01-HL-130230]; Brown
   University Dean's Emerging Areas of New Science (DEANS) award; National
   Institute of General Medical Sciences (NIGMS) [U54-GM-115677]; NIGMS
   [P20-GM-103652]; Veterans Affairs Merit Review
FX This study was supported using facilities at the Providence Veterans
   Affairs Medical Center and by Veterans Affairs Merit Review (S. Rounds),
   National Heart, Lung, and Blood Institute Grant R01-HL-130230 (Q. Lu), a
   Brown University Dean's Emerging Areas of New Science (DEANS) award (S.
   Rounds), National Institute of General Medical Sciences (NIGMS) Grant
   U54-GM-115677 (S. Rounds), and an Institutional Development award from
   NIGMS under Grant P20-GM-103652 (S. Rounds; project 1 to Q. Lu).
CR Abadie Y, 2005, EUR RESPIR J, V25, P139, DOI 10.1183/09031936.04.00065504
   Aghajanian A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008045
   Agrawal A, 2017, LUNG INDIA, V34, P138, DOI 10.4103/0970-2113.201299
   Barbera JA, 2013, PULM CIRC, V3, P160, DOI 10.4103/2045-8932.109949
   Aldonyte R, 2008, COPD, V5, P153, DOI 10.1080/15412550802092936
   Alwis KU, 2015, ENVIRON HEALTH PERSP, V123, P1302, DOI 10.1289/ehp.1409251
   [Anonymous], 2018, TOB FACT SHEET
   Arunachalam G, 2010, BIOCHEM BIOPH RES CO, V393, P66, DOI 10.1016/j.bbrc.2010.01.080
   Barbera JA, 2001, AM J RESP CRIT CARE, V164, P709, DOI 10.1164/ajrccm.164.4.2101023
   Barbieri SS, 2008, ARTERIOSCL THROM VAS, V28, P732, DOI 10.1161/ATVBAHA.107.159434
   Barbieri SS, 2007, FASEB J, V21, P1831, DOI 10.1096/fj.06-7557com
   Barnoya J, 2005, CIRCULATION, V111, P2684, DOI 10.1161/CIRCULATIONAHA.104.492215
   BARROWCLIFFE MP, 1989, ANAESTH INTENS CARE, V17, P422, DOI 10.1177/0310057X8901700405
   Bello S, 2014, CHEST, V146, P1029, DOI 10.1378/chest.13-2853
   Bernhard D, 2005, FASEB J, V19, P1096, DOI 10.1096/fj.04-3192com
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Biswas P, 2006, AM J PATHOL, V169, P314, DOI 10.2353/ajpath.2006.051112
   Bohm F, 2007, CARDIOVASC RES, V76, P8, DOI 10.1016/j.cardiores.2007.06.004
   Borgas D, 2016, AM J RESP CELL MOL, V54, P683, DOI 10.1165/rcmb.2015-0149OC
   Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421
   Brown SM, 2017, THORAX, V72, P311, DOI 10.1136/thoraxjnl-2016-208560
   BURNS AR, 1989, J APPL PHYSIOL, V66, P2109, DOI 10.1152/jappl.1989.66.5.2109
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC
   Chan ED, 2014, TUBERCULOSIS, V94, P544, DOI 10.1016/j.tube.2014.08.010
   Chattopadhyay S, 2013, MBIO, V4, DOI 10.1128/mBio.00636-12
   Chen HY, 2014, PHARMAZIE, V69, P55, DOI 10.1691/ph.2014.3716
   Chun LF, 2017, AM J PHYSIOL-LUNG C, V313, pL193, DOI 10.1152/ajplung.00071.2017
   Demos-Davies KM, 2014, AM J PHYSIOL-HEART C, V307, pH252, DOI 10.1152/ajpheart.00149.2014
   Divo M, 2013, COPD, V10, P275, DOI 10.3109/15412555.2013.795409
   Drannik AG, 2004, AM J RESP CRIT CARE, V170, P1164, DOI 10.1164/rccm.200311-1521OC
   Duong-Quy S, 2011, EUR RESPIR J, V37, P349, DOI 10.1183/09031936.00056610
   Fabbri LM, 2012, AM J RESP CRIT CARE, V186, P117, DOI 10.1164/rccm.201205-0906ED
   Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC
   Ferrer E, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-76
   Ferro TN, 2010, J TRAUMA, V69, P308, DOI 10.1097/TA.0b013e3181e1761e
   Freixa X, 2013, EUR RESPIR J, V41, P784, DOI 10.1183/09031936.00222511
   Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011
   Fukada M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030924
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Garcia-Lucio J, 2016, AM J PHYSIOL-LUNG C, V310, pL583, DOI 10.1152/ajplung.00261.2015
   Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7
   Gill SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088501
   Govindarajan N, 2013, EMBO MOL MED, V5, P52, DOI 10.1002/emmm.201201923
   Green LA, 2012, AM J RESP CELL MOL, V47, P807, DOI 10.1165/rcmb.2012-0132OC
   Guerassimov A, 2004, AM J RESP CRIT CARE, V170, P974, DOI 10.1164/rccm.200309-1270oc
   Guo MZ, 2005, MICROCIRCULATION, V12, P223, DOI 10.1080/10739680590905251
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Heijink IH, 2015, AM J RESP CELL MOL, V52, P554, DOI 10.1165/rcmb.2013-0505OC
   Hengstermann A, 2008, FREE RADICAL BIO MED, V44, P1097, DOI 10.1016/j.freeradbiomed.2007.12.009
   Heo JY, 2006, BIOCHEMISTRY-US, V45, P14481, DOI 10.1021/bi0610101
   Hirsch J, 2014, CRIT CARE, V18, DOI 10.1186/cc13795
   HOLDEN WE, 1989, J APPL PHYSIOL, V66, P443, DOI 10.1152/jappl.1989.66.1.443
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Hsieh SJ, 2014, CRIT CARE MED, V42, P2058, DOI 10.1097/CCM.0000000000000418
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Imai K, 2005, EUR RESPIR J, V25, P250, DOI 10.1183/09031936.05.00023704
   Iribarren C, 2000, CHEST, V117, P163, DOI 10.1378/chest.117.1.163
   Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58
   Jochems J, 2014, NEUROPSYCHOPHARMACOL, V39, P389, DOI 10.1038/npp.2013.207
   JONES JG, 1980, LANCET, V1, P66
   Jorgensen E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-229
   Kang MJ, 2008, J CLIN INVEST, V118, P2771, DOI 10.1172/JCI32709
   Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117
   Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1
   Kelsen SG, 2008, AM J RESP CELL MOL, V38, P541, DOI 10.1165/rcmb.2007-0221OC
   Kim BS, 2013, FREE RADICAL BIO MED, V60, P336, DOI 10.1016/j.freeradbiomed.2013.01.023
   Kispert SE, 2014, AM J PHYSIOL-CELL PH, V307, pC951, DOI 10.1152/ajpcell.00218.2014
   Kitaguchi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038038
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Kratzer A, 2013, J PATHOL, V230, P388, DOI 10.1002/path.4197
   Kubo S, 2005, EUR RESPIR J, V26, P993, DOI 10.1183/09031936.05.00042405
   Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636
   LEHR HA, 1993, FREE RADICAL BIO MED, V14, P573, DOI 10.1016/0891-5849(93)90138-K
   LEHR HA, 1994, P NATL ACAD SCI USA, V91, P7688, DOI 10.1073/pnas.91.16.7688
   Li XY, 1996, THORAX, V51, P465, DOI 10.1136/thx.51.5.465
   Liu H, 2014, J THORAC DIS, V6, P649, DOI 10.3978/j.issn.2072-1439.2014.06.26
   Liu XR, 2017, MOL MED REP, V16, P5294, DOI 10.3892/mmr.2017.7260
   Low B, 2007, J PHARMACOL SCI, V104, P225, DOI 10.1254/jphs.FP0070385
   Lu Q, 2017, AM J RESP CELL MOL, V57, P662, DOI 10.1165/rcmb.2016-0342OC
   Lu Q, 2013, AM J PHYSIOL-LUNG C, V304, pL361, DOI 10.1152/ajplung.00161.2012
   Lu Q, 2012, MICROVASC RES, V83, P56, DOI 10.1016/j.mvr.2011.05.003
   Lu Q, 2011, AM J PHYSIOL-LUNG C, V301, pL847, DOI 10.1152/ajplung.00178.2011
   Lugade AA, 2014, J IMMUNOL, V192, P5226, DOI 10.4049/jimmunol.1302584
   Marwick JA, 2006, AM J PHYSIOL-LUNG C, V290, pL897, DOI 10.1152/ajplung.00116.2005
   Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682
   Milara J, 2010, BRIT J PHARMACOL, V161, P1599, DOI 10.1111/j.1476-5381.2010.00979.x
   Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206
   Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985
   Mizuno S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030678
   Moazed F, 2016, THORAX, V71, P1130, DOI 10.1136/thoraxjnl-2015-207886
   Nana-Sinkam SP, 2007, AM J RESP CRIT CARE, V175, P676, DOI 10.1164/rccm.200605-724OC
   National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014, HLTH CONS SMOK 50 YE
   Ni YF, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-33
   Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006
   Overbeek SA, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-75
   Ozaki K, 2010, J CARDIOL, V56, P307, DOI 10.1016/j.jjcc.2010.07.003
   Panzer AR, 2018, AM J RESP CRIT CARE, V197, P621, DOI 10.1164/rccm.201702-0441OC
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238
   Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058
   Petta V, 2015, EUR J CLIN INVEST, V45, P56, DOI 10.1111/eci.12379
   Phillips E, 2017, MMWR-MORBID MORTAL W, V66, P1209, DOI 10.15585/mmwr.mm6644a2
   Pines H, 2011, AIDS BEHAV, V15, P243, DOI 10.1007/s10461-010-9682-3
   Polverino F, 2017, AM J RESP CRIT CARE, V195, P1464, DOI 10.1164/rccm.201609-1765OC
   Pouwels SD, 2014, MUCOSAL IMMUNOL, V7, P215, DOI 10.1038/mi.2013.77
   Pouwels SD, 2016, AM J PHYSIOL-LUNG C, V311, pL881, DOI 10.1152/ajplung.00135.2016
   Pouwels SD, 2016, AM J PHYSIOL-LUNG C, V310, P1377, DOI 10.1152/ajplung.00174.2015
   Quadri SK, 2007, AM J PHYSIOL-LUNG C, V292, pL334, DOI 10.1152/ajplung.00228.2006
   Reddy KP, 2016, J INFECT DIS, V214, P1672, DOI 10.1093/infdis/jiw430
   Saito S, 2011, BIOCHEM BIOPH RES CO, V408, P630, DOI 10.1016/j.bbrc.2011.04.075
   Sakhatskyy P, 2017, AM J PHYSIOL-LUNG C, V312, pL56, DOI 10.1152/ajplung.00436.2016
   Sakhatskyy P, 2014, MICROVASC RES, V94, P80, DOI 10.1016/j.mvr.2014.05.003
   Santos S, 2002, EUR RESPIR J, V19, P632, DOI 10.1183/09031936.02.00245902
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Schweitzer KS, 2015, AM J PHYSIOL-LUNG C, V309, pL175, DOI 10.1152/ajplung.00411.2014
   Schweitzer KS, 2011, AM J PHYSIOL-LUNG C, V301, pL836, DOI 10.1152/ajplung.00385.2010
   Serban KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep31596
   Shankar-Hari M, 2017, AM J RESP CRIT CARE, V195, P280, DOI 10.1164/rccm.201608-1729ED
   Sharma J, 2012, AM J PHYSIOL-LUNG C, V302, pL47, DOI 10.1152/ajplung.00179.2011
   Shen YM, 1996, AM J PHYSIOL-HEART C, V270, pH1624, DOI 10.1152/ajpheart.1996.270.5.H1624
   Sikka G, 2013, ATHEROSCLEROSIS, V231, P91, DOI 10.1016/j.atherosclerosis.2013.08.026
   Siu ER, 2009, P NATL ACAD SCI USA, V106, P9298, DOI 10.1073/pnas.0813113106
   Staempfli MR, 2009, NAT REV IMMUNOL, V9, P377, DOI 10.1038/nri2530
   Strulovici-Barel Y, 2016, THORAX, V71, P1137, DOI 10.1136/thoraxjnl-2015-208274
   Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091
   Sun SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059989
   Takahashi T, 2012, THORAX, V67, P1067, DOI 10.1136/thoraxjnl-2011-201395
   Tandon S, 2001, BRIT J ANAESTH, V86, P633, DOI 10.1093/bja/86.5.633
   TAYLOR AE, 1970, AM J PHYSIOL, V218, P1133, DOI 10.1152/ajplegacy.1970.218.4.1133
   Thomashow MA, 2013, AM J RESP CRIT CARE, V188, P60, DOI 10.1164/rccm.201209-1697OC
   Tuder RM, 2000, CHEST, V117, p241S, DOI 10.1378/chest.117.5_suppl_1.241S
   Tzima E, 2006, CIRC RES, V98, P176, DOI 10.1161/01.RES.0000200162.94463.d7
   Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565
   Voelkel NF, 2018, AM J RESP CRIT CARE, V197, P274, DOI 10.1164/rccm.201706-1123LE
   Wacharasint P., 2015, CRIT CARE, V19, P238
   Wagner K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132810
   Wagner L, 2007, ENDOTHELIUM-J ENDOTH, V14, P245, DOI 10.1080/10623320701606707
   Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479
   Ward C, 2000, EUR RESPIR J, V15, P285, DOI 10.1034/j.1399-3003.2000.15b11.x
   Ware LB, 2014, AM J TRANSPLANT, V14, P2295, DOI 10.1111/ajt.12853
   Ware LB, 2016, AM J RESP CRIT CARE, V193, P1143, DOI 10.1164/rccm.201507-1418OC
   Wickenden JA, 2003, AM J RESP CELL MOL, V29, P562, DOI 10.1165/rcmb.2002-0235OC
   Winkler R, 2012, DIABETES, V61, P513, DOI 10.2337/db11-0313
   Wong CM, 2013, INFLUENZA OTHER RESP, V7, P531, DOI 10.1111/j.1750-2659.2012.00411.x
   Wright JL, 2012, INHAL TOXICOL, V24, P732, DOI 10.3109/08958378.2012.715698
   Wright JL, 2006, J APPL PHYSIOL, V100, P672, DOI 10.1152/japplphysiol.00274.2005
   Wu MH, 2005, J PHYSIOL-LONDON, V569, P359, DOI 10.1113/jphysiol.2005.096537
   Xiong Y, 2013, P NATL ACAD SCI USA, V110, P4604, DOI 10.1073/pnas.1207586110
   Yao HW, 2012, AM J PHYSIOL-LUNG C, V303, pL557, DOI 10.1152/ajplung.00175.2012
   Yi J, 2008, NEOPLASIA, V10, P41, DOI 10.1593/neo.07754
   Yildiz L, 1996, CLIN CHEM, V42, P483
   Zhang L, 2010, WORLD J SURG, V34, P1676, DOI 10.1007/s00268-010-0493-5
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
   Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06
   Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094
   Zhou Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009224
   Zhou Y, 2009, J IMMUNOL, V182, P8037, DOI 10.4049/jimmunol.0900515
NR 160
TC 46
Z9 47
U1 0
U2 18
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2018
VL 314
IS 5
BP L743
EP L756
DI 10.1152/ajplung.00373.2017
PG 14
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA GP5XN
UT WOS:000440950700005
PM 29351435
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Mascarenhas, JB
   Tchourbanov, AY
   Danilov, SM
   Zhou, T
   Wang, T
   Garcia, JGN
AF Mascarenhas, Joseph B.
   Tchourbanov, Alex Y.
   Danilov, Sergei M.
   Zhou, Tong
   Wang, Ting
   Garcia, Joe G. N.
TI The Splicing Factor hnRNPA1 Regulates Alternate Splicing of the MYLK
   Gene
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ventilator-induced lung injury; cyclic stretch; splicing; heterogeneous nuclear ribonucleoprotein A1; MYLK 
ID LIGHT-CHAIN KINASE; RESPIRATORY-DISTRESS SYNDROME; INFLAMMATORY LUNG
   INJURY; MESSENGER-RNA; IN-VITRO; A1; PROTEINS; ISOFORM; CANCER;
   PERMEABILITY
AB Profound lung vascular permeability is a cardinal feature of acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury (VILI), two syndromes known to centrally involve the nonmuscle isoform of myosin light chain kinase (nmMLCK) in vascular barrier dysregulation. Two main splice variants, nmMLCK1 and nmMLCK2, are well represented in human lung endothelial cells and encoded by MYLK, and they differ only in the presence of exon 11 in nmMLCK1, which contains critical phosphorylation sites (Y-464 and Y-471) that influence nmMLCK enzymatic activity, cellular translocation, and localization in response to vascular agonists. We recently demonstrated the functional role of SNPs in altering MYLK splicing, and in the present study we sought to identify the role of splicing factors in the generation of nmMLCK1 and nmMLCK2 spliced variants. Using bioinformatic in silico approaches, we identified a putative binding site for heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), a recognized splicing factor. We verified hnRNPA1 binding to MYLK by gel shift analyses and that hnRNPA1gene and protein expression is upregulated in mouse lungs obtained from preclinical models of ARDS and VILI and in human endothelial cells exposed to 18% cyclic stretch, a model that reproduces the excessive mechanical stress observed in VILI. Using an MYLK minigene approach, we established a direct role of hnRNPA1 in MYLK splicing and in the context of 18% cyclic stretch. In summary, these data indicate an important regulatory role for hnRNPA1 in MYLK splicing, and they increase understanding of MYLK splicing in the regulation of lung vascular integrity during acute lung inflammation and excessive mechanical stress, such as that observed in ARDS and VILI.
C1 [Mascarenhas, Joseph B.; Danilov, Sergei M.; Wang, Ting; Garcia, Joe G. N.] Univ Arizona, Coll Med, Dept Med, Tucson, AZ 85721, United States.
C1 [Tchourbanov, Alex Y.] Univ Arizona, Arizona Res Labs, Tucson, AZ 85721, United States.
C1 [Danilov, Sergei M.] Univ Illinois, Dept Anesthesiol, Chicago, IL, United States.
C1 [Zhou, Tong] Univ Nevada, Dept Physiol & Cell Biol, Reno Sch Med, Reno, NV 89557, United States.
C3 University of Arizona; University of Arizona; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital; Nevada System of Higher Education (NSHE); University of Nevada
   Reno
RP Garcia, JGN (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Drachman Hall B207,1295 North Martin Ave, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
OI Mascarenhas, Joseph B/0000-0002-4735-3140
FU National Institutes of Health [R01 HL91889, P01 HL126609]
FX Supported by National Institutes of Health grants R01 HL91889 and P01
   HL126609.
CR Bieler S, 2012, J PROTEOME RES, V11, P3947, DOI 10.1021/pr300435c
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200
   Brown M, 2010, MICROVASC RES, V80, P75, DOI 10.1016/j.mvr.2009.12.010
   BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x
   Butt Y, 2016, ARCH PATHOL LAB MED, V140, P345, DOI 10.5858/arpa.2015-0519-RA
   Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854
   Chen M, 2012, NAT STRUCT MOL BIOL, V19, P346, DOI 10.1038/nsmb.2219
   Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513
   Churbanov A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-22
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A
   GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8
   Guo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062729
   Hernandez-Imaz E, 2015, PLOS ONE, V10
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Huang Y, 2013, STEM CELLS, V31, P906, DOI 10.1002/stem.1324
   Jean-Philippe J, 2013, INT J MOL SCI, V14, P18999, DOI 10.3390/ijms140918999
   Jurica MS, 2002, RNA, V8, P426, DOI 10.1017/S1355838202021088
   Kashima T, 2007, HUM MOL GENET, V16, P3149, DOI 10.1093/hmg/ddm276
   Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774
   Mascarenhas JB, 2017, AM J RESP CELL MOL, V56, P29, DOI 10.1165/rcmb.2016-0053OC
   MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T
   MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Moitra J, 2008, TRANSL RES, V151, P141, DOI 10.1016/j.trsl.2007.12.008
   Nadiminty N, 2015, MOL CANCER THER, V14, P1884, DOI 10.1158/1535-7163.MCT-14-1057
   Okunola HL, 2009, MOL CELL BIOL, V29, P5620, DOI 10.1128/MCB.01678-08
   Tavanez JP, 2012, MOL CELL, V45, P314, DOI 10.1016/j.molcel.2011.11.033
   Sun XG, 2014, AM J RESP CELL MOL, V51, P660, DOI 10.1165/rcmb.2014-0117OC
   SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016
   Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100
   Wang T, 2018, PULM CIRC, V8, DOI 10.1177/2045894018764171
   Wee CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115205
   Yu CY, 2014, HUM MOL GENET, V23, P319, DOI 10.1093/hmg/ddt422
   Zhang SL, 2016, CANCER LETT, V371, P214, DOI 10.1016/j.canlet.2015.11.045
NR 43
TC 12
Z9 12
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2018
VL 58
IS 5
BP 604
EP 613
DI 10.1165/rcmb.2017-0141OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA GE4PN
UT WOS:000431198400014
PM 29077485
OA Green Published
DA 2023-08-21
ER

PT J
AU Lu, HL
   Huang, XY
   Luo, YF
   Tan, WP
   Chen, PF
   Guo, YB
AF Lu, Hui-Lun
   Huang, Xin-Yan
   Luo, Yi-Feng
   Tan, Wei-Ping
   Chen, Pei-Fen
   Guo, Yu-Biao
TI Activation of M1 macrophages plays a critical role in the initiation of
   acute lung injury
SO BIOSCIENCE REPORTS
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIA-REPERFUSION INJURY; NF-KAPPA-B;
   POLARIZATION; INFLAMMATION; INHIBITION; RESOLUTION; LIPOPOLYSACCHARIDE;
   POPULATIONS; DEPLETION
AB The goal of the present study was to investigate the role of M1 macrophages in acute lung injury (ALI). To address this, we used lipopolysaccharide (LPS)-treated wild-type and CD11b-DTR mice, and examined their M1 macrophage levels, and the extent of their inflammation and pulmonary injuries. In addition, we evaluated pulmonary function by measuring the expressions of SP-A and SP-B in infiltrated M1 macrophages. Finally, we co-cultured the mouse type II-like alveolar epithelial cells (AT-II) and mouse pulmonary microvascular endothelial cells (PMECs) with M1 macrophages in the presence of TNF-alpha or H2O2 and assessed them for viability and apoptosis. After LPS treatment, we observed that the number of pulmonary M1/M2 macrophages and the serum levels of interleukin-1 beta (IL-1 beta), tumor necrosis factor a (TNF-alpha), and reactive oxygen species (ROS) significantly increased. Furthermore, the increase in cytokines was accompanied with the initiation of lung injury indicated by the decreased levels of SP-A and SP-B. In macrophage-depleted CD11b-DTR mice, ALI was attenuated, serum levels of IL-1 beta, TNF-alpha and ROS were reduced, and lung levels of monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-2 (MIP-2) were decreased. After administering TNF-alpha and H2O2, the proapoptotic effect of M1 macrophages on AT-II or PMECs significantly increased, the cell viabilities significantly decreased, and apoptosis significantly increased. Our results suggest that M1 macrophages are recruited to the lungs where they significantly contribute to an increase in TNF-alpha and ROS production, thus initiating ALI.
C1 [Lu, Hui-Lun] Second Peoples Hosp Longgang Dist, Dept Resp Med, Shenzhen, China.
C1 [Huang, Xin-Yan; Luo, Yi-Feng; Tan, Wei-Ping; Guo, Yu-Biao] Sun Yat Sen Univ, Div Pulm & Crit Care Med, Affiliated Hosp 1, Guangzhou, China.
C1 [Huang, Xin-Yan; Luo, Yi-Feng; Tan, Wei-Ping; Guo, Yu-Biao] Sun Yat Sen Univ, Inst Resp Dis, Guangzhou, China.
C1 [Chen, Pei-Fen] Third Peoples Hosp Shenzhen, Dept Internal Med 2, Shenzhen, China.
C3 Sun Yat Sen University; Sun Yat Sen University; The Third People's
   Hospital of Shenzhen
RP Guo, YB (corresponding author), Sun Yat Sen Univ, Div Pulm & Crit Care Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Guo, YB (corresponding author), Sun Yat Sen Univ, Inst Resp Dis, Guangzhou, Peoples R China.
EM guoyubiao@hotmail.com
RI Chen, Pei-Fen/K-8584-2013; Huang, Xinyan/ABB-8442-2021
OI Chen, Pei-Fen/0000-0001-5470-321X; Huang, Xinyan/0000-0003-2775-6409
FU Science and Technology plan project of Shenzhen [JCYJ20150402092653975]
FX This work was supported by grants from the Science and Technology plan
   project of Shenzhen [JCYJ20150402092653975].
CR Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398
   Antonios JK, 2013, CELL MOL IMMUNOL, V10, P471, DOI 10.1038/cmi.2013.39
   Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Bhatia M, 2000, GUT, V47, P838, DOI 10.1136/gut.47.6.838
   Cabanski M, 2009, AM J PHYSIOL-LUNG C, V297, pL608, DOI 10.1152/ajplung.90433.2008
   Chow CW, 2003, AM J RESP CELL MOL, V29, P427, DOI 10.1165/rcmb.F278
   Di Gregorio GB, 2005, DIABETES, V54, P2305, DOI 10.2337/diabetes.54.8.2305
   Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249
   Fialkow L, 1997, J IMMUNOL, V158, P5409
   FIALKOW L, 1993, J BIOL CHEM, V268, P17131
   Fisher AB, 2005, J LIPID RES, V46, P1248, DOI 10.1194/jlr.M400499-JLR200
   Frieler RA, 2015, BRAIN RES, V1624, P103, DOI 10.1016/j.brainres.2015.07.011
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200
   Johnston LK, 2012, AM J RESP CELL MOL, V47, P417, DOI 10.1165/rcmb.2012-0090OC
   Krishnadasan B, 2003, J THORAC CARDIOV SUR, V125, P261, DOI 10.1067/mtc.2003.16
   Liu SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep37252
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Mukaida N, 1998, INFLAMM RES, V47, pS151
   Nomura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075527
   Opitz B, 2010, AM J RESP CRIT CARE, V181, P1294, DOI 10.1164/rccm.200909-1427SO
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Patel BV, 2013, J IMMUNOL, V190, P4274, DOI 10.4049/jimmunol.1202437
   Schnyder-Candrian S, 2005, J IMMUNOL, V175, P262, DOI 10.4049/jimmunol.175.1.262
   Sone Y, 1999, J APPL PHYSIOL, V87, P1354, DOI 10.1152/jappl.1999.87.4.1354
   Song Y, 2001, AM J PHYSIOL-LUNG C, V281, pL677, DOI 10.1152/ajplung.2001.281.3.L677
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weisser SB, 2012, JOVE-J VIS EXP, DOI 10.3791/4105
   Zhao MQ, 2006, AM J PHYSIOL-LUNG C, V291, pL1018, DOI 10.1152/ajplung.00086.2006
NR 35
TC 61
Z9 61
U1 1
U2 17
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD APR 27
PY 2018
VL 38
AR BSR20171555
DI 10.1042/BSR20171555
PN 2
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GE8TN
UT WOS:000431504200043
PM 29531017
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Huertas, A
   Guignabert, C
   Barbera, JA
   Bartsch, P
   Bhattacharya, J
   Bhattacharya, S
   Bonsignore, MR
   Dewachter, L
   Dinh-Xuan, AT
   Dorfmuller, P
   Gladwin, MT
   Humbert, M
   Kotsimbos, T
   Vassilakopoulos, T
   Sanchez, O
   Savale, L
   Testa, U
   Wilkins, MR
AF Huertas, Alice
   Guignabert, Christophe
   Barbera, Joan A.
   Baertsch, Peter
   Bhattacharya, Jahar
   Bhattacharya, Sunita
   Bonsignore, Maria R.
   Dewachter, Laurence
   Anh Tuan Dinh-Xuan
   Dorfmuller, Peter
   Gladwin, Mark T.
   Humbert, Marc
   Kotsimbos, Tom
   Vassilakopoulos, Theodoros
   Sanchez, Olivier
   Savale, Laurent
   Testa, Ugo
   Wilkins, Martin R.
TI Pulmonary vascular endothelium: the orchestra conductor in respiratory
   diseases
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Review
ID STRESS DOPPLER-ECHOCARDIOGRAPHY; FIBROBLAST GROWTH FACTOR-2; SOLUBLE
   GUANYLATE-CYCLASE; EXHALED NITRIC-OXIDE; CELL-FREE HEMOGLOBIN;
   HIGH-ALTITUDE; PROGENITOR CELLS; ARTERIAL-HYPERTENSION; SMOOTH-MUSCLE;
   RHO-KINASE
AB The European Respiratory Society (ERS) Research Seminar entitled "Pulmonary vascular endothelium: orchestra conductor in respiratory diseases - highlights from basic research to therapy" brought together international experts in dysfunctional pulmonary endothelium, from basic science to translational medicine, to discuss several important aspects in acute and chronic lung diseases. This review will briefly sum up the different topics of discussion from this meeting which was held in Paris, France on October 27-28, 2016. It is important to consider that this paper does not address all aspects of endothelial dysfunction but focuses on specific themes such as: 1) the complex role of the pulmonary endothelium in orchestrating the host response in both health and disease (acute lung injury, chronic obstructive pulmonary disease, high-altitude pulmonary oedema and pulmonary hypertension); and 2) the potential value of dysfunctional pulmonary endothelium as a target for innovative therapies.
C1 [Huertas, Alice; Guignabert, Christophe; Dorfmuller, Peter; Humbert, Marc; Savale, Laurent] Univ Paris Sud, Univ Paris Saclay,INSERM UMR S 999, Hop Bicetre,Ctr Reference Hypertens Pulmonaire Se, Hop Marie Lannelongue,AP HP,Serv Pneumol,DHU Thor, Le Plessis Robinson, France.
C1 [Huertas, Alice; Guignabert, Christophe; Dorfmuller, Peter; Humbert, Marc; Savale, Laurent] Univ Paris Sud, Univ Paris Saclay,INSERM UMR S 999, Hop Bicetre,Ctr Reference Hypertens Pulmonaire Se, Hop Marie Lannelongue,AP HP,Serv Pneumol,DHU Thor, Le Kremlin Bicetre, France.
C1 [Barbera, Joan A.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Hosp Clin, Dept Pulm Med, Barcelona, Spain.
C1 [Barbera, Joan A.] CIBERES, Madrid, Spain.
C1 [Baertsch, Peter] Univ Clin Heidelberg, Dept Internal Med, Heidelberg, Germany.
C1 [Bhattacharya, Jahar; Bhattacharya, Sunita] Columbia Univ, Med Ctr, Dept Med, Lung Biol Lab, New York, NY, United States.
C1 [Bonsignore, Maria R.] Univ Palermo, Inst Biomed & Mol Immunol IBIM, Biomed Dept Internal & Specialist Med DiBiMIS, Natl Res Council CNR, Palermo, Italy.
C1 [Dewachter, Laurence] Univ Libre Bruxelles, Lab Physiol & Pharmacol, Campus Erasme, Brussels, Belgium.
C1 [Anh Tuan Dinh-Xuan] Paris Descartes Univ, Cochin Hosp, Cardiothorac Dept, Resp Physiol Unit, Paris, France.
C1 [Gladwin, Mark T.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh Heart Lung Blood & Vasc Med Inst, Pittsburgh, PA, United States.
C1 [Kotsimbos, Tom] Monash Univ, Alfred Hlth, Melbourne, Vic, Australia.
C1 [Vassilakopoulos, Theodoros] Natl & Kapodistrian Univ Athens, Med Sch, Pulm & Crit Care Med, Athens, Greece.
C1 [Sanchez, Olivier] Paris Descartes Univ, Georges Pompidou European Hosp, AP HP, Med Sch,Sorbonne Paris City,Dept Pulmonol, Paris, France.
C1 [Testa, Ugo] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy.
C1 [Wilkins, Martin R.] Imperial Coll London, Dept Med, Fac Med, London, England, United Kingdom.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre
   - APHP; Hopital Universitaire Paul-Brousse - APHP; Hopital Marie
   Lannelongue; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite Paris Cite;
   Hopital Universitaire Hotel-Dieu - APHP; Universite Paris Saclay;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Antoine-Beclere - APHP; Hopital Universitaire Bicetre - APHP; Hopital
   Universitaire Paul-Brousse - APHP; Hopital Marie Lannelongue; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite Paris Cite; Hopital Universitaire
   Hotel-Dieu - APHP; Universite Paris Saclay; University of Barcelona;
   Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERES; Ruprecht Karls University Heidelberg;
   Columbia University; Consiglio Nazionale delle Ricerche (CNR); Istituto
   di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR);
   University of Palermo; Universite Libre de Bruxelles; UDICE-French
   Research Universities; Universite Paris Cite; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Broca - APHP; Hopital
   Universitaire Cochin - APHP; Hopital Universitaire Necker-Enfants
   Malades - APHP; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Monash University; National &
   Kapodistrian University of Athens; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research
   Universities; Universite Paris Cite; Hopital Universitaire Cochin -
   APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; Hopital
   Universitaire Hotel-Dieu - APHP; Hopital Universitaire Saint-Louis -
   APHP; Istituto Superiore di Sanita (ISS); Imperial College London
RP Huertas, A (corresponding author), Hop Marie Lannelongue, Inserm UMR S 999, 133 Ave Resistance, F-92350 Paris, France.
EM alice.huertas@inserm.fr
RI Huertas, Alice/E-8244-2017; Humbert, Marc/ABD-5112-2021; Testa,
   Ugo/J-6472-2016; DINH-XUAN, Anh Tuan/A-9691-2008; Savale,
   Laurent/AAJ-9781-2020; Bonsignore, Maria/U-6440-2017; Wilkins,
   Martin/ABH-1140-2021; GUIGNABERT, Christophe/G-3873-2013; Bonsignore,
   Maria/T-3983-2019; Humbert, Marc/AAC-8459-2019
OI Huertas, Alice/0000-0001-8545-747X; Testa, Ugo/0000-0001-7900-8942;
   DINH-XUAN, Anh Tuan/0000-0001-8651-5176; Bonsignore,
   Maria/0000-0002-4875-7796; Wilkins, Martin/0000-0003-3926-1171;
   GUIGNABERT, Christophe/0000-0002-8545-4452; Humbert,
   Marc/0000-0003-0703-2892; Dorfmuller, Peter/0000-0003-2499-6829
FU European Respiratory Society (ERS); Association de Recherche en
   Physiopathologie Respiratoire; Elivie; GlaxoSmithKline; Miltenyi Biotec;
   Oxyvie; Teva; Vivisol
FX The research seminar was sponsored by the European Respiratory Society
   (ERS) with the financial support of unrestricted grants from Association
   de Recherche en Physiopathologie Respiratoire, Elivie, GlaxoSmithKline,
   Miltenyi Biotec, Oxyvie, Teva and Vivisol. Funding information for this
   article has been deposited with the Crossref Funder Registry.
CR Abe K, 2016, CARDIOVASC RES, V111, P16, DOI 10.1093/cvr/cvw070
   Adir Y, 2012, CHEST, V142, P1654, DOI 10.1378/chest.11-2816
   Ahluwalia A, 2004, P NATL ACAD SCI USA, V101, P1386, DOI 10.1073/pnas.0304264101
   Ataga KI, 2006, BRIT J HAEMATOL, V134, P109, DOI 10.1111/j.1365-2141.2006.06110.x
   Bartsch P, 2013, NEW ENGL J MED, V368, P2294, DOI 10.1056/NEJMcp1214870
   Bailey DM, 2010, J PHYSIOL-LONDON, V588, P4837, DOI 10.1113/jphysiol.2010.194704
   Barbera JA, 2001, AM J RESP CRIT CARE, V164, P709, DOI 10.1164/ajrccm.164.4.2101023
   Bartsch P, 2005, J APPL PHYSIOL, V98, P1101, DOI 10.1152/japplphysiol.01167.2004
   Bartsch P, 2002, LANCET, V360, P571, DOI 10.1016/S0140-6736(02)09723-4
   BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805
   Basile David P., 2014, Cardiovascular & Hematological Disorders - Drug Targets, V14, P3
   Bei Y, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.105
   Blanco I, 2016, RESPIROLOGY, V21, P984, DOI 10.1111/resp.12772
   Busch T, 2001, AM J RESP CRIT CARE, V163, P368, DOI 10.1164/ajrccm.163.2.2001134
   Chaouat A, 2005, AM J RESP CRIT CARE, V172, P189, DOI 10.1164/rccm.200401-006OC
   De Castro LM, 2008, AM J HEMATOL, V83, P19, DOI 10.1002/ajh.21058
   de Man FS, 2012, AM J RESP CRIT CARE, V186, P780, DOI 10.1164/rccm.201203-0411OC
   Dehnert C, 2006, AM J RESP CRIT CARE, V174, P1132, DOI 10.1164/rccm.200606-780OC
   Dehnert C, 2015, HIGH ALT MED BIOL, V16, P11, DOI 10.1089/ham.2014.1117
   DINHXUAN AT, 1992, EUR RESPIR J, V5, P757
   DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203
   Herrera MD, 2010, AGEING RES REV, V9, P142, DOI 10.1016/j.arr.2009.07.002
   Dominguez-Fandos D, 2015, EUR RESPIR J, V46, P346, DOI 10.1183/09031936.00139914
   Donadee C, 2011, CIRCULATION, V124, P465, DOI 10.1161/CIRCULATIONAHA.110.008698
   Duong-Quy S, 2011, EUR RESPIR J, V37, P349, DOI 10.1183/09031936.00056610
   Duong-Quy S, 2013, PHARMACOL THERAPEUT, V137, P352, DOI 10.1016/j.pharmthera.2012.12.003
   Duplain H, 2000, AM J RESP CRIT CARE, V162, P221, DOI 10.1164/ajrccm.162.1.9908039
   El Assar M, 2013, FREE RADICAL BIO MED, V65, P380, DOI 10.1016/j.freeradbiomed.2013.07.003
   Eldridge MW, 1996, J APPL PHYSIOL, V81, P911, DOI 10.1152/jappl.1996.81.2.911
   Emin MT, 2012, AM J PHYSIOL-LUNG C, V302, pL1209, DOI 10.1152/ajplung.00189.2011
   Fadini GP, 2006, STEM CELLS, V24, P1806, DOI 10.1634/stemcells.2005-0440
   Feng B, 2010, ATHEROSCLEROSIS, V208, P264, DOI 10.1016/j.atherosclerosis.2009.06.037
   Ferrer E, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-76
   Gibson GJ, 2013, EUR RESPIR J, V42, P559, DOI 10.1183/09031936.00105513
   Gladwin MT, 2016, LANCET, V387, P2565, DOI 10.1016/S0140-6736(16)00647-4
   Gladwin MT, 2014, BLOOD, V123, P3689, DOI 10.1182/blood-2014-03-563874
   Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477
   Gordon C, 2011, AM J RESP CRIT CARE, V184, P224, DOI 10.1164/rccm.201012-2061OC
   Grunig E, 2009, CIRCULATION, V119, P1747, DOI 10.1161/CIRCULATIONAHA.108.800938
   Grunig E, 2000, J AM COLL CARDIOL, V35, P980, DOI 10.1016/S0735-1097(99)00633-6
   Guignabert C, 2015, CHEST, V147, P529, DOI 10.1378/chest.14-0862
   Guignabert C, 2013, SEMIN RESP CRIT CARE, V34, P551, DOI 10.1055/s-0033-1356496
   Hilde JM, 2013, EUR RESPIR J, V41, P1031, DOI 10.1183/09031936.00085612
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796
   HOHENHAUS E, 1995, EUR RESPIR J, V8, P1825, DOI 10.1183/09031936.95.08111825
   Hopkins SR, 2005, AM J RESP CRIT CARE, V171, P83, DOI 10.1164/rccm.200406-707OC
   Huertas A, 2016, CHEST, V149, P1482, DOI 10.1016/j.chest.2016.01.004
   Huertas A, 2015, EUR RESPIR J, V45, P1066, DOI 10.1183/09031936.00193014
   Huertas A, 2014, CIRCULATION, V129, P1332, DOI 10.1161/CIRCULATIONAHA.113.004555
   Huertas A, 2013, AM J RESP CELL MOL, V48, P78, DOI 10.1165/rcmb.2011-0402OC
   Huertas A, 2012, EUR RESPIR J, V40, P895, DOI 10.1183/09031936.00159911
   Huertas A, 2010, RESP PHYSIOL NEUROBI, V170, P23, DOI 10.1016/j.resp.2009.10.003
   HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759
   Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818
   Ichimura H, 2003, J CLIN INVEST, V111, P691, DOI 10.1172/JCI200317271
   Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Kiefmann R, 2009, AM J PHYSIOL-LUNG C, V296, pL901, DOI 10.1152/ajplung.90549.2008
   Kubo K, 1998, RESP PHYSIOL, V111, P301, DOI 10.1016/S0034-5687(98)00006-1
   Kuebler WM, 1999, J CLIN INVEST, V104, P495, DOI 10.1172/JCI6872
   Kuebler WM, 2000, J CLIN INVEST, V105, P905, DOI 10.1172/JCI8604
   Le Hiress M, 2015, AM J RESP CRIT CARE, V192, P983, DOI 10.1164/rccm.201402-0322OC
   Llinas L, 2011, PULM PHARMACOL THER, V24, P32, DOI 10.1016/j.pupt.2010.10.010
   Tu L, 2012, AM J RESP CRIT CARE, V186, P666, DOI 10.1164/rccm.201202-0309OC
   Tu L, 2011, AM J RESP CELL MOL, V45, P311, DOI 10.1165/rcmb.2010-0317OC
   Machado RF, 2006, JAMA-J AM MED ASSOC, V296, P310, DOI 10.1001/jama.296.3.310
   Maggiorini M, 2001, CIRCULATION, V103, P2078
   Maggiorini M, 2006, ANN INTERN MED, V145, P497, DOI 10.7326/0003-4819-145-7-200610030-00007
   Marijic J, 2001, CIRC RES, V88, P210
   McLaughlin VV, 2015, J AM COLL CARDIOL, V65, P1976, DOI 10.1016/j.jacc.2015.03.540
   Mehta D, 2004, AM J PHYSIOL-LUNG C, V287, pL1081, DOI 10.1152/ajplung.00268.2004
   Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002
   Nana-Sinkam SP, 2007, AM J RESP CRIT CARE, V175, P676, DOI 10.1164/rccm.200605-724OC
   OELZ O, 1989, LANCET, V2, P1241
   Palange P, 2006, EUR RESPIR J, V27, P529, DOI 10.1183/09031936.06.00120604
   Parent F, 2011, NEW ENGL J MED, V365, P44, DOI 10.1056/NEJMoa1005565
   Peinado VI, 2006, AM J RESP CELL MOL, V34, P257, DOI 10.1165/rcmb.2005-0255OC
   Peinado VI, 1998, AM J PHYSIOL-LUNG C, V274, pL908, DOI 10.1152/ajplung.1998.274.6.L908
   Peinado VI, 2008, CHEST, V134, P808, DOI 10.1378/chest.08-0820
   Peinado VI, 2013, J HEART LUNG TRANSPL, V32, P1262, DOI 10.1016/j.healun.2013.09.007
   Pelosi E, 2014, BLOOD CELL MOL DIS, V52, P186, DOI 10.1016/j.bcmd.2013.11.004
   Petousi N, 2014, J APPL PHYSIOL, V116, P875, DOI 10.1152/japplphysiol.00605.2013
   Pizarro S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106163
   Portillo K, 2015, INT J CHRONIC OBSTR, V10, P1313, DOI 10.2147/COPD.S78180
   Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799
   Ricard N, 2014, CIRCULATION, V129, P1586, DOI 10.1161/CIRCULATIONAHA.113.007469
   Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653
   Rowlands DJ, 2011, J CLIN INVEST, V121, P1986, DOI 10.1172/JCI43839
   RYAN US, 1984, CIRCULATION, V70, P46
   RYAN US, 1986, CLIN INVEST MED, V9, P124
   Santos S, 2002, EUR RESPIR J, V19, P632, DOI 10.1183/09031936.02.00245902
   Sartori C, 1999, CIRCULATION, V99, P2665, DOI 10.1161/01.CIR.99.20.2665
   Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003
   SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605
   Seimetz M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129327
   Seimetz M, 2011, CELL, V147, P293, DOI 10.1016/j.cell.2011.08.035
   Simonneau G, 2013, J AM COLL CARDIOL, V62, pD34, DOI [10.1016/j.jacc.2009.04.012, 10.1016/j.jacc.2013.10.029]
   Soria R, 2016, J APPL PHYSIOL, V121, P1151, DOI 10.1152/japplphysiol.00394.2016
   Stenmark KR, 2005, CIRC RES, V97, P95, DOI 10.1161/01.RES.00000175934.68087.29
   Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f
   Sweatt AJ, 2014, CLIN CHEST MED, V35, P609, DOI 10.1016/j.ccm.2014.08.002
   Swenson ER, 2002, JAMA-J AM MED ASSOC, V287, P2228, DOI 10.1001/jama.287.17.2228
   Swenson ER, 2012, COMPR PHYSIOL, V2, P2753, DOI 10.1002/cphy.c100029
   Sylvester JT, 2012, PHYSIOL REV, V92, P367, DOI 10.1152/physrev.00041.2010
   Takahashi T, 2014, INT J CHRONIC OBSTR, V9, P303, DOI 10.2147/COPD.S38931
   Thomashow MA, 2013, AM J RESP CRIT CARE, V188, P60, DOI 10.1164/rccm.201209-1697OC
   Vanhoutte PM, 2016, CIRC RES, V119, P375, DOI 10.1161/CIRCRESAHA.116.306531
   VISWANATHAN R, 1969, AM REV RESPIR DIS, V100, P334, DOI 10.1164/arrd.1969.100.3.334
   VOCK P, 1991, CHEST, V100, P1306, DOI 10.1378/chest.100.5.1306
   Weissmann N, 2001, AM J PHYSIOL-LUNG C, V280, pL638, DOI 10.1152/ajplung.2001.280.4.L638
   Weissmann N, 2014, AM J RESP CRIT CARE, V189, P1359, DOI 10.1164/rccm.201311-2037OC
   WEST JB, 1974, ANESTHESIOLOGY, V41, P124, DOI 10.1097/00000542-197408000-00004
   Westphalen K, 2012, AM J PHYSIOL-LUNG C, V303, pL107, DOI 10.1152/ajplung.00206.2011
   Wilkins MR, 2015, CIRCULATION, V131, P582, DOI 10.1161/CIRCULATIONAHA.114.006977
   Wilkins MR, 2014, CIRC-CARDIOVASC GENE, V7, P920, DOI 10.1161/CIRCGENETICS.114.000763
   Wright JL, 2011, AM J RESP CRIT CARE, V183, P50, DOI 10.1164/rccm.201003-0399OC
   Ying XY, 1996, CIRC RES, V79, P898, DOI 10.1161/01.RES.79.4.898
   Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471
   Zhao L, 2015, NATURE, V524, P356, DOI 10.1038/nature14620
NR 120
TC 92
Z9 96
U1 3
U2 20
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD APR 1
PY 2018
VL 51
IS 4
AR 1700745
DI 10.1183/13993003.00745-2017
PG 13
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA GC8BH
UT WOS:000430017400014
PM 29545281
OA Bronze, Green Submitted
DA 2023-08-21
ER

PT J
AU Wu, DD
   Wang, YN
   Zhang, H
   Du, MH
   Li, TS
AF Wu, Dongdong
   Wang, Yanan
   Zhang, Heng
   Du, Minghua
   Li, Tanshi
TI Acacetin attenuates mice endotoxin-induced acute lung injury via
   augmentation of heme oxygenase-1 activity
SO INFLAMMOPHARMACOLOGY
LA English
DT Article
DE Acacetin; ALI/ARDS; HO-1 
ID RESPIRATORY-DISTRESS-SYNDROME; CARBON-MONOXIDE; MECHANISMS; ANTIOXIDANT;
   EXPRESSION; PATHWAY; RATS; INTERLEUKIN-1-BETA; PROTECTION; SEPSIS
AB Acacetin, a natural product, has a wide spectrum of biological activities such as antioxidant properties. In the present study, we examined whether Acacetin has any beneficial role on lipopolysaccharide (LPS)-induced acute lung injury (ALI) and, if so, whether its effect is mediated via heme oxygenase-1 (HO-1), an antioxidant enzyme playing an important role in ALI. Male BALB/c mice were stimulated with LPS intratracheal instillation to induce ALI. Acacetin was administrated 2 h after LPS challenge. Samples were harvested 10 h after LPS administration. We demonstrated that LPS challenge significantly induced lung histological alterations such as inflammation and edema. Acacetin administration notably attenuated these changes and reduced tumor necrosis factor-alpha and interleukin-1 beta in lung tissues. The LPS-induced reactive oxygen species generation was markedly suppressed by Acacetin. Furthermore, Acacetin treatment significantly elevated pulmonary HO-1 and nuclear factor erythroid-2-related factor 2 (Nrf2) activities. However, the beneficial action of Acacetin was markedly abolished when pretreated with zinc protoporphyrin, an inhibitor of HO-1. In in vitro studies, Acacetin notably increased the HO-1 expression in pulmonary microvascular endothelial cells. During knockdown of Nrf2 by siRNA, the effect of Acacetin on HO-1 expression was significantly reversed. Acacetin attenuates LPS-induced ALI in mice. This protective effect of Acacetin may be mediated, in part, through an HO-1-dependent pathway.
C1 [Wu, Dongdong; Wang, Yanan; Zhang, Heng; Du, Minghua; Li, Tanshi] Chinese Peoples Liberat Army, Emergency Dept, Gen Hosp, 28 Fuxing Rd, Beijing 100853, China.
C3 Chinese People's Liberation Army General Hospital
RP Li, TS (corresponding author), Chinese Peoples Liberat Army, Emergency Dept, Gen Hosp, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM TanshiLi07@163.com
CR Agarwal Anupam, 2013, Trans Am Clin Climatol Assoc, V124, P111
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999
   Carballo-Villalobos AI, 2014, EUR J PAIN, V18, P396, DOI 10.1002/j.1532-2149.2013.00378.x
   Cheng C, 2007, MOL CELL BIOCHEM, V305, P1, DOI 10.1007/s11010-007-9521-7
   Chi XJ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0793-0
   Cho HI, 2014, J NAT PROD, V77, P2497, DOI 10.1021/np500537x
   Clerigues V, 2012, BIOCHEM PHARMACOL, V83, P395, DOI 10.1016/j.bcp.2011.11.024
   Constantin M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/859235
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Ha SK, 2012, NEUROCHEM RES, V37, P1560, DOI 10.1007/s11064-012-0751-z
   Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200
   Huang WC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/910520
   Joe Y, 2015, AM J PATHOL, V185, P2867, DOI 10.1016/j.ajpath.2015.07.002
   Kim SK, 2017, CELL MOL IMMUNOL, V14, P349, DOI 10.1038/cmi.2015.79
   Kobayashi A, 2004, METHOD ENZYMOL, V378, P273
   Lin WC, 2011, J PHARMACOL EXP THER, V339, P45, DOI 10.1124/jpet.111.181560
   Liu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36435
   Ma JL, 2007, J PHARMACOL SCI, V103, P261, DOI 10.1254/jphs.FP0060270
   Mac Sweeney R, 2016, LANCET, V388, P2416, DOI 10.1016/S0140-6736(16)00578-X
   MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025
   Na HK, 2014, FREE RADICAL BIO MED, V67, P353, DOI 10.1016/j.freeradbiomed.2013.10.819
   Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680
   Qiu P, 2013, CRIT CARE MED, V41, P2419, DOI 10.1097/CCM.0b013e3182982add
   Ryter SW, 2000, METH MOL B, V99, P369
   Takashima K, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0150-x
   Tanigawa N, 2013, IMMUNOPHARM IMMUNOT, V35, P471, DOI 10.3109/08923973.2013.811596
   Tao W, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0200-7
   Tao W, 2012, PULM PHARMACOL THER, V25, P99, DOI 10.1016/j.pupt.2011.12.006
   Tao W, 2012, INFLAMMATION, V35, P150, DOI 10.1007/s10753-011-9300-1
   Tao WD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156854
   TENHUNEN R, 1969, J BIOL CHEM, V244, P6388
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu SY, 2015, ANESTHESIOLOGY, V122, P1327, DOI 10.1097/ALN.0000000000000618
   Xiong J, 2017, INT J MOL MED, V39, P113, DOI 10.3892/ijmm.2016.2809
   Yang WJ, 2014, CHIN MED-UK, V9, DOI 10.1186/s13020-014-0028-3
   Yu JB, 2016, ANESTHESIOLOGY, V125, P1190, DOI 10.1097/ALN.0000000000001333
   Yu JB, 2016, SCI REP-UK, V6, DOI 10.1038/srep36530
   Zhao HL, 2017, AM J PHYSIOL-LUNG C, V312, pL155, DOI 10.1152/ajplung.00449.2016
   Zhu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056407
NR 43
TC 27
Z9 29
U1 1
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925-4692
EI 1568-5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
PD APR
PY 2018
VL 26
IS 2
BP 635
EP 643
DI 10.1007/s10787-017-0398-0
PG 9
WC Immunology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA FZ9JI
UT WOS:000427926400030
PM 28988328
DA 2023-08-21
ER

PT J
AU Li, JJ
   Chen, Q
   He, XH
   Alam, A
   Ning, JL
   Yi, B
   Lu, KZ
   Gu, JT
AF Li, Juanjuan
   Chen, Qian
   He, Xinhai
   Alam, Azeem
   Ning, Jiaolin
   Yi, Bin
   Lu, Kaizhi
   Gu, Jianteng
TI Dexmedetomidine attenuates lung apoptosis induced by renal
   ischemiareperfusion injury through alpha(2)AR/PI3K/Akt pathway
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE ischemia/reperfusion; ALI/ARDS; alpha(2)-adrenoreceptor; Akt/Akt1; apoptosis 
ID ACUTE KIDNEY INJURY; ISCHEMIA-REPERFUSION; CASPASE-3; PROTECTS; MICE
AB Background: Acute lung injury caused by renal ischemia-reperfusion is one of the leading causes of acute kidney injury-related death. Dexmedetomidine, an alpha(2)-adrenergic agonist sedative, has been found to have protective effects against acute kidney injury and remote lung injury. We sought to determine whether dexmedetomidine can exert its anti-apoptotic effects in acute lung injury after acute kidney injury, in addition to its common anti-inflammatory effects, and to determine the underlying mechanisms.
   Methods: In vivo, acute kidney injury was induced by 60 min of kidney ischemia (bilateral occlusion of renal pedicles) followed by 24 h of reperfusion. Mice received dexmedetomidine (25 mu g/kg, i.p.) in the absence or presence of alpha(2)-adrenergic antagonist atipamezole (250 mu g/kg, i.p.) before IR. Histological assessment of the lung was conducted by HE staining and arterial blood gases were measured. Lung apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay. The expression of caspase 3 and p-Akt in lung tissue was detected by western blot. In vitro, C57BL/6J mice pulmonary microvascular endothelial cells were treated with serum from mice obtained following sham or IR. Dexmedetomidine was given before serum stimulation in cells, alone or with atipamezole or LY294002. Cell viability was assessed by CCK 8 assay. Cell apoptosis was examined by Hoechst staining and Annexin V-FITC/PI staining flow cytometry analysis. Mitochondrial membrane potential was measured by flow cytometry. The expression of p-Akt, caspase 3, Bcl-2 and Bax was measured by western blot.
   Results: In vivo, dexmedetomidine remarkably mitigated pathohistological changes and apoptosis and significantly increased p-Akt expression in the lung. In addition, dexmedetomidine also slightly improved oxygenation in mice after IR, which can be abolished by atipamezole. In vitro, dexmedetomidine significantly inhibited IR serum-induced loss of viability and apoptosis in PMVECs. Dexmedetomidine increased p-Akt in a time-and dose-dependent manner, and down-regulated the expression of caspase 3 and Bax and up-regulated the Bcl-2 expression in PMVECs. The changes of MMP were also improved by dexmedetomidine. Whilst these effects were abolished by Atipamezole or LY294002.
   Conclusion: Our results demonstrated that dexmedetomidine attenuates lung apoptosis induced by IR, at least in part, via alpha(2)AR/PI3K/Akt pathway.
C1 [Li, Juanjuan; Chen, Qian; He, Xinhai; Ning, Jiaolin; Yi, Bin; Lu, Kaizhi; Gu, Jianteng] Third Mil Med Univ, Southwest Hosp, Dept Anesthesiol, 30 Gaotanyan Rd, Chongqing 400038, China.
C1 [Alam, Azeem] Imperial Coll London, Fac Med, Dept Surg & Canc, Anaesthet Pain Med & Intens Care, Chelsea & Westminster Campus, London, England, United Kingdom.
C3 Army Medical University; Imperial College London
RP Gu, JT (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Anesthesiol, 30 Gaotanyan Rd, Chongqing 400038, Peoples R China.
EM jiantenggu@hotmail.com
RI yi, bin/ABF-6425-2021
OI yi, bin/0000-0001-5840-2086; Alam, Azeem/0000-0002-4339-6223
FU National Natural Science Foundation of China [81272068, 81772050]
FX The National Natural Science Foundation of China (Nos. 81272068 and
   81772050).
CR Awad AS, 2007, AM J PHYSIOL-RENAL, V293, pF28, DOI 10.1152/ajprenal.00159.2007
   Chen Q, 2016, ONCOTARGET, V7, P55990, DOI 10.18632/oncotarget.10809
   Deng JP, 2004, AM J RESP CRIT CARE, V169, P749, DOI 10.1164/rccm.200303-372OC
   Doi K, 2016, KIDNEY INT, V89, P555, DOI 10.1016/j.kint.2015.11.019
   Doi K, 2011, CLIN EXP NEPHROL, V15, P464, DOI 10.1007/s10157-011-0459-4
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Faubel S, 2016, NAT REV NEPHROL, V12, P48, DOI 10.1038/nrneph.2015.158
   Feltes CM, 2011, SHOCK, V36, P170, DOI 10.1097/SHK.0b013e3182169c76
   Gu J, 2011, ACTA ANAESTH SCAND, V55, P1272, DOI 10.1111/j.1399-6576.2011.02526.x
   Hassoun HT, 2009, AM J PHYSIOL-RENAL, V297, pF125, DOI 10.1152/ajprenal.90666.2008
   Karimi Z, 2016, RENAL FAILURE, V38, P1503, DOI 10.1080/0886022X.2016.1214149
   Klein CL, 2008, KIDNEY INT, V74, P901, DOI 10.1038/ki.2008.314
   Koyner JL, 2014, AM J KIDNEY DIS, V64, P394, DOI 10.1053/j.ajkd.2014.03.018
   Kuribayashi K, 2006, CANCER BIOL THER, V5, P763, DOI 10.4161/cbt.5.7.3228
   Liang H, 2017, INFLAMM RES, V66, P399, DOI 10.1007/s00011-017-1023-9
   Liu JR, 2016, ANESTH ANALG, V123, P1008, DOI 10.1213/ANE.0000000000001527
   Ologunde R, 2014, INT UROL NEPHROL, V46, P2337, DOI 10.1007/s11255-014-0766-2
   Oztay F, 2016, TOXICOL IND HEALTH, V32, P1684, DOI 10.1177/0748233715576615
   White LE, 2012, SHOCK, V38, P320, DOI 10.1097/SHK.0b013e31826359d0
   Wu GJ, 2017, J CELL BIOCHEM, V118, P2635, DOI 10.1002/jcb.25847
   Xia ZN, 2017, SHOCK, V48, P260, DOI 10.1097/SHK.0000000000000826
   Yang B, 2013, EXPERT OPIN THER TAR, V17, P255, DOI 10.1517/14728222.2013.745513
   Yeh JH, 2013, TRANSPL P, V45, P3542, DOI 10.1016/j.transproceed.2013.09.004
   Zang DY, 2013, ULTRASTRUCT PATHOL, V37, P433, DOI 10.3109/01913123.2013.833562
NR 24
TC 59
Z9 69
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAR 23
PY 2018
VL 16
AR 78
DI 10.1186/s12967-018-1455-1
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GA9ET
UT WOS:000428644800001
PM 29566706
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Barabutis, N
   Dimitropoulou, C
   Gregory, B
   Catravas, JD
AF Barabutis, Nektarios
   Dimitropoulou, Christiana
   Gregory, Betsy
   Catravas, John D.
TI Wild-type p53 enhances endothelial barrier function by mediating RAC1
   signalling and RhoA inhibition
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE P53; Inflammation; barrier function 
ID TUMOR-SUPPRESSOR P53; LUNG; EXPRESSION; CHRONOPHIN; STABILITY;
   INFLAMMATION; APE1/REF-1; HSP90
AB Inflammation is the major cause of endothelial barrier hyper-permeability, associated with acute lung injury and acute respiratory distress syndrome. This study reports that p53 "orchestrates" the defence of vascular endothelium against LPS, by mediating the opposing actions of Rac1 and RhoA in pulmonary tissues. Human lung microvascular endothelial cells treated with HSP90 inhibitors activated both Rac1- and P21-activated kinase, which is an essential element of vascular barrier function. 17AAG increased the phosphorylation of both LIMK and cofilin, in contrast to LPS which counteracted those effects. Mouse lung microvascular endothelial cells exposed to LPS exhibited decreased expression of phospho-cofilin. 17AAG treatment resulted in reduced levels of active cofilin. Silencing of cofilin pyridoxal phosphate phosphatase (PDXP) blocked the LPS-induced hyper-permeability, and P53 inhibition reversed the 17AAG-induced PDXP down-regulation. P190RHOGAP suppression enhanced the LPS-triggered barrier dysfunction in endothelial monolayers. 17AAG treatment resulted in P190RHOGAP induction and blocked the LPS-induced pMLC2 up-regulation in wild-type mice. Pulmonary endothelial cells from "super p53" mice, which carry additional p53-tg alleles, exhibited a lower response to LPS than the controls. Collectively, our findings help elucidate the mechanisms by which p53 operates to enhance barrier function.
C1 [Barabutis, Nektarios; Dimitropoulou, Christiana; Gregory, Betsy; Catravas, John D.] Old Dominion Univ, Frank Reidy Res Ctr Bioelect, Norfolk, VA 23529, United States.
C1 [Catravas, John D.] Old Dominion Univ, Coll Hlth Sci, Sch Med Diagnost & Translat Sci, Norfolk, VA, United States.
C3 Old Dominion University; Old Dominion University
RP Barabutis, N (corresponding author), Old Dominion Univ, Frank Reidy Res Ctr Bioelect, Norfolk, VA 23529 USA.
EM barabutis@ulm.edu
FU National Heart, Lung, and Blood Institute Grants [HL101902, HL93460]
FX The authors would like to thank Dr. Manuel Serrano (Institute for
   Research in Biomedicine, Barcelona, Spain) for the kind donation of the
   "super p53" mice. This study was supported by National Heart, Lung, and
   Blood Institute Grants HL101902 and HL93460 to J.D.C. A portion of
   17-AAG was provided by the National Cancer Institute.
CR Alhadidi Q, 2017, MOL NEUROBIOL
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711
   Ashcroft M, 1999, MOL CELL BIOL, V19, P1751
   Barabutis N, 2008, BRIT J CANCER, V98, P1790, DOI 10.1038/sj.bjc.6604386
   Barabutis N, 2013, MED SURG UROL, V2, P1
   Barabutis N, 2017, CHEST, V152, P954, DOI 10.1016/j.chest.2017.07.014
   Barabutis N, 2016, AM J PHYSIOL-LUNG C, V311, pL832, DOI 10.1152/ajplung.00233.2016
   Barabutis N, 2015, AM J PHYSIOL-LUNG C, V308, pL776, DOI 10.1152/ajplung.00334.2014
   Barabutis N, 2013, AM J PHYSIOL-LUNG C, V304, pL883, DOI 10.1152/ajplung.00419.2012
   Barabutis N, 2011, J CELL MOL MED, V15, P1148, DOI 10.1111/j.1582-4934.2010.01096.x
   Barabutis N, 2010, CELL CYCLE, V9, P4110, DOI 10.4161/cc.9.20.13787
   Barabutis N, 2008, P NATL ACAD SCI USA, V105, P20470, DOI 10.1073/pnas.0811209106
   Byrne KM, 2016, CELL SYST, V2, P38, DOI 10.1016/j.cels.2016.01.003
   Catravas JD, 2010, VASC PHARMACOL, V52, P175, DOI 10.1016/j.vph.2009.12.009
   Chaigne-Delalande B, 2006, AM J PATHOL, V168, P562, DOI 10.2353/ajpath.2006.050345
   Chang CY, 2015, INT J MOL SCI, V16, P4095, DOI 10.3390/ijms16024095
   Chen F, 2012, ARTERIOSCL THROM VAS, V32, P2989, DOI 10.1161/ATVBAHA.112.300361
   Cooks T, 2014, CARCINOGENESIS, V35, P1680, DOI 10.1093/carcin/bgu134
   Croft DR, 2011, CELL RES, V21, P666, DOI 10.1038/cr.2010.154
   Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200
   Deng XF, 2016, J GENET GENOMICS, V43, P709, DOI 10.1016/j.jgg.2016.07.002
   densHartog G, 2016, PLOS PATHOG, V12
   Ebata T, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9231057
   Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595
   Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201
   Gudkov AV, 2016, COLD SPRING HARB PER, V6
   Hagn F, 2011, NAT STRUCT MOL BIOL, V18, P1086, DOI 10.1038/nsmb.2114
   He XY, 2015, CELL REP, V13, P888, DOI 10.1016/j.celrep.2015.09.045
   Huang TY, 2008, DEV CELL, V15, P691, DOI 10.1016/j.devcel.2008.09.017
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893
   Lee SJ, 2017, BMB REP, V50, P335, DOI 10.5483/BMBRep.2017.50.6.061
   Li T, 2011, ANN SURG, V253, P185, DOI 10.1097/SLA.0b013e3181f9b88b
   Ma J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066275
   Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559
   Moll UM, 2003, MOL CANCER RES, V1, P1001
   Nieman GF, 2015, CHEST, V148, P1396, DOI 10.1378/chest.15-0990
   Ponik SM, 2013, MOL BIOL CELL, V24, P1688, DOI 10.1091/mbc.E12-05-0386
   Saha T, 2016, SCI REP-UK, V6, DOI 10.1038/srep32626
   Simeonov A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005740
   Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194
   Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993
   Todoric J, 2016, CANCER PREV RES, V9, P895, DOI 10.1158/1940-6207.CAPR-16-0209
   Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060179
   Wang SY, 2016, 2016 INTERNATIONAL SYMPOSIUM ON COMPUTER, CONSUMER AND CONTROL (IS3C), P6, DOI 10.1109/IS3C.2016.12
   Zaika AI, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005099
   Zaky A, 2008, NUCLEIC ACIDS RES, V36, P1555, DOI 10.1093/nar/gkm1173
   Zhang XW, 2017, CANCER J, V23, P201, DOI 10.1097/PPO.0000000000000270
   Zhao Zhuo-Shen, 2012, Cell Logist, V2, P59
NR 53
TC 40
Z9 41
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAR
PY 2018
VL 22
IS 3
BP 1792
EP 1804
DI 10.1111/jcmm.13460
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FX4SU
UT WOS:000426069300036
PM 29363851
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Gutbier, B
   Schonrock, SM
   Ehrler, C
   Haberberger, R
   Dietert, K
   Gruber, AD
   Kummer, W
   Michalick, L
   Kuebler, WM
   Hocke, AC
   Szymanski, K
   Letsiou, E
   Luth, A
   Schumacher, F
   Kleuser, B
   Mitchell, TJ
   Bertrams, W
   Schmeck, B
   Treue, D
   Klauschen, F
   Bauer, TT
   Tonnies, M
   Weissmann, N
   Hippenstiel, S
   Suttorp, N
   Witzenrath, M
AF Gutbier, Birgitt
   Schoenrock, Stefanie M.
   Ehrler, Carolin
   Haberberger, Rainer
   Dietert, Kristina
   Gruber, Achim D.
   Kummer, Wolfgang
   Michalick, Laura
   Kuebler, Wolfgang M.
   Hocke, Andreas C.
   Szymanski, Kolja
   Letsiou, Eleftheria
   Lueth, Anja
   Schumacher, Fabian
   Kleuser, Burkhard
   Mitchell, Timothy J.
   Bertrams, Wilhelm
   Schmeck, Bernd
   Treue, Denise
   Klauschen, Frederick
   Bauer, Torsten T.
   Toennies, Mario
   Weissmann, Norbert
   Hippenstiel, Stefan
   Suttorp, Norbert
   Witzenrath, Martin
CA CAPNETZ Study Grp
TI Sphingosine Kinase 1 Regulates Inflammation and Contributes to Acute
   Lung Injury in Pneumococcal Pneumonia via the Sphingosine-1-Phosphate
   Receptor 2
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE ALI/ARDS; pneumococcal pneumonia; sphingosine kinase 1; S1P/S1PR1/S1PR2/S1PR3 
ID COMMUNITY-ACQUIRED PNEUMONIA; ENDOTHELIAL HYPERPERMEABILITY;
   VASCULAR-PERMEABILITY; 1-PHOSPHATE; MURINE; CELLS; INHIBITION;
   TRANSDUCTION; PNEUMOLYSIN; ACTIVATION
AB Objectives: Severe pneumonia may evoke acute lung injury, and sphingosine-1-phosphate is involved in the regulation of vascular permeability and immune responses. However, the role of sphingosine-1-phosphate and the sphingosine-1-phosphate producing sphingosine kinase 1 in pneumonia remains elusive. We examined the role of the sphingosine-1-phosphate system in regulating pulmonary vascular barrier function in bacterial pneumonia.
   Design: Controlled, in vitro, ex vivo, and in vivo laboratory study.
   Subjects: Female wild-type and SphK1-deficient mice, 8-10 weeks old. Human postmortem lung tissue, human blood-derived macrophages, and pulmonary microvascular endothelial cells.
   Interventions: Wild-type and SphK1-deficient mice were infected with Streptococcus pneumoniae. Pulmonary sphingosine-1-phosphate levels, messenger RNA expression, and permeability as well as lung morphology were analyzed. Human blood-derived macrophages and human pulmonary microvascular endothelial cells were infected with S. pneumoniae. Transcellular electrical resistance of human pulmonary microvascular endothelial cell monolayers was examined. Further, permeability of murine isolated perfused lungs was determined following exposition to sphingosine-1-phosphate and pneumolysin.
   Measurements and Main Results: Following S. pneumoniae infection, murine pulmonary sphingosine-1-phosphate levels and sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 expression were increased. Pneumonia-induced lung hyperpermeability was reduced in SphK1(-/-) mice compared with wild-type mice. Expression of sphingosine kinase 1 in macrophages recruited to inflamed lung areas in pneumonia was observed in murine and human lungs. S. pneumoniae induced the sphingosine kinase 1/sphingosine-1-phosphate system in blood-derived macrophages and enhanced sphingosine-1-phosphate receptor 2 expression in human pulmonary microvascular endothelial cell in vitro. In isolated mouse lungs, pneumolysin-induced hyperpermeability was dose dependently and synergistically increased by sphingosine-1-phosphate. This sphingosine-1-phosphate-induced increase was reduced by inhibition of sphingosine-1-phosphate receptor 2 or its downstream effector Rho-kinase.
   Conclusions: Our data suggest that targeting the sphingosine kinase 1-/sphingosine-1-phosphate-/sphingosine-1-phosphate receptor 2-signaling pathway in the lung may provide a novel therapeutic perspective in pneumococcal pneumonia for prevention of acute lung injury.
C1 [Gutbier, Birgitt; Schoenrock, Stefanie M.; Ehrler, Carolin; Hocke, Andreas C.; Szymanski, Kolja; Letsiou, Eleftheria; Hippenstiel, Stefan; Suttorp, Norbert; Witzenrath, Martin] Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Dept Infect Dis & Pulm Med, Berlin, Germany.
C1 [Gutbier, Birgitt; Schoenrock, Stefanie M.; Ehrler, Carolin; Michalick, Laura; Kuebler, Wolfgang M.; Hocke, Andreas C.; Szymanski, Kolja; Letsiou, Eleftheria; Treue, Denise; Klauschen, Frederick; Hippenstiel, Stefan; Suttorp, Norbert; Witzenrath, Martin] Berlin Inst Hlth, Berlin, Germany.
C1 [Haberberger, Rainer] Flinders Univ S Australia, Anat & Histol, Adelaide, SA, Australia.
C1 [Dietert, Kristina; Gruber, Achim D.] Free Univ Berlin, Inst Vet Pathol, Berlin, Germany.
C1 [Kummer, Wolfgang] Justus Liebig Univ Giessen, Inst Anat & Cell Biol, German Ctr Lung Res, Giessen, Germany.
C1 [Michalick, Laura; Kuebler, Wolfgang M.] Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Dept Physiol, Berlin, Germany.
C1 [Michalick, Laura; Kuebler, Wolfgang M.] Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Ctr Cardiovasc Res, Berlin, Germany.
C1 [Lueth, Anja; Schumacher, Fabian; Kleuser, Burkhard] Univ Potsdam, Inst Nutr Sci, Dept Nutr Toxicol, Nuthetal, Germany.
C1 [Schumacher, Fabian] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany.
C1 [Mitchell, Timothy J.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Birmingham, W Midlands, England, United Kingdom.
C1 [Bertrams, Wilhelm; Schmeck, Bernd] Univ Giessen, Philipps Univ Marburg, Inst Lung Res, Marburg, Germany.
C1 [Bertrams, Wilhelm; Schmeck, Bernd] Univ Marburg, Lung Ctr UGMLC, German Ctr Lung Res, Marburg, Germany.
C1 [Treue, Denise; Klauschen, Frederick] Humboldt Univ, Freie Univ Berlin, Charite Univ Berlin, Dept Pathol, Berlin, Germany.
C1 [Bauer, Torsten T.; Toennies, Mario] HELIOS Klinikum Emil von Behring, Lungenklin Heckeshorn, Berlin, Germany.
C1 [Weissmann, Norbert] Univ Giessen, Excellence Cluster Cardiopulm Syst, Giessen, Germany.
C1 [Weissmann, Norbert] Justus Liebig Univ, German Ctr Lung Res DZL, Marburg Lung Ctr, Giessen, Germany.
C1 [Suttorp, Norbert; Witzenrath, Martin; CAPNETZ Study Grp] CAPNETZ STIFTUNG, Hannover, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Berlin Institute of Health; Flinders
   University South Australia; Free University of Berlin; Justus Liebig
   University Giessen; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   University of Potsdam; University of Duisburg Essen; University of
   Birmingham; Justus Liebig University Giessen; Philipps University
   Marburg; Philipps University Marburg; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   Helios Kliniken; Justus Liebig University Giessen; Justus Liebig
   University Giessen
RP Witzenrath, M (corresponding author), Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Dept Infect Dis & Pulm Med, Berlin, Germany.; Witzenrath, M (corresponding author), Berlin Inst Hlth, Berlin, Germany.; Witzenrath, M (corresponding author), CAPNETZ STIFTUNG, Hannover, Germany.
EM martin.witzenrath@charite.de
RI Gruber, Achim D./ABA-4514-2021; Schumacher, Fabian/ABC-1750-2020; Rohde,
   Gernot GU/F-3060-2013; Rupp, Jan/C-8794-2011; Klauschen,
   Frederick/C-5637-2015; Michalick, Laura/GZG-7201-2022; Michalick,
   Laura/HJJ-1136-2023
OI Schumacher, Fabian/0000-0001-8703-3275; Rohde, Gernot
   GU/0000-0002-5193-7755; Rupp, Jan/0000-0001-8722-1233; Klauschen,
   Frederick/0000-0002-9131-2389; Michalick, Laura/0000-0002-3959-5828;
   Dietert, Kristina/0000-0002-5667-6750; Kummer,
   Wolfgang/0000-0002-3946-0683; Hippenstiel, Stefan/0000-0002-5146-1064;
   Suttorp, Norbert/0000-0002-3958-1151; Stolz, Daiana/0000-0003-0099-882X;
   Kuebler, Wolfgang/0000-0003-4100-2961; Kleuser,
   Burkhard/0000-0002-1888-9595; Treue, Denise/0000-0002-0657-5505;
   Schmeck, Bernd/0000-0002-2767-3606; Kolditz, Martin/0000-0001-6022-6827;
   Bertrams, Wilhelm/0000-0002-0180-2529; Haberberger, Rainer
   Viktor/0000-0001-8043-3786; Weissmann, Norbert/0000-0003-2675-3871
FU German Research Foundation [Kl 988 7-1]; Hessisches Ministerium fur
   Wissenschaft und Kunst (LandesOffensive zur Entwicklung
   Wissenschaftlich-okonomischer Exzellenz Medical RNomics); German Federal
   Ministry of Education and Research [e:Med CAPSyS-FKZ 01ZX1304B/E]
FX Supported, in part, by grants from the German Research Foundation to
   Drs. Gruber, Kummer, Hocke, Schmeck, Hippenstiel, Suttorp, and
   Witzenrath (Transregional Collaborative Research Center 84 "Innate
   Immunity of the Lung," Projects A6, B1, B6, C1, C2, C3, C6, Z1b, Z1a)
   and to Dr. Kleuser (Kl 988 7-1), Hessisches Ministerium fur Wissenschaft
   und Kunst (LandesOffensive zur Entwicklung Wissenschaftlich-okonomischer
   Exzellenz Medical RNomics) to Dr. Schmeck and from the German Federal
   Ministry of Education and Research to Drs. Schmeck, Suttorp, and
   Witzenrath (e:Med CAPSyS-FKZ 01ZX1304B/E).
CR Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   Bird L, 2010, NAT REV DRUG DISCOV, V9, DOI 10.1038/nrd3212
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Dames C, 2014, AM J RESP CELL MOL, V51, P730, DOI 10.1165/rcmb.2014-0052MA
   Dietert K, 2015, HISTOCHEM CELL BIOL, V143, P277, DOI 10.1007/s00418-014-1279-x
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   File TM, 2003, LANCET, V362, P1991, DOI 10.1016/S0140-6736(03)15021-0
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9
   Issuree PDA, 2009, FASEB J, V23, P2412, DOI 10.1096/fj.09-130542
   Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200
   Itagaki K, 2010, SHOCK, V33, P381, DOI 10.1097/SHK.0b013e3181c6bb75
   Komarova Yulia A, 2007, Sci STKE, V2007, pre8
   Lai WQ, 2008, J IMMUNOL, V181, P8010, DOI 10.4049/jimmunol.181.11.8010
   Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097
   Lee C, 2004, J TRAUMA, V57, P955, DOI 10.1097/01.ta.0000149495.44582.76
   Li X, 2008, BLOOD, V111, P3489, DOI 10.1182/blood-2007-05-092148
   Liu HB, 2008, PANCREAS, V36, pE10, DOI 10.1097/MPA.0b013e31815f3905
   Marrie T J, 1999, Semin Respir Infect, V14, P227
   Matute-Bello G, 2001, INFECT IMMUN, V69, P5768, DOI 10.1128/IAI.69.9.5768-5776.2001
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Melendez AJ, 2008, BBA-PROTEINS PROTEOM, V1784, P66, DOI 10.1016/j.bbapap.2007.07.013
   Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596
   Mitchell Tim J, 2014, Subcell Biochem, V80, P145, DOI 10.1007/978-94-017-8881-6_8
   Okazaki M, 2007, AM J TRANSPLANT, V7, P751, DOI 10.1111/j.1600-6143.2006.01710.x
   Oskeritzian CA, 2010, J EXP MED, V207, P465, DOI 10.1084/jem.20091513
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Proia RL, 2015, J CLIN INVEST, V125, P1379, DOI 10.1172/JCI76369
   Puneet P, 2010, SCIENCE, V328, P1290, DOI 10.1126/science.1188635
   Regard JB, 2008, CELL, V135, P561, DOI 10.1016/j.cell.2008.08.040
   Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735
   Seybold J, 2005, BLOOD, V105, P3569, DOI 10.1182/blood-2004-07-2729
   Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002
   Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7
   Sun WY, 2010, AM J PATHOL, V177, P436, DOI 10.2353/ajpath.2010.091016
   Wadgaonkar R, 2009, AM J PHYSIOL-LUNG C, V296, pL603, DOI 10.1152/ajplung.90357.2008
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Witzenrath M, 2007, CRIT CARE MED, V35, P1756, DOI 10.1097/01.CCM.0000269212.84709.23
   Witzenrath M, 2006, AM J PHYSIOL-LUNG C, V291, pL466, DOI 10.1152/ajplung.00011.2005
   Witzenrath M, 2009, CRIT CARE MED, V37, P584, DOI 10.1097/CCM.0b013e3181959814
   Wong LK, 2009, J MED CHEM, V52, P3618, DOI 10.1021/jm900121d
   Woodhead M, 2002, EUR RESPIR J, V20, p20S, DOI 10.1183/09031936.02.00702002
NR 50
TC 14
Z9 15
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAR
PY 2018
VL 46
IS 3
BP e258
EP e267
DI 10.1097/CCM.0000000000002916
PG 10
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FX7WE
UT WOS:000426301500010
PM 29298188
OA Green Published
DA 2023-08-21
ER

PT J
AU Jayne, JG
   Bensman, TJ
   Schaal, JB
   Park, AYJ
   Kimura, E
   Tran, D
   Selsted, ME
   Beringer, PM
AF Jayne, Jordanna G.
   Bensman, Timothy J.
   Schaal, Justin B.
   Park, A. Young J.
   Kimura, Elza
   Tran, Dat
   Selsted, Michael E.
   Beringer, Paul M.
TI Rhesus theta-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury
   by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE LPS; ALI/ARDS; airway inflammation; theta defensin; host defense peptide 
ID MACROPHAGE-INFLAMMATORY PROTEIN-2; RESPIRATORY-DISTRESS-SYNDROME;
   HOST-DEFENSE PEPTIDES; THETA-DEFENSINS; PULMONARY INFLAMMATION;
   ANTIMICROBIAL PEPTIDES; CYCLIC-PEPTIDES; ALPHA-DEFENSINS; IN-VIVO;
   LIPOPOLYSACCHARIDE
AB Acute lung injury (ALI) is a clinical syndrome characterized by acute respiratory failure and is associated with substantial morbidity and mortality. Rhesus theta-defensin (RTD)-1 is an antimicrobial peptide with immunomodulatory activity. As airway inflammation and neutrophil recruitment and activation are hallmarks of ALI, we evaluated the therapeutic efficacy of RTD-1 in preclinical models of the disease. We investigated the effect of RTD-1 on neutrophil chemotaxis and macrophage-driven pulmonary inflammation with human peripheral neutrophils and LPS-stimulated murine alveolar macrophage (denoted MH-S) cells. Treatment and prophylactic single escalating doses were administered subcutaneously in a well-established murine model of direct endotoxin-induced ALI. We assessed lung injury by histopathology, pulmonary edema, inflammatory cell recruitment, and inflammatory cytokines/chemokines in the BAL fluid. In vitro studies demonstrated that RTD-1 suppressed CXCL8-induced neutrophil chemotaxis, TNF-mediated neutrophil-endothelial cell adhesion, and proinflammatory cytokine release in activated murine alveolar immortalized macrophages (MH-S) cells. Treatment with RTD-1 significantly inhibited in vivo LPS-induced ALI by reducing pulmonary edema and histopathological changes. Treatment was associated with dose-and time-dependent inhibition of proinflammatory cytokines (TNF, IL-1 beta, and IL-6), peroxidase activity, and neutrophil recruitment into the airways. Antiinflammatory effects were demonstrated in animals receiving RTD-1 up to 12 hours after LPS challenge. Notably, subcutaneously administered RTD-1 demonstrates good peptide stability as demonstrated by the long in vivo half-life. Taken together, these studies demonstrate that RTD-1 is efficacious in an experimental model of ALI through inhibition of neutrophil chemotaxis and adhesion, and the attenuation of proinflammatory cytokines and gene expression from alveolar macrophages.
C1 [Jayne, Jordanna G.; Bensman, Timothy J.; Park, A. Young J.; Beringer, Paul M.] Univ Southern Calif, Sch Pharm, 1985 Zonal Ave, Los Angeles, CA 90033, United States.
C1 [Schaal, Justin B.; Tran, Dat; Selsted, Michael E.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033, United States.
C1 [Kimura, Elza] Univ Estadual Maringa, Maringa, Parana, Brazil.
C3 University of Southern California; University of Southern California;
   Universidade Estadual de Maringa
RP Beringer, PM (corresponding author), Univ Southern Calif, Sch Pharm, 1985 Zonal Ave, Los Angeles, CA 90033 USA.
EM beringer@usc.edu
RI Beringer, Paul/AAD-7812-2022; Kimura, Elza/B-4690-2015
OI Beringer, Paul/0000-0002-3744-3310; 
FU Webb-Foundation; Cystic Fibrosis Research Inc.; National Center for
   Advancing Translational Sciences grants [UL1TR000130]; National
   Institute of Dental and Craniofacial Research grant [5T90DE021982];
   National Institute of General Medicine grant [F31GM109729]; NIH
   [RO1AI22931, R01DE021341]; National Cancer Institute grant [P30CA014089]
FX This work was supported in part by the Webb-Foundation (P.M.B.), Cystic
   Fibrosis Research Inc. (P.M.B.), National Center for Advancing
   Translational Sciences grants UL1TR000130, formerly by the National
   Center for Research Resources, award number UL1RR031986, National
   Institute of Dental and Craniofacial Research grant 5T90DE021982 and
   National Institute of General Medicine grant F31GM109729 (T.J.B.), NIH
   grants RO1AI22931 and R01DE021341 (M.E.S.), and National Cancer
   Institute grant P30CA014089.
CR Abdel-Latif D, 2004, BLOOD, V104, P832, DOI 10.1182/blood-2003-07-2624
   Amano H, 2000, INFECT IMMUN, V68, P2925, DOI 10.1128/IAI.68.5.2925-2929.2000
   Balloy V, 2014, BRIT J PHARMACOL, V171, P1783, DOI 10.1111/bph.12574
   Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999
   Bdeir K, 2010, AM J RESP CRIT CARE, V181, P935, DOI 10.1164/rccm.200907-1128OC
   Bensman TJ, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00154-17
   Bensman TJ, 2012, PEDIAT PULMONOL, V47, P245
   Beringer PM, 2016, J ANTIMICROB CHEMOTH, V71, P181, DOI 10.1093/jac/dkv301
   De Filippo K, 2008, J IMMUNOL, V180, P4308, DOI 10.4049/jimmunol.180.6.4308
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Ha HL, 2014, BRIT J PHARMACOL, V171, P1551, DOI 10.1111/bph.12547
   Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267
   HUANG S, 1992, AM J PATHOL, V141, P981
   Jeyaseelan S, 2004, INFECT IMMUN, V72, P7247, DOI 10.1128/IAI.72.12.7247-7256.2004
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Koay MA, 2002, AM J RESP CELL MOL, V26, P572, DOI 10.1165/ajrcmb.26.5.4748
   Lehrer RI, 2012, J BIOL CHEM, V287, P27014, DOI 10.1074/jbc.R112.346098
   Levitt JE, 2012, CRIT CARE, V16, DOI 10.1186/cc11144
   Mansour SC, 2014, TRENDS IMMUNOL, V35, P443, DOI 10.1016/j.it.2014.07.004
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matute-Bello G, 2001, AM J PATHOL, V158, P153, DOI 10.1016/S0002-9440(10)63953-3
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Maus UA, 2003, J IMMUNOL, V170, P3273, DOI 10.4049/jimmunol.170.6.3273
   Oppenheim JJ, 2003, ANN RHEUM DIS, V62, P17, DOI 10.1136/ard.62.suppl_2.ii17
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Proudfoot AG, 2011, DIS MODEL MECH, V4, P145, DOI 10.1242/dmm.006213
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Schaal JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051337
   Selsted ME, 2004, CURR PROTEIN PEPT SC, V5, P365, DOI 10.2174/1389203043379459
   Simpson AJ, 2001, J IMMUNOL, V167, P1778, DOI 10.4049/jimmunol.167.3.1778
   Szarka RJ, 1997, J IMMUNOL METHODS, V202, P49, DOI 10.1016/S0022-1759(96)00236-0
   Tai KP, 2015, INNATE IMMUN-LONDON, V21, P17, DOI 10.1177/1753425913514784
   Tasaka S, 1996, AM J RESP CELL MOL, V15, P738, DOI 10.1165/ajrcmb.15.6.8969268
   Tecle T, 2010, INNATE IMMUN-LONDON, V16, P151, DOI 10.1177/1753425910365734
   Tongaonkar P, 2015, J LEUKOCYTE BIOL, V98, P1061, DOI 10.1189/jlb.3A0315-102R
   Tran D, 2002, J BIOL CHEM, V277, P3079, DOI 10.1074/jbc.M109117200
   Tran D, 2008, ANTIMICROB AGENTS CH, V52, P944, DOI 10.1128/AAC.01090-07
   VANDERMEER TJ, 1994, J APPL PHYSIOL, V76, P2006, DOI 10.1152/jappl.1994.76.5.2006
   Wieland CW, 2002, INFECT IMMUN, V70, P1352, DOI 10.1128/IAI.70.3.1352-1358.2002
   Wohlford-Lenane CL, 2009, J VIROL, V83, P11385, DOI 10.1128/JVI.01363-09
NR 40
TC 19
Z9 20
U1 0
U2 9
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAR
PY 2018
VL 58
IS 3
BP 310
EP 319
DI 10.1165/rcmb.2016-0428OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA FY7AJ
UT WOS:000427013700008
PM 28954201
OA Green Published
DA 2023-08-21
ER

PT J
AU Kaziani, K
   Vassiliou, AG
   Kotanidou, A
   Athanasiou, C
   Korovesi, I
   Glynos, K
   Orfanos, SE
AF Kaziani, Katerina
   Vassiliou, Alice G.
   Kotanidou, Anastasia
   Athanasiou, Chariclea
   Korovesi, Ioanna
   Glynos, Konstantinos
   Orfanos, Stylianos E.
TI Activated Protein C has No Effect on Pulmonary Capillary Endothelial
   Function in Septic Patients with Acute Respiratory Distress Syndrome:
   Association of Endothelial Dysfunction with Mortality
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE ACE/ACE2; ALI/ARDS; Prognosis; rhAPC; sepsis 
ID ANGIOTENSIN-CONVERTING ENZYME; ENDOTOXIN; INFLAMMATION; HYPERTENSION;
   DEFINITIONS; SEPSIS; SAFETY
AB Pulmonary capillary endothelium-bound (PCEB) angiotensin-converting enzyme (ACE) activity is a direct and quantifiable index of pulmonary endothelial function that decreases early in acute respiratory distress syndrome (ARDS) and correlates with its severity. Endothelial dysfunction is a major pathophysiology that underlies sepsis-related ARDS. Recombinant human activated protein C (rhAPC), now withdrawn from the market, has been used in the recent past as an endothelial-protective treatment in patients with septic organ dysfunction.
   We investigated the effect of rhAPC on pulmonary endothelial function in 19 septic patients suffering from ARDS. Applying indicator-dilution type techniques, we measured single-pass transpulmonary percent metabolism (%M) and hydrolysis (v) of the synthetic, biologically inactive, and highly specific for ACE substrate, H-3-benzoyl-Phe-Ala-Pro (BPAP), under first-order reaction conditions, and calculated lung functional capillary surface area before and after treatment with rhAPC.
   Pulmonary endothelium ACE activity was severely impaired in septic patients with ARDS, and was not affected by rhAPC treatment. Additionally, poor outcome was related to a more profound decrease in PCEB-ACE activity. Angiotensin-converting enzyme-substrate utilization was statistically significantly lower in non-survivors as compared to survivors, with no changes over time within each group: BPAP %M: 32.7 +/- 3.4% at baseline to 25.6 +/- 2.9% at day 7 in survivors versus 20.8 +/- 2.8 to 15.5 +/- 5%, respectively, in non-survivors (p = 0.044), while hydrolysis (v): 0.41 +/- 0.06 at baseline to 0.30 +/- 0.04 at day 7 in survivors compared to 0.24 +/- 0.04 to 0.18 +/- 0.06, respectively, in non-survivors (p = 0.049).
   rhAPC administration in septic patients with ARDS did not improve PCEB-ACE activity indices. However, these indices might be useful in the early recognition of septic patients with ARDS at high risk of mortality.
C1 [Kaziani, Katerina; Vassiliou, Alice G.; Kotanidou, Anastasia; Athanasiou, Chariclea; Korovesi, Ioanna; Glynos, Konstantinos; Orfanos, Stylianos E.] Natl & Kapodistrian Univ Athens, Dept Crit Care Med & Pulm Serv 1, Evangelismos Hosp, GP Livanos & M Simou Labs,Med Sch, Athens, Greece.
C1 [Kotanidou, Anastasia] Natl & Kapodistrian Univ Athens, Sch Med, Evangelismos Hosp, Dept Crit Care Med & Pulm Serv 1, Athens, Greece.
C1 [Orfanos, Stylianos E.] Natl & Kapodistrian Univ Athens, Sch Med, Attikon Hosp, Dept Crit Care 2, Athens, Greece.
C1 [Kaziani, Katerina] Evangelismos Med Ctr, Dept Internal Med 5, Athens, Greece.
C1 [Kaziani, Katerina] Evangelismos Med Ctr, Infect Dis Unit, Athens, Greece.
C3 CIVIS; National & Kapodistrian University of Athens; Evangelismos
   Hospital; Athens Medical School; CIVIS; National & Kapodistrian
   University of Athens; Evangelismos Hospital; Athens Medical School;
   CIVIS; National & Kapodistrian University of Athens; University Hospital
   Attikon; Evangelismos Hospital; Evangelismos Hospital
RP Kaziani, K (corresponding author), Evangelismos Med Ctr, Dept Internal Med 5, Athens, Greece.; Kaziani, K (corresponding author), Evangelismos Med Ctr, Infect Dis Unit, Athens, Greece.
EM katkaziani@hotmail.com
RI Vassiliou, Alice/AAX-1985-2020; Kotanidou, Anastasia/AAB-4731-2020
OI Vassiliou, Alice/0000-0003-4984-0476; 
FU Pharmaserve-Lilly; "THORAX" Research Center for Intensive and Emergency
   Thoracic Medicine, Athens, Greece; COST (European Cooperation in Science
   and Technology) [BM 1401]
FX This work was funded by an unrestricted grant by Pharmaserve-Lilly, and
   by the nonprofit institute "THORAX" Research Center for Intensive and
   Emergency Thoracic Medicine, Athens, Greece. This article is based on
   work from COST Action "Raman-based applications for clinical
   diagnostics-Raman4Clinics" (BM 1401), supported by COST (European
   Cooperation in Science and Technology). No funding or sponsorship was
   received for the publication of the article.
CR [Anonymous], 2012, JAMA, DOI DOI 10.1001/JAMA.2012.5669
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   CATRAVAS JD, 1984, J APPL PHYSIOL, V57, P1173, DOI 10.1152/jappl.1984.57.4.1173
   Cornet AD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090983
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Glynos C, 2013, PULM CIRC, V3, P419, DOI 10.4103/2045-8932.113189
   Harel F, 2017, EUR J NUCL MED MOL I, V44, P1136, DOI 10.1007/s00259-017-3655-y
   Kotanidou A, 2006, VASC PHARMACOL, V45, P134, DOI 10.1016/j.vph.2006.06.016
   Langleben D, 2008, ARTHRITIS RHEUM-US, V58, P1156, DOI 10.1002/art.23405
   Levi M, 2012, SEMIN IMMUNOPATHOL, V34, P167, DOI 10.1007/s00281-011-0283-7
   Maniatis NA, 2010, CRIT CARE, V14, DOI 10.1186/cc8976
   Millar FR, 2016, THORAX, V71, P462, DOI 10.1136/thoraxjnl-2015-207461
   Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197, DOI 10.1152/ajplung.1997.272.2.L197
   Nick JA, 2004, BLOOD, V104, P3878, DOI 10.1182/blood-2004-06-2140
   Orfanos SE, 2000, CIRCULATION, V102, P2011
   Orfanos SE, 1999, CIRCULATION, V99, P1593, DOI 10.1161/01.CIR.99.12.1593
   Orfanos SE, 2011, TEXTBOOK OF PULMONARY VASCULAR DISEASE, P105, DOI 10.1007/978-0-387-87429-6_7
   Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Slofstra SH, 2006, BRIT J PHARMACOL, V149, P740, DOI 10.1038/sj.bjp.0706915
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
NR 23
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD MAR
PY 2018
VL 7
SU 1
BP 15
EP 25
DI 10.1007/s40121-018-0192-3
PG 11
WC Infectious Diseases
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases
GA FZ7QG
UT WOS:000427795400003
PM 29549655
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Lam, FW
   Da, Q
   Guillory, B
   Cruz, MA
AF Lam, Fong W.
   Da, Qi
   Guillory, Bobby
   Cruz, Miguel A.
TI Recombinant Human Vimentin Binds to P-Selectin and Blocks Neutrophil
   Capture and Rolling on Platelets and Endothelium
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ACUTE LUNG INJURY; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN LIGAND-1;
   TRANSENDOTHELIAL MIGRATION; PULMONARY RECRUITMENT; ABDOMINAL SEPSIS;
   CELL-ADHESION; SEPTIC SHOCK; AGGREGATION; ALPHA
AB Leukocyte adhesion to vascular endothelium and platelets is an early step in the acute inflammatory response. The initial process is mediated through P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes binding to platelets adhered to endothelium and the endothelium itself via P-selectin. Although these interactions are generally beneficial, pathologic inflammation may occur in undesirable circumstances, such as in acute lung injury (ALI) and ischemia and reperfusion injury. Therefore, the development of novel therapies to attenuate inflammation may be beneficial. In this article, we describe the potential benefit of using a recombinant human vimentin (rhVim) on reducing human leukocyte adhesion to vascular endothelium and platelets under shear stress. The addition of rhVim to whole blood and isolated neutrophils decreased leukocyte adhesion to endothelial and platelet monolayers. Furthermore, rhVim blocked neutrophil adhesion to P-selectin-coated surfaces. Binding assays showed that rhVim binds specifically to P-selectin and not to its counterreceptor, PSGL-1. Finally, in an endotoxin model of ALI in C57BL/ 6J mice, treatment with rhVim significantly decreased histologic findings of ALI. These data suggest a potential role for rhVim in attenuating inflammation through blocking P-selectin-PSGL-1 interactions.
C1 [Lam, Fong W.; Da, Qi; Guillory, Bobby; Cruz, Miguel A.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030, United States.
C1 [Lam, Fong W.; Da, Qi] Baylor Coll Med, Dept Pediat, 6621 Fannin St,WT-6006,One Baylor Plaza, Houston, TX 77030, United States.
C1 [Guillory, Bobby; Cruz, Miguel A.] Baylor Coll Med, Dept Med, Houston, TX 77030, United States.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine
RP Lam, FW (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin St,WT-6006,One Baylor Plaza, Houston, TX 77030 USA.
EM flam@bcm.edu
OI Lam, Fong/0000-0003-2034-2625
FU National Institutes of Health/National Heart, Lung, and Blood Institute
   [HL-116524]; National Institutes of Health/National Institute of General
   Medical Sciences [GM-112806, GM-123261]; National Institutes of
   Health/National Institute of Neurological Disorders and Stroke
   [NS-094280]; U.S. Department of Veterans Affairs Biomedical Laboratory
   Research and Development Service [I01 BX002551]
FX This work was supported by National Institutes of Health/National Heart,
   Lung, and Blood Institute Grant HL-116524, National Institutes of
   Health/National Institute of General Medical Sciences Grants GM-112806
   and GM-123261, National Institutes of Health/National Institute of
   Neurological Disorders and Stroke Grant NS-094280, and a Merit Review
   Award (I01 BX002551) from the U.S. Department of Veterans Affairs
   Biomedical Laboratory Research and Development Service.
CR ALTIERI DC, 1990, J BIOL CHEM, V265, P12119
   Asaduzzaman M, 2009, CRIT CARE MED, V37, P1389, DOI 10.1097/CCM.0b013e31819ceb71
   Asaduzzaman M, 2009, BRIT J PHARMACOL, V156, P307, DOI 10.1111/j.1476-5381.2008.00021.x
   Bay-Jensen AC, 2013, ARTHRITIS RHEUM-US, V65, P972, DOI 10.1002/art.37843
   Brentville VA, 2016, CANCER RES, V76, P548, DOI 10.1158/0008-5472.CAN-15-1085
   Chernyatina AA, 2012, P NATL ACAD SCI USA, V109, P13620, DOI 10.1073/pnas.1206836109
   Da Q, 2015, BLOOD, V126, P2338, DOI 10.1182/blood-2015-05-648030
   Da Q, 2014, BLOOD, V123, P2715, DOI 10.1182/blood-2013-10-530428
   Diacovo TG, 1996, BLOOD, V88, P146
   Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200
   Fernandes LS, 2003, THROMB RES, V111, P171, DOI 10.1016/j.thromres.2003.08.017
   Fortenberry JD, 1996, J PEDIATR-US, V128, P670, DOI 10.1016/S0022-3476(96)80133-8
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje
   Huet O, 2013, SHOCK, V39, P488, DOI 10.1097/SHK.0b013e3182939831
   Ise H, 2010, GLYCOBIOLOGY, V20, P843, DOI 10.1093/glycob/cwq039
   Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040
   JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0
   Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014
   Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568
   Konstantopoulos K, 1998, CIRCULATION, V98, P873, DOI 10.1161/01.CIR.98.9.873
   Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949
   Lam FW, 2013, THROMB RES, V132, P69, DOI 10.1016/j.thromres.2013.04.018
   Lam FW, 2011, AM J PHYSIOL-HEART C, V300, pH468, DOI 10.1152/ajpheart.00491.2010
   Lerman YV, 2014, BLOOD, V124, P3515, DOI 10.1182/blood-2014-01-552943
   Li FJ, 2017, J IMMUNOL, V199, P1596, DOI 10.4049/jimmunol.1700473
   Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P4794, DOI 10.1167/iovs.06-0381
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556
   MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175
   MciLwain RB, 2010, LAB INVEST, V90, P128, DOI 10.1038/labinvest.2009.119
   MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445
   MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661
   Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898
   Mor-Vaknin N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01045
   Murohara T, 1996, J IMMUNOL, V156, P3550
   Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355
   Pall T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029305
   Satelli A, 2016, J CANCER, V7, P1824, DOI 10.7150/jca.15622
   SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788
   Thorlacius H, 1997, AM J PHYSIOL-HEART C, V272, pH1725, DOI 10.1152/ajpheart.1997.272.4.H1725
   Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732
   Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
NR 44
TC 34
Z9 34
U1 0
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2018
VL 200
IS 5
BP 1718
EP 1726
DI 10.4049/jimmunol.1700784
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FW8NA
UT WOS:000425591000021
PM 29335256
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Slavin, SA
   Leonard, A
   Grose, V
   Fazal, F
   Rahman, A
AF Slavin, Spencer A.
   Leonard, Antony
   Grose, Valerie
   Fazal, Fabeha
   Rahman, Arshad
TI Autophagy inhibitor 3-methyladenine protects against endothelial cell
   barrier dysfunction in acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE adhesion junction; autophagy; ECs/HPMECs/HUVECs/MPVECs; lung vascular injury 
ID RELA/P65 NUCLEAR TRANSLOCATION; RESPIRATORY-DISTRESS-SYNDROME;
   NF-KAPPA-B; INFLAMMASOME ACTIVATION; VASCULAR-PERMEABILITY; VE-CADHERIN;
   PHOSPHOINOSITIDE 3-KINASE; BRONCHOALVEOLAR LAVAGE; HEMODYNAMIC STRESS;
   DUAL ROLE
AB Autophagy is an evolutionarily conserved cellular process that facilitates the continuous recycling of intracellular components (organelles and proteins) and provides an alternative source of energy when nutrients are scarce. Recent studies have implicated autophagy in many disorders, including pulmonary diseases. However, the role of autophagy in endothelial cell (EC) barrier dysfunction and its relevance in the context of acute lung injury (ALI) remain uncertain. Here, we provide evidence that autophagy is a critical component of EC barrier disruption in ALI. Using an aerosolized bacterial lipopolysaccharide (LPS) inhalation mouse model of ALI, we found that administration of the autophagy inhibitor 3-methyladenine (3-MA), either prophylactically or therapeutically, markedly reduced lung vascular leakage and tissue edema. 3-MA was also effective in reducing the levels of proinflammatory mediators and lung neutrophil sequestration induced by LPS. To test the possibility that autophagy in EC could contribute to lung vascular injury, we addressed its role in the mechanism of EC barrier disruption. Knockdown of ATG5, an essential regulator of autophagy, attenuated thrombin-induced EC barrier disruption, confirming the involvement of autophagy in the response. Similarly, exposure of cells to 3-MA, either before or after thrombin, protected against EC barrier dysfunction by inhibiting the cleavage and loss of vascular endothelial cadherin at adherens junctions, as well as formation of actin stress fibers. 3-MA also reversed LPS-induced EC barrier disruption. Together, these data imply a role of autophagy in lung vascular injury and reveal the protective and therapeutic utility of 3-MA against ALL.
C1 [Slavin, Spencer A.; Leonard, Antony; Grose, Valerie; Fazal, Fabeha; Rahman, Arshad] Univ Rochester, Sch Med & Dent, Dept Pediat Neonatol, Lung Biol & Dis Program, Rochester, NY, United States.
C3 University of Rochester
RP Rahman, A (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Lung Biol & Dis Program, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.
EM arshad_rahman@urmc.rochester.edu
OI Rahman, Arshad/0000-0002-5621-0512
FU National Institutes of Health [HL-116632, HL-130870, ES-01247]
FX This work was supported by National Institutes of Health Grants
   HL-116632, HL-130870, and ES-01247.
CR Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bijli KM, 2016, AM J PHYSIOL-LUNG C, V311, pL517, DOI 10.1152/ajplung.00069.2016
   Bijli KM, 2014, SHOCK, V42, P562, DOI 10.1097/SHK.0000000000000242
   Birukova AA, 2016, CELL SIGNAL, V28, P541, DOI 10.1016/j.cellsig.2016.02.015
   Brest P, 2010, CURR MOL MED, V10, P486, DOI 10.2174/156652410791608252
   Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107
   Dejana E, 2013, PROG MOL BIOL TRANSL, V116, P119, DOI 10.1016/B978-0-12-394311-8.00006-6
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200
   Fazal F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059965
   Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Gao R, 2015, AM J PHYSIOL-LUNG C, V308, pL847, DOI 10.1152/ajplung.00274.2014
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Golovkine G, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003939
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   IDELL S, 1987, AM REV RESPIR DIS, V136, P1466, DOI 10.1164/ajrccm/136.6.1466
   Kobayashi K, 2014, ARTERIOSCL THROM VAS, V34, P1716, DOI 10.1161/ATVBAHA.114.303890
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Minhajuddin M, 2009, J BIOL CHEM, V284, P4052, DOI 10.1074/jbc.M805032200
   Mittal M, 2016, P NATL ACAD SCI USA, V113, pE8151, DOI 10.1073/pnas.1614935113
   Mizumura K, 2016, ANN AM THORAC SOC, V13, pS40, DOI 10.1513/AnnalsATS.201507-450MG
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574
   Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004
   Pu QQ, 2017, J IMMUNOL, V198, P3205, DOI 10.4049/jimmunol.1601196
   Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Ryter SW, 2012, ANNU REV PHYSIOL, V74, P377, DOI 10.1146/annurev-physiol-020911-153348
   Schulz B, 2008, CIRC RES, V102, P1192, DOI 10.1161/CIRCRESAHA.107.169805
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sun Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001931
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tian YF, 2016, J BIOL CHEM, V291, P10032, DOI 10.1074/jbc.M115.690487
   Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200
   Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347
   Torisu T, 2013, NAT MED, V19, P1281, DOI 10.1038/nm.3288
   Trani M, 2015, CURR OPIN HEMATOL, V22, P267, DOI 10.1097/MOH.0000000000000137
   Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu D, 2016, SCI REP-UK, V6, DOI 10.1038/srep30833
   Zhang Y, 2014, AM J PHYSIOL-LUNG C, V307, pL173, DOI 10.1152/ajplung.00083.2014
   Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523
NR 56
TC 50
Z9 54
U1 1
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAR
PY 2018
VL 314
IS 3
BP L388
EP L396
DI 10.1152/ajplung.00555.2016
PG 9
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA GA5WE
UT WOS:000428403800005
PM 29074492
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Liu, WS
   Liu, KZ
   Zhang, S
   Shan, LH
   Tang, JF
AF Liu, Wensheng
   Liu, Kaizhong
   Zhang, Shu
   Shan, Lihong
   Tang, Jiangfeng
TI Tetramethylpyrazine Showed Therapeutic Effects on Sepsis-Induced Acute
   Lung Injury in Rats by Inhibiting Endoplasmic Reticulum Stress Protein
   Kinase RNA-Like Endoplasmic Reticulum Kinase (PERK) Signaling-Induced
   Apoptosis of Pulmonary Microvascular Endothelial Cells
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE apoptosis; permeability; sepsis; COVID-19/SARS-CoV-2/Coronavirus 
ID PATHWAY
AB Background: Acute lung injury (ALI) is a life-threatening complication of sepsis. Tetramethylpyrazine (TMP) has been used in the clinical treatment of vascular diseases. The aim of this study was to investigate the therapeutic effects and possible involved mechanisms on ALI.
   Material/Methods: Cecal ligation and puncture (CLP) was used to establish a sepsis model in rats. TMP at various dosages were administrated to rats using a intragastric method. Animal survival rate was calculated. The lung functions were evaluated by lung weight/dry weight ratio (W/D), PaO2, dynamic compliance (DC), and airway resistance index (ARI). Pulmonary microvascular endothelial cells (PMVECs) were isolated from lungs harvested from rats with sepsis. TUNEL assay was used to detect apoptosis. Protein expression and phosphorylation levels were assessed by western blotting.
   Results: TMP administration increased the survival rate of septic rats. TMP also decreased W/D and DC, but increased PaO2 and ARI in septic rats. Moreover, PMVECs apoptosis was inhibited in septic rats that received TMP treatment. The expression levels of GRP78, ATF4, caspase-12, active caspase-3, as well as the phosphorylation levels of PERK and eIF2 alpha were suppressed in PMVECs isolated from TMP-treated septic rats.
   Conclusions: TMP alleviated sepsis-induced ALI by suppressing PMVECs apoptosis via PERK/eIF2 alpha/ATF4/CHOP apoptotic signaling in endoplasmic reticulum stress.
C1 [Liu, Wensheng; Liu, Kaizhong; Zhang, Shu; Shan, Lihong; Tang, Jiangfeng] Zhejiang Canc Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, China.
C3 Zhejiang Cancer Hospital
RP Liu, KZ (corresponding author), Zhejiang Canc Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China.
EM rqbybm@sina.com
RI liu, wen/HGE-3071-2022
FU Zhejiang Provincial Medical Science and Technology Program Project
   [2017KY245, 2016KYA039]
FX This study was supported by Zhejiang Provincial Medical Science and
   Technology Program Project (2017KY245 and 2016KYA039)
CR [Anonymous], LIFE SCI
   CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Chen X, 2017, BIOCHEM BIOPH RES CO, V24, P32336
   Clemmer JS, 2016, MICROCIRCULATION, V23, P221, DOI 10.1111/micc.12267
   Crouser ED, 2016, CRIT CARE MED, V44, P1626, DOI 10.1097/CCM.0000000000001694
   Fan YZ, 2017, BIOMED PHARMACOTHER, V94, P827, DOI 10.1016/j.biopha.2017.07.162
   Hua S, 2017, MED SCI MONITOR, V23, P1355, DOI 10.12659/MSM.900523
   Khan MM, 2015, SHOCK, V44, P294, DOI 10.1097/SHK.0000000000000425
   Kong FJ, 2018, CLIN SCI, V132, P111, DOI 10.1042/CS20171432
   Lakshmanan AP, 2011, EUR J PHARM SCI, V44, P627, DOI 10.1016/j.ejps.2011.10.009
   Lan L, 2017, BIOSCI REP, V37
   Li L, 2015, CELL PHYSIOL BIOCHEM, V37, P1113, DOI 10.1159/000430236
   Liu ZW, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-158
   Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143
   REID L, 1982, ANN NY ACAD SCI, V384, P3, DOI 10.1111/j.1749-6632.1982.tb21357.x
   Shao ZK, 2017, MED SCI MONITOR, V23, P5277, DOI 10.12659/MSM.904554
   Sun LC, 2017, ARCH PHARM RES
   Tao YK, 2016, BIOMED ENVIRON SCI, V29, P868, DOI 10.3967/bes2016.116
   Wu ZY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02056-w
   Yu B, 2017, AM J TRANSL RES, V9, P4807
   Zhang J, 2017, BIOMED PHARMACOTHER, V96, P513, DOI 10.1016/j.biopha.2017.10.012
   Zou Y, 2018, SHOCK, V49, P213, DOI 10.1097/SHK.0000000000000915
NR 22
TC 26
Z9 32
U1 0
U2 10
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD FEB 28
PY 2018
VL 24
BP 1225
EP 1231
DI 10.12659/MSM.908616
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FZ3UB
UT WOS:000427515000002
PM 29488473
OA Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Liu, XY
   Xu, HX
   Li, JK
   Zhang, D
   Ma, XH
   Huang, LN
   Lu, JH
   Wang, XZ
AF Liu, Xiangyong
   Xu, Hai-Xiao
   Li, Jiankui
   Zhang, Dong
   Ma, Xiao-Hong
   Huang, Lina
   Lu, Junhong
   Wang, Xiaozhi
TI Neferine Protects Endothelial Glycocalyx via Mitochondrial ROS in
   Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; neferine; endothelial glycocalyx (EG); LPS; ROS 
ID NF-KAPPA-B; LOTUS SEED EMBRYO; ACUTE LUNG INJURY; CELLS; ACTIVATION;
   APOPTOSIS; DEGRADATION; GROWTH; DAMAGE
AB Damage to the endothelial glycocalyx is a critical factor in increased pulmonary vascular permeability, which is the basic pathological feature of acute respiratory distress syndrome (ARDS). Neferine (Nef), a bisbenzylisoquinoline alkaloid isolated from green seed embryos of Nelumbo nucifera Gaertn, has extensive pharmacological activity. In this study, we showed that Nef reduced lung-capillary permeability, down-regulated the production of cytokines (IL-1 beta, IL-6, TNF-alpha, and IL-10) and inhibited the activation of the NF-kappa B signaling pathway in mice with lipopolysaccharide (LPS)-induced ARDS. Further analysis indicated that Nef provided protection against endothelial glycocalyx degradation in LPS-induced ARDS mice (in vivo) and in LPS-stimulated human umbilical vein endothelial cells (in vitro). The glycocalyx-protective effect of Nef may be initiated by suppressing the production of mitochondrial ROS (mtROS) and decreasing oxidative damage. Nef was also found to promote glycocalyx restoration by accelerating the removal of mtROS in endothelial cells in LPS-induced ARDS. These results suggested the potential of Nef as a therapeutic agent for ARDS associated with Gram-negative bacterial infections and elucidated the mechanisms underlying the protection and restoration of the endothelial glycocalyx.
C1 [Liu, Xiang-Yong; Huang, Li-Na] Binzhou Med Univ, Dept Cell Biol, Yantai, China.
C1 [Xu, Hai-Xiao; Li, Jian-Kui; Zhang, Dong; Ma, Xiao-Hong] Binzhou Med Univ, Affiliated Hosp, Dept Respirator Med, Binzhou, China.
C1 [Xu, Hai-Xiao; Li, Jian-Kui; Zhang, Dong; Ma, Xiao-Hong] Binzhou Med Univ, Affiliated Hosp, Intens Care Unit, Binzhou, China.
C1 [Lu, Jun-Hong] Chinese Acad Sci, Shanghai Inst Appl Phys, Div Phys Biol, Shanghai, China.
C1 [Lu, Jun-Hong] Chinese Acad Sci, Shanghai Inst Appl Phys, CAS Key Lab Interfacial Phys & Technol, Shanghai, China.
C3 Binzhou Medical University; Binzhou Medical University; Binzhou Medical
   University; Chinese Academy of Sciences; Shanghai Institute of Applied
   Physics, CAS; Chinese Academy of Sciences; Shanghai Institute of Applied
   Physics, CAS
RP Liu, XY (corresponding author), Binzhou Med Univ, Dept Cell Biol, Yantai, Peoples R China.
EM liuxiangyona81@gmail.com; hxicuwxz@163.com
RI Lü, junhong -/AFS-3184-2022; wang, dong/HMP-1439-2023; MA,
   XIAO/HHN-5611-2022
OI Lü, junhong -/0000-0003-2873-3137; 
FU Natural Science Foundation of Shandong Province, China [ZR2017MH065];
   National Natural Science Foundation of China [81670078]; Taishan Scholar
   project of Shandong Province, china; Key clinical specialty project of
   Shandong province, China; Young Teachers' Training and Funding Project
   of Binzhou Medical University, China
FX This work was supported by funding from the Natural Science Foundation
   of Shandong Province, China (ZR2017MH065), National Natural Science
   Foundation of China (Grant No: 81670078), Taishan Scholar project of
   Shandong Province and Key clinical specialty project of Shandong
   province, China, Young Teachers' Training and Funding Project of Binzhou
   Medical University, China.
CR Baskaran R, 2016, BIOFACTORS, V42, P407, DOI 10.1002/biof.1286
   Chelazzi C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0741-z
   Dogne S, 2016, DIABETES, V65, P2742, DOI 10.2337/db15-1662
   Eid W, 2017, J CELL BIOCHEM, V118, P3472, DOI 10.1002/jcb.26006
   El Kamouni S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102181
   Guan GY, 2014, ENDOCRINE, V47, P764, DOI 10.1007/s12020-014-0186-1
   Han S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9260
   Jung HA, 2010, LIFE SCI, V87, P420, DOI 10.1016/j.lfs.2010.08.005
   Kolarova H, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/694312
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P18, DOI 10.1164/rccm.201612-2415CI
   Liborio AB, 2015, AM J TROP MED HYG, V92, P611, DOI 10.4269/ajtmh.14-0232
   Lukasz A, 2017, CARDIOVASC RES, V113, P671, DOI 10.1093/cvr/cvx023
   Ma MM, 2015, INFLAMMATION, V38, P1669, DOI 10.1007/s10753-015-0144-y
   Martin L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3758278
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Naumann DN, 2018, J TRAUMA ACUTE CARE, V84, P81, DOI 10.1097/TA.0000000000001695
   Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc
   Peng ZY, 2011, CAN J PHYSIOL PHARM, V89, P289, DOI [10.1139/Y11-021, 10.1139/y11-021]
   Poornima P, 2014, BIOFACTORS, V40, P121, DOI 10.1002/biof.1115
   Priya LB, 2018, J CELL BIOCHEM, V119, P1441, DOI 10.1002/jcb.26305
   Ramnath R, 2014, FASEB J, V28, P4686, DOI 10.1096/fj.14-252221
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   Salmon AHJ, 2012, J PATHOL, V226, P562, DOI 10.1002/path.3964
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Schott U, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0239-y
   Sieve I, 2018, VASC PHARMACOL, V100, P26, DOI 10.1016/j.vph.2017.09.002
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055852
   Sivalingam KS, 2017, J CELL BIOCHEM, V118, P2865, DOI 10.1002/jcb.25937
   Smith BJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00466
   Song JW, 2017, J PHARMACOL EXP THER, V361, P115, DOI 10.1124/jpet.116.239509
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   van Golen RF, 2014, ANTIOXID REDOX SIGN, V21, P1098, DOI 10.1089/ars.2013.5751
   van Golen RF, 2012, FREE RADICAL BIO MED, V52, P1382, DOI 10.1016/j.freeradbiomed.2012.01.013
   Wang GZ, 2016, EXP THER MED, V12, P1551, DOI 10.3892/etm.2016.3465
   Wang LP, 2016, BIOCHEM BIOPH RES CO, V478, P669, DOI 10.1016/j.bbrc.2016.08.005
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Yang YM, 2017, AM J RESP CELL MOL, V56, P727, DOI 10.1165/rcmb.2016-0338OC
   Yang YM, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23494
   Yen WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117133
   Zeng Y, 2014, AM J PHYSIOL-HEART C, V306, pH363, DOI 10.1152/ajpheart.00687.2013
   Zhang XY, 2012, EUR J PHARMACOL, V677, P47, DOI 10.1016/j.ejphar.2011.12.035
   Zhao LB, 2010, EUR J PHARMACOL, V627, P304, DOI 10.1016/j.ejphar.2009.11.007
   Zhou ES, 2014, INT IMMUNOPHARMACOL, V22, P133, DOI 10.1016/j.intimp.2014.06.004
   Zhou YJ, 2013, THROMB RES, V132, P202, DOI 10.1016/j.thromres.2013.05.018
NR 45
TC 32
Z9 34
U1 0
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD FEB 22
PY 2018
VL 9
AR 102
DI 10.3389/fphys.2018.00102
PG 14
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA FX1AR
UT WOS:000425779900001
PM 29520236
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Lv, JW
   Zeng, JC
   Guo, FK
   Li, YR
   Xu, MY
   Cheng, YX
   Zhang, L
   Cai, SX
   Chen, YH
   Zheng, Y
   Hu, GD
AF Lv, Jiawen
   Zeng, Junchao
   Guo, Fukun
   Li, Yiran
   Xu, Mengying
   Cheng, Yuanxiong
   Zhang, Lin
   Cai, Shaoxi
   Chen, Yinghua
   Zheng, Yi
   Hu, Guodong
TI Endothelial Cdc42 deficiency impairs endothelial regeneration and
   vascular repair after inflammatory vascular injury
SO RESPIRATORY RESEARCH
LA English
DT Article
DE ALI/ARDS; Pulmonary microvascular injury and repair; cre/loxp; Cdc42; PAK1/AKT pathway 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B;
   BREAST-CANCER; SIGNALING PATHWAY; CELLS; ANGIOGENESIS; ACTIVATION; PAK1;
   MICE
AB Background: Endothelial cell (EC) regeneration is essential for inflammation resolution and vascular integrity recovery after inflammatory vascular injury. Cdc42 is a central regulator of cell survival and vessel formation in EC development. However, it is unknown that whether Cdc42 could be a regulating role of EC repair following the inflammatory injury in the lung. The study sought to test the hypothesis that Cdc42 is required for endothelial regeneration and vascular integrity recovery after LPS-induced inflammatory injury.
   Methods and results: The role of Cdc42 for the regulation of pulmonary vascular endothelial repair was tested in vitro and in vivo. In LPS- induced acute lung injury (ALI) mouse models, knockout of the Cdc42 gene in ECs increased inflammatory cell infiltration and pulmonary vascular leakage and inhibited vascular EC proliferation, which eventually resulted in more severe inflammatory lung injury. In addition, siRNA-mediated knockdown of Cdc42 protein on ECs disrupted cell proliferation and migration and tube formation, which are necessary processes for recovery after inflammatory vascular injury, resulting in inflammatory vascular injury recovery defects.
   Conclusion: We found that Cdc42 deficiency impairs EC function and regeneration, which are crucial in the post-inflammatory vascular injury repair process. These findings indicate that Cdc42 is a potential target for novel treatments designed to facilitate endothelial regeneration and vascular repair in inflammatory pulmonary vascular diseases, such as ALI/ARDS.
C1 [Lv, Jiawen; Zeng, Junchao; Li, Yiran; Xu, Mengying; Cheng, Yuanxiong; Cai, Shaoxi; Hu, Guodong] Southern Med Univ, Nanfang Hosp, Dept Resp & Crit Care Med, Guangzhou 510515, Guangdong, China.
C1 [Zhang, Lin; Chen, Yinghua] Southern Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, Guangdong Prov Key Lab Construct & Detect Tissue, Guangzhou 510515, Guangdong, China.
C1 [Guo, Fukun] Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229, United States.
C1 [Zheng, Yi] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH, United States.
C3 Southern Medical University - China; Southern Medical University -
   China; Cincinnati Children's Hospital Medical Center; Cincinnati
   Children's Hospital Research Foundation; Cincinnati Children's Hospital
   Medical Center; Cincinnati Children's Hospital Research Foundation;
   University System of Ohio; University of Cincinnati
RP Hu, GD (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Resp & Crit Care Med, Guangzhou 510515, Guangdong, Peoples R China.; Chen, YH (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, Guangdong Prov Key Lab Construct & Detect Tissue, Guangzhou 510515, Guangdong, Peoples R China.; Zheng, Y (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH USA.
EM 956324887@qq.com; yizheng@cchmc.gov; huguodong123123@126.com
RI chen, ying/HHS-8254-2022
FU National Natural Science Foundation of China [81200060, 81402614];
   Science and Technology Planning Project of Guangdong Province
   [2017A020215188]; Natural Science Funding of Guangdong Province
   [2016A030310381, S2012040006874]
FX This project was supported by the following:; The National Natural
   Science Foundation of China (81200060, 81402614).; The Science and
   Technology Planning Project of Guangdong Province (2017A020215188).; The
   Natural Science Funding of Guangdong Province (2016A030310381,
   S2012040006874).
CR Aksamitiene E, 2011, CELL SIGNAL, V23, P1794, DOI 10.1016/j.cellsig.2011.06.014
   Arias-Romero LE, 2013, EXPERT OPIN THER TAR, V17, P1263, DOI 10.1517/14728222.2013.828037
   Barry DM, 2015, DEVELOPMENT, V142, P3058, DOI 10.1242/dev.125260
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Burbage M, 2015, J EXP MED, V212, P53, DOI 10.1084/jem.20141143
   Czikora I, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00259
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Ding BS, 2011, CELL, V147, P539, DOI 10.1016/j.cell.2011.10.003
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Egom EEA, 2010, J MOL CELL CARDIOL, V48, P406, DOI 10.1016/j.yjmcc.2009.10.009
   Elias BC, 2015, J CELL SCI, V128, P4293, DOI 10.1242/jcs.164509
   Gonzalez-Villasana V, 2015, CLIN CANCER RES, V21, P2127, DOI 10.1158/1078-0432.CCR-14-2279
   Gross CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119918
   Hinoki A, 2010, HYPERTENSION, V55, P161, DOI 10.1161/HYPERTENSIONAHA.109.143057
   Hoang MV, 2011, MICROVASC RES, V81, P34, DOI 10.1016/j.mvr.2010.09.001
   Hu GD, 2011, CHINESE MED J-PEKING, V124, P4155, DOI 10.3760/cma.j.issn.0366-6999.2011.24.007
   Huang XJ, 2016, CIRCULATION, V133, P1093, DOI 10.1161/CIRCULATIONAHA.115.020918
   Jin YX, 2013, MOL CELL BIOL, V33, P4181, DOI 10.1128/MCB.00650-13
   Kandasamy K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063465
   Kawasaki T, 2015, AM J RESP CELL MOL, V53, P500, DOI 10.1165/rcmb.2014-0185OC
   Kesavan G, 2009, CELL, V139, P791, DOI 10.1016/j.cell.2009.08.049
   Kichina JV, 2010, EXPERT OPIN THER TAR, V14, P703, DOI 10.1517/14728222.2010.492779
   Lowe K, 2007, J SURG RES, V143, P70, DOI 10.1016/j.jss.2007.03.047
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040
   Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872
   Rudolph J, 2015, J MED CHEM, V58, P111, DOI 10.1021/jm501613q
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   Shin YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071495
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515
   Tabusa H, 2013, MOL CANCER RES, V11, P109, DOI 10.1158/1541-7786.MCR-12-0466
   Voelkel NF, 2007, CHEST, V131, P874, DOI 10.1378/chest.06-2453
   Wan HJ, 2013, DEV BIOL, V374, P46, DOI 10.1016/j.ydbio.2012.11.030
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu HC, 2016, INT IMMUNOPHARMACOL, V35, P315, DOI 10.1016/j.intimp.2016.04.013
   Yao HY, 2011, BBA-GEN SUBJECTS, V1810, P666, DOI 10.1016/j.bbagen.2011.03.020
   Ye Diana Zi, 2012, Cell Logist, V2, P105
   Zhang Y, 2014, INFLAMMATION, V37, P1654, DOI 10.1007/s10753-014-9893-2
   Zhao CZ, 2014, INFLAMMATION, V37, P566, DOI 10.1007/s10753-013-9770-4
   Zhao YDD, 2014, STEM CELLS, V32, P1855, DOI 10.1002/stem.1690
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
   Zins K, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-295
NR 45
TC 15
Z9 16
U1 4
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-993X
EI 1465-9921
J9 RESP RES
JI Respir. Res.
PD FEB 8
PY 2018
VL 19
AR 27
DI 10.1186/s12931-018-0729-8
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA FV7OB
UT WOS:000424773000001
PM 29422044
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Bruhn, PJ
   Nikolian, VC
   Halaweish, I
   Chang, ZG
   Sillesen, M
   Liu, BL
   Li, YQ
   Alam, HB
AF Bruhn, Peter J.
   Nikolian, Vahagn C.
   Halaweish, Ihab
   Chang, Zhigang
   Sillesen, Martin
   Liu, Baoling
   Li, Yongqing
   Alam, Hasan B.
TI Tubastatin A prevents hemorrhage-induced endothelial barrier dysfunction
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE endothelial barrier dysfunction; histone deacetylase inhibitors; ALI/ARDS; hyperpermeability; injury 
ID MULTIPLE-ORGAN FAILURE; HISTONE DEACETYLASE; MITOCHONDRIAL DYSFUNCTION;
   VALPROIC ACID; SEPTIC SHOCK; BLOOD-FLOW; HYPOXIA; PERMEABILITY;
   GLYCOCALYX; RESUSCITATION
AB Background Microvascular hyperpermeability resulting from endothelial barrier dysfunction (EBD) is associated with worse clinical outcomes in trauma-induced hemorrhagic shock. We have previously shown that treatment with Tubastatin A (TubA), a histone deacetylase 6 inhibitor, improves outcomes in animal models of shock. In this study, we investigate whether TubA treatment may prevent trauma-related EBD.
   Methods Wistar-Kyoto rats subjected to 40% hemorrhage were treated with TubA or vehicle control. Acute lung injury (ALI) was assessed histologically from tissues harvested 6 hours posthemorrhage. In vitro, human umbilical vein endothelial cells (HUVECs) were cultured in EGM BulletKit medium. Medium was exchanged for glucose-free Dulbecco's Modified Eagle Medium (0.5% fetal bovine serum) with or without TubA, and cells were placed in an anoxic chamber (5% CO2, 95% N-2, 20-48 hours). Expression of acetylated tubulin and hypoxia-inducible factor 1 was measured by Western blot. Soluble Intercellular Adhesion Molecule-1 concentration within the medium, a marker of endothelial integrity, was determined using enzyme-linked immunosorbent assay. Monolayers were assessed for permeability via transwell assays using fluorescein isothiocyanate-labeled albumin.
   Results Rats treated with TubA had significantly reduced ALI relative to vehicle control. In vitro, TubA significantly attenuated anoxia-induced hyperpermeability, hypoxia-inducible factor 1 expression, and glycocalyx shedding.
   Conclusions Our findings demonstrate that TubA prevents hemorrhage-induced ALI in rats. Additionally, we have shown that TubA prevents anoxia-induced EBD in vitro. Taken together, these results suggest that TubA could attenuate microvascular hyperpermeability related to hemorrhagic shock.
C1 [Bruhn, Peter J.; Nikolian, Vahagn C.; Halaweish, Ihab; Chang, Zhigang; Sillesen, Martin; Liu, Baoling; Li, Yongqing; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109, United States.
C1 [Bruhn, Peter J.; Sillesen, Martin] Univ Copenhagen Hosp, Rigshosp, Dept Surg Gastroenterol, Copenhagen, Denmark.
C3 University of Michigan System; University of Michigan; Rigshospitalet;
   University of Copenhagen
RP Alam, HB (corresponding author), Univ Michigan Hlth Syst, Taubman Ctr 5331 2920, Univ Michigan Hosp, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM alamh@med.umich.edu
OI Sillesen, Martin/0000-0001-9494-5475
FU National Institute of Heath [R01-GM084127]
FX The authors have no conflicts to declare. This research was funded by a
   grant from the National Institute of Heath, R01-GM084127 awarded to
   H.B.A.
CR Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Campos SB, 2009, AM J PHYSIOL-RENAL, V296, pF487, DOI 10.1152/ajprenal.00112.2008
   Chang ZG, 2015, J TRAUMA ACUTE CARE, V79, P905, DOI 10.1097/TA.0000000000000784
   Chen HY, 2014, PHARMAZIE, V69, P55, DOI 10.1691/ph.2014.3716
   Chong W, 2012, J TRAUMA ACUTE CARE, V72, P347, DOI 10.1097/TA.0b013e318243d8b2
   Chu ZG, 2010, SHOCK, V34, P222, DOI [10.1097/SHK.0b013e3181d75a66, 10.1097/SHK.0b013e3181d8e357]
   Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023
   DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002
   Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003
   Demling RH, 2005, J BURN CARE REHABIL, V26, P207, DOI 10.1097/01.BCR.0000162151.71482.B3
   Duchesne JC, 2015, ANAESTH INTENSIVE TH, V47, P143, DOI 10.5603/AIT.a2014.0052
   Evers LH, 2010, EXP DERMATOL, V19, P777, DOI 10.1111/j.1600-0625.2010.01105.x
   Ferrara JJ, 2006, J TRAUMA, V60, P520
   Fink MP, 2001, CRIT CARE CLIN, V17, P219, DOI 10.1016/S0749-0704(05)70161-5
   Fu BMM, 2013, WIRES SYST BIOL MED, V5, P381, DOI 10.1002/wsbm.1211
   Gulati A, 2016, CURR VASC PHARMACOL, V14, P187, DOI 10.2174/1570161114666151202210221
   Halaweish I, 2015, SHOCK, V44, P6, DOI 10.1097/SHK.0000000000000319
   Ji MH, 2013, INFLAMMATION, V36, P1453, DOI 10.1007/s10753-013-9686-z
   Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d
   Kannan KB, 2011, AM J PHYSIOL-GASTR L, V300, pG853, DOI 10.1152/ajpgi.00459.2010
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kvietys PR, 1997, AM J PHYSIOL-GASTR L, V273, pG1189, DOI 10.1152/ajpgi.1997.273.6.G1189
   Lee CN, 2005, APOPTOSIS, V10, P887, DOI 10.1007/s10495-005-2946-0
   LEE HB, 1985, J NUCL MED, V26, P72
   Levy B, 2006, CURR OPIN CRIT CARE, V12, P315, DOI 10.1097/01.ccx.0000235208.77450.15
   Li YQ, 2008, SURGERY, V144, P217, DOI 10.1016/j.surg.2008.03.037
   Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11
   Lin T, 2007, SURGERY, V141, P784, DOI 10.1016/j.surg.2007.01.014
   Morin-Brureau M, 2011, J NEUROSCI, V31, P10677, DOI 10.1523/JNEUROSCI.5692-10.2011
   Ostrowski SR, 2013, J CRIT CARE, V28, P586, DOI 10.1016/j.jcrc.2013.04.010
   Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc
   Pries AR, 1997, AM J PHYSIOL-HEART C, V273, pH2272, DOI 10.1152/ajpheart.1997.273.5.H2272
   Qi HB, 2011, CELL PHYSIOL BIOCHEM, V27, P251, DOI 10.1159/000327951
   Ramirez R, 2006, J TRAUMA, V60, P515, DOI 10.1097/01.ta.0000204032.43412.20
   Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600
   Rigor RR, 2013, MED RES REV, V33, P911, DOI 10.1002/med.21270
   Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P92
   Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147
   Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3
   Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419
   Torres LN, 2013, J TRAUMA ACUTE CARE, V75, P759, DOI 10.1097/TA.0b013e3182a92514
   Tsiotou AG, 2005, MED SCI MONITOR, V11, pRA76
   Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003
   Videm V, 2008, SCAND J IMMUNOL, V67, P523, DOI 10.1111/j.1365-3083.2008.02029.x
   Wang P, 2013, CELL PHYSIOL BIOCHEM, V32, P859, DOI 10.1159/000354488
   Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434
   Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
   Yeh WL, 2007, MOL PHARMACOL, V72, P440, DOI 10.1124/mol.107.036418
   Zheng HZ, 2003, BURNS, V29, P820, DOI 10.1016/j.burns.2003.08.004
   ZIKRIA BA, 1994, JAMA-J AM MED ASSOC, V272, P202
NR 52
TC 4
Z9 5
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD FEB
PY 2018
VL 84
IS 2
BP 386
EP 392
DI 10.1097/TA.0000000000001753
PG 7
WC Critical Care Medicine; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Surgery
GA FU7QR
UT WOS:000424048300023
PM 29194316
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Ji, YX
   Zhang, GH
   Zhu, HB
   Li, DF
   Jiang, WL
AF Ji, Yunxia
   Zhang, Guanghua
   Zhu, Haibo
   Li, Defang
   Jiang, Wanglin
TI INDINAVIR PLUS METHYLPREDNISOLONE AMELIORATES EXPERIMENTAL ACUTE LUNG
   INJURY IN VITRO AND IN VIVO
SO SHOCK
LA English
DT Article
DE HMGB1/TLR-4; Indinavir; methylprednisolone; NF-kappa B; two-hit ALI 
ID RESPIRATORY-DISTRESS-SYNDROME; SYSTEMIC INFLAMMATION; HMGB1; MECHANISMS;
   RESISTANCE; RECEPTOR; GLUCOCORTICOIDS; AQUAPORIN-5; RELEASE; MODEL
AB Background: An abnormal HMGB1 activation plays a key role in the pathogenesis of ALI. Methods: In this study, the effects of Indinavir plus methylprednisolone on the LPS-mediated activation in human pulmonary microvascular endothelial cells (HPMECs), on the injury of AT I in vitro, and on rats with LPS-induced two-hit model with or without methylprednisolone were investigated. Results: Indinavir treatment resulted in a reduction of HMGB1, its receptor TLR-4, and HMGB1' s downstream p-NF-kappa B, attenuating a decrease of VE-cadherin in LPS-stimulated HPMECs. Apoptosis of AT I was attenuated with an increase of RAGE and aquaporin 5. Compared to methylprednisolone alone, methylprednisolone plus Indinavir attenuated the decrease of GRa and I kappa B-a in cytoplasm and avoid GRa deficiency in LPS-stimulated HPMECs for 96 h, attenuated the increase of p-NF-kappa B in nucleus. Indinavir ameliorated histopathological changes of two-hit ALI model of rats with reductions in microvascular permeability, lower HMGB1, TLR4, p-NF-kappa B, and MPO expression, whereas higher RAGE, aquaporin 5, and VE-cadherin in LPS-instilled lungs. Compared to methylprednisolone alone, methylprednisolone plus Indinavir attenuated the decrease ofGRa and I kappa B-a in cytoplasm, decreased p-NF-kappa B in nucleus of lung tissue of two-hit ALI rats, and enhanced the anti-inflammatory effect of methylprednisolone for avoiding GRa deficiency. Conclusion: It demonstrated that Indinavir prevented experimental ALI model of rats by modulating the HMGB1/TLR-4 pathway to resolve systemic inflammation response in a greater degree with methylprednisolone, reduced the use time and dose of methylprednisolone, and avoided GRa deficiency in ALI and ARDS.
C1 [Ji, Yunxia; Zhang, Guanghua; Zhu, Haibo; Li, Defang; Jiang, Wanglin] Binzhou Med Univ, Sch Pharm, Yantai, China.
C3 Binzhou Medical University
RP Jiang, WL (corresponding author), Binzhou Med Univ, Sch Pharmaceut Sci, Yantai 264003, Peoples R China.
EM jiangwanglin@bzmc.edu.cn
OI Li, Defang/0000-0003-4151-9151
FU National Natural Science Foundation of China [31270391]; Dominant
   Disciplines' Talent Team Development Scheme of Higher Education of
   Shandong Province
FX The study was supported by the National Natural Science Foundation of
   China (grant no. 31270391) and the Dominant Disciplines' Talent Team
   Development Scheme of Higher Education of Shandong Province.
CR Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Entezari M, 2014, REDOX BIOL, V2, P314, DOI 10.1016/j.redox.2014.01.013
   Fanelli Vito, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS3, DOI 10.1513/AnnalsATS.201407-340MG
   Gero D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065994
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Hidaka S, 2011, J SURG RES, V165, P142, DOI 10.1016/j.jss.2009.05.039
   Kudo D, 2013, CLIN EXP IMMUNOL, V173, P276, DOI 10.1111/cei.12106
   Li YM, 2009, J HUAZHONG U SCI-MED, V29, P470, DOI 10.1007/s11596-009-0416-6
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meduri GU, 2005, NEUROIMMUNOMODULAT, V12, P321, DOI 10.1159/000091126
   Meduri GU, 2004, ANN NY ACAD SCI, V1024, P24, DOI 10.1196/annals.1321.004
   Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014
   Murphy TJ, 2005, J LEUKOCYTE BIOL, V77, P16, DOI 10.1189/jlb.0704382
   Nakamura T, 2011, CLIN BIOCHEM, V44, P601, DOI 10.1016/j.clinbiochem.2010.12.014
   Nosengo N, 2016, NATURE, V534, P314, DOI 10.1038/534314a
   Ortiz-Diaz E, 2013, SEMIN RESP CRIT CARE, V34, P448, DOI 10.1055/s-0033-1351118
   Ryan AJ, 2003, J APPL PHYSIOL, V94, P253, DOI 10.1152/japplphysiol.00184.2002
   Sapru A, 2015, PEDIATR CRIT CARE ME, V16, pS6, DOI 10.1097/PCC.0000000000000431
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Sodhi CP, 2015, J IMMUNOL, V194, P4931, DOI 10.4049/jimmunol.1402490
   Standiford TJ, 2016, TRANSL RES, V167, P183, DOI 10.1016/j.trsl.2015.04.015
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Tadie JM, 2013, AM J PHYSIOL-LUNG C, V304, pL342, DOI 10.1152/ajplung.00151.2012
   Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601-001TK
   Tseng CC, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/804654
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   Wu DD, 2016, SHOCK, V46, P329, DOI 10.1097/SHK.0000000000000595
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhou BY, 2007, AM J PHYSIOL-CELL PH, V292, pC1280, DOI 10.1152/ajpcell.00070.2006
NR 34
TC 10
Z9 11
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD FEB
PY 2018
VL 49
IS 2
BP 196
EP 204
DI 10.1097/SHK.0000000000000911
PG 9
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA GC0RF
UT WOS:000429484600012
PM 28562480
DA 2023-08-21
ER

PT J
AU Yang, CY
   Chen, CS
   Yiang, GT
   Cheng, YL
   Yong, SB
   Wu, MY
   Li, CJ
AF Yang, Chin-Yao
   Chen, Chien-Sheng
   Yiang, Giou-Teng
   Cheng, Yeung-Leung
   Yong, Su-Boon
   Wu, Meng-Yu
   Li, Chia-Jung
TI New Insights into the Immune Molecular Regulation of the Pathogenesis of
   Acute Respiratory Distress Syndrome
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE ALI/ARDS; permeability; NETosis; sepsis 
ID ACUTE LUNG INJURY; INHALED NITRIC-OXIDE; ENDOTHELIAL GROWTH-FACTOR;
   END-EXPIRATORY PRESSURE; TUMOR-NECROSIS-FACTOR; RANDOMIZED
   CONTROLLED-TRIAL; INDUCED PULMONARY-FIBROSIS; CHEMOKINE RECEPTORS CXCR1;
   ANGIOTENSIN-II; MECHANICAL VENTILATION
AB Acute respiratory distress syndrome is an inflammatory disease characterized by dysfunction of pulmonary epithelial and capillary endothelial cells, infiltration of alveolar macrophages and neutrophils, cell apoptosis, necroptosis, NETosis, and fibrosis. Inflammatory responses have key effects on every phase of acute respiratory distress syndrome. The severe inflammatory cascades impaired the regulation of vascular endothelial barrier and vascular permeability. Therefore, understanding the relationship between the molecular regulation of immune cells and the pulmonary microenvironment is critical for disease management. This article reviews the current clinical and basic research on the pathogenesis of acute respiratory distress syndrome, including information on the microenvironment, vascular endothelial barrier and immune mechanisms, to offer a strong foundation for developing therapeutic interventions.
C1 [Yang, Chin-Yao] Kaohsiung Vet Gen Hosp, Div Chest Med, Kaohsiung 813, Taiwan.
C1 [Chen, Chien-Sheng; Yiang, Giou-Teng; Wu, Meng-Yu] Taipei Tzu Chi Hosp, Dept Emergency Med, Buddhist Tzu Chi Med Fdn, New Taipei 231, Taiwan.
C1 [Chen, Chien-Sheng; Yiang, Giou-Teng; Wu, Meng-Yu] Tzu Chi Univ, Sch Med, Dept Emergency Med, Hualien 970, Taiwan.
C1 [Cheng, Yeung-Leung] Taipei Tzu Chi Hosp, Div Thorac Surg, Dept Surg, Buddhist Tzu Chi Med Fdn, New Taipei 231, Taiwan.
C1 [Cheng, Yeung-Leung] Tzu Chi Univ, Sch Surg, Hualien 970, Taiwan.
C1 [Yong, Su-Boon] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.
C1 [Yong, Su-Boon] Show Chwan Mem Hosp, Div Pediat Allergy Immunol & Rheumatol, Dept Pediat, Changhua 500, Taiwan.
C1 [Yong, Su-Boon] Meiho Univ, Dept Nursing, Pingtung 912, Taiwan.
C1 [Li, Chia-Jung] Show Chwan Mem Hosp, Res Assistant Ctr, Changhua 500, Taiwan.
C3 Kaohsiung Veterans General Hospital; Buddhist Tzu Chi General Hospital;
   Taipei Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi General
   Hospital; Taipei Tzu Chi Hospital; Tzu Chi University; Chung Shan
   Medical University; Show Chwan Memorial Hospital; Show Chwan Memorial
   Hospital
RP Wu, MY (corresponding author), Taipei Tzu Chi Hosp, Dept Emergency Med, Buddhist Tzu Chi Med Fdn, New Taipei 231, Taiwan.; Wu, MY (corresponding author), Tzu Chi Univ, Sch Med, Dept Emergency Med, Hualien 970, Taiwan.; Li, CJ (corresponding author), Show Chwan Mem Hosp, Res Assistant Ctr, Changhua 500, Taiwan.
EM ycyaoyao@vghks.gov.tw; holeyeye@yahoo.com.tw; gtyiang@gmail.com;
   ndmc0928@yahoo.com.tw; yongsuboon@gmail.com; skyshangrila@gmail.com;
   nigel6761@gmail.com
RI Wu, Meng Yu/J-8772-2019; Yiang, Giou-Teng/IVU-7155-2023; YONG, SU
   BOON/GQZ-7683-2022
OI Wu, Meng Yu/0000-0002-8773-1847; YONG, SU BOON/0000-0002-5175-908X;
   Cheng, Yeung-Leung/0000-0002-1911-1419; Li,
   Chia-Jung/0000-0002-3773-9015
FU Show-Chwan Memorial Hospital, Taiwan [RD106077, RD106078]
FX This study was funded by grants RD106077 and RD106078 from Show-Chwan
   Memorial Hospital, Taiwan.
CR Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292
   Abrams D, 2017, CHEST, V152, P639, DOI 10.1016/j.chest.2017.06.016
   Adhikari NKJ, 2007, BMJ-BRIT MED J, V334, P779, DOI 10.1136/bmj.39139.716794.55
   Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472
   Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201
   Armstrong L, 1997, THORAX, V52, P442, DOI 10.1136/thx.52.5.442
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Azamfirei L, 2010, MINERVA ANESTESIOL, V76, P609
   Barratt S, 2014, RESPIRATION, V87, P329, DOI 10.1159/000356034
   BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Belvitch P, 2013, CRIT CARE MED, V41, P1813, DOI 10.1097/CCM.0b013e3182963cfb
   BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buczek-Thomas JA, 2004, AM J RESP CELL MOL, V31, P344, DOI 10.1165/rcmb.2003-0420OC
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558
   Caironi P, 2010, AM J RESP CRIT CARE, V181, P578, DOI 10.1164/rccm.200905-0787OC
   Capelozzi VL, 2017, ARCH PATHOL LAB MED, V141, P1719, DOI 10.5858/arpa.2017-0115-SA
   Chavez A, 2011, INT REV CEL MOL BIO, V290, P205, DOI 10.1016/B978-0-12-386037-8.00001-6
   Chawla LS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1306-5
   Chen HC, 2004, J BIOMED SCI, V11, P49, DOI 10.1159/000075288
   Chishti AD, 2001, J THORAC CARDIOV SUR, V122, P1162, DOI 10.1067/mtc.2001.116559
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Confalonieri M, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0116-2016
   COOPER CL, 1985, CIRC RES, V56, P97, DOI 10.1161/01.RES.56.1.97
   Cummings CJ, 1999, J IMMUNOL, V162, P2341
   D'Alessio FR, 2016, AM J PHYSIOL-LUNG C, V310, pL733, DOI 10.1152/ajplung.00419.2015
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011
   Eklund L, 2013, EXP CELL RES, V319, P1271, DOI 10.1016/j.yexcr.2013.03.011
   Elder J., 2005, THORAX, V60, P821
   Epelbaum Oleg, 2017, Hosp Pract (1995), V45, P88, DOI 10.1080/21548331.2017.1331687
   Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC
   Estenssoro E, 2002, CRIT CARE MED, V30, P2450, DOI 10.1097/00003246-200211000-00008
   Fanelli V, 2013, J THORAC DIS, V5, P326, DOI 10.3978/j.issn.2072-1439.2013.04.05
   Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1
   Fialkow L, 2006, CRIT CARE, V10, DOI 10.1186/cc5090
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
   Fujishima S, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-32
   FYHRQUIST F, 1995, J HUM HYPERTENS, V9, pS19
   Galani V, 2010, PATHOL RES PRACT, V206, P145, DOI 10.1016/j.prp.2009.12.002
   Garcia JGN, 2009, MICROVASC RES, V77, P1, DOI 10.1016/j.mvr.2009.01.001
   GATTINONI L, 1995, AM J RESP CRIT CARE, V151, P1807, DOI 10.1164/ajrccm.151.6.7767524
   GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959
   GREAVES MW, 1976, POSTGRAD MED J, V52, P631, DOI 10.1136/pgmj.52.612.631
   Greco E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102200
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hamada N, 2005, J IMMUNOL, V175, P1224, DOI 10.4049/jimmunol.175.2.1224
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Heard SO, 1999, ANESTH ANALG, V89, P353, DOI 10.1097/00000539-199908000-00020
   HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009
   Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719
   KASAMA T, 1994, J IMMUNOL, V152, P3559
   Keane MP, 1999, J IMMUNOL, V162, P5511
   Kendrick SFW, 2008, COMPET-BASE CRIT CAR, P5, DOI 10.1007/978-1-84628-939-2_2
   Khilnani GC, 2011, LUNG INDIA, V28, P114, DOI 10.4103/0970-2113.80324
   Kim WY, 2016, TUBERC RESPIR DIS, V79, P53, DOI 10.4046/trd.2016.79.2.53
   Koh Y, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-2
   Lamontagne F, 2013, CAN MED ASSOC J, V185, P216, DOI 10.1503/cmaj.120582
   Lee KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020388
   Lo CJ, 1998, J SURG RES, V79, P179, DOI 10.1006/jsre.1998.5418
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Mac Sweeney R, 2016, LANCET, V388, P2416, DOI 10.1016/S0140-6736(16)00578-X
   MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007
   Manzano F, 2008, CRIT CARE MED, V36, P2225, DOI 10.1097/CCM.0b013e31817b8a92
   Marik P, 2006, NEW ENGL J MED, V355, P316
   Matthay MA, 2017, LANCET RESP MED, V5, P524, DOI 10.1016/S2213-2600(17)30188-1
   Matute-Bello G, 1999, J IMMUNOL, V163, P2217
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Meduri GU, 2008, INTENS CARE MED, V34, P61, DOI 10.1007/s00134-007-0933-3
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Meyer NJ, 2017, LANCET RESP MED, V5, P512, DOI 10.1016/S2213-2600(17)30187-X
   Michael JR, 1998, AM J RESP CRIT CARE, V157, P1372, DOI 10.1164/ajrccm.157.5.96-10089
   MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306
   MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427
   MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485
   Needham DM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2124
   NORMAN JG, 1995, ARCH SURG-CHICAGO, V130, P966
   Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001
   Orfanos SE, 2000, CIRCULATION, V102, P2011
   Ou XM, 2009, INT IMMUNOPHARMACOL, V9, P70, DOI 10.1016/j.intimp.2008.10.002
   Ourradi K, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0602-1
   Overgaard CE, 2011, ANTIOXID REDOX SIGN, V15, P1179, DOI 10.1089/ars.2011.3893
   Pan L, 2016, BIOCHEM BIOPH RES CO, V478, P1602, DOI 10.1016/j.bbrc.2016.08.163
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Paszti-Gere E, 2012, INFLAMMATION, V35, P994, DOI 10.1007/s10753-011-9403-8
   Pelosi P, 2008, INTENS CARE MED, V34, P631, DOI 10.1007/s00134-007-0964-9
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024
   Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003
   Puscas I, 2000, INT J CLIN LAB RES, V30, P119, DOI 10.1007/s005990070010
   Qing DY, 2014, AM J RESP CRIT CARE, V190, P1243, DOI 10.1164/rccm.201406-1095OC
   Figueira ERR, 2010, SURGERY, V147, P415, DOI 10.1016/j.surg.2009.10.018
   Remick DG, 2007, AM J PATHOL, V170, P1435, DOI 10.2353/ajpath.2007.060872
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Rokkam D, 2011, AM J PATHOL, V179, P1081, DOI 10.1016/j.ajpath.2011.05.017
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sawafuji M, 2005, AM J PHYSIOL-LUNG C, V289, pL946, DOI 10.1152/ajplung.00188.2004
   Sharp C, 2015, RESPIRATION, V89, P420, DOI 10.1159/000381102
   SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0
   SILER TM, 1989, EXP LUNG RES, V15, P881, DOI 10.3109/01902148909069633
   SMITH SR, 1994, J LEUKOCYTE BIOL, V55, P711, DOI 10.1002/jlb.55.6.711
   Soini Y, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-70
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Stillie R, 2009, J LEUKOCYTE BIOL, V86, P529, DOI 10.1189/jlb.0208125
   Summers C, 2014, THORAX, V69, P623, DOI 10.1136/thoraxjnl-2013-204742
   Suzuki T, 2009, AM J RESP CELL MOL, V41, P742, DOI 10.1165/rcmb.2008-0157OC
   Tang BMP, 2009, CRIT CARE MED, V37, P1594, DOI 10.1097/CCM.0b013e31819fb507
   Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603
   Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8
   Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003
   Troncy E, 1998, AM J RESP CRIT CARE, V157, P1483, DOI 10.1164/ajrccm.157.5.9707090
   Umbrello M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010064
   Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4
   Walkey Allan J, 2012, Clin Epidemiol, V4, P159, DOI 10.2147/CLEP.S28800
   Wang CY, 2014, INTENS CARE MED, V40, P388, DOI 10.1007/s00134-013-3186-3
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wang LL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155723
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660
   Witherden IR, 2004, AM J RESP CELL MOL, V30, P500, DOI 10.1165/rcmb.4890
   Wrigge H., 2001, YB INTENSIVE CARE EM, V2001, P35
   Wu MY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102034
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Zhao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20156
NR 135
TC 61
Z9 64
U1 4
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2018
VL 19
IS 2
AR 588
DI 10.3390/ijms19020588
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FZ3YN
UT WOS:000427527400272
PM 29462936
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Zou, Y
   Bao, SH
   Wang, F
   Guo, L
   Zhu, JL
   Wang, J
   Deng, XM
   Li, JB
AF Zou, Yun
   Bao, Suhong
   Wang, Fang
   Guo, Long
   Zhu, Jiali
   Wang, Jun
   Deng, Xiaoming
   Li, Jinbao
TI FN14 BLOCKADE ON PULMONARY MICROVASCULAR ENDOTHELIAL CELLS IMPROVES THE
   OUTCOME OF SEPSIS- INDUCED ACUTE LUNG INJURY
SO SHOCK
LA English
DT Article
DE BALF; chemotaxis; CLP; fibrosis; ECs/HPMECs/HUVECs/MPVECs; hyperpermeability; TER 
ID TWEAK RECEPTOR; WEAK INDUCER; APOPTOSIS; REGENERATION; NEUTROPHILS;
   PROTECTS
AB Pulmonary microvascular leakage is one of the characteristics of blood-air barrier dysfunction in septic acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Fibroblast growth factor-inducible 14 (Fn14) exerts diverse functions under certain circumstances. However, the role of Fn14 on the integrity of pulmonary microvascular endothelial cells (PMVECs) during sepsis remains unknown. Septic ALI was induced via cecal ligation and puncture (CLP). Fn14 expression on PMVECs was measured 24 h after surgery. The effects of Fn14 blockade on septic ALI were investigated in vivo and in vitro. Compared with the Sham group, Fn14 expressed in septic PMVECs was increased significantly 24 h after surgery. The protein level in bronchoalveolar lavage fluid, the lung wet to dry ratio, and neutrophil/macrophage infiltration in lungs were reduced in septic mice after Fn14 blockade. Similarly, ICAM-1 and MCP-1 levels were attenuated after Fn14 blockade or knockdown in lungs or human pulmonary microvascular endothelial cells (HPMECs). Furthermore, Fn14 silencing reduced Caspase-3 levels and upregulated the transendothelial electrical resistance level in TNF-like weak inducer of apoptosis-treated HPMECs. In addition, the degree of lung fibrosis was ameliorated and the survival of CLP mice was improved significantly after Fn14 blockade. In conclusion, Fn14 on PMVECs plays an important role in the progress of septic ALI. Fn14 blockade may prove to be an innovative lung-protective strategy for the treatment of septic ALI.
C1 [Zou, Yun; Wang, Fang; Wang, Jun; Deng, Xiaoming] Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol & Intens Care, Shanghai, China.
C1 [Bao, Suhong] Yangzhou Univ, Affiliated Hosp, Dept Anesthesiol, Yangzhou, Jiangsu, China.
C1 [Guo, Long; Zhu, Jiali; Li, Jinbao] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Anesthesiol, Shanghai, China.
C3 Naval Medical University; Yangzhou University; Shanghai Jiao Tong
   University
RP Deng, XM (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol & Intens Care, Shanghai, Peoples R China.; Li, JB (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China.
EM deng_x@yahoo.com; lijinbaoshanghai@163.com
RI Deng, Xiaoming/E-2876-2010
FU National Natural Science Foundation of China [81401576, 81571877]
FX This work was supported by Grant 81401576 and 81571877 from the National
   Natural Science Foundation of China.
CR Ameri H, 2014, INVEST OPHTH VIS SCI, V55, P801, DOI 10.1167/iovs.13-12812
   Baeck C, 2012, GUT, V61, P416, DOI 10.1136/gutjnl-2011-300304
   Sanz AB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090399
   Cantarella G, 2010, NEUROPSYCHOPHARMACOL, V35, P1302, DOI 10.1038/npp.2009.234
   Delano MJ, 2016, IMMUNOL REV, V274, P330, DOI 10.1111/imr.12499
   Farley KS, 2009, AM J PHYSIOL-LUNG C, V296, pL480, DOI 10.1152/ajplung.90201.2008
   Figueroa CD, 2015, INNATE IMMUN-LONDON, V21, P289, DOI 10.1177/1753425914529169
   Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7
   Gill SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088501
   Girgenrath M, 2006, EMBO J, V25, P5826, DOI 10.1038/sj.emboj.7601441
   Haile WB, 2010, J CEREBR BLOOD F MET, V30, P1147, DOI 10.1038/jcbfm.2009.280
   Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0
   Hawiger J, 2015, J THROMB HAEMOST, V13, P1743, DOI 10.1111/jth.13061
   Hotta K, 2011, KIDNEY INT, V79, P179, DOI 10.1038/ki.2010.379
   Huang XJ, 2016, CIRCULATION, V133, P1093, DOI 10.1161/CIRCULATIONAHA.115.020918
   Kangelaris KN, 2015, AM J PHYSIOL-LUNG C, V308, pL1102, DOI 10.1152/ajplung.00380.2014
   Kushimoto S, 2012, CRIT CARE, V16, DOI 10.1186/cc11898
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Meliton AY, 2015, AM J PHYSIOL-LUNG C, V308, pL550, DOI 10.1152/ajplung.00248.2014
   Mock JR, 2014, MUCOSAL IMMUNOL, V7, P1440, DOI 10.1038/mi.2014.33
   Mutlu GM, 2006, NEW ENGL J MED, V354, P416
   Nagai M, 2011, THER APHER DIAL, V15, P342, DOI 10.1111/j.1744-9987.2011.00966.x
   Novoyatleva T, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0325-x
   Parker JC, 2011, COMPR PHYSIOL, V1, P835, DOI 10.1002/cphy.c100013
   Perez JG, 2016, ONCOGENE, V35, P2145, DOI 10.1038/onc.2015.310
   Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200
   Poveda J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00447
   Schapira K, 2009, ARTERIOSCL THROM VAS, V29, P2021, DOI 10.1161/ATVBAHA.109.195040
   Stephan D, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-9
   Villar J, 2014, CURR OPIN CRIT CARE, V20, P3, DOI 10.1097/MCC.0000000000000057
   Wajant H, 2013, BRIT J PHARMACOL, V170, P748, DOI 10.1111/bph.12337
   Wu Rongqian, 2002, Chin J Traumatol, V5, P146
   Zhou H, 2011, MOL CANCER THER, V10, P1276, DOI 10.1158/1535-7163.MCT-11-0161
   Zhu JF, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053196, 10.1371/journal.pone.0055601]
   Zhu XJ, 2016, J SURG RES, V204, P288, DOI 10.1016/j.jss.2016.04.067
NR 35
TC 21
Z9 23
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD FEB
PY 2018
VL 49
IS 2
BP 213
EP 220
DI 10.1097/SHK.0000000000000915
PG 8
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA GC0RF
UT WOS:000429484600014
PM 28562476
DA 2023-08-21
ER

PT J
AU Shaver, CM
   Wickersham, N
   McNeil, JB
   Nagata, H
   Miller, A
   Landstreet, SR
   Kuck, JL
   Diamond, JM
   Lederer, DJ
   Kawut, SM
   Palmer, SM
   Wille, KM
   Weinacker, A
   Lama, VN
   Crespo, MM
   Orens, JB
   Shah, PD
   Hage, CA
   Cantu, E
   Porteous, MK
   Dhillon, G
   McDyer, J
   Bastarache, JA
   Christie, JD
   Ware, LB
AF Shaver, Ciara M.
   Wickersham, Nancy
   McNeil, J. Brennan
   Nagata, Hiromasa
   Miller, Adam
   Landstreet, Stuart R.
   Kuck, Jamie L.
   Diamond, Joshua M.
   Lederer, David J.
   Kawut, Steven M.
   Palmer, Scott M.
   Wille, Keith M.
   Weinacker, Ann
   Lama, Vibha N.
   Crespo, Maria M.
   Orens, Jonathan B.
   Shah, Pali D.
   Hage, Chadi A.
   Cantu, Edward, III
   Porteous, Mary K.
   Dhillon, Gundeep
   McDyer, John
   Bastarache, Julie A.
   Christie, Jason D.
   Ware, Lorraine B.
CA Lung Transplant Outcomes Grp LTOG
TI Cell-free hemoglobin promotes primary graft dysfunction through
   oxidative lung endothelial injury
SO JCI INSIGHT
LA English
DT Article
ID CLINICAL RISK-FACTORS; ISCHEMIA-REPERFUSION INJURY;
   VASCULAR-PERMEABILITY; LIPID-PEROXIDATION; PULMONARY-EDEMA; DONOR
   SMOKING; TRANSPLANTATION; ACETAMINOPHEN; INCREASES; SEPSIS
AB Primary graft dysfunction (PGD) is acute lung injury within 72 hours of lung transplantation. We hypothesized that cell-free hemoglobin (CFH) contributes to PGD by increasing lung microvascular permeability and tested this in patients, ex vivo human lungs, and cultured human lung microvascular endothelial cells. In a nested case control study of 40 patients with severe PGD at 72 hours and 80 matched controls without PGD, elevated preoperative CFH was independently associated with increased PGD risk (odds ratio [OR] 2.75, 95% CI, 1.23-6.16, P = 0.014). The effect of CFH on PGD was magnified by reperfusion fraction of inspired oxygen (FiO(2)) = 0.40 (OR 3.41, P = 0.031). Isolated perfused human lungs exposed to intravascular CFH (100 mg/dl) developed increased vascular permeability as measured by lung weight (CFH 14.4% vs. control 0.65%, P = 0.047) and extravasation of Evans blue-labeled albumin dye (EBD) into the airspace (P = 0.027). CFH (1 mg/dl) also increased paracellular permeability of human pulmonary microvascular endothelial cell monolayers (hPMVECs). Hyperoxia (FiO(2) = 0.95) increased human lung and hPMVEC permeability compared with normoxia (FiO(2) = 0.21). Treatment with acetaminophen (15 mu g/ml), a specific hemoprotein reductant, prevented CFH-dependent permeability in human lungs (P = 0.046) and hPMVECs (P = 0.037). In summary, CFH may mediate PGD through oxidative effects on microvascular permeability, which are augmented by hyperoxia and abrogated by acetaminophen.
C1 [Shaver, Ciara M.; Wickersham, Nancy; McNeil, J. Brennan; Landstreet, Stuart R.; Kuck, Jamie L.; Bastarache, Julie A.; Ware, Lorraine B.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN, United States.
C1 [Nagata, Hiromasa] Keio Univ, Sch Med, Dept Anesthesiol, Tokyo, Japan.
C1 [Miller, Adam] Tennessee Donor Serv, Nashville, TN, United States.
C1 [Diamond, Joshua M.; Kawut, Steven M.; Crespo, Maria M.; Porteous, Mary K.; Christie, Jason D.] Univ Penn, Dept Med, Perelman Sch Med, Div Pulm & Crit Care Med, Philadelphia, PA 19104, United States.
C1 [Lederer, David J.] Columbia Univ, Sch Med, Div Pulm Allergy & Crit Care Med, New York, NY, United States.
C1 [Palmer, Scott M.] Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC, United States.
C1 [Wille, Keith M.] Univ Alabama Birmingham, Div Pulm & Crit Care Med, Birmingham, AL, United States.
C1 [Weinacker, Ann; Dhillon, Gundeep] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Palo Alto, CA 94304, United States.
C1 [Lama, Vibha N.] Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI, United States.
C1 [Orens, Jonathan B.; Shah, Pali D.] Johns Hopkins Univ, Med Ctr, Div Pulm & Crit Care Med, Baltimore, MD 21218, United States.
C1 [Hage, Chadi A.] Indiana Univ Sch Med, Div Pulm Allergy Crit Care & Occupat Med, Indianapolis, IN 46202, United States.
C1 [Cantu, Edward, III] Univ Penn, Perelman Sch Med, Div Cardiovasc Surg, Philadelphia, PA 19104, United States.
C1 [McDyer, John] Univ Pittsburgh, Div Pulm Allergy & Crit Care, Pittsburgh, PA, United States.
C1 [Bastarache, Julie A.; Ware, Lorraine B.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN, United States.
C3 Vanderbilt University; Keio University; University of Pennsylvania;
   Pennsylvania Medicine; Columbia University; Duke University; University
   of Alabama System; University of Alabama Birmingham; Stanford
   University; University of Michigan System; University of Michigan; Johns
   Hopkins University; University System of Maryland; University of
   Maryland Baltimore; Indiana University System; Indiana University
   Bloomington; University of Pennsylvania; Pennsylvania Medicine;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Vanderbilt University
RP Ware, LB (corresponding author), 1161 21st Ave South,Med Ctr North,T-1218, Nashville, TN 37232 USA.
EM lorraine.ware@vanderbilt.edu
RI Ware, Lorraine/AAJ-9307-2021; Hage, Chadi/Z-4903-2019; Hage,
   Chadi/HMP-3255-2023
OI Ware, Lorraine/0000-0002-9429-4702; Palmer, Scott/0000-0002-1370-3771;
   Christie, Jason/0000-0003-0519-218X; Weinacker, Ann/0000-0003-4869-2854;
   Dhillon, Gundeep/0000-0003-0440-1138; Shaver, Ciara/0000-0002-5677-0288;
   McNeil, Joel/0000-0002-9200-1881
FU NIH [HL135849, HL103836, HL087115, HL126176, HL126671, HL117676,
   HL121406, HL136888]; Vanderbilt Faculty Research Scholars; American
   Thoracic Society; Parker B. Francis Family Foundation
FX These studies were funded by NIH HL135849 (LBW, JAB), HL103836 (LBW),
   HL087115 (JDC), HL126176 (LBW), HL126671 (JAB), HL117676 (JAB), HL121406
   (JMD), HL136888 (CMS), Vanderbilt Faculty Research Scholars (CMS),
   American Thoracic Society (CMS), and the Parker B. Francis Family
   Foundation (CMS). We would like to thank Tennessee Donor Services for
   their invaluable assistance in obtaining donor lungs for research. We
   thank the donor families for their gift to research.
CR Baldwin AL, 1999, AM J PHYSIOL-HEART C, V277, pH650, DOI 10.1152/ajpheart.1999.277.2.H650
   Bastarache JA, 2012, THORAX, V67, P1032, DOI 10.1136/thoraxjnl-2012-201781
   Ben Moussa S, 2014, LIBYAN J MED, V9, DOI 10.3402/ljm.v9.23873
   Boutaud O, 2010, P NATL ACAD SCI USA, V107, P2699, DOI 10.1073/pnas.0910174107
   Brittain EL, 2014, CHEST, V146, P1478, DOI 10.1378/chest.14-0809
   Calfee CS, 2007, BIOMARK MED, V1, P285, DOI 10.2217/17520363.1.2.285
   Cantu E, 2016, AM J TRANSPLANT, V16, P833, DOI 10.1111/ajt.13525
   Christie JD, 2007, AM J RESP CRIT CARE, V175, P69, DOI 10.1164/rccm.200606-827OC
   Christie JD, 2009, AM J RESP CRIT CARE, V180, P1010, DOI 10.1164/rccm.200901-0118OC
   Christie JD, 2005, J HEART LUNG TRANSPL, V24, P1454, DOI 10.1016/j.healun.2004.11.049
   Christie JD, 2003, CHEST, V124, P1232, DOI 10.1378/chest.124.4.1232
   Diamond JM, 2011, AM J TRANSPLANT, V11, P561, DOI 10.1111/j.1600-6143.2010.03431.x
   Diamond JM, 2016, J HEART LUNG TRANSPL, V35, P500, DOI 10.1016/j.healun.2015.12.012
   Diamond JM, 2013, CURR OPIN ORGAN TRAN, V18, P518, DOI 10.1097/MOT.0b013e3283651994
   Diamond JM, 2013, AM J RESP CRIT CARE, V187, P527, DOI 10.1164/rccm.201210-1865OC
   Diamond JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051932
   Fessel Joshua P, 2012, Pulm Circ, V2, P201, DOI 10.4103/2045-8932.97606
   Frank JA, 2007, AM J PHYSIOL-LUNG C, V293, pL52, DOI 10.1152/ajplung.00256.2006
   Godzich M, 2006, FASEB J, V20, P1519, DOI 10.1096/fj.05-4708fje
   Hashimoto K, 2016, AM J RESP CRIT CARE, V194, P97, DOI 10.1164/rccm.201510-2115OC
   Hoffman SA, 2009, AM J TRANSPLANT, V9, P389, DOI 10.1111/j.1600-6143.2008.02497.x
   Janz DR, 2015, CRIT CARE MED, V43, P534, DOI 10.1097/CCM.0000000000000718
   Janz DR, 2013, CRIT CARE MED, V41, P784, DOI 10.1097/CCM.0b013e3182741a54
   Krenn K, 2007, AM J TRANSPLANT, V7, P700, DOI 10.1111/j.1600-6143.2006.01673.x
   Krenn K, 2007, EUR J CARDIO-THORAC, V32, P35, DOI 10.1016/j.ejcts.2007.04.006
   Kuntz CL, 2009, CLIN TRANSPLANT, V23, P819, DOI 10.1111/j.1399-0012.2008.00951.x
   Lederer DJ, 2011, AM J RESP CRIT CARE, V184, P1055, DOI 10.1164/rccm.201104-0728OC
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Lisk C, 2013, AM J RESP CELL MOL, V49, P619, DOI 10.1165/rcmb.2012-0440OC
   Liu Yu-Qiang, 2014, J Anal Methods Chem, V2014, P617367, DOI 10.1155/2014/617367
   Lowery EM, 2014, ALCOHOL CLIN EXP RES, V38, P2853, DOI 10.1111/acer.12553
   Mallavia B, 2016, AM J TRANSPLANT, V16, P1306, DOI 10.1111/ajt.13605
   Nosotti M, 2014, TRANSPL P, V46, P2329, DOI 10.1016/j.transproceed.2014.07.042
   Ouellet M, 2001, ARCH BIOCHEM BIOPHYS, V387, P273, DOI 10.1006/abbi.2000.2232
   Porteous MK, 2016, AM J RESP CRIT CARE, V193, P1392, DOI 10.1164/rccm.201508-1522OC
   Porteous MK, 2015, CURR OPIN ORGAN TRAN, V20, P506, DOI 10.1097/MOT.0000000000000232
   Potor L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/676425
   Reeder BJ, 2005, CURR MED CHEM, V12, P2741, DOI 10.2174/092986705774463021
   Risbano MG, 2015, AM J RESP CRIT CARE, V192, P1223, DOI 10.1164/rccm.201501-0145OC
   Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653
   Rusak T, 2014, FREE RADICAL RES, V48, P230, DOI 10.3109/10715762.2013.860225
   Sayah DM, 2015, AM J RESP CRIT CARE, V191, P455, DOI 10.1164/rccm.201406-1086OC
   Schaer DJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a013433
   Shah RJ, 2014, AM J RESP CRIT CARE, V189, P1564, DOI 10.1164/rccm.201312-2121LE
   Shah RJ, 2012, TRANSL RES, V160, P435, DOI 10.1016/j.trsl.2012.08.003
   Shaver CM, 2016, AM J PHYSIOL-LUNG C, V310, pL532, DOI 10.1152/ajplung.00155.2015
   Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344
   Somers J, 2015, J HEART LUNG TRANSPL, V34, P941, DOI 10.1016/j.healun.2015.03.009
   Su G, 2007, AM J RESP CELL MOL, V36, P377, DOI 10.1165/rcmb.2006-0238OC
   Su G, 2013, CRIT CARE MED, V41, P546, DOI 10.1097/CCM.0b013e3182711b1e
   Suzuki Y, 2013, SEMIN RESP CRIT CARE, V34, P305, DOI 10.1055/s-0033-1348474
   Ware LB, 2014, AM J TRANSPLANT, V14, P2295, DOI 10.1111/ajt.12853
   Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X
   Whitson BA, 2006, J THORAC CARDIOV SUR, V131, P73, DOI 10.1016/j.jtcvs.2005.08.039
   Windsant ICV, 2011, J THORAC CARDIOV SUR, V142, P1, DOI 10.1016/j.jtcvs.2011.02.012
NR 55
TC 23
Z9 23
U1 0
U2 5
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JAN 25
PY 2018
VL 3
IS 2
AR e98546
DI 10.1172/jci.insight.98546
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FT7MU
UT WOS:000423337400013
PM 29367464
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Oskolkova, O
   Sarich, N
   Tian, YF
   Gawlak, G
   Meng, F
   Bochkov, VN
   Berdyshev, E
   Birukova, AA
   Birukov, KG
AF Oskolkova, Olga
   Sarich, Nicolene
   Tian, Yufeng
   Gawlak, Grzegorz
   Meng, Fanyong
   Bochkov, Valery N.
   Berdyshev, Evgeny
   Birukova, Anna A.
   Birukov, Konstantin G.
TI Incorporation of iloprost in phospholipase-resistant phospholipid
   scaffold enhances its barrier protective effects on pulmonary
   endothelium
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDUCED LUNG INJURY; OXIDIZED PHOSPHOLIPIDS; ACTIVATION; PERMEABILITY;
   RECEPTOR; KINASE; CELLS; RAP1; RAC; PHARMACOKINETICS
AB Correction of barrier dysfunction and inflammation in acute lung injury (ALI) represents an important problem. Previous studies demonstrate barrier-protective and anti-inflammatory effects of bioactive lipid prostacyclin and its stable analog iloprost (ILO). We generated a phospholipase resistant synthetic phospholipid with iloprost attached at the sn-2 position (ILO-PC) and investigated its biological effects. In comparison to free ILO, ILO-PC caused sustained endothelial cell (EC) barrier enhancement, linked to more prolonged activation of Rap1 and Rac1 GTPases and their cytoskeletal and cell junction effectors: cortactin, PAK1, p120-catenin and VE-cadherin. ILO and ILO-PC equally efficiently suppressed acute, Rho GTPase-dependent EC hyper-permeability caused by thrombin. However, ILO-PC exhibited more sustained barrier-protective and anti-inflammatory effects in the model of chronic EC dysfunction caused by bacterial wall lipopolysacharide (LPS). ILO-PC was also more potent inhibitor of NF kappa B signaling and lung vascular leak in the murine model of LPS-induced ALI. Treatment with ILO-PC showed more efficient ALI recovery over 3 days after LPS challenge than free ILO. In conclusion, this study describes a novel synthetic phospholipid with barrier-enhancing and anti-inflammatory properties superior to existing prostacyclin analogs, which may be used as a prototype for future development of more efficient treatment for ALI and other vascular leak syndromes.
C1 [Oskolkova, Olga; Sarich, Nicolene; Tian, Yufeng; Gawlak, Grzegorz; Meng, Fanyong] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637, United States.
C1 [Oskolkova, Olga; Bochkov, Valery N.] Graz Univ, Dept Pharmaceut Chem, Inst Pharmaceut Sci, A-8010 Graz, Austria.
C1 [Berdyshev, Evgeny] Natl Jewish Hlth, Denver, CO 80206, United States.
C1 [Birukova, Anna A.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201, United States.
C1 [Birukov, Konstantin G.] Univ Maryland, Sch Med, Dept Anesthesia, Baltimore, MD 21201, United States.
C3 University of Chicago; ARQUS; University of Graz; National Jewish
   Health; University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Birukov, KG (corresponding author), Univ Maryland, Sch Med, Dept Anesthesia, Baltimore, MD 21201 USA.
EM kbirukov@som.umaryland.edu
RI Bochkov, Valery/HNR-8336-2023; Birukov, Konstantin/FJB-5755-2022;
   Sarich, Nicolene/IWV-3869-2023
OI Oskolkova, Olga/0000-0001-9443-8705
FU NHLBI NIH HHS [R01 HL076259, R01 HL087823, R01 HL146829, R01 HL130431]
   Funding Source: Medline; NIGMS NIH HHS [R01 GM122940, R01 GM114171]
   Funding Source: Medline
CR Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Baumer Y, 2008, HISTOCHEM CELL BIOL, V129, P765, DOI 10.1007/s00418-008-0422-y
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2015, BBA-MOL BASIS DIS, V1852, P778, DOI 10.1016/j.bbadis.2014.12.016
   Birukova AA, 2014, MOL BIOL CELL, V25, P2006, DOI 10.1091/mbc.E13-12-0743
   Birukova AA, 2013, MOL BIOL CELL, V24, P2678, DOI 10.1091/mbc.E13-02-0098
   Birukova AA, 2013, TRANSL RES, V161, P495, DOI 10.1016/j.trsl.2012.12.008
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002
   Birukova AA, 2009, J APPL PHYSIOL, V107, P1900, DOI 10.1152/japplphysiol.00462.2009
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199
   Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742
   Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006
   BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6
   CAWELLO W, 1994, EUR J CLIN PHARMACOL, V46, P275
   Dejana E, 2009, CELL TISSUE RES, V335, P17, DOI 10.1007/s00441-008-0694-5
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.E02-11-0753
   Hildebrand M, 1997, EUR J CLIN PHARMACOL, V53, P51, DOI 10.1007/s002280050336
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080
   Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010
   McIntyre TM, 2012, BBA-BIOMEMBRANES, V1818, P2456, DOI 10.1016/j.bbamem.2012.03.004
   Melian EB, 2002, DRUGS, V62, P107, DOI 10.2165/00003495-200262010-00005
   Meliton A., 2015, AM J PHYSIOL-LUNG C
   Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200
   Pannekoek WJ, 2009, BBA-BIOMEMBRANES, V1788, P790, DOI 10.1016/j.bbamem.2008.12.010
   Tian YF, 2015, J BIOL CHEM, V290, P4097, DOI 10.1074/jbc.M114.620377
   Togbe D, 2007, INT J EXP PATHOL, V88, P387, DOI 10.1111/j.1365-2613.2007.00566.x
   Watanabe Y, 1999, TETRAHEDRON, V55, P9743, DOI 10.1016/S0040-4020(99)00551-7
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
NR 39
TC 12
Z9 14
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 17
PY 2018
VL 8
AR 879
DI 10.1038/s41598-018-19197-1
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS9DR
UT WOS:000422716900013
PM 29343759
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Brenner, JS
   Kiseleva, RY
   Glassman, PM
   Parhiz, H
   Greineder, CF
   Hood, ED
   Shuvaev, VV
   Muzykantov, VR
AF Brenner, Jacob S.
   Kiseleva, Raisa Yu.
   Glassman, Patrick M.
   Parhiz, Hamideh
   Greineder, Colin F.
   Hood, Elizabeth D.
   Shuvaev, Vladimir V.
   Muzykantov, Vladimir R.
TI The new frontiers of the targeted interventions in the pulmonary
   vasculature: precision and safety (2017 Grover Conference Series)
SO PULMONARY CIRCULATION
LA English
DT Review
DE ALI/ARDS; drug delivery; ECs/HPMECs/HUVECs/MPVECs; Inflammation; vascular targeting 
ID ANGIOTENSIN-CONVERTING-ENZYME; INTERCELLULAR-ADHESION MOLECULE-1;
   ACTIVATED ENDOTHELIAL-CELLS; ALLEVIATES OXIDATIVE STRESS; DRUG-DELIVERY
   SYSTEMS; INDUCED LUNG INJURY; IN-VIVO; SUPEROXIDE-DISMUTASE;
   MONOCLONAL-ANTIBODIES; TISSUE FACTOR
AB The pulmonary vasculature plays an important role in many lung pathologies, such as pulmonary arterial hypertension, primary graft dysfunction of lung transplant, and acute respiratory distress syndrome. Therapy for these diseases is quite limited, largely due to dose-limiting side effects of numerous drugs that have been trialed or approved. High doses of drugs targeting the pulmonary vasculature are needed due to the lack of specific affinity of therapeutic compounds to the vasculature. To overcome this problem, the field of targeted drug delivery aims to target drugs to the pulmonary endothelial cells, especially those in pathological regions. The field uses a variety of drug delivery systems (DDSs), ranging from nano-scale drug carriers, such as liposomes, to methods of conjugating drugs to affinity moieites, such as antibodies. These DDSs can deliver small molecule drugs, protein therapeutics, and imaging agents. Here we review targeted drug delivery to the pulmonary endothelium for the treatment of pulmonary diseases. Cautionary notes are made of the risk-benefit ratio and safety-parameters one should keep in mind when developing a translational therapeutic.
C1 [Brenner, Jacob S.] Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104, United States.
C1 [Kiseleva, Raisa Yu.; Glassman, Patrick M.; Parhiz, Hamideh; Greineder, Colin F.; Hood, Elizabeth D.; Shuvaev, Vladimir V.; Muzykantov, Vladimir R.] Univ Penn, Dept Pharmacol, Perelman Sch Med, Philadelphia, PA 19104, United States.
C3 University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine
RP Muzykantov, VR (corresponding author), 3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
RI Shuvaev, Vladimir V/O-1719-2014; Glassman, Patrick/P-9955-2019; Brenner,
   Jacob/Y-2030-2018
OI Glassman, Patrick/0000-0003-3786-0437; Brenner,
   Jacob/0000-0001-8437-0161; Kiseleva, Raisa/0000-0001-8065-3551
FU National Heart, Lung, and Blood Institute [1RO1 HL125462-02, 1RO1
   HL128398-02, RO1 HL126874-01A1]
FX This research was supported by National Heart, Lung, and Blood Institute
   Grants 1RO1 HL125462-02 (VRM), 1RO1 HL128398-02 (VRM) and RO1
   HL126874-01A1 (VRM).
CR Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195
   ALMENARQUERALT A, 1995, AM J PATHOL, V147, P1278
   Ansar M, 2013, ACS NANO, V7, P10597, DOI 10.1021/nn404719c
   ATOCHINA EN, 1992, LUNG, V170, P349
   Atochina EN, 1998, AM J PHYSIOL-LUNG C, V275, pL806, DOI 10.1152/ajplung.1998.275.4.L806
   Atochina EN, 1997, AM J RESP CRIT CARE, V156, P1114, DOI 10.1164/ajrccm.156.4.96-12116
   Bagam P, 2017, CELL BIOL TOXICOL, V33, P429, DOI 10.1007/s10565-017-9386-9
   Balyasnikova IV, 2006, TISSUE ANTIGENS, V67, P10, DOI 10.1111/j.1399-0039.2005.00516.x
   Balyasnikova IV, 2005, PULM PHARMACOL THER, V18, P251, DOI 10.1016/j.pupt.2004.12.008
   Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   BJORNSSON J, 1985, MAYO CLIN PROC, V60, P16, DOI 10.1016/S0025-6196(12)65277-X
   Brenner Jacob S, 2017, Nanomedicine, V13, P1495, DOI 10.1016/j.nano.2016.12.019
   Brenner JS, 2017, ANN AM THORAC SOC, V14, P561, DOI 10.1513/AnnalsATS.201701-090PS
   Brenner JS, 2015, EXPERT OPIN DRUG DEL, V12, P239, DOI 10.1517/17425247.2015.961418
   Carnemolla R, 2013, J PHARMACOL EXP THER, V347, P339, DOI 10.1124/jpet.113.205104
   Caron E, 2001, PHAGOCYTOSIS
   Carraway MS, 2003, AM J RESP CRIT CARE, V167, P1200, DOI 10.1164/rccm.200204-287OC
   Carvalho AN, 2017, CURR DRUG TARGETS, V18, P705, DOI 10.2174/1389450117666160401120514
   Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146
   Chacko AM, 2011, CURR OPIN COLLOID IN, V16, P215, DOI 10.1016/j.cocis.2011.01.008
   Chen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058275
   Chittasupho C, 2009, EUR J PHARM SCI, V37, P141, DOI 10.1016/j.ejps.2009.02.008
   Chorny M, 2010, J CONTROL RELEASE, V146, P144, DOI 10.1016/j.jconrel.2010.05.003
   Chrastina A, 2010, J VASC RES, V47, P531, DOI 10.1159/000313880
   Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003
   Christofidou-Solomidou M, 2002, AM J PATHOL, V160, P1155, DOI 10.1016/S0002-9440(10)64935-8
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Cook-Mills JM, 2011, ANTIOXID REDOX SIGN, V15, P1607, DOI 10.1089/ars.2010.3522
   Corvo ML, 2002, BBA-BIOMEMBRANES, V1564, P227, DOI 10.1016/S0005-2736(02)00457-1
   Corvo ML, 1999, BBA-BIOMEMBRANES, V1419, P325, DOI 10.1016/S0005-2736(99)00081-4
   CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529
   CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440
   Danielyan K, 2007, J PHARMACOL EXP THER, V321, P947, DOI 10.1124/jpet.107.120535
   DANILOV S, 1994, INT IMMUNOL, V6, P1153, DOI 10.1093/intimm/6.8.1153
   Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335, DOI 10.1152/ajplung.2001.280.6.L1335
   DANILOV SM, 1989, J NUCL MED, V30, P1686
   Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997
   Di Fiore P. P., 2014, CSH PERSPECT BIOL, V6, P8
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   Ding BS, 2005, BLOOD, V106, P4191, DOI 10.1182/blood-2005-05-2002
   Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993
   Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401
   Dziubla TD, 2005, J CONTROL RELEASE, V102, P427, DOI 10.1016/j.jconrel.2004.10.017
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164
   Fan J, 2000, SURGERY, V128, P332, DOI 10.1067/msy.2000.108060
   Feero WG, 1997, GENE THER, V4, P664, DOI 10.1038/sj.gt.3300453
   FORD VA, 1992, J BIOL CHEM, V267, P5446
   FREEMAN BA, 1985, FED PROC, V44, P2591
   Gao BF, 2003, AM J PHYSIOL-LUNG C, V284, pL917, DOI 10.1152/ajplung.00374.2002
   Garnacho C, 2008, J CONTROL RELEASE, V130, P226, DOI 10.1016/j.jconrel.2008.06.007
   Garnacho C, 2008, J PHARMACOL EXP THER, V325, P400, DOI 10.1124/jpet.107.133298
   Gaspar MM, 2007, J CONTROL RELEASE, V117, P186, DOI 10.1016/j.jconrel.2006.10.018
   Gaspar MM, 2003, BBA-BIOMEMBRANES, V1609, P211, DOI 10.1016/S0005-2736(02)00702-2
   Ghaffarian R, 2012, J CONTROL RELEASE, V163, P25, DOI 10.1016/j.jconrel.2012.06.007
   Ghitescu L, 1999, ENDOTHELIUM-J ENDOTH, V6, P241, DOI 10.3109/10623329909053414
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249
   Gonnet M, 2010, J CONTROL RELEASE, V146, P276, DOI 10.1016/j.jconrel.2010.01.037
   Greineder CF, 2017, BLOOD ADV, V1, P1452, DOI 10.1182/bloodadvances.2017007229
   Greineder CF, 2016, J CONTROL RELEASE, V226, P229, DOI 10.1016/j.jconrel.2016.02.006
   Greineder CF, 2015, FASEB J, V29, P3483, DOI 10.1096/fj.15-271213
   Greineder CF, 2013, BLOOD, V122, P1565, DOI 10.1182/blood-2013-03-453498
   Guo P, 2014, P NATL ACAD SCI USA, V111, P14710, DOI 10.1073/pnas.1408556111
   Hajitou A, 2006, CELL, V125, P385, DOI 10.1016/j.cell.2006.02.042
   Han JY, 2015, J CONTROL RELEASE, V210, P39, DOI 10.1016/j.jconrel.2015.05.006
   Han JY, 2012, ACS NANO, V6, P8824, DOI 10.1021/nn302687n
   Han JY, 2011, J PHARMACOL EXP THER, V338, P82, DOI 10.1124/jpet.111.180620
   Haraldsen G, 1996, J IMMUNOL, V156, P2558
   Harari OA, 1999, GENE THER, V6, P801, DOI 10.1038/sj.gt.3300898
   Hegeman MA, 2011, BRIT J PHARMACOL, V163, P1048, DOI 10.1111/j.1476-5381.2011.01314.x
   Heitner T, 2001, J IMMUNOL METHODS, V248, P17, DOI 10.1016/S0022-1759(00)00340-9
   Heitsch H, 2001, HYPERTENSION, V37, P72, DOI 10.1161/01.HYP.37.1.72
   Hood E, 2011, NANOMEDICINE-UK, V6, P1257, DOI [10.2217/NNM.11.92, 10.2217/nnm.11.92]
   Hood ED, 2014, BIOMATERIALS, V35, P3708, DOI 10.1016/j.biomaterials.2014.01.023
   Hood ED, 2012, J CONTROL RELEASE, V163, P161, DOI 10.1016/j.jconrel.2012.08.031
   Hopkins AM, 2004, ADV DRUG DELIVER REV, V56, P763, DOI 10.1016/j.addr.2003.10.043
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   Howard MD, 2014, J CONTROL RELEASE, V177, P34, DOI 10.1016/j.jconrel.2013.12.035
   Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547
   Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1
   Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3
   Kartha S, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700500
   KEELAN ETM, 1994, J NUCL MED, V35, P276
   Kelly KA, 2005, CIRC RES, V96, P327, DOI 10.1161/01.RES.0000155722.17881.dd
   Kessner S, 2001, BBA-BIOMEMBRANES, V1514, P177, DOI 10.1016/S0005-2736(01)00368-6
   Kinniry P, 2006, PEDIATR PULM, V41, P916, DOI 10.1002/ppul.20468
   Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7
   Kok RJ, 2002, PHARM RES-DORDR, V19, P1730, DOI 10.1023/A:1020769716288
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   KOYAMA S, 1992, AM REV RESPIR DIS, V145, P1404, DOI 10.1164/ajrccm/145.6.1404
   Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806
   KUIJPERS TW, 1994, J IMMUNOL, V152, P5060
   KUMAR AG, 1994, J IMMUNOL, V153, P4088
   Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679
   Lannan KL, 2014, DRUG DISCOV TODAY, V19, P1230, DOI 10.1016/j.drudis.2014.04.001
   Lindner JR, 2001, CIRCULATION, V104, P2107, DOI 10.1161/hc4201.097061
   Lindner JR, 2002, BIOMEDICAL ASPECTS OF DRUG TARGETING, P149
   Liu KD, 2008, AM J RESP CRIT CARE, V178, P618, DOI 10.1164/rccm.200803-419OC
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Massey Kerri A, 2009, Proc Am Thorac Soc, V6, P419, DOI 10.1513/pats.200903-011AW
   Mayor S, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016758
   McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398
   Mehta D, 2004, AM J PHYSIOL-LUNG C, V287, pL1081, DOI 10.1152/ajplung.00268.2004
   Meoli DF, 2009, AM J PHYSIOL-LUNG C, V297, pL706, DOI 10.1152/ajplung.90598.2008
   Metzger R, 2011, MICROVASC RES, V81, P206, DOI 10.1016/j.mvr.2010.12.003
   Miller WH, 2005, MOL THER, V12, P321, DOI 10.1016/j.ymthe.2005.02.025
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Morecroft I, 2012, MOL THER, V20, P1516, DOI 10.1038/mt.2012.70
   MORI A, 1995, CANCER CHEMOTH PHARM, V35, P447, DOI 10.1007/s002800050261
   Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759
   Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846
   Murciano JC, 2001, AM J RESP CRIT CARE, V164, P1295, DOI 10.1164/ajrccm.164.7.2010076
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muro S, 2005, BLOOD, V105, P650, DOI 10.1182/blood-2004-05-1714
   Muro S, 2003, AM J PHYSIOL-CELL PH, V285, pC1339, DOI 10.1152/ajpcell.00099.2003
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muro Silvia, 2004, Current Vascular Pharmacology, V2, P281, DOI 10.2174/1570161043385736
   Muro S, 2012, J CONTROL RELEASE, V164, P125, DOI 10.1016/j.jconrel.2012.05.052
   Murohara T, 1996, J IMMUNOL, V156, P3550
   Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909
   Muzykantov VR, 2011, IUBMB LIFE, V63, P583, DOI 10.1002/iub.480
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213
   MUZYKANTOV VR, 1991, J NUCL MED, V32, P453
   Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2
   Nakada MT, 2000, J IMMUNOL, V164, P452, DOI 10.4049/jimmunol.164.1.452
   Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129
   Nowak K, 2007, AM J PHYSIOL-LUNG C, V293, pL162, DOI 10.1152/ajplung.00001.2007
   Nowak K, 2013, ADV EXP MED BIOL, V756, P203, DOI 10.1007/978-94-007-4549-0_26
   Nowak K, 2010, EUR J CARDIO-THORAC, V37, P859, DOI 10.1016/j.ejcts.2009.10.029
   Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580
   Oh P, 2007, NAT BIOTECHNOL, V25, P327, DOI 10.1038/nbt1292
   Oh P, 2014, NAT MED, V20, P1062, DOI 10.1038/nm.3623
   Pan H, 2013, FASEB J, V27, P255, DOI 10.1096/fj.12-218081
   Pardridge WM, 1998, J PHARMACOL EXP THER, V286, P548
   Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512
   Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2
   Pasqualini R, 2001, NAT IMMUNOL, V2, P567, DOI 10.1038/89704
   PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198
   Popova NV, 2013, ACTA NATURAE, V5, P62, DOI 10.32607/20758251-2013-5-3-62-73
   Predescu D, 2004, AM J PHYSIOL-LUNG C, V287, pL895, DOI 10.1152/ajplung.00075.2004
   Preissler G, 2011, TRANSPLANTATION, V92, P380, DOI 10.1097/TP.0b013e318226bc6b
   Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008
   Reynolds AM, 2012, EUR RESPIR J, V39, P329, DOI 10.1183/09031936.00187310
   Reynolds AM, 2007, AM J PHYSIOL-LUNG C, V292, pL1182, DOI 10.1152/ajplung.00020.2006
   Reynolds PN, 2001, NAT BIOTECHNOL, V19, P838, DOI 10.1038/nbt0901-838
   Reynolds PN, 2000, MOL THER, V2, P562, DOI 10.1006/mthe.2000.0205
   Rocksen D, 2003, AM J RESP CELL MOL, V28, P199, DOI 10.1165/rcmb.4899
   ROMER LH, 1995, J IMMUNOL, V154, P6582
   ROTHLEIN R, 1992, KIDNEY INT, V41, P617, DOI 10.1038/ki.1992.94
   Sakamaki F, 2000, CIRCULATION, V102, P2720, DOI 10.1161/01.CIR.102.22.2720
   Scalia R, 1998, J LEUKOCYTE BIOL, V64, P163, DOI 10.1002/jlb.64.2.163
   Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777
   SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399
   Schnitzer JE, 2001, ADV DRUG DELIVER REV, V49, P265, DOI 10.1016/S0169-409X(01)00141-7
   Seo J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03597-w
   Serrano D, 2016, BIOMACROMOLECULES, V17, P3127, DOI 10.1021/acs.biomac.6b00493
   Serrano D, 2012, ARTERIOSCL THROM VAS, V32, P1178, DOI 10.1161/ATVBAHA.111.244186
   Shamay Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7374
   Shuvaev VV, 2007, J PHARMACOL EXP THER, V323, P450, DOI 10.1124/jpet.107.127126
   Shuvaev VV, 2007, J CONTROL RELEASE, V118, P235, DOI 10.1016/j.jconrel.2006.12.025
   Shuvaev Vladimir V., 2004, V283, P3
   Shuvaev VV, 2016, J CONTROL RELEASE, V234, P115, DOI 10.1016/j.jconrel.2016.05.040
   Shuvaev VV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077002
   Shuvaev VV, 2011, ACS NANO, V5, P6991, DOI 10.1021/nn2015453
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shuvaev VV, 2011, J CONTROL RELEASE, V149, P236, DOI 10.1016/j.jconrel.2010.10.026
   Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877
   Siekmeier R, 2007, J CARDIOVASC PHARM T, V12, P265, DOI 10.1177/1074248407299519
   Simone EA, 2008, EXPERT OPIN DRUG DEL, V5, P1283, DOI 10.1517/17425240802567846 
   Simone EA, 2009, BIOMACROMOLECULES, V10, P1324, DOI 10.1021/bm900189x
   SKIDGEL RA, 1992, J CARDIOVASC PHARM, V20, pS4, DOI 10.1097/00005344-199200209-00003
   Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   Stan RV, 1999, J CELL BIOL, V145, P1189, DOI 10.1083/jcb.145.6.1189
   StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212
   Stone WL, 2004, MOL BIOTECHNOL, V27, P217, DOI 10.1385/MB:27:3:217
   Straley KS, 2000, J CELL BIOL, V151, P107, DOI 10.1083/jcb.151.1.107
   Swaminathan TN, 2011, IUBMB LIFE, V63, P640, DOI 10.1002/iub.475
   TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625
   TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347
   TANSWELL AK, 1987, J APPL PHYSIOL, V63, P347, DOI 10.1152/jappl.1987.63.1.347
   Testa JE, 2009, AM J PHYSIOL-LUNG C, V297, pL251, DOI 10.1152/ajplung.90565.2008
   Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027
   Thomson MJ, 2007, CARDIOVASC DRUG THER, V21, P195, DOI 10.1007/s10557-007-6027-1
   Toba M, 2014, AM J PATHOL, V184, P369, DOI 10.1016/j.ajpath.2013.10.008
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e
   Urakami T, 2011, AM J PATHOL, V178, P2489, DOI 10.1016/j.ajpath.2011.02.032
   Ushio-Fukai M, 2009, ANTIOXID REDOX SIGN, V11, P1289, DOI [10.1089/ars.2008.2333, 10.1089/ARS.2008.2333]
   Valadon P, 2010, J BIOL CHEM, V285, P713, DOI 10.1074/jbc.M109.061838
   Van Krieken R, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0844-9
   Vogel SM, 2001, MICROVASC RES, V61, P87, DOI 10.1006/mvre.2000.2274
   VONASMUTH EJU, 1992, EUR J IMMUNOL, V22, P2519, DOI 10.1002/eji.1830221009
   Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002
   Welsh CH, 1996, CHEST, V110, P710, DOI 10.1378/chest.110.3.710
   WHITE CW, 1989, J APPL PHYSIOL, V66, P584, DOI 10.1152/jappl.1989.66.2.584
   White RJ, 2007, AM J PHYSIOL-LUNG C, V293, pL583, DOI 10.1152/ajplung.00321.2006
   Wilson A, 2005, MOL THER, V12, P510, DOI 10.1016/j.ymthe.2005.04.005
   Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76
   Xu XM, 2012, PHARM RES-DORDR, V29, P1919, DOI 10.1007/s11095-012-0720-x
   Yin YJ, 2013, PHARM RES-DORDR, V30, P2050, DOI 10.1007/s11095-013-1058-8
   Zhang Y, 2003, MOL THER, V7, P11, DOI 10.1016/S1525-0016(02)00018-7
   Zhou Y, 2012, ARCH BIOCHEM BIOPHYS, V526, P107, DOI 10.1016/j.abb.2012.05.007
   Zhou Y, 2010, J MOL BIOL, V404, P88, DOI 10.1016/j.jmb.2010.09.006
NR 208
TC 8
Z9 9
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD JAN 12
PY 2018
VL 8
IS 1
AR 2045893217752329
DI 10.1177/2045893217752329
PG 18
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA FX7SG
UT WOS:000426290500001
PM 29261028
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Cao, Z
   Liu, JL
   Wu, S
   Wang, Q
AF Cao, Zheng
   Liu, Jing-Lan
   Wu, Shen
   Wang, Qiao
TI Mechanism of MCP-1 in Acute Lung Injury and Advanced Therapy by
   Drug-Loaded Dextrin Nanoparticle
SO INTERNATIONAL JOURNAL OF POLYMER SCIENCE
LA English
DT Article
ID MACROPHAGES; CHEMOATTRACTANT; INFLAMMATION; INHIBITION; OUTCOMES; RATS;
   PAIN
AB Objective. To observe the expression of monocyte chemotactic protein 1 (MCP-1) in acute lung injury (ALI) rat model, to characterize its effect on the development and progression of ALI, and to identify the potential new drug delivery approach during in vivo experiment. Method. The effects of different doses of lipopolysaccharide (LPS) on human pulmonary artery endothelial cells (HPAEC) were tested. For the animal experiments, thirty Sprague-Dawley (SD) rats were divided into physiological saline control group (NC group), the LPS model group (L group), the antagonist RS102895 combined with LPS group (R+ L group), and the antagonist RS102895-loaded polyaldehyde dextran nanoparticles combined with LPS group (DNPR +L group). The blood gas analysis and dry/wet weight ratio were detected 24 hours after interventions. The levels of inflammatory factors, tumor necrosis factor-alpha (TNF-alpha) and interleuldn-1 beta (IL-1 beta), were tested by ELISA. The expression of monocyte chemoattractant protein-1 (MCP-1) in lung tissues was examined through Western blot, and the change of MCP-1 mRNA expression level was detected by performing RT-PCR. Result. LPS was responsible for inducing ALI in rats, and the degree of cell damage was dose-dependent. Blood gas analysis of L group showed that PaO2 and PaO2/FiO2 levels were significantly lower than those of the NC group (P < 0.05), while the dry/wet weight ratio of lung tissues in L group increased (P < 0.05). Inflammatory factors including TNF-alpha and IL-1 beta and the expression of MCP-1 in both protein and mRNA levels were higher in L group than in the NC group (P < 0.05). The inhibition of the interaction between MCP-1 and chemokines receptor 2 (CCR2) by antagonist RS102895 can significantly alleviate the ALI in rats, which is accompanied by a significant decrease of inflammatory factors and MCP-1 expression (P < 0.05). Compared with R + L group, treatment with DNPR and LPS combination significantly improved the condition of rats and decreased the level of TNF-alpha, IL-1 beta, and MCP-1 expression (P < 0.05). Conclusion. In ALI, RS102895 can inhibit the MCP-1/CCR2 interaction, therefore, retarding the progress of ALI. Because of the high transfection efficiency of inhibitor RS102895packgaed by polyaldehyde dextran nanoparticles, this phenomenon particularly reached a significant level. The results imply new insights for the treatment of ALI.
C1 [Cao, Zheng; Wu, Shen; Wang, Qiao] Shanghai Jiao Tong Univ, Emergency Dept, Shanghai Peoples Hosp 9, Sch Med, Shanghai, China.
C1 [Liu, Jing-Lan] Int Peace Matern & Child Hlth Hosp, China Welf Inst, Shanghai, China.
C3 Shanghai Jiao Tong University
RP Wang, Q (corresponding author), Shanghai Jiao Tong Univ, Emergency Dept, Shanghai Peoples Hosp 9, Sch Med, Shanghai, Peoples R China.
EM wangqiao1298@126.com
FU National Natural Science Foundation of China [51673190]
FX The article is supported by grant 51673190 from the National Natural
   Science Foundation of China, and the data and materials used to support
   the findings of this study are included in the published article.
CR Al-Mazidi S, 2018, EUR J PAIN, V22, P810, DOI 10.1002/ejp.1169
   Bostrom EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134608
   Cao YM, 2016, BIOMED REP, V4, P523, DOI 10.3892/br.2016.620
   Deng GM, 2017, BIOMED PHARMACOTHER, V96, P148, DOI 10.1016/j.biopha.2017.09.094
   Dias-Freitas F, 2016, RESP MED, V119, P23, DOI 10.1016/j.rmed.2016.08.010
   Ding XB, 2017, SCI REP-UK, V7, DOI 10.1038/srep34278
   Gibon E, 2012, J ORTHOP RES, V30, P547, DOI 10.1002/jor.21548
   Guo SX, 2017, BIOMED PHARMACOTHER, V95, P1743, DOI 10.1016/j.biopha.2017.09.034
   Han CH, 2017, MED GAS RES, V7, P220, DOI 10.4103/2045-9912.215753
   He Y, 2017, CELL PHYSIOL BIOCHEM, V42, P1303, DOI 10.1159/000478959
   Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065
   Hilda JN, 2016, HUM IMMUNOL, V77, P63, DOI 10.1016/j.humimm.2015.10.005
   Hu YH, 2017, MOLECULES, V22, DOI 10.3390/molecules22060937
   Kalliomaki J, 2013, SCAND J PAIN, V4, P17, DOI 10.1016/j.sjpain.2012.08.004
   Kalnins A, 2015, SCAND J IMMUNOL, V82, P102, DOI 10.1111/sji.12310
   Lei JJ, 2018, EUR J PHARMACOL, V818, P110, DOI 10.1016/j.ejphar.2017.10.029
   Lomis N, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6060116
   Luo YP, 2017, INT J MOL MED, V39, P297, DOI 10.3892/ijmm.2016.2828
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Mutlu GM, 2006, NEW ENGL J MED, V354, P416
   Panee J, 2012, CYTOKINE, V60, P1, DOI 10.1016/j.cyto.2012.06.018
   Proudfoot AG, 2011, DIS MODEL MECH, V4, P145, DOI 10.1242/dmm.006213
   Rajasekaran S, 2016, J CELL PHYSIOL, V231, P2097, DOI 10.1002/jcp.25316
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sormann P, 2017, INJURY, V48, P2400, DOI 10.1016/j.injury.2017.08.041
   Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932
   von Dossow-Hanfstingl Vera, 2012, Anesthesiol Clin, V30, P629, DOI 10.1016/j.anclin.2012.08.008
   Wang Y., 2018, MOL PAIN, V14
   Wang YL, 2017, MICROB PATHOGENESIS, V110, P375, DOI 10.1016/j.micpath.2017.07.019
   Yadav A, 2010, CLIN CHIM ACTA, V411, P1570, DOI 10.1016/j.cca.2010.07.006
   Yang MD, 2017, THERANOSTICS, V7, P97, DOI 10.7150/thno.16844
   Yu NB, 2016, J ACUTE DIS, V5, P382, DOI 10.1016/j.joad.2016.08.003
   Zhang HM, 2016, J PAIN, V17, P775, DOI 10.1016/j.jpain.2016.02.011
   Zhang Y, 2018, ADV SCI, V5, DOI 10.1002/advs.201700821
NR 34
TC 5
Z9 6
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-9422
EI 1687-9430
J9 INT J POLYM SCI
JI Int. J. Polym. Sci.
PY 2018
VL 2018
AR 9269154
DI 10.1155/2018/9269154
PG 7
WC Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Polymer Science
GA GW4IQ
UT WOS:000446876600001
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Chai, DD
   Zhang, L
   Xi, SW
   Cheng, YY
   Jiang, H
   Hu, R
AF Chai, Dongdong
   Zhang, Lei
   Xi, SiWei
   Cheng, YanYong
   Jiang, Hong
   Hu, Rong
TI Nrf2 Activation Induced by Sirt1 Ameliorates Acute Lung Injury After
   Intestinal Ischemia/Reperfusion Through NOX4-Mediated Gene Regulation
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Nrf2; SIRT1; NOX/NOX1/NOX2/NOX4; migration; angiogenesis 
ID ISCHEMIA-REPERFUSION; SIGNALING PATHWAY; RAT MODEL; CELLS; PERMEABILITY;
   RETINOPATHY; EXPRESSION; PROTECTS; STRESS; MICE
AB Background/Aims: Nuclear erythroid 2-related factor-2 (Nrf2) is a major stress-response transcription factor that has been implicated in regulating ischemic angiogenesis. We investigated the effects of Nrf2 in regulating revascularization and modulating acute lung injury. Methods: The expression of Nrf2 and sirtuin1 (Sirt1) was assessed in lung tissue by western blotting and immunofluorescence staining after intestinal ischemia/reperfusion (IIR) in Nrf2-/-and wild-type (WT) mice. The involvement of Nrf2 in angiogenesis, cell viability, and migration was investigated in human pulmonary microvascular endothelial cells (PMVECs). Additionally, the influence of Nrf2 expression on NOX pathway activation was measured in PMVECs after oxygen-glucose deprivation/reoxygenation. Results: We found activation and nuclear accumulation of Nrf2 in lung tissue after IIR. Compared to IIR in WT mice, IIR in Nrf2-/-mice significantly enhanced leukocyte infiltration and collagen deposit, and inhibited endothelial cell marker CD31 expression. Nrf2 upregulation and translocation into the nucleus stimulated by Sirt1 overexpression exhibited remission of histopathologic changes and enhanced CD31 expression. Nrf2 knockdown repressed non-phagocytic cell oxidase 4 (NOX4), hypoxia-inducible factor (HIF-1 alpha) and vascular endothelial growth factor (VEGF) expression after IIR. Nrf2 upregulation by Sirt1 enhances NOX4, HIF-1 alpha and VEGF expression after IIR in WT mice. Furthermore, Nrf2 knockdown suppressed cell viability, capillary tube formation and cell migration in PMVECs after oxygen-glucose deprivation/reoxygenation and also inhibited NOX4, HIF-1 and VEGF expression. Moreover, NOX4 knockdown in PMVECs decreased the levels of VEGF, HIF-1 alpha and angiogenesis. Conclusion: Nrf2 stimulation by Sirt1 plays an important role in sustaining angiogenic potential through NOX4-mediated gene regulation. \s=c\ 2018 The Author(s) Published by S. Karger AG, Basel.
C1 [Chai, DongDong; Zhang, Lei; Xi, SiWei; Cheng, YanYong; Jiang, Hong; Hu, Rong] Shanghai Jiao Tong Univ, Dept Anesthesiol,Shanghai Peoples Hosp 9, Sch Med,Ctr Specialty Strategy Res, China Hosp Dev Inst, Shanghai, China.
C3 Shanghai Jiao Tong University
RP Jiang, H; Hu, R (corresponding author), Shanghai Jiao Tong Univ, Ctr Specialty Strategy Res, Shanghai Peoples Hosp 9, Dept Anesthesiol, Shanghai, Peoples R China.
EM dr_jianghongjy@163.com; dr_hurong@163.com
FU Shanghai Pujiang Program [17PJD022]; National Natural Science Foundation
   of China [81301655, 81571028]
FX This work is supported by Shanghai Pujiang Program(17PJD022) and
   National Natural Science Foundation of China (81301655, 81571028).
CR Cavriani G, 2004, EUR J PHARMACOL, V494, P241, DOI 10.1016/j.ejphar.2004.04.048
   Cho HY, 2010, TOXICOL APPL PHARM, V244, P43, DOI 10.1016/j.taap.2009.07.024
   Ding MG, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0299-8
   Ding YW, 2016, INT J MOL MED, V37, P1049, DOI 10.3892/ijmm.2016.2503
   Gao Z, 2016, INT J BIOCHEM CELL B, V74, P152, DOI 10.1016/j.biocel.2016.02.018
   Gu LN, 2016, TOXICOL APPL PHARM, V292, P19, DOI 10.1016/j.taap.2015.12.024
   Hou JY, 2016, ASIAN PAC J TROP MED, V9, P73, DOI 10.1016/j.apjtm.2015.12.001
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008
   Liu Y, 2017, CELL PHYSIOL BIOCHEM, V41, P2037, DOI 10.1159/000475434
   Meng QT, 2016, LAB INVEST, V96, P1087, DOI 10.1038/labinvest.2016.87
   Mors K, 2017, CELL PHYSIOL BIOCHEM, V43, P17, DOI 10.1159/000480313
   Mura M, 2007, SHOCK, V28, P227, DOI 10.1097/SHK.0b013e318033e927
   Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Pendyala S, 2011, FREE RADICAL BIO MED, V50, P1749, DOI 10.1016/j.freeradbiomed.2011.03.022
   Potteti HR, 2016, AM J RESP CELL MOL, V54, P697, DOI 10.1165/rcmb.2014-0056OC
   Shen CC, 2016, EXP CELL RES, V344, P86, DOI 10.1016/j.yexcr.2016.04.013
   Shimizu Y, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002368
   Tai WL, 2017, CELL PHYSIOL BIOCHEM, V44, P1526, DOI 10.1159/000485647
   Wang HB, 2014, MOL VIS, V20, P231
   Wei YH, 2016, FREE RADICAL BIO MED, V99, P234, DOI 10.1016/j.freeradbiomed.2016.08.013
   Wei YH, 2015, P NATL ACAD SCI USA, V112, pE6927, DOI 10.1073/pnas.1512683112
   Xu XT, 2017, CELL PHYSIOL BIOCHEM, V44, P1949, DOI 10.1159/000485885
   Yu XB, 2016, CELL PHYSIOL BIOCHEM, V38, P1055, DOI 10.1159/000443056
   Zhang F, 2015, MOL MED REP, V11, P269, DOI 10.3892/mmr.2014.2679
   Zhang HX, 2016, CELL PHYSIOL BIOCHEM, V40, P1603, DOI 10.1159/000453210
   Zhou ZC, 2016, CELL PHYSIOL BIOCHEM, V38, P258, DOI 10.1159/000438627
NR 28
TC 42
Z9 43
U1 1
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 46
IS 2
BP 781
EP 792
DI 10.1159/000488736
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GE3ZF
UT WOS:000431151400030
PM 29621765
OA gold
DA 2023-08-21
ER

PT J
AU Chen, L
   Li, W
   Qi, D
   Wang, DX
AF Chen, Lan
   Li, Wen
   Qi, Di
   Wang, Daoxin
TI Lycium barbarum polysaccharide protects against LPS-induced ARDS by
   inhibiting apoptosis, oxidative stress, and inflammation in pulmonary
   endothelial cells
SO FREE RADICAL RESEARCH
LA English
DT Article
DE LBP; ALI/ARDS; anti-apoptosis; antioxidant; ECs/HPMECs/HUVECs/MPVECs 
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; NF-KAPPA-B; PROGENITOR
   CELLS; IN-VITRO; MITOCHONDRIA; ACTIVATION; FAMILY; DAMAGE; LIVER
AB Acute respiratory distress syndrome (ARDS) is a heterogenous syndrome characterised by diffuse alveolar damage, with an increase in lung endothelial and epithelial permeability. Lycium barbarum polysaccharide (LBP), the most biologically active fraction of wolfberry, possesses antiapoptotic and antioxidative effects in distinct situations. In the present study, the protective effects and potential molecular mechanisms of LBP against lipopolysaccharide (LPS)-induced ARDS were investigated in the mice and in the human pulmonary microvascular endothelial cells (HPMECs). The data indicated that pretreatment with LBP significantly attenuated LPS-induced lung inflammation and pulmonary oedema in vivo. LBP significantly reversed LPS-induced decrease in cell viability, increase in apoptosis and oxidative stress via inhibiting caspase-3 activation and intracellular reactive oxygen species (ROS) production in vitro. Moreover, the scratch assay verified that LBP restored the dysfunction of endothelial cells (ECs) migration induced by LPS stimulation. Furthermore, LBP also significantly suppressed LPS-induced NF-KB activation, and subsequently reversed the release of cytochrome c. These results showed the antiapoptosis and antioxidant LBP could partially protect against LPS-induced ARDS through promoting the ECs survival and scavenging ROS via inhibition of NF-KB signalling pathway. Thus, LBP could be potentially used for ARDS against pulmonary inflammation and pulmonary oedema.
C1 [Chen, Lan; Li, Wen; Qi, Di; Wang, Daoxin] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, 74 Linjiang oad, Chongqing, China.
C3 Chongqing Medical University
RP Wang, DX (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, 74 Linjiang oad, Chongqing, Peoples R China.
EM wangdaoxin01@126.com
CR Bo RN, 2016, INT J BIOL MACROMOL, V85, P294, DOI 10.1016/j.ijbiomac.2015.12.089
   Cheng J, 2015, DRUG DES DEV THER, V9, P33, DOI [10.2147/DDDT.572892, 10.2147/DDDT.S72892]
   Cory G, 2011, METHODS MOL BIOL, V769, P25, DOI 10.1007/978-1-61779-207-6_2
   Cui BK, 2012, INT J BIOL MACROMOL, V51, P314, DOI 10.1016/j.ijbiomac.2012.05.004
   Fang F, 2016, INT J DEV NEUROSCI, V52, P66, DOI 10.1016/j.ijdevneu.2016.05.004
   Galani V, 2010, PATHOL RES PRACT, V206, P145, DOI 10.1016/j.prp.2009.12.002
   Gao K, 2015, MOLECULES, V20, P293, DOI 10.3390/molecules20010293
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   He MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084800
   Kawasaki T, 2015, AM J RESP CELL MOL, V53, P500, DOI 10.1165/rcmb.2014-0185OC
   Kellner M, 2017, ADV EXP MED BIOL, V967, P105, DOI 10.1007/978-3-319-63245-2_8
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P266, DOI 10.1164/rccm.201701-0107CP
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Mac Sweeney R, 2016, LANCET, V388, P2416, DOI 10.1016/S0140-6736(16)00578-X
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Maron-Gutierrez T, 2014, CURR OPIN CRIT CARE, V20, P122, DOI 10.1097/MCC.0000000000000061
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Meduri GU, 2004, ANN NY ACAD SCI, V1024, P24, DOI 10.1196/annals.1321.004
   Moussa MD, 2015, INTENS CARE MED, V41, P231, DOI 10.1007/s00134-014-3589-9
   National Research Council (US) Institute for Laboratory Animal Research, 2011, GUID DESCR AN RES PU
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Petrucci N, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub4
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435
   Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Sinclair K, 2013, RESPIROLOGY, V18, P397, DOI 10.1111/resp.12050
   Umeno A, 2017, FREE RADICAL RES, V51, P413, DOI 10.1080/10715762.2017.1315114
   Varoni MV, 2017, ENVIRON SCI POLLUT R, V24, P2946, DOI 10.1007/s11356-016-8050-x
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Xiao J, 2014, SCI REP-UK, V4, DOI 10.1038/srep05587
   Xiao J, 2012, J ETHNOPHARMACOL, V139, P462, DOI 10.1016/j.jep.2011.11.033
   Yang D, 2017, CLIN EXP OPHTHALMOL, V45, P717, DOI 10.1111/ceo.12950
   Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X
   Zhang QY, 2016, FOOD CHEM, V200, P230, DOI 10.1016/j.foodchem.2016.01.046
   Zhao P, 2017, NEUROCHEM RES, V42, P2798, DOI 10.1007/s11064-017-2293-x
   Zhao WY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9826726
   Zhu J, 2013, CARBOHYD POLYM, V98, P8, DOI 10.1016/j.carbpol.2013.04.057
NR 45
TC 38
Z9 46
U1 5
U2 49
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-5762
EI 1029-2470
J9 FREE RADICAL RES
JI Free Radic. Res.
PY 2018
VL 52
IS 4
BP 480
EP 490
DI 10.1080/10715762.2018.1447105
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GG4AC
UT WOS:000432633800010
PM 29502482
DA 2023-08-21
ER

PT J
AU Chen, XX
   Zhang, YL
   Wang, WJ
   Liu, ZQ
   Meng, JG
   Han, ZH
AF Chen, Xuxin
   Zhang, Yinliang
   Wang, Wenjing
   Liu, Zhenqian
   Meng, Jiguang
   Han, Zhihai
TI Mesenchymal Stem Cells Modified with Heme Oxygenase-1 Have Enhanced
   Paracrine Function and Attenuate Lipopolysaccharide-Induced Inflammatory
   and Oxidative Damage in Pulmonary Microvascular Endothelial Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE mesenchymal stem cell; ALI/ARDS; LPS; HO-1; Paracrine; Inflammation; oxidative stress 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; SMOOTH-MUSCLE-CELLS;
   TOLL-LIKE RECEPTOR; STROMAL CELLS; HEPATIC ISCHEMIA/REPERFUSION;
   MYOCARDIAL-INFARCTION; EPITHELIAL-CELLS; DOWN-REGULATION; GENE-THERAPY
AB Background/Aims: Bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has therapeutic effects on endothelial damage during acute lung injury (ALI). Heme oxygenase-1 (HO-1) can restore homeostasis and implement cytoprotective defense functions in many pathologic states. Therefore, we explored whether transduction of HO-1 into BM-MSCs (MSCs-HO-1) would have an increased beneficial effect on lipopolysaccharide (LPS)induced inflammatory and oxidative damage in human pulmonary microvascular endothelial cells (PVECs). Methods: MSCs were isolated from rat bone marrow and transfected with the HO-1 gene by a lentivirus vector. The phenotype and multilineage differentiation of MSCs were assessed. MSCs or MSCs-HO-1 were co-cultured with PVECs using a transwell system, and LPS was added to induce PVEC injury. The production of reactive oxygen species (ROS), and the activities of lipid peroxide (LPO), malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPx) in PVECs were determined by flow cytometry and colorimetric assays, respectively. The levels of human PVEC-derived tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta and IL-6 in the supernatants of the co-culture system, and the activity of nuclear transcription factor-kappa B and NF-E2-related factor 2 (Nrf2) in PVECs were examined by enzyme-linked immunosorbent assay (ELISA). The mRNA expression of TNF-alpha, IL-1 beta and IL-6 in PVECs was detected by quantitative real-time polymerase chain reaction (qRT-PCR), HO-1 expression and enzymatic activity in PVECs and the influence of zinc protoporphyrin (ZnPP) or HO-1 small interfering RNA on the above inflammatory and oxidative stress markers were evaluated. In addition, the expression of rat MSC-derived hepatocyte growth factor (HGF) and IL-10 was determined by ELISA and qRT-PCR. Results: MSCs showed no significant changes in phenotype or multilineage differentiation after transduction. LPS strongly increased the production of inflammatory and oxidative stress indicators, as well as decreased the levels of antioxidant components and the activity of Nrf2 in PVECs. MSC co-cultivation ameliorated these detrimental effects in PVECs and MSCs-HO-1 further improved the damage to PVECs induced by LPS when compared with MSCs alone. The beneficial effects of MSCs-HO-1 were dependent on HO-1 overexpression and may be attributed to the enhanced paracrine production of HGF and IL-10. Conclusion: MSCs-HO-1 have an enhanced ability to improve LPS-induced inflammatory and oxidative damage in PVECs, and the mechanism may be partially associated with the enhanced paracrine function of the stem cells. These data encourage further testing of the beneficial effects of MSCs-HO-1 in ALI animal models. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Chen, Xuxin; Liu, Zhenqian; Meng, Jiguang; Han, Zhihai] Navy Gen Hosp PLA, Dept Resp Med, 6 Fucheng Rd, Beijing 100037, China.
C1 [Zhang, Yinliang] Xian XD Grp Hosp, Dept Resp Med, Xian, Shaanxi, China.
C1 [Wang, Wenjing] Anqing Municipal Hosp, Cardiothorac Surg ICU, Anqing, China.
C3 Sixth Medical Center of Chinese PLA General Hospital; China XD Group
RP Meng, JG; Han, ZH (corresponding author), Navy Gen Hosp PLA, Dept Resp Med, 6 Fucheng Rd, Beijing 100037, Peoples R China.
EM mjg2016@tom.com; zhihaihandoctor@163.com
RI zhang, jian/HPD-1712-2023; zhan, y/ISA-2807-2023
OI Meng, Jiguang/0000-0001-8018-7255
FU National Natural Science Foundation of China [81300050]; Beijing Natural
   Science Foundation [7182163]; Innovative Cultivation Foundation of Navy
   General Hospital of PLA [CXPY201417]
FX The present study was co-supported by the National Natural Science
   Foundation of China (Grant #81300050), the Beijing Natural Science
   Foundation (Grant #7182163) and the Innovative Cultivation Foundation of
   Navy General Hospital of PLA (Grant #CXPY201417). We thank Ann Turnley,
   PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for
   editing the English text of a draft of this manuscript.
CR An XX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040483
   Birukova AA, 2015, BBA-MOL BASIS DIS, V1852, P778, DOI 10.1016/j.bbadis.2014.12.016
   Burchfield JS, 2008, CIRC RES, V103, P203, DOI 10.1161/CIRCRESAHA.108.178475
   Cao HF, 2015, EXP LUNG RES, V41, P404, DOI 10.3109/01902148.2015.1054053
   Cao TH, 2016, INFLAMMATION, V39, P651, DOI 10.1007/s10753-015-0290-2
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chabannes D, 2007, BLOOD, V110, P3691, DOI 10.1182/blood-2007-02-075481
   Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen XX, 2017, INT J MOL MED, V40, P1921, DOI 10.3892/ijmm.2017.3161
   Chen XX, 2017, INFLAMMATION, V40, P1983, DOI 10.1007/s10753-017-0639-9
   Chen XX, 2011, SHOCK, V35, P198, DOI 10.1097/SHK.0b013e3181f226f3
   Cheng GS, 2017, INT J MOL MED, V39, P223, DOI 10.3892/ijmm.2016.2820
   Cheng GS, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0480-y
   Chi XJ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0793-0
   Choi RJ, 2014, REDOX BIOL, V2, P504, DOI 10.1016/j.redox.2014.02.001
   Choudhery MS, 2015, CYTOTHERAPY, V17, P359, DOI 10.1016/j.jcyt.2014.11.003
   Ding Y, 2017, CELL PHYSIOL BIOCHEM, V44, P1120, DOI 10.1159/000485417
   Feng J, 2011, J CELL BIOCHEM, V112, P1524, DOI 10.1002/jcb.23065
   He HL, 2015, J CELL PHYSIOL, V230, P691, DOI 10.1002/jcp.24794
   He HL, 2015, CELL TRANSPLANT, V24, P1699, DOI 10.3727/096368914X685087
   Ho MSH, 2015, J CELL PHYSIOL, V230, P2606, DOI 10.1002/jcp.25028
   Horie S, 2016, CURR OPIN CRIT CARE, V22, P14, DOI 10.1097/MCC.0000000000000276
   Hu SL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0320-5
   Joshi AD, 2015, AM J PHYSIOL-LUNG C, V309, pL1410, DOI 10.1152/ajplung.00180.2015
   Kang JW, 2012, J PINEAL RES, V53, P67, DOI 10.1111/j.1600-079X.2012.00972.x
   Kao MC, 2015, J SURG RES, V199, P647, DOI 10.1016/j.jss.2015.06.041
   Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Lee JW, 2016, INT J MOL MED, V38, P834, DOI 10.3892/ijmm.2016.2669
   Li BL, 2017, CELL PHYSIOL BIOCHEM, V44, P1295, DOI 10.1159/000485490
   Li JW, 2015, EUR REV MED PHARMACO, V19, P2368
   Li JW, 2014, INT WOUND J, V11, P114, DOI 10.1111/iwj.12202
   Liang OD, 2011, STEM CELLS, V29, P99, DOI 10.1002/stem.548
   Liang ZX, 2011, CHINESE MED J-PEKING, V124, P2715, DOI 10.3760/cma.j.issn.0366-6999.2011.17.027
   Liu XM, 2013, AM J PHYSIOL-HEART C, V304, pH1634, DOI 10.1152/ajpheart.00872.2012
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Masterson C, 2015, MINERVA ANESTESIOL, V81, P179
   Matthay Michael A, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS54, DOI 10.1513/AnnalsATS.201406-254MG
   Meng X, 2018, J CELL PHYSIOL, V233, P587, DOI 10.1002/jcp.25919
   Motterlini R, 2014, ANTIOXID REDOX SIGN, V20, P1810, DOI 10.1089/ars.2013.5658
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Qi XF, 2018, J GEN VIROL, V99, P36, DOI 10.1099/jgv.0.000986
   Qian LL, 2017, J CELL PHYSIOL, V232, P3727, DOI 10.1002/jcp.25849
   Qiao SK, 2016, CELL PHYSIOL BIOCHEM, V40, P1656, DOI 10.1159/000453215
   Reynolds P, 2012, SHOCK, V38, P1, DOI 10.1097/SHK.0b013e31825f396c
   Shalaby SM, 2014, CYTOTHERAPY, V16, P764, DOI 10.1016/j.jcyt.2013.12.006
   Shen XD, 2005, AM J TRANSPLANT, V5, P1793, DOI 10.1111/j.1600-6143.2005.00932.x
   Song X, 2017, J SURG RES, V216, P73, DOI 10.1016/j.jss.2017.04.004
   Wang FJ, 2015, J SURG RES, V194, P599, DOI 10.1016/j.jss.2014.11.031
   Wang L, 2012, MOL MED REP, V6, P287, DOI 10.3892/mmr.2012.922
   Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015
   Wu GuoRong, 2017, Afr J Tradit Complement Altern Med, V14, P201, DOI 10.21010/ajtcam.v14i4.23
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Yamashita K, 2006, FASEB J, V20, P776, DOI 10.1096/fj.05-4791fje
   Yang Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0257-0
   Yin H, 2010, MOL IMMUNOL, V47, P2443, DOI 10.1016/j.molimm.2010.06.013
   Yin XR, 2015, CELL PHYSIOL BIOCHEM, V35, P2149, DOI 10.1159/000374020
   Zhang WB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462472
   Zhang XX, 2017, INFLAMMATION, V40, P351, DOI 10.1007/s10753-016-0481-5
   Zhao YF, 2015, EUR REV MED PHARMACO, V19, P857
   Zhou ZC, 2016, CELL PHYSIOL BIOCHEM, V38, P258, DOI 10.1159/000438627
   Zhu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056407
NR 63
TC 34
Z9 38
U1 1
U2 22
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 49
IS 1
BP 101
EP 122
DI 10.1159/000492847
PG 22
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GT0JW
UT WOS:000444125000008
PM 30153667
OA gold
DA 2023-08-21
ER

PT J
AU Dong, WJ
   He, BF
   Qian, H
   Liu, Q
   Wang, D
   Li, J
   Wei, ZH
   Wang, Z
   Xu, Z
   Wu, GY
   Qian, GS
   Wang, GS
AF Dong, Weijie
   He, Binfeng
   Qian, Hang
   Liu, Qian
   Wang, Dong
   Li, Jin
   Wei, Zhenghua
   Wang, Zi
   Xu, Zhi
   Wu, Guangyu
   Qian, Guisheng
   Wang, Guansong
TI RAB26-dependent autophagy protects adherens junctional integrity in
   acute lung injury
SO AUTOPHAGY
LA English
DT Article
DE ALI/ARDS; adhesion junction; ATG16L1; autophagy; CDH5; RAB26 GTPase; Src 
ID RESPIRATORY-DISTRESS-SYNDROME; VE-CADHERIN; BARRIER FUNCTION;
   ENDOTHELIAL BARRIER; LEUKOCYTE EXTRAVASATION; CELL; RAB26; SRC;
   PHOSPHORYLATION; ACTIVATION
AB Microvascular barrier dysfunction is the central pathophysiological feature of acute lung injury (ALI). RAB26 is a newly identified small GTPase involved in the regulation of endothelial cell (EC) permeability. However, the mechanism behind this protection has not been clearly elucidated. Here we found that RAB26 promoted the integrity of adherens junctions (AJs) in a macroautophagy/autophagy-dependent manner in ALI. RAB26 is frequently downregulated in mouse lungs after LPS treatment. Mice lacking Rab26 exhibited phosphorylated SRC expression and increased CDH5/VE-cadherin phosphorylation, leading to AJ destruction. rab26-null mice showed further aggravation of the effects of endotoxin insult on lung vascular permeability and water content. Depletion of RAB26 resulted in upregulation of phosphorylated SRC, enhancement of CDH5 phosphorylation, and aggravation of CDH5 internalization, thereby weakening AJ integrity and endothelial barrier function in human pulmonary microvascular endothelial cells (HPMECs). RAB26 overexpression caused active interaction between SRC and the autophagy marker LC3-II and promoted degradation of phosphorylated SRC. Furthermore, RAB26 was involved in a direct and activation-dependent manner in autophagy induction through interaction with ATG16L1 in its GTP-bound form. These findings demonstrate that RAB26 exerts a protective effect on endothelial cell (EC) permeability, which is in part dependent on autophagic targeting of active SRC, and the resultant CDH5 dephosphorylation maintains AJ stabilization. Thus, RAB26-mediated autophagic targeting of phosphorylated SRC can maintain barrier integrity when flux through the RAB26-SRC pathway is protected. These findings suggest that activation of RAB26-SRC signaling provides a new therapeutic opportunity to prevent vascular leakage in ALI.
C1 [Dong, Weijie; He, Binfeng; Qian, Hang; Liu, Qian; Wang, Dong; Li, Jin; Wei, Zhenghua; Wang, Zi; Xu, Zhi; Qian, Guisheng; Wang, Guansong] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing, China.
C1 [Wu, Guangyu] Georgia Regents Univ, Dept Pharmacol & Toxicol, Augusta, GA, United States.
C3 Army Medical University; University System of Georgia; Augusta
   University
RP Qian, GS; Wang, GS (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing, Peoples R China.
EM qiangs@tmmu.edu.cn; wanggs@tmmu.edu.cn
RI Qian, Hang/AAR-7627-2021; dong, weijie/HMD-2753-2023; He,
   Binfeng/AAM-9190-2021
OI Qian, Hang/0000-0001-9548-8894; He, Binfeng/0000-0002-7243-1972; Liu,
   Qian/0000-0003-2067-8444; dong, weijie/0000-0002-7376-6491; Xu,
   Zhi/0000-0003-1199-6635; Wang, Guansong/0000-0002-5184-0777
FU National Natural Science Foundation of China [81370168, 81370169]
FX This work was supported by the National Natural Science Foundation of
   China [81370168] and [81370169].
CR Adam AP, 2010, J BIOL CHEM, V285, P7045, DOI 10.1074/jbc.M109.079277
   Binotti B, 2015, ELIFE, V4, DOI 10.7554/eLife.05597
   Cabrera S, 2015, AUTOPHAGY, V11, P670, DOI 10.1080/15548627.2015.1034409
   Cai JT, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6893560
   Chichger H, 2015, FASEB J, V29, P868, DOI 10.1096/fj.14-257212
   Chistiakov DA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00365
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Domigan CK, 2015, J CELL SCI, V128, P2236, DOI 10.1242/jcs.163774
   Dong CM, 2010, J BIOL CHEM, V285, P20369, DOI 10.1074/jbc.M109.081521
   Flemming S, 2015, CARDIOVASC RES, V107, P32, DOI 10.1093/cvr/cvv144
   Fujitani Y, 2009, AUTOPHAGY, V5, P280, DOI 10.4161/auto.5.2.7656
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Gong HX, 2010, SCIENCE, V327, P340, DOI 10.1126/science.1174779
   Gonzalez CD, 2011, AUTOPHAGY, V7, P2, DOI 10.4161/auto.7.1.13044
   Ha CH, 2006, CIRCULATION, V114, P229
   Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9
   Hu R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.274
   Hu Y, 2016, AUTOPHAGY, V12, P2286, DOI 10.1080/15548627.2016.1230584
   Ishibashi K, 2012, MOL BIOL CELL, V23, P3193, DOI 10.1091/mbc.E12-01-0010
   Itoh T, 2008, MOL BIOL CELL, V19, P2916, DOI 10.1091/mbc.E07-12-1231
   Jain N, 2016, AUTOPHAGY, V12, P900, DOI 10.1080/15548627.2016.1147673
   Jin RU, 2014, J CELL SCI, V127, P1018, DOI 10.1242/jcs.138776
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2
   Li CM, 2012, J BIOL CHEM, V287, P42784, DOI 10.1074/jbc.M112.410936
   Li HL, 2017, THERANOSTICS, V7, P2537, DOI 10.7150/thno.17584
   Li J, 2015, J CELL MOL MED, V19, P2341, DOI 10.1111/jcmm.12638
   Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037
   Lo HYG, 2017, GENE DEV, V31, P154, DOI 10.1101/gad.285684.116
   Lo S, 2013, ANN SURG, V257, P352, DOI 10.1097/SLA.0b013e318269d0e2
   Maca J, 2017, RESP CARE, V62, P113, DOI 10.4187/respcare.04716
   Herrera-Garcia AM, 2014, J IMMUNOL, V193, P3023, DOI 10.4049/jimmunol.1400255
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Matthay MA, 2017, LANCET RESP MED, V5, P524, DOI 10.1016/S2213-2600(17)30188-1
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mikelis CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7725
   Mills JC, 2012, BIOESSAYS, V34, P10, DOI 10.1002/bies.201100089
   Nashida T, 2006, ARCH ORAL BIOL, V51, P89, DOI 10.1016/j.archoralbio.2005.06.005
   Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Sandilands E, 2015, CELL SIGNAL, V27, P1816, DOI 10.1016/j.cellsig.2015.05.017
   Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386
   Shrivastava S, 2016, J VIROL, V90, P1387, DOI 10.1128/JVI.02383-15
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Szatmari Z, 2014, AUTOPHAGY, V10, P1154, DOI 10.4161/auto.29395
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Tian XL, 2010, MOL CELL BIOL, V30, P1269, DOI 10.1128/MCB.01328-09
   Turowski P, 2008, J CELL SCI, V121, P29, DOI 10.1242/jcs.022681
   Vestweber D, 2014, SEMIN IMMUNOPATHOL, V36, P177, DOI 10.1007/s00281-014-0419-7
   WAGNER ACC, 1995, BIOCHEM BIOPH RES CO, V207, P950, DOI 10.1006/bbrc.1995.1277
   Wang GS, 2012, TRENDS PHARMACOL SCI, V33, P28, DOI 10.1016/j.tips.2011.09.002
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001
   Xu D, 2016, SCI REP-UK, V6, DOI 10.1038/srep30833
   Yadav H, 2017, AM J RESP CRIT CARE, V195, P725, DOI 10.1164/rccm.201609-1767CI
   Yang JJ, 2015, CELL MOL LIFE SCI, V72, P4849, DOI 10.1007/s00018-015-1973-4
   Yang JJ, 2015, INT J BIOL SCI, V11, P868, DOI 10.7150/ijbs.12045
   Yoshie S, 2000, HISTOCHEM CELL BIOL, V113, P259, DOI 10.1007/s004180000130
   Zhang D, 2017, AM J PHYSIOL-LUNG C, V313, pL384, DOI 10.1152/ajplung.00391.2016
   Zhou ZC, 2016, CELL PHYSIOL BIOCHEM, V38, P258, DOI 10.1159/000438627
NR 62
TC 63
Z9 68
U1 2
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2018
VL 14
IS 10
BP 1677
EP 1692
DI 10.1080/15548627.2018.1476811
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GS9ZO
UT WOS:000444087300004
PM 29965781
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Fang, W
   Xia, L
   Sun, XX
   Cai, SX
   Bai, SW
   Sun, YB
   Zhou, PH
   Liu, X
   Zhao, R
   Shen, B
AF Fang, Wei
   Xia, Lin
   Sun, Xiaoxia
   Cai, Shixia
   Bai, Suwen
   Sun, Yunbo
   Zhou, Peihong
   Liu, Xin
   Zhao, Ren
   Shen, Bing
TI Lipopolysaccharides increase Kir2.1 expression in lung endothelial cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE LPS; Kir2.1; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs 
ID RESPIRATORY-DISTRESS-SYNDROME; RECTIFIER K+ CHANNELS;
   SMOOTH-MUSCLE-CELLS; POTASSIUM CHANNELS; CEREBRAL-ARTERIES;
   SHEAR-STRESS; INJURY; FLOW; INFLAMMATION; MODULATION
AB Kir2.1 is an inwardly rectifying K+ channel that modulates membrane potential. It is expressed widely in smooth muscle, neurons, and endothelial cells. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe clinical syndromes, often causing the damage of epithelial and endothelial cells. Lipopolysaccharides (LPS) usually cause ALI/ARDS, directly or indirectly, and are used to reproduce the model in vivo. Here, we used differentially expressed gene analysis to find increasing Kir2.1 channel expression in human pulmonary microvascular endothelial cells cultured with LPS. Primary cultured mice pulmonary microvascular endothelial cells were verified by immunofluorescence. LPS incubation increased Kir2.1 channel expression in cultured mice pulmonary microvascular endothelial cells. A whole-cell voltage clamp was used to record the K+ current in cultured endothelial cells, showing increased whole-cell current in LPS treatment compared with controls. Additionally, the application of Ba2+, as an inhibitor of Kir2.1 channel, inhibited K+ current in both groups. We demonstrated that LPS may increase Kir2.1 channel expression in mice pulmonary microvascular endothelial cells to increase K+ flux, maintain hyperpolarization, and cause vasodilation, which may increase blood flow in pulmonary vessel bed, leading to pulmonary congestion contributing pneumonemia and ALI/ARDS.
C1 [Fang, Wei; Sun, Xiaoxia; Cai, Shixia; Sun, Yunbo; Zhou, Peihong; Liu, Xin] Qingdao Univ, Affiliated Hosp, Dept ICU, 16 Jiangsu Rd, Qingdao 266071, Shandong, China.
C1 [Xia, Lin; Bai, Suwen; Shen, Bing] Anhui Med Univ, Sch Basic Med Sci, Hefei, Anhui, China.
C1 [Zhao, Ren] Anhui Med Univ, Affiliated Hosp 1, Dept Cardiol, Hefei, Anhui, China.
C3 Qingdao University; Anhui Medical University; Anhui Medical University
RP Fang, W (corresponding author), Qingdao Univ, Affiliated Hosp, Dept ICU, 16 Jiangsu Rd, Qingdao 266071, Shandong, Peoples R China.; Shen, B (corresponding author), Anhui Med Univ, Dept Psychol, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China.
EM doctorfang@163.com; shen-bing@ahmu.edu.cn
OI suwen, bai/0000-0001-9359-014X
FU National Natural Science Foundation of China [81701879, 81570403,
   81600286]; Anhui Provincial Natural Science Foundation [1508085QH164];
   Department of Human Resources and Social Security of Anhui Province;
   Outstanding Young Investigator of Anhui Medical University
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant numbers 81701879, 81570403, 81600286); Anhui
   Provincial Natural Science Foundation (Grant number 1508085QH164);
   Overseas Scholars Start Fund from Department of Human Resources and
   Social Security of Anhui Province; Outstanding Young Investigator of
   Anhui Medical University.
CR Adams DJ, 2004, J CARDIOVASC ELECTR, V15, P598, DOI 10.1046/j.1540-8167.2004.03277.x
   BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361
   Bradley KK, 1999, J PHYSIOL-LONDON, V515, P639, DOI 10.1111/j.1469-7793.1999.639ab.x
   Burns WR, 2004, MICROCIRCULATION, V11, P279, DOI 10.1080/10739680490425985
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71
   Cheng DS, 2007, J IMMUNOL, V178, P6504, DOI 10.4049/jimmunol.178.10.6504
   de Wit C, 2010, PFLUG ARCH EUR J PHY, V459, P897, DOI 10.1007/s00424-010-0830-4
   Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009
   Hoger JH, 2002, P NATL ACAD SCI USA, V99, P7780, DOI 10.1073/pnas.102184999
   Jackson WF, 2005, MICROCIRCULATION, V12, P113, DOI 10.1080/10739680590896072
   Jackson WF, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12319
   Kim HJ, 2006, TOXICOLOGY, V225, P36, DOI 10.1016/j.tox.2006.04.053
   Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318
   Kwan HY, 2003, CIRC RES, V92, P286, DOI 10.1161/01.RES.0000054625.24468.08
   Lau OC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11947
   Lieu DK, 2004, AM J PHYSIOL-CELL PH, V286, pC1367, DOI 10.1152/ajpcell.00243.2003
   Longden TA, 2015, MICROCIRCULATION, V22, P183, DOI 10.1111/micc.12190
   Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206
   Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000
   Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171
   Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415
   NILIUS B, 1993, J PHYSIOL-LONDON, V472, P359, DOI 10.1113/jphysiol.1993.sp019951
   Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Salomonsson M, 2017, ACTA PHYSIOL, V221, P14, DOI 10.1111/apha.12882
   TAKAHASHI T, 1990, J PHYSIOL-LONDON, V423, P47, DOI 10.1113/jphysiol.1990.sp018010
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WELLMAN GC, 1995, J PHARMACOL EXP THER, V274, P47
   Yamamura H, 2016, BIOCHEM BIOPH RES CO, V476, P386, DOI 10.1016/j.bbrc.2016.05.131
   Zhao R, 2015, MOL NUTR FOOD RES, V59, P365, DOI 10.1002/mnfr.201400465
NR 31
TC 2
Z9 5
U1 1
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2018
VL 11
IS 6
BP 2959
EP 2967
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA GN2TA
UT WOS:000438851900003
PM 31938421
DA 2023-08-21
ER

PT J
AU Gao, PY
   Zhao, ZY
   Zhang, CT
   Wang, CX
   Long, KL
   Guo, LX
   Li, BX
AF Gao, Peiyang
   Zhao, Ziyi
   Zhang, Chuantao
   Wang, Chunxia
   Long, Kunlan
   Guo, Liuxue
   Li, Baixue
TI The therapeutic effects of traditional Chinese medicine Fusu agent in
   LPS-induced acute lung injury model rats
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE ALI/ARDS; heparanase; mitochondrial transmembrane potential; ECs/HPMECs/HUVECs/MPVECs; ROS 
ID ENDOTHELIAL GLYCOCALYX; SEPSIS; ACTIVATION; EPIDEMIOLOGY; INFLAMMATION;
   MORTALITY; ADHESION; OUTCOMES; ARDS
AB Purpose: Acute lung injury (ALI) is a common and fatal oxidative stress in the lung, mainly induced by endothelial injury and capillary leakage. In our previous study, "Fusu agent", a traditional Chinese medicine, was found to exert preventive effect on endothelial damage in lipopoly-saccharide (LPS)-induced ALI model rats partially via inhibiting heparanase1 (HPA1) activation and inhibiting the inflammatory factors. However, it is still unknown whether Fusu agent exerts its therapeutic effect in LPS-induced ALI model rats and its potential mechanism.
   Materials and methods: Rats were injected with LPS (3 mg/kg, intraperitoneally) to induced ALI, and the prepared Fusu agent was given (2, 4 or 6 g/kg) 2 hours after LPS challenge. Twenty-four or 48 hours after Fusu agent administration, the biochemical changes in the plasma and lung tissues and the morphological/histological changes in the lung associated with inflammation and injury were evaluated. Human umbilical vein endothelial cells (HUVECs) were employed to confirm the therapeutic effects of Fusu agent and investigate its mechanisms, that is, affecting ROS accumulation, mitochondrial transmembrane potential (MTP) maintenance and decreasing the expression levels of HPA1.
   Results: Administration of Fusu agent obviously improved the lung injury and recovered vascular endothelium loss and injury. CD31 signal, which is a specific marker for endothelial vascular lesions, was decreased after Fusu agent treatment in LPS-induced ALI model rats, indicating its therapeutic effect against endothelial surface layer injury. Meanwhile, Fusu agent also decreased HPA1 expression and inflammatory responses. In vitro, Fusu agent-medicated serum decreased injury and cell death induced by LPS in HUVECs by stabilising MTP and decreasing the leakage of lactate dehydrogenase. Consistently, Fusu agent-medicated serum downregulated HPA1 induced by LPS stimulation.
   Conclusion: These findings suggest that Fusu agent exerts its therapeutic effect in both LPS-induced ALI model rats and HUVECs potentially via suppressing HPA1 expression, and thus exerts prosurvival effect via maintaining MTP and attenuating cell injury.
C1 [Gao, Peiyang; Zhang, Chuantao; Wang, Chunxia; Long, Kunlan; Guo, Liuxue] Chengdu Univ Tradit Chinese Med, Teaching Hosp, Intens Care Unit, Chengdu, Sichuan, China.
C1 [Zhao, Ziyi] Chengdu Univ Tradit Chinese Med, Teaching Hosp, Cent Lab, Chengdu, Sichuan, China.
C1 [Li, Baixue] Chengdu Univ Tradit Chinese Med, Coll Basic Med, 1166 Liutai Ave, Chengdu 611137, Sichuan, China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine
RP Li, BX (corresponding author), Chengdu Univ Tradit Chinese Med, Coll Basic Med, 1166 Liutai Ave, Chengdu 611137, Sichuan, Peoples R China.
EM Baixuelee@163.com
OI Zhang, Chuantao/0000-0003-3726-7748
FU National Natural Science Foundation of China [81373836]
FX This work was supported by National Natural Science Foundation of China
   (no 81373836).
CR Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Bao WW, 2018, J CELL BIOCHEM, V119, P850, DOI 10.1002/jcb.26249
   Blank R, 2011, CRIT CARE CLIN, V27, P439, DOI 10.1016/j.ccc.2011.05.005
   Burke-Gaffney A, 2012, CRIT CARE, V16, DOI 10.1186/cc11239
   Charreau B, 2000, TRANSPLANTATION, V69, P945
   Cohen E, 2005, FEBS LETT, V579, P2334, DOI 10.1016/j.febslet.2005.03.030
   Du QS, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-117
   Freeman C, 1999, BIOCHEM J, V342, P361, DOI 10.1042/0264-6021:3420361
   Gao P, CHINA SOC INTEGRATED
   Gao P, 2018, MOL CELL BIOCHEM, V444, P1
   Han J, 2005, CARBON NANOTUBES: SCIENCE AND APPLICATIONS, P1
   Jehle AB, 2000, J INTERFERON CYTOKIN, V20, P291
   Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379
   Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d
   Keshari RS, 2014, AM J RESP CELL MOL, V50, P439, DOI 10.1165/rcmb.2013-0219OC
   Kong GQ, 2016, INT IMMUNOPHARMACOL, V36, P51, DOI 10.1016/j.intimp.2016.03.039
   Lee HH, 2008, J CELL BIOL, V181, P999, DOI 10.1083/jcb.200710187
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Liu J., 2017, ADV MATER SCI ENG, V4, P1
   Liu XY, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00102
   Malhotra A, 2007, NEW ENGL J MED, V357, P1113, DOI 10.1056/NEJMct074213
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627
   Nelson A, 2008, SHOCK, V30, P623, DOI 10.1097/SHK.0b013e3181777da3
   PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Schoenbein C, 2008, CLIN EXP IMMUNOL, V151, P306, DOI 10.1111/j.1365-2249.2007.03554.x
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   Steppan J, 2011, J SURG RES, V165, P136, DOI 10.1016/j.jss.2009.04.034
   Sun BW, 2008, INT J BIOL SCI, V4, P270
   Vlodavsky I, 2013, MATRIX BIOL, V32, P220, DOI 10.1016/j.matbio.2013.03.001
   von Asmuth E J, 1991, Eur Cytokine Netw, V2, P291
   Wang Chun-Xia, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P200
   Wang YF, 2017, SCI REP-UK, V7, DOI 10.1038/srep46015
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Wei W, 2010, EXPT METHODOLOGY PHA, P389
   Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Zhao J, 2010, BRIEF BIOINFORM, V11, P417, DOI 10.1093/bib/bbp063
NR 42
TC 14
Z9 18
U1 2
U2 15
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2018
VL 12
BP 3867
EP 3878
DI 10.2147/DDDT.S181798
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HA5OM
UT WOS:000450323400001
PM 30518997
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Harrington, EO
   Vang, A
   Braza, J
   Shil, A
   Chichger, H
AF Harrington, Elizabeth O.
   Vang, Alexander
   Braza, Julie
   Shil, Aparna
   Chichger, Havovi
TI Activation of the sweet taste receptor, T1R3, by the artificial
   sweetener sucralose regulates the pulmonary endothelium
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; artificial sweetener; ECs/HPMECs/HUVECs/MPVECs; sweet taste; T1R3 
ID BARRIER FUNCTION; INSULIN-RESISTANCE; VE-CADHERIN; UMAMI TASTE; LUNG
   INJURY; PROTEIN; CELLS; BITTER; PERMEABILITY; EXPRESSION
AB A hallmark of acute respiratory distress syndrome (ARDS) is pulmonary vascular permeability. In these settings, loss of barrier integrity is mediated by cell-contact disassembly and actin remodeling. Studies into molecular mechanisms responsible for improving microvascular barrier function are therefore vital in the development of therapeutic targets for reducing vascular permeability in ARDS. The sweet taste receptor T1R3 is a G protein-coupled receptor, activated following exposure to sweet molecules, to trigger a gustducin-dependent signal cascade. In recent years, extraoral locations for T1R3 have been identified; however, no studies have focused on T1R3 within the vasculature. We hypothesize that activation of T1R3, in the pulmonary vasculature, plays a role in regulating endothelial barrier function in settings of ARDS. Our study demonstrated expression of T1R3 within the pulmonary vasculature, with a drop in expression levels following exposure to barrier-disruptive agents. Exposure of lung microvascular endothelial cells to the intensely sweet molecule sucralose attenuated LPS-and thrombin-induced endothelial barrier dysfunction. Likewise, sucralose exposure attenuated bacteria-induced lung edema formation in vivo. Inhibition of sweet taste signaling, through zinc sulfate, T1R3, or G-protein siRNA, blunted the protective effects of sucralose on the endothelium. Sucralose significantly reduced LPS-induced increased expression or phosphorylation of the key signaling molecules Src, p21-activated kinase (PAK), myosin light chain-2 (MLC2), heat shock protein 27 (HSP27), and p110 alpha phosphatidylinositol 3-kinase (p110 alpha PI3K). Activation of T1R3 by sucralose protects the pulmonary endothelium from edemagenic agent-induced barrier disruption, potentially through abrogation of Src/PAK/p110 alpha PI3K-mediated cell-contact disassembly and Src/MLC2/HSP27-mediated actin remodeling. Identification of sweet taste sensing in the pulmonary vasculature may represent a novel therapeutic target to protect the endothelium in settings of ARDS.
C1 [Harrington, Elizabeth O.; Vang, Alexander; Braza, Julie] Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI, United States.
C1 [Harrington, Elizabeth O.; Braza, Julie] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912, United States.
C1 [Shil, Aparna; Chichger, Havovi] Anglia Ruskin Univ, Biomed Res Grp, Cambridge, England, United Kingdom.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University; Anglia Ruskin University
RP Chichger, H (corresponding author), Anglia Ruskin Univ, Dept Biomed & Forens Sci, Biomed Res Grp, East Rd, Cambridge CB1 1PT, England.
EM havovi.chichger@anglia.ac.uk
RI Chichger, Havovi/Y-7117-2019
OI Chichger, Havovi/0000-0002-8549-7583; Vang,
   Alexander/0000-0001-5691-781X
FU Diabetes UK Grant [15/0005284]; Wellcome Trust [202624/Z/16/Z]; American
   Heart Association [13POST16860031]; National Heart, Lung, and Blood
   Institute [R01-HL-67795, R01-HL-123965, 1R01HL128661]; Institutional
   Development Award (IDeA) under National Institute of General Medical
   Sciences [P20-GM-103652]; Wellcome Trust [202624/Z/16/Z] Funding Source:
   Wellcome Trust
FX This material is based on work supported by Diabetes UK Grant
   15/0005284, Wellcome Trust Grant 202624/Z/16/Z, and American Heart
   Association Grant 13POST16860031 (to H. Chichger). E. O. Harrington was
   supported by National Heart, Lung, and Blood Institute Grants
   R01-HL-67795 and R01-HL-123965 and an Institutional Development Award
   (IDeA) under National Institute of General Medical Sciences Grant
   P20-GM-103652. A. Vang was supported by National Heart, Lung, and Blood
   Institute Grant 1R01HL128661.
CR ABE M, 1990, DIABETES RES CLIN PR, V9, P287, DOI 10.1016/0168-8227(90)90058-2
   Alvarado AG, 2017, CELL STEM CELL, V20, P450, DOI 10.1016/j.stem.2016.12.001
   Antonov A, 2008, AM J RESP CELL MOL, V39, P551, DOI 10.1165/rcmb.2007-0324OC
   Aoki T, 2015, ENDOCRINOLOGY, V156, P4312, DOI 10.1210/en.2014-1988
   Barabutis N, 2013, AM J PHYSIOL-LUNG C, V304, pL883, DOI 10.1152/ajplung.00419.2012
   Behrens M, 2011, PHYSIOL BEHAV, V105, P4, DOI 10.1016/j.physbeh.2011.02.010
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Bruyere O, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0092-x
   Bueter M, 2011, PHYSIOL BEHAV, V104, P709, DOI 10.1016/j.physbeh.2011.07.025
   Cain RJ, 2010, J CELL BIOL, V188, P863, DOI 10.1083/jcb.200907135
   Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Check J, 2010, MOL IMMUNOL, V47, P756, DOI 10.1016/j.molimm.2009.10.012
   Chichger H, 2016, AM J RESP CELL MOL, V54, P769, DOI 10.1165/rcmb.2015-0286OC
   Chichger H, 2015, AM J RESP CELL MOL, V52, P695, DOI 10.1165/rcmb.2013-0489OC
   Chichger H, 2015, AM J PHYSIOL-LUNG C, V308, pL827, DOI 10.1152/ajplung.00184.2014
   Chichger H, 2015, FASEB J, V29, P868, DOI 10.1096/fj.14-257212
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Couch BA, 2013, J COMP NEUROL, V521, P1395, DOI 10.1002/cne.23239
   Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155
   Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237
   Duffy A, 2006, ENDOTHELIUM-J ENDOTH, V13, P9, DOI 10.1080/10623320600659997
   Durkin CH, 2017, DEV CELL, V41, P315, DOI 10.1016/j.devcel.2017.04.010
   Elliott RA, 2011, J UROLOGY, V186, P2455, DOI 10.1016/j.juro.2011.07.083
   Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100
   Franz M, 2010, DIABETES SELF MANAG, V27, P11
   Gallo D, 2015, ENDOCRINOLOGY, V156, P3239, DOI 10.1210/EN.2015-1098
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC
   Havekes R, 2016, ELIFE, V5, DOI 10.7554/eLife.13424
   Hill SM, 2017, CELL SYST, V4, P73, DOI 10.1016/j.cels.2016.11.013
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   Hu JKH, 2017, CELL STEM CELL, V21, P91, DOI 10.1016/j.stem.2017.03.023
   Jeannot P, 2017, ELIFE, V6, DOI [10.7554/eLife.22207.001, 10.7554/eLife.22207]
   Jiang X, 2015, ENDOCRINOLOGY, V156, P1156, DOI 10.1210/en.2014-1619
   Kang QX, 2016, J SURG RES, V202, P87, DOI 10.1016/j.jss.2015.12.034
   Kaske S, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-49
   Keast RSJ, 2004, CHEM SENSES, V29, P513, DOI 10.1093/chemse/bjh053
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Kuppers V, 2014, CELL TISSUE RES, V355, P577, DOI 10.1007/s00441-014-1812-1
   Le Gall M, 2007, J CELL PHYSIOL, V213, P834, DOI 10.1002/jcp.21245
   Levit A, 2014, FASEB J, V28, P1181, DOI 10.1096/fj.13-242594
   Li PP, 2016, CELL, V167, P973, DOI 10.1016/j.cell.2016.10.025
   Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199
   Liu T, 2009, J CELL PHYSIOL, V220, P600, DOI 10.1002/jcp.21773
   Liu XJ, 2013, EXP THER MED, V6, P361, DOI 10.3892/etm.2013.1166
   Mace OJ, 2007, J PHYSIOL-LONDON, V582, P379, DOI 10.1113/jphysiol.2007.130906
   Margolskee RF, 2002, J BIOL CHEM, V277, P1, DOI 10.1074/jbc.R100054200
   Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104
   Masubuchi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054500
   Masuda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035380
   Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270
   MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0
   Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440
   Nakagawa Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005106
   Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2
   Prunier C, 2016, CANCER RES, V76, P3541, DOI 10.1158/0008-5472.CAN-15-1864
   Rentsendorj O, 2008, AM J PHYSIOL-LUNG C, V294, pL686, DOI 10.1152/ajplung.00417.2007
   Roberts A, 2000, FOOD CHEM TOXICOL, V38, pS31, DOI 10.1016/S0278-6915(00)00026-0
   Robinett KS, 2014, AM J RESP CELL MOL, V50, P678, DOI 10.1165/rcmb.2013-0439RC
   Sbarbati A, 2004, J COMP NEUROL, V475, P188, DOI 10.1002/cne.20172
   Sclip A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158295
   Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869
   Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144
   Simon BR, 2013, J BIOL CHEM, V288, P32475, DOI 10.1074/jbc.M113.514034
   Slee JB, 2013, J CELL BIOCHEM, V114, P782, DOI 10.1002/jcb.24416
   Spina D, 2014, CURR OPIN PULM MED, V20, P73, DOI 10.1097/MCP.0000000000000012
   Steinert RE, 2011, CLIN NUTR, V30, P524, DOI 10.1016/j.clnu.2011.01.007
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Sun HR, 2006, MICROCIRCULATION, V13, P237, DOI 10.1080/10739680600556944
   SWEATMAN TW, 1981, XENOBIOTICA, V11, P531, DOI 10.3109/00498258109045864
   Taniguchi K, 2004, J VET MED SCI, V66, P1311, DOI 10.1292/jvms.66.1311
   Tizzano M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-3
   Tizzano M, 2010, P NATL ACAD SCI USA, V107, P3210, DOI 10.1073/pnas.0911934107
   Tizzano M, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-110
   Trani M, 2015, CURR OPIN HEMATOL, V22, P267, DOI 10.1097/MOH.0000000000000137
   Tsai MJ, 2014, ENDOCRINOLOGY, V155, P392, DOI 10.1210/en.2013-1663
   WELBOURN CRB, 1992, BRIT J SURG, V79, P998, DOI 10.1002/bjs.1800791006
   WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049
   Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4
   Zhang XY, 2017, ELIFE, V6, DOI 10.7554/eLife.25158
NR 82
TC 17
Z9 17
U1 0
U2 12
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JAN
PY 2018
VL 314
IS 1
BP L165
EP L176
DI 10.1152/ajplung.00490.2016
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA FX6MN
UT WOS:000426199600002
PM 28971978
OA Green Published, hybrid, Green Accepted
DA 2023-08-21
ER

PT J
AU He, BC
   Geng, S
   Zhou, W
   Rui, YE
   Mu, XM
   Zhang, C
   You, Q
   Su, X
AF He, Binchan
   Geng, Shen
   Zhou, Wei
   Rui, Yuwen
   Mu, Xianmin
   Zhang, Chen
   You, Qiang
   Su, Xin
TI MMI-0100 ameliorates lung inflammation in a mouse model of acute
   respiratory distress syndrome by reducing endothelial expression of
   ICAM-1
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; Inflammation; ALI/ARDS 
ID ACTIVATED PROTEIN-KINASE; MK2; TRISTETRAPROLIN; INHIBITION; CELLS; IL-8
AB Purpose: ICAM-1 plays a critical role in the development of acute respiratory distress syndrome (ARDS). MK2 regulates the expression of ICAM-1 in human pulmonary microvascular endothelial cells. To explore whether the inhibition of MK2 activation has the same effect in experimental animals, MMI-0100, a peptide-mediated inhibitor of MK2, was used to verify whether M MI-0100 can meliorate lung inflammation in a mouse model of ARDS by reducing endothelial expression of ICAM-1.
   Methods: In this study, C57BL/6 mice were randomly divided into three groups: a control group, an lipopolysaccharides (LPS) group, and an LPS plus MMI-0100 group. Mice were killed 24 hours after the administration of LPS and MMI-0100. The mouse lung tissue histopathology, wet/dry weight ratio (W/D), and the neutrophil count were used to measure the severity of lung inflammation in mice. The pulmonary microvascular endothelial cells (PMVECs) of the mice were isolated. The mRNA expression of ICAM-1 in mouse PMVECs was determined using RT-PCR, and the protein expression of MK2 and ICAM-1 in mouse PMVECs was analyzed using Western blotting and immunohistochemistry.
   Results: We found that the level of phosphorylated MK2 in the LPS plus MMI-0100 group was reduced. Compared with the LPS group, the LPS plus MMI-0100 group of mice showed less severe inflammation, including a lower W/D and neutrophil count. The mRNA and protein expression of ICAM-1 in the LPS group was significantly higher than in the control group in mouse PMVECs, and the ICAM-1 level was reduced after the administration of MMI-0100.
   Conclusion: These data indicate that MMI-0100 ameliorates lung inflammation in a mouse model of ARDS by reducing endothelial expression of ICAM-1.
C1 [He, Binchan; Zhou, Wei; Rui, Yuwen; Su, Xin] Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp & Crit Care Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, China.
C1 [Geng, Shen; Su, Xin] Southern Med Univ, Jinling Hosp, Dept Resp & Crit Care Med, Guangzhou 510000, Guangdong, China.
C1 [Mu, Xianmin; Zhang, Chen; You, Qiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Biotherapy, 121 Jiangjiayuan Rd, Nanjing 210002, Jiangsu, China.
C3 Nanjing University; Southern Medical University - China; Nanjing Medical
   University
RP Su, X (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp & Crit Care Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.; You, Q (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Dept Biotherapy, 121 Jiangjiayuan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM qiang.you@live.com; suxinjs@163.com
RI Su, Xin/X-2589-2018
OI Su, Xin/0000-0002-3910-9156; You, Qiang/0000-0003-3308-4127
FU National Natural Science Foundation of China [81670073]; Natural Science
   Foundation of Jiangsu Province [BK20161383]
FX We would like to thank LetPub (www.letpub.com) for its linguistic
   assistance during the preparation of this manuscript. This study was
   supported by the National Natural Science Foundation of China (grant no
   81670073) and the Natural Science Foundation of Jiangsu Province
   (BK20161383).
CR Bird MD, 2010, J BURN CARE RES, V31, P652, DOI 10.1097/BCR.0b013e3181e4c58c
   Brook M, 2006, MOL CELL BIOL, V26, P2408, DOI 10.1128/MCB.26.6.2408-2418.2006
   Chen W, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001849
   MONTEFORT S, 1992, EUR RESPIR J, V5, P815
   Ronkina N, 2007, MOL CELL BIOL, V27, P170, DOI 10.1128/MCB.01456-06
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shi JX, 2012, AM J PHYSIOL-LUNG C, V302, pL793, DOI 10.1152/ajplung.00339.2011
   Sousa A, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/747036
   Su X, 2008, BBA-MOL CELL RES, V1783, P1623, DOI 10.1016/j.bbamcr.2008.04.009
   Sumagin R, 2008, AM J PHYSIOL-HEART C, V295, pH969, DOI 10.1152/ajpheart.00400.2008
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Vittal R, 2013, AM J RESP CELL MOL, V49, P47, DOI 10.1165/rcmb.2012-0389OC
   Ward BC, 2011, J SURG RES, V169, pE27, DOI 10.1016/j.jss.2011.01.043
   Wu T, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0247-8
NR 14
TC 6
Z9 8
U1 1
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2018
VL 12
BP 4253
EP 4260
DI 10.2147/DDDT.S188095
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HE6MZ
UT WOS:000453524400003
PM 30587921
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Lu, XM
   Ma, L
   Yu, YQ
AF Lu, Xiao-Mei
   Ma, Ling
   Yu, Yan-Qiu
TI Lumican overexpression exacerbates LPS induced lung injury in mice
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE LPS; ALI/ARDS; apoptosis 
ID ACUTE KIDNEY INJURY; PROTEOGLYCANS; INFLAMMATION; RECEPTORS; SEPSIS;
   TLR4
AB To investigate the role of lumican in mice with endotoxin-acute lung injury (ALI). Lumican transgenic mice and wild type mice were injected with lipopolysaccha (LPS, 10 mg/kg) to establish the ALI model. Mice were sacrificed at 24 h and lung tissue samples and serum were collected. Lung wet-to-dry weight (W/D) ratio was measured to determine pulmonary edema. ELISA was used to measure the concentrations of cytokines in serum such as proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-4 and IL-10 in LPS-stimulated mice. The expressions of TLR4 and NF kappa B p65 proteins in lung tissues were examined using western blot analysis. Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) was performed to monitor apoptosis of lung tissue. Light microscopy and electron microscopy were used to observe the structure changes of lung tissues. After LPS administration, the values of lung wet-to-dry weight (W/D) in the lumican transgenic group were higher than those in the control group. Compared with those in the control mice, the expression levels of lung TLR4 and NF kappa B, and the cytokines of TNF alpha, IL-6, IL-4 and IL-10 in serum were upregulated in lumican transgenic mice. Apoptosis was detected mainly on pulmonary vascular endothelial cell and pneumocytes. There was significant difference in the optical density of apoptotic body between the control mice and the lumican transgenic mice. Results of light and electron microscopy exhibited more severe alveolar hemorrhage, pulmonary interstitial edema, visible inflammatory cell infiltration and edema of connective tissue in lung interstitium in the lumican transgenic mice than in the control mice. We found that LPS may cause excessive apoptosis in the pneumocytes via the TLR4 signal transduction pathway and ALI. Lumican may play a role in this process and exacerbates ALI.
C1 [Lu, Xiao-Mei; Ma, Ling; Yu, Yan-Qiu] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110001, China.
C3 China Medical University
RP Yu, YQ (corresponding author), China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110001, Peoples R China.
EM yqyu@cmu.edu.cn
FU National Natural Science Foundation of China [81100109]
FX This study was supported in part by a grant from the National Natural
   Science Foundation of China (NO. 81100109).
CR Amjadi Shahriar, 2013, ISRN Ophthalmol, V2013, P632302, DOI 10.1155/2013/632302
   Balk RA, 2014, VIRULENCE, V5, P20, DOI 10.4161/viru.27135
   Brezillon S, 2013, FEBS J, V280, P2369, DOI 10.1111/febs.12210
   Chakravarti S, 2002, GLYCOCONJUGATE J, V19, P287, DOI 10.1023/A:1025348417078
   Cruz-Machado SD, 2010, J PINEAL RES, V49, P183, DOI 10.1111/j.1600-079X.2010.00785.x
   Cui WY, 2011, CLIN EXP PHARMACOL P, V38, P747, DOI 10.1111/j.1440-1681.2011.05584.x
   Frey H, 2013, FEBS J, V280, P2165, DOI 10.1111/febs.12145
   Goldoni S, 2008, INT J CANCER, V123, P2473, DOI 10.1002/ijc.23930
   Hildebrand D, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-22
   Howell GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069520
   Iozzo RV, 2010, FEBS J, V277, P3864, DOI 10.1111/j.1742-4658.2010.07797.x
   Juneja SC, 2013, ARTHRITIS, DOI 10.1155/2013/154812
   Khosravi R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/728987
   Li XJ, 2013, J HUAZHONG U SCI-MED, V33, P680, DOI 10.1007/s11596-013-1180-1
   Lohr K, 2012, INFLAMM BOWEL DIS, V18, P143, DOI 10.1002/ibd.21713
   Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7
   Maeshima N, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00003
   Malinowski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050709
   Nair AR, 2014, FREE RADICAL BIO MED, V71, P16, DOI 10.1016/j.freeradbiomed.2014.03.012
   Naito Zenya, 2005, Journal of Nippon Medical School, V72, P137, DOI 10.1272/jnms.72.137
   Nikitovic D, 2008, IUBMB LIFE, V60, P818, DOI 10.1002/iub.131
   Ramachandran G, 2014, VIRULENCE, V5, P213, DOI 10.4161/viru.27024
   Schaefer L, 2011, J AM SOC NEPHROL, V22, P1200, DOI 10.1681/ASN.2010050570
   Schorr CA, 2014, VIRULENCE, V5, P190, DOI 10.4161/viru.27409
   Shao HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054765
   Striz I, 2014, CLIN SCI, V126, P593, DOI 10.1042/CS20130497
   Tamura Y, 2012, CURR MOL MED, V12, P1198, DOI 10.2174/156652412803306710
   Vij N, 2005, INVEST OPHTH VIS SCI, V46, P88, DOI 10.1167/iovs.04-0833
   Vij N, 2004, EXP EYE RES, V78, P957, DOI 10.1016/j.exer.2003.12.006
   Zhao Yongzhen, 2014, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V26, P153, DOI 10.3760/cma.j.issn.2095-4352.2014.03.006
NR 30
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 2
BP 1200
EP 1207
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FZ2OH
UT WOS:000427417600102
DA 2023-08-21
ER

PT J
AU Luan, ZG
   Hu, B
   Wu, L
   Jin, SZ
   Ma, XC
   Zhang, J
   Wang, AP
AF Luan, Zhenggang
   Hu, Bo
   Wu, Lei
   Jin, Shanzi
   Ma, Xiaochun
   Zhang, Jun
   Wang, Aiping
TI Unfractionated Heparin Alleviates Human Lung Endothelial Barrier
   Dysfunction Induced by High Mobility Group Box 1 Through Regulation of
   P38-GSK3 beta-Snail Signaling Pathway
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; Inflammation; HMGB1; heparin; EndoMT 
ID SEVERE ACUTE-PANCREATITIS; MOLECULAR-WEIGHT HEPARIN; KINASE PATHWAY;
   HMGB1; PROTEIN; INFLAMMATION; INJURY; CELLS; PERMEABILITY; EXPRESSION
AB Background/Aims: The high mobility group box 1 (HMGB1) has been regarded as an important inflammatory mediator. Previous studies showed the involvement of HMGB1 protein in the dysfunction of endothelial barrier function during acute lung injury. However, the molecular mechanism remains unclear. Methods: In this study, we used recombinant human HMGB1 (rhHMGB1) and HMGB1 plasmid to treat human pulmonary microvascular endothelial cell (HPMECs). We examined endothelial permeability by measuring TEER value and HRP flux. Western blot and real-time PCR were used to examined change of endothelial to-mesenchymal transition (EndoMT) markers and related pathways. Immunofluorescence was used to examine localization and expression of ZO-1 and VE-cadherin. SB203580.was used to block p38 pathway. Unfractionated heparin (UFH) and RAGE siRNA were also used to antagonize the effect of HMGB1. Results: We showed that HMGB1 induced EndoMT with downregulation of ZO-1 and VE-cadherin at both mRNA and protein levels in HPMECs. We also demonstrated that HMGB1 upregulated endothelial permeability by measuring TEER value and HRP flux. Moreover, HMGB1 activated p38 / GSK3 beta / Snail signaling pathway and treatment with p38 inhibitor SB203580 abolished its biological effects. In addition, we found that UFH was able to reverse the effect of HMGB1 on EndoMT and endothelial permeability through inhibition of p38 signaling in a dose-dependent manner. We discovered that RAGE, a membrane receptor of HMGB1, transduced p38 / Snail pathway to EndoMT. RAGE siRNA inhibited the effect of HMGB1 induced EndoMT in HPMECs. Conclusion: The present study demonstrated that HMGB1 induced EndoMT through RAGE receptor and p38 / GSK3 beta Snail pathway. While UFH antagonized HMGB1 and maintained the integrity of the endothelial barrier through p38 inhibition. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Luan, Zhenggang; Hu, Bo; Wu, Lei; Jin, Shanzi; Ma, Xiaochun] China Med Univ, Hosp 1, Dept Intens Care Unit, Shenyang, Liaoning, China.
C1 [Zhang, Jun; Wang, Aiping] China Med Univ, Hosp 1, Clin Nursing Sect, 155 Nanjing North St, Shenyang 110001, Liaoning, China.
C3 China Medical University; China Medical University
RP Wang, AP (corresponding author), China Med Univ, Hosp 1, Clin Nursing Sect, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM jianghaoran88@hotmail.com
FU National Natural Science Foundation of China [81471898]; Program for
   Liaoning Excellent Talents in University [LJQ2015116]
FX This work was supported by The National Natural Science Foundation of
   China, No. 81471898 and Program for Liaoning Excellent Talents in
   University, No. LJQ2015116.
CR BANNON PG, 1995, THROMB HAEMOSTASIS, V73, P706
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chen XY, 2013, J PAIN, V14, P1310, DOI 10.1016/j.jpain.2013.05.011
   Chen Y, 2015, J CELL MOL MED, V19, P2715, DOI 10.1111/jcmm.12657
   DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988
   Gonzales JN, 2014, VASC PHARMACOL, V62, P63, DOI 10.1016/j.vph.2014.01.005
   Han JL, 2013, THROMB RES, V132, pE42, DOI 10.1016/j.thromres.2013.03.010
   Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916
   Huang WC, 2012, INFLAMMATION, V35, P350, DOI 10.1007/s10753-011-9325-5
   Jang YH, 2013, LAB INVEST, V93, P194, DOI 10.1038/labinvest.2012.166
   Jiang RZ, 2014, J IMMUNOL, V193, P5000, DOI 10.4049/jimmunol.1303445
   Li L, 2015, CYTOKINE, V72, P36, DOI 10.1016/j.cyto.2014.12.010
   Li X, 2012, THROMB RES, V129, pE223, DOI 10.1016/j.thromres.2012.03.003
   Li YM, 2017, MOL CELL BIOCHEM, V431, P1, DOI 10.1007/s11010-017-2968-2
   Ling Y, 2011, INT IMMUNOPHARMACOL, V11, P187, DOI 10.1016/j.intimp.2010.11.014
   Lipowsky HH, 2017, MICROVASC RES, V112, P72, DOI 10.1016/j.mvr.2017.03.007
   Liu ZY, 2015, MOL MED REP, V12, P3895, DOI 10.3892/mmr.2015.3807
   Lopez D, 2009, ARCH BIOCHEM BIOPHYS, V482, P77, DOI 10.1016/j.abb.2008.11.016
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Luan ZG, 2013, CLIN EXP IMMUNOL, V172, P417, DOI 10.1111/cei.12062
   Luan ZG, 2014, INFLAMMATION, V37, P924, DOI 10.1007/s10753-014-9812-6
   Luan ZG, 2013, IMMUNOBIOLOGY, V218, P1261, DOI 10.1016/j.imbio.2013.04.013
   Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001
   Luan ZG, 2010, PANCREAS, V39, P216, DOI 10.1097/MPA.0b013e3181bab5c5
   Mura M, 2010, AM J PATHOL, V176, P1725, DOI 10.2353/ajpath.2010.090209
   Nagata K, 2016, J TRAUMA ACUTE CARE, V81, P1088, DOI 10.1097/TA.0000000000001215
   Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671
   Ruffer C, 2004, BIOCHEMISTRY-US, V43, P5360, DOI 10.1021/bi035517c
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
   Xie H, 2010, BRAIN RES, V1319, P13, DOI 10.1016/j.brainres.2010.01.023
   Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334
   Zhang XP, 2015, CANCER RES, V75, P4527, DOI 10.1158/0008-5472.CAN-14-3828
   Zhang Y, 2015, ANTIOXID REDOX SIGN, V22, P1084, DOI 10.1089/ars.2014.5978
   Zhao DM, 2012, INFLAMMATION, V35, P1825, DOI 10.1007/s10753-012-9503-0
   Zheng YJ, 2016, MOL MED REP, V13, P513, DOI 10.3892/mmr.2015.4536
NR 36
TC 25
Z9 28
U1 3
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 46
IS 5
BP 1907
EP 1918
DI 10.1159/000489375
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GH1HG
UT WOS:000433153200013
PM 29719300
OA gold
DA 2023-08-21
ER

PT J
AU Morsing, KSH
   Peters, AL
   van Buul, JD
   Vlaar, APJ
AF Morsing, K. S. H.
   Peters, A. L.
   van Buul, Jaap D.
   Vlaar, Alexander P.
TI The role of endothelium in the onset of antibody-mediated TRALI
SO BLOOD REVIEWS
LA English
DT Review
DE ECs/HPMECs/HUVECs/MPVECs; transfusion; ALI/ARDS; Antibodies; HLA; HNA; Transendothelial migration; Cellular adhesion molecules 
ID ACUTE LUNG INJURY; LEUKOCYTE TRANSENDOTHELIAL MIGRATION;
   INTERCELLULAR-ADHESION MOLECULE-1; CLASS-II ANTIBODIES;
   VASCULAR-PERMEABILITY; IN-VITRO; NEUTROPHIL RECRUITMENT; DOCKING
   STRUCTURE; CELL-ADHESION; BLOOD-DONORS
AB Transfusion Related Acute Lung Injury (TRALI) is one of the leading causes of mortality and morbidity following blood transfusion. The mechanisms behind the disease are not yet fully understood but seem to involve many different activating pathways and donor factors, in synergy with patient susceptibility. Studies have focused mostly on neutrophil activation, as aggregates of neutrophils and edema in lungs are found in post-mortem histological sections. This review aims to highlight the role of the endothelium in TRALI, as activated endothelium is the main promoter of leukocyte transmigration, and creates the barrier between blood and tissue. Since recent evidence suggests that a strong endothelial barrier prevents leukocyte transmigration and vascular leakage, we suggest that strengthening this barrier may be key to TRALI prevention.
C1 [Morsing, K. S. H.; van Buul, J. D.] Sanquin, Sanquin Res & Landsteiner Lab, Dept Plasma Prot, Mol Cell Biol Lab, Amsterdam, Netherlands.
C1 [Morsing, K. S. H.; Peters, A. L.; Vlaar, A. P. J.] Acad Med Ctr, Lab Expt Intens Care & Anesthesiol, Amsterdam, Netherlands.
C1 [Peters, A. L.; Vlaar, A. P. J.] Acad Med Ctr, Dept Intens Care Med, Amsterdam, Netherlands.
C3 University of Amsterdam; University of Amsterdam; Academic Medical
   Center Amsterdam; University of Amsterdam; Academic Medical Center
   Amsterdam
RP Vlaar, APJ (corresponding author), Dept Intens Care Med, Room C3-430,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.; Vlaar, APJ (corresponding author), Lab Expt Intens Care Med, Room C3-430,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM a.p.vlaar@amc.uva.nl
OI Vlaar, Alexander/0000-0002-3453-7186; Morsing, Sofia/0000-0002-0504-6855
CR Alcaide P, 2008, BLOOD, V112, P2770, DOI 10.1182/blood-2008-03-147181
   Allingham MJ, 2007, J IMMUNOL, V179, P4053, DOI 10.4049/jimmunol.179.6.4053
   Barreiro O, 2005, BLOOD, V105, P2852, DOI 10.1182/blood-2004-09-3606
   Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126
   Bayat B, 2013, ARTERIOSCL THROM VAS, V33, P2538, DOI 10.1161/ATVBAHA.113.301206
   Benson AB, 2010, INTENS CARE MED, V36, P1710, DOI 10.1007/s00134-010-1954-x
   Berthold T, 2015, TRANSFUSION
   Bless NM, 2000, J IMMUNOL, V164, P2650, DOI 10.4049/jimmunol.164.5.2650
   BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856
   Bux J, 2008, VOX SANG, V94, P277, DOI 10.1111/j.1423-0410.2007.01031.x
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Carman CV, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00603
   Carman CV, 2003, J IMMUNOL, V171, P6135, DOI 10.4049/jimmunol.171.11.6135
   Cook-Mills JM, 2004, BIOCHEM J, V378, P539, DOI 10.1042/BJ20030794
   Cunningham AC, 1997, IMMUNOLOGY, V91, P458, DOI 10.1046/j.1365-2567.1997.d01-2249.x
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Dykes A, 2000, BRIT J HAEMATOL, V109, P674, DOI 10.1046/j.1365-2141.2000.01999.x
   Flesch BK, 2002, BRIT J HAEMATOL, V116, P673, DOI 10.1046/j.0007-1048.2001.03305.x
   Fujihara M, 1999, TRANSFUSION, V39, P498, DOI 10.1046/j.1537-2995.1999.39050498.x
   Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC
   Goldman M, 2005, TRANSFUS MED REV, V19, P2, DOI 10.1016/j.tmrv.2004.10.001
   Gorina R, 2014, J IMMUNOL, V192, P324, DOI 10.4049/jimmunol.1300858
   Griffin GK, 2012, J IMMUNOL, V188, P6287, DOI 10.4049/jimmunol.1200385
   Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399
   Heemskerk N, 2016, J IMMUNOL, V196, P2767, DOI 10.4049/jimmunol.1501322
   Heemskerk N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10493
   Hidalgo A, 2009, NAT MED, V15, P384, DOI 10.1038/nm.1939
   Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489
   Jacobi KE, 2000, J CLIN ANESTH, V12, P94, DOI 10.1016/S0952-8180(00)00122-7
   Kanters E, 2008, J BIOL CHEM, V283, P31830, DOI 10.1074/jbc.M804888200
   Kao GS, 2003, TRANSFUSION, V43, P185, DOI 10.1046/j.1537-2995.2003.00285.x
   Kapur R, 2015, BLOOD
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Knipe L, 2010, BLOOD, V116, P2183, DOI 10.1182/blood-2010-03-276170
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Kuppers V, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23805
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Lyck R, 2003, BLOOD, V102, P3675, DOI 10.1182/blood-2003-02-0358
   Mamdouh Z, 2003, NATURE, V421, P748, DOI 10.1038/nature01300
   Mamdouh Z, 2009, J EXP MED, V206, P2795, DOI 10.1084/jem.20082745
   Martinelli R, 2014, J CELL SCI, V127, P3720, DOI 10.1242/jcs.148619
   Maslanka K, 2007, VOX SANG, V92, P247, DOI 10.1111/j.1423-0410.2007.00890.x
   Mikelis CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7725
   Muller WA, 2011, ANNU REV PATHOL-MECH, V6, P323, DOI 10.1146/annurev-pathol-011110-130224
   Muschter S, 2011, CURR OPIN HEMATOL, V18, P452, DOI 10.1097/MOH.0b013e32834babdd
   Nossaman BD, 2008, OCHSNER J, V8, P32
   Okazaki H, 2014, TRANSFUSION, V54, P3097, DOI 10.1111/trf.12766
   Pasceri V, 2000, CIRCULATION, V102, P2165
   Peters AL, 2015, BRIT J HAEMATOL, V170, P597, DOI 10.1111/bjh.13459
   Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963
   Plotnikov SV, 2013, CURR OPIN CELL BIOL, V25, P619, DOI 10.1016/j.ceb.2013.06.003
   Powers A, 2008, TRANSFUSION, V48, P2549, DOI 10.1111/j.1537-2995.2008.01902.x
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Sachs UJH, 2011, BLOOD, V117, P669, DOI 10.1182/blood-2010-05-286146
   Sage PT, 2012, J IMMUNOL, V188, P3686, DOI 10.4049/jimmunol.1102594
   Schaefer A, 2015, J CELL SCI, V128, P2221, DOI 10.1242/jcs.163055
   Schimmel Lilian, 2017, Small GTPases, V8, P1, DOI 10.1080/21541248.2016.1197872
   Schnoor M, 2011, J EXP MED, V208, P1721, DOI 10.1084/jem.20101920
   Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304
   Seghatchian J, 2000, TRANSFUS SCI, V22, P165, DOI 10.1016/S0955-3886(00)00044-8
   Shaw SK, 2004, J EXP MED, V200, P1571, DOI 10.1084/jem.20040965
   Silliman CC, 2006, CRIT CARE MED, V34, pS124, DOI 10.1097/01.CCM.0000214292.62276.8E
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Strait RT, 2011, J EXP MED, V208, P2525, DOI 10.1084/jem.20110159
   Toy P, 2007, BEST PRACT RES-CLIN, V21, P183, DOI 10.1016/j.bpa.2007.01.003
   Turowski P, 2008, J CELL SCI, V121, P29, DOI 10.1242/jcs.022681
   van Buul JD, 2007, J CELL BIOL, V178, P1279, DOI 10.1083/jcb.200612053
   van Rijssel J, 2012, MOL BIOL CELL, V23, P2831, DOI 10.1091/mbc.E11-11-0907
   van Wetering S, 2003, AM J PHYSIOL-CELL PH, V285, pC343, DOI 10.1152/ajpcell.00048.2003
   van Wetering S, 2002, J CELL SCI, V115, P1837
   Vestweber D, 2012, ANN NY ACAD SCI, V1257, P184, DOI 10.1111/j.1749-6632.2012.06558.x
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Vlaar APJ, 2010, CRIT CARE MED, V38, P771, DOI 10.1097/CCM.0b013e3181cc4d4b
   Wakamoto S, 2011, TRANSFUSION, V51, P993, DOI 10.1111/j.1537-2995.2010.02910.x
   Weisbach V, 1999, VOX SANG, V76, P100
   Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001
   Yang L, 2006, CIRC RES, V98, P394, DOI 10.1161/01.RES.0000201958.59020.1a
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Yang L, 2006, J IMMUNOL, V177, P6440, DOI 10.4049/jimmunol.177.9.6440
NR 83
TC 13
Z9 15
U1 0
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0268-960X
EI 1532-1681
J9 BLOOD REV
JI Blood Rev.
PD JAN
PY 2018
VL 32
IS 1
BP 1
EP 7
DI 10.1016/j.blre.2017.08.003
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA FY8FS
UT WOS:000427100200001
PM 28823763
DA 2023-08-21
ER

PT J
AU Rigonato-Oliveira, NC
   MacKenzie, B
   Bachi, ALL
   Oliveira, MC
   Santos-Dias, A
   Brandao-Rangel, MAR
   Delle, H
   Costa-Guimaraes, T
   Damaceno-Rodrigues, NR
   Dulley, LH
   Benetti, MA
   Malfitano, C
   de Angelis, K
   Albertini, R
   Oliveira, APL
   Abbasi, A
   Northoff, H
   Vieira, RP
AF Rigonato-Oliveira, Nicole Cristine
   MacKenzie, BreAnne
   Lacerda Bachi, Andre Luis
   Oliveira-Junior, Manoel Carneiro
   Santos-Dias, Alana
   Rodrigues Brandao-Rangel, Maysa Alves
   Delle, Humberto
   Costa-Guimaraes, Tamara
   Damaceno-Rodrigues, Nilsa Regina
   Dulley, Larissa Hilario
   Benetti, Marcela Anhesini
   Malfitano, Christiane
   de Angelis, Katia
   Albertini, Regiane
   Ligeiro Oliveira, Ana Paula
   Abbasi, Asghar
   Northoff, Hinnak
   Vieira, Rodolfo Paula
TI Aerobic exercise inhibits acute lung injury: from mouse to human
   evidence Exercise reduced lung injury markers in mouse and in cells
SO EXERCISE IMMUNOLOGY REVIEW
LA English
DT Review
DE exercise immunology; lung inflammation; immune response; ALI/ARDS; cytokines 
ID RESPIRATORY-DISTRESS-SYNDROME; PULMONARY ALVEOLAR MACROPHAGES;
   DISABILITY 5 YEARS; MODERATE EXERCISE; INFLAMMATION; INTERLEUKIN-10;
   STATEMENT; CYTOKINE; STRESS; MICE
AB Acute respiratory distress syndrome (ARDS) is defined as hypoxemic respiratory failure with intense pulmonary inflammation, involving hyperactivation of endothelial cells and neutrophils. Given the anti-inflammatory effects of aerobic exercise (AE), this study investigated whether AE performed daily for 5 weeks would inhibit extra-pulmonary LPS-induced ARDS. C57Bl/6 mice were distributed into Control, Exercise, LPS and Exercise+ LPS groups. AE was performed on a treadmill for 5x/week for four weeks before LPS administration. 24hours after the final AE physical test, animals received 100ug of LPS intra-peritoneally. In addition, whole blood cell culture, neutrophils and human endothelial cells were pre-incubated with IL-10, an anti-inflammatory cytokine induced by exercise. AE reduced total protein levels (p<0.01) and neutrophil accumulation in bronchoalveolar lavage (BAL) (p<0.01) and lung parenchyma (p<0.01). AE reduced BAL inflammatory cytokines IL-1 beta, IL-6 and GM-CSF (p<0.001), CXCL1/KC, IL-17, TNF-alpha and IGF-1 (p<0.01). Systemically, AE reduced IL-1 beta, IL-6 and IFN-gamma (p<0.001), CXCL1/KC (p<0.01) and TNF-alpha (p<0.05). AE increased IL-10 levels in serum (p<0.001) and BAL (p<0.001). Furthermore, AE increased superoxide dismutase SOD (p<0.01) and decreased superoxide anion accumulation in the lungs (p<0.01). Lastly, pre-incubation with IL-10 significantly reduced LPS-induced activation of whole blood cells, neutrophils and HUVECs, as observed by reduced production of IL-1 beta, IL-6, IL-8 and TNF-alpha. Our data suggest that AE inhibited LPS-induced lung inflammation by attenuating inflammatory cytokines and oxidative stress markers in mice and human cell culture via enhanced IL-10 production.
C1 [Rigonato-Oliveira, Nicole Cristine; Delle, Humberto; Ligeiro Oliveira, Ana Paula] Nove Julho Univ, Sao Paulo, SP, Brazil.
C1 [MacKenzie, BreAnne; Lacerda Bachi, Andre Luis; Oliveira-Junior, Manoel Carneiro; Santos-Dias, Alana; Rodrigues Brandao-Rangel, Maysa Alves; Costa-Guimaraes, Tamara; Dulley, Larissa Hilario; Benetti, Marcela Anhesini; Vieira, Rodolfo Paula] Brazilian Inst Teaching & Res Pulm & Exercise Imm, Sao Jose Dos Campos, SP, Brazil.
C1 [Rodrigues Brandao-Rangel, Maysa Alves; Albertini, Regiane; Vieira, Rodolfo Paula] Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human Movement & Rehabil, Santos, SP, Brazil.
C1 [Costa-Guimaraes, Tamara; Vieira, Rodolfo Paula] Univ Brasil, Sao Paulo, SP, Brazil.
C1 [Damaceno-Rodrigues, Nilsa Regina] Univ Sao Paulo, Sch Med, Dept Pathol LIM 59, Sao Paulo, SP, Brazil.
C1 [Malfitano, Christiane] Univ Fed Lavras UFLA, Sci Dept Hlth, Lavras, MG, Brazil.
C1 [de Angelis, Katia] Fed Univ Sao Paulo UNIFESP, Campus Sao Paulo, Sao Paulo, SP, Brazil.
C1 [Abbasi, Asghar] Harbor UCLA Med Ctr, Div Resp & Crit Care Physiol & Med, Los Angeles Biomed Res Inst, Torrance, CA 90509, United States.
C1 [Northoff, Hinnak] Univ Tubingen, Inst Clin & Expt Transfus Med IKET, Tubingen, Germany.
C3 Universidade Nove de Julho; Universidade Federal de Sao Paulo (UNIFESP);
   Universidade Brasil; Universidade de Sao Paulo; Universidade Federal de
   Lavras; Universidade Federal de Sao Paulo (UNIFESP); University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; Lundquist Institute; Eberhard
   Karls University of Tubingen
RP Vieira, RP (corresponding author), Univ Brasil, Inst Pesquisa, Rua Carolina Fonseca 285, BR-08230030 Sao Paulo, SP, Brazil.
EM rodrelena@yahoo.com.br
RI Damaceno-Rodrigues, Nilsa Regina/AAJ-7953-2020; Bachi, Andre
   L.L./G-2946-2012; Dellê, Humberto/N-6353-2019; Rangel,
   Maysa/Q-1999-2017; de Paula Vieira, Rodolfo/E-9315-2011; Oliveira, Ana
   Paula/B-8366-2009; Albertini, Regiane/AAL-7940-2020; Malfitano,
   Christiane/I-2701-2013; Bachi, Andre/T-6931-2018
OI Bachi, Andre L.L./0000-0001-8266-1416; Dellê,
   Humberto/0000-0001-6072-3671; Rangel, Maysa/0000-0002-9284-8695; de
   Paula Vieira, Rodolfo/0000-0001-6379-1143; Oliveira, Ana
   Paula/0000-0003-3787-9138; Albertini, Regiane/0000-0002-4143-0387;
   Bachi, Andre/0000-0001-8266-1416
FU Sao Paulo Research Foundation (FAPESP) [2012/15165-2]; Conselho Nacional
   de Pesquisa e Desenvolvimento (CNPq) [311335-2015-2]; Comissao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [12804/13-4,
   1303/13-9]; FAPESP [2013/24076-6, 2014/23196-0, 2012/14604-8,
   2012/25435-7, 2012/24880-7]; CAPES
FX Sao Paulo Research Foundation (FAPESP) grant 2012/15165-2. Conselho
   Nacional de Pesquisa e Desenvolvimento (CNPq) grant 311335-2015-2.
   Comissao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) grants
   12804/13-4 and 1303/13-9. NCRO holds a MSc fellowship from FAPESP
   2013/24076-6. BM holds a postdoctoral fellowship from FAPESP
   2014/23196-0. MCOJ holds a PhD fellowship from FAPESP 2012/14604-8. ASAS
   holds a MSc fellowship from CAPES. LHD holds a scientific initiation
   fellowship from FAPESP 2012/25435-7. MAB holds a scientific initiation
   fellowship from FAPESP 2012/24880-7.
CR Abbasi A, 2014, BRAIN BEHAV IMMUN, V39, P130, DOI 10.1016/j.bbi.2013.10.023
   Acosta-Herrera M, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0981-y
   Armstrong L, 1997, THORAX, V52, P442, DOI 10.1136/thx.52.5.442
   Bruggemann TR, 2015, INT J SPORTS MED
   Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004
   Dal-Pizzol F, 2011, NEW ENGL J MED, V365, P274, DOI 10.1056/NEJMc1105509
   de Araujo CC, 2012, J APPL PHYSIOL, V112, P1206, DOI 10.1152/japplphysiol.01061.2011
   Debevec T, 2014, MED SCI SPORT EXER, V46, P33, DOI 10.1249/MSS.0b013e31829f87ef
   Donnelly SC, 1996, ANN INTERN MED, V125, P191, DOI 10.7326/0003-4819-125-3-199608010-00005
   Files DC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010283
   Frellstedt L, 2014, AM J RESP CELL MOL, V51, P135, DOI 10.1165/rcmb.2013-0341OC
   Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006
   Gleeson M, 2012, J SPORT SCI, V30, P321, DOI 10.1080/02640414.2011.627371
   Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041
   GONZALEZROTHI RJ, 1991, EXP LUNG RES, V17, P687, DOI 10.3109/01902149109062873
   Gu Y, 2008, EUR J IMMUNOL, V38, P1807, DOI 10.1002/eji.200838331
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b
   Li JT, 2015, J IMMUNOL, V195, P87, DOI 10.4049/jimmunol.1500054
   Li Q, 2015, SCAND J IMMUNOL
   Lowder T, 2010, BRAIN BEHAV IMMUN, V24, P153, DOI 10.1016/j.bbi.2009.09.011
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Memtsoudis Stavros G, 2012, J Intensive Care Med, V27, P306, DOI 10.1177/0885066611411410
   Moon HG, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.10
   Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC
   Pereira PR, 2016, MED SCI SPORTS EXERC
   Prata LO, 2012, EXP BIOL MED, V237, P873, DOI 10.1258/ebm.2012.011334
   Ramos DS, 2010, MED SCI SPORT EXER, V42, P113, DOI 10.1249/MSS.0b013e3181ad1c72
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Goncalves CTR, 2012, CRIT CARE, V16, DOI 10.1186/cc11807
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schnapp LM, 2006, AM J PATHOL, V169, P86, DOI 10.2353/ajpath.2006.050612
   Silva RA, 2010, EUR RESPIR J, V35, P994, DOI 10.1183/09031936.00049509
   Vieira RP, 2009, INT J SPORTS MED, V30, P684, DOI 10.1055/s-0029-1224176
   Vieira RD, 2012, MED SCI SPORT EXER, V44, P1227, DOI 10.1249/MSS.0b013e31824b2877
   Vieira RP, 2008, AM J PHYSIOL-LUNG C, V295, pL670, DOI 10.1152/ajplung.00465.2007
   Vieira RP, 2007, AM J RESP CRIT CARE, V176, P871, DOI 10.1164/rccm.200610-1567OC
   Vieira RP, 2011, RESP PHYSIOL NEUROBI, V175, P383, DOI 10.1016/j.resp.2011.01.002
   Walsh NP, 2011, EXERC IMMUNOL REV, V17, P64
   Walsh NP, 2011, EXERC IMMUNOL REV, V17, P6
   Weinstock C, 1997, MED SCI SPORT EXER, V29, P345, DOI 10.1097/00005768-199703000-00009
NR 42
TC 17
Z9 17
U1 0
U2 16
PU W W F VERLAGSGESELLSCHAFT GMBH
PI GREVEN
PA AM EGGENKAMP 37-39, 48268 GREVEN, GERMANY
SN 1077-5552
J9 EXERC IMMUNOL REV
JI Exerc. Immunol. Rev.
PY 2018
VL 24
BP 48
EP 56
PG 9
WC Immunology; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Sport Sciences
GA GA2GK
UT WOS:000428135000005
DA 2023-08-21
ER

PT J
AU Shao, P
   Zhu, JY
   Ding, H
   Zhou, WJ
   Zhou, WY
   Liu, QF
   Li, YG
   Ma, XG
AF Shao, Ping
   Zhu, Jinyuan
   Ding, Huan
   Zhou, Wenjie
   Zhou, Wenyan
   Liu, Qinfu
   Li, Yuangui
   Ma, Xigang
TI Tripterygium hypoglaucum (Levl.) Hutch attenuates oleic acid-induced
   acute lung injury in rats through up-regulating claudin-5 and ZO-1
   expression
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Tripterygium hypoglaucum; root extract; ALI/ARDS; tight junction; lung barrier function 
ID RESPIRATORY-DISTRESS-SYNDROME; IN-VITRO; TIGHT JUNCTIONS; TOTAL
   ALKALOIDS; VENTILATION; MANAGEMENT; BARRIER; MICE
AB Tripterygium hypoglaucum (Levl.) Hutch (THH), a perennial plant, has shown multiple pharmacological actions; however, there is little knowledge on the activity against lung injury. This study aimed to evaluate the effect of THH on oleic acid-induced acute lung injury (ALI) in rats and explore the underlying mechanisms. Male SD rats were randomly assigned to 5 groups. Rats in the ALI group (n = 15) were orally administered 2 ml of 0.9% physiological saline for 10 successive days, and then ALI was induced in the rats by injection of 0.04 ml/kg oleic acid into the tail vein 1 h after the last oral administration. Animals in the low-, moderate-, and high-dose THH groups were orally administered THH tablets at daily doses of 500, 600, and 700 mg/kg for successive 10 days, and then oleic acid was given at a dose of 0.04 ml/kg by tail vein injection 1 h after the last oral administration. The control rats were given 2 ml 0.9% physiological saline by gavage for 10 successive days, and physiological saline was given at a dose of 0.04 ml/kg by tail vein injection 1 h after the last oral administration. Claudin-5 and ZO-1 expression was determined in rat lung tissues using immunohistochemistry, qRT-PCR, and Western blotting assays, and the lung wet/dry (W/D) weight ratio and lung permeability index (LPI) were measured. Rat lung tissue morphology was observed using HE staining and a lung injury score was estimated, while the ultra-structural changes of the rat lung tissues were visualized using transmission electronic microscopy (TEM). Significantly lower claudin-5 and ZO-1 expression was detected in the ALI group than in the control group at both translational and transcriptional levels (P < 0.05), and the claudin-5 and ZO-1 protein expression was higher in the three THH groups than in the ALI group (P < 0.05). A significant rise was seen in the lung W/D weight ratio, LPI, and LIS in the ALI group in relative to the control group, while THH treatment resulted in a significant reduction in lung W/D weight ratio, LPI, and LIS as compared to the ALI group in a dose-dependent manner. However, no significant differences were found between the low-and moderate-dose THH groups (P > 0.05). Microscopy showed obvious rat lung injury in the ALI group, with edema and intracellular junction disorganization seen in lung tissues. The results of the present study demonstrate that THH attenuates pulmonary vascular endothelial cell injury caused by ALI through up-regulation of claudin-5 and ZO-1 expression, and dose-dependent protection of the lung barrier function. Our findings indicate that claudin-5 and ZO-1 may be potential targets for treatment of ALI.
C1 [Shao, Ping] Ningxia Med Univ, Affiliated Hosp 2, Dept Resp Med, Yinchuan, Ningxia Hui Aut, China.
C1 [Zhu, Jinyuan; Ding, Huan; Zhou, Wenjie; Zhou, Wenyan; Liu, Qinfu; Li, Yuangui; Ma, Xigang] Ningxia Med Univ, Gen Hosp, Dept Crit Care Med, 804 Shengli South St, Yinchuan City 750004, Ningxia Hui Aut, China.
C1 [Shao, Ping] Yinchuan First Peoples Hosp, Yinchuan City 750001, Ningxia Hui Aut, China.
C3 Ningxia Medical University; Ningxia Medical University
RP Ma, XG (corresponding author), Ningxia Med Univ, Gen Hosp, Dept Crit Care Med, 804 Shengli South St, Yinchuan City 750004, Ningxia Hui Aut, Peoples R China.
EM nyfyicu@163.com
FU National Natural Science Foundation of China [81260583]; Natural Science
   Foundation of Ningxia Hui Autonomous Region [NZ10139]
FX The authors would like to thank Prof. Li Jing from the Department of
   Pathology, Prof. Yin Wang from the Department of Molecular Biology, and
   Prof. Jianqiang Yu from the School of Pharmacy, Ningxia Medical
   University for their kind help and assistance during the experiments.
   Thanks are also expressed to Prof. Zhongqin Guo from the Department of
   Biostatistics, Ningxia Medical University for the kind help during the
   data analysis. We sincerely thank Professors Xiangyuan Cao and Xiaohong
   Wang from the Department of Critical Care Medicine, the General Hospital
   of Ningxia Medical University for their valuable comments on our
   manuscript. This study was supported by the grants from the National
   Natural Science Foundation of China (grant no. 81260583) and the Natural
   Science Foundation of Ningxia Hui Autonomous Region (grant no. NZ10139).
CR Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Bastarache JA, 2009, DIS MODEL MECH, V2, P218, DOI 10.1242/dmm.001677
   Chen F, 2014, EUR J CLIN MICROBIOL, V33, P457, DOI 10.1007/s10096-013-1978-6
   Chen WG, 2014, AM J RESP CELL MOL, V50, P328, DOI 10.1165/rcmb.2013-0058OC
   Chen YX, 2009, MILITARY MED J S CHI, V23, P4
   Chiche L, 2007, NEW ENGL J MED, V357, P2518
   Duan HQ, 2000, J NAT PROD, V63, P357, DOI 10.1021/np990281s
   Gao ZM, 2014, EXP THER MED, V8, P1819, DOI 10.3892/etm.2014.1987
   Gibbs RH, 2009, BRIT J HOSP MED, V70, P665, DOI 10.12968/hmed.2009.70.11.45066
   Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8
   Huang YJ, 2006, NEURAL REGEN RES, V1, P553
   Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC
   Jiang X, 2014, J ETHNOPHARMACOL, V151, P292, DOI 10.1016/j.jep.2013.10.045
   Jing HR, 2014, J SURG RES, V187, P252, DOI 10.1016/j.jss.2013.10.009
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Koval M, 2013, ANNU REV PHYSIOL, V75, P551, DOI 10.1146/annurev-physiol-030212-183809
   Li CW, 2015, EVID-BASED COMPL ALT, V2015
   Lin Li-mei, 2005, Chin J Integr Med, V11, P149
   Liu Y, 2003, CHIN J INTEGR TRADIE, V4, P47
   Liu Zhenzhen, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2503
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Ma XP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079584
   Malhotra A, 2007, NEW ENGL J MED, V357, P1113, DOI 10.1056/NEJMct074213
   Marik PE, 2011, CRIT CARE CLIN, V27, P589, DOI 10.1016/j.ccc.2011.05.007
   MARINELLI WA, 1994, CLIN CHEST MED, V15, P517
   Mitchell LA, 2015, AM J PATHOL, V185, P372, DOI 10.1016/j.ajpath.2014.10.010
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Paschoud S, 2007, MODERN PATHOL, V20, P947, DOI 10.1038/modpathol.3800835
   Pelosi P, 2008, INTENS CARE MED, V2008, P214
   Ren Zhe, 2010, Virologica Sinica, V25, P107, DOI 10.1007/s12250-010-3092-6
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Seeley EJ, 2013, ADV CHRONIC KIDNEY D, V20, P14, DOI 10.1053/j.ackd.2012.10.001
   Sun CX, 2013, AM J PHYSIOL-LUNG C, V304, pL135, DOI 10.1152/ajplung.00133.2012
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Wang D, 2011, J APPL ANIM RES, V39, P44, DOI 10.1080/09712119.2011.570048
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Yeh CC, 2006, INT IMMUNOPHARMACOL, V6, P1506, DOI 10.1016/j.intimp.2006.04.015
   You K, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-36
   Zhang L., 1993, Acta Pharmaceutica Sinica, V28, P32
   Zhang Y., 2008, PEOPLE MIL SURG, V51, P463
   [张彦文 ZHANG Yanwen], 2007, [中草药, Chinese Traditional and Herbal Drugs], V38, P493
   Liang ZQ, 2006, WORLD J GASTROENTERO, V12, P1133, DOI 10.3748/wjg.v12.i7.1133
NR 47
TC 2
Z9 3
U1 1
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 7
BP 6634
EP 6647
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GO8WE
UT WOS:000440379700025
DA 2023-08-21
ER

PT J
AU Shi, M
   Wang, LL
   Zhou, J
   Ji, SM
   Wang, NF
   Tong, L
   Bi, J
   Song, YL
   Hu, J
   Chen, XF
AF Shi, Meng
   Wang, Linlin
   Zhou, Jian
   Ji, Shimeng
   Wang, Ningfang
   Tong, Lin
   Bi, Jing
   Song, Yuanlin
   Hu, Jie
   Chen, Xiaofeng
TI Direct factor Xa inhibition attenuates acute lung injury progression via
   modulation of the PAR-2/NF-kappa B signaling pathway
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; factor Xa; NF-kappa B; rivaroxaban 
ID RESPIRATORY-DISTRESS-SYNDROME; ACTIVATED RECEPTOR 2; COAGULATION-FACTOR
   XA; TISSUE FACTOR; THROMBUS FORMATION; ENDOTHELIAL-CELLS; DEFICIENT
   MICE; EXPRESSION; DISEASE; ANTICOAGULANT
AB The role of coagulation in acute lung injury (ALI) remains unclear. As factor Xa-dependent protease-activated receptor 2 (PAR-2) is reported to be an important target in blood coagulation and other processes, an inhibitor of factor Xa, rivaroxaban, was tested in vivo in C57BL/6 mice with ALI induced by intratracheal injections of lipo-polysaccharide (LPS) and in vitro in LPS-stimulated human umbilical vein endothelial cells. Plasma concentrations and coagulation indices were measured in mice fed normal chow or chow containing rivaroxaban (0.2 or 0.4 mg/g) for 10 days. The rivaroxaban-treated mice had significantly reduced neutrophil sequestration with preservation of the lung tissue architecture compared with that in the untreated controls. The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban. Rivaroxaban treatment also ameliorated the LPS-induced PAR-2 increase and nuclear factor kappa B (NF-kappa B) activation. In vitro, cells treated with rivaroxaban had higher cell viability with an attenuation of LPS-induced increases in membrane permeability and proinflammatory cytokine levels, as well as reduced apoptosis. Furthermore, rivaroxaban inhibited the phosphorylation of TAK1 and p65. These data show that rivaroxaban attenuates ALI and inflammation by inhibiting the PAR-2/NF-kappa B signaling pathway.
C1 [Shi, Meng; Chen, Xiaofeng] Fudan Univ, Huashan Hosp, Dept Cardiothorac Surg, 12 Wulumuqi Middle St, Shanghai 200040, China.
C1 [Wang, Linlin; Zhou, Jian; Ji, Shimeng; Wang, Ningfang; Tong, Lin; Bi, Jing; Song, Yuanlin; Hu, Jie] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, 108 Fenglin Rd, Shanghai 200040, China.
C1 [Shi, Meng; Wang, Linlin; Zhou, Jian; Ji, Shimeng; Wang, Ningfang; Tong, Lin; Bi, Jing; Song, Yuanlin; Hu, Jie] Shanghai Resp Res Inst, Shanghai, China.
C3 Fudan University; Fudan University
RP Chen, XF (corresponding author), Fudan Univ, Huashan Hosp, Dept Cardiothorac Surg, 12 Wulumuqi Middle St, Shanghai 200040, Peoples R China.; Hu, J (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pulm Med, 108 Fenglin Rd, Shanghai 200040, Peoples R China.
EM huashan_heart@sina.cn; hs_chenxiaofeng@yeah.net
RI wang, lin/HHM-2225-2022; wang, lin/HZK-4145-2023
FU Natural Science Foundation of China [81490533, 81400018, 81570028,
   81500026, 81770039]; State Key Basic Research Program (973) project
   [2015CB553404]; Shanghai Science and Technology Committee [18140903400,
   15DZ1930600, 15DZ1941103]; Shanghai Three-Year Plan of the Key Subjects
   Construction in Public Health-Infectious Diseases and Pathogenic
   Microorganism [15GWZK0102]
FX This study was supported by the Natural Science Foundation of China
   (81490533, 81400018, 81570028, 81500026, 81770039), the State Key Basic
   Research Program (973) project (2015CB553404), the Shanghai Science and
   Technology Committee (18140903400, 15DZ1930600, 15DZ1941103), and the
   Shanghai Three-Year Plan of the Key Subjects Construction in Public
   Health-Infectious Diseases and Pathogenic Microorganism (15GWZK0102).
CR Aggarwal S, 2014, AM J RESP CELL MOL, V50, P614, DOI 10.1165/rcmb.2013-0193OC
   Alame G, 2015, THROMB HAEMOSTASIS, V113, P385, DOI 10.1160/TH14-05-0399
   Alberelli MA, 2014, VASC PHARMACOL, V62, P72, DOI 10.1016/j.vph.2014.06.001
   Anthoni C, 2007, J EXP MED, V204, P1595, DOI 10.1084/jem.20062354
   Banfi C, 2009, J THROMB HAEMOST, V7, P206, DOI 10.1111/j.1538-7836.2008.03204.x
   Becker PM, 2003, AM J RESP CELL MOL, V28, P478, DOI 10.1165/rcmb.2002-0024OC
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Borensztajn K, 2008, TRENDS MOL MED, V14, P429, DOI 10.1016/j.molmed.2008.08.001
   Borissoff JI, 2011, NEW ENGL J MED, V364, P1746, DOI 10.1056/NEJMra1011670
   Bukowska A, 2013, EUR J PHARMACOL, V718, P114, DOI 10.1016/j.ejphar.2013.09.006
   Camici GG, 2006, CIRCULATION, V114, P1512, DOI 10.1161/CIRCULATIONAHA.106.638460
   Czikora I, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00259
   Duan YL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-4
   Esmon CT, 2014, THROMB HAEMOSTASIS, V111, P625, DOI 10.1160/TH13-09-0730
   Fouassier M, 2009, THROMB RES, V124, P584, DOI 10.1016/j.thromres.2009.06.014
   Galley HF, 2000, CLIN SCI, V99, P405, DOI 10.1042/CS20000073
   Glas GJ, 2013, J THROMB HAEMOST, V11, P17, DOI 10.1111/jth.12047
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Hara T, 2015, ATHEROSCLEROSIS, V242, P639, DOI 10.1016/j.atherosclerosis.2015.03.023
   IDELL S, 1989, J CLIN INVEST, V84, P695, DOI 10.1172/JCI114217
   Komarova YA, 2017, CIRC RES, V120, P179, DOI 10.1161/CIRCRESAHA.116.306534
   Krupiczojc MA, 2008, INT J BIOCHEM CELL B, V40, P1228, DOI 10.1016/j.biocel.2008.02.026
   Lee W, 2015, AM J CHINESE MED, V43, P991, DOI 10.1142/S0192415X15500573
   Madoiwa S, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0075-6
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Oe Y, 2016, ARTERIOSCL THROM VAS, V36, P1525, DOI 10.1161/ATVBAHA.116.307883
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Osuga Yutaka, 2012, Front Biosci (Schol Ed), V4, P1201
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Rohde G, 2008, J CHROMATOGR B, V872, P43, DOI 10.1016/j.jchromb.2008.07.015
   Rothmeier AS, 2012, SEMIN IMMUNOPATHOL, V34, P133, DOI 10.1007/s00281-011-0289-1
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Russell JA, 2003, CRIT CARE MED, V31, pS243, DOI 10.1097/01.CCM.0000057870.61079.3E
   Schwientek P, 2010, PHYSIOL GENOMICS, V42, P397, DOI 10.1152/physiolgenomics.00030.2010
   Scotton CJ, 2009, J CLIN INVEST, V119, P2550, DOI 10.1172/JCI33288
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   Sparkenbaugh EM, 2014, BLOOD, V123, P1747, DOI 10.1182/blood-2013-08-523936
   Su X, 2009, ANAT REC, V292, P580, DOI 10.1002/ar.20846
   Zhang R, 2017, J CELL BIOCHEM, V118, P4587, DOI 10.1002/jcb.26123
NR 39
TC 9
Z9 9
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 8
BP 2335
EP 2349
PG 15
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GS5QU
UT WOS:000443724100009
PM 30210674
DA 2023-08-21
ER

PT J
AU Sieve, I
   Munster-Kuhnel, AK
   Hilfiker-Kleiner, D
AF Sieve, Irina
   Muenster-Kuehnel, Anja K.
   Hilfiker-Kleiner, Denise
TI Regulation and function of endothelial glycocalyx layer in vascular
   diseases
SO VASCULAR PHARMACOLOGY
LA English
DT Review
DE endothelial glycocalyx (EG); ECs/HPMECs/HUVECs/MPVECs; vascular disease; Inflammation 
ID N-ACETYLNEURAMINIC ACID; NECROSIS-FACTOR-ALPHA; REACTIVE OXYGEN; MATRIX
   METALLOPROTEINASES; IN-VIVO; EXTRACELLULAR-MATRIX; XANTHINE-OXIDASE;
   SIALIC ACIDS; NEUTROPHIL ADHESION; SURFACE-LAYER
AB In the vascular system, the endothelial surface layer (ESL) as the inner surface of blood vessels affects mechanotransduction, vascular permeability, rheology, thrombogenesis, and leukocyte adhesion. It creates barriers between endothelial cells and blood and neighbouring cells. The glycocalyx, composed of glycoconjugates and proteoglycans, is an integral component of the ESL and a key element in inter- and intracellular communication and tissue homeostasis. In pathophysiological conditions (atherosclerosis, infection, ischemia/reperfusion injury, diabetes, trauma and acute lung injury) glycocalyx-degrading factors, i.e. reactive oxygen and nitrogen species, matrix metalloproteinases, heparanase and sialidases, damage the ESL, thereby impairing endothelial functions. This leads to increased capillary permeability, leucocyte-endothelium interactions, thrombosis and vascular inflammation, the latter further driving glycocalyx destruction. The present review highlights current knowledge on the vasculoprotective role of the ESL, with specific emphasis on its remodelling in inflammatory vascular diseases and discusses its potential as a novel therapeutic target to treat vascular pathologies.
C1 [Sieve, Irina; Hilfiker-Kleiner, Denise] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
C1 [Muenster-Kuehnel, Anja K.] Hannover Med Sch, Inst Clin Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.
C3 Hannover Medical School; Hannover Medical School
RP Hilfiker-Kleiner, D (corresponding author), Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM hilfiker.denise@mh-hannover.de
FU Deutsche Forschungsgesellschaft (DFG) [1849/2-1]
FX We thank Nina McGuinness for proof reading. We also thank the Deutsche
   Forschungsgesellschaft (DFG, excellence cluster Rebirth H and MU
   1849/2-1).
CR Achour A, 2005, J NEPHROL, V18, P568
   Augustin HG, 2017, SCIENCE, V357, DOI 10.1126/science.aal2379
   Baumann AMT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8673
   Becker BF, 2011, NUCLEOS NUCLEOT NUCL, V30, P1161, DOI 10.1080/15257770.2011.605089
   Becker BF, 2010, CARDIOVASC RES, V87, P300, DOI 10.1093/cvr/cvq137
   Bertram A, 2015, J AM SOC NEPHROL, V26, P2860, DOI 10.1681/ASN.2014050477
   Betteridge KB, 2017, J PHYSIOL-LONDON, V595, P5015, DOI 10.1113/JP274167
   Broekhuizen LN, 2010, DIABETOLOGIA, V53, P2646, DOI 10.1007/s00125-010-1910-x
   Brown DI, 2015, CIRC RES, V116, P531, DOI 10.1161/CIRCRESAHA.116.303584
   Bruegger D, 2011, BASIC RES CARDIOL, V106, P1111, DOI 10.1007/s00395-011-0203-y
   Burke-Gaffney A, 2012, CRIT CARE, V16, DOI 10.1186/cc11239
   Cancel LM, 2016, ATHEROSCLEROSIS, V252, P136, DOI 10.1016/j.atherosclerosis.2016.07.930
   Castro MA, 2008, ATHEROSCLEROSIS, V198, P320, DOI 10.1016/j.atherosclerosis.2007.10.011
   Chappell D, 2010, SHOCK, V34, P133, DOI 10.1097/SHK.0b013e3181cdc363
   Chappell D, 2009, CARDIOVASC RES, V83, P388, DOI 10.1093/cvr/cvp097
   Chen C, 2016, HYPOXIA, V4, P81, DOI 10.2147/HP.S98660
   Chen GP, 2004, BIOCHEMISTRY-US, V43, P4971, DOI 10.1021/bi0356552
   Chen QS, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/928315
   Chen S, 2017, J HISTOCHEM CYTOCHEM, V65, P241, DOI 10.1369/0022155417692536
   Chen YF, 2017, PROG MOL BIOL TRANSL, V147, P267, DOI 10.1016/bs.pmbts.2017.02.003
   Chignalia AZ, 2016, SHOCK, V45, P338, DOI 10.1097/SHK.0000000000000513
   Cioffi DL, 2012, AM J PHYSIOL-LUNG C, V302, pL1067, DOI 10.1152/ajplung.00190.2011
   Coccheri S, 2014, INT ANGIOL, V33, P263
   Cochain C, 2017, PFLUG ARCH EUR J PHY, V469, P485, DOI 10.1007/s00424-017-1941-y
   Cohen M, 2010, OMICS, V14, P455, DOI 10.1089/omi.2009.0148
   Craige SM, 2015, CIRC J, V79, P1145, DOI 10.1253/circj.CJ-15-0464
   Cui N, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/912726
   Curry FE, 2017, CARDIOVASC RES, V113, P559, DOI 10.1093/cvr/cvx044
   Curry FRE, 2005, MICROCIRCULATION, V12, P17, DOI 10.1080/10739680590894993
   DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342
   Neves FMD, 2015, CIRC J, V79, P1511, DOI 10.1253/circj.CJ-14-1195
   Deem TL, 2004, BLOOD, V104, P2385, DOI 10.1182/blood-2004-02-0665
   Dimitrievska S, 2016, ARTERIOSCL THROM VAS, V36, P1847, DOI 10.1161/ATVBAHA.116.308023
   Eberhardt RT, 2005, CIRCULATION, V111, P2398, DOI 10.1161/01.CIR.0000164199.72440.08
   Ebong EE, 2011, ARTERIOSCL THROM VAS, V31, P1908, DOI 10.1161/ATVBAHA.111.225268
   Edovitsky E, 2006, BLOOD, V107, P3609, DOI 10.1182/blood-2005-08-3301
   Eguchi H, 2005, GLYCOBIOLOGY, V15, P1094, DOI 10.1093/glycob/cwj003
   Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0
   Esko JD., 2009, ESSENTIALS GLYCOBIOL, V2
   Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5
   Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x
   FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779
   Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200
   GOROG P, 1985, J PATHOL, V146, P205, DOI 10.1002/path.1711460307
   Gronski TJ, 1997, J BIOL CHEM, V272, P12189, DOI 10.1074/jbc.272.18.12189
   Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C
   Harada LM, 1998, ATHEROSCLEROSIS, V139, P65, DOI 10.1016/S0021-9150(98)00057-4
   Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3
   Henry CBS, 1999, AM J PHYSIOL-HEART C, V277, pH508, DOI 10.1152/ajpheart.1999.277.2.H508
   Henry CBS, 2000, AM J PHYSIOL-HEART C, V279, pH2815, DOI 10.1152/ajpheart.2000.279.6.H2815
   Hobeika MJ, 2007, J VASC SURG, V45, P849, DOI 10.1016/j.jvs.2006.09.066
   Hsia K, 2017, ACTA BIOMATER, V51, P341, DOI 10.1016/j.actbio.2017.01.050
   Iijima R, 2004, FEBS LETT, V561, P163, DOI 10.1016/S0014-5793(04)00164-4
   Jacob M, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0347-z
   Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d
   Docampo MJ, 2017, VET IMMUNOL IMMUNOP, V184, P8, DOI 10.1016/j.vetimm.2016.12.008
   Kolarova H, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/694312
   Kramer A, 2006, J AM SOC NEPHROL, V17, P2513, DOI 10.1681/ASN.2006020184
   Kucur M, 2009, BRATISL MED J, V110, P21
   Kumagai R, 2009, FREE RADICAL BIO MED, V47, P600, DOI 10.1016/j.freeradbiomed.2009.05.034
   Kurzelewski M, 2005, J PHYSIOL PHARMACOL, V56, P163
   Landmesser U, 2007, ARTERIOSCL THROM VAS, V27, P943, DOI 10.1161/01.ATV.0000258415.32883.bf
   Larsen AM, 2013, LEUKEMIA RES, V37, P777, DOI 10.1016/j.leukres.2013.02.015
   Lennon FE, 2011, AM J CARDIOVASC DIS, V1, P200
   Leung WKC, 2016, LIFE SCI, V166, P121, DOI 10.1016/j.lfs.2016.10.015
   Lukasz A, 2017, CARDIOVASC RES, V113, P671, DOI 10.1093/cvr/cvx023
   Majerczak J, 2017, EXP PHYSIOL, V102, P70, DOI 10.1113/EP085887
   Mannello F, 2011, AM J TRANSL RES, V3, P149
   Marechal X, 2008, SHOCK, V29, P572, DOI 10.1097/SHK.0b013e318157e926
   McDonald KK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167576
   Meirovitz A, 2013, FEBS J, V280, P2307, DOI 10.1111/febs.12184
   Mel'nichenko AA, 2005, B EXP BIOL MED+, V140, P51, DOI 10.1007/s10517-005-0409-9
   Meng FY, 2015, AM J RESP CELL MOL, V52, P152, DOI 10.1165/rcmb.2013-0468OC
   Miyagi T, 2012, GLYCOBIOLOGY, V22, P880, DOI 10.1093/glycob/cws057
   Miyoshi T, 2006, LIFE SCI, V79, P525, DOI 10.1016/j.lfs.2006.01.043
   Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200
   Moseley R, 1997, BBA-MOL BASIS DIS, V1362, P221, DOI 10.1016/S0925-4439(97)00083-5
   Mulivor AW, 2009, MICROCIRCULATION, V16, P657, DOI 10.3109/10739680903133714
   Mulivor AW, 2002, AM J PHYSIOL-HEART C, V283, pH1282, DOI 10.1152/ajpheart.00117.2002
   Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Nelson A, 2014, ACTA ANAESTH SCAND, V58, P36, DOI 10.1111/aas.12223
   Nieuwdorp A, 2009, ATHEROSCLEROSIS, V202, P296, DOI 10.1016/j.atherosclerosis.2008.03.024
   Nieuwdorp M, 2006, DIABETES, V55, P480, DOI 10.2337/diabetes.55.02.06.db05-1103
   Nishino T, 2008, FEBS J, V275, P3278, DOI 10.1111/j.1742-4658.2008.06489.x
   OREKHOV AN, 1992, J LIPID RES, V33, P805
   Pesonen E, 2016, ACTA ANAESTH SCAND, V60, P1386, DOI 10.1111/aas.12785
   Pesta D, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0867-2
   Potter DR, 2009, CIRC RES, V104, P1318, DOI 10.1161/CIRCRESAHA.108.191585
   Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307
   Pries AR, 1997, AM J PHYSIOL-HEART C, V273, pH2272, DOI 10.1152/ajpheart.1997.273.5.H2272
   Pshezhetsky AV, 2013, BIOCHEMISTRY-MOSCOW+, V78, P736, DOI 10.1134/S0006297913070067
   Puerta-Guardo H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005738
   Raffetto JD, 2014, INT ANGIOL, V33, P212
   Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076
   Ramnath R, 2014, FASEB J, V28, P4686, DOI 10.1096/fj.14-252221
   Rao G, 2011, DIABETOLOGIA, V54, P1527, DOI 10.1007/s00125-011-2110-z
   Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852
   Riessen R, 1996, CIRCULATION, V93, P1141, DOI 10.1161/01.CIR.93.6.1141
   Rubio-Gayosso I, 2006, AM J PHYSIOL-HEART C, V290, pH2247, DOI 10.1152/ajpheart.00796.2005
   Safrankova B, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/380948
   Sakarya S, 2004, GLYCOBIOLOGY, V14, P481, DOI 10.1093/glycob/cwh065
   Schauer R, 2009, CURR OPIN STRUC BIOL, V19, P507, DOI 10.1016/j.sbi.2009.06.003
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Schott U, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0239-y
   Shirazi LF, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0660-3
   Singleton PA, 2007, J BIOL CHEM, V282, P30643, DOI 10.1074/jbc.M702573200
   Smith ML, 2003, BIOPHYS J, V85, P637, DOI 10.1016/S0006-3495(03)74507-X
   Soltes L, 2006, BIOMACROMOLECULES, V7, P659, DOI 10.1021/bm050867v
   Song JW, 2017, J PHARMACOL EXP THER, V361, P115, DOI 10.1124/jpet.116.239509
   Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66
   Stevens AP, 2007, AM J PHYSIOL-LUNG C, V293, pL328, DOI 10.1152/ajplung.00390.2006
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9
   Szymczak M, 2010, ARCH IMMUNOL THER EX, V58, P45, DOI 10.1007/s00005-009-0061-6
   Tarbell JM, 2016, J INTERN MED, V280, P97, DOI 10.1111/joim.12465
   Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x
   Thurston G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006650
   UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753
   Ushiyama A, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0182-z
   van Golen RF, 2014, ANTIOXID REDOX SIGN, V21, P1098, DOI 10.1089/ars.2013.5751
   van Haare J, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0525-7
   VanTeeffelen JW, 2007, TRENDS CARDIOVAS MED, V17, P101, DOI 10.1016/j.tcm.2007.02.002
   Varga ZV, 2015, BBA-MOL BASIS DIS, V1852, P232, DOI 10.1016/j.bbadis.2014.06.030
   Varki A, 2012, ANN NY ACAD SCI, V1253, P16, DOI 10.1111/j.1749-6632.2012.06517.x
   Varki A, 2011, GLYCOBIOLOGY, V21, P1121, DOI 10.1093/glycob/cwr087
   Vendrov AE, 2007, ARTERIOSCL THROM VAS, V27, P2714, DOI 10.1161/ATVBAHA.107.152629
   Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285, DOI 10.1152/ajpheart.2000.278.1.H285
   Viola M, 2016, CURR MED CHEM, V23, P2958, DOI 10.2174/0929867323666160607104602
   Vlahu CA, 2012, J AM SOC NEPHROL, V23, P1900, DOI 10.1681/ASN.2011121181
   Wang LP, 2016, BIOCHEM BIOPH RES CO, V478, P669, DOI 10.1016/j.bbrc.2016.08.005
   Wang Y, 2016, PHARMACOL THERAPEUT, V158, P91, DOI 10.1016/j.pharmthera.2015.12.005
   Weber K. S., 2004, INFLAMMATION, V28
   Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959
   Weiss R, 2007, DRUGS, V67, P2681, DOI 10.2165/00003495-200767180-00004
   White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745
   Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391
   Yamawaki H, 2009, GLYCOBIOLOGY, V19, P83, DOI 10.1093/glycob/cwn109
   Yang Y, 2014, BBA-GEN SUBJECTS, V1840, P288, DOI 10.1016/j.bbagen.2013.09.031
   Yen WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117133
   Yoon JH, 2017, J VASC RES, V54, P59, DOI 10.1159/000457799
   Zeng Y, 2014, AM J PHYSIOL-HEART C, V306, pH363, DOI 10.1152/ajpheart.00687.2013
NR 142
TC 103
Z9 110
U1 1
U2 61
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1537-1891
EI 1879-3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD JAN
PY 2018
VL 100
BP 26
EP 33
DI 10.1016/j.vph.2017.09.002
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FT6HZ
UT WOS:000423256400003
PM 28919014
DA 2023-08-21
ER

PT J
AU Zhang, D
   Zhou, J
   Ye, LC
   Li, J
   Wu, ZZ
   Li, YP
   Li, CC
AF Zhang, Dan
   Zhou, Jian
   Ye, Le Chi
   Li, Jing
   Wu, Zhenzhou
   Li, Yuping
   Li, Chichi
TI Autophagy maintains the integrity of endothelial barrier in LPS-induced
   lung injury
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; autophagy; LPS; microvascular barrier 
ID RESPIRATORY-DISTRESS-SYNDROME; LIPOPOLYSACCHARIDE; PROTECTS;
   PERMEABILITY; ACTIVATION; APOPTOSIS; LIVER; MODEL
AB Understanding the role and underlying regulation mechanism of autophagy in lipopolysaccharide-induced lung injury (LPS-LI) may provide potentially new pharmacological targets for treatment of acute lung injury. The aim of this study was to investigate the functional significance of autophagy in LPS-LI. The autophagy of human pulmonary microvascular endothelial cells (HPMVECs) and mice was inhibited before they were challenged with LPS. In vitro, permeability, vitality, and the LDH release rate of the cells were detected, the zonula occluden-1 (ZO-1) expression and the stress fiber formation were determined. In vivo, the lung injury was assessed. We found LPS caused high permeability and increased lactate dehydrogenase (LDH) release rate, lowered viability of the cells, inhibited the ZO-1 expression and induced stress fiber formation, these effects were further aggravated by prohibiting the level of autophagy. Consistently, in in vivo experiments, LPS-induced serious lung injury, which was reflected as edema, leukocyte infiltration and hemorrhage in lung tissue, and the high concentration of pro-inflammation cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta in bronchoalveolar lavage fluid (BALF). Inhibiting autophagy further exacerbated LPS-LI. It appears that autophagy played a protective role in LPS-LI in part through restricting the injury of lung microvascular barrier.
C1 [Zhang, Dan; Wu, Zhenzhou; Li, Yuping] Wenzhou Med Univ, Affiliated Hosp 1, Dept Resp Med, Wenzhou City 325000, Zhejiang, China.
C1 [Zhou, Jian; Li, Jing] Fudan Univ, Dept Resp Med, Zhongshan Hosp, Shanghai, China.
C1 [Ye, Le Chi] Wenzhou Med Univ, Affiliated Hosp 1, Dept Surg Oncol, Wenzhou City, Zhejiang, China.
C1 [Li, Chichi] Wenzhou Med Univ, Dept Plast Surg, Affiliated Hosp 1, Wenzhou City 325000, Zhejiang, China.
C3 Wenzhou Medical University; Fudan University; Wenzhou Medical
   University; Wenzhou Medical University
RP Li, YP (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Resp Med, Wenzhou City 325000, Zhejiang, Peoples R China.; Li, CC (corresponding author), Wenzhou Med Univ, Dept Plast Surg, Affiliated Hosp 1, Wenzhou City 325000, Zhejiang, Peoples R China.
EM wzliyp@163.com; 2003130823@163.com
RI WU, ZHEN/GRN-7688-2022; wang, jing/GVT-8700-2022
OI WU, ZHEN/0000-0001-8719-057X; 
FU Zhejiang Natural Science Foundation [LQ16H010002]; science and
   technology planning project of Wenzhou [Y20160221]
FX Zhejiang Natural Science Foundation, Grant number: LQ16H010002; The
   science and technology planning project of Wenzhou, Grant number:
   Y20160221
CR Aguirre A, 2014, J MOL MED, V92, P665, DOI 10.1007/s00109-014-1132-7
   Amir M, 2013, CELL DEATH DIFFER, V20, P878, DOI 10.1038/cdd.2013.21
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Chignard M, 2000, AM J PHYSIOL-LUNG C, V279, pL1083, DOI 10.1152/ajplung.2000.279.6.L1083
   Committee for the Update of the Guide for the Care and Use of Laboratory Animals Institute for Laboratory Animal Research. Division on Earth and Life Studies National Research Council, 2011, DIV EARTH LIF STUD
   Gabrys D, 2007, INT J RADIAT ONCOL, V69, P1553, DOI 10.1016/j.ijrobp.2007.08.039
   Gao M, 2013, MED SCI MONITOR, V19, P1173, DOI 10.12659/MSM.889746
   Giannone PJ, 2009, J PEDIATR GASTR NUTR, V48, P276, DOI 10.1097/MPG.0b013e31818936b8
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Hickson-Bick DLM, 2008, J MOL CELL CARDIOL, V44, P411, DOI 10.1016/j.yjmcc.2007.10.013
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kang P, 2015, EUR J NUTR, V54, P581, DOI 10.1007/s00394-014-0739-3
   Kim K, 2014, ADV MECH ENG, DOI 10.1155/2014/124037
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Li HY, 2014, TRANSL STROKE RES, V5, P618, DOI 10.1007/s12975-014-0354-x
   Li S, 2011, AM J PATHOL, V179, P2822, DOI 10.1016/j.ajpath.2011.08.013
   Ling HB, 2016, INFLAMMATION, V39, P347, DOI 10.1007/s10753-015-0255-5
   Lv QY, 2016, EXP CELL RES, V341, P132, DOI 10.1016/j.yexcr.2016.02.009
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Qiu XC, 2011, INT IMMUNOPHARMACOL, V11, P2130, DOI 10.1016/j.intimp.2011.09.007
   Ryter Stefan W, 2010, Expert Rev Respir Med, V4, P573, DOI 10.1586/ers.10.61
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Smith KM, 1997, CRIT CARE MED, V25, P1888, DOI 10.1097/00003246-199711000-00030
   Su G, 2007, AM J RESP CELL MOL, V36, P377, DOI 10.1165/rcmb.2006-0238OC
   Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140
   Wu F, 2014, AM J PHYSIOL-LUNG C, V307, pL987, DOI 10.1152/ajplung.00063.2014
   Wu Y, 2015, INT J MED SCI, V12, P655, DOI 10.7150/ijms.12460
   Yuan KF, 2012, J CELL SCI, V125, P507, DOI 10.1242/jcs.094573
   Zhang D, 2015, J HEART LUNG TRANSPL, V34, P746, DOI 10.1016/j.healun.2014.12.008
   Zou XJ, 2014, EXP PHYSIOL, V99, P1348, DOI 10.1113/expphysiol.2014.079012
NR 31
TC 56
Z9 66
U1 0
U2 48
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2018
VL 233
IS 1
BP 688
EP 698
DI 10.1002/jcp.25928
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FI3BF
UT WOS:000411829600059
PM 28328069
DA 2023-08-21
ER

PT J
AU Zhang, GH
   Zhang, X
   Huang, HD
   Ji, YX
   Li, DF
   Jiang, WL
AF Zhang, Guanghua
   Zhang, Xue
   Huang, Haidi
   Ji, Yunxia
   Li, Defang
   Jiang, Wanglin
TI Saquinavir plus methylprednisolone ameliorates experimental acute lung
   injury
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Saquinavir; ALI/ARDS; Two-hit; HMGB1; TLR/TLR2/TLR4 
ID RESPIRATORY-DISTRESS-SYNDROME; GROUP BOX 1; ALVEOLAR MACROPHAGES;
   UP-REGULATION; MOUSE MODEL; INFLAMMATION; HMGB1; MECHANISMS; EXPRESSION;
   PROTEIN
AB Glucocorticoid insensitivity is an important barrier to the treatment of several inflammatory diseases, including acute lung injury (ALI). Saquinavir (SQV) is an inhibitor of the human immunodeficiency virus protease, and the therapeutic effects of SQV in ALI accompanied with glucocorticoid insensitivity have not been previously investigated. In this study, the effects of SQV on lipopolysaccharide (LPS)-mediated injury in human pulmonary microvascular endothelial cells (HPMECs), human type I alveolar epithelial cells (AT I), and alveolar macrophages were determined. In addition, the effects of SQV on an LPS-induced ALI model with or without methylprednisolone (MPS) were studied. In LPS-stimulated HPMECs, SQV treatment resulted in a decrease of high mobility group box 1 (HMGB1), phospho-NF-kappa B (p-NF-kappa B), and toll-like receptor 4 (TLR4), and an increase of VE-cadherin. Compared to MPS alone, MPS plus SQV attenuated the decrease of glucocorticoid receptor alpha (GRa) and IkBa in LPS-stimulated HPMECs. HMGB1, TLR4, and p-NF-kappa B expression were also lessened in LPS-stimulated alveolar macrophages with SQV treatment. In addition, SQV reduced the injury in human AT I with a decrease of HMGB1 and p-NF-kappa B, and with an increase of aquaporin 5 (AQP 5). SQV ameliorated the lung injury caused by LPS in rats with reductions in vascular permeability, myeloperoxidase activity (MPO) and histopathological scores, and with lowered HMGB1, TLR4, and p-NF-kappa B expression, but with enhanced VE-cadherin expression. By comparison, SQV plus MPS increased GRa and I kappa B alpha in lung tissues of rats with ALI. This study demonstrated that SQV prevented experimental ALI and improved glucocorticoid insensitivity by modulating the HMGB1/TLR4 pathway.
C1 [Zhang, Guanghua; Zhang, Xue; Huang, Haidi; Ji, Yunxia; Li, Defang; Jiang, Wanglin] Binzhou Med Univ, Sch Pharm, Yantai, China.
C3 Binzhou Medical University
RP Jiang, WL (corresponding author), Binzhou Med Univ, Sch Pharm, Yantai, Peoples R China.
EM jwl518@163.com
OI Li, Defang/0000-0003-4151-9151
FU Dominant Disciplines' Talent Team Development Scheme of Higher Education
   of Shandong Province; National Natural Science Foundation of China
   [31270391]
FX The study was supported by the Dominant Disciplines' Talent Team
   Development Scheme of Higher Education of Shandong Province and the
   National Natural Science Foundation of China (grant No. 31270391). The
   datasets used and/or analyzed during the current study are available
   from the corresponding author on request.
CR Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Altmann C, 2012, AM J PHYSIOL-RENAL, V302, pF421, DOI 10.1152/ajprenal.00559.2010
   Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Beck-Schimmer B, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-61
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Benevolo G, 2011, CANCER-AM CANCER SOC, V117, P1884, DOI 10.1002/cncr.25743
   Cornet AD, 2009, EXPERT OPIN DRUG DIS, V4, P219, DOI 10.1517/17460440902721204
   Entezari M, 2014, REDOX BIOL, V2, P314, DOI 10.1016/j.redox.2014.01.013
   Equils O, 2004, ANTIMICROB AGENTS CH, V48, P3905, DOI 10.1128/AAC.48.10.3905-3911.2004
   Fanelli V, 2013, J THORAC DIS, V5, P326, DOI 10.3978/j.issn.2072-1439.2013.04.05
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222
   Hidaka S, 2011, J SURG RES, V165, P142, DOI 10.1016/j.jss.2009.05.039
   Ji YX, 2018, SHOCK, V49, P196, DOI 10.1097/SHK.0000000000000911
   Jiao GY, 2002, CHINESE MED J-PEKING, V115, P963
   Keenan CR, 2012, DRUG DISCOV TODAY, V17, P1031, DOI 10.1016/j.drudis.2012.05.011
   Kudo D, 2013, CLIN EXP IMMUNOL, V173, P276, DOI 10.1111/cei.12106
   Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Marik PE, 2011, CRIT CARE CLIN, V27, P589, DOI 10.1016/j.ccc.2011.05.007
   Matthay Michael A, 2013, Transl Respir Med, V1, P10, DOI 10.1186/2213-0802-1-10
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meduri GU, 2005, NEUROIMMUNOMODULAT, V12, P321, DOI 10.1159/000091126
   Meduri GU, 2004, ANN NY ACAD SCI, V1024, P24, DOI 10.1196/annals.1321.004
   Moine P, 2000, SHOCK, V13, P85, DOI 10.1097/00024382-200013020-00001
   Nakamura T, 2011, CLIN BIOCHEM, V44, P601, DOI 10.1016/j.clinbiochem.2010.12.014
   Porto BN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00311
   Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Trujillo E, 2004, HISTOL HISTOPATHOL, V19, P435, DOI 10.14670/HH-19.435
   Tseng CC, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/804654
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   Villar J, 2014, CURR OPIN CRIT CARE, V20, P3, DOI 10.1097/MCC.0000000000000057
   Wang X, 2017, ACTA BIOCH BIOPH SIN, V49, P907, DOI 10.1093/abbs/gmx085
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wu XD, 2014, MOL MED REP, V10, P429, DOI 10.3892/mmr.2014.2208
   Zhou BY, 2007, AM J PHYSIOL-CELL PH, V292, pC1280, DOI 10.1152/ajpcell.00070.2006
NR 37
TC 11
Z9 12
U1 0
U2 5
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 2018
VL 51
IS 10
AR e7579
DI 10.1590/1414-431X20187579
PG 12
WC Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA GP4BP
UT WOS:000440801900001
PM 30088541
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Zhou, HS
   Li, M
   Sui, BD
   Wei, L
   Hou, R
   Chen, WS
   Li, Q
   Bi, SH
   Zhang, JZ
   Yi, DH
AF Zhou, Hua-Song
   Li, Meng
   Sui, Bing-Dong
   Wei, Lei
   Hou, Rui
   Chen, Wen-Sheng
   Li, Qiang
   Bi, Sheng-Hui
   Zhang, Jin-Zhou
   Yi, Ding-Hua
TI Lipopolysaccharide impairs permeability of pulmonary microvascular
   endothelial cells via Connexin40
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE LPS; endotoxin; ALI/ARDS; vascular; ECs/HPMECs/HUVECs/MPVECs; permeability; gap junctions; Connexin40; NF-kappa B; PKC pathway 
ID PROTEIN-KINASE-C; LIGHT-CHAIN KINASE; INTERCELLULAR COMMUNICATION;
   VASCULAR-PERMEABILITY; ACTIVATION; EXPRESSION; PATHWAY; INJURY;
   PHOSPHORYLATION; VASODILATION
AB The endotoxin lipopolysaccharide (LPS)-induced pulmonary endothelial barrier disruption is a key pathogenesis of acute lung injury (AU) and acute respiratory distress syndrome (ARDS). However, the molecular mechanisms underlying LPS-impaired permeability of pulmonary microvascular endothelial cells (PMVECs) are not fully understood. Gap junctions, particularly Connexin40 (Cx40), are necessary for the maintenance of normal vascular function. In this study, we for the first time investigated the role of Cx40 in LPS-impaired permeability of PMVECs and provided potential therapeutic approaches based on mechanistic findings of Cx40 regulation by LPS stimuli. Rat PMVECs were isolated, cultured and identified with cell morphology, specific markers, ultra structural characteristics and functional tests. Western blot analysis demonstrated that Cx40 is the major connexin highly expressed in PMVECs. Furthermore, by inhibiting Cx40 in a time-dependent manner, LPS impaired gap junction function and induced permeability injury of PMVECs. The key role of Cx40 decline in mediating detrimental effects of LPS was further confirmed in rescue experiments through Cx40 overexpression. Mechanistically, LPS stress on PMVECs inhibited the protein kinase C (PKC) pathway, which may synergize with the inflammatory nuclear factor kappaB (NF kappa B) signaling activation in suppressing Cx40 expression level and phosphorylation. Moreover, through pharmacological PKC activation or NF kappa B inhibition, Cx40 activity in PMVECs could be restored, leading to maintained barrier function under LPS stress. Our findings uncover a previously unrecognized role of Cx40 and its regulatory mechanisms in impaired endothelial integrity under endotoxin and inflammation, shedding light on intervention approaches to improve pulmonary endothelial barrier function in ALI and ARDS.
C1 [Zhou, Hua-Song; Chen, Wen-Sheng; Li, Qiang; Bi, Sheng-Hui; Zhang, Jin-Zhou; Yi, Ding-Hua] Fourth Mil Med Univ, Xijing Hosp, Dept Cardiovasc Surg, 15 West Changle Rd, Xian 710032, Shaanxi, China.
C1 [Li, Meng; Sui, Bing-Dong; Hou, Rui] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, China.
C1 [Sui, Bing-Dong] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104, United States.
C1 [Wei, Lei] Xian Satellite Control Ctr Clin, Xian 710043, Shaanxi, China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; University of Pennsylvania
RP Zhang, JZ; Yi, DH (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Cardiovasc Surg, 15 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM 1025765702@qq.com; louis1946@163.com
RI Sui, Bingdong/HKN-5071-2023; meng, li/HTQ-7341-2023; meng,
   li/GVT-2063-2022
OI Sui, Bingdong/0000-0002-7282-0935
FU Natural Science Basic Research Program in Shaanxi Province of China
   [2016JM8141]; State Scholarship Fund of China [201603170205]
FX This work was supported by The Natural Science Basic Research Program in
   Shaanxi Province of China (2016JM8141) and The State Scholarship Fund of
   China (201603170205).
CR Antonov A, 2008, AM J RESP CELL MOL, V39, P551, DOI 10.1165/rcmb.2007-0324OC
   Aoki M, 2004, STEM CELLS, V22, P994, DOI 10.1634/stemcells.22-6-994
   Barabutis N, 2015, AM J PHYSIOL-LUNG C, V308, pL776, DOI 10.1152/ajplung.00334.2014
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Bolon ML, 2007, J CELL PHYSIOL, V211, P159, DOI 10.1002/jcp.20928
   Bolon ML, 2005, FASEB J, V19, P1725, DOI 10.1096/fj.04-3446fje
   Bosmann M, 2014, EXPERT OPIN THER TAR, V18, P703, DOI 10.1517/14728222.2014.902938
   Brisset AC, 2009, ANTIOXID REDOX SIGN, V11, P267, DOI 10.1089/ars.2008.2115
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71
   Chen N, 2016, J DENT RES, V95, P1425, DOI 10.1177/0022034516657043
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   De Francesco EM, 2014, CANCER RES, V74, P4053, DOI 10.1158/0008-5472.CAN-13-3590
   de Wit C, 2003, PHYSIOL GENOMICS, V13, P169, DOI 10.1152/physiolgenomics.00169.2002
   de Wit C, 2000, CIRC RES, V86, P649, DOI 10.1161/01.RES.86.6.649
   Denis JF, 2017, ONCOTARGET, V8, P50972, DOI 10.18632/oncotarget.16438
   Dobkin-Bekman M, 2010, ENDOCRINOLOGY, V151, P4894, DOI 10.1210/en.2010-0114
   Figueroa XF, 2003, CIRC RES, V92, P793, DOI 10.1161/01.RES.0000065918.90271.9A
   Goel G, 2007, INT J TOXICOL, V26, P279, DOI 10.1080/10915810701464641
   Gong LY, 2017, ONCOL LETT, V13, P1242, DOI 10.3892/ol.2016.5545
   Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
   Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621
   Haefliger JA, 2004, CARDIOVASC RES, V62, P345, DOI 10.1016/j.cardiores.2003.11.015
   Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052
   Hempel A, 1999, CIRCULATION, V99, P2523, DOI 10.1161/01.CIR.99.19.2523
   Hu CY, 2017, SCI REP-UK, V7, DOI 10.1038/srep45582
   Hunter RW, 2009, J BIOL CHEM, V284, P12339, DOI 10.1074/jbc.M807536200
   Jacquemin M, 2006, BLOOD, V108, P515, DOI 10.1182/blood-2005-11-4571
   Jiang B, 2015, STEM CELLS DEV, V24, P2740, DOI 10.1089/scd.2015.0191
   Johnson TL, 2007, ENDOTHELIUM-J ENDOTH, V14, P215, DOI 10.1080/10623320701617233
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Kini V, 2010, J BIOL CHEM, V285, P33082, DOI 10.1074/jbc.M110.142034
   Kjenseth A, 2010, CELL SIGNAL, V22, P1267, DOI 10.1016/j.cellsig.2010.03.005
   Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112
   Kwon YW, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43057
   Laird DW, 2010, TRENDS CELL BIOL, V20, P92, DOI 10.1016/j.tcb.2009.11.001
   Leithe E, 2016, BBA-REV CANCER, V1865, P133, DOI 10.1016/j.bbcan.2016.02.001
   Leng Yu-Xin, 2014, World J Crit Care Med, V3, P34, DOI 10.5492/wjccm.v3.i1.34
   Li CH, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt456
   Liu AG, 2012, J BIOL CHEM, V287, P16132, DOI 10.1074/jbc.M111.310102
   Liu H, 2015, INT IMMUNOPHARMACOL, V29, P937, DOI 10.1016/j.intimp.2015.10.010
   Mambetsariev I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092670
   Masaki T, 2011, MOL BIOL CELL, V22, P2144, DOI 10.1091/mbc.E10-11-0875
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mazzotta C, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1233-0
   Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871
   Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626
   Park KA, 2007, CARCINOGENESIS, V28, P71, DOI 10.1093/carcin/bgl094
   PATTERSON CE, 1992, J APPL PHYSIOL, V72, P865, DOI 10.1152/jappl.1992.72.3.865
   Peng GY, 2013, J VASC RES, V50, P468, DOI 10.1159/000355271
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615
   Rignault S, 2005, CRIT CARE MED, V33, P1302, DOI 10.1097/01.CCM.0000165968.47343.0D
   Rigor RR, 2013, MED RES REV, V33, P911, DOI 10.1002/med.21270
   Ringvold H C, 2017, Adv Pharmacol, V78, P203, DOI 10.1016/bs.apha.2016.06.002
   Sauer H, 2011, J CELL PHYSIOL, V226, P1642, DOI 10.1002/jcp.22495
   Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144
   Siddiqui MR, 2011, J CELL BIOL, V193, P841, DOI 10.1083/jcb.201012129
   Siddiqui M, 2015, J VASC RES, V52, P396, DOI 10.1159/000445772
   Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002
   Simon AM, 2004, J VASC RES, V41, P323, DOI 10.1159/000079614
   Simon AM, 2002, DEV BIOL, V251, P206, DOI 10.1006/dbio.2002.0826
   Solan J. L., 2017, BIOCH BIOPHYS ACTA
   Sui BD, 2017, THERANOSTICS, V7, P1225, DOI 10.7150/thno.18181
   Sui BD, 2016, SCI REP-UK, V6, DOI 10.1038/srep30186
   Sumagin R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055775
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200
   Tyml K, 2011, CAN J PHYSIOL PHARM, V89, P1, DOI 10.1139/y10-099
   vonDossow-Hanfst, 2012, ANESTHESIOL CLIN, V30, P629
   WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355
   Wang L, 2013, STEM CELLS, V31, P1383, DOI 10.1002/stem.1388
   Wang YX, 2013, J BIOL CHEM, V288, P12852, DOI 10.1074/jbc.M112.410357
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
   Zhao P., 2017, AGING CELL
NR 75
TC 20
Z9 21
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD JAN
PY 2018
VL 115
BP 58
EP 67
DI 10.1016/j.mvr.2017.08.008
PG 10
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA FN1YB
UT WOS:000415786000009
PM 28870649
DA 2023-08-21
ER

PT J
AU Zhou, WJ
   Shi, GC
   Bai, JJ
   Ma, SM
   Liu, QF
   Ma, XG
AF Zhou, Wenjie
   Shi, Guocui
   Bai, Jijia
   Ma, Shenmao
   Liu, Qinfu
   Ma, Xigang
TI Colquhounia Root Tablet Protects Rat Pulmonary Microvascular Endothelial
   Cells against TNF-alpha-Induced Injury by Upregulating the Expression of
   Tight Junction Proteins Claudin-5 and ZO-1
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID ACUTE LUNG INJURY; NF-KAPPA-B; TRIPTERYGIUM-HYPOGLAUCUM; PERMEABILITY;
   INHIBITION; TRIPTOLIDE; DYSFUNCTION; ACTIVATION; COMPLEX; NRF2
AB Background. There are currently limited effective pharmacotherapy agents for acute lung injury (ALI). Inflammatory response in the lungs is the main pathophysiological process of ALI. Our preliminary data have shown that colquhounia root tablet (CRT), a natural herbal medicine, alleviates the pulmonary inflammatory responses and edema in a rat model with oleic acid-induced ALI. However, the potential molecular action mechanisms underlining its protective effects against ALI are poorly understood. This study aimed to investigate the effects and mechanism of CRT in rat pulmonary microvascular endothelial cells (PMEC) with TNF-alpha-induced injury. Methods. PMECs were divided into 6 groups: normal control, TNF-alpha (10 ng/mL TNF-alpha), Dex (1x10(-6) M Dex + 10 ng/mL TNF-alpha), CRT high (1000 ng/mL CRT + 10 ng/mL TNF-alpha), CRT medium (500 ng/mL CRT + 10 ng/mL TNF-alpha), and CRT low group (250 ng/mL CRT + 10 ng/mL TNF-alpha). Cell proliferation and apoptosis were detected by MTT assay and flow cytometry. Cell micromorphology was observed under transmission electron microscope. The localization and expression of tight junction proteins Claudin-5 and ZO-1 were analyzed by immunofluorescence staining and Western blot, respectively. Results. TNF-a had successfully induced an acute endothelial cell injury model. Dex and CRT treatments had significantly stimulated the growth and reduced the apoptosis of PMECs (all p < 0.05 or 0.01) and alleviated the TNF-alpha-induced cell injury. The expression of Claudin-5 and ZO-1 in Dex and all 3 CRT groups was markedly increased compared with TNF-a group (all p < 0.05 or 0.01). Conclusion. CRT effectively protects PMECs from TNF-alpha-induced injury, which might be mediated via stabilizing the structure of tight junction. CRT might be a promising, effective, and safe therapeutic agent for the treatment of ALI.
C1 [Zhou, Wenjie; Bai, Jijia; Liu, Qinfu; Ma, Xigang] Ningxia Med Univ, Gen Hosp, Dept Crit Care Med, Yinchuan 750004, Ningxia, China.
C1 [Shi, Guocui] Cangzhou Peoples Hosp, Dept Resp Med, Cangzhou 061000, Hebei, China.
C1 [Ma, Shenmao] Ningxia Med Univ, Resident Standardized Training Base, Gen Hosp, Yinchuan 750004, Ningxia, China.
C3 Ningxia Medical University; Ningxia Medical University
RP Ma, XG (corresponding author), Ningxia Med Univ, Gen Hosp, Dept Crit Care Med, Yinchuan 750004, Ningxia, Peoples R China.
EM xigangma19560812@hotmail.com
FU Natural Science Foundation of Ningxia Hui Autonomous Region [NZ17151];
   National Natural Science Foundation of China [81260583]
FX This study was supported by the Natural Science Foundation of Ningxia
   Hui Autonomous Region (NZ17151) and the National Natural Science
   Foundation of China (81260583).
CR Al-Harbi NO, 2016, IMMUNOL INVEST, V45, P349, DOI 10.3109/08820139.2016.1157814
   Al-Sadi R, 2016, AM J PATHOL, V186, P1151, DOI 10.1016/j.ajpath.2015.12.016
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Basak C, 2005, J BIOL CHEM, V280, P4279, DOI 10.1074/jbc.M412820200
   Chen XY, 2017, INT IMMUNOPHARMACOL, V50, P270, DOI 10.1016/j.intimp.2017.07.001
   Geng P, 2018, HUM EXP TOXICOL, V37, P626, DOI 10.1177/0960327117721961
   Han R, 2012, BRIT J CLIN PHARMACO, V74, P424, DOI 10.1111/j.1365-2125.2012.04221.x
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004
   Hegeman MA, 2011, BRIT J PHARMACOL, V163, P1048, DOI 10.1111/j.1476-5381.2011.01314.x
   Herrero R, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.18
   Holopainen R, 2001, PEDIATR RES, V49, P162, DOI 10.1203/00006450-200102000-00006
   Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC
   Jia W, 2014, MOL MED REP, V9, P779, DOI 10.3892/mmr.2013.1875
   Koval M, 2013, ANNU REV PHYSIOL, V75, P551, DOI 10.1146/annurev-physiol-030212-183809
   Krug SM, 2014, SEMIN CELL DEV BIOL, V36, P166, DOI 10.1016/j.semcdb.2014.09.002
   Kubo Y, 2018, EXPERT OPIN DRUG MET, V14, P513, DOI 10.1080/17425255.2018.1472764
   Liu YZ, 2015, IMMUNOPHARM IMMUNOT, V37, P527, DOI 10.3109/08923973.2015.1107574
   Ma X. G., 2014, J NINGXIA MED U, V36, P248
   Macconi D, 2000, J AM SOC NEPHROL, V11, P477, DOI 10.1681/ASN.V113477
   Mazzon E, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-75
   Morrison M, 2014, ATHEROSCLEROSIS, V233, P149, DOI 10.1016/j.atherosclerosis.2013.12.027
   Oray M, 2016, EXPERT OPIN DRUG SAF, V15, P457, DOI 10.1517/14740338.2016.1140743
   Peng Anping, 2014, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V30, P635
   Reno TA, 2015, ANN THORAC SURG, V100, P1817, DOI 10.1016/j.athoracsur.2015.05.074
   Shao P, 2018, INT J CLIN EXP MED, V11, P6634
   Shay J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/181260
   Shen HT, 2017, LIFE SCI, V170, P25, DOI 10.1016/j.lfs.2016.11.021
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Tu GW, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1284-7
   Turnage RH, 2002, WORLD J SURG, V26, P848, DOI 10.1007/s00268-002-4063-3
   Wang HB, 2012, DIGEST DIS SCI, V57, P3126, DOI 10.1007/s10620-012-2259-4
   Wang LC, 2015, MICROVASC RES, V99, P102, DOI 10.1016/j.mvr.2015.03.007
   Wei D, 2014, INFLAMMATION, V37, P1307, DOI 10.1007/s10753-014-9858-5
   Wen SH, 2014, INT IMMUNOPHARMACOL, V23, P709, DOI 10.1016/j.intimp.2014.10.027
   Wu Xin-lin, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P30
   Yang L., 2018, MOL MED REPORTS
   Yang YQ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00999
   Zhang Y., 2008, PEOPLE MIL SURG, V51, P463
   Zhao P, 2014, BIOSCI BIOTECH BIOCH, V78, P370, DOI 10.1080/09168451.2014.890035
   Zheng He-zhong, 2012, Zhejiang Da Xue Xue Bao Yi Xue Ban, V41, P425
   Zhou Jian-hua, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P418
NR 42
TC 7
Z9 10
U1 2
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2018
VL 2018
AR 1024634
DI 10.1155/2018/1024634
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA HC5GW
UT WOS:000451832500001
PM 30581478
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Gu, W
   Yao, L
   Li, LX
   Zhang, JP
   Place, AT
   Minshall, RD
   Liu, GQ
AF Gu, Wei
   Yao, Lun
   Li, Lexing
   Zhang, Jianping
   Place, Aaron T.
   Minshall, Richard D.
   Liu, Guoquan
TI ICAM-1 regulates macrophage polarization by suppressing MCP-1 expression
   via miR-124 upregulation
SO ONCOTARGET
LA English
DT Article
DE ICAM-1; miR-124; transcript regulation; macrophage polarization; ALI/ARDS 
ID ENDOTHELIAL-CELLS; PROLIFERATION; INFLAMMATION; CARCINOMA; ADHESION;
   PATHWAY; VCAM-1
AB Intercellular adhesion molecule-1 is the adhesion molecule mediating leukocyte firm adhesion to endothelial cells, plays a critical role in subsequent leukocyte transmigration. ICAM-1 is also expressed in other cells including macrophages; however, the role of this adhesion molecule in mediating macrophage functions remains enigmatic. We report that ICAM-1 regulates macrophage polarization by positively modulating miR-124 expression. We found higher expression levels of monocyte chemotactic protein-1 in lungs of mice lacking ICAM-1. Consistent with this result, siRNA mediated depletion of ICAM-1 in macrophage resulted in increased expression levels of MCP-1. Moreover, ICAM-1 controlled miR-124 expression and downregulated MCP-1 mRNA and protein expression by binding of miR-124 to MCP-1 3' untranslated region. ICAM-1 also induced the transcription factor Sp1 expression, which is important for miR-124 expressing in macrophages. Furthermore, ICAM-1 depletion led to M1 macrophage polarization, in contrast, miR-124 mimics promoted M2 macrophage polarization. Exogenous administration of miR-124 mimics into the lungs prevented lipopolysaccharide-induced myeloperoxidase activity in vivo, suggesting that miR-124 is important for dampening acute lung injury. These results collectively show that adhesion molecule ICAM-1 downregulates MCP-1 expression by controlling Sp1 mediated miR-124 levels, which in turn regulate M2 macrophage polarization. Targeting ICAM-1 and downstream miR-124 may present a new therapeutic strategy for acute lung injury.
C1 [Gu, Wei; Yao, Lun; Li, Lexing; Zhang, Jianping; Liu, Guoquan] Huazhong Agr Univ, Dept Basic Vet Med, Coll Anim Sci & Vet Med, Wuhan 430070, Hubei, China.
C1 [Place, Aaron T.; Minshall, Richard D.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Minshall, Richard D.] Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612, United States.
C3 Huazhong Agricultural University; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Liu, GQ (corresponding author), Huazhong Agr Univ, Dept Basic Vet Med, Coll Anim Sci & Vet Med, Wuhan 430070, Hubei, Peoples R China.
EM liuguoquan@mail.hzau.edu.cn
RI Wei, Gu/AAL-9843-2021
OI Wei, Gu/0000-0002-4421-2326
FU National Natural Science Foundation of China (NSFC) [31372418]; Huazhong
   Agricultural University Scientific & Technology Self-innovation
   Foundation [2012RC011]; 948 Project of Chinese Ministry of Agriculture
   [2015-Z33]; NIH [RO1 HL71626, P01 HL60678]
FX The work is supported by National Natural Science Foundation of China
   (NSFC) (No. 31372418, GL.), Huazhong Agricultural University Scientific
   & Technology Self-innovation Foundation (program No. 2012RC011, G.L.),
   the 948 Project of Chinese Ministry of Agriculture (2015-Z33, GL). NIH
   grants RO1 HL71626 and P01 HL60678 (RM). We thank Dr. S. Reddy,
   University of Illinois at Chicago, for critical reading of the
   manuscript.
CR Ahluwalia PK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00107
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Huang C, 2016, INT IMMUNOPHARMACOL, V32, P46, DOI 10.1016/j.intimp.2016.01.009
   Hubbard AK, 2000, INFLAMMATION, V24, P115, DOI 10.1023/A:1007029409521
   Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075
   Lawson C, 1999, J IMMUNOL, V162, P2990
   Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0
   Li YY, 2014, MOL CELL BIOCHEM, V388, P219, DOI 10.1007/s11010-013-1913-2
   Liu G, 2011, FASEB J, V25
   Liu GQ, 2012, BLOOD, V120, P1942, DOI 10.1182/blood-2011-12-397430
   Liu J, 2015, AM J PHYSIOL-LUNG C, V309, pL226, DOI 10.1152/ajplung.00037.2015
   Madan B, 2004, BIOORGAN MED CHEM, V12, P1431, DOI 10.1016/j.bmc.2003.12.027
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Martinelli R, 2009, MOL BIOL CELL, V20, P995, DOI 10.1091/mbc.E08-06-0636
   McDonald B, 2010, IMMUNITY, V33, P148, DOI 10.1016/j.immuni.2010.08.006
   Mishima T, 2007, BRAIN RES, V1131, P37, DOI 10.1016/j.brainres.2006.11.035
   Mizgerd JP, 2001, J IMMUNOL, V166, P4042, DOI 10.4049/jimmunol.166.6.4042
   Moore LB, 2015, ACTA BIOMATER, V11, P37, DOI 10.1016/j.actbio.2014.09.022
   Nakamachi Y, 2009, ARTHRITIS RHEUM-US, V60, P1294, DOI 10.1002/art.24475
   Naqvi Afsar Raza, 2016, J Microb Biochem Technol, V8, P136
   Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266
   Rossmann MG, 2000, VIROLOGY, V269, P239, DOI 10.1006/viro.2000.0258
   Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821
   Singh RP, 2013, AUTOIMMUN REV, V12, P1160, DOI 10.1016/j.autrev.2013.07.003
   Sun Y, 2016, ACTA PHARMACOL SIN, V37, P889, DOI 10.1038/aps.2016.16
   Sun Y, 2013, CELL RES, V23, P1270, DOI 10.1038/cr.2013.116
   Tan YG, 2015, ONCOTARGET, V6, P17391, DOI 10.18632/oncotarget.3975
   Veremeyko T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081774
   Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107
   Wan HY, 2014, CANCER LETT, V355, P148, DOI 10.1016/j.canlet.2014.09.005
   Wang DR, 2014, CIRC RES, V114, P67, DOI 10.1161/CIRCRESAHA.114.301633
   Wei M, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160068
   Yang HL, 2015, FOOD FUNCT, V6, P230, DOI 10.1039/c4fo00869c
   Yang M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.144
   Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421
   Zhu T, 2016, INT IMMUNOPHARMACOL, V34, P16, DOI 10.1016/j.intimp.2016.02.014
   Zhuang G, 2012, CIRCULATION
NR 38
TC 39
Z9 40
U1 1
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 19
PY 2017
VL 8
IS 67
BP 111882
EP 111901
DI 10.18632/oncotarget.22948
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1VO
UT WOS:000419567000091
PM 29340098
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Meyer, NJ
   Reilly, JP
   Feng, R
   Christie, JD
   Hazen, SL
   Albert, CJ
   Franke, JD
   Hartman, CL
   McHowat, J
   Ford, DA
AF Meyer, Nuala J.
   Reilly, John P.
   Feng, Rui
   Christie, Jason D.
   Hazen, Stanley L.
   Albert, Carolyn J.
   Franke, Jacob D.
   Hartman, Celine L.
   McHowat, Jane
   Ford, David A.
TI Myeloperoxidase-derived 2-chlorofatty acids contribute to human sepsis
   mortality via acute respiratory distress syndrome
SO JCI INSIGHT
LA English
DT Article
ID ACUTE LUNG INJURY; CHLORINATED LIPIDS; CRITICALLY-ILL; NEUTROPHIL;
   IDENTIFICATION; TRAUMA; PLASMALOGENS; ACTIVATION; PREDICTION; TARGET
AB Sepsis-associated acute respiratory distress syndrome (ARDS) is characterized by neutrophilic inflammation and poor survival. Since neutrophil myeloperoxidase (MPO) activity leads to increased plasma 2-chlorofatty acid (2-ClFA) levels, we hypothesized that plasma concentrations of 2-ClFAs would associate with ARDS and mortality in subjects with sepsis. In sequential consenting patients with sepsis, free 2-ClFA levels were significantly associated with ARDS, and with 30-day mortality, for each log increase in free 2-chlorostearic acid. Plasma MPO was not associated with either ARDS or 30-day mortality but was correlated with 2-ClFA levels. Addition of plasma 2-ClFA levels to the APACHE III score improved prediction for ARDS. Plasma 2-ClFA levels correlated with plasma levels of angiopoietin-2, E selectin, and soluble thrombomodulin. Endothelial cells treated with 2-ClFA responded with increased adhesion molecule surface expression, increased angiopoietin-2 release, and dose-dependent endothelial permeability. Our results suggest that 2-ClFAs derived from neutrophil MPO-catalyzed oxidation contribute to pulmonary endothelial injury and have prognostic utility in sepsis-associated ARDS.
C1 [Meyer, Nuala J.; Reilly, John P.; Christie, Jason D.] Univ Penn, Perelman Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104, United States.
C1 [Meyer, Nuala J.; Reilly, John P.; Christie, Jason D.] Univ Penn, Perelman Sch Med, Ctr Translat Lung Biol, Philadelphia, PA 19104, United States.
C1 [Feng, Rui; Christie, Jason D.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104, United States.
C1 [Hazen, Stanley L.] Cleveland Clin, Ctr Microbiome & Human Hlth, Dept Cellular & Mol Med, Cleveland, OH 44106, United States.
C1 [Hazen, Stanley L.] Cleveland Clin, Inst Heart & Vasc, Dept Cardiovasc Med, Cleveland, OH 44106, United States.
C1 [Albert, Carolyn J.; Franke, Jacob D.; Hartman, Celine L.; Ford, David A.] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104, United States.
C1 [Albert, Carolyn J.; Franke, Jacob D.; Hartman, Celine L.; McHowat, Jane; Ford, David A.] St Louis Univ, Sch Med, Ctr Cardiovasc Res, St Louis, MO, United States.
C1 [McHowat, Jane] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104, United States.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; Cleveland Clinic Foundation; Cleveland Clinic
   Foundation; Saint Louis University; Saint Louis University; Saint Louis
   University
RP Ford, DA (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, Doisy Res Ctr, 1100 South Grand Ave, St Louis, MO 63104 USA.
EM fordda@slu.edu
RI Hazen, Stanley L/ABD-5845-2021
OI Young, Celine Hartman/0000-0002-6956-3966
FU NIH [R01GM115553, R01HL122474, P01HL076491]
FX This study was supported by NIH grants R01GM115553 (to DAF and JM),
   R01HL122474 (to NJM), and P01HL076491 (to SLH).
CR Adams JM, 2001, J TRAUMA, V51, P452, DOI 10.1097/00005373-200109000-00005
   Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200
   Anbukumar DS, 2010, J LIPID RES, V51, P1085, DOI 10.1194/jlr.M003673
   Anderson BJ, 2016, J CRIT CARE, V36, P18, DOI 10.1016/j.jcrc.2016.06.012
   [Anonymous], 2012, JAMA, DOI DOI 10.1001/JAMA.2012.5669
   Aziz M, 2013, J LEUKOCYTE BIOL, V93, P329, DOI 10.1189/jlb.0912437
   Beckett CS, 2007, THROMB RES, V120, P259, DOI 10.1016/j.thromres.2006.09.005
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Brahmbhatt VV, 2010, J BIOL CHEM, V285, P41255, DOI 10.1074/jbc.M110.147157
   Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008
   Brealey D, 2000, J ROY COLL PHYS LOND, V34, P428
   Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Cepinskas G, 2008, J CLIN BIOCHEM NUTR, V42, P175, DOI 10.3164/jcbn.2008026
   CHILTON FH, 1988, J BIOL CHEM, V263, P5260
   David S, 2012, CRIT CARE MED, V40, P3034, DOI 10.1097/CCM.0b013e31825fdc31
   DORMAN RV, 1977, BIOCHIM BIOPHYS ACTA, V486, P55, DOI 10.1016/0005-2760(77)90069-8
   Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC
   Fang WF, 2007, AM J PHYSIOL-LUNG C, V293, pL336, DOI 10.1152/ajplung.00011.2007
   FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479
   Ford DA, 2016, J LIPID RES, V57, P1529, DOI 10.1194/jlr.M069005
   Ford DA, 2010, CLIN LIPIDOL, V5, P835, DOI 10.2217/CLP.10.68
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298
   Graler MH, 2012, AM J CLIN EXP IMMUNO, V1, P90
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   HARRISON JE, 1976, J BIOL CHEM, V251, P1371
   HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487
   Hsu FF, 2003, J MASS SPECTROM, V38, P752, DOI 10.1002/jms.491
   Imai K, 2010, PSYCHOL METHODS, V15, P309, DOI 10.1037/a0020761
   Iwata K, 2010, INTERNAL MED, V49, P2423, DOI 10.2169/internalmedicine.49.4010
   Kangelaris KN, 2015, AM J PHYSIOL-LUNG C, V308, pL1102, DOI 10.1152/ajplung.00380.2014
   KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480
   KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619
   Kothari N, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.09.001
   McHowat J, 1997, J CHROMATOGR B, V702, P21, DOI 10.1016/S0378-4347(97)00386-1
   Messner MC, 2008, LIPIDS, V43, P581, DOI 10.1007/s11745-008-3189-y
   Mokart D, 2008, CRIT CARE, V12, DOI 10.1186/cc6791
   MURPHY EJ, 1992, LIPIDS, V27, P150, DOI 10.1007/BF02535816
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   NUYTINCK HKS, 1988, ARCH SURG-CHICAGO, V123, P1519
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   Pepe MS, 2006, BIOMETRICS, V62, P221, DOI 10.1111/j.1541-0420.2005.00420.x
   PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   PORTILLA D, 1995, KIDNEY INT, V47, P1087, DOI 10.1038/ki.1995.155
   Prescott SM, 1999, J CLIN INVEST, V104, P1019, DOI 10.1172/JCI8506
   Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54
   Reilly JP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1398-y
   Reilly JP, 2015, CLIN J AM SOC NEPHRO, V10, P1911, DOI 10.2215/CJN.12201214
   Reilly JP, 2014, CHEST, V145, P753, DOI 10.1378/chest.13-1962
   Robinson-Cohen C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1385-3
   Shah CV, 2010, CHEST, V138, P1054, DOI 10.1378/chest.09-2697
   Shapiro NI, 2010, CRIT CARE, V14, DOI 10.1186/cc9290
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Suratt BT, 2009, CRIT CARE MED, V37, P1322, DOI 10.1097/CCM.0b013e31819c14fa
   Suwa T, 2001, AM J RESP CRIT CARE, V163, P970, DOI 10.1164/ajrccm.163.4.2005132
   Teixeira-da-Cunha MGA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074567
   Thijs A, 1998, KIDNEY INT, V53, pS34
   Thukkani AK, 2005, AM J PHYSIOL-HEART C, V288, pH2955, DOI 10.1152/ajpheart.00834.2004
   Thukkani AK, 2003, J BIOL CHEM, V278, P36365, DOI 10.1074/jbc.M305449200
   Thukkani AK, 2002, J BIOL CHEM, V277, P3842, DOI 10.1074/jbc.M109489200
   Verheul HMW, 2000, BLOOD, V96, P4216, DOI 10.1182/blood.V96.13.4216
   Wacker BK, 2013, FREE RADICAL BIO MED, V59, P92, DOI 10.1016/j.freeradbiomed.2012.06.013
   Wang WY, 2014, ARTERIOSCL THROM VAS, V34, P526, DOI 10.1161/ATVBAHA.113.302544
   Ware LB, 2011, SHOCK, V36, P12, DOI 10.1097/SHK.0b013e318217025a
   WEISS SJ, 1989, NEW ENGL J MED, V320, P365
   Wiedemann HP, 2002, CRIT CARE MED, V30, P1
   Wildsmith KR, 2006, J BIOL CHEM, V281, P16849, DOI 10.1074/jbc.M602505200
   WINDSOR ACJ, 1993, BRIT J SURG, V80, P10, DOI 10.1002/bjs.1800800106
   Zeiher BG, 2004, CRIT CARE MED, V32, P1695, DOI 10.1097/01.CCM.0000133332.48386.85
NR 77
TC 35
Z9 35
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD DEC 7
PY 2017
VL 2
IS 23
AR e96432
DI 10.1172/jci.insight.96432
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FP0QI
UT WOS:000417307600007
PM 29212955
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Lu, Q
   Mundy, M
   Chambers, E
   Lange, T
   Newton, J
   Borgas, D
   Yao, HW
   Choudhary, G
   Basak, R
   Oldham, M
   Rounds, S
AF Lu, Qing
   Mundy, Miles
   Chambers, Eboni
   Lange, Thilo
   Newton, Julie
   Borgas, Diana
   Yao, Hongwei
   Choudhary, Gaurav
   Basak, Rajshekhar
   Oldham, Mahogany
   Rounds, Sharon
TI Alda-1 Protects Against Acrolein-Induced Acute Lung Injury and
   Endothelial Barrier Dysfunction
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE acrolein; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; mitochondrial aldehyde dehydrogenase 2; mitochondrial respiration 
ID MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; BRONCHIAL EPITHELIAL-CELLS;
   PASSIVE CIGARETTE-SMOKING; MOBILITY GROUP BOX-1; OXIDATIVE STRESS;
   PULMONARY-EDEMA; SYNTHETIC SMOKE; KINASE; ACTIVATION; INFLAMMATION
AB Inhalation of acrolein, a highly reactive aldehyde, causes lung edema. The underlying mechanism is poorly understood and there is no effective treatment. In this study, we demonstrated that acrolein not only dose-dependently induced lung edema but also promoted LPS-induced acute lung injury. Importantly, acrolein-induced lung injury was prevented and rescued by Alda-1, an activator of mitochondrial aldehyde dehydrogenase 2. Acrolein also dose-dependently increased monolayer permeability, disrupted adherens junctions and focal adhesion complexes, and caused intercellular gap formation in primary cultured lung microvascular endothelial cells (LMVECs). These effects were attenuated by Alda-1 and the antioxidant N-acetylcysteine, but not by the NADPH inhibitor apocynin. Furthermore, acrolein inhibited AMP-activated protein kinase (AMPK) and increased mitochondrial reactive oxygen species levels in LMVECs-effects that were associated with impaired mitochondrial respiration. AMPK total protein levels were also reduced in lung tissue of mice and LMVECs exposed to acrolein. Activation of AMPK with 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside blunted an acrolein-induced increase in endothelial monolayer permeability, but not mitochondrial oxidative stress or inhibition of mitochondrial respiration. Our results suggest that acroleininduced mitochondrial dysfunction may not contribute
C1 [Lu, Qing; Mundy, Miles; Chambers, Eboni; Lange, Thilo; Newton, Julie; Borgas, Diana; Yao, Hongwei; Choudhary, Gaurav; Basak, Rajshekhar; Oldham, Mahogany; Rounds, Sharon] Brown Univ, Dept Med, Vasc Res Lab, Providence Vet Affairs Med Ctr,Alpert Med Sch, Providence, RI 02912, United States.
C3 Brown University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Providence VA Medical Center
RP Lu, Q (corresponding author), Providence VA Med Ctr, Res Serv, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM qing_lu@brown.edu
RI Yao, Hongwei/G-6444-2010; Rounds, Sharon/AAF-7380-2020; Choudhary,
   Gaurav/M-1643-2019
OI Choudhary, Gaurav/0000-0001-9343-5481; Lu, Qing/0000-0002-4088-6200;
   Mundy, Miles/0000-0003-2173-4268
FU Providence VA Medical Center; U.S. Department of Veterans Affairs Merit
   Review Program; Brown University Dean's Award; National Institutes of
   Health [P20GM103652, RO1 HL130230, U54GM115677, R25 HL088992, HL128661]
FX Supported by the Providence VA Medical Center, the U.S. Department of
   Veterans Affairs Merit Review Program (S.R.), a Brown University Dean's
   Award (S.R.), and National Institutes of Health grants P20GM103652
   (S.R.; project 1, Q.L.), RO1 HL130230 (Q.L.), U54GM115677 (S.R.), R25
   HL088992 (R.B. and M.O.),and HL128661 (G.C.).
CR Agarwal AR, 2013, AM J PHYSIOL-LUNG C, V305, pL764, DOI 10.1152/ajplung.00165.2013
   Alwis KU, 2015, ENVIRON HEALTH PERSP, V123, P1302, DOI 10.1289/ehp.1409251
   Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176
   Bein K, 2011, MOL NUTR FOOD RES, V55, P1342, DOI 10.1002/mnfr.201100279
   Blasch KW, 2016, J OCCUP ENVIRON MED, V58, pS38, DOI 10.1097/JOM.0000000000000792
   Booze TF, 2004, J OCCUP ENVIRON HYG, V1, P296, DOI 10.1080/15459620490442500
   Burcham PC, 2014, TOXICOLOGY, V319, P44, DOI 10.1016/j.tox.2014.02.010
   Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC
   Chen CH, 2008, SCIENCE, V321, P1493, DOI 10.1126/science.1158554
   Chen CH, 2010, CARDIOVASC RES, V88, P51, DOI 10.1093/cvr/cvq192
   Chen DQ, 2013, J BIOL CHEM, V288, P21678, DOI 10.1074/jbc.M113.476630
   DIPPLE KM, 1993, BIOCHEM BIOPH RES CO, V193, P420, DOI 10.1006/bbrc.1993.1640
   Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403
   Fabisiak JP, 2011, MOL NUTR FOOD RES, V55, P1423, DOI 10.1002/mnfr.201100291
   Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95
   GRAFSTROM RC, 1988, CANCER RES, V48, P1717
   Grimsrud PA, 2008, J BIOL CHEM, V283, P21837, DOI 10.1074/jbc.R700019200
   HALES CA, 1992, J APPL PHYSIOL, V72, P555, DOI 10.1152/jappl.1992.72.2.555
   HALES CA, 1988, J APPL PHYSIOL, V64, P1121, DOI 10.1152/jappl.1988.64.3.1121
   Ho KM, 2011, INTENS CARE MED, V37, P981, DOI 10.1007/s00134-011-2184-6
   Ho SSH, 2006, J AIR WASTE MANAGE, V56, P1091, DOI 10.1080/10473289.2006.10464532
   Ho SSH, 2013, J AIR WASTE MANAGE, V63, P864, DOI 10.1080/10962247.2013.797519
   Hristova M, 2012, AM J RESP CELL MOL, V46, P23, DOI 10.1165/rcmb.2011-0134OC
   Hsieh SJ, 2014, CRIT CARE MED, V42, P2058, DOI 10.1097/CCM.0000000000000418
   Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58
   Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC
   Jian MY, 2013, AM J PHYSIOL-LUNG C, V305, pL844, DOI 10.1152/ajplung.00173.2013
   Kasahara DI, 2008, J IMMUNOL, V181, P736, DOI 10.4049/jimmunol.181.1.736
   Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6
   Kim JM, 2015, INT IMMUNOPHARMACOL, V28, P540, DOI 10.1016/j.intimp.2015.07.010
   Kitaguchi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038038
   Lambert C, 2007, J BIOL CHEM, V282, P19666, DOI 10.1074/jbc.M611527200
   Li SY, 2006, J MOL CELL CARDIOL, V40, P283, DOI 10.1016/j.yjmcc.2005.11.006
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Lu Q, 2015, AM J RESP CRIT CARE, V191
   Lu Q, 2004, CIRC RES, V94, P306, DOI 10.1161/01.RES.0000113923.85084.C1
   Lu Q, 2011, AM J PHYSIOL-LUNG C, V301, pL847, DOI 10.1152/ajplung.00178.2011
   Lu Q, 2010, AM J PHYSIOL-LUNG C, V298, pL755, DOI 10.1152/ajplung.00330.2009
   McCaskill ML, 2011, ALCOHOL CLIN EXP RES, V35, P1106, DOI 10.1111/j.1530-0277.2011.01443.x
   Miller AC, 2014, CRIT CARE MED, V42, P413, DOI 10.1097/CCM.0b013e3182a645e5
   MITCHELL DY, 1988, DRUG METAB DISPOS, V16, P37
   Moazed F, 2016, THORAX, V71, P1130, DOI 10.1136/thoraxjnl-2015-207886
   Mohammad MK, 2012, TOXICOL APPL PHARM, V265, P73, DOI 10.1016/j.taap.2012.09.021
   Mulchandani N, 2015, MOL MED, V21, P637, DOI 10.2119/molmed.2015.00179
   PATEL JM, 1985, EXP LUNG RES, V8, P153, DOI 10.3109/01902148509057519
   QUINN DA, 1990, J APPL PHYSIOL, V68, P1962, DOI 10.1152/jappl.1990.68.5.1962
   Raju SV, 2013, AM J RESP CRIT CARE, V188, P1321, DOI 10.1164/rccm.201304-0733OC
   Sakhatskyy P, 2017, AM J PHYSIOL-LUNG C, V312, pL56, DOI 10.1152/ajplung.00436.2016
   Shearn CT, 2014, J BIOL CHEM, V289, P15449, DOI 10.1074/jbc.M113.543942
   SKLAR JL, 1991, TOXICOL APPL PHARM, V107, P535, DOI 10.1016/0041-008X(91)90316-7
   Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412
   Sthijns MMJPE, 2014, BIOCHEM BIOPH RES CO, V446, P1029, DOI 10.1016/j.bbrc.2014.03.081
   Sun AJ, 2014, J MOL CELL CARDIOL, V71, P92, DOI 10.1016/j.yjmcc.2014.01.002
   Sun Y, 2014, TOXICOL LETT, V229, P384, DOI 10.1016/j.toxlet.2014.06.021
   TREITMAN RD, 1980, AM IND HYG ASSOC J, V41, P796, DOI 10.1080/15298668091425662
   Tsoyi K, 2011, BRIT J PHARMACOL, V162, P1498, DOI 10.1111/j.1476-5381.2010.01126.x
   van der Toorn M, 2007, AM J PHYSIOL-LUNG C, V293, pL1156, DOI 10.1152/ajplung.00081.2007
   Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008
NR 58
TC 29
Z9 30
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD DEC
PY 2017
VL 57
IS 6
BP 662
EP 673
DI 10.1165/rcmb.2016-0342OC
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA FO5EC
UT WOS:000416873600008
PM 28763253
OA Green Published
DA 2023-08-21
ER

PT J
AU Qi, D
   Wang, DX
   Zhang, CR
   Tang, XM
   He, J
   Zhao, Y
   Deng, W
   Deng, XY
AF Qi, Di
   Wang, Daoxin
   Zhang, Chunrong
   Tang, Xumao
   He, Jing
   Zhao, Yan
   Deng, Wang
   Deng, Xinyu
TI Vaspin protects against LPS-induced ARDS by inhibiting inflammation,
   apoptosis and reactive oxygen species generation in pulmonary
   endothelial cells via the Akt/GSK-3 beta pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE ALI/ARDS; vaspin; ECs/HPMECs/HUVECs/MPVECs; Inflammation; apoptosis; ROS; AKT/GSK3 beta signaling pathway 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; SYSTEMIC INFLAMMATION;
   KAPPA-B; OBESITY; ACTIVATION; MECHANISMS; ADIPOKINES;
   ALPHA-1-ANTITRYPSIN; ADIPOCYTOKINE
AB Acute respiratory distress syndrome (ARDS) is characterized by uncontrolled extravasation of protein-rich fluids, which is caused by disruption and dysfunction of the barrier of pulmonary endothelial cells (ECs). Visceral adipose tissue-derived serine protease inhibitor (vaspin) is a novel adipokine with pleiotropic properties, which has been reported to exert beneficial effects against obesity-associated systemic vascular diseases; however, its effects on ARDS remain unknown. In the present study, mice were subjected to systemic administration of adenoviral vector expressing vaspin (Ad-vaspin) to examine its effects on lipopolysaccharide (LPS)-induced ARDS in vivo. Histological analysis was then conducted, and cytokine [tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-10] levels, and intercellular cell adhesion molecule-1 (ICAM-1) and adherens junctions (AJs) expression were detected. In addition, human pulmonary microvascular ECs (HPMECs) were treated with recombinant human (rh)-vaspin to further investigate its molecular basis and underlying mechanism. The mRNA expression levels of inflammatory cytokines (TNF-alpha and IL-6) and endothelial-specific adhesion markers [vascular cell adhesion molecule-1 and E-selectin], activation of nuclear factor-kappa B, and cell viability and apoptosis were then examined. Furthermore, the expression of AJs and organization of the cytoskeleton, as well as expression and activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and generation of reactive oxygen species (ROS) were determined. The results indicated that Ad-vaspin protected against LPS-induced ARDS by alleviating the pulmonary inflammatory response and pulmonary EC barrier dysfunction in mice, which was accompanied by activation of the protein kinase B (Akt)/glycogen synthase kinase (GSK)-3 beta pathway. In addition, pretreatment of HPMECs with rh-vaspin attenuated inflammation, apoptosis and ROS generation without alterations in AJs and cytoskeletal organization following LPS insult, which was accompanied by activation of the Akt/GSK3 beta pathway. In conclusion, the present study demonstrated that vaspin protects against LPS-induced ARDS by reversing EC barrier dysfunction via the suppression of inflammation, apoptosis and ROS production in pulmonary ECs, at least partially via activation of the Akt/GSK3 beta pathway. These findings provide evidence of a causal link between vaspin and EC dysfunction in ARDS, and suggest a potential therapeutic intervention for patients with ARDS.
C1 [Qi, Di; Wang, Daoxin; Tang, Xumao; He, Jing; Zhao, Yan; Deng, Wang; Deng, Xinyu] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, Chongqing 400010, China.
C1 [Zhang, Chunrong] Chongqing Med Univ, Dept Emergency, Yongchuan Affiliated Hosp, 439 Xuanhuan Rd, Chongqing 402160, China.
C3 Chongqing Medical University; Chongqing Medical University
RP Zhang, CR (corresponding author), Chongqing Med Univ, Dept Emergency, Yongchuan Affiliated Hosp, 439 Xuanhuan Rd, Chongqing 402160, Peoples R China.
EM cqmuzhangchunrong@163.com
OI Qi, Di/0000-0002-8267-9832
FU National Natural Science Foundation of China [81670071]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 81670071).
CR Anzueto A, 2011, THORAX, V66, P66, DOI 10.1136/thx.2010.145086
   Aust G, 2009, ATHEROSCLEROSIS, V204, P262, DOI 10.1016/j.atherosclerosis.2008.08.028
   Dimova R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/823481
   Fan XF, 2015, CHEST, V147, P969, DOI 10.1378/chest.14-1426
   Feng YL, 2015, J CARDIOVASC PHARM, V66, P96, DOI 10.1097/FJC.0000000000000250
   Gadek JE, 1996, CHEST, V110, pS273, DOI 10.1378/chest.110.6_Supplement.273S
   Galani V, 2010, PATHOL RES PRACT, V206, P145, DOI 10.1016/j.prp.2009.12.002
   Gando S, 2004, INFLAMMATION, V28, P237, DOI 10.1023/B:IFLA.0000049049.81688.fe
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   Hida K, 2005, P NATL ACAD SCI USA, V102, P10610, DOI 10.1073/pnas.0504703102
   Jie ZJ, 2003, CHINESE MED J-PEKING, V116, P1678
   JUNG CH, 2014, CARDIOVASC DIABETOL, V13, DOI DOI 10.1161/CIRCRESAHA.111.300049
   Jung CH, 2011, BIOCHEM BIOPH RES CO, V413, P264, DOI 10.1016/j.bbrc.2011.08.083
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kobat M. A., 2012, BRAZ J MED BIOL RES, V4, P110
   Kobat Mehmet Ali, 2012, J Clin Med Res, V4, P110, DOI 10.4021/jocmr841w
   Konter J, 2013, PULM PHARMACOL THER, V26, P427, DOI 10.1016/j.pupt.2012.03.003
   Konter JM, 2012, J IMMUNOL, V188, P854, DOI 10.4049/jimmunol.1100426
   Lang JD, 2002, CHEST, V122, p314S, DOI 10.1378/chest.122.6_suppl.314S
   Lin Y, 2016, MOL MED REP, V13, P1509, DOI 10.3892/mmr.2015.4708
   Liu SW, 2014, DIABETES RES CLIN PR, V103, P482, DOI 10.1016/j.diabres.2013.12.002
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Manukyan MC, 2010, SHOCK, V34, P442, DOI 10.1097/SHK.0b013e3181e14ea9
   Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218
   Matsuzawa Y, 2011, J ATHEROSCLER THROMB, V18, P629, DOI 10.5551/jat.7922
   Mattu HS, 2013, J ENDOCRINOL, V216, pT17, DOI 10.1530/JOE-12-0232
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Muller-Redetzky HC, 2014, CELL TISSUE RES, V355, P657, DOI 10.1007/s00441-014-1821-0
   Nakatsuka A, 2013, CIRC RES, V112, P771, DOI 10.1161/CIRCRESAHA.111.300049
   *NMAT RES COUNC I, 2011, GUID DESCR AN RES SC, DOI DOI 10.1016/J.BBRC.2011.08.083
   Ohashi K, 2014, TRENDS ENDOCRIN MET, V25, P348, DOI 10.1016/j.tem.2014.03.009
   Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058
   Phalitakul S, 2013, ACTA PHYSIOL, V209, P212, DOI 10.1111/apha.12139
   Phalitakul S, 2012, BIOCHEM BIOPH RES CO, V423, P844, DOI 10.1016/j.bbrc.2012.06.052
   Phalitakul S, 2011, PHARMACOL RES, V64, P493, DOI 10.1016/j.phrs.2011.06.001
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   QI D, 2016, CELL DEATH DIS, V7, DOI DOI 10.4049/JIMMUNOL.1100426
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ryan D, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0028-6
   Shah D, 2015, SCI REP-UK, V5, DOI 10.1038/srep11362
   Shibata R, 2014, CYTOKINE GROWTH F R, V25, P483, DOI 10.1016/j.cytogfr.2014.07.005
   Shiizaki Shigeru, 2013, Advances in Biological Regulation, V53, P135, DOI 10.1016/j.jbior.2012.09.006
   Stapleton RD, 2014, CLIN CHEST MED, V35, P655, DOI 10.1016/j.ccm.2014.08.005
   Stockley RA, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.04.25
   Tasaka S, 2008, ANTIOXID REDOX SIGN, V10, P739, DOI 10.1089/ars.2007.1940
   Taylor NJ, 2009, NEW ENGL J MED, V361, P2102
   TUMEN J, 1988, J APPL PHYSIOL, V65, P835, DOI 10.1152/jappl.1988.65.2.835
   Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487
   Wang C, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/978463
   WEWERS MD, 1988, J CLIN INVEST, V82, P1260, DOI 10.1172/JCI113724
   Yamawaki Hideyuki, 2011, Folia Pharmacologica Japonica, V137, P131, DOI 10.1254/fpj.137.131
NR 54
TC 42
Z9 50
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2017
VL 40
IS 6
BP 1803
EP 1817
DI 10.3892/ijmm.2017.3176
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FQ2ZJ
UT WOS:000418226300020
PM 29039444
OA hybrid, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Wang, XF
   Song, SD
   Hu, ZQ
   Zhang, ZW
   Li, YJ
   Yan, CG
   Li, ZG
   Tang, HF
AF Wang, Xuefeng
   Song, Shunde
   Hu, Zhengqiang
   Zhang, Zhewen
   Li, Yajun
   Yan, Chunguang
   Li, Zigang
   Tang, Huifang
TI Activation of Epac alleviates inflammation and vascular leakage in
   LPS-induced acute murine lung injury
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE LPS; ALI/ARDS; cAMP; Epac; PKA 
ID ENDOTHELIAL BARRIER; ISCHEMIA-REPERFUSION; CAMP; PKA; PATHWAY;
   PERMEABILITY; ANALOGS; RAP1
AB Exchange protein directly activated by cAMP (Epac) is an important molecule in cAMP signal transduction, but the effect of Epac on lipopolysaccharide (LPS)-induced acute lung injury (ALI) is unclear. In this study, we treated in vitro and in vivo models with the Epac activator 8CPT to determine the effect and related mechanisms of Epac. The in vitro results indicate that 8CPT inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-alpha) release from mouse macrophages (MH-S), whereas the protein kinase A (PKA) activator 6BnZ has no effect. Furthermore, Epac over-expression can significantly suppress TNF-alpha release from LPS induced MH-S cell, while Epac siRNA can slightly increase TNF-alpha release. Moreover, 8CPT reduces LPS-induced microvascular permeability in human pulmonary microvascular endothelial cells (HPMVECs), whereas the PKA activator 6BnZ has no effect. In mice with LPS-induced ALI, 8CPT significantly reduces LPS-induced inflammatory cytokine release, neutrophil recruitment, and albumin leakage. LPS simultaneously decreases the Epac but not the PKA levels. However, 8CPT reverses the decreased Epac levels. Furthermore, the mechanism involves the small GTPase Rac1/2 but not the mitogen-activated protein kinase (MAPK) pathway. Thus, Epac activation reduces inflammation and microvascular permeability in LPS-induced lung injury and an Epac activator represents a novel choice for the early therapy of ALI.
C1 [Wang, Xuefeng] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Hangzhou 310005, Zhejiang, China.
C1 [Song, Shunde; Hu, Zhengqiang; Zhang, Zhewen; Li, Yajun; Tang, Huifang] Zhejiang Univ, Sch Basic Med Sci, Zhejiang Resp Drugs Res Lab, Hangzhou 310058, Zhejiang, China.
C1 [Yan, Chunguang] Southeast Univ, Sch Med, Dept Pathogen Biol & Immunol, Nanjing 210009, Jiangsu, China.
C1 [Li, Zigang] Zhejiang Univ, Sch Med, Womens Hosp, Dept Anesthesiol, Hangzhou 310006, Zhejiang, China.
C3 Zhejiang Chinese Medical University; Zhejiang University; Southeast
   University - China; Zhejiang University
RP Tang, HF (corresponding author), Zhejiang Univ, Sch Basic Med Sci, Zhejiang Resp Drugs Res Lab, Hangzhou 310058, Zhejiang, Peoples R China.
EM tanghuifang@zju.edu.cn
RI Tang, Huifang/ADI-7037-2022; Li, Zigang/U-5319-2019; Yan,
   Chunguang/ABE-5021-2021
OI Li, Zigang/0000-0002-9941-9869; 
FU National Natural Science Foundation of China [81202980, 30800497,
   81170536, 31400751, 81570056]
FX This research was supported by grants from the National Natural Science
   Foundation of China (Grant Nos: 81202980, 30800497, 81170536, 31400751
   and 81570056).
CR Adamson RH, 2008, AM J PHYSIOL-HEART C, V294, pH1188, DOI 10.1152/ajpheart.00937.2007
   ADKINS WK, 1992, J APPL PHYSIOL, V72, P492, DOI 10.1152/jappl.1992.72.2.492
   Aslam M, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12175
   Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462
   Butt Y, 2016, ARCH PATHOL LAB MED, V140, P345, DOI 10.5858/arpa.2015-0519-RA
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71
   Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200
   Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987
   Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874
   Garcia-Morales V, 2014, VASC PHARMACOL, V60, P95, DOI 10.1016/j.vph.2014.01.004
   HOFFMANN H, 1991, AM REV RESPIR DIS, V143, P289, DOI 10.1164/ajrccm/143.2.289
   Hsu K, 1996, RES EXP MED, V196, P17, DOI 10.1007/s004330050010
   Hsu Kang, 1993, Proceedings of the National Science Council Republic of China Part B Life Sciences, V17, P57
   Huang RT, 2017, AM J RESP CRIT CARE, V195, P639, DOI 10.1164/rccm.201604-0668OC
   Huang SK, 2008, AM J RESP CELL MOL, V39, P482, DOI 10.1165/rcmb.2008-0080OC
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Moon EY, 2007, IMMUNOL LETT, V110, P121, DOI 10.1016/j.imlet.2007.04.002
   Moon EY, 2005, J NEUROSCI RES, V81, P38, DOI 10.1002/jnr.20535
   Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a
   Oldenburger A, 2014, FASEB J, V28, P4617, DOI 10.1096/fj.13-248930
   Oldenburger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031574
   Poppe H, 2008, NAT METHODS, V5, P277, DOI 10.1038/nmeth0408-277
   Rehmann H, 2013, SCI REP-UK, V3, DOI 10.1038/srep03032
   Schlegel N, 2014, CELL TISSUE RES, V355, P587, DOI 10.1007/s00441-013-1755-y
   SEIBERT AF, 1992, J APPL PHYSIOL, V72, P389, DOI 10.1152/jappl.1992.72.1.389
   Singhmar P, 2016, P NATL ACAD SCI USA, V113, P3036, DOI 10.1073/pnas.1516036113
   Stafford JB, 2008, BIOCHEM BIOPH RES CO, V366, P104, DOI 10.1016/j.bbrc.2007.11.091
   Standiford TJ, 2016, TRANSL RES, V167, P183, DOI 10.1016/j.trsl.2015.04.015
   Tang HF, 2010, INT IMMUNOPHARMACOL, V10, P406, DOI 10.1016/j.intimp.2010.01.003
   TAYLOR A E, 1991, Proceedings of the National Science Council Republic of China Part B Life Sciences, V15, P191
   Thompson MA, 2015, BBA-MOL CELL RES, V1853, P2506, DOI 10.1016/j.bbamcr.2015.06.008
   THORBALL N, 1981, HISTOCHEMISTRY, V71, P209, DOI 10.1007/BF00507826
   Yao HY, 2011, BBA-GEN SUBJECTS, V1810, P666, DOI 10.1016/j.bbagen.2011.03.020
NR 38
TC 16
Z9 19
U1 3
U2 25
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2017
VL 96
BP 1127
EP 1136
DI 10.1016/j.biopha.2017.11.110
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FQ6VL
UT WOS:000418502100134
PM 29174852
DA 2023-08-21
ER

PT J
AU Gutbier, B
   Jiang, XH
   Dietert, K
   Ehrler, C
   Lienau, J
   Van Slyke, P
   Kim, H
   Hoang, VC
   Maynes, JT
   Dumont, DJ
   Gruber, AD
   Weissmann, N
   Mitchell, TJ
   Suttorp, N
   Witzenrath, M
AF Gutbier, Birgitt
   Jiang, Xiaohui
   Dietert, Kristina
   Ehrler, Carolin
   Lienau, Jasmin
   Van Slyke, Paul
   Kim, Harold
   Hoang, Van C.
   Maynes, Jason T.
   Dumont, Daniel J.
   Gruber, Achim D.
   Weissmann, Norbert
   Mitchell, Timothy J.
   Suttorp, Norbert
   Witzenrath, Martin
TI Vasculotide reduces pulmonary hyperpermeability in experimental
   pneumococcal pneumonia
SO CRITICAL CARE
LA English
DT Article
DE pneumococcal pneumonia; pneumolysin; angiopoietin-1/angiopoietin-2; ALI/ARDS; Vasculotide 
ID COMMUNITY-ACQUIRED PNEUMONIA; ACUTE LUNG INJURY; ENDOTHELIAL-CELLS;
   AGONIST PEPTIDE; ANGIOPOIETIN-1; PNEUMOLYSIN; EXPRESSION; PROTECTS;
   DISEASE; TIE2
AB Background: Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide. Despite effective antimicrobial therapy, CAP can induce pulmonary endothelial hyperpermeability resulting in life-threatening lung failure due to an exaggerated host-pathogen interaction. Treatment of acute lung injury is mainly supportive because key elements of inflammation-induced barrier disruption remain undetermined. Angiopoietin-1 (Ang-1)-mediated Tie2 activation reduces, and the Ang-1 antagonist Ang-2 increases, inflammation and endothelial permeability in sepsis. Vasculotide (VT) is a polyethylene glycol-clustered Tie2-binding peptide that mimics the actions of Ang-1. The aim of our study was to experimentally test whether VT is capable of diminishing pneumonia-induced lung injury.
   Methods: VT binding and phosphorylation of Tie2 were analyzed using tryptophan fluorescence spectroscopy and phospho-Tie-2 enzyme-linked immunosorbent assay. Human and murine lung endothelial cells were investigated by immunofluorescence staining and electric cell-substrate impedance sensing. Pulmonary hyperpermeability was quantified in VT-pretreated, isolated, perfused, and ventilated mouse lungs stimulated with the pneumococcal exotoxin pneumolysin (PLY). Furthermore, Streptococcus pneumoniae-infected mice were therapeutically treated with VT.
   Results: VT showed dose-dependent binding and phosphorylation of Tie2. Pretreatment with VT protected lung endothelial cell monolayers from PLY-induced disruption. In isolated mouse lungs, VT decreased PLY-induced pulmonary permeability. Likewise, therapeutic treatment with VT of S. pneumoniae-infected mice significantly reduced pneumonia-induced hyperpermeability. However, effects by VT on the pulmonary or systemic inflammatory response were not observed.
   Conclusions: VT promoted pulmonary endothelial stability and reduced lung permeability in different models of pneumococcal pneumonia. Thus, VT may provide a novel therapeutic perspective for reduction of permeability in pneumococcal pneumonia-induced lung injury.
C1 [Gutbier, Birgitt; Jiang, Xiaohui; Ehrler, Carolin; Lienau, Jasmin; Suttorp, Norbert; Witzenrath, Martin] Charite Univ Med Berlin, Charitepl 1, D-10117 Berlin, Germany.
C1 [Gutbier, Birgitt; Jiang, Xiaohui; Ehrler, Carolin; Lienau, Jasmin; Suttorp, Norbert; Witzenrath, Martin] Free Univ Berlin, Charitepl 1, D-10117 Berlin, Germany.
C1 [Gutbier, Birgitt; Jiang, Xiaohui; Ehrler, Carolin; Lienau, Jasmin; Suttorp, Norbert; Witzenrath, Martin] Humboldt Univ, Charitepl 1, D-10117 Berlin, Germany.
C1 [Gutbier, Birgitt; Jiang, Xiaohui; Ehrler, Carolin; Lienau, Jasmin; Suttorp, Norbert; Witzenrath, Martin] Berlin Inst Hlth, Dept Infect Dis & Pulm Med, Charitepl 1, D-10117 Berlin, Germany.
C1 [Dietert, Kristina; Gruber, Achim D.] Free Univ Berlin, Inst Vet Pathol, Robert von Ostertag Str 15, D-14163 Berlin, Germany.
C1 [Van Slyke, Paul; Kim, Harold; Hoang, Van C.] Vasomune Therapeut, 661 Univ Ave,Suite 465, Toronto, ON M5G 1M1, Canada.
C1 [Maynes, Jason T.] Hosp Sick Children, Dept Anesthesia & Pain Med, Toronto, ON M5G 1X8, Canada.
C1 [Maynes, Jason T.] Univ Toronto, Dept Anesthesia, Toronto, ON M5S 2J7, Canada.
C1 [Maynes, Jason T.] Univ Toronto, Dept Biochem, Toronto, ON M5S 2J7, Canada.
C1 [Dumont, Daniel J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
C1 [Weissmann, Norbert] Justus Liebig Univ, Excellence Cluster Cardiopulm Syst, UGMLC, German Ctr Lung Res DZL, D-35392 Giessen, Germany.
C1 [Mitchell, Timothy J.] Univ Birmingham, Coll Med & Dent Sci, Inst Microbiol & Infect, Birmingham B15 2TT, W Midlands, England, United Kingdom.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Berlin Institute of Health; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Free University of Berlin; University of Toronto; Hospital for
   Sick Children (SickKids); University of Toronto; University of Toronto;
   University of Toronto; Sunnybrook Health Science Center; Sunnybrook
   Research Institute; Justus Liebig University Giessen; University of
   Birmingham
RP Witzenrath, M (corresponding author), Charite Univ Med Berlin, Charitepl 1, D-10117 Berlin, Germany.; Witzenrath, M (corresponding author), Free Univ Berlin, Charitepl 1, D-10117 Berlin, Germany.; Witzenrath, M (corresponding author), Humboldt Univ, Charitepl 1, D-10117 Berlin, Germany.; Witzenrath, M (corresponding author), Berlin Inst Hlth, Dept Infect Dis & Pulm Med, Charitepl 1, D-10117 Berlin, Germany.
EM martin.witzenrath@charite.de
RI Maynes, Jason/AAE-4344-2020; Gruber, Achim D./ABA-4514-2021; Lienau,
   Jasmin/AAY-7795-2021
OI Lienau, Jasmin/0000-0002-4953-3938; Weissmann,
   Norbert/0000-0003-2675-3871; Suttorp, Norbert/0000-0002-3958-1151;
   Dietert, Kristina/0000-0002-5667-6750
FU German Research Foundation [SFB-TR84]; German Federal Ministry of
   Education and Research [e:Med CAPSyS-FKZ 01ZX1304B]
FX This study was supported by the German Research Foundation (SFB-TR84 C6,
   C3, B1, and Z01b [to MW, NW, NS and ADG]) and by the German Federal
   Ministry of Education and Research (e:Med CAPSyS-FKZ 01ZX1304B [to NS
   and MW]).
CR Angus DC, 2002, AM J RESP CRIT CARE, V166, P717, DOI 10.1164/rccm.2102084
   Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61
   Bein T, 2009, ANAESTHESIA, V64, P195, DOI 10.1111/j.1365-2044.2008.05735.x
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cockeran R, 2002, CURR OPIN INFECT DIS, V15, P235, DOI 10.1097/00001432-200206000-00004
   Coffelt SB, 2011, J IMMUNOL, V186, P4183, DOI 10.4049/jimmunol.1002802
   Dames C, 2014, AM J RESP CELL MOL, V51, P730, DOI 10.1165/rcmb.2014-0052MA
   David S, 2011, AM J PHYSIOL-LUNG C, V300, pL851, DOI 10.1152/ajplung.00459.2010
   Eklund L, 2013, EXP CELL RES, V319, P1271, DOI 10.1016/j.yexcr.2013.03.011
   Ewig S, 2009, THORAX, V64, P1062, DOI 10.1136/thx.2008.109785
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004
   File TM, 2003, LANCET, V362, P1991, DOI 10.1016/S0140-6736(03)15021-0
   Fleming I, 2005, J CELL SCI, V118, P4103, DOI 10.1242/jcs.02541
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0
   Gutbier B, 2016, AM J RESP CRIT CARE, V193
   Gutbier B, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA4990
   Korpela E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-614
   Kumpers P, 2011, CRIT CARE, V15, DOI 10.1186/cc10523
   Makinde TO, 2011, AM J RESP CELL MOL, V44, P384, DOI 10.1165/rcmb.2009-0330OC
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   MITCHELL TJ, 1989, BIOCHIM BIOPHYS ACTA, V1007, P67, DOI 10.1016/0167-4781(89)90131-0
   Mitchell TJ, 2000, RES MICROBIOL, V151, P413, DOI 10.1016/S0923-2508(00)00175-3
   Mizgerd JP, 2008, NEW ENGL J MED, V358, P716, DOI 10.1056/NEJMra074111
   Muller-Redetzky HC, 2015, J ANTIMICROB CHEMOTH, V70, P830, DOI 10.1093/jac/dku446
   Muller-Redetzky HC, 2014, CELL TISSUE RES, V355, P657, DOI 10.1007/s00441-014-1821-0
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Patel AS, 2013, EMBO MOL MED, V5, P858, DOI 10.1002/emmm.201302752
   Pizurki L, 2003, BRIT J PHARMACOL, V139, P329, DOI 10.1038/sj.bjp.0705259
   Reppe K, 2015, INFECT IMMUN, V83, P4617, DOI 10.1128/IAI.00948-15
   Reppe K, 2009, AM J RESP CELL MOL, V40, P474, DOI 10.1165/rcmb.2008-0071OC
   Rubig E, 2016, SCI REP-UK, V6, DOI 10.1038/srep22111
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Seybold J, 2005, BLOOD, V105, P3569, DOI 10.1182/blood-2004-07-2729
   Sugiyama MG, 2015, SCI REP-UK, V5, DOI 10.1038/srep11030
   The World Health Organization, TOP 10 CAUS DEATH
   Thomas M, 2009, ANGIOGENESIS, V12, P125, DOI 10.1007/s10456-009-9147-3
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Torres A, 2012, SEMIN RESP CRIT CARE, V33, P266, DOI 10.1055/s-0032-1315638
   Tournaire R, 2004, EMBO REP, V5, P262, DOI 10.1038/sj.embor.7400100
   Van Slyke P, 2009, TISSUE ENG PT A, V15, P1269, DOI 10.1089/ten.tea.2007.0400
   Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
   von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Welte T, 2004, INFECTION, V32, P234, DOI 10.1007/s15010-004-3107-z
   Welte T, 2006, MED KLIN, V101, P313, DOI 10.1007/s00063-006-1040-x
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Witzenrath M, 2006, AM J PHYSIOL-LUNG C, V291, pL466, DOI 10.1152/ajplung.00011.2005
NR 51
TC 23
Z9 23
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD NOV 13
PY 2017
VL 21
AR 274
DI 10.1186/s13054-017-1851-6
PG 12
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FM4CH
UT WOS:000414958300001
PM 29132435
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Kasuda, S
   Kudo, R
   Yuui, K
   Sakurai, Y
   Hatake, K
AF Kasuda, Shogo
   Kudo, Risa
   Yuui, Katsuya
   Sakurai, Yoshihiko
   Hatake, Katsuhiko
TI Acute ethanol intoxication suppresses pentraxin 3 expression in a mouse
   sepsis model involving cecal ligation and puncture
SO ALCOHOL
LA English
DT Article
DE Acute ethanol intoxication; sepsis; Pentraxin 3; ECs/HPMECs/HUVECs/MPVECs; JNK 
ID C-REACTIVE PROTEIN; INNATE IMMUNITY; ENDOTHELIAL-CELLS; BINGE-DRINKING;
   HOST-DEFENSE; LUNG INJURY; PTX3; INFLAMMATION; ALCOHOL; ALPHA
AB Acute ethanol intoxication impairs immunological reactions and increases the risk of sepsis; however, the underlying mechanism remains unclear. Pentraxin (PTX) 3 is a humoral pattern recognition receptor whose levels rapidly increase in response to inflammation. PTX3 production is triggered by tumor necrosis factor (TNF)-alpha and is mediated by c-Jun N-terminal kinase (JNK). As PTX3 exerts protective effects against sepsis as well as acute lung injury, we investigated whether acute ethanol exposure exacerbates sepsis by altering PTX3 expression. Sepsis was induced in C57/BL6 mice by cecal ligation and puncture (CLP) after ethanol/saline administration. Survival rates were significantly lower in ethanol-treated than in saline-treated mice. Increased vascular permeability and attenuation of PTX3 expression were observed in the lungs of ethanol-treated mice 4 h after CLP. Concomitant with a delayed increase of plasma TNF-alpha in ethanol-treated mice, plasma PTX3 was also suppressed in the early phase of sepsis. Although TNF-a level in ethanol-treated mice exceeded that in saline-treated mice 16 h after CLP, PTX3 levels were still suppressed in the former group. JNK phosphorylation in lung tissue was suppressed in both groups 4 and 16 h after CLP. Furthermore, JNK phosphorylation in ethanol-treated human umbilical vein endothelial cells was suppressed even in the presence of exogenous TNF-alpha, resulting in inhibition of PTX3 mRNA and protein expression. Our results suggest that ethanol suppresses de novo PTX3 synthesis via two mechanisms i.e., suppression of TNF-alpha production and inhibition of JNK phosphorylation. PTX3 suppression may therefore contribute to exacerbation of sepsis in acute ethanol intoxication. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Kasuda, Shogo; Kudo, Risa; Yuui, Katsuya; Hatake, Katsuhiko] Nara Med Univ, Dept Legal Med, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
C1 [Sakurai, Yoshihiko] Matsubara Tokushukai Hosp, Dept Pediat, 7-13-26 Amamihigashi, Matsubara, Osaka 5800032, Japan.
C3 Nara Medical University
RP Kasuda, S (corresponding author), Nara Med Univ, Dept Legal Med, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
EM skasuda@naramed-u.ac.jp; rkudo-kobe@umin.ac.jp; yuui@naramed-u.ac.jp;
   ysakurai-th@umin.ac.jp; legalm@naramed-u.ac.jp
RI Sakurai, Yoshihiko/C-5622-2011
OI Sakurai, Yoshihiko/0000-0002-1773-5535; Kasuda,
   Shogo/0000-0001-8527-8367
FU Japan Society for the Promotion of Science KAKENHI grant [15K20351];
   Grants-in-Aid for Scientific Research [15K20351, 17K09273, 16H07131]
   Funding Source: KAKEN
FX This work was supported by the Japan Society for the Promotion of
   Science KAKENHI grant (no. 15K20351 to S.K.).
CR Aman J, 2011, CRIT CARE MED, V39, P89, DOI 10.1097/CCM.0b013e3181feb46a
   Aroor AR, 2004, LIFE SCI, V74, P2339, DOI 10.1016/j.lfs.2003.11.001
   Bhargava R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079037
   Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817
   Daigo K, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005522
   Daigo K, 2014, IMMUNOL LETT, V161, P38, DOI 10.1016/j.imlet.2014.04.012
   Dong Z, 2011, J CELL BIOCHEM, V112, P2097, DOI 10.1002/jcb.23128
   Dushianthan A, 2011, POSTGRAD MED J, V87, P612, DOI 10.1136/pgmj.2011.118398
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756
   Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6
   Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011
   Han B, 2005, J IMMUNOL, V175, P8303, DOI 10.4049/jimmunol.175.12.8303
   Han B, 2012, LAB INVEST, V92, P1285, DOI 10.1038/labinvest.2012.92
   Harris HE, 2006, EMBO REP, V7, P774, DOI 10.1038/sj.embor.7400759
   Hollan I, 2010, ARTHRIT CARE RES, V62, P378, DOI 10.1002/acr.20094
   Huttunen R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017653
   Imaizumi T, 2000, ARTERIOSCL THROM VAS, V20, P410, DOI 10.1161/01.ATV.20.2.410
   Ince C, 2016, SHOCK, V45, P259, DOI 10.1097/SHK.0000000000000473
   Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301
   Kaneider NC, 2007, NAT IMMUNOL, V8, P1303, DOI 10.1038/ni1525
   Koyama K, 2014, CRIT CARE, V18, DOI 10.1186/cc13190
   Lee YJ, 2005, EUR J PHARMACOL, V508, P31, DOI 10.1016/j.ejphar.2004.12.006
   Luedemann C, 2005, ALCOHOL CLIN EXP RES, V29, P930, DOI 10.1097/01.ALC.0000171037.90100.6B
   Mauri T, 2010, INTENS CARE MED, V36, P621, DOI 10.1007/s00134-010-1752-5
   Naassila M, 1996, EUR J PHARMACOL, V313, P273, DOI 10.1016/0014-2999(96)00643-7
   Nelson S, 2002, NAT REV IMMUNOL, V2, P205, DOI 10.1038/nri744
   Pruett SB, 2004, ALCOHOL, V33, P147, DOI 10.1016/j.alcohol.2004.08.001
   Pruett SB, 2010, TOXICOL SCI, V117, P314, DOI 10.1093/toxsci/kfq215
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Sato M, 2002, ANN NY ACAD SCI, V957, P122, DOI 10.1111/j.1749-6632.2002.tb02911.x
   Shi PY, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0766-5
   Spapen H, 2008, ANAT REC, V291, P714, DOI 10.1002/ar.20646
   Sprong T, 2009, SHOCK, V31, P28, DOI 10.1097/SHK.0b013e31817fd543
   Sureshbabu A, 2015, RESP RES, V16, DOI 10.1186/s12931-014-0162-6
   Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x
   Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145
   Ward PA, 2012, EMBO MOL MED, V4, P1234, DOI 10.1002/emmm.201201375
   Woodman GE, 1996, SURGERY, V120, P80, DOI 10.1016/S0039-6060(96)80245-5
NR 38
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-8329
EI 1873-6823
J9 ALCOHOL
JI Alcohol
PD NOV
PY 2017
VL 64
BP 1
EP 9
DI 10.1016/j.alcohol.2017.04.003
PG 9
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA FJ4MT
UT WOS:000412715100001
PM 28965650
DA 2023-08-21
ER

PT J
AU Silliman, CC
   Kelher, MR
   Khan, SY
   West, FB
   McLaughlin, NJD
   Elzi, DJ
   England, K
   Bjornsen, J
   Kuldanek, SA
   Banerjee, A
AF Silliman, Christopher C.
   Kelher, Marguerite R.
   Khan, Samina Y.
   West, F. Bernadette
   McLaughlin, Nathan J. D.
   Elzi, David J.
   England, Kelly
   Bjornsen, Jason
   Kuldanek, Susan A.
   Banerjee, Anirban
TI Supernatants and lipids from stored red blood cells activate pulmonary
   microvascular endothelium through the BLT2 receptor and protein kinase C
   activation
SO TRANSFUSION
LA English
DT Article
ID ACUTE LUNG INJURY; MULTIPLE-ORGAN FAILURE; ROUTINE STORAGE; MEMBRANE
   TRANSLOCATION; NEUTROPHIL ADHESION; TRANSFUSED BLOOD; EARLY PREDICTORS;
   TEMPORAL TRENDS; OLDER BLOOD; P38 MAPK
AB BACKGROUNDAlthough transfusion is a lifesaving intervention, it may be associated with significant morbidity in injured patients. We hypothesize that stored red blood cells (RBCs) induce proinflammatory activation of human pulmonary microvascular endothelial cells (HMVECs) resulting in neutrophil (PMN) adhesion and predisposition to acute lung injury (ALI).
   STUDY DESIGN AND METHODSTen units of RBCs were collected; 50% (by weight) were leukoreduced (LR-RBCs) and the remainder was unmodified and stored in additive solution-5 (AS-5). An additional 10 units of RBCs were collected, leukoreduced, and stored in AS-3. HMVECs were incubated with [10%-40%](FINAL) of the supernatants on Day (D)1 to D42 of storage, lipid extracts, and purified lipids. Endothelial surface expression of intercellular adhesion molecule-1 (ICAM-1), interleukin (IL)-8 release, and PMN adhesion to HMVECs were measured. HMVEC signaling via the BLT2 receptor was evaluated. Supernatants and lipids were also employed as the first event in a two-event model of ALI.
   RESULTSThe supernatants [10%-40%](FINAL) from D21 LR-RBCs and D42 RBCs and LR-RBCs and the lipids from D42 stored in AS-5 induced increased ICAM-1 surface expression on endothelium, IL-8 release, and PMN adhesion. In addition, the supernatants [20%-40%](FINAL) from D21 and D42 RBCs in AS-5 also increased endothelial surface expression of ICAM-1. D42 supernatants and lipids also caused coprecipitation of -arrestin-1 with BLT2, protein kinase C (PKC)(I), and PKC and served as the first event in a two-event rodent model of ALI.
   CONCLUSIONLipids that accumulate during RBC storage activate endothelium and predispose to ALI, which may explain some of the adverse events associated with the transfusion of critically injured patients.
C1 [Silliman, Christopher C.; Kelher, Marguerite R.; Khan, Samina Y.; West, F. Bernadette; McLaughlin, Nathan J. D.; Elzi, David J.; England, Kelly; Bjornsen, Jason; Kuldanek, Susan A.] Bonfils Blood Ctr, Res Lab, 717 Yosemite St, Denver, CO 80230, United States.
C1 [Silliman, Christopher C.; Kelher, Marguerite R.; Elzi, David J.; England, Kelly; Banerjee, Anirban] Univ Colorado Denver, Sch Med, Dept Surg, Aurora, CO, United States.
C1 [Silliman, Christopher C.; Khan, Samina Y.; McLaughlin, Nathan J. D.; Kuldanek, Susan A.] Univ Colorado Denver, Sch Med, Dept Pediat, Denver, CO, United States.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; Children's Hospital Colorado;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver
RP Silliman, CC (corresponding author), Bonfils Blood Ctr, Res Lab, 717 Yosemite St, Denver, CO 80230 USA.
EM christopher.silliman@ucdenver.edu
OI Elzi, David/0000-0002-6637-7607
FU NHLBI NIH HHS [R01 HL059355] Funding Source: Medline; NIGMS NIH HHS [P50
   GM049222] Funding Source: Medline
CR ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668
   Balvers- K, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00024
   Bayat B, 2013, ARTERIOSCL THROM VAS, V33, P2538, DOI 10.1161/ATVBAHA.113.301206
   Bock A, 2015, SHOCK, V44, P137, DOI 10.1097/SHK.0000000000000394
   Brattstrom O, 2010, ACTA ANAESTH SCAND, V54, P1007, DOI 10.1111/j.1399-6576.2010.02266.x
   Brown LM, 2011, AM J SURG, V201, P486, DOI 10.1016/j.amjsurg.2010.02.003
   Chaiwat O, 2009, ANESTHESIOLOGY, V110, P351, DOI 10.1097/ALN.0b013e3181948a97
   Chinthamani S, 2012, AM J PHYSIOL-CELL PH, V302, pC968, DOI 10.1152/ajpcell.00259.2011
   Cho KJ, 2010, AM J RESP CELL MOL, V42, P294, DOI 10.1165/rcmb.2008-0445OC
   Ciesla DJ, 2005, ARCH SURG-CHICAGO, V140, P432, DOI 10.1001/archsurg.140.5.432
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Cryer HG, 2014, J TRAUMA ACUTE CARE, V76, P592
   D'Alessandro A, 2015, VOX SANG, V108, P131, DOI 10.1111/vox.12193
   D'Alessandro A, 2015, TRANSFUSION, V55, P1155, DOI 10.1111/trf.12975
   D'Alessandro A, 2012, HAEMATOL-HEMATOL J, V97, P107, DOI 10.3324/haematol.2011.051789
   D'Amici GM, 2012, BLOOD TRANSFUS-ITALY, V10, pS46, DOI 10.2450/2012.008S
   DASILVA AMT, 1993, NEW ENGL J MED, V328, P1457, DOI 10.1056/NEJM199305203282005
   DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129
   Dudek SM, 2011, AM J RESP CELL MOL, V44, P361, DOI 10.1165/rcmb.2009-0446OC
   Dzieciatkowska M, 2013, VOX SANG, V105, P210, DOI 10.1111/vox.12042
   El Azreq MA, 2011, MOL IMMUNOL, V48, P1408, DOI 10.1016/j.molimm.2011.03.018
   Eun JC, 2011, SHOCK, V35, P240, DOI 10.1097/SHK.0b013e3181faceb3
   Fisher AB, 2011, ANTIOXID REDOX SIGN, V15, P831, DOI 10.1089/ars.2010.3412
   Gevi F, 2012, J PROTEOMICS, V76, P168, DOI 10.1016/j.jprot.2012.03.012
   GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662
   Hassan M, 2011, SHOCK, V35, P3, DOI 10.1097/SHK.0b013e3181e76274
   Hicks A, 2007, EXPERT OPIN INV DRUG, V16, P1909, DOI 10.1517/13543784.16.12.1909
   Holena DN, 2012, J TRAUMA ACUTE CARE, V73, P825, DOI 10.1097/TA.0b013e318256de38
   Howard BM, 2015, J TRAUMA ACUTE CARE, V78, P735, DOI 10.1097/TA.0000000000000583
   Johansson AS, 2010, EXP CELL RES, V316, P2790, DOI 10.1016/j.yexcr.2010.07.016
   Juffermans NP, 2012, BLOOD TRANSFUS-ITALY, V10, P290, DOI 10.2450/2012.0068-11
   Kelher MR, 2017, J LEUKOCYTE BIOL, V101, P261, DOI 10.1189/jlb.3A0813-420RRR
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Kim EY, 2010, FREE RADICAL BIO MED, V49, P1072, DOI 10.1016/j.freeradbiomed.2010.06.023
   Kim GY, 2010, J IMMUNOL, V184, P3946, DOI 10.4049/jimmunol.0901735
   Kim GY, 2009, ARTERIOSCL THROM VAS, V29, P915, DOI 10.1161/ATVBAHA.109.185793
   Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403
   Lee JW, 2013, J BIOL CHEM, V288, P30054, DOI 10.1074/jbc.M113.481283
   Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237
   Lelubre C, 2009, TRANSFUSION, V49, P1384, DOI 10.1111/j.1537-2995.2009.02211.x
   Long K, 2013, AM SURGEON, V79, P810
   Mack JP, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.96.96
   McLaughlin NJD, 2008, J IMMUNOL, V180, P8192, DOI 10.4049/jimmunol.180.12.8192
   McLaughlin NJD, 2006, J IMMUNOL, V176, P7039, DOI 10.4049/jimmunol.176.11.7039
   Mostafa G, 2004, AM SURGEON, V70, P357
   Murrell Z, 2005, AM SURGEON, V71, P781
   Offner PJ, 2004, CRIT CARE, V8, pS24, DOI 10.1186/cc2405
   Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711
   Partrick D A, 1996, New Horiz, V4, P194
   Patel SV, 2014, INJURY, V45, P1522, DOI 10.1016/j.injury.2014.05.015
   Peters AL, 2016, VOX SANG, V112, P25
   Peters AL, 2016, CRIT CARE MED, V44, pE412, DOI 10.1097/CCM.0000000000001614
   Roback JD, 2014, TRANSFUS MED REV, V28, P41, DOI 10.1016/j.tmrv.2014.01.003
   Sadjadi J, 2009, AM SURGEON, V75, P307
   SALZER WL, 1990, J CLIN INVEST, V85, P1135, DOI 10.1172/JCI114545
   Sauaia A, 1998, J TRAUMA, V45, P291, DOI 10.1097/00005373-199808000-00014
   SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39
   Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147
   SAUTER C, 1980, LANCET, V2, P852
   Schroder K, 2012, CIRC RES, V110, P1217, DOI 10.1161/CIRCRESAHA.112.267054
   Sharpe JP, 2013, J TRAUMA ACUTE CARE, V75, P32, DOI 10.1097/TA.0b013e318294672d
   Silliman CC, 2010, VOX SANG, V98, P525, DOI 10.1111/j.1423-0410.2009.01289.x
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684
   Silliman CC, 1996, TRANSFUSION, V36, P133, DOI 10.1046/j.1537-2995.1996.36296181925.x
   Silliman CC, 2017, BLOOD TRANSFUS-ITALY, V15, P131, DOI 10.2450/2017.0314-16
   Silliman CC, 2014, BLOOD, V123, P3488, DOI 10.1182/blood-2013-10-532424
   Silliman CC, 2012, TRANSFUSION, V52, P1155, DOI 10.1111/j.1537-2995.2012.03564.x
   Silliman CC, 2011, TRANSFUSION, V51, P2549, DOI 10.1111/j.1537-2995.2011.03186.x
   Smith CW, 2008, J ALLERGY CLIN IMMUN, V121, pS375, DOI 10.1016/j.jaci.2007.07.030
   Sparrow RL, 2012, BLOOD TRANSFUS-ITALY, V10, pS7, DOI [10.2450/20/2.003S, 10.2450/2012.003S]
   Spinella PC, 2009, CRIT CARE, V13, DOI 10.1186/cc8050
   STARZL TE, 1985, SEMIN LIVER DIS, V5, P334, DOI 10.1055/s-2008-1040630
   STARZL TE, 1982, HEPATOLOGY, V2, P614
   WALL WJ, 1988, CAN MED ASSOC J, V139, P21
   Wang D, 2012, TRANSFUSION, V52, P1184, DOI 10.1111/j.1537-2995.2011.03466.x
   Warren HS, 2010, J INFECT DIS, V201, P223, DOI 10.1086/649557
   Watkins TR, 2008, CRIT CARE MED, V36, P1493, DOI 10.1097/CCM.0b013e318170a9ce
   Weinberg JA, 2008, J TRAUMA, V65, P279, DOI 10.1097/TA.0b013e31817c9687
   Weinberg JA, 2011, TRANSFUSION, V51, P867, DOI 10.1111/j.1537-2995.2011.03098.x
   Weinberg JA, 2010, J TRAUMA, V69, P1427, DOI 10.1097/TA.0b013e3181fa0019
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1
NR 84
TC 12
Z9 12
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD NOV
PY 2017
VL 57
IS 11
BP 2690
EP 2700
DI 10.1111/trf.14271
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA FL9WY
UT WOS:000414611800020
PM 28880373
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Yeh, LC
   Huang, PW
   Hsieh, KH
   Wang, CH
   Kao, YK
   Lin, TH
   Lee, XL
AF Yeh, Li-Chun
   Huang, Ping-Wun
   Hsieh, Kuan-Hsian
   Wang, Chung-Hsuan
   Kao, Yi-Kai
   Lin, Tzu-Hsiang
   Lee, Xiao-Lun
TI Elevated Plasma Levels of Gas6 Are Associated with Acute Lung Injury in
   Patients with Severe Sepsis
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE ALI/ARDS; Growth arrest-specific gene 6 (Gas6); interleukin-8; interleukin-6; sepsis 
ID EARLY IDENTIFICATION; PREDICTION SCORE; DERIVATION; SURVIVAL; PROTEIN
AB Acute lung injury (ALI) is one of the complications of severe sepsis, causing sudden deaths. However, information regarding predictive factors for the onset of ALI in severe sepsis is limited. Growth arrest specific gene 6 (Gas6) is secreted by endothelial cells and is important for the activation of endothelium during inflammation. This study aimed to investigate the predictive effect of plasma Gas6 in patients with severe sepsis. Collection of plasma samples was carried out from 129 participants with severe sepsis following with or without ALI development. We found that the elevated levels of Gas6, interleukin-6 and-8 (IL-6 and IL-8) in plasma were associated with the ALI development (P = 0.003, 0.002, and 0.004, respectively). We also observed the robust correlation between the plasma level of Gas6 and the following ALI development to adjustment for sepsis and administration of vasopressor. Between patients with ALI (n = 18) and those without ALI (n = 111), Gas6 and the Lung Injury Prediction Score (LIPS) showed promising discrimination (AUROC, 0.74 and 0.68, respectively), and in combination with these two indexes, the AUROC was increased to 0.86 (vs. 0.74, P = 0.05), while soluble receptor for advanced glycation end products (sRAGE) and Willebrand factor (vWF) in plasma showed no predictive value for of ALI. Collectively, our findings indicate that higher levels of Gas6 in plasma are obviously correlated with ALI development. An early increase in the plasma Gas6 level suggests that endothelial injury is a key link in the pathogenesis of ALI.
C1 [Yeh, Li-Chun; Huang, Ping-Wun; Kao, Yi-Kai; Lee, Xiao-Lun] Changhua Show Chwan Mem Hosp, Emergency Dept, 542,Sect 1,Chungsang Rd, Changhua 500, Taiwan.
C1 [Hsieh, Kuan-Hsian] Kaohsiung Armed Forces Gen Hosp, Dept Surg, Zuoying Branch, Kaohsiung, Taiwan.
C1 [Wang, Chung-Hsuan] Wu Xing Clin, Changhua, Taiwan.
C1 [Lin, Tzu-Hsiang] Wei Chun Tai Dermatol Clin, Nantou, Taiwan.
C3 Show Chwan Memorial Hospital
RP Lee, XL (corresponding author), Changhua Show Chwan Mem Hosp, Emergency Dept, 542,Sect 1,Chungsang Rd, Changhua 500, Taiwan.
EM leexiaolunm@yahoo.com
CR Barnett N, 2011, CRIT CARE CLIN, V27, P661, DOI 10.1016/j.ccc.2011.04.001
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Calfee CS, 2011, CRIT CARE MED, V39, P711, DOI 10.1097/CCM.0b013e318207ec3c
   Dihingia A, 2017, DIABETES RES CLIN PR, V128, P74, DOI 10.1016/j.diabres.2017.03.026
   Ekman C, 2010, CRIT CARE, V14, DOI 10.1186/cc9233
   Fremont RD, 2010, J TRAUMA, V68, P1121, DOI 10.1097/TA.0b013e3181c40728
   Fujishima S, 2016, RESPIROLOGY, V21, P898, DOI 10.1111/resp.12769
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Happonen KE, 2016, BLOOD, V127, P672, DOI 10.1182/blood-2015-12-683474
   Jiang L., 2009, AM J CLIN PATHOL, V131, P738, DOI [10.1309/AJCP3CX3AUVRBHCF, DOI 10.1309/AJCP3CX3AUVRBHCF]
   Jung Y, 2016, ONCOTARGET, V7, P25698, DOI 10.18632/oncotarget.8365
   Kor DJ, 2011, ANESTHESIOLOGY, V115, P117, DOI 10.1097/ALN.0b013e31821b5839
   Lee E, 2016, J CELL BIOCHEM, V117, P2815, DOI 10.1002/jcb.25582
   Levitt JE, 2012, CRIT CARE, V16, DOI 10.1186/cc11144
   Li WN, 2017, CLIN EXP HYPERTENS, V39, P382, DOI 10.1080/10641963.2017.1288739
   Liu XW, 2012, CRIT CARE, V16, DOI 10.1186/cc11354
   Miyashita T, 2016, IN VIVO, V30, P341
   Nakstad B, 2016, INFECT DRUG RESIST, V9, P171, DOI 10.2147/IDR.S106181
   Nassar M, 2017, P NATL ACAD SCI USA, V114, pE337, DOI 10.1073/pnas.1614926114
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   Pfeiffer D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179850
   Rainer TH, 1999, RESUSCITATION, V42, P187, DOI 10.1016/S0300-9572(99)00089-1
   RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733
   Stalder G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163542
   Trillo-Alvarez C, 2011, EUR RESPIR J, V37, P604, DOI 10.1183/09031936.00036810
   Wang CY, 2016, BIOCHEM BIOPH RES CO, V478, P935, DOI 10.1016/j.bbrc.2016.08.054
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Yang L, 2016, INFLAMMATION, V39, P1805, DOI 10.1007/s10753-016-0416-1
   Zhu XJ, 2016, J SURG RES, V204, P288, DOI 10.1016/j.jss.2016.04.067
NR 29
TC 18
Z9 19
U1 0
U2 3
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD NOV
PY 2017
VL 243
IS 3
BP 187
EP 193
DI 10.1620/tjem.243.187
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA FP9KH
UT WOS:000417965400006
PM 29176262
OA gold
DA 2023-08-21
ER

PT J
AU Zhang, SJ
   Wu, Y
   Xuan, ZA
   Chen, XM
   Zhang, JJ
   Ge, DY
   Wang, XD
AF Zhang, Shujing
   Wu, Ying
   Xuan, Zinan
   Chen, Xiaoming
   Zhang, Junjie
   Ge, Dongyu
   Wang, Xudan
TI Screening differential miRNAs responsible for permeability increase in
   HUVECs infected with influenza A virus
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL-CELLS; ACTIVATION; KINASE; H1N1; HYPERPERMEABILITY;
   PATHOGENESIS
AB Severe influenza infections are featured by acute lung injury, a syndrome of increased pulmonary microvascular permeability. A growing number of evidences have shown that influenza A virus induces cytoskeletal rearrangement and permeability increase in endothelial cells. Although miRNA's involvement in the regulation of influenza virus infection and endothelial cell (EC) function has been well documented, little is known about the miRNA profiles in influenza-infected endothelial cells. Using human umbilical vein endothelial cells (HUVECs) as cell models, the present study aims to explore the differential miRNAs in influenza virus-infected ECs and analyze their target genes involved in EC permeability regulation. As the results showed, permeability increased and F-actin cytoskeleton reorganized after HUVECs infected with influenza A virus (CA07 or PR8) at 30 MOI. MicroRNA microarray revealed a multitude of miRNAs differentially expressed in HUVECs after influenza virus infection. Through target gene prediction, we found that a series of miRNAs were involved in PKC, Rho/ROCK, HRas/Raf/MEK/ERK, and Ca-2+/CaM pathways associated with permeability regulation, and most of these miRNAs were down-regulated after flu infection. It has been reported that PKC, Rho/ROCK, HRas/Raf/MEK/ERK, and Ca-2+/CaM pathways are activated by flu infection and play important roles in permeability regulation. Therefore, the cumulative effects of these down-regulated miRNAs which synergistically enhanced activation of PKC, Rho/ROCK, Ras/Raf/MEK/ERK, and Ca-2+/CaM pathways, can eventually lead to actin rearrangement and hyperpermeability in flu-infected HUVECs.
C1 [Zhang, Shujing; Ge, Dongyu] Beijing Univ Chinese Med, Sci Res Ctr, Beijing, China.
C1 [Wu, Ying; Xuan, Zinan; Chen, Xiaoming; Zhang, Junjie; Wang, Xudan] Beijing Univ Chinese Med, Sch Life Sci, Dept Microbiol & Immunol, Beijing, China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine
RP Wu, Y (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Dept Microbiol & Immunol, Beijing, Peoples R China.
EM aqiwuying@hotmail.com
RI chen, xin/IQW-3432-2023; chen, xia/GXM-5435-2022; chen,
   xi/GXH-3653-2022; chen, xia/GYR-3948-2022
FU National Natural Science Foundation of China [81473520]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81473520) to YW.; This work was supported by
   grants from the National Natural Science Foundation of China (No.
   81473520). We thank Chenyue Zhang, PhD, at the Department of Integrative
   Oncology in Fudan University Shanghai Cancer Center, for language
   proofreading.
CR Alexy T, 2014, PHYSIOL GENOMICS, V46, P833, DOI 10.1152/physiolgenomics.00079.2014
   Armstrong SM, 2013, VIRULENCE, V4, P537, DOI 10.4161/viru.25779
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Arora DJS, 1998, ARCH VIROL, V143, P2029, DOI 10.1007/s007050050439
   Szretter Kristy J, 2006, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/9780471729259.mc15g01s29, 10.1002/0471729256.mc15g01s3]
   Bogatcheva NV, 2011, J CELL PHYSIOL, V226, P3132, DOI 10.1002/jcp.22669
   Buggele WA, 2012, J BIOL CHEM, V287, P31027, DOI 10.1074/jbc.M112.387670
   Chan LY, 2011, J ETHNOPHARMACOL, V137, P1542, DOI 10.1016/j.jep.2011.08.022
   Chowell G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041069
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   Haidari M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021444
   Haidari M, 2009, PHYTOMEDICINE, V16, P1127, DOI 10.1016/j.phymed.2009.06.002
   HARTSHORN KL, 1990, BLOOD, V75, P218
   HARTSHORN KL, 1992, BLOOD, V79, P1049
   Hwang HW, 2006, BR J CANC S, V96, pR40
   Kalani M, 2016, PROBIOTICS ANTIMICRO, V8, P61, DOI 10.1007/s12602-016-9214-1
   Lipatov AS, 2004, J VIROL, V78, P8951, DOI 10.1128/JVI.78.17.8951-8959.2004
   Loveday EK, 2012, J VIROL, V86, P6109, DOI 10.1128/JVI.06892-11
   Ma YJ, 2012, J CELL MOL MED, V16, P2539, DOI 10.1111/j.1582-4934.2012.01572.x
   NUGENT KM, 1984, ARCH VIROL, V81, P163, DOI 10.1007/BF01309305
   OCHIAI H, 1991, ANTIVIR RES, V15, P149, DOI 10.1016/0166-3542(91)90032-M
   Pepini T, 2010, J VIROL, V84, P11929, DOI 10.1128/JVI.01658-10
   Perkins LEL, 2001, VET PATHOL, V38, P149, DOI 10.1354/vp.38-2-149
   Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098
   Root CN, 2000, J GEN VIROL, V81, P2697, DOI 10.1099/0022-1317-81-11-2697
   Ruan W, 2012, CARDIOVASC RES, V93, P623, DOI 10.1093/cvr/cvr290
   Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144
   Song LP, 2010, J VIROL, V84, P8849, DOI 10.1128/JVI.00456-10
   Sun XJ, 2007, CELL MICROBIOL, V9, P1672, DOI 10.1111/j.1462-5822.2007.00900.x
   Tambyah PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076811
   Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044
   Zeng J, 2013, EXP CLIN ENDOCR DIAB, V121, P425, DOI 10.1055/s-0033-1345169
   Zhang CY, 2014, VIRUS RES, V192, P6, DOI 10.1016/j.virusres.2014.07.027
NR 33
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2017
VL 12
IS 10
AR e0186477
DI 10.1371/journal.pone.0186477
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FK3RE
UT WOS:000413403000026
PM 29059211
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Suzuki, T
   Tada, Y
   Gladson, S
   Nishimura, R
   Shimomura, I
   Karasawa, S
   Tatsumi, K
   West, J
AF Suzuki, Toshio
   Tada, Yuji
   Gladson, Santhi
   Nishimura, Rintaro
   Shimomura, Iwao
   Karasawa, Satoshi
   Tatsumi, Koichiro
   West, James
TI Vildagliptin ameliorates pulmonary fibrosis in
   lipopolysaccharide-induced lung injury by inhibiting
   endothelial-to-mesenchymal transition
SO RESPIRATORY RESEARCH
LA English
DT Article
DE endothelial-to-mesenchymal transition; pulmonary fibrosis; dipeptidyl peptidase-4; Post ARDS pulmonary fibrosis 
ID DIPEPTIDYL PEPTIDASE-4 INHIBITOR; RESPIRATORY-DISTRESS-SYNDROME;
   OXIDATIVE STRESS; DPP-4 INHIBITOR; CRITICALLY-ILL; CELLS; MICE;
   LINAGLIPTIN; HYPERGLYCEMIA; METAANALYSIS
AB Background: Pulmonary fibrosis is a late manifestation of acute respiratory distress syndrome (ARDS). Sepsis is a major cause of ARDS, and its pathogenesis includes endotoxin-induced vascular injury. Recently, endothelial-to-mesenchymal transition (EndMT) was shown to play an important role in pulmonary fibrosis. On the other hand, dipeptidyl peptidase (DPP)-4 was reported to improve vascular dysfunction in an experimental sepsis model, although whether DPP-4 affects EndMT and fibrosis initiation during lipopolysaccharide (LPS)-induced lung injury is unclear. The aim of this study was to investigate the anti-EndMT effects of the DPP-4 inhibitor vildagliptin in pulmonary fibrosis after systemic endotoxemic injury.
   Methods: A septic lung injury model was established by intraperitoneal injection of lipopolysaccharide (LPS) in eight-week-old male mice (5 mg/kg for five consecutive days). The mice were then treated with vehicle or vildagliptin (intraperitoneally, 10 mg/kg, once daily for 14 consecutive days from 1 day before the first administration of LPS.). Flow cytometry, immunohistochemical staining, and quantitative polymerase chain reaction (qPCR) analysis was used to assess cell dynamics and EndMT function in lung samples from the mice.
   Results: Lung tissue samples from treated mice revealed obvious inflammatory reactions and typical interstitial fibrosis 2 days and 28 days after LPS challenge. Quantitative flow cytometric analysis showed that the number of pulmonary vascular endothelial cells (PVECs) expressing alpha-smooth muscle actin (a-SMA) or S100 calcium-binding protein A4 (S100A4) increased 28 days after LPS challenge. Similar increases in expression were also confirmed by qPCR of mRNA from isolated PVECs. EndMT cells had higher proliferative activity and migration activity than mesenchymal cells. All of these changes were alleviated by intraperitoneal injection of vildagliptin. Interestingly, vildagliptin and linagliptin significantly attenuated EndMT in the absence of immune cells or GLP-1.
   Conclusions: Inhibiting DPP-4 signaling by vildagliptin could ameliorate pulmonary fibrosis by downregulating EndMT in systemic LPS-induced lung injury.
C1 [Suzuki, Toshio; Gladson, Santhi; West, James] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232, United States.
C1 [Suzuki, Toshio; Tada, Yuji; Nishimura, Rintaro; Shimomura, Iwao; Tatsumi, Koichiro] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan.
C1 [Nishimura, Rintaro] Chiba Univ, Grad Sch Med, Dept Adv Med Pulm Hypertens, Chiba, Japan.
C1 [Karasawa, Satoshi] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba, Japan.
C3 Vanderbilt University; Chiba University; Chiba University; Chiba
   University
RP Suzuki, T (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA.; Suzuki, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan.
EM toshio.suzuki@vanderbilt.edu
RI West, James/E-2960-2010
OI West, James/0000-0002-6004-0202; Suzuki, Toshio/0000-0002-0909-0466
FU Japanese Ministry of Education and Science [G16 K19445]; Uehara Memorial
   Foundation; Grants-in-Aid for Scientific Research [16K19445, 17H04181]
   Funding Source: KAKEN
FX This study was supported by a Grant-in-Aid for Scientific Research (JSPS
   KAKENHI Grant Number G16 K19445) from the Japanese Ministry of Education
   and Science, and by the Uehara Memorial Foundation (to TS).
CR Abu El-Asrar AM, 2015, EXP EYE RES, V132, P179, DOI 10.1016/j.exer.2015.01.023
   Amori RE, 2007, JAMA-J AM MED ASSOC, V298, P194, DOI 10.1001/jama.298.2.194
   ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467
   Bader MS, 2007, SOUTH MED J, V100, P252, DOI 10.1097/01.smj.0000257383.66288.68
   Brenner C, 2016, INT J CARDIOL, V202, P49, DOI 10.1016/j.ijcard.2015.08.175
   Choi SH, 2015, CLIN CANCER RES, V21, P3716, DOI 10.1158/1078-0432.CCR-14-3193
   Echeverria C, 2013, J CELL MOL MED, V17, P800, DOI 10.1111/jcmm.12066
   Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
   Hashimoto N, 2010, AM J RESP CELL MOL, V43, P161, DOI 10.1165/rcmb.2009-0031OC
   He ZY, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-126
   Kanasaki K, 2014, DIABETES, V63, P2120, DOI 10.2337/db13-1029
   Kohashi K, 2016, J ATHEROSCLER THROMB, V23, P441, DOI 10.5551/jat.31997
   Komala MG, 2016, NEPHROLOGY, V21, P423, DOI 10.1111/nep.12618
   Lang HN, 2001, DEV BIOL, V234, P120, DOI 10.1006/dbio.2001.0248
   Mamza J, 2016, DIABETES RES CLIN PR, V116, P288, DOI 10.1016/j.diabres.2016.04.029
   Manrique C, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0414-5
   Maric C, 1997, ANAT EMBRYOL, V195, P503, DOI 10.1007/s004290050070
   Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681
   Nagamine A, 2017, J PHARMACOL SCI, V133, P42, DOI 10.1016/j.jphs.2016.12.003
   Nauck MA, 2009, DIABETES CARE, V32, pS223, DOI 10.2337/dc09-S315
   Nickols J, 2015, AM J PHYSIOL-LUNG C, V309, pL1430, DOI 10.1152/ajplung.00067.2015
   Nieto-Fontarigo JJ, 2016, CLIN REV ALLERGY IMM
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Oyama J, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-21
   Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006
   Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350
   Ranchoux B, 2015, CIRCULATION, V131, P1006, DOI 10.1161/CIRCULATIONAHA.114.008750
   Remm F, 2016, EUR HEART J-CARD PHA, V2, P185, DOI 10.1093/ehjcvp/pvv044
   Romacho T, 2016, J HYPERTENS, V34, P869, DOI 10.1097/HJH.0000000000000886
   Salim HM, 2016, VASC PHARMACOL, V79, P16, DOI 10.1016/j.vph.2015.08.011
   Sekine A, 2016, AM J PHYSIOL-LUNG C, V310, pL1130, DOI 10.1152/ajplung.00375.2014
   Shi S, 2016, BIOCHEM BIOPH RES CO, V471, P184, DOI 10.1016/j.bbrc.2016.01.154
   Shiobara T, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0342-7
   Smith EP, 2014, CELL METAB, V19, P1050, DOI 10.1016/j.cmet.2014.04.005
   Sohal SS, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0337-4
   Stenmark KR, 2016, CIRCULATION, V133, P1734, DOI 10.1161/CIRCULATIONAHA.116.022479
   Steven S, 2017, BRIT J PHARMACOL, V174, P1620, DOI 10.1111/bph.13549
   Suzuki T, 2016, AM J PHYSIOL-LUNG C, V310, pL1185, DOI 10.1152/ajplung.00074.2016
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wort SJ, 1999, BRIT MED BULL, V55, P30, DOI 10.1258/0007142991902286
   Yan F, 2015, MOL MED, V21, DOI 10.2119/molmed.2014.00259
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zhou WQ, 2016, MOL CELL BIOCHEM, V419, P19, DOI 10.1007/s11010-016-2745-7
NR 43
TC 80
Z9 82
U1 4
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-993X
EI 1465-9921
J9 RESP RES
JI Respir. Res.
PD OCT 16
PY 2017
VL 18
AR 177
DI 10.1186/s12931-017-0660-4
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA FJ8HB
UT WOS:000413004100001
PM 29037205
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Gaudet, A
   Chenevier-Gobeaux, C
   Parmentier, E
   Delobel, JE
   Dubucquoi, S
   Mathieu, D
   Lassalle, P
   Caires, ND
AF Gaudet, Alexandre
   Chenevier-Gobeaux, Camille
   Parmentier, Erika
   Delobel, Jean-Edouard
   Dubucquoi, Sylvain
   Mathieu, Daniel
   Lassalle, Philippe
   Caires, Nathalie De Freitas
TI Endocan is a stable circulating molecule in ICU patients
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE sepsis; biomarkers; ELISA; ALI/ARDS; Plasma 
ID SEPSIS; LUNG
AB Background. Endocan is a lung endothelial cell secreted proteoglycan, possessing multiple physiological roles and potential therapeutic and diagnostic utility as biomarker in pneumonia and acute respiratory distress syndrome. Endocan synthesis and secretion can be induced by proinflammatory cytokines such as TNF-alpha, but can also be subject of proteolytic degradation causing preanalytical variation.
   Methods: We investigated the stability of endocan in conventional serum, plasma, anticoagulated whole blood, as well as whole blood and plasma stabilized with protease inhibitors.
   Results: Among the recipient tubes for blood collection, those with EDTA gave minimal interference. No dilution effect was observed on recovery tests from 1:2 to 1:16 (v:v). The recovery test in 10 plasma EDTA samples from healthy subjects or septic patients indicated a median recovery of 104.5% [104%-107.5%], and 97% [88.5%; 102.5%], respectively. Patient's plasma endocan remains stable when stored at room temperature till 72 h, or following 3 freeze thaw cycles. Finally, no interference was observed with hemolytic, icteric or turbidic plasma samples.
   Conclusion: These results are consistent with the view that endocan measured in ICU patients is intact, stable, and accurate. Then, the low endocan level observed in ICU patients who developed ARDS is likely to be reliable.
C1 [Gaudet, Alexandre; Parmentier, Erika; Mathieu, Daniel; Lassalle, Philippe; Caires, Nathalie De Freitas] Univ Lille, CIIL, UMR 8204, U1019, F-59000 Lille, France.
C1 [Gaudet, Alexandre; Parmentier, Erika; Mathieu, Daniel; Lassalle, Philippe; Caires, Nathalie De Freitas] CNRS, UMR 8204, F-59000 Lille, France.
C1 [Gaudet, Alexandre; Parmentier, Erika; Mathieu, Daniel; Lassalle, Philippe; Caires, Nathalie De Freitas] INSERM, U1019, F-59000 Lille, France.
C1 [Gaudet, Alexandre; Parmentier, Erika; Mathieu, Daniel; Lassalle, Philippe; Caires, Nathalie De Freitas] CHU Lille, Pole Reanimat, Hop Roger Salengro, F-59000 Lille, France.
C1 [Gaudet, Alexandre; Parmentier, Erika; Mathieu, Daniel; Lassalle, Philippe; Caires, Nathalie De Freitas] Inst Pasteur, F-59000 Lille, France.
C1 [Chenevier-Gobeaux, Camille] Cochin Hosp, APHP, HUPC, Dept Automated Biol Diag, F-75005 Paris, France.
C1 [Delobel, Jean-Edouard] Lunginnov, F-59000 Lille, France.
C1 [Dubucquoi, Sylvain] CHU Lille, Ctr Biol Pathol Genet, Inst Immunol, F-59000 Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Le Reseau International des Instituts
   Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille;
   Universite de Lille; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Universite de Lille; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE;
   Universite de Lille; Universite de Lille - ISITE; CHU Lille; Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire
   Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Hopital Universitaire Saint-Antoine - APHP; Universite Paris
   Cite; Hopital Universitaire Broca - APHP; Hopital Universitaire Cochin -
   APHP; Hopital Universitaire Necker-Enfants Malades - APHP; Universite de
   Lille - ISITE; CHU Lille
RP Gaudet, A (corresponding author), Inst Pasteur, Equipe 13, INSERM, U1019, 1 Rue Prof Calmette, F-59000 Lille, France.
EM alexandre.gaudet@yahoo.fr
RI Dubucquoi, Sylvain/I-5756-2018; Lassalle, Philippe/L-6705-2018
OI Dubucquoi, Sylvain/0000-0002-8962-3719; Parmentier-Decrucq,
   Erika/0000-0002-5836-5956
CR Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200
   Caires ND, 2013, J PHARMACEUT BIOMED, V78-79, P45, DOI 10.1016/j.jpba.2013.01.035
   Depontieu F, 2012, J IMMUNOL METHODS, V378, P88, DOI 10.1016/j.jim.2012.02.009
   Kao SJ, 2014, CLIN CHEM LAB MED, V52, P445, DOI 10.1515/cclm-2013-0638
   Lassalle P, 1996, J BIOL CHEM, V271, P20458, DOI 10.1074/jbc.271.34.20458
   Lippi G, 2015, CLIN CHEM LAB MED, V53, P357, DOI 10.1515/cclm-2014-1051
   Mikkelsen ME, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.07.077
   Nault JC, 2013, CANCER EPIDEM BIOMAR, V22, P1343, DOI 10.1158/1055-9965.EPI-13-0179
   NUIJENS JH, 1992, J LAB CLIN MED, V119, P159
   Palmiere C, 2014, LEGAL MED-TOKYO, V16, P1, DOI 10.1016/j.legalmed.2013.09.007
   Palud A, 2015, CYTOKINE, V73, P213, DOI 10.1016/j.cyto.2015.02.013
   Scherpereel A, 2003, CANCER RES, V63, P6084
   Scherpereel A, 2006, CRIT CARE MED, V34, P532, DOI 10.1097/01.CCM.0000198525.82124.74
   Seo K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123358
   Tsai JC, 2002, J VASC RES, V39, P148, DOI 10.1159/000057763
   VASSAULT A, 1992, ANN BIOL CLIN-PARIS, V50, P727
NR 16
TC 12
Z9 13
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD OCT
PY 2017
VL 50
IS 15
BP 870
EP 877
DI 10.1016/j.clinbiochem.2017.04.011
PG 8
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA FF0OD
UT WOS:000408600100010
PM 28427918
DA 2023-08-21
ER

PT J
AU Zhang, FM
   Yang, WL
   Brenner, M
   Wang, P
AF Zhang, Fangming
   Yang, Weng-Lang
   Brenner, Max
   Wang, Ping
TI Attenuation of hemorrhage-associated lung injury by adjuvant treatment
   with C23, an oligopeptide derived from cold-inducible RNA-binding
   protein
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE hemorrhagic shock; ALI/ARDS; CIRP; C23 
ID RESPIRATORY-DISTRESS-SYNDROME; MALE GERM-CELLS; FLUID RESUSCITATION;
   CIRP EXPRESSION; GENE-EXPRESSION; SHOCK; ACTIVATION; EPIDEMIOLOGY;
   TRANSCRIPTS; TRANSFUSION
AB BACKGROUND: Hemorrhagic shock (HS) is an important cause of mortality. HS is associated with an elevated incidence of acute lung injury and acute respiratory distress syndrome, significantly contributing to HS morbidity and mortality. Cold-inducible RNA-binding protein (CIRP) is released into the circulation during HS and can cause lung injury. C23 is a CIRP-derived oligopeptide that binds with high affinity to the CIRP receptor and inhibits CIRP-induced phagocyte secretion of TNF-alpha. This study was designed to determine whether C23 is able to attenuate HS-associated lung injury.
   METHODS: C57BL/6 mice were subjected to controlled hemorrhage leading to a mean arterial pressure of 25 +/- 3 mm Hg for 90 minutes. Mice were then volume-resuscitated for 30minutes with normal saline solution alone (vehicle) or plus adjuvant treatment with C23 (8mg/kg BW). At 4.5 hours after resuscitation, the blood and lungs were harvested.
   RESULTS: Serum levels of organ injury markers lactate dehydrogenase, aspartate aminotransferase were significantly elevated in hemorrhaged mice receiving vehicle and were reduced by 51.3% and 52.2% in mice adjuvantly treated with C23, respectively. Similarly, lung mRNA levels of IL-1 beta, TNF-alpha, and IL-6, and lungmyeloperoxidase activity were elevated after HS and reduced by 66.1%, 54.4%, 69.7%, and 24.3%, respectively, in mice treated with C23. Adjuvant treatment with C23 also decreased the lung histology score by 33.9%, lung extravasation of albumin carrying Evans blue dye by 36.8%, and the protein level of intercellular adhesion molecule-1, and indicator of vascular endothelial cell activation, by 40.3%.
   CONCLUSION: Together, these results indicate that adjuvant treatment with the CIRP-derived oligopeptide C23 is able to improve lung inflammation and vascular endothelial activation secondary to HS, lending support to the development of CIRP-targeting adjuvant treatments to minimize lung injury after HS. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [Zhang, Fangming; Yang, Weng-Lang; Brenner, Max; Wang, Ping] Feinstein Inst Med Res, Ctr Immunol & Inflammat, 350 Community Dr, Manhasset, NY 11030, United States.
C1 [Yang, Weng-Lang; Wang, Ping] Hofstra Northwell Sch Med, Dept Surg, Manhasset, NY, United States.
C3 Northwell Health; Northwell Health
RP Wang, P (corresponding author), Feinstein Inst Med Res, Ctr Immunol & Inflammat, 350 Community Dr, Manhasset, NY 11030 USA.
EM pwang@northwell.edu
OI Brenner, Max/0000-0002-8010-148X; Teeter, William/0000-0001-9584-0579;
   Wang, Ping/0000-0002-1557-0394; Hudhud, Muhammad K./0000-0001-9957-858X;
   Stein, Deborah/0000-0003-3683-3963
FU NHLBI NIH HHS [R01 HL076179] Funding Source: Medline
CR Al-Fageeh MB, 2013, MOL BIOTECHNOL, V54, P238, DOI 10.1007/s12033-013-9649-5
   Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502
   [Anonymous], COCHRANE DATABASE SY
   [Anonymous], 2016, SCI REP UK
   Barenco M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r25
   Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2
   Diebel LN, 2012, J TRAUMA ACUTE CARE, V73, P41, DOI 10.1097/TA.0b013e31825e8b32
   El Sayad M, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/638956
   Finfer S, 2004, NEW ENGL J MED, V350, P2247
   FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752
   Godwin A, 2015, SHOCK, V43, P24, DOI 10.1097/SHK.0000000000000251
   Gutierrez G, 2004, CRIT CARE, V8, P373, DOI 10.1186/cc2851
   Hahnefeld Claudia, 2004, Methods Mol Med, V94, P299
   Hirano Y, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0782-3
   Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387
   Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19
   Kelher MR, 2016, TRANSFUSION, V56, P3004, DOI 10.1111/trf.13817
   Korff S, 2016, SHOCK, V46, P519, DOI 10.1097/SHK.0000000000000650
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Masuda T, 2012, P NATL ACAD SCI USA, V109, P10885, DOI 10.1073/pnas.1121524109
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Nishiyama H, 1998, BIOCHEM BIOPH RES CO, V245, P534, DOI 10.1006/bbrc.1998.8482
   Nishiyama H, 1997, GENE, V204, P115, DOI 10.1016/S0378-1119(97)00530-1
   Nishiyama H, 1998, AM J PATHOL, V152, P289
   Pidcoke HF, 2012, J TRAUMA ACUTE CARE, V73, pS445, DOI 10.1097/TA.0b013e3182754796
   Qiang XL, 2013, NAT MED, V19, P1489, DOI 10.1038/nm.3368
   Reilly John P, 2014, Ann Am Thorac Soc, V11, P728, DOI 10.1513/AnnalsATS.201308-280OC
   Roberts I, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004896.pub3
   Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943
   Rudstrom H, 2013, WORLD J SURG, V37, P1981, DOI 10.1007/s00268-013-2061-2
   Sakurai T, 2006, BBA-MOL CELL RES, V1763, P290, DOI 10.1016/j.bbamcr.2006.02.007
   Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720
   Shin HJ, 2007, MOL CELLS, V24, P119
   Sodhi CP, 2015, J IMMUNOL, V194, P4931, DOI 10.4049/jimmunol.1402490
   STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515
   Wang CH, 2014, CRIT CARE MED, V42, P954, DOI 10.1097/CCM.0000000000000050
   Wellmann S, 2004, J CELL SCI, V117, P1785, DOI 10.1242/jcs.01026
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu XW, 2016, SHOCK, V46, P108, DOI 10.1097/SHK.0000000000000652
   Xue JH, 1999, FREE RADICAL BIO MED, V27, P1238, DOI 10.1016/S0891-5849(99)00158-6
   Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200
   Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107
   Yang RQ, 2010, J BIOL CHEM, V285, P8887, DOI 10.1074/jbc.M109.013128
   Zhou M, 2014, BBA-GEN SUBJECTS, V1840, P2253, DOI 10.1016/j.bbagen.2014.02.027
   Zhou YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137721
NR 46
TC 42
Z9 44
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD OCT
PY 2017
VL 83
IS 4
BP 690
EP 697
DI 10.1097/TA.0000000000001566
PG 8
WC Critical Care Medicine; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Surgery
GA FH8PN
UT WOS:000411460500019
PM 28129260
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Zhang, ML
   Yan, X
   Liu, W
   Sun, RL
   Xie, YH
   Jin, FG
AF Zhang, Minlong
   Yan, Xue
   Liu, Wei
   Sun, Ruilin
   Xie, Yonghong
   Jin, Faguang
TI Endothelial semaphorin 7A promotes seawater aspiration-induced acute
   lung injury through plexin C1 and beta 1 integrin
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE semaphorin 7A; ALI/ARDS; seawater; plexin C1; beta 1 integrin 
ID INFLAMMATION; FAMILY; MOLECULES; COLLAPSIN; RESPONSES; INTEGRIN;
   HYPOXIA; GROWTH; CELLS
AB Inflammation and edema are two main characteristics in seawater aspiration-induced acute lung injury (ALI). In a previous study of the authors, it was demonstrated that endothelial semaphorin 7A (SEMA7A) serves an important role in the development of seawater-induced inflammation and edema. However, the mechanism of endothelial SEMA7A-mediated ALI remains unclear. Therefore, the authors explored the effect of SEMA7A in rat pulmonary microvascular endothelial cells (RPMVECs) and the interaction between endothelial SEMA7A and alveolar macrophages during seawater aspiration-induced ALI. The role of SEMA7A in endothelial permeability was detected using plexin C1 blocking antibody or SEMA7A small interfering (si) RNA. In addition, RPMVECs were co-cultured with rat alveolar macrophage cell line-NR8383 cells and pro-inflammatory cytokine production was detected. Interaction between the beta 1 integrin and SEMA7A was detected using the beta 1 integrin blocking antibody or SEMA7A siRNA. Seawater stimulation induced endothelial cytoskeleton remodeling, endothelial permeability, phosphorylation of cofilin, and increased the vascular endothelial growth factor (VEGF) expression in RPMVECs. Moreover, seawater stimulation led to expression of proinflammatory cytokines and activated the nuclear factor-kappa B pathway in co-cultured cells. However, blockage with the plexin C1 antibody inhibited endothelial cytoskeleton remodeling, endothelial permeability, phosphorylation of cofilin, and treatment with SEMA7A siRNA inhibited expression of VEGF in RPMVECs. In addition, blockage with beta 1 integrin antibody reduced expression of proinflammatory cytokines and inhibited activation of NF-kappa B in co-culture cells. These results suggest that SEMA7A promotes seawater induced lung edema via plexin C1 and stimulates seawater induced lung inflammation via beta 1 integrin.
C1 [Zhang, Minlong; Liu, Wei; Sun, Ruilin; Xie, Yonghong; Jin, Faguang] Fourth Mil Med Univ, Tangdu Hosp, Dept Respirat, 1 Xinsi Rd, Xian 710038, Shaanxi, China.
C1 [Yan, Xue] Xianyang Vocat & Tech Coll, Sch Med, Xianyang 712000, Shaanxi, China.
C3 Air Force Military Medical University
RP Xie, YH; Jin, FG (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Respirat, 1 Xinsi Rd, Xian 710038, Shaanxi, Peoples R China.
EM xieyh65@fmmu.edu.cn; jinfag@fmmu.edu.cn
FU National Natural Science Foundation of China [81570,067]
FX The present work was supported by the National Natural Science
   Foundation of China (grant no. 81570,067).
CR CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605
   Czopik AK, 2006, IMMUNITY, V24, P591, DOI 10.1016/j.immuni.2006.03.013
   Gan Y, 2011, ARTHRITIS RHEUM-US, V63, P2484, DOI 10.1002/art.30386
   Holmes S, 2002, SCAND J IMMUNOL, V56, P270, DOI 10.1046/j.1365-3083.2002.01129.x
   Koenig K, 2014, EUR J IMMUNOL, V44, P2648, DOI 10.1002/eji.201343968
   KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z
   Lazova R, 2009, AM J DERMATOPATH, V31, P177, DOI 10.1097/DAD.0b013e318196672d
   Liu ZY, 2015, EXP LUNG RES, V41, P301, DOI 10.3109/01902148.2015.1030803
   Liu ZY, 2014, INT J MOL SCI, V15, P12861, DOI 10.3390/ijms150712861
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9
   Ma LJ, 2016, INT J MOL MED, V37, P165, DOI 10.3892/ijmm.2015.2403
   Ma LJ, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/182132
   Maruyama T, 2008, DEV NEUROBIOL, V68, P317, DOI 10.1002/dneu.20592
   Mizutani N, 2015, EUR J PHARMACOL, V764, P149, DOI 10.1016/j.ejphar.2015.07.004
   Morote-Garcia JC, 2012, P NATL ACAD SCI USA, V109, P14146, DOI 10.1073/pnas.1202165109
   Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790
   PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1
   Roth JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146930
   Soto GJ, 2016, CRIT CARE MED, V44, P2182, DOI 10.1097/CCM.0000000000002001
   Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553
   Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652
   van Rijn A, 2016, J IMMUNOL, V196, P459, DOI 10.4049/jimmunol.1403096
   Zhang M, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0105994, 10.1371/journal.pone.0109589]
   Zhang ML, 2014, INT J MOL SCI, V15, P19650, DOI 10.3390/ijms151119650
NR 27
TC 11
Z9 12
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2017
VL 16
IS 4
BP 4215
EP 4221
DI 10.3892/mmr.2017.7097
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FG9JA
UT WOS:000410753800067
PM 28765893
OA Bronze
DA 2023-08-21
ER

PT J
AU Wang, HL
   Zheng, RQ
   Chen, QH
   Shao, J
   Yu, JQ
   Hu, SL
AF Wang, Hualing
   Zheng, Ruiqiang
   Chen, Qihong
   Shao, Jun
   Yu, Jiangquan
   Hu, Shuling
TI Mesenchymal stem cells microvesicles stabilize endothelial barrier
   function partly mediated by hepatocyte growth factor (HGF)
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stem cells microvesicles; hepatocyte growth factor (HGF); permeability; ALI/ARDS 
ID ACUTE LUNG INJURY; TRANSCELLULAR TRANSPORT; PERMEABILITY; DYSFUNCTION;
   PULMONARY; PATHWAY; MICE
AB Background: Mesenchymal stem cells microvesicles (MSC-MVs) stabilize endothelial barrier function in acute lung injury (ALI); however, the detailed mechanism remains to be further defined. Hepatocyte growth factor (HGF), which is derived from MSC-MVs, might have a key role in the restoration of endothelial barrier function by MSC-MVs.
   Methods: MSCs with lentiviral vector-mediated HGF gene knockdown (siHGF-MSC) were generated. A co-culture model of pulmonary microvascular endothelial cells and MSC-MVs collected from MSCs or siHGF-MSCs after 24 h of hypoxic culture was utilized. Then, endothelial paracellular and transcellular permeabilities were detected. VE-cadherin, and occludin protein expression in the endothelial cells was measured using Western blot. Endothelial cell proliferation was analysed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. Endothelial cell apoptosis was analysed using TUNEL assay. Finally, IL-6 and IL-10 production was determined via an enzyme-linked immunosorbent assay (ELISA).
   Results: Treatment with MSC-MVs significantly decreased LPS-induced endothelial paracellular and transcellular permeabilities, and the effect was significantly inhibited after HGF gene knockdown in MSC-MVs. Furthermore, treatment with MSC-MVs increased the expression of the endothelial intercellular junction proteins VE-cadherin and occludin. Treatment with MSC-MVs also decreased endothelial apoptosis and induced endothelial cell proliferation. Finally, the treatment reduced IL-6 production and increased IL-10 production in the conditioned media of endothelial cells. However, the effects of the treatment with MSC-MVs were inhibited after HGF gene knockdown.
   Conclusions: MSC-MVs protect the barrier functions of pulmonary microvascular endothelial cells, which can be partly attributed to the presence of HGF in the MSC-MVs.
C1 [Wang, Hualing; Zheng, Ruiqiang] Yangzhou Univ, Sch Med, Subei Peoples Hosp, Dept Cardiol, 98 Nantong West Rd, Yangzhou 225001, Jiangsu, China.
C1 [Chen, Qihong; Shao, Jun; Yu, Jiangquan] Yangzhou Univ, Sch Med, Subei Peoples Hosp, Dept Crit Care Med, 98 Nantong West Rd, Yangzhou 225001, Jiangsu, China.
C1 [Hu, Shuling] Fudan Univ, Zhongshan Hosp, Dept Crit Care Med, Shanghai 200032, China.
C3 Yangzhou University; Yangzhou University; Fudan University
RP Chen, QH (corresponding author), Yangzhou Univ, Sch Med, Subei Peoples Hosp, Dept Crit Care Med, 98 Nantong West Rd, Yangzhou 225001, Jiangsu, Peoples R China.
EM chenqihong00@163.com
RI chen, qian/HKE-2403-2023; Chen, QH/GXH-3158-2022; CHEN,
   QING/IXN-5937-2023
OI CHEN, QING/0000-0001-5250-1710
FU Jiangsu Provincial Medical Youth Talent Project [QNRC2016317]; Society
   Development Fund of Jiangsu Province [BE2017691]
FX Jiangsu Provincial Medical Youth Talent Project: contract grant number:
   QNRC2016317; Society Development Fund of Jiangsu Province - new type of
   clinical diagnosis and treatment technology contract grant number:
   BE2017691
CR Akyurekli C, 2015, STEM CELL REV REP, V11, P150, DOI 10.1007/s12015-014-9545-9
   [Anonymous], 2016, SCI REP UK
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Chen QH, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0025-1
   Favaro E, 2014, DIABETOLOGIA, V57, P1664, DOI 10.1007/s00125-014-3262-4
   Hu GC, 2008, CHEM-BIOL INTERACT, V171, P177, DOI 10.1016/j.cbi.2007.08.006
   Hu SL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0320-5
   Jaimes Y, 2017, STEM CELLS, V35, P812, DOI 10.1002/stem.2541
   Ju GQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121534
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Li Z, 2014, J MOL NEUROSCI, V52, P313, DOI 10.1007/s12031-013-0148-8
   Liu L, 2015, CELL TRANSPLANT, V24, P2629, DOI 10.3727/096368915X687499
   Matthay MA, 2017, STEM CELLS, V35, P316, DOI 10.1002/stem.2551
   Matula Z, 2016, STEM CELLS DEV, V25, P1818, DOI 10.1089/scd.2016.0086
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Meng FY, 2015, AM J PHYSIOL-LUNG C, V308, pL452, DOI 10.1152/ajplung.00170.2014
   Minshall R. D., 2006, V176, P107
   Monsel A, 2016, EXPERT OPIN BIOL TH, V16, P859, DOI 10.1517/14712598.2016.1170804
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Tian XY, 2015, MOL BIOL CELL, V26, P636, DOI 10.1091/mbc.E14-02-0725
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Yang Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0257-0
   Yu H, 2017, ENVIRON TOXICOL PHAR, V52, P62, DOI 10.1016/j.etap.2017.01.023
   Yu JB, 2016, ANESTHESIOLOGY, V125, P1190, DOI 10.1097/ALN.0000000000001333
   Zhang Y, 2016, J PINEAL RES, V60, P405, DOI 10.1111/jpi.12322
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 29
TC 42
Z9 46
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD SEP 29
PY 2017
VL 8
AR 211
DI 10.1186/s13287-017-0662-7
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FI7RM
UT WOS:000412195400015
PM 28969681
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Zielinska, KA
   de Cauwer, L
   Knoops, S
   Van der Molen, K
   Sneyers, A
   Thommis, J
   De Souza, JB
   Opdenakker, G
   De Bosscher, K
   Van den Steen, PE
AF Zielinska, Karolina A.
   de Cauwer, Lode
   Knoops, Sofie
   Van der Molen, Kristof
   Sneyers, Alexander
   Thommis, Jonathan
   De Souza, J. Brian
   Opdenakker, Ghislain
   De Bosscher, Karolien
   Van den Steen, Philippe E.
TI Plasmodium berghei NK65 in combination with IFN-gamma Induces
   Endothelial Glucocorticoid Resistance via Sustained Activation of p38
   and JNK
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE malaria; glucocorticoids; ECs/HPMECs/HUVECs/MPVECs; MAPK; interferon-gamma; dexamethasone 
ID TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL COREGULATOR GRIP1; CEREBRAL
   MALARIA; CORTICOSTEROID RESISTANCE; STEROID RESISTANCE; RECEPTOR
   FUNCTION; IMMUNE REGULATION; INTERFERON-GAMMA; DOUBLE-BLIND; LUNG INJURY
AB Malaria-associated acute respiratory distress syndrome (MA-ARDS) is an often lethal complication of malaria. Currently, no adequate therapy for this syndrome exists. Although glucocorticoids (GCs) have been used to improve clinical outcome of ARDS, their therapeutic benefits remain unclear. We previously developed a mouse model of MA-ARDS, in which dexamethasone treatment revealed GC resistance. In the present study, we investigated GC sensitivity of mouse microvascular lung endothelial cells stimulated with interferon-gamma (IFN-gamma) and Plasmodium berghei NK65 (PbNK65). Upon) and Plasmodium berghei NK65 (PbNK65). Upon challenge with IFN-gamma alone, dexamethasone inhibited the expression of CCL5 (RANTES) by 90% and both CCL2 (MCP-1) and CXCL10 (IP-10) by 50%. Accordingly, whole transcriptome analysis revealed that dexamethasone differentially affected several gene clusters and in particular inhibited a large cluster of IFN-gamma-induced genes, including chemokines. In contrast, combined stimulation with IFN-gamma and PbNK65 extract impaired inhibitory actions of GCs on chemokine release, without affecting the capacity of the GC receptor to accumulate in the nucleus. Subsequently, we investigated the effects of GCs on two signaling pathways activated by IFN-gamma. Dexamethasone left phosphorylation and protein levels of signal transducer and activator of transcription 1 (STAT1) unhampered. In contrast, dexamethasone inhibited the IFN-gamma-induced activation of two mitogen-activated protein kinases (MAPK), JNK, and p38. However, PbNK65 extract abolished the inhibitory effects of GCs on MAPK signaling, inducing GC resistance. These data provide novel insights into the mechanisms of GC actions in endothelial cells and show how malaria may impair the beneficial effects of GCs.
C1 [Zielinska, Karolina A.; Knoops, Sofie; Van der Molen, Kristof; Sneyers, Alexander; Opdenakker, Ghislain; Van den Steen, Philippe E.] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Immunobiol Lab, Leuven, Belgium.
C1 [de Cauwer, Lode; Thommis, Jonathan; De Bosscher, Karolien] VIB UGent Ctr Med Biotechnol, Nucl Receptor Lab, Receptor Res Labs, Ghent, Belgium.
C1 [De Souza, J. Brian] London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London, England, United Kingdom.
C3 KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University;
   University of London; London School of Hygiene & Tropical Medicine
RP Van den Steen, PE (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Immunobiol Lab, Leuven, Belgium.
EM philippe.vandensteen@kuleuven.be
RI Opdenakker, Ghislain/V-8562-2019; de Souza, Joseph B/D-4979-2009; De
   Bosscher, Karolien/HKW-0710-2023; Opdenakker, Ghislain/Q-3130-2017; Van
   den Steen, Philippe E/K-5132-2012
OI Opdenakker, Ghislain/0000-0003-1714-2294; De Bosscher,
   Karolien/0000-0001-5059-9718; Opdenakker, Ghislain/0000-0003-1714-2294;
   Van den Steen, Philippe E/0000-0002-7334-9145; Thommis,
   Jonathan/0000-0001-7221-9317; Zielinska, Karolina/0000-0001-8090-5034
FU Research Foundation-Flanders (F.W.O.-Vlaanderen); Geconcerteerde
   OnderzoeksActies of the Research Fund of the KU Leuven [GOA 2013/014,
   C16/17/010]
FX This work has been funded by the Research Foundation-Flanders
   (F.W.O.-Vlaanderen) and the Geconcerteerde OnderzoeksActies (GOA
   2013/014 and C1 project C16/17/010) of the Research Fund of the KU
   Leuven. KB is a Research Professor at U Gent, and PS is a Research
   Professor at the KU Leuven.
CR Amani V, 2000, EUR J IMMUNOL, V30, P1646, DOI 10.1002/1521-4141(200006)30:6&lt;1646::AID-IMMU1646&gt;3.0.CO;2-0
   Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3
   Basilico N, 2017, ACTA TROP, V172, P125, DOI 10.1016/j.actatropica.2017.05.002
   Beaulieu E, 2011, NAT REV RHEUMATOL, V7, P340, DOI 10.1038/nrrheum.2011.59
   Bhandare R, 2010, AM J RESP CELL MOL, V42, P9, DOI 10.1165/rcmb.2009-0239RC
   Bhattacharyya S, 2007, BLOOD, V109, P4313, DOI 10.1182/blood-2006-10-048215
   Bhattacharyya S, 2011, P NATL ACAD SCI USA, V108, P9554, DOI 10.1073/pnas.1017296108
   Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027
   Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016
   Bouazza B, 2014, AM J RESP CELL MOL, V50, P301, DOI 10.1165/rcmb.2012-0522OC
   Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590
   Cain DW, 2017, NAT REV IMMUNOL, V17, P233, DOI 10.1038/nri.2017.1
   Cain DW, 2015, BEST PRACT RES CL EN, V29, P545, DOI 10.1016/j.beem.2015.04.007
   Cheng Q, 2013, J IMMUNOL, V191, P424, DOI 10.4049/jimmunol.1202662
   Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103
   Chinenov Y, 2012, P NATL ACAD SCI USA, V109, P11776, DOI 10.1073/pnas.1206059109
   Clark AR, 2007, MOL CELL ENDOCRINOL, V275, P79, DOI 10.1016/j.mce.2007.04.013
   Coppo M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12254
   Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200
   De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006
   Desmet SJ, 2017, J CLIN INVEST, V127, P1136, DOI 10.1172/JCI88886
   DUARTE MIS, 1985, AM J TROP MED HYG, V34, P31, DOI 10.4269/ajtmh.1985.34.31
   Fan HP, 2014, ARTHRITIS RHEUMATOL, V66, P2059, DOI 10.1002/art.38689
   Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744-14
   Flammer JR, 2010, MOL CELL BIOL, V30, P4564, DOI 10.1128/MCB.00146-10
   Furst R, 2007, FASEB J, V21, P74, DOI 10.1096/fj.06-6752com
   Galliher-Beckley AJ, 2009, IUBMB LIFE, V61, P979, DOI 10.1002/iub.245
   Gazzinelli RT, 2014, NAT REV IMMUNOL, V14, P744, DOI 10.1038/nri3742
   Gibbs J, 2014, NAT MED, V20, P919, DOI 10.1038/nm.3599
   Goleva E, 2009, AM J RESP CELL MOL, V40, P223, DOI 10.1165/rcmb.2007-0327OC
   Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065
   HOFFMAN SL, 1988, J INFECT DIS, V158, P325, DOI 10.1093/infdis/158.2.325
   Holownia A, 2009, EUR J MED RES, V14, P108, DOI 10.1186/2047-783X-14-S4-108
   Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833
   Hunt NH, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00113
   Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144
   King T, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005118
   Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238
   Koenen P, 2012, ANN RHEUM DIS, V71, P729, DOI 10.1136/annrheumdis-2011-200530
   Lagasse HAD, 2016, J LEUKOCYTE BIOL, V99, P659, DOI 10.1189/jlb.4HI0315-130RRR
   Li JJ, 2010, J IMMUNOL, V185, P4401, DOI 10.4049/jimmunol.1001039
   Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005
   Lim HW, 2015, GENOME RES, V25, P836, DOI 10.1101/gr.188581.114
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marke R, 2016, LEUKEMIA, V30, P1599, DOI 10.1038/leu.2015.359
   Mata-Greenwood E, 2015, J MOL ENDOCRINOL, V55, P133, DOI 10.1530/JME-15-0124
   Matsuzawa T, 2012, J IMMUNOL, V189, P813, DOI 10.4049/jimmunol.1102041
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Meunier E, 2016, CELL MICROBIOL, V18, P168, DOI 10.1111/cmi.12546
   Milara J, 2014, J ALLERGY CLIN IMMUN, V134, P314, DOI 10.1016/j.jaci.2014.02.001
   Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528
   Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794
   Oakley RH, 2011, J BIOL CHEM, V286, P3177, DOI 10.1074/jbc.R110.179325
   Pal P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177142
   Pelaia G, 2001, BIOCHEM PHARMACOL, V62, P1719, DOI 10.1016/S0006-2952(01)00791-2
   Ramamoorthy S, 2013, MOL CELL BIOL, V33, P1711, DOI 10.1128/MCB.01151-12
   Rao NAS, 2011, GENOME RES, V21, P1404, DOI 10.1101/gr.118042.110
   Ratman D, 2013, MOL CELL ENDOCRINOL, V380, P41, DOI 10.1016/j.mce.2012.12.014
   Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050
   Sacta MA, 2016, ANNU REV PHYSIOL, V78, P155, DOI 10.1146/annurev-physiol-021115-105323
   Salem S, 2012, BRIT J PHARMACOL, V166, P2036, DOI 10.1111/j.1476-5381.2012.01885.x
   Sercundes MK, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006054
   Souza MC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/168937
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898
   Taylor WRJ, 2012, CHEST, V142, P492, DOI 10.1378/chest.11-2655
   Tliba O, 2006, MOL PHARMACOL, V69, P588, DOI 10.1124/mol.105.019679
   Tliba O, 2008, AM J RESP CELL MOL, V38, P463, DOI 10.1165/rcmb.2007-0226OC
   Uhlenhaut NH, 2013, MOL CELL, V49, P158, DOI 10.1016/j.molcel.2012.10.013
   Valecha N, 2009, AM J TROP MED HYG, V81, P758, DOI 10.4269/ajtmh.2009.09-0348
   Valledor AF, 2008, J IMMUNOL, V180, P4523, DOI 10.4049/jimmunol.180.7.4523
   Van Bogaert T, 2011, J BIOL CHEM, V286, P26555, DOI 10.1074/jbc.M110.212365
   Van den Steen PE, 2008, EUR J IMMUNOL, V38, P1082, DOI 10.1002/eji.200737906
   Van den Steen PE, 2013, TRENDS PARASITOL, V29, P346, DOI 10.1016/j.pt.2013.04.006
   Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC
   Vettorazzi S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8796
   Villegas-Mendez A, 2012, J IMMUNOL, V189, P968, DOI 10.4049/jimmunol.1200688
   Wallace AD, 2010, STEROIDS, V75, P1016, DOI 10.1016/j.steroids.2010.06.015
   Wang XH, 2005, NEUROPSYCHOPHARMACOL, V30, P242, DOI 10.1038/sj.npp.1300606
   WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601
   Weiser S, 2007, CYTOKINE, V37, P84, DOI 10.1016/j.cyto.2007.02.021
   Xia YXC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006138
   Xu Q, 2004, J IMMUNOL, V172, P7110, DOI 10.4049/jimmunol.172.11.7110
   Yang N, 2014, J ENDOCRINOL, V223, P155, DOI 10.1530/JOE-14-0456
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zielinska KA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00592
NR 86
TC 8
Z9 8
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 28
PY 2017
VL 8
AR 1199
DI 10.3389/fimmu.2017.01199
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FI4QE
UT WOS:000411956900001
PM 29033931
OA Green Published, gold, Green Accepted
DA 2023-08-21
ER

PT J
AU Lv, X
   Wen, T
   Song, J
   Xie, D
   Wu, L
   Jiang, XM
   Jiang, P
   Wen, ZM
AF Lv, Xin
   Wen, Tao
   Song, Jiong
   Xie, Dong
   Wu, Liang
   Jiang, Xuemei
   Jiang, Ping
   Wen, Zongmei
TI Extracellular histones are clinically relevant mediators in the
   pathogenesis of acute respiratory distress syndrome
SO RESPIRATORY RESEARCH
LA English
DT Article
DE ALI/ARDS; extracellular histones; Cell damage; Systemic inflammation 
ID ACUTE LUNG INJURY; CIRCULATING HISTONES; CELLULAR INJURY; MAJOR
   MEDIATORS; INFLAMMATION; DEATH; TLR2
AB Background: Extracellular histones were recently identified as an inflammatory mediator involved in the pathogenesis of various organ injuries. This study aimed to examine extracellular histone levels and their clinical implications in acute respiratory distress syndrome (ARDS) patients and to explore histone-mediated effects through ex-vivo investigations.
   Methods: Extracellular histones, cytokine profiles and clinical data from 96 ARDS patients and 30 healthy volunteers were obtained. Human bronchial epithelial cells (BEAS-2B), human pulmonary artery endothelial cells (HPAEC), and human monocytic U937 cells were exposed to bronchoalveolar lavage fluid (BALF) collected from ARDS patients, and cellular damage and cytokine production were assessed. Furthermore, the effect of histone-targeted interventions by heparin or anti-histone antibody was evaluated.
   Results: Plasma and BALF extracellular histone levels were much higher in ARDS patients than in healthy controls. There was a significant association between extracellular histones and ARDS severity and mortality. In addition, extracellular histones correlated with an evident systemic inflammation detected in ARDS patients. Ex-vivo analysis further showed that ARDS patient's BALF remarkably induced epithelial and endothelial cell damage and stimulated cytokine production in the supernatant of U937 cells. The adverse effects on these cells could be abrogated by heparin or anti-histone antibody.
   Conclusions: Extracellular histones in ARDS patients are excessively increased and may contribute to disease aggravation by inducing cellular damage and promoting systemic inflammation. Targeting extracellular histones may provide a promising approach for treating ARDS.
C1 [Lv, Xin; Song, Jiong; Jiang, Xuemei; Wen, Zongmei] Tongji Univ, Sch Med, Dept Anesthesiol, Shanghai Pulm Hosp, Shanghai 200433, China.
C1 [Wen, Tao] Capital Med Univ, Beijing Chao Yang Hosp, Med Res Ctr, Beijing 100020, China.
C1 [Xie, Dong; Wu, Liang] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai 200433, China.
C1 [Jiang, Ping] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Emergency, Shanghai 200433, China.
C3 Tongji University; Capital Medical University; Tongji University; Tongji
   University
RP Wen, ZM (corresponding author), Tongji Univ, Sch Med, Dept Anesthesiol, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China.; Jiang, P (corresponding author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Emergency, Shanghai 200433, Peoples R China.
EM drjiangping2016@sina.com; wzm1103@126.com
RI Lv, Xin/L-2274-2019; Xie, Dong/HGC-8581-2022
OI Xie, Dong/0000-0002-3715-1801
FU National Natural Science Foundation of China, Beijing, P.R. China
   [81400052, 81500076, 81671947]; Beijing Natural Science Foundation
   [7172079]; Shanghai Municipal Committee of Science and Technology,
   Shanghai, P.R. China [14ZR1434400]; Pujiang Talent Program, Shanghai,
   P.R. China [14PJD030]
FX This work was supported by grants from National Natural Science
   Foundation of China (81400052, 81500076, 81671947), Beijing, P.R. China;
   and by Beijing Natural Science Foundation (7172079, to Tao Wen). This
   work was also funded by Shanghai Municipal Committee of Science and
   Technology (14ZR1434400, to Zongmei Wen), Shanghai, P.R. China, and by
   Pujiang Talent Program (14PJD030, to Zongmei Wen), Shanghai, P.R. China.
CR Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC
   Aisiku IP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1470-7
   Alhamdi Y, 2016, CRIT CARE MED, V44, pE278, DOI 10.1097/CCM.0000000000001413
   Allam R, 2014, J MOL MED, V92, P465, DOI 10.1007/s00109-014-1148-z
   Allam R, 2013, EUR J IMMUNOL, V43, P3336, DOI 10.1002/eji.201243224
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bosmann M, 2013, FASEB J, V27, P5010, DOI 10.1096/fj.13-236380
   Chen R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.337
   Cortes DO, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0375-y
   Daigo K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00344
   Ekaney ML, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0543-8
   Favarin DC, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/164202
   Grailer JJ, 2014, INFLAMM CELL SIGNAL, V1, P395
   Hoeksema M, 2016, FUTURE MICROBIOL, V11, P441, DOI 10.2217/fmb.15.151
   Huang H, 2013, J IMMUNOL, V191, P2665, DOI 10.4049/jimmunol.1202733
   Jin H, 2014, MILITARY MED RES, V1, DOI 10.1186/2054-9369-1-7
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Raffray L, 2015, CRIT CARE MED, V43, pE107, DOI 10.1097/CCM.0000000000000879
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061
   Silk E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.52
   Standiford TJ, 2016, TRANSL RES, V167, P183, DOI 10.1016/j.trsl.2015.04.015
   Umbrello M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010064
   Ward Peter A, 2014, Transl Respir Med, V2, P1, DOI 10.1186/2213-0802-2-1
   Wen ZM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.303
   Westman J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005319
   Wildhagen KCAA, 2014, BLOOD, V123, P1098, DOI 10.1182/blood-2013-07-514984
   Xu J, 2011, J IMMUNOL, V187, P2626, DOI 10.4049/jimmunol.1003930
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Zhang YL, 2015, ANESTHESIOLOGY, V122, P127, DOI 10.1097/ALN.0000000000000429
NR 33
TC 42
Z9 44
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-993X
EI 1465-9921
J9 RESP RES
JI Respir. Res.
PD SEP 2
PY 2017
VL 18
AR 165
DI 10.1186/s12931-017-0651-5
PG 9
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA FF3UV
UT WOS:000408847500001
PM 28865478
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Bihari, S
   Dixon, DL
   Lawrence, MD
   De Bellis, D
   Bonder, CS
   Dimasi, DP
   Bersten, AD
AF Bihari, Shailesh
   Dixon, Dani-Louise
   Lawrence, Mark D.
   De Bellis, Dylan
   Bonder, Claudine S.
   Dimasi, David P.
   Bersten, Andrew D.
TI Fluid-induced lung injury-role of TRPV4 channels
SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE Transient receptor potential vanilloid 4 (TRPV4); ALI/ARDS; Lung mechanics; Surfactants; Fluids; 0.9% saline, angiopoietin 2, P-selectin 
ID PULMONARY VASCULAR-PERMEABILITY; RECEPTOR POTENTIAL CHANNELS; EPITHELIAL
   BARRIER FUNCTION; RAPID SALINE INFUSION; DOG LUNGS; RAT LUNG; EDEMA;
   PRESSURE; ACTIVATION; INFLAMMATION
AB Administration of bolus intravenous fluid is associated with respiratory dysfunction and increased mortality, findings with no clear mechanistic explanation. The objective of this study was to examine whether bolus intravenous (i.v.) fluid administration results in acute lung injury in a rat model and further, to examine whether this injury is associated with transient receptor potential vallinoid (TRPV)4 channel function and endothelial inflammatory response. Healthy male Sprague-Dawley rats were administered 60 ml/kg 0.9% saline i.v. over 30 min. Manifestation of acute lung injury was assessed by lung physiology, morphology, and markers of inflammation. The role of TRPV4 channels in fluid-induced lung injury was subsequently examined by the administration of ruthenium red (RR) in this established rat model and again in TRPV4 KO mice. In endothelial cell culture, permeability and P-selectin expression were measured following TRPV4 agonist with and without antagonist; 0.9% saline resulted in an increase in lung water, lavage protein and phospholipase A(2), and plasma angiopoietin-2, with worsening in arterial blood oxygen (PaO2), lung elastance, surfactant activity, and lung histological injury score. These effects were ameliorated following i.v. fluid in rats receiving RR. TRPV4 KO mice did not develop lung edema. Expression of P-selectin increased in endothelial cells following administration of a TRPV4 agonist, which was ameliorated by simultaneous addition of RR. Bolus i.v. 0.9% saline resulted in permeability pulmonary edema. Data from ruthenium red, TRPV4 KO mice, and endothelial cell culture suggest activation of TRPV4 and release of angiopoietin 2 and P-selectin as the central mechanism.
C1 [Bihari, Shailesh; Dixon, Dani-Louise; Lawrence, Mark D.; De Bellis, Dylan; Bersten, Andrew D.] Flinders Univ S Australia, Dept Crit Care Med, Adelaide, SA 5001, Australia.
C1 [Bihari, Shailesh; Dixon, Dani-Louise; Bersten, Andrew D.] Flinders Med Ctr, Intens & Crit Care Unit, Adelaide, SA 5042, Australia.
C1 [Bonder, Claudine S.; Dimasi, David P.] Univ South Australia, Ctr Canc Biol, Adelaide, SA 5000, Australia.
C1 [Bonder, Claudine S.; Dimasi, David P.] SA Pathol, Adelaide, SA 5000, Australia.
C3 Flinders University South Australia; Flinders Medical Centre; Centre for
   Cancer Biology; University of South Australia; SA Pathology
RP Bihari, S (corresponding author), Flinders Univ S Australia, Dept Crit Care Med, Adelaide, SA 5001, Australia.; Bihari, S (corresponding author), Flinders Med Ctr, Intens & Crit Care Unit, Adelaide, SA 5042, Australia.
EM biharishailesh@gmail.com
OI Bonder, Claudine S./0000-0001-9875-967X; De Bellis,
   Dylan/0000-0002-2741-7004; Bihari, Shailesh/0000-0001-7553-8620; Dixon,
   Dani-Louise/0000-0001-6459-1856; Bersten, Andrew/0000-0001-9908-394X
FU NHMRC - Postgraduate Scholarship (Medical/Dental) [APP1038647]; Flinders
   University - Faculty of Medicine, Nursing and Health Sciences - Small
   Competitive Research Grants; NHMRC [GNT1022145]
FX 1. NHMRC - Postgraduate Scholarship (Medical/Dental) APP1038647 to SB.r
   2. Flinders University - Faculty of Medicine, Nursing and Health
   Sciences - Small Competitive Research Grants to ADB, DLD, SB.r 3. NHMRC
   GNT1022145 to CSB.
CR Balakrishna S, 2014, AM J PHYSIOL-LUNG C, V307, pL158, DOI 10.1152/ajplung.00065.2014
   Barth K, 2005, HISTOCHEM CELL BIOL, V124, P453, DOI 10.1007/s00418-005-0048-2
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   Bihari S, 2016, RESP PHYSIOL NEUROBI, V227, P56, DOI 10.1016/j.resp.2016.03.002
   Bihari S, 2015, J APPL PHYSIOL, V119, P783, DOI 10.1152/japplphysiol.00356.2015
   Bihari S, 2014, INTENS CARE MED, V40, P1392, DOI 10.1007/s00134-014-3385-6
   Bihari S, 2013, SHOCK, V40, P28, DOI 10.1097/SHK.0b013e31829727f1
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Davidson KG, 2000, AM J PHYSIOL-LUNG C, V279, pL1091, DOI 10.1152/ajplung.2000.279.6.L1091
   de Wit TR, 2003, ARTERIOSCL THROM VAS, V23, P755, DOI 10.1161/01.ATV.0000069847.72001.E8
   Dixon DL, 2009, AM J RESP CRIT CARE, V180, P181, DOI 10.1164/rccm.200809-1506OC
   dos Santos CC, 2011, AM J RESP CRIT CARE, V183, P471, DOI 10.1164/rccm.201002-0314OC
   Elder ASF, 2013, CHEST, V143, P371, DOI 10.1378/chest.11-2868
   FARNEY RJ, 1977, J APPL PHYSIOL, V43, P246, DOI 10.1152/jappl.1977.43.2.246
   Fernandez-Fernandez JM, 2008, PFLUG ARCH EUR J PHY, V457, P149, DOI 10.1007/s00424-008-0516-3
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   FISHMAN AP, 1973, CIRCULATION, V47, P921, DOI 10.1161/01.CIR.47.5.921
   FORRESTER JS, 1976, NEW ENGL J MED, V295, P1356, DOI 10.1056/NEJM197612092952406
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   HANTOS Z, 1992, J APPL PHYSIOL, V72, P168, DOI 10.1152/jappl.1992.72.1.168
   Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827
   HOGG JC, 1972, J APPL PHYSIOL, V32, P20, DOI 10.1152/jappl.1972.32.1.20
   Imhof BA, 2006, NAT MED, V12, P171, DOI 10.1038/nm0206-171
   Inoue R, 2006, CIRC RES, V99, P119, DOI 10.1161/01.RES.0000233356.10630.8a
   Jian MY, 2008, AM J RESP CELL MOL, V38, P386, DOI 10.1165/rcmb.2007-0192OC
   Jurek SC, 2014, AM J RESP CELL MOL, V50, P1107, DOI 10.1165/rcmb.2013-0163OC
   King LS, 2002, P NATL ACAD SCI USA, V99, P1059, DOI 10.1073/pnas.022626499
   Kohler R, 2006, ARTERIOSCL THROM VAS, V26, P1495, DOI 10.1161/01.ATV.0000225698.36212.6a
   Kuebler WM, 1999, J CLIN INVEST, V104, P495, DOI 10.1172/JCI6872
   Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100
   Litwin M, 1997, J CELL BIOL, V139, P219, DOI 10.1083/jcb.139.1.219
   Lorenzo IM, 2008, P NATL ACAD SCI USA, V105, P12611, DOI 10.1073/pnas.0803970105
   Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005
   Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549
   MARON MB, 1989, J APPL PHYSIOL, V67, P305, DOI 10.1152/jappl.1989.67.1.305
   Matthews BD, 2010, INTEGR BIOL-UK, V2, P435, DOI 10.1039/c0ib00034e
   MILIC-EMILI J, 1971, Bulletin de Physio-Pathologie Respiratoire, V7, P1181
   MINNEAR FL, 1983, J APPL PHYSIOL, V55, P983, DOI 10.1152/jappl.1983.55.3.983
   Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206
   Morty RE, 2014, AM J PHYSIOL-LUNG C, V307, pL817, DOI 10.1152/ajplung.00254.2014
   MUIR AL, 1975, J APPL PHYSIOL, V38, P786, DOI 10.1152/jappl.1975.38.5.786
   Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759
   Nakos G, 2005, CRIT CARE MED, V33, P772, DOI 10.1097/01.CCM.0000158519.80090.74
   NICHOLAS TE, 1990, AM J RESP CELL MOL, V3, P251, DOI 10.1165/ajrcmb/3.3.251
   Pankey EA, 2014, AM J PHYSIOL-HEART C, V306, pH33, DOI 10.1152/ajpheart.00303.2013
   Parker JC, 1998, J APPL PHYSIOL, V84, P1113, DOI 10.1152/jappl.1998.84.4.1113
   Pellegrino R, 2003, J APPL PHYSIOL, V95, P728, DOI 10.1152/japplphysiol.00310.2003
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   RIPPE B, 1984, J APPL PHYSIOL, V57, P233, DOI 10.1152/jappl.1984.57.1.233
   Sidhaye VK, 2008, P NATL ACAD SCI USA, V105, P3345, DOI 10.1073/pnas.0712287105
   Simonsen U, 2016, ACTA PHYSL
   Solymosi EA, 2013, P NATL ACAD SCI USA, V110, pE2308, DOI 10.1073/pnas.1216382110
   STAUB NC, 1967, J APPL PHYSIOL, V22, P227, DOI 10.1152/jappl.1967.22.2.227
   Sukumaran SV, 2013, PHARMACOL RES, V78, P18, DOI 10.1016/j.phrs.2013.09.005
   Sun MJ, 2012, ANAL BIOCHEM, V425, P96, DOI 10.1016/j.ab.2012.03.010
   Sun WY, 2012, AM J PATHOL, V180, P1740, DOI 10.1016/j.ajpath.2011.12.024
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   Villalta PC, 2013, PULM CIRC, V3, P802, DOI 10.1086/674765
   Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30
   Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551
   Yang XR, 2006, AM J PHYSIOL-LUNG C, V290, pL1267, DOI 10.1152/ajplung.00515.2005
   Yin J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   Yin J, 2010, CELL BIOCHEM BIOPHYS, V56, P1, DOI 10.1007/s12013-009-9067-2
NR 64
TC 16
Z9 17
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0031-6768
EI 1432-2013
J9 PFLUG ARCH EUR J PHY
JI Pflugers Arch.
PD SEP
PY 2017
VL 469
IS 9
BP 1121
EP 1134
DI 10.1007/s00424-017-1983-1
PG 14
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA FD6GU
UT WOS:000407627800007
PM 28456852
DA 2023-08-21
ER

PT J
AU Oskolkova, O
   Gawlak, G
   Tian, YF
   Ke, YB
   Sarich, N
   Son, S
   Andreasson, K
   Bochkov, VN
   Birukova, AA
   Birukov, KG
AF Oskolkova, Olga
   Gawlak, Grzegorz
   Tian, Yufeng
   Ke, Yunbo
   Sarich, Nicolene
   Son, Sophia
   Andreasson, Katrin
   Bochkov, Valery N.
   Birukova, Anna A.
   Birukov, Konstantin G.
TI Prostaglandin E receptor-4 receptor mediates endothelial
   barrier-enhancing and anti-inflammatory effects of oxidized
   phospholipids
SO FASEB JOURNAL
LA English
DT Article
DE ALI/ARDS; permeability; cytoskeleton 
ID LUNG VASCULAR-PERMEABILITY; SIGNALING PATHWAY; DIFFERENTIAL REGULATION;
   STAPHYLOCOCCUS-AUREUS; PROTECTIVE RESPONSE; OXIDATION-PRODUCTS;
   GENE-EXPRESSION; S1P(1) RECEPTOR; EP4 RECEPTORS; KNOCKOUT MICE
AB Unlike other agonists that cause transient endothelial cell (EC) response, the products of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC) oxidation that contain cyclopenthenone groups, which recapitulate prostaglandin-like structure, cause sustained enhancement of the pulmonary EC barrier. The mechanisms that drive the sustained effects by oxidized PAPC (OxPAPC) remain unexplored. On the basis of the structural similarity of iso-prostanoid moieties that are present in full-length oxygenated PAPC species, we used an inhibitory approach to perform the screening of prostanoid receptors as potential candidates that mediate OxPAPC effects. Results show that only prostaglandin E receptor-4 (EP4) was involved and mediated the sustained phase of the barrier-enhancing effects of OxPAPC that are associated with the activation of Rac GTPase and its cytoskeletal targets. EC incubation with OxPAPC also induced EP4 mRNA expression in pulmonary ECs and lung tissue. EP4 knockdown using gene-specific small interfering RNA did not affect the rapid phase of OxPAPC-induced EC barrier enhancement or the protective effects against thrombin-induced EC permeability, but abolished the advanced barrier enhancement phase and suppressed the protective effects of OxPAPC against more sustained EC barrier dysfunction and cell inflammatory response caused by TNF-alpha. Endothelial-specific knockout of the EP4 receptor in mice attenuated the protective effect of intravenous OxPAPC administration in the model of acute lung injury caused by intratracheal injection of LPS. Taken together, these results demonstrate a novel role for prostaglandin receptor EP4 in the mediation of barrier-enhancing and anti-inflammatory effects caused by oxidized phospholipids.
C1 [Oskolkova, Olga; Gawlak, Grzegorz; Tian, Yufeng; Ke, Yunbo; Sarich, Nicolene; Son, Sophia; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, 5841 S Maryland Ave, Chicago, IL 60637, United States.
C1 [Andreasson, Katrin] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305, United States.
C1 [Bochkov, Valery N.] Karl Franzens Univ Graz, Dept Pharmaceut Chem, Graz, Austria.
C1 [Ke, Yunbo; Birukova, Anna A.] Univ Maryland, Dept Med, Baltimore, MD 21201, United States.
C1 [Birukov, Konstantin G.] Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201, United States.
C3 University of Chicago; Stanford University; ARQUS; University of Graz;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Birukov, KG (corresponding author), Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA.; Birukov, KG (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, UMSOM Lung Biol Program, 20 Penn St,HSF 2,Room S145, Baltimore, MD 21201 USA.
EM kbirukov@anes.umm.edu
RI Birukov, Konstantin/FJB-5755-2022; Bochkov, Valery/HNR-8336-2023;
   Sarich, Nicolene/IWV-3869-2023
OI Oskolkova, Olga/0000-0001-9443-8705
FU U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood
   Institute [HL076259, HL087823, HL107920, HL130431]; NIH National
   Institute of General Medical Sciences [GM114171]
FX This work was supported by U.S. National Institutes of Health (NIH)
   National Heart, Lung, and Blood Institute Grants HL076259, HL087823,
   HL107920, and HL130431 and NIH National Institute of General Medical
   Sciences Grant GM114171. The authors thank Mohan Tulapurkar (University
   of Maryland, Baltimore, MD, USA), for superior technical assistance and
   analysis of EP4 expression in lung tissue samples.
CR Alfranca A, 2006, CARDIOVASC RES, V70, P446, DOI 10.1016/j.cardiores.2005.12.020
   Bauer J, 2014, BRIT J PHARMACOL, V171, P3115, DOI 10.1111/bph.12677
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2015, BBA-MOL BASIS DIS, V1852, P778, DOI 10.1016/j.bbadis.2014.12.016
   Birukova AA, 2014, MOL BIOL CELL, V25, P2006, DOI 10.1091/mbc.E13-12-0743
   Birukova AA, 2013, MOL BIOL CELL, V24, P2678, DOI 10.1091/mbc.E13-02-0098
   Birukova AA, 2013, TRANSL RES, V161, P495, DOI 10.1016/j.trsl.2012.12.008
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2011, J CELL PHYSIOL, V226, P2052, DOI 10.1002/jcp.22543
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023
   Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199
   Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742
   Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Bustos RI, 2008, CURR BIOL, V18, P1606, DOI 10.1016/j.cub.2008.09.019
   BUTLER BD, 1989, AM J PHYSIOL, V257, pH1466, DOI 10.1152/ajpheart.1989.257.5.H1466
   Cole AL, 2003, ARTERIOSCL THROM VAS, V23, P1384, DOI 10.1161/01.ATV.0000081215.45714.71
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Dejana E, 2009, CELL TISSUE RES, V335, P17, DOI 10.1007/s00441-008-0694-5
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Erridge C, 2008, J BIOL CHEM, V283, P24748, DOI 10.1074/jbc.M800352200
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Goolaerts A, 2011, THORAX, V66, P788, DOI 10.1136/thx.2010.155788
   Guo F, 2012, MOL IMMUNOL, V50, P98, DOI 10.1016/j.molimm.2011.12.009
   Harding P, 2010, AM J PHYSIOL-HEART C, V298, pH623, DOI 10.1152/ajpheart.00746.2009
   Harris ES, 2010, CURR OPIN CELL BIOL, V22, P651, DOI 10.1016/j.ceb.2010.07.006
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.E02-11-0753
   HOCKING DC, 1990, CIRC RES, V67, P68, DOI 10.1161/01.RES.67.1.68
   Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005
   Kakiashvili E, 2009, J BIOL CHEM, V284, P11454, DOI 10.1074/jbc.M805933200
   Khakpour S, 2015, INNATE IMMUN-LONDON, V21, P827, DOI 10.1177/1753425915606525
   Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3
   Konya V, 2015, BRIT J PHARMACOL, V172, P4454, DOI 10.1111/bph.13229
   Konya V, 2013, PHARMACOL THERAPEUT, V138, P485, DOI 10.1016/j.pharmthera.2013.03.006
   Legler DF, 2006, J IMMUNOL, V176, P966, DOI 10.4049/jimmunol.176.2.966
   Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010
   Li M, 2005, BONE, V37, P46, DOI 10.1016/j.bone.2005.03.016
   Li RS, 2006, CIRC RES, V98, P642, DOI 10.1161/01.RES.0000207394.39249.fc
   Liang XB, 2011, J CLIN INVEST, V121, P4362, DOI 10.1172/JCI46279
   Lorenowicz MJ, 2008, EUR J CELL BIOL, V87, P779, DOI 10.1016/j.ejcb.2008.05.004
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Ma Z, 2004, AM J PHYSIOL-LUNG C, V286, pL808, DOI 10.1152/ajplung.00220.2003
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Meliton AY, 2015, AM J PHYSIOL-LUNG C, V308, pL550, DOI 10.1152/ajplung.00248.2014
   Metrich M, 2010, PFLUG ARCH EUR J PHY, V459, P535, DOI 10.1007/s00424-009-0747-y
   Minami M, 2008, J BIOL CHEM, V283, P9692, DOI 10.1074/jbc.M709663200
   Monvoisin A, 2006, DEV DYNAM, V235, P3413, DOI 10.1002/dvdy.20982
   Munoz Nilda M, 2012, Pulm Circ, V2, P182, DOI 10.4103/2045-8932.97604
   Nonas S, 2006, AM J RESP CRIT CARE, V173, P1130, DOI 10.1164/rccm.200511-1737OC
   Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ratcliffe MJ, 2007, EUR RESPIR J, V29, P986, DOI 10.1183/09031936.00131606
   REGAN JW, 1994, MOL PHARMACOL, V46, P213
   Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Singleton PA, 2007, J BIOL CHEM, V282, P30643, DOI 10.1074/jbc.M702573200
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tian YF, 2015, J BIOL CHEM, V290, P4097, DOI 10.1074/jbc.M114.620377
   Vallerie SN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158316
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   Wu TH, 2013, TRANSL RES, V162, P45, DOI 10.1016/j.trsl.2013.03.005
   Yagami T, 2016, MOL NEUROBIOL, V53, P4754, DOI 10.1007/s12035-015-9355-3
   Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195
NR 74
TC 11
Z9 12
U1 0
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2017
VL 31
IS 9
BP 4187
EP 4202
DI 10.1096/fj.201601232RR
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FF2FM
UT WOS:000408713300040
PM 28572443
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Vassiliou, AG
   Manitsopoulos, N
   Kardara, M
   Maniatis, NA
   Orfanos, SE
   Kotanidou, A
AF Vassiliou, Alice G.
   Manitsopoulos, Nikolaos
   Kardara, Matina
   Maniatis, Nikolaos A.
   Orfanos, Stylianos E.
   Kotanidou, Anastasia
TI Differential Expression of Aquaporins in Experimental Models of Acute
   Lung Injury
SO IN VIVO
LA English
DT Article
DE Aquaporins; ALI/ARDS; Inflammation 
ID WATER CHANNELS; INFLAMMATORY RESPONSES; DECREASED EXPRESSION; FLUID
   TRANSPORT; MICE; AQP5; CLEARANCE; MIGRATION; EDEMA; LIPOPOLYSACCHARIDE
AB Aim: The mammalian lung expresses at least three aquaporin (AQP) water channels whose precise role in lung injury or inflammation is still controversial. Materials and Methods: Three murine models of lung inflammation and corresponding controls were used to evaluate the expression of Aqp1, Aqp4, Aqp5 and Aqp9: lipopolysaccharide (LPS)-induced lung injury; HCl-induced lung injury; and ventilation-induced lung injury (VILI). Results: All models yielded increased lung vascular permeability, and inflammatory cell infiltration in the broncho-alveolar lavage fluid; VILI additionally produced altered lung mechanics. Lung expression of Aqp4 decreased in the models that targeted primarily the alveolar epithelium, i.e. acid aspiration and mechanical ventilation, while Aqp5 expression decreased in the model that appeared to target both the capillary endothelium and alveolar epithelium, i.e. LPS. Conclusion: Participation of aquaporins in the acute inflammatory process depends on localization and the type of lung injury.
C1 [Vassiliou, Alice G.; Manitsopoulos, Nikolaos; Kardara, Matina; Maniatis, Nikolaos A.; Orfanos, Stylianos E.; Kotanidou, Anastasia] Univ Athens, Med Sch, Evangelismos Hosp, Dept Crit Care Med & Pulm Serv 1,GP Livanos & M S, Athens, Greece.
C1 [Maniatis, Nikolaos A.; Orfanos, Stylianos E.] Univ Athens, Med Sch, Attikon Hosp, Dept Crit Care 2, Athens, Greece.
C1 [Kotanidou, Anastasia] Univ Athens, Med Sch, Evangelismos Hosp, Dept Crit Care Med & Pulm Serv 1, Athens, Greece.
C3 Evangelismos Hospital; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens; University Hospital
   Attikon; Evangelismos Hospital; National & Kapodistrian University of
   Athens
RP Orfanos, SE (corresponding author), Attikon Hosp, Dept Crit Care 2, 1 Rimini St, Athens 12462, Greece.
EM sorfanos@med.noa.gr
RI Kotanidou, Anastasia/AAB-4731-2020; Vassiliou, Alice/AAX-1985-2020
OI Vassiliou, Alice/0000-0003-4984-0476; Kotanidou,
   Anastasia/0000-0003-4703-0082
FU nonprofit institute THORAX Research Center for Intensive and Emergency
   Thoracic Medicine, Athens, Greece
FX This work was funded by the nonprofit institute THORAX Research Center
   for Intensive and Emergency Thoracic Medicine, Athens, Greece.
CR Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818
   Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138
   BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8
   Borok Z, 2002, J APPL PHYSIOL, V93, P2199, DOI 10.1152/japplphysiol.01171.2001
   Chae YK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002162
   Chae YK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002594
   Fabregat G, 2016, EXP PHYSIOL, V101, P1418, DOI 10.1113/EP085729
   Fabregat G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114247
   FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970
   FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123
   Garcia Joe G N, 2005, Trans Am Clin Climatol Assoc, V116, P205
   Hasan B, 2014, RESP PHYSIOL NEUROBI, V200, P40, DOI 10.1016/j.resp.2014.05.008
   Jiao GY, 2002, CHINESE MED J-PEKING, V115, P963
   Jin LD, 2013, INT IMMUNOPHARMACOL, V16, P288, DOI 10.1016/j.intimp.2013.03.031
   Kamp Ryan, 2008, Proc Am Thorac Soc, V5, P348, DOI 10.1513/pats.200709-152DR
   Kardara M, 2013, PHARM RES-DORDR, V30, P1836, DOI 10.1007/s11095-013-1027-2
   Karlsson T, 2011, J LEUKOCYTE BIOL, V90, P963, DOI 10.1189/jlb.0910540
   KAWANO T, 1987, J APPL PHYSIOL, V62, P27, DOI 10.1152/jappl.1987.62.1.27
   Kong H, 2008, J CELL SCI, V121, P4029, DOI 10.1242/jcs.035758
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   Lavnikova N, 1998, J INFLAMM, V48, P56
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LLEU PL, 1991, ANAL BIOCHEM, V192, P215, DOI 10.1016/0003-2697(91)90210-K
   Loitto VM, 2002, J LEUKOCYTE BIOL, V71, P212
   Maniatis NA, 2012, SHOCK, V38, P381, DOI 10.1097/SHK.0b013e3182690ea2
   Maniatis NA, 2009, AM J RESP CELL MOL, V41, P426, DOI 10.1165/rcmb.2008-0144OC
   Manitsopoulos N, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0173-y
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E
   Modelska K, 1999, AM J RESP CRIT CARE, V160, P1450, DOI 10.1164/ajrccm.160.5.9901096
   NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663
   Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549
   Rump K, 2013, SHOCK, V40, P430, DOI 10.1097/SHK.0000000000000035
   Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460
   Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573
   Song YL, 2000, J PHYSIOL-LONDON, V525, P771, DOI 10.1111/j.1469-7793.2000.00771.x
   Su X, 2004, RESP PHYSIOL NEUROBI, V142, P1, DOI 10.1016/j.resp.2004.05.001
   Sunil VR, 2002, RESP RES, V3, DOI 10.1186/rr171
   Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818
   Vassiliou AG, 2013, CRIT CARE, V17, DOI 10.1186/cc12893
   Verkman AS, 2007, RESP PHYSIOL NEUROBI, V159, P324, DOI 10.1016/j.resp.2007.02.012
   Verkman AS, 2000, AM J PHYSIOL-LUNG C, V278, pL867, DOI 10.1152/ajplung.2000.278.5.L867
   Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10
   WIGGS BR, 1994, J APPL PHYSIOL, V77, P463, DOI 10.1152/jappl.1994.77.1.463
   Woods SJ, 2015, AM J PHYSIOL-LUNG C, V308, pL912, DOI 10.1152/ajplung.00048.2015
   Yasui M, 2004, J PHARMACOL SCI, V96, P260, DOI 10.1254/jphs.FMJ04004X4
   Zhang ZQ, 2011, J TRAUMA, V71, P1305, DOI 10.1097/TA.0b013e3182128528
   Zhang ZQ, 2010, J PATHOL, V221, P210, DOI 10.1002/path.2702
   Zhao YT, 2011, AM J RESP CELL MOL, V45, P426, DOI 10.1165/rcmb.2010-0422OC
NR 51
TC 25
Z9 28
U1 0
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD SEP-OCT
PY 2017
VL 31
IS 5
BP 885
EP 894
DI 10.21873/invivo.11143
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FL5UQ
UT WOS:000414311600013
PM 28882955
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Wu, ZY
   Chang, JX
   Ren, W
   Hu, ZP
   Li, BW
   Liu, HG
AF Wu, Zhiyong
   Chang, Jinxing
   Ren, Wei
   Hu, Zhipeng
   Li, Bowen
   Liu, Huagang
TI Bindarit reduces the incidence of acute aortic dissection complicated
   lung injury via modulating NF-kappa B pathway
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE acute aortic dissection; ALI/ARDS; NF-kappa B; bindarit 
ID SIGNALING PATHWAYS; EXPRESSION; ACTIVATION; INHIBITOR; CELLS; MCP-1;
   PROTEIN; GENE
AB The pathogenesis of acute aortic dissection (AAD) complicated acute lung injury (ALI) is not currently well defined. At present, no effective animal model has been established for AAD complicated ALI, which hinders research and development of an appropriate treatment regimen for the concurrent conditions. The aim of the present study was to evaluate the therapeutic effects of bindarit (Bnd), an indazolic derivative, on the production of monocyte chemoattractant protein (MCP)-1 in angiotensin II (AngII)-induced complicated ALI in rats. An AAD complicated ALI rat model was established using aminopropionitrile (BAPN) and AngII. The pathological features of AAD complicated ALI were assessed via biochemical and histopathological evaluations. AngII-stimulated human pulmonary microvascular endothelial cells (hPMVECs) were used to assess the effects of Bnd on MCP -1 expression. Western blot analysis was performed to analyze the expression of proteins that may be associated with the process. AAD complicated ALI was established following BAPN and AngII interference, and a massive accumulation of macrophages was observed in the lung tissues of the study rats. Bnd was able to significantly attenuate the incidence of AAD complicated ALI (P<0.05), and significantly inhibit the accumulation of macrophages (P<0.05). The overexpression of MCP -1 induced by AngII in hPMVECs was significantly inhibited by Bnd (P<0.05), which may be associated with downregulation of the classical nuclear factor-kappa B pathway. Bnd was able to attenuate the incidence of AAD complicated ALI, and inhibit the accumulation of macrophages in vivo. These findings provide a basis for future applications of Bnd as part of a therapeutic treatment schedule for aortic dissection complicated lung injury.
C1 [Wu, Zhiyong; Chang, Jinxing; Ren, Wei; Hu, Zhipeng; Li, Bowen; Liu, Huagang] Wuhan Univ, Dept Cardiovasc Surg, Renmin Hosp, 238 Zhangzhidong Rd, Wuhan 830054, Hubei, China.
C3 Wuhan University
RP Wu, ZY (corresponding author), Wuhan Univ, Dept Cardiovasc Surg, Renmin Hosp, 238 Zhangzhidong Rd, Wuhan 830054, Hubei, Peoples R China.
EM zhiyongwu889@sina.com
OI Hu, Zhipeng/0000-0002-6384-0037
CR Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A
   Bonser RS, 2011, J AM COLL CARDIOL, V58, P2455, DOI 10.1016/j.jacc.2011.06.067
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Burysek L, 2002, J BIOL CHEM, V277, P33509, DOI 10.1074/jbc.M201941200
   Funakoshi Y, 2001, HYPERTENSION, V38, P100, DOI 10.1161/01.HYP.38.1.100
   Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46
   Guglielmotti A, 2002, INFLAMM RES, V51, P252, DOI 10.1007/PL00000301
   Haase R, 2003, J IMMUNOL, V171, P4294, DOI 10.4049/jimmunol.171.8.4294
   Kamberi Lulzim S, 2011, Med Arh, V65, P89
   Kurihara T, 2012, CIRCULATION, V126, P3070, DOI 10.1161/CIRCULATIONAHA.112.097097
   Leach HG, 2013, AM J RESP CELL MOL, V49, P1093, DOI 10.1165/rcmb.2013-0152OC
   Lee YH, 2010, J CELL SCI, V123, P1634, DOI 10.1242/jcs.063545
   LeMaire SA, 2011, NAT REV CARDIOL, V8, P103, DOI 10.1038/nrcardio.2010.187
   Li WH, 2007, CANCER RES, V67, P2247, DOI 10.1158/0008-5472.CAN-06-3793
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620
   Matsuo H, 2006, KIDNEY INT, V69, P736, DOI 10.1038/sj.ki.5000131
   Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823
   Mirolo M, 2008, EUR CYTOKINE NETW, V19, P119, DOI 10.1684/ecn.2008.0133
   MORTON RE, 1992, ANAL BIOCHEM, V204, P332, DOI 10.1016/0003-2697(92)90248-6
   Nagashima H, 2002, J VASC SURG, V36, P818, DOI 10.1067/mva.2002.126091
   Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622
   Sironi M, 1999, EUR CYTOKINE NETW, V10, P437
   Tanifuji C, 2005, ANTIOXID REDOX SIGN, V7, P1261, DOI 10.1089/ars.2005.7.1261
   Ten RM, 1999, J IMMUNOL, V163, P3851
   Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200
   Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019
NR 28
TC 8
Z9 9
U1 2
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2017
VL 14
IS 3
BP 2613
EP 2618
DI 10.3892/etm.2017.4830
PN B
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FF0MX
UT WOS:000408596900030
PM 28962202
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Barnthaler, T
   Maric, J
   Platzer, W
   Konya, V
   Theiler, A
   Hasenohrl, C
   Gottschalk, B
   Trautmann, S
   Schreiber, Y
   Graier, WF
   Schicho, R
   Marsche, G
   Olschewski, A
   Thomas, D
   Schuligoi, R
   Heinemann, A
AF Barnthaler, Thomas
   Maric, Jovana
   Platzer, Wolfgang
   Konya, Viktoria
   Theiler, Anna
   Hasenohrl, Carina
   Gottschalk, Benjamin
   Trautmann, Sandra
   Schreiber, Yannick
   Graier, Wolfgang F.
   Schicho, Rudolf
   Marsche, Gunther
   Olschewski, Andrea
   Thomas, Dominique
   Schuligoi, Rufina
   Heinemann, Akos
TI The Role of PGE(2) in Alveolar Epithelial and Lung Microvascular
   Endothelial Crosstalk
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDUCED NEUTROPHIL INFILTRATION; RESPIRATORY-DISTRESS-SYNDROME;
   PROSTAGLANDIN-E RECEPTORS; BARRIER FUNCTION; CYCLOOXYGENASE-2
   EXPRESSION; FIBROBLAST PROLIFERATION; AIRWAY FUNCTION; CELL-LINE;
   TNF-ALPHA; II CELLS
AB Disruption of the blood-air barrier, which is formed by lung microvascular endothelial and alveolar epithelial cells, is a hallmark of acute lung injury. It was shown that alveolar epithelial cells release an unidentified soluble factor that enhances the barrier function of lung microvascular endothelial cells. In this study we reveal that primarily prostaglandin (PG) E-2 accounts for this endothelial barrier-promoting activity. Conditioned media from alveolar epithelial cells (primary ATI-like cells) collected from BALB/c mice and A549 cells increased the electrical resistance of pulmonary human microvascular endothelial cells, respectively. This effect was reversed by pretreating alveolar epithelial cells with a cyclooxygenase-2 inhibitor or by blockade of EP4 receptors on endothelial cells, and in A549 cells also by blocking the sphingosine-1-phosphate1 receptor. Cyclooxygenase-2 was constitutively expressed in A549 cells and in primary ATI-like cells, and was upregulated by lipopolysaccharide treatment. This was accompanied by enhanced PGE(2) secretion into conditioned media. Therefore, we conclude that epithelium-derived PGE(2) is a key regulator of endothelial barrier integrity via EP4 receptors under physiologic and inflammatory conditions. Given that pharmacologic treatment options are still unavailable for diseases with compromised air-blood barrier, like acute lung injury, our data thus support the therapeutic potential of selective EP4 receptor agonists.
C1 [Barnthaler, Thomas; Maric, Jovana; Platzer, Wolfgang; Konya, Viktoria; Theiler, Anna; Hasenohrl, Carina; Schicho, Rudolf; Marsche, Gunther; Schuligoi, Rufina; Heinemann, Akos] Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
C1 [Gottschalk, Benjamin; Graier, Wolfgang F.] Med Univ Graz, Inst Mol Biol & Biochem, Graz, Austria.
C1 [Olschewski, Andrea] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria.
C1 [Trautmann, Sandra; Thomas, Dominique] Goethe Univ Frankfurt, Pharmazentrum Frankfurt ZAFES Inst Clin Pharmacol, Frankfurt, Germany.
C1 [Schreiber, Yannick] Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp TMP, Frankfurt, Germany.
C3 Medical University of Graz; Medical University of Graz; Ludwig Boltzmann
   Institute; Goethe University Frankfurt; Fraunhofer Gesellschaft
RP Heinemann, A (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
EM akos.heinemann@medunigraz.at
RI Graier, Wolfgang F/B-7052-2008
OI Graier, Wolfgang F/0000-0003-1871-3298; Olschewski,
   Andrea/0000-0002-8189-3634; Barnthaler, Thomas/0000-0002-4988-3700;
   Gottschalk, Benjamin/0000-0001-5588-7698; Schuligoi,
   Rufina/0000-0002-9338-6904; Marsche, Gunther/0000-0002-2422-5381
FU Austrian Science Fund FWF [P22521-B18, P25531-B23, P25633-B19,
   P22976-B18, P26185-B19]; Jubilaumsfonds of the Austrian National Bank
   [14263]; DK-MOLIN [FWF - W1241]; DOC Fellowship of the Austrian Academy
   of Science at the Institute of Experimental and Clinical Pharmacology;
   DK-MCD (DKplus Metabolic and Cardiovascular Disease) [W 1226-B18];
   Austrian Science Fund (FWF) [P25531, P26185, KLI521, W1241] Funding
   Source: Austrian Science Fund (FWF)
FX We thank Markus Absenger-Novak and Eleonore Frohlich from the core
   facility for microscopy of the Medical University Graz, for their expert
   assistance in image acquisition. We are particularly grateful to Ilse
   Lanz and Martina Ofner for their excellent technical assistance that
   they provided with numerous assays. This work was supported by the
   Austrian Science Fund FWF (Grant P22521-B18 to A.H., P25531-B23 to V.K.,
   P25633-B19 to R.Schi., P22976-B18 to G.M. and P26185-B19 to R. Schu.)
   and the Jubilaumsfonds of the Austrian National Bank (14263 to A. H.).
   T.B. and J.M. were funded by the PhD Program DK-MOLIN (FWF - W1241).
   A.T. is a recipient of a DOC Fellowship of the Austrian Academy of
   Science at the Institute of Experimental and Clinical Pharmacology. C.H.
   was trained within the frame of the PhD Program Molecular Medicine of
   the Medical University of Graz. Benjamin Gottschalk was funded by the
   PhD Program DK-MCD (W 1226-B18, DKplus Metabolic and Cardiovascular
   Disease).
CR BEISKER W, 1987, CYTOMETRY, V8, P235, DOI 10.1002/cyto.990080218
   Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005
   Birrell MA, 2015, THORAX, V70, P740, DOI 10.1136/thoraxjnl-2014-206592
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Cheng J, 2016, FASEB J, V30, P160, DOI 10.1096/fj.14-268458
   Cheng SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054125
   Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933
   CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571
   DeMaio L, 2009, AM J PHYSIOL-LUNG C, V296, pL1051, DOI 10.1152/ajplung.00021.2009
   deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792
   Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930
   EVANS MJ, 1973, AM J PATHOL, V70, P175
   Fanelli V, 2013, J THORAC DIS, V5, P326, DOI 10.3978/j.issn.2072-1439.2013.04.05
   Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36
   Finetti F, 2008, J BIOL CHEM, V283, P2139, DOI 10.1074/jbc.M703090200
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Grill M, 2008, J NEUROCHEM, V104, P1345, DOI 10.1111/j.1471-4159.2007.05078.x
   GRIMMINGER F, 1992, AM J RESP CELL MOL, V6, P9, DOI 10.1165/ajrcmb/6.1.9
   Hattar K, 2013, CANCER IMMUNOL IMMUN, V62, P309, DOI 10.1007/s00262-012-1341-2
   Hermanns MI, 2004, LAB INVEST, V84, P736, DOI 10.1038/labinvest.3700081
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689
   Jandl K, 2016, J ALLERGY CLIN IMMUN, V137, P833, DOI 10.1016/j.jaci.2015.11.012
   Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694
   Katsuyama M, 1998, BIOCHEM BIOPH RES CO, V251, P727, DOI 10.1006/bbrc.1998.9540
   Konya V, 2015, BRIT J PHARMACOL, V172, P4454, DOI 10.1111/bph.13229
   Konya V, 2013, PHARMACOL THERAPEUT, V138, P485, DOI 10.1016/j.pharmthera.2013.03.006
   Konya V, 2013, J ALLERGY CLIN IMMUN, V131, P532, DOI 10.1016/j.jaci.2012.05.008
   Konya V, 2010, J ALLERGY CLIN IMMUN, V125, P1105, DOI 10.1016/j.jaci.2009.12.002
   Lama V, 2002, AM J RESP CELL MOL, V27, P752, DOI 10.1165/rcmb.4857
   Lappi-Blanco E, 2006, AM J CLIN PATHOL, V126, P717, DOI 10.1309/PFGXCLNG2N17PJX9
   Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001
   Lullmann-Rauch R., 2008, HISTOLOGIE
   Mao P, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12288
   Marsh LM, 2009, AM J PHYSIOL-LUNG C, V296, pL442, DOI 10.1152/ajplung.00525.2007
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x
   Moore BB, 2003, AM J PHYSIOL-LUNG C, V284, pL342, DOI 10.1152/ajplung.00168.2002
   Mura M, 2010, AM J PATHOL, V176, P1725, DOI 10.2353/ajpath.2010.090209
   Neuhaus W, 2012, DIFFERENTIATION, V84, P294, DOI 10.1016/j.diff.2012.08.006
   Parent R.A., 2015, COMP BIOL NORMAL LUN
   Pfister R, 2012, INT J CARDIOL, V155, P268, DOI 10.1016/j.ijcard.2010.10.013
   Radnai B, 2016, J CROHNS COLITIS, V10, P1087, DOI 10.1093/ecco-jcc/jjw061
   Ren YL, 2013, MICROVASC RES, V85, P59, DOI 10.1016/j.mvr.2012.10.004
   Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804
   Schmidt H, 2006, PROSTAG OTH LIPID M, V81, P162, DOI 10.1016/j.prostaglandins.2006.09.003
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schnitzer SE, 2009, MOL CANCER RES, V7, P393, DOI 10.1158/1541-7786.MCR-08-0156
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Sun Y, 2011, ARCH PATHOL LAB MED, V135, P1335, DOI 10.5858/arpa.2010-0549-OA
   Theiler A, 2016, VASC PHARMACOL, V87, P180, DOI 10.1016/j.vph.2016.09.008
   Tornehave D, 2000, HISTOCHEM CELL BIOL, V113, P19
   Torres R, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-72
   Ueki T, 2012, BIOL PHARM BULL, V35, P1041, DOI 10.1248/bpb.b110709
   Ulcar R, 2004, EUR J PHARMACOL, V501, P9, DOI 10.1016/j.ejphar.2004.08.003
   Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wang LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055311
   Wardlaw SA, 2000, CARCINOGENESIS, V21, P1371, DOI 10.1093/carcin/21.7.1371
   Weibel E. R., 1984, PATHWAY OXYGEN STRUC
   Wu SJ, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-27
   Xiong YQ, 2014, CURR TOP MICROBIOL, V378, P85, DOI 10.1007/978-3-319-05879-5_4
   Zhang YS, 2011, BLOOD, V118, P5355, DOI 10.1182/blood-2011-04-350587
NR 64
TC 27
Z9 28
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 11
PY 2017
VL 7
AR 7923
DI 10.1038/s41598-017-08228-y
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD3OO
UT WOS:000407442500063
PM 28801643
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Yi, L
   Huang, XQ
   Guo, F
   Zhou, ZD
   Chang, ML
   Huan, JN
AF Yi, Lei
   Huang, Xiaoqin
   Guo, Feng
   Zhou, Zengding
   Chang, Mengling
   Huan, Jingning
TI GSK-3Beta-Dependent Activation of GEF-Hl/ROCK Signaling Promotes
   LPS-Induced Lung Vascular Endothelial Barrier Dysfunction and Acute Lung
   Injury
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE LPS; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; GSK-3beta; GEF-H1; ROCK 
ID GLYCOGEN-SYNTHASE KINASE-3; BETA-CATENIN; CELL JUNCTIONS;
   PROTEIN-KINASE; CROSS-TALK; EXPRESSION; PHOSPHORYLATION; GSK-3-BETA;
   GSK3-BETA; CADHERIN
AB The bacterial endotoxin or lipopolysaccharide (LPS) leads to the extensive vascular endothelial cells (EC) injury under septic conditions. Guanine nucleotide exchange factor-H1 (GEF-H1)/ROCK signaling not only involved in LPS-induced overexpression of pro-inflammatory mediator in ECs but also implicated in LPS-induced endothelial hyper-permeability However, the mechanisms behind LPS induced GEF-H1/ROCK signaling activation in the progress of EC injury remain incompletely understood. GEF-H1 localized on microtubules (MT) and is suppressed in its MT-bound state. MT disassembly promotes OFF Hi release from MT and stimulates downstream ROCK-specific GEF activity. Since glycogen synthase kinase (GSK-3beta) participates in regulating MT dynamics under pathologic conditions, we examined the pivotal roles for GSK-3beta in modulating LPS-induced activation of GEF-H1/ROCK, increase of vascular endothelial permeability and severity of acute lung injury (ALI). In this study, we found that LPS induced human pulmonary endothelial cell (HPMEC) monolayers disruption accompanied by increase in GSK-3beta activity, activation of GEF-H1/ROCK signaling and decrease in beta-catenin and ZO-1 expression. Inhibition of GSK-3beta reduced HPMEC monolayers hyper-permeability and GEF-H1/ROCK activity in response to LPS. GSK-3beta/GEF-H1/ROCK signaling is implicated in regulating the expression of beta-catenin and ZO-1. In vivo, GSK-3beta inhibition attenuated LPS-induced activation of GEF-H1/ROCK pathway, lung edema and subsequent ALI. These findings present a new mechanism of 05K-3beta-dependent exacerbation of lung micro vascular hyper-permeability and escalation of ALI via activation of GEF-H1/ROCK signaling and disruption of intracellular junctional proteins under septic condition.
C1 [Yi, Lei] Shanghai Univ Med & Hlth Sci, Affiliated Peoples Hosp 6, Shanghai Fengxian Cent Hosp, Dept Orthoped, South Campus, Shanghai, China.
C1 [Yi, Lei; Huang, Xiaoqin; Guo, Feng; Zhou, Zengding; Chang, Mengling; Huan, Jingning] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Burn & Plast Surg, Shanghai, China.
C3 Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong
   University
RP Huan, JN (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Burn & Plast Surg, Shanghai, Peoples R China.
EM jnhuan56542@163.com
RI Yi, Lei/AAI-6290-2020; huang, xiaoqin/HZL-4359-2023
FU National Natural Science Foundation of China [81471867, 81401590]; seed
   fund program of Shanghai University of Medicine and Health Sciences
   [HMSF-17-21-023]
FX This study was supported by the National Natural Science Foundation of
   China (nos. 81471867 and 81401590) and the seed fund program of Shanghai
   University of Medicine and Health Sciences (HMSF-17-21-023).
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o
   Barabutis N, 2016, AM J PHYSIOL-LUNG C, V311, pL832, DOI 10.1152/ajplung.00233.2016
   Barton-Pai A, 2011, EUR J PHARMACOL, V657, P159, DOI 10.1016/j.ejphar.2011.01.060
   Baumgart S, 2016, MOL CANCER THER, V15, P491, DOI 10.1158/1535-7163.MCT-15-0309
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Bellei B, 2008, CELL SIGNAL, V20, P1750, DOI 10.1016/j.cellsig.2008.06.001
   Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2
   Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597
   Birkenfeld J, 2008, TRENDS CELL BIOL, V18, P210, DOI 10.1016/j.tcb.2008.02.006
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2015, BBA-MOL BASIS DIS, V1852, P778, DOI 10.1016/j.bbadis.2014.12.016
   Boku S, 2013, BRAIN RES, V1492, P7, DOI 10.1016/j.brainres.2012.11.034
   Borgas D, 2016, AM J RESP CELL MOL, V54, P683, DOI 10.1165/rcmb.2015-0149OC
   Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3
   Chan MMP, 2009, J LEUKOCYTE BIOL, V86, P283, DOI 10.1189/jlb.0708442
   Chang KC, 2016, INT IMMUNOPHARMACOL, V40, P269, DOI 10.1016/j.intimp.2016.08.022
   Chen XS, 2016, SCI REP-UK, V6, DOI 10.1038/srep19455
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Cuo F., 2012, CYTOKINE, V57, P417, DOI [10.1016/j.cyto.2011.12.009, DOI 10.1016/J.CYTO.2011.12.009]
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dong RL, 2015, CELL PHYSIOL BIOCHEM, V37, P1592, DOI 10.1159/000438526
   Dudek S.M, 2001, J APPL PHYSIOL, V91, P1487
   Dugo L, 2007, SHOCK, V27, P113, DOI 10.1097/01.shk.0000238059.23837.68
   Fu PF, 2015, AM J PHYSIOL-LUNG C, V308, pL1025, DOI 10.1152/ajplung.00306.2014
   Gassowska M, 2014, PLOS ONE, V9, DOI DOI 10.1371/J0URNALP0NE.0094259
   Golpich M, 2015, PHARMACOL RES, V97, P16, DOI 10.1016/j.phrs.2015.03.010
   Gong JH, 2013, J SURG RES, V184, P1035, DOI 10.1016/j.jss.2013.04.051
   Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200
   Guo F, 2012, SHOCK, V37, P531, DOI 10.1097/SHK.0b013e31824caa96
   Guo F, 2012, MOL IMMUNOL, V50, P98, DOI 10.1016/j.molimm.2011.12.009
   Guo Y., 2014, CELL DEATH DIS, V5, DOI [10.1038/cddis.2014.254, DOI 10.1038/CDDIS.2014.254]
   Hsieh CH, 2017, MOL CARCINOGEN, V56, P1055, DOI 10.1002/mc.22570
   HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x
   HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061
   Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
   Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040
   Kratzer E, 2012, AM J RESP CELL MOL, V47, P688, DOI 10.1165/rcmb.2012-0161OC
   Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773
   Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu DD, 2016, SCI REP-UK, V6, DOI 10.1038/srep23653
   Liu JJ, 2013, CELL SIGNAL, V25, P447, DOI 10.1016/j.cellsig.2012.10.012
   Liu ZY, 2015, MOL MED, V21, P937, DOI 10.2119/molmed.2015.00198
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Mali RS, 2011, CANCER CELL, V20, P357, DOI 10.1016/j.ccr.2011.07.016
   Mambetsariev I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092670
   Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Mozaffari MS, 2008, AM J HYPERTENS, V21, P570, DOI 10.1038/ajh.2008.25
   Nob K. T., 2011, EXP CELL RES, V317, P1663, DOI [10.1016/4yexcr.2011.03.022, DOI 10.1016/4YEXCR.2011.03.022]
   Noma K, 2012, J CARDIOL, V60, P1, DOI 10.1016/j.jjcc.2012.03.005
   Park DW, 2014, AM J PHYSIOL-LUNG C, V307, pL735, DOI 10.1152/ajplung.00165.2014
   Pinzon-Daza ML, 2014, J CEREBR BLOOD F MET, V34, P1258, DOI 10.1038/jcbfm.2014.100
   Ramirez SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055972
   Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443
   Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419
   Wan R, 2013, J CELL PHYSIOL, V228, P1295, DOI 10.1002/jcp.24286
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wendel M, 2007, INTENS CARE MED, V33, P25, DOI 10.1007/s00134-006-0433-x
   Xu WW, 2015, J BIOL CHEM, V290, P1348, DOI 10.1074/jbc.M114.593830
   Yi L, 2016, SURGERY, V159, P1436, DOI 10.1016/j.surg.2015.12.008
   Zhang YH, 2015, J LEUKOCYTE BIOL, V97, P921, DOI 10.1189/jlb.3A0413-235R
   Zhao T, 2014, NEUROCHEM RES, V39, P1612, DOI 10.1007/s11064-014-1356-5
   Zhao Y, 2014, J ALZHEIMERS DIS, V41, P835, DOI 10.3233/JAD-131799
   Zhou ZD, 2015, SURGERY, V157, P590, DOI 10.1016/j.surg.2014.10.007
   Zhou ZD, 2013, SURGERY, V154, P621, DOI 10.1016/j.surg.2013.04.009
NR 69
TC 11
Z9 12
U1 1
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD AUG 4
PY 2017
VL 7
AR 357
DI 10.3389/fcimb.2017.00357
PG 13
WC Immunology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology
GA FD4RA
UT WOS:000407517200002
PM 28824887
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Laffey, JG
   Matthay, MA
AF Laffey, John G.
   Matthay, Michael A.
TI Cell-based Therapy for Acute Respiratory Distress Syndrome Biology and
   Potential Therapeutic Value
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE mesenchymal stem cell; pulmonary edema; ALI/ARDS 
ID MESENCHYMAL STEM-CELLS; ACUTE LUNG INJURY; ALVEOLAR FLUID CLEARANCE;
   STROMAL CELLS; BONE-MARROW; IN-VITRO; MITOCHONDRIAL TRANSFER;
   INTERNATIONAL-SOCIETY; PART; MICROVESICLES
AB On the basis of several preclinical studies, cell-based therapy has emerged as a potential new therapeutic for acute respiratory distress syndrome (ARDS). Of the various cell-based therapy options, mesenchymal stem/stromal cells (MSCs) from bone marrow, adipose tissue, and umbilical cord have the most experimental data to support their potential efficacy for lung injury from both infectious and noninfectious causes. Mechanistically, MSCs exert their beneficial effects by release of paracrine factors, microvesicles, and transfer of mitochondria, all of which have antiinflammatory and pro-resolving effects on injured lung endothelium and alveolar epithelium, including enhancing the resolution of pulmonary edema by up-regulating sodium-dependent alveolar fluid clearance. MSCs also have antimicrobial effects mediated by release of antimicrobial factors and by up-regulating monocyte/macrophage phagocytosis. Phase 2a clinical trials to establish safety in ARDS are in progress, and two phase 1 trials did not report any serious adverse events. Several issues need further study, including: determining the optimal methods for large-scale production, reconstitution of cryopreserved cells for clinical use, defining cell potency assays, and determining the therapeutic potential of conditioned media derived from MSCs. Because ARDS is a heterogeneous syndrome, targeting MSCs to patients with ARDS with a more hyperinflammatory endotype may further enhance their potential for efficacy.
C1 [Laffey, John G.] Univ Toronto, St Michaels Hosp, Dept Anesthesia, Toronto, ON, Canada.
C1 [Laffey, John G.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.
C1 [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143, United States.
C1 [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anesthesia, San Francisco, CA 94143, United States.
C3 University of Toronto; Saint Michaels Hospital Toronto; University of
   Toronto; Saint Michaels Hospital Toronto; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco
RP Matthay, MA (corresponding author), Univ Calif San Francisco, Moffitt Hosp, 505 Parnassus Ave,M-917, San Francisco, CA 94143 USA.
EM michael.matthay@ucsf.edu
RI Laffey, John/G-4204-2010
OI Laffey, John/0000-0002-1246-9573
FU Canadian Institute of Health Research; Physicians Services Incorporated;
   Merit Award from the University of Toronto Department of Anesthesia;
   National Institutes of Health [NHLBI HL51856, U01HL108713]
FX Supported by the Canadian Institute of Health Research (J.G.L.),
   Physicians Services Incorporated (J.G.L.), a Merit Award from the
   University of Toronto Department of Anesthesia (J.G.L.), and National
   Institutes of Health grants NHLBI HL51856 and U01HL108713 (M.A.M.).
CR Asmussen S, 2014, THORAX, V69, P819, DOI 10.1136/thoraxjnl-2013-204980
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bustos ML, 2014, AM J RESP CRIT CARE, V189, P787, DOI 10.1164/rccm.201306-1043OC
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Chan MCW, 2016, P NATL ACAD SCI USA, V113, P3621, DOI 10.1073/pnas.1601911113
   Curley GF, 2017, CRIT CARE MED, V45, pE202, DOI 10.1097/CCM.0000000000002073
   Curley GF, 2015, CURR OPIN CRIT CARE, V21, P42, DOI 10.1097/MCC.0000000000000171
   Curley GF, 2013, ANESTHESIOLOGY, V118, P924, DOI 10.1097/ALN.0b013e318287ba08
   Curley GF, 2012, THORAX, V67, P496, DOI 10.1136/thoraxjnl-2011-201059
   Darwish I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071761
   Devaney J, 2015, THORAX, V70, P625, DOI 10.1136/thoraxjnl-2015-206813
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC
   Fang XH, 2015, J IMMUNOL, V195, P875, DOI 10.4049/jimmunol.1500244
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Galipeau J, 2016, CYTOTHERAPY, V18, P151, DOI 10.1016/j.jcyt.2015.11.008
   Gazdhar A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt513
   Gennai S, 2015, AM J TRANSPLANT, V15, P2404, DOI 10.1111/ajt.13271
   Goolaerts A, 2014, AM J PHYSIOL-LUNG C, V306, pL975, DOI 10.1152/ajplung.00242.2013
   Gore AV, 2015, J TRAUMA ACUTE CARE, V79, P48, DOI 10.1097/TA.0000000000000681
   Gotts JE, 2014, AM J PHYSIOL-LUNG C, V307, pL395, DOI 10.1152/ajplung.00110.2014
   Hao Q, 2015, STEM CELL TRANSL MED, V4, P832, DOI 10.5966/sctm.2015-0006
   Hayes Mairead, 2015, Intensive Care Med Exp, V3, P29, DOI 10.1186/s40635-015-0065-y
   Hayes M, 2015, ANESTHESIOLOGY, V122, P363, DOI 10.1097/ALN.0000000000000545
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Huang SXL, 2014, NAT BIOTECHNOL, V32, P84, DOI 10.1038/nbt.2754
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Jackson MV, 2016, STEM CELLS, V34, P2210, DOI 10.1002/stem.2372
   Jiang XP, 2015, CYTOTHERAPY, V17, P560, DOI 10.1016/j.jcyt.2015.02.011
   Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367
   Kotton DN, 2012, AM J RESP CRIT CARE, V185, P1255, DOI 10.1164/rccm.201202-0228PP
   Krasnodembskaya A, 2012, AM J PHYSIOL-LUNG C, V302, pL1003, DOI 10.1152/ajplung.00180.2011
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   La Francesca S, 2014, TRANSPLANT RES, V3, DOI 10.1186/2047-1440-3-19
   Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559
   Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC
   Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111
   Li Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0395-z
   Mao YX, 2015, STEM CELLS, V33, P2331, DOI 10.1002/stem.1996
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McAuley DF, 2014, AM J PHYSIOL-LUNG C, V306, pL809, DOI 10.1152/ajplung.00358.2013
   McIntyre BAS, 2014, STEM CELL TRANSL MED, V3, P7, DOI 10.5966/sctm.2013-0119
   Mitsialis SA, 2016, SEMIN PERINATOL, V40, P138, DOI 10.1053/j.semperi.2015.12.002
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Nazarov I, 2012, STEM CELL TRANSL MED, V1, P359, DOI 10.5966/sctm.2011-0021
   Nemeth K, 2010, P NATL ACAD SCI USA, V107, P5652, DOI 10.1073/pnas.0910720107
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472
   Rafat Neysan, 2014, BMC Res Notes, V7, P613, DOI 10.1186/1756-0500-7-613
   Raicevic G, 2011, CELL IMMUNOL, V270, P207, DOI 10.1016/j.cellimm.2011.05.010
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rojas M, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt430
   Ruiz-Delgado GJ, 2009, ACTA HAEMATOL-BASEL, V122, P1, DOI 10.1159/000227267
   Shen QQ, 2015, MOL MED REP, V11, P2831, DOI 10.3892/mmr.2014.3092
   Sjoding MW, 2016, ANN AM THORAC SOC, V13, P1123, DOI 10.1513/AnnalsATS.201601-072OC
   Sun CK, 2015, AM J TRANSL RES, V7, P209
   Sung PH, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt385
   Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8
   Tonelli AR, 2014, INTENS CARE MED, V40, P769, DOI 10.1007/s00134-014-3272-1
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/s2213-2600(14)70291-7, 10.1016/S2213-2600(14)70291-7]
   Wittwer T, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0151-3
   Yin XR, 2015, CELL PHYSIOL BIOCHEM, V35, P2149, DOI 10.1159/000374020
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 66
TC 147
Z9 156
U1 0
U2 28
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD AUG 1
PY 2017
VL 196
IS 3
BP 266
EP 273
DI 10.1164/rccm.201701-0107CP
PG 8
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA FC2KR
UT WOS:000406666800010
PM 28306336
OA Green Published
DA 2023-08-21
ER

PT J
AU Lockyer, P
   Mao, H
   Fan, QY
   Li, LG
   Yu-Lee, LY
   Eissa, NT
   Patterson, C
   Xie, L
   Pi, XC
AF Lockyer, Pamela
   Mao, Hua
   Fan, Qiying
   Li, Luge
   Yu-Lee, Li-Yuan
   Eissa, N. Tony
   Patterson, Cam
   Xie, Liang
   Pi, Xinchun
TI LRP1-Dependent BMPER Signaling Regulates Lipopolysaccharide-Induced
   Vascular Inflammation
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE atherosclerosis; bone morphogenetic proteins; ECs/HPMECs/HUVECs/MPVECs; Inflammation; LPS 
ID RECEPTOR-RELATED PROTEIN; BINDING; CROSSVEINLESS-2; TRANSCRIPTION;
   EXPRESSION; PROMOTER; COMPLEX; NFAT
AB Objective-Bacterial endotoxin (lipopolysaccharide)-mediated sepsis involves dysregulated systemic inflammation, which injures the lung and other organs, often fatally. Vascular endothelial cells act as both targets and mediators of lipopolysaccharide-induced inflammatory responses. Dysfunction of endothelium results in increases of proinflammatory cytokine production and permeability leakage. BMPER (bone morphogenetic protein-binding endothelial regulator), an extracellular modulator of bone morphogenetic protein signaling, has been identified as a vital component in chronic endothelial inflammatory responses and atherosclerosis. However, it is unclear whether BMPER also regulates inflammatory response in an acute setting such as sepsis. To address this question, we investigated the role of BMPER during lipopolysaccharide-induced acute lung injury.
   Approach and Results-Mice missing 1 allele of BMPER (BMPER+/- mice used in the place of BMPER-/- mice that die at birth) were used for lipopolysaccharide challenge. Lipopolysaccharide-induced pulmonary inflammation and injury was reduced in BMPER+/- mice as shown by several measures, including survival rate, infiltration of inflammatory cells, edema, and production of proinflammatory cytokines. Mechanistically, we have demonstrated that BMPER is required and sufficient for the activation of nuclear factor of activated T cells c1. This BMPER-induced nuclear factor of activated T cells activation is coordinated by multiple signaling pathways, including bone morphogenetic protein-independent low-density lipoprotein receptor-related protein 1-extracellular signal-regulated kinase activation, calcineurin signaling, and low-density lipoprotein receptor-related protein 1 beta-mediated nuclear factor 45 nuclear export in response to BMPER treatment.
   Conclusions-We conclude that BMPER plays a pivotal role in pulmonary inflammatory response, which provides new therapeutic options against sepsis shock. The new signaling pathway initiated by BMPER/low-density lipoprotein receptor-related protein 1 axis broadens our understanding about BMPER's role in vascular homeostasis.
C1 [Lockyer, Pamela] Univ North Carolina Chapel Hill, Dept Pathol & Lab Med, Chapel Hill, NC, United States.
C1 [Mao, Hua; Fan, Qiying; Li, Luge; Xie, Liang; Pi, Xinchun] Baylor Coll Med, Dept Med, Sect Athero & Lipo, Cardiovasc Res Inst, Houston, TX 77030, United States.
C1 [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Mol & Cellular Biol, Sect Immunol Allergy & Rheumatol, Integrat Mol & Biomed Sci, Houston, TX 77030, United States.
C1 [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, Sect Immunol Allergy & Rheumatol, Integrat Mol & Biomed Sci, Houston, TX 77030, United States.
C1 [Eissa, N. Tony] Baylor Coll Med, Dept Med, Houston, TX 77030, United States.
C1 [Eissa, N. Tony] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030, United States.
C1 [Patterson, Cam] New York Presbyterian Hosp, New York, NY, United States.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Baylor College of
   Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor
   College of Medicine; Baylor College of Medicine; NewYork-Presbyterian
   Hospital
RP Pi, XC (corresponding author), Baylor Coll Med, Dept Med, Sect Athero & Lipo, Cardiovasc Res Inst, Houston, TX 77030 USA.
EM xpi@bcm.edu
FU National Institutes of Health [R01 HL112890, R01 HL061656, R01 HL122736]
FX This work was supported by National Institutes of Health R01s HL112890
   and HL061656 (to X. Pi) and HL122736 (to L. Xie).
CR Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Ambrosio AL, 2008, DEV CELL, V15, P248, DOI 10.1016/j.devcel.2008.06.013
   Andreakos E, 2004, CRIT CARE MED, V103, P2229, DOI 10.1182/blood-2003-04-1356
   Angus DC, 2013, CRIT CARE MED, V369, P840, DOI 10.1056/NEJMra1208623
   Bacskai BJ, 2000, CRIT CARE MED, V97, P11551, DOI 10.1073/pnas.200238297
   Boucher P, 2011, BIOCHEM PHARMACOL, V81, P1, DOI 10.1016/j.bcp.2010.09.018
   Coles E, 2004, DEVELOPMENT, V131, P5309, DOI 10.1242/dev.01419
   Conley CA, 2000, DEVELOPMENT, V127, P3947
   Dyer L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139209
   Dyer L, 2014, DEV BIOL, V386, P385, DOI 10.1016/j.ydbio.2013.12.019
   Dyer LA, 2014, TRENDS ENDOCRIN MET, V25, P472, DOI 10.1016/j.tem.2014.05.003
   Gill SE, 2014, CRIT CARE MED, V9, DOI [10.1371/jour-nal.pone.0088501, DOI 10.1071/JOURNAL.PONE.0088501]
   Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08
   Gzindhirajan RK, 2013, CRIT CARE MED, V123, P887, DOI 10.1172/JC165647
   Hayashi H, 2007, CRIT CARE MED, V27, P1933, DOI 10.1523/JNEUROSCI.5471-06.2007
   Heinke J, 2008, CIRC RES, V103, P804, DOI 10.1161/CIRCRESAHA.108.178434
   Helbing T, 2013, J PATHOL, V231, P105, DOI 10.1002/path.4215
   Helbing T, 2011, BLOOD, V118, P5040, DOI 10.1182/blood-2011-03-339762
   Helbing T, 2010, ARTERIOSCL THROM VAS, V30, P554, DOI 10.1161/ATVBAHA.109.201087
   Hijiya N, 2002, CRIT CARE MED, V70, P18
   Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8
   Hu KB, 2006, J BIOL CHEM, V281, P2120, DOI 10.1074/jbc.M504988200
   Ikeya M, 2006, DEVELOPMENT, V133, P4463, DOI 10.1242/dev.02647
   Ikeya M, 2010, DEV BIOL, V337, P405, DOI 10.1016/j.ydbio.2009.11.013
   Kamimura M, 2004, DEV DYNAM, V230, P434, DOI 10.1002/dvdy.20069
   Karmakar S, 2010, EMBO J, V29, P3260, DOI 10.1038/emboj.2010.204
   Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064
   Kisseleva T, 2006, CRIT CARE MED, V116, P2955, DOI 10.1172/.1C127392
   Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65
   Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001
   Linde-Zwirble WT, 2004, CRIT CARE, V8, P222, DOI 10.1186/cc2917
   Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386
   Mantuan E, 2008, CRIT CARE MED, V28, P11571, DOI 10.1523/JNELTROSCI.3053-08.2008
   Mantuano E, 2008, CRIT CARE MED, V283, P19904, DOI 10.1074/jbc.M801762200
   Mao H, 2017, CRIT CARE MED, V8, P14960, DOI 10.1038/ncomms14960
   Mao H, 2016, CRIT CARE MED, V36, P350, DOI 10.1161/ATVBAHA.115.306713
   May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200
   Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003
   Moser M, 2007, J MOL CELL CARDIOL, V43, P243, DOI 10.1016/j.yjmcc.2007.05.008
   Nirula A, 1997, J BIOL CHEM, V272, P7736, DOI 10.1074/jbc.272.12.7736
   Pi XC, 2012, CIRC RES, V111, P564, DOI 10.1161/CIRCRESAHA.112.274597
   Pi XC, 2012, ARTERIOSCL THROM VAS, V32, P2214, DOI 10.1161/ATVBAHA.112.252015
   Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002
   Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250
   ROONEY JW, 1995, MOL CELL BIOL, V15, P6299
   Sakamoto S, 2009, MOL CELL BIOL, V29, P3754, DOI 10.1128/MCB.01836-08
   Serpe M, 2008, DEV CELL, V14, P940, DOI 10.1016/j.devcel.2008.03.023
   Shamanna RA, 2011, MOL CELL BIOL, V31, P4832, DOI 10.1128/MCB.05849-11
   Shi Y, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000188
   van der Geer P, 2002, TRENDS CARDIOVAS MED, V12, P160, DOI 10.1016/S1050-1738(02)00154-8
   Zanoni I, 2009, CRIT CARE MED, V460, P264, DOI 10.1038/nature08118
   Zhao GH, 2005, EXP CELL RES, V305, P312, DOI 10.1016/j.yexcr.2004.12.030
NR 53
TC 25
Z9 25
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD AUG
PY 2017
VL 37
IS 8
BP 1524
EP +
DI 10.1161/ATVBAHA.117.309521
PG 28
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA FB7ES
UT WOS:000406304500015
PM 28596374
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Rho, SS
   Ando, K
   Fukuhara, S
AF Rho, Seung-Sik
   Ando, Koji
   Fukuhara, Shigetomo
TI Dynamic Regulation of Vascular Permeability by Vascular Endothelial
   Cadherin-Mediated Endothelial Cell-Cell Junctions
SO JOURNAL OF NIPPON MEDICAL SCHOOL
LA English
DT Review
DE permeability; VE-cadherin; Rap1; actin cytoskeleton; Rho/RhoA 
ID ACUTE LUNG INJURY; VE-CADHERIN; BARRIER FUNCTION; LEUKOCYTE
   EXTRAVASATION; ADHERENS JUNCTIONS; IN-VIVO; ACTIN POLYMERIZATION;
   EXCHANGE FACTORS; ALPHA-CATENIN; BETA-CATENIN
AB Endothelial cells lining blood vessels regulate vascular barrier function, which controls the passage of plasma proteins and circulating cells across the endothelium. In most normal adult tissues, endothelial cells preserve basal vascular permeability at a low level, while they increase permeability in response to inflammation. Therefore, vascular permeability is tightly controlled by a number of extracellular stimuli and mediators to maintain tissue homeostasis. Accordingly, impaired regulation of endothelial permeability causes various diseases, including chronic inflammation, asthma, edema, sepsis, acute respiratory distress syndrome, anaphylaxis, tumor angiogenesis, and diabetic retinopathy. Vascular endothelial (VE)-cadherin, a member of the classical cadherin superfamily, is a component of cell-to-cell adherens junctions in endothelial cells and plays an important role in regulating vascular permeability. VE-cadherin mediates intercellular adhesion through trans-interactions formed by its extracellular domain, while its cytoplasmic domain is anchored to the actin cytoskeleton via alpha- and beta-catenins, leading to stabilization of VE-cadherin at cell-cell junctions. VE-cadherin-mediated cell adhesions are dynamically, but tightly, controlled by mechanisms that involve protein phosphorylation and reorganization of the actomyosin cytoskeleton. Phosphorylation of VE-cadherin, and its associated-catenins, results in dissociation of the VE-cadherin/catenin complex and internalization of VE-cadherin, leading to increased vascular permeability. Furthermore, reorganization of the actomyosin cytoskeleton by Rapt, a small GTPase that belongs to the Ras subfamily, and Rho family small GTPases, regulates VE-cadherinmediated cell adhesions to control vascular permeability. In this review, we describe recent progress in understanding the signaling mechanisms that enable dynamic regulation of VE-cadherin adhesions and vascular permeability. In addition, we discuss the possibility of novel therapeutic approaches targeting the signaling pathways controlling VE-cadherin-mediated cell adhesion in diseases associated with vascular hyper-permeability.
C1 [Rho, Seung-Sik; Fukuhara, Shigetomo] Musashi Kosugi Hosp, Nippon Med Sch, Inst Adv Med Sci, Dept Mol Pathophysiol, Kawasaki, Kanagawa, Japan.
C1 [Ando, Koji] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Cell Biol, Osaka, Japan.
C3 Nippon Medical School; National Cerebral & Cardiovascular Center - Japan
RP Fukuhara, S (corresponding author), Musashi Kosugi Hosp, Nippon Med Sch, Inst Adv Med Sci, Dept Mol Pathophysiol,Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.
EM s-fukuhara@nms.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
   [22113009]; Japan Society for the Promotion of Science [26670107];
   PRIME, the Japan Agency for Medical Research and Development (AMED);
   Takeda Science Foundation; Naito Foundation; Mochida Memorial Foundation
   for Medical and Pharmaceutical Research; Daiichi Sankyo Foundation of
   Life Science; Astellas Foundation for Research on Metabolic Disorders;
   Grants-in-Aid for Scientific Research [16H05125, 26670107, 17K19689,
   22113009] Funding Source: KAKEN
FX This work was supported in part by Grants-in-Aid for Scientific Research
   on Innovative Areas "Fluorescence Live Imaging" (No. 22113009 to S.F.)
   from The Ministry of Education, Culture, Sports, Science, and
   Technology, Japan, by Grants-in-Aid for Scientific Research (B) (No.
   25293050 to S.F.), and for Exploratory Research (No. 26670107 to S.F.)
   from the Japan Society for the Promotion of Science; PRIME, the Japan
   Agency for Medical Research and Development (AMED) (to S.F.); Takeda
   Science Foundation (to S.F.); the Naito Foundation (to S.E); Mochida
   Memorial Foundation for Medical and Pharmaceutical Research (to S.F.),
   Daiichi Sankyo Foundation of Life Science (to S.F.) and Astellas
   Foundation for Research on Metabolic Disorders (to S.F.).
CR Abbasi Taimur, 2013, Handb Exp Pharmacol, P201, DOI 10.1007/978-3-7091-1511-4_10
   Adamson RH, 2008, AM J PHYSIOL-HEART C, V294, pH1188, DOI 10.1152/ajpheart.00937.2007
   Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x
   Ando K, 2013, J CELL BIOL, V202, P901, DOI 10.1083/jcb.201301115
   Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286
   Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Ayollo DV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008027
   Barry DM, 2015, DEVELOPMENT, V142, P3058, DOI 10.1242/dev.125260
   Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647
   Baumer Y, 2008, HISTOCHEM CELL BIOL, V129, P765, DOI 10.1007/s00418-008-0422-y
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2015, BBA-MOL BASIS DIS, V1852, P778, DOI 10.1016/j.bbadis.2014.12.016
   Birukova AA, 2009, J APPL PHYSIOL, V107, P1900, DOI 10.1152/japplphysiol.00462.2009
   Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064
   Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324
   Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073
   Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009
   Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525
   Cain RJ, 2010, J CELL BIOL, V188, P863, DOI 10.1083/jcb.200907135
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Chervin-Petinot A, 2012, J BIOL CHEM, V287, P7556, DOI 10.1074/jbc.M111.328682
   Cinel Ismail, 2012, J Thorac Dis, V4, P30, DOI 10.3978/j.issn.2072-1439.2010.08.04
   Claesson-Welsh L, 2015, UPSALA J MED SCI, V120, P135, DOI 10.3109/03009734.2015.1064501
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dejana E, 2013, PROG MOL BIOL TRANSL, V116, P119, DOI 10.1016/B978-0-12-394311-8.00006-6
   Dorland YL, 2017, CELL MOL LIFE SCI, V74, P279, DOI 10.1007/s00018-016-2325-8
   Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021
   Duluc L, 2014, CELL TISSUE RES, V355, P675, DOI 10.1007/s00441-014-1805-0
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Farmer PJ, 2001, AM J PHYSIOL-LUNG C, V280, pL732, DOI 10.1152/ajplung.2001.280.4.L732
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH-25.387
   Fukuhra S, 2006, J BIOCHEM MOL BIOL, V39, P132
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia-Ponce A, 2015, THROMB HAEMOSTASIS, V113, P20, DOI 10.1160/TH14-04-0298
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gavard Julie, 2014, Cell Adh Migr, V8, P158
   Glading A, 2007, J CELL BIOL, V179, P247, DOI 10.1083/jcb.200705175
   Gorovoy M, 2007, CIRC RES, V101, P50, DOI 10.1161/CIRCRESAHA.106.145847
   Han S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9260
   Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9
   Hoelzle MK, 2012, MOL BIOL CELL, V23, P310, DOI 10.1091/mbc.E11-08-0719
   Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004
   Huveneers S, 2012, J CELL BIOL, V196, P641, DOI 10.1083/jcb.201108120
   Kim DH, 2009, KIDNEY INT, V76, P1180, DOI 10.1038/ki.2009.387
   KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9
   Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080
   Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021
   Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019
   LANGELER EG, 1991, AM J PHYSIOL, V260, pC1052, DOI 10.1152/ajpcell.1991.260.5.C1052
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mikelis CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7725
   Millan J, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-11
   Moy AB, 1998, AM J PHYSIOL-LUNG C, V274, pL1024, DOI 10.1152/ajplung.1998.274.6.L1024
   Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497
   Noda K, 2010, MOL BIOL CELL, V21, P584, DOI 10.1091/mbc.E09-07-0580
   Nottebaum AF, 2008, J EXP MED, V205, P2929, DOI 10.1084/jem.20080406
   Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407
   Oldenburg J, 2014, CELL TISSUE RES, V355, P545, DOI 10.1007/s00441-013-1792-6
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Pannekoek WJ, 2014, CELL ADHES MIGR, V8, P100, DOI 10.4161/cam.27352
   Pannekoek WJ, 2011, CELL SIGNAL, V23, P2056, DOI 10.1016/j.cellsig.2011.07.022
   Pannekoek WJ, 2009, BBA-BIOMEMBRANES, V1788, P790, DOI 10.1016/j.bbamem.2008.12.010
   Park-Windhol C, 2016, ANNU REV PATHOL-MECH, V11, P251, DOI 10.1146/annurev-pathol-012615-044506
   Phng LK, 2015, DEV CELL, V32, P123, DOI 10.1016/j.devcel.2014.11.017
   Post A, 2015, MOL CELL BIOL, V35, P2495, DOI 10.1128/MCB.01453-14
   Post A, 2013, P NATL ACAD SCI USA, V110, P11427, DOI 10.1073/pnas.1306595110
   Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200
   Rao MV, 2016, MOL BIOL CELL, V27, P2844, DOI 10.1091/mbc.E16-06-0429
   Sakurai A, 2006, MOL BIOL CELL, V17, P966, DOI 10.1091/mbc.E05-07-0647
   Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sidibe A, 2014, AM J PHYSIOL-HEART C, V307, pH455, DOI 10.1152/ajpheart.00774.2013
   Sidibe A, 2014, NAT IMMUNOL, V15, P215, DOI 10.1038/ni.2825
   STELZNER TJ, 1989, J CELL PHYSIOL, V139, P157, DOI 10.1002/jcp.1041390122
   Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200
   Stockton RA, 2010, J EXP MED, V207, P881, DOI 10.1084/jem.20091258
   Sui XF, 2005, AM J PATHOL, V166, P1247, DOI 10.1016/S0002-9440(10)62343-7
   Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343
   Taguchi K, 2011, J CELL BIOL, V194, P643, DOI 10.1083/jcb.201104124
   Tian XY, 2015, MOL BIOL CELL, V26, P636, DOI 10.1091/mbc.E14-02-0725
   Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983
   Vestweber D, 2014, SEMIN IMMUNOPATHOL, V36, P177, DOI 10.1007/s00281-014-0419-7
   Wakayama Y, 2015, DEV CELL, V32, P109, DOI 10.1016/j.devcel.2014.11.024
   Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Wilson CW, 2013, BLOOD, V122, P3678, DOI 10.1182/blood-2013-02-483156
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020
   Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7
NR 101
TC 67
Z9 73
U1 1
U2 18
PU MEDICAL ASSOC NIPPON MEDICAL SCH
PI TOKYO
PA 1-1-5, SENDAGI, TOKYO, 113-8602, JAPAN
SN 1345-4676
EI 1347-3409
J9 J NIPPON MED SCH
JI J. Nippon Med. Sch.
PD AUG
PY 2017
VL 84
IS 4
BP 148
EP 159
DI 10.1272/jnms.84.148
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FJ5MF
UT WOS:000412794900001
PM 28978894
OA gold
DA 2023-08-21
ER

PT J
AU Zhang, D
   Li, CC
   Song, YL
   Zhou, J
   Li, YP
   Li, J
   Bai, CX
AF Zhang, Dan
   Li, Chichi
   Song, Yuanlin
   Zhou, Jian
   Li, Yuping
   Li, Jing
   Bai, Chunxue
TI Integrin alpha v beta 5 inhibition protects against
   ischemia-reperfusion-induced lung injury in an autophagy-dependent
   manner
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE autophagy; integrins; ECs/HPMECs/HUVECs/MPVECs; oxygen-glucose deprivation/oxygen-glucose restoration; apoptosis; ischemia/reperfusion; ALI/ARDS 
ID RESPIRATORY-DISTRESS-SYNDROME; SIGNALING PATHWAYS; SELF-DIGESTION;
   CELL-DEATH; APOPTOSIS; DEGRADATION; MECHANISM; INACTIVATION; CROSSTALK;
   CASPASE-8
AB Integrin alpha v beta 5 mediates pulmonary endothelial barrier function and acute lung injury (LI), but its roles in cell apoptosis and autophagy are unclear. Thus, the aims of this study were to investigate the significance of alpha v beta 5 in ischemia-reperfusion (I/R)-induced apoptosis and LI and to explore the relationship between alpha v beta 5 and autophagy. Human pulmonary microvascular endothelial cells (HPMVECs) were pretreated with an alpha v beta 5-blocking antibody (ALULA) and challenged with oxygen-glucose deprivation/ oxygen-glucose restoration, which mimics I/R; then, cellular autophagy and apoptosis were detected, and cell permeability was assessed. In vivo, mice were pretreated with the autophagy inhibitor chloroquine (CLQ), followed by treatment with ALULA. The mice then underwent operative lung I/R. LI was assessed by performing a pathological examination, calculating the wet/dry lung weight ratio and detecting the bronchial alveolar lavage fluid (BALF) protein concentration. alpha v beta 5 inhibition promoted HPMVEC autophagy under I/R in vitro, alleviated cell permeability, decreased the apoptosis ratio, and activated caspase-3 expression. These outcomes were significantly diminished when autophagy was inhibited with a small-interfering RNA construct targeting autophagy-related gene 7 (siATG7). Moreover, ALULA pretreatment alleviated I/R-induced LI (I/R-LI), which manifested as a decreased wet/dry lung weight ratio, an altered BALF protein concentration, and lung edema. Preinhibiting autophagy with CLQ, however, eliminated the protective effects of ALULA on I/R-LI. Therefore, inhibiting alpha v beta 5 effectively ameliorated I/R-induced endothelial cell apoptosis and I/R-LI. This process was dependent on improved autophagy and its inhibitory effects on activated caspase-3.
C1 [Zhang, Dan; Li, Yuping; Bai, Chunxue] Wenzhou Med Univ, Dept Resp Med, Affiliated Hosp 1, Wenzhou City, Zhejiang, China.
C1 [Li, Chichi; Zhou, Jian] Wenzhou Med Univ, Affiliated Hosp 1, Dept Plast Surg, Wenzhou City, Zhejiang, China.
C1 [Song, Yuanlin; Li, Yuping; Li, Jing] Fudan Univ, Zhongshan Hosp, Dept Resp Med, Shanghai, China.
C1 [Song, Yuanlin; Zhou, Jian; Li, Yuping] Shanghai Resp Res Inst, Shanghai, China.
C1 [Song, Yuanlin; Zhou, Jian; Li, Yuping] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, China.
C3 Wenzhou Medical University; Wenzhou Medical University; Fudan
   University; Guangzhou Medical University; State Key Laboratory of
   Respiratory Disease
RP Bai, CX (corresponding author), Wenzhou Med Univ, Dept Resp Med, Affiliated Hosp 1, Wenzhou City, Zhejiang, Peoples R China.; Bai, CX (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Shanghai Resp Res Inst, Fudan Univ, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM cxbai@fudan.edu.cn
RI li, yu/HGL-9518-2022; Li, yu/HHZ-5236-2022; wang, jing/GVT-8700-2022
OI Bai, Chunxue/0000-0001-5798-3130
FU Zhejiang Provincial Natural Science Foundation of China [LQ16H010002];
   Wenzhou City Science and Technology Foundation [Y20160221]; National
   Natural Science Foundation of China [81490533]
FX This work was supported by the Zhejiang Provincial Natural Science
   Foundation of China Grant LQ16H010002, the Wenzhou City Science and
   Technology Foundation Grant Y20160221, and the National Natural Science
   Foundation of China Grant 81490533.
CR Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261
   Han J, 2014, J BIOL CHEM, V289, P6485, DOI 10.1074/jbc.M113.536854
   He QX, 2008, FEBS J, V275, P5725, DOI 10.1111/j.1742-4658.2008.06699.x
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Institute of Laboratory Animal Resources, 1996, GUIDE CARE USE LAB A
   Iwai-Kanai E, 2008, AUTOPHAGY, V4, P322, DOI 10.4161/auto.5603
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lo S, 2013, ANN SURG, V257, P352, DOI 10.1097/SLA.0b013e318269d0e2
   Lotti R, 2010, J INVEST DERMATOL, V130, P2569, DOI 10.1038/jid.2010.195
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Ng CSH, 2005, EUR RESPIR J, V25, P356, DOI 10.1183/09031936.05.00030304
   Oh JE, 2009, EXP CELL RES, V315, P3187, DOI 10.1016/j.yexcr.2009.08.002
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ryter SW, 2009, AUTOPHAGY, V5, P235, DOI 10.4161/auto.5.2.7495
   Sheppard D, 2008, EUR RESPIR REV, V17, P157, DOI 10.1183/09059180.00010909
   Smith KM, 1997, CRIT CARE MED, V25, P1888, DOI 10.1097/00003246-199711000-00030
   Stupack DG, 2004, NAT CELL BIOL, V6, P388, DOI 10.1038/ncb0504-388
   Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070
   Su G, 2007, AM J RESP CELL MOL, V36, P377, DOI 10.1165/rcmb.2006-0238OC
   Su G, 2013, CRIT CARE MED, V41, P546, DOI 10.1097/CCM.0b013e3182711b1e
   Sun J, 2009, EUR RESPIR J, V33, P398, DOI 10.1183/09031936.00142407
   Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725
   vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200
   Wang HJ, 2013, AM J PHYSIOL-CELL PH, V304, pC617, DOI 10.1152/ajpcell.00296.2012
   Wang J, 2000, J CELL SCI, V113, P753
   Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651
   Yen WL, 2008, PHYSIOLOGY, V23, P248, DOI 10.1152/physiol.00013.2008
   Zhang D, 2015, J HEART LUNG TRANSPL, V34, P746, DOI 10.1016/j.healun.2014.12.008
   Zheng YH, 2012, J CELL PHYSIOL, V227, P127, DOI 10.1002/jcp.22709
   Zhu Y, 2015, CARDIOLOGY, V130, P249, DOI 10.1159/000371489
NR 37
TC 12
Z9 13
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG
PY 2017
VL 313
IS 2
BP L384
EP L394
DI 10.1152/ajplung.00391.2016
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA FC3NU
UT WOS:000406746900017
PM 28522565
OA Bronze
DA 2023-08-21
ER

PT J
AU Czikora, I
   Alli, AA
   Sridhar, S
   Matthay, MA
   Pillich, H
   Hudel, M
   Berisha, B
   Gorshkov, B
   Romero, MJ
   Gonzales, J
   Wu, GY
   Huo, YQ
   Su, YC
   Verin, AD
   Fulton, D
   Chakraborty, T
   Eaton, DC
   Lucas, R
AF Czikora, Istvan
   Alli, Abdel A.
   Sridhar, Supriya
   Matthay, Michael A.
   Pillich, Helena
   Hudel, Martina
   Berisha, Besim
   Gorshkov, Boris A.
   Romero, Maritza J.
   Gonzales, Joyce N.
   Wu, Guangyu
   Huo, Yuqing
   Su, Yunchao
   Verin, Alexander D.
   Fulton, David J. R.
   Chakraborty, Trinad
   Eaton, Douglas C.
   Lucas, Rudolf
TI Epithelial Sodium Channnel-alpha Mediates the Protective Effect of the
   TNF-Derived TIP Peptide in Pneumolysin-Induced Endothelial Barrier
   Dysfunction
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE epithelial sodium channel; non-selective cation channel; TNF/TNF-alpha/TNFR1; pneumonia; pneumolysin; endothelial barrier function 
ID LECTIN-LIKE DOMAIN; NECROSIS-FACTOR-ALPHA; ACUTE LUNG INJURY; SENSING
   ION CHANNELS; KINASE-C-ALPHA; VASCULAR ENDOTHELIUM; EDEMA REABSORPTION;
   ENAC ACTIVITY; IN-VITRO; CELLS
AB Background: Streptococcus pneumoniae is a major etiologic agent of bacterial pneumonia. Autolysis and antibiotic-mediated lysis of pneumococci induce release of the pore-forming toxin, pneumolysin (PLY), their major virulence factor, which is a prominent cause of acute lung injury. PLY inhibits alveolar liquid clearance and severely compromises alveolar-capillary barrier function, leading to permeability edema associated with pneumonia. As a consequence, alveolar flooding occurs, which can precipitate lethal hypoxemia by impairing gas exchange. The a subunit of the epithelial sodium channel (ENaC) is crucial for promoting Na+ reabsorption across Na+-transporting epithelia. However, it is not known if human lung microvascular endothelial cells (HL-MVEC) also express ENaC-alpha and whether this subunit is involved in the regulation of their barrier function.
   Methods: The presence of alpha,beta, and gamma subunits of ENaC and protein phosphorylation status in HL-MVEC were assessed in western blotting. The role of ENaC-alpha in monolayer resistance of HL-MVEC was examined by depletion of this subunit by specific siRNA and by employing the TNF-derived TIP peptide, a specific activator that directly binds to ENaC-alpha.
   Results: HL-MVEC express all three subunits of ENaC, as well as acid-sensing ion channel 1a (ASIC1a), which has the capacity to form hybrid non-selective cation channels with ENaC-alpha. Both TIP peptide, which specifically binds to ENaC-alpha, and the specific ASIC1a activator MitTx significantly strengthened barrier function in PLYtreated HL-MVEC. ENaC-alpha depletion significantly increased sensitivity to PLY-induced hyperpermeability and in addition, blunted the protective effect of both the TIP peptide and MitTx, indicating an important role for ENaC-alpha and for hybrid NSC channels in barrier function of HL-MVEC. TIP peptide and MitTx, indicating an important role for ENaC-alpha and for hybrid NSC channels in barrier function of HL-MVEC. TIP peptide blunted PLY-induced phosphorylation of both calmodulin-dependent kinase II (CaMKII) and of its substrate, the actin-binding protein filamin A (FLN-A), requiring the expression of both ENaC-alpha and ASIC1a. Since non-phosphorylated FLN-A promotes ENaC channel open probability and blunts stress fiber formation, modulation of this activity represents an attractive target for the protective actions of ENaC-alpha in both barrier function and liquid clearance.
   Conclusion: Our results in cultured endothelial cells demonstrate a previously unrecognized role for ENaC-alpha in strengthening capillary barrier function that may apply to the human lung. Strategies aiming to activate endothelial NSC channels that contain ENaC-alpha should be further investigated as a novel approach to improve barrier function in the capillary endothelium during pneumonia.
C1 [Czikora, Istvan; Sridhar, Supriya; Gorshkov, Boris; Romero, Maritza J.; Huo, Yuqing; Verin, Alexander D.; Fulton, David; Lucas, Rudolf] Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912, United States.
C1 [Alli, Abdel A.] Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL, United States.
C1 [Alli, Abdel A.] Univ Florida, Coll Med, Dept Med, Div Nephrol Hypertens & Renal Transplantat, Gainesville, FL, United States.
C1 [Matthay, Michael A.] UCSF, Cardiovasc Res Inst, San Francisco, CA, United States.
C1 [Pillich, Helena; Hudel, Martina; Berisha, Besim; Chakraborty, Trinad] Justus Liebig Univ, Inst Med Microbiol, Giessen, Germany.
C1 [Romero, Maritza J.; Wu, Guangyu; Su, Yunchao; Fulton, David; Lucas, Rudolf] Augusta Univ, Dept Pharmacol & Toxicol, Med Coll Georgia, Augusta, GA 30912, United States.
C1 [Gonzales, Joyce; Huo, Yuqing; Verin, Alexander D.; Lucas, Rudolf] Augusta Univ, Dept Med, Med Coll Georgia, Augusta, GA 30912, United States.
C1 [Eaton, Douglas C.] Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322, United States.
C3 University System of Georgia; Augusta University; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; University of California System;
   University of California San Francisco; Justus Liebig University
   Giessen; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; Emory University
RP Czikora, I; Lucas, R (corresponding author), Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.; Lucas, R (corresponding author), Augusta Univ, Dept Pharmacol & Toxicol, Med Coll Georgia, Augusta, GA 30912 USA.; Lucas, R (corresponding author), Augusta Univ, Dept Med, Med Coll Georgia, Augusta, GA 30912 USA.
EM iczikora@augusta.edu; rlucas@augusta.edu
RI Lucas, Rudolf/ABA-3011-2020
OI Czikora, Istvan/0000-0002-8247-9494; Lucas, Rudolf/0000-0003-3805-8868;
   Verin, Alexander/0000-0003-0627-7185; Romero,
   Maritza/0000-0002-4476-2053
FU NHLBI [PO1, HL101902, HL51856]; AHA Scientist Development
   [17SDG33680024]; German Research Foundation (DFG) [TR-84]; ADA
   [1-16-IBS-196];  [K01 DK099617]
FX This work was supported by PO1 grant HL101902 from the NHLBI (to AV and
   DF) and in part by K01 DK099617 (to AAA), Extramural Success Award from
   the Vice President for Research at Augusta University (to RL), AHA
   Scientist Development Grant 17SDG33680024 (to IC), as well as by SFB
   grant TR-84 "Innate Immunity of the Lung" from the German Research
   Foundation (DFG) (to HP and TC). The work was also supported by ADA
   grant #1-16-IBS-196 (to RL, AV, and DF) and NHLBI grant HL51856 (to
   MAM). RL is a Mercator Fellow of the DFG.
CR Alli AA, 2015, AM J PHYSIOL-RENAL, V309, pF456, DOI 10.1152/ajprenal.00631.2014
   Alli AA, 2012, AM J PHYSIOL-RENAL, V303, pF800, DOI 10.1152/ajprenal.00703.2011
   Anderson R, 2007, J ANTIMICROB CHEMOTH, V60, P1155, DOI 10.1093/jac/dkm338
   Azzam ZS, 2015, RAMBAM MAIMONIDES ME, V6, DOI 10.5041/RMMJ.10210
   Baron A, 2013, TOXICON, V75, P187, DOI 10.1016/j.toxicon.2013.04.008
   Bohlen CJ, 2011, NATURE, V479, P410, DOI 10.1038/nature10607
   Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983
   Braun C, 2005, J IMMUNOL, V175, P3402, DOI 10.4049/jimmunol.175.5.3402
   CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882
   Charles RP, 2008, J BIOL CHEM, V283, P2622, DOI 10.1074/jbc.M708829200
   Chen F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099823
   Chrissobolis S, 2017, CURR HYPERTENS REV, V13, P46, DOI 10.2174/1573402113666170228151402
   Czikora I, 2014, AM J RESP CRIT CARE, V190, P522, DOI 10.1164/rccm.201405-0833OC
   Eaton DC, 2009, ANNU REV PHYSIOL, V71, P403, DOI 10.1146/annurev.physiol.010908.163250
   Elia N, 2003, AM J RESP CRIT CARE, V168, P1043, DOI 10.1164/rccm.200206-618OC
   Gessner C, 2003, RESP MED, V97, P1188, DOI 10.1016/S0954-6111(03)00225-7
   Hamacher J, 2010, CRIT CARE MED, V38, P871, DOI 10.1097/CCM.0b013e3181cdf725
   Hartmann EK, 2013, ACTA ANAESTH SCAND, V57, P334, DOI 10.1111/aas.12034
   Hribar M, 1999, EUR J IMMUNOL, V29, P3105
   Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325
   Jeggle P, 2013, HYPERTENSION, V61, P1053, DOI 10.1161/HYPERTENSIONAHA.111.199455
   Ji HL, 2012, AM J PHYSIOL-LUNG C, V303, pL1013, DOI 10.1152/ajplung.00206.2012
   Kashlan OB, 2012, EXP CELL RES, V318, P1011, DOI 10.1016/j.yexcr.2012.02.024
   Kusche-Vihrog K, 2014, PFLUG ARCH EUR J PHY, V466, P851, DOI 10.1007/s00424-013-1356-3
   Lin LH, 2014, J CHEM NEUROANAT, V61-62, P161, DOI 10.1016/j.jchemneu.2014.10.002
   Lin X, 2016, GENE THER, V23, P489, DOI 10.1038/gt.2016.19
   Loose M, 2015, J INFECT DIS, V211, P306, DOI 10.1093/infdis/jiu428
   Lucas R, 2016, J BIOL CHEM, V291, P23440, DOI 10.1074/jbc.M116.718163
   Lucas R, 2012, AM J RESP CELL MOL, V47, P445, DOI 10.1165/rcmb.2011-0332OC
   Lucas R, 2012, P NATL ACAD SCI USA, V109, P2084, DOI 10.1073/pnas.1121075109
   Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Meltzer RH, 2007, J BIOL CHEM, V282, P25548, DOI 10.1074/jbc.M703825200
   Nitta CH, 2014, AM J PHYSIOL-HEART C, V306, pH41, DOI 10.1152/ajpheart.00269.2013
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Reifenberger MS, 2014, AM J PHYSIOL-RENAL, V307, pF86, DOI 10.1152/ajprenal.00251.2013
   Schwameis R, 2014, J CLIN PHARMACOL, V54, P341, DOI 10.1002/jcph.203
   Shabbir W, 2015, BIOCHEM PHARMACOL, V98, P740, DOI 10.1016/j.bcp.2015.08.003
   Snyder PM, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.279pe41
   Statt S, 2015, AM J RESP CELL MOL, V53, P689, DOI 10.1165/rcmb.2014-0391OC
   Trac PT, 2017, AM J PHYSIOL-LUNG C, V312, pL797, DOI 10.1152/ajplung.00379.2016
   Vadasz I, 2008, CRIT CARE MED, V36, P1543, DOI 10.1097/CCM.0b013e31816f485e
   Vadasz I, 2007, INTENS CARE MED, V33, P1243, DOI 10.1007/s00134-007-0661-8
   Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x
   Wolfmeier H, 2016, BBA-GEN SUBJECTS, V1860, P2498, DOI 10.1016/j.bbagen.2016.07.022
   Xiong CL, 2010, VASC PHARMACOL, V52, P207, DOI 10.1016/j.vph.2009.12.010
NR 46
TC 30
Z9 33
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 21
PY 2017
VL 8
AR 842
DI 10.3389/fimmu.2017.00842
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FB2XA
UT WOS:000406005300001
PM 28785264
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Ke, YB
   Zebda, N
   Oskolkova, O
   Afonyushkin, T
   Berdyshev, E
   Tian, YF
   Meng, FY
   Sarich, N
   Bochkov, VN
   Wang, JM
   Birukova, AA
   Birukov, KG
AF Ke, Yunbo
   Zebda, Noureddine
   Oskolkova, Olga
   Afonyushkin, Taras
   Berdyshev, Evgeny
   Tian, Yufeng
   Meng, Fanyong
   Sarich, Nicolene
   Bochkov, Valery N.
   Wang, Ji Ming
   Birukova, Anna A.
   Birukov, Konstantin G.
TI Anti-Inflammatory Effects of OxPAPC Involve Endothelial Cell-Mediated
   Generation of LXA4
SO CIRCULATION RESEARCH
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; Inflammation; lipoxins; ALI/ARDS; phospholipids; pulmonary circulation 
AB Rationale: Oxidation of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) generates a group of bioactive oxidized phospholipid products with a broad range of biological activities. Barrier-enhancing and anti-inflammatory effects of OxPAPC on pulmonary endothelial cells are critical for prevention of acute lung injury caused by bacterial pathogens or excessive mechanical ventilation. Anti-inflammatory properties of OxPAPC are associated with its antagonistic effects on Toll-like receptors and suppression of RhoA GTPase signaling.
   Objective: Because OxPAPC exhibits long-lasting anti-inflammatory and lung-protective effects even after single administration in vivo, we tested the hypothesis that these effects may be mediated by additional mechanisms, such as OxPAPC-dependent production of anti-inflammatory and proresolving lipid mediator, lipoxin A4 (LXA4).
   Methods and Results: Mass spectrometry and ELISA assays detected significant accumulation of LXA4 in the lungs of OxPAPC-treated mice and in conditioned medium of OxPAPC-exposed pulmonary endothelial cells. Administration of LXA4 reproduced anti-inflammatory effect of OxPAPC against tumor necrosis factor-a in vitro and in the animal model of lipopolysaccharide-induced lung injury. The potent barrier-protective and anti-inflammatory effects of OxPAPC against tumor necrosis factor-a and lipopolysaccharide challenge were suppressed in human pulmonary endothelial cells with small interfering RNA-induced knockdown of LXA4 formyl peptide receptor-2 (FPR2/ALX) and in mFPR2(-/-) (mouse formyl peptide receptor 2) mice lacking the mouse homolog of human FPR2/ALX.
   Conclusions: This is the first demonstration that inflammation-and injury-associated phospholipid oxidation triggers production of anti-inflammatory and proresolution molecules, such as LXA4. This lipid mediator switch represents a novel mechanism of OxPAPC-assisted recovery of inflamed lung endothelium.
C1 [Ke, Yunbo; Zebda, Noureddine; Oskolkova, Olga; Afonyushkin, Taras; Tian, Yufeng; Meng, Fanyong; Sarich, Nicolene; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, Chicago, IL 60637, United States.
C1 [Berdyshev, Evgeny] Natl Jewish Hlth, Denver, CO, United States.
C1 [Wang, Ji Ming] NCI, Frederick, MD 21701, United States.
C1 [Bochkov, Valery N.] Karl Franzens Univ Graz, Inst Pharmaceut Sci, Graz, Austria.
C3 University of Chicago; National Jewish Health; National Institutes of
   Health (NIH) - USA; NIH National Cancer Institute (NCI); ARQUS;
   University of Graz
RP Birukov, KG (corresponding author), Univ Maryland, Dept Anesthesiol, UMSOM Lung Biol Program, Sch Med, 20 Penn St,HSF 2,Room S145, Baltimore, MD 21201 USA.
EM kbirukov@anes.umm.edu
RI Birukov, Konstantin/FJB-5755-2022; Sarich, Nicolene/IWV-3869-2023;
   Bochkov, Valery/HNR-8336-2023
OI Oskolkova, Olga/0000-0001-9443-8705
FU National Heart, Lung, and Blood Institute [HL076259, HL087823, HL107920,
   HL130431]; National Institute of General Medical Sciences [GM114171]
FX This work was supported by the grants HL076259, HL087823, HL107920, and
   HL130431 from the National Heart, Lung, and Blood Institute and GM114171
   from the National Institute of General Medical Sciences.
NR 0
TC 32
Z9 34
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD JUL 21
PY 2017
VL 121
IS 3
BP 244
EP +
DI 10.1161/CIRCRESAHA.116.310308
PG 21
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Hematology
GA FB1HD
UT WOS:000405893400011
PM 28522438
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Khoy, K
   Nguyen, MVC
   Masson, D
   Bardy, B
   Drouet, C
   Paclet, MH
AF Khoy, Kathy
   Minh Vu Chuong Nguyen
   Masson, Dominique
   Bardy, Beatrice
   Drouet, Christian
   Paclet, Marie-Helene
TI Transfusion-related acute lung injury: critical neutrophil activation by
   anti-HLA-A2 antibodies for endothelial permeability
SO TRANSFUSION
LA English
DT Article
ID PHAGOCYTE NADPH OXIDASE; IN-VITRO MODEL; MYELOID-LEUKEMIA; PATHOGENESIS;
   MATURATION; TRALI
AB BACKGROUND: Transfusion-related acute lung injury (TRALI) is a major complication of hemotherapy that may occur after the transfusion of any blood type component. Several clinical reports have suggested the presence of anti-HLA antibodies in the blood product. This study sought to examine the role of anti-HLA-A2 antibodies in polymorphonuclear neutrophil (PMN) activation and thus in endothelial permeability.
   STUDY DESIGN AND METHODS: PMN activation was assessed by both nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) activity and reactive oxygen species (ROS) production. A coculture assay of EA.hy926 endothelial cells with PMNs or differentiated-PLB-985 cells, a model of neutrophil-like cells, was performed to estimate the impact of ROS on endothelial permeability.
   RESULTS: Anti-HLA-A2 antibodies significantly increased PMN activation, with subsequent endothelial dysfunction. Phagocyte NADPH oxidase (NOX2) activity was shown to be involved in this process and ROS themselves were demonstrated to induce VE-cadherin cleavage and endothelial permeability.
   CONCLUSION: Our data may support the existence of a critical anti-HLA-A2 antibody threshold for PMN activation, with NOX2 activity and subsequent endothelial permeability in the two-hit model of TRALI.
C1 [Khoy, Kathy; Minh Vu Chuong Nguyen; Drouet, Christian; Paclet, Marie-Helene] Univ Grenoble Alpes, GREPI EA 7408, Grenoble, France.
C1 [Khoy, Kathy] Univ Caen Normandie, CHU Caen, Caen, France.
C1 [Masson, Dominique; Bardy, Beatrice] EFS Rhone Alpes, Site Grenoble, Grenoble, France.
C1 [Drouet, Christian; Paclet, Marie-Helene] CHU Grenoble Alpes, Grenoble, France.
C3 Communaute Universite Grenoble Alpes; UDICE-French Research
   Universities; Universite Grenoble Alpes (UGA); CHU de Caen NORMANDIE;
   Universite de Caen Normandie; CHU Grenoble Alpes
RP Paclet, MH (corresponding author), Univ Grenoble Alpes, GREPI EA 7408, EFS Site Grenoble, 29 Ave Maquis Gresivaudan,BP35, F-38701 La Tronche, France.
EM mhpaclet@chu-grenoble.fr
RI Paclet, Marie-Hélène/AAS-5029-2020; DROUET, Christian/AAE-5682-2020
OI DROUET, Christian/0000-0003-1318-4278
FU Etablissement Francais du Sang (EFS call 2011)
FX This article was supported by a program conducted within the
   Etablissement Francais du Sang (EFS call 2011; C. Drouet, coordinator).
CR Baillet A, 2011, FASEB J, V25, P2333, DOI 10.1096/fj.10-173807
   Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Campion Y, 2007, BIOCHIMIE, V89, P1145, DOI 10.1016/j.biochi.2007.01.010
   Curtis BR, 2006, CRIT CARE MED, V34, pS118, DOI 10.1097/01.CCM.0000214293.72918.D8
   Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC
   Gavard Julie, 2014, Cell Adh Migr, V8, P158
   Goldman M, 2005, TRANSFUS MED REV, V19, P2, DOI 10.1016/j.tmrv.2004.10.001
   Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8
   Leach M, 1998, TRANSFUSION MED, V8, P333
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Marik PE, 2008, CRIT CARE MED, V36, P3080, DOI 10.1097/CCM.0b013e31818c3801
   Middelburg RA, 2008, TRANSFUSION, V48, P2167, DOI 10.1111/j.1537-2995.2008.01810.x
   Peters AL, 2015, BRIT J HAEMATOL, V170, P597, DOI 10.1111/bjh.13459
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744
   SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7
   SEEGER W, 1990, BLOOD, V76, P1438
   Silliman CC, 2014, VOX SANG, V107, P76, DOI 10.1111/vox.12129
   Silliman CC, 2006, CRIT CARE MED, V34, pS124, DOI 10.1097/01.CCM.0000214292.62276.8E
   TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0
   TUCKER KA, 1987, BLOOD, V70, P372
   Vilgrain I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080056
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Vlaar APJ, 2011, BLOOD, V117, P4218, DOI 10.1182/blood-2010-10-313973
   Win N, 2001, TRANSFUSION, V41, P1421, DOI 10.1046/j.1537-2995.2001.41111421.x
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288
   Zhou YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/374963
NR 31
TC 14
Z9 15
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD JUL
PY 2017
VL 57
IS 7
BP 1699
EP 1708
DI 10.1111/trf.14134
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA VI4AP
UT WOS:000482988100032
PM 28608441
OA Bronze
DA 2023-08-21
ER

PT J
AU Lee, YL
   Obiako, B
   Gorodnya, OM
   Ruchko, MV
   Kuck, JL
   Pastukh, VM
   Wilson, GL
   Simmons, JD
   Gillespie, MN
AF Lee, Yann-Leei
   Obiako, Boniface
   Gorodnya, Olena M.
   Ruchko, Mykhaylo V.
   Kuck, Jamie L.
   Pastukh, Viktor M.
   Wilson, Glenn L.
   Simmons, Jon D.
   Gillespie, Mark N.
TI MITOCHONDRIAL DNA DAMAGE INITIATES ACUTE LUNG INJURY AND MULTI-ORGAN
   SYSTEM FAILURE EVOKED IN RATS BY INTRA-TRACHEAL PSEUDOMONAS AERUGINOSA
SO SHOCK
LA English
DT Article
DE mtDNA repair; oxidative stress; Pseudomonas aeruginosa; pneumonia 
ID PULMONARY IMMUNE-RESPONSES; ARTERY ENDOTHELIAL-CELLS;
   MOLECULAR-PATTERNS; TRANSCRIPTION FACTOR; REPAIR; DYSFUNCTION;
   BIOGENESIS; APOPTOSIS; PROTECTS; STRESS
AB Although studies in rat cultured pulmonary artery endothelial cells, perfused lungs, and intact mice support the concept that oxidative mitochondrial (mt) DNA damage triggers acute lung injury (ALI), it has not yet been determined whether enhanced mtDNA repair forestalls development of ALI and its progression to multiple organ system failure (MOSF). Accordingly, here we examined the effect of a fusion protein construct targeting the DNA glycosylase, Ogg1, to mitochondria in a rat model intra-tracheal Pseudomonas aeruginosa (strain 103; PA103)-induced ALI and MOSF. Relative to controls, animals given PA103 displayed increases in lung vascular filtration coefficient accompanied by transient lung tissue oxidative mtDNA damage and variable changes in mtDNA copy number without evidence of nuclear DNA damage. The approximate 40% of animals surviving 24 h after bacterial administration exhibited multiple organ dysfunction, manifest as increased serum and tissue-specific indices of kidney and liver failure, along with depressed heart rate and blood pressure. While administration of mt-targeted Ogg1 to control animals was innocuous, the active fusion protein, but not a DNA repair-deficient mutant, prevented bacteria-induced increases in lung tissue oxidative mtDNA damage, failed to alter mtDNA copy number, and attenuated lung endothelial barrier degradation. These changes were associated with suppression of liver, kidney, and cardiovascular dysfunction and with decreased 24 h mortality. Collectively, the present findings indicate that oxidative mtDNA damage to lung tissue initiates PA103-induced ALI and MOSF in rats.
C1 [Lee, Yann-Leei; Simmons, Jon D.] Univ S Alabama, Coll Med, Dept Surg, Mobile, AL, United States.
C1 [Lee, Yann-Leei; Ruchko, Mykhaylo V.; Kuck, Jamie L.; Pastukh, Viktor M.; Simmons, Jon D.; Gillespie, Mark N.] Univ S Alabama, Coll Med, Ctr Lung Biol, Mobile, AL, United States.
C1 [Obiako, Boniface; Gorodnya, Olena M.; Ruchko, Mykhaylo V.; Kuck, Jamie L.; Pastukh, Viktor M.; Gillespie, Mark N.] Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688, United States.
C1 [Wilson, Glenn L.] Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL, United States.
C3 University of South Alabama; University of South Alabama; University of
   South Alabama; University of South Alabama
RP Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA.
EM mgillesp@southalabama.edu
FU National Institutes of Health [RO1 HL058234, RO1 HL073244, R44 HL114225,
   K08 GM109113]
FX This work was supported in part by grants from the National Institutes
   of Health (RO1 HL058234, RO1 HL073244, R44 HL114225, and K08 GM109113).
CR Athale J, 2012, FREE RADICAL BIO MED, V53, P1584, DOI 10.1016/j.freeradbiomed.2012.08.009
   Audia JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081792
   Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200
   Chaung WW, 2012, INT J MOL MED, V30, P199, DOI 10.3892/ijmm.2012.959
   Choudhary S, 2016, J INNATE IMMUN, V8, P143, DOI 10.1159/000442254
   Chouteau JM, 2011, AM J PHYSIOL-LUNG C, V301, pL892, DOI 10.1152/ajplung.00210.2011
   Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023
   Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001
   Grishko V, 2001, AM J PHYSIOL-LUNG C, V280, pL1300, DOI 10.1152/ajplung.2001.280.6.L1300
   Hashizume M, 2013, AM J PHYSIOL-LUNG C, V304, pL287, DOI 10.1152/ajplung.00071.2012
   Julian MW, 2012, J IMMUNOL, V189, P433, DOI 10.4049/jimmunol.1101375
   Koczor CA, 2009, J BIOL CHEM, V284, P36191, DOI 10.1074/jbc.M109.036020
   Koczor CA, 2009, METHODS MOL BIOL, V554, P233, DOI 10.1007/978-1-59745-521-3_15
   Kuck JL, 2015, AM J PHYSIOL-LUNG C, V308, pL1078, DOI 10.1152/ajplung.00015.2015
   Langley RJ, 2014, AM J RESP CRIT CARE, V190, P445, DOI 10.1164/rccm.201404-0624OC
   Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893
   Levitt JE, 2006, SEMIN RESP CRIT CARE, V27, P426, DOI 10.1055/s-2006-948296
   Li HP, 2015, J TRAUMA ACUTE CARE, V78, P272, DOI 10.1097/TA.0000000000000509
   Mai SHC, 2015, SHOCK, V44, P166, DOI 10.1097/SHK.0000000000000396
   Panduri V, 2009, FREE RADICAL BIO MED, V47, P750, DOI 10.1016/j.freeradbiomed.2009.06.010
   Pastukh VM, 2016, FREE RADICAL BIO MED, V96, P78, DOI 10.1016/j.freeradbiomed.2016.04.011
   Piantadosi CA, 2012, FREE RADICAL BIO MED, V53, P2043, DOI 10.1016/j.freeradbiomed.2012.09.014
   Quiros PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23
   Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004
   Ruchko MV, 2011, FREE RADICAL BIO MED, V50, P1107, DOI 10.1016/j.freeradbiomed.2010.10.692
   Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   von Drygalski A, 2012, THROMB HAEMOSTASIS, V108, P981, DOI 10.1160/TH12-03-0196
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354
   Yao X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139416
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhao C, 2014, J TRAUMA ACUTE CARE, V76, P1222, DOI 10.1097/TA.0000000000000220
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 34
TC 24
Z9 26
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUL
PY 2017
VL 48
IS 1
BP 54
EP 60
DI 10.1097/SHK.0000000000000838
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA FA7DM
UT WOS:000405605100008
PM 28125528
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Sun, HD
   Liu, YJ
   Chen, J
   Chen, MY
   Ouyang, B
   Guan, XD
AF Sun, Hua-Dong
   Liu, Yong-Jun
   Chen, Juan
   Chen, Min-Ying
   Ouyang, Bin
   Guan, Xiang-Dong
TI The pivotal role of HIF-1 alpha in lung inflammatory injury induced by
   septic mesenteric lymph
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE sepsis; HIF/HIF1 alpha; ALI/ARDS; Inflammation; A549; ECs/HPMECs/HUVECs/MPVECs 
ID ASCENDENS STENT PERITONITIS; HEMORRHAGIC-SHOCK; CECAL LIGATION; HYPOXIA;
   SEPSIS; TRAUMA; GUT; LIPOPOLYSACCHARIDE; CELLS; DYSFUNCTION
AB Hypoxia inducible factor-1 alpha (HIF-1 alpha) plays an essential role in hypoxia and inflammatory response. Oxygen metabolic dysfunction and cascade amplification of inflammatory response are prominent pathophysiological characteristics in sepsis induced acute lung injury (ALI).
   In this study, we started with septic mesenteric lymph injection model to investigate whether HIF-1 alpha played a role in the pathogenesis of ALI induced by septic lymph. The data demonstrated that rats injected with septic lymph showed a significant higher Lung Injury Scale and MPO(myeloperoxidase) levels than that of rats injected with normal saline/lymph. ALI was associated with a higher degree of HIF-1 alpha expression in the lungs infused by septic lymph. Intratracheal delivery of YC-1(3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole) significantly attenuated lung inflammatory damages.
   Furthermore, in vitro studies, human alveolar type II epithelial cell (A549)/human pulmonary microvascular endothelial cell (HPMEC) incubated by septic lymph showed dramatically decreased cell viability, higher levels of inflammatory cytokines (TNF-alpha, IL-6 and IL-1 beta) and excitation of HIF-1 alpha expression (Immunofluorescence localization/RT-PCR test) simultaneously. Nevertheless, compared with the non-silencing cell lines, A549/HPMEC with HIF-1 alpha gene silencing manifested increased viability and restrained cytokines' expression after incubation with septic lymph.
   These results indicate that HIF-1 alpha expression can be induced and activated in rats during the acute lung inflammatory damages triggered by septic lymph injection and that lung inflammatory injuries occur via a HIF-1 alpha-dependent pathway. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Sun, Hua-Dong; Liu, Yong-Jun; Chen, Juan; Chen, Min-Ying; Ouyang, Bin; Guan, Xiang-Dong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept SICU, 58 Zhongshan 2 Rd, Guangzhou, Guangdong, China.
C1 [Sun, Hua-Dong; Liu, Yong-Jun] Minist Hlth, Key Lab Asisted Circulat, Guangzhou, Guangdong, China.
C3 Sun Yat Sen University
RP Guan, XD (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept SICU, 58 Zhongshan 2 Rd, Guangzhou, Guangdong, Peoples R China.
EM xiaoshuihu@163.com
FU National Natural Science Foundation of China [81071536, 81201452]
FX The authors wish to acknowledge financial support from the National
   Natural Science Foundation of China (Grant No. 81071536 and No.
   81201452).
CR Adams CA, 2001, SURGERY, V129, P351, DOI 10.1067/msy.2001.111698
   Barlos D, 2009, AM J PHYSIOL-LUNG C, V296, pL404, DOI 10.1152/ajplung.00491.2007
   Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427
   Claridge JA, 2000, J SURG RES, V92, P206, DOI 10.1006/jsre.2000.5899
   Cooke KR, 2000, J IMMUNOL, V165, P6612, DOI 10.4049/jimmunol.165.11.6612
   D'Alessandro A, 2016, BLOOD TRANSFUS-ITALY, V14, P185, DOI 10.2450/2016.0208-15
   Davidson MT, 2004, ANN SURG, V240, P123, DOI 10.1097/01.sla.0000129341.94219.cf
   Deitch EA, 2006, FRONT BIOSCI-LANDMRK, V11, P520, DOI 10.2741/1816
   Deitch EA, 2001, SURGERY, V129, P39, DOI 10.1067/msy.2001.109119
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2
   Halpern MD, 2003, AM J PHYSIOL-GASTR L, V284, pG695, DOI 10.1152/ajpgi.00353.2002
   HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B
   Huber-Lang M, 2014, J IMMUNOL, V192, P5324, DOI 10.4049/jimmunol.1400341
   Ince C, 2016, J APPL PHYSIOL, V120, P226, DOI 10.1152/japplphysiol.00298.2015
   Jiang H, 2012, ACTA PHARMACOL SIN, V33, P635, DOI 10.1038/aps.2012.5
   Kenneth NS, 2008, BIOCHEM J, V414, P19, DOI 10.1042/BJ20081055
   Landahl P, 2015, SURG INFECT, V16, P651, DOI 10.1089/sur.2015.034
   Lustig MK, 2007, SHOCK, V28, P59, DOI 10.1097/SHK.0b013e31802e454f
   Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008
   Magnotti LJ, 1999, ARCH SURG-CHICAGO, V134, P1333, DOI 10.1001/archsurg.134.12.1333
   Maier S, 2004, SHOCK, V21, P505, DOI 10.1097/01.shk.0000126906.52367.dd
   Nishi K, 2008, ANTIOXID REDOX SIGN, V10, P983, DOI 10.1089/ars.2007.1825
   Peyssonnaux C, 2007, J IMMUNOL, V178, P7516, DOI 10.4049/jimmunol.178.12.7516
   Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474
   Singleton KD, 2003, EUR SURG RES, V35, P486, DOI 10.1159/000073387
   Sixt M, 2005, IMMUNITY, V22, P19, DOI 10.1016/j.immuni.2004.11.013
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Traeger T, 2010, JOVE-J VIS EXP, V46, P2299
   Trzeciak S, 2010, CRIT CARE MED, V38, P1092, DOI 10.1097/CCM.0b013e3181cf6fbc
   Watts JA, 2004, J MOL CELL CARDIOL, V36, P141, DOI 10.1016/j.yjmcc.2003.10.015
   Xu DZ, 2004, CRIT CARE MED, V32, P760, DOI 10.1097/01.CCM.0000114815.88622.9D
   Yuan LB, 2011, ANESTHESIOLOGY, V114, P340, DOI 10.1097/ALN.0b013e318206ff6f
   Zallen G, 1999, J SURG RES, V83, P83, DOI 10.1006/jsre.1999.5569
   Zhang L, 2016, BIOMED PHARMACOTHER, V83, P265, DOI 10.1016/j.biopha.2016.06.030
NR 37
TC 16
Z9 16
U1 2
U2 11
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2017
VL 91
BP 476
EP 484
DI 10.1016/j.biopha.2017.04.103
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FB8PB
UT WOS:000406399900055
PM 28478272
DA 2023-08-21
ER

PT J
AU Svedova, J
   Menoret, A
   Mittal, P
   Ryan, JM
   Buturla, JA
   Vella, AT
AF Svedova, Julia
   Menoret, Antoine
   Mittal, Payal
   Ryan, Joseph M.
   Buturla, James A.
   Vella, Anthony T.
TI Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T
   cell-induced acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; Staphylococcus aureus; T cells; ECs/HPMECs/HUVECs/MPVECs; CD54 
ID RESPIRATORY-DISTRESS-SYNDROME; STAPHYLOCOCCAL-ENTEROTOXIN-B;
   INTERCELLULAR-ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL-CELLS; BACTERIAL
   SUPERANTIGEN; INTRANASAL EXPOSURE; AIRWAY INFLAMMATION;
   MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; NEUTROPHIL INFLUX
AB Acute respiratory distress syndrome (ARDS) is a serious, often fatal condition without available pharmacotherapy. Although the role of innate cells in ARDS has been studied extensively, emerging evidence suggests that T cells may be involved in disease etiology. Staphylococcus aureus enterotoxins are potent T-cell mitogens capable of triggering life-threatening shock. We demonstrate that 2 days after inhalation of S. aureus enterotoxin A, mice developed T cell-mediated increases in vascular permeability, as well as expression of injury markers and caspases in the lung. Pulmonary endothelial cells underwent sequential phenotypic changes marked by rapid activation coinciding with inflammatory events secondary to T-cell priming, followed by reductions in endothelial cell number juxtaposing simultaneous T-cell expansion and cytotoxic differentiation. Although initial T-cell activation influenced the extent of lung injury, CD54 (ICAM-1) blocking antibody administered well after enterotoxin exposure substantially attenuated pulmonary barrier damage. Thus CD54-targeted therapy may be a promising candidate for further exploration into its potential utility in treating ARDS patients.
C1 [Svedova, Julia; Menoret, Antoine; Mittal, Payal; Ryan, Joseph M.; Vella, Anthony T.] UConn Hlth, Dept Immunol, Sch Med, 263 Farmington Ave, Farmington, CT 06030, United States.
C1 [Menoret, Antoine] UConn Hlth, Inst Syst Genom, Farmington, CT 06030, United States.
C1 [Buturla, James A.] UConn Hlth, Dept Internal Med, Farmington, CT 06030, United States.
RP Vella, AT (corresponding author), UConn Hlth, Dept Immunol, Sch Med, 263 Farmington Ave, Farmington, CT 06030 USA.
EM vella@uchc.edu
FU National Institute of Allergy and Infectious Diseases [P01AI056172]
FX The study was supported by National Institute of Allergy and Infectious
   Diseases Grant P01AI056172.
CR Aeffner F, 2015, TOXICOL PATHOL, V43, P1074, DOI 10.1177/0192623315598399
   Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0
   Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594
   Anikeeva N, 2005, P NATL ACAD SCI USA, V102, P6437, DOI 10.1073/pnas.0502467102
   Azuma K, 2004, INT J INFECT DIS, V8, P292, DOI 10.1016/j.ijid.2003.12.005
   Bauer TT, 2005, CHEST, V128, P273, DOI 10.1378/chest.128.1.273
   Becker K, 2003, J CLIN MICROBIOL, V41, P1434, DOI 10.1128/JCM.41.4.1434-1439.2003
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bosma KJ, 2010, DRUGS, V70, P1255, DOI 10.2165/10898570-000000000-00000
   BOYD AW, 1988, P NATL ACAD SCI USA, V85, P3095, DOI 10.1073/pnas.85.9.3095
   Carman CV, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00603
   Chen HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101925
   D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498
   DAMLE NK, 1993, J IMMUNOL, V150, P726
   Delgoffe Greg M, 2013, JAKSTAT, V2, pe23060, DOI 10.4161/jkst.23060
   Desouza IA, 2005, BRIT J PHARMACOL, V146, P781, DOI 10.1038/sj.bjp.0706393
   Diener K, 1998, LAB INVEST, V78, P647
   Ferry T, 2005, CLIN INFECT DIS, V41, P771, DOI 10.1086/432798
   Fraser JD, 2008, IMMUNOL REV, V225, P226, DOI 10.1111/j.1600-065X.2008.00681.x
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Grommes J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038917
   Hamai A, 2008, CANCER RES, V68, P9854, DOI 10.1158/0008-5472.CAN-08-0719
   Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007
   Heiss C, 2015, ANTIOXID REDOX SIGN, V22, P1230, DOI 10.1089/ars.2014.6158
   HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525
   Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.3.CO;2-V
   HUMPHREYS H, 1989, J MED MICROBIOL, V28, P163, DOI 10.1099/00222615-28-3-163
   KAVANAUGH AF, 1994, ARTHRITIS RHEUM, V37, P992, DOI 10.1002/art.1780370703
   KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763
   Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378/chest.128.6.3854
   KRAKAUER T, 1994, J LEUKOCYTE BIOL, V56, P458, DOI 10.1002/jlb.56.4.458
   Kumar S, 2013, MUCOSAL IMMUNOL, V6, P1006, DOI 10.1038/mi.2012.138
   Labuda T, 1998, IMMUNOLOGY, V94, P496
   Lang JD, 2005, CLIN EXP IMMUNOL, V141, P211, DOI 10.1111/j.1365-2249.2005.02853.x
   Lesur O, 2000, CRIT CARE MED, V28, P3814, DOI 10.1097/00003246-200012000-00010
   Li JH, 2002, AM J PATHOL, V161, P1485, DOI 10.1016/S0002-9440(10)64424-0
   Li JT, 2015, J IMMUNOL, V195, P87, DOI 10.4049/jimmunol.1500054
   Lundberg AH, 2001, ANN SURG, V233, P213, DOI 10.1097/00000658-200102000-00010
   Mannick JA, 2001, J AM COLL SURGEONS, V193, P237, DOI 10.1016/S1072-7515(01)01011-0
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   MATTIX ME, 1995, TOXICOL PATHOL, V23, P262, DOI 10.1177/019262339502300304
   Matute-Bello G, 1999, J IMMUNOL, V163, P2217
   Matute-Bello G, 2001, AM J PATHOL, V158, P153, DOI 10.1016/S0002-9440(10)63953-3
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Maxwell JR, 2004, J IMMUNOL, V172, P248, DOI 10.4049/jimmunol.172.1.248
   MCCORMACK JE, 1993, J IMMUNOL, V150, P3785
   Menoret A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040184
   Mileski WJ, 2003, J TRAUMA, V54, P950, DOI 10.1097/01.TA.0000030626.84680.11
   Muller AM, 2002, J PATHOL, V198, P270, DOI 10.1002/path.1186
   MULLIGAN MS, 1994, AM J PATHOL, V144, P1008
   Muralimohan G, 2008, J IMMUNOL, V181, P3698, DOI 10.4049/jimmunol.181.5.3698
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Parker D, 2015, J INFECT DIS, V211, P835, DOI 10.1093/infdis/jiu525
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Peterson BT, 1999, EXP LUNG RES, V25, P41, DOI 10.1080/019021499270411
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Powers ME, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003871
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Rajagopalan G, 2006, INFECT IMMUN, V74, P1284, DOI 10.1128/IAI.74.2.1284-1296.2006
   Rajagopalan G, 2006, SHOCK, V25, P647, DOI 10.1097/01.shk.0000209565.92445.7d
   Rao R, 2015, BRIT J PHARMACOL, V172, P1792, DOI 10.1111/bph.13026
NR 64
TC 10
Z9 10
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2017
VL 313
IS 1
BP L177
EP L191
DI 10.1152/ajplung.00050.2017
PG 15
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA EZ8RR
UT WOS:000404995100015
PM 28473322
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Tang, XD
   Shi, L
   Monsel, A
   Li, XY
   Zhu, HL
   Zhu, YG
   Qu, JM
AF Tang, Xiao-Dan
   Shi, Lin
   Monsel, Antoine
   Li, Xiang-Yang
   Zhu, Hui-Li
   Zhu, Ying-Gang
   Qu, Jie-Ming
TI Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice
   Partly Mediated by Ang-1 mRNA
SO STEM CELLS
LA English
DT Article
DE mesenchymal stem cell; ECs/HPMECs/HUVECs/MPVECs; lung; Animal models; Lentiviral vector 
ID ANGIOPOIETIN-1 GENE-THERAPY; ALVEOLAR FLUID CLEARANCE; STROMAL CELLS;
   BACTERIAL CLEARANCE; SURVIVAL; PROTECT; PERMEABILITY; INFLAMMATION;
   SECRETION; DELIVERY
AB Microvesicles (MVs) derived from human mesenchymal stem cells (MSC MVs) were demonstrated to ameliorate inflammation in lungs. We have found their content of mRNA for keratinocyte growth factor was partly involved in their therapeutic effects. As MSC MVs also contained a substantial quantity of angiopoietin-1 (Ang-1) mRNA, which plays an essential role in vascular stabilization and resolving inflammation, we hypothesized that Ang-1 mRNA might similarly account for a part of their therapeutic effects. We downregulated Ang-1 mRNA expression in MVs, using a lentivirus vector carrying Ang-1 short hairpin RNA to transfect MSCs. A mouse model of lipopolysaccharide induced acute lung injury (ALI) was used in vivo. We also studied in vitro interactions between Ang-1 mRNA deficient MVs on macrophages and human lung microvascular endothelial cells. Compared with negative control, Ang-1 mRNA deficient MVs increased the influx of neutrophils and macrophage inflammatory protein-2 levels in bronchoalveolar lavage fluid by 136% and 105%, respectively, suggesting a deteriorative lung inflammation and a failure to restore pulmonary capillary permeability assessed by Evan's blue dye and bronchoalveolar lavage albumin level. In vitro, the addition of Ang-1 mRNA deficient MVs failed to maintain the integrity of endotoxin-stimulated microvascular endothelial cells and abrogated the decrease in tumor necrosis factor-a level and the increase in interleukin-10 level mediated by negative control in RAW 264.7 cells. In summary, the therapeutic effects of MVs in ALI, and their immunomodulatory properties on macrophages were partly mediated through their content of Ang-1 mRNA.
C1 [Tang, Xiao-Dan; Li, Xiang-Yang; Zhu, Hui-Li; Zhu, Ying-Gang] Fudan Univ, Huadong Hosp, Dept Pulm Dis, 221 West Yanan Rd, Shanghai 200040, China.
C1 [Shi, Lin] Fudan Univ, Zhongshan Hosp, Dept Pulm Dis, Shanghai, China.
C1 [Monsel, Antoine] UPMC, La Pitie Salpetriere Hosp, AP HP, Paris, France.
C1 [Qu, Jie-Ming] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, 197 Rui Jin Er Rd, Shanghai 200025, China.
C3 Fudan University; Fudan University; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Paul-Brousse - APHP; Hopital Universitaire
   Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; Hopital Universitaire Cochin - APHP;
   Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire
   Saint-Louis - APHP; Shanghai Jiao Tong University
RP Zhu, YG (corresponding author), Fudan Univ, Huadong Hosp, Dept Pulm Dis, 221 West Yanan Rd, Shanghai 200040, Peoples R China.; Qu, JM (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
EM robin-zyg@gmail.com; jmqu0906@163.com
OI Monsel, Antoine/0000-0002-9647-7043
FU National Natural Science Foundation of China [81400053, 81570066];
   Shanghai Leading Talent Projects [036]; Shanghai Municipal Commission of
   Health and Family Planning [20144Y0114]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 81400053 and 81570066), Shanghai Leading
   Talent Projects (No. 036, 2010), and Shanghai Municipal Commission of
   Health and Family Planning (No. 20144Y0114).
CR Antunes MA, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0118-x
   Baulch JE, 2016, P NATL ACAD SCI USA, V113, P4836, DOI 10.1073/pnas.1521668113
   Bruno S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033115
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798
   Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015
   Gennai S, 2015, AM J TRANSPLANT, V15, P2404, DOI 10.1111/ajt.13271
   Gonzalez-Rey E, 2009, GUT, V58, P929, DOI 10.1136/gut.2008.168534
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Gupta N, 2012, THORAX, V67, P533, DOI 10.1136/thoraxjnl-2011-201176
   Huang YQ, 2008, CRIT CARE MED, V36, P262, DOI 10.1097/01.CCM.0000297955.02633.A4
   Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011
   Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113
   Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC
   Mao YX, 2015, STEM CELLS, V33, P2331, DOI 10.1002/stem.1996
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Radu M, 2013, JOVE-J VIS EXP, DOI 10.3791/50062
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   SINCLAIR DG, 1994, CHEST, V106, P535, DOI 10.1378/chest.106.2.535
   Sun LJ, 2007, BIOCHEM BIOPH RES CO, V357, P779, DOI 10.1016/j.bbrc.2007.04.010
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Xu JG, 2007, AM J PHYSIOL-LUNG C, V293, pL131, DOI 10.1152/ajplung.00431.2006
   Zhao YDD, 2014, STEM CELLS, V32, P1855, DOI 10.1002/stem.1690
   Zheng GP, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/989473
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 41
TC 121
Z9 134
U1 2
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2017
VL 35
IS 7
BP 1849
EP 1859
DI 10.1002/stem.2619
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA EY5JA
UT WOS:000404011900015
PM 28376568
OA Bronze
DA 2023-08-21
ER

PT J
AU Ohmura, T
   Tian, YF
   Sarich, N
   Ke, YB
   Meliton, A
   Shah, AS
   Andreasson, K
   Birukov, KG
   Birukova, AA
AF Ohmura, Tomomi
   Tian, Yufeng
   Sarich, Nicolene
   Ke, Yunbo
   Meliton, Angelo Y.
   Shah, Alok S.
   Andreasson, Katrin
   Birukov, Konstantin G.
   Birukova, Anna A.
TI Regulation of lung endothelial permeability and inflammatory responses
   by prostaglandin A2: role of EP4 receptor
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID NF-KAPPA-B; SIGNAL-TRANSDUCTION; OXIDIZED PHOSPHOLIPIDS; BARRIER
   DYSFUNCTION; INTERCELLULAR-ADHESION; PROSTANOID RECEPTORS; RHO; PATHWAY;
   ACTIVATION; CELLS
AB The role of prostaglandin A2 (PGA2) in modulation of vascular endothelial function is unknown. We investigated effects of PGA2 on pulmonary endothelial cell (EC) permeability and inflammatory activation and identified a receptor mediating these effects. PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall lipopolysaccharide (LPS). Receptor screening using pharmacological and molecular inhibitory approaches identified EP4 as a novel PGA2 receptor. EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP. PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NF.B pathway and expression of EC adhesion molecules ICAM1 and VCAM1. These effects were abolished by pharmacological or molecular inhibition of EP4. In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide. These protective effects were abolished in mice with endothelial-specific EP4 knockout. The results suggest a novel role for the PGA2-EP4 axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and inflammation.
C1 [Ohmura, Tomomi; Tian, Yufeng; Sarich, Nicolene; Ke, Yunbo; Meliton, Angelo; Shah, Alok S.; Birukov, Konstantin G.; Birukova, Anna A.] Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, Chicago, IL 60637, United States.
C1 [Andreasson, Katrin] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305, United States.
C1 [Birukov, Konstantin G.; Birukova, Anna A.] Univ Maryland, Sch Med, Baltimore, MD 21201, United States.
C3 University of Chicago; Stanford University; University System of
   Maryland; University of Maryland Baltimore
RP Birukova, AA (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, Chicago, IL 60637 USA.; Birukova, AA (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
EM abirukova@som.umaryland.edu
RI Birukov, Konstantin/FJB-5755-2022; Sarich, Nicolene/IWV-3869-2023
FU National Heart, Lung, and Blood Institute [HL076259, HL087823, HL107920,
   HL130431]; National Institute of General Medical Sciences [GM114171]
FX This work was supported by Grants HL076259, HL087823, HL107920, and
   HL130431 from the National Heart, Lung, and Blood Institute and GM114171
   from the National Institute of General Medical Sciences.
CR Alfranca A, 2006, CARDIOVASC RES, V70, P446, DOI 10.1016/j.cardiores.2005.12.020
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2013, MOL BIOL CELL, V24, P2678, DOI 10.1091/mbc.E13-02-0098
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2012, J CELL PHYSIOL, V227, P1883, DOI 10.1002/jcp.22916
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2011, J CELL PHYSIOL, V226, P2052, DOI 10.1002/jcp.22543
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006
   Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Comerford KM, 2002, FASEB J, V16, P583, DOI 10.1096/fj.01-0739fje
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068
   Guo F, 2012, MOL IMMUNOL, V50, P98, DOI 10.1016/j.molimm.2011.12.009
   Guo F, 2012, CYTOKINE, V57, P417, DOI 10.1016/j.cyto.2011.12.009
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.E02-11-0753
   Howard Luke S G E, 2005, Paediatr Respir Rev, V6, P285, DOI 10.1016/j.prrv.2005.09.006
   Khakpour S, 2015, INNATE IMMUN-LONDON, V21, P827, DOI 10.1177/1753425915606525
   Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433
   Leduc M, 2009, J PHARMACOL EXP THER, V331, P297, DOI 10.1124/jpet.109.156398
   Liang XB, 2011, J CLIN INVEST, V121, P4362, DOI 10.1172/JCI46279
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Matoba K, 2010, BIOCHEM BIOPH RES CO, V402, P725, DOI 10.1016/j.bbrc.2010.10.093
   Miyoshi J, 2005, ADV DRUG DELIVER REV, V57, P815, DOI 10.1016/j.addr.2005.01.008
   Monvoisin A, 2006, DEV DYNAM, V235, P3413, DOI 10.1002/dvdy.20982
   MUALLEM S, 1989, BIOCHEM J, V263, P769, DOI 10.1042/bj2630769
   Musiek ES, 2005, J BIOL CHEM, V280, P35562, DOI 10.1074/jbc.M504785200
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004
   Schlegel N, 2014, CELL TISSUE RES, V355, P587, DOI 10.1007/s00441-013-1755-y
   Schlegel N, 2009, CRIT CARE MED, V37, P1735, DOI 10.1097/CCM.0b013e31819deb6a
   SMITH CW, 1993, SEMIN HEMATOL, V30, P45
   Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086
   Storer PD, 2005, J NEUROSCI RES, V80, P66, DOI 10.1002/jnr.20413
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Tian YF, 2015, J BIOL CHEM, V290, P4097, DOI 10.1074/jbc.M114.620377
   Tian YF, 2014, MOL CELL BIOL, V34, P3546, DOI 10.1128/MCB.00248-14
   Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046
   Yagami T, 2016, MOL NEUROBIOL, V53, P4754, DOI 10.1007/s12035-015-9355-3
NR 47
TC 26
Z9 26
U1 0
U2 9
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD JUN 15
PY 2017
VL 28
IS 12
BP 1622
EP 1635
DI 10.1091/mbc.E16-09-0639
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FA4SF
UT WOS:000405432800004
PM 28428256
OA hybrid, Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Seo, J
   Conegliano, D
   Farrell, M
   Cho, M
   Ding, XT
   Seykora, T
   Qing, D
   Mangalmurti, NS
   Huh, D
AF Seo, Jeongyun
   Conegliano, David
   Farrell, Megan
   Cho, Minseon
   Ding, Xueting
   Seykora, Thomas
   Qing, Danielle Y.
   Mangalmurti, Nilam S.
   Huh, Dongeun
TI A microengineered model of RBC transfusion-induced pulmonary vascular
   injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ACUTE LUNG INJURY; RED-BLOOD-CELLS; RESPIRATORY-DISTRESS-SYNDROME;
   GLYCATION END-PRODUCTS; SHEAR-STRESS; ENDOTHELIAL-CELLS; CRITICALLY-ILL;
   CYCLIC STRETCH; FLOW; INFLAMMATION
AB Red blood cell (RBC) transfusion poses significant risks to critically ill patients by increasing their susceptibility to acute respiratory distress syndrome. While the underlying mechanisms of this life-threatening syndrome remain elusive, studies suggest that RBC-induced microvascular injury in the distal lung plays a central role in the development of lung injury following blood transfusion. Here we present a novel microengineering strategy to model and investigate this key disease process. Specifically, we created a microdevice for culturing primary human lung endothelial cells under physiological flow conditions to recapitulate the morphology and hemodynamic environment of the pulmonary microvascular endothelium in vivo. Perfusion of the microengineered vessel with human RBCs resulted in abnormal cytoskeletal rearrangement and release of intracellular molecules associated with regulated necrotic cell death, replicating the characteristics of acute endothelial injury in transfused lungs in vivo. Our data also revealed the significant effect of hemodynamic shear stress on RBC-induced microvascular injury. Furthermore, we integrated the microfluidic endothelium with a computer-controlled mechanical stretching system to show that breathing-induced physiological deformation of the pulmonary microvasculature may exacerbate vascular injury during RBC transfusion. Our biomimetic microsystem provides an enabling platform to mechanistically study transfusion-associated pulmonary vascular complications in susceptible patient populations.
C1 [Seo, Jeongyun; Conegliano, David; Farrell, Megan; Cho, Minseon; Ding, Xueting; Seykora, Thomas; Huh, Dongeun] Univ Penn, Dept Bioengn, Philadelphia, PA 19104, United States.
C1 [Qing, Danielle; Mangalmurti, Nilam S.] Perelman Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104, United States.
C3 University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine
RP Huh, D (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
EM huhd@seas.upenn.edu
RI Seykora, Thomas/AAD-4942-2021
OI Seykora, Thomas/0000-0001-7779-6906; Huh, Dongeun/0000-0002-5718-6884;
   Qing, Danielle/0000-0001-5511-5196; Mangalmurti,
   Nilam/0000-0002-9146-1608
FU National Research Foundation of Korea [2012M3A7B4035374]; National
   Institutes of Health [R01 HL126788]; Department of Defense [PR141324];
   University of Pennsylvania; National Institutes of Health (NIH)
   Director's New Innovator Award [1DP2HL127720-01]; National Research
   Foundation of Korea [2012M3A7B4035374] Funding Source: Korea Institute
   of Science & Technology Information (KISTI), National Science &
   Technology Information Service (NTIS)
FX We thank G.A. for helpful discussion. This research was supported by
   grants from the National Research Foundation of Korea
   (2012M3A7B4035374), the National Institutes of Health (R01 HL126788),
   the Department of Defense (PR141324), and the University of
   Pennsylvania. D.H. is a recipient of the National Institutes of Health
   (NIH) Director's New Innovator Award (1DP2HL127720-01).
CR Anniss AM, 2007, AM J HEMATOL, V82, P439, DOI 10.1002/ajh.20837
   Baeyens N, 2015, ELIFE, V4, DOI 10.7554/eLife.04645
   Baeyens N, 2016, J CLIN INVEST, V126, P821, DOI 10.1172/JCI83083
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukov KG, 2009, ANTIOXID REDOX SIGN, V11, P1651, DOI [10.1089/ars.2008.2390, 10.1089/ARS.2008.2390]
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Bux J, 2005, VOX SANG, V89, P1, DOI 10.1111/j.1423-0410.2005.00648.x
   Chatterjee S, 2003, AM J PHYSIOL-CELL PH, V285, pC959, DOI 10.1152/ajpcell.00511.2002
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79
   Croce MA, 2005, J TRAUMA, V59, P19, DOI 10.1097/01.TA.0000171459.21450.DC
   Donati A, 2014, CRIT CARE, V18, DOI 10.1186/cc13730
   Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645
   ELLSWORTH ML, 1986, AM J PHYSIOL, V251, pH869, DOI 10.1152/ajpheart.1986.251.4.H869
   Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529
   Galbraith CG, 1998, CELL MOTIL CYTOSKEL, V40, P317, DOI 10.1002/(SICI)1097-0169(1998)40:4<317::AID-CM1>3.0.CO;2-8
   Hahn C, 2009, NAT REV MOL CELL BIO, V10, P53, DOI 10.1038/nrm2596
   Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601
   Huh D, 2012, LAB CHIP, V12, P2156, DOI 10.1039/c2lc40089h
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   I.W.B, 2011, 2011 NATL BLOOD COLL
   Kiefmann R, 2008, BLOOD, V111, P5205, DOI 10.1182/blood-2007-09-113902
   Kopko P M, 2004, Immunohematology, V20, P103
   Koutsiaris AG, 2007, BIORHEOLOGY, V44, P375
   Linkermann A, 2014, NEW ENGL J MED, V370, P455, DOI 10.1056/NEJMra1310050
   Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C
   Mangalmurti NS, 2013, AM J PHYSIOL-LUNG C, V304, pL250, DOI 10.1152/ajplung.00278.2012
   Mangalmurti NS, 2010, TRANSFUSION, V50, P2353, DOI 10.1111/j.1537-2995.2010.02689.x
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Nakano A, 2003, CLIN HEMORHEOL MICRO, V29, P445
   Nowak P, 2012, ANTICANCER RES, V32, P4067
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Popel AS, 2005, ANNU REV FLUID MECH, V37, P43, DOI 10.1146/annurev.fluid.37.042604.133933
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Qing DY, 2014, AM J RESP CRIT CARE, V190, P1243, DOI 10.1164/rccm.201406-1095OC
   Sakr Y, 2007, CRIT CARE MED, V35, P1639, DOI 10.1097/01.CCM.0000269936.73788.32
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135
   Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929
   Song JW, 2005, ANAL CHEM, V77, P3993, DOI 10.1021/ac050131o
   Strilic B, 2016, NATURE, V536, P215, DOI 10.1038/nature19076
   Tarbell JM, 2010, CARDIOVASC RES, V87, P320, DOI 10.1093/cvr/cvq146
   Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Ware LB, 2014, AM J RESP CRIT CARE, V190, P1331, DOI 10.1164/rccm.201411-2047ED
   Wei ZH, 2004, MICROCIRCULATION, V11, P517, DOI 10.1080/10739680490476367
   Wirtz HR, 2000, RESP PHYSIOL, V119, P1, DOI 10.1016/S0034-5687(99)00092-4
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
   Zilberberg MD, 2007, CRIT CARE, V11, DOI 10.1186/cc5934
NR 53
TC 12
Z9 13
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 13
PY 2017
VL 7
AR 3413
DI 10.1038/s41598-017-03597-w
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EX3NV
UT WOS:000403140000084
PM 28611413
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Ourradi, K
   Blythe, T
   Jarrett, C
   Barratt, SL
   Welsh, GI
   Millar, AB
AF Ourradi, Khadija
   Blythe, Thomas
   Jarrett, Caroline
   Barratt, Shaney L.
   Welsh, Gavin I.
   Millar, Ann B.
TI VEGF isoforms have differential effects on permeability of human
   pulmonary microvascular endothelial cells
SO RESPIRATORY RESEARCH
LA English
DT Article
DE permeability; VEGF/VEGFA; Cell signalling 
ID NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR; IN-VITRO; PROTEIN-KINASE; BARRIER
   FUNCTION; TIGHT JUNCTIONS; LUNG; ACTIVATION; MIGRATION; PATHWAY
AB Background: Alternative splicing of Vascular endothelial growth factor-A mRNA transcripts (commonly referred as VEGF) leads to the generation of functionally differing isoforms, the relative amounts of which have potentially significant physiological outcomes in conditions such as acute respiratory distress syndrome (ARDS). The effect of such isoforms on pulmonary vascular permeability is unknown. We hypothesised that VEGF(165)a and VEGF(165)b isoforms would have differing effects on pulmonary vascular permeability caused by differential activation of intercellular signal transduction pathways.
   Method: To test this hypothesis we investigated the physiological effect of VEGF(165)a and VEGF(165)b on Human Pulmonary Microvascular Endothelial Cell (HPMEC) permeability using three different methods: trans-endothelial electrical resistance (TEER), Electric cell-substrate impedance sensing (ECIS) and FITC-BSA passage. In addition, potential downstream signalling pathways of the VEGF isoforms were investigated by Western blotting and the use of specific signalling inhibitors.
   Results: VEGF(165)a increased HPMEC permeability using all three methods (paracellular and transcellular) and led to associated VE-cadherin and actin stress fibre changes. In contrast, VEGF(165)b decreased paracellular permeability and did not induce changes in VE-cadherin cell distribution. Furthermore, VEGF(165)a and VEGF(165)b had differing effects on both the phosphorylation of VEGF receptors and downstream signalling proteins pMEK, p42/44MAPK, p38 MAPK, pAKT and peNOS. Interestingly specific inhibition of the pMEK, p38 MAPK, PI3 kinase and eNOS pathways blocked the effects of both VEGF(165)a and VEGF(165)b on paracellular permeability and the effect of VEGF(165)a on proliferation/migration, suggesting that this difference in cellular response is mediated by an as yet unidentified signalling pathway(s).
   Conclusion: This study demonstrates that the novel isoform VEGF(165)a and VEGF(165)b induce differing effects on permeability in pulmonary microvascular endothelial cells.
C1 [Ourradi, Khadija; Blythe, Thomas; Jarrett, Caroline; Barratt, Shaney L.; Millar, Ann B.] Univ Bristol, Sch Clin Sci, Acad Resp Unit, Bristol, Avon, England, United Kingdom.
C1 [Welsh, Gavin I.] Univ Bristol, Sch Clin Sci, Bristol Renal, Bistol, England, United Kingdom.
C3 University of Bristol; University of Bristol
RP Millar, AB (corresponding author), Univ Bristol, Sch Clin Sci, Acad Resp Unit, Bristol, Avon, England.
EM ann.millar@bristol.ac.uk
OI Ourradi, Khadija/0000-0002-9031-1931; Welsh, Gavin
   Iain/0000-0002-2148-6658; Barratt, Shaney/0000-0003-3067-7349
FU Novartis PhD Studentship; Welcome Clinical training fellowship
FX This study was funded by an unrestricted Novartis PhD Studentship to KO
   and a Welcome Clinical training fellowship to SL. The funding
   organisations had no role in the design of the study, collection,
   analysis, and interpretation of the data, or writing of the manuscript.
CR Abadie Y, 2005, EUR RESPIR J, V25, P139, DOI 10.1183/09031936.04.00065504
   Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429
   Amerongen GPV, 1999, METH MOL B, V96, P183
   Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   Bates DO, 2002, CANCER RES, V62, P4123
   Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49
   Becker PM, 2001, AM J PHYSIOL-LUNG C, V281, pL1500, DOI 10.1152/ajplung.2001.281.6.L1500
   Bevan HS, 2008, NEPHRON PHYSIOL, V110, P57, DOI 10.1159/000177614
   Bondar VM, 2002, MOL CANCER THER, V1, P989
   CEREIJIDO M, 1993, J CELL SCI, P127
   CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200
   Esser S, 1998, J CELL SCI, V111, P1853
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Forster C, 2008, HISTOCHEM CELL BIOL, V130, P55, DOI 10.1007/s00418-008-0424-9
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Gao F, 2017, J CELL PHYSIOL, V232, P2599, DOI 10.1002/jcp.25791
   Garrido-Urbani S, 2008, BIOCHEM SOC T, V36, P203, DOI 10.1042/BST0360203
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hatakeyama T, 2006, J PHYSIOL-LONDON, V574, P275, DOI 10.1113/jphysiol.2006.108175
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje
   Kaner RJ, 2001, MOL MED, V7, P240, DOI 10.1007/BF03401843
   Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779
   Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651
   Lamalice L, 2006, J BIOL CHEM, V281, P34009, DOI 10.1074/jbc.M603928200
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Maitre B, 2001, EUR RESPIR J, V18, P100, DOI 10.1183/09031936.01.00074701
   Medford ARL, 2009, J CRIT CARE, V24, P236, DOI 10.1016/j.jcrc.2008.04.003
   Smith GA, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150171
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Thickett DR, 2002, AM J RESP CRIT CARE, V166, P1332, DOI 10.1164/rccm.2105057
   Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071
   Varet J, 2010, AM J PHYSIOL-LUNG C, V298, pL768, DOI 10.1152/ajplung.00353.2009
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003
   Wegener J, 1996, J BIOCHEM BIOPH METH, V32, P151, DOI 10.1016/0165-022X(96)00005-X
   Wegener J, 2014, CELL TISSUE RES, V355, P485, DOI 10.1007/s00441-014-1810-3
   Zachary I, 2003, BIOCHEM SOC T, V31, P1171
   Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6
   Zahm JM, 1997, CELL MOTIL CYTOSKEL, V37, P33, DOI 10.1002/(SICI)1097-0169(1997)37:1<33::AID-CM4>3.0.CO;2-I
NR 50
TC 27
Z9 29
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD JUN 2
PY 2017
VL 18
AR 116
DI 10.1186/s12931-017-0602-1
PG 12
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA EX5RD
UT WOS:000403298800005
PM 28578669
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Matthay, MA
   McAuley, DF
   Ware, LB
AF Matthay, Michael A.
   McAuley, Daniel Francis
   Ware, Lorraine B.
TI Clinical trials in acute respiratory distress syndrome: challenges and
   opportunities
SO LANCET RESPIRATORY MEDICINE
LA English
DT Review
ID ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; INTENSIVE-CARE UNITS;
   CELL-FREE HEMOGLOBIN; DEAD-SPACE FRACTION; STEM STROMAL CELLS;
   FLUID-MANAGEMENT; DOUBLE-BLIND; NEUROMUSCULAR BLOCKERS; RANDOMIZED-TRIAL
AB This year is the 50th anniversary of the first description of acute respiratory distress syndrome (ARDS). Since then, much has been learned about the pathogenesis of lung injury in ARDS, with an emphasis on the mechanisms of injury to the lung endothelium and the alveolar epithelium. In terms of treatment, major progress has been made in reducing mortality from ARDS with lung-protective ventilation, using a tidal volume of 6 mL per kg of predicted bodyweight and a plateau airway pressure of less than 30 cm H2O. In more severely hypoxaemic patients with ARDS, neuromuscular blockade and prone positioning have further reduced mortality, probably by extending the therapeutic effects of lung protective ventilation. Fluid-conservative therapy has also increased ventilator-free days in patients with ARDS. The lack of success of pharmacological therapies for ARDS, however, presents a continued challenge in the field. In addition to presenting a brief summary of previous experience with clinical trials in ARDS, we focus in this Review on future opportunities to improve clinical trial design to maximise the likelihood of identifying beneficial pharmacological therapies. In view of the heterogeneity in ARDS, both prognostic and predictive enrichment strategies are needed that target therapies toward specific subgroups of patients with ARDS on the basis of both severity and biology. Approaches to reducing heterogeneity in ARDS clinical trials include using physiological, radiographic, and biological criteria to select patients for both phase 2 and 3 trials. Additionally, interest is growing in the design of preventive clinical trials in ARDS and to initiate early treatment of patients with acute lung injury before the need for endotracheal intubation. We also present promising new approaches to treating ARDS, including combination therapies, cell-based therapies, and generic pharmacological compounds with low-risk profiles that are already in routine clinical use for other clinical indications.
C1 [Matthay, Michael A.] Univ Calif San Francisco, Dept Med, San Francisco, CA, United States.
C1 [Matthay, Michael A.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA, United States.
C1 [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA, United States.
C1 [McAuley, Daniel F.] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland, United Kingdom.
C1 [McAuley, Daniel F.] Belfast Hlth & Social Care Trust, Reg Intens Care Unit, Belfast, Antrim, North Ireland, United Kingdom.
C1 [Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212, United States.
C1 [Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212, United States.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   Queens University Belfast; Vanderbilt University; Vanderbilt University
RP Matthay, MA (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM michael.matthay@ucsf.edu
RI Ware, Lorraine/AAJ-9307-2021
OI Ware, Lorraine/0000-0002-9429-4702; McAuley, Daniel/0000-0002-3283-1947
FU NHBLI [R37 HL51856, U01 HL108713]; Courtney's Race for the Cure;
   Courtney Charneco Family; NIH [HL103836, HL126176]
FX This Review was supported by NHBLI R37 HL51856 and U01 HL108713 (MAM),
   as well as Courtney's Race for the Cure, The Courtney Charneco Family,
   NIH HL103836, and NIH HL126176 (LBW). We thank Andrew Manies for
   assistance with preparation of the manuscript and Diana Lim for her work
   on the figure.
CR Abraham E, 1999, CRIT CARE MED, V27, P1478, DOI 10.1097/00003246-199908000-00013
   Adhikari NKJ, 2007, BMJ-BRIT MED J, V334, P779, DOI 10.1136/bmj.39139.716794.55
   Antonelli M, 2007, CRIT CARE MED, V35, P18, DOI 10.1097/01.CCM.0000251821.44259.F3
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Beitler JR, 2016, CRIT CARE MED, V44, P91, DOI 10.1097/CCM.0000000000001355
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164
   BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927
   Blackwood B, 2014, AM J RESP CRIT CARE, V189, P886, DOI 10.1164/rccm.201309-1645PP
   Boutaud O, 2010, P NATL ACAD SCI USA, V107, P2699, DOI 10.1073/pnas.0910174107
   Boyle AJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0846-4
   Boyle AJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-166
   Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Calfee CS, 2007, CRIT CARE MED, V35, P2243, DOI 10.1097/01.CCM.0000280434.33451.87
   Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Chen W, 2015, CRIT CARE MED, V43, P801, DOI 10.1097/CCM.0000000000000789
   Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC
   Festic E, 2017, CRIT CARE MED, V45, P798, DOI 10.1097/CCM.0000000000002284
   Flori HR, 2005, AM J RESP CRIT CARE, V171, P995, DOI 10.1164/rccm.200404-544OC
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gainnier M, 2004, CRIT CARE MED, V32, P113, DOI 10.1097/01.CCM.0000104114.72614.BC
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gattinoni L, 2010, MINERVA ANESTESIOL, V76, P448
   Gattinoni L, 2013, AM J RESP CRIT CARE, V188, P1286, DOI 10.1164/rccm.201308-1532CI
   Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585
   Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Guervilly C, 2017, INTENS CARE MED, V43, P408, DOI 10.1007/s00134-016-4653-4
   HALLMAN M, 1985, J PEDIATR-US, V106, P963, DOI 10.1016/S0022-3476(85)80253-5
   Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8
   Hough CL, 2014, CLIN CHEST MED, V35, P781, DOI 10.1016/j.ccm.2014.08.014
   Huang DT, 2017, ANN AM THORAC SOC, V14, P124, DOI 10.1513/AnnalsATS.201608-629OT
   Iwashyna TJ, 2015, AM J RESP CRIT CARE, V192, P1045, DOI 10.1164/rccm.201411-2125CP
   Janz DR, 2015, CRIT CARE MED, V43, P534, DOI 10.1097/CCM.0000000000000718
   Janz DR, 2013, CRIT CARE MED, V41, P784, DOI 10.1097/CCM.0b013e3182741a54
   Kallet RH, 2014, RESP CARE, V59, P1611, DOI 10.4187/respcare.02593
   Kangelaris KN, 2016, CRIT CARE MED, V44, P120, DOI 10.1097/CCM.0000000000001359
   Kor DJ, 2016, JAMA-J AM MED ASSOC, V315, P2406, DOI 10.1001/jama.2016.6330
   Levitt JE, 2013, CRIT CARE MED, V41, P1929, DOI 10.1097/CCM.0b013e31828a3d99
   Levitt JE, 2009, CHEST, V135, P936, DOI 10.1378/chest.08-2346
   Lipsky AM, 2013, STAT MED, V32, P3752, DOI 10.1002/sim.5807
   Liu KD, 2008, AM J RESP CRIT CARE, V178, P618, DOI 10.1164/rccm.200803-419OC
   Liu KD, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0022-z
   Luo L, 2017, CHEST, V151, P755, DOI 10.1016/j.chest.2016.09.004
   Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC
   Matthay MA, 2017, STEM CELLS, V35, P316, DOI 10.1002/stem.2551
   Matthay MA, 2016, CHEST, V150, P989, DOI 10.1016/j.chest.2016.05.013
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159
   Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646
   Meyer NJ, 2017, LANCET RESP MED, V5, P512, DOI 10.1016/S2213-2600(17)30187-X
   Mrozek S, 2016, CHEST, V150, P998, DOI 10.1016/j.chest.2016.03.016
   MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720
   Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835
   Paine R, 2012, CRIT CARE MED, V40, P90, DOI 10.1097/CCM.0b013e31822d7bf0
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Pelosi P, 2001, SEM RESP CRIT CARE M, V22, P259, DOI 10.1055/s-2001-15783
   Prescott HC, 2016, AM J RESP CRIT CARE, V194, P147, DOI 10.1164/rccm.201512-2544CP
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435
   Rouby JJ, 2000, INTENS CARE MED, V26, P1046, DOI 10.1007/s001340051317
   Rubenfeld GD, 2015, AM J RESP CRIT CARE, V191, P255, DOI 10.1164/rccm.201408-1574CP
   Neto AS, 2016, LANCET RESP MED, V4, P882, DOI 10.1016/S2213-2600(16)30305-8
   SHAPIRO DL, 1985, PEDIATRICS, V76, P593
   Shaver CM, 2016, AM J PHYSIOL-LUNG C, V310, pL532, DOI 10.1152/ajplung.00155.2015
   Shaver CM, 2014, CLIN CHEST MED, V35, P639, DOI 10.1016/j.ccm.2014.08.004
   Silversides JA, 2017, INTENS CARE MED, V43, P155, DOI 10.1007/s00134-016-4573-3
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614
   Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   Vieillard-Baron A, 2000, AM J RESP CRIT CARE, V161, P1597
   Vincent JL, 2009, CRIT CARE MED, V37, P1874, DOI 10.1097/CCM.0b013e31819fff2c
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Wang CY, 2014, INTENS CARE MED, V40, P388, DOI 10.1007/s00134-013-3186-3
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Warren MA, 2017, AM J RESP C IN PRESS
   Wheeler AP, 2006, NEW ENGL J MED, V354, P2213
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995
   Wiedemann HP, 2002, CRIT CARE MED, V30, P1
   Willson DF, 2015, CHEST, V148, P356, DOI 10.1378/chest.14-1139
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/s2213-2600(14)70291-7, 10.1016/S2213-2600(14)70291-7]
   Yadav H, 2015, AM J PHYSIOL-LUNG C, V309, pL915, DOI 10.1152/ajplung.00266.2015
   Zeiher BG, 2004, CRIT CARE MED, V32, P1695, DOI 10.1097/01.CCM.0000133332.48386.85
   Zeyed YF, 2012, AM J PHYSIOL-LUNG C, V303, pL550, DOI 10.1152/ajplung.00190.2012
NR 99
TC 180
Z9 193
U1 4
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD JUN
PY 2017
VL 5
IS 6
BP 524
EP 534
DI 10.1016/S2213-2600(17)30188-1
PG 11
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA EV9FR
UT WOS:000402091700023
PM 28664851
DA 2023-08-21
ER

PT J
AU Yu, H
   Qing, H
AF Yu, Huang
   Qing, He
TI Inhibition of c-Src protects paraquat induced microvascular endothelial
   injury by modulating caveolin-1 phosphorylation and caveolae mediated
   transcellular permeability
SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Paraquat; ALI/ARDS; caveolin-1; ECs/HPMECs/HUVECs/MPVECs; c-Src 
ID BARRIER DYSFUNCTION; LUNG INJURY; CELLS; EXPRESSION; GROWTH
AB The mechanisms underlying paraquat induced acute lung injury (ALI) is still not clear. C-Src plays an important role in the regulation of microvascular endothelial barrier function and the pathogenesis of ALI. In the present study, we found that paraquat induced cell toxicity and an increase of reactive oxygen species (ROS) in endothelium. Paraquat exposure also induced significant increase of caveolin-1 phosphorylation, caveolae trafficking and albumin permeability in endothelial monolayers. C-Src depletion by siRNA significantly attenuate paraquat induced cell toxicity, caveolin-1 phosphorylation, caveolae formation and endothelial hyperpermeability. N-acetylcysteine (NAC) failed to, protect endothelial monolayers against paraquat induced toxicity. Thus, our findings suggest that paraquat exposure increases paracellular endothelial permeability by increasing caveolin-1 phosphorylation in a c-Src dependant manner. The depletion of c-Src might protect microvascular endothelial function by regulating caveolin-1 phosphorylation and caveolae trafficking during paraquat exposure, and might have potential therapeutic effects on paraquat induced ALI. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Yu, Huang; Qing, He] Chongqing Med Univ, Affiliated Hosp Chengdu 2, Peoples Hosp Chengdu 3, Dept Intens Care Med, Chengdu, China.
C1 [Qing, He] Sichuan Univ, West China Hosp, Dept Resp Dis, Chengdu 610041, China.
C3 Chongqing Medical University; Sichuan University
RP Qing, H (corresponding author), Sichuan Univ, West China Hosp, Dept Resp Dis, Chengdu 610041, Peoples R China.
EM kk555888@126.com
FU laboratory of the Second Affiliated Hospital of West China School of
   Medicine; Natural Science Foundation of China [81071539]; Fundamental
   Research Funds for the Central Universities [2682016YXZT05]
FX This investigation was supported by the laboratory of the Second
   Affiliated Hospital of West China School of Medicine. We thank the
   post-graduate students Bao Yuting and Nai Qing from West China School of
   Medicine for their assistance. The study was supported by the Natural
   Science Foundation of China (81071539). The study was also supported by
   the Fundamental Research Funds for the Central Universities
   (2682016YXZT05).
CR Bazzoni G, 2001, MICROCIRCULATION, V8, P143, DOI 10.1038/sj.mn.7800084
   Bonneh-Barkay D, 2005, MOL BRAIN RES, V134, P52, DOI 10.1016/j.molbrainres.2004.11.005
   Chen CM, 2001, CRIT CARE MED, V29, P2169, DOI 10.1097/00003246-200111000-00020
   Conover CA, 2008, GROWTH HORM IGF RES, V18, P213, DOI 10.1016/j.ghir.2007.09.001
   DEARDEN LC, 1982, TOXICOLOGY, V24, P211, DOI 10.1016/0300-483X(82)90003-8
   Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Eddleston M, 2004, BMJ-BRIT MED J, V328, P42, DOI 10.1136/bmj.328.7430.42
   FORMAN HJ, 1982, J PHARMACOL EXP THER, V221, P428
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Gawarammana IB, 2011, BRIT J CLIN PHARMACO, V72, P745, DOI 10.1111/j.1365-2125.2011.04026.x
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Hu GC, 2008, CHEM-BIOL INTERACT, V171, P177, DOI 10.1016/j.cbi.2007.08.006
   JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139
   Jin Y, 2008, AM J RESP CELL MOL, V39, P171, DOI 10.1165/rcmb.2007-0323OC
   JOHNSON A, 1989, AM J PHYSIOL, V256, pH1012, DOI 10.1152/ajpheart.1989.256.4.H1012
   Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940
   Kim HP, 2005, P NATL ACAD SCI USA, V102, P11319, DOI 10.1073/pnas.0501345102
   Lee YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108772
   Li W, 2013, FREE RADICAL BIO MED, V54, P51, DOI 10.1016/j.freeradbiomed.2012.10.552
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003
   Piegeler T, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-57
   Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005
   Shajahan AN, 2004, J BIOL CHEM, V279, P48055, DOI 10.1074/jbc.M405837200
   Sheth P, 2007, AM J PHYSIOL-GASTR L, V293, pG308, DOI 10.1152/ajpgi.00582.2006
   Shi S, 2000, AM J PHYSIOL-LUNG C, V279, pL441, DOI 10.1152/ajplung.2000.279.3.L441
   Torres VA, 2006, J CELL SCI, V119, P1812, DOI 10.1242/jcs.02894
   Zhou H, 2009, CANCER LETT, V273, P292, DOI 10.1016/j.canlet.2008.08.006
NR 30
TC 15
Z9 16
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1382-6689
EI 1872-7077
J9 ENVIRON TOXICOL PHAR
JI Environ. Toxicol. Pharmacol.
PD JUN
PY 2017
VL 52
BP 62
EP 68
DI 10.1016/j.etap.2017.01.023
PG 7
WC Environmental Sciences; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Pharmacology & Pharmacy; Toxicology
GA EY1OO
UT WOS:000403735400009
PM 28376378
DA 2023-08-21
ER

PT J
AU Wu, ZY
   Hu, ZP
   Cai, X
   Ren, W
   Dai, FF
   Liu, HG
   Chang, JX
   Li, BW
AF Wu, Zhiyong
   Hu, Zhipeng
   Cai, Xin
   Ren, Wei
   Dai, Feifeng
   Liu, Huagang
   Chang, Jinxing
   Li, Bowen
TI Interleukin 22 attenuated angiotensin II induced acute lung injury
   through inhibiting the apoptosis of pulmonary microvascular endothelial
   cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ACUTE AORTIC DISSECTION; NATURAL-KILLER-CELLS; POTENTIAL-ROLE; INDUCIBLE
   FACTOR; RECEPTOR COMPLEXES; VIRUS-INFECTION; HOST-DEFENSE; MOUSE MODEL;
   IL-TIF; IL-22
AB Apoptosis of pulmonary microvascular endothelial cells (PMVECs) was considered to be closely related to the pathogenesis of acute lung injury (ALI). We aim to investigate whether IL-22 plays protective roles in lung injury through inhibiting the apoptosis of PMVECs. ALI model was induced through subcutaneous infusion of angiotensin II (Ang II). Lung injury and infiltration of inflammatory cells were evaluated by determining the PaO2/FiO(2), calculation of dry to weight ratio in lung, and immunohistochemisty analysis. Apoptosis of PMVECs was determined using TUNEL assay and flow cytometry, respectively. Immunofluorescence and Western blot analysis were used to determine the expression and localization of STAT3, as well as the nucleus transmission of STAT3 from cytoplasm after IL22 treatment. Pathological findings showed ALI was induced 1 week after AngII infusion. IL22 inhibited the AngII-induced ALI, attenuated the edema in lung and the infiltration of inflammatory cells. Also, it contributed to the apoptosis of PMVECs induced by AngII. Meanwhile, significant increase was noticed in the expression of STAT3, phosphorylation of Y705-STAT3, and migration from cytoplasm to the nucleus after IL-22 treatment (P < 0.05). The activation of STAT3 by IL22 showed significant attenuation after AG490 treatment. Our data indicated that IL22 showed protective effects on lung injury through inhibiting the AngII-induced PMVECs apoptosis and PMVEC barrier injury by activating the JAK2/STAT3 signaling pathway.
C1 [Wu, Zhiyong; Hu, Zhipeng; Cai, Xin; Ren, Wei; Dai, Feifeng; Liu, Huagang; Chang, Jinxing; Li, Bowen] Wuhan Univ, Dept Cardiovasc Surg, Renmin Hosp, Jiefang Rd 238, Wuhan 430060, China.
C3 Wuhan University
RP Wu, ZY (corresponding author), Wuhan Univ, Dept Cardiovasc Surg, Renmin Hosp, Jiefang Rd 238, Wuhan 430060, Peoples R China.
EM zhiyongwu889@sina.com
OI Hu, Zhipeng/0000-0002-6384-0037
FU Hubei Province health and family planning scientific research
   [WJ2017M013]
FX This study was supported by the Hubei Province health and family
   planning scientific research project (WJ2017M013).
CR Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007
   Andoh A, 2005, GASTROENTEROLOGY, V129, P969, DOI 10.1053/j.gastro.2005.06.071
   Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710
   Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC
   Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465
   Chang H, 2006, J IMMUNOL, V177, P3635, DOI 10.4049/jimmunol.177.6.3635
   Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008
   Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697
   Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814
   Dumoutier L, 2009, J BIOL CHEM, V284, P26377, DOI 10.1074/jbc.M109.007955
   Farina F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056636
   Geboes L, 2009, ARTHRITIS RHEUM-US, V60, P390, DOI 10.1002/art.24220
   Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7
   Guo HL, 2010, J VIROL, V84, P7750, DOI 10.1128/JVI.00187-10
   Hasegawa Y, 1999, J CARDIOVASC SURG, V40, P191
   Ikeuchi H, 2005, ARTHRITIS RHEUM-US, V52, P1037, DOI 10.1002/art.20965
   Jokela TA, 2014, J BIOL CHEM, V289, P18569, DOI 10.1074/jbc.M114.551804
   Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200
   Kurabayashi M, 2010, CIRC J, V74, P2066, DOI 10.1253/circj.CJ-10-0336
   Lejeune D, 2002, J BIOL CHEM, V277, P33676, DOI 10.1074/jbc.M204204200
   Logsdon NJ, 2002, J INTERF CYTOK RES, V22, P1099, DOI 10.1089/10799900260442520
   Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263
   Menden H, 2015, J BIOL CHEM, V290, P5449, DOI 10.1074/jbc.M114.600692
   Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13
   Mitra A, 2012, CYTOKINE, V60, P38, DOI 10.1016/j.cyto.2012.06.316
   Nagem RAP, 2002, STRUCTURE, V10, P1051, DOI 10.1016/S0969-2126(02)00797-9
   Naher L, 2012, INT J ONCOL, V41, P1577, DOI 10.3892/ijo.2012.1594
   Neto MDO, 2008, BIOPHYS J, V94, P1754, DOI 10.1529/biophysj.107.112664
   Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857
   Paget C, 2012, J BIOL CHEM, V287, P8816, DOI 10.1074/jbc.M111.304758
   Qiao YY, 2016, WORLD J GASTROENTERO, V22, P5023, DOI 10.3748/wjg.v22.i21.5023
   Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176
   Sakaguchi R, 2016, INT IMMUNOL, V28, P233, DOI 10.1093/intimm/dxv070
   Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001
   Sestito R, 2011, FASEB J, V25, P916, DOI 10.1096/fj.10-172288
   Shang WQ, 2015, AM J TRANSL RES, V7, P1782
   Simonian PL, 2010, J EXP MED, V207, P2239, DOI 10.1084/jem.20100061
   Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]
   Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018
   Taube C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021799
   Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007
   Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503
   Wu ZY, 2016, AM J TRANSL RES, V8, P1426
   Wu ZY, 2016, AM J TRANSL RES, V8, P28
   Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166
   Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001
   Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720
   Zhu XF, 2012, MOL CELL BIOCHEM, V369, P255, DOI 10.1007/s11010-012-1389-5
NR 48
TC 16
Z9 17
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 19
PY 2017
VL 7
AR 2210
DI 10.1038/s41598-017-02056-w
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EV2VP
UT WOS:000401614900068
PM 28526849
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Oliveira, SDS
   Castellon, M
   Chen, JW
   Bonini, MG
   Gu, XW
   Elliott, MH
   Machado, RF
   Minshall, RD
AF Oliveira, Suellen D. S.
   Castellon, Maricela
   Chen, Jiwang
   Bonini, Marcelo G.
   Gu, Xiaowu
   Elliott, Michael H.
   Machado, Roberto F.
   Minshall, Richard D.
TI Inflammation-induced caveolin-1 and BMPRII depletion promotes
   endothelial dysfunction and TGF-beta-driven pulmonary vascular
   remodeling
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; vascular inflammation; endothelial dysfunction; caveolin-1; TGF-beta signaling; vascular remodeling 
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; MESENCHYMAL
   TRANSITION; II RECEPTOR; CELLS; HYPERTENSION; ACTIVATION; INDUCTION;
   REGULATOR; SURVIVORS
AB Endothelial cell (EC) activation and vascular injury are hallmark features of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Caveolin-1 (Cav-1) is highly expressed in pulmonary microvascular ECs and plays a key role in maintaining vascular homeostasis. The aim of this study was to determine if the lung inflammatory response to Escherichia coli lipopolysaccharide (LPS) promotes priming of ECs via Cav-1 depletion and if this contributes to the onset of pulmonary vascular remodeling. To test the hypothesis that depletion of Cav-1 primes ECs to respond to profibrotic signals, C57BL6 wild-type (WT) mice (Tie2. Cre(-); Cav1(fl/fl)) were exposed to nebulized LPS (10 mg; 1 h daily for 4 days) and compared with EC-specific Cav1(-/-) (Tie2. Cre(+); Cav1(fl/fl)). After 96 h of LPS exposure, total lung Cav-1 and bone morphogenetic protein receptor type II (BMPRII) expression were reduced in WT mice. Moreover, plasma albumin leakage, infiltration of immune cells, and levels of IL-6/IL-6R and transforming growth factor-beta (TGF-beta) were elevated in both LPS-treated WT and EC-Cav1(-/-) mice. Finally, EC-Cav1(-/-) mice exhibited a modest increase in microvascular thickness basally and even more so on exposure to LPS (96 h). EC-Cav1(-/-) mice and LPS-treated WT mice exhibited reduced BMPRII expression and endothelial nitric oxide synthase uncoupling, which along with increased TGF-promoted TGF beta RI-dependent SMAD-2/3 phosphorylation. Finally, human lung sections from patients with ARDS displayed reduced EC Cav-1 expression, elevated TGF-beta levels, and severe pulmonary vascular remodeling. Thus EC Cav-1 depletion, oxidative stress-mediated reduction in BMPRII expression, and enhanced TGF-beta-driven SMAD-2/3 signaling promote pulmonary vascular remodeling in inflamed lungs.
C1 [Oliveira, Suellen D. S.; Castellon, Maricela; Minshall, Richard D.] Univ Illinois, Dept Anesthesiol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612, United States.
C1 [Castellon, Maricela; Minshall, Richard D.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Chen, Jiwang; Bonini, Marcelo G.; Machado, Roberto F.] Univ Illinois, Dept Med, Chicago, IL, United States.
C1 [Gu, Xiaowu; Elliott, Michael H.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Oklahoma System;
   University of Oklahoma Health Sciences Center
RP Minshall, RD (corresponding author), Univ Illinois, Dept Anesthesiol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.
EM rminsh@uic.edu
RI chen, jw/IQW-1558-2023; Oliveira, Suellen D'Arc Santos/F-6276-2014
OI Oliveira, Suellen D'Arc Santos/0000-0002-7654-1909; GU,
   XIAOWU/0000-0003-2266-5516; Machado, Roberto/0000-0002-3722-5954
FU National Institutes of Health [P01-HL-60678, R01-HL-71626,
   R01-HL-125356, R01-HL-127342, R01-HL-111656, 1R01-HL-133951,
   R01-EY-019494]; American Heart Association [SDG 09SDG2250933, DOD
   67263-RT-REP]; CNPq/Science without Borders-Brazil
FX This work was supported in part by National Institutes of Health Grants
   P01-HL-60678, R01-HL-71626, and R01-HL-125356 (to R. Minshall and M.
   Bonini) and R01-HL-127342, R01-HL-111656, 1R01-HL-133951 (to R.
   Machado), and R01-EY-019494 (to M. Elliott); American Heart Association
   SDG 09SDG2250933 and DOD 67263-RT-REP (to M. Bonini and R. Minshall);
   and a Postdoctoral Fellowship from CNPq/Science without Borders-Brazil
   (to S. Oliveira).
CR Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Amsalem AR, 2016, MOL BIOL CELL, V27, P716, DOI 10.1091/mbc.E15-08-0547
   Atkinson C, 2002, CIRCULATION, V105, P1672, DOI 10.1161/01.CIR.0000012754.72951.3D
   Bakhshi FR, 2013, PULM CIRC, V3, P816, DOI 10.1086/674753
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bonini MG, 2014, SYSTEMS BIOL FREE RA, P1343, DOI DOI 10.1007/978-3-642-30018-9_183
   CARLOS TM, 1994, BLOOD, V84, P2068
   Cogan J, 2012, CIRCULATION, V126, P1907, DOI 10.1161/CIRCULATIONAHA.112.106245
   Danese S, 2007, J IMMUNOL, V178, P6017, DOI 10.4049/jimmunol.178.10.6017
   Eligini S, 2001, BRIT J PHARMACOL, V133, P1163, DOI 10.1038/sj.bjp.0704163
   ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634
   Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA
   Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598
   GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158
   Good RB, 2015, AM J PATHOL, V185, P1850, DOI 10.1016/j.ajpath.2015.03.019
   Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450
   Hong KH, 2008, CIRCULATION, V118, P722, DOI 10.1161/CIRCULATIONAHA.107.736801
   Hui-Li G, 2011, CARDIOVASC THER, V29, P153, DOI 10.1111/j.1755-5922.2009.00095.x
   Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132
   Jin Y, 2011, AM J PHYSIOL-LUNG C, V300, pL151, DOI 10.1152/ajplung.00170.2010
   Johnston LK, 2012, AM J RESP CELL MOL, V47, P417, DOI 10.1165/rcmb.2012-0090OC
   Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3
   Karmpaliotis D, 2002, AM J PHYSIOL-LUNG C, V283, pL585, DOI 10.1152/ajplung.00048.2002
   Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552
   Li ZD, 2013, AM J PATHOL, V182, P325, DOI 10.1016/j.ajpath.2012.10.022
   Long L, 2015, NAT MED, V21, P777, DOI 10.1038/nm.3877
   Maniatis NA, 2008, AM J PHYSIOL-LUNG C, V294, pL865, DOI 10.1152/ajplung.00079.2007
   Maniatis Nikolaos A, 2012, Pulm Circ, V2, P452, DOI 10.4103/2045-8932.105033
   Maniatis NA, 2012, ADV EXP MED BIOL, V729, P157, DOI 10.1007/978-1-4614-1222-9_11
   Mao M, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0104101, 10.1371/journal.pone.0109722]
   Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Nohe A, 2005, J CELL SCI, V118, P643, DOI 10.1242/jcs.01402
   Piegeler T, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-57
   Ramos M, 2006, VASC PHARMACOL, V44, P50, DOI 10.1016/j.vph.2005.09.007
   ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632
   Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889
   Sethna S, 2016, J BIOL CHEM, V291, P6494, DOI 10.1074/jbc.M115.687004
   Souza R, 2005, CRIT CARE, V9, pR132, DOI 10.1186/cc3038
   Steiner MK, 2009, CIRC RES, V104, P236, DOI 10.1161/CIRCRESAHA.108.182014
   Sugiura H, 2006, AM J RESP CELL MOL, V34, P592, DOI 10.1165/rcmb.2005-0339OC
   Sverdlov M, 2009, MOL BIOL CELL, V20, P4531, DOI 10.1091/mbc.E08-10-0997
   Walkey Allan J, 2012, Clin Epidemiol, V4, P159, DOI 10.2147/CLEP.S28800
   Wang CY, 2014, INTENS CARE MED, V40, P388, DOI 10.1007/s00134-013-3186-3
   Wertz JW, 2008, BIOCHEM BIOPH RES CO, V375, P557, DOI 10.1016/j.bbrc.2008.08.066
   Yoshimatsu Y, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/724080
   Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200
   Zhao YY, 2009, J CLIN INVEST, V119, P2009, DOI 10.1172/JCI33338
NR 51
TC 33
Z9 35
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2017
VL 312
IS 5
BP 1760
EP 1771
DI 10.1152/ajplung.00484.2016
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA EZ0HO
UT WOS:000404383300018
PM 28188225
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Brenner, JS
AF Brenner, Jacob S.
TI Nanomedicine for the Treatment of Acute Respiratory Distress Syndrome
   The 2016 ATS Bear Cage Award-winning Proposal
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
DE ALI/ARDS; nanotechnology; nanocarrier; liposome 
ID OUTCOMES; CARE
AB After dozens of clinical trials, there are still no Food and Drug Administration-approved drugs that improve mortality in acute respiratory distress syndrome (ARDS). These poor results may be caused in part by three unique pharmacological challenges presented by ARDS: (1) Patients with ARDS are fragile because of concomitant multiple organ dysfunction, so they do not tolerate off-target side effects of drugs; (2) inhaled drug delivery is impeded by the column of proteinaceous fluid covering the injured alveoli; and (3) ARDS is heterogeneous in its underlying pathophysiology, so targeting one pathway is unlikely to improve most patients. To address these three pharmacological problems, I present the development of pulmonary endothelium-targeted liposomes (PELs). PELs are approximately 100-nm drug carriers coated with antibodies that bind to the pulmonary capillary endothelium. In model organisms, intravenously injected PELs strongly concentrate drugs in alveoli, even in animal models displaying severe, spatially heterogeneous pathology similar to severe ARDS. By concentrating drugs in inflamed alveoli, PELs solve pharmacological challenge (1) above. By being obligate intravenous medications, they solve challenge (2). Finally, because PELs can be loaded with at least three drugs, they can solve challenge (3) with combination drug therapy. My colleagues and I are currently testing PELs loaded with numerous candidate drugs inmouse models of ARDS, and we are testing drug distribution in live pigs and ex vivo human lungs. We aim to use such preclinical validation to move PELs into a partnership with industry, and then to patients.
C1 [Brenner, Jacob S.] Univ Penn, Pulm & Crit Care Div, 839 West Gates Bldg,3600 Spruce St, Philadelphia, PA 19104, United States.
C3 University of Pennsylvania
RP Brenner, JS (corresponding author), Univ Penn, Pulm & Crit Care Div, 839 West Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.
EM brennerj@uphs.upenn.edu
RI Brenner, Jacob/Y-2030-2018
OI Brenner, Jacob/0000-0001-8437-0161
FU National Institutes of Health [F32 HL129665-01]
FX Supported by National Institutes of Health grant F32 HL129665-01
   (J.S.B.).
CR Beitler JR, 2016, INTENS CARE MED, V42, P756, DOI 10.1007/s00134-016-4331-6
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Brenner Jacob S, 2017, Nanomedicine, V13, P1495, DOI 10.1016/j.nano.2016.12.019
   Brenner JS, 2015, EXPERT OPIN DRUG DEL, V12, P239, DOI 10.1517/17425247.2015.961418
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Olivier KN, 2017, AM J RESP CRIT CARE, V195, P814, DOI 10.1164/rccm.201604-0700OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Steimbach LM, 2017, MYCOSES, V60, P146, DOI 10.1111/myc.12585
   Unroe M, 2010, ANN INTERN MED, V153, P167, DOI 10.7326/0003-4819-153-3-201008030-00007
   Wellman-Labadie O, 2010, HEALTH POLICY, V95, P216, DOI 10.1016/j.healthpol.2009.12.001
   Wilcox ME, 2013, CRIT CARE MED, V41, pS81, DOI 10.1097/CCM.0b013e3182a16946
NR 13
TC 10
Z9 10
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD APR
PY 2017
VL 14
IS 4
BP 561
EP 564
DI 10.1513/AnnalsATS.201701-090PS
PG 4
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA FS0BH
UT WOS:000419438400017
PM 28304180
OA Green Published
DA 2023-08-21
ER

PT J
AU Evans, CE
   Zhao, YY
AF Evans, Colin E.
   Zhao, You-Yang
TI Impact of thrombosis on pulmonary endothelial injury and repair
   following sepsis
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Review
DE ECs/HPMECs/HUVECs/MPVECs; injury; lung; repair; sepsis; thrombosis 
ID ACTIVATED PROTEIN-C; ACUTE LUNG INJURY; DISSEMINATED INTRAVASCULAR
   COAGULATION; HUMAN SOLUBLE THROMBOMODULIN; NEUTROPHIL EXTRACELLULAR
   TRAPS; MURINE PNEUMOCOCCAL PNEUMONIA; RESPIRATORY-DISTRESS-SYNDROME;
   MOLECULAR-WEIGHT HEPARIN; FACTOR PATHWAY INHIBITOR; NF-KAPPA-B
AB The prevailing morbidity and mortality in sepsis are largely due to multiple organ dysfunction (MOD), most commonly lung injury, as well as renal and cardiac dysfunction. Despite recent advances in defining many aspects of the pathogenesis of sepsis-related MOD, including acute respiratory distress syndrome (ARDS), there are currently no effective pharmacological or cell-based treatments for the disease. Human and animal studies have shown that pulmonary thrombosis is common in sepsis-induced ARDS, and preclinical studies have shown that anticoagulation may improve outcome following sepsis challenge. The potential beneficial effect of anticoagulation on outcome is unconvincing in clinical studies, however, and these discrepancies may arise from the multiple and sometimes opposing actions of thrombosis on the pulmonary endothelium following sepsis. It has been suggested, for example, that mild pulmonary thrombosis prevents escape of bacterial infection into the circulation, while severe thrombosis causes hypoxia and results in pulmonary endothelial damage. Evidence from both human and animal studies has demonstrated the key role of microvascular leakage in determining the outcome of sepsis. In this review, we describe thrombosis-dependent mechanisms that regulate pulmonary endothelial injury and repair following sepsis, including activation of the coagulation cascade by tissue factor and stimulation of vascular repair by hypoxia-inducible factors. Targeting such mechanisms through anticoagulant, anti-inflammatory, and reparative methods may represent a novel approach for the treatment of septic patients.
C1 [Evans, Colin E.; Zhao, You-Yang] Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL, United States.
C1 [Evans, Colin E.; Zhao, You-Yang] Univ Illinois, Ctr Lung & Vasc Biol, Coll Med, Chicago, IL, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Zhao, YY (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL USA.; Zhao, YY (corresponding author), Univ Illinois, Ctr Lung & Vasc Biol, Coll Med, Chicago, IL USA.
EM yyzhao@uic.edu
OI Evans, Colin/0000-0002-9251-357X; ZHAO, YOU-YANG/0000-0002-0041-0339
FU School of Biological Sciences, University of Cambridge, United Kingdom;
   National Heart, Lung, and Blood Institute [123957, 125350, 133951,
   077806]
FX C.E. Evans is supported by a Parke Davis Fellowship from the School of
   Biological Sciences, University of Cambridge, United Kingdom. Y.-Y. Zhao
   is supported in part by National Heart, Lung, and Blood Institute Grants
   123957, 125350, 133951, and 077806.
CR Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238
   Aeffner F, 2015, TOXICOL PATHOL, V43, P1074, DOI 10.1177/0192623315598399
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Bastarache JA, 2012, THORAX, V67, P1032, DOI 10.1136/thoraxjnl-2012-201781
   Belting M, 2005, ARTERIOSCL THROM VAS, V25, P1545, DOI 10.1161/01.ATV.0000171155.05809.bf
   Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003
   Carnemolla R, 2017, FASEB J, V31, P761, DOI 10.1096/fj.201600912R
   Carraway MS, 2003, AM J RESP CRIT CARE, V167, P1200, DOI 10.1164/rccm.200204-287OC
   Chen BX, 2015, MOL PHARMACOL, V88, P95, DOI 10.1124/mol.114.096446
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC
   de Boer JD, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0559-3
   de Stoppelaar SF, 2014, BLOOD, V124, P3781, DOI 10.1182/blood-2014-05-573915
   de Stoppelaar SF, 2014, THROMB HAEMOSTASIS, V112, P666, DOI 10.1160/TH14-02-0126
   Derhaschnig U, 2003, BLOOD, V102, P2093, DOI 10.1182/blood-2003-02-0416
   Dhainaut JFO, 2003, THROMB HAEMOSTASIS, V90, P642, DOI 10.1160/TH02-11-0270
   Dixon B, 2004, ANAESTH INTENS CARE, V32, P619, DOI 10.1177/0310057X0403200502
   DRAKE TA, 1993, AM J PATHOL, V142, P1458
   Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC
   Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC
   Eickmeier O, 2013, MUCOSAL IMMUNOL, V6, P256, DOI 10.1038/mi.2012.66
   Enkhbaatar P, 2000, AM J RESP CRIT CARE, V162, P1752, DOI 10.1164/ajrccm.162.5.9911018
   Evans, 2011, ARTERIOSCL THROM VAS, V31, pE5, DOI 10.1161/ATV.0b013e318209c861
   Evans CE, 2014, THROMB RES, V134, P757, DOI 10.1016/j.thromres.2014.07.024
   Evans CE, 2014, ARTERIOSCL THROM VAS, V34, P565, DOI 10.1161/ATVBAHA.113.302998
   Evans CE, 2012, THROMB RES, V130, P971, DOI 10.1016/j.thromres.2012.08.002
   Evans CE, 2012, THROMB RES, V130, P281, DOI 10.1016/j.thromres.2012.05.006
   Evans CE, 2011, THROMB RES, V128, P346, DOI 10.1016/j.thromres.2011.05.006
   Evans CE, 2010, ARTERIOSCL THROM VAS, V30, P2443, DOI 10.1161/ATVBAHA.110.215038
   Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603
   Giannarelli C, 2014, CIRCULATION, V130, P1274, DOI 10.1161/CIRCULATIONAHA.114.006614
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Green J, 2002, THROMB HAEMOSTASIS, V87, P218
   Griffin JH, 2015, BLOOD, V125, P2898, DOI 10.1182/blood-2015-02-355974
   Gu JY, 2016, CELL BIOL TOXICOL, V32, P1, DOI 10.1007/s10565-016-9313-5
   Han JL, 2013, THROMB RES, V132, pE42, DOI 10.1016/j.thromres.2013.03.010
   Hirota Kiichi, 2015, Cardiovascular & Hematological Disorders - Drug Targets, V15, P29
   Huang XJ, 2016, CIRCULATION, V133, P1093, DOI 10.1161/CIRCULATIONAHA.115.020918
   Iba T, 2007, J TRAUMA, V63, P1093, DOI 10.1097/01.ta.0000251420.41427.d3
   Iba T, 2014, J SURG RES, V187, P581, DOI 10.1016/j.jss.2013.10.058
   Iba T, 2012, THROMB RES, V130, pE129, DOI 10.1016/j.thromres.2012.03.021
   Iba T, 2009, CRIT CARE, V13, DOI 10.1186/cc8210
   Jeong SJ, 2013, CRIT CARE, V17, DOI 10.1186/cc12742
   Kager LM, 2013, J THROMB HAEMOST, V11, P282, DOI 10.1111/jth.12094
   Kager LM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002306
   Kerschen E, 2010, J CLIN INVEST, V120, P3167, DOI 10.1172/JCI42629
   Komarova Yulia A, 2007, Sci STKE, V2007, pre8
   Konecny FA, 2010, J RES MED SCI, V15, P348
   Kraemer BF, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002355
   LaRosa SP, 2006, INT J INFECT DIS, V10, P25, DOI 10.1016/j.ijid.2005.06.001
   Laterre PF, 2003, CRIT CARE MED, V31, pS329, DOI 10.1097/01.CCM.0000057912.71499.A5
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Levi M, 2005, HEMATOLOGY, V10, P129, DOI 10.1080/10245330512331390177
   Levi M, 2013, MINERVA ANESTESIOL, V79, P294
   Levi M, 2015, SEMIN THROMB HEMOST, V41, P9, DOI 10.1055/s-0034-1398376
   Levi M, 2013, SEMIN THROMB HEMOST, V39, P559, DOI 10.1055/s-0033-1343894
   Levi M, 2010, CRIT CARE MED, V38, pS26, DOI 10.1097/CCM.0b013e3181c98d21
   Levi M, 2008, CLIN CHEST MED, V29, P627, DOI 10.1016/j.ccm.2008.06.006
   Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748
   Li X, 2013, INFLAMMATION, V36, P1201, DOI 10.1007/s10753-013-9656-5
   Li Y, 2011, CRIT CARE MED, V39, P1104, DOI 10.1097/CCM.0b013e31820eb718
   Lindenblatt N, 2006, CRIT CARE, V10, DOI 10.1186/cc5074
   Liu G, 2014, SCI REP-UK, V4, DOI 10.1038/srep05543
   Liu MW, 2015, MOL MED REP, V11, P3308, DOI 10.3892/mmr.2015.3146
   Lohde E, 1992, Mediators Inflamm, V1, P177, DOI 10.1155/S0962935192000279
   Luan ZG, 2014, INFLAMMATION, V37, P924, DOI 10.1007/s10753-014-9812-6
   Maas M, 2005, AM J PHYSIOL-HEART C, V288, pH159, DOI 10.1152/ajpheart.00500.2004
   MacLaren R, 2007, PHARMACOTHERAPY, V27, P860, DOI 10.1592/phco.27.6.860
   MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425
   Mao SZ, 2015, ARTERIOSCL THROM VAS, V35, P1635, DOI 10.1161/ATVBAHA.115.305519
   Marti-Carvajal AJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004388.pub6
   Marti-Carvajal AJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004388.pub5
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McDonald B, 2012, CELL HOST MICROBE, V12, P324, DOI 10.1016/j.chom.2012.06.011
   Mihajlovic DM, 2015, CLIN APPL THROMB-HEM, V21, P469, DOI 10.1177/1076029613508600
   Mirza MK, 2010, J EXP MED, V207, P1675, DOI 10.1084/jem.20091857
   Modarai B, 2005, THROMB HAEMOSTASIS, V93, P801, DOI 10.1160/TH04-09-0596
   Mullaly SC, 2006, J IMMUNOL, V177, P8154, DOI 10.4049/jimmunol.177.11.8154
   Munoz FM, 1997, J CLIN INVEST, V100, P2099, DOI 10.1172/JCI119744
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Ning FY, 2015, GENE, V557, P88, DOI 10.1016/j.gene.2014.12.018
   Prabhakaran P, 2003, AM J PHYSIOL-LUNG C, V285, pL20, DOI 10.1152/ajplung.00312.2002
   Rafii S, 2015, NAT CELL BIOL, V17, P123, DOI 10.1038/ncb3096
   Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290
   RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9
   ROBBOY SJ, 1972, HUM PATHOL, V3, P327, DOI 10.1016/S0046-8177(72)80034-0
   Ruan QR, 2001, J VASC RES, V38, P13, DOI 10.1159/000051025
   Ruf W, 2011, J THROMB HAEMOST, V9, P306, DOI 10.1111/j.1538-7836.2011.04318.x
   Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632
   Saha P, 2016, BRIT MED BULL, V117, P107, DOI 10.1093/bmb/ldw006
   Saito H, 2007, J THROMB HAEMOST, V5, P31, DOI 10.1111/j.1538-7836.2006.02267.x
   Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F
   Salgado Roberto, 2001, Angiogenesis, V4, P37, DOI 10.1023/A:1016611230747
   Sandrock CE, 2010, SEMIN RESP CRIT CARE, V31, P66, DOI 10.1055/s-0029-1246290
   Sansbury BE, 2016, CIRC RES, V119, P113, DOI 10.1161/CIRCRESAHA.116.307308
   Schouten M, 2015, THROMB RES, V135, P537, DOI 10.1016/j.thromres.2014.12.020
   Schouten M, 2014, THROMB HAEMOSTASIS, V111, P970, DOI 10.1160/TH13-10-0859
   Schouten M, 2013, EUR RESPIR J, V41, P935, DOI 10.1183/09031936.00015212
   Schouten M, 2011, THROMB HAEMOSTASIS, V106, P1189, DOI 10.1160/TH11-06-0438
   Schouten M, 2010, J INFECT DIS, V202, P1600, DOI 10.1086/656787
   Semeraro N, 2012, THROMB RES, V129, P290, DOI 10.1016/j.thromres.2011.10.013
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Shaikh FM, 2008, CELLS TISSUES ORGANS, V188, P333, DOI 10.1159/000139772
   Shen B, 2013, NATURE, V503, P131, DOI 10.1038/nature12613
   SHIMAMURA K, 1983, ARCH PATHOL LAB MED, V107, P543
   Silasi-Mansat R, 2010, BLOOD, V116, P1002, DOI 10.1182/blood-2010-02-269746
   Takahashi Y, 2016, J TRAUMA ACUTE CARE, V81, P868, DOI 10.1097/TA.0000000000001208
   TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7
   Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145
   Trzeciak S, 2007, ANN EMERG MED, V49, P88, DOI 10.1016/j.annemergmed.2006.08.021
   Tuinman PR, 2012, CRIT CARE, V16, DOI 10.1186/cc11325
   van den Berg YW, 2009, P NATL ACAD SCI USA, V106, P19497, DOI 10.1073/pnas.0905325106
   Vincent JL, 2013, CRIT CARE MED, V41, P2069, DOI 10.1097/CCM.0b013e31828e9b03
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Waltham M, 2000, J VASC SURG, V32, P988, DOI 10.1067/mva.2000.110882
   Wang TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094124
   Wang YM, 2016, NAT MED, V22, P1050, DOI 10.1038/nm.4154
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Ware LB, 2006, AM J PHYSIOL-LUNG C, V291, pL307, DOI 10.1152/ajplung.00157.2006
   Welty-Wolf KE, 2001, AM J RESP CRIT CARE, V164, P1988, DOI 10.1164/ajrccm.164.10.2105027
   Welty-Wolf KE, 2006, AM J PHYSIOL-LUNG C, V290, pL21, DOI 10.1152/ajplung.00155.2005
   Welty-Wolf KE, 2001, SEMIN HEMATOL, V38, P35, DOI 10.1016/S0037-1963(01)90145-3
   Wiersinga WJ, 2008, J THROMB HAEMOST, V6, P32
   Wong CHY, 2013, NAT IMMUNOL, V14, P785, DOI 10.1038/ni.2631
   Xiang BG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3657
   Yadav H, 2015, AM J PHYSIOL-LUNG C, V309, pL915, DOI 10.1152/ajplung.00266.2015
   Yasui H, 2016, AM J PHYSIOL-LUNG C, V311, pL74, DOI 10.1152/ajplung.00429.2015
   Yau JW, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0124-z
   Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
   Yin H, 2013, ARTERIOSCL THROM VAS, V33, P2529, DOI 10.1161/ATVBAHA.113.302339
   Zanardo RCO, 2004, BLOOD, V104, P3766, DOI 10.1182/blood-2004-02-0578
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001
   Zhang X, 2013, OXID MED CELL LONGEV, V2013, DOI [10.1155/2013/185715, DOI 10.1155/2013/185715]
   Zhao Y, 2014, EURASIP J WIREL COMM, P1, DOI 10.1186/1687-1499-2014-208
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 143
TC 24
Z9 25
U1 1
U2 26
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD APR
PY 2017
VL 312
IS 4
BP L441
EP L451
DI 10.1152/ajplung.00441.2016
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA EQ2AL
UT WOS:000397870600001
PM 28130261
OA Green Published
DA 2023-08-21
ER

PT J
AU Ju, ZH
   Ma, JH
   Wang, C
   Yu, J
   Qiao, YR
   Hei, FL
AF Ju, Zhihai
   Ma, Jinhui
   Wang, Chen
   Yu, Jie
   Qiao, Yeru
   Hei, Feilong
TI Exosomes from iPSCs Delivering siRNA Attenuate Intracellular Adhesion
   Molecule-1 Expression and Neutrophils Adhesion in Pulmonary
   Microvascular Endothelial Cells
SO INFLAMMATION
LA English
DT Article
DE ALI/ARDS; induced pluripotent stem cell; exosomes; RNA interference; Inflammation 
ID PLURIPOTENT STEM-CELLS; ACUTE LUNG INJURY; NATURAL CARRIERS; IN-VITRO;
   RNA
AB The pro-inflammatory activation of pulmonary microvascular endothelial cells resulting in continuous expression of cellular adhesion molecules, and subsequently recruiting primed neutrophils to form a firm neutrophils-endothelium (PMN-EC) adhesion, has been examined and found to play a vital role in acute lung injury (ALI). RNA interference (RNAi) is a cellular process through harnessing a natural pathway silencing target gene based on recognition and subsequent degradation of specific mRNA sequences. It opens a promising approach for precision medicine. However, this application was hampered by many obstacles, such as immunogenicity, instability, toxicity problems, and difficulty in across the biological membrane. In this study, we reprogrammed urine exfoliated renal epithelial cells into human induced pluripotent stem cells (huiPSCs) and purified the exosomes (Exo) from huiPSCs as RNAi delivery system. Through choosing the episomal system to deliver transcription factors, we obtained a non-integrating huiPSCs. Experiments in both vitro and vivo demonstrated that these huiPSCs possess the pluripotent properties. The exosomes of huiPSCs isolated by differential centrifugation were visualized by transmission electron microscopy (TEM) showing a typical exosomal appearance with an average diameter of 122 nm. Immunoblotting confirmed the presence of the typical exosomal markers, including CD63, TSG 101, and Alix. Co-cultured PKH26-labeled exosomes with human primary pulmonary microvascular endothelial cells (HMVECs) confirmed that they could be internalized by recipient cells at a time-dependent manner. Then, electroporation was used to introduce siRNA against intercellular adhesion molecule-1 (ICAM-1) into exosomes to form an Exo/siRNA compound. The Exo/siRNA compound efficiently delivered the target siRNA into HMVECs causing selective gene silencing, inhibiting the ICAM-1 protein expression, and PMN-EC adhesion induced by lipopolysaccharide (LPS). These data suggest that huiPSCs exosomes could be used as a natural gene delivery vector to transport therapeutic siRNAs for alleviating inflammatory responses in recipient cells.
C1 [Ju, Zhihai; Ma, Jinhui; Wang, Chen; Yu, Jie; Qiao, Yeru; Hei, Feilong] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, State Key Lab Cardiovasc Dis, Beijing 100037, China.
C1 [Ju, Zhihai; Ma, Jinhui; Wang, Chen; Yu, Jie; Qiao, Yeru; Hei, Feilong] Peking Union Med Coll, Beijing 100037, China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College; Fu
   Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College
RP Hei, FL (corresponding author), Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, State Key Lab Cardiovasc Dis, Beijing 100037, Peoples R China.; Hei, FL (corresponding author), Peking Union Med Coll, Beijing 100037, Peoples R China.
EM heifeilong@126.com
FU National Natural Science Foundation of China [31370993]; Scientific
   Research Foundation of Graduate School of Chinese Academy of Medical
   Sciences & Peking Union Medical College [2015-1002-02-03]
FX This study was funded by the National Natural Science Foundation of
   China (Grant No. 31370993) and the Scientific Research Foundation of
   Graduate School of Chinese Academy of Medical Sciences & Peking Union
   Medical College (Grant No. 2015-1002-02-03).
CR Alexander M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8321
   Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Banerjee A, 2013, SHOCK, V39, P366, DOI 10.1097/SHK.0b013e3182894016
   Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600-0854.2011.01225.x
   Cho RL, 2016, AM J PHYSL LUNG CELL
   EL Andaloussi S, 2013, ADV DRUG DELIVER REV, V65, P391, DOI 10.1016/j.addr.2012.08.008
   El-Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Guo YJ, 2015, BLOOD, V126, P2220, DOI 10.1182/blood-2015-02-622233
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641
   Kumar L, 2015, CURR PHARM DESIGN, V21, P4556, DOI 10.2174/138161282131151013190112
   Lai CP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8029
   Lee IT, 2012, BIOCHEM PHARMACOL, V84, P581, DOI 10.1016/j.bcp.2012.05.005
   Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Shtam TA, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-88
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036
   Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463
   Wang C, 2016, CELL REPROGRAM, V18, P30, DOI 10.1089/cell.2015.0015
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Zhao YJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/195290
   Zhou T, 2012, NAT PROTOC, V7, P2080, DOI 10.1038/nprot.2012.115
NR 28
TC 48
Z9 51
U1 1
U2 18
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD APR
PY 2017
VL 40
IS 2
BP 486
EP 496
DI 10.1007/s10753-016-0494-0
PG 11
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA ER6RB
UT WOS:000398933400013
PM 28000095
DA 2023-08-21
ER

PT J
AU Wang, T
   Gross, C
   Desai, AA
   Zemskov, E
   Wu, XM
   Garcia, AN
   Jacobson, JR
   Yuan, JXJ
   Garcia, JGN
   Black, SM
AF Wang, Ting
   Gross, Christine M.
   Desai, Ankit A.
   Zemskov, Evgeny A.
   Wu, Xiaomin
   Garcia, Alexander N.
   Jacobson, Jeffrey R.
   Yuan, Jason X-J.
   Garcia, Joe G. N.
   Black, Stephen M.
TI Endothelial cell signaling and ventilator-induced lung injury: molecular
   mechanisms, genomic analyses, and therapeutic targets
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Review
DE ALI/ARDS; ventilator-induced lung injury; Inflammation; endothelial barrier dysfunction; transcriptional regulation; mechanical forces 
ID LIGHT-CHAIN-KINASE; RESPIRATORY-DISTRESS-SYNDROME; BLOOD-BRAIN-BARRIER;
   EPIDERMAL-GROWTH-FACTOR; TIGHT JUNCTION PROTEIN; HIGH-TIDAL VOLUME;
   END-EXPIRATORY PRESSURE; COLONY-ENHANCING FACTOR; NITRATION-MEDIATED
   ACTIVATION; PHYSIOLOGICAL CYCLIC STRETCH
AB Mechanical ventilation is a life-saving intervention in critically ill patients with respiratory failure due to acute respiratory distress syndrome (ARDS). Paradoxically, mechanical ventilation also creates excessive mechanical stress that directly augments lung injury, a syndrome known as ventilator-induced lung injury (VILI). The pathobiology of VILI and ARDS shares many inflammatory features including increases in lung vascular permeability due to loss of endothelial cell barrier integrity resulting in alveolar flooding. While there have been advances in the understanding of certain elements of VILI and ARDS pathobiology, such as defining the importance of lung inflammatory leukocyte infiltration and highly induced cytokine expression, a deep understanding of the initiating and regulatory pathways involved in these inflammatory responses remains poorly understood. Prevailing evidence indicates that loss of endothelial barrier function plays a primary role in the development of VILI and ARDS. Thus this review will focus on the latest knowledge related to 1) the key role of the endothelium in the pathogenesis of VILI; 2) the transcription factors that relay the effects of excessive mechanical stress in the endothelium; 3) the mechanical stress-induced posttranslational modifications that influence key signaling pathways involved in VILI responses in the endothelium; 4) the genetic and epigenetic regulation of key target genes in the endothelium that are involved in VILI responses; and 5) the need for novel therapeutic strategies for VILI that can preserve endothelial barrier function.
C1 [Wang, Ting; Desai, Ankit A.; Zemskov, Evgeny; Wu, Xiaomin; Yuan, Jason X-J.; Garcia, Joe G. N.; Black, Stephen M.] Univ Arizona Hlth Sci, Dept Med, Tucson, AZ, United States.
C1 [Gross, Christine] Augusta Univ, Vascular Biol Ctr, Augusta, GA, United States.
C1 [Garcia, Alexander N.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Jacobson, Jeffrey R.] Univ Illinois, Dept Med, Chicago, IL, United States.
C3 University of Arizona; University of Arizona Health Sciences; University
   System of Georgia; Augusta University; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Black, SM (corresponding author), Univ Arizona Hlth Sci, Dept Med, Tucson, AZ USA.
EM steveblack@email.arizona.edu
RI Garcia, Joe GN/E-8862-2010
OI Black, Stephen M./0000-0002-4524-6544; Desai, Ankit/0000-0001-6427-616X
FU National Institutes of Health [HL60190, HL67841, HL101902, HL126609,
   HL115014, HL096887]
FX This research was supported in part by HL60190 (S. M. Black), HL67841
   (S. M. Black), HL101902 (S. M. Black), HL126609 (J. G. N. Garcia),
   HL115014 (J. X.-J. Yuan), and HL096887 (J. R. Jacobson), all from the
   National Institutes of Health.
CR Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005
   Abiko H, 2015, J CELL SCI, V128, P1683, DOI 10.1242/jcs.157503
   Aboab J, 2006, INTENS CARE MED, V32, P1979, DOI 10.1007/s00134-006-0382-4
   Acosta-Herrera M, 2015, J ALLERGY CLIN IMMUN, V136, P1116, DOI 10.1016/j.jaci.2015.04.025
   Adyshev DM, 2014, AM J RESP CELL MOL, V50, P409, DOI 10.1165/rcmb.2013-0292OC
   Aggarwal S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00161
   Agrawal A, 2016, AM J PHYSIOL-LUNG C, V310, pL103, DOI 10.1152/ajplung.00320.2015
   Ali MH, 2004, AM J PHYSIOL-LUNG C, V287, pL486, DOI 10.1152/ajplung.00389.2003
   Ali MH, 2006, AM J PHYSIOL-LUNG C, V291, pL38, DOI 10.1152/ajplung.00287.2004
   Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T
   [Anonymous], J PHARM EXP THER, DOI DOI 10.1124/JPET.112.201079
   [Anonymous], 7 INT S SIGN PROC IT, DOI DOI 10.4049/JIMMUN0L.171.11.5802
   [Anonymous], 1999, AM J RESP CRIT CARE, DOI DOI 10.1164/AJRCCM.160.6.ATS16060
   Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106
   Armstrong HK, 2016, PROSTATE, V76, P1546, DOI 10.1002/pros.23239
   Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016
   AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181
   Bae SH, 2012, CELL RES, V22, P873, DOI 10.1038/cr.2012.38
   Bajwa EK, 2007, CRIT CARE MED, V35, P1290, DOI 10.1097/01.CCM.0000260243.22758.4F
   BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293
   Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X
   Banerji U, 2003, CURR CANCER DRUG TAR, V3, P385, DOI 10.2174/1568009033481813
   Barabutis N, 2013, AM J PHYSIOL-LUNG C, V304, pL883, DOI 10.1152/ajplung.00419.2012
   Barron V, 2007, J MATER SCI-MATER M, V18, P1973, DOI 10.1007/s10856-007-3125-3
   Bazzoni G, 2003, CURR OPIN CELL BIOL, V15, P525, DOI 10.1016/S0955-0674(03)00104-2
   Beasley MB, 2010, ARCH PATHOL LAB MED, V134, P719, DOI 10.1043/1543-2165-134.5.719
   Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289
   BENES AJ, 1985, J CELL SCI, V75, P35
   Berardi DE, 2009, CELL MOL BIOENG, V2, P320, DOI 10.1007/s12195-009-0073-7
   Berlanga J, 2002, BURNS, V28, P435, DOI 10.1016/S0305-4179(02)00023-2
   Bertok S, 2012, THORAX, V67, P244, DOI 10.1136/thoraxjnl-2011-200590
   Biehl M, 2013, RESP CARE, V58, P927, DOI 10.4187/respcare.02347
   Bierman A, 2008, TRANSL RES, V152, P265, DOI 10.1016/j.trsl.2008.10.004
   Bijli KM, 2016, AM J PHYSIOL-LUNG C, V311, pL517, DOI 10.1152/ajplung.00069.2016
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukov KG, 2009, ANTIOXID REDOX SIGN, V11, P1651, DOI [10.1089/ars.2008.2390, 10.1089/ARS.2008.2390]
   Birukov KG, 2011, TEXTBOOK OF PULMONARY VASCULAR DISEASE, P913, DOI 10.1007/978-0-387-87429-6_64
   Birukov KG, 2009, MICROVASC RES, V77, P46, DOI 10.1016/j.mvr.2008.09.006
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Blasig IE, 2006, CELL MOL LIFE SCI, V63, P505, DOI 10.1007/s00018-005-5472-x
   Boitano S, 2004, AM J PHYSIOL-LUNG C, V287, pL455, DOI 10.1152/ajplung.00172.2004
   Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3
   Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brown LM, 2011, AM J SURG, V201, P486, DOI 10.1016/j.amjsurg.2010.02.003
   Brown M, 2010, MICROVASC RES, V80, P75, DOI 10.1016/j.mvr.2009.12.010
   Brown MD, 2006, TRENDS CELL BIOL, V16, P242, DOI 10.1016/j.tcb.2006.03.002
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0
   Campos R, 2012, AM J PHYSIOL-LUNG C, V302, P1640, DOI 10.1152/ajplung.00097.2011
   Chacon-Cabrera A, 2014, TRANSL RES, V164, P477, DOI 10.1016/j.trsl.2014.07.003
   Chan CH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-59
   Chang AL, 2015, FREE RADICAL BIO MED, V78, P179, DOI 10.1016/j.freeradbiomed.2014.10.582
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Chatzizisis YS, 2007, J AM COLL CARDIOL, V49, P2379, DOI 10.1016/j.jacc.2007.02.059
   Chen F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099823
   Chen LY, 2014, INFLAMMATION, V37, P358, DOI 10.1007/s10753-013-9747-3
   Chen WG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16529
   Chian CF, 2016, SHOCK, V46, P194, DOI 10.1097/SHK.0000000000000563
   Chiu YJ, 2004, ENDOTHELIUM-J ENDOTH, V11, P59, DOI 10.1080/10623320490432489
   Christie JD, 2008, CRIT CARE MED, V36, P2794, DOI 10.1097/CCM.0b013e318186b843
   Clarke H, 2000, J CELL SCI, V113, P3187
   Collins NT, 2006, ARTERIOSCL THROM VAS, V26, P62, DOI 10.1161/01.ATV.0000194097.92824.b3
   Copland IB, 2004, AM J RESP CRIT CARE, V169, P739, DOI 10.1164/rccm.200310-1417OC
   Correa-Meyer E, 2002, AM J PHYSIOL-LUNG C, V282, pL883, DOI 10.1152/ajplung.00203.2001
   Cummins PM, 2007, AM J PHYSIOL-HEART C, V292, pH28, DOI 10.1152/ajpheart.00304.2006
   Cummins PM, 2012, MOL CELL BIOL, V32, P242, DOI 10.1128/MCB.06029-11
   D'Alessio FR, 2016, AM J PHYSIOL-LUNG C, V310, pL733, DOI 10.1152/ajplung.00419.2015
   D'Atri F, 2002, J BIOL CHEM, V277, P27757, DOI 10.1074/jbc.M203717200
   Davidovich N, 2013, AM J RESP CELL MOL, V49, P156, DOI 10.1165/rcmb.2012-0252OC
   Davidson BA, 2013, J IMMUNOL, V190, P1714, DOI 10.4049/jimmunol.1202410
   DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Del Sorbo Lorenzo, 2011, Presse Med, V40, pe569, DOI 10.1016/j.lpm.2011.05.028
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159
   Du QS, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-117
   Dubeykovskaya Z, 2009, J BIOL CHEM, V284, P3650, DOI 10.1074/jbc.M804935200
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Duggan M, 2005, ANESTHESIOLOGY, V103, P522, DOI 10.1097/00000542-200509000-00015
   Ebnet K, 2000, J BIOL CHEM, V275, P27979
   EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A
   Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745
   FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375
   Finigan JH, 2009, AM J PHYSIOL-LUNG C, V296, pL1002, DOI 10.1152/ajplung.90555.2008
   Fletcher ME, 2015, AM J PHYSIOL-LUNG C, V308, pL1274, DOI 10.1152/ajplung.00220.2014
   Flores C, 2007, GENET EPIDEMIOL, V31, P296, DOI 10.1002/gepi.20210
   Fontijn RD, 2008, AM J PHYSIOL-HEART C, V294, pH891, DOI 10.1152/ajpheart.01248.2007
   Frank JA, 2008, THORAX, V63, P147, DOI 10.1136/thx.2007.079608
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0
   Frye SR, 2005, PHYSIOL GENOMICS, V21, P124, DOI 10.1152/physiolgenomics.00029.2003
   Fu PF, 2015, PULM CIRC, V5, P619, DOI 10.1086/683693
   Fu PF, 2015, AM J PHYSIOL-LUNG C, V308, pL1025, DOI 10.1152/ajplung.00306.2014
   FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123
   Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891
   Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263
   FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617
   Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1
   Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30
   Gao J, 2014, BIOCHEM BIOPH RES CO, V448, P342, DOI 10.1016/j.bbrc.2014.03.063
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Gao L, 2007, J ALLERGY CLIN IMMUN, V119, P1111, DOI 10.1016/j.jaci.2007.03.019
   Gao R, 2015, AM J PHYSIOL-LUNG C, V309, pL1376, DOI 10.1152/ajplung.00219.2015
   Garcia CSNB, 2006, BRAZ J MED BIOL RES, V39, P697, DOI 10.1590/S0100-879X2006000600001
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia JGN, 2013, AM J RESP CRIT CARE, V188, P631, DOI 10.1164/rccm.201307-1394ED
   GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772
   Gavard J, 2008, NAT CELL BIOL, V10, P883, DOI 10.1038/ncb0808-883
   Glavan BJ, 2011, AM J RESP CRIT CARE, V183, P356, DOI 10.1164/rccm.201003-0351OC
   Goldenberg NM, 2015, N-S ARCH PHARMACOL, V388, P421, DOI 10.1007/s00210-014-1058-1
   Gotsch U, 1997, J CELL SCI, V110, P583
   Gray Keith D, 2004, Surg Infect (Larchmt), V5, P166, DOI 10.1089/sur.2004.5.166
   Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34
   Grobe AC, 2006, AM J PHYSIOL-LUNG C, V290, pL1069, DOI 10.1152/ajplung.00408.2005
   Gross CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119918
   Gross CM, 2014, J CELL PHYSIOL, V229, P1802, DOI 10.1002/jcp.24633
   Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C
   Gu CP, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0217-3
   Gunaydin H, 2009, CHEM RES TOXICOL, V22, P894, DOI 10.1021/tx800463y
   Gundersen GG, 2002, CURR BIOL, V12, pR645, DOI 10.1016/S0960-9822(02)01156-9
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009
   Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A
   Harris TJC, 2010, NAT REV MOL CELL BIO, V11, P502, DOI 10.1038/nrm2927
   Hassoun PM, 2009, J AM COLL CARDIOL, V54, pS10, DOI 10.1016/j.jacc.2009.04.006
   Hassoun PM, 1998, AM J RESP CRIT CARE, V158, P299, DOI 10.1164/ajrccm.158.1.9709116
   Hegeman MA, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/435236
   Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464
   Hoegl S, 2011, AM J RESP CELL MOL, V44, P369, DOI 10.1165/rcmb.2009-0440OC
   Hoegl S, 2009, RESP MED, V103, P463, DOI 10.1016/j.rmed.2008.09.020
   Honda M, 2006, CELL MOL NEUROBIOL, V26, P109, DOI 10.1007/s10571-006-9028-x
   Hong DS, 2013, CANCER TREAT REV, V39, P375, DOI 10.1016/j.ctrv.2012.10.001
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Hou YL, 2015, AM J PHYSIOL-LUNG C, V309, pL593, DOI 10.1152/ajplung.00029.2015
   Howard MD, 2014, J CONTROL RELEASE, V177, P34, DOI 10.1016/j.jconrel.2013.12.035
   Hu ZS, 2015, J SURG RES, V194, P528, DOI 10.1016/j.jss.2014.10.027
   Husari Ahmad, 2014, BMC Res Notes, V7, P664, DOI 10.1186/1756-0500-7-664
   IBA T, 1991, J SURG RES, V50, P457, DOI 10.1016/0022-4804(91)90024-G
   Ichimura H, 2003, J CLIN INVEST, V111, P691, DOI 10.1172/JCI200317271
   Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7
   Infusino GA, 2013, AM J RESP CRIT CARE, V187
   Ishizaki T, 2003, EXP CELL RES, V290, P275, DOI 10.1016/S0014-4827(03)00354-9
   Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351
   Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981
   Jacquemet Guillaume, 2013, Small GTPases, V4, P199, DOI 10.4161/sgtp.27451
   Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041
   Jacquemet G, 2013, J CELL SCI, V126, P4121, DOI 10.1242/jcs.121988
   Jaecklin T, 2010, INTENS CARE MED, V36, P750, DOI 10.1007/s00134-010-1850-4
   JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949
   Jian MY, 2008, AM J RESP CELL MOL, V38, P386, DOI 10.1165/rcmb.2007-0192OC
   Jiang WG, 1999, J CELL PHYSIOL, V181, P319, DOI 10.1002/(SICI)1097-4652(199911)181:2<319::AID-JCP14>3.3.CO;2-J
   Joshi AD, 2015, AM J PHYSIOL-LUNG C, V309, pL1410, DOI 10.1152/ajplung.00180.2015
   Ju YN, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0251-z
   Kaestle SM, 2007, AM J PHYSIOL-LUNG C, V293, pL859, DOI 10.1152/ajplung.00008.2007
   Kage H, 2014, AM J PHYSIOL-LUNG C, V307, pL524, DOI 10.1152/ajplung.00077.2014
   Kandasamy K, 2015, AM J PHYSIOL-LUNG C, V309, pL584, DOI 10.1152/ajplung.00211.2014
   Kangelaris KN, 2015, AM J PHYSIOL-LUNG C, V308, pL1102, DOI 10.1152/ajplung.00380.2014
   Kangelaris KN, 2012, CHEST, V141, P1160, DOI 10.1378/chest.11-1766
   Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215
   Kausalya PJ, 2004, MOL BIOL CELL, V15, P5503, DOI 10.1091/mbc.E04-04-0350
   Kit AH, 2012, BIOCHIMIE, V94, P2314, DOI 10.1016/j.biochi.2012.07.014
   Kluger MS, 2013, ARTERIOSCL THROM VAS, V33, P489, DOI 10.1161/ATVBAHA.112.300893
   Koay YC, 2014, ACS MED CHEM LETT, V5, P771, DOI 10.1021/ml500114p
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Kovacs EM, 2008, CURR BIOL, V18, pR667, DOI 10.1016/j.cub.2008.06.024
   Kuethe DO, 2016, AM J PHYSIOL-LUNG C, V311, pL208, DOI 10.1152/ajplung.00459.2015
   Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832
   Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774
   Khanh LNP, 2015, AM J PHYSIOL-LUNG C, V309, pL995, DOI 10.1152/ajplung.00068.2014
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Letsiou E, 2015, AM J RESP CELL MOL, V52, P193, DOI 10.1165/rcmb.2013-0347OC
   Li XC, 2009, ARTERIOSCL THROM VAS, V29, P1200, DOI 10.1161/ATVBAHA.109.189217
   Li YH, 2005, J MOL BIOL, V352, P151, DOI 10.1016/j.jmb.2005.07.017
   Lindsay CD, 2011, HUM EXP TOXICOL, V30, P701, DOI 10.1177/0960327110376982
   Lingaraju MC, 2015, J SURG RES, V193, P856, DOI 10.1016/j.jss.2014.09.008
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Lutmer J, 2013, J SURG RES, V185, P329, DOI 10.1016/j.jss.2013.05.064
   Ma J, 2014, J CELL PHYSIOL, V229, P916, DOI 10.1002/jcp.24523
   Ma SF, 2005, AM J PHYSIOL-LUNG C, V289, pL468, DOI 10.1152/ajplung.00109.2005
   Ma WY, 2006, MICROSC RES TECHNIQ, V69, P784, DOI 10.1002/jemt.20346
   MACARTHUR H, 1994, BIOCHEM BIOPH RES CO, V200, P395, DOI 10.1006/bbrc.1994.1462
   Machado JC, 2000, J PATHOL, V190, P437
   Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065
   Maitra U, 2009, J BIOL CHEM, V284, P35403, DOI 10.1074/jbc.M109.059501
   Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117
   Martinez-Caro L, 2015, SHOCK, V44, P36, DOI 10.1097/SHK.0000000000000381
   Martinez-Caro L, 2009, INTENS CARE MED, V35, P1110, DOI 10.1007/s00134-009-1469-5
   Mathew B, 2015, AM J PHYSIOL-LUNG C, V309, pL1420, DOI 10.1152/ajplung.00146.2014
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McConnell JR, 2015, BIOORG MED CHEM LETT, V25, P3409, DOI 10.1016/j.bmcl.2015.06.052
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Medina R, 2000, J MEMBRANE BIOL, V178, P235, DOI 10.1007/s002320010031
   Meens MJ, 2013, CARDIOVASC RES, V99, P304, DOI 10.1093/cvr/cvt095
   Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289
   Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646
   Meyer Nuala J, 2007, Proc Am Thorac Soc, V4, P69, DOI 10.1513/pats.200609-157JG
   Meyer NJ, 2013, SEMIN RESP CRIT CARE, V34, P459, DOI 10.1055/s-0033-1351121
   Meyer NJ, 2009, FASEB J, V23, P1325, DOI 10.1096/fj.08-119073
   Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200
   Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Mitra S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100169
   Mitra S, 2011, AM J RESP CRIT CARE, V184, P1030, DOI 10.1164/rccm.201103-0447OC
   Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185
   Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511
   Morrow CMK, 2009, BIOL REPROD, V81, P871, DOI 10.1095/biolreprod.109.077040
   Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001
   Muller SL, 2005, J BIOL CHEM, V280, P3747, DOI 10.1074/jbc.M411365200
   Murakami K, 2007, SHOCK, V28, P477, DOI 10.1097/shk.0b013e31804a59bd
   NARIMANBEKOV IO, 1995, EXP LUNG RES, V21, P239, DOI 10.3109/01902149509068830
   Natale DR, 2002, MECH DEVELOP, V119, pS21, DOI 10.1016/S0925-4773(03)00086-8
   Natarajan V, 2013, AM J RESP CELL MOL, V49, P6, DOI 10.1165/rcmb.2012-0411TR
   Nickles HT, 2014, AM J PHYSIOL-LUNG C, V307, pL27, DOI 10.1152/ajplung.00288.2013
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   O'Donnell JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100931
   Okamoto T, 2014, ATHEROSCLEROSIS, V236, P430, DOI 10.1016/j.atherosclerosis.2014.07.025
   Okamoto T, 2014, EXP CELL RES, V321, P133, DOI 10.1016/j.yexcr.2013.12.002
   Okamoto T, 2011, EXP CELL RES, V317, P348, DOI 10.1016/j.yexcr.2010.10.018
   Ooshio T, 2010, J BIOL CHEM, V285, P5003, DOI 10.1074/jbc.M109.043760
   Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Pacey S, 2006, HANDB EXP PHARM, V172, P331
   Pacey S, 2012, INVEST NEW DRUG, V30, P341, DOI 10.1007/s10637-010-9493-4
   Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927
   Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200
   Papaiahgari S, 2007, AM J RESP CRIT CARE, V176, P1222, DOI 10.1164/rccm.200701-060OC
   Papaiahgari S, 2007, AM J RESP CELL MOL, V36, P304, DOI 10.1165/rcmb.2006-0131OC
   Parker JC, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.121
   Pedreira PR, 2008, AM J PHYSIOL-LUNG C, V295, pL820, DOI 10.1152/ajplung.90211.2008
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Piehl C, 2010, CELL MOL LIFE SCI, V67, P2131, DOI 10.1007/s00018-010-0332-8
   Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Powers MV, 2007, FEBS LETT, V581, P3758, DOI 10.1016/j.febslet.2007.05.040
   Quinn DA, 2002, J APPL PHYSIOL, V93, P517, DOI 10.1152/japplphysiol.00570.2001
   Radisavljevic Z, 2013, J CELL PHYSIOL, V228, P522, DOI 10.1002/jcp.24167
   Rafikov R, 2014, J BIOL CHEM, V289, P4710, DOI 10.1074/jbc.M114.547596
   Rafikov R, 2013, J BIOL CHEM, V288, P6212, DOI 10.1074/jbc.M112.423269
   Rafikova O, 2016, FREE RADICAL BIO MED, V95, P96, DOI 10.1016/j.freeradbiomed.2016.02.029
   Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451
   Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804
   Reddy SP, 2007, ANTIOXID REDOX SIGN, V9, P2003, DOI 10.1089/ars.2007.1770
   Rentsendorj O, 2011, AM J PHYSIOL-LUNG C, V301, pL161, DOI 10.1152/ajplung.00073.2011
   Ribeiro SP, 1996, AM J RESP CRIT CARE, V154, P1843, DOI 10.1164/ajrccm.154.6.8970379
   Rich PB, 2003, J SURG RES, V113, P139, DOI 10.1016/S0022-4804(03)00195-1
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Rodrigues Loreta M, 2012, BMC Res Notes, V5, P250, DOI 10.1186/1756-0500-5-250
   ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877
   Ruffer C, 2004, EUR J CELL BIOL, V83, P135, DOI 10.1078/0171-9335-00366
   Ryb GE, 2010, J NATL MED ASSOC, V102, P865, DOI 10.1016/S0027-9684(15)30700-8
   Saif MW, 2014, CLIN CANCER RES, V20, P445, DOI 10.1158/1078-0432.CCR-13-1257
   Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397
   Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009
   Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   SCHWARTZ MC, 1995, AM J RESP CELL MOL, V12, P434, DOI 10.1165/ajrcmb.12.4.7695923
   Sessa C, 2013, CLIN CANCER RES, V19, P3671, DOI 10.1158/1078-0432.CCR-12-3404
   Shan YX, 2015, ANTIOXID REDOX SIGN, V22, P651, DOI 10.1089/ars.2014.5987
   Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001
   Shimizu Y, 2015, PULM CIRC, V5, P707, DOI 10.1086/684124
   Shohrati M, 2014, INHAL TOXICOL, V26, P507, DOI 10.3109/08958378.2014.920439
   Silachev DN, 2014, HEART LUNG CIRC, V23, P897, DOI 10.1016/j.hlc.2014.05.022
   Simon BA, 2006, AM J PHYSIOL-LUNG C, V291, pL851, DOI 10.1152/ajplung.00463.2005
   SINGER KL, 1994, J BIOL CHEM, V269, P16108
   Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200
   Slutsky Arthur S, 2005, Respir Care, V50, P646
   Slutsky AS, 2001, AM J RESP CRIT CARE, V163, P599, DOI 10.1164/ajrccm.163.3.ed09-01c
   STADDON JM, 1995, J CELL SCI, V108, P609
   STAEHELIN LA, 1973, J CELL SCI, V13, P763
   Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200
   Standiford TJ, 2016, TRANSL RES, V167, P183, DOI 10.1016/j.trsl.2015.04.015
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710
   STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567
   Stone ML, 2015, AM J PHYSIOL-LUNG C, V308, pL1245, DOI 10.1152/ajplung.00302.2014
   Su CL, 2013, CHINESE J PHYSIOL, V56, P219, DOI 10.4077/CJP.2013.BAB106
   Sud N, 2007, AM J PHYSIOL-LUNG C, V293, pL1444, DOI 10.1152/ajplung.00175.2007
   Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007
   Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349
   Sun XG, 2014, AM J RESP CELL MOL, V51, P660, DOI 10.1165/rcmb.2014-0117OC
   Sun XG, 2013, AM J PHYSIOL-LUNG C, V305, pL467, DOI 10.1152/ajplung.00010.2013
   Sun XG, 2012, AM J RESP CELL MOL, V47, P628, DOI 10.1165/rcmb.2012-0048OC
   Sun XG, 2010, J ALLERGY CLIN IMMUN, V126, P241, DOI 10.1016/j.jaci.2010.04.036
   Suzuki T, 2016, AM J PHYSIOL-LUNG C, V310, pL1185, DOI 10.1152/ajplung.00074.2016
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   Sweeney NV, 2005, BIOCHEM BIOPH RES CO, V329, P573, DOI 10.1016/j.bbrc.2005.02.013
   Syrkina O, 2008, RESPIROLOGY, V13, P333, DOI 10.1111/j.1440-1843.2008.01279.x
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Takata M, 1997, AM J RESP CRIT CARE, V156, P272, DOI 10.1164/ajrccm.156.1.9607072
   TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387
   Takenaga Y, 2009, J CEREBR BLOOD F MET, V29, P1099, DOI [10.1038/jcbfm.2009.30, 10.1038/sj.jcbfm.jcbfm200930]
   Takenaka K, 2006, AM J PHYSIOL-LUNG C, V290, pL1078, DOI 10.1152/ajplung.00239.2005
   Tang Beverly T, 2012, Pulm Circ, V2, P470, DOI 10.4103/2045-8932.105035
   Tao SS, 2016, SCI REP-UK, V6, DOI 10.1038/srep18760
   Thangjam GS, 2016, AM J PHYSIOL-LUNG C, V310, pL964, DOI 10.1152/ajplung.00054.2016
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   To EE, 2014, FREE RADICAL RES, V48, P940, DOI 10.3109/10715762.2014.927579
   Tremblay LO, 2007, J BIOL CHEM, V282, P2558, DOI 10.1074/jbc.M608661200
   Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8
   Tschumperlin DJ, 2000, AM J RESP CRIT CARE, V162, P357, DOI 10.1164/ajrccm.162.2.9807003
   Tschumperlin DJ, 2004, CELL CYCLE, V3, P996
   Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543
   Tschumperlin DJ, 1999, J APPL PHYSIOL, V86, P2026, DOI 10.1152/jappl.1999.86.6.2026
   Tschumperlin DJ, 2002, AM J PHYSIOL-LUNG C, V282, pL904, DOI 10.1152/ajplung.00270.2001
   TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573
   Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235
   Uddin M, 2008, EUR RESPIR J, V31, P714, DOI 10.1183/09031936.00144307
   Uddin M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072502
   Ulfhammer E, 2005, J HYPERTENS, V23, P1551, DOI 10.1097/01.hjh.0000175931.71150.02
   Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043
   Usatyuk PV, 2012, J BIOL CHEM, V287, P9360, DOI 10.1074/jbc.M111.294546
   VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x
   Vaporidi K, 2012, AM J PHYSIOL-LUNG C, V303, pL199, DOI 10.1152/ajplung.00370.2011
   Vaporidi K, 2010, AM J PHYSIOL-LUNG C, V299, pL150, DOI 10.1152/ajplung.00341.2009
   Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126
   Villalta PC, 2014, AM J PHYSIOL-LUNG C, V307, pL652, DOI 10.1152/ajplung.00113.2014
   Villar J, 2014, CURR OPIN CRIT CARE, V20, P3, DOI 10.1097/MCC.0000000000000057
   Villar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023914
   Wachtel M, 1999, J CELL SCI, V112, P4347
   Wakabayashi K, 2014, CRIT CARE MED, V42, pE49, DOI 10.1097/CCM.0b013e31829a822a
   Wang HW, 2015, INT J CLIN EXP MED, V8, P15137
   Wang T, 2014, AM J RESP CELL MOL, V50, P1129, DOI 10.1165/rcmb.2013-0434OC
   Wang W, 2016, AM J PHYSIOL-LUNG C, V311, pL494, DOI 10.1152/ajplung.00001.2016
   Wang Y, 2015, ORG BIOMOL CHEM, V13, P4627, DOI 10.1039/c5ob00044k
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Watanabe T, 2015, CELL STRUCT FUNCT, V40, DOI 10.1247/csf.15003
   Watson CJ, 2001, AM J PHYSIOL-CELL PH, V281, pC388, DOI 10.1152/ajpcell.2001.281.2.C388
   WEBB HH, 1974, AM REV RESPIR DIS, V110, P556
   WEINBROUM A, 1995, AM J PHYSIOL-GASTR L, V268, pG988, DOI 10.1152/ajpgi.1995.268.6.G988
   WEISSBACH L, 1994, J BIOL CHEM, V269, P20517
   West JB, 2000, J APPL PHYSIOL, V89, P2483, DOI 10.1152/jappl.2000.89.6.2483
   WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731
   White CD, 2012, CELL SIGNAL, V24, P826, DOI 10.1016/j.cellsig.2011.12.005
   Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787
   Whitmore LC, 2014, AM J PHYSIOL-LUNG C, V307, pL71, DOI 10.1152/ajplung.00054.2014
   Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046
   WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834
   Wilson MR, 2013, ANAESTHESIA, V68, P175, DOI 10.1111/anae.12085
   Wilson MR, 2012, CRIT CARE MED, V40, P2850, DOI 10.1097/CCM.0b013e31825b91ef
   Wilson MR, 2009, AM J RESP CRIT CARE, V179, P914, DOI 10.1164/rccm.200806-877OC
   Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003
   Wirtz HR, 2000, RESP PHYSIOL, V119, P1, DOI 10.1016/S0034-5687(99)00092-4
   Wolfson RK, 2014, MICROVASC RES, V92, P50, DOI 10.1016/j.mvr.2013.12.005
   Woods SJ, 2015, AM J PHYSIOL-LUNG C, V308, pL912, DOI 10.1152/ajplung.00048.2015
   Wu F, 2014, AM J PHYSIOL-LUNG C, V307, pL987, DOI 10.1152/ajplung.00063.2014
   Wung BS, 1996, AM J PHYSIOL-HEART C, V270, pH1462, DOI 10.1152/ajpheart.1996.270.4.H1462
   Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009
   Xiao F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021527
   Yamada S, 2007, J CELL BIOL, V178, P517, DOI 10.1083/jcb.200701058
   Yamamoto M, 2008, AM J PATHOL, V172, P521, DOI 10.2353/ajpath.2008.070076
   Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785
   Yamamoto Y, 2012, SHOCK, V38, P671, DOI 10.1097/SHK.0b013e3182758759
   Yang BO, 2012, EXP THER MED, V4, P611, DOI 10.3892/etm.2012.670
   Yang CQ, 2003, BIOL PHARM BULL, V26, P424
   Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156
   Ye SY, 2015, J VIROL, V89, P2672, DOI 10.1128/JVI.03529-14
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
   Yehya N, 2015, AM J PHYSIOL-LUNG C, V308, pL443, DOI 10.1152/ajplung.00312.2014
   Yilmaz MZ, 2014, J MOL HISTOL, V45, P195, DOI 10.1007/s10735-013-9542-3
   Yin J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   Yin J, 2016, AM J RESP CELL MOL, V54, P370, DOI 10.1165/rcmb.2014-0225OC
   Yin J, 2010, CELL BIOCHEM BIOPHYS, V56, P1, DOI 10.1007/s12013-009-9067-2
   Yu Y, 2009, CIRCULATION, V119, P2313, DOI 10.1161/CIRCULATIONAHA.108.782458
   Yuan L, 2012, J BIOL CHEM, V287, P6582, DOI 10.1074/jbc.M111.300236
   Yumoto Masato, 2005, J Anesth, V19, P287, DOI 10.1007/s00540-005-0338-9
   Zebda N, 2013, J BIOL CHEM, V288, P18290, DOI 10.1074/jbc.M112.432757
   Zenri H, 2004, CRIT CARE MED, V32, P1155, DOI 10.1097/01.CCM.0000126264.00551.C8
   Zhan XQ, 2006, ANAL BIOCHEM, V354, P279, DOI 10.1016/j.ab.2006.05.024
   Zhang XQ, 2013, MOL MED REP, V7, P1417, DOI 10.3892/mmr.2013.1405
   Zhao HG, 2009, BIOCHEM BIOPH RES CO, V389, P599, DOI 10.1016/j.bbrc.2009.09.028
   Zhao T, 2016, RESPIROLOGY, V21, P1404, DOI 10.1111/resp.12858
   Zhao T, 2014, RESP RES, V15, P1, DOI 10.1186/s12931-014-0158-2
   Zhao WC, 2014, LIFE SCI, V108, P80, DOI 10.1016/j.lfs.2014.05.009
   Zheng W, 2004, AM J PHYSIOL-HEART C, V287, pH2739, DOI 10.1152/ajpheart.00410.2004
   Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010
   Zinter MS, 2016, AM J PHYSIOL-LUNG C, V310, pL224, DOI 10.1152/ajplung.00336.2015
NR 387
TC 51
Z9 61
U1 1
U2 22
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD APR
PY 2017
VL 312
IS 4
BP L452
EP L476
DI 10.1152/ajplung.00231.2016
PG 25
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA EQ2AL
UT WOS:000397870600002
PM 27979857
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Chen, F
   Wang, Y
   Rafikov, R
   Haigh, S
   Zhi, WB
   Kumar, S
   Doulias, PT
   Rafikova, O
   Pillich, H
   Chakraborty, T
   Lucas, R
   Verin, AD
   Catravas, JD
   She, JX
   Black, SM
   Fulton, DJR
AF Chen, F.
   Wang, Y.
   Rafikov, Ruslan
   Haigh, Stephen
   Zhi, W. B.
   Kumar, S.
   Doulias, P. T.
   Rafikova, Olga
   Pillich, Helena
   Chakraborty, Trinad
   Lucas, Rudolf
   Verin, Alexander D.
   Catravas, John D.
   She, J. X.
   Black, Stephen M.
   Fulton, David J. R.
TI RhoA S-nitrosylation as a regulatory mechanism influencing endothelial
   barrier function in response to G(+)-bacterial toxins
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE NO; S-nitrosylation; Rho/RhoA; G(+)-toxins; ECs/HPMECs/HUVECs/MPVECs; permeability 
ID RESPIRATORY-DISTRESS-SYNDROME; OXIDE-INDUCED INHIBITION; KINASE-C-ALPHA;
   NITRIC-OXIDE; RYANODINE RECEPTOR; LUNG INJURY; ACTIVATION; NO;
   DENITROSYLATION; NITROSATION
AB Disruption of the endothelial barrier in response to Gram positive (G(+)) bacterial toxins is a major complication of acute lung injury (ALI) and can be further aggravated by antibiotics which stimulate toxin release. The integrity of the pulmonary endothelial barrier is mediated by the balance of disruptive forces such as the small GTPase RhoA, and protective forces including endothelium-derived nitric oxide (NO). How NO protects against the barrier dysfunction is incompletely understood and our goal was to determine whether NO and S-nitrosylation can modulate RhoA activity and whether this mechanism is important for G(+) toxin-induced microvascular permeability. We found that the G(+) toxin listeriolysin-O (LLO) increased RhoA activity and that NO and S-NO donors inhibit RhoA activity. RhoA was robustly S-nitrosylated as determined by biotin-switch and mercury column analysis. MS revealed that three primary cysteine residues are S-nitrosylated including cys16, cys20 and cys159. Mutation of these residues to serine diminished S-nitrosylation to endogenous NO and mutant RhoA was less sensitive to inhibition by S-NO. G(+)-toxins stimulated the denitrosylation of RhoA which was not mediated by S-nitrosoglutathione reductase (GSNOR), thioredoxin (TRX) or thiol-dependent enzyme activity but was instead stimulated directly by elevated calcium levels. Calcium-promoted the direct denitrosylation of WT but not mutant RhoA and mutant RhoA adenovirus was more effective than WT in disrupting the barrier integrity of human lung microvascular endothelial cells. In conclusion, we reveal a novel mechanism by which NO and S-nitrosylation reduces RhoA activity which may be of significance in the management of pulmonary endothelial permeability induced by G(+)-toxins. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Chen, F.] Nanjing Med Univ, Dept Forens Med, Nanjing, Jiangsu, China.
C1 [Chen, F.; Wang, Y.; Rafikov, R.; Haigh, S.; Kumar, S.; Rafikova, O.; Lucas, R.; Verin, A. D.; Black, S. M.; Fulton, D. J. R.] Augusta Univ, Vasc Biol Ctr, 1459 Laney Walker Blvd, Augusta, GA 30912, United States.
C1 [Zhi, W. B.; She, J. X.] Augusta Univ, Ctr Biotechnol & Genom Med, Augusta, GA 30912, United States.
C1 [Lucas, R.; Fulton, D. J. R.] Augusta Univ, Dept Pharmacol, Augusta, GA 30912, United States.
C1 [Doulias, P. T.] Childrens Hosp Philadelphia, Res Inst, Dept Pediat, Philadelphia, PA 19104, United States.
C1 [Pillich, H.; Chakraborty, T.] Justus Liebig Univ, Inst Med Microbiol, Giessen, Germany.
C1 [Catravas, J. D.] Old Dominion Univ, Norfolk, VA, United States.
C3 Nanjing Medical University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; University of Pennsylvania;
   Pennsylvania Medicine; Childrens Hospital of Philadelphia; Justus Liebig
   University Giessen; Old Dominion University
RP Chen, F (corresponding author), Nanjing Med Univ, Dept Forens Med, Nanjing, Jiangsu, Peoples R China.; Chen, F; Fulton, DJR (corresponding author), Augusta Univ, Vasc Biol Ctr, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.
EM fchen@njmu.edu.cn; dfulton@augusta.edu
RI Lucas, Rudolf/ABA-3011-2020; zhi, wen/GVS-6201-2022;
   DeltaOmicronUpsilonLambdaIotaAlphaSigma,
   PiAlphaSigmaChiAlphaLambdaEtaSigma-ThetaOmegaMuAlphaSigma/AAY-1665-2020;
   Chen, Feng/E-1133-2011; Rafikov, Ruslan/AAG-9352-2019
OI Chen, Feng/0000-0003-3508-8834; Rafikov, Ruslan/0000-0001-5950-4076;
   Lucas, Rudolf/0000-0003-3805-8868; Black, Stephen
   M./0000-0002-4524-6544; Verin, Alexander/0000-0003-0627-7185
FU NIH [R01HL092446, P01 HL101902-01A1]; German Research Foundation
   [Transregio 84/2 SFB]; AHA; NSFC [81570378]
FX This work was supported by NIH grants R01HL092446, P01 HL101902-01A1, by
   a Transregio 84/2 SFB grant from the German Research Foundation (TC and
   RL) "Innate Immunity of the Lung" (TC and RL) and by awards from the AHA
   (FC and YW) and NSFC 81570378(FC).
CR Barman SA, 2014, ARTERIOSCL THROM VAS, V34, P1704, DOI 10.1161/ATVBAHA.114.303848
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Benhar M, 2010, BIOCHEMISTRY-US, V49, P6963, DOI 10.1021/bi100619k
   Benhar M, 2009, NAT REV MOL CELL BIO, V10, P721, DOI 10.1038/nrm2764
   Birukov KG, 2009, MICROVASC RES, V77, P46, DOI 10.1016/j.mvr.2008.09.006
   Bogatcheva NV, 2011, J CELL PHYSIOL, V226, P3132, DOI 10.1002/jcp.22669
   Chen F, 2015, FREE RADICAL BIO MED, V89, P793, DOI 10.1016/j.freeradbiomed.2015.09.019
   Chen F, 2015, CURR PHARM DESIGN, V21, P5999, DOI 10.2174/1381612821666151029111528
   Chen F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099823
   Chen F, 2014, FREE RADICAL BIO MED, V73, P201, DOI 10.1016/j.freeradbiomed.2014.04.029
   Chen F, 2012, ARTERIOSCL THROM VAS, V32, P2989, DOI 10.1161/ATVBAHA.112.300361
   Chen F, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00412
   Chen F, 2010, MOL PHARMACOL, V77, P280, DOI 10.1124/mol.109.061077
   Cheng B, 2011, P NATL ACAD SCI USA, V108, P17147, DOI 10.1073/pnas.1112998108
   Chistiakov DA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00365
   Chvanov M, 2006, EMBO J, V25, P3024, DOI 10.1038/sj.emboj.7601207
   Doulias PT, 2013, METHODS, V62, P165, DOI 10.1016/j.ymeth.2012.10.009
   Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139
   Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200
   Forrester MT, 2009, FREE RADICAL BIO MED, V46, P119, DOI 10.1016/j.freeradbiomed.2008.09.034
   Foster MW, 2009, P NATL ACAD SCI USA, V106, P18948, DOI 10.1073/pnas.0900729106
   Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31
   Gao F., 2016, CELL MOL LIFE SCI
   Goeckeler ZM, 2005, J BIOL CHEM, V280, P33083, DOI 10.1074/jbc.M503173200
   Gonzalez DR, 2007, P NATL ACAD SCI USA, V104, P20612, DOI 10.1073/pnas.0706796104
   Han B, 2016, SHOCK
   Harrington EO, 2004, AM J PHYSIOL-LUNG C, V287, pL1091, DOI 10.1152/ajplung.00421.2003
   Iliev AI, 2007, P NATL ACAD SCI USA, V104, P2897, DOI 10.1073/pnas.0608213104
   Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kahlos K, 2003, MOL CELL BIOCHEM, V254, P47, DOI 10.1023/A:1027380828645
   Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984
   Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t
   Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999
   Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596
   Lucas R, 2012, AM J RESP CELL MOL, V47, P445, DOI 10.1165/rcmb.2011-0332OC
   Mansur A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0368-6
   Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1
   McNichol BA, 2006, MOL MICROBIOL, V60, P939, DOI 10.1111/j.1365-2958.2006.05157.x
   Mitchell DA, 2005, NAT CHEM BIOL, V1, P154, DOI 10.1038/nchembio720
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Qian J, 2012, FREE RADICAL BIO MED, V52, P1806, DOI 10.1016/j.freeradbiomed.2012.02.029
   Rafikov R, 2014, J BIOL CHEM, V289, P4710, DOI 10.1074/jbc.M114.547596
   Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c
   Siddiqui MR, 2011, J CELL BIOL, V193, P841, DOI 10.1083/jcb.201012129
   Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0
   Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013
   Visvikis O, 2010, BIOL CELL, V102, P377, DOI 10.1042/BC20090151
   Weycker D, 2010, VACCINE, V28, P4955, DOI 10.1016/j.vaccine.2010.05.030
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Xiong CL, 2010, VASC PHARMACOL, V52, P207, DOI 10.1016/j.vph.2009.12.010
   Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234
   Zuckerbraun BS, 2007, AM J PHYSIOL-CELL PH, V292, pC824, DOI 10.1152/ajpcell.00592.2005
NR 54
TC 9
Z9 11
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 1
PY 2017
VL 127
BP 34
EP 45
DI 10.1016/j.bcp.2016.12.014
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EL1WB
UT WOS:000394411000004
PM 28017778
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Hayashi, K
   Yoshida, H
   Sato, Y
   Tobiume, M
   Suzuki, Y
   Ariyoshi, K
   Hasegawa, H
   Nakajima, N
AF Hayashi, Kentaro
   Yoshida, Hiroshi
   Sato, Yuko
   Tobiume, Minoru
   Suzuki, Yoshio
   Ariyoshi, Koya
   Hasegawa, Hideki
   Nakajima, Noriko
TI Histopathological Findings of Lung with A/H1N1pdm09 Infection-Associated
   Acute Respiratory Distress Syndrome in the Post-Pandemic Season
SO JAPANESE JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID INFLUENZA-A H1N1; VIRUS-INFECTION; PATHOGENESIS; CELLS
AB We herein report the pulmonary histopathological findings of an autopsy case of post pandemic season A/H1N1pdm09 infection-associated acute respiratory distress syndrome (ARDS). The lung histology predominantly exhibited findings indicative of the exudative phase of diffuse alveolar damage, with similar inflammation severity observed in all sections. Furthermore, the lung sections only showed a few A/H1N1pdm09 antigen-positive cells along with a low viral RNA copy number. The sequence of the viral hemagglutinin receptor binding site identified a preference for alpha-2,6 linked sialic acid, suggesting low alveolar epithelial cell infectivity. The pathological findings, in this case, differed in several aspects from those of the first autopsy case of A/H1N1pdm09 infection-associated ARDS in Japan, reported during the 2009 pandemic season. In conclusion, pathological and molecular biological examinations suggested that in the post-pandemic season A/H1N1pdm09 infection, the infection associated ARDS was not caused by direct infection-induced damage to the alveolar epithelial cells but was rather a result of indirect sepsis-mediated endothelial cell damage.
C1 [Hayashi, Kentaro; Sato, Yuko; Tobiume, Minoru; Hasegawa, Hideki; Nakajima, Noriko] Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan.
C1 [Hayashi, Kentaro; Ariyoshi, Koya] Nagasaki Univ, Inst Trop Med, Dept Clin Med, Nagasaki 8528523, Japan.
C1 [Yoshida, Hiroshi; Suzuki, Yoshio] Asahi Gen Hosp, Dept Pathol, Chiba 2892511, Japan.
C3 National Institute of Infectious Diseases (NIID); Nagasaki University
RP Nakajima, N (corresponding author), Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.
EM tenko@nih.go.jp
RI Hasegawa, Hideki/C-7978-2014; Yoshida, Hiroshi/J-2900-2019
FU MEXT KAKENHI [26460447]
FX We thank Drs. Noriyo Nagata, Tadaki Suzuki, and Tetsutaro Sata for their
   valuable discussions. This work was supported by MEXT KAKENHI Grant
   Number 26460447.
CR Belser JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025091
   Guarner J, 2006, CLIN INFECT DIS, V43, P132, DOI 10.1086/505122
   Kuroda M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010256
   Liem NT, 2008, JPN J INFECT DIS, V61, P157
   Liu Y, 2010, J VIROL, V84, P12069, DOI 10.1128/JVI.01639-10
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC
   Nakajima N, 2012, MODERN PATHOL, V25, P1, DOI 10.1038/modpathol.2011.125
   Nakajima N, 2010, JPN J INFECT DIS, V63, P67
   Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252
   Rao S, 2015, J CLIN VIROL, V71, P44, DOI 10.1016/j.jcv.2015.07.308
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
NR 13
TC 1
Z9 1
U1 0
U2 0
PU NATL INST INFECTIOUS DISEASES
PI TOKYO
PA JPN J INFECT DIS ED OFF NATL INST INFECTIOUS DISEASES TOYAMA 1-23-1,
   SHINJUKU-KU, TOKYO, 162-8640, JAPAN
SN 1344-6304
EI 1884-2836
J9 JPN J INFECT DIS
JI Jpn. J. Infect. Dis.
PD MAR
PY 2017
VL 70
IS 2
BP 197
EP 200
DI 10.7883/yoken.JJID.2016.120
PG 4
WC Infectious Diseases
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases
GA EQ8KX
UT WOS:000398335400015
PM 27357984
OA Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Huang, RT
   Wu, D
   Meliton, A
   Oh, MJ
   Krause, M
   Lloyd, JA
   Nigdelioglu, R
   Hamanaka, RB
   Jain, MK
   Birukova, A
   Kress, JP
   Birukov, KG
   Mutlu, GM
   Fang, Y
AF Huang, Ru-Ting
   Wu, David
   Meliton, Angelo Y.
   Oh, Myung-Jin
   Krause, Matthew
   Lloyd, Joyce A.
   Nigdelioglu, Recep
   Hamanaka, Robert B.
   Jain, Mukesh K.
   Birukova, Anna A.
   Kress, John P.
   Birukov, Konstantin G.
   Mutlu, Gokhan M.
   Fang, Yun
TI Experimental Lung Injury Reduces Kruppel-like Factor 2 to Increase
   Endothelial Permeability via Regulation of RAPGEF3-Rac1 Signaling
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE endothelial dysfunction; Rho/RhoA; GTPase; exchange factor directly activated by cyclic adenosine monophosphate; ALI/ARDS 
ID FLUID SHEAR-STRESS; TRANSCRIPTIONAL REGULATOR; DEPENDENT REGULATION;
   BARRIER ENHANCEMENT; SMALL GTPASES; KLF2; EPAC; FLOW; RAC;
   REORGANIZATION
AB Rationale: Acute respiratory distress syndrome (ARDS) is caused by widespread endothelial barrier disruption and uncontrolled cytokine storm. Genome-wide association studies (GWAS) have linked multiple genes to ARDS. Although mechanosensitive transcription factor Kruppel-like factor 2 (KLF2) is a major regulator of endothelial function, its role in regulating pulmonary vascular integrity in lung injury and ARDS-associated GWAS genes remains poorly understood.
   Objectives: To examine KLF2 expression in multiple animal models of acute lung injury and further elucidate the KLF2-mediated pathways involved in endothelial barrier disruption and cytokine storm in experimental lung injury.
   Methods: Animal and in vitro models of acute lung injury were used to characterize KLF2 expression and its downstream effects responding to influenza A virus (A/WSN/33 [H1N1]), tumor necrosis factor-alpha, LPS, mechanical stretch/ventilation, or microvascular flow. KLF2 manipulation, permeability measurements, small GTPase activity, luciferase assays, chromatin immunoprecipitation assays, and network analyses were used to determine the mechanistic roles of KLF2 in regulating endothelial monolayer integrity, ARDS-associated, GWAS genes, and lung pathophysiology.
   Measurements and Main Results: KLF2 is significantly reduced in several animal models of acute lung injury. Microvascular endothelial KLF2 is significantly induced by capillary flow but reduced by pathologic cyclic stretch and inflammatory stimuli. KLF2 is a novel activator of small GTPase Ras-related C3 botulinum toxin substrate 1 by transcriptionally controlling Rap guanine nucleotide exchange factor 3/exchange factor directly activated by cyclic adenosine monophosphate, which maintains vascular integrity. KLF2 regulates multiple ARDS GWAS genes related to cytokine storm, oxidation, and coagulation in lung microvascular endothelium. KLF2 overexpression ameliorates LPS-induced lung injury in mice.
   Conclusions: Disruption of endothelial KLF2 results in dysregulation of lung microvascular homeostasis and contributes to lung pathology in ARDS.
C1 [Huang, Ru-Ting; Wu, David; Meliton, Angelo; Oh, Myung-Jin; Krause, Matthew; Nigdelioglu, Recep; Hamanaka, Robert B.; Birukova, Anna; Kress, John P.; Birukov, Konstantin G.; Mutlu, Goekhan M.; Fang, Yun] Univ Chicago, Dept Med, Sect Pulm Crit Care, Chicago, IL 60637, United States.
C1 [Lloyd, Joyce A.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA, United States.
C1 [Jain, Mukesh K.] Case Western Reserve Univ, Case Cardiovasc Res Inst, Cleveland, OH 44106, United States.
C3 University of Chicago; Virginia Commonwealth University; Case Western
   Reserve University
RP Fang, Y (corresponding author), 5841 South Maryland Ave,MC 6026,Off M628, Chicago, IL 60637 USA.
EM yfang1@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022; Mutlu, Gokhan/HIR-2545-2022
OI Wu, David/0000-0003-3162-3238; Huang, Ru-Ting/0000-0001-8360-9994
FU National Institutes of Health [HL103789, ES015024, R21 ES025644,
   HL87823, HL107920, HL130431, GM114171, T32 HL007381, T32 HL007605];
   American Heart Association [BGIA7080012]
FX Supported by National Institutes of Health grants HL103789 (Y.F.),
   ES015024 (G.M.M.), R21 ES025644 (G.M.M.), HL87823 (K.G.B.), HL107920
   (A.B.), HL130431 (A.B.), GM114171 (A.B.), T32 HL007381 (M.-J.O.), and
   T32 HL007605 (D.W.); and the American Heart Association (BGIA7080012,
   Y.F.).
CR Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141
   ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957
   Atkins GB, 2007, CIRC RES, V100, P1686, DOI 10.1161/01.RES.0000267856.00713.0a
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Chiplunkar AR, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471-213X-13-40
   Civelek M, 2014, NAT REV GENET, V15, P34, DOI 10.1038/nrg3575
   De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC
   de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884
   Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046
   Dekker RJ, 2006, BLOOD, V107, P4354, DOI 10.1182/blood-2005-08-3465
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fang Y, 2012, ARTERIOSCL THROM VAS, V32, P979, DOI 10.1161/ATVBAHA.111.244053
   Gao L, 2009, AM J PHYSIOL-LUNG C, V296, pL713, DOI 10.1152/ajplung.90269.2008
   Hudlicka O, 2006, MICROCIRCULATION, V13, P249, DOI 10.1080/10739680600556951
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005
   Kuo CH, 2014, J MATER CHEM B, V2, P8142, DOI 10.1039/c4tb00977k
   Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996
   Lezoualc'h F, 2016, CIRC RES, V118, P881, DOI 10.1161/CIRCRESAHA.115.306529
   Lin ZY, 2010, ARTERIOSCL THROM VAS, V30, P1952, DOI 10.1161/ATVBAHA.110.211474
   Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1
   London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678
   Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Nayak L, 2013, AM J PATHOL, V182, P1696, DOI 10.1016/j.ajpath.2013.01.029
   Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787
   Perlman CE, 2007, J APPL PHYSIOL, V103, P1037, DOI 10.1152/japplphysiol.00160.2007
   Radigan KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108138
   Reddy AJ, 2009, PHARMACOGENOMICS, V10, P1527, DOI 10.2217/PGS.09.89
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132
   Shi H, 2013, AM J PHYSIOL-HEART C, V304, pH796, DOI 10.1152/ajpheart.00712.2012
   Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Su G, 2012, AM J RESP CRIT CARE, V185, P58, DOI 10.1164/rccm.201108-1381OC
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Thi MM, 2004, P NATL ACAD SCI USA, V101, P16483, DOI 10.1073/pnas.0407474101
   Tzima E, 2006, CIRC RES, V98, P176, DOI 10.1161/01.RES.0000200162.94463.d7
   Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843
   Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weed SA, 1998, J CELL SCI, V111, P2433
   Wu CQ, 2015, CIRC RES, V117, pE41, DOI 10.1161/CIRCRESAHA.117.306457
   Wu DD, 2016, AM J RESP CRIT CARE, V193
   Wu W, 2011, CIRCULATION, V124, P633, DOI 10.1161/CIRCULATIONAHA.110.005108
NR 52
TC 42
Z9 43
U1 2
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAR 1
PY 2017
VL 195
IS 5
BP 639
EP 651
DI 10.1164/rccm.201604-0668OC
PG 13
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA EM5ND
UT WOS:000395357400014
PM 27855271
OA Green Published
DA 2023-08-21
ER

PT J
AU Letsiou, E
   Sammani, S
   Wang, HS
   Belvitch, P
   Dudek, SM
AF Letsiou, Eleftheria
   Sammani, Saad
   Wang, Huashan
   Belvitch, Patrick
   Dudek, Steven M.
TI Parkin regulates lipopolysaccharide-induced proinflammatory responses in
   acute lung injury
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID FACTOR-KAPPA-B; MEDIATED TYROSINE PHOSPHORYLATION; VASCULAR LEAK;
   MITOPHAGY; INFLAMMATION; ASSOCIATION; DYSFUNCTION; IMATINIB; SEPSIS;
   ACTIVATION
AB The acute respiratory distress syndrome (ARDS) is a serious condition resulting from direct or indirect lung injury that is associated with high mortality and morbidity. A key biological event in the pathogenesis of the acute lung injury (ALI) that causes acute respiratory distress syndrome is activation of the lung endothelium cells (ECs), which is triggered by a variety of inflammatory insults leading to barrier disruption and excessive accumulation of neutrophils. Recently, we demonstrated that imatinib protects against lipopolysaccharide (LPS)-induced EC activation by inhibiting c-Abl kinase. In the present study, we explored the role of parkin, a novel c-Abl substrate, in ALI. Parkin is an E3 ubiquitin ligase originally characterized in the pathogenesis of Parkinson disease; however, its potential role in acute inflammatory processes and lung EC function remains largely unknown. Using parkin deficient (PARK2-/-) mice, we now demonstrate that parkin mediates LPS-induced ALI. After LPS, PARK2-/- mice have reduced total protein and cell levels in bronchoalveolar lavage (BAL) compared to wild type. Moreover, in LPS-treated PARK2-/- lungs, the sequestration and activation of neutrophils and release of inflammatory cytokines (interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha)) are significantly reduced. The BAL levels of soluble VCAM-1 and ICAM- I are also decreased in LPS-treated PARK2-/- mice compared to wild type. In cultured human lung endothelial cells, downregulation of parkin by small interfering RNA decreases LPS-induced VCAM- I expression, IL-8 and IL-6 secretion, and NF-kappa B phosphorylation. These results suggest a previously unidentified role of parkin in mediating endotoxin-induced endothelial proinflammatory signaling and indicate that it may play a critical role in acute inflammation.
C1 Univ Illinois, Div Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C1 Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ 85721, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona Health Sciences
RP Letsiou, E (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, COMRB, Room 3160, Chicago, IL 60612 USA.
EM eletsiou@gmail.com
FU American Heart Association Postdoctoral fellowship [13POST17110042]
FX Eleftheria Letsiou was supported by an American Heart Association
   Postdoctoral fellowship (13POST17110042).
CR Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Attia EF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149687
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bouman L, 2011, CELL DEATH DIFFER, V18, P769, DOI 10.1038/cdd.2010.142
   Calfee C, 2009, INTENS CARE MED, V35, P248, DOI 10.1007/s00134-008-1235-0
   Chen BB, 2014, CELL REP, V7, P476, DOI 10.1016/j.celrep.2014.02.048
   Chian CF, 2014, TRANSL RES, V163, P211, DOI 10.1016/j.trsl.2013.10.002
   Chislock EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085231
   de Leseleuc L, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002015
   deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885
   Elliott CL, 2001, MOL HUM REPROD, V7, P787, DOI 10.1093/molehr/7.8.787
   Fu PF, 2015, AM J PHYSIOL-LUNG C, V308, pL1025, DOI 10.1152/ajplung.00306.2014
   Henn IH, 2007, J NEUROSCI, V27, P1868, DOI 10.1523/JNEUROSCI.5537-06.2007
   Imam SZ, 2011, J NEUROSCI, V31, P157, DOI 10.1523/JNEUROSCI.1833-10.2011
   Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849
   Kim IK, 2013, CRIT CARE, V17, DOI 10.1186/cc12786
   Ko HS, 2010, P NATL ACAD SCI USA, V107, P16691, DOI 10.1073/pnas.1006083107
   Larson-Casey JL, 2016, IMMUNITY, V44, P582, DOI 10.1016/j.immuni.2016.01.001
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Letsiou E, 2015, AM J RESP CELL MOL, V52, P193, DOI 10.1165/rcmb.2013-0347OC
   Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005
   Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Mannam P, 2014, AM J PHYSIOL-LUNG C, V306, pL604, DOI 10.1152/ajplung.00272.2013
   Manning AM, 1995, J INFLAMM, V45, P283
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Moore DJ, 2006, BIOCHEM SOC T, V34, P749, DOI 10.1042/BST0340749
   Moreno-Vinasco L, 2014, AM J RESP CELL MOL, V51, P223, DOI 10.1165/rcmb.2012-0519OC
   Piquereau J, 2013, AUTOPHAGY, V9, P1837, DOI 10.4161/auto.26502
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Rizzo AN, 2015, ARTERIOSCL THROM VAS, V35, P1071, DOI 10.1161/ATVBAHA.115.305085
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Seirafi M, 2015, FEBS J, V282, P2076, DOI 10.1111/febs.13249
   Shapiro NI, 2010, CRIT CARE, V14, DOI 10.1186/cc9290
   Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060
   Singleton PA, 2009, J BIOL CHEM, V284, P34964, DOI 10.1074/jbc.M109.013771
   Standiford TJ, 2016, TRANSL RES, V167, P183, DOI 10.1016/j.trsl.2015.04.015
   Stephens RS, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12589
   Stephens RS, 2014, AM J PHYSIOL-CELL PH, V306, pC559, DOI 10.1152/ajpcell.00375.2012
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tanaka A, 2010, FEBS LETT, V584, P1386, DOI 10.1016/j.febslet.2010.02.060
   Tong HB, 2013, J LEUKOCYTE BIOL, V93, P611, DOI 10.1189/jlb.1012487
   Tran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023660
   Williams JA, 2015, PHARMACOL RES, V102, P264, DOI 10.1016/j.phrs.2015.09.020
   Xu L, 2014, J MOL MED, V92, P31, DOI 10.1007/s00109-013-1107-0
   Zanon A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078648
   Zhang XC, 2014, AM J PATHOL, V184, P2730, DOI 10.1016/j.ajpath.2014.06.017
   Zhang Y, 2014, J IMMUNOL, V192, P5296, DOI 10.4049/jimmunol.1400653
   Zhao J, 2015, TRANSL RES, V166, P80, DOI 10.1016/j.trsl.2015.01.008
NR 50
TC 27
Z9 29
U1 5
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1931-5244
EI 1878-1810
J9 TRANSL RES
JI Transl. Res.
PD MAR
PY 2017
VL 181
BP 71
EP 82
DI 10.1016/j.trsl.2016.09.002
PG 12
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA EP4LZ
UT WOS:000397353300006
PM 27693468
DA 2023-08-21
ER

PT J
AU Palumbo, S
   Shin, YJ
   Ahmad, K
   Desai, AA
   Quijada, H
   Mohamed, M
   Knox, A
   Sammani, S
   Colson, BA
   Wang, T
   Garcia, JGN
   Hecker, L
AF Palumbo, Sunmi
   Shin, Yoon-Joo
   Ahmad, Kareem
   Desai, Ankit A.
   Quijada, Hector
   Mohamed, Mohamed
   Knox, Adam
   Sammani, Saad
   Colson, Brett A.
   Wang, Ting
   Garcia, Joe G. N.
   Hecker, Louise
TI Dysregulated Nox4 ubiquitination contributes to redox imbalance and
   age-related severity of acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE senescence; oxidative stress; NOX/NOX1/NOX2/NOX4; ROS 
ID SPHINGOSINE 1-PHOSPHATE; MECHANICAL VENTILATION; NADPH OXIDASE-4;
   LIPOPOLYSACCHARIDE; EXPRESSION; RESPONSES; ENDOTHELIUM; ACTIVATION;
   SENESCENCE; MODEL
AB Acute respiratory distress syndrome (ARDS) is a devastating critical illness disproportionately affecting the elderly population, with both higher incidence and mortality. The integrity of the lung endothelial cell (EC) monolayer is critical for preservation of lung function. However, mechanisms mediating EC barrier regulation in the context of aging remain unclear. We assessed the severity of acute lung injury (ALI) in young (2 mo) and aged (18 mo) mice using a two-hit preclinical model. Compared with young cohorts, aged mice exhibited increased ALI severity, with greater vascular permeability characterized by elevated albumin influx and levels of bronchoalveolar lavage (BAL) cells (neutrophils) and protein. Aged/injured mice also demonstrated elevated levels of reactive oxygen species (ROS) in the BAL, which was associated with upregulation of the ROS-generating enzyme, Nox4. We evaluated the role of aging in human lung EC barrier regulation utilizing a cellular model of replicative senescence. Senescent EC populations were defined by increases in beta-galactosidase activity and p16 levels. In response to lipopolysaccharide (LPS) challenge, senescent ECs demonstrate exacerbated permeability responses compared with control "young" ECs. LPS challenge led to a rapid induction of Nox4 expression in both control and senescent ECs, which was posttranslationally mediated via the proteasome/ubiquitin system. However, senescent ECs demonstrated deficient Nox4 ubiquitination, resulting in sustained expression of Nox4 and alterations in cellular redox homeostasis. Pharmacological inhibition of Nox4 in senescent ECs reduced LPS-induced alterations in permeability. These studies provide insight into the roles of Nox4/senescence in EC barrier responses and offer a mechanistic link to the increased incidence and mortality of ARDS associated with aging.
C1 [Palumbo, Sunmi; Shin, Yoon-Joo; Ahmad, Kareem; Desai, Ankit A.; Quijada, Hector; Mohamed, Mohamed; Knox, Adam; Sammani, Saad; Colson, Brett A.; Wang, Ting; Garcia, Joe G. N.; Hecker, Louise] Univ Arizona, Coll Med, Tucson, AZ, United States.
C1 [Hecker, Louise] Southern Arizona VA Hlth Care Syst SAVAHCS, Tucson, AZ, United States.
C3 University of Arizona; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Southern Arizona Veterans Affairs Health
   Care System
RP Hecker, L (corresponding author), Univ Arizona Hlth Sci, Div Pulm Allergy & Crit Care & Sleep Med, Dept Med, 1656 E,Mabel St,Room 416, Tucson, AZ 85724 USA.
EM lhecker@email.arizona.edu
RI Garcia, Joe GN/E-8862-2010
OI Desai, Ankit/0000-0001-6427-616X
FU Veterans Administration Health System grant [1IK2BX001477]; National
   Institutes of Health (NIH) grant [P01HL126609-01A1]; NIH/NHLBI grant
   [R25HL108837]; Short-Term Training to Increase the Diversity Pipeline in
   Heart/Lung/Blood Research
FX This work was supported by the Veterans Administration Health System
   grant 1IK2BX001477 (L. Hecker) and National Institutes of Health (NIH)
   grant P01HL126609-01A1 (J. Garcia). Salary support for M. Mohamed was
   provided by NIH/NHLBI grant no. R25HL108837, "Short-Term Training to
   Increase the Diversity Pipeline in Heart/Lung/Blood Research."
CR Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70
   Al Ghouleh I, 2008, SHOCK, V29, P553, DOI [10.1097/SHK.0b013e318157ebc8, 10.1097/SHK.0b013e318157cbc8]
   Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174
   Carnesecchi S, 2012, CELL MOL LIFE SCI, V69, P2373, DOI 10.1007/s00018-012-1013-6
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Cherpanath TGV, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0123-8
   Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010
   Cristofalo VJ, 2003, J GERONTOL A-BIOL, V58, P776
   Desai LP, 2014, J BIOL CHEM, V289, P18270, DOI 10.1074/jbc.M114.562249
   Dessap AM, 2012, AM J RESP CELL MOL, V46, P541, DOI 10.1165/rcmb.2011-0306OC
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Goldman JL, 2014, PULM CIRC, V4, P280, DOI 10.1086/675991
   Hecker L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008182
   Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Hood ED, 2012, J CONTROL RELEASE, V163, P161, DOI 10.1016/j.jconrel.2012.08.031
   Koay MA, 2001, INFECT IMMUN, V69, P5991, DOI 10.1128/IAI.69.10.5991-5996.2001
   Krouwer VJD, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-12
   Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Matthay MA, 1999, CRIT CARE MED, V27, P2028, DOI 10.1097/00003246-199909000-00055
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Metnitz PGH, 1999, INTENS CARE MED, V25, P180, DOI 10.1007/s001340050813
   Moitra J, 2008, TRANSL RES, V151, P141, DOI 10.1016/j.trsl.2007.12.008
   Nanthakumar CB, 2015, NAT REV DRUG DISCOV, V14, P693, DOI 10.1038/nrd4592
   Park HS, 2006, CARDIOVASC RES, V72, P447, DOI 10.1016/j.cardiores.2006.09.012
   Pendyala S, 2009, ANTIOXID REDOX SIGN, V11, P747, DOI [10.1089/ars.2008.2203, 10.1089/ARS.2008.2203]
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Reddy SP, 2007, ANTIOXID REDOX SIGN, V9, P2003, DOI 10.1089/ars.2007.1770
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Smith LS, 2010, AM J RESP CELL MOL, V43, P475, DOI 10.1165/rcmb.2009-0039OC
   Tasaka S, 2008, ANTIOXID REDOX SIGN, V10, P739, DOI 10.1089/ars.2007.1940
   Thannickal VJ, 2014, J CLIN INVEST, V124, P4673, DOI 10.1172/JCI74368
   Vadasz I, 2012, CHEST, V141, P763, DOI 10.1378/chest.11-1660
   Van Buul JD, 2005, ANTIOXID REDOX SIGN, V7, P308, DOI 10.1089/ars.2005.7.308
   Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388
   Wilson JN, 2001, HEART LUNG, V30, P370, DOI 10.1067/mhl.2001.118298
   Xiang LS, 2014, AM J PHYSIOL-HEART C, V306, pH684, DOI 10.1152/ajpheart.00868.2013
   Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851
   Zhang Y, 2016, ACTA ANAESTH SCAND, V60, P780, DOI 10.1111/aas.12691
NR 49
TC 27
Z9 29
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAR
PY 2017
VL 312
IS 3
BP 1297
EP 1308
DI 10.1152/ajplung.00305.2016
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA EN1AQ
UT WOS:000395743000001
PM 28062482
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Yu, Y
   Jing, LH
   Zhang, XY
   Gao, CJ
AF Yu, Yang
   Jing, Lihong
   Zhang, Xiangyu
   Gao, Chengjin
TI Simvastatin Attenuates Acute Lung Injury via Regulating CDC42-PAK4 and
   Endothelial Microparticles
SO SHOCK
LA English
DT Article
DE ALI/ARDS; endothelial microparticles; simvastatin 
ID INFLAMMATORY RESPONSES; HEMORRHAGIC-SHOCK; PROGENITOR CELLS; DAMAGE;
   INHIBITION; EXPRESSION; INTEGRITY; ALPHA
AB Background:Simvastatin has lung vascular-protective effects via augmentation of endothelial barrier function. Accordingly, on the basis of our previous study, we hypothesized that endothelial cell (EC) protection by simvastatin is dependent on the stabilization on cytoskeletons.Methods:Sixty C57BL/6 mice were divided into two experimental groups: lipopolysaccharide (LPS) group (L group) and LPS+simvastatin treated group (L+S group). All mice in these two groups received an intraperitoneal injection of LPS (10mg/kg/d). Simvastatin was administered intraperitoneally immediately after the LPS injection in animals of the L+S group at a dose of 20mg/kg/day. Lung injury degree and the protective effects of simvastatin against LPS-induced lung injury were assessed at the time-points of 24, 48, and 72h postinjection. Serum alanine transaminase (ALT), serum creatinine (Scr) were identified to assess the hepatic and renal side-effects of simvastatin.Results:LPS inhibited the cytoskeletal regulating proteins of Cdc42 and PAK4, and was accompanied by an increased circulating endothelial microparticles (EMPs) level. The adherent junction (AJ) protein of VE-cadherin was also decreased by LPS, and was accompanied by a thickening alveolar wall, increased lung W/D values, and high albumin concentration in bronchoalveolar lavage. Protective effects of simvastatin against LPS-induced lung injury were illustrated by regulating and stabilizing cytoskeletons, as well as intercellular AJs. The values of ALT and Scr were all lower than the common upper limits according to assay kits.Conclusion:An increased serous EMP level associated with Cdc42-PAK4 can be deemed as a useful pulmonary injury marker in LPS-treated mice, and our results might be more relevant in guiding the clinical treatment of ALI by intervening Cdc42-PAK4 or EMPs.
C1 [Yu, Yang; Gao, Chengjin] Shanghai Jiao Tong Univ, Emergency Dept, Xinhua Hosp, Sch Med, Shanghai, China.
C1 [Jing, Lihong] Qingdao Univ, Emergency Dept, Affiliated Hosp, Qingdao, Shandong, China.
C1 [Zhang, Xiangyu] Tongji Univ, Sch Med, Dept Crit Care Med, Shanghai Peoples Hosp 10, Shanghai, China.
C3 Shanghai Jiao Tong University; Qingdao University; Tongji University
RP Gao, CJ (corresponding author), 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
EM chengjingao2003@163.com
OI Gao, Chengjin/0000-0002-6867-8024
FU Shanghai Education Committee Foundation [15ZZ021]; Shanghai Science and
   Technology Committee Foundation [15ZR1433100]; Shanghai Talents
   Development Foundation [201563]; Xinjiang Science and Technology Bureau
   Foundation [2015211C211]
FX This study was funded by the Shanghai Education Committee Foundation
   (No.15ZZ021), the Shanghai Science and Technology Committee Foundation
   (No.15ZR1433100), the Shanghai Talents Development Foundation
   (No.201563), and the Xinjiang Science and Technology Bureau Foundation
   (No.2015211C211).
CR Arpino V, 2016, AM J PHYSIOL-HEART C, V310, pH1455, DOI 10.1152/ajpheart.00796.2015
   Chen WG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16529
   Chen WG, 2014, AM J RESP CELL MOL, V50, P328, DOI 10.1165/rcmb.2013-0058OC
   Gao CJ, 2012, J TRAUMA ACUTE CARE, V73, P1152, DOI 10.1097/TA.0b013e318265d04b
   Gao CJ, 2012, J TRAUMA ACUTE CARE, V72, P150, DOI 10.1097/TA.0b013e318230e25d
   Gao CJ, 2011, J TRAUMA, V70, P210, DOI 10.1097/TA.0b013e3181e7432d
   Gordon C, 2011, AM J RESP CRIT CARE, V184, P224, DOI 10.1164/rccm.201012-2061OC
   Gu CP, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0217-3
   Hoogendijk AJ, 2012, SHOCK, V38, P375, DOI 10.1097/SHK.0b013e3182656e7b
   Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC
   Kohama K, 2015, SURGERY, V158, P399, DOI 10.1016/j.surg.2015.03.038
   Lagoa CE, 2005, HEPATOLOGY, V42, P390, DOI 10.1002/hep.20797
   Li H, 2013, CHEST, V144, P876, DOI 10.1378/chest.12-2429
   Patil R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081407
   Seynhaeve ALB, 2014, SURGERY, V155, P545, DOI 10.1016/j.surg.2013.10.019
   Thomashow MA, 2013, AM J RESP CRIT CARE, V188, P60, DOI 10.1164/rccm.201209-1697OC
   Tian YF, 2016, J BIOL CHEM, V291, P10032, DOI 10.1074/jbc.M115.690487
   Wang HQ, 2015, BURNS, V41, P1235, DOI 10.1016/j.burns.2015.02.010
   Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707
   Woods SJ, 2015, AM J PHYSIOL-LUNG C, V308, pL912, DOI 10.1152/ajplung.00048.2015
   Wu SY, 2014, AM J CLIN NUTR, V100, P1232, DOI 10.3945/ajcn.114.088880
   Xu SY, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0364-1
   Zhou ZC, 2016, CELL PHYSIOL BIOCHEM, V38, P258, DOI 10.1159/000438627
NR 23
TC 44
Z9 56
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD MAR
PY 2017
VL 47
IS 3
BP 378
EP 384
DI 10.1097/SHK.0000000000000723
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA EM7UI
UT WOS:000395517400017
PM 27513084
DA 2023-08-21
ER

PT J
AU Ding, RY
   Zhao, DM
   Li, XX
   Liu, BY
   Ma, XC
AF Ding, Renyu
   Zhao, Dongmei
   Li, Xiaoxia
   Liu, Baoyan
   Ma, Xiaochun
TI Rho-kinase inhibitor treatment prevents pulmonary inflammation and
   coagulation in lipopolysaccharide-induced lung injury
SO THROMBOSIS RESEARCH
LA English
DT Article
DE Rho/RhoA; LPS; ALI/ARDS; NF-kappa B; Inflammation; coagulation 
ID RESPIRATORY-DISTRESS-SYNDROME; FACTOR-KAPPA-B; HUMAN ENDOTHELIAL-CELLS;
   INDUCED TISSUE FACTOR; NUCLEAR FACTOR-KB; ALVEOLAR COAGULATION;
   RHO/RHO-KINASE; EXPRESSION; ACTIVATION; FIBRINOLYSIS
AB Introduction: In the pathogenesis of sepsis-induced acute lung injury (ALI), the crosstalk between inflammation and coagulation plays a pivotal role. The aim of this studywas to investigate the role of Rho kinase (ROCK) inhibitor in alleviating pulmonary inflammation and coagulation in lipopolysaccharide (LPS)-induced acute lung injury (ALI) models.
   Methods: In the in vivo study, mice were randomized to four different groups: Control, Y-27632 (Y), LPS, and LPS + Y-27632 (LPS + Y). ALI was induced by intranasally administering LPS (10 mu g in 50 mu L PBS). Y- 27632 (10 mg/kg body weight,) was injected intraperitoneally at 18 h and 1 h before LPS challenge. Mice were euthanized at 3 h or 8 h post LPS challenge (N = 8 per group). In the in vitro study, human pulmonary microvascular endothelial cells (HPMECs) were incubated with LPS alone (1 mu g/mL) or in combination with 10 mu M Y- 27632 or 50 mu M BAY11-7082. Cells were pretreated with the inhibitors 30 min before exposure to LPS. Three hours later, cells were isolated for subsequent analysis.
   Results: The myeloperoxidase (MPO) activity and fibrinogen deposits in the lung tissue significantly decreased and the lung damage in ALI mouse was attenuated. Pretreatment with Y- 27632 markedly reduced the LPS-induced expression of interleukins 1 beta and 6, and the activation of nuclear factor (NF)-kappa B. Furthermore, ROCK inhibitor treatment antagonized the expression of tissue factor (TF) and plasminogen activator inhibitor (PAI)-1 in lung tissue and HPMECs.
   Conclusions: ROCK inhibition protects against the endotoxin-induced pulmonary inflammation and coagulation via NF-kappaB pathway modulation. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Ding, Renyu; Zhao, Dongmei; Li, Xiaoxia; Liu, Baoyan; Ma, Xiaochun] China Med Univ, Hosp 1, Dept Intens Care Unit, Bei St 155, Nanjing 110001, Liaoning, China.
RP Ding, RY; Ma, XC (corresponding author), China Med Univ, Hosp 1, Dept Intens Care Unit, Bei St 155, Nanjing 110001, Liaoning, Peoples R China.
EM renyuding@126.com; xcma2972@sina.com
RI li, xiao/HKV-8405-2023; li, jian/IAQ-2794-2023
FU National Natural Science Foundation of China [81201484, 81100708];
   Natural Science Foundation of Liaoning Province of China [201602819]
FX The research was supported by grants from the National Natural Science
   Foundation of China ( NO. 81201484 and NO. 81100708) and the Natural
   Science Foundation of Liaoning Province of China (201602819).
CR Abraham E, 2000, AM J RESP CELL MOL, V22, P401, DOI 10.1165/ajrcmb.22.4.f184
   Abraham E, 2006, J IMMUNOL, V176, P7753, DOI 10.4049/jimmunol.176.12.7753
   Bao WK, 2004, CARDIOVASC RES, V61, P548, DOI 10.1016/j.cardiores.2003.12.004
   Bastarache JA, 2006, SEMIN RESP CRIT CARE, V27, P365, DOI 10.1055/s-2006-948290
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   DAWSON SJ, 1993, J BIOL CHEM, V268, P10739
   Ding RY, 2011, J SURG RES, V171, pE209, DOI 10.1016/j.jss.2011.08.009
   Ding RY, 2011, THROMB RES, V128, pE160, DOI 10.1016/j.thromres.2011.07.044
   dos Santos CC, 2000, INTENS CARE MED, V26, P638, DOI 10.1007/s001340051217
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   Funakoshi Y, 2001, HYPERTENSION, V38, P100, DOI 10.1161/01.HYP.38.1.100
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hofstra JJH, 2008, CURR MED CHEM, V15, P588, DOI 10.2174/092986708783769696
   Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Iwasaki H, 2008, ATHEROSCLEROSIS, V196, P22, DOI 10.1016/j.atherosclerosis.2006.12.025
   Liao MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056331
   Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005
   Maruyama K, 2012, THROMB RES, V130, pE188, DOI 10.1016/j.thromres.2012.07.002
   McGown CC, 2011, MICROVASC RES, V81, P281, DOI 10.1016/j.mvr.2011.02.003
   Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779
   Nagata K, 2002, ATHEROSCLEROSIS, V163, P39, DOI 10.1016/S0021-9150(01)00750-X
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463
   Rau CS, 2014, TOXICOL SCI, V140, P315, DOI 10.1093/toxsci/kfu097
   REUNING U, 1995, NUCLEIC ACIDS RES, V23, P3887, DOI 10.1093/nar/23.19.3887
   Rikitake Y, 2005, CIRCULATION, V111, P3261, DOI 10.1161/CIRCULATIONAHA.105.534024
   Ruan QR, 2001, J VASC RES, V38, P13, DOI 10.1159/000051025
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schultz MJ, 2006, CRIT CARE MED, V34, P871, DOI [10.1097/01.CCM.0000201882.23917.B8, 10.1097/01.CCM.0000202136.91651.34]
   Sebag SC, 2011, CURR PHARM BIOTECHNO, V12, P1481
   Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X
   Shatanawi A, 2011, AM J PHYSIOL-CELL PH, V300, pC1181, DOI 10.1152/ajpcell.00328.2010
   Shimizu S, 2007, MOL HUM REPROD, V13, P181, DOI 10.1093/molehr/gal113
   Speyer CL, 2003, AM J PATHOL, V163, P2319, DOI 10.1016/S0002-9440(10)63588-2
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Thorlacius K, 2006, J LEUKOCYTE BIOL, V79, P923, DOI 10.1189/jlb.0705406
   Villar J, 2014, CURR OPIN CRIT CARE, V20, P3, DOI 10.1097/MCC.0000000000000057
   Wang YZ, 2015, BIOCHEM BIOPH RES CO, V460, P691, DOI 10.1016/j.bbrc.2015.03.091
   Wang ZY, 2013, CHINESE MED J-PEKING, V126, P318, DOI 10.3760/cma.j.issn.0366-6999.20121412
   Ware Lorraine B., 2005, Keio Journal of Medicine, V54, P142, DOI 10.2302/kjm.54.142
   Welty-Wolf KE, 2002, THROMB HAEMOSTASIS, V88, P17
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wolthuis EK, 2009, CRIT CARE, V13, DOI 10.1186/cc7688
   Wygrecka M, 2008, THROMB HAEMOSTASIS, V99, P494, DOI 10.1160/TH07-11-0666
   Xin HY, 2007, THROMB HAEMOSTASIS, V97, P830, DOI 10.1160/TH06-11-0656
NR 46
TC 18
Z9 21
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD FEB
PY 2017
VL 150
BP 59
EP 64
DI 10.1016/j.thromres.2016.12.020
PG 6
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA EO9YY
UT WOS:000397045200011
PM 28043040
DA 2023-08-21
ER

PT J
AU Belvitch, P
   Brown, ME
   Brinley, BN
   Letsiou, E
   Rizzo, AN
   Garcia, JGN
   Dudek, SM
AF Belvitch, Patrick
   Brown, Mary E.
   Brinley, Brittany N.
   Letsiou, Eleftheria
   Rizzo, Alicia N.
   Garcia, Joe G. N.
   Dudek, Steven M.
TI The ARP 2/3 complex mediates endothelial barrier function and recovery
SO PULMONARY CIRCULATION
LA English
DT Article
DE ALI/ARDS; Arp 2/3; endothelial barrier regulation; cytoskeletal dynamics; lamellipodia 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; SPHINGOSINE
   1-PHOSPHATE; DYNAMIC ACTIN; VASCULAR LEAK; CORTACTIN; INFLAMMATION;
   PERMEABILITY; ACTIVATION; ENHANCEMENT
AB Pulmonary endothelial cell (EC) barrier dysfunction and recovery is critical to the pathophysiology of acute respiratory distress syndrome. Cytoskeletal and subsequent cell membrane dynamics play a key mechanistic role in determination of EC barrier integrity. Here, we characterizAQe the actin related protein 2/3 (Arp 2/3) complex, a regulator of peripheral branched actin polymerization, in human pulmonary EC barrier function through studies of transendothelial electrical resistance (TER), intercellular gap formation, peripheral cytoskeletal structures and lamellipodia. Compared to control, Arp 2/3 inhibition with the small molecule inhibitor CK-666 results in a reduction of baseline barrier function (1,241 +/- 53 vs 988 +/- 64 ohm; p < 0.01), S1P-induced barrier enhancement and delayed recovery of barrier function after thrombin (143 +/- 14 vs 93 +/- 6 min; p < 0.01). Functional changes of Arp 2/3 inhibition on barrier integrity are associated temporally with increased intercellular gap area at baseline (0.456 +/- 0.02 vs 0.299 +/- 0.02; p < 0.05) and thirty minutes after thrombin (0.885 +/- 0.03 vs 0.754 +/- 0.03; p < 0.05). Immunofluorescent microscopy reveals reduced lamellipodia formation after S1P and during thrombin recovery in Arp 2/3 inhibited cells. Individual lamellipodia demonstrate reduced depth following Arp 2/3 inhibition vs vehicle at baseline (1.83 +/- 0.41 vs 2.55 +/- 0.46 mm; p < 0.05) and thirty minutes after S1P treatment (1.53 +/- 0.37 vs 2.09 +/- 0.36 mm; p < 0.05). These results establish a critical role for Arp 2/3 activity in determination of pulmonary endothelial barrier function and recovery through formation of EC lamellipodia and closure of intercellular gaps.
C1 [Belvitch, Patrick; Brown, Mary E.; Letsiou, Eleftheria; Rizzo, Alicia N.; Dudek, Steven M.] Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, 840 South Wood St,MC 719,Room 920-N CSB, Chicago, IL 60612, United States.
C1 [Brinley, Brittany N.] Mercy Hosp & Med Ctr, Chicago, IL, United States.
C1 [Garcia, Joe G. N.] Univ Arizona, Hlth Sci Ctr, Tucson, AZ, United States.
C3 University of Arizona; University of Arizona Health Sciences
RP Belvitch, P (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, 840 South Wood St,MC 719,Room 920-N CSB, Chicago, IL 60612 USA.
EM pbelvitc@uic.edu
RI Garcia, Joe GN/E-8862-2010
FU American Lung Association [RG-349765]; National Institutes of Health
   [HL058064, HL088144]
FX This work was supported by American Lung Association Award RG-349765
   (PB) and National Institutes of Health grants HL058064 (JGNG) and
   HL088144 (SD).
CR ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4
   Abu Taha A, 2014, CELL ADHES MIGR, V8, P125, DOI 10.4161/cam.28243
   Abu Taha A, 2014, MOL BIOL CELL, V25, P245, DOI 10.1091/mbc.E13-07-0404
   Adam AP, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/272858
   Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Belvitch P, 2012, MICROVASC RES, V83, P22, DOI 10.1016/j.mvr.2011.08.012
   Bice T, 2013, SEMIN RESP CRIT CARE, V34, P529, DOI 10.1055/s-0033-1351125
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Breslin JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117970
   Brown M, 2010, MICROVASC RES, V80, P75, DOI 10.1016/j.mvr.2009.12.010
   Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043
   Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454
   Carman CV, 2003, J IMMUNOL, V171, P6135, DOI 10.4049/jimmunol.171.11.6135
   Chavez A, 2011, INT REV CEL MOL BIO, V290, P205, DOI 10.1016/B978-0-12-386037-8.00001-6
   Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110
   Choi S, 2015, AM J PHYSIOL-LUNG C, V309, pL983, DOI 10.1152/ajplung.00062.2015
   Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006
   Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737
   DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Fanelli Vito, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS3, DOI 10.1513/AnnalsATS.201407-340MG
   Fu PF, 2009, TRANSL RES, V153, P166, DOI 10.1016/j.trsl.2008.12.005
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1995, J INVEST MED, V43, P117
   Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025
   Goldenberg NM, 2015, COMPR PHYSIOL, V5, P531, DOI 10.1002/cphy.c140024
   Gonzales JN, 2014, AM J PHYSIOL-LUNG C, V306, pL497, DOI 10.1152/ajplung.00086.2013
   Han SP, 2014, J BIOL CHEM, V289, P7764, DOI 10.1074/jbc.M113.544478
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8
   Hetrick B, 2013, CHEM BIOL, V20, P701, DOI 10.1016/j.chembiol.2013.03.019
   Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649
   Huang L, 2015, CELL MOL BIOENG, V8, P160, DOI 10.1007/s12195-014-0370-7
   Isac L, 2011, ANAL BIOANAL CHEM, V399, P2351, DOI 10.1007/s00216-010-3978-z
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kelley LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013847
   Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6
   Lechler T, 2014, TISSUE BARRIERS, V2, DOI 10.4161/21688362.2014.944445
   Lee J.H., 2006, RES J MICROBIOL, V1, P1, DOI DOI 10.1007/S00418-006-0143-Z
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Li YS, 2004, EXP CELL RES, V298, P107, DOI 10.1016/j.yexcr.2004.03.023
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McDonald DM, 1999, MICROCIRCULATION, V6, P7
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   Mooren OL, 2014, MOL BIOL CELL, V25, P4115, DOI 10.1091/mbc.E14-05-0976
   Nolen BJ, 2009, NATURE, V460, P1031, DOI 10.1038/nature08231
   Nolen BJ, 2004, P NATL ACAD SCI USA, V101, P15627, DOI 10.1073/pnas.0407149101
   Piegeler T, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-57
   Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X
   Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936
   Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533
   Pries A. R., 2006, V176, P1
   Rajput C, 2013, J BIOL CHEM, V288, P4241, DOI 10.1074/jbc.M112.440396
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Rizzo AN, 2015, ARTERIOSCL THROM VAS, V35, P1071, DOI 10.1161/ATVBAHA.115.305085
   Rodrigues SF, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.978720
   Rouiller I, 2008, J CELL BIOL, V180, P887, DOI 10.1083/jcb.200709092
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   Schmidt EP, 2011, PHYSIOLOGY, V26, P334, DOI 10.1152/physiol.00011.2011
   Schnittler H, 2014, CELL TISSUE RES, V355, P529, DOI 10.1007/s00441-014-1856-2
   Schnoor M, 2011, J EXP MED, V208, P1721, DOI 10.1084/jem.20101920
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Tomar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044041
   Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051
   Vestweber D, 2014, SEMIN IMMUNOPATHOL, V36, P177, DOI 10.1007/s00281-014-0419-7
   Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783
   Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29
   West JB, 2013, J APPL PHYSIOL, V115, P1, DOI 10.1152/japplphysiol.00229.2013
   Yang Q.C., 2012, MULTIPURP UTILIZATIO, V3, P3, DOI DOI 10.1016/J.YEXMP.2012.04.009
   Zhao J, 2009, CELL SIGNAL, V21, P1945, DOI 10.1016/j.cellsig.2009.09.002
   Zhou K, 2013, P NATL ACAD SCI USA, V110, pE3820, DOI 10.1073/pnas.1308419110
NR 78
TC 15
Z9 15
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD JAN-MAR
PY 2017
VL 7
IS 1
BP 200
EP 210
DI 10.1086/690307
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA ER8FA
UT WOS:000399052900019
PM 28680579
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Chen, Y
   Wang, L
   Kang, QX
   Zhang, X
   Yu, GF
   Wan, XJ
   Wang, JF
   Zhu, KM
AF Chen, Yi
   Wang, Lei
   Kang, Qiuxiang
   Zhang, Xu
   Yu, Guifang
   Wan, Xiaojian
   Wang, Jiafeng
   Zhu, Keming
TI Heat Shock Protein A12B Protects Vascular Endothelial Cells Against
   Sepsis-Induced Acute Lung Injury in Mice
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE sepsis; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; Heat shock protein A12B 
ID RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR-CAPILLARY BARRIER; CARDIAC
   DYSFUNCTION; HSPA12B; PATHOGENESIS; ACTIVATION; MECHANISMS; APOPTOSIS;
   DEATH
AB Background: Pulmonary endothelial injury is a critical process in the pathogenesis of acute lung injury (ALI) during sepsis. Heat shock protein A12B (HSPA12B) is mainly expressed in endothelial cells and protects against several harmful factors. However, the effects of HSPA12B in sepsis-induced ALI and its potential mechanisms of action remain unclear. Methods: For in vivo experiments, C57BL/6 mice were randomly divided into four groups (n=15): a sham operation group, a cecal ligation and puncture (CLP) group, a HSPA12B siRNA-CLP group and a negative control (NC) siRNA-CLP group. The mice were treated by nasal inhalation of 2-OMe-modified HSPA12B siRNA or NC siRNA. Sepsis was induced by CLP. Samples were harvested 24 and 48 hours post-CLP surgery. Pathological changes and scoring of lung tissue samples were monitored using hematoxylin and eosin staining. Levels of pro-inflammatory cytokines (e.g., interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, and IL-6) and myeloperoxidase activity in bronchoalveolar lavage fluid were analyzed by ELISA. Pulmonary edema was assessed using a wet-to-dry weight ratio. Neutrophils and alveolar macrophages were counted using flow cytometry. Pulmonary endothelial cell apoptosis was detected by TUNEL staining. Expression levels of MAPK family signaling molecules and caspase-3 were measured by Western blot analysis. In addition, 7-day survival was recorded. For in vitro experiments, human umbilical vein endothelial cells were pre-transfected with HSPA12B siRNA or pIRES2-EGFP-HSPA12B-Flag plasmid and treated with lipopolysaccharide; subsequently, the expression levels of MAPK family signaling molecules and caspase-3 were measured by Western blotting. Results: Nasal inhalation of nano-polymer-encapsulated HSPA12B siRNA specifically downregulated mRNA and protein expression levels of HSPA12B in lung tissues. The administration of HSPA12B siRNA aggravated lung pathological injury, upregulated pro-inflammatory cytokine (e.g., IL1 beta, TNF-alpha, and IL-6) expression, and increased myeloperoxidase activity, neutrophil infiltration, pulmonary edema, and pulmonary endothelial cell apoptosis. Additionally, HSPA12B Y. Chen and L. Wang contributed equally to this work. knockdown worsened survival after CLP surgery. The potential protective mechanisms of HSPA12B may involve the inhibition of ERK phosphorylation and caspase-3 activation in vivo and in vitro. Conclusion: HSPA12B protected against sepsis-induced ALI. The potential mechanism may be partly due to the inhibition of ERK phosphorylation and caspase-3 activation. These findings provide a potential therapeutic target for treating sepsis. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Chen, Yi; Wang, Lei; Kang, Qiuxiang; Zhang, Xu; Wan, Xiaojian; Wang, Jiafeng; Zhu, Keming] Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol & Intens Care Med, Shanghai 200433, China.
C1 [Yu, Guifang] Shanghai Jiao Tong Univ, Peoples Hosp 3, Dept Anesthesiol, Shanghai, China.
C3 Naval Medical University; Shanghai Jiao Tong University
RP Zhu, KM (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol & Intens Care Med, Shanghai 200433, Peoples R China.
EM kmzhu@aliyun.com
OI Wang, Jia-feng/0000-0002-1753-6499
FU National Natural Science Foundation of China [81270128]
FX This study was supported by the National Natural Science Foundation of
   China (NO. 81270128) to Keming Zhu.
CR Abraham E, 2007, CRIT CARE MED, V35, P2408, DOI 10.1097/01.CCM.0000282072.56245.91
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bitko Vira, 2007, Drug Discov Today Ther Strateg, V4, P273, DOI 10.1016/j.ddstr.2008.01.001
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3
   Carraway MS, 2003, AM J RESP CRIT CARE, V167, P1200, DOI 10.1164/rccm.200204-287OC
   Chopra M, 2009, EXP BIOL MED, V234, P361, DOI 10.3181/0811-MR-318
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hernu R, 2013, INTENS CARE MED, V39, P2161, DOI 10.1007/s00134-013-3122-6
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Hu R, 2013, FRONT BIOSCI-LANDMRK, V18, P1244, DOI 10.2741/4176
   Ince C, 2016, SHOCK, V45, P259, DOI 10.1097/SHK.0000000000000473
   Kang LH, 2013, NEUROCHEM RES, V38, P311, DOI 10.1007/s11064-012-0922-y
   Kang QX, 2016, J SURG RES, V202, P87, DOI 10.1016/j.jss.2015.12.034
   Lau D, 2006, PHARMACOL THERAPEUT, V111, P16, DOI 10.1016/j.pharmthera.2005.06.023
   Lee IT, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/791231
   Li JJ, 2013, CARDIOVASC RES, V99, P674, DOI 10.1093/cvr/cvt139
   Li XH, 2015, EXP CELL RES, V339, P310, DOI 10.1016/j.yexcr.2015.09.020
   Martin TR, 2003, CRIT CARE MED, V31, pS184, DOI 10.1097/01.CCM.0000057841.33876.B1
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Perl M, 2010, CRIT CARE MED, V38, P1179, DOI 10.1097/CCM.0b013e3181d4563f
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shi JH, 2015, PATHOL RES PRACT, V211, P20, DOI 10.1016/j.prp.2014.06.018
   Wu J, 2015, J CELL MOL MED, V19, P544, DOI 10.1111/jcmm.12464
   Yang KY, 2003, AM J RESP CRIT CARE, V167, P1567, DOI 10.1164/rccm.200207-664OC
   Zhang HX, 2016, CELL PHYSIOL BIOCHEM, V40, P1603, DOI 10.1159/000453210
   Zhang R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101215
   Zhou HM, 2011, CARDIOVASC RES, V89, P109, DOI 10.1093/cvr/cvq268
   Zhu J, 2015, CELL PHYSIOL BIOCHEM, V36, P446, DOI 10.1159/000430111
   Zouein FA, 2013, CARDIOVASC RES, V99, P587, DOI 10.1093/cvr/cvt185
NR 44
TC 22
Z9 22
U1 1
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 42
IS 1
BP 156
EP 168
DI 10.1159/000477308
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FA8YZ
UT WOS:000405734000015
PM 28535510
OA gold
DA 2023-08-21
ER

PT J
AU Fang, Y
   Gao, FY
   Hao, J
   Liu, ZW
AF Fang, Yue
   Gao, Fengying
   Hao, Jing
   Liu, Zhenwei
TI microRNA-1246 mediates lipopolysaccharide-induced pulmonary endothelial
   cell apoptosis and acute lung injury by targeting angiotensin-converting
   enzyme 2
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE ACE/ACE2; apoptosis; Inflammation; miRNA; ALI/ARDS; target genes 
ID RESPIRATORY-DISTRESS-SYNDROME; VASCULAR-PERMEABILITY; ACE2; INFLAMMATION
AB In this study, we aimed to identify potential microRNA (miRNA) regulators of angiotensin-converting enzyme 2 (ACE2) and to explore their roles in lipopolysaccharide (LPS)-induced acute lung injury (ALI). The expression of predicted miRNA regulators of ACE2 was examined in LPS-exposed pulmonary microvascular endothelial cells (PMVECs). Gain-and loss-of-function studies were performed to determine the functions of candidate miRNAs in LPS-induced PMVEC apoptosis and inflammatory response. The roles of the miRNAs in LPS-induced lung inflammation and permeability were investigated in a mouse model. Notably, LPS (1 mu g/mL) significantly induced the expression of miR-1246 in PMVECs. ACE2 was validated as a target gene of miR-1246. Silencing of miR-1246 prevented LPS-induced inhibition of ACE2, which was accompanied by reduced apoptosis and production of IL-1 beta and TNF-alpha. In contrast, ectopic expression of miR-1246 triggered apoptosis in PMVECs and promoted IL-1 beta and TNF-alpha release. MiR-1246-mediated apoptosis of PMVECs was impaired by overexpression of ACE2. Depletion of miR-1246 attenuated lung inflammation, neutrophil infiltration, and vascular permeability and restored pulmonary expression of ACE2 in LPS-exposed mice. Taken together, miR-1246 meditates LPS-induced pulmonary endothelial cell apoptosis in vitro and ALI in mouse models, which are, at least partially, ascribed to repression of ACE2.
C1 [Fang, Yue; Gao, Fengying; Hao, Jing; Liu, Zhenwei] Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 1, Dept Pharm, Shanghai, China.
C3 Shanghai Jiao Tong University
RP Liu, ZW (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 1, Dept Pharm, Shanghai, Peoples R China.
EM KLB-6984321@163.com
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Bao H, 2015, CELL PHYSIOL BIOCHEM, V37, P759, DOI 10.1159/000430393
   Chignard M, 2000, AM J PHYSIOL-LUNG C, V279, pL1083, DOI 10.1152/ajplung.2000.279.6.L1083
   Duan YL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-4
   Fang F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071433
   Fujishima S, 2016, RESPIROLOGY, V21, P898, DOI 10.1111/resp.12769
   Guo ZL, 2014, IMMUNOL LETT, V162, P18, DOI 10.1016/j.imlet.2014.06.008
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Lambert BW, 2014, CLIN SCI, V127, P243, DOI 10.1042/CS20130420
   Li W, 2014, MOL CELL BIOCHEM, V394, P299, DOI 10.1007/s11010-014-2108-1
   Li YanJun, 2016, Journal of Forestry Engineering, V1, P2
   Li Y, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-014-2826-z
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Millar FR, 2016, THORAX, V71, P462, DOI 10.1136/thoraxjnl-2015-207461
   Paladini L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0375-2
   Rajasekaran S, 2016, J CELL PHYSIOL, V231, P2097, DOI 10.1002/jcp.25316
   Rojo de la Vega Montserrat, 2016, Curr Pharmacol Rep, V2, P91
   Sampath V, 2009, FREE RADICAL BIO MED, V46, P663, DOI 10.1016/j.freeradbiomed.2008.12.008
   Santos RAS, 2013, J ENDOCRINOL, V216, pR1, DOI 10.1530/JOE-12-0341
   Tao ZG, 2016, CELL PHYSIOL BIOCHEM, V38, P65, DOI 10.1159/000438609
   Tian X, 2014, INHAL TOXICOL, V26, P14, DOI 10.3109/08958378.2013.850563
   Wang LT, 2016, AM J TRANSL RES, V8, P1246
   Yadam S, 2016, CRIT CARE NURS Q, V39, P190, DOI 10.1097/CNQ.0000000000000111
   Ying HJ, 2015, J IMMUNOL, V194, P1239, DOI 10.4049/jimmunol.1402088
   Yu XB, 2016, CELL PHYSIOL BIOCHEM, V38, P1055, DOI 10.1159/000443056
   Zhang Q, 2015, ONCOL REP, V33, P1335, DOI 10.3892/or.2015.3715
NR 27
TC 63
Z9 66
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2017
VL 9
IS 3
BP 1287
EP 1296
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA ER7XK
UT WOS:000399028800040
PM 28386354
DA 2023-08-21
ER

PT J
AU Frantzeskaki, F
   Armaganidis, A
   Orfanos, SE
AF Frantzeskaki, Frantzeska
   Armaganidis, Apostolos
   Orfanos, Stylianos E.
TI Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks
   between Inflammation and Coagulation
SO RESPIRATION
LA English
DT Review
DE ALI/ARDS; coagulation; Inflammation; immunothrombosis 
ID NEUTROPHIL EXTRACELLULAR TRAPS; ACTIVATED PROTEIN-C; ACUTE LUNG INJURY;
   FACTOR PATHWAY INHIBITOR; MESENCHYMAL STEM-CELLS; HUMAN SOLUBLE
   THROMBOMODULIN; CRITICALLY-ILL PATIENTS; TISSUE FACTOR;
   ENDOTHELIAL-CELL; SEVERE SEPSIS
AB Acute respiratory distress syndrome (ARDS) is defined as a syndrome of acute onset, with bilateral opacities on chest imaging and respiratory failure not caused by cardiac failure, leading to mild, moderate, or severe oxygenation impairment. The syndrome is most commonly a manifestation of sepsis-induced organ dysfunction, characterized by disruption of endothelial barrier integrity and diffuse lung damage. Imbalance between coagulation and inflammation is a predominant characteristic of ARDS, leading to extreme inflammatory response and diffuse fibrin deposition in vascular capillary bed and alveoli. Activated platelets, neutrophils, endothelial cells, neutrophil extracellular traps, microparticles, and coagulation proteases, participate in the complex process of immunothrombosis, which is a key event in ARDS pathophysiology. The present review is focused on the elucidation of immunothrombosis in ARDS and the potential therapeutic implications. (C) 2016 S. Karger AG, Basel
C1 [Frantzeskaki, Frantzeska; Armaganidis, Apostolos; Orfanos, Stylianos E.] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Crit Care 2, Sch Med, 1 Rimini St, GR-12462 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   University Hospital Attikon
RP Orfanos, SE (corresponding author), Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Crit Care 2, Sch Med, 1 Rimini St, GR-12462 Athens, Greece.
EM stylianosorfanosuoa@gmail.com
CR Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238
   Allingstrup M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005370.pub3
   Alvarez P, 2015, Open Respir Med J, V9, P92, DOI 10.2174/1874306401509010092
   Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01
   Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359
   [Anonymous], 2012, JAMA, DOI DOI 10.1001/JAMA.2012.5669
   Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713
   Asaduzzaman M, 2009, CRIT CARE MED, V37, P1389, DOI 10.1097/CCM.0b013e31819ceb71
   Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577
   Assinger A, 2011, J THROMB HAEMOST, V9, P799, DOI 10.1111/j.1538-7836.2011.04193.x
   Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385
   Bastarache JA, 2008, AM J PHYSIOL-LUNG C, V294, pL874, DOI 10.1152/ajplung.00372.2007
   Bastarache JA, 2007, THORAX, V62, P608, DOI 10.1136/thx.2006.063305
   Bastarache JA, 2009, AM J PHYSIOL-LUNG C, V297, pL1035, DOI 10.1152/ajplung.00214.2009
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.iy.13.040195.000425
   BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2
   Boyle AJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0846-4
   Brill A, 2012, J THROMB HAEMOST, V10, P136, DOI 10.1111/j.1538-7836.2011.04544.x
   Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Cardenes N, 2013, RESPIRATION, V85, P267, DOI 10.1159/000347072
   CARVALHO AC, 1987, AM J HEMATOL, V25, P377, DOI 10.1002/ajh.2830250404
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Chen W, 2015, CRIT CARE MED, V43, P801, DOI 10.1097/CCM.0000000000000789
   Choi G, 2006, ANESTHESIOLOGY, V105, P689, DOI 10.1097/00000542-200610000-00013
   CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475
   de Stoppelaar SF, 2014, THROMB HAEMOSTASIS, V112, P666, DOI 10.1160/TH14-02-0126
   DelGiudice LA, 2009, J VET EMERG CRIT CAR, V19, P23, DOI 10.1111/j.1476-4431.2008.00380.x
   Dixon B, 2010, CRIT CARE, V14, DOI 10.1186/cc9269
   Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC
   Douda DN, 2011, J IMMUNOL, V187, P1856, DOI 10.4049/jimmunol.1004201
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   El Kebir D, 2009, AM J RESP CRIT CARE, V180, P311, DOI 10.1164/rccm.200810-1601OC
   Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345
   Etulain J, 2012, THROMB HAEMOSTASIS, V107, P99, DOI 10.1160/TH11-06-0443
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   Freishtat RJ, 2009, AM J RESP CRIT CARE, V179, P467, DOI 10.1164/rccm.200807-1085OC
   Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859
   Futier E, 2013, NEW ENGL J MED, V369, P1862, DOI 10.1056/NEJMc1311316
   Gando S, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0735-x
   Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015
   Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368
   GREENE R, 1981, AM REV RESPIR DIS, V124, P593
   GREENE R, 1987, AM J ROENTGENOL, V148, P501, DOI 10.2214/ajr.148.3.501
   Griffin JH, 2007, J THROMB HAEMOST, V5, P73, DOI 10.1111/j.1538-7836.2007.02491.x
   GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7
   Grommes J, 2012, AM J RESP CRIT CARE, V185, P628, DOI 10.1164/rccm.201108-1533OC
   Guervilly C, 2011, CRIT CARE, V15, DOI 10.1186/cc9978
   Haitsma JJ, 2008, EUR RESPIR J, V32, P1599, DOI 10.1183/09031936.00045908
   HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Hofstra JJ, 2010, J AEROSOL MED PULM D, V23, P105, DOI 10.1089/jamp.2009.0779
   Hu JY, 2012, BLOOD CELL MOL DIS, V48, P30, DOI 10.1016/j.bcmd.2011.09.010
   IDELL S, 1989, CHEST, V96, P1125, DOI 10.1378/chest.96.5.1125
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Isshiki T, 2015, RESPIRATION, V89, P201, DOI 10.1159/000369828
   Jiang JS, 2010, RESPIRATION, V80, P246, DOI 10.1159/000279438
   Johnston LK, 2012, AM J RESP CELL MOL, V47, P417, DOI 10.1165/rcmb.2012-0090OC
   Jy W, 2011, TRANSFUSION, V51, P886, DOI 10.1111/j.1537-2995.2011.03099.x
   Kambas K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00385
   Kambas K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045427
   Kaneider NC, 2007, NAT IMMUNOL, V8, P1303, DOI 10.1038/ni1525
   Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719
   Katz JN, 2011, CHEST, V139, P658, DOI 10.1378/chest.10-1971
   Kirschenbaum LA, 2004, CRIT CARE MED, V32, P1904, DOI 10.1097/01.CCM.0000139918.80602.57
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Kor DJ, 2016, JAMA-J AM MED ASSOC, V315, P2406, DOI 10.1001/jama.2016.6330
   Kor DJ, 2011, CRIT CARE MED, V39, P2393, DOI 10.1097/CCM.0b013e318225757f
   Kor DJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001606
   Kotanidou A, 2006, VASC PHARMACOL, V45, P134, DOI 10.1016/j.vph.2006.06.016
   Kraemer BF, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002355
   Lam FW, 2013, THROMB RES, V132, P69, DOI 10.1016/j.thromres.2013.04.018
   Lechner D, 2008, THROMB RES, V122, pS47, DOI 10.1016/S0049-3848(08)70019-7
   Levi M, 2006, SEMIN THROMB HEMOST, V32, P33, DOI 10.1055/s-2006-933338
   Levy BD, 2014, ANNU REV PHYSIOL, V76, P467, DOI 10.1146/annurev-physiol-021113-170408
   Li XW, 2014, CHINESE MED J-PEKING, V127, P810, DOI 10.3760/cma.j.issn.0366-6999.20131104
   Lim MY, 2013, CURR OPIN HEMATOL, V20, P472, DOI 10.1097/MOH.0b013e328363442f
   Liu KD, 2008, AM J RESP CRIT CARE, V178, P618, DOI 10.1164/rccm.200803-419OC
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Madach K, 2010, CRIT CARE, V14, DOI 10.1186/cc8992
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Masterson C, 2015, MINERVA ANESTESIOL, V81, P179
   Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456
   Mazzeffi M, 2015, ANESTH ANALG, V121, P271, DOI 10.1213/ANE.0000000000000793
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Meyer NJ, 2013, AM J RESP CRIT CARE, V187, P950, DOI 10.1164/rccm.201208-1501OC
   Miller AC, 2009, J BURN CARE RES, V30, P249, DOI 10.1097/BCR.0b013e318198a268
   Milsom C, 2007, PATHOPHYSIOL HAEMO T, V36, P160, DOI 10.1159/000175154
   Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72
   Miyoshi S, 2014, DRUG DES DEV THER, V8, P1211, DOI 10.2147/DDDT.S68030
   Morel O, 2011, ARTERIOSCL THROM VAS, V31, P15, DOI 10.1161/ATVBAHA.109.200956
   Morel O, 2009, HAEMATOL-HEMATOL J, V94, P313, DOI 10.3324/haematol.2009.003657
   Mostefai HA, 2008, J IMMUNOL, V180, P5028, DOI 10.4049/jimmunol.180.7.5028
   NAGY Z, 1995, STROKE, V26, P265, DOI 10.1161/01.STR.26.2.265
   Nishinaka Y, 2011, BIOCHEM BIOPH RES CO, V413, P75, DOI 10.1016/j.bbrc.2011.08.052
   O'Neal HR, 2011, CRIT CARE MED, V39, P1343, DOI 10.1097/CCM.0b013e3182120992
   Oehmcke S, 2009, J INNATE IMMUN, V1, P225, DOI 10.1159/000203700
   Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Peters MJ, 1999, BRIT J HAEMATOL, V106, P391, DOI 10.1046/j.1365-2141.1999.01553.x
   Pfeiler S, 2014, THROMB RES, V133, pS35, DOI 10.1016/j.thromres.2014.03.016
   Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003
   Ray NB, 2010, NAT MED, V16, P1120, DOI 10.1038/nm.2213
   Rehberg S, 2014, J TRAUMA ACUTE CARE, V76, P126, DOI 10.1097/TA.0b013e3182ab0785
   ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002
   Rothmeier AS, 2012, SEMIN IMMUNOPATHOL, V34, P133, DOI 10.1007/s00281-011-0289-1
   Ruf W, 2010, J CLIN INVEST, V120, P3084, DOI 10.1172/JCI44266
   SABHARWAL AK, 1995, AM J RESP CRIT CARE, V151, P758
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   SALDEEN T, 1969, ACTA CHIR SCAND, V135, P653
   Schultz MJ, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/961784
   Schultz MJ, 2004, THORAX, V59, P130, DOI 10.1136/thorax.2003.013888
   Sebag SC, 2011, CURR PHARM BIOTECHNO, V12, P1481
   Sharp C, 2015, RESPIRATION, V89, P420, DOI 10.1159/000381102
   Shpacovitch V, 2008, J LEUKOCYTE BIOL, V83, P1309, DOI 10.1189/jlb.0108001
   Steppich BA, 2008, THROMB HAEMOSTASIS, V100, P1068, DOI 10.1160/TH08-05-0293
   Sun SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059989
   Tasaki O, 2002, CRIT CARE MED, V30, P637, DOI 10.1097/00003246-200203000-00024
   Taylor FB, 2001, SEMIN THROMB HEMOST, V27, P619
   Taylor FB, 1997, BLOOD, V89, P4078, DOI 10.1182/blood.V89.11.4078
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52
   Tsirigotis P, 2016, J CRIT CARE, V32, P9, DOI 10.1016/j.jcrc.2015.11.010
   Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x
   van der Poll T, 2014, THROMB HAEMOSTASIS, V112, P640, DOI 10.1160/TH14-01-0053
   VESCONI S, 1988, CRIT CARE MED, V16, P111, DOI 10.1097/00003246-198802000-00002
   von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322
   Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002
   Ware LB, 2007, CRIT CARE MED, V35, P1821, DOI 10.1097/01.CCM.0000275386.95968.5F
   Weber B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003900
   Weiss DJ, 2013, CHEST, V143, P1590, DOI 10.1378/chest.12-2094
   Wijten P, 2013, ARTERIOSCL THROM VAS, V33, P1635, DOI 10.1161/ATVBAHA.113.301147
   Wildhagen KCAA, 2014, BLOOD, V123, P1098, DOI 10.1182/blood-2013-07-514984
   Williams AE, 2014, AM J PHYSIOL-LUNG C, V306, pL217, DOI 10.1152/ajplung.00311.2013
   Wygrecka M, 2008, THROMB HAEMOSTASIS, V99, P494, DOI 10.1160/TH07-11-0666
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Yadav H, 2015, AM J PHYSIOL-LUNG C, V309, pL915, DOI 10.1152/ajplung.00266.2015
   Yaguchi A, 2004, J THROMB HAEMOST, V2, P2096, DOI 10.1111/j.1538-7836.2004.01009.x
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zawrotniak M, 2013, ACTA BIOCHIM POL, V60, P277
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 143
TC 156
Z9 169
U1 0
U2 16
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0025-7931
EI 1423-0356
J9 RESPIRATION
JI Respiration
PY 2017
VL 93
IS 3
BP 212
EP 225
DI 10.1159/000453002
PG 14
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA EM9WW
UT WOS:000395663200008
PM 27997925
OA Bronze
DA 2023-08-21
ER

PT J
AU Hagiwara, T
   Yoshida, S
   Hidaka, Y
AF Hagiwara, Teruki
   Yoshida, Shigeru
   Hidaka, Yuji
TI Gene expression of the concentration-sensitive sodium channel is
   suppressed in lipopolysaccharide-induced acute lung injury in mice
SO EXPERIMENTAL LUNG RESEARCH
LA English
DT Article
DE ALI/ARDS; alveolar fluid clearance; amiloride-insensitive sodium channel; concentration-sensitive sodium channel; pulmonary edema 
ID RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR EPITHELIAL-CELLS; LIQUID
   CLEARANCE; FLUID CLEARANCE; ALPHA-ENAC; NA-X; DECREASES EXPRESSION;
   SALT-INTAKE; TRANSPORT; ABSORPTION
AB Purpose: The concentration-sensitive sodium channel (Na-C) is expressed in alveolar type II epithelial cells and pulmonary microvascular endothelial cells in mouse lungs. We recently reported that Na-C contributes to amiloride-insensitive sodium transport in mouse lungs (Respiratory Physiology & Neurobiology, 2016). However, details regarding its physiological role in the lung remain unknown. To examine whether Na-C is involved in alveolar fluid clearance during an acute lung injury (ALI), we analyzed the relationship between Na-C gene expression in the lung and the development of pulmonary edema in lipopolysaccharide (LPS)-induced ALI mice. Methods: LPS-induced ALI mice were prepared by the intratracheal administration of LPS. Bronchoalveolar lavage (BAL) neutrophils and lung water content (LWCs) were used as a marker of ALI and pulmonary edema, respectively. Na-C protein production in the lung was detected by immunoblotting and immunofluorescence. The gene expressions of Na-C and the epithelial sodium channel (ENaC) of LPS-induced ALI mice were examined by quantitative RT-PCR over a time course of 14 days. Results: The BAL neutrophil count increased until day 2 after LPS administration and had nearly recovered by day 6. LWCs in LPS-induced mice gradually increased until day 8 and had recovered by day 14. The expression of the Na-C protein in the lungs of LPS-induced mice dramatically decreased from day 2 to day 6, but recovered by day 8. The mRNA expression of Na-C decreased in the lung, as well as those for alpha-, beta-, and gamma-ENaC during ALI. Thus, Na-C expression is suppressed during the development stage of pulmonary edema and then recovers in the convalescent phase. Conclusion: Our results suggest that suppression of the gene expression of Na-C is involved in the development of pulmonary edema in ALI.
C1 [Hagiwara, Teruki; Yoshida, Shigeru; Hidaka, Yuji] Kindai Univ, Fac Sci & Engn, Dept Life Sci, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.
C3 Kindai University (Kinki University)
RP Hagiwara, T (corresponding author), Kindai Univ, Fac Sci & Engn, Dept Life Sci, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.
EM hagi@life.kindai.ac.jp
OI HIDAKA, YUJI/0000-0002-3131-2619
FU MEXT KAKENHI [20790183]; Kindai University [RK18-31]; Grants-in-Aid for
   Scientific Research [16K01925, 20790183] Funding Source: KAKEN
FX This work was supported by MEXT KAKENHI (grant number 20790183) and a
   research grant from Kindai University (RK18-31).
CR Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971
   Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010
   Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002
   Deng W, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-29
   Dobbs LG, 2007, RESP PHYSIOL NEUROBI, V159, P283, DOI 10.1016/j.resp.2007.06.011
   Egli M, 2004, J PHYSIOL-LONDON, V560, P857, DOI 10.1113/jphysiol.2004.066704
   FELIPE A, 1994, J BIOL CHEM, V269, P30125
   Feng Q, 2008, J ETHNOPHARMACOL, V118, P51, DOI 10.1016/j.jep.2008.03.025
   Frank J, 2003, J BIOL CHEM, V278, P43939, DOI 10.1074/jbc.M304882200
   Fronius Martin, 2013, Curr Mol Pharmacol, V6, P13
   GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272
   GEORGE AL, 1992, P NATL ACAD SCI USA, V89, P4893, DOI 10.1073/pnas.89.11.4893
   Hagiwara T, 2016, RESP PHYSIOL NEUROBI, V231, P45, DOI 10.1016/j.resp.2016.05.017
   Hiyama TY, 2013, CELL METAB, V17, P507, DOI 10.1016/j.cmet.2013.02.018
   Hiyama TY, 2002, NAT NEUROSCI, V5, P511, DOI 10.1038/nn856
   Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325
   Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646
   Junor RVJ, 1999, J PHYSIOL-LONDON, V520, P255, DOI 10.1111/j.1469-7793.1999.00255.x
   Marunaka Y, 2014, J PHARMACOL SCI, V126, P21, DOI 10.1254/jphs.14R01SR
   Matsumoto M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126109
   Matthay Michael A, 2005, Proc Am Thorac Soc, V2, P206, DOI 10.1513/pats.200501-009AC
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727
   Norlin A, 1998, AM J PHYSIOL-LUNG C, V274, pL235, DOI 10.1152/ajplung.1998.274.2.L235
   Norlin A, 2001, J APPL PHYSIOL, V90, P1489, DOI 10.1152/jappl.2001.90.4.1489
   O'Brodovich H, 2008, AM J PHYSIOL-LUNG C, V294, pL401, DOI 10.1152/ajplung.00431.2007
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200
   Sheng SJ, 2014, MOL MED REP, V10, P773, DOI 10.3892/mmr.2014.2303
   Shimizu H, 2007, NEURON, V54, P59, DOI 10.1016/j.neuron.2007.03.014
   Tasaka S, 2003, AM J RESP CELL MOL, V29, P252, DOI 10.1165/rcmb.2002-0132OC
   Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174
   Vernooy JHJ, 2001, AM J RESP CELL MOL, V24, P569, DOI 10.1165/ajrcmb.24.5.4156
   Watanabe E, 2000, J NEUROSCI, V20, P7743
   Wilkinson WJ, 2011, PFLUG ARCH EUR J PHY, V462, P267, DOI 10.1007/s00424-011-0971-0
   Xu W, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0286
   Yamagata T, 2009, RESP PHYSIOL NEUROBI, V166, P16, DOI 10.1016/j.resp.2008.12.008
   Zhang B, 2015, ANN HUM GENET, V79, P28, DOI 10.1111/ahg.12085
NR 38
TC 2
Z9 3
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0190-2148
EI 1521-0499
J9 EXP LUNG RES
JI Exp. Lung Res.
PY 2017
VL 43
IS 3
BP 150
EP 157
DI 10.1080/01902148.2017.1321064
PG 8
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA EY2WB
UT WOS:000403832200004
PM 28557567
DA 2023-08-21
ER

PT J
AU Huang, ZW
   Liu, N
   Li, D
   Zhang, HY
   Wang, Y
   Liu, Y
   Zhang, LL
   Ju, XL
AF Huang, Zhi-Wei
   Liu, Ning
   Li, Dong
   Zhang, Hai-Yan
   Wang, Ying
   Liu, Yi
   Zhang, Le-Ling
   Ju, Xiu-Li
TI Angiopoietin-1 Modified Human Umbilical Cord Mesenchymal Stem Cell
   Therapy for Endotoxin-Induced Acute Lung Injury in Rats
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE angiopoietin-1/angiopoietin-2; human umbilical cord mesenchymal stem cell; ALI/ARDS 
ID GENE-THERAPY; LIPOPOLYSACCHARIDE
AB Purpose: Angiopoietin-1 (Ang1) is a critical factor for vascular stabilization and endothelial survival via inhibition of endothelial permeability and leukocyte-endothelium interactions. Hence, we hypothesized that treatment with umbilical cord mesenchymal stem cells (UCMSCs) carrying the Ang1 gene (UCMSCs-Ang1) might be a potential approach for acute lung injury (ALI) induced by lipopolysaccharide (LPS).
   Materials and Methods: UCMSCs with or without transfection with the human Ang1 gene were delivered intravenously into rats one hour after intra-abdominal instillation of LPS to induce ALI. After the rats were sacrificed at 6 hours, 24 hours, 48 hours, 8 days, and 15 days post-injection of LPS, the serum, the lung tissues, and bronchoalveolar lavage fluid (BALF) were harvested for analysis, respectively.
   Results: Administration of fluorescence microscope confirmed the increased presence of UCMSCs in the injured lungs. The evaluation of UCMSCs and UCMSCs-Ang1 actions revealed that Ang1 overexpression further decreased the levels of the pro-inflammatory cytokines TNF-a, TGF-a1, and IL-6 and increased the expression of the anti-inflammatory cytokine IL-10 in the injured lungs. This synergy caused a substantial decrease in lung airspace inflammation and vascular leakage, characterized by significant reductions in wet/dry ratio, differential neutrophil counts, myeloperoxidase activity, and BALF. The rats treated by UCMSCsAng1 showed improved survival and lower ALI scores.
   Conclusion: UCMSCs-Ang1 could improve both systemic inflammation and alveolar permeability in ALI. UC-derived MSCsbased Ang1 gene therapy may be developed as a potential novel strategy for the treatment of ALI.
C1 [Huang, Zhi-Wei; Liu, Ning; Zhang, Hai-Yan; Wang, Ying; Liu, Yi; Zhang, Le-Ling] Shandong Univ, Qilu Childrens Hosp, Dept Hematol, Jingshi Ave 23976, Jinan 250001, Shandong, China.
C1 [Huang, Zhi-Wei; Li, Dong; Ju, Xiu-Li] Shandong Univ, Dept Pediat, Qilu Hosp, Wenhua Xi Ave 107, Jinan 250012, Shandong, China.
C3 Shandong University; Shandong University
RP Zhang, LL (corresponding author), Shandong Univ, Qilu Childrens Hosp, Dept Hematol, Jingshi Ave 23976, Jinan 250001, Shandong, Peoples R China.; Ju, XL (corresponding author), Shandong Univ, Dept Pediat, Qilu Hosp, Wenhua Xi Ave 107, Jinan 250012, Shandong, Peoples R China.
EM 2598260466@qq.com; lyssyl88@sina.com
RI Huang, Zhwei/I-5629-2014
OI Huang, Zhwei/0000-0002-6312-7434
FU Natural Scientific Fund of Shandong Province [ZR2013HM001]
FX This research was supported by a grant of the Natural Scientific Fund of
   Shandong Province ZR2013HM001.
CR Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Bustos ML, 2014, AM J RESP CRIT CARE, V189, P787, DOI 10.1164/rccm.201306-1043OC
   Davies MJ, 2011, J CLIN BIOCHEM NUTR, V48, P8, DOI 10.3164/jcbn.11-006FR
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   Gharib SA, 2006, AM J RESP CRIT CARE, V173, P653, DOI 10.1164/rccm.200509-1473OC
   Gotts JE, 2011, CRIT CARE CLIN, V27, P719, DOI 10.1016/j.ccc.2011.04.004
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kanki-Horimoto S, 2006, CIRCULATION, V114, pI181, DOI 10.1161/CIRCULATIONAHA.105.001487
   Li J, 2012, J ASIA TEFL, V9, P1, DOI 10.1186/1476-9255-9-33
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Paul A, 2012, INT J NANOMED, V7, P663, DOI 10.2147/IJN.S26882
   Piao WH, 2010, ANGIOGENESIS, V13, P203, DOI 10.1007/s10456-010-9169-x
   Slutsky AS, 2006, NEW ENGL J MED, V354, P1839, DOI 10.1056/NEJMe068045
   Thurston G, 2005, EXP SUPPL, V94, P233
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
NR 20
TC 22
Z9 23
U1 2
U2 10
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD JAN
PY 2017
VL 58
IS 1
BP 206
EP 216
DI 10.3349/ymj.2017.58.1.206
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EO0HH
UT WOS:000396378400027
PM 27873515
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Kumar, S
   Sun, XT
   Noonepalle, SK
   Lu, Q
   Zemskov, E
   Wang, T
   Aggarwal, S
   Gross, C
   Sharma, S
   Desai, AA
   Hou, YL
   Dasarathy, S
   Qu, N
   Reddy, V
   Lee, SG
   Cherian-Shaw, M
   Yuan, JXJ
   Catravas, JD
   Rafikov, R
   Garcia, JGN
   Black, SM
AF Kumar, Sanjiv
   Sun, Xutong
   Noonepalle, Satish Kumar
   Lu, Qing
   Zemskov, Evgeny A.
   Wang, Ting
   Aggarwal, Saurabh
   Gross, Christine M.
   Sharma, Shruti
   Desai, Ankit A.
   Hou, Yali
   Dasarathy, Sridevi
   Qu, Ning
   Reddy, Vijay
   Lee, Sung Gon
   Cherian-Shaw, Mary
   Yuan, Jason X-J.
   Catravas, John D.
   Rafikov, Ruslan
   Garcia, Joe G. N.
   Black, Stephen M.
TI Hyper-activation of pp60(Src) limits nitric oxide signaling by
   increasing asymmetric dimethylarginine levels during acute lung injury
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE signal transduction; eNOS; ALI/ARDS 
ID ARTERIAL ENDOTHELIAL-CELLS; NF-KAPPA-B; RESPIRATORY-DISTRESS-SYNDROME;
   GTP CYCLOHYDROLASE I; PULMONARY BLOOD-FLOW; PROTEIN-KINASE-G; MEDIATED
   ACTIVATION; VASCULAR LEAKAGE; SYNTHASE PATHWAY; ENDOTOXIC-SHOCK
AB The molecular mechanisms by which the endothelial barrier becomes compromised during lipopolysaccharide (LPS) mediated acute lung injury (ALI) are still unresolved. We have previously reported that the disruption of the endothelial barrier is due, at least in part, to the uncoupling of endothelial nitric oxide synthase (eNOS) and increased peroxynitrite-mediated nitration of RhoA. The purpose of this study was to elucidate the molecular mechanisms by which LPS induces eNOS uncoupling during ALI. Exposure of pulmonary endothelial cells (PAEC) to LPS increased pp60(Src) activity and this correlated with an increase in nitric oxide (NO) production, but also an increase in NOS derived superoxide, peroxynitrite formation and 3-nitrotyrosine (3-NT) levels. These effects could be simulated by the over-expression of a constitutively active pp60(Src) (Y527FSrc) mutant and attenuated by over-expression of dominant negative pp60(Src) mutant or reducing pp60(Src) expression. LPS induces both RhoA nitration and endothelial barrier disruption and these events were attenuated when pp60(Src) expression was reduced. Endothelial NOS uncoupling correlated with an increase in the levels of asymmetric dimethylarginine (ADMA) in both LPS exposed and Y527FSrc over-expressing PAEC. The effects in PAEC were also recapitulated when we transiently over-expressed Y527FSrc in the mouse lung. Finally, we found that the pp60(Src)-mediated decrease in DDAH activity was mediated by the phosphorylation of 'DDAH II at Y207 and that a Y207F mutant DDAH II was resistant to pp60(Src)-mediated inhibition. We conclude that pp60(Src) can directly inhibit DDAH II and this is involved in the increased ADMA levels that enhance eNOS uncoupling during the development of ALI.
C1 [Kumar, Sanjiv; Gross, Christine; Hou, Yali; Dasarathy, Sridevi; Reddy, Vijay; Lee, Sung Gon; Cherian-Shaw, Mary] Augusta Univ, Vasc Biol Ctr, Augusta, GA, United States.
C1 [Kumar, Sanjiv; Gross, Christine; Hou, Yali; Dasarathy, Sridevi; Reddy, Vijay; Lee, Sung Gon; Cherian-Shaw, Mary] Augusta Univ, Ctr Biotechnol & Genom Med, Augusta, GA, United States.
C1 [Sun, Xutong; Noonepalle, Satish Kumar; Lu, Qing; Zemskov, Evgeny; Wang, Ting; Desai, Ankit A.; Qu, Ning; Yuan, Jason X. -J.; Rafikov, Ruslan; Garcia, Joe G. N.; Black, Stephen M.] Univ Arizona, Dept Med, Tucson, AZ, United States.
C1 [Aggarwal, Saurabh] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL, United States.
C1 [Sharma, Shruti; Catravas, John D.] Old Dominion Univ, Ctr Biotechnol & Genom Med, Norfolk, VA, United States.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University of Arizona; University of
   Alabama System; University of Alabama Birmingham; Old Dominion
   University
RP Black, SM (corresponding author), Univ Arizona, Div Translat & Regenerat Med, Dept Med, Tucson, AZ 85724 USA.
EM steveblack@email.arizona.edu
RI reddy, vijay/HNQ-7289-2023; Noonepalle, Satish/ABD-6753-2021; Rafikov,
   Ruslan/AAG-9352-2019; Garcia, Joe GN/E-8862-2010; Qu, Ning/A-8723-2010
OI Sharma, Shruti/0000-0001-8200-108X; Noonepalle, Satish
   kumar/0000-0002-0346-3882; Black, Stephen M./0000-0002-4524-6544;
   Rafikov, Ruslan/0000-0001-5950-4076; Lu, Qing/0000-0002-1000-3884;
   Desai, Ankit/0000-0001-6427-616X
FU National Institutes of Health [P01HL0101902, HL60190, HL67841]; American
   Heart Association [12PRE12060224];  [14SDG20480354]
FX This research was supported in part by grants P01HL0101902, HL60190, and
   HL67841 from the National Institutes of Health and 14SDG20480354.
   Christine M. Gross was funded in part by a pre-doctoral Fellowship
   award, 12PRE12060224, from the American Heart Association.
CR Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389
   Aggarwal S, 2014, AM J RESP CELL MOL, V50, P614, DOI 10.1165/rcmb.2013-0193OC
   Ali S, 2004, CELL BIOCHEM FUNCT, V22, P67, DOI 10.1002/cbf.1082
   Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13
   BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7
   Boger RH, 2004, J NUTR, V134, p2842S, DOI 10.1093/jn/134.10.2842S
   Boger RH, 2003, ATHEROSCLEROSIS SUPP, V4, P1, DOI 10.1016/S1567-5688(03)00027-8
   Boger RH, 2000, SEMIN THROMB HEMOST, V26, P539, DOI 10.1055/s-2000-13210
   Boger RH, 2003, CLIN CHEM LAB MED, V41, P1467, DOI 10.1515/CCLM.2003.225
   Boger RH, 2003, CARDIOVASC RES, V59, P824, DOI 10.1016/S0008-6363(03)00500-5
   Brennan LA, 2002, IUBMB LIFE, V54, P261, DOI 10.1080/15216540215679
   Chen CA, 2008, J BIOL CHEM, V283, P27038, DOI 10.1074/jbc.M802269200
   Chen LW, 2003, CRIT CARE MED, V31, P2170, DOI 10.1097/01.CCM.0000079605.28852.D0
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Gong P, 2008, J BIOL CHEM, V283, P13437, DOI 10.1074/jbc.M707986200
   Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175
   Gross CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119918
   Gunduz D, 2010, ARTERIOSCL THROM VAS, V30, P1237, DOI 10.1161/ATVBAHA.110.203901
   Guo RF, 2007, ANTIOXID REDOX SIGN, V9, P1991, DOI 10.1089/ars.2007.1785
   Hu GC, 2008, CHEM-BIOL INTERACT, V171, P177, DOI 10.1016/j.cbi.2007.08.006
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092
   Jones LC, 2003, BIOCHEM BIOPH RES CO, V310, P836, DOI 10.1016/j.bbrc.2003.09.097
   Kumar S, 2010, AM J PHYSIOL-LUNG C, V298, pL105, DOI 10.1152/ajplung.00290.2009
   Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172
   Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001
   Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67
   Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200
   Manukyan M, 2009, J IMMUNOL, V182, P3522, DOI 10.4049/jimmunol.0802280
   McMullan DM, 2000, CIRCULATION, V102, P172
   Miyazaki H, 1999, CIRCULATION, V99, P1141, DOI 10.1161/01.CIR.99.9.1141
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Okamoto T, 2004, AM J PHYSIOL-LUNG C, V286, pL198, DOI 10.1152/ajplung.00136.2003
   Parviz M, 1999, ANN THORAC SURG, V67, P522, DOI 10.1016/S0003-4975(98)01141-2
   Pearse DB, 2003, ENDOTHELIUM-J ENDOTH, V10, P309, DOI 10.1080/10623320390272307
   Peng XQ, 2005, AM J RESP CRIT CARE, V172, P470, DOI 10.1164/rccm.200411-1547OC
   Pullamsetti S, 2005, FASEB J, V19, P1175, DOI 10.1096/fj.04-3223fje
   Rafikov R, 2014, REDOX BIOL, V2, P156, DOI 10.1016/j.redox.2013.12.015
   Rafikov R, 2014, J BIOL CHEM, V289, P4710, DOI 10.1074/jbc.M114.547596
   Rafikov R, 2011, J ENDOCRINOL, V210, P271, DOI 10.1530/JOE-11-0083
   Schutte H, 2000, AM J PHYSIOL-LUNG C, V279, pL496, DOI 10.1152/ajplung.2000.279.3.L496
   Shao Z., J AM COLL CARDIOL, V59, P1150
   Sharma S, 2012, FREE RADICAL BIO MED, V53, P216, DOI 10.1016/j.freeradbiomed.2012.03.016
   Sharma S, 2010, VASC PHARMACOL, V52, P182, DOI 10.1016/j.vph.2009.11.010
   Stephens RS, 2010, AM J PHYSIOL-LUNG C, V299, pL323, DOI 10.1152/ajplung.00442.2009
   Sud N, 2008, AM J PHYSIOL-CELL PH, V294, pC1407, DOI 10.1152/ajpcell.00384.2007
   Sun X., AM J RESP CELL MOL B, V45, P163
   Sun XT, 2014, AM J RESP CELL MOL, V50, P1084, DOI 10.1165/rcmb.2013-0187OC
   Sun XT, 2011, AM J RESP CELL MOL, V45, P163, DOI 10.1165/rcmb.2009-0467OC
   Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585
   Thomas S, 2001, J CAN PETROL TECHNOL, V40, P56, DOI 10.2118/01-03-05
   Thomson L, 2007, AM J RESP CELL MOL, V36, P152, DOI 10.1165/rcmb.2006-0288SM
   Tinsley JH, 2002, AM J PHYSIOL-CELL PH, V283, pC1745, DOI 10.1152/ajpcell.00230.2002
   Tran CTL, 2003, ATHEROSCLEROSIS SUPP, V4, P33, DOI 10.1016/S1567-5688(03)00032-1
   Tsuji C, 2000, AM J PHYSIOL-LUNG C, V278, pL719, DOI 10.1152/ajplung.2000.278.4.L719
   Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489
   Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639
   Wedgwood S, 2001, AM J PHYSIOL-LUNG C, V281, pL490, DOI 10.1152/ajplung.2001.281.2.L490
   Yakovlev VA, 2007, BIOCHEMISTRY-US, V46, P11671, DOI 10.1021/bi701107z
   Yokoyama M, 2007, CARDIOVASC RES, V73, P8, DOI 10.1016/j.cardiores.2006.11.009
   Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7
   Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872
NR 63
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN
PY 2017
VL 102
BP 217
EP 228
DI 10.1016/j.freeradbiomed.2016.11.008
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA EI3AG
UT WOS:000392361200018
PM 27838434
OA Green Accepted, Green Submitted
DA 2023-08-21
ER

PT J
AU Li, SJ
   Wang, XJ
   Hu, JB
   Kang, XQ
   Chen, L
   Xu, XL
   Ying, XY
   Jiang, SP
   Du, YZ
AF Li, Shujuan
   Wang, Xiao-Juan
   Hu, Jing-Bo
   Kang, Xuqi
   Chen, Li
   Xu, Xiao-Ling
   Ying, Xiao-Ying
   Jiang, Saiping
   Du, Yongzhong
TI Targeting delivery of simvastatin using ICAM-1 antibody-conjugated
   nanostructured lipid carriers for acute lung injury therapy
SO DRUG DELIVERY
LA English
DT Article
DE lung targeting; nanostructured lipid carrier; ICAM-1; simvastatin delivery; ALI/ARDS 
ID ENDOTHELIAL-CELLS; INFLAMMATION; EXPRESSION; ERYTHROMYCIN; PATHOGENESIS;
   ENDOCYTOSIS; TRANSPORT; RECEPTOR; SIZE
AB Acute lung injury (ALI) is a critical illness without effective therapeutic modalities currently. Recent studies indicated potential efficacy of statins for ALI, while high-dose statins was suggested to be significant for attenuating inflammation in vivo. Therefore, a lung-targeted drug delivery system (DDS) delivering simvastatin (SV) for ALI therapy was developed, attempting to improve the disease with a decreased dose and minimize potential adverse effects. SV-loaded nanostructured lipid carriers (SV/NLCs) with different size were prepared primarily. With particle size increasing from 143.7nm to 337.8 nm, SV/NLCs showed increasing drug-encapsulated efficiency from 66.70% to 91.04%. Although larger SV/NLCs exhibited slower in vitro cellular uptake by human vascular endothelial cell line EAhy926 at initial stage, while in vivo distribution demonstrated higher pulmonary accumulation of the larger ones. Thus, the largest size SV/NLCs (337.8 nm) were conjugated with intercellular adhesion molecule 1 (ICAM-1) antibody (anti-ICAM/SV/NLCs) for lung-targeted study. The anti-ICAM/SV/NLCs exhibited ideal lung-targeted characteristic in lipopolysaccharide-induced ALI mice. In vivo i.v. administration of anti-ICAM/SV/NLCs attenuated TNF-alpha, IL-6 and inflammatory cells infiltration more effectively than free SV or non-targeted SV/NLCs after 48-h administration. Significant histological improvements by anti-ICAM/SV/NLCs were further revealed by H&E stain. Therefore, ICAM-1 antibody-conjugated NLCs may represent a potential lung-targeted DDS contributing to ALI therapy by statins.
C1 [Li, Shu-Juan; Wang, Xiao-Juan; Hu, Jing-Bo; Kang, Xu-Qi; Xu, Xiao-Ling; Ying, Xiao-Ying; Du, Yong-Zhong] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmaceut, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, China.
C1 [Chen, Li; Jiang, Sai-Ping] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Hangzhou, Zhejiang, China.
C3 Zhejiang University; Zhejiang University
RP Du, YZ (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmaceut, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.; Jiang, SP (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Hangzhou, Zhejiang, Peoples R China.
EM j5145@126.com; duyongzhong@zju.edu.cn
RI wang, meng/GWZ-9558-2022
FU National Natural Science Foundation of China [81301611, 81573362];
   Scientific Research Fund of Ministry of Health-Medical Science Major
   Technology Fund Project of Zhejiang Province
FX The authors report no conflicts of interest. This work was supported by
   National Natural Science Foundation of China (grant Nos. 81301611,
   81573362) and the Scientific Research Fund of Ministry of Health-Medical
   Science Major Technology Fund Project of Zhejiang Province.
CR Ansar M, 2013, ACS NANO, V7, P10597, DOI 10.1021/nn404719c
   Bhowmick T, 2012, J CONTROL RELEASE, V157, P485, DOI 10.1016/j.jconrel.2011.09.067
   Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167
   Calderon AJ, 2011, J CONTROL RELEASE, V150, P37, DOI 10.1016/j.jconrel.2010.10.025
   Chai GH, 2014, MOL PHARMACEUT, V11, P3716, DOI 10.1021/mp5004674
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Chen WG, 2012, AM J PHYSIOL-LUNG C, V303, pL279, DOI 10.1152/ajplung.00361.2011
   Cornier MA, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-014-0475-4
   Craig TR, 2011, AM J RESP CRIT CARE, V183, P620, DOI 10.1164/rccm.201003-0423OC
   Du YZ, 2010, ACS NANO, V4, P6894, DOI 10.1021/nn100927t
   Gentile Francesco, 2008, Journal of Nanobiotechnology, V6, P9, DOI 10.1186/1477-3155-6-9
   Gotts JE, 2011, CRIT CARE CLIN, V27, P719, DOI 10.1016/j.ccc.2011.04.004
   Howard M, 2014, ACS NANO, V8, P4100, DOI 10.1021/nn500136z
   Hsu J, 2012, NANOMED-NANOTECHNOL, V8, P731, DOI 10.1016/j.nano.2011.08.014
   Huo MX, 2013, INT IMMUNOPHARMACOL, V15, P442, DOI 10.1016/j.intimp.2013.01.008
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC
   Kilic B, 2006, TOXICOLOGY, V218, P30, DOI 10.1016/j.tox.2005.09.014
   Lanbeck P, 2004, J ANTIMICROB CHEMOTH, V53, P174, DOI 10.1093/jac/dkh056
   Lu YM, 2014, BIOMATERIALS, V35, P530, DOI 10.1016/j.biomaterials.2013.09.093
   Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   McClintock D, 2008, CRIT CARE, V12, DOI 10.1186/cc6846
   Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209
   Muro S, 2008, MOL THER, V16, P1450, DOI 10.1038/mt.2008.127
   Oh B, 2014, J CONTROL RELEASE, V175, P25, DOI 10.1016/j.jconrel.2013.12.008
   Radjabova V, 2015, J IMMUNOL, V195, P3149, DOI 10.4049/jimmunol.1401847
   Sadikot RT, 2014, ADV DRUG DELIVER REV, V77, P27, DOI 10.1016/j.addr.2014.07.004
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Steiner S, 2005, CIRCULATION, V111, P1841, DOI 10.1161/01.CIR.0000158665.27783.0C
   Tang XL, 2016, DRUG DELIV, V23, P2686, DOI 10.3109/10717544.2015.1049720
   Yu Q, 2016, DRUG DELIV, V23, P1469, DOI 10.3109/10717544.2016.1153744
   Yuan H, 2013, MOL PHARMACEUT, V10, P1865, DOI 10.1021/mp300649z
   Zhai YJ, 2014, J CONTROL RELEASE, V193, P90, DOI 10.1016/j.jconrel.2014.05.054
NR 34
TC 29
Z9 29
U1 4
U2 29
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PY 2017
VL 24
IS 1
BP 402
EP 413
DI 10.1080/10717544.2016.1259369
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EM1KZ
UT WOS:000395077800040
PM 28165814
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Ren, W
   Wang, ZW
   Wu, ZY
   Hu, ZP
   Dai, FF
   Chang, JX
   Li, BW
   Liu, HG
   Ruan, YL
AF Ren, Wei
   Wang, Zhiwei
   Wu, Zhiyong
   Hu, Zhipeng
   Dai, Feifeng
   Chang, Jinxing
   Li, Bowen
   Liu, Huagang
   Ruan, Yongle
TI JAK2/STAT3 Pathway Was Associated with the Protective Effects of IL-22
   On Aortic Dissection with Acute Lung Injury
SO DISEASE MARKERS
LA English
DT Article
ID MICROVASCULAR ENDOTHELIAL-CELLS; ANGIOTENSIN-II; PROLIFERATION;
   INFLAMMATION; ACTIVATION; EXPRESSION; RECEPTOR; STAT3
AB Patients with aortic dissection (AD) may present acute lung injury (ALI) that may affect the prognosis. In this study, we aim to investigate the roles and mechanism of IL-22 in the pathogenesis of AD complicated with ALI. Six hundred and twenty-one AD patients were included, and the incidence of ALI and pulmonary CT findings were analyzed. Mouse ALI model was established through AngII, and then IL-22 injection and AG490 were given. The pathological changes, infiltration of inflammatory cells, and expression of STAT3 were determined. For the in vitro experiment, cultivated pulmonary microvascular endothelial cells (PMVECs) were treated by angiotensin II (AngII), followed by treating with IL-22 and/or AG490. The expression and migration of STAT3 was determined. Flow cytometry was carried out to evaluate the apoptosis. IL-22 contributed to the expression of STAT3 in lung tissues and attenuation of ALI. IL-22 obviously inhibited the apoptosis of PMVECs mediated by AngII and downregulated the expression and intranuclear transmission of STAT3. Such phenomenon was completely inhibited upon administration of AG490, an inhibitor of JAK2. Our data showed IL-22 contributed to the inhibition of PMVEC apoptosis mediated by AngII through activating the JAK2/STAT3 signaling pathway, which may attenuate the ALI induced by AngII.
C1 [Ren, Wei; Wang, Zhiwei; Wu, Zhiyong; Hu, Zhipeng; Dai, Feifeng; Chang, Jinxing; Li, Bowen; Liu, Huagang; Ruan, Yongle] Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, Wuhan 430060, Hubei, China.
C1 [Ren, Wei; Wang, Zhiwei; Wu, Zhiyong; Hu, Zhipeng; Dai, Feifeng; Chang, Jinxing; Li, Bowen; Liu, Huagang; Ruan, Yongle] Hubei Key Lab Cardiol, Wuhan 430060, Hubei, China.
C3 Wuhan University
RP Wang, ZW; Wu, ZY (corresponding author), Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, Wuhan 430060, Hubei, Peoples R China.; Wang, ZW; Wu, ZY (corresponding author), Hubei Key Lab Cardiol, Wuhan 430060, Hubei, Peoples R China.
EM wangzhiwei@whu.edu.cn; zhiyongwu889@sina.com
OI Hu, Zhipeng/0000-0002-6384-0037
FU National Natural Science Foundation [81570428, 81501376]; Hubei Province
   Health and Family Planning Scientific Research Project [WJ2017M013]
FX This study was supported by the National Natural Science Foundation
   (nos. 81570428 and 81501376) and Hubei Province Health and Family
   Planning Scientific Research Project (no. WJ2017M013).
CR Agrawal R, 2010, PHARMACOL RES, V61, P269, DOI 10.1016/j.phrs.2009.11.012
   Bae ON, 2015, TOXICOL APPL PHARM, V283, P147, DOI 10.1016/j.taap.2015.01.008
   Bai XZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10277
   Benham H, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4317
   Bhargava M., TRANSLATIONAL RES, V159, P205
   Cambi GE, 2012, MOL BIOSYST, V8, P2351, DOI 10.1039/c2mb25120e
   Chen D, 2014, BBA-MOL CELL RES, V1843, P454, DOI 10.1016/j.bbamcr.2013.11.024
   Del Porto F, 2010, ANN MED, V42, P622, DOI 10.3109/07853890.2010.518156
   Della Penna S. L., 2011, J PHYSL BIOCH, V70, P465
   Deng J, 2012, CAN RESPIR J, V19, P311, DOI 10.1155/2012/951025
   Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814
   Han S, 2015, J IMMUNOL, V194, P5569, DOI 10.4049/jimmunol.1500741
   Kim KW, 2012, ARTHRITIS RHEUM-US, V64, P1015, DOI 10.1002/art.33446
   Leifheit-Nestler M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-170
   Lin J, 2014, SCAND J IMMUNOL, V79, P131, DOI 10.1111/sji.12135
   Lu Z., 2011, CELL IMMUNOL, V304-305, P1
   Luo HY, 2009, PERFUSION-UK, V24, P199, DOI 10.1177/0267659109346671
   Ma WG, 2013, ANN CARDIOTHORAC SUR, V2, P621, DOI 10.3978/j.issn.2225-319X.2013.09.06
   Moriwaki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140750
   Podowski M, 2012, J CLIN INVEST, V122, P229, DOI 10.1172/JCI46215
   Rattik S, 2015, ATHEROSCLEROSIS, V242, P506, DOI 10.1016/j.atherosclerosis.2015.08.006
   Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176
   Savan R, 2011, BLOOD, V117, P575, DOI 10.1182/blood-2010-05-285908
   Sonnenberg GF, 2010, ADV IMMUNOL, V107, P1, DOI [10.1016/S0065-2776(10)07008-2, 10.1016/B978-0-12-381300-8.00001-0]
   Sun LZ, 2011, ANN THORAC SURG, V91, P1147, DOI 10.1016/j.athoracsur.2010.12.005
   Supe S, 2016, BRIT J PHARMACOL, V173, P1618, DOI 10.1111/bph.13462
   Talla K, 2017, INT J CARDIOVAS IMAG, V33, P259, DOI 10.1007/s10554-016-0989-7
   Wang LG, 2015, MOL MED REP, V12, P8261, DOI 10.3892/mmr.2015.4471
   Wolk K, 2010, SEMIN IMMUNOPATHOL, V32, P17, DOI 10.1007/s00281-009-0188-x
   Wu ZY, 2016, AM J TRANSL RES, V8, P1426
   Wu ZY, 2016, AM J TRANSL RES, V8, P28
   Xia Q, 2012, INT J CARDIOL, V154, P187, DOI 10.1016/j.ijcard.2011.10.093
   Yang Y, 2013, J PINEAL RES, V55, P275, DOI 10.1111/jpi.12070
   Yue PB, 2016, CANCER RES, V76, P652, DOI 10.1158/0008-5472.CAN-14-3558
   Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
   Zhang H, 2006, J SURG RES, V134, P190, DOI 10.1016/j.jss.2006.01.026
   Zhao L, 2013, INT J RHEUM DIS, V16, P518, DOI 10.1111/1756-185X.12099
NR 38
TC 8
Z9 9
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PY 2017
VL 2017
AR 1917804
DI 10.1155/2017/1917804
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA FD8HE
UT WOS:000407765000001
PM 28827891
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Simonsen, U
   Wandall-Frostholm, C
   Olivan-Viguera, A
   Kohler, R
AF Simonsen, U.
   Wandall-Frostholm, C.
   Olivan-Viguera, A.
   Kohler, R.
TI Emerging roles of calcium-activated K channels and TRPV4 channels in
   lung oedema and pulmonary circulatory collapse
SO ACTA PHYSIOLOGICA
LA English
DT Review
DE collapse; ECs/HPMECs/HUVECs/MPVECs; KCa3.1; lung oedema; pulmonary circulation; Transient receptor potential vanilloid 4 (TRPV4) 
ID RESPIRATORY-DISTRESS-SYNDROME; POTENTIAL VANILLOID 4; HYPERPOLARIZING
   FACTOR; K(CA)3.1 CHANNELS; POTASSIUM CHANNEL; SMALL-CONDUCTANCE; GENETIC
   DEFICIT; FLUID CLEARANCE; INTERMEDIATE; INJURY
AB It has been suggested that the transient receptor potential cation (TRP) channel subfamily V (vanilloid) type 4 (TRPV4) and intermediate conductance calcium-activated potassium (KCa3.1) channels contribute to endothelium-dependent vasodilation. Here, we summarize very recent evidence for a synergistic interplay of TRPV4 and KCa3.1 channels in lung disease. Among the endothelial Ca (2+)-permeable TRPs, TRPV4 is best characterized and produces arterial dilation by stimulating Ca2+-dependent nitric oxide synthesis and endothelium-dependent hyperpolarization. Besides these roles, some TRP channels control endothelial/epithelial barrier functions and vascular integrity, while KCa3.1 channels provide the driving force required for Cl- and water transport in some cells and most secretory epithelia. The three conditions, increased pulmonary venous pressure caused by left heart disease, high inflation pressure and chemically induced lung injury, may lead to activation of TRPV4 channels followed by Ca (2+) influx leading to activation of KCa3.1 channels in endothelial cells ultimately leading to acute lung injury. We find that a deficiency in KCa3.1 channels protects against TRPV4-induced pulmonary arterial relaxation, fluid extravasation, haemorrhage, pulmonary circulatory collapse and cardiac arrest in vivo. These data identify KCa3.1 channels as crucial molecular components in downstream TRPV4 signal transduction and as a potential target for the prevention of undesired fluid extravasation, vasodilatation and pulmonary circulatory collapse.
C1 [Simonsen, U.; Wandall-Frostholm, C.] Aarhus Univ, Dept Biomed Pulm & Cardiovasc Pharmacol, Aarhus C, Denmark.
C1 [Olivan-Viguera, A.; Kohler, R.] Univ Hosp Miguel Servet, Translat Res Unit, Zaragoza, Spain.
C1 [Olivan-Viguera, A.; Kohler, R.] Aragonese Agcy Invest & Dev ARAID, IACS IIS, Zaragoza, Spain.
C3 Aarhus University; Miguel Servet University Hospital
RP Simonsen, U (corresponding author), Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark.
EM us@biomed.au.dk
RI Oliván-Viguera, Aida/I-4260-2015; Oliván-Viguera, Aida/ABG-4048-2020
OI Oliván-Viguera, Aida/0000-0001-5348-924X; Oliván-Viguera,
   Aida/0000-0001-5348-924X
FU Danish Heart Foundation; Stiftelsen Nordisk Fysiologi, SNF; Novo Nordisk
   Fonden [NNF16OC0023284] Funding Source: researchfish
FX Ulf Simonsen is supported by the Danish Heart Foundation and is part of
   MEMBRANES, Aarhus University. I would like to thank the Stiftelsen
   Nordisk Fysiologi, SNF, for generous support for the AP Symposium on
   'Endothelium-dependent hyperpolarizations 2015'.
CR Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19
   Ataga KI, 2008, BLOOD, V111, P3991, DOI 10.1182/blood-2007-08-110098
   Balakrishna S, 2014, AM J PHYSIOL-LUNG C, V307, pL158, DOI 10.1152/ajplung.00065.2014
   Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010
   Bertuccio CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092013
   Brahler S, 2009, CIRCULATION, V119, P2323, DOI 10.1161/CIRCULATIONAHA.108.846634
   Catalan MA, 2014, CELL CALCIUM, V55, P362, DOI 10.1016/j.ceca.2014.01.005
   Chen L, 2015, ACTA PHYSIOL, V213, P481, DOI 10.1111/apha.12355
   Chen YJ, 2015, STROKE, V46, P237, DOI 10.1161/STROKEAHA.114.007445
   Christophersen P, 2015, CHANNELS, V9, P336, DOI 10.1080/19336950.2015.1071748
   Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196
   Coleman N, 2014, MOL PHARMACOL, V86, P342, DOI 10.1124/mol.114.093286
   Crane GJ, 2003, J PHYSIOL-LONDON, V553, P183, DOI 10.1113/jphysiol.2003.051896
   Duggal A, 2015, MINERVA ANESTESIOL, V81, P567
   Earley S, 2009, AM J PHYSIOL-HEART C, V297, pH1096, DOI 10.1152/ajpheart.00241.2009
   Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388
   Fernandez-Fernandez JM, 2008, PFLUG ARCH EUR J PHY, V457, P149, DOI 10.1007/s00424-008-0516-3
   Goldenberg NM, 2015, N-S ARCH PHARMACOL, V388, P421, DOI 10.1007/s00210-014-1058-1
   Gollasch M, 2016, RESP PHYSIOL NEUROBI, V227, P71, DOI 10.1016/j.resp.2015.10.007
   Grgic I, 2009, PFLUG ARCH EUR J PHY, V458, P291, DOI 10.1007/s00424-008-0619-x
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009
   Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827
   Hasenau AL, 2011, ACTA PHYSIOL, V203, P117, DOI 10.1111/j.1748-1716.2010.02240.x
   Jian MY, 2008, AM J RESP CELL MOL, V38, P386, DOI 10.1165/rcmb.2007-0192OC
   Ke SK, 2015, RESP PHYSIOL NEUROBI, V219, P43, DOI 10.1016/j.resp.2015.08.003
   Kerem A, 2010, CIRC RES, V106, P1103, DOI 10.1161/CIRCRESAHA.109.210542
   Kohler R, 2006, ARTERIOSCL THROM VAS, V26, P1495, DOI 10.1161/01.ATV.0000225698.36212.6a
   Kroigaard C, 2012, BRIT J PHARMACOL, V167, P37, DOI 10.1111/j.1476-5381.2012.01986.x
   Lin MT, 2015, PULM CIRC, V5, P279, DOI 10.1086/680166
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Mall M, 2003, PEDIATR RES, V53, P608, DOI 10.1203/01.PDR.0000057204.51420.DC
   Mauler F, 2004, EUR J NEUROSCI, V20, P1761, DOI 10.1111/j.1460-9568.2004.03615.x
   McGovern TK, 2013, JOVE-J VIS EXP, DOI 10.3791/50172
   McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104
   Morty RE, 2014, AM J PHYSIOL-LUNG C, V307, pL817, DOI 10.1152/ajplung.00254.2014
   Neto AS, 2015, CRIT CARE MED, V43, P2155, DOI 10.1097/CCM.0000000000001189
   Olivan-Viguera A, 2015, MOL PHARMACOL, V87, P338, DOI 10.1124/mol.114.095745
   Pankey EA, 2014, AM J PHYSIOL-HEART C, V306, pH33, DOI 10.1152/ajpheart.00303.2013
   Phillips JE, 2012, PULM PHARMACOL THER, V25, P281, DOI 10.1016/j.pupt.2011.10.001
   Qian X, 2014, ARTERIOSCL THROM VAS, V34, P127, DOI 10.1161/ATVBAHA.113.302506
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Searcy RJ, 2015, THER ADV RESPIR DIS, V9, P302, DOI 10.1177/1753465815599345
   Si H, 2006, CIRC RES, V99, P537, DOI 10.1161/01.RES.0000238377.08219.0c
   Song YL, 2000, J PHYSIOL-LONDON, V525, P771, DOI 10.1111/j.1469-7793.2000.00771.x
   Sonkusare SK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005052
   Sonkusare SK, 2012, SCIENCE, V336, P597, DOI 10.1126/science.1216283
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Sukumaran SV, 2013, PHARMACOL RES, V78, P18, DOI 10.1016/j.phrs.2013.09.005
   Syme CA, 2000, AM J PHYSIOL-CELL PH, V278, pC570, DOI 10.1152/ajpcell.2000.278.3.C570
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498
   Verkman AS, 2007, RESP PHYSIOL NEUROBI, V159, P324, DOI 10.1016/j.resp.2007.02.012
   Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101
   Wandall-Frostholm C, 2015, BRIT J PHARMACOL, V172, P4493, DOI 10.1111/bph.13234
   Wandall-Frostholm C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097687
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807
   Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551
   Wolfle SE, 2009, CARDIOVASC RES, V82, P476, DOI 10.1093/cvr/cvp060
   Xia Y, 2013, AM J PHYSIOL-CELL PH, V305, pC704, DOI 10.1152/ajpcell.00099.2013
   Yang XR, 2012, AM J PHYSIOL-LUNG C, V302, pL555, DOI 10.1152/ajplung.00005.2011
   Yin J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   Yin J, 2016, AM J RESP CELL MOL, V54, P370, DOI 10.1165/rcmb.2014-0225OC
   Yoo HY, 2012, AM J PHYSIOL-CELL PH, V302, pC307, DOI 10.1152/ajpcell.00153.2011
NR 65
TC 22
Z9 22
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1748-1708
EI 1748-1716
J9 ACTA PHYSIOL
JI Acta Physiol.
PD JAN
PY 2017
VL 219
IS 1
BP 176
EP 187
DI 10.1111/apha.12768
PG 12
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA EK4RQ
UT WOS:000393914900015
PM 27497091
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Sun, XG
   Mathew, B
   Sammani, S
   Jacobson, JR
   Garcia, JGN
AF Sun, Xiaoguang
   Mathew, Biji
   Sammani, Saad
   Jacobson, Jeffrey R.
   Garcia, Joe G. N.
TI Simvastatin-induced sphingosine 1-phosphate receptor 1 expression is
   KLF2-dependent in human lung endothelial cells
SO PULMONARY CIRCULATION
LA English
DT Article
DE simvastatin; S1P/S1PR1/S1PR2/S1PR3; promoter activity; KLF2; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS 
ID KRUPPEL-LIKE FACTOR-2; BARRIER ENHANCEMENT; PULMONARY-HYPERTENSION;
   TRANSCRIPTION FACTOR; GENE-EXPRESSION; S1P(1) RECEPTOR; VASCULAR LEAK;
   MURINE; INJURY; STATINS
AB We have demonstrated that simvastatin and sphingosine 1-phosphate (S1P) both attenuate increased vascular permeability in preclinical models of acute respiratory distress syndrome. However, the underlying mechanisms remain unclear. As Kruppel-like factor 2 (KLF2) serves as a critical regulator for cellular stress response in endothelial cells (EC), we hypothesized that simvastatin enhances endothelial barrier function via increasing expression of the barrier-promoting S1P receptor, S1PR1, via a KLF2-dependent mechanism. S1PR1 luciferase reporter promoter activity in human lung artery EC (HPAEC) was tested after simvastatin (5 mu M), and S1PR1 and KLF2 protein expression detected by immunoblotting. In vivo, transcription and expression of S1PR1 and KLF2 in mice lungs were detected by microarray profiling and immunoblotting after exposure to simvastatin (10 mg/kg). Endothelial barrier function was measured by trans-endothelial electrical resistance with the S1PR1 agonist FTY720-(S)-phosphonate. Both S1PR1 and KLF2 gene expression (mRNA, protein) were significantly increased by simvastatin in vitro and in vivo. S1PR1 promoter activity was significantly increased by simvastatin (P < 0.05), which was significantly attenuated by KLF2 silencing (siRNA). Simvastatin induced KLF2 recruitment to the S1PR1 promoter, and consequently, significantly augmented the effects of the S1PR1 agonist on EC barrier enhancement (P < 0.05), which was significantly attenuated by KLF2 silencing (P < 0.05). These results suggest that simvastatin upregulates S1PR1 transcription and expression via the transcription factor KLF2, and consequently augments the effects of S1PR1 agonists on preserving vascular barrier integrity. These results may lead to novel combinatorial therapeutic strategies for lung inflammatory syndromes.
C1 [Sun, Xiaoguang; Sammani, Saad; Garcia, Joe G. N.] Univ Arizona Hlth Sci, Dept Med, Tucson, AZ, United States.
C1 [Mathew, Biji; Jacobson, Jeffrey R.] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C3 University of Arizona; University of Arizona Health Sciences; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital
RP Garcia, JGN (corresponding author), Univ Arizona Hlth Sci, Med, 1295 N Martin Ave,POB 210202, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
RI SUN, XIAOGUANG/ACA-5558-2022
FU National Heart, Lung and Blood Institute [P01HL58064, P01HL98050,
   P01HL126609]
FX This work was supported by National Heart, Lung and Blood Institute
   grants P01HL58064, P01HL98050, and P01HL126609.
CR Amerongen GPV, 2000, CIRCULATION, V102, P2803
   Bai AL, 2007, J IMMUNOL, V178, P7632, DOI 10.4049/jimmunol.178.12.7632
   Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882
   Craig TR, 2011, AM J RESP CRIT CARE, V183, P620, DOI 10.1164/rccm.201003-0423OC
   Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046
   Dekker RJ, 2006, BLOOD, V107, P4354, DOI 10.1182/blood-2005-08-3465
   Ephstein Y, 2013, J BIOL CHEM, V288, P2191, DOI 10.1074/jbc.M112.404780
   Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   Frutos-Vivar Fernando, 2004, Curr Opin Crit Care, V10, P1, DOI 10.1097/00075198-200402000-00001
   Gaengel K, 2012, DEV CELL, V23, P587, DOI 10.1016/j.devcel.2012.08.005
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia JGN, 2011, AM J RESP CRIT CARE, V183, P1287, DOI 10.1164/rccm.201104-0623ED
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Gonzalez-Diez M, 2008, THROMB HAEMOSTASIS, V100, P119, DOI 10.1160/TH07-11-0675
   Haaland RE, 2005, MOL IMMUNOL, V42, P627, DOI 10.1016/j.molimm.2004.09.012
   Han JY, 2012, THER DELIV, V3, P263, DOI 10.4155/TDE.11.151
   Igarashi J, 2007, BRIT J PHARMACOL, V150, P470, DOI 10.1038/sj.bjp.0707114
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC
   Jung B, 2012, DEV CELL, V23, P600, DOI 10.1016/j.devcel.2012.07.015
   Kao PN, 2005, CHEST, V127, P1446, DOI 10.1378/chest.127.4.1446
   Koudritsky M, 2008, NUCLEIC ACIDS RES, V36, P6795, DOI 10.1093/nar/gkn752
   Kumar A, 2011, ARTERIOSCL THROM VAS, V31, P133, DOI 10.1161/ATVBAHA.110.215061
   Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996
   Lee K, 2008, AM J PHYSIOL-HEART C, V295, pH2273, DOI 10.1152/ajpheart.00242.2008
   Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334
   Lin ZY, 2010, ARTERIOSCL THROM VAS, V30, P1952, DOI 10.1161/ATVBAHA.110.211474
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007
   MacIsaac KD, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000773
   Mansur A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0368-6
   Mathew B, 2011, FASEB J, V25, P3388, DOI 10.1096/fj.11-183970
   Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mihos CG, 2014, PHARMACOL RES, V88, P12, DOI 10.1016/j.phrs.2014.02.009
   Moreno-Vinasco L, 2008, J ORGAN DYSFUNCTION, V4, P106, DOI [DOI 10.1080/17471060701505289, 10.1080/17471060701505289]
   Opal SM, 2015, J INTERN MED, V277, P277, DOI 10.1111/joim.12331
   Parmar KM, 2005, J BIOL CHEM, V280, P26714, DOI 10.1074/jbc.C500144200
   Penn MS, 1997, AM J PHYSIOL-HEART C, V272, pH1560, DOI 10.1152/ajpheart.1997.272.4.H1560
   Qiaoli S, 2016, EUR REV MED PHARMACO, V20, P138
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200
   Sen-Banerjee S, 2005, CIRCULATION, V112, P720, DOI 10.1161/CIRCULATIONAHA.104.525774
   SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Steiner S, 2005, CIRCULATION, V111, P1841, DOI 10.1161/01.CIR.0000158665.27783.0C
   Sun X., 2012, ABST APPL ANAL, V2012, P1, DOI DOI 10.1371/J0URNAL.PGEN.1002674
   Sun XG, 2010, J ALLERGY CLIN IMMUN, V126, P241, DOI 10.1016/j.jaci.2010.04.036
   Thomsen RW, 2006, CRIT CARE MED, V34, P1080, DOI 10.1097/01.CCM.0000207345.92928.E4
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   Villar J, 2011, MINERVA ANESTESIOL, V77, P647
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wang Liwen, 2014, Biomed Res Int, V2014, P453972, DOI 10.1155/2014/453972
   Wilkins MR, 2010, AM J RESP CRIT CARE, V181, P1106, DOI [10.1164/rccm.200911-1699OC, 10.1164/rccm.2009111-699OC]
NR 58
TC 12
Z9 13
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD JAN-MAR
PY 2017
VL 7
IS 1
BP 117
EP 125
DI 10.1177/2045893217701162
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA ER8FA
UT WOS:000399052900011
PM 28680571
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Suresh, K
   Servinsky, L
   Reyes, J
   Undem, C
   Zaldumbide, J
   Rentsendorj, O
   Modekurty, S
   Dodd-o, JM
   Scott, A
   Pearse, DB
   Shimoda, LA
AF Suresh, Karthik
   Servinsky, Laura E.
   Reyes, Jose
   Undem, Clark
   Zaldumbide, Joel
   Rentsendorj, Otgonchimeg
   Modekurty, Sruti
   Dodd-o, Jeffrey M.
   Scott, Alan L.
   Pearse, David B.
   Shimoda, Larissa A.
TI CD36 mediates H2O2- induced calcium influx in lung microvascular
   endothelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; calcium; ROS 
ID PROTEIN-TYROSINE KINASES; BARRIER FUNCTION; INJURY; ACTIVATION;
   ISCHEMIA; TRPV4; MOUSE; SRC; INFLAMMATION; REPERFUSION
AB Elevated levels of reactive oxygen species and intracellular Ca2 + play a key role in endothelial barrier dysfunction in acute lung injury. We previously showed that H(2)O(2)induced increases in intracellular calcium concentrations ([ Ca-2 (+)] (i)) in lung microvascular endothelial cells (LMVECs) involve the membrane Ca2+ channel, transient receptor potential vanilloid-4 (TRPV4) and that inhibiting this channel attenuated H2O2-induced barrier disruption in vitro. We also showed that phosphorylation of TRPV4 by the Src family kinase, Fyn, contributes to H2O2-induced Ca2 + influx in LMVEC. In endothelial cells, Fyn is tethered to the cell membrane by CD36, a fatty acid transporter. In this study, we assessed the effect of genetic loss or pharmacological inhibition of CD36 on Ca2 + responses to H2O2. H2O2-induced Ca2 + influx was attenuated in LMVEC isolated from mice lacking CD36 (CD36(- /-)). TRPV4 expression and function was unchanged in LMVEC isolated from wild-type (WT) and CD36 (- / -) mice, as well as mice with deficiency for Fyn (Fyn(-/-) )TRPV4 immunopreipitated with Fcyn, but this interaction was decreased in CD36 (- / -) LMVEC. The amount of phosphorylated TRPV4 was decreased in LMVEC from CD36 (- / -) mice compared with WT controls. Loss of CD36 altered subcellular localization of Fyn, while inhibition of CD36 fatty acid transport with succinimidyl oleate did not attenuate H2O2-induced Ca2 + influx. Lastly, we found that CD36 (- / -) mice were protected from ischemiareperfusion injury in vivo. In conclusion, our data suggest that CD36 plays an important role in H2O2-mediated lung injury and that the mechanism may involve CD36-dependent scaffolding of Fyn to the cell membrane to facilitate TRPV4 phosphorylation.
C1 [Suresh, Karthik; Servinsky, Laura; Reyes, Jose; Undem, Clark; Zaldumbide, Joel; Rentsendorj, Otgonchimeg; Modekurty, Sruti; Pearse, David B.; Shimoda, Larissa A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205, United States.
C1 [Dodd-o, Jeffrey M.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205, United States.
C1 [Scott, Alan] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD, United States.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Suresh, K (corresponding author), Johns Hopkins Asthma & Allergy Bldg, Baltimore, MD 21224 USA.
EM ksuresh2@jhmi.edu
RI Suresh, Karthik/P-6307-2019
FU National Heart, Lung and Blood Institute [F32-HL124930, R01HL-73859,
   R25-HL084762, T32HL-007534]
FX Support for this study was provided by the National Heart, Lung and
   Blood Institute Grants F32-HL124930 (K. Suresh), R01HL-73859 (L. A.
   Shimoda), R25-HL084762 (L. A. Shimoda), and T32HL-007534.
CR Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328
   Anidi IU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071010
   Balakrishna S, 2014, AM J PHYSIOL-LUNG C, V307, pL158, DOI 10.1152/ajplung.00065.2014
   Bocharov AV, 2016, J IMMUNOL, V197, P611, DOI 10.4049/jimmunol.1401028
   Bogeski I, 2011, CELL CALCIUM, V50, P407, DOI 10.1016/j.ceca.2011.07.006
   Bubolz AH, 2012, AM J PHYSIOL-HEART C, V302, pH634, DOI 10.1152/ajpheart.00717.2011
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920
   Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005
   Chu LY, 2013, BLOOD, V122, P1822, DOI 10.1182/blood-2013-01-482315
   Cioffi DL, 2006, MICROCIRCULATION, V13, P709, DOI 10.1080/10739680600930354
   Cioffi DL, 2009, ANTIOXID REDOX SIGN, V11, P765, DOI [10.1089/ars.2008.2221, 10.1089/ARS.2008.2221]
   Dodd-O JM, 2008, AM J PHYSIOL-LUNG C, V294, pL714, DOI 10.1152/ajplung.00185.2007
   Dodd-o JM, 2003, J APPL PHYSIOL, V95, P1971, DOI 10.1152/japplphysiol.00456.2003
   El-Yassimi A, 2008, J BIOL CHEM, V283, P12949, DOI 10.1074/jbc.M707478200
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Kuda O, 2013, J BIOL CHEM, V288, P15547, DOI 10.1074/jbc.M113.473298
   Kuda O, 2011, J BIOL CHEM, V286, P17785, DOI 10.1074/jbc.M111.232975
   Kuhlmann CRW, 2004, J MOL CELL CARDIOL, V36, P675, DOI 10.1016/j.yjmcc.2004.03.001
   Li K, 2014, J CELL SCI, V127, P4574, DOI 10.1242/jcs.141978
   Li W, 2010, J CLIN INVEST, V120, P3996, DOI 10.1172/JCI42823
   Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100
   Martinez J, 2001, ARCH BIOCHEM BIOPHYS, V392, P257, DOI 10.1006/abbi.2001.2439
   Nagendran J, 2013, J MOL CELL CARDIOL, V63, P180, DOI 10.1016/j.yjmcc.2013.07.020
   Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2
   Sarmiento D, 2015, MICROVASC RES, V98, P187, DOI 10.1016/j.mvr.2014.02.001
   Seeley EJ, 2013, J CLIN INVEST, V123, P1015, DOI 10.1172/JCI68093
   Sengupta D, 2009, J CELL BIOL, V186, P41, DOI 10.1083/jcb.200902110
   SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353
   Silverstein R. L., 2009, CLEV CLIN J MED, V76, pS27, DOI DOI 10.3949/CCJM.76.S2.06
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Steinbusch LKM, 2011, AM J PHYSIOL-ENDOC M, V301, pE618, DOI 10.1152/ajpendo.00106.2011
   Stuart LM, 2007, J BIOL CHEM, V282, P27392, DOI 10.1074/jbc.M702887200
   Suresh K, 2015, AM J PHYSIOL-LUNG C, V309, pL1467, DOI 10.1152/ajplung.00275.2015
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   Villalta PC, 2013, PULM CIRC, V3, P802, DOI 10.1086/674765
   Wegierski T, 2009, J BIOL CHEM, V284, P2923, DOI 10.1074/jbc.M805357200
   Weissmann N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1660
   Xu YN, 2010, ANAL BIOCHEM, V400, P207, DOI 10.1016/j.ab.2010.02.003
   Zhao Y, 2012, EUR J HISTOCHEM, V56, P201, DOI 10.4081/ejh.2012.e32
NR 44
TC 19
Z9 20
U1 1
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JAN
PY 2017
VL 312
IS 1
BP L143
EP L153
DI 10.1152/ajplung.00361.2016
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA EK2XT
UT WOS:000393791100014
PM 27913425
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Tsangaris, I
   Tsantes, A
   Vrigkou, E
   Kopterides, P
   Pelekanou, A
   Zerva, K
   Antonakos, G
   Konstantonis, D
   Mavrou, I
   Tsaknis, G
   Kyriazopoulou, E
   Mouktaroudi, M
   Kokori, S
   Orfanos, SE
   Giamarellos-Bourboulis, EJ
   Armaganidis, A
AF Tsangaris, Iraklis
   Tsantes, Argirios
   Vrigkou, Eleni
   Kopterides, Petros
   Pelekanou, Aimilia
   Zerva, Katerina
   Antonakos, George
   Konstantonis, Dimitrios
   Mavrou, Irini
   Tsaknis, Georgios
   Kyriazopoulou, Evdoxia
   Mouktaroudi, Maria
   Kokori, Styliani
   Orfanos, Stylianos E.
   Giamarellos-Bourboulis, Evangelos J.
   Armaganidis, Apostolos
TI Angiopoietin-2 Levels as Predictors of Outcome in Mechanically
   Ventilated Patients with Acute Respiratory Distress Syndrome
SO DISEASE MARKERS
LA English
DT Article
ID ACUTE LUNG INJURY; MORTALITY; INFLAMMATION; ENDOTHELIUM; COAGULATION;
   ACTIVATION; SEVERITY; MARKER; EDEMA
AB Pulmonary endothelium dysfunction is a key characteristic of ARDS. The aim of this study was to investigate endothelium-derived markers, such as angiopoietin-2 (Ang-2) and endothelial cell-specific molecule-1 (endocan), at the vascular and alveolar compartments as outcome predictors in ARDS. Fifty-three consecutive ARDS patients were studied. The primary outcome was 28-day mortality. Secondary endpoints were days of unassisted ventilation and days with organ failure other than ARDS, during the 28-day study period. Nonsurvivors presented higher lung injury scores and epithelial lining fluid (ELF) Ang-2 levels compared to survivors, with no significant differences in plasma Ang-2, endocan, and protein C concentrations between the two groups. In logistic regression analysis, ELF Ang-2 levels > 705 pg/ml were the only independent variable for 28-day mortality among the previous four. Plasma endocan values > 13 ng/pg were the only parameter predictive against days of unassisted ventilation during the 28-day study period. Finally, lung injury score > 2.25 and ELF Ang-2 levels > 705 pg/ml were associated with increased number of days with organ failure, other than ARDS. Our findings suggest that Ang-2 levels are increased in the alveolar compartment of ARDS patients, and this may be associated both with increased mortality and organ failure besides lung.
C1 [Tsangaris, Iraklis; Vrigkou, Eleni; Kopterides, Petros; Konstantonis, Dimitrios; Mavrou, Irini; Tsaknis, Georgios; Orfanos, Stylianos E.; Armaganidis, Apostolos] Natl & Kapodistrian Univ Athens, Med Sch, Dept Crit Care Med 2, Athens, Greece.
C1 [Tsantes, Argirios; Kokori, Styliani] Natl & Kapodistrian Univ Athens, Med Sch, Lab Hematol, Athens, Greece.
C1 [Tsantes, Argirios; Kokori, Styliani] Natl & Kapodistrian Univ Athens, Med Sch, Blood Bank Unit, Athens, Greece.
C1 [Pelekanou, Aimilia; Kyriazopoulou, Evdoxia; Mouktaroudi, Maria; Giamarellos-Bourboulis, Evangelos J.] Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens, Greece.
C1 [Zerva, Katerina; Antonakos, George] Natl & Kapodistrian Univ Athens, Med Sch, Athens Univ Hosp Attikon, Dept Biochem, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; University Hospital Attikon
RP Tsangaris, I (corresponding author), Natl & Kapodistrian Univ Athens, Med Sch, Dept Crit Care Med 2, Athens, Greece.
EM itsagkaris@med.uoa.gr
RI Kokoris, Stella/GYA-1957-2022; Giamarellos-Bourboulis,
   Evangelos/AAD-7155-2019; Tsaknis, Georgios/AAD-2109-2022; Kyriazopoulou,
   Evdoxia/AAT-9746-2021; Tsangaris, Iraklis/AAA-3627-2020
OI Tsaknis, Georgios/0000-0001-8927-9631; Kyriazopoulou,
   Evdoxia/0000-0002-9585-517X; Tsangaris, Iraklis/0000-0003-4395-0471;
   Kokoris, Styliani/0000-0002-1635-7309
CR Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chambers Rachel C, 2012, Proc Am Thorac Soc, V9, P96, DOI 10.1513/pats.201201-006AW
   Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002
   Frantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002
   Freitas C. N. D., 2013, J PHARMACEUT BIOMED, V78-79, P45
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   IDELL S, 1991, AM J PHYSIOL, V261, pL240, DOI 10.1152/ajplung.1991.261.4.L240
   Ioakeimidou A., 2017, EUROPEAN J CLIN MICR
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Kumpers P, 2008, CRIT CARE, V12, DOI 10.1186/cc7130
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Matthay MA, 2004, CRIT CARE MED, V32, pS229, DOI 10.1097/01.CCM.0000126121.56990.D3
   Millar FR, 2016, THORAX, V71, P462, DOI 10.1136/thoraxjnl-2015-207461
   Ong T, 2010, CRIT CARE MED, V38, P1845, DOI 10.1097/CCM.0b013e3181eaa5bf
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Ozolina A, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00064
   Pauly D, 2016, J CRIT CARE, V31, P68, DOI 10.1016/j.jcrc.2015.09.019
   Prabhakaran P, 2003, AM J PHYSIOL-LUNG C, V285, pL20, DOI 10.1152/ajplung.00312.2002
   Roviezzo F, 2005, J PHARMACOL EXP THER, V314, P738, DOI 10.1124/jpet.105.086553
   Sapru A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1330-5
   Sarrazin S, 2006, BBA-REV CANCER, V1765, P25, DOI 10.1016/j.bbcan.2005.08.004
   Tang L, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/625180
   Tsangaris I., 2011, INTENSIVE CARE ME S1, V37
   Tsangaris I, 2009, THROMB RES, V123, P832, DOI 10.1016/j.thromres.2008.07.018
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
NR 29
TC 14
Z9 15
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PY 2017
VL 2017
AR 6758721
DI 10.1155/2017/6758721
PG 6
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA FG5JB
UT WOS:000410349100001
PM 28947844
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Wang, LF
   Mehta, S
   Brock, M
   Gill, SE
AF Wang, Lefeng
   Mehta, Sanjay
   Brock, Michael
   Gill, Sean E.
TI Inhibition of Murine Pulmonary Microvascular Endothelial Cell Apoptosis
   Promotes Recovery of Barrier Function under Septic Conditions
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME;
   TNF-ALPHA; IN-VITRO; PLASMA ANGIOPOIETIN-2; CORNEAL ENDOTHELIUM;
   OXIDATIVE STRESS; MEDICAL PROGRESS; PROGENITOR CELLS
AB Sepsis is characterized by injury of the pulmonary microvasculature and the pulmonary microvascular endothelial cells (PMVEC), leading to barrier dysfunction and acute respiratory distress syndrome (ARDS). Our recent work identified a strong correlation between PMVEC apoptosis and microvascular leak in septic mice in vivo, but the specific role of apoptosis in septic PMVEC barrier dysfunction remains unclear. Thus, we hypothesize that PMVEC apoptosis is likely required for PMVEC barrier dysfunction under septic conditions in vitro. Septic stimulation (mixture of tumour necrosis factor alpha, interleukin 1 beta, and interferon gamma [cytomix]) of isolated murine PMVEC resulted in a significant loss of barrier function as early as 4 h after stimulation, which persisted until 24 h. PMVEC apoptosis, as reflected by caspase activation, DNA fragmentation, and loss of membrane polarity, was first apparent at 8 h after cytomix. Pretreatment of PMVEC with the pan-caspase inhibitor Q-VD significantly decreased septic PMVEC apoptosis and was associated with reestablishment of PMVEC barrier function at 16 and 24 h after stimulation but had no effect on septic PMVEC barrier dysfunction over the first 8 h. Collectively, our data suggest that early septic murine PMVEC barrier dysfunction driven by proinflammatory cytokines is not mediated through apoptosis, but PMVEC apoptosis contributes to late septic PMVEC barrier dysfunction.
C1 [Wang, Lefeng; Mehta, Sanjay; Brock, Michael; Gill, Sean E.] Lawson Hlth Res Inst, Ctr Crit Illness Res, London, ON, Canada.
C1 [Wang, Lefeng; Mehta, Sanjay; Gill, Sean E.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Med, London, ON, Canada.
C1 [Mehta, Sanjay; Gill, Sean E.] Univ Western Ontario, Schulich Sch Med & Dent, Div Respirol, London, ON, Canada.
C1 [Brock, Michael; Gill, Sean E.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario)
RP Gill, SE (corresponding author), Lawson Hlth Res Inst, Ctr Crit Illness Res, London, ON, Canada.; Gill, SE (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Dept Med, London, ON, Canada.; Gill, SE (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Div Respirol, London, ON, Canada.; Gill, SE (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada.
EM sgill8@uwo.ca
RI wang, le/HKN-3406-2023; Mehta, Sanjay/G-3332-2011; Gill, Sean
   E/G-4057-2012
OI Mehta, Sanjay/0000-0002-7707-1056; Brock, Michael/0000-0002-8624-8378;
   Gill, Sean/0000-0003-4791-1576
FU Ontario Thoracic Society; Lawson Health Research Institute Internal
   Research Fund; Program of Experimental Medicine; Heart & Stroke
   Foundation of Ontario/Canada [G-13-0003039]
FX The authors would like to thank the members of the Lung Research Group
   at Western University, especially Drs. Ruud Veldhuizen and Lisa Cameron,
   for helpful discussions. This work was supported by research funding
   from the Ontario Thoracic Society (S. Gill), Lawson Health Research
   Institute Internal Research Fund (S. Gill), the Program of Experimental
   Medicine (S. Gill and S. Mehta), and the Heart & Stroke Foundation of
   Ontario/Canada Grant no. G-13-0003039 (S. Mehta).
CR Abdullah Z, 2014, MOL CELL NEUROSCI, V61, P72, DOI 10.1016/j.mcn.2014.06.002
   Agrawal A, 2013, AM J RESP CRIT CARE, V187, P736, DOI 10.1164/rccm.201208-1460OC
   Lopez-Ramirez MA, 2012, J IMMUNOL, V189, P3130, DOI 10.4049/jimmunol.1103460
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Arpino V, 2016, AM J PHYSIOL-HEART C, V310, pH1455, DOI 10.1152/ajpheart.00796.2015
   Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371
   Bechelli J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138830
   Bull TM, 2010, AM J RESP CRIT CARE, V182, P1123, DOI 10.1164/rccm.201002-0250OC
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Cardoso FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035919
   Cines DB, 1998, BLOOD, V91, P3527
   Curley GF, 2016, CHEST, V150, P1109, DOI 10.1016/j.chest.2016.07.019
   De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC
   De Backer D, 2014, VIRULENCE, V5, P73, DOI 10.4161/viru.26482
   Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997
   Dente CJ, 2001, J SURG RES, V97, P85, DOI 10.1006/jsre.2001.6117
   Drakopanagiotakis F, 2008, EUR RESPIR J, V32, P1631, DOI 10.1183/09031936.00176807
   Edelman DA, 2006, J SURG RES, V135, P305, DOI 10.1016/j.jss.2006.06.010
   ENDO S, 1995, RES COMMUN MOL PATH, V90, P277
   Farley KS, 2006, AM J PHYSIOL-LUNG C, V290, pL1164, DOI 10.1152/ajplung.00248.2005
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   GERRITSEN ME, 1987, BIOCHEM PHARMACOL, V36, P2701, DOI 10.1016/0006-2952(87)90252-8
   Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7
   Gill SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088501
   GLASSBERG MK, 1992, J APPL PHYSIOL, V72, P1681, DOI 10.1152/jappl.1992.72.5.1681
   Glauser MP, 2000, CRIT CARE MED, V28, pS4, DOI 10.1097/00003246-200009001-00002
   GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662
   Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2
   Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008
   Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Husak Liudmila, 2010, Healthc Q, V13 Spec No, P35
   Kuckleburg CJ, 2008, THROMB HAEMOSTASIS, V99, P363, DOI 10.1160/TH07-07-0474
   LAM C, 1994, J CLIN INVEST, V94, P2077, DOI 10.1172/JCI117562
   Liu DX, 2005, BLOOD, V105, P2350, DOI 10.1182/blood-2004-05-1963
   Liu ZH, 1996, AM J PHYSIOL-CELL PH, V270, pC1595, DOI 10.1152/ajpcell.1996.270.6.C1595
   Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC
   Matsuda N, 2007, CARDIOVASC RES, V76, P132, DOI 10.1016/j.cardiores.2007.05.024
   Matsuda N, 2010, AM J PHYSIOL-HEART C, V298, pH92, DOI 10.1152/ajpheart.00069.2009
   Matsuda N, 2009, AM J RESP CRIT CARE, V179, P806, DOI 10.1164/rccm.200804-534OC
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McDonnell CJ, 2016, J THROMB HAEMOST, V14, P2536, DOI 10.1111/jth.13501
   Meguro T, 2001, STROKE, V32, P561, DOI 10.1161/01.STR.32.2.561
   Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195, DOI 10.1164/ajrccm.163.1.9912036
   Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835
   Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296
   Potter DR, 2008, CIRC RES, V102, P770, DOI 10.1161/CIRCRESAHA.107.160226
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021
   Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153
   Sagoo P, 2004, INVEST OPHTH VIS SCI, V45, P3964, DOI 10.1167/iovs.04-0439
   Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F
   Sapru A, 2015, INTENS CARE MED, V41, P470, DOI 10.1007/s00134-015-3648-x
   Semeraro N, 2012, THROMB RES, V129, P290, DOI 10.1016/j.thromres.2011.10.013
   Seynhaeve ALB, 2006, CELL BIOCHEM BIOPHYS, V44, P157, DOI 10.1385/CBB:44:1:157
   Shapiro NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10044
   Shelton JL, 2008, MICROVASC RES, V76, P80, DOI 10.1016/j.mvr.2008.06.001
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   Shivanna M, 2010, INVEST OPHTH VIS SCI, V51, P1575, DOI 10.1167/iovs.09-4343
   Skibsted S, 2013, SHOCK, V39, P427, DOI 10.1097/SHK.0b013e3182903f0d
   Spanos A, 2010, SHOCK, V33, P387, DOI 10.1097/SHK.0b013e3181c6be04
   Subbanna S, 2013, NEUROBIOL DIS, V54, P475, DOI 10.1016/j.nbd.2013.01.022
   Terpstra ML, 2014, CRIT CARE MED, V42, P691, DOI 10.1097/01.ccm.0000435669.60811.24
   Townsley MI, 2012, COMPR PHYSIOL, V2, P675, DOI 10.1002/cphy.c100081
   Trzeciak S, 2007, ANN EMERG MED, V49, P88, DOI 10.1016/j.annemergmed.2006.08.021
   Tyml K, 2011, MICROCIRCULATION, V18, P152, DOI 10.1111/j.1549-8719.2010.00080.x
   Wagner JG, 1999, J LEUKOCYTE BIOL, V66, P10, DOI 10.1002/jlb.66.1.10
   Wagner N.-M., 2016, ANESTHESIA ANALGESIA
   Wang JH, 1997, AM J PHYSIOL-CELL PH, V272, pC1543, DOI 10.1152/ajpcell.1997.272.5.C1543
   Wang LF, 2012, SHOCK, V37, P539, DOI 10.1097/SHK.0b013e31824dcb5a
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu MH, 2005, J PHYSIOL-LONDON, V569, P359, DOI 10.1113/jphysiol.2005.096537
   Xu C, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12636
   Yang Y., 2015, IEEE T PARALL DISTR, P1, DOI DOI 10.18632/0NC0TARGET.3970
   Yang YM, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23494
   Yoder Mervin C, 2011, Proc Am Thorac Soc, V8, P466, DOI 10.1513/pats.201101-006MW
   ZETTER BR, 1981, DIABETES, V30, P24, DOI 10.2337/diab.30.2.S24
   Zhu XJ, 2016, J SURG RES, V204, P288, DOI 10.1016/j.jss.2016.04.067
NR 87
TC 15
Z9 17
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2017
VL 2017
AR 3415380
DI 10.1155/2017/3415380
PG 15
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA EL9RX
UT WOS:000394958900001
PM 28250575
OA gold, Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Wu, Z
   Wang, Z
   Xu, P
   Zhang, M
   Cheng, L
   Gong, B
AF Wu, Z.
   Wang, Z.
   Xu, P.
   Zhang, M.
   Cheng, L.
   Gong, B.
TI A Novel Finding: Macrophages Involved in Inflammation Participate in
   Acute Aortic Dissection Complicated with Acute Lung Injury
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE acute aortic dissection; ALI/ARDS; macrophage; MMP/MMP3/MMP9; angiotensin; MCP-1 
ID KAPPA-B ACTIVATION; EXPRESSION; INHIBITION; PATHWAY; PROTEIN-1; CELLS;
   MICE; HYPERTENSION; BINDARIT; COMPLEX
AB Background: Little is known about the pathogenesis of acute lung injury (ALI) complicated with acute aortic dissection (AAD).
   Objective: We aim to investigate the roles of macrophages-derived matrix metalloproteinase 9 (MMP9) in the development of ALI complicated with AAD and factors involved in the recruitment of macrophages.
   Methods: This study included three parts: (i) Determination of serum MMPs, angiotensin II (AngII) and MCP-1 in patients with AAD complicated with ALI or AAD only, non-ruptured chronic aortic aneurysm patients or healthy volunteers using ELISA method. (ii) A novel AAD complicated with ALI model was established by infusing angiotensin II (AngII) to immature rats treated with beta-aminopropionitrile monofumarate (BAPN) to identify the potential roles of MMP9 and MCP-1 in AAD complicated with ALI. (iii) Cultured pulmonary microvascular endothelial cell (PMVEC) line was used to investigate how AngII was involved in the release of MCP-1 in rat pulmonary vascular endothelial cells.
   Results: Serum MMP9, AngII and MCP-1 were remarkably elevated in patients with AAD complicated with ALI. The MMP9 expressed in pulmonary tissues was derived from macrophages. In the animal model, the release of MMP9 from macrophages finally resulted in ALI, while inhibition of MMP9 and MCP-1 contributed to decreased incidence of AAD complicated with ALI. In vitro experiments indicated that AngII triggered overexpression of MCP-1 in PMVECs by activating NF-kappa B signaling pathway.
   Conclusion: AAD complicated with ALI is highly associated with the macrophages infiltrating the pulmonary interstitial tissue and released MMP9 in response to angiotensin II. MCP-1 is closely related to the recruitment of macrophages.
C1 [Wu, Z.; Wang, Z.; Xu, P.; Zhang, M.; Cheng, L.; Gong, B.] Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, China.
C3 Wuhan University
RP Wu, Z (corresponding author), Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
EM zhiyongwu889@sina.com
FU Hubei Province health and family planning scientific research project
   [WJ2017M013]
FX The study was supported by the Hubei Province health and family planning
   scientific research project (No. WJ2017M013).
CR Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   Belenkiy S, 2013, SHOCK, V39, P495, DOI 10.1097/SHK.0b013e318292c331
   Bhatia M, 2008, INFLAMM RES, V57, P464, DOI 10.1007/s00011-008-7210-y
   Deng YY, 2009, GLIA, V57, P604, DOI 10.1002/glia.20790
   Ergul A, 2004, AM J HYPERTENS, V17, P775, DOI 10.1016/j.amjhyper.2004.06.025
   Gopal K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067098
   Harijith A, 2011, AM J RESP CELL MOL, V44, P621, DOI 10.1165/rcmb.2010-0058OC
   Huang CH, 2013, PHYTOMEDICINE, V20, P303, DOI 10.1016/j.phymed.2012.11.004
   Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498
   Kim JH, 2006, AM J PHYSIOL-LUNG C, V291, pL580, DOI 10.1152/ajplung.00270.2005
   Koullias GJ, 2004, ANN THORAC SURG, V78, P2106, DOI 10.1016/j.athoracsur.2004.05.088
   Krappmann D, 2004, MOL CELL BIOL, V24, P6488, DOI 10.1128/MCB.24.14.6488-6500.2004
   Kurihara T, 2012, CIRCULATION, V126, P3070, DOI 10.1161/CIRCULATIONAHA.112.097097
   Kylhammar D, 2017, ACTA PHYSIOL, V219, P728, DOI 10.1111/apha.12749
   Lee YH, 2010, J CELL SCI, V123, P1634, DOI 10.1242/jcs.063545
   Li Y, 2010, J SURG RES, V163, pE99, DOI 10.1016/j.jss.2010.05.030
   Liang C, 2004, ACTA PHARMACOL SIN, V25, P1426
   Lu Y, 2012, AMINO ACIDS, V43, P2125, DOI 10.1007/s00726-012-1298-7
   Ma B, 2013, EUR REV MED PHARMACO, V17, P1051
   Matt P, 2010, J THORAC CARDIOV SUR, V139, P1041, DOI 10.1016/j.jtcvs.2009.08.039
   Mckie PM, 2010, HYPERTENSION, V56, P1152, DOI 10.1161/HYPERTENSIONAHA.110.159210
   Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13
   Mirolo M, 2008, EUR CYTOKINE NETW, V19, P119, DOI 10.1684/ecn.2008.0133
   MURASE N, 1987, TRANSPLANT P, V19, P71
   Nagashima H, 2002, J VASC SURG, V36, P818, DOI 10.1067/mva.2002.126091
   Proietta M, 2014, ANN MED, V46, P44, DOI 10.3109/07853890.2013.876728
   Ruiz-Ortega M, 1998, J IMMUNOL, V161, P430
   Sangiorgi G, 2006, J CARDIOVASC MED, V7, P307, DOI 10.2459/01.JCM.0000223251.26988.c5
   Shingu Yasushige, 2008, Kyobu Geka, V61, P440
   Stagg HW, 2013, J TRAUMA ACUTE CARE, V75, P1040, DOI 10.1097/TA.0b013e3182aa9c79
   Trocme C, 2015, J PATHOL, V235, P65, DOI 10.1002/path.4423
   Tsai TT, 2006, CIRCULATION, V114, P2226, DOI 10.1161/CIRCULATIONAHA.106.622340
   Viedt C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015609.31253.7F
   Villalta PC, 2014, AM J PHYSIOL-LUNG C, V307, pL652, DOI 10.1152/ajplung.00113.2014
   Wu NC, 2014, TRANSPL P, V46, P1135, DOI 10.1016/j.transproceed.2013.12.020
   Yamamoto A, 2003, INT J CANCER, V103, P822, DOI 10.1002/ijc.10875
   Zhang PX, 2016, UNDERSEA HYPERBAR M, V43, P239
   Zhang Xiang-feng, 2008, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V20, P597
   Zychowski KE, 2016, TOXICOL APPL PHARM, V305, P40, DOI 10.1016/j.taap.2016.06.003
NR 40
TC 11
Z9 14
U1 1
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2017
VL 17
IS 8
BP 568
EP 579
DI 10.2174/1566524018666180222123518
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FZ6CQ
UT WOS:000427685000005
PM 29473501
DA 2023-08-21
ER

PT J
AU Xi, X
   Liu, Y
   Zhu, GF
   Huang, Y
   Li, K
   Wu, CT
AF Xi Xin
   Liu Yan
   Zhu Guangfa
   Huang Yan
   Li Keng
   Wu Chunting
TI Mesenchymal Stem Cells Promoted Lung Wound Repair through Hox A9 during
   Endotoxemia-Induced Acute Lung Injury
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID THERAPY; GENES
AB Objectives. Acute lung injury (ALI) is a common clinical critical disease. Stem cells transplantation is recognized as an effective way to repair injured lung tissues. The present study was designed to evaluate the effects of mesenchymal stem cells (MSCs) on repair of lung and its mechanism. Methods. MSCs carrying GFP were administrated via trachea into wild-type SD rats 4 hours later after LPS administration. The lung histological pathology and the distribution of MSCs were determined by HE staining and fluorescence microscopy, respectively. Next, differentially expressed HOX genes were screened by using real-time PCR array and abnormal expression and function of Hox A9 were analyzed in the lung and the cells. Results. MSCs promoted survival rate of ALI animals. The expression levels of multiple HOX genes had obvious changes after MSCs administration and HOX A9 gene increased by 5.94-fold after MSCs administration into ALI animals. HOX A9 was distributed in endothelial cells and epithelial cells in animal models and overexpression of Hox A9 can promote proliferation and inhibit inflammatory adhesion of MSCs. Conclusion. HoxA9 overexpression induced by MSCs may be closely linked with lung repair after endotoxin shock.
C1 [Xi Xin; Zhu Guangfa; Huang Yan; Li Keng; Wu Chunting] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Pulm & Crit Care Med, Beijing 100029, China.
C1 [Liu Yan; Zhu Guangfa] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Infect Dis, Beijing 100029, China.
C3 Capital Medical University; Capital Medical University
RP Zhu, GF (corresponding author), Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China.; Zhu, GF (corresponding author), Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Infect Dis, Beijing 100029, Peoples R China.
EM guangfa-zhu@yahoo.com
FU Capital Health Development Research and Special Projects of Beijing
   (Risk Factors and Prediction Score of Acute Respiratory Distress
   Syndrome after Cardiac Surgery) [SF-2016-21052]
FX This study was partly supported by a Grant (SF-2016-21052) from the
   Capital Health Development Research and Special Projects of Beijing
   (Risk Factors and Prediction Score of Acute Respiratory Distress
   Syndrome after Cardiac Surgery).
CR Banerjee ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033165
   Bein T, 2016, INTENS CARE MED, V42, P699, DOI 10.1007/s00134-016-4325-4
   Blazquez R, 2016, ACTA BIOMATER, V31, P221, DOI 10.1016/j.actbio.2015.11.057
   Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09
   Chistiakov DA, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-92
   Hrycaj SM, 2015, CELL REP, V12, P903, DOI 10.1016/j.celrep.2015.07.020
   Inamdar AC, 2013, EXP LUNG RES, V39, P315, DOI 10.3109/01902148.2013.816803
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Lin X, 2016, GENE THER, V23, P489, DOI 10.1038/gt.2016.19
   Morgan R, 2016, CURR MOL MED, V16, P322, DOI 10.2174/1566524016666160316145715
   Pinto PB, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005412
   Qin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101469
   Seifert A, 2015, WORLD J STEM CELLS, V7, P583, DOI 10.4252/wjsc.v7.i3.583
   Sun ZR, 2014, J CELL PHYSIOL, V229, P213, DOI 10.1002/jcp.24436
   Takyar S, 2016, FASEB J, V30, P1317, DOI 10.1096/fj.15-275024
   Tan YR, 2013, MOL BIOL REP, V40, P675, DOI 10.1007/s11033-012-2107-9
   van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC
   Yu SL, 2016, MOL CARCINOGEN, V55, P1915, DOI 10.1002/mc.22439
NR 18
TC 7
Z9 8
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2017
VL 2017
AR 3648020
DI 10.1155/2017/3648020
PG 8
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EQ8ER
UT WOS:000398318200001
PM 28465690
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Zhan, J
   Xiao, F
   Zheng, F
   Yuan, QH
   Chen, K
   Wang, YL
   Zhang, ZZ
AF Zhan, Jia
   Xiao, Fei
   Zheng, Fei
   Yuan, Qinghong
   Chen, Kai
   Wang, Yanlin
   Zhang, Zongze
TI Beta-arrestin-1 mediating protective effects of penehyclidine
   hydrochloride on changes of F-actin in lipopolysaccharide-stimulated
   human pulmonary microvascular endothelial cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Beta-arrestin-1 penehyclidine hydrochloride; F-actin; shRNA 
ID BETA-ARRESTINS; BARRIER DYSFUNCTION; MAPK ACTIVATION; RECEPTOR;
   PERMEABILITY; INDUCTION; LUNG; DISRUPTION; EXPRESSION; KINASE
AB In acute lung injury (ALI) and sepsis, the integrity of the endothelial barrier, maintained by endothelial cytoskeleton of microvascular endothelial cells, is important to maintain normal microvascular function. In response to lipopolysaccharide (LPS), F-actin (fibrous actin, F-actin), an essential component of the endothelial cytoskeleton, has been shown to be critical to maintaining the endothelial integrity. Herein, penehyclidine hydrochloride (PHC), an anticholinergic agent manufactured in China, was verified to inhibit p38 MAPK activation, reduce Hsp27 expression, and inhibit LPS-stimulated reorganization of F-actin and formation of stress fiber in this study. Besides, these roles of PHC in human pulmonary microvascular endothelial cells (HPMVEC) were found to be accompanied with its upregulation of beta-arrestin-1. Furthermore, the silencing of beta-arrestin-1 with a shRNA-containing plasmid resulted in an antagonistic effect vs. PHC on the endothelial F-actin function of HPMVEC. In summary, beta-arrestin-1 plays an important role in mediating protective effect of PHC on changes of F-actin in LPS-stimulated HPMVEC.
C1 [Zhan, Jia; Zheng, Fei; Yuan, Qinghong; Chen, Kai; Wang, Yanlin; Zhang, Zongze] Wuhan Univ, Zhongnan Hosp, Dept Anesthesiol, Wuhan 430071, China.
C1 [Xiao, Fei] Huazhong Univ Sci & Technol, Pu Ai Hosp, Dept Orthoped, Wuhan, Hubei, China.
C1 [Zhang, Zongze] Wuhan Univ, Zhongnan Hosp, Dept Anesthesiol, Wuhan, Hubei, China.
C3 Wuhan University; Huazhong University of Science & Technology; Wuhan
   University
RP Zhang, ZZ (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Anesthesiol, Wuhan 430071, Peoples R China.
EM jia19811001@whu.edu.cn
FU National Natural Science Foundation of China [81571291, 81101408]; Youth
   Science Plan for Light of the Morning Sun of Wuhan City
   [2016070204010150]
FX This work was supported by grants from National Natural Science
   Foundation of China (Grant No. 81571291), National Natural Science
   Foundation of China (Grant No. 81101408), and the Youth Science Plan for
   Light of the Morning Sun of Wuhan City (Grant No. 2016070204010150). We
   thank the English writing center at the Ohio State University for their
   excellent assistances in manuscript revision.
CR Adyshev DM, 2013, AM J RESP CELL MOL, V49, P58, DOI 10.1165/rcmb.2012-0397OC
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Brown MD, 2009, CELL SIGNAL, V21, P462, DOI 10.1016/j.cellsig.2008.11.013
   Deshpande DA, 2008, FASEB J, V22, P2134, DOI 10.1096/fj.07-102459
   Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200
   Kaparianos A, 2012, EUR REV MED PHARMACO, V16, P1781
   Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3
   Liu TG, 2010, AM J PHYSIOL-CELL PH, V299, pC363, DOI 10.1152/ajpcell.00057.2010
   Piu F, 2006, ONCOGENE, V25, P218, DOI 10.1038/sj.onc.1209024
   Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862
   Schreiber G, 2009, DRUG NEWS PERSPECT, V22, P467, DOI 10.1358/dnp.2009.22.8.1413787
   Singh D, 2007, AM J PHYSIOL-LUNG C, V293, pL436, DOI 10.1152/ajplung.00097.2007
   Singleton PA, 2010, AM J PHYSIOL-LUNG C, V299, pL639, DOI 10.1152/ajplung.00405.2009
   Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294
   Wilhelmsen K, 2014, J BIOL CHEM, V289, P13079, DOI 10.1074/jbc.M113.536953
   Yang D, 2010, CARDIOVASC RES, V85, P520, DOI 10.1093/cvr/cvp323
   Zhan J, 2013, BRAZ J MED BIOL RES, V46, P1040, DOI 10.1590/1414-431X20133289
   Zhan J, 2011, MOL BIOL REP, V38, P1909, DOI 10.1007/s11033-010-0310-0
   Zhang MF, 2011, MECH DEVELOP, V128, P368, DOI 10.1016/j.mod.2011.07.003
   Zhang YL, 2014, DRUG DES DEV THER, V8, P373, DOI 10.2147/DDDT.S58168
   Zhang YM, 2014, J MOL CELL CARDIOL, V74, P76, DOI 10.1016/j.yjmcc.2014.04.020
   Zhao M, 2004, J BIOL CHEM, V279, P49259, DOI 10.1074/jbc.M405118200
NR 24
TC 0
Z9 0
U1 0
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 4
BP 4273
EP 4282
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA ET8LF
UT WOS:000400550200027
DA 2023-08-21
ER

PT J
AU Kovacs-Kasa, A
   Gorshkov, BA
   Kim, KM
   Kumar, S
   Black, SM
   Fulton, DJ
   Dimitropoulou, C
   Catravas, JD
   Verin, AD
AF Kovacs-Kasa, Anita
   Gorshkov, Boris A.
   Kim, Kyung-mi
   Kumar, Sanjiv
   Black, Stephen M.
   Fulton, David J. R.
   Dimitropoulou, Christiana
   Catravas, John D.
   Verin, Alexander D.
TI The protective role of MLCP-mediated ERM dephosphorylation in
   endotoxin-induced lung injury in vitro and in vivo
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CELL BARRIER ENHANCEMENT; PROTEIN-KINASE-C; LIGHT-CHAIN PHOSPHORYLATION;
   MYOSIN-BINDING SUBUNIT; RHO-ASSOCIATED KINASE; EZRIN/RADIXIN/MOESIN
   PROTEINS; ENDOTHELIAL-CELLS; CYTOSKELETAL REARRANGEMENT; PHOSPHATASE;
   MOESIN
AB The goal of this study was to investigate the role of MLC phosphatase (MLCP) in a LPS model of acute lung injury (ALI). We demonstrate that ectopic expression of a constitutively-active (C/A) MLCP regulatory subunit (MYPT1) attenuates the ability of LPS to increase endothelial (EC) permeability. Down-regulation of MYPT1 exacerbates LPS-induced expression of ICAM1 suggesting an anti-inflammatory role of MLCP. To determine whether MLCP contributes to LPS-induced ALI in vivo, we utilized a nanoparticle DNA delivery method to specifically target lung EC. Expression of a C/A MYPT1 reduced LPS-induced lung inflammation and vascular permeability. Further, increased expression of the CS1 beta (MLCP catalytic subunit) also reduced LPS-induced lung inflammation, whereas the inactive CS1 beta mutant increased vascular leak. We next examined the role of the cytoskeletal targets of MLCP, the ERM proteins (Ezrin/Radixin/Moesin), in mediating barrier dysfunction. LPS-induced increase in EC permeability was accompanied by PKC-mediated increase in ERM phosphorylation, which was more prominent in CS1 beta-depleted cells. Depletion of Moesin and Ezrin, but not Radixin attenuated LPS-induced increases in permeability. Further, delivery of a Moesin phospho-null mutant into murine lung endothelium attenuated LPS-induced lung inflammation and vascular leak suggesting that MLCP opposes LPS-induced ALI by mediating the dephosphorylation of Moesin and Ezrin.
C1 [Kovacs-Kasa, Anita; Gorshkov, Boris A.; Kim, Kyung-Mi; Kumar, Sanjiv; Fulton, David J.; Verin, Alexander D.] Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912, United States.
C1 [Black, Stephen M.] Univ Arizona, Ctr Lung Vasc Pathobiol, Phoenix, AZ, United States.
C1 [Dimitropoulou, Christiana; Catravas, John D.] Old Dominion Univ, Frank Reidy Ctr Bioelect, Norfolk, VA, United States.
C3 University System of Georgia; Augusta University; University of Arizona;
   Old Dominion University
RP Verin, AD (corresponding author), Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.
EM averin@augusta.edu
OI Black, Stephen M./0000-0002-4524-6544; Verin,
   Alexander/0000-0003-0627-7185
FU NIH [HL101902]
FX The authors would like to thank Dr. M. Eto (Thomas Jefferson University,
   Philadelphia, PA) for providing C/A MYPT1 plasmid and acknowledge the
   financial support from NIH Program Project Grant HL101902.
CR Adyshev DM, 2013, AM J PHYSIOL-LUNG C, V305, P1240, DOI 10.1152/ajplung.00355.2012
   Adyshev DM, 2011, CELL SIGNAL, V23, P2086, DOI 10.1016/j.cellsig.2011.08.003
   Aggarwal S, 2014, AM J RESP CELL MOL, V50, P614, DOI 10.1165/rcmb.2013-0193OC
   Altavilla D, 2002, CARDIOVASC RES, V54, P684, DOI 10.1016/S0008-6363(02)00276-6
   Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246
   Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Bogatcheva NV, 2008, MICROVASC RES, V76, P202, DOI 10.1016/j.mvr.2008.06.003
   Bogatcheva NV, 2011, AM J RESP CELL MOL, V45, P1185, DOI 10.1165/rcmb.2011-0092OC
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   Bono P, 2005, EXP CELL RES, V308, P177, DOI 10.1016/j.yexcr.2005.04.017
   Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882
   Canals D, 2012, J BIOL CHEM, V287, P10145, DOI 10.1074/jbc.M111.306456
   Chatterjee A, 2007, AM J RESP CRIT CARE, V176, P667, DOI 10.1164/rccm.200702-291OC
   Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108
   Csortos C, 2007, AM J PHYSIOL-LUNG C, V293, pL843, DOI 10.1152/ajplung.00120.2007
   Dubois T, 2003, BIOCHEM BIOPH RES CO, V302, P186, DOI 10.1016/S0006-291X(03)00130-X
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993
   Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866
   Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409
   Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061
   Grassie ME, 2011, ARCH BIOCHEM BIOPHYS, V510, P147, DOI 10.1016/j.abb.2011.01.018
   Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064
   He F, 2012, BIOCHEM BIOPH RES CO, V425, P182, DOI 10.1016/j.bbrc.2012.07.063
   Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200
   Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00
   Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x
   Ivetic A, 2002, J BIOL CHEM, V277, P2321, DOI 10.1074/jbc.M109460200
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kasa A, 2013, MICROVASC RES, V89, P86, DOI 10.1016/j.mvr.2013.05.003
   Kim KM, 2012, J CELL PHYSIOL, V227, P1701, DOI 10.1002/jcp.22894
   Knezevic N, 2007, MOL CELL BIOL, V27, P6323, DOI 10.1128/MCB.00523-07
   Kolosova IA, 2005, CIRC RES, V97, P115, DOI 10.1161/01.RES.0000175561.55761.69
   Kolosova IA, 2008, AM J PHYSIOL-LUNG C, V294, pL319, DOI 10.1152/ajplung.00283.2007
   Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218
   Lorenowicz MJ, 2007, ARTERIOSCL THROM VAS, V27, P1014, DOI 10.1161/ATVBAHA.106.132282
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647
   Matsumura F, 2008, BIOCHEM BIOPH RES CO, V369, P149, DOI 10.1016/j.bbrc.2007.12.090
   McClatchey AI, 2014, J CELL SCI, V127, P3199, DOI 10.1242/jcs.098343
   Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206
   Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012
   Parameswaran N, 2013, IMMUNOL REV, V256, P63, DOI 10.1111/imr.12104
   Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3
   Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594
   Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565
   Ramachandran G, 2014, VIRULENCE, V5, P213, DOI 10.4161/viru.27024
   SHIMIZU H, 1994, J BIOL CHEM, V269, P30407
   Umapathy NS, 2010, VASC PHARMACOL, V52, P199, DOI 10.1016/j.vph.2009.12.008
   Umapathy NS, 2010, J CELL PHYSIOL, V223, P215, DOI 10.1002/jcp.22029
   Umapathy NS, 2012, EXP LUNG RES, V38, P223, DOI 10.3109/01902148.2012.673049
   Xu H, 2013, INFLAMMATION, V36, P216, DOI 10.1007/s10753-012-9537-3
NR 60
TC 16
Z9 18
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 15
PY 2016
VL 6
AR 39018
DI 10.1038/srep39018
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EH9KE
UT WOS:000392089400001
PM 27976727
OA Green Published, gold, Green Accepted
DA 2023-08-21
ER

PT J
AU Liu, HY
   Zhang, ZL
   Li, PY
   Yuan, X
   Zheng, J
   Liu, JW
   Bai, CQ
   Niu, WK
AF Liu, Huiying
   Zhang, Zili
   Li, Puyuan
   Yuan, Xin
   Zheng, Jing
   Liu, Jinwen
   Bai, Changqing
   Niu, Wenkai
TI Regulation of S1P receptors and sphingosine kinases expression in acute
   pulmonary endothelial cell injury
SO PEERJ
LA English
DT Article
DE S1P/S1PR1/S1PR2/S1PR3; Acute pulmonary endothelial cell injury; mesenchymal stem cell 
ID LUNG INJURY; SPHINGOSINE-1-PHOSPHATE
AB Background. Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) is a severe clinical syndrome with mortality rate as high as 30-40%. There is no treatment yet to improve pulmonary endothelial barrier function in patients with severe pulmonary edema. Developing therapies to protect endothelial barrier integrity and stabilizing gas exchange is getting more and more attention. Sphingosine-l-phosphate (SIP) is able to enhance the resistance of endothelial cell barrier. SIP at physiological concentrations plays an important role in maintaining endothelial barrier function. Proliferation, regeneration and anti-inflammatory activity that mesenchymal stem cells (MSCs) exhibit make it possible to regulate the homeostatic control of SIP.
   Methods. By building a pulmonary endothelial cell model of acute injury, we investigated the regulation of SIP receptors and sphingosine kinases expression by MSCs during the treatment of acute lung injury using RT-PCR, and investigated the HPAECs Micro-electronics impedance using Real Time Cellular Analysis.
   Results. It was found that the down-regulation of TNF-alpha expression was more significant when MSC was used in combination with SIP. The combination effection mainly worked on S1PR2, S1PR3 and SphK2. The results show that when MSCs were used in combination with S1P, the selectivity of SIP receptors was increased and the homeostatic control of SIP concentration was improved through regulation of expression of SIP metabolic enzymes.
   Discussions. The study found that, as a potential treatment, MSCs could work on multiple S1P related genes simultaneously. When it was used in combination with SIP, the expression regulation result of related genes was not simply the superposition of each other, but more significant outcome was obtained. This study establishes the experimental basis for further exploring the efficacy of improving endothelial barrier function in acute lung injury, using MSCs in combination with SIP and their possible synergistic mechanism.
C1 [Liu, Huiying; Zhang, Zili; Li, Puyuan; Yuan, Xin; Zheng, Jing; Bai, Changqing; Niu, Wenkai] PLA, Hosp 307, Dept Resp & Crit Care Dis, Beijing, China.
C1 [Liu, Jinwen] Beijing Oriental Yamei Gene Sci & Technol Inst, Beijing, China.
RP Bai, CQ; Niu, WK (corresponding author), PLA, Hosp 307, Dept Resp & Crit Care Dis, Beijing, Peoples R China.
EM mlp1604@sina.com; niuwk88@sina.com
FU Beijing Natural Science Foundation [7164284]; Innovation Science
   Research Foundation of 307th Hospital of PLA [FC-2014-01]; Public Health
   Major Project [AWS15J007]
FX This study was supported by the Beijing Natural Science Foundation
   (7164284), Innovation Science Research Foundation of 307th Hospital of
   PLA (FC-2014-01), Public Health Major Project (AWS15J007). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Blaho VA, 2014, J LIPID RES, V55, P1596, DOI 10.1194/jlr.R046300
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798
   Cepkova Magda, 2006, J Intensive Care Med, V21, P119, DOI 10.1177/0885066606287045
   Chang YS, 2009, CELL TRANSPLANT, V18, P869, DOI 10.3727/096368909X471189
   Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0
   Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158
   He XL, 2010, J MOL CELL BIOL, V2, P199, DOI 10.1093/jmcb/mjq011
   Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408
   Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629
   Muller-Redetzky HC, 2014, CELL TISSUE RES, V355, P657, DOI 10.1007/s00441-014-1821-0
   Natarajan V, 2013, AM J RESP CELL MOL, V49, P6, DOI 10.1165/rcmb.2012-0411TR
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Rosen H, 2007, TRENDS IMMUNOL, V28, P102, DOI 10.1016/j.it.2007.01.007
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804
   Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974
   Sun XG, 2012, AM J RESP CELL MOL, V47, P628, DOI 10.1165/rcmb.2012-0048OC
   Valcz G, 2011, PATHOL ONCOL RES, V17, P11, DOI 10.1007/s12253-010-9262-x
   Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769c, 10.3727/096368911X582769]
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Yu H, 2012, J BIOCH, V152, P305, DOI [10.1093/jb/mvS090, DOI 10.1093/JB/MVS090]
   Zhang Z, 2012, J GASTROEN HEPATOL, V27, P112, DOI 10.1111/j.1440-1746.2011.07024.x
NR 26
TC 7
Z9 8
U1 1
U2 5
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD DEC 13
PY 2016
VL 4
AR e2712
DI 10.7717/peerj.2712
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EF0YZ
UT WOS:000390053500004
PM 27994962
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Elangovan, VR
   Camp, SM
   Kelly, GT
   Desai, AA
   Adyshev, D
   Sun, XG
   Black, SM
   Wang, T
   Garcia, JGN
AF Elangovan, Venkateswaran Ramamoorthi
   Camp, Sara M.
   Kelly, Gabriel T.
   Desai, Ankit A.
   Adyshev, Djanybek M.
   Sun, Xiaoguang
   Black, Stephen M.
   Wang, Ting
   Garcia, Joe G. N.
TI Endotoxin- and mechanical stress-induced epigenetic changes in the
   regulation of the nicotinamide phosphoribosyltransferase promoter
SO Pulmonary Circulation
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; epigenetics; DNA methylation; epigenetic modifiers; histone acetylation 
ID RESPIRATORY-DISTRESS-SYNDROME; COLONY-ENHANCING FACTOR; INDUCED LUNG
   INJURY; TRANSCRIPTION; ACTIVATION; EXPRESSION; SIRT1
AB Mechanical ventilation, a lifesaving intervention for patients with acute respiratory distress syndrome (ARDS), also unfortunately contributes to excessive mechanical stress and impaired lung physiological and structural integrity. We have elsewhere established the pivotal role of increased nicotinamide phosphoribosyltransferase (NAMPT) transcription and secretion as well as its direct binding to the toll-like receptor 4 (TLR4) in the progression of this devastating syndrome; however, regulation of this critical gene in ventilator-induced lung injury (VILI) is not well characterized. On the basis of an emerging role for epigenetics in enrichment of VILI and CpG sites within the NAMPT promoter and 5'UTR, we hypothesized that NAMPT expression and downstream transcriptional events are influenced by epigenetic mechanisms. Concomitantly, excessive mechanical stress of human pulmonary artery endothelial cells or lipopolysaccharide (LPS) treatment led to both reduced DNA methylation levels in the NAMPT promoter and increased gene transcription. Histone deacetylase inhibition by trichostatin A or Sirt-1-silencing RNA attenuates LPS-induced NAMPT expression. Furthermore, recombinant NAMPT administration induced TLR4-dependent global H3K9 hypoacetylation. These studies suggest a complex epigenetic regulatory network of NAMPT in VILI and ARDS and open novel strategies for combating VILI and ARDS.
C1 [Elangovan, Venkateswaran Ramamoorthi; Camp, Sara M.; Kelly, Gabriel T.; Desai, Ankit A.; Sun, Xiaoguang; Black, Stephen M.; Wang, Ting; Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ, United States.
C1 [Elangovan, Venkateswaran Ramamoorthi; Garcia, Joe G. N.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Elangovan, Venkateswaran Ramamoorthi; Adyshev, Djanybek; Garcia, Joe G. N.] Univ Illinois, Dept Med, Chicago, IL, United States.
C3 University of Arizona; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital
RP Garcia, JGN (corresponding author), 1295 North Martin Ave,Drachman Hall B-207, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
RI RamamoorthiElangovan, Venkateswaran/O-5533-2017
OI Black, Stephen M./0000-0002-4524-6544; Desai, Ankit/0000-0001-6427-616X
FU National Institutes of Health [R01HL94394, P01HL126609, R01HL91889]
FX This study is supported by National Institutes of Health grants
   R01HL94394, P01HL126609, and R01HL91889.
CR Adyshev DM, 2014, AM J RESP CELL MOL, V50, P409, DOI 10.1165/rcmb.2013-0292OC
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Camp SM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13135
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Joss-Moore LA, 2011, MOL GENET METAB, V104, P61, DOI 10.1016/j.ymgme.2011.07.018
   Kamp Ryan, 2008, Proc Am Thorac Soc, V5, P348, DOI 10.1513/pats.200709-152DR
   Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003
   Revollo JR, 2007, CURR OPIN GASTROEN, V23, P164, DOI 10.1097/MOG.0b013e32801b3c8f
   Shen Z, 2009, AM J PHYSIOL-GASTR L, V296, pG1047, DOI 10.1152/ajpgi.00016.2009
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Soliman ML, 2011, MOL CELL BIOCHEM, V352, P173, DOI 10.1007/s11010-011-0751-3
   Sun XG, 2014, AM J RESP CELL MOL, V51, P660, DOI 10.1165/rcmb.2014-0117OC
   Thangjam GS, 2014, AM J RESP CELL MOL, V50, P942, DOI 10.1165/rcmb.2013-0214OC
   Wang T, 2010, AM J RESP CELL MOL, V42, P442, DOI 10.1165/rcmb.2008-0402OC
   Weinhold B, 2006, ENVIRON HEALTH PERSP, V114, pA160, DOI 10.1289/ehp.114-a160
   Wierda RJ, 2010, J CELL MOL MED, V14, P1225, DOI 10.1111/j.1582-4934.2010.01022.x
   Xing SP, 2015, LAB INVEST, V95, P1105, DOI 10.1038/labinvest.2015.97
   Yamamoto M, 2013, P NATL ACAD SCI USA, V110, P14948, DOI 10.1073/pnas.1220606110
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
NR 22
TC 21
Z9 22
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD DEC
PY 2016
VL 6
IS 4
BP 539
EP 544
DI 10.1086/688761
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA EE0XS
UT WOS:000389303800014
PM 28090296
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Kelher, MR
   Banerjee, A
   Gamboni, F
   Anderson, C
   Silliman, CC
AF Kelher, Marguerite R.
   Banerjee, Anirban
   Gamboni, Fabia
   Anderson, Cameron
   Silliman, Christopher C.
TI Antibodies to major histocompatibility complex class II antigens
   directly prime neutrophils and cause acute lung injury in a two-event in
   vivo rat model
SO TRANSFUSION
LA English
DT Article
ID MHC CLASS-II; COLONY-STIMULATING FACTOR; RED-BLOOD-CELLS; HUMAN
   POLYMORPHONUCLEAR NEUTROPHILS; MICROVASCULAR ENDOTHELIAL-CELLS; HLA-DR;
   INTERFERON-GAMMA; T-CELLS; WEGENERS-GRANULOMATOSIS; RESTRICTED ANTIGEN
AB BACKGROUNDTransfusion-related acute lung injury (TRALI) is a significant cause of mortality, especially after transfusions containing antibodies to major histocompatibility complex (MHC) class II antigens. We hypothesize that a first event induces both 1) polymorphonuclear neutrophils (PMNs) to express MHC class II antigens, and 2) activation of the pulmonary endothelium, leading to PMN sequestration, so that the infusion of specific MHC class II antibodies to these antigens causes PMN-mediated acute lung injury (ALI).
   STUDY DESIGN AND METHODSRats were treated with saline (NS), endotoxin (lipopolysaccharide [LPS]), or cytokines (interferon- [IFN], macrophage colony-stimulating factor [MCSF], tumor necrosis factor- [TNF]); the PMNs were isolated; and the surface expression of the MHC class II antigen OX6 and priming by OX6 antibodies were measured by flow cytometry or priming assays.
   RESULTSA two-event model of ALI was completed with NS, LPS, or IFN/MCSF/TNF (first events) and the infusion of OX6 (second event). Compared with NS incubation, rats treated with either LPS or IFN/MCSF/TNF exhibited OX6 PMN surface expression, OX6 antibodies primed the formyl-methionyl-leucyl phenylalanine (fMLF)-activated respiratory burst, and PMN sequestration was increased. OX6 antibody infusion into LPS-incubated or IFN/MCSF/TNF-incubated rats elicited ALI, the OX6 antibody was present on the PMNs, and PMN depletion abrogated ALI.
   CONCLUSIONProinflammatory first events induce PMN MHC class II surface expression, activation of the pulmonary endothelium, and PMN sequestration such that the infusion of cognate antibodies precipitates TRALI.
C1 [Kelher, Marguerite R.; Silliman, Christopher C.] Bonfils Blood Ctr, Res Lab, 717 Yosemite St, Denver, CO 80230, United States.
C1 [Kelher, Marguerite R.; Banerjee, Anirban; Gamboni, Fabia; Anderson, Cameron; Silliman, Christopher C.] Univ Colorado Denver, Dept Surg, Sch Med, Aurora, CO, United States.
C1 [Silliman, Christopher C.] Univ Colorado Denver, Dept Pediat, Sch Med, Aurora, CO, United States.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; Children's Hospital Colorado;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Silliman, CC (corresponding author), Bonfils Blood Ctr, Res Lab, 717 Yosemite St, Denver, CO 80230 USA.
EM christopher.silliman@ucdenver.edu
FU Bonfils Blood Center; National Heart, Lung, and Blood Institute,
   National Institutes of Health [HL59355]; National Institute of General
   Medical Sciences, National Institutes of Health [P50 GM049222]
FX These studies were supported by Bonfils Blood Center and by grant
   HL59355 from the National Heart, Lung, and Blood Institute, National
   Institutes of Health, and grant P50 GM049222 from the National Institute
   of General Medical Sciences, National Institutes of Health.
CR Abdel-Salam BKA, 2012, ALLERGOL IMMUNOPATH, V40, P81, DOI 10.1016/j.aller.2011.02.012
   Abe S, 2010, BLOOD PURIFICAT, V29, P321, DOI 10.1159/000287232
   AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202
   Aysola AE, 2005, TRANSFUSION, V45, p83A
   Beauvillain C, 2007, BLOOD, V110, P2965, DOI 10.1182/blood-2006-12-063826
   Burg J, 2002, AM J PHYSIOL-LUNG C, V283, pL460, DOI 10.1152/ajplung.00249.2001
   Bux J, 2011, VOX SANG, V100, P122, DOI 10.1111/j.1423-0410.2010.01392.x
   Cao YL, 2011, J AM SOC NEPHROL, V22, P1161, DOI 10.1681/ASN.2010101058
   CHANG SC, 1990, TRANSPLANTATION, V49, P1158, DOI 10.1097/00007890-199006000-00026
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Culshaw S, 2008, IMMUNOL LETT, V118, P49, DOI 10.1016/j.imlet.2008.02.008
   Curtis BR, 2011, BLOOD, V117, P378, DOI 10.1182/blood-2010-11-317180
   Davey MS, 2014, J IMMUNOL, V193, P3704, DOI 10.4049/jimmunol.1401018
   Drifte G, 2013, CRIT CARE MED, V41, P820, DOI 10.1097/CCM.0b013e318274647d
   Eder AF, 2013, TRANSFUSION, V53, P1442, DOI 10.1111/j.1537-2995.2012.03935.x
   Eder AF, 2010, TRANSFUSION, V50, P1732, DOI 10.1111/j.1537-2995.2010.02652.x
   Eder AF, 2009, J CLIN APHERESIS, V24, P122, DOI 10.1002/jca.20198
   Fanger NA, 1997, BLOOD, V89, P4128, DOI 10.1182/blood.V89.11.4128
   Fung YL, 2009, TRANSFUS MED REV, V23, P266, DOI 10.1016/j.tmrv.2009.06.001
   Geng S, 2013, BLOOD, V121, P1690, DOI 10.1182/blood-2012-07-445197
   GOSSELIN EJ, 1993, J IMMUNOL, V151, P1482
   Hansch GM, 1999, KIDNEY INT, V55, P1811, DOI 10.1046/j.1523-1755.1999.00446.x
   Hendrickson JE, 2009, ANESTH ANALG, V108, P759, DOI 10.1213/ane.0b013e3181930a6e
   Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004
   IBRAHIM L, 1993, IMMUNOLOGY, V79, P119
   Iking-Konert C, 2001, KIDNEY INT, V60, P2247, DOI 10.1046/j.1523-1755.2001.00068.x
   Kao GS, 2003, TRANSFUSION, V43, P185, DOI 10.1046/j.1537-2995.2003.00285.x
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Keller-Stanislawski B, 2010, VOX SANG, V98, P70, DOI 10.1111/j.1423-0410.2009.01232.x
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Kittur DS, 2002, J HEART LUNG TRANSPL, V21, P882, DOI 10.1016/S1053-2498(02)00407-2
   Kopko PM, 2001, TRANSFUSION, V41, P1244, DOI 10.1046/j.1537-2995.2001.41101244.x
   Lei L, 2001, J LEUKOCYTE BIOL, V70, P80
   McDouall RM, 1997, TRANSPLANTATION, V64, P1175, DOI 10.1097/00007890-199710270-00016
   MUDZINSKI SP, 1995, BLOOD, V86, P2452, DOI 10.1182/blood.V86.6.2452a.bloodjournal8662452a
   NELSON DJ, 1994, J EXP MED, V179, P203, DOI 10.1084/jem.179.1.203
   Nicolle AL, 2004, TRANSFUSION MED, V14, P225, DOI 10.1111/j.0958-7578.2004.00504.x
   Nishimura M, 2007, VOX SANG, V93, P78, DOI 10.1111/j.1423-0410.2007.00925.x
   Nishimura M, 2007, TRANSFUSION MED, V17, P129, DOI 10.1111/j.1365-3148.2006.00721.x
   Nishimura M, 2003, TRANSFUSION MED, V13, P141, DOI 10.1046/j.1365-3148.2003.00434.x
   Oehler L, 1998, J EXP MED, V187, P1019, DOI 10.1084/jem.187.7.1019
   Oliveira R, 2014, CLIN HEMORHEOL MICRO, V56, P175, DOI 10.3233/CH-131725
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Porretti L, 2004, EUR J HAEMATOL, V73, P295, DOI 10.1111/j.1600-0609.2004.00279.x
   Radsak M, 2000, IMMUNOLOGY, V101, P521, DOI 10.1046/j.1365-2567.2000.00140.x
   Reinisch W, 2003, CLIN EXP IMMUNOL, V133, P476, DOI 10.1046/j.1365-2249.2003.02245.x
   Sachs UJH, 2011, BLOOD, V117, P669, DOI 10.1182/blood-2010-05-286146
   Salazar JC, 2003, J IMMUNOL, V171, P2660, DOI 10.4049/jimmunol.171.5.2660
   Sandilands GP, 2006, IMMUNOLOGY, V119, P562, DOI 10.1111/j.1365-2567.2006.02471.x
   Sandilands GP, 2005, IMMUNOLOGY, V114, P354, DOI 10.1111/j.1365-2567.2004.02114.x
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 2003, J LEUKOCYTE BIOL, V73, P511, DOI 10.1189/jlb.0402179
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   Silliman CC, 2014, BLOOD, V123, P3488, DOI 10.1182/blood-2013-10-532424
   Silliman CC, 2011, TRANSFUSION, V51, P2549, DOI 10.1111/j.1537-2995.2011.03186.x
   SPAGNOLI GC, 1995, HUM IMMUNOL, V43, P45, DOI 10.1016/0198-8859(94)00131-9
   SUDA T, 1995, LUNG, V173, P127, DOI 10.1007/BF02981472
   Tvinnereim AR, 2004, J IMMUNOL, V173, P1994, DOI 10.4049/jimmunol.173.3.1994
   Varela M, 2002, TRANSFUSION, V42, P1102, DOI 10.1046/j.1537-2995.2002.00225.x
   Vella A, 2002, INFLAMMATION, V26, P143, DOI 10.1023/A:1016514927365
   Win N, 2003, TRANSFUSION, V43, P545, DOI 10.1046/j.1537-2995.2003.00363.x
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Yamashiro S, 2000, BLOOD, V96, P3958, DOI 10.1182/blood.V96.12.3958.h8003958_3958_3963
   Zarco MA, 1998, HAEMATOLOGICA, V83, P573
NR 64
TC 13
Z9 14
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD DEC
PY 2016
VL 56
IS 12
BP 3004
EP 3011
DI 10.1111/trf.13817
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA EF8KS
UT WOS:000390578300016
PM 27667662
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Sun, XJ
   Zeng, H
   Kumar, A
   Belser, JA
   Maines, TR
   Tumpey, TM
AF Sun, Xiangjie
   Zeng, Hui
   Kumar, Amrita
   Belser, Jessica A.
   Maines, Taronna R.
   Tumpey, Terrence M.
TI Constitutively Expressed IFITM3 Protein in Human Endothelial Cells Poses
   an Early Infection Block to Human Influenza Viruses
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; WEST NILE VIRUS; EPITHELIAL-CELLS;
   RECEPTOR-BINDING; DENGUE VIRUS; LUNG INJURY; PATHOGENESIS; H5N1; PH;
   TRACT
AB A role for pulmonary endothelial cells in the orchestration of cytokine production and leukocyte recruitment during influenza virus infection, leading to severe lung damage, has been recently identified. As the mechanistic pathway for this ability is not fully known, we extended previous studies on influenza virus tropism in cultured human pulmonary endothelial cells. We found that a subset of avian influenza viruses, including potentially pandemic H5N1, H7N9, and H9N2 viruses, could infect human pulmonary endothelial cells (HULEC) with high efficiency compared to human H1N1 or H3N2 viruses. In HULEC, human influenza viruses were capable of binding to host cellular receptors, becoming internalized and initiating hemifusion but failing to uncoat the viral nucleocapsid and to replicate in host nuclei. Unlike numerous cell types, including epithelial cells, we found that pulmonary endothelial cells constitutively express a high level of the restriction protein IFITM3 in endosomal compartments. IFITM3 knockdown by small interfering RNA (siRNA) could partially rescue H1N1 virus infection in HULEC, suggesting IFITM3 proteins were involved in blocking human influenza virus infection in endothelial cells. In contrast, selected avian influenza viruses were able to escape IFITM3 restriction in endothelial cells, possibly by fusing in early endosomes at higher pH or by other, unknown mechanisms. Collectively, our study demonstrates that the human pulmonary endothelium possesses intrinsic immunity to human influenza viruses, in part due to the constitutive expression of IFITM3 proteins. Notably, certain avian influenza viruses have evolved to escape this restriction, possibly contributing to virus-induced pneumonia and severe lung disease in humans.
   IMPORTANCE
   Avian influenza viruses, including H5N1 and H7N9, have been associated with severe respiratory disease and fatal outcomes in humans. Although acute respiratory distress syndrome (ARDS) and progressive pulmonary endothelial damage are known to be present during severe human infections, the role of pulmonary endothelial cells in the pathogenesis of avian influenza virus infections is largely unknown. By comparing human seasonal influenza strains to avian influenza viruses, we provide greater insight into the interaction of influenza virus with human pulmonary endothelial cells. We show that human influenza virus infection is blocked during the early stages of virus entry, which is likely due to the relatively high expression of the host antiviral factors IFITMs (interferon-induced transmembrane proteins) located in membrane-bound compartments inside cells. Overall, this study provides a mechanism by which human endothelial cells limit replication of human influenza virus strains, whereas avian influenza viruses overcome these restriction factors in this cell type.
C1 [Sun, Xiangjie; Zeng, Hui; Kumar, Amrita; Belser, Jessica A.; Maines, Taronna R.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333, United States.
C3 Centers for Disease Control & Prevention - USA
RP Tumpey, TM (corresponding author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM tft9@cdc.gov
RI Sun, Xiangjie/AAP-5409-2020
FU HHS | Centers for Disease Control and Prevention (CDC)
FX This work, including the efforts of Xiangjie Sun, was funded by HHS |
   Centers for Disease Control and Prevention (CDC).
CR Amini-Bavil-Olyaee S, 2013, CELL HOST MICROBE, V13, P452, DOI 10.1016/j.chom.2013.03.006
   Armstrong SM, 2013, VIRULENCE, V4, P537, DOI 10.4161/viru.25779
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Bailey CC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002909
   Banerjee I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068450
   Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017
   Chan MCW, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-102
   Chesarino NM, 2014, FUTURE MICROBIOL, V9, P1151, DOI [10.2217/fmb.14.65, 10.2217/FMB.14.65]
   Desai TM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004048
   Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921
   Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337
   FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8
   Fukuyama S, 2011, CURR OPIN IMMUNOL, V23, P481, DOI 10.1016/j.coi.2011.07.016
   Gao RB, 2013, AM J PATHOL, V183, P1258, DOI 10.1016/j.ajpath.2013.06.023
   Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3
   Herold S, 2015, EUR RESPIR J, V45, P1463, DOI 10.1183/09031936.00186214
   Hickford D, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-155
   Hiyoshi M, 2015, ARCH VIROL, V160, P225, DOI 10.1007/s00705-014-2270-5
   Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258
   Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861
   Jiang D, 2010, J VIROL, V84, P8332, DOI 10.1128/JVI.02199-09
   Kuiken T, 2012, CURR OPIN VIROL, V2, P276, DOI 10.1016/j.coviro.2012.02.013
   Li K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003124
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1257, DOI 10.1038/aps.2013.121
   MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x
   MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991
   MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Ocana-Macchi M, 2009, J VIROL, V83, P12947, DOI 10.1128/JVI.00468-09
   PALESE P, 2007, FIELDS VIROLOGY, P1647
   Perrone Lucy A., 2007, Infectious Disorders - Drug Targets, V7, P294, DOI 10.2174/187152607783018772
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   Poovorawan Y, 2013, PATHOG GLOB HEALTH, V107, P217, DOI 10.1179/2047773213Y.0000000103
   Ramos I, 2011, J VIROL, V85, P4421, DOI 10.1128/JVI.02356-10
   Razinkov VI, 1999, BIOPHYS J, V77, P3144, DOI 10.1016/S0006-3495(99)77144-4
   Rybak SL, 1998, J CELL PHYSIOL, V176, P216, DOI 10.1002/(SICI)1097-4652(199807)176:1<216::AID-JCP23>3.0.CO;2-3
   Sakai T, 2006, J VIROL, V80, P2013, DOI 10.1128/JVI.80.4.2013-2018.2006
   Shelton H, 2013, J GEN VIROL, V94, P1220, DOI 10.1099/vir.0.050526-0
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883
   Stauffer S, 2014, J VIROL, V88, P13029, DOI 10.1128/JVI.01430-14
   Sun XJ, 2007, CELL MICROBIOL, V9, P1672, DOI 10.1111/j.1462-5822.2007.00900.x
   Sun XJ, 2014, VIROLOGY, V464, P156, DOI 10.1016/j.virol.2014.07.004
   Sun XJ, 2005, VIROLOGY, V338, P53, DOI 10.1016/j.virol.2005.05.006
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Wang ZF, 2014, P NATL ACAD SCI USA, V111, P769, DOI 10.1073/pnas.1321748111
   Weidner JM, 2010, J VIROL, V84, P12646, DOI 10.1128/JVI.01328-10
   WHO, 2016, MONTHLY RISK ASSESSM
   Yeh E, 2010, CLIN INFECT DIS, V50, P391, DOI 10.1086/649875
   Zeng H, 2012, J VIROL, V86, P667, DOI 10.1128/JVI.06348-11
   Zeng H, 2011, J VIROL, V85, P686, DOI 10.1128/JVI.01568-10
NR 51
TC 28
Z9 31
U1 0
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2016
VL 90
IS 24
BP 11157
EP 11167
DI 10.1128/JVI.01254-16
PG 11
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA EF2BL
UT WOS:000390129300016
PM 27707929
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Zhang, YP
   Pan, CS
   Yan, L
   Liu, YY
   Hu, BH
   Chang, X
   Li, Q
   Huang, DD
   Sun, HY
   Fu, G
   Sun, K
   Fan, JY
   Han, JY
AF Zhang, Yun-Pei
   Pan, Chun-Shui
   Yan, Li
   Liu, Yu-Ying
   Hu, Bai-He
   Chang, Xin
   Li, Quan
   Huang, Dan-Dan
   Sun, Hao-Yu
   Fu, Ge
   Sun, Kai
   Fan, Jing-Yu
   Han, Jingyan
TI Catalpol restores LPS-elicited rat microcirculation disorder by
   regulation of a network of signaling involving inhibition of TLR-4 and
   SRC
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE hemorrhage; tight junction; extracellular matrix; Focal adhesion kinase (FAK); cathepsin B 
ID CATHEPSIN-B ACTIVITY; ENDOTHELIAL PERMEABILITY; MESENTERIC VENULES;
   NOTOGINSENOSIDE R1; REPERFUSION INJURY; BARRIER FUNCTION; GINSENOSIDE
   RB1; SEVERE SEPSIS; IN-VITRO; LIPOPOLYSACCHARIDE
AB LPS-induced microvascular hyperpermeability and hemorrhage play a key role in the development of sepsis, the attenuation of which might be an important strategy to prevent sepsis. However, the current clinical therapies have proven to be inefficient in improving the prognosis for patients with sepsis. Catalpol, an iridoid glycoside extracted from the roots of Rehmannia, has been reported to protect against LPS-induced acute lung injury through a Toll-like receptor-4 (TLR-4)-mediated NF-kappa B signaling pathway. However, it is still unknown whether catalpol can be an effective treatment to ameliorate the LPS-induced microvascular disorder. The present study aimed to investigate the impact of catalpol on LPS-induced mesenteric microvascular disorder and its underlying mechanism. Male Wistar rats were challenged by infusion of LPS (10 mg.kg(-1).h(-1)) through the left femoral vein for 120 min. Post-treatment with catalpol (10 mg/kg) alleviated the LPS-induced microvascular hyperpermeability and hemorrhage; reduced mortality; ameliorated the alteration in the distribution of claudin-5 and the junctional adhesion molecule-1, as well as the degradation of collagen IV and laminin; and attenuated the increase of TLR-4 level, phosphorylations of Src tyrosine kinase, phosphatidyl inositol 3-kinase, focal adhesion kinase, and cathepsin B activation. In vitro study in human umbilical vein endothelial cells verified these results and further revealed that inhibition of TLR-4 and Src each simulated some, but not all, of the effects that catalpol exerted. Besides, surface plasmon resonance showed that catalpol could directly bind to TLR-4 and Src. These results demonstrated that catalpol was able to ameliorate the LPS-induced microvascular barrier damage and hemorrhage by targeting both TLR-4 and Src, thus attenuating the phosphorylation of Src kinase, phosphatidyl inositol 3-kinase, and focal adhesion kinase, as well as cathepsin B activation.
C1 [Zhang, Yun-Pei; Huang, Dan-Dan; Sun, Hao-Yu; Han, Jing-Yan] Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, 38 Xueyuan Rd, Beijing 100191, China.
C1 [Zhang, Yun-Pei; Pan, Chun-Shui; Yan, Li; Liu, Yu-Ying; Hu, Bai-He; Chang, Xin; Li, Quan; Huang, Dan-Dan; Sun, Hao-Yu; Sun, Kai; Fan, Jing-Yu; Han, Jing-Yan] Peking Univ, Hlth Sci Ctr, Tasly Microcirculat Res Ctr, Beijing, China.
C1 [Zhang, Yun-Pei; Pan, Chun-Shui; Yan, Li; Liu, Yu-Ying; Hu, Bai-He; Chang, Xin; Li, Quan; Huang, Dan-Dan; Sun, Hao-Yu; Sun, Kai; Han, Jing-Yan] State Adm Tradit Chinese Med Peoples Republ China, Key Lab Microcirculat, Beijing, China.
C1 [Zhang, Yun-Pei; Pan, Chun-Shui; Yan, Li; Liu, Yu-Ying; Hu, Bai-He; Chang, Xin; Li, Quan; Huang, Dan-Dan; Sun, Hao-Yu; Sun, Kai; Han, Jing-Yan] State Adm Tradit Chinese Med Peoples Republ China, Key Lab Stasis & Phlegm, Beijing, China.
C1 [Zhang, Yun-Pei; Pan, Chun-Shui; Yan, Li; Liu, Yu-Ying; Hu, Bai-He; Chang, Xin; Li, Quan; Huang, Dan-Dan; Sun, Hao-Yu; Sun, Kai; Han, Jing-Yan] Beijing Microvasc Inst Integrat Chinese & Western, Beijing, China.
C1 [Fu, Ge] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, China.
C3 Peking University; Peking University; Peking University
RP Han, JY (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM hanjingyan@bjmu.edu.cn
RI han, jingyan/HJG-6568-2022; Huang, Dandan/I-3108-2013
FU Production of New Medicine Program of Ministry of Science and Technology
   of the People's Republic of China [2013ZX09402202]
FX This work was supported by the Production of New Medicine Program of
   Ministry of Science and Technology of the People's Republic of China
   (Grant 2013ZX09402202).
CR Alfieri A, 2012, CRIT CARE, V16, DOI 10.1186/cc11666
   Berthelsen LO, 2011, THROMB RES, V128, P103, DOI 10.1016/j.thromres.2010.12.002
   Breslin JW, 2008, SHOCK, V29, P349, DOI 10.1097/shk.0b013e3181454975
   Cardoso FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035919
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Cohen J, 2015, LANCET INFECT DIS, V15, P581, DOI 10.1016/S1473-3099(15)70112-X
   Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294
   Fu K, 2014, INT IMMUNOPHARMACOL, V23, P400, DOI 10.1016/j.intimp.2014.07.011
   Guo J, 2008, SHOCK, V29, P205, DOI 10.1097/SHK.0b013e318070c61a
   Han JY, 2013, BLOOD, V122, P4140, DOI 10.1182/blood-2013-03-491423
   Iba T, 2014, POL ARCH MED WEWN, V124, P321, DOI 10.20452/pamw.2299
   Li A, 2013, MICROCIRCULATION, V20, P617, DOI 10.1111/micc.12061
   Li C, 2014, AM J PHYSIOL-GASTR L, V306, pG111, DOI 10.1152/ajpgi.00123.2013
   Li JH, 2009, AM J PATHOL, V175, P1124, DOI 10.2353/ajpath.2009.090113
   Li QD, 1997, IMMUNOPHARM IMMUNOT, V19, P215, DOI 10.3109/08923979709007660
   Ma LQ, 2014, MICROCIRCULATION, V21, P649, DOI 10.1111/micc.12144
   Mao XW, 2015, SCI REP-UK, V5, DOI 10.1038/srep11155
   McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mu HN, 2015, FREE RADICAL BIO MED, V85, P237, DOI 10.1016/j.freeradbiomed.2015.04.033
   Pan CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126640
   Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9
   Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632
   Sha T, 2007, EUR J PHARMACOL, V571, P231, DOI 10.1016/j.ejphar.2007.06.027
   Shoji A, 2014, J PHARMACEUT BIOMED, V95, P47, DOI 10.1016/j.jpba.2014.02.009
   Singh AK, 2007, TOXICOL MECH METHOD, V17, P331, DOI 10.1080/15376510601077029
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Sun K, 2006, CLIN HEMORHEOL MICRO, V34, P103
   Sun K, 2015, ENDOCR METAB IMMUNE
   Sun K, 2007, LIFE SCI, V81, P509, DOI 10.1016/j.lfs.2007.06.008
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Tang PS, 2006, J CELL PHYSIOL, V209, P457, DOI 10.1002/jcp.20751
   Valimaki E, 2013, MOL CELL PROTEOMICS, V12, P749, DOI 10.1074/mcp.M112.024661
   Victor BC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3058
   Vreemann A, 2009, BIOL CHEM, V390, P481, DOI 10.1515/BC.2009.055
   Wan R, 2013, J CELL PHYSIOL, V228, P1295, DOI 10.1002/jcp.24286
   Wang CX, 2007, PROG NEUROBIOL, V83, P140, DOI 10.1016/j.pneurobio.2007.07.006
   Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200
   Xiao SL, 2016, BIOMATERIALS, V78, P74, DOI 10.1016/j.biomaterials.2015.11.034
   Yamada M, 2005, J MED CHEM, V48, P7457, DOI 10.1021/jm050623t
   Yuan HQ, 2015, NEOPLASIA, V17, P410, DOI 10.1016/j.neo.2015.04.002
   Yuan Q, 2009, SHOCK, V32, P310, DOI 10.1097/SHK.0b013e31819c36e8
   Yuan SY, 2012, MICROVASC RES, V83, P82, DOI 10.1016/j.mvr.2011.06.015
   Zhang Y, 2014, AM J PHYSIOL-GASTR L, V306, pG289, DOI 10.1152/ajpgi.00168.2013
NR 44
TC 24
Z9 30
U1 0
U2 20
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
EI 1522-1547
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD DEC
PY 2016
VL 311
IS 6
BP G1091
EP G1104
DI 10.1152/ajpgi.00159.2016
PG 14
WC Gastroenterology & Hepatology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Physiology
GA EF1VV
UT WOS:000390114000010
PM 27789455
OA Bronze
DA 2023-08-21
ER

PT J
AU Zhang, YL
   Guan, L
   Yu, J
   Zhao, ZM
   Mao, LJ
   Li, SQ
   Zhao, JY
AF Zhang, Yanlin
   Guan, Li
   Yu, Jie
   Zhao, Zanmei
   Mao, Lijun
   Li, Shuqiang
   Zhao, Jinyuan
TI Pulmonary endothelial activation caused by extracellular histones
   contributes to neutrophil activation in acute respiratory distress
   syndrome
SO RESPIRATORY RESEARCH
LA English
DT Article
DE extracellular histones; ALI/ARDS; Inflammation; ECs/HPMECs/HUVECs/MPVECs; neutrophil 
ID VON-WILLEBRAND-FACTOR; ACUTE LUNG INJURY; P-SELECTIN; CIRCULATING
   HISTONES; PATHOGENESIS; RECEPTORS; MEDIATORS; FAILURE
AB Background: During the acute respiratory distress syndrome (ARDS), neutrophils play a central role in the pathogenesis, and their activation requires interaction with the endothelium. Extracellular histones have been recognized as pivotal inflammatory mediators. This study was to investigate the role of pulmonary endothelial activation during the extracellular histone-induced inflammatory response in ARDS.
   Methods: ARDS was induced in male C57BL/6 mice by intravenous injection with lipopolysaccharide (LPS) or exogenous histones. Concurrent with LPS administration, anti-histone H4 antibody (anti-H4) or non-specific IgG was administered to study the role of extracellular histones. The circulating von Willebrand factor (vWF) and soluble thrombomodulin (sTM) were measured with ELISA kits at the preset time points. Myeloperoxidase (MPO) activity in lung tissue was measured with a MPO detection kit. The translocation of P-selectin and neutrophil infiltration were measured by immunohistochemical detection. For in vitro studies, histone H4 in the supernatant of mouse lung vascular endothelial cells (MLVECs) was measured by Western blot. The binding of extracellular histones with endothelial membrane was examined by confocal laser microscopy. Endothelial P-selectin translocation was measured by cell surface ELISA. Adhesion of neutrophils to MLVECs was assessed with a color video digital camera.
   Results: The results showed that during LPS-induced ARDS extracellular histones caused endothelial and neutrophil activation, as seen by P-selectin translocation, release of vWF, an increase of circulating sTM, lung neutrophil infiltration and increased MPO activity. Extracellular histones directly bound and activated MLVECs in a dose-dependent manner. On the contrary, the direct stimulatory effect of exogenous histones on neutrophils was very limited, as measured by neutrophil adhesion and MPO activity. With the contribution of activated endothelium, extracellular histones could effectively activating neutrophils. Both inhibiting the endothelial activation with an anti-P-toll like receptor (TLR) antibody and inhibiting the interaction of the endothelium with neutrophil using an anti-P-selectin antibody decreased the degree of neutrophil activation.
   Conclusions: Extracellular histones are pro-inflammatory mediators in LPS-induced ARDS in mice. In addition to direct action to neutrophils, extracellular histones promote neutrophil adhesion and subsequent activation by first activating the pulmonary endothelium via TLR signaling. Thus, endothelial activation is important for extracellular histone-induced inflammatory injury.
C1 [Zhang, Yanlin; Guan, Li; Yu, Jie; Zhao, Zanmei; Mao, Lijun; Li, Shuqiang; Zhao, Jinyuan] Peking Univ, Hosp 3, Res Ctr Occupat Med, 49 North Garden Rd, Beijing 100191, China.
C3 Peking University
RP Li, SQ; Zhao, JY (corresponding author), Peking Univ, Hosp 3, Res Ctr Occupat Med, 49 North Garden Rd, Beijing 100191, Peoples R China.
EM shuqiangli@263.net; zhaojinyuan@sina.com
FU National Science Foundation Committee of China [30571551]
FX This work was supported by grant from the National Science Foundation
   Committee of China (Grant No. 30571551).
CR Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC
   Allam R, 2014, J MOL MED, V92, P465, DOI 10.1007/s00109-014-1148-z
   Arnaudo AM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-24
   Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006
   Freeman CG, 2013, BIOMATERIALS, V34, P5670, DOI 10.1016/j.biomaterials.2013.03.091
   Grassle S, 2014, ARTERIOSCL THROM VAS, V34, P1382, DOI 10.1161/ATVBAHA.113.303016
   HATTORI R, 1989, J BIOL CHEM, V264, P7768
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lemieux C, 2005, BLOOD, V105, P1523, DOI 10.1182/blood-2004-09-3531
   Looney MR, 2009, NAT MED, V15, P364, DOI 10.1038/nm0409-364
   LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623
   Luo GP, 2012, ACTA HAEMATOL-BASEL, V128, P158, DOI 10.1159/000339426
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3
   Neeli I, 2008, J IMMUNOL, V180, P1895, DOI 10.4049/jimmunol.180.3.1895
   Nieuwenhuizen L, 2009, EUR J HAEMATOL, V82, P413, DOI 10.1111/j.1600-0609.2009.01238.x
   Ochoa CD, 2010, SEMIN THROMB HEMOST, V36, P301, DOI 10.1055/s-0030-1253452
   Petri B, 2010, BLOOD, V116, P4712, DOI 10.1182/blood-2010-03-276311
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967
   Scheiermann C, 2010, CURR OPIN HEMATOL, V17, P25, DOI 10.1097/MOH.0b013e328333d2a3
   Singh NRP, 2012, EUR J CLIN INVEST, V42, P1342, DOI 10.1111/j.1365-2362.2012.02720.x
   Swamydas M, 2013, JOVE-J VIS EXP, DOI 10.3791/50586
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Tsukamoto T, 2010, INJURY, V41, P21, DOI 10.1016/j.injury.2009.07.010
   van Hinsbergh VWM, 2012, SEMIN IMMUNOPATHOL, V34, P93, DOI 10.1007/s00281-011-0285-5
   Wang HB, 2007, NAT IMMUNOL, V8, P882, DOI 10.1038/ni1491
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Westman J, 2012, PLOS PATHOG, V11
   WEYRICH AS, 1995, J LEUKOCYTE BIOL, V57, P45, DOI 10.1002/jlb.57.1.45
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
NR 37
TC 25
Z9 30
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-993X
EI 1465-9921
J9 RESP RES
JI Respir. Res.
PD NOV 21
PY 2016
VL 17
AR 155
DI 10.1186/s12931-016-0472-y
PG 9
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA EF7EO
UT WOS:000390493100001
PM 27871277
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Tian, YF
   Gawlak, G
   Tian, XY
   Shah, AS
   Sarich, N
   Citi, S
   Birukova, AA
AF Tian, Yufeng
   Gawlak, Grzegorz
   Tian, Xinyong
   Shah, Alok S.
   Sarich, Nicolene
   Citi, Sandra
   Birukova, Anna A.
TI Role of Cingulin in Agonist-induced Vascular Endothelial Permeability
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; permeability; Rho/RhoA; signal transduction; vascular biology 
ID NUCLEOTIDE EXCHANGE FACTOR; TIGHT JUNCTIONS; BARRIER DYSFUNCTION;
   GENE-EXPRESSION; CLAUDIN-2 EXPRESSION; PULMONARY-EDEMA; CELL-ADHESION;
   IN-VIVO; RHO; GEF-H1
AB Agonist-induced activation of Rho GTPase signaling leads to endothelial cell (EC) permeability and may culminate in pulmonary edema, a devastating complication of acute lung injury. Cingulin is an adaptor protein first discovered in epithelium and is involved in the organization of the tight junctions. This study investigated the role of cingulin in control of agonist-induced lung EC permeability via interaction with RhoA-specific activator GEF-H1. The siRNA-induced cingulin knockdown augmented thrombin-induced EC permeability monitored by measurements of transendothelial electrical resistance and endothelial cell permeability for macromolecules. Increased thrombin-induced permeability in ECs with depleted cingulin was associated with increased activation of GEF-H1 and RhoA detected in pulldown activation assays. Increased GEF-H1 association with cingulin was essential for down-regulation of thrombin-induced RhoA barrier disruptive signaling. Using cingulin-truncated mutants, we determined that GEF-H1 interaction with the rod + tail domain of cingulin was required for inactivation of GEF-H1 and endothelial cell barrier preservation. The results demonstrate the role for association of GEF-H1 with cingulin as the mechanism of RhoA pathway inactivation and rescue of EC barrier after agonist challenge.
C1 [Tian, Yufeng; Gawlak, Grzegorz; Tian, Xinyong; Shah, Alok S.; Sarich, Nicolene; Birukova, Anna A.] Univ Chicago, Sect Pulm & Crit Care Med, Dept Med, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637, United States.
C1 [Citi, Sandra] Univ Geneva, Dept Cell Biol, CH-1205 Geneva, Switzerland.
C3 University of Chicago; University of Geneva
RP Birukova, AA (corresponding author), Univ Chicago, Sect Pulm & Crit Care Med, Dept Med, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
RI Sarich, Nicolene/IWV-3869-2023
FU National Institutes of Health Grants from NHLBI [HL107920, HL130431];
   National Institutes of Health Grant from NIGMS [GM114171]
FX This work was supported by National Institutes of Health Grants HL107920
   and HL130431 from NHLBI and National Institutes of Health Grant GM114171
   from NIGMS. The authors declare that they have no conflicts of interest
   with the contents of this article. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Aijaz S, 2005, DEV CELL, V8, P777, DOI 10.1016/j.devcel.2005.03.003
   Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Bazzoni G, 2006, THROMB HAEMOSTASIS, V95, P36, DOI 10.1160/TH05-07-0488
   Beckers CML, 2010, THROMB HAEMOSTASIS, V103, P40, DOI 10.1160/TH09-06-0403
   Benais-Pont G, 2003, J CELL BIOL, V160, P729, DOI 10.1083/jcb.200211047
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Birukova AA, 2016, CELL SIGNAL, V28, P541, DOI 10.1016/j.cellsig.2016.02.015
   Birukova AA, 2013, MOL BIOL CELL, V24, P2678, DOI 10.1091/mbc.E13-02-0098
   Birukova AA, 2013, MICROVASC RES, V87, P50, DOI 10.1016/j.mvr.2012.12.006
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012
   Citi S, 2000, J STRUCT BIOL, V131, P135, DOI 10.1006/jsbi.2000.4284
   CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0
   Citi Sandra, 2014, Small GTPases, V5, P1, DOI 10.4161/21541248.2014.973760
   Citi S, 2009, ANN NY ACAD SCI, V1165, P88, DOI 10.1111/j.1749-6632.2009.04053.x
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569
   Dejana E, 2009, CELL TISSUE RES, V335, P17, DOI 10.1007/s00441-008-0694-5
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0
   Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025
   Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9
   Gawlak G, 2014, FASEB J, V28, P3249, DOI 10.1096/fj.13-245142
   Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6
   Guillemot L, 2004, J CELL SCI, V117, P5245, DOI 10.1242/jcs.01399
   Guillemot L, 2006, MOL BIOL CELL, V17, P3569, DOI 10.1091/mbc.E06-02-0122
   Guillemot L, 2012, J CELL SCI, V125, P5005, DOI 10.1242/jcs.101261
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459
   Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200
   Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773
   Le Guelte A, 2011, BIOL CELL, V103, P593, DOI 10.1042/BC20110069
   LO SK, 1985, J APPL PHYSIOL, V58, P1421, DOI 10.1152/jappl.1985.58.5.1421
   Mammoto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2774
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Miyoshi J, 2005, ADV DRUG DELIVER REV, V57, P815, DOI 10.1016/j.addr.2005.01.008
   Ogita H, 2010, P JPN ACAD B-PHYS, V86, P621, DOI 10.2183/pjab.86.621
   Paschoud S, 2008, MOL MEMBR BIOL, V25, P1, DOI 10.1080/09687680701474009
   Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954
   Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220
   Schossleitner K, 2016, ARTERIOSCL THROM VAS, V36, P647, DOI 10.1161/ATVBAHA.115.307032
   Terry SJ, 2011, NAT CELL BIOL, V13, P159, DOI 10.1038/ncb2156
   Tian XY, 2014, J BIOL CHEM, V289, P5168, DOI 10.1074/jbc.M113.493924
   Tietz S, 2015, J CELL BIOL, V209, P493, DOI 10.1083/jcb.201412147
   Tsukita S, 2009, ANN NY ACAD SCI, V1165, P44, DOI 10.1111/j.1749-6632.2009.04056.x
   Vikis Haris G, 2004, Methods Mol Biol, V261, P175
   Zebda N, 2013, J BIOL CHEM, V288, P18290, DOI 10.1074/jbc.M112.432757
NR 54
TC 16
Z9 16
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 4
PY 2016
VL 291
IS 45
BP 23681
EP 23692
DI 10.1074/jbc.M116.720763
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EC1RH
UT WOS:000387884400028
PM 27590342
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Yi, L
   Huang, XG
   Guo, F
   Zhou, ZD
   Change, ML
   Tang, JJ
   Huang, JN
AF Yi, Lei
   Huang, Xiaogin
   Guo, Feng
   Zhou, Zengding
   Change, Mengling
   Tang, Jiajun
   Huang, Jingning
TI Lipopolysaccharide Induces Human Pulmonary Micro-Vascular Endothelial
   Apoptosis via the YAP Signaling Pathway
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE LPS; ECs/HPMECs/HUVECs/MPVECs; Yes-associated protein; P73; apoptosis 
ID YES-ASSOCIATED PROTEIN; SHIGA TOXIN; CELLS; P73; ACTIVATION; EXPRESSION;
   DOMAIN; INHIBITION
AB Gram-negative bacterial lipopolysaccharide (LPS) induces a pathologic increase in lung vascular leakage under septic conditions. LPS-induced human pulmonary micro-vascular endothelial cell (HPMEC) apoptosis launches and aggravates micro-vascular hyper-permeability and acute lung injury (ALI). Previous studies show that the activation of intrinsic apoptotic pathway is vital for LPS-induced EC apoptosis. Yes-associated protein (YAP) has been reported to positively regulate intrinsic apoptotic pathway in tumor cells apoptosis. However, the potential role of YAP protein in LPS-induced HPMEC apoptosis has not been determined. In this study, we found that LPS-induced activation and nuclear accumulation of YAP accelerated HPMECs apoptosis. LPS-induced YAP translocation from cytoplasm to nucleus by the increased phosphorylation on Y357 resulted in the interaction between YAP and transcription factor P73. Furthermore, inhibition of YAP by small interfering RNA (siRNA) not only suppressed the LPS-induced HPMEC apoptosis but also regulated P73-mediated up-regulation of BAX and down-regulation of BCL-2. Taken together, our results demonstrated that activation of the YAP/P73/(BAX and BCL-2)/caspase-3 signaling pathway played a critical role in LPS-induced HPMEC apoptosis. Inhibition of the YAP might be a potential therapeutic strategy for lung injury under sepsis.
C1 [Yi, Lei] Shanghai Jiao Tong Univ, Branch Peoples Hosp 6, Shanghai Fengxian Cent Hosp, Dept Orthoped, Shanghai, China.
C1 [Huang, Xiaogin; Guo, Feng; Zhou, Zengding; Change, Mengling; Tang, Jiajun; Huang, Jingning] Shanghai Jiao Tong Univ, Ruin Hosp, Sch Med, Dept Burn & Plast Surg, Shanghai, China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Huang, JN (corresponding author), Shanghai Jiao Tong Univ, Ruin Hosp, Sch Med, Dept Burn & Plast Surg, Shanghai, Peoples R China.
EM jinhuan56542@163.com
RI Yi, Lei/AAI-6290-2020; Tang, JiaJun/J-1320-2014
OI Tang, JiaJun/0000-0002-0413-8862
FU National Natural Science Foundation of China [81272094, 81471867,
   81301633, 81401590]; Natural Science Foundation of Shanghai
   [13ZR1457300]
FX This study was supported by the National Natural Science Foundation of
   China (nos. 81272094, 81471867, 81301633, and 81401590) and Natural
   Science Foundation of Shanghai (nos. 13ZR1457300).
CR Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8
   Bannerman DD, 2004, AM J PATHOL, V165, P1423, DOI 10.1016/S0002-9440(10)63400-1
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200
   Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1
   Chipuk JE, 2009, CELL CYCLE, V8, P2692, DOI 10.4161/cc.8.17.9412
   Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185
   Chopra M, 2009, EXP BIOL MED, V234, P361, DOI 10.3181/0811-MR-318
   Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554
   Damarla M, 2014, AM J RESP CELL MOL, V50, P932, DOI 10.1165/rcmb.2013-0361OC
   Erwert RD, 2002, J BIOL CHEM, V277, P40567, DOI 10.1074/jbc.M206351200
   Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7
   Gill SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088501
   Guo LW, 2015, INT J ONCOL, V46, P1444, DOI 10.3892/ijo.2015.2877
   Gustot T, 2011, CURR OPIN CRIT CARE, V17, P153, DOI 10.1097/MCC.0b013e328344b446
   Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002
   Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009
   Jemal A., 2020, CA-CANCER J CLIN, V70, p7, DOI DOI 10.3322/caac.21208
   Karahashi H, 2009, J IMMUNOL, V182, P7280, DOI 10.4049/jimmunol.0801376
   Kim KY, 2002, J PHARMACOL EXP THER, V300, P709, DOI 10.1124/jpet.300.2.709
   Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200
   Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019
   Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063
   Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022
   Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810
   LOUISE CB, 1992, INFECT IMMUN, V60, P1536, DOI 10.1128/IAI.60.4.1536-1543.1992
   Lu J, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/187070
   Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200
   O'Loughlin EV, 2001, MICROBES INFECT, V3, P493, DOI 10.1016/S1286-4579(01)01405-8
   OBRIG TG, 1993, J BIOL CHEM, V268, P15484
   Schlichting DE, 2011, MICROVASC RES, V81, P216, DOI 10.1016/j.mvr.2010.11.011
   Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008
   Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200
   Tiwary R, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2801
   Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601
   Wang H, 2014, CANCER METAST REV, V33, P173, DOI 10.1007/s10555-013-9463-3
   Wang HL, 2007, J IMMUNOL, V179, P1834, DOI 10.4049/jimmunol.179.3.1834
   Wendel M, 2007, INTENS CARE MED, V33, P25, DOI 10.1007/s00134-006-0433-x
   Xu ZP, 2015, TUMOR BIOL, V36, P8047, DOI 10.1007/s13277-015-3539-3
   Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551
   Yi L, 2016, SURGERY, V159, P1436, DOI 10.1016/j.surg.2015.12.008
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461
   Zahran AM, 2016, PEDIATR EMERG CARE, V32, P163, DOI 10.1097/PEC.0000000000000727
   Zhou ZD, 2013, SURGERY, V154, P621, DOI 10.1016/j.surg.2013.04.009
NR 46
TC 19
Z9 19
U1 1
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD OCT 19
PY 2016
VL 6
AR 133
DI 10.3389/fcimb.2016.00133
PG 12
WC Immunology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology
GA DZ2BF
UT WOS:000385646300001
PM 27807512
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Shigematsu, M
   Koga, T
   Ishimori, A
   Saeki, K
   Ishii, Y
   Taketomi, Y
   Ohba, M
   Jo-Watanabe, A
   Okuno, T
   Harada, N
   Harayama, T
   Shindou, H
   Li, JD
   Murakami, M
   Hoka, S
   Yokomizo, T
AF Shigematsu, Misako
   Koga, Tomoaki
   Ishimori, Ayako
   Saeki, Kazuko
   Ishii, Yumiko
   Taketomi, Yoshitaka
   Ohba, Mai
   Jo-Watanabe, Airi
   Okuno, Toshiaki
   Harada, Norihiro
   Harayama, Takeshi
   Shindou, Hideo
   Li, Jian-Dong
   Murakami, Makoto
   Hoka, Sumio
   Yokomizo, Takehiko
TI Leukotriene B-4 receptor type 2 protects against pneumolysin-dependent
   acute lung injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STREPTOCOCCUS-PNEUMONIAE;
   12-HYDROXYHEPTADECATRIENOIC ACID; BLT2; INFLAMMATION;
   HYPERRESPONSIVENESS; MECHANISMS; MORTALITY; MIGRATION; GPR17
AB Although pneumococcal infection is a serious problem worldwide and has a high mortality rate, the molecular mechanisms underlying the lethality caused by pneumococcus remain elusive. Here, we show that BLT2, a G protein-coupled receptor for leukotriene B4 and 12(S)-hydroxyheptadecatrienoic acid (12-HHT), protects mice from lung injury caused by a pneumococcal toxin, pneumolysin (PLY). Intratracheal injection of PLY caused lethal acute lung injury (ALI) in BLT2-deficient mice, with evident vascular leakage and bronchoconstriction. Large amounts of cysteinyl leukotrienes (cysLTs), classically known as a slow reactive substance of anaphylaxis, were detected in PLY-treated lungs. PLY-dependent vascular leakage, bronchoconstriction, and death were markedly ameliorated by treatment with a CysLT1 receptor antagonist. Upon stimulation by PLY, mast cells produced cysLTs that activated CysLT1 expressed in vascular endothelial cells and bronchial smooth muscle cells, leading to lethal vascular leakage and bronchoconstriction. Treatment of mice with aspirin or loxoprofen inhibited the production of 12-HHT and increased the sensitivity toward PLY, which was also ameliorated by the CysLT1 antagonist. Thus, the present study identifies the molecular mechanism underlying PLY-dependent ALI and suggests the possible use of CysLT1 antagonists as a therapeutic tool to protect against ALI caused by pneumococcal infection.
C1 [Shigematsu, Misako; Koga, Tomoaki; Saeki, Kazuko; Ohba, Mai; Jo-Watanabe, Airi; Okuno, Toshiaki; Yokomizo, Takehiko] Juntendo Univ, Sch Med, Dept Biochem, Tokyo, Japan.
C1 [Shigematsu, Misako; Hoka, Sumio] Kyushu Univ, Grad Sch Med Sci, Dept Anesthesiol & Crit Care Med, Fukuoka, Japan.
C1 [Ishimori, Ayako; Harada, Norihiro] Juntendo Univ, Sch Med, Dept Resp Med, Tokyo, Japan.
C1 [Ishii, Yumiko] Kyushu Univ, Chest Dis Res Inst, Grad Sch Med Sci, Fukuoka, Japan.
C1 [Taketomi, Yoshitaka; Murakami, Makoto] Tokyo Metropolitan Inst Med Sci, Lipid Metab Project, Tokyo, Japan.
C1 [Harayama, Takeshi; Shindou, Hideo] Natl Ctr Global Hlth & Med, Lipid Signaling Project, Tokyo, Japan.
C1 [Harayama, Takeshi] Univ Geneva, Dept Biochem, Geneva, Switzerland.
C1 [Li, Jian-Dong] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303, United States.
C3 Juntendo University; Kyushu University; Juntendo University; Kyushu
   University; Tokyo Metropolitan Institute of Medical Science; National
   Center for Global Health & Medicine - Japan; University of Geneva;
   University System of Georgia; Georgia State University
RP Yokomizo, T (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Tokyo, Japan.
EM yokomizo-tky@umin.ac.jp
RI Harada, Norihiro/N-8827-2019; Jo-watanabe, Airi/W-3308-2019; Yokomizo,
   Takehiko/P-5673-2016; Harayama, Takeshi/AAD-8852-2022
OI Harada, Norihiro/0000-0002-0962-5731; Yokomizo,
   Takehiko/0000-0002-5219-1553; Harayama, Takeshi/0000-0003-2255-4197; Li,
   Jian-Dong/0000-0002-5593-050X; Ishii, Yumiko/0000-0002-7438-3695
FU MEXT/JSPS KAKENHI [22116001, 22116002, 15H05901, 15H05904, 15H04708,
   15H06604, 25860223, 15K19032, 24590386, 15K08316, 25460374]; Naito
   Foundation; Ono Medical Research Foundation; Uehara Memorial Foundation;
   Mitsubishi Foundation; Nakatomi Foundation; Takeda Science Foundation;
   Foundation of Strategic Research Projects in Private Universities from
   the MEXT [S1311011]; Institute for Environmental and Gender-Specific
   Medicine; Grants-in-Aid for Scientific Research [15KK0320, 15K19032,
   15H04708, 15H05904, 15K08316, 24590386, 16K08596, 25860223, 16K15122,
   15H06604, 15H05897, 16H02613] Funding Source: KAKEN
FX This work was supported by MEXT/JSPS KAKENHI Grant Numbers, 22116001,
   22116002, 15H05901, 15H05904, 15H04708, 15H06604, 25860223, 15K19032,
   24590386, 15K08316, and 25460374, and grants from the Naito Foundation,
   the Ono Medical Research Foundation, the Uehara Memorial Foundation, the
   Mitsubishi Foundation, the Nakatomi Foundation and the Takeda Science
   Foundation. This study was supported in part by a Grant-in-Aid
   (S1311011) from the Foundation of Strategic Research Projects in Private
   Universities from the MEXT and a grant from the Institute for
   Environmental and Gender-Specific Medicine. We thank Dr. Atsushi
   Furuhata (Division of Biomedical Imaging Research, Juntendo University),
   Dr. Yukari Asai (Research Institute for Diseases of the Chest, Graduate
   School of Medical Sciences, Kyushu University) and the Support Center
   for Education and Research (Kyushu University) for technical supports.
CR Abdulnour REE, 2014, P NATL ACAD SCI USA, V111, P16526, DOI 10.1073/pnas.1407123111
   Austen KF, 2009, J ALLERGY CLIN IMMUN, V124, P406, DOI 10.1016/j.jaci.2009.05.046
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]
   Brandenburg JA, 2000, J GEN INTERN MED, V15, P638, DOI 10.1046/j.1525-1497.2000.04429.x
   Cho KJ, 2010, J IMMUNOL, V185, P6329, DOI 10.4049/jimmunol.1001213
   Cockeran R, 2002, CURR OPIN INFECT DIS, V15, P235, DOI 10.1097/00001432-200206000-00004
   Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933
   Dewi BE, 2004, J VIROL METHODS, V121, P171, DOI 10.1016/j.jviromet.2004.06.013
   ESPOSITO AL, 1984, AM REV RESPIR DIS, V130, P857
   Eum SY, 2003, AM J RESP CELL MOL, V28, P25, DOI 10.1165/rcmb.4532
   GREEN TP, 1988, J LAB CLIN MED, V111, P173
   Hamaguchi M, 2010, J CLIN BIOCHEM NUTR, V47, P138, DOI 10.3164/jcbn.10-33
   Harayama T, 2014, CELL METAB, V20, P295, DOI 10.1016/j.cmet.2014.05.019
   Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262
   Hollingshead SK, 2001, CURR OPIN MICROBIOL, V4, P71, DOI 10.1016/S1369-5274(00)00167-3
   Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200
   Iizuka Y, 2010, FASEB J, V24, P4678, DOI 10.1096/fj.10-165050
   Ishii Y., 2015, FASEB J IN PRESS, DOI [10.1096/fj.1015-279653, DOI 10.1096/FJ.1015-279653]
   Jefferies S, 2012, POSTGRAD MED J, V88, P21, DOI 10.1136/postgradmedj-2011-130217
   Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453
   Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704
   Levy BD, 2014, ANNU REV PHYSIOL, V76, P467, DOI 10.1146/annurev-physiol-021113-170408
   Lim JH, 2007, IMMUNITY, V27, P349, DOI 10.1016/j.immuni.2007.07.011
   Liu M, 2014, J EXP MED, V211, P1063, DOI 10.1084/jem.20132063
   Lynch KR, 1999, NATURE, V399, P789
   Maekawa A, 2010, J IMMUNOL, V185, P1846, DOI 10.4049/jimmunol.1001131
   Maekawa A, 2009, P NATL ACAD SCI USA, V106, P11685, DOI 10.1073/pnas.0905364106
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Matsunobu T, 2013, J LIPID RES, V54, P2979, DOI 10.1194/jlr.M037754
   Messika J, 2014, J CRIT CARE, V29, P733, DOI 10.1016/j.jcrc.2014.05.021
   Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885
   Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329
   Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Rossjohn J, 1998, J MOL BIOL, V284, P449, DOI 10.1006/jmbi.1998.2167
   RUBINS JB, 1993, INFECT IMMUN, V61, P1352, DOI 10.1128/IAI.61.4.1352-1358.1993
   Sobczak Magdalena, 2010, J Vis Exp, DOI 10.3791/2316
   STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515
   Taketomi Y, 2013, NAT IMMUNOL, V14, P554, DOI 10.1038/ni.2586
   Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217
   Voiriot G, 2011, CHEST, V139, P387, DOI 10.1378/chest.09-3102
   WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421
   Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506
NR 44
TC 21
Z9 21
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 5
PY 2016
VL 6
AR 34560
DI 10.1038/srep34560
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DX8TN
UT WOS:000384662500001
PM 27703200
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Cheng, Y
   Jin, M
   Dong, XH
   Sun, LZ
   Liu, J
   Wang, R
   Yang, YW
   Lin, PR
   Hou, SY
   Ma, YH
   Wang, YF
   Pan, XD
   Lu, JK
   Cheng, WP
AF Cheng, Yi
   Jin, Mu
   Dong, Xiuhua
   Sun, Lizhong
   Liu, Jing
   Wang, Rong
   Yang, Yanwei
   Lin, Peirong
   Hou, Siyu
   Ma, Yuehua
   Wang, Yuefeng
   Pan, Xudong
   Lu, Jiakai
   Cheng, Weiping
TI Mechanism and early intervention research on ALI during emergence
   surgery of Stanford type-A AAD Study protocol for a prospective,
   double-blind, clinical trial
SO MEDICINE
LA English
DT Article
DE ALI/ARDS; coagulation; Inflammation; Stanford type-A acute aortic dissection 
ID ACUTE AORTIC DISSECTION; C-REACTIVE PROTEIN; OXYGENATION
AB Background: Stanford type-A acute aortic dissection (AAD) is a severe cardiovascular disease demonstrating the characteristics of acute onset and rapid development, with high morbidity and mortality. The available evidence shows that preoperative acute lung injury (ALI) induced by Stanford type-A AAD is a frequent and important cause for a number of untoward consequences. However, there is no study assessing the incidence of preoperative ALI and its independent determinants before Standford type-A AAD surgery in Chinese adult patients.
   Methods/design: This is a prospective, double-blind, signal-center clinical trial. We will recruit 130 adult patients undergoing Stanford type-A AAD surgery. The incidence of preoperative ALI will be evaluated. Perioperative clinical baselines and serum variables including coagulation, fibrinolysis, inflammatory, reactive oxygen species, and endothelial cell function will be assayed. The independent factors affecting the occurrence of preoperative ALI will be identified by multiple logistic regression analysis.
C1 [Cheng, Yi; Jin, Mu; Dong, Xiuhua; Wang, Rong; Yang, Yanwei; Lin, Peirong; Hou, Siyu; Ma, Yuehua; Wang, Yuefeng; Lu, Jiakai; Cheng, Weiping] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Anesthesiol, 2 Anzhen Rd, Beijing 100029, China.
C1 [Sun, Lizhong; Pan, Xudong] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Cardiol, Beijing, China.
C1 [Liu, Jing] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Epidemiol, Beijing, China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University
RP Lu, JK; Cheng, WP (corresponding author), Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Anesthesiol, 2 Anzhen Rd, Beijing 100029, Peoples R China.
EM lujiakai620@163.com; ch_eng9735@sina.com
RI WANG, YUE/GWQ-9256-2022
FU Capital medical development research foundation [2011-2006-03]; Beijing
   Municipal Science & Technology Commission [Z141107002514135]; research
   special fund for public welfare industry of health [201402009]
FX The study was supported by grants from Capital medical development
   research foundation (no. 2011-2006-03), Beijing Municipal Science &
   Technology Commission (no. Z141107002514135), and the research special
   fund for public welfare industry of health (no. 201402009).
CR Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678
   Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc13-S011, 10.2337/dc14-S081, 10.2337/dc13-S067, 10.2337/dc11-S062, 10.2337/dc12-s064, 10.2337/dc11-S011, 10.2337/dc10-S062, 10.2337/dc10-S011]
   [Anonymous], 2012, JAMA, DOI DOI 10.1001/JAMA.2012.5669
   Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152
   Golledge J, 2008, LANCET, V372, P55, DOI 10.1016/S0140-6736(08)60994-0
   Hagan PG, 2000, JAMA-J AM MED ASSOC, V283, P897, DOI 10.1001/jama.283.7.897
   Hasegawa Y, 1999, J CARDIOVASC SURG, V40, P191
   Komukai K, 2005, INT HEART J, V46, P795, DOI 10.1536/ihj.46.795
   Levey AS, 2015, JAMA-J AM MED ASSOC, V313, P837, DOI 10.1001/jama.2015.0602
   Liu Li-Sheng, 2011, Zhonghua Xin Xue Guan Bing Za Zhi, V39, P579
   Ma WG, 2013, ANN CARDIOTHORAC SUR, V2, P621, DOI 10.3978/j.issn.2225-319X.2013.09.06
   MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720
   NAGY Z, 1995, STROKE, V26, P265, DOI 10.1161/01.STR.26.2.265
   Nienaber CA, 2003, CIRCULATION, V108, P628, DOI 10.1161/01.CIR.0000087009.16755.E4
   Sugano Y, 2005, INT J CARDIOL, V102, P39, DOI 10.1016/j.ijcard.2004.03.076
   Sun LZ, 2011, ANN THORAC SURG, V91, P1147, DOI 10.1016/j.athoracsur.2010.12.005
   Sun LZ, 2011, CIRCULATION, V123, P971, DOI 10.1161/CIRCULATIONAHA.110.015081
   Tomita K, 2014, INT J ANGIOL, V23, P53, DOI 10.1055/s-0033-1349398
   Wang YH, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-118
   Yan TD, 2014, CIRCULATION, V129, P1610, DOI 10.1161/CIRCULATIONAHA.113.006421
NR 20
TC 9
Z9 11
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2016
VL 95
IS 42
AR e5164
DI 10.1097/MD.0000000000005164
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EB0EU
UT WOS:000387017000031
PM 27759648
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Kono, M
   Saigo, K
   Yamamoto, S
   Shirai, K
   Iwamoto, S
   Uematsu, T
   Takahashi, T
   Imoto, S
   Hashimoto, M
   Minami, Y
   Wada, A
   Takenokuchi, M
   Kawano, S
AF Kono, Mari
   Saigo, Katsuyasu
   Yamamoto, Shiori
   Shirai, Kohei
   Iwamoto, Shuta
   Uematsu, Tomoko
   Takahashi, Takayuki
   Imoto, Shion
   Hashimoto, Makoto
   Minami, Yosuke
   Wada, Atsushi
   Takenokuchi, Mariko
   Kawano, Seiji
TI Iron-chelating agent, deferasirox, inhibits neutrophil activation and
   extracellular trap formation
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE iron chelators; morphology; neutrophils 
ID ACUTE LUNG INJURY; BETA-THALASSEMIA; DEATH; INFLAMMATION; EXPRESSION;
   MECHANISM; AUTOPHAGY; STRESS; CELLS; MTOR
AB Iron-chelating agents, which are frequently prescribed to transfusion-dependent patients, have various useful biological effects in addition to chelation. Reactive oxygen species (ROS) produced by neutrophils can cause pulmonary endothelial cell damage, which can lead to acute lung injury (ALI). We previously reported that deferasirox (DFS), an iron-chelating agent, inhibits phorbol myristate acetate (PMA) or formyl-methionyl-leucyl-phenylalanine (fMLP)-induced ROS production in neutrophils, in vitro. Here, we investigate whether DFS inhibits vacuolization in neutrophils and neutrophil extracellular trap (NET) formation. Human neutrophils were incubated with DFS and stimulated with PMA or fMLP. Human neutrophils were separated from heparinized peripheral blood using density gradient centrifugation, and subsequently incubated with DFS. After 10minutes, neutrophils were stimulated by PMA or fMLP. Vacuole formation was observed by electron microscopy. For observing NET formations using microscopes, immunohistological analyses using citrullinated histone H3 and myeloperoxidase antibodies, and SYTOX Green (an impermeable DNA detection dye) staining, were conducted. NET formation was measured as the quantity of double-stranded DNA (dsDNA), using the AccuBlue Broad Range dsDNA Quantitation Kit. DFS (50mol/L) inhibited vacuole formation in the cytoplasm and NET formation. Additionally, 5-100mol/L concentration of DFS inhibited the release of dsDNA in a dose-independent manner. We demonstrate that DFS inhibits not only ROS production but also vacuolization and NET formation in neutrophils. These results suggest the possibility of protective effects of DFS against NET-related adverse effects, including ALI and thrombosis.
C1 [Kono, Mari; Yamamoto, Shiori; Wada, Atsushi] Sysmex Corp, Sci Res, Sci Affairs, Kobe, Hyogo, Japan.
C1 [Saigo, Katsuyasu; Shirai, Kohei; Iwamoto, Shuta; Uematsu, Tomoko; Takenokuchi, Mariko] Himeji Dokkyo Univ, Fac Pharmacol Sci, Himeji, Hyogo, Japan.
C1 [Takahashi, Takayuki] Shinko Hosp, Dept Hematol, Kobe, Hyogo, Japan.
C1 [Imoto, Shion] Kobe Tokiwa Univ, Dept Hlth Sci, Kobe, Hyogo, Japan.
C1 [Hashimoto, Makoto; Minami, Yosuke; Kawano, Seiji] Kobe Univ Hosp, Kobe, Hyogo, Japan.
C3 Sysmex Corporation; Himeji Dokkyo University; Kobe University
RP Kono, M (corresponding author), SYSMEX Corp, Sci Res, Sci Affairs, Nishi Ku, 1-3-2 Murotani, Kobe, Hyogo 6512241, Japan.
EM kono.mari@sysmex.co.jp
CR Alberts B, 2015, MOLECULAR BIOLOGY OF THE CELL, SIXTH EDITION, P1
   Arai Y, 2013, BIOL BLOOD MARROW TR, V19, P1683, DOI 10.1016/j.bbmt.2013.09.005
   Banerjee A, 2015, BRIT J HAEMATOL, V168, P576, DOI 10.1111/bjh.13151
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Chang HH, 2015, ANN HEMATOL, V94, P1945, DOI 10.1007/s00277-015-2476-y
   Czaikoski PG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148142
   Dupre-Crochet S, 2013, J LEUKOCYTE BIOL, V94, P657, DOI 10.1189/jlb.1012544
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   Ghoti H, 2010, HAEMATOL-HEMATOL J, V95, P1433, DOI 10.3324/haematol.2010.024992
   Itakura A, 2013, AM J PHYSIOL-CELL PH, V305, pC348, DOI 10.1152/ajpcell.00108.2013
   Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396
   Kono M, 2013, BLOOD TRANSFUS-ITALY, V11, P53, DOI 10.2450/2012.0141-11
   Lui GYL, 2013, MOL PHARMACOL, V83, P179, DOI 10.1124/mol.112.081893
   McInturff AM, 2012, BLOOD, V120, P3118, DOI 10.1182/blood-2012-01-405993
   Messa E, 2010, HAEMATOL-HEMATOL J, V95, P1308, DOI 10.3324/haematol.2009.016824
   Mihalache CC, 2011, J IMMUNOL, V186, P6532, DOI 10.4049/jimmunol.1004055
   Mitroulis I, 2010, EUR J IMMUNOL, V40, P1461, DOI 10.1002/eji.200940025
   Ohyashiki JH, 2009, CANCER SCI, V100, P970, DOI 10.1111/j.1349-7006.2009.01131.x
   Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675
   Remijsen Q, 2011, CELL DEATH DIFFER, V18, P581, DOI 10.1038/cdd.2011.1
   Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150
   Saigo Katsuyasu, 2013, J Clin Med Res, V5, P57, DOI 10.4021/jocmr1180w
   Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   Walter PB, 2008, HAEMATOLOGICA, V93, P817, DOI 10.3324/haematol.11755
NR 25
TC 14
Z9 14
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD OCT
PY 2016
VL 43
IS 10
BP 915
EP 920
DI 10.1111/1440-1681.12612
PG 6
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA DW4QV
UT WOS:000383629000005
PM 27333499
DA 2023-08-21
ER

PT J
AU Viswanathan, P
   Ephstein, Y
   Garcia, JGN
   Cho, M
   Dudek, SM
AF Viswanathan, P.
   Ephstein, Y.
   Garcia, Joe G. N.
   Cho, Myoung Rae
   Dudek, Steven M.
TI Differential elastic responses to barrier-altering agonists in two types
   of human lung endothelium
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE AFM; Barrier regulation; ECs/HPMECs/HUVECs/MPVECs; S1P/S1PR1/S1PR2/S1PR3; FTY720 
ID SPHINGOSINE 1-PHOSPHATE; CYTOSKELETAL REARRANGEMENT; MECHANICS;
   PERMEABILITY; ENHANCEMENT; CELLS; MODULATION; INTEGRITY; CORTACTIN;
   THROMBIN
AB Vascular integrity is primarily determined by endothelial cell (EC) cytoskeletal structure that is differentially regulated by various stimuli. In this study, atomic force microscopy (AFM) was used to characterize structural and mechanical properties in the cytoskeleton of cultured human pulmonary artery EC (HPAEC) and human lung microvascular EC (HLMVEC) by determining elastic properties (Young's modulus) in response to endogenous barrier protective agents sphingosine 1-phosphate (SIP) and hepatocyte growth factor (HGF), or the barrier disruptive molecule thrombin. Initial studies in unstimulated cells indicate higher baseline peripheral elastic modulus values in HPAEC (mean 2.9 KPa) than in HLMVEC (1.8 KPa). After 30 min of stimulation, SW induced the highest Young's modulus increase (6.1 KPa) compared to the other barrier enhancing stimuli, HGF (5.8 KPa) and the pharmaceutical agent and SIP analog FTY720 (4.1 KPa). In contrast, the barrier disruptive agent thrombin decreased values from 2.5 KPa to 0.7 KPa depending on the cell type and treatment time. AFM topographical imaging supports these quantitative biophysical data regarding differential peripheral elastic properties in EC. Overall, these AFM studies provide novel insights into the biomechanical properties of human lung EC that regulate vascular barrier function and have potential applicability to pathophysiologic vascular leak syndromes such as acute lung injury. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ephstein, Y.; Dudek, S. M.] Univ Illinois, Div Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C1 [Viswanathan, P.; Cho, M.] Univ Illinois, Dept Bioengn, Chicago, IL, United States.
C1 [Garcia, J. G. N.] Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Arizona; University of Arizona Health Sciences
RP Dudek, SM (corresponding author), Univ Illinois, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
EM sdudek@uic.edu
OI Cho, Myoung Rae/0000-0002-8191-8045
FU NIH [PO1 58064, R56 HL088144]
FX We thank Dr. Shan Sun, University of Illinois at Chicago for her
   essential expertise with the AFM. We also thank the Nanotechnology Core
   Facility (NCF), University of Illinois for permission to use their
   facility. This work was supported by: NIH Funding; PO1 58064 [PI
   Garcia], R56 HL088144 [Dudek].
CR Alcaraz J, 2003, BIOPHYS J, V84, P2071, DOI 10.1016/S0006-3495(03)75014-0
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Arce FT, 2013, NANOMED-NANOTECHNOL, V9, P875, DOI 10.1016/j.nano.2013.03.006
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Bogatcheva NV, 2003, AM J PHYSIOL-LUNG C, V285, pL415, DOI 10.1152/ajplung.00364.2001
   Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544
   Costa KD, 1999, J BIOMECH ENG-T ASME, V121, P462, DOI 10.1115/1.2835074
   Donati C, 2006, BBA-BIOMEMBRANES, V1758, P2037, DOI 10.1016/j.bbamem.2006.06.015
   Dudek SM, 2007, CELL SIGNAL, V19, P1754, DOI 10.1016/j.cellsig.2007.03.011
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Hiesgen R., 2009, ENCY ELECTROCHEMICAL, P696, DOI DOI 10.1016/B978-044452745-5.00073-3
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Kuznetsova TG, 2007, MICRON, V38, P824, DOI 10.1016/j.micron.2007.06.011
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com
   McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006
   O'Callaghan R, 2011, AM J PHYSIOL-LUNG C, V301, pL353, DOI 10.1152/ajplung.00342.2010
   Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691
   Prasain N, 2009, MICROVASC RES, V77, P53, DOI 10.1016/j.mvr.2008.09.012
   Radmacher M, 2002, METHOD CELL BIOL, V68, P67
   Rotsch C, 2000, BIOPHYS J, V78, P520, DOI 10.1016/S0006-3495(00)76614-8
   Titushkin I, 2007, BIOPHYS J, V93, P3693, DOI 10.1529/biophysj.107.107797
   Titushkin I, 2009, BIOPHYS J, V96, P717, DOI 10.1016/j.bpj.2008.09.035
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep11097
   Wozniak MJ, 2009, MICRON, V40, P870, DOI 10.1016/j.micron.2009.06.002
   Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D
NR 33
TC 5
Z9 5
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 16
PY 2016
VL 478
IS 2
BP 599
EP 605
DI 10.1016/j.bbrc.2016.07.112
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DW3FX
UT WOS:000383528600015
PM 27473658
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Wang, LP
   Huang, X
   Kong, GQ
   Xu, HX
   Li, JK
   Hao, D
   Wang, T
   Han, SS
   Han, CL
   Sun, YY
   Liu, XY
   Wang, XZ
AF Wang, Lipeng
   Huang, Xiao
   Kong, Guiqing
   Xu, Haixiao
   Li, Jiankui
   Hao, Dong
   Wang, Tao
   Han, Shasha
   Han, Chunlei
   Sun, Yeying
   Liu, Xiangyong
   Wang, Xiaozhi
TI Ulinastatin attenuates pulmonary endothelial glycocalyx damage and
   inhibits endothelial heparanase activity in LPS-induced ARDS
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE ALI/ARDS; ulinastatin; endothelial glycocalyx (EG); heparanase; Lysosome 
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; VASCULAR-PERMEABILITY;
   SEPSIS; MECHANOTRANSDUCTION; INFLAMMATION; MORTALITY; SULFATE
AB Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure characterized by major pathologic mechanisms of increased microvascular permeability and inflammation. The glycocalyx lines on the endothelial surface, which determines the vascular permeability, and heparanase play pivotal roles in the degradation of heparan sulfate (HS). HS is the major component of the glycocalyx. The aim of this study is to examine the effects of Ulinastatin (UTI) on vascular permeability and pulmonary endothelial glycocalyx dysfunction induced by lipopolysaccharide (LPS). In our study, C57BL/6 mice and human umbilical vein endothelial cells were stimulated with LPS to induce injury models. After 6 h of LPS stimulation, pulmonary pathological changes, pulmonary edema, and vascular permeability were notably attenuated by UTI. UTI inhibited LPS-induced endothelial glycocalyx destruction and significantly decreased the production of HS as determined by ELISA and immunofluorescence. UTI also reduced the active form of heparanase (50 kDa) expression and heparanase activity. Moreover, lysosome pH was investigated because heparanase (65 kDa) can be reduced easily in its active form at 50 kDa in a low pH environment within lysosome. Results showed that UTI could inhibit LPS-induced pH elevation in lysosome. In conclusion, UTI protects pulmonary endothelial glycocalyx integrity and inhibits heparanase activity during LPS-induced ARDS. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Wang, Lipeng; Huang, Xiao; Kong, Guiqing; Xu, Haixiao; Li, Jiankui; Hao, Dong; Wang, Tao; Wang, Xiaozhi] Binzhou Med Univ, Affiliated Hosp, Dept Intens Care Unit, Binzhou 256603, Shandong, China.
C1 [Han, Shasha] Binzhou Med Univ, Affiliated Hosp, Dept Resp Med, Binzhou 256603, Shandong, China.
C1 [Wang, Lipeng; Sun, Yeying; Liu, Xiangyong] Binzhou Med Univ, Dept Cell Biol, Yantai 264003, Shandong, China.
C1 [Han, Chunlei] Binzhou Med Univ, Dept Hlth Stat, Yantai 264003, Shandong, China.
C3 Binzhou Medical University; Binzhou Medical University; Binzhou Medical
   University; Binzhou Medical University
RP Wang, XZ (corresponding author), Binzhou Med Univ, Affiliated Hosp, Dept Resp Med, Binzhou 256603, Shandong, Peoples R China.; Liu, XY (corresponding author), Binzhou Med Univ, Dept Cell Biol, Yantai 264003, Shandong, Peoples R China.; Wang, XZ (corresponding author), Binzhou Med Univ, Intens Care Unit, Affiliated Hosp, Binzhou 256603, Shandong, Peoples R China.
EM liuxiangyong81@gmail.com; hxicuwxz@163.com
OI Hao, Dingjun/0000-0002-6555-9521
FU Natural Science Foundation of Shandong Province [ZR2014HM112,
   ZR2014HL004, ZR2013CL003, UF201403]; Binzhou medical university student
   science and tecnology innovation project [BY2015DKCX083]; Science and
   Technology Development Plan of Binzhou medical college [BY2012KJ21];
   Taishan Scholar project of Shandong Province; key clinical specialty
   project of Shandong Province
FX This work has received funding from the Natural Science Foundation of
   Shandong Province, (ZR2014HM112, ZR2014HL004, ZR2013CL003, UF201403),
   Binzhou medical university student science and tecnology innovation
   project (BY2015DKCX083), the Science and Technology Development Plan of
   Binzhou medical college (BY2012KJ21), Taishan Scholar project of
   Shandong Province and key clinical specialty project of Shandong
   Province.
CR Barakat AI, 2008, CIRC RES, V102, P747, DOI 10.1161/CIRCRESAHA.108.174839
   Becker BF, 2010, BASIC RES CARDIOL, V105, P687, DOI 10.1007/s00395-010-0118-z
   Burke-Gaffney A, 2012, CRIT CARE, V16, DOI 10.1186/cc11239
   Chappell D, 2008, BIOL CHEM, V389, P79, DOI 10.1515/BC.2008.005
   Cohen E, 2005, FEBS LETT, V579, P2334, DOI 10.1016/j.febslet.2005.03.030
   Fang Y, 2011, J TRAUMA, V71, P1297, DOI 10.1097/TA.0b013e3182127d48
   Fu BMM, 2013, WIRES SYST BIOL MED, V5, P381, DOI 10.1002/wsbm.1211
   GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213
   Inoue KI, 2005, MOL PHARMACOL, V67, P673, DOI 10.1124/mol.104.005967
   Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d
   Kolarova H, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/694312
   Kong GQ, 2016, INT IMMUNOPHARMACOL, V36, P51, DOI 10.1016/j.intimp.2016.03.039
   Lennon FE, 2011, AM J CARDIOVASC DIS, V1, P200
   Linder A, 2014, INTENS CARE MED, V40, P1164, DOI 10.1007/s00134-014-3366-9
   Mammoto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2774
   Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627
   NAKAJIMA M, 1986, ANAL BIOCHEM, V157, P162, DOI 10.1016/0003-2697(86)90209-5
   Nakatani K, 2001, J LEUKOCYTE BIOL, V69, P241
   Nelson A, 2008, SHOCK, V30, P623, DOI 10.1097/SHK.0b013e3181777da3
   Nishina K, 1997, ANESTH ANALG, V84, P1097, DOI 10.1097/00000539-199705000-00026
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417
   Pries A.R., 2014, PFLUGERS ARCH, V440, P653
   Pugia MJ, 2005, CLIN CHEM LAB MED, V43, P1, DOI 10.1515/CCLM.2005.001
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Steppan J, 2011, J SURG RES, V165, P136, DOI 10.1016/j.jss.2009.04.034
   Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x
   Uemura K, 2008, J SURG ONCOL, V98, P309, DOI 10.1002/jso.21098
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068
NR 32
TC 32
Z9 41
U1 0
U2 29
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 16
PY 2016
VL 478
IS 2
BP 669
EP 675
DI 10.1016/j.bbrc.2016.08.005
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DW3FX
UT WOS:000383528600026
PM 27498004
DA 2023-08-21
ER

PT J
AU Di, A
   Mehta, D
   Malik, AB
AF Di, Anke
   Mehta, Dolly
   Malik, Asrar B.
TI ROS-activated calcium signaling mechanisms regulating endothelial
   barrier function
SO CELL CALCIUM
LA English
DT Review
ID PROTEIN-KINASE-C; NF-KAPPA-B; INCREASED VASCULAR-PERMEABILITY;
   VON-WILLEBRAND-FACTOR; OXIDATIVE STRESS; CA2+ ENTRY; NADPH OXIDASE; TRP
   CHANNELS; HYDROGEN-PEROXIDE; ANGIOTENSIN-II
AB Increased vascular permeability is a common pathogenic feature in many inflammatory diseases. For example in acute lung injury (ALI) and its most severe form, the acute respiratory distress syndrome (ARDS), lung microvessel endothelia lose their junctional integrity resulting in leakiness of the endothelial barrier and accumulation of protein rich edema. Increased reactive oxygen species (ROS) generated by neutrophils (PMNs) and other inflammatory cells play an important role in increasing endothelial permeability. In essence, multiple inflammatory syndromes are caused by dysfunction and compromise of the barrier properties of the endothelium as a consequence of unregulated acute inflammatory response. This review focuses on the role of ROS signaling in controlling endothelial permeability with particular focus on ALI. We summarize below recent progress in defining signaling events leading to increased endothelial permeability and ALI. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Di, Anke; Mehta, Dolly; Malik, Asrar B.] Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Malik, AB (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA.
EM abmalik@uic.edu
OI Malik, Asrar/0000-0002-8205-7128
FU NIH grant [P01HL77806]
FX This work was supported by NIH grant P01HL77806.
CR Abramowitz J, 2009, FASEB J, V23, P297, DOI 10.1096/fj.08-119495
   Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z
   Allingham MJ, 2007, J IMMUNOL, V179, P4053, DOI 10.4049/jimmunol.179.6.4053
   Barandier C, 2003, BIOCHEM BIOPH RES CO, V304, P714, DOI 10.1016/S0006-291X(03)00668-5
   BARNARD ML, 1992, J APPL PHYSIOL, V72, P1724, DOI 10.1152/jappl.1992.72.5.1724
   Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9
   Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bendall JK, 2007, CIRC RES, V100, P1016, DOI 10.1161/01.RES.0000263381.83835.7b
   BIRCH KA, 1994, J CELL PHYSIOL, V160, P545, DOI 10.1002/jcp.1041600318
   Bird GS, 2009, CURR BIOL, V19, P1724, DOI 10.1016/j.cub.2009.08.022
   Birnbaumer L, 2009, ANNU REV PHARMACOL, V49, P395, DOI 10.1146/annurev.pharmtox.48.113006.094928
   Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Bogeski I, 2011, CELL CALCIUM, V50, P407, DOI 10.1016/j.ceca.2011.07.006
   Bumstock G, 2008, NEUROCHEM INT, V52, P14, DOI 10.1016/j.neuint.2007.03.007
   Cahalan MD, 2009, NAT CELL BIOL, V11, P669, DOI 10.1038/ncb0609-669
   Chow CW, 2003, AM J RESP CELL MOL, V29, P427, DOI 10.1165/rcmb.F278
   Cioffi DL, 2009, ANTIOXID REDOX SIGN, V11, P765, DOI [10.1089/ars.2008.2221, 10.1089/ARS.2008.2221]
   Cleator JH, 2006, BLOOD, V107, P2736, DOI 10.1182/blood-2004-07-2698
   Datla SR, 2007, ARTERIOSCL THROM VAS, V27, P2319, DOI 10.1161/ATVBAHA.107.149450
   DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160
   Dietrich A, 2008, CIRC RES, V102, P275, DOI 10.1161/CIRCRESAHA.107.170548
   Ding YF, 2011, J BIOL CHEM, V286, P31799, DOI 10.1074/jbc.M111.248344
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Erent A, 2007, J PHYSIOL-LONDON, V583, P195, DOI 10.1113/jphysiol.2007.132993
   Evans JH, 2006, MOL BIOL CELL, V17, P56, DOI 10.1091/mbc.e05-06-0499
   Fink K, 2008, J IMMUNOL, V180, P6911, DOI 10.4049/jimmunol.180.10.6911
   Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914
   Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s
   Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI [10.1089/ars.2008.2220, 10.1089/ARS.2008.2220]
   Fu J, 2005, J BIOL CHEM, V280, P3178, DOI 10.1074/jbc.M410044200
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gianni D, 2008, MOL BIOL CELL, V19, P2984, DOI 10.1091/mbc.E08-02-0138
   Gianni D, 2010, MOL BIOL CELL, V21, P4287, DOI 10.1091/mbc.E10-08-0685
   Graham S, 2010, J BIOL CHEM, V285, P23464, DOI 10.1074/jbc.M109.093500
   Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5
   Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5
   Hawkins BJ, 2010, J CELL BIOL, V190, P391, DOI 10.1083/jcb.201004152
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hecquet C.M., 2009, THROMB HAEMOST, V101
   Hecquet CM, 2008, CIRC RES, V102, P347, DOI 10.1161/CIRCRESAHA.107.160176
   Hecquet CM, 2014, CIRC RES, V114, P469, DOI 10.1161/CIRCRESAHA.114.302414
   Hecquet CM, 2010, ADV EXP MED BIOL, V661, P155, DOI 10.1007/978-1-60761-500-2_10
   Hordijk PL, 2003, CELL BIOCHEM BIOPHYS, V38, P305, DOI 10.1385/CBB:38:3:305
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454
   JOHNSON A, 1989, AM J PHYSIOL, V256, pH1012, DOI 10.1152/ajpheart.1989.256.4.H1012
   Kakkar AK, 2004, CURR OPIN PHARMACOL, V4, P154, DOI 10.1016/j.coph.2004.01.003
   Kini V, 2010, J BIOL CHEM, V285, P33082, DOI 10.1074/jbc.M110.142034
   Klarenbach SW, 2003, CIRC RES, V92, P272, DOI 10.1161/01.RES.0000057386.15390.A3
   Knowles H, 2013, IMMUNOL RES, V55, P241, DOI 10.1007/s12026-012-8373-8
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Konior A, 2014, ANTIOXID REDOX SIGN, V20, P2794, DOI 10.1089/ars.2013.5607
   Konstantoulaki M, 2003, AM J PHYSIOL-LUNG C, V285, pL434, DOI 10.1152/ajplung.00075.2003
   Kuhn FJP, 2005, PFLUG ARCH EUR J PHY, V451, P212, DOI 10.1007/s00424-005-1446-y
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   Lesur O, 1999, Can Respir J, V6, P71
   Li DY, 2013, INVEST OPHTH VIS SCI, V54, P5661, DOI 10.1167/iovs.13-12473
   Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200
   Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967
   Lin CH, 2006, J IMMUNOL, V177, P3427, DOI 10.4049/jimmunol.177.5.3427
   Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719
   LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663
   Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68
   Massullo P, 2006, SEMIN CELL DEV BIOL, V17, P654, DOI 10.1016/j.semcdb.2006.11.006
   Matsushita K, 2005, J CELL BIOL, V170, P73, DOI 10.1083/jcb.200502031
   Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544
   Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200
   Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Miller BA, 2006, J MEMBRANE BIOL, V209, P31, DOI 10.1007/s00232-005-0839-3
   Ming XF, 2004, CIRCULATION, V110, P3708, DOI 10.1161/01.CIR.0000142867.26182.32
   Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0
   Moskovitz J, 2002, ARCH BIOCHEM BIOPHYS, V397, P354, DOI 10.1006/abbi.2001.2692
   Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551
   O'Donnell RW, 2003, ENDOTHELIUM-J ENDOTH, V10, P291, DOI 10.1080/10623320390272280
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004
   Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028
   Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200
   Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100
   Peshavariya H, 2009, N-S ARCH PHARMACOL, V380, P193, DOI 10.1007/s00210-009-0413-0
   Peshavariya HM, 2007, FREE RADICAL RES, V41, P699, DOI 10.1080/10715760701297354
   Petry A, 2006, ANTIOXID REDOX SIGN, V8, P1473, DOI 10.1089/ars.2006.8.1473
   Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003
   Polgar J, 2005, J THROMB HAEMOST, V3, P1590, DOI 10.1111/j.1538-7836.2005.01373.x
   Poteser M, 2006, J BIOL CHEM, V281, P13588, DOI 10.1074/jbc.M512205200
   Prins D, 2011, EMBO REP, V12, P1182, DOI 10.1038/embor.2011.173
   Putney JW, 2010, MOL INTERV, V10, P209, DOI 10.1124/mi.10.4.4
   PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6
   Reyland ME, 2009, FRONT BIOSCI-LANDMRK, V14, P2386, DOI 10.2741/3385
   Rodriguez EM, 2009, J CELL PHYSIOL, V221, P171, DOI 10.1002/jcp.21841
   Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473
   Satpathy M, 2004, EXP EYE RES, V79, P477, DOI 10.1016/j.exer.2004.06.018
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16
   Shimizu S, 2014, HANDB EXP PHARMACOL, V223, P767, DOI 10.1007/978-3-319-05161-1_3
   SiflingerBirnboim A, 1996, AM J PHYSIOL-LUNG C, V270, pL973, DOI 10.1152/ajplung.1996.270.6.L973
   SIFLINGERBIRNBOIM A, 1992, LAB INVEST, V67, P24
   Simon F, 2013, CELL SIGNAL, V25, P1614, DOI 10.1016/j.cellsig.2013.03.023
   Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200
   Soboloff J, 2012, NAT REV MOL CELL BIO, V13, P549, DOI 10.1038/nrm3414
   Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419
   Sundivakkam PC, 2013, J BIOL CHEM, V288, P17030, DOI 10.1074/jbc.M112.411272
   Sundivakkam PC, 2009, AM J PHYSIOL-CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008
   Takahashi N, 2011, CELL CALCIUM, V50, P279, DOI 10.1016/j.ceca.2011.04.006
   Takano M, 2002, AM J PHYSIOL-HEART C, V283, pH2054, DOI 10.1152/ajpheart.01001.2001
   Tatin F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7
   Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347
   Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355
   WAGNER DD, 1993, THROMB HAEMOSTASIS, V70, P105
   Wang G, 2006, HYPERTENSION, V48, P482, DOI 10.1161/01.HYP.0000236647.55200.07
   Wang Q, 2000, J IMMUNOL, V164, P6487, DOI 10.4049/jimmunol.164.12.6487
   Wang Q, 2002, ANTIOXID REDOX SIGN, V4, P39, DOI 10.1089/152308602753625843
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weber EW, 2015, J EXP MED, V212, P1883, DOI 10.1084/jem.20150353
   Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200
   WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101
   Weissmann N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1660
   Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012
   Wu LJ, 2010, PHARMACOL REV, V62, P381, DOI 10.1124/pr.110.002725
   Xue JP, 2009, PHYSIOL GENOMICS, V38, P42, DOI 10.1152/physiolgenomics.00012.2009
   Yamamoto S, 2010, PROG BIOPHYS MOL BIO, V103, P18, DOI 10.1016/j.pbiomolbio.2010.05.005
   Yao XQ, 2005, CIRC RES, V97, P853, DOI 10.1161/01.RES.0000187473.85419.3e
   Yuan JP, 2009, CHANNELS, V3, P221, DOI 10.4161/chan.3.4.9198
   ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367
   Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200
   Zhang WY, 2006, AM J PHYSIOL-CELL PH, V290, pC1146, DOI 10.1152/ajpcell.00205.2005
   Zheng HZ, 2003, BURNS, V29, P820, DOI 10.1016/j.burns.2003.08.004
   Zupancic G, 2002, J PHYSIOL-LONDON, V544, P741, DOI 10.1113/jphysiol.2002.027490
NR 137
TC 57
Z9 63
U1 1
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0143-4160
EI 1532-1991
J9 CELL CALCIUM
JI Cell Calcium
PD SEP
PY 2016
VL 60
IS 3
SI SI
BP 163
EP 171
DI 10.1016/j.ceca.2016.02.002
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DW8YB
UT WOS:000383940300003
PM 26905827
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Qi, D
   Tang, XM
   He, J
   Wang, DX
   Zhao, Y
   Deng, W
   Deng, XY
   Zhou, GQ
   Xia, J
   Zhong, X
   Pu, SL
AF Qi, Di
   Tang, Xumao
   He, Jing
   Wang, Daoxin
   Zhao, Yan
   Deng, Wang
   Deng, Xinyu
   Zhou, Guoqi
   Xia, Jing
   Zhong, Xi
   Pu, Shenglan
TI Omentin protects against LPS-induced ARDS through suppressing pulmonary
   inflammation and promoting endothelial barrier via an Akt/eNOS-dependent
   mechanism
SO CELL DEATH & DISEASE
LA English
DT Article
ID ACUTE LUNG INJURY; SYSTEMIC INFLAMMATION; METABOLIC SYNDROME; SERUM
   OMENTIN-1; OBESITY; ADIPOKINES; KINASE; CELLS; FAT; ADIPOCYTOKINE
AB Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary inflammation and endothelial barrier permeability. Omentin has been shown to benefit obesity-related systemic vascular diseases; however, its effects on ARDS are unknown. In the present study, the level of circulating omentin in patients with ARDS was assessed to appraise its clinical significance in ARDS. Mice were subjected to systemic administration of adenoviral vector expressing omentin (Ad-omentin) and one-shot treatment of recombinant human omentin (rh-omentin) to examine omentin's effects on lipopolysaccharide (LPS)-induced ARDS. Pulmonary endothelial cells (ECs) were treated with rh-omentin to further investigate its underlying mechanism. We found that a decreased level of circulating omentin negatively correlated with white blood cells and procalcitonin in patients with ARDS. Ad-omentin protected against LPS-induced ARDS by alleviating the pulmonary inflammatory response and endothelial barrier injury in mice, accompanied by Akt/eNOS pathway activation. Treatment of pulmonary ECs with rh-omentin attenuated inflammatory response and restored adherens junctions (AJs), and cytoskeleton organization promoted endothelial barrier after LPS insult. Moreover, the omentin-mediated enhancement of EC survival and differentiation was blocked by the Akt/eNOS pathway inactivation. Therapeutic rh-omentin treatment also effectively protected against LPS-induced ARDS via the Akt/eNOS pathway. Collectively, these data indicated that omentin protects against LPS-induced ARDS by suppressing inflammation and promoting the pulmonary endothelial barrier, at least partially, through an Akt/eNOS-dependent mechanism. Therapeutic strategies aiming to restore omentin levels may be valuable for the prevention or treatment of ARDS.
C1 [Qi, Di; Tang, Xumao; He, Jing; Wang, Daoxin; Zhao, Yan; Deng, Wang; Deng, Xinyu; Zhou, Guoqi; Xia, Jing; Zhong, Xi; Pu, Shenglan] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, 76 L, Chongqing 400010, China.
C3 Chongqing Medical University
RP Wang, DX (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, 76 L, Chongqing 400010, Peoples R China.
EM wangdaoxin0163@163.com
OI Wang, Daoxin/0000-0001-8327-3650; Qi, Di/0000-0002-8267-9832
FU National Natural Science Foundation of China [81270141]
FX We thank all the members of Wang's laboratory for full cooperation and
   to Zhui Li, PhD, for his generous help and valuable advice in this
   study. This study was supported by the National Natural Science
   Foundation of China (grant no. 81270141).
CR Anzueto A, 2011, THORAX, V66, P66, DOI 10.1136/thx.2010.145086
   Atkinson RL, 2014, TRENDS ENDOCRIN MET, V25, P283, DOI 10.1016/j.tem.2014.03.003
   Dias-Junior Carlos Alan, 2008, J. bras. pneumol., V34, P412, DOI 10.1590/S1806-37132008000600012
   Duan XY, 2011, AMINO ACIDS, V41, P1223, DOI 10.1007/s00726-010-0800-3
   El-Mesallamy HO, 2011, DIABETIC MED, V28, P1194, DOI 10.1111/j.1464-5491.2011.03353.x
   Fan XF, 2015, CHEST, V147, P969, DOI 10.1378/chest.14-1426
   Gando S, 2004, INFLAMMATION, V28, P237, DOI 10.1023/B:IFLA.0000049049.81688.fe
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   He J, 2015, EXP CELL RES, V331, P164, DOI 10.1016/j.yexcr.2014.09.024
   Hiramatsu-Ito M, 2016, CARDIOVASC RES, V110, P107, DOI 10.1093/cvr/cvv282
   Hu GC, 2009, MICROVASC RES, V77, P21, DOI 10.1016/j.mvr.2008.10.002
   Jaikanth C, 2013, EXP CLIN ENDOCR DIAB, V121, P377, DOI 10.1055/s-0033-1345123
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kataoka Y, 2014, J AM COLL CARDIOL, V63, P2722, DOI 10.1016/j.jacc.2014.03.032
   Katsi V, 2014, HEART LUNG CIRC, V23, P802, DOI 10.1016/j.hlc.2014.03.013
   Kazama K, 2014, BIOCHEM BIOPH RES CO, V452, P142, DOI 10.1016/j.bbrc.2014.08.070
   Konter J, 2013, PULM PHARMACOL THER, V26, P427, DOI 10.1016/j.pupt.2012.03.003
   Konter JM, 2012, J IMMUNOL, V188, P854, DOI 10.4049/jimmunol.1100426
   Levine YC, 2007, J BIOL CHEM, V282, P20351, DOI 10.1074/jbc.M702182200
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Manukyan MC, 2010, SHOCK, V34, P442, DOI 10.1097/SHK.0b013e3181e14ea9
   Moreno-Navarrete JM, 2011, OBESITY, V19, P1552, DOI 10.1038/oby.2010.351
   Maruyama S, 2012, J BIOL CHEM, V287, P408, DOI 10.1074/jbc.M111.261818
   Matsuzawa Y, 2011, J ATHEROSCLER THROMB, V18, P629, DOI 10.5551/jat.7922
   Mattu HS, 2013, J ENDOCRINOL, V216, pT17, DOI 10.1530/JOE-12-0232
   Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Muller-Redetzky HC, 2014, CELL TISSUE RES, V355, P657, DOI 10.1007/s00441-014-1821-0
   Ohashi K, 2014, TRENDS ENDOCRIN MET, V25, P348, DOI 10.1016/j.tem.2014.03.009
   Qi D, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0159-1
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shah D, 2015, SCI REP-UK, V5, DOI 10.1038/srep11362
   Shibata R, 2014, CYTOKINE GROWTH F R, V25, P483, DOI 10.1016/j.cytogfr.2014.07.005
   Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F
   Stapleton RD, 2014, CLIN CHEST MED, V35, P655, DOI 10.1016/j.ccm.2014.08.005
   Tan BK, 2010, TRENDS CARDIOVAS MED, V20, P143, DOI 10.1016/j.tcm.2010.12.002
   Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487
   Wang C, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/978463
   Wang QY, 2013, ANN CLIN BIOCHEM, V50, P230, DOI 10.1177/0004563212473275
   Wu SS, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/368970
   Yamawaki H, 2011, BIOCHEM BIOPH RES CO, V408, P339, DOI 10.1016/j.bbrc.2011.04.039
   Yamawaki Hideyuki, 2011, Folia Pharmacologica Japonica, V137, P131, DOI 10.1254/fpj.137.131
   Yamawaki H, 2010, BIOCHEM BIOPH RES CO, V393, P668, DOI 10.1016/j.bbrc.2010.02.053
   Yang RZ, 2006, AM J PHYSIOL-ENDOC M, V290, pE1253, DOI 10.1152/ajpendo.00572.2004
   Zhao LR, 2015, MOL MED REP, V11, P1859, DOI 10.3892/mmr.2014.2937
   Zhong X, 2012, BIOCHEM BIOPH RES CO, V425, P401, DOI 10.1016/j.bbrc.2012.07.110
   Zhou JY, 2014, CURR VASC PHARMACOL, V12, P136, DOI 10.2174/1570161112999140217095038
NR 48
TC 57
Z9 66
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP
PY 2016
VL 7
AR e2360
DI 10.1038/cddis.2016.265
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EC2QF
UT WOS:000387968100010
PM 27607575
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Yang, J
   Zhao, YF
   Zhang, P
   Li, YH
   Yang, Y
   Yang, Y
   Zhu, JJ
   Song, X
   Jiang, GN
   Fan, J
AF Yang, Jie
   Zhao, Yanfeng
   Zhang, Peng
   Li, Yuehua
   Yang, Yong
   Yang, Yang
   Zhu, Junjie
   Song, Xiao
   Jiang, Gening
   Fan, Jie
TI Hemorrhagic shock primes for lung vascular endothelial cell pyroptosis:
   role in pulmonary inflammation following LPS
SO CELL DEATH & DISEASE
LA English
DT Article
ID NLRP3 INFLAMMASOME; INTRACELLULAR LPS; MACROPHAGE DEATH;
   ENDOTOXIC-SHOCK; INNATE IMMUNITY; GASDERMIN D; CASPASE 1; ACTIVATION;
   INJURY; MECHANISMS
AB Hemorrhagic shock (HS) often renders patients more susceptible to lung injury by priming for an exaggerated response to a second infectious stimulus. Acute lung injury (ALI) is a major component of multiple organ dysfunction syndrome following HS and regularly serves as a major cause of patient mortality. The lung vascular endothelium is an active organ that has a central role in the development of ALI through synthesizing and releasing of a number of inflammatory mediators. Cell pyroptosis is a caspase-1-dependent regulated cell death, which features rapid plasma membrane rupture and release of proinflammatory intracellular contents. In this study, we demonstrated an important role of HS in priming for LPS-induced lung endothelial cell (EC) pyroptosis. We showed that LPS through TLR4 activates Nlrp3 (NACHT, LRR, and PYD domains containing protein 3) inflammasome in mouse lung vascular EC, and subsequently induces caspase-1 activation. However, HS induced release of high-mobility group box 1 (HMGB1), which acting through the receptor for advanced glycation end products initiates EC endocytosis of HMGB1, and subsequently triggers a cascade of molecular events, including cathepsin B release from ruptured lysosomes followed by pyroptosome formation and caspase-1 activation. These HS-induced events enhance LPS-induced EC pyroptosis. We further showed that lung vascular EC pyroptosis significantly exaggerates lung inflammation and injury. The present study explores a novel mechanism underlying HS-primed ALI and thus presents a potential therapeutic target for post-HS ALI.
C1 [Yang, Jie; Zhao, Yanfeng; Zhang, Peng; Yang, Yong; Yang, Yang; Zhu, Junjie; Song, Xiao; Jiang, Gening; Fan, Jie] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, China.
C1 [Yang, Jie; Li, Yuehua; Yang, Yong; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213, United States.
C1 [Li, Yuehua; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240, United States.
C1 [Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219, United States.
C3 Tongji University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Pittsburgh Healthcare System;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Jiang, GN; Fan, J (corresponding author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.; Fan, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, VAPHS, Bldg 1,1W142,151U,Univ Dr, Pittsburgh, PA 15213 USA.
EM jgnwp@aliyun.com; jif7@pitt.edu
RI LI, Yue/GRS-8071-2022; li, yueyue/IVH-9846-2023; li, yue/HSF-7296-2023
FU National Institutes of Health [HL-079669, HL-123882, HL076179]; VA Merit
   Award [1I01BX002729]; National Natural Science Foundation of China
   [81470262, 81400056]; Shanghai Rising-Star Program [14QA1403200];
   Shanghai Medical New Excellent Youth [XYQ2013115]
FX This work was supported by the National Institutes of Health Grant
   HL-079669 (JF), National Institutes of Health Grant HL-123882 (JF),
   National Institutes of Health Grant HL076179 (JF), VA Merit Award
   1I01BX002729 (JF), National Natural Science Foundation of China 81470262
   (JF), National Natural Science Foundation of China 81400056 (YZ),
   Shanghai Rising-Star Program 14QA1403200 (PZ), and Shanghai Medical New
   Excellent Youth XYQ2013115 (PZ).
CR Aachoui Y, 2013, SCIENCE, V339, P975, DOI 10.1126/science.1230751
   Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Bergsbaken T, 2007, PLOS PATHOG, V3, P1570, DOI 10.1371/journal.ppat.0030161
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x
   Cotter MJ, 2001, AM J PATHOL, V159, P473, DOI 10.1016/S0002-9440(10)61719-1
   Daniel TO, 2000, ANNU REV PHYSIOL, V62, P649, DOI 10.1146/annurev.physiol.62.1.649
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200
   Fan J, 2007, J IMMUNOL, V178, P6573, DOI 10.4049/jimmunol.178.10.6573
   Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105
   Galluzzi L, 2016, IMMUNITY, V44, P221, DOI 10.1016/j.immuni.2016.01.020
   Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Hilbi H, 1997, INFECT IMMUN, V65, P5165, DOI 10.1128/IAI.65.12.5165-5170.1997
   HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Iivanainen E, 2003, MICROSC RES TECHNIQ, V60, P13, DOI 10.1002/jemt.10238
   Jiang RZ, 2014, J IMMUNOL, V193, P5000, DOI 10.4049/jimmunol.1303445
   Jones LJ, 1997, ANAL BIOCHEM, V251, P144, DOI 10.1006/abio.1997.2259
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kepp O, 2010, EUR J IMMUNOL, V40, P627, DOI 10.1002/eji.200940160
   Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Laubach VE, 2016, CURR OPIN ORGAN TRAN, V21, P246, DOI 10.1097/MOT.0000000000000304
   Liu YJ, 2009, J IMMUNOL, V182, P572, DOI 10.4049/jimmunol.182.1.572
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7
   Mariathasan S, 2005, J EXP MED, V202, P1043, DOI 10.1084/jem.20050977
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Meunier E, 2014, NATURE, V509, P366, DOI 10.1038/nature13157
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659
   Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525
   Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154
   Sun GW, 2005, CELL MICROBIOL, V7, P1447, DOI 10.1111/j.1462-5822.2005.00569.x
   Sun Q, 2013, J BIOL CHEM, V288, P15947, DOI 10.1074/jbc.M112.426791
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Xiang M, 2011, J IMMUNOL, V187, P4809, DOI 10.4049/jimmunol.1102093
   Xu J, 2014, CELL DEATH DIFFER, V21, P1229, DOI 10.1038/cdd.2014.40
   Xu P, 2013, J IMMUNOL, V190, P5247, DOI 10.4049/jimmunol.1203182
   Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009
   Zhu WQ, 2012, NATURE, V492, P252, DOI 10.1038/nature11603
NR 55
TC 86
Z9 95
U1 2
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP
PY 2016
VL 7
AR e2363
DI 10.1038/cddis.2016.274
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EC2QF
UT WOS:000387968100014
PM 27607578
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Chen, Q
   Yi, B
   Ma, JB
   Ning, JL
   Wu, LZ
   Ma, DQ
   Lu, KZ
   Gu, JT
AF Chen, Qian
   Yi, Bin
   Ma, Jianbo
   Ning, Jiaoling
   Wu, Lingzhi
   Ma, Daqing
   Lu, Kaizhi
   Gu, Jianteng
TI alpha(2)-adrenoreceptor modulated FAK pathway induced by dexmedetomidine
   attenuates pulmonary microvascular hyper-permeability following kidney
   injury
SO ONCOTARGET
LA English
DT Article
DE dexmedetomidine; alpha(2)-adrenoreceptor; Focal adhesion kinase (FAK); ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; Pathology Section 
ID ISCHEMIA-REPERFUSION INJURY; REMOTE LUNG INJURY; CARDIAC-SURGERY; RENAL
   ISCHEMIA; HYPERPERMEABILITY; DAMAGE; ACTIN; RISK
AB Renal ischemia-reperfusion (rI/R) could cause remote acute lung injury (ALI) and combination of these two organ injuries can remarkably increase the mortality. This study aims to determine whether dexmedetomidine, an alpha(2)-adrenoreceptor agonist sedative, can ameliorate pulmonary microvascular hyper-permeability following rI/R injury and explore the underlying mechanisms. In vivo, C57BL/6J mice received dexmedetomidine (25 mu g/kg, i.p.) in the absence or presence of alpha(2) adrenergic antagonist atipamezole (250 mu g/kg, i.p.) or focal adhesion kinase (FAK) inhibitor (30mg/kg, i.p.) before bilateral renal pedicle clamping for 45 minutes followed by 24 hours reperfusion. The lung histopathological changes and the permeability of pulmonary microvascular were assessed respectively. In vitro, the cultured C57BL/6J mice pulmonary microvascular endothelial cells (PMVECs) were treated with serum from mice with rI/R with or without dexmedetomidine and atipamezole. Trans-endothelial permeability and phospho-tyrosine (397)FAK, F-actin, VE-cadherin and ZO-1 in monolayer PMVECs were measured respectively in the presence or absence of rI/R serum, dexmedetomidine and FAK inhibitor. In vivo, dexmedetomidine remarkably attenuated lung injury and pulmonary microvascular hyper-permeability caused by rI/R injury, which was abolished by atipamezole or FAK inhibitor co-administration. In vitro, the permeability of PMVECs monolayer following exposure to serum from rI/R mice was increased significantly, and decreased by dexmedetomidine. Dexmedetomidine increased phospho-tyrosine397FAK in a time-and dose-dependent manner, which was correlated with the changes in trans-endothelial permeability. Our data indicated that dexmedetomidine is able to ameliorate remote pulmonary microvascular hyper-permeability induced by rI/R, at least in part, via FAK modulation.
C1 [Chen, Qian; Yi, Bin; Ma, Jianbo; Ning, Jiaoling; Lu, Kaizhi; Gu, Jianteng] Third Mil Med Univ, Southwest Hosp, Dept Anesthesiol, Chongqing, China.
C1 [Wu, Lingzhi; Ma, Daqing] Imperial Coll London, Dept Surg & Canc, Fac Med, Anaesthet Pain Med & Intens Care, Chelsea & Westminster Campus, London, England, United Kingdom.
C3 Army Medical University; Imperial College London
RP Lu, KZ; Gu, JT (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Anesthesiol, Chongqing, Peoples R China.
EM kaizhilu@hotmail.com; jiantenggu@hotmail.com
RI Ma, Daqing/GLT-2735-2022
OI Ma, Daqing/0000-0003-1235-0537; Ma, Daqing/0000-0002-0688-2097
FU National Natural Science Foundation, P.R. China [81272068]; Basic and
   Frontier Research Fund, Chongqing [cstc2015jcyjA10055]
FX This work was supported by the National Natural Science Foundation, P.R.
   China (No. 81272068) and the Basic and Frontier Research Fund, Chongqing
   (No. cstc2015jcyjA10055)..
CR Alesutan I, 2013, CELL PHYSIOL BIOCHEM, V32, P728, DOI 10.1159/000354475
   Awad AS, 2009, KIDNEY INT, V75, P689, DOI 10.1038/ki.2008.648
   Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef
   Chen C, 2014, J SURG RES, V187, P211, DOI 10.1016/j.jss.2013.09.018
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Dahmani S, 2005, ANESTHESIOLOGY, V103, P969, DOI 10.1097/00000542-200511000-00011
   Ding XD, 2016, INT J NEUROSCI, V126, P249, DOI 10.3109/00207454.2015.1005291
   Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016
   Feltes CM, 2011, SHOCK, V36, P170, DOI 10.1097/SHK.0b013e3182169c76
   Gargiulo S, 2012, ILAR J, V53, pE55, DOI 10.1093/ilar.53.1.55
   Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v
   Gu J, 2011, ACTA ANAESTH SCAND, V55, P1272, DOI 10.1111/j.1399-6576.2011.02526.x
   Gu JT, 2011, CRIT CARE, V15, DOI 10.1186/cc10283
   Gungor-Ordueri NE, 2014, HISTOL HISTOPATHOL, V29, P977, DOI 10.14670/HH-29.977
   Han S, 2015, J IMMUNOL, V194, P5569, DOI 10.4049/jimmunol.1500741
   Hansen MK, 2015, J CARDIOTHOR VASC AN, V29, P617, DOI 10.1053/j.jvca.2014.08.020
   Hassoun HT, 2009, AM J PHYSIOL-RENAL, V297, pF125, DOI 10.1152/ajprenal.90666.2008
   Ibacache M, 2012, BBA-MOL BASIS DIS, V1822, P537, DOI 10.1016/j.bbadis.2011.12.013
   Karkouti K, 2009, CIRCULATION, V119, P495, DOI 10.1161/CIRCULATIONAHA.108.786913
   Kelly KJ, 2003, J AM SOC NEPHROL, V14, P1549, DOI 10.1097/01.ASN.0000064946.94590.46
   Khajuria Ankur, 2014, Acta Anaesthesiol Taiwan, V52, P176, DOI 10.1016/j.aat.2014.10.001
   Koksel O, 2005, PHARMACOL RES, V51, P453, DOI 10.1016/j.phrs.2004.11.007
   Lai YC, 2009, J SURG RES, V154, P212, DOI 10.1016/j.jss.2008.07.010
   Liu MC, 2008, J AM SOC NEPHROL, V19, P1360, DOI 10.1681/ASN.2007080901
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Mehta D, 2012, MICROVASC RES, V83, P1, DOI 10.1016/j.mvr.2011.10.001
   Mehta RL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014692.19351.52
   Ologunde R, 2014, INT UROL NEPHROL, V46, P2337, DOI 10.1007/s11255-014-0766-2
   Parikh CR, 2011, J AM SOC NEPHROL, V22, P1737, DOI 10.1681/ASN.2010111163
   Park SW, 2011, LAB INVEST, V91, P63, DOI 10.1038/labinvest.2010.151
   Qiao H, 2009, CRIT CARE, V13, DOI 10.1186/cc8012
   Sanders RD, 2010, ACTA ANAESTH SCAND, V54, P710, DOI 10.1111/j.1399-6576.2009.02177.x
   Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010
   Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20
   Sun CX, 2013, AM J PHYSIOL-LUNG C, V304, pL135, DOI 10.1152/ajplung.00133.2012
   Tharakan B, 2010, CLIN EXP PHARMACOL P, V37, P939, DOI 10.1111/j.1440-1681.2010.05414.x
   Wang LC, 2015, MICROVASC RES, V99, P102, DOI 10.1016/j.mvr.2015.03.007
   Xia R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/238041
   Xiang H, 2014, INFLAMMATION, V37, P1763, DOI 10.1007/s10753-014-9906-1
   Yang CL, 2011, J SURG RES, V167, pE273, DOI 10.1016/j.jss.2010.02.020
   Zhang XY, 2012, ANESTHESIOLOGY, V116, P1035, DOI 10.1097/ALN.0b013e3182503964
   Zhao HL, 2015, KIDNEY INT, V87, P738, DOI 10.1038/ki.2014.388
NR 42
TC 27
Z9 30
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 30
PY 2016
VL 7
IS 35
BP 55990
EP 56001
DI 10.18632/oncotarget.10809
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EA8TL
UT WOS:000386911600005
PM 27463003
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Dinu, D
   Chu, C
   Veith, A
   Lingappan, K
   Couroucli, X
   Jefcoate, CR
   Sheibani, N
   Moorthy, B
AF Dinu, Daniela
   Chu, Chun
   Veith, Alex
   Lingappan, Krithika
   Couroucli, Xanthi
   Jefcoate, Colin R.
   Sheibani, Nader
   Moorthy, Bhagavatula
TI Mechanistic role of cytochrome P450 (CYP)1B1 in oxygen-mediated toxicity
   in pulmonary cells: A novel target for prevention of hyperoxic lung
   injury
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Cytochrome P450; CYP1B1; hyperoxia; lung; ECs/HPMECs/HUVECs/MPVECs 
ID ARYL-HYDROCARBON RECEPTOR; BRONCHOPULMONARY DYSPLASIA; OXIDATIVE STRESS;
   INCREASED SUSCEPTIBILITY; ALVEOLAR SIMPLIFICATION; ENDOTHELIAL-CELLS;
   EXPRESSION; CYP1B1; MICE; RATS
AB Supplemental oxygen, which is routinely administered to preterm infants with pulmonary insufficiency, contributes to bronchopulmonary dysplasia (BPD) in these infants. Hyperoxia also contributes to the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in adults. The mechanisms of oxygen-mediated pulmonary toxicity are not completely understood. Recent studies have suggested an important role for cytochrome P450 (CYP)1A1/1A2 in the protection against hyperoxic lung injury. The role of CYP1B1 in oxygen-mediated pulmonary toxicity has not been studied. In this investigation, we tested the hypothesis that CYP1B1 plays a mechanistic role in oxygen toxicity in pulmonary cells in vitro. In human bronchial epithelial cell line BEAS-2B, hyperoxic treatment for 1-3 days led to decreased cell viability by about 50-80%. Hyperoxic cytotoxicity was accompanied by an increase in levels of reactive oxygen species (ROS) by up to 110%, and an increase of TUNEL-positive cells by up to 4.8-fold. Western blot analysis showed hyperoxia to significantly down-regulate CYP1B1 protein level. Also, there was a decrease of CYP1B1 mRNA by up to 38% and Cyplbl promoter activity by up to 65%. On the other hand, CYP1B1 siRNA appeared to rescue the cell viability under hyperoxia stress, and over expression of CYP1B1 significantly attenuated hyperoxic cytotoxicity after 48 h of incubation. In immortalized lung endothelial cells derived from Cyplbl-null and wild-type mice, hyperoxia increased caspase 3/7 activities in a time-dependent manner, but endothelial cells lacking the Cyplbl gene showed significantly decreased caspase 3/7 activities after 48 and 7211 of incubation, implying that CYP1B1 might promote apoptosis in wild type lung endothelial cells under hyperoxic stress. In conclusion, our results support the hypothesis that CYP1B1 plays a mechanistic role in pulmonary oxygen toxicity, and CYP1B1 mediated apoptosis could be one of the mechanisms of oxygen toxicity. Thus, CYP1B1 could be a novel target for preventative and/or therapeutic interventions against BPD in infants and ALI/ARDS in adults. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Dinu, Daniela; Chu, Chun; Veith, Alex; Lingappan, Krithika; Couroucli, Xanthi; Moorthy, Bhagavatula] Baylor Coll Med, Dept Pediat, Houston, TX 77030, United States.
C1 [Jefcoate, Colin R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI, United States.
C1 [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Ophthalmol & Visual Sci, Madison, WI, United States.
C3 Baylor College of Medicine; University of Wisconsin System; University
   of Wisconsin Madison; University of Wisconsin System; University of
   Wisconsin Madison
RP Moorthy, B (corresponding author), Baylor Coll Med, Sect Neonatol, 1102 Bates St,FC 530-04, Houston, TX 77030 USA.
EM bmoorthy@bcm.edu
RI Sheibani, Nader/AAG-2379-2020
OI Sheibani, Nader/0000-0003-2723-9217; Dinu, Daniela/0000-0001-9937-494X
FU R01 grants [ES-019689, ES-009132, HL-112516, HL-129794, HL-087174]; NIH
   [P30 EY016665]; Environmental Protection Agency [83573701]; 
   [HL-088343];  [K08HL127103];  [EY022883];  [DK090249]
FX This work was supported in part by R01 grants ES-019689, ES-009132,
   HL-112516, HL-129794, and HL-087174 to BM, HL-088343 to XIC, K08HL127103
   to KL, EY022883, NIH P30 EY016665, Environmental Protection Agency
   83573701 to NS, and DK090249 to CRJ.
CR Bhakta KY, 2008, TOXICOL APPL PHARM, V233, P169, DOI 10.1016/j.taap.2008.08.016
   Bhandari A, 2009, PEDIATRICS, V123, P1562, DOI 10.1542/peds.2008-1962
   Buczynski BW, 2013, SEMIN PERINATOL, V37, P69, DOI 10.1053/j.semperi.2013.01.002
   Bussmann UA, 2006, BIOL REPROD, V74, P417, DOI 10.1095/biolreprod.105.043901
   Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chang TKH, 2003, TOXICOL SCI, V71, P11, DOI 10.1093/toxsci/71.1.11
   Cheung Catherine Y. S., 2004, Journal of Pharmacological and Toxicological Methods, V49, P97, DOI 10.1016/j.vascn.2003.10.005
   Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7
   Chow CW, 2003, AM J RESP CELL MOL, V29, P427, DOI 10.1165/rcmb.F278
   Couroucli XI, 2002, MOL PHARMACOL, V61, P507, DOI 10.1124/mol.61.3.507
   Fisher AO, 2012, PEDIATR PULM, V47, P979, DOI 10.1002/ppul.22517
   Gore A, 2010, J IMMUNOTOXICOL, V7, P239, DOI 10.3109/1547691X.2010.492254
   Jiang WW, 2011, BIOCHEM BIOPH RES CO, V407, P79, DOI 10.1016/j.bbrc.2011.02.113
   Jiang WW, 2004, J PHARMACOL EXP THER, V310, P512, DOI 10.1124/jpet.103.059766
   Lingappan K, 2015, TOXICOLOGY, V331, P14, DOI 10.1016/j.tox.2015.01.019
   Madurga A, 2013, AM J PHYSIOL-LUNG C, V305, pL893, DOI 10.1152/ajplung.00267.2013
   Moorthy B, 2000, J PHARMACOL EXP THER, V292, P553
   Moorthy B, 2003, J PHARMACOL EXP THER, V305, P394, DOI 10.1124/jpet.102.044271
   Moorthy B, 1997, TOXICOL LETT, V90, P67, DOI 10.1016/S0378-4274(96)03832-5
   Murray GI, 2001, ANNU REV PHARMACOL, V41, P297, DOI 10.1146/annurev.pharmtox.41.1.297
   Natarajan G, 2012, EARLY HUM DEV, V88, P509, DOI 10.1016/j.earlhumdev.2011.12.013
   Olsen L, 2015, ADV DRUG DELIVER REV, V86, P61, DOI 10.1016/j.addr.2015.04.020
   Savas U, 1997, ARCH BIOCHEM BIOPHYS, V347, P181, DOI 10.1006/abbi.1997.0339
   Shimada T, 1996, CANCER RES, V56, P2979
   Shivanna B, 2013, TOXICOL APPL PHARM, V267, P209, DOI 10.1016/j.taap.2013.01.003
   Shivanna B, 2011, FREE RADICAL BIO MED, V51, P1910, DOI 10.1016/j.freeradbiomed.2011.08.013
   Sinha A, 2005, TOXICOL SCI, V87, P204, DOI 10.1093/toxsci/kfi226
   SPRONG C, 1991, MED HYPOTHESES, V34, P296, DOI 10.1016/0306-9877(91)90045-Z
   Tang YX, 2010, AM J PHYSIOL-CELL PH, V298, pC665, DOI 10.1152/ajpcell.00153.2009
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Thakur VS, 2014, TOXICOL LETT, V230, P322, DOI 10.1016/j.toxlet.2014.03.006
   Tiwari KK, 2014, BIOCHEM BIOPH RES CO, V450, P1345, DOI 10.1016/j.bbrc.2014.06.132
   Uppstad H, 2010, TOXICOL LETT, V192, P221, DOI 10.1016/j.toxlet.2009.10.025
   Wang LH, 2015, FREE RADICAL BIO MED, V82, P147, DOI 10.1016/j.freeradbiomed.2015.01.019
   Zhang SJ, 2015, TOXICOL APPL PHARM, V286, P92, DOI 10.1016/j.taap.2015.03.023
NR 36
TC 9
Z9 14
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 5
PY 2016
VL 476
IS 4
BP 346
EP 351
DI 10.1016/j.bbrc.2016.05.125
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DR4QE
UT WOS:000379886500026
PM 27235555
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Aman, J
   Weijers, EM
   Amerongen, GPV
   Malik, AB
   van Hinsbergh, VWM
AF Aman, Jurjan
   Weijers, Ester M.
   Amerongen, Geerten P. van Nieuw
   Malik, Asrar B.
   van Hinsbergh, Victor W. M.
TI Using cultured endothelial cells to study endothelial barrier
   dysfunction: Challenges and opportunities
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Review
DE ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; cell culture 
ID RESPIRATORY-DISTRESS-SYNDROME; BLOOD-BRAIN-BARRIER; ACUTE LUNG INJURY;
   HIGH-FREQUENCY OSCILLATION; FLUID SHEAR-STRESS; IN-VITRO;
   VASCULAR-PERMEABILITY; EPITHELIAL-CELLS; PROGENITOR CELLS; CYCLIC
   STRETCH
AB Despite considerable progress in the understanding of endothelial barrier regulation and the identification of approaches that have the potential to improve endothelial barrier function, no drug- or stem cell-based therapy is presently available to reverse the widespread vascular leak that is observed in acute respiratory distress syndrome (ARDS) and sepsis. The translational gap suggests a need to develop experimental approaches and tools that better mimic the complex environment of the microcirculation in which the vascular leak develops. Recent studies have identified several elements of this microenvironment. Among these are composition and stiffness of the extracellular matrix, fluid shear stress, interaction of endothelial cells (ECs) with pericytes, oxygen tension, and the combination of toxic and mechanic injurious stimuli. Development of novel cell culture techniques that integrate these elements would allow in-depth analysis of EC biology that closely approaches the (patho) physiological conditions in situ. In parallel, techniques to isolate organ-specific ECs, to define EC heterogeneity in its full complexity, and to culture patient-derived ECs from inducible pluripotent stem cells or endothelial progenitor cells are likely to advance the understanding of ARDS and lead to development of therapeutics. This review 1) summarizes the advantages and pitfalls of EC cultures to study vascular leak in ARDS, 2) provides an overview of elements of the microvascular environment that can directly affect endothelial barrier function, and 3) discusses alternative methods to bridge the gap between basic research and clinical application with the intent of improving the translational value of present EC culture approaches.
C1 [Aman, Jurjan; Weijers, Ester M.; Amerongen, Geerten P. van Nieuw; van Hinsbergh, Victor W. M.] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Dept Physiol, Amsterdam, Netherlands.
C1 [Aman, Jurjan] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Dept Pulm Dis, Amsterdam, Netherlands.
C1 [Malik, Asrar B.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL, United States.
C3 Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital
RP Aman, J (corresponding author), Dept Physiol, O2 Bldg,11W-53,De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands.
EM j.aman@vumc.nl
OI Malik, Asrar/0000-0002-8205-7128
FU Dutch Heart Foundation [2014T064, 2011T072]; Netherlands Institute for
   Regenerative Medicine;  [P01 HL60678];  [P01 HL077806];  [R01 HL45638]
FX This work was funded by Dutch Heart Foundation grant number 2014T064 (J.
   Aman) and 2011T072 (G. P. van Nieuw Amerongen) and the Netherlands
   Institute for Regenerative Medicine (E. M. Weijers). In addition, this
   work was funded by grant numbers P01 HL60678, P01 HL077806, and R01
   HL45638 (A. B. Malik).
CR Abaci HE, 2014, SCI REP-UK, V4, DOI 10.1038/srep04951
   Adamson RH, 2013, AM J PHYSIOL-HEART C, V304, pH1077, DOI 10.1152/ajpheart.00956.2012
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Amado-Azevedo J, 2014, CELL TISSUE RES, V355, P557, DOI 10.1007/s00441-014-1828-6
   Aman J, 2013, ENDOTHELIAL CYTOSKEL, P167
   Aman J, 2013, AM J RESP CRIT CARE, V188, P1171, DOI 10.1164/rccm.201301-0136LE
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Amerongen GPV, 2000, CIRCULATION, V102, P2803
   Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522
   Asahara T, 2011, STEM CELLS, V29, P1650, DOI 10.1002/stem.745
   BARNARD ML, 1992, J APPL PHYSIOL, V72, P1724, DOI 10.1152/jappl.1992.72.5.1724
   Baumer Y, 2009, J CELL PHYSIOL, V220, P716, DOI 10.1002/jcp.21819
   Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298
   Bellingan G, 2014, LANCET RESP MED, V2, P98, DOI 10.1016/S2213-2600(13)70259-5
   Bengalli R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/801214
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bichsel CA, 2015, TISSUE ENG PT A, V21, P2166, DOI [10.1089/ten.TEA.2014.0545, 10.1089/ten.tea.2014.0545]
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002
   Booth R, 2014, LAB CHIP, V14, P1880, DOI 10.1039/c3lc51304a
   BOUEIZ A, 2014, CELL ADHES MIGR, V8, P517, DOI DOI 10.1016/J.MVR.2008.10.005
   Carnevale-Schianca F, 2011, J CLIN ONCOL, V29, pE691, DOI 10.1200/JCO.2011.35.6733
   Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100
   Chowdhury F, 2010, EXP LUNG RES, V36, P1, DOI 10.3109/01902140903026582
   Conway DE, 2013, CURR BIOL, V23, P1024, DOI 10.1016/j.cub.2013.04.049
   DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519
   Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3
   Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201
   Duluc L, 2014, CELL TISSUE RES, V355, P675, DOI 10.1007/s00441-014-1805-0
   Duong Heng T, 2011, Pulm Circ, V1, P475, DOI 10.4103/2045-8932.93547
   Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993
   Edelman DA, 2007, J TRAUMA, V62, P89, DOI 10.1097/TA.0b013e31802dd712
   Edwards AM, 2015, NAT REV DRUG DISCOV, V14, P149, DOI 10.1038/nrd4565
   Eisenstein M, 2015, NATURE, V519, pS16, DOI 10.1038/519S16a
   Esch EW, 2015, NAT REV DRUG DISCOV, V14, P248, DOI 10.1038/nrd4539
   Estrada R, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3608137
   Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386
   Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554
   Fink MP, 2014, NAT REV DRUG DISCOV, V13, P741, DOI 10.1038/nrd4368
   Fontijn RD, 2008, AM J PHYSIOL-HEART C, V294, pH891, DOI 10.1152/ajpheart.01248.2007
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gawlak G, 2014, FASEB J, V28, P3249, DOI 10.1096/fj.13-245142
   Geiger M, 1997, AM J PHYSIOL-LUNG C, V273, pL275, DOI 10.1152/ajplung.1997.273.1.L275
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Gorbunova EE, 2011, J VIROL, V85, P2296, DOI 10.1128/JVI.02319-10
   Gross CM, 2014, J CELL PHYSIOL, V229, P1802, DOI 10.1002/jcp.24633
   Hartmann C, 2007, EXP CELL RES, V313, P1318, DOI 10.1016/j.yexcr.2007.01.024
   Henderson-Toth CE, 2012, DEV BIOL, V369, P330, DOI 10.1016/j.ydbio.2012.07.009
   Hermanns MI, 2009, CELL TISSUE RES, V336, P91, DOI 10.1007/s00441-008-0750-1
   Hermanns MI, 2004, LAB INVEST, V84, P736, DOI 10.1038/labinvest.3700081
   Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960
   Hotchkiss RS, 2015, SCIENCE, V347, P1201, DOI 10.1126/science.aaa8334
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Huveneers S, 2015, CIRC RES, V116, P895, DOI 10.1161/CIRCRESAHA.116.305720
   Huynh J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002761
   Hwa C, 2007, AM J PHYSIOL-HEART C, V293, pH2667, DOI 10.1152/ajpheart.00704.2007
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   INAUEN W, 1990, FREE RADICAL BIO MED, V9, P219, DOI 10.1016/0891-5849(90)90031-D
   Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Jennings RT, 2014, METHODS MOL BIOL, V1124, P79, DOI 10.1007/978-1-62703-845-4_6
   Jiang YZ, 2015, ARTERIOSCL THROM VAS, V35, P1317, DOI 10.1161/ATVBAHA.115.303427
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110
   Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094
   Kang H, 2014, ATHEROSCLEROSIS, V233, P682, DOI 10.1016/j.atherosclerosis.2014.01.056
   Kim CO, 2008, SHOCK, V30, P92, DOI 10.1097/SHK.0b013e31815d19ad
   KING GL, 1987, DIABETES, V36, P1460, DOI 10.2337/diabetes.36.12.1460
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Kiss J, 2007, EUR J IMMUNOL, V37, P3334, DOI 10.1002/eji.200737793
   Kogej T, 2013, DRUG DISCOV TODAY, V18, P1014, DOI 10.1016/j.drudis.2012.10.011
   Krishnan R, 2011, AM J PHYSIOL-CELL PH, V300, pC146, DOI 10.1152/ajpcell.00195.2010
   Kuebler WM, 2000, J CLIN INVEST, V105, P905, DOI 10.1172/JCI8604
   Kuppers V, 2014, CELL TISSUE RES, V355, P577, DOI 10.1007/s00441-014-1812-1
   Kurimoto N, 2004, AM J PHYSIOL-HEART C, V287, pH100, DOI 10.1152/ajpheart.00922.2003
   Lee H, 2014, MICROVASC RES, V91, P90, DOI 10.1016/j.mvr.2013.12.001
   Li YSJ, 2005, J BIOMECH, V38, P1949, DOI 10.1016/j.jbiomech.2004.09.030
   Liu ZJ, 2010, P NATL ACAD SCI USA, V107, P9944, DOI 10.1073/pnas.0914547107
   LOHP, 2001, J PEDIATR SURG, V36, P1136
   Lonigro AJ, 1996, DIABETES, V45, pS38, DOI 10.2337/diab.45.1.S38
   Machida T, 2015, NEUROSCI LETT, V599, P109, DOI 10.1016/j.neulet.2015.05.028
   MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647
   Mammoto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2774
   Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Miao H, 2005, J VASC RES, V42, P77, DOI 10.1159/000083094
   Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Morgan JP, 2013, NAT PROTOC, V8, P1820, DOI 10.1038/nprot.2013.110
   Mul FPJ, 2000, J LEUKOCYTE BIOL, V68, P529
   Mulivor AW, 2004, AM J PHYSIOL-HEART C, V286, pH1672, DOI 10.1152/ajpheart.00832.2003
   Nalayanda DD, 2007, EXP LUNG RES, V33, P321, DOI 10.1080/01902140701557754
   Nalayanda DD, 2010, J PEDIATR SURG, V45, P45, DOI 10.1016/j.jpedsurg.2009.10.008
   NATIONAL H, 2014, NEW ENGL J MED, V370, P2191, DOI DOI 10.1056/NEJMOA1401520
   Neuhaus W, 2012, DIFFERENTIATION, V84, P294, DOI 10.1016/j.diff.2012.08.006
   OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546
   Otto M, 2001, PATHOBIOLOGY, V69, P159, DOI 10.1159/000048771
   Overbeek MJ, 2008, EUR RESPIR J, V32, P232, DOI 10.1183/09031936.00054407
   Parker JC, 2006, AM J PHYSIOL-LUNG C, V291, pL30, DOI 10.1152/ajplung.00317.2005
   Payne DK, 1996, FREE RADICAL RES, V25, P229, DOI 10.3109/10715769609149048
   Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037
   Potter DR, 2008, CIRC RES, V102, P770, DOI 10.1161/CIRCRESAHA.107.160226
   QIAO RL, 1993, AM J PHYSIOL, V264, pL382, DOI 10.1152/ajplung.1993.264.4.L382
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290
   Rexius-Hall ML, 2014, LAB CHIP, V14, P4688, DOI 10.1039/c4lc01168f
   Ricard N, 2014, CIRCULATION, V129, P1586, DOI 10.1161/CIRCULATIONAHA.113.007469
   Rous P, 1930, J EXP MED, V51, P27, DOI 10.1084/jem.51.1.27
   Roy A, 2010, CURR PHARM BIOTECHNO, V11, P764, DOI 10.2174/138920110792927757
   Sackmann EK, 2014, NATURE, V507, P181, DOI 10.1038/nature13118
   Samapati R, 2012, AM J RESP CRIT CARE, V185, P160, DOI 10.1164/rccm.201104-0717OC
   Sandow SL, 2000, CIRC RES, V86, P341, DOI 10.1161/01.RES.86.3.341
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Sellgren KL, 2014, LAB CHIP, V14, P3349, DOI 10.1039/c4lc00552j
   Shamir ER, 2014, NAT REV MOL CELL BIO, V15, P647, DOI 10.1038/nrm3873
   Shao JB, 2010, BIOMED MICRODEVICES, V12, P81, DOI 10.1007/s10544-009-9362-0
   Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001
   SHIMA DT, 1995, DIFFERENTIATION, V58, P217, DOI 10.1046/j.1432-0436.1995.5830217.x
   Silva R, 2008, ARTERIOSCL THROM VAS, V28, P1703, DOI 10.1161/ATVBAHA.108.172015
   Simons M, 2015, CIRC RES, V116, pE99, DOI 10.1161/RES.0000000000000054
   Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Snyder-Talkington BN, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-35
   Srinivasan B, 2015, JALA-J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   STAUB NC, 1974, PHYSIOL REV, V54, P678, DOI 10.1152/physrev.1974.54.3.678
   Steward R, 2015, AM J PHYSIOL-CELL PH, V308, pC657, DOI 10.1152/ajpcell.00363.2014
   Swift J, 2014, J CELL SCI, V127, P3005, DOI 10.1242/jcs.149203
   Szulcek R, 2013, CARDIOVASC RES, V99, P471, DOI 10.1093/cvr/cvt075
   Tarbell JM, 2010, CARDIOVASC RES, V87, P320, DOI 10.1093/cvr/cvq146
   Tasev D, 2016, ANGIOGENESIS, V19, P325, DOI 10.1007/s10456-016-9506-9
   Terblanche M, 2006, LANCET INFECT DIS, V6, P242, DOI 10.1016/S1473-3099(06)70439-X
   Thanabalasundaram G, 2011, INT J BIOCHEM CELL B, V43, P1284, DOI 10.1016/j.biocel.2011.05.002
   Thanabalasundaram G, 2010, BRAIN RES, V1347, P1, DOI 10.1016/j.brainres.2010.05.096
   Tian XY, 2015, MOL BIOL CELL, V26, P636, DOI 10.1091/mbc.E14-02-0725
   Tsai M, 2012, J CLIN INVEST, V122, P408, DOI 10.1172/JCI58753
   TUCKER VL, 1988, AM J PHYSIOL, V254, pH317, DOI 10.1152/ajpheart.1988.254.2.H317
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   Uhlig S, 2014, CELL PHYSIOL BIOCHEM, V34, P1, DOI 10.1159/000362980
   van der Heijden M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023448
   Wang YL, 2007, EYE, V21, P1501, DOI 10.1038/sj.eye.6702716
   Warboys CM, 2010, AM J PHYSIOL-HEART C, V298, pH1850, DOI 10.1152/ajpheart.00114.2010
   Weppler A, 2006, EXP LUNG RES, V32, P455, DOI 10.1080/01902140601059463
   Westphalen K, 2012, AM J PHYSIOL-LUNG C, V303, pL107, DOI 10.1152/ajplung.00206.2011
   Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004
   Wojciak-Stothard B, 2012, CIRC RES, V110, P1423, DOI 10.1161/CIRCRESAHA.112.264473
   Wong KHK, 2010, BIOMATERIALS, V31, P4706, DOI 10.1016/j.biomaterials.2010.02.041
   Wu LT, 2015, STEM CELL REP, V5, P10, DOI 10.1016/j.stemcr.2015.05.016
   Yeon JH, 2012, BIOMED MICRODEVICES, V14, P1141, DOI 10.1007/s10544-012-9680-5
   Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716
   Yuan K, 2015, AM J PATHOL, V185, P69, DOI 10.1016/j.ajpath.2014.09.013
   Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314
   Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109
   Zhang J, 2012, AM J PHYSIOL-HEART C, V302, pH983, DOI 10.1152/ajpheart.00168.2011
   Zheng Y, 2012, P NATL ACAD SCI USA, V109, P9342, DOI 10.1073/pnas.1201240109
   Zloza A, 2014, J INTERF CYTOK RES, V34, P915, DOI 10.1089/jir.2013.0155
   Zozulya A, 2008, BRAIN RES, V1189, P1, DOI 10.1016/j.brainres.2007.10.099
NR 167
TC 46
Z9 49
U1 1
U2 23
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG 1
PY 2016
VL 311
IS 2
BP L453
EP L466
DI 10.1152/ajplung.00393.2015
PG 14
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA DT6XP
UT WOS:000381628600023
PM 27343194
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Bijli, KM
   Fazal, F
   Slavin, SA
   Leonard, A
   Grose, V
   Alexander, WB
   Smrcka, AV
   Rahman, A
AF Bijli, Kaiser M.
   Fazal, Fabeha
   Slavin, Spencer A.
   Leonard, Antony
   Grose, Valerie
   Alexander, William B.
   Smrcka, Alan V.
   Rahman, Arshad
TI Phospholipase C-epsilon signaling mediates endothelial cell inflammation
   and barrier disruption in acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; adhesion molecules; transcription factor; signal transduction; lung inflammation 
ID NF-KAPPA-B; RELA/P65 NUCLEAR TRANSLOCATION;
   RESPIRATORY-DISTRESS-SYNDROME; PROTEIN-KINASE; BRONCHOALVEOLAR LAVAGE;
   ICAM-1 EXPRESSION; GENE-EXPRESSION; VE-CADHERIN; ACTIVATION; RECEPTOR
AB Phospholipase C-epsilon (PLC-epsilon) is a unique PLC isoform that can be regulated by multiple signaling inputs from both Ras family GTPases and heterotrimeric G proteins and has primary sites of expression in the heart and lung. Whereas the role of PLC-epsilon in cardiac function and pathology has been documented, its relevance in acute lung injury (ALI) is unclear. We used PLC-epsilon(-/-) mice to address the role of PLC-epsilon in regulating lung vascular inflammation and injury in an aerosolized bacterial LPS inhalation mouse model of ALI. PLC-epsilon(-/-) mice showed a marked decrease in LPS-induced proinflammatory mediators (ICAM-1, VCAM-1, TNF-alpha, IL-1 beta, IL-6, macrophage inflammatory protein 2, keratinocyte-derived cytokine, monocyte chemoattractant protein 1, and granulocyte-macrophage colony-stimulating factor), lung neutrophil infiltration and microvascular leakage, and loss of VE-cadherin compared with PLC-epsilon(+/+) mice. These data identify PLC-epsilon as a critical determinant of proinflammatory and leaky phenotype of the lung. To test the possibility that PLC-epsilon activity in endothelial cells (EC) could contribute to ALI, we determined its role in EC inflammation and barrier disruption. RNAi knockdown of PLC-epsilon inhibited NF-kappa B activity in response to diverse proinflammatory stimuli, thrombin, LPS, TNF-alpha, and the nonreceptor agonist phorbol 13-myristate 12-acetate (phorbol esters) in EC. Depletion of PLC-epsilon also inhibited thrombin-induced expression of NF-kappa B target gene, VCAM-1. Importantly, PLC-epsilon knockdown also protected against thrombin-induced EC barrier disruption by inhibiting the loss of VE-cadherin at adherens junctions and formation of actin stress fibers. These data identify PLC-epsilon as a novel regulator of EC inflammation and permeability and show a hitherto unknown role of PLC-epsilon in the pathogenesis of ALI.
C1 [Bijli, Kaiser M.; Fazal, Fabeha; Slavin, Spencer A.; Leonard, Antony; Grose, Valerie; Alexander, William B.; Rahman, Arshad] Univ Rochester, Sch Med & Dent, Lung Biol & Dis Program, Dept Pediat, Box 850,601 Elmwood Ave, Rochester, NY 14642, United States.
C1 [Smrcka, Alan V.] Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Lung Biol & Dis Program, Rochester, NY, United States.
C3 University of Rochester; University of Rochester
RP Rahman, A (corresponding author), Univ Rochester, Sch Med & Dent, Lung Biol & Dis Program, Dept Pediat, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.
EM Arshad_Rahman@URMC.Rochester.edu
OI Alexander, William/0000-0002-5675-304X; Rahman,
   Arshad/0000-0002-5621-0512
FU National Heart, Lung, and Blood Institute [HL116632, HL096907]; National
   Institute of Environmental Health Sciences Center (EHSC) [ES-01247]; SDG
   Grant from American Heart Association
FX This work was supported in part by National Heart, Lung, and Blood
   Institute grants HL116632 and HL096907. This study was also supported in
   part by National Institute of Environmental Health Sciences Center
   (EHSC) grant ES-01247 and an SDG Grant from American Heart Association
   (K. Bijli).
CR Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965
   BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bijli KM, 2014, SHOCK, V42, P562, DOI 10.1097/SHK.0000000000000242
   Bijli KM, 2012, AM J RESP CELL MOL, V47, P660, DOI 10.1165/rcmb.2012-0047OC
   Birukova AA, 2015, BBA-MOL BASIS DIS, V1852, P778, DOI 10.1016/j.bbadis.2014.12.016
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Bunney TD, 2006, TRENDS CELL BIOL, V16, P640, DOI 10.1016/j.tcb.2006.10.007
   Citro S, 2007, P NATL ACAD SCI USA, V104, P15543, DOI 10.1073/pnas.0702943104
   Dejana E, 2013, PROG MOL BIOL TRANSL, V116, P119, DOI 10.1016/B978-0-12-394311-8.00006-6
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dusaban SS, 2015, J BIOL CHEM, V290, P26776, DOI 10.1074/jbc.M115.676098
   Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200
   Fazal F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059965
   Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444
   Fu PF, 2015, AM J PHYSIOL-LUNG C, V308, pL1025, DOI 10.1152/ajplung.00306.2014
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Gao R, 2015, AM J PHYSIOL-LUNG C, V308, pL847, DOI 10.1152/ajplung.00274.2014
   Gareus R, 2008, CELL METAB, V8, P372, DOI 10.1016/j.cmet.2008.08.016
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Harada Y, 2011, BIOCHEM BIOPH RES CO, V414, P106, DOI 10.1016/j.bbrc.2011.09.032
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   IDELL S, 1987, AM REV RESPIR DIS, V136, P1466, DOI 10.1164/ajrccm/136.6.1466
   Ikuta S, 2008, CANCER RES, V68, P64, DOI 10.1158/0008-5472.CAN-07-3245
   Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200
   Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743
   Leonard A, 2013, AM J PHYSIOL-LUNG C, V305, pL651, DOI 10.1152/ajplung.00071.2013
   Li MZ, 2009, CARCINOGENESIS, V30, P1424, DOI 10.1093/carcin/bgp125
   Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minami T, 2005, TRENDS CARDIOVAS MED, V15, P174, DOI 10.1016/j.tcm.2005.06.002
   Minhajuddin M, 2009, J BIOL CHEM, V284, P4052, DOI 10.1074/jbc.M805032200
   Rahman A, 1999, J IMMUNOL, V162, P5466
   Rahman A, 1999, MOL PHARMACOL, V55, P575
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Smrcka AV, 2012, CELL SIGNAL, V24, P1333, DOI 10.1016/j.cellsig.2012.01.009
   Speyer CL, 2005, AM J PHYSIOL-CELL PH, V288, pC881, DOI 10.1152/ajpcell.00467.2004
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347
   Tiruppathi C, 2014, NAT IMMUNOL, V15, P239, DOI 10.1038/ni.2823
   VANDENBROUCKE ST, 2012, CIRC RES, V111, P739, DOI DOI 10.1161/CIRCRESAHA.112.269654
   Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014
   Waldo GL, 2010, SCIENCE, V330, P974, DOI 10.1126/science.1193438
   Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weis SM, 2008, CURR OPIN HEMATOL, V15, P243, DOI 10.1097/MOH.0b013e3282f97d86
   Yao HW, 2008, AM J RESP CELL MOL, V39, P7, DOI 10.1165/rcmb.2007-0342OC
   Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
   You J, 2010, MOL CELL ENDOCRINOL, V320, P111, DOI 10.1016/j.mce.2010.01.036
   Zhang LH, 2011, J BIOL CHEM, V286, P23012, DOI 10.1074/jbc.M111.231993
NR 55
TC 21
Z9 23
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG 1
PY 2016
VL 311
IS 2
BP L517
EP L524
DI 10.1152/ajplung.00069.2016
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA DT6XP
UT WOS:000381628600028
PM 27371732
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Liu, ZF
   Zheng, D
   Fan, GC
   Peng, TQ
   Su, L
AF Liu, Zhi-feng
   Zheng, Dong
   Fan, Guo-chang
   Peng, Tianqing
   Su, Lei
TI Heat stress prevents lipopolysaccharide-induced apoptosis in pulmonary
   microvascular endothelial cells by blocking calpain/p38 MAPK signalling
SO APOPTOSIS
LA English
DT Article
DE heat stress; Calpain; MAPK; apoptosis; LPS 
ID ACUTE LUNG INJURY; SHOCK PROTEINS; PROTECTION; SEPSIS; MICE; ACTIVATION;
   MECHANISMS
AB Pulmonary microvascular endothelial cells (PMECs) injury including apoptosis plays an important role in the pathogenesis of acute lung injury during sepsis. Our recent study has demonstrated that calpain activation contributes to apoptosis in PMECs under septic conditions. This study investigated how calpain activation mediated apoptosis and whether heat stress regulated calpain activation in lipopolysaccharides (LPS)-stimulated PMECs. In cultured mouse primary PMECs, incubation with LPS (1 mu g/ml, 24 h) increased active caspase-3 fragments and DNA fragmentation, indicative of apoptosis. These effects of LPS were abrogated by pre-treatment with heat stress (43 degrees C for 2 h). LPS also induced calpain activation and increased phosphorylation of p38 MAPK. Inhibition of calpain and p38 MAPK prevented apoptosis induced by LPS. Furthermore, inhibition of calpain blocked p38 MAPK phosphorylation in LPS-stimulated PMECs. Notably, heat stress decreased the protein levels of calpain-1/2 and calpain activities, and blocked p38 MAPK phosphorylation in response to LPS. Additionally, forced up-regulation of calpain-1 or calpain-2 sufficiently induced p38 MAPK phosphorylation and apoptosis in PMECs, both of which were inhibited by heat stress. In conclusion, heat stress prevents LPS-induced apoptosis in PMECs. This effect of heat stress is associated with down-regulation of calpain expression and activation, and subsequent blockage of p38 MAPK activation in response to LPS. Thus, blocking calpain/p38 MAPK pathway may be a novel mechanism underlying heat stress-mediated inhibition of apoptosis in LPS-stimulated endothelial cells.
C1 [Liu, Zhi-feng; Su, Lei] Guangzhou Mil Command, Gen Hosp, Dept Intens Care Unit, Guangzhou 510010, Guangdong, China.
C1 [Liu, Zhi-feng; Zheng, Dong; Peng, Tianqing] Univ Western Ontario, Lawson Hlth Res Inst, Crit Illness Res, Dept Med, London, ON N6A 4G5, Canada.
C1 [Liu, Zhi-feng; Zheng, Dong; Peng, Tianqing] Univ Western Ontario, Lawson Hlth Res Inst, Crit Illness Res, Dept Pathol, London, ON N6A 4G5, Canada.
C1 [Fan, Guo-chang] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267, United States.
C1 [Su, Lei] Guangzhou Mil Command, Gen Hosp, PLA, Key Lab Hot Zone Trauma Care & Tissue Repair, Guangzhou 510010, Guangdong, China.
C3 Southern Theater Command General Hospital; Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); University System of Ohio; University of Cincinnati;
   Southern Theater Command General Hospital
RP Su, L (corresponding author), Guangzhou Mil Command, Gen Hosp, Dept Intens Care Unit, Guangzhou 510010, Guangdong, Peoples R China.; Su, L (corresponding author), Guangzhou Mil Command, Gen Hosp, PLA, Key Lab Hot Zone Trauma Care & Tissue Repair, Guangzhou 510010, Guangdong, Peoples R China.
EM slei_icu@163.com
RI Peng, Tianqing/G-3340-2011; Fan, Guo-Chang/E-1153-2012
OI Fan, Guo-Chang/0000-0002-0439-8277
FU National Natural Science Foundation of China [81571940]; Project Team of
   Natural Science Foundation of Guangdong Province [s2013030013217];
   Project of Medical Research of PLA [BWS12J108]; Guangzhou Science and
   Technology Planning Project of China [201504281714528]; Heart & Stroke
   Foundation of Canada; Canadian Institutes of Health Research
FX This work was supported by Grants from the National Natural Science
   Foundation of China [No. 81571940], the Project Team of Natural Science
   Foundation of Guangdong Province [No. s2013030013217], and the Project
   of Medical Research of PLA [No. BWS12J108], the Guangzhou Science and
   Technology Planning Project of China [No. 201504281714528], and the
   Heart & Stroke Foundation of Canada (Awarded to T.P.). T.P. is a
   recipient of a New Investigator Award from the Canadian Institutes of
   Health Research.
CR Abraham E, 2005, CLIN INFECT DIS, V41, pS459, DOI 10.1086/431997
   AMRANI M, 1994, ANN THORAC SURG, V57, P157, DOI 10.1016/0003-4975(94)90385-9
   Averna M, 2008, FEBS J, V275, P2501, DOI 10.1111/j.1742-4658.2008.06394.x
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089
   Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295
   Brinton MR, 2012, INT J HYPERTHER, V28, P163, DOI 10.3109/02656736.2011.638963
   Chen G, 2001, J SURG RES, V95, P79, DOI 10.1006/jsre.2000.5896
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X
   Farley KS, 2008, MICROVASC RES, V76, P208, DOI 10.1016/j.mvr.2008.07.004
   Gill RR, 1998, J MOL CELL CARDIOL, V30, P2739, DOI 10.1006/jmcc.1998.0837
   Gray CC, 1999, INT J BIOCHEM CELL B, V31, P559, DOI 10.1016/S1357-2725(99)00004-7
   Heidemann SM, 2005, INFLAMMATION, V29, P47, DOI 10.1007/s10753-006-8969-4
   Hu HX, 2009, MICROVASC RES, V78, P33, DOI 10.1016/j.mvr.2009.04.005
   Jarrar D, 1999, INT J MOL MED, V4, P575
   Joyeux M, 2000, BRIT J PHARMACOL, V130, P345, DOI 10.1038/sj.bjp.0703312
   Joyeux-Faure M, 2003, CARDIOVASC RES, V60, P469, DOI 10.1016/j.cardiores.2003.08.012
   Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1
   Kitamura Y, 2001, AM J RESP CRIT CARE, V163, P762, DOI 10.1164/ajrccm.163.3.2003065
   Li XP, 2004, J APPL PHYSIOL, V97, P1535, DOI 10.1152/japplphysiol.00519.2004
   Li Y, 2011, DIABETES, V60, P2985, DOI 10.2337/db10-1333
   Lizama C, 2009, J CELL PHYSIOL, V221, P296, DOI 10.1002/jcp.21868
   Matsuda N, 2007, CARDIOVASC RES, V76, P132, DOI 10.1016/j.cardiores.2007.05.024
   Matute-Bello G, 2004, CLIN DIAGN LAB IMMUN, V11, P358, DOI 10.1128/CDLI.11.2.358-361.2004
   MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5
   Mizumura K, 2010, INT IMMUNOPHARMACOL, V10, P1062, DOI 10.1016/j.intimp.2010.06.006
   Moulin M, 2006, EXP CELL RES, V312, P1765, DOI 10.1016/j.yexcr.2006.02.008
   Nagai H, 2007, J BIOCHEM MOL BIOL, V40, P1
   Namisaki T, 2006, J HEPATOL, V44, P568, DOI 10.1016/j.jhep.2005.08.018
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Peng TQ, 2004, FASEB J, V18, P293, DOI 10.1096/fj.04-2289fje
   Rittirsch D, 2008, J IMMUNOL, V180, P7664, DOI 10.4049/jimmunol.180.11.7664
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sahara S, 2010, BIOCHEM BIOPH RES CO, V393, P806, DOI 10.1016/j.bbrc.2010.02.087
   Shen E, 2007, J MOL CELL CARDIOL, V43, P308, DOI 10.1016/j.yjmcc.2007.06.007
   Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841
   Strassheim D, 2002, INT J BIOCHEM CELL B, V34, P1527, DOI 10.1016/S1357-2725(02)00049-3
   Sugimoto N, 2014, CELL BIOCHEM BIOPHYS, V70, P301, DOI 10.1007/s12013-014-9912-9
   Suzuki K, 2011, INT IMMUNOL, V23, P185, DOI 10.1093/intimm/dxq471
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wong HR, 1996, AM J RESP CELL MOL, V15, P745, DOI 10.1165/ajrcmb.15.6.8969269
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Zafrani L, 2012, AM J RESP CRIT CARE, V185, P744, DOI 10.1164/rccm.201109-1686OC
   Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548
NR 44
TC 34
Z9 39
U1 1
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD AUG
PY 2016
VL 21
IS 8
BP 896
EP 904
DI 10.1007/s10495-016-1263-0
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DS3MT
UT WOS:000380687800002
PM 27325431
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Zhu, XJ
   Zou, Y
   Wang, B
   Zhu, JL
   Chen, Y
   Wang, L
   Li, JB
   Deng, XM
AF Zhu, Xuejiao
   Zou, Yun
   Wang, Bing
   Zhu, Jiali
   Chen, Yi
   Wang, Lei
   Li, Jinbao
   Deng, Xiaoming
TI Blockade of CXC chemokine receptor 3 on endothelial cells protects
   against sepsis-induced acute lung injury
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE sepsis; ALI/ARDS; CXCR3; ECs/HPMECs/HUVECs/MPVECs; apoptosis 
ID RESPIRATORY-DISTRESS-SYNDROME; AIRWAY EPITHELIAL-CELLS; UP-REGULATION;
   BARRIER DYSFUNCTION; CECAL LIGATION; APOPTOSIS; INFLAMMATION;
   EXPRESSION; HYPERPERMEABILITY; PATHOPHYSIOLOGY
AB Background: CXCR3, a G-protein coupled chemokine receptor, has been shown to play a critical role in recruiting inflammatory cells into lungs in several studies. However, its roles in polymicrobial septic acute lung injury (ALI) is yet unknown. Therefore, the purpose of this study was to elucidate the protective effects of CXCR3 blockade on pulmonary microvascular endothelial cells (PMVECs) in septic ALI and explore potential mechanisms.
   Materials and methods: ALI was induced by polymicrobial sepsis through cecal ligation and puncture surgery. The expression of CXCR3 on pulmonary microvascular endothelial cells was measured 24 h after cecal ligation and puncture surgery. In addition, the protective effects of neutralizing antibody were detected, including protein concentration, inflammation cell counts, lung wet-to-dry ratio, and lung damages. In human umbilical vein endothelial cells (HUVECs) culture condition, CXCR3 expression was measured after exposure to tumor necrosis factor-alpha. The permeability and apoptosis ratio were detected through CXCR3 gene silencing on HUVECs. The p38 mitogen-activated protein kinase (MAPK) was analyzed with Western blot.
   Results: CXCR3 expression was upregulated both in vivo and in vitro. After CXCR3 neutralizing antibody administrated intraperitoneally, the protein concentration, inflammatory cell counts in BALF and lung wet-to-dry ratio were decreased significantly, as well as the lung tissue damages. In vitro, CXCR3 gene silencing inhibited tumor necrosis factor-alpha and CXCL10-induced hyperpermeability and apoptosis in HUVECs. In addition, p38 mitogen-activated protein kinase activation was essential for CXCR3-mediated apoptosis.
   Conclusions: CXCR3 blockade exerts protective effects on ALI at least partly by inhibiting endothelial cells apoptosis and decreasing the leakage of protein-rich fluid and inflammatory cells. Blockade of CXCR3 may be a promising therapeutic strategy for severe sepsis-induced ALI. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Zhu, Xuejiao] Xuzhou Med Coll, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Jiangsu, China.
C1 [Zhu, Xuejiao] Jiangsu Prov Key Lab Anesthesia & Analgesia Appli, Xuzhou, Jiangsu, China.
C1 [Zhu, Xuejiao; Zou, Yun; Wang, Bing; Zhu, Jiali; Chen, Yi; Wang, Lei; Li, Jinbao; Deng, Xiaoming] Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol & Intens Care, Shanghai 200433, China.
C1 [Li, Jinbao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Anesthesiol, Shanghai, China.
C3 Xuzhou Medical University; Naval Medical University; Shanghai Jiao Tong
   University
RP Li, JB; Deng, XM (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol & Intens Care, Shanghai 200433, Peoples R China.
EM lijinbaoshanghai@163.com; deng_x@yahoo.com
RI Deng, Xiaoming/E-2876-2010
FU National Natural Science Foundation of China [81171788, 81471845]
FX This work was supported by Grants 81171788 and 81471845 from the
   National Natural Science Foundation of China.
CR Aksoy MO, 2006, AM J PHYSIOL-LUNG C, V290, pL909, DOI 10.1152/ajplung.00430.2005
   Bao SH, 2015, INT IMMUNOPHARMACOL, V28, P429, DOI 10.1016/j.intimp.2015.06.022
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Cines DB, 1998, BLOOD, V91, P3527
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Darwish I, 2013, VIRULENCE, V4, P572, DOI 10.4161/viru.25740
   De Maio A, 2005, SHOCK, V23, P11, DOI 10.1097/01.shk.0000144134.03598.c5
   Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7
   Green LA, 2014, AM J PHYSIOL-LUNG C, V306, pL372, DOI 10.1152/ajplung.00193.2013
   Green LA, 2012, AM J RESP CELL MOL, V47, P807, DOI 10.1165/rcmb.2012-0132OC
   Herzig DS, 2012, CRIT CARE, V16, DOI 10.1186/cc11642
   Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e
   Ichikawa A, 2013, AM J RESP CRIT CARE, V187, P65, DOI 10.1164/rccm.201203-0508OC
   Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117
   Kelsen SG, 2004, AM J PHYSIOL-LUNG C, V287, pL584, DOI 10.1152/ajplung.00453.2003
   Lacotte S, 2009, ANN NY ACAD SCI, V1173, P310, DOI 10.1111/j.1749-6632.2009.04813.x
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Muller M, 2010, NEUROPATH APPL NEURO, V36, P368, DOI 10.1111/j.1365-2990.2010.01089.x
   Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Repesse X, 2016, CURR OPIN CRIT CARE, V22, P38, DOI 10.1097/MCC.0000000000000267
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sawant DA, 2014, J PHYSIOL BIOCHEM, V70, P971, DOI 10.1007/s13105-014-0366-8
   Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Yan XR, 2015, J SURG RES, V199, P592, DOI 10.1016/j.jss.2015.06.013
   Zellweger R, 1997, CRIT CARE MED, V25, P106, DOI 10.1097/00003246-199701000-00021
   Zheng YJ, 2016, MOL MED REP, V13, P513, DOI 10.3892/mmr.2015.4536
NR 32
TC 11
Z9 11
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 2016
VL 204
IS 2
BP 288
EP 296
DI 10.1016/j.jss.2016.04.067
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA DU5CP
UT WOS:000382230100004
PM 27565063
DA 2023-08-21
ER

PT J
AU Bocharov, AV
   Wu, TH
   Baranova, IN
   Birukova, AA
   Sviridov, D
   Vishnyakova, TG
   Remaley, AT
   Eggerman, TL
   Patterson, AP
   Birukov, KG
AF Bocharov, Alexander V.
   Wu, Tinghuai
   Baranova, Irina N.
   Birukova, Anna A.
   Sviridov, Denis
   Vishnyakova, Tatyana G.
   Remaley, Alan T.
   Eggerman, Thomas L.
   Patterson, Amy P.
   Birukov, Konstantin G.
TI Synthetic Amphipathic Helical Peptides Targeting CD36 Attenuate
   Lipopolysaccharide-Induced Inflammation and Acute Lung Injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; RECEPTOR CLASS-B;
   SERUM-AMYLOID-A; MIMETIC PEPTIDE; SR-BI; BACTERIAL RECOGNITION;
   SCAVENGER RECEPTORS; CHOLESTEROL EFFLUX; WESTERN DIET
AB Synthetic amphipathic helical peptides (SAHPs) designed as apolipoprotein A-I mimetics are known to bind to class B scavenger receptors (SR-Bs), SR-BI, SR-BII, and CD36, receptors that mediate lipid transport and facilitate pathogen recognition. In this study, we evaluated SAHPs, selected for targeting human CD36, by their ability to attenuate LPS-induced inflammation, endothelial barrier dysfunction, and acute lung injury (ALI). L37pA, which targets CD36 and SR-BI equally, inhibited LPS-induced IL-8 secretion and barrier dysfunction in cultured endothelial cells while reducing lung neutrophil infiltration by 40% in a mouse model of LPS-induced ALI. A panel of 20 SAHPs was tested in HEK293 cell lines stably transfected with various SR-Bs to identify SAHPs with preferential selectivity toward CD36. Among several SAHPs targeting both SR-BI/BII and CD36 receptors, ELK-B acted predominantly through CD36. Compared with L37pA, 5A, and ELK SAHPs, ELK-B was most effective in reducing the pulmonary barrier dysfunction, neutrophil migration into the lung, and lung inflammation induced by LPS. We conclude that SAHPs with relative selectivity toward CD36 are more potent at inhibiting acute pulmonary inflammation and dysfunction. These data indicate that therapeutic strategies using SAHPs targeting CD36, but not necessarily mimicking all apolipoprotein A-I functions, may be considered a possible new treatment approach for inflammation-induced ALI and pulmonary edema.
C1 [Bocharov, Alexander V.; Baranova, Irina N.; Vishnyakova, Tatyana G.; Eggerman, Thomas L.; Patterson, Amy P.] NIH, Dept Lab Med, Ctr Clin, Bldg 9,Room 1N128,8800 Rockville Pike, Bethesda, MD 20892, United States.
C1 [Bocharov, Alexander V.; Remaley, Alan T.] NHLBI, Bldg 10, Bethesda, MD 20892, United States.
C1 [Wu, Tinghuai; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Lung Injury Ctr, Chicago, IL 60637, United States.
C1 [Sviridov, Denis; Eggerman, Thomas L.] NIDDK, Bethesda, MD 20892, United States.
C1 [Patterson, Amy P.] NIH, Off Sci Policy, Off Director, Bldg 10, Bethesda, MD 20892, United States.
C3 National Institutes of Health (NIH) - USA; NIH Clinical Center (CC);
   National Institutes of Health (NIH) - USA; NIH National Heart Lung &
   Blood Institute (NHLBI); University of Chicago; National Institutes of
   Health (NIH) - USA; NIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA
RP Bocharov, AV (corresponding author), NIH, Dept Lab Med, Ctr Clin, Bldg 9,Room 1N128,8800 Rockville Pike, Bethesda, MD 20892 USA.
EM abocharov@mail.cc.nih.gov
RI Baranova, Irina/IQR-8854-2023; Birukov, Konstantin/FJB-5755-2022
FU National Institutes of Health Intramural Research Programs at the
   Clinical Center; National Institute of Diabetes, Digestive, and Kidney
   Diseases; National Institutes of Allergy and Infectious Diseases;
   National Heart, Lung, and Blood Institute; National Institutes of Health
FX This work was supported by the National Institutes of Health Intramural
   Research Programs at the Clinical Center, National Institute of
   Diabetes, Digestive, and Kidney Diseases, National Institutes of Allergy
   and Infectious Diseases, and National Heart, Lung, and Blood Institute,
   as well as by National Institutes of Health grants to the Lung Injury
   Center, The University of Chicago.
CR BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558
   Baranova IN, 2005, J BIOL CHEM, V280, P8031, DOI 10.1074/jbc.M405009200
   Baranova IN, 2008, J IMMUNOL, V181, P7147, DOI 10.4049/jimmunol.181.10.7147
   Baranova IN, 2016, J IMMUNOL, V196, P3135, DOI 10.4049/jimmunol.1501709
   Baranova IN, 2012, J IMMUNOL, V188, P1371, DOI 10.4049/jimmunol.1100350
   Baranova IN, 2010, J BIOL CHEM, V285, P8492, DOI 10.1074/jbc.M109.007526
   Barter Philip J, 2007, Curr Cardiol Rep, V9, P493, DOI 10.1007/BF02938394
   Barth H, 2008, J VIROL, V82, P3466, DOI 10.1128/JVI.02478-07
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200
   Bocharov AV, 2004, J BIOL CHEM, V279, P36072, DOI 10.1074/jbc.M314264200
   Buga GM, 2008, J LIPID RES, V49, P192, DOI 10.1194/jlr.M700433-JLR200
   Buga GM, 2006, J LIPID RES, V47, P2148, DOI 10.1194/jlr.M600214-JLR200
   Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200
   Cai L, 2008, J CLIN INVEST, V118, P364, DOI 10.1172/JCI31539
   Charles-Schoeman C, 2008, CLIN IMMUNOL, V127, P234, DOI 10.1016/j.clim.2008.01.016
   D'Souza W, 2010, CIRC RES, V107, P217, DOI 10.1161/CIRCRESAHA.110.216507
   Di Bartolo BA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-224
   Feng H, 2011, ARTERIOSCL THROM VAS, V31, P2543, DOI 10.1161/ATVBAHA.111.234716
   Florentin M, 2008, CURR OPIN CARDIOL, V23, P370, DOI 10.1097/HCO.0b013e3283043806
   Gao DT, 2015, METHODS MOL BIOL, V1208, P29, DOI 10.1007/978-1-4939-1441-8_3
   Gao DT, 2010, J BIOL CHEM, V285, P4447, DOI 10.1074/jbc.M109.082800
   Getz GS, 2009, CURR OPIN LIPIDOL, V20, P171, DOI 10.1097/MOL.0b013e32832ac051
   Gordon SM, 2011, TRENDS ENDOCRIN MET, V22, P9, DOI 10.1016/j.tem.2010.10.001
   Hoekstra M, 2010, WORLD J GASTROENTERO, V16, P5916, DOI 10.3748/wjg.v16.i47.5916
   Hu GC, 2010, CRIT CARE MED, V38, P194, DOI 10.1097/CCM.0b013e3181bc7c17
   Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634
   Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011
   Kwon WY, 2012, J TRAUMA ACUTE CARE, V72, P1576, DOI 10.1097/TA.0b013e3182493ab4
   Leelahavanichkul A, 2012, J IMMUNOL, V188, P2749, DOI 10.4049/jimmunol.1003445
   LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040
   Meliton AY, 2013, AM J PHYSIOL-LUNG C, V304, pL689, DOI 10.1152/ajplung.00047.2013
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
   Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061
   Navab M, 2000, J LIPID RES, V41, P1481
   Navab M, 2005, TRENDS CARDIOVAS MED, V15, P158, DOI 10.1016/j.tcm.2005.05.008
   Navab M, 2006, NAT CLIN PRACT CARD, V3, P540, DOI 10.1038/ncpcardio0661
   Nicholls SJ, 2005, CIRCULATION, V111, P1543, DOI 10.1161/01.CIR.0000159351.95399.50
   Nofer JR, 2006, J LIPID RES, V47, P794, DOI 10.1194/jlr.M500502-JLR200
   Okamura DM, 2009, J AM SOC NEPHROL, V20, P495, DOI 10.1681/ASN.2008010009
   PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607
   Puranik R, 2008, ATHEROSCLEROSIS, V196, P240, DOI 10.1016/j.atherosclerosis.2007.05.008
   Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200
   Robbesyn F, 2005, ARTERIOSCL THROM VAS, V25, P1206, DOI 10.1161/01.ATV.0000164805.73558.80
   Robbesyn F, 2003, FASEB J, V17, P743, DOI 10.1096/fj.02-0240fje
   Rodrigues CD, 2008, CELL HOST MICROBE, V4, P271, DOI 10.1016/j.chom.2008.07.012
   SEGREST JP, 1992, J LIPID RES, V33, P141
   Sethi AA, 2008, J BIOL CHEM, V283, P32273, DOI 10.1074/jbc.M804461200
   Sethi AA, 2007, CURR OPIN INVEST DR, V8, P201
   Sharifov OF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064486
   Souza ACP, 2016, KIDNEY INT, V89, P809, DOI 10.1016/j.kint.2015.12.043
   Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001
   Van Lenten BJ, 2004, CIRCULATION, V110, P3252, DOI 10.1161/01.CIR.0000147232.75456.B3
   Van Lenten BJ, 2008, J LIPID RES, V49, P2302, DOI 10.1194/jlr.M800075-JLR200
   Vaziri ND, 2009, KIDNEY INT, V76, P437, DOI 10.1038/ki.2009.177
   Vishnyakova TG, 2006, P NATL ACAD SCI USA, V103, P16888, DOI 10.1073/pnas.0602126103
   Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200
   Wu JX, 2015, ANTIOXID REDOX SIGN, V22, P308, DOI 10.1089/ars.2013.5743
   Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143
   Yao XL, 2011, J IMMUNOL, V186, P576, DOI 10.4049/jimmunol.1001534
NR 60
TC 24
Z9 27
U1 2
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUL 15
PY 2016
VL 197
IS 2
BP 611
EP 619
DI 10.4049/jimmunol.1401028
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA DQ8ZL
UT WOS:000379500100019
PM 27316682
OA Bronze
DA 2023-08-21
ER

PT J
AU Kong, GQ
   Huang, X
   Wang, LP
   Li, Y
   Sun, T
   Han, SS
   Zhu, WW
   Ma, MM
   Xu, HX
   Li, JK
   Zhang, XH
   Liu, XY
   Wang, XZ
AF Kong, Guiqing
   Huang, Xiao
   Wang, Lipeng
   Li, Yan
   Sun, Ting
   Han, Shasha
   Zhu, Weiwei
   Ma, Mingming
   Xu, Haixiao
   Li, Jiankui
   Zhang, Xiaohua
   Liu, Xiangyong
   Wang, Xiaozhi
TI Astilbin alleviates LPS-induced ARDS by suppressing MAPK signaling
   pathway and protecting pulmonary endothelial glycocalyx
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE ALI/ARDS; Astilbin; MAPK; endothelial glycocalyx (EG); heparanase 
ID ACUTE RESPIRATORY-DISTRESS; ACTIVATED PROTEIN-KINASE; ACUTE LUNG INJURY;
   NF-KAPPA-B; HEPARAN-SULFATE; DENDRITIC CELLS; TNF-ALPHA; INFLAMMATION;
   INHIBITOR; INDUCTION
AB Acute respiratory distress syndrome (ARDS) is a devastating disorder that is characterized by increased vascular endothelial permeability and inflammation. Unfortunately, no effective treatment beyond supportive care is available for ARDS. Astilbin, a flavonoid compound isolated from Rhizoma Smilacis Glabrae, has been used for anti-hepatic, anti-arthritic, and anti-renal injury treatments. This study examined the effects of Astilbin on pulmonary inflammatory activation and endothelial cell barrier dysfunction caused by Gram-negative bacterial endotoxin lipopolysaccharide (LPS). Endothelial cells from human umbilical veins or male Kunming mice were pretreated with Astilbin 24 h before LPS stimulation. Results showed that Astilbin significantly attenuated the pulmonary histopathological changes and neutrophil infiltration 6 h after the LPS challenge. Astilbin suppressed the activities of myeloperoxidase and malondialdehyde, as well as the expression of tumor necrosis factor-alpha and interleukin-6 in vivo and in vitro. As indices of pulmonary edema, lung wet-to-dry weight ratios, were markedly decreased by Astilbin pretreatment. Western blot analysis also showed that Astilbin inhibited LPS-induced activation of mitogen-activated protein kinase (MAPK) pathways in lung tissues. Furthermore, Astilbin significantly inhibited the activity of heparanase and reduced the production of heparan sulfate in the blood serum as determined by ELISA. These findings indicated that Astilbin can alleviate LPS-induced ARDS, which potentially contributed to the suppression of MAPK pathway activation and the degradation of endothelial glycocalyx. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Kong, Guiqing; Huang, Xiao; Wang, Lipeng; Zhu, Weiwei; Xu, Haixiao; Li, Jiankui; Wang, Xiaozhi] Binzhou Med Univ, Affiliated Hosp, Dept Intens Care Unit, Binzhou 256603, Shandong, China.
C1 [Ma, Mingming] Hulunbeier Peoples Hosp, Dept Intens Care Unit, Hulunbeier 021000, Inner Mongolia, China.
C1 [Li, Yan; Sun, Ting; Han, Shasha] Binzhou Med Univ, Affiliated Hosp, Dept Resp Med, Binzhou 256603, Shandong, China.
C1 [Kong, Guiqing; Zhang, Xiaohua] Binzhou Med Univ, Dept Biotechnol, Yantai 264003, Shandong, China.
C1 [Liu, Xiangyong] Binzhou Med Univ, Dept Cell Biol, Yantai 264003, Shandong, China.
C1 [Wang, Xiaozhi] Binzhou Med Univ, Affiliated Hosp, Dept Resp Med, Binzhou 256603, China.
C1 [Wang, Xiaozhi] Binzhou Med Univ, Affiliated Hosp, Intens Care Unit, Binzhou 256603, China.
C3 Binzhou Medical University; Binzhou Medical University; Binzhou Medical
   University; Binzhou Medical University; Binzhou Medical University;
   Binzhou Medical University
RP Zhang, XH (corresponding author), Binzhou Med Univ, Dept Biotechnol, Yantai 264003, Shandong, Peoples R China.
EM xiaohua124@gmail.com; liuxiangyong81@gmail.com; hxicuwxz@163.com
FU Natural Science Foundation of Shandong Province [ZR2014HM112,
   ZR2014HL004, UF201403]; Science and Technology Development Plan of
   Shandong Province [2011GSF11830]; Science and Technology Development
   Plan of Binzhou Medical College [BY2012KJ21]; Taishan Scholar Project of
   Shandong Province
FX This work has received funding from the Natural Science Foundation of
   Shandong Province, (ZR2014HM112, ZR2014HL004, UF201403), the Science and
   Technology Development Plan of Shandong Province (2011GSF11830), the
   Science and Technology Development Plan of Binzhou Medical College
   (BY2012KJ21), and Taishan Scholar Project of Shandong Province.
CR [Anonymous], 2012, EUR J PHARMACOL
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   Cechinel V, 2000, ARZNEIMITTELFORSCH, V50, pE281
   Chappell D, 2008, BIOL CHEM, V389, P79, DOI 10.1515/BC.2008.005
   Chen LY, 2011, PLANTA MED, V77, P1769, DOI 10.1055/s-0030-1271135
   Closa D, 1997, PROSTAG LEUKOTR ESS, V56, P331, DOI 10.1016/S0952-3278(97)90578-0
   Ding YB, 2014, BIOCHEM BIOPH RES CO, V446, P529, DOI 10.1016/j.bbrc.2014.02.136
   Haddad E, 2001, BRIT J PHARMACOL, V132, P1715, DOI 10.1038/sj.bjp.0704022
   Han LK, 1998, J NAT PROD, V61, P1006, DOI 10.1021/np980107o
   Haraguchi H, 1996, BIOSCI BIOTECH BIOCH, V60, P945, DOI 10.1271/bbb.60.945
   Huang HQ, 2011, J AGR FOOD CHEM, V59, P4562, DOI 10.1021/jf2002969
   Karapetsa M, 2013, FOOD CHEM TOXICOL, V61, P106, DOI 10.1016/j.fct.2013.03.026
   Kuo MY, 2011, FOOD CHEM TOXICOL, V49, P2660, DOI 10.1016/j.fct.2011.07.012
   Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296
   Li Y, 2014, WORLD J GASTROENTERO, V20, P5849, DOI 10.3748/wjg.v20.i19.5849
   Ma MM, 2015, INFLAMMATION, V38, P1669, DOI 10.1007/s10753-015-0144-y
   Mayeux P.R., 1977, J TOXICOL ENV HLTH, V51, P415
   Meirovitz A, 2013, FEBS J, V280, P2307, DOI 10.1111/febs.12184
   Motoyashiki T, 1998, BIOL PHARM BULL, V21, P517, DOI 10.1248/bpb.21.517
   Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151
   Nishina K, 1997, ANESTH ANALG, V84, P1097, DOI 10.1097/00000539-199705000-00026
   Pereira LGB, 2002, PEST MANAG SCI, V58, P503, DOI 10.1002/ps.478
   Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307
   Qiu XC, 2011, INT IMMUNOPHARMACOL, V11, P2130, DOI 10.1016/j.intimp.2011.09.007
   Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Vlodavsky I, 2013, MATRIX BIOL, V32, P220, DOI 10.1016/j.matbio.2013.03.001
   Wang J, 2004, J PHARM PHARMACOL, V56, P495, DOI 10.1211/0022357023033
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yang J, 1999, SURGERY, V126, P216, DOI 10.1067/msy.1999.98753
   Yi HW, 2008, INT IMMUNOPHARMACOL, V8, P1467, DOI 10.1016/j.intimp.2008.06.006
   Zmijewski JW, 2009, AM J RESP CRIT CARE, V179, P694, DOI 10.1164/rccm.200806-851OC
   Zou S, 2010, TRANSPL P, V42, P3798, DOI 10.1016/j.transproceed.2010.06.031
NR 34
TC 43
Z9 49
U1 2
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL
PY 2016
VL 36
BP 51
EP 58
DI 10.1016/j.intimp.2016.03.039
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA DP4GB
UT WOS:000378453300007
PM 27111514
DA 2023-08-21
ER

PT J
AU Miyashita, T
   Ahmed, AK
   Nakanuma, S
   Okamoto, K
   Sakai, S
   Kinoshita, J
   Makino, I
   Nakamura, K
   Hayashi, H
   Oyama, K
   Tajima, H
   Takamura, H
   Ninomiya, I
   Fushida, S
   Harmon, JW
   Ohta, T
AF Miyashita, Tomoharu
   Ahmed, Ali Karim
   Nakanuma, Shinichi
   Okamoto, Koichi
   Sakai, Seisho
   Kinoshita, Jun
   Makino, Isamu
   Nakamura, Keishi
   Hayashi, Hironori
   Oyama, Katsunobu
   Tajima, Hidehiro
   Takamura, Hiroyuki
   Ninomiya, Itasu
   Fushida, Sachio
   Harmon, John W.
   Ohta, Tetsuo
TI A Three-phase Approach for the Early Identification of Acute Lung Injury
   Induced by Severe Sepsis
SO IN VIVO
LA English
DT Review
DE sepsis; ALI/ARDS; neutrophil extracellular traps; extravasated platelet aggregation (EPA); veno-occlusive disease; review 
ID RESPIRATORY-DISTRESS-SYNDROME; DISSEMINATED INTRAVASCULAR COAGULATION;
   NEUTROPHIL EXTRACELLULAR TRAPS; INFLAMMATORY RESPONSE SYNDROME; MULTIPLE
   ORGAN DYSFUNCTION; SEPTIC SHOCK; PULMONARY-HYPERTENSION;
   PLATELET-AGGREGATION; ELASTASE INHIBITOR; TRAUMA PATIENTS
AB A number of studies have reported that acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are independent risk factors for organ dysfunction and mortality in patients with sepsis. Although ALI/ARDS might be an essential therapeutic target during the management of sepsis, severe sepsis should be treated effectively and as soon as identified. We have classified three phases, ranging from sepsis to organ dysfunction, characterizing the interaction between neutrophils and platelets. The first phase is neutrophil extracellular trap (NET) formation and intravasated platelet aggregation. The next phase is extravasated platelet aggregation (EPA), promoted by NET-facilitated detachment of endothelial cells. The final phase is organ dysfunction, caused by pulmonary veno-occlusive disease (VOD), fibrosis, and immunoparalysis induced by EPA. Severe sepsis is characterized by a continuum of coagulopathy, with coagulation abnormalities often developing before the onset of clinical symptoms. The initial medical treatment for ALI/ARDS is inhibition of NET formation and intravasated platelet aggregation to prevent endothelial cell damage (Phase 1). Beraprost and silvestat, phosphodiesterase 3 (PDE3) inhibitors, are often administered in clinical practice. To determine hypercoagulopathy, plasma levels of thrombin-antithrombin complex and plasmin-plasmin inhibitor complex are continuously monitored in patients with suspected sepsis. Furthermore, the implementation of quality indicators for the early management of severe sepsis and septic shock is strongly associated with a reduced mortality. We conclude that pathophysiology of organ dysfunction from severe sepsis is caused by pulmonary VOD, fibrosis, and EPA-facilitated immunoparalysis. In order to prevent ALI/ARDS in patients with sepsis, countermeasures for NET and platelet aggregation should be pre-emptively employed and confirmed by several trials.
C1 [Miyashita, Tomoharu; Nakanuma, Shinichi; Okamoto, Koichi; Sakai, Seisho; Kinoshita, Jun; Makino, Isamu; Nakamura, Keishi; Hayashi, Hironori; Oyama, Katsunobu; Tajima, Hidehiro; Takamura, Hiroyuki; Ninomiya, Itasu; Fushida, Sachio; Ohta, Tetsuo] Kanazawa Univ Hosp, Dept Surg Gastroenterol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.
C1 [Ahmed, Ali Karim; Harmon, John W.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205, United States.
C3 Kanazawa University; Johns Hopkins University
RP Miyashita, T (corresponding author), Kanazawa Univ Hosp, Dept Surg Gastroenterol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.
EM tomoharumiya@gmail.com
OI Harmon, John/0000-0002-2857-3850; Nakanuma, Shinichi/0000-0002-5118-2225
CR Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916
   ASAKURA H, 1994, BLOOD COAGUL FIBRIN, V5, P829, DOI 10.1097/00001721-199410000-00022
   Asakura H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-20
   BARRADAS MA, 1993, THROMB RES, V71, P227, DOI 10.1016/0049-3848(93)90097-8
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170
   Chen R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.337
   Cheng OZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00001
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Daurat A, 2016, INJURY, V47, P147, DOI 10.1016/j.injury.2015.08.031
   Eguchi T, 2013, INFLAMMATION, V36, P1479, DOI 10.1007/s10753-013-9689-9
   Fein AM, 2000, CRIT CARE CLIN, V16, P289, DOI 10.1016/S0749-0704(05)70111-1
   Gando S, 1996, THROMB HAEMOSTASIS, V75, P224
   Gando S, 1998, CRIT CARE MED, V26, P2005, DOI 10.1097/00003246-199812000-00030
   Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338
   Georgescu A, 2007, EUR J PHARMACOL, V570, P149, DOI 10.1016/j.ejphar.2007.05.031
   Ghasemzadeh M, 2013, THROMB RES, V131, P191, DOI 10.1016/j.thromres.2012.11.028
   Hayakawa M, 2010, SHOCK, V33, P14, DOI 10.1097/SHK.0b013e3181aa95c4
   Hirasawa H, 2009, WORLD J GASTROENTERO, V15, P4132, DOI 10.3748/wjg.15.4132
   Hotchkiss RS, 2009, NAT MED, V15, P496, DOI 10.1038/nm0509-496
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Johnston CJ, 2003, CHEST, V124, P653, DOI 10.1378/chest.124.2.653
   Kambas K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00385
   Katz JN, 2011, CHEST, V139, P658, DOI 10.1378/chest.10-1971
   Kawahara Y, 2010, DIS ESOPHAGUS, V23, P329, DOI 10.1111/j.1442-2050.2009.01010.x
   Khadaroo RG, 2002, CRIT CARE CLIN, V18, P127, DOI 10.1016/S0749-0704(03)00069-1
   Klok FA, 2012, SEMIN RESP CRIT CARE, V33, P199, DOI 10.1055/s-0032-1311800
   Kubota T, 2011, CELL METAB, V13, P294, DOI 10.1016/j.cmet.2011.01.018
   Kuhlen R, 2007, Pneumologie, V61, P249, DOI 10.1055/s-2007-959172
   Lee JH, 2002, BRIT J HAEMATOL, V118, P1087, DOI 10.1046/j.1365-2141.2002.03748.x
   LEIBOVICI L, 1995, QJM-INT J MED, V88, P181
   Li P, 1998, J CARDIOVASC PHARM, V32, P198, DOI 10.1097/00005344-199808000-00005
   Lobato EB, 2006, BRIT J ANAESTH, V96, P317, DOI 10.1093/bja/ael009
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Fiusa MML, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0327-2
   Manns JM, 2002, THROMB HAEMOSTASIS, V87, P873, DOI 10.1055/s-0037-1613099
   Martinod K, 2014, BLOOD, V123, P2768, DOI 10.1182/blood-2013-10-463646
   McDonald B, 2012, CELL HOST MICROBE, V12, P324, DOI 10.1016/j.chom.2012.06.011
   Miller TW, 2013, MATRIX BIOL, V32, P316, DOI 10.1016/j.matbio.2013.02.009
   Mizock BA, 2000, CRIT CARE CLIN, V16, P319, DOI 10.1016/S0749-0704(05)70112-3
   Moerland M, 2011, J CARDIOVASC PHARM, V58, P575, DOI 10.1097/FJC.0b013e31822f6b8d
   Nakanuma S, 2015, EXP THER MED, V9, P1119, DOI 10.3892/etm.2015.2245
   NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633
   Nurden AT, 2007, ENDOCRINOLOGY, V148, P3053, DOI 10.1210/en.2007-0506
   Ogura H, 2007, SHOCK, V28, P411, DOI 10.1097/shk.0b013e31804f7844
   Oliveira Raquel Hermes Rosa, 2006, J. bras. pneumol., V32, P35, DOI 10.1590/S1806-37132006000100009
   Pakala R, 1999, ARTERIOSCL THROM VAS, V19, P2316, DOI 10.1161/01.ATV.19.10.2316
   Parenti A, 2002, CARDIOVASC RES, V55, P201, DOI 10.1016/S0008-6363(02)00326-7
   Pohlers D, 2009, BBA-MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004
   Proudfoot AG, 2011, DIS MODEL MECH, V4, P145, DOI 10.1242/dmm.006213
   Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036
   Raghavendran K, 2008, CURR MED CHEM, V15, P1911, DOI 10.2174/092986708785132942
   RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117
   Russwurm S, 2002, SHOCK, V17, P263, DOI 10.1097/00024382-200204000-00004
   Sakai S, 2014, DIGEST DIS SCI, V59, P787, DOI 10.1007/s10620-013-2963-8
   Santin AD, 2000, J VIROL, V74, P4729, DOI 10.1128/JVI.74.10.4729-4737.2000
   Schlom J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22546
   Schror K, 2002, DIABETES OBES METAB, V4, pS14, DOI 10.1046/j.1463-1326.2002.0040s2s14.x
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   Sun B, 2007, CELL SIGNAL, V19, P1765, DOI 10.1016/j.cellsig.2007.03.012
   Sundar KM, 2013, INDIAN J CRIT CARE M, V17, P162, DOI 10.4103/0972-5229.117054
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068
   Taylor Jodie H, 2005, Surg Infect (Larchmt), V6, P233, DOI 10.1089/sur.2005.6.233
   Terme M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25156
   Utsunomiya K, 2012, VASC HEALTH RISK MAN, V8, P429, DOI 10.2147/VHRM.S32357
   van der Poll T, 2012, CURR VASC PHARMACOL, V10, P632, DOI 10.2174/157016112801784549
   Vincent JL, 2005, CRIT CARE CLIN, V21, P469, DOI 10.1016/j.ccc.2005.04.002
   Wang S, 2014, J NUTR BIOCHEM, V25, P1, DOI 10.1016/j.jnutbio.2013.09.001
   Wieser V, 2013, ARCH IMMUNOL THER EX, V61, P119, DOI 10.1007/s00005-012-0210-1
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671
   Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001
NR 73
TC 33
Z9 41
U1 0
U2 9
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD JUL-AUG
PY 2016
VL 30
IS 4
BP 341
EP 349
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DQ8UN
UT WOS:000379486900002
PM 27381595
DA 2023-08-21
ER

PT J
AU Yu, JY
   Ma, ZS
   Shetty, S
   Ma, MS
   Fu, J
AF Yu, Jinyan
   Ma, Zhongsen
   Shetty, Sreerama
   Ma, Mengshi
   Fu, Jian
TI Selective HDAC6 inhibition prevents TNF-alpha-induced lung endothelial
   cell barrier disruption and endotoxin-induced pulmonary edema
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE catenin; ECs/HPMECs/HUVECs/MPVECs; histone deacetylase 6; ALI/ARDS; tubulin 
ID VE-CADHERIN; ACTIN; MICROTUBULES; TUBULIN; CYTOSKELETON; ACETYLATION;
   DYSFUNCTION; SURVIVAL; KINASE; PHOSPHORYLATION
AB Selective HDAC6 inhibition prevents TNF-alpha-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema. Am J Physiol Lung Cell Mol Physiol 311:L39-L47, 2016. First published May 17, 2016; doi:10.1152/ajplung.00051.2016.-Lung endothelial damage contributes to the pathogenesis of acute lung injury. New strategies against lung endothelial barrier dysfunction may provide therapeutic benefits against lung vascular injury. Cell-cell junctions and microtubule cytoskeleton are basic components in maintaining endothelial barrier integrity. HDAC6, a deacetylase primarily localized in the cytoplasm, has been reported to modulate nonnuclear protein function through deacetylation. Both alpha-tubulin and beta-catenin are substrates for HDAC6. Here, we examined the effects of tubastatin A, a highly selective HDAC6 inhibitor, on TNF-alpha induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema. Selective HDAC6 inhibition by tubastatin A blocked TNF-alpha-induced lung endothelial cell hyperpermeability, which was associated with increased alpha-tubulin acetylation and microtubule stability. Tubastatin A pretreatment inhibited TNF-alpha-induced endothelial cell contraction and actin stress fiber formation with reduced myosin light chain phosphorylation. Selective HDAC6 inhibition by tubastatin A also induced beta-catenin acetylation in human lung endothelial cells, which was associated with increased membrane localization of beta-catenin and stabilization of adherens junctions. HDAC6 knockdown by small interfering RNA also prevented TNF-alpha-induced barrier dysfunction and increased alpha-tubulin and beta-catenin acetylation in endothelial cells. Furthermore, in a mouse model of endotoxemia, tubastatin A was able to prevent endotoxin-induced deacetylation of alpha-tubulin and beta-catenin in lung tissues, which was associated with reduced pulmonary edema. Collectively, our data indicate that selective HDAC6 inhibition by tubastatin A is a potent approach against lung endothelial barrier dysfunction.
C1 [Yu, Jinyan; Ma, Zhongsen; Ma, Mengshi] Jilin Univ, Hosp 2, Changchun, Jilin, China.
C1 [Yu, Jinyan; Ma, Mengshi; Fu, Jian] Univ Kentucky, Coll Med, Ctr Res Environm Dis, Lexington, KY 40536, United States.
C1 [Yu, Jinyan; Fu, Jian] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, Lexington, KY 40536, United States.
C1 [Shetty, Sreerama] Univ Texas Hlth Sci Ctr, Ctr Biomed Res, Tyler, TX, United States.
C3 Jilin University; University of Kentucky; University of Kentucky;
   University of Texas System; University of Texas at Tyler; University of
   Texas-Health Sciences Center at Tyler (UTHSCT)
RP Fu, J (corresponding author), Univ Kentucky, Coll Med, Ctr Res Environm Dis, Lexington, KY 40536 USA.; Fu, J (corresponding author), Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.
EM jian.fu@uky.edu
CR Alieva IB, 2014, BIOCHEMISTRY-MOSCOW+, V79, P964, DOI 10.1134/S0006297914090119
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Bobrowska A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020696
   Bogatcheva NV, 2008, MICROVASC RES, V76, P202, DOI 10.1016/j.mvr.2008.06.003
   Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v
   Chang ZG, 2015, J TRAUMA ACUTE CARE, V79, P905, DOI 10.1097/TA.0000000000000784
   Chattopadhyay S, 2013, MBIO, V4
   Cheng X, 2015, J SURG RES, V197, P39, DOI 10.1016/j.jss.2015.02.070
   Choi SY, 2015, VASC PHARMACOL, V72, P130, DOI 10.1016/j.vph.2015.04.006
   Coles CH, 2015, CURR BIOL, V25, pR677, DOI 10.1016/j.cub.2015.06.020
   D'Alessandro M, 2015, DEV CELL, V35, P186, DOI 10.1016/j.devcel.2015.09.018
   Dejana E, 2013, PROG MOL BIOL TRANSL, V116, P119, DOI 10.1016/B978-0-12-394311-8.00006-6
   Fu J, 2005, J BIOL CHEM, V280, P3178, DOI 10.1074/jbc.M410044200
   Gao R, 2015, AM J PHYSIOL-LUNG C, V308, pL847, DOI 10.1152/ajplung.00274.2014
   Geiger RC, 2009, AM J RESP CELL MOL, V40, P76, DOI 10.1165/rcmb.2007-0307OC
   GOLDBLUM SE, 1993, AM J PHYSIOL, V264, pC894, DOI 10.1152/ajpcell.1993.264.4.C894
   Han JY, 2013, BLOOD, V122, P4140, DOI 10.1182/blood-2013-03-491423
   Hordijk PL, 1999, J CELL SCI, V112, P1915
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Iaconelli J, 2015, ACS CHEM BIOL, V10, P883, DOI 10.1021/cb500838r
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636
   Lee J, 2015, INT J RHEUM DIS, V18, P514, DOI 10.1111/1756-185X.12501
   Li LF, 2015, SCI REP-UK, V5, DOI 10.1038/srep08895
   Li YQ, 2015, J TRAUMA ACUTE CARE, V78, P378, DOI 10.1097/TA.0000000000000510
   Li Y, 2008, J BIOL CHEM, V283, P12686, DOI 10.1074/jbc.C700185200
   Marcos-Ramiro B, 2014, THROMB HAEMOSTASIS, V112, P1088, DOI 10.1160/TH14-04-0299
   Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682
   McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401
   Ochoa CD, 2011, AM J PHYSIOL-LUNG C, V300, pL132, DOI 10.1152/ajplung.00185.2010
   Perdiz D, 2011, CELL SIGNAL, V23, P763, DOI 10.1016/j.cellsig.2010.10.014
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Prasain N, 2009, MICROVASC RES, V77, P53, DOI 10.1016/j.mvr.2008.09.012
   Rodrigues SF, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.978720
   Shivanna M, 2009, EXP EYE RES, V89, P950, DOI 10.1016/j.exer.2009.08.004
   Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027
   Szyk A, 2014, CELL, V157, P1405, DOI 10.1016/j.cell.2014.03.061
   Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431
   Trani M, 2015, CURR OPIN HEMATOL, V22, P267, DOI 10.1097/MOH.0000000000000137
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565
   Vishwakarma S, 2013, INT IMMUNOPHARMACOL, V16, P72, DOI 10.1016/j.intimp.2013.03.016
   Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639
   Warfel JM, 2011, TOXINS, V3, P1278, DOI 10.3390/toxins3101278
   Woan KV, 2015, MOL ONCOL, V9, P1447, DOI 10.1016/j.molonc.2015.04.002
   Yan B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110718
   Yang JJ, 2015, CELL MOL LIFE SCI, V72, P4849, DOI 10.1007/s00018-015-1973-4
   Youn GS, 2015, GLIA, V63, P1953, DOI 10.1002/glia.22865
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
   Zhao T, 2016, J TRAUMA ACUTE CARE, V80, P34, DOI 10.1097/TA.0000000000000897
   Zhao T, 2014, J SURG RES, V190, P647, DOI 10.1016/j.jss.2014.01.056
   Zhao T, 2014, SURGERY, V156, P235, DOI 10.1016/j.surg.2014.03.033
   Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813
NR 55
TC 32
Z9 32
U1 1
U2 13
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL 1
PY 2016
VL 311
IS 1
BP L39
EP L47
DI 10.1152/ajplung.00051.2016
PG 9
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA DS4RE
UT WOS:000380767700005
PM 27190059
OA Bronze
DA 2023-08-21
ER

PT J
AU Lee, JY
   Linge, HM
   Ochani, K
   Lin, K
   Miller, EJ
AF Lee, Ji Young
   Linge, Helena M.
   Ochani, Kanta
   Lin, Ke
   Miller, Edmund J.
TI N-Ethylmaleimide Sensitive Factor (NSF) Inhibition Prevents Vascular
   Instability following Gram-Positive Pulmonary Challenge
SO PLOS ONE
LA English
DT Article
ID WEIBEL-PALADE BODIES; ENDOTHELIAL-CELLS; ANGIOPOIETIN-2; EXOCYTOSIS;
   MORTALITY; SEPSIS; CARE
AB Background
   The Acute Respiratory Distress Syndrome (ARDS), remains a significant source of morbidity and mortality in critically ill patients. Pneumonia and sepsis are leading causes of ARDS, the pathophysiology of which includes increased pulmonary microvascular permeability and hemodynamic instability resulting in organ dysfunction. We hypothesized that N-ethylmaleimide sensitive factor (NSF) regulates exocytosis of inflammatory mediators, such as Angiopoietin-2 (Ang-2), and cytoskeletal stability by modulating myosin light chain (MLC) phosphorylation. Therefore, we challenged pulmonary cells, in vivo and in vitro, with Gram Positive bacterial cell wall components, lipoteichoic acid (LTA), and peptidoglycan (PGN) and examined the effects of NSF inhibition.
   Methods
   Mice were pre-treated with an inhibitor of NSF, TAT-NSF700 (to prevent Ang-2 release). After 30min, LTA and PGN (or saline alone) were instilled intratracheally. Pulse oximetry was assessed in awake mice prior to, and 6 hour post instillation. Post mortem, tissues were collected for studies of inflammation and Ang-2. In vitro, pulmonary endothelial cells were assessed for their responses to LTA and PGN.
   Results
   Pulmonary challenge induced signs of airspace and systemic inflammation such as changes in neutrophil counts and protein concentration in bronchoalveolar lavage fluid and tissue Ang-2 concentration, and decreased physiological parameters including oxygen saturation and pulse distention. TAT-NSF700 pre-treatment reduced LTA-PGN induced changes in lung tissue Ang-2, oxygen saturation and pulse distention. In vitro, LTA-PGN induced a rapid (<2 min) release of Ang-2, which was significantly attenuated by TAT-NSF700 or anti TLR2 antibody. Furthermore, TAT-NSF700 reduced LTA-PGN-induced MLC phosphorylation at low concentrations of 1-10 nM.
   Conclusions
   TAT-NSF700 decreased Ang-2 release, improved oxygen saturation and pulse distention following pulmonary challenge by inhibiting MLC phosphorylation, an important component of endothelial cell retraction. The data suggest that inhibition of NSF in pneumonia and sepsis may be beneficial to prevent the pulmonary microvascular and hemodynamic instability associated with ARDS.
C1 [Lee, Ji Young; Miller, Edmund J.] Elmezzi Grad Sch Mol Med, Manhasset, NY 11030, United States.
C1 [Linge, Helena M.; Ochani, Kanta; Lin, Ke; Miller, Edmund J.] Feinstein Inst Med Res, Ctr Heart & Lung Res, Manhasset, NY, United States.
C1 [Miller, Edmund J.] Hofstra North Shore LIJ Med Sch, Hempstead, NY, United States.
C1 [Lee, Ji Young] Univ S Alabama, Dept Pulm & Crit Care Med, Mobile, AL 36688, United States.
C3 Northwell Health; Northwell Health; Hofstra University; University of
   South Alabama
RP Lee, JY (corresponding author), Elmezzi Grad Sch Mol Med, Manhasset, NY 11030 USA.; Lee, JY (corresponding author), Univ S Alabama, Dept Pulm & Crit Care Med, Mobile, AL 36688 USA.
EM jiyounglee98@gmail.com
OI Linge, Helena/0000-0002-8919-0300; Lee, Ji Young/0000-0002-8005-2446
FU Elmezzi Graduate School of Molecular Medicine; Feinstein Institute for
   Medical Research
FX This study was supported by funds from The Elmezzi Graduate School of
   Molecular Medicine and The Feinstein Institute for Medical Research.
CR Aikawa N, 1996, Nihon Geka Gakkai Zasshi, V97, P771
   Aird WC, ROLE ENDOTHELIUM SEV, P3765
   Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Calvert JW, 2007, CIRC RES, V101, P1247, DOI 10.1161/CIRCRESAHA.107.162610
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Friedman G, 1998, INTENS CARE MED, V24, P118, DOI 10.1007/s001340050531
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Goel A, 2010, CIRC RES, V107, P242, DOI 10.1161/CIRCRESAHA.109.210229
   Linge HM, 2015, EXP LUNG RES, V41, P216, DOI 10.3109/01902148.2014.999174
   Linge HM, 2010, CRITICAL CARE S2, V14, pP8
   Matsushita K, 2005, MOL PHARMACOL, V67, P1137, DOI 10.1124/mol.104.004275
   Morrell CN, 2005, J PHARMACOL EXP THER, V314, P155, DOI 10.1124/jpet.104.082529
   National Institutes of Health. National Heart LaBI, 2007, NAT HEART LABI AC RE
   Oynebraten I, 2004, BLOOD, V104, P314, DOI 10.1182/blood-2003-08-2891
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Pittoni GM, 2009, CURR OPIN ANESTHESIO, V22, P232, DOI 10.1097/ACO.0b013e328323f9a8
   Ricciuto DR, 2011, CRIT CARE MED, V39, P702, DOI 10.1097/CCM.0b013e318206d285
   Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P1002, DOI 10.1161/01.ATV.0000209501.56852.6c
   Roviezzo F, 2005, J PHARMACOL EXP THER, V314, P738, DOI 10.1124/jpet.105.086553
   Sheldon R, 1993, ROLE MYOSIN LIGHT CH, pL606
   Shen Q, 2010, MYOSIN LIGHT CHAIN K, P272
   Siner JM, 2009, SHOCK, V31, P348, DOI 10.1097/SHK.0b013e318188bd06
   SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2
   Tran Q. -K., 2006, V176, P145
   Valentijn KM, 2011, BLOOD, V117, P5033, DOI 10.1182/blood-2010-09-267492
   Valentijn KM, 2010, MULTIGRANULAR EXOCYT
   Vincent JL, 1998, J ANTIMICROB CHEMOTH, V41, P9, DOI 10.1093/jac/41.suppl_1.9
   Wu SW, 2014, PULM CIRC, V4, P110, DOI 10.1086/674879
   Yamakuchi Munekazu, 2008, V440, P203, DOI 10.1007/978-1-59745-178-9_15
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
   Zupancic G, 2002, J PHYSIOL-LONDON, V544, P741, DOI 10.1113/jphysiol.2002.027490
NR 32
TC 5
Z9 5
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2016
VL 11
IS 6
AR e0157837
DI 10.1371/journal.pone.0157837
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DQ0AM
UT WOS:000378859400021
PM 27355324
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Zhang, Y
   Shan, PY
   Srivastava, A
   Jiang, G
   Zhang, XC
   Lee, PJ
AF Zhang, Yi
   Shan, Peiying
   Srivastava, Anup
   Jiang, Ge
   Zhang, Xuchen
   Lee, Patty J.
TI An Endothelial Hsp70-TLR4 Axis Limits Nox3 Expression and Protects
   Against Oxidant Injury in Lungs
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID NADPH OXIDASE; CUTTING EDGE; TLR4; DEFICIENCY; CELLS; ROS; FLUORESCENCE;
   DYSFUNCTION; ACTIVATION; RESISTANCE
AB Aims: Oxidants play a critical role in the pathogenesis of acute lung injury (ALI). Nox3 is a novel member of the NADPH oxidase (Nox) family of oxidant-generating enzymes, which our laboratory had previously identified to be induced in the lungs of TLR4(-/-) mice. However, the physiologic role of Nox3 induction in lungs and its precise relationship to TLR4 are unknown. Furthermore, the cell compartment involved and the signaling mechanisms of Nox3 induction are unknown. Results: We identified that Nox3 is regulated by heat shock protein 70 (Hsp70) signaling via a TLR4-Trif-signal transducer and activator of transcription 3 (Stat3) pathway and that Nox3 induction leads to increased oxidant injury and death in mice and lung endothelial cells. We generated Nox3(-/-)/TLR4(-/-) double knockout mice, endothelial-targeting lentiviral silencing constructs, and endothelial-targeted Stat3(-/-) mice to specifically demonstrate that Nox3 induction is responsible for the pro-oxidant, proapoptotic phenotype of TLR4(-/-) mice. We also show that an endothelial Hsp70-TLR4-Trif-Stat3 axis is required to suppress deleterious Nox3 induction. Innovation: To date, a physiologic role for Nox3 in oxidant-induced ALI has not been identified. In addition, we generated unique double knockout mice and endothelial-targeted lentiviral silencing constructs to specifically demonstrate the role of a TLR4 signaling pathway in regulating pro-oxidant generation. Conclusions: We identified an endothelial TLR4-Trif antioxidant pathway that leads to the inhibition of a novel NADPH oxidase, Nox3, in lungs and lung endothelial cells. We also identified the role of a TLR4 ligand, Hsp70, in suppressing Nox3 in basal and pro-oxidant conditions. These studies identify potentially new therapeutic targets in oxidant-induced ALI.
C1 [Zhang, Yi; Shan, Peiying; Srivastava, Anup; Jiang, Ge; Lee, Patty J.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, POB 208057, New Haven, CT 06520, United States.
C1 [Zhang, Xuchen] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520, United States.
C1 [Zhang, Xuchen] VA Connecticut Healthcare Syst, New Haven, CT, United States.
C3 Yale University; Yale University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Connecticut Healthcare System
RP Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, POB 208057, New Haven, CT 06520 USA.
EM patty.lee@yale.edu
RI zhang, xu/GYE-3558-2022
OI Zhang, Xuchen/0000-0002-1484-4672
FU NIH [HL 071595, HL 090660, FAMRI 82384]
FX The authors thank Dr. Tej Pandita for the Hsp70<SUP>-/-</SUP> mice, Dr.
   S. Akira for TLR4<SUP>-/-</SUP> mice, and Dr. X. Fu for endothelial
   Stat3-deficient mice (Stat3<SUP>E-/-</SUP>). P.J.L. was supported by NIH
   Grants, HL 071595, HL 090660, and FAMRI 82384.
CR Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200
   Benipal B, 2015, REDOX BIOL, V4, P321, DOI 10.1016/j.redox.2015.01.011
   Cai Hua, 2007, V139, P293
   Cantu E, 2015, J THORAC CARDIOV SUR, V149, P596, DOI 10.1016/j.jtcvs.2014.09.077
   Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8
   Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P372, DOI 10.1089/ars.2012.4886
   Frame FM, 2010, EXP CELL RES, V316, P3161, DOI 10.1016/j.yexcr.2010.08.004
   Gao D, 2010, J BIOL CHEM, V285, P29965, DOI 10.1074/jbc.M110.128694
   Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200
   Hecker L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008182
   Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004
   Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077
   Konior A, 2014, ANTIOXID REDOX SIGN, V20, P2794, DOI 10.1089/ars.2013.5607
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   Liu XY, 2015, TUMOR BIOL, V36, P1493, DOI 10.1007/s13277-014-2639-9
   Montezano AC, 2015, CAN J CARDIOL, V31, P631, DOI 10.1016/j.cjca.2015.02.008
   Morimoto H, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.127647
   Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504
   Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589
   Peshavariya HM, 2007, FREE RADICAL RES, V41, P699, DOI 10.1080/10715760701297354
   Qureshi ST, 2006, J IMMUNOL, V176, P4950, DOI 10.4049/jimmunol.176.8.4950
   Ruwanpura SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078095
   Rybak LP, 2012, CELL MOL LIFE SCI, V69, P2429, DOI 10.1007/s00018-012-1016-3
   Sanders YY, 2015, FREE RADICAL BIO MED, V79, P197, DOI 10.1016/j.freeradbiomed.2014.12.008
   Siner JM, 2007, FASEB J, V21, P1422, DOI 10.1096/fj.06-6661com
   Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]
   Takyar S, 2016, FASEB J, V30, P1317, DOI 10.1096/fj.15-275024
   Valente AJ, 2007, FREE RADICAL BIO MED, V43, P384, DOI 10.1016/j.freeradbiomed.2007.04.022
   Wojtala A, 2014, METHOD ENZYMOL, V542, P243, DOI 10.1016/B978-0-12-416618-9.00013-3
   Wu F, 2014, AM J PHYSIOL-LUNG C, V307, pL987, DOI 10.1152/ajplung.00063.2014
   Zhang XC, 2005, J IMMUNOL, V175, P4834, DOI 10.4049/jimmunol.175.8.4834
   Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200
   Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje
   Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139
   Zhang Y, 2014, J IMMUNOL, V192, P5296, DOI 10.4049/jimmunol.1400653
   Zhang Y, 2013, FASEB J, V27, P4041, DOI 10.1096/fj.13-231225
   Zhang Y, 2013, J IMMUNOL, V191, P1393, DOI 10.4049/jimmunol.1300052
NR 38
TC 13
Z9 17
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUN 10
PY 2016
VL 24
IS 17
BP 991
EP 1012
DI 10.1089/ars.2015.6505
PG 22
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DO8PO
UT WOS:000378045800003
PM 26905942
OA Green Published
DA 2023-08-21
ER

PT J
AU Chichger, H
   Braza, J
   Duong, H
   Boni, G
   Harrington, EO
AF Chichger, Havovi
   Braza, Julie
   Duong, Huetran
   Boni, Geraldine
   Harrington, Elizabeth O.
TI Select Rab GTPases Regulate the Pulmonary Endothelium via Endosomal
   Trafficking of Vascular Endothelial-Cadherin
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE endocytosis; Rab GTPase; ECs/HPMECs/HUVECs/MPVECs; VE-cadherin; ALI/ARDS 
ID GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; VE-CADHERIN; BARRIER
   FUNCTION; IN-VIVO; LEUKOCYTE EXTRAVASATION; CELL PERMEABILITY; ESCORT
   PROTEIN; ERK PATHWAY; LUNG INJURY
AB Pulmonary edema occurs in settings of acute lung injury, in diseases, such as pneumonia, and in acute respiratory distress syndrome. The lung interendothelial junctions are maintained in part by vascular endothelial (VE)-cadherin, an adherens junction protein, and its surface expressionis regulated by endocytic trafficking. TheRab family of small GTPases are regulators of endocytic trafficking. The key trafficking pathways are regulated by Rab4, -7, and -9. Rab4 regulates the recycling of endosomes to the cell surface througha rapid-shuttle process, whereas Rab7 and -9 regulate trafficking to the late endosome/lysosome for degradation or from the trans-Golgi network to the late endosome, respectively. We recently demonstrated a role for the endosomal adaptor protein, p18, in regulation of the pulmonary endothelium through enhanced recycling of VE-cadherin to adherens junction. Thus, we hypothesized that Rab4, -7, and -9 regulate pulmonary endothelial barrier function through modulating trafficking of VE-cadherin-positive endosomes. We used Rab mutants with varying activities and associations to the endosome to study endothelial barrier function in vitro and in vivo. Our study demonstrates a key role for Rab4 activation and Rab9 inhibition in regulation of vascular permeability through enhanced VE-cadherin expression at the interendothelial junction. We further showed that endothelial barrier function mediated through Rab4 is dependent on extracellular signal-regulated kinase phosphorylation and activity. Thus, we demonstrate that Rab4 and -9 regulate VE-cadherin levels at the cell surface to modulate the pulmonary endothelium through extracellular signal-regulated kinase-dependent and - independent pathways, respectively. We propose that regulating select Rab GTPases represents novel therapeutic strategies for patients suffering with acute respiratory distress syndrome.
C1 Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI, United States.
C1 Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912, United States.
C1 Anglia Ruskin Univ, Biomed Res Grp, Dept Life Sci, Fac Sci & Technol, OPT 024,East Rd, Cambridge CB1 1PT, England, United Kingdom.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University
RP Chichger, H (corresponding author), Anglia Ruskin Univ, Biomed Res Grp, Dept Life Sci, Fac Sci & Technol, OPT 024,East Rd, Cambridge CB1 1PT, England.
EM havovi.chichger@anglia.ac.uk
RI Chichger, Havovi/Y-7117-2019
OI Chichger, Havovi/0000-0002-8549-7583; Harrington,
   Elizabeth/0000-0002-3207-5301
FU National Heart, Lung, and Blood Institute [R01 HL067795]; American Heart
   Association [10GRNT4160055, 13POST16860031]; Center of Biomedical
   Research Excellence National Institute of General Medical Sciences award
   [5P20 GM103652]; University Medicine Foundation of Rhode Island Hospital
   grant
FX This work was supported by National Heart, Lung, and Blood Institute
   grant R01 HL067795, American Heart Association grant 10GRNT4160055,
   Center of Biomedical Research Excellence National Institute of General
   Medical Sciences award 5P20 GM103652, and University Medicine Foundation
   of Rhode Island Hospital grant (E.O.H.); H.C. was supported by American
   Heart Association grant 13POST16860031.
CR Anastasiadis PZ, 2000, J CELL SCI, V113, P1319
   Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8
   Bastin G, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.466888
   Bhuin T, 2010, CELL BIOL INT, V34, P1113, DOI 10.1042/CBI20100155
   Bridges D, 2012, J BIOL CHEM, V287, P20913, DOI 10.1074/jbc.M111.334060
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525
   Cabrera M, 2013, J BIOL CHEM, V288, P28704, DOI 10.1074/jbc.M113.488213
   Chen TY, 2014, CANCER CELL, V25, P682, DOI 10.1016/j.ccr.2014.03.009
   Chichger H, 2015, AM J RESP CELL MOL, V52, P695, DOI 10.1165/rcmb.2013-0489OC
   Chichger H, 2015, FASEB J, V29, P868, DOI 10.1096/fj.14-257212
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559
   de Leeuw HPJC, 1998, BRIT J HAEMATOL, V103, P15, DOI 10.1046/j.1365-2141.1998.00965.x
   Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601
   FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435
   Flinn RJ, 2010, MOL BIOL CELL, V21, P833, DOI 10.1091/mbc.E09-09-0756
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC
   Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012
   Jones MC, 2009, TRAFFIC, V10, P754, DOI 10.1111/j.1600-0854.2009.00898.x
   Jopling HM, 2014, CELLS-BASEL, V3, P363, DOI 10.3390/cells3020363
   Jopling HM, 2009, ARTERIOSCL THROM VAS, V29, P1119, DOI 10.1161/ATVBAHA.109.186239
   Kabouridis PS, 2006, MOL MEMBR BIOL, V23, P49, DOI 10.1080/09687860500453673
   Kachhap SK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000844
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Klinger JR, 2007, J APPL PHYSIOL, V103, P2084, DOI 10.1152/japplphysiol.00695.2007
   Konstantoulaki M, 2003, AM J PHYSIOL-LUNG C, V285, pL434, DOI 10.1152/ajplung.00075.2003
   Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Li L, 2010, J BIOL CHEM, V285, P19705, DOI 10.1074/jbc.C110.102483
   Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867
   LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x
   LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6
   Nada S, 2009, EMBO J, V28, P477, DOI 10.1038/emboj.2008.308
   Pfeffer SR, 2013, CURR OPIN CELL BIOL, V25, P414, DOI 10.1016/j.ceb.2013.04.002
   Qi JS, 2015, INT J CLIN EXP PATHO, V8, P4963
   Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761
   Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   SASAKI T, 1990, J BIOL CHEM, V265, P2333
   Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0
   Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304
   Shen F, 1996, J BIOL CHEM, V271, P3692
   Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419
   Su G, 2012, AM J RESP CRIT CARE, V185, P58, DOI 10.1164/rccm.201108-1381OC
   Takahashi Y, 2012, BIOCHEM BIOPH RES CO, V417, P1151, DOI 10.1016/j.bbrc.2011.12.082
   VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313
   Wang JF, 2015, P NATL ACAD SCI USA, V112, P148, DOI 10.1073/pnas.1412089112
   Wang YZ, 2007, BLOOD, V110, P962, DOI 10.1182/blood-2007-01-066027
   White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004
   Yang JJ, 2015, INT J BIOL SCI, V11, P868, DOI 10.7150/ijbs.12045
   Yao M, 2009, J IMMUNOL, V183, P1751, DOI 10.4049/jimmunol.0900249
NR 57
TC 9
Z9 11
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUN 1
PY 2016
VL 54
IS 6
BP 769
EP 781
DI 10.1165/rcmb.2015-0286OC
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA DT7XQ
UT WOS:000381702000003
PM 26551054
OA Green Published
DA 2023-08-21
ER

PT J
AU Suzuki, T
   Tada, Y
   Nishimura, R
   Kawasaki, T
   Sekine, A
   Urushibara, T
   Kato, F
   Kinoshita, T
   Ikari, J
   West, J
   Tatsumi, K
AF Suzuki, Toshio
   Tada, Yuji
   Nishimura, Rintaro
   Kawasaki, Takeshi
   Sekine, Ayumi
   Urushibara, Takashi
   Kato, Fumiaki
   Kinoshita, Taku
   Ikari, Jun
   West, James
   Tatsumi, Koichiro
TI Endothelial-to-mesenchymal transition in lipopolysaccharide-induced
   acute lung injury drives a progenitor cell-like phenotype
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; cell transformation; endothelial-to-mesenchymal transition; progenitor cells; ROS 
ID PULMONARY-FIBROSIS; MEDICAL PROGRESS; SEPSIS; STEM; ANGIOGENESIS;
   TRANSDIFFERENTIATION; REGENERATION; CAPACITY; SURVIVAL; PATHWAY
AB Pulmonary vascular endothelial function may be impaired by oxidative stress in endotoxemia-derived acute lung injury. Growing evidence suggests that endothelial-to-mesenchymal transition (EndMT) could play a pivotal role in various respiratory diseases; however, it remains unclear whether EndMT participates in the injury/repair process of septic acute lung injury. Here, we analyzed lipopolysaccharide (LPS)-treated mice whose total number of pulmonary vascular endothelial cells (PVECs) transiently decreased after production of reactive oxygen species (ROS), while the population of EndMT-PVECs significantly increased. NAD(P)H oxidase inhibition suppressed EndMT of PVECs. Most EndMT-PVECs derived from tissue-resident cells, not from bone marrow, as assessed by mice with chimeric bone marrow. Bromodeoxyuridine-incorporation assays revealed higher proliferation of capillary EndMT-PVECs. In addition, EndMT-PVECs strongly expressed c-kit and CD133. LPS loading to human lung microvascular endothelial cells (HMVEC-Ls) induced reversible EndMT, as evidenced by phenotypic recovery observed after removal of LPS. LPS-induced EndMT-HMVEC-Ls had increased vasculogenic ability, aldehyde dehydrogenase activity, and expression of drug resistance genes, which are also fundamental properties of progenitor cells. Taken together, our results demonstrate that LPS induces EndMT of tissue-resident PVECs during the early phase of acute lung injury, partly mediated by ROS, contributing to increased proliferation of PVECs.
C1 [Suzuki, Toshio; Tada, Yuji; Nishimura, Rintaro; Kawasaki, Takeshi; Sekine, Ayumi; Urushibara, Takashi; Kato, Fumiaki; Kinoshita, Taku; Ikari, Jun; Tatsumi, Koichiro] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan.
C1 [West, James] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN, United States.
C3 Chiba University; Vanderbilt University
RP Suzuki, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Respirol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.
EM toshiosuzuki@chiba-u.jp
RI West, James/E-2960-2010
OI West, James/0000-0002-6004-0202; Suzuki, Toshio/0000-0002-0909-0466
FU Ministry of Health, Labor and Welfare of Japan; Japan Agency for Medical
   Research and Development (AMED); Grants-in-Aid for Scientific Research
   [16K19445] Funding Source: KAKEN
FX This work was supported in part by a grant from the Ministry of Health,
   Labor and Welfare of Japan awarded to the Respiratory Failure Research
   Group, and another from the Japan Agency for Medical Research and
   Development (AMED) awarded to the Pulmonary Hypertension Research Group.
CR Altabas V, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/848272
   Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007
   Arciniegas E, 2005, ENDOTHELIUM-J ENDOTH, V12, P193, DOI 10.1080/10623320500227283
   Arciniegas E, 2000, ANAT RECORD, V258, P47, DOI 10.1002/(SICI)1097-0185(20000101)258:1<47::AID-AR6>3.0.CO;2-W
   Arciniegas E, 2007, AM J PHYSIOL-LUNG C, V293, pL1, DOI 10.1152/ajplung.00378.2006
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Burton VJ, 2011, BLOOD, V117, P333, DOI 10.1182/blood-2010-05-285973
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chen XP, 2010, FREE RADICAL RES, V44, P587, DOI 10.3109/10715761003709802
   DeRuiter MC, 1997, CIRC RES, V80, P444, DOI 10.1161/01.RES.80.4.444
   Dimmeler S, 1995, EUR J PHARMACOL, V287, P257, DOI 10.1016/0014-2999(95)00499-8
   Dzau VJ, 2001, HYPERTENSION, V37, P1047, DOI 10.1161/01.HYP.37.4.1047
   Echeverria C, 2014, INFECT IMMUN, V82, P3678, DOI 10.1128/IAI.02158-14
   Echeverria C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094146
   Echeverria C, 2013, J CELL MOL MED, V17, P800, DOI 10.1111/jcmm.12066
   Fang ST, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001407
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Grandel U, 2003, CRIT REV IMMUNOL, V23, P267, DOI 10.1615/CritRevImmunol.v23.i4.20
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Hashimoto N, 2010, AM J RESP CELL MOL, V43, P161, DOI 10.1165/rcmb.2009-0031OC
   He ZY, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-126
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Hurley TD, 2012, ALCOHOL RES-CURR REV, V34, P339
   Ishida Y, 2012, J CLIN INVEST, V122, P711, DOI 10.1172/JCI43027
   Kawasaki T, 2015, AM J RESP CELL MOL, V53, P500, DOI 10.1165/rcmb.2014-0185OC
   Kokudo T, 2008, J CELL SCI, V121, P3317, DOI 10.1242/jcs.028282
   Krishnamurthy S, 2010, CANCER RES, V70, P9969, DOI 10.1158/0008-5472.CAN-10-1712
   Lee IT, 2012, BIOCHEM PHARMACOL, V84, P581, DOI 10.1016/j.bcp.2012.05.005
   Li SC, 2015, MOL MED REP, V11, P4454, DOI 10.3892/mmr.2015.3258
   Lin F, 2012, IUBMB LIFE, V64, P717, DOI 10.1002/iub.1059
   Mahler GJ, 2013, ARTERIOSCL THROM VAS, V33, P121, DOI 10.1161/ATVBAHA.112.300504
   Medici D, 2012, SEMIN CANCER BIOL, V22, P379, DOI 10.1016/j.semcancer.2012.04.004
   Modrykamien Ariel M, 2015, Proc (Bayl Univ Med Cent), V28, P163
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Montorfano I, 2014, LAB INVEST, V94, P1068, DOI 10.1038/labinvest.2014.100
   Nishimura R, 2015, AM J PHYSIOL-LUNG C, V308, pL746, DOI 10.1152/ajplung.00243.2014
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350
   Peters K, 2003, CARDIOVASC RES, V60, P49, DOI 10.1016/S0008-6363(03)00397-3
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sakao S, 2007, FASEB J, V21, P3640, DOI 10.1096/fj.07-8432com
   Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735
   Schniedermann J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-50
   Unno K, 2012, CIRC RES, V110, P1355, DOI 10.1161/CIRCRESAHA.111.243014
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220
   Wort SJ, 1999, BRIT MED BULL, V55, P30, DOI 10.1258/0007142991902286
   Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513
   Zhu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep05524
NR 54
TC 20
Z9 22
U1 2
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUN 1
PY 2016
VL 310
IS 11
BP L1185
EP L1198
DI 10.1152/ajplung.00074.2016
PG 14
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA DN9YB
UT WOS:000377435500017
PM 27106288
OA Bronze
DA 2023-08-21
ER

PT J
AU Wang, GY
   Zhang, JW
   Xu, CM
   Han, X
   Gao, YY
   Chen, HL
AF Wang, Guanyu
   Zhang, Jingwen
   Xu, Caiming
   Han, Xiao
   Gao, Yanyan
   Chen, Hailong
TI Inhibition of SOCs Attenuates Acute Lung Injury Induced by Severe Acute
   Pancreatitis in Rats and PMVECs Injury Induced by Lipopolysaccharide
SO INFLAMMATION
LA English
DT Article
DE ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; apoptosis; SOCs 
ID PROSTATE-CANCER CELLS; CRAC CHANNEL; APOPTOSIS; BAX; STORE;
   INTERLEUKIN-6; ACTIVATION; BARRIER; ORAI1; STIM1
AB Acute lung injury (ALI) is a critical complication of the severe acute pancreatitis (SAP), characterized by increased pulmonary permeability with high mortality. Pulmonary microvascular endothelial cells (PMVECs) injury and apoptosis play a key role in ALI. Previous studies indicated that store-operated calcium entry (SOCE) could regulate a variety of cellular processes. The present study was to investigate the effects of SOCE inhibition on ALI induced by SAP in Sprague-Dawley rats, and PMVECs injury induced by lipopolysaccharide (LPS). Rat model of SAP-associated ALI were established by the retrograde infusion of sodium deoxycholate. Serum levels of amylase, TNF-alpha, and IL-6, histological changes, water content of the lung, oxygenation index, and ultrastructural changes of PMVECs were examined in ALI rats with or without store-operated Ca2+ channels (SOCs) pharmacological inhibitor (2-aminoethoxydiphenyl borate, 2-APB) pretreatment. For in vitro studies, PMVECs were transiently transfected with or without small interfering RNA (siRNA) against calcium release-activated calcium channel protein1 (Orai1) and stromal interaction molecule1 (STIM1), the two main molecular constituents of SOCs, then exposed to LPS. The viability of PMVECs was determined. The expression of STIM1, Orai1, Bax, and caspase3, both in lung tissue and in PMVECs, were assessed by quantitative real-time PCR and western blot. Administration of sodium deoxycholate upregulated the expression of SOCs proteins in lung tissue. Similarly, the SOCs proteins were increased in PMVECs induced by LPS. 2-APB reduced the serum levels of amylase, TNF-alpha, and IL-6, and attenuated lung water content and histological findings. In addition, the decreased oxygenation index and ultrastructural damage in PMVECs associated with SAP were ameliorated after administration of 2-APB. Knockdown of STIM1 and Orai1 inhibited LPS-induced PMVECs death. Furthermore, blockade of SOCE significantly suppressed Orai1, STIM1, Bax, and caspase3 expression both in vivo and in vitro. These results suggest that SOCE may play a critical role in SAP-associated ALI and the protective effects of inhibition of SOCs could be mediated, at least partially, by restraining mitochondrial associated apoptosis of PMVECs.
C1 [Wang, Guanyu; Zhang, Jingwen; Xu, Caiming; Han, Xiao] Dalian Med Univ, Dalian 116044, Liaoning, China.
C1 [Gao, Yanyan] Dalian Municipal Cent Hosp, Dept Cent Lab, Dalian 116033, Liaoning, China.
C1 [Chen, Hailong] Dalian Med Univ, Affiliated Hosp 1, Dept Acute Abdominal Surg, 222 ZhongShan Rd, Dalian 116011, Liaoning, China.
C3 Dalian Medical University; Dalian Medical University
RP Chen, HL (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Dept Acute Abdominal Surg, 222 ZhongShan Rd, Dalian 116011, Liaoning, Peoples R China.
EM hailongchen2014@yeah.net
RI Zhang, Jing/GWZ-7332-2022; Zhang, Junwen/L-5554-2016; Xu,
   Caiming/CAA-3267-2022; Xu, Caiming/AAG-9883-2022
OI Zhang, Junwen/0000-0001-8041-1608; Xu, Caiming/0000-0001-7794-2301; 
FU National Natural Science Foundation of China [81173452, 81573751]; Basic
   Research Fund of Key Laboratory of Liaoning provincial education
   department [LZ2014042]
FX This study was supported by National Natural Science Foundation of China
   (81173452, 81573751), and Basic Research Fund of Key Laboratory of
   Liaoning provincial education department (LZ2014042).
CR Aoun E, 2009, PANCREATOLOGY, V9, P777, DOI 10.1159/000214191
   Buter A, 2002, BRIT J SURG, V89, P298, DOI 10.1046/j.0007-1323.2001.02025.x
   Chang Y, 2008, MOL BIOL REP, V35, P285, DOI 10.1007/s11033-007-9083-5
   De Campos Tercio, 2007, Surg Infect (Larchmt), V8, P107, DOI 10.1089/sur.2006.011
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152
   Ikei S, 1998, J GASTROEN HEPATOL, V13, P1274, DOI 10.1046/j.1440-1746.1998.01793.x
   Li N, 2008, J CELL PHYSIOL, V216, P172, DOI 10.1002/jcp.21385
   Li N, 2009, AM J PHYSIOL-CELL PH, V296, pC267, DOI 10.1152/ajpcell.00390.2008
   Li Y., 2013, MOL CARDIOLOGY CHINA, P501
   Liu ZB, 2009, J CELL BIOCHEM, V108, P195, DOI 10.1002/jcb.22241
   Lodola F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042541
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Malleo G, 2007, THESCIENTIFICWORLDJO, V7, P431, DOI 10.1100/tsw.2007.98
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Mayer J, 1999, PANCREAS, V19, P62, DOI 10.1097/00006676-199907000-00010
   Meng G, 2010, J OCCUP HEALTH, V52, P48, DOI 10.1539/joh.L9047
   Mizuta M, 2008, BIOL PHARM BULL, V31, P386, DOI 10.1248/bpb.31.386
   Moccia F, 2014, CURR MOL MED, V14, P457, DOI 10.2174/1566524013666131118113410
   Motiani RK, 2013, PFLUG ARCH EUR J PHY, V465, P1249, DOI 10.1007/s00424-013-1254-8
   Osman MO, 1998, GUT, V43, P232, DOI 10.1136/gut.43.2.232
   Pan Z, 2012, JOVE-J VIS EXP, V60, P1
   Parrau D, 2013, AM J PHYSIOL-LUNG C, V304, pL540, DOI 10.1152/ajplung.00024.2012
   Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122
   Rao W, 2013, BIOCHEM BIOPH RES CO, V441, P351, DOI 10.1016/j.bbrc.2013.10.054
   Rongione AJ, 1997, GASTROENTEROLOGY, V112, P960, DOI 10.1053/gast.1997.v112.pm9041259
   Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003
   Salido GM, 2009, CELL SIGNAL, V21, P457, DOI 10.1016/j.cellsig.2008.11.005
   Sari E, 2015, J UROLOGY, V193, P1036, DOI 10.1016/j.juro.2014.09.120
   Shields Conor J, 2002, Curr Opin Crit Care, V8, P158, DOI 10.1097/00075198-200204000-00012
   Steer ML, 2001, RESP PHYSIOL, V128, P13, DOI 10.1016/S0034-5687(01)00259-6
   Tenner S, 1997, GASTROENTEROLOGY, V113, P899, DOI 10.1016/S0016-5085(97)70185-9
   Varga-Szabo D, 2011, CELL CALCIUM, V50, P270, DOI 10.1016/j.ceca.2011.04.002
   Wang YX, 2013, INT J MOL MED, V32, P568, DOI 10.3892/ijmm.2013.1420
   Yang Y, 2011, MOL BIOL REP, V38, P3615, DOI 10.1007/s11033-010-0473-8
   Zhang JW, 2015, WORLD J GASTROENTERO, V21, P3537, DOI 10.3748/wjg.v21.i12.3537
   Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147
   Zhong LR, 2013, ASIAN PAC J CANCER P, V14, P5983, DOI 10.7314/APJCP.2013.14.10.5983
NR 39
TC 23
Z9 29
U1 2
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD JUN
PY 2016
VL 39
IS 3
BP 1049
EP 1058
DI 10.1007/s10753-016-0335-1
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA DN2XY
UT WOS:000376927500011
PM 27025854
DA 2023-08-21
ER

PT J
AU Li, JT
   Wang, WQ
   Wang, L
   Liu, NN
   Zhao, YL
   Zhu, XS
   Liu, QQ
   Gao, CF
   Yang, AG
   Jia, LT
AF Li, Jun-Tang
   Wang, Wei-Qi
   Wang, Ling
   Liu, Ning-Ning
   Zhao, Ya-Li
   Zhu, Xiao-Shan
   Liu, Qin-Qin
   Gao, Chun-Fang
   Yang, An-Gang
   Jia, Lin-Tao
TI Subanesthetic isoflurane relieves zymosan-induced neutrophil
   inflammatory response by targeting NMDA glutamate receptor and Toll-like
   receptor 2 signaling
SO ONCOTARGET
LA English
DT Article
DE isoflurane; zymosan; neutrophil; NMDA receptor; TLR/TLR2/TLR4; Immunology and Microbiology Section; immune response; Immunity 
ID NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY; OXIDATIVE STRESS; MURINE
   SEPSIS; ENDOTHELIAL-CELLS; TYROSINE KINASE; INOS EXPRESSION; NADPH
   OXIDASE; PROTEIN LEAK; C-SRC
AB Neutrophil release of NO/ONOO-induces endothelial cell barrier dysfunction in inflammatory acute lung injury (ALI). Previous studies using zymosan-triggered inflammation and ALI model revealed that zymosan promotes inducible NO synthase (iNOS) expression in neutrophils, and that isoflurane inhibits zymosan-induced oxidative stress and iNOS biosynthesis. However, the underlying mechanisms remain largely unknown. We found here that in zymosan-primed neutrophils, iNOS is transcriptionally activated by NF-kappa B, whose nuclear translocation is triggered by excessive reactive oxygen species (ROS) and consequently activated p38 MAPK. ROS production is attributed to zymosan-initiated Toll-like receptor 2 (TLR2) signaling, in which the adaptor MyD88 recruits and activates c-Src, and c-Src activates NADPH oxidase to generate ROS. Subanesthetic isoflurane counteracts the aforementioned zymosan-induced signaling by targeting N-methyl-D-aspartic acid (NMDA) glutamate receptor and thereby suppressing calcium influx and c-Src activation. Whereas iNOS accelerates NO/ONOO-production in neutrophils which eventually promote protein leak from pulmonary microvascular endothelial cells (PMVEC), isoflurane reduced NO/ONOO-release from zymosan-treated neutrophils, and thus relieves trans-PMVEC protein leak. This study provides novel insights into the roles of neutrophils and the underlying mechanisms in zymosan-induced ALI, and has implications for the therapeutic potential of subanesthetic isoflurane in attenuating inflammatory responses causing lung endothelial cell damage.
C1 [Li, Jun-Tang; Liu, Ning-Ning; Zhao, Ya-Li; Zhu, Xiao-Shan; Liu, Qin-Qin; Gao, Chun-Fang] 150th Cent Hosp PLA, Ctr Inflammat & Canc Res, Luoyang, Henan, China.
C1 [Li, Jun-Tang; Yang, An-Gang] Fourth Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, Xian 710032, Shaanxi, China.
C1 [Li, Jun-Tang; Jia, Lin-Tao] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian 710032, Shaanxi, China.
C1 [Wang, Wei-Qi] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, China.
C1 [Wang, Wei-Qi] Fourth Mil Med Univ, Sch Stomatol, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, China.
C1 [Wang, Wei-Qi] Fourth Mil Med Univ, Sch Stomatol, Shaanxi Clin Res Ctr Oral Dis, Dept Oral & Maxillofacial Surg, Xian 710032, Shaanxi, China.
C1 [Wang, Ling] 150th Cent Hosp PLA, Dept Anesthesiol, Luoyang, Henan, China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University; Air Force Military
   Medical University; Air Force Military Medical University
RP Li, JT (corresponding author), 150th Cent Hosp PLA, Ctr Inflammat & Canc Res, Luoyang, Henan, Peoples R China.; Li, JT; Yang, AG (corresponding author), Fourth Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.; Li, JT; Jia, LT (corresponding author), Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.
EM juntangli@163.com; agyang@fmmu.edu.cn; jialth@fmmu.edu.cn
OI , juntang/0000-0003-0819-4201
FU National Key Research Program of China [2014ZX09J14101-01A]; National
   Natural Sciences Foundation of China [81472631]
FX This work was supported by the National Key Research Program of China
   (No. 2014ZX09J14101-01A) and the National Natural Sciences Foundation of
   China (No. 81472631). The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Al-Gayyar MMH, 2010, AM J PATHOL, V177, P1187, DOI 10.2353/ajpath.2010.091289
   Altamirano F, 2012, J BIOL CHEM, V287, P20876, DOI 10.1074/jbc.M112.344929
   Boldyrev AA, 2012, BIOCHEMISTRY-MOSCOW+, V77, P128, DOI 10.1134/S0006297912020022
   Bryushkova EA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P467, DOI 10.1134/S0006297911040109
   Burchell SR, 2013, J INVEST MED, V61, P1078, DOI 10.2310/JIM.0b013e3182a07921
   Chaves HV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/707985
   Cheresh P, 2013, BBA-MOL BASIS DIS, V1832, P1028, DOI 10.1016/j.bbadis.2012.11.021
   Coleman CG, 2013, J NEUROSCI, V33, P4308, DOI 10.1523/JNEUROSCI.3061-12.2013
   Crystal GJ, 2012, ACTA ANAESTH SCAND, V56, P39, DOI 10.1111/j.1399-6576.2011.02583.x
   Cuzzocrea S, 2001, SHOCK, V16, P51, DOI 10.1097/00024382-200116010-00010
   DELICONSTANTINOS G, 1995, BIOCHEM PHARMACOL, V49, P1589, DOI 10.1016/0006-2952(95)00094-G
   Elnakish MT, 2013, J PATHOL, V231, P290, DOI 10.1002/path.4255
   Gianni D, 2008, MOL BIOL CELL, V19, P2984, DOI 10.1091/mbc.E08-02-0138
   Gui PC, 2006, J BIOL CHEM, V281, P14015, DOI 10.1074/jbc.M600433200
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Huang WC, 2009, IMMUNOLOGY, V128, pe275, DOI 10.1111/j.1365-2567.2008.02959.x
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jang JH, 2005, BIOCHEM BIOPH RES CO, V331, P1421, DOI 10.1016/j.bbrc.2005.04.057
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Kinoshita H, 2012, ANESTH ANALG, V115, P54, DOI 10.1213/ANE.0b013e318254270d
   KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4
   Lange M, 2012, SHOCK, V37, P468, DOI 10.1097/SHK.0b013e31824b1793
   Lee IT, 2012, BIOCHEM PHARMACOL, V84, P581, DOI 10.1016/j.bcp.2012.05.005
   Li JS, 2008, BRAIN RES, V1210, P223, DOI 10.1016/j.brainres.2008.03.007
   Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2
   Li JT, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/108928
   Li XY, 2010, CYTOKINE, V49, P1, DOI 10.1016/j.cyto.2009.08.010
   Li Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125873
   Lin CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132204
   Maa MC, 2008, J BIOL CHEM, V283, P31408, DOI 10.1074/jbc.M801158200
   METZ C, 1991, CHEST, V100, P1110, DOI 10.1378/chest.100.4.1110
   Miura T, 1999, FEMS IMMUNOL MED MIC, V24, P131
   Noubade R, 2014, NATURE, V509, P235, DOI 10.1038/nature13152
   Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897
   Obasanjo-Blackshire K, 2006, CARDIOVASC RES, V71, P672, DOI 10.1016/j.cardiores.2006.05.026
   Pang YL, 2012, J ANESTH, V26, P822, DOI 10.1007/s00540-012-1456-9
   Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002
   Razavi HM, 2005, CRIT CARE MED, V33, P1333, DOI 10.1097/01.CCM.0000165445.48350.4F
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5
   Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368
   Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417
   Schwechter B, 2013, P NATL ACAD SCI USA, V110, P14462, DOI 10.1073/pnas.1304340110
   Shelton JL, 2008, MICROVASC RES, V76, P80, DOI 10.1016/j.mvr.2008.06.001
   Shelton JL, 2007, MICROVASC RES, V74, P23, DOI 10.1016/j.mvr.2007.02.008
   Stateva SR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128783
   Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023
   Santos RCV, 2012, INFLAMMATION, V35, P1198, DOI 10.1007/s10753-012-9429-6
   Volman TJH, 2005, SHOCK, V23, P291, DOI 10.1097/01.shk.0000155350.95435.28
   Wang H, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/851692
   Wang H, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/479628
   Wang LF, 2012, SHOCK, V37, P539, DOI 10.1097/SHK.0b013e31824dcb5a
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Weih F, 1997, J IMMUNOL, V158, P5211
NR 54
TC 9
Z9 11
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 31
PY 2016
VL 7
IS 22
BP 31772
EP 31789
DI 10.18632/oncotarget.9091
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4JP
UT WOS:000377748500013
PM 27144523
OA Green Submitted, Green Published, gold
DA 2023-08-21
ER

PT J
AU Wu, T
   Shi, JX
   Geng, S
   Zhou, W
   Shi, Y
   Su, X
AF Wu, Ting
   Shi, Jia-Xin
   Geng, Shen
   Zhou, Wei
   Shi, Yi
   Su, Xin
TI The MK2/HuR signaling pathway regulates TNF-alpha-induced ICAM-1
   expression by promoting the stabilization of ICAM-1 mRNA
SO BMC PULMONARY MEDICINE
LA English
DT Article
DE MK2; HuR; ICAM-1; interleukin-8; ECs/HPMECs/HUVECs/MPVECs 
ID ACTIVATED PROTEIN-KINASE; ACUTE LUNG INJURY; TUMOR-NECROSIS-FACTOR;
   BINDING PROTEIN; ADHESION MOLECULE-1; CANCER CELLS; HUR;
   PHOSPHORYLATION; TRISTETRAPROLIN; INTERLEUKIN-8
AB Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by acute lung inflammation. Intercellular adhesion molecule-1 (ICAM-1) and interleukin-8 (IL-8) play an important role in the development of these diseases. Mitogen-activated protein kinase (MAPK) p38/activated protein kinase 2 (MK2) regulates the expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells (HPMECs) stimulated by tumor necrosis factor-a (TNF-alpha); however, the underlying molecular mechanism remains unclear. Here, we show that human antigen R (HuR), an RNA binding protein which binds preferentially to AU-rich elements (AREs) and stabilizes mRNAs, regulates TNF-alpha-induced ICAM-1 expression in the MK2/HuR signaling pathway.
   Method: MK2 and HuR were silenced respectively in HPMECs and then HPMECs were stimulatied with TNF-alpha. Nucleo-cytoplasmic shuttling of HuR was detected by subcellular fractionation and confocal microscopy in MK2 knockdown HPMECs. In HuR silencing cells, protein and mRNA levels of ICAM-1 and IL-8 were measured by western blot analysis, ELISA and real-time PCR; mRNA stabilization were measured by real-time PCR after actinomycin D (ActD) blocking transcription. Furthermore, we performed neutrophil adhesion assay to assess the adhering capacity after HuR silencing.
   Results: MK2 were subjected to a knockdown by interfering RNA, the mRNA and protein levels of HuR in human pulmonary microvascular endothelial cells (HPMECs) were not affected. However, after the stimulation of TNF-alpha, silencing MK2 inhibited HuR accumulation to cytoplasm from nucleus in HPMECs. Consequently, knockdown of HuR by RNA interference in HPMECs, there was reduction in the stability of ICAM-1 mRNA and ICAM-1 protein level. This event was accompanied by a decrease in the adhesion of neutrophils towards HPMECs. Nevertheless, HuR silencing had no effect on the mRNA and protein levels of IL-8.
   Conclusion: These results indicate that MK2 post-transcriptionally regulates TNF-alpha-induced ICAM-1 expression by altering the cytoplasmic localization of HuR in HPMECs.
C1 [Wu, Ting; Shi, Jia-Xin; Zhou, Wei; Shi, Yi; Su, Xin] Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp & Crit Care Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, China.
C1 [Shi, Jia-Xin] Nanjing Med Univ, Lianyungang Peoples Hosp 1, Affiliated Hosp, Dept Resp Med,Xuzhou Med Coll,Clin Med Sch, Lianyungang 222002, China.
C1 [Geng, Shen] Southern Med Univ, Jinling Hosp, Dept Resp & Crit Care Med, Guangzhou 510000, Guangdong, China.
C3 Nanjing University; Nanjing Medical University; Xuzhou Medical
   University; Southern Medical University - China
RP Shi, Y; Su, X (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp & Crit Care Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM shiyi56@126.com; suxinjs@163.com
RI SHI, Yi/IXD-7826-2023; Su, Xin/X-2589-2018
OI Su, Xin/0000-0002-3910-9156
FU National Natural Science Foundation of China [81270138, 81300052];
   Natural Science Foundation of Jiangsu Province [BK20130402]; Medicine
   and Technology Foundation of Chinese PLA [CWS12J008]; China Postdoctoral
   Science Foundation [2015 M570420]; Jiangsu provincial health and Family
   Planning Commission Science Foundation [H 201558]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 81270138 and 81300052), the Natural Science Foundation
   of Jiangsu Province (BK20130402), the Medicine and Technology Foundation
   of Chinese PLA (No. CWS12J008), the China Postdoctoral Science
   Foundation (Grant No. 2015 M570420) and the Jiangsu provincial health
   and Family Planning Commission Science Foundation (Grant No. H 201558).
CR Calfee C, 2009, INTENS CARE MED, V35, P248, DOI 10.1007/s00134-008-1235-0
   Chignard M, 2000, AM J PHYSIOL-LUNG C, V279, pL1083, DOI 10.1152/ajplung.2000.279.6.L1083
   Choi HJ, 2009, TOXICOL APPL PHARM, V240, P46, DOI 10.1016/j.taap.2009.06.023
   D'Agostino VG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072426
   Doller A, 2008, CELL SIGNAL, V20, P2165, DOI 10.1016/j.cellsig.2008.05.007
   Donahue JM, 2011, BIOCHEM J, V437, P89, DOI 10.1042/BJ20110028
   Eberhardt W, 2012, CURR PROTEIN PEPT SC, V13, P380, DOI 10.2174/138920312801619439
   Farooq F, 2009, HUM MOL GENET, V18, P4035, DOI 10.1093/hmg/ddp352
   Gurgis FMS, 2015, ONCOGENE, V34, P2934, DOI 10.1038/onc.2014.225
   Hasegawa H, 2009, BRIT J CANCER, V100, P1943, DOI 10.1038/sj.bjc.6605084
   HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038
   Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061
   Kotteas EA, 2014, ANTICANCER RES, V34, P4665
   Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09
   Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003
   Lal S, 2014, CANCER RES, V74, P1128, DOI 10.1158/0008-5472.CAN-13-1915
   Lin FY, 2006, ARTERIOSCL THROM VAS, V26, P2622, DOI 10.1161/01.ATV.0000246779.78003.cf
   Long EO, 2011, J IMMUNOL, V186, P5021, DOI 10.4049/jimmunol.1100646
   Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144
   Mokra D, 2015, RESP PHYSIOL NEUROBI, V209, P52, DOI 10.1016/j.resp.2014.10.006
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Nabors LLB, 2003, CANCER RES, V63, P4181
   Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200
   O'Dea KP, 2011, LUNG CELL MOL PHYSL, V301, pL812
   Ronkina N, 2010, BIOCHEM PHARMACOL, V80, P1915, DOI 10.1016/j.bcp.2010.06.021
   Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639
   Shi JX, 2014, INT IMMUNOPHARMACOL, V22, P480, DOI 10.1016/j.intimp.2014.07.031
   Shtokalo D, 2012, MOL GENET GENOMICS, V287, P867
   Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921
   Su X, 2008, BBA-MOL CELL RES, V1783, P1623, DOI 10.1016/j.bbamcr.2008.04.009
   Sumagin R, 2014, MUCOSAL IMMUNOL, V7, P905, DOI 10.1038/mi.2013.106
   Sumagin R, 2008, AM J PHYSIOL-HEART C, V295, pH969, DOI 10.1152/ajpheart.00400.2008
   Taooka Y, 2013, RESPIRATION, V86, P367, DOI 10.1159/000345390
   Tiedje C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002977
   Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003
   Williams AE, 2014, AM J PHYSIOL-LUNG C, V306, pL217, DOI 10.1152/ajplung.00311.2013
   Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969
NR 37
TC 15
Z9 17
U1 5
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2466
J9 BMC PULM MED
JI BMC Pulm. Med.
PD MAY 23
PY 2016
VL 16
AR 84
DI 10.1186/s12890-016-0247-8
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA DN7PK
UT WOS:000377269100002
PM 27215284
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Borgas, D
   Chambers, E
   Newton, J
   Ko, J
   Rivera, S
   Rounds, S
   Lu, Q
AF Borgas, Diana
   Chambers, Eboni
   Newton, Julie
   Ko, Junsuk
   Rivera, Stephanie
   Rounds, Sharon
   Lu, Qing
TI Cigarette Smoke Disrupted Lung Endothelial Barrier Integrity and
   Increased Susceptibility to Acute Lung Injury via Histone Deacetylase 6
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE cigarette smoke; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; permeability; histone deacetylase 6 
ID OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-DISTRESS-SYNDROME; ADHERENS
   JUNCTIONS; OXIDATIVE STRESS; VE-CADHERIN; GUINEA-PIG; IN-VIVO; HDAC6;
   CELL; DYSFUNCTION
AB Epidemiologic evidence indicates that cigarette smoke (CS) is associated with the development of acute lung injury (ALI). We have previously shown that brief CS exposure exacerbates lipopolysaccharide (LPS)-induced ALI in vivo and endothelial barrier dysfunction in vitro. In this study, we found that CS also exacerbated Pseudomonas-induced ALI in mice. We demonstrated that lung microvascular endothelial cells (ECs) isolated from mice exposed to CS had a greater permeability or incomplete recovery after challenges by LPS and thrombin. Histone deacetylase (HDAC) 6 deacetylates proteins essential for maintenance of endothelial barrier function. We found that HDAC6 phosphorylation at serine-22 was increased in lung tissues of mice exposed to CS and in lung ECs exposed to cigarette smoke extract (CSE). Inhibition of HDAC6 attenuated CSE-induced increases in EC permeability and CS priming of ALI. Similar barrier protection was provided by the microtubule stabilizer taxol, which preserved alpha-tubulin acetylation. CSE decreased a-tubulin acetylation and caused microtubule depolymerization. In coordination with increased HDAC6 phosphorylation, CSE inhibited Akt and activated glycogen synthase kinase (GSK)-3 beta; these effects were ameliorated by the antioxidant N-acetyl cysteine. Our results suggest that CS increases lung EC permeability, thereby enhancing susceptibility to ALI, likely through oxidative stress-induced Akt inactivation and subsequent GSK-3 beta activation. Activated GSK-3 beta may activate HDAC6 via phosphorylation of serine-22, leading to alpha-tubulin deacetylation and microtubule disassembly. Inhibition of HDAC6 may be a novel therapeutic option for ALI in cigarette smokers.
C1 [Borgas, Diana; Chambers, Eboni; Newton, Julie; Ko, Junsuk; Rivera, Stephanie; Rounds, Sharon; Lu, Qing] Brown Univ, Alpert Med Sch, Dept Med, Vasc Res Lab,Providence Vet Affairs Med Ctr, Providence, RI 02912, United States.
C3 Brown University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Providence VA Medical Center
RP Lu, Q (corresponding author), Providence Vet Affairs Med Ctr, Res Serv, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM qing_lu@brown.edu
RI Rounds, Sharon/AAF-7380-2020; Ko, Junsuk (Josh)/E-4235-2019
OI Ko, Junsuk (Josh)/0000-0003-4042-4716
FU Institutional Development Award from the National Institute of General
   Medical Sciences of National Institutes of Health [P20GM103652];
   American Thoracic Society/Pulmonary Hypertension Association [PH05015,
   R25 HL088992, T32 ES007272]; Providence Veterans Affairs (VA) Medical
   Center; VA Merit Review
FX This work was supported by the use of facilities at the Providence
   Veterans Affairs (VA) Medical Center and by an Institutional Development
   Award from the National Institute of General Medical Sciences of the
   National Institutes of Health under grant P20GM103652 (Q.L., project 1),
   P20GM103652 (S. Rounds), VA Merit Review (S. Rounds), American Thoracic
   Society/Pulmonary Hypertension Association research grant PH05015
   (Q.L.), R25 HL088992 (S. Rivera), and T32 ES007272 (E.C.).
CR Barbera JA, 2013, PULM CIRC, V3, P160, DOI 10.4103/2045-8932.109949
   Barbera JA, 2009, DRUGS, V69, P1153, DOI 10.2165/00003495-200969090-00002
   [Anonymous], 2014, HLTH CONS SMOK 50 YE
   BAZIN M, 1981, REV CAN BIOL EXPTL, V40, P263
   Bernhard D, 2005, FASEB J, V19, P1096, DOI 10.1096/fj.04-3192com
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   BURNS AR, 1989, J APPL PHYSIOL, V66, P2109, DOI 10.1152/jappl.1989.66.5.2109
   Calfee CS, 2015, CRIT CARE MED, V43, P1790, DOI 10.1097/CCM.0000000000001089
   Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC
   Chattopadhyay S, 2013, MBIO, V4
   Chen HY, 2014, PHARMAZIE, V69, P55, DOI 10.1691/ph.2014.3716
   Chen SG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010848
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Demos-Davies KM, 2014, AM J PHYSIOL-HEART C, V307, pH252, DOI 10.1152/ajpheart.00149.2014
   Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576
   Drannik AG, 2004, AM J RESP CRIT CARE, V170, P1164, DOI 10.1164/rccm.200311-1521OC
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Durgadoss L, 2012, FASEB J, V26, P1473, DOI 10.1096/fj.11-194100
   Feldman C, 2013, J INFECTION, V67, P169, DOI 10.1016/j.jinf.2013.05.004
   Ferrer E, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-76
   Fukada M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030924
   Govindarajan N, 2013, EMBO MOL MED, V5, P52, DOI 10.1002/emmm.201201923
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Hayashi I, 2007, MUTAT RES-GEN TOX EN, V631, P55, DOI 10.1016/j.mrgentox.2007.04.006
   Hirsch J, 2014, CRIT CARE, V18, DOI 10.1186/cc13795
   Ho KM, 2011, INTENS CARE MED, V37, P981, DOI 10.1007/s00134-011-2184-6
   HOLDEN WE, 1989, J APPL PHYSIOL, V66, P443, DOI 10.1152/jappl.1989.66.1.443
   Hsieh SJ, 2014, CRIT CARE MED, V42, P2058, DOI 10.1097/CCM.0000000000000418
   Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Iribarren C, 2000, CHEST, V117, P163, DOI 10.1378/chest.117.1.163
   Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892
   Jochems J, 2014, NEUROPSYCHOPHARMACOL, V39, P389, DOI 10.1038/npp.2013.207
   Kaidanovich Oksana, 2002, Expert Opin Ther Targets, V6, P555
   Kaluza D, 2011, EMBO J, V30, P4142, DOI 10.1038/emboj.2011.298
   Kang MJ, 2008, J CLIN INVEST, V118, P2771, DOI 10.1172/JCI32709
   Kim SY, 2011, J BIOL CHEM, V286, P31932, DOI 10.1074/jbc.M111.267633
   Kramer OH, 2014, TRENDS PHARMACOL SCI, V35, P501, DOI 10.1016/j.tips.2014.08.001
   Lafarga V, 2012, EMBO J, V31, P856, DOI 10.1038/emboj.2011.466
   Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636
   Li Y, 2008, J BIOL CHEM, V283, P12686, DOI 10.1074/jbc.C700185200
   Lu Q, 2004, CIRC RES, V94, P306, DOI 10.1161/01.RES.0000113923.85084.C1
   Lu Q, 2006, J APPL PHYSIOL, V101, P375, DOI 10.1152/japplphysiol.01515.2005
   Lu Q, 2011, AM J PHYSIOL-LUNG C, V301, pL847, DOI 10.1152/ajplung.00178.2011
   Lu Q, 2010, AM J PHYSIOL-LUNG C, V298, pL755, DOI 10.1152/ajplung.00330.2009
   Lugade AA, 2014, J IMMUNOL, V192, P5226, DOI 10.4049/jimmunol.1302584
   Maini C L, 1987, Radiol Med, V74, P520
   Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682
   Mercado N, 2011, BIOCHEM BIOPH RES CO, V406, P292, DOI 10.1016/j.bbrc.2011.02.035
   Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206
   Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985
   Ni YF, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-33
   OBRODOVICH H, 1987, LUNG, V165, P1, DOI 10.1007/BF02714416
   Ochoa CD, 2011, AM J PHYSIOL-LUNG C, V300, pL132, DOI 10.1152/ajplung.00185.2010
   Ozaki K, 2010, J CARDIOL, V56, P307, DOI 10.1016/j.jjcc.2010.07.003
   Peinado VI, 2008, CHEST, V134, P808, DOI 10.1378/chest.08-0820
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Rajendrasozhan S, 2009, COPD, V6, P291, DOI 10.1080/15412550903049132
   Saito S, 2011, BIOCHEM BIOPH RES CO, V408, P630, DOI 10.1016/j.bbrc.2011.04.075
   Schweitzer KS, 2011, AM J PHYSIOL-LUNG C, V301, pL836, DOI 10.1152/ajplung.00385.2010
   Stevens TC, 2014, AM J PHYSIOL-LUNG C, V306, pL915, DOI 10.1152/ajplung.00135.2013
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   van Buul JD, 2005, J BIOL CHEM, V280, P21129, DOI 10.1074/jbc.M500898200
   Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565
   Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479
   Wang J, 2010, INVEST OPHTH VIS SCI, V51, P2943, DOI 10.1167/iovs.09-4639
   Ware LB, 2014, AM J TRANSPLANT, V14, P2295, DOI 10.1111/ajt.12853
   Watabe M, 2011, J CELL SCI, V124, P1519, DOI 10.1242/jcs.081778
   Winkler R, 2012, DIABETES, V61, P513, DOI 10.2337/db11-0313
   Wright JL, 2008, J APPL PHYSIOL, V104, P1462, DOI 10.1152/japplphysiol.00520.2007
   WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113
   Xiong Y, 2013, P NATL ACAD SCI USA, V110, P4604, DOI 10.1073/pnas.1207586110
   Yao HW, 2012, AM J PHYSIOL-LUNG C, V303, pL557, DOI 10.1152/ajplung.00175.2012
   Zhang L, 2010, WORLD J SURG, V34, P1676, DOI 10.1007/s00268-010-0493-5
   Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
   Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06
NR 77
TC 46
Z9 47
U1 0
U2 10
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2016
VL 54
IS 5
BP 683
EP 696
DI 10.1165/rcmb.2015-0149OC
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA DO2EJ
UT WOS:000377592300010
PM 26452072
OA Green Published
DA 2023-08-21
ER

PT J
AU Millar, FR
   Summers, C
   Griffiths, MJ
   Toshner, MR
   Proudfoot, AG
AF Millar, Fraser R.
   Summers, Charlotte
   Griffiths, Mark J.
   Toshner, Mark R.
   Proudfoot, Alastair G.
TI The pulmonary endothelium in acute respiratory distress syndrome:
   insights and therapeutic opportunities
SO THORAX
LA English
DT Review
ID ACUTE LUNG INJURY; ACTIVATED PROTEIN-C; NEUTROPHIL EXTRACELLULAR TRAPS;
   ATRIAL-NATRIURETIC-PEPTIDE; ENZYME 2 ACE2; PROGENITOR CELLS; VASCULAR
   LEAK; BARRIER FUNCTION; IN-VIVO; PHENOTYPIC HETEROGENEITY
AB The pulmonary endothelium is a dynamic, metabolically active layer of squamous endothelial cells ideally placed to mediate key processes involved in lung homoeostasis. Many of these are disrupted in acute respiratory distress syndrome (ARDS), a syndrome with appreciable mortality and no effective pharmacotherapy. In this review, we consider the role of the pulmonary endothelium as a key modulator and orchestrator of ARDS, highlighting advances in our understanding of endothelial pathobiology and their implications for the development of endothelial-targeted therapeutics including cell-based therapies. We also discuss mechanisms to facilitate the translation of preclinical data into effective therapies including the application of biomarkers to phenotype patients with ARDS with a predominance of endothelial injury and emerging biotechnologies that could enhance delivery, discovery and testing of lung endothelial-specific therapeutics.
C1 [Millar, Fraser R.; Griffiths, Mark J.; Proudfoot, Alastair G.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London, England, United Kingdom.
C1 [Summers, Charlotte] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England, United Kingdom.
C1 [Summers, Charlotte; Toshner, Mark R.] Papworth Hosp NHS Fdn Trust, Cambridge, England, United Kingdom.
C1 [Griffiths, Mark J.] NHS Fdn Trust, Royal Brompton & Harefield Hosp, NIHR Resp Biomed Res Unit, London, England, United Kingdom.
C1 [Proudfoot, Alastair G.] Spectrum Hlth, Frederick Meijer Heart & Vasc Inst, 100 Michigan St NE, Grand Rapids, MI 49503, United States.
C3 Imperial College London; University of Cambridge; Papworth Hospital;
   Oxford University Hospitals NHS Foundation Trust; Royal Brompton &
   Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton
   Hospital; Michigan State University; Michigan State University College
   of Human Medicine
RP Proudfoot, AG (corresponding author), Spectrum Hlth, Frederick Meijer Heart & Vasc Inst, 100 Michigan St NE, Grand Rapids, MI 49503 USA.
EM Alastair.Proudfoot@spectrumhealth.org
RI Proudfoot, Alastair/AAG-3235-2021; Summers, Charlotte/A-6973-2012
OI Summers, Charlotte/0000-0002-7269-2873; Griffiths,
   Mark/0000-0002-1615-1896; Toshner, Mark/0000-0002-3969-6143; Millar,
   Fraser/0000-0002-0740-5436
FU Wellcome Trust [WT101692MA]
FX CS is a Wellcome Trust Postdoctoral Clinical Research Training Fellow
   (WT101692MA).
CR Agrawal A, 2013, AM J RESP CRIT CARE, V187, P736, DOI 10.1164/rccm.201208-1460OC
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Alfieri A, 2012, CRIT CARE, V16, DOI 10.1186/cc11666
   Aman J, 2013, AM J RESP CRIT CARE, V188, P1171, DOI 10.1164/rccm.201301-0136LE
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Ando K, 2013, J CELL BIOL, V202, P901, DOI 10.1083/jcb.201301115
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Azoulay E, 2002, CRIT CARE MED, V30, P781, DOI 10.1097/00003246-200204000-00010
   BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589
   Barry DM, 2015, DEVELOPMENT, V142, P3058, DOI 10.1242/dev.125260
   Bellingan G, 2014, LANCET RESP MED, V2, P98, DOI 10.1016/S2213-2600(13)70259-5
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Birukova AA, 2008, EXP CELL RES, V314, P3466, DOI 10.1016/j.yexcr.2008.09.003
   Boueiz A, 2009, MICROVASC RES, V77, P26, DOI 10.1016/j.mvr.2008.10.005
   Broman MT, 2007, TRENDS CARDIOVAS MED, V17, P151, DOI 10.1016/j.tcm.2007.03.004
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Cabrera-Benitez NE, 2015, CRIT CARE MED, V43, pE551, DOI 10.1097/CCM.0000000000001280
   Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Carnevale-Schianca F, 2011, J CLIN ONCOL, V29, pE691, DOI 10.1200/JCO.2011.35.6733
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Chambers Rachel C, 2012, Proc Am Thorac Soc, V9, P96, DOI 10.1513/pats.201201-006AW
   Chen WG, 2012, AM J PHYSIOL-LUNG C, V303, pL279, DOI 10.1152/ajplung.00361.2011
   CHOLLETMARTIN S, 1992, AM REV RESPIR DIS, V146, P990, DOI 10.1164/ajrccm/146.4.990
   Christiaans SC, 2013, AM J PHYSIOL-LUNG C, V305, pL455, DOI 10.1152/ajplung.00093.2013
   Cioffi DL, 2012, AM J PHYSIOL-LUNG C, V302, pL1067, DOI 10.1152/ajplung.00190.2011
   Collins SR, 2013, ANESTH ANALG, V117, P664, DOI 10.1213/ANE.0b013e3182975b85
   Cornet AD, 2013, J THROMB HAEMOST, V11, P894, DOI 10.1111/jth.12179
   Cornet AD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090983
   Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987
   Daneshjou N, 2015, J CELL BIOL, V208, P23, DOI 10.1083/jcb.201409108
   David S, 2012, CRIT CARE MED, V40, P3034, DOI 10.1097/CCM.0b013e31825fdc31
   de Stoppelaar SF, 2014, BLOOD, V124, P3781, DOI 10.1182/blood-2014-05-573915
   Ding BS, 2011, CELL, V147, P539, DOI 10.1016/j.cell.2011.10.003
   Doerschuk C M, 2000, Respir Res, V1, P136, DOI 10.1186/rr24
   DOERSCHUK CM, 1992, AM J RESP CELL MOL, V7, P140, DOI 10.1165/ajrcmb/7.2.140
   Doyle NA, 1997, J CLIN INVEST, V99, P526, DOI 10.1172/JCI119189
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Emin MT, 2012, AM J PHYSIOL-LUNG C, V302, pL1209, DOI 10.1152/ajplung.00189.2011
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Esch EW, 2015, NAT REV DRUG DISCOV, V14, P248, DOI 10.1038/nrd4539
   Ferrer MCC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102329
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   Frye M, 2015, J EXP MED, V212, P2267, DOI 10.1084/jem.20150718
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Goldenberg NM, 2015, COMPR PHYSIOL, V5, P531, DOI 10.1002/cphy.c140024
   Gong HX, 2014, J EXP MED, V211, P579, DOI 10.1084/jem.20131190
   Gong P, 2008, J BIOL CHEM, V283, P13437, DOI 10.1074/jbc.M707986200
   Gorbunov NV, 2007, ANTIOXID REDOX SIGN, V9, P483, DOI 10.1089/ars.2006.1296
   Greineder CF, 2015, FASEB J, V29, P3483, DOI 10.1096/fj.15-271213
   Griffin JH, 2015, BLOOD, V125, P2898, DOI 10.1182/blood-2015-02-355974
   Hager DN, 2015, CLIN CHEST MED, V36, P481, DOI 10.1016/j.ccm.2015.05.002
   HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831
   Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012
   Horvath L, 2015, SCI REP-UK, V5, DOI 10.1038/srep07974
   Huang FM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4595
   Huang LS, 2015, THORAX, V70, P1138, DOI 10.1136/thoraxjnl-2014-206684
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Huh Dongeun Dan, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS42, DOI 10.1513/AnnalsATS.201410-442MG
   HURLEY JV, 1982, ANN NY ACAD SCI, V384, P269, DOI 10.1111/j.1749-6632.1982.tb21378.x
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Itoh T, 2007, AM J PHYSIOL-LUNG C, V293, pL446, DOI 10.1152/ajplung.00412.2005
   Iwaki M, 2009, BIOCHEM BIOPH RES CO, V389, P531, DOI 10.1016/j.bbrc.2009.09.020
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315
   Jose RJ, 2015, J IMMUNOL, V194, P6024, DOI 10.4049/jimmunol.1500124
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200
   Kangelaris KN, 2015, AM J PHYSIOL-LUNG C, V308, pL1102, DOI 10.1152/ajplung.00380.2014
   Kawasaki T, 2015, AM J RESP CELL MOL, V53, P500, DOI 10.1165/rcmb.2014-0185OC
   Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuck JL, 2015, AM J PHYSIOL-LUNG C, V308, pL1078, DOI 10.1152/ajplung.00015.2015
   Lee JH, 2014, CELL, V156, P440, DOI 10.1016/j.cell.2013.12.039
   Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001
   Letourneau M, 2013, J NUCL MED, V54, P1789, DOI 10.2967/jnumed.112.118984
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Letsiou E, 2015, AM J RESP CELL MOL, V52, P193, DOI 10.1165/rcmb.2013-0347OC
   Li LF, 2015, SCI REP-UK, V5, DOI 10.1038/srep08895
   Lin MT, 2015, PULM CIRC, V5, P279, DOI 10.1086/680166
   Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com
   Liu KD, 2008, AM J RESP CRIT CARE, V178, P618, DOI 10.1164/rccm.200803-419OC
   Looney MR, 2014, ANNU REV PHYSIOL, V76, P431, DOI 10.1146/annurev-physiol-021113-170331
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Mathew B, 2011, FASEB J, V25, P3388, DOI 10.1096/fj.11-183970
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Meng FY, 2015, AM J PHYSIOL-LUNG C, V308, pL452, DOI 10.1152/ajplung.00170.2014
   Mitaka C, 1998, CHEST, V114, P223, DOI 10.1378/chest.114.1.223
   Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209
   Muller HC, 2010, THORAX, V65, P1077, DOI 10.1136/thx.2010.135996
   Muller-Redetzky HC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035832
   Naikawadi RP, 2012, CIRC RES, V111, P1517, DOI 10.1161/CIRCRESAHA.112.273078
   Nakahira K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001577
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Natarajan V, 2013, AM J RESP CELL MOL, V49, P6, DOI 10.1165/rcmb.2012-0411TR
   Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835
   Ormiston ML, 2010, AM J RESP CELL MOL, V43, P546, DOI 10.1165/rcmb.2009-0152OC
   Pannekoek WJ, 2014, CELL ADHES MIGR, V8, P100, DOI 10.4161/cam.27352
   Parikh SM, 2013, VIRULENCE, V4, P517, DOI 10.4161/viru.24906
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691
   Perlot T, 2013, MICROBES INFECT, V15, P866, DOI 10.1016/j.micinf.2013.08.003
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Pfeil U, 2009, AM J PHYSIOL-LUNG C, V297, pL837, DOI 10.1152/ajplung.90608.2008
   Phillipson M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001649
   Proudfoot AG, 2014, AM J RESP CRIT CARE, V189
   Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002
   RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4
   Rafat N, 2013, AM J RESP CELL MOL, V48, P399, DOI 10.1165/rcmb.2011-0132TR
   Rafii S, 2015, NAT CELL BIOL, V17, P123, DOI 10.1038/ncb3096
   Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701
   Rizzo AN, 2015, AM J PHYSIOL-LUNG C, V309, pL1294, DOI 10.1152/ajplung.00031.2015
   Rogers AJ, 2014, AM J PHYSIOL-LUNG C, V306, pL957, DOI 10.1152/ajplung.00376.2013
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z
   Rowlands DJ, 2011, J CLIN INVEST, V121, P1986, DOI 10.1172/JCI43839
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sapru A, 2015, INTENS CARE MED, V41, P470, DOI 10.1007/s00134-015-3648-x
   Sayah DM, 2015, AM J RESP CRIT CARE, V191, P455, DOI 10.1164/rccm.201406-1086OC
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V300, pL667, DOI 10.1152/ajplung.00433.2010
   Schmidt EP, 2014, J BIOL CHEM, V289, P8194, DOI 10.1074/jbc.M113.539452
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020
   Schmidt TT, 2013, AM J PHYSIOL-LUNG C, V305, pL291, DOI 10.1152/ajplung.00094.2013
   Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304
   Shea BS, 2010, AM J RESP CELL MOL, V43, P662, DOI 10.1165/rcmb.2009-0345OC
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Singla Sunit, 2012, Pulm Circ, V2, P397, DOI 10.4103/2045-8932.105028
   Stephens RS, 2014, AM J PHYSIOL-CELL PH, V306, pC559, DOI 10.1152/ajpcell.00375.2012
   Sugiyama MG, 2015, SCI REP-UK, V5, DOI 10.1038/srep11030
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Summers C, 2014, THORAX, V69, P623, DOI 10.1136/thoraxjnl-2013-204742
   Sun SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059989
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Suratt BT, 2003, AM J RESP CRIT CARE, V168, P318, DOI 10.1164/rccm.200301-145OC
   Szczepaniak WS, 2008, TRANSL RES, V152, P213, DOI 10.1016/j.trsl.2008.09.002
   Tauseef M, 2012, J EXP MED, V209, P1953
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Terpstra ML, 2014, CRIT CARE MED, V42, P691, DOI 10.1097/01.ccm.0000435669.60811.24
   Tian YF, 2015, J BIOL CHEM, V290, P4097, DOI 10.1074/jbc.M114.620377
   Tian YF, 2015, BBA-MOL BASIS DIS, V1852, P104, DOI 10.1016/j.bbadis.2014.10.012
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   Uhlig S, 2014, CELL PHYSIOL BIOCHEM, V34, P1, DOI 10.1159/000362980
   VANDENBROUCKE ST, 2012, CIRC RES, V111, P739, DOI DOI 10.1161/CIRCRESAHA.112.269654
   Vincent JL, 2009, CRIT CARE MED, V37, P1874, DOI 10.1097/CCM.0b013e31819fff2c
   Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100
   Wang CS, 2015, AM J RESP CELL MOL, V53, P459, DOI 10.1165/rcmb.2014-0373OC
   Wang LC, 2015, MICROVASC RES, V99, P102, DOI 10.1016/j.mvr.2015.03.007
   Wang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep11097
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Weyrich AS, 2013, ANNU REV PHYSIOL, V75, P569, DOI 10.1146/annurev-physiol-030212-183752
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/s2213-2600(14)70291-7, 10.1016/S2213-2600(14)70291-7]
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Yadav H, 2015, AM J PHYSIOL-LUNG C, V309, pL915, DOI 10.1152/ajplung.00266.2015
   Yamada M, 2005, THORAX, V60, P410, DOI 10.1136/thx.2004.034058
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846
   Yiming MT, 2008, AM J RESP CELL MOL, V39, P569, DOI 10.1165/rcmb.2007-0332OC
   Yin J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   Yin J, 2016, AM J RESP CELL MOL, V54, P370, DOI 10.1165/rcmb.2014-0225OC
   Yoder Mervin C, 2011, Proc Am Thorac Soc, V8, P466, DOI 10.1513/pats.201101-006MW
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zhang KJ, 2014, MOL BIOL REP, V41, P4253, DOI 10.1007/s11033-014-3296-1
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zimmerman GA, 1999, CHEST, V116, p18S, DOI 10.1378/chest.116.suppl_1.18S
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 181
TC 127
Z9 138
U1 1
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD MAY
PY 2016
VL 71
IS 5
BP 462
EP 473
DI 10.1136/thoraxjnl-2015-207461
PG 12
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA DK6ZR
UT WOS:000375075000013
PM 26968969
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Nelin, LD
   White, HA
   Jin, Y
   Trittmann, JK
   Chen, B
   Liu, YS
AF Nelin, Leif D.
   White, Hilary A.
   Jin, Yi
   Trittmann, Jennifer K.
   Chen, Bernadette
   Liu, Yusen
TI The Src family tyrosine kinases src and yes have differential effects on
   inflammation-induced apoptosis in human pulmonary microvascular
   endothelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE caspase-1/caspase-3/caspase-11; ERK/ERK1/ERK2; cytokines 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE SYNTHASE;
   BRONCHOPULMONARY DYSPLASIA; KAPPA-B; ACTIVATION; GROWTH; EXPRESSION;
   PROLIFERATION; DEGRADATION
AB Endothelial cells are essential for normal lung function: they sense and respond to circulating factors and hemodynamic alterations. In inflammatory lung diseases such as acute respiratory distress syndrome, endothelial cell apoptosis is an inciting event in pathogenesis and a prominent pathological feature. Endothelial cell apoptosis is mediated by circulating inflammatory factors, which bind to receptors on the cell surface, activating signal transduction pathways, leading to caspase-3-mediated apoptosis. We hypothesized that yes and src have differential effects on caspase-3 activation in human pulmonary microvascular endothelial cells (hPMVEC) due to differential downstream signaling effects. To test this hypothesis, hPMVEC were treated with siRNA against src (siRNAsrc), siRNA against yes (siRNAyes), or their respective scramble controls. After recovery, the hPMVEC were treated with cytomix (LPS, IL-1 beta, TNF-alpha, and IFN-gamma). Treatment with cytomix induced activation of the extracellular signal-regulated kinase (ERK) pathway and caspase-3-mediated apoptosis. Treatment with siRNAsrc blunted cytomix-induced ERK activation and enhanced cleaved caspase-3 levels, while treatment with siRNAyes enhanced cytomix-induced ERK activation and attenuated levels of cleaved caspase-3. Inhibition of the ERK pathway using U0126 enhanced cytomix-induced caspase-3 activity. Treatment of hPMVEC with cytomix induced Akt activation, which was inhibited by siRNAsrc. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway using LY294002 prevented cytomix-induced ERK activation and augmented cytomix-induced caspase-3 cleavage. Together, our data demonstrate that, in hPMVEC, yes activation blunts the ERK cascade in response to cytomix, resulting in greater apoptosis, while cytomixinduced src activation induces the phosphatidylinositol 3-kinase pathway, which leads to activation of Akt and ERK and attenuation of apoptosis.
C1 Nationwide Childrens Hosp, Res Inst, Ctr Perinatal Res, Pulm Hypertens Grp, Columbus, OH, United States.
C1 Ohio State Univ, Dept Pediat, Columbus, OH 43210, United States.
C3 University System of Ohio; Ohio State University; Nationwide Childrens
   Hospital; Research Institute at Nationwide Children's Hospital;
   University System of Ohio; Ohio State University
RP Nelin, LD (corresponding author), 575 Childrens Crossroads, Columbus, OH 43215 USA.
EM Leif.Nelin@nationwidechildrens.org
RI Chen, Bernadette/E-2878-2011; Liu, Yusen/E-3527-2011; Nelin,
   Leif/AAC-8475-2020
OI Liu, Yusen/0000-0002-0994-0109; Trittmann, Jennifer/0000-0002-3932-9204;
   Chen, Bernadette/0000-0002-9117-7121
FU National Institutes of Health [K08 HL-105677, R21 AI-113930]
FX This study was supported in part by National Institutes of Health Grants
   K08 HL-105677 (B. Chen) and R21 AI-113930 (Y. Liu).
CR Alphonse RS, 2011, AM J RESP CELL MOL, V44, P146, DOI 10.1165/rcmb.2009-0182OC
   Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006
   Byeon SE, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/512926
   Cepkova Magda, 2006, J Intensive Care Med, V21, P119, DOI 10.1177/0885066606287045
   Chang R, 2008, AM J PHYSIOL-LUNG C, V295, pL688, DOI 10.1152/ajplung.00504.2007
   Chen YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106812
   Cui HM, 2011, CLIN EXP PHARMACOL P, V38, P796, DOI 10.1111/j.1440-1681.2011.05609.x
   Das KC, 2004, ANTIOXID REDOX SIGN, V6, P109, DOI 10.1089/152308604771978417
   Du CP, 2012, CNS NEUROSCI THER, V18, P754, DOI 10.1111/j.1755-5949.2012.00357.x
   Galani V, 2010, PATHOL RES PRACT, V206, P145, DOI 10.1016/j.prp.2009.12.002
   Gien J, 2011, CURR OPIN PEDIATR, V23, P305, DOI 10.1097/MOP.0b013e328346577f
   Han JY, 2013, BLOOD, V122, P4140, DOI 10.1182/blood-2013-03-491423
   Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007
   Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200
   Ikeda Y, 2013, J CARDIOVASC PHARM, V61, P423, DOI 10.1097/FJC.0b013e318287d526
   Jin Y, 2015, J BIOL CHEM, V290, P2099, DOI 10.1074/jbc.M114.599985
   Kim MP, 2009, CELL TISSUE RES, V335, P249, DOI 10.1007/s00441-008-0682-9
   Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001
   Lewis-Tuffin LJ, 2015, MOL ONCOL, V9, P1783, DOI 10.1016/j.molonc.2015.06.001
   Li YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep08209
   May M, 2004, EUR RESPIR J, V23, P113, DOI 10.1183/09031936.03.00038403
   Mokres LM, 2010, AM J PHYSIOL-LUNG C, V298, pL23, DOI 10.1152/ajplung.00251.2009
   Niture SK, 2011, J BIOL CHEM, V286, P28821, DOI 10.1074/jbc.M111.255042
   Ortiz-Diaz E, 2013, SEMIN RESP CRIT CARE, V34, P448, DOI 10.1055/s-0033-1351118
   Oyaizu T, 2012, INTENS CARE MED, V38, P894, DOI 10.1007/s00134-012-2498-z
   Raghavendran K, 2008, CURR MED CHEM, V15, P1911, DOI 10.2174/092986708785132942
   Reinehr Roland, 2013, Biomol Concepts, V4, P129, DOI 10.1515/bmc-2012-0047
   Sato A, 2012, ONCOL REP, V28, P1889, DOI 10.3892/or.2012.2010
   Severgnini M, 2005, AM J RESP CRIT CARE, V171, P858, DOI 10.1164/rccm.200407-981OC
   Sylte MJ, 2005, MICROB PATHOGENESIS, V39, P121, DOI 10.1016/j.micpath.2005.07.001
   Taraseviciene-Stewart L, 2006, AM J PHYSIOL-LUNG C, V291, pL668, DOI 10.1152/ajplung.00491.2005
   Toby IT, 2010, AM J PHYSIOL-LUNG C, V298, pL600, DOI 10.1152/ajplung.00122.2009
   Uhlig U, 2011, COMPR PHYSIOL, V1, P635, DOI 10.1002/cphy.c100004
   Viscardi RM, 2012, SEMIN FETAL NEONAT M, V17, P30, DOI 10.1016/j.siny.2011.08.002
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Watanabe T, 2005, CIRCULATION, V112, P1798, DOI 10.1161/CIRCULATIONAHA.104.509760
   Zhao T, 2014, RESP RES, V15, P1, DOI 10.1186/s12931-014-0158-2
NR 37
TC 9
Z9 11
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY 1
PY 2016
VL 310
IS 9
BP L880
EP L888
DI 10.1152/ajplung.00306.2015
PG 9
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA DK7PB
UT WOS:000375117100010
PM 26919896
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Yi, L
   Huang, XQ
   Guo, F
   Zhou, ZD
   Dou, Y
   Huan, JN
AF Yi, Lei
   Huang, Xiaoqin
   Guo, Feng
   Zhou, Zengding
   Dou, Yi
   Huan, Jingning
TI Yes-associated protein (YAP) signaling regulates
   lipopolysaccharide-induced tissue factor expression in human endothelial
   cells
SO SURGERY
LA English
DT Article
ID ACUTE LUNG INJURY; FACTOR-ALPHA EXPRESSION; NF-KAPPA-B; HIPPO PATHWAY;
   FIBRIN DEPOSITION; MEDICAL PROGRESS; BAX EXPRESSION; SEVERE SEPSIS;
   UP-REGULATION; RHO-KINASE
AB Background. Sepsis-induced acute lung injury (ALI) is characterized by fibrin deposition, which indicates the local activation of coagulation. Tissue factor (TF), expressed in the pulmonary microvasculature, acts as a critical initiator of blood coagulation and ALI in sepsis. The molecular mechanism of lipopolysaccharide (LPS)-induced TF expression in endothelial cells (ECs), however, has not been determined. In this study, we implicate the Rho-associated protein kinase (ROCK)/Yes associated protein (YAP)/early growth response (Egr-1) signaling pathway in LPS-induced TF expression in vitro and in sepsis-induced ALI in vivo.
   Methods. Human umbilical vein ECs incubated with LPS were pretreated with or without the ROCK inhibitor Y-27632, a YAP small, interfering RNA (siRNA) and an Egr-1 siRNA. ROCK, YAP and Egr-1 signaling induced protein expression was investigated by Western blot. The LPS-induced activation of YAP was analyzed by an immunofluorescent assay. Furthermore, we intratracheally injected YAP siRNA to assess septic ALI in mice by hematoxylin and eosin staining.
   Results. I,PS rapidly induced ROCK activation and increased TF expression in ECs. LPS caused YAP shuttling into the nuclei of ECs and combined with Egr-1 via the activation of ROCK Furthermore, the I PS-mediated TF expression increase was prevented by ROCK inactivation, YAP knockdown and Egr-1 depletion, suggesting that LPS-induced TF expression is closely associated with the ROCK/YAP/Egr-1 signaling pathway in ECs. Finally, an intratracheal injection of YAP siRNA relieved lung injury in septic mice.
   Conclusion. This study not only suggests that ROCK/YAP/Egr-1 signaling regulates TF expression after stimulation with LPS in ECs, but it also indicates that LPS-induced activation of YAP signaling plays an important role in septic ALI in mice. Our findings provide a new insight into the pathogenic mechanism of TF expression, which is closely linked to septic ALI, and YAP signaling is considered to be a novel target for therapeutic intervention under septic conditions.
C1 [Yi, Lei; Huang, Xiaoqin; Guo, Feng; Zhou, Zengding; Dou, Yi; Huan, Jingning] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Burn & Plast Surg, Shanghai 230022, China.
C3 Shanghai Jiao Tong University
RP Huan, JN (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Burn & Plast Surg, Shanghai 230022, Peoples R China.
EM friendshiper@live.cn
RI Yi, Lei/AAI-6290-2020; huang, xiaoqin/HZL-4359-2023
FU National Science Foundation of China [81272094, 81471867, 81301633,
   81401590]; Doctoral Innovation Fund Projects from the Shanghai Jiao Tong
   University School of Medicine
FX This study was supported by the National Science Foundation of China
   (nos. 81272094, 81471867, 81301633, and 81401590) and the Doctoral
   Innovation Fund Projects from the Shanghai Jiao Tong University School
   of Medicine.
CR Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371
   Bode M, 2014, VASC PHARMACOL, V62, P57, DOI 10.1016/j.vph.2014.05.005
   Camino-Lopez S, 2007, CARDIOVASC RES, V73, P208, DOI 10.1016/j.cardiores.2006.10.017
   CAO XM, 1993, J BIOL CHEM, V268, P16949
   Carraway MS, 2003, AM J RESP CRIT CARE, V167, P1200, DOI 10.1164/rccm.200204-287OC
   Chu AJ, 2005, ARCH BIOCHEM BIOPHYS, V440, P123, DOI 10.1016/j.abb.2005.06.005
   Ding L, 2011, J BIOL CHEM, V286, P27027, DOI 10.1074/jbc.M111.235176
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B
   Farivar AS, 2005, J HEART LUNG TRANSPL, V24, P2235, DOI 10.1016/j.healun.2005.06.005
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Gordon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075483
   Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429
   Guo F, 2012, SHOCK, V37, P531, DOI 10.1097/SHK.0b013e31824caa96
   Guo F, 2012, MOL IMMUNOL, V50, P98, DOI 10.1016/j.molimm.2011.12.009
   Guo F, 2012, CYTOKINE, V57, P417, DOI 10.1016/j.cyto.2011.12.009
   Guo LW, 2015, INT J ONCOL, V46, P1444, DOI 10.3892/ijo.2015.2877
   Hetzel M, 2005, LUNG, V183, P225, DOI 10.1007/s00408-004-2534-z
   Hofstra JJH, 2008, CURR MED CHEM, V15, P588, DOI 10.2174/092986708783769696
   Hong WJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004573
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Hsueh YJ, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.14
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Idell S, 1994, New Horiz, V2, P566
   Kim J, 2010, CIRC RES, V107, P871, DOI 10.1161/CIRCRESAHA.110.221168
   Kono K, 2014, DEV BIOL, V394, P142, DOI 10.1016/j.ydbio.2014.06.023
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Levi M, 2006, SEMIN THROMB HEMOST, V32, P33, DOI 10.1055/s-2006-933338
   LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934
   Mackman N, 2009, J THROMB HAEMOST, V7, P136, DOI 10.1111/j.1538-7836.2009.03368.x
   Mali RS, 2011, CANCER CELL, V20, P357, DOI 10.1016/j.ccr.2011.07.016
   Mana-Capelli S, 2014, MOL BIOL CELL, V25, P1676, DOI 10.1091/mbc.E13-11-0701
   Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992
   Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005
   Mishra S, 2006, P NATL ACAD SCI USA, V103, P5191, DOI 10.1073/pnas.0600241103
   Mizumura K, 2010, INT IMMUNOPHARMACOL, V10, P1062, DOI 10.1016/j.intimp.2010.06.006
   Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112
   Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115
   Noma K, 2012, J CARDIOL, V60, P1, DOI 10.1016/j.jjcc.2012.03.005
   Nukuda A, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.24
   PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612
   Regue L, 2013, BIOESSAYS, V35, P430, DOI 10.1002/bies.201200163
   Ruf W, 2003, CRIT CARE MED, V31, pS231, DOI 10.1097/01.CCM.0000057848.27456.04
   Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031
   Sebag SC, 2011, CURR PHARM BIOTECHNO, V12, P1481
   Simmons J, 2015, CURR OPIN ANESTHESIO, V28, P227, DOI 10.1097/ACO.0000000000000163
   Slotta JE, 2008, J INVEST MED, V56, P720, DOI 10.2310/JIM.0b013e31816c3e81
   Sun Q, 2012, INT IMMUNOPHARMACOL, V12, P88, DOI 10.1016/j.intimp.2011.10.018
   Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Tsuneki M, 2014, J BIOL CHEM, V289, P5357, DOI 10.1074/jbc.M113.529313
   Valencia-Sama I, 2015, J BIOL CHEM, V290, P16906, DOI 10.1074/jbc.M115.642363
   Vandenbroucke RE, 2011, EMBO MOL MED, V3, P367, DOI 10.1002/emmm.201100146
   Vincent JL, 2003, CRIT CARE MED, V31, pS296, DOI 10.1097/01.CCM.0000057906.89552.8F
   WADA H, 1995, BLOOD COAGUL FIBRIN, V6, pS26, DOI 10.1097/00001721-199506001-00005
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Welty-Wolf KE, 2002, THROMB HAEMOSTASIS, V88, P17
   Welty-Wolf KE, 2001, AM J RESP CRIT CARE, V164, P1988, DOI 10.1164/ajrccm.164.10.2105027
   Welty-Wolf KE, 2006, AM J PHYSIOL-LUNG C, V290, pL21, DOI 10.1152/ajplung.00155.2005
   Welty-Wolf KE, 2001, SEMIN HEMATOL, V38, P35, DOI 10.1016/S0037-1963(01)90145-3
   Xue MM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0518-9
   Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037
   Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461
   Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216
   Zhang H, 2011, APOPTOSIS, V16, P808, DOI 10.1007/s10495-011-0608-y
   Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106328
   Zhang Y, 2014, J BIOL CHEM, V289, P12876, DOI 10.1074/jbc.M113.535831
   Zhang YC, 2014, CELL SIGNAL, V26, P2504, DOI 10.1016/j.cellsig.2014.07.031
   Zhou ZD, 2015, SURGERY, V157, P590, DOI 10.1016/j.surg.2014.10.007
   Zhou ZD, 2013, SURGERY, V154, P621, DOI 10.1016/j.surg.2013.04.009
   Zhu C, 2015, ACTA BIOCH BIOPH SIN, V47, P16, DOI 10.1093/abbs/gmu110
NR 74
TC 21
Z9 23
U1 5
U2 32
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD MAY
PY 2016
VL 159
IS 5
BP 1436
EP 1448
DI 10.1016/j.surg.2015.12.008
PG 13
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA DJ4WI
UT WOS:000374208400024
PM 26791271
OA hybrid
DA 2023-08-21
ER

PT J
AU Hu, SL
   Li, JZ
   Xu, XP
   Liu, AR
   He, HL
   Xu, JY
   Chen, QH
   Liu, SQ
   Liu, L
   Qiu, HB
   Yang, Y
AF Hu, Shuling
   Li, Jinze
   Xu, Xiuping
   Liu, Airan
   He, Hongli
   Xu, Jingyuan
   Chen, Qihong
   Liu, Songqiao
   Liu, Ling
   Qiu, Haibo
   Yang, Yi
TI The hepatocyte growth factor-expressing character is required for
   mesenchymal stem cells to protect the lung injured by lipopolysaccharide
   in vivo
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE ALI/ARDS; mesenchymal stem cell; Hepatic growth factor; permeability 
ID RESPIRATORY-DISTRESS-SYNDROME; ENDOTHELIAL-CELLS; PULMONARY-FIBROSIS;
   LIVER FIBROSIS; VITRO; PERMEABILITY; ACTIVATION; RESISTANCE; PROMOTES;
   RATS
AB Background: Acute respiratory distress syndrome (ARDS) is a life-threatening condition in critically ill patients. Recently, we have found that mesenchymal stem cells (MSC) improved the permeability of human lung microvascular endothelial cells by secreting hepatocyte growth factor (HGF) in vitro. However, the properties and functions of MSC may change under complex circumstances in vivo. Here, we sought to determine the role of the HGF-expressing character of MSC in the therapeutic effects of MSC on ARDS in vivo.
   Methods: MSC with HGF gene knockdown (MSC-ShHGF) were constructed using lentiviral transduction. The HGF mRNA and protein levels in MSC-ShHGF were detected using quantitative real-time polymerase chain reaction and Western blotting analysis, respectively. HGF levels in the MSC culture medium were measured by enzyme-linked immunosorbent assay (ELISA). Rats with ARDS induced by lipopolysaccharide received MSC infusion via the tail vein. After 1, 6, and 24 h, rats were sacrificed. MSC retention in the lung was assessed by immunohistochemical assay. The lung wet weight to body weight ratio (LWW/BW) and Evans blue dye extravasation were obtained to reflect lung permeability. The VE-cadherin was detected with inmmunofluorescence, and the lung endothelial cell apoptosis was assessed by TUNEL assay. The severity of lung injury was evaluated using histopathology. The cytokines and HGF levels in the lung were measured by ELISA.
   Results: MSC-ShHGF with markedly lower HGF expression were successfully constructed. Treatment with MSC or MSC carrying green fluorescent protein (MSC-GFP) maintained HGF expression at relatively high levels in the lung at 24 h. MSC or MSC-GFP decreased the LWW/BW and the Evans Blue Dye extravasation, protected adherens junction VE-cadherin, and reduced the lung endothelial cell apoptosis. Furthermore, MSC or MSC-GFP reduced the inflammation and alleviated lung injury based on histopathology. However, HGF gene knockdown significantly decreased the HGF levels without any changes in the MSC retention in the lung, and diminished the protective effects of MSC on the injured lung, indicating the therapeutic effects of MSC on ARDS were partly associated with the HGF-expressing character of MSC.
   Conclusions: MSC restores lung permeability and lung injury in part by maintaining HGF levels in the lung and the HGF-expressing character is required for MSC to protect the injured lung.
C1 [Hu, Shuling; Li, Jinze; Xu, Xiuping; Liu, Airan; He, Hongli; Xu, Jingyuan; Chen, Qihong; Liu, Songqiao; Liu, Ling; Qiu, Haibo; Yang, Yi] Southeast Univ, Sch Med, Zhongda Hosp, Dept Crit Care Med, 87 Dingjiaqiao Rd, Nanjing 210009, Jiansu, China.
C3 Southeast University - China
RP Yang, Y (corresponding author), Southeast Univ, Sch Med, Zhongda Hosp, Dept Crit Care Med, 87 Dingjiaqiao Rd, Nanjing 210009, Jiansu, Peoples R China.
EM yiyiyang2004@163.com
RI Chen, QH/GXH-3158-2022; 刘, 松桥/ACA-6923-2022; Qiu, Haibo/AAS-9047-2021;
   Xu, Xiuping/W-5865-2019; chen, qian/HKE-2403-2023; CHEN,
   QING/IXN-5937-2023
OI 刘, 松桥/0000-0002-1875-1131; Qiu, Haibo/0000-0001-8589-4717; Xu,
   Xiuping/0000-0003-3950-3425; CHEN, QING/0000-0001-5250-1710
FU National Natural Science Foundation of China [81170057]
FX We all thank Yanli An for assistance with the experimental techniques.
   We are also thankful to Pablo Gabatto and Fengyun Xu. The authors are
   grateful for the financial support of the National Natural Science
   Foundation of China (Grant No. 81170057).
CR Adachi E, 2014, PHARMACOLOGY, V94, P190, DOI 10.1159/000363412
   Awada HK, 2014, MACROMOL BIOSCI, V14, P679, DOI 10.1002/mabi.201300486
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buregeya E, 2014, GLOB HEART, V9, P289, DOI 10.1016/j.gheart.2014.08.003
   Chakraborty S, 2013, EXPERT OPIN INV DRUG, V22, P499, DOI 10.1517/13543784.2013.778972
   Chen QH, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0025-1
   Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   Ding SL, 2003, BLOOD, V101, P4816, DOI 10.1182/blood-2002-06-1731
   Gazdhar A, 2007, AM J PHYSIOL-LUNG C, V292, pL529, DOI 10.1152/ajplung.00082.2006
   Gazdhar A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt513
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   He HL, 2015, CELL TRANSPLANT, V24, P1699, DOI 10.3727/096368914X685087
   Higginbotham K, 2014, CELL SIGNAL, V26, P2306, DOI 10.1016/j.cellsig.2014.07.032
   Kim MD, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.49
   Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Li J, 2015, STEM CELLS DEV, V24, P1817, DOI 10.1089/scd.2014.0521
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Liu AR, 2013, J CELL PHYSIOL, V228, P1270, DOI 10.1002/jcp.24282
   Loghmanpour NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111264
   Martin TA, 2002, J CELL PHYSIOL, V192, P268, DOI 10.1002/jcp.10133
   Matthay Michael A, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS54, DOI 10.1513/AnnalsATS.201406-254MG
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d
   Meng FY, 2015, AM J PHYSIOL-LUNG C, V308, pL452, DOI 10.1152/ajplung.00170.2014
   Molnarfi N, 2015, AUTOIMMUN REV, V14, P293, DOI 10.1016/j.autrev.2014.11.013
   Panganiban RAM, 2011, ACTA PHARMACOL SIN, V32, P12, DOI 10.1038/aps.2010.90
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sastry L, 2002, GENE THER, V9, P1155, DOI 10.1038/sj.gt.3301731
   Seo KW, 2014, CELL BIOL INT, V38, P106, DOI 10.1002/cbin.10186
   Wang H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124420
   Wang XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095247
   Yang X, 2014, HEPATOLOGY, V59, P1874, DOI 10.1002/hep.26941
   Yu F, 2015, CELL BIOL INT, V39, P310, DOI 10.1002/cbin.10397
   Zhang JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114670
NR 35
TC 58
Z9 65
U1 1
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD APR 29
PY 2016
VL 7
AR 66
DI 10.1186/s13287-016-0320-5
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA DK8SM
UT WOS:000375198600001
PM 27129877
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Cai, YQ
   Bolte, C
   Le, T
   Goda, C
   Xu, Y
   Kalin, TV
   Kalinichenko, VV
AF Cai, Yuqi
   Bolte, Craig
   Le, Tien
   Goda, Chinmayee
   Xu, Yan
   Kalin, Tanya V.
   Kalinichenko, Vladimir V.
TI FOXF1 maintains endothelial barrier function and prevents edema after
   lung injury
SO SCIENCE SIGNALING
LA English
DT Article
ID FOXM1 TRANSCRIPTION FACTOR; FORKHEAD BOX F1;
   RESPIRATORY-DISTRESS-SYNDROME; MICE HETEROZYGOUS NULL; SPHINGOSINE
   1-PHOSPHATE; PULMONARY VASCULATURE; EPITHELIAL-CELLS; RECEPTOR S1P(1);
   GENE; EXPRESSION
AB Multiple signaling pathways, structural proteins, and transcription factors are involved in the regulation of endothelial barrier function. The forkhead protein FOXF1 is a key transcriptional regulator of embryonic lung development, and we used a conditional knockout approach to examine the role of FOXF1 in adult lung homeostasis, injury, and repair. Tamoxifen-regulated deletion of both Foxf1 alleles in endothelial cells of adult mice (Pdgfb-iCreER/Foxf1(-/-)) caused lung inflammation and edema, leading to respiratory insufficiency and death. Deletion of a single Foxf1 allele made heterozygous Pdgfb-iCreER/Foxf1(+/-) mice more susceptible to acute lung injury. FOXF1 abundance was decreased in pulmonary endothelial cells of human patients with acute lung injury. Gene expression analysis of pulmonary endothelial cells with homozygous FOXF1 deletion indicated reduced expression of genes critical for maintenance and regulation of adherens junctions. FOXF1 knockdown in vitro and in vivo disrupted adherens junctions, enhanced lung endothelial permeability, and increased the abundance of the mRNA and protein for sphingosine 1-phosphate receptor 1 (S1PR1), a key regulator of endothelial barrier function. Chromatin immunoprecipitation and luciferase reporter assays demonstrated that FOXF1 directly bound to and induced the transcriptional activity of the S1pr1 promoter. Pharmacological administration of S1P to injured Pdgfb-iCreER/Foxf1(+/-) mice restored endothelial barrier function, decreased lung edema, and improved survival. Thus, FOXF1 promotes normal lung homeostasis and repair, in part, by enhancing endothelial barrier function through activation of the S1P/S1PR1 signaling pathway.
C1 [Cai, Yuqi; Bolte, Craig; Le, Tien; Goda, Chinmayee; Xu, Yan; Kalin, Tanya V.; Kalinichenko, Vladimir V.] Cincinnati Childrens Res Fdn, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229, United States.
C1 [Kalin, Tanya V.; Kalinichenko, Vladimir V.] Cincinnati Childrens Res Fdn, Perinatal Inst, Cincinnati, OH 45229, United States.
C3 Cincinnati Children's Hospital Medical Center; Cincinnati Children's
   Hospital Research Foundation; Cincinnati Children's Hospital Medical
   Center; Cincinnati Children's Hospital Research Foundation
RP Kalin, TV; Kalinichenko, VV (corresponding author), Cincinnati Childrens Res Fdn, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Kalin, TV; Kalinichenko, VV (corresponding author), Cincinnati Childrens Res Fdn, Perinatal Inst, Cincinnati, OH 45229 USA.
EM tatiana.kalin@cchmc.org; vladimir.kalinichenko@cchmc.org
RI Goda, Chinmayee/AAQ-5215-2021
OI Goda, Chinmayee/0000-0002-3718-585X; , Yan/0000-0003-2025-027X
FU NIH [HL84151, HL123490, CA142724]
FX This work was supported by NIH grants HL84151 (V.V.K.), HL123490
   (V.V.K.), and CA142724 (T.V.K.).
CR Anders S, 2012, GENOME RES, V22, P2008, DOI 10.1101/gr.133744.111
   Bai AL, 2007, J IMMUNOL, V178, P7632, DOI 10.4049/jimmunol.178.12.7632
   Balli D, 2012, ONCOGENE, V31, P3875, DOI 10.1038/onc.2011.549
   Balli D, 2013, EMBO J, V32, P231, DOI 10.1038/emboj.2012.336
   Balli D, 2011, CANCER RES, V71, P40, DOI 10.1158/0008-5472.CAN-10-2004
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Cai YQ, 2013, J BIOL CHEM, V288, P22527, DOI 10.1074/jbc.M113.455089
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
   Claxton S, 2008, GENESIS, V46, P74, DOI 10.1002/dvg.20367
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Gaengel K, 2012, DEV CELL, V23, P587, DOI 10.1016/j.devcel.2012.08.005
   Galvani S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2581
   Gurkan OU, 2011, EXP LUNG RES, V37, P575, DOI 10.3109/01902148.2011.620680
   Hoggatt AM, 2013, J BIOL CHEM, V288, P28477, DOI 10.1074/jbc.M113.478974
   Jung B, 2012, DEV CELL, V23, P600, DOI 10.1016/j.devcel.2012.07.015
   Kalin TV, 2008, AM J RESP CELL MOL, V39, P390, DOI 10.1165/rcmb.2008-0044OC
   Kalin TV, 2008, P NATL ACAD SCI USA, V105, P19330, DOI 10.1073/pnas.0806748105
   Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005
   Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200
   Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001
   Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322
   Kim IM, 2005, J BIOL CHEM, V280, P37908, DOI 10.1074/jbc.M506531200
   Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200
   Krump-Konvalinkova V, 2005, ARTERIOSCL THROM VAS, V25, P546, DOI 10.1161/01.ATV.0000154360.36106.d9
   Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Mahlapuu M, 2001, DEVELOPMENT, V128, P2397
   Mahlapuu M, 2001, DEVELOPMENT, V128, P155
   Malin D, 2007, MOL CELL BIOL, V27, P2486, DOI 10.1128/MCB.01736-06
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Pradhan A, 2016, ONCOTARGET, V7, P1912, DOI 10.18632/oncotarget.6422
   Ren XM, 2014, CIRC RES, V115, P709, DOI 10.1161/CIRCRESAHA.115.304382
   Ren XM, 2013, MOL CELL BIOL, V33, P371, DOI 10.1128/MCB.00934-12
   Ren XM, 2010, MOL CELL BIOL, V30, P5381, DOI 10.1128/MCB.00876-10
   Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   Ustiyan V, 2012, DEV BIOL, V370, P198, DOI 10.1016/j.ydbio.2012.07.028
   Wang IC, 2012, MOL CELL BIOL, V32, P3838, DOI 10.1128/MCB.00355-12
   Wang IC, 2010, DEV BIOL, V347, P301, DOI 10.1016/j.ydbio.2010.08.027
   Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609
   Wang LC, 2014, CRIT CARE MED, V42, pE189, DOI 10.1097/CCM.0000000000000097
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
NR 47
TC 59
Z9 61
U1 1
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD APR 19
PY 2016
VL 9
IS 424
AR ra40
DI 10.1126/scisignal.aad1899
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DJ8YS
UT WOS:000374501100003
PM 27095594
OA Bronze
DA 2023-08-21
ER

PT J
AU Huang, XJ
   Dai, ZY
   Cai, L
   Sun, K
   Cho, J
   Albertine, KH
   Malik, AB
   Schraufnagel, DE
   Zhao, YY
AF Huang, Xiaojia
   Dai, Zhiyu
   Cai, Lei
   Sun, Kai
   Cho, Jaehyung
   Albertine, Kurt H.
   Malik, Asrar B.
   Schraufnagel, Dean E.
   Zhao, You-Yang
TI Endothelial p110 gamma PI3K Mediates Endothelial Regeneration and
   Vascular Repair After Inflammatory Vascular Injury
SO CIRCULATION
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; vascular; endothelial regeneration; Inflammation; vascular disease; vascular repair 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; PHOSPHOINOSITIDE
   3-KINASES; PI3K-GAMMA INHIBITION; CORONARY ANGIOPLASTY; NEUTROPHIL
   MIGRATION; SEPSIS; FOXM1; ACTIVATION; MECHANISMS
AB Background The integrity of endothelial monolayer is a sine qua non for vascular homeostasis and maintenance of tissue-fluid balance. However, little is known about the signaling pathways regulating regeneration of the endothelial barrier after inflammatory vascular injury.
   Methods and Results Using genetic and pharmacological approaches, we demonstrated that endothelial regeneration selectively requires activation of p110PI3K signaling, which thereby mediates the expression of the endothelial reparative transcription factor Forkhead box M1 (FoxM1). We observed that FoxM1 induction in the pulmonary vasculature was inhibited in mice treated with a p110-selective inhibitor and in Pik3cg(-/-) mice after lipopolysaccharide challenge. Pik3cg(-/-) mice exhibited persistent lung inflammation induced by sepsis and sustained increase in vascular permeability. Restoration of expression of either p110 or FoxM1 in pulmonary endothelial cells of Pik3cg(-/-) mice restored endothelial regeneration and normalized the defective vascular repair program. We also observed diminished expression of p110 in pulmonary vascular endothelial cells of patients with acute respiratory distress syndrome, suggesting that impaired p110-FoxM1 vascular repair signaling pathway is a critical factor in persistent leaky lung microvessels and edema formation in the disease.
   Conclusions We identify p110 as the critical mediator of endothelial regeneration and vascular repair after sepsis-induced inflammatory injury. Thus, activation of p110-FoxM1 endothelial regeneration may represent a novel strategy for the treatment of inflammatory vascular diseases.
C1 [Huang, Xiaojia; Dai, Zhiyu; Cai, Lei; Sun, Kai; Cho, Jaehyung; Malik, Asrar B.; Zhao, You-Yang] Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,MSB E403, Chicago, IL 60612, United States.
C1 [Huang, Xiaojia; Dai, Zhiyu; Cai, Lei; Sun, Kai; Malik, Asrar B.; Zhao, You-Yang] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C1 [Schraufnagel, Dean E.] Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612, United States.
C1 [Albertine, Kurt H.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT, United States.
C1 [Albertine, Kurt H.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Zhao, YY (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,MSB E403, Chicago, IL 60612 USA.
EM yyzhao@uic.edu
RI Dai, Zhiyu/H-3453-2019
OI Dai, Zhiyu/0000-0002-2945-7923; Cho, Jaehyung/0000-0003-2404-3446; ZHAO,
   YOU-YANG/0000-0002-0041-0339; Malik, Asrar/0000-0002-8205-7128;
   Schraufnagel, Dean/0000-0003-0063-7223
FU National Institutes of Health [R01HL123957, R01HL125350, P01HL077806, 3]
FX This work was supported in part by National Institutes of Health grants
   R01HL123957, R01HL125350, and P01HL077806 (Project 3) to Dr Zhao.
CR Aird WC, 2008, PHARMACOL REP, V60, P139
   Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0
   AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Cepinskas G, 1997, CIRC RES, V81, P618, DOI 10.1161/01.RES.81.4.618
   Cines DB, 1998, BLOOD, V91, P3527
   Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Fergus GJ, 2007, NAT CELL BIOL, V9, P86, DOI 10.1038/ncb1517
   Fernandez-Borja M, 2010, CARDIOVASC RES, V86, P202, DOI 10.1093/cvr/cvq003
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Guillermet-Guibert J, 2008, P NATL ACAD SCI USA, V105, P8292, DOI 10.1073/pnas.0707761105
   Hers I, 2007, BLOOD, V110, P4243, DOI 10.1182/blood-2006-10-050633
   Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049
   Huang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050094
   Kaestner KH, 2000, GENE DEV, V14, P142
   Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200
   Kim DI, 2012, J CLIN IMMUNOL, V32, P340, DOI 10.1007/s10875-011-9628-1
   Kok K, 2009, TRENDS BIOCHEM SCI, V34, P115, DOI 10.1016/j.tibs.2009.01.003
   Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678
   Martin EL, 2010, AM J RESP CRIT CARE, V182, P762, DOI 10.1164/rccm.201001-0088OC
   Maus UA, 2007, AM J RESP CRIT CARE, V175, P958, DOI 10.1164/rccm.200610-1533OC
   MCFADDEN EP, 1993, CIRCULATION, V88, P2076, DOI 10.1161/01.CIR.88.5.2076
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Mirza MK, 2010, J EXP MED, V207, P1675, DOI 10.1084/jem.20091857
   Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714
   Ong E, 2005, AM J PHYSIOL-LUNG C, V289, pL1094, DOI 10.1152/ajplung.00179.2005
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   Prandini MH, 2005, ONCOGENE, V24, P2992, DOI 10.1038/sj.onc.1208483
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Ruckle T, 2006, NAT REV DRUG DISCOV, V5, P903, DOI 10.1038/nrd2145
   Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040
   Schroeder FC, 2005, J NAT PROD, V68, P574, DOI 10.1021/np049624z
   SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5
   Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7
   Tibolla G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053808
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Wang HX, 2010, CARCINOGENESIS, V31, P1132, DOI 10.1093/carcin/bgq058
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0
   Williams DL, 2004, J IMMUNOL, V172, P449, DOI 10.4049/jimmunol.172.1.449
   Wrann CD, 2007, J IMMUNOL, V178, P5940, DOI 10.4049/jimmunol.178.9.5940
   Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626
   Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 50
TC 44
Z9 48
U1 3
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAR 15
PY 2016
VL 133
IS 11
BP 1093
EP 1103
DI 10.1161/CIRCULATIONAHA.115.020918
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA DG3ZE
UT WOS:000372008900007
PM 26839042
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Ghosh, CC
   David, S
   Zhang, RY
   Berghelli, A
   Milam, K
   Higgins, SJ
   Hunter, J
   Mukherjee, A
   Wei, YY
   Tran, M
   Suber, F
   Kobzik, L
   Kain, KC
   Lu, SL
   Santel, A
   Yano, K
   Guha, P
   Dumont, DJ
   Christiani, DC
   Parikh, SM
AF Ghosh, Chandra C.
   David, Sascha
   Zhang, Ruyang
   Berghelli, Anthony
   Milam, Katelyn
   Higgins, Sarah J.
   Hunter, Jon
   Mukherjee, Aditi
   Wei, Yongyue
   Tran, Mei
   Suber, Freeman
   Kobzik, Lester
   Kain, Kevin C.
   Lu, Shulin
   Santel, Ansgar
   Yano, Kiichiro
   Guha, Prajna
   Dumont, Daniel J.
   Christiani, David C.
   Parikh, Samir M.
TI Gene control of tyrosine kinase TIE2 and vascular manifestations of
   infections
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Tie1/Tie2; ECs/HPMECs/HUVECs/MPVECs; infection; angiopoietin-1/angiopoietin-2; permeability 
ID MULTIPLE ORGAN DYSFUNCTION; ACUTE LUNG INJURY; RNA INTERFERENCE;
   ANGIOPOIETIN 2; SEVERE SEPSIS; SEPTIC SHOCK; IN-VIVO; CELL;
   PERMEABILITY; PROTEIN
AB Ligands of the endothelial-enriched tunica interna endothelial cell kinase 2 (Tie2) are markedly imbalanced in severe infections associated with vascular leakage, yet regulation of the receptor itself has been understudied in this context. Here, we show that TIE2 gene expression may constitute a novel vascular barrier control mechanism in diverse infections. Tie2 expression declined rapidly in wide-ranging models of leak-associated infections, including anthrax, influenza, malaria, and sepsis. Forced Tie2 suppression sufficed to attenuate barrier function and sensitize endothelium to permeability mediators. Rapid reduction of pulmonary Tie2 in otherwise healthy animals attenuated downstream kinase signaling to the barrier effector vascular endothelial (VE)-cadherin and induced vascular leakage. Compared with wild-type littermates, mice possessing one allele of Tie2 suffered more severe vascular leakage and higher mortality in two different sepsis models. Common genetic variants that influence TIE2 expression were then sought in the HapMap3 cohort. Remarkably, each of the three strongest predicted cis-acting SNPs in HapMap3 was also associated with the risk of acute respiratory distress syndrome (ARDS) in an intensive care unit cohort of 1,614 subjects. The haplotype associated with the highest TIE2 expression conferred a 28% reduction in the risk of ARDS independent of other major clinical variables, including disease severity. In contrast, the most common haplotype was associated with both the lowest TIE2 expression and 31% higher ARDS risk. Together, the results implicate common genetic variation at the TIE2 locus as a determinant of vascular leak-related clinical outcomes from common infections, suggesting new tools to identify individuals at unusual risk for deleterious complications of infection.
C1 [Ghosh, Chandra C.; David, Sascha; Berghelli, Anthony; Milam, Katelyn; Higgins, Sarah J.; Hunter, Jon; Mukherjee, Aditi; Tran, Mei; Lu, Shulin; Yano, Kiichiro; Parikh, Samir M.] Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215, United States.
C1 [Ghosh, Chandra C.; David, Sascha; Berghelli, Anthony; Milam, Katelyn; Higgins, Sarah J.; Hunter, Jon; Mukherjee, Aditi; Tran, Mei; Lu, Shulin; Yano, Kiichiro; Parikh, Samir M.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215, United States.
C1 [Ghosh, Chandra C.; David, Sascha; Berghelli, Anthony; Milam, Katelyn; Higgins, Sarah J.; Hunter, Jon; Mukherjee, Aditi; Tran, Mei; Lu, Shulin; Yano, Kiichiro; Parikh, Samir M.] Harvard Univ, Sch Med, Boston, MA 02215, United States.
C1 [David, Sascha] Hannover Med Sch, Div Hypertens & Nephrol, D-30625 Hannover, Germany.
C1 [Zhang, Ruyang; Wei, Yongyue; Christiani, David C.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114, United States.
C1 [Zhang, Ruyang; Wei, Yongyue; Christiani, David C.] Harvard Univ, Sch Med, Boston, MA 02114, United States.
C1 [Zhang, Ruyang; Wei, Yongyue; Suber, Freeman; Kobzik, Lester; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115, United States.
C1 [Higgins, Sarah J.; Kain, Kevin C.] Univ Toronto, Sandra Rotman Ctr Global Hlth, Univ Hlth Network, 100 Coll St, Toronto, ON M5S 1A1, Canada.
C1 [Higgins, Sarah J.; Kain, Kevin C.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada.
C1 [Santel, Ansgar] Silence Therapeut GmbH, D-13125 Berlin, Germany.
C1 [Guha, Prajna] Roger Williams Med Ctr, Providence, RI 02908, United States.
C1 [Dumont, Daniel J.] Univ Toronto, Sunnybrook Inst, Toronto, ON M4N 3M5, Canada.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   University; Beth Israel Deaconess Medical Center; Harvard University;
   Harvard Medical School; Hannover Medical School; Harvard University;
   Massachusetts General Hospital; Harvard University; Harvard Medical
   School; Harvard University; Harvard T.H. Chan School of Public Health;
   University of Toronto; University Health Network Toronto; University of
   Toronto; Roger Williams Medical Center; University of Toronto;
   Sunnybrook Health Science Center
RP Ghosh, CC; Parikh, SM (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215 USA.; Ghosh, CC; Parikh, SM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.; Ghosh, CC; Parikh, SM (corresponding author), Harvard Univ, Sch Med, Boston, MA 02215 USA.
EM cghosh@bidmc.harvard.edu; sparikh1@bidmc.harvard.edu
RI Parikh, Samir M/HJY-8612-2023; Wei, Yongyue/GYV-5660-2022; ZHOU,
   yf/IAO-5497-2023; David, Sascha/AAL-6909-2021
OI Parikh, Samir M/0000-0002-1038-981X; Wei, Yongyue/0000-0002-1132-1796;
   Kain, Kevin/0000-0001-6068-1272; Tran, Mei/0000-0003-1114-0984
FU NIH [HL093234, HL093234-S1, HL125275]; German Research Foundation [DFG
   DA1209/1-1]; Canada Research Chair; Canadian Institutes of Health
   Research [MOP-115160, 136813, 13721]
FX We thank Prof. Manolis Dermitzakis (University of Geneva) for detailed
   advice on cis-eQTL analysis. This study was supported by research
   funding from the NIH (Grants HL093234, HL093234-S1, and HL125275 to
   S.M.P.). S.D. was supported by the German Research Foundation (Grant DFG
   DA1209/1-1). K.C.K. was supported by a Canada Research Chair and grants
   from the Canadian Institutes of Health Research (Grants MOP-115160,
   136813, and 13721).
CR Anderson CA, 2010, NAT PROTOC, V5, P1564, DOI 10.1038/nprot.2010.116
   Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200
   Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082
   Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393
   Dallabrida SM, 2005, CIRC RES, V96, DOI 10.1161/01.RES.0000158285.57191.60
   David S, 2012, CRIT CARE MED, V40, P3034, DOI 10.1097/CCM.0b013e31825fdc31
   David S, 2011, ARTERIOSCL THROM VAS, V31, P2643, DOI 10.1161/ATVBAHA.111.233189
   David S, 2011, AM J PHYSIOL-LUNG C, V300, pL851, DOI 10.1152/ajplung.00459.2010
   Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177
   Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992
   Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376
   Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Findley CM, 2007, ARTERIOSCL THROM VAS, V27, P2619, DOI 10.1161/ATVBAHA.107.150482
   Gaieski DF, 2010, CRIT CARE MED, V38, P1045, DOI 10.1097/CCM.0b013e3181cc4824
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gavrilovskaya IN, 2008, J VIROL, V82, P5797, DOI 10.1128/JVI.02397-07
   Ghosh CC, 2012, P NATL ACAD SCI USA, V109, P10024, DOI 10.1073/pnas.1120755109
   Ghosh S, 2011, AM J RESP CELL MOL, V45, P1036, DOI 10.1165/rcmb.2010-0349OC
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Gong HX, 2014, J EXP MED, V211, P579, DOI 10.1084/jem.20131190
   Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962
   Higgins SJ, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-105
   Jeansson M, 2011, J CLIN INVEST, V121, P2278, DOI 10.1172/JCI46322
   Kim MS, 2009, CIRCULATION, V120, P2240, DOI 10.1161/CIRCULATIONAHA.109.856815
   Kugathasan L, 2009, J EXP MED, V206, P2221, DOI 10.1084/jem.20090389
   Kurniati NF, 2013, INTENS CARE MED, V39, P1262, DOI 10.1007/s00134-013-2899-7
   Lai PS, 2013, CURR INFECT DIS REP, V15, P407, DOI 10.1007/s11908-013-0358-9
   Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531
   MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903
   Parikh SM, 2013, VIRULENCE, V4, P517, DOI 10.4161/viru.24906
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Rasmussen AL, 2014, SCIENCE, V346, P987, DOI 10.1126/science.1259595
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Stiehl T, 2014, CRIT CARE MED, V42, pE654, DOI 10.1097/CCM.0000000000000524
   Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Wei YY, 2015, CHEST, V147, P607, DOI 10.1378/chest.14-1246
   Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159
   Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E
   Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567
   Xie ZH, 2012, BLOOD, V119, P4321, DOI 10.1182/blood-2011-08-375816
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
NR 53
TC 68
Z9 70
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2016
VL 113
IS 9
BP 2472
EP 2477
DI 10.1073/pnas.1519467113
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF2WG
UT WOS:000371204500055
PM 26884170
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Han, X
   Wang, YX
   Chen, HL
   Zhang, JW
   Xu, CM
   Li, J
   Li, MY
AF Han, Xiao
   Wang, Yuxi
   Chen, Hailong
   Zhang, Jingwen
   Xu, Caiming
   Li, Jian
   Li, Mingyue
TI Enhancement of ICAM-1 via the JAK2/STAT3 signaling pathway in a rat
   model of severe acute pancreatitis-associated lung injury
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE ICAM-1; JAK2; STAT3/STAT5; ALI/ARDS; severe acute pancreatitis; rat 
ID INTERCELLULAR-ADHESION MOLECULE-1; NF-KAPPA-B; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; ACTIVATION; ALPHA; IMMUNOGLOBULIN; DEXAMETHASONE;
   INFLAMMATION; RECRUITMENT
AB Acute lung injury (ALI), which is associated with severe acute pancreatitis (SAP), results from damage to the pulmonary microvascular endothelial cells (PMVECs), which in turn leads to high levels of inflammatory cytokines that destroy PMVECs. However, the molecular mechanisms underlying SAP-associated ALI (SAP-ALI) are currently not well understood. Intercellular adhesion molecule-1 (ICAM-1) has been implicated in the persistent migration and accumulation of neutrophils and macrophages, which in turn has been associated with the increased permeability of microvascular endothelial cells. Signal transduction via the Janus kinase-2 (JAK2)/signal transducer and activator of transcription-3 (STAT3) transcription factors has been shown to be involved in inflammation. The present study aimed to investigate the expression levels of ICAM-1 and JAK2/STAT3 signaling components in a rat model of SAP-ALI. SAP was induced in the rat model, and dexamethasone (DEX) was administered to the treatment group. Subsequently, ICAM-1, interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-alpha, JAK2, STAT3 and nuclear factor (NF)-kappa B mRNA expression levels were determined using reverse transcription-polymerase chain reaction; ICAM-1 protein expression levels were determined using western blotting; and IL-6, IL-8 and TNF-alpha levels were measured via an enzyme-linked immunosorbent assay. In addition, an immunohistochemical analysis of ICAM-1, NF-kappa B, JAK2 and STAT3 was conducted, and the protein expression and cell morphology of the lungs in all rats was analyzed. ICAM-1 mRNA and protein expression levels were significantly increased following induction of SAP, and were significantly decreased in the DEX-treated group. Furthermore, treatment with DEX significantly reduced serum expression levels of IL-6, IL-8 and TNF-alpha and decreased expression levels of NF-kappa B, JAK2 and STAT3 in the lung tissue, as compared with the untreated SAP group. The present study demonstrated that DEX treatment was able to suppress ICAM-1 mRNA and protein expression in a rat model of SAP-ALI via the inhibition of IL-6 and TNF-alpha-induced JAK2/STAT3 activation; thus suggesting that DEX treatment may be considered a potential strategy in the treatment of patients with SAP-ALI.
C1 [Han, Xiao; Chen, Hailong; Zhang, Jingwen; Xu, Caiming; Li, Jian; Li, Mingyue] Dalian Med Univ, Affiliated Hosp 1, Dept Gen Surg, 222 Zhongshan Rd, Dalian 116011, Liaoning, China.
C1 [Wang, Yuxi] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian 116023, Liaoning, China.
C3 Dalian Medical University; Dalian Medical University
RP Chen, HL (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Dept Gen Surg, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
EM chenhailong2012@aliyun.com
RI Xu, Caiming/AAG-9883-2022; Zhang, Junwen/L-5554-2016; Zhang,
   Jing/GWZ-7332-2022; Xu, Caiming/CAA-3267-2022
OI Zhang, Junwen/0000-0001-8041-1608; Xu, Caiming/0000-0001-7794-2301
FU National Natural Science Foundation of China [81173452]
FX The present study was supported by The National Natural Science
   Foundation of China (grant no. 81173452). The present study was
   conducted at the Laboratory of the First Affiliated Hospital of Dalian
   Medical University and Dalian Center Hospital (Dalian, China). The
   authors would like to thank Dr Hao Zhang for assistance with editing.
CR Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011
   Boengler K, 2008, PHARMACOL THERAPEUT, V120, P172, DOI 10.1016/j.pharmthera.2008.08.002
   Brown MD, 2009, CELL SIGNAL, V21, P462, DOI 10.1016/j.cellsig.2008.11.013
   Castillo R L, 2015, Open Respir Med J, V9, P83, DOI 10.2174/1874306401509010083
   Chatterjee PK, 2009, AM J PHYSIOL-CELL PH, V297, pC1294, DOI 10.1152/ajpcell.00160.2009
   Chen C, 2009, ARCH MED RES, V40, P79, DOI 10.1016/j.arcmed.2008.11.004
   Chen SC, 2006, BRIT J PHARMACOL, V148, P226, DOI 10.1038/sj.bjp.0706647
   Choi JS, 2004, J NUTR, V134, P1013, DOI 10.1093/jn/134.5.1013
   COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214
   DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D
   Dong LH, 2015, INT J CLIN EXP PATHO, V8, P7654
   Hou SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087826
   Jung J, 2012, IMMUNOLOGY, V137, P98, DOI 10.1111/j.1365-2567.2012.03618.x
   Kojima R, 2015, INT IMMUNOPHARMACOL, V24, P267, DOI 10.1016/j.intimp.2014.12.016
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Li HL, 2005, INT J MOL MED, V16, P41
   Liu TE, 2013, LEUKEMIA RES, V37, P1322, DOI 10.1016/j.leukres.2013.06.026
   Lund H, 2006, SCAND J GASTROENTERO, V41, P234, DOI 10.1080/00365520510024133
   Madan B, 2000, MOL PHARMACOL, V58, P526, DOI 10.1124/mol.58.3.526
   Meager A, 1999, CYTOKINE GROWTH F R, V10, P27, DOI 10.1016/S1359-6101(98)00024-0
   Min JK, 2005, J IMMUNOL, V175, P531, DOI 10.4049/jimmunol.175.1.531
   Minhajuddin M, 2009, J BIOL CHEM, V284, P4052, DOI 10.1074/jbc.M805032200
   Ramudo L, 2010, PANCREAS, V39, P1057, DOI 10.1097/MPA.0b013e3181da0f3e
   Rani N, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0004-7
   Rao RM, 2007, CIRC RES, V101, P234, DOI 10.1161/CIRCRESAHA.107.151860b
   Renzulli P, 2005, PANCREATOLOGY, V5, P145, DOI 10.1159/000085266
   Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876
   Shields Conor J, 2002, Curr Opin Crit Care, V8, P158, DOI 10.1097/00075198-200204000-00012
   STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5
   Storme L, 2013, ARCH CARDIOVASC DIS, V106, P169, DOI 10.1016/j.acvd.2012.12.005
   Wang YX, 2013, INT J MOL MED, V32, P568, DOI 10.3892/ijmm.2013.1420
   Williams M, 1999, CRIT CARE MED, V27, P901, DOI 10.1097/00003246-199905000-00023
   Williams MR, 2011, TRENDS IMMUNOL, V32, P461, DOI 10.1016/j.it.2011.06.009
   Wu FH, 2012, BIOL PHARM BULL, V35, P1171, DOI 10.1248/bpb.b110586
   Wu L, 2013, INFLAMMATION, V36, P1020, DOI 10.1007/s10753-013-9634-y
   Yang NS, 2008, NEPHROL DIAL TRANSPL, V23, P91, DOI 10.1093/ndt/gfm509
   Yu R, 2004, ATHEROSCLEROSIS, V174, P35, DOI 10.1016/j.atherosclerosis.2003.11.024
   Yuan Q, 2014, J INFLAMM-LOND, V11, DOI 10.1186/s12950-014-0040-5
   Zhu HH, 2012, WORLD J GASTROENTERO, V18, P2554, DOI 10.3748/wjg.v18.i20.2554
NR 39
TC 28
Z9 32
U1 1
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAR
PY 2016
VL 11
IS 3
BP 788
EP 796
DI 10.3892/etm.2016.2988
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DC9PV
UT WOS:000369554400014
PM 26997994
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Hashimoto, K
   Kim, H
   Oishi, H
   Chen, M
   Iskender, I
   Sakamoto, J
   Ohsumi, A
   Guan, ZH
   Hwang, D
   Waddell, TK
   Cypel, M
   Liu, MY
   Keshavjee, S
AF Hashimoto, Kohei
   Kim, Hyunhee
   Oishi, Hisashi
   Chen, Manyin
   Iskender, Ilker
   Sakamoto, Jin
   Ohsumi, Akihiro
   Guan, Zehong
   Hwang, David
   Waddell, Thomas K.
   Cypel, Marcelo
   Liu, Mingyao
   Keshavjee, Shaf
TI Annexin V homodimer protects against ischemia reperfusion-induced acute
   lung injury in lung transplantation
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
DE diannexin; primary graft dysfunction; ischemia/reperfusion; apoptosis 
ID PLASMINOGEN-ACTIVATOR INHIBITOR; PRIMARY GRAFT DYSFUNCTION;
   GENE-EXPRESSION; P-GLYCOPROTEIN; CELL APOPTOSIS; IN-VIVO; DIANNEXIN;
   INDUCTION; PHOSPHATIDYLSERINE; FIBRINOLYSIS
AB Objective: We hypothesized that administration of a homodimer of recombinant annexin V, diannexin, could shield phosphatidylserine on the endothelium, and inhibit leukocyte and platelet adhesion, thereby potentially reducing ischemia reperfusion injury (IRI) in lung transplantation. This hypothesis was tested using a rat syngeneic single left-lung transplant model.
   Methods: Rats were randomly assigned to receive diannexin (DN group; n = 10) or normal saline (control group; n = 10). Diannexin (1000 mu g/kg) was administered to the donor lung in the pulmonary flush solution, and to the recipient intravenously, 5 minutes after initiation of reperfusion. Grafts were reperfused for 2 hours.
   Results: The transplanted grafts in the DN group performed significantly better in gas exchange with higher partial pressure of oxygen (control group: 179 +/- 121 vs DN group: 330 +/- 54 mm Hg; P = .007) and lower partial pressure of carbon dioxide (control: 55.1 +/- 26 vs DN: 34.2 +/- 11 mm Hg; P = .04), as well as lower peak airway pressure (control: 20.5 +/- 8.5 vs DN: 12.0 +/- 7.9 cm H2O; P = .035) after 2 hours of reperfusion. Wet-to-dry lung weight ratio (P = .054), and alveolar fibrin deposition score (P = .04), were reduced in the DN group. Caspase-cleaved cytokeratin 18 in plasma (a marker of epithelial apoptosis) was significantly reduced in the DN group (P = .013). Furthermore, gene-expression levels of proinflammatory cytokines in the transplanted graft, including interleukin-6 (P = .04) and macrophage inflammatory protein 2 (P = .03) were significantly decreased in the DN group.
   Conclusions: A homodimer of recombinant annexin V reduced ischemia reperfusion injury in a lung transplant animal model, by reducing cell death and tissue inflammation.
C1 [Hashimoto, Kohei; Kim, Hyunhee; Oishi, Hisashi; Chen, Manyin; Iskender, Ilker; Sakamoto, Jin; Ohsumi, Akihiro; Guan, Zehong; Waddell, Thomas K.; Cypel, Marcelo; Liu, Mingyao; Keshavjee, Shaf] Univ Toronto, Univ Hlth Network, Div Thorac Surg, Latner Thorac Surg Res Labs, Toronto, ON, Canada.
C1 [Hwang, David] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto; University of
   Toronto
RP Keshavjee, S (corresponding author), Univ Toronto, Div Thorac Surg, Toronto Gen Hosp, Univ Hlth Network, 190 Elizabeth St,RFE 1-408, Toronto, ON M5G 2C4, Canada.
EM Shaf.Keshavjee@uhn.ca
RI Iskender, Ilker/J-8923-2019
OI Iskender, Ilker/0000-0003-0530-2561; Keshavjee,
   Shaf/0000-0003-4547-8094; Cypel, Marcelo/0000-0001-5652-1938; Waddell,
   Thomas/0000-0002-3235-9208; Ohsumi, Akihiro/0000-0002-2847-9653; Liu,
   Mingyao/0000-0002-9188-8417
FU Canadian Institutes of Health Research (OOP, Ottawa, Ontario, Canada)
   [312227]; Mitsukoshi Health and Welfare Foundation, Tokyo, Japan;
   Ishidsu Shun Memorial Scholarship (Tokyo, Japan)
FX This work was supported by the Canadian Institutes of Health Research
   (OOP#312227, Ottawa, Ontario, Canada). K.H. is supported by a grant from
   the Mitsukoshi Health and Welfare Foundation, Tokyo, Japan, and by an
   Ishidsu Shun Memorial Scholarship (Tokyo, Japan).
CR Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429
   Cheng EY, 2010, TRANSPLANTATION, V90, P709, DOI 10.1097/TP.0b013e3181ed55d8
   Christie JD, 2007, AM J RESP CRIT CARE, V175, P69, DOI 10.1164/rccm.200606-827OC
   Christie JD, 2005, J HEART LUNG TRANSPL, V24, P1454, DOI 10.1016/j.healun.2004.11.049
   Christie JD, 2005, CHEST, V127, P161, DOI 10.1378/chest.127.1.161
   Christie JD, 2005, AM J RESP CRIT CARE, V171, P1312, DOI 10.1164/rccm.200409-1243OC
   Cooper M, 2010, AM J TRANSPLANT, V10, P83
   Covarrubias M, 2007, AM J TRANSPLANT, V7, P2573, DOI 10.1111/j.1600-6143.2007.01981.x
   Daud SA, 2007, AM J RESP CRIT CARE, V175, P507, DOI 10.1164/rccm.200608-1079OC
   de Perrot M, 2005, ANN THORAC SURG, V79, P2169, DOI 10.1016/j.athoracsur.2004.01.043
   De Perrot M, 2002, AM J RESP CRIT CARE, V165, P211, DOI 10.1164/ajrccm.165.2.2011151
   Fischer S, 2000, AM J RESP CRIT CARE, V162, P1932, DOI 10.1164/ajrccm.162.5.9910064
   Fischer S, 2000, ANN SURG, V231, P424, DOI 10.1097/00000658-200003000-00016
   Hale SL, 2011, CARDIOVASC THER, V29, pE42, DOI 10.1111/j.1755-5922.2010.00223.x
   Henson PM, 2008, AM J PHYSIOL-LUNG C, V294, pL601, DOI 10.1152/ajplung.00320.2007
   Huls M, 2007, KIDNEY INT, V72, P1233, DOI 10.1038/sj.ki.5002522
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Kuypers FA, 2007, THROMB HAEMOSTASIS, V97, P478, DOI 10.1160/TH06-08-0436
   Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Mathur A, 2006, ANN THORAC SURG, V81, P1844, DOI 10.1016/j.athoracsur.2005.11.053
   MIZUTA T, 1989, J THORAC CARDIOV SUR, V97, P578
   Molski M, 2009, ANN PLAS SURG, V63, P564, DOI 10.1097/SAP.0b013e3181935a4e
   Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307
   Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880
   Quadri SM, 2005, AM J TRANSPLANT, V5, P292, DOI 10.1111/j.1600-6143.2004.00701.x
   Rand ML, 2012, J THROMB HAEMOST, V10, P1109, DOI 10.1111/j.1538-7836.2012.04716.x
   Roth GA, 2004, SHOCK, V22, P218, DOI 10.1097/01.shk.0000136098.49672.0e
   Sack FU, 2006, TRANSPLANT P, V38, P737, DOI 10.1016/j.transproceed.2006.01.060
   SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440
   Shen XD, 2007, AM J TRANSPLANT, V7, P2463, DOI 10.1111/j.1600-6143.2007.01967.x
   Teoh NC, 2007, GASTROENTEROLOGY, V133, P632, DOI 10.1053/j.gastro.2007.05.027
   Ware LB, 2007, CRIT CARE MED, V35, P1821, DOI 10.1097/01.CCM.0000275386.95968.5F
   Wever KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024276
   Xiao HL, 2010, MOL CELL BIOL, V30, P5545, DOI 10.1128/MCB.00382-10
NR 35
TC 24
Z9 25
U1 2
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2016
VL 151
IS 3
BP 861
EP 869
DI 10.1016/j.jtcvs.2015.10.112
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DD9KR
UT WOS:000370244700068
PM 26725713
OA hybrid
DA 2023-08-21
ER

PT J
AU Yang, C
   Jiang, JX
   Yang, XT
   Wang, HY
   Du, J
AF Yang, Ce
   Jiang, Jianxin
   Yang, Xuetao
   Wang, Haiyan
   Du, Juan
TI Stem/progenitor cells in endogenous repairing responses: new toolbox for
   the treatment of acute lung injury
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE lung; proliferation; regeneration; repair; stem/progenitor cell; trauma 
ID MESENCHYMAL STEM-CELLS; RESPIRATORY-DISTRESS-SYNDROME; ENDOTHELIAL
   PROGENITOR CELLS; BONE-MARROW; STROMAL CELLS; IN-VITRO; AUTOLOGOUS
   TRANSPLANTATION; BACTERIAL CLEARANCE; CONDITIONED MEDIUM; AIRWAY
   EPITHELIUM
AB The repair of organs and tissues has stepped into a prospective era of regenerative medicine. However, basic research and clinical practice in the lung regeneration remains crawling. Owing to the complicated three dimensional structures and above 40 types of pulmonary cells, the regeneration of lung tissues becomes a great challenge. Compelling evidence has showed that distinct populations of intrapulmonary and extrapulmonary stem/progenitor cells can regenerate epithelia as well as endothelia in various parts of the respiratory tract. Recently, the discovery of human lung stem cells and their relevant studies has opened the door of hope again, which might put us on the path to repair our injured body parts, lungs on demand. Herein, we emphasized the role of endogenous and exogenous stem/progenitor cells in lungs as well as artificial tissue repair for the injured lungs, which constitute a marvelous toolbox for the treatment of acute lung injury. Finally, we further discussed the potential problems in the pulmonary remodeling and regeneration.
C1 [Yang, Ce; Jiang, Jianxin; Yang, Xuetao; Wang, Haiyan; Du, Juan] Third Mil Med Univ, Daping Hosp, State Key Lab Trauma Burns & Combined Injury, Inst Surg Res, Chongqing 400042, China.
C3 Army Medical University
RP Yang, C; Jiang, JX (corresponding author), Third Mil Med Univ, Daping Hosp, State Key Lab Trauma Burns & Combined Injury, Inst Surg Res, Chongqing 400042, Peoples R China.
EM sepsismd@126.com; hellojjx@126.com
FU Special Funds for Major State Basic Research Projects [2012CB518104];
   Natural Science Foundation of China [81530063, 81372105, 31271242];
   Medical Research Funding of PLA [AWS14C001, AWS14C003]
FX The authors declare that they have no competing interests. This work was
   partly supported by the Special Funds for Major State Basic Research
   Projects (2012CB518104), the grants from Natural Science Foundation of
   China (81530063, 81372105, 31271242), and Medical Research Funding of
   PLA (AWS14C001, AWS14C003).
CR Abe S, 2004, AM J RESP CRIT CARE, V170, P1158, DOI 10.1164/rccm.200307-908OC
   Ahn YC, 2014, BIOMED OPT EXPRESS, V5, P312, DOI 10.1364/BOE.5.000312
   Akyurekli C, 2015, STEM CELL REV REP, V11, P150, DOI 10.1007/s12015-014-9545-9
   Arimura Kosei, 2005, Haematologica, V90, pECR10
   Beckett T, 2005, MOL THER, V12, P680, DOI 10.1016/j.ymthe.2005.05.007
   Borthwick DW, 2001, AM J RESP CELL MOL, V24, P662, DOI 10.1165/ajrcmb.24.6.4217
   Burnham E, 2006, MINERVA ANESTESIOL, V72, P369
   Burnham EL, 2010, AM J RESP CELL MOL, V43, P326, DOI 10.1165/rcmb.2009-0015OC
   Bustos ML, 2014, AM J RESP CRIT CARE, V189, P787, DOI 10.1164/rccm.201306-1043OC
   Bustos ML, 2013, STEM CELL TRANSL MED, V2, P884, DOI 10.5966/sctm.2013-0033
   Cai DS, 2013, CELL PHYSIOL BIOCHEM, V32, P1577, DOI 10.1159/000356594
   Cao JP, 2012, ANESTHESIOLOGY, V116, P1278, DOI 10.1097/ALN.0b013e3182567f84
   Castro-Manrreza ME, 2014, STEM CELLS DEV, V23, P1217, DOI 10.1089/scd.2013.0363
   Chang Y, 2014, J KOREAN MED SCI, V29, P438, DOI 10.3346/jkms.2014.29.3.438
   Chen HY, 2012, STEM CELLS, V30, P1948, DOI 10.1002/stem.1150
   Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083303
   Curley GF, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt179
   Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930
   Ding Tao, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P1414
   Driscoll Barbara, 2012, Methods Mol Biol, V879, P109, DOI 10.1007/978-1-61779-815-3_7
   Elizur A, 2007, AM J PHYSIOL-LUNG C, V293, pL383, DOI 10.1152/ajplung.00024.2007
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Fu XB, 2001, LANCET, V358, P1067, DOI 10.1016/S0140-6736(01)06202-X
   Fujino N, 2012, RESPIR INVESTIG, V50, P110, DOI 10.1016/j.resinv.2012.07.002
   Gao P, 2013, INT J MOL MED, V31, P1313, DOI 10.3892/ijmm.2013.1328
   Garcia O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071679
   Goolaerts A, 2014, AM J PHYSIOL-LUNG C, V306, pL975, DOI 10.1152/ajplung.00242.2013
   Gotts JE, 2014, CLIN CHEST MED, V35, P797, DOI 10.1016/j.ccm.2014.08.015
   Guan XJ, 2013, J CELL BIOCHEM, V114, P323, DOI 10.1002/jcb.24377
   Gupta K, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt167
   Gupta N, 2012, THORAX, V67, P533, DOI 10.1136/thoraxjnl-2011-201176
   Hannoush EJ, 2013, SURGERY, V153, P44, DOI 10.1016/j.surg.2012.06.020
   Hayes M, 2012, CRIT CARE, V16, DOI 10.1186/cc10570
   He HL, 2015, CELL TRANSPLANT, V24, P1699, DOI 10.3727/096368914X685087
   Hegab AE, 2008, MOL THER, V16, P1417, DOI 10.1038/mt.2008.137
   Hegab AE, 2010, STEM CELLS DEV, V19, P523, DOI 10.1089/scd.2009.0287
   Hodges RJ, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/709763
   Hong KU, 2004, AM J PHYSIOL-LUNG C, V286, pL643, DOI 10.1152/ajplung.00155.2003
   Huang XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088814
   Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011
   Ishizawa K, 2004, FEBS LETT, V556, P249, DOI 10.1016/S0014-5793(03)01399-1
   Ishizawa K, 2004, BIOCHEM BIOPH RES CO, V324, P276, DOI 10.1016/j.bbrc.2004.09.049
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Kahler CM, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-50
   Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324
   Karoubi G, 2009, LAB INVEST, V89, P1100, DOI 10.1038/labinvest.2009.73
   Kim CF, 2007, AM J PHYSIOL-LUNG C, V293, pL1092, DOI 10.1152/ajplung.00015.2007
   Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032
   Kneyber MCJ, 2009, CRIT CARE MED, V37, P3191, DOI 10.1097/CCM.0b013e3181bc7a18
   Lalu MM, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-48
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   Lenssen Josephine, 2007, Int J Chron Obstruct Pulmon Dis, V2, P131
   Li H, 2013, CHEST, V144, P876, DOI 10.1378/chest.12-2429
   Li J, 2012, J ASIA TEFL, V9, P1, DOI 10.1186/1476-9255-9-33
   Li JW, 2014, INT WOUND J, V11, P114, DOI 10.1111/iwj.12202
   Li LF, 2013, BIOMATERIALS, V34, P78, DOI 10.1016/j.biomaterials.2012.09.042
   Liang ZD, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-179
   Lim R, 2013, RESPIRATION, V85, P332, DOI 10.1159/000343078
   Liu Qiu-Ping, 2014, Patholog Res Int, V2014, P104962, DOI 10.1155/2014/104962
   Liu Xiaoming, 2008, Proc Am Thorac Soc, V5, P682, DOI 10.1513/pats.200801-003AW
   Liu Yu-Qiang, 2014, J Anal Methods Chem, V2014, P617367, DOI 10.1155/2014/617367
   Liu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066760
   Liu YR, 2011, J EXP MED, V208, P1473, DOI 10.1084/jem.20102041
   Maron-Gutierrez T, 2013, CRIT CARE MED, V41, pE319, DOI 10.1097/CCM.0b013e31828a663e
   Martinez-Gonzalez I, 2013, AM J RESP CELL MOL, V49, P552, DOI 10.1165/rcmb.2012-0406OC
   Masuda S, 2012, CHEST, V141, P1120, DOI 10.1378/chest.11-2790
   McGuire JK, 2013, PEDIATR CRIT CARE ME, V14, P555, DOI 10.1097/PCC.0b013e31828a8198
   McIntyre BAS, 2014, STEM CELL TRANSL MED, V3, P7, DOI 10.5966/sctm.2013-0119
   McQualter JL, 2010, P NATL ACAD SCI USA, V107, P1414, DOI 10.1073/pnas.0909207107
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Murakami S, 2005, AM J RESP CRIT CARE, V172, P581, DOI 10.1164/rccm.200409-1280OC
   Ning J, 2009, SCI CHINA SER C, V52, P1016, DOI 10.1007/s11427-009-0139-8
   Perl AKT, 2011, AM J RESP CRIT CARE, V183, P511, DOI 10.1164/rccm.201005-0744OC
   Pritchard S, 2011, PLACENTA, V32, pS298, DOI 10.1016/j.placenta.2011.04.007
   Qi YY, 2013, PEDIATR CRIT CARE ME, V14, pE233, DOI 10.1097/PCC.0b013e31828a7242
   Qi YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033859
   Randolph AG, 2009, CRIT CARE MED, V37, P2448, DOI 10.1097/CCM.0b013e3181aee5dd
   Reynolds SD, 2004, AM J PHYSIOL-LUNG C, V287, pL1256, DOI 10.1152/ajplung.00203.2004
   Rojas M, 2005, AM J RESP CELL MOL, V33, P145, DOI 10.1165/rcmb.2004-0330OC
   Saito S, 2011, AM J PATHOL, V179, P1088, DOI 10.1016/j.ajpath.2011.05.027
   Sdrimas K, 2014, ANTIOXID REDOX SIGN, V21, P1905, DOI 10.1089/ars.2013.5784
   Shalaby SM, 2014, CYTOTHERAPY, V16, P764, DOI 10.1016/j.jcyt.2013.12.006
   Shu SY, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-31
   Sueblinvong V, 2010, TRANSL RES, V156, P188, DOI 10.1016/j.trsl.2010.06.007
   Sun N, 2009, P NATL ACAD SCI USA, V106, P15720, DOI 10.1073/pnas.0908450106
   Sun RW, 2013, RESPIR INVESTIG, V51, P229, DOI 10.1016/j.resinv.2013.04.006
   Teng Y, 2010, BIOCHEM BIOPH RES CO, V392, P373, DOI 10.1016/j.bbrc.2010.01.028
   Tian ZF, 2013, EXP BIOL MED, V238, P242, DOI 10.1177/1535370212473706
   Toya SP, 2011, AM J PATHOL, V178, P313, DOI 10.1016/j.ajpath.2010.09.041
   Tropea KA, 2012, AM J PHYSIOL-LUNG C, V302, pL829, DOI 10.1152/ajplung.00347.2011
   Warburton David, 2008, Proc Am Thorac Soc, V5, P703, DOI 10.1513/pats.200801-012AW
   Weinbroum AA, 2011, CRIT CARE MED, V39, P2554, DOI 10.1097/CCM.0b013e31822a5bfd
   Weiss DJ, 2014, STEM CELLS, V32, P16, DOI 10.1002/stem.1506
   Wen ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075383
   Westerterp M, 2012, CELL STEM CELL, V11, P195, DOI 10.1016/j.stem.2012.04.024
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu HY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/283525
   Wu XD, 2014, J CELL MOL MED, V18, P1612, DOI 10.1111/jcmm.12283
   Yang C, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0300-9
   Yang C, 2011, INJURY, V42, P905, DOI 10.1016/j.injury.2010.02.035
   Yang C, 2011, J SURG RES, V168, P262, DOI 10.1016/j.jss.2009.10.002
   Yang C, 2011, CYTOKINE, V54, P29, DOI 10.1016/j.cyto.2010.12.011
   Yang C, 2009, CHIN J TRAUMATOL, V12, P350, DOI 10.3760/cma.j.issn.1008-1275.2009.06.006
   Yang C, 2008, J TRAUMA, V65, P1471, DOI 10.1097/TA.0b013e318166d279
   Yang JX, 2015, J BIOL CHEM, V290, P1994, DOI 10.1074/jbc.M114.605063
   Yip HK, 2013, J PINEAL RES, V54, P207, DOI 10.1111/jpi.12020
   Zhang SJ, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt161
   Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157
   Zhao YJ, 2013, INT IMMUNOPHARMACOL, V15, P246, DOI 10.1016/j.intimp.2012.12.008
   Zheng DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071028
   Zheng DH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0048451, 10.1371/journal.pone.0049495]
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhou JY, 2010, BRIT J SURG, V97, P281, DOI 10.1002/bjs.6820
   Zhou QL, 2014, STEM CELL TRANSL MED, V3, P675, DOI 10.5966/sctm.2013-0142
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
   Zickri Maha Baligh, 2014, International Journal of Stem Cells, V7, P1, DOI 10.15283/ijsc.2014.7.1.1
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 117
TC 11
Z9 15
U1 1
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD FEB 11
PY 2016
VL 14
AR 47
DI 10.1186/s12967-016-0804-1
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DD5BK
UT WOS:000369937100001
PM 26865361
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Dora, KA
   Stanley, CP
   Al Jaaly, E
   Fiorentino, F
   Ascione, R
   Reeves, BC
   Angelini, GD
AF Dora, Kim A.
   Stanley, Christopher P.
   Al Jaaly, Emad
   Fiorentino, Francesca
   Ascione, Raimondo
   Reeves, Barnaby C.
   Angelini, Gianni D.
TI Isolated Human Pulmonary Artery Structure and Function Pre- and
   Post-Cardiopulmonary Bypass Surgery
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE bradykinin; cardiopulmonary bypass; lung; thromboxane; vasoconstriction; vasodilation 
ID INFLAMMATORY RESPONSE; CARDIAC-SURGERY; LUNG INJURY; STRESS;
   DYSFUNCTION; PERFUSION
AB Background-Pulmonary dysfunction is a known complication after cardiac surgery using cardiopulmonary bypass, ranging from subclinical functional changes to prolonged postoperative ventilation, acute lung injury, and acute respiratory distress syndrome. Whether human pulmonary arterial function is compromised is unknown. The aim of the present study was to compare the structure and function of isolated and cannulated human pulmonary arteries obtained from lung biopsies after the chest was opened (pre-cardiopulmonary bypass) to those obtained at the end of cardiopulmonary bypass (post-cardiopulmonary bypass) from patients undergoing coronary artery bypass graft surgery.
   Methods and Results-Pre- and post-cardiopulmonary bypass lung biopsies were received from 12 patients undergoing elective surgery. Intralobular small arteries were dissected, cannulated, pressurized, and imaged using confocal microscopy. Functionally, the thromboxane mimetic U46619 produced concentration-dependent vasoconstriction in 100% and 75% of pre- and post-cardiopulmonary bypass arteries, respectively. The endothelium-dependent agonist bradykinin stimulated vasodilation in 45% and 33% of arteries pre- and post-cardiopulmonary bypass, respectively. Structurally, in most arteries smooth muscle cells aligned circumferentially; live cell viability revealed that although 100% of smooth muscle and 90% of endothelial cells from pre-cardiopulmonary bypass biopsies had intact membranes and were considered viable, only 60% and 58%, respectively, were viable from post-cardiopulmonary bypass biopsies.
   Conclusions-We successfully investigated isolated pulmonary artery structure and function in fresh lung biopsies from patients undergoing heart surgery. Pulmonary artery contractile tone and endothelium-dependent dilation were significantly reduced in post-cardiopulmonary bypass biopsies. The decreased functional responses were associated with reduced cell viability.
C1 [Dora, Kim A.; Stanley, Christopher P.] Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England, United Kingdom.
C1 [Al Jaaly, Emad; Fiorentino, Francesca; Angelini, Gianni D.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Cardiothorac Surg, London, England, United Kingdom.
C1 [Ascione, Raimondo; Reeves, Barnaby C.; Angelini, Gianni D.] Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS8 1TH, Avon, England, United Kingdom.
C1 [Stanley, Christopher P.] Victor Chang Cardiac Res Inst, Sydney, NSW, Australia.
C3 University of Oxford; Imperial College London; Bristol Royal Infirmary;
   University of Bristol; Victor Chang Cardiac Research Institute
RP Dora, KA (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.
EM kim.dora@pharm.ox.ac.uk
RI Stanley, Chris/L-8949-2019
OI Stanley, Christopher/0000-0003-0875-7158; angelini,
   gianni/0000-0002-1753-3730; Reeves, Barnaby/0000-0002-5101-9487
FU British Heart Foundation (BHF) [FS/13/16/30199, PG/13/9/29990]; Oxford
   BHF Centre of Research Excellence; Garfield Weston Trust; UK National
   Institute for Health Research (NIHR) Bristol Cardiovascular Biomedical
   Research Unit; BHF; NIHR; British Heart Foundation [FS/13/16/30199,
   PG/10/40/28369, PG/13/9/29990] Funding Source: researchfish; Medical
   Research Council [MR/L012723/1] Funding Source: researchfish; Science
   and Technology Facilities Council [ST/G002479/1] Funding Source:
   researchfish; MRC [MR/L012723/1] Funding Source: UKRI; STFC
   [ST/G002479/1] Funding Source: UKRI
FX This work was generously supported by the British Heart Foundation (BHF;
   FS/13/16/30199, PG/13/9/29990), and the Oxford BHF Centre of Research
   Excellence; the Garfield Weston Trust; and the UK National Institute for
   Health Research (NIHR) Bristol Cardiovascular Biomedical Research Unit.
   Kim Dora is a BHF-funded Senior Basic Science Research Fellow; Al Jaaly
   is a NIHR-funded Academic Clinical Fellow.
CR Aiello VD, 2003, MODERN PATHOL, V16, P411, DOI 10.1097/01.MP.0000067685.57858.D7
   Ascione R, 2000, ANN THORAC SURG, V69, P1198, DOI 10.1016/S0003-4975(00)01152-8
   Ascione R, 1999, ANN THORAC SURG, V68, P2237, DOI 10.1016/S0003-4975(99)01123-6
   Bagher P, 2012, P NATL ACAD SCI USA, V109, P18174, DOI 10.1073/pnas.1211946109
   Clifford PS, 2011, ARTERIOSCL THROM VAS, V31, P2889, DOI 10.1161/ATVBAHA.111.236570
   Demaio L, 2001, AM J PHYSIOL-HEART C, V281, pH105, DOI 10.1152/ajpheart.2001.281.1.H105
   Fiorentino F, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0696-z
   Gao DX, 2003, ANN THORAC SURG, V75, P74, DOI 10.1016/S0003-4975(02)04163-2
   Goebel U, 2008, EUR J CARDIO-THORAC, V34, P1165, DOI 10.1016/j.ejcts.2008.07.031
   JOHNSON D, 1994, J THORAC CARDIOV SUR, V107, P1193, DOI 10.1016/S0022-5223(94)70037-0
   Kubo K, 2000, RESP PHYSIOL, V120, P71, DOI 10.1016/S0034-5687(00)00090-6
   Mazzolai L, 2011, J VASC RES, V48, P443, DOI 10.1159/000324844
   Ng CSH, 2002, CHEST, V121, P1269, DOI 10.1378/chest.121.4.1269
   Ortiz PP, 1998, HISTOL HISTOPATHOL, V13, P315, DOI 10.14670/HH-13.315
   Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X
   Rothenburger M, 2001, SHOCK, V16, P44, DOI 10.1097/00024382-200116001-00009
   Schreiber JU, 2012, J CARDIOTHOR VASC AN, V26, P448, DOI 10.1053/j.jvca.2012.01.034
   Serraf A, 1999, AM J RESP CRIT CARE, V159, P544, DOI 10.1164/ajrccm.159.2.9803024
   Stenmark KR, 2011, COMPR PHYSIOL, V1, P141, DOI 10.1002/cphy.c090017
   TAGGART DP, 1993, ANN THORAC SURG, V56, P1123, DOI 10.1016/0003-4975(95)90029-2
   Townsley MI, 2012, COMPR PHYSIOL, V2, P675, DOI 10.1002/cphy.c100081
   Yu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083236
NR 22
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD FEB
PY 2016
VL 5
IS 2
AR e002822
DI 10.1161/JAHA.115.002822
PG 9
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA DO9TW
UT WOS:000378131100013
PM 26908407
OA Green Submitted, Green Published, gold
DA 2023-08-21
ER

PT J
AU Lomas-Neira, JL
   Heffernan, DS
   Ayala, A
   Monaghan, SF
AF Lomas-Neira, Joanne L.
   Heffernan, Daithi S.
   Ayala, Alfred
   Monaghan, Sean F.
TI BLOCKADE OF ENDOTHELIAL GROWTH FACTOR, ANGIOPOIETIN-2, REDUCES INDICES
   OF ARDS AND MORTALITY IN MICE RESULTING FROM THE DUAL-INSULTS OF
   HEMORRHAGIC SHOCK AND SEPSIS
SO SHOCK
LA English
DT Article
DE ALI/ARDS; angiopoietin-1/angiopoietin-2; ECs/HPMECs/HUVECs/MPVECs; hemorrhage; neutrophil; priming; sepsis 
ID TIDAL VOLUME; MACROPHAGE; CELLS; ANGIOGENESIS; INFLAMMATION;
   NEUTROPHILS; APOPTOSIS
AB We have demonstrated hemorrhagic shock priming for the development of indirect acute respiratory distress syndrome (iARDS) in mice following subsequent septic challenge, and show pathology characteristic of patients with iARDS, including increased lung microvascular permeability and arterial PO2/FI0(2) reduced to levels comparable to mild/moderate ARDS during the 48h following hemorrhage. Loss of endothelial cell (EC) barrier function is a major component in the development of iARDS. EC growth factors, Angiopoietin (Ang)-1 and 2, maintain vascular homeostasis via tightly regulated competitive interaction with tyrosine kinase receptor, Tie2, expressed on ECs. Ang-2/Tie2 binding, in contrast to Ang-1, is believed to produce vessel destabilization, pulmonary leakage, and inflammation. Recent clinical findings from our trauma/surgical intensive care units and others have reported elevated Ang-2 in the plasma from patients that develop ARDS. We have previously described similarly elevated Ang-2 in plasma and lung tissue in our shock/sepsis model for the development of iARDS, and demonstrated effective reduction in indices of inflammation and lung tissue injury following siRNA inhibition of Ang-2 protein synthesis. In this study we show that Ang-2 in lung tissue and plasma spikes following hemorrhage (priming) and remain elevated at sepsis induction. In addition, that transient inhibition of Ang-2 function immediately following hemorrhage, suppressing priming, but not following sepsis, impacts the development of iARDS in our model. Our data demonstrate that selective temporal blockade of Ang-2 function following hemorrhagic shock priming significantly improved PO2/FIO2, decreased lung protein leak and indices of inflammation, and improved 10-day survival in our murine model for the development iARDS.
C1 [Lomas-Neira, Joanne L.; Heffernan, Daithi S.; Ayala, Alfred; Monaghan, Sean F.] Brown Univ, Div Surg Res, Dept Surg, Rhode Isl Hosp,Alpert Sch Med, 593 Eddy St,Aldrich 244, Providence, RI 02903, United States.
C3 Brown University; Lifespan Health Rhode Island; Rhode Island Hospital
RP Lomas-Neira, JL (corresponding author), Brown Univ, Div Surg Res, Dept Surg, Rhode Isl Hosp,Alpert Sch Med, 593 Eddy St,Aldrich 244, Providence, RI 02903 USA.
EM jlomasneira@lifespan.org
OI Heffernan, Daithi/0000-0002-3417-2893; Ayala, Alfred/0000-0002-5034-2995
FU Rhode Island Foundation; Surgical Infection Society; Armand D. Versaci
   Research Scholar in Surgical Sciences Award; National Institutes of
   Health [5P20GM103652 NIGMS, GM107149]
FX This work was supported by a grant from The Rhode Island Foundation
   (JLL-N), a Fellowship from the Surgical Infection Society (JLL-N), the
   Armand D. Versaci Research Scholar in Surgical Sciences Award (SFM), and
   grants from the National Institutes of Health 5P20GM103652 NIGMS
   (JLL-N), GM107149 (AA).
CR Ayala A, 2002, AM J PATHOL, V161, P2283, DOI 10.1016/S0002-9440(10)64504-X
   BOWTON DL, 1989, CRIT CARE MED, V17, P908, DOI 10.1097/00003246-198909000-00014
   Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454
   Childs EW, 2008, AM J PHYSIOL-HEART C, V294, pH2285, DOI 10.1152/ajpheart.01361.2007
   Choi JS, 2013, MED SCI MONITOR, V19, P28
   Cooke CR, 2008, CRIT CARE MED, V36, P1412, DOI 10.1097/CCM.0b013e318170a375
   CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311
   Feltes CM, 2011, SHOCK, V36, P170, DOI 10.1097/SHK.0b013e3182169c76
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kong J, 2013, MOL ENDOCRINOL, V27, P2116, DOI 10.1210/me.2013-1146
   Lemieux C, 2005, BLOOD, V105, P1523, DOI 10.1182/blood-2004-09-3531
   Lomas JL, 2003, SHOCK, V19, P358, DOI 10.1097/00024382-200304000-00011
   Lomas-Neira J, 2006, AM J PHYSIOL-LUNG C, V290, pL51, DOI 10.1152/ajplung.00028.2005
   Lomas-Neira J, 2005, CYTOKINE, V31, P169, DOI 10.1016/j.cyto.2005.04.005
   Lomas-Neira JL, 2005, J LEUKOCYTE BIOL, V77, P846, DOI 10.1189/jlb.1004617
   Lomas-Neira J, 2014, AM J RESP CELL MOL, V50, P193, DOI 10.1165/rcmb.2013-0148OC
   Ogura H, 1999, J TRAUMA, V46, P774, DOI 10.1097/00005373-199905000-00004
   Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030
   Pelosi P, 2006, EUR RESPIR J, V22, p48s, DOI [10.1183/09031936.03.00420803, DOI 10.1183/09031936.03.00420803]
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Simon TP, 2012, CRIT CARE, V16, DOI 10.1186/cc11161
   Siner JM, 2009, SHOCK, V31, P348, DOI 10.1097/SHK.0b013e318188bd06
   STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222
   Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5
   Tiesi G, 2013, SHOCK, V39, P507, DOI 10.1097/SHK.0b013e318293d020
   Tressel SL, 2008, ARTERIOSCL THROM VAS, V28, P1989, DOI 10.1161/ATVBAHA.108.175463
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wiedemann HP, 2002, CRIT CARE MED, V30, P1
   Yan ZX, 2012, AM J PHYSIOL-HEART C, V302, pH215, DOI 10.1152/ajpheart.00895.2011
NR 36
TC 19
Z9 20
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD FEB
PY 2016
VL 45
IS 2
BP 157
EP 165
DI 10.1097/SHK.0000000000000499
PG 9
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA DD5UB
UT WOS:000369988900008
PM 26529660
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Rajput, C
   Tauseef, M
   Farazuddin, M
   Yazbeck, P
   Amin, MR
   Avin, BRV
   Sharma, T
   Mehta, D
AF Rajput, Charu
   Tauseef, Mohammad
   Farazuddin, Mohammad
   Yazbeck, Pascal
   Amin, Ruhul
   Avin, Vijay B. R.
   Sharma, Tiffany
   Mehta, Dolly
TI MicroRNA-150 Suppression of Angiopoetin-2 Generation and Signaling Is
   Crucial for Resolving Vascular Injury
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE adhesion junction; angiopoietin-1/angiopoietin-2; endothelial growth response 2; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; miR-150; sepsis 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME;
   PULMONARY-HYPERTENSION; ENDOTHELIAL-CELLS; IN-VIVO; CIRCULATING
   ANGIOPOIETIN-2; SMOOTH-MUSCLE; ANGIOGENESIS; PERMEABILITY; EXPRESSION
AB Objective Increased vascular permeability is a hallmark of sepsis and acute respiratory distress syndrome. Angiopoietin (Ang2) induces vascular leak, and excess Ang2 generation is associated with patient mortality from these diseases. However, mechanisms dampening Ang2 generation during injury remain unclear. Interestingly, microRNA (miR)-150 levels were decreased in septic patients. miR regulate signaling networks by silencing mRNAs containing complementary sequences. Thus, we hypothesized that miR-150 suppresses Ang2 generation and thereby resolves vascular injury.
   Approach and Results Wild-type or miR-150(-/-) mice or endothelial cells were exposed to lipopolysaccharide or sepsis, and Ang2 levels, adherens junction reannealing, endothelial barrier function, and mortality were determined. Although Ang2 transiently increased during lipopolysaccharide-induced injury in wild-type endothelial cells and lungs, miR-150 expression was elevated only during recovery from injury. Deletion of miR-150 caused a persistent increase in Ang2 levels and impaired adherens junctions reannealing after injury, resulting thereby in an irreversible increase in vascular permeability. Also, miR-150(-/-) mice died rapidly after sepsis. Rescuing miR-150 expression in endothelial cells prevented Ang2 generation, thereby restoring vascular barrier function in miR-150(-/-) mice. miR-150 terminated Ang2 generation by targeting the transcription factor, early growth response 2. Thus, early growth response 2 or Ang2 depletion in miR-150(-/-) endothelial cells restored junctional reannealing and reinstated barrier function. Importantly, upregulating miR-150 expression by injecting a chemically synthesized miR-150 mimic into wild-type mice vasculature decreased early growth response 2 and Ang2 levels and hence mortality from sepsis.
   Conclusions miR-150 is a novel suppressor of Ang2 generation with a key role in resolving vascular injury and reducing mortality resulting from sepsis.
C1 Univ Illinois, Dept Pharmacol, Chicago, IL 60612, United States.
C1 Univ Illinois, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Mehta, D (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, 835 S Wolcott Ave, Chicago, IL 60612 USA.
EM dmehta@uic.edu
RI Avin, Vijay/AAB-4220-2019; Farazuddin, Mohammad/AAI-2580-2021
OI Avin, Vijay/0000-0001-6032-4048; 
FU National Institute of Health [HL71794, HL84153, HL060678]
FX This work was supported by National Institute of Health grants HL71794,
   HL84153, HL060678.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Chava KR, 2009, ARTERIOSCL THROM VAS, V29, P809, DOI 10.1161/ATVBAHA.109.185777
   Chu D, 2004, ANN THORAC SURG, V77, P449, DOI 10.1016/S0003-4975(03)01350-X
   Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103
   Deleuze V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040484
   Deng L, 2015, CIRC RES, V117, P870, DOI 10.1161/CIRCRESAHA.115.306806
   Diamond JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051932
   Dillon RL, 2007, MOL CELL BIOL, V27, P8648, DOI 10.1128/MCB.00866-07
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Fang F, 2011, AM J PATHOL, V178, P2077, DOI 10.1016/j.ajpath.2011.01.035
   Fu PF, 2015, AM J PHYSIOL-LUNG C, V308, pL1025, DOI 10.1152/ajplung.00306.2014
   Gale NW, 2002, COLD SPRING HARB SYM, V67, P267, DOI 10.1101/sqb.2002.67.267
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Gonzales JN, 2014, AM J PHYSIOL-LUNG C, V306, pL497, DOI 10.1152/ajplung.00086.2013
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Ichimura A, 2011, FEBS J, V278, P1610, DOI 10.1111/j.1742-4658.2011.08087.x
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Komarova Yulia A, 2007, Sci STKE, V2007, pre8
   Luo ZL, 2013, STEM CELLS, V31, P1749, DOI 10.1002/stem.1448
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Mammoto T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073407
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Menden H, 2015, J BIOL CHEM, V290, P5449, DOI 10.1074/jbc.M114.600692
   Meyer NJ, 2011, AM J RESP CRIT CARE, V183, P1344, DOI 10.1164/rccm.201005-0701OC
   Minami T, 2013, CELL REP, V4, P709, DOI 10.1016/j.celrep.2013.07.021
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Poirier R, 2008, FRONT NEUROSCI-SWITZ, V2, P47, DOI 10.3389/neuro.01.002.2008
   Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126
   Roderburg C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054612
   Roviezzo F, 2005, J PHARMACOL EXP THER, V314, P738, DOI 10.1124/jpet.105.086553
   Schmidt WM, 2009, BIOCHEM BIOPH RES CO, V380, P437, DOI 10.1016/j.bbrc.2008.12.190
   Sullivan CC, 2003, P NATL ACAD SCI USA, V100, P12331, DOI 10.1073/pnas.1933740100
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Taylor Molly A, 2014, Mol Cell Ther, V2, P1, DOI 10.1186/2052-8426-2-30
   Thistlethwaite PA, 2001, J THORAC CARDIOV SUR, V122, P65, DOI 10.1067/mtc.2001.113753
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Vasilescu C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007405
   Wada T, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-6
   Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021
   Xue Y, 2008, P NATL ACAD SCI USA, V105, P10167, DOI 10.1073/pnas.0802486105
   Young JA, 2013, BLOOD, V122, P2911, DOI 10.1182/blood-2012-12-473017
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 52
TC 37
Z9 40
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD FEB
PY 2016
VL 36
IS 2
BP 380
EP 388
DI 10.1161/ATVBAHA.115.306997
PG 9
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA DC8PX
UT WOS:000369483200023
PM 26743170
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Sugiyama, MG
   Gamage, A
   Zyla, R
   Armstrong, SM
   Advani, S
   Advani, A
   Wang, CS
   Lee, WL
AF Sugiyama, Michael G.
   Gamage, Asela
   Zyla, Roman
   Armstrong, Susan M.
   Advani, Suzanne
   Advani, Andrew
   Wang, Changsen
   Lee, Warren L.
TI Influenza Virus Infection Induces Platelet-Endothelial Adhesion Which
   Contributes to Lung Injury
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NEUTROPHIL EXTRACELLULAR TRAPS; ALVEOLAR EPITHELIAL-CELLS; NF-KAPPA-B;
   MICROVASCULAR ENDOTHELIUM; ACETYLSALICYLIC-ACID; IN-VIVO; INFLAMMATION;
   AGGREGATION; FIBRONECTIN; ACTIVATION
AB Lung injury after influenza infection is characterized by increased permeability of the lung microvasculature, culminating in acute respiratory failure. Platelets interact with activated endothelial cells and have been implicated in the pathogenesis of some forms of acute lung injury. Autopsy studies have revealed pulmonary microthrombi after influenza infection, and epidemiological studies suggest that influenza vaccination is protective against pulmonary thromboembolism; however, the effect of influenza infection on platelet-endothelial interactions is unclear. We demonstrate that endothelial infection with both laboratory and clinical strains of influenza virus increased the adhesion of human platelets to primary human lung microvascular endothelial cells. Platelets adhered to infected cells as well as to neighboring cells, suggesting a paracrine effect. Influenza infection caused the upregulation of von Willebrand factor and ICAM-1, but blocking these receptors did not prevent platelet-endothelial adhesion. Instead, platelet adhesion was inhibited by both RGDS peptide and a blocking antibody to platelet integrin alpha(5)beta(1), implicating endothelial fibronectin. Concordantly, lung histology from infected mice revealed viral dose-dependent colocalization of viral nucleoprotein and the endothelial marker PECAM-1, while platelet adhesion and fibronectin deposition also were observed in the lungs of influenza-infected mice. Inhibition of platelets using acetylsalicylic acid significantly improved survival, a finding confirmed using a second antiplatelet agent. Thus, influenza infection induces platelet-lung endothelial adhesion via fibronectin, contributing to mortality from acute lung injury. The inhibition of platelets may constitute a practical adjunctive strategy to the treatment of severe infections with influenza.
C1 [Sugiyama, Michael G.; Gamage, Asela; Zyla, Roman; Armstrong, Susan M.; Advani, Suzanne; Advani, Andrew; Wang, Changsen; Lee, Warren L.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada.
C1 [Gamage, Asela; Armstrong, Susan M.; Lee, Warren L.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
C1 [Sugiyama, Michael G.; Lee, Warren L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
C1 [Lee, Warren L.] Univ Toronto, Div Crit Care Med, Div Resp Interdept, Toronto, ON, Canada.
C3 University of Toronto; Li Ka Shing Knowledge Institute; Saint Michaels
   Hospital Toronto; University of Toronto; University of Toronto;
   University of Toronto
RP Lee, WL (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Lee, WL (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.; Lee, WL (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Lee, WL (corresponding author), Univ Toronto, Div Crit Care Med, Div Resp Interdept, Toronto, ON, Canada.
EM leew@smh.ca
OI Lee, Warren/0000-0002-1788-6587
FU Government of Ontario Early Researcher Award [ERA-07]; Gouvernement du
   Canada \ Canadian Institutes of Health Research (CIHR) [MOP130564, OCN
   126577]
FX Government of Ontario Early Researcher Award provided funding to Warren
   Lester Lee under grant number ERA-07. This work was funded by
   Gouvernement du Canada vertical bar Canadian Institutes of Health
   Research (CIHR) under grant MOP130564. This work was funded by
   Gouvernement du Canada vertical bar Canadian Institutes of Health
   Research (CIHR) under grant OCN 126577.
CR Adachi M, 1997, INT ARCH ALLERGY IMM, V113, P307, DOI 10.1159/000237584
   Advani A, 2009, HYPERTENSION, V54, P261, DOI 10.1161/HYPERTENSIONAHA.109.128645
   Agarwal PP, 2009, AM J ROENTGENOL, V193, P1488, DOI 10.2214/AJR.09.3599
   Armstrong SM, 2013, ANTIVIR RES, V99, P113, DOI 10.1016/j.antiviral.2013.05.003
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Azizi PM, 2015, MOL BIOL CELL, V26, P740, DOI 10.1091/mbc.E14-08-1307
   Bagamery K, 2005, CYTOM PART A, V65A, P84, DOI 10.1002/cyto.a.20133
   Szretter Kristy J, 2006, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/9780471729259.mc15g01s29, 10.1002/0471729256.mc15g01s3]
   Bombeli T, 1999, BLOOD, V93, P3831, DOI 10.1182/blood.V93.11.3831
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   Brandes M, 2013, CELL, V154, P197, DOI 10.1016/j.cell.2013.06.013
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Chan MCW, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-102
   Chen RH, 2000, AM J PHYSIOL-LUNG C, V279, pL161, DOI 10.1152/ajplung.2000.279.1.L161
   Cho J, 2006, J THROMB HAEMOST, V4, P1461, DOI 10.1111/j.1538-7836.2006.01943.x
   Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   FINE KM, 1976, AM J PATHOL, V84, P11
   Fortier ME, 2004, AM J PHYSIOL-REG I, V287, pR759, DOI 10.1152/ajpregu.00293.2004
   Getie-Kebtie M, 2013, INFLUENZA OTHER RESP, V7, P521, DOI 10.1111/irv.12001
   Grauslund M, 2007, MOL PHARMACOL, V72, P1003, DOI 10.1124/mol.107.036970
   Ito Y, 2015, AM J PHYSIOL-LUNG C, V308, pL1178, DOI 10.1152/ajplung.00290.2014
   Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025
   Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789
   Lumadue JA, 1996, AM J CLIN PATHOL, V106, P795
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024
   Mazur I, 2007, CELL MICROBIOL, V9, P1683, DOI 10.1111/j.1462-5822.2007.00902.x
   McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   MORI I, 1995, J GEN VIROL, V76, P2869, DOI 10.1099/0022-1317-76-11-2869
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Nguyen JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031006
   Pan H, 2014, AM J PHYSIOL-LUNG C, V306, pL183, DOI 10.1152/ajplung.00147.2013
   Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Rondina MT, 2013, CIRC RES, V112, P1506, DOI 10.1161/CIRCRESAHA.113.300512
   Ruggeri ZM, 2007, CIRC RES, V100, P1673, DOI 10.1161/01.RES.0000267878.97021.ab
   Schanzer DL, 2007, EPIDEMIOL INFECT, V135, P1109, DOI 10.1017/S0950268807007923
   Sreeramkumar V, 2014, SCIENCE, V346, P1234, DOI 10.1126/science.1256478
   Sugiyama MG, 2015, SCI REP-UK, V5, DOI 10.1038/srep11030
   SUZUKA H, 1995, J CARDIOVASC PHARM, V25, P9, DOI 10.1097/00005344-199501000-00003
   Tate MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017618
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   TOIVANEN J, 1985, THROMB RES, V37, P493, DOI 10.1016/0049-3848(85)90095-7
   van den Boogaard FE, 2015, CRIT CARE MED, V43, pE75, DOI 10.1097/CCM.0000000000000853
   van der Vries E, 2011, CURR OPIN INFECT DIS, V24, P599, DOI 10.1097/QCO.0b013e32834cfb43
   Le VB, 2015, AM J RESP CRIT CARE, V191, P804, DOI 10.1164/rccm.201406-1031OC
   Wang CS, 2015, AM J RESP CELL MOL, V53, P459, DOI 10.1165/rcmb.2014-0373OC
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   WEIBEL ER, 1964, J CELL BIOL, V21, P367, DOI 10.1083/jcb.21.3.367
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zhu TN, 2009, THROMB HAEMOSTASIS, V102, P1259, DOI 10.1160/TH09-04-0222
NR 54
TC 48
Z9 52
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2016
VL 90
IS 4
BP 1812
EP 1823
DI 10.1128/JVI.02599-15
PG 12
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA DC3XL
UT WOS:000369152700010
PM 26637453
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Tang, M
   Chen, L
   Li, B
   Wang, YX
   Li, SN
   Wen, AQ
   Yao, SL
   Shang, Y
AF Tang, Min
   Chen, Lin
   Li, Bo
   Wang, Yaxin
   Li, Shengnan
   Wen, Aiqing
   Yao, Shanglong
   Shang, You
TI BML-111 attenuates acute lung injury in endotoxemic mice
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE BML-111; endotoxemia; LPS; ALI/ARDS; permeability; Junction protein 
ID LIPOXIN RECEPTOR AGONIST; ENDOTHELIAL-CELLS; VE-CADHERIN; A(4);
   INFLAMMATION; INHIBITION; EXPRESSION; JUNCTIONS; PATHWAY; BARRIER
AB Background: BML-111 is a lipoxin receptor agonist that has protective effects in various lung injury models. We tried to elucidate whether BML-111 could mitigate lung injury in a mouse model of endotoxemia and endothelial hyperpermeability in vitro.
   Methods: The effect of BML-111 on lung injury was evaluated using C57BL/6 mice and human umbilical vein endothelial cells (HUVECs). Male C57BL/6 mice were intraperitoneally injected with normal saline, BML-111, and/or the lipoxin receptor antagonist Boc-2. Then, either lipopolysaccharide (LPS) or normal saline was given intraperitoneally. Lung injury was assessed by a pathohistologic examination for neutrophil infiltration, pulmonary endothelial permeability, and inflammatory cytokines in lung tissue and bronchoalveolar lavage fluid. HUVECs were treated with or without BML-111 before incubation with LPS for 24 h. Boc-2 was also tested as a novel inhibitor of BML-111. A Transwell assay was used to evaluate the permeability of HUVECs. Junction protein expression was also assessed.
   Results: BML-111 significantly improved the mouse survival rate, reduced body weight loss, attenuated the pulmonary pathologic changes, inhibited neutrophil infiltration and proinflammatory cytokine production, and mitigated endothelial hyperpermeability. The decreased expression of junction proteins induced by LPS in lung tissue and endothelial cells were upregulated by BML-111. In addition, BML-111 inhibited the activation of the Akt, ERK1/2, and p38 MAPK signaling pathways. However, the beneficial effects of BML-111 were abolished by Boc-2.
   Conclusions: BML-111 attenuated lung injury in endotoxemic mice and mitigated endothelial hyperpermeability by upregulating the expression of junction proteins. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tang, Min; Chen, Lin; Li, Bo; Wang, Yaxin; Li, Shengnan; Yao, Shanglong; Shang, You] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Crit Care Med, Union Hosp, Wuhan 430022, Hubei, China.
C1 [Tang, Min; Chen, Lin; Li, Bo; Wang, Yaxin; Li, Shengnan; Yao, Shanglong; Shang, You] Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Anesthesia & Crit Care, Union Hosp, Wuhan 430022, Hubei, China.
C1 [Wen, Aiqing] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Blood Transfus, Chongqing, China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Army Medical University
RP Shang, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Crit Care Med, Inst Anesthesia & Crit Care,Union Hosp, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
EM you_shang@yahoo.com
OI shang, you/0000-0003-4097-6131
FU National Natural Science Foundation of China [30930089, 81372036,
   81171790]; Key Clinical Project of Ministry of Health of China [2012-47]
FX This study was supported by grants from the National Natural Science
   Foundation of China (no. 30930089, 81372036, 81171790) and Key Clinical
   Project of Ministry of Health of China (2012-47).
CR Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   ARDITI M, 1995, J IMMUNOL, V155, P3994
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Brandolini L, 2000, PULM PHARMACOL THER, V13, P71, DOI 10.1006/pupt.2000.0232
   Bucher M, 2002, INTENS CARE MED, V28, P642, DOI 10.1007/s00134-002-1264-z
   Cardoso FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035919
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Fiorucci S, 2004, P NATL ACAD SCI USA, V101, P15736, DOI 10.1073/pnas.0404722101
   Forsman H, 2009, SCAND J IMMUNOL, V70, P396, DOI 10.1111/j.1365-3083.2009.02311.x
   Gong J, 2014, BRIT J PHARMACOL, V171, P3539, DOI 10.1111/bph.12714
   Gong J, 2012, RESUSCITATION, V83, P907, DOI 10.1016/j.resuscitation.2011.12.035
   Gotsch U, 1997, J CELL SCI, V110, P583
   Grumbach Y, 2009, AM J PHYSIOL-LUNG C, V296, pL101, DOI 10.1152/ajplung.00018.2008
   He JC, 2011, J OCUL PHARMACOL TH, V27, P235, DOI 10.1089/jop.2010.0187
   Hsu JT, 2013, J SURG RES, V182, P319, DOI 10.1016/j.jss.2012.10.926
   Jeyaseelan S, 2004, INFECT IMMUN, V72, P7247, DOI 10.1128/IAI.72.12.7247-7256.2004
   Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25
   Kilkenny C, 2011, J CEREBR BLOOD F MET, V31, P991, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476-5381.2010.00872.x]
   Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748
   Li HB, 2014, SHOCK, V41, P311, DOI 10.1097/SHK.0000000000000104
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matsuda T, 2005, AM J TRANSPLANT, V5, P484, DOI 10.1046/j.1600-6143.2004.00716.x
   Olanders K, 2002, SHOCK, V18, P86, DOI 10.1097/00024382-200207000-00016
   Sadowitz B, 2011, EXPERT REV ANTI-INFE, V9, P1169, DOI [10.1586/ERI.11.141, 10.1586/eri.11.141]
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Shang Y, 2009, J SURG RES, V155, P104, DOI 10.1016/j.jss.2008.10.003
   Su SC, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M110.157271
   Van Itallie CM, 2009, MOL BIOL CELL, V20, P3930, DOI 10.1091/mbc.E09-04-0320
   Wang CY, 2014, INTENS CARE MED, V40, P388, DOI 10.1007/s00134-013-3186-3
   Wu SH, 2008, INFLAMM RES, V57, P430, DOI 10.1007/s00011-008-7147-1
   Wu Y, 2012, J MOL NEUROSCI, V46, P483, DOI 10.1007/s12031-011-9620-5
   Yang SJ, 2011, INJURY, V42, P638, DOI 10.1016/j.injury.2010.07.242
   Ye XH, 2010, BRAIN RES, V1323, P174, DOI 10.1016/j.brainres.2010.01.079
   Zhang L, 2007, HEPATOL RES, V37, P948, DOI 10.1111/j.1872-034X.2007.00154.x
NR 35
TC 20
Z9 22
U1 1
U2 21
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD FEB
PY 2016
VL 200
IS 2
BP 619
EP 630
DI 10.1016/j.jss.2015.09.005
PG 12
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA CZ1BU
UT WOS:000366841500026
PM 26432471
DA 2023-08-21
ER

PT J
AU Preira, P
   Forel, JM
   Robert, P
   Negre, P
   Biarnes-Pelicot, M
   Xeridat, F
   Bongrand, P
   Papazian, L
   Theodoly, O
AF Preira, Pascal
   Forel, Jean-Marie
   Robert, Philippe
   Negre, Paulin
   Biarnes-Pelicot, Martine
   Xeridat, Francois
   Bongrand, Pierre
   Papazian, Laurent
   Theodoly, Olivier
TI The leukocyte-stiffening property of plasma in early acute respiratory
   distress syndrome (ARDS) revealed by a microfluidic single-cell study:
   the role of cytokines and protection with antibodies
SO CRITICAL CARE
LA English
DT Article
ID NEUTROPHIL ELASTASE INHIBITOR; TUMOR-NECROSIS-FACTOR; LUNG INJURY;
   DEFORMABILITY; SEPSIS; ADHESION; SEQUESTRATION; EXPRESSION; SIVELESTAT;
   INCREASES
AB Background: Leukocyte-mediated pulmonary inflammation is a key pathophysiological mechanism involved in acute respiratory distress syndrome (ARDS). Massive sequestration of leukocytes in the pulmonary microvasculature is a major triggering event of the syndrome. We therefore investigated the potential role of leukocyte stiffness and adhesiveness in the sequestration of leukocytes in microvessels.
   Methods: This study was based on in vitro microfluidic assays using patient sera. Cell stiffness was assessed by measuring the entry time (ET) of a single cell into a microchannel with a 6 x 9-mu m cross-section under a constant pressure drop (Delta P = 160 Pa). Primary neutrophils and monocytes, as well as the monocytic THP-1 cell line, were used. Cellular adhesiveness to human umbilical vein endothelial cells was examined using the laminar flow chamber method. We compared the properties of cells incubated with the sera of healthy volunteers (n = 5), patients presenting with acute cardiogenic pulmonary edema (ACPE; n = 6), and patients with ARDS (n = 22), of whom 13 were classified as having moderate to severe disease and the remaining 9 as having mild disease.
   Results: Rapid and strong stiffening of primary neutrophils and monocytes was induced within 30 minutes (mean ET > 50 seconds) by sera from the ARDS group compared with both the healthy subjects and the ACPE groups (mean ET <1 second) (p < 0.05). Systematic measurements with the THP-1 cell line allowed for the establishment of a strong correlation between stiffening and the severity of respiratory status (mean ET 0.82 +/- 0.08 seconds for healthy subjects, 1.6 +/- 1.0 seconds for ACPE groups, 10.5 +/- 6.1 seconds for mild ARDS, and 20.0 +/- 8.1 seconds for moderate to severe ARDS; p < 0.05). Stiffening correlated with the cytokines interleukin IL-1 beta, IL-8, tumor necrosis factor TNF-alpha, and IL-10 but not with interferon-gamma, transforming growth factor-beta, IL-6, or IL-17. Strong stiffening was induced by IL-1 alpha, IL-8, and TNF-alpha but not by IL-10, and incubations with sera and blocking antibodies against IL-1 beta, IL-8, or TNF-alpha significantly diminished the stiffening effect of serum. In contrast, the measurements of integrin expression (CD11b, CD11a, CD18, CD49d) and leukocyte-endothelium adhesion showed a weak and slow response after incubation with the sera of patients with ARDS (several hours), suggesting a lesser role of leukocyte adhesiveness compared with leukocyte stiffness in early ARDS.
   Conclusions: The leukocyte stiffening induced by cytokines in the sera of patients might play a role in the sequestration of leukocytes in the lung capillary beds during early ARDS. The inhibition of leukocyte stiffening with blocking antibodies might inspire future therapeutic strategies.
C1 [Preira, Pascal; Robert, Philippe; Negre, Paulin; Biarnes-Pelicot, Martine; Bongrand, Pierre; Theodoly, Olivier] Univ Aix Marseille, Adhes & Inflammat, INSERM U1067, CNRS UMR7333, F-13009 Marseille, France.
C1 [Preira, Pascal; Robert, Philippe; Negre, Paulin; Biarnes-Pelicot, Martine; Bongrand, Pierre; Theodoly, Olivier] Assistance Publ Hop Marseille, Lab Immunol, F-13285 Marseille 05, France.
C1 [Forel, Jean-Marie; Xeridat, Francois; Papazian, Laurent] Hop Nord Marseille, Assistance Publ Hop Marseille, Reanimat Detresses Resp & Infect Severes, F-13015 Marseille, France.
C1 [Forel, Jean-Marie; Xeridat, Francois; Papazian, Laurent] Aix Marseille Univ, Fac Med, URMITE UMR CNRS 7278, F-13005 Marseille, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Physics (INP); Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Aix-Marseille Universite;
   UDICE-French Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; UDICE-French Research Universities;
   Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille;
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Aix-Marseille Universite
RP Theodoly, O (corresponding author), Univ Aix Marseille, Adhes & Inflammat, INSERM U1067, CNRS UMR7333, 163 Ave Luminy, F-13009 Marseille, France.
EM olivier.theodoly@inserm.fr
RI Robert, Philippe/P-9597-2016; Bongrand, Pierre/C-4456-2013; theodoly,
   olivier/P-5402-2016
OI Robert, Philippe/0000-0002-1343-994X; Bongrand,
   Pierre/0000-0001-6185-6572; theodoly, olivier/0000-0001-8787-3709
FU Provence Alpes Cote d'Azur region and Capsum; Labex INFORM
FX The authors thank the Provence Alpes Cote d'Azur region and Capsum SAS
   for their financial support of PP's doctoral grant; the Solvay company
   (LOF, Pessac, France), and F. Bedu and I. Ozerov (CINaM, CNRS UPR 3118,
   Marseilles, France) for technical support with microfabrication; Labex
   INFORM for financial support; Cyrille Mionnet for support with cytometry
   experiments; C. Farnarier (Laboratoire d'immunologie - Hopital de la
   Conception, Marseille, France) for initial treatment of the sera
   library; and the cell culture platform of INSERM at Marseille-Luminy.
CR Abraham E, 1998, LANCET, V351, P929
   Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   [Anonymous], 2003, CRIT CARE MED, DOI DOI 10.1097/01.CCM.0000050454.01978.3B
   Azoulay E, 2011, AM J RESP CRIT CARE, V183, P279, DOI 10.1164/ajrccm.183.2.279b
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083
   Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5
   Hayakawa M, 2010, SHOCK, V33, P14, DOI 10.1097/SHK.0b013e3181aa95c4
   Hirsh M, 2001, SHOCK, V16, P102, DOI 10.1097/00024382-200116020-00003
   HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249
   Ibbotson GC, 2001, NAT MED, V7, P465, DOI 10.1038/86539
   Inoue Y, 2006, J TRAUMA, V60, P936, DOI 10.1097/01.ta.0000217271.25809.a0
   Iyer SS, 2006, J IMMUNOL, V176, P3686, DOI 10.4049/jimmunol.176.6.3686
   Kreisel D, 2010, P NATL ACAD SCI USA, V107, P18073, DOI 10.1073/pnas.1008737107
   Lam WA, 2007, BLOOD, V109, P3505, DOI 10.1182/blood-2006-08-043570
   Lautenschlager F, 2009, P NATL ACAD SCI USA, V106, P15696, DOI 10.1073/pnas.0811261106
   Lavkan AH, 1998, CRIT CARE MED, V26, P1677, DOI 10.1097/00003246-199810000-00021
   Lewis SM, 2009, AM J RESP CELL MOL, V40, P724, DOI 10.1165/rcmb.2008-0252OC
   Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904
   Maniatis NA, 2012, SHOCK, V38, P381, DOI 10.1097/SHK.0b013e3182690ea2
   Mokart D, 2003, CHEST, V124, P644, DOI 10.1378/chest.124.2.644
   Nandi B, 2011, J EXP MED, V208, P2251, DOI 10.1084/jem.20110919
   Ng JMK, 2002, ELECTROPHORESIS, V23, P3461, DOI 10.1002/1522-2683(200210)23:20<3461::AID-ELPS3461>3.0.CO;2-8
   Nishino M, 2005, J TRAUMA, V59, P1425, DOI 10.1097/01.ta.0000197356.83144.72
   O'Dea KP, 2011, AM J PHYSIOL-LUNG C, V301, pL812, DOI 10.1152/ajplung.00092.2011
   Okayama Naoko, 2006, J Anesth, V20, P6, DOI 10.1007/s00540-005-0362-9
   Preira P, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4802272
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Robert P, 2011, J IMMUNOL, V186, P5273, DOI 10.4049/jimmunol.1003141
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   SHYY YJ, 1993, J CLIN INVEST, V92, P1745, DOI 10.1172/JCI116762
   Skoutelis AT, 2000, CYTOKINE, V12, P1737, DOI 10.1006/cyto.2000.0761
   Skoutelis AT, 2000, CRIT CARE MED, V28, P2355, DOI 10.1097/00003246-200007000-00029
   Slotman GJ, 2011, J TRAUMA, V71, P1406, DOI 10.1097/TA.0b013e3182159c61
   Volpe S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010159
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WESTLIN WF, 1992, J LEUKOCYTE BIOL, V52, P43, DOI 10.1002/jlb.52.1.43
   WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255
   Yang SC, 2013, J IMMUNOL, V190, P6511, DOI 10.4049/jimmunol.1202215
   Yen YT, 2006, J VIROL, V80, P2684, DOI 10.1128/JVI.80.6.2684-2693.2006
   Yodice PC, 1997, AM J RESP CRIT CARE, V155, P38, DOI 10.1164/ajrccm.155.1.9001286
   Yoshida K, 2006, AM J RESP CRIT CARE, V174, P689, DOI 10.1164/rccm.200502-276OC
NR 42
TC 26
Z9 27
U1 1
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JAN 12
PY 2016
VL 20
AR 8
DI 10.1186/s13054-015-1157-5
PG 11
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DA9IA
UT WOS:000368121000001
PM 26757701
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Ben-Mahdi, MH
   Dang, PMC
   Gougerot-Pocidalo, MA
   O'Dowd, Y
   El-Benna, J
   Pasquier, C
AF Ben-Mahdi, Meriem H.
   Dang, Pham My-Chan
   Gougerot-Pocidalo, Marie-Anne
   O'Dowd, Yvonne
   El-Benna, Jamel
   Pasquier, Catherine
TI Xanthine Oxidase-Derived ROS Display a Biphasic Effect on Endothelial
   Cells Adhesion and FAK Phosphorylation
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID PROTEIN-TYROSINE-PHOSPHATASE; PEROXIDE-INDUCED APOPTOSIS; MAP KINASE;
   OXIDATIVE STRESS; SURVIVAL; FAMILY; INACTIVATION; NEUTROPHILS;
   INHIBITION; ACTIVATION
AB In pathological situations such as ischemia-reperfusion and acute respiratory distress syndrome, reactive oxygen species (ROS) are produced by different systems which are involved in endothelial cells injury, ultimately leading to severe organ dysfunctions. The aim of this work was to study the effect of ROS produced by hypoxanthine-xanthine oxidase (Hx-XO) on the adhesion of human umbilical vein endothelial cells (HUVEC) and on the signaling pathways involved. Results show that Hx-XO-derived ROS induced an increase in HUVEC adhesion in the early stages of the process (less than 30 min), followed by a decrease in adhesion in the later stages of the process. Interestingly, Hx-XO-derived ROS induced the same biphasic effect on the phosphorylation of the focal adhesion kinase (FAK), a nonreceptor tyrosine kinase critical for cell adhesion, but not on ERK1/2 phosphorylation. The biphasic effect was not seen with ERK1/2 where a decrease in phosphorylation only was observed. Wortmannin, a PI3-kinase inhibitor, inhibited ROS-induced cell adhesion and FAK phosphorylation. Orthovanadate, a protein tyrosine phosphatase inhibitor, and Resveratrol (Resv), an antioxidant agent, protected FAK and ERK1/2 from dephosphorylation and HUVEC from ROS-induced loss of adhesion. This study shows that ROS could have both stimulatory and inhibitory effects on HUVEC adhesion and FAK phosphorylation and suggests that PI3-kinase and tyrosine phosphatase control these effects.
C1 [Ben-Mahdi, Meriem H.] Vet Natl Super Sch Algiers, BP 161, Algiers 16200, Algeria.
C1 [Ben-Mahdi, Meriem H.; Dang, Pham My-Chan; Gougerot-Pocidalo, Marie-Anne; O'Dowd, Yvonne; El-Benna, Jamel; Pasquier, Catherine] CNRS ERL 8252, Ctr Rech IInflammat, INSERM U1149, F-75018 Paris, France.
C1 [Ben-Mahdi, Meriem H.; Dang, Pham My-Chan; Gougerot-Pocidalo, Marie-Anne; O'Dowd, Yvonne; El-Benna, Jamel; Pasquier, Catherine] Univ Paris Diderot, Fac Med, Lab Excellence Inflamex, Sorbonne Paris Cite,DHU FIRE, Site Xavier Bichat, F-75018 Paris, France.
C3 Ecole Nationale Superieure Veterinaire; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; UDICE-French
   Research Universities; Universite Paris Cite; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard -
   APHP
RP Ben-Mahdi, MH (corresponding author), Vet Natl Super Sch Algiers, BP 161, Algiers 16200, Algeria.; Ben-Mahdi, MH; El-Benna, J (corresponding author), CNRS ERL 8252, Ctr Rech IInflammat, INSERM U1149, F-75018 Paris, France.; Ben-Mahdi, MH; El-Benna, J (corresponding author), Univ Paris Diderot, Fac Med, Lab Excellence Inflamex, Sorbonne Paris Cite,DHU FIRE, Site Xavier Bichat, F-75018 Paris, France.
EM mhbenmahdi@gmail.com; jamel.elbenna@inserm.fr
CR ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5
   Belambri SA, 2014, METHODS MOL BIOL, V1124, P427, DOI 10.1007/978-1-62703-845-4_25
   Ben-Mahdi MH, 2000, ANTIOXID REDOX SIGN, V2, P789, DOI 10.1089/ars.2000.2.4-789
   Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028
   Cai WJ, 1997, ATHEROSCLEROSIS, V131, P177, DOI 10.1016/S0021-9150(97)06099-1
   Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901
   Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329
   Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497
   Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324
   Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404
   FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499
   FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6
   Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793
   GRANGER DN, 1989, AM J PHYSIOL, V257, pG683, DOI 10.1152/ajpgi.1989.257.5.G683
   GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0
   Hoyt DG, 1996, AM J PHYSIOL-LUNG C, V270, pL689, DOI 10.1152/ajplung.1996.270.4.L689
   Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383
   Ilic D, 1998, J CELL BIOL, V143, P547
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7
   KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V
   Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1
   Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103
   LEWIS T, 1995, J CELL SCI, V108, P2885
   Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385
   Mian MF, 2008, CHEM-BIOL INTERACT, V171, P57, DOI 10.1016/j.cbi.2007.08.009
   Muda M, 1996, J BIOL CHEM, V271, P4319
   Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200
   POLUNOVSKY VA, 1993, J CLIN INVEST, V92, P388, DOI 10.1172/JCI116578
   Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x
   Rotondo S, 1998, BRIT J PHARMACOL, V123, P1691, DOI 10.1038/sj.bjp.0701784
   SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   SELLAK H, 1994, BLOOD, V83, P2669
   Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895
   Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566
   Sonoda Y., 2004, BIOCHIM BIOPHYS ACTA, V1683, P22
   SUZUKI M, 1989, AM J PHYSIOL, V257, pH1740, DOI 10.1152/ajpheart.1989.257.5.H1740
   Suzuki Y, 1996, IMMUNOLOGY, V87, P396, DOI 10.1046/j.1365-2567.1996.431546.x
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
NR 41
TC 14
Z9 14
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 9346242
DI 10.1155/2016/9346242
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DT0RY
UT WOS:000381191900001
PM 27528888
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Camp, SM
   Chiang, ET
   Sun, CD
   Usatyuk, PV
   Bittman, R
   Natarajan, V
   Garcia, JGN
   Dudek, SM
AF Camp, Sara M.
   Chiang, Eddie T.
   Sun, Chaode
   Usatyuk, Peter V.
   Bittman, Robert
   Natarajan, Viswanathan
   Garcia, Joe G. N.
   Dudek, Steven M.
TI "Pulmonary Endothelial Cell Barrier Enhancement by Novel FTY720 Analogs:
   Methoxy-FTY720, Fluoro-FTY720, and beta-Glucuronide-FTY720"
SO CHEMISTRY AND PHYSICS OF LIPIDS
LA English
DT Article
DE FTY720; S1P/S1PR1/S1PR2/S1PR3; G protein-couple receptors; Endothelial barrier regulation; ALI/ARDS 
ID ACUTE LUNG INJURY; S1P RECEPTOR AGONISTS; SMOOTH-MUSCLE-CELLS;
   SPHINGOSINE 1-PHOSPHATE; VASCULAR-PERMEABILITY; MULTIPLE-SCLEROSIS; SIP1
   RECEPTOR; FINGOLIMOD; KINASE; SPHINGOSINE-1-PHOSPHATE
AB Effective therapeutic agents are lacking for the prevention and reversal of vascular leak, a frequent pathophysiologic result of inflammatory processes such as acute respiratory distress syndrome (ARDS) and sepsis. We previously demonstrated the potent barrier-enhancing effects of related compounds sphingosine 1-phosphate (S1P), the pharmaceutical agent FTY720, and its analog (S)-FTY720 phosphonate (Tys) in. models of inflammatory lung injury. In this study, we characterize additional novel FTY720 analogs for their potential to reduce vascular leak as well as utilize them as tools to better understand the mechanisms by which this class of agents modulates permeability. Transendothelial resistance (TER) and labeled dextran studies demonstrate that (R)-methoxy-FTY720 ((R)-OMe-FTY), (R)/(S)-fluoro-FTY720 (FTY-F), and beta-glucuronide-FTY720 (FTY-G) compounds display in vitro barrier-enhancing properties comparable or superior to FTY720 and SIP. In contrast, the (S)-methoxy-FTY720 ((S)-OMe-FTY) analog disrupts lung endothelial cell (EC) barrier integrity in TER studies in association with actin stress fiber formation and robust intracellular calcium release, but independent of myosin light chain or ERK phosphorylation. Additional mechanistic studies with (R)-OMe-FTY, FTY-F, and FTY-G suggest that lung EC barrier enhancement is mediated through lipid raft signaling, Gi-linked receptor coupling to downstream tyrosine phosphorylation events, and S1PR1-dependent receptor ligation. These results provide important mechanistic insights into modulation of pulmonary vascular barrier function by FTY720-related compounds and highlight common signaling events that may assist the development of novel therapeutic tools in the prevention or reversal of the pulmonary vascular leak that characterizes ARDS. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Camp, Sara M.; Chiang, Eddie T.; Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ, United States.
C1 [Usatyuk, Peter V.; Natarajan, Viswanathan; Dudek, Steven M.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ, United States.
C1 [Usatyuk, Peter V.; Natarajan, Viswanathan; Dudek, Steven M.] Univ Illinois, Dept Med, Div Pulm & Crit Care Med, Chicago, IL, United States.
C1 [Sun, Chaode; Bittman, Robert] CUNY Queens Coll, Dept Chem & Biochem, New York, NY, United States.
C3 University of Arizona; University of Arizona; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital; City University of New York (CUNY) System
RP Dudek, SM (corresponding author), Univ Illinois, Med Div Pulm Crit Care Sleep & Allergy, COMRB 3143,MC 719,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM sdudek@uic.edu
RI Garcia, Joe GN/E-8862-2010
FU National Institutes of Health [P01HL 58064, P01HL 98050]
FX This work was supported by the National Institutes of Health grants
   P01HL 58064 (JGNG) and P01HL 98050 (VN). This article is dedicated to
   the memory of Dr. Robert Bittman. Dr. Bittman was a dear friend and
   exceptional lipid biochemist without whose insight, enthusiasm, and
   friendship this research would have never been completed. The
   conception, design, and synthesis of the novel compounds described in
   this study were performed entirely under his direction and would not
   have been possible without his vast experience and outstanding
   scientific acumen.
CR Brown BA, 2007, ANN PHARMACOTHER, V41, P1660, DOI 10.1345/aph.1G424
   Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544
   Clemens JJ, 2005, BIOORG MED CHEM LETT, V15, P3568, DOI 10.1016/j.bmcl.2005.05.097
   Don AS, 2007, J BIOL CHEM, V282, P15833, DOI 10.1074/jbc.M609124200
   Dudek SM, 2007, CELL SIGNAL, V19, P1754, DOI 10.1016/j.cellsig.2007.03.011
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828
   Foss FW, 2005, BIOORG MED CHEM LETT, V15, P4470, DOI 10.1016/j.bmcl.2005.07.057
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115
   Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102
   Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3501, DOI 10.1016/j.bmcl.2004.04.070
   Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3351, DOI 10.1016/j.bmcl.2004.02.106
   Hanessian S, 2007, BIOORG MED CHEM LETT, V17, P491, DOI 10.1016/j.bmcl.2006.10.014
   Imeri F, 2014, NEUROPHARMACOLOGY, V85, P314, DOI 10.1016/j.neuropharm.2014.05.012
   Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643
   Koide Y, 2002, J MED CHEM, V45, P4629, DOI 10.1021/jm020080c
   Lim KG, 2011, CELL SIGNAL, V23, P1590, DOI 10.1016/j.cellsig.2011.05.010
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Muller HC, 2011, PULM PHARMACOL THER, V24, P377, DOI 10.1016/j.pupt.2011.01.017
   Nakayama S, 2008, BIOORGAN MED CHEM, V16, P7705, DOI 10.1016/j.bmc.2008.07.003
   Oo ML, 2011, J CLIN INVEST, V121, P2290, DOI 10.1172/JCI45403
   Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2
   Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Rosen H, 2009, ANNU REV BIOCHEM, V78, P743, DOI 10.1146/annurev.biochem.78.072407.103733
   Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com
   Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200
   Shea BS, 2010, AM J RESP CELL MOL, V43, P662, DOI 10.1165/rcmb.2009-0345OC
   Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Usatyuk PV, 2003, AM J PHYSIOL-LUNG C, V285, pL1006, DOI 10.1152/ajplung.00408.2002
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Wang LC, 2014, CRIT CARE MED, V42, pE189, DOI 10.1097/CCM.0000000000000097
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Waters D, 2006, FASEB J, V20, pA1058
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Zhu R, 2007, J MED CHEM, V50, P6428, DOI 10.1021/jm7010172
NR 42
TC 13
Z9 13
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-3084
EI 1873-2941
J9 CHEM PHYS LIPIDS
JI Chem. Phys. Lipids
PD JAN
PY 2016
VL 194
SI SI
BP 85
EP 93
DI 10.1016/j.chemphyslip.2015.10.004
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DD4GH
UT WOS:000369880000010
PM 26496151
DA 2023-08-21
ER

PT J
AU Guo, CR
   Goodwin, A
   Buie, JNJ
   Cook, J
   Halushka, P
   Argraves, K
   Zingarelli, B
   Zhang, X
   Wang, LP
   Fan, HK
AF Guo, Changrun
   Goodwin, Andrew J.
   Buie, Joy N. Jones
   Cook, James A.
   Halushka, Perry V.
   Argraves, Kelley
   Zingarelli, Basilia
   Zhang, Xian
   Wang, Liping
   Fan, Hongkuan
TI A Stromal Cell-Derived Factor 1 alpha Analogue Improves Endothelial Cell
   Function in Lipopolysaccharide-Induced Acute Respiratory Distress
   Syndrome
SO MOLECULAR MEDICINE
LA English
DT Article
ID LUNG VASCULAR-PERMEABILITY; BARRIER-ENHANCEMENT; PROGENITOR CELLS;
   MICRORNAS; CONTRIBUTES; DYSFUNCTION; INTEGRITY; PROTECTS; RECOVERY;
   RECEPTOR
AB Endothelial cell (EC) dysfunction is a critical mediator of the acute respiratory distress syndrome (ARDS). Recent studies have demonstrated that stromal cell-derived factor 1 alpha (SDF-1 alpha) promotes EC barrier integrity. Our previous studies used a SDF-1 alpha analogue CTCE-0214 (CTCE) in experimental sepsis and demonstrated that it attenuated vascular leak and modulated microRNA (miR) levels. We examined the hypothesis that CTCE improves EC function in lipopolysaccharide (LPS)-induced ARDS through increasing miR-126 expression. Human microvascular endothelial cells (HMVECs) were treated with thrombin to disrupt the EC integrity followed by incubation with CTCE or SDF-1 alpha. Barrier function was determined by trans-endothelial electrical resistance assay. CTCE-induced alterations in miRNA expression and signaling pathways involved in barrier function were determined. Thrombin-induced vascular leak was abrogated by both CTCE and SDF-1 alpha. CTCE also prevented thrombin-induced decreases of vascular endothelial (VE)-cadherin cell surface expression and expansion of the intercellular space. CTCE increased miR-126 levels and induced activation of AKT/Rac 1 signaling. Cotreatment with a miR-126 inhibitor blocked the protective effects of CTCE on AKT activation and endothelial permeability. In subsequent in vivo studies, ARDS was induced by intratracheal instillation of LPS. Intravenous injection of CTCE diminished the injury severity as evidenced by significant reductions in protein, immune cells, inflammatory cytokines and chemokines in the bronchoalveolar lavage fluid, increased miR-126 expression and decreased pulmonary vascular leak and alveolar edema. Taken together, our data show that CTCE improves endothelial barrier integrity through increased expression of miR-126 and activation of Rac 1 signaling and represents an important potential therapeutic strategy in ARDS.
C1 [Guo, Changrun; Buie, Joy N. Jones; Cook, James; Fan, Hongkuan] Med Univ South Carolina, Dept Neurosci, Charleston, SC, United States.
C1 [Goodwin, Andrew] Med Univ South Carolina, Pulm Crit Care Allergy & Sleep Med, Charleston, SC, United States.
C1 [Halushka, Perry] Med Univ South Carolina, Med, Charleston, SC, United States.
C1 [Halushka, Perry] Med Univ South Carolina, Pharmacol, Charleston, SC, United States.
C1 [Argraves, Kelley] Med Univ South Carolina, Regenerat Med & Cell Biol, Charleston, SC, United States.
C1 [Zhang, Xian] Med Univ South Carolina, Div Rheumatol & Immunol, Charleston, SC, United States.
C1 [Fan, Hongkuan] Med Univ South Carolina, Pathol & Lab Med, Charleston, SC, United States.
C1 [Guo, Changrun; Wang, Liping] Jilin Univ, Coll Life Sci, Changchun, China.
C1 [Zingarelli, Basilia] Cincinnati Childrens Hosp Med Ctr, Div Crit Care Med, Cincinnati, OH 45229, United States.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; Medical University of
   South Carolina; Medical University of South Carolina; Medical University
   of South Carolina; Medical University of South Carolina; Jilin
   University; Cincinnati Children's Hospital Medical Center
RP Fan, HK (corresponding author), Dept Pathol & Lab Med, 173 Ashley Ave,CRI Room 605B, Charleston, SC 29425 USA.
EM fanhong@musc.edu
RI , Basilia/AAV-7582-2021; , B/HZK-8896-2023
OI Fan, Hongkuan/0000-0002-9441-9405
FU [GM113995];  [GM27673];  [GM67202];  [KL2 TR000060];  [UL1 TR 000062]; 
   [UL1TR001450]
FX The authors acknowledge the technical support of Ms Sarah Ashton. This
   work was supported in part by GM113995 (H Fan), GM27673 (J Cook, P
   Halushka), GM67202 (B Zingarelli), KL2 TR000060, UL1 TR 000062 (A
   -Goodwin) and UL1TR001450 -(P Halushka).
CR Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   [Anonymous], 2013, P WORLD C ENG, DOI DOI 10.1039/C3RA43480J
   Barabutis N, 2015, AM J PHYSIOL-LUNG C, V308, pL776, DOI 10.1152/ajplung.00334.2014
   D'Ambrosi N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00279
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fan HK, 2014, AM J RESP CRIT CARE, V189, P1509, DOI 10.1164/rccm.201312-2163OC
   Fan HK, 2012, INFLAMMATION, V35, P130, DOI 10.1007/s10753-011-9297-5
   Gerrits H, 2008, GENESIS, V46, P235, DOI 10.1002/dvg.20387
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Guan SW, 2015, IMMUNOLOGY, V144, P405, DOI 10.1111/imm.12382
   Gunduz D, 2010, ARTERIOSCL THROM VAS, V30, P1237, DOI 10.1161/ATVBAHA.110.203901
   Kane NM, 2010, ARTERIOSCL THROM VAS, V30, P1389, DOI 10.1161/ATVBAHA.110.204800
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kobayashi K, 2014, ARTERIOSCL THROM VAS, V34, P1716, DOI 10.1161/ATVBAHA.114.303890
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lorenzen JM, 2015, J PHYSIOL-LONDON, V593, P1777, DOI 10.1113/JP270318
   Lu Q, 2012, AM J RESP CELL MOL, V47, P604, DOI 10.1165/rcmb.2012-0012OC
   Ma HY, 2014, BIOCHEM BIOPH RES CO, V450, P1560, DOI 10.1016/j.bbrc.2014.07.024
   Marques-Rocha JL, 2015, FASEB J, V29, P3595, DOI 10.1096/fj.14-260323
   Meng S, 2012, J MOL CELL CARDIOL, V53, P64, DOI 10.1016/j.yjmcc.2012.04.003
   Nie ZC, 2015, INT J CLIN EXP PATHO, V8, P4745
   Pepini T, 2010, J VIROL, V84, P11929, DOI 10.1128/JVI.01658-10
   Petruzziello-Pellegrini TN, 2012, J CLIN INVEST, V122, P759, DOI 10.1172/JCI57313
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shah D, 2014, AM J PHYSIOL-LUNG C, V306, pL152, DOI 10.1152/ajplung.00229.2013
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Spragg RG, 2011, AM J RESP CRIT CARE, V183, P1055, DOI 10.1164/rccm.201009-1424OC
   Staszel T, 2011, POL ARCH MED WEWN, V121, P361, DOI 10.20452/pamw.1093
   Suurna MV, 2006, AM J PHYSIOL-RENAL, V290, pF1398, DOI 10.1152/ajprenal.00194.2005
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Tian XY, 2015, MOL BIOL CELL, V26, P636, DOI 10.1091/mbc.E14-02-0725
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   Trzeciak S, 2008, ACAD EMERG MED, V15, P399, DOI 10.1111/j.1553-2712.2008.00109.x
   Umapathy NS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059733
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van den Berg BM, 2003, CIRC RES, V92, P592, DOI 10.1161/01.RES.0000065917.53950.75
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wei YY, 2013, ARTERIOSCL THROM VAS, V33, P449, DOI 10.1161/ATVBAHA.112.300279
   Wilkerson BA, 2012, J BIOL CHEM, V287, P44645, DOI 10.1074/jbc.M112.423426
   Young JA, 2013, BLOOD, V122, P2911, DOI 10.1182/blood-2012-12-473017
NR 42
TC 14
Z9 18
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PY 2016
VL 22
DI 10.2119/molmed.2015.00240
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA DT5KW
UT WOS:000381523100001
PM 27031787
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Lee, JY
   Linge, HM
   Ochani, K
   Lin, K
   Miller, EJ
AF Lee, Ji Young
   Linge, Helena M.
   Ochani, Kanta
   Lin, Ke
   Miller, Edmund J.
TI Regulation of angiopoietin-2 secretion from human pulmonary
   microvascular endothelial cells
SO EXPERIMENTAL LUNG RESEARCH
LA English
DT Article
DE angiopoietin-1/angiopoietin-2; ECs/HPMECs/HUVECs/MPVECs; exocytosis; pulmonary; secretion 
ID WEIBEL-PALADE BODIES; ACUTE LUNG INJURY; VON-WILLEBRAND-FACTOR; ORGAN
   DYSFUNCTION; SEVERE SEPSIS; SEPTIC SHOCK; ANTIMICROBIAL THERAPY;
   MORTALITY; SURVIVAL; HETEROGENEITY
AB Introduction: Sepsis is characterized by dysregulated systemic inflammation and cytokine storm. Angiopoietin-2 (Ang-2) is known to closely correlate with severity of sepsis-related acute lung injury and mortality. The aim of this study was to clarify the mechanisms involved in Ang-2 secretion to better understand the pathophysiology of sepsis. Materials and Methods: The concentration of Ang-2 was assessed in culture medium of pulmonary microvascular endothelial cells in the presence or absence of Gram-positive bacteria cell wall components [lipoteichoic acid (LTA) and peptidoglycan (PGN)] stimulation at different time points ranging from 15 minutes to 24 hours. Constitutive and LTA-PGN-stimulated Ang-2 level changes were also assessed after cells were pretreated with different pathway inhibitors for 1 hour. Results: Two distinctive mechanisms of Ang-2 secretion, constitutive and stimulated secretion, were identified. Constitutive secretion resulted in slow but continuous increase in Ang-2 in culture medium over time. It was regulated by 3'5'-cyclic adenosine monophosphate (cAMP)-protein kinaseA(PKA)-Ca2+ and nitric oxide (NO)-3'5'-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG)-Ca2+ pathways and partially regulated by N-ethyl-maleimide-sensitive factor-Ca2+ pathways. LTA-PGN stimulation caused rapid and potent increase followed by gradual decrease of Ang-2. It was partially regulated by both Ral A-phospholipase D and NSF-Ca2+ pathways. Conclusions: We demonstrated characteristics and involved pathways for two distinctive secretory mechanisms, constitutive and stimulated, of Ang-2 in pulmonary microvascular endothelial cells. Considering the close correlation of Ang-2 with sepsis outcomes, our findings provide a better understanding of an important mechanism associated with sepsis pathophysiology and identify possible therapeutic targets to improve outcomes in the potentially lethal disease.
C1 [Lee, Ji Young; Miller, Edmund J.] Elmezzi Grad Sch Mol Med, Manhasset, NY, United States.
C1 [Lee, Ji Young] Univ S Alabama, Dept Pulm & Crit Care Med, 2451 Fillingim St,Suite 10-G, Mobile, AL 36617, United States.
C1 [Linge, Helena M.; Ochani, Kanta; Lin, Ke; Miller, Edmund J.] Feinstein Inst Med Res, Ctr Heart & Lung Res, Manhasset, NY, United States.
C1 [Miller, Edmund J.] Hofstra North Shore LIJ Med Sch, Hempstead, NY, United States.
C3 Northwell Health; University of South Alabama; Northwell Health; Hofstra
   University
RP Lee, JY (corresponding author), Univ S Alabama, Dept Pulm & Crit Care Med, 2451 Fillingim St,Suite 10-G, Mobile, AL 36617 USA.
EM jiyounglee98@gmail.com
OI Linge, Helena/0000-0002-8919-0300; Lee, Ji Young/0000-0002-8005-2446
FU Elmezzi Graduate School of Molecular Medicine; Feinstein Institute for
   Medical Research
FX Supported by funds from The Elmezzi Graduate School of Molecular
   Medicine and The Feinstein Institute for Medical Research.
CR Agrawal A, 2013, AM J RESP CRIT CARE, V187, P736, DOI 10.1164/rccm.201208-1460OC
   Akata T, 2007, J ANESTH, V21, P232, DOI 10.1007/s00540-006-0488-4
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   [Anonymous], 2003, CRIT CARE MED, DOI DOI 10.1097/01.CCM.0000050454.01978.3B
   Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303
   BESUNDER JB, 1991, CRIT CARE CLIN, V7, P659, DOI 10.1016/S0749-0704(18)30300-2
   Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017
   Choi JS, 2013, MED SCI MONITOR, V19, P28
   David S, 2013, J PHARMACOL EXP THER, V345, P2, DOI 10.1124/jpet.112.201061
   David S, 2012, CRIT CARE MED, V40, P3034, DOI 10.1097/CCM.0b013e31825fdc31
   Davis JS, 2010, CRIT CARE, V14, DOI 10.1186/cc9020
   Deleuze V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040484
   Dellinger R, 2013, INTENS CARE MED, V41, P580, DOI DOI 10.1007/s00134-012-2769-8
   Ebihara I, 2011, THER APHER DIAL, V15, P349, DOI 10.1111/j.1744-9987.2011.00963.x
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Giblin JP, 2008, BLOOD, V112, P957, DOI 10.1182/blood-2007-12-130740
   Giuliano JS, 2007, SHOCK, V28, P650, DOI 10.1097/shk.0b013e318123867b
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Jaiswal JK, 2009, CELL, V137, P1308, DOI 10.1016/j.cell.2009.04.064
   Jang C, 2009, ARTERIOSCL THROM VAS, V29, P401, DOI 10.1161/ATVBAHA.108.172676
   Khardori R, 2012, MED CLIN N AM, V96, P1095, DOI 10.1016/j.mcna.2012.09.005
   Klijn E, 2008, CLIN CHEST MED, V29, P643, DOI 10.1016/j.ccm.2008.06.008
   Kraft MD, 2005, AM J HEALTH-SYST PH, V62, P1663, DOI 10.2146/ajhp040300
   Kranidioti H, 2009, IMMUNOL LETT, V125, P65, DOI 10.1016/j.imlet.2009.06.006
   Krump-Konvalinkova V, 2001, LAB INVEST, V81, P1717, DOI 10.1038/labinvest.3780385
   Kumpers P, 2009, CRIT CARE, V13, DOI 10.1186/cc7866
   Kumar A, 2009, CHEST, V136, P1237, DOI 10.1378/chest.09-0087
   Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9
   Lee J. Y., 2014, Journal of Pulmonary and Respiratory Medicine, V4, P1000172
   Lee Jay Wook, 2010, Electrolyte Blood Press, V8, P72, DOI 10.5049/EBP.2010.8.2.72
   Lee JY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157837
   Lee JY, 2014, J PULM RESP MED, P4172
   Lehr HA, 2000, J PATHOL, V190, P373, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;373::AID-PATH593&gt;3.0.CO;2-3
   Linge HM, 2015, EXP LUNG RES, V41, P216, DOI 10.3109/01902148.2014.999174
   Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005
   Lukasz A, 2008, CRIT CARE, V12, DOI 10.1186/cc6966
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Matsushita K, 2005, MOL PHARMACOL, V67, P1137, DOI 10.1124/mol.104.004275
   Micek ST, 2006, CRIT CARE MED, V34, P2707, DOI 10.1097/01.CCM.0000241151.25426.D7
   Miller EJ, 1996, CRIT CARE MED, V24, P1448, DOI 10.1097/00003246-199609000-00004
   MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39
   Morrell CN, 2005, J PHARMACOL EXP THER, V314, P155, DOI 10.1124/jpet.104.082529
   Nightingale TD, 2011, J CELL BIOL, V194, P613, DOI 10.1083/jcb.201011119
   Ong T, 2010, CRIT CARE MED, V38, P1845, DOI 10.1097/CCM.0b013e3181eaa5bf
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Park HY, 2012, YONSEI MED J, V53, P369, DOI 10.3349/ymj.2012.53.2.369
   Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318
   Ricciuto DR, 2011, CRIT CARE MED, V39, P702, DOI 10.1097/CCM.0b013e318206d285
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Rondaij MG, 2008, BLOOD, V112, P56, DOI 10.1182/blood-2007-07-099309
   Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P1002, DOI 10.1161/01.ATV.0000209501.56852.6c
   Russell FD, 1998, J CARDIOVASC PHARM, V31, P424, DOI 10.1097/00005344-199803000-00014
   Russell JA, 2000, CRIT CARE MED, V28, P3405, DOI 10.1097/00003246-200010000-00005
   SIEGEL LM, 1994, TRENDS ENDOCRIN MET, V5, P324, DOI 10.1016/1043-2760(94)90161-9
   Stalker A L, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P10
   Thorin E, 1998, PHARMACOL THERAPEUT, V78, P155, DOI 10.1016/S0163-7258(98)00005-9
   Tsai LCL, 2011, MOL PHARMACOL, V79, P639, DOI 10.1124/mol.110.069104
   Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   van der Heijden M, 2010, SHOCK, V33, P263, DOI 10.1097/SHK.0b013e3181b2f978
   van der Heijden M, 2009, INTENS CARE MED, V35, P1567, DOI 10.1007/s00134-009-1560-y
   van der Heijden M, 2009, EXPERT OPIN THER TAR, V13, P39, DOI [10.1517/14728220802626256, 10.1517/14728220802626256 ]
   Vezzosi D, 2011, EUR J ENDOCRINOL, V165, P177, DOI 10.1530/EJE-10-1123
   Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A
   Vincent JL, 2005, CRIT CARE, V9, pS9, DOI 10.1186/cc3748
   Wang JE, 2003, SHOCK, V20, P402, DOI 10.1097/01.shk.0000092268.01859.0d
   Weibel ER, 2012, J THROMB HAEMOST, V10, P979, DOI 10.1111/j.1538-7836.2012.04718.x
   Wu SW, 2014, PULM CIRC, V4, P110, DOI 10.1086/674879
NR 69
TC 6
Z9 7
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0190-2148
EI 1521-0499
J9 EXP LUNG RES
JI Exp. Lung Res.
PY 2016
VL 42
IS 7
BP 335
EP 345
DI 10.1080/01902148.2016.1218977
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA EA8QV
UT WOS:000386904100001
PM 27585839
DA 2023-08-21
ER

PT J
AU Liang, XS
   Zhang, B
   Chen, Q
   Zhang, J
   Lei, B
   Li, B
   Wei, YC
   Zhai, R
   Liang, ZQ
   He, SQ
   Tang, B
AF Liang, Xingsi
   Zhang, Bin
   Chen, Quan
   Zhang, Jing
   Lei, Biao
   Li, Bo
   Wei, Yangchao
   Zhai, Run
   Liang, Zhiqing
   He, Songqing
   Tang, Bo
TI The mechanism underlying alpinetin-mediated alleviation of
   pancreatitis-associated lung injury through upregulating aquaporin-1
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE alpinetin; aquaporin 1; severe acute pancreatitis; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; TNF/TNF-alpha/TNFR1 
ID DYSFUNCTION; EXPRESSION; PROTEIN; CELLS
AB Characterized by its acute onset, critical condition, poor prognosis, and high mortality rate, severe acute pancreatitis (SAP) can cause multiple organ failure at its early stage, particularly acute lung injury (ALI). The pathogenesis of ALI is diffuse alveolar damage, including an increase in pulmonary microvascular permeability, a decrease in compliance, and invasion of many inflammatory cells. Corticosteroids are the main treatment method for ALI; however, the associated high toxicity and side effects induce pain in patients. Recent studies show that the effective components in many traditional Chinese medicines can effectively inhibit inflammation with few side effects, which can decrease the complications caused by steroid consumption. Based on these observations, the main objective of the current study is to investigate the effect of alpinetin, which is a flavonoid extracted from Alpinia katsumadai Hayata, on treating lung injury induced by SAP and to explore the mechanism underlying the alpinetin-mediated decrease in the extent of ALI. In this study, we have shown through in vitro experiments that a therapeutic dose of alpinetin can promote human pulmonary microvascular endothelial cell proliferation. We have also shown via in vitro and in vivo experiments that alpinetin upregulates aquaporin-1 and, thereby, inhibits tumor necrosis factor-alpha expression as well as reduces the degree of lung injury. Overall, our study shows that alpinetin alleviates SAP-induced ALI. The likely molecular mechanism includes upregulated aquaporin expression, which inhibits tumor necrosis factor-alpha and, thus, alleviates SAP-induced ALI.
C1 [Liang, Xingsi; Zhang, Jing; Lei, Biao; Wei, Yangchao; Zhai, Run; He, Songqing; Tang, Bo] Guilin Med Univ, Lab Liver Injury & Repair Mol Med, Guilin, Guangxi, China.
C1 [Liang, Xingsi; Liang, Zhiqing] Guilin Med Univ, Affiliated Hosp, Dept Infect Dis, 15 Lequn Rd, Guilin 541001, Guangxi, China.
C1 [Zhang, Bin] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Liaoning, China.
C1 [Chen, Quan] Liaoning Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Jinzhou, Liaoning, China.
C1 [Zhang, Jing; Lei, Biao; Li, Bo; Wei, Yangchao; Zhai, Run; He, Songqing] Guilin Med Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Guilin, Guangxi, China.
C3 Guilin Medical University; Guilin Medical University; Dalian Medical
   University; Jinzhou Medical University; Guilin Medical University
RP Liang, ZQ (corresponding author), Guilin Med Univ, Affiliated Hosp, Dept Infect Dis, 15 Lequn Rd, Guilin 541001, Guangxi, Peoples R China.; Tang, B (corresponding author), Guilin Med Univ, Affiliated Hosp, Lab Liver Injury & Repair Mol Med, 15 Lequn Rd, Guilin 541001, Guangxi, Peoples R China.
EM lzqliangzhi@163.com; dytangbo@163.com
RI Hooshangnejad, Hamed/AGX-7818-2022
OI Hooshangnejad, Hamed/0000-0002-1953-0568
FU Pharmaceutical Technology Special Project of the Health Department in
   Guangxi [GZPT13-45]; Construction Project of Key Laboratory of Molecular
   Medicine in Liver Damage and Repair, Guangxi [SYS2013009]; Self-financed
   Projects of the Guangxi Department of Health [Z2013464]
FX This research was supported in part by the Pharmaceutical Technology
   Special Project of the Health Department in Guangxi (GZPT13-45), the
   Construction Project of Key Laboratory of Molecular Medicine in Liver
   Damage and Repair, Guangxi (SYS2013009), and Self-financed Projects of
   the Guangxi Department of Health (Z2013464).
CR Akbarshahi H, 2012, RESP MED, V106, P1199, DOI 10.1016/j.rmed.2012.06.003
   Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138
   DENKER BM, 1988, J BIOL CHEM, V263, P15634
   Favarin DC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/576479
   Gao ZM, 2014, EXP THER MED, V8, P1819, DOI 10.3892/etm.2014.1987
   Halonen KI, 2002, CRIT CARE MED, V30, P1274, DOI 10.1097/00003246-200206000-00019
   Huai JP, 2012, WORLD J GASTROENTERO, V18, P5122, DOI 10.3748/wjg.v18.i36.5122
   Huo MX, 2012, INT IMMUNOPHARMACOL, V12, P241, DOI 10.1016/j.intimp.2011.11.017
   Kylanpaa L, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/360685
   Lv P, 2014, PATHOL RES PRACT, V210, P558, DOI 10.1016/j.prp.2014.04.022
   Ma T, 2013, INT UROL NEPHROL, V45, P1187, DOI 10.1007/s11255-012-0355-1
   Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491
   Pastor CM, 2003, CHEST, V124, P2341, DOI 10.1378/chest.124.6.2341
   Sala A, 2003, EUR J PHARMACOL, V461, P53, DOI 10.1016/S0014-2999(02)02953-9
   Su X, 2004, RESP PHYSIOL NEUROBI, V142, P1, DOI 10.1016/j.resp.2004.05.001
   Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818
   Uzel A, 2005, MICROBIOL RES, V160, P189, DOI 10.1016/j.micres.2005.01.002
   Weng TI, 2012, SHOCK, V37, P478, DOI 10.1097/SHK.0b013e31824653be
   Yuan Z, 2011, J GASTROINTEST SURG, V15, P1670, DOI 10.1007/s11605-011-1643-2
   Zhang YL, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0199-1
   Zhang ZQ, 2011, J TRAUMA, V71, P1305, DOI 10.1097/TA.0b013e3182128528
NR 21
TC 16
Z9 23
U1 0
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2016
VL 10
DI 10.2147/DDDT.S97614
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DE9DE
UT WOS:000370934900001
PM 26966354
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Shao, M
   Tang, ST
   Liu, B
   Zhu, HQ
AF Shao, Min
   Tang, Song-Tao
   Liu, Bao
   Zhu, Hua-Qing
TI Rac1 mediates HMGB1-induced hyperpermeability in pulmonary microvascular
   endothelial cells via MAPK signal transduction
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE HMGB1; Rac1; ALI/ARDS; hyperpermeability; MAPK 
ID ACUTE LUNG INJURY; RHO; GTPASES
AB The pathology of acute respiratory distress syndrome (ARDS) is closely associated with the failure of alveolar-capillary barrier integrity and alveolar filling by high protein pulmonary edema, resulting from hyperpermeability. High mobility group box 1 (HMGB1) is a novel late mediator of sepsis, which is specifically involved in endotoxin-induced acute lung injury and sepsis-associated lethality. Although the role of HMGB1 in endothelial cell cytoskeletal rearrangement and vascular permeability have been investigated preliminarily, the molecular mechanisms remain to be fully elucidated. As the ras-related C3 botulinum toxin substrate 1 (Rac1) gene is important role in regulating microvascular barrier maintenance, the present study was designed to determine whether Rac1 is involved in HMGB1-induced hyperpermeability in pulmonary microvascular endothelial cells (PMVECs). The results of the present study demonstrated that HMGB1 induced dose and time-dependent decreases in transendothelial electrical resistance (TER). Notably, HMGB1 induced a dose-dependent increase in the activity and expression levels of Rac1. Using small interfering RNA and an agonist of Rac1, the present study demonstrated that Rac1 was a novel factor mediating the HMGB1-induced decrease in TER via extracellular signal-regulated kinase and p38 mitogen-activated protein kinase (MAPK) activation. These data suggested that Rac1 is involved in HMGB1-induced hyperpermeability in PMVECs via MAPK signal transduction.
C1 [Shao, Min; Liu, Bao] Anhui Med Univ, Affiliated Prov Hosp, Dept Crit Care Med, Hefei 230001, China.
C1 [Tang, Song-Tao; Zhu, Hua-Qing] Anhui Med Univ, Mol Biol Lab, Hefei 230032, Anhui, China.
C1 [Tang, Song-Tao; Zhu, Hua-Qing] Anhui Med Univ, Dept Biochem, Hefei 230032, Anhui, China.
C1 [Tang, Song-Tao] Anhui Med Univ, Affiliated Hosp 1, Dept Endocrinol, Hefei 230022, Anhui, China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University; Anhui Medical University
RP Liu, B (corresponding author), Anhui Med Univ, Affiliated Prov Hosp, Dept Crit Care Med, 17 Lujiang Rd, Hefei 230001, Peoples R China.
EM linux306@126.com; aydzhq@126.com
FU National Natural Science Foundation of China [81070232, 81270372];
   Natural Science Foundation of Anhui Province [1408085MH170]
FX The present study was supported by the National Natural Science
   Foundation of China (grant nos. 81070232 and 81270372) and the Natural
   Science Foundation of Anhui Province (grant no. 1408085MH170).
CR Adamson RH, 2008, AM J PHYSIOL-HEART C, V294, pH1188, DOI 10.1152/ajpheart.00937.2007
   Baumer Y, 2009, J CELL PHYSIOL, V220, P716, DOI 10.1002/jcp.21819
   Beckers CML, 2010, THROMB HAEMOSTASIS, V103, P40, DOI 10.1160/TH09-06-0403
   Birukova AA, 2009, J APPL PHYSIOL, V107, P1900, DOI 10.1152/japplphysiol.00462.2009
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Gao M, 2011, SHOCK, V36, P228, DOI 10.1097/SHK.0b013e318225b29a
   Guo XH, 2006, APMIS, V114, P874, DOI 10.1111/j.1600-0463.2006.apm_372.x
   Kim DC, 2011, INFLAMM RES, V60, P1161, DOI 10.1007/s00011-011-0381-y
   Kim JY, 2005, AM J PHYSIOL-LUNG C, V288, pL958, DOI 10.1152/ajplung.00359.2004
   Lin CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104746
   Shao M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055213
   Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086
   van Wetering S, 2002, J CELL SCI, V115, P1837
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Wang YX, 2011, AM J PHYSIOL-CELL PH, V301, pC695, DOI 10.1152/ajpcell.00322.2010
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Waschke J, 2004, AM J PHYSIOL-HEART C, V286, pH394, DOI 10.1152/ajpheart.00221.2003
   Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
NR 22
TC 15
Z9 18
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2016
VL 13
IS 1
BP 529
EP 535
DI 10.3892/mmr.2015.4521
PN A
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DA5UG
UT WOS:000367867500074
PM 26549372
OA Bronze
DA 2023-08-21
ER

PT J
AU Tauseef, M
   Farazuddin, M
   Sukriti, S
   Rajput, C
   Meyer, JO
   Ramasamy, SK
   Mehta, D
AF Tauseef, Mohammad
   Farazuddin, Mohammad
   Sukriti, Sukriti
   Rajput, Charu
   Meyer, James Otto
   Ramasamy, Suresh Kumar
   Mehta, Dolly
TI Transient receptor potential channel 1 maintains adherens junction
   plasticity by suppressing sphingosine kinase 1 expression to induce
   endothelial hyperpermeability
SO FASEB JOURNAL
LA English
DT Article
DE ALI/ARDS; thrombin; TRPC; VE-cadherin 
ID OPERATED CA2+ ENTRY; LUNG VASCULAR-PERMEABILITY; VE-CADHERIN; TRPC1
   EXPRESSION; INDUCED INCREASE; KAPPA-B; ACTIVATION;
   SPHINGOSINE-1-PHOSPHATE; SEPSIS; INFLUX
AB Stability of endothelial cell (EC) adherens junctions (AJs) is central for prevention of tissue edema, the hallmark of chronic inflammatory diseases including acute respiratory distress syndrome. Here, we demonstrate a previously unsuspected role of sphingosine kinase 1 (SPHK1) in the mechanism by which transient receptor potential channel 1 (Trpc1)-mediated Ca2+ entry destabilizes AJs. Trpc(-/-) monolayers showed a 2.2-fold increase in vascular endothelial (VE)-cadherin cell-surface expression above wild-type (WT) monolayers. Thrombin increased endothelial permeability (evident by a 5-fold increase in interendothelial gap area and 60% decrease in transendothelial electrical resistance) in WT but not Trpc1(-/-) ECs. Trpc1(-/-) mice resisted the hyperpermeability effects of the edemagenic agonists used and exhibited 60% less endotoxin-induced mortality. Because sphingosine-1-phosphate (S1P) strengthens AJs, we determined if TRPC1 functioned by inhibiting SPHK1 activity, which generates S1P. Intriguingly, Trpc1(-/-) ECs or ECs transducing a TRPC1-inactive mutant showed a 1.5-fold increase in basal SPHK1 expression compared with WT ECs, resulting in a 2-fold higher S1P level. SPHK1 inhibitor SK1-I decreased basal transendothelial electrical resistance more in WT ECs (48 and 72% reduction at 20 and 50 mu M, respectively) than in Trpc1(-/-) ECs. However, SK1-I pretreatment rescued thrombin-induced EC permeability in Trpc1(-/-) ECs. Thus, TRPC1 suppression of basal SPHK1 activity enables EC-barrier destabilization by edemagenic agonists.-Tauseef, M., Farazuddin, M., Sukriti, S., Rajput, C., Meyer, J. O., Ramasamy, S. K., Mehta, D. Transient receptor potential channel 1 maintains adherens junction plasticity by suppressing sphingosine kinase 1 expression to induce endothelial hyperpermeability. FASEB J. 30, 102-110 (2016). www.fasebj.org
C1 [Mehta, Dolly] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612, United States.
C1 Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.
EM dmehta@uic.edu
RI Farazuddin, Mohammad/AAI-2580-2021
OI Baweja, Sukriti/0000-0002-8677-9857
FU U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood
   Institute [HL-71794, HL-84153, HL-060678]
FX This work was supported by U.S. National Institutes of Health (NIH)
   National Heart, Lung, and Blood Institute Grants HL-71794, HL-84153, and
   HL-060678. The authors thank I. S Ambudkar (NIH) for providing TRPC1
   mutant constructs and V. Natarajan (University of Illinois, Chicago, IL,
   USA) for his gift of SPHK1 luciferase promoter. The authors also thank
   L. Birnbaumer (NIH) and A. Dietrich (Walther-Straub-Institute for
   Pharmacology and Toxicology, Munich, Germany) for providing
   TRPC1<SUP>-/-</SUP> mice.
CR Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200
   Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359
   BARNARD JW, 1995, J IMMUNOL, V155, P4876
   Beech DJ, 2013, CIRC J, V77, P570, DOI 10.1253/circj.CJ-13-0154
   Chavez A, 2015, J CELL SCI, V128, P878, DOI 10.1242/jcs.154476
   Chavez A, 2011, INT REV CEL MOL BIO, V290, P205, DOI 10.1016/B978-0-12-386037-8.00001-6
   Cioffi DL, 2006, MICROCIRCULATION, V13, P709, DOI 10.1080/10739680600930354
   Cioffi DL, 2011, ANTIOXID REDOX SIGN, V15, P1567, DOI 10.1089/ars.2010.3740
   Cioffi DL, 2009, ANTIOXID REDOX SIGN, V11, P765, DOI [10.1089/ars.2008.2221, 10.1089/ARS.2008.2221]
   Daneshjou N, 2015, J CELL BIOL, V209, P181, DOI 10.1083/jcb.20140910803202015c
   DebRoy A, 2014, J BIOL CHEM, V289, P24188, DOI 10.1074/jbc.M114.570051
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dietrich A, 2005, PFLUG ARCH EUR J PHY, V451, P72, DOI 10.1007/s00424-005-1460-0
   Dietrich A, 2010, THROMB HAEMOSTASIS, V103, P262, DOI 10.1160/TH09-08-0517
   Earley S, 2015, PHYSIOL REV, V95, P645, DOI 10.1152/physrev.00026.2014
   Gavard Julie, 2014, Cell Adh Migr, V8, P158
   Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200
   Gong H., 2015, J CLIN INVEST, V125, P1364
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Gong HX, 2014, J EXP MED, V211, P579, DOI 10.1084/jem.20131190
   Harikumar KB, 2014, NAT IMMUNOL, V15, P231, DOI 10.1038/ni.2810
   Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711
   Jho D, 2005, CIRC RES, V96, P1282, DOI 10.1161/01.RES.0000171894.03801.03
   Kaneider NC, 2007, NAT IMMUNOL, V8, P1303, DOI 10.1038/ni1525
   Kim EY, 2014, FASEB J, V28, P4347, DOI 10.1096/fj.14-251611
   Kini V, 2010, J BIOL CHEM, V285, P33082, DOI 10.1074/jbc.M110.142034
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Komarova YA, 2012, MOL CELL, V48, P914, DOI 10.1016/j.molcel.2012.10.011
   Kowalczyk Andrew P, 2012, Subcell Biochem, V60, P197, DOI 10.1007/978-94-007-4186-7_9
   Kusaba T, 2010, P NATL ACAD SCI USA, V107, P19308, DOI 10.1073/pnas.1008544107
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Marfe G, 2015, MINI-REV MED CHEM, V15, P300, DOI 10.2174/1389557515666150227105415
   Mathew B, 2011, FASEB J, V25, P3388, DOI 10.1096/fj.11-183970
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200
   Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Natarajan V, 2013, AM J RESP CELL MOL, V49, P6, DOI 10.1165/rcmb.2012-0411TR
   Ong HL, 2007, J BIOL CHEM, V282, P9105, DOI 10.1074/jbc.M608942200
   Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004
   Paria BC, 2006, J BIOL CHEM, V281, P20715, DOI 10.1074/jbc.M600722200
   Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958
   Rajput C, 2013, J BIOL CHEM, V288, P4241, DOI 10.1074/jbc.M112.440396
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200
   Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720
   Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974
   St Amant EV, 2012, CIRC RES, V111, P739, DOI 10.1161/CIRCRESAHA.112.269654
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Sun XG, 2013, AM J PHYSIOL-LUNG C, V305, pL467, DOI 10.1152/ajplung.00010.2013
   Sundivakkam PC, 2012, MOL PHARMACOL, V81, P510, DOI 10.1124/mol.111.074658
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Wadgaonkar R, 2009, AM J PHYSIOL-LUNG C, V296, pL603, DOI 10.1152/ajplung.90357.2008
   Xiong YQ, 2014, CURR TOP MICROBIOL, V378, P85, DOI 10.1007/978-3-319-05879-5_4
   Zhao YDD, 2009, CIRC RES, V105, P696, DOI 10.1161/CIRCRESAHA.109.199778
NR 60
TC 15
Z9 19
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2016
VL 30
IS 1
BP 102
EP 110
DI 10.1096/fj.15-275891
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA DA2JL
UT WOS:000367621000012
PM 26316271
OA Green Published
DA 2023-08-21
ER

PT J
AU Wu, W
   Luo, RJ
   Lin, ZQ
   Xia, Q
   Xue, P
AF Wu, Wei
   Luo, Ruijie
   Lin, Ziqi
   Xia, Qing
   Xue, Ping
TI Key Molecular Mechanisms of Chaiqinchengqi Decoction in Alleviating the
   Pulmonary Albumin Leakage Caused by Endotoxemia in Severe Acute
   Pancreatitis Rats
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID CHENGQI DECOCTION; IN-VITRO; KAPPA-B; LUNG INJURY; C-SRC; EXPRESSION;
   INFLAMMATION; PERMEABILITY; APOPTOSIS; BARRIER
AB To reveal the key molecular mechanisms of Chaiqinchengqi decoction (CQCQD) in alleviating the pulmonary albumin leakage caused by endotoxemia in severe acute pancreatitis (SAP) rats. Rats models of SAP endotoxemia-induced acute lung injury were established, the studies in vivo provided the important evidences that the therapy of CQCQD significantly ameliorated the increases in plasma levels of lipopolysaccharide (LPS), sCd14, and Lbp, the elevation of serum amylase level, the enhancements of systemic and pulmonary albumin leakage, and the depravation of airways indicators, thus improving respiratory dysfunction and also pancreatic and pulmonary histopathological changes. According to the analyses of rats pulmonary tissue microarray and protein-protein interaction network, c-Fos, c-Src, and p85 alpha were predicted as the target proteins for CQCQD in alleviating pulmonary albumin leakage. To confirm these predictions, human umbilical vein endothelial cells were employed in in vitro studies, which provide the evidences that (1) LPS-induced paracellular leakage and proinflammatory cytokines release were suppressed by pretreatment with inhibitors of c-Src (PP1) or PI3K (LY294002) or by transfection with siRNAs of c-Fos; (2) fortunately, CQCQD imitated the actions of these selective inhibitions agents to inhibit LPS-induced high expressions of p-Src, p-p85 alpha, and c-Fos, therefore attenuating paracellular leakage and proinflammatory cytokines release.
C1 [Wu, Wei; Luo, Ruijie; Lin, Ziqi; Xia, Qing; Xue, Ping] Sichuan Univ, Dept Integrated Tradit Chinese & Western Med, West China Hosp, Chengdu 610041, China.
C3 Sichuan University
RP Xue, P (corresponding author), Sichuan Univ, Dept Integrated Tradit Chinese & Western Med, West China Hosp, Chengdu 610041, Peoples R China.
EM weijunhr001@163.com
FU National Natural Science Foundation of China [81573766]; Science and
   Technology Support Program of Sichuan [2011SZ0291]; Remeadjohn
   Technology Co., Ltd., Chengdu, China
FX This project was supported by National Natural Science Foundation of
   China (no. 81573766), Science and Technology Support Program of Sichuan
   (no. 2011SZ0291), and Remeadjohn Technology Co., Ltd., Chengdu 610044,
   China.
CR Armstrong SM, 2012, AM J PATHOL, V180, P1308, DOI 10.1016/j.ajpath.2011.12.002
   Ben DF, 2012, J SURG RES, V174, P326, DOI 10.1016/j.jss.2010.12.005
   Cao XF, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0191-9
   dos Santos MD, 2006, BIOL PHARM BULL, V29, P2236, DOI 10.1248/bpb.29.2236
   Deng Li-Hui, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P176, DOI 10.3736/jcim20080214
   Deng LH, 2009, WORLD J GASTROENTERO, V15, P4439, DOI 10.3748/wjg.15.4439
   Du Anqing, 2012, Hua Xi Kou Qiang Yi Xue Za Zhi, V30, P430
   Gill SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088501
   Guo J, 2015, CHIN J INTEGR MED, V21, P29, DOI 10.1007/s11655-014-1750-5
   Guo J, 2013, CHIN J INTEGR MED, V19, P913, DOI 10.1007/s11655-013-1653-x
   Guo Jia, 2011, Sichuan Da Xue Xue Bao Yi Xue Ban, V42, P704
   Gustems M, 2014, NUCLEIC ACIDS RES, V42, P3059, DOI 10.1093/nar/gkt1323
   Hermanns MI, 2014, IN VITRO CELL DEV-AN, V50, P287, DOI 10.1007/s11626-013-9707-0
   Hu X, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/825805
   HUANG L, 2012, CHIN J INTEGR MED
   Huang L, 2013, TURK J GASTROENTEROL, V24, P502, DOI 10.4318/tjg.2013.0544
   Huang YJ, 2015, VASC PHARMACOL, V72, P43, DOI 10.1016/j.vph.2015.04.012
   Jia G., 2015, J TRADITIONAL CHINES, V35, P434, DOI DOI 10.1016/S0254-6272(15)30121-7
   Kamisoglu K, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0783-2
   Kim JY, 2015, BIOL PHARM BULL, V38, P66, DOI 10.1248/bpb.b14-00567
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kondrikov D, 2014, J BIOL CHEM, V289, P33355, DOI 10.1074/jbc.M114.585356
   Kourtidis A, 2015, NAT CELL BIOL, V17, P1145, DOI 10.1038/ncb3227
   Lee TH, 2014, BIOCHEM BIOPH RES CO, V445, P615, DOI 10.1016/j.bbrc.2014.02.046
   Li Y. H., 2006, ZHONG XI YI JIE HE X, V6, P180
   Lim HA, 2012, BIOGERONTOLOGY, V13, P133, DOI 10.1007/s10522-011-9361-4
   Lin ZQ, 2014, J TRADIT CHIN MED, V34, P178, DOI 10.1016/S0254-6272(14)60075-3
   Liu MW, 2014, INT J MOL MED, V34, P1492, DOI 10.3892/ijmm.2014.1943
   Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218
   Ma LQ, 2014, MICROCIRCULATION, V21, P649, DOI 10.1111/micc.12144
   Okkenhaug K, 2001, Sci STKE, V2001, ppe1
   Pan CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126640
   Pfannkuche A, 2011, HEPATOLOGY, V53, P1127, DOI 10.1002/hep.24214
   Singh N, 2014, PANCREAS, V43, P867, DOI 10.1097/MPA.0000000000000124
   Srinivasan B, 2015, JALA-J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   Stopa B, 2006, INT J BIOL MACROMOL, V40, P1, DOI 10.1016/j.ijbiomac.2006.05.002
   Wang L, 2011, J ZHEJIANG UNIV-SC B, V12, P1034, DOI 10.1631/jzus.B1000406
   Wang Zhong-Chao, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P322
   Wu W, 2012, ASIAN PAC J TROP MED, V5, P901, DOI 10.1016/S1995-7645(12)60168-0
   Wu YL, 2010, CHEM-BIOL INTERACT, V188, P526, DOI 10.1016/j.cbi.2010.09.008
   Xiong Y., 2016, J INNATE IMMUNITY, V8
   Xiong YB, 2016, J INNATE IMMUN, V8, P171, DOI 10.1159/000440838
   Xu XF, 2013, INT J CLIN EXP MED, V6, P524
   Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648
   Xue Ping, 2005, Zhong Xi Yi Jie He Xue Bao, V3, P263
   Xue P, 2008, WORLD J GASTROENTERO, V14, P2343, DOI 10.3748/wjg.14.2343
   Xue P, 2014, CHIN J INTEGR MED, V20, P770, DOI 10.1007/s11655-013-1661-x
   Xue Ping, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P66
   Zarzycka M, 2015, ANDROLOGY-US, V3, P569, DOI 10.1111/andr.12028
   Zhou Lin, 2014, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V30, P151
   Zhu J, 2013, EXP THER MED, V5, P1345, DOI 10.3892/etm.2013.988
   Zou ZY, 2015, FITOTERAPIA, V105, P139, DOI 10.1016/j.fitote.2015.06.005
NR 52
TC 8
Z9 9
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2016
VL 2016
AR 3265368
DI 10.1155/2016/3265368
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA DQ2QH
UT WOS:000379047100001
PM 27413385
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Wu, ZY
   Dai, FF
   Ren, W
   Liu, HG
   Li, BW
   Chang, JX
AF Wu, Zhiyong
   Dai, Feifeng
   Ren, Wei
   Liu, Huagang
   Li, Bowen
   Chang, Jinxing
TI Angiotensin II induces apoptosis of human pulmonary microvascular
   endothelial cells in acute aortic dissection complicated with lung
   injury patients through modulating the expression of monocyte
   chemoattractant protein-1
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Aortic dissection; ALI/ARDS; MCP-1; angiotensin; apoptosis 
ID SMOOTH-MUSCLE-CELLS; C-REACTIVE PROTEIN; INFLAMMATORY RESPONSE;
   CHEMOTACTIC PROTEIN-1; IN-VITRO; OXYGENATION; INHIBITION; MACROPHAGES;
   DYSFUNCTION; ACTIVATION
AB Patients with acute aortic dissection (AAD) usually showed acute lung injury (ALI). However, its pathogenesis is still not well defined. Apoptosis of pulmonary microvascular endothelial cells (PMVECs) is closely related to the alveolus-capillary barrier injury and the increased vascular permeability. In this study, we aim to investigate the human PMVECs (hPMVECs) apoptosis induced by angiotensin II (AngII) and monocyte chemoattractant protein-1 (MCP-1) and their potential interaction in the pathogenesis of AAD complicated with ALI. Fifty-eight newly diagnosed AAD, 12 matched healthy individuals were included. Pulmonary tissues of AAD complicated with lung injury were obtained from 2 cadavers to determine the levels of AngII type 1 receptor (AT1-R) and MCP-1. Serum AngII was measured using commercial ELISA kit. H&E staining and immunohistostaining were performed to determine the expression of AT1-R and MCP-1. For the in vitro experiment, hPMVECs were divided into control, AngII group, AngII+ Bindarit group and Bindarit group, respectively. Flow cytometry was performed to analyze the apoptosis in each group. Reverse transcription-polymerase chain reaction was performed to determine the mRNA expression of MCP-1. Western blot analysis was performed to evaluate the expression of MCP-1 and apoptosis related protein. Apoptosis of hPMVECs was observed in the lung tissues in the cadavers with AAD complicated with ALI. Besides, the expression of AT1-R and MCP-1 was remarkably elevated. Compared with normal individuals and the non-lung injury AAD patients, the expression of serum AngII was remarkably elevated in AAD patients complicated with ALI. In vitro experiments showed AngII contributed to the apoptosis and elevation of MCP1 in hPMVECs. Besides, it involved in the down-regulation of Bcl-2 protein, and up-regulation of Bax and Caspase-3. Such phenomenon was completely reversed after administration of MCP-1 inhibitor (Bindarit). The production of MCP-1 and cellular apoptosis induced by AngII in hPMVECs are closely related to the pathogenesis of AAD complicated with ALI. The association between MCP-1 and AngII is crucial in the apoptosis of hPMVECs.
C1 [Wu, Zhiyong; Dai, Feifeng; Ren, Wei; Liu, Huagang; Li, Bowen; Chang, Jinxing] Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, 238 Zhangzhidong Rd, Wuhan 430072, China.
C3 Wuhan University
RP Wu, ZY (corresponding author), Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, 238 Zhangzhidong Rd, Wuhan 430072, Peoples R China.
EM zhiyongwu889@sina.com
CR Chen XL, 1998, CIRC RES, V83, P952
   Damarla M, 2014, AM J RESP CELL MOL, V50, P932, DOI 10.1165/rcmb.2013-0361OC
   Filsoufi F, 2008, CHEST, V133, P713, DOI 10.1378/chest.07-1028
   Funakoshi Y, 2001, HYPERTENSION, V38, P100, DOI 10.1161/01.HYP.38.1.100
   Golledge J, 2008, LANCET, V372, P55, DOI 10.1016/S0140-6736(08)60994-0
   Gupta A, 2007, J AM SOC NEPHROL, V18, P860, DOI 10.1681/ASN.2006101167
   Hagiwara S, 2009, CRIT CARE MED, V37, P626, DOI 10.1097/CCM.0b013e3181958d91
   Hasegawa Y, 1999, J CARDIOVASC SURG, V40, P191
   Hernandez JS, 2014, J CELL MOL MED, V18, P709, DOI 10.1111/jcmm.12220
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Kazumasa O, 2012, ANN CASC DIS, V5, P310
   Komukai K, 2005, INT HEART J, V46, P795, DOI 10.1536/ihj.46.795
   Kurabayashi M, 2010, CIRC J, V74, P2066, DOI 10.1253/circj.CJ-10-0336
   Kurihara T, 2012, CIRCULATION, V126, P3070, DOI 10.1161/CIRCULATIONAHA.112.097097
   Leach HG, 2013, AM J RESP CELL MOL, V49, P1093, DOI 10.1165/rcmb.2013-0152OC
   Lee YH, 2010, J CELL SCI, V123, P1634, DOI 10.1242/jcs.063545
   Li Qin-Shan, 2010, Shengli Xuebao, V62, P63
   Liu HL, 2014, BIOMED PHARMACOTHER, V68, P267, DOI 10.1016/j.biopha.2013.12.003
   Mirolo M, 2008, EUR CYTOKINE NETW, V19, P119, DOI 10.1684/ecn.2008.0133
   Mokart D, 2003, CHEST, V124, P644, DOI 10.1378/chest.124.2.644
   NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532
   Pueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645
   RANDOLPH GJ, 1995, J IMMUNOL, V155, P3610
   Richardson MA, 2008, J PHARMACOL EXP THER, V325, P17, DOI 10.1124/jpet.107.130609
   Sironi M, 1999, EUR CYTOKINE NETW, V10, P437
   Sugano Y, 2005, INT J CARDIOL, V102, P39, DOI 10.1016/j.ijcard.2004.03.076
NR 26
TC 17
Z9 20
U1 0
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 1
BP 28
EP 36
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DE1EN
UT WOS:000370369600003
PM 27069537
DA 2023-08-21
ER

PT J
AU Wu, ZY
   Liu, HG
   Ren, W
   Dai, FF
   Chang, JX
   Li, BW
AF Wu, Zhiyong
   Liu, Huagang
   Ren, Wei
   Dai, Feifeng
   Chang, Jinxing
   Li, Bowen
TI VE-cadherin involved in the pulmonary microvascular endothelial cell
   barrier injury induced by angiotensin II through modulating the cellular
   apoptosis and skeletal rearrangement
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE VE-cadherin; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; angiotensin; apoptosis; skeletal rearrangement 
ID ACUTE AORTIC DISSECTION; LUNG INJURY; TYROSINE PHOSPHORYLATION;
   VASCULAR-PERMEABILITY; EXPRESSION; JUNCTIONS; ANGIOGENESIS; ASSOCIATION;
   MONOLAYERS; COMPLEX
AB Objective: Angiotensin II (AngII) involved in the pathogenesis of pulmonary injury through impairing the integrity of pulmonary microvascular endothelial barrier, but the mechanism is still not clear. We aim to determine the roles of VE-cadherin, playing crucial roles in the adhesion of the vascular endothelial barrier and the barrier function, in the pulmonary microvascular endothelial cell (PMVEC) barrier injury mediated by AngII. Methods: Mice acute lung injury (ALI) model was induced through pumping of AngII. The infiltration of macrophages and neutrophils as well as the PMVEC permeability were determined in order to determine the barrier injury in vivo and in vitro. Knockdown of VE-cadherin was established using siRNA technique, and its roles in the apoptosis and skeletal rearrangement in the PMVECs were evaluated. Results: After AngII interference, the expression of VE-cadherin in the PMVECs and pulmonary tissues in mice was down-regulated. Upon VE-cadherin knockdown through siRNA technique, AngII induced susceptibility of PMVECs to apoptosis. Knockdown of VE-cadherin contributed to the skeletal rearrangement in the endothelial cells, together with increase of permeability. Conclusions: VE-cadherin expression is closely related to the apoptosis and skeletal rearrangement of PMVECs induced by AngII.
C1 [Wu, Zhiyong; Liu, Huagang; Ren, Wei; Dai, Feifeng; Chang, Jinxing; Li, Bowen] Wuhan Univ, Dept Cardiovasc Surg, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, China.
C3 Wuhan University
RP Wu, ZY (corresponding author), Wuhan Univ, Dept Cardiovasc Surg, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Peoples R China.
EM zhiyongwu889@sina.com
CR Abu Taha A, 2014, CELL ADHES MIGR, V8, P125, DOI 10.4161/cam.28243
   Adam AP, 2010, J BIOL CHEM, V285, P7045, DOI 10.1074/jbc.M109.079277
   Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   Audia JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081792
   Barry AK, 2015, J CELL SCI, V128, P1341, DOI 10.1242/jcs.159954
   Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647
   Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697
   Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   Chaki SP, 2015, MOL BIOL CELL, V26, P3047, DOI 10.1091/mbc.E15-06-0338
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Huang YR, 2015, BIOCHEM BIOPH RES CO, V468, P119, DOI 10.1016/j.bbrc.2015.10.150
   Kandasamy K, 2015, AM J PHYSIOL-LUNG C, V309, pL584, DOI 10.1152/ajplung.00211.2014
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Lin B, 2015, INT J CLIN EXP PATHO, V8, P7685
   Liu GQ, 2015, INT J OPHTHALMOL-CHI, V8, P1083, DOI 10.3980/j.issn.2222-3959.2015.06.01
   Maretta M, 2014, INT J CLIN EXP PATHO, V7, P4539
   Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298
   O'Leary H, 2010, CANCER MICROENVIRON, V3, P67, DOI 10.1007/s12307-010-0035-6
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Padmanabhan A, 2015, CURR OPIN CELL BIOL, V36, P32, DOI 10.1016/j.ceb.2015.06.008
   Parra ER, 2007, RESPIRATION, V74, P159, DOI 10.1159/000097133
   Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Sheng W, 2015, SAUDI MED J, V36, P940, DOI 10.15537/smj.2015.8.11583
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   Taveau JC, 2008, BIOCHEM SOC T, V36, P189, DOI 10.1042/BST0360189
   Wallez Y, 2007, ONCOGENE, V26, P1067, DOI 10.1038/sj.onc.1209855
   Weidert E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108092
   Wu ZY, 2016, AM J TRANSL RES, V8, P1426
   Wu ZY, 2016, AM J TRANSL RES, V8, P28
   Yang JJ, 2015, CELL MOL LIFE SCI, V72, P4849, DOI 10.1007/s00018-015-1973-4
   Yu XB, 2016, CELL PHYSIOL BIOCHEM, V38, P1055, DOI 10.1159/000443056
NR 35
TC 8
Z9 10
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 10
BP 4310
EP 4319
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EB8OI
UT WOS:000387650100027
PM 27830014
DA 2023-08-21
ER

PT J
AU Wu, ZY
   Wang, ZW
   Dai, FF
   Liu, HG
   Ren, W
   Chang, JX
   Li, BW
AF Wu, Zhiyong
   Wang, Zhiwei
   Dai, Feifeng
   Liu, Huagang
   Ren, Wei
   Chang, Jinxing
   Li, Bowen
TI Dephosphorylation of Y685-VE-Cadherin Involved in Pulmonary
   Microvascular Endothelial Barrier Injury Induced by Angiotensin II
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID ACUTE AORTIC DISSECTION; VE-CADHERIN; VASCULAR-PERMEABILITY; LUNG
   INJURY; TYROSINE PHOSPHORYLATION; BETA-CATENIN; IN-VIVO; JUNCTIONS;
   ADHESION; CELLS
AB Angiotensin II (AngII) caused pulmonary microvascular endothelial barrier injury, which induced acute aortic dissection (AAD) combined with acute lung injury (ALI). However, the exact mechanism is unclear. We investigated the role of dephosphorylation of Y685-VE-cadherin in the AngII induced pulmonary microvascular endothelial barrier injury. Mice or pulmonary microvascular endothelial cells (PMVECs) were divided into control group, AngII group, AngII+PP2 (Src kinase inhibitor) group, and PP2 group. PP2 was used to inhibit the phosphorylation of Y685-VE-cadherin. Pathological changes, infiltration of macrophages and neutrophils, and pulmonary microvascular permeability were used to determine the pulmonary microvascular endothelial barrier function. Flow cytometry was used to determine the apoptosis of PMVECs, and immunofluorescence was used to determine the skeletal arrangement. Transendothelial resistance was used to detect the permeability of endothelial barrier. Phosphorylation of Y685-VE-cadherin was significantly reduced after AngII stimulation (p < 0.05), together with skeletal rearrangement, and elevation of endothelial permeability which finally induced endothelial barrier injury. After PP2 interference, the phosphorylation of Y685-VE- cadherin was further reduced and the endothelial permeability was further elevated. These data indicated that AngII could induce pulmonary injury by triggering endothelial barrier injury, and such process may be related to the dephosphorylation of Y685-VE-cadherin and the endothelial skeletal rearrangement.
C1 [Wu, Zhiyong; Wang, Zhiwei; Dai, Feifeng; Liu, Huagang; Ren, Wei; Chang, Jinxing; Li, Bowen] Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, Wuhan 430060, China.
C3 Wuhan University
RP Wu, ZY (corresponding author), Wuhan Univ, Renmin Hosp, Dept Cardiovasc Surg, Wuhan 430060, Peoples R China.
EM zhiyongwu889@sina.com
CR Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007
   Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   Audia JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081792
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Farina F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056636
   Feng G, 2015, J CELL SCI, V128, P576, DOI 10.1242/jcs.159053
   Galkina E, 2007, ARTERIOSCL THROM VAS, V27, P2292, DOI 10.1161/ATVBAHA.107.149179
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gavard Julie, 2014, Cell Adh Migr, V8, P158
   Griffiths GS, 2011, J CELL PHYSIOL, V226, P2287, DOI 10.1002/jcp.22565
   Haidari M, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-105
   Haines RJ, 2015, BIOCHEM BIOPH RES CO, V456, P190, DOI 10.1016/j.bbrc.2014.11.057
   Harris ES, 2010, CURR OPIN CELL BIOL, V22, P651, DOI 10.1016/j.ceb.2010.07.006
   Hasegawa Y, 1999, J CARDIOVASC SURG, V40, P191
   He HL, 2015, J CELL PHYSIOL, V230, P691, DOI 10.1002/jcp.24794
   Kamberi Lulzim S, 2011, Med Arh, V65, P89
   Konstantoulaki M, 2003, AM J PHYSIOL-LUNG C, V285, pL434, DOI 10.1152/ajplung.00075.2003
   Kurabayashi M, 2010, CIRC J, V74, P2066, DOI 10.1253/circj.CJ-10-0336
   Liu DZ, 2010, ANN NEUROL, V67, P526, DOI 10.1002/ana.21924
   Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894
   Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298
   Onken MD, 2014, CYTOSKELETON, V71, P695, DOI 10.1002/cm.21203
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Sheng W, 2015, SAUDI MED J, V36, P940, DOI 10.15537/smj.2015.8.11583
   Sidibe A, 2014, AM J PHYSIOL-HEART C, V307, pH455, DOI 10.1152/ajpheart.00774.2013
   Sugano Y, 2005, INT J CARDIOL, V102, P39, DOI 10.1016/j.ijcard.2004.03.076
   Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014
   Wallez Y, 2007, ONCOGENE, V26, P1067, DOI 10.1038/sj.onc.1209855
   Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003
   Weidemann A, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-80
   Weidert E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108092
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Wu ZY, 2016, AM J TRANSL RES, V8, P1426
   Wu ZY, 2016, AM J TRANSL RES, V8, P28
   Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020
   Yu XB, 2016, CELL PHYSIOL BIOCHEM, V38, P1055, DOI 10.1159/000443056
NR 38
TC 10
Z9 10
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2016
VL 2016
AR 8696481
DI 10.1155/2016/8696481
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA EH8IL
UT WOS:000392015300001
PM 28119542
OA Green Submitted, Green Published, gold
DA 2023-08-21
ER

PT J
AU Yang, Y
   Hu, SL
   Xu, XP
   Li, JZ
   Liu, AR
   Han, JB
   Liu, SQ
   Liu, L
   Qiu, HB
AF Yang, Yi
   Hu, Shuling
   Xu, Xiuping
   Li, Jinze
   Liu, Airan
   Han, Jibin
   Liu, Songqiao
   Liu, Ling
   Qiu, Haibo
TI The Vascular Endothelial Growth Factors-Expressing Character of
   Mesenchymal Stem Cells Plays a Positive Role in Treatment of Acute Lung
   Injury In Vivo
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; STROMAL CELLS; EPITHELIAL-CELLS;
   PROMOTES; INFLAMMATION; MANAGEMENT; RECOVERY; REPAIR; PHASE
AB Recently, mesenchymal stemcells (MSC) have been proved to be beneficial in acute respiratory distress syndrome (ARDS). Vascular endothelial growth factor (VEGF) is an important angiogenesis factor that MSC release. However, the precise role of VEGF-expressing character of MSC in the MSC treatment for ARDS remains obscure. Here, we firstly knocked down the gene VEGF in MSC (MSC-ShVEGF) with lentiviral transduction. Then we injected the MSC-ShVEGF to rats with lipopolysaccharide-induced acute lung injury (ALI) via the tail vein. Data showed that MSC transplantation significantly increased VEGF levels in the lung, reduced lung permeability, protected lung endothelium from apoptosis, facilitated VE-cadherin recovery, controlled inflammation, and attenuated lung injury. However, VEGF gene knockdown in MSC led to relatively insufficient VEGF expression in the injured lung and significantly diminished the therapeutic effects of MSC on ALI, suggesting an important role of VEGF-expressing behavior of MSC in the maintenance of VEGF in the lung and the MSC treatment for ALI. Hence, we conclude that MSC restores the lung permeability and attenuates lung injury in rats with ALI in part by maintaining a "sufficient" VEGF level in the lung and the VEGF-expressing character of MSC plays a positive role in the therapeutic effects of MSC on ARDS.
C1 [Yang, Yi; Liu, Airan; Liu, Songqiao; Liu, Ling; Qiu, Haibo] Southeast Univ, Sch Med, Zhongda Hosp, Dept Crit Care Med, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, China.
C1 [Hu, Shuling; Xu, Xiuping; Li, Jinze; Han, Jibin] Southeast Univ, Sch Med, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, China.
C3 Southeast University - China; Southeast University - China
RP Qiu, HB (corresponding author), Southeast Univ, Sch Med, Zhongda Hosp, Dept Crit Care Med, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM haiboq2000@163.com
RI yang, yang/GVT-5210-2022; Qiu, Haibo/AAS-9047-2021; 刘, 松桥/ACA-6923-2022;
   Lang, Ming/HIK-0758-2022; Xu, Xiuping/W-5865-2019; yang,
   yang/HGT-7999-2022
OI Qiu, Haibo/0000-0001-8589-4717; 刘, 松桥/0000-0002-1875-1131; Xu,
   Xiuping/0000-0003-3950-3425; 
FU National Natural Science Foundation of China [81571874, 81372093,
   81170057, 81300060]
FX The authors would like to thank Yanli An for her assistance with the
   lentiviral transduction experiment techniques. In addition, the authors
   are grateful for the financial support from the National Natural Science
   Foundation of China (Grants nos. 81571874, 81372093, 81170057, and
   81300060).
CR Barratt S, 2014, RESPIRATION, V87, P329, DOI 10.1159/000356034
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brown KRS, 2001, AM J PHYSIOL-LUNG C, V281, pL1001, DOI 10.1152/ajplung.2001.281.4.L1001
   Buregeya E, 2014, GLOB HEART, V9, P289, DOI 10.1016/j.gheart.2014.08.003
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   Cruz FF, 2015, STEM CELL TRANSL MED, V4, P1302, DOI 10.5966/sctm.2014-0280
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   He HL, 2015, CELL TRANSPLANT, V24, P1699, DOI 10.3727/096368914X685087
   Ho MSH, 2015, J CELL PHYSIOL, V230, P2606, DOI 10.1002/jcp.25028
   Hu SL, 2014, CRIT CARE, V18, DOI 10.1186/cc13896
   Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779
   Karihaloo A, 2005, MOL CELL BIOL, V25, P7441, DOI 10.1128/MCB.25.17.7441-7448.2005
   Kim YG, 2000, KIDNEY INT, V58, P2390, DOI 10.1046/j.1523-1755.2000.00422.x
   Kim Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0236-5
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Liu AR, 2013, J CELL PHYSIOL, V228, P1270, DOI 10.1002/jcp.24282
   Liu C, 2015, INT J CARDIOL, V188, P22, DOI 10.1016/j.ijcard.2015.03.425
   Madonna R, 2015, CARDIOVASC RES, V108, P39, DOI 10.1093/cvr/cvv197
   Maitre B, 2001, EUR RESPIR J, V18, P100, DOI 10.1183/09031936.01.00074701
   Matthay Michael A, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS54, DOI 10.1513/AnnalsATS.201406-254MG
   Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004
   Okazaki T, 2008, NEUROSCI LETT, V430, P109, DOI 10.1016/j.neulet.2007.10.046
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Perkins GD, 2005, THORAX, V60, P153, DOI 10.1136/thx.2004.027912
   Pers YM, 2015, OSTEOARTHR CARTILAGE, V23, P2027, DOI 10.1016/j.joca.2015.07.004
   Song JF, 2015, LUNG, V193, P1029, DOI 10.1007/s00408-015-9803-x
   Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053
   Tang KC, 2004, J APPL PHYSIOL, V97, P1559, DOI 10.1152/japplphysiol.00221.2004
   Thickett DR, 2002, AM J RESP CRIT CARE, V166, P1332, DOI 10.1164/rccm.2105057
   Wang SP, 2012, MOL MED REP, V6, P848, DOI 10.3892/mmr.2012.997
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zhang L, 2015, EUR REV MED PHARMACO, V19, P2621
NR 37
TC 44
Z9 51
U1 2
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2016
VL 2016
AR 2347938
DI 10.1155/2016/2347938
PG 12
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA DO0CD
UT WOS:000377446100001
PM 27313398
OA Green Submitted, Green Published, gold
DA 2023-08-21
ER

PT J
AU Yu, XB
   Lin, Q
   Qin, X
   Ruan, Z
   Zhou, JH
   Lin, ZF
   Su, YJ
   Zheng, J
   Liu, ZW
AF Yu, Xiaobo
   Lin, Qiang
   Qin, Xiong
   Ruan, Zheng
   Zhou, Jianhua
   Lin, Zhifeng
   Su, Yijiang
   Zheng, Jian
   Liu, Zhenwei
TI ACE2 Antagonizes VEGFa to Reduce Vascular Permeability During Acute Lung
   Injury
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE ALI/ARDS; ACE/ACE2; VEGF/VEGFA; Vessel permeability; lung function 
ID ENDOTHELIAL GROWTH-FACTOR; CONVERTING ENZYME 2; ACUTE
   RESPIRATORY-DISTRESS; INHIBITS APOPTOSIS; CELLS; MICE; MODEL;
   ACTIVATION; FIBROSIS; SU5416
AB Background/Aims: Angiotensin converting enzyme 2 (ACE2) treatment suppresses the severity of acute lung injury (ALI), through antagonizing hydrolyzing angiotensin II (AngII) and the ALI-induced apoptosis of pulmonary endothelial cells. Nevertheless, the effects of ACE2 on vessel permeability and its relationship with vascular endothelial growth factor a (VEGFa) remain ill-defined. In the current study, we examined the relationship between ACE2 and VEGFa in ALI model in mice. Methods: Here, we used a previously published bleomycin method to induce ALI in mice, and treated the mice with ACE2. We analyzed the levels of VEGFa in these mice. The mouse lung vessel permeability was determined by a fluorescence pharmacokinetic assay following i.v. injection of 62.5 mu g/kg Visudyne. VEGFa pump or SU5416 pump was given to increase or decrease VEGFa effects, respectively. The long-term effects on lung function were determined by measurement of lung resistance using methacholine. Results: ACE2 treatment did not alter VEGFa levels in lung, but antagonized the effects of VEGFa on increases of lung vessel permeability. Ectogenic VEGFa abolished the antagonizing effects of ACE2 on the vessel permeability against VEGFa. On the other hand, suppression of VEGF signaling mimicked the effects of ACE2 on the vessel permeability against VEGFa. The suppression of vessel permeability resulted in improvement of lung function after ALI. Conclusion: ACE2 may antagonize the VEGFa-mediated increases in lung vessel permeability during ALI, resulting in improvement of lung function after ALI. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Yu, Xiaobo; Lin, Qiang; Qin, Xiong; Ruan, Zheng; Zhou, Jianhua; Lin, Zhifeng; Su, Yijiang; Zheng, Jian] Shanghai Jiao Tong Univ, Dept Thorac Surg, Shanghai Gen Hosp, Shanghai 200030, China.
C1 [Liu, Zhenwei] Shanghai Jiao Tong Univ, Dept Resp Med, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Liu, ZW (corresponding author), Shanghai Jiao Tong Univ, Dept Resp Med, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM zhenweiliu69@163.com
CR ASHBAUGH DG, 1967, LANCET, V2, P319
   Bao H, 2015, CELL PHYSIOL BIOCHEM, V37, P759, DOI 10.1159/000430393
   Chen J, 2015, CELL PHYSIOL BIOCHEM, V37, P1830, DOI 10.1159/000438545
   Deng XQ, 2015, CELL PHYSIOL BIOCHEM, V36, P937, DOI 10.1159/000430268
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Epiphanio S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000916
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Jesmin S, 2012, INFLAMMATION, V35, P484, DOI 10.1007/s10753-011-9337-1
   Ji Y, 2015, CELL PHYSIOL BIOCHEM, V35, P2203, DOI 10.1159/000374025
   Li L, 2015, CELL PHYSIOL BIOCHEM, V37, P1113, DOI 10.1159/000430236
   Liu D, 2014, MOL CELL BIOCHEM, V394, P155, DOI 10.1007/s11010-014-2091-6
   Liu FB, 2014, CELL BIOCHEM FUNCT, V32, P580, DOI 10.1002/cbf.3054
   Liu S, 2015, CELL PHYSIOL BIOCHEM, V36, P2003, DOI 10.1159/000430168
   Liu W, 2014, INT J CLIN EXP MED, V7, P3392
   Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29
   Min F, 2015, MOL MED REP, V11, P2387, DOI 10.3892/mmr.2014.3025
   Nieves BJ, 2009, BIOFACTORS, V35, P332, DOI 10.1002/biof.46
   Oliveira GP, 2015, CELL PHYSIOL BIOCHEM, V36, P1644, DOI 10.1159/000430325
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200
   Sukbuntherng J, 2001, J PHARM PHARMACOL, V53, P1629, DOI 10.1211/0022357011778232
   Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Vohra PK, 2012, AM J PHYSIOL-LUNG C, V302, pL185, DOI 10.1152/ajplung.00274.2010
   Xiao XW, 2014, DIABETOLOGIA, V57, P991, DOI 10.1007/s00125-014-3179-y
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Yin XR, 2015, CELL PHYSIOL BIOCHEM, V35, P2149, DOI 10.1159/000374020
NR 30
TC 35
Z9 41
U1 1
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 38
IS 3
BP 1055
EP 1062
DI 10.1159/000443056
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA DH1EE
UT WOS:000372526400018
PM 26938051
OA gold
DA 2023-08-21
ER

PT J
AU Zhou, ZC
   You, ZJ
AF Zhou, Zichao
   You, Zhijian
TI Mesenchymal Stem Cells Alleviate LPS-Induced Acute Lung Injury in Mice
   by MiR-142a-5p-Controlled Pulmonary Endothelial Cell Autophagy
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE mesenchymal stem cell; ALI/ARDS; Beclin-1; MiR-142a-5p; LPS 
ID MACROPHAGES
AB Background/Aims: Damages of pulmonary endothelial cells (PECs) represent a critical pathological process during acute lung injury (ALI), and precede pulmonary epithelial cell injury, and long-term lung dysfunction. Transplantation of mesenchymal stem cells (MSCs) has proven therapeutic effects on ALI, whereas the underlying mechanisms remain ill-defined. Method: We transplanted MSCs in mice and then induced ALI using Lipopolysaccharides (LPS). We analyzed the changes in permeability index and lung histology. Mouse PECs were isolated by flow cytometry based on CD31 expression and then analyzed for autophagy-associated factors LC3 and Beclin-1 by Western blot. Beclin-1 mRNA was determined by RT-qPCR. In vitro, we performed bioinformatics analyses to identify the MSCs-regulated miRNAs that target Beclin-1, and confirmed that the binding was functional by 3'-UTR luciferase reporter assay. Results: We found that MSCs transplantation significantly reduced the severity of LPS-induced ALI in mice. MSCs increased autophagy of PECs to promote PEC survival. MSCs increased Beclin-1 protein but not mRNA. MiR-142a-5p was found to target the 3'-UTR of Beclin-1 mRNA to inhibit its protein translation in PECs. MSCs reduced the levels of miR-142a-5p in PECs from LPS-treated mice. Conclusion: MSCs may alleviate LPS-ALI through downregulation of miR-142a-5p, which allows PECs to increase Beclin-1-mediated cell autophagy. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Zhou, Zichao] Taizhou Hosp Tradit Chinese Med, Dept Anesthesiol, 6 Yimiao St, Taizhou 225300, China.
C1 [You, Zhijian] Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Anesthesiol, Shantou, China.
C3 Shantou University
RP Zhou, ZC (corresponding author), Taizhou Hosp Tradit Chinese Med, Dept Anesthesiol, 6 Yimiao St, Taizhou 225300, Peoples R China.
EM zhou_zi_chao@163.com
CR ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Cao XC, 2014, INT J BIOCHEM CELL B, V53, P372, DOI 10.1016/j.biocel.2014.06.003
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Danger R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060702
   Deng XQ, 2015, CELL PHYSIOL BIOCHEM, V36, P937, DOI 10.1159/000430268
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Ji Y, 2015, CELL PHYSIOL BIOCHEM, V35, P2203, DOI 10.1159/000374025
   Lan AP, 2014, CELL PHYSIOL BIOCHEM, V34, P368, DOI 10.1159/000363006
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li B, 2015, CELL PHYSIOL BIOCHEM, V35, P433, DOI 10.1159/000369708
   Liu S, 2015, CELL PHYSIOL BIOCHEM, V36, P2003, DOI 10.1159/000430168
   Liu WX, 2015, CELL PHYSIOL BIOCHEM, V35, P858, DOI 10.1159/000369743
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Song XL, 2015, INFLAMMATION, V38, P485, DOI 10.1007/s10753-014-9954-6
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Zhang JF, 2015, CELL PHYSIOL BIOCHEM, V35, P1219, DOI 10.1159/000373945
   Zipori D, 2004, BLOOD CELL MOL DIS, V33, P211, DOI 10.1016/j.bcmd.2004.08.019
NR 24
TC 41
Z9 45
U1 0
U2 17
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 38
IS 1
BP 258
EP 266
DI 10.1159/000438627
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA DC6KU
UT WOS:000369329600024
PM 26784440
OA gold
DA 2023-08-21
ER

PT J
AU Mitra, S
   Wewers, MD
   Sarkar, A
AF Mitra, Srabani
   Wewers, Mark D.
   Sarkar, Anasuya
TI Mononuclear Phagocyte-Derived Microparticulate Caspase-1 Induces
   Pulmonary Vascular Endothelial Cell Injury
SO PLOS ONE
LA English
DT Article
ID IL-1-BETA-CONVERTING ENZYME; ACUTE LUNG; MEMBRANE MICROPARTICLES;
   EPITHELIAL-CELLS; FAS-LIGAND; APOPTOSIS; ACTIVATION; DEATH; IL-1-BETA;
   INFLAMMASOME
AB Lung endothelial cell apoptosis and injury occurs throughout all stages of acute lung injury (ALI/ARDS) and impacts disease progression. Lung endothelial injury has traditionally been focused on the role of neutrophil trafficking to lung vascular integrin receptors induced by proinflammatory cytokine expression. Although much is known about the pathogenesis of cell injury and death in ALI/ARDS, gaps remain in our knowledge; as a result of which there is currently no effective pharmacologic therapy. Enzymes known as caspases are essential for completion of the apoptotic program and secretion of pro-inflammatory cytokines. We hypothesized that caspase-1 may serve as a key regulator of human pulmonary microvascular endothelial cell (HPMVEC) apoptosis in ALI/ARDS. Our recent experiments confirm that microparticles released from stimulated monocytic cells (THP1) induce lung endothelial cell apoptosis. Microparticles pretreated with the caspase-1 inhibitor, YVAD, or pan-caspase inhibitor, ZVAD, were unable to induce cell death of HPMVEC, suggesting the role of caspase-1 or its substrate in the induction of HPMVEC cell death. Neither un-induced microparticles (control) nor direct treatment with LPS induced apoptosis of HPMVEC. Further experiments showed that caspase-1 uptake into HPMVEC and the induction of HPMVEC apoptosis was facilitated by caspase-1 interactions with microparticulate vesicles. Altering vesicle integrity completely abrogated apoptosis of HPMVEC suggesting an encapsulation requirement for target cell uptake of active caspase-1. Taken together, we confirm that microparticle centered caspase-1 can play a regulator role in endothelial cell injury.
C1 [Mitra, Srabani; Wewers, Mark D.; Sarkar, Anasuya] Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43210, United States.
C3 University System of Ohio; Ohio State University
RP Sarkar, A (corresponding author), Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43210 USA.
EM anasuya.sarkar@osumc.edu
RI Wewers, Mark/AAB-6202-2021
FU NHLBI [RO1-HL076278, R21-HL102629]; AAT Foundation
FX This work was supported by NHLBI RO1-HL076278 to MDW; NHLBI R21-HL102629
   and AAT Foundation grant to AS.
CR Aoki N, 2007, ENDOCRINOLOGY, V148, P3850, DOI 10.1210/en.2006-1479
   Baroni M, 2007, FASEB J, V21, P1926, DOI 10.1096/fj.06-7238com
   BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366
   Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342
   Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308
   Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126
   Diamant M, 2004, EUR J CLIN INVEST, V34, P392, DOI 10.1111/j.1365-2362.2004.01355.x
   Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1
   Dinarello CA, 2001, ANN RHEUM DIS, V60, pIII18
   Distler JHW, 2005, APOPTOSIS, V10, P731, DOI 10.1007/s10495-005-2941-5
   Distler JHW, 2006, AUTOIMMUNITY, V39, P683, DOI 10.1080/08916930601061538
   Exline MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090968
   Fahy RJ, 2008, AM J RESP CRIT CARE, V177, P983, DOI 10.1164/rccm.200703-418OC
   GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Hamacher J, 2002, AM J RESP CRIT CARE, V166, P651, DOI 10.1164/rccm.2109004
   Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943
   Huber LC, 2007, APOPTOSIS, V12, P363, DOI 10.1007/s10495-006-0622-7
   Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004
   Imanishi T, 2002, ATHEROSCLEROSIS, V161, P143, DOI 10.1016/S0021-9150(01)00631-1
   Ismail N, 2013, BLOOD, V121, P984, DOI 10.1182/blood-2011-08-374793
   Kahlenberg JM, 2004, J LEUKOCYTE BIOL, V76, P676, DOI 10.1189/jlb.0404221
   Kim HJ, 2004, J IMMUNOL, V172, P4948, DOI 10.4049/jimmunol.172.8.4948
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0
   Kurtovic Jelica, 2004, Trop Gastroenterol, V25, P9
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Mallat Z, 2000, BRIT J PHARMACOL, V130, P947, DOI 10.1038/sj.bjp.0703407
   Mangan DF, 1991, J IMMUNOL, V163, P1755
   Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E
   Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Matute-Bello G, 2005, J IMMUNOL, V175, P4069, DOI 10.4049/jimmunol.175.6.4069
   Matute-Bello G, 2003, CRIT CARE, V7, P355, DOI 10.1186/cc1861
   McKechnie NM, 2006, EXP EYE RES, V83, P304, DOI 10.1016/j.exer.2005.11.028
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A
   Nakamura M, 2004, AM J PATHOL, V164, P1949, DOI 10.1016/S0002-9440(10)63755-8
   Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913
   Santos RL, 2001, INFECT IMMUN, V69, P2293, DOI 10.1128/IAI.69.4.2293-2301.2001
   Sarkar A, 2006, AM J RESP CRIT CARE, V174, P1003, DOI 10.1164/rccm.200604-546OC
   Sarkar A, 2006, J IMMUNOL, V176, P4979, DOI 10.4049/jimmunol.176.8.4979
   Sarkar A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007140
   Sue W, 2006, AM J CLIN NUTR, V83, p470S
   Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788
   Tiwary R, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3063
   van der Velden AWM, 2003, J IMMUNOL, V171, P6742, DOI 10.4049/jimmunol.171.12.6742
   Wang J, 2000, J CELL SCI, V113, P753
   Watanabe JJ, 2003, J BIOL CHEM, V278, P33161, DOI 10.1074/jbc.M305321200
   Wewers MD, 2004, P NATL ACAD SCI USA, V101, P10241, DOI 10.1073/pnas.0403971101
   WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388
   Wilson HL, 2004, J IMMUNOL, V173, P1202, DOI 10.4049/jimmunol.173.2.1202
   Zimmerman GA, 1999, CHEST, V116, p18S, DOI 10.1378/chest.116.suppl_1.18S
NR 54
TC 33
Z9 35
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 28
PY 2015
VL 10
IS 12
AR e0145607
DI 10.1371/journal.pone.0145607
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CZ9XO
UT WOS:000367451400065
PM 26710067
OA gold, Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Yang, Y
   Chen, QH
   Liu, AR
   Xu, XP
   Han, JB
   Qiu, HB
AF Yang, Yi
   Chen, Qihong
   Liu, Airan
   Xu, Xiu-ping
   Han, Jibin
   Qiu, Haibo
TI Synergism of MSC-secreted HGF and VEGF in stabilising endothelial
   barrier function upon lipopolysaccharide stimulation via the Rac1
   pathway
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE mesenchymal stem cell; VEGF/VEGFA; hepatocyte growth factor (HGF); permeability; ALI/ARDS 
ID ACUTE LUNG INJURY; MEDIATED TRANSCELLULAR PATHWAY; CONDITIONED MEDIA;
   CROSS-TALK; IN-VITRO; PERMEABILITY; TRANSPORT; CELLS; MICE; THERAPY
AB Background: Mesenchymal stem cells (MSCs) stabilise endothelial barrier function in acute lung injury via paracrine hepatocyte growth factor (HGF). Vascular endothelial growth factor (VEGF), which is secreted by MSCs, is another key regulator of endothelial permeability; however, its role in adjusting permeability remains controversial. In addition, whether an interaction occurs between HGF and VEGF, which are secreted by MSCs, is not completely understood.
   Methods: We introduced a co-cultured model of human pulmonary microvascular endothelial cells (HPMECs) and MSC conditioned medium (CM) collected from MSCs after 24 h of hypoxic culture. The presence of VEGF and HGF in the MSC-CM was neutralised by anti-VEGF and anti-HGF antibodies, respectively. To determine the roles and mechanisms of MSC-secreted HGF and VEGF, we employed recombinant humanised HGF and recombinant humanised VEGF to co-culture with HPMECs. Additionally, we employed the RhoA inhibitor C3 transferase and the Rac1 inhibitor NSC23766 to inhibit the activities of RhoA and Rac1 in HPMECs treated with MSC-CM or VEGF/HGF with the same dosage as in the MSC-CM. Then, endothelial paracellular and transcellular permeability was detected. VE-cadherin, occludin and caveolin-1 protein expression in HPMECs was measured by western blot. Adherens junction proteins, including F-actin and VE-cadherin, were detected by immunofluorescence.
   Results: MSC-CM treatment significantly decreased lipopolysaccharide-induced endothelial paracellular and transcellular permeability, which was significantly inhibited by pretreatment with HGF antibody or with both VEGF and HGF antibodies. Furthermore, MSC-CM treatment increased the expression of the endothelial intercellular adherence junction proteins VE-cadherin and occludin and decreased the expression of caveolin-1 protein. MSC-CM treatment also decreased endothelial apoptosis and induced endothelial cell proliferation; however, the effects of MSC-CM treatment were inhibited by pretreatment with HGF antibody or with both HGF and VEGF antibodies. Additionally, the effects of MSC-CM and VEGF/HGF on reducing endothelial paracellular and transcellular permeability were weakened when HPMECs were pretreated with the Rac1 inhibitor NSC23766.
   Conclusion: HGF secreted by MSCs protects the endothelial barrier function; however, VEGF secreted by MSCs may synergize with HGF to stabilise endothelial cell barrier function. Rac1 is the pathway by which MSC-secreted VEGF and HGF regulate endothelial permeability.
C1 [Yang, Yi; Chen, Qi-hong; Liu, Ai-ran; Xu, Xiu-ping; Han, Ji-bin; Qiu, Hai-bo] Southeast Univ, Dept Crit Care Med, Zhong Da Hosp, Sch Med, Nanjing 210009, Jiangsu, China.
C3 Southeast University - China
RP Qiu, HB (corresponding author), Southeast Univ, Dept Crit Care Med, Zhong Da Hosp, Sch Med, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM haiboq2000@163.com
RI CHEN, QING/IXN-5937-2023; Xu, Xiuping/W-5865-2019; Chen,
   QH/GXH-3158-2022; Qiu, Haibo/AAS-9047-2021; chen, qian/HKE-2403-2023
OI CHEN, QING/0000-0001-5250-1710; Xu, Xiuping/0000-0003-3950-3425; Qiu,
   Haibo/0000-0001-8589-4717; 
FU National Natural Science Foundations of China [81170057, 81201489,
   81300060, 81372093, 81471843]; Clinical Medicine Science and Technology
   Projects in Jiangsu Province [BL2013030]; Graduate Innovation Project in
   Jiangsu Province of China [CXLX13_123, KYZZ_0072]
FX Contract grant sponsor: National Natural Science Foundations of China;
   Contract grant numbers: 81170057, 81201489; 81300060, 81372093, and
   81471843. Contact grant sponsor: Clinical Medicine Science and
   Technology Projects in Jiangsu Province; Contract grant number:
   BL2013030. Contract grant sponsor: Graduate Innovation Project in
   Jiangsu Province of China; Contract grant numbers: CXLX13_123 and
   KYZZ_0072.
CR Abreu SC, 2011, INTENS CARE MED, V37, P1421, DOI 10.1007/s00134-011-2268-3
   Angoulvant D, 2011, J HEART LUNG TRANSPL, V30, P95, DOI 10.1016/j.healun.2010.08.023
   Armstrong SM, 2012, AM J PATHOL, V180, P1308, DOI 10.1016/j.ajpath.2011.12.002
   Aslam M, 2013, J PHYSIOL-LONDON, V591, P461, DOI 10.1113/jphysiol.2012.237834
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Chen W, 2012, CARDIOVASC RES, V93, P141, DOI 10.1093/cvr/cvr279
   Dohgu S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-167
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   Goolaerts A, 2014, AM J PHYSIOL-LUNG C, V306, pL975, DOI 10.1152/ajplung.00242.2013
   He HL, 2015, CELL TRANSPLANT, V24, P1699, DOI 10.3727/096368914X685087
   Hu GC, 2008, CHEM-BIOL INTERACT, V171, P177, DOI 10.1016/j.cbi.2007.08.006
   Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011
   Koh H, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-60
   Kotton DN, 2005, AM J RESP CELL MOL, V33, P328, DOI 10.1165/rcmb.2005-0175RC
   Li Z, 2014, J MOL NEUROSCI, V52, P313, DOI 10.1007/s12031-013-0148-8
   Liu AY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0083736, 10.1371/journal.pone.0090229]
   Madrigal M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0260-8
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Meng FY, 2015, AM J PHYSIOL-LUNG C, V308, pL452, DOI 10.1152/ajplung.00170.2014
   Minshall R. D., 2006, V176, P107
   Page Patrick, 2014, Int J Cell Biol, V2014, P601063, DOI 10.1155/2014/601063
   Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013
   Seebach J, 2005, THROMB HAEMOSTASIS, V94, P620, DOI 10.1160/TH05-01-0015
   Sulpice E, 2009, BIOL CELL, V101, P525, DOI 10.1042/BC20080221
   Sun Y, 2011, METHODS MOL BIOL, V763, P303, DOI 10.1007/978-1-61779-191-8_21
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Zhang W, 2014, BIOMED RES INT, V2014
NR 32
TC 108
Z9 114
U1 2
U2 32
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 16
PY 2015
VL 6
AR 250
DI 10.1186/s13287-015-0257-0
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CZ1VP
UT WOS:000366894100001
PM 26674641
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Nickols, J
   Obiako, B
   Ramila, KC
   Putinta, K
   Schilling, S
   Sayner, SL
AF Nickols, Jordan
   Obiako, Boniface
   Ramila, K. C.
   Putinta, Kevin
   Schilling, Sarah
   Sayner, Sarah L.
TI Lipopolysaccharide-induced pulmonary endothelial barrier disruption and
   lung edema: critical role for bicarbonate stimulation of AC10
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE compartmentalized cAMP; LPS; lung edema; soluble adenylate cyclase; bicarbonate 
ID SOLUBLE ADENYLYL-CYCLASE; PSEUDOMONAS-AERUGINOSA; MEDICAL PROGRESS;
   CAMP; REVEALS; PHOSPHORYLATION; ACTIVATION; MECHANISMS; BACTERIAL;
   CALCIUM
AB Bacteria-induced sepsis is a common cause of pulmonary endothelial barrier dysfunction and can progress toward acute respiratory distress syndrome. Elevations in intracellular cAMP tightly regulate pulmonary endothelial barrier integrity; however, cAMP signals are highly compartmentalized: whether cAMP is barrier-protective or -disruptive depends on the compartment (plasma membrane or cytosol, respectively) in which the signal is generated. The mammalian soluble adenylyl cyclase isoform 10 (AC10) is uniquely stimulated by bicarbonate and is expressed in pulmonary microvascular endothelial cells (PMVECs). Elevated extracellular bicarbonate increases cAMP in PMVECs to disrupt the endothelial barrier and increase the filtration coefficient (K-f) in the isolated lung. We tested the hypothesis that sepsis-induced endothelial barrier disruption and increased permeability are dependent on extracellular bicarbonate and activation of AC10. Our findings reveal that LPS-induced endothelial barrier disruption is dependent on extracellular bicarbonate: LPS-induced barrier failure and increased permeability are exacerbated in elevated bicarbonate compared with low extracellular bicarbonate. The AC10 inhibitor KH7 attenuated the bicarbonate-dependent LPS-induced barrier disruption. In the isolated lung, LPS failed to increase Kf in the presence of minimal perfusate bicarbonate. An increase in perfusate bicarbonate to the physiological range (24 mM) revealed the LPS-induced increase in Kf, which was attenuated by KH7. Furthermore, in PMVECs treated with LPS for 6 h, there was a dose-dependent increase in AC10 expression. Thus these findings reveal that LPS-induced pulmonary endothelial barrier failure requires bicarbonate activation of AC10.
C1 [Nickols, Jordan; Ramila, K. C.; Putinta, Kevin; Sayner, Sarah L.] Univ S Alabama, Dept Physiol & Cell Biol, Mobile, AL 36688, United States.
C1 [Obiako, Boniface] Univ S Alabama, Dept Pharmacol, Mobile, AL 36688, United States.
C1 [Obiako, Boniface; Sayner, Sarah L.] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688, United States.
C1 [Schilling, Sarah] Univ Appl Sci Bingen, Bingen Am Rhein, Germany.
C3 University of South Alabama; University of South Alabama; University of
   South Alabama
RP Sayner, SL (corresponding author), Univ S Alabama, Ctr Lung Biol, Dept Physiol & Cell Biol, Coll Med, Mobile, AL 36688 USA.
EM ssayner@southalabama.edu
FU Parker B. Francis Fellowship Foundation; National Heart, Lung, and Blood
   Institute [HL-121513]
FX This work was supported by a Parker B. Francis Fellowship Foundation
   Award (S. L. Sayner) and National Heart, Lung, and Blood Institute Grant
   HL-121513 (S. L. Sayner).
CR Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Balczon R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074343
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Barabutis N, 2015, AM J PHYSIOL-LUNG C, V308, pL776, DOI 10.1152/ajplung.00334.2014
   Beckert U, 2014, BIOCHEM BIOPH RES CO, V450, P870, DOI 10.1016/j.bbrc.2014.06.088
   Birukova AA, 2014, BIOCHIM BIOPHYS ACTA, V1852, P778
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2010, MICROVASC RES, V79, P128, DOI 10.1016/j.mvr.2009.11.007
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79
   Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625
   Chetham PM, 1997, AM J PHYSIOL-LUNG C, V273, pL22, DOI 10.1152/ajplung.1997.273.1.L22
   Chichger H, 2015, FASEB J, V29, P868, DOI 10.1096/fj.14-257212
   Cioffi DL, 2002, J CELL BIOL, V157, P1267, DOI 10.1083/jcb.200204022
   Creighton J, 2008, J CELL SCI, V121, P110, DOI 10.1242/jcs.011692
   Dudek SM, 2011, AM J RESP CELL MOL, V44, P361, DOI 10.1165/rcmb.2009-0446OC
   Feng QP, 2006, BIOCHIMIE, V88, P319, DOI 10.1016/j.biochi.2005.09.003
   Flemming S, 2014, SHOCK, V41, P537, DOI 10.1097/SHK.0000000000000152
   Geng WD, 2005, AM J PHYSIOL-CELL PH, V288, pC1305, DOI 10.1152/ajpcell.00584.2004
   Glynos C, 2007, AM J PHYSIOL-REG I, V292, pR1448, DOI 10.1152/ajpregu.00341.2006
   Gottle M, 2010, BIOCHEMISTRY-US, V49, P5494, DOI 10.1021/bi100684g
   Hasan A, 2014, BIOCHEM BIOPH RES CO, V448, P236, DOI 10.1016/j.bbrc.2014.04.099
   Jian MY, 2013, AM J PHYSIOL-LUNG C, V305, pL844, DOI 10.1152/ajplung.00173.2013
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Kleinboelting S, 2014, FEBS J, V281, P4151, DOI 10.1111/febs.12913
   KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106
   MARTIN MA, 1992, CLIN INFECT DIS, V14, P1213, DOI 10.1093/clinids/14.6.1213
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   MEYRICK B, 1986, Critical Care Clinics, V2, P405
   Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203
   Morrow KA, 2015, AM J PHYSIOL-LUNG C, V309, pL1199, DOI 10.1152/ajplung.00165.2015
   Obiako B, 2013, AM J PHYSIOL-LUNG C, V305, pL185, DOI 10.1152/ajplung.00392.2012
   Ochoa CD, 2012, J BIOL CHEM, V287, P25407, DOI 10.1074/jbc.M111.301440
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Prasain N, 2009, AM J PHYSIOL-LUNG C, V297, pL73, DOI 10.1152/ajplung.90577.2008
   RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492
   Risoe PK, 2007, BBA-MOL BASIS DIS, V1772, P32, DOI 10.1016/j.bbadis.2006.08.007
   Rubenfeld GD, 2015, AM J RESP CRIT CARE, V191, P255, DOI 10.1164/rccm.201408-1574CP
   Sayner S, 2006, BIOCHEM SOC T, V34, P492, DOI 10.1042/BST0340492
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V301, pL117, DOI 10.1152/ajplung.00417.2009
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V300, pL667, DOI 10.1152/ajplung.00433.2010
   Sayner SL, 2006, CIRC RES, V98, P675, DOI 10.1161/01.RES.0000209516.84815.3e
   Sayner SL, 2004, CIRC RES, V95, P196, DOI 10.1161/01.RES.0000134922.25721.d9
   Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x
   Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119
   Stevens TC, 2014, AM J PHYSIOL-LUNG C, V306, pL915, DOI 10.1152/ajplung.00135.2013
   Thangjam GS, 2014, AM J RESP CELL MOL, V50, P942, DOI 10.1165/rcmb.2013-0214OC
   TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507
   Uhlig S, 2014, CELL PHYSIOL BIOCHEM, V34, P1, DOI 10.1159/000362980
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Zippin JH, 2004, J CELL BIOL, V164, P527, DOI 10.1083/jcb.200311119
   Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje
NR 56
TC 13
Z9 15
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC 15
PY 2015
VL 309
IS 12
BP L1430
EP L1437
DI 10.1152/ajplung.00067.2015
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CY8AU
UT WOS:000366631600007
PM 26475732
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Suresh, K
   Servinsky, L
   Reyes, J
   Baksh, S
   Undem, C
   Caterina, M
   Pearse, DB
   Shimoda, LA
AF Suresh, Karthik
   Servinsky, Laura E.
   Reyes, Jose
   Baksh, Syeda
   Undem, Clark
   Caterina, Michael
   Pearse, David B.
   Shimoda, Larissa A.
TI Hydrogen peroxide-induced calcium influx in lung microvascular
   endothelial cells involves TRPV4
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; calcium; ROS; Transient receptor potential vanilloid 4 (TRPV4) 
ID PROTEIN-KINASE-G; INCREASES ANTIOXIDANT FUNCTION; OPERATED CA2+ ENTRY;
   RUTHENIUM RED; TYROSINE PHOSPHORYLATION; VASCULAR-PERMEABILITY; BARRIER
   DYSFUNCTION; CHANNEL; ACTIVATION; INJURY
AB In acute respiratory distress syndrome, both reactive oxygen species (ROS) and increased intracellular calcium ([Ca2+](i)) are thought to play important roles in promoting endothelial paracellular permeability, but the mechanisms linking ROS and [Ca2+](i) in microvascular endothelial cells are not known. In this study, we assessed the effect of hydrogen peroxide (H2O2) on [Ca2+](i) in mouse and human lung microvascular endothelial cells (MLMVEC and HLMVEC, respectively). We found that in both MLMVECs and HLMVECs, exogenously applied H2O2 increased [Ca2+](i) through Ca2+ influx and that pharmacologic inhibition of the calcium channel transient receptor potential vanilloid 4 (TRPV4) attenuated the H2O2- induced Ca2+ influx. Additionally, knockdown of TRPV4 in HLMVEC also attenuated calcium influx following H2O2 challenge. Administration of H2O2 or TRPV4 agonists decreased transmembrane electrical resistance (TER), suggesting increased barrier permeability. To explore the regulatory mechanisms underlying TRPV4 activation by ROS, we examined H2O2-induced Ca2+ influx in MLMVECs and HLMVECs with either genetic deletion, silencing, or pharmacologic inhibition of Fyn, a Src family kinase. In both MLMVECs derived from mice deficient for Fyn and HLMVECs treated with either siRNA targeted to Fyn or the Src family kinase inhibitor SU-6656 for 24 or 48 h, the H2O2-induced Ca2+ influx was attenuated. Treatment with SU-6656 decreased the levels of phosphorylated, but not total, TRPV4 protein and had no effect on TRPV4 response to the external agonist, GSK1016790A. In conclusion, our data suggest that application of exogenous H2O2 increases [Ca2+](i) and decreases TER in microvascular endothelial cells via activation of TRPV4 through a mechanism that requires the Src kinase Fyn.
C1 [Suresh, Karthik; Servinsky, Laura; Reyes, Jose; Baksh, Syeda; Undem, Clark; Pearse, David B.; Shimoda, Larissa A.] Johns Hopkins Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD, United States.
C1 [Caterina, Michael] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD, United States.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Shimoda, LA (corresponding author), Johns Hopkins Asthma & Allergy Bldg, Baltimore, MD 21224 USA.
EM lshimod1@jhmi.edu
RI Suresh, Karthik/P-6307-2019
FU National Heart, Lung, and Blood Institute [F32HL-124930-02,
   T32HL-007534, R01HL-73859, R01HL-075078]
FX Support for this study was provided by National Heart, Lung, and Blood
   Institute Grants F32HL-124930-02, T32HL-007534, R01HL-73859, and
   R01HL-075078.
CR Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X
   Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200
   Alessandri-Haber N, 2008, J NEUROSCI, V28, P1046, DOI 10.1523/JNEUROSCI.4497-07.2008
   Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19
   Anidi IU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071010
   BAIRD BR, 1986, J APPL PHYSIOL, V61, P2224, DOI 10.1152/jappl.1986.61.6.2224
   Balakrishna S, 2014, AM J PHYSIOL-LUNG C, V307, pL158, DOI 10.1152/ajplung.00065.2014
   BRIGHAM KL, 1987, J APPL PHYSIOL, V63, P840, DOI 10.1152/jappl.1987.63.2.840
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920
   Chetham PM, 1999, AM J PHYSIOL-LUNG C, V276, pL41, DOI 10.1152/ajplung.1999.276.1.L41
   Chi AY, 2010, ANTIOXID REDOX SIGN, V12, P603, DOI 10.1089/ars.2009.2861
   Cioffi DL, 2009, ANTIOXID REDOX SIGN, V11, P765, DOI [10.1089/ars.2008.2221, 10.1089/ARS.2008.2221]
   Clark J, 2008, AM J PHYSIOL-LUNG C, V294, pL431, DOI 10.1152/ajplung.00316.2007
   Colton C, 1996, MOL CHEM NEUROPATHOL, V28, P15, DOI 10.1007/BF02815200
   CORBALANGARCIA S, 1992, BIOCHEM J, V287, P767, DOI 10.1042/bj2870767
   CUTLER RG, 1995, OXIDATIVE STRESS AGI
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   Gebb S, 2004, MICROVASC RES, V68, P1, DOI 10.1016/j.mvr.2004.02.002
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   Hecquet CM, 2008, CIRC RES, V102, P347, DOI 10.1161/CIRCRESAHA.107.160176
   Hills CE, 2012, EXP DIABETES RES, DOI 10.1155/2012/936518
   Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200
   Huang BK, 2014, REDOX BIOL, V2, P955, DOI 10.1016/j.redox.2014.08.001
   Kanda S, 2011, MOL BIOL CELL, V22, P1824, DOI 10.1091/mbc.E10-12-0929
   Kaspar JW, 2011, FASEB J, V25, P1076, DOI 10.1096/fj.10-171553
   Kawasaki BT, 2006, P NATL ACAD SCI USA, V103, P335, DOI 10.1073/pnas.0508030102
   Kuhlmann CRW, 2004, J MOL CELL CARDIOL, V36, P675, DOI 10.1016/j.yjmcc.2004.03.001
   Lin MT, 2015, PULM CIRC, V5, P279, DOI 10.1086/680166
   Lowe K, 2007, J SURG RES, V143, P70, DOI 10.1016/j.jss.2007.03.047
   Martinez J, 2001, ARCH BIOCHEM BIOPHYS, V392, P257, DOI 10.1006/abbi.2001.2439
   Mastore M, 2005, FEBS J, V272, P2407, DOI 10.1111/j.1742-4658.2005.04661.x
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Moldovan L, 2006, CARDIOVASC RES, V71, P236, DOI 10.1016/j.cardiores.2006.05.003
   Morty RE, 2014, AM J PHYSIOL-LUNG C, V307, pL817, DOI 10.1152/ajplung.00254.2014
   Mungai PT, 2011, MOL CELL BIOL, V31, P3531, DOI 10.1128/MCB.05124-11
   Parikh J, 2015, BIOPHYS J, V108, P1566, DOI 10.1016/j.bpj.2015.01.034
   Pearse DB, 2003, ENDOTHELIUM-J ENDOTH, V10, P309, DOI 10.1080/10623320390272307
   Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182
   Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879
   Saksena S, 2008, BIOCHEM J, V416, P99, DOI 10.1042/BJ20070960
   Sarmiento D, 2015, MICROVASC RES, V98, P187, DOI 10.1016/j.mvr.2014.02.001
   SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443
   Sidhaye VK, 2006, P NATL ACAD SCI USA, V103, P4747, DOI 10.1073/pnas.0511211103
   Stephens RS, 2014, AM J PHYSIOL-CELL PH, V306, pC559, DOI 10.1152/ajpcell.00375.2012
   Stephens RS, 2010, AM J PHYSIOL-LUNG C, V299, pL323, DOI 10.1152/ajplung.00442.2009
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   TATE RM, 1982, AM REV RESPIR DIS, V126, P802
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7
   Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347
   Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Varani James, 1994, Biological Signals, V3, P1
   Veit F, 2015, ANTIOXID REDOX SIGN, V22, P537, DOI 10.1089/ars.2014.6234
   Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807
   Wegierski T, 2009, J BIOL CHEM, V284, P2923, DOI 10.1074/jbc.M805357200
   Weissmann N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1660
   Wu F, 2014, AM J PHYSIOL-LUNG C, V307, pL987, DOI 10.1152/ajplung.00063.2014
   Wu SW, 2009, AM J PHYSIOL-LUNG C, V297, pL650, DOI 10.1152/ajplung.00015.2009
   Xia Y, 2013, AM J PHYSIOL-CELL PH, V305, pC704, DOI 10.1152/ajpcell.00099.2013
   Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200
   Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680
NR 71
TC 72
Z9 78
U1 0
U2 14
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC 15
PY 2015
VL 309
IS 12
BP L1467
EP L1477
DI 10.1152/ajplung.00275.2015
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CY8AU
UT WOS:000366631600011
PM 26453519
OA Green Published
DA 2023-08-21
ER

PT J
AU Huang, YR
   Tan, QD
   Chen, R
   Cao, B
   Li, WH
AF Huang, Yiran
   Tan, Qindong
   Chen, Rui
   Cao, Biao
   Li, Wenhong
TI Sevoflurane prevents lipopolysaccharide-induced barrier dysfunction in
   human lung microvascular endothelial cells: Rho-mediated alterations of
   VE-cadherin
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE ALI/ARDS; permeability; ECs/HPMECs/HUVECs/MPVECs; Sevoflurane; RhoA/ROCK signaling pathway; VE-cadherin 
ID INJURY; PERMEABILITY; PROTECTS; PATHWAY; INHIBITION; EXCHANGE; GTPASES;
   KINASE; DAMAGE; MAPK
AB Acute lung injury (AU) mainly occurs as increased permeability of lung tissue and pleural effusion. Inhaled anesthetic sevoflurane has been demonstrated to alleviate lung permeability by upregulating junction proteins after ischemia-reperfusion. However, the exact mechanisms of its protective effect on reperfusion injury remain elusive. The aim of this study was to assess possible preconditioning with sevoflurane in an in vitro model of lipopolysaccharide (LPS)-induced barrier dysfunction in human lung microvascular endothelial cells (HMVEC-Ls). In this study, HMVEC-Ls were exposed to minimum alveolar concentration of sevoflurane for 2 h. LPS significantly increased the permeability of HMVEC-I. Moreover, the distribution of junction protein, vascular endothelial (VE)-cadherin, in cell cell junction area and the total expression in HMVEC-Ls were significantly decreased by LPS treatment. However, the abnormal distribution and decreased expression of VE-cadherin and hyperpermeability of HMVEC-Ls were significantly reversed by pretreatment with sevoflurane. Furthermore, LPS-induced activation of the RhoA/ROCK signaling pathway was significantly inhibited with sevoflurane. Such activation, abnormal distribution and decreased expression of VE-cadherin and hyperpermeability of HMVEC-Ls were significantly inhibited with sevoflurane pretreatment or knockdown of RhoA or ROCK-2. In conclusion, sevoflurane prevented LPS-induced rupture of HMVEC-L monolayers by suppressing the RhoA/ROCK-mediated VE-cadherin signaling pathway. Our results may explain, at least in part, some beneficial effects of sevoflurane on pulmonary dysfunction such as ischemia-reperfusion injury. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Huang, Yiran; Chen, Rui; Cao, Biao; Li, Wenhong] Guangzhou Mil Command PLA, Dept Anesthesiol, Gen Hosp, Affiliated Hosp 157, Guangzhou 510510, Guangdong, China.
C1 [Tan, Qindong] Cent S Univ, Xiangya Hosp, Dept Anesthesiol, Changsha 410008, Hunan, China.
C3 Southern Theater Command General Hospital; Central South University
RP Huang, YR (corresponding author), Guangzhou Mil Command PLA, Dept Anesthesiol, Guangzhou Gen Hosp, Hosp 157, Guangzhoudadaobei Rd, Guangzhou 510510, Guangdong, Peoples R China.
EM Hyr88955@163.com
CR Alcaide P, 2012, AM J PHYSIOL-CELL PH, V303, pC385, DOI 10.1152/ajpcell.00126.2012
   Ashina K, 2015, BIOCHEM BIOPH RES CO, V464, P590, DOI 10.1016/j.bbrc.2015.07.014
   Barabutis N, 2015, AM J PHYSIOL-LUNG C, V308, pL776, DOI 10.1152/ajplung.00334.2014
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   Chai J, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.27
   Dittmar MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130408
   Gavard Julie, 2014, Cell Adh Migr, V8, P158
   Gong HX, 2014, J EXP MED, V211, P579, DOI 10.1084/jem.20131190
   Guazzi M, 2015, PROG CARDIOVASC DIS, V57, P454, DOI 10.1016/j.pcad.2014.11.003
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Li Y, 2010, MED SCI MONITOR, V16, pBR112
   Liang H, 2012, J ANESTH, V26, P381, DOI 10.1007/s00540-011-1317-y
   Liao Zhongji, 2014, J Biomed Sci Eng, V7, P1105
   Liu XJ, 2013, EXP THER MED, V6, P361, DOI 10.3892/etm.2013.1166
   Meliton AY, 2015, AM J PHYSIOL-LUNG C, V308, pL550, DOI 10.1152/ajplung.00248.2014
   Meng FY, 2015, AM J PHYSIOL-LUNG C, V308, pL452, DOI 10.1152/ajplung.00170.2014
   Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964
   Vasko R, 2013, ANTIOXID REDOX SIGN, V19, P211, DOI 10.1089/ars.2012.4768
   Voigtsberger S, 2009, ANESTHESIOLOGY, V111, P1238, DOI 10.1097/ALN.0b013e3181bdf857
   Xie KL, 2015, SHOCK, V44, P58, DOI 10.1097/SHK.0000000000000365
   Yang JJ, 2015, CELL MOL LIFE SCI, V72, P4849, DOI 10.1007/s00018-015-1973-4
   Zhang WZ, 2015, INFLAMMATION, V38, P1406, DOI 10.1007/s10753-015-0115-3
   Zhao JL, 2013, CIRCULATION, V128, pS121, DOI 10.1161/CIRCULATIONAHA.112.000045
   Zhou HQ, 2011, INFLAMM RES, V60, P981, DOI 10.1007/s00011-011-0359-9
   Zhou ZD, 2013, SURGERY, V154, P621, DOI 10.1016/j.surg.2013.04.009
NR 27
TC 24
Z9 26
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 4
PY 2015
VL 468
IS 1-2
BP 119
EP 124
DI 10.1016/j.bbrc.2015.10.150
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CY2LS
UT WOS:000366240800019
PM 26529544
DA 2023-08-21
ER

PT J
AU Cabrera-Benitez, NE
   Valladares, F
   Garcia-Hernandez, S
   Ramos-Nuez, A
   Martin-Barrasa, JL
   Martinez-Saavedra, MT
   Rodriguez-Gallego, C
   Muros, M
   Flores, C
   Liu, MY
   Slutsky, AS
   Villar, J
AF Cabrera-Benitez, Nuria E.
   Valladares, Francisco
   Garcia-Hernandez, Sonia
   Ramos-Nuez, Angela
   Martin-Barrasa, Jose L.
   Martinez-Saavedra, Maria-Teresa
   Rodriguez-Gallego, Carlos
   Muros, Mercedes
   Flores, Carlos
   Liu, Mingyao
   Slutsky, Arthur S.
   Villar, Jesus
TI Altered Profile of Circulating Endothelial-Derived Microparticles in
   Ventilator-Induced Lung Injury
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE ALI/ARDS; mechanical ventilation; platelet-endothelial cell adhesion molecule; ventilator-induced lung injury 
ID INFLAMMATION; EXPRESSION; MECHANISMS; GENERATION; PROTECTION; PECAM-1;
   REPAIR; BENCH
AB Objectives: Pulmonary endothelial cell injury is central to the pathophysiology of acute lung injury. Mechanical ventilation can cause endothelial disruption and injury, even in the absence of preexisting inflammation. Platelet-endothelial cell adhesion molecule-1 is a transmembrane protein connecting adjacent endothelial cells. We hypothesized that injurious mechanical ventilation will increase circulating lung endothelial-derived microparticles, defined as microparticles positive for platelet-endothelial cell adhesion molecule-1, which could serve as potential biomarkers and mediators of ventilator-induced lung injury.
   Design: Prospective randomized, controlled, animal investigation.
   Setting: A hospital preclinical animal laboratory.
   Subjects: Forty-eight Sprague-Dawley rats.
   Interventions: Animals were randomly allocated to one of the three following ventilatory protocols for 4 hours: spontaneous breathing (control group), mechanical ventilation with low tidal volume (6 mL/kg), and mechanical ventilation with high tidal volume (20 mL/kg). In both mechanical ventilation groups, positive end-expiratory pressure of 2 cm H2O was applied.
   Measurements and Main Results: We analyzed histologic lung damage, gas exchange, wet-to-dry lung weight ratio, serum cytokines levels, circulating endothelial-derived microparticles, platelet-endothelial cell adhesion molecule-1 lung protein content, and immunohistochemistry. When compared with low-tidal volume mechanical ventilation, high-tidal volume ventilation increased lung edema score and caused gas-exchange deterioration. These changes were associated with a marked increased of circulating endothelial-derived microparticles and a reduction of platelet-endothelial cell adhesion molecule-1 protein levels in the high-tidal volume lungs (p < 0.0001).
   Conclusions: There is an endothelial-derived microparticle profile associated with disease-specific features of ventilator-induced lung injury. This profile could serve both as a biomarker of acute lung injury and, potentially, as a mediator of systemic propagation of pulmonary inflammatory response.
C1 [Cabrera-Benitez, Nuria E.; Valladares, Francisco; Ramos-Nuez, Angela; Flores, Carlos; Villar, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
C1 [Cabrera-Benitez, Nuria E.; Ramos-Nuez, Angela; Martin-Barrasa, Jose L.; Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Las Palmas Gran Canaria, Spain.
C1 [Valladares, Francisco; Garcia-Hernandez, Sonia] Univ La Laguna, Dept Anat Pathol & Histol, Tenerife, Spain.
C1 [Martinez-Saavedra, Maria-Teresa] Hosp Univ Dr Negrin, Dept Immunol, Las Palmas Gran Canaria, Spain.
C1 [Rodriguez-Gallego, Carlos] Hosp San Espases, Dept Immunol, Palma De Mallorca, Spain.
C1 [Muros, Mercedes] Hosp Univ NS Candelaria, Dept Clin Biochem, Tenerife, Spain.
C1 [Flores, Carlos] Hosp Univ NS Candelaria, Res Unit, Tenerife, Spain.
C1 [Liu, Mingyao] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
C1 [Liu, Mingyao] Univ Hlth Network, Toronto Gen Res Inst, Resp & Crit Care Res Grp, Toronto, ON, Canada.
C1 [Slutsky, Arthur S.; Villar, Jesus] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, Toronto, ON M5B 1W8, Canada.
C1 [Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de
   Salud Carlos III; Universidad de la Laguna; Hospital Universitari Son
   Espases; University of Toronto; University of Toronto; University Health
   Network Toronto; Toronto General Hospital; University of Toronto; Li Ka
   Shing Knowledge Institute; Saint Michaels Hospital Toronto; University
   of Toronto
RP Villar, J (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
EM jesus.villar54@gmail.com
RI Villar, Jesús/R-4526-2019; RODRIGUEZ-GALLEGO, CARLOS/AAB-7516-2022;
   Slutsky, Arthur/M-3325-2019; Flores, Carlos/R-1159-2019; Slutsky,
   Arthur/IQT-0428-2023; Martín-Barrasa, José Luis/GLR-3921-2022
OI Villar, Jesús/0000-0001-5687-3562; Martín-Barrasa, José
   Luis/0000-0002-3280-9838; Flores, Carlos/0000-0001-5352-069X; Martinez
   de Saavedra Alvarez, Maria Teresa/0000-0001-8579-226X; Liu,
   Mingyao/0000-0002-9188-8417; Rodriguez-Gallego,
   Carlos/0000-0002-4344-8644
FU Instituto de Salud Carlos III, Madrid, Spain [CB06/06/1088, PI10/0393];
   Asociacion Cientifica Pulmon y Ventilacion Mecanica, Spain; Canadian
   Institutes of Health Research
FX Supported, in part, by grants from Instituto de Salud Carlos III,
   Madrid, Spain (CB06/06/1088 and PI10/0393) and by Asociacion Cientifica
   Pulmon y Ventilacion Mecanica, Spain.; Dr. Slutsky received support for
   article research from the Canadian Institutes of Health Research and
   disclosed financial relationships with Maquet Critical Care
   (consultant), Novalung (consultant), PneumRx (Chair, Data Monitoring
   Committee), Asthmatx/Boston Scientific (Chair), and Data and Safety
   Monitoring Board (DSMB) Ferring (Chair, DSMB). The remaining authors
   have disclosed that they do not have any potential conflicts of
   interest.
CR Abdelhafeez AH, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23498
   Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009
   Bhatt AJ, 2001, AM J RESP CRIT CARE, V164, P1971, DOI 10.1164/ajrccm.164.10.2101140
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buesing KL, 2011, J SURG RES, V166, P32, DOI 10.1016/j.jss.2010.05.036
   Burger D, 2013, CLIN SCI, V124, P423, DOI 10.1042/CS20120309
   Burns KEA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014623
   Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985
   Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Densmore JC, 2006, SHOCK, V26, P464, DOI 10.1097/01.shk.0000228791.10550.36
   Distler JHW, 2006, AUTOIMMUNITY, V39, P683, DOI 10.1080/08916930601061538
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   Fornasa G, 2010, J IMMUNOL, V184, P5485, DOI 10.4049/jimmunol.0902219
   Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI200213595
   Hegeman MA, 2009, CRIT CARE, V13, DOI 10.1186/cc8168
   Herrera MT, 2003, INTENS CARE MED, V29, P1345, DOI 10.1007/s00134-003-1756-5
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kuipers MT, 2012, ANESTHESIOLOGY, V116, P1104, DOI 10.1097/ALN.0b013e3182518bc0
   Leonetti D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073088
   Maas M, 2005, AM J PHYSIOL-HEART C, V288, pH159, DOI 10.1152/ajpheart.00500.2004
   Mastronardi ML, 2011, CRIT CARE MED, V39, P1739, DOI 10.1097/CCM.0b013e3182190b4b
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Meziani F, 2010, CRIT CARE, V14, DOI 10.1186/cc9231
   Moriondo A, 2007, J APPL PHYSIOL, V103, P747, DOI 10.1152/japplphysiol.00056.2007
   Muller AM, 2002, J PATHOL, V198, P270, DOI 10.1002/path.1186
   Newman PJ, 1997, J CLIN INVEST, V100, pS25
   Nomura S, 2000, THROMB RES, V98, P257, DOI 10.1016/S0049-3848(00)00186-9
   Nonas SA, 2007, AM J PHYSIOL-LUNG C, V293, pL292, DOI 10.1152/ajplung.00481.2006
   PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024
   Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X
   Rodriguez-Carrio J, 2015, CLIN SCI, V128, P437, DOI 10.1042/CS20140675
   Roseblade A, 2013, J PHARM PHARM SCI, V16, P238, DOI 10.18433/J3989X
   Shirafuji T, 2009, MUSCLE NERVE, V39, P586, DOI 10.1002/mus.21311
   Sinning JM, 2011, EUR HEART J, V32, P2034, DOI 10.1093/eurheartj/ehq478
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Tarbell JM, 2010, CARDIOVASC RES, V87, P320, DOI 10.1093/cvr/cvq146
   Teoh NC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104376
   Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259
   Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8
   Villar J, 2011, MINERVA ANESTESIOL, V77, P647
   Villar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023914
   Villar J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-27
   Villar J, 2009, ANESTHESIOLOGY, V110, P1341, DOI 10.1097/ALN.0b013e31819fcba9
   Visovatti SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040829
   WEBB HH, 1974, AM REV RESPIR DIS, V110, P556
   Webster NR, 2009, BRIT J ANAESTH, V103, P70, DOI 10.1093/bja/aep128
   Wheway J, 2014, J IMMUNOL, V193, P3378, DOI 10.4049/jimmunol.1303431
   Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456
NR 50
TC 23
Z9 25
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD DEC
PY 2015
VL 43
IS 12
BP E551
EP E559
DI 10.1097/CCM.0000000000001280
PG 9
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CX1UT
UT WOS:000365481800002
PM 26308427
DA 2023-08-21
ER

PT J
AU Li, HP
   Qiu, HB
   Wang, HQ
AF Li, Hong-Peng
   Qiu, Haibo
   Wang, Hai-Qin
TI Effect of lipopolysaccharide on angiotensin II type 1 receptor
   expression and function in human pulmonary microvascular endothelial
   cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE angiotensin; ALI/ARDS; LPS 
ID LUNG INJURY; AT(1) RECEPTOR; AT1 RECEPTOR; RAT LUNG; ACTIVATION;
   ENDOCYTOSIS; ANTAGONISTS; APOPTOSIS; AT(2)
AB Lipopolysaccharides (LPSs) are an important initiation factor in acute respiratory distress syndrome. The aim of the present study was to investigate the effect of LPSs on the regulation of angiotensin II (Ang II) receptors in human pulmonary microvascular endothelial cells (HPMECs). HPMECs were treated with 0, 50, 100 or 200 ng/ml LPS and incubated for 4, 8, 12 or 16 h. The expression of Ang II type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R) was determined using reverse transcription-polymerase chain reaction and western blot analysis. The affinity to Ang II was measured using a radioligand binding assay. No AT2R expression was detected with or without LPS administration in HPMECs, and LPS treatment increased the expression level of AT1R. A time-dependent increase of AT1R transcription was observed in the 50 ng/ml group, while in the 100 and 200 ng/ml groups, the AT1R mRNA levels reached peak values at 4 h and remained unchanged. The protein level of AT1R increased significantly in a dose-dependent manner for each incubation time period. A time-dependent increase in the protein level was observed in the 50 and 100 ng/ml groups. As for the 200 ng/ml group, the level of AT1R reached a peak value at 8 h. Maximal binding (Bmax) significantly increased following LPS treatment and Bmax of the 50 ng/ml group exhibited a time-dependent increase. The Bmax of the 100 and 200 ng/ml groups reached peak values at 12 and 8 h, respectively, and decreased thereafter. The dissociation constant remained unchanged following LPS treatment. Thus, treatment with LPS increased AT1R expression and its Bmax to Ang II in HPMECs, however, did not alter the affinity of AT1R to Ang II.
C1 [Li, Hong-Peng; Qiu, Hai-Bo] Southeast Univ, Zhongda Hosp, Dept Crit Care Med, Nanjing 210009, Jiangsu, China.
C1 [Li, Hong-Peng] Yuncheng Cent Hosp, Dept Crit Care Med, Yuncheng 044000, Shanxi, China.
C1 [Wang, Hai-Qin] Fudan Univ, Sch Publ Hlth, Dept Hlth Serv Management, Shanghai 200433, China.
C3 Southeast University - China; Shanxi Medical University; Fudan
   University
RP Li, HP (corresponding author), Yuncheng Cent Hosp, Dept Crit Care Med, 3690 Hedong East St, Yuncheng 044000, Shanxi, Peoples R China.
EM liroc119@163.com; haiboq2000@yahoo.com.cn
RI Qiu, Haibo/AAS-9047-2021
OI Qiu, Haibo/0000-0001-8589-4717
FU National Natural Science Foundation of China [30640012]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 30640012).
CR Bechara RI, 2005, AM J PHYSIOL-LUNG C, V289, pL363, DOI 10.1152/ajplung.00141.2005
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Brasier AR, 2002, ARTERIOSCL THROM VAS, V22, P1257, DOI 10.1161/01.ATV.0000021412.56621.A2
   Chan LYY, 2005, J AM SOC NEPHROL, V16, P2306, DOI 10.1681/ASN.2004121117
   Dincer HE, 2001, AM J PHYSIOL-LUNG C, V281, pL624, DOI 10.1152/ajplung.2001.281.3.L624
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1
   IDELL S, 1987, CHEST, V91, P52, DOI 10.1378/chest.91.1.52
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Li DY, 1999, AM J PHYSIOL-HEART C, V276, pH786, DOI 10.1152/ajpheart.1999.276.3.H786
   Li H, 2007, INT J RESP, V27, P1761
   Li JS, 1998, HYPERTENSION, V31, P487, DOI 10.1161/01.HYP.31.1.487
   Li JY, 1999, ENDOCRINOLOGY, V140, P4988, DOI 10.1210/en.140.11.4988
   Li XP, 2004, J APPL PHYSIOL, V97, P1535, DOI 10.1152/japplphysiol.00519.2004
   Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215
   Marshall RP, 2004, AM J PHYSIOL-LUNG C, V286, pL156, DOI 10.1152/ajplung.00313.2002
   Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004
   Masaki H, 1998, J CLIN INVEST, V101, P527, DOI 10.1172/JCI1885
   Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759
   Raiden S, 2002, J PHARMACOL EXP THER, V303, P45, DOI 10.1124/jpet.102.037382
   Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266
   Sasamura H, 1997, HYPERTENSION, V30, P35, DOI 10.1161/01.HYP.30.1.35
   TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cellbio.9.1.129
   Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2
   Zhang H, 2006, J SURG RES, V134, P190, DOI 10.1016/j.jss.2006.01.026
NR 25
TC 5
Z9 6
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2015
VL 12
IS 6
BP 8289
EP 8293
DI 10.3892/mmr.2015.4481
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CZ6CT
UT WOS:000367189500064
PM 26497066
OA Bronze
DA 2023-08-21
ER

PT J
AU Liu, H
   Yu, X
   Yu, SL
   Kou, JP
AF Liu, Han
   Yu, Xiu
   Yu, Sulan
   Kou, Junping
TI Molecular mechanisms in lipopolysaccharide-induced pulmonary endothelial
   barrier dysfunction
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Review
DE ALI/ARDS; LPS; ECs/HPMECs/HUVECs/MPVECs; barrier dysfunction; hyperpermeability 
ID ACUTE LUNG INJURY; LIGHT-CHAIN KINASE; VASCULAR-PERMEABILITY;
   PARACELLULAR PATHWAY; ACTIVATION; PROTEINS; REPAIR; CELLS; TLR4;
   DISRUPTION
AB The confluent pulmonary endothelium plays an important role as a semi-permeable barrier between the vascular space of blood vessels and the underlying tissues, and it contributes to the maintenance of circulatory fluid homeostasis. Pulmonary endothelial barrier dysfunction is a pivotal early step in the development of a variety of high mortality diseases, such as acute lung injury (ALI). Endothelium barrier dysfunction in response to inflammatory or infectious mediators, including lipopolysacdiaride (LPS), is accompanied by invertible cell deformation and interendothelial gap formation. However, specific pharmacological therapies aiming at ameliorating pulmonary endothelial barrier function in patients are still lacking. A full understanding of the fundamental mechanisms that are involved in the regulation of pulmonary endothelial permeability is essential for the development of barrier protective therapeutic strategies. Therefore, this review summarizes several important molecular mechanisms involved in LPS-induced changes in pulmonary endothelial barrier function. As for barrierdisruption, the activation of myosin light chain kinase (MLCK), RhoA and tyrosine kinases; increase of calcium influx; and apoptosis of the endothelium lead to an elevation of lung endothelial permeability. Additionally, the activation of Rac1, Cdc42, protease activated receptor 1 (PAR1) and adenosine receptors (ARs), as well as the increase of cyclic AMP and sphingosine-1 -phosphate (SIP) content, protect against LPS-induced lung endothelial barrier dysfunction. Furthermore, current regulatory factors and strategies against the development of LPS-induced lung endothelial hyper-permeability are discussed. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Liu, Han; Yu, Xiu; Yu, Sulan; Kou, Junping] China Pharmaceut Univ, Jiangsu Key Lab TCM Evaluat & Translat Res, State Key Lab Nat Prod, Dept Complex Prescript TCM, Nanjing 211198, Jiangsu, China.
C3 China Pharmaceutical University
RP Kou, JP (corresponding author), China Pharmaceut Univ, Jiangsu Key Lab TCM Evaluat & Translat Res, State Key Lab Nat Prod, Dept Complex Prescript TCM, 639 Longmian Rd, Nanjing 211198, Jiangsu, Peoples R China.
EM junpingkou@cpu.edu.cn
FU National Natural Science Foundation of China [81274131]; Program for
   Excellent Scientific and Technological Innovation Team of Jiangsu Higher
   Education; Priority Academic Program Development of Jiangsu Higher
   Education Institutions
FX The present research was supported by the National Natural Science
   Foundation of China (No. 81274131), 2011' Program for Excellent
   Scientific and Technological Innovation Team of Jiangsu Higher
   Education, a Project Funded by the Priority Academic Program Development
   of Jiangsu Higher Education Institutions. The authors declared no
   disclosures.
CR Anjum F, 2012, AM J RESP CELL MOL, V47, P94, DOI 10.1165/rcmb.2010-0458OC
   Antonov A, 2008, AM J RESP CELL MOL, V39, P551, DOI 10.1165/rcmb.2007-0324OC
   Aulakh GK, 2014, AM J PHYSIOL-LUNG C, V306, pL58, DOI 10.1152/ajplung.00368.2012
   Barabutis N, 2015, AM J PHYSIOL-LUNG C, V308, pL776, DOI 10.1152/ajplung.00334.2014
   Barabutis N, 2013, AM J PHYSIOL-LUNG C, V304, pL883, DOI 10.1152/ajplung.00419.2012
   Berdyshev EV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016571
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Birukova AA, 2010, MICROVASC RES, V79, P128, DOI 10.1016/j.mvr.2009.11.007
   Bogatcheva NV, 2011, J CELL PHYSIOL, V226, P3132, DOI 10.1002/jcp.22669
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324
   Bosmann M, 2014, EXPERT OPIN THER TAR, V18, P703, DOI 10.1517/14728222.2014.902938
   Chen BX, 2015, MOL PHARMACOL, V88, P95, DOI 10.1124/mol.114.096446
   Chichger H, 2015, FASEB J, V29, P868, DOI 10.1096/fj.14-257212
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Cioffi DL, 2010, ADV EXP MED BIOL, V661, P137, DOI 10.1007/978-1-60761-500-2_9
   Damarla M, 2014, AM J RESP CELL MOL, V50, P932, DOI 10.1165/rcmb.2013-0361OC
   DebRoy A, 2014, J BIOL CHEM, V289, P24188, DOI 10.1074/jbc.M114.570051
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Duluc L, 2014, CELL TISSUE RES, V355, P675, DOI 10.1007/s00441-014-1805-0
   Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA
   Esquibies AE, 2008, PEDIATR RES, V63, P20, DOI 10.1203/PDR.0b013e31815b4857
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   Gong P, 2008, J BIOL CHEM, V283, P13437, DOI 10.1074/jbc.M707986200
   Gonzales JN, 2014, AM J PHYSIOL-LUNG C, V306, pL497, DOI 10.1152/ajplung.00086.2013
   Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
   Gowda S, 2011, AM J PHYSIOL-LUNG C, V300, pL430, DOI 10.1152/ajplung.00208.2010
   Gross CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119918
   Gulino-Debrac D, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24180
   Han JY, 2013, BLOOD, V122, P4140, DOI 10.1182/blood-2013-03-491423
   Harari OA, 2006, CIRC RES, V98, P1134, DOI 10.1161/01.RES.0000220105.85182.28
   Hu GC, 2008, CHEM-BIOL INTERACT, V171, P177, DOI 10.1016/j.cbi.2007.08.006
   Huang XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044301
   Jian MY, 2013, AM J PHYSIOL-LUNG C, V305, pL844, DOI 10.1152/ajplung.00173.2013
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Koh H, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-60
   Kratzer E, 2012, AM J RESP CELL MOL, V47, P688, DOI 10.1165/rcmb.2012-0161OC
   Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112
   Lamothe B, 2008, J BIOL CHEM, V283, P24871, DOI 10.1074/jbc.M802749200
   Leng Yu-Xin, 2014, World J Crit Care Med, V3, P34, DOI 10.5492/wjccm.v3.i1.34
   Liu AG, 2012, J BIOL CHEM, V287, P16132, DOI 10.1074/jbc.M111.310102
   Mambetsariev Y. T. T. W. Isa, 2014, PLOS ONE, V9
   Meng FY, 2015, AM J PHYSIOL-LUNG C, V308, pL452, DOI 10.1152/ajplung.00170.2014
   Mirza MK, 2010, J EXP MED, V207, P1675, DOI 10.1084/jem.20091857
   Muller-Redetzky HC, 2014, CELL TISSUE RES, V355, P657, DOI 10.1007/s00441-014-1821-0
   Ngamsri KC, 2010, J IMMUNOL, V185, P4374, DOI 10.4049/jimmunol.1000433
   Plociennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018-014-1762-5
   Popoff MR, 2009, BBA-BIOMEMBRANES, V1788, P797, DOI 10.1016/j.bbamem.2009.01.011
   Rafikov R, 2014, J BIOL CHEM, V289, P4710, DOI 10.1074/jbc.M114.547596
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254
   Rigor RR, 2013, MED RES REV, V33, P911, DOI 10.1002/med.21270
   Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597
   Sadok A., 2014, SMALL GTPASES, V5
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V300, pL667, DOI 10.1152/ajplung.00433.2010
   Schick MA, 2012, J PHYSIOL-LONDON, V590, P2693, DOI 10.1113/jphysiol.2012.232116
   Sen P, 2011, BLOOD, V117, P3199, DOI 10.1182/blood-2010-09-310706
   Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144
   Su G, 2012, AM J RESP CRIT CARE, V185, P58, DOI 10.1164/rccm.201108-1381OC
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Sun XG, 2012, AM J RESP CELL MOL, V47, P628, DOI 10.1165/rcmb.2012-0048OC
   Sundaram J, 2014, J THROMB HAEMOST, V12, P690, DOI 10.1111/jth.12532
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Umapathy NS, 2010, J CELL PHYSIOL, V223, P215, DOI 10.1002/jcp.22029
   van Hooren KWEM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091346
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Villalta PC, 2013, PULM CIRC, V3, P802, DOI 10.1086/674765
   Vogel SM, 2012, COMPR PHYSIOL, V2, P449, DOI 10.1002/cphy.c100006
   von Dossow-Hanfstingl Vera, 2012, Anesthesiol Clin, V30, P629, DOI 10.1016/j.anclin.2012.08.008
   Wagner R, 2010, AM J PHYSIOL-LUNG C, V299, pL502, DOI 10.1152/ajplung.00083.2010
   Wu F, 2014, AM J PHYSIOL-LUNG C, V307, pL987, DOI 10.1152/ajplung.00063.2014
   Xie WL, 2013, LAB INVEST, V93, P991, DOI 10.1038/labinvest.2013.80
   Xing JJ, 2013, AM J PATHOL, V182, P1021, DOI 10.1016/j.ajpath.2012.11.022
   Xu Q, 2015, PLOS ONE, V10
   Yao HY, 2011, BBA-GEN SUBJECTS, V1810, P666, DOI 10.1016/j.bbagen.2011.03.020
   Yu Y, 2012, FEBS J, V279, P1485, DOI 10.1111/j.1742-4658.2012.08541.x
   Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7
   Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162
   Zhang Y, 2014, AM J PHYSIOL-GASTR L, V306, pG289, DOI 10.1152/ajpgi.00168.2013
   Zhao YDD, 2014, STEM CELLS, V32, P1855, DOI 10.1002/stem.1690
   Zhao YDD, 2009, CIRC RES, V105, P696, DOI 10.1161/CIRCRESAHA.109.199778
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
   Zhao YT, 2011, AM J RESP CELL MOL, V45, P426, DOI 10.1165/rcmb.2010-0422OC
   Zhou ZD, 2013, SURGERY, V154, P621, DOI 10.1016/j.surg.2013.04.009
NR 88
TC 65
Z9 75
U1 0
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2015
VL 29
IS 2
BP 937
EP 946
DI 10.1016/j.intimp.2015.10.010
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA CY9ZL
UT WOS:000366764800089
PM 26462590
DA 2023-08-21
ER

PT J
AU Meliton, A
   Meng, FY
   Tian, YF
   Shah, AA
   Birukova, AA
   Birukov, KG
AF Meliton, Angelo Y.
   Meng, Fanyong
   Tian, Yufeng
   Shah, Alok A.
   Birukova, Anna A.
   Birukov, Konstantin G.
TI Role of Krev Interaction Trapped-1 in Prostacyclin- Induced Protection
   against Lung Vascular Permeability Induced by Excessive Mechanical
   Forces and Thrombin Receptor Activating Peptide 6
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE cyclic stretch; ventilator-induced lung injury; KRIT1; Rho/RhoA; Rap1 
ID CEREBRAL CAVERNOUS MALFORMATIONS; ENDOTHELIAL BARRIER DYSFUNCTION;
   TGF-BETA ACTIVATION; OXIDIZED PHOSPHOLIPIDS; CYCLIC STRETCH;
   MICROVASCULAR PERMEABILITY; SIGNALING PATHWAY; RHOA ACTIVATION; CELL
   JUNCTIONS; INTEGRITY
AB Mechanisms of vascular endothelial cell (EC) barrier regulation during acute lung injury (ALI) or other pathologies associated with increased vascular leakiness are an active area of research. Adaptor protein krev interaction trapped-1 (KRIT1) participates in angiogenesis, lumen formation, and stabilization of EC adherens junctions (AJs) in mature vasculature. We tested a role of KRIT1 in the regulation of Rho-GTPase signaling induced by mechanical stimulation and barrier dysfunction relevant to ventilator-induced lung injury and investigated KRIT1 involvement in EC barrier protection by prostacyclin (PC). PC stimulated Ras-related protein 1 (Rap1)-dependent association of KRIT1 with vascular endothelial cadherin at AJs, with KRIT1-dependent cortical cytoskeletal remodeling leading to EC barrier enhancement. KRIT1 knockdown exacerbated Rho-GTPase activation and EC barrier disruption induced by pathologic 18% cyclic stretch and thrombin receptor activating peptide (TRAP) 6 and attenuated the protective effects of PC. In the two-hit model of ALI caused by high tidal volume (HTV) mechanical ventilation and TRAP6 injection, KRIT1 functional deficiency in KRIT11/2 mice increased basal lung vascular leak and augmented vascular leak and lung injury caused by exposure to HTV andTRAP6. Down-regulationofKRIT1 also diminished the protective effects of PC against TRAP6/HTV-induced lung injury. These results demonstrate a KRIT1-dependent mechanism of vascular EC barrier control in basal conditions and in the two-hit model of ALI caused by excessivemechanical forces and TRAP6 via negative regulation of Rho activity and enhancement of cell junctions. We also conclude that the stimulation of the Rap1-KRIT1 signaling module is a major mechanism of vascular endothelial barrier protection by PC in the injured lung.
C1 Univ Chicago, Lung Injury Ctr, Chicago, IL 60637, United States.
C1 Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637, United States.
C3 University of Chicago; University of Chicago
RP Birukov, KG (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, 5841 S Maryland Ave,Off N-611, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022
FU National Heart, Lung, and Blood Institutes [HL87823, HL076259, HL107920]
FX This work was supported by National Heart, Lung, and Blood Institutes
   grants HL87823, HL076259, and HL107920.
CR Awad IA, 2005, SURG NEUROL, V63, P317, DOI 10.1016/j.surneu.2004.12.032
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2012, J CELL PHYSIOL, V227, P1883, DOI 10.1002/jcp.22916
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2011, J CELL PHYSIOL, V226, P2052, DOI 10.1002/jcp.22543
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002
   Birukova AA, 2010, MICROVASC RES, V79, P128, DOI 10.1016/j.mvr.2009.11.007
   Birukova AA, 2009, J APPL PHYSIOL, V107, P1900, DOI 10.1152/japplphysiol.00462.2009
   Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006
   Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197
   Denier C, 2002, MECH DEVELOP, V117, P363, DOI 10.1016/S0925-4773(02)00209-5
   Desai LP, 2007, AM J PHYSIOL-LUNG C, V293, pL769, DOI 10.1152/ajplung.00127.2007
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867
   Fisher OS, 2014, CELL MOL LIFE SCI, V71, P1881, DOI 10.1007/s00018-013-1532-9
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Gawlak G, 2014, FASEB J, V28, P3249, DOI 10.1096/fj.13-245142
   GEE MH, 1987, CIRC RES, V61, P420, DOI 10.1161/01.RES.61.3.420
   Guilluy C, 2011, NAT CELL BIOL, V13, P722, DOI 10.1038/ncb2254
   Guo F, 2012, MOL IMMUNOL, V50, P98, DOI 10.1016/j.molimm.2011.12.009
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Howard Luke S G E, 2005, Paediatr Respir Rev, V6, P285, DOI 10.1016/j.prrv.2005.09.006
   Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183
   Kleaveland B, 2009, NAT MED, V15, P169, DOI 10.1038/nm.1918
   Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080
   Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021
   Lampugnani MG, 2010, J CELL SCI, V123, P1073, DOI 10.1242/jcs.059329
   Liu JJ, 2011, MOL BIOL CELL, V22, P2509, DOI 10.1091/mbc.E11-02-0157
   Liu WZ, 2013, MOL CELL, V49, P719, DOI 10.1016/j.molcel.2012.12.005
   Lu Q, 2006, J APPL PHYSIOL, V101, P375, DOI 10.1152/japplphysiol.01515.2005
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002
   Schwartz MA, 2008, CURR OPIN CELL BIOL, V20, P551, DOI 10.1016/j.ceb.2008.05.005
   Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268
   Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001
   Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086
   Stockton RA, 2010, J EXP MED, V207, P881, DOI 10.1084/jem.20091258
   Storck J, 1996, THROMB RES, V81, P121, DOI 10.1016/0049-3848(95)00220-0
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Ueno Y, 1997, PROSTAGLANDINS, V53, P279, DOI 10.1016/S0090-6980(97)89601-3
   Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126
   Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783
   Whitehead KJ, 2004, DEVELOPMENT, V131, P1437, DOI 10.1242/dev.01036
   Xu MY, 2009, AM J PATHOL, V174, P1264, DOI 10.2353/ajpath.2009.080160
   Zawistowski JS, 2002, HUM MOL GENET, V11, P389, DOI 10.1093/hmg/11.4.389
NR 53
TC 13
Z9 13
U1 0
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD DEC
PY 2015
VL 53
IS 6
BP 834
EP 843
DI 10.1165/rcmb.2014-0376OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA DB3NW
UT WOS:000368419400009
PM 25923142
OA Green Published
DA 2023-08-21
ER

PT J
AU Rizzo, AN
   Sammani, S
   Esquinca, AE
   Jacobson, JR
   Garcia, JGN
   Letsiou, E
   Dudek, SM
AF Rizzo, Alicia N.
   Sammani, Saad
   Esquinca, Adilene E.
   Jacobson, Jeffrey R.
   Garcia, Joe G. N.
   Letsiou, Eleftheria
   Dudek, Steven M.
TI Imatinib attenuates inflammation and vascular leak in a clinically
   relevant two-hit model of acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; imatinib; ECs/HPMECs/HUVECs/MPVECs; LPS; mechanical ventilation; NF-kappa B 
ID NF-KAPPA-B; TYROSINE KINASE INHIBITORS; ACTIVATED PROTEIN-KINASE;
   LIGHT-CHAIN KINASE; C-ABL; MEDICAL PROGRESS; MESYLATE; NILOTINIB;
   REVERSAL; CELLS
AB Acute lung injury/acute respiratory distress syndrome (ALI/ARDS), an illness characterized by life-threatening vascular leak, is a significant cause of morbidity and mortality in critically ill patients. Recent preclinical studies and clinical observations have suggested a potential role for the chemotherapeutic agent imatinib in restoring vascular integrity. Our prior work demonstrates differential effects of imatinib in mouse models of ALI, namely attenuation of LPS-induced lung injury but exacerbation of ventilator-induced lung injury (VILI). Because of the critical role of mechanical ventilation in the care of patients with ARDS, in the present study we pursued an assessment of the effectiveness of imatinib in a "two-hit" model of ALI caused by combined LPS and VILI. Imatinib significantly decreased bronchoalveolar lavage protein, total cells, neutrophils, and TNF-alpha levels in mice exposed to LPS plus VILI, indicating that it attenuates ALI in this clinically relevant model. In subsequent experiments focusing on its protective role in LPS-induced lung injury, imatinib attenuated ALI when given 4 h after LPS, suggesting potential therapeutic effectiveness when given after the onset of injury. Mechanistic studies in mouse lung tissue and human lung endothelial cells revealed that imatinib inhibits LPS-induced NF-kappa B expression and activation. Overall, these results further characterize the therapeutic potential of imatinib against inflammatory vascular leak.
C1 [Rizzo, Alicia N.; Sammani, Saad; Esquinca, Adilene E.; Jacobson, Jeffrey R.; Letsiou, Eleftheria; Dudek, Steven M.] Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60612, United States.
C1 [Rizzo, Alicia N.; Dudek, Steven M.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Garcia, Joe G. N.] Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona Health Sciences
RP Dudek, SM (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, CSB 915,840 S Wood St, Chicago, IL 60612 USA.
EM sdudek@uic.edu
RI Garcia, Joe GN/E-8862-2010
OI Rizzo, Alicia/0000-0001-9289-4635
FU NHLBI/NIH [HL058064, F30HL121982, AHA 14PRE18860021]; University of
   Illinois institutional funds
FX This work was supported by NHLBI/NIH HL058064 (J. Garcia), F30HL121982
   (A. Rizzo), AHA 14PRE18860021 (A. Rizzo), and University of Illinois
   institutional funds.
CR Adzemovic MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056586
   Akashi N, 2011, MOD RHEUMATOL, V21, P267, DOI 10.1007/s10165-010-0392-5
   Aman J, 2013, AM J RESP CRIT CARE, V188, P1171, DOI 10.1164/rccm.201301-0136LE
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200
   Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200
   Carnevale-Schianca F, 2011, J CLIN ONCOL, V29, pE691, DOI 10.1200/JCO.2011.35.6733
   Chen A, 2011, MOL CELL BIOL, V31, P3445, DOI 10.1128/MCB.05383-11
   Chislock EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085231
   Chislock EM, 2013, P NATL ACAD SCI USA, V110, P12432, DOI 10.1073/pnas.1304188110
   Ciarcia R, 2012, J CELL PHYSIOL, V227, P2798, DOI 10.1002/jcp.23029
   COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214
   Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603
   de Menorval MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041733
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Garcia AN, 2011, METHODS MOL BIOL, V763, P333, DOI 10.1007/978-1-61779-191-8_23
   Goldman JL, 2014, PULM CIRC, V4, P280, DOI 10.1086/675991
   Goldsby R, 2002, J PEDIAT HEMATOL ONC, V24, P694, DOI 10.1097/00043426-200211000-00020
   Hagerkvist R, 2007, FASEB J, V21, P618, DOI 10.1096/fj.06-6910com
   Held HD, 2001, AM J RESP CRIT CARE, V163, P711, DOI 10.1164/ajrccm.163.3.2003001
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Kim IK, 2013, CRIT CARE, V17, DOI 10.1186/cc12786
   Ko YA, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-69
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Li LF, 2004, AM J RESP CRIT CARE, V169, P518, DOI 10.1164/rccm.200305-660OC
   Lin SM, 2007, SHOCK, V28, P453, DOI 10.1097/shk.0b013e3180487fb5
   Liu YY, 2009, TRANSL RES, V154, P228, DOI 10.1016/j.trsl.2009.06.006
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Mokhtari D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024831
   Ning QM, 2007, MED HYPOTHESES, V68, P356, DOI 10.1016/j.mehy.2006.06.053
   Overbeek MJ, 2008, EUR RESPIR J, V32, P232, DOI 10.1183/09031936.00054407
   Peng B, 2005, CLIN PHARMACOKINET, V44, P879, DOI 10.2165/00003088-200544090-00001
   Pugin J, 2003, CRIT CARE MED, V31, pS200, DOI 10.1097/01.CCM.0000057844.31307.ED
   Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061
   Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353
   Scheinfeld Noah, 2006, J Drugs Dermatol, V5, P228
   Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838
   Shu YS, 2014, J TRAUMA ACUTE CARE, V76, P1417, DOI 10.1097/TA.0000000000000229
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Stephens RS, 2014, AM J PHYSIOL-CELL PH, V306, pC559, DOI 10.1152/ajpcell.00375.2012
   Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787
   Tan SY, 2011, J PHARM PHARMACOL, V63, P918, DOI 10.1111/j.2042-7158.2011.01296.x
   Uhlig U, 2002, EUR RESPIR J, V20, P946, DOI 10.1183/09031936.02.01612001
   Wadgaonkar R, 2005, J CELL BIOCHEM, V94, P351, DOI 10.1002/jcb.20250
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wolf AM, 2005, P NATL ACAD SCI USA, V102, P13622, DOI 10.1073/pnas.0501758102
NR 52
TC 62
Z9 66
U1 0
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC 1
PY 2015
VL 309
IS 11
BP L1294
EP L1304
DI 10.1152/ajplung.00031.2015
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CX7JF
UT WOS:000365877300005
PM 26432864
OA Green Submitted, Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Shimizu, Y
   Camp, SM
   Sun, XG
   Zhou, T
   Wang, T
   Garcia, JGN
AF Shimizu, Yuka
   Camp, Sara M.
   Sun, Xiaoguang
   Zhou, Tong
   Wang, Ting
   Garcia, Joe G. N.
TI Sp1-mediated nonmuscle myosin light chain kinase expression and enhanced
   activity in vascular endothelial growth factor-induced vascular
   permeability
SO PULMONARY CIRCULATION
LA English
DT Article
DE VEGF/VEGFA; MYLK; MLCK; Sp1; promoter; transcription factor; ECs/HPMECs/HUVECs/MPVECs; permeability; ALI/ARDS 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; CELL BARRIER
   ENHANCEMENT; FIBRIN-GEL INVESTMENT; SPHINGOSINE 1-PHOSPHATE; FUNCTIONAL
   PROMOTER; ASTHMATIC INFLAMMATION; MECHANICAL-STRESS; GAP FORMATION;
   CONFER RISK
AB Despite the important role played by the nonmuscle isoform of myosin light chain kinase (nmMLCK) in vascular barrier regulation and the implication of both nmMLCK and vascular endothelial growth factor (VEGF) in the pathogenesis of acute respiratory distress syndrome (ARDS), the role played by nmMLCK in VEGF-induced vascular permeability is poorly understood. In this study, the role played by nmMLCK in VEGF-induced vascular hyperpermeability was investigated. Human lung endothelial cell barrier integrity in response to VEGF is examined in both the absence and the presence of nmMLCK small interfering RNAs. Levels of nmMLCK messenger RNA (mRNA), protein, and promoter activity expression were monitored after VEGF stimulation in lung endothelial cells. nmMYLK promoter activity was assessed using nmMYLK promoter luciferase reporter constructs with a series of nested deletions. nmMYLK transcriptional regulation was further characterized by examination of a key transcriptional factor. nmMLCK plays an important role in VEGF-induced permeability. We found that activation of the VEGF signaling pathway in lung endothelial cells increases MYLK gene product at both mRNA and protein levels. Increased nmMLCK mRNA and protein expression is a result of increased nmMYLK promoter activity, regulated in part by binding of the Sp1 transcription factor on triggering by the VEGF signaling pathway. Taken together, these findings suggest that MYLK is an important ARDS candidate gene and a therapeutic target that is highly influenced by excessive VEGF concentrations in the inflamed lung.
C1 Univ Arizona, Dept Med, Tucson, AZ 85721, United States.
C1 Univ Arizona, Resp Ctr, Tucson, AZ 85721, United States.
C3 University of Arizona; University of Arizona
RP Garcia, JGN (corresponding author), Univ Arizona, Univ Arizona Hlth Sci, 1295 North Martin Ave,POB 210202, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
RI SUN, XIAOGUANG/ACA-5558-2022
FU National Institutes of Health/National Heart, Lung, and Blood Institute
   [P01-HL058064, R01-HL091889]
FX This work was supported by National Institutes of Health/National Heart,
   Lung, and Blood Institute grants P01-HL058064 (JGNG) and R01-HL091889
   (JGNG and TW).
CR Azamfirei L, 2010, MINERVA ANESTESIOL, V76, P609
   Barratt S, 2014, RESPIRATION, V87, P329, DOI 10.1159/000356034
   Becker PM, 2001, AM J PHYSIOL-LUNG C, V281, pL1500, DOI 10.1152/ajplung.2001.281.6.L1500
   BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211
   Brown LM, 2011, AM J SURG, V201, P486, DOI 10.1016/j.amjsurg.2010.02.003
   Brown M, 2010, MICROVASC RES, V80, P75, DOI 10.1016/j.mvr.2009.12.010
   Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Christie JD, 2008, CRIT CARE MED, V36, P2794, DOI 10.1097/CCM.0b013e318186b843
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459
   DVORAK HF, 1979, J IMMUNOL, V122, P166
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Feltis BN, 2006, AM J RESP CRIT CARE, V173, P1201, DOI 10.1164/rccm.200507-1105OC
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Flores C, 2008, TRANSL RES, V152, P11, DOI 10.1016/j.trsl.2008.05.006
   Flores C, 2007, GENET EPIDEMIOL, V31, P296, DOI 10.1002/gepi.20210
   Frech K, 1997, J MOL BIOL, V270, P674, DOI 10.1006/jmbi.1997.1140
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Gao L, 2007, J ALLERGY CLIN IMMUN, V119, P1111, DOI 10.1016/j.jaci.2007.03.019
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1995, J INVEST MED, V43, P117
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   GOLDBLUM SE, 1989, INFECT IMMUN, V57, P1218, DOI 10.1128/IAI.57.4.1218-1226.1989
   Grigoryev DN, 2004, CRIT CARE, V8, P440, DOI 10.1186/cc2901
   Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005
   Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885
   Klingenhoff A, 1999, BIOINFORMATICS, V15, P180, DOI 10.1093/bioinformatics/15.3.180
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Ma SF, 2011, AM J RESP CELL MOL, V45, P1203, DOI 10.1165/rcmb.2011-0179OC
   Ma SF, 2008, GENET EPIDEMIOL, V32, P757, DOI 10.1002/gepi.20343
   MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007
   McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   Mirzapoiazova T, 2006, AM J PHYSIOL-LUNG C, V291, pL718, DOI 10.1152/ajplung.00014.2006
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Mitra S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100169
   Moitra J, 2008, TRANSL RES, V151, P141, DOI 10.1016/j.trsl.2007.12.008
   MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995
   Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001
   PENN MS, 1991, CIRC RES, V68, P1259, DOI 10.1161/01.RES.68.5.1259
   Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com
   Rossi JL, 2007, AM J PHYSIOL-LUNG C, V292, pL1327, DOI 10.1152/ajplung.00380.2006
   Simon BA, 2006, AM J PHYSIOL-LUNG C, V291, pL851, DOI 10.1152/ajplung.00463.2005
   Sun XG, 2014, AM J RESP CELL MOL, V51, P660, DOI 10.1165/rcmb.2014-0117OC
   Sun XG, 2013, AM J PHYSIOL-LUNG C, V305, pL467, DOI 10.1152/ajplung.00010.2013
   Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071
   Wadgaonkar R, 2005, J CELL BIOCHEM, V94, P351, DOI 10.1002/jcb.20250
   Wang T, 2015, EUR J HUM GENET, V23, P874, DOI 10.1038/ejhg.2014.201
   Wang T, 2014, AM J RESP CELL MOL, V50, P1129, DOI 10.1165/rcmb.2013-0434OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074
   Zhai R, 2007, THORAX, V62, P718, DOI 10.1136/thx.2006.069393
NR 59
TC 13
Z9 14
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD DEC
PY 2015
VL 5
IS 4
BP 707
EP 715
DI 10.1086/684124
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA DK9BN
UT WOS:000375225000012
PM 26697178
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Zhang, XJ
   Li, JJ
   Li, CF
   Li, YH
   Zhu, WN
   Zhou, HM
   Ding, ZN
   Liu, L
AF Zhang, Xiaojin
   Li, Jingjin
   Li, Chuanfu
   Li, Yuehua
   Zhu, Weina
   Zhou, Hongmei
   Ding, Zhengnian
   Liu, Li
TI HSPA12B attenuates acute lung injury during endotoxemia in mice
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE ALI/ARDS; HSPA12B; endotoxemia; vascular leakage; Inflammation 
ID CARDIAC DYSFUNCTION; INFLAMMATORY RESPONSE; EXPERIMENTAL-MODEL;
   EXPRESSION; SEPSIS; CELLS; GLUTAMINE; MORTALITY; ICAM-1; TRANSMIGRATION
AB Acute lung injury (ALI) is a critical manifestation of sepsis/septic shock. Heat shock protein A12B (HSPA12B), an endothelial cell-expressed heat shock protein, shows a negative regulation of lipopolysaccharide (LPS)-induced inflammation in myocardium and endothelial cells. However, it is unclear whether HSPA12B exerts protective effects against ALI during sepsis/septic shock. In this study, we treated HSPA12B transgenic mice (Tg) and wild type littermates (WT) with LPS for 6 h to induce endotoxemia. LPS treatment significantly caused pulmonary injuries as evidenced by microarchitecture destruction, vascular leakage and neutrophil recruitment in lungs of WT mice. However, the LPS-induced pulmonary injuries were significantly attenuated in Tg mice. Moreover, the LPS-induced activation of extracellular signal-regulated kinases (ERKs) and upregulation of intercellular adhesion molecule-1 (ICAM-1) and Cyclooxygenase-2 (Cox-2) were inhibited in Tg lungs compared with that in WT mice. Additionally, Tg lungs showed a significant lower level of vascular endothelial growth factor (VEGF) compared with WT mice. Our results demonstrate a pulmonary protective effect of HSPA12B against endotoxin challenge, which indicates management of HSPA12B expression could serve as a potential therapeutic target for ALI during sepsis/septic shock. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Xiaojin; Zhu, Weina; Zhou, Hongmei; Liu, Li] Nanjing Med Univ, Affiliated Hosp 1, Dept Geriatr, Nanjing 210029, Jiangsu, China.
C1 [Li, Jingjin; Ding, Zhengnian] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Jiangsu, China.
C1 [Li, Chuanfu] E Tennessee State Univ, Dept Surg, Johnson City, TN 37614, United States.
C1 [Li, Yuehua] Nanjing Med Univ, Dept Pathophysiol, Nanjing 210029, Jiangsu, China.
C3 Nanjing Medical University; Nanjing Medical University; East Tennessee
   State University; Nanjing Medical University
RP Liu, L (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Geriatr, Nanjing 210029, Jiangsu, Peoples R China.
EM liuli@njmu.edu.cn
RI li, yue/HSF-7296-2023; liu, liu/GXF-0906-2022; liu, li/HGC-0900-2022;
   li, yueyue/IVH-9846-2023; liu, liu/HPD-9677-2023; liu,
   liu/HTR-2254-2023; LI, Yue/GRS-8071-2022
OI Ding, zhengnian/0000-0003-4108-6034; Zhang, Xiaojin/0000-0002-2410-0044
FU National Natural Science Foundation of China [81370260, 81371450,
   81170321]; Jiangsu Province's Outstanding Medical Academic Leader
   program [LJ201124]; Priority Academic Program Development of Jiangsu
   Higher Education Institutions (PAPD); Collaborative Innovation Center
   for Cardiovascular Disease Translational Medicine
FX This work was supported by the National Natural Science Foundation of
   China (81370260, 81371450, 81170321), by Jiangsu Province's Outstanding
   Medical Academic Leader program (LJ201124), by Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD), and by a grant from Collaborative Innovation Center
   for Cardiovascular Disease Translational Medicine.
CR Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563
   Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117
   Bhandary YP, 2009, AM J RESP CRIT CARE, V179, P288, DOI 10.1164/rccm.200712-1787OC
   Bromberg Z, 2008, CRIT CARE MED, V36, P246, DOI 10.1097/01.CCM.0000295473.56522.EF
   Di Paola R, 2009, INT J IMMUNOPATH PH, V22, P937, DOI 10.1177/039463200902200409
   Edelman DA, 2007, J SURG RES, V140, P171, DOI 10.1016/j.jss.2006.12.560
   Ejima K, 2003, FASEB J, V17, P1325, DOI 10.1096/fj.02-1078fje
   Fan J, 1998, J IMMUNOL, V161, P440
   Giffard RG, 2008, ANESTHESIOLOGY, V109, P339, DOI 10.1097/ALN.0b013e31817f4ce0
   Han ZH, 2003, P NATL ACAD SCI USA, V100, P1256, DOI 10.1073/pnas.252764399
   Hu G, 2006, J CELL SCI, V119, P4117, DOI 10.1242/jcs.03179
   Jeong SJ, 2013, CRIT CARE, V17, DOI 10.1186/cc12742
   Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779
   Karmpaliotis D, 2002, AM J PHYSIOL-LUNG C, V283, pL585, DOI 10.1152/ajplung.00048.2002
   Koh Y, 1999, Respirology, V4, P325, DOI 10.1046/j.1440-1843.1999.00200.x
   Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679
   Kwon JY, 2007, ANN NY ACAD SCI, V1095, P513, DOI 10.1196/annals.1397.055
   Kwon WY, 2010, BRIT J NUTR, V103, P890, DOI 10.1017/S0007114509992509
   Lee JW, 2009, CRIT CARE, V13, DOI 10.1186/cc8171
   Li JJ, 2013, CARDIOVASC RES, V99, P674, DOI 10.1093/cvr/cvt139
   Liang C, 2013, J BIOMED RES, V27, P51, DOI 10.7555/JBR.27.20120048
   Liu K, 2008, J BIOL CHEM, V283, P9977, DOI 10.1074/jbc.M710257200
   Lomas JL, 2003, SHOCK, V19, P358, DOI 10.1097/00024382-200304000-00011
   Lomas-Neira J, 2006, AM J PHYSIOL-LUNG C, V290, pL51, DOI 10.1152/ajplung.00028.2005
   Ma YJ, 2013, BBA-MOL BASIS DIS, V1832, P57, DOI 10.1016/j.bbadis.2012.10.003
   Nakagomi T, 2004, AM J PATHOL, V165, P1279, DOI 10.1016/S0002-9440(10)63387-1
   Sarantos MR, 2008, J IMMUNOL, V181, P8660, DOI 10.4049/jimmunol.181.12.8660
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323
   Singleton KD, 2005, CRIT CARE MED, V33, P1206, DOI 10.1097/01.CCM.0000166357.10996.8A
   Singleton KD, 2006, AM J PHYSIOL-LUNG C, V290, pL956, DOI 10.1152/ajplung.00466.2005
   Singleton KD, 2007, AM J PHYSIOL-REG I, V292, pR1839, DOI 10.1152/ajpregu.00755.2006
   Steagall RJ, 2006, ARTERIOSCL THROM VAS, V26, P2012, DOI 10.1161/01.ATV.0000235720.61091.c7
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   van Griensven M, 2006, SHOCK, V25, P254, DOI 10.1097/01.shk.0000196497.49683.13
   VILLAR J, 1994, CRIT CARE MED, V22, P914
   Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100
   Weiss YG, 2002, J CLIN INVEST, V110, P801, DOI 10.1172/JCI200215888
   Weiss YG, 2007, CRIT CARE MED, V35, P2128, DOI 10.1097/01.CCM.0000278915.78030.74
   Wheeler DS, 2007, CRIT CARE MED, V35, P2226, DOI 10.1097/01.CCM.0000281463.22808.96
   Wischmeyer PE, 2009, AM J PHYSIOL-LUNG C, V296, pL286, DOI 10.1152/ajplung.00003.2009
   Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E
   Yang RK, 2009, CRIT CARE, V13, DOI 10.1186/cc7782
   You WJ, 2009, SHOCK, V32, P108, DOI 10.1097/SHK.0b013e318199165d
   Zhang HL, 2008, J IMMUNOL, V181, P4320, DOI 10.4049/jimmunol.181.6.4320
   Zhou HM, 2011, CARDIOVASC RES, V89, P109, DOI 10.1093/cvr/cvq268
NR 46
TC 7
Z9 9
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2015
VL 29
IS 2
BP 599
EP 606
DI 10.1016/j.intimp.2015.09.022
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA CY9ZL
UT WOS:000366764800046
PM 26428851
DA 2023-08-21
ER

PT J
AU Choi, S
   Camp, SM
   Dan, A
   Garcia, JGN
   Dudek, SM
   Leckband, DE
AF Choi, Sangwook
   Camp, Sara M.
   Dan, Arkaprava
   Garcia, Joe G. N.
   Dudek, Steven M.
   Leckband, Deborah E.
TI A genetic variant of cortactin linked to acute lung injury impairs
   lamellipodia dynamics and endothelial wound healing
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; endothelial wound healing; wound healing assay; cortactin 
ID CELL BARRIER ENHANCEMENT; SPHINGOSINE 1-PHOSPHATE; SOFT LITHOGRAPHY;
   ACTIN; PROMOTES; POLYMORPHISM; MIGRATION; RISK; CYTOSKELETON; MECHANISMS
AB Inflammatory mediators released in acute lung injury (ALI) trigger the disruption of interendothelial junctions, leading to loss of vascular barrier function, protein-rich pulmonary edema, and severe hypoxemia. Genetic signatures that predict patient recovery or disease progression are poorly defined, but recent genetic screening of ALI patients has identified an association between lung inflammatory disease and a single nucleotide polymorphism (SNP) in the gene for the actin-binding and barrier-regulatory protein cortactin. This study investigated the impact of this disease-linked cortactin variant on wound healing processes that may contribute to endothelial barrier restoration. A microfabricated platform was used to quantify wound healing in terms of gap closure speed, lamellipodia dynamics, and cell velocity. Overexpression of wild-type cortactin in endothelial cells (ECs) improved directional cell motility and enhanced lamellipodial protrusion length, resulting in enhanced gap closure rates. By contrast, the cortactin SNP impaired wound closure and cell locomotion, consistent with the observed reduction in lamellipodial protrusion length and persistence. Overexpression of the cortactin SNP in lung ECs mitigated the barrier-enhancing activity of sphingosine 1-phosphate. These findings suggest that this common cortactin variant may functionally contribute to ALI predisposition by impeding endothelial wound healing.
C1 [Choi, Sangwook; Dan, Arkaprava; Leckband, Deborah E.] Univ Illinois, Dept Biomol & Chem Engn, Urbana, IL 61801, United States.
C1 [Camp, Sara M.; Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ, United States.
C1 [Dudek, Steven M.] Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C1 [Leckband, Deborah E.] Univ Illinois, Dept Chem, Urbana, IL 61801, United States.
C3 University of Illinois System; University of Illinois Urbana-Champaign;
   University of Arizona; University of Illinois System; University of
   Illinois Urbana-Champaign
RP Leckband, DE (corresponding author), Univ Illinois, Dept Biomol & Chem Engn, 600 Mathews Ave, Urbana, IL 61801 USA.
EM leckband@illinois.edu
RI Garcia, Joe GN/E-8862-2010
FU National Institutes of Health [5RO1 GM-097443, R01 HL-88144, P01
   HL-58064]
FX This work was supported by National Institutes of Health Grants 5RO1
   GM-097443 (D. E. Leckband), R01 HL-88144 (S. M. Dudek), and P01 HL-58064
   (J. G. N. Garcia).
CR Anon E, 2012, P NATL ACAD SCI USA, V109, P10891, DOI 10.1073/pnas.1117814109
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   BEMENT WM, 1993, J CELL BIOL, V121, P565, DOI 10.1083/jcb.121.3.565
   Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043
   Chiang ET, 2011, TEXTBOOK OF PULMONARY VASCULAR DISEASE, P197, DOI 10.1007/978-0-387-87429-6_12
   Cordelieres FP, 2015, MANUAL TRACKING
   Csortos C, 2007, AM J PHYSIOL-LUNG C, V293, pL843, DOI 10.1152/ajplung.00120.2007
   DIMILLA PA, 1992, AICHE J, V38, P1092, DOI 10.1002/aic.690380712
   Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dudek SM, 2010, SINGLE NUCL POLYM HU, V181, pA1040
   Dudek SM, 2008, AM J RESP CRIT CARE, V177, pA844
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026
   Gong MN, 2004, CHEST, V125, P203, DOI 10.1378/chest.125.1.203
   GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799
   Gross SR, 2013, CELL ADHES MIGR, V7, P199, DOI 10.4161/cam.23176
   Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770
   Isenberg BC, 2009, BIOPHYS J, V97, P1313, DOI 10.1016/j.bpj.2009.06.021
   Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643
   Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586
   Lin Z, 2000, CLIN GENET, V58, P181, DOI 10.1034/j.1399-0004.2000.580305.x
   Lodish H., 1995, MOL CELL BIOL
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McDonald DM, 1999, MICROCIRCULATION, V6, P7
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4
   O'Keefe GE, 2002, J TRAUMA, V52, P817, DOI 10.1097/00005373-200205000-00001
   Pagano MaG., 2018, PRINCIPLES BIOSTATIS
   Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729
   Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234
   Ren G, 2009, CELL MOTIL CYTOSKEL, V66, P865, DOI 10.1002/cm.20380
   Schnoor M, 2011, J EXP MED, V208, P1721, DOI 10.1084/jem.20101920
   STRIETER RM, 1994, J INVEST MED, V42, P640
   Szulcek R, 2014, JOVE-J VIS EXP, DOI 10.3791/51300
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   TRANQUILLO RT, 1988, J CELL BIOL, V106, P303, DOI 10.1083/jcb.106.2.303
   Turnage R H, 1994, New Horiz, V2, P463
   Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7
   Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29
   Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335
NR 46
TC 11
Z9 11
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD NOV 1
PY 2015
VL 309
IS 9
BP L983
EP L994
DI 10.1152/ajplung.00062.2015
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CV2PD
UT WOS:000364097800006
PM 26361873
OA Green Published
DA 2023-08-21
ER

PT J
AU Kawasaki, T
   Nishiwaki, T
   Sekine, A
   Nishimura, R
   Suda, R
   Urushibara, T
   Suzuki, T
   Takayanagi, S
   Terada, J
   Sakao, S
   Tatsumi, K
AF Kawasaki, Takeshi
   Nishiwaki, Tetsu
   Sekine, Ayumi
   Nishimura, Rintaro
   Suda, Rika
   Urushibara, Takashi
   Suzuki, Toshio
   Takayanagi, Shin
   Terada, Jiro
   Sakao, Seiichiro
   Tatsumi, Koichiro
TI Vascular Repair by Tissue-Resident Endothelial Progenitor Cells in
   Endotoxin-Induced Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; endothelial progenitor cells; vascular regeneration; endothelial repair; LPS 
ID POSTNATAL NEOVASCULARIZATION; BACTERIAL PNEUMONIA; SIGNALING PROMOTES;
   OXIDATIVE STRESS; POPULATION; CONTRIBUTE; SURVIVAL; MECHANISMS;
   EXPRESSION
AB Vascular disruption is one of the pathological hallmarks in acute respiratory distress syndrome. Bone marrow (BM)-derived circulating endothelial progenitor cells (EPCs) and lung tissue-resident EPCs have been considered to play a pivotal role in pulmonary vascular repair; however, which population is predominant in local pulmonary vasculogenesis remains to be clarified. We therefore examined the origin of EPCs participating in the regenerative process of pulmonary vascular endothelial cells (PVECs) in experimental acute respiratory distress syndrome. Lung samples from mice administered LPS intratracheally were investigated for cell dynamics and EPC functions. Quantitative flow cytometric analysis demonstrated that the number of PVECs decreased by roughly 20% on Day 1 and then recovered on Day 7 of LPS challenge. Bromodeoxyuridine-incorporation assays and immunofluorescence microscopy demonstrated that proliferating PVECs preferentially located in the capillary vessels. Experiments using BM chimera mice revealed that most of the regenerating PVECs were tissue-resident cells, and BM-derived cells hardly engrafted as PVECs. The population of circulating putative phenotypical EPCs decreased during the first week after LPS challenge. The regenerating PVECs were characterized by high colony-forming and vasculogenic capacities, intracellular reactive oxygen species scavenging and aldehyde dehydrogenase activites, and enhanced gene expression of Abcb1b (a drug-resistant gene), suggesting that the population of PVECs included tissue-resident EPCs activated during regenerative process of PVECs. The proliferating PVECs expressed CD34, Flk-1/KDR, and c-kit more strongly and Prom1/CD133 less strongly on the surface than nonproliferating PVECs. Our findings indicated that lung tissue-resident EPCs predominantly contribute to pulmonary vascular repair after endotoxin-induced injury.
C1 [Kawasaki, Takeshi; Nishiwaki, Tetsu; Sekine, Ayumi; Nishimura, Rintaro; Suda, Rika; Urushibara, Takashi; Suzuki, Toshio; Takayanagi, Shin; Terada, Jiro; Sakao, Seiichiro; Tatsumi, Koichiro] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba 2608670, Japan.
C3 Chiba University
RP Kawasaki, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Respirol, Chiba 2608670, Japan.
EM kawatake1978@yahoo.co.jp
OI Suzuki, Toshio/0000-0002-0909-0466
FU Ministry of Health, Labor, and Welfare of Japan; Chiba Foundation for
   Health Promotion and Disease Prevention
FX This work was supported by in part by grants from the Ministry of
   Health, Labor, and Welfare of Japan and the Chiba Foundation for Health
   Promotion and Disease Prevention awarded to the Respiratory Failure
   Research Group.
CR Aicher A, 2007, CIRC RES, V100, P581, DOI 10.1161/01.RES.0000259562.63718.35
   Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Asosingh K, 2008, AM J PATHOL, V172, P615, DOI 10.2353/ajpath.2008.070705
   Balber AE, 2011, STEM CELLS, V29, P570, DOI 10.1002/stem.613
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Case J, 2008, ANTIOXID REDOX SIGN, V10, P1895, DOI 10.1089/ars.2008.2118
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Fang ST, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001407
   Fleissner F, 2011, ANTIOXID REDOX SIGN, V15, P933, DOI 10.1089/ars.2010.3502
   Hurley TD, 2012, ALCOHOL RES-CURR REV, V34, P339
   Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057
   Kahler CM, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-50
   Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Krishnamurthy S, 2010, CANCER RES, V70, P9969, DOI 10.1158/0008-5472.CAN-10-1712
   Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0
   Ohle SJ, 2012, AM J RESP CELL MOL, V47, P11, DOI 10.1165/rcmb.2011-0180OC
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   Ran S, 2003, NEOPLASIA, V5, P297, DOI 10.1016/S1476-5586(03)80023-4
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Rovira M, 2010, P NATL ACAD SCI USA, V107, P75, DOI 10.1073/pnas.0912589107
   Sainz J, 2006, ARTERIOSCL THROM VAS, V26, P281, DOI 10.1161/01.ATV.0000197793.83391.91
   Schniedermann J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-50
   Serikov VB, 2008, LUNG, V186, P179, DOI 10.1007/s00408-008-9078-6
   Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367
   Sun XT, 2012, WORLD J GASTROENTERO, V18, P4925, DOI 10.3748/wjg.v18.i35.4925
   Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106
   Tousoulis D, 2008, ATHEROSCLEROSIS, V201, P236, DOI 10.1016/j.atherosclerosis.2008.05.034
   Toya SP, 2012, IMMUNOBIOLOGY, V217, P569, DOI 10.1016/j.imbio.2011.03.006
   Unno K, 2012, CIRC RES, V110, P1355, DOI 10.1161/CIRCRESAHA.111.243014
   Voswinckel R, 2003, CIRC RES, V93, P372, DOI 10.1161/01.RES.0000087643.60150.C2
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wary KK, 2009, STEM CELLS, V27, P3112, DOI 10.1002/stem.241
   Yamada M, 2005, THORAX, V60, P410, DOI 10.1136/thx.2004.034058
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
   Yoder Mervin C, 2011, Proc Am Thorac Soc, V8, P466, DOI 10.1513/pats.201101-006MW
NR 44
TC 44
Z9 49
U1 0
U2 17
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD OCT
PY 2015
VL 53
IS 4
BP 500
EP 512
DI 10.1165/rcmb.2014-0185OC
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA CZ9UL
UT WOS:000367442400008
PM 25719275
DA 2023-08-21
ER

PT J
AU Saito, Y
   Fujii, Y
   Yashiro, M
   Tsuge, M
   Nosaka, N
   Yamashita, N
   Yamada, N
   Tsukahara, H
   Morishima, T
AF Saito, Yukie
   Fujii, Yousuke
   Yashiro, Masato
   Tsuge, Mitsuru
   Nosaka, Nobuyuki
   Yamashita, Nobuko
   Yamada, Nlutsuko
   Tsukahara, Hirokazu
   Morishima, Tsuneo
TI Inhibitory Effects of Edaravone, a Free Radical Scavenger, on
   Cytokine-induced Hyperpermeability of Human Pulmonary Microvascular
   Endothelial Cells: A Comparison with Dexamethasone and Nitric Oxide
   Synthase Inhibitor
SO ACTA MEDICA OKAYAMA
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; permeability; edaravone; VE-cadherin; zonula occludens 1 
ID ADHESION MOLECULE EXPRESSION; INDUCED LUNG INJURY; VE-CADHERIN;
   IN-VITRO; ALPHA; ANTIOXIDANTS; ACTIVATION; INCREASES; JUNCTIONS; DISEASE
AB Lung hyperpermeability affects the development of acute respiratory distress syndrome (ARDS), but therapeutic strategies for the control of microvascular permeability have not been established. We examined the effects of edaravone, dexamethasone, and N-monomethyl-L-arginine (L-NMMA) on permeability changes in human pulmonary microvascular endothelial cells (PMVEC) under a hypercytokinemic state. Human PMVEC were seeded in a Boyden chamber. After monolayer confluence was achieved, the culture media were replaced respectively by culture media containing edaravone, dexamethasone, and L-NMMA. After 24-h incubation, the monolayer was stimulated with tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta). Fluorescein-labeled dextran was added. Then the trans-human PMVEC leak was measured. Expressions of vascular endothelial-cadherin (VE-cadherin) and zonula occludens-I protein (ZO-I) were evaluated using real-time quantitative polymerase chain reaction and immunofluorescence microscopy. The results showed that TNF-alpha + IL-1 beta markedly increased pulmonary microvascular permeability. Pretreatment with edaravone, dexamethasone, or L-NMMA attenuated the hyperpermeability and inhibited the cytokine-induced reduction of VE-cadherin expression on immunofluorescence staining. Edaravone and dexamethasone increased the expression of ZO-I at both the mRNN and protein levels. Edaravone and dexamethasone inhibited the permeability changes of human PMVEC, at least partly through an enhancement of VE-cadherin. Collectively, these results suggest a potential therapeutic approach for intervention in patients with ARDS.
C1 [Saito, Yukie; Fujii, Yousuke; Yashiro, Masato; Tsuge, Mitsuru; Nosaka, Nobuyuki; Yamada, Nlutsuko; Tsukahara, Hirokazu; Morishima, Tsuneo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat, Okayama 7008558, Japan.
C1 [Yamashita, Nobuko] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Virol, Okayama 7008558, Japan.
C3 Okayama University; Okayama University
RP Saito, Y (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat, Okayama 7008558, Japan.
EM yukiepr@yahoo.co.jp
RI Nosaka, Nobuyuki/H-7817-2019
OI Nosaka, Nobuyuki/0000-0002-7722-0701
CR Blecharz KG, 2008, J CEREBR BLOOD F MET, V28, P1139, DOI 10.1038/jcbfm.2008.2
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Fukuhra S, 2006, J BIOCHEM MOL BIOL, V39, P132
   Haubner F, 2007, BIOCHEM BIOPH RES CO, V360, P560, DOI 10.1016/j.bbrc.2007.06.044
   Itoh Y, 2009, NATURE, V460, P1021, DOI 10.1038/nature08260
   Jiang MZ, 2005, RESP MED, V99, P580, DOI 10.1016/j.rmed.2004.10.007
   Jiang MZ, 2004, LIFE SCI, V75, P1159, DOI 10.1016/j.lfs.2004.01.031
   Jiang MZ, 2004, FREE RADICAL RES, V38, P473, DOI 10.1080/1071576042000209826
   Kawashima H, 2010, CRIT CARE, V14, DOI 10.1186/cc8918
   Kikuchi K, 2011, INT J MOL MED, V28, P899, DOI 10.3892/ijmm.2011.795
   KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0
   Lehle K, 2007, BIOCHEM BIOPH RES CO, V357, P308, DOI 10.1016/j.bbrc.2007.03.147
   Lutgendorf MA, 2014, REPROD SCI, V21, P483, DOI 10.1177/1933719113503410
   MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710
   Matsuo N, 1999, SURG TODAY, V29, P1068, DOI 10.1007/s005950050646
   Morozumi J, 2005, J TRAUMA, V59, P570, DOI 10.1097/01.ta.0000183504.38346.45
   Ohta Y, 2009, INTERNAL MED, V48, P593, DOI 10.2169/internalmedicine.48.1871
   Omori K, 2007, AM J PHYSIOL-CELL PH, V293, pC1523, DOI 10.1152/ajpcell.00524.2006
   Onodera H, 2013, BRAIN RES, V1534, P87, DOI 10.1016/j.brainres.2013.08.019
   Pabst D, 2011, EUR J INTERN MED, V22, pE119, DOI 10.1016/j.ejim.2011.08.014
   Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8183
   SIBBALD WJ, 1981, CHEST, V79, P133, DOI 10.1378/chest.79.2.133
   Tajima S, 2008, EUR RESPIR J, V32, P1337, DOI 10.1183/09031936.00164407
   Tajima S, 2008, RESPIROLOGY, V13, P646, DOI 10.1111/j.1440-1843.2008.01322.x
   Tran D, 2012, PEDIATRICS, V130, P397, DOI 10.1542/peds.2011-3216
   Tsuge M, 2010, MICROBIOL IMMUNOL, V54, P417, DOI 10.1111/j.1348-0421.2010.00226.x
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wittchen ES, 2009, FRONT BIOSCI-LANDMRK, V14, P2522, DOI 10.2741/3395
   Yang T, 2012, INFLAMM RES, V61, P563, DOI 10.1007/s00011-012-0445-7
   Yang T, 2010, EUR J PHARMACOL, V630, P152, DOI 10.1016/j.ejphar.2009.12.025
   Zhu YT, 2008, INVEST OPHTH VIS SCI, V49, P3879, DOI 10.1167/iovs.08-1693
NR 33
TC 2
Z9 4
U1 1
U2 6
PU OKAYAMA UNIV MED SCHOOL
PI OKAYAMA
PA EDITORIAL OFFICE, ACTA MEDICA OKAYAMA OKAYAMA UNIVERSITY MEDICAL SCHOOL
   2-5-1 SHIKATA-CHO, KITA-KU, OKAYAMA, 700-8558, JAPAN
SN 0386-300X
J9 ACTA MED OKAYAMA
JI Acta Med. Okayama
PD OCT
PY 2015
VL 69
IS 5
BP 279
EP 290
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CX2IE
UT WOS:000365519600004
PM 26490025
DA 2023-08-21
ER

PT J
AU Wang, CS
   Armstrong, SM
   Sugiyama, MG
   Tabuchi, A
   Krauszman, A
   Kuebler, WM
   Mullen, B
   Advani, S
   Advani, A
   Lee, WL
AF Wang, Changsen
   Armstrong, Susan M.
   Sugiyama, Michael G.
   Tabuchi, Arata
   Krauszman, Adrienn
   Kuebler, Wolfgang M.
   Mullan, Barbara A.
   Advani, Suzanne
   Advani, Andrew
   Lee, Warren L.
TI Influenza-Induced Priming and Leak of Human Lung Microvascular
   Endothelium upon Exposure to Staphylococcus aureus
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE influenza; pneumonia; superinfection; pulmonary edema; TNF/TNF-alpha/TNFR1 
ID RESPIRATORY-DISTRESS-SYNDROME; VIRUS-INFECTION; PROTEIN-A; BACTERIAL
   PNEUMONIA; ASIAN INFLUENZA; CELL-WALL; IN-VITRO; MICE; ACTIVATION;
   APOPTOSIS
AB A major cause of death after influenza virus infection is lung injury due to a bacterial superinfection, yet the mechanism is unknown. Death has been attributed to virus-induced immunosuppression and bacterial overgrowth, but this hypothesis is based on data from the preantibiotic era and animal models that omit antimicrobial therapy. Because of diagnostic uncertainty, most patients with influenza receive antibiotics, making bacterial overgrowth unlikely. Respiratory failure after superinfection presents as acute respiratory distress syndrome, a disorder characterized by lung microvascular leak and edema. The objective of this study was to determine whether the influenza virus sensitizes the lung endothelium to leak upon exposure to circulating bacterial-derived molecular patterns from Staphylococcus aureus. In vitro as well as in vivo models of influenza followed by S. aureus superinfectionwere used. Molecular mechanisms were explored using molecular biology, knockout mice, and human autopsy specimens. Influenza virus infection sensitized human lung endothelium to leak when challenged with S. aureus, even at low doses of influenza and even when the pathogens were given days apart. Influenza virus increased endothelial expression of TNFR1 both in vitro and in intact lungs, a finding corroborated by human autopsy specimens of patients with influenza. Leak was recapitulated with protein A, a TNFR1 ligand, and sequential infection caused protein A-dependent loss of I kappa B, cleavage of caspases 8 and 3, and lung endothelial apoptosis. Mice infected sequentially with influenza virus and S. aureus developed significantly increased lung edema that was protein A and TNFR1 dependent. Influenza virus primes the lung endothelium to leak, predisposing patients to acute respiratory distress syndrome upon exposure to S. aureus.
C1 [Wang, Changsen; Armstrong, Susan M.; Sugiyama, Michael G.; Tabuchi, Arata; Krauszman, Adrienn; Kuebler, Wolfgang M.; Advani, Suzanne; Advani, Andrew; Lee, Warren L.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON M5B 1W8, Canada.
C1 [Armstrong, Susan M.; Lee, Warren L.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
C1 [Sugiyama, Michael G.; Lee, Warren L.] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada.
C1 [Lee, Warren L.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada.
C1 [Advani, Andrew; Lee, Warren L.] Univ Toronto, Dept Med, Toronto, ON, Canada.
C1 [Mullen, Brendan] Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada.
C3 University of Toronto; Saint Michaels Hospital Toronto; University of
   Toronto; University of Toronto; University of Toronto; University of
   Toronto; University of Toronto; Sinai Health System Toronto; Lunenfeld
   Tanenbaum Research Institute
RP Lee, WL (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.
EM leew@smh.ca
OI Kuebler, Wolfgang/0000-0003-4100-2961; Lee, Warren/0000-0002-1788-6587
FU Canadian Institutes of Health Research (CIHR) [MOP 130564]; Health
   Research Grant from the Physicians' Services Incorporated Foundation
   [PSI 10-14]; Institute of Circulatory and Respiratory Health at the CIHR
   [OCN 126577]; CIHR; McLaughlin Centre for Molecular Medicine
FX This work was supported by an operating grant from the Canadian
   Institutes of Health Research (CIHR) MOP 130564, a Health Research Grant
   from the Physicians' Services Incorporated Foundation (PSI 10-14), and
   bridge funds from the Institute of Circulatory and Respiratory Health at
   the CIHR, grant OCN 126577 (all W.L.L.). S.M.A. receives M.D./Ph.D.
   funding from the CIHR and the McLaughlin Centre for Molecular Medicine.
CR ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059
   Armstrong SM, 2013, AM J RESP CRIT CARE, V187, pA4980
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371
   Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298
   Becker S, 2014, P NATL ACAD SCI USA, V111, P1574, DOI 10.1073/pnas.1317181111
   Burg J, 2002, AM J PHYSIOL-LUNG C, V283, pL460, DOI 10.1152/ajplung.00249.2001
   Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078
   Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997
   Cox KH, 2007, INFECT IMMUN, V75, P2638, DOI 10.1128/IAI.01320-06
   DEMARIA TF, 1978, INFECT IMMUN, V21, P114, DOI 10.1128/IAI.21.1.114-123.1978
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   Fortier ME, 2004, AM J PHYSIOL-REG I, V287, pR759, DOI 10.1152/ajpregu.00293.2004
   Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005
   Gatheral T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042386
   Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079
   Groskreutz DJ, 2006, J IMMUNOL, V176, P1733, DOI 10.4049/jimmunol.176.3.1733
   HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831
   Hall HTL, 2008, EUR J IMMUNOL, V38, P64, DOI 10.1002/eji.200737393
   Hamacher J, 2002, AM J RESP CRIT CARE, V166, P651, DOI 10.1164/rccm.2109004
   Iverson AR, 2011, J INFECT DIS, V203, P880, DOI 10.1093/infdis/jiq113
   Kim YG, 2011, CELL HOST MICROBE, V9, P496, DOI 10.1016/j.chom.2011.05.006
   Kuehnert MJ, 2006, J INFECT DIS, V193, P172, DOI 10.1086/499632
   Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025
   Kuster SP, 2010, EUR J CLIN MICROBIOL, V29, P835, DOI 10.1007/s10096-010-0935-x
   Lee WL, 2011, CURR OPIN HEMATOL, V18, P191, DOI 10.1097/MOH.0b013e328345a3d1
   Lee WL, 2001, SEMIN RESP CRIT CARE, V22, P269, DOI 10.1055/s-2001-15784
   LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789
   MARTIN CM, 1959, ARCH INTERN MED, V103, P532, DOI 10.1001/archinte.1959.00270040018002
   MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710
   McCullers JA, 2014, NAT REV MICROBIOL, V12, P252, DOI 10.1038/nrmicro3231
   McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584
   Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   MORI I, 1995, MICROB PATHOGENESIS, V19, P237, DOI 10.1016/S0882-4010(95)90290-2
   Munoz-Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729
   Mura M, 2010, AM J PATHOL, V176, P1725, DOI 10.2353/ajpath.2010.090209
   Murray PJ, 2009, NAT IMMUNOL, V10, P1053, DOI 10.1038/ni1009-1053
   Murray RJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008705
   Muscedere J, 2013, CHEST, V144, P39, DOI 10.1378/chest.12-1861
   Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x
   Ocana-Macchi M, 2009, J VIROL, V83, P12947, DOI 10.1128/JVI.00468-09
   Oliveira EC, 2001, CHEST, V119, P1717, DOI 10.1378/chest.119.6.1717
   OSEASOHN R, 1959, NEW ENGL J MED, V260, P509, DOI 10.1056/NEJM195903122601101
   Pandey AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000500
   Podewils LJ, 2005, CLIN INFECT DIS, V40, P1693, DOI 10.1086/430424
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Ruby J, 1997, J EXP MED, V186, P1591, DOI 10.1084/jem.186.9.1591
   Sabbah A, 2009, NAT IMMUNOL, V10, P1073, DOI 10.1038/ni.1782
   Schreiber MP, 2011, J CRIT CARE, V26, P395, DOI 10.1016/j.jcrc.2010.09.002
   SELLERS TF, 1961, J EXP MED, V114, P237, DOI 10.1084/jem.114.2.237
   Shahangian A, 2009, J CLIN INVEST, V119, P1910, DOI 10.1172/JCI35412
   Speshock JL, 2007, INFECT IMMUN, V75, P3102, DOI 10.1128/IAI.01943-06
   Subrt N, 2011, J ANTIMICROB CHEMOTH, V66, P979, DOI 10.1093/jac/dkr043
   Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Thorburn K, 2006, THORAX, V61, P611, DOI 10.1136/thx.2005.048397
   WEIBEL ER, 1964, J CELL BIOL, V21, P367, DOI 10.1083/jcb.21.3.367
   Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
NR 61
TC 17
Z9 18
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD OCT
PY 2015
VL 53
IS 4
BP 459
EP 470
DI 10.1165/rcmb.2014-0373OC
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA CZ9UL
UT WOS:000367442400004
PM 25693001
DA 2023-08-21
ER

PT J
AU Gill, SE
   Rohan, M
   Mehta, S
AF Gill, Sean E.
   Rohan, Marta
   Mehta, Sanjay
TI Role of pulmonary microvascular endothelial cell apoptosis in murine
   sepsis-induced lung injury in vivo
SO RESPIRATORY RESEARCH
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; RESPIRATORY-DISTRESS-SYNDROME; MICROCIRCULATORY
   ALTERATIONS; BARRIER DYSFUNCTION; ORGAN DYSFUNCTION; OXIDATIVE STRESS;
   MEDICAL PROGRESS; SEPTIC SHOCK; PROTEIN LEAK; BLOOD-FLOW
AB Background: Sepsis remains a common and serious condition with significant morbidity and mortality due to multiple organ dysfunction, especially acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Sepsis-induced ALI is characterized by injury and dysfunction of the pulmonary microvasculature and pulmonary microvascular endothelial cells (PMVEC), resulting in enhanced pulmonary microvascular sequestration and pulmonary infiltration of polymorphonuclear leukocytes (PMN) as well as disruption of the normal alveolo-capillary permeability barrier with leak of albumin-rich edema fluid into pulmonary interstitium and alveoli. The role of PMVEC death and specifically apoptosis in septic pulmonary microvascular dysfunction in vivo has not been established.
   Methods: In a murine cecal ligation/perforation (CLP) model of sepsis, we quantified and correlated time-dependent changes in pulmonary microvascular Evans blue (EB)-labeled albumin permeability with (1) PMVEC death (propidium iodide [PI]-staining) by both fluorescent intravital videomicroscopy (IVVM) and histology, and (2) PMVEC apoptosis using histologic fluorescent microscopic assessment of a panel of 3 markers: cell surface phosphatidylserine (detected by Annexin V binding), caspase activation (detected by FLIVO labeling), and DNA fragmentation (TUNEL labeling).
   Results: Compared to sham mice, CLP-sepsis resulted in pulmonary microvascular barrier dysfunction, quantified by increased EB-albumin leak, and PMVEC death (PI+ staining) as early as 2 h and more marked by 4 h after CLP. Septic PMVEC also exhibited increased presence of all 3 markers of apoptosis (Annexin V+, FLIVO+, TUNEL+) as early as 30 mins - 1 h after CLP-sepsis, which all similarly increased markedly until 4 h. The time-dependent changes in septic pulmonary microvascular albumin-permeability barrier dysfunction were highly correlated with PMVEC death (PI+; r = 0.976, p < 0.01) and PMVEC apoptosis (FLIVO+; r = 0.991, p < 0.01). Treatment with the pan-caspase inhibitor Q-VD prior to CLP reduced PMVEC death/apoptosis and attenuated septic pulmonary microvascular dysfunction, including both albumin-permeability barrier dysfunction and pulmonary microvascular PMN sequestration (p < 0.05). Septic PMVEC apoptosis and pulmonary microvascular dysfunction were also abrogated following CLP-sepsis in mice deficient in iNOS (Nos2(-/-)) or NADPH oxidase (p47(phox-/-) or gp91(phox-/-)) and in wild-type mice treated with the NADPH oxidase inhibitor, apocynin.
   Conclusions: Septic murine pulmonary microvascular dysfunction in vivo is due to PMVEC death, which is mediated through caspase-dependent apoptosis and iNOS/NADPH-oxidase dependent signaling.
C1 [Gill, Sean E.; Rohan, Marta; Mehta, Sanjay] London Hlth Sci Ctr, Lawson Hlth Res Inst, Ctr Crit Illness Res, London, ON, Canada.
C1 [Gill, Sean E.; Mehta, Sanjay] Univ Western Ontario, Div Respirol, Schulich Sch Med & Dent, London, ON, Canada.
C1 [Gill, Sean E.; Mehta, Sanjay] Univ Western Ontario, Dept Med, Schulich Sch Med & Dent, London, ON, Canada.
C1 [Gill, Sean E.] Univ Western Ontario, Dept Physiol & Pharmacol, Schulich Sch Med & Dent, London, ON, Canada.
C1 [Mehta, Sanjay] Victoria Hosp, London Hlth Sci Ctr, Div Respirol, London, ON N6A 5W9, Canada.
C3 London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario); Western University
   (University of Western Ontario); London Health Sciences Centre;
   University of Victoria; Western University (University of Western
   Ontario)
RP Mehta, S (corresponding author), London Hlth Sci Ctr, Lawson Hlth Res Inst, Ctr Crit Illness Res, London, ON, Canada.
EM Sanjay.Mehta@lhsc.on.ca
RI Gill, Sean E/G-4057-2012; Mehta, Sanjay/G-3332-2011
OI Mehta, Sanjay/0000-0002-7707-1056
FU Heart & Stroke Foundation of Ontario/Canada [G-13-0003039]; Ontario
   Thoracic Society; Lawson Health Research Institute
FX This work was supported by Heart & Stroke Foundation of Ontario/Canada
   grant #G-13-0003039, the Ontario Thoracic Society, and the Lawson Health
   Research Institute.
CR Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359
   [Anonymous], CRIT CARE MED
   Bastarache JA, 2009, AM J PHYSIOL-LUNG C, V297, pL1035, DOI 10.1152/ajplung.00214.2009
   Boerma EC, 2007, CRIT CARE MED, V35, P1055, DOI 10.1097/01.CCM.0000259527.89927.F9
   Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429
   Boos CJ, 2006, J THROMB HAEMOST, V4, P2509, DOI 10.1111/j.1538-7836.2006.02172.x
   Cines DB, 1998, BLOOD, V91, P3527
   Darwish I, 2013, VIRULENCE, V4, P572, DOI 10.4161/viru.25740
   De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC
   De Backer D, 2014, VIRULENCE, V5, P73, DOI 10.4161/viru.26482
   De Backer D, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-27
   Dellinger R, 2013, INTENS CARE MED, V41, P580, DOI DOI 10.1007/s00134-012-2769-8
   Deutschman CS, 2014, IMMUNITY, V40, P464, DOI 10.1016/j.immuni.2014.04.001
   DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012
   Farley KS, 2008, MICROVASC RES, V76, P208, DOI 10.1016/j.mvr.2008.07.004
   Farley KS, 2009, AM J PHYSIOL-LUNG C, V296, pL480, DOI 10.1152/ajplung.90201.2008
   Farley KS, 2006, AM J PHYSIOL-LUNG C, V290, pL1164, DOI 10.1152/ajplung.00248.2005
   Ferrer R, 2009, AM J RESP CRIT CARE, V180, P861, DOI 10.1164/rccm.200812-1912OC
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Gill SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088501
   Glauser MP, 2000, CRIT CARE MED, V28, pS4, DOI 10.1097/00003246-200009001-00002
   GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662
   Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831
   Hasleton PS, 1999, HISTOPATHOLOGY, V34, P285
   Hebert MJ, 1998, AM J PATHOL, V152, P523
   Hemmer CJ, 2008, CRIT CARE MED, V36, P2562, DOI 10.1097/CCM.0b013e31818441ee
   Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214
   Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Hu HX, 2009, MICROVASC RES, V78, P33, DOI 10.1016/j.mvr.2009.04.005
   Husak Liudmila, 2010, Healthc Q, V13 Spec No, P35
   Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje
   Edul VSK, 2012, CRIT CARE MED, V40, P1443, DOI 10.1097/CCM.0b013e31823dae59
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   KINDT GC, 1991, J APPL PHYSIOL, V70, P1575, DOI 10.1152/jappl.1991.70.4.1575
   King EG, 2014, LAB INVEST, V94, P4, DOI 10.1038/labinvest.2013.110
   Kovarova M, 2012, J IMMUNOL, V189, P2006, DOI 10.4049/jimmunol.1201065
   LAM C, 1994, J CLIN INVEST, V94, P2077, DOI 10.1172/JCI117562
   Lang JD, 2002, CHEST, V122, p314S, DOI 10.1378/chest.122.6_suppl.314S
   Li G, 2010, J CELL BIOL, V191, P1113, DOI 10.1083/jcb.201006121
   Li JM, 2007, FREE RADICAL BIO MED, V43, P976, DOI 10.1016/j.freeradbiomed.2007.06.001
   Liaudet L, 2013, CURR VASC PHARMACOL, V11, P196
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Matsuda N, 2007, CARDIOVASC RES, V76, P132, DOI 10.1016/j.cardiores.2007.05.024
   Matsuda N, 2010, AM J PHYSIOL-HEART C, V298, pH92, DOI 10.1152/ajpheart.00069.2009
   Maurer K, 2015, CELL HOST MICROBE, V17, P429, DOI 10.1016/j.chom.2015.03.001
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Mehta S, 2005, VASC PHARMACOL, V43, P390, DOI 10.1016/j.vph.2005.08.013
   Nguyen HB, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-6
   Opal SM, 2015, J INTERN MED, V277, P277, DOI 10.1111/joim.12331
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Qing DY, 2014, AM J RESP CRIT CARE, V190, P1243, DOI 10.1164/rccm.201406-1095OC
   Razavi HM, 2005, CRIT CARE MED, V33, P1333, DOI 10.1097/01.CCM.0000165445.48350.4F
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Razavi HM, 2002, CRIT CARE MED, V30, P868, DOI 10.1097/00003246-200204000-00026
   Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021
   Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003
   Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F
   Sandrock CE, 2010, SEMIN RESP CRIT CARE, V31, P66, DOI 10.1055/s-0029-1246290
   Schmidt EP, 2011, PHYSIOLOGY, V26, P334, DOI 10.1152/physiol.00011.2011
   Semeraro N, 2012, THROMB RES, V129, P290, DOI 10.1016/j.thromres.2011.10.013
   Shapiro NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10044
   Sharma S, 2010, VASC PHARMACOL, V52, P182, DOI 10.1016/j.vph.2009.11.010
   Shelton JL, 2008, MICROVASC RES, V76, P80, DOI 10.1016/j.mvr.2008.06.001
   Shelton JL, 2007, MICROVASC RES, V74, P23, DOI 10.1016/j.mvr.2007.02.008
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   Skibsted S, 2013, SHOCK, V39, P427, DOI 10.1097/SHK.0b013e3182903f0d
   Starr A, 2008, CARDIOVASC RES, V78, P139, DOI 10.1093/cvr/cvn012
   Stearns-Kurosawa DJ, 2011, ANNU REV PATHOL-MECH, V6, P19, DOI 10.1146/annurev-pathol-011110-130327
   Subbanna S, 2013, NEUROBIOL DIS, V54, P475, DOI 10.1016/j.nbd.2013.01.022
   Sukriti S, 2014, PULM CIRC, V4, P535, DOI 10.1086/677356
   Trzeciak S, 2007, ANN EMERG MED, V49, P88, DOI 10.1016/j.annemergmed.2006.08.021
   Tyml K, 2011, MICROCIRCULATION, V18, P152, DOI 10.1111/j.1549-8719.2010.00080.x
   Vallet B, 2002, CRIT CARE MED, V30, pS229, DOI 10.1097/00003246-200205001-00010
   Wang LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055311
   Wang LF, 2012, SHOCK, V37, P539, DOI 10.1097/SHK.0b013e31824dcb5a
   Wang LF, 2010, BIOCHEM BIOPH RES CO, V401, P207, DOI 10.1016/j.bbrc.2010.09.029
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Wang L, 2007, AM J RESP CELL MOL, V36, P497, DOI 10.1165/rcmb.2005-0425OC
   Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu F, 2014, AM J PHYSIOL-LUNG C, V307, pL987, DOI 10.1152/ajplung.00063.2014
   Xing K, 2012, CRIT CARE, V16, DOI 10.1186/cc11145
   Zhao JL, 2015, AM J TRANSL RES, V7, P474
   Zhou M, 2004, ANN SURG, V240, P321, DOI 10.1097/01.sla.0000133253.45591.5b
NR 92
TC 126
Z9 144
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD SEP 16
PY 2015
VL 16
AR 109
DI 10.1186/s12931-015-0266-7
PG 13
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA CR6KD
UT WOS:000361454600001
PM 26376777
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Konya, V
   Maric, J
   Jandl, K
   Luschnig, P
   Aringer, I
   Lanz, I
   Platzer, W
   Theiler, A
   Barnthaler, T
   Frei, R
   Marsche, G
   Marsh, LM
   Olschewski, A
   Lippe, IT
   Heinemann, A
   Schuligoi, R
AF Konya, Viktoria
   Maric, J.
   Jandl, Katharina
   Luschnig, P.
   Aringer, I.
   Lanz, I.
   Platzer, Wolfgang
   Theiler, Anna
   Baernthaler, T.
   Frei, R.
   Marsche, Gunther
   Marsh, Leigh M.
   Olschewski, Andrea
   Lippe, I. T.
   Heinemann, Akos
   Schuligoi, Rufina
TI Activation of EP4 receptors prevents endotoxin-induced neutrophil
   infiltration into the airways and enhances microvascular barrier
   function
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; PROSTAGLANDIN E-2; LUNG INFLAMMATION; PULMONARY;
   OUTCOMES; ASTHMA; PGE(2); PERMEABILITY; PHARMACOLOGY; ASSOCIATION
AB Background and PurposePulmonary vascular dysfunction is a key event in acute lung injury. We recently demonstrated that PGE(2), via activation of E-prostanoid (EP)(4) receptors, strongly enhances microvascular barrier function in vitro. The aim of this study was to investigate the beneficial effects of concomitant EP4 receptor activation in murine models of acute pulmonary inflammation.
   Experimental ApproachPulmonary inflammation in male BALB/c mice was induced by LPS (20 g per mouse intranasally) or oleic acid (0.15 Lg(-1), i.v(.)). In-vitro, endothelial barrier function was determined by measuring electrical impedance.
   Key ResultsPGE(2) activation of EP4 receptors reduced neutrophil infiltration, pulmonary vascular leakage and TNF- concentration in bronchoalveolar lavage fluid from LPS-induced pulmonary inflammation. Similarly, pulmonary vascular hyperpermeability induced by oleic acid was counteracted by EP4 receptor activation. In lung function assays, the EP4 agonist ONO AE1-329 restored the increased resistance and reduced compliance upon methacholine challenge in mice treated with LPS or oleic acid. In agreement with these findings, EP4 receptor activation increased the in vitro vascular barrier function of human and mouse pulmonary microvascular endothelial cells and diminished the barrier disruption induced by LPS. The EP2 agonist ONO AE1-259 likewise reversed LPS-induced lung dysfunction without enhancing vascular barrier function.
   Conclusion and ImplicationsOur results show that activation of the EP4 receptor strengthens the microvascular barrier function and thereby ameliorates the pathology of acute lung inflammation, including neutrophil infiltration, vascular oedema formation and airway dysfunction. This suggests a potential benefit for EP4 agonists in acute pulmonary inflammation.
C1 [Konya, V.; Maric, J.; Jandl, K.; Luschnig, P.; Aringer, I.; Lanz, I.; Platzer, W.; Theiler, A.; Baernthaler, T.; Frei, R.; Marsche, G.; Lippe, I. T.; Heinemann, A.; Schuligoi, R.] Med Univ Graz, Inst Expt & Clin Pharmacol, A-8010 Graz, Austria.
C1 [Aringer, I.] Med Univ Graz, Dept Internal Med, Clin Div Nephrol, Graz, Austria.
C1 [Marsh, L. M.; Olschewski, A.] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Ludwig Boltzmann
   Institute
RP Heinemann, A (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.
EM akos.heinemann@medunigraz.at
RI Marsh, Leigh/AAB-5125-2021
OI Marsh, Leigh/0000-0002-1754-9249; Heinemann, Akos/0000-0002-8554-2372;
   Jandl, Katharina/0000-0002-7892-6618; Schuligoi,
   Rufina/0000-0002-9338-6904; Olschewski, Andrea/0000-0002-8189-3634;
   Barnthaler, Thomas/0000-0002-4988-3700; Konya,
   Viktoria/0000-0002-7999-9093; Marsche, Gunther/0000-0002-2422-5381
FU Austrian Science Fund FWF [P22521-B18, P25531-B23, P26185-B19,
   P21004-B02, P22976-B18]; Jubilaumsfonds of Austrian National Bank
   [14263, 14853]; DK-MOLIN [FWF - W1241]; Austrian Science Fund (FWF)
   [P21004, P22976, P25531, P26185, W1241] Funding Source: Austrian Science
   Fund (FWF); Austrian Science Fund (FWF) [P 22521, P 22976, P 21004]
   Funding Source: researchfish
FX This work was supported by the Austrian Science Fund FWF (Grant
   P22521-B18 to A. H., P25531-B23 to V. K., P26185-B19 to R. S. and
   P21004-B02, P22976-B18 to G. M.) and the Jubilaumsfonds of the Austrian
   National Bank (14263 to A. H. and 14853 to G. M.). K. J., I. A. and J.
   M. were funded by the PhD Program DK-MOLIN (FWF - W1241). The authors
   appreciate the excellent technical assistance of Martina Ofner and Iris
   Red.
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   af Forselles KJ, 2011, BRIT J PHARMACOL, V164, P1847, DOI 10.1111/j.1476-5381.2011.01495.x
   Aggarwal S, 2010, CLIN EXP ALLERGY, V40, P85, DOI 10.1111/j.1365-2222.2009.03386.x
   Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445
   Amann R, 1999, INFLAMM RES, V48, P632, DOI 10.1007/s000110050514
   Benyahia C, 2012, PULM PHARMACOL THER, V25, P115, DOI 10.1016/j.pupt.2011.12.012
   Bhargava R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061405
   Birrell MA, 2015, THORAX, V70, P740, DOI 10.1136/thoraxjnl-2014-206592
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002
   Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028
   Buckley J, 2011, THORAX, V66, P1029, DOI 10.1136/thx.2010.158568
   Bull TM, 2010, AM J RESP CRIT CARE, V182, P1123, DOI 10.1164/rccm.201002-0250OC
   deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792
   El-Gamal D, 2012, ANTIOXID REDOX SIGN, V16, P129, DOI 10.1089/ars.2011.4090
   Goldman JL, 2014, PULM CIRC, V4, P280, DOI 10.1086/675991
   Haegens A, 2009, J IMMUNOL, V182, P7990, DOI 10.4049/jimmunol.0800377
   HOCKING DC, 1990, CIRC RES, V67, P68, DOI 10.1161/01.RES.67.1.68
   HORVATH CJ, 1988, P NATL ACAD SCI USA, V85, P9219, DOI 10.1073/pnas.85.23.9219
   Jacobson JR, 2007, CURR DRUG TARGETS, V8, P509, DOI 10.2174/138945007780362719
   Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI200214459
   Kilkenny C, 2011, J CEREBR BLOOD F MET, V31, P991, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476-5381.2010.00872.x]
   Konya V, 2013, PHARMACOL THERAPEUT, V138, P485, DOI 10.1016/j.pharmthera.2013.03.006
   Konya V, 2013, J ALLERGY CLIN IMMUN, V131, P532, DOI 10.1016/j.jaci.2012.05.008
   Konya V, 2010, J ALLERGY CLIN IMMUN, V125, P1105, DOI 10.1016/j.jaci.2009.12.002
   Lee IT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072783
   Lesur I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011485
   Lin JY, 1996, INT IMMUNOL, V8, P499, DOI 10.1093/intimm/8.4.499
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Maruyama T, 2000, Tanpakushitsu Kakusan Koso, V45, P1001
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006
   MILLAR AB, 1989, LANCET, V2, P712, DOI 10.1016/S0140-6736(89)90772-1
   Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200
   Nemmar A, 2011, BRIT J PHARMACOL, V164, P1871, DOI 10.1111/j.1476-5381.2011.01442.x
   PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Peters T, 2010, J PHARMACOL EXP THER, V335, P424, DOI 10.1124/jpet.109.163253
   Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976
   Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273
   Tilley SL, 2003, AM J PHYSIOL-LUNG C, V284, pL599, DOI 10.1152/ajplung.00324.2002
   van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004
   Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368
   Xu S, 2014, CELL BIOCHEM BIOPHYS, V70, P521, DOI 10.1007/s12013-014-9951-2
   Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195
   Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037
NR 54
TC 16
Z9 17
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD SEP
PY 2015
VL 172
IS 18
BP 4454
EP 4468
DI 10.1111/bph.13229
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CQ3GT
UT WOS:000360490800002
PM 26103450
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Li, L
   Zhang, H
   Min, D
   Zhang, RY
   Wu, J
   Qu, HP
   Tang, YQ
AF Li, Lei
   Zhang, Hong
   Min, Dong
   Zhang, Ruyuan
   Wu, Jun
   Qu, Hongping
   Tang, Yaoqing
TI Sox9 Activation is Essential for the Recovery of Lung Function after
   Acute Lung Injury
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE ALI/ARDS; Sox9; miR-101; Lung recovery 
ID ENDOTHELIAL PROGENITOR CELLS; BERLIN DEFINITION; EPITHELIUM; ARDS;
   CANCER; ROLES; PLAYS; RATS
AB Background/Aims: Acute lung injury (ALI) often predisposes acute respiratory distress syndrome (ARDS) in humans, and is featured with neutrophilic alveolitis, injury of the alveolar epithelium and endothelium, hyaline membrane formation, and microvascular thrombi. Although the pathogenesis of ALI is relatively well studied, the knowledge on the molecular regulation of the post-ALI lung recovery are poorly understood. Methods: Here, we used a widely applied bleomycin-induced ALI model to study the molecular mechanisms that underlie the post-ALI lung recovery in mice. We analyzed Sox9 expression in mouse lung by RT-qPCR, Western blot and immunohistochemistry. We analyzed miR-101 levels in mouse lung by RT-qPCR. We inhibited Sox9 in mouse lung by expressing either shRNA for Sox9 or miR-101, and analyzed the effects of Sox9 suppression on lung recovery. Results: We detected a significant increase in Sox9 protein but not mRNA, and a significant decrease in miR-101 levels in the mouse lung after ALI. MiR-101 was found to target 3'-UTR of Sox9 mRNA to inhibit its expression. Sox9 inhibition by either shRNA for Sox9 or by miR-101 further impaired the functional recovery of the lung after ALI. Conclusion: Our data suggest that Sox9 activation is essential for the recovery of lung function after ALI, which highlights a previously unappreciated mechanism that controls the post-ALI lung recovery. Copyright (C) 2015 S. Karger AG, Basel
C1 [Li, Lei; Zhang, Hong; Min, Dong; Zhang, Ruyuan; Wu, Jun; Qu, Hongping; Tang, Yaoqing] Shanghai Jiao Tong Univ, RuiJin Hosp, Dept Crit Care Med, Sch Med, Shanghai 200025, China.
C3 Shanghai Jiao Tong University
RP Wu, J (corresponding author), Shanghai Jiao Tong Univ, RuiJin Hosp, Dept Crit Care Med, Sch Med, 197 RuiJinEr Rd, Shanghai 200025, Peoples R China.
EM wujun_15@163.com
CR ASHBAUGH DG, 1967, LANCET, V2, P319
   Cai DS, 2013, CELL PHYSIOL BIOCHEM, V32, P1577, DOI 10.1159/000356594
   Dai LH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4114
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Ji Y, 2015, CELL PHYSIOL BIOCHEM, V35, P2203, DOI 10.1159/000374025
   Kangelaris KN, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-4
   Khemani RG, 2013, INTENS CARE MED, V39, P2213, DOI 10.1007/s00134-013-3094-6
   Landgraf MA, 2014, CELL PHYSIOL BIOCHEM, V33, P835, DOI 10.1159/000358656
   Moniot B, 2004, DEVELOPMENT, V131, P3795, DOI 10.1242/dev.01259
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Perl AKT, 2005, GENESIS, V41, P23, DOI 10.1002/gene.20093
   Rockich BE, 2013, P NATL ACAD SCI USA, V110, pE4456, DOI 10.1073/pnas.1311847110
   Thompson BT, 2013, AM J RESP CRIT CARE, V187, P675, DOI 10.1164/rccm.201302-0385ED
   Turcatel G, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-117
   Uhlig S, 2014, CELL PHYSIOL BIOCHEM, V34, P1, DOI 10.1159/000362980
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Yin XR, 2015, CELL PHYSIOL BIOCHEM, V35, P2149, DOI 10.1159/000374020
NR 19
TC 23
Z9 24
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PD SEP
PY 2015
VL 37
IS 3
BP 1113
EP 1122
DI 10.1159/000430236
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CT0YT
UT WOS:000362524800026
PM 26402323
OA gold
DA 2023-08-21
ER

PT J
AU Ming, GF
   Ma, XH
   Xu, DM
   Liu, ZY
   Ai, YH
   Liu, HX
   Shi, ZH
AF Ming, Guang-Feng
   Ma, Xin-Hua
   Xu, Dao-Miao
   Liu, Zhi-Yong
   Ai, Yu-Hang
   Liu, Hui-Xia
   Shi, Zan-Hua
TI PBEF promotes the apoptosis of pulmonary microvascular endothelial cells
   and regulates the expression of inflammatory factors and AQP1 through
   the MAPK pathways
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE ALI/ARDS; pre-B cell colony-enhancing factor; aquaporin 1; MAPK; ECs/HPMECs/HUVECs/MPVECs 
ID COLONY-ENHANCING FACTOR; ACUTE LUNG INJURY;
   RESPIRATORY-DISTRESS-SYNDROME; DOWN-REGULATION; VISFATIN; PERMEABILITY;
   INHIBITION; AQUAPORINS; KINASES; GENE
AB Pre-B cell colony-enhancing factor (PBEF) has been shown to have a variety of biological functions. Studies have proven that PBEF plays a functional role in acute lung injury (ALI). Therefore, in this study, we aimed to confirm the importance of PBEF in ALI. The effects of PBEF overexpression on the apoptosis of human pulmonary microvascular endothelial cells (HPMECs) were analyzed by flow cytometry, and the results indicated that PBEF promoted the apoptosis of HPMECs, which aggravated the development of ALI. Comparative experiments involving increasing and decreasing PBEF expression demonstrated that PBEF promoted the expression of inflammatory factors, such as interleukin (IL)-1 beta, IL-6 and IL-8 in the HPMECs, thus intensifying the inflammatory response. PBEF also inhibited the expression of aquaporin 1 (AQP1), which caused a dysfunction and imbalance in water transport. Moreover, we also found that tumor necrosis factor (TNF)-alpha promoted the expression of PBEF in the HPMECs. After blocking the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, we found that PBEF regulated the expression of inflammatory factors and AQP1, mainly through the MAPK pathways. Taken together, these results demonstrate that the increase in intracellular PBEF expression promoted the apoptosis of HPMECs and the expression of inflammatory factors and thus enhanced the inflammatory response and inhibited the expression of AQP1, which resulted in abnormal water transport, diminishing the regulatory effects of AQP1 on water transport.
C1 [Ming, Guang-Feng; Ma, Xin-Hua; Xu, Dao-Miao; Liu, Zhi-Yong; Ai, Yu-Hang] Cent S Univ, Xiangya Hosp, Dept Crit Care Med, Changsha 410008, Hunan, China.
C1 [Liu, Hui-Xia] Cent S Univ, Xiangya Hosp, Dept Geriatr, Changsha 410008, Hunan, China.
C1 [Shi, Zan-Hua] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, China.
C3 Central South University; Central South University; Central South
   University
RP Shi, ZH (corresponding author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM bright900@163.com
FU Hunan Provincial Natural Science Foundation of China [2015JJ4056]; Hunan
   Provincial Science and Technology Plan Project of China [2013FJ4106];
   High Technology Industry Department, Development and Reform Commission
   of Hunan Province, China [2012-1493]
FX This study was supported by the Hunan Provincial Natural Science
   Foundation of China (2015JJ4056), Hunan Provincial Science and
   Technology Plan Project of China (2013FJ4106) and the High Technology
   Industry Department, Development and Reform Commission of Hunan
   Province, China (2012-1493).
CR Bajwa EK, 2007, CRIT CARE MED, V35, P1290, DOI 10.1097/01.CCM.0000260243.22758.4F
   de Souza PM, 2005, CURR OPIN PHARMACOL, V5, P232, DOI 10.1016/j.coph.2005.01.012
   Fujita-Yoshigaki J, 2008, AM J PHYSIOL-CELL PH, V294, pC774, DOI 10.1152/ajpcell.00472.2007
   Gao W, 2011, RESP PHYSIOL NEUROBI, V178, P235, DOI 10.1016/j.resp.2011.06.016
   Hector J, 2007, HORM METAB RES, V39, P250, DOI 10.1055/s-2007-973075
   Jiang Q, 2009, INT J MOL MED, V23, P771, DOI 10.3892/ijmm_00000191
   Kamp Ryan, 2008, Proc Am Thorac Soc, V5, P348, DOI 10.1513/pats.200709-152DR
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   Li HL, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-15
   Li JH, 2011, RESP PHYSIOL NEUROBI, V176, P39, DOI 10.1016/j.resp.2011.01.005
   Licker M, 2009, CURR OPIN ANESTHESIO, V22, P61, DOI 10.1097/ACO.0b013e32831b466c
   Liu P, 2009, J BIOL CHEM, V284, P27344, DOI 10.1074/jbc.M109.002519
   Liu P, 2009, CELL BIOL INT, V33, P19, DOI 10.1016/j.cellbi.2008.10.015
   Liu SW, 2009, HORM METAB RES, V41, P281, DOI 10.1055/s-0028-1102914
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Martin TR, 2003, CRIT CARE MED, V31, pS184, DOI 10.1097/01.CCM.0000057841.33876.B1
   Moschen AR, 2007, J IMMUNOL, V178, P1748, DOI 10.4049/jimmunol.178.3.1748
   Ognjanovic S, 2002, AM J OBSTET GYNECOL, V187, P1051, DOI 10.1067/mob.2002.126295
   Pilz S, 2007, J ENDOCRINOL INVEST, V30, P138, DOI 10.1007/BF03347412
   Raghavendran K, 2008, CURR MED CHEM, V15, P1911, DOI 10.2174/092986708785132942
   Schindler JF, 2007, J DENT RES, V86, P800, DOI 10.1177/154405910708600902
   Shankardas J, 2010, MOL VIS, V16, P1538
   Su X, 2004, RESP PHYSIOL NEUROBI, V142, P1, DOI 10.1016/j.resp.2004.05.001
   Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818
   Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200
   Verkman AS, 2007, RESP PHYSIOL NEUROBI, V159, P324, DOI 10.1016/j.resp.2007.02.012
   Wang BW, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-27
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ye SQ, 2005, MICROVASC RES, V70, P142, DOI 10.1016/j.mvr.2005.08.003
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
NR 30
TC 9
Z9 12
U1 2
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2015
VL 36
IS 3
BP 890
EP 896
DI 10.3892/ijmm.2015.2283
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CR2DH
UT WOS:000361134700034
PM 26178576
OA Bronze
DA 2023-08-21
ER

PT J
AU Hoegl, S
   Brodsky, KS
   Blackburn, MR
   Karmouty-Quintana, H
   Zwissler, B
   Eltzschig, HK
AF Hoegl, Sandra
   Brodsky, Kelley S.
   Blackburn, Michael R.
   Karmouty-Quintana, Harry
   Zwissler, Bernhard
   Eltzschig, Holger K.
TI Alveolar Epithelial A2B Adenosine Receptors in Pulmonary Protection
   during Acute Lung Injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; HYPOXIA-INDUCIBLE FACTOR; INFLAMMATION;
   CELLS; DISEASE; MODEL; MICE; IDENTIFICATION; MECHANISMS; CLEARANCE
AB Acute lung injury (ALI) is an acute inflammatory lung disease that causes morbidity and mortality in critically ill patients. However, there are many instances where ALI resolves spontaneously through endogenous pathways that help to control excessive lung inflammation. Previous studies have implicated the extracellular signaling molecule adenosine and signaling events through the A2B adenosine receptor in lung protection. In this context, we hypothesized that tissue-specific expression of the A2B adenosine receptor is responsible for the previously described attenuation of ALI. To address this hypothesis, we exposed mice with tissue-specific deletion of Adora2b to ALI, utilizing a two-hit model where intratracheal LPS treatment is followed by injurious mechanical ventilation. Interestingly, a head-to-head comparison of mice with deletion of Adora2b in the myeloid lineage (Adora2b(loxP/loxP) LysM Cre(+)), endothelial cells (Adora2b(loxP/loxP) VE-cadherin Cre(+)), or alveolar epithelial cells (Adora2b(loxP/loxP) SPC Cre(+)) revealed a selective increase in disease susceptibility in Adora2b(loxP/loxP) SPC Cre(+) mice. More detailed analysis of Adora2b(loxP/loxP) SPC Cre(+) mice confirmed elevated lung inflammation and attenuated alveolar fluid clearance. To directly deliver an A2B adenosine receptor-specific agonist to alveolar epithelial cells, we subsequently performed studies with inhaled BAY 60-6583. Indeed, aerosolized BAY 60-6583 treatment was associated with attenuated pulmonary edema, improved histologic lung injury, and dampened lung inflammation. Collectively, these findings suggest that alveolar epithelial A2B adenosine receptor signaling contributes to lung protection, and they implicate inhaled A2B adenosine receptor agonists in ALI treatment.
C1 [Hoegl, Sandra; Brodsky, Kelley S.; Eltzschig, Holger K.] Univ Colorado, Sch Med, Dept Anesthesiol, Organ Protect Program, Aurora, CO 80045, United States.
C1 [Hoegl, Sandra; Zwissler, Bernhard] Univ Munich, Univ Hosp, German Ctr Lung Res, Dept Anesthesiol,Comprehens Pneumol Ctr Munich, D-81377 Munich, Germany.
C1 [Blackburn, Michael R.; Karmouty-Quintana, Harry] Univ Texas Houston, Hlth Sci Ctr Houston, Houston, TX 77030, United States.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Munich; University of Texas System; University of
   Texas Health Science Center Houston
RP Hoegl, S (corresponding author), Univ Munich, Univ Hosp, Dept Anesthesiol, Marchioninistr 15, D-81377 Munich, Germany.
EM Sandra.Hoegl@med.uni-muenchen.de
RI Karmouty-Quintana, Harry/ABC-9144-2020
OI Karmouty-Quintana, Harry/0000-0003-4753-9823; Blackburn,
   Michael/0000-0002-1394-9966; Frank, Sandra/0000-0002-1749-0339
FU Leopoldina-Postdoc-Stipendium from the Deutsche Akademie der
   Naturforscher Leopoldina-German National Academy of Science [LPDS
   2012-02]; National Institutes of Health [HL114457, R01 DK097075, R01
   HL0921, R01 DK083385, R01 HL098294, POIHL114457-01]; Crohn's and Colitis
   Foundation of America
FX This work was supported by research funding by the
   Leopoldina-Postdoc-Stipendium (LPDS 2012-02) from the Deutsche Akademie
   der Naturforscher Leopoldina-German National Academy of Science (to
   S.H.), National Institutes of Health Program Project Grant HL114457 (to
   M.R.B.), National Institutes of Health Grants R01 DK097075, R01 HL0921,
   R01 DK083385, R01 HL098294, and POIHL114457-01, and by a grant from the
   Crohn's and Colitis Foundation of America (to H.K.E.).
CR Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643
   Belikoff BG, 2011, J IMMUNOL, V186, P2444, DOI 10.4049/jimmunol.1001567
   Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159
   Cagnina RE, 2009, AM J PHYSIOL-LUNG C, V297, pL467, DOI 10.1152/ajplung.90553.2008
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5
   Csoka B, 2010, J IMMUNOL, V185, P542, DOI 10.4049/jimmunol.0901295
   Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203
   Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127
   Eckle T, 2014, J IMMUNOL, V192, P1249, DOI 10.4049/jimmunol.1100593
   Eckle T, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001665
   Eckle T, 2013, FASEB J, V27, P3078, DOI 10.1096/fj.13-228551
   Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009
   Ehrentraut H, 2013, FASEB J, V27, P2207, DOI 10.1096/fj.12-225201
   Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Grenz A, 2012, J IMMUNOL, V189, P4566, DOI 10.4049/jimmunol.1201651
   Hardiman KM, 2001, AM J PHYSIOL-LUNG C, V281, pL722, DOI 10.1152/ajplung.2001.281.3.L722
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Hoegl S, 2011, AM J RESP CELL MOL, V44, P369, DOI 10.1165/rcmb.2009-0440OC
   Hoegl S, 2009, RESP MED, V103, P463, DOI 10.1016/j.rmed.2008.09.020
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085
   Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876
   Karmouty-Quintana H, 2012, FASEB J, V26, P2546, DOI 10.1096/fj.11-200907
   Krombach F, 1996, EUR RESPIR J, V9, P984, DOI 10.1183/09031936.96.09050984
   Linden J, 2012, ARTERIOSCL THROM VAS, V32, P2097, DOI 10.1161/ATVBAHA.111.226837
   Manzo ND, 2012, AM J RESP CELL MOL, V47, P349, DOI 10.1165/rcmb.2011-0257OC
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Messier EM, 2012, EXP LUNG RES, V38, P363, DOI 10.3109/01902148.2012.713077
   Mikkelsen ME, 2013, SHOCK, V40, P375, DOI 10.1097/SHK.0b013e3182a64682
   Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a
   Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009
   Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schelling G, 2000, INTENS CARE MED, V26, P1304, DOI 10.1007/s001340051342
   Schingnitz U, 2010, J IMMUNOL, V184, P5271, DOI 10.4049/jimmunol.0903035
   Schneider T, 1996, J IMMUNOL METHODS, V198, P1, DOI 10.1016/0022-1759(96)00143-3
   Singer K., 2011, AM J RESP CRIT CARE, V183, pA5105
   Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581
   SMEDIRA N, 1991, J APPL PHYSIOL, V70, P1827, DOI 10.1152/jappl.1991.70.4.1827
   Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303
   Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669
   Taylor CT, 2010, PHYSIOLOGY, V25, P272, DOI 10.1152/physiol.00029.2010
   Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105
   Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933
   Zhou Y, 2011, J IMMUNOL, V186, P1097, DOI 10.4049/jimmunol.1002907
NR 51
TC 67
Z9 68
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2015
VL 195
IS 4
BP 1815
EP 1824
DI 10.4049/jimmunol.1401957
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CP6QO
UT WOS:000360013200051
PM 26188061
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Liu, TG
   Warburton, RR
   Hill, NS
   Kayyali, US
AF Liu, Tiegang
   Warburton, Rod R.
   Hill, Nicholas S.
   Kayyali, Usamah S.
TI Anthrax lethal toxin-induced lung injury and treatment by activating MK2
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; permeability; MK2; heat shock protein 27; ALI/ARDS 
ID RESPIRATORY-DISTRESS-SYNDROME; BACILLUS-ANTHRACIS; ENDOTHELIAL
   PERMEABILITY; BERLIN DEFINITION; EDEMA TOXIN; HYPOXIA; VIRULENCE;
   PATHWAYS; PROTEIN; CELLS
AB Anthrax is associated with severe vascular leak, which is caused by the bacterial lethal toxin (LeTx). Pleural effusions and pulmonary edema that occur in anthrax are believed to reflect endothelial injury caused by the anthrax toxin. Since vascular leak can also be observed consistently in rats injected intravenously with LeTx, the latter might present a simple physiologically relevant animal model of acute lung injury (ALI). Such a model could be utilized in evaluating and developing better treatment for ALI or acute respiratory distress syndrome (ARDS), as other available rodent models do not consistently produce the endothelial permeability that is a major component of ARDS. The biological activity of LeTx resides in the lethal factor metalloprotease that specifically degrades MAP kinase kinases (MKKs). Recently, we showed that LeTx inactivation of p38 MAP kinase signaling via degradation of MKK3 in pulmonary vascular endothelial cells can be linked to compromise of the endothelial permeability barrier. LeTx effects were linked specifically to blocking activation of p38 substrate and MAP kinase-activated protein kinase 2 (MAPKAPK2 or MK2) and phosphorylation of the latter's substrate, heat shock protein 27 (HSP27). We have now designed a peptide that directly and specifically activates MK2, causing HSP27 phosphorylation in cells and in vivo. The MK2-activating peptide (MK2-AP) also blocks the effects of LeTx on endothelial barriers in cultured cells and reduces LeTx-induced pulmonary vascular leak in rats. Hence, MK2-AP has the therapeutic potential to counteract anthrax or pulmonary edema and vascular leak due to other causes.
C1 Tufts Med Ctr, Pulm Crit Care & Sleep Div, Dept Med, Tupper Res Inst, Boston, MA 02111, United States.
C1 Tufts Univ, Sch Med, Boston, MA 02111, United States.
C3 Tufts Medical Center; Tufts University
RP Kayyali, US (corresponding author), Tufts Med Ctr, Pulm Crit Care & Sleep Div, 800 Washington St,257, Boston, MA 02111 USA.
EM ukayyali@tuftsmedicalcenter.org
FU National Institute of Allergy and Infectious Diseases [AI-096087]
FX This work was supported by National Institute of Allergy and Infectious
   Diseases Grant AI-096087 (to U. S. Kayyali).
CR An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004
   Bradley KA, 2010, CELL HOST MICROBE, V8, P394, DOI 10.1016/j.chom.2010.10.011
   Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869
   Kuo SR, 2008, MICROB PATHOGENESIS, V44, P467, DOI 10.1016/j.micpath.2007.12.001
   Kushimoto S, 2013, CRIT CARE, V17, DOI 10.1186/cc12811
   Liu TG, 2007, AM J RESP CELL MOL, V37, P507, DOI 10.1165/rcmb.2007-0077OC
   Liu TG, 2012, J CELL PHYSIOL, V227, P1438, DOI 10.1002/jcp.22859
   Liu TG, 2010, AM J PHYSIOL-CELL PH, V299, pC363, DOI 10.1152/ajpcell.00057.2010
   Liu T, 2009, J CELL PHYSIOL, V220, P600, DOI 10.1002/jcp.21773
   Lovchik JA, 2012, INFECT IMMUN, V80, P2414, DOI 10.1128/IAI.06340-11
   Lui SH, 2010, CELL HOST MICROBE, V8, P455, DOI 10.1016/j.chom.2010.10.004
   McCormick C, 2006, J VIROL, V80, P6165, DOI 10.1128/JVI.02331-05
   McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779
   Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]
   Parker JC, 2004, AM J PHYSIOL-LUNG C, V286, pL231, DOI 10.1152/ajplung.00049.2003
   PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892
   Tessier DJ, 2004, J VASC SURG, V40, P106, DOI 10.1016/j.jvs.2004.03.028
   Tessier J, 2007, INFECT IMMUN, V75, P1895, DOI 10.1128/IAI.01632-06
NR 20
TC 6
Z9 6
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD AUG 15
PY 2015
VL 119
IS 4
BP 412
EP 419
DI 10.1152/japplphysiol.00335.2015
PG 8
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Sport Sciences
GA CP2QB
UT WOS:000359720900011
PM 26066827
OA Green Published
DA 2023-08-21
ER

PT J
AU Ahn, JJ
   Jung, JP
   Park, SE
   Lee, M
   Kwon, B
   Cho, HR
AF Ahn, Jong J.
   Jung, Jong P.
   Park, Soon E.
   Lee, Minhyun
   Kwon, Byungsuk
   Cho, Hong R.
TI Involvement of Protein Kinase C-delta in Vascular Permeability in Acute
   Lung Injury
SO IMMUNE NETWORK
LA English
DT Article
DE ALI/ARDS; protein kinase C; permeability 
AB Pulmonary edema is a major cause of mortality due to acute lung injury (ALI). The involvement of protein kinase C-delta (PKC-delta) in ALI has been a controversial topic. Here we investigated PKC-delta function in ALI using PKC-delta knockout (KO) mice and PKC inhibitors. Our results indicated that although the ability to produce proinflammatory mediators in response to LPS injury in PKC-delta KO mice was similar to that of control mice, they showed enhanced recruitment of neutrophils to the lung and more severe pulmonary edema. PKC-delta inhibition promoted barrier dysfunction in an endothelial cell layer in vitro, and administration of a PKC-delta-specific inhibitor significantly increased steady state vascular permeability. A neutrophil transmigration assay indicated that the PKC-delta inhibition increased neutrophil transmigration through an endothelial monolayer. This suggests that PKC-delta inhibition induces structural changes in endothelial cells, allowing extravasation of proteins and neutrophils.
C1 [Ahn, Jong J.] Univ Ulsan, Ulsan Univ Hosp, Sch Med, Dept Internal Med, Ulsan 44033, South Korea.
C1 [Jung, Jong P.] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Thorac Surg, Ulsan 44033, South Korea.
C1 [Park, Soon E.; Lee, Minhyun] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, Ulsan 44033, South Korea.
C1 [Kwon, Byungsuk] Univ Ulsan, Sch Biol Sci, Ulsan 44610, South Korea.
C1 [Kwon, Byungsuk; Cho, Hong R.] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Biomed Res Ctr, Ulsan 44033, South Korea.
C1 [Cho, Hong R.] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Surg, 877 Bangeojinsunwhando Ro, Ulsan 44033, South Korea.
C3 University of Ulsan; Ulsan University Hospital; University of Ulsan;
   Ulsan University Hospital; University of Ulsan; Ulsan University
   Hospital; University of Ulsan; University of Ulsan; Ulsan University
   Hospital; University of Ulsan; Ulsan University Hospital
RP Cho, HR (corresponding author), Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Surg, 877 Bangeojinsunwhando Ro, Ulsan 44033, South Korea.
EM bkwon@ulsan.ac.kr; hrcho@uuh.ulsan.kr
FU Ulsan University Hospital (Biomedical Research Center Promotion Fund)
   [11-02]
FX This work was funded by Ulsan University Hospital (Biomedical Research
   Center Promotion Fund 11-02).
CR Baudin B, 2007, NAT PROTOC, V2, P481, DOI 10.1038/nprot.2007.54
   Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Gaudreault N, 2008, ARTERIOSCL THROM VAS, V28, P1527, DOI 10.1161/ATVBAHA.108.166975
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Klinger JR, 2007, J APPL PHYSIOL, V103, P2084, DOI 10.1152/japplphysiol.00695.2007
   Lomas-Neira J, 2005, CYTOKINE, V31, P169, DOI 10.1016/j.cyto.2005.04.005
   Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a
   Neff TA, 2005, AM J PATHOL, V166, P685, DOI 10.1016/S0002-9440(10)62290-0
   PATTERSON CE, 1992, J APPL PHYSIOL, V72, P865, DOI 10.1152/jappl.1992.72.3.865
   Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002
NR 11
TC 3
Z9 3
U1 0
U2 4
PU KOREA ASSOC IMMUNOLOGISTS
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, RM 701, 7 GIL 22, TEHERAN-RO, (635-4
   YEOKSAM-DONG) GANGMAN-GU, SEOUL, 06130, SOUTH KOREA
SN 1598-2629
EI 2092-6685
J9 IMMUNE NETW
PD AUG
PY 2015
VL 15
IS 4
BP 206
EP 211
DI 10.4110/in.2015.15.4.206
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA V7T3F
UT WOS:000421271800006
PM 26330807
OA Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Bock, A
   Tucker, N
   Kelher, MR
   Khan, SY
   Gonzalez, E
   Wohlauer, M
   Hansen, K
   Dzieciatkowska, M
   Sauaia, A
   Banerjee, A
   Moore, EE
   Silliman, CC
AF Bock, Ashley
   Tucker, Nicole
   Kelher, Marguerite R.
   Khan, Samina Y.
   Gonzalez, Eduardo
   Wohlauer, Max
   Hansen, Kirk
   Dzieciatkowska, Monika
   Sauaia, Angels
   Banerjee, Anirban
   Moore, Ernest E.
   Silliman, Christopher C.
TI alpha-ENOLASE CAUSES PROINFLAMMATORY ACTIVATION OF PULMONARY
   MICROVASCULAR ENDOTHELIAL CELLS AND PRIMES NEUTROPHILS THROUGH PLASMIN
   ACTIVATION OF PROTEASE-ACTIVATED RECEPTOR 2
SO SHOCK
LA English
DT Article
DE Organ injury; plasma; proteomics; red blood cells; serine proteases; transfusion 
ID MULTIPLE ORGAN FAILURE; ACUTE LUNG INJURY; PROTEOMIC ANALYSIS;
   GLYCOLYTIC ENZYME; BLOOD; STORAGE; RECRUITMENT; ADHERENCE; TRAUMA; PAR-2
AB Proinflammatory activation of vascular endothelium leading to increased surface expression of adhesion molecules and neutrophil (PMN) sequestration and subsequent activation is paramount in the development of acute lung injury and organ injury in injured patients. We hypothesize that -enolase, which accumulates in injured patients, primes PMNs and causes proinflammatory activation of endothelial cells leading to PMN-mediated cytotoxicity. Methods: Proteomic analyses of field plasma samples from injured versus healthy patients were used for protein identification. Human pulmonary microvascular endothelial cells (HMVECs) were incubated with -enolase or thrombin, and intercellular adhesion molecule-1 surface expression was measured by flow cytometry. A two-event in vitro model of PMN cytotoxicity HMVECs activated with -enolase, thrombin, or buffer was used as targets for lysophosphatidylcholine-primed or buffer-treated PMNs. The PMN priming activity of -enolase was completed, and lysates from both PMNs and HMVECs were immunoblotted for protease-activated receptor 1 (PAR-1) and PAR-2 and coprecipitation of -enolase with PAR-2 and plasminogen/plasmin. Results: -Enolase increased 10.8-fold in injured patients (P < 0.05). Thrombin and -enolase significantly increased intercellular adhesion molecule-1 surface expression on HMVECs, which was inhibited by antiproteases, induced PMN adherence, and served as the first event in the two-event model of PMN cytotoxicity. -Enolase coprecipitated with PAR-2 and plasminogen/plasmin on HMVECs and PMNs and induced PMN priming, which was inhibited by tranexamic acid, and enzymatic activity was not required. Conclusions: -Enolase increases after injury and may activate pulmonary endothelial cells and prime PMNs through plasmin activity and PAR-2 activation. Such proinflammatory endothelial activation may predispose to PMN-mediated organ injury.
C1 [Bock, Ashley; Tucker, Nicole; Kelher, Marguerite R.; Khan, Samina Y.; Silliman, Christopher C.] Univ Colorado Denver, Bonfils Blood Ctr, Res Lab, Aurora, CO, United States.
C1 [Bock, Ashley] Univ Colorado Denver, Sch Med, Aurora, CO, United States.
C1 [Kelher, Marguerite R.; Gonzalez, Eduardo; Wohlauer, Max; Sauaia, Angels; Banerjee, Anirban; Moore, Ernest E.; Silliman, Christopher C.] Univ Colorado Denver, Sch Med, Dept Surg, Aurora, CO, United States.
C1 [Khan, Samina Y.; Silliman, Christopher C.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO, United States.
C1 [Hansen, Kirk; Dzieciatkowska, Monika] Univ Colorado Denver, Sch Med, Dept Cell Biol, Aurora, CO, United States.
C1 [Sauaia, Angels] Univ Colorado, Sch Publ Hlth, Denver, CO 80202, United States.
C1 [Moore, Ernest E.] Denver Hlth Med Ctr, Dept Surg, Denver, CO, United States.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; Children's Hospital Colorado;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; Children's Hospital Colorado; University of Colorado System;
   University of Colorado Anschutz Medical Campus; Children's Hospital
   Colorado; University of Colorado System; University of Colorado Anschutz
   Medical Campus; Children's Hospital Colorado; University of Colorado
   System; University of Colorado Anschutz Medical Campus; Colorado School
   of Public Health; University of Colorado System; University of Colorado
   Denver; Denver Health Medical Center
RP Silliman, CC (corresponding author), Bonfils Blood Ctr, Res Lab, 717 Yosemite St, Denver, CO 80230 USA.
EM christopher.silliman@ucdenver.edu
FU Bonfils Blood Center; National Institute of General Medical Sciences,
   National Institutes of Health [P50 GM049222]
FX These studies were funded by Bonfils Blood Center and grant P50 GM049222
   from National Institute of General Medical Sciences, National Institutes
   of Health.
CR Belvitch P, 2014, MICROVASC RES, V95, P94, DOI 10.1016/j.mvr.2014.07.007
   Bergmann SN, 2004, INDIAN J MED RES, V119, P29
   Chumchua V, 2008, BIOINFORMATION, V3, P18, DOI 10.6026/97320630003018
   Ciesla DJ, 2005, ARCH SURG-CHICAGO, V140, P432, DOI 10.1001/archsurg.140.5.432
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   D'Alessandro A, 2014, SHOCK, V42, P509, DOI 10.1097/SHK.0000000000000259
   Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795
   Domotor E, 2002, J NEUROCHEM, V80, P746, DOI 10.1046/j.0022-3042.2002.00759.x
   Dzieciatkowska M, 2013, VOX SANG, V105, P210, DOI 10.1111/vox.12042
   Dzieciatkowska M, 2014, SHOCK, V42, P485, DOI 10.1097/SHK.0000000000000249
   Ghosh AK, 2011, MEM I OSWALDO CRUZ, V106, P85, DOI 10.1590/S0074-02762011000900011
   Gonzales JN, 2014, VASC PHARMACOL, V62, P63, DOI 10.1016/j.vph.2014.01.005
   Gonzalez E, 2014, SHOCK, V41, P48
   Hirano Katsuya, 2003, J Atheroscler Thromb, V10, P211
   Kang HJ, 2008, ACTA CRYSTALLOGR D, V64, P651, DOI 10.1107/S0907444908008561
   KARIKO K, 1993, INT J ONCOL, V3, P1089
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   McLaughlin NJD, 2006, J IMMUNOL, V176, P7039, DOI 10.4049/jimmunol.176.11.7039
   Miles LA, 2003, THROMB HAEMOSTASIS, V90, P564
   Molino M, 1997, J BIOL CHEM, V272, P11133
   Pancholi V, 2003, MICROB PATHOGENESIS, V35, P293, DOI 10.1016/j.micpath.2003.08.004
   Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910
   PARTRICK DA, 1996, NEW HORIZ, V4, P194
   SALZER WL, 1990, J CLIN INVEST, V85, P1135, DOI 10.1172/JCI114545
   SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39
   Schultz MJ, 2006, CRIT CARE MED, V34, P871, DOI [10.1097/01.CCM.0000201882.23917.B8, 10.1097/01.CCM.0000202136.91651.34]
   SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684
   Smith CW, 2008, J ALLERGY CLIN IMMUN, V121, pS375, DOI 10.1016/j.jaci.2007.07.030
   Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025
   VERCELLOTTI GM, 1989, J LEUKOCYTE BIOL, V45, P483, DOI 10.1002/jlb.45.6.483
   Weinberg JA, 2010, J TRAUMA, V69, P1427, DOI 10.1097/TA.0b013e3181fa0019
   Wygrecka M, 2009, BLOOD, V113, P5588, DOI 10.1182/blood-2008-08-170837
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1
NR 35
TC 16
Z9 17
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD AUG
PY 2015
VL 44
IS 2
BP 137
EP 142
DI 10.1097/SHK.0000000000000394
PG 6
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA CM9RQ
UT WOS:000358047000007
PM 25944790
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Greineder, CF
   Brenza, JB
   Carnemolla, R
   Zaitsev, S
   Hood, ED
   Pan, DC
   Ding, BS
   Esmon, CT
   Chacko, AM
   Muzykantov, VR
AF Greineder, Colin F.
   Brenza, Jacob B.
   Carnemolla, Ronald
   Zaitsev, Sergei
   Hood, Elizabeth D.
   Pan, Daniel C.
   Ding, Bi-Sen
   Esmon, Charles T.
   Chacko, Ann Marie
   Muzykantov, Vladimir R.
TI Dual targeting of therapeutics to endothelial cells: collaborative
   enhancement of delivery and effect
SO FASEB JOURNAL
LA English
DT Article
DE drug delivery; PECAM-1; thrombomodulin; EPCR 
ID PROTEIN-C RECEPTOR; SOLUBLE THROMBOMODULIN ART-123; SEVERE SEPSIS;
   IN-VITRO; ESCHERICHIA-COLI; DRUG-DELIVERY; ACTIVATION; MODEL;
   COAGULATION; RELEASE
AB Anchoring pharmacologic agents to the vascular lumen has the potential to modulate critical processes at the blood-tissue interface, avoiding many of the off-target effects of systemically circulating agents. We report a novel strategy for endothelial dual targeting of therapeutics, which both enhances drug delivery and enables targeted agents to partner enzymatically to generate enhanced biologic effect. Based on the recent discovery that paired antibodies directed to adjacent epitopes of platelet endothelial cell adhesion molecule (PECAM)-1 stimulate each other's binding, we fused single-chain fragments (scFv) of paired anti-mouse PECAM-1 antibodies to recombinant murine thrombomodulin (TM) and endothelial protein C receptor (EPCR), endothelial membrane proteins that partner in activation of protein C (PC). scFv/TM and scFv/EPCR bound to mouse endothelial PECAM-1 with high affinity (EC50 1.5 and 3.8 nM, respectively), and codelivery induced a 5-fold increase in PC activation not seen when TM and EPCR are anchored to distinct cell adhesion molecules. In a mouse model of acute lung injury, dual targeting reduces both the expression of lung inflammatory markers and trans-endothelial protein leak by as much as 40%, as compared to either agent alone. These findings provide proof of principle for endothelial dual targeting, an approach with numerous potential biomedical applications.-Greineder, C. F., Brenza, J. B., Carnemolla, R., Zaitsev, S., Hood, E. D., Pan, D. C., Ding, B.-S., Esmon, C. T., Chacko, A. M., Muzykantov, V. R. Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect.
C1 [Greineder, Colin F.; Carnemolla, Ronald; Zaitsev, Sergei; Hood, Elizabeth D.; Pan, Daniel C.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104, United States.
C1 [Greineder, Colin F.; Brenza, Jacob B.; Carnemolla, Ronald; Zaitsev, Sergei; Hood, Elizabeth D.; Pan, Daniel C.; Chacko, Ann Marie; Muzykantov, Vladimir R.] Univ Penn, Inst Translat Med & Therapeut, Ctr Targeted Therapeut & Translat Nanomed, Perelman Sch Med, Philadelphia, PA 19104, United States.
C1 [Chacko, Ann Marie] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104, United States.
C1 [Greineder, Colin F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104, United States.
C1 [Ding, Bi-Sen] Weill Cornell Med Coll, Howard Hughes Med Inst, Dept Med Genet, New York, NY, United States.
C1 [Esmon, Charles T.] Howard Hughes Med Inst, Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK, United States.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; University of Pennsylvania; Pennsylvania
   Medicine; Cornell University; Weill Cornell Medicine; Howard Hughes
   Medical Institute; Howard Hughes Medical Institute; Oklahoma Medical
   Research Foundation
RP Muzykantov, VR (corresponding author), Univ Penn, Inst Translat Med & Therapeut, Translat Res Ctr, Perelman Sch Med, TRC 10-125,3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
OI Greineder, Colin/0000-0001-9740-7672; Chacko,
   Ann-Marie/0000-0001-5140-2622
FU Institute of Translational Medicine and Therapeutics at the University
   of Pennsylvania; American Heart Association Fellow-to-Faculty Grant
   [10FTF4150053]; U. S. National Institutes of Health Grant from the
   National Heart, Lung, and Blood Institute [R01-HL091950]
FX The authors thank Dr. Annunciata Vecchi (Mario Negri Institute of
   Pharmacology Research, Milan, Italy) for her generous gift of Mec13
   hybridoma lysate. This work was supported by a Junior Investigator
   Preliminary/Feasibility Grant Program grant from the Institute of
   Translational Medicine and Therapeutics at the University of
   Pennsylvania (to C.F.G.), as well as an American Heart Association
   Fellow-to-Faculty Grant 10FTF4150053 (to C.F.G.), and a U. S. National
   Institutes of Health Grant R01-HL091950 from the National Heart, Lung,
   and Blood Institute (to V.R.M.).
CR Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Boehme MWJ, 1996, IMMUNOLOGY, V87, P134
   Carnemolla R, 2012, J IMMUNOL METHODS, V384, P21, DOI 10.1016/j.jim.2012.06.012
   Carnemolla R, 2010, SEMIN THROMB HEMOST, V36, P332, DOI 10.1055/s-0030-1253455
   Chacko AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034958
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   DUBEL S, 1994, J IMMUNOL METHODS, V175, P89, DOI 10.1016/0022-1759(94)90334-4
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Esmon CT, 2001, CRIT CARE, V5, pS7, DOI 10.1186/cc1333
   ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164
   ESMON CT, 1989, J BIOL CHEM, V264, P4743
   Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603
   Feistritzer C, 2006, J BIOL CHEM, V281, P20077, DOI 10.1074/jbc.M600506200
   Greineder CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080110
   Greineder CF, 2013, BLOOD, V122, P1565, DOI 10.1182/blood-2013-03-453498
   Gu JM, 2000, BLOOD, V95, P1687, DOI 10.1182/blood.V95.5.1687.005k08_1687_1693
   Han HS, 2001, J BIOMAT SCI-POLYM E, V12, P1075, DOI 10.1163/15685620152691869
   Kador KE, 2011, ACTA BIOMATER, V7, P2508, DOI 10.1016/j.actbio.2011.03.015
   Kearon C, 2005, J THROMB HAEMOST, V3, P962, DOI 10.1111/j.1538-7836.2005.01251.x
   Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404
   KISHIDA A, 1994, BIOMATERIALS, V15, P848, DOI 10.1016/0142-9612(94)90041-8
   Koren E, 2011, IUBMB LIFE, V63, P586, DOI 10.1002/iub.496
   Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725
   Li W, 2005, J THROMB HAEMOST, V3, P1351, DOI 10.1111/j.1538-7836.2005.01385.x
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muzykantov V.R., 2013, ISRN VASC MED, V2013, DOI DOI 10.1155/2013/916254
   Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909
   Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129
   Opal SM, 2013, AM J RESP CRIT CARE, V187, P1041, DOI 10.1164/rccm.201303-0505ED
   REDL H, 1995, J INFECT DIS, V171, P1522, DOI 10.1093/infdis/171.6.1522
   Saito H, 2007, J THROMB HAEMOST, V5, P31, DOI 10.1111/j.1538-7836.2006.02267.x
   Schouten M, 2014, THROMB HAEMOSTASIS, V111, P970, DOI 10.1160/TH13-10-0859
   SOLIS MM, 1991, J VASC SURG, V14, P599
   Sperling C, 2004, BIOMATERIALS, V25, P5101, DOI 10.1016/j.biomaterials.2003.12.014
   StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212
   Su EJ, 2011, J THROMB HAEMOST, V9, P1174, DOI 10.1111/j.1538-7836.2011.04269.x
   Sun J, 2000, J CELL SCI, V113, P1459
   TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902
   Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   Tseng PY, 2006, BIOMATERIALS, V27, P2768, DOI 10.1016/j.biomaterials.2005.11.032
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038
   Zhang HL, 2013, BIOCONJUGATE CHEM, V24, P550, DOI 10.1021/bc300399f
NR 46
TC 22
Z9 22
U1 0
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2015
VL 29
IS 8
BP 3483
EP 3492
DI 10.1096/fj.15-271213
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA CN9VA
UT WOS:000358796900034
PM 25953848
OA Green Published
DA 2023-08-21
ER

PT J
AU Ma, MM
   Li, Y
   Liu, XY
   Zhu, WW
   Ren, X
   Kong, GQ
   Huang, X
   Wang, LP
   Luo, LQ
   Wang, XZ
AF Ma, Mingming
   Li, Yan
   Liu, Xiangyong
   Zhu, Wei-Wei
   Ren, Xiang
   Kong, Guiqing
   Huang, Xiao
   Wang, Li-Peng
   Luo, Liqing
   Wang, Xiaozhi
TI Cyanidin-3-O-Glucoside Ameliorates Lipopolysaccharide-Induced Injury
   Both In Vivo and In Vitro Suppression of NF-kappa B and MAPK Pathways
SO INFLAMMATION
LA English
DT Article
DE ALI/ARDS; LPS; C3G; NF-kappa B; MAPK 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; OXIDATIVE STRESS;
   TNF-ALPHA; ANTIOXIDANT SUPPLEMENTATION; SEPTIC SHOCK; MICE;
   INFLAMMATION; SUPEROXIDE; CELLS
AB Cyanidin-3-O-glucoside (C3G), an anthocyanin belonging to the flavonoid family and commonly present in food and vegetables in human diet, has exhibited anti-inflammatory and anti-oxidant effects. This study aimed to investigate the protective ability of C3G against inflammatory and oxidative injuries, as well as to clarify the possible mechanism in lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs) in vitro and acute respiratory distress syndrome mouse model in vivo. HUVECs or male Kunming mice were pretreated with C3G 1 h before LPS stimulation. C3G significantly inhibited the production of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin (IL) -6, and IL-1 beta) in cell supernatants and bronchoalveolar lavage fluid (BALF) as determined by enzyme-linked immunosorbent assay. Histopathologic examination with hematoxylin and eosinstaining showed that C3G pretreatment substantially suppressed inflammatory cell infiltration, alveolar wall thickening, and interstitial edemain lung tissues. C3G markedly prevented LPS-induced elevation of malondialdehyde and myeloperoxidase levels in lung tissue homogenates, wet to dry ratio of lung tissues, total cells, and inflammatory cells (neutrophils and macrophages) in BALF. Moreover, C3G reduced superoxide dismutase activity in the lung tissue homogenates. Western blot assay also showed that C3G pretreatment significantly suppressed LPS-induced activation of nuclear factor-kappaB (NF-kappa B) and mitogen-activated protein kinase (MAPK) signaling pathways by blocking the phosphorylation of inhibitor kappa B-alpha, NF-kappa B/P65, extracellular signal-regulated kinase, p38, and c-Jun NH2-terminal kinase in the lung tissues. In summary, C3G may ameliorate LPS-induced injury, which results from inflammation and oxidation, by inhibiting NF-kappa B and MAPK pathways and playing important anti-inflammatory and anti-oxidative roles.
C1 [Ma, Ming-Ming; Li, Yan; Zhu, Wei-Wei; Kong, Gui-Qing; Huang, Xiao; Wang, Li-Peng; Wang, Xiao-Zhi] Binzhou Med Univ, Affiliated Hosp, Dept Respirator Med & Intens Care Unit, Binzhou 256603, Shandong, China.
C1 [Liu, Xiang-Yong] Binzhou Med Univ, Dept Cell Biol, Yantai 264003, Shandong, China.
C1 [Ren, Xiang] Binzhou Med Univ, Affiliated Hosp, Pediat Surg, Binzhou 256603, Shandong, China.
C1 [Luo, Li-Qing] Binzhou Med Univ, Affiliated Hosp, Cell Morphol Room, Binzhou 256603, Shandong, China.
C3 Binzhou Medical University; Binzhou Medical University; Binzhou Medical
   University; Binzhou Medical University
RP Liu, XY (corresponding author), Binzhou Med Univ, Dept Cell Biol, Yantai 264003, Shandong, Peoples R China.
EM liuxiangyong81@gmail.com; hxicuwxz@163.com
OI Ren, Xiang/0000-0002-9923-6077
FU Natural Science Foundation of Shandong Province [ZR2014HM112,
   ZR2014HL004]; Science and Technology Development Plan of Shandong
   Province [2011GSF11830]; Taishan Scholar project of Shandong Province
FX This work has received funding from the Natural Science Foundation of
   Shandong Province, (ZR2014HM112 and ZR2014HL004), the Science and
   Technology Development Plan of Shandong Province (2011GSF11830), and
   Taishan Scholar project of Shandong Province.
CR [Anonymous], ADV THEOR APPL MECH
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086
   Chon H, 2010, COMP IMMUNOL MICROB, V33, pE41, DOI 10.1016/j.cimid.2009.11.002
   Conti G, 2010, MAGN RESON MATER PHY, V23, P93, DOI 10.1007/s10334-010-0203-1
   Cribbs SK, 2010, CRIT CARE MED, V38, P2379, DOI 10.1097/CCM.0b013e3181f96f5f
   Faffe DS, 2000, EUR RESPIR J, V15, P85, DOI 10.1034/j.1399-3003.2000.15a16.x
   Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25
   Fu YH, 2014, J LIPID RES, V55, P1111, DOI 10.1194/jlr.M047340
   Fu YH, 2014, BIOCHEM PHARMACOL, V90, P126, DOI 10.1016/j.bcp.2014.05.004
   Gawel Stefan, 2004, Wiad Lek, V57, P453
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Liu Y, 2011, INT IMMUNOPHARMACOL, V11, P1606, DOI 10.1016/j.intimp.2011.05.022
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Macarthur H, 2000, P NATL ACAD SCI USA, V97, P9753, DOI 10.1073/pnas.97.17.9753
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mishra V, 2007, CLIN LAB, V53, P199
   Nasri Sima, 2011, Pathophysiology, V18, P273, DOI 10.1016/j.pathophys.2011.03.001
   Parker JC, 2004, AM J PHYSIOL-LUNG C, V286, pL231, DOI 10.1152/ajplung.00049.2003
   Sakaguchi S, 2006, FEMS IMMUNOL MED MIC, V47, P167, DOI 10.1111/j.1574-695X.2006.00072.x
   Schuepbach RA, 2009, THROMB HAEMOSTASIS, V101, P724, DOI 10.1160/TH08-10-0632
   Speciale A, 2013, MOL NUTR FOOD RES, V57, P1979, DOI 10.1002/mnfr.201300102
   Speciale A, 2010, J AGR FOOD CHEM, V58, P12048, DOI 10.1021/jf1029515
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Ueda J, 2008, FREE RADICAL BIO MED, V45, P897, DOI 10.1016/j.freeradbiomed.2008.06.016
   Urso ML, 2003, TOXICOLOGY, V189, P41, DOI 10.1016/S0300-483X(03)00151-3
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zhang X, 2010, INJURY, V41, P746, DOI 10.1016/j.injury.2010.02.029
   Zhou ES, 2014, INT IMMUNOPHARMACOL, V22, P133, DOI 10.1016/j.intimp.2014.06.004
NR 33
TC 47
Z9 48
U1 2
U2 39
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD AUG
PY 2015
VL 38
IS 4
BP 1669
EP 1682
DI 10.1007/s10753-015-0144-y
PG 14
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA CM4PD
UT WOS:000357666000034
PM 25752620
DA 2023-08-21
ER

PT J
AU Yang, W
   Xv, M
   Yang, WC
   Wang, N
   Zhang, XZ
   Li, WZ
AF Yang, Wang
   Xv, Meng
   Yang, Wan Chao
   Wang, Nan
   Zhang, Xue Zhong
   Li, Wen Zhi
TI Exogenous alpha-calcitonin gene-related peptide attenuates
   lipopolysaccharide-induced acute lung injury in rats
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ALI/ARDS; calcitonin gene-related peptide; LPS 
ID RESPIRATORY-DISTRESS-SYNDROME; RECEPTOR-LIKE RECEPTOR; CELL-FUNCTION;
   NEUROPEPTIDE; INFLAMMATION; MICE; CGRP; TIME; IDENTIFICATION; MECHANISMS
AB alpha-Calcitonin gene-related peptide (a-CGRP) is a 37 amino-acid neuropeptide that is primarily released from C-type sensory neurons. alpha-CGRP exerts multiple modulatory effects on immune responses and visceral organ function, but the role of exogenous alpha-CGRP in lipopolysaccharide (LPS)-induced acute lung injury (ALI) has remained to be elucidated. Forty-eight rats were randomized to receive continuous intraperitoneal infusion of alpha-CGRP (0.4 mu g/kg/min) or normal saline for 30 min, followed by intratracheal injection of 0.5 mg/kg LPS or saline. There were four groups of animals: The saline-saline (S-S) group; the saline-alpha-CGRP (S-C) group; the LPS-saline (L-S) group and the LPS-alpha-CGRP (L-C) group. Mean arterial pressure and arterial blood gases were assessed prior to alpha-CGRP and LPS administration and every hour following LPS treatment. After 4 h, bronchoalveolar lavage was performed and used to assess total cell count and levels of tumor necrosis factor-a, interleukin-1 beta, intracellular cell adhesion molecule 1 and macrophage inflammatory protein 2. Lung tissue was also collected for assessing wet-to-dry (W/D) ratio, histology and Evans blue (EB) dye extravasation. Pulmonary alpha-CGRP concentration and alpha-CGRP receptor expression were also examined, and inducible cyclic adenosine monophosphate early repressor (ICER) and TNF-alpha mRNA expression levels were measured. Treatment with exogenous alpha-CGRP improved oxygenation during LPS-induced ALI. Correspondingly, histological injury, total cell count, inflammatory cytokine levels, W/D ratio and EB dye extravasation were also significantly reduced. alpha-CGRP receptor 1 expression was noted in pulmonary endothelial cells and alveolar macrophages and alpha-CGRP receptor expression levels were decreased during ALI, whereas pulmonary alpha-CGRP expression was continuously increased. Furthermore, exogenous alpha-CGRP induced upregulation of ICER during LPS-induced ALI. In conclusion, exogenous alpha-CGRP improved oxygenation and ameliorated lung damage in LPS-induced ALI, and these effects were associated with the upregulation of ICER.
C1 [Yang, Wang; Xv, Meng; Yang, Wan Chao; Wang, Nan; Zhang, Xue Zhong; Li, Wen Zhi] Harbin Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Harbin 150001, Heilongjiang, China.
C1 [Yang, Wang; Xv, Meng; Yang, Wan Chao; Wang, Nan; Zhang, Xue Zhong; Li, Wen Zhi] Harbin Med Univ, Educ Dept Heilongjiang Prov, Anesthesiol Key Lab, Harbin 150001, Heilongjiang, China.
C3 Harbin Medical University; Harbin Medical University
RP Li, WZ (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 148 Baojian St, Harbin 150001, Heilongjiang, Peoples R China.
EM wenzhili9@126.com
FU Major Basic Research Project of the Second Affiliated Hospital of Harbin
   Medical University (Harbin, China) [100286]
FX The present study was supported by the Major Basic Research Project of
   the Second Affiliated Hospital of Harbin Medical University (Harbin,
   China; no. 100286).
CR Altmayr F, 2010, J BIOL CHEM, V285, P3525, DOI 10.1074/jbc.M109.066787
   Aoki-Nagase T, 2007, RESPIROLOGY, V12, P807, DOI 10.1111/j.1440-1843.2007.01172.x
   Aslam M, 2012, BRIT J PHARMACOL, V165, P208, DOI 10.1111/j.1476-5381.2011.01540.x
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   BUCKLEY TL, 1991, BRIT J PHARMACOL, V103, P1515, DOI 10.1111/j.1476-5381.1991.tb09819.x
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71
   COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715
   Cueille C, 2002, BIOCHEM BIOPH RES CO, V294, P340, DOI 10.1016/S0006-291X(02)00487-4
   Dakhama A, 2004, CURR OPIN PHARMACOL, V4, P215, DOI 10.1016/j.coph.2004.01.006
   Dang HX, 2012, TOHOKU J EXP MED, V227, P129, DOI 10.1620/tjem.227.129
   Ding WH, 2007, J INVEST DERMATOL, V127, P2357, DOI 10.1038/sj.jid.5700858
   Doerschuk CM, 1996, J IMMUNOL, V157, P4609
   Fox FE, 1997, J INVEST DERMATOL, V108, P43, DOI 10.1111/1523-1747.ep12285627
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c
   Hagner S, 2002, CELL TISSUE RES, V310, P41, DOI 10.1007/s00441-002-0616-x
   Hartopo AB, 2013, AM J RESP CELL MOL, V48, P465, DOI 10.1165/rcmb.2012-0354OC
   Harzenetter MD, 2007, J IMMUNOL, V179, P607, DOI 10.4049/jimmunol.179.1.607
   Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9
   Ho CY, 2001, RESP PHYSIOL, V127, P113, DOI 10.1016/S0034-5687(01)00241-9
   Huang J, 2011, BRAIN BEHAV IMMUN, V25, P787, DOI 10.1016/j.bbi.2011.02.007
   Ji P, 2013, J SURG RES, V184, P782, DOI 10.1016/j.jss.2012.12.011
   KENNEDY TP, 1989, ANESTH ANALG, V69, P87
   Kroeger I, 2009, J HEPATOL, V51, P342, DOI 10.1016/j.jhep.2009.03.022
   Kuwano K, 2000, AM J RESP CELL MOL, V22, P147, DOI 10.1165/ajrcmb.22.2.f178
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma WY, 2010, IMMUNOLOGY, V130, P399, DOI 10.1111/j.1365-2567.2009.03239.x
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Ogoshi M, 2006, PEPTIDES, V27, P3154, DOI 10.1016/j.peptides.2006.09.011
   Okajima K, 2005, CRIT CARE MED, V33, P847, DOI 10.1097/01.CCM.0000159721.72629.49
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Rochlitzer S, 2011, CLIN EXP ALLERGY, V41, P1609, DOI 10.1111/j.1365-2222.2011.03822.x
   SIREN AL, 1988, J PHARMACOL EXP THER, V247, P69
   Walker CS, 2010, TRENDS PHARMACOL SCI, V31, P476, DOI 10.1016/j.tips.2010.06.006
   Wang W, 2005, J BIOL CHEM, V280, P20325, DOI 10.1074/jbc.M413864200
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612
   Yamasawa H, 1999, INFLAMMATION, V23, P263
   Yuan Y, 2012, J GERIATR CARDIOL, V9, P17, DOI 10.3724/SP.J.1263.2012.00017
   Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134
NR 45
TC 7
Z9 9
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2015
VL 12
IS 2
BP 2181
EP 2188
DI 10.3892/mmr.2015.3620
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CN8GR
UT WOS:000358678600080
PM 25892548
OA Bronze
DA 2023-08-21
ER

PT J
AU Bayat, B
   Tjahjono, Y
   Berghofer, H
   Werth, S
   Deckmyn, H
   De Meyer, SF
   Sachs, UJ
   Santoso, S
AF Bayat, Behnaz
   Tjahjono, Yudy
   Berghoefer, Heike
   Werth, Silke
   Deckmyn, Hans
   De Meyer, Simon F.
   Sachs, Ulrich J. H.
   Santoso, Sentot
TI Choline Transporter-Like Protein-2 New von Willebrand Factor-Binding
   Partner Involved in Antibody-Mediated Neutrophil Activation and
   Transfusion-Related Acute Lung Injury
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE cholin transporter-like protein 2; von Willebrand factor 
ID MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; HOMOTYPIC ADHESION;
   ENDOTHELIAL-CELLS; MICE; ADAMTS13; INFLAMMATION; DAMAGE; TRAPS; MODEL;
   TRALI
AB Objective In contrast to other antibodies involved in transfusion-related acute lung injury, anti-HNA-3a antibodies are incapable of inducing direct neutrophil activation and seem to interact with endothelial cells (ECs) primarily. In animal studies, anti-HNA-3a-mediated transfusion-related acute lung injury could be precipitated in the absence of neutrophils, but was stronger when neutrophils were present. In a different context the target protein of these antibodies, choline transporter-like protein-2 (CTL-2), was reported to interact with a protein of the inner ear carrying 2 von Willebrand factor (VWF) A-domains. These observations prompted us to investigate whether VWF might be involved in anti-HNA-3a-mediated neutrophil activation, and whether signaling via CD11b/CD18 is involved, as in various other experimental settings.
   Approach and Results Cell adhesion demonstrated specific binding of CTL-2 to VWF. Immunoprecipitation analysis of CTL-2/CD11b/CD18 coexpressing cells indicated that anti-HNA-3a colocalizes CTL-2 and CD11b/CD18 when VWF is present. Functional studies revealed that anti-HNA-3a-mediated neutrophil agglutination is an active, protein kinase C-dependent and partially Fc-dependent process. Agglutination and the production of reactive oxygen species seem to require the formation of a trimolecular complex between the target antigen (CTL-2), CD11b/CD18 and VWF. In line with these observations, anti-HNA-3a induced less severe transfusion-related acute lung injury and less neutrophil recruitment to the alveolar space in VWF knockout mice.
   Conclusions We introduce CTL-2 as a new binding partner for VWF. Interaction of neutrophils with VWF via CTL-2 allows anti-HNA-3a to induce signal transduction via CD11b/CD18, which leads to neutrophil activation and agglutination. In transfusion-related acute lung injury, this mechanism may further aggravate endothelial leakage.
C1 [Bayat, Behnaz; Tjahjono, Yudy; Berghoefer, Heike; Werth, Silke; Sachs, Ulrich J.; Santoso, Sentot] Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany.
C1 [Deckmyn, Hans; De Meyer, Simon F.] KU Leuven Kulak, Lab Thrombosis Res, Kortrijk, Belgium.
C3 Justus Liebig University Giessen; 1EUROPE; KU Leuven
RP Santoso, S (corresponding author), Univ Giessen, Inst Clin Immunol & Transfus Med, Langhansstr 7, D-35392 Giessen, Germany.
EM sentot.santoso@med.uni-giessen.de
RI Deckmyn, Hans/L-9434-2015; Sachs, Ulrich/GSI-7824-2022; Werth,
   Silke/I-4757-2012; Deckmyn, Hans/N-8932-2019
OI Deckmyn, Hans/0000-0003-3952-5501; Werth, Silke/0000-0002-4981-7850;
   Deckmyn, Hans/0000-0003-3952-5501; Tjahjono, Yudy/0000-0003-0187-0270;
   De Meyer, Simon/0000-0002-1807-5882
FU German Research Foundation [TR-SFB84]; Excellence Cluster
   Cardiopulmonary System; University Hospital Giessen; Marburg intramural
   research grant
FX This work was supported by the German Research Foundation TR-SFB84 (to
   S. Santoso), the Excellence Cluster Cardiopulmonary System (to S.
   Santoso and B. Bayat) and a University Hospital Giessen and Marburg
   intramural research grant (to U.J. Sachs and S. Santoso). The article
   contains parts of a doctoral thesis of Y. Tjahjono.
CR Bayat B, 2013, ARTERIOSCL THROM VAS, V33, P2538, DOI 10.1161/ATVBAHA.113.301206
   Bayat B, 2012, CURR PHARM DESIGN, V18, P3236, DOI 10.2174/1381612811209023236
   Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Chauhan AK, 2008, J EXP MED, V205, P2065, DOI 10.1084/jem.20080130
   Curtis BR, 2010, BLOOD, V115, P2073, DOI 10.1182/blood-2009-11-248336
   Danielson C, 2008, TRANSFUSION, V48, P2401, DOI 10.1111/j.1537-2995.2008.01879.x
   De Meyer SF, 2012, BLOOD, V120, P5217, DOI 10.1182/blood-2012-06-439935
   Gandhi C, 2012, BLOOD, V120, P5224, DOI 10.1182/blood-2012-06-440255
   Grassle S, 2014, ARTERIOSCL THROM VAS, V34, P1382, DOI 10.1161/ATVBAHA.113.303016
   Greinacher A, 2010, NAT MED, V16, P45, DOI 10.1038/nm.2070
   Hillgruber C, 2014, J INVEST DERMATOL, V134, P77, DOI 10.1038/jid.2013.292
   KIEFEL V, 1987, BLOOD, V70, P1722
   Kirschenbaum LA, 2004, CRIT CARE MED, V32, P1904, DOI 10.1097/01.CCM.0000139918.80602.57
   Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905
   Kommareddi PK, 2007, JARO-J ASSOC RES OTO, V8, P435, DOI 10.1007/s10162-007-0099-2
   MCCULLOUGH J, 1988, TRANSFUSION, V28, P358, DOI 10.1046/j.1537-2995.1988.28488265267.x
   MERRILL JT, 1990, J IMMUNOL, V145, P2608
   Neelamegham S, 2000, J IMMUNOL, V164, P3798, DOI 10.4049/jimmunol.164.7.3798
   Pendu R, 2006, BLOOD, V108, P3746, DOI 10.1182/blood-2006-03-010322
   Petri B, 2010, BLOOD, V116, P4712, DOI 10.1182/blood-2010-03-276311
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Sachs UJ, 2012, TRANSFUS CLIN BIOL, V19, P109, DOI 10.1016/j.tracli.2012.03.003
   Sachs UJ, 2011, CURR OPIN HEMATOL, V18, P436, DOI 10.1097/MOH.0b013e32834bab01
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   Yamakuchi M, 2007, P NATL ACAD SCI USA, V104, P1301, DOI 10.1073/pnas.0602035104
   YODER MC, 1990, J APPL PHYSIOL, V69, P207, DOI 10.1152/jappl.1990.69.1.207
   Zhang X, 2009, AM J TRANSPLANT, V9, P2459, DOI 10.1111/j.1600-6143.2009.02819.x
NR 29
TC 27
Z9 28
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUL
PY 2015
VL 35
IS 7
BP 1616
EP 1622
DI 10.1161/ATVBAHA.115.305259
PG 7
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA CL3RE
UT WOS:000356867300010
PM 25931511
OA Bronze
DA 2023-08-21
ER

PT J
AU Shah, D
   Romero, F
   Duong, M
   Wang, ND
   Paudyal, B
   Suratt, BT
   Kallen, CB
   Sun, JX
   Zhu, Y
   Walsh, K
   Summer, R
AF Shah, Dilip
   Romero, Freddy
   Duong, Michelle
   Wang, Nadan
   Paudyal, Bishnuhari
   Suratt, Benjamin T.
   Kallen, Caleb B.
   Sun, Jianxin
   Zhu, Ying
   Walsh, Kenneth
   Summer, Ross
TI Obesity-induced adipokine imbalance impairs mouse pulmonary vascular
   endothelial function and primes the lung for injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PHENOTYPIC HETEROGENEITY; NEUTROPHIL RECRUITMENT; ADIPOSE-TISSUE;
   INFLAMMATION; DYSFUNCTION; MECHANISMS; JUNCTIONS; RESPONSES
AB Obesity is a risk factor for the development of acute respiratory distress syndrome (ARDS) but mechanisms mediating this association are unknown. While obesity is known to impair systemic blood vessel function, and predisposes to systemic vascular diseases, its effects on the pulmonary circulation are largely unknown. We hypothesized that the chronic low grade inflammation of obesity impairs pulmonary vascular homeostasis and primes the lung for acute injury. The lung endothelium from obese mice expressed higher levels of leukocyte adhesion markers and lower levels of cell-cell junctional proteins when compared to lean mice. We tested whether systemic factors are responsible for these alterations in the pulmonary endothelium; treatment of primary lung endothelial cells with obese serum enhanced the expression of adhesion proteins and reduced the expression of endothelial junctional proteins when compared to lean serum. Alterations in pulmonary endothelial cells observed in obese mice were associated with enhanced susceptibility to LPS-induced lung injury. Restoring serum adiponectin levels reversed the effects of obesity on the lung endothelium and attenuated susceptibility to acute injury. Our work indicates that obesity impairs pulmonary vascular homeostasis and enhances susceptibility to acute injury and provides mechanistic insight into the increased prevalence of ARDS in obese humans.
C1 [Shah, Dilip; Romero, Freddy; Duong, Michelle; Wang, Nadan; Sun, Jianxin; Zhu, Ying; Summer, Ross] Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107, United States.
C1 [Shah, Dilip; Romero, Freddy; Duong, Michelle; Wang, Nadan; Zhu, Ying; Summer, Ross] Thomas Jefferson Univ, Jane & Leonard Korman Lung Ctr, Philadelphia, PA 19107, United States.
C1 [Paudyal, Bishnuhari] Thomas Jefferson Univ, Dept Radiol, Philadelphia, PA 19107, United States.
C1 [Suratt, Benjamin T.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405, United States.
C1 [Kallen, Caleb B.] Thomas Jefferson Univ, Dept Obstet & Gynecol, Philadelphia, PA 19107, United States.
C1 [Zhu, Ying] Second Mil Med Univ, Changhai Hosp, Dept Resp Med, Shanghai, China.
C1 [Walsh, Kenneth] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118, United States.
C3 Jefferson University; Jefferson University; Jefferson University;
   University of Vermont; Jefferson University; Naval Medical University;
   Boston University
RP Summer, R (corresponding author), Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA.
EM Ross.Summer@jefferson.edu
RI , Ben/L-5749-2019
OI Shah, Dilip/0000-0002-4248-5611; Kallen, Caleb/0000-0002-4156-6719;
   Wang, Nadan/0000-0002-1682-080X; Paudyal, Ben/0000-0002-8388-9057
FU National Institute of Health (NIH) [R01HL105490]
FX Funding for this work was provided by the National Institute of Health
   (NIH) R01HL105490. The authors would like to thank Drs. Steven McKenzie
   and Shaji Abrabram, Cardeza Foundation for Hematologic Research and
   Department of Medicine, Thomas Jefferson University, for providing
   equipment for performing complete blood counts.
CR Ahasic AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089170
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Alexander J, 2006, INT J OBESITY, V30, P50, DOI 10.1038/sj.ijo.0803110
   Boschetto P, 2012, RESPIROLOGY, V17, P422, DOI 10.1111/j.1440-1843.2011.02118.x
   Cohen TS, 2013, J CLIN INVEST, V123, P1630, DOI 10.1172/JCI66142
   Dalmas E, 2011, TRENDS IMMUNOL, V32, P307, DOI 10.1016/j.it.2011.04.008
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Gu WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090426
   Han MS, 2013, SCIENCE, V339, P218, DOI 10.1126/science.1227568
   Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X
   Ikeda Y, 2005, J BIOL CHEM, V280, P29661, DOI 10.1074/jbc.M411694200
   Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245
   Koh GCKW, 2012, CRIT CARE MED, V40, P1835, DOI 10.1097/CCM.0b013e31824e1696
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Konter J, 2013, PULM PHARMACOL THER, V26, P427, DOI 10.1016/j.pupt.2012.03.003
   Konter JM, 2012, J IMMUNOL, V188, P854, DOI 10.4049/jimmunol.1100426
   Kordonowy LL, 2012, AM J RESP CELL MOL, V47, P120, DOI 10.1165/rcmb.2011-0334OC
   Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Orrington-Myers J, 2006, AM J PHYSIOL-LUNG C, V291, pL764, DOI 10.1152/ajplung.00502.2005
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Ouedraogo R, 2007, J CLIN INVEST, V117, P1718, DOI 10.1172/JCI29623
   Parker-Duffen JL, 2014, J BIOL CHEM, V289, P16200, DOI 10.1074/jbc.M114.548115
   Qin FZ, 2012, CIRCULATION, V125, P1757, DOI 10.1161/CIRCULATIONAHA.111.067801
   Raghavendran K, 2011, CRIT CARE MED, V39, P818, DOI 10.1097/CCM.0b013e31820a856b
   Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701
   Romero F., 2014, AM J RESP CELL MOL B
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   SAYE JA, 1989, AM J PHYSIOL, V256, pC448, DOI 10.1152/ajpcell.1989.256.2.C448
   Shah D, 2014, AM J PHYSIOL-LUNG C, V306, pL152, DOI 10.1152/ajplung.00229.2013
   Stapleton RD, 2010, CHEST, V138, P568, DOI 10.1378/chest.10-0014
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Ubags ND, 2014, CRIT CARE MED, V42, pE143, DOI 10.1097/CCM.0000000000000048
   Van Eeden S, 2012, AM J RESP CRIT CARE, V186, P11, DOI 10.1164/rccm.201203-0455PP
   Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487
   van Meurs M, 2012, SHOCK, V37, P392, DOI 10.1097/SHK.0b013e318248225e
   Vernooy JHJ, 2013, PULM PHARMACOL THER, V26, P464, DOI 10.1016/j.pupt.2013.03.016
NR 44
TC 62
Z9 66
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 12
PY 2015
VL 5
AR 11362
DI 10.1038/srep11362
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CK3YK
UT WOS:000356152600001
PM 26068229
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Chichger, H
   Braza, J
   Duong, H
   Harrington, EO
AF Chichger, Havovi
   Braza, Julie
   Duong, Huetran
   Harrington, Elizabeth O.
TI SH2 Domain-Containing Protein Tyrosine Phosphatase 2 and Focal Adhesion
   Kinase Protein Interactions Regulate Pulmonary Endothelium Barrier
   Function
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; SH2 domain-containing protein tyrosine phosphatase 2; pulmonary edema; ALI/ARDS; Focal adhesion kinase (FAK) 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; ADHERENS JUNCTION
   PROTEINS; IN-VIVO; OXIDATIVE STRESS; CELL-MIGRATION; SMALL GTPASES;
   SHP2; PERMEABILITY; PHOSPHORYLATION
AB Enhanced protein tyrosine phosphorylation is associated with changes in vascular permeability through formation and dissolution of adherens junctions and regulation of stress fiber formation. Inhibition of the protein tyrosine phosphorylase SH2 domain-containing protein tyrosine phosphatase 2 (SHP2) increases tyrosine phosphorylation of vascular endothelial cadherin and beta-catenin, resulting in disruption of the endothelial monolayer and edema formation in the pulmonary endothelium. Vascular permeability is a hallmark of acute lung injury (ALI); thus, enhanced SHP2 activity offers potential therapeutic value for the pulmonary vasculature in diseases such as ALI, but this has not been characterized. To assess whether SHP2 activity mediates protection against edema in the endothelium, we assessed the effect of molecular activation of SHP2 on lung endothelial barrier function in response to the edemagenic agents LPS and thrombin. Both LPS and thrombin reduced SHP2 activity, correlated with decreased focal adhesion kinase (FAK) phosphorylation (Y-397 and Y-925) and diminished SHP2 protein-protein associations with FAK. Overexpression of constitutively active SHP2 (SHP2(D61A)) enhanced baseline endothelial monolayer resistance and completely blocked LPS-and thrombin-induced permeability in vitro and significantly blunted pulmonary edema formation induced by either endotoxin (LPS) or Pseudomonas aeruginosa exposure in vivo. Chemical inhibition of FAK decreased SHP2 protein-protein interactions with FAK concomitant with increased permeability; however, overexpression of SHP2(D61A) rescued the endothelium and maintained FAK activity and FAK-SHP2 protein interactions. Our data suggest that SHP2 activation offers the pulmonary endothelium protection against barrier permeability mediators downstream of the FAK signaling pathway. We postulate that further studies into the promotion of SHP2 activation in the pulmonary endothelium may offer a therapeutic approach for patients suffering from ALI.
C1 [Chichger, Havovi; Braza, Julie; Duong, Huetran; Harrington, Elizabeth O.] Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI 02908, United States.
C1 [Chichger, Havovi; Braza, Julie; Duong, Huetran; Harrington, Elizabeth O.] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University
RP Harrington, EO (corresponding author), Providence Vet Affairs Med Ctr, Res Serv 151, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM elizabeth_harrington@brown.edu
RI Chichger, Havovi/Y-7117-2019; Chichger, Havovi/M-5129-2015
OI Chichger, Havovi/0000-0002-8549-7583; Chichger,
   Havovi/0000-0002-8549-7583; Harrington, Elizabeth/0000-0002-3207-5301
FU National Institutes of Health (NIH), National Heart, Lung, and Blood
   Institute (NHLBI) [R01 HL-67795]; American Heart Association
   [10GRNT4160055, 13POST16860031]; COBRE National Institute of General
   Medical Sciences award [5P20 GM103652]; University Medicine Foundation
   of the Rhode Island Hospital; Leadership Alliance; NIH NHLBI [R25
   HL088992]; Providence Veterans Affairs Medical Center
FX This work was supported by Providence Veterans Affairs Medical Center
   and National Institutes of Health (NIH), National Heart, Lung, and Blood
   Institute (NHLBI) grant R01 HL-67795, American Heart Association grant
   10GRNT4160055, COBRE National Institute of General Medical Sciences
   award 5P20 GM103652, the University Medicine Foundation of the Rhode
   Island Hospital (E.O.H.), American Heart Association Fellowship award
   13POST16860031 (H.C.), and by the Leadership Alliance and the NIH NHLBI
   grant R25 HL088992.
CR Adyshev DM, 2013, AM J PHYSIOL-LUNG C, V305, P1240, DOI 10.1152/ajplung.00355.2012
   Arnold KM, 2013, MICROCIRCULATION, V20, P637, DOI 10.1111/micc.12063
   Belvitch P, 2012, MICROVASC RES, V83, P22, DOI 10.1016/j.mvr.2011.08.012
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   CALALB MB, 1995, MOL CELL BIOL, V15, P954
   Chen JS, 2013, CARCINOGENESIS, V34, P10, DOI 10.1093/carcin/bgs274
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Chignard M, 2000, AM J PHYSIOL-LUNG C, V279, pL1083, DOI 10.1152/ajplung.2000.279.6.L1083
   Coulombe G, 2013, MOL CELL BIOL, V33, P2275, DOI 10.1128/MCB.00043-13
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793
   Ganter MT, 2009, AM J RESP CELL MOL, V40, P108, DOI 10.1165/rcmb.2007-0454OC
   Grinnell KL, 2010, AM J PHYSIOL-LUNG C, V298, pL361, DOI 10.1152/ajplung.00374.2009
   Grinnell K, 2012, J CELL PHYSIOL, V227, P1899, DOI 10.1002/jcp.22918
   Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC
   Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4
   Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1
   Han JY, 2013, BLOOD, V122, P4140, DOI 10.1182/blood-2013-03-491423
   Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   HORGAN MJ, 1987, J APPL PHYSIOL, V63, P1993, DOI 10.1152/jappl.1987.63.5.1993
   Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Laird AD, 2003, MOL CANCER THER, V2, P461
   Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001
   Li FF, 2012, J IMMUNOL, V189, P3159, DOI 10.4049/jimmunol.1200197
   Lu Q, 2011, AM J PHYSIOL-LUNG C, V301, pL847, DOI 10.1152/ajplung.00178.2011
   Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0
   Marin TM, 2008, CIRC RES, V103, P813, DOI 10.1161/CIRCRESAHA.108.179754
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791
   Ochoa CD, 2012, J BIOL CHEM, V287, P25407, DOI 10.1074/jbc.M111.301440
   Pazdrak K, 2008, J IMMUNOL, V180, P4182, DOI 10.4049/jimmunol.180.6.4182
   Puri P, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.104414
   Qin XJ, 2012, ALLERGY, V67, P1547, DOI 10.1111/all.12048
   Quadri SK, 2003, J BIOL CHEM, V278, P13342, DOI 10.1074/jbc.M209922200
   Rafiq K, 2006, J BIOL CHEM, V281, P19781, DOI 10.1074/jbc.M513040200
   Sarai K, 2009, AM J PHYSIOL-CELL PH, V297, pC945, DOI 10.1152/ajpcell.00606.2008
   SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2
   Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623
   Schmidt TT, 2013, AM J PHYSIOL-LUNG C, V305, pL291, DOI 10.1152/ajplung.00094.2013
   Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042
   Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002
   Sun XG, 2009, MICROVASC RES, V77, P304, DOI 10.1016/j.mvr.2008.12.004
   Timmerman I, 2012, MOL BIOL CELL, V23, P4212, DOI 10.1091/mbc.E12-01-0038
   UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7
   Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Waypa GB, 1996, J APPL PHYSIOL, V80, P1197, DOI 10.1152/jappl.1996.80.4.1197
   XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413
   Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125
   Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4
   Zhang X, 2012, FASEB J, V26, P2338, DOI 10.1096/fj.11-200139
   Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094
   Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407
NR 62
TC 20
Z9 21
U1 0
U2 14
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUN
PY 2015
VL 52
IS 6
BP 695
EP 707
DI 10.1165/rcmb.2013-0489OC
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA CQ2YI
UT WOS:000360468100005
PM 25317600
OA Green Published
DA 2023-08-21
ER

PT J
AU Sapru, A
   Flori, H
   Quasney, MW
   Dahmer, MK
AF Sapru, Anil
   Flori, Heidi
   Quasney, Michael W.
   Dahmer, Mary K.
CA Pediatric Acute Lung Injury Consen
TI Pathobiology of Acute Respiratory Distress Syndrome
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE ALI/ARDS; pediatrics; pathobiology 
ID ACUTE LUNG INJURY; BRONCHOALVEOLAR LAVAGE FLUID; ENDOTHELIAL
   GROWTH-FACTOR; SURFACTANT PROTEIN-A; PLASMINOGEN-ACTIVATOR INHIBITOR-1;
   PULMONARY-EDEMA FLUID; VON-WILLEBRAND-FACTOR; ALVEOLAR EPITHELIAL
   BARRIER; TIDAL VOLUME VENTILATION; III PROCOLLAGEN PEPTIDE
AB The unique characteristics of pulmonary circulation and alveolar-epithelial capillary-endothelial barrier allow for maintenance of the air-filled, fluid-free status of the alveoli essential for facilitating gas exchange, maintaining alveolar stability, and defending the lung against inhaled pathogens. The hallmark of pathophysiology in acute respiratory distress syndrome is the loss of the alveolar capillary permeability barrier and the presence of protein-rich edema fluid in the alveoli. This alteration in permeability and accumulation of fluid in the alveoli accompanies damage to the lung epithelium and vascular endothelium along with dysregulated inflammation and inappropriate activity of leukocytes and platelets. In addition, there is uncontrolled activation of coagulation along with suppression of fibrinolysis and loss of surfactant. These pathophysiological changes result in the clinical manifestations of acute respiratory distress syndrome, which include hypoxemia, radiographic opacities, decreased functional residual capacity, increased physiologic deadspace, and decreased lung compliance. Resolution of acute respiratory distress syndrome involves the migration of cells to the site of injury and re-establishment of the epithelium and endothelium with or without the development of fibrosis. Most of the data related to acute respiratory distress syndrome, however, originate from studies in adults or in mature animals with very few studies performed in children or juvenile animals. The lack of studies in children is particularly problematic because the lungs and immune system are still developing during childhood and consequently the pathophysiology of pediatric acute respiratory distress syndrome may differ in significant ways from that seen in acute respiratory distress syndrome in adults. This article describes what is known of the pathophysiologic processes of pediatric acute respiratory distress syndrome as we know it today while also presenting the much greater body of evidence on these processes as elucidated by adult and animal studies. It is also our expressed intent to generate enthusiasm for larger and more in-depth investigations of the mechanisms of disease and repair specific to children in the years to come.
C1 [Sapru, Anil] Univ Calif San Francisco, Dept Pediat, Div Crit Care, San Francisco, CA, United States.
C1 [Flori, Heidi] Childrens Hosp Oakland, Pediat Intens Care Unit, Dept Med, Oakland, CA, United States.
C1 [Flori, Heidi] Res Ctr Oakland, Div Pediat Crit Care, Oakland, CA, United States.
C1 [Quasney, Michael W.; Dahmer, Mary K.] Univ Michigan, Div Pediat Crit Care, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109, United States.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Benioff Children's Hospital Oakland;
   University of Michigan System; University of Michigan
RP Dahmer, MK (corresponding author), Univ Michigan, Div Pediat Crit Care, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.
EM mkdahmer@umich.edu
RI Jouvet, Philippe A/H-3293-2018; Sapru, Anil/L-3220-2019
OI Jouvet, Philippe A/0000-0001-5684-3398; sapru, anil/0000-0003-1528-8249;
   Macrae, Duncan/0000-0002-7158-6585; ESSOURI,
   Sandrine/0000-0001-9144-0957
FU Department of Pediatrics, The Pennsylvania State University College of
   Medicine; Health outcome axis-Ste Justine research center, Montreal,
   Canada; Respiratory research network of Fonds de Recherche du
   Quebec-Sante, Quebec, Canada; Mother and children French-speaking
   network; French-speaking group in pediatric emergency and intensive care
   (Groupe Francophone de Reanimation et Urgences Pediatriques),
   French-speaking intensive care society (Societe de Reanimation de Langue
   Francaise); Children's Hospital Foundation of Children's Hospital of
   Richmond at Virginia Commonwealth University; Division of Pediatric
   Critical Care Medicine, C.S. Mott Children's Hospital at the University
   of Michigan; Department of Anesthesia and Critical Care, Children's
   Hospital of Philadelphia; respiratory research network of Fonds de
   Recherche du Quebec-Sante; Reseau mere enfant de la francophonie;
   Research Center of Ste-Justine Hospital; NIH
FX Supported, in part, by Department of Pediatrics, The Pennsylvania State
   University College of Medicine; Health outcome axis-Ste Justine research
   center, Montreal, Canada; Respiratory research network of Fonds de
   Recherche du Quebec-Sante, Quebec, Canada; Mother and children
   French-speaking network; French-speaking group in pediatric emergency
   and intensive care (Groupe Francophone de Reanimation et Urgences
   Pediatriques), French-speaking intensive care society (Societe de
   Reanimation de Langue Francaise); European Society for Pediatric and
   Neonatal Intensive Care Society for the travel support of European
   expert. Financial support for publication of the supplement in Pediatric
   Critical Care Medicine is from the Children's Hospital Foundation of
   Children's Hospital of Richmond at Virginia Commonwealth University, the
   Division of Pediatric Critical Care Medicine, C.S. Mott Children's
   Hospital at the University of Michigan, and the Department of Anesthesia
   and Critical Care, Children's Hospital of Philadelphia.; Dr. Jouvet
   received grants from the respiratory research network of Fonds de
   Recherche du Quebec-Sante, Reseau mere enfant de la francophonie, and
   Research Center of Ste-Justine Hospital related to the submitted work;
   and received equipment on loan from Philips and Maquet outside the
   submitted work. Dr. Thomas served on the Advisory Board for Discovery
   Laboratories and Ikaria outside the submitted work; received a grant
   from United States Food and Drug Administration Office of Orphan Product
   Development outside the submitted work. Dr. Willson served on the
   Advisory Board for Discovery Laboratories outside the submitted work.
   Drs. Khemani, Smith, Dahmer, and Watson received grants from the
   National Institutes of Health (NIH) outside the submitted work. Dr.
   Zimmerman received research grants from the NIH, Seattle Children's
   Research Institute, and ImmuneXpress outside the submitted work. Drs.
   Flori and Sapru received grants from the NIH related to the submitted
   work. Dr. Cheifetz served as a consultant with Philips and Hill-Rom
   outside the submitted work; and received grants from Philips, Care
   Fusion, Covidien, Teleflex, and Ikaria outside the submitted work. Drs.
   Rimensberger and Kneyber received travel support from the European
   Societiy of Pediatric and Neonatal Intensive Care related to this work.
   Dr. Tamburro received a grant from United States Food and Drug
   Administration Office of Orphan Product Development outside the
   submitted work. Dr. Emeriaud received a grant from Respiratory Health
   Network of the Fonds de la Recherche du Quebec-Sante outside the
   submitted work. Dr. Newth served as a consultant for Philips Medical
   outside the submitted work. Drs. Erickson, Quasney, Curley, Nadkarni,
   Valentine, Carroll, Essouri, Dalton, Macrae, Lopez-Cruces, Santschi, and
   Bembea have disclosed that they do not have any potential conflicts of
   interest.
CR Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC
   Adamzik M, 2007, EUR RESPIR J, V29, P482, DOI 10.1183/09031936.00046106
   Agrawal A, 2013, AM J RESP CRIT CARE, V187, P736, DOI 10.1164/rccm.201208-1460OC
   Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z
   Alvira CM, 2007, AM J RESP CRIT CARE, V175, P805, DOI 10.1164/rccm.200608-1162OC
   Ariel A, 2013, J PATHOL, V229, P250, DOI 10.1002/path.4108
   ASHBAUGH DG, 1967, LANCET, V2, P319
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589
   BARTLETT D, 1970, RESP PHYSIOL, V9, P58, DOI 10.1016/0034-5687(70)90006-X
   Bastarache JA, 2007, THORAX, V62, P608, DOI 10.1136/thx.2006.063305
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   BHATTACHARYA J, 1988, J APPL PHYSIOL, V64, P2562, DOI 10.1152/jappl.1988.64.6.2562
   BHATTACHARYA J, 1980, J APPL PHYSIOL, V48, P444, DOI 10.1152/jappl.1980.48.3.444
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bhattacharya S, 2003, AM J RESP CELL MOL, V28, P218, DOI 10.1165/rcmb.4763
   BHATTACHARYA S, 1989, CIRC RES, V64, P167, DOI 10.1161/01.RES.64.1.167
   BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2
   BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320
   BORTOLUSSI R, 1993, PEDIATR RES, V34, P243, DOI 10.1203/00006450-199309000-00001
   Bozza FA, 2009, AM J RESP CELL MOL, V40, P123, DOI 10.1165/rcmb.2008-0241TR
   Burri PH, 2006, BIOL NEONATE, V89, P313, DOI 10.1159/000092868
   CAGLE PT, 1988, AM REV RESPIR DIS, V138, P1314, DOI 10.1164/ajrccm/138.5.1314
   Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Chapman HA, 2011, J CLIN INVEST, V121, P2855, DOI 10.1172/JCI57673
   Chen CY, 2009, AM J RESP CRIT CARE, V180, P751, DOI 10.1164/rccm.200902-0222OC
   Cheng IW, 2003, CRIT CARE MED, V31, P20, DOI 10.1097/00003246-200301000-00003
   Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124
   Chu MA, 2013, ALLERGY ASTHMA RESPI, V1, P235, DOI 10.4168/aard.2013.1.3.235
   CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003
   Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009
   Dahmer MK, 2011, CRIT CARE MED, V39, P1138, DOI 10.1097/CCM.0b013e31820a9416
   Determann RM, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-6
   Dobyns EL, 1999, J PEDIATR-US, V135, P246, DOI 10.1016/S0022-3476(99)70029-6
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   DOYLE IR, 1995, AM J RESP CRIT CARE, V152, P307, DOI 10.1164/ajrccm.152.1.7599839
   Doyle IR, 1997, AM J RESP CRIT CARE, V156, P1217, DOI 10.1164/ajrccm.156.4.9603061
   Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5
   EFFMANN EL, 1985, RADIOLOGY, V157, P69, DOI 10.1148/radiology.157.1.4034980
   Eickmeier O, 2013, MUCOSAL IMMUNOL, V6, P256, DOI 10.1038/mi.2012.66
   Eisner MD, 2003, THORAX, V58, P983, DOI 10.1136/thorax.58.11.983
   El Solh AA, 2006, INTENS CARE MED, V32, P110, DOI 10.1007/s00134-005-2847-2
   Fahy RJ, 2003, AM J RESP CELL MOL, V28, P499, DOI 10.1165/rcmb.2002-0092OC
   FEIN A, 1979, AM J MED, V67, P32, DOI 10.1016/0002-9343(79)90066-4
   Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006
   Fernandez LG, 2012, TOPICS THORACIC SURG
   Finnerty CC, 2008, MOL MED, V14, P553, DOI 10.2119/2007-00132.Finnerty
   Fligiel SEG, 2006, HUM PATHOL, V37, P422, DOI 10.1016/j.humpath.2005.11.023
   Flori HR, 2007, PEDIATR CRIT CARE ME, V8, P96, DOI 10.1097/01.PCC.0000257097.42640.6F
   Flori Heidi R, 2003, Pediatr Crit Care Med, V4, P315, DOI 10.1097/01.PCC.0000074583.27727.8E
   Flori HR, 1999, NEW HORIZ-SCI PRACT, V7, P287
   Flori HR, 2005, AM J RESP CRIT CARE, V171, P995, DOI 10.1164/rccm.200404-544OC
   Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087
   Fremont RD, 2010, J TRAUMA, V68, P1121, DOI 10.1097/TA.0b013e3181c40728
   Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107
   FuchsBuder T, 1996, AM J RESP CRIT CARE, V153, P163, DOI 10.1164/ajrccm.153.1.8542111
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Ganter MT, 2006, AM J PHYSIOL-LUNG C, V291, pL354, DOI 10.1152/ajplung.00405.2005
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Gao L, 2009, AM J PHYSIOL-LUNG C, V296, pL713, DOI 10.1152/ajplung.90269.2008
   Grau GE, 1996, LAB INVEST, V74, P761
   Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117
   Greene KE, 2002, EUR RESPIR J, V19, P439, DOI 10.1183/09031936.02.00081102
   GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523
   Groeneveld ABJ, 1997, THROMB HAEMOSTASIS, V78, P1444
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Gunther A, 1996, AM J RESP CRIT CARE, V153, P176
   Gunther A, 1999, AM J RESP CRIT CARE, V159, P244
   Guo WA, 2012, INTENS CARE MED, V38, P1588, DOI 10.1007/s00134-012-2624-y
   Hammer J, 1998, AM J RESP CRIT CARE, V158, P526, DOI 10.1164/ajrccm.158.2.9710096
   Hartel C, 2005, CLIN EXP IMMUNOL, V142, P446, DOI 10.1111/j.1365-2249.2005.02928.x
   Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847
   Hashimoto S, 2001, BRIT J PHARMACOL, V132, P270, DOI 10.1038/sj.bjp.0703787
   HAWORTH ST, 1995, J APPL PHYSIOL, V79, P615, DOI 10.1152/jappl.1995.79.2.615
   He XL, 2007, SHOCK, V28, P106, DOI 10.1097/SHK.0b013e3180310f3a
   Herwig MC, 2008, PATHOL RES PRACT, V204, P725, DOI 10.1016/j.prp.2008.04.014
   HONDA Y, 1995, AM J RESP CRIT CARE, V152, P1860, DOI 10.1164/ajrccm.152.6.8520747
   IDELL S, 1991, AM J PHYSIOL, V261, pL240, DOI 10.1152/ajplung.1991.261.4.L240
   Inoue Y, 1997, AM J RESP CRIT CARE, V156, P109, DOI 10.1164/ajrccm.156.1.9612043
   Garcia-Laorden MI, 2011, CRIT CARE, V15, DOI 10.1186/cc10030
   Jerng JS, 2007, THORAX, V62, P527, DOI 10.1136/thx.2006.061945
   Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324
   KATZ R, 1987, CLIN CHEST MED, V8, P635
   Kawasaki Y, 2011, PEDIATR PULM, V46, P18, DOI 10.1002/ppul.21270
   Kawasaki Y, 2009, J MED VIROL, V81, P2104, DOI 10.1002/jmv.21634
   Koh H, 2008, RESPIROLOGY, V13, P281, DOI 10.1111/j.1440-1843.2007.01193.x
   KOHNO N, 1993, AM REV RESPIR DIS, V148, P637, DOI 10.1164/ajrccm/148.3.637
   Kong MYF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022596
   Kong MYF, 2009, INT J MED SCI, V6, P9
   Kovach MA, 2011, INT IMMUNOPHARMACOL, V11, P1399, DOI 10.1016/j.intimp.2011.05.013
   Kropski JA, 2009, CHEST, V135, P1440, DOI 10.1378/chest.08-2465
   Kuebler WM, 1999, J CLIN INVEST, V104, P495, DOI 10.1172/JCI6872
   Kuwano K, 2002, RESPIROLOGY, V7, P15, DOI 10.1046/j.1440-1843.2002.00369.x
   LAIFOOK SJ, 1982, J APPL PHYSIOL, V52, P9, DOI 10.1152/jappl.1982.52.1.9
   Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368
   Lanchou J, 2003, CRIT CARE MED, V31, P536, DOI 10.1097/01.CCM.0000048626.02184.F8
   Lee SM, 1996, BLOOD, V88, P945
   Levesque BM, 2013, NEONATOLOGY, V104, P56, DOI 10.1159/000351040
   Levi M, 2002, CRIT CARE MED, V30, pS220, DOI 10.1097/00003246-200205001-00008
   LeVine AM, 1996, CRIT CARE MED, V24, P1062, DOI 10.1097/00003246-199606000-00029
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Lim MJ, 2001, MICROVASC RES, V62, P366, DOI 10.1006/mvre.2001.2355
   Lin Z, 2000, CLIN GENET, V58, P181, DOI 10.1034/j.1399-0004.2000.580305.x
   Lin ZW, 2005, BIOCHEM J, V389, P403, DOI 10.1042/BJ20042032
   Liu KD, 2007, CRIT CARE MED, V35, P2755, DOI 10.1097/01.CCM.0000291649.72238.6D
   Liu XW, 2012, CRIT CARE, V16, DOI 10.1186/cc11354
   LORENTE JA, 1993, CHEST, V103, P1536, DOI 10.1378/chest.103.5.1536
   Madtes DK, 1998, AM J RESP CRIT CARE, V158, P424, DOI 10.1164/ajrccm.158.2.9711112
   Mandal RV, 2007, EXP MOL PATHOL, V83, P327, DOI 10.1016/j.yexmp.2007.08.005
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024
   Manzanares D, 2007, BIOCHEMISTRY-US, V46, P5604, DOI 10.1021/bi062304p
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Marshall RP, 2004, AM J PHYSIOL-LUNG C, V286, pL156, DOI 10.1152/ajplung.00313.2002
   Matthay MA, 2000, CLIN CHEST MED, V21, P477, DOI 10.1016/S0272-5231(05)70160-X
   Matthay MA, 2002, CHEST, V122, p340S, DOI 10.1378/chest.122.6_suppl.340S
   Matthay MA, 2002, J APPL PHYSIOL, V93, P1533, DOI 10.1152/japplphysiol.01210.2001
   MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578
   MATTHAY MA, 1994, CHEST, V105, pS67, DOI 10.1378/chest.105.3_Supplement.67S
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Max M, 1996, ACP-APPL CARDIOPUL P, V6, P111
   McClintock D, 2008, CRIT CARE, V12, DOI 10.1186/cc6846
   McGrath-Morrow SA, 2015, AM J RESP CELL MOL, V52, P323, DOI 10.1165/rcmb.2014-0100OC
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   Medford ARL, 2009, CHEST, V136, P457, DOI 10.1378/chest.09-0383
   Meyer NJ, 2013, AM J RESP CRIT CARE, V187, P950, DOI 10.1164/rccm.201208-1501OC
   Meyer NJ, 2011, AM J RESP CRIT CARE, V183, P1344, DOI 10.1164/rccm.201005-0701OC
   MEYRICK B, 1986, Critical Care Clinics, V2, P405
   MOALLI R, 1989, AM REV RESPIR DIS, V140, P287, DOI 10.1164/ajrccm/140.2.287
   Mosbah Amira A Abd El-rahman, 2012, J Egypt Soc Parasitol, V42, P25
   MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720
   Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195, DOI 10.1164/ajrccm.163.1.9912036
   Nakajima C, 1998, PEDIATR SURG INT, V13, P341, DOI 10.1007/s003830050334
   Newth CJL, 2000, ACTA PAEDIATR, V89, P893, DOI 10.1080/080352500750043279
   Newth CJL, 1997, PEDIATR PULM, V23, P169, DOI 10.1002/(SICI)1099-0496(199703)23:3<169::AID-PPUL1>3.0.CO;2-J
   NUSSBAUM E, 1983, CLIN PEDIATR, V22, P401, DOI 10.1177/000992288302200601
   Ochs M, 2004, AM J RESP CRIT CARE, V169, P120, DOI 10.1164/rccm.200308-1107OC
   Orfanos SE, 2000, CIRCULATION, V102, P2011
   Orwoll B, 2015, PED AC SOC ANN M SAN
   Orwoll B, 2014, ARCH DIS CHILD S, V99, pA56
   Papayannopoulos V, 2009, TRENDS IMMUNOL, V30, P513, DOI 10.1016/j.it.2009.07.011
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Parker JC, 2006, AM J PHYSIOL-LUNG C, V291, pL30, DOI 10.1152/ajplung.00317.2005
   PARSONS PE, 1985, AM REV RESPIR DIS, V132, P490
   Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC
   Parsons PE, 2005, AM J PHYSIOL-LUNG C, V288, pL426, DOI 10.1152/ajplung.00302.2004
   Patwari PP, 2008, PEDIATR CRIT CARE ME, V9, P553, DOI 10.1097/PCC.0b013e31818d32f1
   Pespeni M, 2005, J SURG RES, V126, P41, DOI 10.1016/j.jss.2005.01.012
   PETERS AMJ, 1993, BIOL NEONATE, V63, P157
   PFENNINGER J, 1982, J PEDIATR-US, V101, P352, DOI 10.1016/S0022-3476(82)80057-7
   PISON U, 1995, SURFACTANT THERAPY L, P167
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   Prabhakaran P, 2003, AM J PHYSIOL-LUNG C, V285, pL20, DOI 10.1152/ajplung.00312.2002
   Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036
   QIAO RL, 1991, J APPL PHYSIOL, V71, P2152, DOI 10.1152/jappl.1991.71.6.2152
   Quadri SK, 2003, J BIOL CHEM, V278, P13342, DOI 10.1074/jbc.M209922200
   Quasney MW, 2004, CRIT CARE MED, V32, P1115, DOI 10.1097/01.CCM.0000124872.55243.5A
   Quesnel C, 2012, CRIT CARE MED, V40, P21, DOI 10.1097/CCM.0b013e31822d718b
   QUINN DA, 1987, AM REV RESPIR DIS, V135, P100
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ratjen F, 1996, EUR RESPIR J, V9, P328, DOI 10.1183/09031936.96.09020328
   Ricou B, 1996, AM J RESP CRIT CARE, V154, P346, DOI 10.1164/ajrccm.154.2.8756805
   Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108
   Rodriguez-Capote K, 2006, BIOPHYS J, V90, P2808, DOI 10.1529/biophysj.105.073106
   Rokkam D, 2011, AM J PATHOL, V179, P1081, DOI 10.1016/j.ajpath.2011.05.017
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Russell R, 2010, PEDIATR CRIT CARE ME, V11, P731, DOI 10.1097/PCC.0b013e3181ce7497
   SABHARWAL AK, 1995, AM J RESP CRIT CARE, V151, P758
   Sakuma T, 2006, CRIT CARE MED, V34, P676, DOI 10.1097/01.CCM.0000201403.70636.0F
   Santschi M, 2010, PEDIATR CRIT CARE ME, V11, P681, DOI 10.1097/PCC.0b013e3181d904c0
   Sapru A, 2015, INTENS CARE MED, V41, P470, DOI 10.1007/s00134-015-3648-x
   Sapru A, 2010, INTENS CARE MED, V36, P157, DOI 10.1007/s00134-009-1690-2
   Sapru A, 2009, ANESTHESIOLOGY, V110, P1086, DOI 10.1097/ALN.0b013e3181a1081d
   Sartori C, 2002, EUR RESPIR J, V20, P1299, DOI 10.1183/09031936.02.00401602
   Sato H, 2004, EUR RESPIR J, V23, P142, DOI 10.1183/09031936.03.00070303
   SCARPATI EM, 1989, J BIOL CHEM, V264, P20705
   Schmidt R, 2001, AM J RESP CRIT CARE, V163, P95, DOI 10.1164/ajrccm.163.1.9903029
   Schultz MJ, 2006, CRIT CARE MED, V34, P871, DOI [10.1097/01.CCM.0000201882.23917.B8, 10.1097/01.CCM.0000202136.91651.34]
   Seki H, 2010, J IMMUNOL, V184, P836, DOI 10.4049/jimmunol.0901809
   Shahabuddin S, 1998, CLIN DIAGN LAB IMMUN, V5, P632, DOI 10.1128/CDLI.5.5.632-635.1998
   Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003
   SHETH SB, 1991, AM J HEMATOL, V36, P14, DOI 10.1002/ajh.2830360104
   SINCLAIR DG, 1994, CHEST, V106, P535, DOI 10.1378/chest.106.2.535
   SIVAN Y, 1991, PEDIATR PULM, V11, P103, DOI 10.1002/ppul.1950110205
   Smith LS, 2013, PEDIATR CRIT CARE ME, V14, P631, DOI 10.1097/PCC.0b013e318291753f
   Smith LS, 2010, AM J RESP CELL MOL, V43, P475, DOI 10.1165/rcmb.2009-0039OC
   Steagall WK, 2007, AM J PHYSIOL-LUNG C, V292, pL448, DOI 10.1152/ajplung.00307.2006
   STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736
   Su X, 2005, J IMMUNOL, V175, P2598, DOI 10.4049/jimmunol.175.4.2598
   Sun AP, 2003, RESP MED, V97, P964, DOI 10.1016/S0954-6111(03)00124-0
   Takala A, 2002, SHOCK, V17, P252, DOI 10.1097/00024382-200204000-00002
   Tanjore H, 2009, AM J RESP CRIT CARE, V180, P657, DOI 10.1164/rccm.200903-0322OC
   Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071
   Todd DA, 2010, PEDIATR CRIT CARE ME, V11, P82, DOI 10.1097/PCC.0b013e3181ae5a4c
   Tolle LB, 2013, J PATHOL, V229, P145, DOI 10.1002/path.4124
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   Torii K, 1997, AM J RESP CRIT CARE, V155, P43, DOI 10.1164/ajrccm.155.1.9001287
   Tsangaris I, 2009, THROMB RES, V123, P832, DOI 10.1016/j.thromres.2008.07.018
   TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573
   Uddin M, 2011, PROG LIPID RES, V50, P75, DOI 10.1016/j.plipres.2010.09.002
   Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002
   VELDHUIZEN RAW, 1995, AM J RESP CRIT CARE, V152, P1867, DOI 10.1164/ajrccm.152.6.8520748
   WALKER TA, 1994, PEDIATR CLIN N AM, V41, P1365
   Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2007, CRIT CARE MED, V35, P1821, DOI 10.1097/01.CCM.0000275386.95968.5F
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731
   Weyrich AS, 2013, ANNU REV PHYSIOL, V75, P569, DOI 10.1146/annurev-physiol-030212-183752
   Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK
   Wood JH, 2010, CURR OPIN PEDIATR, V22, P315, DOI 10.1097/MOP.0b013e328338da48
   Wort SJ, 1999, BRIT MED BULL, V55, P30, DOI 10.1258/0007142991902286
   WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255
   WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16
   Xiang M, 2010, MOL MED, V16, P69, DOI 10.2119/molmed.2009.00097
   Yamamoto T, 1997, JPN J PHARMACOL, V73, P33, DOI 10.1254/jjp.73.33
   Yao SL, 2008, J SURG RES, V145, P25, DOI 10.1016/j.jss.2007.03.075
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
   Zarbock A, 2009, FRONT BIOSCI-LANDMRK, V14, P150, DOI 10.2741/3236
   Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR
   Zenri H, 2004, CRIT CARE MED, V32, P1155, DOI 10.1097/01.CCM.0000126264.00551.C8
   Zhang HB, 2013, AM J RESP CRIT CARE, V187, P118, DOI 10.1164/rccm.201211-2025ED
   Zheng DH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0048451, 10.1371/journal.pone.0049495]
   Zimmerman JJ, 2009, PEDIATRICS, V124, P87, DOI 10.1542/peds.2007-2462
   Zingarelli B, 2009, CRIT CARE MED, V37, P1978, DOI 10.1097/CCM.0b013e31819feb4d
   Zinter M, 2015, PED AC SOC ANN M SAN
NR 232
TC 63
Z9 68
U1 5
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1529-7535
EI 1947-3893
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD JUN
PY 2015
VL 16
IS 5
SU S
BP S6
EP S22
DI 10.1097/PCC.0000000000000431
PG 17
WC Critical Care Medicine; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Pediatrics
GA DD5PX
UT WOS:000369977500002
PM 26035365
OA Bronze
DA 2023-08-21
ER

PT J
AU Bai, XZ
   Fan, L
   He, T
   Jia, WB
   Yang, LL
   Zhang, J
   Liu, Y
   Shi, JH
   Su, LL
   Hu, DH
AF Bai, Xiaozhi
   Fan, Lei
   He, Ting
   Jia, Wenbin
   Yang, Longlong
   Zhang, Jun
   Liu, Yang
   Shi, Jihong
   Su, Linlin
   Hu, Dahai
TI SIRT1 protects rat lung tissue against severe burn-induced remote ALI by
   attenuating the apoptosis of PMVECs via p38 MAPK signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PERIODONTAL-LIGAMENT CELLS; OXIDATIVE STRESS; ENDOTHELIAL-CELLS;
   INFLAMMATORY RESPONSE; VASCULAR-PERMEABILITY; RESVERATROL PROTECTS;
   OVINE MODEL; IN-VIVO; INJURY; SEPSIS
AB Silent information regulator type-1 (SIRT1) has been reported to be involved in the cardiopulmonary protection. However, its role in the pathogenesis of burn-induced remote acute lung injury (ALI) is currently unknown. The present study aims to investigate the role of SIRT1 in burn-induced remote ALI and the involved signaling pathway. We observed that SIRT1 expression in rat lung tissue after burn injury appeared an increasing trend after a short period of suppression. The upregulation of SIRT1 stimulated by resveratrol exhibited remission of histopathologic changes, reduction of cell apoptosis, and downregulation of pro-inflammatory cytokines in rat pulmonary tissues suffering from severe burn. We next used primary pulmonary microvascular endothelial cells (PMVECs) challenged by burn serum (BS) to simulate in vivo rat lung tissue after burn injury, and found that BS significantly suppressed SIRT1 expression, increased cell apoptosis, and activated p38 MAPK signaling. The use of resveratrol reversed these effects, while knockdown of SIRT1 by shRNA further augmented BS-induced increase of cell apoptosis and activation of p38 MAPK. Taken together, these results indicate that SIRT1 might protect lung tissue against burn-induced remote ALI by attenuating PMVEC apoptosis via p38 MAPK signaling, suggesting its potential therapeutic effects on the treatment of ALI.
C1 [Bai, Xiaozhi; Fan, Lei; He, Ting; Jia, Wenbin; Yang, Longlong; Liu, Yang; Shi, Jihong; Su, Linlin; Hu, Dahai] Fourth Mil Med Univ, Xijing Hosp, Dept Burns & Cutaneous Surg, Xian 710032, Shaanxi, China.
C1 [Zhang, Jun] 205 Hosp Chinese Peoples Liberat Army, Dept Burn & Plast Surg, Jinzhou, Liaoning, China.
C3 Air Force Military Medical University
RP Hu, DH (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Burns & Cutaneous Surg, Xian 710032, Shaanxi, Peoples R China.
EM linlinsu@fmmu.edu.cn; burnlab@fmmu.edu.cn
OI Hu, Dahai/0000-0001-5543-092X
FU National Natural Science Foundation of China [81372069]; Xijing Hospital
   Natural Science Funds for Distinguished Young Scientists [XJZT14J06]
FX This study was supported by National Natural Science Foundation of China
   (grant no: 81372069 to D.H.) and Xijing Hospital Natural Science Funds
   for Distinguished Young Scientists (grant no: XJZT14J06 to L.S.)
CR Bao XM, 2009, ACTA PHARMACOL SIN, V30, P1392, DOI 10.1038/aps.2009.135
   Bardales RH, 1996, AM J PATHOL, V149, P845
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5
   Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Csiszar A, 2008, AM J PHYSIOL-HEART C, V294, pH2721, DOI 10.1152/ajpheart.00235.2008
   Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101
   Du G, 2014, INT J MOL MED, V34, P177, DOI 10.3892/ijmm.2014.1740
   Fang Y, 2011, J TRAUMA, V71, P1297, DOI 10.1097/TA.0b013e3182127d48
   Fang Y, 2011, J BURN CARE RES, V32, pE82, DOI 10.1097/BCR.0b013e318217f84f
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Galani V, 2010, PATHOL RES PRACT, V206, P145, DOI 10.1016/j.prp.2009.12.002
   Gloor B, 2000, PANCREAS, V21, P414, DOI 10.1097/00006676-200011000-00013
   Guo F, 2009, BURNS, V35, P210, DOI 10.1016/j.burns.2008.05.021
   Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Hoshi T, 1998, ANTICANCER RES, V18, P4347
   Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002
   Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jonkam CC, 2009, CRIT CARE, V13, DOI 10.1186/cc7720
   Kao CL, 2010, J ATHEROSCLER THROMB, V17, P970, DOI 10.5551/jat.4333
   Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1
   Kim YS, 2010, J CELL BIOCHEM, V111, P1310, DOI 10.1002/jcb.22858
   Kitamura Y, 2010, NEUROL MED-CHIR, V50, P456, DOI 10.2176/nmc.50.456
   Knobloch J, 2014, BASIC CLIN PHARMACOL, V114, P202, DOI 10.1111/bcpt.12129
   Lange M, 2008, CRIT CARE MED, V36, P1284, DOI 10.1097/CCM.0b013e318169ef74
   Lee SI, 2011, J ENDODONT, V37, P1525, DOI 10.1016/j.joen.2011.07.006
   Lee YM, 2011, J PERIODONTAL RES, V46, P712, DOI 10.1111/j.1600-0765.2011.01394.x
   Liang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068786
   Marko Peter, 2003, Curr Opin Anaesthesiol, V16, P183, DOI 10.1097/00001503-200304000-00012
   Maybauer MO, 2009, ANAESTHESIST, V58, P805, DOI 10.1007/s00101-009-1560-x
   Monafo WW, 1996, NEW ENGL J MED, V335, P1581, DOI 10.1056/NEJM199611213352108
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Parihar A, 2008, BURNS, V34, P6, DOI 10.1016/j.burns.2007.04.009
   Park GJ, 2013, J PERIODONTAL RES, V48, P483, DOI 10.1111/jre.12030
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Rieder SA, 2012, BRIT J PHARMACOL, V167, P1244, DOI 10.1111/j.1476-5381.2012.02063.x
   Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003
   Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604
   Schmid E, 1997, SHOCK, V8, P119, DOI 10.1097/00024382-199708000-00010
   Turnage RH, 2002, WORLD J SURG, V26, P848, DOI 10.1007/s00268-002-4063-3
   Uruno A, 2008, HYPERTENS RES, V31, P2085, DOI 10.1291/hypres.31.2085
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6
   Winnik S, 2012, CURR VASC PHARMACOL, V10, P693, DOI 10.2174/157016112803520756
   Xia L, 2011, HUM CELL, V24, P127, DOI 10.1007/s13577-011-0031-2
   Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006
   You QH, 2010, J SURG RES, V162, P110, DOI 10.1016/j.jss.2009.01.019
   Zhang JP, 2008, J TRAUMA, V65, P401, DOI 10.1097/TA.0b013e31817cf732
   Zhang WF, 2011, J BURN CARE RES, V32, pE51, DOI 10.1097/BCR.0b013e318217f8ae
NR 56
TC 42
Z9 46
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 20
PY 2015
VL 5
AR 10277
DI 10.1038/srep10277
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CJ3OC
UT WOS:000355392700001
PM 25992481
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Fu, PF
   Usatyuk, PV
   Lele, A
   Harijith, A
   Gregorio, CC
   Garcia, JGN
   Salgia, R
   Natarajan, V
AF Fu, Panfeng
   Usatyuk, Peter V.
   Lele, Abhishek
   Harijith, Anantha
   Gregorio, Carol C.
   Garcia, Joe G. N.
   Salgia, Ravi
   Natarajan, Viswanathan
TI c-Abl mediated tyrosine phosphorylation of paxillin regulates
   LPS-induced endothelial dysfunction and lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE paxillin; c-Abl; LPS; tyrosine kinase; permeability; endothelial dysfunction; cytoskeleton 
ID ADHERENS JUNCTION PROTEINS; FOCAL ADHESION KINASE; NBT-II CELLS;
   VASCULAR-PERMEABILITY; FAK PHOSPHORYLATION; BARRIER FUNCTION; RHOA
   ACTIVITY; MIGRATION; INVOLVEMENT; ACTIVATION
AB Paxillin is phosphorylated at multiple residues; however, the role of tyrosine phosphorylation of paxillin in endothelial barrier dysfunction and acute lung injury (ALI) remains unclear. We used siRNA and site-specific nonphosphorylable mutants of paxillin to abrogate the function of paxillin to determine its role in lung endothelial permeability and ALI. In vitro, lipopolysaccharide (LPS) challenge of human lung microvascular endothelial cells (HLMVECs) resulted in enhanced tyrosine phosphorylation of paxillin at Y31 and Y118 with no significant change in Y181 and significant barrier dysfunction. Knockdown of paxillin with siRNA attenuated LPS-induced endothelial barrier dysfunction and destabilization of VE-cadherin. LPS-induced paxillin phosphorylation at Y31 and Y118 was mediated by c-Abl tyrosine kinase, but not by Src and focal adhesion kinase. c-Abl siRNA significantly reduced LPS-induced endothelial barrier dysfunction. Transfection of HLMVECs with paxillin Y31F, Y118F, and Y31/118F double mutants mitigated LPS-induced barrier dysfunction and VE-cadherin destabilization. In vivo, the c-Abl inhibitor AG957 attenuated LPS-induced pulmonary permeability in mice. Together, these results suggest that c-Abl mediated tyrosine phosphorylation of paxillin at Y31 and Y118 regulates LPS-mediated pulmonary vascular permeability and injury.
C1 [Fu, Panfeng; Usatyuk, Peter V.; Lele, Abhishek; Natarajan, Viswanathan] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Harijith, Anantha] Univ Illinois, Dept Pediat, Chicago, IL, United States.
C1 [Natarajan, Viswanathan] Univ Illinois, Coll Med, Dept Med, Chicago, IL, United States.
C1 [Gregorio, Carol C.] Univ Arizona, Coll Med, Dept Cellular & Mol Med, Tucson, AZ, United States.
C1 [Garcia, Joe G. N.] Univ Arizona, Coll Med, Dept Med, Tucson, AZ, United States.
C1 [Salgia, Ravi] Univ Chicago, Dept Med, Chicago, IL 60637, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona; University of Chicago
RP Fu, PF (corresponding author), COMRB Bldg,Rm 3140,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM pfu@uic.edu
RI Fu, Panfeng/F-7345-2015; Garcia, Joe GN/E-8862-2010; Harijith,
   Anantha/AAA-5708-2021
OI Fu, Panfeng/0000-0001-8813-9258; 
FU National Heart, Lung, and Blood Institute [P01HL58064, P01HL98050]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants P01HL58064 and P01HL98050 to V. Natarajan.
CR Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771
   Bannerman DD, 1999, LAB INVEST, V79, P1181
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL593, DOI 10.1152/ajplung.90257.2008
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131
   Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008
   Daniel R, 2001, ONCOGENE, V20, P2618, DOI 10.1038/sj.onc.1204361
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fu PF, 2013, AM J RESP CELL MOL, V48, P477, DOI 10.1165/rcmb.2012-0242OC
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401
   Gonzalez-Lopez A, 2011, AM J PHYSIOL-LUNG C, V301, pL500, DOI 10.1152/ajplung.00010.2011
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Huang Z, 2008, CELL SIGNAL, V20, P2002, DOI 10.1016/j.cellsig.2008.07.014
   Iwasaki T, 2002, INT J CANCER, V97, P330, DOI 10.1002/ijc.1609
   Kleveta G, 2012, J CELL BIOCHEM, V113, P80, DOI 10.1002/jcb.23330
   Kratzer E, 2012, AM J RESP CELL MOL, V47, P688, DOI 10.1165/rcmb.2012-0161OC
   Le Q, 1998, J IMMUNOL, V160, P3330
   Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Pasapera AM, 2010, J CELL BIOL, V188, P877, DOI 10.1083/jcb.200906012
   Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957
   Romanova LY, 2004, J CELL SCI, V117, P3759, DOI 10.1242/jcs.01206
   Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025
   Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273
   Scheswohl Danielle M, 2008, J Mol Signal, V3, P1, DOI 10.1186/1750-2187-3-1
   Shephard V, 2004, PUBLIC HEALTH, V118, P310, DOI 10.1016/j.puhe.2004.03.001
   Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001
   Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com
   Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002
   Singleton PA, 2009, J BIOL CHEM, V284, P34964, DOI 10.1074/jbc.M109.013771
   Su G, 2007, AM J RESP CELL MOL, V36, P377, DOI 10.1165/rcmb.2006-0238OC
   Sun XG, 2009, MICROVASC RES, V77, P304, DOI 10.1016/j.mvr.2008.12.004
   Teranishi S, 2009, INVEST OPHTH VIS SCI, V50, P5646, DOI 10.1167/iovs.08-2534
   Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870
   Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117
   Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851
   Turner CE, 2000, J CELL SCI, V113, P4139
   Usatyuk PV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063007
   Usatyuk PV, 2005, AM J PHYSIOL-LUNG C, V289, pL999, DOI 10.1152/ajplung.00211.2005
   Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200
   Vindis C, 2004, J BIOL CHEM, V279, P27965, DOI 10.1074/jbc.M401295200
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094
   Yuan D, 2012, J APPL PHYSIOL, V113, P1110, DOI 10.1152/japplphysiol.00102.2012
NR 48
TC 28
Z9 30
U1 0
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY 15
PY 2015
VL 308
IS 10
BP L1025
EP L1038
DI 10.1152/ajplung.00306.2014
PG 14
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CI4JE
UT WOS:000354713700004
PM 25795725
OA Green Published
DA 2023-08-21
ER

PT J
AU Hecker, M
   Linder, T
   Ott, J
   Walmrath, HD
   Lohmeyer, J
   Vadasz, I
   Marsh, LM
   Herold, S
   Reichert, M
   Buchbinder, A
   Morty, RE
   Bausch, B
   Fischer, T
   Schulz, R
   Grimminger, F
   Witzenrath, M
   Barnes, M
   Seeger, W
   Mayer, K
AF Hecker, Matthias
   Linder, Tomke
   Ott, Juliane
   Walmrath, Hans-Dieter
   Lohmeyer, Juergen
   Vadasz, Istvan
   Marsh, Leigh M.
   Herold, Susanne
   Reichert, Martin
   Buchbinder, Anja
   Morty, Rory Edward
   Bausch, Britta
   Fischer, Tobias
   Schulz, Richard
   Grimminger, Friedrich
   Witzenrath, Martin
   Barnes, Matt
   Seeger, Werner
   Mayer, Konstantin
TI Immunomodulation by lipid emulsions in pulmonary inflammation: a
   randomized controlled trial
SO CRITICAL CARE
LA English
DT Article
ID ACUTE LUNG INJURY; POLYUNSATURATED FATTY-ACIDS;
   RESPIRATORY-DISTRESS-SYNDROME; CONTROLLED CLINICAL-TRIAL; CRITICALLY-ILL
   PATIENTS; TUMOR-NECROSIS-FACTOR; FISH-OIL; PARENTERAL-NUTRITION;
   ENDOTHELIAL-CELLS; HUMAN MONOCYTES
AB Introduction: Acute respiratory distress syndrome (ARDS) is a major cause of mortality in intensive care units. As there is rising evidence about immuno-modulatory effects of lipid emulsions required for parenteral nutrition of ARDS patients, we sought to investigate whether infusion of conventional soybean oil (SO)-based or fish oil (FO)-based lipid emulsions rich in either n-6 or n-3 fatty acids, respectively, may influence subsequent pulmonary inflammation.
   Methods: In a randomized controlled, single-blinded pilot study, forty-two volunteers received SO, FO, or normal saline for two days. Thereafter, volunteers inhaled pre-defined doses of lipopolysaccharide (LPS) followed by bronchoalveolar lavage (BAL) 8 or 24 h later. In the murine model of LPS-induced lung injury a possible involvement of resolvin E1 (RvE1) receptor ChemR23 was investigated. Wild-type and ChemR23 knockout mice were infused with both lipid emulsions and challenged with LPS intratracheally.
   Results: In volunteers receiving lipid emulsions, the fatty acid profile in the plasma and in isolated neutrophils and monocytes was significantly changed. Adhesion of isolated monocytes to endothelial cells was enhanced after infusion of SO and reduced by FO, however, no difference of infusion on an array of surface adhesion molecules was detected. In neutrophils and monocytes, LPS-elicited generation of pro-inflammatory cytokines increased in the SO and decreased in the FO group. LPS inhalation in volunteers evoked an increase in neutrophils in BAL fluids, which decreased faster in the FO group. While TNF-alpha in the BAL was increased in the SO group, IL-8 decreased faster in the FO group. In the murine model of lung injury, effects of FO similar to the volunteer group observed in wild-type mice were abrogated in ChemR23 knockout mice.
   Conclusions: After infusion of conventional lipid emulsions, leukocytes exhibited increased adhesive and pro-inflammatory features. In contrast, FO-based lipid emulsions reduced monocyte adhesion, decreased pro-inflammatory cytokines, and neutrophil recruitment into the alveolar space possibly mediated by ChemR23-signaling. Lipid emulsions thus exert differential effects in human volunteers and mice in vivo.
C1 [Hecker, Matthias; Linder, Tomke; Ott, Juliane; Walmrath, Hans-Dieter; Lohmeyer, Juergen; Vadasz, Istvan; Marsh, Leigh M.; Herold, Susanne; Reichert, Martin; Buchbinder, Anja; Bausch, Britta; Fischer, Tobias; Schulz, Richard; Grimminger, Friedrich; Seeger, Werner; Mayer, Konstantin] Univ Giessen, D-35392 Giessen, Germany.
C1 [Hecker, Matthias; Linder, Tomke; Ott, Juliane; Walmrath, Hans-Dieter; Lohmeyer, Juergen; Vadasz, Istvan; Marsh, Leigh M.; Herold, Susanne; Reichert, Martin; Buchbinder, Anja; Bausch, Britta; Fischer, Tobias; Schulz, Richard; Grimminger, Friedrich; Seeger, Werner; Mayer, Konstantin] Univ Giessen, Marburg Lung Ctr UGMLC, D-35392 Giessen, Germany.
C1 [Morty, Rory Edward] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodelling, Bad Nauheim, Germany.
C1 [Witzenrath, Martin] Charite, Med Klin Schwerpunkt Infektiol & Pneumol, D-13353 Berlin, Germany.
C1 [Barnes, Matt] Takeda Cambridge Ltd, Cambridge, England, United Kingdom.
C1 [Mayer, Konstantin] Univ Giessen, Marburg Lung Ctr UGMLC, Med Clin 2, D-35392 Giessen, Germany.
C3 Justus Liebig University Giessen; Justus Liebig University Giessen; Max
   Planck Society; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Justus Liebig University
   Giessen
RP Mayer, K (corresponding author), Univ Giessen, Klinikstr 33, D-35392 Giessen, Germany.
EM konstantin.mayer@innere.med.uni-giessen.de
RI Vadasz, Istvan/AAO-8288-2021; Marsh, Leigh/AAB-5125-2021
OI Marsh, Leigh/0000-0002-1754-9249; Vadasz, Istvan/0000-0003-1370-9783;
   Seeger, Werner/0000-0003-1946-0894; Herold, Susanne/0000-0001-6343-0911
FU Deutsche Forschungsgemeinschaft (Project C3) [SFB Transregio 84];
   Bundesministerium fur Bildung und Forschung (Klinische Forschergruppe
   Pneumonie, Project A); German Center for Lung Research (DZL)
FX The great technical assistance of Andrea Mohr and Juliane Mest is
   greatfully acknowledged. This study has been funded by Deutsche
   Forschungsgemeinschaft (SFB Transregio 84, Project C3),
   Bundesministerium fur Bildung und Forschung (Klinische Forschergruppe
   Pneumonie, Project A), and German Center for Lung Research (DZL). The
   funding bodies played no role in the design, collection, analysis and
   interpretation of data or in writing of the manuscript, or in the
   decision to submit the manuscript for publication.
CR Adrie C, 2001, AM J RESP CRIT CARE, V164, P389, DOI 10.1164/ajrccm.164.3.2009088
   Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651
   Barbosa VM, 2010, CRIT CARE, V14, DOI 10.1186/cc8844
   Calder PC, 2007, PROSTAG LEUKOTR ESS, V77, P327, DOI 10.1016/j.plefa.2007.10.015
   Calfee CS, 2007, CHEST, V131, P913, DOI 10.1378/chest.06-1743
   Cash JL, 2008, J EXP MED, V205, P767, DOI 10.1084/jem.20071601
   Caughey GE, 1997, J IMMUNOL, V158, P351
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chen B, 2010, JPEN-PARENTER ENTER, V34, P387, DOI 10.1177/0148607110362532
   ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501
   Grau-Carmona T, 2015, CRIT CARE MED, V43, P31, DOI 10.1097/CCM.0000000000000612
   Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627
   Hecker M, 2014, CRIT CARE, V18, DOI 10.1186/cc13850
   Hoogerwerf JJ, 2008, AM J RESP CRIT CARE, V178, P34, DOI 10.1164/rccm.200708-1261OC
   Hughes DA, 1996, AM J CLIN NUTR, V63, P267, DOI 10.1093/ajcn/63.2.267
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144
   Marik PE, 2008, INTENS CARE MED, V34, P1980, DOI 10.1007/s00134-008-1213-6
   Maris NA, 2005, AM J RESP CRIT CARE, V172, P878, DOI 10.1164/rccm.200503-451OC
   Torrinhas RSMD, 2013, CLIN NUTR, V32, P503, DOI 10.1016/j.clnu.2012.12.008
   Mayer K, 2006, CURR OPIN CLIN NUTR, V9, P140, DOI 10.1097/01.mco.0000214573.75062.0a
   Mayer K, 2003, J IMMUNOL, V171, P4837, DOI 10.4049/jimmunol.171.9.4837
   Mayer K, 2003, INTENS CARE MED, V29, P1472, DOI 10.1007/s00134-003-1900-2
   Mayer K, 2003, AM J RESP CRIT CARE, V167, P1321, DOI 10.1164/rccm.200207-674OC
   Mayer K, 2008, CURR OPIN CLIN NUTR, V11, P121, DOI 10.1097/MCO.0b013e3282f4cdc6
   Mayer K, 2009, AM J RESP CRIT CARE, V179, P474, DOI 10.1164/rccm.200807-1064OC
   Pradelli L, 2012, CRIT CARE, V16, DOI 10.1186/cc11668
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137
   Rustan AC, 1998, BBA-LIPID LIPID MET, V1390, P245, DOI 10.1016/S0005-2760(97)00194-X
   Schaefer MB, 2008, ATHEROSCLEROSIS, V197, P630, DOI 10.1016/j.atherosclerosis.2007.09.004
   Schaefer MB, 2007, CRIT CARE MED, V35, P544, DOI 10.1097/01.CCM.0000253811.74112.B6
   Schober A, 2005, ANTIOXID REDOX SIGN, V7, P1249, DOI 10.1089/ars.2005.7.1249
   Schutte H, 1996, EUR RESPIR J, V9, P1858, DOI 10.1183/09031936.96.09091858
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Sibelius U, 2002, CRIT CARE MED, V30, P2306, DOI 10.1097/00003246-200210000-00020
   Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024
   Smith DF, 2005, AM J PHYSIOL-HEART C, V289, pH1976, DOI 10.1152/ajpheart.00153.2005
   SPERLING RI, 1993, J CLIN INVEST, V91, P651, DOI 10.1172/JCI116245
   Stapleton RD, 2011, CRIT CARE MED, V39, P1655, DOI 10.1097/CCM.0b013e318218669d
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
NR 41
TC 29
Z9 30
U1 0
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 12
PY 2015
VL 19
AR 226
DI 10.1186/s13054-015-0933-6
PG 13
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CI6GC
UT WOS:000354855700001
PM 25962383
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Herold, S
   Becker, C
   Ridge, KM
   Budinger, GRS
AF Herold, Susanne
   Becker, Christin
   Ridge, Karen M.
   Budinger, G. R. Scott
TI Influenza virus-induced lung injury: pathogenesis and implications for
   treatment
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID N-LINKED GLYCOSYLATION; RECEPTOR-BINDING SPECIFICITY; ALVEOLAR
   EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; AIRWAY STEM-CELLS; A VIRUS;
   PANDEMIC INFLUENZA; DENDRITIC CELLS; T-CELLS; NEURAMINIDASE INHIBITORS
AB The influenza viruses are some of the Most important human pathogens, causing substantial seasonal and pandemic morbidity and mortality. In humans, infection of the lower respiratory tract of can result in flooding of the alveolar compartment, development of acute respiratory distress syndrome and death from respiratory failure. Influenza-mediated damage of the airway, alveolar epithelium and alveolar endothelium results from a combination of: 1) intrinsic viral pathogenicity, attributable to its tropism for host airway and alveolar epithelial cells; and 2) a robust host innate immune response, which, while contributing to viral clearance, can worsen the severity of lung injury. In this review, we summarise the molecular events at the virus host interface during influenza virus infection, highlighting some of the important cellular responses. We discuss immune-mediated viral clearance, the mechanisms promoting or perpetuating lung injury, lung regeneration after influenza-induced injury, and recent advances in influenza prevention and therapy.
C1 [Herold, Susanne; Becker, Christin] Univ Giessen, Univ Giessen & Marburg Lung Ctr, Dept Internal Med 2, D-35390 Giessen, Germany.
C1 [Ridge, Karen M.; Budinger, G. R. Scott] Northwestern Univ, Pulm & Crit Care Med, Chicago, IL 60611, United States.
C3 Justus Liebig University Giessen; Northwestern University
RP Herold, S (corresponding author), Univ Giessen & Marburg Lung Ctr, Dept Internal Med 2, Klin Str 33, D-35392 Giessen, Germany.
EM susanne.herold@innere.med.uni-giessen.de
OI Peteranderl, Christin/0000-0003-3799-8268; Herold,
   Susanne/0000-0001-6343-0911
FU NHLBI NIH HHS [R01 HL124664, P01 HL071643] Funding Source: Medline
CR Abe Y, 2004, J VIROL, V78, P9605, DOI 10.1128/JVI.78.18.9605-9611.2004
   Aldridge JR, 2009, P NATL ACAD SCI USA, V106, P5306, DOI 10.1073/pnas.0900655106
   Anikina AG, 2014, B EXP BIOL MED+, V156, P833, DOI 10.1007/s10517-014-2463-7
   [Anonymous], 2014, Wkly Epidemiol Rec, V89, P93
   Antunes I, 2010, J VIROL, V84, P12564, DOI 10.1128/JVI.01559-10
   Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710
   Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Bedford T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000918
   Belser JA, 2007, J INFECT DIS, V196, P1493, DOI 10.1086/522609
   Belshe RB, 2009, NEW ENGL J MED, V360, P2667, DOI 10.1056/NEJMe0903995
   Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000
   Berri F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003229
   Beyleveld G, 2013, ANTIVIR RES, V100, P120, DOI 10.1016/j.antiviral.2013.07.018
   Blackburne BP, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000058
   Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166
   Bradel-Tretheway BG, 2011, J VIROL, V85, P8569, DOI 10.1128/JVI.00496-11
   Brandes M, 2013, CELL, V154, P197, DOI 10.1016/j.cell.2013.06.013
   Bright RA, 2006, JAMA-J AM MED ASSOC, V295, P891, DOI 10.1001/jama.295.8.joc60020
   Brincks EL, 2008, J IMMUNOL, V181, P4918, DOI 10.4049/jimmunol.181.7.4918
   Cakarova L, 2009, AM J RESP CRIT CARE, V180, P521, DOI 10.1164/rccm.200812-1837OC
   Cameron CM, 2008, J VIROL, V82, P11308, DOI 10.1128/JVI.00691-08
   Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612
   Capelozzi VL, 2010, CLINICS, V65, P1229, DOI 10.1590/S1807-59322010001200003
   Carlson CM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001136
   Childs RA, 2009, NAT BIOTECHNOL, V27, P797, DOI 10.1038/nbt0909-797
   Chutinimitkul S, 2010, J VIROL, V84, P11802, DOI 10.1128/JVI.01136-10
   Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262
   Cortes Garcia M, 2012, J INFECTION, V64, P218
   Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407
   Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526
   Davidson S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4864
   Dawson TC, 2000, AM J PATHOL, V156, P1951, DOI 10.1016/S0002-9440(10)65068-7
   De Clercq E, 2007, BIOCHEM PHARMACOL, V73, P911, DOI 10.1016/j.bcp.2006.09.014
   Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930
   Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538
   Droebner K, 2011, ANTIVIR RES, V92, P195, DOI 10.1016/j.antiviral.2011.08.002
   Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101
   Enserink M, 2005, SCIENCE, V309, P1976
   Estenssoro E, 2010, AM J RESP CRIT CARE, V182, P41, DOI [10.1164/201001-0037OC, 10.1164/rccm.201001-0037OC]
   Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921
   Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gack MU, 2009, CELL HOST MICROBE, V5, P439, DOI 10.1016/j.chom.2009.04.006
   Gannage M, 2009, CELL HOST MICROBE, V6, P367, DOI 10.1016/j.chom.2009.09.005
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365
   Ghoneim HE, 2013, J IMMUNOL, V191, P1250, DOI 10.4049/jimmunol.1300014
   Ghosh S, 2011, AM J RESP CELL MOL, V45, P1036, DOI 10.1165/rcmb.2010-0349OC
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691
   Guo HL, 2010, J VIROL, V84, P7750, DOI 10.1128/JVI.00187-10
   Hashimoto Y, 2007, J IMMUNOL, V178, P2448, DOI 10.4049/jimmunol.178.4.2448
   Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774
   Helft J, 2012, J CLIN INVEST, V122, P4037, DOI 10.1172/JCI60659
   Herold S, 2014, AM J RESP CRIT CARE, V189, P609, DOI 10.1164/rccm.201311-2041LE
   Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065
   Herold S, 2011, AM J RESP CRIT CARE, V183, P1380, DOI 10.1164/rccm.201009-1431OC
   Herold S, 2008, J EXP MED, V205, P3065, DOI 10.1084/jem.20080201
   Hillaire MLB, 2013, J INNATE IMMUN, V5, P197, DOI 10.1159/000346374
   Hogner K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003188
   Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012
   Huang FM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4595
   Hufford MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046581
   Hufford MM, 2011, J EXP MED, V208, P167, DOI 10.1084/jem.20101850
   Hui DSC, 2013, INFLUENZA OTHER RESP, V7, P52, DOI 10.1111/irv.12171
   Ichikawa A, 2013, AM J RESP CRIT CARE, V187, P65, DOI 10.1164/rccm.201203-0508OC
   Ichinohe T, 2013, P NATL ACAD SCI USA, V110, P17963, DOI 10.1073/pnas.1312571110
   Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108
   Igarashi M, 2008, VIROLOGY, V376, P323, DOI 10.1016/j.virol.2008.03.036
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Ivanov S, 2013, J VIROL, V87, P6911, DOI 10.1128/JVI.02943-12
   Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665
   Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695
   Jamieson AM, 2013, SCIENCE, V340, P1230, DOI 10.1126/science.1233632
   Janssen WJ, 2011, AM J RESP CRIT CARE, V184, P547, DOI 10.1164/rccm.201011-1891OC
   Jefferson T, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008965.pub4, 10.1002/14651858.CD008965.pub3]
   Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5106
   Jia DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013927
   Karlstrom A, 2009, J INFECT DIS, V199, P311, DOI 10.1086/596051
   Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541
   KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989
   Khoufache K, 2013, J CLIN INVEST, V123, P206, DOI 10.1172/JCI61667
   Kim HM, 2008, J VIROL, V82, P4265, DOI 10.1128/JVI.02602-07
   Kim TS, 2014, IMMUNITY, V40, P400, DOI 10.1016/j.immuni.2014.02.004
   Kim TS, 2011, TRENDS IMMUNOL, V32, P225, DOI 10.1016/j.it.2011.02.006
   Kim TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004204
   Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951
   Kohlmeier JE, 2010, IMMUNITY, V33, P96, DOI 10.1016/j.immuni.2010.06.016
   Korteweg C, 2008, AM J PATHOL, V172, P1155, DOI 10.2353/ajpath.2008.070791
   Kourtis AP, 2014, NEW ENGL J MED, V371, P1077, DOI [10.1056/NEJMra1213566, 10.1056/NEJMc1408436]
   Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025
   Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013
   Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001
   Lackenby A, 2008, CURR OPIN INFECT DIS, V21, P626, DOI 10.1097/QCO.0b013e3283199797
   Lazrak A, 2009, FASEB J, V23, P3829, DOI 10.1096/fj.09-135590
   Leeman KT, 2014, CURR TOP DEV BIOL, V107, P207, DOI 10.1016/B978-0-12-416022-4.00008-1
   Li Q, 2014, NEW ENGL J MED, V370, P520, DOI 10.1056/NEJMoa1304617
   Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005
   Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673
   Lin KL, 2008, J IMMUNOL, V180, P2562, DOI 10.4049/jimmunol.180.4.2562
   Lin KL, 2011, J IMMUNOL, V186, P508, DOI 10.4049/jimmunol.1001002
   Liu Y, 2010, J VIROL, V84, P12069, DOI 10.1128/JVI.01639-10
   Ljungman P, 2011, HAEMATOL-HEMATOL J, V96, P1231, DOI 10.3324/haematol.2011.041913
   Londino JD, 2013, AM J PHYSIOL-LUNG C, V304, pL582, DOI 10.1152/ajplung.00314.2012
   Louie JK, 2012, CLIN INFECT DIS, V55, P1198, DOI 10.1093/cid/cis636
   Ludwig S, 2014, INT J MED MICROBIOL, V304, P894, DOI 10.1016/j.ijmm.2014.08.016
   Ludwig S, 2009, J ANTIMICROB CHEMOTH, V64, P1, DOI 10.1093/jac/dkp161
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI [10.1056/NEJMoa1401480, 10.1056/NEJMc1412050]
   Maelfait J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002570
   Maines TR, 2009, SCIENCE, V325, P484, DOI 10.1126/science.1177238
   Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC
   MASON RJ, 1994, AM J RESP CELL MOL, V11, P561, DOI 10.1165/ajrcmb.11.5.7524567
   Mazur I, 2007, CELL MICROBIOL, V9, P1683, DOI 10.1111/j.1462-5822.2007.00902.x
   McAuley JL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001014
   McGill J, 2008, J EXP MED, V205, P1635, DOI 10.1084/jem.20080314
   McGill J, 2010, J EXP MED, V207, P521, DOI 10.1084/jem.20091711
   Miller MA, 2009, NEW ENGL J MED, V360, P2595, DOI 10.1056/NEJMp0903906
   Mock JR, 2014, MUCOSAL IMMUNOL, V7, P1440, DOI 10.1038/mi.2014.33
   Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1038/ni.2131, 10.1031/ni.2131]
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Morens DM, 2012, NATURE, V486, P335, DOI 10.1038/nature11170
   Morgan OW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009694
   Morita M, 2013, CELL, V153, P112, DOI 10.1016/j.cell.2013.02.027
   Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740
   Moser EK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004315
   Moss RB, 2012, J INFECT DIS, V206, P1844, DOI 10.1093/infdis/jis622
   Narasaraju T, 2010, AM J RESP CELL MOL, V42, P732, DOI 10.1165/rcmb.2008-0423OC
   Ortiz JR, 2013, AM J RESP CRIT CARE, V188, P710, DOI 10.1164/rccm.201212-2341OC
   Pauli EK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000196
   Pinto LH, 2007, MOL BIOSYST, V3, P18, DOI 10.1039/b611613m
   Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200
   Pociask DA, 2013, AM J PATHOL, V182, P1286, DOI 10.1016/j.ajpath.2012.12.007
   Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256
   Radigan KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035788
   Rajsbaum R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003059
   Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945
   Reading PC, 2007, ADV EXP MED BIOL, V598, P279
   Riscili BP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018166
   Rodrigue-Gervais IG, 2014, CELL HOST MICROBE, V15, P23, DOI 10.1016/j.chom.2013.12.003
   Rossman JS, 2011, VIROLOGY, V411, P229, DOI 10.1016/j.virol.2010.12.003
   ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U
   Russell CA, 2008, SCIENCE, V320, P340, DOI 10.1126/science.1154137
   Rust MJ, 2004, NAT STRUCT MOL BIOL, V11, P567, DOI 10.1038/nsmb769
   Sakai S, 2000, J VIROL, V74, P2472, DOI 10.1128/JVI.74.5.2472-2476.2000
   Santesso N, 2013, INFLUENZA OTHER RESP, V7, P76, DOI 10.1111/irv.12085
   Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681
   SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8
   Shahangian A, 2009, J CLIN INVEST, V119, P1910, DOI 10.1172/JCI35412
   Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a
   Shirey KA, 2013, NATURE, V497, P498, DOI 10.1038/nature12118
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Shrestha SS, 2011, CLIN INFECT DIS, V52, pS75, DOI 10.1093/cid/ciq012
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637
   Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025
   Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Sturrock A, 2012, AM J PHYSIOL-LUNG C, V302, pL343, DOI 10.1152/ajplung.00276.2011
   Sun J, 2013, CURR OPIN VIROL, V3, P425, DOI 10.1016/j.coviro.2013.05.001
   Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929
   Sun K, 2008, NAT MED, V14, P558, DOI 10.1038/nm1765
   Sun SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022844
   Szretter KJ, 2007, J VIROL, V81, P2736, DOI 10.1128/JVI.02336-06
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   Tate MD, 2014, VIRUSES-BASEL, V6, P1294, DOI 10.3390/v6031294
   Tate MD, 2011, J IMMUNOL, V187, P1884, DOI 10.4049/jimmunol.1100295
   Tate MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017618
   Taubenberger J, 2006, P AM PHILOS SOC, V150, P1
   Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230
   Teijaro JR, 2014, P NATL ACAD SCI USA, V111, P3799, DOI 10.1073/pnas.1400593111
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006
   Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057
   Thorlund K, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-134
   Topham DJ, 1997, J IMMUNOL, V159, P5197
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   Tsai SY, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003848
   Tumpey TM, 2007, SCIENCE, V315, P655, DOI 10.1126/science.1136212
   Tumpey TM, 2005, J VIROL, V79, P14933, DOI 10.1128/JVI.79.23.14933-14944.2005
   Uhlendorff J, 2009, ARCH VIROL, V154, P945, DOI 10.1007/s00705-009-0393-x
   Unkel B, 2012, J CLIN INVEST, V122, P3652, DOI 10.1172/JCI62139
   Uyeki TM, 2014, NEW ENGL J MED, V370, P789, DOI 10.1056/NEJMp1400034
   van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248
   van Riel D, 2010, AM J PATHOL, V176, P1614, DOI 10.2353/ajpath.2010.090949
   Ventetuolo CE, 2014, AM J RESP CRIT CARE, V190, P497, DOI 10.1164/rccm.201404-0736CI
   Vigerust DJ, 2007, J VIROL, V81, P8593, DOI 10.1128/JVI.00769-07
   Waffarn EE, 2011, J IMMUNOL, V186, P3823, DOI 10.4049/jimmunol.1002090
   Wang J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3106
   Wang JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029879
   Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000
   Worobey M, 2014, NATURE, V508, P254, DOI 10.1038/nature13016
   Yang ZY, 2007, SCIENCE, V317, P825, DOI 10.1126/science.1135165
   Yoshizumi T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5713
   Zamarin Dmitriy, 2005, PLoS Pathogens, V1, P40
   Zhang W, 2013, J VIROL, V87, P5949, DOI 10.1128/JVI.00545-13
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
   Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903
NR 200
TC 262
Z9 271
U1 9
U2 61
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD MAY
PY 2015
VL 45
IS 5
BP 1463
EP 1478
DI 10.1183/09031936.00186214
PG 16
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA CH6KI
UT WOS:000354145100030
PM 25792631
OA Bronze
DA 2023-08-21
ER

PT J
AU Rizzo, AN
   Aman, J
   Amerongen, GPV
   Dudek, SM
AF Rizzo, Alicia N.
   Aman, Jurjan
   Amerongen, Geerten P. van Nieuw
   Dudek, Steven M.
TI Targeting Abl Kinases to Regulate Vascular Leak During Sepsis and Acute
   Respiratory Distress Syndrome
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Review
DE ALI/ARDS; c-Abl; cytoskeleton; ECs/HPMECs/HUVECs/MPVECs; imatinib; respiratory distress syndrome, adult; sepsis 
ID ENDOTHELIAL BARRIER ENHANCEMENT; BLOOD-BRAIN-BARRIER; ACUTE LUNG INJURY;
   C-ABL; TYROSINE KINASE; IMATINIB MESYLATE; SPHINGOSINE 1-PHOSPHATE;
   FAMILY KINASES; FOCAL ADHESION; CELL-CELL
AB The vascular endothelium separates circulating fluid and inflammatory cells from the surrounding tissues. Vascular leak occurs in response to wide-spread inflammatory processes, such as sepsis and acute respiratory distress syndrome, because of the formation of gaps between endothelial cells. Although these disorders are leading causes of mortality in the intensive care unit, no medical therapies exist to restore endothelial cell barrier function. Recent evidence highlights a key role for the Abl family of nonreceptor tyrosine kinases in regulating vascular barrier integrity. These kinases have welldescribed roles in cancer progression and neuronal morphogenesis, but their functions in the vasculature have remained enigmatic until recently. The Abl family kinases, c-Abl (Abl1) and Abl related gene (Arg, Abl2), phosphorylate several cytoskeletal effectors that mediate vascular permeability, including nonmuscle myosin light chain kinase, cortactin, vinculin, and beta-catenin. They also regulate cell-cell and cell-matrix junction dynamics, and the formation of actin-based cellular protrusions in multiple cell types. In addition, both c-Abl and Arg are activated by hyperoxia and contribute to oxidant-induced endothelial cell injury. These numerous roles of Abl kinases in endothelial cells and the current clinical usage of imatinib and other Abl kinase inhibitors have spurred recent interest in repurposing these drugs for the treatment of vascular barrier dysfunction. This review will describe the structure and function of Abl kinases with an emphasis on their roles in mediating vascular barrier integrity. We will also provide a critical evaluation of the potential for exploiting Abl kinase inhibition as a novel therapy for inflammatory vascular leak syndromes.
C1 [Rizzo, Alicia N.; Dudek, Steven M.] Univ Illinois, Coll Med, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C1 [Rizzo, Alicia N.; Amerongen, Geerten P. van Nieuw; Dudek, Steven M.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Aman, Jurjan; Amerongen, Geerten P. van Nieuw] Vrije Univ Amsterdam, Med Ctr, Dept Physiol, Inst Cardiovasc Res, Amsterdam, Netherlands.
C1 [Aman, Jurjan] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, Inst Cardiovasc Res, Amsterdam, Netherlands.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam
RP Dudek, SM (corresponding author), Univ Illinois Hosp, Div Pulm Crit Care Sleep & Allergy, 840 S Wood St,CSB 915, Chicago, IL 60612 USA.
EM sdudek@uic.edu
OI Rizzo, Alicia/0000-0001-9289-4635
FU National Heart, Lung, and Blood Institute [F30HL121982]; American Heart
   Association [14PRE18860021]; University of Illinois Institutional Funds;
   Dutch Heart Foundation [2014T064, 2011T072]
FX This work acknowledges support from National Heart, Lung, and Blood
   Institute (F30HL121982 to A.N. Rizzo), American Heart Association
   (14PRE18860021 to A.N. Rizzo), University of Illinois Institutional
   Funds, and the Dutch Heart Foundation (grant 2014T064 to JA and grant
   2011T072 to G.P. van Nieuw Amerongen).
CR ABELSON HT, 1970, CANCER RES, V30, P2213
   Aman J, 2013, AM J RESP CRIT CARE, V188, P1171, DOI 10.1164/rccm.201301-0136LE
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Bays JL, 2014, J CELL BIOL, V205, P251, DOI 10.1083/jcb.201309092
   BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176
   Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057
   Bradley WD, 2006, MOL BIOL CELL, V17, P4827, DOI 10.1091/mbc.E06-02-0132
   Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859
   Breccia M, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.003
   Burton EA, 2005, MOL CELL BIOL, V25, P8834, DOI 10.1128/MCB.25.20.8834-8843.2005
   Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200
   Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200
   Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200
   Carnevale-Schianca F, 2011, J CLIN ONCOL, V29, pE691, DOI 10.1200/JCO.2011.35.6733
   Chen S, 2014, AM J RESP CELL MOL, V50, P1076, DOI 10.1165/rcmb.2013-0438OC
   Chislock EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085231
   Chislock EM, 2013, P NATL ACAD SCI USA, V110, P12432, DOI 10.1073/pnas.1304188110
   Ciarcia R, 2012, J CELL PHYSIOL, V227, P2798, DOI 10.1002/jcp.23029
   Cleary RA, 2014, AM J PHYSIOL-CELL PH, V306, pC753, DOI 10.1152/ajpcell.00327.2013
   Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6
   COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214
   Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   Fraunfelder FW, 2003, J OCUL PHARMACOL TH, V19, P371, DOI 10.1089/108076803322279426
   Galkin VE, 2005, J MOL BIOL, V346, P565, DOI 10.1016/j.jmb.2004.11.078
   Gu JJ, 2009, IMMUNOL REV, V228, P170, DOI 10.1111/j.1600-065X.2008.00751.x
   Hagerkvist R, 2007, FASEB J, V21, P618, DOI 10.1096/fj.06-6910com
   Hernandez SE, 2004, CURR BIOL, V14, P691, DOI 10.1016/j.cub.2004.03.062
   Hoeper MM, 2013, CIRCULATION, V127, P1128, DOI 10.1161/CIRCULATIONAHA.112.000765
   Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963
   Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315
   Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446
   Kim IK, 2013, CRIT CARE, V17, DOI 10.1186/cc12786
   Kim JY, 2014, ARTERIOSCL THROM VAS, V34, P1459, DOI 10.1161/ATVBAHA.114.303575
   Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7
   KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802
   Kurimoto N, 2004, AM J PHYSIOL-HEART C, V287, pH100, DOI 10.1152/ajpheart.00922.2003
   Lapetina S, 2009, J CELL BIOL, V185, P503, DOI 10.1083/jcb.200809085
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Letsiou E, 2015, AM J PHYSIOL-LUNG C, V308, pL259, DOI 10.1152/ajplung.00323.2014
   Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225
   Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174
   Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542
   Lin YC, 2013, J NEUROSCI, V33, P1846, DOI 10.1523/JNEUROSCI.4284-12.2013
   Ma QY, 2011, ANN NEUROL, V70, P920, DOI 10.1002/ana.22549
   Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057
   Mokhtari D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024831
   Moresco EMY, 2005, J NEUROSCI, V25, P6105, DOI 10.1523/JNEUROSCI.1432-05.2005
   Overbeek MJ, 2008, EUR RESPIR J, V32, P232, DOI 10.1183/09031936.00054407
   Paniagua RT, 2006, J CLIN INVEST, V116, P2633, DOI 10.1172/JCI28546
   Peacock JG, 2007, MOL BIOL CELL, V18, P3860, DOI 10.1091/mbc.E07-01-0075
   Peacock JG, 2010, CYTOSKELETON, V67, P666, DOI 10.1002/cm.20479
   Qiu ZZ, 2010, P NATL ACAD SCI USA, V107, P1136, DOI 10.1073/pnas.0913131107
   Rhee CK, 2011, RESPIRATION, V82, P273, DOI 10.1159/000327719
   Ribeiro AL, 2008, LEUKEMIA RES, V32, P1809, DOI 10.1016/j.leukres.2008.03.020
   Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061
   Ruan J, 2013, BLOOD, V121, P5192, DOI 10.1182/blood-2013-03-490763
   Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056/NEJMoa0912614
   Schiffer CA, 2007, NEW ENGL J MED, V357, P258, DOI 10.1056/NEJMct071828
   SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200
   Stephens RS, 2014, AM J PHYSIOL-CELL PH, V306, pC559, DOI 10.1152/ajpcell.00375.2012
   Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787
   Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457
   Tiribelli M, 2008, AM J HEMATOL, V83, P517, DOI 10.1002/ajh.21157
   TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M
   VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325
   Waller CF, 2014, RECENT RESULTS CANC, V201, P1, DOI 10.1007/978-3-642-54490-3_1
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Wolf AM, 2005, P NATL ACAD SCI USA, V102, P13622, DOI 10.1073/pnas.0501758102
   Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171
   Zandy NL, 2008, CELL CYCLE, V7, P444, DOI 10.4161/cc.7.4.5452
   Zandy NL, 2007, P NATL ACAD SCI USA, V104, P17686, DOI 10.1073/pnas.0703077104
NR 84
TC 54
Z9 57
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAY
PY 2015
VL 35
IS 5
BP 1071
EP 1079
DI 10.1161/ATVBAHA.115.305085
PG 9
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA CG5MF
UT WOS:000353335300006
PM 25814671
OA Green Accepted, hybrid
DA 2023-08-21
ER

PT J
AU Sauler, M
   Zhang, Y
   Min, JN
   Leng, L
   Shan, PY
   Roberts, S
   Jorgensen, WL
   Bucala, R
   Lee, PJ
AF Sauler, Maor
   Zhang, Yi
   Min, Jin-Na
   Leng, Lin
   Shan, Peiying
   Roberts, Scott
   Jorgensen, William L.
   Bucala, Richard
   Lee, Patty J.
TI Endothelial CD74 mediates macrophage migration inhibitory factor
   protection in hyperoxic lung injury
SO FASEB JOURNAL
LA English
DT Article
DE apoptosis; ECs/HPMECs/HUVECs/MPVECs; H2AX; MIF 
ID RESPIRATORY-DISTRESS-SYNDROME; D-DOPACHROME TAUTOMERASE; PULMONARY
   ARTERIAL-HYPERTENSION; DNA-DAMAGE; OXIDATIVE STRESS; FACTOR MIF; HISTONE
   H2AX; CELL-CYCLE; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS
AB Exposure to hyperoxia results in acute lung injury. A pathogenic consequence of hyperoxia is endothelial injury. Macrophage migration inhibitory factor (MIF) has a cytoprotective effect on lung endothelial cells; however, the mechanism is uncertain. We postulate that the MIF receptor CD74 mediates this protective effect. Using adult wild-type (WT), MIF-deficient (Mif(-/-)), CD74-deficient (Cd74(-/-)) mice and MIF receptor inhibitor treated mice, we report that MIF deficiency or inhibition of MIF receptor binding results in increased sensitivity to hyperoxia. Mif(-/-) and Cd74(-/-) mice demonstrated decreased median survival following hyperoxia compared to WT mice. Mif(-/-) mice demonstrated an increase in bronchoalveolar protein (48%) and lactate dehydrogenase (LDH) (68%) following 72 hours of hyperoxia. Similarly, treatment with MIF receptor antagonist resulted in a 59% and 91% increase in bronchoalveolar lavage protein and LDH, respectively. Inhibition of CD74 in primary murine lung endothelial cells (MLECs) abrogated the protective effect of MIF, including decreased hyperoxia-mediated AKT phosphorylation and a 20% reduction in the antiapoptotic effect of exogenous MIF. Treatment with MIF decreased hyperoxia-mediated H2AX phosphorylation in a CD74-dependent manner. These data suggest that therapeutic manipulation of the MIF-CD74 axis in lung endothelial cells may be a novel approach to protect against acute oxidative stress.
C1 [Sauler, Maor; Zhang, Yi; Min, Jin-Na; Shan, Peiying; Lee, Patty J.] Yale Univ, Sch Med, Sect Pulm, Crit Care & Sleep Med, New Haven, CT 06520, United States.
C1 [Leng, Lin; Roberts, Scott; Bucala, Richard] Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520, United States.
C1 [Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06520, United States.
C3 Yale University; Yale University; Yale University
RP Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm, Crit Care & Sleep Med, 333 Cedar St,POB 208057, New Haven, CT 06520 USA.
EM patty.lee@yale.edu
RI /AAW-1187-2021
OI Leng, Lin/0000-0002-0605-358X
FU U.S. National Institutes of Health [T32007778, R01AI043210, R01HL090660,
   R01HL071595]; FAMRI Clinical Investigator Award
FX These studies were funded by the following grants from the U.S. National
   Institutes of Health: T32007778 (to M.S.), R01AI043210 (to R.B.), and
   R01HL090660, R01HL071595, and FAMRI Clinical Investigator Award (to
   P.J.L.).
CR Ahmad A, 2006, FREE RADICAL BIO MED, V40, P1108, DOI 10.1016/j.freeradbiomed.2005.10.045
   Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218
   Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002
   Becker-Herman S, 2005, MOL BIOL CELL, V16, P5061, DOI 10.1091/mbc.E05-04-0327
   Beswick EJ, 2005, INFECT IMMUN, V73, P2736, DOI 10.1128/IAI.73.5.2736-2743.2005
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917
   CRAPO JD, 1982, AM REV RESPIR DIS, V126, P332
   Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942
   Damico RL, 2008, AM J RESP CELL MOL, V39, P77, DOI 10.1165/rcmb.2007-0248OC
   Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320
   Gonzalez JE, 2012, ANAL QUANT CYTOL, V34, P66
   Fallica J, 2014, AM J RESP CELL MOL, V51, P94, DOI 10.1165/rcmb.2013-0371OC
   Faure-Andre G, 2008, SCIENCE, V322, P1705, DOI 10.1126/science.1159894
   Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100
   Fingerle-Rowson G, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-22
   FISHER AB, 1980, AM REV RESPIR DIS, V122, P61, DOI 10.1164/arrd.1980.122.5P2.61
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Gao L, 2007, TRANSL RES, V150, P18, DOI 10.1016/j.trsl.2007.02.007
   Guo Yubiao, 2002, Zhonghua Jiehe He Huxi Zazhi, V25, P337
   Hare AA, 2010, BIOORG MED CHEM LETT, V20, P5811, DOI 10.1016/j.bmcl.2010.07.129
   Hirakawa H, 2007, AM J RESP CRIT CARE, V176, P778, DOI 10.1164/rccm.200704-519OC
   Ivashkevich A, 2012, CANCER LETT, V327, P123, DOI 10.1016/j.canlet.2011.12.025
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X
   Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550
   Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591
   Kulkarni A, 2008, AM J PHYSIOL-LUNG C, V294, pL998, DOI 10.1152/ajplung.00004.2008
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Leng L, 2011, J IMMUNOL, V186, P527, DOI 10.4049/jimmunol.1001767
   Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318
   Marsh LM, 2009, AM J PHYSIOL-LUNG C, V296, pL442, DOI 10.1152/ajplung.00525.2007
   MARTINS EAL, 1991, MUTAT RES, V250, P95, DOI 10.1016/0027-5107(91)90166-L
   Mathew B, 2013, AM J RESP CELL MOL, V49, P269, DOI 10.1165/rcmb.2012-0291OC
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Merk M, 2012, CYTOKINE, V59, P10, DOI 10.1016/j.cyto.2012.03.014
   Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113
   Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599
   Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002
   Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337
   O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291
   Paine R, 2012, CRIT CARE MED, V40, P90, DOI 10.1097/CCM.0b013e31822d7bf0
   Pasupuleti V, 2014, J BIOL CHEM, V289, P3713, DOI 10.1074/jbc.M113.500694
   Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2
   PERO RW, 1990, CANCER RES, V50, P4619
   Petrenko O, 2005, MOL CELL, V17, P225, DOI 10.1016/j.molcel.2004.11.052
   Qi DK, 2014, J CLIN INVEST, V124, P3540, DOI 10.1172/JCI73061
   Rabinovitch M, 2014, CIRC RES, V115, P165, DOI 10.1161/CIRCRESAHA.113.301141
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Sauler M, 2014, AM J PHYSIOL-LUNG C, V306, pL487, DOI 10.1152/ajplung.00284.2013
   Schwartz V, 2012, EUR J CELL BIOL, V91, P435, DOI 10.1016/j.ejcb.2011.08.006
   Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F
   Sun HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060560
   Sun HX, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-27
   Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587
   Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Xin D, 2010, MOL CANCER RES, V8, P1601, DOI 10.1158/1541-7786.MCR-10-0101
   Zhang XC, 2005, J IMMUNOL, V175, P4834, DOI 10.4049/jimmunol.175.8.4834
   Zhang Y, 2014, J IMMUNOL, V192, P5296, DOI 10.4049/jimmunol.1400653
   Zhang Y, 2013, FASEB J, V27, P4041, DOI 10.1096/fj.13-231225
   Zhang Y, 2013, J IMMUNOL, V191, P1393, DOI 10.4049/jimmunol.1300052
NR 68
TC 31
Z9 33
U1 0
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2015
VL 29
IS 5
BP 1940
EP 1949
DI 10.1096/fj.14-260299
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA CH5ZJ
UT WOS:000354114600028
PM 25609432
OA Green Published
DA 2023-08-21
ER

PT J
AU Wang, LC
   Bittman, R
   Garcia, JGN
   Dudek, SM
AF Wang, Lichun
   Bittman, Robert
   Garcia, Joe G. N.
   Dudek, Steven M.
TI Junctional complex and focal adhesion rearrangement mediates pulmonary
   endothelial barrier enhancement by FTY720 S-phosphonate
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Pulmonary vascular barrier; FTY720 S-phosphonate; ALI/ARDS; VE-cadherin; Rac1 
ID ACUTE LUNG INJURY; SPHINGOSINE 1-PHOSPHATE; CYTOSKELETAL REARRANGEMENT;
   VASCULAR LEAK; GROWTH-FACTOR; PERMEABILITY; KINASE; RECEPTOR; PROTEIN;
   FAK
AB Rationale: Modulation of pulmonary vascular barrier function is an important clinical goal given the devastating effects of vascular leak in acute lung injury (ALI). We previously demonstrated that FTY720 S-phosphonate (Tys), an analog of sphingosine 1-phosphate (S1P) and FTY720, has more potent pulmonary barrier protective effects than these agents in vitro and in mouse models of ALI. Tys preserves expression of the barrier-promoting S1P1 receptor (S1PR1), whereas S1P and FTY720 induce its ubiquitination and degradation. Here we further characterize the novel barrier promoting effects of Tys in cultured human pulmonary endothelial cells (EC).
   Methods/Results: In human lung EC, Tys significantly increased peripheral redistribution of adherens junction proteins VE-cadherin and beta-catenin and tight junction protein ZO-1. Inhibition of VE-cadherin with blocking antibody significantly attenuated Tys-induced transendothelial resistance (TER) elevation, while ZO-1 siRNA partially inhibited this elevation. Tys significantly increased focal adhesion formation and phosphorylation of focal adhesion kinase (FAK). Pharmacologic inhibition of FAK significantly attenuated Tys-induced TER elevation. Tys significantly increased phosphorylation and peripheral redistribution of the actin-binding protein, cortactin, while cortactin siRNA partially attenuated Tys-induced TER elevation. Although Tys significantly increased phosphorylation of Akt and GSK3 beta, neither PI3 kinase nor GSK3 beta inhibition altered Tys-induced TER elevation. Tys significantly increased Rac1 activity, while inhibition of Rac1 activity significantly attenuated Tys-induced VE-cadherin redistribution and TER elevation.
   Conclusion: Junctional complex, focal adhesion rearrangement and Rac1 activation play critical roles in Tys-mediated barrier protection in pulmonary EC. These results provide mechanistic insights into the effects of this potential ALI therapy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Wang, Lichun; Dudek, Steven M.] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60612, United States.
C1 [Bittman, Robert] CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367, United States.
C1 [Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; City University of New York
   (CUNY) System; Queens College NY (CUNY); University of Arizona
RP Dudek, SM (corresponding author), Univ Illinois, Div Pulm Crit Care Sleep & Allergy, COMRB 3143,MC 719,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM sdudek@uic.edu
RI Garcia, Joe GN/E-8862-2010
FU National Heart Lung Blood Institute [P01 HL 58064, R01 HL 88144, P01 HL
   98050]
FX This work was supported by grants P01 HL 58064 (JGNG), R01 HL 88144
   (SMD), and P01 HL 98050 (VN) from the National Heart Lung Blood
   Institute. This paper is dedicated to the memory of our wonderful
   collaborator, Dr. Robert Bittman, whose recent passing is a significant
   loss to his family, friends, and the scientific field.
CR Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Belvitch P, 2012, MICROVASC RES, V83, P22, DOI 10.1016/j.mvr.2011.08.012
   Birukova AA, 2007, MICROVASC RES, V73, P173, DOI 10.1016/j.mvr.2006.12.004
   Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544
   Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157
   Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dudek SM, 2007, CELL SIGNAL, V19, P1754, DOI 10.1016/j.cellsig.2007.03.011
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   ILLC D, 1995, NATURE, V377, P539
   Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Koyrakh L, 2005, AM J TRANSPLANT, V5, P529, DOI 10.1111/j.1600-6143.2005.00754.x
   Krump-Konvalinkova V, 2005, ARTERIOSCL THROM VAS, V25, P546, DOI 10.1161/01.ATV.0000154360.36106.d9
   Lee JF, 2006, J BIOL CHEM, V281, P29190, DOI 10.1074/jbc.M604310200
   Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Young HL, 2007, AM J RESP CELL MOL, V37, P485, DOI 10.1165/rcmb.2006-0439OC
   Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com
   Lu XQ, 2009, J ORG CHEM, V74, P3192, DOI 10.1021/jo900023u
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965
   Oo ML, 2011, J CLIN INVEST, V121, P2290, DOI 10.1172/JCI45403
   Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Quadri SK, 2007, AM J PHYSIOL-LUNG C, V292, pL334, DOI 10.1152/ajplung.00228.2006
   Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Wang LC, 2014, CRIT CARE MED, V42, pE189, DOI 10.1097/CCM.0000000000000097
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wu MH, 2003, J PHYSIOL-LONDON, V552, P691, DOI 10.1113/jphysiol.2003.048405
   Zhao J, 2009, CELL SIGNAL, V21, P1945, DOI 10.1016/j.cellsig.2009.09.002
   Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094
NR 42
TC 25
Z9 26
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAY
PY 2015
VL 99
BP 102
EP 109
DI 10.1016/j.mvr.2015.03.007
PG 8
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA CI0IL
UT WOS:000354420200014
PM 25862132
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Xie, RF
   Hu, P
   Wang, ZC
   Yang, J
   Yang, YM
   Gao, L
   Fan, HH
   Zhu, YM
AF Xie, Ru Feng
   Hu, Ping
   Wang, Zhi Cheng
   Yang, Jie
   Yang, Yi Ming
   Gao, Li
   Fan, Hua Hua
   Zhu, Yong Ming
TI Platelet-derived microparticles induce polymorphonuclear
   leukocyte-mediated damage of human pulmonary microvascular endothelial
   cells
SO TRANSFUSION
LA English
DT Article
ID ACUTE LUNG INJURY; BLOOD; STORAGE; CD154; CD40
AB BackgroundPlatelets (PLTs) stored at 22 degrees C accumulate microparticles and biologic response modifiers (BRMs) that induce inflammatory reactions in transfusion recipients. However, soluble BRMs are fully diluted in the recipient's blood circulation. The mechanisms by which BRMs exert their effects have not been elucidated. The objectives of this study were to determine the effect of PLT microparticles (PMPs) on polymorphonuclear leukocyte (PMN)-mediated human pulmonary microvascular endothelial cell (HMVEC) damage and determine the role of soluble CD40 ligand (sCD40L).
   Study Design and MethodsPMPs were isolated from apheresis PLT concentrates. We used a two-insult in vitro model of HMVEC damage to investigate the effects of PMP and sCD40L and role of apocynin, an inhibitor of PMN respiratory burst. Their priming activities were measured using hydrogen peroxide production. The expression of intercellular cell adhesion molecule-1 (ICAM-1) and integrin M (CD11b) were also determined.
   ResultsLipopolysaccharide (LPS)-activated HMVEC damage and PMN respiratory burst depend on the presence of PMP and the concentration of sCD40L. PMP-induced PMN-mediated HMVEC damage was significantly reduced by apocynin-treated PMNs (p<0.05). The surface expression of ICAM-1 on HMVEC was increased by LPS stimulation. The expression of CD11b on PMNs was increased by PMP priming. Blocking ICAM-1 with a monoclonal antibody (MoAb) CD54 significantly reduced HMVEC damage (p<0.05). The treatment of endothelial cells but not PMN with a MoAb targeting CD40 failed to prevent the HMVEC damage caused by PMPs (p>0.05).
   ConclusionPMPs carry a concentrated CD40L signal, promote PMN-mediated HMVEC damage, and may affect the development of transfusion-related acute lung injury.
C1 [Xie, Ru Feng; Yang, Jie; Yang, Yi Ming; Gao, Li; Fan, Hua Hua; Zhu, Yong Ming] Shanghai Blood Ctr, Shanghai 200051, China.
C1 [Hu, Ping] E China Normal Univ, Inst Life Sci, Shanghai 200062, China.
C1 [Wang, Zhi Cheng] Huashan Hosp, Shanghai, China.
C3 East China Normal University; Fudan University
RP Xie, RF (corresponding author), Shanghai Blood Ctr, Blood Engn Lab, Room 701,1191 Hong Qiao Rd, Shanghai 200051, Peoples R China.
EM rufeng33@hotmail.com; zhuyongming@sbc.org.cn
FU National Science Foundation of China [81270650]; Shanghai Municipal
   Health Bureau [20114294]
FX This study was supported by the research funds of National Science
   Foundation of China 81270650 and funds of Shanghai Municipal Health
   Bureau 20114294.
CR Cardo LJ, 2008, TRANSFUS APHER SCI, V38, P117, DOI 10.1016/j.transci.2008.01.004
   GEORGE JN, 1986, BLOOD, V68, P307
   Jin R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064631
   Jy W, 2011, TRANSFUSION, V51, P886, DOI 10.1111/j.1537-2995.2011.03099.x
   Kaufman J, 2007, J THROMB HAEMOST, V5, P788, DOI 10.1111/j.1538-7836.2007.02412.x
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Middelburg RA, 2012, TRANSFUSION, V52, P658, DOI 10.1111/j.1537-2995.2011.03352.x
   Rank A, 2011, VOX SANG, V100, P179, DOI 10.1111/j.1423-0410.2010.01385.x
   Silliman CC, 2003, BLOOD, V101, P454, DOI 10.1182/blood-2002-03-0958
   Sprague DL, 2008, BLOOD, V111, P5028, DOI 10.1182/blood-2007-06-097410
   Tanaka S, 2010, TRANSFUSION, V50, P1096, DOI 10.1111/j.1537-2995.2009.02547.x
   Tung JP, 2012, CRIT CARE, V16, DOI 10.1186/cc11178
   Urner M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033403
   Vanichakarn P, 2008, THROMB RES, V122, P346, DOI 10.1016/j.thromres.2007.12.019
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Vlaar APJ, 2010, BLOOD, V116, P1360, DOI 10.1182/blood-2009-10-248732
   Wozniak MJ, 2013, CIRCULATION, V128
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Xie RF, 2014, VOX SANG, V106, P234, DOI 10.1111/vox.12092
NR 19
TC 38
Z9 40
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD MAY
PY 2015
VL 55
IS 5
BP 1051
EP 1057
DI 10.1111/trf.12952
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA CH8JB
UT WOS:000354281500021
PM 25565376
DA 2023-08-21
ER

PT J
AU Zhang, D
   Li, CC
   Zhou, J
   Song, YL
   Fang, XC
   Ou, JX
   Li, J
   Bai, CX
AF Zhang, Dan
   Li, Chichi
   Zhou, Jian
   Song, Yuanlin
   Fang, Xiaocong
   Ou, Jiaxian
   Li, Jing
   Bai, Chunxue
TI Autophagy protects against ischemia/reperfusion-induced lung injury
   through alleviating blood-air barrier damage
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE ALI/ARDS; autophagy; ERK/ERK1/ERK2; ischemia/reperfusion; rapamycin 
ID HT-29 CELLS; MACROAUTOPHAGY; DEGRADATION; PATHWAYS; DISEASE; KINASE
AB BACKGROUND: Understanding the role and underlying regulation mechanism of autophagy in ischemia/reperfusion (I/R)-induced lung injury may provide potentially new pharmacologic targets for treatment of acute lung injury. The aim of this study was to adjust autophagy with pharmacologic agents to determine its functional significance in I/R-induced lung injury.
   METHODS: Human pulmonary microvascular endothelial cells (HPMVECs) and mice were preconditioned with autophagy inhibitor chloroquine or promoter rapamycin before they were challenged with oxygen-glucose deprivation/oxygen-glucose restoration (OGD) and lung I/R, respectively. Extracellular signal-regulated kinase (ERK)1/2 inhibitor U0126 was pre-injected into I/R-induced mice to test the role of ERK1/2 in regulating autophagy.
   RESULTS: OGD caused tight conjunction damage and cell death in HPMVECs, which Was further aggravated by blocking autophagy, yet ameliorated through promoting autophagy. On a consistent basis, inhibiting autophagy aggravated I/R-induced lung edema and tissue inflammation, which was significantly alleviated by promoting autophagy with rapamycin. In addition, inhibition of ERK1/2 increased expression of active mammalian target-of-rapamycin and thus decreased I/R-induced autophagy.
   CONCLUSIONS: It appears that autophagy plays a protective role in I/R-induced lung injury and this effect may be enhanced by moderately improving autophagy level. Meanwhile, the ERK1/2 signal pathway has a positively regulating role in lung I/R-induced autophagy. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Zhang, Dan; Zhou, Jian; Song, Yuanlin; Fang, Xiaocong; Ou, Jiaxian; Li, Jing; Bai, Chunxue] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai 200032, China.
C1 [Li, Chichi] Wenzhou Med Univ, Affiliated Hosp 1, Dept Plast Surg, Wenzhou City, Zhejiang, China.
C3 Fudan University; Wenzhou Medical University
RP Bai, CX (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pulm Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM cxbai@fudan.edu.cn
RI wang, jing/GVT-8700-2022
OI Bai, Chunxue/0000-0001-5798-3130
CR Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Cicora F, 2010, TRANSPL P, V42, P365, DOI 10.1016/j.transproceed.2009.11.013
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x
   Kim I, 2011, AM J PHYSIOL-CELL PH, V300, pC308, DOI 10.1152/ajpcell.00056.2010
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lee SJ, 2011, AM J RESP CRIT CARE, V183, P649, DOI 10.1164/rccm.201005-0746OC
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Ryter SW, 2009, AUTOPHAGY, V5, P235, DOI 10.4161/auto.5.2.7495
   Schmeisser H, 2013, AUTOPHAGY, V9, P683, DOI 10.4161/auto.23921
   Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com
   Sekiguchi A, 2012, J NEUROTRAUM, V29, P946
   Wang HJ, 2013, AM J PHYSIOL-CELL PH, V304, pC617, DOI 10.1152/ajpcell.00296.2012
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Zhang J, 2013, J SURG RES, V182, pE79, DOI 10.1016/j.jss.2012.11.014
NR 22
TC 32
Z9 37
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD MAY
PY 2015
VL 34
IS 5
BP 746
EP 755
DI 10.1016/j.healun.2014.12.008
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA CH7QD
UT WOS:000354230800016
PM 25934479
DA 2023-08-21
ER

PT J
AU Dagvadorj, J
   Shimada, K
   Chen, S
   Jones, HD
   Tumurkhuu, G
   Zhang, WX
   Wawrowsky, KA
   Crother, TR
   Arditi, M
AF Dagvadorj, Jargalsaikhan
   Shimada, Kenichi
   Chen, Shuang
   Jones, Heather D.
   Tumurkhuu, Gantsetseg
   Zhang, Wenxuan
   Wawrowsky, Kolja A.
   Crother, Timothy R.
   Arditi, Moshe
TI Lipopolysaccharide Induces Alveolar Macrophage Necrosis via CD14 and the
   P2X7 Receptor Leading to Interleukin-1 alpha Release
SO IMMUNITY
LA English
DT Article
ID ACUTE LUNG INJURY; INFLAMMATORY RESPONSE; BACTERIAL LIPOPOLYSACCHARIDE;
   ENDOTHELIAL-CELLS; MOUSE MODEL; IN-VIVO; STERILE INFLAMMATION; SIGNALING
   PATHWAY; P2X(7) RECEPTORS; ALPHA PRODUCTION
AB Acute lung injury (ALI) remains a serious health issue with little improvement in our understanding of the pathophysiology and therapeutic approaches. We investigated the mechanism that lipopolysaccharide (LPS) induces early neutrophil recruitment to lungs and increases pulmonary vascular permeability during ALI. Intratracheal LPS induced release of pro-interleukin-1 alpha (IL-1 alpha) from necrotic alveolar macrophages (AM), which activated endothelial cells (EC) to induce vascular leakage via loss of vascular endothelial (VE)-cadherin. LPS triggered the AM purinergic receptor P2X7(R) to induce Ca2+ influx and ATP depletion, which led to necrosis. P2X7R deficiency significantly reduced necrotic death of AM and release of pro-IL-1 alpha into the lung. CD14 was required for LPS binding to P2X7R, as CD14 neutralization significantly diminished LPS induced necrotic death of AM and pro-IL-1 alpha release. These results demonstrate a key role for pro-IL-1 alpha from necrotic alveolar macrophages in LPS-mediated ALI, as a critical initiator of increased vascular permeability and early neutrophil infiltration.
C1 [Dagvadorj, Jargalsaikhan; Shimada, Kenichi; Chen, Shuang; Tumurkhuu, Gantsetseg; Zhang, Wenxuan; Crother, Timothy R.; Arditi, Moshe] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048, United States.
C1 [Dagvadorj, Jargalsaikhan; Shimada, Kenichi; Chen, Shuang; Tumurkhuu, Gantsetseg; Zhang, Wenxuan; Crother, Timothy R.; Arditi, Moshe] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048, United States.
C1 [Dagvadorj, Jargalsaikhan; Shimada, Kenichi; Chen, Shuang; Tumurkhuu, Gantsetseg; Zhang, Wenxuan; Crother, Timothy R.; Arditi, Moshe] Cedars Sinai Med Ctr, Dept Pediat, Div Infect Dis, Los Angeles, CA 90048, United States.
C1 [Dagvadorj, Jargalsaikhan; Shimada, Kenichi; Chen, Shuang; Tumurkhuu, Gantsetseg; Zhang, Wenxuan; Crother, Timothy R.; Arditi, Moshe] Cedars Sinai Med Ctr, Div Immunol, Los Angeles, CA 90048, United States.
C1 [Shimada, Kenichi; Chen, Shuang; Jones, Heather D.; Crother, Timothy R.; Arditi, Moshe] Cedars Sinai Med Ctr, Infect & Immunol Dis Res Ctr, Los Angeles, CA 90048, United States.
C1 [Jones, Heather D.] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048, United States.
C1 [Wawrowsky, Kolja A.] Cedars Sinai Med Ctr, Confocal Core, Los Angeles, CA 90048, United States.
C1 [Arditi, Moshe] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90048, United States.
C3 Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai
   Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical
   Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Arditi, M (corresponding author), Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.
EM moshe.arditi@cshs.org
RI Crother, Timothy R/E-2879-2010
OI Crother, Timothy R/0000-0001-8465-6127
FU National Institutes of Health (NIH) [RO1AI-067995, 2R56AI067995-06];
   American Heart Association [13BGIA17220050]
FX This work was supported by National Institutes of Health (NIH) grants
   RO1AI-067995 and 2R56AI067995-06 to M.A. K.S. is supported by the
   American Heart Association 13BGIA17220050. The authors would like to
   thank Ganghua Huang and Polly Sun for technical support and Bill Parks
   for his help in the editing of this manuscript.
CR Aggarwal S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00161
   Andonegui G, 2009, J CLIN INVEST, V119, P1921, DOI 10.1172/JCI36411
   Barry KC, 2013, J IMMUNOL, V190, P6329, DOI 10.4049/jimmunol.1300100
   Baumann CL, 2010, J EXP MED, V207, P2689, DOI 10.1084/jem.20101111
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004
   Brunn GJ, 2008, CIRC RES, V102, P823, DOI 10.1161/CIRCRESAHA.107.165332
   Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Costa HM, 2011, PURINERG SIGNAL, V7, P7, DOI 10.1007/s11302-011-9215-1
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Eigenbrod T, 2008, J IMMUNOL, V181, P8194, DOI 10.4049/jimmunol.181.12.8194
   Garcia-Marcos M, 2006, J LIPID RES, V47, P705, DOI 10.1194/jlr.M500408-JLR200
   Gross O, 2012, IMMUNITY, V36, P388, DOI 10.1016/j.immuni.2012.01.018
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Han JL, 2013, THROMB RES, V132, pE42, DOI 10.1016/j.thromres.2013.03.010
   HARMSEN AG, 1988, INFECT IMMUN, V56, P1858, DOI 10.1128/IAI.56.8.1858-1863.1988
   Herold S, 2011, AM J RESP CRIT CARE, V183, P1380, DOI 10.1164/rccm.201009-1431OC
   Hou B, 2008, IMMUNITY, V29, P272, DOI 10.1016/j.immuni.2008.05.016
   Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207
   Jun DJ, 2007, J BIOL CHEM, V282, P37350, DOI 10.1074/jbc.M707915200
   Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106
   Kitchens RL, 1998, J IMMUNOL, V161, P5534
   Kitchens RL, 1998, J IMMUNOL, V160, P1920
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Leiva-Salcedo E, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/152625
   Lemaire I, 2003, DRUG DEVELOP RES, V59, P118, DOI 10.1002/ddr.10209
   London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678
   Lucattelli M, 2011, AM J RESP CELL MOL, V44, P423, DOI 10.1165/rcmb.2010-0038OC
   Makinde TO, 2011, AM J RESP CELL MOL, V44, P384, DOI 10.1165/rcmb.2009-0330OC
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Matzner N, 2008, J IMMUNOL, V181, P6803, DOI 10.4049/jimmunol.181.10.6803
   Mishra A, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-26
   Moncao-Ribeiro LC, 2011, RESP PHYSIOL NEUROBI, V179, P314, DOI 10.1016/j.resp.2011.09.015
   MOSLEY B, 1987, J BIOL CHEM, V262, P2941
   Myrtek D, 2008, J IMMUNOL, V181, P2181, DOI 10.4049/jimmunol.181.3.2181
   Naiki Y, 2005, J BIOL CHEM, V280, P29242, DOI 10.1074/jbc.M503225200
   Noulin N, 2005, J IMMUNOL, V175, P6861, DOI 10.4049/jimmunol.175.10.6861
   Olsson S, 2006, MOL IMMUNOL, V43, P607, DOI 10.1016/j.molimm.2005.04.011
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7
   Rider P, 2011, J IMMUNOL, V187, P4835, DOI 10.4049/jimmunol.1102048
   ROYALL JA, 1989, AM J PHYSIOL, V257, pL399, DOI 10.1152/ajplung.1989.257.6.L399
   SALGADO A, 1994, HAEMOSTASIS, V24, P132
   Schlegel N, 2009, CRIT CARE MED, V37, P1735, DOI 10.1097/CCM.0b013e31819deb6a
   Seabra V, 1998, J LEUKOCYTE BIOL, V64, P615, DOI 10.1002/jlb.64.5.615
   Tachado SD, 2010, BLOOD, V115, P3606, DOI 10.1182/blood-2009-10-250787
   Tanabe M, 2005, J MED MICROBIOL, V54, P7, DOI 10.1099/jmm.0.45736-0
   Triantafilou M, 2002, J CELL SCI, V115, P2603
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   ULICH TR, 1991, AM J PATHOL, V138, P521
   ULICH TR, 1991, AM J PATHOL, V138, P1097
   Volonte C, 2012, CNS NEUROL DISORD-DR, V11, P705, DOI 10.2174/187152712803581137
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311
   Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200
   Xing JJ, 2012, MICROVASC RES, V83, P194, DOI 10.1016/j.mvr.2011.09.012
   Zanoni I, 2010, IMMUNOBIOLOGY, V215, P709, DOI 10.1016/j.imbio.2010.05.026
   Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118
   Zhao YT, 2011, AM J RESP CELL MOL, V45, P426, DOI 10.1165/rcmb.2010-0422OC
   Zhou XY, 2006, J BIOL CHEM, V281, P31337, DOI 10.1074/jbc.M602739200
   Zhu WQ, 2012, NATURE, V492, P252, DOI 10.1038/nature11603
   Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506
NR 69
TC 88
Z9 92
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD APR 21
PY 2015
VL 42
IS 4
BP 640
EP 653
DI 10.1016/j.immuni.2015.03.007
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CG5QF
UT WOS:000353347500011
PM 25862090
OA Green Published, Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Hahn, CS
   Scott, DW
   Xu, X
   Roda, MA
   Payne, GA
   Wells, JM
   Viera, L
   Winstead, CJ
   Bratcher, P
   Sparidans, RW
   Redegeld, FA
   Jackson, PL
   Folkerts, G
   Blalock, JE
   Patel, RP
   Gaggar, A
AF Hahn, Cornelia S.
   Scott, David W.
   Xu, Xin
   Roda, Mojtaba Abdul
   Payne, Gregory A.
   Wells, J. Michael
   Viera, Liliana
   Winstead, Colleen J.
   Bratcher, Preston
   Sparidans, Rolf W.
   Redegeld, Frank A.
   Jackson, Patricia L.
   Folkerts, Gert
   Blalock, J. Edwin
   Patel, Rakesh P.
   Gaggar, Amit
TI The matrikine N-alpha-PGP couples extracellular matrix fragmentation to
   endothelial permeability
SO SCIENCE ADVANCES
LA English
DT Article
AB The compartmentalization and transport of proteins and solutes across the endothelium is a critical biologic function altered during inflammation and disease, leading to pathology inmultiple disorders. The impact of tissue damage and subsequent extracellularmatrix (ECM) fragmentation in regulating this process is unknown. We demonstrate that the collagen-derived matrikine acetylated proline-glycine-proline (N-alpha-PGP) serves as a critical regulator of endothelial permeability. N-alpha-PGP activates human endothelial cells via CXC-chemokine receptor 2 (CXCR2), triggeringmonolayer permeability through a discrete intracellular signaling pathway. In vivo, N-alpha-PGP induces local vascular leak after subcutaneous administration and pulmonary vascular permeability after systemic administration. Furthermore, neutralization of N-alpha-PGP attenuates lipopolysaccharide-induced lung leak. Finally, we demonstrate that plasma from patients with acute respiratory distress syndrome (ARDS) induces VE-cadherin phosphorylation in human endothelial cells, and this activation is attenuated by N-alpha-PGP blockade with a concomitant improvement in endothelial monolayer impedance. These results identify N-alpha-PGP as a novel ECM-derivedmatrikine regulating paracellular permeability during inflammatory disease and demonstrate the potential to target this ligand in various disorders characterized by excessive matrix turnover and vascular leak such as ARDS.
C1 [Hahn, Cornelia S.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC 27599, United States.
C1 [Hahn, Cornelia S.; Xu, Xin; Roda, Mojtaba Abdul; Payne, Gregory A.; Wells, J. Michael; Viera, Liliana; Bratcher, Preston; Jackson, Patricia L.; Blalock, J. Edwin; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294, United States.
C1 [Scott, David W.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599, United States.
C1 [Scott, David W.] Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599, United States.
C1 [Scott, David W.; Winstead, Colleen J.; Patel, Rakesh P.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294, United States.
C1 [Xu, Xin; Wells, J. Michael; Viera, Liliana; Bratcher, Preston; Jackson, Patricia L.; Blalock, J. Edwin; Patel, Rakesh P.; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL 35294, United States.
C1 [Roda, Mojtaba Abdul; Sparidans, Rolf W.; Redegeld, Frank A.; Folkerts, Gert] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands.
C1 [Wells, J. Michael; Blalock, J. Edwin; Gaggar, Amit] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL 35294, United States.
C1 [Wells, J. Michael; Gaggar, Amit] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233, United States.
C1 [Blalock, J. Edwin; Gaggar, Amit] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294, United States.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of Alabama
   System; University of Alabama Birmingham; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina;
   University of North Carolina Chapel Hill; University of Alabama System;
   University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; Utrecht University; University of
   Alabama System; University of Alabama Birmingham; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs
   Medical Center - Birmingham; University of Alabama System; University of
   Alabama Birmingham
RP Gaggar, A (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
EM agaggar1@uab.edu
RI Wells, James Michael/ABA-2755-2021; Redegeld, Frank A/O-6534-2016
OI Redegeld, Frank A/0000-0001-8830-7960; Patel,
   Rakesh/0000-0002-1526-4303; Payne, Gregory/0000-0002-8525-8603
FU American Heart Association predoctoral fellowship; Howard Hughes Medical
   Institute Med-to-Grad fellowship; NIH [3T32CA009156]; Netherlands
   Organization for Scientific Research [017.008.029]; National Heart,
   Lung, and Blood Institute [HL07783, HL090999, HL087824, HL92624,
   HL102371]; Veterans Administration [1 I01 BX001756]; Ismail Moustapha
   Scholar Fund; NIH; Family Smoking Prevention and Tobacco Control Act
FX This work was supported by an American Heart Association predoctoral
   fellowship (D.W.S.), a Howard Hughes Medical Institute Med-to-Grad
   fellowship (D.W.S.), and NIH training grant 3T32CA009156 (D.W.S.).
   M.A.R. was supported by a Mosaic grant from the Netherlands Organization
   for Scientific Research (017.008.029). Additional funding from the
   National Heart, Lung, and Blood Institute (HL07783, HL090999, and
   HL087824 to J.E.B.; HL92624 to R.P.P.; and HL102371 to A. G.), the
   Veterans Administration (1 I01 BX001756 to A.G.), and the Ismail
   Moustapha Scholar Fund (to A.G.). Research reported in this publication
   was supported by the NIH and the Family Smoking Prevention and Tobacco
   Control Act. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the NIH or the Food
   and Drug Administration.
CR Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269
   Braber S, 2011, EUR J PHARMACOL, V668, P443, DOI 10.1016/j.ejphar.2011.03.025
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Dwyer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045562
   Gaggar A, 2008, J IMMUNOL, V180, P5662, DOI 10.4049/jimmunol.180.8.5662
   Gaggar A, 2006, CLIN CHIM ACTA, V372, P24, DOI 10.1016/j.cca.2006.04.019
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   Gavard J, 2009, MOL CELL BIOL, V29, P2469, DOI 10.1128/MCB.01304-08
   Hardison MT, 2009, J IMMUNOL, V182, P4423, DOI 10.4049/jimmunol.0802457
   Hardison Matthew Thomas, 2012, Front Biosci (Elite Ed), V4, P2402
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Jozwiak M, 2013, CRIT CARE MED, V41, P472, DOI 10.1097/CCM.0b013e31826ab377
   Kantrow SP, 2009, AM J PHYSIOL-LUNG C, V297, pL738, DOI 10.1152/ajplung.00045.2009
   Kim KH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/863892
   Koelink PJ, 2014, GUT, V63, P578, DOI 10.1136/gutjnl-2012-303252
   Kong MYF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022596
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Lin M, 2008, AM J PATHOL, V173, P144, DOI 10.2353/ajpath.2008.080081
   Monaghan-Benson E, 2013, METHODS MOL BIOL, V1046, P335, DOI 10.1007/978-1-62703-538-5_20
   O'Reilly P, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-38
   O'Reilly PJ, 2009, J NEUROIMMUNOL, V217, P51, DOI 10.1016/j.jneuroim.2009.09.020
   Overbeek SA, 2011, EUR J PHARMACOL, V668, P428, DOI 10.1016/j.ejphar.2011.03.022
   Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC
   Petreaca ML, 2007, MOL BIOL CELL, V18, P5014, DOI 10.1091/mbc.E07-01-0004
   PFISTER RR, 1995, INVEST OPHTH VIS SCI, V36, P1306
   POSTLETHWAITE AE, 1976, J EXP MED, V143, P1299, DOI 10.1084/jem.143.6.1299
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reddy AT, 2012, J IMMUNOL, V189, P5411, DOI 10.4049/jimmunol.1201487
   Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009
   Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094
   Scott DW, 2013, GLYCOBIOLOGY, V23, P622, DOI 10.1093/glycob/cwt014
   Scott DW, 2012, ARTERIOSCL THROM VAS, V32, pE51, DOI 10.1161/ATVBAHA.112.253203
   Singh S, 2011, MICROVASC RES, V82, P318, DOI 10.1016/j.mvr.2011.06.011
   Snelgrove RJ, 2010, SCIENCE, V330, P90, DOI 10.1126/science.1190594
   Stockton R, 2007, MOL BIOL CELL, V18, P2346, DOI 10.1091/mbc.E06-07-0584
   van Houwelingen AH, 2008, FASEB J, V22, P3403, DOI 10.1096/fj.07-096230
   Weathington NM, 2006, NAT MED, V12, P317, DOI 10.1038/nm1361
   Wells JM, 2014, AM J RESP CRIT CARE, V190, P51, DOI 10.1164/rccm.201401-0145OC
   White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095
   Xu X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015781
NR 40
TC 34
Z9 38
U1 0
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD APR
PY 2015
VL 1
IS 3
AR e1500175
DI 10.1126/sciadv.1500175
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V0V3L
UT WOS:000216592400017
PM 26229981
OA Green Published, Green Accepted, gold
DA 2023-08-21
ER

PT J
AU Kimura, T
   Nojiri, T
   Hosoda, H
   Ishikane, S
   Shintani, Y
   Inoue, M
   Miyazato, M
   Okumura, M
   Kangawa, K
AF Kimura, Toru
   Nojiri, Takashi
   Hosoda, Hiroshi
   Ishikane, Shin
   Shintani, Yasushi
   Inoue, Masayoshi
   Miyazato, Mikiya
   Okumura, Meinoshin
   Kangawa, Kenji
TI C-type natriuretic peptide attenuates lipopolysaccharide-induced acute
   lung injury in mice
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE C-type natriuretic peptide; ALI/ARDS; pulmonary inflammation; Anti-inflammation 
ID ENDOTHELIAL-CELLS; KAPPA-B; INFLAMMATION; CNP; MECHANISMS; DELIVERY;
   RATS
AB Background: C-type natriuretic peptide (CNP), secreted by vascular endothelial cells, belongs to a family of peptides that includes atrial and brain natriuretic peptides. CNP exhibits many vasoprotective effects against pulmonary hypertension and pulmonary fibrosis. The objective of this study was to investigate the prophylactic effects of CNP in a mouse model of lipopolysaccharide (LPS)-induced acute lung injury (ALI).
   Materials and methods: C57BL/6 mice were divided into three groups as follows: normal control mice (n = 13), LPS mice treated with vehicle (n = 12), and LPS mice treated with CNP (n = 12). Twenty-four hours after tail vein injection of LPS, histopathologic, gene expression, and bronchoalveolar lavage fluid (BALF) assessments were performed on the lungs. To examine the neutrophils in the lungs, cells positive for myeloperoxidase staining were detected by immunohistochemistry. BALF cytokine levels were analyzed by enzyme-linked immunosorbent assays. Gene expression in lung tissue was analyzed by real-time polymerase chain reaction.
   Results: CNP significantly attenuated the elevation of leukocyte cell counts and levels of tumor necrosis factor-alpha, macrophage inflammatory protein-2, monocyte chemoattractant protein1, interleukin-6, and keratinocyte-derived chemokine in the BALF after LPS injection. Furthermore, there were significantly fewer myeloperoxidase-positive cells in lungs treated with CNP after LPS injection. In lungs of CNP-treated mice, expression of the monocyte chemoattractant protein-1, S100A8, and E-selectin geneswas significantly lower than that in vehicle-treated mice.
   Conclusions: CNP had a protective effect on ALI induced by LPS by reducing inflammatory cell infiltration. CNP may hold promise in therapeutic strategies for ALI after pulmonary resection surgery. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Kimura, Toru; Nojiri, Takashi; Ishikane, Shin; Miyazato, Mikiya; Kangawa, Kenji] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan.
C1 [Kimura, Toru; Nojiri, Takashi; Shintani, Yasushi; Inoue, Masayoshi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka, Japan.
C1 [Hosoda, Hiroshi] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Regenerat Med & Tissue Engn, Suita, Osaka 5658565, Japan.
C3 National Cerebral & Cardiovascular Center - Japan; Osaka University;
   National Cerebral & Cardiovascular Center - Japan
RP Nojiri, T (corresponding author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biochem, 5-7-1 Fujishir Odai, Suita, Osaka 5658565, Japan.
EM kimura@thoracic.med.osaka-u.ac.jp
OI Kimura, Toru/0000-0003-4504-232X
FU [90580796]; Grants-in-Aid for Scientific Research [26861135, 22126002,
   26293316] Funding Source: KAKEN
FX This work was supported in part by a grant-in-aid for Scientific
   Research (90580796).
CR Ahluwalia A, 2004, BASIC RES CARDIOL, V99, P83, DOI 10.1007/s00395-004-0459-6
   Alam N, 2007, ANN THORAC SURG, V84, P1085, DOI 10.1016/j.athoracsur.2007.05.053
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Del Ry S, 2013, PEPTIDES, V40, P93, DOI 10.1016/j.peptides.2012.12.010
   Feng XS, 2014, INFLAMMATION, V37, P1091, DOI 10.1007/s10753-014-9833-1
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Itoh T, 2004, AM J RESP CRIT CARE, V170, P1204, DOI 10.1164/rccm.200404-455OC
   Jubeli E, 2012, J CONTROL RELEASE, V158, P194, DOI 10.1016/j.jconrel.2011.09.084
   Kiemer AK, 2002, ENDOCRINOLOGY, V143, P846, DOI 10.1210/en.143.3.846
   Langenickel TH, 2006, P NATL ACAD SCI USA, V103, P4735, DOI 10.1073/pnas.0510019103
   Liu F, 2013, J SURG RES, V185, P300, DOI 10.1016/j.jss.2013.05.083
   Murakami S, 2004, AM J PHYSIOL-LUNG C, V287, pL1172, DOI 10.1152/ajplung.00087.2004
   Nojiri T, 2014, PULM PHARMACOL THER, V29, P24, DOI 10.1016/j.pupt.2014.01.003
   Obata H, 2007, BIOCHEM BIOPH RES CO, V356, P60, DOI 10.1016/j.bbrc.2007.02.085
   Ogino K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092710
   Rautureau Y., 2010, Autonomic & Autacoid Pharmacology, V30, P185, DOI 10.1111/j.1474-8673.2009.00449.x
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schachner T, 2004, EUR J CARDIO-THORAC, V25, P585, DOI 10.1016/j.ejcts.2003.07.013
   Shenkar R, 1999, J IMMUNOL, V163, P954
   Socki T, 2005, J AM COLL CARDIOL, V45, P608, DOI 10.1016/j.jacc.2004.10.067
   SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K
   SUGA S, 1993, ENDOCRINOLOGY, V133, P3038, DOI 10.1210/en.133.6.3038
   SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933
   THEEUWES F, 1976, ANN BIOMED ENG, V4, P343, DOI 10.1007/BF02584524
   Vandal K, 2003, J IMMUNOL, V171, P2602, DOI 10.4049/jimmunol.171.5.2602
NR 25
TC 21
Z9 24
U1 1
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD APR
PY 2015
VL 194
IS 2
BP 631
EP 637
DI 10.1016/j.jss.2014.11.023
PG 7
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA CD4OC
UT WOS:000351061900041
PM 25483737
DA 2023-08-21
ER

PT J
AU Li, YC
   Zeng, Z
   Li, YC
   Huang, WF
   Zhou, M
   Zhang, XL
   Jiang, W
AF Li, Yingchuan
   Zeng, Zhen
   Li, Yachun
   Huang, Weifeng
   Zhou, Ming
   Zhang, Xiaoli
   Jiang, Wei
TI ANGIOTENSIN-CONVERTING ENZYME INHIBITION ATTENUATES
   LIPOPOLYSACCHARIDE-INDUCED LUNG INJURY BY REGULATING THE BALANCE BETWEEN
   ANGIOTENSIN-CONVERTING ENZYME AND ANGIOTENSIN-CONVERTING ENZYME 2 AND
   INHIBITING MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION
SO SHOCK
LA English
DT Article
DE ALI/ARDS; LPS; ACE/ACE2; captopril; MAPK 
ID RESPIRATORY-DISTRESS-SYNDROME; IN-VIVO; KAPPA-B; EXPRESSION;
   POLYMORPHISM; SYSTEM; GENE
AB Activation of the renin-angiotensin system (angiotensin-converting enzyme [ACE]/angiotensin II [Ang II] and angiotensin-converting enzyme 2 [ACE2]/Ang-1-7) has been implicated in the pathophysiology of inflammatory response and acute lung injury (ALI). Previous studies have shown that the ACE inhibitor captopril (Cap) may be a potent therapeutic drug for ALI. However, the mechanisms of its protective effects on ALI are still largely unknown. In this study, we evaluated the effects of Cap on preventing lipopolysaccharide (LPS)-induced lung injury and further investigated the underlying mechanisms of these protective effects. Rats were intraperitoneally pretreated with Cap (50 mg/kg) 30 min prior to an intravenous administration of LPS (7.5 mg/kg). Furthermore, following a 30-min pretreatment with Cap (10(-5) mol/mL) or combined with the ACE2 inhibitor MLN4760 (10(-7) mol/mL), rat pulmonary microvascular endothelial cells (PMVECs) were stimulated with LPS (1 mg/mL). Captopril pretreatment significantly attenuated LPS-induced pathophysiological changes in the lung, inhibited secretion of tumor necrosis factor alpha and interleukin 6, reduced the ratio of Ang II to Ang-1-7, and reversed the increased ratio of ACE to ACE2, which was remarkably decreased from 7.07 (LPS only) to 1.71 (LPS + Cap). The protective effects of Cap on ALI were also confirmed by in vitro studies, in which Cap suppressed LPS-induced secretion of proinflammatory cytokines and modulated the expression levels of ACE and ACE2. After Cap pretreatment, the ratio of ACE to ACE2 expression was remarkably decreased from 5.18 (LPS alone) to 1.52 (LPS + Cap). Furthermore, Cap given before LPS administration led to inhibition of p38 mitogen-activated protein kinase (MAPK), ERK (extracellular signal-regulated kinase) 1/2, and JNK (c-Jun N-terminal kinase) phosphorylation in PMVECs, whereas MLN4760 abolished the protective effects of Cap on LPS-induced secretion of proinflammatory cytokines and abolished Cap-induced blockade of p38MAPK, ERK1/2, and JNK phosphorylation. Our findings reveal that Cap exerts protective effects on LPS-induced lung injury and the cytotoxicity of PMVECs, and these effects may, at least in part, regulate the balance of ACE and ACE2 expression and inhibit the activation of MAPKs.
C1 [Li, Yingchuan; Zeng, Zhen; Li, Yachun; Huang, Weifeng; Zhou, Ming; Zhang, Xiaoli; Jiang, Wei] Shanghai Jiao Tong Univ, Dept Anesthesiol, Peoples Hosp 6, Shanghai 200233, China.
C3 Shanghai Jiao Tong University
RP Jiang, W (corresponding author), Shanghai Jiao Tong Univ, Dept Anesthesiol, Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM jiangw@sjtu.edu.cn
RI Zhou, Ming/HSD-2621-2023
FU National Natural Science Foundation of China [81272145]
FX This work was supported by the National Natural Science Foundation of
   China (no. 81272145).
CR Asaduzzaman M, 2008, CRIT CARE MED, V36, P482, DOI 10.1097/01.CCM.0B013E31816204FA
   Asperen RMWV, 2008, EUR RESPIR J, V31, P363, DOI 10.1183/09031936.00060207
   Banerjee A, 2013, SHOCK, V39, P366, DOI 10.1097/SHK.0b013e3182894016
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chen LN, 2013, SHOCK, V40, P420, DOI 10.1097/SHK.0b013e3182a6953e
   Cheng C, 2007, MOL CELL BIOCHEM, V305, P1, DOI 10.1007/s11010-007-9521-7
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Faffe DS, 2000, EUR RESPIR J, V15, P85, DOI 10.1034/j.1399-3003.2000.15a16.x
   Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D
   Hagiwara S, 2009, CRIT CARE MED, V37, P626, DOI 10.1097/CCM.0b013e3181958d91
   Herridge MS, 2005, NEW ENGL J MED, V353, P1736, DOI 10.1056/NEJMe058205
   IDELL S, 1987, CHEST, V91, P52, DOI 10.1378/chest.91.1.52
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jerng JS, 2007, THORAX, V62, P527, DOI 10.1136/thx.2006.061945
   Jerng JS, 2006, CRIT CARE MED, V34, P1001, DOI 10.1097/01.CCM.0000206107.92476.39
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kohlstedt K, 2005, HYPERTENSION, V45, P126, DOI 10.1161/01.HYP.0000150159.48992.11
   Kohlstedt K, 2004, CIRC RES, V94, P60, DOI 10.1161/01.RES.0000107195.13573.E4
   Lin CY, 2010, SHOCK, V34, P352, DOI 10.1097/SHK.0b013e3181d8e61d
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004
   Meng Y, 2014, AM J RESP CELL MOL, V50, P723, DOI 10.1165/rcmb.2012-0451OC
   Mikkelsen ME, 2013, SHOCK, V40, P375, DOI 10.1097/SHK.0b013e3182a64682
   Murakami K, 2002, SHOCK, V18, P236, DOI 10.1097/00024382-200209000-00006
   Phillips M Ian, 2002, Curr Opin Investig Drugs, V3, P569
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004
   Rey-Parra GJ, 2012, J MOL MED, V90, P637, DOI 10.1007/s00109-012-0859-2
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Satar M, 2012, J MATERN-FETAL NEO M, V25, P1712, DOI 10.3109/14767058.2012.663017
   Shen LH, 2009, SHOCK, V31, P500, DOI 10.1097/SHK.0b013e318189017a
   Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Treml B, 2010, CRIT CARE MED, V38, P596, DOI 10.1097/CCM.0b013e3181c03009
   Uhal BD, 2011, AM J PHYSIOL-LUNG C, V301, pL269, DOI 10.1152/ajplung.00222.2010
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wosten-van Asperen RM, 2010, AM J PATHOL, V176, P2219, DOI 10.2353/ajpath.2010.090565
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
NR 41
TC 62
Z9 74
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD APR
PY 2015
VL 43
IS 4
BP 395
EP 404
DI 10.1097/SHK.0000000000000302
PG 10
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA CF0GW
UT WOS:000352222200013
PM 25768373
OA Bronze
DA 2023-08-21
ER

PT J
AU Mokra, D
   Kosutova, P
AF Mokra, Daniela
   Kosutova, Petra
TI Biomarkers in acute lung injury
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE ALI/ARDS; biomarkers; Inflammation; lung edema 
ID RESPIRATORY-DISTRESS-SYNDROME; KERATINOCYTE GROWTH-FACTOR;
   BRONCHOALVEOLAR LAVAGE FLUID; III PROCOLLAGEN PEPTIDE; GLYCATION
   END-PRODUCTS; PULMONARY-EDEMA FLUID; SURFACTANT PROTEIN-A;
   PLASMA-LEVELS; CLINICAL-OUTCOMES; SOLUBLE RECEPTOR
AB Acute respiratory distress syndrome (ARDS) and its milder form acute lung injury (ALI) may result from various diseases and situations including sepsis, pneumonia, trauma, acute pancreatitis, aspiration of gastric contents, near-drowning etc. ALI/ARDS is characterized by diffuse alveolar injury, lung edema formation, neutrophil-derived inflammation, and surfactant dysfunction. Clinically, ALI/ARDS is manifested by decreased lung compliance, severe hypoxemia, and bilateral pulmonary infiltrates. Severity and further characteristics of ALI/ARDS may be detected by biomarkers in the plasma and bronchoalveolar lavage fluid (or tracheal aspirate) of patients. Changed concentrations of individual markers may suggest injury or activation of the specific types of lung cells-epithelial or endothelial cells, neutrophils, macrophages, etc.), and thereby help in diagnostics and in evaluation of the patient's clinical status and the treatment efficacy. This chapter reviews various biomarkers of acute lung injury and evaluates their usefulness in diagnostics and prognostication of ALI/ARDS. (C) 2014 Published by Elsevier B.V.
C1 [Mokra, Daniela; Kosutova, Petra] Comenius Univ, Jessenius Fac Med Martin, Dept Physiol, SK-03601 Martin, Slovakia.
C3 Comenius University Bratislava
RP Mokra, D (corresponding author), Comenius Univ, Jessenius Fac Med Martin, Dept Physiol, Mala Hora 4, SK-03601 Martin, Slovakia.
EM mokra@jfmed.uniba.sk; petra.kosutova@gmail.com
RI Košútová, Petra/X-6534-2018
OI Košútová, Petra/0000-0002-1596-3702
FU VEGA [1/0305/14, UK/201/2014]; BioMed (ITMS) [26220220187]; 
   [APVV-0435-11]
FX Supported by Projects APVV-0435-11, VEGA 1/0305/14, UK/201/2014, BioMed
   (ITMS 26220220187).
CR Agrawal A, 2012, AM J PHYSIOL-LUNG C, V303, pL634, DOI 10.1152/ajplung.00195.2012
   Aman J, 2011, CRIT CARE MED, V39, P89, DOI 10.1097/CCM.0b013e3181feb46a
   Armstrong L, 1997, THORAX, V52, P442, DOI 10.1136/thx.52.5.442
   Bajwa EK, 2009, CHEST, V136, P471, DOI 10.1378/chest.08-2413
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304
   Bhargava M, 2012, TRANSL RES, V159, P205, DOI 10.1016/j.trsl.2012.01.007
   Bhargava R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061405
   Bouros Demosthenes, 2004, BMC Pulm Med, V4, P6, DOI 10.1186/1471-2466-4-6
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   Calfee C, 2009, INTENS CARE MED, V35, P248, DOI 10.1007/s00134-008-1235-0
   Chandel NS, 2009, CRIT CARE MED, V37, P1678, DOI 10.1097/CCM.0b013e31819fc81a
   Cheng IW, 2003, CRIT CARE MED, V31, P20, DOI 10.1097/00003246-200301000-00003
   Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124
   Chiang KH, 2009, CORONARY ARTERY DIS, V20, P267, DOI 10.1097/MCA.0b013e32832c459c
   CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003
   Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152
   Cross LJM, 2011, CRIT CARE CLIN, V27, P355, DOI 10.1016/j.ccc.2010.12.005
   Determann RM, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-6
   Determann Rogier M, 2009, BMC Pulm Med, V9, P49, DOI 10.1186/1471-2466-9-49
   DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E
   Donnelly SC, 1996, ANN INTERN MED, V125, P191, DOI 10.7326/0003-4819-125-3-199608010-00005
   Dushianthan A, 2011, POSTGRAD MED J, V87, P612, DOI 10.1136/pgmj.2011.118398
   Eisner MD, 2003, THORAX, V58, P983, DOI 10.1136/thorax.58.11.983
   Fioretto JR, 2012, RESP CARE, V57, P273, DOI 10.4187/respcare.01289
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Ishizaka A, 2004, AM J PHYSIOL-LUNG C, V286, pL1088, DOI 10.1152/ajplung.00420.2002
   Jabaudon M, 2011, CRIT CARE MED, V39, P480, DOI 10.1097/CCM.0b013e318206b3ca
   Katayama M, 2010, INTENS CARE MED, V36, P479, DOI 10.1007/s00134-009-1719-6
   Lang JD, 2002, CHEST, V122, p314S, DOI 10.1378/chest.122.6_suppl.314S
   Lesur O, 2006, INTENS CARE MED, V32, P1167, DOI 10.1007/s00134-006-0235-1
   Marshall RP, 2000, AM J RESP CRIT CARE, V162, P1783, DOI 10.1164/ajrccm.162.5.2001061
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mauri T, 2010, TOHOKU J EXP MED, V222, P105, DOI 10.1620/tjem.222.105
   McClintock D, 2008, CRIT CARE, V12, DOI 10.1186/cc6846
   McClintock DE, 2006, AM J PHYSIOL-LUNG C, V291, pL566, DOI 10.1152/ajplung.00457.2005
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Miyazaki E, 2007, CHEST, V131, P1726, DOI 10.1378/chest.06-2596
   Mokra D, 2007, J PHYSIOL PHARMACOL, V58, P389
   Mortelliti MP, 2002, AM FAM PHYSICIAN, V65, P1823
   Okajima K, 2006, TRANSL RES, V148, P295, DOI 10.1016/j.trsl.2006.07.009
   Ong T, 2010, CRIT CARE MED, V38, P1845, DOI 10.1097/CCM.0b013e3181eaa5bf
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Parsons PE, 2005, AM J PHYSIOL-LUNG C, V288, pL426, DOI 10.1152/ajplung.00302.2004
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Raposeiras-Roubin S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074302
   Raymondos K, 2012, INJURY, V43, P189, DOI 10.1016/j.injury.2011.05.034
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Seeley EJ, 2013, ADV CHRONIC KIDNEY D, V20, P14, DOI 10.1053/j.ackd.2012.10.001
   Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187
   Stern JB, 2000, CRIT CARE MED, V28, P2326, DOI 10.1097/00003246-200007000-00024
   SZNAJDER JI, 1989, CHEST, V96, P606, DOI 10.1378/chest.96.3.606
   Tasaka S, 2008, ANTIOXID REDOX SIGN, V10, P739, DOI 10.1089/ars.2007.1940
   Thickett DR, 2002, AM J RESP CRIT CARE, V166, P1332, DOI 10.1164/rccm.2105057
   Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071
   Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC
   Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111
   Villar J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006818
   Wada T, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-6
   Wang HM, 2008, EUR SURG RES, V40, P305, DOI 10.1159/000121471
   Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002
   Ware LB, 2005, EUR RESPIR J, V26, P101, DOI 10.1183/09031936.05.00106604
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2007, CRIT CARE MED, V35, P1821, DOI 10.1097/01.CCM.0000275386.95968.5F
   Ware Lorraine B., 2005, Keio Journal of Medicine, V54, P142, DOI 10.2302/kjm.54.142
   Ware LB, 2013, CRIT CARE, V17, DOI 10.1186/cc13080
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Wiedermann FJ, 2004, CHEST, V125, P212, DOI 10.1378/chest.125.1.212
   Winterbourn CC, 2000, CRIT CARE MED, V28, P143, DOI 10.1097/00003246-200001000-00024
   Wygrecka M, 2008, THROMB HAEMOSTASIS, V99, P494, DOI 10.1160/TH07-11-0666
   Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068
NR 75
TC 171
Z9 195
U1 8
U2 54
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD APR
PY 2015
VL 209
SI SI
BP 52
EP 58
DI 10.1016/j.resp.2014.10.006
PG 7
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CE9OC
UT WOS:000352172300010
PM 25466727
DA 2023-08-21
ER

PT J
AU Meliton, AY
   Meng, FY
   Tian, YF
   Sarich, N
   Mutlu, GM
   Birukova, AA
   Birukov, KG
AF Meliton, Angelo Y.
   Meng, Fanyong
   Tian, Yufeng
   Sarich, Nicolene
   Mutlu, Gokhan M.
   Birukova, Anna A.
   Birukov, Konstantin G.
TI Oxidized phospholipids protect against lung injury and endothelial
   barrier dysfunction caused by heat-inactivated Staphylococcus aureus
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE oxidized phospholipids; cytoskeleton; ECs/HPMECs/HUVECs/MPVECs; Inflammation; vascular leakage 
ID NF-KAPPA-B; IN-VIVO; VASCULAR-PERMEABILITY; OXIDATION-PRODUCTS;
   LIPOTEICHOIC ACID; UNITED-STATES; CROSS-TALK; RHO; INFLAMMATION;
   ACTIVATION
AB Increased endothelial cell (EC) permeability and vascular inflammation along with alveolar epithelial damage are key features of acute lung injury (ALI). Products of 1-palmitoyl-2-arachidonoyl-sn-glycero-3phosphorylcholine oxidation (OxPAPC) showed protective effects against inflammatory signaling and vascular EC barrier dysfunction induced by gram-negative bacterial wall lipopolysaccharide (LPS). We explored the more general protective effects of OxPAPC and investigated whether delayed posttreatment with OxPAPC boosts the recovery of lung inflammatory injury and EC barrier dysfunction triggered by intratracheal injection of heat-killed gram-positive Staphylococcus aureus (HKSA) bacteria. HKSA-induced pulmonary EC permeability, activation of p38 MAP kinase and NF-kappa B inflammatory cascades, secretion of IL-8 and soluble ICAM1, fibronectin deposition, and expression of adhesion molecules ICAM1 and VCAM1 by activated EC were significantly attenuated by cotreatment as well as posttreatment with OxPAPC up to 16 h after HKSA addition. Remarkably, posttreatment with OxPAPC up to 24 h post-HKSA challenge dramatically accelerated lung recovery by restoring lung barrier properties monitored by Evans blue extravasation and protein content in bronchoalveolar lavage (BAL) fluid and reducing inflammation reflected by decreased MIP-1, KC, TNF-alpha, IL-13 levels and neutrophil count in BAL samples. These studies demonstrate potent in vivo and in vitro protective effects of posttreatment with anti-inflammatory oxidized phospholipids in the model of ALI caused by HKSA. These results warrant further investigations into the potential use of Ox-PAPC compounds combined with antibiotic therapies as a treatment of sepsis and ALI induced by gram-positive bacterial pathogens.
C1 Univ Chicago, Sect Pulm & Crit Care, Chicago, IL 60637, United States.
C1 Univ Chicago, Dept Med, Lung Injury Ctr, Chicago, IL 60637, United States.
C3 University of Chicago; University of Chicago
RP Birukov, KG (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, 5841 S Maryland Ave,Off N-611, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Mutlu, Gokhan/HIR-2545-2022; Sarich, Nicolene/IWV-3869-2023; Birukov,
   Konstantin/FJB-5755-2022
FU National Heart, Lung, and Blood Institute [HL87823, HL076259, HL089257,
   HL107920]
FX This research was supported by National Heart, Lung, and Blood Institute
   Grants HL87823 and HL076259 for K. G. Birukov and HL089257 and HL107920
   for A. A. Birukova.
CR Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Beckers CML, 2010, THROMB HAEMOSTASIS, V103, P40, DOI 10.1160/TH09-06-0403
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL593, DOI 10.1152/ajplung.90257.2008
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2013, MOL BIOL CELL, V24, P2678, DOI 10.1091/mbc.E13-02-0098
   Birukova AA, 2013, TRANSL RES, V161, P495, DOI 10.1016/j.trsl.2012.12.008
   Birukova AA, 2012, J CELL PHYSIOL, V227, P3405, DOI 10.1002/jcp.24041
   Birukova AA, 2012, J CELL PHYSIOL, V227, P1883, DOI 10.1002/jcp.22916
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2011, J CELL PHYSIOL, V226, P2052, DOI 10.1002/jcp.22543
   Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023
   Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   Deng XL, 2011, BRAIN RES, V1387, P1, DOI 10.1016/j.brainres.2011.02.059
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Hayashida A, 2009, AM J PATHOL, V174, P509, DOI 10.2353/ajpath.2009.080394
   Huang F, 2005, AM J PHYSIOL-LUNG C, V289, pL176, DOI 10.1152/ajplung.00003.2005
   Kagan VE, 2004, ANTIOXID REDOX SIGN, V6, P199, DOI 10.1089/152308604322899260
   Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428-7435.2005
   Lang JD, 2002, CHEST, V122, p314S, DOI 10.1378/chest.122.6_suppl.314S
   LECHNER AJ, 1993, MICROSC RES TECHNIQ, V26, P444, DOI 10.1002/jemt.1070260512
   Leemans JC, 2002, AM J RESP CRIT CARE, V165, P1445, DOI 10.1164/rccm.2106045
   Luhrmann A, 2002, INFECT IMMUN, V70, P3785, DOI 10.1128/IAI.70.7.3785-3792.2002
   Ma Z, 2004, AM J PHYSIOL-LUNG C, V286, pL808, DOI 10.1152/ajplung.00220.2003
   Manukyan M, 2009, J IMMUNOL, V182, P3522, DOI 10.4049/jimmunol.0802280
   Melamed A, 2009, CRIT CARE, V13, DOI 10.1186/cc7733
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543
   Nonas S, 2006, AM J RESP CRIT CARE, V173, P1130, DOI 10.1164/rccm.200511-1737OC
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189
   Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248
   Sun HR, 2006, MICROCIRCULATION, V13, P237, DOI 10.1080/10739680600556944
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tian XY, 2014, J BIOL CHEM, V289, P5168, DOI 10.1074/jbc.M113.493924
   Tyurina YY, 2009, METHODS MOL BIOL, V580, P153, DOI 10.1007/978-1-60761-325-1_9
   Wang JE, 2003, SHOCK, V20, P402, DOI 10.1097/01.shk.0000092268.01859.0d
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   Zeng WG, 2002, J IMMUNOL, V169, P4905, DOI 10.4049/jimmunol.169.9.4905
NR 47
TC 41
Z9 42
U1 1
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAR 15
PY 2015
VL 308
IS 6
BP L550
EP L562
DI 10.1152/ajplung.00248.2014
PG 13
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CD4OE
UT WOS:000351062100006
PM 25575515
OA Green Published
DA 2023-08-21
ER

PT J
AU Li, LF
   Hu, JY
   He, T
   Zhang, Q
   Yang, X
   Lan, XD
   Zhang, DX
   Mei, H
   Chen, B
   Huang, YS
AF Li, Lingfei
   Hu, Jiongyu
   He, Ting
   Zhang, Qiong
   Yang, Xu
   Lan, Xiaodong
   Zhang, Dongxia
   Mei, Hao
   Chen, Bing
   Huang, Yuesheng
TI P38/MAPK contributes to endothelial barrier dysfunction via MAP4
   phosphorylation-dependent microtubule disassembly in
   inflammation-induced acute lung injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VASCULAR-PERMEABILITY; CELL PERMEABILITY; INDUCED APOPTOSIS; DYNAMICS;
   NECROSIS; KINASE; PROTEINS; PATHWAY; P38; DESTABILIZATION
AB Excessive activation of inflammation and the accompanying lung vascular endothelial barrier disruption are primary pathogenic features of acute lung injury (ALI). Microtubule-associated protein 4 (MAP4), a tubulin assembly-promoting protein, is important for maintaining the microtubule (MT) cytoskeleton and cell-cell junctional structures. However, both the involvement and exact mechanism of MAP4 in the development of endothelial barrier disruption in ALI remains unknown. In this study, lipopolysaccharide (LPS) and tumour necrosis factor-a (TNF-alpha) were applied to human pulmonary microvascular endothelial cells (HPMECs) to mimic the endothelial damage during inflammation in vitro. We demonstrated that the MAP4 (Ser696 and Ser787) phosphorylation increased concomitantly with the p38/MAPK pathway activation by the LPS and TNF-a stimulation of HPMECs, which induced MT disassembly followed by hyperpermeability. Moreover, the application of taxol, the overexpression of a MAP4 (Ala) mutant, or the application of the p38/MAPK inhibitor SB203580 inhibited the MT disruption and the intracellular junction dysfunction. In contrast, MKK6 (Glu), which constitutively activated p38/MAPK, resulted in microtubule depolymerisation and, subsequently, hyperpermeability. Our findings reveal a novel role of MAP4 in endothelial barrier dysfunction.
C1 [Li, Lingfei; He, Ting; Zhang, Qiong; Lan, Xiaodong; Zhang, Dongxia; Huang, Yuesheng] Third Mil Med Univ, Southwest Hosp, State Key Lab Trauma Burns & Combined Injury, Inst Burn Res, Chongqing, China.
C1 [Hu, Jiongyu; Chen, Bing] Third Mil Med Univ, Southwest Hosp, Dept Endocrinol, Chongqing, China.
C1 [Yang, Xu] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing, China.
C1 [Mei, Hao] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT 06520, United States.
C3 Army Medical University; Army Medical University; Army Medical
   University; Yale University
RP Huang, YS (corresponding author), Third Mil Med Univ, Southwest Hosp, State Key Lab Trauma Burns & Combined Injury, Inst Burn Res, Chongqing, Peoples R China.
EM chenbing3@medmail.com.cn; yshuang.tmmu@gmail.com
FU National Natural Science Foundation of China [81270030]; State Key
   Laboratory of Trauma, Burns and Combined Injury Research Foundation
   [2012ZZII05, SKLZZ201103]; National Programme on Key Basic Research
   Project of China (973 Programme) [2012CB518101]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81270030), State Key Laboratory of Trauma, Burns and Combined
   Injury Research Foundation (No. 2012ZZII05, No. SKLZZ201103), and
   National Programme on Key Basic Research Project of China (973
   Programme; No. 2012CB518101).
CR Andonegui G, 2009, J CLIN INVEST, V119, P1921, DOI 10.1172/JCI36411
   Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Bogatcheva NV, 2007, AM J PHYSIOL-LUNG C, V292, pL487, DOI 10.1152/ajplung.00217.2006
   Chang W, 2001, J CELL SCI, V114, P2879
   Chu ZG, 2010, SHOCK, V34, P222, DOI [10.1097/SHK.0b013e3181d75a66, 10.1097/SHK.0b013e3181d8e357]
   Curry FRE, 2010, CARDIOVASC RES, V87, P218, DOI 10.1093/cvr/cvq115
   Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee
   Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6
   Ebneth A, 1999, CELL MOTIL CYTOSKEL, V44, P209, DOI 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.3.CO;2-W
   Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200
   Hu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.369
   Hu JY, 2010, CELL MOL LIFE SCI, V67, P321, DOI 10.1007/s00018-009-0187-z
   Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834
   Joel R., 1996, MOL CELL BIO, V16, P1247
   Juskewitch JE, 2012, SCI REP-UK, V2, DOI 10.1038/srep00918
   Kitazawa H, 2000, CELL STRUCT FUNCT, V25, P33, DOI 10.1247/csf.25.33
   Kratzer E, 2012, AM J RESP CELL MOL, V47, P688, DOI 10.1165/rcmb.2012-0161OC
   Lee JSY, 2002, CARDIOVASC PATHOL, V11, P135, DOI 10.1016/S1054-8807(01)00080-1
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Miki Y, 2013, BIOL PHARM BULL, V36, P215, DOI 10.1248/bpb.b12-00567
   Monaghan-Benson E, 2011, METHODS MOL BIOL, V763, P281, DOI 10.1007/978-1-61779-191-8_19
   Nwariaku FE, 2002, SHOCK, V18, P82, DOI 10.1097/00024382-200207000-00015
   Ortiz-Ferron G, 2006, CELL DEATH DIFFER, V13, P1857, DOI 10.1038/sj.cdd.4401875
   Patel BV, 2013, J IMMUNOL, V190, P4274, DOI 10.4049/jimmunol.1202437
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Putnam AJ, 1998, J CELL SCI, V111, P3379
   Samora CP, 2011, NAT CELL BIOL, V13, P1040, DOI 10.1038/ncb2297
   Stagg HW, 2013, AM J SURG, V205, P419, DOI 10.1016/j.amjsurg.2012.10.027
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Tian XY, 2012, FASEB J, V26, P3862, DOI 10.1096/fj.12-207746
   Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3
   Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932
   Webster DR, 2006, CELL MOTIL CYTOSKEL, V63, P512, DOI 10.1002/cm.20140
   Yang D, 2010, CARDIOVASC RES, V85, P520, DOI 10.1093/cvr/cvp323
   Zhang LY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01681
NR 39
TC 55
Z9 60
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 9
PY 2015
VL 5
AR 8895
DI 10.1038/srep08895
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC7ME
UT WOS:000350551100004
PM 25746230
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Chichger, H
   Duong, H
   Braza, J
   Harrington, EO
AF Chichger, Havovi
   Huetran Duong
   Braza, Julie
   Harrington, Elizabeth O.
TI p18, a novel adaptor protein, regulates pulmonary endothelial barrier
   function via enhanced endocytic recycling of VE-cadherin
SO FASEB JOURNAL
LA English
DT Article
DE endosome; adhesion junction; endocytosis; ALI/ARDS 
ID ACUTE LUNG INJURY; CELL-CELL ADHESION; IN-VIVO; VASCULAR-PERMEABILITY;
   TYROSINE PHOSPHORYLATION; LEUKOCYTE EXTRAVASATION; DEPENDENT
   ENDOCYTOSIS; ADHERENS JUNCTIONS; CATENIN COMPLEX; BETA-CATENIN
AB Vascular permeability is a hallmark of several disease states including acute lung injury (ALI). Endocytosis of VE-cadherin, away from the interendothelial junction (IEJ), causes acute endothelial barrier permeability. A novel protein, p18, anchors to the endosome membrane and plays a role in late endosomal signaling via MAPK and mammalian target of rapamycin. However, the fate of the VE-cadherin-positive endosome has yet to be elucidated. We sought to elucidate a role for p18 in VE-cadherin trafficking and thus endothelial barrier function, in settings of ALI. Endothelial cell (EC) resistance, whole-cell ELISA, and filtration coefficient were studied in mice or lung ECs overexpressing wild-type or nonendosomal-binding mutant p18, using green fluorescent protein as a control. We demonstrate a protective role for the endocytic protein p18 in endothelial barrier function in settings of ALI in vitro and in vivo, through enhanced recycling of VE-cadherin-positive early endosomes to the IEJ. In settings of LPS-induced ALI, we show that Src tethered to the endosome tyrosine phosphorylates p18 concomitantly with VE-cadherin internalization and pulmonary edema formation. We conclude that p18 regulates pulmonary endothelial barrier function in vitro and in vivo, by enhancing recycling of VE-cadherin-positive endosomes to the IEJ.
C1 Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI, United States.
C1 Brown Univ, Alpert Med Sch, Dept Med, Providence, RI 02912, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University
RP Chichger, H (corresponding author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM havovi_chichger@brown.edu
RI Chichger, Havovi/Y-7117-2019; Chichger, Havovi/M-5129-2015
OI Chichger, Havovi/0000-0002-8549-7583; Chichger,
   Havovi/0000-0002-8549-7583; Harrington, Elizabeth/0000-0002-3207-5301
FU U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood
   Institute Grant [R01 HL-67795]; American Heart Association Grant
   [10GRNT4160055, 13POST16860031]; COBRE NIH National Institute of General
   Medical Sciences Award [5P20 GM103652]; University Medicine Foundation
   of Rhode Island Hospital
FX This material is the result of work supported with resources and the use
   of facilities at the Providence Veterans Affairs Medical Center. The
   work was supported by the U.S. National Institutes of Health (NIH)
   National Heart, Lung, and Blood Institute Grant R01 HL-67795, American
   Heart Association Grant 10GRNT4160055, COBRE NIH National Institute of
   General Medical Sciences Award 5P20 GM103652, and University Medicine
   Foundation of Rhode Island Hospital (to E.O.H.). H.C. was supported by
   American Heart Association Grant 13POST16860031. The views expressed in
   this article are those of the authors and do not necessarily reflect the
   position or policy of the Department of Veterans Affairs.
CR Adam AP, 2010, J BIOL CHEM, V285, P7045, DOI 10.1074/jbc.M109.079277
   Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800
   BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229
   Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525
   Buttenschoen K, 2008, LANGENBECK ARCH SURG, V393, P473, DOI 10.1007/s00423-008-0317-3
   Chiasson CM, 2009, MOL BIOL CELL, V20, P1970, DOI 10.1091/mbc.E08-07-0735
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111
   de Leeuw HPJC, 1998, BRIT J HAEMATOL, V103, P15, DOI 10.1046/j.1365-2141.1998.00965.x
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   Durrbach A, 1996, J CELL SCI, V109, P457
   Gao XP, 2000, AM J PHYSIOL-LUNG C, V279, pL1218, DOI 10.1152/ajplung.2000.279.6.L1218
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gotsch U, 1997, J CELL SCI, V110, P583
   Grinnell KL, 2010, AM J PHYSIOL-LUNG C, V298, pL361, DOI 10.1152/ajplung.00374.2009
   Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC
   Guillaumot P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010977
   Hatanaka K, 2011, AM J PHYSIOL-HEART C, V300, pH162, DOI 10.1152/ajpheart.00650.2010
   Hoshino D, 2011, J BIOL CHEM, V286, P3139, DOI 10.1074/jbc.M110.159715
   Hoshino D, 2009, J BIOL CHEM, V284, P27315, DOI 10.1074/jbc.M109.041400
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203
   Li HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081903
   Luttrell LM, 2013, PROG MOL BIOL TRANSL, V118, P115, DOI 10.1016/B978-0-12-394440-5.00005-X
   Maniatis Nikolaos A, 2012, Pulm Circ, V2, P452, DOI 10.4103/2045-8932.105033
   Nada S, 2009, EMBO J, V28, P477, DOI 10.1038/emboj.2008.308
   Nanes BA, 2012, J CELL BIOL, V199, P365, DOI 10.1083/jcb.201205029
   Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149
   Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787
   Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471
   Oyaizu T, 2012, INTENS CARE MED, V38, P894, DOI 10.1007/s00134-012-2498-z
   Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046
   Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200
   Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304
   Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003
   Soma-Nagae T, 2013, J CELL SCI, V126, P3575, DOI 10.1242/jcs.121913
   Stasyk T, 2010, PROTEOMICS, V10, P4117, DOI 10.1002/pmic.201000258
   Stevens TC, 2014, AM J PHYSIOL-LUNG C, V306, pL915, DOI 10.1152/ajplung.00135.2013
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Takahashi Y, 2012, BIOCHEM BIOPH RES CO, V417, P1151, DOI 10.1016/j.bbrc.2011.12.082
   UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   Wang Y, 2013, MOL BIOL REP, V40, P3093, DOI 10.1007/s11033-012-2383-4
   Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440
   Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200
   Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407
NR 51
TC 24
Z9 24
U1 0
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAR
PY 2015
VL 29
IS 3
BP 868
EP 881
DI 10.1096/fj.14-257212
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA CC8QK
UT WOS:000350633000014
PM 25404710
OA Green Published
DA 2023-08-21
ER

PT J
AU He, HL
   Liu, L
   Chen, QH
   Cai, SX
   Han, JB
   Hu, SL
   Chun, P
   Yang, Y
   Guo, FM
   Huang, YZ
   Qiu, HB
AF He, Hongli
   Liu, Ling
   Chen, Qihong
   Cai, Shixia
   Han, Jibin
   Hu, Shuling
   Chun, Pan
   Yang, Yi
   Guo, Fengmei
   Huang, Yingzi
   Qiu, Haibo
TI MSCs Modified With ACE2 Restore Endothelial Function Following LPS
   Challenge by Inhibiting the Activation of RAS
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ACUTE LUNG INJURY; MESENCHYMAL STEM-CELLS; ANGIOTENSIN-CONVERTING
   ENZYME-2; GENE-THERAPY; LIPOPOLYSACCHARIDE; PERMEABILITY; MECHANISMS;
   RECEPTOR; PATHWAY; SEPSIS
AB Angiotensin (Ang) II plays an important role in the process of endothelial dysfunction in acute lung injury (ALI) and is degraded by angiotensin-converting enzyme2 (ACE2). However, treatments that target ACE2 to injured endothelium and promote endothelial repair of ALI are lacking. Mesenchymal stem cells (MSCs) are capable of homing to the injured site and delivering a protective gene. Our study aimed to evaluate the effects of genetically modified MSCs, which overexpress the ACE2 protein in a sustained manner via a lentiviral vector, on Ang II production in endothelium and in vitro repair of lipopolysaccharide (LPS)-induced endothelial injury. We found that the efficiency of lentiviral vector transduction of MSCs was as high as 97.8% and was well maintained over 30 passages. MSCs modified with ACE2 showed a sustained high expression of ACE2 mRNA and protein. The modified MSCs secreted soluble ACE2 protein into the culture medium, which reduced the concentration of Ang II and increased the production of Ang 1-7. MSCs modified with ACE2 were more effective at restoring endothelial function than were unmodified MSCs, as shown by the enhanced survival of endothelial cells; the downregulated production of inflammatory mediators, including ICAM-1, VCAM-1, TNF-, and IL-6; reduced paracellular permeability; and increased expression of VE-cadherin. These data demonstrate that MSCs modified to overexpress the ACE2 gene can produce biologically active ACE2 protein over a sustained period of time and have an enhanced ability to promote endothelial repair after LPS challenge. These results encourage further testing of the beneficial effects of ACE2-modified MSCs in an ALI animal model. J. Cell. Physiol. 230: 691-701, 2015. (c) 2014 Wiley Periodicals, Inc., A Wiley Company
C1 [He, Hong-li; Liu, Ling; Chen, Qi-hong; Cai, Shi-xia; Han, Ji-bin; Hu, Shu-ling; Chun, Pan; Yang, Yi; Guo, Feng-mei; Huang, Ying-zi; Qiu, Hai-bo] Southeast Univ, Sch Med, Zhong Da Hosp, Dept Crit Care Med, Nanjing 210009, Jiangsu, China.
C3 Southeast University - China
RP Qiu, HB (corresponding author), Southeast Univ, Sch Med, Zhong Da Hosp, Dept Crit Care Med, 87 Ding Jiaqiao, Nanjing 210009, Jiangsu, Peoples R China.
EM haiboq2000@gmail.com
RI chen, qian/HKE-2403-2023; CHEN, QING/IXN-5937-2023; Qiu,
   Haibo/AAS-9047-2021; Chen, QH/GXH-3158-2022
OI CHEN, QING/0000-0001-5250-1710; Qiu, Haibo/0000-0001-8589-4717; 
FU National Natural Science Foundation of China [81000828, 81070049,
   81170057, 81372093]; Natural Science Foundation of Jiangsu Province of
   China [BK20131302]; Graduate Innovation Project in Jiangsu Province of
   China [CXLX_0151, CXLX_0153]
FX Contract grant sponsor: National Natural Science Foundation of China;;
   Contract grant numbers: 81000828, 81070049, 81170057, 81372093.;
   Contract grant sponsor: Natural Science Foundation of Jiangsu Province
   of China;; Contract grant number: BK20131302.; Contract grant sponsor:
   Graduate Innovation Project in Jiangsu Province of China;; Contract
   grant numbers: CXLX_0151, CXLX_0153.
CR Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Campbell AIM, 2001, CIRCULATION, V104, P2242, DOI 10.1161/hc4201.097838
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Dandona P, 2007, J HUM HYPERTENS, V21, P20, DOI 10.1038/sj.jhh.1002101
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006
   Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000
   Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217
   Imai Y, 2007, CELL MOL LIFE SCI, V64, P2006, DOI 10.1007/s00018-007-6228-6
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Imai Y, 2010, CIRC J, V74, P405, DOI 10.1253/circj.CJ-10-0045
   Kanki-Horimoto S, 2006, CIRCULATION, V114, pI181, DOI 10.1161/CIRCULATIONAHA.105.001487
   Kim YC, 2012, AM J PHYSIOL-LUNG C, V303, pL228, DOI 10.1152/ajplung.00087.2012
   Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Lee YH, 2010, J CELL SCI, V123, P1634, DOI 10.1242/jcs.063545
   Lin X, 2011, CRIT CARE CLIN, V27, P705, DOI 10.1016/j.ccc.2011.04.002
   Liu AR, 2013, J CELL PHYSIOL, V228, P1270, DOI 10.1002/jcp.24282
   Liu L, 2009, ARCH BIOCHEM BIOPHYS, V481, P131, DOI 10.1016/j.abb.2008.09.019
   Lund DD, 2007, AM J PHYSIOL-HEART C, V293, pH3726, DOI 10.1152/ajpheart.01116.2007
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McGinley L, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt53
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Molthen RC, 2012, RESPIROLOGY, V17, P1261, DOI 10.1111/j.1440-1843.2012.02247.x
   MORRISON DC, 1978, AM J PATHOL, V93, P526
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171
   Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   Rentzsch B, 2008, HYPERTENSION, V52, P967, DOI 10.1161/HYPERTENSIONAHA.108.114322
   SCHALLER MD, 1985, AM J PHYSIOL, V249, P1086, DOI 10.1152/ajpheart.1985.249.6.H1086
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wang HL, 2007, J IMMUNOL, V179, P1834, DOI 10.4049/jimmunol.179.3.1834
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Wiel E, 2004, INTENS CARE MED, V30, P1652, DOI 10.1007/s00134-004-2198-4
   Wort SJ, 1999, BRIT MED BULL, V55, P30, DOI 10.1258/0007142991902286
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Xu JG, 2007, AM J PHYSIOL-LUNG C, V293, pL131, DOI 10.1152/ajplung.00431.2006
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
   Zhao YDD, 2005, CIRC RES, V96, P442, DOI 10.1161/01.RES.0000157672.70560.7b
   Zhao YDD, 2009, CIRC RES, V105, P696, DOI 10.1161/CIRCRESAHA.109.199778
NR 44
TC 30
Z9 36
U1 1
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2015
VL 230
IS 3
BP 691
EP 701
DI 10.1002/jcp.24794
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA AU3JI
UT WOS:000345508400023
PM 25200929
DA 2023-08-21
ER

PT J
AU Meng, FY
   Meliton, A
   Moldobaeva, N
   Mutlu, G
   Kawasaki, Y
   Akiyama, T
   Birukova, AA
AF Meng, Fanyong
   Meliton, Angelo Y.
   Moldobaeva, Nurgul
   Mutlu, Gokhan M.
   Kawasaki, Yoshihiro
   Akiyama, Tetsu
   Birukova, Anna A.
TI Asef mediates HGF protective effects against LPS-induced lung injury and
   endothelial barrier dysfunction
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE hepatocyte growth factor (HGF); guanine nucleotide exchange factors; cytoskeleton; ECs/HPMECs/HUVECs/MPVECs; Inflammation; permeability; vascular leakage 
ID HEPATOCYTE GROWTH-FACTOR; ATRIAL-NATRIURETIC-PEPTIDE; OXIDIZED
   PHOSPHOLIPIDS; VASCULAR-PERMEABILITY; KINASE INHIBITOR; SCATTER FACTOR;
   IN-VIVO; C-MET; INFLAMMATION; MECHANISM
AB Increased vascular endothelial permeability and inflammation are major pathological mechanisms of pulmonary edema and its life-threatening complication, the acute respiratory distress syndrome (ARDS). We have previously described potent protective effects of hepatocyte growth factor (HGF) against thrombin-induced hyperpermeability and identified the Rac pathway as a key mechanism of HGF-mediated endothelial barrier protection. However, anti-inflammatory effects of HGF are less understood. This study examined effects of HGF on the pulmonary endothelial cell (EC) inflammatory activation and barrier dysfunction caused by the gram-negative bacterial pathogen lipopolysaccharide (LPS). We tested involvement of the novel Rac-specific guanine nucleotide exchange factor Asef in the HGF anti-inflammatory effects. HGF protected the pulmonary EC monolayer against LPS-induced hyperpermeability, disruption of monolayer integrity, activation of NF-kB signaling, expression of adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, and production of IL-8. These effects were critically dependent on Asef. Small-interfering RNA-induced down-regulation of Asef attenuated HGF protective effects against LPS-induced EC barrier failure. Protective effects of HGF against LPS-induced lung inflammation and vascular leak were also diminished in Asef knockout mice. Taken together, these results demonstrate potent anti-inflammatory effects by HGF and delineate a key role of Asef in the mediation of the HGF barrier protective and anti-inflammatory effects. Modulation of Asef activity may have important implications in therapeutic strategies aimed at the treatment of sepsis and acute lung injury/ARDS-induced gram-negative bacterial pathogens.
C1 [Meng, Fanyong; Meliton, Angelo; Moldobaeva, Nurgul; Mutlu, Gokhan; Birukova, Anna A.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637, United States.
C1 [Kawasaki, Yoshihiro; Akiyama, Tetsu] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Tokyo, Japan.
C3 University of Chicago; University of Tokyo
RP Birukova, AA (corresponding author), Univ Chicago, Lung Injury Ctr, Dept Med, Sect Pulm & Crit Med, 5841 S Maryland Ave,Off N613, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
RI Mutlu, Gokhan/HIR-2545-2022
FU National Heart, Lung, and Blood Institute [HL-107920]; Grants-in-Aid for
   Scientific Research [22112004] Funding Source: KAKEN
FX This work was supported by Grant HL-107920 from the National Heart,
   Lung, and Blood Institute.
CR Aoki M, 2000, J Atheroscler Thromb, V7, P71
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Cheng HT, 2013, J INVEST MED, V61, P1097, DOI 10.2310/JIM.0b013e3182a32fdb
   Deng XL, 2011, BRAIN RES, V1387, P1, DOI 10.1016/j.brainres.2011.02.059
   DOSQUET C, 1992, NOUV REV FR HEMATOL, V34, pS55
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Giannopoulou M, 2008, AM J PATHOL, V173, P30, DOI 10.2353/ajpath.2008.070583
   Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937
   Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194
   Kawasaki Y, 2010, J BIOL CHEM, V285, P1199, DOI 10.1074/jbc.M109.040691
   Kratzer E, 2012, AM J RESP CELL MOL, V47, P688, DOI 10.1165/rcmb.2012-0161OC
   Lindsay CD, 2011, HUM EXP TOXICOL, V30, P701, DOI 10.1177/0960327110376982
   Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Meliton AY, 2013, AM J PHYSIOL-LUNG C, V304, pL689, DOI 10.1152/ajplung.00047.2013
   Meliton AY, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-14
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2
   Ricard JD, 2003, EUR RESPIR J, V22, p2S, DOI 10.1183/09031936.03.00420103
   Rosen EM, 1995, ADV CANCER RES, V67, P257, DOI 10.1016/S0065-230X(08)60715-0
   Sagara M, 2009, ONCOGENE, V28, P1357, DOI 10.1038/onc.2008.478
   Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419
   Singleton PA, 2007, J BIOL CHEM, V282, P30643, DOI 10.1074/jbc.M702573200
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Slotta JE, 2006, INFLAMM RES, V55, P364, DOI 10.1007/s00011-006-6013-2
   SMITH CW, 1993, SEMIN HEMATOL, V30, P45
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Tian XY, 2014, J BIOL CHEM, V289, P5168, DOI 10.1074/jbc.M113.493924
   Tomita N, 2000, J Atheroscler Thromb, V7, P1
   Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111
   Wang Q, 2002, ANTIOXID REDOX SIGN, V4, P39, DOI 10.1089/152308602753625843
   Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001
   Wu TH, 2013, TRANSL RES, V162, P45, DOI 10.1016/j.trsl.2013.03.005
   Xing JJ, 2012, MICROVASC RES, V83, P194, DOI 10.1016/j.mvr.2011.09.012
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.3.CO;2-0
NR 51
TC 37
Z9 40
U1 0
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAR 1
PY 2015
VL 308
IS 5
BP L452
EP L463
DI 10.1152/ajplung.00170.2014
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CD4OD
UT WOS:000351062000005
PM 25539852
OA Green Published
DA 2023-08-21
ER

PT J
AU Lu, HY
   Poirier, C
   Cook, T
   Traktuev, DO
   Merfeld-Clauss, S
   Lease, B
   Petrache, I
   March, KL
   Bogatcheva, NV
AF Lu, Hongyan
   Poirier, Christophe
   Cook, Todd
   Traktuev, Dmitry O.
   Merfeld-Clauss, Stephanie
   Lease, Benjamin
   Petrache, Irina
   March, Keith L.
   Bogatcheva, Natalia V.
TI Conditioned media from adipose stromal cells limit
   lipopolysaccharide-induced lung injury, endothelial hyperpermeability
   and apoptosis
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Adipose stromal cells; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; apoptosis 
ID MESENCHYMAL STEM-CELLS; RESPIRATORY-DISTRESS-SYNDROME; AUTOLOGOUS
   TRANSPLANTATION; TISSUE; MICE; DAMAGE; MODEL; INVOLVEMENT; SEPSIS;
   FAMILY
AB Background: Acute Respiratory Distress Syndrome (ARDS) is a condition that contributes to morbidity and mortality of critically ill patients. We investigated whether factors secreted by adipose stromal cells (ASC) into conditioned media (ASC-CM) will effectively decrease lung injury in the model of lipopolysaccharide (LPS)-induced ARDS.
   Methods: To assess the effect of ASC-CM on ARDS indices, intravenous delivery of ASC and ASC-CM to C57Bl/6 mice was carried out 4 h after LPS oropharyngeal aspiration; Evans Blue Dye (EBD) was injected intravenously 1 h prior to animal sacrifice (48 h post-LPS). Lungs were either fixed for histopathology, or used to extract bronchoalveolar lavage fluid (BALF) or EBD. To assess the effect of ASC-CM on endothelial barrier function and apoptosis, human pulmonary artery endothelial cells were treated with ASC-CM for 48-72 h.
   Results: ASC-CM markedly reduced LPS-induced histopathologic changes of lung, protein extravasation into BALF, and suppressed the secretion of proinflammatory cytokines TNF alpha and IL6. White Blood Cells (WBC) from BALF of LPS-challenged mice receiving ASC-CM had decreased reactive oxygen species (ROS) generation compared to WBC from LPS-challenged mice receiving control media injection. Treatment of pulmonary endothelial monolayers with ASC-CM significantly suppressed H2O2-induced leakage of FITC dextran and changes in transendothelial resistance, as well as gap formation in endothelial monolayer. ASC-CM exposure reduced the percentage of endothelial cells expressing ICAM-1, and suppressed TNF alpha-induced expression of E-selectin and cleavage of caspase-3. ASC-CM reduced the endothelial level of pro-apoptotic protein Bim, but did not affect the level of Bcl-2, Bad, or Bad phosphorylation.
   Conclusions: Factors secreted by ASC efficiently reduce ARDS indices, endothelial barrier hyperpermeability, and activation of pro-inflammatory and pro-apoptotic pathways in endothelium.
C1 [Lu, Hongyan; Cook, Todd; Traktuev, Dmitry O.; Merfeld-Clauss, Stephanie; March, Keith L.; Bogatcheva, Natalia V.] Indiana Univ, Div Cardiol, Indianapolis, IN 46204, United States.
C1 [Lu, Hongyan; Cook, Todd; Traktuev, Dmitry O.; Merfeld-Clauss, Stephanie; Lease, Benjamin; Petrache, Irina; March, Keith L.; Bogatcheva, Natalia V.] Indiana Ctr Vasc Biol & Med, Indiana, PA, United States.
C1 [Lu, Hongyan; Cook, Todd; Traktuev, Dmitry O.; Merfeld-Clauss, Stephanie; Lease, Benjamin; Petrache, Irina; March, Keith L.; Bogatcheva, Natalia V.] VC CAST Signature Ctr, Indianapolis, IN, United States.
C1 [Lu, Hongyan; Traktuev, Dmitry O.; Merfeld-Clauss, Stephanie; Petrache, Irina; March, Keith L.; Bogatcheva, Natalia V.] Indiana Univ, Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46204, United States.
C1 [Poirier, Christophe; Petrache, Irina] Indiana Univ, Div Pulm & Crit Care Med, Indianapolis, IN 46204, United States.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis; Indiana University System; Indiana University-Purdue
   University Indianapolis; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Richard L. Roudebush VA Medical Center;
   Indiana University System; Indiana University-Purdue University
   Indianapolis
RP Bogatcheva, NV (corresponding author), Indiana Univ, Div Cardiol, Indianapolis, IN 46204 USA.
EM nbogatch@iu.edu
RI Traktuev, Dmitry/AAP-1160-2020; Traktuev, Dmitry/HJI-8659-2023;
   Petrache, Irina/AAZ-9648-2020
OI Traktuev, Dmitry/0000-0002-6757-512X; Bogatcheva,
   Natalia/0000-0002-5177-5872; March, Keith/0000-0001-5677-0379
FU Krannert Institute of Cardiology Endowment Fund [AHA SDG 0930038,
   10SDG2720016, R01 HL105772]; Vascular and Cardiac Center for Adult Stem
   Cell Therapy; Cryptic Masons Medical Research Foundation
FX This work was supported by Krannert Institute of Cardiology Endowment
   Fund (NB), AHA SDG 0930038 N (NB) and 10SDG2720016 (DT), R01 HL105772
   (IP, KM) and support from Vascular and Cardiac Center for Adult Stem
   Cell Therapy and the Cryptic Masons Medical Research Foundation. The
   authors are grateful to Daria Barwinska and Drs. Yameena Jawed, Reef
   Hardy, Jie Xie, and Ru Yi for the technical assistance with some of the
   experiments.
CR Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004
   Bogatcheva NV, 2007, AM J PHYSIOL-LUNG C, V292, pL487, DOI 10.1152/ajplung.00217.2006
   Boyle AJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-166
   Chang CL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-244
   Chien MH, 2012, CRIT CARE MED, V40, P1245, DOI 10.1097/CCM.0b013e31823bc89a
   Danchuk S, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt68
   Dooner MS, 2008, STEM CELLS DEV, V17, P207, DOI 10.1089/scd.2007.0195
   Fanelli V, 2013, J THORAC DIS, V5, P326, DOI 10.3978/j.issn.2072-1439.2013.04.05
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hayes Mairead, 2012, F1000 Med Rep, V4, P2, DOI 10.3410/M4-2
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Klopp AH, 2012, CLIN CANCER RES, V18, P771, DOI 10.1158/1078-0432.CCR-11-1916
   Krasnodembskaya A, STEM CELLS
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Liang ZD, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-179
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B
   Shin S, 2013, INT J MED SCI, V10, P8, DOI 10.7150/ijms.5385
   Sroussi HY, 2010, FREE RADICAL RES, V44, P389, DOI 10.3109/10715760903431434
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Sueblinvong V, 2010, TRANSL RES, V156, P188, DOI 10.1016/j.trsl.2010.06.007
   Sun CK, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-118
   Tatsumi K, 2013, BIOCHEM BIOPH RES CO, V431, P203, DOI 10.1016/j.bbrc.2012.12.134
   Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475
   Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Zhang SJ, 2014, STEM CELLS, V32, P1616, DOI 10.1002/stem.1632
   Zhang SJ, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt161
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
   Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987
NR 37
TC 22
Z9 23
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD FEB 21
PY 2015
VL 13
AR 67
DI 10.1186/s12967-015-0422-3
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CD1XT
UT WOS:000350868600001
PM 25889857
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Xu, QL
   Liu, JX
   Wang, ZL
   Guo, XH
   Zhou, GB
   Liu, YA
   Huang, QB
   Su, L
AF Xu, Qiulin
   Liu, Jingxian
   Wang, Zhenglian
   Guo, Xiaohua
   Zhou, Gengbiao
   Liu, Yanan
   Huang, Qiaobing
   Su, Lei
TI Heat Stress-Induced Disruption of Endothelial Barrier Function Is via
   PAR1 Signaling and Suppressed by Xuebijing Injection
SO PLOS ONE
LA English
DT Article
ID GLYCATION END-PRODUCTS; EZRIN/RADIXIN/MOESIN PROTEINS; MOESIN
   PHOSPHORYLATION; CELLS; PERMEABILITY; MICE; STROKE; INCREASES; INJURY
AB Increased vascular permeability leading to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is central to the pathogenesis of heatstroke. Protease-activated receptor 1 (PAR1), the receptor for thrombin, plays a key role in disruption of endothelial barrier function in response to extracellular stimuli. However, the role of PAR1 in heat stress-induced endothelial hyper-permeability is unknown. In this study, we measured PAR1 protein expression in heat-stressed human umbilical venous endothelial cells (HUVECs), investigated the influences of PAR1 on endothelial permeability, F-actin rearrangement, and moesin phosphorylation by inhibiting PAR1 with its siRNA, neutralizing antibody (anti-PAR1), specific inhibitor(RWJ56110), and Xuebijing injection (XBJ), a traditional Chinese medicine used for sepsis treatment, and evaluated the role of PAR1 in heatstroke- related ALI/ARDS in mice by suppressing PAR1 with RWJ56110, anti-PAR1and XBJ. We found that heat stress induced PAR1 protein expression 2h after heat stress in endothelial cells, caused the release of endothelial matrix metalloprotease 1, an activator of PAR1, after 60 or 120 min of heat stimulation, as well as promoted endothelial hyper-permeability and F-actin rearrangement, which were inhibited by suppressing PAR1 with RWJ56110, anti-PAR1 and siRNA. PAR1 mediated moesin phosphorylation, which caused F-actin rearrangement and disruption of endothelial barrier function. To corroborate findings from in vitro experiments, we found that RWJ56110 and the anti-PAR1 significantly decreased lung edema, pulmonary microvascular permeability, protein exudation, and leukocytes infiltrations in heatstroke mice. Additionally, XBJ was found to suppress PAR1-moesin signal pathway and confer protective effects on maintaining endothelial barrier function both in vitro and in vivo heat-stressed model, similar to those observed above with the inhibition of PAR1. These results suggest that PAR1 is a potential therapeutic target in heatstroke.
C1 [Xu, Qiulin; Su, Lei] Guangzhou Mil Command, Gen Hosp, Dept ICU, Key Lab Trop Zone Trauma Care & Tissue Repair PLA, Guangzhou, Guangdong, China.
C1 [Xu, Qiulin] Huabo Biopharmaceut Res Inst, Postdoctoral Workstn, Guangzhou, Guangdong, China.
C1 [Liu, Jingxian; Liu, Yanan] Southern Med Univ, Guangzhou, Guangdong, China.
C1 [Wang, Zhenglian; Zhou, Gengbiao] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, China.
C1 [Guo, Xiaohua; Huang, Qiaobing] Southern Med Univ, Dept Pathophysiol, Guangzhou, Guangdong, China.
C3 Southern Theater Command General Hospital; Southern Medical University -
   China; Guangzhou University of Chinese Medicine; Southern Medical
   University - China
RP Huang, QB (corresponding author), Southern Med Univ, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China.
EM bing@smu.edu.cn; slei_icu@163.com
OI Xu, Qiulin/0000-0002-1592-6434
FU Natural Science Foundation of Guangdong Province, China
   [S2013040015661]; China Postdoctoral Science Foundation [2014M552180];
   National Natural Science Foundation of China [31300950]; Project of
   Medical Research of People's Liberation Army [BWS12J108]
FX This work was supported by the PhD Start-up Fund of Natural Science
   Foundation of Guangdong Province, China (S2013040015661,
   http://pro.gdstc.gov.cn/egrantweb/), China Postdoctoral Science
   Foundation(2014M552180,
   http://jj.chinapostdoctor.org.cn/V1/Program1/Default.aspx), National
   Natural Science Foundation of China (31300950, http://www.nsfc.gov.cn/),
   and Project of Medical Research of People's Liberation Army (BWS12J108).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adyshev DM, 2013, AM J PHYSIOL-LUNG C, V305, P1240, DOI 10.1152/ajplung.00355.2012
   Asehnoune K, 2013, CRIT CARE, V17, DOI 10.1186/cc12502
   Austin KM, 2013, BLOOD, V121, P431, DOI 10.1182/blood-2012-09-355958
   Broquet A, 2014, CRIT CARE MED, V42, pE441, DOI 10.1097/CCM.0000000000000311
   Chen Y, 2013, J TRADIT CHIN MED, V33, P243, DOI 10.1016/S0254-6272(13)60133-8
   Chui A., 2014, PLACENTA
   Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001
   Guo XH, 2009, AM J PHYSIOL-HEART C, V297, pH238, DOI 10.1152/ajpheart.00196.2009
   Helwig BG, 2011, PHYSIOL GENOMICS, V43, P1096, DOI 10.1152/physiolgenomics.00076.2011
   Hirano Katsuya, 2003, J Atheroscler Thromb, V10, P211
   Jeon S, 2010, NEUROCHEM INT, V56, P810, DOI 10.1016/j.neuint.2010.03.005
   Ji J, 2014, EXP THER MED, V7, P1745, DOI 10.3892/etm.2014.1639
   Juncker-Jensen A, 2013, CANCER RES, V73, P4196, DOI 10.1158/0008-5472.CAN-12-4495
   Kim HS, 2010, J NEUROCHEM, V113, P1565, DOI 10.1111/j.1471-4159.2010.06713.x
   Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218
   Li QQ, 2011, BRAIN RES, V1373, P1, DOI 10.1016/j.brainres.2010.12.032
   Ng KY, 2004, J PHARM SCI-US, V93, P896, DOI 10.1002/jps.20015
   Pirot N, 2014, AM J PHYSIOL-LUNG C, V306, pL775, DOI 10.1152/ajplung.00200.2013
   SHARMA HS, 1990, ACT NEUR S, V51, P383
   Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145
   Varghese GM, 2005, EMERG MED J, V22, P185, DOI 10.1136/emj.2003.009365
   Wang JP, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-7
   Wang LJ, 2012, ACTA DIABETOL, V49, P47, DOI 10.1007/s00592-011-0267-z
   Wang LQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090472
   WIJSMAN JA, 1993, ACTA NEUROPATHOL, V86, P49, DOI 10.1007/BF00454898
   Zhang YL, 2013, J MOL MED, V91, P117, DOI 10.1007/s00109-012-0940-x
NR 26
TC 11
Z9 18
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2015
VL 10
IS 2
AR e0118057
DI 10.1371/journal.pone.0118057
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC0WZ
UT WOS:000350061500092
PM 25693178
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Tian, XY
   Tian, YF
   Gawlak, G
   Meng, FY
   Kawasaki, Y
   Akiyama, T
   Birukova, AA
AF Tian, Xinyong
   Tian, Yufeng
   Gawlak, Grzegorz
   Meng, Fanyong
   Kawasaki, Yoshihiro
   Akiyama, Tetsu
   Birukova, Anna A.
TI Asef controls vascular endothelial permeability and barrier recovery in
   the lung
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID HEPATOCYTE GROWTH-FACTOR; ADENOMATOUS POLYPOSIS-COLI; OXIDIZED
   PHOSPHOLIPIDS; SPHINGOSINE 1-PHOSPHATE; RHO GTPASES; RAC ACTIVATION;
   CELL-CELL; THROMBIN; CORTACTIN; ENHANCEMENT
AB Increased levels of hepatocyte growth factor (HGF) in injured lungs may reflect a compensatory response to diminish acute lung injury (ALI). HGF-induced activation of Rac1 GTPase stimulates endothelial barrier protective mechanisms. This study tested the involvement of Rac-specific guanine nucleotide exchange factor Asef in HGF-induced endothelial cell (EC) cytoskeletal dynamics and barrier protection in vitro and in a two-hit model of ALI. HGF induced membrane translocation of Asef and stimulated Asef Rac1-specific nucleotide exchange activity. Expression of constitutively activated Asef mutant mimicked HGF-induced peripheral actin cytoskeleton enhancement. In contrast, siRNA-induced Asef knockdown or expression of dominant-negative Asef attenuated HGF-induced Rac1 activation evaluated by Rac-GTP pull down and FRET assay with Rac1 biosensor. Molecular inhibition of Asef attenuated HGF-induced peripheral accumulation of cortactin, formation of lamellipodia-like structures, and enhancement of VE-cadherin adherens junctions and compromised HGF-protective effect against thrombin-induced RhoA GTPase activation, Rho-dependent cytoskeleton remodeling, and EC permeability. Intravenous HGF injection attenuated lung inflammation and vascular leak in the two-hit model of ALI induced by excessive mechanical ventilation and thrombin signaling peptide TRAP6. This effect was lost in Asef(-/-) mice. This study shows for the first time the role of Asef in HGF-mediated protection against endothelial hyperpermeability and lung injury.
C1 [Tian, Xinyong; Tian, Yufeng; Gawlak, Grzegorz; Meng, Fanyong; Birukova, Anna A.] Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637, United States.
C1 [Kawasaki, Yoshihiro; Akiyama, Tetsu] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan.
C3 University of Chicago; University of Tokyo
RP Birukova, AA (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
FU National Heart, Lung, and Blood Institute [HL89257, HL107920]; Ministry
   of Education, Culture, Sports, Science and Technology, Japan;
   Grants-in-Aid for Scientific Research [22112004] Funding Source: KAKEN
FX We thank Katalin Szaszi (St. Michael's Hospital, Toronto, Canada) for
   sharing the RacG15A construct. This work was supported by grants from
   the National Heart, Lung, and Blood Institute (HL89257 and HL107920) to
   A.B. and Grants-in-Aid for Scientific Research on Innovative Areas
   (Integrative Research on Cancer Microenvironment Network), Ministry of
   Education, Culture, Sports, Science and Technology, Japan, to T.A.
CR Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296
   Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588
   Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016
   Baumer Y, 2009, J CELL PHYSIOL, V220, P716, DOI 10.1002/jcp.21819
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2012, J CELL PHYSIOL, V227, P3405, DOI 10.1002/jcp.24041
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241
   Blank R, 2011, CRIT CARE CLIN, V27, P439, DOI 10.1016/j.ccc.2011.05.005
   BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0
   Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cheng HT, 2013, J INVEST MED, V61, P1097, DOI 10.2310/JIM.0b013e3182a32fdb
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867
   Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9
   Geiser T, 2003, SWISS MED WKLY, V133, P586
   Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.E02-11-0753
   Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937
   Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194
   Kawasaki Y, 2013, CANCER SCI, V104, P1135, DOI 10.1111/cas.12180
   Kawasaki Y, 2010, J BIOL CHEM, V285, P1199, DOI 10.1074/jbc.M109.040691
   Kawasaki Y, 2009, J BIOL CHEM, V284, P22436, DOI 10.1074/jbc.M109.020768
   Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com
   Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Meliton AY, 2013, AM J PHYSIOL-LUNG C, V304, pL689, DOI 10.1152/ajplung.00047.2013
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200
   Poh YC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007886
   Quesnel C, 2008, AM J PHYSIOL-LUNG C, V294, pL334, DOI 10.1152/ajplung.00096.2007
   Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200
   Singleton PA, 2007, J BIOL CHEM, V282, P30643, DOI 10.1074/jbc.M702573200
   Stern JB, 2000, CRIT CARE MED, V28, P2326, DOI 10.1097/00003246-200007000-00024
   Storck J, 1996, THROMB RES, V81, P121, DOI 10.1016/0049-3848(95)00220-0
   Stultiens Audrey, 2012, Commun Integr Biol, V5, P99
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tian YF, 2014, MOL CELL BIOL, V34, P3546, DOI 10.1128/MCB.00248-14
   Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051
   Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7
   Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111
   Vouret-Craviari V, 2002, J CELL SCI, V115, P2475
   Waheed F, 2013, MOL BIOL CELL, V24, P1068, DOI 10.1091/mbc.E12-09-0661
   Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001
   Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783
   Weed SA, 1998, J CELL SCI, V111, P2433
   Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X
   Zebda N, 2013, J BIOL CHEM, V288, P18290, DOI 10.1074/jbc.M112.432757
   Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9
NR 63
TC 21
Z9 23
U1 2
U2 6
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD FEB 15
PY 2015
VL 26
IS 4
BP 636
EP 650
DI 10.1091/mbc.E14-02-0725
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CE6KJ
UT WOS:000351945000005
PM 25518936
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Li, YC
   Cao, YM
   Zeng, Z
   Liang, MF
   Xue, Y
   Xi, CH
   Zhou, M
   Jiang, W
AF Li, Yingchuan
   Cao, Yongmei
   Zeng, Zhen
   Liang, Mengfan
   Xue, Ying
   Xi, Caihua
   Zhou, Ming
   Jiang, Wei
TI Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents
   lipopolysaccharide-induced apoptosis of pulmonary microvascular
   endothelial cells by inhibiting JNK/NF-kappa B pathways
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LUNG INJURY INVOLVEMENT; TOLL-LIKE RECEPTOR; ALDOSTERONE SYSTEM;
   ACTIVATION; EXPRESSION; PROTECTS; FIBROSIS; ACE2; P38; CONTRIBUTES
AB ACE2 and Ang-(1-7) have important roles in preventing acute lung injury. However, it is not clear whether upregulation of the ACE2/Ang-(1-7)/Mas axis prevents LPS-induced injury in pulmonary microvascular endothelial cells (PMVECs) by inhibiting the MAPKs/NF-kappa B pathways. Primary cultured rat PMVECs were transduced with lentiviral-borne Ace2 or shRNA-Ace2, and then treated or not with Mas receptor blocker (A779) before exposure to LPS. LPS stimulation resulted in the higher levels of AngII, Ang-(1-7), cytokine secretion, and apoptosis rates, and the lower ACE2/ACE ratio. Ace2 reversed the ACE2/ACE imbalance and increased Ang-(1-7) levels, thus reducing LPS-induced apoptosis and inflammation, while inhibition of Ace2 reversed all these effects. A779 abolished these protective effects of Ace2. LPS treatment was associated with activation of the ERK, p38, JNK, and NF-kappa B pathways, which were aggravated by A779. Pretreatment with A779 prevented the Ace2-induced blockade of p38, JNK, and NF-kappa B phosphorylation. However, only JNK inhibitor markedly reduced apoptosis and cytokine secretion in PMVECs with Ace2 deletion and A779 pretreatment. These results suggest that the ACE2/Ang-(1-7)/Mas axis has a crucial role in preventing LPS-induced apoptosis and inflammation of PMVECs, by inhibiting the JNK/NF-kappa B pathways.
C1 [Li, Yingchuan; Cao, Yongmei; Zeng, Zhen; Liang, Mengfan; Xue, Ying; Xi, Caihua; Zhou, Ming; Jiang, Wei] Shanghai Jiao Tong Univ, Dept Anesthesiol, Peoples Hosp 6, Shanghai 200233, China.
C3 Shanghai Jiao Tong University
RP Jiang, W (corresponding author), Shanghai Jiao Tong Univ, Dept Anesthesiol, Peoples Hosp 6, Shanghai 200233, Peoples R China.
EM jiangw@sjtu.edu.cn
RI Zhou, Ming/HSD-2621-2023
FU National Nature Science Foundation of China [81272145]
FX This work was supported by the National Nature Science Foundation of
   China (No. 81272145).
CR Abraham E, 2003, J INFECT DIS, V187, pS364, DOI 10.1086/374750
   [Anonymous], 2012, EUR J PHARMACOL
   Asaduzzaman M, 2008, CRIT CARE MED, V36, P482, DOI 10.1097/01.CCM.0B013E31816204FA
   Badiei A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/848570
   BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Chen LN, 2013, SHOCK, V40, P420, DOI 10.1097/SHK.0b013e3182a6953e
   Cheng C, 2007, MOL CELL BIOCHEM, V305, P1, DOI 10.1007/s11010-007-9521-7
   Choi MS, 2007, EUR J PHARMACOL, V556, P181, DOI 10.1016/j.ejphar.2006.10.054
   Chou CH, 2013, MOL CELL ENDOCRINOL, V366, P21, DOI 10.1016/j.mce.2012.11.004
   de Man FS, 2012, AM J RESP CRIT CARE, V186, P780, DOI 10.1164/rccm.201203-0411OC
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Faffe DS, 2000, EUR RESPIR J, V15, P85, DOI 10.1034/j.1399-3003.2000.15a16.x
   Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037, DOI 10.1152/ajplung.2001.281.5.L1037
   Ferrario CM, 2010, AM J PHYSIOL-RENAL, V298, pF1297, DOI 10.1152/ajprenal.00110.2010
   Ferreira AJ, 2011, EXP PHYSIOL, V96, P287, DOI 10.1113/expphysiol.2010.055277
   Gallagher PE, 2008, AM J PHYSIOL-CELL PH, V295, pC1169, DOI 10.1152/ajpcell.00145.2008
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Klein N, 2013, CRIT CARE MED, V41, pE334, DOI 10.1097/CCM.0b013e31828a6688
   Lee VY, 2005, AM J PHYSIOL-LUNG C, V289, pL521, DOI 10.1152/ajplung.00340.2004
   Liu S, 2008, EUR J PHARMACOL, V584, P159, DOI 10.1016/j.ejphar.2008.02.009
   Meng Y, 2014, AM J RESP CELL MOL, V50, P723, DOI 10.1165/rcmb.2012-0451OC
   Phillips M Ian, 2002, Curr Opin Investig Drugs, V3, P569
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Santos RAS, 2013, J ENDOCRINOL, V216, pR1, DOI 10.1530/JOE-12-0341
   Schuh K, 2009, BIOCHEM PHARMACOL, V77, P1827, DOI 10.1016/j.bcp.2009.03.012
   Shen WF, 2009, PHARMACOL RES, V60, P296, DOI 10.1016/j.phrs.2009.04.007
   Shenoy V, 2010, AM J RESP CRIT CARE, V182, P1065, DOI 10.1164/rccm.200912-1840OC
   Siddiqui SS, 2007, AM J PHYSIOL-LUNG C, V292, pL114, DOI 10.1152/ajplung.00257.2005
   Song B, 2013, CIRC J, V77, P2997, DOI 10.1253/circj.CJ-13-0805
   Sukumaran V, 2011, INT J BIOL SCI, V7, P1077, DOI 10.7150/ijbs.7.1077
   Sun SX, 2011, CELL BIOCHEM BIOPHYS, V61, P123, DOI 10.1007/s12013-011-9168-6
   Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Togbe D, 2007, INT J EXP PATHOL, V88, P387, DOI 10.1111/j.1365-2613.2007.00566.x
   Uhal BD, 2011, AM J PHYSIOL-LUNG C, V301, pL269, DOI 10.1152/ajplung.00222.2010
   Wang YL, 2014, INT IMMUNOPHARMACOL, V23, P205, DOI 10.1016/j.intimp.2014.09.002
   Weir MR, 1999, AM J HYPERTENS, V12, p205S
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
   Zhong JC, 2010, CIRCULATION, V122, P717, DOI 10.1161/CIRCULATIONAHA.110.955369
   Zhou ZG, 2007, CELL SIGNAL, V19, P1238, DOI 10.1016/j.cellsig.2006.12.013
NR 49
TC 59
Z9 67
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 3
PY 2015
VL 5
AR 8209
DI 10.1038/srep08209
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA1XW
UT WOS:000348703200020
PM 25644821
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Brenner, JS
   Greineder, C
   Shuvaev, V
   Muzykantov, V
AF Brenner, Jacob S.
   Greineder, Colin F.
   Shuvaev, Vladimir V.
   Muzykantov, Vladimir R.
TI Endothelial nanomedicine for the treatment of pulmonary disease
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE ALI/ARDS; drug delivery; ECs/HPMECs/HUVECs/MPVECs; lung transplantation; nanomedicine; pulmonary arterial hypertension; primary graft dysfunction; pulmonary; pulmonary embolism; vascular targeting 
ID ANGIOTENSIN-CONVERTING-ENZYME; ISCHEMIA-REPERFUSION INJURY; ACUTE LUNG
   INJURY; INHALED NITRIC-OXIDE; RESPIRATORY-DISTRESS-SYNDROME;
   CELL-ADHESION MOLECULE-1; RIGHT-VENTRICULAR FUNCTION; PECAM-TARGETED
   DELIVERY; RHO-KINASE INHIBITOR; IN-VIVO
AB Introduction: Even though pulmonary diseases are among the leading causes of morbidity and mortality in the world, exceedingly few life-prolonging therapies have been developed for these maladies. Relief may finally come from nanomedicine and targeted drug delivery.
   Areas covered: Here, we focus on four conditions for which the pulmonary endothelium plays a pivotal role: acute respiratory distress syndrome, primary graft dysfunction occurring immediately after lung transplantation, pulmonary arterial hypertension and pulmonary embolism. For each of these diseases, we first evaluate the targeted drug delivery approaches that have been tested in animals. Then we suggest a 'need specification' for each disease: a list of criteria (e. g., macroscale delivery method, stability, etc.) that nanomedicine agents must meet in order to warrant human clinical trials and investment from industry.
   Expert opinion: For the diseases profiled here, numerous nanomedicine agents have shown promise in animal models. However, to maximize the chances of creating products that reach patients, nanomedicine engineers and clinicians must work together and use each disease's need specification to guide the design of practical and effective nanomedicine agents.
C1 [Brenner, Jacob S.; Greineder, Colin; Shuvaev, Vladimir; Muzykantov, Vladimir] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104, United States.
C1 [Brenner, Jacob S.; Greineder, Colin; Shuvaev, Vladimir; Muzykantov, Vladimir] Ctr Targeted Therapeut & Translat Nanomed, Philadelphia, PA 19104, United States.
C1 [Brenner, Jacob S.] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Dept Med, Philadelphia, PA 19104, United States.
C1 [Greineder, Colin] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104, United States.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine
RP Muzykantov, V (corresponding author), Univ Penn, Perelman Sch Med, Dept Pharmacol, TRC10-125,3600 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
RI Shuvaev, Vladimir V/O-1719-2014; Brenner, Jacob/Y-2030-2018
OI Brenner, Jacob/0000-0001-8437-0161; Greineder, Colin/0000-0001-9740-7672
FU NHLBI NIH HHS [F32 HL129665, R01 HL087036, R01 HL125462] Funding Source:
   Medline
CR Afshari A, 2011, ANESTH ANALG, V112, P1411, DOI 10.1213/ANE.0b013e31820bd185
   Aird WC, 2008, PHARMACOL REP, V60, P139
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195
   ALMENARQUERALT A, 1995, AM J PATHOL, V147, P1278
   ALPERT JS, 1978, CHEST, V73, P795, DOI 10.1378/chest.73.6.795
   Ameshima S, 2003, CIRC RES, V92, P1162, DOI 10.1161/01.RES.0000073585.50092.14
   Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Ardehali A, 2001, TRANSPLANTATION, V72, P112, DOI 10.1097/00007890-200107150-00022
   Atochina EN, 1998, AM J PHYSIOL-LUNG C, V275, pL806, DOI 10.1152/ajplung.1998.275.4.L806
   Balyasnikova IV, 2006, TISSUE ANTIGENS, V67, P10, DOI 10.1111/j.1399-0039.2005.00516.x
   Becattini C, 2008, THROMB HAEMOSTASIS, V100, P747, DOI 10.1160/TH08-06-0356
   Bellingan G, 2014, LANCET RESP MED, V2, P98, DOI 10.1016/S2213-2600(13)70259-5
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Boldt J, 1996, J CARDIOTHOR VASC AN, V10, P854, DOI 10.1016/S1053-0770(96)80045-0
   Bonnet S, 2007, P NATL ACAD SCI USA, V104, P11418, DOI 10.1073/pnas.0610467104
   Bottiger BW, 1996, CHEST, V110, P1041, DOI 10.1378/chest.110.4.1041
   Caironi P, 2005, AM J RESP CRIT CARE, V172, P334, DOI 10.1164/rccm.200501-034OC
   Chacko AM, 2011, CURR OPIN COLLOID IN, V16, P215, DOI 10.1016/j.cocis.2011.01.008
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chen L, 2011, HYPERTENSION, V57, P343, DOI 10.1161/HYPERTENSIONAHA.110.157032
   Chen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058275
   Christofidou-Solomidou M, 2002, AM J PATHOL, V160, P1155, DOI 10.1016/S0002-9440(10)64935-8
   Cook-Mills JM, 2011, ANTIOXID REDOX SIGN, V15, P1607, DOI 10.1089/ars.2010.3522
   Crosswhite P, 2014, MOL MED, V20, P191, DOI 10.2119/molmed.2013.00165
   Cypel M, 2011, NEW ENGL J MED, V364, P1431, DOI 10.1056/NEJMoa1014597
   Dahal BK, 2010, AM J RESP CRIT CARE, V181, P158, DOI 10.1164/rccm.200811-1682OC
   DANILOV S, 1994, INT IMMUNOL, V6, P1153, DOI 10.1093/intimm/6.8.1153
   Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335, DOI 10.1152/ajplung.2001.280.6.L1335
   DANILOV SM, 1989, J NUCL MED, V30, P1686
   de Oliveira IS, 2008, CLINICS, V63, P77, DOI 10.1590/S1807-59322008000100014
   Dias-Junior CA, 2005, PULM PHARMACOL THER, V18, P181, DOI 10.1016/j.pupt.2004.11.010
   Dichek DA, 1996, CIRCULATION, V93, P301, DOI 10.1161/01.CIR.93.2.301
   Diepenhorst GMP, 2009, ANN SURG, V249, P889, DOI 10.1097/SLA.0b013e3181a38f45
   Ding BS, 2008, BLOOD, V111, P1999, DOI 10.1182/blood-2007-07-103002
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   Ding BS, 2005, BLOOD, V106, P4191, DOI 10.1182/blood-2005-05-2002
   Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143
   Dixon JT, 2012, ARCH PHYSIOL BIOCHEM, V118, P72, DOI 10.3109/13813455.2012.665463
   Dziubla TD, 2005, J CONTROL RELEASE, V102, P427, DOI 10.1016/j.jconrel.2004.10.017
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   EPPINGER MJ, 1995, J SURG RES, V58, P713, DOI 10.1006/jsre.1995.1112
   ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164
   Ewert R, 2012, AM J RESP CRIT CARE, V186, P1196, DOI 10.1164/ajrccm.186.11.1196
   Fan J, 2000, SURGERY, V128, P332, DOI 10.1067/msy.2000.108060
   FORD VA, 1992, J BIOL CHEM, V267, P5446
   Fujita H, 2010, HEART VESSELS, V25, P144, DOI 10.1007/s00380-009-1176-8
   Garnacho C, 2008, J CONTROL RELEASE, V130, P226, DOI 10.1016/j.jconrel.2008.06.007
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   GOLDMAN G, 1995, SURGERY, V117, P83, DOI 10.1016/S0039-6060(05)80233-8
   Greineder CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080110
   Greineder CF, 2013, BLOOD, V122, P1565, DOI 10.1182/blood-2013-03-453498
   Gupta V, 2013, J CONTROL RELEASE, V167, P189, DOI 10.1016/j.jconrel.2013.01.011
   Han JY, 2011, J PHARMACOL EXP THER, V338, P82, DOI 10.1124/jpet.111.180620
   Harari OA, 1999, GENE THER, V6, P801, DOI 10.1038/sj.gt.3300898
   Hegeman MA, 2011, BRIT J PHARMACOL, V163, P1048, DOI 10.1111/j.1476-5381.2011.01314.x
   Herber-Jonat S, 2011, INFLAMM RES, V60, P245, DOI 10.1007/s00011-010-0260-y
   Hoeper MM, 2013, CIRCULATION, V127, P1128, DOI 10.1161/CIRCULATIONAHA.112.000765
   Hood E, 2011, NANOMEDICINE-UK, V6, P1257, DOI [10.2217/NNM.11.92, 10.2217/nnm.11.92]
   Hood ED, 2014, BIOMATERIALS, V35, P3708, DOI 10.1016/j.biomaterials.2014.01.023
   Hood ED, 2012, J CONTROL RELEASE, V163, P161, DOI 10.1016/j.jconrel.2012.08.031
   Howard MD, 2014, J CONTROL RELEASE, V177, P34, DOI 10.1016/j.jconrel.2013.12.035
   Howard MD, 2014, ANNU REV PHARMACOL, V54, P205, DOI 10.1146/annurev-pharmtox-011613-140002
   Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547
   ISCHIROPOULOS H, 1995, AM J PHYSIOL-LUNG C, V269, pL158, DOI 10.1152/ajplung.1995.269.2.L158
   Ito K, 2004, EUR J CARDIO-THORAC, V25, P530, DOI 10.1016/j.ejcts.2003.12.017
   Izikki M, 2009, J CLIN INVEST, V119, P512, DOI 10.1172/JCI35070
   Jarvinen TAH, 2007, AM J PATHOL, V171, P702, DOI 10.2353/ajpath.2007.061251
   Jurek SC, 2014, AM J RESP CELL MOL, V50, P1107, DOI 10.1165/rcmb.2013-0163OC
   Kaynar AM, 2008, AM J RESP CELL MOL, V39, P53, DOI 10.1165/rcmb.2007-0315OC
   KEELAN ETM, 1994, J NUCL MED, V35, P276
   Kelly KA, 2005, CIRC RES, V96, P327, DOI 10.1161/01.RES.0000155722.17881.dd
   KENNEL SJ, 1990, NUCL MED BIOL, V17, P193, DOI 10.1016/0883-2897(90)90147-S
   Kermeen FD, 2007, J HEART LUNG TRANSPL, V26, P850, DOI 10.1016/j.healun.2007.05.016
   Keshavjee S, 2005, J THORAC CARDIOV SUR, V129, P423, DOI 10.1016/j.jtcvs.2004.06.048
   Kessner S, 2001, BBA-BIOMEMBRANES, V1514, P177, DOI 10.1016/S0005-2736(01)00368-6
   KIELY JM, 1995, ARTERIOSCL THROM VAS, V15, P1211, DOI 10.1161/01.ATV.15.8.1211
   Kimura S, 2009, HYPERTENSION, V53, P877, DOI 10.1161/HYPERTENSIONAHA.108.121418
   Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7
   Kok RJ, 2002, PHARM RES-DORDR, V19, P1730, DOI 10.1023/A:1020769716288
   Kooter AJ, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-18
   Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806
   KUIJPERS TW, 1994, J IMMUNOL, V152, P5060
   Lakshminarayana PH, 2012, CRIT CARE, V16, DOI [10.1186/CC11392, 10.1186/cc11392]
   Leucuta SE, 2013, CURR DRUG DELIV, V10, P208
   Lin BW, 2012, AM J EMERG MED, V30, P1774, DOI 10.1016/j.ajem.2012.02.012
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   LYNCH MJ, 1988, J SURG RES, V44, P538, DOI 10.1016/0022-4804(88)90159-X
   Maeda H, 2012, J CONTROL RELEASE, V164, P138, DOI 10.1016/j.jconrel.2012.04.038
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398
   Metzger R, 2011, MICROVASC RES, V81, P206, DOI 10.1016/j.mvr.2010.12.003
   Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097
   Miller RL, 1998, CHEST, V113, P665, DOI 10.1378/chest.113.3.665
   Miller WH, 2005, MOL THER, V12, P321, DOI 10.1016/j.ymthe.2005.02.025
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Mitsopoulos P, 2008, INT J PHARMACEUT, V363, P106, DOI 10.1016/j.ijpharm.2008.07.015
   Mizuno S, 2012, AM J RESP CELL MOL, V47, P679, DOI 10.1165/rcmb.2012-0077OC
   Morecroft I, 2012, MOL THER, V20, P1516, DOI 10.1038/mt.2012.70
   Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477
   Mulivor AW, 2002, AM J PHYSIOL-HEART C, V283, pH1282, DOI 10.1152/ajpheart.00117.2002
   MULLER DWM, 1994, CIRC RES, V75, P1039, DOI 10.1161/01.RES.75.6.1039
   Murciano JC, 2003, BLOOD, V101, P3977, DOI 10.1182/blood-2002-09-2853
   Murciano JC, 2001, AM J RESP CRIT CARE, V164, P1295, DOI 10.1164/ajrccm.164.7.2010076
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muro S, 2005, BLOOD, V105, P650, DOI 10.1182/blood-2004-05-1714
   Muro S, 2003, AM J PHYSIOL-CELL PH, V285, pC1339, DOI 10.1152/ajpcell.00099.2003
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muro Silvia, 2004, V283, P21
   Muro Silvia, 2004, Current Vascular Pharmacology, V2, P281, DOI 10.2174/1570161043385736
   Murohara T, 1996, J IMMUNOL, V156, P3550
   Muzykantov V.R., 1995, TARGETED DELIVERY IM, P465
   Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213
   MUZYKANTOV VR, 1991, J NUCL MED, V32, P453
   Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2
   Muzykantov VR, 1996, AM J PHYSIOL-LUNG C, V270, pL704, DOI 10.1152/ajplung.1996.270.5.L704
   MUZYKANTOV VR, 1989, AM REV RESPIR DIS, V139, P1464, DOI 10.1164/ajrccm/139.6.1464
   Muzykantov VR, 1996, J PHARMACOL EXP THER, V279, P1026
   Muzykantov VR, 1998, PATHOPHYSIOLOGY, V5, P15, DOI DOI 10.1016/S0928-4680(98)00006-6
   Nakada MT, 2000, J IMMUNOL, V164, P452, DOI 10.4049/jimmunol.164.1.452
   NEWMAN PJ, 1992, NOUV REV FR HEMATOL, V34, pS9
   Novick RJ, 1996, AM J RESP CRIT CARE, V154, P98, DOI 10.1164/ajrccm.154.1.8680706
   Nowak K, 2007, AM J PHYSIOL-LUNG C, V293, pL162, DOI 10.1152/ajplung.00001.2007
   Nowak K, 2013, ADV EXP MED BIOL, V756, P203, DOI 10.1007/978-94-007-4549-0_26
   Nowak K, 2010, EUR J CARDIO-THORAC, V37, P859, DOI 10.1016/j.ejcts.2009.10.029
   Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580
   Oh P, 2007, NAT BIOTECHNOL, V25, P327, DOI 10.1038/nbt1292
   Pan H, 2013, FASEB J, V27, P255, DOI 10.1096/fj.12-218081
   Parikh SM, 2013, VIRULENCE, V4, P517, DOI 10.4161/viru.24906
   Pasqualini R, 2001, NAT IMMUNOL, V2, P567, DOI 10.1038/89704
   Pasqualini R, 2010, SEMIN THROMB HEMOST, V36, P343, DOI 10.1055/s-0030-1253456
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC
   Perros F, 2008, AM J RESP CRIT CARE, V178, P81, DOI 10.1164/rccm.200707-1037OC
   Perry JL, 2011, ACCOUNTS CHEM RES, V44, P990, DOI 10.1021/ar2000315
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Preissler G, 2011, TRANSPLANTATION, V92, P380, DOI 10.1097/TP.0b013e318226bc6b
   Pugh ME, 2013, CLIN CHEST MED, V34, P841, DOI 10.1016/j.ccm.2013.08.007
   Pullamsetti SS, 2012, AM J RESP CRIT CARE, V185, P409, DOI 10.1164/rccm.201106-1093OC
   Rai PR, 2008, AM J RESP CRIT CARE, V178, P558, DOI 10.1164/rccm.200709-1369PP
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Reynolds AM, 2012, EUR RESPIR J, V39, P329, DOI 10.1183/09031936.00187310
   Reynolds AM, 2007, AM J PHYSIOL-LUNG C, V292, pL1182, DOI 10.1152/ajplung.00020.2006
   Reynolds PN, 2011, EXPERT OPIN BIOL TH, V11, P133, DOI 10.1517/14712598.2011.542139
   Reynolds PN, 2001, NAT BIOTECHNOL, V19, P838, DOI 10.1038/nbt0901-838
   Reynolds PN, 2000, MOL THER, V2, P562, DOI 10.1006/mthe.2000.0205
   Rocksen D, 2003, AM J RESP CELL MOL, V28, P199, DOI 10.1165/rcmb.4899
   ROMER LH, 1995, J IMMUNOL, V154, P6582
   Ryan JJ, 2013, HANDB EXP PHARMACOL, V218, P105, DOI 10.1007/978-3-642-38664-0_5
   SAKUMA T, 1994, AM J RESP CRIT CARE, V150, P305, DOI 10.1164/ajrccm.150.2.8049807
   Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777
   Schnitzer JE, 1998, NEW ENGL J MED, V339, P472, DOI 10.1056/NEJM199808133390711
   Schoepf UJ, 2004, CIRCULATION, V110, P3276, DOI 10.1161/01.CIR.0000147612.59751.4C
   Schutte H, 2001, TRANSPLANTATION, V72, P1363
   Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999
   Shuvaev VV, 2007, J CONTROL RELEASE, V118, P235, DOI 10.1016/j.jconrel.2006.12.025
   Shuvaev VV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077002
   Shuvaev VV, 2011, ACS NANO, V5, P6991, DOI 10.1021/nn2015453
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877
   Shyamsundar M, 2014, AM J RESP CRIT CARE, V189, P1520, DOI 10.1164/rccm.201310-1892OC
   Simone EA, 2009, BIOMACROMOLECULES, V10, P1324, DOI 10.1021/bm900189x
   Simone EA, 2009, PHARM RES-DORD, V26, P250, DOI 10.1007/s11095-008-9744-7
   Singleton PA, 2007, AM J RESP CELL MOL, V37, P222, DOI 10.1165/rcmb.2006-0327OC
   SKIDGEL RA, 1992, J CARDIOVASC PHARM, V20, pS4, DOI 10.1097/00005344-199200209-00003
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   Staquicini FI, 2011, P NATL ACAD SCI USA, V108, P18637, DOI 10.1073/pnas.1114503108
   Steiner MK, 2009, CIRC RES, V104, P236, DOI 10.1161/CIRCRESAHA.108.182014
   Straley KS, 2000, J CELL BIOL, V151, P107, DOI 10.1083/jcb.151.1.107
   Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057
   Suntres ZE, 1998, J DRUG TARGET, V6, P175, DOI 10.3109/10611869808997891
   Suntres ZE, 2000, BIOCHEM PHARMACOL, V59, P1155, DOI 10.1016/S0006-2952(99)00411-6
   Suzuki Y, 2013, SEMIN RESP CRIT CARE, V34, P305, DOI 10.1055/s-0033-1348474
   Sweitzer TD, 2003, FREE RADICAL BIO MED, V34, P1035, DOI 10.1016/S0891-5849(03)00029-7
   Szebeni J, 2012, ADV DRUG DELIVER REV, V64, P1706, DOI 10.1016/j.addr.2012.07.005
   ten Wolde M, 2004, ARCH INTERN MED, V164, P1685, DOI 10.1001/archinte.164.15.1685
   Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027
   Toba M, 2014, AM J PATHOL, V184, P369, DOI 10.1016/j.ajpath.2013.10.008
   TODD MH, 1983, AM HEART J, V105, P769, DOI 10.1016/0002-8703(83)90239-9
   Treml B, 2010, CRIT CARE MED, V38, P596, DOI 10.1097/CCM.0b013e3181c03009
   TRUBETSKOY VS, 1992, BIOCONJUGATE CHEM, V3, P323, DOI 10.1021/bc00016a011
   Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e
   UENO Y, 1995, THROMB RES, V77, P193, DOI 10.1016/0049-3848(95)91625-U
   Urakami T, 2011, AM J PATHOL, V178, P2489, DOI 10.1016/j.ajpath.2011.02.032
   van den Hoven JM, 2013, EUR J PHARM SCI, V49, P265, DOI 10.1016/j.ejps.2013.03.007
   Venkataraman S, 2011, ADV DRUG DELIVER REV, V63, P1228, DOI 10.1016/j.addr.2011.06.016
   Voelkel NF, 2012, EUR RESPIR J, V40, P1555, DOI 10.1183/09031936.00046612
   VONASMUTH EJU, 1992, EUR J IMMUNOL, V22, P2519, DOI 10.1002/eji.1830221009
   Wang ZJ, 2011, IUBMB LIFE, V63, P659, DOI 10.1002/iub.485
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Watts JA, 2013, PULM PHARMACOL THER, V26, P205, DOI 10.1016/j.pupt.2012.10.009
   Waxman AB, 2008, ARCH INTERN MED, V168, P2164, DOI 10.1001/archinte.168.19.2164
   Xia ZY, 2007, INJURY, V38, P53, DOI 10.1016/j.injury.2006.09.021
   Yamashita CM, 2012, EXPERT OPIN EMERG DR, V17, P1, DOI 10.1517/14728214.2012.667800
   Yin YJ, 2013, PHARM RES-DORDR, V30, P2050, DOI 10.1007/s11095-013-1058-8
   Zenios SA, 2009, BIODESIGN THE PROCES
   Zhao L, 2012, CIRCULATION, V126, P455, DOI 10.1161/CIRCULATIONAHA.112.103176
   Zhou ZY, 2014, J SURG RES, V188, P290, DOI 10.1016/j.jss.2013.11.1086
NR 208
TC 34
Z9 35
U1 0
U2 46
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD FEB
PY 2015
VL 12
IS 2
BP 239
EP 261
DI 10.1517/17425247.2015.961418
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AZ3QW
UT WOS:000348142800007
PM 25394760
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Gong, HX
   Rehman, J
   Tang, HY
   Wary, K
   Mittal, M
   Chatturvedi, P
   Zhao, YY
   Komorova, YA
   Vogel, SM
   Malik, AB
AF Gong, Haixia
   Rehman, Jalees
   Tang, Haiyang
   Wary, Kishore
   Mittal, Manish
   Chatturvedi, Pallavi
   Zhao, Youyang
   Komorova, Yulia A.
   Vogel, Stephen M.
   Malik, Asrar B.
TI HIF2 alpha signaling inhibits adherens junctional disruption in acute
   lung injury
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR; RESPIRATORY-DISTRESS-SYNDROME; VE-CADHERIN;
   ENDOTHELIAL-CELLS; LEUKOCYTE EXTRAVASATION; VASCULAR-PERMEABILITY;
   ALVEOLAR HYPOXIA; BARRIER FUNCTION; FACTOR 1-ALPHA; IN-VIVO
AB Vascular endothelial barrier dysfunction underlies diseases such as acute respiratory distress syndrome (ARDS), characterized by edema and inflammatory cell infiltration. The transcription factor HIF2 alpha is highly expressed in vascular endothelial cells (ECs) and may regulate endothelial barrier function. Here, we analyzed promoter sequences of genes encoding proteins that regulate adherens junction (AJ) integrity and determined that vascular endothelial protein tyrosine phosphatase (VE-PTP) is a HIF2 alpha target HIF2 alpha-induced VE-PTP expression enhanced dephosphorylation of VE-cadherin, which reduced VE-cadherin endocytosis and thereby augmented AJ integrity and endothelial barrier function. Mice harboring an EC-specific deletion of Hif2 alpha exhibited decreased VE-PTP expression and increased VE-cadherin phosphorylation, resulting in defective AJs. Mice lacking HIF2 alpha in ECs had increased lung vascular permeability and water content, both of which were further exacerbated by endotoxin-mediated injury. Treatment of these mice with Fg4497, a prolyl hydroxylase domain 2 (PHD2) inhibitor, activated HIF2 alpha-mediated transcription in a hypoxia-independent manner. HIF2 alpha activation increased VE-PTP expression, decreased VE-cadherin phosphorylation, promoted AJ integrity, and prevented the loss of endothelial barrier function. These findings demonstrate that HIF2 alpha enhances endothelial barrier integrity, in part through VE-PTP expression and the resultant VE-cadherin dephosphorylation-mediated assembly of AJs. Moreover, activation of HIF2 alpha/VE-PTP signaling via PHD2 inhibition has the potential to prevent the formation of leaky vessels and edema in inflammatory diseases such as ARDS.
C1 [Gong, Haixia; Rehman, Jalees; Tang, Haiyang; Wary, Kishore; Mittal, Manish; Chatturvedi, Pallavi; Zhao, Youyang; Komorova, Yulia A.; Vogel, Stephen M.; Malik, Asrar B.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Gong, Haixia; Rehman, Jalees; Tang, Haiyang; Wary, Kishore; Mittal, Manish; Chatturvedi, Pallavi; Zhao, Youyang; Komorova, Yulia A.; Vogel, Stephen M.; Malik, Asrar B.] Univ Illinois, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C1 [Rehman, Jalees] Univ Illinois, Dept Med, Cardiol Sect, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Malik, AB (corresponding author), Univ Illinois, Dept Pharmacol, 835 South Wolcott Ave, Chicago, IL 60612 USA.
EM jalees@uic.edu; abmalik@uic.edu
RI Rehman, Jalees/GVU-1981-2022; TANG, HAIYANG/J-4006-2013; Rehman,
   Jalees/J-8258-2012
OI Rehman, Jalees/0000-0002-2787-9292; Rehman, Jalees/0000-0002-2787-9292;
   ZHAO, YOU-YANG/0000-0002-0041-0339; Wary, Kishore/0000-0001-8851-8565;
   Malik, Asrar/0000-0002-8205-7128
FU NIH [P01 HL60678, R01 HL45638, R01HL118068, R01 GM094220]; AHA
   [13SDG16910050]
FX The studies were supported by NIH grants P01 HL60678, R01 HL45638,
   R01HL118068, and R01 GM094220, and by AHA grant 13SDG16910050.
CR Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200
   Bernhardt WM, 2010, J AM SOC NEPHROL, V21, P2151, DOI 10.1681/ASN.2010010116
   BLAND RD, 1977, CIRC RES, V40, P269, DOI 10.1161/01.RES.40.3.269
   Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427
   BRESSACK MA, 1980, CIRC RES, V46, P111, DOI 10.1161/01.RES.46.1.111
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Farahani RM, 2012, J COMP NEUROL, V520, P3803, DOI 10.1002/cne.23162
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164
   Gong HX, 2014, J EXP MED, V211, P579, DOI 10.1084/jem.20131190
   Gong HX, 2010, SCIENCE, V327, P340, DOI 10.1126/science.1174779
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683
   He K, 2014, KIDNEY INT, V85, P276, DOI 10.1038/ki.2013.342
   Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200
   Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kapitsinou PP, 2014, J CLIN INVEST, V124, P2396, DOI 10.1172/JCI69073
   Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300
   Komarova Yulia A, 2007, Sci STKE, V2007, pre8
   Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150
   Kuppers V, 2014, CELL TISSUE RES, V355, P577, DOI 10.1007/s00441-014-1812-1
   Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566
   Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Nottebaum AF, 2008, J EXP MED, V205, P2929, DOI 10.1084/jem.20080406
   OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Pipeling MR, 2010, JAMA-J AM MED ASSOC, V304, P2521, DOI 10.1001/jama.2010.1752
   Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033
   Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2009, ANN NY ACAD SCI, V1177, P2, DOI 10.1111/j.1749-6632.2009.05032.x
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581
   Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026
   Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320
   Vestweber D, 2014, SEMIN IMMUNOPATHOL, V36, P177, DOI 10.1007/s00281-014-0419-7
   Vockel M, 2013, BLOOD, V122, P2512, DOI 10.1182/blood-2013-04-499228
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159
   Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001
   Yacyshyn OK, 2009, ANGIOGENESIS, V12, P25, DOI 10.1007/s10456-008-9126-0
   Yuan GX, 2013, P NATL ACAD SCI USA, V110, pE1788, DOI 10.1073/pnas.1305961110
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
NR 54
TC 92
Z9 93
U1 1
U2 22
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2015
VL 125
IS 2
BP 652
EP 664
DI 10.1172/JCI77701
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CA5QK
UT WOS:000348962700022
PM 25574837
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Letsiou, E
   Rizzo, AN
   Sammani, S
   Naureckas, P
   Jacobson, JR
   Garcia, JGN
   Dudek, SM
AF Letsiou, Eleftheria
   Rizzo, Alicia N.
   Sammani, Saad
   Naureckas, P.
   Jacobson, Jeffrey R.
   Garcia, Joe G. N.
   Dudek, Steven M.
TI Differential and opposing effects of imatinib on LPS- and
   ventilator-induced lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; ventilator-induced lung injury; imatinib; c-Abl; Arginine; LPS; stretch; ECs/HPMECs/HUVECs/MPVECs; permeability 
ID ABL TYROSINE KINASE; FACTOR-KAPPA-B; FAMILY KINASES; PERIORBITAL EDEMA;
   BARRIER FUNCTION; MECHANISMS; ACTIVATION; STRETCH; INHIBITORS; RESPONSES
AB Endothelial dysfunction underlies the pathophysiology of vascular disorders such as acute lung injury (ALI) syndromes. Recent work has identified the Abl family kinases (c-Abl and Arg) as important regulators of endothelial cell (EC) barrier function and suggests that their inhibition by currently available pharmaceutical agents such as imatinib may be EC protective. Here we describe novel and differential effects of imatinib in regulating lung pathophysiology in two clinically relevant experimental models of ALI. Imatinib attenuates endotoxin (LPS)-induced vascular leak and lung inflammation in mice but exacerbates these features in a mouse model of ventilator-induced lung injury (VILI). We next explored these discrepant observations in vitro through investigation of the roles for Abl kinases in cultured lung EC. Imatinib attenuates LPS-induced lung EC permeability, restores VE-cadherin junctions, and reduces inflammation by suppressing VCAM-1 expression and inflammatory cytokine (IL-8 and IL-6) secretion. Conversely, in EC exposed to pathological 18% cyclic stretch (CS) (in vitro model of VILI), imatinib decreases VE-cadherin expression, disrupts cell-cell junctions, and increases IL-8 levels. Downregulation of c-Abl expression with siRNA attenuates LPS-induced VCAM-1 expression, whereas specific reduction of Arg reduces VE-cadherin expression in 18% CS-challenged ECs to mimic the imatinib effects. In summary, imatinib exhibits pulmonary barrier-protective and anti-inflammatory effects in LPS-injured mice and lung EC; however, imatinib exacerbates VILI as well as dysfunction in 18% CS-EC. These findings identify the Abl family kinases as important modulators of EC function and potential therapeutic targets in lung injury syndromes.
C1 [Letsiou, E.; Rizzo, A. N.; Sammani, S.; Naureckas, P.; Jacobson, J. R.; Dudek, S. M.] Univ Illinois, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60680, United States.
C1 [Garcia, J. G. N.] Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ 85721, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona Health Sciences
RP Dudek, SM (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, CSB 915,840 S Wood St, Chicago, IL 60612 USA.
EM sdudek@uic.edu
RI Garcia, Joe GN/E-8862-2010
OI Rizzo, Alicia/0000-0001-9289-4635
FU National Heart, Lung, and Blood Institute [HL058064]; American Heart
   Association [14PRE18860021]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grant HL058064 (J. G. N. Garcia) and American Heart Association Grant
   14PRE18860021 (A. N. Rizzo).
CR Aman J, 2013, AM J RESP CRIT CARE, V188, P1171, DOI 10.1164/rccm.201301-0136LE
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Amma H, 2005, BRIT J PHARMACOL, V145, P364, DOI 10.1038/sj.bjp.0706182
   Baron F, 2002, BLOOD, V99, P2107, DOI 10.1182/blood.V99.6.2107
   Berlin AA, 2005, AM J RESP CRIT CARE, V171, P35, DOI 10.1164/rccm.200403-385OC
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Chislock EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085231
   Chislock EM, 2013, P NATL ACAD SCI USA, V110, P12432, DOI 10.1073/pnas.1304188110
   Ciarcia R, 2012, J CELL PHYSIOL, V227, P2798, DOI 10.1002/jcp.23029
   Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6
   Contreras M, 2012, CRIT CARE MED, V40, P2622, DOI 10.1097/CCM.0b013e318258f8b4
   Dejana E, 2013, J CELL SCI, V126, P2545, DOI 10.1242/jcs.124529
   Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645
   dos Santos LV, 2013, J NATL COMPR CANC NE, V11, P1187, DOI 10.6004/jnccn.2013.0140
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Esmaeli B, 2004, EYE, V18, P760, DOI 10.1038/sj.eye.6701315
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gavard J, 2009, FEBS LETT, V583, P1, DOI 10.1016/j.febslet.2008.11.032
   Gawlak G, 2014, FASEB J, V28, P3249, DOI 10.1096/fj.13-245142
   Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563
   Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9-3-271
   Halbertsma FJJ, 2005, NETH J MED, V63, P382
   Held HD, 2001, AM J RESP CRIT CARE, V163, P711, DOI 10.1164/ajrccm.163.3.2003001
   Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003
   Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje
   Iwaki M, 2009, BIOCHEM BIOPH RES CO, V389, P531, DOI 10.1016/j.bbrc.2009.09.020
   Kim IK, 2013, CRIT CARE, V17, DOI 10.1186/cc12786
   Ko YA, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-69
   Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667
   Ma SF, 2011, AM J RESP CELL MOL, V45, P1203, DOI 10.1165/rcmb.2011-0179OC
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McClelland CM, 2010, CLIN OPHTHALMOL, V4, P427
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Moen MD, 2007, DRUGS, V67, P299, DOI 10.2165/00003495-200767020-00010
   Moreno-Vinasco L, 2014, AM J RESP CELL MOL, V51, P223, DOI 10.1165/rcmb.2012-0519OC
   Muller WA, 2009, CIRC RES, V105, P223, DOI 10.1161/CIRCRESAHA.109.200717
   Nagar B, 2007, J NUTR, V137, p1518S, DOI 10.1093/jn/137.6.1518S
   Ning QM, 2007, RESPIROLOGY, V12, P792, DOI 10.1111/j.1440-1843.2007.01166.x
   Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440
   Ostro D, 2007, LEUKEMIA LYMPHOMA, V48, P195, DOI 10.1080/10428190600923157
   Peacock JG, 2010, CYTOSKELETON, V67, P666, DOI 10.1002/cm.20479
   Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5
   Plataki Maria, 2010, Expert Rev Respir Med, V4, P373, DOI 10.1586/ers.10.28
   Rhee CK, 2011, RESPIRATION, V82, P273, DOI 10.1159/000327719
   Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061
   Schouten M, 2008, J LEUKOCYTE BIOL, V83, P536, DOI 10.1189/jlb.0607373
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Stephens RS, 2014, AM J PHYSIOL-CELL PH, V306, pC559, DOI 10.1152/ajpcell.00375.2012
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wolf AM, 2005, P NATL ACAD SCI USA, V102, P13622, DOI 10.1073/pnas.0501758102
   Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622
   Zandy NL, 2007, P NATL ACAD SCI USA, V104, P17686, DOI 10.1073/pnas.0703077104
NR 63
TC 47
Z9 49
U1 0
U2 14
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD FEB 1
PY 2015
VL 308
IS 3
BP L259
EP L269
DI 10.1152/ajplung.00323.2014
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA CB0GU
UT WOS:000349304700003
PM 25480336
OA Green Published
DA 2023-08-21
ER

PT J
AU Letsiou, E
   Sammani, S
   Zhang, W
   Zhou, T
   Quijada, H
   Moreno-Vinasco, L
   Dudek, SM
   Garcia, JGN
AF Letsiou, Eleftheria
   Sammani, Saad
   Zhang, Wei
   Zhou, Tong
   Quijada, Hector
   Moreno-Vinasco, Liliana
   Dudek, Steven M.
   Garcia, Joe G. N.
TI Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung
   Endothelial Microparticle Shedding
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE microparticles; ventilator-induced lung injury; cyclic stretch; LPS; proteomics 
ID RESPIRATORY-DISTRESS-SYNDROME; CIRCULATING MICROPARTICLES; CYCLIC
   STRETCH; IN-VITRO; INJURY; CELLS; DISEASE; DYSFUNCTION; PLASMA;
   EZRIN/RADIXIN/MOESIN
AB Acute lung injury (ALI) results from infectious challenges and from pathologic lung distention produced by excessive tidal volume delivered during mechanical ventilation (ventilator-induced lung injury [VILI]) and is characterized by extensive alveolar and vascular dysfunction. Identification of novel ALI therapies is hampered by the lack of effective ALI/VILI biomarkers. We explored endothelial cell (EC)-derived microparticles (EMPs) (0.1-1 mm) as potentially important markers and potential mediators of lung vascular injury in preclinical models of ALI and VILI. We characterized EMPs(annexin V and CD31 immunoreactivity) produced from human lung ECs exposed to physiologic or pathologic mechanical stress (5 or 18% cyclic stretch [CS]) or to endotoxin (LPS). EC exposure to 18% CS or to LPS resulted in increased EMP shedding compared with static cells (similar to 4-fold and similar to 2.5-fold increases, respectively). Proteomic analysis revealed unique 18% CS-derived (n = 10) and LPS-derived EMP proteins (n = 43). VILI-challenged mice (40 ml/kg, 4 h) exhibited increased plasma and bronchoalveolar lavage CD62E (E-selectin)-positive MPs compared with control mice. Finally, mice receiving intratracheal instillation of 18% CS-derived EMPs displayed significant lung inflammation and injury. These findings indicate that ALI/VILI-producing stimuli induce significant shedding of distinct EMP populations that may serve as potential ALI biomarkers and contribute to the severity of lung injury.
C1 [Letsiou, Eleftheria; Sammani, Saad; Moreno-Vinasco, Liliana; Dudek, Steven M.] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C1 [Zhang, Wei] Univ Illinois, Dept Pediat, Chicago, IL, United States.
C1 [Zhang, Wei] Univ Illinois, Inst Human Genet, Chicago, IL, United States.
C1 [Zhou, Tong; Quijada, Hector; Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ 85721, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona
RP Garcia, JGN (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Drachman Hall,Room B-207,1295 North Martin Ave, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
FU National Heart, Lung and Blood Institute/National Institutes of Health
   [HL058064, HL98050, HL94394]; American Heart Association
   [13POST17110042]
FX This work was supported by National Heart, Lung and Blood
   Institute/National Institutes of Health grants HL058064, HL98050, and
   HL94394 (J.G.N.G.) and by Midwest Postdoctoral fellowship 13POST17110042
   from the American Heart Association (E.L.).
CR Adyshev DM, 2013, AM J PHYSIOL-LUNG C, V305, P1240, DOI 10.1152/ajplung.00355.2012
   Adyshev DM, 2011, CELL SIGNAL, V23, P2086, DOI 10.1016/j.cellsig.2011.08.003
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Banfi C, 2005, PROTEOMICS, V5, P4443, DOI 10.1002/pmic.200402017
   Bastarache JA, 2009, AM J PHYSIOL-LUNG C, V297, pL1035, DOI 10.1152/ajplung.00214.2009
   Belizaire RM, 2012, J AM COLL SURGEONS, V214, P648, DOI 10.1016/j.jamcollsurg.2011.12.032
   Bernimoulin M, 2009, J THROMB HAEMOST, V7, P1019, DOI 10.1111/j.1538-7836.2009.03434.x
   Bhargava M, 2012, TRANSL RES, V159, P205, DOI 10.1016/j.trsl.2012.01.007
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5
   Brodsky SV, 2004, AM J PHYSIOL-HEART C, V286, pH1910, DOI 10.1152/ajpheart.01172.2003
   Buesing KL, 2011, J SURG RES, V166, P32, DOI 10.1016/j.jss.2010.05.036
   Chironi GN, 2009, CELL TISSUE RES, V335, P143, DOI 10.1007/s00441-008-0710-9
   Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Densmore JC, 2006, SHOCK, V26, P464, DOI 10.1097/01.shk.0000228791.10550.36
   Distler JHW, 2005, P NATL ACAD SCI USA, V102, P2892, DOI 10.1073/pnas.0409781102
   Distler JHW, 2006, AUTOIMMUNITY, V39, P683, DOI 10.1080/08916930601061538
   Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645
   George FD, 2008, THROMB RES, V122, pS55, DOI 10.1016/S0049-3848(08)70020-3
   GOLDBLUM SE, 1993, J CELL PHYSIOL, V157, P13, DOI 10.1002/jcp.1041570103
   Guervilly C, 2011, CRIT CARE, V15, DOI 10.1186/cc9978
   Hargett LA, 2013, PULMONARY CIRCULATIO, V3, P95
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004
   Jansen F, 2012, ARTERIOSCL THROM VAS, V32, P1925, DOI 10.1161/ATVBAHA.112.253229
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1_18
   LEE CH, 1995, SHOCK, V3, P96, DOI 10.1097/00024382-199502000-00003
   Letsiou E, 2013, AM J RESP CRIT CARE, V187
   Letsiou E, 2012, AM J RESP CRIT CARE, V185, pA5502
   Little KM, 2010, SEMIN THROMB HEMOST, V36, P845, DOI 10.1055/s-0030-1267038
   Mastronardi ML, 2011, FUND CLIN PHARMACOL, V25, P653, DOI 10.1111/j.1472-8206.2010.00898.x
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Mitra S, 2011, AM J RESP CRIT CARE, V184, P1030, DOI 10.1164/rccm.201103-0447OC
   Morel O, 2011, ARTERIOSCL THROM VAS, V31, P15, DOI 10.1161/ATVBAHA.109.200956
   Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012
   Peterson DB, 2008, PROTEOMICS, V8, P2430, DOI 10.1002/pmic.200701029
   Philippova M, 2011, EUR HEART J, V32, P760, DOI 10.1093/eurheartj/ehq206
   Piccin A, 2007, BLOOD REV, V21, P157, DOI 10.1016/j.blre.2006.09.001
   Ramacciotti E, 2010, THROMB RES, V125, pE269, DOI 10.1016/j.thromres.2010.01.019
   Sander TL, 2008, SHOCK, V29, P504, DOI 10.1097/SHK.0b013e3181454898
   Sapet C, 2006, BLOOD, V108, P1868, DOI 10.1182/blood-2006-04-014175
   Stern JB, 2006, INTENS CARE MED, V32, P910, DOI 10.1007/s00134-006-0124-7
   Sun XG, 2012, AM J RESP CELL MOL, V47, P628, DOI 10.1165/rcmb.2012-0048OC
   Thomashow MA, 2013, AM J RESP CRIT CARE, V188, P60, DOI 10.1164/rccm.201209-1697OC
   Tual-Chalot S, 2010, AM J RESP CRIT CARE, V182, P261, DOI 10.1164/rccm.200909-1347OC
   Turiak L, 2011, J PROTEOMICS, V74, P2025, DOI 10.1016/j.jprot.2011.05.023
   Viera AJ, 2012, J AM SOC HYPERTENS, V6, P243, DOI 10.1016/j.jash.2012.06.003
   Vion AC, 2013, PULM CIRC, V3, P95, DOI 10.4103/2045-8932.109921
   Wang JG, 2011, BLOOD, V118, P2366, DOI 10.1182/blood-2011-01-330878
   Watts JA, 2012, THROMB RES, V130, P122, DOI 10.1016/j.thromres.2011.09.016
   YANO Y, 1994, BIOCHEM J, V299, P303, DOI 10.1042/bj2990303
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 57
TC 57
Z9 62
U1 1
U2 9
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD FEB
PY 2015
VL 52
IS 2
BP 193
EP 204
DI 10.1165/rcmb.2013-0347OC
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA CF0BK
UT WOS:000352207300006
PM 25029266
OA Green Published
DA 2023-08-21
ER

PT J
AU Audi, SH
   Jacobs, ER
   Zhao, M
   Roerig, DL
   Haworth, ST
   Clough, AV
AF Audi, Said H.
   Jacobs, Elizabeth R.
   Zhao, Ming
   Roerig, David L.
   Haworth, Steven T.
   Clough, Anne V.
TI In vivo detection of hyperoxia-induced pulmonary endothelial cell death
   using Tc-99m-Duramycin
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE apoptosis; Lung imaging; ALI/ARDS 
ID ACUTE LUNG INJURY; TC-99M-HEXAMETHYLPROPYLENEAMINE OXIME; RAT LUNGS;
   OXYGEN; PROTECTION; APOPTOSIS
AB Introduction: Tc-99m-duramycin, DU, is a SPECT biomarker of tissue injury identifying cell death. The objective of this study is to investigate the potential of DU imaging to quantify capillary endothelial cell death in rat lung injury resulting from hyperoxia exposure as a model of acute lung injury.
   Methods: Rats were exposed to room air (normoxic) or >98% O-2 for 48 or 60 hours. DU was injected i.v. in anesthetized rats, scintigraphy images were acquired at steady-state, and lung DU uptake was quantified from the images. Post-mortem, the lungs were removed for histological studies. Sequential lung sections were immunostained for caspase activation and endothelial and epithelial cells.
   Results: Lung DU uptake increased significantly (p < 0.001) by 39% and 146% in 48-hr and 60-hr exposed rats, respectively, compared to normoxic rats. There was strong correlation (r(2) = 0.82, p = 0.005) between lung DU uptake and the number of cleaved caspase 3 (CC3) positive cells, and endothelial cells accounted for more than 50% of CC3 positive cells in the hyperoxic lungs. Histology revealed preserved lung morphology through 48 hours. By 60 hours there was evidence of edema, and modest neutrophilic infiltrate.
   Conclusions: Rat lung DU uptake in vivo increased after just 48 hours of >98% O-2 exposure, prior to the onset of any substantial evidence of lung injury. These results suggest that apoptotic endothelial cells are the primary contributors to the enhanced DU lung uptake, and support the utility of DU imaging for detecting early endothelial cell death in vivo. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Audi, Said H.; Clough, Anne V.] Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53201, United States.
C1 [Audi, Said H.; Jacobs, Elizabeth R.; Haworth, Steven T.; Clough, Anne V.] Med Coll Wisconsin, Div Pulm & Crit Care Med, Milwaukee, WI, United States.
C1 [Jacobs, Elizabeth R.; Roerig, David L.] Zablocki VA Med Ctr, Milwaukee, WI 53295, United States.
C1 [Zhao, Ming] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Evanston, IL 60208, United States.
C1 [Roerig, David L.] Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI, United States.
C1 [Roerig, David L.] Med Coll Wisconsin, Dept Pharmacol Toxicol, Milwaukee, WI, United States.
C3 Marquette University; Medical College of Wisconsin; Northwestern
   University; Feinberg School of Medicine; Medical College of Wisconsin;
   Medical College of Wisconsin
RP Clough, AV (corresponding author), Marquette Univ, Dept Math Stat & Comp Sci, POB 1881, Milwaukee, WI 53201 USA.
EM anne.clough@marquette.edu
FU NIH [8UL1TR000055, 1R01HL116530, 5R01HL102085]; VA Merit Review Award
   [BX001681]; Alvin and Marion Birnschein Foundation; Marquette University
   Graduate School; National Center for Advancing Translational Sciences,
   NIH [8UL1TR000055]
FX This work was supported by NIH grants 8UL1TR000055 (CTSI) (Audi,
   Clough), 1R01HL116530 (Jacobs, Audi, Clough), and 5R01HL102085 (Zhao),
   VA Merit Review Award BX001681 (Jacobs, Audi, Clough), The Alvin and
   Marion Birnschein Foundation, and Marquette University Graduate School
   (Audi, Clough). Statistical analysis was supported by the National
   Center for Advancing Translational Sciences, NIH grant 8UL1TR000055. The
   authors gratefully acknowledge the contributions of Dr. Naveen Bansal
   (Marquette University), Dr. Aniko Szabo and Ms. Natasha Sahr (Medical
   College of Wisconsin) in providing statistical consultation.
CR Ali I, 2012, ANN THORAC SURG, V93, P282, DOI 10.1016/j.athoracsur.2011.08.074
   Audi S, 2012, NUCL MED BIOL, V39, P821, DOI 10.1016/j.nucmedbio.2012.02.004
   Audi SH, 2012, J APPL PHYSIOL, V113, P658, DOI 10.1152/japplphysiol.00441.2012
   Brueckl C, 2006, AM J RESP CELL MOL, V34, P453, DOI 10.1165/rcmb.2005-0223OC
   Clough AV, 2012, J NUCL MED, V53, P1984, DOI 10.2967/jnumed.112.108498
   CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123
   Fisher AB, 2008, AM J PHYSIOL-LUNG C, V295, pL1066, DOI 10.1152/ajplung.90486.2008
   Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30
   Herasevich V, 2009, INTENS CARE MED, V35, P1018, DOI 10.1007/s00134-009-1460-1
   Howlett CE, 1999, AM J PHYSIOL-LUNG C, V277, pL596, DOI 10.1152/ajplung.1999.277.3.L596
   Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963
   Kawamura T, 2013, AM J PHYSIOL-LUNG C, V304, pL646, DOI 10.1152/ajplung.00164.2012
   Levitt JE, 2012, CRIT CARE, V16, DOI 10.1186/cc11144
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Merker MP, 2007, AM J PHYSIOL-LUNG C, V293, pL809, DOI 10.1152/ajplung.00448.2006
   Otterbein LE, 1998, AM J PHYSIOL-LUNG C, V275, pL14, DOI 10.1152/ajplung.1998.275.1.L14
   Rogers LK, 2009, PEDIATR RES, V65, P33, DOI 10.1203/PDR.0b013e31818a1d0a
   ROYSTON BD, 1990, J APPL PHYSIOL, V69, P1532, DOI 10.1152/jappl.1990.69.4.1532
   Sun QA, 2011, J SURG RES, V165, pE43, DOI 10.1016/j.jss.2010.09.024
   Zhao M, 2008, J NUCL MED, V49, P1345, DOI 10.2967/jnumed.107.048603
NR 20
TC 25
Z9 25
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0969-8051
EI 1872-9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD JAN
PY 2015
VL 42
IS 1
BP 46
EP 52
DI 10.1016/j.nucmedbio.2014.08.010
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA AX5DL
UT WOS:000346947100006
PM 25218023
OA Green Submitted, Green Accepted
DA 2023-08-21
ER

PT J
AU Bai, LT
   Andersson, HA
   McConnell, KI
   Chan, DL
   Hernandez, M
   Gonzalez, J
   Liu, XW
   La Francesca, S
   Sakamoto, JH
   Serda, RE
AF Bai, Litao
   Andersson, Helen A.
   McConnell, Kellie I.
   Chan, Diana L.
   Hernandez, Michael
   Gonzalez, Javier
   Liu, Xuewu
   La Francesca, Saverio
   Sakamoto, Jason H.
   Serda, Rita E.
TI Silencing of Tumor Necrosis Factor Receptor-1 in Human Lung
   Microvascular Endothelial Cells Using Particle Platforms for siRNA
   Delivery
SO CURRENT DRUG TARGETS
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; liposome; lung; porous silicon; siRNA; TNF/TNF-alpha/TNFR1 
ID INDUCED PNEUMONIA; DRUG-DELIVERY; PATHOGENESIS; INJURY; ICAM-1; ALPHA
AB Acute lung injury (ALI) and its most severe manifestation, acute respiratory distress syndrome (ARDS), is a clinical syndrome defined by acute hypoxemic respiratory failure and bilateral pulmonary infiltrates consistent with edema. In-hospital mortality is 38.5% for AL, and 41.1% for ARDS. Activation of alveolar macrophages in the donor lung causes the release of pro-inflammatory chemokines and cytokines, such as TNF-alpha. To determine the relevance of TNF-alpha in disrupting bronchial endothelial cell function, we stimulated human THP-1 macrophages with lipopolysaccharide (LPS) and used the resulting cytokine-supplemented media to disrupt normal endothelial cell functions. Endothelial tube formation was disrupted in the presence of LPS-activated THP1 conditioned media, with reversal of the effect occurring in the presence of 0.1 mu g/ml Enbrel, indicating that TNF-a was the major serum component inhibiting endothelial tube formation. To facilitate lung conditioning, we tested liposomal and porous silicon (pSi) delivery systems for their ability to selectively silence TNFR1 using siRNA technology. Of the three types of liposomes tested, only cationic liposomes had substantial endothelial uptake, with human cells taking up 10-fold more liposomes than their pig counterparts; however, non-specific cellular activation prohibited their use as immunosuppressive agents. On the other hand, pSi microparticles enabled the accumulation of large amounts of siRNA in endothelial cells compared to standard transfection with Lipofectamine (R) LTX, in the absence of non-specific activation of endothelia. Silencing of TNFR1 decreased TNF-alpha mediated inhibition of endothelial tube formation, as well as TNF-alpha-induced upregulation of ICAM-1, VCAM, and E-selection in human lung microvascular endothelial cells.
C1 [Bai, Litao; Andersson, Helen A.; McConnell, Kellie I.; Chan, Diana L.; Gonzalez, Javier; Liu, Xuewu; La Francesca, Saverio; Sakamoto, Jason H.; Serda, Rita E.] Houston Methodist Res Inst, Dept Nanomed, Houston, TX, United States.
C1 [Hernandez, Michael] Hitachi High Technol Amer Inc, Clarksburg, MD, United States.
C1 [Gonzalez, Javier; Sakamoto, Jason H.; Serda, Rita E.] Escuela Biotecnol & Alimentos, Escuela Med & Ciencias Salud, Inst Tecnol Estudios Super Monterrey, Monterrey, VA, United States.
C1 [La Francesca, Saverio] Methodist Hosp Houston, Methodist DeBakey Heart & Vasc Ctr, Houston, TX, United States.
C1 [Serda, Rita E.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030, United States.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; Hitachi
   Limited; Tecnologico de Monterrey; The Methodist Hospital System; The
   Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center;
   Baylor College of Medicine
RP Serda, RE (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, One Baylor Plaza,R512, Houston, TX 77030 USA.
EM rita.serda@bcm.edu
RI lu, qian/IUN-7445-2023; Bai, Litao/C-7767-2009
OI Chan, Diana/0000-0002-5394-6030
FU Alliance for Nano-Health, Department of Defense grant
   [W81XWH-11-02-0168]
FX This research was supported by the Alliance for Nano-Health, Department
   of Defense grant #W81XWH-11-02-0168.
CR Al-Lamki RS, 2001, LAB INVEST, V81, P1503, DOI 10.1038/labinvest.3780364
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   den Hengst WA, 2010, AM J PHYSIOL-HEART C, V299, pH1283, DOI 10.1152/ajpheart.00251.2010
   FAJARDO LF, 1992, AM J PATHOL, V140, P539
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kay J, 2009, CORE EVID, V4, P159
   Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Qin L, 1996, J IMMUNOL, V157, P5016
   Savage DJ, 2013, CURR OPIN PHARMACOL, V13, P834, DOI 10.1016/j.coph.2013.06.006
   Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555
   Serda RE, 2009, BIOMATERIALS, V30, P2440, DOI 10.1016/j.biomaterials.2009.01.019
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x
NR 15
TC 2
Z9 2
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2015
VL 16
IS 13
BP 1531
EP 1539
DI 10.2174/1389450115666140828105507
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CV8HE
UT WOS:000364522400012
PM 26201489
DA 2023-08-21
ER

PT J
AU Bao, H
   Gao, FY
   Xie, GG
   Liu, ZW
AF Bao, Hong
   Gao, Fengying
   Xie, Guogang
   Liu, Zhenwei
TI Angiotensin-Converting Enzyme 2 Inhibits Apoptosis of Pulmonary
   Endothelial Cells During Acute Lung Injury Through Suppressing MiR-4262
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE ALI/ARDS; ACE/ACE2; Hydrolyzing angiotensin II (AngII); Bcl-2; MiR-4262 
ID CANCER-CELLS; BCL-2; SMAD2; PROLIFERATION; MICE; ACTIVATION; RECEPTORS;
   PROMOTE; GENE
AB Background/Aims: Angiotensin converting enzyme 2 (ACE2) treatment suppresses the severity of acute lung injury (ALI). The effects of ACE2 in ALI have been shown to not only result from its antagonizing hydrolyzing angiotensin II (AngII), which is responsible for reduction in the vascular tension and pulmonary accumulation of inflammatory cells, but also result from a role of ACE2 in suppressing the ALI-induced apoptosis of pulmonary endothelial cells (PECs). Nevertheless, the underlying mechanisms of the role of ACE2 on PEC apoptosis are not completely understood. Methods: Here, we used a bleomycin-induced mouse model for ALI that has been published in our previous studies. We analyzed the mRNA and protein levels of an anti-apoptotic protein Bcl-2 in the ALI-mice that have been treated w/o ACE2. We analyzed miR-4262 levels in the mouse lung in these mice. Bcl-2-targeting miRNAs were predicted using bioinformatics algorithms and a luciferase reporter assay was applied to examine the effects of miR-4262 on the Bcl-2 protein translation upon their binding to 3'-UTR of Bcl-2 mRNA. Adeno-associated viruses carrying either miR-4262 mimics or antisense were injected into ALI-mice without ACE2, and their effects on the apoptosis in mouse lung cells were analyzed by Western blot. Results: ACE2 inhibited the ALI-induced apoptosis of pulmonary cells in vivo partially through upregulation of Bcl-2 protein, but not Bcl-2 mRNA. ACE2 appeared to significantly suppress the upregulation of miR-4262 in mouse lung after ALI. MiR-4262 was found to target 3'-UTR of Bcl-2 mRNA to inhibit its protein translation in PECs. In vivo administration of antisense of miR-4262 decreased apoptosis of pulmonary cells and severity of the ALI in mice. Conclusion: ACE2-induced suppression of miR-4262 partially contribute to the inhibition of the PEC apoptosis after ALI through Bcl-2. MiR-4262 may be a novel promising treatment target for ALI and ARDS. Copyright (C) 2015 S. Karger AG, Basel
C1 [Bao, Hong] Fudan Univ, Shanghai Pudong Hosp, Pudong Med Ctr, Dept Resp Med, Shanghai 200433, China.
C1 [Gao, Fengying] Shanghai JianGong Hosp, Dept Resp Med, Shanghai, China.
C1 [Xie, Guogang; Liu, Zhenwei] Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Resp Med, Shanghai 200080, China.
C3 Fudan University; Shanghai Jiao Tong University
RP Liu, ZW (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Resp Med, Shanghai 200080, Peoples R China.
EM zhenweiliu69@163.com
CR ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748
   Akl H, 2013, BBA-REV CANCER, V1835, P180, DOI 10.1016/j.bbcan.2012.12.001
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Bader AM, 2014, CELL PHYSIOL BIOCHEM, V34, P646, DOI 10.1159/000363030
   Chen D, 2014, XENOBIOTICA, P1
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Decuypere Jean-Paul, 2011, J Aging Res, V2011, P920178, DOI 10.4061/2011/920178
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Huang SQ, 2014, TUMOR BIOL, V35, P6265, DOI 10.1007/s13277-014-1818-z
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Ji Y, 2015, CELL PHYSIOL BIOCHEM, V35, P2203, DOI 10.1159/000374025
   Kim YH, 2014, PLANT PHYSIOL BIOCH, V80, P168, DOI 10.1016/j.plaphy.2014.04.002
   Lauf PK, 2013, CELL PHYSIOL BIOCHEM, V31, P257, DOI 10.1159/000343366
   Liu D, 2014, MOL CELL BIOCHEM, V394, P155, DOI 10.1007/s11010-014-2091-6
   Liu FB, 2014, CELL BIOCHEM FUNCT, V32, P580, DOI 10.1002/cbf.3054
   Liu W, 2014, INT J CLIN EXP MED, V7, P3392
   Min F, 2015, MOL MED REP, V11, P2387, DOI 10.3892/mmr.2014.3025
   Monaco G, 2015, J BIOL CHEM, V290, P9150, DOI 10.1074/jbc.M114.622514
   Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200
   Sun RR, 2015, TUMOR BIOL, V36, P1173, DOI 10.1007/s13277-014-2699-x
   Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826
   Vervliet T, 2014, J CELL SCI, V127, P2782, DOI 10.1242/jcs.150011
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Xia Q, 2014, TUMOR BIOL, V35, P8537, DOI 10.1007/s13277-014-2368-0
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Yu YH, 2015, CELL PHYSIOL BIOCHEM, V35, P1756, DOI 10.1159/000373987
   Zhu Y, 2013, CELL PHYSIOL BIOCHEM, V32, P1225, DOI 10.1159/000354521
NR 28
TC 54
Z9 59
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 37
IS 2
BP 759
EP 767
DI 10.1159/000430393
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CR2JM
UT WOS:000361155400030
PM 26356266
OA gold
DA 2023-08-21
ER

PT J
AU Ji, Y
   Gao, FY
   Sun, B
   Hao, J
   Liu, ZW
AF Ji, Yong
   Gao, Fengying
   Sun, Bo
   Hao, Jing
   Liu, Zhenwei
TI Angiotensin-Converting Enzyme 2 Inhibits Apoptosis of Pulmonary
   Endothelial Cells During Acute Lung Injury Through Suppressing SMAD2
   Phosphorylation
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE ALI/ARDS; ACE/ACE2; Hydrolyzing angiotensin II (AngII); NO; SMAD2; SMAD7 
ID BERLIN DEFINITION; BLEOMYCIN; GENE; MICE; RECEPTOR; PATHWAY; ARDS
AB Background/Aims: Angiotensin converting enzyme 2 (ACE2) has an established role in suppressing the severity of acute lung injury (ALI), especially when it was applied together with transplantation of human umbilical cord mesenchymal stem cells (uMSCs). Although the effects of ACE2 in ALI are believed to mainly result from its role in hydrolyzing angiotensin II (AngII), which subsequently reduces the vascular tension and subsequent pulmonary accumulation of inflammatory cells, we and others have recently reported a possible role of ACE2 in suppressing the ALI-induced apoptosis of pulmonary endothelial cells. However, the underlying mechanisms remain undetermined. Methods: Here, we analyzed the alteration in lung injury severity in ALI after ACE2, by histology and inflammatory cytokine levels. We analyzed apoptosis-associated proteins in lung after ALI, as well as in cultured endothelial cells treated with nitric oxide (NO). We overexpressed SMAD7 to inhibit SMAD2 signaling in cultured endothelial cells and examined its effects on NO-induced cell apoptosis. Results: ACE2 alleviated severity of lung injury after ALI. ACE2 significantly decreased the ALI-induced apoptosis of pulmonary cells in vivo, and ACE2 protected endothelial cells against NO-induced apoptosis in vitro. NO induced phosphorylation of a key factor of transforming growth factor beta (TGF beta) receptor signaling, SMAD2, which could be dose-dependently inhibited by ACE2. Inhibition of SMAD2 phosphorylation through expression of its inhibitor SMAD7 significantly inhibited NO-induced cell apoptosis, without need for ACE2. Conclusion: Our data suggest that ACE2-mediated AngII degradation may inhibit AngII-mediated SMAD2-phophorylation, possibly through a TGF beta-independent manner, which subsequently suppresses the ALI-induced cell death. Our results thus reveal a novel molecular pathway that controls the pathogenesis of ALI. Copyright (C) 201 S. Karger AG, Basel
C1 [Ji, Yong; Liu, Zhenwei] Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Resp Med, Shanghai 200080, China.
C1 [Gao, Fengying] Shanghai JianGong Hosp, Dept Resp Med, Shanghai, China.
C1 [Sun, Bo] Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Pharm, Shanghai 200030, China.
C1 [Hao, Jing] Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Nephrol, Shanghai 200030, China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Liu, ZW (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Resp Med, Shanghai 200080, Peoples R China.
EM Zhenweiliu69@163.com
CR ASHBAUGH DG, 1967, LANCET, V2, P319
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Gao FY, 2014, EXP LUNG RES, V40, P392, DOI 10.3109/01902148.2014.938200
   Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Kangelaris KN, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-4
   Liu D, 2014, MOL CELL BIOCHEM, V394, P155, DOI 10.1007/s11010-014-2091-6
   Liu FB, 2014, CELL BIOCHEM FUNCT, V32, P580, DOI 10.1002/cbf.3054
   Liu W, 2014, INT J CLIN EXP MED, V7, P3392
   Mehta S, 2005, VASC PHARMACOL, V43, P390, DOI 10.1016/j.vph.2005.08.013
   Min F, 2015, MOL MED REP, V11, P2387, DOI 10.3892/mmr.2014.3025
   Rodriguez-Vita J, 2005, CIRCULATION, V111, P2509, DOI 10.1161/01.CIR.0000165133.84978.E2
   Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200
   Thompson BT, 2013, AM J RESP CRIT CARE, V187, P675, DOI 10.1164/rccm.201302-0385ED
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Zhang XM, 2015, EXP LUNG RES, V41, P32, DOI 10.3109/01902148.2014.963901
NR 17
TC 38
Z9 39
U1 2
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 6
BP 2203
EP 2212
DI 10.1159/000374025
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CL3FA
UT WOS:000356834600011
PM 25896672
OA gold
DA 2023-08-21
ER

PT J
AU Li, HX
   Meng, XY
   Gao, Y
   Cai, SH
AF Li, Hongxia
   Meng, Xiangyu
   Gao, Yue
   Cai, Shaohua
TI Isolation and phenotypic characteristics of microparticles in acute
   respiratory distress syndrome
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ALI/ARDS; microparticles; inflammatory mediator 
ID PLATELET MICROPARTICLES; ENDOTHELIAL MICROPARTICLES; EXOSOMES; RELEASE;
   BLOOD; DYSFUNCTION; ACTIVATION; LEUKOCYTES
AB Objective: To investigate the alterations of microparticles in acute respiratory distress syndrome (ARDS) in rats. Methods: 18 Wistar male rats were randomly divided into three groups: no intervention, sham (saline control) group and ARDS group (LPS induced). Blood was collected from abdominal aorta and microparticles were extracted through multiple rounds of centrifugation. Particles were analyzed by flow cytometry and transmission electron microscope. Results: The circulating concentration of total microparticles of rats with ARDS induced by lipopolysaccharide (LPS) did not change compared with other two groups. However, ARDS rats expressed higher concentration of leukocyte-and endothelium-derived microparticles in the three groups. Conclusion: Our results indicate that leukocyte and endothelial cell-derived particles may play an important role in ARDS. Thus it is important not only to monitor total microparticle levels but also the phenotypes, which may contribute to the prevention and early treatment of ARDS.
C1 [Li, Hongxia] Chinese Peoples Liberat Army Gen Hosp, Dept Resp Med, Beijing 100853, China.
C1 [Meng, Xiangyu; Cai, Shaohua] Chinese Peoples Liberat Army Gen Hosp, Special Inpatient Unit, Dept Resp Med, Beijing 100853, China.
C1 [Gao, Yue] Acad Mil Med Sci, Inst Radiat Med, Beijing 100039, China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital; Academy of Military Medical Sciences -
   China
RP Cai, SH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Special Inpatient Unit, Dept Resp Med, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM gyamms@126.com; csh301@yeah.net
CR Amabile N, 2005, J AM SOC NEPHROL, V16, P3381, DOI 10.1681/ASN.2005050535
   Antoniak S, 2009, J THROMB HAEMOST, V7, P871, DOI 10.1111/j.1538-7836.2009.03323.x
   Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC
   Berckmans RJ, 2011, BLOOD, V117, P3172, DOI 10.1182/blood-2010-06-290460
   Berckmans RJ, 2005, ARTHRITIS RES THER, V7, pR536, DOI 10.1186/ar1706
   Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235
   Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5
   Buesing KL, 2011, J SURG RES, V166, P32, DOI 10.1016/j.jss.2010.05.036
   Connor DE, 2010, THROMB HAEMOSTASIS, V103, P1044, DOI 10.1160/TH09-09-0644
   Diamant M, 2004, EUR J CLIN INVEST, V34, P392, DOI 10.1111/j.1365-2362.2004.01355.x
   Enjeti AK, 2007, SEMIN THROMB HEMOST, V33, P771, DOI 10.1055/s-2007-1000369
   Gutwein P, 2005, CLIN CANCER RES, V11, P2492, DOI 10.1158/1078-0432.CCR-04-1688
   Horstman LL, 1999, CRIT REV ONCOL HEMAT, V30, P111, DOI 10.1016/S1040-8428(98)00044-4
   Jy WC, 1995, BLOOD CELL MOL DIS, V21, P217, DOI 10.1006/bcmd.1995.0025
   Lee RD, 2012, THROMB RES, V129, P80, DOI 10.1016/j.thromres.2011.06.004
   Lo SC, 2006, J BIOMED SCI, V13, P787, DOI 10.1007/s11373-006-9107-5
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Macey MG, 2011, CYTOM PART B-CLIN CY, V80B, P57, DOI 10.1002/cyto.b.20551
   Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841
   Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Messer L, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2648
   Mortaza S, 2009, CRIT CARE MED, V37, P2045, DOI 10.1097/CCM.0b013e3181a00629
   Ogura H, 2004, J TRAUMA, V56, P823, DOI 10.1097/01.TA.0000084517.39244.46
   Osumi K, 2001, THROMB HAEMOSTASIS, V85, P326, DOI 10.1055/s-0037-1615688
   PASCUAL M, 1994, J EXP MED, V179, P889, DOI 10.1084/jem.179.3.889
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296
   Rautou PE, 2011, CIRC RES, V109, P593, DOI 10.1161/CIRCRESAHA.110.233163
   Schwarz MI, 2004, CHEST, V125, P1530, DOI 10.1378/chest.125.4.1530
   Sekula M, 2011, CELL MOL BIOL LETT, V16, P69, DOI 10.2478/s11658-010-0040-2
   Soriano AO, 2005, CRIT CARE MED, V33, P2540, DOI 10.1097/01.CCM.0000186414.86162.03
   Tissot JD, 2010, CURR OPIN HEMATOL, V17, P571, DOI 10.1097/MOH.0b013e32833ec217
   van Beers EJ, 2009, HAEMATOL-HEMATOL J, V94, P1513, DOI 10.3324/haematol.2009.008938
   VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x
   Yuana Y, 2011, THROMB HAEMOSTASIS, V105, P396, DOI 10.1160/TH10-09-0595
   Zahra S, 2011, BRIT J HAEMATOL, V152, P688, DOI 10.1111/j.1365-2141.2010.08452.x
NR 40
TC 6
Z9 7
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 2
BP 1640
EP 1648
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CF2IU
UT WOS:000352371800055
PM 25973049
DA 2023-08-21
ER

PT J
AU Liu, S
   Tang, J
   Huang, L
   Xu, QR
   Ling, X
   Liu, JC
AF Liu, Sheng
   Tang, Jian
   Huang, Lei
   Xu, Qirong
   Ling, Xiang
   Liu, Jichun
TI Cordyceps Militaris Alleviates Severity of Murine Acute Lung Injury
   Through miRNAs-Mediated CXCR2 Inhibition
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE ALI/ARDS; Cordyceps militaris (CM); miR-1321; miR-3188; CXCR2 
ID ENDOTHELIAL PROGENITOR CELLS; BERLIN DEFINITION; CANCER; MICE; ARDS;
   IMMUNITY; INSULIN; RATS
AB Background/Aims: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are lethal diseases in humans, and the current treatments have limited therapeutic effects. Cordyceps militaris (CM) is a caterpillar-grown traditional medicinal mushroom, and has been used as a natural invigorant for longevity, endurance, and vitality in China. Recently, purified extracts from CM have been shown to have beneficial effects on various diseases including cancer. Nevertheless, a role of CM in ALI has not been examined previously. Methods: Here, we used a bleomycin-induced ALI model to study the effects of CM on the severity of ALI in mice. The levels of CXCR2, a receptor for Interleukin 8 (IL-8) in pulmonary microvascular endothelial cells, were examined in different experimental groups. The levels of microRNA (miR)-1321 and miR-3188 were also examined in lung samples and in CM. Adeno-associated viruses carrying miR-1321 and miR-3188 were injected into bleomycin-treated mice for evaluation their effects on the severity of ALI. Results: CM treatment significantly alleviated the severity of bleomycin-induced ALI in mice. The increases in lung CXCR2 by bleomycin were significantly reduced by CM at protein level, but not at mRNA level. CM contained high levels of 2 miRNAs (miR-1321 and miR-3188) that target 3'-UTR of CXCR2 mRNA to inhibit its expression. Overexpression of miR-1321 and miR-3188 in mouse lung through AAV-mediated gene therapy mimicked the effects of CM. Conclusion: CM may alleviate severity of murine ALI through miRNAs-mediated CXCR2 inhibition. Copyright (C) 2015 S. Karger AG, Basel
C1 [Liu, Sheng; Tang, Jian; Huang, Lei; Xu, Qirong; Ling, Xiang; Liu, Jichun] Nanchang Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanchang 330006, China.
C3 Nanchang University
RP Liu, JC (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, 17 Yongwai Main St, Nanchang 330006, Peoples R China.
EM liusheng_15@163.com
CR Allen TC, 2014, ARCH PATHOL LAB MED, V138, P266, DOI 10.5858/arpa.2013-0182-RA
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849
   Cai DS, 2013, CELL PHYSIOL BIOCHEM, V32, P1577, DOI 10.1159/000356594
   Cao YH, 2013, CELL METAB, V18, P478, DOI 10.1016/j.cmet.2013.08.008
   Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013
   Jeong MH, 2013, ONCOL REP, V30, P1996, DOI 10.3892/or.2013.2660
   Ji Y, 2015, CELL PHYSIOL BIOCHEM, V35, P2203, DOI 10.1159/000374025
   Kangelaris KN, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-4
   Khemani RG, 2013, INTENS CARE MED, V39, P2213, DOI 10.1007/s00134-013-3094-6
   Konrad FM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/740987
   Landgraf MA, 2014, CELL PHYSIOL BIOCHEM, V33, P835, DOI 10.1159/000358656
   Lomas-Neira JL, 2004, J LEUKOCYTE BIOL, V76, P58, DOI 10.1189/jlb.1103541
   Mollah ML, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/249217
   Murukesh N, 2010, BRIT J CANCER, V102, P8, DOI 10.1038/sj.bjc.6605483
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Silva RC, 2013, CELL PHYSIOL BIOCHEM, V31, P179, DOI 10.1159/000343359
   Strieter Robert M., 2005, Current Drug Targets - Inflammation and Allergy, V4, P299, DOI 10.2174/1568010054022178
   Thompson BT, 2013, AM J RESP CRIT CARE, V187, P675, DOI 10.1164/rccm.201302-0385ED
   Uhlig S, 2014, CELL PHYSIOL BIOCHEM, V34, P1, DOI 10.1159/000362980
   Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7
   Wang M, 2012, CARBOHYD POLYM, V89, P461, DOI 10.1016/j.carbpol.2012.03.029
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Yang XF, 2015, INT IMMUNOPHARMACOL, V26, P401, DOI 10.1016/j.intimp.2015.04.017
   Yin XR, 2015, CELL PHYSIOL BIOCHEM, V35, P2149, DOI 10.1159/000374020
   Zarbock A, 2008, BRIT J PHARMACOL, V155, P357, DOI 10.1038/bjp.2008.270
   Zhu SJ, 2013, J ETHNOPHARMACOL, V149, P713, DOI 10.1016/j.jep.2013.07.037
NR 29
TC 19
Z9 24
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 36
IS 5
BP 2003
EP 2011
DI 10.1159/000430168
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CN6BI
UT WOS:000358518000028
PM 26202360
OA gold
DA 2023-08-21
ER

PT J
AU Shao, HZ
   Qin, BY
AF Shao, H-Z.
   Qin, B-Y.
TI rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates
   LPS-induced acute lung injury in mice by inhibiting neutrophil migration
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Recombinant PSGL-1-Ig fusion protein; LPS; ALI/ARDS; neutrophil migration 
ID SELECTIN GLYCOPROTEIN LIGAND-1; LEUKOCYTE RECRUITMENT; ADHESION;
   INFLAMMATION
AB The binding of selectin to P-selectin glycoprotein ligand-1 (PSGL-1) mediates the tethering and rolling of leukocytes on the endothelium during leukocyte migration and inflammation. Recombinant human PSGL-1-Ig fusion protein (rPSGL-1-Ig) is a widely used selectin inhibitor that prevents neutrophil entry into inflamed or reperfused tissues. We hypothesized that rPSGL-1-Ig could be used to as a drug for the treatment of acute lung injury (ALI). We induced murine ALI by injecting mice with lipopolysaccharide (LPS) and then treated the mice with rPSGL-1-Ig. We determined the lung injury index, wet/dry ratio, and inflammatory cytokine level in differentially treated mice. The symptoms of LPS-induced lung injury were alleviated by rPSGL-1-Ig treatment. The histopathological index of LPS-induced lung injury improved after rPSGL-1-Ig treatment. rPSGL-1-Ig treatment also reduced the recruitment of inflammatory cells, including neutrophils, into the lung, as well as reducing the level of inflammatory cytokines. These data suggest that rPSGL-1-Ig protein has a therapeutic effect on LPS-induced lung injury.
C1 [Shao, H-Z.; Qin, B-Y.] Henan Prov Peoples Hosp, Zhengzhou 450003, China.
C3 Zhengzhou University
RP Qin, BY (corresponding author), Henan Prov Peoples Hosp, Zhengzhou 450003, Peoples R China.
EM qin-byu424@126.com
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   [Anonymous], 1998, J IMMUNOL, V161, P474
   Asaduzzaman M, 2009, BRIT J PHARMACOL, V156, P307, DOI 10.1111/j.1476-5381.2008.00021.x
   Bauer TT, 2006, CLIN INFECT DIS, V43, P748, DOI 10.1086/506430
   CARLOS TM, 1994, BLOOD, V84, P2068
   Gray KD, 2003, AM J SURG, V186, P526, DOI 10.1016/j.amjsurg.2003.07.010
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329
   Hoffmann U., REGULATION MIGRATORY
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Luo Yi, 2001, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0320s22
   Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275
   Mangan PR, 2005, AM J PATHOL, V167, P1661, DOI 10.1016/S0002-9440(10)61249-7
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matuschak George M, 2010, Mo Med, V107, P252
   Miner JJ, 2008, BLOOD, V112, P2035, DOI 10.1182/blood-2008-04-149468
   MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446
   Rijcken EM, 2004, AM J PHYSIOL-GASTR L, V287, pG115, DOI 10.1152/ajpgi.00207.2003
   Santen S, 2007, INFLAMM RES, V56, P452, DOI 10.1007/s00011-007-7071-9
   Stadtmann A, 2013, J EXP MED, V210, P2171, DOI 10.1084/jem.20130664
   Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181
   von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407
   Zarbock A, 2009, CURR TOP MICROBIOL, V334, P129, DOI 10.1007/978-3-540-93864-4_6
NR 25
TC 3
Z9 3
U1 0
U2 3
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2015
VL 61
IS 1
BP 1
EP 6
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CE9BB
UT WOS:000352137200001
PM 25817339
DA 2023-08-21
ER

PT J
AU Silva, PL
   Rocco, PRM
   Pelosi, P
AF Silva, Pedro Leme
   Rocco, Patricia Rieken Macedo
   Pelosi, Paolo
TI FG-4497: a new target for acute respiratory distress syndrome?
SO EXPERT REVIEW OF RESPIRATORY MEDICINE
LA English
DT Article
DE ALI/ARDS; adhesion junction; ECs/HPMECs/HUVECs/MPVECs; hypoxia; VE-cadherin 
ID ACUTE LUNG INJURY; INDUCIBLE TRANSCRIPTION FACTORS; DEVELOPING
   MOUSE-BRAIN; RECRUITMENT MANEUVER; HYPOXIA; PULMONARY; PRESSURE;
   ETIOLOGY; EXPRESSION; SURVIVAL
AB The morbidity and mortality rates associated with acute respiratory distress syndrome ( ARDS) remain high and the development of new therapeutic strategies is urgently required. Some pharmacological treatments, proposed or under evaluation for ARDS, seek to protect the endothelium and consequently mitigate fluid extravasation into the alveolar space. FG-4497 is a new compound which acts as a prolyl hydroxylase domain 2 inhibitor and mimics hypoxia in the activation of hypoxia-inducible factor-2 alpha signaling, decreasing VE-cadherin phosphorylation and thus promoting integrity of adherens junctions. In this special report, we discuss the pharmacological characteristics of FG-4497, its effect on lung parenchyma and other organs and future perspectives in ARDS. In short, FG-4497 may be considered a novel pharmacological option targeting endothelial cell repair in lung diseases such as ARDS. Further experimental and clinical studies are warranted to better understand the mechanisms of action of FG-4497 in different types of lung injury.
C1 [Silva, Pedro Leme; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, BR-21941902 Rio De Janeiro, Brazil.
C1 [Pelosi, Paolo] Univ Genoa, IRCCS AOU San Martino IST, Dept Surg Sci & Integrated Diagnost, I-16132 Genoa, Italy.
C3 Universidade Federal do Rio de Janeiro; University of Genoa; IRCCS AOU
   San Martino IST
RP Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ave Carlos Chagas Filho 373, BR-21941902 Rio De Janeiro, Brazil.
EM prmrocco@gmail.com
RI Silva, Pedro Leme/AAD-8236-2019; Rocco, Patricia/I-7460-2012
OI Silva, Pedro Leme/0000-0001-5838-4949; Rocco,
   Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023
FU European Community [HEALTH-F4-2011-282095]; Brazilian Council for
   Scientific and Technological Development (CNPq); Rio de Janeiro State
   Research Foundation (FAPERJ); CNPq
FX This work was funded by the European Community's Seventh Framework
   Programme under grant agreement no. HEALTH-F4-2011-282095 (TARKINAID
   project), the Brazilian Council for Scientific and Technological
   Development (CNPq) and the Rio de Janeiro State Research Foundation
   (FAPERJ). The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed. Editorial assistance funded
   by the CNPq grant was provided by ME Schottler and F Vasconcellos in the
   production of this manuscript.
CR Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639
   Bernhardt WM, 2009, P NATL ACAD SCI USA, V106, P21276, DOI 10.1073/pnas.0903978106
   Brackmann FA, 2013, BRAIN RES, V1531, P65, DOI 10.1016/j.brainres.2013.07.039
   Chao MC, 2012, RESP PHYSIOL NEUROBI, V173, P179
   Eliasson P, 2010, EXP HEMATOL, V38, P301, DOI 10.1016/j.exphem.2010.01.005
   Gong HX, 2015, J CLIN INVEST, V125, P652, DOI 10.1172/JCI77701
   Herwig MC, 2013, PATHOBIOLOGY, V80, P245, DOI 10.1159/000347062
   Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Keranen MAI, 2013, AM J TRANSPLANT, V13, P600, DOI 10.1111/ajt.12064
   Laitala A, 2012, BLOOD, V120, P3336, DOI 10.1182/blood-2012-07-441824
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014
   Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004
   Nagai J, 2014, BIOCHEM BIOPH RES CO, V450, P476, DOI 10.1016/j.bbrc.2014.05.146
   Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
   Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033
   Rosenberger C, 2007, J AM SOC NEPHROL, V18, P343, DOI 10.1681/ASN.2006070792
   Rubenfeld Gordon D, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS58, DOI 10.1513/AnnalsATS.201409-414MG
   Saddy F, 2013, CRIT CARE, V17, DOI 10.1186/cc13051
   Santos CL, 2014, CRIT CARE, V18, DOI 10.1186/cc13920
   Santos FB, 2006, J APPL PHYSIOL, V100, P98, DOI 10.1152/japplphysiol.00395.2005
   Shaver CM, 2014, CLIN CHEST MED, V35, P639, DOI 10.1016/j.ccm.2014.08.004
   Silva PL, 2013, CRIT CARE MED, V41, pE256, DOI 10.1097/CCM.0b013e31828a3c13
   Silva PL, 2010, CRIT CARE, V14, DOI 10.1186/cc9063
   Spieth PM, 2015, ANESTHESIOLOGY, V122, P106, DOI 10.1097/ALN.0000000000000415
   Trollmann R, 2014, NEUROSCIENCE, V278, P327, DOI 10.1016/j.neuroscience.2014.08.019
   Uhlig C, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-56
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
NR 29
TC 4
Z9 4
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1747-6348
EI 1747-6356
J9 EXPERT REV RESP MED
JI Expert Rev. Respir. Med.
PY 2015
VL 9
IS 4
BP 405
EP 409
DI 10.1586/17476348.2015.1065181
PG 5
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA CR4SB
UT WOS:000361327300006
PM 26181437
DA 2023-08-21
ER

PT J
AU Tian, YF
   Mambetsariev, I
   Sarich, N
   Meng, FY
   Birukova, AA
AF Tian, Yufeng
   Mambetsariev, Isa
   Sarich, Nicolene
   Meng, Fanyong
   Birukova, Anna A.
TI Role of microtubules in attenuation of PepG-induced vascular endothelial
   dysfunction by atrial natriuretic peptide
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; permeability; cytoskeleton; vascular leakage; ALI/ARDS 
ID ACUTE LUNG INJURY; CARDIOGENIC PULMONARY-EDEMA; PROTEIN-KINASE-A;
   STAPHYLOCOCCUS-AUREUS; BARRIER DYSFUNCTION; LIPOTEICHOIC ACID; IN-VIVO;
   PERMEABILITY; ACTIVATION; MECHANISMS
AB Apart from control of circulating fluid, atrial natriuretic peptide (ANP) exhibits anti-inflammatory effects in the lung. However, molecular mechanisms of ANP anti-inflammatory effects are not well-understood. Peripheral microtubule (MT) dynamics is essential for agonist-induced regulation of vascular endothelial permeability. Here we studied the role of MT-dependent signaling in ANP protective effects against endothelial cell (EC) barrier dysfunction and acute lung injury induced by Staphylococcus aureus-derived peptidoglican-G (PepG). PepG-induced vascular endothelial dysfunction was accompanied by MT destabilization and disruption of MT network. ANP attenuated PepG-induced MT disassembly, NF kappa B signaling and activity of MT-associated Rho activator GEF-H1 leading to attenuation of EC inflammatory activation reflected by expression of adhesion molecules ICAM1 and VCAM1. ANP-induced EC barrier preservation and MT stabilization were linked to phosphorylation and inactivation of MT-depolymerizing protein stathmin. Expression of stathmin phosphorylation-deficient mutant abolished ANP protective effects against PepG-induced inflammation and EC permeability. In contrast, siRNA-mediated stathmin knockdown prevented PepG-induced peripheral MT disassembly and endothelial barrier dysfunction. ANP protective effects in a murine model of PepG-induced lung injury were associated with increased phosphorylation of stathmin, while exacerbated lung injury in the ANP knockout mice was accompanied by decreased pool of stable MT. Stathmin knockdown in vivo reversed exacerbation of lung injury in the ANP knockout mice. These results show a novel MT-mediated mechanism of endothelial barrier protection by ANP in pulmonary EC and animal model of PepG-induced lung injury via stathmin-dependent control of MT assembly. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Tian, Yufeng; Mambetsariev, Isa; Sarich, Nicolene; Meng, Fanyong; Birukova, Anna A.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukova, AA (corresponding author), Univ Chicago, Lung Injury Ctr, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
RI Sarich, Nicolene/IWV-3869-2023
FU Public Health Service from the National Heart, Lung, and Blood Institute
   [HL89257, HL107920]
FX This work was supported by Public Health Service grants HL89257 and
   HL107920 from the National Heart, Lung, and Blood Institute. The authors
   wish to thank K. Szaszi (St. Michael's Hospital, Toronto, Canada) for
   sharing the RhoG17A construct.
CR Ahluwalia A, 2004, BASIC RES CARDIOL, V99, P83, DOI 10.1007/s00395-004-0459-6
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Chiu WT, 2009, CHEM-BIOL INTERACT, V181, P430, DOI 10.1016/j.cbi.2009.06.011
   Dodd-O JM, 2008, AM J PHYSIOL-LUNG C, V294, pL714, DOI 10.1152/ajplung.00185.2007
   Doust JA, 2005, BRIT MED J, V330, P625, DOI 10.1136/bmj.330.7492.625
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9
   Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131
   Guo LJ, 2013, AM J PHYSIOL-RENAL, V304, pF930, DOI 10.1152/ajprenal.00638.2012
   Irwin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL849, DOI 10.1152/ajplung.00294.2004
   Kakiashvili E, 2009, J BIOL CHEM, V284, P11454, DOI 10.1074/jbc.M805933200
   Karmpaliotis D, 2007, CHEST, V131, P964, DOI 10.1378/chest.06-1247
   Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428-7435.2005
   Kokot F., 1998, International Urology and Nephrology, V30, P357, DOI 10.1007/BF02550323
   Komarova Y, 2009, J CELL BIOL, V184, P691, DOI 10.1083/jcb.200807179
   Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773
   Kulhanek-Heinze S, 2004, J HEPATOL, V41, P414, DOI 10.1016/j.jhep.2004.05.017
   Ladetzki-Baehs K, 2007, ENDOCRINOLOGY, V148, P332, DOI 10.1210/en.2006-0935
   Leemans JC, 2002, AM J RESP CRIT CARE, V165, P1445, DOI 10.1164/rccm.2106045
   LOFTON CE, 1991, J MOL CELL CARDIOL, V23, P919, DOI 10.1016/0022-2828(91)90134-8
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Meliton AY, 2013, AM J PHYSIOL-LUNG C, V304, pL689, DOI 10.1152/ajplung.00047.2013
   Mitaka C, 1998, CHEST, V114, P223, DOI 10.1378/chest.114.1.223
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Moro C, 2007, DIABETOLOGIA, V50, P1038, DOI 10.1007/s00125-007-0614-3
   Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543
   OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Potter LR, 2005, FRONT BIOSCI-LANDMRK, V10, P1205, DOI 10.2741/1613
   Rana R, 2006, CRIT CARE MED, V34, P1941, DOI 10.1097/01.CCM.0000220492.15645.47
   Rentsendorj O, 2008, AM J PHYSIOL-LUNG C, V294, pL686, DOI 10.1152/ajplung.00417.2007
   ROWLANDS DC, 1995, J CLIN PATHOL-CL MOL, V48, pM88
   Sanghi S, 2005, REGUL PEPTIDES, V132, P1, DOI 10.1016/j.regpep.2005.06.007
   Shivanna M, 2009, EXP EYE RES, V89, P950, DOI 10.1016/j.exer.2009.08.004
   Slotta JE, 2006, INFLAMM RES, V55, P364, DOI 10.1007/s00011-006-6013-2
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Tian XY, 2014, J BIOL CHEM, V289, P5168, DOI 10.1074/jbc.M113.493924
   Tian XY, 2012, FASEB J, V26, P3862, DOI 10.1096/fj.12-207746
   Ueda S, 2006, SHOCK, V26, P134, DOI 10.1097/01.shk.0000226266.99960.d0
   von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741
   Wang JE, 2003, SHOCK, V20, P402, DOI 10.1097/01.shk.0000092268.01859.0d
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8
   Weber NC, 2003, J LEUKOCYTE BIOL, V74, P932, DOI 10.1189/jlb.0603254
   Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200
   Xing JJ, 2012, MICROVASC RES, V83, P194, DOI 10.1016/j.mvr.2011.09.012
   Xing JJ, 2011, J APPL PHYSIOL, V110, P213, DOI 10.1152/japplphysiol.00284.2010
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Yamagata T, 2009, RESP PHYSIOL NEUROBI, V166, P16, DOI 10.1016/j.resp.2008.12.008
NR 57
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JAN
PY 2015
VL 1852
IS 1
BP 104
EP 119
DI 10.1016/j.bbadis.2014.10.012
PG 16
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AZ8ST
UT WOS:000348485600011
PM 25445540
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Yin, XR
   Liang, ZD
   Yun, Y
   Pei, L
AF Yin, Xiuru
   Liang, Zuodi
   Yun, Yue
   Pei, Ling
TI Intravenous Transplantation of BMP2-Transduced Endothelial Progenitor
   Cells Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rats
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE endothelial progenitor cells; bone morphogenetic proteins; LPS; ALI/ARDS; gene therapy 
ID NITRIC-OXIDE SYNTHASE; PROTEIN-RECEPTOR II; PULMONARY-HYPERTENSION;
   GENE-TRANSFER; ISCHEMIC MUSCLE; IN-VIVO; REPAIR; RABBITS; ANGIOGENESIS;
   SURVIVAL
AB Background/Aims: Acute lung injury (ALI) and its aggressive stage, acute respiratory distress syndrome (ARDS), are characterized by diffuse damage and increased permeability of the endothelial barrier, leading to alveolar infiltrates and interstitial edema. Enhancing endothelial integrity represents a novel therapeutic strategy for ALI/ARDS. Endothelial progenitor cells (EPCs) have been reported to participate in endothelial repair of ALI and also serve as a tool for gene therapy. Further, bone morphogenetic protein 2 (BMP2) is an essential signaling molecule that regulates the fate of different cell types. The aim of our study is to explore whether bone marrow-derived EPCs transduced with lentiviral-mediated BMP2 gene might benefit lipopolysaccharide (LPS)-induced ALI in a rat model. Methods: Rats were divided randomly into five groups. The sham group was given normal saline via the trachea and right jugular vein. The other four groups underwent intratracheal-LPS-induced ALI followed after 30 min by treatment with either normal saline, EPCs, EPCs transduced with empty lentiviral vector (EPCs-null), or EPCs transduced with BMP2 (EPCs-BMP2) via the right jugular vein. Results: We found that the lung injury score, oxygenation, and inflammatory response were significantly ameliorated in the three EPC-treated groups (EPCs, EPCs-null, and EPCs-BMP2). In addition, EPCs-BMP2 further improved endothelium repair and capillary permeability, causing markedly reduced wet-to-dry lung-weight ratio and BALF protein content, and increased levels of BMP2 protein, BMP2 mRNA, and eNOS protein in lung tissues. Conclusion: Transplantation of BMP2-transduced EPCs effectively attenuates edema and protein exudation compared with EPCs alone in LPS-induced ALI via enhanced expression of BMP2 and eNOS. Copyright (C) 2015 S. Karger AG, Basel
C1 [Yin, Xiuru; Liang, Zuodi; Yun, Yue; Pei, Ling] China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Liaoning Provin, China.
C3 China Medical University
RP Pei, L (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing North St 155, Shenyang 110001, Liaoning Provin, Peoples R China.
EM lingpei49@vip.sina.com
FU Natural Science Foundation of China [81071530]
FX This study was supported by a program grant from the Natural Science
   Foundation of China (Grant number: 81071530).
CR Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948
   Anderson L, 2010, AM J PHYSIOL-REG I, V298, pR833, DOI 10.1152/ajpregu.00534.2009
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Belmokhtar K, 2011, STEM CELL REV REP, V7, P847, DOI 10.1007/s12015-011-9254-6
   Burton VJ, 2011, BLOOD, V117, P333, DOI 10.1182/blood-2010-05-285973
   Cao JP, 2012, ANESTHESIOLOGY, V116, P1278, DOI 10.1097/ALN.0b013e3182567f84
   Chen L, 2010, CARDIOVASC RES, V88, P462, DOI 10.1093/cvr/cvq207
   Frutos-Vivar Fernando, 2004, Curr Opin Crit Care, V10, P1, DOI 10.1097/00075198-200402000-00001
   Gangopahyay A, 2011, J BIOL CHEM, V286, P33134, DOI 10.1074/jbc.M111.274100
   Gao XF, 2011, INT IMMUNOPHARMACOL, V11, P1584, DOI 10.1016/j.intimp.2011.05.019
   Hatakeyama T, 2006, J PHYSIOL-LONDON, V574, P275, DOI 10.1113/jphysiol.2006.108175
   Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06
   Hur J, 2007, STEM CELLS, V25, P1769, DOI 10.1634/stemcells.2006-0385
   Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673
   Kuliszewski MA, 2011, MOL THER, V19, P895, DOI 10.1038/mt.2011.18
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   Lam CF, 2011, ANESTH ANALG, V112, P620, DOI 10.1213/ANE.0b013e3182075da4
   Li H, 2013, CHEST, V144, P876, DOI 10.1378/chest.12-2429
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Nagaya N, 2003, CIRCULATION, V108, P889, DOI 10.1161/01.CIR.0000079161.56080.22
   Park SJ, 2009, FEBS LETT, V583, P3235, DOI 10.1016/j.febslet.2009.09.014
   Picanco-Castro Virginia, 2012, Recent Pat DNA Gene Seq, V6, P82
   Rabelink TJ, 2004, ARTERIOSCL THROM VAS, V24, P834, DOI 10.1161/01.ATV.0000124891.57581.9f
   Raida M, 2006, INT J MOL MED, V18, P735
   Song MB, 2009, VASC PHARMACOL, V51, P205, DOI 10.1016/j.vph.2009.06.009
   Teichert-Kuliszewska K, 2006, CIRC RES, V98, P209, DOI 10.1161/01.RES.0000200180.01710.e6
   ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016
   Timmermans F, 2007, ARTERIOSCL THROM VAS, V27, P1572, DOI 10.1161/ATVBAHA.107.144972
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
   Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081
   Zhang YM, 2009, AM J PHYSIOL-HEART C, V296, pH1675, DOI 10.1152/ajpheart.00665.2008
   Zhao Q, 2007, ANN THORAC SURG, V84, P544, DOI 10.1016/j.athoracsur.2007.03.067
NR 32
TC 30
Z9 33
U1 0
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 6
BP 2149
EP 2158
DI 10.1159/000374020
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CL3FA
UT WOS:000356834600006
PM 25896232
OA gold
DA 2023-08-21
ER

PT J
AU Wu, F
   Szczepaniak, WS
   Shiva, S
   Liu, HB
   Wang, YN
   Wang, L
   Wang, Y
   Kelley, EE
   Chen, AF
   Gladwin, MT
   McVerry, BJ
AF Wu, Feng
   Szczepaniak, William S.
   Shiva, Sruti
   Liu, Huanbo
   Wang, Yinna
   Wang, Ling
   Wang, Ying
   Kelley, Eric E.
   Chen, Alex F.
   Gladwin, Mark T.
   McVerry, Bryan J.
TI Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled
   superoxide production and endothelial barrier dysfunction in acute lung
   injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; eNOS; endothelial barrier function; NO; NOX/NOX1/NOX2/NOX4 
ID NITRIC-OXIDE SYNTHASE; IMPROVED PATIENT OUTCOMES; SPHINGOSINE
   1-PHOSPHATE; NADPH OXIDASE; CLINICAL-EVIDENCE; RADICAL FORMATION;
   NAD(P)H OXIDASE; CELL-SHAPE; INHIBITION; MECHANISM
AB Microvascular barrier integrity is dependent on bioavailable nitric oxide (NO) produced locally by endothelial NO synthase (eNOS). Under conditions of limited substrate or cofactor availability or by enzymatic modification, eNOS may become uncoupled, producing superoxide in lieu of NO. This study was designed to investigate how eNOS-dependent superoxide production contributes to endothelial barrier dysfunction in inflammatory lung injury and its regulation. C57BL/6J mice were challenged with intratracheal LPS. Bronchoalveolar lavage fluid was analyzed for protein accumulation, and lung tissue homogenate was assayed for endothelial NOS content and function. Human lung microvascular endothelial cell (HLMVEC) monolayers were exposed to LPS in vitro, and barrier integrity and superoxide production were measured. Biopterin species were quantified, and coimmunoprecipitation (Co-IP) assays were performed to identify protein interactions with eNOS that putatively drive uncoupling. Mice exposed to LPS demonstrated eNOS-dependent increased alveolar permeability without evidence for altered canonical NO signaling. LPS-induced superoxide production and permeability in HLMVEC were inhibited by the NOS inhibitor nitro-L-arginine methyl ester, eNOS-targeted siRNA, the eNOS cofactor tetrahydrobiopterin, and superoxide dismutase. Co-IP indicated that LPS stimulated the association of eNOS with NADPH oxidase 2 (Nox2), which correlated with augmented eNOS S-glutathionylation both in vitro and in vivo. In vitro, Nox2-specific inhibition prevented LPS-induced eNOS modification and increases in both superoxide production and permeability. These data indicate that eNOS uncoupling contributes to superoxide production and barrier dysfunction in the lung microvasculature after exposure to LPS. Furthermore, the results implicate Nox2-mediated eNOS-S-glutathionylation as a mechanism underlying LPS-induced eNOS uncoupling in the lung microvasculature.
C1 [Wu, Feng; Szczepaniak, William S.; Wang, Ying; Gladwin, Mark T.; McVerry, Bryan J.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213, United States.
C1 [Shiva, Sruti; Wang, Yinna; Wang, Ling; Kelley, Eric E.; Chen, Alex F.; Gladwin, Mark T.; McVerry, Bryan J.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA, United States.
C1 [Shiva, Sruti] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261, United States.
C1 [Liu, Huanbo; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA, United States.
C1 [Kelley, Eric E.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261, United States.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP McVerry, BJ (corresponding author), UPMC, Montefiore NW628,3459 Fifth Ave, Pittsburgh, PA 15213 USA.
EM mcverrybj@upmc.edu
RI McVerry, Bryan/AAS-7790-2021
OI McVerry, Bryan/0000-0002-1175-4874; Wang, Ling/0000-0003-4333-3158;
   Szczepaniak, William/0000-0002-8458-241X
FU NHLBI [K08-HL83101]; American Heart Association [12GRNT11820019,
   10SDG3560005]; University of Pittsburgh Vascular Medicine Institute;
   Institute for Transfusion Medicine
FX This project was supported by the NHLBI (K08-HL83101 to B. McVerry), the
   American Heart Association (12GRNT11820019 to B. McVerry, 10SDG3560005
   to E. Kelley), and the University of Pittsburgh Vascular Medicine
   Institute in collaboration with the Institute for Transfusion Medicine
   (B. McVerry).
CR Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005
   Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730
   Alef MJ, 2011, J CLIN INVEST, V121, P1646, DOI 10.1172/JCI44079
   Bahrami S, 2000, SHOCK, V13, P386, DOI 10.1097/00024382-200005000-00007
   Bansal V, 2003, CURR OPIN CLIN NUTR, V6, P223, DOI 10.1097/00075197-200303000-00012
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Belik J, 2009, AM J PHYSIOL-LUNG C, V297, pL1170, DOI 10.1152/ajplung.00168.2009
   Bucci M, 2005, P NATL ACAD SCI USA, V102, P904, DOI 10.1073/pnas.0408906102
   Budinger GRS, 2011, AM J RESP CRIT CARE, V183, P1043, DOI 10.1164/rccm.201002-0181OC
   Bull TM, 2010, AM J RESP CRIT CARE, V182, P1123, DOI 10.1164/rccm.201002-0250OC
   Carnesecchi S, 2009, AM J RESP CRIT CARE, V180, P972, DOI 10.1164/rccm.200902-0296OC
   Chen CA, 2011, J BIOL CHEM, V286, P29098, DOI 10.1074/jbc.M111.240127
   Cruz JA, 2012, AM J PHYSIOL-HEART C, V302, pH2518, DOI 10.1152/ajpheart.01140.2011
   Davidson TA, 1999, AM J RESP CRIT CARE, V160, P1838, DOI 10.1164/ajrccm.160.6.9903058
   Dzau VJ, 2006, CIRCULATION, V114, P2871, DOI 10.1161/CIRCULATIONAHA.106.655761
   Dzau VJ, 2006, CIRCULATION, V114, P2850, DOI 10.1161/CIRCULATIONAHA.106.655688
   Fitzal F, 2002, SHOCK, V18, P158, DOI 10.1097/00024382-200208000-00012
   Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI [10.1089/ars.2008.2220, 10.1089/ARS.2008.2220]
   Gajic O, 2007, CRIT CARE, V11, DOI 10.1186/cc5909
   Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garland A, 2013, CRIT CARE, V17, DOI 10.1186/cc13026
   GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Griffith B, 2009, ANTIOXID REDOX SIGN, V11, P2505, DOI [10.1089/ars.2009.2599, 10.1089/ARS.2009.2599]
   Han M, 2010, FREE RADICAL BIO MED, V48, P128, DOI 10.1016/j.freeradbiomed.2009.10.034
   Herridge Margaret S, 2011, N Engl J Med, V364, P1293, DOI 10.1056/NEJMoa1011802
   HINSHAW DB, 1989, J SURG RES, V46, P339, DOI 10.1016/0022-4804(89)90199-6
   Jane-Wit D, 2012, J GERONTOL A-BIOL, V67, P236, DOI 10.1093/gerona/glr248
   Johnston CJ, 2003, CHEST, V124, P653, DOI 10.1378/chest.124.2.653
   Kaestle SM, 2007, AM J PHYSIOL-LUNG C, V293, pL859, DOI 10.1152/ajplung.00008.2007
   Karuppiah K, 2011, AM J PHYSIOL-HEART C, V301, pH903, DOI 10.1152/ajpheart.00936.2010
   Kim JH, 2009, J APPL PHYSIOL, V107, P1249, DOI 10.1152/japplphysiol.91393.2008
   Liochev SI, 2013, FREE RADICAL BIO MED, V60, P1, DOI 10.1016/j.freeradbiomed.2013.02.011
   Malik UZ, 2011, FREE RADICAL BIO MED, V51, P179, DOI 10.1016/j.freeradbiomed.2011.04.004
   Maller C, 2011, ANTIOXID REDOX SIGN, V14, P49, DOI 10.1089/ars.2010.3149
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Milovanova T, 2008, BBA-MOL CELL RES, V1783, P1866, DOI 10.1016/j.bbamcr.2008.05.010
   Mo L, 2012, FREE RADICAL BIO MED, V53, P1440, DOI 10.1016/j.freeradbiomed.2012.07.080
   Muzaffar S, 2005, THORAX, V60, P305, DOI 10.1136/thx.2003.018796
   O'Rourke MF, 2010, VASC MED, V15, P461, DOI 10.1177/1358863X10382946
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037
   Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com
   Schmidt EP, 2008, AM J PHYSIOL-LUNG C, V295, pL1056, DOI 10.1152/ajplung.90329.2008
   SHASBY DM, 1985, BLOOD, V65, P605
   Speyer CL, 2003, AM J PATHOL, V163, P2319, DOI 10.1016/S0002-9440(10)63588-2
   Stamm Jason A, 2011, Pulm Circ, V1, P95, DOI 10.4103/2045-8932.78104
   Szczepaniak WS, 2008, TRANSL RES, V152, P213, DOI 10.1016/j.trsl.2008.09.002
   Tie L, 2009, AM J PHYSIOL-ENDOC M, V296, pE1423, DOI 10.1152/ajpendo.00150.2009
   Totzeck M, 2012, CIRCULATION, V126, P325, DOI 10.1161/CIRCULATIONAHA.111.087155
   Vaporidi K, 2010, AM J PHYSIOL-LUNG C, V299, pL150, DOI 10.1152/ajplung.00341.2009
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   WANG XZ, 1994, AM J RESP CRIT CARE, V150, P1449, DOI 10.1164/ajrccm.150.5.7952574
   Wojciak-Stothard B, 2006, AM J PHYSIOL-LUNG C, V290, pL1173, DOI 10.1152/ajplung.00309.2005
   Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804
   Yang Y, 2010, EUR RESPIR J, V36, P417, DOI 10.1183/09031936.00095609
NR 58
TC 32
Z9 35
U1 0
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC 15
PY 2014
VL 307
IS 12
BP L987
EP L997
DI 10.1152/ajplung.00063.2014
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA AW8AN
UT WOS:000346483100009
PM 25326583
OA Green Published
DA 2023-08-21
ER

PT J
AU Yuan, Q
   Jiang, YW
   Ma, TT
   Fang, QH
   Pan, L
AF Yuan, Qing
   Jiang, Yanwen
   Ma, Ting-ting
   Fang, Qiuhong
   Pan, Lei
TI Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats
SO JOURNAL OF INFLAMMATION-LONDON
LA English
DT Article
DE ALI/ARDS; ICAM-1; Ginsenoside Rb1; MPO; NF-kappa B; LPS 
ID INDUCED MICROCIRCULATORY DISTURBANCE; LEUKOCYTE RECRUITMENT; NEUTROPHIL
   MIGRATION; ENDOTHELIAL-CELLS; LIPOPOLYSACCHARIDE; INFLAMMATION;
   ACTIVATION; APOPTOSIS; MICE; PRETREATMENT
AB Background: Sepsis causes neutrophil sequestration in the lung which leads to acute lung injury (ALI). Radix Ginseng (RG), a traditional herb used as herbal remedy in eastern Asia for thousands of years, which has been traditionally used in China to improve blood circulation and ameliorate pathological hemostasis. This study investigated whether Ginsenoside Rb1, the main components of RG, can attenuate ALI induced by LPS.
   Methods: In vivo, 30 male Wistar rats were divided into three groups (n = 10 each groups) on the basis of the reagent used, which were subjected to LPS injection with or without Ginsenoside Rb1 (5 mg/kg) treatments to induce ALI model. Lung injury was assessed by pulmonary histology, lung wet-weight to dry-weight (W/D) ratio, the number of myeloperoxidase (MPO) positive cells, immunohistochemical analysis of intercellular adhesion molecule-1 (ICAM-1), gene expression of ICAM-1, ultrastructure changes of pulmonary microvasculature, concentration of inflammatory markers and in plasma. In vitro, pulmonary microvascular endothelial cells (PMVECs) were stimulated with LPS in the presence and absence of Ginsenoside Rb1 (50 mM), nuclear factor-kappa B (NF-kappa B) p65 was measured by immunocytochemistry staining and western blotting.
   Results: Infusion of LPS induced lung injury, in vivo, as demonstrated by pulmonary edema with infiltration of neutrophils and hemorrhage, the increase in lung W/D ratio, the number of MPO positive cells, the level of inflammatory markers such as TNF-alpha, MCP-1 and IL-8, enhanced expression of ICAM-1 and ICAM-1 gene. Moreover, resulted in the changes of intercellular junctions in the endothelial cells of pulmonary microvasculature. In vitro, the significant increased release of NF-kappa B p65 and its subsequent translocation into the nucleus in PMVECs were observed. In contrast, Ginsenoside Rb1 treatment significantly ameliorated the LPS-induced lung injury, as judged by the marked improvement in all these indices.
   Conclusions: These results indicate that Ginsenoside Rb1 attenuated LPS-induced lung injury through an inhibition of the inflammatory signaling pathway, besides the direct inhibitory effect on proinflammatory molecules.
C1 [Yuan, Qing] Capital Med Univ, Beijing Shijitan Hosp, Intens Care Unit Geriatr, Beijing 100038, China.
C1 [Jiang, Yan-wen; Fang, Qiu-hong] Capital Med Univ, Beijing Shijitan Hosp, Dept Pulm & Crit Care Med, Beijing 100038, China.
C1 [Ma, Ting-ting; Pan, Lei] Capital Med Univ, Beijing Shijitan Hosp, Dept Geriatr, Beijing 100038, China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University
RP Pan, L (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Dept Geriatr, 10 Tieyi Rd, Beijing 100038, Peoples R China.
EM Leipan61@aliyun.com
FU Beijing Municipal Health Bureau Youth Research Foundation, Beijing,
   China [QN2010-022]
FX The study was supported by Beijing Municipal Health Bureau Youth
   Research Foundation (QN2010-022), Beijing, China. The funders had no
   role in study design, data collection and analysis, decision to publish
   or preparation of the manuscript. Study on Railway Workers Chronic
   Disease Management Network Information Platform No. 2013Z003-C.
CR Chlopicki S, 2005, J Physiol Pharmacol, V56 Suppl 4, P47
   Dal-Secco D, 2010, N-S ARCH PHARMACOL, V381, P483, DOI 10.1007/s00210-010-0500-2
   Dang O, 2004, SHOCK, V21, P470, DOI 10.1097/00024382-200405000-00012
   Davis BB, 2011, BIOCHEM BIOPH RES CO, V410, P494, DOI 10.1016/j.bbrc.2011.06.008
   El Kebir D, 2008, CIRC RES, V103, P352, DOI 10.1161/01.RES.0000326772.76822.7a
   FABIANI JN, 1986, ANN CARDIOL ANGEIOL, V35, P439
   Fernandez-Pisonero I, 2012, J IMMUNOL, V189, P5402, DOI 10.4049/jimmunol.1201309
   Friedman GB, 1998, J CELL PHYSIOL, V176, P76, DOI 10.1002/(SICI)1097-4652(199807)176:1<76::AID-JCP9>3.0.CO;2-5
   Henriksen PA, 2004, J IMMUNOL, V172, P4535, DOI 10.4049/jimmunol.172.7.4535
   KIM N-S, 1991, Yonsei Medical Journal, V32, P303
   Malaviya R, 2010, TOXICOL APPL PHARM, V248, P89, DOI 10.1016/j.taap.2010.07.018
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   McCarter SA, 2006, EXP BIOL MED, V231, P985
   Morote-Garcia JC, 2012, P NATL ACAD SCI USA, V109, P14146, DOI 10.1073/pnas.1202165109
   Ramudo L, 2010, PANCREAS, V39, P1057, DOI 10.1097/MPA.0b013e3181da0f3e
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Rizzolo LJ, 2007, MOL VIS, V13, P1259
   Saeed RW, 2004, J IMMUNOL, V173, P6376, DOI 10.4049/jimmunol.173.10.6376
   Schuepbach RA, 2009, THROMB HAEMOSTASIS, V101, P724, DOI 10.1160/TH08-10-0632
   Shen WF, 2009, PHARMACOL RES, V60, P296, DOI 10.1016/j.phrs.2009.04.007
   Storme L, 2013, ARCH CARDIOVASC DIS, V106, P169, DOI 10.1016/j.acvd.2012.12.005
   Sun K, 2007, LIFE SCI, V81, P509, DOI 10.1016/j.lfs.2007.06.008
   van Oostrom AJHHM, 2006, ATHEROSCLEROSIS, V185, P331, DOI 10.1016/j.atherosclerosis.2005.06.045
   Wang J, 2013, MOLECULES, V18, P1214, DOI 10.3390/molecules18011214
   Wang W, 2006, AM J PHYSIOL-RENAL, V291, pF1090, DOI 10.1152/ajprenal.00517.2005
   White LE, 2012, SHOCK, V38, P320, DOI 10.1097/SHK.0b013e31826359d0
   Wu LL, 2014, BIOMED ENVIRON SCI, V27, P300, DOI 10.3967/bes2014.053
   Xie KL, 2012, SHOCK, V37, P548, DOI 10.1097/SHK.0b013e31824ddc81
   YABLONKAREUVENI Z, 1989, DEV BIOL, V132, P230, DOI 10.1016/0012-1606(89)90219-4
   Yang Y, 2011, MOL BIOL REP, V38, P3615, DOI 10.1007/s11033-010-0473-8
   Yen FL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063845
   Yuan Q, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-10
   Yuan Q, 2009, SHOCK, V32, P310, DOI 10.1097/SHK.0b013e31819c36e8
   Yuan XP, 2012, INFLAMMATION, V35, P1161, DOI 10.1007/s10753-011-9424-3
NR 34
TC 38
Z9 40
U1 3
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-9255
J9 J INFLAMM-LOND
JI J. Inflamm.-Lond.
PD DEC 5
PY 2014
VL 11
AR 40
DI 10.1186/s12950-014-0040-5
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA AZ9OW
UT WOS:000348545100001
PM 25530718
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Bijli, KM
   Kanter, BG
   Minhajuddin, M
   Leonard, A
   Xu, L
   Fazal, F
   Rahman, A
AF Bijli, Kaiser M.
   Kanter, Bryce G.
   Minhajuddin, Mohammad
   Leonard, Antony
   Xu, Lei
   Fazal, Fabeha
   Rahman, Arshad
TI REGULATION OF ENDOTHELIAL CELL INFLAMMATION AND LUNG POLYMORPHONUCLEAR
   LYMPHOCYTE INFILTRATION BY TRANSGLUTAMINASE 2
SO SHOCK
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; signal transduction; transcription factor; adhesion molecules; sepsis 
ID NF-KAPPA-B; RESPIRATORY-DISTRESS-SYNDROME; PROTEIN-C PREVENTS; TISSUE
   TRANSGLUTAMINASE; VASCULAR INJURY; MOUSE MODELS; ACTIVATION; EXPRESSION;
   PATHWAY; COAGULATION
AB We addressed the role of transglutaminase 2 (TG2), a calcium-dependent enzyme that catalyzes cross-linking of proteins, in the mechanism of endothelial cell (EC) inflammation and lung polymorphonuclear lymphocyte (PMN) infiltration. Exposure of EC to thrombin, a procoagulant and proinflammatory mediator, resulted in activation of the transcription factor nuclear factor kappa B (NF-kappa B) and its target genes, vascular cell adhesion molecule 1, monocyte chemotactic protein 1, and interleukin 6. RNAi knockdown of TG2 inhibited these responses. Analysis of NF-kappa B activation pathway showed that TG2 knockdown was associated with inhibition of thrombin-induced DNA binding as well as serine phosphorylation of RelA/p65, a crucial event that controls transcriptional capacity of the DNA-bound RelA/p65. These results implicate an important role for TG2 in mediating EC inflammation by promoting DNA-binding and transcriptional activity of RelA/p65. Because thrombin is released in high amounts during sepsis, and its concentration is elevated in plasma and lavage fluids of patients with acute respiratory distress syndrome, we determined the in vivo relevance of TG2 in a mouse model of sepsis-induced lung PMN recruitment. A marked reduction in NF-kappa B activation, adhesion molecule expression, and lung PMN sequestration was observed in TG2 knockout mice compared with wild-type mice exposed to endotoxemia. Together, these results identify TG2 as an important mediator of EC inflammation and lung PMN sequestration associated with intravascular coagulation and sepsis.
C1 [Bijli, Kaiser M.; Kanter, Bryce G.; Minhajuddin, Mohammad; Leonard, Antony; Fazal, Fabeha; Rahman, Arshad] Univ Rochester, Sch Med & Dent, Dept Pediat, Lung Biol & Dis Program, Rochester, NY 14642, United States.
C1 [Xu, Lei] Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Lung Biol & Dis Program, Rochester, NY 14642, United States.
C3 University of Rochester; University of Rochester
RP Rahman, A (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Lung Biol & Dis Program, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.
EM Arshad_Rahman@URMC.Rochester.edu
RI Minhajuddin, Mohammad/AAC-9227-2022
FU National Heart, Lung, and Blood Institute [HL67424, HL096907, HL116632];
   National Institute of Environmental Health Sciences Center [ES-01247];
   American Heart Association
FX This work was supported by National Heart, Lung, and Blood Institute
   grants HL67424, HL096907, and HL116632. This study was also supported in
   part by National Institute of Environmental Health Sciences Center grant
   ES-01247, and an SDG grant from American Heart Association (K.M.B.).
CR Bijli KM, 2012, AM J RESP CELL MOL, V47, P660, DOI 10.1165/rcmb.2012-0047OC
   Conway EM, 2002, J EXP MED, V196, P565, DOI 10.1084/jem.20020077
   De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Falasca L, 2008, J IMMUNOL, V180, P2616, DOI 10.4049/jimmunol.180.4.2616
   Fazal F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059965
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008
   Kefer J, 2001, SHOCK, V15, P11, DOI 10.1097/00024382-200115010-00002
   Kumar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049321
   Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240
   Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200
   Levi M, 2005, TRENDS CARDIOVAS MED, V15, P254, DOI 10.1016/j.tcm.2005.07.004
   Li XL, 2008, SHOCK, V29, P377, DOI 10.1097/shk.0b013e31815abe80
   Lin CC, 2011, EUR J PHARMACOL, V672, P180, DOI 10.1016/j.ejphar.2011.10.005
   Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014
   MALIK AB, 1987, AM REV RESPIR DIS, V136, P467, DOI 10.1164/ajrccm/136.2.467
   Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457
   Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197, DOI 10.1152/ajplung.1997.272.2.L197
   Niessen F, 2009, BLOOD, V113, P2859, DOI 10.1182/blood-2008-12-192385
   Oh K, 2011, J EXP MED, V208, P1707, DOI 10.1084/jem.20101457
   Paria BC, 2006, J BIOL CHEM, V281, P20715, DOI 10.1074/jbc.M600722200
   Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW
   Siegel M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001861
   Song DM, 2009, BLOOD, V114, P2521, DOI 10.1182/blood-2009-02-205914
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902
   Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Xu HL, 2010, J PATHOL, V220, P490, DOI 10.1002/path.2666
   Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
NR 35
TC 15
Z9 15
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD DEC
PY 2014
VL 42
IS 6
BP 562
EP 569
DI 10.1097/SHK.0000000000000242
PG 8
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA AT9FX
UT WOS:000345234400011
PM 25057925
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Gao, ZM
   Xu, JF
   Sun, DG
   Zhang, RX
   Liang, R
   Wang, LM
   Fan, R
AF Gao, Zhenming
   Xu, Junfeng
   Sun, Deguang
   Zhang, Rixin
   Liang, Rui
   Wang, Liming
   Fan, Rong
TI Traditional Chinese medicine, Qing Ying Tang, ameliorates the severity
   of acute lung injury induced by severe acute pancreatitis in rats via
   the upregulation of aquaporin-1
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE aquaporin 1; qing yin tang; ALI/ARDS; severe acute pancreatitis 
ID IMPAIRMENT; PROTEINS; MICE
AB Aquaporin-1 (AQP-1) is expressed in lung endothelial cells and regulates water transport; thus, AQP-1 plays an important role in a number of edema-associated lung diseases. Qing Yin Tang (QYT), a traditional Chinese medicine, has been shown to effectively reduce the mortality rate of acute lung injury (ALI) induced by severe acute pancreatitis (SAP). The current study aimed to investigate the detailed mechanisms underlying the effects of QYT on ALI induced by SAP, particularly the effects on the expression levels of AQP-I in the lung tissue. ALI was established in Wister rats who were subsequently divided into four groups: SHAM, ALI, dexamethasone (DEX) and QYT groups (n=8 per group). In the QYT group, 20 ml/kg QYT was administered by gavage immediately following the induction of SAP. Blood and lung tissues were collected 8 h following the induction of pancreatitis. The lung wet/dry ratio, as well as the levels of blood gases, serum amylase and tumor necrosis factor-alpha (TNF-alpha), were measured at 4, 8 and 12 h following SAP-associated ALL induction surgery. The expression levels of AQP-1 in the lung tissue were detected by quantitative polymerase chain reaction, immunohistochemistry and western blot analysis. No statistically significant differences were observed with regard to the levels of serum amylase, wet/dry ratio, partial pressure of oxygen, serum TNF-alpha and pathological changes in the pulmonary tissue between, the QYT and DEX groups; however, a statistically significant difference was observed when compared with the ALL group. The expression levels of AQP-1 significantly increased (P<0.05) and lung edema was alleviated in the QYT and DEX groups, when compared with ALI group. Therefore, the expression level of AQP-1 is associated with pulmonary edema. QYT protects the lungs from injury induced by SAP via the upregulation of AQP-1, which suppresses TNF-alpha expression.
C1 [Gao, Zhenming; Xu, Junfeng; Sun, Deguang; Zhang, Rixin; Liang, Rui; Wang, Liming] Dalian Med Univ, Affiliated Hosp 2, Hepatopancreatobiliary Surg Dept, Dalian 116027, Liaoning, China.
C1 [Fan, Rong] Dalian Med Univ, Affiliated Hosp 2, VIP Ward 2, Dalian 116027, Liaoning, China.
C3 Dalian Medical University; Dalian Medical University
RP Fan, R (corresponding author), Dalian Med Univ, Affiliated Hosp 2, VIP Ward 2, 467 Zhongshan Rd, Dalian 116027, Liaoning, Peoples R China.
EM fanrong6799@163.com
FU Liaoning Province Natural Science Foundation [2013023021]
FX The study was supported by a grant from the Liaoning Province Natural
   Science Foundation (no. 2013023021).
CR Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659
   Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849
   Benga G, 2012, MOL ASPECTS MED, V33, P514, DOI 10.1016/j.mam.2012.04.003
   DENKER BM, 1988, J BIOL CHEM, V263, P15634
   Heinrich S, 2006, ANN SURG, V243, P154, DOI 10.1097/01.sla.0000197334.58374.70
   Kandil E, 2006, WORLD J GASTROENTERO, V12, P6806, DOI 10.3748/wjg.v12.i42.6806
   Li ZZ, 2012, WORLD J PEDIATR, V8, P335, DOI 10.1007/s12519-012-0378-9
   Li ZL, 1998, WORLD J GASTROENTERO, V4, P357
   Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296
   Mayer J, 2000, GUT, V47, P546, DOI 10.1136/gut.47.4.546
   Mosbasheri A, 2004, AM J PHYSIOL-CELL PH, V286, pC529, DOI 10.1152/ajpcell.00408.2003
   Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460
   Shields Conor J, 2002, Curr Opin Crit Care, V8, P158, DOI 10.1097/00075198-200204000-00012
   Sugiyama Yusuke, 2005, Inflammopharmacology, V13, P291, DOI 10.1163/156856005774423728
   Surbatovic Maja, 2005, Srp Arh Celok Lek, V133, P76
   Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818
   Verkman AS, 2012, ANNU REV MED, V63, P303, DOI 10.1146/annurev-med-043010-193843
   Verkman A. S., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000690
   Windsor JA, 2013, GUT, V62, P4, DOI 10.1136/gutjnl-2012-303725
   Xue DB, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/26295
   Yang Dong-ying, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P1122
   Zhang H, 2013, J CLIN INVEST, V123, P1019, DOI 10.1172/JCI64931
   Zhang MJ, 2008, WORLD J GASTROENTERO, V14, P3574, DOI 10.3748/wjg.14.3574
   Zhang XP, 2007, J PANCREAS, V8, P704
   Zhang YW, 2009, CLIN EXP PHARMACOL P, V36, P734, DOI 10.1111/j.1440-1681.2009.05156.x
   Zhao YQ, 2004, WORLD J GASTROENTERO, V10, P1005
   Zhou MT, 2010, WORLD J GASTROENTERO, V16, P2094, DOI 10.3748/wjg.v16.i17.2094
NR 27
TC 21
Z9 25
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2014
VL 8
IS 6
BP 1819
EP 1824
DI 10.3892/etm.2014.1987
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AU9YN
UT WOS:000345948000026
PM 25371738
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Qing, DY
   Conegliano, D
   Shashaty, MGS
   Seo, J
   Reilly, JP
   Worthen, GS
   Huh, D
   Meyer, NJ
   Mangalmurti, NS
AF Qing, Danielle Y.
   Conegliano, David
   Shashaty, Michael G. S.
   Seo, Jeongyun
   Reilly, John P.
   Worthen, G. Scott
   Huh, Dongeun
   Meyer, Nuala J.
   Mangalmurti, Nilam S.
TI Red Blood Cells Induce Necroptosis of Lung Endothelial Cells and
   Increase Susceptibility to Lung Inflammation
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE RBC transfusion; necroptosis; ECs/HPMECs/HUVECs/MPVECs; HMGB1; RIP3 
ID RESPIRATORY-DISTRESS-SYNDROME; GROUP BOX-1 PROTEIN; GLYCATION
   END-PRODUCTS; PROGRAMMED NECROSIS; CRITICALLY-ILL; NECROTIC CELLS;
   CLINICAL-TRIAL; INCREASED RISK; LATE MEDIATOR; HMGB1
AB Rationale: Red blood cell (RBC) transfusions are associated with increased risk of acute respiratory distress syndrome (ARDS) in the critically ill, yet the mechanisms for enhanced susceptibility to ARDS conferred by RBC transfusions remain unknown.
   Objectives: To determine the mechanisms of lung endothelial cell (EC) High Mobility Group Box 1 (HMGB1) release following exposure to RBCs and to determine whether RBC transfusion increases susceptibility to lung inflammation in vivo through release of the danger signal HMGB1.
   Methods: In vitro studies examining human lung EC viability and HMGB1 release following exposure to allogenic RBCs were conducted under static conditions and using a microengineered model of RBC perfusion. The plasma from transfused and nontransfused patients with severe sepsis was examined for markers of cellular injury. A murine model of RBC transfusion followed by LPS administration was used to determine the effects-of RBC transfusion and FIMGB1 release on LPS-induced lung inflammation.
   Measurements and Main Results: After incubation with RBCs, lung ECs underwent regulated necrotic cell death (necroptosis) and released the essential mediator of necroptosis, receptor-interacting serine/threonine-protein kinase 3 (RIP3), and HMGB1. RIP3 was detectable in the plasma of patients with severe sepsis, and was increased with blood transfusion and among nonsurvivors of sepsis. RBC transfusion sensitized mice to LPS-induced lung inflammation through release of the danger signal HMGBI.
   Conclusions: RBC transfusion enhances susceptibility to lung inflammation through release of HMGBI and induces necroptosis of lung EC. Necroptosis and subsequent danger signal release is a novel mechanism of injury following transfusion that may account for the increased risk of ARDS in critically ill transfused patients.
C1 [Qing, Danielle Y.; Shashaty, Michael G. S.; Reilly, John P.; Meyer, Nuala J.; Mangalmurti, Nilam S.] Univ Penn, Perelman Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104, United States.
C1 [Conegliano, David; Seo, Jeongyun; Huh, Dongeun] Univ Penn, Dept Bioengn, Philadelphia, PA 19104, United States.
C1 [Worthen, G. Scott] Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104, United States.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia
RP Mangalmurti, NS (corresponding author), Univ Penn, Gates Bldg,Room 5043,3600 Spruce St, Philadelphia, PA 19104 USA.
EM nspatel@mail.med.upenn.edu
RI Shashaty, Michael/X-3690-2019
OI Shashaty, Michael/0000-0002-8766-3418; Mangalmurti,
   Nilam/0000-0002-9146-1608; Qing, Danielle/0000-0001-5511-5196; Reilly,
   John/0000-0003-3937-5320
FU Cardiovascular Medical Research and Education Fund
FX Lung microvascular endothelial cells for studies in the microengineered
   model were provided by Drs. Horace Delisser, Kaori Ihida-Stansbury, and
   Steven Kawut under the Pulmonary Hypertension Breakthrough Initiative.
   Funding for the Pulmonary Hypertension Breakthrough Initiative is
   provided by the Cardiovascular Medical Research and Education Fund.
CR Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950
   Andonegui G, 2009, J CLIN INVEST, V119, P1921, DOI 10.1172/JCI36411
   Bell CW, 2006, AM J PHYSIOL-CELL PH, V291, pC1318, DOI 10.1152/ajpcell.00616.2005
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79
   Croce MA, 2005, J TRAUMA, V59, P19, DOI 10.1097/01.TA.0000171459.21450.DC
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300
   Gibot S, 2007, INTENS CARE MED, V33, P1347, DOI 10.1007/s00134-007-0691-2
   Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14
   Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601
   Holena DN, 2012, J TRAUMA ACUTE CARE, V73, P825, DOI 10.1097/TA.0b013e318256de38
   Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Janz DR, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-33
   Jiang WW, 2007, J IMMUNOL, V178, P6495, DOI 10.4049/jimmunol.178.10.6495
   Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341
   Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857
   Kiefmann R, 2008, BLOOD, V111, P5205, DOI 10.1182/blood-2007-09-113902
   Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403
   Kor DJ, 2012, AM J RESP CRIT CARE, V185, P842, DOI 10.1164/rccm.201107-1332OC
   Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019
   Mangalmurti NS, 2014, AM J RESP CRIT CARE, V189
   Mangalmurti NS, 2013, AM J PHYSIOL-LUNG C, V304, pL250, DOI 10.1152/ajplung.00278.2012
   Mangalmurti NS, 2010, TRANSFUSION, V50, P2353, DOI 10.1111/j.1537-2995.2010.02689.x
   Mangalmurti NS, 2009, BLOOD, V113, P1158, DOI 10.1182/blood-2008-07-166264
   Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018
   Nakamura T, 2011, CLIN BIOCHEM, V44, P601, DOI 10.1016/j.clinbiochem.2010.12.014
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200
   Reilly JP, 2014, CHEST, V145, P753, DOI 10.1378/chest.13-1962
   Roberts R, 2005, J TRAUMA, V59, P23
   Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Vanlangenakker N, 2012, CELL DEATH DIFFER, V19, P75, DOI 10.1038/cdd.2011.164
   Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117
   Wolfson RK, 2014, MICROVASC RES, V92, P50, DOI 10.1016/j.mvr.2013.12.005
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
   Wu YT, 2011, CELL DEATH DIFFER, V18, P26, DOI 10.1038/cdd.2010.72
   Xie T, 2013, CELL REP, V5, P70, DOI 10.1016/j.celrep.2013.08.044
   Yang YH, 2004, J BIOL CHEM, V279, P38820, DOI 10.1074/jbc.M401663200
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zilberberg MD, 2007, CRIT CARE, V11, DOI 10.1186/cc5934
NR 52
TC 77
Z9 84
U1 1
U2 11
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD DEC 1
PY 2014
VL 190
IS 11
BP 1243
EP 1254
DI 10.1164/rccm.201406-1095OC
PG 12
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA AW5RF
UT WOS:000346331000008
PM 25329368
OA Green Published
DA 2023-08-21
ER

PT J
AU Sakaguchi, M
   Marutani, E
   Shin, HS
   Chen, W
   Hanaoka, K
   Xian, M
   Ichinose, F
AF Sakaguchi, Masahiro
   Marutani, Eizo
   Shin, Hae-sook
   Chen, Wei
   Hanaoka, Kenjiro
   Xian, Ming
   Ichinose, Fumito
TI Sodium Thiosulfate Attenuates Acute Lung Injury in Mice
SO ANESTHESIOLOGY
LA English
DT Article
ID HYDROGEN-SULFIDE; PROTECTS; INFLAMMATION; ACTIVATION; CISPLATIN;
   FAILURE; SEPSIS
AB Background: Acute lung injury is characterized by neutrophilic inflammation and increased lung permeability. Thiosulfate is a stable metabolite of hydrogen sulfide, a gaseous mediator that exerts antiinflammatory effects. Although sodium thiosulfate (STS) has been used as an antidote, the effect of STS on acute lung injury is unknown. The authors assessed the effects of STS on mice lung and vascular endothelial cells subjected to acute inflammation.
   Methods: Lung injury was assessed in mice challenged with intratracheal lipopolysaccharide or subjected to cecal ligation and puncture with or without STS. Effects of STS on endothelial permeability and the production of inflammatory cytokines and reactive oxygen species were examined in cultured endothelial cells incubated with lipopolysaccharide or tumor necrosis factor-a. Levels of sulfide and sulfane sulfur were measured using novel fluorescence probes.
   Results: STS inhibited lipopolysaccharide-induced production of cytokines (interleukin-6 [pg/ml]; 313 +/- 164, lipopolysaccharide; 79 +/- 27, lipopolysaccharide + STS [n = 10]), lung permeability, histologic lung injury, and nuclear factor-kappa B activation in the lung. STS also prevented up-regulation of interleukin-6 in the mouse lung subjected to cecal ligation and puncture. In endothelial cells, STS increased intracellular levels of sulfide and sulfane sulfur and inhibited lipopolysaccharide or tumor necrosis factor-alpha-induced production of cytokines and reactive oxygen species. The beneficial effects of STS were associated with attenuation of the lipopolysaccharide-induced nuclear factor-kappa B activation through the inhibition of tumor necrosis factor receptor-associated factor 6 ubiquitination.
   Conclusions: STS exerts robust antiinflammatory effects in mice lung and vascular endothelium. The results suggest a therapeutic potential of STS in acute lung injury.
C1 [Sakaguchi, Masahiro; Marutani, Eizo; Shin, Hae-sook; Ichinose, Fumito] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114, United States.
C1 [Sakaguchi, Masahiro; Marutani, Eizo; Shin, Hae-sook; Ichinose, Fumito] Harvard Univ, Sch Med, Boston, MA, United States.
C1 [Chen, Wei; Xian, Ming] Washington State Univ, Dept Chem, Pullman, WA 99164, United States.
C1 [Hanaoka, Kenjiro] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Washington State University; University of Tokyo
RP Ichinose, F (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM fichinose@mgh.harvard.edu
OI Chen, Wei/0000-0001-5567-7463
FU National Institutes of Health (Bethesda, Maryland) [R01HL101930]
FX This study was supported by a National Institutes of Health (Bethesda,
   Maryland) grant R01HL101930 (to Dr. Ichinose).
CR Adirekkiat S, 2010, NEPHROL DIAL TRANSPL, V25, P1923, DOI 10.1093/ndt/gfp755
   Bernard GR, 2005, AM J RESP CRIT CARE, V172, P798, DOI 10.1164/rccm.200504-663OE
   Chen W, 2013, CHEM SCI, V4, P2892, DOI 10.1039/c3sc50754h
   Chung JY, 2002, J CELL SCI, V115, P679
   Cicone JS, 2004, AM J KIDNEY DIS, V43, P1104, DOI 10.1053/j.ajkd.2004.03.018
   Faller S, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-26
   Francis RC, 2011, ANESTHESIOLOGY, V115, P1012, DOI 10.1097/ALN.0b013e31823306cf
   GOEL R, 1989, J NATL CANCER I, V81, P1552, DOI 10.1093/jnci/81.20.1552
   Ichinose F, 2001, CIRC RES, V88, P832, DOI 10.1161/hh0801.089177
   Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345
   Koh H, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-60
   Kondo K, 2013, CIRCULATION, V127, P1116, DOI 10.1161/CIRCULATIONAHA.112.000855
   Liu SQ, 2011, CELL RES, V21, P6, DOI 10.1038/cr.2010.170
   MARKMAN M, 1985, CANCER, V56, P2364, DOI 10.1002/1097-0142(19851115)56:10<2364::AID-CNCR2820561003>3.0.CO;2-4
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Menden H, 2013, AM J PHYSIOL-LUNG C, V304, pL445, DOI 10.1152/ajplung.00261.2012
   Neuwelt EA, 1998, J PHARMACOL EXP THER, V286, P77
   Olson KR, 2011, AM J PHYSIOL-REG I, V301, pR297, DOI 10.1152/ajpregu.00045.2011
   Pan LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019766
   Pasch A, 2008, KIDNEY INT, V74, P1444, DOI 10.1038/ki.2008.455
   Peters K, 2003, CARDIOVASC RES, V60, P49, DOI 10.1016/S0008-6363(03)00397-3
   PETTERSEN JC, 1985, TOXICOL APPL PHARM, V81, P265, DOI 10.1016/0041-008X(85)90163-2
   Reddy AT, 2012, J IMMUNOL, V189, P5411, DOI 10.4049/jimmunol.1201487
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sasakura K, 2011, J AM CHEM SOC, V133, P18003, DOI 10.1021/ja207851s
   Sen N, 2012, MOL CELL, V45, P13, DOI 10.1016/j.molcel.2011.10.021
   Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364
   Shibuya N, 2009, J BIOCHEM, V146, P623, DOI 10.1093/jb/mvp111
   Shibuya N, 2009, ANTIOXID REDOX SIGN, V11, P703, DOI [10.1089/ars.2008.2253, 10.1089/ARS.2008.2253]
   Shirozu K, 2014, ANTIOXID REDOX SIGN, V20, P204, DOI 10.1089/ars.2013.5354
   Suzuki K, 2011, P NATL ACAD SCI USA, V108, P13829, DOI 10.1073/pnas.1105121108
   Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425
   Tokuda K, 2012, ANTIOXID REDOX SIGN, V17, P11, DOI 10.1089/ars.2011.4363
   Toohey JI, 2011, ANAL BIOCHEM, V413, P1, DOI 10.1016/j.ab.2011.01.044
   Whiteman M, 2010, ANTIOXID REDOX SIGN, V12, P1147, DOI 10.1089/ars.2009.2899
   Zhang XF, 2013, CELL RES, V23, P366, DOI 10.1038/cr.2013.21
   Zou L, 2011, SHOCK, V36, P370, DOI 10.1097/SHK.0b013e3182279868
NR 37
TC 58
Z9 60
U1 1
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD DEC
PY 2014
VL 121
IS 6
BP 1248
EP 1257
DI 10.1097/ALN.0000000000000456
PG 10
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA AU2FB
UT WOS:000345430700016
PM 25260144
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Shaver, CM
   Bastarache, JA
AF Shaver, Ciara M.
   Bastarache, Julie A.
TI Clinical and Biological Heterogeneity in Acute Respiratory Distress
   Syndrome Direct Versus Indirect Lung Injury
SO CLINICS IN CHEST MEDICINE
LA English
DT Article
DE Direct lung injury; ALI/ARDS 
ID QUALITY-OF-LIFE; GLYCATION END-PRODUCTS; TIDAL VOLUME VENTILATION;
   EPITHELIAL LINING FLUID; PRONE POSITION; CIRCULATING ANGIOPOIETIN-2;
   VASCULAR-PERMEABILITY; RECRUITMENT MANEUVER; EXTRAPULMONARY ARDS;
   PULMONARY-FUNCTION
AB The acute respiratory distress syndrome (ARDS) is a heterogeneous group of illnesses affecting the pulmonary parenchyma with acute onset bilateral inflammatory pulmonary infiltrates with associated hypoxemia. ARDS occurs after 2 major types of pulmonary injury: direct lung injury affecting the lung epithelium or indirect lung injury disrupting the vascular endothelium. Greater understanding of the differences between direct and indirect lung injury may refine the classification of patients with ARDS and lead to development of new therapeutics targeted at specific subpopulations of patients with ARDS.
C1 [Shaver, Clara M.; Bastarache, Julie A.] Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care Med, Sch Med,Med Ctr North, Nashville, TN 37232, United States.
C3 Vanderbilt University
RP Shaver, CM (corresponding author), Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care Med, Sch Med,Med Ctr North, T-1218, Nashville, TN 37232 USA.
EM ciara.shaver@vanderbilt.edu
OI Shaver, Ciara/0000-0002-5677-0288
FU National Institutes of Health [HL087738, HL090785]; American Heart
   Association [11CRP7820021]
FX National Institutes of Health, grant HL087738 (C.M. Shaver); National
   Institutes of Health, grant HL090785, American Heart Association, grant
   11CRP7820021 (J.A. Bastarache).
CR Agarwal R, 2008, CHEST, V133, P1463, DOI 10.1378/chest.07-2182
   Agarwal R, 2006, CHEST, V130, P724, DOI 10.1378/chest.130.3.724
   Albaiceta GM, 2003, INTENS CARE MED, V29, P1943, DOI 10.1007/s00134-003-1965-y
   Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201
   Araujo IM, 2010, CRIT CARE MED, V38, P1733, DOI 10.1097/CCM.0b013e3181e796d2
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bhargava R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061405
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6
   Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Capelozzi VL, 2008, CURR OPIN CRIT CARE, V14, P56, DOI 10.1097/MCC.0b013e3282f449de
   Chen X, 2013, BIOCHEM BIOPH RES CO, V441, P1, DOI 10.1016/j.bbrc.2013.09.027
   D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498
   Desai SR, 2001, RADIOLOGY, V218, P689, DOI 10.1148/radiology.218.3.r01mr31689
   Dowdy DW, 2006, INTENS CARE MED, V32, P1115, DOI 10.1007/s00134-006-0217-3
   Egli M, 2004, J PHYSIOL-LONDON, V560, P857, DOI 10.1113/jphysiol.2004.066704
   Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093
   Galani V, 2010, PATHOL RES PRACT, V206, P145, DOI 10.1016/j.prp.2009.12.002
   Garibaldi BT, 2013, AM J RESP CELL MOL, V48, P35, DOI 10.1165/rcmb.2012-0198OC
   Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031
   Gong MN, 2005, EUR RESPIR J, V26, P382, DOI 10.1183/09031936.05.00000505
   Goodman LR, 1999, RADIOLOGY, V213, P545, DOI 10.1148/radiology.213.2.r99nv42545
   Gurkan OU, 2011, EXP LUNG RES, V37, P575, DOI 10.3109/01902148.2011.620680
   Herridge MS, 2011, CRIT CARE CLIN, V27, P685, DOI 10.1016/j.ccc.2011.04.003
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Hoelz C, 2001, PATHOL RES PRACT, V197, P521
   Ishizaka A, 2004, AM J PHYSIOL-LUNG C, V286, pL1088, DOI 10.1152/ajplung.00420.2002
   Janz DR, 2013, SEMIN RESP CRIT CARE, V34, P537, DOI 10.1055/s-0033-1351124
   Kesecioglu J, 2009, AM J RESP CRIT CARE, V180, P989, DOI 10.1164/rccm.200812-1955OC
   Kondo T, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-32
   Kuiper JW, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-26
   LAMY M, 1976, AM REV RESPIR DIS, V114, P267
   Leite JHP, 2008, CRIT CARE MED, V36, P2621, DOI 10.1097/CCM.0b013e3181847b43
   Lim CM, 2003, CRIT CARE MED, V31, P411, DOI 10.1097/01.CCM.0000048631.88155.39
   Lim CM, 2001, INTENS CARE MED, V27, P477, DOI 10.1007/s001340000848
   Lomas-Neira J, 2014, AM J RESP CELL MOL, V50, P193, DOI 10.1165/rcmb.2013-0148OC
   Maron-Gutierrez T, 2013, CRIT CARE MED, V41, pE319, DOI 10.1097/CCM.0b013e31828a663e
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004
   Meng ZH, 2001, AM J PHYSIOL-CELL PH, V280, pC343, DOI 10.1152/ajpcell.2001.280.2.C343
   Mommsen P, 2011, CYTOKINE, V53, P60, DOI 10.1016/j.cyto.2010.09.005
   Monchi M, 1998, AM J RESP CRIT CARE, V158, P1076, DOI 10.1164/ajrccm.158.4.9802009
   Negri EM, 2002, PATHOL RES PRACT, V198, P355, DOI 10.1078/0344-0338-00266
   Ong T, 2010, CRIT CARE MED, V38, P1845, DOI 10.1097/CCM.0b013e3181eaa5bf
   Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Parker CM, 2006, INTENS CARE MED, V32, P1895, DOI 10.1007/s00134-006-0344-x
   Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC
   Pelosi P, 1999, AM J RESP CRIT CARE, V159, P872, DOI 10.1164/ajrccm.159.3.9802090
   Pelosi P, 2003, EUR RESPIR J, V22, p48S, DOI 10.1183/09031936.03.00420803
   Pelosi P, 2002, EUR RESPIR J, V20, P1017, DOI 10.1183/09031936.02.00401702
   Serra André Peres e, 2006, Clinics, V61, P497, DOI 10.1590/S1807-59322006000600002
   Perl M, 2005, AM J PATHOL, V167, P1545, DOI 10.1016/S0002-9440(10)61240-0
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003
   PUTENSEN C, 1992, ANESTH ANALG, V74, P793
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Rialp G, 2001, AM J RESP CRIT CARE, V164, P243, DOI 10.1164/ajrccm.164.2.2002087
   Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
   Rouby JJ, 2000, INTENS CARE MED, V26, P1046, DOI 10.1007/s001340051317
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733
   Santos FB, 2006, J APPL PHYSIOL, V100, P98, DOI 10.1152/japplphysiol.00395.2005
   Schelling G, 2000, INTENS CARE MED, V26, P1304, DOI 10.1007/s001340051342
   Schmidt EP, 2014, J BIOL CHEM, V289, P8194, DOI 10.1074/jbc.M113.539452
   Simmons EM, 2004, KIDNEY INT, V65, P1357, DOI 10.1111/j.1523-1755.2004.00512.x
   Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181
   Su X, 2009, AM J PHYSIOL-LUNG C, V297, pL1, DOI 10.1152/ajplung.90546.2008
   Suntharalingam G, 2001, CRIT CARE MED, V29, P562
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Tejera P, 2012, J MED GENET, V49, P671, DOI 10.1136/jmedgenet-2012-100972
   Thakkar RK, 2011, SHOCK, V36, P138, DOI 10.1097/SHK.0b013e31821c236d
   Tugrul S, 2003, CRIT CARE MED, V31, P738, DOI 10.1097/01.CCM.0000053554.76355.72
   Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   van der Heijden M, 2009, INTENS CARE MED, V35, P1567, DOI 10.1007/s00134-009-1560-y
   Venet F, 2010, AM J PATHOL, V176, P764, DOI 10.2353/ajpath.2010.090765
   Venet F, 2009, J IMMUNOL, V183, P3472, DOI 10.4049/jimmunol.0804119
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Willson DF, 2011, RESP CARE, V56, P1369, DOI 10.4187/respcare.01306
   Winer-Muram HT, 1998, RADIOLOGY, V208, P193, DOI 10.1148/radiology.208.1.9646813
   Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368
   Yang Y, 2014, MOL BIOL REP, V41, P1325, DOI 10.1007/s11033-013-2978-4
NR 86
TC 86
Z9 91
U1 7
U2 45
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-5231
EI 1557-8216
J9 CLIN CHEST MED
JI Clin. Chest Med.
PD DEC
PY 2014
VL 35
IS 4
BP 639
EP +
DI 10.1016/j.ccm.2014.08.004
PG 16
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA AW3WO
UT WOS:000346214200004
PM 25453415
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Sukriti, S
   Tauseef, M
   Yazbeck, P
   Mehta, D
AF Sukriti, Sukriti
   Tauseef, Mohammad
   Yazbeck, Pascal
   Mehta, Dolly
TI Mechanisms regulating endothelial permeability
SO PULMONARY CIRCULATION
LA English
DT Review
DE ECs/HPMECs/HUVECs/MPVECs; adhesion junction; permeability; signaling mechanism 
ID LUNG VASCULAR-PERMEABILITY; OPERATED CA2+ ENTRY; PROTEIN-KINASE-C; TIGHT
   JUNCTION PROTEINS; FOCAL ADHESION KINASE; BLOOD-BRAIN-BARRIER;
   VE-CADHERIN; TRPC CHANNELS; THROMBIN RECEPTOR; RHO-KINASE
AB The endothelial monolayer partitioning underlying tissue from blood components in the vessel wall maintains tissue fluid balance and host defense through dynamically opening intercellular junctions. Edemagenic agonists disrupt endothelial barrier function by signaling the opening of the intercellular junctions leading to the formation of protein-rich edema in the interstitial tissue, a hallmark of tissue inflammation that, if left untreated, causes fatal diseases, such as acute respiratory distress syndrome. In this review, we discuss how intercellular junctions are maintained under normal conditions and after stimulation of endothelium with edemagenic agonists. We have focused on reviewing the new concepts dealing with the alteration of adherens junctions after inflammatory stimulus.
C1 [Mehta, Dolly] Univ Illinois, Coll Med, Dept Pharmacol, 835 South Wolcott Ave, Chicago, IL 60612, United States.
C1 Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 South Wolcott Ave, Chicago, IL 60612 USA.
EM dmehta@uic.edu
OI Tauseef, Mohammad/0000-0001-5317-4379; Baweja,
   Sukriti/0000-0002-8677-9857
FU National Institutes of Health [HL71794, HL84153, HL060678]; American
   Heart Association [12 Post 12080112]
FX This work was supported by National Institutes of Health grants HL71794,
   HL84153, and HL060678 as well as an American Heart Association
   postdoctoral fellowship to SS (12 Post 12080112).
CR Abramowitz J, 2009, FASEB J, V23, P297, DOI 10.1096/fj.08-119495
   Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z
   Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429
   Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001
   Arcangeli ML, 2013, ARCH IMMUNOL THER EX, V61, P15, DOI 10.1007/s00005-012-0199-5
   Arnold KM, 2013, MICROCIRCULATION, V20, P637, DOI 10.1111/micc.12063
   ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699
   Aurrand-Lions MA, 2000, CURR TOP MICROBIOL, V251, P91
   Bajer Seweryn, 2009, Postepy Biochem, V55, P223
   Barr AJ, 1997, J BIOL CHEM, V272, P2223
   Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9
   Bird GS, 2009, CURR BIOL, V19, P1724, DOI 10.1016/j.cub.2009.08.022
   Birnbaumer L, 2009, ANNU REV PHARMACOL, V49, P395, DOI 10.1146/annurev.pharmtox.48.113006.094928
   Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X
   Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039
   Broman MT, 2006, CIRC RES, V98, P73, DOI 10.1161/01.RES.0000198387.44395.e9
   Cahalan MD, 2009, NAT CELL BIOL, V11, P669, DOI 10.1038/ncb0609-669
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   CARTER TD, 1994, PFLUG ARCH EUR J PHY, V428, P476, DOI 10.1007/BF00374568
   Chava KR, 2012, BLOOD, V119, P308, DOI 10.1182/blood-2011-02-339473
   Chavez A, 2011, INT REV CEL MOL BIO, V290, P205, DOI 10.1016/B978-0-12-386037-8.00001-6
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Chen ZL, 2012, MOL BIOL CELL, V23, P1388, DOI 10.1091/mbc.E11-09-0811
   CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U
   Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987
   Curry FRE, 2006, CIRC RES, V99, P915, DOI 10.1161/01.RES.0000249618.51440.c6
   Dejana E, 2012, CURR OPIN HEMATOL, V19, P218, DOI 10.1097/MOH.0b013e3283523e1c
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005
   Dietrich A, 2010, THROMB HAEMOSTASIS, V103, P262, DOI 10.1160/TH09-08-0517
   Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100
   Esser S, 1998, J CELL SCI, V111, P1853
   Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745
   Field JJ, 2013, CHEM BIOL, V20, P301, DOI 10.1016/j.chembiol.2013.01.014
   Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Giorgi D, 2001, GENOMICS, V75, P49, DOI 10.1006/geno.2001.6571
   Glading A, 2007, J CELL BIOL, V179, P247, DOI 10.1083/jcb.200705175
   GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613
   Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178
   Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072
   Grinnell KL, 2012, MICROVASC RES, V83, P12, DOI 10.1016/j.mvr.2011.04.005
   Harper MT, 2010, PLATELETS, V21, P445, DOI 10.3109/09537104.2010.483295
   Harrington EO, 2003, AM J RESP CELL MOL, V28, P626, DOI 10.1165/rcmb.2002-0085OC
   HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703
   Hatanaka K, 2011, AM J PHYSIOL-HEART C, V300, pH162, DOI 10.1152/ajpheart.00650.2010
   Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550
   Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3
   Huang F, 2005, AM J PHYSIOL-LUNG C, V289, pL176, DOI 10.1152/ajplung.00003.2005
   Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454
   HUNG DT, 1992, J BIOL CHEM, V267, P20831
   Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Jho D, 2005, CIRC RES, V96, P1282, DOI 10.1161/01.RES.0000171894.03801.03
   Kaneider NC, 2007, NAT IMMUNOL, V8, P1303, DOI 10.1038/ni1525
   Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669
   KAYE AD, 1995, AM J PHYSIOL-LUNG C, V269, pL507, DOI 10.1152/ajplung.1995.269.4.L507
   KEDEM O, 1958, BIOCHIM BIOPHYS ACTA, V27, P229, DOI 10.1016/0006-3002(58)90330-5
   KEDEM O, 1989, BIOCHIM BIOPHYS ACTA, V1000, P411, DOI 10.1016/S0006-3002(89)80036-8
   Kevil CG, 1998, MICROCIRCULATION-LON, V5, P197, DOI 10.1038/sj.mn.7300011
   Klarenbach SW, 2003, CIRC RES, V92, P272, DOI 10.1161/01.RES.0000057386.15390.A3
   Knezevic N, 2007, MOL CELL BIOL, V27, P6323, DOI 10.1128/MCB.00523-07
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Koenen RR, 2009, BLOOD, V113, P4799, DOI 10.1182/blood-2008-04-152330
   KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Komarova Yulia A, 2007, Sci STKE, V2007, pre8
   Komarova YA, 2012, MOL CELL, V48, P914, DOI 10.1016/j.molcel.2012.10.011
   Kouklis P, 2004, CIRC RES, V94, P159, DOI 10.1161/01.RES.0000110418.38500.31
   Lakshmi SP, 2012, AM J PHYSIOL-LUNG C, V303, pL758, DOI 10.1152/ajplung.00107.2012
   Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774
   Li WJ, 2011, J CELL BIOL, V193, P973, DOI 10.1083/jcb.201101108
   Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733
   Lippoldt A, 2000, NEUROREPORT, V11, P1427, DOI 10.1097/00001756-200005150-00015
   Loot AE, 2009, J EXP MED, V206, P2889, DOI 10.1084/jem.20090449
   Lowe K, 2007, J SURG RES, V143, P70, DOI 10.1016/j.jss.2007.03.047
   Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17
   Malek AM, 1999, BIOCHEM BIOPH RES CO, V254, P231, DOI 10.1006/bbrc.1998.9921
   Mavrakis AG, 2012, NEUROSCI LETT, V528, P180, DOI 10.1016/j.neulet.2012.08.066
   Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Melchior B, 2010, AM J PHYSIOL-CELL PH, V299, pC621, DOI 10.1152/ajpcell.00156.2010
   Minshall RD, 2010, MICROVASC RES, V80, P240, DOI 10.1016/j.mvr.2010.04.007
   Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597
   Miyawaki-Shimizu K, 2006, AM J PHYSIOL-LUNG C, V290, pL405, DOI 10.1152/ajplung.00292.2005
   Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0
   MOREL NML, 1990, INFLAMMATION, V14, P571, DOI 10.1007/BF00914277
   Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185
   Munoz-Chapuli R, 1999, DIFFERENTIATION, V64, P133, DOI 10.1046/j.1432-0436.1999.6430133.x
   Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Nottebaum AF, 2008, J EXP MED, V205, P2929, DOI 10.1084/jem.20080406
   Obukhov AG, 1998, NEUROSCIENCE, V85, P487, DOI 10.1016/S0306-4522(97)00616-7
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Padrick SB, 2010, ANNU REV BIOCHEM, V79, P707, DOI 10.1146/annurev.biochem.77.060407.135452
   Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004
   Park C, 2013, CIRC RES, V112, P1380, DOI 10.1161/CIRCRESAHA.113.301078
   Parker JC, 2006, AM J PHYSIOL-LUNG C, V291, pL30, DOI 10.1152/ajplung.00317.2005
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725
   Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019
   Putney JW, 2010, MOL INTERV, V10, P209, DOI 10.1124/mi.10.4.4
   Quadri SK, 2007, AM J PHYSIOL-LUNG C, V292, pL334, DOI 10.1152/ajplung.00228.2006
   Rajput C, 2013, J BIOL CHEM, V288, P4241, DOI 10.1074/jbc.M112.440396
   Ramchandran R, 2008, AM J PHYSIOL-LUNG C, V295, pL363, DOI 10.1152/ajplung.90241.2008
   Rao K, 1991, Adv Exp Med Biol, V304, P369
   Rigor RR, 2013, MED RES REV, V33, P911, DOI 10.1002/med.21270
   Runkle EA, 2013, CANCER LETT, V337, P41, DOI 10.1016/j.canlet.2013.05.038
   Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Schlegel N, 2008, AM J PHYSIOL-CELL PH, V294, pC178, DOI 10.1152/ajpcell.00273.2007
   Schmidt TT, 2013, AM J PHYSIOL-LUNG C, V305, pL291, DOI 10.1152/ajplung.00094.2013
   Shajahan AN, 2004, J BIOL CHEM, V279, P48055, DOI 10.1074/jbc.M405837200
   Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200
   SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929
   Smyth JT, 2010, J CELL MOL MED, V14, P2337, DOI 10.1111/j.1582-4934.2010.01168.x
   Soboloff J, 2012, NAT REV MOL CELL BIO, V13, P549, DOI 10.1038/nrm3414
   Stec-Martyna E, 2012, CURR CANCER DRUG TAR, V12, P658, DOI 10.2174/156800912801784893
   Stevens Troy, 2008, Proc Am Thorac Soc, V5, P783, DOI 10.1513/pats.200803-027HR
   Sun XG, 2013, AM J PHYSIOL-LUNG C, V305, pL467, DOI 10.1152/ajplung.00010.2013
   Sun XG, 2009, MICROVASC RES, V77, P304, DOI 10.1016/j.mvr.2008.12.004
   Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343
   Sundivakkam PC, 2013, J BIOL CHEM, V288, P17030, DOI 10.1074/jbc.M112.411272
   Sundivakkam PC, 2012, MOL PHARMACOL, V81, P510, DOI 10.1124/mol.111.074658
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069
   TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Thennes T, 2012, MICROVASC RES, V83, P31, DOI 10.1016/j.mvr.2011.05.004
   Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013
   Tian ZG, 2013, ANN THORAC SURG, V95, P1028, DOI 10.1016/j.athoracsur.2012.11.023
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7
   Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347
   Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797
   TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869
   Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x
   Tsukita S, 2009, ANN NY ACAD SCI, V1165, P44, DOI 10.1111/j.1749-6632.2009.04056.x
   Van Itallie CM, 2010, J CELL SCI, V123, P2844, DOI 10.1242/jcs.065581
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   VANDENBROUCKE ST, 2012, CIRC RES, V111, P739, DOI DOI 10.1161/CIRCRESAHA.112.269654
   vanRijen HVM, 1997, AM J PHYSIOL-CELL PH, V272, pC117, DOI 10.1152/ajpcell.1997.272.1.C117
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   Vignaud T, 2012, TRENDS CELL BIOL, V22, P671, DOI 10.1016/j.tcb.2012.08.012
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Vogel SM, 2012, COMPR PHYSIOL, V2, P449, DOI 10.1002/cphy.c100006
   VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V
   Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100
   Wang YL, 2011, J IMMUNOL, V186, P3180, DOI 10.4049/jimmunol.1001252
   Wang ZJ, 2013, THER DELIV, V4, P131, DOI [10.4155/tde.12.140, 10.4155/TDE.12.140]
   Watanabe H, 2001, FASEB J, V15, P282, DOI 10.1096/fj.00-0587fje
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Wu SW, 2001, J CELL BIOL, V154, P1225, DOI 10.1083/jcb.200106156
   Wu TT, 2013, AM J PHYSIOL-RENAL, V304, pF820, DOI 10.1152/ajprenal.00294.2012
   Yanase M, 2003, BIOCHEM BIOPH RES CO, V305, P223, DOI 10.1016/S0006-291X(03)00726-5
   Ying ZK, 2009, ARTERIOSCL THROM VAS, V29, P1657, DOI 10.1161/ATVBAHA.109.190892
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
   Yuan JP, 2007, NAT CELL BIOL, V9, P636, DOI 10.1038/ncb1590
   Yuan JP, 2009, CHANNELS, V3, P221, DOI 10.4161/chan.3.4.9198
   Yuan Y, 1997, AM J PHYSIOL-HEART C, V272, pH1437, DOI 10.1152/ajpheart.1997.272.3.H1437
   Zebda N, 2013, J BIOL CHEM, V288, P18290, DOI 10.1074/jbc.M112.432757
   Zhang JZ, 2010, RESPIRATION, V80, P236, DOI 10.1159/000274384
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
NR 177
TC 177
Z9 179
U1 0
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD DEC
PY 2014
VL 4
IS 4
BP 535
EP 551
DI 10.1086/677356
PG 17
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA V47WR
UT WOS:000209982400002
PM 25610592
OA hybrid, Green Published
DA 2023-08-21
ER

PT J
AU Kondrikov, D
   Gross, C
   Black, SM
   Su, YC
AF Kondrikov, Dmitry
   Gross, Christine M.
   Black, Stephen M.
   Su, Yunchao
TI Novel Peptide for Attenuation of Hyperoxia-induced Disruption of Lung
   Endothelial Barrier and Pulmonary Edema via Modulating Peroxynitrite
   Formation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; OXYGEN-INDUCED RETINOPATHY; INJURY; APOPTOSIS;
   ENOS; PERMEABILITY; MONOLAYERS; TOXICITY; CELLS; NO
AB Pulmonary damages of oxygen toxicity include vascular leakage and pulmonary edema. We have previously reported that hyperoxia increases the formation of NO and peroxynitrite in lung endothelial cells via increased interaction of endothelial nitric oxide (eNOS) with beta-actin. A peptide (P326TAT) with amino acid sequence corresponding to the actin binding region of eNOS residues 326-333 has been shown to reduce the hyperoxia-induced formation of NO and peroxynitrite in lung endothelial cells. In the present study, we found that exposure of pulmonary artery endothelial cells to hyperoxia (95% oxygen and 5% CO2) for 48 h resulted in disruption of monolayer barrier integrity in two phases, and apoptosis occurred in the second phase. NOS inhibitor NG-nitro-L-arginine methyl ester attenuated the endothelial barrier disruption in both phases. Peroxynitrite scavenger uric acid did not affect the first phase but ameliorated the second phase of endothelial barrier disruption and apoptosis. P326TAT inhibited hyperoxia-induced disruption of monolayer barrier integrity in two phases and apoptosis in the second phase. More importantly, injection of P326TAT attenuated vascular leakage, pulmonary edema, and endothelial apoptosis in the lungs of mice exposed to hyperoxia. P326TAT also significantly reduced the increase in eNOS-beta-actin association and protein tyrosine nitration. Together, these results indicate that peptide P326TAT ameliorates barrier dysfunction of hyperoxic lung endothelial monolayer and attenuates eNOS-beta-actin association, peroxynitrite formation, endothelial apoptosis, and pulmonary edema in lungs of hyperoxic mice. P326TAT can be a novel therapeutic agent to treat or prevent acute lung injury in oxygen toxicity.
C1 [Kondrikov, Dmitry; Su, Yunchao] Georgia Regents Univ, Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912, United States.
C1 [Su, Yunchao] Georgia Regents Univ, Med Coll Georgia, Dept Med, Augusta, GA 30912, United States.
C1 [Gross, Christine; Black, Stephen M.; Su, Yunchao] Georgia Regents Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912, United States.
C1 [Su, Yunchao] Georgia Regents Univ, Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912, United States.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University
RP Su, YC (corresponding author), Georgia Regents Univ, Med Coll Georgia, Dept Pharmacol & Toxicol, 1120 15th St, Augusta, GA 30912 USA.
EM ysu@gru.edu
OI Black, Stephen M./0000-0002-4524-6544
FU National Institutes of Health [HL088261, HL115078, HL0101902]; Flight
   Attendants Medical Research Institute [113018_CIA]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants HL088261 and HL115078 (to Y. S.) and HL0101902 (to S. M.
   B.). This work was also supported by Flight Attendants Medical Research
   Institute Grant 113018_CIA (to Y. S.).
CR Abdelsaid MA, 2010, J PHARMACOL EXP THER, V332, P125, DOI 10.1124/jpet.109.157941
   Allen BW, 2009, J APPL PHYSIOL, V106, P662, DOI 10.1152/japplphysiol.91109.2008
   Beauchamp MH, 2004, FREE RADICAL BIO MED, V37, P1885, DOI 10.1016/j.freeradbiomed.2004.09.008
   Bhandari V, 2006, FREE RADICAL BIO MED, V41, P4, DOI 10.1016/j.freeradbiomed.2006.01.027
   Bove K, 2001, AM J PHYSIOL-LUNG C, V280, pL914, DOI 10.1152/ajplung.2001.280.5.L914
   BRASCH RC, 1993, PEDIATR RADIOL, V23, P495, DOI 10.1007/BF02012128
   Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432
   Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002
   Gustafsson AB, 2005, METH MOLEC MED, V112, P81
   Klings ES, 2009, AM J PATHOL, V175, P2309, DOI 10.2353/ajpath.2009.081017
   Kondrikov D, 2011, FREE RADICAL BIO MED, V50, P1689, DOI 10.1016/j.freeradbiomed.2011.03.020
   Kondrikov D, 2010, J BIOL CHEM, V285, P35479, DOI 10.1074/jbc.M110.140269
   Kondrikov D, 2010, J BIOL CHEM, V285, P4319, DOI 10.1074/jbc.M109.063172
   Li LF, 2007, CRIT CARE, V11, DOI 10.1186/cc6101
   McGrath-Morrow SA, 2001, AM J RESP CELL MOL, V25, P150, DOI 10.1165/ajrcmb.25.2.4362
   Modol T, 2011, BIOCHEM PHARMACOL, V81, P451, DOI 10.1016/j.bcp.2010.10.017
   NOZIK ES, 1995, RESP PHYSIOL, V100, P63, DOI 10.1016/0034-5687(94)00116-H
   Payne DK, 1996, FREE RADICAL RES, V25, P229, DOI 10.3109/10715769609149048
   PHILLIPS PG, 1988, J APPL PHYSIOL, V64, P1196, DOI 10.1152/jappl.1988.64.3.1196
   Radomski A, 1998, BRIT J PHARMACOL, V125, P1455, DOI 10.1038/sj.bjp.0702216
   Sanchez FA, 2009, P NATL ACAD SCI USA, V106, P6849, DOI 10.1073/pnas.0812694106
   Su YC, 2003, AM J PHYSIOL-CELL PH, V284, pC1542, DOI 10.1152/ajpcell.00248.2002
   Veress LA, 2010, AM J RESP CRIT CARE, V182, P1352, DOI 10.1164/rccm.200910-1618OC
   WEIR KLI, 1994, AM J RESP CRIT CARE, V150, P784, DOI 10.1164/ajrccm.150.3.8087353
NR 26
TC 10
Z9 10
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 28
PY 2014
VL 289
IS 48
BP 33355
EP 33363
DI 10.1074/jbc.M114.585356
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AU5HC
UT WOS:000345636600026
PM 25315770
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Sun, XG
   Elangovan, VR
   Mapes, B
   Camp, SM
   Sammani, S
   Saadat, L
   Ceco, E
   Ma, SF
   Flores, C
   MacDougall, MS
   Quijada, H
   Liu, B
   Kempf, CL
   Wang, T
   Chiang, ET
   Garcia, JGN
AF Sun, Xiaoguang
   Elangovan, Venkateswaran Ramamoorthi
   Mapes, Brandon
   Camp, Sara M.
   Sammani, Saad
   Saadat, Laleh
   Ceco, Ermelinda
   Ma, Shwu Fan
   Flores, Carlos
   MacDougall, Matthew S.
   Quijada, Hector
   Liu, Bin
   Kempf, Carrie L.
   Wang, Ting
   Chiang, Eddie T.
   Garcia, Joe G. N.
TI The NAMPT Promoter Is Regulated by Mechanical Stress, Signal Transducer
   and Activator of Transcription 5, and Acute Respiratory Distress
   Syndrome-Associated Genetic Variants
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; cyclic stretch; nicotinamide phosphoribosyltransferase; B cell colony-enhancing factor; STAT3/STAT5 
ID COLONY-ENHANCING FACTOR; ACUTE LUNG INJURY; DNA-BINDING; CELL;
   EXPRESSION; VISFATIN; ROLES; STAT5
AB Increased nicotinamide phosphoribosyltransferase (NAMPT) transcription is mechanistically linked to ventilator-induced inflammatory lung injury (VILI), with VILI severity attenuated by reduced NAMPT bioavailability. The molecular mechanisms of NAMPT promoter regulation in response to excessive mechanical stress remain poorly understood. The objective of this study was to define the contribution of specific transcription factors, acute respiratory distress syndrome (ARDS)-associated single nucleotide polymorphisms (SNPs), and promoter demethylation to NAMPT transcriptional regulation in response to mechanical stress. In vivo NAMPT protein expression levels were examined in mice exposed to high tidal volume mechanical ventilation. In vitro NAMPT expression levels were examined in human pulmonary artery endothelial cells exposed to 5 or 18% cyclic stretch (CS), with NAMPT promoter activity assessed using NAMPT promoter luciferase reporter constructs with a series of nested deletions. In vitro NAMPT transcriptional regulation was further characterized by measuring luciferase activity, DNA demethylation, and chromatin immunoprecipitation. VILI-challenged mice exhibited significantly increased NAMPT expression in bronchoalveolar lavage leukocytes and in lung endothelium. A mechanical stress-inducible region (MSIR) was identified in the NAMPT promoter from 22,428 to 22,128 bp. This MSIR regulates NAMPT promoter activity, mRNA expression, and signal transducer and activator of transcription 5 (STAT5) binding, which is significantly increased by 18% CS. In addition, NAMPT promoter activity was increased by pharmacologic promoter demethylation and inhibited by STAT5 silencing. ARDS-associated NAMPT promoter SNPs rs59744560 (2948G/T) and rs7789066 (22,422A/G) each significantly elevated NAMPT promoter activity in response to 18% CS in a STAT5-dependent manner. Our results show that NAMPT is a key novel ARDS therapeutic target and candidate gene with genetic/epigenetic transcriptional regulation in response to excessive mechanical stress.
C1 [Sun, Xiaoguang; Mapes, Brandon; Sammani, Saad; Saadat, Laleh; Ceco, Ermelinda; MacDougall, Matthew S.; Liu, Bin; Garcia, Joe G. N.] Univ Illinois, Dept Med, Chicago, IL, United States.
C1 [Elangovan, Venkateswaran Ramamoorthi; Garcia, Joe G. N.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C1 [Elangovan, Venkateswaran Ramamoorthi; Camp, Sara M.; Quijada, Hector; Kempf, Carrie L.; Wang, Ting; Chiang, Eddie T.; Garcia, Joe G. N.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721, United States.
C1 [Elangovan, Venkateswaran Ramamoorthi; Sammani, Saad; Quijada, Hector; Kempf, Carrie L.; Wang, Ting; Chiang, Eddie T.; Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ 85721, United States.
C1 [Ma, Shwu-Fan] Univ Chicago, Dept Med, Chicago, IL 60637, United States.
C1 [Flores, Carlos] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp Enfermeda, Madrid, Spain.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Arizona; University of Arizona; University of Chicago;
   CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de
   Salud Carlos III
RP Garcia, JGN (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Roy P Drachman Hall,1295 N Martin Ave,POB 210202, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
RI SUN, XIAOGUANG/ACA-5558-2022; Flores, Carlos/R-1159-2019;
   RamamoorthiElangovan, Venkateswaran/O-5533-2017
OI MacDougall, Matthew/0000-0002-7946-6721; Flores,
   Carlos/0000-0001-5352-069X; Mapes, Brandon/0000-0001-8495-3439
FU National Institutes of Health/National Heart, Lung and Blood Institute
   [R01-HL73994]
FX This work was supported by the National Institutes of Health/National
   Heart, Lung and Blood Institute grant R01-HL73994 (J.G.N.G.).
CR Adyshev DM, 2014, AM J RESP CELL MOL, V50, P409, DOI 10.1165/rcmb.2013-0292OC
   Bajwa EK, 2007, CRIT CARE MED, V35, P1290, DOI 10.1097/01.CCM.0000260243.22758.4F
   Bertolino E, 2005, NAT IMMUNOL, V6, P836, DOI 10.1038/ni1226
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Clawson H, 2009, UCSC GENOME BROWSER
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D
   Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34
   Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143
   Hermann-Kleiter N, 2010, BLOOD, V115, P2989, DOI 10.1182/blood-2009-10-233585
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Honsho S, 2009, CIRC RES, V105, P1149, DOI 10.1161/CIRCRESAHA.109.208199
   Leander K, 2012, CLIN CHIM ACTA, V413, P727, DOI 10.1016/j.cca.2012.01.002
   Malin S, 2010, NAT IMMUNOL, V11, P171, DOI 10.1038/ni.1827
   Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Moreno-Vinasco L, AM J RESPIR IN PRESS
   Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350
   Ognjanovic S, 2005, AM J OBSTET GYNECOL, V193, P273, DOI 10.1016/j.ajog.2004.11.003
   Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282
   Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54
   Reich Nancy C, 2013, JAKSTAT, V2, pe27080, DOI 10.4161/jkst.27080
   SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431
   Simon BA, 2006, AM J PHYSIOL-LUNG C, V291, pL851, DOI 10.1152/ajplung.00463.2005
   Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0
   Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0
   Wade M, 2010, AM J RESP CRIT CARE, V181
   Wang T, 2006, NAT STRUCT MOL BIOL, V13, P661, DOI 10.1038/nsmb1114
   Wolfson RK, 2014, MICROVASC RES, V92, P50, DOI 10.1016/j.mvr.2013.12.005
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
   Zhang YY, 2006, OBESITY, V14, P2119, DOI 10.1038/oby.2006.247
NR 34
TC 37
Z9 40
U1 1
U2 10
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD NOV
PY 2014
VL 51
IS 5
BP 660
EP 667
DI 10.1165/rcmb.2014-0117OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AY2KP
UT WOS:000347419400007
PM 24821571
OA Green Published
DA 2023-08-21
ER

PT J
AU Zhang, CY
   Wu, Y
   Xuan, ZN
   Zhang, SJ
   Wang, XD
   Hao, Y
   Wu, J
   Zhang, S
AF Zhang, Chenyue
   Wu, Ying
   Xuan, Zinan
   Zhang, Shujing
   Wang, Xudan
   Hao, Yu
   Wu, Jun
   Zhang, Shu
TI p38MAPK, Rho/ROCK and PKC pathways are involved in influenza-induced
   cytoskeletal rearrangement and hyperpermeability in PMVEC via
   phosphorylating ERM
SO VIRUS RESEARCH
LA English
DT Article
DE influenza; permeability; ERM; MAPK; Rho/ROCK pathway; protein kinase C 
ID ENDOTHELIAL-CELL BARRIER; LUNG MICROVASCULAR ENDOTHELIUM; N-TERMINAL
   DOMAIN; EZRIN/RADIXIN/MOESIN PROTEINS; BINDING-SITE; IN-VITRO; EZRIN;
   PERMEABILITY; MOESIN; RADIXIN
AB Severe influenza infections are featured by acute lung injury, a syndrome of pulmonary microvascular leak. A growing number of evidences have shown that the pulmonary microvascular endothelial cells (PMVEC) are critical target of influenza virus, promoting microvascular leak. It is reported that there are multiple mechanisms by which influenza virus could elicit increased pulmonary endothelial permeability, in both direct and indirect manners. Ezrin/radixin/moesin family proteins, the linkers between plasma membrane and actin cytoskeleton, have been reported to be involved in cell adhesion, motility and may modulate endothelial permeability. Studies have also shown that ERM is phosphorylated in response to various stimuli via p38MAPK, Rho/ROCK or PKC pathways. However, it is unclear that whether influenza infection could induce ERM phosphorylation and its relocalization. In the present study, we have found that there are cytoskeletal reorganization and permeability increases in the course of influenza virus infection, accompanied by upregulated levels of p-ERM. p-ERM's aggregation along the periphery of PMVEC upon influenza virus infection was detected via confocal microscopy. Furthermore, we sought to determine the role of p38MAPK, Rho/ROCK and PKC pathways in ERM phosphorylation as well as their involvement in influenza virus-induced endothelial malfunction. The activation of p38MAPK, Rho/ROCK and PKC pathways upon influenza virus stimulation were observed, as evidenced by the evaluation of phosphorylated p38 (p-p38), phosphorylated MKK (p-MKK) in p38MAPK pathway, ROCK1 in Rho/ROCK pathway and phosphorylated PKC (p-PKC) in PKC pathway. We also showed that virus-induced ERM phosphorylation was reduced by using p38MAPK inhibitor, SB203580 (20 mu M), Rho/ROCK inhibitor, Y27632 (20 mu M), PKC inhibitor, LY317615 (10 mu M). Additionally, influenza virus-induced F-actin reorganization and hyperpermeability were attenuated by pretreatment with SB203580, Y27632 and LY317615. Taken together, we provide the first evidence that p38MAPK, Rho/ROCK and PKC are involved in influenza-induced cytoskeletal changes and permeability increases in PMVEC via phosphorylating ERM. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Zhang, Chenyue; Wu, Ying; Xuan, Zinan; Zhang, Shujing; Wang, Xudan; Hao, Yu; Wu, Jun; Zhang, Shu] Beijing Univ Chinese Med, Dept Microbiol & Immunol, Beijing 100029, China.
C3 Beijing University of Chinese Medicine
RP Wu, Y (corresponding author), Beijing Univ Chinese Med, Dept Microbiol & Immunol, 11 Bei San Huan Dong Rd, Beijing 100029, Peoples R China.
EM aqiwuying@hotmail.com
FU National Natural Science Foundation of China [81102697, 30772871]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81102697, No. 30772871).
CR Adyshev DM, 2013, AM J PHYSIOL-LUNG C, V305, P1240, DOI 10.1152/ajplung.00355.2012
   Adyshev DM, 2011, CELL SIGNAL, V23, P2086, DOI 10.1016/j.cellsig.2011.08.003
   Armstrong SM, 2013, ANTIVIR RES, V99, P113, DOI 10.1016/j.antiviral.2013.05.003
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Armstrong SM, 2012, AM J PATHOL, V180, P1308, DOI 10.1016/j.ajpath.2011.12.002
   Arumugam P, 2013, J GASTROINTEST SURG, V17, P2082, DOI 10.1007/s11605-013-2384-1
   Bogatcheva NV, 2011, AM J RESP CELL MOL, V45, P1185, DOI 10.1165/rcmb.2011-0092OC
   CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199
   Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866
   Fievet B, 2007, BBA-MOL CELL RES, V1773, P653, DOI 10.1016/j.bbamcr.2006.06.013
   Finnerty CM, 2004, J CELL SCI, V117, P1547, DOI 10.1242/jcs.01038
   GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061
   Gavrilovskaya IN, 2008, J VIROL, V82, P5797, DOI 10.1128/JVI.02397-07
   Guo XH, 2009, AM J PHYSIOL-HEART C, V297, pH238, DOI 10.1152/ajpheart.00196.2009
   Haas MA, 2007, J NEUROSCI RES, V85, P34, DOI 10.1002/jnr.21102
   Haidari M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021444
   Hebert M, 2008, J IMMUNOL, V181, P5963, DOI 10.4049/jimmunol.181.9.5963
   Hecker C, 1997, VIRUS RES, V49, P215, DOI 10.1016/S0168-1702(97)00039-7
   Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200
   Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x
   Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218
   Kubo Y, 2008, VIROLOGY, V375, P130, DOI 10.1016/j.virol.2008.01.047
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710
   Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Moilanen J, 2003, GYNECOL ONCOL, V90, P273, DOI 10.1016/S0090-8258(03)00262-2
   Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723
   Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012
   Nuesch JPF, 2009, J VIROL, V83, P5854, DOI 10.1128/JVI.00039-09
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   Sedgwick JB, 2002, J ALLERGY CLIN IMMUN, V110, P752, DOI 10.1067/mai.2002.128581
   Short KR, 2013, LANCET INFECT DIS
   Shrivastava-Ranjan P, 2010, J VIROL, V84, P11227, DOI 10.1128/JVI.01405-10
   Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002
   Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200
   Tamma G, 2007, AM J PHYSIOL-CELL PH, V292, pC1476, DOI 10.1152/ajpcell.00375.2006
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044
   You QH, 2010, INFLAMM RES, V59, P949, DOI 10.1007/s00011-010-0207-3
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
NR 44
TC 28
Z9 33
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD NOV
PY 2014
VL 192
BP 6
EP 15
DI 10.1016/j.virusres.2014.07.027
PG 10
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA AR5LN
UT WOS:000343626300002
PM 25150189
DA 2023-08-21
ER

PT J
AU Zhang, ML
   Wang, L
   Dong, MQ
   Li, ZC
   Jin, FG
AF Zhang, Minlong
   Wang, Li
   Dong, Mingqing
   Li, Zhichao
   Jin, Faguang
TI Endothelial Semaphorin 7A Promotes Inflammation in Seawater
   Aspiration-Induced Acute Lung Injury
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE semaphorin 7A; ALI/ARDS; seawater 
ID RESPIRATORY-DISTRESS-SYNDROME; KAPPA-B; HYPOXIA; FAMILY; CELLS;
   MOLECULES; MIGRATION; COLLAPSIN; GROWTH
AB Inflammation is involved in the pathogenesis of seawater aspiration-induced acute lung injury (ALI). Although several studies have shown that Semaphorin 7A (SEMA7A) promotes inflammation, there are limited reports regarding immunological function of SEMA7A in seawater aspiration-induced ALI. Therefore, we investigated the role of SEMA7A during seawater aspiration-induced ALI. Male Sprague-Dawley rats were underwent seawater instillation. Then, lung samples were collected at an indicated time for analysis. In addition, rat pulmonary microvascular endothelial cells (RPMVECs) were cultured and then stimulated with 25% seawater for indicated time point. After these treatments, cells samples were collected for analysis. In vivo, seawater instillation induced lung histopathologic changes, pro-inflammation cytokines release and increased expression of SEMA7A. In vitro, seawater stimulation led to pro-inflammation cytokine release, cytoskeleton remodeling and increased monolayer permeability in pulmonary microvascular endothelial cells. In addition, knockdown of hypoxia-inducible factor (HIF)-1 alpha inhibited the seawater induced increase expression of SEMA7A. Meanwhile, knockdown of SEMA7A by specific siRNA inhibited the seawater induced aberrant inflammation, endothelial cytoskeleton remodeling and endothelial permeability. These results suggest that SEMA7A is critical in the development of lung inflammation and pulmonary edema in seawater aspiration-induced ALI, and may be a therapeutic target for this disease.
C1 [Zhang, Minlong; Wang, Li; Jin, Faguang] Fourth Mil Med Univ, Tangdu Hosp, Dept Respirat, Xian 710038, China.
C1 [Dong, Mingqing; Li, Zhichao] Fourth Mil Med Univ, Dept Pathol & Pathophysiol, Xian 710032, China.
C3 Air Force Military Medical University; Air Force Military Medical
   University
RP Li, ZC (corresponding author), Fourth Mil Med Univ, Dept Pathol & Pathophysiol, Xian 710032, Peoples R China.
EM 15991798305@163.com; wangli344@163.com; dongmqxh@fmmu.edu.cn;
   lizhic@fmmu.edu.cn; jinfag@fmmu.edu.cn
RI dong, ming-qing/HTO-3001-2023
OI dong, ming-qing/0000-0001-9720-535X
FU National Nature Science Foundation of China [81270124]
FX This work was supported by National Nature Science Foundation of China
   (No. 81270124).
CR CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Czopik AK, 2006, IMMUNITY, V24, P591, DOI 10.1016/j.immuni.2006.03.013
   Ding XM, 2006, PHARMACOL RES, V53, P372, DOI 10.1016/j.phrs.2006.01.006
   Ecklund MM, 2012, CRIT CARE NURS CLIN, V24, P601, DOI 10.1016/j.ccell.2012.07.002
   Fan QX, 2011, PULM PHARMACOL THER, V24, P673, DOI 10.1016/j.pupt.2011.07.002
   Frutos-Vivar F, 2006, SEM RESP CRIT CARE M, V27, P327, DOI 10.1055/s-2006-948287
   Gan Y, 2011, ARTHRITIS RHEUM-US, V63, P2484, DOI 10.1002/art.30386
   Han F, 2012, RESP PHYSIOL NEUROBI, V182, P71, DOI 10.1016/j.resp.2012.05.012
   Holmes S, 2002, SCAND J IMMUNOL, V56, P270, DOI 10.1046/j.1365-3083.2002.01129.x
   Ibsen LM, 2002, CRIT CARE MED, V30, pS402, DOI 10.1097/00003246-200211001-00004
   KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z
   Konrad FM, 2012, AM J PHYSIOL-LUNG C, V303, pL425, DOI 10.1152/ajplung.00387.2011
   Lazova R, 2009, AM J DERMATOPATH, V31, P177, DOI 10.1097/DAD.0b013e318196672d
   Li JH, 2011, RESP PHYSIOL NEUROBI, V176, P39, DOI 10.1016/j.resp.2011.01.005
   LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9
   Ma LJ, 2013, RESP PHYSIOL NEUROBI, V185, P608, DOI 10.1016/j.resp.2012.11.016
   Maruyama T, 2008, DEV NEUROBIOL, V68, P317, DOI 10.1002/dneu.20592
   Morote-Garcia JC, 2012, P NATL ACAD SCI USA, V109, P14146, DOI 10.1073/pnas.1202165109
   Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790
   PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1
   Suzuki K, 2007, J SYN ORG CHEM JPN, V65, P1
   Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624
   Xie XY, 2011, EXP LUNG RES, V37, P482, DOI 10.3109/01902148.2011.594144
   You QH, 2010, J SURG RES, V162, P110, DOI 10.1016/j.jss.2009.01.019
NR 25
TC 17
Z9 19
U1 0
U2 8
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2014
VL 15
IS 11
BP 19650
EP 19661
DI 10.3390/ijms151119650
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AU3QR
UT WOS:000345529200019
PM 25353180
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Leonard, A
   Paton, AW
   El-Quadi, M
   Paton, JC
   Fazal, F
AF Leonard, Antony
   Paton, Adrienne W.
   El-Quadi, Monaliza
   Paton, James C.
   Fazal, Fabeha
TI Preconditioning with Endoplasmic Reticulum Stress Ameliorates
   Endothelial Cell Inflammation
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; RELA/P65
   NUCLEAR TRANSLOCATION; UNFOLDED PROTEIN RESPONSE; TISSUE-FACTOR;
   RHEUMATOID-ARTHRITIS; SIGNALING PATHWAYS; ICAM-1 EXPRESSION; INDUCED
   INCREASE
AB Endoplasmic Reticulum (ER) stress, caused by disturbance in ER homeostasis, has been implicated in several pathological conditions such as ischemic injury, neurodegenerative disorders, metabolic diseases and more recently in inflammatory conditions. Our present study aims at understanding the role of ER stress in endothelial cell (EC) inflammation, a critical event in the pathogenesis of acute lung injury (ALI). We found that preconditioning human pulmonary artery endothelial cells (HPAEC) to ER stress either by depleting ER chaperone and signaling regulator BiP using siRNA, or specifically cleaving (inactivating) BiP using subtilase cytotoxin (SubAB), alleviates EC inflammation. The two approaches adopted to abrogate BiP function induced ATF4 protein expression and the phosphorylation of eIF2 alpha, both markers of ER stress, which in turn resulted in blunting the activation of NF-kappa B, and restoring endothelial barrier integrity. Pretreatment of HPAEC with BiP siRNA inhibited thrombin-induced IkB alpha degradation and its resulting downstream signaling pathway involving NF-kappa B nuclear translocation, DNA binding, phosphorylation at serine536, transcriptional activation and subsequent expression of adhesion molecules. However, TNF alpha-mediated NF-kappa B signaling was unaffected upon BiP knockdown. In an alternative approach, SubAB-mediated inactivation of NF-kappa B was independent of IkB alpha degradation. Mechanistic analysis revealed that pretreatment of EC with SubAB interfered with the binding of the liberated NF-kappa B to the DNA, thereby resulting in reduced expression of adhesion molecules, cytokines and chemokines. In addition, both knockdown and inactivation of BiP stimulated actin cytoskeletal reorganization resulting in restoration of endothelial permeability. Together our studies indicate that BiP plays a central role in EC inflammation and injury via its action on NF-kappa B activation and regulation of vascular permeability.
C1 [Leonard, Antony; El-Quadi, Monaliza; Fazal, Fabeha] Univ Rochester, Sch Med & Dent, Dept Pediat, Lung Biol & Dis Program, Rochester, NY 14627, United States.
C1 [Paton, Adrienne W.; Paton, James C.] Univ Adelaide, Res Ctr Infect Dis, Sch Mol & Biomed Sci, Adelaide, SA, Australia.
C3 University of Rochester; University of Adelaide
RP Fazal, F (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Lung Biol & Dis Program, Rochester, NY 14627 USA.
EM Fabeha_Fazal@URMC.Rochester.edu
FU National Heart, Lung and Blood Institute [HL096907]
FX This work was supported by National Heart, Lung and Blood Institute
   Grant HL096907. The funder had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Adachi T, 2012, ARCH BIOCHEM BIOPHYS, V520, P30, DOI 10.1016/j.abb.2012.01.014
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Anthoni C, 2007, J EXP MED, V204, P1595, DOI 10.1084/jem.20062354
   Bair AM, 2009, J BIOL CHEM, V284, P563, DOI 10.1074/jbc.M803984200
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bijli KM, 2012, AM J RESP CELL MOL, V47, P660, DOI 10.1165/rcmb.2012-0047OC
   Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209
   Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151
   Dudek J, 2009, CELL MOL LIFE SCI, V66, P1556, DOI 10.1007/s00018-009-8745-y
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005
   Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200
   Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Harama D, 2009, J IMMUNOL, V183, P1368, DOI 10.4049/jimmunol.0804066
   Hayakawa K, 2010, J AM SOC NEPHROL, V21, P73, DOI 10.1681/ASN.2009040432
   Hayakawa K, 2009, J IMMUNOL, V182, P1182, DOI 10.4049/jimmunol.182.2.1182
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hu CCA, 2009, J EXP MED, V206, P2429, DOI 10.1084/jem.20090782
   Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Inagi R, 2008, J AM SOC NEPHROL, V19, P915, DOI 10.1681/ASN.2007070745
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kitamura M, 2009, ANTIOXID REDOX SIGN, V11, P2353, DOI [10.1089/ars.2008.2391, 10.1089/ARS.2008.2391]
   LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933
   Levitt JE, 2006, SEMIN RESP CRIT CARE, V27, P426, DOI 10.1055/s-2006-948296
   Li JM, 2011, J BIOL CHEM, V286, P4912, DOI 10.1074/jbc.M110.199729
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823
   Nakajima S, 2011, MOL CELL BIOL, V31, P1710, DOI 10.1128/MCB.00939-10
   Paton AW, 2006, NATURE, V443, P548, DOI 10.1038/nature05124
   Paton AW, 2004, J EXP MED, V200, P35, DOI 10.1084/jem.20040392
   Prell T, 2014, J NEUROIMMUNOL, V270, P29, DOI 10.1016/j.jneuroim.2014.03.005
   Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488
   Rahman A, 1999, J IMMUNOL, V162, P5466
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   Rath E, 2011, EUR J NUTR, V50, P219, DOI 10.1007/s00394-011-0197-0
   Sabit R, 2010, CHEST, V138, P47, DOI 10.1378/chest.09-2764
   SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X
   Shenderov K, 2014, J IMMUNOL, V192, P2029, DOI 10.4049/jimmunol.1302549
   Tam AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045078
   Undas A, 2010, THROMB HAEMOSTASIS, V104, P224, DOI 10.1160/TH10-02-0091
   Usuki F, 2013, SCI REP-UK, V3, DOI 10.1038/srep02346
   Vaidyula VR, 2009, THROMB RES, V124, P259, DOI 10.1016/j.thromres.2008.12.030
   van der Poll T, 2008, CRIT CARE, V12, DOI 10.1186/cc7026
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weiss WA, 2007, NAT CHEM BIOL, V3, P739, DOI 10.1038/nchembio1207-739
   Wolfson JJ, 2008, CELL MICROBIOL, V10, P1775, DOI 10.1111/j.1462-5822.2008.01164.x
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yoo SA, 2012, J EXP MED, V209, P871, DOI 10.1084/jem.20111783
NR 57
TC 35
Z9 36
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2014
VL 9
IS 10
AR e110949
DI 10.1371/journal.pone.0110949
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AX2HU
UT WOS:000346765000033
PM 25356743
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Hu, RY
   Cheng, Y
   Jing, H
   Wu, HW
AF Hu, Ruoyu
   Cheng, Yan
   Jing, Hua
   Wu, Haiwei
TI ERYTHROPOIETIN PROMOTES THE PROTECTIVE PROPERTIES OF TRANSPLANTED
   ENDOTHELIAL PROGENITOR CELLS AGAINST ACUTE LUNG INJURY VIA PI3K/AKT
   PATHWAY
SO SHOCK
LA English
DT Article
DE ALI/ARDS; endothelial progenitor cells; erythropoietin; PI3K/Akt pathway 
ID ATTENUATES ISCHEMIA; MICROVESSEL DENSITY; IN-VITRO; APOPTOSIS
AB Introduction: Accumulating evidences have indicted the participation and repairing effects of endothelial progenitor cells (EPCs) on acute lung injury (ALI). Researchers have also revealed that erythropoietin (EPO) may exert multiple effects on EPCs including proliferative and adhesive properties. The present study was designed to investigate whether EPO can promote the healing efficiency of transplanted EPCs against ALI and the potential mechanism. Methods: Endothelial progenitor cells were derived from bone marrow mononuclear cells of BALB/c mice. In our in vitro studies, we tested the proproliferative and antiapoptotic effects of EPO on cultured EPCs. In our in vivo studies, we induced BALB/c mice ALI model by intratracheal instillation of lipopolysaccharide and treated with/without intravenous injection of enhanced green fluorescent protein-EPCs harvested from enhanced green fluorescent protein-BALB/c mice. Mice that received EPC transplantation either underwent EPO administration or not. The effects of EPO and EPC treatment on promoting pulmonary endothelial repair, decreasing pulmonary capillary permeability, alleviating pulmonary inflammation, improving gas exchange, and promoting pulmonary vessel angiogenesis were tested. The potential mechanisms that mediate EPO functions on EPC were also investigated. Results: Our studies revealed a significant antiapoptotic property of EPO on cultured EPCs as well as its promotion on EPC proliferation. We also found the severity of ALI was reduced by EPC therapy, and the protective effects of EPCs were highly enhanced when combined with EPO administration. However, all these stimulating effects of EPO on EPCs were consisted with the expression of phospho-Akt and were abrogated by PI3K inhibitors. Conclusions: Transplanted EPCs directly incorporated into the injured pulmonary vessels and maintain the integrity of pulmonary endothelium. Erythropoietin improved the survival and proliferation of transplanted EPCs and recruited them to the injured sites to exert their repairing functions. PI3K/Akt pathway mediated EPO's functions on EPCs. The combination of EPO and EPC treatment may be a promising cell-based therapy for ALI patients.
C1 [Hu, Ruoyu; Jing, Hua; Wu, Haiwei] Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Cardiothorac Surg, Nanjing 210008, Jiangsu, China.
C1 [Cheng, Yan] Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Cardiol, Nanjing 210008, Jiangsu, China.
C3 Nanjing University; Nanjing University
RP Wu, HW (corresponding author), Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Cardiothorac Surg, 305 Zhongshan East Rd, Nanjing 210008, Jiangsu, Peoples R China.
EM wuhaiwei_cts@163.com
FU Natural Science Foundation of China [81101723]
FX This study was supported by research grants from the Natural Science
   Foundation of China (no. 81101723).
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Bahlmann FH, 2003, KIDNEY INT, V64, P1648, DOI 10.1046/j.1523-1755.2003.00279.x
   Balasubramaniam V, 2007, AM J PHYSIOL-LUNG C, V292, pL1073, DOI 10.1152/ajplung.00347.2006
   BLOCK ER, 1992, AM J MED SCI, V304, P136, DOI 10.1097/00000441-199208000-00009
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Burnham EL, 2010, AM J RESP CELL MOL, V43, P326, DOI 10.1165/rcmb.2009-0015OC
   George J, 2005, CARDIOVASC RES, V68, P299, DOI 10.1016/j.cardiores.2005.06.022
   Grieb G, 2011, LANGENBECK ARCH SURG, V396, P1255, DOI 10.1007/s00423-011-0839-y
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06
   Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396
   Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673
   Kakavas S, 2011, EUR J CLIN PHARMACOL, V67, P1, DOI 10.1007/s00228-010-0938-7
   Klopsch C, 2009, J CELL MOL MED, V13, P664, DOI 10.1111/j.1582-4934.2008.00546.x
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   Lau AN, 2012, MOL THER, V20, P1116, DOI 10.1038/mt.2012.37
   Lee JH, 2007, J KOREAN MED SCI, V22, P1042, DOI 10.3346/jkms.2008.22.6.1042
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007
   Poon RTP, 2002, J CLIN ONCOL, V20, P1775, DOI 10.1200/JCO.2002.07.089
   Prunier F, 2007, AM J PHYSIOL-HEART C, V292, pH522, DOI 10.1152/ajpheart.00357.2006
   Reinisch A, 2009, BLOOD, V113, P6716, DOI 10.1182/blood-2008-09-181362
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sautina L, 2010, BLOOD, V115, P896, DOI 10.1182/blood-2009-04-216432
   Schmidt-Lucke C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013790
   Sieveking DP, 2008, J AM COLL CARDIOL, V51, P660, DOI 10.1016/j.jacc.2007.09.059
   Taskinen M, 2010, EUR J CANCER, V46, P2506, DOI 10.1016/j.ejca.2010.06.014
   Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1
   Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907
   Wu HW, 2006, EUR J CARDIO-THORAC, V29, P902, DOI 10.1016/j.ejcts.2006.02.036
   Wu HW, 2009, EUR J PHARMACOL, V602, P406, DOI 10.1016/j.ejphar.2008.11.037
   Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081
   Zhang XT, 2007, APOPTOSIS, V12, P743, DOI 10.1007/s10495-006-0018-8
   Zimmerman GA, 1999, CHEST, V116, p18S, DOI 10.1378/chest.116.suppl_1.18S
NR 35
TC 21
Z9 30
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD OCT
PY 2014
VL 42
IS 4
BP 327
EP 336
DI 10.1097/SHK.0000000000000216
PG 10
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA AQ0HY
UT WOS:000342465100007
PM 25051281
OA Bronze
DA 2023-08-21
ER

PT J
AU Liu, TG
   Ghamloush, MM
   Aldawood, A
   Warburton, R
   Toksoz, D
   Hill, NS
   Tang, DD
   Kayyali, US
AF Liu, Tiegang
   Ghamloush, Maher M.
   Aldawood, Ali
   Warburton, Rod
   Toksoz, Deniz
   Hill, Nicholas S.
   Tang, Dale D.
   Kayyali, Usamah S.
TI Modulating Endothelial Barrier Function by Targeting Vimentin
   Phosphorylation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID INTERMEDIATE-FILAMENTS; P21-ACTIVATED KINASE; CELLS; PERMEABILITY;
   HYPOXIA; ALTERS; PATHWAYS; INVITRO; SER-56
AB Vimentin is a major intermediate filament protein in vascular endothelial cells which might be involved in their function as a barrier tissue. It is proposed to dynamically maintain integrity of the endothelium as a tightly regulated permeability barrier that is subjected to a variety of shear and contractile forces. The results described in this report demonstrate that vimentin plays that role through mechanisms that are dependent on its phosphorylation state. Withaferin A (WFA), a vimentin targeting drug is shown to disrupt endothelial barrier function through its effects on vimentin filament distribution and physical properties. These effects are related to WFA's ability to increase vimentin phosphorylation. Through overexpressing a non-phosphorylatable vimentin mutant we can block the effects of WFA on vimentin distribution and barrier permeability. The barrier augmentation effect appears to extend to endothelial cells that do not express detectable mutant vimentin which might suggest transmissible effects across cells. Blocking vimentin phosphorylation also protects the endothelial barrier against LPS endotoxin, implicating it as a target for drug development against pulmonary edema and acute respiratory distress syndrome (ARDS). (C) 2014 Wiley Periodicals, Inc.
C1 [Liu, Tiegang; Ghamloush, Maher M.; Aldawood, Ali; Warburton, Rod; Toksoz, Deniz; Hill, Nicholas S.; Kayyali, Usamah S.] Tufts Univ, Sch Med, Dept Med, Pulm & Crit Care Div,Tupper Res Inst,Tufts Med Ct, Boston, MA 02111, United States.
C1 [Tang, Dale D.] Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208, United States.
C3 Tufts Medical Center; Tufts University; Albany Medical College
RP Kayyali, US (corresponding author), Tufts Med Ctr, Pulm & Crit Care Div, 800 Washington St 257, Boston, MA 02111 USA.
EM ukayyali@tuftsmedicalcenter.org
RI T, Dale/AAE-9643-2020
OI T, Dale/0000-0002-7339-9249
FU NIH [AI096087, HL089671-04]
FX Contract grant sponsor: NIH;; Contract grant numbers: AI096087,
   HL089671-04.
CR An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004
   Bargagna-Mohan P, 2007, CHEM BIOL, V14, P623, DOI 10.1016/j.chembiol.2007.04.010
   Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K
   Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906
   EVANS RM, 1989, J CELL BIOL, V108, P67, DOI 10.1083/jcb.108.1.67
   GARCIA JGN, 1995, J INVEST MED, V43, P117
   Grin B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039065
   INAGAKI M, 1988, J BIOL CHEM, V263, P5970
   Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200
   Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011
   Li QF, 2006, J BIOL CHEM, V281, P34716, DOI 10.1074/jbc.M607715200
   Liu TG, 2010, AM J PHYSIOL-CELL PH, V299, pC363, DOI 10.1152/ajpcell.00057.2010
   Liu T, 2009, J CELL PHYSIOL, V220, P600, DOI 10.1002/jcp.21773
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3
   Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355
   Shasby DM, 2002, AM J PHYSIOL-LUNG C, V282, pL1330, DOI 10.1152/ajplung.00329.2001
   Tang DD, 2005, BIOCHEM J, V388, P773, DOI 10.1042/BJ20050065
   Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938
NR 21
TC 19
Z9 19
U1 0
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2014
VL 229
IS 10
BP 1484
EP 1493
DI 10.1002/jcp.24590
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA AJ9MC
UT WOS:000338034300022
PM 24648251
DA 2023-08-21
ER

PT J
AU Nojiri, T
   Hosoda, H
   Tokudome, T
   Miura, K
   Ishikane, S
   Kimura, T
   Shintani, Y
   Inoue, M
   Sawabata, N
   Miyazato, M
   Okumura, M
   Kangawa, K
AF Nojiri, Takashi
   Hosoda, Hiroshi
   Tokudome, Takeshi
   Miura, Koichi
   Ishikane, Shin
   Kimura, Toru
   Shintani, Yasushi
   Inoue, Masayoshi
   Sawabata, Noriyoshi
   Miyazato, Mikiya
   Okumura, Meinoshin
   Kangawa, Kenji
TI Atrial natriuretic peptide inhibits lipopolysaccharide-induced acute
   lung injury
SO PULMONARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
DE Atrial natriuretic peptide; ALI/ARDS; pulmonary inflammation 
ID IN-VIVO; SELECTIN; NEUTROPHILS; DYSFUNCTION; RESECTION; THERAPY; CANCER;
   ROLL
AB Objectives: We recently reported that administration of atrial natriuretic peptide during the perioperative period has prophylactic effects with respect to not only cardiovascular but also respiratory complications following pulmonary resection. However, its mechanisms are not well understood. The objective of the present study was to investigate the mechanism of the prophylactic effects of atrial natriuretic peptide in an acute lung injury model.
   Methods: For the evaluation of the early phase of pulmonary inflammation, in vitro and in vivo studies using lipopolysaccharide were used. In the in vitro study, the effects of atrial natriuretic peptide on the induction of E-selectin by lipopolysaccharide in human pulmonary artery endothelial cells were evaluated. In the in vivo study, the effects of atrial natriuretic peptide on lipopolysaccharide-induced inflammatory cell infiltration and cytokine levels including tumor necrosis factor-alpha and interleukin-6 in the bronchoalveolar lavage fluid in the lungs of C57/B6 mice were examined. The number of myeloperoxidase-positive staining cells in the tissue sections of the lung of lipopolysaccharide-administered C57/B6 mice was also evaluated.
   Results: Atrial natriuretic peptide significantly attenuated the up-regulation of E-selectin expression induced by lipopolysaccharide in human pulmonary artery endothelial cells. There were significantly lower cell counts and levels of tumor necrosis factor-alpha and interleukin-6 in the bronchoalveolar lavage fluid of atrial natriuretic peptide-treated mice compared to control mice after lipopolysaccharide injection. In addition, there were significantly fewer myeloperoxidase-positive cells in atrial natriuretic peptide-treated mice than in control mice after lipopolysaccharide injection.
   Conclusions: Atrial natriuretic peptide had a protective effect in the lipopolysaccharide-induced acute lung injury model. Atrial natriuretic peptide may be of value in therapeutic strategies aimed at the treatment of acute lung injury such as pneumonia or acute respiratory distress syndrome. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Nojiri, Takashi; Tokudome, Takeshi; Ishikane, Shin; Miyazato, Mikiya; Kangawa, Kenji] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan.
C1 [Nojiri, Takashi; Kimura, Toru; Shintani, Yasushi; Inoue, Masayoshi; Sawabata, Noriyoshi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka, Japan.
C1 [Hosoda, Hiroshi; Miura, Koichi] Natl Cerebral & Cardiovasc Ctr, Dept Regenerat Med & Tissue Engn, Suita, Osaka 5658565, Japan.
C3 National Cerebral & Cardiovascular Center - Japan; Osaka University;
   National Cerebral & Cardiovascular Center - Japan
RP Nojiri, T (corresponding author), Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Biochem, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.
EM nojiri@ri.ncvc.go.jp
RI Sawabata, Noriyoshi/AAJ-1025-2021
OI Sawabata, Noriyoshi/0000-0002-4899-1005
FU Takeda Science Foundation;  [23791581]; Grants-in-Aid for Scientific
   Research [26861319, 22126002] Funding Source: KAKEN
FX This work was supported in part by a grant-in-aid for Scientific
   Research (23791581) and a grant from the Takeda Science Foundation.
CR Alam N, 2007, ANN THORAC SURG, V84, P1085, DOI 10.1016/j.athoracsur.2007.05.053
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Henriques GMO, 1996, BLOOD, V87, P5297, DOI 10.1182/blood.V87.12.5297.bloodjournal87125297
   Kiemer AK, 2000, J IMMUNOL, V165, P175, DOI 10.4049/jimmunol.165.1.175
   Ladetzki-Baehs K, 2007, ENDOCRINOLOGY, V148, P332, DOI 10.1210/en.2006-0935
   LAWRENCE MB, 1993, J IMMUNOL, V151, P6338
   LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D
   LEY K, 1995, J IMMUNOL, V155, P525
   Nishikimi T, 2006, CARDIOVASC RES, V69, P318, DOI 10.1016/j.cardiores.2005.10.001
   Nishikimi T, 2009, REGUL PEPTIDES, V154, P44, DOI 10.1016/j.regpep.2009.02.006
   Nojiri T, 2013, EUR J CARDIO-THORAC, V44, P98, DOI 10.1093/ejcts/ezs646
   Nojiri T, 2012, EUR J CARDIO-THORAC, V41, P1330, DOI 10.1093/ejcts/ezr202
   Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200
   Reinhart K, 2001, CRIT CARE MED, V29, pS121, DOI 10.1097/00003246-200107001-00037
   SAITO Y, 1987, CIRCULATION, V76, P115, DOI 10.1161/01.CIR.76.1.115
   Sezai A, 2010, J AM COLL CARDIOL, V55, P1844, DOI 10.1016/j.jacc.2009.11.085
   WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218
   Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E
   Xing JJ, 2011, J APPL PHYSIOL, V110, P213, DOI 10.1152/japplphysiol.00284.2010
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
NR 20
TC 30
Z9 31
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1094-5539
J9 PULM PHARMACOL THER
JI Pulm. Pharmacol. Ther.
PD OCT
PY 2014
VL 29
IS 1
BP 24
EP 30
DI 10.1016/j.pupt.2014.01.003
PG 7
WC Pharmacology & Pharmacy; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Respiratory System
GA AP2KQ
UT WOS:000341901500004
PM 24462877
DA 2023-08-21
ER

PT J
AU Zhang, Y
   Du, ZH
   Zhou, Q
   Wang, YL
   Li, JG
AF Zhang, Ying
   Du, Zhaohui
   Zhou, Qing
   Wang, Yanlin
   Li, Jianguo
TI Remifentanil Attenuates Lipopolysaccharide-Induced Acute Lung Injury by
   Downregulating the NF-kappa B Signaling Pathway
SO INFLAMMATION
LA English
DT Article
DE remifentanil; LPS; ALI/ARDS; cytokines; NF-kappa B 
ID RESPIRATORY-DISTRESS-SYNDROME; SEPTIC SHOCK; ENDOTOXIN; RATS;
   INFLAMMATION; ACTIVATION; EXPRESSION; PROPOFOL
AB Remifentanil significantly represses cell immune responses and influences neutrophil migration through endothelial cell monolayers. The present study determines the beneficial effects of remifentanil and the mechanisms by which it attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI). Rats were intratracheally instilled with 2 mg/kg LPS to induce ALI. Results showed that remifentanil could resolve lung injury, as evidenced by remarkable decreases in lung edema (wet-to-dry weight ratio), neutrophil infiltration (myeloperoxidase activity), and pulmonary permeability [total number of cells and protein concentrations in bronchoalveolar lavage fluid (BALF)]. Remifentanil also attenuated the concentrations of proinflammatory cytokines tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 in BALF, as well as effectively repressed the activation of nuclear factor-kappaB (NF-kappa B), which has been associated with the inhibition of I kappa B alpha degradation.These results suggest that remifentanil may be a suitable treatment for LPS-induced ALI. Remifentanil exerts beneficial effects on the inhibition of proinflammatory cytokine production by downregulating the NF-kappa B pathway.
C1 [Zhang, Ying; Du, Zhaohui; Zhou, Qing; Wang, Yanlin; Li, Jianguo] Wuhan Univ, Zhongnan Hosp, Dept Anesthesia, Crit Care Med & Emergency Med Ctr, Wuhan 430071, Hubei Province, China.
C3 Wuhan University
RP Li, JG (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Anesthesia, Crit Care Med & Emergency Med Ctr, Wuhan 430071, Hubei Province, Peoples R China.
EM 2010lijianguo@sina.cn
FU National Natural Science Foundation of China [30972852]
FX This work was financially supported by the National Natural Science
   Foundation of China (no. 30972852).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Blackwell TS, 1996, J IMMUNOL, V157, P1630
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037, DOI 10.1152/ajplung.2001.281.5.L1037
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2
   Hofbauer R, 2000, ACTA ANAESTH SCAND, V44, P1232, DOI 10.1034/j.1399-6576.2000.441008.x
   Hopkins Stephen John, 2003, Leg Med (Tokyo), V5 Suppl 1, pS45, DOI 10.1016/S1344-6223(02)00088-3
   Ke JJ, 2008, ANAESTH INTENS CARE, V36, P74, DOI 10.1177/0310057X0803600113
   Kwak SH, 2004, J KOREAN MED SCI, V19, P55, DOI 10.3346/jkms.2004.19.1.55
   Kwalk JH, 2008, ARCH PHARM RES, V31, P133, DOI 10.1007/s12272-001-1131-4
   Li GA, 2010, TOHOKU J EXP MED, V222, P7, DOI 10.1620/tjem.222.7
   Lin Y, 2011, CHINESE MED J-PEKING, V124, P1069, DOI 10.3760/cma.j.issn.0366-6999.2011.07.022
   Liu SF, 1997, J IMMUNOL, V159, P3976
   Mason Paula, 2002, Intensive Crit Care Nurs, V18, P355, DOI 10.1016/S0964-3397(02)00087-3
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Paladino JD, 2009, MICROVASC RES, V77, P8, DOI 10.1016/j.mvr.2008.09.001
   Sacerdote P, 2001, INT IMMUNOPHARMACOL, V1, P713, DOI 10.1016/S1567-5769(01)00005-4
   Schwartz MD, 1996, CRIT CARE MED, V24, P1285, DOI 10.1097/00003246-199608000-00004
   Song XM, 2008, SHOCK, V30, P468, DOI 10.1097/SHK.0b013e31816d5e49
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Xu CQ, 2010, EUR J PHARMACOL, V642, P146, DOI 10.1016/j.ejphar.2010.05.012
   Zhang ZZ, 2010, MOL BIOL REP, V37, P2803, DOI 10.1007/s11033-009-9828-4
NR 26
TC 37
Z9 41
U1 1
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD OCT
PY 2014
VL 37
IS 5
BP 1654
EP 1660
DI 10.1007/s10753-014-9893-2
PG 7
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA AP9YN
UT WOS:000342438200033
PM 24748477
DA 2023-08-21
ER

PT J
AU Storch, EK
   Hillyer, CD
   Shaz, BH
AF Storch, Emily K.
   Hillyer, Christopher D.
   Shaz, Beth H.
TI Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies
SO BLOOD
LA English
DT Article
ID ACUTE LUNG INJURY; TRANSPORTER-LIKE PROTEIN-2; TRANSFECTED CELL-LINES;
   ENDOTHELIAL-CELLS; DONOR PLASMA; TRANSFUSION; ALLOANTIBODIES; MODEL;
   RISK; PREVENTION
AB Human neutrophil antigen-3a (HNA-3a) antibodies contained in donor plasma can result in severe, sometimes fatal transfusion-related acute lung injury (TRALI). Recent developments in TRALI secondary to antibodies to HNA-3a antigen span diagnosis, pathophysiology, treatment, and prevention resulting in improved understanding, potential treatments, and mitigation strategies. First, on the molecular level, characterization of HNA-3 antigen has allowed for genotyping methods that clarify population prevalence. Related work has led to generation of multiple antibody detection assays. These assays aid in determining potential populations at risk and potential mitigation strategies. Second, the development of TRALI requires a hit from the patient and from the product. Anti-HNA-3a is one of the product-derived factors and appears to result in TRALI by binding directly to pulmonary endothelium as well as to neutrophils expressing the corresponding antigen. Finally, potential mitigation strategies include red blood cell product filtration to remove anti-HNA-3a as well as other antibodies.
C1 [Storch, Emily K.; Hillyer, Christopher D.; Shaz, Beth H.] New York Blood Ctr, New York, NY 10065, United States.
C1 [Hillyer, Christopher D.] Weill Cornell Med Coll, Dept Med, New York, NY, United States.
C1 [Shaz, Beth H.] Emory Univ, Dept Pathol & Lab Med, Ctr Transfus & Cellular Therapies, Atlanta, GA 30322, United States.
C3 New York Blood Center; Cornell University; Weill Cornell Medicine; Emory
   University
RP Shaz, BH (corresponding author), New York Blood Ctr, 310 East 67th St, New York, NY 10065 USA.
EM bshaz@nybloodcenter.org
OI Shaz, Beth/0000-0002-2270-4821
CR [Anonymous], FAT REP FDA FOLL BLO
   Bayat B, 2013, ARTERIOSCL THROM VAS, V33, P2538, DOI 10.1161/ATVBAHA.113.301206
   Bayat B, 2012, TRANSFUSION, V52, P613, DOI 10.1111/j.1537-2995.2011.03303.x
   Berthold T, 2011, TRANSFUSION, V51, P2160, DOI 10.1111/j.1537-2995.2011.03115.x
   Bierling P, 2009, VOX SANG, V96, P266, DOI 10.1111/j.1423-0410.2008.01144.x
   Bougie DW, 2013, BLOOD, V122
   Bowens KL, 2012, TRANSFUSION, V52, P2368, DOI 10.1111/j.1537-2995.2012.03600.x
   Bux J, 2011, VOX SANG, V100, P122, DOI 10.1111/j.1423-0410.2010.01392.x
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Curtis BR, 2011, TRANSFUSION, V51, P2168, DOI 10.1111/j.1537-2995.2011.03145.x
   Curtis BR, 2010, BLOOD, V115, P2073, DOI 10.1182/blood-2009-11-248336
   Davoren A, 2003, TRANSFUSION, V43, P641, DOI 10.1046/j.1537-2995.2003.00374.x
   Eder AF, 2013, TRANSFUSION, V53, P1442, DOI 10.1111/j.1537-2995.2012.03935.x
   Fadeyi EA, 2007, TRANSFUSION, V47, P545, DOI 10.1111/j.1537-2995.2006.01148.x
   Flesch BK, 2013, TRANSFUSION, V53, P3217, DOI 10.1111/trf.12160
   Flesland O, 2007, Intensive Care Med, V33 Suppl 1, pS17, DOI 10.1007/s00134-007-2875-1
   Greinacher A, 2010, NAT MED, V16, P45, DOI 10.1038/nm.2070
   GRIMMINGER F, 1991, CIRC RES, V68, P503, DOI 10.1161/01.RES.68.2.503
   Kanack AJ, 2012, TRANSFUSION, V52, P1112, DOI 10.1111/j.1537-2995.2011.03411.x
   Keller-Stanislawski B, 2010, VOX SANG, V98, P70, DOI 10.1111/j.1423-0410.2009.01232.x
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Kleinman S, 2010, TRANSFUSION, V50, P1312, DOI 10.1111/j.1537-2995.2010.02659.x
   Kommareddi PK, 2010, PROTEIN J, V29, P417, DOI 10.1007/s10930-010-9268-y
   Kommareddi PK, 2009, LARYNGOSCOPE, V119, P924, DOI 10.1002/lary.20136
   Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968
   Lin YL, 2012, TRANSFUSION, V52, P567, DOI 10.1111/j.1537-2995.2011.03330.x
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Reil A, 2011, TRANSFUSION, V51, P18, DOI 10.1111/j.1537-2995.2010.02751.x
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   SEEGER W, 1990, BLOOD, V76, P1438
   Segel GB, 2011, J LEUKOCYTE BIOL, V89, P359, DOI 10.1189/jlb.0910538
   Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   Silliman CC, 2014, BLOOD, V123, P3488, DOI 10.1182/blood-2013-10-532424
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932
   Wiersum-Osselton JC, 2011, TRANSFUSION, V51, P1278, DOI 10.1111/j.1537-2995.2010.02969.x
   Wozniak MJ, 2012, TRANSFUSION, V52, P1458, DOI 10.1111/j.1537-2995.2011.03490.x
NR 39
TC 15
Z9 18
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD SEP 18
PY 2014
VL 124
IS 12
BP 1868
EP 1872
DI 10.1182/blood-2014-05-538181
PG 5
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA AQ4JT
UT WOS:000342762800007
PM 25006121
OA Bronze
DA 2023-08-21
ER

PT J
AU Belvitch, P
   Adyshev, D
   Elangovan, VR
   Brown, ME
   Naureckas, C
   Rizzo, AN
   Siegler, JH
   Garcia, JGN
   Dudek, SM
AF Belvitch, Patrick
   Adyshev, Djanybek M.
   Elangovan, Venkateswaran Ramamoorthi
   Brown, Mary E.
   Naureckas, Caitlin
   Rizzo, Alicia N.
   Siegler, Jessica H.
   Garcia, Joe G. N.
   Dudek, Steven M.
TI Proline-rich region of non-muscle myosin light chain kinase modulates
   kinase activity and endothelial cytoskeletal dynamics
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; barrier function; cytoskeleton; Non-muscle myosin light chain kinase; cortactin; Stress fibers; Membrane dynamics 
ID SPHINGOSINE 1-PHOSPHATE; BARRIER INTEGRITY; CORTACTIN; ABL; SRC;
   ENHANCEMENT; MECHANICS; ISOFORM; ROLES; MOUSE
AB Disruption of the pulmonary endothelial barrier and subsequent vascular leak is a hallmark of acute lung injury. Dynamic rearrangements in the endothelial cell (EC) peripheral membrane and underlying cytoskeleton are critical determinants of barrier function. The cytoskeletal effector protein non-muscle myosin light chain kinase (nmMLCK) and the actin-binding regulatory protein cortactin are important regulators of the endothelial barrier. In the present study we functionally characterize a proline-rich region of nmMLCK previously identified as the possible site of interaction between nmMLCK and cortactin. A mutant nmMLCK construct deficient in proline residues at the putative sites of cortactin binding (amino acids 973, 976, 1019, 1022) was generated. Co-immunoprecipitation studies in human lung EC transfected with wild-type or mutant nmMLCK demonstrated similar levels of cortactin interaction at baseline and after stimulation with the barrier-enhancing agonist, sphingosine 1-phosphate (S1P). In contrast, binding studies utilizing recombinant nmMLCK fragments containing the wild-type or proline-deficient sequence demonstrated a two-fold increase in cortactin binding (p < 0.01) to the mutant construct. Immunofluorescent microscopy revealed an increased stress fiber density in ECs expressing GFP-labeled mutant nmMLCK at baseline (p = 0.02) and after thrombin (p = 0.01) or SIP (p = 0.02) when compared to wild-type. Mutant nmMLCK demonstrated an increase in kinase activity in response to thrombin (p < 0.01). Kymographic analysis demonstrated an increased EC membrane retraction distance and velocity (p < 0.01) in response to the barrier disrupting agent thrombin in cells expressing the mutant vs. the wildtype nmMLCK construct. These results provide evidence that critical prolines within nmMLCK (amino acids 973, 976, 1019, 1022) regulate cytoskeletal and membrane events associated with pulmonary endothelial barrier function. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Belvitch, Patrick; Adyshev, Djanybek; Elangovan, Venkateswaran R.; Brown, Mary E.; Naureckas, Caitlin; Rizzo, Alicia N.; Siegler, Jessica H.; Dudek, Steven M.] Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60612, United States.
C1 [Garcia, Joe G. N.] Univ Arizona, Hlth Sci Ctr, Tucson, AZ, United States.
C3 University of Arizona; University of Arizona Health Sciences
RP Dudek, SM (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, COMRB 3143,MC 719,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM sdudek@uic.edu
RI RamamoorthiElangovan, Venkateswaran/O-5533-2017; Garcia, Joe
   GN/E-8862-2010
OI Rizzo, Alicia/0000-0001-9289-4635
FU National Heart, Lung and Blood Institute NIH [NIH T32 HL 082547, NIH R01
   HL 88144, NIH P01 HL 58064]
FX This work was supported by grants from the National Heart, Lung and
   Blood Institute NIH grants NIH T32 HL 082547, R01 HL 88144, and P01 HL
   58064. The authors would like to thank Lakshmi Natarajan for her expert
   technical assistance in cell culture.
CR Adamson RH, 2002, J PHYSIOL-LONDON, V539, P295, DOI 10.1113/jphysiol.2001.013117
   Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20
   Barfod ET, 2011, MOL BIOL CELL, V22, P634, DOI 10.1091/mbc.E10-06-0514
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324
   Brown M, 2010, MICROVASC RES, V80, P75, DOI 10.1016/j.mvr.2009.12.010
   Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043
   Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006
   Doggett TM, 2011, JOVE-J VIS EXP, DOI 10.3791/3187
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829
   Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025
   Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911
   Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Lee JF, 2006, HISTOCHEM CELL BIOL, V126, P297, DOI 10.1007/s00418-006-0143-z
   Li YS, 2004, EXP CELL RES, V298, P107, DOI 10.1016/j.yexcr.2004.03.023
   McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   Moitra J, 2008, TRANSL RES, V151, P141, DOI 10.1016/j.trsl.2007.12.008
   Ott C., 2012, CURR PROTOC CELL BIO, V57, P1
   Peacock JG, 2007, MOL BIOL CELL, V18, P3860, DOI 10.1091/mbc.E07-01-0075
   Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976
   Sahdev S., 2008, MOL CELL BIOCHEM, V307, P249
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   Shen Q, 2009, CELL HEALTH CYTOSKEL, V1, P43
   Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144
   Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126
   Vogel SM, 2012, COMPR PHYSIOL, V2, P449, DOI 10.1002/cphy.c100006
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yi K, 2011, NAT CELL BIOL, V13, P1252, DOI 10.1038/ncb2320
   Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8
   Zhao J, 2009, CELL SIGNAL, V21, P1945, DOI 10.1016/j.cellsig.2009.09.002
NR 42
TC 13
Z9 14
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD SEP
PY 2014
VL 95
BP 94
EP 102
DI 10.1016/j.mvr.2014.07.007
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA AQ9RO
UT WOS:000343193400014
PM 25072537
OA Green Accepted, Green Submitted
DA 2023-08-21
ER

PT J
AU Jiang, H
   Hu, R
   Sun, LL
   Chai, DD
   Cao, ZD
   Li, QF
AF Jiang, Hong
   Hu, Rong
   Sun, Lulu
   Chai, Dongdong
   Cao, Zhendong
   Li, Qifang
TI CRITICAL ROLE OF TOLL-LIKE RECEPTOR 4 IN HYPOXIA-INDUCIBLE FACTOR 1
   alpha ACTIVATION DURING TRAUMA/HEMORRHAGIC SHOCK-INDUCED ACUTE LUNG
   INJURY AFTER LYMPH INFUSION IN MICE
SO SHOCK
LA English
DT Article
DE ALI/ARDS; TLR/TLR2/TLR4; HIF/HIF1 alpha; trauma/hemorrhagic shock 
ID NF-KAPPA-B; HEMORRHAGIC-SHOCK; MESENTERIC LYMPH; TRAUMA; HIF-1;
   RESUSCITATION; INFLAMMATION; HIF-1-ALPHA; SATURATION; INHIBITION
AB The nuclear transcription factor hypoxia-inducible factor 1 alpha (HIF-1 alpha) is a key regulator of gene expression under hypoxic and inflammatory conditions. The germline-encoded pattern recognition receptor toll-like receptor 4 (TLR4) recognizes molecular motifs shared by large groups of microorganisms as well as by endogenous ligands released from stressed and/or injured tissues. We have previously demonstrated that local inhibition of HIF-1 alpha ameliorates lung injury induced by trauma/hemorrhagic shock (T/HS) in rats. In the current study, we directly determined the role of TLR4 in HIF-1 alpha activation during T/HS-induced acute lung injury in mice. C3H/HeJ mice that harbor a TLR4 mutation and wild-type (WT) mice were infused T/HS or trauma/sham shock (T/SS) lymph from Sprague-Dawley rats. Evans blue dye lung permeability, lung water content, myeloperoxidase levels, and lung histological analysis confirmed that TLR4-deficient mice are resistant to lung injury after T/HS lymph infusion. Lungs from WT and TLR4(mut) mice after T/SS lymph infusion expressed negligible levels of HIF-1 alpha. The induction of HIF-1 alpha in lung homogenates from TLR4(mut) mice after T/HS or T/HS lymph infusion was markedly reduced as compared with their WT counterparts but remained elevated as compared with TLR4(mut) mice after T/SS lymph infusion. Endothelial cells from TLR4(mut) mice and silence of TLR4 in cells from WT mice showed a remarkable reduction of HIF-1 alpha on T/HS lymph stimulation. Blocking of nuclear factor-kappa B activity by SN50 or Bay 11-7085 in WT cells diminished T/HS lymph-induced HIF-1 alpha accumulation when compared with T/SS lymph incubation. Thus, our data suggest that TLR4 activation by T/HS is necessary for T/HS-induced lung injury and an augmented pulmonary HIF-1 alpha response, which will provide more insights into the pathogenesis of shock-induced acute lung injury and identify potential therapeutic targets.
C1 [Jiang, Hong; Hu, Rong; Sun, Lulu; Chai, Dongdong; Li, Qifang] Shanghai Jiao Tong Univ, Dept Anesthesiol, Sch Med, Shanghai Peoples Hosp 9, Shanghai 200011, China.
C1 [Cao, Zhendong] Shanghai Jiao Tong Univ, Dept Chinese Tradit Med, Sch Med, Shanghai Peoples Hosp 9, Shanghai 200011, China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Li, QF (corresponding author), Shanghai Jiao Tong Univ, Dept Anesthesiol, Sch Med, Shanghai Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM liqifang2004@gmail.com
OI , qifang/0000-0002-5593-720X
FU National Nature Science Foundation of China [81272083]; Natural Science
   Foundation of the Shanghai Science Committee [12ZR1417200]; Major
   Foundation of Shanghai Health Bureau [2012021]
FX This study was supported by the National Nature Science Foundation of
   China (grant no. 81272083), by the Natural Science Foundation of the
   Shanghai Science Committee (grant no. 12ZR1417200), and by the Major
   Foundation of Shanghai Health Bureau (grant no. 2012021).
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   BENJAMIN E, 1994, CRIT CARE MED, V22, P1616
   Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761
   Coornaert B, 2009, J BIOL CHEM, V284, P8217, DOI 10.1074/jbc.R800032200
   Dehne N, 2009, EXP CELL RES, V315, P1791, DOI 10.1016/j.yexcr.2009.03.019
   Feinman R, 2010, AM J PHYSIOL-GASTR L, V299, pG833, DOI 10.1152/ajpgi.00065.2010
   Frede S, 2006, BIOCHEM J, V396, P517, DOI 10.1042/BJ20051839
   Gale DP, 2010, INT J BIOCHEM CELL B, V42, P486, DOI 10.1016/j.biocel.2009.10.012
   Gonzalez RJ, 2000, SHOCK, V14, P404, DOI 10.1097/00024382-200014030-00028
   Hauser CJ, 2005, SHOCK, V24, P24, DOI 10.1097/01.shk.0000191387.18818.43
   HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249
   Imtiyaz HZ, 2010, CURR TOP MICROBIOL, V345, P105, DOI 10.1007/82_2010_74
   Jantsch J, 2011, J LEUKOCYTE BIOL, V90, P551, DOI 10.1189/jlb.1210683
   Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315
   Jiang H, 2012, ACTA PHARMACOL SIN, V33, P635, DOI 10.1038/aps.2012.5
   Jiang H, 2010, AM J PHYSIOL-LUNG C, V298, pL660, DOI 10.1152/ajplung.00394.2009
   Kan WH, 2008, J APPL PHYSIOL, V105, P595, DOI 10.1152/japplphysiol.00012.2008
   KANNAN KB, 2010, AM J PHYSIOL-GASTR L, V300, pG853
   Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004
   Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200
   Koury J, 2004, SHOCK, V22, P270, DOI 10.1097/01.shk.0000135256.67441.3f
   Latz E, 2003, J CLIN INVEST, V112, P1136, DOI 10.1172/JCI200320040
   Leone M, 2009, ANESTHESIOLOGY, V111, P366, DOI 10.1097/ALN.0b013e3181aae72d
   Levy RM, 2006, AM J PHYSIOL-REG I, V291, pR970, DOI 10.1152/ajpregu.00793.2005
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255
   Magnotti LJ, 1999, ARCH SURG-CHICAGO, V134, P1333, DOI 10.1001/archsurg.134.12.1333
   Mannam P, 2013, J IMMUNOL, V190, P1264, DOI 10.4049/jimmunol.1202012
   McCloskey CA, 2004, SHOCK, V22, P380, DOI 10.1097/01.shk.0000140660.78744.bf
   Navarrete-Navarro P, 2001, INTENS CARE MED, V27, P1133, DOI 10.1007/s001340100955
   Nizet V, 2009, NAT REV IMMUNOL, V9, P609, DOI 10.1038/nri2607
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Peyssonnaux C, 2007, J IMMUNOL, V178, P7516, DOI 10.4049/jimmunol.178.12.7516
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   Ramanathan M, 2009, J LEUKOCYTE BIOL, V86, P681, DOI 10.1189/jlb.0109021
   Reino DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014829
   Salomao R, 2012, SHOCK, V38, P227, DOI 10.1097/SHK.0b013e318262c4b0
   Sambol JT, 2000, SHOCK, V14, P416, DOI 10.1097/00024382-200014030-00030
   Senthil M, 2007, ANN SURG, V246, P822, DOI 10.1097/SLA.0b013e3180caa3af
   Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685
   Song Y, 2001, AM J PHYSIOL-LUNG C, V281, pL677, DOI 10.1152/ajplung.2001.281.3.L677
   White NJ, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-64
   Xiang M, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/916425
   Zallen G, 2000, J TRAUMA, V48, P45, DOI 10.1097/00005373-200001000-00008
NR 44
TC 15
Z9 15
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD SEP
PY 2014
VL 42
IS 3
BP 271
EP 278
DI 10.1097/SHK.0000000000000212
PG 8
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA AO6WW
UT WOS:000341494400015
PM 24978883
OA Bronze
DA 2023-08-21
ER

PT J
AU Yuan, Q
   Jiang, YW
   Fang, QH
AF Yuan, Qing
   Jiang, Yanwen
   Fang, Qiuhong
TI Improving effect of Sivelestat on lipopolysaccharide-induced lung injury
   in rats
SO APMIS
LA English
DT Article
DE ALI/ARDS; ICAM-1; Sivelestat; MPO; NF-kappa B; LPS 
ID NEUTROPHIL ELASTASE INHIBITOR; LEUKOCYTE RECRUITMENT; ENDOTHELIAL-CELLS;
   INFLAMMATION; ACTIVATION; APOPTOSIS; MICE; EXPRESSION; MIGRATION;
   ADHESION
AB Sepsis causes neutrophil sequestration in the lung, which leads to acute lung injury (ALI). Neutrophil elastase (NE) is thought to play an important role in the pathogenesis of ALI. This study investigated whether Sivelestat, a specific NE inhibitor, can attenuate ALI induced by lipopolysaccharide (LPS). In vivo, 30 male Wistar rats were divided into three groups (n = 10 each groups) on the basis of the reagent used, which were subjected to LPS injection with or without Sivelestat treatments to induce ALI model. Lung injury was assessed by pulmonary histology, lung wet-weight to dry-weight (W/D) ratio, immunohistochemical analysis of intercellular adhesion molecule-1 (ICAM-1), the number of myeloperoxidase (MPO)-positive cells, and gene expression of ICAM-1. In vitro, pulmonary microvascular endothelial cells (PMVECs) were stimulated with LPS in the presence and absence of Sivelestat; nuclear factor-kappa B (NF-kappa B) p65 was measured by immunocytochemistry staining and Western blotting. Infusion of LPS induced lung injury, in vivo, as demonstrated by pulmonary edema with infiltration of neutrophils, the increase in lung W/D ratio, the number of MPO-positive cells and enhanced expression of ICAM-1 and ICAM-1 gene. In vitro, the significant increased release of NF-kappa B p65 and its subsequent translocation into the nucleus in PMVECs. In contrast, Sivelestat treatment significantly ameliorated the LPS-induced lung injury, as judged by the marked improvement in all these indices. These results indicated that inhibition of NE attenuated LPS-induced lung injury through an inhibition of the inflammatory signaling pathway, besides the direct inhibitory effect on NE.
C1 [Yuan, Qing; Jiang, Yan-Wen; Fang, Qiu-Hong] Capital Med Univ, Beijing Shijitan Hosp, Dept Pulm & Crit Care Med, Beijing 100038, China.
C3 Capital Medical University
RP Yuan, Q (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Dept Pulm & Crit Care Med, 10 Tieyi Rd, Beijing 100038, Peoples R China.
EM docyuanqing@sina.cn
FU Beijing Municipal Health Bureau Youth Research Foundation, Beijing,
   China [QN2010-022]
FX The study was supported by Beijing Municipal Health Bureau Youth
   Research Foundation (QN2010-022), Beijing, China. The funders had no
   role in study design, data collection and analysis, decision to publish
   or preparation of the manuscript.
CR Chlopicki S, 2005, J Physiol Pharmacol, V56 Suppl 4, P47
   Dal-Secco D, 2010, N-S ARCH PHARMACOL, V381, P483, DOI 10.1007/s00210-010-0500-2
   Dang O, 2004, SHOCK, V21, P470, DOI 10.1097/00024382-200405000-00012
   Davis BB, 2011, BIOCHEM BIOPH RES CO, V410, P494, DOI 10.1016/j.bbrc.2011.06.008
   El Kebir D, 2008, CIRC RES, V103, P352, DOI 10.1161/01.RES.0000326772.76822.7a
   FABIANI JN, 1986, ANN CARDIOL ANGEIOL, V35, P439
   Fernandez-Pisonero I, 2012, J IMMUNOL, V189, P5402, DOI 10.4049/jimmunol.1201309
   Friedman GB, 1998, J CELL PHYSIOL, V176, P76, DOI 10.1002/(SICI)1097-4652(199807)176:1<76::AID-JCP9>3.0.CO;2-5
   Fujimura N, 2013, J SURG RES, V180, pE31, DOI 10.1016/j.jss.2012.04.037
   Hagio T, 2008, PULM PHARMACOL THER, V21, P884, DOI 10.1016/j.pupt.2008.10.002
   Henriksen PA, 2004, J IMMUNOL, V172, P4535, DOI 10.4049/jimmunol.172.7.4535
   KIM N-S, 1991, Yonsei Medical Journal, V32, P303
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   McCarter SA, 2006, EXP BIOL MED, V231, P985
   Morote-Garcia JC, 2012, P NATL ACAD SCI USA, V109, P14146, DOI 10.1073/pnas.1202165109
   Ramudo L, 2010, PANCREAS, V39, P1057, DOI 10.1097/MPA.0b013e3181da0f3e
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Rizzolo LJ, 2007, MOL VIS, V13, P1259
   Saeed RW, 2004, J IMMUNOL, V173, P6376, DOI 10.4049/jimmunol.173.10.6376
   Schuepbach RA, 2009, THROMB HAEMOSTASIS, V101, P724, DOI 10.1160/TH08-10-0632
   Shen WF, 2009, PHARMACOL RES, V60, P296, DOI 10.1016/j.phrs.2009.04.007
   Storme L, 2013, ARCH CARDIOVASC DIS, V106, P169, DOI 10.1016/j.acvd.2012.12.005
   Tao W, 2012, PULM PHARMACOL THER, V25, P99, DOI 10.1016/j.pupt.2011.12.006
   Toda Y, 2007, INT J MOL MED, V19, P237
   Wang W, 2006, AM J PHYSIOL-RENAL, V291, pF1090, DOI 10.1152/ajprenal.00517.2005
   White LE, 2012, SHOCK, V38, P320, DOI 10.1097/SHK.0b013e31826359d0
   Xie KL, 2012, SHOCK, V37, P548, DOI 10.1097/SHK.0b013e31824ddc81
   YABLONKAREUVENI Z, 1989, DEV BIOL, V132, P230, DOI 10.1016/0012-1606(89)90219-4
   Yang Y, 2011, MOL BIOL REP, V38, P3615, DOI 10.1007/s11033-010-0473-8
   Yen FL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063845
   Yuan Q, 2009, SHOCK, V32, P310, DOI 10.1097/SHK.0b013e31819c36e8
   Yuan XP, 2012, INFLAMMATION, V35, P1161, DOI 10.1007/s10753-011-9424-3
NR 32
TC 12
Z9 14
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD SEP
PY 2014
VL 122
IS 9
BP 810
EP 817
DI 10.1111/apm.12222
PG 8
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA AO2KT
UT WOS:000341151300013
PM 24484066
DA 2023-08-21
ER

PT J
AU Kumar, S
   Xu, JY
   Kumar, RS
   Lakshmikanthan, S
   Kapur, R
   Kofron, M
   Chrzanowska-Wodnicka, M
   Filippi, MD
AF Kumar, Sachin
   Xu, Juying
   Kumar, Rupali Sani
   Lakshmikanthan, Sribalaji
   Kapur, Reuben
   Kofron, Matthew
   Chrzanowska-Wodnicka, Magdalena
   Filippi, Marie-Dominique
TI The small GTPase Rap1b negatively regulates neutrophil chemotaxis and
   transcellular diapedesis by inhibiting Akt activation
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; ACUTE LUNG INJURY; MATRIX-METALLOPROTEINASE;
   VASCULAR ENDOTHELIUM; CELL FUNCTIONS; MIGRATION; ADHESION; PROTEIN;
   INFLAMMATION; CYTOTOXICITY
AB Neutrophils are the first line of cellular defense in response to infections and inflammatory injuries. However, neutrophil activation and accumulation into tissues trigger tissue damage due to release of a plethora of toxic oxidants and proteases, a cause of acute lung injury (ALI). Despite its clinical importance, the molecular regulation of neutrophil migration is poorly understood. The small GTPase Rap1b is generally viewed as a positive regulator of immune cell functions by controlling bidirectional integrin signaling. However, we found that Rap1b-deficient mice exhibited enhanced neutrophil recruitment to inflamed lungs and enhanced susceptibility to endotoxin shock. Unexpectedly, Rap1b deficiency promoted the transcellular route of diapedesis through endothelial cell. Increased transcellular migration of Rap1b-deficient neutrophils in vitro was selectively mediated by enhanced PI3K-Akt activation and invadopodia-like protrusions. Akt inhibition in vivo suppressed excessive Rap1b-deficient neutrophil migration and associated endotoxin shock. The inhibitory action of Rap1b on PI3K signaling may be mediated by activation of phosphatase SHP-1. Thus, this study reveals an unexpected role for Rap1b as a key suppressor of neutrophil migration and lung inflammation.
C1 [Kumar, Sachin; Xu, Juying; Kumar, Rupali Sani; Filippi, Marie-Dominique] Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229, United States.
C1 [Kumar, Sachin; Xu, Juying; Kumar, Rupali Sani; Filippi, Marie-Dominique] Univ Cincinnati, Coll Med, Cincinnati, OH 45229, United States.
C1 [Lakshmikanthan, Sribalaji; Chrzanowska-Wodnicka, Magdalena] Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI 53214, United States.
C1 [Kapur, Reuben] Indiana Univ Sch Med, Canc Res Inst, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202, United States.
C1 [Kofron, Matthew] Cincinnati Childrens Res Fdn, Div Dev Biol, Cincinnati, OH 45229, United States.
C3 Cincinnati Children's Hospital Medical Center; Cincinnati Children's
   Hospital Research Foundation; University System of Ohio; University of
   Cincinnati; Versiti Blood Center of Wisconsin; Indiana University
   System; Indiana University Bloomington; Cincinnati Children's Hospital
   Medical Center; Cincinnati Children's Hospital Research Foundation
RP Filippi, MD (corresponding author), Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
EM Marie-Dominique.Filippi@cchmc.org
RI Lakshmikanthan, Sribalaji/J-6882-2015; Kumar, Sachin/AAB-8679-2019
OI Lakshmikanthan, Sribalaji/0000-0002-1112-3730; kumar,
   sachin/0000-0002-3835-8935; Kofron, Matthew/0000-0001-6427-4148;
   Chrzanowska, Magdalena/0000-0003-4182-2126
FU National Institutes of Health [HL090676, HL111582, R01HL077177,
   R01HL081111, R01CA173852, R01CA134777]
FX The work was supported by National Institutes of Health (HL090676 to
   M.-D. Filippi; HL111582 to M. Chrzanowska-Wodnicka,; and R01HL077177,
   R01HL081111, R01CA173852, and R01CA134777 to R. Kapur).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177
   Awasthi A, 2010, J EXP MED, V207, P1923, DOI 10.1084/jem.20100040
   Boettner B, 2009, CURR OPIN CELL BIOL, V21, P684, DOI 10.1016/j.ceb.2009.06.004
   Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3
   Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436
   Carbo C, 2010, J LEUKOCYTE BIOL, V88, P313, DOI 10.1189/jlb.0110049
   Carman CV, 2008, CURR OPIN CELL BIOL, V20, P533, DOI 10.1016/j.ceb.2008.05.007
   Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015
   Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129
   Carman CV, 2003, J IMMUNOL, V171, P6135, DOI 10.4049/jimmunol.171.11.6135
   Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238
   Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2
   Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015
   Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973
   Cicchetti G, 2002, CRIT REV ORAL BIOL M, V13, P220, DOI 10.1177/154411130201300302
   Delacourt C, 2002, AM J RESP CELL MOL, V26, P290, DOI 10.1165/ajrcmb.26.3.4611
   Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903
   Filippi MD, 2007, BLOOD, V109, P1257, DOI 10.1182/blood-2006-04-017731
   Gerard A, 2009, BLOOD, V113, P6138, DOI 10.1182/blood-2008-07-167668
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hamacher J, 2002, AM J RESP CRIT CARE, V166, P651, DOI 10.1164/rccm.2109004
   HEWETT JA, 1992, LAB INVEST, V66, P347
   Hidalgo A, 2009, NAT MED, V15, P384, DOI 10.1038/nm.1939
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950
   Katagiri K, 2011, METHODS MOL BIOL, V757, P279, DOI 10.1007/978-1-61779-166-6_18
   Kumar S, 2012, BLOOD, V120, P3563, DOI 10.1182/blood-2012-04-426981
   Lakshmikanthan S, 2011, BLOOD, V118, P2015, DOI 10.1182/blood-2011-04-349282
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Li Y, 2007, J IMMUNOL, V179, P8322, DOI 10.4049/jimmunol.179.12.8322
   Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4
   Liu XW, 2012, NAT IMMUNOL, V13, P457, DOI 10.1038/ni.2258
   Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200
   M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140
   Mamdouh Z, 2009, J EXP MED, V206, P2795, DOI 10.1084/jem.20082745
   McMillan SJ, 2013, BLOOD, V121, P2084, DOI 10.1182/blood-2012-08-449983
   Muller WA, 2011, ANNU REV PATHOL-MECH, V6, P323, DOI 10.1146/annurev-pathol-011110-130224
   Nusrat A, 1997, GASTROENTEROLOGY, V113, P1489, DOI 10.1053/gast.1997.v113.pm9352851
   Nystrom A, 2009, BLOOD, V114, P4897, DOI 10.1182/blood-2009-02-207134
   OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925
   Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514
   Plitas G, 2003, J AM COLL SURGEONS, V196, P761, DOI 10.1016/S1072-7515(03)00134-0
   Raaijmakers JH, 2009, J BIOL CHEM, V284, P10995, DOI 10.1074/jbc.R800061200
   Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9
   Sage PT, 2009, FRONT BIOSCI-LANDMRK, V14, P5066, DOI 10.2741/3587
   Sasawatari S, 2010, IMMUNITY, V32, P200, DOI 10.1016/j.immuni.2010.01.012
   Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295
   Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133
   Shulman Z, 2009, IMMUNITY, V30, P384, DOI 10.1016/j.immuni.2008.12.020
   SIKORSKI EE, 1993, J IMMUNOL, V151, P5239
   Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3
   Szczur K, 2009, BLOOD, V114, P4527, DOI 10.1182/blood-2008-12-195164
   Tremblay GM, 2002, CHEST, V121, P582, DOI 10.1378/chest.121.2.582
   Tsui FWL, 2006, IMMUNOL RES, V35, P127, DOI 10.1385/IR:35:1:127
   von Wedel-Parlow M, 2011, BRAIN RES, V1367, P62, DOI 10.1016/j.brainres.2010.09.076
   Wittchen Erika S, 2011, Small GTPases, V2, P65
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR
   Zhang H, 2005, IMMUNITY, V22, P235, DOI 10.1016/j.immuni.2005.01.004
   Zhang H, 2006, IMMUNITY, V25, P285, DOI 10.1016/j.immuni.2006.06.014
NR 63
TC 48
Z9 50
U1 1
U2 18
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD AUG 25
PY 2014
VL 211
IS 9
BP 1741
EP 1758
DI 10.1084/jem.20131706
PG 18
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA AQ4EA
UT WOS:000342744500007
PM 25092872
OA Green Published, Green Submitted, hybrid
DA 2023-08-21
ER

PT J
AU Zhang, ML
   Dong, MQ
   Liu, W
   Wang, L
   Luo, YC
   Li, ZC
   Jin, FG
AF Zhang, Minlong
   Dong, Mingqing
   Liu, Wei
   Wang, Li
   Luo, Ying
   Li, Zhichao
   Jin, Faguang
TI 1 alpha, 25-Dihydroxyvitamin D-3 Ameliorates Seawater Aspiration-Induced
   Acute Lung Injury via NF-kappa B and RhoA/Rho Kinase Pathways
SO PLOS ONE
LA English
DT Article
ID VITAMIN-D-RECEPTOR; RHO-KINASE; ENDOTHELIAL-CELLS;
   1-ALPHA,25-DIHYDROXYVITAMIN D-3; INHIBITION; ACTIVATION; EXPRESSION;
   MYOSIN; PHOSPHORYLATION; PREVENTION
AB Introduction: Inflammation and pulmonary edema are involved in the pathogenesis of seawater aspiration-induced acute injury (ALI). Although several studies have reported that 1 alpha, 25-Dihydroxyvitamin D-3 (calcitriol) suppresses inflammation, it has not been confirmed to be effective in seawater aspiration-induced ALI. Thus, we investigated the effect of calcitriol on seawater aspiration-induced ALI and explored the probable mechanism.
   Methods: Male SD rats receiving different doses of calcitriol or not, underwent seawater instillation. Then lung samples were collected at 4 h for analysis. In addition, A549 cells and rat pulmonary microvascular endothelial cells (RPMVECs) were cultured with calcitriol or not and then stimulated with 25% seawater for 40 min. After these treatments, cells samples were collected for analysis.
   Results: Results from real-time PCR showed that seawater stimulation up-regulated the expression of vitamin D receptor in lung tissues, A549 cells and RPMVECs. Seawater stimulation also activates NF-kappa B and RhoA/Rho kinase pathways. However, we found that pretreatment with calcitriol significantly inhibited the activation of NF-kappa B and RhoA/Rho kinase pathways. Meanwhile, treatment of calcitriol also improved lung histopathologic changes, reduced inflammation, lung edema and vascular leakage.
   Conclusions: These results demonstrated that NF-kappa B and RhoA/Rho kinase pathways are critical in the development of lung inflammation and pulmonary edema and that treatment with calcitriol could ameliorate seawater aspiration-induced ALI, which was probably through the inhibition of NF-kappa B and RhoA/Rho kinase pathways.
C1 [Zhang, Minlong; Liu, Wei; Wang, Li; Jin, Faguang] Fourth Mil Med Univ, Tangdu Hosp, Dept Respirat, Xian 710032, China.
C1 [Dong, Mingqing; Luo, Ying; Li, Zhichao] Fourth Mil Med Univ, Dept Pathol & Pathophysiol, Xian 710032, China.
C1 [Dong, Mingqing; Liu, Wei; Luo, Ying; Li, Zhichao; Jin, Faguang] Fourth Mil Med Univ, Lung Injury & Repair Ctr, Xian 710032, China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University
RP Li, ZC (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Respirat, Xian 710032, Peoples R China.
EM lizhic@fmmu.edu.cn; jinfag@fmmu.edu.cn
RI dong, ming-qing/HTO-3001-2023
OI dong, ming-qing/0000-0001-9720-535X
FU National Nature Science Foundation of China [81270124]
FX This work was supported by National Nature Science Foundation of China
   (No. 81270124). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308
   Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246
   BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294
   Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004
   Ding XM, 2006, PHARMACOL RES, V53, P372, DOI 10.1016/j.phrs.2006.01.006
   Dong XY, 2003, J BIOL CHEM, V278, P49378, DOI 10.1074/jbc.M308448200
   Ecklund MM, 2012, CRIT CARE NURS CLIN, V24, P601, DOI 10.1016/j.ccell.2012.07.002
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   Fan QX, 2011, PULM PHARMACOL THER, V24, P673, DOI 10.1016/j.pupt.2011.07.002
   Fukuoka M, 1998, BRIT J PHARMACOL, V124, P1433, DOI 10.1038/sj.bjp.0701988
   Gorovoy M, 2007, CIRC RES, V101, P50, DOI 10.1161/CIRCRESAHA.106.145847
   Han F, 2012, RESP PHYSIOL NEUROBI, V182, P71, DOI 10.1016/j.resp.2012.05.012
   Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13
   Ibsen LM, 2002, CRIT CARE MED, V30, pS402, DOI 10.1097/00003246-200211001-00004
   Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210
   Konrad FM, 2012, AM J PHYSIOL-LUNG C, V303, pL425, DOI 10.1152/ajplung.00387.2011
   Li JH, 2011, RESP PHYSIOL NEUROBI, V176, P39, DOI 10.1016/j.resp.2011.01.005
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Lips P, 2006, PROG BIOPHYS MOL BIO, V92, P4, DOI 10.1016/j.pbiomolbio.2006.02.016
   Ma LJ, 2013, RESP PHYSIOL NEUROBI, V185, P608, DOI 10.1016/j.resp.2012.11.016
   Matsumura F, 2008, BIOCHEM BIOPH RES CO, V369, P149, DOI 10.1016/j.bbrc.2007.12.090
   Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779
   Penna G, 2009, PROSTATE, V69, P480, DOI 10.1002/pros.20896
   Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463
   Rostkowska-Nadolska B, 2010, ADV MED SCI-POLAND, V55, P86, DOI 10.2478/v10039-010-0012-9
   Salomez F, 2004, RESUSCITATION, V63, P261, DOI 10.1016/j.resuscitation.2004.06.007
   Schmeck B, 2003, INFLAMMATION, V27, P89, DOI 10.1023/A:1023278600596
   Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   Takahashi K, 2002, IMMUNOPHARM IMMUNOT, V24, P1, DOI 10.1081/IPH-120003399
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Takano Y, 2011, STEROIDS, V76, P1305, DOI 10.1016/j.steroids.2011.06.009
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   van Beeck EF, 2005, B WORLD HEALTH ORGAN, V83, P853
   VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295
   Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2
   Xie XY, 2011, EXP LUNG RES, V37, P482, DOI 10.3109/01902148.2011.594144
   You QH, 2010, J SURG RES, V162, P110, DOI 10.1016/j.jss.2009.01.019
   Zhang Y, 2011, BIOL PHARM BULL, V34, P1052, DOI 10.1248/bpb.34.1052
   Zheng C, 2011, CELL RES, V21, P183, DOI 10.1038/cr.2010.171
NR 44
TC 20
Z9 28
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2014
VL 9
IS 8
AR e104507
DI 10.1371/journal.pone.0104507
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AN9BM
UT WOS:000340900600063
PM 25118599
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Ma, HY
   Shi, JH
   Wang, CS
   Guo, L
   Gong, YL
   Li, J
   Gong, YT
   Yun, FX
   Zhao, HW
   Li, EY
AF Ma Hongyan
   Shi Jinghui
   Wang Changsong
   Guo Lei
   Gong Yulei
   Li Jie
   Gong Yongtai
   Yun Fengxiang
   Zhao Hongwei
   Li Enyou
TI Blockade of PDE4B limits lung vascular permeability and lung
   inflammation in LPS-induced acute lung injury
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE PDE4B; ALI/ARDS; LPS; Vascular barrier dysfunction 
ID INHIBITION; ACTIVATION
AB Acute lung injury (ALI), acute respiratory distress syndrome (ARDS), is actually involved in an ongoing and uncontrolled inflammatory response in lung tissues. Although extensive studies suggested that phospodiesterase type 4B (PDE4B) may be related to inflammation, the underlying cell biological mechanism of ALI remains unclear. To further investigate the mechanism how PDE4B take part in inflammatory response and the maintenance of vascular integrity, we established the experimental model of ALI in vitro and in vivo. In vitro, we found that Cilomilast, Diazepam and PDE4B knockout could potently inhibit the LPS-induced NF-kappa B activation and inflammatory response in multiple cell types, including lung epithelial cells (A549), pulmonary microvascular endothelial cells (PMVECs) and vascular smooth muscle cells (VSMCs). Besides, PDE4B deletion attenuated the LPS-induced ROS generation. In vivo, PDE4B deletion could attenuate the lung water content, histological signs of pulmonary injury and elevate the ratio of partial pressure of arterial O-2 to fraction of inspired O-2 (PaO2/FIO2 ratio). Additionally, PDE4B deletion reduced LPS-induced vascular permeability. Collectively, our results strongly indicates that PDE4B is a valid target for anti-ALI. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Ma Hongyan; Shi Jinghui; Wang Changsong; Guo Lei; Gong Yulei; Li Enyou] Harbin Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Harbin 150001, Heilongjiang Pr, China.
C1 [Gong Yongtai; Yun Fengxiang; Zhao Hongwei] Harbin Med Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Harbin 150001, Heilongjiang Pr, China.
C1 [Li Jie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Anesthesiol, Guangzhou 510000, Guangdong, China.
C3 Harbin Medical University; Harbin Medical University; Sun Yat Sen
   University
RP Li, EY (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 23 Youzheng St, Harbin 150001, Heilongjiang Pr, Peoples R China.
EM lienyouhydyymzk@yeah.net
OI wang, changsong/0000-0002-0079-5259
FU Scientific and Technological Planning Project of Heilongjiang Province,
   China [GC09C409-3, GC12C305-5]; Science and Technology Planning Project
   of Guangdong Province, China [2010A030100011-06]; Fundamental Research
   Funds for the Central Universities in China [12ykpy26]; National Natural
   Science Foundation of China [30972839]
FX This work was supported by Scientific and Technological Planning Project
   of Heilongjiang Province, China (No. GC09C409-3; No. GC12C305-5);
   Science and Technology Planning Project of Guangdong Province, China
   (2010A030100011-06); the Fundamental Research Funds for the Central
   Universities in China (No. 12ykpy26); Financial support by grants from
   the National Natural Science Foundation of China (No. 30972839).
CR Aizawa T, 2003, CIRC RES, V93, P406, DOI 10.1161/01.RES.0000091074.33584.F0
   Blackman BE, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.203604
   El-Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Gandhirajan RK, 2013, J CLIN INVEST, V123, P887, DOI 10.1172/JCI65647
   He X, 2013, CELL SIGNAL, V25, P1913, DOI 10.1016/j.cellsig.2013.05.024
   Huang EW, 2012, APOPTOSIS, V17, P1120, DOI 10.1007/s10495-012-0743-0
   Hwang TL, 2012, TOXICOL APPL PHARM, V260, P193, DOI 10.1016/j.taap.2012.02.011
   Jeon KI, 2010, P NATL ACAD SCI USA, V107, P9795, DOI 10.1073/pnas.0914414107
   Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599
   Keravis T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028899
   Kim SW, 2009, BLOOD, V113, P6153, DOI 10.1182/blood-2009-02-206128
   Komatsu K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2674
   Li J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059257
   Li W, 2013, ACTA PHARMACOL SIN, V34, P1164, DOI 10.1038/aps.2013.82
   MacKenzie KF, 2011, BIOCHEM J, V435, P755, DOI 10.1042/BJ20101184
   Martina SD, 2006, ANN PHARMACOTHER, V40, P1822, DOI 10.1345/aph.1H049
   Sobczak Magdalena, 2010, J Vis Exp, DOI 10.3791/2316
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Wang G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079757
   Woyda K, 2009, EUR RESPIR J, V33, P861, DOI 10.1183/09031936.00109008
   Yang H, 2012, HYPERTENSION, V60, P1287, DOI 10.1161/HYPERTENSIONAHA.112.198648
   Yougbare I, 2011, AM J PHYSIOL-LUNG C, V301, pL441, DOI 10.1152/ajplung.00407.2010
NR 22
TC 17
Z9 19
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 8
PY 2014
VL 450
IS 4
BP 1560
EP 1567
DI 10.1016/j.bbrc.2014.07.024
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AO4UY
UT WOS:000341338100054
PM 25019986
DA 2023-08-21
ER

PT J
AU Gonzales, JN
   Kim, KM
   Zemskova, MA
   Rafikov, R
   Heeke, B
   Varn, MN
   Black, S
   Kennedy, TP
   Verin, AD
   Zemskov, EA
AF Gonzales, Joyce N.
   Kim, Kyung-mi
   Zemskova, Marina A.
   Rafikov, Ruslan
   Heeke, Brenten
   Varn, Matthew N.
   Black, Stephen M.
   Kennedy, Thomas P.
   Verin, Alexander D.
   Zemskov, Evgeny A.
TI Low anticoagulant heparin blocks thrombin-induced endothelial
   permeability in a PAR-dependent manner
SO VASCULAR PHARMACOLOGY
LA English
DT Article
DE heparin; Thrombin; PAR; ODSH; ECs/HPMECs/HUVECs/MPVECs 
ID ACUTE LUNG INJURY; HUMAN ALPHA-THROMBIN; MYOSIN PHOSPHATASE;
   CYTOSKELETON STRUCTURE; BARRIER DYSFUNCTION; MLC PHOSPHORYLATION;
   CRYSTAL-STRUCTURE; BINDING EXOSITE; CELLS; RHO
AB Acute lung injury and acute respiratory distress syndrome are accompanied by thrombin activation and fibrin deposition that enhance lung inflammation, activate endothelial cells and disrupt lung paracellular permeability. Heparin possesses anti-inflammatory properties but its clinical use is limited by hemorrhage and heparin induced thrombocytopenia. We studied the effects of heparin and low anticoagulant 2-O, 3-O desulfated heparin (ODSH) on thrombin-induced increases in paracellular permeability of cultured human pulmonary endothelial cells (ECs). Pretreatment with heparin or ODSH blocked thrombin-induced decrease in the EC transendothelial electrical resistance (TER), attenuated thrombin-stimulated paracellular gap formation and actin cytoskeletal rearrangement. Our data demonstrated that heparin and ODSH had inhibitory effects on thrombin-induced RhoA activation and intracellular calcium elevation. Thrombin-stimulated phosphorylation of the cytoskeletal regulatory proteins, myosin light chain and ezrin/radixin/moesin was also reduced. In these effects, low anticoagulant ODSH was more potent than heparin. Heparin or ODSH alone produced decreases in the EC TER that were abolished by siRNA-mediated depletion of the thrombin receptor, PAR-1. We also demonstrated that, in contrast to heparin, ODSH did not possess thrombin-binding activity. Results suggest that heparin and low anticoagulant ODSH can interfere with thrombin-activated signaling. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Gonzales, Joyce N.; Kim, Kyung-mi; Zemskova, Marina A.; Rafikov, Ruslan; Heeke, Brenten; Varn, Matthew N.; Black, Stephen; Verin, Alexander D.; Zemskov, Evgeny A.] Georgia Regents Univ, Vasc Biol Ctr, Augusta, GA 30912, United States.
C1 [Gonzales, Joyce N.; Kennedy, Thomas P.] Georgia Regents Univ, Dept Internal Med, Div Pulm & Crit Care Med, Augusta, GA 30912, United States.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University
RP Gonzales, JN (corresponding author), Georgia Regents Univ, Div Pulm & Crit Care Med, Room BBR 5513,1120 15th St, Augusta, GA 30912 USA.
EM jgonzales@gru.edu; i60p68@hotmail.com; mzemskova@gru.edu;
   rrafikov@gru.edu; bheeke@gru.edu; mvarn@gru.edu; sblack@gru.edu;
   tkennedy@gru.edu; averin@gru.edu; ezemskov@gru.edu
RI Rafikov, Ruslan/AAG-9352-2019
OI Verin, Alexander/0000-0003-0627-7185; Black, Stephen
   M./0000-0002-4524-6544; Rafikov, Ruslan/0000-0001-5950-4076
FU NIH [HL101902]; GHSU CVDI Intramural Grant; American Heart Association
   [11SDG7670035]; NIH T32 fellowship grant
FX Funding support provided by NIH grant HL101902 (Dr. Verin and Dr.
   Black), GHSU CVDI Intramural Grant and the American Heart Association
   11SDG7670035 (Dr. Zemskov) and by funds generously supplied to Drs.
   Gonzales and Kennedy by Dr. Michael Madaio from the Department of
   Internal Medicine, Georgia Regents University. Dr. Gonzales was
   supported by the NIH T32 fellowship grant. None of the sponsors had a
   role in the study design; in the collection, analysis and interpretation
   of data; in the writing of the report; and in the decision to submit the
   article for publication.
CR Bao YX, 2012, MOL MED REP, V5, P873, DOI 10.3892/mmr.2011.739
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   BODE W, 1992, PROTEIN SCI, V1, P426
   Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324
   Cadroy Y, 1996, THROMB HAEMOSTASIS, V75, P190
   CARDIN AD, 1991, METHOD ENZYMOL, V203, P556
   Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200
   Casu B, 2010, MATRIX BIOL, V29, P442, DOI 10.1016/j.matbio.2010.04.003
   Chung AWY, 2002, BRIT J PHARMACOL, V135, P1123, DOI 10.1038/sj.bjp.0704559
   Csortos C, 2007, AM J PHYSIOL-LUNG C, V293, pL843, DOI 10.1152/ajplung.00120.2007
   De Candia E, 1999, CIRCULATION, V99, P3308, DOI 10.1161/01.CIR.99.25.3308
   De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200
   De Cristofaro R, 2003, J THROMB THROMBOLYS, V15, P151, DOI 10.1023/B:THRO.0000011370.80989.7b
   Di Ciano-Oliveira C, 2003, AM J PHYSIOL-CELL PH, V285, pC555, DOI 10.1152/ajpcell.00086.2003
   Doutremepuich C, 1996, THROMB RES, V83, P217, DOI 10.1016/0049-3848(96)00130-2
   Ellis CA, 1999, AM J PHYSIOL, V276, pC38
   FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066
   Forster M, 2006, BIOCHEM SOC T, V34, P431, DOI 10.1042/BST0340431
   Fryer A, 1997, J PHARMACOL EXP THER, V282, P208
   Gori AM, 1999, THROMB HAEMOSTASIS, V81, P589
   Green JV, 2013, J INFECT DIS, V208, P1695, DOI 10.1093/infdis/jit391
   Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100
   IDELL S, 1989, AM J PATHOL, V135, P387
   Kim KM, 2012, J CELL PHYSIOL, V227, P1701, DOI 10.1002/jcp.22894
   LI EHH, 1976, ARCH BIOCHEM BIOPHYS, V175, P153, DOI 10.1016/0003-9861(76)90494-X
   LIU LW, 1991, J BIOL CHEM, V266, P16977
   Loke C, 2012, DM-DIS MON, V58, P424, DOI 10.1016/j.disamonth.2012.04.005
   Macfarlane SR, 2001, PHARMACOL REV, V53, P245
   McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200
   Momota F, 2006, BIOCHEM BIOPH RES CO, V342, P365, DOI 10.1016/j.bbrc.2006.01.165
   Murphy JT, 2001, J TRAUMA, V50, P213, DOI 10.1097/00005373-200102000-00005
   O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502
   Popovic M, 2010, J THROMB THROMBOLYS, V30, P164, DOI 10.1007/s11239-010-0447-7
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Satpathy M, 2004, EXP EYE RES, V79, P477, DOI 10.1016/j.exer.2004.06.018
   Schmidt B, 1996, PEDIATR RES, V39, P798, DOI 10.1203/00006450-199605000-00009
   Seminario-Vidal L, 2009, J BIOL CHEM, V284, P20638, DOI 10.1074/jbc.M109.004762
   SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518
   Smurova K M, 2004, Tsitologiia, V46, P695
   SOBEL M, 1992, J BIOL CHEM, V267, P8857
   Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003
   Tar K, 2006, J CELL BIOCHEM, V98, P931, DOI 10.1002/jcb.20829
   Vadasz I, 2005, AM J RESP CELL MOL, V33, P343, DOI 10.1165/rcmb.2004-0407OC
   Amerongen GPV, 2008, AM J PHYSIOL-CELL PH, V294, pC1234, DOI 10.1152/ajpcell.00551.2007
   Villar J, 2011, RESP CARE, V56, P1539, DOI 10.4187/respcare.01395
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Ware Lorraine B., 2005, Keio Journal of Medicine, V54, P142, DOI 10.2302/kjm.54.142
   Warkentin TE, 2001, NEW ENGL J MED, V344, P1286, DOI 10.1056/NEJM200104263441704
   Weitz DS, 2010, J THROMB THROMBOLYS, V29, P199, DOI 10.1007/s11239-009-0411-6
   WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775
   Ruiz-Loredo AY, 2011, J CELL PHYSIOL, V226, P414, DOI 10.1002/jcp.22347
NR 53
TC 25
Z9 27
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1537-1891
EI 1879-3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD AUG
PY 2014
VL 62
IS 2
BP 63
EP 71
DI 10.1016/j.vph.2014.01.005
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AM9OW
UT WOS:000340211900003
PM 24469066
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Moreno-Vinasco, L
   Quijada, H
   Sammani, S
   Siegler, J
   Letsiou, E
   Deaton, R
   Saadat, L
   Zaidi, RS
   Messana, J
   Gann, PH
   Machado, RF
   Ma, W
   Camp, SM
   Wang, T
   Garcia, JGN
AF Moreno-Vinasco, Liliana
   Quijada, Hector
   Sammani, Saad
   Siegler, Jessica
   Letsiou, Eleftheria
   Deaton, Ryan
   Saadat, Laleh
   Zaidi, Rafe S.
   Messana, Joe
   Gann, Peter H.
   Machado, Roberto F.
   Ma, Wenli
   Camp, Sara M.
   Wang, Ting
   Garcia, Joe G. N.
TI Nicotinamide Phosphoribosyltransferase Inhibitor Is a Novel Therapeutic
   Candidate in Murine Models of Inflammatory Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE apoptosis; FK-866; nicotinamide phosphoribosyltransferase; polymorphonuclear neutrophil; ECs/HPMECs/HUVECs/MPVECs 
ID COLONY-ENHANCING FACTOR; BIOSYNTHESIS INHIBITOR; APOPTOSIS; FK866; NAD;
   PATHWAY; GENE
AB We previously identified the intracellular nicotinamide phosphoribosyltransferase (iNAMPT, aka pre-B-cell colony enhancing factor) as a candidate gene promoting acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury (VILI) with circulating nicotinamide phosphoribosyltransferase potently inducing NF-kappa B signaling in lung endothelium. iNAMPT also synthesizes intracellular nicotinamide adenine dinucleotide (iNAD) in response to extracellular oxidative stress, contributing to the inhibition of apoptosis via ill-defined mechanisms. We now further define the role of iNAMPT activity in the pathogenesis of ARDS/VILI using the selective iNAMPT inhibitor FK-866. C57/B6 mice were exposed to VILI (40 ml/kg, 4 h) or LPS (1.5 mg/kg, 18 h) after osmotic pump delivery of FK-866 (100 mg/kg/d, intraperitoneally). Assessment of total bronchoalveolar lavage (BAL) protein, polymorphonuclear neutrophil (PMN) levels, cytokine levels (TNF-alpha, IL-6, IL-1 alpha), lung iNAD levels, and injury scores revealed that FK866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS-and VILI-exposed mice. FK-866 further increased lung PMN apoptosis, as reflected by caspase-3 activation in BAL PMNs. These findings support iNAMPT inhibition via FK-866 as a novel therapeutic agent for ARDS via enhanced apoptosis in inflammatory PMNs.
C1 [Moreno-Vinasco, Liliana; Sammani, Saad; Siegler, Jessica; Letsiou, Eleftheria; Deaton, Ryan; Saadat, Laleh; Zaidi, Rafe S.; Messana, Joe; Machado, Roberto F.; Garcia, Joe G. N.] Univ Illinois, Inst Personalized Resp Med, Chicago, IL, United States.
C1 [Moreno-Vinasco, Liliana; Sammani, Saad; Siegler, Jessica; Letsiou, Eleftheria; Deaton, Ryan; Saadat, Laleh; Zaidi, Rafe S.; Messana, Joe; Machado, Roberto F.; Garcia, Joe G. N.] Univ Illinois, Dept Med, Chicago, IL, United States.
C1 [Gann, Peter H.] Univ Illinois, Dept Pathol, Chicago, IL, United States.
C1 [Quijada, Hector; Ma, Wenli; Camp, Sara M.; Wang, Ting; Garcia, Joe G. N.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721, United States.
C1 [Ma, Wenli; Camp, Sara M.; Wang, Ting; Garcia, Joe G. N.] Univ Arizona, Dept Med, Tucson, AZ 85721, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona
RP Garcia, JGN (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Drachman Hall,Room B-207,1295 North Martin Ave, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
OI Machado, Roberto/0000-0002-3722-5954
FU National Heart, Lung and Blood Institute [HL94394]
FX This study was supported by National Heart, Lung and Blood Institute
   grant HL94394 (J.G.N. G.).
CR Bajwa EK, 2007, CRIT CARE MED, V35, P1290, DOI 10.1097/01.CCM.0000260243.22758.4F
   Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267
   Cheng Q, 2011, J MOL ENDOCRINOL, V47, P13, DOI 10.1530/JME-10-0106
   Dahl TB, 2010, J CLIN ENDOCR METAB, V95, P3039, DOI 10.1210/jc.2009-2148
   Dessap AM, 2012, AM J RESP CELL MOL, V46, P541, DOI 10.1165/rcmb.2011-0306OC
   Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66
   Filippatos TD, 2010, CURR VASC PHARMACOL, V8, P12, DOI 10.2174/157016110790226679
   Hasmann M, 2003, CANCER RES, V63, P7436
   Holen K, 2008, INVEST NEW DRUG, V26, P45, DOI 10.1007/s10637-007-9083-2
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI 10.1172/JCI19930
   Klapczynski Marcin, 2012, J Pathol Inform, V3, P20, DOI 10.4103/2153-3539.95456
   Laudes M, 2010, HORM METAB RES, V42, P268, DOI 10.1055/s-0029-1243638
   Luk T, 2008, J LEUKOCYTE BIOL, V83, P804, DOI 10.1189/jlb.0807581
   Meyer NJ, 2009, FASEB J, V23, P1325, DOI 10.1096/fj.08-119073
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Montecucco F, 2013, ANTIOXID REDOX SIGN, V18, P630, DOI 10.1089/ars.2011.4487
   Moschen AR, 2011, HEPATOLOGY, V54, P675, DOI 10.1002/hep.24416
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200
   Pillai VB, 2013, AM J PHYSIOL-HEART C, V304, pH415, DOI 10.1152/ajpheart.00468.2012
   Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271
   Pogrebniak A, 2006, EUR J MED RES, V11, P313
   Van Gool F, 2009, NAT MED, V15, P206, DOI 10.1038/nm.1906
   Ye SQ, 2005, MICROVASC RES, V70, P142, DOI 10.1016/j.mvr.2005.08.003
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
NR 26
TC 33
Z9 36
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD AUG
PY 2014
VL 51
IS 2
BP 223
EP 228
DI 10.1165/rcmb.2012-0519OC
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AY2JW
UT WOS:000347417100007
PM 24588101
OA Green Published
DA 2023-08-21
ER

PT J
AU Thangavel, J
   Malik, AB
   Elias, HK
   Rajasingh, S
   Simpson, AD
   Sundivakkam, PK
   Vogel, SM
   Xuan, YT
   Dawn, B
   Rajasingh, J
AF Thangavel, Jayakumar
   Malik, Asrar B.
   Elias, Harold K.
   Rajasingh, Sheeja
   Simpson, Andrew D.
   Sundivakkam, Premanand K.
   Vogel, Stephen M.
   Xuan, Yu-Ting
   Dawn, Buddhadeb
   Rajasingh, Johnson
TI Combinatorial Therapy with Acetylation and Methylation Modifiers
   Attenuates Lung Vascular Hyperpermeability in Endotoxemia-Induced Mouse
   Inflammatory Lung Injury
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; DNA METHYLATION; TRICHOSTATIN-A;
   STEM-CELLS; 5-AZACYTIDINE; TRANSCRIPTION; PERMEABILITY; MODEL;
   NEUTROPHILS; DISRUPTION
AB Impairment of tissue fluid homeostasis and migration of inflammatory cells across the vascular endothelial barrier are crucial factors in the pathogenesis of acute lung injury (ALI). The goal for treatment of ALI is to target pathways that Lead to profound dysregulation of the lung endothelial barrier. Although studies have shown that chemical epigenetic modifiers can limit lung inflammation in experimental ALI models, studies to date have not examined efficacy of a combination of DNA methyl transferase inhibitor 5-Aza 2-deoxycytidine and histone deacetylase inhibitor trichostatin A (herein referred to as Aza+TSA) after endotoxemia-induced mouse lung injury. We tested the hypothesis that treatment with Aza+TSA after Lipopolysaccharide induction of ALI through epigenetic modification of Lung endothelial cells prevents inflammatory lung injury. Combinatorial treatment with Aza+TSA mitigated the increased endothelial permeability response after lipopolysaccharide challenge. In addition, we observed reduced lung inflammation and lung injury. Aza+TSA also significantly reduced mortality in the ALI model. The protection was ascribed to inhibition of the eN0S-Cav1-MLC2 signaling pathway and enhanced acetylation of histone markers on the vascular endothelial-cadherin promoter. In summary, these data show for the first time the efficacy of combinatorial Aza+TSA therapy in preventing ALI in lipopolysaccharide-induced endotoxemia and raise the possibility of an essential role of DNA methyl transferase and histone deacetylase in the mechanism of ALI.
C1 [Thangavel, Jayakumar; Elias, Harold K.; Rajasingh, Sheeja; Simpson, Andrew D.; Xuan, Yu-Ting; Dawn, Buddhadeb; Rajasingh, Johnson] Univ Kansas, Med Ctr, Dept Internal Med, Div Cardiovasc Dis, Kansas City, KS 66160, United States.
C1 [Rajasingh, Johnson] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Inst, Kansas City, KS 66160, United States.
C1 [Malik, Asrar B.; Sundivakkam, Premanand K.; Vogel, Stephen M.] Univ Illinois, Dept Pharmacol, Chicago, IL, United States.
C3 University of Kansas; University of Kansas Medical Center; University of
   Kansas; University of Kansas Medical Center; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital
RP Rajasingh, J (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Inst,Dept Internal Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.
EM rjohnson9@kumc.edu
RI Rajasingh, Johnson/AAT-1985-2021; Elias, Harold/F-6457-2015
OI Rajasingh, Johnson/0000-0002-6172-4083; Elias,
   Harold/0000-0002-6189-4752; Malik, Asrar/0000-0002-8205-7128
FU American Heart Association grant-Jon Holden DeHaan Foundation grant
   [10SDG2630181]; NIH; NIH [R21HL97349, R01 HL-117730]
FX Supported in part by American Heart Association grant-Jon Holden DeHaan
   Foundation grant 10SDG2630181, and NIH-supported clinical and
   translational science award Frontiers Pilot grant (J.R.), and NIH grants
   R21HL97349 (J.R.) and R01 HL-117730 (B.D.).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Atochin DN, 2010, PFLUG ARCH EUR J PHY, V460, P965, DOI 10.1007/s00424-010-0867-4
   Avila AM, 2007, J CLIN INVEST, V117, P659, DOI 10.1172/JCI29562
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4
   Butt MU, 2009, J SURG RES, V156, P290, DOI 10.1016/j.jss.2009.04.012
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen ZL, 2012, MOL BIOL CELL, V23, P1388, DOI 10.1091/mbc.E11-09-0811
   Choi Y, 2008, EXP MOL MED, V40, P574, DOI 10.3858/emm.2008.40.5.574
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Dhawan S, 2011, DEV CELL, V20, P419, DOI 10.1016/j.devcel.2011.03.012
   Di AK, 2010, J BIOL CHEM, V285, P15848, DOI 10.1074/jbc.M109.075549
   Furumai R, 2011, CANCER SCI, V102, P1081, DOI 10.1111/j.1349-7006.2011.01904.x
   Garcia AN, 2011, METHODS MOL BIOL, V763, P333, DOI 10.1007/978-1-61779-191-8_23
   Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158
   Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST
   Iwata K, 2002, CELL IMMUNOL, V218, P26, DOI 10.1016/S0008-8749(02)00523-3
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kaminskas E, 2005, ONCOLOGIST, V10, P176, DOI 10.1634/theoncologist.10-3-176
   Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello
   Lin T, 2007, SURGERY, V141, P784, DOI 10.1016/j.surg.2007.01.014
   Lindbom L, 2003, CHEM IMMUNOL, V83, P146
   LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681
   Maniatis NA, 2008, AM J PHYSIOL-LUNG C, V294, pL865, DOI 10.1152/ajplung.00079.2007
   MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Miyawaki-Shimizu K, 2006, AM J PHYSIOL-LUNG C, V290, pL405, DOI 10.1152/ajplung.00292.2005
   Nemeth K, 2010, J MOL MED, V88, P5, DOI 10.1007/s00109-009-0523-7
   O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679
   Price LC, 2012, AM J PHYSIOL-LUNG C, V302, pL803, DOI 10.1152/ajplung.00355.2011
   Qian Q, 2012, STEM CELLS DEV, V21, P67, DOI 10.1089/scd.2010.0519
   Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X
   Rajasingh J, 2008, CIRC RES, V102, pE107, DOI 10.1161/CIRCRESAHA.108.176115
   Rajasingh J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022550
   Sassi FD, 2014, J MOL NEUROSCI
   Schaefer MB, 2008, EUR RESPIR J, V32, P1344, DOI 10.1183/09031936.00035808
   SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5
   Sdek P, 2011, J CELL BIOL, V194, P407, DOI 10.1083/jcb.201012049
   Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144
   Siddiqui MR, 2011, J CELL BIOL, V193, P841, DOI 10.1083/jcb.201012129
   Song Y, 2001, AM J PHYSIOL-LUNG C, V281, pL677, DOI 10.1152/ajplung.2001.281.3.L677
   Suzuki T, 2005, CURR MED CHEM, V12, P2867, DOI 10.2174/092986705774454706
   Trojer P, 2006, CELL, V125, P213, DOI 10.1016/j.cell.2006.04.003
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu CJ, 2013, INT ARCH ALLERGY IMM, V160, P356, DOI 10.1159/000343030
   Wunderlich C, 2006, BIOCHEM BIOPH RES CO, V340, P702, DOI 10.1016/j.bbrc.2005.12.058
   Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91
   Zhang L, 2010, WORLD J SURG, V34, P1676, DOI 10.1007/s00268-010-0493-5
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 51
TC 39
Z9 39
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2014
VL 184
IS 8
BP 2237
EP 2249
DI 10.1016/j.ajpath.2014.05.008
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AM0JY
UT WOS:000339533100010
PM 24929240
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Piegeler, T
   Dull, RO
   Hu, G
   Castellon, M
   Chignalia, AZ
   Koshy, RG
   Votta-Velis, EG
   Borgeat, A
   Schwartz, DE
   Beck-Schimmer, B
   Minshall, RD
AF Piegeler, Tobias
   Dull, Randal O.
   Hu, Guochang
   Castellon, Maricela
   Chignalia, Andreia Z.
   Koshy, Ruben G.
   Votta-Velis, E. Gina
   Borgeat, Alain
   Schwartz, David E.
   Beck-Schimmer, Beatrice
   Minshall, Richard D.
TI Ropivacaine attenuates endotoxin plus hyperinflation-mediated acute lung
   injury via inhibition of early-onset Src-dependent signaling
SO BMC ANESTHESIOLOGY
LA English
DT Article
DE ALI/ARDS; ventilator-induced lung injury; Local anesthetics; ECs/HPMECs/HUVECs/MPVECs; caveolin-1; Src 
ID ENDOTHELIAL-CELLS; NEUTROPHIL ADHESION; VE-CADHERIN; KAPPA-B;
   CAVEOLIN-1; PHOSPHORYLATION; INFLAMMATION; CONTRIBUTES; ACTIVATION;
   EXPRESSION
AB Background: Acute lung injury (ALI) is associated with high mortality due to the lack of effective therapeutic strategies. Mechanical ventilation itself can cause ventilator-induced lung injury. Pulmonary vascular barrier function, regulated in part by Src kinase-dependent phosphorylation of caveolin-1 and intercellular adhesion molecule-1 (ICAM-1), plays a crucial role in the development of protein-/neutrophil-rich pulmonary edema, the hallmark of ALI. Amide-linked local anesthetics, such as ropivacaine, have anti-inflammatory properties in experimental ALI. We hypothesized ropivacaine may attenuate inflammation in a "double-hit" model of ALI triggered by bacterial endotoxin plus hyperinflation via inhibition of Src-dependent signaling.
   Methods: C57BL/6 (WT) and ICAM-1(-/-) mice were exposed to either nebulized normal saline (NS) or lipopolysaccharide (LPS, 10 mg) for 1 hour. An intravenous bolus of 0.33 mg/kg ropivacaine or vehicle was followed by mechanical ventilation with normal (7 ml/kg, NTV) or high tidal volume (28 ml/kg, HTV) for 2 hours. Measures of ALI (excess lung water (ELW), extravascular plasma equivalents, permeability index, myeloperoxidase activity) were assessed and lungs were homogenized for Western blot analysis of phosphorylated and total Src, ICAM-1 and caveolin-1. Additional experiments evaluated effects of ropivacaine on LPS-induced phosphorylation/expression of Src, ICAM-1 and caveolin-1 in human lung microvascular endothelial cells (HLMVEC).
   Results: WT mice treated with LPS alone showed a 49% increase in ELW compared to control animals (p = 0.001), which was attenuated by ropivacaine (p = 0.001). HTV ventilation alone increased measures of ALI even more than LPS, an effect which was not altered by ropivacaine. LPS plus hyperinflation ("double-hit") increased all ALI parameters (ELW, EVPE, permeability index, MPO activity) by 3-4 fold compared to control, which were again decreased by ropivacaine. Western blot analyses of lung homogenates as well as HLMVEC treated in culture with LPS alone showed a reduction in Src activation/expression, as well as ICAM-1 expression and caveolin-1 phosphorylation. In ICAM-1(-/-) mice, neither addition of LPS to HTV ventilation alone nor ropivacaine had an effect on the development of ALI.
   Conclusions: Ropivacaine may be a promising therapeutic agent for treating the cause of pulmonary edema by blocking inflammatory Src signaling, ICAM-1 expression, leukocyte infiltration, and vascular hyperpermeability.
C1 [Piegeler, Tobias; Dull, Randal O.; Hu, Guochang; Castellon, Maricela; Chignalia, Andreia Z.; Koshy, Ruben G.; Votta-Velis, E. Gina; Schwartz, David E.; Minshall, Richard D.] Univ Illinois Hosp & Hlth Sci Syst, Dept Anesthesiol, Chicago, IL 60612, United States.
C1 [Dull, Randal O.; Hu, Guochang; Castellon, Maricela; Minshall, Richard D.] Univ Illinois Hosp Hlth Sci Syst, Dept Pharmacol, Chicago, IL, United States.
C1 [Dull, Randal O.; Minshall, Richard D.] Univ Illinois Hosp Hlth Sci Syst, Dept Bioengn, Chicago, IL, United States.
C1 [Minshall, Richard D.] Univ Illinois Hosp Hlth Sci Syst, Ctr Lung & Vasc Biol, Chicago, IL, United States.
C1 [Beck-Schimmer, Beatrice] Univ Zurich Hosp, Inst Anesthesiol, Zurich, Switzerland.
C1 [Borgeat, Alain] Balgrist Univ Hosp, Dept Anesthesiol, Zurich, Switzerland.
C1 [Votta-Velis, E. Gina] Jesse Brown VA Med Ctr, Dept Anesthesiol, Chicago, IL, United States.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Jesse Brown VA Medical Center
RP Minshall, RD (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Dept Anesthesiol, 835 S Wolcott Ave M-C 868, Chicago, IL 60612 USA.
EM rminsh@uic.edu
OI Chignalia, Andreia/0000-0002-3220-0942
FU Society of Cardiovascular Anesthesiologists Foundation/IARS; European
   Society of Regional Anaesthesia & Pain Medicine Research Grant; NIH
   NHLBI [R01 HL071626, P01 HL060678, R01 HL104092]
FX This work was supported in part by the Society of Cardiovascular
   Anesthesiologists Foundation/IARS Starter Grant (TP), European Society
   of Regional Anaesthesia & Pain Medicine Research Grant (AB), and NIH
   NHLBI grants R01 HL071626 and P01 HL060678 (RDM), and R01 HL104092 (GH).
   Received from the Department of Anesthesiology, University of Illinois
   at Chicago.
CR Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369
   Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004
   Beck-Schimmer B, 2002, EUR RESPIR J, V19, P1142, DOI 10.1183/09031936.02.00236602
   Beck-Schimmer B, 1998, INFLAMM RES, V47, P308, DOI 10.1007/s000110050334
   BeckSchimmer B, 1997, AM J RESP CELL MOL, V17, P344, DOI 10.1165/ajrcmb.17.3.2861
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Blumenthal S, 2006, ANESTHESIOLOGY, V104, P961, DOI 10.1097/00000542-200605000-00012
   Boscher C, 2012, ADV EXP MED BIOL, V729, P29, DOI 10.1007/978-1-4614-1222-9_3
   Cho YS, 2013, KOREAN J PHYSIOL PHA, V17, P133, DOI 10.4196/kjpp.2013.17.2.133
   Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003
   Costantini R, 2011, INT J CLIN PHARM TH, V49, P116, DOI 10.5414/CP201401
   Cusato M, 2011, EUR J CLIN PHARMACOL, V67, P399, DOI 10.1007/s00228-010-0927-x
   Daniel AE, 2013, J INNATE IMMUN, V5, P324, DOI 10.1159/000348828
   de Klaver MJM, 2006, ANESTH ANALG, V102, P1108, DOI 10.1213/01.ane.0000200310.39031.1f
   de Klaver MJM, 2003, ANESTH ANALG, V97, P465, DOI 10.1213/01.ANE.0000073162.27208.E9
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dejana E, 2012, CURR OPIN HEMATOL, V19, P218, DOI 10.1097/MOH.0b013e3283523e1c
   Frank JA, 2003, CRIT CARE, V7, P233, DOI 10.1186/cc1829
   FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
   Gajic O, 2003, AM J RESP CRIT CARE, V167, P1057, DOI 10.1164/rccm.200208-889OC
   Hegeman MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057374
   Hoetzel A, 2009, CRIT CARE MED, V37, P1708, DOI 10.1097/CCM.0b013e31819efa31
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Hu GC, 2008, AM J PHYSIOL-LUNG C, V294, pL178, DOI 10.1152/ajplung.00263.2007
   Hu GC, 2010, CRIT CARE MED, V38, P194, DOI 10.1097/CCM.0b013e3181bc7c17
   Hu GC, 2009, MICROVASC RES, V77, P21, DOI 10.1016/j.mvr.2008.10.002
   Jiao H, 2013, J IMMUNOL, V191, P6191, DOI 10.4049/jimmunol.1300873
   Jin Y, 2011, AM J PHYSIOL-LUNG C, V300, pL151, DOI 10.1152/ajplung.00170.2010
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kang JL, 2005, J TOXICOL ENV HEAL A, V68, P1643, DOI 10.1080/15287390500192114
   Kronstein R, 2012, CARDIOVASC RES, V93, P130, DOI 10.1093/cvr/cvr256
   Liu DJ, 2012, AM J PHYSIOL-LUNG C, V302, pL370, DOI 10.1152/ajplung.00349.2011
   Liu GQ, 2012, BLOOD, V120, P1942, DOI 10.1182/blood-2011-12-397430
   Liu GQ, 2011, ARTERIOSCL THROM VAS, V31, P1342, DOI 10.1161/ATVBAHA.110.222208
   Maniatis NA, 2008, AM J PHYSIOL-LUNG C, V294, pL865, DOI 10.1152/ajplung.00079.2007
   Maniatis Nikolaos A, 2012, Pulm Circ, V2, P452, DOI 10.4103/2045-8932.105033
   Maniatis NA, 2012, ADV EXP MED BIOL, V729, P157, DOI 10.1007/978-1-4614-1222-9_11
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x
   Muller WA, 2011, ANNU REV PATHOL-MECH, V6, P323, DOI 10.1146/annurev-pathol-011110-130224
   Ngiam N, 2010, AM J RESP CRIT CARE, V181, P947, DOI 10.1164/rccm.200908-1297OC
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Piegeler T, 2014, ANESTHESIOLOGY, V120, P1414, DOI 10.1097/ALN.0000000000000174
   Piegeler T, 2012, ANESTHESIOLOGY, V117, P548, DOI 10.1097/ALN.0b013e3182661977
   Place AT, 2011, MOL PHARMACOL, V80, P665, DOI 10.1124/mol.111.073957
   Plataki Maria, 2010, Expert Rev Respir Med, V4, P373, DOI 10.1586/ers.10.28
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ricard JD, 2003, EUR RESPIR J, V22, p2S, DOI 10.1183/09031936.03.00420103
   Rosenberg PH, 2005, ACTA ANAESTH SCAND, V49, P913, DOI 10.1111/j.1399-6576.2005.00774.x
   Slutsky Arthur S, 2005, Respir Care, V50, P646
   Su X, 2007, AM J RESP CELL MOL, V37, P186, DOI 10.1165/rcmb.2006-0240OC
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Tamizhselvi R, 2010, EXP CELL RES, V316, P1625, DOI 10.1016/j.yexcr.2010.02.044
   Vlahakis NE, 2005, AM J RESP CRIT CARE, V171, P1328, DOI 10.1164/rccm.200408-1036SO
NR 55
TC 25
Z9 27
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2253
J9 BMC ANESTHESIOL
JI BMC Anesthesiol.
PD JUL 19
PY 2014
VL 14
AR 57
DI 10.1186/1471-2253-14-57
PG 14
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA AM0FO
UT WOS:000339519600002
PM 25097454
OA Green Published, gold, Green Accepted
DA 2023-08-21
ER

PT J
AU Chen, F
   Kumar, S
   Yu, YF
   Aggarwal, S
   Gross, C
   Wang, YS
   Chakraborty, T
   Verin, AD
   Catravas, JD
   Lucas, R
   Black, SM
   Fulton, DJR
AF Chen, Feng
   Kumar, Sanjiv
   Yu, Yanfang
   Aggarwal, Saurabh
   Gross, Christine M.
   Wang, Yusi
   Chakraborty, Trinad
   Verin, Alexander D.
   Catravas, John D.
   Lucas, Rudolf
   Black, Stephen M.
   Fulton, David J. R.
TI PKC-Dependent Phosphorylation of eNOS at T495 Regulates eNOS Coupling
   and Endothelial Barrier Function in Response to G(+) -Toxins
SO PLOS ONE
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-C; ACUTE LUNG INJURY;
   MICROVASCULAR PERMEABILITY; SUPEROXIDE ANION; STREPTOCOCCUS-PNEUMONIAE;
   PNEUMOCOCCAL PNEUMONIA; VASCULAR-PERMEABILITY; PORE FORMATION;
   PNEUMOLYSIN
AB Gram positive (G(+)) infections make up similar to 50% of all acute lung injury cases which are characterized by extensive permeability edema secondary to disruption of endothelial cell (EC) barrier integrity. A primary cause of increased permeability are cholesterol-dependent cytolysins (CDCs) of G(+)-bacteria, such as pneumolysin (PLY) and listeriolysin-O (LLO) which create plasma membrane pores, promoting Ca2+-influx and activation of PKC alpha. In human lung microvascular endothelial cells (HLMVEC), pretreatment with the nitric oxide synthase (NOS) inhibitor, ETU reduced the ability of LLO to increase microvascular cell permeability suggesting an endothelial nitric oxide synthase (eNOS)-dependent mechanism. LLO stimulated superoxide production from HLMVEC and this was prevented by silencing PKC alpha or NOS inhibition suggesting a link between these pathways. Both LLO and PLY stimulated eNOS T495 phosphorylation in a PKC-dependent manner. Expression of a phosphomimetic T495D eNOS (human isoform) resulted in increased superoxide and diminished nitric oxide (NO) production. Transduction of HLMVEC with an active form of PKC alpha resulted in the robust phosphorylation of T495 and increased peroxynitrite production, indicative of eNOS uncoupling. To determine the mechanisms underlying eNOS uncoupling, HLMVEC were stimulated with LLO and the amount of hsp90 and caveolin-1 bound to eNOS determined. LLO stimulated the dissociation of hsp90, and in particular, caveolin-1 from eNOS. Both hsp90 and caveolin-1 have been shown to influence eNOS uncoupling and a peptide mimicking the scaffolding domain of caveolin-1 blocked the ability of PKC alpha to stimulate eNOS-derived superoxide. Collectively, these results suggest that the G(+) pore-forming toxins promote increased EC permeability via activation of PKC alpha, phosphorylation of eNOS-T495, loss of hsp90 and caveolin-1 binding which collectively promote eNOS uncoupling and the production of barrier disruptive superoxide.
C1 [Chen, Feng] Nanjing Med Univ, Dept Forens Med, Nanjing, Jiangsu, China.
C1 [Chen, Feng; Kumar, Sanjiv; Yu, Yanfang; Aggarwal, Saurabh; Gross, Christine; Wang, Yusi; Verin, Alexander D.; Lucas, Rudolf; Black, Stephen M.; Fulton, David J. R.] Georgia Regents Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30901, United States.
C1 [Lucas, Rudolf; Fulton, David J. R.] Georgia Regents Univ, Med Coll Georgia, Dept Pharmacol, Augusta, GA, United States.
C1 [Chakraborty, Trinad] Univ Giessen, Inst Med Microbiol, D-35390 Giessen, Germany.
C1 [Catravas, John D.] Old Dominion Univ, Norfolk, VA, United States.
C3 Nanjing Medical University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; Justus
   Liebig University Giessen; Old Dominion University
RP Fulton, DJR (corresponding author), Georgia Regents Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30901 USA.
EM dfulton@gru.edu
RI Lucas, Rudolf/ABA-3011-2020; Chen, Feng/E-1133-2011
OI Chen, Feng/0000-0003-3508-8834; Verin, Alexander/0000-0003-0627-7185;
   Black, Stephen M./0000-0002-4524-6544; Lucas, Rudolf/0000-0003-3805-8868
FU National Institutes of Health [RO1 HL085827, P01 HL101902-01A1,
   R01HL092446, R01HL094609]; AHA
FX This work was supported by the National Institutes of Health RO1
   HL085827, P01 HL101902-01A1 (DJRF), R01HL092446 (DF), R01HL094609 (RL)
   and by a Postdoctoral Fellowship from the AHA (FC). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR ANANTHRAMAN A, 1983, RESPIRATION, V44, P153, DOI 10.1159/000194542
   Bonev BB, 2001, J BIOL CHEM, V276, P5714, DOI 10.1074/jbc.M005126200
   Cai L, 2014, AM J PHYSL LUNG CELL
   Catravas JD, 2010, VASCUL PHARM
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Chen CA, 2008, J BIOL CHEM, V283, P27038, DOI 10.1074/jbc.M802269200
   Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0
   Chiasson VL, 2011, J PHARMACOL EXP THER, V337, P718, DOI 10.1124/jpet.110.178095
   Church JE, 2006, J BIOL CHEM, V281, P1477, DOI 10.1074/jbc.M505968200
   Cockeran R, 2001, J INFECT DIS, V183, P604, DOI 10.1086/318536
   DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199
   Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139
   Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125
   Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810
   Ferro TJ, 1997, AM J PHYSIOL-LUNG C, V272, pL979, DOI 10.1152/ajplung.1997.272.5.L979
   Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677
   Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s
   Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Fulton D, 2005, J BIOL CHEM, V280, P35943, DOI 10.1074/jbc.M504606200
   Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934
   GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237
   GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437
   GUICE KS, 1989, ANN SURG, V210, P740, DOI 10.1097/00000658-198912000-00008
   Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200
   Iliev AI, 2007, P NATL ACAD SCI USA, V104, P2897, DOI 10.1073/pnas.0608213104
   Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939
   Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522
   Karuppiah K, 2011, AM J PHYSIOL-HEART C, V301, pH903, DOI 10.1152/ajpheart.00936.2010
   Knepler JL, 2001, AM J PHYSIOL-CELL PH, V281, pC1064, DOI 10.1152/ajpcell.2001.281.3.C1064
   KUROSE I, 1995, CIRC RES, V76, P30, DOI 10.1161/01.RES.76.1.30
   Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200
   Lucas R, 2012, AM J RESP CELL MOL, V47, P445, DOI 10.1165/rcmb.2011-0332OC
   McElroy MC, 1997, AM J PHYSIOL-LUNG C, V272, pL631, DOI 10.1152/ajplung.1997.272.4.L631
   McQuaid KE, 1997, EXP PHYSIOL, V82, P369, DOI 10.1113/expphysiol.1997.sp004032
   Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200
   NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200
   PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510
   Qian J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00347
   Qian J, 2012, FREE RADICAL BIO MED, V52, P1806, DOI 10.1016/j.freeradbiomed.2012.02.029
   Repp H, 2002, CELL MICROBIOL, V4, P483, DOI 10.1046/j.1462-5822.2002.00207.x
   RUBINS JB, 1994, INFECT IMMUN, V62, P3829, DOI 10.1128/IAI.62.9.3829-3836.1994
   RUBINS JB, 1995, J CLIN INVEST, V95, P142, DOI 10.1172/JCI117631
   Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200
   SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x
   Sprague RS, 1998, J PHARMACOL EXP THER, V284, P443
   Stringaris AK, 2002, NEUROBIOL DIS, V11, P355, DOI 10.1006/nbdi.2002.0561
   Sud N, 2007, AM J PHYSIOL-LUNG C, V293, pL1444, DOI 10.1152/ajplung.00175.2007
   Sugimoto M, 2007, BIOCHEM BIOPH RES CO, V361, P462, DOI 10.1016/j.bbrc.2007.07.030
   Sun X, 2014, AM J RESP CELL MOL B
   Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918
   Tanita T, 1999, SURG TODAY, V29, P755, DOI 10.1007/BF02482321
   TERADA LS, 1992, P NATL ACAD SCI USA, V89, P3362, DOI 10.1073/pnas.89.8.3362
   Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033
   TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919
   WALKER JA, 1987, INFECT IMMUN, V55, P1184, DOI 10.1128/IAI.55.5.1184-1189.1987
   Weycker D, 2010, VACCINE, V28, P4955, DOI 10.1016/j.vaccine.2010.05.030
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Witzenrath M, 2007, CRIT CARE MED, V35, P1756, DOI 10.1097/01.CCM.0000269212.84709.23
   Wright JK, 1999, ARCH SURG-CHICAGO, V134, P293, DOI 10.1001/archsurg.134.3.293
   Xiong C, 2010, VASCUL PHARM
   Xiong CL, 2010, VASC PHARMACOL, V52, P207, DOI 10.1016/j.vph.2009.12.010
   Yamashita T, 2000, CIRCULATION, V101, P931, DOI 10.1161/01.CIR.101.8.931
   Zhao YY, 2009, J CLIN INVEST, V119, P2009, DOI 10.1172/JCI33338
NR 66
TC 50
Z9 51
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2014
VL 9
IS 7
AR e99823
DI 10.1371/journal.pone.0099823
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM1PC
UT WOS:000339618600004
PM 25020117
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Zhang, KJ
   Wang, P
   Huang, SS
   Wang, X
   Li, TH
   Jin, YH
   Hehir, M
   Xu, CY
AF Zhang, Kejing
   Wang, Ping
   Huang, Shuaishuai
   Wang, Xue
   Li, Taohong
   Jin, Yuhong
   Hehir, Michael
   Xu, Chiyi
TI Different mechanism of LPS-induced calcium increase in human lung
   epithelial cell and microvascular endothelial cell: a cell culture study
   in a model for ARDS
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Human lung epithelial cell; ECs/HPMECs/HUVECs/MPVECs; interleukin-8; TNF/TNF-alpha/TNFR1; Cell proliferation; CaSR; ALI/ARDS 
ID RESPIRATORY-DISTRESS-SYNDROME; EXTRACELLULAR CALCIUM; SENSING RECEPTOR;
   PARATHYROID-GLAND; CA2+ ENTRY; EXPRESSION; PROTEIN; A549;
   LIPOPOLYSACCHARIDE; VENTILATION
AB Acute respiratory distress syndrome (ARDS) is a contemporary term incorporating the historic 'acute lung injury' and the colloquial term 'shock lung'. ARDS remains a serious and enigmatic human disease, causing significant mortality. The mechanisms involved at the alveolar cell/capillary endothelial interface have been explored but to date we lack clarity on the role of intracellular calcium ([Ca2+]i) fluxes across this interface. To explore the mechanisms of Ca2+ induced inflammatory reaction in epithelial cells and pulmonary microvascular endothelial cells (HMVEC) located at the two sides of blood-air barrier, lung epithelial A549 and HMVEC cells were treated with LPS. Our results demonstrated that LPS evoked the increase of [Ca2+]i, TNF-alpha and IL-8 in both cells types. The [Ca2+]i increases involved intracellular but not extracellular Ca2+ sources in A549, but both intracellular and extracellular Ca2+ sources in HMVEC cells. The effects of LPS on both cells types were completely inhibited by the combination of LPS and CaSR-targeted siRNA. Furthermore, LPS-inhibited cell proliferations were significantly reversed by the combined treatment. Therefore, LPS induced different mechanisms of [Ca2+]i increase during the activation of CaSR in A549 and HMVEC cells, which translates into functional outputs related to ARDS.
C1 [Zhang, Kejing; Li, Taohong; Jin, Yuhong; Xu, Chiyi] Ningbo Univ, Sch Med, LiHuiLi Hosp, Ningbo Med Ctr, Ningbo 315041, Zhejiang, China.
C1 [Wang, Ping; Huang, Shuaishuai; Wang, Xue; Hehir, Michael] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Ningbo 315211, China.
C3 Ningbo University; Ningbo University
RP Xu, CY (corresponding author), Ningbo Univ, Sch Med, LiHuiLi Hosp, Ningbo Med Ctr, Ningbo 315041, Zhejiang, Peoples R China.
EM pinoav@hotmail.com; phyllice@sohu.com
FU National Natural Science Foundation of China [30800577, 81071653];
   Natural Science Foundation of Ningbo City [2012A 610241, 2009A610175];
   K. C. Wong Magna Fund in Ningbo University
FX This work was supported by the grants from National Natural Science
   Foundation of China (30800577, 81071653), Natural Science Foundation of
   Ningbo City (2012A 610241, 2009A610175) and K. C. Wong Magna Fund in
   Ningbo University.
CR Arakawa M, 2007, LIFE SCI, V80, P2076, DOI 10.1016/j.lfs.2007.03.012
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Canaff L, 2001, J BIOL CHEM, V276, P4070, DOI 10.1074/jbc.M009317200
   Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012
   Chen H, 2007, EXP MOL PATHOL, V83, P377, DOI 10.1016/j.yexmp.2007.08.016
   Chen RA, 2004, AM J PHYSIOL-RENAL, V286, pF1005, DOI 10.1152/ajprenal.00013.2004
   Cortijo J, 2010, CHEM-BIOL INTERACT, V183, P25, DOI 10.1016/j.cbi.2009.09.011
   Dull RO, 2002, CIRC RES, V90, P1143, DOI 10.1161/01.RES.0000023047.87638.76
   DUNN DL, 1991, CHEST, V100, pS164, DOI 10.1378/chest.100.3.164S
   Gao YD, 2010, PULM PHARMACOL THER, V23, P182, DOI 10.1016/j.pupt.2009.12.005
   Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817
   Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005
   Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   IMAI Y, 1994, AM J RESP CRIT CARE, V150, P1550, DOI 10.1164/ajrccm.150.6.7952613
   Iwaki M, 2009, BIOCHEM BIOPH RES CO, V389, P531, DOI 10.1016/j.bbrc.2009.09.020
   Jiang QS, 2011, MOL BIOL REP, V38, P2863, DOI 10.1007/s11033-010-0432-4
   Johnson JP, 2001, J NEUROSCI, V21, P4143, DOI 10.1523/JNEUROSCI.21-12-04143.2001
   Justinich CJ, 2008, AM J PHYSIOL-GASTR L, V294, pG120, DOI 10.1152/ajpgi.00226.2006
   Kavitha CV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022745
   McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114
   Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Ning QM, 2012, ASIAN PAC J TROP MED, V5, P638, DOI 10.1016/S1995-7645(12)60131-X
   Padar S, 2004, BRIT J PHARMACOL, V142, P305, DOI 10.1038/sj.bjp.0705755
   Patroniti N, 2002, ANESTHESIOLOGY, V96, P788, DOI 10.1097/00000542-200204000-00004
   Rastogi P, 2009, RESP PHYSIOL NEUROBI, V165, P167, DOI 10.1016/j.resp.2008.11.006
   RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492
   Salnikow K, 1999, TOXICOL APPL PHARM, V160, P127, DOI 10.1006/taap.1999.8759
   Shenkar R, 1999, J IMMUNOL, V163, P954
   Shih YRV, 2009, CELL PROLIFERAT, V42, P461, DOI 10.1111/j.1365-2184.2009.00614.x
   Su X, 2008, BBA-MOL CELL RES, V1783, P1623, DOI 10.1016/j.bbamcr.2008.04.009
   Wang P, 2007, LIFE SCI, V81, P1130, DOI 10.1016/j.lfs.2007.08.016
   Wang P, 2009, CELL BIOL INT, V33, P1149, DOI 10.1016/j.cellbi.2009.08.002
   Wang P, 2009, CELL BIOL TOXICOL, V25, P479, DOI 10.1007/s10565-008-9102-x
   Ward DT, 2004, CELL CALCIUM, V35, P217, DOI 10.1016/j.ceca.2003.10.017
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Xue HH, 2000, J BIOCHEM, V128, P329, DOI 10.1093/oxfordjournals.jbchem.a022757
   Zhao K, 2012, MOL BIOL REP, V39, P2607, DOI 10.1007/s11033-011-1013-x
NR 41
TC 12
Z9 18
U1 1
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2014
VL 41
IS 7
BP 4253
EP 4259
DI 10.1007/s11033-014-3296-1
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AK2XH
UT WOS:000338283000010
PM 24584519
DA 2023-08-21
ER

PT J
AU Zhao, YDD
   Huang, XJ
   Yi, F
   Dai, ZY
   Qian, ZJ
   Tiruppathi, C
   Tran, K
   Zhao, YY
AF Zhao, Yidan D.
   Huang, Xiaojia
   Yi, Fan
   Dai, Zhiyu
   Qian, Zhijian
   Tiruppathi, Chinnaswamy
   Tran, Khiem
   Zhao, You-Yang
TI Endothelial FoxM1 Mediates Bone Marrow Progenitor Cell-Induced Vascular
   Repair and Resolution of Inflammation following Inflammatory Lung Injury
SO STEM CELLS
LA English
DT Article
DE Adult stem cells; ALI/ARDS; FoxM1; Inflammation; vascular integrity 
ID MESENCHYMAL STEM-CELLS; RESPIRATORY-DISTRESS-SYNDROME; STROMAL CELLS;
   IN-VIVO; SPHINGOSINE 1-PHOSPHATE; MICE; SURVIVAL; SEPSIS; PERMEABILITY;
   EXPRESSION
AB Adult stem cell treatment is a potential novel therapeutic approach for acute respiratory distress syndrome. Given the extremely low rate of cell engraftment, it is believed that these cells exert their beneficial effects via paracrine mechanisms. However, the endogenous mediator(s) in the pulmonary vasculature remains unclear. Using the mouse model with endothelial cell (EC)-restricted disruption of FoxM1 (FoxM1 CKO), here we show that endothelial expression of the reparative transcriptional factor FoxM1 is required for the protective effects of bone marrow progenitor cells (BMPC) against LPS-induced inflammatory lung injury and mortality. BMPC treatment resulted in rapid induction of FoxM1 expression in wild type (WT) but not FoxM1 CKO lungs. BMPC-induced inhibition of lung vascular injury, resolution of lung inflammation, and survival, as seen in WT mice, were abrogated in FoxM1 CKO mice following LPS challenge. Mechanistically, BMPC treatment failed to induce lung EC proliferation in FoxM1 CKO mice, which was associated with impaired expression of FoxM1 target genes essential for cell cycle progression. We also observed that BMPC treatment enhanced endothelial barrier function in WT but not in FoxM1-deficient EC monolayers. Restoration of beta-catenin expression in FoxM1-deficient ECs normalized endothelial barrier enhancement in response to BMPC treatment. These data demonstrate the requisite role of endothelial FoxM1 in the mechanism of BMPC-induced vascular repair to restore vascular integrity and accelerate resolution of inflammation, thereby promoting survival following inflammatory lung injury.
C1 [Zhao, Yidan D.; Huang, Xiaojia; Yi, Fan; Dai, Zhiyu; Tiruppathi, Chinnaswamy; Tran, Khiem; Zhao, You-Yang] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Zhao, Yidan D.; Huang, Xiaojia; Yi, Fan; Dai, Zhiyu; Tiruppathi, Chinnaswamy; Tran, Khiem; Zhao, You-Yang] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C1 [Qian, Zhijian] Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612, United States.
C1 [Huang, Xiaojia] Jiangsu Univ, Sch Med Sci & Lab Sci, Dept Pharmacol, Zhenjiang, Jiangsu, China.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Jiangsu University
RP Zhao, YY (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 South Wolcott Ave,MSB E403, Chicago, IL 60612 USA.
EM yyzhao@uic.edu
RI Dai, Zhiyu/H-3453-2019
OI Dai, Zhiyu/0000-0002-2945-7923; ZHAO, YOU-YANG/0000-0002-0041-0339
FU NIH [R01 HL085462, R01HL085462-3S1, R56HL085462, P01HL077806]
FX The work was supported in part by NIH grants R01 HL085462,
   R01HL085462-3S1, R56HL085462, and P01HL077806 (project 4) to Y.Y.Z.
CR Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Choi YH, 2011, HUM GENE THER, V22, P3, DOI 10.1089/hum.2010.211
   Cines DB, 1998, BLOOD, V91, P3527
   Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108
   Danchuk S, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt68
   Ezaki T, 2001, AM J PATHOL, V158, P2043, DOI 10.1016/S0002-9440(10)64676-7
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Gothert JR, 2004, BLOOD, V104, P1769, DOI 10.1182/blood-2003-11-3952
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Huang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050094
   Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Kotton DN, 2005, AM J RESP CELL MOL, V33, P328, DOI 10.1165/rcmb.2005-0175RC
   Krasnodembskaya A, 2012, AM J PHYSIOL-LUNG C, V302, pL1003, DOI 10.1152/ajplung.00180.2011
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Mirza MK, 2010, J EXP MED, V207, P1675, DOI 10.1084/jem.20091857
   Mirza MK, 2010, AM J PATHOL, V176, P2344, DOI 10.2353/ajpath.2010.091088
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291
   Ohle SJ, 2012, AM J RESP CELL MOL, V47, P11, DOI 10.1165/rcmb.2011-0180OC
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005
   Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schinkothe T, 2008, STEM CELLS DEV, V17, P199, DOI 10.1089/scd.2007.0175
   Szczepaniak WS, 2008, TRANSL RES, V152, P213, DOI 10.1016/j.trsl.2008.09.002
   van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC
   Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wary KK, 2009, STEM CELLS, V27, P3112, DOI 10.1002/stem.241
   Yamada M, 2005, THORAX, V60, P410, DOI 10.1136/thx.2004.034058
   Zhao YD, 2010, AM J PHYSIOL-LUNG C, V298, pL36, DOI 10.1152/ajplung.00064.2009
   Zhao YDD, 2009, CIRC RES, V105, P696, DOI 10.1161/CIRCRESAHA.109.199778
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
   Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261
NR 45
TC 24
Z9 25
U1 1
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2014
VL 32
IS 7
BP 1855
EP 1864
DI 10.1002/stem.1690
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA AJ6FI
UT WOS:000337785200014
PM 24578354
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU O'Donnell, JJ
   Birukova, AA
   Beyer, EC
   Birukov, KG
AF O'Donnell, James J., III
   Birukova, Anna A.
   Beyer, Eric C.
   Birukov, Konstantin G.
TI Gap Junction Protein Connexin43 Exacerbates Lung Vascular Permeability
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL-CELLS; DIFFERENTIAL REGULATION; BARRIER FUNCTION;
   EXPRESSION; LIPOPOLYSACCHARIDE; INFLAMMATION; ACTIVATION; STRETCH;
   INJURY; RHO
AB Increased vascular permeability causes pulmonary edema that impairs arterial oxygenation and thus contributes to morbidity and mortality associated with Acute Respiratory Distress Syndrome and sepsis. Although components of intercellular adhesive and tight junctions are critical for maintaining the endothelial barrier, there has been limited study of the roles of gap junctions and their component proteins (connexins). Since connexins can modulate inflammatory signaling in other systems, we hypothesized that connexins may also regulate pulmonary endothelial permeability. The relationships between connexins and the permeability response to inflammatory stimuli were studied in cultured human pulmonary endothelial cells. Prolonged treatment with thrombin, lipopolysaccharide, or pathological cyclic stretch increased levels of mRNA and protein for the major connexin, connexin43 (Cx43). Thrombin and lipopolysaccharide both increased intercellular communication assayed by transfer of microinjected Lucifer yellow. Although thrombin decreased transendothelial resistance in these cells, the response was attenuated by pretreatment with the connexin inhibitor carbenoxolone. Additionally, the decreases of transendothelial resistance produced by either thrombin or lipopolysaccharide were attenuated by reducing Cx43 expression by siRNA knockdown. Both carbenoxolone and Cx43 knockdown also abrogated thrombin-induced phosphorylation of myosin light chain. Taken together, these data suggest that increased lung vascular permeability induced by inflammatory conditions may be amplified via increased expression of Cx43 and intercellular communication among pulmonary endothelial cells.
C1 [O'Donnell, James J., III; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637, United States.
C1 [O'Donnell, James J., III; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Dept Med, Lung Injury Ctr, Chicago, IL 60637, United States.
C1 [Beyer, Eric C.] Univ Chicago, Dept Pediat, Chicago, IL 60637, United States.
C3 University of Chicago; University of Chicago; University of Chicago
RP Birukov, KG (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022
OI Beyer, Eric/0000-0001-8044-1356
FU National Institutes of Health [NHLBI HL089257]; NIH [NHLBI HL087823]; 
   [T32HL007605];  [HL59199]
FX Funding sources that supported this work include: T32HL007605, HL59199,
   National Institutes of Health NHLBI HL089257, and NIH NHLBI HL087823.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agrawal A, 2012, AM J PHYSIOL-LUNG C, V303, pL634, DOI 10.1152/ajplung.00195.2012
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Baker SM, 2008, FEBS LETT, V582, P4039, DOI 10.1016/j.febslet.2008.10.043
   Bastarache JA, 2006, SEMIN RESP CRIT CARE, V27, P365, DOI 10.1055/s-2006-948290
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukov KG, 2013, COMPR PHYSIOL, V3, P429, DOI 10.1002/cphy.c100066
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2012, J CELL PHYSIOL, V227, P3405, DOI 10.1002/jcp.24041
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030957
   Bolon ML, 2007, J CELL PHYSIOL, V211, P159, DOI 10.1002/jcp.20928
   Chadjichristos CE, 2010, CIRCULATION, V121, P123, DOI 10.1161/CIRCULATIONAHA.109.867176
   Davey A, 2011, EUR RESPIR J, V38, P959, DOI 10.1183/09031936.00032111
   De Vuyst E, 2007, MOL BIOL CELL, V18, P34, DOI 10.1091/mbc.E06-03-0182
   Fernandez-Cobo M, 1999, CYTOKINE, V11, P216, DOI 10.1006/cyto.1998.0422
   Fernandez-Cobo M, 1998, SHOCK, V10, P97, DOI 10.1097/00024382-199808000-00003
   Gemel J, 2012, J MEMBRANE BIOL, V245, P231, DOI 10.1007/s00232-012-9444-4
   Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705
   Harris AL, 2007, PROG BIOPHYS MOL BIO, V94, P120, DOI 10.1016/j.pbiomolbio.2007.03.011
   JARA PI, 1995, P NATL ACAD SCI USA, V92, P7011, DOI 10.1073/pnas.92.15.7011
   Juszczak GR, 2009, PROG NEURO-PSYCHOPH, V33, P181, DOI 10.1016/j.pnpbp.2008.12.014
   Kwak BR, 2003, CIRCULATION, V107, P1033, DOI 10.1161/01.CIR.0000051364.70064.D1
   LARSON DM, 1990, CIRC RES, V66, P1074, DOI 10.1161/01.RES.66.4.1074
   Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Meliton AY, 2013, AM J PHYSIOL-LUNG C, V304, pL689, DOI 10.1152/ajplung.00047.2013
   Nagasawa K, 2006, J CELL PHYSIOL, V208, P123, DOI 10.1002/jcp.20647
   Parthasarathi K, 2006, J CLIN INVEST, V116, P2193, DOI 10.1172/JCI26605
   Parthasarathi K, 2012, AM J PHYSIOL-LUNG C, V303, pL33, DOI 10.1152/ajplung.00219.2011
   Rignault S, 2007, SHOCK, V28, P78, DOI 10.1097/shk.0b013e3180310bd1
   Salameh A, 2013, BBA-BIOMEMBRANES, V1828, P147, DOI 10.1016/j.bbamem.2011.12.030
   Sarieddine MZR, 2009, J CELL MOL MED, V13, P4560, DOI 10.1111/j.1582-4934.2008.00654.x
   Seminario-Vidal L, 2009, J BIOL CHEM, V284, P20638, DOI 10.1074/jbc.M109.004762
   Starosta V, 2012, AM J RESP CELL MOL, V46, P331, DOI 10.1165/rcmb.2011-0153OC
   Tyml K, 2011, CAN J PHYSIOL PHARM, V89, P1, DOI 10.1139/y10-099
   Wong CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441
   Yeager M, 2007, CURR OPIN CELL BIOL, V19, P521, DOI 10.1016/j.ceb.2007.09.001
   Zhou XH, 2012, FRONT BIOSCI-LANDMRK, V17, P2278, DOI 10.2741/4051
   Ziliene Violeta, 2004, Medicina (Kaunas), V40, P1124
NR 45
TC 52
Z9 53
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2014
VL 9
IS 6
AR e100931
DI 10.1371/journal.pone.0100931
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK2WP
UT WOS:000338280800085
PM 24967639
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Mitra, S
   Wade, MS
   Sun, XG
   Moldobaeva, N
   Flores, C
   Ma, SF
   Zhang, W
   Garcia, JGN
   Jacobson, JR
AF Mitra, Sumegha
   Wade, Michael S.
   Sun, Xiaoguang
   Moldobaeva, Nurgul
   Flores, Carlos
   Ma, Shwu Fan
   Zhang, Wei
   Garcia, Joe G. N.
   Jacobson, Jeffrey R.
TI GADD45a Promoter Regulation by a Functional Genetic Variant Associated
   with Acute Lung Injury
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; COLONY-ENHANCING FACTOR; POLYMORPHISMS;
   SEPSIS; EXPRESSION; RISK; SUSCEPTIBILITY; TRANSCRIPTION; DEFINITIONS;
   HAPLOTYPE
AB Rationale: Growth arrest DNA damage inducible alpha (GADD45a) is a stress-induced gene we have shown to participate in the pathophysiology of ventilator-induced lung injury (VILI) via regulation of mechanical stress-induced Akt ubiquitination and phosphorylation. The regulation of GADD45a expression by mechanical stress and its relationship with acute lung injury (ALI) susceptibility and severity, however, remains unknown.
   Objectives: We examined mechanical stress-dependent regulatory elements (MSRE) in the GADD45a promoter and the contribution of promoter polymorphisms in GADD45a expression and ALI susceptibility.
   Methods and Results: Initial studies in GADD45a knockout and heterozygous mice confirmed the relationship of GADD45a gene dose to VILI severity. Human lung endothelial cells (EC) transfected with a luciferase vector containing the full length GADD45a promoter sequence (-771 to +223) demonstrated a >4 fold increase in GADD45a expression in response to 18% cyclic stretch (CS, 4 h) compared to static controls while specific promoter regions harboring CS-dependent MSRE were identified using vectors containing serial deletion constructs of the GADD45a promoter. In silico analyses of GADD45a promoter region (-371 to -133) revealed a potential binding site for specificity protein 1 (SP1), a finding supported by confirmed SP1 binding with the GADD45a promoter and by the significant attenuation of CS-dependent GADD45a promoter activity in response to SP1 silencing. Separately, case-control association studies revealed a significant association of a GADD45a promoter SNP at -589 (rs581000, G>C) with reduced ALI susceptibility. Subsequently, we found allelic variation of this SNP is associated with both differential GADD45a expression in mechanically stressed EC (18% CS, 4 h) and differential binding site of interferon regulatory factor 7 (IRF7) at this site.
   Conclusion: These results strongly support a functional role for GADD45a in ALI/VILI and identify a specific gene variant that confers risk for ALI.
C1 [Mitra, Sumegha; Wade, Michael S.; Sun, Xiaoguang; Moldobaeva, Nurgul; Zhang, Wei; Jacobson, Jeffrey R.] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60607, United States.
C1 [Flores, Carlos] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp, Madrid, Spain.
C1 [Flores, Carlos] Hosp Univ Nuestra Senora Candelaria, Res Unit, Tenerife, Spain.
C1 [Ma, Shwu-Fan] Univ Illinois, Div Pulm Crit Care & Sleep, Chicago, IL, United States.
C1 [Zhang, Wei] Univ Illinois, Dept Pediat, Chicago, IL, United States.
C1 [Garcia, Joe G. N.] Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital; University of Illinois System; University of Illinois
   Chicago; University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona Health Sciences
RP Jacobson, JR (corresponding author), Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60607 USA.
EM jrjacob@uic.edu
RI SUN, XIAOGUANG/ACA-5558-2022; Flores, Carlos/R-1159-2019; Garcia, Joe
   GN/E-8862-2010
OI Flores, Carlos/0000-0001-5352-069X; Mitra, Sumegha/0000-0002-5567-3347
FU NCATS NIH HHS [UL1 TR000430] Funding Source: Medline
CR Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Cao YX, 2003, J CELL BIOCHEM, V89, P887, DOI 10.1002/jcb.10555
   Flores C, 2008, TRANSL RES, V152, P11, DOI 10.1016/j.trsl.2008.05.006
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Gao L, 2007, TRANSL RES, V150, P18, DOI 10.1016/j.trsl.2007.02.007
   Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34
   Han YJ, 2012, J MOL MED, V90, P299, DOI 10.1007/s00109-011-0820-9
   Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Lin Z, 2000, CLIN GENET, V58, P181, DOI 10.1034/j.1399-0004.2000.580305.x
   Liu YX, 2012, CLIN CHEM LAB MED, V50, P1917, DOI 10.1515/cclm-2012-0238
   Ma SF, 2011, AM J RESP CELL MOL, V45, P1203, DOI 10.1165/rcmb.2011-0179OC
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Meyer NJ, 2009, FASEB J, V23, P1325, DOI 10.1096/fj.08-119073
   Mitra S, 2006, MATURITAS, V55, P27, DOI 10.1016/j.maturitas.2006.01.003
   Mitra S, 2011, AM J RESP CRIT CARE, V184, P1030, DOI 10.1164/rccm.201103-0447OC
   Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001
   Nemeth E, 2000, AM J OBSTET GYNECOL, V182, P50, DOI 10.1016/S0002-9378(00)70490-X
   Ney L, 2000, NEW ENGL J MED, V343, P812
   O'Mahony DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051104
   Pino-Yanes M, 2011, AM J RESP CELL MOL, V45, P740, DOI 10.1165/rcmb.2010-0292OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Seefried L, 2010, EUR CELLS MATER, V20, P344
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Song ZJ, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-168
   Tejera P, 2012, J MED GENET, V49, P671, DOI 10.1136/jmedgenet-2012-100972
   Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
NR 35
TC 12
Z9 12
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2014
VL 9
IS 6
AR e100169
DI 10.1371/journal.pone.0100169
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK6AC
UT WOS:000338508200080
PM 24940746
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Aitken, EH
   Negri, EM
   Barboza, R
   Lima, MR
   Alvarez, JM
   Marinho, CRF
   Caldini, EG
   Epiphanio, S
AF Aitken, Elizabeth H.
   Negri, Elnara M.
   Barboza, Renato
   Lima, Maria Ri
   Alvarez, Jose M.
   Marinho, Claudio R. F.
   Caldini, Elia G.
   Epiphanio, Sabrina
TI Ultrastructure of the lung in a murine model of malaria-associated acute
   lung injury/acute respiratory distress syndrome
SO MALARIA JOURNAL
LA English
DT Article
DE malaria; Plasmodium; ALI/ARDS; Transmission electron microscopy; Murine model 
ID PATHOGENESIS; INFLAMMATION; LEUKOCYTES
AB Background: The mechanisms through which infection with Plasmodium spp. result in lung disease are largely unknown. Recently a number of mouse models have been developed to research malaria-associated lung injury but no detailed ultrastructure studies of the disease in its terminal stages in a murine model have yet been published. The goal was to perform an ultrastructural analysis of the lungs of mice that died with malaria-associated acute lung injury/acute respiratory distress syndrome to better determine the relevancy of the murine models and investigate the mechanism of disease.
   Methods: DBA/2 mice were infected with Plasmodium berghei strain ANKA. Mice had their lungs removed immediately after death, processed using standard methods and viewed by transmission electron microscopy (TEM).
   Results: Infected red blood cell: endothelium contact, swollen endothelium with distended cytoplasmic extensions and thickening of endothelium basement membrane were observed. Septa were thick and filled with congested capillaries and leukocytes and the alveolar spaces contained blood cells, oedema and cell debris.
   Conclusion: Results show that the lung ultrastructure of P. berghei ANKA-infected mice has similar features to what has been described in post-mortem TEM studies of lungs from individuals infected with Plasmodium falciparum. These data support the use of murine models to study malaria-associated acute lung injury.
C1 [Aitken, Elizabeth H.; Lima, Maria Ri; Alvarez, Jose M.; Epiphanio, Sabrina] Univ Sao Paulo, Dept Immunol, Sao Paulo, Brazil.
C1 [Negri, Elnara M.; Caldini, Elia G.] Univ Sao Paulo, Fac Med, Lab Med Invest 59, Sao Paulo, Brazil.
C1 [Barboza, Renato] Univ Fed Sao Paulo, Dept Phys & Earth Sci, Diadema, Brazil.
C1 [Marinho, Claudio R. F.] Univ Sao Paulo, Dept Parasitol, Sao Paulo, Brazil.
C1 [Epiphanio, Sabrina] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade
   Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade
   de Sao Paulo
RP Epiphanio, S (corresponding author), Univ Sao Paulo, Dept Immunol, Sao Paulo, Brazil.
EM sabrina.epiphanio@gmail.com
RI Caldini, Elia Garcia/F-1105-2011; Marinho, Claudio Romero
   Farias/F-7507-2012; Epiphanio, Sabrina/S-2564-2019; Barboza,
   Renato/G-5833-2012; D'Império Lima, Maria Regina/I-4747-2012; Epiphanio,
   Sabrina/C-7572-2012; Aitken, Elizabeth/I-8756-2019; Negri, Elnara
   M/F-3643-2019; Alvarez, Jose M/I-6181-2012
OI Marinho, Claudio Romero Farias/0000-0002-1227-3845; Epiphanio,
   Sabrina/0000-0001-6094-9750; Barboza, Renato/0000-0002-6441-7513;
   D'Império Lima, Maria Regina/0000-0002-4683-7709; Epiphanio,
   Sabrina/0000-0001-6094-9750; Aitken, Elizabeth/0000-0002-2677-6208;
   Negri, Elnara M/0000-0002-6428-6066; Alvarez, Jose
   M/0000-0002-9711-4914; Caldini, Elia Garcia/0000-0001-5322-3812
FU Sao Paulo Research Foundation (FAPESP) [2009/53256-7, 2009/53889-0];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [306668/2012-2]; FAPESP [2011/195252-0]
FX We thank Bernardo Paulo Albe for technical support. Financial support
   was provided by grants 2009/53256-7 (SE) and 2009/53889-0 (CRFM) from
   the Sao Paulo Research Foundation (FAPESP) and the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) 306668/2012-2. EHA was
   supported by a FAPESP fellowship (2011/195252-0).
CR Adamson IYR, 1990, LUNG BIOL HLTH DIS, V48, P165
   Baron RM, 2009, LUNG BIOL HEALTH DIS, V233, P59
   Carr R, 1999, AM J TROP MED HYG S1, V61, P260
   Chua CLL, 2013, TRENDS PARASITOL, V29, P26, DOI 10.1016/j.pt.2012.10.002
   CORBETT CEP, 1989, J TROP MED HYG, V92, P112
   Deroost K, 2013, AM J RESP CELL MOL, V48, P589, DOI 10.1165/rcmb.2012-0450OC
   Diep BA, 2010, P NATL ACAD SCI USA, V107, P5587, DOI 10.1073/pnas.0912403107
   DUARTE MIS, 1985, AM J TROP MED HYG, V34, P31, DOI 10.4269/ajtmh.1985.34.31
   Epiphanio S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000916
   Fauci A, 2008, HARRISONS PRINC INTE
   Fonager J, 2012, J EXP MED, V209, P93, DOI 10.1084/jem.20110762
   Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007
   Hee L, 2011, INT J PARASITOL, V41, P81, DOI 10.1016/j.ijpara.2010.07.013
   Huebner RH, 2008, BIOTECHNIQUES, V44, P507, DOI 10.2144/000112729
   KAWANAMI O, 1992, ACTA PATHOL JAPON, V42, P177
   Lacerda-Queiroz N, 2013, INT J PARASITOL, V43, P11, DOI 10.1016/j.ijpara.2012.11.008
   Lovegrove FE, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000068
   Mackenzie C, 1999, AM J TROP MED HYG S1, V61
   MACPHERSON GG, 1985, AM J PATHOL, V119, P385
   PUNYAGUPTA S, 1974, American Journal of Tropical Medicine and Hygiene, V23, P551
   SENALDI G, 1994, INFECT IMMUN, V62, P1144, DOI 10.1128/IAI.62.4.1144-1149.1994
   SUZUKI M, 1975, T ROY SOC TROP MED H, V69, P20
   Taylor WRJ, 2012, CHEST, V142, P492, DOI 10.1378/chest.11-2655
   Thompson BT, 2013, SEMIN RESP CRIT CARE, V34, P441, DOI 10.1055/s-0033-1351162
   Van den Steen PE, 2013, TRENDS PARASITOL, V29, P346, DOI 10.1016/j.pt.2013.04.006
   Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC
   Viebig NK, 2005, INFECT IMMUN, V73, P3271, DOI 10.1128/IAI.73.6.3271-3277.2005
NR 27
TC 19
Z9 19
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 13
PY 2014
VL 13
AR 230
DI 10.1186/1475-2875-13-230
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL1MH
UT WOS:000338889000001
PM 24927627
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Goldman, JL
   Sammani, S
   Kempf, C
   Saadat, L
   Letsiou, E
   Wang, T
   Moreno-Vinasco, L
   Rizzo, AN
   Fortman, JD
   Garcia, JGN
AF Goldman, Julia L.
   Sammani, Saad
   Kempf, Carrie L.
   Saadat, Laleh
   Letsiou, Eleftheria
   Wang, Ting
   Moreno-Vinasco, Liliana
   Rizzo, Alicia N.
   Fortman, Jeffrey D.
   Garcia, Joe G. N.
TI Pleiotropic effects of interleukin-6 in a "two-hit" murine model of
   acute respiratory distress syndrome
SO PULMONARY CIRCULATION
LA English
DT Article
DE ALI/ARDS; interleukin-6; LPS; ventilator-induced lung injury 
AB Patients with acute respiratory distress syndrome (ARDS) exhibit elevated levels of interleukin-6 (IL-6), which correlate with increased morbidity and mortality. The exact role of IL-6 in ARDS has proven difficult to study because it exhibits either pro-or anti-inflammatory actions in mouse models of lung injury, depending on the model utilized. In order to improve understanding of the role of this complex cytokine in ARDS, we evaluated IL-6 using the clinically relevant combination of lipopolysaccharide (LPS) and ventilator-induced lung injury (VILI) in IL-6(-/-) mice. Bronchoalveolar lavage fluid (BAL), whole-lung tissue, and histology were evaluated for inflammatory markers of injury. Transendothelial electrical resistance was used to evaluate the action of IL-6 on endothelial cells in vitro. In wild-type mice, the combination model showed a significant increase in lung injury compared to either LPS or VILI alone. IL-6(-/-) mice exhibited a statistically significant decrease in BAL cellular inflammation as well as lower histologic scores for lung injury, changes observed only in the combination model. A paradoxical increase in BAL total protein was observed in IL-6(-/-) mice exposed to LPS, suggesting that IL-6 provides protection from vascular leakage. However, in vitro data showed that IL-6, when combined with its soluble receptor, actually caused a significant increase in endothelial cell permeability, suggesting that the protection seen in vivo was likely due to complex interactions of IL-6 and other inflammatory mediators rather than to direct effects of IL-6. These studies suggest that a dual-injury model exhibits utility in evaluating the pleiotropic effects of IL-6 in ARDS on inflammatory cells and lung endothelium.
C1 [Goldman, Julia L.; Sammani, Saad; Kempf, Carrie; Saadat, Laleh; Letsiou, Eleftheria; Wang, Ting; Moreno-Vinasco, Liliana; Rizzo, Alicia N.; Garcia, Joe G. N.] Univ Illinois, Inst Personalized Resp Med, Chicago, IL, United States.
C1 [Goldman, Julia L.; Fortman, Jeffrey D.] Univ Illinois, Biol Resources Lab, Chicago, IL, United States.
C1 [Garcia, Joe G. N.] Univ Illinois, Off Vice President Hlth Affairs, Chicago, IL, United States.
C1 [Kempf, Carrie; Wang, Ting; Garcia, Joe G. N.] Univ Arizona, Div Pulm & Crit Care, Sleep Med, Arizona Resp Ctr, Tucson, AZ, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Arizona
RP Garcia, JGN (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Hlth Sci, 1295 North Martin Ave, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
FU National Institutes of Health/National Heart, Lung, and Blood Institute
   [R01 HL058064, 1R25RR032021]
FX This work was supported by the National Institutes of Health/National
   Heart, Lung, and Blood Institute grants R01 HL058064 (to JGNG) and
   1R25RR032021.
CR Bhargava R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061405
   Biffl WL, 1996, J TRAUMA, V40, P575, DOI 10.1097/00005373-199604000-00009
   Brasier AR, 2010, CARDIOVASC RES, V86, P211, DOI 10.1093/cvr/cvq076
   Desai TR, 2002, J SURG RES, V104, P118, DOI 10.1006/jsre.2002.6415
   Dushianthan A, 2011, POSTGRAD MED J, V87, P612, DOI 10.1136/pgmj.2011.118398
   Eulenfeld R, 2012, EUR J CELL BIOL, V91, P486, DOI 10.1016/j.ejcb.2011.09.010
   Flores C, 2008, TRANSL RES, V152, P11, DOI 10.1016/j.trsl.2008.05.006
   Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gurkan OU, 2011, EXP LUNG RES, V37, P575, DOI 10.3109/01902148.2011.620680
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jawa Randeep S, 2011, J Intensive Care Med, V26, P3, DOI 10.1177/0885066610395678
   Klein CL, 2008, KIDNEY INT, V74, P901, DOI 10.1038/ki.2008.314
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Kruttgen A, 2012, J INTERF CYTOK RES, V32, P60, DOI 10.1089/jir.2011.0062
   Leemans JC, 2002, AM J RESP CRIT CARE, V165, P1445, DOI 10.1164/rccm.2106045
   Liberati TA, 2013, COMPARATIVE MED, V63, P114
   Makena PS, 2011, J APPL PHYSIOL, V111, P1467, DOI 10.1152/japplphysiol.00539.2011
   MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Meyer Nuala J, 2007, Proc Am Thorac Soc, V4, P69, DOI 10.1513/pats.200609-157JG
   Meyer NJ, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-52
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Moreno-Vinasco L, 2008, J ORGAN DYSFUNCTION, V4, P106, DOI [DOI 10.1080/17471060701505289, 10.1080/17471060701505289]
   Mul FPJ, 2000, J LEUKOCYTE BIOL, V68, P529
   Nonas SA, 2007, AM J PHYSIOL-LUNG C, V293, pL292, DOI 10.1152/ajplung.00481.2006
   Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008
   Saito F, 2008, AM J RESP CELL MOL, V38, P566, DOI 10.1165/rcmb.2007-0299OC
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Takala A, 2002, SHOCK, V17, P252, DOI 10.1097/00024382-200204000-00002
   Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808
   Wolters PJ, 2009, J IMMUNOL, V182, P8056, DOI 10.4049/jimmunol.0801323
   Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368
   Yanagawa Y, 2012, BMJ CASE REP
NR 43
TC 62
Z9 69
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD JUN
PY 2014
VL 4
IS 2
BP 280
EP 288
DI 10.1086/675991
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA V47WP
UT WOS:000209982200016
PM 25006447
OA Green Published
DA 2023-08-21
ER

PT J
AU Jurek, SC
   Hirano-Kobayashi, M
   Chiang, H
   Kohane, DS
   Matthews, BD
AF Jurek, Samuel C.
   Hirano-Kobayashi, Mariko
   Chiang, Homer
   Kohane, Daniel S.
   Matthews, Benjamin D.
TI Prevention of Ventilator-Induced Lung Edema by Inhalation of
   Nanoparticles Releasing Ruthenium Red
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; ventilator-induced lung injury; Transient receptor potential vanilloid 4 (TRPV4); ex vivo ventilation perfusion; inhalation 
ID HEAT-EVOKED ACTIVATION; TRPV4 CHANNELS; DRUG-DELIVERY; MOUSE; CALCIUM;
   INJURY; PERMEABILITY; DETERMINANTS; EXPRESSION; RESISTANCE
AB The acute respiratory distress syndrome (ARDS), a devastating lung disease that has no cure, is exacerbated by life-supportive mechanical ventilation that worsens lung edema and inflammation through the syndrome of ventilator-induced lung injury. Recently, the membrane ion channel transient receptor potential vanilloid 4 (TRPV4) on alveolar macrophages was shown to mediate murine lung vascular permeability induced by high-pressure mechanical ventilation. The objective of this study was to determine whether inhalation of nanoparticles (NPs) containing the TRPV4 inhibitor ruthenium red (RR) prevents ventilator-induced lung edema in mice. Poly-lactic-co-glycolic acid NPs containing RR were evaluated in vitro for their ability to block TRPV4-mediated calcium signaling in alveolar macrophages and capillary endothelial cells. Lungs from adult C57BL6 mice treated with nebulized NPs were then used in ex vivo ventilation perfusion experiments to assess the ability of the NPs to prevent high-pressure mechanical ventilation-induced lung edema. Poly-lactic-co-glycolic acid NPs (300 nm) released RR for 150 hours in vitro, and blocked TRPV4-mediated calcium signaling in cells up to 7 days after phagocytosis. Inhaled NPs deposited in alveoli of spontaneously breathing mice were rapidly phagocytosed by alveolar macrophages, and blocked increased vascular permeability from high-pressure mechanical ventilation for 72 hours in ex vivo ventilation perfusion experiments. These data offer proof of principle that inhalation of NPs containing a TRPV4 inhibitor prevents ventilator damage for several days, and imply that this novel drug delivery strategy could be used to target alveolar macrophages in patients at risk of ventilator-induced lung injury before initiating mechanical ventilation.
C1 [Jurek, Samuel C.; Matthews, Benjamin D.] Boston Childrens Hosp, Dept Med, Boston, MA 02115, United States.
C1 [Jurek, Samuel C.; Hirano-Kobayashi, Mariko; Matthews, Benjamin D.] Boston Childrens Hosp, Vasc Biol Program, Dept Pathol, Boston, MA 02115, United States.
C1 [Jurek, Samuel C.; Hirano-Kobayashi, Mariko; Matthews, Benjamin D.] Boston Childrens Hosp, Dept Surg, Boston, MA 02115, United States.
C1 [Chiang, Homer; Kohane, Daniel S.] Boston Childrens Hosp, Dept Anesthesiol, Boston, MA 02115, United States.
C1 [Chiang, Homer; Kohane, Daniel S.] Harvard Univ, Sch Med, Boston, MA, United States.
C3 Harvard University; Boston Children's Hospital; Harvard University;
   Boston Children's Hospital; Harvard University; Boston Children's
   Hospital; Harvard University; Boston Children's Hospital; Harvard
   University; Harvard Medical School
RP Matthews, BD (corresponding author), Boston Childrens Hosp, Div Med Crit Care, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM benjamin.matthews@childrens.harvard.edu
FU National Institutes of Health [R01 GM073626]
FX This work was supported by National Institutes of Health grant R01
   GM073626 (D.S.K.).
CR Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19
   Beck-Broichsitter M, 2011, J NANOMATER, V2011, DOI 10.1155/2011/163791
   Beck-Broichsitter M, 2010, J AEROSOL MED PULM D, V23, P47, DOI 10.1089/jamp.2009.0759
   Beck-Broichsitter M, 2009, INT J PHARMACEUT, V367, P169, DOI 10.1016/j.ijpharm.2008.09.017
   BROWER RG, 1990, J APPL PHYSIOL, V69, P1746, DOI 10.1152/jappl.1990.69.5.1746
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   CURRY FE, 1984, HDB PHYSL CARDIOVASC, V4, P309, DOI DOI 10.1152/JAPPLPHYSIOL.00389.2006
   DEINUM J, 1985, BIOCHIM BIOPHYS ACTA, V838, P197, DOI 10.1016/0304-4165(85)90079-0
   Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1
   FUJIMOTO K, 1990, AM REV RESPIR DIS, V142, P1414, DOI 10.1164/ajrccm/142.6_Pt_1.1414
   Guler AD, 2002, J NEUROSCI, V22, P6408
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009
   HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Kannurpatti SS, 2000, NEUROCHEM RES, V25, P1527, DOI 10.1023/A:1026602100160
   Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159
   Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4
   Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760
   Matthews BD, 2010, INTEGR BIOL-UK, V2, P435, DOI 10.1039/c0ib00034e
   Michard F, 2007, CRIT CARE MED, V35, P1186, DOI 10.1097/01.CCM.0000259539.49339.66
   Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003
   Parker JC, 2008, AM J PHYSIOL-LUNG C, V295, pL235, DOI 10.1152/ajplung.00064.2008
   PARKER JC, 1984, J APPL PHYSIOL, V57, P1809, DOI 10.1152/jappl.1984.57.6.1809
   Parker JC, 2004, AM J PHYSIOL-LUNG C, V286, pL231, DOI 10.1152/ajplung.00049.2003
   Parker JC, 1999, J APPL PHYSIOL, V87, P1421, DOI 10.1152/jappl.1999.87.4.1421
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RIPPE B, 1987, J APPL PHYSIOL, V62, P1206, DOI 10.1152/jappl.1987.62.3.1206
   Rogueda PGA, 2007, EXPERT OPIN DRUG DEL, V4, P595, DOI 10.1517/17425247.4.6.595
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rytting E, 2008, EXPERT OPIN DRUG DEL, V5, P629, DOI 10.1517/17425247.5.6.629 
   SASAKI T, 1992, J BIOL CHEM, V267, P21518
   Slutsky AS, 2003, INTENS CARE MED, V29, P1218, DOI 10.1007/s00134-003-1793-0
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4
   Takahashi N, 2011, CELL CALCIUM, V50, P279, DOI 10.1016/j.ceca.2011.04.006
   Thodeti CK, 2009, CIRC RES, V104, P1123, DOI 10.1161/CIRCRESAHA.108.192930
   Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276
   Vincent F, 2011, CURR TOP MED CHEM, V11, P2216, DOI 10.2174/156802611796904861
   Vincent F, 2009, BIOCHEM BIOPH RES CO, V389, P490, DOI 10.1016/j.bbrc.2009.09.007
   Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200
   von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052
   Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101
   Ware LB, 2005, NEW ENGL J MED, V353, P2788, DOI 10.1056/NEJMcp052699
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807
   Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200
   Yamada A, 2000, BIOCHEM J, V349, P797, DOI 10.1042/bj3490797
   Yamashiro K, 2010, BIOCHEM BIOPH RES CO, V398, P284, DOI 10.1016/j.bbrc.2010.06.082
NR 51
TC 19
Z9 19
U1 2
U2 11
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUN
PY 2014
VL 50
IS 6
BP 1107
EP 1117
DI 10.1165/rcmb.2013-0163OC
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AI4JV
UT WOS:000336832400011
PM 24405281
OA Green Published
DA 2023-08-21
ER

PT J
AU Liu, MJ
   Gu, CP
   Wang, YL
AF Liu, Mengjie
   Gu, Changping
   Wang, Yuelan
TI Upregulation of the tight junction protein occludin: effects on
   ventilation-induced lung injury and mechanisms of action
SO BMC PULMONARY MEDICINE
LA English
DT Article
DE ventilator-induced lung injury; tight junction; Occludin; PKC inhibitor 
ID PHOSPHORYLATION; DYSFUNCTION
AB Background: Occludin, a tight junction protein, plays an important role in maintaining the integrity of the lung epithelial barrier; however, its role in ventilation-induced lung injury has not been explored. Here, we measured the expression of occludin with different tidal volumes. Our study indicated that the level of occludin was significantly decreased and alveolar permeability was increased owing to acute lung injury.
   Methods: Thirty healthy Wistar rats (15 female, 15 male) weighing 250-300 g, were randomly divided into 5 groups (n = 6 in each group): a control group (group C), a low tidal volume group (group L), a low tidal volume + protein kinase C(PKC) inhibitor group (group L + P), a high tidal volume group (group H) and a high tidal volume + PKC inhibitor group (group H + P). Tracheas of rats in the control group underwent incision without any special treatment. The other four groups were mechanically ventilated for 4 h. The rats in groups L + P and H + P were treated with a PKC inhibitor (bisindolylmaleimide I, 0.12 mg/kg) by intramuscular injection 1 h before anesthesia. Rats were sacrificed after mechanical ventilation. Specimens of lung tissues were harvested. Lung pathological changes were observed using an optical microscope, and lung wet/dry weight ratio was measured. The occludin protein level was assayed by immunohistochemistry and Western blotting.
   Results: HE staining and immunohistochemistry results showed that occludin was mainly located in alveolar epithelial cells and some alveolar endothelial cells. The lung injury and alveolar edema were more serious in high tidal volume groups than in low tidal volume groups. Occludin expression was reduced and PKC activation was increased in rats in the high tidal volume groups compared with rats in the low tidal volume groups. Rats that were pretreated with the PKC inhibitor had less pulmonary edema induced by the high tidal volume ventilation.
   Conclusion: Mechanical ventilation can activate the PKC signaling pathway and tight junction proteins participate in this pathway. Up-regulation of occludin can reduce ventilation-induced lung injury.
C1 [Liu, Mengjie; Gu, Changping; Wang, Yuelan] Shandong Univ, Dept Anesthesiol, Qianfo Mt Hosp, Jinan 250014, China.
C3 Shandong University
RP Wang, YL (corresponding author), Shandong Univ, Dept Anesthesiol, Qianfo Mt Hosp, Jinan 250014, Peoples R China.
EM wyldgf@163.com
CR Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891
   Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Han XN, 2004, AM J PHYSIOL-LUNG C, V286, pL259, DOI 10.1152/ajplung.00187.2003
   Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012
   Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7
   Hinman LE, 1997, AM J PHYSIOL-LUNG C, V273, pL1242, DOI 10.1152/ajplung.1997.273.6.L1242
   Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200
   Jain Manu, 2005, Proc Am Thorac Soc, V2, P202, DOI 10.1513/pats.200501-006AC
   [姜威 Jiang W], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P6236
   Ju H-P, 2012, J KUNMING MED U, V33, P43
   Li YH, 2005, J MOL BIOL, V352, P151, DOI 10.1016/j.jmb.2005.07.017
   McNeil E, 2006, MOL BIOL CELL, V17, P1922, DOI 10.1091/mbc.E05-07-0650
   Rao R, 2009, ANN NY ACAD SCI, V1165, P62, DOI 10.1111/j.1749-6632.2009.04054.x
   Ricard JD, 2001, AM J RESP CRIT CARE, V163, P1176, DOI 10.1164/ajrccm.163.5.2006053
   Ricard JD, 2003, EUR RESPIR J, V22, p2S, DOI 10.1183/09031936.03.00420103
   Sakai Hiroyasu, 2010, Journal of Smooth Muscle Research, V46, P225, DOI 10.1540/jsmr.46.225
   Seth A, 2007, J BIOL CHEM, V282, P11487, DOI 10.1074/jbc.M610597200
   Wang J-e, 2010, PROGR ANATOMICAL SCI, V16, P149
   Wang YL, 2012, J HUAZHONG U SCI-MED, V32, P839, DOI 10.1007/s11596-012-1044-0
   Wang YL, 2011, AM J PHYSIOL-LUNG C, V301, pL197, DOI 10.1152/ajplung.00048.2011
   WEBB HH, 1974, AM REV RESPIR DIS, V110, P556
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Wu Shan-bin, 2011, Journal of China Medical University, V40, P217
   Zhang W-z, 2007, MED J QILU, V22, P204
NR 26
TC 42
Z9 45
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2466
J9 BMC PULM MED
JI BMC Pulm. Med.
PD MAY 29
PY 2014
VL 14
AR 94
DI 10.1186/1471-2466-14-94
PG 7
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA AK6YH
UT WOS:000338572700001
PM 24884662
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Uhlig, C
   Silva, PL
   Ornellas, D
   Santos, RS
   Miranda, PJ
   Spieth, PM
   Kiss, T
   Kasper, M
   Wiedemann, B
   Koch, T
   Morales, MM
   Pelosi, P
   de Abreu, MG
   Rocco, PRM
AF Uhlig, Christopher
   Silva, Pedro Leme
   Ornellas, Debora S.
   Santos, Raquel Souza
   Miranda, Paulo J.
   Spieth, Peter M.
   Kiss, Thomas
   Kasper, Michael
   Wiedemann, Baerbel
   Koch, Thea
   Morales, Marcelo Marcos
   Pelosi, Paolo
   de Abreu, Marcelo Gama
   Rocco, Patricia Rieken Macedo
TI The effects of salbutamol on epithelial ion channels depend on the
   etiology of acute respiratory distress syndrome but not the route of
   administration
SO RESPIRATORY RESEARCH
LA English
DT Article
DE Salbutamol; ALI/ARDS; Elastance; alveolar epithelial cells; epithelial sodium channel; Edema 
ID ACUTE LUNG INJURY; ALVEOLAR FLUID CLEARANCE; SODIUM-CHANNELS;
   PULMONARY-EDEMA; IN-VITRO; AGONISTS; RECEPTOR; VIVO; PERMEABILITY;
   SALMETEROL
AB Introduction: We investigated the effects of intravenous and intratracheal administration of salbutamol on lung morphology and function, expression of ion channels, aquaporin, and markers of inflammation, apoptosis, and alveolar epithelial/endothelial cell damage in experimental pulmonary (p) and extrapulmonary (exp) mild acute respiratory distress syndrome (ARDS).
   Methods: In this prospective randomized controlled experimental study, 56 male Wistar rats were randomly assigned to mild ARDS induced by either intratracheal (n = 28, ARDSp) or intraperitoneal (n = 28, ARDSexp) administration of E. coli lipopolysaccharide. Four animals with no lung injury served as controls (NI). After 24 hours, animals were anesthetized, mechanically ventilated in pressure controlled mode with low tidal volume (6 mL/kg), and randomly assigned to receive salbutamol (SALB) or saline 0.9% (CTRL), intravenously (i.v., 10 mu g/kg/h) or intratracheally (bolus, 25 mu g). Salbutamol doses were targeted at an increase of approximate to 20% in heart rate. Hemodynamics, lung mechanics, and arterial blood gases were measured before and after (at 30 and 60 min) salbutamol administration. At the end of the experiment, lungs were extracted for analysis of lung histology and molecular biology analysis. Values are expressed as mean +/- standard deviation, and fold changes relative to NI, CTRL vs. SALB.
   Results: The gene expression of ion channels and aquaporin was increased in mild ARDSp, but not ARDSexp. In ARDSp, intravenous salbutamol resulted in higher gene expression of alveolar epithelial sodium channel (0.20 +/- 0.07 vs. 0.68 +/- 0.24, p < 0.001), aquaporin-1 (0.44 +/- 0.09 vs. 0.96 +/- 0.12, p < 0.001) aquaporin-3 (0.31 +/- 0.12 vs. 0.93 +/- 0.20, p < 0.001), and Na-K-ATPase-a (0.39 +/- 0.08 vs. 0.92 +/- 0.12, p < 0.001), whereas intratracheal salbutamol increased the gene expression of aquaporin-1 (0.46 +/- 0.11 vs. 0.92 +/- 0.06, p < 0.001) and Na-K-ATPase-a (0.32 +/- 0.07 vs. 0.58 +/- 0.15, p < 0.001). In ARDSexp, the gene expression of ion channels and aquaporin was not influenced by salbutamol. Morphological and functional variables and edema formation were not affected by salbutamol in any of the ARDS groups, regardless of the route of administration.
   Conclusion: Salbutamol administration increased the expression of alveolar epithelial ion channels and aquaporin in mild ARDSp, but not ARDSexp, with no effects on lung morphology and function or edema formation. These results may contribute to explain the negative effects of beta 2-agonists on clinical outcome in ARDS.
C1 [Uhlig, Christopher; Silva, Pedro L.; Ornellas, Debora; Santos, Raquel S.; Miranda, Paulo J.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, BR-21941902 Rio De Janeiro, Brazil.
C1 [Uhlig, Christopher; Spieth, Peter M.; Kiss, Thomas; Koch, Thea; de Abreu, Marcelo Gama] Tech Univ Dresden, Univ Hosp Dresden, Pulm Engn Grp, Dept Anesthesiol & Intens Care Therapy, D-01307 Dresden, Germany.
C1 [Ornellas, Debora; Morales, Marcelo M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Labo Cellular & Mol Physiol, BR-21941902 Rio De Janeiro, Brazil.
C1 [Kasper, Michael] Tech Univ Dresden, Fac Med, Inst Anat, D-01307 Dresden, Germany.
C1 [Wiedemann, Baerbel] Tech Univ Dresden, Fac Med, Inst Biometr & Med Informat, D-01307 Dresden, Germany.
C1 [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, IRCCS AOU San Martino IST, I-16132 Genoa, Italy.
C3 Universidade Federal do Rio de Janeiro; Technische Universitat Dresden;
   Carl Gustav Carus University Hospital; Universidade Federal do Rio de
   Janeiro; Technische Universitat Dresden; Technische Universitat Dresden;
   University of Genoa; IRCCS AOU San Martino IST
RP de Abreu, MG (corresponding author), Tech Univ Dresden, Univ Hosp Dresden, Pulm Engn Grp, Dept Anesthesiol & Intens Care Therapy, Fetscherstr, D-01307 Dresden, Germany.
EM mgabreu@uniklinikum-dresden.de; prmrocco@biof.ufrj.br
RI Silva, Pedro Leme/AAD-8236-2019; Spieth, Peter/C-2928-2011; Rocco,
   Patricia/I-7460-2012
OI Silva, Pedro Leme/0000-0001-5838-4949; Rocco,
   Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023; Spieth,
   Peter/0000-0003-3953-3253
FU personnel exchange grant (PROBRAL) of the Coordination for the
   Improvement of Higher Education Personnel (CAPES), Brasilia, Brazil;
   German Academic Exchange Service (DAAD), Bonn, Germany; Carlos Chagas
   Filho Rio de Janeiro State Research Foundation (FAPERJ), Rio de Janeiro,
   Brazil; Brazilian Council for Scientific and Technological Development
   (CNPq), Brasilia, Brazil
FX This study was financially supported by a personnel exchange grant
   (PROBRAL) of the Coordination for the Improvement of Higher Education
   Personnel (CAPES), Brasilia, Brazil, and the German Academic Exchange
   Service (DAAD), Bonn, Germany, as well as educational grants of the
   Carlos Chagas Filho Rio de Janeiro State Research Foundation (FAPERJ),
   Rio de Janeiro, Brazil, and the Brazilian Council for Scientific and
   Technological Development (CNPq), Brasilia, Brazil.
CR BASRAN GS, 1986, EUR J NUCL MED, V12, P381
   Bassford CR, 2012, CRIT CARE, V16, DOI 10.1186/cc11221
   BENNETT JA, 1994, THORAX, V49, P771, DOI 10.1136/thx.49.8.771
   Bosmann M, 2012, FASEB J, V26, P2137, DOI 10.1096/fj.11-201640
   Brant KA, 2013, AM J RESP CELL MOL, V49, P105, DOI 10.1165/rcmb.2012-0297OC
   Chen XJ, 2002, AM J PHYSIOL-LUNG C, V282, pL609, DOI 10.1152/ajplung.00356.2001
   Curley G, 2011, CRIT CARE, V15, DOI 10.1186/cc9994
   Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362
   Dincer HE, 2001, AM J PHYSIOL-LUNG C, V281, pL624, DOI 10.1152/ajplung.2001.281.3.L624
   Downs CA, 2012, AM J PHYSIOL-LUNG C, V302, pL1167, DOI 10.1152/ajplung.00038.2012
   Frank JA, 2000, J APPL PHYSIOL, V89, P1255, DOI 10.1152/jappl.2000.89.4.1255
   He X, 2013, CELL SIGNAL, V25, P1913, DOI 10.1016/j.cellsig.2013.05.024
   Herrero R, 2013, AM J PHYSIOL-LUNG C, V305, pL377, DOI 10.1152/ajplung.00271.2012
   Hollenhorst MI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/174306
   Maris NA, 2005, AM J RESP CRIT CARE, V172, P878, DOI 10.1164/rccm.200503-451OC
   Martin TR, 2011, CRIT CARE CLIN, V27, P735, DOI 10.1016/j.ccc.2011.05.013
   Marunaka Y, 1999, J PHYSIOL-LONDON, V515, P669, DOI 10.1111/j.1469-7793.1999.669ab.x
   MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561
   McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E
   Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004
   MINNEAR FL, 1989, AM J PHYSIOL, V257, pH1613, DOI 10.1152/ajpheart.1989.257.5.H1613
   Morina P, 1997, INTENS CARE MED, V23, P58, DOI 10.1007/s001340050291
   Mutlu GM, 2008, AM J RESP CELL MOL, V38, P127, DOI 10.1165/rcmb.2007-0198TR
   Perkins GD, 2008, THORAX, V63, P215, DOI 10.1136/thx.2007.080382
   Perkins GD, 2004, CRIT CARE, V8, P25, DOI 10.1186/cc2417
   Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC
   Pesce L, 2003, AM J PHYSIOL-LUNG C, V285, pL802, DOI 10.1152/ajplung.00266.2002
   PESENTI A, 1993, CRIT CARE MED, V21, P78, DOI 10.1097/00003246-199301000-00016
   PETERSON BT, 1982, J APPL PHYSIOL, V52, P1661, DOI 10.1152/jappl.1982.52.6.1661
   Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
   Rocco PRM, 2009, MINERVA ANESTESIOL, V75, P730
   Sakuma T, 1996, J APPL PHYSIOL, V80, P1681, DOI 10.1152/jappl.1996.80.5.1681
   Sakuma T, 1997, AM J RESP CRIT CARE, V155, P506, DOI 10.1164/ajrccm.155.2.9032186
   Santos FB, 2006, J APPL PHYSIOL, V100, P98, DOI 10.1152/japplphysiol.00395.2005
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Spieth PM, 2011, CRIT CARE MED, V39, P746, DOI 10.1097/CCM.0b013e318206bda6
   Tan KS, 2007, CELL SIGNAL, V19, P251, DOI 10.1016/j.cellsig.2006.06.007
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
NR 40
TC 26
Z9 26
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-993X
EI 1465-9921
J9 RESP RES
JI Respir. Res.
PD MAY 2
PY 2014
VL 15
AR 56
DI 10.1186/1465-9921-15-56
PG 12
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA AJ0BC
UT WOS:000337312900001
PM 24886221
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Damarla, M
   Parniani, AR
   Johnston, L
   Maredia, H
   Serebreni, L
   Hamdan, O
   Sidhaye, VK
   Shimoda, LA
   Myers, AC
   Crow, MT
   Schmidt, EP
   Machamer, CE
   Gaestel, M
   Rane, MJ
   Kolb, TM
   Kim, BS
   Damico, RL
   Hassoun, PM
AF Damarla, Mahendra
   Parniani, Ahmad R.
   Johnston, Laura
   Maredia, Hasina
   Serebreni, Leonid
   Hamdan, Omar
   Sidhaye, Venkataramana K.
   Shimoda, Larissa A.
   Myers, Allen C.
   Crow, Michael T.
   Schmidt, Eric P.
   Machamer, Carolyn E.
   Gaestel, Matthias
   Rane, Madhavi J.
   Kolb, Todd M.
   Kim, Bo S.
   Damico, Rachel L.
   Hassoun, Paul M.
TI Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Mediates
   Apoptosis during Lung Vascular Permeability by Regulating Movement of
   Cleaved Caspase 3
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE apoptosis; ALI/ARDS; caspase-1/caspase-3/caspase-11; nuclear translocation; kinases 
ID RESPIRATORY-DISTRESS-SYNDROME; ENDOTHELIAL-CELL APOPTOSIS; PROTEOLYTIC
   ACTIVATION; MECHANICAL VENTILATION; NUCLEAR TRANSLOCATION; REPERFUSION
   INJURY; BAX TRANSLOCATION; HEPATIC ISCHEMIA; CYTOCHROME-C; MICE
AB Apoptosis is a key pathologic feature in acute lung injury. Animal studies have demonstrated that pathways regulating apoptosis are necessary in the development of acute lung injury, and that activation of p38 mitogen-activated protein kinase (MAPK) is linked to the initiation of the apoptotic cascade. In this study, we assessed the role of the MAPK-activated protein kinase (MK) 2, one of p38 MAPK's immediate downstream effectors, in the development of apoptosis in an animal model of LPS-induced pulmonary vascular permeability. Our results indicate that wild-type (WT) mice exposed to LPS demonstrate increased apoptosis, as evidenced by cleavage of caspase 3 and poly (ADP-ribose) polymerase 1 and increased deoxynucleotidyl transferase-mediated dUDP nick-end labeling staining, which is accompanied by increases in markers of vascular permeability. In contrast, MK2(-/-) mice are protected from pulmonary vascular permeability and apoptosis in response to LPS. Although there was no difference in activation of caspase 3 in MK2(-/-) compared with WT mice, interestingly, cleaved caspase 3 translocated to the nucleus in WT mice while it remained in the cytosol of MK2(-/-) mice in response to LPS. In separate experiments, LPS-induced apoptosis in human lung microvascular endothelial cells was also associated with nuclear translocation of cleaved caspase 3 and apoptosis, which were both prevented by MK2 silencing. In conclusion, our data suggest that MK2 plays a critical role in the development of apoptosis and pulmonary vascular permeability, and its effects on apoptosis are in part related to its ability to regulate nuclear translocation of cleaved caspase 3.
C1 [Damarla, Mahendra; Johnston, Laura; Serebreni, Leonid; Hamdan, Omar; Sidhaye, Venkataramana K.; Shimoda, Larissa A.; Myers, Allen C.; Crow, Michael T.; Kolb, Todd M.; Kim, Bo S.; Damico, Rachel L.; Hassoun, Paul M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205, United States.
C1 [Parniani, Ahmad R.; Rane, Madhavi J.] Univ Louisville, Sch Med, Louisville, KY 40292, United States.
C1 [Maredia, Hasina] Brown Univ, Providence, RI 02912, United States.
C1 [Schmidt, Eric P.] Univ Colorado, Sch Med, Dept Med, Aurora, CO, United States.
C1 [Machamer, Carolyn E.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD, United States.
C1 [Gaestel, Matthias] Hannover Med Sch, Dept Biochem, Hannover, Germany.
C3 Johns Hopkins University; University of Louisville; Brown University;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; Johns Hopkins University; Hannover Medical School
RP Damarla, M (corresponding author), Dept Med, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21218 USA.
EM mdamarl1@jhmi.edu
RI Kolb, Todd/ABD-8204-2020; Sidhaye, Venkataramana/AAC-3930-2019; Gaestel,
   Matthias/A-6560-2013
OI Sidhaye, Venkataramana/0000-0002-4506-8549; Gaestel,
   Matthias/0000-0002-4944-4652; Schmidt, Eric/0000-0002-7360-0504
FU NCATS NIH HHS [UL1 TR001079] Funding Source: Medline; NHLBI NIH HHS [K08
   HL105538] Funding Source: Medline
CR Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009
   Cao GD, 2001, J NEUROSCI, V21, P4678, DOI 10.1523/JNEUROSCI.21-13-04678.2001
   Chen SWC, 2009, TRANSPLANTATION, V87, P1478, DOI 10.1097/TP.0b013e3181a3c691
   Concannon CG, 2001, GENE EXPRESSION, V9, P195, DOI 10.3727/000000001783992605
   Damarla M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004600
   Damico R, 2011, AM J RESP CELL MOL, V44, P323, DOI 10.1165/rcmb.2009-0379OC
   De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018
   Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265
   Dolinay T, 2004, AM J RESP CRIT CARE, V170, P613, DOI 10.1164/rccm.200401-023OC
   Dolinay T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001601
   Ferrari G, 2012, MOL CANCER RES, V10, P605, DOI 10.1158/1541-7786.MCR-11-0507
   Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335
   Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432
   Hirahara N, 2012, ANTICANCER RES, V32, P2631
   Hollander JM, 2004, CIRCULATION, V110, P3544, DOI 10.1161/01.CIR.0000148825.99184.50
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104
   Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402
   Kamada S, 2005, MOL CELL BIOL, V25, P9469, DOI 10.1128/MCB.25.21.9469-9477.2005
   Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200
   Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1
   Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061
   Le A, 2008, J APPL PHYSIOL, V105, P1282, DOI 10.1152/japplphysiol.90689.2008
   Le Berre R, 2004, INTENS CARE MED, V30, P1204, DOI 10.1007/s00134-004-2165-0
   Li LF, 2007, CRIT CARE, V11, DOI 10.1186/cc5704
   Luo M, 2010, CELL RES, V20, P211, DOI 10.1038/cr.2010.9
   MacIntyre NR, 2005, CHEST, V128, p561S, DOI 10.1378/chest.128.5_suppl_2.561S
   Martin TR, 2003, CRIT CARE MED, V31, pS184, DOI 10.1097/01.CCM.0000057841.33876.B1
   Matute-Bello G, 2003, CRIT CARE, V7, P355, DOI 10.1186/cc1861
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510
   Park SW, 2009, AM J PHYSIOL-RENAL, V297, pF885, DOI 10.1152/ajprenal.00317.2009
   Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002
   Petrilli V, 2004, J CLIN INVEST, V114, P1072, DOI 10.1172/JCI200421854
   Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Shiroto K, 2005, J MOL CELL CARDIOL, V38, P93, DOI 10.1016/j.yjmcc.2004.10.018
   So KS, 2008, ARCH PHARM RES, V31, P438, DOI 10.1007/s12272-001-1176-7
   Tang PS, 2008, AM J PHYSIOL-LUNG C, V294, pL632, DOI 10.1152/ajplung.00262.2007
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Vaschetto R, 2008, ANESTHESIOLOGY, V108, P261, DOI 10.1097/01.anes.0000299434.86640.15
   Voss OH, 2007, J BIOL CHEM, V282, P25088, DOI 10.1074/jbc.M701740200
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155
   Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943
   Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536
NR 50
TC 35
Z9 39
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2014
VL 50
IS 5
BP 932
EP 941
DI 10.1165/rcmb.2013-0361OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AG8DB
UT WOS:000335647900016
PM 24304496
OA Green Published
DA 2023-08-21
ER

PT J
AU Stevens, TC
   Ochoa, CD
   Morrow, KA
   Robson, MJ
   Prasain, N
   Zhou, C
   Alvarez, DF
   Frank, DW
   Balczon, R
   Stevens, T
AF Stevens, Trevor C.
   Ochoa, Cristhiaan D.
   Morrow, K. Adam
   Robson, Matthew J.
   Prasain, Nutan
   Zhou, Chun
   Alvarez, Diego F.
   Frank, Dara W.
   Balczon, Ron
   Stevens, Troy
TI The Pseudomonas aeruginosa exoenzyme Y impairs endothelial cell
   proliferation and vascular repair following lung
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE pulmonary edema; permeability; cyclase; tau; microtubule 
ID ANTHRACIS EDEMA FACTOR; ADENYLATE-CYCLASE; NUCLEAR-TAU;
   BORDETELLA-PERTUSSIS; BARRIER DYSFUNCTION; IN-VIVO; PROTEIN; CAMP;
   PHOSPHORYLATION; LOCALIZATION
AB Exoenzyme Y (ExoY) is a Pseudomonas aeruginosa toxin that is introduced into host cells through the type 3 secretion system (T3SS). Once inside the host cell cytoplasm, ExoY generates cyclic nucleotides that cause tau phosphorylation and microtubule breakdown. Microtubule breakdown causes interendothelial cell gap formation and tissue edema. Although ExoY transiently induces interendothelial cell gap formation, it remains unclear whether ExoY prevents repair of the endothelial cell barrier. Here, we test the hypothesis that ExoY intoxication impairs recovery of the endothelial cell barrier following gap formation, decreasing migration, proliferation, and lung repair. Pulmonary microvascular endothelial cells (PMVECs) were infected with P. aeruginosa strains for 6 h, including one possessing an active ExoY (PA103 exoUexoT::Tc pUCPexoY; ExoY(+)), one with an inactive ExoY (PA103 Delta exoUexoT:: Tc pUCPexoY(K81M); ExoY(K81M)), and one that lacks PcrV required for a functional T3SS (Delta PcrV). ExoY(+) induced interendothelial cell gaps, whereas ExoY(K81M) and Delta PcrV did not promote gap formation. Following gap formation, bacteria were removed and endothelial cell repair was examined. PMVECs were unable to repair gaps even 3-5 days after infection. Serum-stimulated growth was greatly diminished following ExoY intoxication. Intratracheal inoculation of ExoY(+) and ExoY(K81)M caused severe pneumonia and acute lung injury. However, whereas the pulmonary endothelial cell barrier was functionally improved 1 wk following ExoY(K81M) infection, pulmonary endothelium was unable to restrict the hyper-permeability response to elevated hydrostatic pressure following ExoY(+) infection. In conclusion, ExoY is an edema factor that chronically impairs endothelial cell barrier integrity following lung injury.
C1 [Morrow, K. Adam; Alvarez, Diego F.; Stevens, Troy] Univ S Alabama, Dept Pharmacol, Mobile, AL 36688, United States.
C1 [Alvarez, Diego F.; Stevens, Troy] Univ S Alabama, Dept Med, Mobile, AL 36688, United States.
C1 [Balczon, Ron] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688, United States.
C1 [Stevens, Trevor C.; Morrow, K. Adam; Robson, Matthew J.; Zhou, Chun; Alvarez, Diego F.; Balczon, Ron; Stevens, Troy] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688, United States.
C1 [Ochoa, Cristhiaan D.] Univ Texas SW Med Ctr Dallas, Dept Med, Phys Scientist Training Program, Dallas, TX 75390, United States.
C1 [Ochoa, Cristhiaan D.] Univ Texas SW Med Ctr Dallas, Div Pulm & Crit Care, Dallas, TX 75390, United States.
C1 [Prasain, Nutan] Indiana Univ, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN, United States.
C1 [Frank, Dara W.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226, United States.
C1 [Frank, Dara W.] Med Coll Wisconsin, Ctr Infect Dis Res, Milwaukee, WI 53226, United States.
C3 University of South Alabama; University of South Alabama; University of
   South Alabama; University of South Alabama; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas;
   Indiana University System; Indiana University-Purdue University
   Indianapolis; Medical College of Wisconsin; Medical College of Wisconsin
RP Stevens, T (corresponding author), Univ S Alabama, Coll Med, Ctr Lung Biol, Dept Pharmacol, Mobile, AL 36688 USA.
EM tstevens@southalabama.edu
RI Alvarez, Diego/AAT-3897-2020
OI Alvarez, Diego/0000-0001-8244-629X; Ochoa,
   Cristhiaan/0000-0001-9113-2137
FU  [HL60024];  [HL66299];  [HL07612];  [HL107122]
FX This work was supported by HL60024 (T. Stevens), HL66299 (T. Stevens, D.
   F. Alvarez, C. D. Ochoa, K. A. Morrow, and R. Balczon), and HL07612,
   HL107122 (C. D. Ochoa).
CR Ahuja N, 2004, CRIT REV MICROBIOL, V30, P187, DOI 10.1080/10408410490468795
   Baig S, 2009, NEUROSCIENCE, V163, P561, DOI 10.1016/j.neuroscience.2009.06.045
   Balczon R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074343
   Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com
   BRAUN N, 1988, VIRCHOWS ARCH B, V56, P25, DOI 10.1007/BF02889998
   Cioffi DL, 2002, J CELL BIOL, V157, P1267, DOI 10.1083/jcb.200204022
   Creighton JR, 2003, AM J PHYSIOL-LUNG C, V284, pL100, DOI 10.1152/ajplung.00083.2002
   El-Solh AA, 2012, CRIT CARE MED, V40, P1157, DOI 10.1097/CCM.0b013e3182377906
   Engel J, 2009, CURR OPIN MICROBIOL, V12, P61, DOI 10.1016/j.mib.2008.12.007
   GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x
   Gottle M, 2012, TOXINS, V4, P505, DOI 10.3390/toxins4070505
   Gottle M, 2010, BIOCHEMISTRY-US, V49, P5494, DOI 10.1021/bi100684g
   GREENWOOD JA, 1995, EXP CELL RES, V220, P332, DOI 10.1006/excr.1995.1323
   Le Berre R, 2011, CRIT CARE MED, V39, P2113, DOI 10.1097/CCM.0b013e31821e899f
   LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162
   LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Nakamura M, 2008, ACTA NEUROPATHOL, V115, P327, DOI 10.1007/s00401-007-0337-z
   Ochoa CD, 2012, J BIOL CHEM, V287, P25407, DOI 10.1074/jbc.M111.301440
   Ochoa CD, 2012, AM J PHYSIOL-LUNG C, V302, pL275, DOI [10.1152/ajplung.00215.2011, 10.1152/ajplung.00215.2011.]
   Parker JC, 2008, AM J PHYSIOL-LUNG C, V295, pL235, DOI 10.1152/ajplung.00064.2008
   Parra-Bonilla G, 2010, AM J PHYSIOL-LUNG C, V299, pL513, DOI 10.1152/ajplung.00274.2009
   Prasain N., 2009, THESIS U S ALABAMA A
   Prasain N, 2009, AM J PHYSIOL-LUNG C, V297, pL73, DOI 10.1152/ajplung.90577.2008
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Sayner SL, 2004, CIRC RES, V95, P196, DOI 10.1161/01.RES.0000134922.25721.d9
   Seifert R, 2013, BMC PHARM TOXICOL S1, V14
   Sjoberg MK, 2006, J CELL SCI, V119, P2025, DOI 10.1242/jcs.02907
   STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696
   Thurston VC, 1996, CHROMOSOMA, V105, P20, DOI 10.1007/BF02510035
   Thurston VC, 1997, CELL MOTIL CYTOSKEL, V38, P100, DOI 10.1002/(SICI)1097-0169(1997)38:1<100::AID-CM9>3.0.CO;2-C
   Vance RE, 2005, INFECT IMMUN, V73, P1706, DOI 10.1128/IAI.73.3.1706-1713.2005
   Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565
   Winn WC, 2008, PULMONARY PATHOLOGY, P228
   Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899
NR 35
TC 61
Z9 64
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2014
VL 306
IS 10
BP L915
EP L924
DI 10.1152/ajplung.00135.2013
PG 10
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA AI1GP
UT WOS:000336598600002
PM 24705722
OA Green Published
DA 2023-08-21
ER

PT J
AU Zhao, YF
   Xiong, W
   Wu, XL
AF Zhao, Yun-Feng
   Xiong, Wei
   Wu, Xue-Ling
TI Mesenchymal stem cell-based developmental endothelial locus-1 gene
   therapy for acute lung injury induced by lipopolysaccharide in mice
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ALI/ARDS; mesenchymal stem cell; gene therapy 
ID RECRUITMENT; ENGRAFTMENT; ADHESION; OUTCOMES; SEPSIS; REPAIR; ICAM-1
AB Studies have suggested that bone marrow-derived mesenchymal stem cells (MSCs) may be used as a tool for gene therapy. Developmental endothelial locus-1 (Del-1) is a critical factor for cell migration and infiltration via the inhibition of the function of a major leukocyte adhesion receptor LFA-1 which prevents leukocyte adhesion to the endothelium. In the present study, we hypothesized that MSC-based Del-1 gene therapy may have potential therapeutic applications for lipopolysaccharide (LPS)-induced lung injury. The MSCs in the present assay were isolated from 6 week-old male mice. In order to investigate the therapeutic effect of the Del-1 gene on LPS-induced ALI mice, a lentivirus vector containing the Del-1 gene was constructed and transduced into the MSCs. In the in vivo assay, we induced lung injury with LPS injection and treated mice with different groups of MSCs, and compared with groups treated with MSCs alone, we observed that the administration with MSCs carrying Del-1 (MSCs-Dell) markedly alleviated the LPS-induced lung injury. There were significant decreases in the number of neutrophils in bronchoalveolar lavage (BAL) and the serum levels of TNF-alpha and IL-6 in the Del-l-expressed MSC-treated mice. Furthermore, compared with MSCs treated alone, Dell-MSC-treated mice also exhibited low lung injury scores, high protein concentrations and myeloperoxidase activity. In conclusion, treatment with Del-l-expressed MSCs significantly decreases the severity of endotoxin-induced acute lung injury and the level of inflammatory cytokines in mice.
C1 [Zhao, Yun-Feng; Xiong, Wei] Gongli Hosp, Pudong New Area, Dept Resp Med, Shanghai 200135, China.
C1 [Wu, Xue-Ling] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Med, Chongqing 400037, China.
C3 Army Medical University
RP Wu, XL (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Inst Resp Med, 183 Xinqiaozheng St, Chongqing 400037, Peoples R China.
EM wxueling@yeah.net
FU Pudong New Area health bureau Foundation of Shanghai [PWRd 2012-07];
   National Natural Science Foundation of China [81070056, 81270130]
FX The authors thank all subjects enrolled in this study. The present study
   was supported by grants from the Pudong New Area health bureau
   Foundation of Shanghai (grant no. PWRd 2012-07 to Yun-feng Zhao) and the
   National Natural Science Foundation of China (grant no. 81070056 and
   81270130 to Xue-ling Wu).
CR Aslam M, 2009, AM J RESP CRIT CARE, V180, P1122, DOI 10.1164/rccm.200902-0242OC
   Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126
   Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005
   Choi EY, 2008, SCIENCE, V322, P1101, DOI 10.1126/science.1165218
   Choi Eun Young, 2009, Immune Netw, V9, P153, DOI 10.4110/in.2009.9.5.153
   Cribbs SK, 2010, CRIT CARE MED, V38, P2379, DOI 10.1097/CCM.0b013e3181f96f5f
   Das R, 2010, TISSUE ENG PART B-RE, V16, P159, DOI 10.1089/ten.TEB.2009.0296
   Gray KD, 2003, AM J SURG, V186, P526, DOI 10.1016/j.amjsurg.2003.07.010
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hu X, 2010, ACTA PAEDIATR, V99, P715, DOI 10.1111/j.1651-2227.2010.01685.x
   Krause Diane S, 2008, Proc Am Thorac Soc, V5, P323, DOI 10.1513/pats.200712-169DR
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2
   Lee JW, 2009, EXPERT OPIN BIOL TH, V9, P1259, DOI 10.1517/14712590903213651
   Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925
   Rojas M, 2005, AM J RESP CELL MOL, V33, P145, DOI 10.1165/rcmb.2004-0330OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Xu JG, 2007, AM J PHYSIOL-LUNG C, V293, pL131, DOI 10.1152/ajplung.00431.2006
NR 24
TC 16
Z9 19
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2014
VL 9
IS 5
BP 1583
EP 1589
DI 10.3892/mmr.2014.1988
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AJ3HR
UT WOS:000337557600010
PM 24573341
OA Bronze
DA 2023-08-21
ER

PT J
AU Mambetsariev, I
   Tian, YF
   Wu, TH
   Lavoie, T
   Solway, J
   Birukov, KG
   Birukova, AA
AF Mambetsariev, Isa
   Tian, Yufeng
   Wu, Tinghuai
   Lavoie, Tera
   Solway, Julian
   Birukov, Konstantin G.
   Birukova, Anna A.
TI Stiffness-Activated GEF-H1 Expression Exacerbates LPS-Induced Lung
   Inflammation
SO PLOS ONE
LA English
DT Article
ID VASCULAR-PERMEABILITY; INJURY; MICROTUBULES; INHIBITION
AB Acute lung injury (ALI) is accompanied by decreased lung compliance. However, a role of tissue mechanics in modulation of inflammation remains unclear. We hypothesized that bacterial lipopolysacharide (LPS) stimulates extracellular matrix (ECM) production and vascular stiffening leading to stiffness-dependent exacerbation of endothelial cell (EC) inflammatory activation and lung barrier dysfunction. Expression of GEF-H1, ICAM-1, VCAM-1, ECM proteins fibronectin and collagen, lysyl oxidase (LOX) activity, interleukin-8 and activation of Rho signaling were analyzed in lung samples and pulmonary EC grown on soft (1.5 or 2.8 kPa) and stiff (40 kPa) substrates. LPS induced EC inflammatory activation accompanied by expression of ECM proteins, increase in LOX activity, and activation of Rho signaling. These effects were augmented in EC grown on stiff substrate. Stiffness-dependent enhancement of inflammation was associated with increased expression of Rho activator, GEF-H1. Inhibition of ECM crosslinking and stiffening by LOX suppression reduced EC inflammatory activation and GEF-H1 expression in response to LPS. In vivo, LOX inhibition attenuated LPS-induced expression of GEF-H1 and lung dysfunction. These findings present a novel mechanism of stiffness-dependent exacerbation of vascular inflammation and escalation of ALI via stimulation of GEF-H1 - Rho pathway. This pathway represents a fundamental mechanism of positive feedback regulation of inflammation.
C1 [Mambetsariev, Isa; Tian, Yufeng; Wu, Tinghuai; Lavoie, Tera; Solway, Julian; Birukov, Konstantin G.; Birukova, Anna A.] Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukova, AA (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022
FU NIH [HL89257, HL107920, HL76259]
FX Funding was provided by NIH HL89257, HL107920, HL76259. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aratyn-Schaus Y, 2011, MOL BIOL CELL, V22, P1330, DOI 10.1091/mbc.E10-11-0891
   Aratyn-Schaus Yvonne, 2010, J Vis Exp, DOI 10.3791/2173
   Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208
   Berg JT, 1997, J APPL PHYSIOL, V83, P120, DOI 10.1152/jappl.1997.83.1.120
   Bershadsky AD, 2006, EUR J CELL BIOL, V85, P165, DOI 10.1016/j.ejcb.2005.11.001
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005
   Birukova AA, 2013, MICROVASC RES, V87, P50, DOI 10.1016/j.mvr.2012.12.006
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Chandler EM, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015008
   Deng XL, 2011, BRAIN RES, V1387, P1, DOI 10.1016/j.brainres.2011.02.059
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Guilluy C, 2011, NAT CELL BIOL, V13, P722, DOI 10.1038/ncb2254
   Guo F, 2012, MOL IMMUNOL, V50, P98, DOI 10.1016/j.molimm.2011.12.009
   Guo F, 2012, CYTOKINE, V57, P417, DOI 10.1016/j.cyto.2011.12.009
   Heck JN, 2012, MOL BIOL CELL, V23, P2583, DOI 10.1091/mbc.E11-10-0876
   Huang XW, 2012, AM J RESP CELL MOL, V47, P340, DOI 10.1165/rcmb.2012-0050OC
   Karsdal MA, 2013, ASSAY DRUG DEV TECHN, V11, P70, DOI 10.1089/adt.2012.474
   Kratzer E, 2012, AM J RESP CELL MOL, V47, P688, DOI 10.1165/rcmb.2012-0161OC
   Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773
   Lavoie TL, 2012, AM J RESP CRIT CARE, V186, P225, DOI 10.1164/rccm.201202-0368OC
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Ly DL, 2013, AM J PHYSIOL-CELL PH, V304, pC115, DOI 10.1152/ajpcell.00290.2012
   Mammoto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2774
   Maruthamuthu V, 2011, P NATL ACAD SCI USA, V108, P4708, DOI 10.1073/pnas.1011123108
   Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rocco PRM, 2009, MINERVA ANESTESIOL, V75, P730
   Rodriguez C, 2008, DRUG NEWS PERSPECT, V21, P218, DOI 10.1358/dnp.2008.21.4.1213351
   Schmeck B, 2003, INFLAMMATION, V27, P89, DOI 10.1023/A:1023278600596
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Togbe D, 2007, INT J EXP PATHOL, V88, P387, DOI 10.1111/j.1365-2613.2007.00566.x
   Wang Q, 2002, ANTIOXID REDOX SIGN, V4, P39, DOI 10.1089/152308602753625843
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041
NR 37
TC 28
Z9 30
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2014
VL 9
IS 4
AR e92670
DI 10.1371/journal.pone.0092670
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI4VW
UT WOS:000336863900012
PM 24739883
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Shikata, F
   Sakaue, T
   Nakashiro, K
   Okazaki, M
   Kurata, M
   Okamura, T
   Okura, M
   Ryugo, M
   Nakamura, Y
   Yasugi, T
   Higashiyama, S
   Izutani, H
AF Shikata, Fumiaki
   Sakaue, Tomohisa
   Nakashiro, Koh-ichi
   Okazaki, Mikio
   Kurata, Mie
   Okamura, Toru
   Okura, Masahiro
   Ryugo, Masahiro
   Nakamura, Yuki
   Yasugi, Takumi
   Higashiyama, Shigeki
   Izutani, Hironori
TI Pathophysiology of Lung Injury Induced by Common Bile Duct Ligation in
   Mice
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIN-B RECEPTOR; NITRIC-OXIDE SYNTHASE; HEPATOPULMONARY-SYNDROME;
   RAT MODEL; ARTERIOVENOUS-MALFORMATIONS; PORTAL-HYPERTENSION; POTENTIAL
   ROLE; MATRIX-METALLOPROTEINASE-9; PATHOGENESIS; EXPRESSION
AB Background: Liver dysfunction and cirrhosis affect vasculature in several organ systems and cause impairment of organ functions, thereby increasing morbidity and mortality. Establishment of a mouse model of hepatopulmonary syndrome (HPS) would provide greater insights into the genetic basis of the disease. Our objectives were to establish a mouse model of lung injury after common bile duct ligation (CBDL) and to investigate pulmonary pathogenesis for application in future therapeutic approaches.
   Methods: Eight-week-old Balb/c mice were subjected to CBDL. Immunohistochemical analyses and real-time quantitative reverse transcriptional polymerase chain reaction were performed on pulmonary tissues. The presence of HPS markers was detected by western blot and microarray analyses.
   Results: We observed extensive proliferation of CD31-positive pulmonary vascular endothelial cells at 2 weeks after CBDL and identified 10 upregulated and 9 down-regulated proteins that were associated with angiogenesis. TNF-a and MMP-9 were highly expressed at 3 weeks after CBDL and were less expressed in the lungs of the control group.
   Conclusions: We constructed a mouse lung injury model by using CBDL. Contrary to our expectation, lung pathology in our mouse model exhibited differences from that of rat models, and the mechanisms responsible for these differences are unknown. This phenomenon may be explained by contrasting processes related to TNF induction of angiogenic signaling pathways in the inflammatory phase. Thus, we suggest that our mouse model can be applied to pulmonary pathological analyses in the inflammatory phase, i.e., to systemic inflammatory response syndrome, acute lung injury, and multiple organ dysfunction syndrome.
C1 [Shikata, Fumiaki; Okazaki, Mikio; Okamura, Toru; Okura, Masahiro; Ryugo, Masahiro; Nakamura, Yuki; Yasugi, Takumi; Izutani, Hironori] Ehime Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Matsuyama, Ehime 790, Japan.
C1 [Sakaue, Tomohisa; Higashiyama, Shigeki] Ehime Univ, Dept Cell Growth & Tumor Regulat, Proteo Sci Ctr, Matsuyama, Ehime 790, Japan.
C1 [Sakaue, Tomohisa; Higashiyama, Shigeki] Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Matsuyama, Ehime 790, Japan.
C1 [Nakashiro, Koh-ichi] Ehime Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Matsuyama, Ehime 790, Japan.
C1 [Kurata, Mie] Ehime Univ, Grad Sch Med, Dept Pathol, Div Pathogen, Matsuyama, Ehime 790, Japan.
C3 Ehime University; Ehime University; Ehime University; Ehime University;
   Ehime University
RP Izutani, H (corresponding author), Ehime Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Matsuyama, Ehime 790, Japan.
EM izutani@m.ehime-u.ac.jp
RI Nakamura, Yuki/N-4234-2019; Nakashiro, Koichi/AAV-6317-2020; OKAZAKI,
   MIKIO/AGN-1218-2022
OI Nakamura, Yuki/0000-0003-0023-4985; OKAZAKI, MIKIO/0000-0002-7202-244X;
   Nakashiro, Koh-ichi/0000-0002-9975-902X; Kurata, Mie/0000-0001-6596-2436
FU JSPS KAKENHI [11008958]; Grants-in-Aid for Scientific Research
   [24390457] Funding Source: KAKEN
FX This work was supported in part by JSPS KAKENHI grant number 11008958
   (http://www.jsps.go.jp/english/index.html). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. No additional external funding received
   for this study.
CR Alaish SM, 2005, SHOCK, V24, P412, DOI 10.1097/01.shk.0000183392.83272.97
   Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR
   Beierle EA, 1996, AM J SURG, V171, P202, DOI 10.1016/S0002-9610(99)80100-7
   Bendeck MP, 2004, CIRC RES, V94, P138, DOI 10.1161/01.RES.0000117525.23089.1A
   Chakrabarti S, 2006, J LEUKOCYTE BIOL, V79, P214, DOI 10.1189/jlb.0605353
   Chakrabarti S, 2005, EXP LUNG RES, V31, P599, DOI 10.1080/019021490944232
   CHANG SW, 1992, AM REV RESPIR DIS, V145, P798, DOI 10.1164/ajrccm/145.4_Pt_1.798
   Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599
   Fallon MB, 1997, GASTROENTEROLOGY, V113, P606, DOI 10.1053/gast.1997.v113.pm9247483
   Garcia-Prieto E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013242
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
   Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62
   Kato T, 1999, BREAST CANCER RES TR, V53, P19, DOI 10.1023/A:1006193024382
   Keck T, 2006, PANCREATOLOGY, V6, P316, DOI 10.1159/000092797
   Keck T, 2002, GASTROENTEROLOGY, V122, P188, DOI 10.1053/gast.2002.30348
   Kim JH, 2006, AM J PHYSIOL-LUNG C, V291, pL580, DOI 10.1152/ajplung.00270.2005
   Kirkland JG, 2010, J SURG RES, V164, P221, DOI 10.1016/j.jss.2009.08.010
   Kochar R, 2011, PULMONARY MANIFESTAT, P381
   Kong MYF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022596
   Kong MYF, 2009, INT J MED SCI, V6, P9
   Ling YQ, 2004, HEPATOLOGY, V39, P1593, DOI 10.1002/hep.20244
   Liu LC, 2001, HEPATOLOGY, V33, P722, DOI 10.1053/jhep.2001.22701
   Luo B, 2004, AM J PHYSIOL-GASTR L, V286, pG294, DOI 10.1152/ajpgi.00298.2003
   Machicao VI, 2012, SEMIN RESP CRIT CARE, V33, P11, DOI 10.1055/s-0032-1301730
   Miniati D, 2010, AM J PHYSIOL-LUNG C, V298, pL169, DOI 10.1152/ajplung.00188.2009
   Oggionni T, 2006, EUR J HISTOCHEM, V50, P317
   Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514
   Roberts KE, 2010, GASTROENTEROLOGY, V139, P130, DOI 10.1053/j.gastro.2010.03.044
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood-2007-08-108597
   Sari S, 2012, DIGEST DIS SCI, V57, P175, DOI 10.1007/s10620-011-1832-6
   Schranz D, 2004, LANCET, V364, P26, DOI 10.1016/S0140-6736(04)16582-3
   Sugiyama M, 1997, ARCH SURG-CHICAGO, V132, P1129
   Tang LP, 2007, AM J PHYSIOL-LUNG C, V292, pL1467, DOI 10.1152/ajplung.00446.2006
   Tanikella R, 2008, LIVER TRANSPLANT, V14, P1199, DOI 10.1002/lt.21482
   Thenappan T, 2011, AM J RESP CRIT CARE, V183, P1080, DOI 10.1164/rccm.201008-1303OC
   Tipps RS, 2008, J THORAC CARDIOV SUR, V136, P283, DOI 10.1016/j.jtcvs.2008.02.011
   Van Steenkiste C, 2010, LAB INVEST, V90, P1558, DOI 10.1038/labinvest.2010.138
   Walkin L, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-18
   Wang BL, 2011, MOL MED REP, V4, P243, DOI 10.3892/mmr.2011.425
   Zhang JL, 2012, NAT REV GASTRO HEPAT, V9, P539, DOI 10.1038/nrgastro.2012.123
   Zhang JL, 2009, GASTROENTEROLOGY, V136, P1070, DOI 10.1053/j.gastro.2008.12.001
   Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200
NR 43
TC 22
Z9 23
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2014
VL 9
IS 4
AR e94550
DI 10.1371/journal.pone.0094550
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI6GP
UT WOS:000336970400051
PM 24733017
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Jones, R
   Capen, DE
AF Jones, Rosemary
   Capen, Diane E.
TI Imaging Circulating Monocytic Cells Fusing to Endothelial Cells in
   Acutely Injured and Regenerating Capillaries
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Blood-borne cells; fusion to endothelium; immunopositive cell 
ID LUNG NEOVASCULARIZATION MODEL; PULMONARY-HYPERTENSION; SMOOTH-MUSCLE;
   GROWTH-FACTOR; T-CELLS; PROGENITOR CELLS; HYPEROXIC INJURY; PRECURSOR
   CELLS; ANGIOGENESIS; WALL
AB The present studies focus on monocytic circulating cells (CCs) interacting with the endothelial cells of pulmonary capillaries in acute lung injury. The CCs are further defined into sub-sets based on their structural profiles, i.e. CC1-3. They are shown to move into close apposition to adjacent capillary endothelium and to fuse to endothelial plasmalemmal membranes. Similarly, CCs are seen to fuse to the endothelial cells of regenerating capillaries after injury. Immunogold labeling studies demonstrate that CCs express a mediator promoting endothelial cell migration, proliferation and stability, i.e. VEGF, further supporting the potential of a paracrine interaction between the fusing cells, while the expression of CXCR4 by CCs, and of SDF-1 alpha by adjacent endothelial cells, demonstrates a mechanism for retention of these cells at the capillary surface. Myeloid VEGF-R2(+)CD11b(+) precursors and PDGF-R beta(+) expressing cells are identified within the CC population. The findings establish that, by fusing to endothelial cells, the monocytic CC population studied has the potential to promote capillary surface stability/integrity through a paracrine mechanism.
C1 [Jones, Rosemary; Capen, Diane E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114, United States.
C1 [Jones, Rosemary] Harvard Univ, Sch Med, Boston, MA, United States.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School
RP Jones, R (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,MGH EAST CNY, 149 13th St, Boston, MA 02115 USA.
EM rcjones@partners.org
FU NIH HL [R01 089252]
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. This work was
   supported by NIH HL R01 089252.
CR Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007
   Ball SG, 2007, J CELL BIOL, V177, P489, DOI 10.1083/jcb.200608093
   HUDAK BB, 1993, PHARMACOGENETICS, V3, P135, DOI 10.1097/00008571-199306000-00003
   Hur J, 2007, CIRCULATION, V116, P1671, DOI 10.1161/CIRCULATIONAHA.107.694778
   Johnston CJ, 1998, EXP LUNG RES, V24, P189, DOI 10.3109/01902149809099582
   Jones R, 2013, BRIT J GEN PRACT, V63, P395, DOI 10.3399/bjgp13X670480
   Jones R, 2006, CELL TISSUE RES, V326, P759, DOI 10.1007/s00441-006-0177-5
   Jones R, 2006, ULTRASTRUCT PATHOL, V30, P267, DOI 10.1080/01913120600820336
   Jones R, 2009, J CELL MOL MED, V13, P3720, DOI 10.1111/j.1582-4934.2009.00785.x
   Jones RC, 2008, NAT PROTOC, V3, P378, DOI 10.1038/nprot.2007.536
   Jones RC, 2008, NAT PROTOC, V3, P388, DOI 10.1038/nprot.2007.537
   Jones RC, 2012, ULTRASTRUCT PATHOL, V36, P260, DOI 10.3109/01913123.2012.662820
   Kotton DN, 2012, AM J RESP CRIT CARE, V185, P1255, DOI 10.1164/rccm.201202-0228PP
   Magnusson PU, 2007, ARTERIOSCL THROM VAS, V27, P2142, DOI 10.1161/01.ATV.0000282198.60701.94
   Majesky MW, 2012, CELLS TISSUES ORGANS, V195, P73, DOI 10.1159/000331413
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Ohle SJ, 2012, AM J RESP CELL MOL, V47, P11, DOI 10.1165/rcmb.2011-0180OC
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Schniedermann J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-50
   Stevens Troy, 2008, Proc Am Thorac Soc, V5, P783, DOI 10.1513/pats.200803-027HR
   Tamosiuniene R, 2011, CIRC RES, V109, P867, DOI 10.1161/CIRCRESAHA.110.236927
   Timmermans F, 2009, J CELL MOL MED, V13, P87, DOI 10.1111/j.1582-4934.2008.00598.x
NR 22
TC 2
Z9 2
U1 0
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0191-3123
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD APR
PY 2014
VL 38
IS 2
BP 93
EP 103
DI 10.3109/01913123.2013.846450
PG 11
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA AC7TX
UT WOS:000332735900005
PM 24605767
DA 2023-08-21
ER

PT J
AU Valbuena, G
   Halliday, H
   Borisevich, V
   Goez, Y
   Rockx, B
AF Valbuena, Gustavo
   Halliday, Hailey
   Borisevich, Viktoriya
   Goez, Yenny
   Rockx, Barry
TI A Human Lung Xenograft Mouse Model of Nipah Virus Infection
SO PLOS PATHOGENS
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; HENIPAVIRUS INFECTION; ENDOTHELIAL-CELLS;
   SCID MICE; IN-VIVO; BANGLADESH; PATHOGENESIS; MALAYSIA; TRANSMISSION;
   ENCEPHALITIS
AB Nipah virus (NiV) is a member of the genus Henipavirus (family Paramyxoviridae) that causes severe and often lethal respiratory illness and encephalitis in humans with high mortality rates (up to 92%). NiV can cause Acute Lung Injury (ALI) in humans, and human-to-human transmission has been observed in recent outbreaks of NiV. While the exact route of transmission to humans is not known, we have previously shown that NiV can efficiently infect human respiratory epithelial cells. The molecular mechanisms of NiV-associated ALI in the human respiratory tract are unknown. Thus, there is an urgent need for models of henipavirus infection of the human respiratory tract to study the pathogenesis and understand the host responses. Here, we describe a novel human lung xenograft model in mice to study the pathogenesis of NiV. Following transplantation, human fetal lung xenografts rapidly graft and develop mature structures of adult lungs including cartilage, vascular vessels, ciliated pseudostratified columnar epithelium, and primitive "air'' spaces filled with mucus and lined by cuboidal to flat epithelium. Following infection, NiV grows to high titers (10(7) TCID50/gram lung tissue) as early as 3 days post infection (pi). NiV targets both the endothelium as well as respiratory epithelium in the human lung tissues, and results in syncytia formation. NiV infection in the human lung results in the production of several cytokines and chemokines including IL-6, IP-10, eotaxin, G-CSF and GM-CSF on days 5 and 7 pi. In conclusion, this study demonstrates that NiV can replicate to high titers in a novel in vivo model of the human respiratory tract, resulting in a robust inflammatory response, which is known to be associated with ALI. This model will facilitate progress in the fundamental understanding of henipavirus pathogenesis and virus-host interactions; it will also provide biologically relevant models for other respiratory viruses.
C1 [Valbuena, Gustavo; Halliday, Hailey; Borisevich, Viktoriya; Goez, Yenny; Rockx, Barry] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555, United States.
C1 [Valbuena, Gustavo; Borisevich, Viktoriya; Rockx, Barry] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555, United States.
C1 [Rockx, Barry] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555, United States.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston; University of Texas System; University of Texas
   Medical Branch Galveston
RP Rockx, B (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
EM barry.rockx@utmb.edu
OI Rockx, Barry/0000-0003-2463-027X
FU Department of Pathology, University of Texas Medical Branch; Institute
   of Human Infections and Immunity, University of Texas Medical Branch;
   NIAID/NIH [U54 AI057156]
FX This study was financially supported by start-up funds by the Department
   of Pathology and Institute of Human Infections and Immunity, University
   of Texas Medical Branch to BR and by NIAID/NIH U54 AI057156 to GV. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the RCE Programs Office,
   NIAID, or NIH. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abele-Ohl S, 2012, AM J TRANSPLANT, V12, P1720, DOI 10.1111/j.1600-6143.2012.04018.x
   Baskin CR, 2009, P NATL ACAD SCI USA, V106, P3455, DOI 10.1073/pnas.0813234106
   Bossart KN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004241
   Bossart KN, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000642
   Calderon VE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063331
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Chua KB, 1999, LANCET, V354, P1257, DOI 10.1016/S0140-6736(99)04299-3
   Clayton BA, 2012, EMERG INFECT DIS, V18, P1983, DOI 10.3201/eid1812.120875
   DeBuysscher BL, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002024
   Dhondt KP, 2013, J INFECT DIS, V207, P142, DOI 10.1093/infdis/jis653
   Dups J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040308
   Erbar S, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-142
   Escaffre O, 2013, J INFECT DEV COUNTR, V7, P308, DOI 10.3855/jidc.3648
   Gao RB, 2013, AM J PATHOL, V183, P1258, DOI 10.1016/j.ajpath.2013.06.023
   Geisbert TW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010690
   Gurley ES, 2007, EMERG INFECT DIS, V13, P1031, DOI 10.3201/eid1307.061128
   Headley AS, 1997, CHEST, V111, P1306, DOI 10.1378/chest.111.5.1306
   Hossain MJ, 2008, CLIN INFECT DIS, V46, P977, DOI 10.1086/529147
   Hsu VP, 2004, EMERG INFECT DIS, V10, P2082, DOI 10.3201/eid1012.040701
   Kollmann TR, 1996, P NATL ACAD SCI USA, V93, P3126, DOI 10.1073/pnas.93.7.3126
   Lo MK, 2010, VIROLOGY, V404, P78, DOI 10.1016/j.virol.2010.05.005
   Maisner A, 2009, THROMB HAEMOSTASIS, V102, P1014, DOI 10.1160/TH09-05-0310
   Mathieu C, 2011, J VIROL, V85, P7863, DOI 10.1128/JVI.00549-11
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Paton NI, 1999, LANCET, V354, P1253, DOI 10.1016/S0140-6736(99)04379-2
   Podesta JE, 2009, SMALL, V5, P1176, DOI 10.1002/smll.200801572
   Rockx B, 2012, ANTIVIR RES, V95, P135, DOI 10.1016/j.antiviral.2012.05.008
   Rockx B, 2011, J VIROL, V85, P7658, DOI 10.1128/JVI.00473-11
   Rockx B, 2009, J VIROL, V83, P7062, DOI 10.1128/JVI.00127-09
   Savidge TC, 2003, GASTROENTEROLOGY, V125, P413, DOI 10.1016/S0016-5085(03)00902-8
   SAVIDGE TC, 1995, DIFFERENTIATION, V58, P361, DOI 10.1046/j.1432-0436.1995.5850361.x
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248
   Wong KT, 2003, AM J PATHOL, V163, P2127, DOI 10.1016/S0002-9440(10)63569-9
   Wong KT, 2002, AM J PATHOL, V161, P2153, DOI 10.1016/S0002-9440(10)64493-8
NR 36
TC 31
Z9 32
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2014
VL 10
IS 4
AR e1004063
DI 10.1371/journal.ppat.1004063
PG 11
WC Microbiology; Parasitology; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microbiology; Parasitology; Virology
GA AP4FW
UT WOS:000342033600029
PM 24699832
OA Green Submitted, Green Published, gold
DA 2023-08-21
ER

PT J
AU Howard, MD
   Greineder, CF
   Hood, ED
   Muzykantov, VR
AF Howard, Melissa D.
   Greineder, Colin F.
   Hood, Elizabeth D.
   Muzykantov, Vladimir R.
TI Endothelial targeting of liposomes encapsulating SOD/catalase mimetic
   EUK-134 alleviates acute pulmonary inflammation
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Targeted drug delivery; Endothelial targeting; liposome; Inflammation; Antioxidant therapy; Antioxidant enzyme mimetic 
ID ANGIOTENSIN-CONVERTING ENZYME; CELL-ADHESION MOLECULE-1; ISCHEMIC
   BRAIN-INJURY; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; VASCULAR
   ENDOTHELIUM; N-ACETYLCYSTEINE; NADPH OXIDASES; IN-VIVO; CATALASE
AB Production of excessive levels of reactive oxygen species (ROS) in the vascular endothelium is a common pathogenic pathway in many dangerous conditions, including acute lung injury, ischemia-reperfusion, and inflammation. Ineffective delivery of antioxidants to the endothelium limits their utility for management of these conditions. In this study, we devised a novel translational antioxidant intervention targeted to the vascular endothelium using PEG-liposomes loaded with EUK-134 (EUK), a potent superoxide dismutase/catalasemimetic. EUK loaded into antibody-coated liposomes (size 197.8 +/- 4.5 nm diameter, PDI 0.179 +/- 0.066) exerted partial activity in the intact carrier, while full activity was recovered upon liposome disruption. For targeting we used antibodies (Abs) to platelet-endothelial cell adhesion molecule (PECAM-1). Both streptavidin-biotin and SATA/SMCC conjugation chemistries provided binding of 125-150 Ab molecules per liposome. Ab/EUK/liposomes, but not IgG/EUK/liposomes: i) bound to endothelial cells and inhibited cytokine-induced inflammatory activation in vitro; and, ii) accumulated in lungs after intravascular injection, providing >60% protection against pulmonary edema in endotoxin-challenged mice (vs <6% protection afforded by IgG/liposome/EUK counterpart). Since the design elements of this drug delivery system are already in clinical use (PEG-liposomes, antibodies, SATA/SMCC conjugation), it is an attractive candidate for translational interventions using antioxidant molecules such as EUK and other clinically acceptable drugs. (C) 2014 Elsevier B. V. All rights reserved.
C1 [Howard, Melissa D.; Greineder, Colin F.; Hood, Elizabeth D.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104, United States.
C1 [Howard, Melissa D.; Greineder, Colin F.; Hood, Elizabeth D.; Muzykantov, Vladimir R.] Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Philadelphia, PA 19104, United States.
C1 [Greineder, Colin F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104, United States.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; University of Pennsylvania; Pennsylvania Medicine
RP Muzykantov, VR (corresponding author), Univ Penn, Perelman Sch Med, Dept Pharmacol, TRC10-125,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
OI Greineder, Colin/0000-0001-9740-7672
FU NIH NHLBI [HL087036, HL073940]; University of Pennsylvania Hematology
   T32 Training Grant [T32 HL07439]
FX This work was supported by NIH NHLBI grants HL087036 and HL073940. MH
   acknowledges financial support from the University of Pennsylvania
   Hematology T32 Training Grant (Grant number T32 HL07439).
CR Adrian JE, 2010, J CONTROL RELEASE, V144, P341, DOI 10.1016/j.jconrel.2010.03.003
   Baker K, 1998, J PHARMACOL EXP THER, V284, P215
   Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876
   Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164
   Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   Ding BS, 2006, MOL INTERV, V6, P98, DOI 10.1124/mi.6.2.7
   Fisher AB, 2009, ANTIOXID REDOX SIGN, V11, P1349, DOI [10.1089/ars.2008.2378, 10.1089/ARS.2008.2378]
   FLAHERTY JT, 1994, CIRCULATION, V89, P1982, DOI 10.1161/01.CIR.89.5.1982
   Guzik TJ, 2006, DRUG DISCOV TODAY, V11, P524, DOI 10.1016/j.drudis.2006.04.003
   Han JY, 2012, ACS NANO, V6, P8824, DOI 10.1021/nn302687n
   Han JY, 2011, J PHARMACOL EXP THER, V338, P82, DOI 10.1124/jpet.111.180620
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Hood ED, 2012, J CONTROL RELEASE, V163, P161, DOI 10.1016/j.jconrel.2012.08.031
   Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011
   Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806
   Manickam DS, 2012, J CONTROL RELEASE, V162, P636, DOI 10.1016/j.jconrel.2012.07.044
   MARUYAMA K, 1990, J PHARM SCI, V79, P978, DOI 10.1002/jps.2600791107
   Mitsopoulos P, 2008, INT J PHARMACEUT, V363, P106, DOI 10.1016/j.ijpharm.2008.07.015
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213
   Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2
   Muzykantov VR, 1996, AM J PHYSIOL-LUNG C, V270, pL704, DOI 10.1152/ajplung.1996.270.5.L704
   Nowak K, 2007, AM J PHYSIOL-LUNG C, V293, pL162, DOI 10.1152/ajplung.00001.2007
   Park W, 2009, BIOORG MED CHEM LETT, V19, P614, DOI 10.1016/j.bmcl.2008.12.063
   Riley DP, 1999, CHEM REV, V99, P2573, DOI 10.1021/cr980432g
   Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897
   Shuvaev VV, 2007, J PHARMACOL EXP THER, V323, P450, DOI 10.1124/jpet.107.127126
   Shuvaev VV, 2011, J CONTROL RELEASE, V153, P56, DOI 10.1016/j.jconrel.2011.03.022
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877
   Supinski GS, 2006, AM J RESP CRIT CARE, V173, P1240, DOI 10.1164/rccm.200410-1346OC
   Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027
   van der Vliet A, 2008, FREE RADICAL BIO MED, V44, P938, DOI 10.1016/j.freeradbiomed.2007.11.016
   Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302
NR 39
TC 73
Z9 76
U1 0
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 10
PY 2014
VL 177
BP 34
EP 41
DI 10.1016/j.jconrel.2013.12.035
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA AC3CQ
UT WOS:000332393000005
PM 24412573
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Aggarwal, S
   Gross, CM
   Kumar, S
   Dimitropoulou, C
   Sharma, S
   Gorshkov, BA
   Sridhar, S
   Lu, Q
   Bogatcheva, NV
   Jezierska-Drutel, AJ
   Lucas, R
   Verin, AD
   Catravas, JD
   Black, SM
AF Aggarwal, Saurabh
   Gross, Christine M.
   Kumar, Sanjiv
   Dimitropoulou, Christiana
   Sharma, Shruti
   Gorshkov, Boris A.
   Sridhar, Supriya
   Lu, Qing
   Bogatcheva, Natalia V.
   Jezierska-Drutel, Agnieszka J.
   Lucas, Rudolf
   Verin, Alexander D.
   Catravas, John D.
   Black, Stephen M.
TI Dimethylarginine Dimethylaminohydrolase II Overexpression Attenuates
   LPS-Mediated Lung Leak in Acute Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE dimethylarginine dimethylaminohydrolase II; asymmetric dimethylarginine; nitrative stress; ALI/ARDS; gene delivery 
ID NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ASYMMETRIC DIMETHYLARGININE;
   ENDOTHELIAL BARRIER; DDAH/ADMA PATHWAY; MOUSE MODEL; IN-VIVO; INHIBITOR;
   CELLS; LIPOPOLYSACCHARIDE
AB Acute lung injury (ALI) is a severe hypoxemic respiratory insufficiency associated with lung leak, diffuse alveolar damage, inflammation, and loss of lung function. Decreased dimethylaminohydrolase (DDAH) activity and increases in asymmetric dimethylarginine (ADMA), together with exaggerated oxidative/nitrative stress, contributes to the development of ALI in mice exposed to LPS. Whether restoring DDAH function and suppressing ADMA levels can effectively ameliorate vascular hyperpermeability and lung injury in ALI is unknown, and was the focus of this study. In human lung microvascular endothelial cells, DDAH II overexpression prevented the LPSdependent increase in ADMA, superoxide, peroxynitrite, and protein nitration. DDAH II also attenuated the endothelial barrier disruption associated with LPS exposure. Similarly, in vivo, we demonstrated that the targeted overexpression of DDAH II in the pulmonary vasculature significantly inhibited the accumulation of ADMA and the subsequent increase in oxidative/nitrative stress in the lungs of mice exposed to LPS. In addition, augmenting pulmonary DDAH II activity before LPS exposure reduced lung vascular leak and lung injury and restored lung function when DDAH activity was increased after injury. Together, these data suggest that enhancing DDAH II activity may prove a useful adjuvant therapy to treat patients with ALI.
C1 [Aggarwal, Saurabh; Gross, Christine M.; Kumar, Sanjiv; Dimitropoulou, Christiana; Sharma, Shruti; Gorshkov, Boris A.; Sridhar, Supriya; Lu, Qing; Bogatcheva, Natalia V.; Jezierska-Drutel, Agnieszka J.; Lucas, Rudolf; Verin, Alexander D.; Catravas, John D.; Black, Stephen M.] Georgia Regents Univ, Vasc Biol Ctr, Pulm Dis Program, Augusta, GA 30912, United States.
C3 University System of Georgia; Augusta University
RP Black, SM (corresponding author), Georgia Regents Univ, Vasc Biol Ctr, 1459 Laney Walker Blvd,CB 3211-B, Augusta, GA 30912 USA.
EM sblack@gru.edu
RI Lucas, Rudolf/ABA-3011-2020
OI Bogatcheva, Natalia/0000-0002-5177-5872; Verin,
   Alexander/0000-0003-0627-7185; Lu, Qing/0000-0002-1000-3884; Lucas,
   Rudolf/0000-0003-3805-8868; Black, Stephen M./0000-0002-4524-6544;
   Sharma, Shruti/0000-0001-8200-108X
FU National Institutes of Health [P01HL0101902, HL60190, HL67841,
   HL094609]; American Heart Association [12PRE12060224]
FX This work was supported in part by National Institutes of Health grants
   P01HL0101902, HL60190, and HL67841. C. M. G. is funded in part by
   American Heart Association predoctoral Fellowship award 12PRE12060224.
   R. L. is funded in part by National Institutes of Health grant HL094609.
CR Abdih H, 2000, EUR SURG RES, V32, P347, DOI 10.1159/000052216
   Aggarwal S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00161
   Aggarwal S, 2011, J CELL PHYSIOL, V226, P3104, DOI 10.1002/jcp.22692
   Ahmad T, 2010, AM J RESP CELL MOL, V42, P3, DOI 10.1165/rcmb.2009-0137RC
   Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057
   Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300
   Antonicelli F, 2004, AM J PHYSIOL-LUNG C, V286, pL1319, DOI 10.1152/ajplung.00329.2003
   Boger RH, 2004, J NUTR, V134, p2842S, DOI 10.1093/jn/134.10.2842S
   Boger RH, 2000, SEMIN THROMB HEMOST, V26, P539, DOI 10.1055/s-2000-13210
   Boger RH, 2003, CLIN CHEM LAB MED, V41, P1467, DOI 10.1515/CCLM.2003.225
   Boger RH, 2003, CARDIOVASC RES, V59, P824, DOI 10.1016/S0008-6363(03)00500-5
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cardounel AJ, 2007, J BIOL CHEM, V282, P879, DOI 10.1074/jbc.M603606200
   Catravas JD, 2010, VASC PHARMACOL, V52, P175, DOI 10.1016/j.vph.2009.12.009
   Chen XM, 2013, INT IMMUNOPHARMACOL, V16, P322, DOI 10.1016/j.intimp.2013.04.009
   Eid HMA, 2007, ATHEROSCLEROSIS, V194, pE1, DOI 10.1016/j.atherosclerosis.2006.11.008
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Gonzalez-Rey E, 2006, J EXP MED, V203, P563, DOI 10.1084/jem.20052017
   Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062
   Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092
   Janardhan KS, 2006, FRONT BIOSCI-LANDMRK, V11, P1569, DOI 10.2741/1904
   Klein E, 2010, AM J PHYSIOL-LUNG C, V299, pL816, DOI 10.1152/ajplung.00188.2010
   Lange M, 2012, EXP LUNG RES, V38, P157, DOI 10.3109/01902148.2012.663453
   Leiper J, 2002, P NATL ACAD SCI USA, V99, P13527, DOI 10.1073/pnas.212269799
   Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67
   Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6
   Matsumoto K, 1998, NEPHRON, V78, P403, DOI 10.1159/000044968
   Matute-Bello G, 2001, AM J PATHOL, V158, P153, DOI 10.1016/S0002-9440(10)63953-3
   Mundy AL, 2000, BRIT J ANAESTH, V85, P570, DOI 10.1093/bja/85.4.570
   MURPHY TL, 1995, MOL CELL BIOL, V15, P5258
   Nagase T, 2003, AM J PHYSIOL-LUNG C, V284, pL720, DOI 10.1152/ajplung.00396.2002
   Okamoto I, 2000, AM J RESP CRIT CARE, V162, P716, DOI 10.1164/ajrccm.162.2.9907039
   Poirier C, 2011, RESP PHYSIOL NEUROBI, V179, P334, DOI 10.1016/j.resp.2011.08.012
   Pope AJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1679, DOI 10.1152/ajpcell.00224.2007
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Pullamsetti SS, 2011, CIRCULATION, V123, P1194, DOI 10.1161/CIRCULATIONAHA.110.941484
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Scalera F, 2004, ARTERIOSCL THROM VAS, V24, P1816, DOI 10.1161/01.ATV.0000141843.77133.fc
   Sharma S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041555
   Sharma S, 2010, VASC PHARMACOL, V52, P182, DOI 10.1016/j.vph.2009.11.010
   Son YH, 2008, J CARDIOVASC PHARM, V51, P71, DOI 10.1097/FJC.0b013e31815bd23d
   Sousse LE, 2011, SHOCK, V35, P282, DOI 10.1097/SHK.0b013e3181fddd82
   Sud N, 2008, AM J PHYSIOL-CELL PH, V294, pC1407, DOI 10.1152/ajpcell.00384.2007
   Sun XT, 2013, ANTIOXID REDOX SIGN, V18, P1739, DOI 10.1089/ars.2012.4806
   Tran CTL, 2003, ATHEROSCLEROSIS SUPP, V4, P33, DOI 10.1016/S1567-5688(03)00032-1
   Vallance P, 2004, ARTERIOSCL THROM VAS, V24, P1023, DOI 10.1161/01.ATV.0000128897.54893.26
   Waschke J, 2004, AM J PHYSIOL-HEART C, V286, pH394, DOI 10.1152/ajpheart.00221.2003
   Wojciak-Stothard B, 2007, J CELL SCI, V120, P929, DOI 10.1242/jcs.002212
   Xin HY, 2007, THROMB HAEMOSTASIS, V97, P830, DOI 10.1160/TH06-11-0656
   Yakovlev VA, 2007, BIOCHEMISTRY-US, V46, P11671, DOI 10.1021/bi701107z
NR 50
TC 35
Z9 39
U1 1
U2 6
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAR
PY 2014
VL 50
IS 3
BP 614
EP 625
DI 10.1165/rcmb.2013-0193OC
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AC4TJ
UT WOS:000332513500014
PM 24134589
OA Green Published
DA 2023-08-21
ER

PT J
AU Stephens, RS
   Servinsky, LE
   Rentsendorj, O
   Kolb, TM
   Pfeifer, A
   Pearse, DB
AF Stephens, R. Scott
   Servinsky, Laura E.
   Rentsendorj, Otgonchimeg
   Kolb, Todd M.
   Pfeifer, Alexander
   Pearse, David B.
TI Protein kinase G increases antioxidant function in lung microvascular
   endothelial cells by inhibiting the c-Abl tyrosine kinase
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; oxidant injury; protein kinase G; c-Abl 
ID GROWTH-FACTOR RECEPTOR; OXIDATIVE STRESS; CYCLIC-GMP; BARRIER
   DYSFUNCTION; NATRIURETIC-PEPTIDE; REPERFUSION INJURY; IMATINIB MESYLATE;
   CELLULAR-RESPONSE; DEATH RESPONSE; DNA-DAMAGE
AB Oxidant injury contributes to acute lung injury (ALI). We previously reported that activation of protein kinase G(I) (PKG(I)) posttranscriptionally increased the key antioxidant enzymes catalase and glutathione peroxidase 1 (Gpx-1) and attenuated oxidant-induced cytotoxicity in mouse lung microvascular endothelial cells (MLMVEC). The present studies tested the hypothesis that the antioxidant effect of PKG(I) is mediated via inhibition of the c-Abl tyrosine kinase. We found that activation of PKG(I) with the cGMP analog 8pCPT-cGMP inhibited c-Abl activity and decreased c-Abl expression in wild-type but not PKG(I)(-/-) MLMVEC. Treatment of wild-type MLMVEC with atrial natriuretic peptide also inhibited c-Abl activation. Moreover, treatment of MLMVEC with the c-Abl inhibitor imatinib increased catalase and GPx-1 protein in a posttranscriptional fashion. In imatinib-treated MLMVEC, there was no additional effect of 8pCPT-cGMP on catalase or GPx-1. The imatinib-induced increase in antioxidant proteins was associated with an increase in extracellular H2O2 scavenging by MLMVEC, attenuation of oxidant-induced endothelial barrier dysfunction, and prevention of oxidant-induced endothelial cell death. Finally, in the isolated perfused lung, imatinib prevented oxidant-induced endothelial toxicity. We conclude that cGMP, through activation of PKG(I), inhibits c-Abl, leading to increased key antioxidant enzymes and resistance to lung endothelial oxidant injury. Inhibition of c-Abl by active PKG(I) may be the downstream mechanism underlying PKG(I)-mediated antioxidant signaling. Tyrosine kinase inhibitors may represent a novel therapeutic approach in oxidant-induced ALI.
C1 [Stephens, R. Scott; Servinsky, Laura E.; Rentsendorj, Otgonchimeg; Kolb, Todd M.; Pearse, David B.] Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD, United States.
C1 [Pfeifer, Alexander] Univ Bonn, Inst Pharmacol & Toxicol, Bonn, Germany.
C1 [Pfeifer, Alexander] Univ Bonn, Biomed Ctr, Bonn, Germany.
C3 Johns Hopkins University; University of Bonn; University of Bonn
RP Stephens, RS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle,4th Floor, Baltimore, MD 21224 USA.
EM rsteph13@jhmi.edu
RI Kolb, Todd/ABD-8204-2020
FU National Heart, Lung, and Blood Institute [HL-067189]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grant HL-067189 (to D. B. Pearse).
CR Agami R, 1999, NATURE, V399, P809
   Akashi N, 2011, MOD RHEUMATOL, V21, P267, DOI 10.1007/s10165-010-0392-5
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Awazu M, 1997, KIDNEY INT, V52, P356, DOI 10.1038/ki.1997.341
   Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200
   Bruecher-Encke B, 2001, LEUKEMIA, V15, P1424, DOI 10.1038/sj.leu.2402214
   Buchdunger E, 2002, EUR J CANCER, V38, pS28, DOI 10.1016/S0959-8049(02)80600-1
   Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200
   Cao C, 2003, BIOCHEMISTRY-US, V42, P10348, DOI 10.1021/bi035023f
   Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200
   Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003
   Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6
   Conforti F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.27
   Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6
   Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8
   Das A, 2006, J BIOL CHEM, V281, P38644, DOI 10.1074/jbc.M606142200
   Dodd-O JM, 2008, AM J PHYSIOL-LUNG C, V294, pL714, DOI 10.1152/ajplung.00185.2007
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280
   Huang P, 2009, FASEB J, V23, P2539, DOI 10.1096/fj.09-129833
   Jacob M, 2009, CELL SIGNAL, V21, P1308, DOI 10.1016/j.cellsig.2009.03.016
   Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898
   Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7
   Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806
   Kumar S, 2003, MOL PHARMACOL, V63, P276, DOI 10.1124/mol.63.2.276
   Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200
   LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965
   Lee JC, 2011, CLIN CHEST MED, V32, P279, DOI 10.1016/j.ccm.2011.02.007
   Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624
   Li ML, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-66
   Lunghi P, 2009, CLIN CANCER RES, V15, P6495, DOI 10.1158/1078-0432.CCR-09-1229
   Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Motiwala T, 2009, J BIOL CHEM, V284, P455, DOI 10.1074/jbc.M802840200
   Pearse DB, 2003, ENDOTHELIUM-J ENDOTH, V10, P309, DOI 10.1080/10623320390272307
   Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045
   Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48
   PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086
   Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004
   Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2
   Polte T, 1997, FEBS LETT, V409, P46, DOI 10.1016/S0014-5793(97)00480-8
   Raina D, 2002, MOL PHARMACOL, V61, P1489, DOI 10.1124/mol.61.6.1489
   Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877
   Stephens RS, 2010, AM J PHYSIOL-LUNG C, V299, pL323, DOI 10.1152/ajplung.00442.2009
   Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200
   Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457
   Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200
   Tang PS, 2008, AM J PHYSIOL-LUNG C, V294, pL632, DOI 10.1152/ajplung.00262.2007
   VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325
   Vittal R, 2007, J PHARMACOL EXP THER, V321, P35, DOI 10.1124/jpet.106.113407
   Wang L, 2010, EUR RESP J
   Weiss ES, 2009, J THORAC CARDIOV SUR, V137, P1249, DOI 10.1016/j.jtcvs.2008.12.040
   Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622
   Xing HY, 2012, LEUKEMIA RES, V36, P509, DOI 10.1016/j.leukres.2011.12.018
   Xu JY, 2010, BLOOD, V115, P2709, DOI 10.1182/blood-2009-05-223776
   Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704
   Zhu B, 2009, AM J PHYSIOL-LUNG C, V296, pL220, DOI 10.1152/ajplung.90474.2008
   Zhuang D, 2005, AM J PHYSIOL-HEART C, V288, pH1859, DOI 10.1152/ajpheart.01031.2004
NR 62
TC 19
Z9 20
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD MAR
PY 2014
VL 306
IS 6
BP C559
EP C569
DI 10.1152/ajpcell.00375.2012
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA AD5YV
UT WOS:000333330400007
PM 24401847
OA Green Published
DA 2023-08-21
ER

PT J
AU Wang, ZJ
   Li, J
   Cho, J
   Malik, AB
AF Wang, Zhenjia
   Li, Jing
   Cho, Jaehyung
   Malik, Asrar B.
TI Prevention of vascular inflammation by nanoparticle targeting of
   adherent neutrophils
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID FC-GAMMA RECEPTOR; EXPRESSION; MONOCYTES; INTEGRIN; DELIVERY; THERAPY;
   DISEASE; INJURY
AB Inflammatory diseases such as acute lung injury and ischaemic tissue injury are caused by the adhesion of a type of white blood cell-polymorphonuclear neutrophils-to the lining of the circulatory system or vascular endothelium and unchecked neutrophil transmigration(1),(2). Nanoparticle-mediated targeting of activated neutrophils on vascular endothelial cells at the site of injury may be a useful means of directly inactivating neutrophil transmigration and hence mitigating vascular inflammation(3). Here, we report a method employing drug-loaded albumin nanoparticles, which efficiently deliver drugs into neutrophils adherent to the surface of the inflamed endothelium. Using intravital microscopy of tumour necrosis factor-a-challenged mouse cremaster post-capillary venules, we demonstrate that fluorescently tagged albumin nanoparticles are largely internalized by neutrophils adherent to the activated endothelium via cell surface Fc gamma receptors. Administration of albumin nanoparticles loaded with the spleen tyrosine kinase inhibitor, piceatannol, which blocks `outside- in' beta 2 integrin signalling in leukocytes, detached the adherent neutrophils and elicited their release into the circulation. Thus, internalization of drug-loaded albumin nanoparticles into neutrophils inactivates the pro-inflammatory function of activated neutrophils, thereby offering a promising approach for treating inflammatory diseases resulting from inappropriate neutrophil sequestration and activation.
C1 [Wang, Zhenjia; Li, Jing; Cho, Jaehyung; Malik, Asrar B.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Wang, Zhenjia; Cho, Jaehyung; Malik, Asrar B.] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C1 [Cho, Jaehyung] Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Malik, AB (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.
EM abmalik@uic.edu
OI Malik, Asrar/0000-0002-8205-7128; Cho, Jaehyung/0000-0003-2404-3446
FU American Heart Association [11SDG7490013]; National Institutes of Health
   [K25HL111157, R01 HL109439, P01 P01HL77806]
FX This work was supported by grant no. 11SDG7490013 from the American
   Heart Association and National Institutes of Health grants K25HL111157
   to Z. W., R01 HL109439 to J.C. and P01 P01HL77806 to A.B.M.
CR BULL HB, 1978, BIOPOLYMERS, V17, P2121, DOI 10.1002/bip.1978.360170907
   Chen K, 2012, BLOOD, V120, P4421, DOI 10.1182/blood-2011-12-401133
   Evans R, 2011, BLOOD, V117, P3331, DOI 10.1182/blood-2010-06-289140
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   GEAHLEN RL, 1989, BIOCHEM BIOPH RES CO, V165, P241, DOI 10.1016/0006-291X(89)91060-7
   Hahm E, 2013, BLOOD, V121, P3789, DOI 10.1182/blood-2012-11-467985
   Hidalgo A, 2009, NAT MED, V15, P384, DOI 10.1038/nm.1939
   Hu GC, 2010, CRIT CARE MED, V38, P194, DOI 10.1097/CCM.0b013e3181bc7c17
   INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389
   LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681
   Lockwood CM, 1999, CLIN IMMUNOL, V93, P93, DOI 10.1006/clim.1999.4764
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Nakatani K, 1999, CLIN EXP IMMUNOL, V117, P418
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   SHARAR SR, 1991, SURGERY, V110, P213
   Sumagin R, 2010, J IMMUNOL, V185, P7057, DOI 10.4049/jimmunol.1001638
   Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720
   Wagner DD, 2008, BLOOD, V111, P5271, DOI 10.1182/blood-2008-01-078204
   Wang ZJ, 2011, IUBMB LIFE, V63, P659, DOI 10.1002/iub.485
   Wang ZJ, 2009, ACS NANO, V3, P4110, DOI 10.1021/nn9012274
   Weber C, 2000, INT J PHARM, V196, P197, DOI 10.1016/S0378-5173(99)00420-2
   Wisel S, 2009, J PHARMACOL EXP THER, V329, P543, DOI 10.1124/jpet.109.150839
   Wong CHY, 2010, CARDIOVASC RES, V86, P183, DOI 10.1093/cvr/cvq040
   Xu JS, 2008, NAT IMMUNOL, V9, P880, DOI 10.1038/ni.1628
   Zarbock A, 2007, IMMUNITY, V26, P773, DOI 10.1016/j.immuni.2007.04.011
NR 27
TC 201
Z9 205
U1 10
U2 178
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD MAR
PY 2014
VL 9
IS 3
BP 204
EP 210
DI 10.1038/NNANO.2014.17
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA AC6MI
UT WOS:000332637200014
PM 24561355
OA Green Accepted
DA 2023-08-21
ER

PT J
AU You, QH
   Zhang, D
   Niu, CC
   Zhu, ZM
   Wang, N
   Yue, Y
   Sun, GY
AF You, Qing-hai
   Zhang, Dan
   Niu, Cheng-cheng
   Zhu, Zhong-ming
   Wang, Nan
   Yue, Yang
   Sun, Geng-yun
TI Expression of IL-17A and IL-17F in lipopolysaccharide-induced acute lung
   injury and the counteraction of anisodamine or methylprednisolone
SO CYTOKINE
LA English
DT Article
DE ALI/ARDS; LPS; cytokines; Interleukin-17; ECs/HPMECs/HUVECs/MPVECs 
ID MICROVASCULAR ENDOTHELIAL-CELLS; RESPIRATORY-DISTRESS-SYNDROME;
   RANDOMIZED CONTROLLED-TRIAL; AND/OR TNF-ALPHA; AT(1) RECEPTOR; TH17
   CYTOKINES; CSF PRODUCTION; PATHWAY; INFLAMMATION; INTERLEUKIN-17
AB Th17 cytokines IL-17A and IL-17F as pro-inflammatory cytokines played an important role in triggering inflammatory responses. However, little was known about the expression of IL-17A and IL-17F in acute lung injury (ALI). Therefore, the present study investigated the expression of IL-17A and IL-17F in lipopolysaccharide (LPS)-induced ALI in rats and rat pulmonary microvascular endothelial cells (PMVEC) by enzyme-linked immunosorbant assay or reverse transcription-polymerase chains reaction. Anisodamine and methylprednisolone were also investigated as anti-inflammatory strategy in the process of LPS-induced ALI. Lung injury was evaluated by histological changes, right lung wet weight:body weight (LW/BW) ratios, and protein education and total leukocyte count of bronchoalveolar lavage fluid (BALF). Our findings showed that LPS exposure elevated the levels of leukocyte number, protein education in BALF and the ratios of LW/BW, increased the expression of IL-17A and IL-17F in the lung tissues homogenate, BALF and serum of ALL rats. Up-regulation of IL-17F expression was also observed after LPS challenge in rat PMVEC. Treatment with anisodamine or methylprednisolone significantly inhibited the increases of parameters of ALI induced by LPS, and markedly reduced the expression of IL-17A and IL17F in rats and the IL-17F expression in PMVEC. These data suggested that IL-17A and IL-17F maybe play an important role in LPS-induced ALI via autocrine and paracrine mechanisms, and anisodamine is similar in extent to methylprednisolone that contributes to relieve LPS-induced ALI. (c) 2014 Elsevier Ltd. All rights reserved.
C1 [You, Qing-hai; Zhang, Dan; Zhu, Zhong-ming; Wang, Nan; Yue, Yang; Sun, Geng-yun] Anhui Med Univ, Affiliated Hosp 1, Dept Resp Med, Hefei 230022, Anhui, China.
C1 [Zhang, Dan; Wang, Nan] Anhui Med Univ, Affiliated Hosp 1, Dept Emergency, Hefei 230022, Anhui, China.
C1 [Niu, Cheng-cheng] Anhui Med Univ, Affiliated Hosp 1, Dept Nurse, Hefei 230022, Anhui, China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University
RP Sun, GY (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Resp Med, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
EM sungengy@126.com
FU National Natural Science Foundation of China [81100053, 81070054]
FX This work was supported by a Grant from the National Natural Science
   Foundation of China (Nos. 81100053, 81070054).
CR Botero JE, 2008, ORAL MICROBIOL IMMUN, V23, P291, DOI 10.1111/j.1399-302X.2007.00427.x
   Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005
   Crimi Ettore, 2004, Best Pract Res Clin Anaesthesiol, V18, P477, DOI 10.1016/S1521-6896(03)00121-6
   Dzierzewicz Z, 2003, FEMS MICROBIOL LETT, V219, P69, DOI 10.1016/S0378-1097(02)01199-0
   Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106
   Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x
   Fujie H, 2012, INFLAMMATION, V35, P1119, DOI 10.1007/s10753-011-9419-0
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Hoshino A, 2008, J AUTOIMMUN, V31, P79, DOI 10.1016/j.jaut.2008.03.006
   Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P444, DOI 10.1016/j.jaci.2004.03.047
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Li Q, 2011, LIFE SCI, V89, P395, DOI 10.1016/j.lfs.2011.07.008
   Liu C, 2009, CRIT CARE MED, V37, P634, DOI 10.1097/CCM.0b013e31819598f5
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014
   Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159
   Miyamoto M, 2003, J IMMUNOL, V170, P4665, DOI 10.4049/jimmunol.170.9.4665
   Nakajima T, 2010, J IMMUNOL, V184, P5835, DOI 10.4049/jimmunol.0903238
   Numasaki M, 2004, IMMUNOL LETT, V95, P175, DOI 10.1016/j.imlet.2004.07.002
   Numasaki M, 2004, IMMUNOL LETT, V95, P97, DOI 10.1016/j.imlet.2004.06.010
   Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Prause O, 2009, PULM PHARMACOL THER, V22, P199, DOI 10.1016/j.pupt.2008.12.005
   Ruan QR, 2001, J VASC RES, V38, P13, DOI 10.1159/000051025
   RUIJUAN X, 1982, JAMA-J AM MED ASSOC, V247, P1458, DOI 10.1001/jama.1982.03320350062033
   Takahashi K, 2005, J CLIN PERIODONTOL, V32, P369, DOI 10.1111/j.1600-051X.2005.00676.x
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797
   Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC
   WORTHEN GS, 1987, AM REV RESPIR DIS, V136, P19, DOI 10.1164/ajrccm/136.1.19
   Wu SH, 2008, INFLAMM RES, V57, P430, DOI 10.1007/s00011-008-7147-1
   Wang XQ, 2008, RESPIROLOGY, V13, P772, DOI 10.1111/j.1440-1843.2008.01344.x
   Xu ZP, 2011, INT IMMUNOPHARMACOL, V11, P260, DOI 10.1016/j.intimp.2010.12.001
   Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978
   You QH, 2010, INFLAMM RES, V59, P949, DOI 10.1007/s00011-010-0207-3
   You QH, 2010, J SURG RES, V162, P110, DOI 10.1016/j.jss.2009.01.019
   Zhang F, 2010, CONNECT TISSUE RES, V51, P359, DOI 10.3109/03008200903456942
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
   Zhang H, 2006, J SURG RES, V134, P190, DOI 10.1016/j.jss.2006.01.026
   Zhou Y, 2007, CYTOKINE, V38, P157, DOI 10.1016/j.cyto.2007.06.002
NR 41
TC 29
Z9 40
U1 0
U2 18
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD MAR
PY 2014
VL 66
IS 1
BP 78
EP 86
DI 10.1016/j.cyto.2013.12.019
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA AD8DJ
UT WOS:000333496400011
PM 24548428
DA 2023-08-21
ER

PT J
AU Rafikov, R
   Dimitropoulou, C
   Aggarwal, S
   Kangath, A
   Gross, C
   Pardo, D
   Sharma, S
   Jezierska-Drutel, A
   Patel, V
   Snead, C
   Lucas, R
   Verin, A
   Fulton, D
   Catravas, JD
   Black, SM
AF Rafikov, Ruslan
   Dimitropoulou, Christiana
   Aggarwal, Saurabh
   Kangath, Archana
   Gross, Christine M.
   Pardo, Daniel
   Sharma, Shruti
   Jezierska-Drutel, Agnieszka J.
   Patel, Vijay
   Snead, Connie
   Lucas, Rudolf
   Verin, Alexander D.
   Fulton, David J. R.
   Catravas, John D.
   Black, Stephen M.
TI Lipopolysaccharide- induced Lung Injury Involves the Nitration- mediated
   Activation of RhoA*
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE ALI/ARDS; Post-translational Modification; Protein Structure; Recombinant Protein Expression; Redox Regulation; Superoxide Ion; Enzymology 
ID MICROVASCULAR ENDOTHELIAL-CELLS; TYROSINE NITRATION; CRYSTAL-STRUCTURE;
   NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; PROTEIN NITRATION; BARRIER FUNCTION;
   AIRWAY DISEASE; CDC42; PEROXYNITRITE
AB Background: The activation of RhoA is a critical event in acute lung injury (ALI), but the role of nitration in this process is unresolved. Results: The nitration of RhoA at Tyr(34) produced GEF-like conformational changes that stimulate RhoA by decreasing GDP binding. Conclusion: We have identified a new mechanism of RhoA activation. Significance: Preventing RhoA nitration may be useful for the management of ALI.
   Acute lung injury (ALI) is characterized by increased endothelial hyperpermeability. Protein nitration is involved in the endothelial barrier dysfunction in LPS-exposed mice. However, the nitrated proteins involved in this process have not been identified. The activation of the small GTPase RhoA is a critical event in the barrier disruption associated with LPS. Thus, in this study we evaluated the possible role of RhoA nitration in this process. Mass spectroscopy identified a single nitration site, located at Tyr(34) in RhoA. Tyr(34) is located within the switch I region adjacent to the nucleotide-binding site. Utilizing this structure, we developed a peptide designated NipR1 (nitration inhibitory peptide for RhoA 1) to shield Tyr(34) against nitration. TAT-fused NipR1 attenuated RhoA nitration and barrier disruption in LPS-challenged human lung microvascular endothelial cells. Further, treatment of mice with NipR1 attenuated vessel leakage and inflammatory cell infiltration and preserved lung function in a mouse model of ALI. Molecular dynamics simulations suggested that the mechanism by which Tyr(34) nitration stimulates RhoA activity was through a decrease in GDP binding to the protein caused by a conformational change within a region of Switch I, mimicking the conformational shift observed when RhoA is bound to a guanine nucleotide exchange factor. Stopped flow kinetic analysis was used to confirm this prediction. Thus, we have identified a new mechanism of nitration-mediated RhoA activation involved in LPS-mediated endothelial barrier dysfunction and show the potential utility of shielding peptides to prevent RhoA nitration in the management of ALI.
C1 [Rafikov, Ruslan; Dimitropoulou, Christiana; Aggarwal, Saurabh; Kangath, Archana; Gross, Christine; Pardo, Daniel; Sharma, Shruti; Jezierska-Drutel, Agnieszka; Snead, Connie; Lucas, Rudolf; Verin, Alexander; Fulton, David; Catravas, John D.; Black, Stephen M.] Georgia Regents Univ, Vasc Biol Ctr, Program Pulm Vasc Dis, Augusta, GA 30912, United States.
C1 [Patel, Vijay] Georgia Regents Univ, Dept Surg, Augusta, GA 30912, United States.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University
RP Black, SM (corresponding author), Georgia Regents Univ, Vasc Biol Ctr, 1459 Laney Walker Blvd,CB 3210-B, Augusta, GA 30912 USA.
EM sblack@gru.edu
RI Rafikov, Ruslan/AAG-9352-2019; Lucas, Rudolf/ABA-3011-2020
OI Black, Stephen M./0000-0002-4524-6544; Rafikov,
   Ruslan/0000-0001-5950-4076; Sharma, Shruti/0000-0001-8200-108X; Verin,
   Alexander/0000-0003-0627-7185; Lucas, Rudolf/0000-0003-3805-8868
FU National Institutes of Health [P01HL0101902]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant P01HL0101902.
CR Bruewer M, 2004, AM J PHYSIOL-CELL PH, V287, pC327, DOI 10.1152/ajpcell.00087.2004
   Budge PJ, 2004, J VIROL, V78, P5015, DOI 10.1128/JVI.78.10.5015-5022.2004
   Burg J, 2002, AM J PHYSIOL-LUNG C, V283, pL460, DOI 10.1152/ajplung.00249.2001
   Buttenschoen K, 2008, LANGENBECK ARCH SURG, V393, P473, DOI 10.1007/s00423-008-0317-3
   Carbajal JM, 1999, AM J PHYSIOL-CELL PH, V277, pC955, DOI 10.1152/ajpcell.1999.277.5.C955
   Catravas JD, 2010, VASC PHARMACOL, V52, P175, DOI 10.1016/j.vph.2009.12.009
   Choi JC, 2008, J KOREAN MED SCI, V23, P288, DOI 10.3346/jkms.2008.23.2.288
   Ckless K, 2008, J IMMUNOL, V181, P4255, DOI 10.4049/jimmunol.181.6.4255
   Dechend R, 2003, CIRCULATION, V108, P261, DOI 10.1161/01.CIR.0000083367.93022.78
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Goeckeler ZM, 2005, J BIOL CHEM, V280, P33083, DOI 10.1074/jbc.M503173200
   Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006
   Groshaus HE, 2004, CRIT CARE, V8, P234, DOI 10.1186/cc2875
   Guilgen G, 2011, BLOOD PURIFICAT, V32, P296, DOI 10.1159/000330327
   Harrington EO, 2004, AM J PHYSIOL-LUNG C, V287, pL1091, DOI 10.1152/ajplung.00421.2003
   Heo J, 2005, J BIOL CHEM, V280, P31003, DOI 10.1074/jbc.M504768200
   Heo JY, 2006, BIOCHEMISTRY-US, V45, P14481, DOI 10.1021/bi0610101
   Huang F, 2005, AM J PHYSIOL-LUNG C, V289, pL176, DOI 10.1152/ajplung.00003.2005
   Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656
   ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U
   Kallet Richard H, 2004, Respir Care, V49, P793
   Knapp LT, 2001, BIOCHEM BIOPH RES CO, V286, P764, DOI 10.1006/bbrc.2001.5448
   Kondrikov D, 2011, FREE RADICAL BIO MED, V50, P1689, DOI 10.1016/j.freeradbiomed.2011.03.020
   Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999
   Lucas R, 2012, P NATL ACAD SCI USA, V109, P2084, DOI 10.1073/pnas.1121075109
   Magder S, 2006, J VASC RES, V43, P447, DOI 10.1159/000095162
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   McNichol BA, 2006, MOL MICROBIOL, V60, P939, DOI 10.1111/j.1365-2958.2006.05157.x
   Quint P, 2006, FREE RADICAL BIO MED, V40, P453, DOI 10.1016/j.freeradbiomed.2005.08.045
   Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983
   Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392
   Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c
   Sharma S, 2008, AM J PHYSIOL-LUNG C, V294, pL46, DOI 10.1152/ajplung.00247.2007
   Sharma S, 2010, VASC PHARMACOL, V52, P182, DOI 10.1016/j.vph.2009.11.010
   Shen Q, 2009, CELL HEALTH CYTOSKEL, V1, P43
   Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199
   Sud N, 2007, AM J PHYSIOL-LUNG C, V293, pL1444, DOI 10.1152/ajplung.00175.2007
   Sugiura H, 2004, FREE RADICAL RES, V38, P49, DOI 10.1080/10715760310001633817
   Visvikis O, 2010, BIOL CELL, V102, P377, DOI 10.1042/BC20090151
   Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699
   WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Yarbrough ML, 2009, SCIENCE, V323, P269, DOI 10.1126/science.1166382
   Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728
NR 45
TC 41
Z9 41
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 21
PY 2014
VL 289
IS 8
BP 4710
EP 4722
DI 10.1074/jbc.M114.547596
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AB2FF
UT WOS:000331607900018
PM 24398689
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Adyshev, DM
   Elangovan, VR
   Moldobaeva, N
   Mapes, B
   Sun, XG
   Garcia, JGN
AF Adyshev, Djanybek M.
   Elangovan, Venkateswaran Ramamoorthi
   Moldobaeva, Nurgul
   Mapes, Brandon
   Sun, Xiaoguang
   Garcia, Joe G. N.
TI Mechanical Stress Induces Pre-B-cell Colony-Enhancing Factor/NAMPT
   Expression via Epigenetic Regulation by miR-374a and miR-568 in Human
   Lung Endothelium
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE miRNA; PBEF/NAMPT; ALI/ARDS; ventilator-induced lung injury; ECs/HPMECs/HUVECs/MPVECs 
ID GENE-EXPRESSION; MICRORNAS; TARGET; PROMOTES; INFLAMMATION;
   POLYMORPHISMS; DEADENYLATION; INVOLVEMENT; INDUCTION; PROTEINS
AB Increased lung vascular permeability and alveolar edema are cardinal features of inflammatory conditions such as acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury (VILI). We previously demonstrated that pre-B-cell colony-enhancing factor (PBEF)/NAMPT, the proinflammatory cytokine encoded by NAMPT, participates in ARDS and VILI inflammatory syndromes. The present study evaluated posttranscriptional regulation of PBEF/NAMPT gene expression in human lung endothelium via 3'-untranslated region (UTR) microRNA (miRNA) binding. In silico analysis identified hsa-miR-374a and hsa-miR-568 as potential miRNA candidates. Increased PBEF/NAMPT transcription (by RT-PCR) and expression (by Western blotting) induced by 18% cyclic stretch (CS) (2 h: 3.4 +/- 0.06 mRNA fold increase (FI); 10 h: 1.5 +/- 0.06 protein FI) and by LPS (4 h: 3.8 +/- 0.2 mRNA FI; 48 h: 2.6 +/- 0.2 protein FI) were significantly attenuated by transfection with mimics of hsa-miR-374a or hsa-miR-568 (40-60% reductions each). LPS and 18% CS increased the activity of a PBEF/NAMPT 3'-UTR luciferase reporter (2.4-3.25 FI) with induction reduced by mimics of each miRNA (44-60% reduction). Specific miRNA inhibitors (antagomirs) for each PBEF/NAMPT miRNA significantly increased the endogenous PBEF/NAMPT mRNA (1.4-3.4 +/- 0.1 FI) and protein levels (1.2-1.4 +/- 0.1 FI) and 3'-UTR luciferase activity (1.4-1.7 +/- 0.1 FI) compared with negative antagomir controls. Collectively, these data demonstrate that increased PBEF/NAMPT expression induced by bioactive agonists (i.e., excessive mechanical stress, LPS) involves epigenetic regulation with hsa-miR-374a and hsa-miR-568, representing novel therapeutic strategies to reduce inflammatory lung injury.
C1 [Adyshev, Djanybek M.; Elangovan, Venkateswaran Ramamoorthi; Moldobaeva, Nurgul; Mapes, Brandon; Sun, Xiaoguang; Garcia, Joe G. N.] Univ Illinois, Dept Med, Inst Personalized Resp Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Garcia, JGN (corresponding author), Univ Arizona, Roy P Drachman Hall Bldg,B207, Tucson, AZ 85721 USA.
EM skipgarcia@email.arizona.edu
RI RamamoorthiElangovan, Venkateswaran/O-5533-2017; SUN,
   XIAOGUANG/ACA-5558-2022
OI Mapes, Brandon/0000-0001-8495-3439
FU National Institutes of Health/Heart Lung Blood Institute [P01 HL58064,
   P01 HL98050, R01 HL94394]
FX This work was supported by National Institutes of Health/Heart Lung
   Blood Institute grants P01 HL58064, P01 HL98050, and R01 HL94394.
CR Adyshev DM, 2013, AM J RESP CELL MOL, V49, P58, DOI 10.1165/rcmb.2012-0397OC
   Adyshev DM, 2011, CELL SIGNAL, V23, P2086, DOI 10.1016/j.cellsig.2011.08.003
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Bajwa EK, 2007, CRIT CARE MED, V35, P1290, DOI 10.1097/01.CCM.0000260243.22758.4F
   Barrett LW, 2012, CELL MOL LIFE SCI, V69, P3613, DOI 10.1007/s00018-012-0990-9
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Chamorro-Jorganes A, 2013, PHARMACOL RES, V75, P15, DOI 10.1016/j.phrs.2013.04.002
   Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452
   Dahl TB, 2007, CIRCULATION, V115, P972, DOI 10.1161/CIRCULATIONAHA.106.665893
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Hug C, 2005, SCIENCE, V307, P366, DOI 10.1126/science.1106933
   Ji F, 2013, J GENET GENOMICS, V40, P61, DOI 10.1016/j.jgg.2012.12.008
   Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI 10.1172/JCI19930
   Kohlstedt K, 2013, CIRC RES, V112, P1150, DOI 10.1161/CIRCRESAHA.113.301282
   Kornfeld JW, 2013, NATURE, V494, P111, DOI 10.1038/nature11793
   Leaver SK, 2007, BMJ-BRIT MED J, V335, P389, DOI 10.1136/bmj.39293.624699.AD
   Levitt JE, 2006, SEMIN RESP CRIT CARE, V27, P426, DOI 10.1055/s-2006-948296
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li HL, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-15
   Li N, 2012, J BIOL CHEM, V287, P17386, DOI 10.1074/jbc.M111.321158
   Liu N, 2012, NATURE, V482, P519, DOI 10.1038/nature10810
   Liu P, 2009, CELL BIOL INT, V33, P19, DOI 10.1016/j.cellbi.2008.10.015
   Liu Z, 2013, J GASTROENTEROL, V48, P86, DOI 10.1007/s00535-012-0609-9
   Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292
   Mitra S, 2011, AM J RESP CRIT CARE, V184, P1030, DOI 10.1164/rccm.201103-0447OC
   Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240
   Nielsen JA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-98
   O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106
   Ognjanovic S, 2001, J MOL ENDOCRINOL, V26, P107, DOI 10.1677/jme.0.0260107
   Persengiev SP, 2012, DISCOV MED, V13, P211
   Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105
   Ranjha R, 2013, INFLAMM RES, V62, P343, DOI 10.1007/s00011-013-0600-9
   Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sokolov MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031028
   Sommer G, 2008, CLIN SCI, V115, P13, DOI 10.1042/CS20070226
   Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tomankova T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-159
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Witkos TM, 2011, CURR MOL MED, V11, P93
   Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   Ye SQ, 2005, MICROVASC RES, V70, P142, DOI 10.1016/j.mvr.2005.08.003
   Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC
   Zhang R, 2009, J GENET GENOMICS, V36, P1, DOI 10.1016/S1673-8527(09)60001-1
   Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108
   Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010
NR 55
TC 56
Z9 58
U1 1
U2 15
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD FEB
PY 2014
VL 50
IS 2
BP 409
EP 418
DI 10.1165/rcmb.2013-0292OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AB4YJ
UT WOS:000331795600016
PM 24053186
OA Green Published
DA 2023-08-21
ER

PT J
AU Akinosoglou, K
   Alexopoulos, D
AF Akinosoglou, Karolina
   Alexopoulos, Dimitrios
TI Use of antiplatelet agents in sepsis: A glimpse into the future
SO THROMBOSIS RESEARCH
LA English
DT Review
DE antiplatelet; platelet; P2Y12 inhibitors; sepsis; GPIIb/IIIa antagonists 
ID ACUTE LUNG INJURY; SYSTEMIC INFLAMMATORY RESPONSE; PLATELET-FUNCTION;
   ACTIVATED PLATELETS; IN-VITRO; CLOPIDOGREL; ASPIRIN; THERAPY;
   ENDOTOXEMIA; ACID
AB As mechanisms of sepsis pathophysiology have been elucidated with time, sepsis may be considered nowadays, as an uncontrolled inflammatory and pro-coagulant response to a pathogen. In this cascade of events, platelets play a key role, via interaction with endothelial cells and modulation of both innate and adaptive immune system. In thatmanner, inhibition of platelet function could represent a useful tool for attenuating inflammatory response and improving outcomes. Data on current antiplatelet agents, including acetylsalicylic acid, P2Y12 inhibitors and GPIIb/IIIa antagonists, in animal models are promising. Clinical data in patients hospitalized for pneumonia, at risk for acute lung injury, and/or critically ill revealed an association between antiplatelet therapy and reduction in both short-termmortality and prevalence of acute lung injury, as well as, the need for intensive care unit admission, without a concomitant increased bleeding risk. In need of innovative approach in the treatment of sepsis, further prospective, interventional, randomized trials are pivotal to establish potential use of antiplatelet agents in this context. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Akinosoglou, Karolina] Univ Gen Hosp Patras, Dept Internal Med, Rion 26504, Greece.
C1 [Alexopoulos, Dimitrios] Univ Gen Hosp Patras, Dept Cardiol, Rion 26504, Greece.
RP Akinosoglou, K (corresponding author), Univ Hosp Patras, Dept Internal Med, Rion 26504, Greece.
EM akin@upatras.gr
CR Alberti C, 2005, AM J RESP CRIT CARE, V171, P461, DOI 10.1164/rccm.200403-324OC
   Almsherqi ZA, 2007, INT J CARDIOL, V117, P415, DOI 10.1016/j.ijcard.2006.05.058
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Aslam R, 2006, BLOOD, V107, P637, DOI 10.1182/blood-2005-06-2202
   Behan MW, 2010, CURR OPIN CARDIOL, V25, P321, DOI 10.1097/HCO.0b013e328338f7b5
   Blasco-Colmenares E, 2009, ARCH INTERN MED, V169, P788, DOI 10.1001/archinternmed.2009.42
   BOLDT J, 1994, CHEST, V106, P899, DOI 10.1378/chest.106.3.899
   Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329
   Braun O, 2013, J AM COLL CARDIOL, V61, p10S
   Cartin-Ceba R, 2011, AM J RESP CRIT CARE, V183, pA4698
   Christaki E, 2011, EXPERT REV ANTI-INFE, V9, P1013, DOI [10.1586/eri.11.122, 10.1586/ERI.11.122]
   COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373
   Czabanka M, 2007, CURR VASC PHARMACOL, V5, P266, DOI 10.2174/157016107782023389
   del Soldato P, 1999, TRENDS PHARMACOL SCI, V20, P319, DOI 10.1016/S0165-6147(99)01353-X
   Derhaschnig U, 2003, THROMB HAEMOSTASIS, V90, P1054, DOI 10.1160/TH03-04-0233
   Derhaschnig U, 2010, PLATELETS, V21, P320, DOI 10.3109/09537101003735572
   Diacovo TG, 1996, BLOOD, V88, P146
   Dorsam RT, 2004, J CLIN INVEST, V113, P340, DOI 10.1172/JCI200420986
   Eisen DP, 2012, CRIT CARE MED, V40, P1761, DOI 10.1097/CCM.0b013e318246b9df
   Erlich JM, 2011, CHEST, V139, P289, DOI 10.1378/chest.10-0891
   Evangelista V, 2005, THROMB HAEMOSTASIS, V94, P568, DOI 10.1160/TH05-01-0020
   Evangelista V, 2007, J THROMB HAEMOST, V5
   Freishtat RJ, 2009, AM J RESP CRIT CARE, V179, P467, DOI 10.1164/rccm.200807-1085OC
   Frelinger AL, 2007, THROMB HAEMOSTASIS, V98, P192, DOI 10.1160/TH07-01-0010
   Gawaz M, 1997, INTENS CARE MED, V23, P379, DOI 10.1007/s001340050344
   Goff CD, 1997, ANN THORAC SURG, V64, P826, DOI 10.1016/S0003-4975(97)00490-6
   Gonano C, 2006, CRIT CARE, V10, DOI 10.1186/cc5098
   Gross AK, 2013, J THROMB THROMBOLYS, V35, P147, DOI 10.1007/s11239-012-0833-4
   HALUSHKA PV, 1981, J PHARMACOL EXP THER, V218, P464
   HINSHAW LB, 1967, J PHARMACOL EXP THER, V157, P665
   ISOGAI E, 1989, ZBL BAKT-INT J MED M, V271, P186
   Itoh H, 1996, THROMB RES, V83, P405, DOI 10.1016/0049-3848(96)00151-X
   Jilma B, 1999, AM J RESP CRIT CARE, V159, P857, DOI 10.1164/ajrccm.159.3.9805087
   Johansson D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026928
   Katz JN, 2011, CHEST, V139, P658, DOI 10.1378/chest.10-1971
   Kerrigan SW, 2010, CELL MOL LIFE SCI, V67, P513, DOI 10.1007/s00018-009-0207-z
   Kor DJ, 2011, CRIT CARE MED, V39, P2393, DOI 10.1097/CCM.0b013e318225757f
   Lechi C, 1996, THROMB HAEMOSTASIS, V76, P791
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Losche Wolfgang, 2012, Thrombosis, V2012, P720254, DOI 10.1155/2012/720254
   Luckner G, 2008, OPEN CRIT CARE MED J, V1, P1
   MATERA C, 1992, J MED, V23, P327
   Mavrommatis AC, 2000, CRIT CARE MED, V28, P451, DOI 10.1097/00003246-200002000-00027
   Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477
   Muhlestein JB, 2010, THROMB HAEMOSTASIS, V103, P71, DOI 10.1160/TH09-03-0177
   O'Neal HR, 2011, CRIT CARE MED, V39, P1343, DOI 10.1097/CCM.0b013e3182120992
   Otto GP, 2012, PLATELETS
   Pernerstorfer T, 1999, CLIN PHARMACOL THER, V66, P51, DOI 10.1016/S0009-9236(99)70053-6
   Pu Q, 2001, CRIT CARE MED, V29, P1181, DOI 10.1097/00003246-200106000-00019
   Reinhofer M, 2008, BLOOD COAGUL FIBRIN, V19, P212, DOI 10.1097/MBC.0b013e3282f3f9d4
   Reininger AJ, 1998, THROMB HAEMOSTASIS, V79, P998
   Russwurm S, 2002, SHOCK, V17, P263, DOI 10.1097/00024382-200204000-00004
   SABA HI, 1984, THROMB RES, V34, P19, DOI 10.1016/0049-3848(84)90103-8
   Seidel M, 2009, J THROMB HAEMOST, V7, P1030, DOI 10.1111/j.1538-7836.2009.03352.x
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Serebruany VL, 2010, CARDIOLOGY, V117, P231, DOI 10.1159/000322789
   Setzer F, 2006, PLATELETS, V17, P571, DOI 10.1080/09537100600760244
   Sharron M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041549
   Sheu JR, 2000, THROMB RES, V99, P249, DOI 10.1016/S0049-3848(00)00244-9
   Sossdorf M, 2013, CRIT CARE, V17, DOI 10.1186/cc11886
   Spiel AO, 2012, CLIN SCI, V123, P591, DOI 10.1042/CS20120194
   Storey RF, 2006, CURR PHARM DESIGN, V12, P1255, DOI 10.2174/138161206776361318
   Storey RF, 2012, J AM COLL CARDIOL, V59, pE482, DOI 10.1016/S0735-1097(12)60483-5
   Taylor FB, 1997, BLOOD, V89, P4078, DOI 10.1182/blood.V89.11.4078
   Totani L, 2012, THROMB HAEMOSTASIS, V107, P1130, DOI 10.1160/TH11-12-0867
   Valerio-Rojas JC, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/782573
   Varenhorst C, 2012, J AM COLL CARDIOL, V60, P1623, DOI 10.1016/j.jacc.2012.07.021
   Vincent JL, 2002, CRIT CARE MED, V30, pS313, DOI 10.1097/00003246-200205001-00022
   Walther A, 2004, MICROCIRCULATION, V11, P79, DOI 10.1080/10739680490266216
   Warkentin Theodore E, 2003, Hematology Am Soc Hematol Educ Program, P497
   Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003
   Winning J, 2007, CRIT CARE, V11, pP27
   Winning J, 2010, CRIT CARE MED, V38, P32, DOI 10.1097/CCM.0b013e3181b4275c
   Winning J, 2009, PLATELETS, V20, P50, DOI 10.1080/09537100802503368
   Yaguchi A, 2001, INTENS CARE MED, V27, pS166
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
NR 76
TC 91
Z9 96
U1 0
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
EI 1879-2472
J9 THROMB RES
JI Thromb. Res.
PD FEB
PY 2014
VL 133
IS 2
BP 131
EP 138
DI 10.1016/j.thromres.2013.07.002
PG 8
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 287WI
UT WOS:000329572600002
PM 24103487
DA 2023-08-21
ER

PT J
AU Allen, TC
   Kurdowska, A
AF Allen, Timothy Craig
   Kurdowska, Anna
TI Interleukin 8 and Acute Lung Injury
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Review
ID RESPIRATORY-DISTRESS-SYNDROME; FC-GAMMA-RIIA; IMMUNE-COMPLEXES; IGG
   RECEPTORS; AUTOANTIBODY; CONTRACTILITY; INFLAMMATION; CELLS; FLUID; MICE
AB Acute lung injury is a complex clinical syndrome involving acute inflammation, microvascular damage, and increased pulmonary vascular and epithelial permeability, frequently resulting in acute respiratory failure culminating in often-fatal acute respiratory distress syndrome. Interleukin 8 (IL-8), a potent neutrophil attractant and activator, plays a significant role in acute lung injury via the formation of anti-IL-8 autoantibody: IL-8 complexes and those complexes' interaction with Fc gamma RIIa receptors, leading to the development of acute lung injury by, among other possible mechanisms, effecting neutrophil apoptosis. These complexes may also interact with lung endothelial cells in patients with acute respiratory distress syndrome. Continuing research of the role of neutrophils, IL-8, anti-IL-8 autoantibody: IL-8 complexes, and Fc gamma RIIa receptors may ultimately provide molecular therapies that could lower acute respiratory distress syndrome mortality, as well as reduce or even prevent the development of acute lung injury altogether.
C1 [Allen, Timothy Craig] Univ Texas Tyler, Hlth Sci Ctr, Dept Pathol, Tyler, TX 75799, United States.
C1 [Kurdowska, Anna] Univ Texas Tyler, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75799, United States.
C3 University of Texas System; University of Texas at Tyler; University of
   Texas-Health Sciences Center at Tyler (UTHSCT); University of Texas
   System; University of Texas at Tyler; University of Texas-Health
   Sciences Center at Tyler (UTHSCT)
RP Allen, TC (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
EM tcallen@utmb.edu
CR Allen TC, 2007, ARCH PATHOL LAB MED, V131, P452
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Bdeir K, 2010, AM J RESP CRIT CARE, V181, P935, DOI 10.1164/rccm.200907-1128OC
   Bhandary YP, 2009, AM J RESP CRIT CARE, V179, P288, DOI 10.1164/rccm.200712-1787OC
   Chen CY, 2009, AM J RESP CRIT CARE, V180, P751, DOI 10.1164/rccm.200902-0222OC
   Fudala R, 2008, CLIN SCI, V114, P403, DOI 10.1042/CS20070272
   Fudala R, 2007, AM J PHYSIOL-LUNG C, V293, pL364, DOI 10.1152/ajplung.00179.2006
   Fudala R, 2011, ARCH PATHOL LAB MED, V135, P647, DOI 10.1043/2009-0660-OAR1.1
   Huang FF, 2011, AM J RESP CRIT CARE, V184, P259, DOI 10.1164/rccm.201012-2036OC
   Krupa A, 2004, AM J PHYSIOL-LUNG C, V286, pL1105, DOI 10.1152/ajplung.00277.2003
   Krupa A, 2007, AM J RESP CELL MOL, V37, P532, DOI 10.1165/rcmb.2006-0395OC
   Krupa A, 2009, AM J RESP CELL MOL, V41, P155, DOI 10.1165/rcmb.2008-0183OC
   Kurdowska A, 1996, J IMMUNOL, V157, P2699
   Kurdowska A, 2002, CRIT CARE MED, V30, P2335, DOI 10.1097/00003246-200210000-00024
   Kurdowska A, 2001, AM J RESP CRIT CARE, V163, P463, DOI 10.1164/ajrccm.163.2.2005109
   Matthay MA, 2010, AM J RESP CRIT CARE, V181, P1027, DOI 10.1164/rccm.201001-0074UP
   Midde KK, 2011, SHOCK, V36, P128, DOI 10.1097/SHK.0b013e31821d60a4
   MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427
   MONTGOMERY AB, 1991, CHEST, V99, P261, DOI 10.1378/chest.99.1.261
   Nassar T, 2011, AM J RESP CELL MOL, V45, P1015, DOI 10.1165/rcmb.2010-0302OC
   Nassar T, 2011, AM J PHYSIOL-LUNG C, V301, pL307, DOI 10.1152/ajplung.00429.2010
   Nassar T, 2010, AM J RESP CELL MOL, V43, P703, DOI 10.1165/rcmb.2009-0257OC
   Paul-Clark MJ, 2009, AM J RESP CRIT CARE, V179, P299, DOI 10.1164/rccm.200707-1019OC
   Sardjono CT, 2003, IMMUNOL CELL BIOL, V81, P374, DOI 10.1046/j.1440-1711.2003.01182.x
   Sloggett AT, 1915, MEMORANDUM TREATMENT, P115
   VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
NR 28
TC 88
Z9 92
U1 0
U2 22
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD FEB
PY 2014
VL 138
IS 2
BP 266
EP 269
DI 10.5858/arpa.2013-0182-RA
PG 4
WC Medical Laboratory Technology; Medicine, Research & Experimental;
   Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; Research & Experimental Medicine;
   Pathology
GA AM0QF
UT WOS:000339550000021
PM 23782136
DA 2023-08-21
ER

PT J
AU Chen, WG
   Sharma, R
   Rizzo, AN
   Siegler, JH
   Garcia, JGN
   Jacobson, JR
AF Chen, Weiguo
   Sharma, Rajesh
   Rizzo, Alicia N.
   Siegler, Jessica H.
   Garcia, Joe G. N.
   Jacobson, Jeffrey R.
TI Role of Claudin-5 in the Attenuation of Murine Acute Lung Injury by
   Simvastatin
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE statins; claudins; ECs/HPMECs/HUVECs/MPVECs; permeability 
ID STATIN THERAPY; TIGHT JUNCTIONS; SEVERE SEPSIS; UP-REGULATION;
   VE-CADHERIN; BARRIER; CELLS; PERMEABILITY; INFLAMMATION; DYSFUNCTION
AB The statins are now recognized to have pleiotropic properties, including augmentation of endothelial barrier function. To explore the mechanisms involved, we investigated the effect of simvastatin on endothelial cell (EC) tight junctions. Western blotting of human pulmonary artery ECs treated with simvastatin (5 mu M) confirmed a significant time-dependent increase (16-48 h) in claudin-5 protein expression compared with controls, without detectable alterations in zonula occludens-1 or occludin. These effects were associated with membrane translocation of VE-cadherin, whereas translocation of vascular endothelial cadherin (VE-cadherin; silencing RNA) inhibited simvastatin-induced claudin-5 up-regulation. Moreover, simvastatin treatment of ECs induced increased phosphorylation of both FoxO1 and beta-catenin, transcriptional regulators of claudin-5 expression mediated by VE-cadherin. Subsequently, we found no effect of claudin-5 silencing on EC barrier protection by simvastatin in response to thrombin stimulation, as measured by either transendothelial electrical resistance or by EC monolayer flux of FITC-dextran (2,000 kD). However, silencing of claudin-5 did significantly attenuate simvastatin-mediated EC barrier protection in response to thrombin, as measured by monolayer flux of sodium fluorescein (376 Da). Finally, employing a murine model of LPS-induced acute lung injury, there was no effect of claudin-5 silencing in vivo (intratracheal injection) on bronchoalveolar lavage fluid protein or cell counts, but LPS-induced lung tissue extravasation of the small molecular weight markers, sodium fluorescein and Hochst stain (562 Da), were significantly increased in claudin-5-silenced animals compared with simvastatin-treated control animals. These findings implicate a distinct mechanism underlying size-selective endothelial barrier-protective properties of statins, and may ultimately lead to new novel therapeutic targets for patients with acute lung injury.
C1 [Chen, Weiguo; Sharma, Rajesh; Rizzo, Alicia N.; Siegler, Jessica H.; Garcia, Joe G. N.; Jacobson, Jeffrey R.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Inst Personalized Resp Med, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Jacobson, JR (corresponding author), Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Inst Personalized Resp Med, 840 South Wood St,920-N CSB, Chicago, IL 60612 USA.
EM jrjacob@uic.edu
RI Garcia, Joe GN/E-8862-2010
OI Rizzo, Alicia/0000-0001-9289-4635
FU National Institutes of Health [HL096887]
FX This work was supported by National Institutes of Health grant HL096887
   (J.R.J.).
CR Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Belli S, 2011, J SURG RES, V167, pE283, DOI 10.1016/j.jss.2010.01.035
   Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a
   Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Chen WG, 2012, AM J PHYSIOL-LUNG C, V303, pL279, DOI 10.1152/ajplung.00361.2011
   Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002
   Craig TR, 2011, AM J RESP CRIT CARE, V183, P620, DOI 10.1164/rccm.201003-0423OC
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115
   Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012
   Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC
   Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC
   Kim JW, 2010, CLIN EXP PHARMACOL P, V37, P1055, DOI 10.1111/j.1440-1681.2010.05431.x
   Kruger P, 2006, INTENS CARE MED, V32, P75, DOI 10.1007/s00134-005-2859-y
   Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129
   Liu PY, 2009, CIRCULATION, V119, P131, DOI 10.1161/CIRCULATIONAHA.108.813311
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185
   Morofuji Y, 2010, CELL MOL NEUROBIOL, V30, P727, DOI 10.1007/s10571-010-9497-9
   Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   O'Neal HR, 2011, CRIT CARE MED, V39, P1343, DOI 10.1097/CCM.0b013e3182120992
   Schmidt H, 2006, INTENS CARE MED, V32, P1248, DOI 10.1007/s00134-006-0246-y
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Takeda I, 2007, CANCER SCI, V98, P890, DOI 10.1111/j.1349-7006.2007.00471.x
   Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464
   Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55
NR 35
TC 36
Z9 40
U1 0
U2 10
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD FEB
PY 2014
VL 50
IS 2
BP 328
EP 336
DI 10.1165/rcmb.2013-0058OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AB4YJ
UT WOS:000331795600010
PM 24028293
OA Green Published
DA 2023-08-21
ER

PT J
AU Hou, SK
   Ding, H
   Lv, Q
   Yin, XF
   Song, JQ
   Landen, NX
   Fan, HJ
AF Hou, Shike
   Ding, Hui
   Lv, Qi
   Yin, Xiaofeng
   Song, Jianqi
   Landen, Ning Xu
   Fan, Haojun
TI Therapeutic Effect of Intravenous Infusion of Perfluorocarbon Emulsion
   on LPS-Induced Acute Lung Injury in Rats
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; LIQUID
   VENTILATION; OXYGEN CARRIERS; IN-VITRO; INHIBITION; RELEASE; ARDS
AB Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS) are the leading causes of death in critical care. Despite extensive efforts in research and clinical medicine, mortality remains high in these diseases. Perfluorocarbon (PFC), a chemical compound known as liquid ventilation medium, is capable of dissolving large amounts of physiologically important gases (mainly oxygen and carbon dioxide). In this study we aimed to investigate the effect of intravenous infusion of PFC emulsion on lipopolysaccharide (LPS) induced ALI in rats and elucidate its mechanism of action. Forty two Wistar rats were randomly divided into three groups: 6 rats were treated with saline solution by intratracheal instillation (control group), 18 rats were treated with LPS by intratracheal instillation (LPS group) and the other 18 rats received PFC through femoral vein prior to LPS instillation (LPS+ PFC group). The rats in the control group were sacrificed 6 hours later after saline instillation. At 2, 4 and 6 hours of exposure to LPS, 6 rats in the LPS group and 6 rats in LPS+ PFC group were sacrificed at each time point. By analyzing pulmonary pathology, partial pressure of oxygen in the blood (PaO2) and lung wet-dry weight ratio (W/D) of each rat, we found that intravenous infusion of PFC significantly alleviated acute lung injury induced by LPS. Moreover, we showed that the expression of pulmonary myeloperoxidase (MPO), intercellular adhesion molecule-1 (ICAM-1) of endothelial cells and CD11b of polymorphonuclear neutrophils (PMN) induced by LPS were significantly decreased by PFC treatment in vivo. Our results indicate that intravenous infusion of PFC inhibits the infiltration of PMNs into lung tissue, which has been shown as the core pathogenesis of ALI/ARDS. Thus, our study provides a theoretical foundation for using intravenous infusion of PFC to prevent and treat ALI/ARDS in clinical practice.
C1 [Hou, Shike; Ding, Hui; Lv, Qi; Yin, Xiaofeng; Song, Jianqi; Fan, Haojun] Logist Univ Chinese Peoples Armed Police Forces, Affiliated Hosp, Rescue Med Res Inst, Tianjin, China.
C1 [Landen, Ning Xu] Karolinska Univ Hosp, Mol Dermatol Res Grp, CMM, Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska University Hospital
RP Fan, HJ (corresponding author), Logist Univ Chinese Peoples Armed Police Forces, Affiliated Hosp, Rescue Med Res Inst, Tianjin, Peoples R China.
EM haojunfan86@163.com
RI Landén, Ning Xu/AFL-2883-2022
OI Landén, Ning Xu/0000-0003-4868-3798; Lv, Qi/0000-0001-9076-7042; Fan,
   Haojun/0000-0003-1111-0232
FU capital development fund [2009-3091]; Key program of PAPF [WJHQ2010-08]
FX This work was supported by grants from the capital development fund
   (2009-3091), Key program of PAPF (WJHQ2010-08). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albaghdadi AS, 2010, RESUSCITATION, V81, P353, DOI 10.1016/j.resuscitation.2009.11.018
   Angus DC, 2006, CRIT CARE MED, V34, P2885, DOI 10.1097/01.CCM.0000248727.29055.25
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Baba A, 2000, CRIT CARE MED, V28, P1113, DOI 10.1097/00003246-200004000-00034
   Bernard GR, 1999, CHEST, V116, p260S
   Bollen CW, 2005, CRIT CARE, V9, pR430, DOI 10.1186/cc3737
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8
   Castro CI, 2010, ARTIF ORGANS, V34, P622, DOI 10.1111/j.1525-1594.2009.00944.x
   Chang H, 2005, INTENS CARE MED, V31, P977, DOI 10.1007/s00134-005-2652-y
   Chopra M, 2009, EXP BIOL MED, V234, P361, DOI 10.3181/0811-MR-318
   Dickinson S, 2011, CRIT CARE CLIN, V27, P511, DOI 10.1016/j.ccc.2011.05.010
   Doerschuk CM, 1996, J IMMUNOL, V157, P4609
   Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995
   Faithfull NS, 1998, VOX SANG, V74, P243, DOI 10.1111/j.1423-0410.1998.tb05426.x
   Gale SC, 2007, J SURG RES, V138, P135, DOI 10.1016/j.jss.2006.08.029
   Garber BG, 1996, CRIT CARE MED, V24, P687, DOI 10.1097/00003246-199604000-00023
   Gardinali M, 2000, AM J RESP CRIT CARE, V161, P1022, DOI 10.1164/ajrccm.161.3.9901066
   GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6
   Greenspan JS, 2000, SEMIN PERINATOL, V24, P396, DOI 10.1053/sper.2000.20092
   Hadjiliadis D, 2000, SEM RESP CRIT CARE M, V21, P175, DOI 10.1055/s-2000-9852
   Hale DF, 2012, J TRAUMA ACUTE CARE, V72, P1634, DOI 10.1097/TA.0b013e318247cd4f
   Keipert PE, 2001, ANASTH INTENSIV NOTF, V36, pS104
   KERINS DM, 1994, AM J MED SCI, V307, P218, DOI 10.1097/00000441-199403000-00009
   Lu YM, 2004, INTENS CARE MED, V30, P2197, DOI 10.1007/s00134-004-2479-y
   [马希刚 MA Xigang], 2006, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V26, P363
   Michetti C, 2003, J SURG RES, V115, P92, DOI 10.1016/S0022-4804(03)00219-1
   Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC
   Riess JG, 2006, ARTIF CELL BLOOD SUB, V34, P567, DOI 10.1080/10731190600973824
   Sharma J, 2009, J IMMUNOL METHODS, V351, P30, DOI 10.1016/j.jim.2009.09.008
   Shashikant BN, 2005, CRIT CARE MED, V33, P1096, DOI 10.1097/01.CCM.0000163218.79770.29
   Shen Y, 2011, EXPERT REV RESP MED, V5, P107, DOI [10.1586/ers.10.80, 10.1586/ERS.10.80]
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Solovjov DA, 2005, J BIOL CHEM, V280, P1336, DOI 10.1074/jbc.M406968200
   Spahn DR, 1999, CRIT CARE, V3, pR93, DOI 10.1186/cc364
   Spiess BD, 2009, J APPL PHYSIOL, V106, P1444, DOI 10.1152/japplphysiol.90995.2008
   Taut FJH, 2008, CHEST, V134, P724, DOI 10.1378/chest.08-0362
   Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603
   Thompson BT, 2003, CRIT CARE MED, V31, pS253, DOI 10.1097/01.CCM.0000057900.19201.55
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Wang X, 2013, CLIN RESPIR  J, DOI [10.1111/crj.12053, DOI 10.1111/CRJ.12053.[]
   Wolfson MR, 2004, PAEDIATR ANAESTH, V14, P15, DOI 10.1046/j.1460-9592.2003.01206.x
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716
   Yoxall CW, 1997, THORAX, V52, pS3, DOI 10.1136/thx.52.2008.S3
   Zhang XP, 2009, J PANCREAS, V10, P8
   Zhou XH, 2012, FRONT BIOSCI-LANDMRK, V17, P2278, DOI 10.2741/4051
NR 47
TC 31
Z9 38
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 28
PY 2014
VL 9
IS 1
AR e87826
DI 10.1371/journal.pone.0087826
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 301CJ
UT WOS:000330510000152
PM 24489970
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Braach, N
   Buschmann, K
   Pflaum, J
   Hudalla, H
   Koch, L
   Ryschich, E
   Poeschl, J
   Frommhold, D
AF Braach, Natascha
   Buschmann, Kirsten
   Pflaum, Johanna
   Hudalla, Hannes
   Koch, Lutz
   Ryschich, Eduard
   Poeschl, Johannes
   Frommhold, David
TI Anti-Inflammatory Functions of Protein C Require RAGE and ICAM-1 in a
   Stimulus-Dependent Manner
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID GLYCATION END-PRODUCTS; LEUKOCYTE RECRUITMENT; ACUTE-INFLAMMATION;
   ENDOTHELIAL-CELLS; IMPROVES SURVIVAL; LUNG INJURY; RECEPTOR; ADHESION;
   ANTICOAGULANT; ENDOTOXEMIA
AB By binding beta(2)-integrins both ICAM-1 and the receptor for advanced glycation end products (RAGE) mediate leukocyte recruitment in a stimulus-dependent manner. Using different inflammatory mouse models we investigated how RAGE and ICAM-1 are involved in anti-inflammatory functions of protein C (PC; Ceprotin, 100 U/kg). We found that, depending on the stimulus, RAGE and ICAM-1 are cooperatively involved in PC-induced inhibition of leukocyte recruitment in cremaster models of inflammation. During short-term proinflammatory stimulation (trauma, fMLP, and CXCL1), ICAM-1 is more important for mediation of anti-inflammatory effects of PC, whereas RAGE plays a major role after longer proinflammatory stimulation (TNF alpha). In contrast to WT and Icam-1(-/-) mice, PC had no effect on bronchoalveolar neutrophil emigration in RAGE(-/-) mice during LPS-induced acute lung injury, suggesting that RAGE critically mediates PC effects during acute lung inflammation. In parallel, PC treatment effectively blocked leukocyte recruitment and improved survival of WT mice and Icam-1-deficient mice in LPS-induced endotoxemia, but failed to do so in RAGE-deficient mice. Exploring underlying mechanisms, we found that PC is capable of downregulating intracellular RAGE and extracellular ICAM-1 in endothelial cells. Taken together, our data show that RAGE and ICAM-1 are required for the anti-inflammatory functions of PC.
C1 [Braach, Natascha; Buschmann, Kirsten; Pflaum, Johanna; Hudalla, Hannes; Koch, Lutz; Poeschl, Johannes; Frommhold, David] Ruprecht Karls Univ Hosp Heidelberg, Dept Neonatol, D-69120 Heidelberg, Germany.
C1 [Ryschich, Eduard] Ruprecht Karls Univ Hosp Heidelberg, Dept Surg, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Frommhold, D (corresponding author), Ruprecht Karls Univ Hosp Heidelberg, Dept Neonatol, D-69120 Heidelberg, Germany.
EM david.frommhold@med.uni-heidelberg.de
RI Koch, Lutz/H-2166-2011
OI Koch, Lutz/0000-0003-3683-2274
FU Deutsche Forschungsgemeinschaft; Ruprecht-Karls-Universitat Heidelberg
FX The authors thank Melitta Weissinger for her excellent technical
   assistance in performing intravital microscopy and Professor Peter
   Nawroth (Department of Medicine I & Clinical Chemistry, University
   Heidelberg) for providing RAGE<SUP>-/-</SUP> and Icam-1<SUP>-/-</SUP>
   mice and MAECs. In addition, they thank Professor Berend Isermann and
   Dr. Hongjie Wang (both from University Magdeburg, Germany) for
   assistance in performing the APC capture assay and Dr. Sandra Ehrle
   (Baxter, Unterschleissheim, Germany) for providing the Ceprotin. In
   addition, we acknowledge the financial support of the Deutsche
   Forschungsgemeinschaft and Ruprecht-Karls-Universitat Heidelberg within
   the funding programme Open Access Publishing.
CR Abeyama K, 2005, J CLIN INVEST, V115, P1267, DOI 10.1172/JCI200522782
   Bae JS, 2011, BLOOD, V118, P3952, DOI 10.1182/blood-2011-06-360701
   Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005
   Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125-009-1458-9
   BRETT J, 1993, AM J PATHOL, V143, P1699
   Buschmann K, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/739176
   Cao CZ, 2010, J CLIN INVEST, V120, P1971, DOI 10.1172/JCI40380
   Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800
   Dinarvand P, 2014, BLOOD, V123, P935, DOI 10.1182/blood-2013-09-529602
   Elphick GF, 2009, BLOOD, V113, P4078, DOI 10.1182/blood-2008-09-180968
   Foy DS, 2000, MICROVASC RES, V60, P249, DOI 10.1006/mvre.2000.2272
   Frommhold D, 2011, AM J PATHOL, V179, P2637, DOI 10.1016/j.ajpath.2011.07.023
   Frommhold D, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-56
   Frommhold D, 2010, BLOOD, V116, P841, DOI 10.1182/blood-2009-09-244293
   Frommhold D, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-31
   Guitton C, 2011, AM J PHYSIOL-CELL PH, V300, pC833, DOI 10.1152/ajpcell.00003.2010
   Isermann B, 2007, NAT MED, V13, P1349, DOI 10.1038/nm1667
   Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9
   Jackson CJ, 2008, INT J BIOCHEM CELL B, V40, P2692, DOI 10.1016/j.biocel.2007.12.013
   Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200
   Kau JH, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-98
   Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404
   Kobayashi M, 2005, J ATHEROSCLER THROMB, V12, P138, DOI 10.5551/jat.12.138
   Lange-Sperandio B, 2007, CURR PEDIATR REV, V3, P1, DOI 10.2174/157339607779941598
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Liaw PCY, 2003, J THROMB HAEMOST, V1, P662, DOI 10.1046/j.1538-7836.2003.00153.x
   Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704
   Luo Y, 2013, BIOCHEM BIOPH RES CO, V438, P732, DOI 10.1016/j.bbrc.2013.07.098
   Messaris E, 2010, CRIT CARE MED, V38, P209, DOI 10.1097/CCM.0b013e3181b4a972
   Ramsgaard L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020132
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Reynolds PR, 2010, AM J RESP CELL MOL, V42, P545, DOI 10.1165/rcmb.2008-0265OC
   Rezaie AR, 2010, CURR MED CHEM, V17, P2059, DOI 10.2174/092986710791233706
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   Scaldaferri F, 2007, J CLIN INVEST, V117, P1951, DOI 10.1172/JCI31027
   Sopel MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045663
   SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143
   Sturn DH, 2003, BLOOD, V102, P1499, DOI 10.1182/blood-2002-12-3880
   Su X, 2009, AM J PHYSIOL-LUNG C, V297, pL1, DOI 10.1152/ajplung.90546.2008
   Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC
   van Zoelen Marieke A D, 2011, Front Biosci (Schol Ed), V3, P1119
   Wang J, 2012, INFLAMMATION, V35, P859, DOI 10.1007/s10753-011-9387-4
   Weiler H, 2001, ARTERIOSCL THROM VAS, V21, P1531, DOI 10.1161/hq0901.094496
   Weiler H, 2010, CRIT CARE MED, V38, pS18, DOI 10.1097/CCM.0b013e3181c9cbb5
   XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95
   Xu X, 2013, CLIN EXP IMMUNOL, V173, P523, DOI 10.1111/cei.12139
   Yamamoto Y, 2011, J IMMUNOL, V186, P3248, DOI 10.4049/jimmunol.1002253
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
NR 48
TC 4
Z9 5
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
VL 2014
AR 743678
DI 10.1155/2014/743678
PG 12
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA AH4UW
UT WOS:000336125200001
PM 24876676
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Li, Y
   Wu, WK
AF Li, Yan
   Wu, Weikang
TI Beneficial Effects of Hirudin in a Murine Model of Acute Lung Injury Via
   Protection of Vascular Endothelial Barrier
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; hirudin; MLCK; PMN; Rho/ROCK pathway 
ID LIGHT-CHAIN PHOSPHORYLATION; KINASE PATHWAY; LIPOPOLYSACCHARIDE;
   THROMBIN; PERMEABILITY; MICE; INHIBITOR; CELLS; THROMBOCYTOPENIA;
   RESPONSES
AB A large amount of lung polymorphonuclear neutrophils (PMNs) transmigration and infiltration across vascular endothelial barrier are the pathological features of acute lung injury (ALI) inflammation progress. We previously demonstrated that fasudil attenuates lipopolysaccharide (LPS) -induced ALI in mice through the Rho/Rho kinase pathway, resulting in the loss of endothelial cell integrity and pulmonary vascular hyperpermeability. In this study, mice were exposed to LPS to induce ALI. Thirty min before LPS inhalation, we used hirudin in preventing ALI and heparin as the control drug, and observed protective effects of high, medium, or low dose hirudin group at 16 h after LPS inhalation. We found that the pathophysiological mechanism of hirudin application in ALI may be partly related to the protection of endothelial barrier and thus attenuating PMNs' transendothelial aggregation in lung. Additionally, we showed that the inhibition of Rho/Rho kinase and myosin light chain kinases (MLCK) pathway is the potential mechanism of hirudin's application in ALI.
C1 [Li, Yan] Bengbu Med Coll, Dept Pathophysiol, Bengbu 233030, Anhui, China.
C1 [Wu, Weikang] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, China.
C3 Bengbu Medical College; Sun Yat Sen University
RP Wu, WK (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, Peoples R China.
EM weikangwu09@gmail.com
FU National Natural Science Foundation of China [81202833]; Natural Science
   Foundation of Anhui Province, China [1308085MH140]; Research Foundation
   of Education Bureau of Anhui Province, China [KJ2012B100]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81202833), the Natural Science Foundation of Anhui
   Province, China (Grant No. 1308085MH140) and the Research Foundation of
   Education Bureau of Anhui Province, China (Grant No. KJ2012B100).
CR Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Bao YX, 2012, MOL MED REP, V5, P873, DOI 10.3892/mmr.2011.739
   Bogatcheva NV, 2011, J CELL PHYSIOL, V226, P3132, DOI 10.1002/jcp.22669
   Chen DX, 2013, THROMB RES, V132, P750, DOI 10.1016/j.thromres.2013.10.002
   Chignard M, 2000, AM J PHYSIOL-LUNG C, V279, pL1083, DOI 10.1152/ajplung.2000.279.6.L1083
   Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985
   Greinacher A, 2008, THROMB HAEMOSTASIS, V99, P819, DOI 10.1160/TH07-11-0693
   Han JL, 2013, THROMB RES, V132, pE42, DOI 10.1016/j.thromres.2013.03.010
   HOFFMANN H, 1990, AM REV RESPIR DIS, V142, P782, DOI 10.1164/ajrccm/142.4.782
   Inoue KI, 2005, INT J MOL MED, V16, P1029
   Jansson AH, 2004, LUNG, V182, P163, DOI 10.1007/s00408-004-1803-1
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Li Y, 2010, MED SCI MONITOR, V16, pBR112
   Lubenow N, 2002, SEMIN THROMB HEMOST, V28, P431, DOI 10.1055/s-2002-35283
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043
   Ragaller Maximillian, 2010, J Emerg Trauma Shock, V3, P43, DOI 10.4103/0974-2700.58663
   Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915
   Shimizu T, 2013, ARTERIOSCL THROM VAS, V33, P2780, DOI 10.1161/ATVBAHA.113.301357
   Ware LB, 2013, SEMIN RESP CRIT CARE, V34, P439, DOI 10.1055/s-0033-1351163
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Yu Y, 2012, FEBS J, V279, P1485, DOI 10.1111/j.1742-4658.2012.08541.x
   Yuan SY, 2012, MICROVASC RES, V83, P82, DOI 10.1016/j.mvr.2011.06.015
NR 25
TC 0
Z9 0
U1 1
U2 3
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326-2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2014
VL 33
IS 7
BP 1075
EP 1081
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AT4SP
UT WOS:000344932500003
DA 2023-08-21
ER

PT J
AU Lomas-Neira, J
   Venet, F
   Chung, CS
   Thakkar, R
   Heffernan, D
   Ayala, A
AF Lomas-Neira, Joanne L.
   Venet, Fabienne
   Chung, Chun-Shiang
   Thakkar, Rajan
   Heffernan, Daithi S.
   Ayala, Alfred
TI Neutrophil-Endothelial Interactions Mediate Angiopoietin-2-Associated
   Pulmonary Endothelial Cell Dysfunction in Indirect Acute Lung Injury in
   Mice
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE angiopoietin-1/angiopoietin-2; ALI/ARDS; neutrophil; siRNA; ECs/HPMECs/HUVECs/MPVECs 
ID TIE-2 LIGAND ANGIOPOIETIN-2; SEVERE SEPSIS; EXPRESSION; ANGIOGENESIS;
   INFLAMMATION; ACTIVATION; MACROPHAGE; APOPTOSIS; SEVERITY; RECEPTOR
AB Unresolved inflammation in the lung is thought to elicit loss of endothelial cell (EC) barrier integrity and impaired lung function. We have shown, in a mouse model of shock/sepsis, that neutrophil interactions with resident pulmonary cells appear central to the pathogenesis of indirect acute lung injury (iALI). Normally, EC growth factors angiopoietin (Ang)-1 and Ang-2 maintain vascular homeostasis through tightly regulated interaction with the kinase receptor Tie2 expressed on ECs. Although Ang-1/Tie2 has been shown to promote vessel integrity, stimulating downstream prosurvival/antiinflammatory signaling, Ang-2, released from activated ECs, is reported to promote vessel destabilization. This mechanism of regulation, together with recent clinical findings that plasma Ang-2 levels are significantly elevated in patients who develop acute respiratory distress syndrome, has focused our investigation on the contribution of Ang-2 to the development of iALI. A murine model of hemorrhagic shock-induced priming for the development of iALI after subsequent septic challenge was used in this study. Our findings show that 1) Ang-2 is elevated in our experimental model for iALI, 2) direct EC/neutrophil interactions contribute significantly to ECAng-2 release, and 3) suppression of Ang-2 significantly decreases inflammatory lung injury, neutrophil influx, and lung and plasma IL-6 and TNF-alpha. These findings support our hypothesis and suggest that Ang-2 plays a role in the loss of pulmonary EC barrier function in the development of iALI in mice resultant from the sequential insults of hemorrhagic shock and sepsis and that this is mediated by EC interaction with activated neutrophils.
C1 [Lomas-Neira, Joanne; Chung, Chun-Shiang; Thakkar, Rajan; Heffernan, Daithi; Ayala, Alfred] Brown Univ, Rhode Isl Hosp, Alpert Sch Med, Dept Surg,Div Surg Res, Providence, RI 02903, United States.
C1 [Venet, Fabienne] Hosp Civils Lyon, Immunol Labs, Lyon, France.
C3 Brown University; Lifespan Health Rhode Island; Rhode Island Hospital;
   CHU Lyon
RP Lomas-Neira, J (corresponding author), Brown Univ, Rhode Isl Hosp, Alpert Sch Med, Dept Surg,Div Surg Res, 593 Eddy St,Aldrich 244, Providence, RI 02903 USA.
EM jlomasneira@lifespan.org
OI Heffernan, Daithi/0000-0002-3417-2893; Ayala,
   Alfred/0000-0002-5034-2995; Venet, Fabienne/0000-0003-0462-4235
FU Rhode Island Foundation; Surgical Infection Society; National Institutes
   of Health [P20-GM103652-01A1, 8257, R01-GM107149-01]
FX This work was supported by a grant from The Rhode Island Foundation
   (J.L.-N.), a Fellowship from the Surgical Infection Society (J.L.-N.),
   and grants P20-GM103652-01A1 [Sub-Project ID: 8257] (J.L.-N.) as well as
   R01-GM107149-01 (A.A.) from the National Institutes of Health.
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Childs EW, 2008, AM J PHYSIOL-HEART C, V294, pH2285, DOI 10.1152/ajpheart.01361.2007
   Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103
   Fan J, 1998, J IMMUNOL, V161, P440
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Ganta VC, 2010, INFLAMM BOWEL DIS, V16, P1029, DOI 10.1002/ibd.21150
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Grutkoski PS, 2003, J LEUKOCYTE BIOL, V74, P916, DOI 10.1189/jlb.0303108
   Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e
   Kayakabe K, 2012, RHEUMATOLOGY, V51, P1571, DOI 10.1093/rheumatology/kes093
   Lemieux C, 2005, BLOOD, V105, P1523, DOI 10.1182/blood-2004-09-3531
   Lentsch AB, 2001, RESP PHYSIOL, V128, P17, DOI 10.1016/S0034-5687(01)00260-2
   Li WX, 2005, INT IMMUNOL, V17, P429, DOI 10.1093/intimm/dxh223
   Lomas JL, 2003, SHOCK, V19, P358, DOI 10.1097/00024382-200304000-00011
   Lomas-Neira J, 2006, AM J PHYSIOL-LUNG C, V290, pL51, DOI 10.1152/ajplung.00028.2005
   Lomas-Neira J, 2005, CYTOKINE, V31, P169, DOI 10.1016/j.cyto.2005.04.005
   Lomas-Neira J, 2012, SHOCK, V37, P611, DOI 10.1097/SHK.0b013e318254fa6a
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Minino A, 2004, NATL VITAL STAT REPO
   Nag S, 2005, LAB INVEST, V85, P1189, DOI 10.1038/labinvest.3700325
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Shapiro NI, 2010, CRIT CARE, V14, DOI 10.1186/cc9290
   Su WR, 2012, J ALLERGY CLIN IMMUN, V130, P444, DOI 10.1016/j.jaci.2012.05.011
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tsigkos S, 2006, J CELL PHYSIOL, V207, P506, DOI 10.1002/jcp.20592
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   Wang H, 2009, THORAX, V64, P283, DOI 10.1136/thx.2007.094870
   Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086
   Wesche-Soldato DE, 2007, AM J PATHOL, V171, P87, DOI 10.2353/ajpath.2007.061099
NR 43
TC 38
Z9 44
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JAN
PY 2014
VL 50
IS 1
BP 193
EP 200
DI 10.1165/rcmb.2013-0148OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 291IF
UT WOS:000329820900019
PM 23980650
OA Green Published
DA 2023-08-21
ER

PT J
AU Maretta, M
   Toth, S
   Jonecova, Z
   Kruzliak, P
   Kubatka, P
   Pingorova, S
   Vesela, J
AF Maretta, Milan
   Toth, Stefan
   Jonecova, Zuzana
   Kruzliak, Peter
   Kubatka, Peter
   Pingorova, Stanislava
   Vesela, Jarmila
TI Immunohistochemical expression of MPO, CD163 and VEGF in inflammatory
   cells in acute respiratory distress syndrome: a case report
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ALI/ARDS; MPO; VEGF/VEGFA; CD163; immunohistochemistry 
ID ENDOTHELIAL-CELLS; ALVEOLAR MONOCYTE; APOPTOSIS; BRONCHOALVEOLAR;
   MYELOPEROXIDASE; INFECTION; MICE
AB Acute respiratory distress syndrome (ARDS) is a serious medical condition occurring in patients with polytrauma, pulmonary or non-pulmonary sepsis, pneumonia and many other circumstances. It causes inflammation of the lung parenchyma leading to impaired gas exchange with a systemic release of inflammatory mediators, causing consequential lung tissue injury, hypoxemia and frequently multiple organ failure. The aim of current study was to describe expression of inflammatory markers (myeloperoxidase, CD163 and vascular endothelial growth factor) by the cells in acute phase of ARDS. The lung samples of a 20-year-old man who had suffered a serious motorbike accident were obtained for histological examination. He died on the seventh day as a consequence of respiratory failure. Our results imply that expression of CD163 was restricted to activated alveolar macrophages and monocytes. Immunopositivity of MPO was observed in neutrophil granulocytes within lung alveoli and lung blood vessels. Myeloperoxidase positivity was observed in alveolar macrophages, too. Vascular endothelial growth factor was expressed in cytoplasm of neutrophil granulocytes, monocytes, small-sized alveolar macrophages and type II pneumocytes localized mostly inside lung alveoli. On the contrary, no positivity was observed in lung endothelial cells of blood vessels.
C1 [Maretta, Milan; Toth, Stefan; Jonecova, Zuzana; Vesela, Jarmila] Pavol Jozef Safarik Univ, Fac Med, Dept Histol & Embryol, Kosice, Slovakia.
C1 [Kruzliak, Peter] St Annes Univ Hosp, Int Clin Res Ctr, Brno 65691, Czech Republic.
C1 [Kruzliak, Peter] Masaryk Univ, Brno 65691, Czech Republic.
C1 [Pingorova, Stanislava] Pavol Jozef Safarik Univ, Fac Med, Dept Traumatol, Kosice, Slovakia.
C1 [Pingorova, Stanislava] Louis Pasteur Univ Hosp, Kosice, Slovakia.
C1 [Kubatka, Peter] Comenius Univ, Dept Med Biol, Jessenius Fac Med, Bratislava, Slovakia.
C3 University of Pavol Jozef Safarik Kosice; St Anne's University Hospital
   Brno (FNUSA-ICRC); Masaryk University Brno; University of Pavol Jozef
   Safarik Kosice; Comenius University Bratislava
RP Kruzliak, P (corresponding author), St Annes Univ Hosp, Int Clin Res Ctr, Pekarska 53, Brno 65691, Czech Republic.
EM peter.kruzliak@savba.sk
OI Toth, Stefan/0000-0003-3467-7485; Vesela, Jarmila/0000-0003-2734-2804;
   Maretta, Milan/0000-0002-8792-4032; Kubatka, Peter/0000-0003-4312-5076
FU European Regional Development Fund-Project FNUSA-ICRC
   [CZ.1.05/1.1.00/02.0123]; VEGA [1/0043/12];  [CEMIO-ITMS-26220120058]
FX This study was supported by the grant of European Regional Development
   Fund-Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123),
   CEMIO-ITMS-26220120058 and VEGA 1/0043/12. We gratefully acknowledge
   material and technical assistance of A. Hantke.
CR [Anonymous], 2012, JAMA, V307
   Cranshawand JH, 2003, CURR ANAESTH CRIT CA, V14, P66
   Crimi Ettore, 2004, Best Pract Res Clin Anaesthesiol, V18, P477, DOI 10.1016/S1521-6896(03)00121-6
   Fabriek BO, 2005, IMMUNOBIOLOGY, V210, P153, DOI 10.1016/j.imbio.2005.05.010
   Franze E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069839
   Grattendick K, 2002, AM J RESP CELL MOL, V26, P716, DOI 10.1165/ajrcmb.26.6.4723
   Kennedy AD, 2009, IMMUNOL RES, V43, P25, DOI 10.1007/s12026-008-8049-6
   LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283
   Maus U, 2002, AM J RESP CRIT CARE, V166, P268, DOI 10.1164/rccm.2112012
   Maus U, 2001, AM J PHYSIOL-LUNG C, V280, pL58, DOI 10.1152/ajplung.2001.280.1.L58
   Mura M, 2010, AM J PATHOL, V176, P1725, DOI 10.2353/ajpath.2010.090209
   Rosseau S, 2000, AM J PHYSIOL-LUNG C, V279, pL25, DOI 10.1152/ajplung.2000.279.1.L25
   Schutte H, 1996, EUR RESPIR J, V9, P1858, DOI 10.1183/09031936.96.09091858
   Signorelli S, 2010, CELL PHYSIOL BIOCHEM, V25, P135, DOI 10.1159/000272066
   Sugamata R, 2012, MICROBIOL IMMUNOL, V56, P171, DOI 10.1111/j.1348-0421.2011.00424.x
   SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016
   Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397
   Toth S, 2009, FOLIA HISTOCHEM CYTO, V47, P431, DOI 10.2478/v10042-009-0046-7
   Wenzel I, 1996, EUR J IMMUNOL, V26, P2758, DOI 10.1002/eji.1830261131
   ZWADLOKLARWASSER G, 1990, INT ARCH ALLER A IMM, V91, P175, DOI 10.1159/000235111
NR 20
TC 12
Z9 13
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 7
BP 4539
EP 4544
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA AO3VJ
UT WOS:000341264400122
PM 25120850
DA 2023-08-21
ER

PT J
AU Mondrinos, MJ
   Zhang, T
   Sun, S
   Kennedy, PA
   King, DJ
   Wolfson, MR
   Knight, LC
   Scalia, R
   Kilpatric, LE
AF Mondrinos, Mark J.
   Zhang, Ting
   Sun, Shuang
   Kennedy, Paul A.
   King, Devon J.
   Wolfson, Marla R.
   Knight, Linda C.
   Scalia, Rosario
   Kilpatric, Laurie E.
TI Pulmonary Endothelial Protein Kinase C-Delta (PKC delta) Regulates
   Neutrophil Migration in Acute Lung Inflammation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B; TNF-ALPHA;
   STREPTOCOCCUS-PNEUMONIAE; ADHESION MOLECULE-1; LEUKOCYTE ADHESION;
   GENE-EXPRESSION; RECRUITMENT; CELLS; ACTIVATION
AB Excessive neutrophil migration across the pulmonary endothelium into the lung and release of oxidants and proteases are key elements in pathogenesis of acute lung injury. Previously, we identified protein kinase C-delta (PKC delta) as an important regulator of proinflammatory signaling in human neutrophils and demonstrated that intratracheal instillation of a TAT-conjugated PKC delta inhibitory peptide (PKC delta-TAT) is lung protective in a rat model of sepsis-induced indirect pulmonary injury (cecal ligation and puncture). In the present study, intratracheal instillation of this PKC delta inhibitor resulted in peptide distribution throughout the lung parenchyma and pulmonary endothelium and decreased neutrophil influx, with concomitant attenuation of sepsis-induced endothelial ICAM-1 and VCAM-1 expression in this model. To further delineate the role of PKC delta in regulating neutrophil migration, we used an in vitro transmigration model with human pulmonary microvascular endothelial cells (PMVECs). Consistent with in vivo findings, inhibition of PMVEC PKC delta decreased IL-1 beta-mediated neutrophil transmigration. PKC delta regulation was stimulus-dependent; PKC delta was required for transmigration mediated by IL-1 beta and fMLP (integrin-dependent), but not IL-8 (integrin-independent). PKC delta was essential for IL-1 beta-mediated neutrophil adherence and NF-kappa B-dependent expression of ICAM-1 and VCAM-1. In PMVECs, IL-1 beta-mediated production of ROS and activation of redox-sensitive NF-kappa B were PKC delta dependent, suggesting an upstream signaling role. Thus, PKC delta has an important role in regulating neutrophil-endothelial cell interactions and recruitment to the inflamed lung.
C1 [Mondrinos, Mark J.; Zhang, Ting; Sun, Shuang; Kennedy, Paul A.; King, Devon J.; Wolfson, Marla R.; Scalia, Rosario; Kilpatric, Laurie E.] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140, United States.
C1 [Mondrinos, Mark J.; Zhang, Ting; Sun, Shuang; Kennedy, Paul A.; King, Devon J.; Wolfson, Marla R.; Kilpatric, Laurie E.] Temple Univ, Sch Med, Ctr Inflammat Translat & Clin Lung Res, Philadelphia, PA 19140, United States.
C1 [Mondrinos, Mark J.; Knight, Linda C.; Kilpatric, Laurie E.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140, United States.
C1 [Knight, Linda C.] Temple Univ, Sch Med, Dept Radiol, Philadelphia, PA 19140, United States.
C1 [Scalia, Rosario] Temple Univ, Sch Med, Cardiovasc Res Ctr, Philadelphia, PA 19140, United States.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); Temple University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Temple University
RP Kilpatric, LE (corresponding author), Temple Univ, Sch Med, Ctr Inflammat Translat & Clin Lung Res, Broad St,Room 1153 MERB, Philadelphia, PA 19140 USA.
EM laurie.kilpatrick@temple.edu
OI Scalia, Rosario/0000-0002-1829-943X
FU NIH [RO1 HL111552, R01 DK064344, 5T32-HL007777]; DoD/ONR
   [N00014-12-1-0597]
FX Supported in part by NIH grants RO1 HL111552 (L.E.K.), R01 DK064344
   (R.S.), 5T32-HL007777 (M.J.M.) and DoD/ONR N00014-12-1-0597 (M.R.W.).
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x
   Aldridge AJ, 2002, EUR J SURG, V168, P204, DOI 10.1080/11024150260102807
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Asaduzzaman M, 2008, SHOCK, V30, P254, DOI 10.1097/shk.0b013e318162c567
   Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121
   Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200
   Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Cai WJ, 2010, AM J PHYSIOL-CELL PH, V298, pC624, DOI 10.1152/ajpcell.00463.2009
   Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Chou WH, 2004, J CLIN INVEST, V114, P49, DOI 10.1172/JC1200421655
   Cohen P, 2009, CURR OPIN CELL BIOL, V21, P317, DOI 10.1016/j.ceb.2009.01.015
   Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200
   de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193
   Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s
   Gaestel M, 2009, NAT REV DRUG DISCOV, V8, P480, DOI 10.1038/nrd2829
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   Guo RF, 2002, FREE RADICAL BIO MED, V33, P303, DOI 10.1016/S0891-5849(02)00823-7
   Guo RF, 2002, J IMMUNOL, V169, P307, DOI 10.4049/jimmunol.169.1.307
   Hu R, 2013, FRONT BIOSCI-LANDMRK, V18, P1244, DOI 10.2741/4176
   Ibbotson GC, 2001, NAT MED, V7, P465, DOI 10.1038/86539
   Kadioglu A, 2011, J IMMUNOL, V186, P5907, DOI 10.4049/jimmunol.1001533
   Kilpatrick LE, 2006, J LEUKOCYTE BIOL, V80, P1512, DOI 10.1189/jlb.0406284
   Kilpatrick LE, 2011, J LEUKOCYTE BIOL, V89, P3, DOI 10.1189/jlb.0510281
   Kilpatrick LE, 2010, J LEUKOCYTE BIOL, V87, P153, DOI 10.1189/jlb.0408230
   Kilpatrick LE, 2004, AM J PHYSIOL-CELL PH, V287, pC633, DOI 10.1152/ajpcell.00486.2003
   Kilpatrick LE, 2002, AM J PHYSIOL-CELL PH, V283, pC48, DOI 10.1152/ajpcell.00385.2001
   Kilpatrick LE, 2000, AM J PHYSIOL-CELL PH, V279, pC2011, DOI 10.1152/ajpcell.2000.279.6.C2011
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Li QA, 2006, MOL CELL BIOL, V26, P140, DOI 10.1128/MCB.26.1.140-154.2006
   Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719
   Mackarel AJ, 2001, J IMMUNOL, V167, P2839, DOI 10.4049/jimmunol.167.5.2839
   Mackarel AJ, 2000, AM J RESP CELL MOL, V23, P154, DOI 10.1165/ajrcmb.23.2.3853
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Martins JO, 2011, J LEUKOCYTE BIOL, V89, P1, DOI 10.1189/jlb.0810452
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200
   Minhajuddin M, 2009, J BIOL CHEM, V284, P4052, DOI 10.1074/jbc.M805032200
   Mondrinos MJ, 2013, SHOCK, V39, P467, DOI 10.1097/SHK.0b013e318294f85a
   Moreland JG, 2004, J IMMUNOL, V172, P426, DOI 10.4049/jimmunol.172.1.426
   Muller S, 2010, EXPERT OPIN DRUG DIS, V5, P867, DOI 10.1517/17460441.2010.504203
   Muller AM, 2002, J PATHOL, V198, P270, DOI 10.1002/path.1186
   O'Brien CD, 2003, BLOOD, V101, P2816, DOI 10.1182/blood-2002-08-2396
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681
   Pelosi P, 2003, EUR RESPIR J, V22, p48S, DOI 10.1183/09031936.03.00420803
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Qin Y, 2012, J DRUG TARGET, V20, P235, DOI 10.3109/1061186X.2011.639022
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Ramnath RD, 2010, J MOL MED, V88, P1055, DOI 10.1007/s00109-010-0647-9
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Reutershan J, 2004, CRIT CARE, V8, P453, DOI 10.1186/cc2881
   Rossaint J, 2013, J INNATE IMMUN, V5, P348, DOI 10.1159/000345943
   Sevransky JE, 2008, CHEST, V134, P534, DOI 10.1378/chest.08-0309
   Sheu CC, 2010, INTENS CARE MED, V36, P963, DOI 10.1007/s00134-010-1851-3
   Shukla A, 2007, AM J PATHOL, V170, P140, DOI 10.2353/ajpath.2007.060381
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736
   Ushio-Fukai M, 2009, ANTIOXID REDOX SIGN, V11, P1289, DOI [10.1089/ars.2008.2333, 10.1089/ARS.2008.2333]
   WARE LB, 2000, NEW ENGL J MED, V342, P1334, DOI [DOI 10.1056/NEJM200005043421806, 10.1056/NEJM200005043421806]
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Woo CH, 2005, AM J PHYSIOL-LUNG C, V288, pL307, DOI 10.1152/ajplung.00105.2004
   Yan SR, 2004, IMMUNOL CELL BIOL, V82, P435, DOI 10.1111/j.0818-9641.2004.01268.x
NR 72
TC 33
Z9 36
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2014
VL 184
IS 1
BP 200
EP 213
DI 10.1016/j.ajpath.2013.09.010
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 278DU
UT WOS:000328870100021
PM 24211111
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Moraes, L
   Santos, CL
   Santos, RS
   Cruz, FF
   Saddy, F
   Morales, MM
   Capelozzi, VL
   Silva, PL
   de Abreu, MG
   Garcia, CSNB
   Pelosi, P
   Rocco, PRM
AF Moraes, Lillian
   Santos, Cintia Lourenco
   Santos, Raquel Souza
   Cruz, Fernanda Ferreira
   Saddy, Felipe
   Morales, Marcelo Marcos
   Capelozzi, Vera Luiza
   Silva, Pedro Leme
   de Abreu, Marcelo Gama
   Nascimento Baez Garcia, Cristiane Sousa
   Pelosi, Paolo
   Macedo Rocco, Patricia Rieken
TI Effects of sigh during pressure control and pressure support ventilation
   in pulmonary and extrapulmonary mild acute lung injury
SO CRITICAL CARE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; IMPROVES GAS-EXCHANGE; RECRUITMENT
   MANEUVERS; VARIABILITY; STRATEGIES; MECHANICS; FREQUENCY; ETIOLOGY
AB Introduction: Sigh improves oxygenation and lung mechanics during pressure control ventilation (PCV) and pressure support ventilation (PSV) in patients with acute respiratory distress syndrome. However, so far, no study has evaluated the biological impact of sigh during PCV or PSV on the lung and distal organs in experimental pulmonary (p) and extrapulmonary (exp) mild acute lung injury (ALI).
   Methods: In 48 Wistar rats, ALI was induced by Escherichia coli lipopolysaccharide either intratracheally (ALIp) or intraperitoneally (ALlexp). After 24 hours, animals were anesthetized and mechanically ventilated with PCV or PSV with a tidal volume of 6 mL/kg, FiO(2)=0.4, and PEEP = 5 cmH(2)O for 1 hour. Both ventilator strategies were then randomly assigned to receive periodic sighs (10 sighs/hour, Sigh) or not (non-Sigh, NS). Ventilatory and mechanical parameters, arterial blood gases, lung histology, interleukin (IL)-1 beta, IL-6, caspase-3, and type III procollagen (PCIII) mRNA expression in lung tissue, and number of apoptotic cells in lung, liver, and kidney specimens were analyzed.
   Results: In both ALI etiologies: (1) PCV-Sigh and PSV-Sigh reduced transpulmonary pressure, and (2) PSV-Sigh reduced the respiratory drive compared to PSV-NS. In ALIp: (1) PCV-Sigh and PSV-Sigh decreased alveolar collapse as well as IL-1 beta, IL-6, caspase-3, and PCIII expressions in lung tissue, (2) PCV-Sigh increased alveolar-capillary membrane and endothelial cell damage, and (3) abnormal myofibril with Z-disk edema was greater in PCV-NS than PSV-NS. In ALlexp: (1) PSV-Sigh reduced alveolar collapse, but led to damage to alveolar-capillary membrane, as well as type II epithelial and endothelial cells, (2) PCV-Sigh and PSV-Sigh increased IL-1 beta IL-6, caspase-3, and PCIII expressions, and (3) PCV-Sigh increased the number of apoptotic cells in the lung compared to PCV-NS.
   Conclusions: In these models of mild ALIp and ALlexp, sigh reduced alveolar collapse and transpulmonary pressures during both PCV and PSV; however, improved lung protection only during PSV in ALIp.
C1 [Moraes, Lillian; Santos, Cintia Lourenco; Santos, Raquel Souza; Cruz, Fernanda Ferreira; Saddy, Felipe; Silva, Pedro Leme; Nascimento Baez Garcia, Cristiane Sousa; Macedo Rocco, Patricia Rieken] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ctr Ciencias Saude,Ilha Fundao, BR-21941902 Rio De Janeiro, RJ, Brazil.
C1 [Santos, Cintia Lourenco] Univ Fed Rio de Janeiro, Fac Med, Expt Surg Lab, BR-21941901 Rio De Janeiro, RJ, Brazil.
C1 [Saddy, Felipe] Hosp Procardiaco, BR-22280003 Rio De Janeiro, RJ, Brazil.
C1 [Saddy, Felipe] Hosp Copa DOr, BR-22031011 Rio De Janeiro, RJ, Brazil.
C1 [Morales, Marcelo Marcos] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Cellular & Mol Physiol, BR-21941901 Rio De Janeiro, RJ, Brazil.
C1 [Capelozzi, Vera Luiza] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05508070 Sao Paulo, Brazil.
C1 [de Abreu, Marcelo Gama] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Anesthesiol & Intens Care Therapy, Pulm Engn Grp, D-01069 Dresden, Germany.
C1 [Nascimento Baez Garcia, Cristiane Sousa] Rio de Janeiro Fed Inst Educ Sci & Technol, BR-25715000 Rio De Janeiro, RJ, Brazil.
C1 [Pelosi, Paolo] Univ Genoa, IRCCS AOU San Martino IST, Dept Surg Sci & Integrated Diagnost, I-16132 Genoa, Italy.
C3 Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de
   Janeiro; Universidade Federal do Rio de Janeiro; Universidade de Sao
   Paulo; Technische Universitat Dresden; Carl Gustav Carus University
   Hospital; University of Genoa; IRCCS AOU San Martino IST
RP Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ctr Ciencias Saude,Ilha Fundao, Ave Carlos Chagas Filho S-N,Bloco G-014, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM prmrocco@gmail.com
RI , Capelozzi/N-1737-2019; Cruz, Fernanda F/P-1193-2016; Capelozzi, Vera
   Luiza/C-6363-2013; Rocco, Patricia/I-7460-2012; Silva, Pedro
   Leme/AAD-8236-2019
OI , Capelozzi/0000-0001-9732-5853; Cruz, Fernanda F/0000-0001-9443-3648;
   Rocco, Patricia/0000-0003-1412-7136; Silva, Pedro
   Leme/0000-0001-5838-4949; delmonte, samuel/0000-0002-3289-4577; Gama de
   Abreu, Marcelo/0000-0002-3554-883X; Pelosi, Paolo/0000-0001-5055-3023
FU Centers of Excellence Program (PRONEX-FAPERJ); Brazilian Council for
   Scientific and Technological Development (CNPq); Rio de Janeiro State
   Research Foundation (FAPERJ); Sao Paulo State Research Foundation
   (FAPESP); National Institute of Science and Technology of Drugs and
   Medicine (INCT-INOFAR); Coordination for the Improvement of Higher Level
   Personnel (CAPES); European Community
FX This study was supported by the Centers of Excellence Program
   (PRONEX-FAPERJ), the Brazilian Council for Scientific and Technological
   Development (CNPq), the Rio de Janeiro State Research Foundation
   (FAPERJ), the Sao Paulo State Research Foundation (FAPESP), the National
   Institute of Science and Technology of Drugs and Medicine (INCT-INOFAR),
   the Coordination for the Improvement of Higher Level Personnel (CAPES),
   and the European Community Seventh Framework Programme (TARKINAID,
   FP7-2007-2013).
CR BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Brack T, 2002, AM J RESP CRIT CARE, V165, P1260, DOI 10.1164/rccm.2201018
   Brander L, 2006, CRIT CARE, V10, DOI 10.1186/cc3953
   Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124
   Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC
   Fanelli V, 2009, CRIT CARE MED, V37, P1046, DOI 10.1097/CCM.0b013e3181968e7e
   Foti G, 2000, INTENS CARE MED, V26, P501, DOI 10.1007/s001340051196
   Galletly D, 1999, BRIT J ANAESTH, V83, P552, DOI 10.1093/bja/83.4.552
   Guerin C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-9
   Laffey JG, 2004, INTENS CARE MED, V30, P347, DOI 10.1007/s00134-003-2051-1
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Nacoti M, 2012, MINERVA ANESTESIOL, V78, P920
   Oliveira GP, 2009, CRIT CARE, V13, DOI 10.1186/cc7888
   Passaro CP, 2009, CRIT CARE MED, V37, P1011, DOI 10.1097/CCM.0b013e3181962d85
   Patroniti N, 2002, ANESTHESIOLOGY, V96, P788, DOI 10.1097/00000542-200204000-00004
   Pelosi P, 1999, AM J RESP CRIT CARE, V159, P872, DOI 10.1164/ajrccm.159.3.9802090
   Pelosi P, 2001, AM J RESP CRIT CARE, V164, P122, DOI 10.1164/ajrccm.164.1.2007010
   Perlman CE, 2007, J APPL PHYSIOL, V103, P1037, DOI 10.1152/japplphysiol.00160.2007
   Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011
   Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
   Saddy F, 2013, CRIT CARE, V17, DOI 10.1186/cc13051
   Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6
   Santiago VR, 2010, CRIT CARE MED, V38, P2207, DOI 10.1097/CCM.0b013e3181f3e076
   Santos CL, 2012, INTENS CARE MED, V38, P499, DOI 10.1007/s00134-011-2451-6
   Silva PL, 2013, CRIT CARE MED, V41, pE256, DOI 10.1097/CCM.0b013e31828a3c13
   Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281
   Steimback PW, 2009, INTENS CARE MED, V35, P1120, DOI 10.1007/s00134-009-1439-y
   Suki B, 2014, CURR OPIN CRIT CARE, V20, P17, DOI 10.1097/MCC.0000000000000043
   Weibel ER, 1990, MODELS LUNG DIS MICR, V47, P199
NR 30
TC 21
Z9 23
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2014
VL 18
IS 4
AR 474
DI 10.1186/s13054-014-0474-4
PG 13
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CA4MJ
UT WOS:000348878200052
PM 25113136
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Short, KR
   Kroeze, EJBV
   Fouchier, RAM
   Kuiken, T
AF Short, Kirsty R.
   Kroeze, Edwin J. B. Veldhuis
   Fouchier, Ron A. M.
   Kuiken, Thijs
TI Pathogenesis of influenza-induced acute respiratory distress syndrome
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID ALVEOLAR EPITHELIAL-CELLS; VIRUS-INDUCED PNEUMONIA;
   TUMOR-NECROSIS-FACTOR; DOUBLE-STRANDED-RNA; A H5N1 VIRUSES; AVIAN
   INFLUENZA; PANDEMIC INFLUENZA; HUMAN MACROPHAGES; CYTOKINE RESPONSES;
   ENDOTHELIAL-CELLS
AB Acute respiratory distress syndrome (ARDS) is a fatal complication of influenza infection. In this Review we provide an integrated model for its pathogenesis. ARDS involves damage to the epithelial endothelial barrier, fluid leakage into the alveolar lumen, and respiratory insufficiency. The most important part of the epithelial endothelial barrier is the alveolar epithelium, strengthened by tight junctions. Influenza virus targets these epithelial cells, reducing sodium pump activity, damaging tight junctions, and killing infected cells. Infected epithelial cells produce cytokines that attract leucocytes-neutrophils and macrophages and activate adjacent endothelial cells. Activated endothelial cells and infiltrated leucocytes stimulate further infiltration, and leucocytes induce production of reactive oxygen species and nitric oxide that damage the barrier. Activated macrophages also cause direct apoptosis of epithelial cells. This model for influenza-induced ARDS differs from the dassic model, which is centred on endothelial damage, and provides a rationale for therapeutic intervention to moderate host response in influenza-induced ARDS.
C1 [Short, Kirsty R.; Kroeze, Edwin J. B. Veldhuis; Fouchier, Ron A. M.; Kuiken, Thijs] Erasmus MC, Dept Virosci, NL-3015 GE Rotterdam, Zuid Holland, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP Kuiken, T (corresponding author), Erasmus MC, Dept Virosci, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Zuid Holland, Netherlands.
EM t.kuiken@erasmusmc.nl
RI Fouchier, Ron A/A-1911-2014
OI Fouchier, Ron A/0000-0001-8095-2869; Short, Kirsty/0000-0003-4963-6184;
   Kuiken, Thijs/0000-0001-5501-9049
FU NHMRC CJ Martin postdoctoral fellowship [1054081]; NIH/NIAID
   [HHSN266200700010C]; European Union FP7 ANTIGONE [278976]
FX We thank Lonneke Leijten for doing Pankeratin and von Willebrand factor
   staining. We thank Judith van den Brand for the provision of histology
   sections and Debby van Riel for the provision of histology sections and
   critical reading of the Review. KRS is supported by an NHMRC CJ Martin
   postdoctoral fellowship (1054081). RAMF is supported by NIH/NIAID
   contract HHSN266200700010C. TK is supported by European Union FP7
   ANTIGONE contract 278976.
CR Adachi M, 1997, INT ARCH ALLERGY IMM, V113, P307, DOI 10.1159/000237584
   Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448
   Alexander DJ, 2000, VET MICROBIOL, V74, P3, DOI 10.1016/S0378-1135(00)00160-7
   Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942
   Armstrong SM, 2013, VIRULENCE, V4, P537, DOI 10.4161/viru.25779
   Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323
   Arndt U, 2002, J VIROL, V76, P9298, DOI 10.1128/JVI.76.18.9298-9306.2002
   Bandyopadhyay U, 1999, CURR SCI INDIA, V77, P658
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Basler CF, 2008, ANTIVIR RES, V79, P166, DOI 10.1016/j.antiviral.2008.04.006
   Bellingan GJ, 2002, THORAX, V57, P540, DOI 10.1136/thorax.57.6.540
   Bemasconi D, 2005, J BIOL CHEM, V280, P24127
   Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010
   Brundage JF, 2008, EMERG INFECT DIS, V14, P1193, DOI 10.3201/eid1408.071313
   Brunkhorst FM, 1999, CRIT CARE MED, V27, P2172, DOI 10.1097/00003246-199910000-00016
   Brydon EWA, 2003, J GEN VIROL, V84, P2389, DOI 10.1099/vir.0.18913-0
   Budinger GRS, 2006, CLIN CHEST MED, V27, P655, DOI 10.1016/j.ccm.2006.06.007
   Cameron CM, 2008, J VIROL, V82, P11308, DOI 10.1128/JVI.00691-08
   Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135
   Chan MCW, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-102
   Chen XJ, 2004, AM J PHYSIOL-LUNG C, V287, pL366, DOI 10.1152/ajplung.00011.2004
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   Chien YW, 2009, NEW ENGL J MED, V361, P2582, DOI 10.1056/NEJMc0908216
   Childs RA, 2009, NAT BIOTECHNOL, V27, P797, DOI 10.1038/nbt0909-797
   CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M
   Chotpitayasunondh T, 2005, EMERG INFECT DIS, V11, P201, DOI 10.3201/eid1102.041061
   Chutinimitkul S, 2010, J VIROL, V84, P6825, DOI 10.1128/JVI.02737-09
   Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/eri.11.56, 10.1586/ERI.11.56]
   Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4
   Dawson TC, 2000, AM J PATHOL, V156, P1951, DOI 10.1016/S0002-9440(10)65068-7
   Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004
   Fiers W, 2004, VIRUS RES, V103, P173, DOI 10.1016/j.virusres.2004.02.030
   Folkesson HG, 2006, AM J RESP CELL MOL, V35, P10, DOI 10.1165/rcmb.2006-0080SF
   Friesenhagen J, 2012, J LEUKOCYTE BIOL, V92, P11, DOI 10.1189/jlb.0911479
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Geiler J, 2011, MED MICROBIOL IMMUN, V200, P53, DOI 10.1007/s00430-010-0173-y
   Golebiewski L, 2011, J VIROL, V85, P10639, DOI 10.1128/JVI.05070-11
   GORIN AB, 1979, J APPL PHYSIOL, V47, P1315, DOI 10.1152/jappl.1979.47.6.1315
   Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3
   Guarner J, 2009, ARCH MED RES, V40, P655, DOI 10.1016/j.arcmed.2009.10.001
   Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200
   Hale BG, 2010, FUTURE MICROBIOL, V5, P23, DOI 10.2217/FMB.09.108
   Hemmers S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022043
   Herold S, 2006, J IMMUNOL, V177, P1817, DOI 10.4049/jimmunol.177.3.1817
   Herold S, 2008, J EXP MED, V205, P3065, DOI 10.1084/jem.20080201
   Hogner K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003188
   HOLT PG, 1986, CLIN EXP IMMUNOL, V63, P261
   Horby P, 2013, NATURE, V496, P399, DOI 10.1038/496399a
   Huber D, 1999, INVAS METAST, V18, P70
   Hui KPY, 2009, J IMMUNOL, V182, P1088, DOI 10.4049/jimmunol.182.2.1088
   Husain AN, 2010, ROBBINS COTRAN PATHO, P715
   Ichikawa A, 2013, AM J RESP CRIT CARE, V187, P65, DOI 10.1164/rccm.201203-0508OC
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Ishiguro N, 2004, ARCH VIROL, V149, P17, DOI 10.1007/s00705-003-0208-4
   Jaeschke H, 1997, J LEUKOCYTE BIOL, V61, P647, DOI 10.1002/jlb.61.6.647
   Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022
   Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541
   Kash JC, 2006, VIRUS RES, V119, P111, DOI 10.1016/j.virusres.2005.10.013
   Koval M, 2013, ANNU REV PHYSIOL, V75, P551, DOI 10.1146/annurev-physiol-030212-183809
   Kuiken T, 2010, VET PATHOL, V47, P893, DOI 10.1177/0300985810378651
   Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025
   Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997
   Lam WY, 2008, J VIROL, V82, P2741, DOI 10.1128/JVI.01712-07
   Lazrak A, 2009, FASEB J, V23, P3829, DOI 10.1096/fj.09-135590
   LEFKOWITZ DL, 1995, MED HYPOTHESES, V44, P58, DOI 10.1016/0306-9877(95)90303-8
   Lehmann C, 1996, RES VIROLOGY, V147, P123, DOI 10.1016/0923-2516(96)80226-3
   MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338
   Matikainen S, 2000, VIROLOGY, V276, P138, DOI 10.1006/viro.2000.0542
   Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC
   Michaelis M, 2010, MED MICROBIOL IMMUN, V199, P291, DOI 10.1007/s00430-010-0155-0
   Mok KP, 2009, J INFECT DIS, V200, P1104, DOI 10.1086/605606
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Morens DM, 2007, J INFECT DIS, V195, P1018, DOI 10.1086/511989
   MULLIN JM, 1990, CANCER RES, V50, P2172
   Nakajima N, 2013, MODERN PATHOL, V26, P357, DOI 10.1038/modpathol.2012.193
   Narasaraju T, 2010, AM J RESP CELL MOL, V42, P732, DOI 10.1165/rcmb.2008-0423OC
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Ocana-Macchi M, 2009, J VIROL, V83, P12947, DOI 10.1128/JVI.00468-09
   ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070
   Okada T, 2011, J STRENGTH COND RES, V25, P252, DOI 10.1519/JSC.0b013e3181b22b3e
   Osterlund P, 2010, J VIROL, V84, P1414, DOI 10.1128/JVI.01619-09
   Padalko E, 2004, P NATL ACAD SCI USA, V101, P11731, DOI 10.1073/pnas.0400518101
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Peiris JSM, 2009, TRENDS IMMUNOL, V30, P574, DOI 10.1016/j.it.2009.09.004
   Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5
   Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   PINKERTON KE, 1992, COMP BIOL NORMAL LUN, P121
   Pirhonen J, 1999, J IMMUNOL, V162, P7322
   Ramsey C, 2011, CURR OPIN CRIT CARE, V17, P64, DOI 10.1097/MCC.0b013e3283427259
   Reperant LA, 2012, J VIROL, V86, P1158, DOI 10.1128/JVI.06375-11
   Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200
   Sakai S, 2000, J VIROL, V74, P2472, DOI 10.1128/JVI.74.5.2472-2476.2000
   Salomon R, 2007, P NATL ACAD SCI USA, V104, P12479, DOI 10.1073/pnas.0705289104
   SchultzCherry S, 1996, J VIROL, V70, P8624, DOI 10.1128/JVI.70.12.8624-8629.1996
   Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757
   Sevransky JE, 2009, CRIT CARE, V13, DOI 10.1186/cc8048
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a
   Snelgrove RJ, 2006, EUR J IMMUNOL, V36, P1364, DOI 10.1002/eji.200635977
   Stevens J, 2006, J MOL BIOL, V355, P1143, DOI 10.1016/j.jmb.2005.11.002
   Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1
   Sugamata R, 2012, MICROBIOL IMMUNOL, V56, P171, DOI 10.1111/j.1348-0421.2011.00424.x
   Sumikoshi M, 2008, J MED VIROL, V80, P1072, DOI 10.1002/jmv.21185
   Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6
   Szretter KJ, 2007, J VIROL, V81, P2736, DOI 10.1128/JVI.02336-06
   Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996
   Tapper H, 1996, J LEUKOCYTE BIOL, V59, P613, DOI 10.1002/jlb.59.5.613
   Tate MD, 2010, J VIROL, V84, P7569, DOI 10.1128/JVI.00291-10
   Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497
   Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   To KKW, 2010, CLIN INFECT DIS, V50, P850, DOI 10.1086/650581
   Uiprasertkui M, 2007, EMERG INFECT DIS, V13, P708, DOI 10.3201/eid1305.060572
   Uiprasertkul M, 2005, EMERG INFECT DIS, V11, P1036, DOI 10.3201/eid1107.041313
   Valberg PA, 1992, COMP BIOL NORMAL LUN, P681
   van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548
   van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248
   van Riel D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002099
   Visseren FLJ, 1999, J LAB CLIN MED, V134, P623, DOI 10.1016/S0022-2143(99)90103-8
   Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443
   Vlahos R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001271
   von Kockritz-Blickwede M, 2009, J MOL MED, V87, P775, DOI 10.1007/s00109-009-0481-0
   WALKER DC, 1995, MICROVASC RES, V50, P397, DOI 10.1006/mvre.1995.1067
   Wang JP, 2008, BLOOD, V112, P2028, DOI 10.1182/blood-2008-01-132860
   Webster RG, 2006, EMERG INFECT DIS, V12, P3, DOI 10.3201/eid1201.051024
   WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218
   WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388
   Wolk KE, 2008, AM J RESP CRIT CARE, V178, P969, DOI 10.1164/rccm.200803-455OC
   Woo PCY, 2010, J INFECT DIS, V201, P346, DOI 10.1086/649785
   Wyble CW, 1997, J SURG RES, V73, P107, DOI 10.1006/jsre.1997.5207
   YAMAMOTO K, 1991, J INFECT DIS, V164, P8, DOI 10.1093/infdis/164.1.8
   Yu WCL, 2011, J VIROL, V85, P6844, DOI 10.1128/JVI.02200-10
   Zeng H, 2013, J VIROL, V87, P2597, DOI 10.1128/JVI.02885-12
   Zeng H, 2012, J VIROL, V86, P667, DOI 10.1128/JVI.06348-11
   Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105
NR 139
TC 334
Z9 362
U1 10
U2 63
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JAN
PY 2014
VL 14
IS 1
BP 57
EP 69
DI 10.1016/S1473-3099(13)70286-X
PG 13
WC Infectious Diseases
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases
GA 281DC
UT WOS:000329079100022
PM 24239327
DA 2023-08-21
ER

PT J
AU Uhlig, S
   Yang, Y
   Waade, J
   Wittenberg, C
   Babendreyer, A
   Kuebler, WM
AF Uhlig, Stefan
   Yang, Yang
   Waade, Josephine
   Wittenberg, Claudia
   Babendreyer, Aaron
   Kuebler, Wolfgang M.
TI Differential Regulation of Lung Endothelial Permeability in Vitro and in
   Situ
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Review
DE ECs/HPMECs/HUVECs/MPVECs; pulmonary edema; permeability; Platelet activating factor; calcium; Rho/RhoA; Thrombin; LPS; TNF/TNF-alpha/TNFR1; S1P/S1PR1/S1PR2/S1PR3 
ID TUMOR-NECROSIS-FACTOR; PLATELET-ACTIVATING-FACTOR; ISOLATED RAT LUNGS;
   TNF-ALPHA; VASCULAR-PERMEABILITY; RHO-KINASE; BARRIER DYSFUNCTION;
   PULMONARY-EDEMA; MICROVASCULAR PERMEABILITY; PROINFLAMMATORY RESPONSES
AB In the lungs, increased vascular permeability can lead to acute lung injury. Because vascular permeability is regulated primarily by endothelial cells, many researchers have studied endothelial cell monolayers in culture, in order to understand the pathomechanisms of pulmonary edema. Such studies are based on the assumption that endothelial cells in culture behave like endothelial cells in situ. Here we show that this assumption is largely unfounded. Cultured endothelial cells show profound differences compared to their physiological counterparts, including a dysregulated calcium homeostasis. They fail to reproduce the pulmonary responses to agents such as platelet activating factor. In contrast, they respond in a Rho-kinase depend fashion to thrombin, LPS or TNF. This is a striking finding for three reasons: (i) in the lungs, none of these agents increases vascular permeability by a direct interaction with endothelial cells; (ii) The endothelial Rho-kinase pathway seems to play little role in the development of pulmonary edema; (iii) This response pattern is similar for many endothelial cells in culture irrespective of their origin, which is in contrast to the stark heterogeneity of endothelial cells in situ. It appears that most endothelial in culture tend to develop a similar phenotyp that is not representative of any of the known endothelial cells of the lungs. We conclude that at present cultured endothelial cells are not useful to study the pathomechanisms of pulmonary edema. Copyright (C) 2014 S. Karger AG, Basel
C1 [Uhlig, Stefan; Yang, Yang; Waade, Josephine; Babendreyer, Aaron] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, D-52076 Aachen, Germany.
C1 [Wittenberg, Claudia; Kuebler, Wolfgang M.] Charite, Inst Physiol, D-13353 Berlin, Germany.
C1 [Kuebler, Wolfgang M.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada.
C1 [Kuebler, Wolfgang M.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada.
C3 RWTH Aachen University; Free University of Berlin; Humboldt University
   of Berlin; Charite Universitatsmedizin Berlin; University of Toronto;
   University of Toronto
RP Uhlig, S (corresponding author), Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Wendlingweg 2, D-52076 Aachen, Germany.
EM suhlig@ukaachen.de
RI Uhlig, Stefan/A-7290-2014
OI Uhlig, Stefan/0000-0003-2332-1280; Kuebler,
   Wolfgang/0000-0003-4100-2961; Babendreyer, Aaron/0000-0001-7207-8139
FU Deutsche Forschungsgemeinschaft [SPP1267]
FX This study was supported by the Deutsche Forschungsgemeinschaft within
   the SPP1267 "Sphingolipids - Signal and Disease".
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Adamson RH, 2003, AM J PHYSIOL-HEART C, V285, pH406, DOI 10.1152/ajpheart.00021.2003
   Adamson RH, 2002, J PHYSIOL-LONDON, V539, P295, DOI 10.1113/jphysiol.2001.013117
   Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19
   Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006
   Aranguren XL, 2013, BLOOD, V122, P3982, DOI 10.1182/blood-2013-02-483255
   Bel-Brunon A, 2014, J MECH BEHAV BIOMED, V29, P360, DOI 10.1016/j.jmbbm.2013.09.018
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2013, MICROVASC RES, V87, P50, DOI 10.1016/j.mvr.2012.12.006
   Birukova AA, 2013, EUR RESPIR J, V41, P165, DOI 10.1183/09031936.00148311
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   BONSIGNORE MR, 1992, J APPL PHYSIOL, V73, P173, DOI 10.1152/jappl.1992.73.1.173
   Bove K, 2001, AM J PHYSIOL-LUNG C, V280, pL914, DOI 10.1152/ajplung.2001.280.5.L914
   BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977
   BUSSOLINO F, 1987, J IMMUNOL, V139, P2439
   CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980
   Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Chian CF, 2012, SHOCK, V38, P196, DOI 10.1097/SHK.0b013e31825a1982
   Chignard M, 2000, AM J PHYSIOL-LUNG C, V279, pL1083, DOI 10.1152/ajplung.2000.279.6.L1083
   Curry FRE, 2010, CARDIOVASC RES, V87, P218, DOI 10.1093/cvr/cvq115
   D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2
   DODAM JR, 1994, EXP LUNG RES, V20, P131, DOI 10.3109/01902149409064378
   Dreymueller D, 2012, EMBO MOL MED, V4, P412, DOI 10.1002/emmm.201200217
   Dudek SM, 2011, AM J RESP CELL MOL, V44, P361, DOI 10.1165/rcmb.2009-0446OC
   Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993
   FARHI LE, 1990, ADV EXP MED BIOL, V277, P579
   Ferro T, 2000, AM J PHYSIOL-LUNG C, V278, pL1107, DOI 10.1152/ajplung.2000.278.6.L1107
   Ferro TJ, 1997, AM J PHYSIOL-LUNG C, V272, pL979, DOI 10.1152/ajplung.1997.272.5.L979
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   GATTI S, 1993, CLIN EXP IMMUNOL, V91, P456
   GOERDT S, 1989, EXP CELL BIOL, V57, P185
   Goggel R, 2005, EUR RESPIR J, V25, P849, DOI 10.1183/09031936.05.00069804
   Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977
   GOLDBLUM SE, 1989, INFECT IMMUN, V57, P1218, DOI 10.1128/IAI.57.4.1218-1226.1989
   Gonzalez R, 2005, AM J PHYSIOL-LUNG C, V288, pL179, DOI 10.1152/ajplung.00272.2004
   Gorovoy M, 2007, CIRC RES, V101, P50, DOI 10.1161/CIRCRESAHA.106.145847
   HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831
   Hall CN, 2009, NITRIC OXIDE-BIOL CH, V21, P92, DOI 10.1016/j.niox.2009.07.002
   Hall SM, 2002, AM J RESP CELL MOL, V26, P333, DOI 10.1165/ajrcmb.26.3.4698
   Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007
   Hattar K, 2010, EUR RESPIR J, V36, P187, DOI 10.1183/09031936.00143308
   HEFLIN AC, 1981, J CLIN INVEST, V68, P1253, DOI 10.1172/JCI110371
   HIRAFUJI M, 1988, BIOCHEM BIOPH RES CO, V154, P910, DOI 10.1016/0006-291X(88)90226-4
   HOCKING DC, 1990, CIRC RES, V67, P68, DOI 10.1161/01.RES.67.1.68
   Hoefer IE, 2013, CARDIOVASC RES, V99, P276, DOI 10.1093/cvr/cvt089
   HORGAN MJ, 1993, AM J PHYSIOL, V264, pH1161, DOI 10.1152/ajpheart.1993.264.4.H1161
   HORGAN MJ, 1987, J APPL PHYSIOL, V63, P1993, DOI 10.1152/jappl.1987.63.5.1993
   Huynh J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002761
   Ito S, 2010, AM J RESP CELL MOL, V43, P26, DOI 10.1165/rcmb.2009-0073OC
   Jian MY, 2008, AM J RESP CELL MOL, V38, P386, DOI 10.1165/rcmb.2007-0192OC
   JOHNSON J, 1991, AM REV RESPIR DIS, V144, P179, DOI 10.1164/ajrccm/144.1.179
   Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC
   Kasper B, 2006, BLOOD, V107, P1768, DOI 10.1182/blood-2005-06-2501
   Kerem A, 2010, CIRC RES, V106, P1103, DOI 10.1161/CIRCRESAHA.109.210542
   Kim MH, 2009, AM J PHYSIOL-CELL PH, V296, pC848, DOI 10.1152/ajpcell.00520.2008
   Kim YH, 2008, DEVELOPMENT, V135, P3755, DOI 10.1242/dev.022475
   Knezevic II, 2009, J BIOL CHEM, V284, P5381, DOI 10.1074/jbc.M808958200
   Koksel O, 2005, EUR J PHARMACOL, V510, P135, DOI 10.1016/j.ejphar.2004.12.010
   KOPANIAK MM, 1983, AM J PATHOL, V110, P13
   Krishnan R, 2011, AM J PHYSIOL-CELL PH, V300, pC146, DOI 10.1152/ajpcell.00195.2010
   Kuebler WM, 2000, J CLIN INVEST, V105, P905, DOI 10.1172/JCI8604
   Kuebler WM, 2002, AM J PHYSIOL-LUNG C, V282, pL917, DOI 10.1152/ajplung.00275.2001
   Kuebler WM, 2007, J APPL PHYSIOL, V102, P1255, DOI 10.1152/japplphysiol.00786.2006
   Kuebler WM, 2010, CELL PHYSIOL BIOCHEM, V26, P29, DOI 10.1159/000315103
   Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9
   Lacorre DA, 2004, BLOOD, V103, P4164, DOI 10.1182/blood-2003-10-3537
   Lechner AJ, 1997, J CRIT CARE, V12, P28, DOI 10.1016/S0883-9441(97)90023-X
   LIN AY, 1994, BBA-MOL CELL RES, V1224, P323, DOI 10.1016/0167-4889(94)90206-2
   Lindner K, 2005, BRIT J PHARMACOL, V145, P132, DOI 10.1038/sj.bjp.0706173
   Lindner K, 2005, THESIS U LUBECK
   Liu F, 2010, J CELL BIOL, V190, P693, DOI 10.1083/jcb.201004082
   Liu HB, 2013, J CARDIOVASC PHARM, V61, P461, DOI 10.1097/FJC.0b013e31828c0933
   LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Ludwig A, 2011, METHODS MOL BIOL, V763, P319, DOI 10.1007/978-1-61779-191-8_22
   MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153
   Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005
   MARON MB, 1982, AM J PHYSIOL, V242, pH565, DOI 10.1152/ajpheart.1982.242.4.H565
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703
   MICHEL CC, 1988, J PHYSIOL-LONDON, V404, P1
   Mong PY, 2008, J IMMUNOL, V180, P550, DOI 10.4049/jimmunol.180.1.550
   MOREL NML, 1990, INFLAMMATION, V14, P571, DOI 10.1007/BF00914277
   Muller-Marschhausen K, 2008, AM J PHYSIOL-CELL PH, V294, pC324, DOI 10.1152/ajpcell.00319.2007
   Naikawadi RP, 2012, CIRC RES, V111, P1517, DOI 10.1161/CIRCRESAHA.112.273078
   NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037
   Neumann P, 2006, AM J PHYSIOL-LUNG C, V290, pL674, DOI 10.1152/ajplung.00391.2005
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   Ota Hiroki, 2011, Pulm Circ, V1, P399, DOI 10.4103/2045-8932.87309
   Parker JC, 2006, AM J PHYSIOL-LUNG C, V291, pL30, DOI 10.1152/ajplung.00317.2005
   Parker JC, 2004, AM J PHYSIOL-LUNG C, V286, pL231, DOI 10.1152/ajplung.00049.2003
   Parthasarathi K, 2002, J IMMUNOL, V169, P7078, DOI 10.4049/jimmunol.169.12.7078
   Parthasarathi K, 2006, J CLIN INVEST, V116, P2193, DOI 10.1172/JCI26605
   PARTRIDGE CA, 1993, AM J PHYSIOL, V265, pL438, DOI 10.1152/ajplung.1993.265.5.L438
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   Predescu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075846
   Pries A. R., 2006, V176, P1
   QIAO RL, 1991, J APPL PHYSIOL, V71, P2152, DOI 10.1152/jappl.1991.71.6.2152
   Qiu YC, 2000, J VASC RES, V37, P147, DOI 10.1159/000025726
   Rajagopalan LE, 2010, J PHARMACOL EXP THER, V333, P707, DOI 10.1124/jpet.110.166033
   Rausch SMK, 2011, J MECH BEHAV BIOMED, V4, P583, DOI 10.1016/j.jmbbm.2011.01.006
   Regan ER, 2012, CIRC RES, V111, P110, DOI 10.1161/CIRCRESAHA.111.261701
   Reiss LK, 2012, N-S ARCH PHARMACOL, V385, P74
   REVEL JP, 1971, P NATL ACAD SCI USA, V68, P2924, DOI 10.1073/pnas.68.12.2924
   Robinson KG, 2012, J BIOMED MATER RES A, V100A, P1356, DOI 10.1002/jbm.a.34075
   ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607
   Ryan AJ, 2003, J APPL PHYSIOL, V94, P253, DOI 10.1152/japplphysiol.00184.2002
   Samapati R, 2012, AM J RESP CRIT CARE, V185, P160, DOI 10.1164/rccm.201104-0717OC
   Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735
   Schulman CI, 2002, SHOCK, V18, P75, DOI 10.1097/00024382-200207000-00014
   Seebach J, 2000, LAB INVEST, V80, P1819, DOI 10.1038/labinvest.3780193
   Shao M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055213
   Shea BS, 2010, AM J RESP CELL MOL, V43, P662, DOI 10.1165/rcmb.2009-0345OC
   Siore AM, 2005, AM J PHYSIOL-LUNG C, V289, pL769, DOI 10.1152/ajplung.00137.2005
   STAVERMAN AJ, 1952, T FARADAY SOC, V48, P176, DOI 10.1039/tf9524800176
   STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   Suki B, 2005, J APPL PHYSIOL, V98, P1892, DOI 10.1152/japplphysiol.01087.2004
   SUTOVSKY P, 1993, BIOL REPROD, V49, P1277, DOI 10.1095/biolreprod49.6.1277
   Szczepaniak WS, 2010, AM J PHYSIOL-LUNG C, V299, pL137, DOI 10.1152/ajplung.00233.2009
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548
   Troyanovsky B, 2008, AM J PHYSIOL-LUNG C, V294, pL266, DOI 10.1152/ajplung.00107.2007
   UCHIBA M, 1995, THROMB RES, V78, P117, DOI 10.1016/0049-3848(95)00040-2
   Uhlig S, 2005, PHARMACOL REP, V57, P206
   Uhlig S, 2002, 22ND MEETING OF THE EUROPEAN SOCIETY FOR MICROCIRCULATION: MICROCIRCULATION AND VASCULAR BIOLOGY, P221
   UHLIG S, 1995, AM J PATHOL, V146, P1235
   UHLIG S, 1994, J APPL PHYSIOL, V77, P262, DOI 10.1152/jappl.1994.77.1.262
   Uhlig S, 1997, J PHARMACOL TOXICOL, V37, P119, DOI 10.1016/S1056-8719(97)00021-X
   Uhlig S., 1998, METHODS PULMONARY RE, P29
   Uhlig Stefan, 2013, Handb Exp Pharmacol, P227, DOI 10.1007/978-3-7091-1511-4_11
   Umapathy NS, 2010, J CELL PHYSIOL, V223, P215, DOI 10.1002/jcp.22029
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Watanabe K, 1996, CELL SIGNAL, V8, P247, DOI 10.1016/0898-6568(96)00044-7
   Waypa GB, 1996, J APPL PHYSIOL, V80, P1197, DOI 10.1152/jappl.1996.80.4.1197
   WELSH CH, 1989, J APPL PHYSIOL, V66, P112, DOI 10.1152/jappl.1989.66.1.112
   WINN R, 1988, J APPL PHYSIOL, V64, P2463, DOI 10.1152/jappl.1988.64.6.2463
   Wu SW, 2009, AM J PHYSIOL-LUNG C, V297, pL650, DOI 10.1152/ajplung.00015.2009
   Xing JJ, 2013, AM J PATHOL, V182, P1021, DOI 10.1016/j.ajpath.2012.11.022
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Yan W, 1996, J CELL PHYSIOL, V166, P561, DOI 10.1002/(SICI)1097-4652(199603)166:3<561::AID-JCP10>3.0.CO;2-A
   Yang Y, 2010, EUR RESPIR J, V36, P417, DOI 10.1183/09031936.00095609
   Yang Yang, 2011, Ther Adv Respir Dis, V5, P325, DOI 10.1177/1753465811406772
   Yang YM, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23494
   Yao HY, 2011, BBA-GEN SUBJECTS, V1810, P666, DOI 10.1016/j.bbagen.2011.03.020
   Yin J, 2008, CIRC RES, V102, P966, DOI 10.1161/CIRCRESAHA.107.168724
   Ying XY, 1996, CIRC RES, V79, P898, DOI 10.1161/01.RES.79.4.898
NR 158
TC 50
Z9 53
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2014
VL 34
IS 1
BP 1
EP 19
DI 10.1159/000362980
PG 19
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA AR7MO
UT WOS:000343764000001
PM 24977477
OA gold
DA 2023-08-21
ER

PT J
AU Villar, J
   Muros, M
   Cabrera-Benitez, NE
   Valladares, F
   Lopez-Hernandez, M
   Flores, C
   Martin-Barrasa, JL
   Blanco, J
   Liu, MY
   Kacmarek, RM
AF Villar, Jesus
   Muros, Mercedes
   Cabrera-Benitez, Nuria E.
   Valladares, Francisco
   Lopez-Hernandez, Milagros
   Flores, Carlos
   Martin-Barrasa, Jose L.
   Blanco, Jesus
   Liu, Mingyao
   Kacmarek, Robert M.
TI Soluble platelet-endothelial cell adhesion molecule-1, a biomarker of
   ventilator-induced lung injury
SO CRITICAL CARE
LA English
DT Article
ID MECHANICAL VENTILATION; PECAM-1; MICROPARTICLES; PRESSURE; SEPSIS;
   INFLAMMATION; DYSFUNCTION; EXPRESSION; PROTECTION; CORRELATE
AB Introduction: Endothelial cell injury is an important component of acute lung injury. Platelet-endothelial cell adhesion molecule-1 (PECAM1) is a transmembrane protein that connects endothelial cells to one another and can be detected as a soluble, truncated protein (sPECAM1) in serum. We hypothesized that injurious mechanical ventilation (MV) leads to shedding of PECAM1 from lung endothelial cells resulting in increasing sPECAM1 levels in the systemic circulation.
   Methods: We studied 36 Sprague-Dawley rats in two prospective, randomized, controlled studies (healthy and septic) using established animal models of ventilator-induced lung injury. Animals (n = 6 in each group) were randomized to spontaneous breathing or two MV strategies: low tidal volume (V-T) (6 ml/kg) and high-V-T (20 ml/kg) on 2 cmH(2)O of positive end-expiratory pressure (PEEP). In low-V-T septic animals, 10 cmH(2)O of PEEP was applied. We performed pulmonary histological and physiological evaluation and measured lung PECAM1 protein content and serum sPECAM1 levels after four hours ventilation period.
   Results: High-V-T MV caused severe lung injury in healthy and septic animals, and decreased lung PECAM1 protein content (P < 0.001). Animals on high-V-T had a four-to six-fold increase of mean sPECAM1 serum levels than the unventilated counterpart (35.4 +/- 10.4 versus 5.6 +/- 1.7 ng/ml in healthy rats; 156.8 +/- 47.6 versus 35.6 +/- 12.6 ng/ml in septic rats) (P < 0.0001). Low-V-T MV prevented these changes. Levels of sPECAM1 in healthy animals on high-V-T MV paralleled the sPECAM1 levels of non-ventilated septic animals.
   Conclusions: Our findings suggest that circulating sPECAM1 may represent a promising biomarker for the detection and monitoring of ventilator-induced lung injury.
C1 [Villar, Jesus; Muros, Mercedes; Cabrera-Benitez, Nuria E.; Valladares, Francisco; Flores, Carlos; Martin-Barrasa, Jose L.; Blanco, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
C1 [Villar, Jesus; Cabrera-Benitez, Nuria E.; Martin-Barrasa, Jose L.] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Net, Las Palmas Gran Canaria, Spain.
C1 [Villar, Jesus] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
C1 [Muros, Mercedes] Hosp Univ NS de Candelaria, Dept Clin Biochem, Tenerife, Spain.
C1 [Valladares, Francisco; Lopez-Hernandez, Milagros] Univ La Laguna, Dept Anat Pathol & Histol, Tenerife, Spain.
C1 [Flores, Carlos] Hosp Univ NS de Candelaria, Res Unit, Santa Cruz De Tenerife, Spain.
C1 [Blanco, Jesus] Hosp Univ Rio Hortega, Intens Care Unit, Valladolid, Spain.
C1 [Liu, Mingyao] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada.
C1 [Liu, Mingyao] Univ Hlth Network, Toronto Gen Res Inst, Resp & Crit Care Res Grp, Toronto, ON, Canada.
C1 [Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114, United States.
C1 [Kacmarek, Robert M.] Harvard Univ, Dept Anesthesiol, Boston, MA 02115, United States.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de
   Salud Carlos III; University of Toronto; Li Ka Shing Knowledge
   Institute; Saint Michaels Hospital Toronto; Universidad de la Laguna;
   Hospital del Rio Hortega; University of Toronto; University of Toronto;
   University Health Network Toronto; Toronto General Hospital; Harvard
   University; Massachusetts General Hospital; Harvard University
RP Villar, J (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
EM jesus.villar54@gmail.com
RI Villar, Jesús/R-4526-2019; Martín-Barrasa, José Luis/GLR-3921-2022;
   Flores, Carlos/R-1159-2019
OI Villar, Jesús/0000-0001-5687-3562; Martín-Barrasa, José
   Luis/0000-0002-3280-9838; Flores, Carlos/0000-0001-5352-069X; Liu,
   Mingyao/0000-0002-9188-8417
FU Instituto de Salud Carlos III, Madrid, Spain [PI10/0393, CB06/06/1088]
FX Supported in part by grants (PI10/0393, CB06/06/1088) from Instituto de
   Salud Carlos III, Madrid, Spain.
CR Amabile N, 2008, AM J RESP CRIT CARE, V177, P1268, DOI 10.1164/rccm.200710-1458OC
   Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009
   Bhatt AJ, 2001, AM J RESP CRIT CARE
   Bhattacharya S, 2003, AM J RESP CELL MOL, V28, P218, DOI 10.1165/rcmb.4763
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854
   Burns KEA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014623
   Chiumello D, 2008, AM J RESP CRIT CARE, V178, P346, DOI 10.1164/rccm.200710-1589OC
   Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009
   Densmore JC, 2006, SHOCK, V26, P464, DOI 10.1097/01.shk.0000228791.10550.36
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   Fornasa G, 2010, J IMMUNOL, V184, P5485, DOI 10.4049/jimmunol.0902219
   FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123
   GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183
   Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI200213595
   Hegeman MA, 2009, CRIT CARE, V13, DOI 10.1186/cc8168
   Herrera MT, 2003, INTENS CARE MED, V29, P1345, DOI 10.1007/s00134-003-1756-5
   Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com
   Krauss T, 1997, AM J OBSTET GYNECOL, V177, P443, DOI 10.1016/S0002-9378(97)70213-8
   Lopez-Aguilar J, 2006, CRIT CARE MED, V34, P1106, DOI 10.1097/01.CCM.0000205757.66971.DA
   Maas M, 2005, AM J PHYSIOL-HEART C, V288, pH159, DOI 10.1152/ajpheart.00500.2004
   Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1
   Muller AM, 2002, J PATHOL, V198, P270, DOI 10.1002/path.1186
   MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449
   Newman PJ, 1997, J CLIN INVEST, V100, pS25
   NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453
   Nonas SA, 2007, AM J PHYSIOL-LUNG C, V293, pL292, DOI 10.1152/ajplung.00481.2006
   PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024
   Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X
   Privratsky JR, 2011, J CELL SCI, V124, P1477, DOI 10.1242/jcs.082271
   Protti A, 2011, AM J RESP CRIT CARE, V183, P1354, DOI 10.1164/rccm.201010-1757OC
   Pugin J, 2002, INTENS CARE MED, V28, P817, DOI 10.1007/s00134-002-1320-8
   Shehabi Y, 2008, CRIT CARE, V12, DOI 10.1186/cc6860
   Sinning JM, 2011, EUR HEART J, V32, P2034, DOI 10.1093/eurheartj/ehq478
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI [10.1056/NEJMra1208707, 10.1056/NEJMc1400293]
   Soriano AO, 2005, CRIT CARE MED, V33, P2540, DOI 10.1097/01.CCM.0000186414.86162.03
   Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8
   TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573
   Villar J, 2011, MINERVA ANESTESIOL, V77, P647
   Villar J, 2011, INTENS CARE MED, V37, P1201, DOI 10.1007/s00134-011-2234-0
   Villar J, 2010, INTENS CARE MED, V36, P1049, DOI 10.1007/s00134-010-1799-3
   Villar J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-27
   Villar J, 2009, ANESTHESIOLOGY, V110, P1341, DOI 10.1097/ALN.0b013e31819fcba9
   WEBB HH, 1974, AM REV RESPIR DIS, V110, P556
   Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456
NR 45
TC 8
Z9 9
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2014
VL 18
IS 2
AR R41
DI 10.1186/cc13754
PG 9
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AM1SA
UT WOS:000339627400059
PM 24588994
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Yamashita, CM
   Fessler, MB
   Vasanthamohan, L
   Lac, J
   Madenspacher, J
   McCaig, L
   Yao, LJ
   Wang, LF
   Puntorieri, V
   Mehta, S
   Lewis, JF
   Veldhuizen, RAW
AF Yamashita, Cory M.
   Fessler, Michael B.
   Vasanthamohan, Lakshman
   Lac, Joanne
   Madenspacher, Jennifer H.
   McCaig, Lynda
   Yao, Lijuan
   Wang, Lefeng
   Puntorieri, Valeria
   Mehta, Sanjay
   Lewis, Jim F.
   Veldhuizen, Ruud A. W.
TI Apolipoprotein E-Deficient Mice Are Susceptible to the Development of
   Acute Lung Injury
SO RESPIRATION
LA English
DT Article
DE Apolipoprotein E; ALI/ARDS; Acid aspiration; hyperoxia; Oxidized low-density lipoprotein; Gastric acid aspiration 
ID RESPIRATORY-DISTRESS-SYNDROME; LOW-DENSITY-LIPOPROTEIN; GENE-EXPRESSION;
   OXIDIZED LDL; TNF-ALPHA; ATHEROSCLEROSIS; APOE; INFLAMMATION;
   PROGRESSION; SURFACTANT
AB Background: Apolipoprotein E (apoE) has been shown to play a pivotal role in the development of cardiovascular disease, attributable to its function in lipid trafficking and immune modulating properties; however, its role in modulating inflammation in the setting of acute lung injury (ALI) is unknown. Objective: To determine whether apoE-deficient mice (apoE-/-) are more susceptible to ALI compared to wild-type (WT) animals. Methods: Two independent models of ALI were employed. Firstly, WT and apoE-/- mice were randomized to acid aspiration (50 mu l of 0.1 N hydrochloric acid) followed by 4 h of mechanical ventilation. Secondly, WT and apoE-/- mice were randomized to 72 h of hyperoxia exposure or room air. Thereafter, the intrinsic responses of WT and apoE-/- mice were assessed using the isolated perfused mouse lung (IPML) setup. Finally, based on elevated levels of oxidized low-density lipoprotein (oxLDL) in apoE-/-, the effect of oxLDL on lung endothelial permeability and inflammation was assessed. Results: In both in vivo models, apoE-/- mice demonstrated greater increases in lung lavage protein levels, neutrophil counts, and cytokine expression (p < 0.05) compared to WT mice. Experiments utilizing the IPML setup demonstrated no differences in intrinsic lung responses to injury between apoE-/- and WT mice, suggesting the presence of a circulating factor as being responsible for the in vivo observations. Finally, the exposure of lung endothelial cells to oxLDL resulted in increased monolayer permeability and IL-6 release compared to native (nonoxidized) LDL. Conclusions: Our findings demonstrate a susceptibility of apoE-/- animals to ALI that may occur, in part, due to elevated levels of oxLDL. (C) 2014 S. Karger AG, Basel
C1 [Yamashita, Cory M.; Vasanthamohan, Lakshman; Lac, Joanne; Madenspacher, Jennifer; McCaig, Lynda; Yao, Lijuan; Wang, Lefeng; Puntorieri, Valeria; Mehta, Sanjay; Lewis, Jim F.; Veldhuizen, Ruud A. W.] Lawson Hlth Res Inst, London, ON, Canada.
C1 [Fessler, Michael B.] Natl Inst Environm Hlth Sci, NIH, Res Triangle Pk, NC, United States.
C3 Western University (University of Western Ontario); National Institutes
   of Health (NIH) - USA; NIH National Institute of Environmental Health
   Sciences (NIEHS)
RP Yamashita, CM (corresponding author), St Josephs Hlth Ctr, Lawson Hlth Res Inst, Room B3-116, London, ON N6H 4B2, Canada.
EM cyamash@uwo.ca
RI Lewis, James F./GVS-8247-2022; Lewis, Jim/G-3320-2011; Mehta,
   Sanjay/G-3332-2011; wang, le/HKN-3406-2023; Veldhuizen,
   Ruud/G-3352-2011; Yamashita, Cory/G-3359-2011; Fessler, Michael
   B/C-6323-2019
OI Mehta, Sanjay/0000-0002-7707-1056; Veldhuizen, Ruud/0000-0002-8802-1580;
   Fessler, Michael B/0000-0002-8262-8613; Yamashita,
   Cory/0000-0003-2040-4996
FU Ontario Thoracic Society/Ontario Lung Association; Western University
   Department of Medicine, Program of Experimental Medicine; National
   Institutes of Health NIEHS [Z01 ES102005]
FX The authors would like to thank Ms. Shannon Seney of the Screening Lab
   for Immune Disorders, Lawson Health Research Institute, for her
   assistance with the multiplex analysis. This research was supported by
   the Ontario Thoracic Society/Ontario Lung Association (C.Y., J.F.L., and
   R. A. W. V.), the Western University Department of Medicine, Program of
   Experimental Medicine (C.Y.), and the Intramural Research Program of the
   National Institutes of Health NIEHS (Z01 ES102005) (M.B.F.).
CR Ali K, 2005, CIRC RES, V97, P922, DOI 10.1161/01.RES.0000187467.67684.43
   Arunachalam G, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-34
   Bourdillon MC, 2000, ARTERIOSCL THROM VAS, V20, P2630, DOI 10.1161/01.ATV.20.12.2630
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chow SE, 2007, J APPL PHYSIOL, V102, P1520, DOI 10.1152/japplphysiol.00881.2006
   Dossett LA, 2008, CHEST, V134, P974, DOI 10.1378/chest.08-0079
   Farley KS, 2009, AM J PHYSIOL-LUNG C, V296, pL480, DOI 10.1152/ajplung.90201.2008
   FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009
   Goldklang M, 2012, AM J PHYSIOL-LUNG C, V302, pL1200, DOI 10.1152/ajplung.00454.2010
   Kato R, 2009, ARTERIOSCL THROM VAS, V29, P33, DOI 10.1161/ATVBAHA.108.164723
   KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776
   Kitagawa K, 2002, ATHEROSCLEROSIS, V160, P305, DOI 10.1016/S0021-9150(01)00587-1
   KNIGHT PR, 1992, ANESTHESIOLOGY, V77, P772, DOI 10.1097/00000542-199210000-00023
   Lewis JE, 2003, ANNU REV PHYSIOL, V65, P613, DOI 10.1146/annurev.physiol.65.092101.142434
   Lin WC, 2010, EXP BIOL MED, V235, P57, DOI 10.1258/ebm.2009.009256
   Martin EL, 2007, AM J PHYSIOL-LUNG C, V293, pL779, DOI 10.1152/ajplung.00442.2006
   Massaro D, 2008, AM J PHYSIOL-LUNG C, V294, pL991, DOI 10.1152/ajplung.00013.2008
   Memtsoudis Stavros G, 2012, J Intensive Care Med, V27, P306, DOI 10.1177/0885066611411410
   Moghadasian MH, 2001, FASEB J, V15, P2623, DOI 10.1096/fj.01-0463com
   OBRIENLADNER AR, 1995, AM J RESP CELL MOL, V12, P275, DOI 10.1165/ajrcmb.12.3.7873193
   Patterson EK, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/586895
   Ponnuswamy P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030193
   Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Shea LM, 1996, J IMMUNOL, V157, P3902
   van der Zwan LP, 2009, J LIPID RES, V50, P342, DOI 10.1194/jlr.P800030-JLR200
   Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4
   Walker MG, 2011, RESPIRATION, V81, P333, DOI 10.1159/000323609
   Walker MG, 2009, EXP LUNG RES, V35, P591, DOI 10.1080/01902140902780460
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weber C, 2011, J CLIN INVEST, V121, P3825, DOI 10.1172/JCI60457
   Wouters K, 2005, CLIN CHEM LAB MED, V43, P470, DOI 10.1515/CCLM.2005.085
   Wu Z, 2011, INFECT IMMUN, V79, P2865, DOI 10.1128/IAI.01317-10
   Yamashita CM, 2012, EXPERT OPIN EMERG DR, V17, P1, DOI 10.1517/14728214.2012.667800
   Yao XL, 2010, AM J RESP CRIT CARE, V182, P1228, DOI 10.1164/rccm.201002-0308OC
   Zemans RL, 2004, CRIT CARE, V8, P469, DOI 10.1186/cc2906
NR 36
TC 26
Z9 26
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0025-7931
EI 1423-0356
J9 RESPIRATION
JI Respiration
PY 2014
VL 87
IS 5
BP 416
EP 427
DI 10.1159/000358438
PG 12
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA AH1YF
UT WOS:000335917000010
PM 24662316
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Chen, C
   Zhang, Y
   Du, ZH
   Zhang, M
   Niu, L
   Wang, YL
   Li, JG
AF Chen, Chao
   Zhang, Ying
   Du, Zhaohui
   Zhang, Min
   Niu, Li
   Wang, Yanlin
   Li, Jianguo
TI Vagal Efferent Fiber Stimulation Ameliorates Pulmonary Microvascular
   Endothelial Cell Injury by Downregulating Inflammatory Responses
SO INFLAMMATION
LA English
DT Article
DE vagal stimulation; LPS; ALI/ARDS; Src-suppressed C kinase substrate; E-selectin 
ID ACUTE LUNG INJURY; C KINASE SUBSTRATE; PROTEINS; NEUTROPHILS; ADHESION;
   RECEPTOR
AB Electrical stimulation of the vagus nerve may have positive effects on many inflammatory diseases. This study determined the beneficial effects of vagus nerve stimulation and the mechanisms by which it attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI). Rats were intraperitoneally injected with 10 mg/kg LPS to induce ALI. The results showed that vagus nerve stimulation could improve lung injury, as evidenced by remarkable reductions in lung edema (wet-to-dry weight ratio), neutrophil infiltration (myeloperoxidase activity), and pulmonary permeability [total number of cells and protein concentrations in bronchoalveolar lavage fluid (BALF)]. In addition, vagus nerve stimulation not only decreased the expressions of Src-suppressed C kinase substrate and E-selectin proteins in lung tissue but also effectively attenuated the concentrations of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in BALF. These suggest that vagus nerve stimulation is a suitable treatment for LPS-induced ALI and indicate that it helps ameliorate pulmonary microvascular endothelial cell injury by downregulating inflammatory responses.
C1 [Chen, Chao; Zhang, Ying; Du, Zhaohui; Zhang, Min; Niu, Li; Wang, Yanlin; Li, Jianguo] Wuhan Univ, Zhongnan Hosp, Dept Anesthesia, Crit Care Med & Emergency Med Ctr, Wuhan 430071, Hubei Province, China.
C3 Wuhan University
RP Du, ZH (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Anesthesia, Crit Care Med & Emergency Med Ctr, Wuhan 430071, Hubei Province, Peoples R China.
EM drdu1969@163.com
FU Natural Science Foundation of Hubei Province of China [2011CDB518]
FX This work was financially supported by the Natural Science Foundation of
   Hubei Province of China (NO.2011CDB518).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335
   Cheng C, 2007, BIOCHEM BIOPH RES CO, V358, P342, DOI 10.1016/j.bbrc.2007.04.147
   Cines DB, 1998, BLOOD, V91, P3527
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1
   Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2
   Hopkins Stephen John, 2003, Leg Med (Tokyo), V5 Suppl 1, pS45, DOI 10.1016/S1344-6223(02)00088-3
   Kitamura H, 2002, J HISTOCHEM CYTOCHEM, V50, P245, DOI 10.1177/002215540205000212
   Kwak SH, 2004, J KOREAN MED SCI, V19, P55, DOI 10.3346/jkms.2004.19.1.55
   Lin Y, 2011, CHINESE MED J-PEKING, V124, P1069, DOI 10.3760/cma.j.issn.0366-6999.2011.07.022
   Lubbers T, 2010, WORLD J GASTROENTERO, V16, P1683, DOI 10.3748/wjg.v16.i14.1683
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Meregnani J, 2011, AUTON NEUROSCI-BASIC, V160, P82, DOI 10.1016/j.autneu.2010.10.007
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Paladino JD, 2009, MICROVASC RES, V77, P8, DOI 10.1016/j.mvr.2008.09.001
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   Ruegg C, 2002, ENDOTHELIUM-J ENDOTH, V9, P151, DOI 10.1080/10623320290016591
   Song XM, 2008, SHOCK, V30, P468, DOI 10.1097/SHK.0b013e31816d5e49
   Volk T, 2000, INFLAMM RES, V49, P185, DOI 10.1007/s000110050579
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yeboah MM, 2008, KIDNEY INT, V74, P62, DOI 10.1038/ki.2008.94
   You QH, 2010, INFLAMM RES, V59, P949, DOI 10.1007/s00011-010-0207-3
NR 26
TC 6
Z9 9
U1 1
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD DEC
PY 2013
VL 36
IS 6
BP 1567
EP 1575
DI 10.1007/s10753-013-9701-4
PG 9
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 248IM
UT WOS:000326692200047
PM 23912647
DA 2023-08-21
ER

PT J
AU Jian, MY
   Alexeyev, MF
   Wolkowicz, PE
   Zmijewski, JW
   Creighton, JR
AF Jian, Ming-Yuan
   Alexeyev, Mikhail F.
   Wolkowicz, Paul E.
   Zmijewski, Jaroslaw W.
   Creighton, Judy R.
TI Metformin-stimulated AMPK-alpha 1 promotes microvascular repair in acute
   lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; LPS; sepsis; ALI/ARDS; edema; permeability 
ID ACTIVATED PROTEIN-KINASE; RESPIRATORY-DISTRESS-SYNDROME; AMPK;
   HETEROGENEITY; CAVEOLAE; INHIBITION; THERAPIES; SEVERITY; ANIMALS;
   ANCIENT
AB Jian M-Y, Alexeyev MF, Wolkowicz PE, Zmijewski JW, Creighton JR. Metformin-stimulated AMPK-alpha 1 promotes microvascular repair in acute lung injury. Am J Physiol Lung Cell Mol Physiol 305: L844-L855, 2013. First published October 4, 2013; doi:10.1152/ajplung.00173.2013.-Acute lung injury secondary to sepsis is a leading cause of mortality in sepsis-related death. Present therapies are not effective in reversing endothelial cell dysfunction, which plays a key role in increased vascular permeability and compromised lung function. AMP-activated protein kinase (AMPK) is a molecular sensor important for detection and mediation of cellular adaptations to vascular disruptive stimuli. In this study, we sought to determine the role of AMPK in resolving increased endothelial permeability in the sepsis-injured lung. AMPK function was determined in vivo using a rat model of endotoxin-induced lung injury, ex vivo using the isolated lung, and in vitro using cultured rat pulmonary microvascular endothelial cells (PMVECs). AMPK stimulation using N1-(alpha-D-ribofuranosyl)-5-aminoimidizole-4-carboxamide or metformin decreased the LPS-induced increase in permeability, as determined by filtration coefficient (K-f) measurements, and resolved edema as indicated by decreased wet-to-dry ratios. The role of AMPK in the endothelial response to LPS was determined by shRNA designed to decrease expression of the AMPK-alpha 1 isoform in capillary endothelial cells. Permeability, wounding, and barrier resistance assays using PMVECs identified AMPK-alpha 1 as the molecule responsible for the beneficial effects of AMPK in the lung. Our findings provide novel evidence for AMPK-alpha 1 as a vascular repair mechanism important in the pulmonary response to sepsis and identify a role for metformin treatment in the management of capillary injury.
C1 [Jian, Ming-Yuan; Wolkowicz, Paul E.; Creighton, Judy R.] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL, United States.
C1 [Jian, Ming-Yuan; Wolkowicz, Paul E.; Creighton, Judy R.] Univ Alabama Birmingham, Dept Cell & Mol Biol, Birmingham, AL, United States.
C1 [Zmijewski, Jaroslaw W.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL, United States.
C1 [Jian, Ming-Yuan; Wolkowicz, Paul E.; Zmijewski, Jaroslaw W.; Creighton, Judy R.] Univ Alabama Birmingham, Ctr Pulm Injury & Repair, Birmingham, AL, United States.
C1 [Alexeyev, Mikhail F.] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688, United States.
C1 [Alexeyev, Mikhail F.] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688, United States.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of South Alabama; University of South Alabama
RP Creighton, JR (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, BMR 2,901 19th St, Birmingham, AL 35294 USA.
EM jcreighton@uab.edu
FU NIH [HL102296, HL 110803, OD010944]
FX This work was supported by NIH Grants HL102296, HL 110803 (to J.
   Creighton), and OD010944 (to M. Alexeyev).
CR Baines Deborah, 2013, Curr Mol Pharmacol, V6, P50
   Boyle JG, 2010, DIABETIC MED, V27, P1097, DOI 10.1111/j.1464-5491.2010.03098.x
   Creighton J, 2011, AM J PHYSIOL-CELL PH, V301, pC1293, DOI 10.1152/ajpcell.00358.2011
   Creighton J, 2011, FASEB J, V25, P3356, DOI 10.1096/fj.10-179218
   Ewart MA, 2011, PHARMACOL THERAPEUT, V131, P242, DOI 10.1016/j.pharmthera.2010.11.002
   Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14
   Gusarova GA, 2011, MOL CELL BIOL, V31, P3546, DOI 10.1128/MCB.05114-11
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327
   Honiden S, 2009, CRIT CARE MED, V37, P2455, DOI 10.1097/CCM.0b013e3181a0fea5
   Insel PA, 2009, CURR OPIN NEPHROL HY, V18, P50, DOI 10.1097/MNH.0b013e3283186f82
   Iscimen R, 2008, CRIT CARE MED, V36, P1518, DOI 10.1097/CCM.0b013e31816fc2c0
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Levitt JE, 2012, CRIT CARE, V16, DOI 10.1186/cc11144
   Lowe K, 2007, J SURG RES, V143, P70, DOI 10.1016/j.jss.2007.03.047
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001
   National Library of Medicine, DAILYMED
   Patel H. H., 2008, V186, P167, DOI 10.1007/978-3-540-72843-6_7
   Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Salt IP, 2012, EXPERT OPIN INV DRUG, V21, P1155, DOI 10.1517/13543784.2012.696609
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   Stevens Troy, 2008, Proc Am Thorac Soc, V5, P783, DOI 10.1513/pats.200803-027HR
   Tadie JM, 2012, MOL MED, V18, P659, DOI 10.2119/molmed.2011.00401
   Vadasz I, 2011, AM J RESP CRIT CARE, V183, P1147, DOI 10.1164/rccm.201102-0327UP
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Viollet B, 2011, HANDB EXP PHARMACOL, V203, P303, DOI 10.1007/978-3-642-17214-4_13
   Viollet B, 2010, CRIT REV BIOCHEM MOL, V45, P276, DOI 10.3109/10409238.2010.488215
   Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P19, DOI 10.2741/3229
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wiener-Kronish JP, 2011, SEMIN RESP CRIT CARE, V32, P228, DOI 10.1055/s-0031-1275535
   Woollhead AM, 2007, BRIT J PHARMACOL, V151, P1204, DOI 10.1038/sj.bjp.0707343
   Xing JJ, 2013, AM J PATHOL, V182, P1021, DOI 10.1016/j.ajpath.2012.11.022
   Yamashita CM, 2012, EXPERT OPIN EMERG DR, V17, P1, DOI 10.1517/14728214.2012.667800
   Zhang YY, 2012, MOL CELL BIOCHEM, V368, P69, DOI 10.1007/s11010-012-1344-5
   Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008
   Zmijewski JW, 2008, AM J RESP CRIT CARE, V178, P168, DOI 10.1164/rccm.200710-1602OC
NR 42
TC 68
Z9 72
U1 1
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC
PY 2013
VL 305
IS 11
BP L844
EP L855
DI 10.1152/ajplung.00173.2013
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 272RR
UT WOS:000328478500007
PM 24097562
OA Green Published
DA 2023-08-21
ER

PT J
AU Kong, J
   Zhu, XD
   Shi, YY
   Liu, TJ
   Chen, YZ
   Bhan, I
   Zhao, Q
   Thadhani, R
   Li, YC
AF Kong, Juan
   Zhu, Xiangdong
   Shi, Yongyan
   Liu, Tianjing
   Chen, Yunzi
   Bhan, Ishir
   Zhao, Qun
   Thadhani, Ravi
   Li, Yan Chun
TI VDR Attenuates Acute Lung Injury by Blocking Ang-2-Tie-2 Pathway and
   Renin-Angiotensin System
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID VITAMIN-D-RECEPTOR; LIGHT-CHAIN PHOSPHORYLATION; SMOOTH-MUSCLE-CELLS;
   1,25-DIHYDROXYVITAMIN D-3; DIABETIC-NEPHROPATHY; GAP FORMATION; MICE;
   EXPRESSION; ASTHMA; LIPOPOLYSACCHARIDE
AB Acute lung injury (ALI) is a hallmark of systemic inflammation associated with high mortality. Although the vitamin D receptor (VDR) is highly expressed in the lung, its role in lung physiology remains unclear. We investigated the effect of VDR deletion on ALI using a lipopolysaccharide (LPS)-induced sepsis model. After LPS challenge VDR-null mice exhibited more severe ALI and higher mortality compared with wild-type (WT) counterparts, manifested by increased pulmonary vascular leakiness, pulmonary edema, apoptosis, neutrophil infiltration, and pulmonary inflammation, which was accompanied by excessive induction of angiopoietin (Ang)-2 and myosin light chain (MLC) phosphorylation in the lung. 1,25-Dihydroxyvitamin D blocked LPS-induced Ang-2 expression by blocking nuclear factor-kappa B activation in human pulmonary artery endothelial cells. The severity of lung injury seen in VDR-null mice was ameliorated by pretreatment with L1-10, an antagonist of Ang-2, suggesting that VDR signaling protects the pulmonary vascular barrier by targeting the Ang-2-Tie-2-MLC kinase cascade. Severe ALI in VDR-null mice was also accompanied by an increase in pulmonary renin and angiotensin II levels, and pretreatment of VDR-null mice with angiotensin II type 1 receptor blocker losartan partially ameliorated the severity of LPS-induced lung injury. Taken together, these observations provide evidence that the vitamin D-VDR signaling prevents lung injury by blocking the Ang-2-Tie-2-MLC kinase cascade and the renin-angiotensin system.
C1 [Kong, Juan; Zhu, Xiangdong; Shi, Yongyan; Liu, Tianjing; Chen, Yunzi; Li, Yan Chun] Univ Chicago, Dept Med, Div Biol Sci, Chicago, IL 60637, United States.
C1 [Kong, Juan; Chen, Yunzi; Li, Yan Chun] China Med Univ, Shengjing Hosp, Lab Metab Dis Res & Drug Dev, Shenyang 110000, China.
C1 [Shi, Yongyan] China Med Univ, Shengjing Hosp, Dept Pediat, Shenyang 110000, China.
C1 [Liu, Tianjing; Zhao, Qun] China Med Univ, Shengjing Hosp, Key Lab Congenital Malformat, Minist Hlth, Shenyang 110000, China.
C1 [Bhan, Ishir; Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol, Boston, MA 02114, United States.
C3 University of Chicago; China Medical University; China Medical
   University; China Medical University; Harvard University; Harvard
   Medical School; Massachusetts General Hospital
RP Kong, J (corresponding author), China Med Univ, Lab Metab Dis Res & Drug Dev, Shenyang 110000, Peoples R China.
EM kong_juan@hotmail.com; thadhani.ravi@mgh.harvard.edu;
   cyan@medicine.bsd.uchicago.edu
RI chen, yunzi/B-2964-2011; ZHAO, QUN/HMP-0262-2023
OI zhu, xiangdong/0000-0002-5627-8082
FU American Heart Association [10SDG4280066]; National Institutes of Health
   [R01HL085793, R01DK092143, R01DK84974]; CTSA from National Center for
   Research Resources [UL1 RR024999]; National Natural Science Foundation
   of China [30971401, 81170065]
FX This work was supported by American Heart Association Scientist
   Development Grant 10SDG4280066 (to J.K.), National Institutes of Health
   grants R01HL085793 (to Y.C.L.), R01DK092143, and R01DK84974 (to R.T.),
   CTSA grant UL1 RR024999 from National Center for Research Resources, as
   well as by National Natural Science Foundation of China (Grants 30971401
   and 81170065).
CR Banerjee A, 2008, BRIT J PHARMACOL, V155, P84, DOI 10.1038/bjp.2008.232
   Beck-Schimmer B, 2004, NEWS PHYSIOL SCI, V19, P129, DOI 10.1152/nips.01508.2003
   Bhatt AJ, 2001, AM J RESP CRIT CARE, V164, P1971, DOI 10.1164/ajrccm.164.10.2101140
   Bosse Y, 2007, PHYSIOL GENOMICS, V29, P161, DOI 10.1152/physiolgenomics.00134.2006
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004
   Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12
   Chen Y, 2013, J BIOL CHEM, V288, P19450, DOI 10.1074/jbc.M113.467670
   Chen YZ, 2013, J IMMUNOL, V190, P3687, DOI 10.4049/jimmunol.1203273
   Deb DK, 2009, AM J PHYSIOL-RENAL, V296, pF1212, DOI 10.1152/ajprenal.00002.2009
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Eutamene H, 2005, EUR RESPIR J, V25, P789, DOI 10.1183/09031936.05.00064704
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7
   Grant WB, 2008, PHOTOCHEM PHOTOBIOL, V84, P356, DOI 10.1111/j.1751-1097.2007.00266.x
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1
   Kitamura Y, 2001, AM J RESP CRIT CARE, V163, P762, DOI 10.1164/ajrccm.163.3.2003065
   Klaff LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049076
   Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831
   Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]
   Li YC, 2001, AM J PHYSIOL-ENDOC M, V281, pE558, DOI 10.1152/ajpendo.2001.281.3.E558
   Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028
   Liu L, 2009, ARCH BIOCHEM BIOPHYS, V481, P131, DOI 10.1016/j.abb.2008.09.019
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Mofarrahi M, 2008, AM J PHYSIOL-LUNG C, V294, pL955, DOI 10.1152/ajplung.00449.2007
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Podowski M, 2012, J CLIN INVEST, V122, P229, DOI 10.1172/JCI46215
   Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc
   Quintero PA, 2010, J IMMUNOL, V184, P1575, DOI 10.4049/jimmunol.0900290
   Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC
   Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Tinsley JH, 2004, AM J PHYSIOL-LUNG C, V286, pL841, DOI 10.1152/ajplung.00341.2003
   Tsiani E, 2002, AM J PHYSIOL-ENDOC M, V282, pE161, DOI 10.1152/ajpendo.2002.282.1.E161
   VERIN AD, 1995, AM J PHYSIOL-LUNG C, V269, pL99, DOI 10.1152/ajplung.1995.269.1.L99
   Wang F, 2009, CYTOKINE, V48, P246, DOI 10.1016/j.cyto.2009.08.001
   Wang HL, 2007, J IMMUNOL, V179, P1834, DOI 10.4049/jimmunol.179.3.1834
   Wang YL, 2012, J AM SOC NEPHROL, V23, P1977, DOI 10.1681/ASN.2012040383
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432
   Wittke A, 2007, ARCH BIOCHEM BIOPHYS, V460, P306, DOI 10.1016/j.abb.2006.12.011
   Wjst M, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-2
   Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567
   Yuan WH, 2007, J BIOL CHEM, V282, P29821, DOI 10.1074/jbc.M705495200
   Zhang Z, 2008, KIDNEY INT, V73, P163, DOI 10.1038/sj.ki.5002572
   Zhang Z, 2007, KIDNEY INT, V72, P193, DOI 10.1038/sj.ki.5002296
NR 52
TC 105
Z9 110
U1 2
U2 23
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD DEC
PY 2013
VL 27
IS 12
BP 2116
EP 2125
DI 10.1210/me.2013-1146
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 262LZ
UT WOS:000327738200012
PM 24196349
OA Green Published
DA 2023-08-21
ER

PT J
AU Lv, WZ
   Lv, CQ
   Yu, SH
   Yang, YX
   Kong, HR
   Xie, JM
   Sun, HW
   Andersson, R
   Xu, D
   Chen, BC
   Zhou, MT
AF Lv, Wanzhi
   Lv, Chongqing
   Yu, Suhui
   Yang, Yunxiu
   Kong, Hongru
   Xie, Jianming
   Sun, Hongwei
   Andersson, Roland
   Xu, Dan
   Chen, Bicheng
   Zhou, Mengtao
TI Lipoxin A4 attenuation of endothelial inflammation response mimicking
   pancreatitis-induced lung injury
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; lipoxin A4; TNF/TNF-alpha/TNFR1; Inflammation; NF-kappa B 
ID NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; DIET-INDUCED PANCREATITIS; HEME
   OXYGENASE; ANTI-INFLAMMATION; FACTOR-ALPHA; CELLS; A(4); EXPRESSION;
   ADHESION
AB Lipoxins (LXs) and their analogues are known to display potent anti-inflammatory actions. Previously, we reported that lipoxin A4 (LXA4) possessed powerful anti-inflammatory properties in acute pancreatitis in rats and that it may ameliorate the concomitant acute lung injury by reducing cytokine generation and inhibiting neutrophil activation. Considering that the vascular endothelium plays an important role during adherence, migration and activation of leukocytes, the present study was designed to investigate the effects of LXA4 on the inflammatory response induced by tumor necrosis factor a (TNF-alpha) in human pulmonary microvascular endothelial cells (HPMECs) and explore the potential mechanisms involved in these processes. We found that LXA4 markedly down-regulated the expression of monocyte chemotactic protein-1 (MCP-1), E-selectin, and interleukin-6 (IL-6) mRNA, as well as intercellular adhesion molecule-1 (ICAM-1) in TNF-alpha-exposed HPMECs. Moreover, LXA4 inhibited the phosphorylation and nuclear translocation of nuclear factor-kappa B/p65 (NF-kappa B/p65) and phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) in HPMECs following TNF-alpha stimulation. Heme oxygenase-1 (HO-1), a cytoprotective enzyme, was up-regulated by LXA4 in both non- and TNF-alpha-stimulated HPMECs. In conclusion, the protective effects of LXA4 to ALI may be executed through inhibition inflammation pathways of NF-kappa B and p38 MAPK and up-regulation of cytoprotective HO-1.
C1 [Lv, Wanzhi; Lv, Chongqing; Yu, Suhui; Yang, Yunxiu; Kong, Hongru; Xie, Jianming; Sun, Hongwei; Chen, Bicheng; Zhou, Mengtao] Wenzhou Med Coll, Affiliated Hosp 1, Dept Surg, Wenzhou 325000, Zhejiang, China.
C1 [Andersson, Roland] Lund Univ, Clin Sci Lund, Dept Surg, SE-22185 Lund, Sweden.
C1 [Andersson, Roland] Univ Lund Hosp, SE-22185 Lund, Sweden.
C1 [Xu, Dan] Wenzhou Med Coll, Sch Optometry & Ophthalmol, Wenzhou 325000, Zhejiang, China.
C3 Wenzhou Medical University; Lund University; Lund University; Skane
   University Hospital; Wenzhou Medical University
RP Zhou, MT (corresponding author), Wenzhou Med Coll, Affiliated Hosp 1, Dept Surg, Wenzhou 325000, Zhejiang, Peoples R China.
EM zmt0417@hotmail.com
OI Zhou, Mengtao/0000-0002-2455-250X
FU National Natural Science Foundation of China [81070372]; Provincial
   Department of Construction Project [WKJ2012-2-033]; Science and
   Technology Department Commonwealth Technology Applied Research Project
   of Zhejiang Province [2012C23108]; Natural Science Foundation of
   Zhejiang Province [Z2100853, LY12H03005]; Zhejiang Provincial Top Key
   Discipline in Surgery; Zhejiang Provincial Program for the Cultivation
   of High-level Innovative Health talents
FX This project was sponsored by grants of the National Natural Science
   Foundation of China (Grant No. 81070372), the Provincial Department of
   Construction Project (Grant No. WKJ2012-2-033), the Science and
   Technology Department Commonwealth Technology Applied Research Project
   of Zhejiang Province (Grant No. 2012C23108), the Natural Science
   Foundation of Zhejiang Province (Grant No. Z2100853, No. LY12H03005),
   Zhejiang Provincial Top Key Discipline in Surgery, and Zhejiang
   Provincial Program for the Cultivation of High-level Innovative Health
   talents. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ABRAHAM NG, 1988, BIOCHEM BIOPH RES CO, V150, P717, DOI 10.1016/0006-291X(88)90450-0
   Baker N, 2009, J IMMUNOL, V182, P3819, DOI 10.4049/jimmunol.0803175
   Callicutt CS, 2003, SURGERY, V133, P186, DOI 10.1067/msy.2003.84
   Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554
   De Campos Tercio, 2007, Surg Infect (Larchmt), V8, P107, DOI 10.1089/sur.2006.011
   DeBeaux AC, 1996, SCAND J GASTROENTERO, V31, P43, DOI 10.3109/00365529609104999
   Freitas A, 2006, BRIT J PHARMACOL, V149, P345, DOI 10.1038/sj.bjp.0706882
   Frossard JL, 2011, J CLIN PATHOL, V64, P387, DOI 10.1136/jcp.2010.088500
   Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621
   Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923
   Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663
   Jozsef L, 2002, P NATL ACAD SCI USA, V99, P13266, DOI 10.1073/pnas.202296999
   Kure I, 2010, J PHARMACOL EXP THER, V332, P541, DOI 10.1124/jpet.109.159046
   LESER HG, 1991, GASTROENTEROLOGY, V101, P782, DOI 10.1016/0016-5085(91)90539-W
   Lundberg AH, 2000, ANN SURG, V231, P213, DOI 10.1097/00000658-200002000-00010
   Lundberg AH, 2000, J GASTROINTEST SURG, V4, P248, DOI 10.1016/S1091-255X(00)80073-6
   Mandi Y, 1997, INT ARCH ALLERGY IMM, V114, P329, DOI 10.1159/000237690
   Matsuda N, 2006, J PHARMACOL SCI, V101, P189, DOI 10.1254/jphs.CRJ06010X
   Michetti C, 2003, J SURG RES, V115, P92, DOI 10.1016/S0022-4804(03)00219-1
   Nascimento-Silva V, 2005, AM J PHYSIOL-CELL PH, V289, pC557, DOI 10.1152/ajpcell.00045.2005
   Ohira T, 2004, J IMMUNOL, V173, P2091, DOI 10.4049/jimmunol.173.3.2091
   Pan LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019766
   Panes J, 1998, GASTROENTEROLOGY, V114, P1066, DOI 10.1016/S0016-5085(98)70328-2
   Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967
   Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002
   Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3
   Shields Conor J, 2002, Curr Opin Crit Care, V8, P158, DOI 10.1097/00075198-200204000-00012
   Su X, 2008, BBA-MOL CELL RES, V1783, P1623, DOI 10.1016/j.bbamcr.2008.04.009
   Takahashi T, 2001, CIRC RES, V88, P422
   Vachharajani TJ, 2000, AM J PHYSIOL-HEART C, V278, pH1613, DOI 10.1152/ajpheart.2000.278.5.H1613
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009
   Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416
   Wang YP, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-95
   Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87
   Wu SH, 2008, INFLAMM RES, V57, P430, DOI 10.1007/s00011-008-7147-1
   Zhang XP, 2009, J PANCREAS, V10, P8
   Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6
   Zhou MT, 2010, WORLD J GASTROENTERO, V16, P2094, DOI 10.3748/wjg.v16.i17.2094
   Zhou MT, 2011, SCAND J GASTROENTERO, V46, P211, DOI 10.3109/00365521.2010.525715
NR 39
TC 24
Z9 28
U1 0
U2 15
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD DEC
PY 2013
VL 238
IS 12
BP 1388
EP 1395
DI 10.1177/1535370213502611
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 259ES
UT WOS:000327510800008
PM 24000382
DA 2023-08-21
ER

PT J
AU Zang, DY
   Shao, YZ
   Li, XM
AF Zang, Dongyu
   Shao, Youzhi
   Li, Xiaoming
TI Ultrastructural Pathology of Rat Lung Injury Induced by Ischemic Acute
   Kidney Injury
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Acute kidney injury; ALI/ARDS; apoptosis; necroptosis; necrosis; ultrastructure 
ID ACUTE-RENAL-FAILURE; PULMONARY
AB Ischemic acute kidney injury (AKI) is a common complication during inpatient hospitalization, and often induces acute lung injury (ALI). A lot of studies have concentrated on the relevance between AKI and ALI, but the underlying mechanisms of AKI- associated ALI have remained unclear until now. One reason is that evidence of the ultrastructural pathology of AKI-associated ALI has been scarce and needed to be accumulated. The aims of present study are to observe ultrastructural changes, and to reveal leukocyte trafficking of ALI induced by ischemic AKI in rats. For this purpose light microscopy (LM) and electron microscopy (EM), as well as morphometric analysis, were employed in present study. LM observations revealed distinct regions of collapsed alveoli, hemorrhage in alveoli, and interstitial edema in AKI-induced ALI. EM examinations provided facts that alveolar epithelial cells, including type I and type II cells, were necrotic, and endothelia cells undergoing apoptosis as well as interstitial cells undergoing necroptosis were noted in AKI lungs. In addition, shrinkage and decreased or disappeared lamellar bodies were evident in alveolar type II cell of AKI rat lungs. Leukocyte numerical density on area (N-A) in AKI lungs was significantly more than that in sham lungs. Based on the morphological criteria from EM examinations and morphometric analysis, a conclusion was that necrosis, including necroptosis, and apoptosis were involved in damaged lung induced by AKI. And inflammation also contributed to acute lung injury of rats with AKI.
C1 [Zang, Dongyu] Liaoning Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Jinzhou 121001, Liaoning, China.
C1 [Shao, Youzhi] Liaoning Med Univ, Cent Lab, Jinzhou 121001, Liaoning, China.
C1 [Shao, Youzhi; Li, Xiaoming] Liaoning Med Univ, Dept Histol & Embryol, Coll Basic Med, Jinzhou 121001, Liaoning, China.
C1 [Shao, Youzhi; Li, Xiaoming] Liaoning Med Univ, Lab Renal Biol, Jinzhou 121001, Liaoning, China.
C3 Jinzhou Medical University; Jinzhou Medical University; Jinzhou Medical
   University; Jinzhou Medical University
RP Li, XM (corresponding author), Liaoning Med Univ, Dept Histol & Embryol, 40,Sect 3,Songpo Rd, Jinzhou 121001, Liaoning, Peoples R China.
EM lixiaoming68327@163.com
FU Natural Science Foundation of Liaoning Province [201202135]
FX This work was supported by a grant from Natural Science Foundation of
   Liaoning Province, grant number 201202135.
CR ANDERSON WR, 1992, ULTRASTRUCT PATHOL, V16, P615, DOI 10.3109/01913129209023751
   Bonventre JV, 2004, KIDNEY INT, V66, P480, DOI 10.1111/j.1523-1755.2004.761_2.x
   Deng JP, 2004, AM J RESP CRIT CARE, V169, P749, DOI 10.1164/rccm.200303-372OC
   Faubel S, 2009, Minerva Urol Nefrol, V61, P171
   Fehrenbach A, 2003, AM J RESP CRIT CARE, V167, P1264, DOI 10.1164/rccm.200112-132OC
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004
   Golab F, 2009, KIDNEY INT, V75, P783, DOI 10.1038/ki.2008.683
   Hassoun HT, 2007, AM J PHYSIOL-RENAL, V293, pF30, DOI 10.1152/ajprenal.00023.2007
   Hassoun HT, 2009, AM J PHYSIOL-RENAL, V297, pF125, DOI 10.1152/ajprenal.90666.2008
   Knudsen L, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-79
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004
   Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016
   Weibel ER, 2007, J APPL PHYSIOL, V102, P459, DOI 10.1152/japplphysiol.00808.2006
   Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410
NR 16
TC 5
Z9 6
U1 0
U2 8
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0191-3123
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD DEC
PY 2013
VL 37
IS 6
BP 433
EP 439
DI 10.3109/01913123.2013.833562
PG 7
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA 251WL
UT WOS:000326963200007
PM 24134858
DA 2023-08-21
ER

PT J
AU Greineder, CF
   Chacko, AM
   Zaytsev, S
   Zern, BJ
   Carnemolla, R
   Hood, ED
   Han, JY
   Ding, BS
   Esmon, CT
   Muzykantov, VR
AF Greineder, Colin F.
   Chacko, Ann Marie
   Zaytsev, Sergei
   Zern, Blaine J.
   Carnemolla, Ronald
   Hood, Elizabeth D.
   Han, Jingyan
   Ding, Bi-Sen
   Esmon, Charles T.
   Muzykantov, Vladimir R.
TI Vascular Immunotargeting to Endothelial Determinant ICAM-1 Enables
   Optimal Partnering of Recombinant scFv-Thrombomodulin Fusion with
   Endogenous Cofactor
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-C; DISSEMINATED INTRAVASCULAR COAGULATION; SOLUBLE
   THROMBOMODULIN; CARDIAC-ARREST; SEVERE SEPSIS; RECEPTOR; DYSFUNCTION;
   THROMBOSIS; EXPRESSION; PECAM-1
AB The use of targeted therapeutics to replenish pathologically deficient proteins on the luminal endothelial membrane has the potential to revolutionize emergency and cardiovascular medicine. Untargeted recombinant proteins, like activated protein C (APC) and thrombomodulin (TM), have demonstrated beneficial effects in acute vascular disorders, but have failed to have a major impact on clinical care. We recently reported that TM fused with an scFv antibody fragment to platelet endothelial cell adhesion molecule-1 (PECAM-1) exerts therapeutic effects superior to untargeted TM. PECAM-1 is localized to cell-cell junctions, however, whereas the endothelial protein C receptor (EPCR), the key co-factor of TM/APC, is exposed in the apical membrane. Here we tested whether anchoring TM to the intercellular adhesion molecule (ICAM-1) favors scFv/TM collaboration with EPCR. Indeed: i) endothelial targeting scFv/TM to ICAM-1 provides similar to 15-fold greater activation of protein C than its PECAM-targeted counterpart; ii) blocking EPCR reduces protein C activation by scFv/TM anchored to endothelial ICAM-1, but not PECAM-1; and iii) anti-ICAM scFv/TM fusion provides more profound anti-inflammatory effects than anti-PECAM scFv/TM in a mouse model of acute lung injury. These findings, obtained using new translational constructs, emphasize the importance of targeting protein therapeutics to the proper surface determinant, in order to optimize their microenvironment and beneficial effects.
C1 [Greineder, Colin F.; Zaytsev, Sergei; Zern, Blaine J.; Carnemolla, Ronald; Hood, Elizabeth D.; Han, Jingyan; Ding, Bi-Sen; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104, United States.
C1 [Greineder, Colin F.; Chacko, Ann-Marie; Zaytsev, Sergei; Zern, Blaine J.; Carnemolla, Ronald; Hood, Elizabeth D.; Han, Jingyan; Ding, Bi-Sen; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Inst Translat Med & Therapeut, Ctr Targeted Therapeut & Translat Nanomed, Philadelphia, PA 19104, United States.
C1 [Chacko, Ann-Marie] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104, United States.
C1 [Greineder, Colin F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104, United States.
C1 [Esmon, Charles T.] Oklahoma Med Res Fdn, Howard Hughes Med Inst, Cardiovasc Biol Res Program, Oklahoma City, OK 73104, United States.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; University of Pennsylvania; Pennsylvania
   Medicine; Howard Hughes Medical Institute; Oklahoma Medical Research
   Foundation
RP Muzykantov, VR (corresponding author), Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
RI han, jingyan/HJG-6568-2022
OI Greineder, Colin/0000-0001-9740-7672; Chacko,
   Ann-Marie/0000-0001-5140-2622
FU Institute of Translational Medicine and Therapeutics (ITMAT) at the
   University of Pennsylvania; American Heart Association [10FTF4150053];
   National Institutes of Health [R01-HL091950]
FX This work was supported by a Junior Investigator Preliminary/Feasibility
   Grant from the Institute of Translational Medicine and Therapeutics
   (ITMAT) at the University of Pennsylvania (CFG), as well as an American
   Heart Association Fellow to Faculty grant 10FTF4150053 (CFG), and
   National Institutes of Health Grant R01-HL091950 (VRM). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Adrie C, 2005, J AM COLL CARDIOL, V46, P21, DOI 10.1016/j.jacc.2005.03.046
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059
   Bae JS, 2007, P NATL ACAD SCI USA, V104, P2867, DOI 10.1073/pnas.0611493104
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Chacko AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034958
   Chrastina A, 2010, J VASC RES, V47, P531, DOI 10.1159/000313880
   Christofidou-Solomidou M, 2002, AM J PATHOL, V160, P1155, DOI 10.1016/S0002-9440(10)64935-8
   CROWE JS, 1989, NUCLEIC ACIDS RES, V17, P7992, DOI 10.1093/nar/17.19.7992
   Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335, DOI 10.1152/ajplung.2001.280.6.L1335
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   DUBEL S, 1994, J IMMUNOL METHODS, V175, P89, DOI 10.1016/0022-1759(94)90334-4
   Esmon CT, 2001, CRIT CARE, V5, pS7, DOI 10.1186/cc1333
   ESMON CT, 1989, J BIOL CHEM, V264, P4743
   Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603
   Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571
   Gentry CA, 2009, CRIT CARE MED, V37, P19, DOI 10.1097/CCM.0b013e318192843b
   GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151
   Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404
   Kim AY, 2002, CIRC RES, V90, P205, DOI 10.1161/hh0202.105097
   Kowalski PS, 2011, IUBMB LIFE, V63, P648, DOI 10.1002/iub.487
   Laszik ZG, 2001, AM J PATHOL, V159, P797, DOI 10.1016/S0002-9440(10)61753-1
   Li W, 2005, J THROMB HAEMOST, V3, P1351, DOI 10.1111/j.1538-7836.2005.01385.x
   Lin SM, 2008, CRIT CARE MED, V36, P683, DOI 10.1097/CCM.0B013E31816537D8
   Liu KD, 2008, AM J RESP CRIT CARE, V178, P618, DOI 10.1164/rccm.200803-419OC
   MacGregor IR, 1997, AM J RESP CRIT CARE, V155, P47, DOI 10.1164/ajrccm.155.1.9001288
   MOORE KL, 1989, BLOOD, V73, P159
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muro Silvia, 2004, Current Vascular Pharmacology, V2, P281, DOI 10.2174/1570161043385736
   Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909
   NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460
   Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652
   Newby AC, 1999, CURR OPIN CARDIOL, V14, P489, DOI 10.1097/00001573-199911000-00007
   NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x
   Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129
   Pasqualini R, 2000, CANCER RES, V60, P722
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Saito H, 2007, J THROMB HAEMOST, V5, P31, DOI 10.1111/j.1538-7836.2006.02267.x
   SIDO B, 1995, TRANSPLANTATION, V60, P462, DOI 10.1097/00007890-199509000-00010
   Simone E, 2009, CELL TISSUE RES, V335, P283, DOI 10.1007/s00441-008-0676-7
   STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O
   StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212
   Su EJ, 2011, J THROMB HAEMOST, V9, P1174, DOI 10.1111/j.1538-7836.2011.04269.x
   Tabuchi N, 2004, EUR J CARDIO-THORAC, V26, P995, DOI 10.1016/j.ejcts.2004.07.028
   TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902
   TEASDALE MS, 1994, IMMUNOL CELL BIOL, V72, P480, DOI 10.1038/icb.1994.72
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   van Buul JD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011336
   Van de Wouwer M, 2004, ARTERIOSCL THROM VAS, V24, P1374, DOI 10.1161/01.ATV.0000134298.25489.92
   Waugh JM, 1999, CIRC RES, V84, P84
   Weiler H, 2001, ARTERIOSCL THROM VAS, V21, P1531, DOI 10.1161/hq0901.094496
   Zhang N, 2008, BIOCONJUGATE CHEM, V19, P145, DOI 10.1021/bc700227z
NR 54
TC 40
Z9 40
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 14
PY 2013
VL 8
IS 11
AR e80110
DI 10.1371/journal.pone.0080110
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 254DJ
UT WOS:000327143800123
PM 24244621
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Bayat, B
   Tjahjono, Y
   Sydykov, A
   Werth, S
   Hippenstiel, S
   Weissmann, N
   Sachs, UJ
   Santoso, S
AF Bayat, Behnaz
   Tjahjono, Yudy
   Sydykov, Akylbek
   Werth, Silke
   Hippenstiel, Stefan
   Weissmann, Norbert
   Sachs, Ulrich J. H.
   Santoso, Sentot
TI Anti-Human Neutrophil Antigen-3a Induced Transfusion-Related Acute Lung
   Injury in Mice by Direct Disturbance of Lung Endothelial Cells
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; ROS 
ID TRANSPORTER-LIKE PROTEINS; ANTIBODIES; TRALI; ALLOANTIBODIES;
   ACTIVATION; PHOSPHORYLATION; PATHOGENESIS; P120-CATENIN; INSIGHTS;
   BINDING
AB Objective Antibodies against human neutrophil antigen-3a (HNA-3a) located on choline transporter-like protein 2 induce severe transfusion-related acute lung injury (TRALI). This study aims to identify the mechanism implicated in anti-HNA-3a-mediated TRALI.
   Approach and Results Our analysis shows that anti-HNA-3a recognizes 2 choline transporter-like protein 2 isoforms (P1 and P2) on human microvascular endothelial cells from lung blood vessels but reacts only with the P1 isoform on neutrophils. Direct treatment of HNA-3a-positive endothelial cells with anti-HNA-3a, but not with anti-HNA-3b, leads to reactive oxygen species production, increased albumin influx, and decreased endothelial resistance associated with the formation of actin stress filaments and loosening of junctional vascular endothelium-cadherin. In a novel in vivo mouse model, TRALI was documented by significant increase in lung water content, albumin concentration, and neutrophil numbers in the bronchoalveolar lavage on injection of human anti-HNA-3a in lipopolysaccharides-treated, as well as nontreated mice. Interestingly, although neutrophil depletion alleviated severity of lung injury, it failed to prevent TRALI in this model. Infusion of anti-HNA-3a F(ab)(2) fragments caused moderate TRALI. Finally, mice lacking nicotinamide adenine dinucleotide phosphate oxidase (NOX2(y/-)) were protected from anti-HNA-3a-mediated TRALI.
   Conclusions These data demonstrate the initiation of endothelial barrier dysfunction in vitro and in vivo by direct binding of anti-HNA-3a on endothelial cells. It seems, however, that the presence of neutrophils aggravates barrier dysfunction. This novel mechanism of TRALI primarily mediated by endothelial cell dysfunction via choline transporter-like protein 2 may help to define new treatment strategies to decrease TRALI-related mortality.
C1 [Bayat, Behnaz; Tjahjono, Yudy; Werth, Silke; Sachs, Ulrich J.; Santoso, Sentot] Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany.
C1 [Sydykov, Akylbek; Weissmann, Nobert] Univ Giessen, Dept Internal Med 2 5, ECCPS, D-35392 Giessen, Germany.
C1 [Sydykov, Akylbek; Weissmann, Nobert] Marburg Lung Ctr UGMLC, Giessen, Germany.
C1 [Hippenstiel, Stefan] Charite, Dept Infect Dis & Resp Med, D-13353 Berlin, Germany.
C3 Justus Liebig University Giessen; Justus Liebig University Giessen; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Santoso, S (corresponding author), Univ Giessen, Inst Clin Immunol & Transfus Med, Langhansstr 7, D-35392 Giessen, Germany.
EM sentot.santoso@med.uni-giessen.de
RI Sydykov, Akylbek/O-1049-2017; Sachs, Ulrich/GSI-7824-2022; Sydykov,
   Akylbek/K-8463-2019; Werth, Silke/I-4757-2012
OI Sydykov, Akylbek/0000-0002-8122-7033; Sydykov,
   Akylbek/0000-0002-8122-7033; Werth, Silke/0000-0002-4981-7850; Tjahjono,
   Yudy/0000-0003-0187-0270; Weissmann, Norbert/0000-0003-2675-3871;
   Hippenstiel, Stefan/0000-0002-5146-1064
FU German Research Foundation [TR-FB84]; Excellence Cluster Cardiopulmonary
   System; University Hospital Giessen and Marburg
FX This work was supported by the German Research Foundation, TR-FB84 (to
   S. Santoso) and the Excellence Cluster Cardiopulmonary System (S.
   Santoso, B. Bayat, N. Weissmann), and an University Hospital Giessen and
   Marburg intramural research grant (to U.J. Sachs and S. Santoso).
CR Bayat B, 2012, CURR PHARM DESIGN, V18, P3236, DOI 10.2174/1381612811209023236
   Bayat B, 2012, TRANSFUSION, V52, P613, DOI 10.1111/j.1537-2995.2011.03303.x
   Bian H, 1999, J IMMUNOL, V163, P1010
   Boueiz A, 2009, MICROVASC RES, V77, P26, DOI 10.1016/j.mvr.2008.10.005
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Curtis BR, 2010, BLOOD, V115, P2073, DOI 10.1182/blood-2009-11-248336
   Davoren A, 2003, TRANSFUSION, V43, P641, DOI 10.1046/j.1537-2995.2003.00374.x
   Dechend R, 2003, CIRCULATION, V107, P1632, DOI 10.1161/01.CIR.0000058200.90059.B1
   Flesch BK, 2013, TRANSFUSION, DOI [10.1111/trf.12160, DOI 10.1111/TRF.12160.HTTP://0NLINELIBRARY.WILEY.C0M/D0I/10.1111/TRF.12160/ABSTRACT;JSESSI0NID=]
   Frenette PS, 2010, NAT MED, V16, P382, DOI 10.1038/nm0410-382
   Greinacher A, 2010, NAT MED, V16, P45, DOI 10.1038/nm.2070
   Hatanaka K, 2011, AM J PHYSIOL-HEART C, V300, pH162, DOI 10.1152/ajpheart.00650.2010
   Immenschuh S, 2013, FREE RADICAL BIO MED, V54, P85, DOI 10.1016/j.freeradbiomed.2012.10.551
   Jerke U, 2011, J BIOL CHEM, V286, P7070, DOI 10.1074/jbc.M110.171256
   Karpinich NO, 2011, CURR HYPERTENS REV, V7, P228, DOI 10.2174/157340211799304761
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Kommareddi PK, 2010, PROTEIN J, V29, P417, DOI 10.1007/s10930-010-9268-y
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968
   Koprivica Z, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/918312
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027
   Liu RM, 2010, J BIOL CHEM, V285, P16239, DOI 10.1074/jbc.M110.111732
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Makar RS, 2012, TRANSFUS MED REV, V26, P305, DOI 10.1016/j.tmrv.2012.03.001
   Michel V, 2006, EXP BIOL MED, V231, P490
   Nakamura T, 2010, BIOL PHARM BULL, V33, P691, DOI 10.1248/bpb.33.691
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Sachs UJ, 2012, TRANSFUS CLIN BIOL, V19, P109, DOI 10.1016/j.tracli.2012.03.003
   Sachs UJ, 2011, CURR OPIN HEMATOL, V18, P436, DOI 10.1097/MOH.0b013e32834bab01
   SCHNITTLER HJ, 1990, J PHYSIOL-LONDON, V431, P379, DOI 10.1113/jphysiol.1990.sp018335
   SEEGER W, 1990, BLOOD, V76, P1438
   Semple JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031357
   Shakib F, 1990, HUMAN IGG SUBCLASSES, P280
   Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   Silliman CC, 2009, BLOOD REV, V23, P245, DOI 10.1016/j.blre.2009.07.005
   Steiner AA, 2011, J PHYSIOL-LONDON, V589, P2415, DOI 10.1113/jphysiol.2010.202465
   Strait RT, 2011, J EXP MED, V208, P2525, DOI 10.1084/jem.20110159
   Stroncek DF, 2007, SEMIN HEMATOL, V44, P2, DOI 10.1053/j.seminhematol.2006.09.014
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   Tian XY, 2012, J MOL CELL CARDIOL, V52, P237, DOI 10.1016/j.yjmcc.2011.10.013
   Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51
   Traiffort E, 2005, J NEUROCHEM, V92, P1116, DOI 10.1111/j.1471-4159.2004.02962.x
   Van Buul JD, 2005, ANTIOXID REDOX SIGN, V7, P308, DOI 10.1089/ars.2005.7.308
   VANBUREN NL, 1990, TRANSFUSION, V30, P42
   VISCHER UM, 1995, BLOOD, V85, P3164, DOI 10.1182/blood.V85.11.3164.bloodjournal85113164
   Vlaar AP, 2009, NETH J MED, V67, P320
   Vlaar APJ, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/720950
   Weissmann N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1660
   Xia WJ, 2011, TRANSFUSION, V51, P1271, DOI 10.1111/j.1537-2995.2010.02979.x
   Zhang X, 2009, AM J TRANSPLANT, V9, P2459, DOI 10.1111/j.1600-6143.2009.02819.x
NR 55
TC 41
Z9 43
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD NOV
PY 2013
VL 33
IS 11
BP 2538
EP 2548
DI 10.1161/ATVBAHA.113.301206
PG 11
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 244VQ
UT WOS:000326418700015
PM 24008160
OA Bronze
DA 2023-08-21
ER

PT J
AU Iliodromiti, Z
   Zygouris, D
   Sifakis, S
   Pappa, KI
   Tsikouras, P
   Salakos, N
   Daniilidis, A
   Siristatidis, C
   Vrachnis, N
AF Iliodromiti, Zoe
   Zygouris, Dimitrios
   Sifakis, Stavros
   Pappa, Kalliopi I.
   Tsikouras, Panagiotis
   Salakos, Nikolaos
   Daniilidis, Angelos
   Siristatidis, Charalambos
   Vrachnis, Nikolaos
TI Acute lung injury in preterm fetuses and neonates: mechanisms and
   molecular pathways
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE ALI/ARDS; Inflammation; preterm neonates; reactive nitrogen species; ROS 
ID TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR;
   RESPIRATORY-DISTRESS-SYNDROME; FETAL INFLAMMATORY RESPONSE;
   HYALINE-MEMBRANE DISEASE; END-EXPIRATORY PRESSURE; FACTOR-ALPHA; RAT
   LUNG; BRONCHOPULMONARY DYSPLASIA; INTRAAMNIOTIC ENDOTOXIN
AB Acute lung injury (ALI) results in high morbidity and mortality among preterm neonates and efforts have therefore been devoted to both antenatal and postnatal prevention of the disease. ALI is the result of an inflammatory response which is triggered by a variety of different mechanisms. It mostly affects the fetal lung and, in particular, causes damage to the integrity of the lung's alveolar-capillary unit while weakening its cellular linings. Chemotactic activity and inflammatory products, such as proinflammatory cytokines TNF-alpha, IL-1, IL-6, IL-11, VEGF, TGF-alpha and TGF-beta, provoke serious damage to the capillary endothelium and the alveolar epithelium, resulting in hyaline membrane formation and leakage of protein-rich edema fluid into the alveoli. Chorioamnionitis plays a major part in triggering fetal lung inflammation, while mechanical ventilation, the application of which is frequently necessary in preterm neonates, also causes ALI by inducing proinflammatory cytokines. Many different ventilation-strategies have been developed in order to reduce potential lung injury. Furthermore, tissue injury may occur as a result of injurious oxygen by-products (Reactive Oxygen Species, ROS), secondary to hyperoxia. Knowledge of the inflammatory pathways that connect intra-amniotic inflammation and ALI can lead to the formulation of novel interventional procedures. Future research should concentrate on the pathophysiology of ALI in preterm neonates and on possible pharmaceutical interventions targeting prevention and/or resolution of ALI.
C1 [Iliodromiti, Zoe; Salakos, Nikolaos; Vrachnis, Nikolaos] Univ Athens, Sch Med, Aretaieio Hosp, Dept Obstet & Gynecol 2, GR-11527 Athens, Greece.
C1 [Zygouris, Dimitrios; Siristatidis, Charalambos] Univ Athens, Sch Med, Attikon Hosp, Dept Obstet & Gynecol 3, GR-11527 Athens, Greece.
C1 [Sifakis, Stavros] Univ Hosp Heraklion, Dept Obstet & Gynaecol, Iraklion, Crete, Greece.
C1 [Pappa, Kalliopi I.] Univ Athens, Sch Med, Dept Obstet & Gynecol 1, Alexandra Hosp, GR-11527 Athens, Greece.
C1 [Tsikouras, Panagiotis] Democritus Univ Thrace, Dept Obstet & Gynecol, Univ Hosp Alexandroupolis, Alexandroupolis, Greece.
C1 [Daniilidis, Angelos] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol, GR-54006 Thessaloniki, Greece.
C3 Athens Medical School; CIVIS; National & Kapodistrian University of
   Athens; Athens Medical School; CIVIS; National & Kapodistrian University
   of Athens; University Hospital Attikon; University Hospital of
   Heraklion; Alexandra Hospital; Athens Medical School; CIVIS; National &
   Kapodistrian University of Athens; Democritus University of Thrace;
   Aristotle University of Thessaloniki
RP Iliodromiti, Z (corresponding author), 2 Anninou St, Attiki 15771, Greece.
EM ziliodromiti@yahoo.gr
RI iliodromiti, Zoi/HNB-7534-2023; Siristatidis, Charalambos/AAD-6990-2019;
   PAPPA, KALLIOPI/K-9345-2018
OI Siristatidis, Charalambos/0000-0003-0850-6623; DANIILIDIS,
   ANGELOS/0000-0003-0044-9214; PAPPA, KALLIOPI/0000-0002-1061-7405;
   Zygouris, Dimitrios/0000-0001-6533-1298
CR Agrawal A, 2012, AM J PHYSIOL-LUNG C, V303, pL634, DOI 10.1152/ajplung.00195.2012
   Aikio O, 2000, PEDIATRICS, V105, P1013, DOI 10.1542/peds.105.5.1013
   Alejandre-Alcazar MA, 2007, AM J PHYSIOL-LUNG C, V292, pL537, DOI 10.1152/ajplung.00050.2006
   BAGCHI A, 1994, PEDIATR RES, V36, P244, DOI 10.1203/00006450-199408000-00017
   Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180
   Barton L, 1999, PEDIATRICS, V103, P446, DOI 10.1542/peds.103.2.446
   Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754
   Been JV, 2009, ARCH DIS CHILD-FETAL, V94, pF218, DOI 10.1136/adc.2008.150458
   Ben-Ari J, 2000, ISRAEL MED ASSOC J, V2, P365
   Bhandari V, 2006, FREE RADICAL BIO MED, V41, P4, DOI 10.1016/j.freeradbiomed.2006.01.027
   Bhandari V, 2010, SEMIN FETAL NEONAT M, V15, P223, DOI 10.1016/j.siny.2010.03.009
   BIFFL WL, 1994, ARCH SURG-CHICAGO, V129, P1131
   Bland RD, 2005, BIOL NEONATE, V88, P181, DOI 10.1159/000087581
   Capoluongo E, 2005, EUR CYTOKINE NETW, V16, P199
   Chakraborty M, 2010, PAEDIATR RESPIR REV, V11, P162, DOI 10.1016/j.prrv.2010.03.002
   Coalson Jacqueline J, 2003, Semin Neonatol, V8, P73, DOI 10.1016/S1084-2756(02)00193-8
   Coalson JJ, 1999, AM J RESP CRIT CARE, V160, P1333, DOI 10.1164/ajrccm.160.4.9810071
   D'Angio CT, 1999, EXP LUNG RES, V25, P443
   Dasgupta C, 2009, AM J PHYSIOL-LUNG C, V296, pL1031, DOI 10.1152/ajplung.90392.2008
   Deng H, 2000, AM J RESP CRIT CARE, V162, P2316, DOI 10.1164/ajrccm.162.6.9911020
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159
   Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014
   Goepfert AR, 2004, AM J OBSTET GYNECOL, V191, P1375, DOI 10.1016/j.ajog.2004.06.086
   Gomez R, 1998, AM J OBSTET GYNECOL, V179, P194, DOI 10.1016/S0002-9378(98)70272-8
   Grande JP, 1997, P SOC EXP BIOL MED, V214, P27
   Gunther A, 1996, AM J RESP CRIT CARE, V153, P176
   Hanna N, 2005, PEDIATR RES, V57, P56, DOI 10.1203/01.PDR.0000147568.14392.F0
   Hillman NH, 2011, AM J PHYSIOL-LUNG C, V301, pL712, DOI 10.1152/ajplung.00157.2011
   Hillman NH, 2011, AM J PHYSIOL-LUNG C, V300, pL232, DOI 10.1152/ajplung.00294.2010
   Hitti J, 1997, AM J OBSTET GYNECOL, V177, P50, DOI 10.1016/S0002-9378(97)70437-X
   Horowitz S, 1999, CHEST, V116, p64S, DOI 10.1378/chest.116.suppl_1.64S
   Janer J, 2006, AM J RESP CRIT CARE, V174, P326, DOI 10.1164/rccm.200508-1291OC
   Jobe AH, 1998, EARLY HUM DEV, V53, P81, DOI 10.1016/S0378-3782(98)00045-0
   Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00007
   Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723
   Johnston CJ, 1997, EXP LUNG RES, V23, P537, DOI 10.3109/01902149709039242
   Jones CA, 1996, PEDIATR RES, V39, P966, DOI 10.1203/00006450-199606000-00007
   Kallapur SG, 2004, AM J PHYSIOL-LUNG C, V287, pL1178, DOI 10.1152/ajplung.00049.2004
   Kallapur SG, 2003, AM J RESP CRIT CARE, V167, P779, DOI 10.1164/rccm.2203030
   Kinsella JP, 2007, J PEDIATR-US, V151, P10, DOI 10.1016/j.jpeds.2007.02.010
   Koenig JM, 2005, PEDIATR RES, V57, P424, DOI 10.1203/01.PDR.0000153945.49022.96
   Kotecha S, 1996, EUR J PEDIATR, V155, pS14, DOI 10.1007/BF01958074
   Kotecha S, 2003, THORAX, V58, P961, DOI 10.1136/thorax.58.11.961
   Kramer BW, 2009, SEMIN FETAL NEONAT M, V14, P2, DOI 10.1016/j.siny.2008.08.011
   Kunzmann S, 2007, AM J PHYSIOL-LUNG C, V292, pL223, DOI 10.1152/ajplung.00159.2006
   Lassus P, 2000, PEDIATR RES, V47, P602, DOI 10.1203/00006450-200005000-00008
   Li Y, 2012, WORLD J PEDIATR, V8, P43, DOI 10.1007/s12519-012-0334-8
   Lindsay L, 2000, INFLAMMATION, V24, P347, DOI 10.1023/A:1007096931078
   LITTLE S, 1995, THORAX, V50, P1073, DOI 10.1136/thx.50.10.1073
   Malamitsi-Puchner A, 2006, ANN NY ACAD SCI, V1092, P440, DOI 10.1196/annals.1365.043
   MARKOS J, 1993, J APPL PHYSIOL, V74, P2627, DOI 10.1152/jappl.1993.74.6.2627
   Matsuda T, 1997, AM J OBSTET GYNECOL, V177, P1402, DOI 10.1016/S0002-9378(97)70082-6
   MATSUOKA T, 1994, J APPL PHYSIOL, V76, P539, DOI 10.1152/jappl.1994.76.2.539
   Maxwell NC, 2006, CURR OPIN INFECT DIS, V19, P253, DOI 10.1097/01.qco.0000224819.42729.2e
   MEREDITH KS, 1989, J APPL PHYSIOL, V66, P2150, DOI 10.1152/jappl.1989.66.5.2150
   Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004
   Nakanishi H, 2007, AM J PHYSIOL-LUNG C, V293, pL151, DOI 10.1152/ajplung.00389.2006
   O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291
   PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024
   Ramsay PL, 1998, PEDIATRICS, V102, P927, DOI 10.1542/peds.102.4.927
   Sapru A, 2010, INTENS CARE MED, V36, P157, DOI 10.1007/s00134-009-1690-2
   Saugstad Ola Didrik, 2003, Semin Neonatol, V8, P39, DOI 10.1016/S1084-2756(02)00194-X
   Schittny JC, 1998, AM J RESP CELL MOL, V18, P786, DOI 10.1165/ajrcmb.18.6.3031
   Sime PJ, 1998, AM J PATHOL, V153, P825, DOI 10.1016/S0002-9440(10)65624-6
   Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a
   Speer CP, 2001, BIOL NEONATE, V79, P205
   Su JL, 2004, CANCER RES, V64, P554, DOI 10.1158/0008-5472.CAN-03-1301
   TAN ND, 1995, PEDIATR RES, V38, P11, DOI 10.1203/00006450-199507000-00003
   Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071
   Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174
   Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259
   Tsuchida S, 2005, AM J PHYSIOL-LUNG C, V289, pL554, DOI 10.1152/ajplung.00143.2005
   Valentine SL, 2012, CRIT CARE MED, V40, P2883, DOI 10.1097/CCM.0b013e31825bc54d
   Viscardi RM, 2004, PEDIATR RES, V55, P1009, DOI 10.1203/01.pdr.0000127015.60185.8a
   Vosdoganes P, 2012, PEDIATRICS, V130, P727, DOI 10.1542/peds.2011-2576
   Vrachnis N, 2010, ANN NY ACAD SCI, V1205, P118, DOI 10.1111/j.1749-6632.2010.05684.x
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Warner BB, 1998, AM J PHYSIOL-LUNG C, V275, pL110, DOI 10.1152/ajplung.1998.275.1.L110
   Watterberg KL, 1996, PEDIATRICS, V97, P210
   WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U
   Willet KE, 2000, PEDIATR RES, V48, P782, DOI 10.1203/00006450-200012000-00014
   Willson DF, 2011, RESP CARE, V56, P1369, DOI 10.4187/respcare.01306
   Yoon BH, 1999, AM J OBSTET GYNECOL, V181, P773, DOI 10.1016/S0002-9378(99)70299-1
   Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P825, DOI 10.1016/S0002-9378(97)70276-X
NR 85
TC 37
Z9 42
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD NOV
PY 2013
VL 26
IS 17
BP 1696
EP 1704
DI 10.3109/14767058.2013.798284
PG 9
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 238YT
UT WOS:000325989000006
PM 23611524
DA 2023-08-21
ER

PT J
AU Klein, N
   Gembardt, F
   Supe, S
   Kaestle, SM
   Nickles, H
   Erfinanda, L
   Lei, XH
   Yin, J
   Wang, LM
   Mertens, M
   Szaszi, K
   Walther, T
   Kuebler, WM
AF Klein, Nadine
   Gembardt, Florian
   Supe, Stephanie
   Kaestle, Stephanie M.
   Nickles, Hannah
   Erfinanda, Lasti
   Lei, Xiaohong
   Yin, Jun
   Wang, Liming
   Mertens, Michael
   Szaszi, Katalin
   Walther, Thomas
   Kuebler, Wolfgang M.
TI Angiotensin-(1-7) Protects From Experimental Acute Lung Injury
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE ALI/ARDS; angiotensin; Inflammation; permeability; renin-angiotensin system 
ID RESPIRATORY-DISTRESS-SYNDROME; COUPLED-RECEPTOR MAS; CONVERTING-ENZYME;
   PULMONARY-HYPERTENSION; NITRIC-OXIDE; ENDOTHELIAL FUNCTION; ANTAGONIST;
   BRAIN; RESENSITIZATION; POLYMORPHISM
AB Objectives: Recently, recombinant angiotensin-converting enzyme 2 was shown to protect mice from acute lung injury, an effect attributed to reduced bioavailability of angiotensin II. Since angiotensin-converting enzyme 2 metabolizes angiotensin II to angiotensin-(1-7), we hypothesized that this effect is alternatively mediated by angiotensin-(1-7) and activation of its receptor(s).
   Design: To test this hypothesis, we investigated the effects of intravenously infused angiotensin-(1-7) in three experimental models of acute lung injury.
   Setting: Animal research laboratory.
   Subjects: Male Sprague-Dawley rats, Balb/c mice, and C57Bl6/J mice.
   Interventions: Angiotensin-(1-7) was administered with ventilator- or acid aspiration-induced lung injury in mice or 30 minutes after oleic acid infusion in rats. In vitro, the effect of angiotensin-(1-7) on transendothelial electrical resistance of human pulmonary microvascular endothelial cells was analyzed.
   Measurements and Main Results: Infusion of angiotensin-(1-7) starting 30 minutes after oleic acid administration protected rats from acute lung injury as evident by reduced lung edema, myeloperoxidase activity, histological lung injury score, and pulmonary vascular resistance while systemic arterial pressure was stabilized. Such effects were largely reproduced by the nonpeptidic angiotensin-(1-7) analog AVE0991. Infusion of angiotensin-(1-7) was equally protective in murine models of ventilator- or acid aspiration-induced lung injury. In the oleic acid model, the two distinct angiotensin-(1-7) receptor blockers A779 and d-Pro(7)-angiotensin-(1-7) reversed the normalizing effects of angiotensin-(1-7) on systemic and pulmonary hemodynamics, but only d-Pro(7)-angiotensin-(1-7) blocked the protection from lung edema and protein leak, whereas A779 restored the infiltration of neutrophils. Rats were also protected from acute lung injury by the AT(1) antagonist irbesartan; however, this effect was again blocked by A779 and d-Pro(7)-angiotensin-(1-7). In vitro, angiotensin-(1-7) protected pulmonary microvascular endothelial cells from thrombin-induced barrier failure, yet d-Pro(7)-angiotensin-(1-7) or NO synthase inhibition blocked this effect.
   Conclusions: Angiotensin-(1-7) or its analogs attenuate the key features of acute lung injury and may present a promising therapeutic strategy for the treatment of this disease.
C1 [Klein, Nadine; Supe, Stephanie; Kaestle, Stephanie M.; Nickles, Hannah; Erfinanda, Lasti; Lei, Xiaohong; Mertens, Michael; Kuebler, Wolfgang M.] Charite, Dept Physiol, D-13353 Berlin, Germany.
C1 [Gembardt, Florian] Excellencecluster Cardiopulm Syst, Dept Cardiac Pathobiol, Giessen, Germany.
C1 [Gembardt, Florian] Univ Hosp Dresden, Dept Nephrol MK3, Dresden, Germany.
C1 [Yin, Jun; Wang, Liming; Szaszi, Katalin; Kuebler, Wolfgang M.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada.
C1 [Walther, Thomas] Heidelberg Univ, Med Fac Mannheim, Inst Expt, Mannheim, Germany.
C1 [Walther, Thomas] Univ Leipzig, Ctr Fetal Med, D-04109 Leipzig, Germany.
C1 [Walther, Thomas] Univ Leipzig, Dept Obstet, Div Women & Child Hlth, D-04109 Leipzig, Germany.
C1 [Walther, Thomas] Natl Univ Ireland Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland.
C1 [Kuebler, Wolfgang M.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada.
C1 [Kuebler, Wolfgang M.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Technische Universitat Dresden; Carl Gustav
   Carus University Hospital; University of Toronto; Li Ka Shing Knowledge
   Institute; Saint Michaels Hospital Toronto; Ruprecht Karls University
   Heidelberg; Leipzig University; Leipzig University; University College
   Cork; University of Toronto; University of Toronto
RP Walther, T (corresponding author), Heidelberg Univ, Med Fac Mannheim, Inst Expt, Mannheim, Germany.
EM thomas.walther2011@gmail.com
RI Gembardt, Florian/H-2360-2011
OI Gembardt, Florian/0000-0003-2739-345X; Kuebler,
   Wolfgang/0000-0003-4100-2961; Yin, Jun/0009-0008-5428-9969; Szaszi,
   Katalin/0000-0002-2490-8422; Nickles, Hannah Theresa/0000-0003-0807-9668
FU Deutsche Forschungsgemeinschaft [KU1218/7-1, WA 1441/21-1]; Ontario Lung
   Association/Ontario Thoracic Society; DFG; GIF; NIH; DAAD
FX Supported, in part, by grants of the Deutsche Forschungsgemeinschaft
   (KU1218/7-1 and WA 1441/21-1) and the Ontario Lung Association/Ontario
   Thoracic Society.; Drs. Walther and Kuebler are the inventors of the
   patent "Use of an Ang-(1-7) receptor agonist in acute lung injury"
   (Application No. 08016142.5-2107), which is exclusively licensed to
   Tarix Pharmaceuticals. Dr. Walther received grant support from DFG, GIF,
   NIH, and DAAD; consulted for Tarix Ltd and Ironwood; and lectured for
   Merck. Dr. Kuebler received grant support from Deutsche
   Forschungsgemeinschaft and Ontario Lung Association/Ontario Thoracic
   Society. The remaining authors have disclosed that they do not have any
   potential conflicts of interest.
CR Adamzik M, 2007, EUR RESPIR J, V29, P482, DOI 10.1183/09031936.00046106
   [Anonymous], 2000, NEW ENGL J MED
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Bueltmann M, 2009, INTENS CARE MED, V35, P171, DOI 10.1007/s00134-008-1344-9
   Chai SY, 2004, CELL MOL LIFE SCI, V61, P2728, DOI 10.1007/s00018-004-4246-1
   Chen ZL, 2005, HYPERTENSION, V46, P1368, DOI 10.1161/01.HYP.0000188905.20884.63
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Faber F, 2006, REGUL PEPTIDES, V136, P130, DOI 10.1016/j.regpep.2006.06.001
   Ferrario CM, 1998, J AM SOC NEPHROL, V9, P1716
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009
   Hoffmann J, 2011, EUR RESPIR J, V37, P1400, DOI 10.1183/09031936.00043310
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kostenis E, 2005, CIRCULATION, V111, P1806, DOI 10.1161/01.CIR.0000160867.23556.7D
   Kuebler WM, 1996, INT J MICROCIRC, V16, P89, DOI 10.1159/000179155
   Kuebler WM, 2011, AM J PHYSIOL-LUNG C, V301, pL157, DOI 10.1152/ajplung.00192.2011
   Lemos VS, 2005, J CARDIOVASC PHARM, V46, P274, DOI 10.1097/01.fjc.0000175237.41573.63
   Liu L, 2009, ARCH BIOCHEM BIOPHYS, V481, P131, DOI 10.1016/j.abb.2008.09.019
   Marcic B, 1999, HYPERTENSION, V33, P835, DOI 10.1161/01.HYP.33.3.835
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Mercure C, 2008, CIRC RES, V103, P1319, DOI 10.1161/CIRCRESAHA.108.184911
   Mertens M, 2009, CRIT CARE MED, V37, P2604, DOI 10.1097/CCM.0b013e3181a5544d
   Moncada S., 2006, V176, P213
   Peiro C, 2007, J HYPERTENS, V25, P2421, DOI 10.1097/HJH.0b013e3282f0143c
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f
   Santos RAS, 2000, REGUL PEPTIDES, V91, P45, DOI 10.1016/S0167-0115(00)00138-5
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Santos RAS, 2003, HYPERTENSION, V41, P737, DOI 10.1161/01.HYP.0000052947.60363.24
   SCHUSTER DP, 1994, AM J RESP CRIT CARE, V149, P245, DOI 10.1164/ajrccm.149.1.8111590
   Shenoy V, 2010, AM J RESP CRIT CARE, V182, P1065, DOI 10.1164/rccm.200912-1840OC
   Silva DMR, 2007, PEPTIDES, V28, P702, DOI 10.1016/j.peptides.2006.10.007
   Tabuchi A, 2008, J APPL PHYSIOL, V104, P338, DOI 10.1152/japplphysiol.00348.2007
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weir MR, 1999, AM J HYPERTENS, V12, p205S
   Wiemer G, 2002, HYPERTENSION, V40, P847, DOI 10.1161/01.HYP.0000037979.53963.8F
   Wilson WL, 2005, BRAIN RES, V1060, P108, DOI 10.1016/j.brainres.2005.08.032
   Yao SL, 2008, J SURG RES, V145, P25, DOI 10.1016/j.jss.2007.03.075
   Yin N, 2009, CRIT CARE MED, V37, P980, DOI 10.1097/CCM.0b013e3181962ce6
   Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968
NR 44
TC 72
Z9 79
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD NOV
PY 2013
VL 41
IS 11
BP E334
EP E343
DI 10.1097/CCM.0b013e31828a6688
PG 10
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 243BO
UT WOS:000326291600004
PM 23949470
DA 2023-08-21
ER

PT J
AU Leonard, A
   Marando, C
   Rahman, A
   Fazal, F
AF Leonard, Antony
   Marando, Catherine
   Rahman, Arshad
   Fazal, Fabeha
TI Thrombin selectively engages LIM kinase 1 and slingshot-1L phosphatase
   to regulate NF-kappa B activation and endothelial cell inflammation
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; transcription factor; cytoskeleton; signal transduction; adhesion molecules; Inflammation 
ID RELA/P65 NUCLEAR TRANSLOCATION; ADHESION MOLECULE-1 EXPRESSION; ACTIN
   CYTOSKELETON; ICAM-1 EXPRESSION; TRANSCRIPTIONAL REGULATION; SYSTEMIC
   INFLAMMATION; BINDING PROTEINS; COFILIN ACTIVITY; TISSUE FACTOR;
   TNF-ALPHA
AB Endothelial cell (EC) inflammation is a central event in the pathogenesis of many pulmonary diseases such as acute lung injury and its more severe form acute respiratory distress syndrome. Alterations in actin cytoskeleton are shown to be crucial for NF-kappa B regulation and EC inflammation. Previously, we have described a role of actin binding protein cofilin in mediating cytoskeletal alterations essential for NF-kappa B activation and EC inflammation. The present study describes a dynamic mechanism in which LIM kinase 1 (LIMK1), a cofilin kinase, and slingshot-1Long (SSH-1L), a cofilin phosphatase, are engaged by procoagulant and proinflammatory mediator thrombin to regulate these responses. Our data show that knockdown of LIMK1 destabilizes whereas knockdown of SSH-1L stabilizes the actin filaments through modulation of cofilin phosphorylation; however, in either case thrombin-induced NF-kappa B activity and expression of its target genes (ICAM-1 and VCAM-1) is inhibited. Further mechanistic analyses reveal that knockdown of LIMK1 or SSH-1L each attenuates nuclear translocation and thereby DNA binding of RelA/p65. In addition, LIMK1 or SSH-1L depletion inhibited RelA/p65 phosphorylation at Ser536, a critical event conferring transcriptional competency to the bound NF-kappa B. However, unlike SSH-1L, LIMK1 knockdown also impairs the release of RelA/p65 by blocking IKK beta-dependent phosphorylation/degradation of I kappa B alpha. Interestingly, LIMK1 or SSH-1L depletion failed to inhibit TNF-alpha-induced RelA/p65 nuclear translocation and proinflammatory gene expression. Thus this study provides evidence for a novel role of LIMK1 and SSH-1L in selectively regulating EC inflammation associated with intravascular coagulation.
C1 [Leonard, Antony; Marando, Catherine; Rahman, Arshad; Fazal, Fabeha] Univ Rochester, Sch Med & Dent, Lung Biol & Dis Program, Dept Pediat Neonatol, Rochester, NY, United States.
C3 University of Rochester
RP Fazal, F (corresponding author), Univ Rochester, Sch Med, Dept Pediat, Lung Biol & Dis Program, 601 Elmwood Ave Box 850, Rochester, NY 14642 USA.
EM fabeha_fazal@urmc.rochester.edu
OI Marando, Catherine/0000-0003-1613-6781
FU National Heart, Lung, and Blood Institute [HL096907, HL67424, HL116632]
FX This work was supported in part by National Heart, Lung, and Blood
   Institute Grants HL096907, HL67424, and HL116632.
CR Anthoni C, 2007, J EXP MED, V204, P1595, DOI 10.1084/jem.20062354
   Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965
   Bair AM, 2009, J BIOL CHEM, V284, P563, DOI 10.1074/jbc.M803984200
   Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0
   BARKALOW K, 1995, CURR BIOL, V5, P1000, DOI 10.1016/S0960-9822(95)00200-4
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001
   Bijli KM, 2007, AM J PHYSIOL-LUNG C, V292, pL396, DOI 10.1152/ajplung.00163.2006
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Cairns NJ, 2004, J PATHOL, V204, P438, DOI 10.1002/path.1650
   Cernuda-Morollon E, 2006, CIRC RES, V98, P757, DOI 10.1161/01.RES.0000210579.35304.d3
   Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849
   COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214
   Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209
   Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193
   Endo M, 2007, J BIOL CHEM, V282, P13692, DOI 10.1074/jbc.M610873200
   Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005
   Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200
   Fazal F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059965
   Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335
   Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200
   Johnson RF, 2011, CANCER RES, V71, P5588, DOI 10.1158/0008-5472.CAN-10-4252
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kustermans G, 2008, BIOCHEM PHARMACOL, V76, P1214, DOI 10.1016/j.bcp.2008.08.017
   Kustermans G, 2008, BIOCHEM PHARMACOL, V76, P1310, DOI 10.1016/j.bcp.2008.05.028
   Laroche G, 2005, J BIOL CHEM, V280, P23215, DOI 10.1074/jbc.M414071200
   Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X
   Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291
   LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933
   Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   Maguire O, 2011, CYTOM PART A, V79A, P461, DOI 10.1002/cyto.a.21068
   Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Minami T, 2005, TRENDS CARDIOVAS MED, V15, P174, DOI 10.1016/j.tcm.2005.06.002
   Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823
   Mong PY, 2008, J IMMUNOL, V180, P550, DOI 10.4049/jimmunol.180.1.550
   Nishita M, 2005, J CELL BIOL, V171, P349, DOI 10.1083/jcb.200504029
   Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9
   Oh J, 2005, J VIROL, V79, P12852, DOI 10.1128/JVI.79.20.12852-12860.2005
   Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577
   Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x
   Papakonstanti EA, 2008, FEBS LETT, V582, P2120, DOI 10.1016/j.febslet.2008.02.064
   Rahman A, 1999, J IMMUNOL, V162, P5466
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Ramaekers FCS, 2004, J PATHOL, V204, P351, DOI 10.1002/path.1665
   Sabit R, 2010, CHEST, V138, P47, DOI 10.1378/chest.09-2764
   Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353
   San Martin A, 2008, CIRC RES, V102, P432, DOI 10.1161/CIRCRESAHA.107.158923
   SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X
   Smith PJ, 2000, CYTOMETRY, V40, P280, DOI 10.1002/1097-0320(20000801)40:4<280::AID-CYTO4>3.0.CO;2-7
   Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Undas A, 2010, THROMB HAEMOSTASIS, V104, P224, DOI 10.1160/TH10-02-0091
   Uribe R, 2009, MOL BIOL REP, V36, P121, DOI 10.1007/s11033-007-9159-2
   Vaidyula VR, 2009, THROMB RES, V124, P259, DOI 10.1016/j.thromres.2008.12.030
   Volovyk ZM, 2006, J BIOL CHEM, V281, P9773, DOI 10.1074/jbc.M511435200
   WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355
   Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B
   Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
   Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X
NR 67
TC 20
Z9 20
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD NOV
PY 2013
VL 305
IS 9
BP L651
EP L664
DI 10.1152/ajplung.00071.2013
PG 14
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 246WK
UT WOS:000326571100008
PM 24039253
OA Green Published
DA 2023-08-21
ER

PT J
AU Silva, PL
   Moraes, L
   Santos, RS
   Samary, C
   Ramos, MBA
   Santos, CL
   Morales, MM
   Capelozzi, VL
   Garcia, CSNB
   de Abreu, MG
   Pelosi, P
   Marini, JJ
   Rocco, PRM
AF Silva, Pedro Leme
   Moraes, Lillian
   Santos, Raquel Souza
   Samary, Cynthia dos Santos
   Ramos, Maira B. A.
   Santos, Cintia Lourenco
   Morales, Marcelo Marcos
   Capelozzi, Vera Luiza
   Garcia, Cristiane S. N. B.
   de Abreu, Marcelo Gama
   Pelosi, Paolo
   Marini, John J.
   Rocco, Patricia Rieken Macedo
TI Recruitment Maneuvers Modulate Epithelial and Endothelial Cell Response
   According to Acute Lung Injury Etiology
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE alveolar collapse; ECs/HPMECs/HUVECs/MPVECs; morphometry; recruitment maneuvers; respiratory epithelium; respiratory mechanics 
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; MECHANICAL
   VENTILATION; LEUKOCYTE KINETICS; ADHESION MOLECULES; PULMONARY; EDEMA;
   INFLATION; PRODUCTS; RECEPTOR
AB Objective: To investigate the effects of the rate of increase in airway pressure and duration of lung recruitment maneuvers in experimental pulmonary and extrapulmonary acute lung injury.
   Design: Prospective, randomized, controlled experimental study.
   Settings: University research laboratory.
   Subjects: Fifty adult male Wistar rats.
   Interventions: Acute lung injury was induced by Escherichia coli lipopolysaccharide either intratracheally (pulmonary acute lung injury) or intraperitoneally (extrapulmonary acute lung injury). After 24 hours, animals were assigned to one of three different recruitment maneuvers, targeted to maximal airway pressure of 30cm H2O: 1) continuous positive airway pressure for 30 seconds (CPAP-30); 2) stepwise airway pressure increase (5cm H2O/step, 8.5 s at each step) over 51 seconds (STEP-51) to achieve a pressure-time product similar to that of CPAP-30; and 3) stepwise airway pressure increase (5cm H2O/step, 5 s at each step) over 30 seconds with maximum pressure sustained for a further 30 seconds (STEP-30/30).
   Measurements and Main Results: All recruitment maneuvers reduced static lung elastance independent of acute lung injury etiology. In pulmonary acute lung injury, CPAP-30 yielded lower surfactant protein-B and higher type III procollagen expressions compared with STEP-30/30. In extrapulmonary acute lung injury, CPAP-30 and STEP-30/30 increased vascular cell adhesion molecule-1 expression, but the type of recruitment maneuver did not influence messenger ribonucleic acid expression of receptor for advanced glycation end products, surfactant protein-B, type III procollagen, and pro-caspase 3.
   Conclusions: CPAP-30 worsened markers of potential epithelial cell damage in pulmonary acute lung injury, whereas both CPAP-30 and STEP-30/30 yielded endothelial injury in extrapulmonary acute lung injury. In both acute lung injury groups, recruitment maneuvers improved respiratory mechanics, but stepwise recruitment maneuver without sustained airway pressure appeared to associate with less biological impact on lungs.
C1 [Silva, Pedro L.; Moraes, Lillian; Santos, Raquel S.; Samary, Cynthia; Ramos, Maira B. A.; Santos, Cintia L.; Garcia, Cristiane S. N. B.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, BR-21941902 Rio De Janeiro, RJ, Brazil.
C1 [Santos, Cintia L.] Univ Fed Rio de Janeiro, Fac Med, Lab Expt Surg, BR-21941902 Rio De Janeiro, RJ, Brazil.
C1 [Morales, Marcelo M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Cellular & Mol Physiol, BR-21941902 Rio De Janeiro, RJ, Brazil.
C1 [Capelozzi, Vera L.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
C1 [Garcia, Cristiane S. N. B.] Rio de Janeiro Fed Inst Educ Sci & Technol, Rio De Janeiro, Brazil.
C1 [de Abreu, Marcelo Gama] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Anesthesiol & Intens Care Therapy, Pulm Engn Grp, Dresden, Germany.
C1 [Pelosi, Paolo] Univ Genoa, IRCCS AOU San Martino IST, Dept Surg Sci & Integrated Diagnost, Genoa, Italy.
C1 [Marini, John J.] Univ Minnesota, Minnesota Reg Hosp, Minneapolis, MN, United States.
C3 Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de
   Janeiro; Universidade Federal do Rio de Janeiro; Universidade de Sao
   Paulo; Technische Universitat Dresden; Carl Gustav Carus University
   Hospital; University of Genoa; IRCCS AOU San Martino IST; University of
   Minnesota System; University of Minnesota Twin Cities
RP Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ctr Ciencias Saude,Ilha Fundao, Ave Carlos Chagas Filho S-N,Bloco G-014, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM prmrocco@biof.ufrj.br
RI Capelozzi, Vera Luiza/C-6363-2013; , Capelozzi/N-1737-2019; Silva, Pedro
   Leme/AAD-8236-2019; Rocco, Patricia/I-7460-2012
OI , Capelozzi/0000-0001-9732-5853; Silva, Pedro Leme/0000-0001-5838-4949;
   Rocco, Patricia/0000-0003-1412-7136; samary,
   cynthia/0000-0002-1860-4166; delmonte, samuel/0000-0002-3289-4577;
   Pelosi, Paolo/0000-0001-5055-3023
FU Centers of Excellence Program (PRONEX-FAPERJ); Brazilian Council for
   Scientific and Technological Development (CNPq); Rio de Janeiro State
   Research Supporting Foundation (FAPERJ); Sao Paulo State Research
   Supporting Foundation (FAPESP); National Institute of Science and
   Technology of Drugs and Medicine (INCT-INOFAR); Coordination for the
   Improvement of Higher Level Personnel (CAPES); Drager Medical AG;
   Novalung GmbH
FX Supported, in part, by Centers of Excellence Program (PRONEX-FAPERJ),
   Brazilian Council for Scientific and Technological Development (CNPq),
   Rio de Janeiro State Research Supporting Foundation (FAPERJ), Sao Paulo
   State Research Supporting Foundation (FAPESP), National Institute of
   Science and Technology of Drugs and Medicine (INCT-INOFAR), and
   Coordination for the Improvement of Higher Level Personnel (CAPES).;
   Drs. Rocco, Silva, Moraes, R. S. Santos, Samary, Ramos, C. L. Santos,
   Morales, Capelozzi, Garcia received support for article research from
   the Centers of Excellence Program (PRONEX-FAPERJ), Brazilian Council for
   Scientific and Technological Development (CNPq), Rio de Janeiro State
   Research Supporting Foundation (FAPERJ), Sao Paulo State Research
   Supporting Foundation (FAPESP), National Institute of Science and
   Technology of Drugs and Medicine (INCT-INOFAR), and Coordination for the
   Improvement of Higher Level Personnel (CAPES). Dr. Abreu consulted for
   Novalung GmbH, received grant support from Drager Medical AG and
   Novalung GmbH, lectured for Drager Medical AG and Novalung GmbH;
   received payment for manuscript preparation from Drager Medical AG; has
   patents with Drager Medical AG; received payment for development of
   educational presentations from Drager Medical AG; and support for travel
   from Drager Medical AG and Novalung GmbH. Dr. Marini received textbook
   royalties from Lippincott. Dr. Pelosi disclosed that he does not have
   any potential conflicts of interest.
CR BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788
   Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588
   Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124
   Constantin JM, 2007, ANESTHESIOLOGY, V106, P944, DOI 10.1097/01.anes.0000265153.17062.64
   CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148
   D'Angelo E, 2004, J APPL PHYSIOL, V97, P260, DOI 10.1152/japplphysiol.01175.2003
   de Prost N, 2007, J APPL PHYSIOL, V102, P794, DOI 10.1152/japplphysiol.00742.2006
   Dessap AM, 2012, AM J RESP CELL MOL, V46, P541, DOI 10.1165/rcmb.2011-0306OC
   Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC
   Gattinoni L, 2012, CURR OPIN ANESTHESIO, V25, P141, DOI 10.1097/ACO.0b013e3283503125
   Hodgson Carol L, 2011, J Intensive Care Med, V26, P41, DOI 10.1177/0885066610383953
   Laffey JG, 2004, INTENS CARE MED, V30, P347, DOI 10.1007/s00134-003-2051-1
   Leite JHP, 2008, CRIT CARE MED, V36, P2621, DOI 10.1097/CCM.0b013e3181847b43
   Lowhagen K, 2011, ACTA ANAESTH SCAND, V55, P175, DOI 10.1111/j.1399-6576.2010.02366.x
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Miserocchi G, 2001, NEWS PHYSIOL SCI, V16, P66
   Miyao N, 2006, AM J PHYSIOL-LUNG C, V290, pL1059, DOI 10.1152/ajplung.00365.2005
   Moran I, 2011, MINERVA ANESTESIOL, V77, P1167
   Nag K, 1999, AM J PHYSIOL-LUNG C, V277, pL1179, DOI 10.1152/ajplung.1999.277.6.L1179
   Nishio K, 1998, AM J RESP CRIT CARE, V157, P599, DOI 10.1164/ajrccm.157.2.9704102
   Nucci G, 2003, J APPL PHYSIOL, V95, P348, DOI 10.1152/japplphysiol.01179.2001
   Palestini P, 2003, J APPL PHYSIOL, V95, P1446, DOI 10.1152/japplphysiol.00208.2003
   Passaro CP, 2009, CRIT CARE MED, V37, P1011, DOI 10.1097/CCM.0b013e3181962d85
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Perlman CE, 2007, J APPL PHYSIOL, V103, P1037, DOI 10.1152/japplphysiol.00160.2007
   RAGHU G, 1985, AM REV RESPIR DIS, V131, P281, DOI 10.1164/ajrccm/138.3.703
   Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
   Roan E, 2011, AM J PHYSIOL-LUNG C, V301, pL625, DOI 10.1152/ajplung.00105.2011
   Santiago VR, 2010, CRIT CARE MED, V38, P2207, DOI 10.1097/CCM.0b013e3181f3e076
   Savla U, 2002, J PHYSIOL-LONDON, V539, P285, DOI 10.1113/jphysiol.2001.012945
   Silva PL, 2011, CRIT CARE MED, V39, P1074, DOI 10.1097/CCM.0b013e318206d69a
   Silva PL, 2010, CRIT CARE, V14, DOI 10.1186/cc9063
   Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281
   Spieth PM, 2012, CRIT CARE, V16, DOI 10.1186/cc11177
   Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC
NR 35
TC 45
Z9 52
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD OCT
PY 2013
VL 41
IS 10
BP E256
EP E265
DI 10.1097/CCM.0b013e31828a3c13
PG 10
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 225AP
UT WOS:000324935000002
PM 23887231
DA 2023-08-21
ER

PT J
AU Aires, RD
   Capettini, LSA
   Silva, JF
   Rodrigues-Machado, MD
   Pinho, V
   Teixeira, MM
   Cortes, SF
   Lemos, VS
AF Aires, Rosaria D.
   Capettini, Luciano S. A.
   Silva, Josiane F.
   Rodrigues-Machado, Maria da Gloria
   Pinho, Vanessa
   Teixeira, Mauro M.
   Cortes, Steyner F.
   Lemos, Virginia S.
TI Paraquat Poisoning Induces TNF-alpha-Dependent iNOS/NO Mediated
   Hyporesponsiveness of the Aorta to Vasoconstrictors in Rats
SO PLOS ONE
LA English
DT Article
ID SYNTHASE GENE-EXPRESSION; RESPIRATORY-DISTRESS-SYNDROME; INDUCED
   OXIDATIVE STRESS; NITRIC-OXIDE; HYDROGEN-PEROXIDE; LUNG TOXICITY;
   DYSFUNCTION; MECHANISM; ANGIOTENSIN-(1-7); ACCUMULATION
AB Paraquat is a toxic herbicide that may induce acute lung injury, circulatory failure and death. The present work aimed at investigating whether there is systemic inflammation and vascular dysfunction after paraquat exposure and whether these parameters were related. There was neutrophilia and accumulation of neutrophils in lung and bronchoalveolar lavage of animals given paraquat. This was associated with an increase in serum levels of TNF-alpha. In rats given paraquat, the relaxant response of aortic rings to acetylcholine was not modified but the contractile response to phenylephrine was greatly reduced. Endothelium removal or treatment with non-selective (L-NAME) or selective (L-NIL) inhibitors of inducible nitric oxide synthase (iNOS) restored contraction of aortas. There was greater production of nitric oxide (NO), which was restored to basal level by L-NIL, and greater expression of iNOS in endothelial cells, as seen by Western blot analyses and confocal microscopy. Blockade of TNF-alpha reduced pulmonary and systemic inflammation and vascular dysfunction. Together, our results clearly show that paraquat causes pulmonary and systemic inflammation, and vascular dysfunction in rats. Vascular dysfunction is TNF-alpha dependent, associated with enhanced expression of iNOS in aortic endothelial cells and greater NO production, which accounts for the decreased responsiveness of aortas to vasoconstrictors. Blockers of TNF-alpha may be useful in patients with paraquat poisoning.
C1 [Aires, Rosaria D.; Silva, Josiane F.; Rodrigues-Machado, Maria da Gloria; Lemos, Virginia S.] Univ Fed Minas Gerais, Dept Physiol & Biophys, ICB, Belo Horizonte, MG, Brazil.
C1 [Capettini, Luciano S. A.; Cortes, Steyner F.] Univ Fed Minas Gerais, Dept Pharmacol, ICB, Belo Horizonte, MG, Brazil.
C1 [Pinho, Vanessa] Univ Fed Minas Gerais, Dept Morphol, ICB, Belo Horizonte, MG, Brazil.
C1 [Teixeira, Mauro M.] Univ Fed Minas Gerais, Dept Biochem & Immunol, ICB, Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais; Universidade Federal de
   Minas Gerais
RP Lemos, VS (corresponding author), Univ Fed Minas Gerais, Dept Physiol & Biophys, ICB, Belo Horizonte, MG, Brazil.
EM vslemos@icb.ufmg.br
RI Pinho, Vanessa/GXM-8532-2022; Teixeira, Mauro M/A-4587-2008; Cortes,
   Steyner Franca/F-5449-2010; da Glória Rodrigues-Machado,
   Maria/H-1484-2019; Lemos, Virginia S/B-7305-2018; Pinho,
   Vanessa/AAR-1686-2021; Silva, Josiane/AAC-8361-2019; pinho,
   vanessa/AAC-8437-2020
OI Pinho, Vanessa/0000-0003-1038-2324; Teixeira, Mauro
   M/0000-0002-6944-3008; Cortes, Steyner Franca/0000-0002-4340-2574;
   Lemos, Virginia S/0000-0003-1234-9325; Silva,
   Josiane/0000-0002-6623-7946; pinho, vanessa/0000-0003-1038-2324;
   Capettini, Luciano/0000-0002-6487-9558
FU FAPEMIG (Fundacao de Apoio a Pesquisa do Estado de Minas Gerais)/PRONEX;
   CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)/Brazil
FX FAPEMIG (Fundacao de Apoio a Pesquisa do Estado de Minas Gerais)/PRONEX
   and CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)/Brazil. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adachi J, 2003, ARCH TOXICOL, V77, P353, DOI 10.1007/s00204-003-0449-8
   Barcelos LS, 2009, MICROVASC RES, V78, P148, DOI 10.1016/j.mvr.2009.04.009
   BERISHA HI, 1994, P NATL ACAD SCI USA, V91, P7445, DOI 10.1073/pnas.91.16.7445
   BUS JS, 1976, ENVIRON HEALTH PERSP, V16, P139, DOI 10.2307/3428594
   Capettini LSA, 2011, BRIT J PHARMACOL, V164, P1738, DOI 10.1111/j.1476-5381.2011.01500.x
   Capettini LSA, 2008, AM J PHYSIOL-HEART C, V295, pH2503, DOI 10.1152/ajpheart.00731.2008
   Chan MMY, 1998, BIOCHEM PHARMACOL, V55, P1955, DOI 10.1016/S0006-2952(98)00114-2
   Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760
   Dinis-Oliveira RJ, 2008, CRIT REV TOXICOL, V38, P13, DOI 10.1080/10408440701669959
   Dinis-Oliveira RJ, 2006, TOXICOLOGY, V227, P73, DOI 10.1016/j.tox.2006.07.025
   Dinis-Oliveira RJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007149
   Gil HW, 2008, CLIN TOXICOL, V46, P515, DOI 10.1080/15563650701549403
   Gocgeldi E, 2008, EXP BIOL MED, V233, P1133, DOI 10.3181/0802-RM-65
   Hecker M, 1999, GEN PHARMACOL, V32, P9, DOI 10.1016/S0306-3623(98)00082-2
   HOFFER E, 1993, TOXICOL APPL PHARM, V120, P8, DOI 10.1006/taap.1993.1080
   Hong SY, 2000, TOXICOL LETT, V118, P53, DOI 10.1016/S0378-4274(00)00264-2
   HSU KS, 1995, EUR J PHARM-ENVIRON, V292, P315
   Jo YH, 2011, RESUSCITATION, V82, P487, DOI 10.1016/j.resuscitation.2010.11.028
   Kang YJ, 2003, BIOCHEM PHARMACOL, V65, P457, DOI 10.1016/S0006-2952(02)01549-6
   Koo JR, 2002, AM J KIDNEY DIS, V39, P55, DOI 10.1053/ajkd.2002.29880
   Lemos VS, 2002, BRIT J PHARMACOL, V135, P1743, DOI 10.1038/sj.bjp.0704630
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Luh Shi-Ping, 2007, Journal of Zhejiang University-Science B, V8, P60, DOI 10.1631/jzus.2007.B0060
   Mainwaring G, 2006, TOXICOLOGY, V225, P157, DOI 10.1016/j.tox.2006.05.017
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Margolis AS, 2000, BBA-GEN SUBJECTS, V1524, P253, DOI 10.1016/S0304-4165(00)00167-7
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Mitra S, 2006, BBA-MOL BASIS DIS, V1762, P732, DOI 10.1016/j.bbadis.2006.06.011
   Moran JM, 2010, J BIOCHEM MOL TOXIC, V24, P402, DOI 10.1002/jbt.20348
   Nandi J, 2010, MOL CELL BIOCHEM, V336, P17, DOI 10.1007/s11010-009-0259-2
   ROSE MS, 1976, BIOCHEM PHARMACOL, V25, P419, DOI 10.1016/0006-2952(76)90344-0
   ROSE MS, 1974, NATURE, V252, P314, DOI 10.1038/252314b0
   Russo RC, 2009, AM J RESP CELL MOL, V40, P410, DOI 10.1165/rcmb.2007-0364OC
   Silva DMR, 2007, PEPTIDES, V28, P702, DOI 10.1016/j.peptides.2006.10.007
   Soares AC, 2006, MICROBES INFECT, V8, P1321, DOI 10.1016/j.micinf.2005.12.017
   Suntres ZE, 2002, TOXICOLOGY, V180, P65, DOI 10.1016/S0300-483X(02)00382-7
   Suratt BT, 2006, CLIN CHEST MED, V27, P579, DOI 10.1016/j.ccm.2006.06.005
   Takizawa M, 2007, TOXICOL IN VITRO, V21, P355, DOI 10.1016/j.tiv.2006.09.003
   Tsukamoto M, 2002, TOXICOL APPL PHARM, V178, P82, DOI 10.1006/taap.2001.9325
   Venkatesan N, 1999, LIFE SCI, V66, pPL21, DOI 10.1016/S0024-3205(99)00576-7
   Zerin T, 2012, TOXICOL LETT, V208, P101, DOI 10.1016/j.toxlet.2011.10.019
   Zocrato LBR, 2010, TOXICOL IN VITRO, V24, P1019, DOI 10.1016/j.tiv.2009.12.003
NR 42
TC 26
Z9 29
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2013
VL 8
IS 9
AR e73562
DI 10.1371/journal.pone.0073562
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 244QV
UT WOS:000326405300092
PM 24039983
OA gold, Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Ali, I
   Nanchal, R
   Husnain, F
   Audi, S
   Konduri, GG
   Densmore, JC
   Medhora, M
   Jacobs, ER
AF Ali, Irshad
   Nanchal, Rahul
   Husnain, Fouad
   Audi, Said H.
   Konduri, G. Ganesh
   Densmore, John C.
   Medhora, Meetha
   Jacobs, Elizabeth R.
TI Hypoxia preconditioning increases survival and decreases expression of
   Toll-like receptor 4 in pulmonary artery endothelial cells exposed to
   lipopolysaccharide
SO PULMONARY CIRCULATION
LA English
DT Article
DE endotoxin; hypoxia; caspase-1/caspase-3/caspase-11; TLR/TLR2/TLR4; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT); ECs/HPMECs/HUVECs/MPVECs 
ID SIGNAL-TRANSDUCTION INHIBITOR; LUNG INJURY; APOPTOSIS; TAK-242;
   MOLECULE; SHOCK; TLR4
AB Pulmonary or systemic infections and hypoxemic respiratory failure are among the leading causes of admission to intensive care units, and these conditions frequently exist in sequence or in tandem. Inflammatory responses to infections are reproduced by lipopolysaccharide (LPS) engaging Toll-like receptor 4 (TLR4). Apoptosis is a hallmark of lung injury in sepsis. This study was conducted to determine whether preexposure to LPS or hypoxia modulated the survival of pulmonary artery endothelial cells (PAECs). We also investigated the role TLR4 receptor expression plays in apoptosis due to these conditions. Bovine PAECs were cultured in hypoxic or normoxic environments and treated with LPS. TLR4 antagonist TAK-242 was used to probe the role played by TLR4 receptors in cell survival. Cell apoptosis and survival were measured by caspase 3 activity and 3-(4,5dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) incorporation. TLR4 expression and tumor necrosis factor alpha (TNF-alpha) production were also determined. LPS increased caspase 3 activity in a TAK-242-sensitive manner and decreased MTT incorporation. Apoptosis was decreased in PAECs preconditioned with hypoxia prior to LPS exposure. LPS increased TNF-alpha production, and hypoxic preconditioning blunted it. Hypoxic preconditioning reduced LPS-induced TLR4 messenger RNA and TLR4 protein. TAK-242 decreased to baseline the LPS-stimulated expression of TLR4 messenger RNA regardless of environmental conditions. In contrast, LPS followed by hypoxia substantially increased apoptosis and cell death. In conclusion, protection from LPS-stimulated PAEC apoptosis by hypoxic preconditioning is attributable in part to reduction in TLR4 expression. If these signaling pathways apply to septic patients, they may account for differing sensitivities of individuals to acute lung injury depending on oxygen tensions in PAECs in vivo.
C1 [Ali, Irshad; Nanchal, Rahul; Husnain, Fouad; Medhora, Meetha; Jacobs, Elizabeth R.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226, United States.
C1 [Nanchal, Rahul; Konduri, G. Ganesh; Jacobs, Elizabeth R.] Med Coll Wisconsin, Milwaukee Initiat Crit Care Outcomes Res Grp MICC, Milwaukee, WI 53226, United States.
C1 [Audi, Said; Jacobs, Elizabeth R.] Clement J Zablocki Vet Affairs Med Ctr, 5000 West Natl Ave, Milwaukee, WI 53295, United States.
C1 [Audi, Said] Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233, United States.
C1 [Konduri, G. Ganesh; Densmore, John C.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226, United States.
C1 [Medhora, Meetha] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226, United States.
C3 Medical College of Wisconsin; Medical College of Wisconsin; Marquette
   University; Medical College of Wisconsin; Medical College of Wisconsin
RP Jacobs, ER (corresponding author), Clement J Zablocki Vet Affairs Med Ctr, 5000 West Natl Ave, Milwaukee, WI 53295 USA.
EM ejacobs@mcw.edu
RI audi, said/GZA-7511-2022
FU National Heart, Lung, and Blood Institute [HL-68627, HL-49294,
   HL-116530, BX001681, UL1RR031973, 8UL1TR000055]
FX National Heart, Lung, and Blood Institute: HL-68627, HL-49294,
   HL-116530, and BX001681 to ERJ; UL1RR031973 to GGK and ERJ; and
   8UL1TR000055 to SA.
CR Ali I, 2012, ANN THORAC SURG, V93, P282, DOI 10.1016/j.athoracsur.2011.08.074
   Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   Bernardini C, 2005, CELL STRESS CHAPERON, V10, P340, DOI 10.1379/CSC-98R1.1
   Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427
   Casanova JL, 2011, ANNU REV IMMUNOL, V29, P447, DOI 10.1146/annurev-immunol-030409-101335
   CENDAN JC, 1994, ARCH SURG-CHICAGO, V129, P1296
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   Dhanasekaran A, 2008, AM J PHYSIOL-HEART C, V294, pH724, DOI 10.1152/ajpheart.00979.2007
   Dhanasekaran A, 2009, AM J PHYSIOL-HEART C, V296, pH777, DOI 10.1152/ajpheart.01087.2008
   Edelman DA, 2006, J SURG RES, V134, P22, DOI 10.1016/j.jss.2006.03.007
   Fan J, 2002, J IMMUNOL, V168, P5252, DOI 10.4049/jimmunol.168.10.5252
   Favaloro B, 2012, AGING-US, V4, P330, DOI 10.18632/aging.100459
   Hara Y, 2009, MOL VIS, V15, P2515
   Ibeagha-Awemu EM, 2008, VET RES, V39, DOI 10.1051/vetres:2007047
   Irish Critical Care Trials Group, 2008, Crit Care, V12, pR30, DOI 10.1186/cc6808
   Ishida I, 2002, J IMMUNOL, V169, P2069, DOI 10.4049/jimmunol.169.4.2069
   Janardhan KS, 2006, HISTOL HISTOPATHOL, V21, P687, DOI 10.14670/HH-21.687
   Kawamoto T, 2008, EUR J PHARMACOL, V584, P40, DOI 10.1016/j.ejphar.2008.01.026
   Kietzmann T, 2002, BIOCHEM PHARMACOL, V64, P903, DOI 10.1016/S0006-2952(02)01160-7
   Leeper-Woodford SK, 1999, AM J PHYSIOL-LUNG C, V276, pL909, DOI 10.1152/ajplung.1999.276.6.L909
   Marino E, 2003, CYTOKINE, V22, P142, DOI 10.1016/S1043-4666(03)00150-9
   Marzo F, 2008, J THROMB THROMBOLYS, V26, P183, DOI 10.1007/s11239-008-0212-3
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Medhora M, 2008, AM J PHYSIOL-LUNG C, V294, pL902, DOI 10.1152/ajplung.00278.2007
   Ock J, 2007, J NEUROSCI RES, V85, P1989, DOI 10.1002/jnr.21322
   ROBAYE B, 1991, AM J PATHOL, V138, P447
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Saito T, 2005, CELL TISSUE RES, V321, P75, DOI 10.1007/s00441-005-1113-9
   Sampath V, 2009, FREE RADICAL BIO MED, V46, P663, DOI 10.1016/j.freeradbiomed.2008.12.008
   Seki H, 2010, INFLAMM RES, V59, P837, DOI 10.1007/s00011-010-0195-3
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   Sha T, 2007, EUR J PHARMACOL, V571, P231, DOI 10.1016/j.ejphar.2007.06.027
   Takashima K, 2009, BRIT J PHARMACOL, V157, P1250, DOI 10.1111/j.1476-5381.2009.00297.x
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Thambiayya K, 2011, AM J PHYSIOL-LUNG C, V300, pL624, DOI 10.1152/ajplung.00376.2010
   Wang NP, 2001, CIRC RES, V88, P1223, DOI 10.1161/hh1201.093162
   Welsh SJ, 2003, MOL CANCER THER, V2, P235
   WENDT CH, 1994, AM J PHYSIOL-CELL PH, V267, pC893, DOI 10.1152/ajpcell.1994.267.4.C893
   Wittebole X, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/568396
   Yu EZ, 2004, LAB INVEST, V84, P553, DOI 10.1038/labinvest.3700071
NR 40
TC 15
Z9 16
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD SEP
PY 2013
VL 3
IS 3
BP 578
EP 588
DI 10.1086/674337
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA V47WJ
UT WOS:000209981600011
PM 24618542
OA Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Collins, SR
   Blank, RS
   Deatherage, LS
   Dull, RO
AF Collins, Stephen R.
   Blank, Randal S.
   Deatherage, Lindy S.
   Dull, Randal O.
TI The Endothelial Glycocalyx: Emerging Concepts in Pulmonary Edema and
   Acute Lung Injury
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID CATECHOLAMINE-INDUCED INCREASE; RESPIRATORY-DISTRESS-SYNDROME;
   MOLECULAR-WEIGHT HYALURONAN; ISOLATED RAT LUNGS; NITRIC-OXIDE;
   CAPILLARY-PERMEABILITY; HYDRAULIC CONDUCTIVITY; VASCULAR PRESSURE;
   SURFACE-LAYER; SHEAR-STRESS
AB The endothelial glycocalyx is a dynamic layer of macromolecules at the luminal surface of vascular endothelium that is involved in fluid homeostasis and regulation. Its role in vascular permeability and edema formation is emerging but is still not well understood. In this special article, we highlight key concepts of endothelial dysfunction with regards to the glycocalyx and provide new insights into the glycocalyx as a mediator of processes central to the development of pulmonary edema and lung injury.
C1 [Collins, Stephen R.; Blank, Randal S.] Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA, United States.
C1 [Deatherage, Lindy S.] Univ Utah, Dept Anesthesiol, Salt Lake City, UT, United States.
C1 [Dull, Randal O.] Univ Illinois, Coll Med, Dept Anesthesiol & Bioengn, Chicago, IL 60612, United States.
C3 University of Virginia; Utah System of Higher Education; University of
   Utah; University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Dull, RO (corresponding author), Univ Illinois, Coll Med, Dept Anesthesiol & Bioengn, 1740 W Taylor St,Suite 3200,M-C 515, Chicago, IL 60612 USA.
EM rdull@uic.edu
RI Collins, Stephen/M-1568-2019
FU NHLBI NIH HHS [R01 HL085255] Funding Source: Medline
CR ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264
   Adamson RH, 2004, J PHYSIOL-LONDON, V557, P889, DOI 10.1113/jphysiol.2003.058255
   ADAMSON RH, 1990, J PHYSIOL-LONDON, V428, P1
   Anglade D, 1998, J APPL PHYSIOL, V84, P1011, DOI 10.1152/jappl.1998.84.3.1011
   Becker BF, 2010, CARDIOVASC RES, V87, P300, DOI 10.1093/cvr/cvq137
   Briot R, 2009, CRIT CARE, V13, DOI 10.1186/cc8137
   Broccard AF, 2002, CRIT CARE MED, V30, P2183, DOI 10.1097/00003246-200210000-00002
   Broccard AF, 1998, AM J RESP CRIT CARE, V157, P1935, DOI 10.1164/ajrccm.157.6.9612006
   Bruegger D, 2008, CRIT CARE, V12, DOI 10.1186/cc6913
   Bruegger D, 2009, J THORAC CARDIOV SUR, V138, P1445, DOI 10.1016/j.jtcvs.2008.07.063
   Bucci M, 2005, P NATL ACAD SCI USA, V102, P904, DOI 10.1073/pnas.0408906102
   Chappell D, 2009, CARDIOVASC RES, V83, P388, DOI 10.1093/cvr/cvp097
   Chappell D, 2009, BASIC RES CARDIOL, V104, P78, DOI 10.1007/s00395-008-0749-5
   Chen EP, 1996, CIRCULATION, V94, P412
   Constantinescu AA, 2003, ARTERIOSCL THROM VAS, V23, P1541, DOI 10.1161/01.ATV.0000085630.24353.3D
   CROUCH JD, 1987, ANN THORAC SURG, V43, P613, DOI 10.1016/S0003-4975(10)60231-7
   CURRY FE, 1980, MICROVASC RES, V20, P96, DOI 10.1016/0026-2862(80)90024-2
   Curry FRE, 2010, CARDIOVASC RES, V87, P195, DOI 10.1093/cvr/cvq188
   Czarnowska E, 1996, FOLIA HISTOCHEM CYTO, V34, P25
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dull RO, 2007, AM J PHYSIOL-LUNG C, V292, pL1452, DOI 10.1152/ajplung.00376.2006
   Dull RO, 2012, AM J PHYSIOL-LUNG C, V302, pL816, DOI 10.1152/ajplung.00080.2011
   DULL RO, 1991, MICROVASC RES, V41, P390, DOI 10.1016/0026-2862(91)90037-C
   Dull RO, 2003, AM J PHYSIOL-LUNG C, V285, pL986, DOI 10.1152/ajplung.00022.2003
   Effros RM, 2009, MICROVASC RES, V78, P71, DOI 10.1016/j.mvr.2009.03.004
   EHRHART IC, 1994, J APPL PHYSIOL, V76, P2342, DOI 10.1152/jappl.1994.76.6.2342
   EHRHART IC, 1992, J APPL PHYSIOL, V72, P211, DOI 10.1152/jappl.1992.72.1.211
   Fernandez ER, 2005, CHEST, V128, p129S, DOI 10.1378/chest.128.4_MeetingAbstracts.129S-a
   Filaire M, 2007, J THORAC CARDIOV SUR, V133, P770, DOI 10.1016/j.jtcvs.2006.09.052
   Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5
   Gao LJ, 2010, MICROVASC RES, V80, P394, DOI 10.1016/j.mvr.2010.06.005
   Garcia-Delgado M, 2001, CRIT CARE MED, V29, P931, DOI 10.1097/00003246-200105000-00003
   Giantsos KM, 2009, BIOMATERIALS, V30, P5885, DOI 10.1016/j.biomaterials.2009.06.048
   Giantsos-Adams K, 2011, BIOMATERIALS, V32, P288, DOI 10.1016/j.biomaterials.2010.08.092
   Grichnik Katherine P, 2004, Semin Cardiothorac Vasc Anesth, V8, P317, DOI 10.1177/108925320400800405
   Henry CBS, 1999, AM J PHYSIOL-HEART C, V277, pH508, DOI 10.1152/ajpheart.1999.277.2.H508
   Henry CBS, 2000, AM J PHYSIOL-HEART C, V279, pH2815, DOI 10.1152/ajpheart.2000.279.6.H2815
   HIRATA A, 1995, AM J PHYSIOL-LUNG C, V269, pL403, DOI 10.1152/ajplung.1995.269.3.L403
   Hotchkiss JR, 2000, AM J RESP CRIT CARE, V161, P463, DOI 10.1164/ajrccm.161.2.9811008
   Hotchkiss JR, 2001, CRIT CARE MED, V29, P1593, DOI 10.1097/00003246-200108000-00016
   Huxley VH, 2000, AM J PHYSIOL-HEART C, V278, pH1177, DOI 10.1152/ajpheart.2000.278.4.H1177
   Jacob M, 2007, CARDIOVASC RES, V73, P575, DOI 10.1016/j.cardiores.2006.11.021
   Jordan S, 2000, EUR RESPIR J, V15, P790, DOI 10.1034/j.1399-3003.2000.15d26.x
   KASLOVSKY RA, 1990, CIRC RES, V67, P795, DOI 10.1161/01.RES.67.4.795
   Kuebler WM, 2003, AM J RESP CRIT CARE, V168, P1391, DOI 10.1164/rccm.200304-562OC
   Kuebler WM, 2002, AM J PHYSIOL-LUNG C, V282, pL917, DOI 10.1152/ajplung.00275.2001
   Kurzelewski M, 2005, J PHYSIOL PHARMACOL, V56, P163
   Landis EM, 1927, AM J PHYSIOL, V82, P217, DOI 10.1152/ajplegacy.1927.82.2.217
   LANDOLT CC, 1983, CIRC RES, V52, P335, DOI 10.1161/01.RES.52.3.335
   Levick JR, 2004, J PHYSIOL-LONDON, V557, P704, DOI 10.1113/jphysiol.2004.066118
   Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6
   Licker M, 2003, ANESTH ANALG, V97, P1558, DOI 10.1213/01.ANE.0000087799.85495.8A
   Lipowsky HH, 2012, ANN BIOMED ENG, V40, P840, DOI 10.1007/s10439-011-0427-x
   Liu YY, 2008, CRIT CARE, V12, DOI 10.1186/cc6982
   Lopez-Quintero SV, 2009, AM J PHYSIOL-HEART C, V296, pH1451, DOI 10.1152/ajpheart.00894.2008
   MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   MATHRU M, 1990, CHEST, V98, P1216, DOI 10.1378/chest.98.5.1216
   Michel CC, 1997, EXP PHYSIOL, V82, P1
   Mochizuki S, 2003, AM J PHYSIOL-HEART C, V285, pH722, DOI 10.1152/ajpheart.00691.2002
   Motosugi H, 1998, AM J RESP CRIT CARE, V157, P192, DOI 10.1164/ajrccm.157.1.9602095
   Mulivor AW, 2004, AM J PHYSIOL-HEART C, V286, pH1672, DOI 10.1152/ajpheart.00832.2003
   Mulivor AW, 2002, AM J PHYSIOL-HEART C, V283, pH1282, DOI 10.1152/ajpheart.00117.2002
   NETTELBLADT O, 1989, AM REV RESPIR DIS, V140, P1028, DOI 10.1164/ajrccm/140.4.1028
   Nieuwdorp M, 2008, J APPL PHYSIOL, V104, P845, DOI 10.1152/japplphysiol.00440.2007
   NOGAE C, 1995, J MOL CELL CARDIOL, V27, P2091, DOI 10.1016/S0022-2828(95)91155-3
   O'Callaghan R, 2011, AM J PHYSIOL-LUNG C, V301, pL353, DOI 10.1152/ajplung.00342.2010
   OHKUDA K, 1978, CIRC RES, V43, P152, DOI 10.1161/01.RES.43.2.152
   PAPPENHEIMER JR, 1948, AM J PHYSIOL, V152, P471, DOI 10.1152/ajplegacy.1948.152.3.471
   Park BJ, 2007, SEMIN THORAC CARDIOV, V19, P374, DOI 10.1053/j.semtcvs.2007.10.003
   Parker JC, 1997, J APPL PHYSIOL, V83, P1962, DOI 10.1152/jappl.1997.83.6.1962
   Parker JC, 2002, AM J PHYSIOL-LUNG C, V283, pL1203, DOI 10.1152/ajplung.00488.2001
   PARKER RE, 1981, CIRC RES, V49, P1164, DOI 10.1161/01.RES.49.5.1164
   Parquin F, 1996, EUR J CARDIO-THORAC, V10, P929, DOI 10.1016/S1010-7940(96)80392-7
   Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   RIPPE B, 1984, J APPL PHYSIOL, V57, P233, DOI 10.1152/jappl.1984.57.1.233
   Rubio-Gayosso I, 2006, AM J PHYSIOL-HEART C, V290, pH2247, DOI 10.1152/ajpheart.00796.2005
   Schilling T, 2005, ANESTH ANALG, V101, P957, DOI 10.1213/01.ane.0000172112.02902.77
   Schreiber T, 2006, INTENS CARE MED, V32, P740, DOI 10.1007/s00134-006-0117-6
   Schreiber T, 2007, CRIT CARE MED, V35, P1741, DOI 10.1097/01.CCM.0000269374.85160.BF
   SHIMADA K, 1991, JPN CIRC J, V55, P1016, DOI 10.1253/jcj.55.1016
   SHIRLEY HH, 1957, AM J PHYSIOL, V190, P189, DOI 10.1152/ajplegacy.1957.190.2.189
   Singleton PA, 2010, AM J PHYSIOL-LUNG C, V299, pL639, DOI 10.1152/ajplung.00405.2009
   Slinger PD, 2006, ANESTHESIOLOGY, V105, P2, DOI 10.1097/00000542-200607000-00003
   Starling E H, 1896, J Physiol, V19, P312
   Tarbell JM, 1999, J APPL PHYSIOL, V87, P261, DOI 10.1152/jappl.1999.87.1.261
   Tarbell JM, 2010, CARDIOVASC RES, V87, P320, DOI 10.1093/cvr/cvq146
   Thi MM, 2004, P NATL ACAD SCI USA, V101, P16483, DOI 10.1073/pnas.0407474101
   TOWNSLEY MI, 1987, J APPL PHYSIOL, V63, P2460, DOI 10.1152/jappl.1987.63.6.2460
   TURNAGE WS, 1993, CHEST, V103, P1646, DOI 10.1378/chest.103.6.1646
   Ueda A, 2004, AM J PHYSIOL-HEART C, V287, pH2287, DOI 10.1152/ajpheart.00808.2003
   Van den Berg B, 2006, AM J PHYSIOL-HEART C, V290, pH2174, DOI 10.1152/ajpheart.00197.2006
   van den Berg BM, 2003, CIRC RES, V92, P592, DOI 10.1161/01.RES.0000065917.53950.75
   van Haaren PMA, 2005, AM J PHYSIOL-HEART C, V289, pH2503, DOI 10.1152/ajpheart.00587.2005
   van Haaren PMA, 2003, AM J PHYSIOL-HEART C, V285, pH2848, DOI 10.1152/ajpheart.00117.2003
   vanderWerff YD, 1997, CHEST, V111, P1278, DOI 10.1378/chest.111.5.1278
   VanTeeffelen JWGE, 2005, AM J PHYSIOL-HEART C, V289, pH2508, DOI 10.1152/ajpheart.00446.2005
   Vink H, 2000, CIRCULATION, V101, P1500, DOI 10.1161/01.CIR.101.13.1500
   Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285, DOI 10.1152/ajpheart.2000.278.1.H285
   Vink H, 1996, CIRC RES, V79, P581, DOI 10.1161/01.RES.79.3.581
   Waller DA, 1996, ANN THORAC SURG, V61, P1435, DOI 10.1016/0003-4975(96)00103-8
   Wang SF, 2012, WORLD J GASTROENTERO, V18, P4771, DOI 10.3748/wjg.v18.i34.4771
   WASSERMAN K, 1955, CIRC RES, V3, P594, DOI 10.1161/01.RES.3.6.594
   Weinbaum S, 1998, ANN BIOMED ENG, V26, P627, DOI 10.1114/1.134
   Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959
   Williams EA, 1999, EUR RESPIR J, V14, P745, DOI 10.1034/j.1399-3003.1999.14d04.x
   Williams EA, 1998, EUR RESPIR J, V11, P1028, DOI 10.1183/09031936.98.11051028
   Wrigge H, 2004, ANESTH ANALG, V98, P775
   ZELDIN RA, 1984, J THORAC CARDIOV SUR, V87, P359
   Zhang XB, 2006, AM J PHYSIOL-HEART C, V291, pH2950, DOI 10.1152/ajpheart.01160.2005
   Zharikov SI, 2001, AM J PHYSIOL-LUNG C, V280, pL465, DOI 10.1152/ajplung.2001.280.3.L465
NR 114
TC 59
Z9 62
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 2013
VL 117
IS 3
BP 664
EP 674
DI 10.1213/ANE.0b013e3182975b85
PG 11
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA 248JJ
UT WOS:000326695200019
PM 23835455
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Herrero, R
   Tanino, M
   Smith, LS
   Kajikawa, O
   Wong, VA
   Mongovin, S
   Matute-Bello, G
   Martin, TR
AF Herrero, Raquel
   Tanino, Mishie
   Smith, Lincoln S.
   Kajikawa, Osamu
   Wong, Venus A.
   Mongovin, Steve
   Matute-Bello, Gustavo
   Martin, Thomas R.
TI The Fas/FasL pathway impairs the alveolar fluid clearance in mouse lungs
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE apoptosis; edema; epithelium; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; alveolar epithelial fluid transport; Fas 
ID RESPIRATORY-DISTRESS-SYNDROME; EPITHELIAL-CELL APOPTOSIS;
   NECROSIS-FACTOR-ALPHA; FAS LIGAND; LIQUID CLEARANCE; EDEMA FLUID;
   TNF-ALPHA; SODIUM-TRANSPORT; INJURY; MECHANISMS
AB Alveolar epithelial damage is a critical event that leads to protein-rich edema in acute lung injury (ALI), but the mechanisms leading to epithelial damage are not completely understood. Cell death by necrosis and apoptosis occurs in alveolar epithelial cells in the lungs of patients with ALI. Fas activation induces apoptosis of alveolar epithelial cells, but its role in the formation of lung edema is unclear. The main goal of this study was to determine whether activation of the Fas/Fas ligand pathway in the lungs could alter the function of the lung epithelium, and the mechanisms involved. The results show that Fas activation alters the alveolar barrier integrity and impairs the ability of the lung alveolar epithelium to reabsorb fluid from the air spaces. This result was dependent on the presence of a normal Fas receptor and was not affected by inflammation induced by Fas activation. Alteration of the fluid transport properties of the alveolar epithelium was partially restored by beta-adrenergic stimulation. Fas activation also caused apoptosis of alveolar endothelial cells, but this effect was less pronounced than the effect on the alveolar epithelium. Thus, activation of the Fas pathway impairs alveolar epithelial function in mouse lungs by mechanisms involving caspase-dependent apoptosis, suggesting that targeting apoptotic pathways could reduce the formation of lung edema in ALI.
C1 [Herrero, Raquel; Tanino, Mishie; Mongovin, Steve; Matute-Bello, Gustavo; Martin, Thomas R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Ctr, Med Res Serv, Seattle, WA 98195, United States.
C1 [Herrero, Raquel; Tanino, Mishie; Kajikawa, Osamu; Wong, Venus A.; Matute-Bello, Gustavo; Martin, Thomas R.] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA, United States.
C1 [Smith, Lincoln S.; Kajikawa, Osamu; Matute-Bello, Gustavo] Univ Washington, Dept Med, Ctr Lung Biol, Div Pulm & Crit Care Med, Seattle, WA, United States.
C1 [Herrero, Raquel] Hosp Univ Getafe, CIBER Enfermedades Resp, Madrid, Spain.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of
   Washington; University of Washington Seattle; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERES; Hospital Universitario de
   Getafe
RP Martin, TR (corresponding author), Novartis Pharmaceut, 1 Hlth Plaza, E Hanover, NJ USA.
EM trmartin@u.washington.edu
RI Tanino, Mishie/G-2062-2012
OI Herrero, Raquel/0000-0001-8789-0904
FU Medical Research Service of the Department of Veterans Affairs; National
   Institutes of Health [HL-081764, HL-083044, HL-075381, P30-DK-17047];
   Instituto de Salud Carlos III, Ministerio de Economia y Competitividad,
   Madrid, Spain [PI12/02451]; Grants-in-Aid for Scientific Research
   [24590406] Funding Source: KAKEN
FX This work was supported in part by the Medical Research Service of the
   Department of Veterans Affairs, by National Institutes of Health Grants
   HL-081764, HL-083044, HL-075381, and P30-DK-17047, and Grant PI12/02451
   from the Instituto de Salud Carlos III, Ministerio de Economia y
   Competitividad, Madrid, Spain.
CR Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Bardales RH, 1996, AM J PATHOL, V149, P845
   Berthiaume Y, 1999, THORAX, V54, P150, DOI 10.1136/thx.54.2.150
   Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010
   Borjesson A, 2000, AM J PHYSIOL-LUNG C, V278, pL3, DOI 10.1152/ajplung.2000.278.1.L3
   Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002
   Farnand AW, 2011, AM J RESP CELL MOL, V45, P650, DOI 10.1165/rcmb.2010-0153OC
   FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009
   Fukuda N, 2001, AM J PHYSIOL-LUNG C, V280, pL1258, DOI 10.1152/ajplung.2001.280.6.L1258
   Hagimoto N, 1999, AM J RESP CELL MOL, V21, P436, DOI 10.1165/ajrcmb.21.3.3397
   Hamann KJ, 1998, AM J RESP CELL MOL, V19, P537, DOI 10.1165/ajrcmb.19.4.3100
   Hardiman KM, 2001, AM J PHYSIOL-LUNG C, V281, pL722, DOI 10.1152/ajplung.2001.281.3.L722
   Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007
   Herrero R, 2011, J CLIN INVEST, V121, P1174, DOI 10.1172/JCI43004
   Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200
   Lee JW, 2007, J BIOL CHEM, V282, P24109, DOI 10.1074/jbc.M700821200
   Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC
   Martin TR, 2002, J CLIN INVEST, V110, P1603, DOI 10.1172/JCI200217302
   Matthay MA, 2000, CLIN CHEST MED, V21, P477, DOI 10.1016/S0272-5231(05)70160-X
   Matthay MA, 1998, P ASSOC AM PHYSICIAN, V110, P496
   MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250
   Matute-Bello G, 2005, J IMMUNOL, V175, P4069, DOI 10.4049/jimmunol.175.6.4069
   Matute-Bello G, 1999, J IMMUNOL, V163, P2217
   Matute-Bello G, 2001, INFECT IMMUN, V69, P5768, DOI 10.1128/IAI.69.9.5768-5776.2001
   Matute-Bello G, 2001, AM J PHYSIOL-LUNG C, V281, pL328, DOI 10.1152/ajplung.2001.281.2.L328
   Matute-Bello G, 2001, AM J PATHOL, V158, P153, DOI 10.1016/S0002-9440(10)63953-3
   Matute-Bello G, 2007, AM J RESP CELL MOL, V37, P210, DOI 10.1165/rcmb.2006-0471OC
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Mutlu GM, 2004, AM J RESP CRIT CARE, V170, P1270, DOI 10.1164/rccm.200404-470CP
   Nakamura M, 2004, AM J PATHOL, V164, P1949, DOI 10.1016/S0002-9440(10)63755-8
   PITTET JF, 1994, J CLIN INVEST, V94, P663, DOI 10.1172/JCI117383
   Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991
   Rezaiguia S, 1997, J CLIN INVEST, V99, P325, DOI 10.1172/JCI119161
   Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200
   Sakuma T, 2006, CRIT CARE MED, V34, P676, DOI 10.1097/01.CCM.0000201403.70636.0F
   SMEDIRA N, 1991, J APPL PHYSIOL, V70, P1827, DOI 10.1152/jappl.1991.70.4.1827
   STONER GD, 1975, CANCER RES, V35, P2177
   Tang PS, 2008, AM J PHYSIOL-LUNG C, V294, pL632, DOI 10.1152/ajplung.00262.2007
   van den Berg E, 2011, AM J PHYSIOL-LUNG C, V301, pL451, DOI 10.1152/ajplung.00368.2010
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Yamagata T, 2009, RESP PHYSIOL NEUROBI, V166, P16, DOI 10.1016/j.resp.2008.12.008
   Yin W, 2007, LEUKEMIA, V21, P1669, DOI 10.1038/sj.leu.2404791
   Yue G, 1997, AM J PHYSIOL-LUNG C, V272, pL407, DOI 10.1152/ajplung.1997.272.3.L407
   Zemans RL, 2011, P NATL ACAD SCI USA, V108, P15990, DOI 10.1073/pnas.1110144108
NR 45
TC 23
Z9 24
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD SEP
PY 2013
VL 305
IS 5
BP L377
EP L388
DI 10.1152/ajplung.00271.2012
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 212YR
UT WOS:000324019600005
PM 23812636
OA Green Published
DA 2023-08-21
ER

PT J
AU Konrad, FM
   Neudeck, G
   Vollmer, I
   Ngamsri, KC
   Thiel, M
   Reutershan, J
AF Konrad, Franziska M.
   Neudeck, Gianna
   Vollmer, Irene
   Ngamsri, Kristian C.
   Thiel, Manfred
   Reutershan, Joerg
TI Protective effects of pentoxifylline in pulmonary inflammation are
   adenosine receptor A(2A) dependent
SO FASEB JOURNAL
LA English
DT Article
DE neutrophils; migration; oxidative burst; phosphodiesterase inhibitor; PTX 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; NECROSIS-FACTOR-ALPHA;
   PHOSPHODIESTERASE INHIBITION; NEUTROPHIL ACTIVATION; DOUBLE-BLIND;
   SEQUESTRATION; PERMEABILITY; LISOFYLLINE; MIGRATION
AB Pentoxifylline (PTX) has been shown to exert anti-inflammatory effects in experimental acute lung injury. However, results in humans were controversial. Recent in vitro studies suggested that the adenosine receptor A(2A) may be required for PTX to be effective. Therefore, we studied the association between A(2A) and PTX in a murine model of LPS-induced pulmonary inflammation. PTX treatment (10 mg/kg) reduced cellular influx (by 40%), microvascular permeability (30%), and the release of chemotactic cytokines into the alveolar space (TNF- 60%, IL-6 60%, and CXCL2/3 53%, respectively). These protective effects were abolished completely in A(2A)(-/-) mice and in wild-type mice that had been treated with the selective A(2A) antagonist (1 mg/kg), but effects were not different in mice with altered adenosine levels. In vitro transmigration assays revealed a pivotal role of the endothelium in PTX-mediated PMN migration, with a reduction of 50% (2 mM PTX). This effect was also A(2A) dependent. Further, oxidative burst of human PMNs was A(2A)-dependently reduced by 53% after PTX treatment. In summary, PTX exhibits its anti-inflammatory effects in LPS-induced lung injury through an A(2A)-dependent pathway. These results will help to better understand previous conflicting data on PTX in inflammation and will direct further studies to consider the predominant role of A(2A).Konrad, F. M., Neudeck, G., Vollmer, I., Ngamsri, K. C., Thiel, M., Reutershan, J. Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A(2A) dependent.
C1 [Konrad, Franziska M.; Neudeck, Gianna; Vollmer, Irene; Ngamsri, Kristian C.; Reutershan, Joerg] Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany.
C1 [Thiel, Manfred] Univ Med Ctr, Dept Anesthesiol, Mannheim, Germany.
C3 CIVIS; Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; 4EU+; Ruprecht Karls University Heidelberg
RP Reutershan, J (corresponding author), Univ Tubingen, Dept Anesthesiol & Intens Care Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.
EM joerg.reutershan@uni-tuebingen.de
OI Ngamsri, Kristian-Christos/0000-0001-8274-0691
FU German Research Foundation [RE 1683/3-1]
FX This work was supported by German Research Foundation grant RE 1683/3-1
   (to J.R.).
CR Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Bursten SL, 1996, CRIT CARE MED, V24, P1129, DOI 10.1097/00003246-199607000-00011
   Bursten SL, 1998, J PHARMACOL EXP THER, V284, P337
   Cepkova Magda, 2006, J Intensive Care Med, V21, P119, DOI 10.1177/0885066606287045
   Coimbra R, 2006, J TRAUMA, V60, P115, DOI 10.1097/01.ta.0000200075.12489.74
   Coimbra R, 2004, J TRAUMA, V57, P1157, DOI 10.1097/01.TA.0000151261.28640.F7
   Costantini TW, 2010, IMMUNOPHARM IMMUNOT, V32, P82, DOI 10.3109/08923970903183557
   de Campos T, 2008, PANCREAS, V37, P42, DOI 10.1097/MPA.0b013e3181612d19
   de Oliveira IS, 2008, CLINICS, V63, P77, DOI 10.1590/S1807-59322008000100014
   Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697
   Ege T, 2004, THORAC CARDIOV SURG, V52, P10, DOI 10.1055/s-2004-815798
   El-Lakkany N, 2011, EXP PARASITOL, V129, P152, DOI 10.1016/j.exppara.2011.06.015
   Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC
   George CLS, 1999, AM J PHYSIOL-LUNG C, V276, pL776, DOI 10.1152/ajplung.1999.276.5.L776
   Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137
   Haddad JJ, 2002, J PHARMACOL EXP THER, V300, P559, DOI 10.1124/jpet.300.2.559
   HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962
   Konrad FM, 2012, AM J PHYSIOL-LUNG C, V303, pL425, DOI 10.1152/ajplung.00387.2011
   Korhonen K, 2004, PEDIATR RES, V56, P901, DOI 10.1203/01.PDR.0000145256.19073.E4
   Kreth S, 2010, SHOCK, V34, P10, DOI 10.1097/SHK.0b013e3181cdc3e2
   KUDOH I, 1995, ANESTHESIOLOGY, V82, P531, DOI 10.1097/00000542-199502000-00023
   Kudoh I, 2001, CRIT CARE MED, V29, P1621, DOI 10.1097/00003246-200108000-00020
   Lall RN, 2006, J AM COLL SURGEONS, V202, P10, DOI 10.1016/j.jamcollsurg.2005.07.018
   Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mazar J, 2005, ANESTHESIOLOGY, V102, P1174, DOI 10.1097/00000542-200506000-00017
   Michetti C, 2003, J SURG RES, V115, P92, DOI 10.1016/S0022-4804(03)00219-1
   Miyazaki H, 1999, ANESTHESIOLOGY, V90, P1650, DOI 10.1097/00000542-199906000-00022
   MORIUCHI H, 1995, CRIT CARE MED, V23, P357, DOI 10.1097/00003246-199502000-00023
   Ngamsri KC, 2010, J IMMUNOL, V185, P4374, DOI 10.4049/jimmunol.1000433
   Olson TS, 2002, AM J PHYSIOL-REG I, V282, pR1245, DOI 10.1152/ajpregu.00540.2001
   PORTER JM, 1982, AM HEART J, V104, P66, DOI 10.1016/0002-8703(82)90642-1
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009
   Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254
   Reutershan J, 2007, AM J RESP CRIT CARE, V175, P1027, DOI 10.1164/rccm.200612-1822OC
   Reyes G, 2011, MOL MEMBR BIOL, V28, P412, DOI 10.3109/09687688.2011.604861
   Rhee CK, 2009, CRIT CARE, V13, DOI 10.1186/cc8149
   RICE GC, 1994, P NATL ACAD SCI USA, V91, P3857, DOI 10.1073/pnas.91.9.3857
   Schick MA, 2012, J PHYSIOL-LONDON, V590, P2693, DOI 10.1113/jphysiol.2012.232116
   Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5
   Schulte G, 2004, ACTA PHYSIOL SCAND, V182, P133, DOI 10.1111/j.1365-201X.2004.01350.x
   Spindler V, 2011, AM J PATHOL, V178, P2424, DOI 10.1016/j.ajpath.2011.01.014
   STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364
   Wagner R, 2010, AM J PHYSIOL-LUNG C, V299, pL502, DOI 10.1152/ajplung.00083.2010
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WELSH CH, 1988, AM REV RESPIR DIS, V138, P1106, DOI 10.1164/ajrccm/138.5.1106
   Wiedemann HP, 2002, CRIT CARE MED, V30, P1
   Zeni F, 1996, CRIT CARE MED, V24, P207, DOI 10.1097/00003246-199602000-00005
   Zhang J. S., 2011, PLOS ONE, V6
NR 53
TC 30
Z9 30
U1 0
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2013
VL 27
IS 9
BP 3524
EP 3535
DI 10.1096/fj.13-228122
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 277SV
UT WOS:000328840500013
PM 23699177
DA 2023-08-21
ER

PT J
AU Li, H
   Qiang, Y
   Wang, L
   Wang, GM
   Yi, J
   Jing, H
   Wu, HW
AF Li, Hao
   Qiang, Yong
   Wang, Lian
   Wang, Gaoming
   Yi, Jun
   Jing, Hua
   Wu, Haiwei
TI Repair of Lipopolysaccharide-Induced Acute Lung Injury in Mice by
   Endothelial Progenitor Cells, Alone and in Combination With Simvastatin
SO CHEST
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; STEM-CELLS; IMPROVES SURVIVAL; STATIN
   THERAPY; MURINE MODEL; INFLAMMATION; SEPSIS; TRANSPLANTATION; ISCHEMIA;
   PROTECTS
AB Background: Endothelial progenitor cells (EPCs) are involved in endothelium repair of acute lung injury (ALI). Numerous studies have demonstrated that statins can promote EPC function in vitro and in vivo; therefore, the purpose of this study was to determine whether simvastatin enhances the function of EPCs participating in the repair of ALI.
   Methods: BALB/C mice were initially pretreated with simvastatin by intraperitoneal administration 24 h before, and again at the time of, intratracheal instillation of lipopolysaccharide (LPS) and subsequently treated with EPCs by IV transplantation 2 h later. The effects of capillary permeability, endothelium repair, and inflammatory cytokines were measured.
   Results: This study revealed that both simvastatin administration and EPC transplantation can reduce the severity of LPS-induced ALI in mice, and the effect can be further improved by combining the two therapies.
   Conclusions: The administration of simvastatin and EPC transplantation can reduce the severity of LPS-induced ALI in mice, and improvement is moderately enhanced in some respects when EPC transplantation is combined with simvastatin administration. The beneficial role of simvastatin on EPCs may be a component of its pleiotropic effects. Although the exact mechanism remains unknown, the combined administration of simvastatin and EPC transplantation may be a potentially important, cell-based, inflammation-mediated therapy for patients with ALI/ARDS.
C1 [Li, Hao; Qiang, Yong; Wang, Lian; Yi, Jun; Jing, Hua; Wu, Haiwei] Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Cardiothorac Surg, Nanjing 210008, Jiangsu, China.
C1 [Wang, Gaoming] Xuzhou Cent Hosp, Dept Cardiothorac Surg, Xuzhou, China.
C3 Nanjing University
RP Wu, HW (corresponding author), 305 Zhongshan E Rd, Nanjing, Jiangsu, Peoples R China.
EM wuhaiweicts@163.com
OI Wang, Lian/0000-0001-9201-6517
FU Natural Science Foundation of China [30972969]
FX This study was supported by research grant from the Natural Science
   Foundation of China [30972969].
CR Aguilar S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008013
   Aliotta JM, 2009, STEM CELLS DEV, V18, P773, DOI 10.1089/scd.2008.0237
   Alm AS, 2010, RESP PHYSIOL NEUROBI, V171, P157, DOI 10.1016/j.resp.2010.02.009
   Aslam M, 2009, AM J RESP CRIT CARE, V180, P1122, DOI 10.1164/rccm.200902-0242OC
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Comellas AP, 2009, TRANSL RES, V153, P263, DOI 10.1016/j.trsl.2009.02.007
   Cribbs SK, 2012, INTENS CARE MED, V38, P429, DOI 10.1007/s00134-012-2480-9
   Cui X, 2009, NEUROBIOL DIS, V36, P35, DOI 10.1016/j.nbd.2009.06.012
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152
   Donnelly SC, 1996, ANN INTERN MED, V125, P191, DOI 10.7326/0003-4819-125-3-199608010-00005
   Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011
   Gao XF, 2011, INT IMMUNOPHARMACOL, V11, P1584, DOI 10.1016/j.intimp.2011.05.019
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hu ZL, 2008, J BIOMED SCI, V15, P509, DOI 10.1007/s11373-008-9243-1
   Huang YQ, 2008, CRIT CARE MED, V36, P262, DOI 10.1097/01.CCM.0000297955.02633.A4
   Infusino GA, 2012, MICROVASC RES, V83, P89, DOI 10.1016/j.mvr.2011.09.011
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Janet CG, 2011, GUIDE CARE USE LAB A, P1
   Jeon O, 2007, J BIOMED SCI, V14, P323, DOI 10.1007/s11373-007-9145-7
   Kawamoto A, 2001, CIRCULATION, V103, P634
   Kim YS, 2009, TISSUE ENG REGEN MED, V6, P1072
   Kupatt C, 2005, CIRCULATION, V112, pI117, DOI 10.1161/CIRCULATIONAHA.104.524801
   Lam CF, 2011, ANESTH ANALG, V112, P620, DOI 10.1213/ANE.0b013e3182075da4
   LI XY, 1995, AM J RESP CELL MOL, V13, P185, DOI 10.1165/ajrcmb.13.2.7626286
   Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC
   O'Neal HR, 2011, CRIT CARE MED, V39, P1343, DOI 10.1097/CCM.0b013e3182120992
   Rafat N, 2012, ANASTH INTENSIVMED, V53, P196
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712
   Serikov VB, 2008, LUNG, V186, P179, DOI 10.1007/s00408-008-9078-6
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Takahashi S, 2008, AM J PHYSIOL-LUNG C, V294, pL882, DOI 10.1152/ajplung.00238.2007
   Takano K, 2011, J PHARMACOL EXP THER, V336, P381, DOI 10.1124/jpet.110.171462
   Toya SP, 2011, AM J PATHOL, V178, P313, DOI 10.1016/j.ajpath.2010.09.041
   Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816
   Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55
   Weil BR, 2009, ANN SURG, V250, P19, DOI 10.1097/SLA.0b013e3181a77b9c
   Wu BJ, 2009, ARTERIOSCL THROM VAS, V29, P1537, DOI 10.1161/ATVBAHA.109.184713
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
NR 43
TC 22
Z9 28
U1 1
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD SEP
PY 2013
VL 144
IS 3
BP 876
EP 886
DI 10.1378/chest.12-2429
PG 11
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA 241JC
UT WOS:000326161700023
PM 23539119
DA 2023-08-21
ER

PT J
AU Predescu, DN
   Bardita, C
   Tandon, R
   Predescu, SA
AF Predescu, Dan N.
   Bardita, Cristina
   Tandon, Rajive
   Predescu, Sanda A.
TI Intersectin-1s: an important regulator of cellular and molecular
   pathways in lung injury
SO PULMONARY CIRCULATION
LA English
DT Review
DE intersectin-1s; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; apoptosis; permeability 
ID RESPIRATORY-DISTRESS-SYNDROME; GENOME-WIDE ASSOCIATION; INDUCED
   PULMONARY INFLAMMATION; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE
   SYNTHASE; GROWTH-FACTOR VEGF; ANIMAL-MODELS; ADHESION MOLECULES;
   DOWN-SYNDROME; MEMBRANE MICROPARTICLES
AB Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe syndromes resulting from the diffuse damage of the pulmonary parenchyma. ALI and ARDS are induced by a plethora of local or systemic insults, leading to the activation of multiple pathways responsible for injury, resolution, and repair or scarring of the lungs. Despite the large efforts aimed at exploring the roles of different pathways in humans and animal models and the great strides made in understanding the pathogenesis of ALI/ARDS, the only viable treatment options are still dependent on ventilator and cardiovascular support. Investigation of the pathophysiological mechanisms responsible for initiation and resolution or advancement toward lung scarring in ALI/ARDS animal models led to a better understanding of the disease's complexity and helped in elucidating the links between ALI and systemic multiorgan failure. Although animal models of ALI/ARDS have pointed out a variety of new ideas for study, there are still limited data regarding the initiating factors, the critical steps in the progression of the disease, and the central mechanisms dictating its resolution or progression to lung scarring. Recent studies link deficiency of intersectin-1s (ITSN-1s), a prosurvival protein of lung endothelial cells, to endothelial barrier dysfunction and pulmonary edema as well as to the repair/recovery from ALI. This review discusses the effects of ITSN-1s deficiency on pulmonary endothelium and its significance in the pathology of ALI/ARDS.
C1 [Predescu, Dan N.; Bardita, Cristina; Predescu, Sanda A.] Rush Univ, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Predescu, Dan N.; Tandon, Rajive; Predescu, Sanda A.] Rush Univ, Dept Pulm & Crit Care Med, Chicago, IL 60612, United States.
C3 Rush University; Rush University
RP Predescu, SA (corresponding author), Rush Univ, 1735 West Harrison St, Chicago, IL 60612 USA.
EM sanda_predescu@rush.edu
OI Predescu, Sanda/0000-0002-9386-6756
CR Adams A, 2000, J BIOL CHEM, V275, P27414
   Adamson RH, 2004, J PHYSIOL-LONDON, V557, P889, DOI 10.1113/jphysiol.2003.058255
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Aird WC, 2004, CRIT CARE MED, V32, pS271, DOI 10.1097/01.CCM.0000129669.21649.40
   Aird WC, 2008, PHARMACOL REP, V60, P139
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Alam N, 2007, ANN THORAC SURG, V84, P1085, DOI 10.1016/j.athoracsur.2007.05.053
   Arnout J., 2006, V176, P1
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Bardales RH, 1996, AM J PATHOL, V149, P845
   Bardita C, 2013, APOPTOSIS, V18, P57, DOI 10.1007/s10495-012-0762-x
   Bastarache JA, 2009, AM J PHYSIOL-LUNG C, V297, pL1035, DOI 10.1152/ajplung.00214.2009
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Becher UM, 2011, CURR HYPERTENS REP, V13, P86, DOI 10.1007/s11906-010-0171-x
   Bem RA, 2010, J IMMUNOL, V184, P931, DOI 10.4049/jimmunol.0903029
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   BRUNS RR, 1968, J CELL BIOL, V37, P277, DOI 10.1083/jcb.37.2.277
   BRUNS RR, 1968, J CELL BIOL, V37, P244, DOI 10.1083/jcb.37.2.244
   BUNDGAARD M, 1984, J ULTRA MOL STRUCT R, V88, P1, DOI 10.1016/S0022-5320(84)90177-1
   Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Busse R, 2006, Handb Exp Pharmacol, P43
   Carnesecchi S, 2012, CELL MOL LIFE SCI, V69, P2373, DOI 10.1007/s00018-012-1013-6
   Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5
   Cataldo AM, 2008, AM J PATHOL, V173, P370, DOI 10.2353/ajpath.2008.071053
   Chang KT, 2009, P NATL ACAD SCI USA, V106, P17117, DOI 10.1073/pnas.0904397106
   Christie JD, 2008, CRIT CARE MED, V36, P2794, DOI 10.1097/CCM.0b013e318186b843
   Christie JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028268
   Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7
   COX G, 1995, AM J RESP CELL MOL, V12, P232, DOI 10.1165/ajrcmb.12.2.7865221
   Crabtree MJ, 2011, NITRIC OXIDE-BIOL CH, V25, P81, DOI 10.1016/j.niox.2011.04.004
   Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009
   CROSS AS, 1993, INFECT IMMUN, V61, P2741, DOI 10.1128/IAI.61.7.2741-2747.1993
   Cross LJM, 2011, CRIT CARE CLIN, V27, P355, DOI 10.1016/j.ccc.2010.12.005
   Curry FRE, 2010, CARDIOVASC RES, V87, P218, DOI 10.1093/cvr/cvq115
   de Prost N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-28
   Denis CV, 2008, THROMB HAEMOSTASIS, V99, P271, DOI 10.1160/TH07-10-0629
   Densmore JC, 2006, SHOCK, V26, P464, DOI 10.1097/01.shk.0000228791.10550.36
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Desai LP, 2007, AM J PHYSIOL-LUNG C, V293, pL769, DOI 10.1152/ajplung.00127.2007
   Desai TJ, 2001, RESPIR RES, V3, DOI 10.1186/rr169
   Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230
   Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75
   Dos Santos CC, 2008, INTENS CARE MED, V34, P619, DOI 10.1007/s00134-007-0963-x
   Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880
   Dyson A, 2009, CRIT CARE MED, V37, pS30, DOI 10.1097/CCM.0b013e3181922bd3
   Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   Fan XM, 2006, ANN THORAC SURG, V81, P896, DOI 10.1016/j.athoracsur.2005.09.032
   Flores C, 2008, TRANSL RES, V152, P11, DOI 10.1016/j.trsl.2008.05.006
   Flores C, 2009, CRIT CARE MED, V37, P2759, DOI 10.1097/CCM.0b013e3181a57b90
   Flores C, 2008, CRIT CARE, V12, DOI 10.1186/cc7098
   Forstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424-010-0808-2
   FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655
   Frank JA, 2007, AM J PHYSIOL-LUNG C, V293, pL52, DOI 10.1152/ajplung.00256.2006
   FRANK L, 1978, J APPL PHYSIOL, V45, P699, DOI 10.1152/jappl.1978.45.5.699
   Freeman MR, 2012, ADV EXP MED BIOL, V729, P95, DOI 10.1007/978-1-4614-1222-9_7
   Gao L, 2007, TRANSL RES, V150, P18, DOI 10.1016/j.trsl.2007.02.007
   GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772
   GEORGE JN, 1986, BLOOD, V68, P307
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gibson G, 2008, NAT REV GENET, V9, P575, DOI 10.1038/nrg2383
   GIL J, 1982, ANN NY ACAD SCI, V384, P31, DOI 10.1111/j.1749-6632.1982.tb21359.x
   Gong MN, 2007, CRIT CARE MED, V35, P48, DOI 10.1097/01.CCM.0000251132.10689.F3
   Gong MN, 2004, CHEST, V125, P203, DOI 10.1378/chest.125.1.203
   Gong MN, 2006, EUR RESPIR J, V27, P674, DOI 10.1183/09031936.06.00046405
   Gong MN, 2005, EUR RESPIR J, V26, P382, DOI 10.1183/09031936.05.00000505
   Gorbunov NV, 2007, ANTIOXID REDOX SIGN, V9, P483, DOI 10.1089/ars.2006.1296
   Guervilly C, 2011, CRIT CARE, V15, DOI 10.1186/cc9978
   Guinee D, 1997, AM J PATHOL, V151, P999
   Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100
   Harding M, 2012, CURR OPIN MICROBIOL, V15, P85, DOI 10.1016/j.mib.2011.11.010
   Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007
   Hattersley AT, 2005, LANCET, V366, P1315, DOI 10.1016/S0140-6736(05)67531-9
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Iles MM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040033
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200
   Jerng JS, 2006, CRIT CARE MED, V34, P1001, DOI 10.1097/01.CCM.0000206107.92476.39
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Kamanna VS, 2008, AM J CARDIOL, V101, p20B, DOI 10.1016/j.amjcard.2008.02.029
   Kawashima H, 2012, ANN NY ACAD SCI, V1253, P112, DOI 10.1111/j.1749-6632.2011.06356.x
   Keating DJ, 2006, AGEING RES REV, V5, P388, DOI 10.1016/j.arr.2005.11.001
   Kian H, 2007, CHEST, V131, P1308, DOI 10.1378/chest.06-3048
   Knezevic I, 2011, J CELL MOL MED, V15, P2364, DOI 10.1111/j.1582-4934.2010.01226.x
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Kozarov E, 2012, FUTUR CARDIOL, V8, P123, DOI [10.2217/fca.11.75, 10.2217/FCA.11.75]
   Kranenburg AR, 2002, AM J RESP CELL MOL, V27, P517, DOI 10.1165/rcmb.4474
   Kubota Yoshiaki, 2012, Keio Journal of Medicine, V61, P47
   Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200
   Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002
   Kuhn M, 2012, BRIT J PHARMACOL, V166, P522, DOI 10.1111/j.1476-5381.2012.01827.x
   Kume T, 2012, ADV EXP MED BIOL, V727, P210, DOI 10.1007/978-1-4614-0899-4_16
   Kutlu CA, 2000, ANN THORAC SURG, V69, P376, DOI 10.1016/S0003-4975(99)01090-5
   Kuwano K, 2007, CELL MOL IMMUNOL, V4, P419
   LACHMANN B, 1980, ACTA ANAESTH SCAND, V24, P231, DOI 10.1111/j.1399-6576.1980.tb01541.x
   Lahm T, 2012, AM J RESP CRIT CARE, V185, P965, DOI 10.1164/rccm.201107-1293OC
   Lamas S, 2012, SEMIN NEPHROL, V32, P156, DOI 10.1016/j.semnephrol.2012.02.002
   Laycock H., 2010, British Journal of Medical Practitioners, V3, P324
   Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Ley K, 2006, Handb Exp Pharmacol, P97
   Li XP, 2004, J APPL PHYSIOL, V97, P1535, DOI 10.1152/japplphysiol.00519.2004
   Ling S, 2012, MINI-REV MED CHEM, V12, P175, DOI 10.2174/138955712798995057
   Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200
   Loeb CRK, 2006, J BIOL CHEM, V281, P28326, DOI 10.1074/jbc.M604544200
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007
   Magrone T., 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P310
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Marie B, 2004, NEURON, V43, P207, DOI 10.1016/j.neuron.2004.07.001
   Maris NA, 2005, THROMB HAEMOSTASIS, V93, P1036, DOI 10.1160/TH04-08-0492
   Marshall RP, 2000, AM J RESP CRIT CARE, V162, P1783, DOI 10.1164/ajrccm.162.5.2001061
   Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC
   Martin TR, 2011, CRIT CARE CLIN, V27, P735, DOI 10.1016/j.ccc.2011.05.013
   Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com
   Matthay Michael A, 2008, Proc Am Thorac Soc, V5, P297, DOI 10.1513/pats.200708-141DR
   Matute-Bello G, 2003, CRIT CARE, V7, P355, DOI 10.1186/cc1861
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46
   McVey M, 2012, AM J PHYSIOL-LUNG C, V303, pL364, DOI 10.1152/ajplung.00354.2011
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   Medford ARL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-27
   Meduri GU, 1996, EUR RESPIR J, V9, P2650, DOI 10.1183/09031936.96.09122650
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mercier I, 2012, ADV EXP MED BIOL, V729, P83, DOI 10.1007/978-1-4614-1222-9_6
   Meyer NJ, 2009, AM J RESP CRIT CARE, V179, P89, DOI 10.1164/rccm.200810-1565ED
   Meyer NJ, 2009, FASEB J, V23, P1325, DOI 10.1096/fj.08-119073
   Miller F, 2012, VIRULENCE, V3, P222, DOI 10.4161/viru.19697
   Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014
   Moore BB, 2008, AM J PHYSIOL-LUNG C, V294, pL152, DOI 10.1152/ajplung.00313.2007
   Morissette Mathieu C, 2009, Int J Chron Obstruct Pulmon Dis, V4, P19
   Morrell NW, ALTERED GROWTH RESPO
   Mukherjee S, 2006, CIRC RES, V98, P743, DOI 10.1161/01.RES.0000214545.99387.e3
   Nick JA, 2004, BLOOD, V104, P3878, DOI 10.1182/blood-2004-06-2140
   OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904
   Orfanos SE, 1993, ANN REV CARDIAC SURG, V6th, P52
   PALADE GE, 1979, ACTA PHYSIOL SCAND, P11
   Parnell E, 2012, BRIT J PHARMACOL, V166, P434, DOI 10.1111/j.1476-5381.2011.01808.x
   Pelosi P, 2008, INTENS CARE MED, V34, P631, DOI 10.1007/s00134-007-0964-9
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   Popov D, 2001, MARC MALPIG SYMP SER, V7, P405
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Predescu D, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3264
   Predescu DN, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/672705
   Predescu SA, 2007, J BIOL CHEM, V282, P17166, DOI 10.1074/jbc.M608996200
   Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006
   Primeau M, 2011, FEBS LETT, V585, P847, DOI 10.1016/j.febslet.2011.02.022
   Proudfoot AG, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-132
   Pucharcos C, 1999, EUR J HUM GENET, V7, P704, DOI 10.1038/sj.ejhg.5200356
   Quasney MW, 2008, CRIT CARE MED, V36, P2678, DOI 10.1097/CCM.0b013e3181843df2
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rocco PRM, 2009, MINERVA ANESTESIOL, V75, P730
   Rose S, 2007, MOL BIOL CELL, V18, P5091, DOI 10.1091/mbc.E07-05-0460
   Roy SK, 2011, PHARMACOL RES, V64, P580, DOI 10.1016/j.phrs.2011.06.012
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sakuma T, 1999, AM J PHYSIOL-LUNG C, V276, pL137, DOI 10.1152/ajplung.1999.276.1.L137
   Salvucci O, 2012, ADV CANCER RES, V114, P21, DOI 10.1016/B978-0-12-386503-8.00002-8
   Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366
   Schmidt E P, 2010, J Cell Death, V3, P41
   SCHUSTER DP, 1994, AM J RESP CRIT CARE, V149, P245, DOI 10.1164/ajrccm.149.1.8111590
   Sehgal PB, 2007, AM J RESP CELL MOL, V37, P31, DOI 10.1165/rcmb.2007-0066TR
   Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165
   Shcheglovitova O. N., 2011, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, P54
   Shimabukuro DW, 2003, CRIT CARE MED, V31, pS524, DOI 10.1097/01.CCM.0000081437.06466.B3
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Simak J, 2006, TRANSFUS MED REV, V20, P1, DOI 10.1016/j.tmrv.2005.08.001
   SIMIONESCU M, 1977, J CELL BIOL, V74, P98, DOI 10.1083/jcb.74.1.98
   SIMIONESCU M, 1991, CELL BIOL REV, V25, P5
   SIMIONESCU N, 1973, J CELL BIOL, V57, P424, DOI 10.1083/jcb.57.2.424
   SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536
   Singla S, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-46
   Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187
   Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748
   Specht K, 2009, BREAST CANCER RES TR, V118, P45, DOI 10.1007/s10549-008-0207-y
   Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008
   Syed Aitizaz, 2004, Heart Lung Circ, V13, P168, DOI 10.1016/j.hlc.2004.03.015
   Tandon S, 2001, BRIT J ANAESTH, V86, P633, DOI 10.1093/bja/86.5.633
   Tasaka S, 2008, ANTIOXID REDOX SIGN, V10, P739, DOI 10.1089/ars.2007.1940
   Todd JL, 2011, AM J RESP CRIT CARE, V184, P873, DOI 10.1164/rccm.201106-0971PP
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200
   Tsangaris I, 2009, THROMB RES, V123, P832, DOI 10.1016/j.thromres.2008.07.018
   Tse D, 2010, SEMIN THROMB HEMOST, V36, P236, DOI 10.1055/s-0030-1253447
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Tushuizen ME, 2011, ARTERIOSCL THROM VAS, V31, P4, DOI 10.1161/ATVBAHA.109.200998
   van Hinsbergh VWM, 2012, SEMIN IMMUNOPATHOL, V34, P93, DOI 10.1007/s00281-011-0285-5
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Voelkel NF, 2003, EUR RESPIR J, V22, p28S, DOI 10.1183/09031936.03.00000503
   Wang HM, 2008, EUR SURG RES, V40, P305, DOI 10.1159/000121471
   Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536
   Warburton D, 2001, AM J RESP CRIT CARE, V164, pS59, DOI 10.1164/ajrccm.164.supplement_2.2106064
   WARD PA, 1986, RESPIRATION, V50, P5, DOI 10.1159/000195082
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Wesselkamper SC, 2005, AM J RESP CRIT CARE, V172, P1399, DOI 10.1164/rccm.200502-286OC
   WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
   WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388
   WINDSOR ACJ, 1993, AM J MED SCI, V306, P111, DOI 10.1097/00000441-199308000-00010
   Wurfel MM, 2008, AM J RESP CRIT CARE, V178, P710, DOI 10.1164/rccm.200803-462OC
   Wurfel MM, 2005, J IMMUNOL, V175, P2570, DOI 10.4049/jimmunol.175.4.2570
   Yilmaz M, 2007, CRIT CARE MED, V35, P1660, DOI 10.1097/01.CCM.0000269037.66955.F0
   Young MP, 2004, CRIT CARE MED, V32, P1260, DOI 10.1097/01.CCM.0000127784.54727.56
   Yu Y, 2008, HUM MOL GENET, V17, P3281, DOI 10.1093/hmg/ddn224
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
   Zhai RH, 2007, CRIT CARE MED, V35, P893, DOI 10.1097/01.CCM.0000256845.92640.38
NR 215
TC 7
Z9 8
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD SEP
PY 2013
VL 3
IS 3
BP 478
EP 498
DI 10.1086/674439
PG 21
WC Cardiac & Cardiovascular Systems; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Respiratory System
GA V47WJ
UT WOS:000209981600004
PM 24618535
OA hybrid, Green Published
DA 2023-08-21
ER

PT J
AU Wang, YX
   Chen, HL
   Li, HL
   Zhang, JW
   Gao, YY
AF Wang, Yuxi
   Chen, Hailong
   Li, Hailong
   Zhang, Jingwen
   Gao, Yanyan
TI Effect of angiopoietin-like protein 4 on rat pulmonary microvascular
   endothelial cells exposed to LPS
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE angiopoietin-like protein 4; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; F-actin 
ID ACTIVATED-RECEPTOR-GAMMA; GASTRIC-MUCOSAL INJURY; PPAR-GAMMA;
   ISCHEMIA-REPERFUSION; LIPID-METABOLISM; EXPRESSION; LIGAND;
   PIOGLITAZONE; INHIBITION; INFLAMMATION
AB Pulmonary microvascular endothelial cells (PMVECs) possess highly proliferative and angiogenic capacities and are localized at the critical interface between the blood and microvessel wall; they are the primary targets of inflammatory cytokines during lung inflammation. Angiopoietin-like protein 4 (Angptl4) is a circulating protein that has recently been im-plicated in the regulation of angiogenesis and metastasis. This study aimed to investigate the effect of Angptl4 on rat PMVECs (RPMVECs) exposed to lipopolysaccharide (LPS). The cell culture was stimulated with LPS. Total Angptl4 cDNA was obtained from Source BioScience. The PCR product was cloned into the pcDNA3.1-eGFP or the pcDNA3.1-eGFP-Angptl4 vector, which were then transfected into the RPMVECs using SuperFect transfection reagent. The Angptl4 mRNA levels, protein levels and cell morphology of the RPMVECs in the experimental groups were detected using real time-PCR, western blot analysis, MTT assay, ELISA and confocal microscopy methods, respectively. The Angptl4 expression vector, pcDNA3.1-eGFP-Angptl4, was successfully constructed. The Angptl4 mRNA level in the LPS-pcDNA3.1-eGFP-transfected group (blank control) was slightly increased and was significantly higher in the experimental group compared with the empty vector and blank control group with significant differences. Pro-apoptotic caspase-8, -9 and Bax protein were inhibited, while p-AKT/AKT and p-MEK1/2 protein expression was also decreased. The rosiglitazone group had significantly decreased levels of the inflammatory cytokine, tumor necrosis factor (TNF)-alpha (P<0.01). The overexpression of Angptl4 inhibited the LPS-induced increase in the permeability of the RPMVECs, which was associated with the depolymerization of central F-actin in the RPMVECs. In conclusion, our study demonstrates that the overexpression of Angptl4 exerts protective, anti-inflammatory and anti-angiogenic effects. It represents a novel therapeutic target gene for the treatment of acute lung injury induced by LPS.
C1 [Wang, Yuxi; Li, Hailong; Zhang, Jingwen] Dalian Med Univ, Dalian 116011, Liaoning, China.
C1 [Chen, Hailong] Dalian Med Univ, Dept Gen Surg, Affiliated Hosp 1, Dalian 116011, Liaoning, China.
C1 [Gao, Yanyan] Dalian Municipal Cent Hosp, Dept Cent Lab, Dalian, Liaoning, China.
C1 [Li, Hailong] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211, United States.
C3 Dalian Medical University; Dalian Medical University; University of
   Missouri System; University of Missouri Columbia
RP Chen, HL (corresponding author), Dalian Med Univ, Dept Gen Surg, Affiliated Hosp 1, 222 ZhongShan Rd, Dalian 116011, Liaoning, Peoples R China.
EM chenhailong2012@yahoo.com.cn
RI Zhang, Jing/HII-4294-2022; Zhang, Jing/GWZ-7332-2022
FU National Natural Science Foundation of China [FNSFC_81173452]
FX This study was supported by The National Natural Science Foundation of
   China (FNSFC_81173452). We completed this study at the Laboratory of the
   First Affiliated Hospital of Dalian Medical University and Dalian Center
   Hospital. The authors thank HaiLong Li, Jun Ji and DongShang for their
   helpful discussions.
CR Adkison JB, 2006, MICROVASC RES, V71, P175, DOI 10.1016/j.mvr.2006.02.007
   Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021
   Brunckhorst MK, 2010, CANCER RES, V70, P7283, DOI 10.1158/0008-5472.CAN-09-4125
   Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91
   CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Cheng C, 2007, MOL CELL BIOCHEM, V305, P1, DOI 10.1007/s11010-007-9521-7
   Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8
   Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543
   Faulkner A, 2006, EAR HEARING, V27, P139, DOI 10.1097/01.aud.0000202357.40662.85
   Feingold KR, 2012, BIOCHEM BIOPH RES CO, V421, P612, DOI 10.1016/j.bbrc.2012.04.055
   Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103
   Gao GG, 2001, RNA, V7, P1335, DOI 10.1017/S1355838201018076
   Ge HF, 2004, J LIPID RES, V45, P2071, DOI 10.1194/jlr.M400138-JLR200
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002
   Ichikawa H, 2002, REDOX REP, V7, P343, DOI 10.1179/135100002125000956
   Kersten S, 2005, BIOCHEM SOC T, V33, P1059, DOI 10.1042/BST0331059
   Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603
   Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814
   Koliwad SK, 2009, J BIOL CHEM, V284, P25593, DOI 10.1074/jbc.M109.025452
   Konturek PC, 2003, SCAND J GASTROENTERO, V38, P468, DOI 10.1080/00365520310002904
   Lappas M, 2006, PLACENTA, V27, P1060, DOI 10.1016/j.placenta.2005.11.009
   Li KQ, 2004, CHINESE MED J-PEKING, V117, P1364
   Liu FF, 2013, TOXICOLOGY, V304, P158, DOI 10.1016/j.tox.2012.12.020
   Lu B, 2010, BIOCHEM BIOPH RES CO, V391, P1737, DOI 10.1016/j.bbrc.2009.12.145
   Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200
   Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200
   Masamune A, 2009, CLIN GASTROENTEROL H, V7, pS48, DOI 10.1016/j.cgh.2009.07.038
   Naito Y, 2001, ALIMENT PHARM THERAP, V15, P865, DOI 10.1046/j.1365-2036.2001.00983.x
   Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Slomiany A, 2002, J PHYSIOL PHARMACOL, V53, P21
   Sukonina V, 2006, P NATL ACAD SCI USA, V103, P17450, DOI 10.1073/pnas.0604026103
   Takagi T, 2004, REDOX REP, V9, P376, DOI 10.1179/135100004225006911
   Villegas I, 2004, EUR J PHARMACOL, V505, P195, DOI 10.1016/j.ejphar.2004.10.020
   Wada K, 2004, AM J PHYSIOL-GASTR L, V287, pG452, DOI 10.1152/ajpgi.00523.2003
   Wu FH, 2012, BIOL PHARM BULL, V35, P1171, DOI 10.1248/bpb.b110586
   Xu AM, 2005, P NATL ACAD SCI USA, V102, P6086, DOI 10.1073/pnas.0408452102
   Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776
   Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022
   Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018
NR 41
TC 15
Z9 20
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2013
VL 32
IS 3
BP 568
EP 576
DI 10.3892/ijmm.2013.1420
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 190VS
UT WOS:000322371000006
PM 23783408
OA hybrid, Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Anidi, IU
   Servinsky, LE
   Rentsendorj, O
   Stephens, RS
   Scott, AL
   Pearse, DB
AF Anidi, Ifeanyi U.
   Servinsky, Laura E.
   Rentsendorj, Otgonchimeg
   Stephens, R. Scott
   Scott, Alan L.
   Pearse, David B.
TI CD36 and Fyn Kinase Mediate Malaria-Induced Lung Endothelial Barrier
   Dysfunction in Mice Infected with Plasmodium berghei
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; PARASITE SEQUESTRATION;
   VASCULAR-PERMEABILITY; HYDROGEN-PEROXIDE; TYROSINE KINASE;
   CELL-ADHESION; IN-VITRO; FALCIPARUM; INJURY; OXYGEN
AB Severe malaria can trigger acute lung injury characterized by pulmonary edema resulting from increased endothelial permeability. However, the mechanism through which lung fluid conductance is altered during malaria remains unclear. To define the role that the scavenger receptor CD36 may play in mediating this response, C57BL/6J (WT) and CD36-/- mice were infected with P. berghei ANKA and monitored for changes in pulmonary endothelial barrier function employing an isolated perfused lung system. WT lungs demonstrated a >10-fold increase in two measures of paracellular fluid conductance and a decrease in the albumin reflection coefficient (sigma alb) compared to control lungs indicating a loss of barrier function. In contrast, malaria-infected CD36-/- mice had near normal fluid conductance but a similar reduction in sigma alb. In WT mice, lung sequestered iRBCs demonstrated production of reactive oxygen species (ROS). To determine whether knockout of CD36 could protect against ROS-induced endothelial barrier dysfunction, mouse lung microvascular endothelial monolayers (MLMVEC) from WT and CD36-/- mice were exposed to H2O2. Unlike WT monolayers, which showed dose-dependent decreases in transendothelial electrical resistance (TER) from H2O2 indicating loss of barrier function, CD36-/- MLMVEC demonstrated dose-dependent increases in TER. The differences between responses in WT and CD36-/- endothelial cells correlated with important differences in the intracellular compartmentalization of the CD36-associated Fyn kinase. Malaria infection increased total lung Fyn levels in CD36-/- lungs compared to WT, but this increase was due to elevated production of the inactive form of Fyn further suggesting a dysregulation of Fyn-mediated signaling. The importance of Fyn in CD36-dependent endothelial signaling was confirmed using in vitro Fyn knockdown as well as Fyn-/- mice, which were also protected from H2O2- and malaria-induced lung endothelial leak, respectively. Our results demonstrate that CD36 and Fyn kinase are critical mediators of the increased lung endothelial fluid conductance caused by malaria infection.
C1 [Anidi, Ifeanyi U.; Scott, Alan L.] Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD, United States.
C1 [Servinsky, Laura E.; Rentsendorj, Otgonchimeg; Stephens, R. Scott; Pearse, David B.] Johns Hopkins Med Inst, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205, United States.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Medicine
RP Pearse, DB (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA.
EM dpearse@jhmi.edu
FU NIH [HL075236]; Johns Hopkins Malaria Research Institute; Johns Hopkins
   MD/PhD training program [T32 GM007309]; Johns Hopkins University
   Libraries
FX This work was supported by NIH grant HL075236 (DBP), a grant from the
   Johns Hopkins Malaria Research Institute (DBP), a predoctoral fellowship
   from the Johns Hopkins Malaria Research Institute (IUA) and the Johns
   Hopkins MD/PhD training program (T32 GM007309). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Publication of this article was funded in
   part by the Open Access Promotion Fund of the Johns Hopkins University
   Libraries.
CR APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z
   ATAMNA H, 1993, MOL BIOCHEM PARASIT, V61, P231, DOI 10.1016/0166-6851(93)90069-A
   Bolcato-Bellemin AL, 2007, P NATL ACAD SCI USA, V104, P16050, DOI 10.1073/pnas.0707831104
   BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0
   Butzloff S, 2012, CYTOM PART A, V81A, P698, DOI 10.1002/cyto.a.22081
   Cambos M, 2010, INT J PARASITOL, V40, P1003, DOI 10.1016/j.ijpara.2010.02.007
   Chang WL, 2001, INFECT IMMUN, V69, P7341, DOI 10.1128/IAI.69.12.7341-7348.2001
   Cox-Singh J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-10
   Cunha-Rodrigues M, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-32
   Curry FRE, 2010, CARDIOVASC RES, V87, P218, DOI 10.1093/cvr/cvq115
   Davis SP, 2012, FASEB J, V26, P1119, DOI 10.1096/fj.11-196923
   Deroost K, 2013, AM J RESP CELL MOL, V48, P589, DOI 10.1165/rcmb.2012-0450OC
   Dodd-O JM, 2008, AM J PHYSIOL-LUNG C, V294, pL714, DOI 10.1152/ajplung.00185.2007
   Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Filby A, 2007, J IMMUNOL, V179, P4635, DOI 10.4049/jimmunol.179.7.4635
   Fonager J, 2012, J EXP MED, V209, P93, DOI 10.1084/jem.20110762
   Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779
   Franke-Fayard B, 2005, P NATL ACAD SCI USA, V102, P11468, DOI 10.1073/pnas.0503386102
   Gadue P, 1999, J EXP MED, V190, P1189, DOI 10.1084/jem.190.8.1189
   Gamain B, 2007, INT J PARASITOL, V37, P273, DOI 10.1016/j.ijpara.2006.11.011
   Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005
   Gillrie MR, 2007, BLOOD, V110, P3426, DOI 10.1182/blood-2007-04-084582
   Gillrie MR, 2012, AM J PATHOL, V180, P1028, DOI 10.1016/j.ajpath.2011.11.037
   Graewe Stefanie, 2009, Biotechnology Journal, V4, P895, DOI 10.1002/biot.200900035
   Gruring C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1169
   Haldar K, 2007, ANNU REV PATHOL-MECH, V2, P217, DOI 10.1146/annurev.pathol.2.010506.091913
   Han JY, 2011, J PHARMACOL EXP THER, V338, P82, DOI 10.1124/jpet.111.180620
   Hu GC, 2009, MICROVASC RES, V77, P21, DOI 10.1016/j.mvr.2008.10.002
   JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Lovegrove FE, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000068
   Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Mishra Neerad C., 1994, Indian Journal of Malariology, V31, P77
   Mohan Alladi, 2008, Journal of Vector Borne Diseases, V45, P179
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Moldobaeva A, 2005, AM J PHYSIOL-LUNG C, V288, pL1117, DOI 10.1152/ajplung.00370.2004
   MONS B, 1985, PARASITOLOGY, V91, P423, DOI 10.1017/S0031182000062673
   Mota MM, 2000, INFECT IMMUN, V68, P4135, DOI 10.1128/IAI.68.7.4135-4144.2000
   Pearse DB, 2003, ENDOTHELIUM-J ENDOTH, V10, P309, DOI 10.1080/10623320390272307
   Pearse DB, 2001, AM J PHYSIOL-HEART C, V280, pH918, DOI 10.1152/ajpheart.2001.280.2.H918
   Pearse DB, 1996, AM J RESP CRIT CARE, V153, P196, DOI 10.1164/ajrccm.153.1.8542116
   Pino P, 2003, J INFECT DIS, V187, P1283, DOI 10.1086/373992
   Postma NS, 1996, PHARM WORLD SCI, V18, P121, DOI 10.1007/BF00717727
   Qin Y, 2008, CELL BIOL INT, V32, P224, DOI 10.1016/j.cellbi.2007.08.028
   Rentsendorj O, 2008, AM J PHYSIOL-LUNG C, V294, pL686, DOI 10.1152/ajplung.00417.2007
   Rentsendorj O, 2011, AM J PHYSIOL-LUNG C, V301, pL161, DOI 10.1152/ajplung.00073.2011
   SAKURADA H, 1992, ARCH DERMATOL RES, V284, P114, DOI 10.1007/BF00373382
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Schmidt EP, 2008, AM J PHYSIOL-LUNG C, V295, pL1056, DOI 10.1152/ajplung.90329.2008
   Seydel KB, 2006, J INFECT DIS, V194, P208, DOI 10.1086/505078
   Sherman IW, 2003, MICROBES INFECT, V5, P897, DOI 10.1016/S1286-4579(03)00162-X
   Siracusa MC, 2008, J LEUKOCYTE BIOL, V84, P1422, DOI 10.1189/jlb.0308199
   Smith JD, 1998, MOL BIOCHEM PARASIT, V97, P133, DOI 10.1016/S0166-6851(98)00145-5
   Sponaas AM, 2009, BLOOD, V114, P5522, DOI 10.1182/blood-2009-04-217489
   STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y
   Stephens RS, 2010, AM J PHYSIOL-LUNG C, V299, pL323, DOI 10.1152/ajplung.00442.2009
   Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311
   Taylor Walter R J, 2006, Treat Respir Med, V5, P419, DOI 10.2165/00151829-200605060-00007
   van der Heyde HC, 2001, INFECT IMMUN, V69, P3460, DOI 10.1128/IAI.69.5.3460-3465.2001
NR 61
TC 17
Z9 17
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2013
VL 8
IS 8
AR e71010
DI 10.1371/journal.pone.0071010
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 204OU
UT WOS:000323378000027
PM 23967147
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Parikh, SM
AF Parikh, Samir M.
TI Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS
SO VIRULENCE
LA English
DT Review
DE angiopoietin-1/angiopoietin-2; Tie1/Tie2; VE-PTP; VE-cadherin; permeability; vascular leakage; sepsis; infection; ALI/ARDS 
ID RECEPTOR TYROSINE KINASE; ACUTE LUNG INJURY; MULTIPLE ORGAN DYSFUNCTION;
   BLOOD-VESSEL DEVELOPMENT; ACUTE KIDNEY INJURY; SEPTIC SHOCK;
   ENDOTHELIAL-CELLS; VASCULAR LEAKAGE; PLASMA LEAKAGE; TIE2 RECEPTOR
AB Dynamic changes in microvascular endothelial structure and function are pivotal in the acute inflammatory response, the body's rapid, coordinated effort to localize, sequester, and eliminate microbial invaders at their portal of entry. To achieve this, the endothelium becomes leaky and inflamed, providing innate immune cells and humoral effector molecules access to the site of infection. During sepsis this locally adaptive response becomes manifest throughout the body, leading to dangerous host consequences. Increased leakiness in the pulmonary circulation contributes to acute respiratory distress syndrome (ARDS), a complication of sepsis associated with 40% mortality. Understanding the molecular governance of vascular leak and inflammation has major diagnostic, prognostic, and potentially therapeutic implications for this common and pernicious disease. This review summarizes results from cell-based experiments, animal models, and observational human studies; together, these studies suggest that an endothelial receptor called Tie2 and its ligands, called angiopoietins, form a signaling axis key to the vascular dyshomeostasis that underlies sepsis.
C1 [Parikh, Samir M.] Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Div Nephrol, Boston, MA 02215, United States.
C1 [Parikh, Samir M.] Harvard Univ, Sch Med, Boston, MA, United States.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   University; Harvard Medical School
RP Parikh, SM (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Div Nephrol, Boston, MA 02215 USA.
EM sparikh1@bidmc.harvard.edu
RI Parikh, Samir M/HJY-8612-2023
OI Parikh, Samir M/0000-0002-1038-981X
FU NIH [R01-HL093234, R01-DK095072]; American Diabetes Association
   [1-13-BS-141]
FX The author would like to thank Drs Ananth Karumanchi, Sascha David, and
   Chandra Ghosh for critical feedback. Dr Parikh is supported by NIH
   grants R01-HL093234 and R01-DK095072 and by the American Diabetes
   Association (1-13-BS-141).
CR Alves BE, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-143
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005
   BARACOS V, 1983, NEW ENGL J MED, V308, P553, DOI 10.1056/NEJM198303103081002
   Barton WA, 2005, STRUCTURE, V13, P825, DOI 10.1016/j.str.2005.03.009
   Barton WA, 2006, NAT STRUCT MOL BIOL, V13, P524, DOI 10.1038/nsmb1101
   BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103
   David S, 2013, J PHARMACOL EXP THER, V345, P2, DOI 10.1124/jpet.112.201061
   David S, 2012, CRIT CARE MED, V40, P3034, DOI 10.1097/CCM.0b013e31825fdc31
   David S, 2011, AM J PHYSIOL-LUNG C, V300, pL851, DOI 10.1152/ajplung.00459.2010
   David S, 2010, CRIT CARE, V14, DOI 10.1186/cc9090
   Davis JS, 2010, CRIT CARE, V14, DOI 10.1186/cc9020
   Diamond JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051932
   DUMONT DJ, 1992, ONCOGENE, V7, P1471
   DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897
   Ebihara I, 2009, THER APHER DIAL, V13, P520, DOI 10.1111/j.1744-9987.2009.00777.x
   ESKANDARI MK, 1992, J IMMUNOL, V148, P2724
   Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603
   Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Gallagher DC, 2007, CLIN CANCER RES, V13, P2115, DOI 10.1158/1078-0432.CCR-06-2509
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Ghosh CC, 2012, P NATL ACAD SCI USA, V109, P10024, DOI 10.1073/pnas.1120755109
   Giamarellos-Bourboulis EJ, 2008, CYTOKINE, V44, P310, DOI 10.1016/j.cyto.2008.09.003
   Giuliano JS, 2007, SHOCK, V28, P650, DOI 10.1097/shk.0b013e318123867b
   HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503
   Jeansson M, 2011, J CLIN INVEST, V121, P2278, DOI 10.1172/JCI46322
   Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3
   Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200
   Kumpers P, 2011, CRIT CARE, V15, DOI 10.1186/cc10523
   Kumpers P, 2010, INTENS CARE MED, V36, P462, DOI 10.1007/s00134-009-1726-7
   Kumpers P, 2008, CRIT CARE, V12, DOI 10.1186/cc7130
   Kumpers P, 2009, CRIT CARE, V13, DOI 10.1186/cc7866
   Kurniati NF, 2013, NEPHROL DIAL TRANSPL, V28, P567, DOI 10.1093/ndt/gfs336
   Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740
   Lovegrove FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004912
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Mankhambo LA, 2010, CRIT CARE, V14, DOI 10.1186/cc9025
   Marshall JC, 2005, SHOCK, V24, P1, DOI 10.1097/01.shk.0000191383.34066.4b
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Meyer NJ, 2011, AM J RESP CRIT CARE, V183, P1344, DOI 10.1164/rccm.201005-0701OC
   Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Page AV, 2011, CLIN INFECT DIS, V52, pE157, DOI 10.1093/cid/cir125
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Ricciuto DR, 2011, CRIT CARE MED, V39, P702, DOI 10.1097/CCM.0b013e318206d285
   Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715
   SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355
   Seegar TCM, 2010, MOL CELL, V37, P643, DOI 10.1016/j.molcel.2010.02.007
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Siner JM, 2009, SHOCK, V31, P348, DOI 10.1097/SHK.0b013e318188bd06
   Su L, 2009, INTENS CARE MED, V35, P1024, DOI 10.1007/s00134-009-1413-8
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Tabruyn SP, 2010, AM J PATHOL, V177, P3233, DOI 10.2353/ajpath.2010.100059
   Tadros A, 2003, BLOOD, V102, P4407, DOI 10.1182/blood-2003-05-1602
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tracey K J, 1988, Prog Clin Biol Res, V272, P77
   TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0
   Tzepi IM, 2012, J PHARMACOL EXP THER, V343, P278, DOI 10.1124/jpet.112.195180
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   van der Heijden M, 2009, INTENS CARE MED, V35, P1567, DOI 10.1007/s00134-009-1560-y
   Van Slyke P, 2009, TISSUE ENG PT A, V15, P1269, DOI 10.1089/ten.tea.2007.0400
   Whitcomb DC, 2010, AM J GASTROENTEROL, V105, P2287, DOI 10.1038/ajg.2010.183
   Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159
   Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E
   Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567
   Yamakawa D, 2013, J BIOL CHEM, V288, P12469, DOI 10.1074/jbc.M112.433979
   Yeo TW, 2008, P NATL ACAD SCI USA, V105, P17097, DOI 10.1073/pnas.0805782105
   Yuan HT, 2007, FASEB J, V21, P3171, DOI 10.1096/fj.07-8487com
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
   Zhang JH, 2011, J BIOL CHEM, V286, P8055, DOI 10.1074/jbc.M110.192641
NR 85
TC 64
Z9 66
U1 2
U2 15
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2150-5594
EI 2150-5608
J9 VIRULENCE
JI Virulence
PD AUG 15
PY 2013
VL 4
IS 6
BP 517
EP 524
DI 10.4161/viru.24906
PG 8
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA 277IP
UT WOS:000328812500016
PM 23652985
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Menendez, C
   Martinez-Caro, L
   Moreno, L
   Nin, N
   Moral-Sanz, J
   Morales, D
   Cogolludo, A
   Esteban, A
   Lorente, JA
   Perez-Vizcaino, F
AF Menendez, Carmen
   Martinez-Caro, Leticia
   Moreno, Laura
   Nin, Nicolas
   Moral-Sanz, Javier
   Morales, Daniel
   Cogolludo, Angel
   Esteban, Andres
   Lorente, Jose Angel
   Perez-Vizcaino, Francisco
TI Pulmonary Vascular Dysfunction Induced by High Tidal Volume Mechanical
   Ventilation
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE endothelial dysfunction; hypoxic pulmonary vasoconstriction; mechanical ventilation; pulmonary artery; ventilator-induced lung injury 
ID INDUCED LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; ADP-RIBOSE
   POLYMERASE; NEUTRAL SPHINGOMYELINASE; ENDOTOXIN; VASOCONSTRICTION;
   MODEL; SEPSIS; HYPORESPONSIVENESS; INHIBITORS
AB Objectives: Acute lung injury and acute respiratory distress syndrome are characterized by increased pulmonary artery pressure and ventilation-perfusion mismatch. We analyzed the changes in the pulmonary vascular function in a model of ventilator-induced acute lung injury.
   Design: Controlled in vivo laboratory study.
   Setting: Animal research laboratory.
   Subjects: Anesthetized male Sprague-Dawley rats.
   Interventions: Rats were ventilated for 120 minutes using low tidal volume ventilation (control group, tidal volume 9mL/kg, positive end-expiratory pressure 5cm H2O, n = 15), high tidal volume ventilation (high tidal volume group, tidal volume 25mL/kg, zero positive end-expiratory pressure, n = 14), or high tidal volume ventilation plus the poly-(adenosine diphosphate-ribose) polymerase inhibitor 3-aminobenzamide (10mg/kg IP, high tidal volume group + 3-aminobenzamide group, n = 7). Vascular rings from small pulmonary arteries were mounted in a myograph for isometric tension recording. Lung messenger RNA and protein expression were analyzed by reverse transcriptase-polymerase chain reaction and Western blot, respectively.
   Measurements and Main Results: High tidal volume ventilation impaired phenylephrine- and acetylcholine-induced responses in pulmonary arteries in vitro, which were accompanied by induction of inducible nitric oxide synthase messenger RNA and protein. These effects, as well as hypoxemia and hypotension, were prevented by 3-aminobenzamide. Hypoxic pulmonary vasoconstriction and responses to exogenous sphingomyelinase were increased, whereas the responses to serotonin, K-v current density, and inhibition of K-v currents by hypoxia were unaffected by high tidal volume.
   Conclusions: High tidal volume ventilation-induced pulmonary vascular dysfunction was characterized by reduced alpha-adrenergic-induced vasoconstriction, reduced endothelium-dependent vasodilatation, and enhanced hypoxic pulmonary vasoconstriction. (Crit Care Med 2013; 41:e149-e155)
C1 [Menendez, Carmen; Moreno, Laura; Moral-Sanz, Javier; Morales, Daniel; Cogolludo, Angel; Perez-Vizcaino, Francisco] Univ Complutense Madrid, Fac Med, Dept Farmacol, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, E-28040 Madrid, Spain.
C1 [Menendez, Carmen; Martinez-Caro, Leticia; Moreno, Laura; Nin, Nicolas; Moral-Sanz, Javier; Morales, Daniel; Cogolludo, Angel; Esteban, Andres; Lorente, Jose A.; Perez-Vizcaino, Francisco] Ciber Enfermedades Resp CIBERES, Madrid, Spain.
C1 [Martinez-Caro, Leticia; Nin, Nicolas; Esteban, Andres; Lorente, Jose A.] Hosp Univ Getafe, Dept Crit Care, Madrid, Spain.
C3 Complutense University of Madrid; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERES; Hospital Universitario de Getafe
RP Perez-Vizcaino, F (corresponding author), Univ Complutense Madrid, Fac Med, Dept Farmacol, E-28040 Madrid, Spain.
EM fperez@med.ucm.es
RI Cano, Daniel Morales/A-3550-2017; Perez-Vizcaino, Francisco/A-9735-2011;
   Moreno, Laura/A-9433-2010; Nin, Nicolas/X-4938-2019; Martinez-Caro,
   Leticia/AAD-9010-2019; Moral-Sanz, Javier/AAB-1371-2019; Cogolludo,
   Angel/A-6129-2011
OI Cano, Daniel Morales/0000-0002-1692-4633; Perez-Vizcaino,
   Francisco/0000-0001-6309-7418; Moreno, Laura/0000-0001-9028-2299;
   Moral-Sanz, Javier/0000-0001-8602-8554; Cogolludo,
   Angel/0000-0002-1382-1698; NIN, NICOLAS/0000-0001-6037-2357;
   Martinez-Caro, Leticia/0000-0003-3486-4678
FU Ministerio de Ciencia e Innovacion [SAF2008-03948, SAF 2011-28150,
   SAF2010-22066-C02-02]; Insituto de Salud Carlos III [PS09/02644];
   Ministerio de Educacion; Mutua Madrilena [AP/67842009]; European Union
   [AOR PERG05-GA-2009-249165]; Fundacion Lilly; Ministry of Science and
   Health
FX Supported, in part, by Ministerio de Ciencia e Innovacion (grants
   SAF2008-03948 and SAF 2011-28150 to Dr. Perez-Vizcaino,
   SAF2010-22066-C02-02 to Dr. Cogolludo, Juan de la Cierva contract to Dr.
   Moreno, and predoctoral FPI grant to Dr. Menendez), Insituto de Salud
   Carlos III (PS09/02644), Ministerio de Educacion (predoctoral FPU grant
   to Dr. Moral-Sanz), and Mutua Madrilena (AP/67842009), European Union
   FP7-PEOPLE (AOR PERG05-GA-2009-249165) to Drs. Perez-Vizcaino and
   Moreno, and Fundacion Lilly to Dr. Esteban.; Drs. Menendez, Vizcaino,
   Moreno, Moral-Sanz, Morales, and Cogolludo received grant support from
   the Ministry of Science and Health. Drs. Martinez-Caro, Nin, Esteban,
   and Lorente received grant support from the Instituto de Salud Carlos
   III. Dr. Vizcaino is a board member with the Agency for Quality of
   Universitites, Castilla y Leon.
CR Caironi P, 2005, AM J RESP CRIT CARE, V172, P334, DOI 10.1164/rccm.200501-034OC
   Chauhan SD, 2003, FASEB J, V17, P773, DOI 10.1096/fj.02-0668fje
   CHEN TY, 1993, J APPL PHYSIOL, V74, P423, DOI 10.1152/jappl.1993.74.1.423
   CHRISTMAN BW, 1990, AM REV RESPIR DIS, V142, P1272, DOI 10.1164/ajrccm/142.6_Pt_1.1272
   Cogolludo A, 2006, CIRC RES, V98, P931, DOI 10.1161/01.RES.0000216858.04599.e1
   Cogolludo A, 2009, CARDIOVASC RES, V82, P296, DOI 10.1093/cvr/cvn349
   Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P73, DOI 10.1124/jpet.106.108100
   Finigan JH, 2009, AM J PHYSIOL-LUNG C, V296, pL1002, DOI 10.1152/ajplung.90555.2008
   FOX GA, 1994, AM J PHYSIOL-HEART C, V267, pH1377, DOI 10.1152/ajpheart.1994.267.4.H1377
   Frank DU, 1996, J APPL PHYSIOL, V81, P1316, DOI 10.1152/jappl.1996.81.3.1316
   Frank JA, 2003, CRIT CARE, V7, P233, DOI 10.1186/cc1829
   Frazziano G, 2011, J CELL PHYSIOL, V226, P2633, DOI 10.1002/jcp.22611
   FULLERTON DA, 1995, AM J PHYSIOL-LUNG C, V268, pL1029, DOI 10.1152/ajplung.1995.268.6.L1029
   GREENFIELD LJ, 1964, ANESTHESIOLOGY, V25, P312, DOI 10.1097/00000542-196405000-00009
   Griffiths MJD, 1997, AM J RESP CRIT CARE, V156, P654, DOI 10.1164/ajrccm.156.2.9606110
   HAUSCHILDT S, 1991, BIOCHEM BIOPH RES CO, V179, P865, DOI 10.1016/0006-291X(91)91898-M
   Kapetanakis T, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-8
   Kiefmann R, 2004, INTENS CARE MED, V30, P1421, DOI 10.1007/s00134-004-2301-x
   Kim JH, 2008, CRIT CARE, V12, DOI 10.1186/cc6995
   Liu R, 2007, AM J PHYSIOL-LUNG C, V293, pL1300, DOI 10.1152/ajplung.00396.2006
   LIU SF, 1992, J APPL PHYSIOL, V72, P1044, DOI 10.1152/jappl.1992.72.3.1044
   Martinez-Caro L, 2009, INTENS CARE MED, V35, P1110, DOI 10.1007/s00134-009-1469-5
   Nin N, 2005, J TRAUMA, V59, P711, DOI 10.1097/01.ta.0000177753.77471.46
   Nin N, 2008, INTENS CARE MED, V34, P948, DOI 10.1007/s00134-007-0959-6
   Nin N, 2011, SHOCK, V36, P156, DOI 10.1097/SHK.0b013e31821e50de
   PerezVizcaino F, 1996, J VASC RES, V33, P249, DOI 10.1159/000159152
   Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54
   Sheridan BC, 1999, AM J PHYSIOL-LUNG C, V277, pL861, DOI 10.1152/ajplung.1999.277.5.L861
   Suchner U, 2001, CRIT CARE MED, V29, P1569, DOI 10.1097/00003246-200108000-00012
   Vaschetto R, 2010, CRIT CARE, V14, DOI 10.1186/cc8932
   VILLAMOR E, 1995, BRIT J PHARMACOL, V115, P261, DOI 10.1111/j.1476-5381.1995.tb15872.x
   Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375
   Ward JPT, 2009, CURR OPIN PHARMACOL, V9, P287, DOI 10.1016/j.coph.2009.02.006
   WEIR EK, 1976, J LAB CLIN MED, V88, P975
   ZAPOL WM, 1977, NEW ENGL J MED, V296, P476, DOI 10.1056/NEJM197703032960903
   ZELENKOV P, 1993, AM J PHYSIOL, V265, pL346, DOI 10.1152/ajplung.1993.265.4.L346
NR 36
TC 25
Z9 25
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2013
VL 41
IS 8
BP E149
EP E155
DI 10.1097/CCM.0b013e318287ef4a
PG 7
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 235FH
UT WOS:000325701500002
PM 23514752
DA 2023-08-21
ER

PT J
AU Schmidt, TT
   Tauseef, M
   Yue, LL
   Bonini, MG
   Gothert, J
   Shen, TL
   Guan, JL
   Predescu, S
   Sadikot, R
   Mehta, D
AF Schmidt, Tracy Thennes
   Tauseef, Mohammad
   Yue, Lili
   Bonini, Marcelo G.
   Gothert, Joachim
   Shen, Tang-Long
   Guan, Jun-Lin
   Predescu, Sanda A.
   Sadikot, Ruxana
   Mehta, Dolly
TI Conditional deletion of FAK in mice endothelium disrupts lung vascular
   barrier function due to destabilization of RhoA and Rac1 activities
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE Focal adhesion kinase (FAK); adhesion junction; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs 
ID FOCAL ADHESION KINASE; JUNCTION PROTEINS; PDZ-RHOGEF; IN-VIVO;
   PERMEABILITY; CELLS; ACTIVATION; ADHERENS; PHOSPHORYLATION; P190RHOGAP
AB Loss of lung-fluid homeostasis is the hallmark of acute lung injury (ALI). Association of catenins and actin cytoskeleton with vascular endothelial (VE)-cadherin is generally considered the main mechanism for stabilizing adherens junctions (AJs), thereby preventing disruption of lung vascular barrier function. The present study identifies endothelial focal adhesion kinase (FAK), a nonreceptor tyrosine kinase that canonically regulates focal adhesion turnover, as a novel AJ-stabilizing mechanism. In wild-type mice, induction of ALI by intraperitoneal administration of lipopolysaccharide or cecal ligation and puncture markedly decreased FAK expression in lungs. Using a mouse model in which FAK was conditionally deleted only in endothelial cells (ECs), we show that loss of EC-FAK mimicked key features of ALI (diffuse lung hemorrhage, increased transvascular albumin influx, edema, and neutrophil accumulation in the lung). EC-FAK deletion disrupted AJs due to impairment of the fine balance between the activities of RhoA and Rac1 GTPases. Deletion of EC-FAK facilitated RhoA's interaction with p115-RhoA guanine exchange factor, leading to activation of RhoA. Activated RhoA antagonized Rac1 activity, destabilizing AJs. Inhibition of Rho kinase, a downstream effector of RhoA, reinstated normal endothelial barrier function in FAK(-/-) ECs and lung vascular integrity in EC-FAK(-/-) mice. Our findings demonstrate that EC-FAK plays an essential role in maintaining AJs and thereby lung vascular barrier function by establishing the normal balance between RhoA and Rac1 activities.
C1 [Schmidt, Tracy Thennes; Tauseef, Mohammad; Yue, Lili; Bonini, Marcelo G.; Mehta, Dolly] Univ Illinois, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Schmidt, Tracy Thennes; Tauseef, Mohammad; Yue, Lili; Mehta, Dolly] Univ Illinois, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C1 [Bonini, Marcelo G.] Univ Illinois, Cardiol Sect, Chicago, IL 60612, United States.
C1 [Gothert, Joachim] Univ Hosp Essen, Dept Hematol, Essen, Germany.
C1 [Shen, Tang-Long; Guan, Jun-Lin] Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI, United States.
C1 [Predescu, Sanda] Rush Univ, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Sadikot, Ruxana] Univ Illinois, Jesse Brown Vet Affairs Hosp, Sect Pulm Crit Care & Sleep Med, Chicago, IL 60612, United States.
C1 [Sadikot, Ruxana] Univ Illinois, Jesse Brown Vet Affairs Hosp, Dept Vet Affairs, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Duisburg Essen;
   University of Michigan System; University of Michigan; Rush University;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical
   Center; University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical
   Center
RP Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.
EM dmehta@uic.edu
OI Shen, Tang-Long/0000-0001-6264-3608; Tauseef,
   Mohammad/0000-0001-5317-4379; Gothert, Joachim/0000-0001-8957-6732;
   Predescu, Sanda/0000-0002-9386-6756
FU National Heart, Lung, and Blood Institute [HL-71794, HL-84153,
   HL-060678]; American Heart Association [10PRE2610268];  [HL-007829]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants HL-71794, HL-84153, and HL-060678. T. Thennes was supported by
   HL-007829 and by an American Heart Association predoctoral fellowship
   (10PRE2610268).
CR Bachmaier K, 2007, NAT MED, V13, P920, DOI 10.1038/nm1607
   Birukov KG, 2009, MICROVASC RES, V77, P46, DOI 10.1016/j.mvr.2008.09.006
   Braren R, 2006, J CELL BIOL, V172, P151, DOI 10.1083/jcb.200506184
   Carbajal JM, 1999, AM J PHYSIOL-CELL PH, V277, pC955, DOI 10.1152/ajpcell.1999.277.5.C955
   Chan KT, J BIOL CHEM, V285, P11418
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012
   Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200
   Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867
   Gothert JR, 2004, BLOOD, V104, P1769, DOI 10.1182/blood-2003-11-3952
   Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112
   He DH, 2009, J BIOL CHEM, V284, P24123, DOI 10.1074/jbc.M109.007393
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579
   Manchinelly SA, J BIOL CHEM, V285, P26923
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200
   Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437
   Quadri SK, 2007, AM J PHYSIOL-LUNG C, V292, pL334, DOI 10.1152/ajplung.00228.2006
   Quadri SK, 2003, J BIOL CHEM, V278, P13342, DOI 10.1074/jbc.M209922200
   Rajput C, 2013, J BIOL CHEM, V288, P4241, DOI 10.1074/jbc.M112.440396
   Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003
   Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155
   Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com
   Shiratsuchi H, 2004, AM J PHYSIOL-CELL PH, V286, pC1358, DOI 10.1152/ajpcell.00553.2003
   Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007
   Su L, 2009, EXP CELL RES, V315, P1347, DOI 10.1016/j.yexcr.2009.02.014
   Sun XG, 2009, MICROVASC RES, V77, P304, DOI 10.1016/j.mvr.2008.12.004
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Tang PS, 2006, J CELL PHYSIOL, V209, P457, DOI 10.1002/jcp.20751
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Thennes T, 2012, MICROVASC RES, V83, P31, DOI 10.1016/j.mvr.2011.05.004
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200
   VANDENBROUCKE ST, 2012, CIRC RES, V111, P739, DOI DOI 10.1161/CIRCRESAHA.112.269654
   Waschke J, 2004, AM J PHYSIOL-HEART C, V286, pH394, DOI 10.1152/ajpheart.00221.2003
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Wu MH, 2003, J PHYSIOL-LONDON, V552, P691, DOI 10.1113/jphysiol.2003.048405
NR 46
TC 40
Z9 41
U1 1
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG
PY 2013
VL 305
IS 4
BP L291
EP L300
DI 10.1152/ajplung.00094.2013
PG 10
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 205DX
UT WOS:000323423100003
PM 23771883
OA Green Published
DA 2023-08-21
ER

PT J
AU Van Ness, M
   Jensen, H
   Adamson, GN
   Kysar, PE
   Holland, P
AF Van Ness, Michael
   Jensen, Hanne
   Adamson, Grete N.
   Kysar, Patricia E.
   Holland, Paul
TI Neutrophils Contain Cholesterol Crystals in Transfusion-Related Acute
   Lung Injury (TRALI)
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE transfusion; Technique; pulmonary; Basic science 
ID BIOLOGICAL-MEMBRANES; CRYSTALLIZATION; LEUKOCYTES; PATHOLOGY; GRANULES;
   ANTIBODY; DAMAGE
AB Objectives: Intracellular components of transfusion-related acute lung injury (TRALI) were investigated by transmission electron microscopy. Methods: The lungs from 2 fatal TRALI cases and 2 controls, previously studied by scanning electron microscopy, were studied by transmission electron microscopy. Morphologic data by light and phase microscopy, along with scanning and transmission electron microscopic observations, were collated. Results: The 2 fatal TRALI cases exhibited dense laminated material within capillaries and postcapillary venules, similar to material identified within their neutrophils when viewed by transmission electron microscopy. This material polarized light and is presumed to be cholesterol crystals. Conclusions: The damage to the pulmonary vascular endothelium in TRALI is related to formation of cholesterol crystals originating within neutrophils.
C1 [Van Ness, Michael; Jensen, Hanne; Adamson, Grete N. N.; Kysar, Patricia E. E.; Holland, Paul] Univ Calif Davis Hlth Syst, Dept Pathol & Lab Med, Sacramento, CA, United States.
C1 [Jensen, Hanne] Univ Calif Davis, Med Ctr, Dept Pathol, 4400 5 St, Sacramento, CA 95817, United States.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis
RP Jensen, H (corresponding author), Univ Calif Davis, Med Ctr, Dept Pathol, 4400 5 St, Sacramento, CA 95817 USA.
FU Department of Pathology and Laboratory Medicine, University of
   California, Davis Medical Center, Sacramento, California
FX This work was supported by a grant from the Department of Pathology and
   Laboratory Medicine, University of California, Davis Medical Center,
   Sacramento, California. Transmission electron microscopy was done in the
   Electron Microscopy Core Laboratory of the Department of Pathology and
   Laboratory Medicine at the University of California at Davis.
CR Abela GS, 2006, SCANNING, V28, P1, DOI 10.1002/sca.4950280101
   BAINTON DF, 1966, J CELL BIOL, V28, P277, DOI 10.1083/jcb.28.2.277
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Bux J, 2011, VOX SANG, V100, P122, DOI 10.1111/j.1423-0410.2010.01392.x
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   CHUNG DS, 1993, P NATL ACAD SCI USA, V90, P11341, DOI 10.1073/pnas.90.23.11341
   Danielson C, 2008, TRANSFUSION, V48, P2401, DOI 10.1111/j.1537-2995.2008.01879.x
   Dry SM, 1999, AM J CLIN PATHOL, V112, P216
   FEIN A, 1979, AM J MED, V67, P32, DOI 10.1016/0002-9343(79)90066-4
   Gadeela N, 2011, JACC-CARDIOVASC INTE, V4, P521, DOI 10.1016/j.jcin.2011.02.010
   GEBB SA, 1995, J APPL PHYSIOL, V79, P493, DOI 10.1152/jappl.1995.79.2.493
   Guichard C, 2005, J BIOL CHEM, V280, P37021, DOI 10.1074/jbc.M506594200
   Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004
   Jensen HM, 2010, VOX SANG, V98, P130, DOI 10.1111/j.1423-0410.2009.01235.x
   Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891, DOI 10.1161/01.ATV.19.8.1891
   KONIKOFF FM, 1992, J CLIN INVEST, V90, P1155, DOI 10.1172/JCI115935
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Looney MR, 2004, CHEST, V126, P249, DOI 10.1378/chest.126.1.249
   Mason RP, 2003, BBA-BIOMEMBRANES, V1610, P198, DOI 10.1016/S0005-2736(03)00018-X
   Nakagawa M, 2004, TRANSFUSION, V44, P1689, DOI 10.1111/j.0041-1132.2004.04194.x
   POPOVSKY MA, 1983, AM REV RESPIR DIS, V128, P185, DOI 10.1164/arrd.1983.128.1.185
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Reesink HW, 2012, VOX SANG, V103, P231, DOI 10.1111/j.1423-0410.2012.01596.x
   Sachs UJ, 2011, CURR OPIN HEMATOL, V18, P436, DOI 10.1097/MOH.0b013e32834bab01
   Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929
   SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684
   Takahashi D, 2010, VOX SANG, V98, P560, DOI 10.1111/j.1423-0410.2010.01311.x
   Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51
   Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932
   Venneman NG, 2010, GASTROENTEROL CLIN N, V39, P171, DOI 10.1016/j.gtc.2010.02.010
   WARREN BA, 1976, BRIT J EXP PATHOL, V57, P67
   Wiersum-Osselton JC, 2011, TRANSFUSION, V51, P1278, DOI 10.1111/j.1537-2995.2010.02969.x
   Ziblat R, 2010, J AM CHEM SOC, V132, P9920, DOI 10.1021/ja103975g
NR 35
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD AUG 1
PY 2013
VL 140
IS 2
BP 170
EP 176
DI 10.1309/AJCPGKOJV15AVZNT
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA VL8QO
UT WOS:000919509000005
OA Bronze
DA 2023-08-21
ER

PT J
AU Van Ness, M
   Jensen, H
   Adamson, GN
   Kysar, PE
   Holland, P
AF Van Ness, Michael
   Jensen, Hanne
   Adamson, Grete N.
   Kysar, Patricia E.
   Holland, Paul
TI Neutrophils Contain Cholesterol Crystals in Transfusion-Related Acute
   Lung Injury (TRALI)
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE transfusion; Technique; pulmonary; Basic science 
ID BIOLOGICAL-MEMBRANES; CRYSTALLIZATION; PATHOGENESIS; LEUKOCYTES;
   PATHOLOGY; GRANULES; ANTIBODY; DAMAGE
AB Objectives: Intracellular components of transfusion-related acute lung injury (TRALI) were investigated by transmission electron microscopy.
   Methods: The lungs from 2 fatal TRALI cases and 2 controls, previously studied by scanning electron microscopy, were studied by transmission electron microscopy. Morphologic data by light and phase microscopy, along with scanning and transmission electron microscopic observations, were collated.
   Results: The 2 fatal TRALI cases exhibited dense laminated material within capillaries and postcapillary venules, similar to material identified within their neutrophils when viewed by transmission electron microscopy. This material polarized light and is presumed to be cholesterol crystals.
   Conclusions: The damage to the pulmonary vascular endothelium in TRALI is related to formation of cholesterol crystals originating within neutrophils.
C1 [Van Ness, Michael; Jensen, Hanne; Adamson, Grete N.; Kysar, Patricia E.; Holland, Paul] Univ Calif Davis Hlth Syst, Dept Pathol & Lab Med, Sacramento, CA, United States.
C3 University of California System; University of California Davis
RP Jensen, H (corresponding author), UC Davis Med Ctr, Dept Pathol, 4400 V St, Sacramento, CA 95817 USA.
FU Department of Pathology and Laboratory Medicine, University of
   California, Davis Medical Center, Sacramento, California
FX This work was supported by a grant from the Department of Pathology and
   Laboratory Medicine, University of California, Davis Medical Center,
   Sacramento, California. Transmission electron microscopy was done in the
   Electron Microscopy Core Laboratory of the Department of Pathology and
   Laboratory Medicine at the University of California at Davis.
CR Abela GS, 2006, SCANNING, V28, P1, DOI 10.1002/sca.4950280101
   BAINTON DF, 1966, J CELL BIOL, V28, P277, DOI 10.1083/jcb.28.2.277
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Bux J, 2011, VOX SANG, V100, P122, DOI 10.1111/j.1423-0410.2010.01392.x
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   CHUNG DS, 1993, P NATL ACAD SCI USA, V90, P11341, DOI 10.1073/pnas.90.23.11341
   Danielson C, 2008, TRANSFUSION, V48, P2401, DOI 10.1111/j.1537-2995.2008.01879.x
   Dry SM, 1999, AM J CLIN PATHOL, V112, P216
   FEIN A, 1979, AM J MED, V67, P32, DOI 10.1016/0002-9343(79)90066-4
   Gadeela N, 2011, JACC-CARDIOVASC INTE, V4, P521, DOI 10.1016/j.jcin.2011.02.010
   GEBB SA, 1995, J APPL PHYSIOL, V79, P493, DOI 10.1152/jappl.1995.79.2.493
   Guichard C, 2005, J BIOL CHEM, V280, P37021, DOI 10.1074/jbc.M506594200
   Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004
   Jensen HM, 2010, VOX SANG, V98, P130, DOI 10.1111/j.1423-0410.2009.01235.x
   Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891, DOI 10.1161/01.ATV.19.8.1891
   KONIKOFF FM, 1992, J CLIN INVEST, V90, P1155, DOI 10.1172/JCI115935
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Looney MR, 2004, CHEST, V126, P249, DOI 10.1378/chest.126.1.249
   Mason RP, 2003, BBA-BIOMEMBRANES, V1610, P198, DOI 10.1016/S0005-2736(03)00018-X
   Nakagawa M, 2004, TRANSFUSION, V44, P1689, DOI 10.1111/j.0041-1132.2004.04194.x
   POPOVSKY MA, 1983, AM REV RESPIR DIS, V128, P185, DOI 10.1164/arrd.1983.128.1.185
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Reesink HW, 2012, VOX SANG, V103, P231, DOI 10.1111/j.1423-0410.2012.01596.x
   Sachs UJ, 2011, CURR OPIN HEMATOL, V18, P436, DOI 10.1097/MOH.0b013e32834bab01
   Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929
   SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684
   Takahashi D, 2010, VOX SANG, V98, P560, DOI 10.1111/j.1423-0410.2010.01311.x
   Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51
   Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932
   Venneman NG, 2010, GASTROENTEROL CLIN N, V39, P171, DOI 10.1016/j.gtc.2010.02.010
   WARREN BA, 1976, BRIT J EXP PATHOL, V57, P67
   Wiersum-Osselton JC, 2011, TRANSFUSION, V51, P1278, DOI 10.1111/j.1537-2995.2010.02969.x
   Ziblat R, 2010, J AM CHEM SOC, V132, P9920, DOI 10.1021/ja103975g
NR 35
TC 3
Z9 3
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD AUG
PY 2013
VL 140
IS 2
BP 170
EP 176
DI 10.1309/AJCPGKOJV15AVZNT
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 187VM
UT WOS:000322149600006
OA Bronze
DA 2023-08-21
ER

PT J
AU Adyshev, DM
   Moldobaeva, N
   Mapes, B
   Elangovan, V
   Garcia, JGN
AF Adyshev, Djanybek M.
   Moldobaeva, Nurgul
   Mapes, Brandon
   Elangovan, Venkate
   Garcia, Joe G. N.
TI MicroRNA Regulation of Nonmuscle Myosin Light Chain Kinase Expression in
   Human Lung Endothelium
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE miRNA; MLCK; ALI/ARDS; ventilator-induced lung injury; ECs/HPMECs/HUVECs/MPVECs 
ID TRANSCRIPTION FACTORS; TARGET; PROTEINS; DEADENYLATION; INFLAMMATION;
   SPECIFICITY; INVOLVEMENT; ACTIVATION; INDUCTION; NETWORK
AB Increased lung vascular permeability, the consequence of endothelial cell (EC) barrier dysfunction, is a cardinal feature of inflammatory conditions such as acute lung injury and sepsis and leads to lethal physiological dysfunction characterized by alveolar flooding, hypoxemia, and pulmonary edema. We previously demonstrated that the nonmuscle myosin light chain kinase isoform (nmMLCK) plays a key role in agonist-induced pulmonary EC barrier regulation. The present study evaluated posttranscriptional regulation of MYLK expression, the gene encoding nmMLCK, via 39 untranslated region (UTR) binding by microRNAs (miRNAs) with in silico analysis identifying hsa-miR-374a, hsa-miR-374b, hsa-miR-520c-3p, and hsa-miR-1290 as miRNA candidates. We identified increased MYLK gene transcription induced by TNF-alpha (24 h; 4.7 +/- 6 0.45 fold increase [FI]), LPS (4 h; 2.85 +/- 0.15 [FI]), and 18% cyclic stretch (24 h; 4.6 +/- 0.24 FI) that was attenuated by transfection of human lung ECs with mimics of hsa-miR-374a, hsa-miR-374b, hsa-miR-520c-3p, or hsa-miR-1290 (20-80% reductions by each miRNA). TNF-alpha, LPS, and 18% cyclic stretch each increased the activity of a MYLK 3'UTR luciferase reporter (2.5-7.0 FI) with induction reduced by mimics of each miRNA (30-60% reduction). MiRNA inhibitors (antagomirs) for each MYLK miRNA significantly increased 3'UTR luciferase activity (1.2-2.3 FI) and rescued the decreased MLCK-3'UTR reporter activity produced by miRNA mimics (70-110% increases for each miRNA; P < 0.05). These data demonstrate that increased human lung EC expression of MYLK by bioactive agonists (excessive mechanical stress, LPS, TNF-alpha) is regulated in part by specific miRNAs (hsa-miR-374a, hsa-miR-374b, hsa-miR-520c-3p, and hsa-miR-1290), representing a novel therapeutic strategy for reducing inflammatory lung injury.
C1 [Adyshev, Djanybek M.; Moldobaeva, Nurgul; Mapes, Brandon; Elangovan, Venkate; Garcia, Joe G. N.] Univ Illinois, Inst Personalized Resp Med, Dept Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Garcia, JGN (corresponding author), Univ Illinois, Inst Personalized Resp Med, COMRB 3143,MC 719,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM jggarcia@uic.edu
RI Garcia, Joe GN/E-8862-2010; RamamoorthiElangovan,
   Venkateswaran/O-5533-2017
OI Mapes, Brandon/0000-0001-8495-3439
FU National Institutes of Health Heart, Lung, and Blood Institute [P01
   HL58064, P01 HL98050, R01 HL91889]
FX This work was supported by National Institutes of Health Heart, Lung,
   and Blood Institute grants P01 HL58064, P01 HL98050, and R01 HL91889.
CR Adyshev DM, 2011, CELL SIGNAL, V23, P2086, DOI 10.1016/j.cellsig.2011.08.003
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Cai ZG, 2012, CAN J PHYSIOL PHARM, V90, P37, DOI [10.1139/Y11-095, 10.1139/y11-095]
   Courboulin A, 2011, J EXP MED, V208, P535, DOI 10.1084/jem.20101812
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Flores C, 2006, SEM RESP CRIT CARE M, V27, P389, DOI 10.1055/s-2006-948292
   Friedman JM, 2009, SWISS MED WKLY, V139, P466, DOI smw-12794
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817
   Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829
   Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025
   Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689
   Greene CM, 2008, EXPERT OPIN THER TAR, V12, P1481, DOI 10.1517/14728220802515293 
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu Z, 2013, J GASTROENTEROL, V48, P86, DOI 10.1007/s00535-012-0609-9
   Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240
   Murphy AJ, 2010, J IMMUNOL, V184, P5029, DOI 10.4049/jimmunol.0903463
   Nielsen JA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-98
   O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shalgi R, 2007, PLOS COMPUT BIOL, V3, P1291, DOI 10.1371/journal.pcbi.0030131
   Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828
   Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Tomankova T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-159
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Tu K, 2009, NUCLEIC ACIDS RES, V37, P5969, DOI 10.1093/nar/gkp638
   Usatyuk PV, 2012, J BIOL CHEM, V287, P9360, DOI 10.1074/jbc.M111.294546
   van Rooij E, 2012, CIRC RES, V110, P496, DOI 10.1161/CIRCRESAHA.111.247916
   Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408
   Witkos TM, 2011, CURR MOL MED, V11, P93
   Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103
   Yang SZ, 2012, AM J PATHOL, V180, P484, DOI 10.1016/j.ajpath.2011.10.005
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Zampetaki A, 2012, CIRC RES, V110, P508, DOI 10.1161/CIRCRESAHA.111.247445
   Zhang R, 2008, NUCLEIC ACIDS RES, V36, P4621, DOI 10.1093/nar/gkn431
   Zhang R, 2009, J GENET GENOMICS, V36, P1, DOI 10.1016/S1673-8527(09)60001-1
   Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010
   Zhou YM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-396
NR 55
TC 35
Z9 36
U1 2
U2 14
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUL
PY 2013
VL 49
IS 1
BP 58
EP 66
DI 10.1165/rcmb.2012-0397OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 173TE
UT WOS:000321101400007
PM 23492194
OA Green Published
DA 2023-08-21
ER

PT J
AU Kardara, M
   Hatziantoniou, S
   Sfika, A
   Vassiliou, AG
   Mourelatou, E
   Magkou, C
   Armaganidis, A
   Roussos, C
   Orfanos, SE
   Kotanidou, A
   Maniatis, NA
AF Kardara, Matina
   Hatziantoniou, Sophia
   Sfika, Aggeliki
   Vassiliou, Aliki G.
   Mourelatou, Elena
   Magkou, Christina
   Armaganidis, Apostolos
   Roussos, Charalambos
   Orfanos, Stylianos E.
   Kotanidou, Anastasia
   Maniatis, Nikolaos A.
TI Caveolar Uptake and Endothelial-Protective Effects of Nanostructured
   Lipid Carriers in Acid Aspiration Murine Acute Lung Injury
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE ALI/ARDS; ERK/ERK1/ERK2; nanomedicine; permeability; thrombin 
ID DRUG-DELIVERY; NANOPARTICLES; NANOEMULSIONS; CERAMIDES; PROPOFOL; BRAIN
AB Nanostructured lipid carriers (NLC), nanosized phospholipids/triglyceride particles developed for drug delivery, are considered biologically inactive. We assessed the efficacy of unloaded NLC as experimental treatment for acute lung injury (ALI).
   To induce ALI, C57Black/6 male mice received intratracheal injections of HCl or saline; A single dose of 16 mg/Kg NLC or saline was injected intravenously concomitantly with HCl challenge. NLC uptake mechanisms and effects on endothelial permeability and signaling were studied in cultured endothelial cells and neutrophils.
   NLC pre-treatment attenuated pulmonary microvascular protein leak, airspace inflammatory cells, thrombin proteolytic activity and histologic lung injury score 24 h post insult. Using fluorescence measurements and flow cytometry in mouse lung microvascular endothelial cell culture homogenates, we determined that NLC rendered fluorescent by curcumin labeling are taken up by endothelial cells from mice expressing caveolin-1, the coat protein of caveolar endocytic vesicles, but not from caveolin-1 gene-disrupted mice, which lack caveolae. In contrast, conventional emulsions (CE), consisting of larger particles, were not incorporated. In addition, NLC pre-treatment of cultured human lung microvascular endothelial cells abrogated thrombin-induced activation of p44/42, albumin permeability response, actin cytoskeletal remodeling and interleukin-6 production. Finally, NLC but not CE abrogated lipopolysaccharide-triggered interleukin-8 release.
   NLC are engulfed by endothelial caveolae and possess endothelial-protective effects. These novel properties may be of potential utility in ALI.
C1 [Kardara, Matina; Sfika, Aggeliki; Vassiliou, Aliki G.; Armaganidis, Apostolos; Roussos, Charalambos; Orfanos, Stylianos E.; Kotanidou, Anastasia; Maniatis, Nikolaos A.] Univ Athens, Sch Med, Dept Crit Care Med & Pulm Serv 1, GP Livanos & M Simou Labs,Evangelismos Hosp, GR-11527 Athens, Greece.
C1 [Roussos, Charalambos; Kotanidou, Anastasia] Univ Athens, Sch Med, Dept Crit Care & Pulm Serv 1, Evangelismos Hosp, GR-11527 Athens, Greece.
C1 [Orfanos, Stylianos E.; Maniatis, Nikolaos A.] Univ Athens, Sch Med, Attikon Hosp, Dept Crit Care 2, GR-11527 Athens, Greece.
C1 [Hatziantoniou, Sophia; Mourelatou, Elena] Univ Athens, Sch Pharm, Dept Pharmaceut Technol, Athens, Greece.
C1 [Magkou, Christina] Evangelismos Med Ctr, Dept Pathol, Athens, Greece.
C3 Athens Medical School; CIVIS; National & Kapodistrian University of
   Athens; Evangelismos Hospital; Athens Medical School; CIVIS; National &
   Kapodistrian University of Athens; Evangelismos Hospital; Athens Medical
   School; CIVIS; National & Kapodistrian University of Athens; University
   Hospital Attikon; CIVIS; National & Kapodistrian University of Athens;
   Evangelismos Hospital
RP Maniatis, NA (corresponding author), Ploutarhou 3,2nd Floor, Athens 10675, Greece.
EM nmaniatis@med.uoa.gr
RI Vassiliou, Alice/AAX-1985-2020; MAGKOU, CHRISTINA/HLW-4665-2023;
   Kotanidou, Anastasia/AAB-4731-2020
OI Vassiliou, Alice/0000-0003-4984-0476; Kotanidou,
   Anastasia/0000-0003-4703-0082; Hatziantoniou, Sophia/0000-0002-5877-9091
FU American Thoracic Society/Sepsis Alliance Research Grant; "THORAX"
   Research Center for Intensive and Emergency Thoracic Medicine, Athens,
   Greece
FX This study was funded by an American Thoracic Society/Sepsis Alliance
   Research Grant and by the "THORAX" Research Center for Intensive and
   Emergency Thoracic Medicine, Athens, Greece
CR Alam MI, 2012, J PSYCHIATR RES, V46, P1133, DOI 10.1016/j.jpsychires.2012.05.014
   Angelova A, 2011, ACCOUNTS CHEM RES, V44, P47
   Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003
   Das S, 2011, AAPS PHARMSCITECH, V12, P62, DOI 10.1208/s12249-010-9563-0
   Deli G, 2009, J LIPOSOME RES, V19, P180, DOI 10.1080/08982100802702046
   Donahoe Michael, 2011, Pulm Circ, V1, P192, DOI 10.4103/2045-8932.83454
   Garcia-Fuentes M, 2005, J COLLOID INTERF SCI, V285, P590, DOI 10.1016/j.jcis.2004.10.012
   Haque S, 2012, DRUG DEV IND PHARM, V38, P387, DOI 10.3109/03639045.2011.608191
   Hatziantoniou S, 2007, MICRON, V38, P819, DOI 10.1016/j.micron.2007.06.010
   Hatziantoniou S, 2010, METHODS MOL BIOL, V606, P363, DOI 10.1007/978-1-60761-447-0_24
   Hatziantoniou S, 2006, J LIPOSOME RES, V16, P321, DOI 10.1080/08982100600992278
   Joshi MD, 2009, EUR J PHARM BIOPHARM, V71, P161, DOI 10.1016/j.ejpb.2008.09.003
   Kalimeris K, 2011, ACTA ANAESTH SCAND, V55, P740, DOI 10.1111/j.1399-6576.2011.02461.x
   Kolhe P, 2003, INT J PHARM, V259, P143, DOI 10.1016/S0378-5173(03)00225-4
   Kotanidou A, 2006, VASC PHARMACOL, V45, P134, DOI 10.1016/j.vph.2006.06.016
   Krump-Konvalinkova V, 2001, LAB INVEST, V81, P1717, DOI 10.1038/labinvest.3780385
   Langer R, 1998, NATURE, V392, P5
   Liu R, 2012, J PHARM SCI-US, V101, P3833, DOI 10.1002/jps.23251
   Marik PE, 2012, HOSP PRACT MINNEAP, V38, P35
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Oh P, 2007, NAT BIOTECHNOL, V25, P327, DOI 10.1038/nbt1292
   Ott J, 2011, PROSTAG LEUKOTR ESS, V85, P267, DOI 10.1016/j.plefa.2011.04.011
   Psallidas I, 2012, ONCOGENE
   Suchner U, 2001, CRIT CARE MED, V29, P1569, DOI 10.1097/00003246-200108000-00012
   Wang ZJ, 2011, IUBMB LIFE, V63, P659, DOI 10.1002/iub.485
   Yang X.-y., 2012, CANC LETT
   Ypsilantis P, 2007, ANESTH ANALG, V105, P155, DOI 10.1213/01.ane.0000265544.44948.0b
   Zhen G, 2012, MOL PHARM
NR 28
TC 18
Z9 19
U1 0
U2 27
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUL
PY 2013
VL 30
IS 7
BP 1836
EP 1847
DI 10.1007/s11095-013-1027-2
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 158WQ
UT WOS:000320005100012
PM 23549752
DA 2023-08-21
ER

PT J
AU Natarajan, V
   Dudek, SM
   Jacobson, JR
   Moreno-Vinasco, L
   Huang, LS
   Abassi, T
   Mathew, B
   Zhao, YT
   Wang, LC
   Bittman, R
   Weichselbaum, R
   Berdyshev, E
   Garcia, JGN
AF Natarajan, Viswanathan
   Dudek, Steven M.
   Jacobson, Jeffrey R.
   Moreno-Vinasco, Liliana
   Huang, Longshuang
   Abassi, Taimur
   Mathew, Biji
   Zhao, Yutong
   Wang, Lichun
   Bittman, Robert
   Weichselbaum, Ralph
   Berdyshev, Evgeny
   Garcia, Joe G. N.
TI Sphingosine-1-Phosphate, FTY720, and Sphingosine-1-Phosphate Receptors
   in the Pathobiology of Acute Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Review
DE sphingolipids; S1P/S1PR1/S1PR2/S1PR3; sphingosine kinase; sepsis 
ID PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; BARRIER ENHANCEMENT;
   VASCULAR LEAK; PROTEASOMAL DEGRADATION; FINGOLIMOD FTY720;
   SMOOTH-MUSCLE; GROWTH-FACTOR; DRUG FTY720; IN-VITRO
AB Acute lung injury (ALI) attributable to sepsis or mechanical ventilation and subacute lung injury because of ionizing radiation (RILI) share profound increases in vascular permeability as a key element and a common pathway driving increased morbidity and mortality. Unfortunately, despite advances in the understanding of lung pathophysiology, specific therapies do not yet exist for the treatment of ALI or RILI, or for the alleviation of unremitting pulmonary leakage, which serves as a defining feature of the illness. A critical need exists for new mechanistic insights that can lead to novel strategies, biomarkers, and therapies to reduce lung injury. Sphingosine 1-phosphate (S1P) is a naturally occurring bioactive sphingolipid that acts extracellularly via its G protein-coupled S1P1-5 as well as intracellularly on various targets. S1P-mediated cellular responses are regulated by the synthesis of S1P, catalyzed by sphingosine kinases 1 and 2, and by the degradation of S1P mediated by lipid phosphate phosphatases, S1P phosphatases, and S1P lyase. We and othershave demonstrated that S1P is a potent angiogenic factor that enhances lung endothelial cell integrity and an inhibitor of vascular permeability and alveolar flooding in preclinical animal models of ALI. In addition to S1P, S1P analogues such as 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720), FTY720 phosphate, and FTY720 phosphonates offer therapeutic potential in murine models of lung injury. This translational review summarizes the roles of S1P, S1P analogues, S1P-metabolizing enzymes, and S1P receptors in the pathophysiology of lung injury, with particular emphasis on the development of potential novel biomarkers and S1P-based therapies for ALI and RILI.
C1 [Natarajan, Viswanathan; Huang, Long Shuang] Univ Illinois, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Natarajan, Viswanathan; Abassi, Taimur; Mathew, Biji; Wang, Lichun; Berdyshev, Evgeny; Garcia, Joe G. N.] Univ Illinois, Dept Med, Chicago, IL 60612, United States.
C1 [Natarajan, Viswanathan; Dudek, Steven M.; Jacobson, Jeffrey R.; Moreno-Vinasco, Liliana; Huang, Long Shuang; Abassi, Taimur; Mathew, Biji; Wang, Lichun; Berdyshev, Evgeny; Garcia, Joe G. N.] Univ Illinois, Inst Personalized Resp Med, Chicago, IL 60612, United States.
C1 [Zhao, Yutong] Univ Pittsburgh, Dept Med, Pittsburgh, PA, United States.
C1 [Bittman, Robert] CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367, United States.
C1 [Weichselbaum, Ralph] Univ Chicago, Dept Radiat Oncol, Chicago, IL 60637, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; City
   University of New York (CUNY) System; Queens College NY (CUNY);
   University of Chicago
RP Natarajan, V (corresponding author), Univ Illinois, Dept Pharmacol, 909 South Wolcott Ave,COMRB Bldg,Room 3137, Chicago, IL 60612 USA.
EM visnatar@uic.edu
RI Huang, Longshuang/H-9553-2016; Garcia, Joe GN/E-8862-2010
FU National Institutes of Health [PPG HL58064, PPG HL98050]
FX This work was supported by National Institutes of Health grants PPG
   HL58064 and PPG HL98050 (V.N., J.G.N. G, S. M. D, and J.R.J.).
CR Allende ML, 2011, J BIOL CHEM, V286, P7348, DOI 10.1074/jbc.M110.171819
   Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200
   Bachmaier K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030742
   Bandhuvula P, 2005, J BIOL CHEM, V280, P33697, DOI 10.1074/jbc.C500294200
   Bandhuvula P, 2007, TRENDS MOL MED, V13, P210, DOI 10.1016/j.molmed.2007.03.005
   Bektas M, 2010, J BIOL CHEM, V285, P10880, DOI 10.1074/jbc.M109.081489
   Berdyshev EV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016571
   Berdyshev EV, 2009, J BIOL CHEM, V284, P5467, DOI 10.1074/jbc.M805186200
   Bikman BT, 2011, J CLIN INVEST, V121, P4222, DOI 10.1172/JCI57144
   Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200
   Brindley DN, 2009, J LIPID RES, V50, pS225, DOI 10.1194/jlr.R800055-JLR200
   Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544
   Canals D, 2011, BRIT J PHARMACOL, V163, P694, DOI 10.1111/j.1476-5381.2011.01279.x
   Chae YC, 2008, MOL BIOL CELL, V19, P3111, DOI 10.1091/mbc.E07-04-0337
   Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064
   Clemens JJ, 2005, BIOORG MED CHEM LETT, V15, P3568, DOI 10.1016/j.bmcl.2005.05.097
   DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523
   Dudek SM, 2007, CELL SIGNAL, V19, P1754, DOI 10.1016/j.cellsig.2007.03.011
   Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828
   Foss FW, 2005, BIOORG MED CHEM LETT, V15, P4470, DOI 10.1016/j.bmcl.2005.07.057
   Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474
   Gangoiti P, 2010, PROG LIPID RES, V49, P316, DOI 10.1016/j.plipres.2010.02.004
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GIMBRONE MA, 1969, NATURE, V222, P33, DOI 10.1038/222033a0
   Gorshkova I, 2012, J LIPID RES, V53, P1553, DOI 10.1194/jlr.M026039
   Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D
   Gowda S, 2011, AM J PHYSIOL-LUNG C, V300, pL430, DOI 10.1152/ajplung.00208.2010
   Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com
   Hailemariam TK, 2008, ARTERIOSCL THROM VAS, V28, P1519, DOI 10.1161/ATVBAHA.108.168682
   Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3351, DOI 10.1016/j.bmcl.2004.02.106
   Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5
   Jacobson JR, 2007, CURR DRUG TARGETS, V8, P509, DOI 10.2174/138945007780362719
   KANOSUEOKA T, 1979, P NATL ACAD SCI USA, V76, P5741, DOI 10.1073/pnas.76.11.5741
   Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643
   Kariya Y, 2005, GENES CELLS, V10, P605, DOI 10.1111/j.1365-2443.2005.00862.x
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kono M, 2008, BBA-MOL CELL BIOL L, V1781, P435, DOI 10.1016/j.bbalip.2008.07.001
   Kovarik JM, 2004, THER DRUG MONIT, V26, P585, DOI 10.1097/00007691-200412000-00001
   Krump-Konvalinkova V, 2008, BIOCHEM BIOPH RES CO, V370, P603, DOI 10.1016/j.bbrc.2008.03.144
   Kumar A, 2011, CELL SIGNAL, V23, P1144, DOI 10.1016/j.cellsig.2011.02.009
   Lahiri S, 2009, J BIOL CHEM, V284, P16090, DOI 10.1074/jbc.M807438200
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Lu XQ, 2009, J ORG CHEM, V74, P3192, DOI 10.1021/jo900023u
   Ma S-F, 2011, AM J RESP CELL MOL B, V183, pA3875
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Mathew B, 2011, FASEB J, V25, P3388, DOI 10.1096/fj.11-183970
   Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200
   Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029
   Muller HC, 2011, PULM PHARMACOL THER, V24, P377, DOI 10.1016/j.pupt.2011.01.017
   Nakanaga K, 2010, J BIOCHEM, V148, P13, DOI 10.1093/jb/mvq052
   Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200
   Okazaki M, 2007, AM J TRANSPLANT, V7, P751, DOI 10.1111/j.1600-6143.2006.01710.x
   Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200
   Oo ML, 2011, J CLIN INVEST, V121, P2290, DOI 10.1172/JCI45403
   Oravecz T, 2007, BLOOD, V110, p679A
   Patwardhan GA, 2011, PROG LIPID RES, V50, P104, DOI 10.1016/j.plipres.2010.10.003
   Paugh SW, 2006, MOL PHARMACOL, V70, P41, DOI 10.1124/mol.105.020552
   Payne SG, 2007, BLOOD, V109, P1077, DOI 10.1182/blood-2006-03-011437
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Perrotta C, 2010, PHYSIOLOGY, V25, P64, DOI 10.1152/physiol.00048.2009
   Petrache I, 2010, AM J RESP CRIT CARE, V181
   Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001
   Prakash H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010657
   Puneet P, 2010, SCIENCE, V328, P1290, DOI 10.1126/science.1188635
   Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385
   Ratajczak MZ, 2012, ADV EXP MED BIOL, V946, P37, DOI 10.1007/978-1-4614-0106-3_3
   Roberts KG, 2010, CANCER RES, V70, P5438, DOI 10.1158/0008-5472.CAN-09-2544
   Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com
   Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200
   Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   Schmahl J, 2007, NAT GENET, V39, P52, DOI 10.1038/ng1922
   Shea BS, 2010, AM J RESP CELL MOL, V43, P662, DOI 10.1165/rcmb.2009-0345OC
   Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151
   Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123
   Strader CR, 2011, J NAT PROD, V74, P900, DOI 10.1021/np2000528
   Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200
   Sun X, 2011, AM J RESP CRIT CARE, V183
   Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8
   Tani M, 2005, J LIPID RES, V46, P2458, DOI 10.1194/jlr.M500268-JLR200
   Tarrason G, 2011, INT IMMUNOPHARMACOL, V11, P1773, DOI 10.1016/j.intimp.2011.07.004
   Tonelli F, 2010, CELL SIGNAL, V22, P1536, DOI 10.1016/j.cellsig.2010.05.022
   Ugolev Y, 2008, J BIOL CHEM, V283, P22257, DOI 10.1074/jbc.M800734200
   Uhlig S, 2008, AM J RESP CRIT CARE, V178, P1100, DOI 10.1164/rccm.200804-595SO
   Upadhyaya P, 2012, BIOCHEM BIOPH RES CO, V424, P18, DOI 10.1016/j.bbrc.2012.06.012
   Usatyuk PV, 2011, AM J PHYSIOL-LUNG C, V300, pL840, DOI 10.1152/ajplung.00404.2010
   Valentine WJ, 2010, CELL SIGNAL, V22, P1543, DOI 10.1016/j.cellsig.2010.05.023
   Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244
   Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845
   Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456
   Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112
   Wadgaonkar R, 2009, AM J PHYSIOL-LUNG C, V296, pL603, DOI 10.1152/ajplung.90357.2008
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wang LH, 2011, NAT PHOTONICS, V5, P183, DOI 10.1038/nphoton.2011.24
   Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269
   WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551
   Yang Yang, 2011, Ther Adv Respir Dis, V5, P325, DOI 10.1177/1753465811406772
   Yatomi Y, 2008, BBA-GEN SUBJECTS, V1780, P606, DOI 10.1016/j.bbagen.2007.10.006
   Zemann B, 2007, IMMUNOL LETT, V109, P56, DOI 10.1016/j.imlet.2007.01.001
   Zhao YT, 2007, J BIOL CHEM, V282, P14165, DOI 10.1074/jbc.M701279200
   Zhao YT, 2011, AM J RESP CELL MOL, V45, P426, DOI 10.1165/rcmb.2010-0422OC
   Zhu R, 2007, J MED CHEM, V50, P6428, DOI 10.1021/jm7010172
NR 110
TC 105
Z9 110
U1 2
U2 25
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUL
PY 2013
VL 49
IS 1
BP 6
EP 17
DI 10.1165/rcmb.2012-0411TR
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 173TE
UT WOS:000321101400002
PM 23449739
OA Green Published
DA 2023-08-21
ER

PT J
AU Obiako, B
   Calchary, W
   Xu, NY
   Kunstadt, R
   Richardson, B
   Nix, J
   Sayner, SL
AF Obiako, Boniface
   Calchary, Wendy
   Xu, Ningyong
   Kunstadt, Ryan
   Richardson, Bianca
   Nix, Jessica
   Sayner, Sarah L.
TI Bicarbonate disruption of the pulmonary endothelial barrier via
   activation of endogenous soluble adenylyl cyclase, isoform 10
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE soluble adenylate cyclase; phosphodiesterase; edema; lung; compartmentalization 
ID ELECTROGENIC NA+-HCO3-COTRANSPORTER; RESPIRATORY-DISTRESS-SYNDROME;
   INDUCED LUNG INJURY; PSEUDOMONAS-AERUGINOSA; HYPERCAPNIC ACIDOSIS; CELL
   BARRIER; CYCLIC-AMP; RAT-BRAIN; CAMP; PERMEABILITY
AB It is becoming increasingly apparent that cAMP signals within the pulmonary endothelium are highly compartmentalized, and this compartmentalization is critical to maintaining endothelial barrier integrity. Studies demonstrate that the exogenous soluble bacterial toxin, ExoY, and heterologous expression of the forskolin-stimulated soluble mammalian adenylyl cyclase (AC) chimera, sACI/II, elevate cytosolic cAMP and disrupt the pulmonary microvascular endothelial barrier. The barrier-disruptive effects of cytosolic cAMP generated by exogenous soluble ACs are in contrast to the barrier-protective effects of subplasma membrane cAMP generated by transmembrane AC, which strengthens endothelial barrier integrity. Endogenous soluble AC isoform 10 (AC10 or commonly known as sAC) lacks transmembrane domains and localizes within the cytosolic compartment. AC10 is uniquely activated by bicarbonate to generate cytosolic cAMP, yet its role in regulation of endothelial barrier integrity has not been addressed. Here we demonstrate that, within the pulmonary circulation, AC10 is expressed in pulmonary microvascular endothelial cells (PMVECs) and pulmonary artery endothelial cells (PAECs), yet expression in PAECs is lower. Furthermore, pulmonary endothelial cells selectively express bicarbonate cotransporters. While extracellular bicarbonate generates a phosphodiesterase 4-sensitive cAMP pool in PMVECs, no such cAMP response is detected in PAECs. Finally, addition of extracellular bicarbonate decreases resistance across the PMVEC monolayer and increases the filtration coefficient in the isolated perfused lung above osmolality controls. Collectively, these findings suggest that PMVECs have a bicarbonate-sensitive cytosolic cAMP pool that disrupts endothelial barrier integrity. These studies could provide an alternative mechanism for the controversial effects of bicarbonate correction of acidosis of acute respiratory distress syndrome patients.
C1 [Calchary, Wendy; Kunstadt, Ryan; Richardson, Bianca; Nix, Jessica; Sayner, Sarah L.] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688, United States.
C1 [Obiako, Boniface; Xu, Ningyong] Univ S Alabama, Dept Pharmacol, Mobile, AL 36688, United States.
C1 [Obiako, Boniface; Calchary, Wendy; Xu, Ningyong; Kunstadt, Ryan; Richardson, Bianca; Nix, Jessica; Sayner, Sarah L.] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688, United States.
C3 University of South Alabama; University of South Alabama; University of
   South Alabama
RP Sayner, SL (corresponding author), Univ S Alabama, Coll Med, Ctr Lung Biol, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA.
EM ssayner@southalabama.edu
OI Xu, Ningyong/0000-0003-3483-3097
FU American Heart Association [AHA11GRNT7430039]; Parker B. Francis
   Fellowship Foundation Award; National Heart, Lung, and Blood Institute
   [HL-076125]
FX This work was supported by American Heart Association Grant
   AHA11GRNT7430039 (S. L. Sayner), the Parker B. Francis Fellowship
   Foundation Award (S. L. Sayner), and National Heart, Lung, and Blood
   Institute Grant HL-076125 (R. Kunstadt).
CR Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012
   Bevensee MO, 2000, AM J PHYSIOL-CELL PH, V278, pC1200, DOI 10.1152/ajpcell.2000.278.6.C1200
   Bogatcheva NV, 2008, MICROVASC RES, V76, P202, DOI 10.1016/j.mvr.2008.06.003
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79
   Buck J, 2011, SENSORS-BASEL, V11, P2112, DOI 10.3390/s110202112
   Cann MJ, 2003, J BIOL CHEM, V278, P35033, DOI 10.1074/jbc.M303025200
   Cann MJ, 2004, IUBMB LIFE, V56, P529, DOI 10.1080/15216540400013861
   Chen J, 2012, AM J PHYSIOL-HEART C, V302, pH538, DOI 10.1152/ajpheart.00701.2011
   Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625
   Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615
   Creighton J, 2008, J CELL SCI, V121, P110, DOI 10.1242/jcs.011692
   Damkier HH, 2006, AM J PHYSIOL-HEART C, V290, pH172, DOI 10.1152/ajpheart.00713.2005
   Dessauer CW, 2009, MOL PHARMACOL, V76, P935, DOI 10.1124/mol.109.059345
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Farrell J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003251
   FARRUKH IS, 1987, J APPL PHYSIOL, V62, P47, DOI 10.1152/jappl.1987.62.1.47
   Feng QP, 2006, BIOCHIMIE, V88, P319, DOI 10.1016/j.biochi.2005.09.003
   Fischmeister R, 2006, CIRC RES, V98, P582, DOI 10.1161/01.RES.0000215564.22445.7e
   GARBERS DL, 1982, J BIOL CHEM, V257, P8980
   Geng WD, 2005, AM J PHYSIOL-CELL PH, V288, pC1305, DOI 10.1152/ajpcell.00584.2004
   Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007
   Jaiswal BS, 2003, P NATL ACAD SCI USA, V100, P10676, DOI 10.1073/pnas.1831008100
   Kamenetsky M, 2006, J MOL BIOL, V362, P623, DOI 10.1016/j.jmb.2006.07.045
   Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375
   Kelly JJ, 1998, AM J PHYSIOL-LUNG C, V274, pL810, DOI 10.1152/ajplung.1998.274.5.L810
   KINDIG NB, 1983, CHEST, V83, P712, DOI 10.1378/chest.83.4.712a
   KOBAYASHI H, 1987, J APPL PHYSIOL, V63, P2201, DOI 10.1152/jappl.1987.63.6.2201
   KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106
   Kumar S, 2009, J BIOL CHEM, V284, P14760, DOI 10.1074/jbc.M900925200
   Laffey JG, 2000, AM J RESP CRIT CARE, V161, P141, DOI 10.1164/ajrccm.161.1.9905080
   Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200
   Majumdar D, 2010, NEUROSCIENCE, V171, P951, DOI 10.1016/j.neuroscience.2010.09.037
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703
   Nichol AD, 2009, CRIT CARE MED, V37, P2953, DOI 10.1097/CCM.0b013e3181b028ce
   Ochoa CD, 2012, J BIOL CHEM, V287, P25407, DOI 10.1074/jbc.M111.301440
   Parker MD, 2008, J BIOL CHEM, V283, P12777, DOI 10.1074/jbc.M707829200
   Parker MD, 2013, PHYSIOL REV, V93, P803, DOI 10.1152/physrev.00023.2012
   Pastor-Soler N, 2003, J BIOL CHEM, V278, P49523, DOI 10.1074/jbc.M309543200
   Pastor-Soler NM, 2008, AM J PHYSIOL-CELL PH, V294, pC488, DOI 10.1152/ajpcell.00537.2007
   Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425
   Sayner S, 2006, BIOCHEM SOC T, V34, P492, DOI 10.1042/BST0340492
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V301, pL117, DOI 10.1152/ajplung.00417.2009
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V300, pL667, DOI 10.1152/ajplung.00433.2010
   Sayner SL, 2006, CIRC RES, V98, P675, DOI 10.1161/01.RES.0000209516.84815.3e
   Sayner SL, 2004, CIRC RES, V95, P196, DOI 10.1161/01.RES.0000134922.25721.d9
   Schmid A, 2007, J GEN PHYSIOL, V130, P99, DOI 10.1085/jgp.200709784
   Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M
   SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948
   STELZNER TJ, 1989, J CELL PHYSIOL, V139, P157, DOI 10.1002/jcp.1041390122
   STEVENS T, 1994, CELL CALCIUM, V16, P404, DOI 10.1016/0143-4160(94)90033-7
   Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   Taylor CJ, 2006, J PHYSIOL-LONDON, V576, P769, DOI 10.1113/jphysiol.2006.117374
   TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507
   Topal H, 2012, J MOL BIOL, V416, P271, DOI 10.1016/j.jmb.2011.12.045
   Tresguerres M, 2011, PFLUGERS ARCH, V460, P953
   Wolfgang MC, 2003, DEV CELL, V4, P253, DOI 10.1016/S1534-5807(03)00019-4
   Xie F, 2006, DEV BIOL, V296, P353, DOI 10.1016/j.ydbio.2006.05.038
   Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899
   Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje
NR 62
TC 18
Z9 18
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2013
VL 305
IS 2
BP L185
EP L192
DI 10.1152/ajplung.00392.2012
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 183MC
UT WOS:000321818300009
PM 23686854
OA Green Published
DA 2023-08-21
ER

PT J
AU Wu, TH
   Xing, JJ
   Birukova, AA
AF Wu, Tinghuai
   Xing, Junjie
   Birukova, Anna A.
TI Cell-type-specific crosstalk between p38 MAPK and Rho signaling in lung
   micro- and macrovascular barrier dysfunction induced by Staphylococcus
   aureus-derived pathogens
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID NF-KAPPA-B; ENDOTHELIAL BARRIER; DIFFERENTIAL REGULATION; LIPOTEICHOIC
   ACID; OXIDIZED PHOSPHOLIPIDS; KINASE INHIBITOR; INJURY; ACTIVATION;
   PEPTIDOGLYCAN; PERMEABILITY
AB Lung inflammation and alterations in endothelial cell (EC) micro- and macrovascular permeability are key events to development of acute lung injury. Using ECs derived from human pulmonary artery and lung microvasculature, we investigated the interplay between p38 stress mitogen-activated protein kinase (MAPK) and Rho guanosine triphosphatase signaling in inflammatory and hyperpermeability responses. Both cell types were treated with Staphylococcus aureus-derived peptidoglycan (PepG) and lipoteichoic acid (LTA) with or without pretreatment with p38 MAPK or Rho kinase inhibitors. LTA and PepG increased permeability markedly in both pulmonary macrovascular and microvascular ECs. Agonist-induced hyperpermeability was accompanied by cytoskeletal remodeling, disruption of cell-cell contacts, formation of paracellular gaps, and activation of p38 MAPK, nuclear factor kappa-B (NF kappa B), and Rho/Rho kinase signaling. In macrovascular ECs, pharmacologic inhibition of Rho kinase with Y27632 suppressed p38 MAP kinase cascade activation significantly, whereas inhibition of p38 MAPK with SB203580 had no effect on Rho activation. In contrast, inhibition of p38 MAPK in microvascular ECs suppressed LTA/PepG-induced activation of Rho, whereas the Rho inhibitor suppressed activation of p38 MAPK. Inhibition of either p38 MAPK or Rho kinase attenuated activation of NF kappa B signaling substantially. These results demonstrate cell-type-specific differences in signaling induced by Staphylococcus aureus-derived pathogens in pulmonary endothelium. Thus, although Gram-positive bacterial compounds caused barrier dysfunction in both EC types, it was induced by a different pattern of crosstalk between Rho, p38 MAPK, and NF kappa B signaling. These observations may have important implications in defining microvasculature-specific therapeutic strategies aimed at the treatment of sepsis and acute lung injury induced by Gram-positive bacterial pathogens.
C1 [Wu, Tinghuai; Xing, Junjie; Birukova, Anna A.] Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukova, AA (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Med, 5841 S Maryland Ave,MC-6026,Off N-613, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
FU National Heart, Lung, and Blood Institutes [HL89257, HL107920]
FX The authors' work was funded by the National Heart, Lung, and Blood
   Institutes (grants HL89257 and HL107920).
CR Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2012, AM J PHYSIOL-LUNG C, V302, pL965, DOI 10.1152/ajplung.00292.2011
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Cioffi DL, 2009, ANTIOXID REDOX SIGN, V11, P765, DOI [10.1089/ars.2008.2221, 10.1089/ARS.2008.2221]
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0
   Gacouin A, 2009, ANESTH ANALG, V109, P1584, DOI 10.1213/ANE.0b013e3181b6e9b6
   Hayashida A, 2009, AM J PATHOL, V174, P509, DOI 10.2353/ajpath.2009.080394
   He F, 2011, NEUROSCIENCE, V188, P35, DOI 10.1016/j.neuroscience.2011.04.025
   Hocke AC, 2006, HISTOCHEM CELL BIOL, V126, P305, DOI 10.1007/s00418-006-0174-5
   Hortal J, 2009, INTENS CARE MED, V35, P1518, DOI 10.1007/s00134-009-1523-3
   Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014
   Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428-7435.2005
   Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3
   LECHNER AJ, 1993, MICROSC RES TECHNIQ, V26, P444, DOI 10.1002/jemt.1070260512
   Leemans JC, 2002, AM J RESP CRIT CARE, V165, P1445, DOI 10.1164/rccm.2106045
   Liu S, 2008, EUR J PHARMACOL, V584, P159, DOI 10.1016/j.ejphar.2008.02.009
   Lowe K, 2007, J SURG RES, V143, P70, DOI 10.1016/j.jss.2007.03.047
   Manukyan M, 2009, J IMMUNOL, V182, P3522, DOI 10.4049/jimmunol.0802280
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Mayer AK, 2007, J IMMUNOL, V178, P3134, DOI 10.4049/jimmunol.178.5.3134
   Melamed A, 2009, CRIT CARE, V13, DOI 10.1186/cc7733
   Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543
   Nwariaku FE, 2002, SHOCK, V18, P82, DOI 10.1097/00024382-200207000-00015
   Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189
   Ruse M, 2006, IMMUNOL RES, V34, P33, DOI 10.1385/IR:34:1:33
   Schmeck B, 2003, INFLAMMATION, V27, P89, DOI 10.1023/A:1023278600596
   Shibolet O, 2007, J BIOL CHEM, V282, P35308, DOI 10.1074/jbc.M704426200
   Slotta JE, 2006, INFLAMM RES, V55, P364, DOI 10.1007/s00011-006-6013-2
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Teusch N, 2004, J IMMUNOL, V173, P507, DOI 10.4049/jimmunol.173.1.507
   Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639
   Wang JE, 2003, SHOCK, V20, P402, DOI 10.1097/01.shk.0000092268.01859.0d
   Xing JJ, 2011, J APPL PHYSIOL, V110, P213, DOI 10.1152/japplphysiol.00284.2010
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
NR 46
TC 17
Z9 19
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1931-5244
EI 1878-1810
J9 TRANSL RES
JI Transl. Res.
PD JUL
PY 2013
VL 162
IS 1
BP 45
EP 55
DI 10.1016/j.trsl.2013.03.005
PG 11
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA 173OU
UT WOS:000321089600005
PM 23571093
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Birukova, AA
   Starosta, V
   Tian, XY
   Higginbotham, K
   Koroniak, L
   Berliner, JA
   Birukov, KG
AF Birukova, Anna A.
   Starosta, Vitaliy
   Tian, Xinyong
   Higginbotham, Katherine
   Koroniak, Lukas
   Berliner, Judith A.
   Birukov, Konstantin G.
TI Fragmented oxidation products define barrier disruptive endothelial cell
   response to OxPAPC
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID ACUTE LUNG INJURY; MONOCYTE CHEMOTACTIC PROTEIN-1; OXIDIZED
   PHOSPHOLIPIDS; VE-CADHERIN; IN-VIVO; VASCULAR LEAK; RHO KINASE;
   RECEPTOR; IDENTIFICATION; INFLAMMATION
AB Excessive concentrations of oxidized phospholipids (OxPL), the products of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine (PAPC) oxidation have been detected in atherosclerosis, septic inflammation, and acute lung injury (ALI) and have been shown to induce vascular barrier dysfunction. In contrast, oxidized PAPC (OxPAPC) at low concentrations exhibit potent barrier protective effects. The nature of such biphasic effects remains unclear. We tested the hypothesis that barrier-disruptive effects of high OxPAPC doses on endothelial cell (EC) monolayer are defined by fragmented products of PAPC oxidation (lysophosphatidyl choline (lyso-PC), 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-phosphatidylcholine (POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-phosphatidylcholine (PGPC)), whereas barrier enhancing effects are mediated by full length oxidated PAPC products and may be reproduced by single compounds contained in the OxPAPC such as 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphatidyl choline (PEIPC). All 3 fragmented OxPAPC products increased EC permeability in a dose-dependent manner, whereas PEIPC decreased it and reversed barrier disruptive effects of lyso-PC, POVPC, and PGPC monitored by measurements of transendothelial electrical resistance. Immunofluorescence staining and western blot analysis showed that PGPC mimicked the cytoskeletal remodeling and tyrosine phosphorylation of adherens junction (AJ) protein vascular endothelial (VE)-cadherin leading to EC barrier dysfunction induced by high OxPAPC concentrations. Barrier-disruptive effects of PGPC were abrogated by reactive oxygen species (ROS) inhibitor, N-acetyl cysteine, or Src kinase inhibitor, PP-2. The results of this study show that barrier disruptive effects of fragmented OxPAPC constituents (lyso-PC, POVPC, PGPC) are balanced by barrier enhancing effects of full length oxygenated products (PEIPC). These data strongly suggest that barrier disruptive effects of OxPAPC at higher concentrations are dictated by predominant effects of fragmented phospholipids such as PGPC, which promote ROS-dependent activation of Src kinase and VE-cadherin phosphorylation at Tyr(658) and Tyr(731) leading to disruption of endothelial cell AJs.
C1 [Birukov, Konstantin G.] Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, Chicago, IL 60637, United States.
C1 Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90024, United States.
C1 Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024, United States.
C3 University of Chicago; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles
RP Birukov, KG (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022
FU  [HL087823];  [HL076259];  [HL107920];  [HL064731]
FX Supported by HL087823, HL076259 (K.G.B.); HL107920 (A.A.B.) and HL064731
   (L.K., J.A.B.).
CR Alcaide P, 2008, BLOOD, V112, P2770, DOI 10.1182/blood-2008-03-147181
   Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukov Konstantin G, 2006, Curr Atheroscler Rep, V8, P223, DOI 10.1007/s11883-006-0077-x
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030957
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Birukova AA, 2011, J CELL PHYSIOL, V226, P2052, DOI 10.1002/jcp.22543
   Bochkov VN, 2010, ANTIOXID REDOX SIGN, V12, P1009, DOI 10.1089/ars.2009.2597
   Bochkov VN, 2003, J MOL MED, V81, P613, DOI 10.1007/s00109-003-0467-2
   Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023
   Carpenter CT, 1998, CHEST, V114, P1653, DOI 10.1378/chest.114.6.1653
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Erridge C, 2008, J BIOL CHEM, V283, P24748, DOI 10.1074/jbc.M800352200
   Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867
   Furnkranz A, 2004, CURR PHARM DESIGN, V10, P915
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jerlich A, 2003, FREE RADICAL RES, V37, P645, DOI 10.1080/1071576031000091720
   Jung ME, 2008, ORG LETT, V10, P4207, DOI 10.1021/ol8014804
   Lee H, 2000, CIRC RES, V87, P516
   Li RS, 2006, CIRC RES, V98, P642, DOI 10.1161/01.RES.0000207394.39249.fc
   Ma Z, 2004, AM J PHYSIOL-LUNG C, V286, pL808, DOI 10.1152/ajplung.00220.2003
   Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063
   Nonas S, 2006, AM J RESP CRIT CARE, V173, P1130, DOI 10.1164/rccm.200511-1737OC
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Oskolkova OV, 2010, J IMMUNOL, V185, P7706, DOI 10.4049/jimmunol.0903594
   Pegorier S, 2006, ATHEROSCLEROSIS, V188, P433, DOI 10.1016/j.atherosclerosis.2005.11.015
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Qiao J, 2006, AM J PHYSIOL-LUNG C, V291, pL91, DOI 10.1152/ajplung.00508.2005
   Quinlan GJ, 1996, CRIT CARE MED, V24, P241, DOI 10.1097/00003246-199602000-00010
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Starosta V, 2012, AM J RESP CELL MOL, V46, P331, DOI 10.1165/rcmb.2011-0153OC
   Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248
   Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   Zimman A, 2007, ARTERIOSCL THROM VAS, V27, P332, DOI 10.1161/01.ATV.0000252842.57585.df
   Zmijewski JW, 2005, BIOCHEM SOC T, V33, P1385, DOI 10.1042/BST0331385
NR 40
TC 56
Z9 57
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-5244
J9 TRANSL RES
JI Transl. Res.
PD JUN
PY 2013
VL 161
IS 6
BP 495
EP 504
DI 10.1016/j.trsl.2012.12.008
PG 10
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA 152NC
UT WOS:000319537400005
PM 23305708
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Gao, P
   Yang, X
   Mungur, L
   Kampo, S
   Wen, QP
AF Gao, Peng
   Yang, Xu
   Mungur, Luckshmanraj
   Kampo, Sylvanus
   Wen, Qingping
TI Adipose tissue-derived stem cells attenuate acute lung injury through
   eNOS and eNOS-derived NO
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE ALI/ARDS; adipose tissue-derived stem cell; eNOS; NO 
ID NITRIC-OXIDE; BONE-MARROW; ENDOTHELIAL-CELLS; EXPRESSION; SURVIVAL;
   REPAIR
AB Acute lung injury (ALI) is among the most common causes of mortality in intensive care units. Recent in vivo and in vitro studies have suggested that mesenchymal stem cells (MSCs) attenuate pulmonary edema and inflammatory factors, but the mechanisms of the effects of MSCs on pulmonary vascular function remain unknown. It is believed that nitric oxide (NO) and endothelial nitric oxide synthase (eNOS) play an essential role in the regulation of vascular function and homeostasis. In the present study, we investigated the effect of adipose tissue-derived stem cells (ADSCs) on pulmonary microvascular endothelial cells (PMVECs) and the lung in a lipopolysaccharide (LPS)-induced ALI model in vitro and in vivo. Our results showed that ADSCs were able to attenuate the severity of ALI and pulmonary edema. Increased expression of the eNOS protein was also observed in pulmonary PMVECs and in the lung following treatment with ADSCs. Furthermore, ADSCs increased the concentration of eNOS-derived NO to remodel ALI. The results suggest that ADSCs may be a promising candidate for ALI treatment through interaction with eNOS and eNOS-derived NO.
C1 [Gao, Peng] Dalian Med Univ, Dept Anesthesiol, Dalian 116044, Liaoning, China.
C1 [Yang, Xu; Mungur, Luckshmanraj; Kampo, Sylvanus; Wen, Qingping] Dalian Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Dalian 116011, Liaoning, China.
C3 Dalian Medical University; Dalian Medical University
RP Wen, QP (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
EM dmuwqp@163.com
OI Kampo, Dr Sylvanus/0000-0002-3002-5124
FU National Natural Science Fund of China [81273923]
FX This study was supported by the National Natural Science Fund of China
   (no. 81273923).
CR Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Chieregato K, 2011, CYTOTHERAPY, V13, P933, DOI 10.3109/14653249.2011.583232
   De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165-2478(03)00108-1
   Farley KS, 2008, MICROVASC RES, V76, P208, DOI 10.1016/j.mvr.2008.07.004
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hatakeyama T, 2006, J PHYSIOL-LONDON, V574, P275, DOI 10.1113/jphysiol.2006.108175
   Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796
   Ito H, 2013, SURG TODAY, V43, P293, DOI 10.1007/s00595-012-0293-7
   Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021
   Kotton DN, 2001, DEVELOPMENT, V128, P5181
   Lang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043433
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Maron BA, 2012, CIRCULATION, V126, P963, DOI 10.1161/CIRCULATIONAHA.112.094722
   Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Rojas M, 2005, AM J RESP CELL MOL, V33, P145, DOI 10.1165/rcmb.2004-0330OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   RYAN US, 1982, TISSUE CELL, V14, P597, DOI 10.1016/0040-8166(82)90050-7
   Sanchez FA, 2006, AM J PHYSIOL-HEART C, V291, pH1058, DOI 10.1152/ajpheart.00370.2006
   Solodushko V, 2008, AM J RESP CELL MOL, V38, P491, DOI 10.1165/rcmb.2007-0127OC
   Subramani J, 2010, EUR J PHARMACOL, V630, P84, DOI 10.1016/j.ejphar.2009.12.026
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 23
TC 12
Z9 15
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUN
PY 2013
VL 31
IS 6
BP 1313
EP 1318
DI 10.3892/ijmm.2013.1328
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 150BQ
UT WOS:000319365600004
PM 23563270
OA Bronze
DA 2023-08-21
ER

PT J
AU Mondrinos, MJ
   Kennedy, PA
   Lyons, M
   Deutschman, CS
   Kilpatrick, LE
AF Mondrinos, Mark J.
   Kennedy, Paul A.
   Lyons, Melanie
   Deutschman, Clifford S.
   Kilpatrick, Laurie E.
TI PROTEIN KINASE C AND ACUTE RESPIRATORY DISTRESS SYNDROME
SO SHOCK
LA English
DT Review
DE Inflammation; Pathogen-associated molecular patterns (PAMPs); DAMPs; ALI/ARDS; neutrophils; cytokines; adhesion molecules; alveolar permeability 
ID ACUTE LUNG INJURY; FACTOR-KAPPA-B; ALVEOLAR EPITHELIAL-CELLS;
   ENDOTHELIAL-CELLS; PKC-DELTA; ADHESION MOLECULE-1; HUMAN NEUTROPHILS;
   TNF-ALPHA; BETA-II; ISCHEMIA-REPERFUSION
AB The acute respiratory distress syndrome (ARDS) is a major public health problem and a leading source of morbidity in intensive care units. Lung tissue in patients with ARDS is characterized by inflammation, with exuberant neutrophil infiltration, activation, and degranulation that is thought to initiate tissue injury through the release of proteases and oxygen radicals. Treatment of ARDS is supportive primarily because the underlying pathophysiology is poorly understood. This gap in knowledge must be addressed to identify urgently needed therapies. Recent research efforts in anti-inflammatory drug development have focused on identifying common control points in multiple signaling pathways. The protein kinase C (PKC) serine-threonine kinases are master regulators of proinflammatory signaling hubs, making them attractive therapeutic targets. Pharmacological inhibition of broad-spectrum PKC activity and, more importantly, of specific PKC isoforms (as well as deletion of PKCs in mice) exerts protective effects in various experimental models of lung injury. Furthermore, PKC isoforms have been implicated in inflammatory processes that may be involved in the pathophysiologic changes that result in ARDS, including activation of innate immune and endothelial cells, neutrophil trafficking to the lung, regulation of alveolar epithelial barrier functions, and control of neutrophil proinflammatory and prosurvival signaling. This review focuses on the mechanistic involvement of PKC isoforms in the pathogenesis of ARDS and highlights the potential of developing new therapeutic paradigms based on the selective inhibition (or activation) of specific PKC isoforms.
C1 [Mondrinos, Mark J.; Kennedy, Paul A.; Kilpatrick, Laurie E.] Temple Univ, Sch Med, Ctr Inflammat Translat & Clin Lung Res, Philadelphia, PA 19122, United States.
C1 [Mondrinos, Mark J.; Kilpatrick, Laurie E.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA, United States.
C1 [Mondrinos, Mark J.; Kennedy, Paul A.; Kilpatrick, Laurie E.] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA, United States.
C1 [Lyons, Melanie; Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104, United States.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; University of Pennsylvania;
   Pennsylvania Medicine
RP Kilpatrick, LE (corresponding author), Temple Univ, Sch Med, Ctr Inflammat Translat & Clin Lung Res, 3500 North Broad St,MERB 1153, Philadelphia, PA 19122 USA.
EM laurie.kilpatrick@temple.edu
RI Deutschman, Clifford/AAN-2742-2021
OI Lyons, M.Melanie/0000-0003-3153-8324
FU National Heart Lung and Blood Institute [R01HL111552]; National
   Institute of General Medicine Sciences [R41GM103193]; National Institute
   for Nursing Research [F31NR012100]; National Heart Lung and Blood
   Institute, National Institutes of Health, Bethesda, Maryland
   [5T32-HL007777]
FX This work was supported by grants from the National Heart Lung and Blood
   Institute (R01HL111552) and the National Institute of General Medicine
   Sciences (R41GM103193) to L. E. K., the National Institute for Nursing
   Research (F31NR012100) to M. L., and the National Heart Lung and Blood
   Institute (5T32-HL007777) to M.J.M, National Institutes of Health,
   Bethesda, Maryland.
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Akakura Shin, 2012, J Signal Transduct, V2012, P529179, DOI 10.1155/2012/529179
   Arnold R, 2005, J IMMUNOL, V174, P7359, DOI 10.4049/jimmunol.174.11.7359
   Asehnoune K, 2005, CELL SIGNAL, V17, P385, DOI 10.1016/j.cellsig.2004.08.005
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Ashbaugh DG, 1967, LANCET
   Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bertram A, 2012, J IMMUNOL, V188, P4043, DOI 10.4049/jimmunol.1101651
   Bertram A, 2011, ARCH IMMUNOL THER EX, V59, P79, DOI 10.1007/s00005-011-0112-7
   Bosma KJ, 2007, EXPERT OPIN EMERG DR, V12, P461, DOI 10.1517/14728214.12.3.461
   Bosma KJ, 2010, DRUGS, V70, P1255, DOI 10.2165/10898570-000000000-00000
   Bourdonnay E, 2012, J LEUKOCYTE BIOL, V92, P219, DOI 10.1189/jlb.1211590
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4
   Budas GR, 2007, BIOCHEM SOC T, V35, P1021, DOI 10.1042/BST0351021
   Budas GR, 2007, PHARMACOL RES, V55, P523, DOI 10.1016/j.phrs.2007.04.005
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Butler JP, 2012, NEW ENGL J MED, V367, P244, DOI 10.1056/NEJMoa1203983
   Caraballo JC, 2011, AM J PHYSIOL-LUNG C, V300, pL569, DOI 10.1152/ajplung.00109.2010
   Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P101
   Chakrabarti S, 2006, J LEUKOCYTE BIOL, V79, P214, DOI 10.1189/jlb.0605353
   Chakrabarti S, 2008, MICROCIRCULATION, V15, P555, DOI 10.1080/10739680801949732
   Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012
   Cho SC, 2011, EXP MOL MED, V43, P525, DOI 10.3858/emm.2011.43.9.060
   Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0
   Chou WH, 2004, J CLIN INVEST, V114, P49, DOI 10.1172/JC1200421655
   Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482
   Churchill E, 2008, ANNU REV PHARMACOL, V48, P569, DOI 10.1146/annurev.pharmtox.48.121806.154902
   Churchill EN, 2009, TRENDS ENDOCRIN MET, V20, P25, DOI 10.1016/j.tem.2008.10.002
   Cohen P, 2009, CURR OPIN CELL BIOL, V21, P317, DOI 10.1016/j.ceb.2009.01.015
   Collins SL, 2011, AM J RESP CELL MOL, V45, P675, DOI 10.1165/rcmb.2010-0387OC
   Corsini E, 2001, IMMUNOL LETT, V76, P89, DOI 10.1016/S0165-2478(00)00327-8
   Costa ELV, 2013, CURR OPIN CRIT CARE, V19, P16, DOI 10.1097/MCC.0b013e32835c50b1
   Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200
   Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200
   Daffara R, 2004, J APPL PHYSIOL, V97, P1575, DOI 10.1152/japplphysiol.00236.2004
   DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4
   Diaz-Meco MT, 2012, IMMUNOL REV, V246, P154, DOI 10.1111/j.1600-065X.2012.01093.x
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E
   Ertel W, 1998, J TRAUMA, V44, P767, DOI 10.1097/00005373-199805000-00005
   Evans SE, 2012, INNATE IMMUN-LONDON, V18, P709, DOI 10.1177/1753425912436763
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120
   Faisal A, 2008, J BIOL CHEM, V283, P18591, DOI 10.1074/jbc.M710330200
   Ferro T, 2000, AM J PHYSIOL-LUNG C, V278, pL1107, DOI 10.1152/ajplung.2000.278.6.L1107
   Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s
   Fronhofer V, 2006, J LEUKOCYTE BIOL, V79, P408, DOI 10.1189/jlb.0805438
   Gaestel M, 2009, NAT REV DRUG DISCOV, V8, P480, DOI 10.1038/nrd2829
   Gea-Sorl S, 2011, J PATHOL, V223, P417, DOI 10.1002/path.2814
   Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hegde A, 2010, INT J INFLAMM, V2010, DOI 10.4061/2010/601098
   Hendey B, 2002, J LEUKOCYTE BIOL, V71, P863
   Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065
   Hillyer P, 2003, CLIN EXP IMMUNOL, V134, P431, DOI 10.1111/j.1365-2249.2003.02323.x
   Hu J, 2002, J IMMUNOL, V168, P3910, DOI 10.4049/jimmunol.168.8.3910
   Huang F, 2005, AM J PHYSIOL-LUNG C, V289, pL176, DOI 10.1152/ajplung.00003.2005
   Huda R, 2004, SHOCK, V21, P500, DOI 10.1097/01.shk.0000124029.92586.5a
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119
   Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X
   Kawakami A, 2006, CIRCULATION, V114, P681, DOI 10.1161/CIRCULATIONAHA.106.622514
   Kent JD, 1996, J IMMUNOL, V157, P4641
   Kheifets V, 2007, PHARMACOL RES, V55, P467, DOI 10.1016/j.phrs.2007.04.014
   Kilpatrick LE, 2006, J LEUKOCYTE BIOL, V80, P1512, DOI 10.1189/jlb.0406284
   Kilpatrick LE, 2011, J LEUKOCYTE BIOL, V89, P3, DOI 10.1189/jlb.0510281
   Kilpatrick LE, 2010, J LEUKOCYTE BIOL, V87, P153, DOI 10.1189/jlb.0408230
   Kilpatrick LE, 2004, AM J PHYSIOL-CELL PH, V287, pC633, DOI 10.1152/ajpcell.00486.2003
   Kilpatrick LE, 2002, AM J PHYSIOL-CELL PH, V283, pC48, DOI 10.1152/ajpcell.00385.2001
   Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315
   Korchak HA, 2007, BBA-MOL CELL RES, V1773, P440, DOI 10.1016/j.bbamcr.2006.10.007
   Korchak HM, 2001, J BIOL CHEM, V276, P8910, DOI 10.1074/jbc.M008326200
   Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292
   Kubo-Murai M, 2007, MOL IMMUNOL, V44, P2257, DOI 10.1016/j.molimm.2006.11.005
   Lag M, 2005, TOXICOLOGY, V211, P253, DOI 10.1016/j.tox.2005.03.012
   Langlet C, 2010, EUR J IMMUNOL, V40, P505, DOI 10.1002/eji.200939391
   Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042
   Leverence JT, 2011, CHEM-BIOL INTERACT, V189, P72, DOI 10.1016/j.cbi.2010.09.026
   Li JJ, 2013, AM J RESP CELL MOL, V48, P314, DOI 10.1165/rcmb.2012-0278OC
   Li XC, 2004, BLOOD, V104, P1716, DOI 10.1182/blood-2003-11-3744
   Loegering Daniel J, 2011, Enzyme Res, V2011, P537821, DOI 10.4061/2011/537821
   Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013
   MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Martins JO, 2008, CELL PHYSIOL BIOCHEM, V21, P297, DOI 10.1159/000129388
   Martins JO, 2011, J LEUKOCYTE BIOL, V89, P1, DOI 10.1189/jlb.0810452
   MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081
   McGettrick AF, 2006, P NATL ACAD SCI USA, V103, P9196, DOI 10.1073/pnas.0600462103
   Meldrum DR, 1998, SHOCK, V9, P256, DOI 10.1097/00024382-199804000-00004
   Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281
   MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427
   Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200
   Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871
   MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516
   Moreland JG, 2004, J IMMUNOL, V172, P426, DOI 10.4049/jimmunol.172.1.426
   Moulakakis C, 2007, J IMMUNOL, V179, P4480, DOI 10.4049/jimmunol.179.7.4480
   Muller S, 2010, EXPERT OPIN DRUG DIS, V5, P867, DOI 10.1517/17460441.2010.504203
   Muenzer JT, 2010, INFECT IMMUN, V78, P1582, DOI 10.1128/IAI.01213-09
   Nagpala PG, 1996, J CELL PHYSIOL, V166, P249, DOI 10.1002/(SICI)1097-4652(199602)166:2<249::AID-JCP2>3.0.CO;2-P
   O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070
   Oeckler RA, 2007, EUR RESPIR J, V30, P1216, DOI 10.1183/09031936.00104907
   OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681
   Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496
   Park GY, 2006, CURR DRUG TARGETS, V7, P661, DOI 10.2174/138945006777435317
   Perl M, 2008, MOL MED, V14, P465, DOI 10.2119/2008-00011.Perl
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   Prince LR, 2011, CURR OPIN PHARMACOL, V11, P397, DOI 10.1016/j.coph.2011.06.007
   Puneet P, 2010, SCIENCE, V328, P1290, DOI 10.1126/science.1188635
   Rahman A, 1999, MOL PHARMACOL, V55, P575
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Ramnath RD, 2010, J MOL MED, V88, P1055, DOI 10.1007/s00109-010-0647-9
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reutershan J, 2004, CRIT CARE, V8, P453, DOI 10.1186/cc2881
   Roe MT, 2008, CIRCULATION, V117, P886, DOI 10.1161/CIRCULATIONAHA.107.759167
   Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008
   Saiepour D, 2006, INFLAMM RES, V55, P85, DOI 10.1007/s00011-005-0009-1
   Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778
   Schmidt E P, 2010, J Cell Death, V3, P41
   Sender V, 2011, J IMMUNOL, V186, P2397, DOI 10.4049/jimmunol.1002446
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Sergeant S, 1997, J IMMUNOL, V159, P2877
   Shi CB, 2007, VASC PHARMACOL, V46, P406, DOI 10.1016/j.vph.2007.01.009
   Shukla A, 2003, AM J RESP CELL MOL, V29, P198, DOI 10.1165/rcmb.2002-0248OC
   Shukla A, 2007, AM J PATHOL, V170, P140, DOI 10.2353/ajpath.2007.060381
   Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736
   Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Thille AW, 2013, AM J RESP CRIT CARE, V187, P761, DOI 10.1164/rccm.201211-1981OC
   TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548
   Tinsley JH, 2004, AM J PHYSIOL-CELL PH, V286, pC105, DOI 10.1152/ajpcell.00340.2003
   Tsai BM, 2007, SHOCK, V27, P36, DOI 10.1097/01.shk.0000235128.97610.b2
   Vadasz I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046696
   Waerhaug K, 2008, CRIT CARE, V12, DOI 10.1186/cc6985
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388
   Williams MR, 2011, TRENDS IMMUNOL, V32, P461, DOI 10.1016/j.it.2011.06.009
   Woo CH, 2005, AM J PHYSIOL-LUNG C, V288, pL307, DOI 10.1152/ajplung.00105.2004
   Wrann CD, 2007, CELL IMMUNOL, V245, P63, DOI 10.1016/j.cellimm.2007.04.001
   Xiang M, 2010, MOL MED, V16, P69, DOI 10.2119/molmed.2009.00097
   Xu J, 2010, SHOCK, V33, P49, DOI 10.1097/SHK.0b013e3181a76d77
   Yang SL, 1998, SHOCK, V9, P199, DOI 10.1097/00024382-199803000-00007
   Yao HW, 2010, J BIOL CHEM, V285, P5405, DOI 10.1074/jbc.M109.041418
   Zhao X, 2006, RESP PHYSIOL NEUROBI, V152, P16, DOI 10.1016/j.resp.2005.07.005
   Zhi L, 2013, TRANSFUSION, V53, P722, DOI 10.1111/j.1537-2995.2012.03811.x
   Zhou XY, 2006, J BIOL CHEM, V281, P31337, DOI 10.1074/jbc.M602739200
   Zimmerman GA, 1999, CHEST, V116, p18S, DOI 10.1378/chest.116.suppl_1.18S
NR 163
TC 27
Z9 30
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2013
VL 39
IS 6
BP 467
EP 479
DI 10.1097/SHK.0b013e318294f85a
PG 13
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 147WL
UT WOS:000319200700002
PM 23572089
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Rittirsch, D
   Flierl, MA
   Nadeau, BA
   Day, DE
   Huber-Lang, MS
   Grailer, JJ
   Zetoune, FS
   Andjelkovic, AV
   Fasano, A
   Ward, PA
AF Rittirsch, Daniel
   Flierl, Michael A.
   Nadeau, Brian A.
   Day, Danielle E.
   Huber-Lang, Markus S.
   Grailer, Jamison J.
   Zetoune, Firas S.
   Andjelkovic, Anuska V.
   Fasano, Alessio
   Ward, Peter A.
TI Zonulin as prehaptoglobin2 regulates lung permeability and activates the
   complement system
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE Inflammation; ALI/ARDS; tight junction; C3a; C5a 
ID RESPIRATORY-DISTRESS-SYNDROME; EPITHELIAL BARRIER FUNCTION;
   SERINE-PROTEASE; TIGHT JUNCTIONS; INFLAMMATORY INJURY; INTESTINAL
   PERMEABILITY; CELIAC-DISEASE; C5A; HAPTOGLOBIN; EXPRESSION
AB Zonulin is a protein involved in the regulation of tight junctions (TJ) in epithelial or endothelial cells. Zonulin is known to affect TJ in gut epithelial cells, but little is known about its influences in other organs. Prehaptoglobin2 has been identified as zonulin and is related to serine proteases (MASPs, C1qrs) that activate the complement system. The current study focused on the role of zonulin in development of acute lung injury (ALI) in C57BL/6 male mice following intrapulmonary deposition of IgG immune complexes. A zonulin antagonist (AT-1001) and a related peptide with permeability agonist activities (AT-1002) were employed and given intratracheally or intravenously. Also, zonulin was blocked in lung with a neutralizing antibody. In a dose-dependent manner, AT-1001 or zonulin neutralizing antibody attenuated the intensity of ALI (as quantitated by albumin leak, neutrophil accumulation, and proinflammatory cytokines). A similar pattern was found using the bacterial lipopolysaccharide model of ALI. Using confocal microscopy on sections of injured lungs, staining patterns for TJ proteins were discontinuous, reduced, and fragmented. As expected, the leak of blood products into the alveolar space confirmed the passage of 3 and 20 kDa dextran, and albumin. In contrast to AT-1001, application of the zonulin agonist AT-1002 intensified ALI. Zonulin both in vitro and in vivo induced generation of complement C3a and C5a. Collectively, these data suggest that zonulin facilitates development of ALI both by enhancing albumin leak and complement activation as well as increased buildup of neutrophils and cytokines during development of ALI.
C1 [Rittirsch, Daniel; Flierl, Michael A.; Nadeau, Brian A.; Day, Danielle E.; Grailer, Jamison J.; Zetoune, Firas S.; Andjelkovic, Anuska V.; Ward, Peter A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109, United States.
C1 [Rittirsch, Daniel] Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland.
C1 [Flierl, Michael A.] Univ Colorado, Sch Med, Dept Orthopaed Surg, Denver Hlth Med Ctr, Denver, CO, United States.
C1 [Huber-Lang, Markus S.] Univ Hosp Ulm, Dept Trauma Hand & Reconstruct Surg, Ulm, Germany.
C1 [Fasano, Alessio] Univ Maryland, Mucosal Biol Res Ctr, Baltimore, MD 21201, United States.
C3 University of Michigan System; University of Michigan; University of
   Zurich; University Zurich Hospital; Denver Health Medical Center;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver; Ulm University; University System
   of Maryland; University of Maryland Baltimore
RP Rittirsch, D (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Ramistr 100, CH-8091 Zurich, Switzerland.
EM drittirsch@gmail.com
RI Fasano, Alessio/K-5486-2016; Huber-Lang, Markus/AAJ-2209-2020
OI Fasano, Alessio/0000-0002-2134-0261; Rittirsch,
   Daniel/0000-0002-1185-2431
FU National Institutes of Health [GM-029507, GM-061656, HL-007517-29,
   NS-075757, DK-048373]
FX This study was supported by National Institutes of Health Grants
   GM-029507, GM-061656 (P. A. Ward), HL-007517-29 (J. J. Grailer),
   NS-075757 (A. V. Andjelkovic), and DK-048373 (A. Fasano).
CR Arrieta MC, 2009, GUT, V58, P41, DOI 10.1136/gut.2008.150888
   Asleh R, 2003, CIRC RES, V92, P1193, DOI 10.1161/01.RES.0000076889.23082.F1
   Bosmann M, 2012, FASEB J, V26, P2137, DOI 10.1096/fj.11-201640
   BOWMAN BH, 1982, ADV HUM GENET, V12, P453
   Clemente MG, 2003, GUT, V52, P218, DOI 10.1136/gut.52.2.218
   Czermak BJ, 1999, AM J PATHOL, V154, P1513, DOI 10.1016/S0002-9440(10)65405-3
   Fasano A, 2000, LANCET, V355, P1518, DOI 10.1016/S0140-6736(00)02169-3
   Fasano A, 2001, GASTROENTEROLOGY, V120, P636, DOI 10.1053/gast.2001.22123
   FLIERL MA, 2006, MED HYPOTHESIS RES, V3, P727
   Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185
   Frank JA, 2012, ANN NY ACAD SCI, V1257, P175, DOI 10.1111/j.1749-6632.2012.06533.x
   Goldblum SE, 2011, FASEB J, V25, P144, DOI 10.1096/fj.10-158972
   Gonzalez-Mariscal L, 2005, ADV DRUG DELIVER REV, V57, P811, DOI 10.1016/j.addr.2005.01.004
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   HAMMERSCHMIDT DE, 1980, LANCET, V1, P947
   HAUGEN TH, 1981, J BIOL CHEM, V256, P1055
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Jin W, RESPIROLOGY IN PRESS
   Kolpuru S, 2006, J PEDIAT GASTROENTER, V43, pE52
   Koval M, 2009, AM J PHYSIOL-LUNG C, V297, pL217, DOI 10.1152/ajplung.00196.2009
   KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388
   Lee DBN, 2006, AM J PHYSIOL-RENAL, V290, pF20, DOI 10.1152/ajprenal.00052.2005
   MAEDA N, 1984, NATURE, V309, P131, DOI 10.1038/309131a0
   Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281
   MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055
   Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818
   Neff TA, 2005, AM J PATHOL, V166, P685, DOI 10.1016/S0002-9440(10)62290-0
   Rittirsch D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000464
   Rokkam D, 2011, AM J PATHOL, V179, P1081, DOI 10.1016/j.ajpath.2011.05.017
   Romem A, 2012, AM J RESP CRIT CARE, V185, pA4266
   Sapone A, 2006, DIABETES, V55, P1443, DOI 10.2337/db05-1593
   Shanley TP, 1997, AM J PATHOL, V151, P193
   Skardelly M, 2009, TRANSL ONCOL, V2, P117, DOI 10.1593/tlo.09115
   SOLOMKIN JS, 1985, SURGERY, V97, P668
   Speyer CL, 2004, AM J PATHOL, V165, P2187, DOI 10.1016/S0002-9440(10)63268-3
   Sun L, 2009, FASEB J, V23, P3808, DOI 10.1096/fj.09-133694
   TOSI M, 1989, J MOL BIOL, V208, P709, DOI 10.1016/0022-2836(89)90161-7
   Tripathi A, 2009, P NATL ACAD SCI USA, V106, P16799, DOI 10.1073/pnas.0906773106
   Uzzau S, 1999, MICROB PATHOGENESIS, V27, P377, DOI 10.1006/mpat.1999.0312
   Wang Wenle, 2000, World Journal of Gastroenterology, V6, P330
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374
   Wray C, 2009, AM J PHYSIOL-LUNG C, V297, pL219, DOI 10.1152/ajplung.00043.2009
   Zhu Y, 2005, EMBO J, V24, P382, DOI 10.1038/sj.emboj.7600533
NR 45
TC 46
Z9 46
U1 0
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUN
PY 2013
VL 304
IS 12
BP L863
EP L872
DI 10.1152/ajplung.00196.2012
PG 10
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 164WT
UT WOS:000320443200006
PM 23564505
OA Green Published
DA 2023-08-21
ER

PT J
AU Kandasamy, K
   Bezavada, L
   Escue, RB
   Parthasarathi, K
AF Kandasamy, Kathirvel
   Bezavada, Lavanya
   Escue, Rachel B.
   Parthasarathi, Kaushik
TI Lipopolysaccharide Induces Endoplasmic Store Ca2+-Dependent Inflammatory
   Responses in Lung Microvessels
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; INDUCED CYTOKINE PRODUCTION; ENDOTHELIAL-CELLS;
   PROINFLAMMATORY RESPONSES; CALCIUM OSCILLATION; SIGNALING PATHWAY;
   GENE-EXPRESSION; ACTIVATION; RECEPTOR; PROTEIN
AB The pulmonary microvasculature plays a critical role in endotoxin-induced acute lung injury. However, the relevant signaling remain unclear. Specifically the role of endothelial Ca2+ in the induction of endotoxin-mediated responses in lung microvessels remains undefined. Toward elucidating this, we used the isolated blood-perfused rat lung preparation. We loaded microvessels with the Ca2+ indicator, Fura 2 AM and then determined Ca2+ responses to infusions of lipopolysaccharide (LPS) into the microvessels. LPS induced a more than two-fold increase in the amplitude of cytosolic Ca2+ oscillations. Inhibiting inositol 1,4,5 trisphosphate receptors on endoplasmic reticulum (ER) Ca2+ stores with Xestospongin C (XeC), blocked the LPS-induced increase in the Ca2+ oscillation amplitude. However, XeC did not affect entry of external Ca2+ via plasma membrane Ca2+ channels in lung microvascular endothelial cells. This suggested that LPS augmented the oscillations via release of Ca2+ from ER stores. In addition, XeC also blocked LPS-mediated activation and nuclear translocation of nuclear factor-kappa B in lung microvessels. Further, inhibiting ER Ca2+ release blunted increases in intercellular adhesion molecule-1 expression and retention of naive leukocytes in LPS-treated microvessels. Taken together, the data suggest that LPS-mediated Ca2+ release from ER stores underlies nuclear factor-kappa B activation and downstream inflammatory signaling in lung microvessels. Thus, we show for the first time a role for inositol 1,4,5 trisphosphate-mediated ER Ca2+ release in the induction of LPS responses in pulmonary microvascular endothelium. Mechanisms that blunt this signaling may mitigate endotoxin-induced morbidity.
C1 [Kandasamy, Kathirvel; Bezavada, Lavanya; Escue, Rachel B.; Parthasarathi, Kaushik] Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163, United States.
C1 [Parthasarathi, Kaushik] Univ Tennessee, Ctr Hlth Sci, Dept Orthoped Surg & Biomed Engn, Memphis, TN 38163, United States.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center
RP Parthasarathi, K (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA.
EM kparthas@uthsc.edu
OI Bezavada, Lavanya/0000-0001-8434-3323; Kandasamy,
   Kathirvel/0000-0002-4966-4604; Helms, Rachel/0000-0001-5027-7153
FU National Heart, Lung, and Blood Institute, National Institutes of Health
   [HL75503]
FX This study was funded by the National Heart, Lung, and Blood Institute,
   National Institutes of Health, grant number HL75503. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Adachi T, 1997, HEPATOLOGY, V26, P295, DOI 10.1002/hep.510260207
   Antonsson A, 2003, MOL CELL BIOL, V23, P1418, DOI 10.1128/MCB.23.4.1418-1427.2003
   Aul R, 2012, BRIT J CLIN PHARMACO, V74, P1023, DOI 10.1111/j.1365-2125.2012.04287.x
   BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406
   Beck A, 2008, J PHYSIOL-LONDON, V586, P427, DOI 10.1113/jphysiol.2007.145151
   Berendji-Grun D, 2001, MOL MED, V7, P748, DOI 10.1007/BF03401964
   BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0
   Chin ER, 2005, J APPL PHYSIOL, V99, P414, DOI 10.1152/japplphysiol.00015.2005
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   Guo F, 2012, CYTOKINE, V57, P417, DOI 10.1016/j.cyto.2011.12.009
   Hoffmann A, 2003, J NEUROSCI, V23, P4410
   Hu QH, 2002, BIOCHEM BIOPH RES CO, V292, P325, DOI 10.1006/bbrc.2002.6675
   Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200
   Ichimura H, 2003, J CLIN INVEST, V111, P691, DOI 10.1172/JCI200317271
   Inoue R, 2009, CIRC RES, V104, P1399, DOI 10.1161/CIRCRESAHA.108.193227
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799
   Kandasamy K, 2012, MICROVASC RES, V83, P323, DOI 10.1016/j.mvr.2012.01.006
   Karpurapu M, 2011, BLOOD, V118, P5255, DOI 10.1182/blood-2011-03-341123
   Kayama H, 2008, J BIOL CHEM, V283, P12468, DOI 10.1074/jbc.M709965200
   Kiefmann R, 2009, AM J PHYSIOL-LUNG C, V296, pL901, DOI 10.1152/ajplung.90549.2008
   Kojima S, 2000, BLOOD, V95, P1309
   Lai DZ, 2009, P NATL ACAD SCI USA, V106, P1169, DOI 10.1073/pnas.0811274106
   Lawson C, 1999, J IMMUNOL, V162, P2990
   Lowry MAR, 1999, DEV COMP IMMUNOL, V23, P253, DOI 10.1016/S0145-305X(99)00004-X
   Lu ZY, 2012, ARTERIOSCL THROM VAS, V32, P1696, DOI 10.1161/ATVBAHA.112.251181
   Maloney E, 2009, ARTERIOSCL THROM VAS, V29, P1370, DOI 10.1161/ATVBAHA.109.188813
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110
   Otterson MF, 2012, LIFE SCI, V91, P771, DOI 10.1016/j.lfs.2012.08.018
   Parthasarathi K, 2002, J IMMUNOL, V169, P7078, DOI 10.4049/jimmunol.169.12.7078
   Parthasarathi K, 2006, J CLIN INVEST, V116, P2193, DOI 10.1172/JCI26605
   Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906
   Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2
   Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206
   Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351
   Scharbrodt W, 2009, J CEREBR BLOOD F MET, V29, P57, DOI 10.1038/jcbfm.2008.87
   SCHUMANN MA, 1993, J BIOL CHEM, V268, P2134
   Segura BJ, 2005, MOL BRAIN RES, V133, P325, DOI 10.1016/j.molbrainres.2004.10.016
   Shinji H, 1997, J IMMUNOL, V158, P1370
   Song YX, 2013, EUR J PHARMACOL, V705, P49, DOI 10.1016/j.ejphar.2013.02.008
   Stevens Troy, 2011, Proc Am Thorac Soc, V8, P453, DOI 10.1513/pats.201101-004MW
   Tauseef M, 2012, J EXP MED, V209, P1953, DOI 10.1084/jem.20111355
   Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007
   Thor D, 2012, VASCUL PHARM, V53, P230
   Tullai JW, 2007, J BIOL CHEM, V282, P23981, DOI 10.1074/jbc.M702044200
   Valdes JA, 2007, AM J PHYSIOL-CELL PH, V292, pC1960, DOI 10.1152/ajpcell.00320.2006
   Wang Q, 2005, AM J PHYSIOL-LUNG C, V288, pL359, DOI 10.1152/ajplung.00292.2004
   Wehrhahn J, 2010, J IMMUNOL, V184, P2386, DOI 10.4049/jimmunol.0902474
   Wildner O, 1992, Exp Dermatol, V1, P191, DOI 10.1111/j.1600-0625.1992.tb00188.x
   Wurster AL, 2011, MOL IMMUNOL, V48, P2178, DOI 10.1016/j.molimm.2011.07.016
   Xie YC, 1997, J LEUKOCYTE BIOL, V61, P745, DOI 10.1002/jlb.61.6.745
   Yamashiro K, 2010, BIOCHEM BIOPH RES CO, V398, P284, DOI 10.1016/j.bbrc.2010.06.082
   Zhou XY, 2006, J BIOL CHEM, V281, P31337, DOI 10.1074/jbc.M602739200
NR 54
TC 32
Z9 33
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2013
VL 8
IS 5
AR e63465
DI 10.1371/journal.pone.0063465
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 143FO
UT WOS:000318852400041
PM 23675486
OA Green Submitted, gold, Green Published
DA 2023-08-21
ER

PT J
AU Caires, ND
   Legendre, B
   Parmentier, E
   Scherpereel, A
   Tsicopoulos, A
   Mathieu, D
   Lassalle, P
AF Caires, Nathalie De Freitas
   Legendre, Benjamin
   Parmentier, Erika
   Scherpereel, Arnaud
   Tsicopoulos, Anne
   Mathieu, Daniel
   Lassalle, Philippe
TI Identification of a 14 kDa endocan fragment generated by cathepsin G, a
   novel circulating biomarker in patients with sepsis
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE sepsis; ECs/HPMECs/HUVECs/MPVECs; Endocan; Cathepsin G; biomarkers; Immunoassay 
ID CELL-SPECIFIC MOLECULE-1; EPIDEMIOLOGY; LUNG
AB Severe septic syndrome, which is the most prevalent and lethal cause of acute respiratory distress syndrome, remains one of the most frequent causes of admission and death in intensive care units (ICU). Inflammatory phenomenon leading to severe sepsis are multiple and not yet completely understood. The main target damage during severe sepsis is the endothelium. Endocan, specifically secreted by activated-pulmonary vascular endothelial cells, is thought to play a key role in the control of the lung inflammatory reaction. A recent clinical investigation found that a low plasma endocan level was predictive of respiratory failure. In this study, the hypothesis that low levels of endocan may result from proteolysis was tested. We demonstrate that cathepsin G (CG), neutrophil elastase (NE), and to a lesser extent proteinase 3 (PR3), degrade endocan. Interestingly, a novel endocan peptide fragment of 14 kDa, named p14, was identified, resulting from the specific cleavage of endocan by CG, corresponding to the N-terminal 111-116 amino acids of the endocan polypeptide. An immunoassay specific for p14 endocan fragment was then developed, and revealed increased plasma levels of p14 in 20 out of 55 severe septic patients, ranging from 0.52 to 10.40 ng/mL versus undetectable p14 in plasma from 32 control subjects (p = 0.0011). No correlations were found between p14 and endocan blood levels in severe septic patients. Taken together, the p14 endocan fragment represents a novel interesting biomarker which could participate to the pathogenesis of sepsis. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Caires, Nathalie De Freitas; Legendre, Benjamin; Scherpereel, Arnaud; Tsicopoulos, Anne; Lassalle, Philippe] Inst Pasteur, Ctr Infect & Immun Lille, F-59019 Lille, France.
C1 [Caires, Nathalie De Freitas; Legendre, Benjamin; Scherpereel, Arnaud; Tsicopoulos, Anne; Lassalle, Philippe] Univ Lille Nord France, F-59000 Lille, France.
C1 [Caires, Nathalie De Freitas; Legendre, Benjamin; Scherpereel, Arnaud; Tsicopoulos, Anne; Lassalle, Philippe] CNRS, UMR 8204, F-59021 Lille, France.
C1 [Caires, Nathalie De Freitas; Legendre, Benjamin; Scherpereel, Arnaud; Tsicopoulos, Anne; Lassalle, Philippe] Inst Natl Sante & Rech Med, U1019, F-59019 Lille, France.
C1 [Caires, Nathalie De Freitas] Lunginnov, F-59000 Lille, France.
C1 [Parmentier, Erika; Scherpereel, Arnaud; Mathieu, Daniel] CHRU Lille, Hop Calmette, F-59037 Lille, France.
C3 Le Reseau International des Instituts Pasteur (RIIP); Universite de
   Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite
   de Lille - ISITE; Universite de Lille; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le
   Reseau International des Instituts Pasteur (RIIP); Universite de Lille -
   ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Universite de Lille -
   ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille
RP Lassalle, P (corresponding author), Inst Pasteur, INSERM, U1019, Equipe 11, 1 Rue Pr A Calmette, F-59019 Lille, France.
EM philippe.lassalle@pasteur-lille.fr
RI Lassalle, Philippe/L-6705-2018; Tsicopoulos, Anne/C-2260-2019
OI Tsicopoulos, Anne/0000-0002-1579-2763; Parmentier-Decrucq,
   Erika/0000-0002-5836-5956; lassalle, philippe/0000-0001-6434-0344
FU OSEO [A08120004N]; Santelys (Loos, France)
FX We thank Herve Drobecq (U8161, Lille, France), Willy Morelle (U8576,
   Villeneuve d'Ascq, France) for the mass spectrometry analyses, Philippe
   Hauw, Gwenola Kervoaze, and Genevieve Marchandise for their technical
   help and advice. The authors also thank Pr. Francis Gauthier (U618,
   Tours, France) for his helpful advice. This work was supported in part
   by OSEO (grant no. A08120004N) and by Santelys (Loos, France).
CR Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462
   Aird WC, 2007, CURR DRUG TARGETS, V8, P501, DOI 10.2174/138945007780362782
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Attucci S, 2002, BIOCHEM J, V366, P965, DOI 10.1042/BJ20020321
   Bechard D, 2000, J VASC RES, V37, P417, DOI 10.1159/000025758
   Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200
   BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4
   BrunBuisson C, 1996, AM J RESP CRIT CARE, V154, P617, DOI 10.1164/ajrccm.154.3.8810595
   Depontieu F, 2012, J IMMUNOL METHODS, V378, P88, DOI 10.1016/j.jim.2012.02.009
   Feinberg M., 2009, GUIDE VALIDATION MET
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Harrois A, 2011, CURR OPIN CRIT CARE, V17, P303, DOI 10.1097/MCC.0b013e3283466ba0
   Lassalle P, 1996, J BIOL CHEM, V271, P20458, DOI 10.1074/jbc.271.34.20458
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Mikkelsen ME, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.07.077
   RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117
   Rehault S, 1999, J BIOL CHEM, V274, P13810, DOI 10.1074/jbc.274.20.13810
   Scherpereel A, 2006, CRIT CARE MED, V34, P532, DOI 10.1097/01.CCM.0000198525.82124.74
   Slade E, 2003, CRIT CARE, V7, P1, DOI 10.1186/cc1876
   Tsai JC, 2002, J VASC RES, V39, P148, DOI 10.1159/000057763
NR 21
TC 32
Z9 34
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731-7085
EI 1873-264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD MAY 5
PY 2013
VL 78-79
BP 45
EP 51
DI 10.1016/j.jpba.2013.01.035
PG 7
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 124DA
UT WOS:000317442800008
PM 23454598
DA 2023-08-21
ER

PT J
AU Faller, S
   Spassov, SG
   Zimmermann, KK
   Ryter, SW
   Buerkle, H
   Loop, T
   Schmidt, R
   Strosing, KM
   Hoetzel, A
AF Faller, Simone
   Spassov, Sashko G.
   Zimmermann, Kornelia K.
   Ryter, Stefan W.
   Buerkle, Hartmut
   Loop, Torsten
   Schmidt, Rene
   Strosing, Karl M.
   Hoetzel, Alexander
TI Hydrogen Sulfide Prevents Hyperoxia-induced Lung Injury by
   Downregulating Reactive Oxygen Species Formation and Angiopoietin-2
   Release
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE hydrogen sulfide; hyperoxia; ALI/ARDS; ROS; angiopoietin-1/angiopoietin-2; organ protection; hyperoxia 
ID ENDOTHELIAL-CELLS; ISCHEMIA/REPERFUSION INJURY; PULMONARY INFLAMMATION;
   OXIDATIVE STRESS; PC12 CELLS; PROTECTS; DEATH; RATS; ACTIVATION;
   EXPRESSION
AB Oxygen therapy is a life-sustaining treatment for patients with respiratory failure. However, prolonged exposure to high oxygen concentrations often results in hyperoxia-induced acute lung injury (HALI). At present, no effective therapeutic intervention can attenuate the development of HALI. In the present study, we investigated whether hydrogen sulfide (H2S) can confer lung protection in a mouse model of HALI. C57BL/6 mice were either exposed to room air or 90 vol% oxygen and received either the H2S donor sodium hydrosulfide (NaHS, 10 mg/kg) or vehicle. Lung injury was assessed by an HALI score in tissue sections. Bronchoalveolar lavage fluid was analyzed for protein content and cellular infiltration. Reactive oxygen species (ROS) were detected by dihydroethidium staining. Angiopoietin-2 was detected by Western Blotting. Pulmonary epithelial, endothelial, and macrophage cells were stimulated to produce ROS either in the absence or presence of NaHS. Mice exposed to hyperoxia developed substantial lung injury, characterized by an elevated HALI score, cellular infiltration, protein leakage, ROS production, and overexpression of angiopoietin-2. NaHS treatment abolished morphological indices of HALI. Angiopoietin-2 expression was significantly reduced by NaHS in vivo. In endothelial cells and macrophages, angiopoietin-2 was released due to ROS formation and decreased in the presence of NaHS. In conclusion, H2S protects from HALI by preventing ROS production and angiopoietin-2 release.
C1 [Faller, Simone; Spassov, Sashko G.; Zimmermann, Kornelia K.; Buerkle, Hartmut; Loop, Torsten; Schmidt, Rene; Strosing, Karl M.; Hoetzel, Alexander] Univ Med Ctr Freiburg, Dept Anesthesiol & Crit Care Med, D-79106 Freiburg, Germany.
C1 [Ryter, Stefan W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pulm & Crit Care Med, Boston, MA 02115, United States.
C3 University of Freiburg; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School
RP Hoetzel, A (corresponding author), Univ Med Ctr Freiburg, Dept Anesthesiol & Crit Care Med, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM alexander.hoetzel@uniklinik-freiburg.de
RI Spassov, Sashko G/C-2105-2013; Buerkle, Hartmut/I-5785-2014
OI Spassov, Sashko G/0000-0002-3585-3682; Faller,
   Simone/0000-0001-5345-8523
FU Deutsche Forschungsgemeinschaft (DFG, Bonn, Germany) [DFG HO 2464/3-1]
FX We thank Thomas Borschet for skilled preparation of HUVEC cells. This
   work was supported by a grant from the Deutsche Forschungsgemeinschaft
   (DFG, Bonn, Germany) to Alexander Hoetzel (DFG HO 2464/3-1).
CR Altemeier WA, 2007, CURR OPIN CRIT CARE, V13, P73, DOI 10.1097/MCC.0b013e32801162cb
   Barlos D, 2009, AM J PHYSIOL-LUNG C, V296, pL404, DOI 10.1152/ajplung.00491.2007
   Bhandari V, 2012, AM J RESP CELL MOL B
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Bhatia M, 2006, AM J PHYSIOL-LUNG C, V291, pL896, DOI 10.1152/ajplung.00053.2006
   Biermann J, 2011, MOL VIS, V17, P1275
   Chai W, 2011, J SURG RES
   Chen H, 2007, EXP MOL PATHOL, V83, P377, DOI 10.1016/j.yexmp.2007.08.016
   Chen SL, 2010, CLIN EXP PHARMACOL P, V37, P316, DOI 10.1111/j.1440-1681.2009.05289.x
   Chen ZF, 2011, CHINESE MED J-PEKING, V124, P3460, DOI 10.3760/cma.j.issn.0366-6999.2011.21.005
   Crumpton TL, 2001, BREAST CANCER RES TR, V66, P143, DOI 10.1023/A:1010603816003
   Esechie A, 2008, CLIN SCI, V115, P91, DOI 10.1042/CS20080021
   Faller S, 2012, LAB INVEST
   Faller S, 2010, ANESTHESIOLOGY, V113, P104, DOI 10.1097/ALN.0b013e3181de7107
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004
   Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094
   Harijith A, 2011, AM J RESP CELL MOL, V44, P621, DOI 10.1165/rcmb.2010-0058OC
   KANEKO M, 1990, CLIN EXP PHARMACOL P, V17, P849, DOI 10.1111/j.1440-1681.1990.tb01288.x
   Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje
   Kolliputi N, 2009, AM J PHYSIOL-LUNG C, V297, pL6, DOI 10.1152/ajplung.90381.2008
   Lang YD, 2010, FREE RADICAL BIO MED, V49, P88, DOI 10.1016/j.freeradbiomed.2010.03.022
   Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184
   Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011
   Li L, 2011, ANNU REV PHARMACOL, V51, P169, DOI 10.1146/annurev-pharmtox-010510-100505
   Li TS, 2008, EXP BIOL MED, V233, P1081, DOI 10.3181/0712-RM-354
   Osborne NN, 2012, NEUROCHEM INT, V60, P365, DOI 10.1016/j.neuint.2012.01.015
   Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002
   Park HJ, 2012, ACTA PHYSIOL, V205, P61, DOI 10.1111/j.1748-1716.2012.02425.x
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   Shi YX, 2007, AM J PHYSIOL-HEART C, V293, pH2093, DOI 10.1152/ajpheart.00088.2007
   Sodha NR, 2009, J THORAC CARDIOV SUR, V138, P977, DOI 10.1016/j.jtcvs.2008.08.074
   Spiller F, 2010, AM J RESP CRIT CARE, V182, P360, DOI 10.1164/rccm.200907-1145OC
   Tang XQ, 2008, CLIN EXP PHARMACOL P, V35, P180, DOI 10.1111/j.1440-1681.2007.04799.x
   Tyagi N, 2009, ANTIOXID REDOX SIGN, V11, P25, DOI 10.1089/ars.2008.2073
   Whiteman M, 2011, CLIN SCI, V121, P459, DOI 10.1042/CS20110267
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Wong HR, 1998, AM J PHYSIOL-LUNG C, V275, pL836, DOI 10.1152/ajplung.1998.275.4.L836
   Wu JA, 2008, BIOL REPROD, V79, P1054, DOI 10.1095/biolreprod.108.070268
   Yang CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021971
   Yin WL, 2009, LIFE SCI, V85, P269, DOI 10.1016/j.lfs.2009.05.023
   Zaher TE, 2007, FREE RADICAL BIO MED, V42, P897, DOI 10.1016/j.freeradbiomed.2007.01.021
   Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC
NR 43
TC 27
Z9 33
U1 0
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAY
PY 2013
VL 19
IS 15
BP 2715
EP 2721
DI 10.2174/1381612811319150006
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 116BC
UT WOS:000316856300006
PM 23092319
DA 2023-08-21
ER

PT J
AU Jin, WT
   Rong, LY
   Liu, YK
   Song, YL
   Li, Y
   Pan, J
AF Jin, Wenting
   Rong, Linyi
   Liu, Yinkun
   Song, Yuanlin
   Li, Yan
   Pan, Jue
TI Increased claudin-3, -4 and -18 levels in bronchoalveolar lavage fluid
   reflect severity of acute lung injury
SO RESPIROLOGY
LA English
DT Article
DE ALI/ARDS; BALF; claudins; Pseudomonas aeruginosa; tight junction 
ID RESPIRATORY-DISTRESS SYNDROME; ALVEOLAR EPITHELIAL-CELLS; TIGHT JUNCTION
   STRANDS; PSEUDOMONAS-AERUGINOSA; BARRIER FUNCTION; EXPRESSION;
   PERMEABILITY; VENTILATION; RATS; SIZE
AB Background and objective Acute lung injury (ALI) is characterized by disruption of lung epithelial and endothelial cells, leading to increased membrane permeability and loss of barrier function. Claudins are key components of tight junctions (TJ) that regulate paracellular permeability, and play an important role in alveolar epithelial barrier function and fluid clearance. However, whether claudin-3, -4, -18 or -5 expression changes in Pseudomonas aeruginosa (PA)-induced ALI and the clinical significance of such change is unknown. Methods Rats underwent intratracheal instillation of PA, and samples were collected prior to and 3, 9 and 24h after instillation. Lung injury was evaluated by bronchoalveolar lavage fluid (BALF) total protein, arterial blood gas analysis, lung injury score, and expression of surfactant protein and von Willebrand factor. Claudin expression in lung was measured with quantitative real-time polymerase chain reaction and western blotting, and in BALF by enzyme-linked immunosorbent assay. The relationship between claudins in BALF and lung injury grade were analysed with Spearman's rank correlation. Alveolar epithelium, endothelium and TJ ultrastructure were observed with electron microscopy. Results Claudin-4, -18 and -5mRNA levels increased significantly 24h after PA instillation in the most severe lung injury cases, whereas there was no significant change in protein levels. Claudin-3, -4 and -18 levels in BALF increased most 24h after PA instillation; this paralleled alveolar epithelial disruption and lung injury severity. Conclusions Claudin-3, -4 and -18 released into the alveolar compartment is highly associated with barrier function loss caused by alveolar epithelial injury.
C1 [Jin, Wenting; Rong, Linyi; Song, Yuanlin; Pan, Jue] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai 200433, China.
C1 [Liu, Yinkun; Li, Yan] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai 200433, China.
C1 [Song, Yuanlin] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Qingpu Branch, Shanghai 200433, China.
C1 [Jin, Wenting] Fudan Univ, Shanghai Peoples Hosp 1, Dept Pulm Med, Shanghai 200433, China.
C1 [Liu, Yinkun; Li, Yan] Fudan Univ, Inst Biomed Sci, Shanghai 200433, China.
C1 [Song, Yuanlin] Univ Calif San Francisco, Dept Anesthesia, Surg Res Lab, Cardiovasc Res Inst, San Francisco, CA 94143, United States.
C1 [Song, Yuanlin] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Surg, Surg Res Lab, San Francisco, CA 94143, United States.
C1 [Song, Yuanlin] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Surg Res Lab, San Francisco, CA 94143, United States.
C1 [Song, Yuanlin] Univ Calif San Francisco, Inst Mol Med, San Francisco, CA 94143, United States.
C3 Fudan University; Fudan University; Fudan University; Fudan University;
   Fudan University; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco
RP Pan, J (corresponding author), Dept Pulm Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM panjue2003@yahoo.com.cn
FU Zhongshan Hospital Youth Fund, Fudan University
FX This work was supported by a grant from Zhongshan Hospital Youth Fund,
   Fudan University.
CR Chen SP, 2005, J APPL PHYSIOL, V98, P322, DOI 10.1152/japplphysiol.00681.2004
   Cohen TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011322
   Coraux C, 2004, AM J RESP CELL MOL, V30, P605, DOI 10.1165/rcmb.2003-0056OC
   Coyne CB, 2003, AM J PHYSIOL-LUNG C, V285, pL1166, DOI 10.1152/ajplung.00182.2003
   Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093
   El SA, 2008, AM J RESP CRIT CARE, V178, P513
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Fernandez AL, 2007, ALCOHOL, V41, P371, DOI 10.1016/j.alcohol.2007.04.010
   Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D
   Hauser AR, 2008, AM J RESP CRIT CARE, V178, P438, DOI 10.1164/rccm.200805-789ED
   Kaarteenaho-Wiik R, 2009, J HISTOCHEM CYTOCHEM, V57, P187, DOI 10.1369/jhc.2008.951566
   Koval M, 2010, AM J RESP CELL MOL, V42, P172, DOI 10.1165/rcmb.2008-0270OC
   LaFemina MJ, 2010, AM J PHYSIOL-LUNG C, V299, pL724, DOI 10.1152/ajplung.00233.2010
   Lau GW, 2005, TRENDS MICROBIOL, V13, P389, DOI 10.1016/j.tim.2005.05.011
   McElroy MC, 1997, AM J PHYSIOL-LUNG C, V273, pL1228, DOI 10.1152/ajplung.1997.273.6.L1228
   Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185
   Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511
   Newman V, 2000, AM J RESP CRIT CARE, V161, P990, DOI 10.1164/ajrccm.161.3.9901042
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736
   Rokkam D, 2011, AM J PATHOL, V179, P1081, DOI 10.1016/j.ajpath.2011.05.017
   Smith KM, 1997, CRIT CARE MED, V25, P1888, DOI 10.1097/00003246-199711000-00030
   STONE KC, 1992, AM J RESP CELL MOL, V6, P235, DOI 10.1165/ajrcmb/6.2.235
   TAMAOKI J, 1995, AM J RESP CRIT CARE, V151, P1582, DOI 10.1164/ajrccm.151.5.7735618
   Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Wray C, 2009, AM J PHYSIOL-LUNG C, V297, pL219, DOI 10.1152/ajplung.00043.2009
   Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134
   Zhang ZQ, 2011, J TRAUMA, V71, P1305, DOI 10.1097/TA.0b013e3182128528
   Zimmerman JJ, 2009, PEDIATRICS, V124, P87, DOI 10.1542/peds.2007-2462
NR 30
TC 23
Z9 27
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-7799
J9 RESPIROLOGY
JI Respirology
PD MAY
PY 2013
VL 18
IS 4
BP 643
EP 651
DI 10.1111/resp.12034
PG 9
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA 134SV
UT WOS:000318235700008
PM 23253121
DA 2023-08-21
ER

PT J
AU Meliton, AY
   Munoz, NM
   Meliton, LN
   Birukova, AA
   Leff, AR
   Birukov, KG
AF Meliton, Angelo Y.
   Munoz, Nilda M.
   Meliton, Lucille N.
   Birukova, Anna A.
   Leff, Alan R.
   Birukov, Konstantin G.
TI Mechanical induction of group V phospholipase A(2) causes lung
   inflammation and acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; cyclic stretch; group V soluble phospholipase A(2) inflammation; neutrophil adhesion; ALI/ARDS 
ID CYCLIC STRETCH; SECRETORY PHOSPHOLIPASE-A2; BRONCHOALVEOLAR LAVAGE;
   OXIDIZED PHOSPHOLIPIDS; RESPIRATORY-DISTRESS; ENDOTHELIAL-CELLS; PAF
   SYNTHESIS; IN-VITRO; DIVERSITY; PERMEABILITY
AB Ventilation at high tidal volume may cause lung inflammation and barrier dysfunction that culminates in ventilator-induced lung injury (VILI). However, the mechanisms by which mechanical stimulation triggers the inflammatory response have not been fully elucidated. This study tested the hypothesis that onset of VILI is triggered by activation of secretory group V phospholipase A(2) (gVPLA2) in pulmonary vascular endothelium exposed to excessive mechanical stretch. High-magnitude cyclic stretch (18% CS) increased expression and surface exposure of gVPLA2 in human pulmonary endothelial cells (EC). CS-induced gVPLA2 activation was required for activation of ICAM-1 expression and polymorphonuclear neutrophil (PMN) adhesion to CS-preconditioned EC. By contrast, physiological CS (5% CS) had no effect on gVPLA2 activation or EC-PMN adhesion. CS-induced ICAM-1 expression and EC-PMN adhesion were attenuated by the gVPLA2-blocking antibody (MCL-3G1), general inhibitor of soluble PLA2, LY311727, or siRNA-induced EC gVPLA2 knockdown. In vivo, ventilator-induced lung leukocyte recruitment, cell and protein accumulation in the alveolar space, and total lung myeloperoxidase activity were strongly suppressed in gVPLA2 mouse knockout model or upon administration of MCL-3G1. These results demonstrate a novel role for gVPLA2 as the downstream effector of pathological mechanical stretch leading to an inflammatory response associated with VILI.
C1 [Meliton, Angelo Y.; Meliton, Lucille N.; Birukova, Anna A.; Leff, Alan R.; Birukov, Konstantin G.] Univ Chicago, Sect Pulm & Crit Med, Dept Med, Chicago, IL 60637, United States.
C1 [Meliton, Angelo Y.; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Dept Med, Lung Injury Ctr, Chicago, IL 60637, United States.
C1 [Munoz, Nilda M.] St Lukes Med Ctr, Res & Biotechnol Div, Quezon City, Philippines.
C3 University of Chicago; University of Chicago; Saint Lukes Medical Center
   - Philippines
RP Birukov, KG (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, 5841 S Maryland Ave,Off N-611, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022
FU NIH [HL076259, HL089257, HL087823]; Glaxo Smith Kline Center of
   Excellence
FX This work was supported by NIH grants HL076259, HL089257, HL087823, and
   a grant from the Glaxo Smith Kline Center of Excellence to A. Leff.
CR Attalah HL, 2003, EUR RESPIR J, V21, P1040, DOI 10.1183/09031936.03.00093002
   Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289
   Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P197, DOI 10.1038/sj.bjp.0704215
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2009, J APPL PHYSIOL, V107, P1900, DOI 10.1152/japplphysiol.00462.2009
   Birukova AA, 2008, EXP CELL RES, V314, P3466, DOI 10.1016/j.yexcr.2008.09.003
   De Luca D, 2008, INTENS CARE MED, V34, P1858, DOI 10.1007/s00134-008-1224-3
   DENNIS EA, 1994, J BIOL CHEM, V269, P13057
   Dignat-George F, 2011, ARTERIOSCL THROM VAS, V31, P27, DOI 10.1161/ATVBAHA.110.218123
   DOSQUET C, 1992, NOUV REV FR HEMATOL, V34, pS55
   Fleisch JH, 1996, J PHARMACOL EXP THER, V278, P252
   Halbertsma FJJ, 2005, NETH J MED, V63, P382
   Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881
   Iwaki M, 2009, BIOCHEM BIOPH RES CO, V389, P531, DOI 10.1016/j.bbrc.2009.09.020
   Marchand C, 2006, J CELL BIOCHEM, V98, P1095, DOI 10.1002/jcb.20840
   Meliton AY, 2008, J LEUKOCYTE BIOL, V83, P344, DOI 10.1189/jlb.0707495
   Meliton AY, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-14
   Munoz Nilda M, 2012, Pulm Circ, V2, P182, DOI 10.4103/2045-8932.97604
   Munoz NM, 2009, AM J PHYSIOL-LUNG C, V296, pL879, DOI 10.1152/ajplung.90580.2008
   Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200
   Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4
   Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Ohtsuki M, 2006, J BIOL CHEM, V281, P36420, DOI 10.1074/jbc.M607975200
   Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766
   Sapet C, 2006, BLOOD, V108, P1868, DOI 10.1182/blood-2006-04-014175
   Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   YANO Y, 1993, THROMB RES, V71, P385, DOI 10.1016/0049-3848(93)90163-I
NR 32
TC 26
Z9 26
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2013
VL 304
IS 10
BP L689
EP L700
DI 10.1152/ajplung.00047.2013
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 144US
UT WOS:000318966800006
PM 23525785
OA Green Published
DA 2023-08-21
ER

PT J
AU Reys, LG
   Ortiz-Pomales, YT
   Lopez, N
   Cheadle, G
   de Oliveira, PG
   Eliceiri, B
   Bansal, V
   Costantini, TW
   Coimbra, R
AF Reys, Luiz G.
   Ortiz-Pomales, Yan T.
   Lopez, Nicole
   Cheadle, Gerald
   de Oliveira, Paulo Goncalves
   Eliceiri, Brian
   Bansal, Vishal
   Costantini, Todd W.
   Coimbra, Raul
TI Uncovering the neuroenteric-pulmonary axis: Vagal nerve stimulation
   prevents acute lung injury following hemorrhagic shock
SO LIFE SCIENCES
LA English
DT Article
DE tight junction; Intestinal barrier; permeability; Occludin; zonula occludens 1 
ID NF-KAPPA-B; NICOTINIC ACETYLCHOLINE-RECEPTOR; INFLAMMATORY RESPONSE;
   MESENTERIC LYMPH; NITRIC-OXIDE; IN-VIVO; PHOSPHODIESTERASE INHIBITION;
   HYPERTONIC SALINE; INTESTINAL INJURY; ORGAN INJURY
AB Aims: Trauma/hemorrhagic shock (T/HS) induced gut injury is known to initiate a systemic inflammatory response which can lead to secondary lung injury. We have shown that vagal nerve stimulation (VNS) protects intestinal epithelial integrity after a severe burn insult. We hypothesize that VNS will protect the lung from injury following T/HS by preventing intestinal barrier failure.
   Main methods: Male Balb/c mice were subjected to a T/HS model with and without cervical VNS. Intestinal injury was evaluated by measuring changes in gut barrier function and tight junction protein localization. Lung injury was evaluated using histology and markers of lung inflammation. Using NF-kB-luciferase (NF-kB-luc) transgenic mice, NF-kb-DNA binding was measured by photon emission analysis at 4 after injury.
   Key findings: T/HS is associated gut injury characterized by histologic injury, increased epithelial permeability, and altered localization of gut tight junction proteins. Cervical VNS prevented the T/HS-induced changes in gut barrier integrity. Gut injury after T/HS was associated with acute lung injury at 24 h characterized by histologic injury, increased number of MPO positive stained cells and MPO enzymatic activity, and increased ICAM-1 expression in lung endothelium. VNS decreased T/HS-induced lung injury with a marked decrease in lung inflammation compared to T/HS alone. Lungs harvested from NF-kB-luc mice at 4 h post VNS + T/HS demonstrated decreased DNA binding of NF-kB compared to T/HS alone as measured by changes in bioluminescence.
   Significance: VNS is effective in protecting against acute lung injury caused by hemorrhagic shock through its ability to prevent gut barrier dysfunction. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Ortiz-Pomales, Yan T.; Lopez, Nicole; Cheadle, Gerald; Eliceiri, Brian; Bansal, Vishal; Costantini, Todd W.; Coimbra, Raul] Univ Calif San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA, United States.
C1 [Reys, Luiz G.; de Oliveira, Paulo Goncalves] Univ Brasilia, BR-70910900 Brasilia, DF, Brazil.
C3 University of California System; University of California San Diego;
   Universidade de Brasilia
RP Coimbra, R (corresponding author), 200 W Arbor Dr,8896, San Diego, CA 92103 USA.
EM rcoimbra@ucsd.edu
RI Coimbra, Raul/AAP-3019-2020; Lopez, Nicole/GZL-3059-2022; COimbra,
   Raul/HJP-1207-2023
OI Coimbra, Raul/0000-0002-3759-6851; COimbra, Raul/0000-0002-3759-6851;
   Lopez, Nicole/0000-0002-4807-7360; Eliceiri, Brian/0000-0003-1811-1916
CR Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]
   Barlos D, 2009, AM J PHYSIOL-LUNG C, V296, pL404, DOI 10.1152/ajplung.00491.2007
   Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124
   BERTHOUD HR, 1990, J COMP NEUROL, V301, P65, DOI 10.1002/cne.903010107
   Boland C, 2011, INFLAMMATION, V34, P29, DOI 10.1007/s10753-010-9204-5
   Bregeon F, 2007, J PHYSIOL-LONDON, V581, P1333, DOI 10.1113/jphysiol.2007.131326
   Brovkovych V, 2008, AM J PHYSIOL-LUNG C, V295, pL96, DOI 10.1152/ajplung.00450.2007
   Chernyavsky AI, 2012, WOUND REPAIR REGEN, V20, P103, DOI 10.1111/j.1524-475X.2011.00753.x
   Chima RS, 2008, CRIT CARE MED, V36, P2849, DOI 10.1097/CCM.0b013e318187810e
   Cockerill GW, 2001, CIRCULATION, V103, P108
   Coimbra R, 2006, J TRAUMA, V60, P115, DOI 10.1097/01.ta.0000200075.12489.74
   Coimbra R, 2004, J TRAUMA, V56, P442, DOI 10.1097/01.TA.0000096642.54111.E8
   Costantini TW, 2012, AM J PATHOL, V181, P478, DOI 10.1016/j.ajpath.2012.04.005
   Costantini TW, 2010, AM J PHYSIOL-GASTR L, V299, pG1308, DOI 10.1152/ajpgi.00156.2010
   Costantini TW, 2010, CLINICS, V65, P621, DOI 10.1590/S1807-59322010000600010
   Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0
   Costantini TW, 2010, MOL IMAGING, V9, P30, DOI 10.2310/7290.2010.00001
   Curtis BJ, 2012, LIFE SCI, V91, P1070, DOI 10.1016/j.lfs.2012.08.020
   Curtis BJ, 2012, J INVEST DERMATOL, V132, P28, DOI 10.1038/jid.2011.264
   Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014
   Deitch EA, 2006, FRONT BIOSCI-LANDMRK, V11, P520, DOI 10.2741/1816
   DEITCH EA, 1990, J TRAUMA, V30, P942, DOI 10.1097/00005373-199008000-00002
   Deree J, 2007, J TRAUMA, V62, P104, DOI 10.1097/TA.0b013e31802d96cb
   Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083
   Estenssoro E, 2002, CRIT CARE MED, V30, P2450, DOI 10.1097/00003246-200211000-00008
   Gonzalez RJ, 2003, J TRAUMA, V54, P219, DOI 10.1097/01.TA.0000047807.12644.95
   Gonzalez RJ, 2001, J TRAUMA, V51, P1069, DOI 10.1097/00005373-200112000-00008
   Hassoun HT, 2001, SHOCK, V15, P1, DOI 10.1097/00024382-200115010-00001
   Ho TY, 2007, BIOMATERIALS, V28, P4370, DOI 10.1016/j.biomaterials.2007.07.005
   Hsieh CH, 2008, J IMMUNOL, V181, P2806, DOI 10.4049/jimmunol.181.4.2806
   Krzyzaniak M, 2012, J TRAUMA ACUTE CARE, V72, P355, DOI 10.1097/TA.0b013e31824484fe
   Krzyzaniak M, 2011, J TRAUMA, V70, P1168, DOI 10.1097/TA.0b013e318216f754
   Krzyzaniak MJ, 2011, SURGERY, V150, P379, DOI 10.1016/j.surg.2011.06.008
   Li YH, 2009, AM J PHYSIOL-REG I, V297, pR1670, DOI 10.1152/ajpregu.00445.2009
   LIRA SA, 1994, J EXP MED, V180, P2039, DOI 10.1084/jem.180.6.2039
   Michetti C, 2003, J SURG RES, V115, P92, DOI 10.1016/S0022-4804(03)00219-1
   Nydam TL, 2009, SHOCK, V31, P466, DOI 10.1097/SHK.0b013e31818ec47d
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105
   SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006
   Senthil M, 2007, ANN SURG, V246, P822, DOI 10.1097/SLA.0b013e3180caa3af
   Shenkar R, 1999, J IMMUNOL, V163, P954
   Shenkar R, 1997, AM J RESP CELL MOL, V16, P145, DOI 10.1165/ajrcmb.16.2.9032121
   Song XM, 2010, BURNS, V36, P75, DOI 10.1016/j.burns.2009.02.002
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722
   Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354
   Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
NR 48
TC 23
Z9 27
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD APR 19
PY 2013
VL 92
IS 13
BP 783
EP 792
DI 10.1016/j.lfs.2013.02.009
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AL6QX
UT WOS:000339258800006
PM 23439327
DA 2023-08-21
ER

PT J
AU Banerjee, A
   Moore, EE
   McLaughlin, NJ
   Lee, L
   Jones, WL
   Johnson, JL
   Nydam, TL
   Silliman, CC
AF Banerjee, Anirban
   Moore, Ernest E.
   McLaughlin, Nathan J. D.
   Lee, Luis
   Jones, Wilbert L.
   Johnson, Jeffrey L.
   Nydam, Trevor L.
   Silliman, Christopher C.
TI HYPEROSMOLARITY ATTENUATES TNF-alpha-MEDIATED PROINFLAMMATORY ACTIVATION
   OF HUMAN PULMONARY MICROVASCULAR ENDOTHELIAL CELLS
SO SHOCK
LA English
DT Article
DE ALI/ARDS; neutrophils; NF-kappa B; MAPK; ECs/HPMECs/HUVECs/MPVECs; interleukin-8; ICAM-1; hypertonic saline 
ID HYPERTONIC SALINE RESUSCITATION; HEMORRHAGIC-SHOCK; HUMAN NEUTROPHILS;
   LUNG INJURY; EXPRESSION; CYTOTOXICITY; CD11B/CD18; SUPEROXIDE;
   ADHERENCE; RELEASE
AB Firm neutrophil (PMN)-endothelial (EC) adhesion is crucial to the PMN-mediated hyperinflammation observed in acute lung injury. Hypertonic saline (HTS) used for resuscitation of hemorrhagic shock has been associated with a decreased incidence of PMN-mediated lung injury/acute respiratory distress syndrome. We hypothesize that physiologically accessible hypertonic incubation (170 vs. 140 mM, osmolarity ranging from 360 to 300 mOsm/L) inhibits proinflammatory activation of human pulmonary microvascular endothelial cells (HMVECs). Proinflammatory activation of HMVECs was investigated in response to tumor necrosis factor-alpha (TNF-alpha), including interleukin 8 (IL-8) release, intercellular adhesion molecule 1 (ICAM-1) surface expression, PMN adhesion, and signaling mechanisms under both isotonic (control) and hypertonic conditions. Hyperosmolarity alone had no effect on either basal IL-8 release or ICAM-1 surface expression but did lead to concentration-dependent decreases in TNF-alpha-induced IL-8 release, ICAM-1 surface expression, and PMN-HMVEC adhesion. Conversely, HTS activated p38 mitogen-activated protein kinase (MAPK) and enhanced TNF-alpha activation of p38 MAPK. Despite this basal activation, hyperosmolar incubation attenuated TNF-alpha-stimulated IL-8 release and ICAM-1 surface expression and subsequent PMN adherence, while p38 MAPK inhibition did not further influence the effects of hyperosmolar conditions on ICAM-1 surface expression. In addition, TNF-alpha induced nuclear factor-kappa B DNA binding, but HTS conditions attenuated this by 31% (P < 0.01). In conclusion, HTS reduces PMN-HMVEC adhesion and TNF-alpha-induced proinflammatory activation of primary HMVECs via attenuation of nuclear factor-kappa B signaling.
C1 [Banerjee, Anirban; Moore, Ernest E.; Lee, Luis; Jones, Wilbert L.; Johnson, Jeffrey L.; Nydam, Trevor L.; Silliman, Christopher C.] Univ Colorado Denver, Denver Hlth Med Ctr, Dept Surg, Aurora, CO 80045, United States.
C1 [McLaughlin, Nathan J.; Silliman, Christopher C.] Bonfils Blood Ctr, Res Dept, Denver, CO, United States.
C1 [McLaughlin, Nathan J.; Silliman, Christopher C.] Univ Colorado Denver, Dept Pediat, Aurora, CO 80045, United States.
C3 Children's Hospital Colorado; Denver Health Medical Center; University
   of Colorado System; University of Colorado Anschutz Medical Campus;
   Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus
RP Banerjee, A (corresponding author), Univ Colorado Denver, Dept Surg, Anschutz Med Campus,12700 E 19th Ave,RC 2,Mail St, Aurora, CO 80045 USA.
EM Anirban.Banerjee@ucdenver.edu
OI Banerjee, Anirban/0000-0003-1690-2618
FU National Institutes of Health [P50GM49222, T32GM09315, M0l-RR-69]
FX Supported in part by National Institutes of Health Grants P50GM49222 and
   T32GM09315 and a Clinical Associate Physician Award (M0l-RR-69).
CR Angle N, 1998, SHOCK, V9, P164, DOI 10.1097/00024382-199803000-00002
   Barnett CC, 1998, AM J PHYSIOL-CELL PH, V274, pC1634, DOI 10.1152/ajpcell.1998.274.6.C1634
   Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41
   Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   Ciesla DJ, 2001, SHOCK, V16, P285, DOI 10.1097/00024382-200116040-00009
   Ciesla DJ, 2000, SHOCK, V14, P265, DOI 10.1097/00024382-200014030-00004
   Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024
   FARHOOD A, 1995, J LEUKOCYTE BIOL, V57, P368, DOI 10.1002/jlb.57.3.368
   FONTES B, 1995, J SURG RES, V58, P599, DOI 10.1006/jsre.1995.1094
   Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982
   Gonzalez RJ, 2002, SHOCK, V18, P29, DOI 10.1097/00024382-200207000-00006
   Grau GE, 1996, LAB INVEST, V74, P761
   ISSEKUTZ AC, 1992, IMMUNOLOGY, V76, P655
   Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354
   KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812
   Koliakos G, 2008, CONNECT TISSUE RES, V49, P157, DOI 10.1080/03008200802151581
   Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303
   Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975
   McLaughlin NJD, 2006, J IMMUNOL, V176, P7039, DOI 10.4049/jimmunol.176.11.7039
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263
   NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283
   Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015
   Partrick DA, 1998, J TRAUMA, V44, P592, DOI 10.1097/00005373-199804000-00006
   Pascual JL, 2003, J TRAUMA, V54, P121, DOI 10.1097/00005373-200301000-00015
   Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1
   Sheppard FR, 2005, J TRAUMA, V58, P752, DOI 10.1097/01.TA.0000159246.33364.72
   Song Yong, 2003, Zhonghua Yi Xue Za Zhi, V83, P691
   Tamura DY, 1998, SURGERY, V124, P403, DOI 10.1067/msy.1998.90483
   VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372
   Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Yada-Langui MM, 2004, EXP BIOL MED, V229, P684, DOI 10.1177/153537020422900713
NR 36
TC 20
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD APR
PY 2013
VL 39
IS 4
BP 366
EP 372
DI 10.1097/SHK.0b013e3182894016
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 108ZT
UT WOS:000316335600007
PM 23364439
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Rafat, N
   Tonshoff, B
   Bierhaus, A
   Beck, GC
AF Rafat, Neysan
   Toenshoff, Burkhard
   Bierhaus, Angelika
   Beck, Grietje C.
TI Endothelial Progenitor Cells in Regeneration after Acute Lung Injury Do
   They Play a Role?
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Review
DE endothelial progenitor cells; ALI/ARDS; neovascularization; endothelial regeneration 
ID MARROW-DERIVED CELLS; BONE-MARROW; CD34(+) CELLS; CONTRIBUTE; STEM;
   BLOOD; TRANSPLANTATION; EXPRESSION; HIERARCHY; APOPTOSIS
AB Acute lung injury (ALI) and acute respiratory distress syndrome(ARDS) are common disorders in patients requiring critical care. The clinical management of these disorders is difficult and unrewarding, and thus they are among the most common causes of death in intensive care units. The activation and damage of pulmonary endothelium comprise the hallmark of ALI/ARDS. Therefore, the recruitment of circulating endothelial progenitor cells (EPCs) to these lesions may exert a beneficial effect on the clinical course of ALI/ARDS. Consequently, cell-based therapies using stem cells to regenerate lung tissue have emerged as potential novel treatment strategies. Although initial studies suggested implantations of exogenously administered bone marrow-derived progenitor cells into damaged vessel walls, recent evidence indicates that this is rather a rare occurrence with uncertain physiologic significance. In the past few years, different populations of progenitor cells were identified, with different functional capacities. This review (1) highlights the different populations of EPCs identified or administered in different models of ALI/ARDS, (2) reports on whether beneficial effects of EPCs could be demonstrated, and (3) puts the conflicting results of different studies into perspective.
C1 [Rafat, Neysan; Toenshoff, Burkhard] Univ Childrens Hosp Heidelberg, Dept Pediat 1, D-69120 Heidelberg, Germany.
C1 [Bierhaus, Angelika] Heidelberg Univ, Dept Med 1, Heidelberg, Germany.
C1 [Bierhaus, Angelika] Heidelberg Univ, Dept Clin Chem, Heidelberg, Germany.
C1 [Beck, Grietje C.] Dr Horst Schmidt Kliniken, Dept Anesthesiol, Wiesbaden, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg
RP Rafat, N (corresponding author), Univ Childrens Hosp Heidelberg, Dept Pediat 1, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.
EM Neysan.Rafat@med.uni-heidelberg.de
FU Post Doc Program of the University of Heidelberg; European Union
   [223326]
FX N.R. was supported by a research scholarship from the Post Doc Program
   of the University of Heidelberg. A.B. was supported by European Union
   FP7-proposal number 223326 (CASCADE).
CR Aicher A, 2007, CIRC RES, V100, P581, DOI 10.1161/01.RES.0000259562.63718.35
   Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   BALLIEUX BEPB, 1994, EUR J IMMUNOL, V24, P3211, DOI 10.1002/eji.1830241245
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Burnham EL, 2010, AM J RESP CELL MOL, V43, P326, DOI 10.1165/rcmb.2009-0015OC
   Case J, 2007, EXP HEMATOL, V35, P1109, DOI 10.1016/j.exphem.2007.04.002
   Chang JC, 2005, AM J RESP CELL MOL, V33, P335, DOI 10.1165/rcmb.2005-0129OC
   Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656
   Estes Myka L, 2010, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0933s52
   Forbes S, 2002, J PATHOL, V197, P510, DOI 10.1002/path.1163
   Ghani U, 2005, STROKE, V36, P151, DOI 10.1161/01.STR.0000149944.15406.16
   Goon PKY, 2005, CLIN LAB, V51, P531
   Hemmen K, 2011, ANGIOGENESIS, V14, P163, DOI 10.1007/s10456-011-9200-x
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Hillebrands JL, 2002, NAT MED, V8, P194, DOI 10.1038/nm0302-194
   Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5
   Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057
   Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396
   Ito H, 1999, CANCER LETT, V143, P5, DOI 10.1016/S0304-3835(99)00160-3
   Kahler CM, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-50
   Kotton DN, 2005, AM J RESP CELL MOL, V33, P328, DOI 10.1165/rcmb.2005-0175RC
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   Lam CF, 2011, ANESTH ANALG, V112, P620, DOI 10.1213/ANE.0b013e3182075da4
   Liu He-liang, 2003, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V21, P37
   Mancuso P, 2003, ADV EXP MED BIOL, V522, P83
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Medina RJ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-18
   Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471
   Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195, DOI 10.1164/ajrccm.163.1.9912036
   Nowak K, 2010, EUR J CARDIO-THORAC, V37, P758, DOI 10.1016/j.ejcts.2009.10.002
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   Perry TE, 2009, CARDIOVASC RES, V84, P317, DOI 10.1093/cvr/cvp215
   Povsic TJ, 2009, AM HEART J, V157, P335, DOI 10.1016/j.ahj.2008.10.010
   Prater DN, 2007, LEUKEMIA, V21, P1141, DOI 10.1038/sj.leu.2404676
   Qi YY, 2010, INFLAMM RES, V59, P889, DOI 10.1007/s00011-010-0201-9
   Rafat N, 2012, ANASTH INTENSIVMED, V53, P196
   Rafat N, 2007, CRIT CARE MED, V35, P1677, DOI 10.1097/01.CCM.0000269034.86817.59
   Rafat N, 2010, J NEUROSURG, V112, P43, DOI 10.3171/2009.5.JNS081074
   Rafat N, 2009, STROKE, V40, P432, DOI 10.1161/STROKEAHA.108.529420
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537
   Richardson MR, 2011, J MOL CELL CARDIOL, V50, P266, DOI 10.1016/j.yjmcc.2010.07.009
   Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408
   Schniedermann J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-50
   Suratt BT, 2003, AM J RESP CRIT CARE, V168, P318, DOI 10.1164/rccm.200301-145OC
   Timmermans F, 2007, ARTERIOSCL THROM VAS, V27, P1572, DOI 10.1161/ATVBAHA.107.144972
   Timmermans F, 2009, J CELL MOL MED, V13, P87, DOI 10.1111/j.1582-4934.2008.00598.x
   Voswinckel R, 2003, CIRC RES, V93, P372, DOI 10.1161/01.RES.0000087643.60150.C2
   Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Wary KK, 2009, STEM CELLS, V27, P3112, DOI 10.1002/stem.241
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
   Yoder MC, 2009, J THROMB HAEMOST, V7, P49, DOI 10.1111/j.1538-7836.2009.03407.x
   Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471
   Yoder Mervin C, 2011, Proc Am Thorac Soc, V8, P466, DOI 10.1513/pats.201101-006MW
   Zhao YD, 2010, AM J PHYSIOL-LUNG C, V298, pL36, DOI 10.1152/ajplung.00064.2009
   Zhao YDD, 2009, CIRC RES, V105, P696, DOI 10.1161/CIRCRESAHA.109.199778
   Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C
NR 61
TC 27
Z9 28
U1 0
U2 14
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD APR
PY 2013
VL 48
IS 4
BP 399
EP 405
DI 10.1165/rcmb.2011-0132TR
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 135EH
UT WOS:000318269700005
PM 23103996
DA 2023-08-21
ER

PT J
AU Murata, T
   Aritake, K
   Tsubosaka, Y
   Maruyama, T
   Nakagawa, T
   Hori, M
   Hirai, H
   Nakamura, M
   Narumiya, S
   Urade, Y
   Ozaki, H
AF Murata, Takahisa
   Aritake, Kosuke
   Tsubosaka, Yoshiki
   Maruyama, Toshihiko
   Nakagawa, Takayuki
   Hori, Masatoshi
   Hirai, Hiroyuki
   Nakamura, Masataka
   Narumiya, Shuh
   Urade, Yoshihiro
   Ozaki, Hiroshi
TI Anti-inflammatory role of PGD(2) in acute lung inflammation and
   therapeutic application of its signal enhancement
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE permeability; pneumonia; lipid mediator; respiratory infection 
ID PROSTAGLANDIN D-2; ALLERGIC INFLAMMATION; INJURY; RECEPTOR; RESOLUTION;
   CELLS; CRTH2; MEDIATOR; PLAYS; J(2)
AB We investigated the role of prostaglandin D-2 (PGD(2)) signaling in acute lung injury (ALI), focusing on its producer-effector interaction in vivo. Administration of endotoxin increased edema and neutrophil infiltration in the WT mouse lung. Gene disruption of hematopoietic PGD synthase (H-PGDS) aggravated all of the symptoms. Experiments involving bone marrow transplantation between WT and H-PGDS-deficient mice showed that PGD(2) derived from alveolar nonhematopoietic lineage cells (i.e., endothelial cells and epithelial cells) promotes vascular barrier function during the early phase (day 1), whereas neutrophil-derived PGD(2) attenuates its own infiltration and cytokine expression during the later phase (day 3) of ALI. Treatment with either an agonist to the PGD(2) receptor, DP, or a degradation product of PGD(2), 15-deoxy-Delta(12,14)-PGJ(2), exerted a therapeutic action against ALI. Data obtained from bone marrow transplantation between WT and DP-deficient mice suggest that the DP signal in alveolar endothelial cells is crucial for the anti-inflammatory reactions of PGD(2). In vitro, DP agonism directly enhanced endothelial barrier formation, and 15-deoxy-Delta(12,14)-PGJ(2) attenuated both neutrophil migration and cytokine expression. These observations indicate that the PGD(2) signaling between alveolar endothelial/epithelial cells and infiltrating neutrophils provides anti-inflammatory effects in ALI, and suggest the therapeutic potential of these signaling enhancements.
C1 [Murata, Takahisa; Tsubosaka, Yoshiki; Hori, Masatoshi; Ozaki, Hiroshi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Tokyo 1138657, Japan.
C1 [Aritake, Kosuke; Maruyama, Toshihiko; Urade, Yoshihiro] Osaka Biosci Inst, Dept Mol Behav Biol, Osaka 5650874, Japan.
C1 [Nakagawa, Takayuki] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Surg, Tokyo 1138657, Japan.
C1 [Hirai, Hiroyuki] BML Inc, Adv Med & Dev, Saitama 3501101, Japan.
C1 [Nakamura, Masataka] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138150, Japan.
C1 [Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.
C3 University of Tokyo; University of Tokyo; BML, Inc.; Tokyo Medical &
   Dental University (TMDU); Kyoto University
RP Murata, T (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Tokyo 1138657, Japan.
EM amurata@mail.ecc.u-tokyo.ac.jp
OI Murata, Takahisa/0000-0002-3328-0796
FU Ministry of Education, Culture, Sports, Science and Technology; Japan
   Society for the Promotion of Science; Takeda Science Foundation;
   Pharmacological Research Foundation, Tokyo; Grants-in-Aid for Scientific
   Research [24658243, 22688024] Funding Source: KAKEN
FX This work was supported by a Grant-in-Aid for Young Scientists (A) and a
   Grant-in-Aid for Challenging Exploratory Research from the Ministry of
   Education, Culture, Sports, Science and Technology, and by the Japan
   Society for the Promotion of Science, Takeda Science Foundation, and
   Pharmacological Research Foundation, Tokyo.
CR Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303
   Cuzzocrea S, 2002, BIOCHEM PHARMACOL, V63, P785, DOI 10.1016/S0006-2952(01)00908-X
   Frank JA, 2005, AM J RESP CRIT CARE, V172, P261, DOI 10.1164/rccm.2505008
   Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033
   Genovese T, 2005, EUR RESPIR J, V25, P225, DOI 10.1183/09031936.05.00049704
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Goggel R, 2002, AM J RESP CRIT CARE, V166, P657, DOI 10.1164/rccm.20011.0710C
   HINSHAW LB, 1967, J PHARMACOL EXP THER, V157, P665
   Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255
   Honda K, 2003, J EXP MED, V198, P533, DOI 10.1084/jem.20022218
   Ishitsuka Y, 2004, J PHARM PHARMACOL, V56, P513, DOI 10.1211/0022357023150
   Kostenis E, 2006, TRENDS MOL MED, V12, P148, DOI 10.1016/j.molmed.2006.02.005
   Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759
   Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013
   Mochizuki M, 2005, AM J RESP CRIT CARE, V171, P1260, DOI 10.1164/rccm.200406-755OC
   Mohri I, 2006, J NEUROSCI, V26, P4383, DOI 10.1523/JNEUROSCI.4531-05.2006
   Murata T, 2011, P NATL ACAD SCI USA, V108, P19802, DOI 10.1073/pnas.1110011108
   Murata T, 2008, P NATL ACAD SCI USA, V105, P20009, DOI 10.1073/pnas.0805171105
   Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104
   Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621
   Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008
   Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
NR 24
TC 75
Z9 78
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 26
PY 2013
VL 110
IS 13
BP 5205
EP 5210
DI 10.1073/pnas.1218091110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 131XN
UT WOS:000318031900073
PM 23479612
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Fazal, F
   Bijli, KM
   Murrill, M
   Leonard, A
   Minhajuddin, M
   Anwar, KN
   Finkelstein, JN
   Watterson, DM
   Rahman, A
AF Fazal, Fabeha
   Bijli, Kaiser M.
   Murrill, Matthew
   Leonard, Antony
   Minhajuddin, Mohammad
   Anwar, Khandaker N.
   Finkelstein, Jacob N.
   Watterson, D. Martin
   Rahman, Arshad
TI Critical Role of Non-Muscle Myosin Light Chain Kinase in
   Thrombin-Induced Endothelial Cell Inflammation and Lung PMN Infiltration
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1;
   RESPIRATORY-DISTRESS-SYNDROME; RELA/P65 NUCLEAR TRANSLOCATION;
   NEUTROPHIL ADHESION; ACTIN CYTOSKELETON; ICAM-1 EXPRESSION; VASCULAR
   INJURY; TISSUE-FACTOR; COAGULATION
AB The pathogenesis of acute lung injury (ALI) involves bidirectional cooperation and close interaction between inflammatory and coagulation pathways. A key molecule linking coagulation and inflammation is the procoagulant thrombin, a serine protease whose concentration is elevated in plasma and lavage fluids of patients with ALI and acute respiratory distress syndrome (ARDS). However, little is known about the mechanism by which thrombin contributes to lung inflammatory response. In this study, we developed a new mouse model that permits investigation of lung inflammation associated with intravascular coagulation. Using this mouse model and in vitro approaches, we addressed the role of non-muscle myosin light chain kinase (nmMLCK) in thrombin-induced endothelial cell (EC) inflammation and lung neutrophil (PMN) infiltration. Our in vitro experiments revealed a key role of nmMLCK in ICAM-1 expression by its ability to control nuclear translocation and transcriptional capacity of RelA/p65 in EC. When subjected to intraperitoneal thrombin challenge, wild type mice showed a marked increase in lung PMN infiltration via expression of ICAM-1. However, these responses were markedly attenuated in mice deficient in nmMLCK. These results provide mechanistic insight into lung inflammatory response associated with intravascular coagulation and identify nmMLCK as a critical target for modulation of lung inflammation.
C1 [Fazal, Fabeha; Bijli, Kaiser M.; Murrill, Matthew; Leonard, Antony; Minhajuddin, Mohammad; Finkelstein, Jacob N.; Rahman, Arshad] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642, United States.
C1 [Anwar, Khandaker N.] Univ Illinois, Coll Med, Dept Med, Chicago, IL, United States.
C1 [Watterson, D. Martin] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Chicago, IL 60611, United States.
C3 University of Rochester; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital; Northwestern
   University
RP Fazal, F (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA.
EM Fabeha_Fazal@URMC.Rochester.edu
RI Minhajuddin, Mohammad/AAC-9227-2022
OI Murrill, Matthew/0000-0001-7567-7727; Watterson, Daniel
   Martin/0000-0001-7605-5866
FU National Heart, Lung, and Blood Institute [HL67424, HL096907]; National
   Institute of Environmental Health Sciences Center (EHSC) [ES-01247];
   Biomedical Research Grant from American Lung Association
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants HL67424 and HL096907. This study was also supported in part by
   National Institute of Environmental Health Sciences Center (EHSC) Grant
   ES-01247, and a Biomedical Research Grant from American Lung
   Association. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148
   Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965
   Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005
   Cernuda-Morollon E, 2006, CIRC RES, V98, P757, DOI 10.1161/01.RES.0000210579.35304.d3
   Cirino G, 2006, CURR OPIN PHARMACOL, V6, P428, DOI 10.1016/j.coph.2006.05.001
   COLOTTA F, 1994, AM J PATHOL, V144, P975
   Conway EM, 2002, J EXP MED, V196, P565, DOI 10.1084/jem.20020077
   COOPER JA, 1984, J APPL PHYSIOL, V57, P826, DOI 10.1152/jappl.1984.57.3.826
   Delekta PC, 2010, J BIOL CHEM, V285, P41432, DOI 10.1074/jbc.M110.158949
   DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0
   Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200
   Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   Gando S, 1999, J TRAUMA, V47, P719, DOI 10.1097/00005373-199910000-00017
   Gao XP, 2001, J IMMUNOL, V167, P2895, DOI 10.4049/jimmunol.167.5.2895
   Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200
   Knezevic N, 2012, J EXP MED
   Kudryashov DS, 1999, FEBS LETT, V463, P67, DOI 10.1016/S0014-5793(99)01591-4
   Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679
   Levi M, 2005, TRENDS CARDIOVAS MED, V15, P254, DOI 10.1016/j.tcm.2005.07.004
   Levitt JE, 2006, SEMIN RESP CRIT CARE, V27, P426, DOI 10.1055/s-2006-948296
   Li XL, 2007, AM J PHYSIOL-LUNG C, V292, pL1193, DOI 10.1152/ajplung.00408.2006
   Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B
   MALIK AB, 1987, AM REV RESPIR DIS, V136, P467, DOI 10.1164/ajrccm/136.2.467
   MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minami T, 2005, TRENDS CARDIOVAS MED, V15, P174, DOI 10.1016/j.tcm.2005.06.002
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Niessen F, 2009, BLOOD, V113, P2859, DOI 10.1182/blood-2008-12-192385
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Rahman A, 1999, J IMMUNOL, V162, P5466
   Rahman A, 2012, AM J RESP CELL MOL B
   Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Ranaivo HR, 2007, AM J PATHOL, V170, P439, DOI 10.2353/ajpath.2007.060219
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111
   Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   van der Poll T, 2008, CRIT CARE, V12, DOI 10.1186/cc7026
   Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wu SP, 2010, AM J PATHOL, V177, P686, DOI 10.2353/ajpath.2010.090998
   Wu Z, 2012, BLOOD, V119, P2422, DOI 10.1182/blood-2011-04-350413
   Xu JS, 2008, NAT IMMUNOL, V9, P880, DOI 10.1038/ni.1628
   Xu N, 2002, AM J PHYSIOL-LUNG C, V282, pL796, DOI 10.1152/ajplung.00298.2001
   Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
NR 53
TC 18
Z9 18
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2013
VL 8
IS 3
AR e59965
DI 10.1371/journal.pone.0059965
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 111UM
UT WOS:000316546400072
PM 23555849
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Sun, SQ
   Sursal, T
   Adibnia, Y
   Zhao, C
   Zheng, Y
   Li, HP
   Otterbein, LE
   Hauser, CJ
   Itagaki, K
AF Sun, Shiqin
   Sursal, Tolga
   Adibnia, Yasaman
   Zhao, Cong
   Zheng, Yi
   Li, Haipeng
   Otterbein, Leo E.
   Hauser, Carl J.
   Itagaki, Kiyoshi
TI Mitochondrial DAMPs Increase Endothelial Permeability through Neutrophil
   Dependent and Independent Pathways
SO PLOS ONE
LA English
DT Article
ID OPERATED CALCIUM-ENTRY; SPHINGOSINE 1-PHOSPHATE; GENE-EXPRESSION; DANGER
   SIGNALS; MAP KINASE; DNA; CELLS; INFLAMMATION; ACTIVATION; INFLUX
AB Trauma and sepsis can cause acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) in part by triggering neutrophil (PMN)-mediated increases in endothelial cell (EC) permeability. We had shown that mitochondrial (mt) damage-associated molecular patterns (DAMPs) appear in the blood after injury or shock and activate human PMN. So we now hypothesized that mitochondrial DAMPs (MTD) like mitochondrial DNA (mtDNA) and peptides might play a role in increased EC permeability during systemic inflammation and proceeded to evaluate the underlying mechanisms. MtDNA induced changes in EC permeability occurred in two phases: a brief, PMN-independent 'spike' in permeability was followed by a prolonged PMN-dependent increase in permeability. Fragmented mitochondria (MTD) caused PMN-independent increase in EC permeability that were abolished with protease treatment. Exposure to mtDNA caused PMN-EC adherence by activating expression of adherence molecule expression in both cell types. Cellular activation was manifested as an increase in PMN calcium flux and EC MAPK phosphorylation. Permeability and PMN adherence were attenuated by endosomal TLR inhibitors. EC lacked formyl peptide receptors but were nonetheless activated by mt-proteins, showing that non-formylated mt-protein DAMPs can activate EC. Mitochondrial DAMPs can be released into the circulation by many processes that cause cell injury and lead to pathologic endothelial permeability. We show here that mitochondria contain multiple DAMP motifs that can act on EC and/or PMN via multiple pathways. This can enhance PMN adherence to EC, activate PMN-EC interactions and subsequently increase systemic endothelial permeability. Mitochondrial DAMPs may be important therapeutic targets in conditions where inflammation pathologically increases endothelial permeability.
C1 [Sun, Shiqin; Sursal, Tolga; Adibnia, Yasaman; Zhao, Cong; Zheng, Yi; Li, Haipeng; Otterbein, Leo E.; Hauser, Carl J.; Itagaki, Kiyoshi] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215, United States.
C1 [Li, Haipeng] Beijing Army Gen Hosp, Dept Orthoped Surg, Beijing, China.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School
RP Hauser, CJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA.
EM cjhauser@bidmc.harvard.edu; kitagaki@bidmc.harvard.edu
RI Itagaki, Kiyoshi/M-5501-2015; Sursal, Tolga/AAN-8585-2021; Hauser, Carl
   J./Y-1189-2019
OI Itagaki, Kiyoshi/0000-0002-6033-1122; Hauser, Carl/0000-0003-3167-1846
FU NIGMS/NIH [5R01GM089711-02]; Department of Defense
   [W81XWH-09-1-0472/DR0809]; Center for Integration of Medicine and
   Innovative Technology [W81XWH-09-2-0001]
FX 5R01GM089711-02 (NIGMS/NIH, CJH), W81XWH-09-1-0472/DR0809 (Department of
   Defense, CJH), W81XWH-09-2-0001 (Center for Integration of Medicine and
   Innovative Technology, CJH). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Benko S, 2008, CYTOKINE, V43, P368, DOI 10.1016/j.cyto.2008.07.013
   EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896
   Hart OM, 2005, J IMMUNOL, V175, P1636, DOI 10.4049/jimmunol.175.3.1636
   Hauser CJ, 2010, J ORTHOP TRAUMA, V24, P534, DOI 10.1097/BOT.0b013e3181ec4991
   Hauser CJ, 2000, J TRAUMA, V48, P592, DOI 10.1097/00005373-200004000-00003
   Hauser CJ, 2001, J LEUKOCYTE BIOL, V69, P63
   Hopson KP, 2011, AM J PHYSIOL-CELL PH, V300, pC919, DOI 10.1152/ajpcell.00350.2010
   Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200
   Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063
   Itagaki K, 2011, SHOCK, V36, P548, DOI 10.1097/SHK.0b013e3182369fb2
   Itagaki K, 2010, SHOCK, V33, P381, DOI 10.1097/SHK.0b013e3181c6bb75
   Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631
   Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116
   Lucke S, 2010, CELL PHYSIOL BIOCHEM, V26, P87, DOI 10.1159/000315109
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   Oka T, 2012, NATURE, V485, P251, DOI 10.1038/nature10992
   Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002
   Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173
   Raoof M, 2010, J TRAUMA, V68, P1328, DOI 10.1097/TA.0b013e3181dcd28d
   Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Strub GM, 2010, ADV EXP MED BIOL, V688, P141
   Tornquist K, 2012, ACTA PHYSIOL, V204, P151, DOI 10.1111/j.1748-1716.2011.02265.x
   Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
   Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 31
TC 152
Z9 156
U1 1
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2013
VL 8
IS 3
AR e59989
DI 10.1371/journal.pone.0059989
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 125SW
UT WOS:000317562600109
PM 23527291
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Uriarte, SM
   Rane, MJ
   Merchant, ML
   Jin, SY
   Lentsch, AB
   Ward, RA
   McLeish, KR
AF Uriarte, Silvia M.
   Rane, Madhavi J.
   Merchant, Michael L.
   Jin, Shunying
   Lentsch, Alex B.
   Ward, Richard A.
   McLeish, Kenneth R.
TI INHIBITION OF NEUTROPHIL EXOCYTOSIS AMELIORATES ACUTE LUNG INJURY IN
   RATS
SO SHOCK
LA English
DT Article
DE complement; proteomics; immune complex 
ID COMPLEMENT ACTIVATION; INFLAMMATORY INJURY; MEMBRANE-FUSION; C5A;
   PROTEINS; GRANULES; GENERATION; CELLS; SNARE; MODEL
AB Exocytosis of neutrophil granules contributes to acute lung injury (ALI) induced by infection or inflammation, suggesting that inhibition of neutrophil exocytosis in vivo could be a viable therapeutic strategy. This study was conducted to determine the effect of a cell-permeable fusion protein that inhibits neutrophil exocytosis (TAT-SNAP-23) on ALI using an immune complex deposition model in rats. The effect of inhibition of neutrophil exocytosis by intravenous administration of TAT-SNAP-23 on ALI was assessed by albumin leakage, neutrophil infiltration, lung histology, and proteomic analysis of bronchoalveolar lavage fluid (BALF). Administration of TAT-SNAP-23, but not TAT-control, significantly reduced albumin leakage, total protein levels in the BALF, and intra-alveolar edema and hemorrhage. Evidence that TAT-SNAP-23 inhibits neutrophil exocytosis included a reduction in plasma membrane CD18 expression by BALF neutrophils and a decrease in neutrophil granule proteins in BALF. Similar degree of neutrophil accumulation in the lungs and/or BALF suggests that TAT-SNAP-23 did not alter vascular endothelial cell function. Proteomic analysis of BALF revealed that components of the complement and coagulation pathways were significantly reduced in BALF from TAT-SNAP-23-treated animals. Our results indicate that administration of a TAT-fusion protein that inhibits neutrophil exocytosis reduces in vivo ALI. Targeting neutrophil exocytosis is a potential therapeutic strategy to ameliorate ALI.
C1 [Uriarte, Silvia M.; Rane, Madhavi J.; Merchant, Michael L.; Jin, Shunying; Ward, Richard A.; McLeish, Kenneth R.] Univ Louisville, Dept Med, Louisville, KY 40202, United States.
C1 [Lentsch, Alex B.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267, United States.
C1 [McLeish, Kenneth R.] Robley Rex VA Med Ctr, Louisville, KY, United States.
C3 University of Louisville; University System of Ohio; University of
   Cincinnati
RP Uriarte, SM (corresponding author), Univ Louisville, Baxter 1 Res Bldg,102D,570 S Preston St, Louisville, KY 40202 USA.
EM silvia.uriarte@louisville.edu
RI Merchant, Michael L/N-7444-2013; Merchant, Michael/F-7109-2013; McLeish,
   Kenneth R./B-9819-2013
OI Merchant, Michael L/0000-0003-4128-4057; McLeish, Kenneth
   R./0000-0002-7816-3286
FU Department of Veterans Affair Merit Review Board; American Heart
   Association [BGIA 0765387B]; University of Louisville School of
   Medicine; National Institutes of Health [K99/R00 HL087924, R01 AI075212]
FX This work was supported by grants from the Department of Veterans Affair
   Merit Review Board (to K.R.M.), the American Heart Association (BGIA
   0765387B to S.M.U.), University of Louisville School of Medicine (to
   S.M.U.), and the National Institutes of Health (K99/R00 HL087924 to
   S.M.U., R01 AI075212 to M.J.R.).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Asberg AE, 2008, SCAND J IMMUNOL, V67, P354, DOI 10.1111/j.1365-3083.2008.02077.x
   Bosmann M, 2012, ADV EXP MED BIOL, V946, P147, DOI 10.1007/978-1-4614-0106-3_9
   Camous L, 2011, BLOOD, V117, P1340, DOI 10.1182/blood-2010-05-283564
   Chang DW, 2008, AM J RESP CRIT CARE, V178, P701, DOI 10.1164/rccm.200712-1895OC
   Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017
   Czermak BJ, 1998, J LEUKOCYTE BIOL, V64, P40, DOI 10.1002/jlb.64.1.40
   Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008
   Flierl MA, 2008, SHOCK, V29, P25, DOI 10.1097/shk.0b013e3180556a0b
   Gao HW, 2006, ANNU REV PATHOL-MECH, V1, P215, DOI 10.1146/annurev.pathol.1.110304.100155
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Guo RF, 2002, FREE RADICAL BIO MED, V33, P303, DOI 10.1016/S0891-5849(02)00823-7
   Guo RF, 2002, AM J PATHOL, V161, P275, DOI 10.1016/S0002-9440(10)64179-X
   Huber-Lang M, 2002, AM J PATHOL, V161, P1849, DOI 10.1016/S0002-9440(10)64461-6
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434
   Lentsch AB, 1999, J IMMUNOL, V162, P1071
   Lentsch AB, 2001, RESP PHYSIOL, V128, P17, DOI 10.1016/S0034-5687(01)00260-2
   Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200
   Luerman GC, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.001552
   Merchant ML, 2010, PROTEOM CLIN APPL, V4, P84, DOI 10.1002/prca.200800093
   Morrell CN, 2005, J PHARMACOL EXP THER, V314, P155, DOI 10.1124/jpet.104.082529
   Mukherjee G, 1998, ARCH BIOCHEM BIOPHYS, V357, P164, DOI 10.1006/abbi.1998.0807
   MULLIGAN MS, 1992, J IMMUNOL, V148, P1847
   Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Ritis K, 2006, J IMMUNOL, V177, P4794, DOI 10.4049/jimmunol.177.7.4794
   Sarma VJ, 2006, AUTOIMMUNITY, V39, P387, DOI 10.1080/08916930600739456
   Schlaf G, 2004, EUR J IMMUNOL, V34, P3257, DOI 10.1002/eji.200324806
   Soehnlein O, 2008, EUR RESPIR J, V32, P405, DOI 10.1183/09031936.00173207
   Sudhof TC, 2009, SCIENCE, V323, P474, DOI 10.1126/science.1161748
   Uriarte SM, 2008, J IMMUNOL, V180, P5575, DOI 10.4049/jimmunol.180.8.5575
   Uriarte Silvia M, 2011, J Immunol, V187, P391, DOI 10.4049/jimmunol.1003112
   Ward PA, 2002, MOL CELL BIOCHEM, V234, P225, DOI 10.1023/A:1015944709177
   WARD PA, 1970, J IMMUNOL, V104, P535
NR 35
TC 33
Z9 34
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD MAR
PY 2013
VL 39
IS 3
BP 286
EP 292
DI 10.1097/SHK.0b013e318282c9a1
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 093IU
UT WOS:000315186100009
PM 23364427
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Davidson, BA
   Vethanayagam, RR
   Grimm, MJ
   Mullan, BA
   Raghavendran, K
   Blackwell, TS
   Freeman, ML
   Ayyasamy, V
   Singh, KK
   Sporn, MB
   Itagaki, K
   Hauser, CJ
   Knight, PR
   Segal, BH
AF Davidson, Bruce A.
   Vethanayagam, R. Robert
   Grimm, Melissa J.
   Mullan, Barbara A.
   Raghavendran, Krishnan
   Blackwell, Timothy S.
   Freeman, Michael L.
   Ayyasamy, Vanniarajan
   Singh, Keshav K.
   Sporn, Michael B.
   Itagaki, Kiyoshi
   Hauser, Carl J.
   Knight, Paul R.
   Segal, Brahm H.
TI NADPH Oxidase and Nrf2 Regulate Gastric Aspiration-Induced Inflammation
   and Acute Lung Injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NEUTROPHIL EXTRACELLULAR TRAPS; REACTIVE OXYGEN; ACID ASPIRATION;
   ADAPTIVE RESPONSE; HYPOCHLOROUS ACID; HOST-DEFENSE; CELL-DEATH;
   ACTIVATION; PATHOGENESIS; PROTECTION
AB Recruitment of neutrophils and release of reactive oxygen species are considered to be major pathogenic components driving acute lung injury (ALI). However, NADPH oxidase, the major source of reactive oxygen species in activated phagocytes, can paradoxically limit inflammation and injury. We hypothesized that NADPH oxidase protects against ALI by limiting neutrophilic inflammation and activating Nrf2, a transcriptional factor that induces antioxidative and cytoprotective pathways. Our objective was to delineate the roles of NADPH oxidase and Nrf2 in modulating acute lung inflammation and injury in clinically relevant models of acute gastric aspiration injury, a major cause of ALI. Acid aspiration caused increased ALI (as assessed by bronchoalveolar lavage fluid albumin concentration) in both NADPH oxidase-deficient mice and Nrf2(-/-) mice compared with wild-type mice. NADPH oxidase reduced airway neutrophil accumulation, but Nrf2 decreased ALI without affecting neutrophil recovery. Acid injury resulted in a 120-fold increase in mitochondrial DNA, a proinflammatory and injurious product of cellular necrosis, in cell-free bronchoalveolar lavage fluid. Pharmacologic activation of Nrf2 by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1,9 (11)-dien-28-oyl]imidazole limited aspiration-induced ALI in wild-type mice and reduced endothelial cell injury caused by mitochondrial extract-primed human neutrophils, leading to the conclusion that NADPH oxidase and Nrf2 have coordinated, but distinct, functions in modulating inflammation and injury. These results also point to Nrf2 as a therapeutic target to limit ALI by attenuating neutrophil-induced cellular injury. The Journal of Immunology, 2013, 190: 1714-1724.
C1 [Davidson, Bruce A.; Mullan, Barbara A.; Knight, Paul R.] SUNY Buffalo, Dept Anesthesiol, Sch Med, Buffalo, NY 14214, United States.
C1 [Davidson, Bruce A.] SUNY Buffalo, Dept Pathol & Anat Sci, Sch Med, Buffalo, NY 14214, United States.
C1 [Davidson, Bruce A.; Mullan, Barbara A.; Knight, Paul R.] Vet Adm Western New York Healthcare Syst, Dept Anesthesiol, Buffalo, NY 14215, United States.
C1 [Vethanayagam, R. Robert; Grimm, Melissa J.; Segal, Brahm H.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263, United States.
C1 [Raghavendran, Krishnan] Univ Michigan Hlth Syst, Dept Surg, Ann Arbor, MI 48109, United States.
C1 [Blackwell, Timothy S.] Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232, United States.
C1 [Freeman, Michael L.] Vanderbilt Univ, Dept Radiat Oncol, Sch Med, Nashville, TN 37232, United States.
C1 [Ayyasamy, Vanniarajan] Roswell Pk Canc Inst, Dept Genet, Buffalo, NY 14263, United States.
C1 [Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Sch Med, Birmingham, AL 35294, United States.
C1 [Sporn, Michael B.] Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755, United States.
C1 [Itagaki, Kiyoshi; Hauser, Carl J.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215, United States.
C1 [Segal, Brahm H.] SUNY Buffalo, Dept Med, Sch Med, Buffalo, NY 14214, United States.
C1 [Segal, Brahm H.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263, United States.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo; Roswell Park Comprehensive Cancer
   Center; University of Michigan System; University of Michigan;
   Vanderbilt University; Vanderbilt University; Roswell Park Comprehensive
   Cancer Center; University of Alabama System; University of Alabama
   Birmingham; Dartmouth College; Harvard University; Beth Israel Deaconess
   Medical Center; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo; Roswell Park Comprehensive Cancer
   Center
RP Segal, BH (corresponding author), Roswell Pk Canc Inst, Elm & Carlton St, Buffalo, NY 14263 USA.
EM brahm.segal@roswellpark.org
RI Davidson, Bruce/AAW-5753-2021; Segal, Brahm/AAW-2706-2020; Itagaki,
   Kiyoshi/M-5501-2015; raghavendran, krishnan/J-4662-2013; Hauser, Carl
   J./Y-1189-2019; Vanniarajan, A./AAB-4896-2022
OI Itagaki, Kiyoshi/0000-0002-6033-1122; Hauser, Carl/0000-0003-3167-1846;
   Davidson, Bruce/0000-0001-8223-1870
FU National Institutes of Health [AI079253, CA016056, HL048889, AI084410,
   CA116430, NIGMS 5 R01 GM089711-03]; Department of Defense
   [W81XWH-09-1-0472]
FX This work was supported by grants from the National Institutes of Health
   (AI079253 to B.H.S., CA016056 [Center Support Grant to Roswell Park
   Cancer Institute], HL048889 to B.A.D. and P.R.K., AI084410 to B.A.D. and
   P.R.K., CA116430 to K.K.S., and NIGMS 5 R01 GM089711-03 to C.J.H.) and
   Department of Defense Hypothesis Grant award W81XWH-09-1-0472 (to
   C.J.H.).
CR Adhikari N., 2004, COCHRANE DB SYST REV, V4, DOI [DOI 10.1002/14651858.CD004477.PUB2, 10.1002/14651858.CD004477.pub2]
   Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464
   Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC
   Cooke CR, 2009, CRIT CARE MED, V37, P1913, DOI 10.1097/CCM.0b013e3181a009b4
   Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2
   Davidson BA, 2005, AM J PHYSIOL-LUNG C, V288, pL699, DOI 10.1152/ajplung.00229.2004
   Davidson BA, 1999, ANESTHESIOLOGY, V91, P486, DOI 10.1097/00000542-199908000-00024
   Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510
   EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093
   Estenssoro E, 2002, CRIT CARE MED, V30, P2450, DOI 10.1097/00003246-200211000-00008
   Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005
   Fernandez-Boyanapalli RF, 2009, BLOOD, V113, P2047, DOI 10.1182/blood-2008-05-160564
   Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeradbiomed.2006.09.030
   FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974
   GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896
   GOLDMAN G, 1992, J APPL PHYSIOL, V73, P571, DOI 10.1152/jappl.1992.73.2.571
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Inci I, 2007, ANN THORAC SURG, V84, P240, DOI 10.1016/j.athoracsur.2007.03.082
   Itagaki K, 2011, SHOCK, V36, P548, DOI 10.1097/SHK.0b013e3182369fb2
   Itagaki K, 2010, SHOCK, V33, P381, DOI 10.1097/SHK.0b013e3181c6bb75
   JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751
   Jang JS, 2009, J CLIN BIOCHEM NUTR, V45, P37, DOI 10.3164/jcbn.08-262
   KENNEDY TP, 1989, ANESTH ANALG, V69, P87
   Knight PR, 2004, EXP LUNG RES, V30, P535, DOI 10.1080/01902140490489162
   KNIGHT PR, 1992, ANESTHESIOLOGY, V77, P772, DOI 10.1097/00000542-199210000-00023
   KNIGHT PR, 1993, ANESTH ANALG, V77, P754
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Kubo H, 1996, J CLIN INVEST, V97, P2680, DOI 10.1172/JCI118718
   Liby K, 2005, CANCER RES, V65, P4789, DOI 10.1158/0008-5472.CAN-04-4539
   Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462
   Nader ND, 2005, ANESTH ANALG, V101, P213, DOI 10.1213/01.ANE.0000152188.65226.FE
   Nader-Djalal N, 1998, ANESTH ANALG, V87, P127, DOI 10.1097/00000539-199807000-00028
   Phadke AP, 2005, MED MYCOL, V43, pS173, DOI 10.1080/13693780500052099
   Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182
   Raghavendran K, 2005, AM J PHYSIOL-LUNG C, V289, pL134, DOI 10.1152/ajplung.00390.2004
   Rahman I, 2006, CURR DRUG TARGETS, V7, P707, DOI 10.2174/138945006777435254
   Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a
   Ruchaud-Sparagano MH, 1998, EUR J IMMUNOL, V28, P80, DOI 10.1002/(SICI)1521-4141(199801)28:01<80::AID-IMMU80>3.0.CO;2-7
   Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004
   Segal BH, 2000, INFECT IMMUN, V68, P2374, DOI 10.1128/IAI.68.4.2374-2378.2000
   Segal BH, 2007, AM J PHYSIOL-LUNG C, V292, pL760, DOI 10.1152/ajplung.00281.2006
   Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   Siddiqui S., 2007, CLIN INFECT DIS, V45, P673, DOI [10.1086/520985, DOI 10.1086/520985]
   Tasaka S, 2008, ANTIOXID REDOX SIGN, V10, P739, DOI 10.1089/ars.2007.1940
   Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   van Bruggen R, 2010, BLOOD, V115, P5398, DOI 10.1182/blood-2009-10-250803
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919
   Woods CG, 2009, TOXICOL APPL PHARM, V238, P27, DOI 10.1016/j.taap.2009.04.007
   Yamada M, 2011, AM J RESP CRIT CARE, V183, P1391, DOI 10.1164/rccm.201004-0592OC
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC
   Zhu LX, 2008, AM J PHYSIOL-LUNG C, V294, pL469, DOI 10.1152/ajplung.00310.2007
   Zmijewski JW, 2009, AM J RESP CRIT CARE, V179, P694, DOI 10.1164/rccm.200806-851OC
NR 69
TC 43
Z9 44
U1 0
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2013
VL 190
IS 4
BP 1714
EP 1724
DI 10.4049/jimmunol.1202410
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 088HS
UT WOS:000314825400035
PM 23296708
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Wang, LF
   Taneja, R
   Wang, W
   Yao, LJ
   Veldhuizen, RAW
   Gill, SE
   Fortin, D
   Inculet, R
   Malthaner, R
   Mehta, S
AF Wang, Lefeng
   Taneja, Ravi
   Wang, Wei
   Yao, Li-Juan
   Veldhuizen, Ruud A. W.
   Gill, Sean E.
   Fortin, Dalilah
   Inculet, Richard
   Malthaner, Richard
   Mehta, Sanjay
TI Human Alveolar Epithelial Cells Attenuate Pulmonary Microvascular
   Endothelial Cell Permeability under Septic Conditions
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; NITRIC-OXIDE SYNTHASE;
   MURINE SEPSIS; PROTEIN LEAK; IN-VITRO; MIGRATION; KINASE; MODEL;
   PATHOGENESIS
AB Acute lung injury (ALI) and its most severe form, acute respiratory distress syndrome (ARDS), are characterised by high-protein pulmonary edema and severe hypoxaemic respiratory failure due to increased permeability of pulmonary microvascular endothelial cells (PMVEC). Alveolar epithelial cells (AEC) contribute importantly to normal alveolar function, and AEC dysfunction in ALI/ARDS is associated with worse outcomes. We hypothesized that AEC can modulate human PMVEC barrier function, and investigated the effects of AEC presence on human PMVEC barrier under septic conditions in vitro. PMVEC isolated from human lung were treated in vitro with septic stimulation (lipopolysaccharide [LPS], a mixture of clinically-relevant cytokines [cytomix], or plasma from patients with severe sepsis), and the trans-PMVEC leak of Evans Blue dye-labeled albumin assessed. PMVEC septic responses were compared in the presence/absence of co-cultured A549 epithelial cell line or primary human AEC. Septic stimulation with LPS, cytomix, or septic plasma induced marked PMVEC hyper-permeability (10.2 +/- 1.8, 8.9 +/- 2.2, and 3.7 +/- 0.2 fold-increase vs. control, respectively, p<0.01 for all). The presence of A549 cells or primary human AEC in a non-contact co-culture model attenuated septic PMVEC hyper-permeability by 39 +/- 4% to 100 +/- 3%, depending on the septic stimulation (p<0.05). Septic PMVEC hyper-permeability was also attenuated following treatment with culture medium conditioned by previous incubation with either naive or cytomix-treated A549 cells (p<0.05), and this protective effect of A549 cell-conditioned medium was both heat-stable and transferable following lipid extraction. Cytomix-stimulated PMN-dependent PMVEC hyper-permeability and trans-PMVEC PMN migration were also inhibited in the presence of A549 cells or A549 cell-conditioned medium (p<0.05). Human AEC appear to protect human PMVEC barrier function under septic conditions in vitro, through release of a soluble mediator(s), which are at least partly lipid in nature. This study suggests a scientific and potential clinical therapeutic importance of epithelial-endothelial cross talk in maintaining alveolar integrity in ALI/ARDS.
C1 [Wang, Lefeng; Taneja, Ravi; Wang, Wei; Yao, Li-Juan; Veldhuizen, Ruud A. W.; Gill, Sean E.; Mehta, Sanjay] London Hlth Sci Ctr, Lawson Hlth Res Inst, Ctr Crit Illness Res, Div Respirol, London, ON, Canada.
C1 [Wang, Lefeng; Wang, Wei; Veldhuizen, Ruud A. W.; Gill, Sean E.; Mehta, Sanjay] Univ Western Ontario, Schulich Fac Med & Dent, Dept Med, London, ON, Canada.
C1 [Taneja, Ravi] Univ Western Ontario, Schulich Fac Med & Dent, Dept Anesthesia, London, ON, Canada.
C1 [Taneja, Ravi; Fortin, Dalilah] Univ Western Ontario, Schulich Fac Med & Dent, Dept Crit Care Med, London, ON, Canada.
C1 [Fortin, Dalilah; Inculet, Richard; Malthaner, Richard] Univ Western Ontario, Schulich Fac Med & Dent, Dept Thorac Surg, London, ON, Canada.
C3 London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Mehta, S (corresponding author), London Hlth Sci Ctr, Lawson Hlth Res Inst, Ctr Crit Illness Res, Div Respirol, London, ON, Canada.
EM Sanjay.Mehta@lhsc.on.ca
RI Mehta, Sanjay/G-3332-2011; wang, le/HKN-3406-2023; Veldhuizen,
   Ruud/G-3352-2011; Gill, Sean E/G-4057-2012
OI Mehta, Sanjay/0000-0002-7707-1056; Veldhuizen, Ruud/0000-0002-8802-1580;
   
FU Heart & Stroke Foundation of Ontario/Canada [T6461]; Ontario Thoracic
   Society; Lawson Health Research Institute; LHSC Department of Medicine
   Program of Experimental Medicine
FX Funding support by Heart & Stroke Foundation of Ontario/Canada grant
   #T6461, Ontario Thoracic Society, Lawson Health Research Institute, LHSC
   Department of Medicine Program of Experimental Medicine. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bastarache JA, 2009, AM J PHYSIOL-LUNG C, V297, pL1035, DOI 10.1152/ajplung.00214.2009
   Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481
   Breslin JW, 2004, AM J PHYSIOL-HEART C, V286, pH1057, DOI 10.1152/ajpheart.00841.2003
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Clerici C, 2011, AM J PHYSIOL-LUNG C, V301, pL20, DOI 10.1152/ajplung.00126.2011
   DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012
   Ehrhardt Carsten, 2005, Methods Mol Med, V107, P207
   Farley KS, 2006, AM J PHYSIOL-LUNG C, V290, pL1164, DOI 10.1152/ajplung.00248.2005
   GORIN AB, 1979, J APPL PHYSIOL, V47, P1315, DOI 10.1152/jappl.1979.47.6.1315
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hermanns MI, 2009, CELL TISSUE RES, V336, P91, DOI 10.1007/s00441-008-0750-1
   Jacobs ER, 2001, AM J PHYSIOL-HEART C, V280, pH1, DOI 10.1152/ajpheart.2001.280.1.H1
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Mason RJ, 2006, RESPIROLOGY, V11, pS12, DOI 10.1111/j.1440-1843.2006.00800.x
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Moss M, 1996, CRIT CARE MED, V24, P1782, DOI 10.1097/00003246-199611000-00004
   Ochoa CD, 2012, AM J PHYSIOL-LUNG C, V302, pL275, DOI [10.1152/ajplung.00215.2011, 10.1152/ajplung.00215.2011.]
   Orgeig S, 2010, RESP PHYSIOL NEUROBI, V173, pS43, DOI 10.1016/j.resp.2010.04.023
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Pober JS, 2009, ANNU REV PATHOL-MECH, V4, P71, DOI 10.1146/annurev.pathol.4.110807.092155
   Razavi HM, 2005, CRIT CARE MED, V33, P1333, DOI 10.1097/01.CCM.0000165445.48350.4F
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976
   Schnitzer SE, 2009, MOL CANCER RES, V7, P393, DOI 10.1158/1541-7786.MCR-08-0156
   Shelton JL, 2008, MICROVASC RES, V76, P80, DOI 10.1016/j.mvr.2008.06.001
   Shelton JL, 2007, MICROVASC RES, V74, P23, DOI 10.1016/j.mvr.2007.02.008
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC
   Thorley AJ, 2007, J IMMUNOL, V178, P463, DOI 10.4049/jimmunol.178.1.463
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   Wang LF, 2012, SHOCK, V37, P539, DOI 10.1097/SHK.0b013e31824dcb5a
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Wang L, 2007, AM J RESP CELL MOL, V36, P497, DOI 10.1165/rcmb.2005-0425OC
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weppler A, 2006, EXP LUNG RES, V32, P455, DOI 10.1080/01902140601059463
   Witherden IR, 2004, AM J RESP CELL MOL, V30, P500, DOI 10.1165/rcmb.4890
   Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528
NR 42
TC 32
Z9 38
U1 1
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2013
VL 8
IS 2
AR e55311
DI 10.1371/journal.pone.0055311
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 086NV
UT WOS:000314692800022
PM 23393568
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Gandhirajan, RK
   Meng, S
   Chandramoorthy, HC
   Mallilankaraman, K
   Mancarella, S
   Gao, H
   Razmpour, R
   Yang, XF
   Houser, SR
   Chen, J
   Koch, WJ
   Wang, H
   Soboloff, J
   Gill, DL
   Madesh, M
AF Gandhirajan, Rajesh Kumar
   Meng, Shu
   Chandramoorthy, Harish C.
   Mallilankaraman, Karthik
   Mancarella, Salvatore
   Gao, Hui
   Razmpour, Roshanak
   Yang, Xiao-Feng
   Houser, Steven R.
   Chen, Ju
   Koch, Walter J.
   Wang, Hong
   Soboloff, Jonathan
   Gill, Donald L.
   Madesh, Muniswamy
TI Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced
   vascular inflammation
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID CALCIUM SENSORS STIM1; ENDOTHELIAL-CELLS; CA2+ INFLUX; INOSITOL
   1,4,5-TRISPHOSPHATE; S-GLUTATHIONYLATION; GENE-EXPRESSION;
   UNITED-STATES; TNF-ALPHA; ACTIVATION; PROTEIN
AB During sepsis, acute lung injury (ALI) results from activation of innate immune cells and endothelial cells by endotoxins, leading to systemic inflammation through proinflammatory cytokine overproduction, oxidative stress, and intracellular Ca2+ overload. Despite considerable investigation, the underlying molecular mechanism(s) leading to LPS-induced ALI remain elusive. To determine whether stromal interaction molecule 1-dependent (STIM1-dependent) signaling drives endothelial dysfunction in response to LPS, we investigated oxidative and STIM1 signaling of EC-specific Stim1-knockout mice. Here we report that LPS-mediated Ca2+ oscillations are ablated in ECs deficient in Nox2, Stim1, and type II inositol triphosphate receptor (Itpr2). LPS-induced nuclear factor of activated T cells (NEAT) nuclear accumulation was abrogated by either antioxidant supplementation or Ca2+ chelation. Moreover, ECs lacking either Nox2 or Stim1 failed to trigger store-operated Ca2+ entry (SOCe) and NFAT nuclear accumulation. LPS-induced vascular permeability changes were reduced in EC-specific Stim1(-/-) mice, despite elevation of systemic cytokine levels. Additionally, inhibition of STIM1 signaling prevented receptor-interacting protein 3-dependent (RIP3-dependent) EC death. Remarkably, BTP2, a small-molecule calcium release-activated calcium (CRAC) channel blocker administered after insult, halted LPS-induced vascular leakage and pulmonary edema. These results indicate that ROS-driven Ca2+ signaling promotes vascular barrier dysfunction and that the SOCe machinery may provide crucial therapeutic targets to limit sepsis-induced ALI.
C1 [Gandhirajan, Rajesh Kumar; Chandramoorthy, Harish C.; Mallilankaraman, Karthik; Mancarella, Salvatore; Soboloff, Jonathan; Gill, Donald L.; Madesh, Muniswamy] Temple Univ, Dept Biochem, Philadelphia, PA 19140, United States.
C1 [Gandhirajan, Rajesh Kumar; Chandramoorthy, Harish C.; Mallilankaraman, Karthik; Koch, Walter J.; Madesh, Muniswamy] Temple Univ, Ctr Translat Med, Philadelphia, PA 19140, United States.
C1 [Meng, Shu; Yang, Xiao-Feng; Koch, Walter J.; Wang, Hong] Temple Univ, Dept Pharmacol, Philadelphia, PA 19140, United States.
C1 [Gao, Hui; Houser, Steven R.] Temple Univ, Dept Physiol, Cardiovasc Res Ctr, Philadelphia, PA 19140, United States.
C1 [Razmpour, Roshanak] Temple Univ, Dept Anat & Cell Biol, Philadelphia, PA 19140, United States.
C1 [Chen, Ju] UCSD, Dept Med, La Jolla, CA, United States.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); Temple University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Temple University;
   University of California System; University of California San Diego
RP Madesh, M (corresponding author), Temple Univ, Ctr Translat Med, 950 MERB,3500 N Broad St, Philadelphia, PA 19140 USA.
EM madeshm@temple.edu
RI Soboloff, Jonathan/I-6995-2012; Chandramoorthy, Harish C/A-6533-2019;
   Chen, Ju/E-5579-2011
OI Soboloff, Jonathan/0000-0001-5192-1297; MALLILANKARAMAN,
   KARTHIK/0000-0002-9492-9050; Chinna Konda Chandramoorthy,
   Harish/0000-0002-8780-8971; Gandhirajan, Rajesh
   Kumar/0000-0002-0039-771X
FU NIH [HL086699, 1S10RR027327-01, 1R21HL109920-01]
FX This work was supported by NIH grants HL086699 (to M. Madesh),
   1S10RR027327-01 (to M. Madesh), and 1R21HL109920-01 (to M. Madesh and J.
   Soboloff). We thank Anjana Rao (La Jolla Institute for Allergy and
   Immunology, La Jolla, California, USA), Suresh Joseph (Thomas Jefferson
   University, Philadelphia, Pennsylvania, USA), and Gary Koretzky
   (University of Pennsylvania, Philadelphia, Pennsylvania, USA) for
   providing the Stim1<SUP>fl/fl</SUP> mice, InsP<INF>3</INF>RI antibody,
   and NFAT-luciferase plasmid construct, respectively. We are grateful to
   Aron B. Fisher, G. Scott Worthen, and Troy Stevens for critical comments
   on the results.
CR Aird WC, 2007, CURR DRUG TARGETS, V8, P501, DOI 10.2174/138945007780362782
   Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Bae YS, 2009, CIRC RES, V104, P210, DOI 10.1161/CIRCRESAHA.108.181040
   Baluk P, 2009, J CLIN INVEST, V119, P2954, DOI 10.1172/JCI37626
   Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866
   Bergner A, 2002, J GEN PHYSIOL, V119, P187, DOI 10.1085/jgp.119.2.187
   Berna-Erro A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000522
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Bogeski I, 2011, CELL CALCIUM, V50, P407, DOI 10.1016/j.ceca.2011.07.006
   Cheng KT, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001025
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Craige SM, 2011, CIRCULATION, V124, P731, DOI 10.1161/CIRCULATIONAHA.111.030775
   Czermak BJ, 1999, AM J PATHOL, V154, P1057, DOI 10.1016/S0002-9440(10)65358-8
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Dupont G., 2011, COLD SPRING HARB PER, V3
   Estrada IA, 2012, CIRC RES, V111, P1166, DOI 10.1161/CIRCRESAHA.112.275743
   Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702
   GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022
   Gunther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400
   Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200
   Hawkins BJ, 2007, MOL CELL BIOL, V27, P7582, DOI 10.1128/MCB.00493-07
   Hawkins BJ, 2007, MOL BIOL CELL, V18, P2002, DOI 10.1091/mbc.E06-09-0830
   Hawkins BJ, 2010, J CELL BIOL, V190, P391, DOI 10.1083/jcb.201004152
   He LP, 2005, J BIOL CHEM, V280, P10997, DOI 10.1074/jbc.M411797200
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200
   Hu QH, 2000, J BIOL CHEM, V275, P15749, DOI 10.1074/jbc.M000381200
   Hu QH, 2002, J BIOL CHEM, V277, P32546, DOI 10.1074/jbc.M201550200
   Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454
   Kar P, 2011, J BIOL CHEM, V286, P14795, DOI 10.1074/jbc.M111.220582
   Krapivinsky G, 2011, P NATL ACAD SCI USA, V108, P19234, DOI 10.1073/pnas.1117231108
   Lamb FS, 2012, J BIOL CHEM, V287, P12395, DOI 10.1074/jbc.M111.306530
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055
   Lock JT, 2011, AM J PHYSIOL-HEART C, V300, pH493, DOI 10.1152/ajpheart.01073.2010
   Luik RM, 2008, NATURE, V454, P538, DOI 10.1038/nature07065
   Madesh M, 2005, J CELL BIOL, V170, P1079, DOI 10.1083/jcb.200505022
   Mallilankaraman K, 2011, JOVE-J VIS EXP, DOI 10.3791/3511
   Mancarella S, 2011, J BIOL CHEM, V286, P44788, DOI 10.1074/jbc.M111.303081
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Matsumoto M, 2011, IMMUNITY, V34, P703, DOI 10.1016/j.immuni.2011.03.016
   Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818
   Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574
   Ohga K, 2008, INT IMMUNOPHARMACOL, V8, P1787, DOI 10.1016/j.intimp.2008.08.016
   Palty R, 2012, CELL, V149, P425, DOI 10.1016/j.cell.2012.01.055
   Parekh AB, 2011, TRENDS BIOCHEM SCI, V36, P78, DOI 10.1016/j.tibs.2010.07.013
   Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589
   Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514
   Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019
   Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632
   Simon F, 2009, J HYPERTENS, V27, P1202, DOI 10.1097/HJH.0b013e328329e31c
   Soboloff J, 2012, NAT REV MOL CELL BIO, V13, P549, DOI 10.1038/nrm3414
   Soboloff J, 2011, NAT CHEM BIOL, V7, P488, DOI 10.1038/nchembio.619
   Srikanth S, 2012, P NATL ACAD SCI USA, V109, P8682, DOI 10.1073/pnas.1200667109
   Srikanth S, 2010, NAT CELL BIOL, V12, P436, DOI 10.1038/ncb2045
   Takezawa R, 2006, MOL PHARMACOL, V69, P1413, DOI 10.1124/mol.105.021154
   Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200
   VARANI J, 1994, SHOCK, V2, P311, DOI 10.1097/00024382-199411000-00001
   Varga-Szabo D, 2008, J EXP MED, V205, P1583, DOI 10.1084/jem.20080302
   Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883
   Wada Y, 2005, FASEB J, V19, P1914, DOI 10.1096/fj.05-4037fje
   Wu SQ, 2005, AM J PHYSIOL-HEART C, V289, pH873, DOI 10.1152/ajpheart.00993.2004
   Xiao BL, 2011, NAT CHEM BIOL, V7, P351, DOI [10.1038/nchembio.558, 10.1038/NCHEMBIO.558]
   Zhang L, 2011, J CELL PHYSIOL, V226, P1694, DOI 10.1002/jcp.22500
   Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103
   Zhu LP, 2008, J CELL SCI, V121, P2511, DOI 10.1242/jcs.031997
   Zitt C, 2004, J BIOL CHEM, V279, P12427, DOI 10.1074/jbc.M309297200
NR 72
TC 163
Z9 168
U1 1
U2 44
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2013
VL 123
IS 2
BP 887
EP 902
DI 10.1172/JCI65647
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 084QG
UT WOS:000314553600041
PM 23348743
OA Green Published
DA 2023-08-21
ER

PT J
AU Klinger, JR
   Tsai, SW
   Green, S
   Grinnell, KL
   Machan, JT
   Harrington, EO
AF Klinger, James R.
   Tsai, Shu-Whei
   Green, Sabrina
   Grinnell, Katie L.
   Machan, Jason T.
   Harrington, Elizabeth O.
TI Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in
   mice with targeted disruption of the gene for natriuretic peptide
   receptor-A
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; natriuretic peptide; pulmonary edema; receptors; permeability 
ID GAS-EXCHANGE; NITRIC-OXIDE; VASCULAR-PERMEABILITY; BARRIER DYSFUNCTION;
   CYTOPLASMIC DOMAIN; PHYSIOLOGICAL-ROLE; ENDOTHELIAL-CELLS;
   DOWN-REGULATION; PLASMA-VOLUME; ALPHA-HANP
AB Klinger JR, Tsai S, Green S, Grinnell K, Machan JT, Harrington EO. Atrial natriuretic peptide attenuates agonist induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A. J Appl Physiol 114: 307-315, 2013. First published November 29, 2012; doi:10.1152/japplphysiol.01249.2011.-Atrial natriuretic peptide (ANP) inhibits agonist-induced pulmonary edema formation, but the signaling pathway responsible is not well defined. To investigate the role of the particulate guanylate cyclase-linked receptor, natriuretic peptide receptor-A (NPR-A), we measured acute lung injury responses in intact mice and pulmonary microvascular endothelial cells (PMVEC) with normal and disrupted expression of NPR-A. NPR-A wild-type (NPR-A+/+), heterozygous (NPR-A+/-), and knockout (NPR-A-/-) mice were anesthetized and treated with thrombin receptor agonist peptide (TRAP) or lipopolysaccharide (LPS). Lung injury was assessed by lung wet-to-dry (W/D) weight and by protein and cell concentration of bronchoalveolar lavage (BAL) fluid. No difference in pulmonary edema formation was seen between NPR-A genotypes under baseline conditions. TRAP and LPS increased lung W/D weight and BAL fluid cell counts more in NPR-A-/- mice than in NPR-A+/- or NPR-A+/+ mice, but no genotype-related differences were seen in TRAP-induced increases in bloodless lung W/D weight or LPS-induced increases in BAL protein concentration. Pretreatment with ANP infusion completely blocked TRAP-induced increases in lung W/D weight and blunted LPS-induced increases in BAL cell counts and protein concentration in both NPR-A-/- and NPR-A+/+ mice. Thrombin decreased transmembrane electrical resistance in monolayers of PMVECs in vitro, and this effect was attenuated by ANP in PMVECs isolated from both genotypes. Administration of the NPR-C-specific ligand, cANF, also blocked TRAP-induced increases in lung W/D weight and LPS-induced increases in BAL cell count and protein concentration in NPR-A+/+ and NPR-A-/- mice. We conclude that ANP is capable of attenuating agonist-induced lung edema in the absence of NPR-A. The protective effect of ANP on agonist-induced lung injury and pulmonary barrier function may be mediated by NPR-C.
C1 [Klinger, James R.; Tsai, Shu-Whei; Green, Sabrina; Grinnell, Katie L.; Harrington, Elizabeth O.] Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI, United States.
C1 [Klinger, James R.; Machan, Jason T.] Rhode Isl Hosp, Providence, RI 02903, United States.
C1 [Klinger, James R.; Tsai, Shu-Whei; Grinnell, Katie L.; Machan, Jason T.; Harrington, Elizabeth O.] Brown Univ, Alpert Med Sch, Providence, RI 02912, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Lifespan Health Rhode Island; Rhode Island
   Hospital; Brown University
RP Klinger, JR (corresponding author), Rhode Isl Hosp, Div Pulm Sleep & Crit Care Med, 593 Eddy St, Providence, RI 02903 USA.
EM James_Klinger@brown.edu
RI Machan, Jason Timothy/D-3897-2013
OI Machan, Jason Timothy/0000-0003-2048-4914; Harrington,
   Elizabeth/0000-0002-3207-5301
FU National Heart, Lung, and Blood Institute [HL-088328, HL-088328-03S1];
   VA Merit Review;  [HL67795];  [T32 HL094300]
FX This material is the result of work supported with resources and the use
   of facilities at the Providence VA Medical Center and supported with
   National Heart, Lung, and Blood Institute Grants HL-088328 and
   HL-088328-03S1 (J. R. Klinger), VA Merit Review and HL67795 Grants (E.
   O. Harrington), and T32 HL094300 (supported K. L. Grinnell).
CR ALMEIDA FA, 1986, LIFE SCI, V39, P1193, DOI 10.1016/0024-3205(86)90351-6
   AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324
   Atkinson B, 2004, ISOLATION MOUSE LUNG
   BARON DA, 1989, P NATL ACAD SCI USA, V86, P3394, DOI 10.1073/pnas.86.9.3394
   Bindels AJGH, 2001, CRIT CARE, V5, P151, DOI 10.1186/cc1015
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   BUCHAN KW, 1992, BRIT J PHARMACOL, V107, P932, DOI 10.1111/j.1476-5381.1992.tb13388.x
   Curry FRE, 2005, J CLIN INVEST, V115, P1458, DOI 10.1172/JCI25417
   Dodd-O JM, 2008, AM J PHYSIOL-LUNG C, V294, pL714, DOI 10.1152/ajplung.00185.2007
   DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199
   EISON HB, 1988, CHEST, V94, P1040, DOI 10.1378/chest.94.5.1040
   FLUCKIGER JP, 1986, AM J PHYSIOL, V251, pH880, DOI 10.1152/ajpheart.1986.251.4.H880
   Fukuda N, 2000, J APPL PHYSIOL, V89, P672, DOI 10.1152/jappl.2000.89.2.672
   Furst R, 2005, CIRC RES, V96, P43, DOI 10.1161/01.RES.0000151983.01148.06
   Hashim S, 2006, AM J PHYSIOL-HEART C, V291, pH3144, DOI 10.1152/ajpheart.00327.2006
   Hempel A, 1998, AM J PHYSIOL-HEART C, V275, pH1818, DOI 10.1152/ajpheart.1998.275.5.H1818
   Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499
   Holz GG, 2006, J PHYSIOL-LONDON, V577, P5, DOI 10.1113/jphysiol.2006.119644
   IMAMURA T, 1988, LIFE SCI, V42, P403, DOI 10.1016/0024-3205(88)90078-1
   INOMATA N, 1987, JPN J PHARMACOL, V44, P211, DOI 10.1254/jjp.44.211
   Irwin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL849, DOI 10.1152/ajplung.00294.2004
   Irwin DC, 2001, HIGH ALT MED BIOL, V2, P349, DOI 10.1089/15270290152608525
   Klinger JR, 2011, AM J RESP CRIT CARE, V183
   Klinger JR, 1999, AM J PHYSIOL-LUNG C, V276, pL868, DOI 10.1152/ajplung.1999.276.5.L868
   KLINGER JR, 1992, P SOC EXP BIOL MED, V201, P154
   Klinger JR, 2006, EXP CELL RES, V312, P401, DOI 10.1016/j.yexcr.2005.11.001
   KLINGER JR, 1994, J APPL PHYSIOL, V77, P1309, DOI 10.1152/jappl.1994.77.3.1309
   Klinger JR, 2002, AM J PHYSIOL-HEART C, V282, pH58, DOI 10.1152/ajpheart.2002.282.1.H58
   Klinger JR, 2012, AM J RESP CRIT CARE, V185, pA5517
   KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777
   LI HB, 1995, AM J PHYSIOL-LUNG C, V268, pL328, DOI 10.1152/ajplung.1995.268.2.L328
   Li Y, 2006, CARDIOVASC RES, V72, P464, DOI 10.1016/j.cardiores.2006.08.012
   LOFTON CE, 1991, J MOL CELL CARDIOL, V23, P919, DOI 10.1016/0022-2828(91)90134-8
   MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385
   Mitaka C, 2002, CRIT CARE MED, V30, P1570, DOI 10.1097/00003246-200207000-00029
   Mitaka C, 1998, CHEST, V114, P223, DOI 10.1378/chest.114.1.223
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Murthy KS, 1999, J BIOL CHEM, V274, P17587, DOI 10.1074/jbc.274.25.17587
   Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730
   Pearse DB, 2003, ENDOTHELIUM-J ENDOTH, V10, P309, DOI 10.1080/10623320390272307
   Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200
   PERREAULT T, 1995, AM J RESP CRIT CARE, V151, P226, DOI 10.1164/ajrccm.151.1.7812560
   Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200
   Sabrane K, 2005, J CLIN INVEST, V115, P1666, DOI 10.1172/JCI23360
   Suttorp N, 1996, AM J PHYSIOL-CELL PH, V270, pC778, DOI 10.1152/ajpcell.1996.270.3.C778
   Suzuki T, 2001, CARDIOVASC RES, V51, P489, DOI 10.1016/S0008-6363(01)00238-3
   WAKABAYASHI G, 1990, AM J PHYSIOL, V258, pR690, DOI 10.1152/ajpregu.1990.258.3.R690
   WESTENDORP RGJ, 1993, AM REV RESPIR DIS, V148, P304, DOI 10.1164/ajrccm/148.2.304
   WESTENDORP RGJ, 1994, J VASC RES, V31, P42, DOI 10.1159/000159030
   WIJEYARATNE CN, 1993, J CLIN ENDOCR METAB, V76, P343, DOI 10.1210/jcem.76.2.8432776
   Xing JJ, 2011, J APPL PHYSIOL, V110, P213, DOI 10.1152/japplphysiol.00284.2010
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Zhao L, 1999, CIRCULATION, V99, P605, DOI 10.1161/01.CIR.99.5.605
NR 54
TC 7
Z9 8
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD FEB
PY 2013
VL 114
IS 3
BP 307
EP 315
DI 10.1152/japplphysiol.01249.2011
PG 9
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Sport Sciences
GA 084FA
UT WOS:000314521900002
PM 23195629
OA Green Published
DA 2023-08-21
ER

PT J
AU Mannam, P
   Zhang, XC
   Shan, PY
   Zhang, Y
   Shinn, AS
   Zhang, YT
   Lee, PJ
AF Mannam, Praveen
   Zhang, Xuchen
   Shan, Peiying
   Zhang, Yi
   Shinn, Amanda S.
   Zhang, Yitao
   Lee, Patty J.
TI Endothelial MKK3 Is a Critical Mediator of Lethal Murine Endotoxemia and
   Acute Lung Injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NF-KAPPA-B; PROTEIN-KINASE PATHWAY; MITOCHONDRIAL SUPEROXIDE;
   GENE-EXPRESSION; ACTIVATION; MICE; RESISTANCE; ICAM-1; SHOCK; AP-1
AB Sepsis is a leading cause of intensive care unit admissions, with high mortality and morbidity. Although outcomes have improved with better supportive care, specific therapies are limited. Endothelial activation and oxidant injury are key events in the pathogenesis of sepsis-induced lung injury. The signaling pathways leading to these events remain poorly defined. We sought to determine the role of MAPK kinase 3 (MKK3), a kinase of the p38 group, in the pathogenesis of sepsis. We used a murine i.p. LPS model of systemic inflammation to mimic sepsis. Lung injury parameters were assessed in lung tissue and bronchoalveolar lavage specimens. Primary lung endothelial cells were cultured and assessed for mediators of inflammation and injury, such as ICAM-1, AP-1, NF-kappa B, and mitochondrial reactive oxygen species. Our studies demonstrate that MKK3 deficiency confers virtually complete protection against organ injury after i.p. LPS. Specifically, MKK3(-/-) mice were protected against acute lung injury, as assessed by reduced inflammation, mitochondrial reactive oxygen species generation, endothelial injury, and ICAM-1 expression after LPS administration. Our results show that endothelial MKK3 is required for inflammatory cell recruitment to the lungs, mitochondrial oxidant-mediated AP-1, NF-kappa B activation, and ICAM-1 expression during LPS challenge. Collectively, these studies identify a novel role for MKK3 in lethal LPS responses and provide new therapeutic targets against sepsis and acute lung injury. The Journal of Immunology, 2013, 190: 1264-1275.
C1 [Mannam, Praveen; Shan, Peiying; Zhang, Yi; Shinn, Amanda S.; Zhang, Yitao; Lee, Patty J.] Yale Univ, Dept Internal Med, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT 06520, United States.
C1 [Zhang, Xuchen] Yale Univ, Dept Pathol, Sch Med, New Haven, CT 06520, United States.
C3 Yale University; Yale University
RP Lee, PJ (corresponding author), Yale Univ, Dept Internal Med, Sch Med, Sect Pulm Crit Care & Sleep Med, 333 Cedar St,POB 208057, New Haven, CT 06520 USA.
EM patty.lee@yale.edu
RI zhang, xu/GYE-3558-2022
OI Zhang, Xuchen/0000-0002-1484-4672
FU American Heart Association [AHA 09FTF2090019]; National Institutes of
   Health/National Heart, Lung, and Blood Institute [R01 HL090660, R01
   HL071595]
FX This work was supported by American Heart Association Grant AHA
   09FTF2090019 (to P.M.) and by National Institutes of Health/National
   Heart, Lung, and Blood Institute, Grants R01 HL090660 and R01 HL071595
   (to P.J.L.).
CR Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522
   Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Carre JE, 2010, AM J RESP CRIT CARE, V182, P745, DOI 10.1164/rccm.201003-0326OC
   De Plaen IG, 2006, IMMUNOLOGY, V118, P153, DOI 10.1111/j.1365-2567.2006.02344.x
   Deans KJ, 2005, J TRAUMA, V58, P867, DOI 10.1097/01.TA.0000158244.69179.94
   DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144
   Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601
   Dolinay T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001601
   Fan HY, 2002, AM J PHYSIOL-HEART C, V282, pH1778, DOI 10.1152/ajpheart.00796.2000
   Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004
   Fukuda K, 2008, LAB INVEST, V88, P398, DOI 10.1038/labinvest.2008.10
   HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033
   Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5
   Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Kepp O, 2011, NAT IMMUNOL, V12, P199, DOI 10.1038/ni0311-199
   Kisseleva T, 2006, J CLIN INVEST, V116, P2955, DOI 10.1172/JCI27392
   Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002
   Lee JH, 2004, J IMMUNOL, V172, P608, DOI 10.4049/jimmunol.172.1.608
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Lim AKH, 2009, DIABETOLOGIA, V52, P347, DOI 10.1007/s00125-008-1215-5
   Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845
   Ma FY, 2007, AM J PHYSIOL-RENAL, V293, pF1556, DOI 10.1152/ajprenal.00010.2007
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106
   Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Otterbein LE, 2003, AM J PATHOL, V163, P2555, DOI 10.1016/S0002-9440(10)63610-3
   Panes J, 1995, AM J PHYSIOL-HEART C, V269, pH1955, DOI 10.1152/ajpheart.1995.269.6.H1955
   Pantano C, 2006, ANTIOXID REDOX SIGN, V8, P1791, DOI 10.1089/ars.2006.8.1791
   Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]
   Roebuck KA, 1999, INT J MOL MED, V4, P223
   SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4
   Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Wang Y, 2009, REDOX REP, V14, P243, DOI 10.1179/135100009X12525712409896
   Warn PA, 2003, LAB ANIM-UK, V37, P126, DOI 10.1258/00236770360563769
   Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763
   XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200
   Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200
   Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139
NR 49
TC 34
Z9 39
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2013
VL 190
IS 3
BP 1264
EP 1275
DI 10.4049/jimmunol.1202012
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 074AM
UT WOS:000313784200044
PM 23275604
OA Bronze, Green Accepted
DA 2023-08-21
ER

PT J
AU Sun, CX
   Beard, RS
   McLean, DL
   Rigor, RR
   Konia, T
   Wu, MH
   Yuan, SY
AF Sun, Chongxiu
   Beard, Richard S., Jr.
   McLean, Danielle L.
   Rigor, Robert R.
   Konia, Thomas
   Wu, Mack H.
   Yuan, Sarah Y.
TI ADAM15 deficiency attenuates pulmonary hyperpermeability and acute lung
   injury in lipopolysaccharide-treated mice
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE permeability; metalloproteinase; endothelial dysfunction; Inflammation 
ID REGULATES ENDOTHELIAL PERMEABILITY; VE-CADHERIN; MECHANISMS; EXPRESSION;
   ADAM-15; METALLOPROTEASE; PATHOPHYSIOLOGY; METARGIDIN; THERAPIES;
   PROTEIN
AB Sun C, Beard RS Jr, McLean DL, Rigor RR, Konia T, Wu MH, Yuan SY. ADAM15 deficiency attenuates pulmonary hyperpermeability and acute lung injury in lipopolysaccharide-treated mice. Am J Physiol Lung Cell Mol Physiol 304: L135-L142, 2013. First published November 16, 2012; doi: 10.1152/ajplung.00133.2012.ADAM15 is a disintegrin and metalloprotease recently implicated in cancer and chronic immune disorders. We have recently characterized ADAM15 as a mediator of endothelial barrier dysfunction. Whether this molecule contributes to acute inflammation has not been evaluated. The purpose of this study was to investigate the role of ADAM15 in mediating pulmonary microvascular leakage during acute inflammatory injury. Immunofluorescent staining and Western blotting revealed that the endothelium was the main source of ADAM15 in lung tissue. In a mouse model of acute lung injury induced by lipopolysaccharide (LPS), upregulation of ADAM15 was observed in association with pulmonary edema and neutrophil infiltration. The LPS-induced inflammatory injury, as demonstrated by bronchoalveolar lavage neutrophil count, lung wet-to-dry weight ratio, and myeloperoxidase activity, was significantly attenuated in Adam15(-/-) mice. Studies with primary cell culture demonstrated abundant ADAM15 expression in endothelial cells (ECs) of mouse lung but not in neutrophils. Deficiency of ADAM15 in ECs had no obvious effect on basal permeability but significantly attenuated hyperpermeability response to LPS as evidenced by albumin flux assay and measurements of transendothelial electrical resistance, respectively. ADAM15 deficiency also reduced neutrophil chemotactic transmigration across endothelial barriers in the presence or absence of formyl-methionyl-leucyl-phenylalanine (fMLP). Rescue expression of ADAM15 in Adam15(-/-) ECs restored neutrophil transendothelial migration. These data indicate that ADAM15 upregulation contributes to inflammatory lung injury by promoting endothelial hyperpermeability and neutrophil transmigration.
C1 [Beard, Richard S., Jr.; McLean, Danielle L.; Wu, Mack H.; Yuan, Sarah Y.] Univ S Florida, Morsani Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612, United States.
C1 [Sun, Chongxiu; Rigor, Robert R.; Wu, Mack H.; Yuan, Sarah Y.] Univ Calif Davis, Sch Med, Dept Surg, Div Res, Sacramento, CA 95817, United States.
C1 [Konia, Thomas] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817, United States.
C3 State University System of Florida; University of South Florida;
   University of California System; University of California Davis;
   University of California System; University of California Davis
RP Yuan, SY (corresponding author), Univ S Florida, Morsani Coll Med, Dept Mol Pharmacol & Physiol, 12901 Bruce B Downs Blvd,MDC 8, Tampa, FL 33612 USA.
EM syuan@health.usf.edu
RI Beard, Richard S/E-2051-2013; Rigor, Robert/HMV-7108-2023; Yuan, Sarah
   Y/A-2111-2012; Beard, Richard Scott/I-3695-2019
OI Beard, Richard S/0000-0001-8545-3014; Beard, Richard
   Scott/0000-0001-8545-3014; Rigor, Robert/0000-0001-6234-1992; ,
   ChongXiu/0000-0001-8425-5024
FU National Heart, Lung, and Blood Institute [HL61507, HL84542, HL96640]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants HL61507, HL84542, and HL96640.
CR Al-Fakhri N, 2003, J CELL BIOCHEM, V89, P808, DOI 10.1002/jcb.10550
   Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002
   Bohm BB, 2001, ARTHRITIS RHEUM-US, V44, P2046, DOI 10.1002/1529-0131(200109)44:9<2046::AID-ART354>3.0.CO;2-3
   Charrier L, 2005, AM J PHYSIOL-GASTR L, V288, pG346, DOI 10.1152/ajpgi.00262.2004
   Charrier-Hisamuddin L, 2008, FASEB J, V22, P641, DOI 10.1096/fj.07-8876rev
   Cinel I, 2007, CURR OPIN INFECT DIS, V20, P345, DOI 10.1097/QCO.0b013e32818be70a
   Czabanka M, 2007, CURR VASC PHARMACOL, V5, P266, DOI 10.2174/157016107782023389
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012
   Gong P, 2008, J BIOL CHEM, V283, P13437, DOI 10.1074/jbc.M707986200
   GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662
   Guo M, 2008, AM J PHYSIOL-CELL PH, V294, pC977, DOI 10.1152/ajpcell.90607.2007
   Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960
   Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Jacobson JR, 2007, CURR DRUG TARGETS, V8, P509, DOI 10.2174/138945007780362719
   Kratzschmar J, 1996, J BIOL CHEM, V271, P4593
   Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112
   Langer H, 2005, THROMB HAEMOSTASIS, V94, P555, DOI 10.1160/TH04-12-0784
   Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895
   Lucas N, 2009, CURR PHARM DESIGN, V15, P2311, DOI 10.2174/138161209788682370
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mikawa K, 2004, CRIT CARE MED, V32, P209, DOI 10.1097/01.CCM.0000104954.22016.D2
   Najy AJ, 2008, CANCER RES, V68, P1092, DOI 10.1158/0008-5472.CAN-07-2432
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Schulz B, 2008, CIRC RES, V102, P1192, DOI 10.1161/CIRCRESAHA.107.169805
   Sun CX, 2010, CARDIOVASC RES, V87, P348, DOI 10.1093/cvr/cvq060
   Winters BD, 2010, CRIT CARE MED, V38, P1276, DOI 10.1097/CCM.0b013e3181d8cc1d
   Wood KA, 2004, PHARMACOECONOMICS, V22, P895, DOI 10.2165/00019053-200422140-00001
   Yuan SY, 2000, MICROCIRCULATION, V7, P395
NR 30
TC 26
Z9 26
U1 0
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD FEB
PY 2013
VL 304
IS 3
BP L135
EP L142
DI 10.1152/ajplung.00133.2012
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 085WY
UT WOS:000314646200001
PM 23161886
OA Green Published
DA 2023-08-21
ER

PT J
AU Abrams, ST
   Zhang, N
   Manson, J
   Liu, TT
   Dart, C
   Baluwa, F
   Wang, SS
   Brohi, K
   Kipar, A
   Yu, WP
   Wang, GZ
   Toh, CH
AF Abrams, Simon T.
   Zhang, Nan
   Manson, Joanna
   Liu, Tingting
   Dart, Caroline
   Baluwa, Florence
   Wang, Susan Siyu
   Brohi, Karim
   Kipar, Anja
   Yu, Weiping
   Wang, Guozheng
   Toh, Cheng-Hock
TI Circulating Histones Are Mediators of Trauma-associated Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE lung; trauma; histones 
ID MULTIPLE ORGAN FAILURE; EXTRACELLULAR HISTONES; THROMBIN GENERATION;
   PROTEIN; BINDING; DEATH; IDENTIFICATION; PERMEABILITY; NEUTROPHILS;
   RECEPTOR
AB Rationale: Acute lung injury is a common complication after severe trauma, which predisposes patients to multiple organ failure. This syndrome largely accounts for the late mortality that arises and despite many theories, the pathological mechanism is not fully understood. Discovery of histone-induced toxicity in mice presents a new dimension for elucidating the underlying pathophysiology.
   Objectives: To investigate the pathological roles of circulating histones in trauma-induced lung injury.
   Methods: Circulating histone levels in patients with severe trauma were determined and correlated with respiratory failure and Sequential Organ Failure Assessment (SOFA) scores. Their cause effect relationship was studied using cells and mouse models.
   Measurements and Main Results: In a cohort of 52 patients with severe nonthoracic blunt trauma, circulating histones surged immediately after trauma to levels that were toxic to cultured endothelial cells. The high levels were significantly associated with the incidence of acute lung injury and SOFA scores, as well as markers of endothelial damage and coagulation activation. In in vitro systems, histones damaged endothelial cells, stimulated cytokine release, and induced neutrophil extracellular trap formation and myeloperoxidase release. Cellular toxicity resulted from their direct membrane interaction and resultant calcium influx. In mouse models, cytokines and markers for endothelial damage and coagulation activation significantly increased immediately after trauma or histone infusion. Pathological examinations showed that lungs were the predominantly affected organ with edema, hemorrhage, microvascular thrombosis, and neutrophil congestion. An anti-histone antibody could reduce these changes and protect mice from histone-induced lethality.
   Conclusions: This study elucidates a new mechanism for acute lung injury after severe trauma and proposes that circulating histones are viable therapeutic targets for improving survival outcomes in patients.
C1 [Abrams, Simon T.; Toh, Cheng-Hock] Royal Liverpool Univ Hosp, Natl Inst Hlth Res, Biomed Res Ctr, Liverpool L7 8XP, Merseyside, England, United Kingdom.
C1 [Abrams, Simon T.; Liu, Tingting; Baluwa, Florence; Wang, Guozheng; Toh, Cheng-Hock] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3GA, Merseyside, England, United Kingdom.
C1 [Zhang, Nan; Yu, Weiping] Southeast Univ, Sch Med, Nanjing, Jiangsu, China.
C1 [Manson, Joanna; Brohi, Karim] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England, United Kingdom.
C1 [Dart, Caroline] Univ Liverpool, Inst Integrat Biol, Liverpool L69 3BX, Merseyside, England, United Kingdom.
C1 [Wang, Susan Siyu] Univ Cambridge, Sch Clin Med, Cambridge, England, United Kingdom.
C1 [Kipar, Anja] Univ Liverpool, Sch Vet Sci, Liverpool L69 3BX, Merseyside, England, United Kingdom.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool; Southeast University - China; University of London; Queen
   Mary University London; University of Liverpool; University of
   Cambridge; University of Liverpool
RP Toh, CH (corresponding author), Royal Liverpool Univ Hosp, Natl Inst Hlth Res, Biomed Res Ctr, Liverpool L7 8XP, Merseyside, England.
EM wangg@liv.ac.uk; toh@liv.ac.uk
RI Kipar, Anja/L-7214-2014; liu, ting/GZM-3326-2022
OI Kipar, Anja/0000-0001-7289-3459; Dart, Caroline/0000-0002-3509-8349;
   Wang, Susan Siyu/0000-0002-6546-8240; Abrams, Simon/0000-0003-3949-2455
FU Royal College of Surgeons, England; National Institute of Health
   Research (NIHR Biomedical Research Centre in Microbial Disease) [3515];
   National Institute of Health Research (NIHR Innovation for Invention
   Grant) [II-LS-1010-14061]; National Institutes of Health Research (NIHR)
   [BRF-2011-026, II-FS-0509-12093, II-LS-1010-10045] Funding Source:
   National Institutes of Health Research (NIHR); National Institute for
   Health Research [II-FS-0509-12093, BRF-2011-026, II-LS-1010-10045]
   Funding Source: researchfish
FX The authors are indebted to participating patients and their attending
   clinical staff. J.M. has a research fellowship from the Royal College of
   Surgeons, England. The authors also acknowledge the National Institute
   of Health Research (NIHR Biomedical Research Centre in Microbial Disease
   Grant Project [3515] and NIHR Innovation for Invention Grant
   [II-LS-1010-14061]) for infrastructural and project support.
CR Abakushin DN, 1999, BIOCHEMISTRY-MOSCOW+, V64, P693
   Ammollo CT, 2011, J THROMB HAEMOST, V9, P1795, DOI 10.1111/j.1538-7836.2011.04422.x
   BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001
   Becker PM, 2003, AM J RESP CELL MOL, V28, P478, DOI 10.1165/rcmb.2002-0024OC
   Brill A, 2012, J THROMB HAEMOST, V10, P136, DOI 10.1111/j.1538-7836.2011.04544.x
   Ciesla DJ, 2005, SURGERY, V138, P749, DOI 10.1016/j.surg.2005.07.020
   Constans J, 2006, CLIN CHIM ACTA, V368, P33, DOI 10.1016/j.cca.2005.12.030
   Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024
   Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676
   Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107
   Ganapathy V, 2005, LIFE SCI, V76, P2631, DOI 10.1016/j.lfs.2005.01.002
   Gauthier VJ, 1996, J IMMUNOL, V156, P1151
   Gierer P, 2008, J SURG RES, V147, P68, DOI 10.1016/j.jss.2007.07.025
   GIL J, 1980, ANNU REV PHYSIOL, V42, P177, DOI 10.1146/annurev.ph.42.030180.001141
   Gil J, 2011, TEXTBOOK OF PULMONARY VASCULAR DISEASE, P13, DOI 10.1007/978-0-387-87429-6_2
   Gomberg BFC, 1999, INJURY, V30, P431, DOI 10.1016/S0020-1383(99)00138-2
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HAALAND AK, 1991, THROMB RES, V61, P253, DOI 10.1016/0049-3848(91)90101-2
   Holdenrieder S, 2001, ANN NY ACAD SCI, V945, P93
   Holdenrieder S, 2009, CRIT REV CL LAB SCI, V46, P1, DOI [10.1080/10408360802485875, 10.1080/10408360802485875 ]
   Huang H, 2011, HEPATOLOGY, V54, P999, DOI 10.1002/hep.24501
   Jawa Randeep S, 2011, J Intensive Care Med, V26, P73, DOI 10.1177/0885066610395679
   Kleine TJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1925, DOI 10.1152/ajpcell.1997.273.6.C1925
   Leyland ML, 2004, J BIOL CHEM, V279, P43427, DOI 10.1074/jbc.M407575200
   Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239
   Li YQ, 2011, SURGERY, V150, P442, DOI 10.1016/j.surg.2011.07.003
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Malangoni MA, 2005, SURGERY, V138, P757
   MARTIN AM, 1968, J TRAUM, V8, P687, DOI 10.1097/00005373-196809000-00007
   MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3
   Moore EE, 2005, SHOCK, V24, P71, DOI 10.1097/01.shk.0000191336.01036.fe
   Moore FA, 1999, AM J SURG, V178, P449, DOI 10.1016/S0002-9610(99)00231-7
   ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, P1
   Partrick D A, 1996, New Horiz, V4, P194
   Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173
   Pemberton AD, 2010, PROTEOMICS, V10, P1484, DOI 10.1002/pmic.200900818
   PEREIRA LF, 1994, CLIN EXP IMMUNOL, V97, P175
   Perez-Casal M, 2009, HAEMATOL-HEMATOL J, V94, P387, DOI 10.3324/haematol.13547
   Perl M, 2012, SHOCK, V38, P98, DOI 10.1097/SHK.0b013e318254be6a
   Reino DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014829
   Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092
   Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065
   Tsukamoto T, 2010, INJURY, V41, P21, DOI 10.1016/j.injury.2009.07.010
   Wang G, 2012, 4 ANN INT C ANT ICA
   Xu J, 2011, J IMMUNOL, V187, P2626, DOI 10.4049/jimmunol.1003930
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Zallen G, 1999, J TRAUMA, V46, P42, DOI 10.1097/00005373-199901000-00007
NR 51
TC 378
Z9 404
U1 1
U2 59
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JAN 15
PY 2013
VL 187
IS 2
BP 160
EP 169
DI 10.1164/rccm.201206-1037OC
PG 10
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA 075YY
UT WOS:000313924600012
PM 23220920
OA Green Published
DA 2023-08-21
ER

PT J
AU Choi, JS
   Kwak, KA
   Park, MJ
   Kim, YH
   Gil, HW
   Song, HY
   Hong, SY
AF Choi, Jae-Sung
   Kwak, Kyung-A
   Park, Min-Ju
   Kim, Young-Hee
   Gil, Hyo-Wook
   Song, Ho-yeon
   Hong, Sae-yong
TI Ratio of Angiopoietin-2 to Angiopoietin-1 predicts mortality in acute
   lung injury induced by paraquat
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE paraquat; ALI/ARDS; angiopoietin-1/angiopoietin-2; ECs/HPMECs/HUVECs/MPVECs 
ID VON-WILLEBRAND-FACTOR; RESPIRATORY-DISTRESS-SYNDROME; FACTOR ANTIGEN
   LEVELS; CIRCULATING ANGIOPOIETIN-2; PATHOGENETIC SIGNIFICANCE; AIRWAY
   INFLAMMATION; ENDOTHELIAL-CELLS; SEPSIS; PLASMA; SERUM
AB Background: To determine whether initial reactive oxygen species (ROS)-induced endothelial cell injury is involved in early death after paraquat intoxication and concentrations of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and von Willebrand factor (VWF) reflecting endothelial cell injury, we investigated the initial endothelial cell injury marker involved in the pathogenesis of death within 5 days after paraquat ingestion.
   Material/Methods: Sixty patients with paraquat poisoning were prospectively enrolled. Plasma samples were collected at admission. Plasma concentrations of Ang-1, Ang-2, and VWF were measured by enzyme-linked immunosorbent assay. The patients were classified into 3 categories: survivors, early death (died within 5 days after ingestion), and late death (died more than 5 days after ingestion).
   Results: The baseline concentration of Ang-2 and the Ang-2: Ang-1 ratio were significantly higher in patients who died (Ang-2 [pg/mL], 1012.75 +/- 468.02 vs. 1986.07 +/- 1675.37 [p = 0.002]; Ang-2: Ang-1, 0.90 +/- 0.49 vs. 2.16 +/- 2.28 [p= 0.002]). The Ang-2: Ang-1 ratio was significantly higher in the early death group (2.41 +/- 2.54) than in the survivors (0.90 +/- 0.49) and the late death group (1.33 +/- 0.64). The Ang-2: Ang-1 ratio was significantly associated with early death (OR, 2.602; 95% CI, 1.106-6.117; p= 0.028) after adjusting for plasma levels of paraquat, age, PCO2, and creatinine. VWF did not predict mortality.
   Conclusions: Endothelial cell damage could be involved in the pathogenesis of early death following paraquat ingestion.
C1 [Choi, Jae-Sung; Gil, Hyo-Wook; Hong, Sae-yong] Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea.
C1 [Choi, Jae-Sung; Kwak, Kyung-A; Park, Min-Ju; Kim, Young-Hee; Gil, Hyo-Wook; Song, Ho-yeon; Hong, Sae-yong] Soonchunhyang Univ, Cheonan Hosp, Inst Pesticide Poisoning, Cheonan, South Korea.
C1 [Kwak, Kyung-A; Park, Min-Ju; Kim, Young-Hee; Song, Ho-yeon] Soonchunhyang Univ, Sch Med, Dept Microbiol & Immunol, Cheonan, South Korea.
C3 Soonchunhyang University; Soonchunhyang University; Soonchunhyang
   University
RP Gil, HW (corresponding author), Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea.
EM hwgil@schmc.ac.kr
RI Song, Ho-Yeon/G-7168-2016
OI hong, saeyong/0000-0001-7854-3871
FU Rural Development Administration, Republic of Korea [PJ008246]
FX This work was carried out with the support of "Cooperative Research
   Program for Agriculture Science & Technology Development (Project No.
   PJ008246)" Rural Development Administration, Republic of Korea
CR Bhandari V, 2012, AM J RESP CELL MOL, V46, P668, DOI 10.1165/rcmb.2011-0074OC
   BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   DELAVAL PM, 1985, CRIT CARE MED, V13, P1056, DOI 10.1097/00003246-198512000-00015
   Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002
   Gallagher DC, 2008, SHOCK, V29, P656, DOI 10.1097/SHK.0b013e31815dd92f
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Giamarellos-Bourboulis EJ, 2008, CYTOKINE, V44, P310, DOI 10.1016/j.cyto.2008.09.003
   Giuliano JS, 2007, SHOCK, V28, P650, DOI 10.1097/shk.0b013e318123867b
   Koutsostathis S, 2011, CYTOKINE, V56, P817, DOI 10.1016/j.cyto.2011.09.017
   Kumpers P, 2008, CRIT CARE, V12, DOI 10.1186/cc7130
   Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317
   MOSS M, 1995, AM J RESP CRIT CARE, V151, P15, DOI 10.1164/ajrccm.151.1.7812545
   Ong T, 2010, CRIT CARE MED, V38, P1845, DOI 10.1097/CCM.0b013e3181eaa5bf
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771
   Ricciuto DR, 2011, CRIT CARE MED, V39, P702, DOI 10.1097/CCM.0b013e318206d285
   ROSE MS, 1974, NATURE, V252, P314, DOI 10.1038/252314b0
   SABHARWAL AK, 1995, AM J RESP CRIT CARE, V151, P758
   Simoes DCM, 2008, AM J RESP CRIT CARE, V177, P1314, DOI 10.1164/rccm.200708-1141OC
   Siner JM, 2009, SHOCK, V31, P348, DOI 10.1097/SHK.0b013e318188bd06
   Tabruyn SP, 2010, AM J PATHOL, V177, P3233, DOI 10.2353/ajpath.2010.100059
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   VALE JA, 1987, HUM TOXICOL, V6, P41, DOI 10.1177/096032718700600107
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Ware LB, 2001, CRIT CARE MED, V29, P2325, DOI 10.1097/00003246-200112000-00016
   WEBB DB, 1984, BRIT MED J, V288, P1259, DOI 10.1136/bmj.288.6426.1259
   Zou YG, 2011, J CHROMATOGR B, V879, P1809, DOI 10.1016/j.jchromb.2011.05.004
NR 31
TC 11
Z9 12
U1 0
U2 2
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JAN 9
PY 2013
VL 19
BP 28
EP 33
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 156KS
UT WOS:000319821400001
PM 23302768
DA 2023-08-21
ER

PT J
AU Duke-Novakovski, T
   Singh-Suri, S
   Kajikawa, O
   Caldwell, S
   Charavaryamath, C
   Singh, B
AF Duke-Novakovski, Tanya
   Singh-Suri, Sarabjeet
   Kajikawa, Osamu
   Caldwell, Sarah
   Charavaryamath, Chandarshekhar
   Singh, Baljit
TI Immuno-phenotypic and functional characterization of rabbit pulmonary
   intravascular macrophages
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE PIM; Acute lung inflammation; Gadolinium chloride; Macrophage depletion; endotoxin 
ID ACUTE LUNG INJURY; PSEUDOMONAS-AERUGINOSA PNEUMONIA; MONONUCLEAR
   PHAGOCYTE SYSTEM; RAT MODEL; PORCINE LUNG; INFLAMMATION; ENDOTOXIN;
   LIPOPOLYSACCHARIDE; DEPLETION; EXPRESSION
AB Pulmonary intravascular macrophages (PIMs) are present in species such as cattle, sheep and horse and promote acute lung inflammation (ALI). Rabbits are often used as a model of ALI but there is controversy about the presence of PIMs in these species. Rabbits were treated with 10 mg/kg of gadolinium chloride intravenously (GC; n = 6) or saline (n = 6) followed by euthanasia at 48 h post-treatment to determine the presence of PIMs. In a subsequent study, rabbits were pre-treated with GC or 0.9 % saline followed by 100 mu g/kg of E. coli lipopolysaccharide intravenously 48 h later. Rabbits were euthanized 24 h post-LPS treatment. Light and electron microscopy showed that PIMs attached to the capillary endothelium and were positive for RAM-11 anti-macrophage antibody. While GC treatment induced apoptotic PIMs, there was no difference in the PIM number between control and GC-treated rabbits. Rabbits administered with LPS were 3.5 times more likely to die before the end of the 24-h period than those pre-treated with GC. Lung heterophil accumulation and IL-1 beta, TNF alpha and IL-6 mRNA expression were significantly higher in rabbits administered with LPS compared to those administered with GC before the LPS injection. PIMs from the LPS-treated rabbits were positive for TNF alpha. Lung, BAL and serum IL-8 and MCP-1 expression was not different between LPS rabbits with or without pre-treatment with GC. We conclude that rabbit lungs contain PIMs and that their depletion reduces endotoxin-induced lung inflammation. The presence of PIMs in rabbit lungs may need to be considered while using rabbit to model acute lung injury.
C1 [Duke-Novakovski, Tanya; Singh-Suri, Sarabjeet; Caldwell, Sarah; Charavaryamath, Chandarshekhar; Singh, Baljit] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Biomed Sci, Saskatoon, SK S7N 5B4, Canada.
C1 [Kajikawa, Osamu] VA Puget Sound Hlth Ctr, Med Res Serv, Seattle, WA, United States.
C3 University of Saskatchewan
RP Singh, B (corresponding author), Univ Saskatchewan, Western Coll Vet Med, Dept Vet Biomed Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.
EM baljit.singh@usask.ca
RI Charavaryamath, Chandrashekhar/AFV-9659-2022
OI Charavaryamath, Chandrashekhar/0000-0002-5217-1608; Singh,
   Baljit/0000-0002-7987-7336
FU Equine Health Research Fund of the Western College of Veterinary
   Medicine; Natural Science and Engineering Research Council of Canada
FX The research was supported through a grant to Dr. Duke-Novakovski and
   Dr. Singh from the Equine Health Research Fund of the Western College of
   Veterinary Medicine and a grant from the Natural Science and Engineering
   Research Council of Canada to Dr. Baljit Singh.
CR Aharonson-Raz K, 2010, CAN J VET RES, V74, P45
   Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004
   ATWAL OS, 1985, ACTA ANAT, V124, P245
   ATWAL OS, 1989, AM J ANAT, V186, P285, DOI 10.1002/aja.1001860305
   Ben-Shaul V, 1999, SHOCK, V12, P288, DOI 10.1097/00024382-199910000-00007
   Bidani A, 1999, LUNG, V177, P111, DOI 10.1007/PL00007630
   Brain JD, 1999, AM J PHYSIOL-LUNG C, V276, pL146, DOI 10.1152/ajplung.1999.276.1.L146
   CARRASCO L, 1991, J COMP PATHOL, V105, P345, DOI 10.1016/S0021-9975(08)80202-2
   CHANG SW, 1994, J CLIN INVEST, V94, P2009, DOI 10.1172/JCI117554
   Frevert CW, 2000, METH MOL B, V138, P319
   FREVERT CW, 1992, J VET INTERN MED, V6, P154, DOI 10.1111/j.1939-1676.1992.tb00331.x
   Gazoni LM, 2007, ANN THORAC SURG, V84, P247, DOI 10.1016/j.athoracsur.2007.02.036
   Gill SS, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-69
   Hildebrand F, 2006, AM J PATHOL, V169, P784, DOI 10.2353/ajpath.2006.060010
   Horiguchi T, 1996, J APPL PHYSIOL, V80, P56, DOI 10.1152/jappl.1996.80.1.56
   Horiguchi T, 1992, Masui, V41, P1260
   Janardhan KS, 2006, HISTOL HISTOPATHOL, V21, P687, DOI 10.14670/HH-21.687
   Janardhan KS, 2004, HISTOCHEM CELL BIOL, V121, P383, DOI 10.1007/s00418-004-0649-1
   Jesmin S, 2004, THROMB HAEMOSTASIS, V92, P966, DOI 10.1160/TH04-03-0160
   Kajikawa O, 1996, J IMMUNOL METHODS, V197, P19, DOI 10.1016/0022-1759(96)00101-9
   Kawashima M, 2004, VET PATHOL, V41, P682, DOI 10.1354/vp.41-6-682
   Kuebler WM, 2005, PHARMACOL REP, V57, P196
   Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124
   Kurahashi K, 2009, AM J PHYSIOL-LUNG C, V296, pL198, DOI 10.1152/ajplung.90472.2008
   Longworth KE., 1997, FRONT BIOSCI-LANDMRK, V2, pD232, DOI [DOI 10.2741/A186, 10.2741/A186]
   MATHISON JC, 1979, J IMMUNOL, V123, P2133
   MATHISON JC, 1981, J IMMUNOL, V126, P1575
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Molina RM, 2007, EXP LUNG RES, V33, P53, DOI 10.1080/01902140701198542
   Parbhakar OP, 2005, VET RES, V36, P557, DOI 10.1051/vetres:2005016
   Parbhakar OP, 2004, VET RES, V35, P39, DOI 10.1051/vetres:2003041
   Poli-De-Figueiredo LF, 2008, SHOCK, V30, P53, DOI 10.1097/SHK.0b013e318181a343
   Ramadori G, 2008, J PHYSIOL PHARMACOL, V59, P107
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   RIBBLE CS, 1995, CAN J VET RES, V59, P167
   Schneberger D, 2012, AM J PHYSIOL-LUNG C, V302, pL498, DOI 10.1152/ajplung.00322.2011
   Schneider T, 1996, J IMMUNOL METHODS, V198, P1, DOI 10.1016/0022-1759(96)00143-3
   Shimada H, 2006, SHOCK, V26, P311, DOI 10.1097/01.shk.0000224960.17274.6f
   Singh B, 2004, AM J PHYSIOL-LUNG C, V286, pL363, DOI 10.1152/ajplung.00003.2003
   Singh B, 1998, INT J EXP PATHOL, V79, P151
   Sone Y, 1999, J APPL PHYSIOL, V87, P1354, DOI 10.1152/jappl.1999.87.4.1354
   STAUB NC, 1994, ANNU REV PHYSIOL, V56, P47
   WARNER AE, 1986, LAB INVEST, V55, P276
   WARNER AE, 1990, AM J PHYSIOL, V258, pL1, DOI 10.1152/ajplung.1990.258.2.L1
   Werners AH, 2005, EQUINE VET J, V37, P371, DOI 10.2746/0425164054529418
   WINKLER GC, 1985, J LEUKOCYTE BIOL, V38, P471, DOI 10.1002/jlb.38.4.471
   WINKLER GC, 1988, AM J ANAT, V181, P217, DOI 10.1002/aja.1001810302
   WINKLER GC, 1987, MICROVASC RES, V33, P224, DOI 10.1016/0026-2862(87)90019-7
NR 48
TC 6
Z9 6
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD JAN
PY 2013
VL 351
IS 1
BP 149
EP 160
DI 10.1007/s00441-012-1509-2
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 064JA
UT WOS:000313069800014
PM 23073615
DA 2023-08-21
ER

PT J
AU Herwig, MC
   Tsokos, M
   Hermanns, MI
   Kirkpatrick, CJ
   Muller, AM
AF Herwig, Martina C.
   Tsokos, Michael
   Hermanns, M. Iris
   Kirkpatrick, C. James
   Mueller, Annette M.
TI Vascular Endothelial Cadherin Expression in Lung Specimens of Patients
   with Sepsis-Induced Acute Respiratory Distress Syndrome and Endothelial
   Cell Cultures
SO PATHOBIOLOGY
LA English
DT Article
DE ALI/ARDS; cadherin; Cell cultures; ECs/HPMECs/HUVECs/MPVECs; Human lung; VE-cadherin; Vessel type 
ID VE-CADHERIN; TNF-ALPHA; TYROSINE PHOSPHORYLATION; MONOLAYER
   PERMEABILITY; PARACELLULAR PATHWAY; ADHESION MOLECULE; IN-VITRO;
   PROTEINS; IDENTIFICATION; ACTIVATION
AB Aims: Vascular endothelial (VE) cadherin is a cell adhesion molecule localized at endothelial cell (EC) junctions. As a major component of endothelial adherens junctions, its main function is the maintenance and regulation of EC integrity. In the acute respiratory distress syndrome (ARDS), increased vascular permeability is a major mechanism in pulmonary edema and lung dysfunction. In this study, VE-cadherin expression was investigated in ARDS lungs and control tissue as well as in an ARDS cell culture model. Methods: Lung specimens of patients with ARDS due to Gram-negative sepsis (n = 20; control lung tissue: n = 41) and cell cultures of human pulmonary microvascular ECs and human umbilical vein ECs stimulated with LPS, TNF-alpha and IFN-gamma were stained with a VE-cadherin antibody. Staining intensity was semiquantitatively evaluated by conventional light and immunofluorescence microscopy. Results: VE-cadherin expression was statistically significantly reduced in the endothelium of all vessel types in ARDS lungs compared to control tissue. Cell cultures showing disrupted cellular borders confirmed these results. Conclusion: Reduced expression of VE-cadherin has to be considered as a major mechanism of increased vessel permeability in ARDS. The previously described vessel-type-specific expression pattern of VE-cadherin in the human lung is not influenced by ARDS. Copyright (C) 2013 S. Karger AG, Basel
C1 [Herwig, Martina C.] Univ Bonn, Dept Ophthalmol, Div Ophthalm Pathol, DE-53127 Bonn, Germany.
C1 [Mueller, Annette M.] Univ Bonn, Dept Pediat Pathol, DE-53127 Bonn, Germany.
C1 [Tsokos, Michael] Charite, Inst Legal Med & Forens Sci, D-13353 Berlin, Germany.
C1 [Hermanns, M. Iris; Kirkpatrick, C. James] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Pathol, Mainz, Germany.
C3 University of Bonn; University of Bonn; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   Johannes Gutenberg University of Mainz
RP Muller, AM (corresponding author), Univ Bonn, Dept Pediat Pathol, Sigmund Freud Str 25, DE-53127 Bonn, Germany.
EM annette.mueller@ukb.uni-bonn.de
RI Herwig-Carl, Martina Christina/AAI-2618-2019; Hermanns, Maria
   Iris/HKN-8374-2023
OI Herwig-Carl, Martina Christina/0000-0002-5943-7675; Kirkpatrick, Charles
   James/0000-0002-0088-418X
CR Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006
   Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371
   Birukova AA, 2012, J CELL PHYSIOL, V227, P3405, DOI 10.1002/jcp.24041
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025
   Carden D, 1998, AM J PHYSIOL-HEART C, V275, pH385, DOI 10.1152/ajpheart.1998.275.2.H385
   Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601
   DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497
   Friedl J, 2003, INT J ONCOL, V23, P611
   Geny B, 2007, AM J PATHOL, V170, P1003, DOI 10.2353/ajpath.2007.060583
   Gillrie MR, 2007, BLOOD, V110, P3426, DOI 10.1182/blood-2007-04-084582
   Gong P, 2008, J BIOL CHEM, V283, P13437, DOI 10.1074/jbc.M707986200
   HEIMARK RL, 1990, J CELL BIOL, V110, P1745, DOI 10.1083/jcb.110.5.1745
   Hermant B, 2003, J BIOL CHEM, V278, P14002, DOI 10.1074/jbc.M300351200
   Herwig MC, 2008, PATHOL RES PRACT, V204, P725, DOI 10.1016/j.prp.2008.04.014
   Herwig MC, 2006, THESIS RUHR U BOCHUM
   Hordijk PL, 1999, J CELL SCI, V112, P1915
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   KIRKPATRICK CJ, 1985, AM J PATHOL, V118, P15
   LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Mueller Annette M., 2008, Legal Medicine, V10, P257, DOI 10.1016/j.legalmed.2008.02.003
   Muller AM, 2002, EXP MOL PATHOL, V73, P171, DOI 10.1006/exmp.2002.2446
   Muller AM, 2002, EXP MOL PATHOL, V72, P221, DOI 10.1006/exmp.2002.2424
   Orrington-Myers J, 2006, AM J PHYSIOL-LUNG C, V291, pL764, DOI 10.1152/ajplung.00502.2005
   REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323
   Sawant DA, 2011, MICROCIRCULATION, V18, P46, DOI 10.1111/j.1549-8719.2010.00067.x
   Schlegel N, 2009, CRIT CARE MED, V37, P1735, DOI 10.1097/CCM.0b013e31819deb6a
   Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323
   Ventetuolo CE, 2008, CLIN J AM SOC NEPHRO, V3, P571, DOI 10.2215/CJN.01370307
   Wagner M, 1999, AM J PHYSIOL-LUNG C, V277, pL1026, DOI 10.1152/ajplung.1999.277.5.L1026
   Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B
   Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010
   Wong RK, 1999, AM J PHYSIOL-HEART C, V276, pH736
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
   Zhang RY, 2010, J INT MED RES, V38, P1497, DOI 10.1177/147323001003800433
NR 36
TC 49
Z9 54
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-2008
EI 1423-0291
J9 PATHOBIOLOGY
JI Pathobiology
PY 2013
VL 80
IS 5
BP 245
EP 251
DI 10.1159/000347062
PG 7
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 161UM
UT WOS:000320218800004
PM 23635392
OA Bronze
DA 2023-08-21
ER

PT J
AU Land, WG
AF Land, Walter G.
TI Transfusion-Related Acute Lung Injury: The Work of DAMPs
SO TRANSFUSION MEDICINE AND HEMOTHERAPY
LA English
DT Review
DE transfusion; ALI/ARDS; innate immunity; Inflammation; DAMPs 
ID RED-BLOOD-CELLS; INNATE IMMUNITY; STERILE INFLAMMATION; PATHOGEN
   RECOGNITION; PATTERN-RECOGNITION; NLRP3 INFLAMMASOME; NALP3
   INFLAMMASOME; HEMORRHAGIC-SHOCK; OXIDATIVE STRESS; HUMAN PLATELETS
AB Current notions in immunology hold that not only pathogen-mediated tissue injury but any injury activates the innate immune system. In principle, this evolutionarily highly conserved, rapid first-line defense system responds to pathogen-induced injury with the creation of infectious inflammation, and non-pathogen-induced tissue injury with 'sterile' tissue inflammation. In this review, evidence has been collected in support of the notion that the transfusion-related acute lung injury induces a 'sterile' inflammation in the lung of transfused patients in terms of an acute innate inflammatory disease. The inflammatory response is mediated by the patient's innate immune cells including lung-passing neutrophils and pulmonary endothelial cells, which are equipped with pattern recognition receptors. These receptors are able to sense injury-induced, damage-associated molecular patterns (DAMPs) generated during collection, processing, and storage of blood/blood components. The recognition process leads to activation of these innate cells. A critical role for a protein complex known as the NLRP3 inflammasome has been suggested to be at the center of such a scenario. This complex undergoes an initial 'priming' step mediated by 1 class of DAMPs and then an 'activating' step mediated by another class of DAMPs to activate interleukin-1beta and interleukin-18. These 2 cytokines then promote, via transactivation, the formation of lung inflammation.
C1 [Land, Walter G.] German Acad Transplantat Med, Munich, Germany.
RP Land, WG (corresponding author), Koeglweg 32, D-82024 Taufkirchen, Germany.
EM walterland@aol.com
OI Land, Walter Gottlieb/0000-0002-0090-0629
CR Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Ardoin SP, 2007, SCAND J IMMUNOL, V66, P159, DOI 10.1111/j.1365-3083.2007.01984.x
   Arruda MA, 2005, MEM I OSWALDO CRUZ, V100, P799, DOI 10.1590/S0074-02762005000700022
   Bauernfeind F, 2011, CELL MOL LIFE SCI, V68, P765, DOI 10.1007/s00018-010-0567-4
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Belizaire RM, 2012, J AM COLL SURGEONS, V214, P648, DOI 10.1016/j.jamcollsurg.2011.12.032
   BODE AP, 1991, BLOOD, V77, P887
   Bours Martijn Jan Leo, 2011, Front Biosci (Schol Ed), V3, P1443
   Busso N, 2012, RHEUMATOLOGY, V51, P1154, DOI 10.1093/rheumatology/ker524
   Chaudhary R, 2012, BLOOD TRANSFUS-ITALY, V10, P59, DOI 10.2450/2011.0107-10
   Chong DLW, 2011, CONTRIB MICROBIOL, V17, P86, DOI 10.1159/000324022
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152
   Contreras M., 2008, TRANSFUSION ALTERNAT, V10, P112, DOI DOI 10.1111/J.1778-428X.2008.00116.X
   Crittenden DB, 2011, BULL HOSP JT DIS, V69, P257
   Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200
   Dey-Hazra E, 2010, VASC HEALTH RISK MAN, V6, P1125, DOI 10.2147/VHRM.S13236
   Donadee C, 2011, CIRCULATION, V124, P465, DOI 10.1161/CIRCULATIONAHA.110.008698
   Donelan Kent J, 2011, S D Med, V64, P85
   Dumaswala UJ, 1999, FREE RADICAL BIO MED, V27, P1041, DOI 10.1016/S0891-5849(99)00149-5
   Eikelenboom P, 2011, CURR ALZHEIMER RES, V8, P142, DOI 10.2174/156720511795256080
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Fubini B, 2003, FREE RADICAL BIO MED, V34, P1507, DOI 10.1016/S0891-5849(03)00149-7
   Gkoumassi E, 2012, TRANSFUSION, V52, P489, DOI 10.1111/j.1537-2995.2011.03298.x
   GREENWALT TJ, 1991, VOX SANG, V61, P14, DOI 10.1111/j.1423-0410.1991.tb00920.x
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   Haubelt H, 2008, PLATELETS, V19, P496, DOI 10.1080/09537100802302225
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Huang LF, 2011, CYTOKINE, V53, P29, DOI 10.1016/j.cyto.2010.09.010
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Kamel N, 2010, BLOOD TRANSFUS-ITALY, V8, P260, DOI [10.2450/2009.0131.09, 10.2450/2009.0131-09]
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008
   Keating SE, 2011, TRENDS IMMUNOL, V32, P574, DOI 10.1016/j.it.2011.08.004
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Kim-Shapiro DB, 2011, TRANSFUSION, V51, P844, DOI 10.1111/j.1537-2995.2011.03100.x
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   KOERNER TAW, 1992, BLOOD CELLS, V18, P481
   Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976
   Land W., 2003, TRANSPLANT REV-ORLAN, V17, P67, DOI 10.1016/S0955-470X(02)00009-5
   Land WG, 2011, INNATE ALLOIMMUNIT 2, P229
   Land WG, 2011, INNATE ALLOIMMUNIT 2, P576
   Land WG, 2011, INNATE ALLOIMMUNIT 2, P603
   LATHAM JT, 1982, TRANSFUSION, V22, P158, DOI 10.1046/j.1537-2995.1982.22282177126.x
   Lawrie AS, 2008, VOX SANG, V95, P197, DOI 10.1111/j.1423-0410.2008.01081.x
   Lawrie AS, 2009, VOX SANG, V96, P206, DOI 10.1111/j.1423-0410.2008.01151.x
   Lehner J, 2012, ANTICANCER RES, V32, P2059
   Lin TA, 2010, J INFECT DIS, V202, P624, DOI 10.1086/654929
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2010, CURR OPIN HEMATOL, V17, P418, DOI 10.1097/MOH.0b013e32833c07d3
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Looney MR, 2004, CHEST, V126, P249, DOI 10.1378/chest.126.1.249
   Lundberg AM, 2010, CLIN IMMUNOL, V134, P5, DOI 10.1016/j.clim.2009.07.016
   MacLennan S., 2004, VOX SANG, V87, pS2
   Mangalmurti NS, 2010, TRANSFUSION, V50, P2353, DOI 10.1111/j.1537-2995.2010.02689.x
   Mankan AK, 2012, EUR J IMMUNOL, V42, P710, DOI 10.1002/eji.201141921
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Matijevic N, 2011, J TRAUMA, V70, P71, DOI 10.1097/TA.0b013e318207abec
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Miyabe K, 2004, THROMB RES, V114, P29, DOI 10.1016/j.thromres.2004.04.003
   Morel O, 2011, SEMIN IMMUNOPATHOL, V33, P469, DOI 10.1007/s00281-010-0239-3
   MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112
   Murphy TJ, 2005, J LEUKOCYTE BIOL, V77, P16, DOI 10.1189/jlb.0704382
   Newton K, 2012, COLD SPRING HARB PER, V4
   Nurden AT, 2011, THROMB HAEMOSTASIS, V105, pS13, DOI 10.1160/THS10-11-0720
   Opal SM, 2010, CONTRIB NEPHROL, V167, P14, DOI 10.1159/000315915
   Osoegawa A, 2011, SURG TODAY, V41, P903, DOI 10.1007/s00595-010-4371-4
   Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001
   Paterson HM, 2003, J IMMUNOL, V171, P1473, DOI 10.4049/jimmunol.171.3.1473
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173
   PERREGAUX D, 1994, J BIOL CHEM, V269, P15195
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Porretti I., 2012, BLOOD TRANSFUS, V2, P1
   Puddu Paolo, 2010, Can J Cardiol, V26, P140
   Ramasamy R, 2011, ANN NY ACAD SCI, V1243, P88, DOI 10.1111/j.1749-6632.2011.06320.x
   Rank A, 2011, VOX SANG, V100, P179, DOI 10.1111/j.1423-0410.2010.01385.x
   Robert C, 2011, IMMUNOBIOLOGY, V216, P1203, DOI 10.1016/j.imbio.2011.07.025
   Rock KL, 2010, ANNU REV IMMUNOL, V28, P321, DOI 10.1146/annurev-immunol-030409-101311
   Rouhiainen A, 2000, THROMB HAEMOSTASIS, V84, P1087
   Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744
   Sachs UJ, 2011, CURR OPIN HEMATOL, V18, P436, DOI 10.1097/MOH.0b013e32834bab01
   Sadallah S, 2011, J IMMUNOL, V186, P6543, DOI 10.4049/jimmunol.1002788
   Saidenberg E, 2010, TRANSFUS MED REV, V24, P305, DOI 10.1016/j.tmrv.2010.05.005
   Scheuplein F, 2009, J IMMUNOL, V182, P2898, DOI 10.4049/jimmunol.0801711
   Semple JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031357
   Seneviratne AN, 2012, CLIN CHIM ACTA, V413, P3, DOI 10.1016/j.cca.2011.08.021
   Shah MD, 2008, PLATELETS, V19, P365, DOI 10.1080/09537100802054107
   Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135
   Shet AS, 2008, VASC HEALTH RISK MAN, V4, P769, DOI 10.2147/VHRM.S955
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   Sowemimo-Coker SO, 2002, TRANSFUS MED REV, V16, P46, DOI 10.1053/tmrv.2002.29404
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Stubbs JR, 2011, TRANSFUS MED REV, V25, P66, DOI 10.1016/j.tmrv.2010.08.008
   Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51
   Triulzi DJ, 2009, ANESTH ANALG, V108, P770, DOI 10.1213/ane.0b013e31819029b2
   van Zoelen MAD, 2008, SHOCK, V29, P441, DOI 10.1097/SHK.0b013e318157eddd
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Vlaar AP, 2009, NETH J MED, V67, P320
   Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018
   Wu B, 2009, INFLAMM RES, V58, P321, DOI 10.1007/s00011-009-8230-y
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Xiang M, 2011, J IMMUNOL, V187, P4809, DOI 10.4049/jimmunol.1102093
   Yamanashi Y, 2009, ASAIO J, V55, P478, DOI 10.1097/MAT.0b013e3181b17f34
NR 108
TC 45
Z9 47
U1 0
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1660-3796
EI 1660-3818
J9 TRANSFUS MED HEMOTH
JI Transfus. Med. Hemother.
PY 2013
VL 40
IS 1
BP 3
EP 13
DI 10.1159/000345688
PG 11
WC Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Immunology
GA 087ZK
UT WOS:000314803300001
PM 23637644
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Lucas, R
   Czikora, I
   Sridhar, S
   Zemskov, EA
   Oseghale, A
   Circo, S
   Cederbaum, SD
   Chakraborty, T
   Fulton, DJ
   Caldwell, RW
   Romero, MJ
AF Lucas, Rudolf
   Czikora, Istvan
   Sridhar, Supriya
   Zemskov, Evgeny A.
   Oseghale, Aluya
   Circo, Sebastian
   Cederbaum, Stephen D.
   Chakraborty, Trinad
   Fulton, David J. R.
   Caldwell, Robert W.
   Romero, Maritza J.
TI Arginase 1: an unexpected mediator of pulmonary capillary barrier
   dysfunction in models of acute lung injury
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE pneumonia; capillary leak; pneumolysin; arginase 1; eNOS 
ID TUMOR-NECROSIS-FACTOR; KINASE-C-ALPHA; NITRIC-OXIDE; ENDOTHELIAL
   PERMEABILITY; PKC-ALPHA; PROTEIN; PNEUMOLYSIN; PHOSPHORYLATION;
   ACTIVATION; INFLAMMATION
AB The integrity of epithelial and endothelial barriers in the lower airspaces of the lungs has to be tightly regulated, in order to prevent leakage and to assure efficient gas exchange between the alveoli and capillaries. Both G and GP bacterial toxins, such as lipopolysaccharide and pneumolysin, respectively, can be released in high concentrations within the pulmonary compartments upon antibiotic treatment of patients suffering from acute respiratory distress syndrome (ARDS) or severe pneumonia. These toxins are able to impair endothelial barrier function, either directly, or indirectly, by induction of pro-inflammatory mediators and neutrophil sequestration. Toxin-induced endothelial hyperpermeability can involve myosin light chain phosphorylation and/or microtubule rearrangement. Endothelial nitric oxide synthase (eNOS) was proposed to be a guardian of basal barrier function, since eNOS knock-out mice display an impaired expression of inter-endothelial junction proteins and as such an increased vascular permeability, as compared to wild type mice. The enzyme arginase, the activity of which can be regulated by the redox status of the cell, exists in two isoforms arginase 1 (cytosolic) and arginase 2 (mitochondrial) both of which can be expressed in lung microvascular endothelial cells. Upon activation, arginase competes with eNOS for the substrate barginine, as such impairing eNOS-dependent NO generation and promoting reactive oxygen species generation by the enzyme. This mini-review will discuss recent findings regarding the interaction between bacterial toxins and arginase during acute lung injury and will as such address the role of arginase in bacterial toxin-induced pulmonary endothelial barrier dysfunction.
C1 [Lucas, Rudolf; Czikora, Istvan; Sridhar, Supriya; Zemskov, Evgeny A.; Oseghale, Aluya; Fulton, David J.; Romero, Maritza J.] Georgia Regents Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912, United States.
C1 [Lucas, Rudolf; Fulton, David J.; Caldwell, Robert W.; Romero, Maritza J.] Georgia Regents Univ, Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912, United States.
C1 [Lucas, Rudolf; Circo, Sebastian] Georgia Regents Univ, Med Coll Georgia, Div Pulm Med, Augusta, GA 30912, United States.
C1 [Cederbaum, Stephen D.] Univ Calif Los Angeles, IDDRC NPI, Los Angeles, CA, United States.
C1 [Chakraborty, Trinad] Univ Giessen, Inst Med Microbiol, Giessen, Germany.
C1 [Romero, Maritza J.] Georgia Regents Univ, Med Coll Georgia, Dept Anesthesiol & Peri Operat Med, Augusta, GA 30912, United States.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University of California System; University of California
   Los Angeles; Justus Liebig University Giessen; University System of
   Georgia; Augusta University
RP Lucas, R (corresponding author), Georgia Regents Univ, Vasc Biol Ctr, Dept Pharmacol & Toxicol, Div Pulm Med, Room CB3713,1459 Laney Walker Blvd, Augusta, GA 30912 USA.
EM rlucas@gru.edu
RI chakraborty, trinad/D-1812-2014; Lucas, Rudolf/ABA-3011-2020
OI Lucas, Rudolf/0000-0003-3805-8868; Romero, Maritza/0000-0002-4476-2053;
   Czikora, Istvan/0000-0002-8247-9494
FU National Institutes of Health/National Heart, Lung, and Blood Institute
   [R01HL094609, R01HL070215, P01HL101902]; Deutsche Forschungsgemeinschaft
   [TRR84]
FX Supported by National Institutes of Health/National Heart, Lung, and
   Blood Institute grants R01HL094609 (Rudolf Lucas), R01HL070215 (Robert
   W. Caldwell), and P01HL101902 (David J. Fulton) and by a grant from the
   Deutsche Forschungsgemeinschaft through the Transregio Initiative TRR84
   Project A4 (Trinad Chakraborty).
CR Anderson R, 2007, J ANTIMICROB CHEMOTH, V60, P1155, DOI 10.1093/jac/dkm338
   Beleznai T, 2011, AM J PHYSIOL-HEART C, V300, pH777, DOI 10.1152/ajpheart.00831.2010
   Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010
   Billiet L, 2005, J BIOL CHEM, V280, P40310, DOI 10.1074/jbc.M503644200
   Billiet Ludivine, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P293, DOI 10.2174/187152908786786179
   Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359
   Carraway MS, 1998, EXP LUNG RES, V24, P253, DOI 10.3109/01902149809041533
   Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012
   Chandra S, 2012, BRIT J PHARMACOL, V165, P506, DOI 10.1111/j.1476-5381.2011.01584.x
   Chen F, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00412
   Ckless K, 2008, J IMMUNOL, V181, P4255, DOI 10.4049/jimmunol.181.6.4255
   Ckless K, 2007, AM J RESP CELL MOL, V36, P645, DOI 10.1165/rcmb.2006-0329SM
   Deignan JL, 2006, MOL GENET METAB, V89, P87, DOI 10.1016/j.ymgme.2006.04.007
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dworakowski R, 2008, PHARMACOL REP, V60, P21
   Feola DJ, 2010, ANTIMICROB AGENTS CH, V54, P2437, DOI 10.1128/AAC.01424-09
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gutierrez F, 2008, DRUG AGING, V25, P585, DOI 10.2165/00002512-200825070-00005
   Harrington EO, 2003, AM J RESP CELL MOL, V28, P626, DOI 10.1165/rcmb.2002-0085OC
   Helms MN, 2005, AM J PHYSIOL-CELL PH, V289, pC717, DOI 10.1152/ajpcell.00006.2005
   HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215
   Hundsberger H, 2008, FRONT BIOSCI-LANDMRK, V13, P5374, DOI 10.2741/3087
   Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011
   Jiang JJ, 2011, AM J PHYSIOL-LUNG C, V301, pL361, DOI 10.1152/ajplung.00464.2010
   Kim KM, 2013, MICROVASC RES, V88, P19, DOI 10.1016/j.mvr.2013.04.002
   Klasen S, 2001, BRIT J PHARMACOL, V132, P1349, DOI 10.1038/sj.bjp.0703951
   Kolosova IA, 2004, AM J PHYSIOL-LUNG C, V287, pL970, DOI 10.1152/ajplung.00398.2003
   Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200
   LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299
   Lucas R, 2012, AM J RESP CELL MOL, V47, P445, DOI 10.1165/rcmb.2011-0332OC
   Lucas R, 2012, P NATL ACAD SCI USA, V109, P2084, DOI 10.1073/pnas.1121075109
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Maarsingh H, 2011, EUR RESPIR J, V38, P318, DOI 10.1183/09031936.00057710
   Maarsingh H, 2008, N-S ARCH PHARMACOL, V378, P171, DOI 10.1007/s00210-008-0286-7
   Matsuo Y, 2013, CYTOKINE GROWTH F R, V24, P345, DOI 10.1016/j.cytogfr.2013.01.001
   Maus UA, 2004, J IMMUNOL, V173, P1307, DOI 10.4049/jimmunol.173.2.1307
   McGee DJ, 2006, J BIOL CHEM, V281, P3290, DOI 10.1074/jbc.M506139200
   Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298
   Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458
   Nakamura H, 2009, ADV DRUG DELIVER REV, V61, P303, DOI 10.1016/j.addr.2009.01.003
   Nakamura T, 2005, ANTIOXID REDOX SIGN, V7, P60, DOI 10.1089/ars.2005.7.60
   Peng J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-28
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004
   Redente EF, 2010, J LEUKOCYTE BIOL, V88, P159, DOI 10.1189/jlb.0609378
   Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026
   Rodriguez N, 2007, PHYSIOL GENOMICS, V30, P134, DOI 10.1152/physiolgenomics.00011.2007
   Romero MJ, 2008, CIRC RES, V102, P95, DOI 10.1161/CIRCRESAHA.107.155028
   Roy RM, 2012, J IMMUNOL, V189, P2545, DOI 10.4049/jimmunol.1200689
   Rubins JB, 1996, AM J RESP CRIT CARE, V153, P1339, DOI 10.1164/ajrccm.153.4.8616564
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x
   Sharma S, 2010, VASC PHARMACOL, V52, P182, DOI 10.1016/j.vph.2009.11.010
   Shatanawi A, 2011, AM J PHYSIOL-CELL PH, V300, pC1181, DOI 10.1152/ajpcell.00328.2010
   SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418
   Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002
   Song JY, 2008, EUKARYOT CELL, V7, P2160, DOI 10.1128/EC.00106-08
   Speyer CL, 2003, AM J PATHOL, V163, P2319, DOI 10.1016/S0002-9440(10)63588-2
   Stringaris AK, 2002, NEUROBIOL DIS, V11, P355, DOI 10.1006/nbdi.2002.0561
   Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331
   Waterer GW, 2011, AM J RESP CRIT CARE, V183, P157, DOI 10.1164/rccm.201002-0272CI
   White AR, 2006, HYPERTENSION, V47, P245, DOI 10.1161/01.HYP.0000198543.34502.d7
   Witzenrath M, 2006, CRIT CARE MED, V34, P1947, DOI 10.1097/01.CCM.0000220496.48295.A9
   Worrall NK, 1997, AM J PHYSIOL-HEART C, V273, pH2565, DOI 10.1152/ajpheart.1997.273.6.H2565
   Xu H, 2008, FREE RADICAL BIO MED, V44, P1656, DOI 10.1016/j.freeradbiomed.2008.01.023
   Yang LF, 2010, BIOCHEM BIOPH RES CO, V400, P16, DOI 10.1016/j.bbrc.2010.07.126
   Yashiro M, 2013, CRIT CARE MED, V41, P171, DOI 10.1097/CCM.0b013e3182676352
NR 70
TC 22
Z9 23
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2013
VL 4
AR 228
DI 10.3389/fimmu.2013.00228
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA V38WS
UT WOS:000209374100224
PM 23966993
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Ma, LJ
   Li, YY
   Zhao, YL
   Wang, QW
   Nan, YD
   Mu, DG
   Li, WP
   Sun, RL
   Jin, FG
   Liu, XY
AF Ma, Lijie
   Li, Yanyan
   Zhao, Yilin
   Wang, Qingwei
   Nan, Yandong
   Mu, Deguang
   Li, Wangping
   Sun, Ruilin
   Jin, Faguang
   Liu, Xueying
TI 3,5,4 '-tri-O-acetylresveratrol Ameliorates Seawater Exposure-Induced
   Lung Injury by Upregulating Connexin 43 Expression in Lung
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID GAP-JUNCTION CHANNEL; PERMEABILITY; RESVERATROL; PATHWAYS
AB The aim of the present study was to examine the effects of 3,5,4'-tri-O-acetylresveratrol on connexin 43 (Cx43) in acute lung injury (ALI) in rats induced by tracheal instillation of artificial seawater. Different doses (50, 150, and 450 mg/kg) of 3,5,4'-tri-O-acetylresveratrol were administered orally for 7 days before modeling. Four hours after seawater inhalation, histological changes, contents of TNF-alpha, IL-1 beta and IL-10, and the expression of Cx43 in lungs were detected. Besides, the gap junction communication in A549 cells and human umbilical vein endothelial cells (HUVECs) challenged by seawater was also evaluated. Histological changes, increased contents of inflammatory factors, upregulation in gene level, and deregulation in protein level of Cx43 in lungs stimulated by seawater were observed. On the other hand, pretreatment with 3,5,4'-tri-O-acetylresveratrol significantly inhibited infiltration of inflammation, development of pulmonary edema, and contents of inflammatory mediators in lungs. Above all, 3,5,4'-tri-Oacetylresveratrol upregulated the expression of Cx43 in both gene and protein levels, and its intermediate metabolite, resveratrol, also enhanced the gap junction communication in the two cell lines. The results of the present study suggested that administration of 3,5,4'-tri-O-acetylresveratrol may be beneficial for treatment of inflammatorycells in lung.
C1 [Ma, Lijie; Li, Yanyan; Zhao, Yilin; Nan, Yandong; Mu, Deguang; Li, Wangping; Sun, Ruilin; Jin, Faguang] Fourth Mil Med Univ, Dept Respirat, Tangdu Hosp, Xian 710038, China.
C1 [Wang, Qingwei] Fourth Mil Med Univ, Dept Pharm, Tangdu Hosp, Xian 710038, China.
C1 [Liu, Xueying] Fourth Mil Med Univ, Dept Med Chem, Sch Pharm, Xian 710032, China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University
RP Jin, FG (corresponding author), Fourth Mil Med Univ, Dept Respirat, Tangdu Hosp, Xian 710038, Peoples R China.
EM jinfag@fmmu.edu.cn; weiyingxuan427@163.com
RI ma, li/HOH-7275-2023
FU G&k gold surface project: the mechanisms of hypoxia-inducible factor
   1alpha (HIF-1alpha) in seawater drowning-induced acute lung injury
   (SWD-ALI) [81270124]
FX This work was supported by Grants from the 2012 G&k gold surface
   project: the mechanisms of hypoxia-inducible factor 1 alpha (HIF-1
   alpha) in seawater drowning-induced acute lung injury (SWD-ALI),
   (Project 81270124). Besides, the copyright of this paper has nothing to
   do with those corporations mentioned above who provided the experimental
   materials.
CR Brink PR, 2006, J UROLOGY, V175, P381, DOI 10.1016/S0022-5347(05)00007-8
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6
   Ecklund MM, 2012, CRIT CARE NURS CLIN, V24, P601, DOI 10.1016/j.ccell.2012.07.002
   Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20
   Fragopoulou E, 2007, J AGR FOOD CHEM, V55, P80, DOI 10.1021/jf0627221
   Gregorakos L, 2009, LUNG, V187, P93, DOI 10.1007/s00408-008-9132-4
   Koide K, 2011, ACS MED CHEM LETT, V2, P270, DOI 10.1021/ml100159p
   Li JH, 2011, CLIN EXP PHARMACOL P, V38, P269, DOI 10.1111/j.1440-1681.2011.05498.x
   Li JH, 2011, RESP PHYSIOL NEUROBI, V176, P39, DOI 10.1016/j.resp.2011.01.005
   Li L., 2011, STUDY PHARMACOKINETI
   Li Q, 2010, J TRAUMA, V68, P802, DOI 10.1097/TA.0b013e3181bb80ea
   Mann Ashley, 2012, Mo Med, V109, P371
   Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770
   Neves AR, 2012, CURR MED CHEM, V19, P1663
   Scheckenbach KEL, 2011, J VASC RES, V48, P91, DOI 10.1159/000316942
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   van Beeck EF, 2005, B WORLD HEALTH ORGAN, V83, P853
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Zhang JZ, 2010, RESPIRATION, V80, P236, DOI 10.1159/000274384
   Zhang Y, 2011, BIOL PHARM BULL, V34, P1052, DOI 10.1248/bpb.34.1052
NR 20
TC 12
Z9 13
U1 0
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2013
VL 2013
AR 182132
DI 10.1155/2013/182132
PG 8
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 112PD
UT WOS:000316603600001
PM 23576849
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Mao, M
   Xu, XL
   Zhang, Y
   Zhang, B
   Fu, ZH
AF Mao, Mei
   Xu, Xilin
   Zhang, Yong
   Zhang, Bo
   Fu, Zu-hong
TI Endothelial progenitor cells: the promise of cell-based therapies for
   acute lung injury
SO INFLAMMATION RESEARCH
LA English
DT Review
DE endothelial progenitor cells; angiogenesis; ALI/ARDS; Stem cell therapy 
ID RESPIRATORY-DISTRESS-SYNDROME; AUTOLOGOUS TRANSPLANTATION;
   SUPEROXIDE-DISMUTASE; PERIPHERAL-BLOOD; VASCULAR REPAIR; ARTERY-DISEASE;
   ATHEROSCLEROSIS; RABBITS; NEOVASCULARIZATION; EPIDEMIOLOGY
AB Endothelial progenitor cells (EPCs) are defined as a special type of stem cell that have been found to directly incorporate into injured vessels and that participate in angiogenesis and reconstruction by differentiation into endothelial cells. EPCs are widely used to therapeutically treat cardiovascular disease, limb ischemia and vascular repair. However, the role of EPCs in inflammatory diseases, especially in lung injury, is less studied.
   To investigate the application of EPCs to vascular repair, and the role of EPCs in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
   A computer-based online search was performed in the PubMed database and Web of Science database for articles published, concerning EPCs, angiogenesis, ALI/ARDS and stem cell transplantation
   EPCs have a therapeutic potential for vascular regeneration and may emerge as novel strategy for the diseases that are associated with ALI/ARDS.
C1 [Mao, Mei] PLA, Hosp 324, Dept Resp Med, Chongqing 400020, China.
C1 [Xu, Xilin; Zhang, Yong; Zhang, Bo; Fu, Zu-hong] Guangzhou Mil Command, Wuhan Gen Hosp, Dept Resp Med, Wuhan 430072, China.
RP Mao, M (corresponding author), PLA, Hosp 324, Dept Resp Med, Chongqing 400020, Peoples R China.
EM maomei270@163.com
CR Alev C, 2011, ANTIOXID REDOX SIGN, V15, P949, DOI 10.1089/ars.2010.3872
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Blank R, 2011, CRIT CARE CLIN, V27, P439, DOI 10.1016/j.ccc.2011.05.005
   Bogoslovsky T, 2010, NEUROLOGY, V75, P2059, DOI 10.1212/WNL.0b013e318200d741
   Bompais H, 2004, BLOOD, V103, P2577, DOI 10.1182/blood-2003-08-2770
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   Cao JP, 2012, ANESTHESIOLOGY, V116, P1278, DOI 10.1097/ALN.0b013e3182567f84
   Ding DC, 2007, CELL TRANSPLANT, V16, P273, DOI 10.3727/000000007783464777
   Du FY, 2012, FRONT BIOSCI-LANDMRK, V17, P2327, DOI 10.2741/4055
   Fan CL, 2005, ACTA PHARMACOL SIN, V26, P1069, DOI 10.1111/j.1745-7254.2005.00168.x
   Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919
   Gao XF, 2011, INT IMMUNOPHARMACOL, V11, P1584, DOI 10.1016/j.intimp.2011.05.019
   Germani A, 2009, CARDIOVASC THER, V27, P289, DOI 10.1111/j.1755-5922.2009.00105.x
   He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f
   He TR, 2004, STROKE, V35, P2378, DOI 10.1161/01.STR.0000141893.33677.5d
   HENNIG B, 1993, PROG FOOD NUTR SCI, V17, P119
   Hung HS, 2009, CELL TRANSPLANT, V18, P1003, DOI 10.3727/096368909X12483162196683
   Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06
   Jujo K, 2008, J MOL CELL CARDIOL, V45, P530, DOI 10.1016/j.yjmcc.2008.08.003
   Kahler CM, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-50
   Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032
   Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO
   Krenning G, 2009, TRENDS MOL MED, V15, P180, DOI 10.1016/j.molmed.2009.02.001
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   Lam CF, 2011, ANESTH ANALG, V112, P620, DOI 10.1213/ANE.0b013e3182075da4
   Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012
   Lasala GP, 2011, CARDIOVASC REVASCULA, V12, P29, DOI 10.1016/j.carrev.2010.01.001
   Liu F, 2009, LIVER TRANSPLANT, V15, P1092, DOI 10.1002/lt.21845
   Liu KD, 2008, CLIN J AM SOC NEPHRO, V3, P578, DOI 10.2215/CJN.01630407
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Matsubara Y, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-2
   Matuschak George M, 2010, Mo Med, V107, P252
   Naruse Keiko, 2005, Nihon Rinsho, V63 Suppl 6, P622
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Prieto J, 2008, GENE THER, V15, P765, DOI 10.1038/gt.2008.44
   Qian C, 2007, CARDIOVASC PATHOL, V16, P127, DOI 10.1016/j.carpath.2006.11.008
   Ribatti D, 2007, LEUKEMIA RES, V31, P439, DOI 10.1016/j.leukres.2006.10.014
   Sheridan M, 2008, CRIT CARE, V12, DOI 10.1186/cc6808
   Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2
   Tanaka K, 2009, CURR PHARM DESIGN, V15, P2760, DOI 10.2174/138161209788923868
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   Toya SP, 2011, AM J PATHOL, V178, P313, DOI 10.1016/j.ajpath.2010.09.041
   Tsuchiya K, 2010, INT J ONCOL, V36, P1379, DOI 10.3892/ijo_00000622
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Urbich C, 2005, J MOL CELL CARDIOL, V39, P733, DOI 10.1016/j.yjmcc.2005.07.003
   Varma NRS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030310
   Wary KK, 2009, STEM CELLS, V27, P3112, DOI 10.1002/stem.241
   Watt SM, 2010, J R SOC INTERFACE, V7, pS731, DOI [10.1098/rsif.2010.0377.focus, 10.1098/rsif.2010.0377.focas]
   Werner N, 2006, J CELL MOL MED, V10, P318, DOI 10.1111/j.1582-4934.2006.tb00402.x
   Werner N, 2007, BASIC RES CARDIOL, V102, P565, DOI 10.1007/s00395-007-0680-1
   WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6
   Xia L, 2009, CYTOTHERAPY, V11, P492, DOI 10.1080/14653240902960460
   Yamada M, 2005, THORAX, V60, P410, DOI 10.1136/thx.2004.034058
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
   Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081
   ZAPOL WM, 1987, AM REV RESPIR DIS, V136, P471, DOI 10.1164/ajrccm/136.2.471
NR 56
TC 8
Z9 14
U1 1
U2 22
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
J9 INFLAMM RES
JI Inflamm. Res.
PD JAN
PY 2013
VL 62
IS 1
BP 3
EP 8
DI 10.1007/s00011-012-0570-3
PG 6
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 063NC
UT WOS:000313005500002
PM 23138575
DA 2023-08-21
ER

PT J
AU Huang, XJ
   Zhao, YY
AF Huang, Xiaojia
   Zhao, You-Yang
TI Transgenic Expression of FoxM1 Promotes Endothelial Repair following
   Lung Injury Induced by Polymicrobial Sepsis in Mice
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; M1B TRANSCRIPTION FACTOR; BETA-CATENIN;
   CELLS; LIVER; PROLIFERATION; PERMEABILITY; REGENERATION; MECHANISMS;
   JUNCTIONS
AB Enhancing endothelial barrier integrity for the treatment of acute lung injury (ALI) is an emerging novel therapeutic strategy. Our previous studies have demonstrated the essential role of FoxM1 in mediating endothelial regeneration and barrier repair following lipopolysaccharide-induced lung injury. However, it remains unclear whether FoxM1 expression is sufficient to promote endothelial repair in experimental models of sepsis. Here, employing the FoxM1 transgenic (FoxM1 Tg) mice, we showed that transgenic expression of FoxM1 promoted rapid recovery of endothelial barrier function and survival in a clinically relevant model of sepsis induced by cecal ligation and puncture (CLP). We observed lung vascular permeability was rapidly recovered and returned to levels similar to baseline at 48 h post-CLP challenge in FoxM1 Tg mice whereas it remained markedly elevated in WT mice. Lung edema and inflammation were resolved only in FoxM1 Tg mice at 24 h post-CLP. 5-bromo-2-deoxyuridine incorporation assay revealed a drastic induction of endothelial proliferation in FoxM1 Tg lungs at 24h post-CLP, correlating with early induction of expression of FoxM1 target genes essential for cell cycle progression. Additionally, deletion of FoxM1 in endothelial cells, employing the mouse model with endothelial cell-restricted disruption of FoxM1 (FoxM1 CKO) resulted in impaired endothelial repair following CLP challenge. Together, these data suggest FoxM1 expression in endothelial cells is necessary and sufficient to mediate endothelial repair and thereby promote survival following sepsis challenge.
C1 [Huang, Xiaojia; Zhao, You-Yang] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607, United States.
C1 [Huang, Xiaojia; Zhao, You-Yang] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Zhao, YY (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607 USA.
EM yyzhao@uic.edu
OI ZHAO, YOU-YANG/0000-0002-0041-0339
FU National Institutes of Health [R01HL085462, P01HL077806]
FX This study was supported by National Institutes of Health grants
   R01HL085462 and P01HL077806 to YYZ. The funders had no role in design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854
   Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157
   Cines DB, 1998, BLOOD, V91, P3527
   CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200
   Kaestner KH, 2000, GENE DEV, V14, P142
   Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200
   Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704
   Kolosova IA, 2008, AM J PHYSIOL-LUNG C, V294, pL319, DOI 10.1152/ajplung.00283.2007
   Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   Liu YR, 2011, J EXP MED, V208, P1473, DOI 10.1084/jem.20102041
   Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Mirza MK, 2010, J EXP MED, V207, P1675, DOI 10.1084/jem.20091857
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005
   Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299
   Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
   Ye HG, 1999, MOL CELL BIOL, V19, P8570
   Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 31
TC 24
Z9 24
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 20
PY 2012
VL 7
IS 11
AR e50094
DI 10.1371/journal.pone.0050094
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 043II
UT WOS:000311535700068
PM 23185540
OA Green Submitted, Green Published, gold
DA 2023-08-21
ER

PT J
AU Chichger, H
   Grinnell, KL
   Casserly, B
   Chung, CS
   Braza, J
   Lomas-Neira, J
   Ayala, A
   Rounds, S
   Klinger, JR
   Harrington, EO
AF Chichger, Havovi
   Grinnell, Katie L.
   Casserly, Brian
   Chung, Chun-Shiang
   Braza, Julie
   Lomas-Neira, Joanne L.
   Ayala, Alfred
   Rounds, Sharon
   Klinger, James R.
   Harrington, Elizabeth O.
TI Genetic disruption of protein kinase C delta reduces endotoxin-induced
   lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
ID KAPPA-B ACTIVATION; PKC-DELTA; ENDOTHELIAL-CELLS; BARRIER FUNCTION;
   PULMONARY-EDEMA; IN-VIVO; EXPRESSION; PHOSPHORYLATION; PROLIFERATION;
   INVOLVEMENT
AB Chichger H, Grinnell KL, Casserly B, Chung C, Braza J, Lomas-Neira J, Ayala A, Rounds S, Klinger JR, Harrington EO. Genetic disruption of protein kinase C delta reduces endotoxin-induced lung injury. Am J Physiol Lung Cell Mol Physiol 303: L880-L888, 2012. First published September 14, 2012; doi:10.1152/ajplung.00169.2012.-The pathogenesis of acute lung injury and acute respiratory distress syndrome is characterized by sequestration of leukocytes in lung tissue, disruption of capillary integrity, and pulmonary edema. PKC delta plays a critical role in RhoA-mediated endothelial barrier function and inflammatory responses. We used mice with genetic deletion of PKC delta (PKC delta(-/-)) to assess the role of PKC delta in susceptibility to LPS-induced lung injury and pulmonary edema. Under baseline conditions or in settings of increased capillary hydrostatic pressures, no differences were noted in the filtration coefficients (k(f)) or wet-to-dry weight ratios between PKC delta(-/-) and PKC delta(-/-) mice. However, at 24 h after exposure to LPS, the kf values were significantly higher in lungs isolated from PKC delta(-/-) than PKC delta(-/-) mice. In addition, bronchoalveolar lavage fluid obtained from LPS-exposed PKC delta(-/-) mice displayed increased protein and cell content compared with LPS-exposed PKC delta(-/-) mice, but similar changes in inflammatory cytokines were measured. Histology indicated elevated LPS-induced cellularity and inflammation within PKC delta(-/-) mouse lung parenchyma relative to PKC delta(-/-) mouse lungs. Transient overexpression of catalytically inactive PKC delta cDNA in the endothelium significantly attenuated LPS-induced endothelial barrier dysfunction in vitro and increased k(f) lung values in PKC delta(-/-) mice. However, transient overexpression of wild-type PKC delta cDNA in PKC delta(-/-) mouse lung vasculature did not alter the protective effects of PKC delta deficiency against LPS-induced acute lung injury. We conclude that PKC delta plays a role in the pathological progression of endotoxin-induced lung injury, likely mediated through modulation of inflammatory signaling and pulmonary vascular barrier function.
C1 [Chichger, Havovi; Grinnell, Katie L.; Casserly, Brian; Braza, Julie; Rounds, Sharon; Klinger, James R.; Harrington, Elizabeth O.] Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI, United States.
C1 [Chichger, Havovi; Grinnell, Katie L.; Casserly, Brian; Braza, Julie; Rounds, Sharon; Klinger, James R.; Harrington, Elizabeth O.] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912, United States.
C1 [Chung, Chun-Shiang; Lomas-Neira, Joanne; Ayala, Alfred] Brown Univ, Dept Surg, Alpert Med Sch, Providence, RI 02912, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University; Brown University
RP Harrington, EO (corresponding author), Providence VA Med Ctr, Res Serv, 151 830 Chalkstone Ave, Providence, RI 02908 USA.
EM Elizabeth_Harrington@brown.edu
RI Chichger, Havovi/Y-7117-2019; Rounds, Sharon/AAF-7380-2020; Chichger,
   Havovi/M-5129-2015
OI Chichger, Havovi/0000-0002-8549-7583; Chichger,
   Havovi/0000-0002-8549-7583; Harrington, Elizabeth/0000-0002-3207-5301;
   Ayala, Alfred/0000-0002-5034-2995
FU National Heart, Lung, and Blood Institute [R01 HL-67795, T32 HL-094300];
   American Heart Association [10GRNT4160055]
FX This material is the result of work supported with resources and the use
   of facilities at the Providence Veterans Affairs Medical Center and
   supported by National Heart, Lung, and Blood Institute Grant R01
   HL-67795 and American Heart Association Grant 10GRNT4160055 to E. O.
   Harrington. K. L. Grinnell was supported by National Heart, Lung, and
   Blood Institute Grant T32 HL-094300.
CR Bai X, 2010, ARTERIOSCL THROM VAS, V30, P2467, DOI 10.1161/ATVBAHA.110.215723
   Bair AM, 2009, J BIOL CHEM, V284, P563, DOI 10.1074/jbc.M803984200
   Bey EA, 2004, J IMMUNOL, V173, P5730, DOI 10.4049/jimmunol.173.9.5730
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004
   Bright R, 2007, BRAIN RES, V1144, P146, DOI 10.1016/j.brainres.2007.01.113
   Chou WH, 2004, J CLIN INVEST, V114, P49, DOI 10.1172/JC1200421655
   Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817
   Gaudreault N, 2008, ARTERIOSCL THROM VAS, V28, P1527, DOI 10.1161/ATVBAHA.108.166975
   Grinnell KL, 2010, AM J PHYSIOL-LUNG C, V298, pL361, DOI 10.1152/ajplung.00374.2009
   Grinnell K, 2012, J CELL PHYSIOL, V227, P1899, DOI 10.1002/jcp.22918
   Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC
   Harrington EO, 2005, EXP CELL RES, V308, P407, DOI 10.1016/j.yexcr.2005.05.005
   Harrington EO, 2003, AM J RESP CELL MOL, V28, P626, DOI 10.1165/rcmb.2002-0085OC
   Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200
   Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310
   Kandasamy K, 2012, MICROVASC RES, V83, P323, DOI 10.1016/j.mvr.2012.01.006
   Kilpatrick LE, 2011, J LEUKOCYTE BIOL, V89, P3, DOI 10.1189/jlb.0510281
   Kim YA, 2010, NEUROSCI LETT, V468, P254, DOI 10.1016/j.neulet.2009.11.007
   Klinger JR, 2007, J APPL PHYSIOL, V103, P2084, DOI 10.1152/japplphysiol.00695.2007
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Leitges M, 2001, J CLIN INVEST, V108, P1505
   Lu Q, 2009, AM J PHYSIOL-LUNG C, V296, pL825, DOI 10.1152/ajplung.90307.2008
   Martin K, 2008, LUNG, V186, P145, DOI 10.1007/s00408-008-9073-y
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mayr M, 2004, AM J PHYSIOL-HEART C, V287, pH946, DOI 10.1152/ajpheart.00878.2003
   Mayr M, 2004, AM J PHYSIOL-HEART C, V287, pH937, DOI 10.1152/ajpheart.00877.2003
   Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a
   Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200
   Minhajuddin M, 2009, J BIOL CHEM, V284, P4052, DOI 10.1074/jbc.M805032200
   Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a
   Qi X, 2008, J CLIN INVEST, V118, P173, DOI 10.1172/JCI32636
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934
   Shukla A, 2007, AM J PATHOL, V170, P140, DOI 10.2353/ajpath.2007.060381
   Tinsley JH, 2004, AM J PHYSIOL-CELL PH, V286, pC105, DOI 10.1152/ajpcell.00340.2003
   Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200
   UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7
   Waki K, 2006, FREE RADICAL RES, V40, P359, DOI 10.1080/10715760500539121
   Zhao XX, 2005, J LEUKOCYTE BIOL, V77, P414, DOI 10.1189/jlb.0504284
   Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407
NR 41
TC 24
Z9 26
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD NOV
PY 2012
VL 303
IS 10
BP L880
EP L888
DI 10.1152/ajplung.00169.2012
PG 9
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 038XW
UT WOS:000311208400005
PM 22983354
OA Green Published
DA 2023-08-21
ER

PT J
AU Coulthard, MG
   Morgan, M
   Woodruff, TM
   Arumugam, TV
   Taylor, SM
   Carpenter, TC
   Lackmann, M
   Boyd, AW
AF Coulthard, Mark G.
   Morgan, Michael
   Woodruff, Trent M.
   Arumugam, Thiruma V.
   Taylor, Stephen M.
   Carpenter, Todd C.
   Lackmann, Martin
   Boyd, Andrew W.
TI Eph/Ephrin Signaling in Injury and Inflammation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Review
ID RECEPTOR TYROSINE KINASE; FACTOR-ALPHA INDUCTION; EPH RECEPTORS;
   ENDOTHELIAL-CELLS; UP-REGULATION; RETINAL NEOVASCULARIZATION; AXONAL
   REGENERATION; SUPERIOR COLLICULUS; ASTROCYTIC GLIOSIS; REPERFUSION
   INJURY
AB The Eph/ephrin receptor-ligand system plays an important role in embryogenesis and adult life, principally by influencing cell behavior through signaling pathways, resulting in modification of the cell cytoskeleton and cell adhesion. There are 10 EphA receptors, and six EphB receptors, distinguished on sequence difference and binding preferences, that interact with the six glycosylphosphatidylinositol-linked ephrin-A ligands and the three transmembrane ephrin-B ligands, respectively. The Eph/ephrin proteins, originally described as developmental regulators that are expressed at low levels postembryonically, are re-expressed after injury to the optic nerve, spinal cord, and brain in fish, amphibians, rodents, and humans. In rodent spinal cord injury, the upregulation of EphA4 prevents recovery by inhibiting axons from crossing the injury site. Eph/ephrin proteins may be partly responsible for the phenotypic changes to the vascular endothelium in inflammation, which, allows fluid and inflammatory cells to pass from the vascular space into the interstitial tissues. Specifically, EphA2/ephrin-A1 signaling in the lung may be responsible for pulmonary inflammation in acute lung injury. A role in T-cell maturation and chronic inflammation (heart failure, inflammatory bowel disease, and rheumatoid arthritis) is also reported. Although there remains much to learn about Eph/ephrin signaling in human disease, and specifically in injury and inflammation, this area of research raises the exciting prospect that novel therapies will be developed that precisely target these pathways. (Am J Pathol 2012, 181:1493-1503; http://dx.doi.org/10.1016/j.ajpath.2012.06.043)
C1 [Coulthard, Mark G.] Royal Childrens Hosp, Paediat Intens Care Unit, Herston, Qld 4029, Australia.
C1 [Coulthard, Mark G.; Boyd, Andrew W.] Royal Childrens Hosp, Queensland Childrens Med Res Inst, Herston, Qld 4029, Australia.
C1 [Coulthard, Mark G.] Univ Queensland, Acad Discipline Paediat & Child Hlth, Herston, Qld, Australia.
C1 [Coulthard, Mark G.; Boyd, Andrew W.] Queensland Inst Med Res, Leukaemia Fdn Lab, Herston, Qld 4006, Australia.
C1 [Morgan, Michael; Woodruff, Trent M.; Arumugam, Thiruma V.; Taylor, Stephen M.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia.
C1 [Carpenter, Todd C.] Univ Colorado Denver, Pediat Crit Care Sect, Aurora, CO, United States.
C1 [Lackmann, Martin] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia.
C1 [Boyd, Andrew W.] Univ Queensland, Royal Brisbane Womens Hosp, Acad Discipline Med, Herston, Qld, Australia.
C3 Royal Children's Hospital Brisbane; Royal Children's Hospital Brisbane;
   University of Queensland; QIMR Berghofer Medical Research Institute;
   University of Queensland; Children's Hospital Colorado; University of
   Colorado System; University of Colorado Anschutz Medical Campus; Monash
   University; Royal Brisbane & Women's Hospital; University of Queensland
RP Coulthard, MG (corresponding author), Royal Childrens Hosp, Paediat Intens Care Unit, Herston, Qld 4029, Australia.
EM mark_coulthard@health.qld.gov.au
RI Morgan, Michael/AAC-2044-2021; Arumugam, Thiruma/AAG-6958-2019;
   Woodruff, Trent M/B-4861-2009; Coulthard, Mark G/AAT-7735-2021;
   Coulthard, Mark Graeme/E-9444-2010; Carpenter, Todd/A-7503-2011;
   Arumugam, Thiruma Valavan/B-4898-2011; Morgan, Michael/C-1323-2015;
   Woodruff, Trent/AAS-4629-2020
OI Morgan, Michael/0000-0002-3641-2774; Woodruff, Trent
   M/0000-0003-1382-911X; Coulthard, Mark G/0000-0001-7400-5582; Coulthard,
   Mark Graeme/0000-0001-7400-5582; Carpenter, Todd/0000-0002-9855-0021;
   Morgan, Michael/0000-0002-3641-2774; Woodruff,
   Trent/0000-0003-1382-911X; Arumugam, Thiruma/0000-0002-3377-0939
CR Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875
   Afshari FT, 2010, J NEUROSCI, V30, P4246, DOI 10.1523/JNEUROSCI.3351-09.2010
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Ait-Oufella H, 2010, INTENS CARE MED, V36, P1286, DOI 10.1007/s00134-010-1893-6
   Arocho LC, 2011, CELL MOL NEUROBIOL, V31, P1057, DOI 10.1007/s10571-011-9705-2
   Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408
   Baldwin C, 2006, AM J PHYSIOL-RENAL, V291, pF960, DOI 10.1152/ajprenal.00020.2006
   Baum CL, 2005, DERMATOL SURG, V31, P674
   Beckers CML, 2010, THROMB HAEMOSTASIS, V103, P40, DOI 10.1160/TH09-06-0403
   Bernhardt RR, 1999, EXP NEUROL, V157, P223, DOI 10.1006/exnr.1999.7059
   Blits-Huizinga CT, 2004, IUBMB LIFE, V56, P257, DOI 10.1080/15216540412331270076
   Bundesen LQ, 2003, J NEUROSCI, V23, P7789
   Cannon RO, 2005, NAT CLIN PRACT CARD, V2, P88, DOI 10.1038/ncpcardio0096
   Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027
   Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009
   Carpenter TC, 2012, AM J RESP CELL MOL, V46, P40, DOI 10.1165/rcmb.2011-0044OC
   Cercone MA, 2009, AM J PHYSIOL-LUNG C, V297, pL856, DOI 10.1152/ajplung.00118.2009
   Chan B, 2009, THROMB RES, V123, P745, DOI 10.1016/j.thromres.2008.07.010
   Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007
   Chen J, 2006, EXP EYE RES, V82, P664, DOI 10.1016/j.exer.2005.09.004
   Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200
   Cowan CW, 2005, NEURON, V46, P205, DOI 10.1016/j.neuron.2005.03.019
   Cruz-Orengo L, 2006, EXP NEUROL, V202, P421, DOI 10.1016/j.expneurol.2006.07.005
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184
   DIXIT VM, 1990, J BIOL CHEM, V265, P2973
   Dries JL, 2011, J PHYSIOL-LONDON, V589, P1725, DOI 10.1113/jphysiol.2010.202366
   Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460-9568.2007.05859.x
   Fang BW, 2008, J CELL SCI, V121, P358, DOI 10.1242/jcs.017145
   Flanagan JG, 1997, CELL, V90, P403
   Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149
   Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048
   Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867
   Goichberg P, 2011, CIRC RES, V108, P1071, DOI 10.1161/CIRCRESAHA.110.239459
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004
   Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006
   Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636
   Goldshmit Y, 2010, J NEUROTRAUM, V27, P1321, DOI 10.1089/neu.2010.1294
   Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849
   Hafner C, 2005, WORLD J GASTROENTERO, V11, P4511, DOI 10.3748/wjg.v11.i29.4511
   Hafner C, 2005, WORLD J GASTROENTERO, V11, P4024, DOI 10.3748/wjg.v11.i26.4024
   Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237
   Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107
   Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004
   Hui SP, 2010, DEV DYNAM, V239, P2962, DOI 10.1002/dvdy.22438
   Hwan AY, 2006, BIOCHEM BIOPH RES CO, V348, P560, DOI 10.1016/j.bbrc.2006.07.105
   Irizarry-Ramirez M, 2005, J NEUROTRAUM, V22, P929, DOI 10.1089/neu.2005.22.929
   Islam S, 2010, DIGEST DIS SCI, V55, P2478, DOI 10.1007/s10620-009-1102-z
   Ivanov AI, 2005, PHYSIOL GENOMICS, V21, P152, DOI 10.1152/physiolgenomics.00043.2004
   Ivanov AI, 2006, IUBMB LIFE, V58, P389, DOI 10.1080/15216540600756004
   Janes PW, 2012, SEMIN CELL DEV BIOL, V23, P43, DOI 10.1016/j.semcdb.2012.01.001
   Janes PW, 2011, J CELL BIOL, V195, P1033, DOI 10.1083/jcb.201104037
   Janes PW, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000215
   Munoz JJ, 2011, NEUROIMMUNOMODULAT, V18, P271, DOI 10.1159/000329490
   Kitamura T, 2008, AM J PHYSIOL-CELL PH, V294, pC189, DOI 10.1152/ajpcell.00314.2007
   Knoll B, 2001, MECH DEVELOP, V106, P119, DOI 10.1016/S0925-4773(01)00431-2
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Kume T, 2010, HISTOL HISTOPATHOL, V25, P637, DOI 10.14670/HH-25.637
   Lackmann M, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.115re2
   Larson J, 2008, AM J PHYSIOL-LUNG C, V295, pL431, DOI 10.1152/ajplung.90256.2008
   Li YY, 1998, AM J PHYSIOL-HEART C, V274, pH331, DOI 10.1152/ajpheart.1998.274.1.H331
   Liu X, 2006, J NEUROSCI, V26, P3087, DOI 10.1523/JNEUROSCI.4797-05.2006
   London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678
   Maeda S, 2011, CELL MOL LIFE SCI, V68, P1115, DOI 10.1007/s00018-010-0551-z
   Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020
   Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Miao H, 2012, SEMIN CELL DEV BIOL, V23, P16, DOI 10.1016/j.semcdb.2011.10.013
   Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012
   Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625
   Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018-011-0900-6
   Ojima T, 2006, AM J PATHOL, V168, P331, DOI 10.2353/ajpath.2006.050435
   Okazaki T, 2009, AM J PATHOL, V174, P2388, DOI 10.2353/ajpath.2009.080949
   Orsulic S, 2000, J CELL SCI, V113, P1793
   PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pfaff D, 2008, J CELL SCI, V121, P3842, DOI 10.1242/jcs.030627
   Pitulescu ME, 2010, GENE DEV, V24, P2480, DOI 10.1101/gad.1973910
   Robbins SL, 1999, ROBBINS PATHOLOGIC B, P52
   Rodger J, 2001, EUR J NEUROSCI, V14, P1929, DOI 10.1046/j.0953-816x.2001.01822.x
   Rosas OR, 2011, DEV NEUROBIOL, V71, P595, DOI 10.1002/dneu.20848
   Ruan JP, 2010, ANESTHESIOLOGY, V112, P1234, DOI 10.1097/ALN.0b013e3181d3e0df
   Schruefer R, 2006, J VASC RES, V43, P1, DOI 10.1159/000088975
   Scicolone G, 2009, BRAIN RES BULL, V79, P227, DOI 10.1016/j.brainresbull.2009.03.008
   Sharfe N, 2008, MOL IMMUNOL, V45, P1208, DOI 10.1016/j.molimm.2007.09.019
   Sobel RA, 2005, BRAIN PATHOL, V15, P35
   Sohl M, 2010, BIOCHEM BIOPH RES CO, V391, P24, DOI 10.1016/j.bbrc.2009.10.146
   Tanaka M, 2005, J BIOL CHEM, V280, P42375, DOI 10.1074/jbc.M503786200
   Tat SK, 2008, ARTHRITIS RHEUM-US, V58, P3820, DOI 10.1002/art.24029
   Ting MJ, 2010, EXP HEMATOL, V38, P1087, DOI 10.1016/j.exphem.2010.07.007
   Trinidad EM, 2010, CELL ADHES MIGR, V4, P363, DOI 10.4161/cam.4.3.11586
   Vearing CJ, 2005, GROWTH FACTORS, V23, P67, DOI 10.1080/08977190500055869
   Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje
   Wilkinson DG, 2000, INT REV CYTOL, V196, P177
   Willson CA, 2006, J MOL HISTOL, V37, P369, DOI 10.1007/s10735-006-9067-0
   Wong SY, 2010, J R SOC INTERFACE, V7, pS351, DOI 10.1098/rsif.2010.0018.focus
   Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328
   Yamashita T, 2008, J BIOL CHEM, V283, P18926, DOI 10.1074/jbc.M709133200
   Zamora DO, 2006, CELL IMMUNOL, V242, P99, DOI 10.1016/j.cellimm.2006.10.001
   Zhang R, 2010, PSYCHIAT RES, V180, P5, DOI 10.1016/j.psychres.2010.04.037
   Zhou N, 2011, MICROVASC RES, V82, P113, DOI 10.1016/j.mvr.2011.06.005
NR 102
TC 151
Z9 153
U1 4
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2012
VL 181
IS 5
BP 1493
EP 1503
DI 10.1016/j.ajpath.2012.06.043
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 031QK
UT WOS:000310656800002
PM 23021982
OA hybrid
DA 2023-08-21
ER

PT J
AU Sugimoto, R
   Okamoto, T
   Nakao, A
   Zhan, J
   Wang, Y
   Kohmoto, J
   Tokita, D
   Farver, CF
   Tarpey, MM
   Billiar, TR
   Gladwin, MT
   McCurry, KR
AF Sugimoto, R.
   Okamura, Toru
   Nakao, A.
   Zhan, J.
   Wang, Y.
   Kohmoto, J.
   Tokita, D.
   Farver, C. F.
   Tarpey, M. M.
   Billiar, Timothy R.
   Gladwin, Mark T.
   McCurry, K. R.
TI Nitrite Reduces Acute Lung Injury and Improves Survival in a Rat Lung
   Transplantation Model
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Nitrite; NO; lung transplantation; ischemia/reperfusion; rat 
ID ISCHEMIA-REPERFUSION INJURY; ISCHEMIA/REPERFUSION INJURY;
   CARBON-MONOXIDE; MYOCARDIAL-ISCHEMIA; OXIDE SYNTHASE; IN-VIVO; XANTHINE
   OXIDOREDUCTASE; OXIDATIVE STRESS; SODIUM-NITRITE; PROTECTS
AB Ischemia/reperfusion injury (IRI) is the most common cause of early mortality following lung transplantation (LTx). We hypothesized that nitrite, an endogenous source of nitric oxide (NO), may protect lung grafts from IRI. Rat lung grafts were stored in preservation solution at 4 degrees C for 6 hours. Both grafts and recipients were treated with nitrite. Nitrite treatment was associated with significantly higher levels of tissue oxygenation, lower levels of cytokines and neutrophil/macrophage infiltration, lower myeloperoxidase activity, reduced oxidative injury and increased cGMP levels in grafts than in the controls. Treatment with either a nitric oxide scavenger or a soluble guanylyl cyclase (sGC) inhibitor diminished the beneficial effects of nitrite and decreased cGMP concentrations. These results suggest that nitric oxide, generated from nitrite, is the molecule responsible for the effects of nitrite via the nitric oxide/sGC/cGMP pathway. Allopurinol, a xanthine oxidoreductase (XOR) inhibitor, abrogated the protective effects of nitrite, suggesting that XOR is a key enzyme in the conversion of nitrite to nitric oxide. In vitro experiments demonstrated that nitrite prevented apoptosis in pulmonary endothelial cells. Nitrite also exhibits longer survival rate in recipients than control. In conclusion, nitrite inhibits lung IRI following cold preservation and had higher survival rate in LTx model.
C1 [Okamoto, T.; McCurry, K. R.] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44106, United States.
C1 [Sugimoto, R.; Nakao, A.; Zhan, J.; Wang, Y.; Kohmoto, J.; Tokita, D.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA, United States.
C1 [Tarpey, M. M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261, United States.
C1 [Billiar, T. R.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA, United States.
C1 [Gladwin, M. T.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA, United States.
C1 [Gladwin, M. T.] Univ Pittsburgh, Sch Med, Vasc Med Inst, Pittsburgh, PA, United States.
C1 [McCurry, K. R.] Cleveland Clin, Thorac & Cardiovasc Surg Heart & Vasc Inst, Cleveland, OH 44106, United States.
C3 Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic
   Foundation
RP McCurry, KR (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44106 USA.
EM mccurrk@ccf.org
FU NIH [R01HL098032, RO1HL096973, PO1HL103455]; Institute for Transfusion
   Medicine; Hemophilia Center of Western Pennsylvania
FX R.S. and T.O. contributed equally to this work and should be considered
   as first authors. Dr. Gladwin receives research support from NIH grants
   R01HL098032, RO1HL096973 and PO1HL103455, the Institute for Transfusion
   Medicine and the Hemophilia Center of Western Pennsylvania. We thank
   David Wheeler for proofreading the manuscript.
CR AIBA M, 1992, J HEART LUNG TRANSPL, V11, P1025
   Alef MJ, 2011, J CLIN INVEST, V121, P1646, DOI 10.1172/JCI44079
   Aoshiba K, 2003, INHAL TOXICOL, V15, P1029, DOI 10.1080/08958370390226431
   ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203
   Basireddy M, 2006, AM J PHYSIOL-RENAL, V290, pF779, DOI 10.1152/ajprenal.00334.2005
   Berry CE, 2004, J PHYSIOL-LONDON, V555, P589, DOI 10.1113/jphysiol.2003.055913
   Bittner F, 2010, PLANT CELL MONOGR, V17, P119, DOI [10.1016/j.bbamcr.2006.03.013, 10.1007/978-3-642-10613-2_6]
   Bolli R, 2001, J MOL CELL CARDIOL, V33, P1897, DOI 10.1006/jmcc.2001.1462
   Christie JD, 2005, AM J RESP CRIT CARE, V171, P1312, DOI 10.1164/rccm.200409-1243OC
   Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954
   Date H, 1996, J THORAC CARDIOV SUR, V111, P913, DOI 10.1016/S0022-5223(96)70364-1
   Deguchi K, 2008, BRAIN RES, V1188, P1, DOI 10.1016/j.brainres.2007.07.104
   Dejam A, 2007, CIRCULATION, V116, P1821, DOI 10.1161/CIRCULATIONAHA.107.712133
   Dezfulian C, 2007, CARDIOVASC RES, V75, P327, DOI 10.1016/j.cardiores.2007.05.001
   Dong BM, 2009, AM J TRANSPLANT, V9, P2707, DOI 10.1111/j.1600-6143.2009.02840.x
   Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493
   Eppinger MJ, 1997, AM J PATHOL, V150, P1773
   Fischer S, 2000, AM J RESP CRIT CARE, V162, P1932, DOI 10.1164/ajrccm.162.5.9910064
   Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420
   Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308
   Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757
   Goldstein S, 2003, J BIOL CHEM, V278, P50949, DOI 10.1074/jbc.M308317200
   Hendgen-Cotta UB, 2008, P NATL ACAD SCI USA, V105, P10256, DOI 10.1073/pnas.0801336105
   Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011
   Jung KH, 2006, STROKE, V37, P2744, DOI 10.1161/01.STR.0000245116.40163.1c
   Kaizu T, 2005, SURGERY, V138, P229, DOI 10.1016/j.surg.2005.06.015
   Kayano K, 1999, CIRCULATION, V100, P257
   Kohmotoa J, 2007, AM J TRANSPLANT, V7, P2279, DOI 10.1111/j.1600-6143.2007.01940.x
   Leon L, 2008, NITRIC OXIDE-BIOL CH, V19, P77, DOI 10.1016/j.niox.2008.04.014
   Li HT, 2004, J BIOL CHEM, V279, P16939, DOI 10.1074/jbc.M314336200
   Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026
   Lu Ping, 2005, Hepatobiliary Pancreat Dis Int, V4, P350
   Lundberg JO, 2005, ARTERIOSCL THROM VAS, V25, P915, DOI 10.1161/01.ATV.0000161048.72004.c2
   Lundberg JO, 2009, NAT CHEM BIOL, V5, P865, DOI 10.1038/nchembio.260
   Meade MO, 2003, AM J RESP CRIT CARE, V167, P1483, DOI 10.1164/rccm.2203034
   Meyer KC, 1998, CHEST, V113, P1360, DOI 10.1378/chest.113.5.1360
   Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8
   Neto JS, 2004, AM J PHYSIOL-RENAL, V287, pF979, DOI 10.1152/ajprenal.00158.2004
   Perrin G, 2006, CHEST, V129, P1024, DOI 10.1378/chest.129.4.1024
   PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086
   Poli G, 2008, MED RES REV, V28, P569, DOI 10.1002/med.20117
   Rassaf T, 2007, CIRC RES, V100, P1749, DOI 10.1161/CIRCRESAHA.107.152488
   Serrick C, 1997, ANN THORAC SURG, V63, P202
   Shiva S, 2007, J EXP MED, V204, P2089, DOI 10.1084/jem.20070198
   Shiva S, 2009, J MOL CELL CARDIOL, V46, P1, DOI 10.1016/j.yjmcc.2008.10.005
   Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6
   Tang ZL, 2002, MOL CELL BIOCHEM, V234, P211, DOI 10.1023/A:1015930927407
   Tripatara P, 2007, J AM SOC NEPHROL, V18, P570, DOI 10.1681/ASN.2006050450
   Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101
   Webb AJ, 2008, HYPERTENSION, V51, P784, DOI 10.1161/HYPERTENSIONAHA.107.103523
   Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954
   Zhao MQ, 2006, AM J PHYSIOL-LUNG C, V291, pL1018, DOI 10.1152/ajplung.00086.2006
   Zuckerbraun BS, 2010, CIRCULATION, V121, P98, DOI 10.1161/CIRCULATIONAHA.109.891077
   ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804
NR 54
TC 32
Z9 33
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2012
VL 12
IS 11
BP 2938
EP 2948
DI 10.1111/j.1600-6143.2012.04169.x
PG 11
WC Surgery; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery; Transplantation
GA 029EW
UT WOS:000310478600012
PM 23016570
DA 2023-08-21
ER

PT J
AU Sun, XG
   Singleton, PA
   Letsiou, E
   Zhao, J
   Belvitch, P
   Sammani, S
   Chiang, ET
   Moreno-Vinasco, L
   Wade, MS
   Zhou, T
   Liu, B
   Parastatidis, I
   Thomson, L
   Ischiropoulos, H
   Natarajan, V
   Jacobson, JR
   Machado, RF
   Dudek, SM
   Garcia, JGN
AF Sun, Xiaoguang
   Singleton, Patrick A.
   Letsiou, Eleftheria
   Zhao, Jing
   Belvitch, Patrick
   Sammani, Saad
   Chiang, Eddie T.
   Moreno-Vinasco, Liliana
   Wade, Michael S.
   Zhou, Tong
   Liu, Bin
   Parastatidis, Ioannis
   Thomson, Leonor
   Ischiropoulos, Harry
   Natarajan, Viswanathan
   Jacobson, Jeffrey R.
   Machado, Roberto F.
   Dudek, Steven M.
   Garcia, Joe G. N.
TI Sphingosine-1-Phosphate Receptor-3 Is a Novel Biomarker in Acute Lung
   Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; S1P/S1PR1/S1PR2/S1PR3; microparticles; nitration; biomarkers 
ID SPHINGOSINE 1-PHOSPHATE; TYROSINE NITRATION; TISSUE FACTOR;
   MICROPARTICLES; PERMEABILITY; INFLAMMATION; KINASE; IDENTIFICATION;
   COAGULATION; VENTILATION
AB The inflamed lung exhibits oxidative and nitrative modifications of multiple target proteins, potentially reflecting disease severity and progression. We identified sphingosine-1-phosphate receptor-3 (S1PR3), a critical signaling molecule mediating cell proliferation and vascular permeability, as a nitrated plasma protein in mice with acute lung injury (ALI). We explored S1PR3 as a potential biomarker in murine and human ALI. In vivo nitrated and total S1PR3 concentrations were determined by immunoprecipitation and microarray studies in mice, and by ELISA in human plasma. In vitro nitrated S1PR3 concentrations were evaluated in human lung vascular endothelial cells (ECs) or within microparticles shed from ECs after exposure to barrier-disrupting agonists (LPS, low-molecular-weight hyaluronan, and thrombin). The effects of S1PR3-containing microparticles on EC barrier function were assessed by transendothelial electrical resistance (TER). Nitrated S1PR3 was identified in the plasma of murine ALI and in humans with severe sepsis-induced ALI. Elevated total S1PR3 plasma concentrations (> 251 pg/ml) were linked to sepsis and ALI mortality. In vitro EC exposure to barrier-disrupting agents induced S1PR3 nitration and the shedding of S1PR3-containing microparticles, which significantly reduced TER, consistent with increased permeability. These changes were attenuated by reduced S1PR3 expression (small interfering RNAs). These results suggest that microparticles containing nitrated S1PR3 shed into the circulation during inflammatory lung states, and represent a novel ALI biomarker linked to disease severity and outcome.
C1 [Sun, Xiaoguang; Letsiou, Eleftheria; Belvitch, Patrick; Sammani, Saad; Chiang, Eddie T.; Moreno-Vinasco, Liliana; Wade, Michael S.; Zhou, Tong; Liu, Bin; Natarajan, Viswanathan; Jacobson, Jeffrey R.; Machado, Roberto F.; Dudek, Steven M.; Garcia, Joe G. N.] Univ Chicago, Inst Personalized Resp Med, Coll Med, Chicago, IL 60637, United States.
C1 [Singleton, Patrick A.] Univ Chicago, Dept Med, Chicago, IL 60637, United States.
C1 [Zhao, Jing] Univ Pittsburgh, Dept Med, Pittsburgh, PA, United States.
C1 [Parastatidis, Ioannis; Thomson, Leonor; Ischiropoulos, Harry] Univ Penn, Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104, United States.
C1 [Parastatidis, Ioannis; Thomson, Leonor; Ischiropoulos, Harry] Univ Penn, Dept Pediat & Pharmacol, Philadelphia, PA 19104, United States.
C3 University of Chicago; University of Chicago; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; University
   of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania
RP Garcia, JGN (corresponding author), Univ Chicago, Inst Personalized Resp Med, Coll Med, 914 S Wood St,MC 719, Chicago, IL 60637 USA.
EM jggarcia@uic.edu
RI Garcia, Joe GN/E-8862-2010; SUN, XIAOGUANG/ACA-5558-2022; Thomson,
   Leonor/C-4684-2008
OI Thomson, Leonor/0000-0002-2574-8520; Machado,
   Roberto/0000-0002-3722-5954
FU National Heart, Lung, and Blood Institute from the National Institutes
   of Health [P01HL58064, HL91889, P01HL98050]
FX This work was supported by National Heart, Lung, and Blood Institute
   grants P01HL58064, HL91889, and P01HL98050 from the National Institutes
   of Health (J.G.N.G.).
CR Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Calfee CS, 2011, CRIT CARE MED, V39, P711, DOI 10.1097/CCM.0b013e318207ec3c
   Cepkova M, 2006, CRIT CARE, V10, DOI 10.1186/cc5037
   Christie JD, 2008, CRIT CARE MED, V36, P2794, DOI 10.1097/CCM.0b013e318186b843
   Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985
   Cribbs SK, 2008, CRIT CARE MED, V36, P2457, DOI 10.1097/CCM.0b013e318181052a
   English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia JGN, 2011, AM J RESP CRIT CARE, V183, P1287, DOI 10.1164/rccm.201104-0623ED
   Geiser T, 2001, AM J RESP CRIT CARE, V163, P1384, DOI 10.1164/ajrccm.163.6.2006131
   Ghesquiere B, 2009, MOL CELL PROTEOMICS, V8, P2642, DOI 10.1074/mcp.M900259-MCP200
   Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961
   Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC
   Kamp Ryan, 2008, Proc Am Thorac Soc, V5, P348, DOI 10.1513/pats.200709-152DR
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Leroyer AS, 2010, THROMB HAEMOSTASIS, V104, P456, DOI 10.1160/TH10-02-0111
   Levitt Joseph E, 2009, J Intensive Care Med, V24, P151, DOI 10.1177/0885066609332603
   Marsolais D, 2009, NAT REV DRUG DISCOV, V8, P297, DOI 10.1038/nrd2356
   Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E
   McClintock D, 2008, CRIT CARE, V12, DOI 10.1186/cc6846
   Mirzapoiazova T, 2011, AM J RESP CELL MOL, V44, P40, DOI 10.1165/rcmb.2009-0197OC
   Niessen F, 2008, NATURE, V452, P654, DOI 10.1038/nature06663
   Parastatidis I, 2008, J BIOL CHEM, V283, P33846, DOI 10.1074/jbc.M805522200
   Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X
   Rahaman M, 2006, AM J RESP CELL MOL, V34, P233, DOI 10.1165/rcmb.2005-0126OC
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Sapet C, 2006, BLOOD, V108, P1868, DOI 10.1182/blood-2006-04-014175
   Shet AS, 2003, BLOOD, V102, P2678, DOI 10.1182/blood-2003-03-0693
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Singleton PA, 2007, AM J RESP CELL MOL, V37, P222, DOI 10.1165/rcmb.2006-0327OC
   Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200
   Singleton PA, 2010, AM J PHYSIOL-LUNG C, V299, pL639, DOI 10.1152/ajplung.00405.2009
   Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187
   Sun XG, 2010, J ALLERGY CLIN IMMUN, V126, P241, DOI 10.1016/j.jaci.2010.04.036
   Szotowski B, 2007, CARDIOVASC RES, V73, P806, DOI 10.1016/j.cardiores.2006.12.018
   Thomson L, 2007, AM J RESP CELL MOL, V36, P152, DOI 10.1165/rcmb.2006-0288SM
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002
   Ware LB, 2010, CHEST, V137, P288, DOI 10.1378/chest.09-1484
   Zhao J, 2009, CELL SIGNAL, V21, P1945, DOI 10.1016/j.cellsig.2009.09.002
NR 44
TC 62
Z9 69
U1 1
U2 16
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD NOV
PY 2012
VL 47
IS 5
BP 628
EP 636
DI 10.1165/rcmb.2012-0048OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 082QE
UT WOS:000314406400009
PM 22771388
OA Green Published
DA 2023-08-21
ER

PT J
AU Armstrong, SM
   Wang, CS
   Tigdi, J
   Si, XE
   Dumpit, C
   Charles, S
   Gamage, A
   Moraes, TJ
   Lee, WL
AF Armstrong, Susan M.
   Wang, Changsen
   Tigdi, Jayesh
   Si, Xiaoe
   Dumpit, Carlo
   Charles, Steffany
   Gamage, Asela
   Moraes, Theo J.
   Lee, Warren L.
TI Influenza Infects Lung Microvascular Endothelium Leading to
   Microvascular Leak: Role of Apoptosis and Claudin-5
SO PLOS ONE
LA English
DT Article
ID TIGHT JUNCTION STRANDS; BLOOD-BRAIN-BARRIER; CELLS; VIRUS; INJURY;
   EXPRESSION; HOSPITALIZATION; PERMEABILITY; DYSFUNCTION; MECHANISMS
AB Severe influenza infections are complicated by acute lung injury, a syndrome of pulmonary microvascular leak. The pathogenesis of this complication is unclear. We hypothesized that human influenza could directly infect the lung microvascular endothelium, leading to loss of endothelial barrier function. We infected human lung microvascular endothelium with both clinical and laboratory strains of human influenza. Permeability of endothelial monolayers was assessed by spectrofluorimetry and by measurement of the transendothelial electrical resistance. We determined the molecular mechanisms of flu-induced endothelial permeability and developed a mouse model of severe influenza. We found that both clinical and laboratory strains of human influenza can infect and replicate in human pulmonary microvascular endothelium, leading to a marked increase in permeability. This was caused by apoptosis of the lung endothelium, since inhibition of caspases greatly attenuated influenza-induced endothelial leak. Remarkably, replication-deficient virus also caused a significant degree of endothelial permeability, despite displaying no cytotoxic effects to the endothelium. Instead, replication-deficient virus induced degradation of the tight junction protein claudin-5; the adherens junction protein VE-cadherin and the actin cytoskeleton were unaffected. Over-expression of claudin-5 was sufficient to prevent replication-deficient virus-induced permeability. The barrier-protective agent formoterol was able to markedly attenuate flu-induced leak in association with dose-dependent induction of claudin-5. Finally, mice infected with human influenza developed pulmonary edema that was abrogated by parenteral treatment with formoterol. Thus, we describe two distinct mechanisms by which human influenza can induce pulmonary microvascular leak. Our findings have implications for the pathogenesis and treatment of acute lung injury from severe influenza.
C1 [Armstrong, Susan M.; Gamage, Asela; Moraes, Theo J.; Lee, Warren L.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada.
C1 [Wang, Changsen; Tigdi, Jayesh; Dumpit, Carlo; Charles, Steffany; Lee, Warren L.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada.
C1 [Si, Xiaoe; Moraes, Theo J.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
C1 [Lee, Warren L.] Univ Toronto, Fac Med, Div Respirol, Toronto, ON, Canada.
C1 [Lee, Warren L.] Univ Toronto, Fac Med, Interdept Div Crit Care Med, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto; Li Ka Shing Knowledge
   Institute; Saint Michaels Hospital Toronto; University of Toronto;
   Hospital for Sick Children (SickKids); University of Toronto; University
   of Toronto
RP Lee, WL (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada.
EM warren.lee@utoronto.ca
RI Moraes, Theo/CAJ-3254-2022
OI Moraes, Theo/0000-0001-9968-6601; Lee, Warren/0000-0002-1788-6587
FU Canadian Institutes of Health Research; Ontario Thoracic Society;
   Physician Services Incorporated Foundation; Government of Ontario; CIHR;
   McLaughlin Centre
FX WLL is supported by the Canadian Institutes of Health Research, the
   Ontario Thoracic Society, the Physician Services Incorporated Foundation
   and an Early Researcher Award from the Government of Ontario. SMA is
   supported by a MD/PhD Studentship award from the CIHR and an MD/PhD
   Studentship award from the McLaughlin Centre. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abe Y, 1999, J IMMUNOL, V163, P2867
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Armstrong SM, 2012, AM J PATHOL, V180, P1308, DOI 10.1016/j.ajpath.2011.12.002
   Szretter Kristy J, 2006, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/9780471729259.mc15g01s29, 10.1002/0471729256.mc15g01s3]
   Beese M, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-68
   COLDENSTANFIELD M, 1993, J IMMUNOL, V151, P310
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Cottey R, 2001, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1911s42
   CRAWFORD DH, 1983, J GEN VIROL, V64, P697, DOI 10.1099/0022-1317-64-3-697
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   Feldmann A, 2000, J VIROL, V74, P8018, DOI 10.1128/JVI.74.17.8018-8027.2000
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gillrie MR, 2007, BLOOD, V110, P3426, DOI 10.1182/blood-2007-04-084582
   Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011
   Goto H, 2010, AM J RESP CRIT CARE, V181, P1336, DOI 10.1164/rccm.200907-1002OC
   HANASAKI K, 1994, J BIOL CHEM, V269, P10637
   Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Ishizaki T, 2003, EXP CELL RES, V290, P275, DOI 10.1016/S0014-4827(03)00354-9
   Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC
   Kaneider NC, 2007, NAT IMMUNOL, V8, P1303, DOI 10.1038/ni1525
   Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1
   Klenk HD, 2005, THROMB HAEMOSTASIS, V94, P262, DOI 10.1160/TH05-04-0264
   KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415
   Kuster SP, 2010, EUR J CLIN MICROBIOL, V29, P835, DOI 10.1007/s10096-010-0935-x
   Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001
   Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040
   London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678
   Mandel I, 2012, J CELL BIOCHEM, V113, P2415, DOI 10.1002/jcb.24118
   McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185
   Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   PATTERSON CE, 1992, J APPL PHYSIOL, V72, P865, DOI 10.1152/jappl.1992.72.3.865
   Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35
   Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V300, pL667, DOI 10.1152/ajplung.00433.2010
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344
   Visseren FLJ, 1999, J LAB CLIN MED, V134, P623, DOI 10.1016/S0022-2143(99)90103-8
   Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044
   Warfel JM, 2005, AM J PATHOL, V166, P1871, DOI 10.1016/S0002-9440(10)62496-0
   WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132
   Yao L, 2008, FASEB J, V22, P733, DOI 10.1096/fj.06-7880com
   Yuan L, 2012, J BIOL CHEM
NR 49
TC 85
Z9 90
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2012
VL 7
IS 10
AR e47323
DI 10.1371/journal.pone.0047323
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 026VC
UT WOS:000310310200034
PM 23115643
OA gold, Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Tauseef, M
   Knezevic, N
   Chava, KR
   Smith, M
   Sukriti, S
   Gianaris, N
   Obukhov, AG
   Vogel, SM
   Schraufnagel, DE
   Dietrich, A
   Birnbaumer, L
   Malik, AB
   Mehta, D
AF Tauseef, Mohammad
   Knezevic, Nebojsa
   Chava, Koteswara Rao
   Smith, Monica
   Sukriti, Sukriti
   Gianaris, Nicholas
   Obukhov, Alexander G.
   Vogel, Stephen M.
   Schraufnagel, Dean E.
   Dietrich, Alexander
   Birnbaumer, Lutz
   Malik, Asrar B.
   Mehta, Dolly
TI TLR4 activation of TRPC6-dependent calcium signaling mediates
   endotoxin-induced lung vascular permeability and inflammation
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID LIGHT-CHAIN KINASE; NF-KAPPA-B; INCREASED ENDOTHELIAL PERMEABILITY;
   PATTERN-RECOGNITION RECEPTORS; C REGULATES ACTIVATION; TOLL-LIKE
   RECEPTOR-4; PHOSPHOLIPASE-C; CA2+ ENTRY; IN-VIVO; MICROVASCULAR
   PERMEABILITY
AB Lung vascular endothelial barrier disruption and the accompanying inflammation are primary pathogenic features of acute lung injury (ALI); however, the basis for the development of both remains unclear. Studies have shown that activation of transient receptor potential canonical (TRPC) channels induces Ca2+ entry, which is essential for increased endothelial permeability. Here, we addressed the role of Toll-like receptor 4 (TLR4) intersection with TRPC6-dependent Ca2+ signaling in endothelial cells (ECs) in mediating lung vascular leakage and inflammation. We find that the endotoxin (lipopolysaccharide; LPS) induces Ca2+ entry in ECs in a TLR4-dependent manner. Moreover, deletion of TRPC6 renders mice resistant to endotoxin-induced barrier dysfunction and inflammation, and protects against sepsis-induced lethality. TRPC6 induces Ca2+ entry in ECs, which is secondary to the generation of diacylglycerol (DAG) induced by LPS. Ca2+ entry mediated by TRPC6, in turn, activates the nonmuscle myosin light chain kinase (MYLK), which not only increases lung vascular permeability but also serves as a scaffold to promote the inter-action of myeloid differentiation factor 88 and IL-1R-associated kinase 4, which are required for NF-kappa B activation and lung inflammation. Our findings suggest that TRPC6-dependent Ca2+ entry into ECs, secondary to TLR4-induced DAG generation, participates in mediating both lung vascular barrier disruption and inflammation induced by endotoxin.
C1 [Tauseef, Mohammad; Knezevic, Nebojsa; Chava, Koteswara R.; Smith, Monica; Sukriti, Sukriti; Vogel, Stephen M.; Malik, Asrar B.; Mehta, Dolly] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 61605, United States.
C1 [Tauseef, Mohammad; Knezevic, Nebojsa; Chava, Koteswara R.; Smith, Monica; Sukriti, Sukriti; Vogel, Stephen M.; Malik, Asrar B.; Mehta, Dolly] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 61605, United States.
C1 [Schraufnagel, Dean E.] Univ Illinois, Coll Med, Dept Med, Chicago, IL 61605, United States.
C1 [Gianaris, Nicholas; Obukhov, Alexander G.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202, United States.
C1 [Dietrich, Alexander] Univ Munich, Walther Straub Inst Pharmacol & Toxicol, D-80336 Munich, Germany.
C1 [Birnbaumer, Lutz] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Indiana University System;
   Indiana University Bloomington; University of Munich; National
   Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 61605 USA.
EM dmehta@uic.edu
RI Knezevic, MD, PhD, Nebojsa Nick/H-9921-2019; Dietrich,
   Alexander/G-8619-2013; Obukhov, Alexander G/C-7246-2008
OI Knezevic, MD, PhD, Nebojsa Nick/0000-0001-8028-1495; Dietrich,
   Alexander/0000-0002-1168-8707; Obukhov, Alexander G/0000-0002-3862-6004;
   Tauseef, Mohammad/0000-0001-5317-4379; Baweja,
   Sukriti/0000-0002-8677-9857; Schraufnagel, Dean/0000-0003-0063-7223;
   Malik, Asrar/0000-0002-8205-7128
FU National Institutes of Health [HL71794, HL84153, P01-HL60678]; American
   Heart Association postdoctoral fellowship [10POST2600336]; Intramural
   Research Division of the National Institutes of Health [Z01-ES-101684]
FX This work was supported by National Institutes of Health grants HL71794
   (D. Mehta), HL84153 (D. Mehta) and P01-HL60678 (D. Mehta and A.B.
   Malik), American Heart Association postdoctoral fellowship to M. Tauseef
   (10POST2600336), and in part by the Intramural Research Division of the
   National Institutes of Health (project Z01-ES-101684 to LB).
CR Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   Andonegui G, 2002, J IMMUNOL, V169, P2111, DOI 10.4049/jimmunol.169.4.2111
   Andonegui G, 2009, J CLIN INVEST, V119, P1921, DOI 10.1172/JCI36411
   Bachmaier K, 2007, NAT MED, V13, P920, DOI 10.1038/nm1607
   BARNARD JW, 1995, J IMMUNOL, V155, P4876
   Bertocchi C, 2011, CELL PHYSIOL BIOCHEM, V28, P625, DOI 10.1159/000335758
   Blue EK, 2002, AM J PHYSIOL-CELL PH, V282, pC451, DOI 10.1152/ajpcell.00333.2001
   Cheng HW, 2006, ARTERIOSCL THROM VAS, V26, P1768, DOI 10.1161/01.ATV.0000231518.86795.0f
   Di AK, 2012, NAT IMMUNOL, V13, P29, DOI 10.1038/ni.2171
   Di AK, 2010, J BIOL CHEM, V285, P15848, DOI 10.1074/jbc.M109.075549
   Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee
   Dietrich A, 2005, PFLUG ARCH EUR J PHY, V451, P72, DOI 10.1007/s00424-005-1460-0
   Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005
   Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158
   Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995
   Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829
   Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853
   Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3
   Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Into T, 2007, J BIOL CHEM, V282, P8134, DOI 10.1074/jbc.M609962200
   Karpurapu M, 2011, BLOOD, V118, P5255, DOI 10.1182/blood-2011-03-341123
   Kawagoe T, 2008, NAT IMMUNOL, V9, P684, DOI 10.1038/ni.1606
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kim TJ, 2009, J CELL PHYSIOL, V218, P285, DOI 10.1002/jcp.21598
   Kini V, 2010, J BIOL CHEM, V285, P33082, DOI 10.1074/jbc.M110.142034
   Knezevic N, 2007, MOL CELL BIOL, V27, P6323, DOI 10.1128/MCB.00523-07
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Lin SC, 2010, NATURE, V465, P885, DOI 10.1038/nature09121
   Lloyd-Jones KL, 2008, J IMMUNOL, V181, P1446, DOI 10.4049/jimmunol.181.2.1446
   Loiarro M, 2009, J BIOL CHEM, V284, P28093, DOI 10.1074/jbc.M109.004465
   Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209
   Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Monick MM, 1999, J IMMUNOL, V162, P3005
   Nicholas C, 2007, J IMMUNOL, V179, P7121, DOI 10.4049/jimmunol.179.10.7121
   Obukhov AG, 2005, J NEUROSCI, V25, P1234, DOI 10.1523/JNEUROSCI.4451-04.2005
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003
   Ranaivo HR, 2007, AM J PATHOL, V170, P439, DOI 10.2353/ajpath.2007.060219
   Rossi JL, 2007, AM J PHYSIOL-LUNG C, V292, pL1327, DOI 10.1152/ajplung.00380.2006
   SANDS WA, 1994, BIOCHEM BIOPH RES CO, V199, P461, DOI 10.1006/bbrc.1994.1251
   Sel S, 2008, CLIN EXP ALLERGY, V38, P1548, DOI 10.1111/j.1365-2222.2008.03043.x
   Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Toya SP, 2011, AM J PATHOL, V178, P313, DOI 10.1016/j.ajpath.2010.09.041
   Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125
   Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Wadgaonkar R, 2005, J CELL BIOCHEM, V95, P849, DOI 10.1002/jcb.20472
   Wadgaonkar R, 2005, J CELL BIOCHEM, V94, P351, DOI 10.1002/jcb.20250
   Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100
   Wang YL, 2011, J IMMUNOL, V186, P3180, DOI 10.4049/jimmunol.1001252
   Weissmann N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1660
   Xu JS, 2008, NAT IMMUNOL, V9, P880, DOI 10.1038/ni.1628
   Xu SJ, 2005, ACTA PHARMACOL SIN, V26, P1497, DOI 10.1111/j.1745-7254.2005.00217.x
   Yamamoto H, 1997, BIOCHEM J, V325, P223, DOI 10.1042/bj3250223
   Zhang FH, 2001, J LEUKOCYTE BIOL, V69, P1060
   Zhang L, 2011, J CELL PHYSIOL, V226, P1694, DOI 10.1002/jcp.22500
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
   Zhou H, 2009, J IMMUNOL, V183, P5244, DOI 10.4049/jimmunol.0901309
NR 66
TC 171
Z9 183
U1 3
U2 34
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD OCT 22
PY 2012
VL 209
IS 11
BP 1953
EP 1968
DI 10.1084/jem.20111355
PG 16
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA 027QT
UT WOS:000310368800005
PM 23045603
OA Green Submitted, Green Published, hybrid
DA 2023-08-21
ER

PT J
AU Miyashita, H
   Watanabe, T
   Hayashi, H
   Suzuki, Y
   Nakamura, T
   Ito, S
   Ono, M
   Hoshikawa, Y
   Okada, Y
   Kondo, T
   Sato, Y
AF Miyashita, Hiroki
   Watanabe, Tatsuaki
   Hayashi, Hideki
   Suzuki, Yasuhiro
   Nakamura, Takanobu
   Ito, Soichi
   Ono, Manabu
   Hoshikawa, Yasushi
   Okada, Yoshinori
   Kondo, Takashi
   Sato, Yasufumi
TI Angiogenesis Inhibitor Vasohibin-1 Enhances Stress Resistance of
   Endothelial Cells via Induction of SOD2 and SIRT1
SO PLOS ONE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; NEGATIVE FEEDBACK REGULATOR; DNA-DAMAGE
   RESPONSE; SUPEROXIDE-DISMUTASE; DEACETYLASE SIRT1; OXIDATIVE STRESS;
   SENESCENCE; MICE; OVEREXPRESSION; PROTEIN
AB Vasohibin-1 (VASH1) is isolated as an endothelial cell (EC)-produced angiogenesis inhibitor. We questioned whether VASH1 plays any role besides angiogenesis inhibition, knocked-down or overexpressed VASH1 in ECs, and examined the changes of EC property. Knock-down of VASH1 induced premature senescence of ECs, and those ECs were easily killed by cellular stresses. In contrast, overexpression of VASH1 made ECs resistant to premature senescence and cell death caused by cellular stresses. The synthesis of VASH1 was regulated by HuR-mediated post-transcriptional regulation. We sought to define the underlying mechanism. VASH1 increased the expression of (superoxide dismutase 2) SOD2, an enzyme known to quench reactive oxygen species (ROS). Simultaneously, VASH1 augmented the synthesis of sirtuin 1 (SIRT1), an anti-aging protein, which improved stress tolerance. Paraquat generates ROS and causes organ damage when administered in vivo. More VASH1 (+/-) mice died due to acute lung injury caused by paraquat. Intratracheal administration of an adenovirus vector encoding human VASH1 augmented SOD2 and SIRT1 expression in the lungs and prevented acute lung injury caused by paraquat. Thus, VASH1 is a critical factor that improves the stress tolerance of ECs via the induction of SOD2 and SIRT1.
C1 [Miyashita, Hiroki; Watanabe, Tatsuaki; Hayashi, Hideki; Suzuki, Yasuhiro; Nakamura, Takanobu; Ito, Soichi; Ono, Manabu; Sato, Yasufumi] Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan.
C1 [Watanabe, Tatsuaki; Hoshikawa, Yasushi; Okada, Yoshinori; Kondo, Takashi] Tohoku Univ, Dept Thorac Surg, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan.
C3 Tohoku University; Tohoku University
RP Sato, Y (corresponding author), Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan.
EM y-sato@idac.tohoku.ac.jp
RI Suzuki, Yasuhiro/GOE-4553-2022; Sato, Yasufumi/AAF-3367-2019
OI Suzuki, Yasuhiro/0000-0001-9046-5466; Ono, Manabu/0000-0003-3831-9773
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [22112006, 22590821]; Mitsubishi Foundation; Grants-in-Aid for
   Scientific Research [22590821, 22112006] Funding Source: KAKEN
FX This work was supported by grants from the programs Grant-in-Aid for
   Scientific Research on Innovative Areas "Integrative Research on Cancer
   Microenvironment Network" (22112006) and Grants-in-Aid for Scientific
   Research (C) [ 22590821] from the Ministry of Education, Culture,
   Sports, Science, and Technology of Japan, and by the 38th Research
   Grants in the Natural Sciences from the Mitsubishi Foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299
   Andreassi MG, 2009, MUTAT RES-FUND MOL M, V667, P35, DOI 10.1016/j.mrfmmm.2008.10.018
   Bertram C, 2008, BIOL CHEM, V389, P211, DOI 10.1515/BC.2008.031
   Chen J, 2008, J NEPHROL, V21, P337
   de Perrot M, 2003, AM J RESP CRIT CARE, V167, P490, DOI 10.1164/rccm.200207-670SO
   Didion SP, 2005, ARTERIOSCL THROM VAS, V25, P90, DOI 10.1161/01.ATV.0000149868.74075.5d
   DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95
   Erusalimsky JD, 2005, EXP GERONTOL, V40, P634, DOI 10.1016/j.exger.2005.04.010
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999
   Gorospe M, 2008, TRENDS CELL BIOL, V18, P77, DOI 10.1016/j.tcb.2007.11.007
   Gurevich F, 2009, AM J MED, V122, P322, DOI 10.1016/j.amjmed.2008.11.025
   Han MLK, 2011, AM J RESP CRIT CARE, V183, P1311, DOI 10.1164/rccm.201102-0280UP
   Heishi T, 2010, AM J PATHOL, V176, P1950, DOI 10.2353/ajpath.2010.090829
   Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6
   Hosaka T, 2009, AM J PATHOL, V175, P430, DOI 10.2353/ajpath.2009.080788
   Jang YC, 2009, J GERONTOL A-BIOL, V64, P1114, DOI 10.1093/gerona/glp100
   Jerkic M, 2011, CARDIOVASC RES, V92, P375, DOI 10.1093/cvr/cvr232
   Kimura H, 2009, BLOOD, V113, P4810, DOI 10.1182/blood-2008-07-170316
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Minamino T, 2008, FRONT BIOSCI-LANDMRK, V13, P2971, DOI 10.2741/2902
   Miyashita H, 2011, PHARMACEUTICALS, V4, P782, DOI 10.3390/ph4060782
   Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367
   Nakamaru Y, 2009, FASEB J, V23, P2810, DOI 10.1096/fj.08-125468
   Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257
   Nasu T, 2009, DIABETES, V58, P2365, DOI 10.2337/db08-1790
   O'Riordan E, 2007, AM J PHYSIOL-HEART C, V292, pH285, DOI 10.1152/ajpheart.00560.2006
   Ono M, 2008, CANCER SCI, V99, P1501, DOI 10.1111/j.1349-7006.2008.00853.x
   Orimo M, 2009, ARTERIOSCL THROM VAS, V29, P889, DOI 10.1161/ATVBAHA.109.185694
   Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015
   Potente M, 2008, CELL CYCLE, V7, P2117, DOI 10.4161/cc.7.14.6267
   Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107
   Rajawat YS, 2009, AGEING RES REV, V8, P199, DOI 10.1016/j.arr.2009.05.001
   Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC
   Saito D, 2011, AM J PHYSIOL-RENAL, V300, pF873, DOI 10.1152/ajprenal.00503.2010
   Shibuya T, 2006, ARTERIOSCL THROM VAS, V26, P1051, DOI 10.1161/01.ATV.0000216747.66660.26
   Shimizu K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI 10.1016/j.bbrc.2004.12.073
   Siedlinski M, 2009, EUR RESPIR J, V33, P986, DOI 10.1183/09031936.00171507
   Stein S, 2010, EUR HEART J, V31, P2301, DOI 10.1093/eurheartj/ehq107
   SUZUKI K, 1993, AM J PHYSIOL, V265, pH1173, DOI 10.1152/ajpheart.1993.265.4.H1173
   Suzuki Y, 2010, J CELL SCI, V123, P3094, DOI 10.1242/jcs.067538
   Takemura A, 2011, ARTERIOSCL THROM VAS, V31, P2054, DOI 10.1161/ATVBAHA.110.216739
   Tomita M, 2007, TOXICOLOGY, V231, P200, DOI 10.1016/j.tox.2006.12.005
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   Yamashita H, 2006, BIOCHEM BIOPH RES CO, V345, P919, DOI 10.1016/j.bbrc.2006.04.176
   Zhan H, 2010, J BIOL CHEM, V285, P29662, DOI 10.1074/jbc.M110.125138
   Zhang QJ, 2008, CARDIOVASC RES, V80, P191, DOI 10.1093/cvr/cvn224
NR 48
TC 54
Z9 56
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2012
VL 7
IS 10
AR e46459
DI 10.1371/journal.pone.0046459
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 020RP
UT WOS:000309831500042
PM 23056314
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Maeda, S
   Takahashi, S
   Sato, M
AF Maeda, Sumiko
   Takahashi, Satomi
   Sato, Masami
TI Serum Thrombomodulin as a Newly Identified Biomarker for Postoperative
   Lung Injury: A Prospective Observational Study
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; lung resection; pulmonary capillary vessel; thrombomodulin 
ID RESPIRATORY-DISTRESS-SYNDROME; DISSEMINATED INTRAVASCULAR COAGULATION;
   IDIOPATHIC PULMONARY-FIBROSIS; PROTEIN-C; PLASMA THROMBOMODULIN;
   NEUTROPHIL; MORTALITY; RESECTION; CANCER; ARDS
AB Postoperative lung injury after lung cancer resection is still a difficult problem to be solved. Thrombomodulin (TM) is a membrane-bound glycoprotein of endothelial cells, and its serum level is elevated in patients with acute lung injury or acute respiratory distress syndrome. In fact, TM is abundant in the pulmonary capillary vessels. Lung resection reduces the volume of pulmonary capillary vessels; however, the change in the serum levels of TM after lung resection remains to be investigated. We therefore analyzed the postoperative changes in the serum TM levels in 60 patients who underwent thoracotomy without lung resection (n = 3), partial resection of the lung (n = 15), or lobectomy (n = 42). Preoperative and postoperative day-1 laboratory data including the serum levels of TM and KL-6, a sialylated carbohydrate antigen (a biomarker for pulmonary fibrosis), and oxygenation index were collected. Unexpectedly, the postoperative serum levels of TM were lower than preoperative values in lobectomy group, whereas they remained unchanged after thoracotomy without lung resection and after partial resection of the lung. In addition, the serum TM level decreased proportional to the resected lung volume. Eight out of 42 patients with lobectomy presented high postoperative serum levels of TM, and 3 out of these 8 patients presented postoperative impaired oxygenation. Postoperative impaired oxygenation occurred only in patients with elevated TM levels; namely, an increase of serum TM is associated with impaired oxygenation after lung resection. In conclusion, serum TM is a possible biomarker for predicting the occurrence of postoperative lung injury.
C1 [Maeda, Sumiko; Takahashi, Satomi; Sato, Masami] Miyagi Canc Ctr, Dept Thorac Surg, Natori, Miyagi 9811293, Japan.
C3 Miyagi Cancer Center
RP Maeda, S (corresponding author), Tohoku Univ Hosp, Dept Thorac Surg, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.
EM sumaeda-ths@umin.ac.jp
RI Maeda, Sumiko/A-5628-2019
OI Maeda, Sumiko/0000-0003-0242-1872
CR Alam N, 2007, ANN THORAC SURG, V84, P1085, DOI 10.1016/j.athoracsur.2007.05.053
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Boehme MWJ, 2002, IMMUNOLOGY, V107, P340, DOI 10.1046/j.1365-2567.2002.01469.x
   Chida M, 2008, EUR J CARDIO-THORAC, V34, P878, DOI 10.1016/j.ejcts.2008.07.028
   Colice GL, 2007, CHEST, V132, p161S, DOI 10.1378/chest.07-1359
   Collard HR, 2010, AM J PHYSIOL-LUNG C, V299, pL3, DOI 10.1152/ajplung.90637.2008
   Cone JB, 2003, J TRAUMA, V54, P731, DOI 10.1097/01.TA.0000054652.38788.5A
   Dulu A, 2006, CHEST, V130, P73, DOI 10.1016/S0012-3692(15)50955-0
   ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249
   FORD VA, 1992, J BIOL CHEM, V267, P5446
   Gando S, 2004, INFLAMMATION, V28, P237, DOI 10.1023/B:IFLA.0000049049.81688.fe
   Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011
   ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618
   KOHNO N, 1989, CHEST, V96, P68, DOI 10.1378/chest.96.1.68
   Maeda S, 2002, LAB INVEST, V82, P293, DOI 10.1038/labinvest.3780423
   Miyazaki Y, 1998, AM J RESP CRIT CARE, V157, P89, DOI 10.1164/ajrccm.157.1.9612021
   OHDAMA S, 1994, AM J CLIN PATHOL, V101, P109, DOI 10.1093/ajcp/101.1.109
   Reid PT, 2000, CRIT CARE MED, V28, P3161, DOI 10.1097/00003246-200009000-00006
   Ruffini E, 2001, EUR J CARDIO-THORAC, V20, P30, DOI 10.1016/S1010-7940(01)00760-6
   Saito H, 2011, EUR J CARDIO-THORAC, V39, P190, DOI 10.1016/j.ejcts.2010.05.017
   Sakata R, 2010, GEN THORAC CARDIOVAS, V58, P356, DOI 10.1007/s11748-010-0604-0
   Sakuma T, 1999, SURG TODAY, V29, P121, DOI 10.1007/BF02482236
   SAWADA K, 1992, THROMB RES, V65, P199, DOI 10.1016/0049-3848(92)90240-B
   TAKANO S, 1990, BLOOD, V76, P2024
   TANAKA A, 1991, CLIN CHEM, V37, P269
   Tang SSK, 2008, EUR J CARDIO-THORAC, V34, P898, DOI 10.1016/j.ejcts.2008.06.020
   Terada Y, 2003, LAB INVEST, V83, P1165, DOI 10.1097/01.LAB.0000080606.96797.A5
   van der Poll T, 2005, AM J RESP CRIT CARE, V171, P1125, DOI 10.1164/rccm.200411-1483OC
   WADA H, 1993, AM J HEMATOL, V44, P85, DOI 10.1002/ajh.2830440203
   Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002
   Watanabe S, 2004, ANN THORAC SURG, V78, P999, DOI 10.1016/j.athoracsur.2004.04.007
NR 31
TC 5
Z9 7
U1 0
U2 4
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD OCT
PY 2012
VL 228
IS 2
BP 135
EP 141
DI 10.1620/tjem.228.135
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 024FQ
UT WOS:000310095500007
PM 22990590
OA Bronze
DA 2023-08-21
ER

PT J
AU Mikkelsen, ME
   Shah, CV
   Scherpereel, A
   Lanken, PN
   Lassalle, P
   Bellamy, SL
   Localio, AR
   Albelda, SM
   Meyer, NJ
   Christie, JD
AF Mikkelsen, Mark E.
   Shah, Chirag V.
   Scherpereel, Arnaud
   Lanken, Paul N.
   Lassalle, Philippe
   Bellamy, Scarlett L.
   Localio, A. Russell
   Albelda, Steven M.
   Meyer, Nuala J.
   Christie, Jason D.
TI Lower serum endocan levels are associated with the development of acute
   lung injury after major trauma
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE trauma; ALI/ARDS; biomarkers; ECs/HPMECs/HUVECs/MPVECs 
ID RESPIRATORY-DISTRESS-SYNDROME; CELL-SPECIFIC MOLECULE-1; HOSPITAL
   MORTALITY; TRANSFUSION; OUTCOMES; NEUTROPHILS; SIMULATION
AB Purpose: Endocan is a proteoglycan expressed by endothelial cells in the lung that may inhibit leukocyte recruitment and thus prevent the development of acute lung injury (ALI). We tested the association of serum endocan levels with subsequent development of ALI after major trauma.
   Materials and Methods: This was a single-center nested case-control study within a prospective cohort study of major trauma patients. Using an enzyme-linked immunosorbent assay test, we measured endocan levels from admission serum in 24 controls (no ALI) and 24 cases (ALI within 5 days of trauma). Multivariable logistic regression was used to test the association of admission serum endocan levels with subsequent ALI.
   Results: Patients who developed ALI had lower levels of endocan on admission (mean, 3.5 +/- 1.4 ng/mL vs 4.9 +/- 2.6 ng/mL in controls; P = .02). For each 1-unit increase in serum endocan level, the odds ratio for ALI development decreased (0.69; 95% confidence interval, 0.49-0.97; P = .03). Lower endocan levels remained associated with a higher incidence of ALI after adjustment for age and illness severity.
   Conclusions: Lower levels of serum endocan on admission are associated with subsequent development of ALI in trauma patients. These observations may be explained by endocan-mediated blockade of leukocyte recruitment in the lung. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Mikkelsen, Mark E.; Shah, Chirag V.; Lanken, Paul N.; Albelda, Steven M.; Meyer, Nuala J.; Christie, Jason D.] Univ Penn, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104, United States.
C1 [Shah, Chirag V.; Bellamy, Scarlett L.; Localio, A. Russell; Christie, Jason D.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104, United States.
C1 [Scherpereel, Arnaud; Lassalle, Philippe] CHRU Lille, INSERM, Pasteur Inst Lille, F-59019 Lille, France.
C3 University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille
RP Mikkelsen, ME (corresponding author), Univ Penn, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA.
EM mark.mikkelsen@uphs.upenn.edu
RI Lassalle, Philippe/L-6705-2018
OI Christie, Jason/0000-0003-0519-218X; lassalle,
   philippe/0000-0001-6434-0344; Bellamy, Scarlett/0000-0002-2906-4046
FU National Institutes of Health; National Heart, Lung, and Blood
   Institute, Bethesda, MD;  [T32 HL07891];  [HL079063];  [HL081619]
FX The study was supported in part by T32 HL07891 training grant, HL079063
   (Program Project Grant), HL081619 (R01), and the National Institutes of
   Health; National Heart, Lung, and Blood Institute, Bethesda, MD.
CR [Anonymous], CRIT CARE, DOI DOI 10.1186/CC8057
   [Anonymous], 2008, STAT SOFTW REL 10 0
   Arcasoy SM, 2003, AM J RESP CRIT CARE, V167, P735, DOI 10.1164/rccm.200210-1130OC
   Bechard D, 2000, J VASC RES, V37, P417, DOI 10.1159/000025758
   Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200
   Bechard D, 2001, J IMMUNOL, V167, P3099, DOI 10.4049/jimmunol.167.6.3099
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Calfee CS, 2007, CRIT CARE MED, V35, P2243, DOI 10.1097/01.CCM.0000280434.33451.87
   Calfee C, 2009, INTENS CARE MED, V35, P248, DOI 10.1007/s00134-008-1235-0
   CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012
   Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1
   Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619
   Lassalle P, 1996, J BIOL CHEM, V271, P20458, DOI 10.1074/jbc.271.34.20458
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813
   Marik PE, 2008, CRIT CARE MED, V36, P3080, DOI 10.1097/CCM.0b013e31818c3801
   Martin TR, 1997, EUR RESPIR J, V10, P770
   Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50
   Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001
   Netzer G, 2007, CHEST, V132, P1116, DOI 10.1378/chest.07-0145
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Scherpereel A, 2006, CRIT CARE MED, V34, P532, DOI 10.1097/01.CCM.0000198525.82124.74
   Shah CV, 2008, CRIT CARE MED, V36, P2309, DOI 10.1097/CCM.0b013e318180dc74
   Shah CV, 2008, AM J RESP CRIT CARE, V177, pA629
   Ware LB, 2004, AM J RESP CRIT CARE, V170, P766, DOI 10.1164/rccm.200310-1434OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Woodward M., 2005, EPIDEMIOLOGY STUDY D
NR 30
TC 52
Z9 58
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD OCT
PY 2012
VL 27
IS 5
AR 522.e11
DI 10.1016/j.jcrc.2011.07.077
PG 7
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 025PP
UT WOS:000310204300023
PM 21958978
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Pan, C
   Wang, JQ
   Liu, W
   Liu, L
   Jing, L
   Yang, Y
   Qiu, HB
AF Pan, Chun
   Wang, Jianqiang
   Liu, Wei
   Liu, Ling
   Jing, Liang
   Yang, Yi
   Qiu, Haibo
TI Low tidal volume protects pulmonary vasomotor function from "second-hit"
   injury in acute lung injury rats
SO RESPIRATORY RESEARCH
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; mechanical ventilation; Vascular reactivity; Vascular injury; ALI/ARDS; pulmonary hypertension 
ID RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; SYSTEMIC
   INFLAMMATION; VASCULAR DYSFUNCTION; ENDOTHELIAL-CELLS; PORCINE MODEL;
   HYPERTENSION; SEPSIS; RELAXATION; ACTIVATION
AB Background: Sepsis could induce indirect acute lung injury(ALI), and pulmonary vasomotor dysfunction. While low tidal volume is advocated for treatment of ALI patients. However, there is no evidence for low tidal volume that it could mitigate pulmonary vasomotor dysfunction in indirect ALI. Our study is to evaluate whether low tidal volume ventilation could protect the pulmonary vascular function in indirect lipopolysaccharide (LPS) induced acute lung injury rats.
   Methods: An indirect ALI rat model was induced by intravenous infusion of LPS. Thirty rats (n = 6 in each group) were randomly divided into (1) Control group; (2) ALI group; (3) LV group (tidal volume of 6mL/kg); (4) MV group (tidal volume of 12mL/kg); (5) VLV group (tidal volume of 3mL/kg). Mean arterial pressure and blood gas analysis were monitored every 2 hours throughout the experiment. Lung tissues and pulmonary artery rings were immediately harvested after the rats were bled to be killed to detect the contents of endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS) and TNF-alpha. Acetylcholine (Ache)-induced endothelium-dependent and sodium nitroprusside (SNP)-induced endothelium-independent relaxation of isolated pulmonary artery rings were measured by tensiometry.
   Results: There was no difference within groups concerning blood pressure, PaCO2 and SNP-induced endothelium-independent relaxation of pulmonary artery rings. Compared with MV group, LV group significantly reduced LPS-induced expression of ET-1 level (113.79 +/- 7.33pg/mL vs. 152.52 +/- 12.75pg/mL, P < 0.05) and TNF-alpha (3305.09 +/- 334.29pg/mL vs. 4144.07 +/- 608.21pg/mL, P < 0.05), increased the expression of eNOS (IOD: 15032.05 +/- 5925.07 vs. 11454.32 +/- 6035.47, P < 0.05). While Ache (10(-7)mol/L-10(-4)mol/L)-induced vasodilatation was ameliorated 30% more in LV group than in MV group.
   Conclusions: Low tidal volume could protect the pulmonary vasodilative function during indirect ALI by decreasing vasoconstrictor factors, increasing expressions of vasodilator factors in pulmonary endothelial cells, and inhibiting inflammation injuries.
C1 [Pan, Chun; Liu, Ling; Yang, Yi; Qiu, Haibo] Southeast Univ, Dept Crit Care Med, Zhongda Hosp, Sch Med, Nanjing, Jiangsu, China.
C1 [Wang, Jianqiang] Jintan Hosp, Dept Crit Care Med, Changzhou, Jiangsu, China.
C1 [Liu, Wei] China Pharmaceut Univ, Sch Pharm, Nanjing, Jiangsu, China.
C1 [Jing, Liang] Southeast Univ, Dept Anesthesiol, Zhongda Hosp, Nanjing, Jiangsu, China.
C3 Southeast University - China; China Pharmaceutical University; Southeast
   University - China
RP Qiu, HB (corresponding author), Southeast Univ, Dept Crit Care Med, Zhongda Hosp, Sch Med, Nanjing, Jiangsu, Peoples R China.
EM haiboq2000@yahoo.com.cn
RI yang, yang/GVT-5210-2022; Qiu, Haibo/AAS-9047-2021; Lang,
   Ming/HIK-0758-2022; yang, yang/HGT-7999-2022
OI Qiu, Haibo/0000-0001-8589-4717; Liu, Wei/0000-0001-8211-034X
CR Birukova AA, 2012, AM J PHYSL LUNG CELL
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Bull TM, 2010, AM J RESP CRIT CARE, V182, P1123, DOI 10.1164/rccm.201002-0250OC
   Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006
   Fineman JR, 1999, PEDIATR PULM, V27, P147, DOI 10.1002/(SICI)1099-0496(199903)27:3<147::AID-PPUL1>3.3.CO;2-G
   Gando S, 2004, INFLAMMATION, V28, P237, DOI 10.1023/B:IFLA.0000049049.81688.fe
   Grossi L, 2005, J MED CHEM, V48, P2622, DOI 10.1021/jm049857n
   Hamal KR, 2010, AM J PHYSIOL-REG I, V298, pR235, DOI 10.1152/ajpregu.00451.2009
   Iwaki M, 2009, BIOCHEM BIOPH RES CO, V389, P531, DOI 10.1016/j.bbrc.2009.09.020
   Jaecklin T, 2011, AM J PHYSIOL-LUNG C, V300, pL648, DOI 10.1152/ajplung.00305.2010
   Kobr J, 2010, IN VIVO, V24, P699
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mauro M, 2004, BRIT J HAEMATOL, V124, P200, DOI 10.1046/j.1365-2141.2003.04743.x
   MITAKA C, 1993, CHEST, V104, P476, DOI 10.1378/chest.104.2.476
   Moloney ED, 2003, EUR RESPIR J, V21, P720, DOI 10.1183/09031936.03.00120102
   Morrell ED, 2006, SHOCK, V25, P214, DOI 10.1097/01.shk.0000191380.44972.46
   Nin N, 2006, CRIT CARE MED, V34, P1093, DOI 10.1097/01.CCM.0000205663.92384.E7
   Nin N, 2005, J TRAUMA, V59, P711, DOI 10.1097/01.ta.0000177753.77471.46
   Nin N, 2008, INTENS CARE MED, V34, P948, DOI 10.1007/s00134-007-0959-6
   ODonnell DC, 1996, J APPL PHYSIOL, V81, P2013, DOI 10.1152/jappl.1996.81.5.2013
   Richard JC, 2002, INTENS CARE MED, V28, P1078, DOI 10.1007/s00134-002-1349-8
   Roy SK, 2012, SHOCK, V37, P424, DOI 10.1097/SHK.0b013e318245f2f9
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Smith KM, 1997, CRIT CARE MED, V25, P1888, DOI 10.1097/00003246-199711000-00030
   Subramani J, 2010, EUR J PHARMACOL, V630, P84, DOI 10.1016/j.ejphar.2009.12.026
   Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2
   Toda M, 2008, J BIOTECHNOL, V133, P239, DOI 10.1016/j.jbiotec.2007.08.009
   Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4
   Wort SJ, 1999, BRIT MED BULL, V55, P30, DOI 10.1258/0007142991902286
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
NR 31
TC 21
Z9 24
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-993X
EI 1465-9921
J9 RESP RES
JI Respir. Res.
PD SEP 6
PY 2012
VL 13
AR 77
DI 10.1186/1465-9921-13-77
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA 046DI
UT WOS:000311745300001
PM 22954351
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Konrad, FM
   Witte, E
   Vollmer, I
   Stark, S
   Reutershan, J
AF Konrad, Franziska M.
   Witte, Esther
   Vollmer, Irene
   Stark, Stefanie
   Reutershan, Joerg
TI Adenosine receptor A(2b) on hematopoietic cells mediates LPS-induced
   migration of PMNs into the lung interstitium
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; permeability; neutrophils 
ID RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE SYNTHASE; INDUCED VASCULAR
   LEAK; PULMONARY INFLAMMATION; DEFICIENT MICE; DEPENDENT INDUCTION;
   EPITHELIAL-CELLS; MURINE SEPSIS; A2B RECEPTOR; INJURY
AB Konrad FM, Witte E, Vollmer I, Stark S, Reutershan J. Adenosine receptor A(2b) on hematopoietic cells mediates LPS-induced migration of PMNs into the lung interstitium. Am J Physiol Lung Cell Mol Physiol 303: L425-L438, 2012. First published June 15, 2012; doi:10.1152/ajplung.00387.2011.-Uncontrolled transmigration of polymorphonuclear leukocytes (PMNs) into the different compartments of the lungs (intravascular, interstitial, alveolar) is a critical event in the early stage of acute lung injury and acute respiratory distress syndrome. Adenosine receptor A(2b) is highly expressed in the inflamed lungs and has been suggested to mediate cell trafficking. In a murine model of LPS-induced lung inflammation, we investigated the role of A(2b) on migration of PMNs into the different compartments of the lung. In A(2b)(-/-) mice, LPS-induced accumulation of PMNs was significantly higher in the interstitium, but not in the alveolar space. In addition, pulmonary clearance of PMNs was delayed in A(2b)(-/-) mice. Using chimeric mice, we identified A(2b) on hematopoietic cells as crucial for PMN migration. A(2b) did not affect the release of relevant chemokines into the alveolar space. LPS-induced microvascular permeability was under the control of A(2b) on both hematopoietic and nonhematopoietic cells. Activation of A(2b) on endothelial cells also reduced formation of LPS-induced stress fibers, highlighting its role for endothelial integrity. A specific A(2b) agonist (BAY 60-6583) was effective in decreasing PMN migration into the lung interstitium and microvascular permeability. In addition, in vitro transmigration of human PMNs through a layer of human endothelial or epithelial cells was A(2b) dependent. Activation of A(2b) on human PMNs reduced oxidative burst activity. Together, our results demonstrate anti-inflammatory effects of A(2b) on two major characteristics of acute lung injury, with a distinct role of hematopoietic A(2b) for cell trafficking and endothelial A(2b) for microvascular permeability.
C1 [Konrad, Franziska M.; Witte, Esther; Vollmer, Irene; Stark, Stefanie; Reutershan, Joerg] Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Reutershan, J (corresponding author), Univ Tubingen, Dept Anesthesiol & Intens Care Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.
EM joerg.reutershan@uni-tuebingen.de
FU German Research Foundation [RE 1683/3-1]
FX This work was supported by German Research Foundation Grant RE 1683/3-1
   (to J. Reutershan).
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Anvari F, 2010, J THORAC CARDIOV SUR, V140, P871, DOI 10.1016/j.jtcvs.2010.06.051
   Baughman RP, 1996, AM J RESP CRIT CARE, V154, P76, DOI 10.1164/ajrccm.154.1.8680703
   Beukers MW, 2000, MOL PHARMACOL, V58, P1349, DOI 10.1124/mol.58.6.1349
   Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cagnina RE, 2009, AM J PHYSIOL-LUNG C, V297, pL467, DOI 10.1152/ajplung.90553.2008
   Cepkova Magda, 2006, J Intensive Care Med, V21, P119, DOI 10.1177/0885066606287045
   Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203
   Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044
   Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127
   Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Eltzschig HK, 2009, ANESTHESIOLOGY, V111, P904, DOI 10.1097/ALN.0b013e3181b060f2
   Forlow SB, 2001, BLOOD, V98, P3309, DOI 10.1182/blood.V98.12.3309
   Fredholm BB, 2001, BIOCHEM PHARMACOL, V61, P443, DOI 10.1016/S0006-2952(00)00570-0
   GREEN TP, 1988, J LAB CLIN MED, V111, P173
   Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003
   HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962
   Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498
   Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003
   Kolachala VL, 2008, GASTROENTEROLOGY, V135, P861, DOI 10.1053/j.gastro.2008.05.049
   Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com
   Lukashev DE, 2003, BIOCHEM PHARMACOL, V65, P2081, DOI 10.1016/S0006-2952(03)00158-8
   MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007
   Martin C, 2000, CRIT CARE MED, V28, P3198, DOI 10.1097/00003246-200009000-00014
   Mirakaj V, 2010, AM J RESP CRIT CARE, V181, P815, DOI 10.1164/rccm.200905-0717OC
   Morote-Garcia JC, 2008, BLOOD, V111, P5571, DOI 10.1182/blood-2007-11-126763
   Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037
   Ngamsri KC, 2010, J IMMUNOL, V185, P4374, DOI 10.4049/jimmunol.1000433
   Olah ME, 1997, J BIOL CHEM, V272, P337
   Olson TS, 2002, AM J PHYSIOL-REG I, V282, pR1245, DOI 10.1152/ajpregu.00540.2001
   PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7
   Quinton LJ, 2005, ALCOHOL CLIN EXP RES, V29, P1198, DOI 10.1097/01.ALC.0000171927.66130.AA
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009
   Reutershan J, 2006, ANESTHESIOLOGY, V104, P511, DOI 10.1097/00000542-200603000-00019
   Reutershan J, 2010, EUR RESPIR J, V35, P1137, DOI 10.1183/09031936.00085509
   Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701
   Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254
   Reutershan J, 2007, AM J RESP CRIT CARE, V175, P1027, DOI 10.1164/rccm.200612-1822OC
   Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Ryzhov S, 2008, J PHARMACOL EXP THER, V324, P694, DOI 10.1124/jpet.107.131540
   Schingnitz U, 2010, J IMMUNOL, V184, P5271, DOI 10.4049/jimmunol.0903035
   Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200
   STAUB NC, 1981, ANNU REV MED, V32, P291, DOI 10.1146/annurev.me.32.020181.001451
   Strieter Robert M., 2005, Current Drug Targets - Inflammation and Allergy, V4, P299, DOI 10.2174/1568010054022178
   Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303
   Wagner R, 2010, AM J PHYSIOL-LUNG C, V299, pL502, DOI 10.1152/ajplung.00083.2010
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933
   Zaynagetdinov R, 2010, AM J RESP CELL MOL, V42, P564, DOI 10.1165/rcmb.2008-0391OC
   Zhou Y, 2009, J IMMUNOL, V182, P8037, DOI 10.4049/jimmunol.0900515
NR 57
TC 33
Z9 35
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD SEP
PY 2012
VL 303
IS 5
BP L425
EP L438
DI 10.1152/ajplung.00387.2011
PG 14
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 001MA
UT WOS:000308463600007
PM 22707616
OA Green Published
DA 2023-08-21
ER

PT J
AU White, LE
   Cui, Y
   Shelak, CMF
   Lie, ML
   Hassoun, HT
AF White, Laura E.
   Cui, Yan
   Shelak, Carolyn M. Feltes
   Lie, Mihaela L.
   Hassoun, Heitham T.
TI LUNG ENDOTHELIAL CELL APOPTOSIS DURING ISCHEMIC ACUTE KIDNEY INJURY
SO SHOCK
LA English
DT Article
DE ischemia/reperfusion; ALI/ARDS; crosstalk; programmed cell death; multiple organ failure 
ID ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; IN-VITRO; BARRIER
   DYSFUNCTION; ORGAN CROSSTALK; CECAL LIGATION; FAS LIGAND; TNF-ALPHA;
   SEPSIS; MICE
AB Kidney ischemia-reperfusion injury (IRI) activates cellular and soluble mediators that drive lung inflammatory cascades, tumor necrosis factor receptor 1 (TNFR1)-mediated programmed cell death, and microvascular barrier dysfunction, leading to acute lung injury. We hypothesized that lung microvascular endothelial cells (ECs), with their integral role in maintaining the lung-semipermeable barrier, were key cellular targets of TNFR1-mediated apoptosis during ischemic AKI. Male C57/BL6 mice and Sprague-Dawley rats underwent 60 min of bilateral renal pedicle occlusion (IRI) or sham laparotomy (sham) and were killed at 4 or 24 h. Colocalization with TUNEL, DAPI, and CD34 was performed to identify EC-specific apoptosis. Mouse ECs (CD45(-)/CD31(+)) isolated with novel tissue digestion techniques and magnetic microbead sorting underwent quantitative real-time polymerase chain reaction Super Array analysis with 84 apoptosis-related genes. In parallel, rat lung microvascular ECs grown to confluence were treated with serum from rats obtained following sham or kidney IRI. Rat lung microvascular ECs treated +/- etanercept, a TNF-alpha/TNFR1 signaling inhibitor, underwent custom real-time polymerase chain reaction analysis for proapoptotic and TNF superfamily transcriptional events, and apoptosis was identified with caspase 3 and poly(ADP-ribose) polymerase activity assays. In vivo, TUNEL-positive cells colocalized with CD34 in whole-lung tissue and isolated lung ECs demonstrated a proapoptotic transcriptome during ischemic AKI. In vitro, ischemic AKI incited proapoptotic (FasL, Dapk1, Bcl10) and TNF superfamily (TNFR1, TNFR2, TNF-alpha) gene activation and increased caspase 3 and poly(ADPribose) polymerase activity at 24 h versus sham. Compared with vehicle, treatment of rat lung microvascular ECs with etanercept inhibited proinflammatory gene activation (E-selectin, intercellular adhesion molecule 1, interleukin 6, RhoB) and apoptosis during ischemic AKI. Ischemic AKI drives distinct proinflammatory and proapoptotic changes in the pulmonary EC transcriptome with TNFR1-dependent caspase activation and programmed cell death. Further investigation of potential EC mechanisms of kidney-lung crosstalk during AKI may identify potential therapeutic targets for this deadly disease.
C1 [White, Laura E.; Cui, Yan; Hassoun, Heitham T.] Methodist Hosp & Res Inst, Dept Surg, Houston, TX, United States.
C1 [Shelak, Carolyn M. Feltes; Lie, Mihaela L.] Johns Hopkins Sch Med, Baltimore, MD, United States.
C1 [Hassoun, Heitham T.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX, United States.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; The
   Methodist Hospital Research Institute; Johns Hopkins University; Johns
   Hopkins Medicine; The Methodist Hospital System; The Methodist Hospital
   - Houston; Methodist DeBakey Heart & Vascular Center
RP Hassoun, HT (corresponding author), Weill Cornell Med Coll, 6550 Fannin St,SM 1401, Houston, TX 77030 USA.
EM hhassoun@tmhs.org
FU NIH/NHLBI [K08HL089181]; American Vascular Association/American College
   of Surgeons Lifeline Award
FX This study was supported by grants from the NIH/NHLBI K08HL089181 and
   the American Vascular Association/American College of Surgeons Lifeline
   Award.
CR Barry M., 2007, BRENNER RECTORS KIDN
   Bertok S, 2011, AM J PHYSIOL-LUNG C, V300, pL781, DOI 10.1152/ajplung.00326.2010
   Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   Ebach DR, 2005, SHOCK, V23, P311, DOI 10.1097/01.shk.0000157301.87051.77
   Feltes CM, 2011, SHOCK, V36, P170, DOI 10.1097/SHK.0b013e3182169c76
   Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011
   Grattendick KJ, 2008, INT IMMUNOPHARMACOL, V8, P679, DOI 10.1016/j.intimp.2008.01.013
   Hassoun HT, 2007, AM J PHYSIOL-RENAL, V293, pF30, DOI 10.1152/ajprenal.00023.2007
   Hassoun HT, 2009, AM J PHYSIOL-RENAL, V297, pF125, DOI 10.1152/ajprenal.90666.2008
   Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002
   Hoste EAJ, 2003, J AM SOC NEPHROL, V14, P1022, DOI 10.1097/01.ASN.0000059863.48590.E9
   Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915
   Kelly KJ, 2003, J AM SOC NEPHROL, V14, P1549, DOI 10.1097/01.ASN.0000064946.94590.46
   Ko GJ, 2009, BLOOD PURIFICAT, V28, P75, DOI 10.1159/000218087
   Koyner JL, 2010, BLOOD PURIFICAT, V29, P52, DOI 10.1159/000259585
   Kramer AA, 1999, KIDNEY INT, V55, P2362, DOI 10.1046/j.1523-1755.1999.00460.x
   Li X, 2009, CURR OPIN CRIT CARE, V15, P481, DOI 10.1097/MCC.0b013e328332f69e
   Lim YC, 2006, METH MOL B, V341, P141
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mahabeleshwar Ganapati H., 2006, V129, P197
   Matute-Bello G, 1999, J IMMUNOL, V163, P2217
   MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081
   Mehta RL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014692.19351.52
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   Rabb H, 2003, KIDNEY INT, V63, P600, DOI 10.1046/j.1523-1755.2003.00753.x
   Rafi AQ, 1998, J IMMUNOL, V161, P3077
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813
   van Meurs M, 2008, SHOCK, V29, P291, DOI 10.1097/shk.0b013e318145a7c1
   Wajant H, 2011, FEBS J, V278, P861, DOI 10.1111/j.1742-4658.2011.08014.x
   White LE, 2011, J SURG RES, V167, P306, DOI 10.1016/j.jss.2010.11.923
   White LE, 2011, J AM COLL SURGEONS, V213, pS62
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Wilson MR, 2007, AM J PHYSIOL-LUNG C, V293, pL60, DOI 10.1152/ajplung.00284.2006
NR 35
TC 39
Z9 43
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD SEP
PY 2012
VL 38
IS 3
BP 320
EP 327
DI 10.1097/SHK.0b013e31826359d0
PG 8
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 990KC
UT WOS:000307628400014
PM 22777112
DA 2023-08-21
ER

PT J
AU Chen, WG
   Sammani, S
   Mitra, S
   Ma, SF
   Garcia, JGN
   Jacobson, JR
AF Chen, Weiguo
   Sammani, Saad
   Mitra, Sumegha
   Ma, Shwu Fan
   Garcia, Joe G. N.
   Jacobson, Jeffrey R.
TI Critical role for integrin-beta 4 in the attenuation of murine acute
   lung injury by simvastatin
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE statins; integrins; ECs/HPMECs/HUVECs/MPVECs 
ID STATIN THERAPY; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; BETA-4;
   ALPHA-6-BETA-4; INFLAMMATION; SEPSIS; ALPHA-V-BETA-5; DYSFUNCTION;
   INHIBITION
AB Chen W, Sammani S, Mitra S, Ma SF, Garcia JGN, Jacobson JR. Critical role for integrin-beta 4 in the attenuation of murine acute lung injury by simvastatin. Am J Physiol Lung Cell Mol Physiol 303: L279-L285, 2012. First published June 8, 2012; doi:10.1152/ajplung.00361.2011.-The statins are a class of 3-hydroxy-3-methylglutaryl-coenzyme A-reductase inhibitors that are recognized to have pleiotropic properties. We previously reported the attenuation of LPS-induced murine acute lung injury (ALI) by simvastatin in vivo and identified relevant effects of simvastatin on endothelial cell (EC) signaling, activation, and barrier function in vitro. In particular, simvastatin induces the upregulation of integrin-beta 4, which in turn inhibits EC inflammatory responses via attenuation of MAPK signaling. The role of integrin-beta 4 in murine ALI protection by simvastatin, however, is unknown. We initially confirmed a time-and dose-dependent effect of simvastatin on increased integrin-beta 4 mRNA expression in human lung EC with peak protein expression evident at 16 h. Subsequently, reciprocal immunoprecipitation demonstrated an attenuation of LPS-induced integrin-beta 4 tyrosine phosphorylation by simvastatin (5 mu M, 16 h). Increased expression of EC inflammatory cytokines [IL-6, IL-8, monocyte chemoattractant protein (MCP)-1, regulated on activation normal T cell expressed and secreted (RANTES)] by LPS (500 ng/ml, 4 h) was also significantly attenuated by simvastatin pretreatment (5 mu M, 16 h), but this effect was reversed by cotreatment with an integrin-beta 4-blocking antibody. Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1 beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta 4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). These findings support integrin-beta 4 as an important mediator of ALI protection by simvastatin and implicate signaling by integrin-beta 4 as a novel therapeutic target in patients with ALI.
C1 [Chen, Weiguo; Sammani, Saad; Mitra, Sumegha; Garcia, Joe G. N.; Jacobson, Jeffrey R.] Univ Illinois, Inst Personalized Resp Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL 60612, United States.
C1 [Ma, Shwu Fan] Univ Chicago, Sect Pulm & Crit Care, Chicago, IL 60637, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Chicago
RP Jacobson, JR (corresponding author), Univ Illinois, Inst Personalized Resp Med, Sect Pulm Crit Care Sleep & Allergy, 840 S Wood St,920-N CSB, Chicago, IL 60612 USA.
EM jrjacob@uic.edu
RI Garcia, Joe GN/E-8862-2010
OI Mitra, Sumegha/0000-0002-5567-3347
FU NHLBI [HL 77134, HL 58064]
FX This work was supported by the NHLBI (HL 77134, HL 58064).
CR Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1
   Bellia A, ATHEROSCLER IN PRESS, V210, P199
   Chen WG, 2008, AM J PHYSIOL-LUNG C, V295, pL575, DOI 10.1152/ajplung.00428.2007
   Chen WG, 2010, J CELL BIOCHEM, V110, P718, DOI 10.1002/jcb.22582
   Craig TR, AM J RESP CRIT CARE, V183, P620
   Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200
   Falagas ME, 2008, J ANTIMICROB CHEMOTH, V61, P774, DOI 10.1093/jac/dkn019
   Feng C, 2004, BIOCHEM BIOPH RES CO, V323, P858, DOI 10.1016/j.bbrc.2004.08.171
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Grossman HB, 2000, ONCOL REP, V7, P13
   HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC
   Kitajiri S, 2002, PATHOL INT, V52, P438, DOI 10.1046/j.1440-1827.2002.01379.x
   Kruger P, 2006, INTENS CARE MED, V32, P75, DOI 10.1007/s00134-005-2859-y
   Morikawa Shigeru, 2004, J Atheroscler Thromb, V11, P62
   Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209
   Naidu BV, 2003, J THORAC CARDIOV SUR, V126, P482, DOI 10.1016/S0022-5223(03)00699-8
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Schmidt H, 2006, INTENS CARE MED, V32, P1248, DOI 10.1007/s00134-006-0246-y
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Su G, 2007, AM J RESP CELL MOL, V36, P377, DOI 10.1165/rcmb.2006-0238OC
   Suda K, 2011, J APPL PHYSIOL, V111, P1118, DOI 10.1152/japplphysiol.00158.2011
   Tagliabue E, 1998, CLIN CANCER RES, V4, P407
   Turner NA, 2007, J CARDIOVASC PHARM, V50, P458, DOI 10.1097/FJC.0b013e318123767f
   VANWAES C, 1991, CANCER RES, V51, P2395
   Wu X, EUR J PHARM, V636, P114
   Xu JS, 2008, NAT IMMUNOL, V9, P880, DOI 10.1038/ni.1628
   Zhang LQ, 2008, GENE EXPRESSION, V14, P229, DOI 10.3727/105221608786883834
NR 29
TC 25
Z9 26
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG
PY 2012
VL 303
IS 4
BP L279
EP L285
DI 10.1152/ajplung.00361.2011
PG 7
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 995KJ
UT WOS:000308006600001
PM 22683568
OA Green Published
DA 2023-08-21
ER

PT J
AU Qiu, Z
   Hu, JL
   Van den Steen, PE
   Opdenakker, G
AF Qiu, Zheng
   Hu, Jialiang
   Van den Steen, Philippe E.
   Opdenakker, Ghislain
TI Targeting Matrix Metalloproteinases in Acute Inflammatory Shock
   Syndromes
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article
DE Inflammation; LPS; MMP/MMP3/MMP9; neutrophil; sepsis 
ID TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; CHEMICALLY-MODIFIED
   TETRACYCLINES; BLOOD-BRAIN-BARRIER; ACUTE LUNG INJURY; DISSEMINATED
   INTRAVASCULAR COAGULATION; NEUTROPHIL ELASTASE INHIBITOR;
   CONVERTING-ENZYME-INHIBITOR; GELATINASE B/MATRIX METALLOPROTEINASE-9;
   HEPATIC MICROVASCULAR DYSFUNCTION
AB The integrity of the vascular wall and its intrinsic basement membrane structures ensure that plasma and the corpuscular elements of the blood remain confined to the intravascular milieu and can enter into the extravascular compartment in a well controlled fashion in cases of tissue infection or inflammation. However, sometimes inflammatory stimuli act on blood leukocytes and on endothelial cells from within the blood vessels and in an overwhelming way, leading to inflammatory shock syndromes. These severe conditions with high mortality rates are characterized by intravascular neutrophil degranulation, permeability changes of endothelia and disintegration of basement membranes and lead to almost uncontrollable edema, coagulation changes and multi-organ failure. Matrix metalloproteinases (MMPs) have been functionally linked with septic and endotoxin shock, with cytokine release syndromes and with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Here we review a number of association studies, compare inflammatory shock data from gene knockout studies in mice and provide some insights from recent investigations with inhibitors of MMPs. This evaluation strengthens the expectation that MMP inhibitors, in particular those blocking neutrophil proteases, may become useful in the early phase of acute inflammatory shock syndromes.
C1 [Van den Steen, Philippe E.; Opdenakker, Ghislain] Univ Louvain, Rega Inst Med Res, Immunobiol Lab, B-3000 Louvain, Belgium.
C1 [Qiu, Zheng; Hu, Jialiang] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, China.
C3 KU Leuven; China Pharmaceutical University
RP Opdenakker, G (corresponding author), Univ Louvain, Rega Inst Med Res, Immunobiol Lab, Minderbroedersstr 10, B-3000 Louvain, Belgium.
EM ghislain.opdenakker@rega.kuleuven.be
RI Van den Steen, Philippe E/K-5132-2012; Opdenakker, Ghislain/V-8562-2019;
   Opdenakker, Ghislain/Q-3130-2017
OI Van den Steen, Philippe E/0000-0002-7334-9145; Opdenakker,
   Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294
FU Geconcerteerde OnderzoeksActies [GOA2007/015, GOA2012/017]; Fund for
   Scientific Research of Flanders (FWO-Vlaanderen) in Leuven, Belgium;
   Fundamental Research Funds for the Central Universities [JKQ2011041,
   JKQ2011049]; National Science and Technology Major Projects of New Drugs
   in China [2012ZX09103301-004]
FX The present study was supported by the "Geconcerteerde OnderzoeksActies"
   GOA2007/015 and GOA2012/017, the Fund for Scientific Research of
   Flanders (FWO-Vlaanderen) in Leuven, Belgium, the Fundamental Research
   Funds for the Central Universities JKQ2011041 and JKQ2011049 and the
   National Science and Technology Major Projects of New Drugs
   2012ZX09103301-004 in China. PVdS holds a BOF-ZAP research professorship
   of the KU Leuven.
CR Acharya MR, 2004, DRUG RESIST UPDATE, V7, P195, DOI 10.1016/j.drup.2004.04.002
   Albaiceta GM, 2008, AM J PHYSIOL-LUNG C, V294, pL535, DOI 10.1152/ajplung.00334.2007
   Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007
   Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z
   Bjorklund M, 2003, COMB CHEM HIGH T SCR, V6, P29
   Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n
   Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133
   CASTELHANO AL, 1995, BIOORG MED CHEM LETT, V5, P1415, DOI 10.1016/0960-894X(95)00233-J
   Cauwe B, 2007, CRIT REV BIOCHEM MOL, V42, P113, DOI 10.1080/10409230701340019
   Cauwe B, 2010, CRIT REV BIOCHEM MOL, V45, P351, DOI 10.3109/10409238.2010.501783
   Cena J, 2008, EUR J PHARMACOL, V582, P116, DOI 10.1016/j.ejphar.2007.12.019
   Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x
   Chong DLW, 2011, CONTRIB MICROBIOL, V17, P86, DOI 10.1159/000324022
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Crocker SJ, 2008, GLIA, V56, P1187, DOI 10.1002/glia.20689
   Dankesreiter S, 2000, J IMMUNOL, V164, P4804, DOI 10.4049/jimmunol.164.9.4804
   Deaciuc IV, 2001, ALCOHOL CLIN EXP RES, V25, P935
   Dejonckheere E, 2011, DRUG DISCOV TODAY, V16, P762, DOI 10.1016/j.drudis.2011.06.009
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ferry G, 1997, MOL DIVERS, V2, P135, DOI 10.1007/BF01682201
   FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243
   Fligiel SEG, 2006, HUM PATHOL, V37, P422, DOI 10.1016/j.humpath.2005.11.023
   Giebler R, 1999, CRIT CARE MED, V27, P597, DOI 10.1097/00003246-199903000-00042
   GOMEZ C, 1992, Sangre (Saragossa), V37, P5
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   Grobmyer SR, 1999, MOL MED, V5, P585, DOI 10.1007/BF03402071
   Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006
   Hadler-Olsen E, 2011, FEBS J, V278, P28, DOI 10.1111/j.1742-4658.2010.07920.x
   Hagiwara S, 2009, INFLAMM RES, V58, P198, DOI 10.1007/s00011-008-8131-5
   Hagiwara S, 2008, INFLAMMATION, V31, P227, DOI 10.1007/s10753-008-9069-z
   Halter JM, 2006, SHOCK, V26, P587, DOI 10.1097/01.shk.0000245019.63246.31
   HOFFMANN H, 1990, AM REV RESPIR DIS, V142, P782, DOI 10.1164/ajrccm/142.4.782
   Hoffmann U, 2009, CRIT CARE, V13, DOI 10.1186/cc8156
   Hu JL, 2007, NAT REV DRUG DISCOV, V6, P480, DOI 10.1038/nrd2308
   Hu JL, 2006, COMB CHEM HIGH T SCR, V9, P599, DOI 10.2174/138620706778249758
   Hu JL, 2005, BIOCHEM PHARMACOL, V70, P535, DOI 10.1016/j.bcp.2005.04.047
   Hu JL, 2005, ANAL CHEM, V77, P2116, DOI 10.1021/ac048631p
   Hu JL, 2004, BIOCHEM PHARMACOL, V67, P1001, DOI 10.1016/j.bcp.2003.10.030
   Ikejiri M, 2005, J ORG CHEM, V70, P5709, DOI 10.1021/jo050339+
   Inoue KI, 2005, EXP BIOL MED, V230, P281
   Ishii K, 2002, SHOCK, V18, P163, DOI 10.1097/00024382-200208000-00013
   Jiang WL, 2009, SHOCK, V32, P608, DOI 10.1097/SHK.0b013e3181a48e86
   Jourdain M, 1997, AM J RESP CRIT CARE, V156, P1825, DOI 10.1164/ajrccm.156.6.9611100
   Jourdain M, 1997, CRIT CARE MED, V25, P452, DOI 10.1097/00003246-199703000-00014
   Jung WK, 2008, INT J BIOCHEM CELL B, V40, P2572, DOI 10.1016/j.biocel.2008.05.005
   Kim JH, 2004, AM J PHYSIOL-LUNG C, V287, pL127, DOI 10.1152/ajplung.00047.2003
   Klawitter M, 2011, J NEGAT RESULTS BIOM, V10, DOI 10.1186/1477-5751-10-9
   Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200
   KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6
   Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703
   Kolaczkowska E, 2009, IMMUNOL LETT, V126, P73, DOI 10.1016/j.imlet.2009.08.002
   KORBUT R, 1994, BRIT J PHARMACOL, V112, P289, DOI 10.1111/j.1476-5381.1994.tb13066.x
   Kruger A, 2010, BBA-MOL CELL RES, V1803, P95, DOI 10.1016/j.bbamcr.2009.09.016
   Lalu MM, 2003, MOL CELL BIOCHEM, V251, P61, DOI 10.1023/A:1025417529167
   Lee MH, 2005, J BIOL CHEM, V280, P15967, DOI 10.1074/jbc.M500897200
   Lin M, 2008, AM J PATHOL, V173, P144, DOI 10.2353/ajpath.2008.080081
   Locati M, 2002, J IMMUNOL, V168, P3557, DOI 10.4049/jimmunol.168.7.3557
   Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   Lorente L, 2009, CRIT CARE, V13, DOI 10.1186/cc8115
   Lukkonen A, 2000, INT J CANCER, V86, P577, DOI 10.1002/(SICI)1097-0215(20000515)86:4<577::AID-IJC21>3.3.CO;2-A
   Maitra SR, 2003, SHOCK, V20, P280, DOI 10.1097/00024382-200309000-00014
   Malik M, 2007, J IMMUNOL, V178, P1013, DOI 10.4049/jimmunol.178.2.1013
   MASURE S, 1990, BIOCHIM BIOPHYS ACTA, V1054, P317, DOI 10.1016/0167-4889(90)90103-K
   MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x
   Matsumoto Y, 2002, SHOCK, V17, P411, DOI 10.1097/00024382-200205000-00012
   Matsuzaki H, 2004, CLIN DIAGN LAB IMMUN, V11, P1140, DOI 10.1128/CDLI.11.6.1140-1147.2004
   Milano S, 1997, ANTIMICROB AGENTS CH, V41, P117, DOI 10.1128/AAC.41.1.117
   Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667
   Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203
   MURPHY G, 1995, METHOD ENZYMOL, V248, P496
   MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120
   Noman Abu Shadat M, 2009, Innate Immun, V15, P33, DOI 10.1177/1753425908099317
   Noman ASM, 2009, FEMS IMMUNOL MED MIC, V56, P204, DOI 10.1111/j.1574-695X.2009.00567.x
   Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975
   Opdenakker G, 2003, TRENDS IMMUNOL, V24, P94, DOI 10.1016/S1471-4906(02)00037-6
   Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851
   Overall CM, 2006, CANCER METAST REV, V25, P69, DOI 10.1007/s10555-006-7890-0
   Paemen L, 1995, EUR J BIOCHEM, V234, P759, DOI 10.1111/j.1432-1033.1995.759_a.x
   Paemen L, 1996, BIOCHEM PHARMACOL, V52, P105, DOI 10.1016/0006-2952(96)00168-2
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Pfefferkorn T, 2003, STROKE, V34, P2025, DOI 10.1161/01.STR.0000083051.93319.28
   Pham D, 2000, J CARDIOVASC PHARM, V36, pS362
   Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514
   Pu Q, 2001, CRIT CARE MED, V29, P1181, DOI 10.1097/00003246-200106000-00019
   Qiu Z., 2011, J ENZYME IN IN PRESS
   Quintero PA, 2010, J IMMUNOL, V184, P1575, DOI 10.4049/jimmunol.0900290
   Ramamurthy NS, 2002, J PERIODONTOL, V73, P726, DOI 10.1902/jop.2002.73.7.726
   RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349
   Reel B, 2011, BRIT J PHARMACOL, V163, P1679, DOI 10.1111/j.1476-5381.2011.01298.x
   Reis J, 2008, INNATE IMMUN, V14, P319, DOI 10.1177/1753425908096855
   Renckens R, 2006, J IMMUNOL, V176, P3735, DOI 10.4049/jimmunol.176.6.3735
   Rikimaru A, 2007, GENES CELLS, V12, P1091, DOI 10.1111/j.1365-2443.2007.01110.x
   ROBERTSON FM, 1994, ARCH SURG-CHICAGO, V129, P149
   Rosenberg GA, 2007, BRAIN RES, V1133, P186, DOI 10.1016/j.brainres.2006.11.041
   Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180
   Russell JA, 2011, CONTRIB MICROBIOL, V17, P48, DOI 10.1159/000324009
   Sato H, 1996, J BIOCHEM-TOKYO, V119, P209
   SATO K, 1995, INFECT IMMUN, V63, P2859, DOI 10.1128/IAI.63.8.2859-2866.1995
   Scherer Ralf U., 1996, Seminars in Thrombosis and Hemostasis, V22, P357, DOI 10.1055/s-2007-999032
   Sen AI, 2010, EXP LUNG RES, V36, P615, DOI 10.3109/01902148.2010.497201
   Senft AP, 2005, J IMMUNOL, V174, P4953, DOI 10.4049/jimmunol.174.8.4953
   Shapira L, 1996, INFECT IMMUN, V64, P825, DOI 10.1128/IAI.64.3.825-828.1996
   Shimanovich I, 2004, J PATHOL, V204, P519, DOI 10.1002/path.1674
   Shubin NJ, 2011, CONTRIB MICROBIOL, V17, P108, DOI 10.1159/000324024
   SIEBECK M, 1992, CIRC SHOCK, V36, P174
   Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007
   Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852
   Stach K, 2011, CARDIOLOGY, V118, P107, DOI 10.1159/000327547
   Steinberg J, 2005, SHOCK, V24, P348, DOI 10.1097/01.shk.0000180619.06317.2c
   Steinberg J, 2003, J SURG RES, V111, P185, DOI 10.1016/S0022-4804(03)00089-1
   StPierre Y, 1996, CYTOMETRY, V25, P374, DOI 10.1002/(SICI)1097-0320(19961201)25:4<374::AID-CYTO9>3.0.CO;2-D
   Sugiyama T, 2004, MICROBIOL IMMUNOL, V48, P957, DOI 10.1111/j.1348-0421.2004.tb03625.x
   Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312
   Tilahun AY, 2010, MOL THER, V18, P1143, DOI 10.1038/mt.2010.53
   Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145
   Tsuji F, 2002, CYTOKINE, V17, P294, DOI 10.1006/cyto.2002.1015
   Tumurkhuu G, 2011, INNATE IMMUN-LONDON, V17, P97, DOI 10.1177/1753425909353641
   Ueki M, 2007, J BIOSCI BIOENG, V104, P315, DOI 10.1263/jbb.104.315
   Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546
   van der Poll T, 2011, CONTRIB MICROBIOL, V17, P125, DOI 10.1159/000324026
   Van Lint P, 2007, J LEUKOCYTE BIOL, V82, P1375, DOI 10.1189/jlb.0607338
   Wakahara K, 2005, J INFECT DIS, V191, P930, DOI 10.1086/428134
   Weitzberg E, 1996, BRIT J PHARMACOL, V118, P617, DOI 10.1111/j.1476-5381.1996.tb15446.x
   Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543
   Wiel E, 2004, INTENS CARE MED, V30, P1652, DOI 10.1007/s00134-004-2198-4
   Wielockx B, 2001, NAT MED, V7, P1202, DOI 10.1038/nm1101-1202
   Wohlschlaeger J, 2005, PATHOL RES PRACT, V201, P809, DOI 10.1016/j.prp.2005.08.009
   WU CC, 1995, BRIT J PHARMACOL, V114, P1666, DOI 10.1111/j.1476-5381.1995.tb14955.x
   Yamazaki M, 1999, BLOOD COAGUL FIBRIN, V10, P321, DOI 10.1097/00001721-199909000-00002
   YAMAZAKI M, 1994, THROMB HAEMOSTASIS, V72, P393
   Yin CS, 2005, TOXICON, V45, P81, DOI 10.1016/j.toxicon.2004.09.017
   Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807
   Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571
   Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496
   Yuksel M, 2003, J PHARMACOL EXP THER, V305, P298, DOI 10.1124/jpet.102.041988
   Zhou NM, 1997, FEBS LETT, V414, P562, DOI 10.1016/S0014-5793(97)01072-7
   Zhou R, 2006, J PHARMACOL EXP THER, V316, P121, DOI 10.1124/jpet.105.093179
NR 137
TC 18
Z9 19
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386-2073
EI 1875-5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PD AUG
PY 2012
VL 15
IS 7
BP 555
EP 570
DI 10.2174/138620712801619159
PG 16
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA 975FC
UT WOS:000306491800006
PM 22537195
DA 2023-08-21
ER

PT J
AU Wilhelmsen, K
   Mesa, KR
   Prakash, A
   Xu, FY
   Hellman, J
AF Wilhelmsen, Kevin
   Mesa, Kailin R.
   Prakash, Arun
   Xu, Fengyun
   Hellman, Judith
TI Activation of endothelial TLR2 by bacterial lipoprotein upregulates
   proteins specific for the neutrophil response
SO INNATE IMMUNITY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; Inflammation; lipoprotein; neutrophil; TLR/TLR2/TLR4 
ID COLONY-STIMULATING FACTOR; TOLL-LIKE RECEPTOR-2;
   PEPTIDOGLYCAN-ASSOCIATED LIPOPROTEIN; GENE-EXPRESSION DATA; NF-KAPPA-B;
   GRANULOCYTE-COLONY; IN-VIVO; TRANSENDOTHELIAL MIGRATION; STERILE
   INFLAMMATION; ADHESION MOLECULE-1
AB The vascular endothelium is integrally involved in the host response to infection and in organ failure during acute inflammatory disorders such as sepsis. Gram-negative and Gram-positive bacterial lipoproteins circulate in sepsis and can directly activate the endothelium by binding to endothelial cell (EC) TLR2. In this report, we perform the most comprehensive analysis to date of the immune-related genes regulated after activation of endothelial TLR2 by bacterial di- and triacylated lipopeptides. We found that TLR2 activation specifically induces the expression of the genes IL-6, IL-8, CSF2, CSF3, ICAM1 and SELE by human umbilical vein ECs and human lung microvascular ECs. These proteins participate in neutrophil recruitment, adherence and activation at sites of inflammation. Significantly, our studies demonstrate that TLR2-mediated EC responses are specifically geared towards recruitment, activation, and survival of neutrophils and not mononuclear leukocytes, that ECs do not require priming by other inflammatory stimuli to respond to bacterial lipopeptides and, unlike mononuclear leukocytes, TLR2 agonists do not induce ECs to secrete TNF-alpha. This study suggests that endothelial TLR2 may be an important regulator of neutrophil trafficking to sites of infection in general, and that direct activation of lung endothelial TLR2 may contribute to acute lung injury during sepsis.
C1 [Hellman, Judith] Univ Calif San Francisco, Div Crit Care Med, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143, United States.
C3 University of California System; University of California San Francisco
RP Hellman, J (corresponding author), Univ Calif San Francisco, Div Crit Care Med, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.
EM hellmanj@anesthesia.ucsf.edu
OI Mesa, Kailin/0000-0003-4452-9048
FU NIH [NIAID] [R01AI058106]; UCSF Department of Anesthesia and
   Perioperative Care
FX This work was supported by a grant from the NIH [NIAID
   R01AI058106/Hellman] and the UCSF Department of Anesthesia and
   Perioperative Care.
CR Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Akbarzadeh S, 2001, VITAM HORM, V63, P159, DOI 10.1016/S0083-6729(01)63006-1
   Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z
   Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010
   BOBER LA, 1995, INT J IMMUNOPHARMACO, V17, P385, DOI 10.1016/0192-0561(95)00025-W
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   BROUDY VC, 1987, J IMMUNOL, V139, P464
   BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0
   Chan JR, 2001, J EXP MED, V193, P1149, DOI 10.1084/jem.193.10.1149
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214
   Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668
   DEMETRI GD, 1991, BLOOD, V78, P2791
   DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696
   Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018
   Gillrie MR, 2010, EUR J IMMUNOL, V40, P1639, DOI 10.1002/eji.200939929
   Grote K, 2010, BLOOD, V115, P2543, DOI 10.1182/blood-2009-05-224402
   GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Hellman J, 2002, J BIOL CHEM, V277, P14274, DOI 10.1074/jbc.M109696200
   Hickey MJ, 2009, NAT REV IMMUNOL, V9, P364, DOI 10.1038/nri2532
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0
   Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
   Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241
   Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463
   Kang JY, 2011, ANNU REV BIOCHEM, V80, P917, DOI 10.1146/annurev-biochem-052909-141507
   Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018
   Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3
   Kumar V, 2010, INT IMMUNOPHARMACOL, V10, P1325, DOI 10.1016/j.intimp.2010.08.012
   Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Li YH, 2009, AM J PHYSIOL-REG I, V297, pR1670, DOI 10.1152/ajpregu.00445.2009
   Liang MD, 2005, J INFECT DIS, V191, P939, DOI 10.1086/427815
   Lin Q, 2011, INT IMMUNOPHARMACOL, V11, P1422, DOI 10.1016/j.intimp.2011.04.026
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   McLoughlin RM, 2003, J CLIN INVEST, V112, P598, DOI 10.1172/JCI200317129
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5
   Muller WA, 2011, ANNU REV PATHOL-MECH, V6, P323, DOI 10.1146/annurev-pathol-011110-130224
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007
   Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004
   Petersen B, 2008, AM J PHYSIOL-LUNG C, V294, pL300, DOI 10.1152/ajplung.00243.2007
   Remer KA, 2006, J IMMUNOL METHODS, V313, P1, DOI 10.1016/j.jim.2005.07.026
   Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
   ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A
   Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720
   Satta N, 2008, MOL IMMUNOL, V46, P145, DOI 10.1016/j.molimm.2008.07.017
   Schmidt RR, 2011, ORG BIOMOL CHEM, V9, P2040, DOI 10.1039/c0ob00794c
   Shin HS, 2011, J IMMUNOL, V186, P1119, DOI 10.4049/jimmunol.1001647
   Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x
   Simon SI, 2000, J IMMUNOL, V164, P4348, DOI 10.4049/jimmunol.164.8.4348
   SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111
   Soehnlein O, 2009, BLOOD, V114, P4613, DOI 10.1182/blood-2009-06-221630
   Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V
   Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Talreja J, 2004, IMMUNOLOGY, V113, P224, DOI 10.1111/j.1365-2567.2004.01946.x
   WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0
   Willems E, 2008, ANAL BIOCHEM, V379, P127, DOI 10.1016/j.ab.2008.04.036
   Zahringer U, 2008, IMMUNOBIOLOGY, V213, P205, DOI 10.1016/j.imbio.2008.02.005
   Zarbock A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502
NR 67
TC 46
Z9 51
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-4259
J9 INNATE IMMUN-LONDON
JI Innate Immun.
PD AUG
PY 2012
VL 18
IS 4
BP 602
EP 616
DI 10.1177/1753425911429336
PG 15
WC Biochemistry & Molecular Biology; Immunology; Medicine, Research &
   Experimental; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology; Research & Experimental
   Medicine; Microbiology
GA 974HQ
UT WOS:000306424200005
PM 22186927
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Anjum, F
   Joshi, K
   Grinkina, N
   Gowda, S
   Cutaia, M
   Wadgaonkar, R
AF Anjum, Fatima
   Joshi, Keval
   Grinkina, Natalia
   Gowda, Satish
   Cutaia, Michael
   Wadgaonkar, Raj
TI Role of Sphingomyelin Synthesis in Pulmonary Endothelial Cell
   Cytoskeletal Activation and Endotoxin-Induced Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE sphingomyelin synthase; endothelial barrier dysfunction; cytoskeletal rearrangement 
ID NF-KAPPA-B; PHOSPHOLIPASE-C; SPHINGOSINE 1-PHOSPHATE; BARRIER FUNCTION;
   ADHESION MOLECULE-1; GENE-EXPRESSION; LIPID RAFTS; SYNTHASE; D609;
   DIACYLGLYCEROL
AB Sphingomyelin (SM), a major sphingolipid in the lipid raft microdomains of the cell membrane, is synthesized by plasma membrane-bound sphingomyelin synthase 2 (SMS2). SMS2 is required for the maintenance of plasma membrane microdomain fluidity and receptor-mediated responses to inflammation in macrophages. However, the exact mechanism of SMS2 activation in endothelial barrier disruption and lung injury is not fully understood. To define the role of SMS activation in lung injury, we hypothesized that the inhibition of SM synthesis may provide protection against acute lung injury (ALI) by preserving endothelial barrier function. Using SMS2-silencing RNA (siRNA) treatment in human pulmonary endothelial cells (HPAECs) and tricyclodecan-9-yl-xanthogenate (D609), a competitive inhibitor of SMS, and phosphatidylcholine-specific phospholipase C in a murine model of bacterial LPS injury, we studied the role of sphingomyelin synthesis in ALI. Results show that pretreating mice with D609 significantly attenuated LPS-induced lung injury, as measured by a significant decrease in wet to dry ratio, bronchoalveolar lavage fluid cell and protein counts, and myeloperoxidase activity in lung tissue. Similarly, LPS-induced endothelial barrier disruption was significantly reduced in HPAECs pretreated with D609 or SMS2 siRNA, as demonstrated by an increase in paracellular integrity on an FITC-dextran assay, by the inhibition of LPS-induced stress fibers, and by the formation of cortical actin rings and lamellipodia at the periphery. These results indicate that D609 attenuates LPS-mediated endothelial barrier dysfunction and lung injury in mice through inhibition of SMS, suggesting a novel and essential role of SMS inhibition in modulating endothelial barrier integrity via actin cytoskeletal activation, with a potential therapeutic role in ALI.
C1 [Cutaia, Michael; Wadgaonkar, Raj] Vet Adm Med Ctr, Mol Med Lab, Brooklyn, NY 11203, United States.
C1 [Anjum, Fatima; Joshi, Keval; Grinkina, Natalia; Gowda, Satish; Wadgaonkar, Raj] Suny Downstate Med Ctr, Dept Pulm & Crit Care Med, Brooklyn, NY 11203, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   State University of New York (SUNY) System; State University of New York
   (SUNY) Downstate Medical Center
RP Wadgaonkar, R (corresponding author), Vet Adm Med Ctr, Mol Med Lab, Brooklyn, NY 11203 USA.
EM raj.wadgaonkar@downstate.edu
FU Veterans Administration Merit Grant; New York State ECRIP Grant
FX This work was supported by a Veterans Administration Merit Grant (R.W.)
   and a New York State ECRIP Grant (R.W.).
CR Adibhatla RM, 2010, MOL NEUROBIOL, V41, P206, DOI 10.1007/s12035-010-8100-1
   Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287
   Bannerman DD, 1999, LAB INVEST, V79, P1181
   Bannerman DD, 1997, AM J PHYSIOL-LUNG C, V273, pL217, DOI 10.1152/ajplung.1997.273.1.L217
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Chiang ET, 2009, MICROVASC RES, V77, P174, DOI 10.1016/j.mvr.2008.11.007
   Cobb RR, 1996, MOL PHARMACOL, V49, P998
   Cuschieri Joseph, 2007, Surg Infect (Larchmt), V8, P91, DOI 10.1089/sur.2006.050
   Ding T, 2008, J LIPID RES, V49, P376, DOI 10.1194/jlr.M700401-JLR200
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025
   Gowda S, 2011, AM J PHYSIOL-LUNG C, V300, pL430, DOI 10.1152/ajplung.00208.2010
   Hailemariam TK, 2008, ARTERIOSCL THROM VAS, V28, P1519, DOI 10.1161/ATVBAHA.108.168682
   Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034
   Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC
   Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X
   Li F, 2006, J CELL BIOCHEM, V98, P1615, DOI 10.1002/jcb.20806
   Li ZQ, 2007, BBA-MOL CELL BIOL L, V1771, P1186, DOI 10.1016/j.bbalip.2007.05.007
   Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com
   Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550
   Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760
   Machleidt T, 1996, J EXP MED, V184, P725, DOI 10.1084/jem.184.2.725
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Meng AM, 2004, EXP CELL RES, V292, P385, DOI 10.1016/j.yexcr.2003.10.001
   Monick MM, 1999, J IMMUNOL, V162, P3005
   Parker JC, 2000, J APPL PHYSIOL, V89, P2241, DOI 10.1152/jappl.2000.89.6.2241
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Sultana R, 2006, J NEUROSCI RES, V84, P409, DOI 10.1002/jnr.20876
   Szczepaniak WS, 2008, TRANSL RES, V152, P213, DOI 10.1016/j.trsl.2008.09.002
   Tafesse FG, 2007, J BIOL CHEM, V282, P17537, DOI 10.1074/jbc.M702423200
   Tafesse FG, 2006, J BIOL CHEM, V281, P29421, DOI 10.1074/jbc.R600021200
   Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259
   Triantafilou M, 2002, J CELL SCI, V115, P2603
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wadgaonkar R, 2009, AM J PHYSIOL-LUNG C, V296, pL603, DOI 10.1152/ajplung.90357.2008
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WEBER C, 1995, ARTERIOSCL THROM VAS, V15, P622, DOI 10.1161/01.ATV.15.5.622
   Yang Y, 2010, EUR RESPIR J, V36, P417, DOI 10.1183/09031936.00095609
   Zhang FH, 2001, INT IMMUNOPHARMACOL, V1, P1375, DOI 10.1016/S1567-5769(01)00069-8
   Zhou DH, 2001, J PHARMACOL EXP THER, V298, P103
NR 44
TC 17
Z9 19
U1 0
U2 8
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUL
PY 2012
VL 47
IS 1
BP 94
EP 103
DI 10.1165/rcmb.2010-0458OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 986SO
UT WOS:000307365100012
PM 22362386
DA 2023-08-21
ER

PT J
AU Bhattacharya, M
   Su, G
   Su, X
   Oses-Prieto, JA
   Li, JT
   Huang, X
   Hernandez, H
   Atakilit, A
   Burlingame, AL
   Matthay, MA
   Sheppard, D
AF Bhattacharya, Mallar
   Su, George
   Su, X.
   Oses-Prieto, J. A.
   Li, John T.
   Huang, X.
   Hernandez, H.
   Atakilit, Amha
   Burlingame, A. L.
   Matthay, Michael A.
   Sheppard, Dean
TI IQGAP1 is necessary for pulmonary vascular barrier protection in murine
   acute lung injury and pneumonia
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE S1P/S1PR1/S1PR2/S1PR3; cortical actin; proteomics 
ID SPHINGOSINE 1-PHOSPHATE; PERMEABILITY; MICE; SPHINGOSINE-1-PHOSPHATE;
   ACTIVATION; PATHWAYS; DYNAMICS; BINDING; PROTEIN; DOMAIN
AB Bhattacharya M, Su G, Su X, Oses-Prieto JA, Li JT, Huang X, Hernandez H, Atakilit A, Burlingame AL, Matthay MA, Sheppard D. IQGAP1 is necessary for pulmonary vascular barrier protection in murine acute lung injury and pneumonia. Am J Physiol Lung Cell Mol Physiol 303: L12-L19, 2012. First published May 4, 2012; doi:10.1152/ajplung.00375.2011.-We recently reported that integrin alpha v beta(3) is necessary for vascular barrier protection in mouse models of acute lung injury and peritonitis. Here, we used mass spectrometric sequencing of integrin complexes to isolate the novel beta(3)-integrin binding partner IQGAP1. Like integrin beta(3), IQGAP1 localized to the endothelial cell-cell junction after sphingosine-1-phosphate (S1P) treatment, and IQGAP1 knockdown prevented cortical actin formation and barrier enhancement in response to S1P. Furthermore, knockdown of IQGAP1 prevented localization of integrin alpha v beta(3) to the cell-cell junction. Similar to beta(3)-null animals, IQGAP1-null mice had increased pulmonary vascular leak compared with wild-type controls 3 days after intratracheal LPS. In an Escherichia coli pneumonia model, IQGAP1 knockout mice had increased lung weights, lung water, and lung extravascular plasma equivalents of I-125-labeled albumin compared with wild-type controls. Taken together, these experiments indicate that IQGAP1 is necessary for S1P-mediated vascular barrier protection during acute lung injury and is required for junctional localization of the barrier-protective integrin alpha v beta(3).
C1 [Bhattacharya, M.; Su, G.; Li, J. T.; Huang, X.; Atakilit, A.; Sheppard, D.] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94158, United States.
C1 [Bhattacharya, M.; Su, G.; Su, X.; Matthay, M. A.; Sheppard, D.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158, United States.
C1 [Bhattacharya, M.; Su, G.; Su, X.; Matthay, M. A.; Sheppard, D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158, United States.
C1 [Bhattacharya, M.; Su, G.; Su, X.; Matthay, M. A.; Sheppard, D.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94158, United States.
C1 [Oses-Prieto, J. A.; Hernandez, H.; Burlingame, A. L.] Univ Calif San Francisco, Mass Spectrometry Facil, San Francisco, CA 94158, United States.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Bhattacharya, M (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Rock Hall,Rm 545,1550 4th St, San Francisco, CA 94158 USA.
EM mallar.bhattacharya@ucsf.edu
RI Su, Xiao/CAG-9884-2022
OI Su, Xiao/0000-0002-8692-8365; Oses-Prieto, Juan/0000-0003-4759-2341
FU UCSF Cardiovascular Research Institute [NIH T32 HL007185]; NIH
   [1F32HL099026-01A1, 5K08HL083097-03, R01 HL053949, U19AI077439-04];
   Parker B. Francis Career Award [HL51854]; NIAID [A1053194]; National
   Center for Research Resources, NIH NCRR [RR001614, 1S10RR019934]
FX This work was supported by a UCSF Cardiovascular Research Institute
   training grant NIH T32 HL007185, NIH grant 1F32HL099026-01A1 awarded to
   M. Bhattacharya, NIH grant 5K08HL083097-03 awarded to G. Su, a Parker B.
   Francis Career Award to X. Su, HL51854 and NIAID A1053194 awarded to M.
   A. Matthay, and NIH grants R01 HL053949 and U19AI077439-04 awarded to D.
   Sheppard. The UCSF Mass Spectrometry Facility (A. L. Burlingame,
   Director) was supported by the Biomedical Research Technology Program of
   the National Center for Research Resources, NIH NCRR RR001614, and
   1S10RR019934.
CR Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555
   Berdyshev EV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016571
   Brandt DT, 2007, EMBO REP, V8, P1019, DOI 10.1038/sj.embor.7401089
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516
   David S, 2011, ARTERIOSCL THROM VAS, V31, P2643, DOI 10.1161/ATVBAHA.111.233189
   Delon I, 2007, CURR OPIN CELL BIOL, V19, P43, DOI 10.1016/j.ceb.2006.12.013
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Humphries JD, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000396
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Li SH, 2000, MOL CELL BIOL, V20, P697, DOI 10.1128/MCB.20.2.697-701.2000
   Liu HB, 2008, PANCREAS, V36, pE10, DOI 10.1097/MPA.0b013e31815f3905
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Mateer SC, 2004, CELL MOTIL CYTOSKEL, V58, P231, DOI 10.1002/cm.20013
   Mathew B, 2011, FASEB J, V25, P3388, DOI 10.1096/fj.11-183970
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Robinson SD, 2004, ARTERIOSCL THROM VAS, V24, P2108, DOI 10.1161/01.ATV.0000143857.27408.de
   ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B
   Safdar Z, 2003, J CLIN INVEST, V112, P1541, DOI 10.1172/JCI200318370
   Su G, 2012, AM J RESP CRIT CARE, V185, P58, DOI 10.1164/rccm.201108-1381OC
   Su X, 2005, J IMMUNOL, V175, P2598, DOI 10.4049/jimmunol.175.4.2598
   Su X, 2004, EXP LUNG RES, V30, P479, DOI 10.1080/01902140490476382
   Usatyuk PV, 2011, AM J PHYSIOL-LUNG C, V300, pL840, DOI 10.1152/ajplung.00404.2010
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Ware LB, 2005, NEW ENGL J MED, V353, P2788, DOI 10.1056/NEJMcp052699
   Wickstrom SA, 2010, DEV CELL, V19, P574, DOI 10.1016/j.devcel.2010.09.007
NR 27
TC 19
Z9 21
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2012
VL 303
IS 1
BP L12
EP L19
DI 10.1152/ajplung.00375.2011
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 972KM
UT WOS:000306276000002
PM 22561460
OA Green Published
DA 2023-08-21
ER

PT J
AU Carnesecchi, S
   Pache, JC
   Barazzone-Argiroffo, C
AF Carnesecchi, Stephanie
   Pache, Jean-Claude
   Barazzone-Argiroffo, Constance
TI NOX enzymes: potential target for the treatment of acute lung injury
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE NOX/NOX1/NOX2/NOX4; ALI/ARDS 
ID KAPPA-B ACTIVATION; IDIOPATHIC PULMONARY-FIBROSIS; HYDROGEN-PEROXIDE
   PRODUCTION; OXYGEN SPECIES PRODUCTION; ATP-MEDIATED ACTIVATION; NADPH
   OXIDASE SUBUNIT; NAD(P)H OXIDASE; EPITHELIAL-CELLS; ENDOTHELIAL-CELLS;
   OXIDATIVE STRESS
AB Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), is characterized by acute inflammation, disruption of the alveolar-capillary barrier, and in the organizing stage by alveolar pneumocytes hyperplasia and extensive lung fibrosis. The cellular and molecular mechanisms leading to the development of ALI/ARDS are not completely understood, but there is evidence that reactive oxygen species (ROS) generated by inflammatory cells as well as epithelial and endothelial cells are responsible for inflammatory response, lung damage, and abnormal repair. Among all ROS-producing enzymes, the members of NADPH oxidases (NOXs), which are widely expressed in different lung cell types, have been shown to participate in cellular processes involved in the maintenance of lung integrity. It is not surprising that change in NOXs' expression and function is involved in the development of ALI/ARDS. In this context, the use of NOX inhibitors could be a possible therapeutic perspective in the management of this syndrome. In this article, we summarize the current knowledge concerning some cellular aspects of NOXs localization and function in the lungs, consider their contribution in the development of ALI/ARDS and discuss the place of NOX inhibitors as potential therapeutical target.
C1 [Carnesecchi, Stephanie; Barazzone-Argiroffo, Constance] Ctr Med Univ Geneva, Dept Pediat Pathol & Immunol, CH-1211 Geneva, Switzerland.
C1 [Pache, Jean-Claude] Ctr Med Univ Geneva, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland.
C3 University of Geneva; University of Geneva
RP Carnesecchi, S (corresponding author), Ctr Med Univ Geneva, Dept Pediat Pathol & Immunol, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.
EM stephanie.carnesecchi@unige.ch
CR Al Ghouleh I, 2008, SHOCK, V29, P553, DOI [10.1097/SHK.0b013e318157ebc8, 10.1097/SHK.0b013e318157cbc8]
   Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730
   Amara N, 2007, AM J PHYSIOL-LUNG C, V293, pL170, DOI 10.1152/ajplung.00445.2006
   Amara N, 2010, THORAX, V65, P733, DOI 10.1136/thx.2009.113456
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589
   Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Ben-Shaul V, 2001, TOXICOL LETT, V123, P1, DOI 10.1016/S0378-4274(01)00369-1
   BERG JT, 1995, EXP LUNG RES, V21, P175, DOI 10.3109/01902149509031752
   Black SM, 2004, P ANN INT IEEE EMBS, V26, P5053
   Boots AW, 2009, J BIOL CHEM, V284, P17858, DOI 10.1074/jbc.M809761200
   BOYCE NW, 1989, EXP LUNG RES, V15, P491, DOI 10.3109/01902148909087873
   Brueckl C, 2006, AM J RESP CELL MOL, V34, P453, DOI 10.1165/rcmb.2005-0223OC
   Budinger GRS, 2011, AM J RESP CRIT CARE, V183, P1043, DOI 10.1164/rccm.201002-0181OC
   Carnesecchi S, 2011, ANTIOXID REDOX SIGN, V15, P607, DOI 10.1089/ars.2010.3829
   Carnesecchi S, 2009, AM J RESP CRIT CARE, V180, P972, DOI 10.1164/rccm.200902-0296OC
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chapman KE, 2005, AM J PHYSIOL-LUNG C, V289, pL834, DOI 10.1152/ajplung.00069.2005
   Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8
   Chess PR, 2005, J APPL PHYSIOL, V99, P1226, DOI 10.1152/japplphysiol.01105.2004
   Chiang E, 2006, J IMMUNOL, V176, P5720, DOI 10.4049/jimmunol.176.10.5720
   Chowdhury AK, 2005, J BIOL CHEM, V280, P20700, DOI 10.1074/jbc.M411722200
   Clempus RE, 2007, ARTERIOSCL THROM VAS, V27, P42, DOI 10.1161/01.ATV.0000251500.94478.18
   CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721
   CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123
   Crestani B, 2011, INT J BIOCHEM CELL B, V43, P1086, DOI 10.1016/j.biocel.2011.04.003
   Cutz E, 2009, ADV EXP MED BIOL, V648, P427, DOI 10.1007/978-90-481-2259-2_49
   Dhaunsi GS, 2004, J BIOMED SCI, V11, P617, DOI 10.1159/000079674
   Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132
   Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200
   Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696
   Fan J, 2007, J BIOTECHNOL, V130, P455, DOI 10.1016/j.jbiotec.2007.05.023
   Farley KS, 2009, AM J PHYSIOL-LUNG C, V296, pL480, DOI 10.1152/ajplung.90201.2008
   Fischer H, 2007, AM J PHYSIOL-LUNG C, V292, pL1506, DOI 10.1152/ajplung.00029.2007
   Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007
   Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC
   Frank AJ, 2010, CURR OPIN CRIT CARE, V16, P62, DOI 10.1097/MCC.0b013e328334b151
   Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374
   FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123
   Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974
   Garrido-Urbani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014665
   Gauldie J, 2002, AM J RESP CRIT CARE, V165, P1205, DOI 10.1164/rccm.2202054
   Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje
   Girard TD, 2007, CHEST, V131, P921, DOI 10.1378/chest.06-1515
   GOLDMAN G, 1992, J APPL PHYSIOL, V73, P571, DOI 10.1152/jappl.1992.73.2.571
   Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071
   Griffith B, 2009, ANTIOXID REDOX SIGN, V11, P2505, DOI [10.1089/ars.2009.2599, 10.1089/ARS.2009.2599]
   Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C
   Harper RW, 2005, FEBS LETT, V579, P4911, DOI 10.1016/j.febslet.2005.08.002
   Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005
   Horowitz JC, 2006, SEMIN RESP CRIT CARE, V27, P600, DOI 10.1055/s-2006-957332
   Kampfrath T, 2011, CIRC RES, V108, P716, DOI 10.1161/CIRCRESAHA.110.237560
   Kawahara T, 2005, AM J PHYSIOL-CELL PH, V288, pC450, DOI 10.1152/ajpcell.00319.2004
   Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4
   KISTLER GS, 1967, J CELL BIOL, V32, P605, DOI 10.1083/jcb.32.3.605
   KNIGHT PR, 1993, ANESTH ANALG, V77, P754
   Koay MA, 2001, INFECT IMMUN, V69, P5991, DOI 10.1128/IAI.69.10.5991-5996.2001
   Koff JL, 2006, J IMMUNOL, V177, P8693, DOI 10.4049/jimmunol.177.12.8693
   Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   Lane CR, 2010, AM J RESP CRIT CARE, V181
   Lavigne MC, 2005, BIOCHEM BIOPH RES CO, V330, P194, DOI 10.1016/j.bbrc.2005.02.144
   Li S, 2008, ANTIOXID REDOX SIGN, V10, P1687, DOI 10.1089/ars.2008.2035
   Liu JQ, 2005, CHEST, V128, p594S, DOI 10.1378/chest.128.6_suppl.594S
   Liu JQ, 2006, AM J PHYSIOL-LUNG C, V290, pL2, DOI 10.1152/ajplung.00135.2005
   Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005
   Malec V, 2010, FREE RADICAL BIO MED, V48, P1626, DOI 10.1016/j.freeradbiomed.2010.03.008
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Manoury B, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-11
   Mata-Greenwood E, 2005, AM J PHYSIOL-LUNG C, V289, pL288, DOI 10.1152/ajplung.00417.2004
   Matsushita H, 2001, J CELL BIOCHEM, P99
   Matthay MA, 1999, CRIT CARE MED, V27, P2028, DOI 10.1097/00003246-199909000-00055
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mittal M, 2007, CIRC RES, V101, P258, DOI 10.1161/CIRCRESAHA.107.148015
   Miyoshi T, 2010, IMMUNOLOGY, V131, P331, DOI 10.1111/j.1365-2567.2010.03303.x
   Nagai K, 2008, ANTIOXID REDOX SIGN, V10, P705, DOI 10.1089/ars.2007.1941
   Nakanaga T, 2007, AM J PHYSIOL-LUNG C, V292, pL1289, DOI 10.1152/ajplung.00356.2006
   Oeckler RA, 2007, EUR RESPIR J, V30, P1216, DOI 10.1183/09031936.00104907
   Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE
   Pache JC, 1998, MODERN PATHOL, V11, P1064
   Pache JC, 2011, NAT MED, V17, P31, DOI 10.1038/nm0111-31
   Pacquelet S, 2007, BIOCHEM J, V403, P451, DOI 10.1042/BJ20061184
   Pantano C, 2007, AM J RESP CELL MOL, V36, P473, DOI 10.1165/rcmb.2006-0109OC
   Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002
   Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589
   Park HS, 2006, CARDIOVASC RES, V72, P447, DOI 10.1016/j.cardiores.2006.09.012
   Park S, 2010, J MOL MED, V88, P807, DOI 10.1007/s00109-010-0622-5
   Patel DN, 2006, BIOCHEM BIOPH RES CO, V347, P1113, DOI 10.1016/j.bbrc.2006.07.015
   Pendyala S, 2011, FREE RADICAL BIO MED, V50, P1749, DOI 10.1016/j.freeradbiomed.2011.03.022
   Pendyala S, 2009, ANTIOXID REDOX SIGN, V11, P747, DOI [10.1089/ars.2008.2203, 10.1089/ARS.2008.2203]
   Prescott SM, 1999, J CLIN INVEST, V104, P1019, DOI 10.1172/JCI8506
   Puca R, 2010, FREE RADICAL BIO MED, V48, P1338, DOI 10.1016/j.freeradbiomed.2010.02.015
   Rada B, 2010, FEBS LETT, V584, P917, DOI 10.1016/j.febslet.2010.01.025
   Rada Balazs, 2008, V15, P164, DOI 10.1159/000136357
   Ranjan P, 2006, ANTIOXID REDOX SIGN, V8, P1447, DOI 10.1089/ars.2006.8.1447
   Sadikot RT, 2004, J IMMUNOL, V172, P1801, DOI 10.4049/jimmunol.172.3.1801
   Salvemini D, 2002, FREE RADICAL BIO MED, V33, P1173, DOI 10.1016/S0891-5849(02)00961-9
   Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com
   Schultz MJ, 2008, MED SCI MONITOR, V14, pRA22
   Schwarzer C, 2004, J BIOL CHEM, V279, P36454, DOI 10.1074/jbc.M404983200
   Segal BH, 2007, AM J PHYSIOL-LUNG C, V292, pL760, DOI 10.1152/ajplung.00281.2006
   Selman Moises, 2006, Proc Am Thorac Soc, V3, P364, DOI 10.1513/pats.200601-003TK
   Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102
   SMITH LJ, 1988, J LAB CLIN MED, V111, P449
   Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66
   Soucy-Faulkner A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000930
   Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005
   Swain SD, 2004, INFECT IMMUN, V72, P5722, DOI 10.1128/IAI.72.10.5722-5732.2004
   Syrkina O, 2008, RESPIROLOGY, V13, P333, DOI 10.1111/j.1440-1843.2008.01279.x
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tasaka S, 2008, ANTIOXID REDOX SIGN, V10, P739, DOI 10.1089/ars.2007.1940
   Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601-001TK
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Thompson BT, 2010, MINERVA ANESTESIOL, V76, P441
   Thompson B Taylor, 2006, ACP J Club, V145, P34
   Usatyuk PV, 2007, J BIOL CHEM, V282, P23284, DOI 10.1074/jbc.M700535200
   van der Vliet A, 2008, FREE RADICAL BIO MED, V44, P938, DOI 10.1016/j.freeradbiomed.2007.11.016
   vanKlaveren RJ, 1997, THORAX, V52, P465, DOI 10.1136/thx.52.5.465
   Victor VM, 2003, INT IMMUNOPHARMACOL, V3, P97, DOI 10.1016/S1567-5769(02)00232-1
   Vlahos R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001271
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wesley UV, 2007, J BIOL CHEM, V282, P3213, DOI 10.1074/jbc.M606533200
   Willson DF, 2005, JAMA-J AM MED ASSOC, V293, P470, DOI 10.1001/jama.293.4.470
   Yang CS, 2009, J IMMUNOL, V182, P3696, DOI 10.4049/jimmunol.0802217
   Zhang WJ, 2011, FREE RADICAL BIO MED, V50, P1517, DOI 10.1016/j.freeradbiomed.2011.02.027
   Zhang WJ, 2009, FREE RADICAL BIO MED, V46, P791, DOI 10.1016/j.freeradbiomed.2008.12.003
   Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC
   Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139
NR 129
TC 48
Z9 60
U1 0
U2 19
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JUL
PY 2012
VL 69
IS 14
BP 2373
EP 2385
DI 10.1007/s00018-012-1013-6
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 965CV
UT WOS:000305744700008
PM 22581364
OA Bronze, Green Submitted, Green Published
DA 2023-08-21
ER

PT J
AU Curtis, BR
AF Curtis, Brian R.
TI Future Preventive and Therapeutic Targets for Transfusion-Related Acute
   Lung Injury
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE transfusion; ALI/ARDS; treatment; prevention; leukocyte antibodies; neutrophils; platelet; ALI/ARDS 
ID RESPIRATORY-DISTRESS-SYNDROME; TRANSPORTER-LIKE PROTEIN-2; FC-GAMMA
   RECEPTORS; STORED-BLOOD COMPONENTS; CRITICALLY-ILL; HLA ANTIBODIES;
   NADPH OXIDASE; ANIMAL-MODEL; HUMAN GENOME; RISK-FACTORS
AB Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-associated death for nearly a decade. Recent TRALI mitigation strategies focused on reduction of leukocyte antibodies in high volume plasma products appear to be successful in reducing TRALI events and deaths, but additional preventive measures are needed. Future possibilities include, screening of donors for neutrophil antibodies, processing of blood products to reduce or remove biologic response modifiers, and the more judicious use of blood. There are currently no specific TRALI therapies. The pathogenesis of TRALI and acute lung injury-acute respiratory distress syndrome (ALI-ARDS) is quite similar; both involving interactions of activated platelets, neutrophils, and pulmonary endothelium resulting in lung damage, capillary leak, and pulmonary edema. Greater understanding of these interactions and the key molecules involved will lead to development of potential new targets for therapy. In this review, future possible preventive measures to further reduce the occurrence of TRALI will be discussed, including TRALI caused by biologic response modifiers (BRMs), like bioactive lipids and sCD40L, which are not addressed by current preventive actions that only target leukocyte antibodies in high-volume plasma products. Insights already gained from studies of ALI-ARDS treatments will be summarized and discussed as possible therapeutic targets for treatment of patients experiencing TRALI.
C1 BloodCtr Wisconsin, Platelet & Neutrophil Immunol Lab, Milwaukee, WI 53201, United States.
C3 Versiti Blood Center of Wisconsin
RP Curtis, BR (corresponding author), BloodCtr Wisconsin, Platelet & Neutrophil Immunol Lab, POB 2178, Milwaukee, WI 53201 USA.
EM Brian.curtis@bcw.edu
RI Curtis, Brian Ronald/AAT-7861-2020
CR [Anonymous], 2011, ABC NEWSLETTER   JUN, P22
   Balloy V, 2003, AM J RESP CELL MOL, V28, P746, DOI 10.1165/rcmb.2002-0119OC
   BARNARD RD, 1951, NEW YORK STATE J MED, V51, P2399
   Bassuni Wafaa Y, 2008, Hematol Oncol Stem Cell Ther, V1, P106
   Bayat B, 2012, TRANSFUSION, V52, P613, DOI 10.1111/j.1537-2995.2011.03303.x
   Bercovitz RS, 2010, BLOOD, V116, P664
   Berthold T, 2011, TRANSFUSION, V51, P2160, DOI 10.1111/j.1537-2995.2011.03115.x
   Blumberg N, 2007, CLIN INFECT DIS, V45, P1014, DOI 10.1086/521897
   Blumberg N, 2010, TRANSFUSION, V50, P2738, DOI 10.1111/j.1537-2995.2010.02748.x
   Bray RA, 2004, HUM IMMUNOL, V65, P240, DOI 10.1016/j.humimm.2003.12.007
   BRITTINGHAM TE, 1957, JAMA-J AM MED ASSOC, V165, P819, DOI 10.1001/jama.1957.02980250053013
   Brower RG, 2001, CHEST, V120, P1347, DOI 10.1378/chest.120.4.1347
   Caliezi C, 2000, PHARMACOL REV, V52, P91
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001
   Curtis BR, 2006, CRIT CARE MED, V34, pS118, DOI 10.1097/01.CCM.0000214293.72918.D8
   Curtis BR, 2011, TRANSFUSION, V51, P2168, DOI 10.1111/j.1537-2995.2011.03145.x
   Curtis BR, 2010, EXPERT REV HEMATOL, V3, P373, DOI [10.1586/ehm.10.38, 10.1586/EHM.10.38]
   Curtis BR, 2010, BLOOD, V115, P2073, DOI 10.1182/blood-2009-11-248336
   Davis J, 2008, AM J HEALTH-SYST PH, V65, P1609, DOI 10.2146/ajhp080043
   Davoren A, 2003, TRANSFUSION, V43, P641, DOI 10.1046/j.1537-2995.2003.00374.x
   Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x
   FDA/CBER, 2010, FAT REP FDA FOLL BLO
   Flores C, 2010, MINERVA ANESTESIOL, V76, P860
   Fudala R, 2010, CLIN SCI, V118, P519, DOI 10.1042/CS20090422
   Fung YL, 2009, TRANSFUS MED REV, V23, P266, DOI 10.1016/j.tmrv.2009.06.001
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Gajic O, 2007, CRIT CARE MED, V35, P1645, DOI 10.1097/01.CCM.0000269036.16398.0D
   Gao L, 2009, AM J PHYSIOL-LUNG C, V296, pL713, DOI 10.1152/ajplung.90269.2008
   Gottschall JL, 2009, TRANSFUSION, V49, p46A
   Gottschall JL, 2011, TRANSFUSION, V51, P820, DOI 10.1111/j.1537-2995.2010.02913.x
   Greinacher A, 2010, NAT MED, V16, P45, DOI 10.1038/nm.2070
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Hardy J, 2009, NEW ENGL J MED, V360, P1759, DOI 10.1056/NEJMra0808700
   He Lei, 2009, Human Genomics, V3, P195
   Hecker M, 2008, TRANSFUS MED HEMOTH, V35, P80, DOI 10.1159/000117582
   Hellstern P, 2004, CURR OPIN HEMATOL, V11, P346, DOI 10.1097/01.moh.0000137915.88478.23
   Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688
   Hishizawa M, 2009, INTERNAL MED, V48, P1979, DOI 10.2169/internalmedicine.48.2569
   Ishitsuka Y, 2009, J PHARMACOL SCI, V111, P211, DOI 10.1254/jphs.09128SC
   Kanack AJ, 2012, TRANSFUSION, V52, P1112, DOI 10.1111/j.1537-2995.2011.03411.x
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Kian H, 2007, CHEST, V131, P1308, DOI 10.1378/chest.06-3048
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Kommareddi PK, 2010, PROTEIN J, V29, P417, DOI 10.1007/s10930-010-9268-y
   Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968
   Lenahan SE, 2001, ARCH PATHOL LAB MED, V125, P523
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Mangalmurti NS, 2009, BLOOD, V113, P1158, DOI 10.1182/blood-2008-07-166264
   Masuda Atsuhiro, 2009, Inflammation & Allergy Drug Targets, V8, P80
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   McCullough J, 2003, CLIN INFECT DIS, V37, P88, DOI 10.1086/375232
   McFarland Janice G, 2006, Clin Adv Hematol Oncol, V4, P584
   McFarland JG, 2006, CLIN ADV HEMATOL ONC, V4, P94
   Meduri GU, 2008, INTENS CARE MED, V34, P61, DOI 10.1007/s00134-007-0933-3
   Middelburg RA, 2008, TRANSFUSION, V48, P2167, DOI 10.1111/j.1537-2995.2008.01810.x
   Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818
   Munafo DB, 2009, J INNATE IMMUN, V1, P527, DOI 10.1159/000235860
   Nair TS, 2004, J NEUROSCI, V24, P1772, DOI 10.1523/JNEUROSCI.5063-03.2004
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   O'Regan S, 2000, P NATL ACAD SCI USA, V97, P1835, DOI 10.1073/pnas.030339697
   Palfi M, 2001, TRANSFUSION, V41, P317, DOI 10.1046/j.1537-2995.2001.41030317.x
   Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015
   Pearson TA, 2008, JAMA-J AM MED ASSOC, V299, P1335, DOI 10.1001/jama.299.11.1335
   POPOVSKY MA, 1983, AM REV RESPIR DIS, V128, P185, DOI 10.1164/arrd.1983.128.1.185
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Raghavendran K, 2008, CURR MED CHEM, V15, P1911, DOI 10.2174/092986708785132942
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Sachs UJ, 2011, CURR OPIN HEMATOL, V18, P436, DOI 10.1097/MOH.0b013e32834bab01
   Shashidharamurthy R, 2008, BLOOD, V111, P894, DOI 10.1182/blood-2007-04-085944
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x
   Silliman CC, 2006, CRIT CARE MED, V34, pS124, DOI 10.1097/01.CCM.0000214292.62276.8E
   Silliman CC, 2003, J LEUKOCYTE BIOL, V73, P511, DOI 10.1189/jlb.0402179
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   SILLIMAN CC, 1992, VOX SANG, V63, P133, DOI 10.1111/j.1423-0410.1992.tb02500.x
   Silliman CC, 1996, TRANSFUSION, V36, P133, DOI 10.1046/j.1537-2995.1996.36296181925.x
   Silliman CC, 2009, BLOOD REV, V23, P245, DOI 10.1016/j.blre.2009.07.005
   Sokolovic Mladen, 2010, Expert Rev Respir Med, V4, P387, DOI 10.1586/ers.10.22
   STACK G, 1994, TRANSFUSION, V34, P20, DOI 10.1046/j.1537-2995.1994.34194098597.x
   Strait RT, 2011, J EXPT MED
   Triulzi DJ, 2009, TRANSFUSION, V49, P1825, DOI 10.1111/j.1537-2995.2009.02206.x
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Tuinman PR, 2011, CLIN EXP IMMUNOL, V165, P278, DOI 10.1111/j.1365-2249.2011.04422.x
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2
   Vangerow B, 2001, INTENS CARE MED, V27, P1526, DOI 10.1007/s001340101036
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Vlaar A P, 2011, Clin Lab, V57, P267
   Vlaar APJ, 2011, TRANSFUSION, V51, P2358, DOI 10.1111/j.1537-2995.2011.03177.x
   Vlaar APJ, 2011, BLOOD, V117, P4218, DOI 10.1182/blood-2010-10-313973
   Vlaar APJ, 2010, BLOOD, V116, P1360, DOI 10.1182/blood-2009-10-248732
   Vlaar APJ, 2010, ANESTHESIOLOGY, V113, P92, DOI 10.1097/ALN.0b013e3181de6f25
   Vlaar APJ, 2010, CRIT CARE MED, V38, P771, DOI 10.1097/CCM.0b013e3181cc4d4b
   Vlaar Alexander P. J., 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P319, DOI 10.2174/187152507782109845
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zarbock A, 2009, FRONT BIOSCI-LANDMRK, V14, P150, DOI 10.2741/3236
NR 98
TC 2
Z9 2
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUL
PY 2012
VL 18
IS 22
BP 3285
EP 3292
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 976IA
UT WOS:000306573600020
PM 22621267
DA 2023-08-21
ER

PT J
AU Ellison, MA
   Ambruso, DR
   Silliman, CC
AF Ellison, Michael A.
   Ambruso, Daniel R.
   Silliman, Christopher C.
TI Therapeutic Options for Transfusion Related Acute Lung Injury; the
   Potential of the G2A Receptor
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE transfusion; ALI/ARDS; lysophospholipid; lysophosphatidylcholine; G2A receptor; G-protein coupled receptor; clathrin-mediated endocytosis 
ID PLATELET-ACTIVATING-FACTOR; NEUTROPHIL NADPH OXIDASE; STORED-BLOOD
   COMPONENTS; ENDOTHELIAL DAMAGE; PRIMING ACTIVITY; ROUTINE STORAGE;
   ANIMAL-MODEL; LIPIDS; LYSOPHOSPHATIDYLCHOLINE; ANTIBODY
AB Priming of polymorphonuclear leukocytes (PMNs) enhances their adhesion to endothelium, the release of their granule content and their production of reactive oxygen species. These effects are etiological in transfusion related acute lung injury (TRALI) and many clinically important mediators of TRALI prime PMNs. A priming activity that develops over time in stored blood products has been shown to be due to the accumulation of lysophospatidylcholines (lyso-PCs) and has been found to be related clinically to TRALI. Lyso-PCs prime PMNs activating the G2A receptor and several inhibitors of this receptor, which could potentially be therapeutic in TRALI, have been identified. Recent work has described early steps in the signaling from the G2A receptor which has revealed potential targets for novel antagonists of lyso-PC mediated priming via G2A. Additionally, characterization of the process by which lyso-PCs are generated in stored blood products could allow development of inhibitors and additive solutions to block their formation in the first place.
C1 [Ellison, Michael A.; Ambruso, Daniel R.; Silliman, Christopher C.] Univ Colorado Denver, Belle Bonfils Mem Blood Ctr, Aurora, CO, United States.
C1 [Ambruso, Daniel R.; Silliman, Christopher C.] Univ Colorado Denver, Dept Pediat, Sch Med, Aurora, CO, United States.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; Children's Hospital Colorado;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Ellison, MA (corresponding author), Belle Bonfils Mem Blood Ctr, 717 Yosemite St, Denver, CO 80230 USA.
EM Michael_Ellison@bonfils.org
FU Belle Bonfils Memorial Blood Center; Stacy Marie True Memorial Trust;
   NIH [K07 HL088968, GM049222]
FX We would like to acknowledge support from Belle Bonfils Memorial Blood
   Center, the Stacy Marie True Memorial Trust and NIH Grants K07 HL088968
   and GM049222.
CR AIDA Y, 1991, J IMMUNOL, V146, P1271
   Ambruso DR, 2011, TRANSFUSION, V51, P1220, DOI 10.1111/j.1537-2995.2010.02983.x
   BOXER LA, 1990, BLOOD CELLS, V16, P25
   Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9
   Condliffe AM, 1998, CLIN SCI, V94, P461, DOI 10.1042/cs0940461
   COREY SJ, 1991, J LAB CLIN MED, V118, P343
   Covin RB, 2004, TRANSFUSION MED, V14, P375, DOI 10.1111/j.0958-7578.2004.00529.x
   Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   Flesch BK, 2002, BRIT J HAEMATOL, V116, P673, DOI 10.1046/j.0007-1048.2001.03305.x
   Frasch SC, 2007, J IMMUNOL, V178, P6540, DOI 10.4049/jimmunol.178.10.6540
   GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656
   HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2
   HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869
   HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962
   Insunza A, 2004, TRANSFUSION MED, V14, P157, DOI 10.1111/j.0958-7578.2004.00492.x
   Jackson SK, 2008, PHARMACOL THERAPEUT, V119, P104, DOI 10.1016/j.pharmthera.2008.04.001
   Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781
   Khan SY, 2010, BIOCHEM J, V432, P35, DOI 10.1042/BJ20091087
   Kitchen E, 1996, BLOOD, V88, P4330
   Kopko PM, 2001, TRANSFUSION, V41, P1244, DOI 10.1046/j.1537-2995.2001.41101244.x
   POPOVSKY MA, 1983, AM REV RESPIR DIS, V128, P185, DOI 10.1164/arrd.1983.128.1.185
   POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   SHEPPARD GS, 1994, J MED CHEM, V37, P2011, DOI 10.1021/jm00039a015
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x
   Silliman CC, 2006, CRIT CARE MED, V34, pS124, DOI 10.1097/01.CCM.0000214292.62276.8E
   Silliman CC, 1999, TRANSFUS MED REV, V13, P177, DOI 10.1016/S0887-7963(99)80031-5
   Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929
   Silliman CC, 2003, J LEUKOCYTE BIOL, V73, P511, DOI 10.1189/jlb.0402179
   Silliman CC, 2003, BLOOD, V101, P454, DOI 10.1182/blood-2002-03-0958
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   SILLIMAN CC, 1993, LIPIDS, V28, P415, DOI 10.1007/BF02535939
   SILLIMAN CC, 1992, VOX SANG, V63, P133, DOI 10.1111/j.1423-0410.1992.tb02500.x
   SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684
   Silliman CC, 1996, TRANSFUSION, V36, P133, DOI 10.1046/j.1537-2995.1996.36296181925.x
   Silliman CC, 2011, TRANSFUSION
   VERCELLOTTI GM, 1988, BLOOD, V71, P1100
   Vlaar AP, 2011, TRANSFUSION
   Wang L, 2005, MOL BIOL CELL, V16, P2234, DOI 10.1091/mbc.E04-12-1044
   WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0
   WEISS SJ, 1989, NEW ENGL J MED, V320, P365
   Witte ON, 2005, SCIENCE, V307, P206
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989
   YOMTOVIAN R, 1984, LANCET, V1, P244
NR 48
TC 10
Z9 11
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUL
PY 2012
VL 18
IS 22
BP 3255
EP 3259
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 976IA
UT WOS:000306573600016
PM 22621271
DA 2023-08-21
ER

PT J
AU Wei, ZF
   Yang, J
   Xia, YF
   Huang, WZ
   Wang, ZT
   Dai, Y
AF Wei, Zhifeng
   Yang, Jian
   Xia, Yu-Feng
   Huang, Wen-Zhe
   Wang, Zheng-Tao
   Dai, Yue
TI Cardamonin protects septic mice from acute lung injury by preventing
   endothelial barrier dysfunction
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE Cardamonin; ALI/ARDS; sepsis; MAPK 
ID RESPIRATORY-DISTRESS-SYNDROME; ACTIN REORGANIZATION; MEDICAL PROGRESS;
   SEPSIS; KINASE; CELLS; PERMEABILITY; DEFINITIONS; MEDIATORS
AB Cardamonin, a flavone compound isolated from Alpinia katsumadai Heyata seeds, has been reported to possess anti-inflammatory and anticoagulative activities, and it might be beneficial for management of sepsis. This study was conducted to examine the protective effects of cardamonin on experimental sepsis and resultant acute lung injury (ALI). Cardamonin (30 and 100 mg/kg) significantly elevated the survival rate of septic mice, alleviated ALI and lung microvascular leak, and lowered the serum levels of proinflammatory cytokines TNF-a, IL-1 beta, and IL-6. In vitro, it (25 and 50 mu M) concentration dependently inhibited endothelium permeability and downregulated phosphorylation of P38 in rat lung microvascular endothelial cells induced by lipopolysaccharide (LPS). P38 inhibitor inhibited the endothelium permeability. In RAW 264.7 macrophage cells, cardamonin also showed selective inhibition of P38 phosphorylation induced by LPS. These results indicate that cardamonin can protect septic mice from ALI by preventing endothelium barrier dysfunction via selectively inhibiting P38 activation. (c) 2012 Wiley Periodicals, Inc. J Biochem Mol Toxicol 26:282290, 2012; View this article online at . DOI 10.1002/jbt.21420
C1 [Wei, Zhifeng; Yang, Jian; Xia, Yu-Feng; Dai, Yue] China Pharmaceut Univ, State Key Lab Nat Med, Dept Pharmacol Chinese Mat Med, Nanjing 210009, China.
C1 [Huang, Wen-Zhe; Wang, Zheng-Tao] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai 201203, China.
C3 China Pharmaceutical University; Shanghai University of Traditional
   Chinese Medicine
RP Dai, Y (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China.
EM yuedaicpu@hotmail.com
RI Wang, Zhengtao/AAH-7360-2019
OI Wang, Zhengtao/0000-0003-2797-4625
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions
FX Contract Grant Sponsor: Priority Academic Program Development of Jiangsu
   Higher Education Institutions.
CR Ahmad S, 2006, EUR J PHARMACOL, V538, P188, DOI 10.1016/j.ejphar.2006.03.070
   Awad SS, 2003, AM J SURG, V186, p23S, DOI 10.1016/j.amjsurg.2003.10.004
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bogatcheva NV, 2007, AM J PHYSIOL-LUNG C, V292, pL487, DOI 10.1152/ajplung.00217.2006
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   BURRELL R, 1988, AM REV RESPIR DIS, V137, P100, DOI 10.1164/ajrccm/137.1.100
   Cai H, 2008, CARDIOVASC RES, V77, P30, DOI 10.1093/cvr/cvm010
   CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   GOLDBLUM SE, 1993, J CELL PHYSIOL, V157, P13, DOI 10.1002/jcp.1041570103
   Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2
   GUDGEON JR, 1989, BRIT J PHARMACOL, V98, P1267, DOI 10.1111/j.1476-5381.1989.tb12673.x
   Hatziieremia S, 2006, BRIT J PHARMACOL, V149, P188, DOI 10.1038/sj.bjp.0706856
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Huang Wen-zhe, 2006, Journal of Plant Resources and Environment, V15, P37
   Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383
   Jantan I, 2008, PHYTOMEDICINE, V15, P306, DOI 10.1016/j.phymed.2007.08.002
   Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3
   KIM N-S, 1991, Yonsei Medical Journal, V32, P303
   Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3
   Lee JH, 2006, J PHARMACOL EXP THER, V316, P271, DOI 10.1124/jpet.105.092486
   Matsuda Naoyuki, 2007, Journal of Smooth Muscle Research, V43, P117, DOI 10.1540/jsmr.43.117
   Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703
   Perl M, 2008, MOL MED, V14, P465, DOI 10.2119/2008-00011.Perl
   PHILLIPS PG, 1989, AM J PHYSIOL, V257, pC562, DOI 10.1152/ajpcell.1989.257.3.C562
   Regnault V, 2007, CRIT CARE, V11, DOI 10.1186/cc5135
   Verbrugge SJC, 2007, CLIN PHYSIOL FUNCT I, V27, P67, DOI 10.1111/j.1475-097X.2007.00722.x
   Wagner EM, 2006, J APPL PHYSIOL, V100, P1224, DOI 10.1152/japplphysiol.01060.2005
   Wang T, 2010, AM J RESP CELL MOL, V42, P442, DOI 10.1165/rcmb.2008-0402OC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Welsh MJ, 1998, ANN NY ACAD SCI, V851, P28, DOI 10.1111/j.1749-6632.1998.tb08973.x
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Yang J, 2009, PHYTOTHER RES, V23, P267, DOI 10.1002/ptr.2610
NR 35
TC 27
Z9 29
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD JUL
PY 2012
VL 26
IS 7
BP 282
EP 290
DI 10.1002/jbt.21420
PG 9
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA 973ZN
UT WOS:000306399500006
PM 22696397
DA 2023-08-21
ER

PT J
AU Westphalen, K
   Monma, E
   Islam, MN
   Bhattacharya, J
AF Westphalen, Kristin
   Monma, Eiji
   Islam, Mohammad N.
   Bhattacharya, Jahar
TI Acid contact in the rodent pulmonary alveolus causes proinflammatory
   signaling by membrane pore formation
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE calcium; hydrogen peroxide; nitric oxide synthase 2; NO; ROS; catalase; flash photolysis; resealing; clodronate 
ID PLASMA-MEMBRANE; ASPIRATION PNEUMONITIS; OXIDATIVE STRESS; LUNG INJURY;
   CELLS; EXOCYTOSIS; SECRETION; MECHANISM; RESPONSES; REPAIR
AB Westphalen K, Monma E, Islam MN, Bhattacharya J. Acid contact in the rodent pulmonary alveolus causes proinflammatory signaling by membrane pore formation. Am J Physiol Lung Cell Mol Physiol 303: L107-L116, 2012. First published May 4, 2012; doi:10.1152/ajplung.00206.2011.-Although gastric acid aspiration causes rapid lung inflammation and acute lung injury, the initiating mechanisms are not known. To determine alveolar epithelial responses to acid, we viewed live alveoli of the isolated lung by fluorescence microscopy, then we microinjected the alveoli with HCl at pH of 1.5. The microinjection caused an immediate but transient formation of molecule-scale pores in the apical alveolar membrane, resulting in loss of cytosolic dye. However, the membrane rapidly resealed. There was no cell damage and no further dye loss despite continuous HCl injection. Concomitantly, reactive oxygen species (ROS) increased in the adjacent perialveolar microvascular endothelium in a Ca2+-dependent manner. By contrast, ROS did not increase in wild-type mice in which we gave intra-alveolar injections of polyethylene glycol (PEG)-catalase, in mice overexpressing alveolar catalase, or in mice lacking functional NADPH oxidase (Nox2). Together, our findings indicate the presence of an unusual proinflammatory mechanism in which alveolar contact with acid caused membrane pore formation. The effect, although transient, was nevertheless sufficient to induce Ca2+ entry and Nox2-dependent H2O2 release from the alveolar epithelium. These responses identify alveolar H2O2 release as the signaling mechanism responsible for lung inflammation induced by acid and suggest that intra-alveolar PEG-catalase might be therapeutic in acid-induced lung injury.
C1 [Westphalen, Kristin; Monma, Eiji; Islam, Mohammad N.; Bhattacharya, Jahar] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, Lung Biol Lab, New York, NY 10032, United States.
C3 Columbia University
RP Bhattacharya, J (corresponding author), 630 W 168th St,BB 17-1705B, New York, NY 10032 USA.
EM jb39@columbia.edu
OI Islam, Mohammad Naimul/0000-0001-7929-9444
FU National Heart, Lung, and Blood Institute [HL-36024, HL-69514, HL-64896,
   HL-78645]
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants HL-36024, HL-69514, HL-64896, and HL-78645.
CR Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944
   Armstrong JK, 2004, BIOPHYS J, V87, P4259, DOI 10.1529/biophysj.104.047746
   Ashino Y, 2000, AM J PHYSIOL-LUNG C, V279, pL5, DOI 10.1152/ajplung.2000.279.1.L5
   Atuma C, 2001, AM J PHYSIOL-GASTR L, V280, pG922, DOI 10.1152/ajpgi.2001.280.5.G922
   Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217
   BASTACKY J, 1995, J APPL PHYSIOL, V79, P1615, DOI 10.1152/jappl.1995.79.5.1615
   Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004
   Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747
   Fisher JL, 2004, AM J RESP CELL MOL, V31, P200, DOI 10.1165/rcmb.2003-0224OC
   FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009
   Frank JA, 2006, AM J PHYSIOL-LUNG C, V291, pL1191, DOI 10.1152/ajplung.00055.2006
   Granfeldt D, 2002, J LEUKOCYTE BIOL, V71, P611
   Ichimura H, 2003, J CLIN INVEST, V111, P691, DOI 10.1172/JCI200317271
   Ichimura H, 2006, AM J PHYSIOL-LUNG C, V291, pL596, DOI 10.1152/ajplung.00036.2006
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Kiefmann R, 2008, BLOOD, V111, P5205, DOI 10.1182/blood-2007-09-113902
   KNIGHT PR, 1993, ANESTH ANALG, V77, P754
   Kuebler WM, 2000, J CLIN INVEST, V105, P905, DOI 10.1172/JCI8604
   Kuebler WM, 2007, J APPL PHYSIOL, V102, P1255, DOI 10.1152/japplphysiol.00786.2006
   Lindert J, 2007, AM J RESP CELL MOL, V36, P688, DOI 10.1165/rcmb.2006-0347OC
   Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101
   Oeckler RA, 2008, RESP PHYSIOL NEUROBI, V163, P44, DOI 10.1016/j.resp.2008.06.019
   Parthasarathi K, 2002, J IMMUNOL, V169, P7078, DOI 10.4049/jimmunol.169.12.7078
   Ragette R, 1997, J CLIN INVEST, V100, P685, DOI 10.1172/JCI119581
   RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189
   Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161
   SELINGER SL, 1975, J APPL PHYSIOL, V39, P773, DOI 10.1152/jappl.1975.39.5.773
   Shigemitsu H, 2007, CURR OPIN PULM MED, V13, P192, DOI 10.1097/MCP.0b013e3280f629f0
   Shuvaev VV, 2011, J CONTROL RELEASE, V153, P56, DOI 10.1016/j.jconrel.2011.03.022
   STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084
   Togbe D, 2007, INT J EXP PATHOL, V88, P387, DOI 10.1111/j.1365-2613.2007.00566.x
   van Westerloo DJ, 2005, CRIT CARE MED, V33, P1770, DOI 10.1097/01.CCM.0000172277.41033.F0
   von Garnier C, 2005, J IMMUNOL, V175, P1609, DOI 10.4049/jimmunol.175.3.1609
   Weiser MR, 1997, J APPL PHYSIOL, V83, P1090, DOI 10.1152/jappl.1997.83.4.1090
   Zarbock A, 2009, J IMMUNOL, V183, P4715, DOI 10.4049/jimmunol.0802592
NR 37
TC 16
Z9 16
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2012
VL 303
IS 2
BP L107
EP L116
DI 10.1152/ajplung.00206.2011
PG 10
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 974FJ
UT WOS:000306415500003
PM 22561462
OA Green Published
DA 2023-08-21
ER

PT J
AU Cao, JP
   He, XY
   Xu, HT
   Zou, Z
   Shi, XY
AF Cao, Jian-Ping
   He, Xing-Ying
   Xu, Hai-Tao
   Zou, Zui
   Shi, Xue-Yin
TI Autologous Transplantation of Peripheral Blood-derived Circulating
   Endothelial Progenitor Cells Attenuates Endotoxin-induced Acute Lung
   Injury in Rabbits by Direct Endothelial Repair and Indirect
   Immunomodulation
SO ANESTHESIOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; MESENCHYMAL STEM-CELLS; NITRIC-OXIDE
   SYNTHASE; SUPEROXIDE-DISMUTASE; CRITICALLY-ILL; ANGIOGENESIS;
   MOBILIZATION; EXPRESSION; ISCHEMIA; DISEASES
AB Background: Studies have demonstrated the role of circulating endothelial progenitor cells (EPCs) in maintaining normal endothelial function and in endothelial repairing. This study was aimed to observe the protective effects of autologous transplantation of circulating EPCs against endotoxin- induced acute lung injury in rabbits and to investigate the underlying mechanisms.
   Methods: One-hundred-and-fifty rabbits were enrolled. After acute lung injury was induced by endotoxin, autologous circulating EPCs, endothelial cell, or normal saline were transfused intravenously, respectively. PaO2/FiO(2) ratios, concentrations of plasma nitric oxide, malonyldialdehyde, and activity of superoxide dismutase were examined. The lung wet-to-dry weight ratios were counted; polymorphonuclear cell ratios and areas of hyaline membrane formation and hemorrhage were measured. The levels of interleukin-1 beta, E-selectin, intercellular adhesion molecule-1, interleukin-10, vascular endothelial growth factor protein, and inducible nitric oxide synthase protein were analyzed.
   Results: PaO2/FiO(2) ratios were significantly increased with EPC transfusion. Infiltration of polymorphonuclear cells, lung wet-to-dry weight ratios, and area of hyaline membrane and hemorrhage in lung tissue were significantly decreased after EPC transplantation. Plasma level of nitric oxide and malondialdehyde were significantly inhibited, and the activity of superoxide dismutase was enhanced in the EPC-treated animals. EPC transplantation significantly increased level of interleukin-10 and vascular endothelial growth factor protein and reduced levels of interleukin-1 beta, E-selectin, intercellular adhesion molecule-1, and inducible nitric oxide synthase in injury lung tissues.
   Conclusions: Autologous transplantation of circulating EPCs can partly restore the pulmonary endothelial function and effectively attenuate endotoxin-induced acute lung injury by direct endothelial repair and indirect immunomodulation of antioxidation and antiinflammation.
C1 [Cao, Jian-Ping; He, Xing-Ying; Xu, Hai-Tao; Zou, Zui; Shi, Xue-Yin] Second Mil Med Univ, Dept Anesthesiol, Changzheng Hosp, Shanghai, China.
C1 [Cao, Jian-Ping] PLA455 Hosp, Dept Anesthesiol, Shanghai, China.
C3 Naval Medical University
RP Shi, XY (corresponding author), Second Mil Med Univ, Dept Anesthesiol, Changzheng Hosp, 415 Fengyang Rd, Shanghai, Peoples R China.
EM shixueyin1128@yahoo.com.cn
RI Cao, Jianping/AFL-5468-2022
OI Cao, Jianping/0000-0002-1974-0047; Zou, Zui/0000-0002-8433-8388
FU National Nature Science Funds [30772092]; Military Science and
   Technology Funds [08G0712]; Key Basic Research Projects [09JC1405600];
   Science and Technology Commission, Shanghai Municipality, China
   [10411951300]
FX Received from the Department of Anesthesiology, Changzheng Hospital, The
   Second Military Medical University, Shanghai, China. Submitted for
   publication December 3, 2010. Accepted for publication February 9, 2012.
   Supported by National Nature Science Funds (grant no. 30772092),
   Military Science and Technology Funds (grant no. 08G0712), Key Basic
   Research Projects (grant no. 09JC1405600), and Key Medical Research
   Projects (grant no. 10411951300) from Science and Technology Commission,
   Shanghai Municipality, China. Drs. Jian-Ping Cao and Xing-Ying He
   contributed equally to this work.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Aslam M, 2009, AM J RESP CRIT CARE, V180, P1122, DOI 10.1164/rccm.200902-0242OC
   Asti C, 2000, PULM PHARMACOL THER, V13, P61, DOI 10.1006/pupt.2000.0231
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657
   Hanawa H, 2002, MOL THER, V5, P242, DOI 10.1006/mthe.2002.0549
   He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f
   He TR, 2004, STROKE, V35, P2378, DOI 10.1161/01.STR.0000141893.33677.5d
   Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673
   Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035
   Knepler JL, 2001, AM J PHYSIOL-CELL PH, V281, pC1064, DOI 10.1152/ajpcell.2001.281.3.C1064
   Kristof AS, 1998, AM J RESP CRIT CARE, V158, P1883, DOI 10.1164/ajrccm.158.6.9802100
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   LAMY M, 1976, AM REV RESPIR DIS, V114, P267
   Lee JW, 2009, EXPERT OPIN BIOL TH, V9, P1259, DOI 10.1517/14712590903213651
   Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904
   Liu Y, 2011, J BIOL CHEM, V286, P25007, DOI 10.1074/jbc.M110.213108
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Mao M, 2010, SHOCK, V34, P196, DOI 10.1097/SHK.0b013e3181d49457
   Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13
   Mikawa K, 1998, CRIT CARE MED, V26, P905, DOI 10.1097/00003246-199805000-00026
   Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195, DOI 10.1164/ajrccm.163.1.9912036
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Newman Robert E., 2009, Inflammation & Allergy Drug Targets, V8, P110
   Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002
   OBERLEY LW, 1979, CANCER RES, V39, P1141
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Phua J, 2008, CRIT CARE MED, V36, P2912, DOI 10.1097/CCM.0b013e31817d20bd
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weiss Daniel J, 2008, Proc Am Thorac Soc, V5, P637, DOI 10.1513/pats.200804-037DW
   Yamada M, 2005, THORAX, V60, P410, DOI 10.1136/thx.2004.034058
   Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266
NR 37
TC 41
Z9 47
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2012
VL 116
IS 6
BP 1278
EP 1287
DI 10.1097/ALN.0b013e3182567f84
PG 10
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA 946MR
UT WOS:000304356500018
PM 22546965
OA Bronze
DA 2023-08-21
ER

PT J
AU Emin, MT
   Sun, L
   Huertas, A
   Das, S
   Bhattacharya, J
   Bhattacharya, S
AF Emin, Memet T.
   Sun, Li
   Huertas, Alice
   Das, Shonit
   Bhattacharya, Jahar
   Bhattacharya, Sunita
TI Platelets induce endothelial tissue factor expression in a mouse model
   of acid-induced lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE von Willebrand factor; P-selectin; ROS; CD41; gp91phox-/- 
ID PERMEABILITY; COAGULATION; MECHANISMS; THROMBOSIS; PRESSURE; ADHESION;
   PROTEIN; CELLS
AB Emin MT, Sun L, Huertas A, Das S, Bhattacharya J, Bhattacharya S. Platelets induce endothelial tissue factor expression in a mouse model of acid-induced lung injury. Am J Physiol Lung Cell Mol Physiol 302: L1209-L1220, 2012. First published April 13, 2012; doi: 10.1152/ajplung.00189.2011.-Although the lung expresses procoagulant proteins under inflammatory conditions, underlying mechanisms remain unclear. Here, we addressed lung endothelial expression of tissue factor (TF), which initiates the coagulation cascade and expression of which signifies development of a procoagulant phenotype in the vasculature. To establish the model of acid-induced acute lung injury (ALI), we intranasally instilled anesthetized mice with saline or acid. Then 2 h later, we isolated pulmonary vascular cells for flow cytometry and confocal microscopy to detect the leukocyte antigen, CD45 and the endothelial markers VE-cadherin and von Willebrand factor (vWf). Acid increased both the number of vWf-expressing cells as well as TF and P-selectin expressions on these cells. All of these effects were markedly inhibited by treating mice with antiplatelet serum, suggesting the involvement of platelets. The increased expressions of TF, vWf, and P-selectin in response to acid also occurred in platelets. Moreover, the effects were replicated in endothelial cells derived from isolated, blood-perfused lungs. However, the effect was inhibited completely in lungs perfused with platelet-depleted and, to a lesser extent, with leukocyte-depleted blood. Acid injury increased endothelial expressions of the platelet proteins, CD41 and CD42b, providing evidence that platelet proteins were transferred to the vascular surface. Reactive oxygen species (ROS) were implicated in these responses, in that the endothelial and platelet protein expressions were inhibited. We conclude that acid-induced ALI causes NOX2-mediated ROS generation that activates platelets, which then generate a procoagulant endothelial surface.
C1 [Bhattacharya, Sunita] Columbia Univ, Dept Pediat, Coll Phys & Surg, New York, NY 10032, United States.
C1 [Emin, Memet T.; Sun, Li; Huertas, Alice; Das, Shonit; Bhattacharya, Jahar; Bhattacharya, Sunita] Columbia Univ, Dept Pulm Allergy & Crit Care Med, Coll Phys & Surg, New York, NY 10032, United States.
C3 Columbia University; Columbia University
RP Bhattacharya, S (corresponding author), Columbia Univ, Dept Pediat, Coll Phys & Surg, 630 W 168th St,BB 8-812, New York, NY 10032 USA.
EM sb80@columbia.edu
RI Huertas, Alice/E-8244-2017
OI Huertas, Alice/0000-0001-8545-747X
FU National Institutes of Health [HL36024]
FX This study was supported by National Institutes of Health Grant HL36024
   (to J. Bhattacharya).
CR Allen GB, 2009, AM J PHYSIOL-LUNG C, V296, pL277, DOI 10.1152/ajplung.90475.2008
   Andrews RK, 2008, J CLIN INVEST, V118, P3009, DOI 10.1172/JCI36883
   Bhattacharya S, 2003, AM J RESP CELL MOL, V28, P218, DOI 10.1165/rcmb.4763
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Chetham PM, 1999, AM J PHYSIOL-LUNG C, V276, pL41, DOI 10.1152/ajplung.1999.276.1.L41
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095
   Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082
   Ichimura H, 2005, AM J PHYSIOL-LUNG C, V289, pL407, DOI 10.1152/ajplung.00048.2005
   Ichimura H, 2003, J CLIN INVEST, V111, P691, DOI 10.1172/JCI200317271
   IDELL S, 1989, J CLIN INVEST, V84, P181, DOI 10.1172/JCI114139
   Kretz CA, 2010, ARTERIOSCL THROM VAS, V30, P900, DOI 10.1161/ATVBAHA.108.177477
   Kuebler WM, 1999, J CLIN INVEST, V104, P495, DOI 10.1172/JCI6872
   Kyriakides C, 2000, SURGERY, V128, P327, DOI 10.1067/msy.2000.108216
   Lu QJ, 2011, ARTIF ORGANS, V35, P137, DOI 10.1111/j.1525-1594.2010.01051.x
   Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175
   Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530
   Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727
   Osterud B, 2010, THROMB RES, V125, pS31, DOI 10.1016/j.thromres.2010.01.032
   Owens AP, 2010, THROMB HAEMOSTASIS, V104, P432, DOI 10.1160/TH09-11-0771
   Pawlinski R, 2010, BLOOD, V116, P806, DOI 10.1182/blood-2009-12-259267
   Prabhakaran P, 2003, AM J PHYSIOL-LUNG C, V285, pL20, DOI 10.1152/ajplung.00312.2002
   Ruggeri ZM, 2007, CIRC RES, V100, P1673, DOI 10.1161/01.RES.0000267878.97021.ab
   Solovey A, 2004, BLOOD, V104, P840, DOI 10.1182/blood-2003-10-3719
   Tabuchi A, 2008, VASC PHARMACOL, V49, P141, DOI 10.1016/j.vph.2008.06.004
   Terrisse AD, 2010, J THROMB HAEMOST, V8, P2810, DOI 10.1111/j.1538-7836.2010.04088.x
   Totani L, 2010, ARTERIOSCL THROM VAS, V30, P2357, DOI 10.1161/ATVBAHA.110.207480
   Valentijn KM, 2011, BLOOD, V117, P5033, DOI 10.1182/blood-2010-09-267492
   Van der Poll T, 2008, CRIT CARE, V12, P1
   Yiming MT, 2008, AM J RESP CELL MOL, V39, P569, DOI 10.1165/rcmb.2007-0332OC
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
NR 33
TC 14
Z9 15
U1 0
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUN
PY 2012
VL 302
IS 11
BP L1209
EP L1220
DI 10.1152/ajplung.00189.2011
PG 12
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 960VR
UT WOS:000305420600009
PM 22505671
OA Green Published
DA 2023-08-21
ER

PT J
AU Rahman, M
   Roller, J
   Zhang, S
   Syk, I
   Menger, MD
   Jeppsson, B
   Thorlacius, H
AF Rahman, Milladur
   Roller, Jonas
   Zhang, Su
   Syk, Ingvar
   Menger, Michael D.
   Jeppsson, Bengt
   Thorlacius, Henrik
TI Metalloproteinases regulate CD40L shedding from platelets and pulmonary
   recruitment of neutrophils in abdominal sepsis
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Adhesion; neutrophils; chemokines; ALI/ARDS; sepsis 
ID CECAL LIGATION; LUNG INJURY; MATRIX METALLOPROTEINASES; SEPTIC SHOCK;
   SEQUESTRATION; PUNCTURE; RATS; INFLAMMATION; INHIBITION; MECHANISMS
AB Platelets promote sepsis-induced activation of neutrophils via secretion of CD40L. However, the mechanism regulating the release of platelet-derived CD40L is not known. We hypothesized that matrix metalloproteinases (MMPs) might regulate shedding of platelet-expressed CD40L and neutrophil activation in sepsis.
   Wild-type C57BL/6 mice were subjected to cecal ligation and puncture (CLP). Animals were pretreated with a broad-range MMP inhibitor, GM6001, prior to CLP induction. Edema formation, CXC chemokine and myeloperoxidase (MPO) levels and bronchoalveolar neutrophils in the lung as well as plasma levels of CD40L were quantified. Flow cytometry was used to determine expression of Mac-1 on neutrophils and CD40L on platelets. Intravital fluorescence microscopy was used to analyze leukocyte-endothelial cell interactions in the pulmonary microcirculation.
   The MMP inhibitor reduced sepsis-induced release of CD40L and maintained normal levels of CD40L on platelets. Inhibition of MMP decreased CLP-induced neutrophil expression of Mac-1, formation of CXC chemokines and edema as well as neutrophil infiltration in the lung. Intravital fluorescence microscopy revealed that the MMP inhibitor attenuated leukocyte adhesion in venules whereas capillary trapping of leukocytes was not affected by MMP inhibition.
   We describe a novel role of metalloproteinases in regulating platelet-dependent activation and infiltration of neutrophils in septic lung injury which might be related to controlling CD40L shedding from platelets. We conclude that targeting metalloproteinases may be a useful strategy for limiting acute lung injury in abdominal sepsis.
C1 [Rahman, Milladur; Roller, Jonas; Zhang, Su; Syk, Ingvar; Jeppsson, Bengt; Thorlacius, Henrik] Lund Univ, Sect Surg, Dept Clin Sci, Skane Univ Hosp, S-20502 Malmo, Sweden.
C1 [Roller, Jonas; Menger, Michael D.] Univ Saarland, Inst Clin & Expt Surg, D-6650 Homburg, Germany.
C3 Lund University; Skane University Hospital; Saarland University
RP Thorlacius, H (corresponding author), Lund Univ, Sect Surg, Dept Clin Sci, Skane Univ Hosp, S-20502 Malmo, Sweden.
EM henrik.thorlacius@med.lu.se
RI Rahman, Milladur/ABF-9885-2021
OI Rahman, Milladur/0000-0002-8883-4848
FU Swedish Medical Research Council [2009-4872]; Crafoordska stiftelsen;
   Einar och Inga Nilssons stiftelse; Harald och Greta Jaenssons stiftelse;
   Greta och Johan Kocks stiftelser; Froken Agnes Nilssons stiftelse;
   Franke och Margareta Bergqvists stiftelse for framjande av
   cancerforskning; Magnus Bergvalls stiftelse; Mossfelts stiftelse; Nanna
   Svartz stiftelse; Ruth och Richard Julins stiftelse; Svenska
   Lakaresallskapet; Allmana sjukhusets i Malmo stiftelse for bekampande av
   cancer; MAS; Malmo University Hospital; Lund University
FX This work was supported by grants from the Swedish Medical Research
   Council (2009-4872), Crafoordska stiftelsen, Einar och Inga Nilssons
   stiftelse, Harald och Greta Jaenssons stiftelse, Greta och Johan Kocks
   stiftelser, Froken Agnes Nilssons stiftelse, Franke och Margareta
   Bergqvists stiftelse for framjande av cancerforskning, Magnus Bergvalls
   stiftelse, Mossfelts stiftelse, Nanna Svartz stiftelse, Ruth och Richard
   Julins stiftelse, Svenska Lakaresallskapet, Allmana sjukhusets i Malmo
   stiftelse for bekampande av cancer, MAS fonder, Malmo University
   Hospital and Lund University.
CR Asaduzzaman M, 2008, SHOCK, V30, P254, DOI 10.1097/shk.0b013e318162c567
   Asaduzzaman M, 2009, CRIT CARE MED, V37, P1389, DOI 10.1097/CCM.0b013e31819ceb71
   Babayigit H, 2005, INTENS CARE MED, V31, P865, DOI 10.1007/s00134-005-2629-x
   Cena JJ, AM J PHYSL HEART CIR, V298, pH45
   Chew M, 2010, INFLAMM RES, V59, P979, DOI 10.1007/s00011-010-0213-5
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Czermak BJ, 1999, AM J PATHOL, V154, P1057, DOI 10.1016/S0002-9440(10)65358-8
   DOWNEY GP, 1993, AM REV RESPIR DIS, V147, P168, DOI 10.1164/ajrccm/147.1.168
   GORBACH SL, 1974, NEW ENGL J MED, V290, P1177, DOI 10.1056/NEJM197405232902106
   Henn V, 2001, BLOOD, V98, P1047, DOI 10.1182/blood.V98.4.1047
   Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006
   Inwald DP, 2006, INTENS CARE MED, V32, P1432, DOI 10.1007/s00134-006-0250-2
   Maitra SR, 2003, SHOCK, V20, P280, DOI 10.1097/00024382-200309000-00014
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Nolte D, 2004, EUR SURG RES, V36, P331, DOI 10.1159/000081641
   PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008
   Ra HJ, 2007, MATRIX BIOL, V26, P587, DOI 10.1016/j.matbio.2007.07.001
   Rahman M, 2009, ANN SURG, V250, P783, DOI 10.1097/SLA.0b013e3181bd95b7
   Remick DG, 2007, AM J PATHOL, V170, P1435, DOI 10.2353/ajpath.2007.060872
   Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004
   Schramm R, 2003, INFECT IMMUN, V71, P2542, DOI 10.1128/IAI.71.5.2542-2547.2003
   Senft AP, 2005, J IMMUNOL, V174, P4953, DOI 10.4049/jimmunol.174.8.4953
   Sikora L, 2003, AM J PATHOL, V162, P2019, DOI 10.1016/S0002-9440(10)64334-9
   SIMON GL, 1984, GASTROENTEROLOGY, V86, P174
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Steinberg J, 2003, J SURG RES, V111, P185, DOI 10.1016/S0022-4804(03)00089-1
   WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
   Yoshida K, 2006, AM J RESP CRIT CARE, V174, P689, DOI 10.1164/rccm.200502-276OC
NR 28
TC 32
Z9 34
U1 0
U2 2
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD JUN
PY 2012
VL 61
IS 6
BP 571
EP 579
DI 10.1007/s00011-012-0446-6
PG 9
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 939OB
UT WOS:000303820100006
PM 22349180
OA Green Submitted
DA 2023-08-21
ER

PT J
AU Saeed, AI
   Rieder, SA
   Price, RL
   Barker, J
   Nagarkatti, P
   Nagarkatti, M
AF Saeed, Ali Imran
   Rieder, Sadiye Amcaoglu
   Price, Robert L.
   Barker, James
   Nagarkatti, Prakash
   Nagarkatti, Mitzi
TI Acute Lung Injury Induced by Staphylococcal enterotoxin B: Disruption of
   Terminal Vessels as a Mechanism of Induction of Vascular Leak
SO MICROSCOPY AND MICROANALYSIS
LA English
DT Article
DE electron microscopy; pulmonary vascular leak; ALI/ARDS 
ID RESPIRATORY-DISTRESS-SYNDROME; EUROPEAN CONSENSUS CONFERENCE; RED-CELL
   TRAVERSE; ARDS; INVOLVEMENT; STRATEGIES
AB The current hypothesis of alveolar capillary membrane dysfunction fails to completely explain the severe and persistent leak of protein-rich fluid into the pulmonary interstitium, seen in the exudative phase of acute lung injury (ALI). The presence of intact red blood cells in the pulmonary interstitium may suggest mechanical failure of pulmonary arterioles and venules. These studies involved the pathological and ultrastructural evaluation of the pulmonary vasculature in Staphylococcal enterotoxin B (SEB)-induced ALI. Administration of SEB resulted in a significant increase in the protein concentration of bronchoalveolar lavage fluid and vascular leak in SEB-exposed mice compared to vehicle-treated mice. In vivo imaging of mice demonstrated the pulmonary edema and leakage in the lungs of SEB-administered mice. The histopathological studies showed intense clustering of inflammatory cells around the alveolar capillaries with subtle changes in architecture. Electron microscopy studies further confirmed the diffuse damage and disruption in the muscularis layer of the terminal vessels. Cell death in the endothelial cells of the terminal vessels was confirmed with TUNEL staining. In this study, we demonstrated that in addition to failure of the alveolar capillary membrane, disruption of the pulmonary arterioles and venules may explain the persistent and severe interstitial and alveolar edema.
C1 [Rieder, Sadiye Amcaoglu; Nagarkatti, Prakash; Nagarkatti, Mitzi] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29209, United States.
C1 [Saeed, Ali Imran; Barker, James] Univ S Carolina, Sch Med, Dept Internal Med, Div Pulmonol, Columbia, SC 29209, United States.
C1 [Price, Robert L.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29209, United States.
C3 University of South Carolina System; University of South Carolina
   Columbia; University of South Carolina System; University of South
   Carolina Columbia; University of South Carolina System; University of
   South Carolina Columbia
RP Nagarkatti, M (corresponding author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29209 USA.
EM Mitzi.Nagarkatti@uscmed.sc.edu
OI Nagarkatti, Prakash/0000-0003-2663-0759
FU NCCIH NIH HHS [P01 AT003961] Funding Source: Medline
CR Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005
   Beasley MB, 2010, ARCH PATHOL LAB MED, V134, P719, DOI 10.1043/1543-2165-134.5.719
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Campbell WN, 1997, AM J PHYSIOL-LUNG C, V273, pL31, DOI 10.1152/ajplung.1997.273.1.L31
   Collar JE, 2001, KIDNEY INT, V59, P2069, DOI 10.1046/j.1523-1755.2001.0590062069.x
   Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee
   Fraser JD, 2008, IMMUNOL REV, V225, P226, DOI 10.1111/j.1600-065X.2008.00681.x
   Green DR, 2011, MOL CELL, V44, P9, DOI 10.1016/j.molcel.2011.09.003
   Henghold WB, 2004, DERMATOL CLIN, V22, P257, DOI 10.1016/j.det.2004.03.004
   Liapis H, 2002, KIDNEY INT, V61, P762, DOI 10.1046/j.1523-1755.2002.00181.x
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   MATTIX ME, 1995, TOXICOL PATHOL, V23, P262, DOI 10.1177/019262339502300304
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Maybauer MO, 2006, NEW ENGL J MED, V354, P416
   MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61, DOI 10.1152/ajplung.1994.266.1.L61
   Neumann B, 1997, J IMMUNOL, V158, P1862
   PERSSON CCA, 1986, EUR J RESPIR DIS, V68, P190
   PETER J.V., 2007, BMJ-BRIT MED J, V336, P1006
   Rafi AQ, 1998, J IMMUNOL, V161, P3077
   Rafi-Janajreh AQ, 1999, J IMMUNOL, V163, P1619
   Rieder SA, 2011, INFECT IMMUN, V79, P3141, DOI 10.1128/IAI.00177-11
   Teke Z, 2011, SURG TODAY, V41, P955, DOI 10.1007/s00595-010-4394-x
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
NR 27
TC 18
Z9 18
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1431-9276
EI 1435-8115
J9 MICROSC MICROANAL
JI Microsc. microanal.
PD JUN
PY 2012
VL 18
IS 3
BP 445
EP 452
DI 10.1017/S1431927612000190
PG 8
WC Materials Science, Multidisciplinary; Microscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science; Microscopy
GA 949VJ
UT WOS:000304604000003
PM 22571856
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Tulapurkar, ME
   Almutairy, EA
   Shah, NG
   He, JR
   Puche, AC
   Shapiro, P
   Singh, IS
   Hasday, JD
AF Tulapurkar, Mohan E.
   Almutairy, Eid A.
   Shah, Nirav G.
   He, Ju-ren
   Puche, Adam C.
   Shapiro, Paul
   Singh, Ishwar S.
   Hasday, Jeffrey D.
TI Febrile-Range Hyperthermia Modifies Endothelial and Neutrophilic
   Functions to Promote Extravasation
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; neutrophil; ECs/HPMECs/HUVECs/MPVECs; febrile-range hyperthermia; MAPK 
ID ACTIVATED PROTEIN-KINASE; RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG
   INJURY; IN-VIVO; CRITICALLY-ILL; MAP KINASE; MIGRATION; CELLS;
   TEMPERATURE; RECRUITMENT
AB Acute respiratory distress syndrome (ARDS) is a neutrophil (polymorphonuclear leukocyte; PMN)-driven lung injury that is associated with fever and heat-stroke, and involves approximately 40% mortality. In murine models of acute lung injury (ALI), febrile-range hyperthermia (FRH) enhanced PMN accumulation, vascular permeability, and epithelial injury, in part by augmenting pulmonary cysteine-x-cysteine (CXC) chemokine expression. To determine whether FRH increases chemokine responsiveness within the lung, we used in vivo and in vitro models that bypass the endogenous generation of chemokines. We measured PMN transalveolar migration (TAM) in mice after intratracheal instillations of the human CXC chemokine IL-8 in vivo, and of IL-8-directed PMN transendothelial migration (TEM) through human lung microvascular endothelial cell (HMVEC-L) monolayers in vitro. Pre-exposure to FRH increased in vivo IL-8-directed PMN TAM by 23.5-fold and in vitro TEM by 7-fold. Adoptive PMN transfer demonstrated that enhanced PMN TAM required both PMN donors and recipients to be exposed to FRH, suggesting interdependent effects on PMNs and endothelium. FRH exposure caused the activation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase in lung homogenates and circulating PMNs, with an associated increase in HSP27 phosphorylation and stress-fiber formation. The inhibition of these signaling pathways with U0126 and SB203580 blocked the effects of FRH on PMN extravasation in vivo and in vitro. Collectively, these results (1) demonstrate that FRH augments chemokine-directed PMN extravasation through direct effects on endothelium and PMNs, (2) identify ERK and p38 signaling pathways in the effect, and (3) underscore the complex effects of physiologic temperature change on innate immune function and its potential consequences for lung injury.
C1 [Hasday, Jeffrey D.] Univ Maryland, Div Pulm & Crit Care, Dept Med, Sch Med,Hlth Sci Facil 2, Baltimore, MD 21201, United States.
C1 [Tulapurkar, Mohan E.; Singh, Ishwar S.; Hasday, Jeffrey D.] Univ Maryland, Mucosal Biol Res Ctr, Sch Med, Baltimore, MD 21201, United States.
C1 [Shapiro, Paul] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201, United States.
C1 [Puche, Adam C.] Univ Maryland, Dept Anat & Neurobiol, Baltimore, MD 21201, United States.
C1 [He, Ju-ren; Singh, Ishwar S.; Hasday, Jeffrey D.] Baltimore Vet Adm Med Ctr, Res Serv, Baltimore, MD, United States.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Hasday, JD (corresponding author), Univ Maryland, Div Pulm & Crit Care, Dept Med, Sch Med,Hlth Sci Facil 2, Rm S347,20 Penn St, Baltimore, MD 21201 USA.
EM jhasday@umaryland.edu
RI tulapurkar, mohan/F-1926-2015; Al-Mutairy, Eid Abdullah/IZE-2971-2023
OI tulapurkar, mohan/0000-0002-2476-5417; Al-Mutairy, Eid
   Abdullah/0009-0002-2306-0842
FU National Institutes of Heath grants [GM069431, GM066855, HL69057,
   HL085256]; Veterans Administration Merit Review grants
FX This work was supported by National Institutes of Heath grants GM069431
   (I.S.S.), GM066855, HL69057, and HL085256 (J.D.H.), and by Veterans
   Administration Merit Review grants (J.D.H. and I.S.S.).
CR Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005
   Bokemeyer D, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017576.50319.AC
   Bota DP, 2004, INTENS CARE MED, V30, P811, DOI 10.1007/s00134-004-2166-z
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cara DC, 2001, J IMMUNOL, V167, P6552, DOI 10.4049/jimmunol.167.11.6552
   Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC
   Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928
   Cross AS, 2003, J BIOL CHEM, V278, P4112, DOI 10.1074/jbc.M207591200
   Damarla M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004600
   DOERSCHUK CM, 1993, J APPL PHYSIOL, V74, P3040, DOI 10.1152/jappl.1993.74.6.3040
   ELKASSIMI FA, 1986, CHEST, V90, P571, DOI 10.1378/chest.90.4.571
   Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817
   Hasday JD, 2003, AM J PATHOL, V162, P2005, DOI 10.1016/S0002-9440(10)64333-7
   Hasday JD, 2001, J APPL PHYSIOL, V90, P90, DOI 10.1152/jappl.2001.90.1.90
   Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038
   Jog NR, 2007, J IMMUNOL, V178, P2421, DOI 10.4049/jimmunol.178.4.2421
   Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174
   Laupland KB, 2008, CRIT CARE MED, V36, P1531, DOI 10.1097/CCM.0b013e318170efd3
   LEE J, 1995, J IMMUNOL, V155, P2158
   MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221
   MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231
   MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903
   Nagarsekar A, 2005, IMMUNOL INVEST, V34, P381, DOI 10.1081/IMM-200067648
   Nagarsekar A, 2008, J IMMUNOL, V181, P2636, DOI 10.4049/jimmunol.181.4.2636
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Rice P, 2005, J IMMUNOL, V174, P3676, DOI 10.4049/jimmunol.174.6.3676
   Sareh H, 2010, CELL STRESS CHAPERON
   Seo SM, 2001, AM J PHYSIOL-CELL PH, V281, pC1568, DOI 10.1152/ajpcell.2001.281.5.C1568
   Singh IS, 2008, AM J RESP CELL MOL, V39, P235, DOI 10.1165/rcmb.2007-0294OC
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Stein BN, 2003, J IMMUNOL, V171, P6097, DOI 10.4049/jimmunol.171.11.6097
   Szczur K, 2006, BLOOD, V108, P4205, DOI 10.1182/blood-2006-03-013789
   Takami M, 2002, J IMMUNOL, V168, P4559, DOI 10.4049/jimmunol.168.9.4559
   Tulapurkar ME, 2009, CELL STRESS CHAPERON, V14, P499, DOI 10.1007/s12192-009-0103-3
   Wagner JG, 2000, PHARMACOL REV, V52, P349
   Wang Q, 2005, AM J PHYSIOL-LUNG C, V288, pL359, DOI 10.1152/ajplung.00292.2004
   Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877
   Ward KW, 2001, PHARMACEUT RES, V18, P1336, DOI 10.1023/A:1013002414678
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Woodfin A, 2009, BLOOD, V113, P6246, DOI 10.1182/blood-2008-11-188375
NR 42
TC 25
Z9 25
U1 0
U2 6
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD JUN
PY 2012
VL 46
IS 6
BP 807
EP 814
DI 10.1165/rcmb.2011-0378OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 986RS
UT WOS:000307362800012
PM 22281986
OA Green Published
DA 2023-08-21
ER

PT J
AU Umapathy, NS
   Gonzales, J
   Fulzele, S
   Kim, KM
   Lucas, R
   Verin, AD
AF Umapathy, Nagavedi Siddaramappa
   Gonzales, Joyce N.
   Fulzele, Sadanand
   Kim, Kyung-mi
   Lucas, Rudolf
   Verin, Alexander D.
TI beta-Nicotinamide adenine dinucleotide attenuates
   lipopolysaccharide-induced inflammatory effects in a murine model of
   acute lung injury
SO EXPERIMENTAL LUNG RESEARCH
LA English
DT Article
DE ALI/ARDS; cytokines; Inflammation; LPS; beta-NAD 
ID RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE SYNTHASE; EXTRACELLULAR
   NAD(+); HUMAN GRANULOCYTES; ENDOTHELIAL-CELLS; ANIMAL-MODELS; SEPTIC
   SHOCK; ACTIVATION; SEPSIS; PERMEABILITY
AB Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) occur in approximately 200,000 patients per year. Studies indicate that lung endothelium plays a significant role in ALI. The authors' recent in vitro studies demonstrate a novel mechanism of beta-nicotinamide adenine dinucleotide (beta-NAD)-induced protection against gram-positive (pneumolysin, PLY) and gram-negative (lipopolysaccharide, LPS) toxin-induced lung endothelial cell (EC) barrier dysfunction. The objective of the current study was to evaluate the protective effect of beta-NAD against LPS-induced ALI in mice. C57BL/6J mice were randomly divided into 4 groups: vehicle, beta-NAD, LPS, and LPS/beta-NAD. After surgery, mice were allowed to recover for 24 hours. Evans blue dye-albumin (EBA) was given through the internal jugular vein 2 hours prior to the termination of the experiments. Upon sacrificing the animals, bronchoalveolar lavage fluid (BALF) was collected and the lungs were harvested. beta-NAD treatment significantly attenuated the inflammatory response by means of reducing the accumulation of cells and protein in BALF, blunting the parenchymal neutrophil infiltration, and preventing capillary leak. In addition, the histological examination demonstrated decreased interstitial edema in the LPS/beta-NAD specimens, as compared to the LPS-only specimens. The mRNA levels of the anti-inflammatory cytokines were up-regulated in the LPS group treated with beta-NAD compared to the LPS-only-treated group. beta-NAD treatment down-regulated the mRNA levels of the proinflammatory cytokines. These findings suggest that beta-NAD could be investigated as a therapeutic option against bacterial toxin-induced lung inflammation and ALI in mice.
C1 [Umapathy, Nagavedi Siddaramappa; Gonzales, Joyce; Kim, Kyung-mi; Lucas, Rudolf; Verin, Alexander Dimitrievich] Georgia Hlth Sci Univ, Vasc Biol Ctr, Augusta, GA 30912, United States.
C1 [Umapathy, Nagavedi Siddaramappa; Gonzales, Joyce; Verin, Alexander Dimitrievich] Georgia Hlth Sci Univ, Sect Pulm & Crit Care Med, Augusta, GA 30912, United States.
C1 [Fulzele, Sadanand] Georgia Hlth Sci Univ, Dept Orthopaed Surg, Augusta, GA 30912, United States.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University
RP Umapathy, NS (corresponding author), Georgia Hlth Sci Univ, Vasc Biol Ctr, 1459 Laney Walker Blvd,CB3701, Augusta, GA 30912 USA.
EM usiddaramappa@georgiahealth.edu
RI Lucas, Rudolf/G-5197-2012; Lucas, Rudolf/ABA-3011-2020
OI Verin, Alexander/0000-0003-0627-7185; Lucas, Rudolf/0000-0003-3805-8868
FU American Lung Association (Southeast); National Institute of Health
   [HL094609, HL083327, HL101902]
FX This work was supported, in part, by grants, Biomedical Research Grant
   from the American Lung Association (Southeast) to N.S.U. and the
   National Institute of Health (HL094609 to R. L. and HL083327 and
   HL101902 to A. D. V. and N.S.U.).
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200
   Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010
   [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004477.PUB2
   Bastarache JA, 2009, DIS MODEL MECH, V2, P218, DOI 10.1242/dmm.001677
   Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006
   BERSTEN A, 1989, CRIT CARE CLIN, V5, P49
   Boe DM, 2010, ALCOHOL CLIN EXP RES, V34, P1723, DOI 10.1111/j.1530-0277.2010.01259.x
   Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235
   Bruzzone S, 2006, BIOCHEM J, V393, P697, DOI 10.1042/BJ20051302
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972
   Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503
   Han XN, 2003, J PHARMACOL EXP THER, V307, P443, DOI 10.1124/jpet.103.056556
   Imai SI, 2010, BBA-PROTEINS PROTEOM, V1804, P1584, DOI 10.1016/j.bbapap.2009.10.024
   Imai SI, 2009, BIOCH BIOPHYS A 1106
   Kim JY, 2005, AM J PHYSIOL-LUNG C, V288, pL958, DOI 10.1152/ajplung.00359.2004
   Kolosova IA, 2008, AM J PHYSIOL-LUNG C, V294, pL319, DOI 10.1152/ajplung.00283.2007
   Li YQ, 2009, SHOCK, V32, P517, DOI 10.1097/SHK.0b013e3181a44c79
   Liu Jing-Chen, 2008, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V33, P1095
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   Luce JM, 1998, CRIT CARE MED, V26, P369, DOI 10.1097/00003246-199802000-00043
   Mako V, 2010, CYTOM PART A, V77A, P962, DOI 10.1002/cyto.a.20952
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mehta D, 2004, AM J PHYSIOL-LUNG C, V287, pL1081, DOI 10.1152/ajplung.00268.2004
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206
   Moreschi I, 2006, J BIOL CHEM, V281, P31419, DOI 10.1074/jbc.M606625200
   Mutafova-Yambolieva VN, 2007, P NATL ACAD SCI USA, V104, P16359, DOI 10.1073/pnas.0705510104
   Pillai VB, 2009, J BIOL CHEM     1124
   Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003
   Schmickl CN, 2011, CHEST           1026
   Seitz DH, 2011, SHOCK           1115
   Smyth LM, 2004, J BIOL CHEM, V279, P48893, DOI 10.1074/jbc.M407266200
   Spandidos A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-633
   Suda K, 2011, AM J RESP CELL MOL, V45, P510, DOI 10.1165/rcmb.2010-0169OC
   Tang SM, 2009, ALCOHOL CLIN EXP RES, V33, P1197, DOI 10.1111/j.1530-0277.2009.00943.x
   Umapathy NS, 2010, J CELL PHYSIOL, V223, P215, DOI 10.1002/jcp.22029
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Virag L, 2005, PHARMACOL RES, V52, P83, DOI 10.1016/j.phrs.2005.02.012
   Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017
   Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672
   Zhang L, 2011, J CELL PHYSIOL, V226, P1694, DOI 10.1002/jcp.22500
   Zheng C, 2012, NEUROSCI LETT   0112
NR 51
TC 12
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0190-2148
EI 1521-0499
J9 EXP LUNG RES
JI Exp. Lung Res.
PD JUN
PY 2012
VL 38
IS 5
BP 223
EP 232
DI 10.3109/01902148.2012.673049
PG 10
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA 937OY
UT WOS:000303669000001
PM 22563684
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Bercovitz, RS
   Kelher, MR
   Khan, SY
   Land, KJ
   Berry, TH
   Silliman, CC
AF Bercovitz, R. S.
   Kelher, Marguerite R.
   Khan, Samina Y.
   Land, K. J.
   Berry, T. H.
   Silliman, Christopher C.
TI The pro-inflammatory effects of platelet contamination in plasma and
   mitigation strategies for avoidance
SO VOX SANGUINIS
LA English
DT Article
DE plasma; sCD40L; transfusion; ALI/ARDS 
ID ACUTE LUNG INJURY; RED-BLOOD-CELLS; ROUTINE STORAGE; GROWTH-FACTORS;
   LIGAND CD154; TRANSFUSION; TRALI; NEUTROPHILS; CD40; REDUCTION
AB Background and Objectives Plasma and platelet concentrates are disproportionately implicated in transfusion-related acute lung injury (TRALI). Platelet-derived pro-inflammatory mediators, including soluble CD40 ligand (sCD40L), accumulate during storage. We hypothesized that platelet contamination induces sCD40L generation that causes neutrophil [polymorphonuclear leucocyte (PMN)] priming and PMN-mediated cytotoxicity. Materials and Methods Plasma was untreated, centrifuged (12 500 g) or separated from leucoreduced whole blood (WBLR) prior to freezing. Platelet counts and sCD40L concentrations were measured 1-5 days post-thaw. The plasma was assayed for PMN priming activity and was used in a two-event in vitro model of PMN-mediated human pulmonary microvascular endothelial cell (HMVEC) cytotoxicity. Results Untreated plasma contained 42 +/- 4 2 . 10(3) / ll platelets, which generated sCD40L accumulation (1 6-eight-fold vs. controls). Priming activity and HMVEC cytotoxicity were directly proportional to sCD40L concentration. WBLR and centrifugation reduced platelet and sCD40L contamination, abrogating the pro-inflammatory potential. Conclusion Platelet contamination causes sCD40L accumulation in stored plasma that may contribute to TRALI. Platelet reduction is potentially the first TRALI mitigation effort in plasma manufacturing.
C1 [Bercovitz, R. S.; Kelher, M. R.; Khan, S. Y.; Berry, T. H.; Silliman, C. C.] Bonfils Blood Ctr, Denver, CO, United States.
C1 [Bercovitz, R. S.; Khan, S. Y.; Silliman, C. C.] Univ Colorado, Dept Paediat, Sch Med, Aurora, CO, United States.
C1 [Kelher, M. R.; Silliman, C. C.] Univ Colorado, Dept Surg, Sch Med, Aurora, CO, United States.
C1 [Land, K. J.] S Texas Blood & Tissue Ctr, San Antonio, TX, United States.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus
RP Bercovitz, RS (corresponding author), 13123 E 16th Ave,B-115, Aurora, CO 80045 USA.
EM bercovitz.rachel@tchden.org
RI Land, Kevin/AAB-3037-2022
OI Land, Kevin/0000-0001-9652-1617; Bercovitz, Rachel/0000-0002-6399-1249
FU National Institutes of Health, NIGMS [P50 GM49222]
FX Dr. Bercovitz is supported by the National Blood Foundation Research
   Scientist Training Grant. We would like to thank the Production and
   Quality Control Departments for their assistance in the acquisition and
   processing of the blood components. We would like to thank the
   Specialized Donation Department at Bonfils Blood Centre for their
   assistance in arranging volunteer donations. This work was also
   supported in part by a grant from National Institutes of Health, NIGMS
   (P50 GM49222).
CR AABB, 1996, STAND BLOOD BANKS TR
   American Association of Blood Banks, 2011, TECHN MAN AM ASS BLO, V203-204, P279
   Ancelin M, 2004, LAB INVEST, V84, P502, DOI 10.1038/labinvest.3700053
   Asaduzzaman M, 2009, CRIT CARE MED, V37, P1389, DOI 10.1097/CCM.0b013e31819ceb71
   Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7
   Blumberg N, 2006, TRANSFUSION, V46, P1813, DOI 10.1111/j.1537-2995.2006.00979.x
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Chin Tad Muon M, 2005, BLOOD TRANSFUSIONS E, P159
   Densmore TL, 1999, TRANSFUSION, V39, P103, DOI 10.1046/j.1537-2995.1999.39199116901.x
   Dunn P, 2008, NEW ZEAL MED J, V121, P42
   Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x
   Eder AF, 2010, TRANSFUSION, V50, P1732, DOI 10.1111/j.1537-2995.2010.02652.x
   Eder AF, 2009, J CLIN APHERESIS, V24, P122, DOI 10.1002/jca.20198
   Elzi DJ, 1997, BIOCHEM BIOPH RES CO, V240, P763, DOI 10.1006/bbrc.1997.7740
   FDA, 2008, FAT REP FDA FOLL BLO
   Fung YL, 2009, TRANSFUS MED REV, V23, P266, DOI 10.1016/j.tmrv.2009.06.001
   Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC
   Gerdes Joan, 2005, J Trauma Nurs, V12, P57
   Glenister KM, 2010, TRANSFUSION, V50, P185, DOI 10.1111/j.1537-2995.2009.02353.x
   Henn V, 2001, BLOOD, V98, P1047, DOI 10.1182/blood.V98.4.1047
   Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004
   Hume HA, 2009, TRANSFUSION, V49, P402, DOI 10.1111/j.1537-2995.2008.02090.x
   Insunza A, 2004, TRANSFUSION MED, V14, P157, DOI 10.1111/j.0958-7578.2004.00492.x
   Kanter J, 2008, CLIN CANCER RES, V14, P3942, DOI 10.1158/1078-0432.CCR-07-4824
   Kaufman J, 2007, J THROMB HAEMOST, V5, P788, DOI 10.1111/j.1538-7836.2007.02412.x
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Keller-Stanislawski B, 2010, VOX SANG, V98, P70, DOI 10.1111/j.1423-0410.2009.01232.x
   Keller-Stanislawski B, 2009, TRANSFUSION MED, V19, P340, DOI 10.1111/j.1365-3148.2009.00947.x
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Maurer AM, 2006, GROWTH FACTORS, V24, P242, DOI 10.1080/08977190600988225
   Pamukcu B, 2011, ANN MED, V43, P331, DOI 10.3109/07853890.2010.546362
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Powers A, 2008, TRANSFUSION, V48, P2549, DOI 10.1111/j.1537-2995.2008.01902.x
   Rahman M, 2009, ANN SURG, V250, P783, DOI 10.1097/SLA.0b013e3181bd95b7
   Report of the US Department of Health and Human Services, 2011, REP US DEP HLTH HUM
   Salgado Roberto, 2001, Angiogenesis, V4, P37, DOI 10.1023/A:1016611230747
   Services CB, 2004, CIRC INF
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 1999, TRANSFUS MED REV, V13, P177, DOI 10.1016/S0887-7963(99)80031-5
   Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51
   Triulzi DJ, 2009, TRANSFUSION, V49, P1825, DOI 10.1111/j.1537-2995.2009.02206.x
   Tuinman PR, 2011, CLIN EXP IMMUNOL, V165, P278, DOI 10.1111/j.1365-2249.2011.04422.x
   Urahama N, 2003, TRANSFUSION, V43, P1553, DOI 10.1046/j.1537-2995.2003.00542.x
   van Stein D, 2010, TRANSFUSION, V50, P213, DOI 10.1111/j.1537-2995.2009.02345.x
   von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7
   Wehrli G, 2009, TRANSFUSION, V49, P2625, DOI 10.1111/j.1537-2995.2009.02342.x
   Whitaker BI, 2008, 2007 NATL BLOOD COLL
   Wiersum-Osselton JC, 2011, TRANSFUSION, V51, P1278, DOI 10.1111/j.1537-2995.2010.02969.x
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   Zupanska B, 2007, VOX SANG, V93, P70, DOI 10.1111/j.1423-0410.2007.00920.x
NR 55
TC 16
Z9 16
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD MAY
PY 2012
VL 102
IS 4
BP 345
EP 353
DI 10.1111/j.1423-0410.2011.01559.x
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 927HJ
UT WOS:000302897800009
PM 22092073
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Birukova, AA
   Tian, YF
   Meliton, A
   Leff, A
   Wu, TH
   Birukov, KG
AF Birukova, Anna A.
   Tian, Yufeng
   Meliton, Angelo Y.
   Leff, Alan R.
   Wu, Tinghuai
   Birukov, Konstantin G.
TI Stimulation of Rho signaling by pathologic mechanical stretch is a
   "second hit" to Rho-independent lung injury induced by IL-6
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE cyclic stretch; actin; interleukin-6; permeability; ECs/HPMECs/HUVECs/MPVECs 
ID OXIDIZED PHOSPHOLIPIDS; CYCLIC STRETCH; PERMEABILITY; VENTILATION;
   ADHESION; PATHWAY; MECHANOTRANSDUCTION; INTERLEUKIN-6; INFLAMMATION;
   EXPRESSION
AB Birukova AA, Tian Y, Meliton A, Leff A, Wu T, Birukov KG. Stimulation of Rho signaling by pathologic mechanical stretch is a "second hit" to Rho-independent lung injury induced by IL-6. Am J Physiol Lung Cell Mol Physiol 302: L965-L975, 2012. First published February 17, 2012; doi: 10.1152/ajplung.00292.2011.-Most patients with acute lung injury (ALI) and acute respiratory distress syndrome of septic and nonseptic nature require assisted ventilation with positive pressure, which at suboptimal range may further exacerbate lung dysfunction. Previous studies described enhancement of agonist-induced Rho GTPase signaling and endothelial cell (EC) permeability in EC cultures exposed to pathologically relevant cyclic stretch (CS) magnitudes. This study examined a role of pathologic CS in modulation of pulmonary EC permeability caused by IL-6, a cytokine increased in sepsis and acting in a Rho-independent manner. IL-6 increased EC permeability, which was associated with activation of Jak/signal transducers and activators of transcription, p38 MAP kinase, and NF-kappa B signaling and was augmented by EC exposure to 18% CS. Rho kinase inhibitor Y-27632 suppressed the synergistic effect of 18% CS on IL-6-induced EC monolayer disruption but did not alter the IL-6 effects on static EC culture. 18% CS also increased IL-6-induced ICAM-1 expression by pulmonary EC and neutrophil adhesion, which was attenuated by Y-27632. Intratracheal IL-6 administration in C57BL/6J mice increased protein content and cell count in bronchoalveolar lavage fluid. These changes were augmented by high tidal volume mechanical ventilation (HTV; 30 ml/kg, 4 h). Intravenous injection of Y-27632 suppressed IL6/HTV-induced lung injury. In conclusion, this study proposes a novel mechanism contributing to two-hit model of ALI: in addition to synergistic effects on Rho-dependent endothelial hyper-permeability triggered by thrombin, TNF alpha, LPS, or other agonists, ventilator-induced lung injury-relevant CS may also exacerbate Rho-independent mechanisms of EC permeability induced by other inflammatory mediators such as IL-6 via mechanisms involving Rho activity.
C1 [Birukova, Anna A.; Tian, Yufeng; Meliton, Angelo; Leff, Alan; Wu, Tinghuai; Birukov, Konstantin G.] Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukov, KG (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, 5841 S Maryland Ave,Off N-611, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022
FU National Heart, Lung, and Blood Institute [HL-87823, HL-076259,
   HL-058064, HL-089257, HL-107920]; American Heart Association
FX Support for this work was provided by National Heart, Lung, and Blood
   Institute Grants HL-87823, HL-076259, and HL-058064 (to K. G. Birukov)
   and HL-089257 and HL-107920 and American Heart Association Midwest
   Affiliate Grant-in-Aid (to A. A. Birukova).
CR Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289
   Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL612, DOI 10.1152/ajplung.90236.2008
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009
   Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002
   Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645
   Dreyfuss D, 2005, CLIN CHEST MED, V26, P105, DOI 10.1016/j.ccm.2004.10.014
   Finigan JH, 2009, AM J PHYSIOL-LUNG C, V296, pL1002, DOI 10.1152/ajplung.90555.2008
   Frank JA, 2003, CRIT CARE, V7, P233, DOI 10.1186/cc1829
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Garcia CSNB, 2006, BRAZ J MED BIOL RES, V39, P697, DOI 10.1590/S0100-879X2006000600001
   Garcia MC, 2009, J BIOL CHEM, V284, P20936, DOI 10.1074/jbc.M109.020271
   Hammerschmidt S, 2004, AM J RESP CELL MOL, V30, P396, DOI 10.1165/rcmb.2003-0136OC
   Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016
   Hou WH, 2011, J CELL SCI, V124, P1231, DOI 10.1242/jcs.078154
   Kakiashvili E, 2009, J BIOL CHEM, V284, P11454, DOI 10.1074/jbc.M805933200
   Kim HA, 2011, J CONTROL RELEASE, V156, P60, DOI 10.1016/j.jconrel.2011.06.041
   Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916
   Manjavachi MN, 2010, PAIN, V151, P345, DOI 10.1016/j.pain.2010.07.018
   Matoba K, 2010, BIOCHEM BIOPH RES CO, V402, P725, DOI 10.1016/j.bbrc.2010.10.093
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Meliton AY, 2008, J LEUKOCYTE BIOL, V83, P344, DOI 10.1189/jlb.0707495
   Meliton AY, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-14
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092
   Sutherland RE, 2008, J IMMUNOL, V181, P5598, DOI 10.4049/jimmunol.181.8.5598
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001
   Villar J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-27
   Wang YL, 2011, J IMMUNOL, V186, P3180, DOI 10.4049/jimmunol.1001252
   Waxman AB, 2009, AM J RESP CELL MOL, V41, P385, DOI 10.1165/rcmb.2008-0302OC
   Wolters PJ, 2009, J IMMUNOL, V182, P8056, DOI 10.4049/jimmunol.0801323
   Wurfel Mark M, 2007, Proc Am Thorac Soc, V4, P77, DOI 10.1513/pats.200608-149JG
   Yamauchi-Takihara K, 2008, FUTUR CARDIOL, V4, P427, DOI 10.2217/14796678.4.4.427
   Yang GG, 2005, GENE, V363, P166, DOI 10.1016/j.gene.2005.08.006
   Zoubeidi A, 2009, MOL CANCER RES, V7, P142, DOI 10.1158/1541-7786.MCR-08-0117
NR 42
TC 55
Z9 60
U1 1
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2012
VL 302
IS 9
BP L965
EP L975
DI 10.1152/ajplung.00292.2011
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 936TW
UT WOS:000303613900017
PM 22345573
OA Green Published
DA 2023-08-21
ER

PT J
AU Birukova, AA
   Fu, PF
   Wu, TH
   Dubrovskyi, O
   Sarich, N
   Poroyko, V
   Birukov, KG
AF Birukova, Anna A.
   Fu, Panfeng
   Wu, Tinghuai
   Dubrovskyi, Oleksii
   Sarich, Nicolene
   Poroyko, Valery
   Birukov, Konstantin G.
TI Afadin controls p120-catenin-ZO-1 interactions leading to endothelial
   barrier enhancement by oxidized phospholipids
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ACUTE LUNG INJURY; CELL JUNCTION FORMATION; IN-VIVO; PROTECTIVE
   RESPONSE; ADHERENS JUNCTIONS; EXCHANGE FACTORS; E-CADHERIN; NECTIN;
   RAP1; RAC
AB Afadin is a novel regulator of epithelial cell junctions assembly. However, its role in the formation of endothelial cell junctions and the regulation of vascular permeability remains obscure. We previously described protective effects of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) in the in vitro and in vivo models of lung endothelial barrier dysfunction and acute lung injury, which were mediated by Rac GTPase. This study examined a role of afadin in the OxPAPC-induced enhancement of interactions between adherens junctions and tight junctions as a novel mechanism of endothelial cell (EC) barrier preservation. OxPAPC induced Rap1-dependent afadin accumulation at the cell periphery and Rap1-dependent afadin interaction with adherens junction and tight junction proteins p120-catenin and ZO-1, respectively. Afadin knockdown using siRNA or ectopic expression of afadin mutant lacking Rap1 GTPase binding domain suppressed OxPAPC-induced EC barrier enhancement and abolished barrier protective effects of OxPAPC against thrombin-induced EC permeability. Afadin knockdown also abolished protective effects of OxPAPC against ventilator-induced lung injury in vivo. These results demonstrate for the first time a critical role of afadin in the regulation of vascular barrier function in vitro and in vivo via coordination of adherens junctiontight junction interactions. J. Cell. Physiol. 227: 1883-1890, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Birukova, Anna A.; Fu, Panfeng; Wu, Tinghuai; Dubrovskyi, Oleksii; Sarich, Nicolene; Poroyko, Valery; Birukov, Konstantin G.] Univ Chicago, Sect Pulm & Crit Med, Lung Injury Ctr, Dept Med, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukov, KG (corresponding author), Univ Chicago, Sect Pulm & Crit Med, Lung Injury Ctr, Dept Med, 5841 S Maryland Ave,Off N-611, Chicago, IL 60637 USA.
EM kbirukov@medicine.bsd.uchicago.edu
RI Birukov, Konstantin/FJB-5755-2022; Fu, Panfeng/F-7345-2015; Sarich,
   Nicolene/IWV-3869-2023
OI Fu, Panfeng/0000-0001-8813-9258; 
FU National Heart, Lung, and Blood Institutes [HL87823, HL76259, HL58064,
   HL89257]; American Heart Association
FX Contract grant sponsor: National Heart, Lung, and Blood Institutes;;
   Contract grant numbers: HL87823, HL76259, HL58064, HL89257.; Contract
   grant sponsor: American Heart Association Midwest Affiliate
   Grant-in-Aid.
CR Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL593, DOI 10.1152/ajplung.90257.2008
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Birukova AA, 2007, MICROVASC RES, V73, P173, DOI 10.1016/j.mvr.2006.12.004
   Birukova AA, 2007, J CELL PHYSIOL, V211, P608, DOI 10.1002/jcp.20966
   Birukova AA, 2011, J CELL PHYSIOL, V226, P2052, DOI 10.1002/jcp.22543
   Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023
   Boettner B, 2009, CURR OPIN CELL BIOL, V21, P684, DOI 10.1016/j.ceb.2009.06.004
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Dejana E, 2009, CELL TISSUE RES, V335, P17, DOI 10.1007/s00441-008-0694-5
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200
   Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2
   Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300
   Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200
   Kooistra MRH, 2007, J CELL SCI, V120, P17, DOI 10.1242/jcs.03306
   Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080
   Ma Z, 2004, AM J PHYSIOL-LUNG C, V286, pL808, DOI 10.1152/ajplung.00220.2003
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Miyoshi J, 2005, ADV DRUG DELIVER REV, V57, P815, DOI 10.1016/j.addr.2005.01.008
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Pannekoek WJ, 2009, BBA-BIOMEMBRANES, V1788, P790, DOI 10.1016/j.bbamem.2008.12.010
   Prasain N, 2009, MICROVASC RES, V77, P53, DOI 10.1016/j.mvr.2008.09.012
   Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167
   Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339
   Tawa H, 2010, CIRC RES, V106, P1731, DOI 10.1161/CIRCRESAHA.110.216747
   Tsukita S, 2009, ANN NY ACAD SCI, V1165, P44, DOI 10.1111/j.1749-6632.2009.04056.x
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200
NR 38
TC 40
Z9 40
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2012
VL 227
IS 5
BP 1883
EP 1890
DI 10.1002/jcp.22916
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 879ZS
UT WOS:000299373900012
PM 21732359
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Dixon, JT
   Gozal, E
   Roberts, AM
AF Dixon, James T.
   Gozal, Evelyne
   Roberts, Andrew M.
TI Platelet-mediated vascular dysfunction during acute lung injury
SO ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Review
DE ischemia/reperfusion; oxidative stress; nitric oxide synthase; fibrinogen 
ID NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; NF-KAPPA-B;
   PEROXYNITRITE-INDUCED APOPTOSIS; ENDOTHELIAL CELL-INTERACTIONS;
   OXIDATIVE STRESS; TYROSINE NITRATION; ADHESION MOLECULES; SUPEROXIDE
   ANION; NAD(P)H OXIDASE
AB Context: Platelets have significant roles in initiating and mediating reduced alveolar blood flow, microvascular leak, and ventilation/perfusion mismatch caused by metabolic changes and altered signal transduction caused by ischemia-reperfusion.
   Objective: This review focuses on platelet mechanisms of vascular dysfunction in the lung and presents a hypothesis for interplay between platelet activation, endothelial damage and fibrinogen. The purpose is to discuss current knowledge regarding mechanisms of platelet-mediated endothelial injury and implications for new strategies to treat vascular dysfunction associated with acute lung injury (ALI).
   Methods: Literature from a number of fields was searched using Medline and Google Scholar.
   Results: Activated platelets contribute to redox imbalance through reactive oxygen species production, pro-leak molecules such as PAF and serotonin, and recruitment of inflammatory cytokines and leukocytes to the damaged endothelium.
   Conclusion: Platelets are a critical component of pulmonary ALI, acting in conjunction with fibrinogen to mediate endothelial damage through multiple signal transduction pathways.
C1 [Roberts, Andrew M.] Univ Louisville, Sch Med, Dept Physiol & Biophys, Hlth Sci Ctr A 1115, Louisville, KY 40292, United States.
C1 [Gozal, Evelyne; Roberts, Andrew M.] Univ Louisville, Sch Med, Dept Pediat, Louisville, KY 40292, United States.
C1 [Gozal, Evelyne] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292, United States.
C3 University of Louisville; University of Louisville; University of
   Louisville
RP Roberts, AM (corresponding author), Univ Louisville, Sch Med, Dept Physiol & Biophys, Hlth Sci Ctr A 1115, Louisville, KY 40292 USA.
EM Andrew.Roberts@louisville.edu
RI Roberts, Andrew/B-7286-2014
OI Dixon, James/0000-0002-8729-2821
CR Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730
   Alberio L, 2000, BLOOD, V95, P1694, DOI 10.1182/blood.V95.5.1694.005k24_1694_1702
   Alberts MJ, 2004, CLIN DRUG INVEST, V24, P245, DOI 10.2165/00044011-200424050-00001
   Anaya-Prado R, 2002, J SURG RES, V105, P248, DOI 10.1006/jsre.2002.6385
   Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247
   Asaduzzaman M, 2009, CRIT CARE MED, V37, P1389, DOI 10.1097/CCM.0b013e31819ceb71
   Azizova OA, 2009, B EXP BIOL MED+, V147, P201, DOI 10.1007/s10517-009-0474-6
   AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S
   Brindicci C, 2010, AM J RESP CRIT CARE, V181, P21, DOI 10.1164/rccm.200904-0493OC
   Brown K., 2006, LANCET, V368, P157, DOI [10.1016/S0140-6736(06)69005-3, DOI 10.1016/S0140-6736(06)69005-3]
   Buttery LDK, 1996, LAB INVEST, V75, P77
   Canobbio I, 2001, J BIOL CHEM, V276, P26022, DOI 10.1074/jbc.M102639200
   Carbajal JM, 2000, AM J PHYSIOL-CELL PH, V279, pC195
   Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6
   Chakrabarti S, 2004, THROMB RES, V113, P225, DOI 10.1016/j.thromres.2004.02.018
   Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833
   CHINTALA MS, 1994, J PHARMACOL EXP THER, V271, P1203
   Coller BS, 2008, BLOOD, V112, P3011, DOI 10.1182/blood-2008-06-077891
   COOPER, 2002, CARDIOVASC TOXICOL, V2, P165
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024
   Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014
   Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203
   DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074
   den Hengst WA, 2010, AM J PHYSIOL-HEART C, V299, pH1283, DOI 10.1152/ajpheart.00251.2010
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Erlich JH, 2000, AM J PATHOL, V157, P1849, DOI 10.1016/S0002-9440(10)64824-9
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   Gawaz M, 2004, CARDIOVASC RES, V61, P498, DOI 10.1016/j.cardiores.2003.11.036
   Gilles S, 2003, CARDIOVASC RES, V60, P608, DOI 10.1016/j.cardiores.2003.08.016
   Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647
   Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961
   Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200
   Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB
   Guo FH, 1998, ENVIRON HEALTH PERSP, V106, P1119, DOI 10.2307/3433973
   Guo M, 2004, THROMB HAEMOSTASIS, V92, P858, DOI 10.1160/TH04-04-0261
   Guo MZ, 2009, ARTERIOSCL THROM VAS, V29, P394, DOI 10.1161/ATVBAHA.108.180950
   Harker LA, 1998, CEREBROVASC DIS, V8, P8, DOI 10.1159/000047513
   Hattori Y, 2004, CARDIOVASC RES, V63, P31, DOI 10.1016/j.cardiores.2004.03.014
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755
   Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183
   Jennewein C, 2011, MOL MED, V17, P568, DOI 10.2119/molmed.2010.00146
   Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728
   Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6
   Kanko M, 2006, J CARDIOVASC PHARM, V48, P797, DOI 10.1097/01.fjc.0000211795.45281.9d
   Kim SH, 2002, NITRIC OXIDE-BIOL CH, V7, P67, DOI 10.1016/S1089-8603(02)00008-3
   Kis A, 2003, BRIT J PHARMACOL, V138, P894, DOI 10.1038/sj.bjp.0705108
   Knepler JL, 2001, AM J PHYSIOL-CELL PH, V281, pC1064, DOI 10.1152/ajpcell.2001.281.3.C1064
   Koenen RR, 2010, SEMIN THROMB HEMOST, V36, P163, DOI 10.1055/s-0030-1251500
   Konya D, 2008, GROWTH FACTORS, V26, P74, DOI 10.1080/08977190802025339
   Krishnadasan B, 2003, J THORAC CARDIOV SUR, V125, P261, DOI 10.1067/mtc.2003.16
   Krotz F, 2004, ARTERIOSCL THROM VAS, V24, P1988, DOI 10.1161/01.ATV.0000145574.90840.7d
   Krotz F, 2002, BLOOD, V100, P917, DOI 10.1182/blood.V100.3.917
   Kuebler WM, 2006, J CLIN INVEST, V116, P3106, DOI 10.1172/JCI30664
   Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569
   Kwon KY, 2004, TRANSPL P, V36, P1936, DOI 10.1016/j.transproceed.2004.08.026
   LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794
   Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172
   Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737
   Lefer AM, 1996, CARDIOVASC RES, V32, P743, DOI 10.1016/0008-6363(96)00073-9
   Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7
   Li N, 2008, J LEUKOCYTE BIOL, V83, P1069, DOI 10.1189/jlb.0907615
   Li XM, 2009, TEX HEART I J, V36, P134
   Lipinski B, 2001, J DIABETES COMPLICAT, V15, P203, DOI 10.1016/S1056-8727(01)00143-X
   Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175
   Lominadze D, 2010, ACTA PHYSIOL, V198, P1, DOI 10.1111/j.1748-1716.2009.02037.x
   LOPEZNEBLINA F, 1995, TRANSPLANT P, V27, P1883
   Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861
   Loscalzo J, 2003, BIOCHEM SOC T, V31, P1059
   Lupidi G, 1999, FEBS LETT, V462, P236, DOI 10.1016/S0014-5793(99)01500-8
   MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6
   Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294
   Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507
   May AE, 2002, CIRCULATION, V106, P2111, DOI 10.1161/01.CIR.0000033597.45947.0F
   McNally JS, 2003, AM J PHYSIOL-HEART C, V285, pH2290, DOI 10.1152/ajpheart.00515.2003
   Merten M, 1999, CIRCULATION, V99, P2577, DOI 10.1161/01.CIR.99.19.2577
   Miller DL, 1999, ANN THORAC SURG, V67, P323, DOI 10.1016/S0003-4975(99)00019-3
   Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002
   Monaco S, 2007, BIOCHEM J, V402, P503, DOI 10.1042/BJ20061064
   Monroe D, 2002, ARTERIOSCL THROM VAS, V22, P1381, DOI 10.1161/01.ATV.0000031340.68494.34
   Murphy JT, 2001, J TRAUMA, V50, P213, DOI 10.1097/00005373-200102000-00005
   Musashi K, 2005, INVEST OPHTH VIS SCI, V46, P2561, DOI 10.1167/iovs.04-1102
   Naidu BV, 2003, J THORAC CARDIOV SUR, V126, P200, DOI 10.1016/S0022-5223(03)00390-8
   Nowak P, 2002, PLATELETS, V13, P293, DOI 10.1080/0953770021000007230
   Nowak P, 2007, THROMB RES, V121, P163, DOI 10.1016/j.thromres.2007.03.017
   Ohmori H, 1998, TRANSPLANTATION, V66, P579, DOI 10.1097/00007890-199809150-00005
   Ovechkin Alexander V., 2007, Archives of Physiology and Biochemistry, V113, P1, DOI 10.1080/13813450601118976
   Ovechkin AV, 2005, J APPL PHYSIOL, V99, P2423, DOI 10.1152/japplphysiol.01302.2004
   Parastatidis I, 2008, J BIOL CHEM, V283, P33846, DOI 10.1074/jbc.M805522200
   Parviz M, 1999, ANN THORAC SURG, V67, P522, DOI 10.1016/S0003-4975(98)01141-2
   Pfeilschifter J, 2001, EUR J PHARMACOL, V429, P279, DOI 10.1016/S0014-2999(01)01326-7
   PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551
   Phillips L, 2009, J INVEST SURG, V22, P46, DOI 10.1080/08941930802709470
   Pluskota E, 2000, EUR J BIOCHEM, V267, P4693, DOI 10.1046/j.1432-1327.2000.01520.x
   Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200
   RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4
   Rauch BH, 2007, EUR J PHARMACOL, V577, P54, DOI 10.1016/j.ejphar.2007.08.041
   Reneman RS, 2006, J VASC RES, V43, P251, DOI 10.1159/000091648
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003
   Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227
   SASE K, 1995, LIFE SCI, V57, P2049, DOI 10.1016/0024-3205(95)02191-K
   Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8903, DOI 10.1021/bi9525031
   Sedoris Kara C., 2009, Archives of Physiology and Biochemistry, V115, P34, DOI 10.1080/13813450902785267
   Sedoris KC, 2011, ACTA PHYSL OXF
   Shacka JJ, 2006, CELL DEATH DIFFER, V13, P1506, DOI 10.1038/sj.cdd.4401831
   Singbartl K, 2001, FASEB J, V15, P2337, DOI 10.1096/fj.01-0199com
   Soccal PM, 2000, TRANSPLANTATION, V70, P998, DOI 10.1097/00007890-200010150-00002
   Spear N, 1997, J NEUROCHEM, V69, P53
   Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732
   Sud N, 2007, AM J PHYSIOL-LUNG C, V293, pL1444, DOI 10.1152/ajplung.00175.2007
   Szmitko PE, 2003, CIRCULATION, V108, P1917, DOI 10.1161/01.CIR.0000089190.95415.9F
   Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619
   Vadseth C, 2004, J BIOL CHEM, V279, P8820, DOI 10.1074/jbc.M306101200
   van der Heijden M, 2008, APOPTOSIS, V13, P404, DOI 10.1007/s10495-007-0173-6
   van Gils JM, 2009, J LEUKOCYTE BIOL, V85, P195, DOI 10.1189/jlb.0708400
   Vinas JL, 2007, AM J PHYSIOL-RENAL, V292, pF1673, DOI 10.1152/ajprenal.00356.2006
   Vink H, 2000, CIRCULATION, V101, P1500, DOI 10.1161/01.CIR.101.13.1500
   Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC
   Wallentin L, 2009, EUR HEART J, V30, P1964, DOI 10.1093/eurheartj/ehp296
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wolfrum S, 2004, ARTERIOSCL THROM VAS, V24, P1842, DOI 10.1161/01.ATV.0000142813.33538.82
   Wu B, 2009, INFLAMM RES, V58, P321, DOI 10.1007/s00011-009-8230-y
   Xu YQ, 2006, AM J PHYSIOL-HEART C, V290, pH692, DOI 10.1152/ajpheart.00634.2005
   Zarbock A., 2006, FRONT BIOSCI, V14, P150
   Zarbock A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502
   Zarbock A, 2007, BLOOD REV, V21, P99, DOI 10.1016/j.blre.2006.06.001
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zhao YY, 2009, TRENDS CARDIOVAS MED, V19, P238, DOI 10.1016/j.tcm.2010.02.003
   Zhou JL, 2003, WORLD J GASTROENTERO, V9, P1318, DOI 10.3748/wjg.v9.i6.1318
NR 135
TC 28
Z9 28
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1381-3455
EI 1744-4160
J9 ARCH PHYSIOL BIOCHEM
JI Arch. Physiol. Biochem.
PD MAY
PY 2012
VL 118
IS 2
BP 72
EP 82
DI 10.3109/13813455.2012.665463
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Endocrinology &
   Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Endocrinology &
   Metabolism; Physiology
GA 936QX
UT WOS:000303606200005
PM 22439828
DA 2023-08-21
ER

PT J
AU Dreymueller, D
   Martin, C
   Kogel, T
   Pruessmeyer, J
   Hess, FM
   Horiuchi, K
   Uhlig, S
   Ludwig, A
AF Dreymueller, Daniela
   Martin, Christian
   Kogel, Tanja
   Pruessmeyer, Jessica
   Hess, Franz M.
   Horiuchi, Keisuke
   Uhlig, Stefan
   Ludwig, Andreas
TI Lung endothelial ADAM17 regulates the acute inflammatory response to
   lipopolysaccharide
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE Inflammation; metalloproteinase; neutrophil recruitment; oedema; shedding 
ID ALPHA-CONVERTING-ENZYME; TNF-ALPHA; DISINTEGRIN; INJURY;
   METALLOPROTEINASES; PERMEABILITY; EXPRESSION; INHIBITORS; ENDOTOXIN;
   INACTIVATION
AB Acute lung injury (ALI) is associated with increased vascular permeability, leukocyte recruitment, and pro-inflammatory mediator release. We investigated the role of the metalloproteinase ADAM17 in endotoxin-induced ALI with focus on endothelial ADAM17. In vitro, endotoxin-mediated induction of endothelial permeability and IL-8-induced transmigration of neutrophils through human microvascular endothelial cells required ADAM17 as shown by inhibition with GW280264X or shRNA-mediated knockdown. In vivo, ALI was induced by intranasal endotoxin-challenge combined with GW280264X treatment or endothelial adam17-knockout. Endotoxin-triggered upregulation of ADAM17 mRNA in the lung was abrogated in knockout mice and associated with reduced ectodomain shedding of the junctional adhesion molecule JAM-A and the transmembrane chemokine CX3CL1. Induced vascular permeability, oedema formation, release of TNF-a and IL-6 and pulmonary leukocyte recruitment were all markedly reduced by GW280264X or endothelial adam17-knockout. Intranasal application of TNF-a could not restore leukocyte recruitment and oedema formation in endothelial adam17-knockout animals. Thus, activation of endothelial ADAM17 promotes acute pulmonary inflammation in response to endotoxin by multiple endothelial shedding events most likely independently of endothelial TNF-a release leading to enhanced vascular permeability and leukocyte recruitment.
C1 [Dreymueller, Daniela; Kogel, Tanja; Pruessmeyer, Jessica; Ludwig, Andreas] Rhein Westfal TH Aachen, Interdisciplinary Ctr Clin Res, Aachen, Germany.
C1 [Martin, Christian; Hess, Franz M.; Uhlig, Stefan; Ludwig, Andreas] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Aachen, Germany.
C1 [Horiuchi, Keisuke] Keio Univ, Sch Med, Dept Orthoped Surg, Tokyo, Japan.
C3 RWTH Aachen University; RWTH Aachen University; Keio University
RP Ludwig, A (corresponding author), Rhein Westfal TH Aachen, Interdisciplinary Ctr Clin Res, Aachen, Germany.
EM aludwig@ukaachen.de
RI Horiuchi, Keisuke/L-2277-2013; Yildiz, Daniela/AAP-9473-2020; Ludwig,
   Andreas/I-5685-2012; Dreymueller, Daniela/B-9590-2016; Uhlig,
   Stefan/A-7290-2014
OI Horiuchi, Keisuke/0000-0001-7063-9609; Yildiz,
   Daniela/0000-0002-9702-8581; Ludwig, Andreas/0000-0001-8536-4986;
   Dreymueller, Daniela/0000-0002-9702-8581; Uhlig,
   Stefan/0000-0003-2332-1280
FU IZKF Aachen of the RWTH Aachen University; German Research Foundation
   [Lu869/5-1]
FX We thank Carl Blobel for providing Tie2-adam17<SUP>-/-</SUP> mice,
   generous support, and constructive discussions. We thank Felix Heymann
   and Frank Tacke (Medizinische Klinik III, RWTH Aachen University
   Hospital) for cell sorting. We thank Nadine Ruske and Melanie Esser for
   expert technical assistance, and Julian Schumacher for lentivirus
   production. The work has been supported by the IZKF Aachen of the RWTH
   Aachen University and the German Research Foundation Lu869/5-1.
CR Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362
   Alm AS, 2010, RESP PHYSIOL NEUROBI, V171, P157, DOI 10.1016/j.resp.2010.02.009
   Armstrong L, 2006, AM J RESP CELL MOL, V34, P219, DOI 10.1165/rcmb.2005-0087OC
   Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x
   Canault M, 2006, ATHEROSCLEROSIS, V187, P82, DOI 10.1016/j.atherosclerosis.2005.08.031
   Canault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013433
   Cesaro A, 2009, AM J PHYSIOL-GASTR L, V296, pG1332, DOI 10.1152/ajpgi.90641.2008
   Chalaris A, 2010, J EXP MED, V207, P1617, DOI 10.1084/jem.20092366
   Dijkstra A, 2009, VIRCHOWS ARCH, V454, P441, DOI 10.1007/s00428-009-0748-4
   Dreymueller D, 2012, EUR J CELL BIOL, V91, P472, DOI 10.1016/j.ejcb.2011.09.003
   Gungor N, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-24
   Haarmann A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013568
   Haczku A, 2000, AM J RESP CRIT CARE, V161, P952, DOI 10.1164/ajrccm.161.3.9905046
   Horiuchi K, 2007, J IMMUNOL, V179, P2686, DOI 10.4049/jimmunol.179.5.2686
   Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775
   Koenen RR, 2009, BLOOD, V113, P4799, DOI 10.1182/blood-2008-04-152330
   Laukoetter MG, 2007, J EXP MED, V204, P3067, DOI 10.1084/jem.20071416
   Li Y, 2006, BLOOD, V108, P2275, DOI 10.1182/blood-2006-02-005827
   Long CM, 2010, J LEUKOCYTE BIOL, V87, P1097, DOI 10.1189/jlb.1109763
   Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mazzon E, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-75
   Nonas S, 2006, AM J RESP CRIT CARE, V173, P1130, DOI 10.1164/rccm.200511-1737OC
   O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111
   Paulissen G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-127
   Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281
   Ponnuchamy B, 2008, CIRC RES, V102, P1139, DOI 10.1161/CIRCRESAHA.108.177394
   Pruessmeyer J, 2010, J BIOL CHEM, V285, P555, DOI 10.1074/jbc.M109.059394
   Pruessmeyer J, 2009, SEMIN CELL DEV BIOL, V20, P164, DOI 10.1016/j.semcdb.2008.09.005
   Pucci F, 2009, BLOOD, V114, P901, DOI 10.1182/blood-2009-01-200931
   Rabinowitz MH, 2001, J MED CHEM, V44, P4252, DOI 10.1021/jm0102654
   Reiss LK, 2012, EUR J CELL BIOL, V91, P590, DOI 10.1016/j.ejcb.2011.11.004
   Schnyder-Candrian S, 2005, J IMMUNOL, V175, P262, DOI 10.4049/jimmunol.175.1.262
   Schwarz N, 2010, CELL MOL LIFE SCI, V67, P4233, DOI 10.1007/s00018-010-0433-4
   Shimizu M, 2009, SHOCK, V32, P535, DOI 10.1097/SHK.0b013e3181a2adb7
   Singh RJR, 2005, CARDIOVASC RES, V67, P39, DOI 10.1016/j.cardiores.2005.02.020
   Smith S, 1998, AM J RESP CELL MOL, V19, P881, DOI 10.1165/ajrcmb.19.6.3146
   Song Y, 2001, AM J PHYSIOL-LUNG C, V281, pL677, DOI 10.1152/ajplung.2001.281.3.L677
   STRIETER RM, 1994, J INVEST MED, V42, P640
   Trifilieff A, 2002, BRIT J PHARMACOL, V135, P1655, DOI 10.1038/sj.bjp.0704616
   Walcheck B, 2006, EUR J IMMUNOL, V36, P968, DOI 10.1002/eji.200535257
   Ward PA, 2003, EUR RESPIR J, V22, p22S, DOI 10.1183/09031936.03.00000703a
   Weskamp G, 2010, CIRC RES, V106, P932, DOI 10.1161/CIRCRESAHA.109.207415
   Yoshikawa S, 2004, J APPL PHYSIOL, V97, P2190, DOI 10.1152/japplphysiol.00324.2004
   Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x
NR 45
TC 71
Z9 73
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAY
PY 2012
VL 4
IS 5
BP 412
EP 423
DI 10.1002/emmm.201200217
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 935DK
UT WOS:000303498900007
PM 22367719
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Grinnell, KL
   Chichger, H
   Braza, J
   Duong, H
   Harrington, EO
AF Grinnell, Katie L.
   Chichger, Havovi
   Braza, Julie
   Duong, Huetran
   Harrington, Elizabeth O.
TI Protection against LPS-Induced Pulmonary Edema through the Attenuation
   of Protein Tyrosine Phosphatase-1B Oxidation
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; PTP1B; pulmonary edema; oxidation; ALI/ARDS 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B;
   ENDOTHELIAL-CELLS; IN-VIVO; DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION;
   BIOLOGICAL MARKERS; HUMAN-PLACENTA; VE-CADHERIN
AB One hallmark of acute lung injury is the disruption of the pulmonary endothelial barrier. Such disruption correlates with increased endothelial permeability, partly through the disruption of cell-cell contacts. Protein tyrosine phosphatases (PTPs) are known to affect the stability of both cell-extracellular matrix adhesions and intercellular adherens junctions (AJs). However, evidence for the role of select PTPs in regulating endothelial permeability is limited. Our investigations noted that the inhibition of PTP1B in cultured pulmonary endothelial cells (ECs), as well as in the vasculature of intact murine lungs via the transient overexpression of a catalytically inactive PTP1B, decreased the baseline resistance of cultured EC monolayers and increased the formation of edema in murine lungs, respectively. In addition, we observed that the overexpression of wild-type PTP1B enhanced basal barrier function in vitro. Immunohistochemical analyses of pulmonary ECs and the coimmunoprecipitation of murine lung homogenates demonstrated the association of PTP1B with the AJ proteins beta-catenin, p120-catenin, and VE-cadherin both in vitro and ex vivo. Using LPS in a model of sepsis-induced acute lung injury, we showed that reactive oxygen species were generated in response to LPS, which correlated with enhanced PTP1B oxidation, inhibited phosphatase activity, and attenuation of the interactions between PTP1B and beta-catenin, as well as enhanced beta-catenin tyrosine phosphorylation. Finally, the overexpression of a cytosolic PTP1B fragment, shown to be resistant to nicotinamide adenine di-nucleotide phosphate-reduced oxidase-4 (Nox4)-mediated oxidation, significantly attenuated LPS-induced endothelial barrier dysfunction and the formation of lung edema, and preserved the associations of PTP1B with AJ protein components, independent of PTP1B phosphatase activity. We conclude that PTP1B plays an important role in maintaining the pulmonary endothelial barrier, and PTP1B oxidation appears to contribute to sepsis-induced pulmonary vascular dysfunction, possibly through the disruption of AJs.
C1 [Harrington, Elizabeth O.] Providence Vet Affairs Med Ctr, Vasc Res Lab, Res Serv 151, Providence, RI 02908, United States.
C1 Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI 02912, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University
RP Harrington, EO (corresponding author), Providence Vet Affairs Med Ctr, Vasc Res Lab, Res Serv 151, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM Elizabeth_Harrington@brown.edu
RI Chichger, Havovi/M-5129-2015; Chichger, Havovi/Y-7117-2019
OI Chichger, Havovi/0000-0002-8549-7583; Chichger,
   Havovi/0000-0002-8549-7583; Harrington, Elizabeth/0000-0002-3207-5301
FU National Institutes of Heath [R01 HL67795, T32 HL094300]; American Heart
   Association [10GRNT4160055]
FX This work was supported by National Institutes of Heath grant R01
   HL67795 and American Heart Association Grant-in-Aid 10GRNT4160055 (to
   E.O.H.) and National Institutes of Heath grant T32 HL094300 (to K.L.G.).
CR Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7
   Ali MI, 2009, CIRC RES, V105, P1013, DOI 10.1161/CIRCRESAHA.109.206318
   Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286
   Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522
   Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801
   Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610
   Bobba A, 2008, INT J MOL MED, V21, P737
   Buttenschoen K, 2008, LANGENBECK ARCH SURG, V393, P473, DOI 10.1007/s00423-008-0317-3
   Cepkova M, 2006, CRIT CARE, V10, DOI 10.1186/cc5037
   Chabot F, 1998, EUR RESPIR J, V11, P745
   Chan EL, 2003, J SURG RES, V111, P120, DOI 10.1016/S0022-4804(03)00050-7
   Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049
   Chernoff J, 1999, J CELL PHYSIOL, V180, P173
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Dadke S, 2003, J BIOL CHEM, V278, P40607, DOI 10.1074/jbc.M306772200
   Eden ER, 2010, NAT CELL BIOL, V12, P267, DOI 10.1038/ncb2026
   Edens JW, 2010, J TRAUMA, V69, pS81, DOI 10.1097/TA.0b013e3181e44a32
   Esser S, 1998, J CELL SCI, V111, P1853
   Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021
   Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562
   Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175
   FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x
   Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14
   Grinnell KL, 2010, AM J PHYSIOL-LUNG C, V298, pL361, DOI 10.1152/ajplung.00374.2009
   Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200
   Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390
   Harrington EO, 2001, AM J PHYSIOL-LUNG C, V280, pL342, DOI 10.1152/ajplung.2001.280.2.L342
   Huang CJ, 2010, J BIOL CHEM, V285, P339, DOI 10.1074/jbc.M109.024190
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Klinger JR, 2007, J APPL PHYSIOL, V103, P2084, DOI 10.1152/japplphysiol.00695.2007
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Koren S, 2007, BEST PRACT RES CL EN, V21, P621, DOI 10.1016/j.beem.2007.08.004
   Lokuta MA, 2003, P NATL ACAD SCI USA, V100, P4006, DOI 10.1073/pnas.0636533100
   Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001
   Nakamura Y, 2008, CIRC RES, V102, P1182, DOI 10.1161/CIRCRESAHA.107.167080
   Orrington-Myers J, 2006, AM J PHYSIOL-LUNG C, V291, pL764, DOI 10.1152/ajplung.00502.2005
   Pan ZXK, 2004, AM J PHYSIOL-LUNG C, V286, pL918, DOI 10.1152/ajplung.00381.2003
   Park HS, 2006, CARDIOVASC RES, V72, P447, DOI 10.1016/j.cardiores.2006.09.012
   Pendyala S, 2009, ANTIOXID REDOX SIGN, V11, P841, DOI [10.1089/ars.2008.2231, 10.1089/ARS.2008.2231]
   Pennington J E, 1986, Semin Respir Infect, V1, P145
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   Salmeen A, 2005, ANTIOXID REDOX SIGN, V7, P560, DOI 10.1089/ars.2005.7.560
   Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200
   Sheth P, 2007, BIOCHEM J, V402, P291, DOI 10.1042/BJ20060665
   Sim ATR, 2002, IUBMB LIFE, V53, P283, DOI 10.1080/15216540213462
   Simon F, 2009, J HYPERTENS, V27, P1202, DOI 10.1097/HJH.0b013e328329e31c
   TONKS NK, 1988, J BIOL CHEM, V263, P6731
   TONKS NK, 1988, J BIOL CHEM, V263, P6722
   Wang Chen, 2004, Yichuan, V26, P941
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Yip SC, 2010, TRENDS BIOCHEM SCI, V35, P442, DOI 10.1016/j.tibs.2010.03.004
   Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X
   Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407
NR 56
TC 28
Z9 31
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2012
VL 46
IS 5
BP 623
EP 632
DI 10.1165/rcmb.2011-0271OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 956CX
UT WOS:000305068500009
PM 22180868
OA Green Published
DA 2023-08-21
ER

PT J
AU Kandasamy, K
   Sahu, G
   Parthasarathi, K
AF Kandasamy, Kathirvel
   Sahu, Geetaram
   Parthasarathi, Kaushik
TI Real-time imaging reveals endothelium-mediated leukocyte retention in
   LPS-treated lung microvessels
SO MICROVASCULAR RESEARCH
LA English
DT Article
ID INDUCED NEUTROPHIL RECRUITMENT; TOLL-LIKE RECEPTOR-4; PROINFLAMMATORY
   RESPONSES; BONE-MARROW; P-SELECTIN; MOUSE LUNG; SEQUESTRATION; INJURY;
   ICAM-1; PNEUMONIA
AB Endotoxemia, a major feature of sepsis, is a common cause of acute lung injury and initiates rapid accumulation of leukocytes in the lung vasculature. Endothelial mechanisms that underlie this accumulation remain unclear, as current experimental models of endotoxemia are less suitable for targeted activation of the endothelium. Toward elucidating this, we used the isolated blood-perfused rat lung preparation. With a micro-catheter inserted through a left atrial cannula, we cleared blood cells from a small lung region and then infused lipopolysaccharide (LPS) into microvessels. After a Ringer's wash to remove residual LPS, we infused fluorescently-labeled autologous leukocytes and imaged their transit through the treated microvessels. Image analysis revealed that leukocytes infused 90 min after LPS treatment were retained more in treated venules and capillaries than untreated vessels. Further, pretreatment with either the intercellular adhesion molecule-1 (ICAM-1) mAb or polymyxin-B blunted LPS-induced leukocyte retention in both microvessel segments. In addition, retention of leukocytes treated ex vivo with LPS in LPS-treated microvessels was higher compared to retention of untreated leukocytes. In situ immunofluorescence experiments revealed that LPS significantly increased microvessel ICAM-1 expression at 90 min post treatment. Polymyxin pretreatment inhibited this increase. Taken together, the data suggest that LPS increased leukocyte retention in both venules and capillaries and this response was mediated by the increased expression of endothelial ICAM-1. Thus, endothelial mechanisms may themselves play a major role in LPS-induced leukocyte retention in lung microvessels. Blunting the endothelial responses may mitigate endotoxin-induced morbidity. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kandasamy, Kathirvel; Sahu, Geetaram; Parthasarathi, Kaushik] Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163, United States.
C1 [Parthasarathi, Kaushik] Univ Tennessee, Ctr Hlth Sci, Dept Biomed Engn & Imaging, Memphis, TN 38163, United States.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center
RP Parthasarathi, K (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Nash 207, Memphis, TN 38163 USA.
EM kparthas@uthsc.edu
OI Kandasamy, Kathirvel/0000-0002-4966-4604
FU  [HL75503]
FX This work was supported by HL75503 (KP).
CR Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   Aoki T, 1997, AM J PHYSIOL-HEART C, V273, pH2361, DOI 10.1152/ajpheart.1997.273.5.H2361
   Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005
   BURNS AR, 1994, J IMMUNOL, V153, P3189
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   DOHERTY DE, 1994, J IMMUNOL, V153, P241
   Doyle NA, 1997, J CLIN INVEST, V99, P526, DOI 10.1172/JCI119189
   Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf
   GEBB SA, 1995, J APPL PHYSIOL, V79, P493, DOI 10.1152/jappl.1995.79.2.493
   Grimminger F, 2000, AM J PHYSIOL-LUNG C, V278, pL268, DOI 10.1152/ajplung.2000.278.2.L268
   Hattar K, 2010, EUR RESPIR J, V36, P187, DOI 10.1183/09031936.00143308
   Hu GC, 2010, CRIT CARE MED, V38, P194, DOI 10.1097/CCM.0b013e3181bc7c17
   Ichimura H, 2005, AM J PHYSIOL-LUNG C, V289, pL407, DOI 10.1152/ajplung.00048.2005
   Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310
   Kuebler WM, 2000, AM J RESP CRIT CARE, V161, P36, DOI 10.1164/ajrccm.161.1.9901039
   KUHNLE GEH, 1995, AM J RESP CRIT CARE, V152, P1221, DOI 10.1164/ajrccm.152.4.7551374
   Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679
   LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933
   Melamed A, 2009, CRIT CARE, V13, DOI 10.1186/cc7733
   Mizgerd Joseph P., 2004, BMC Immunology, V5
   NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417
   Parthasarathi K, 2002, J IMMUNOL, V169, P7078, DOI 10.4049/jimmunol.169.12.7078
   Parthasarathi K, 2006, J CLIN INVEST, V116, P2193, DOI 10.1172/JCI26605
   Ploppa A, 2010, CRIT CARE, V14, DOI 10.1186/cc9322
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rowlands DJ, 2011, J CLIN INVEST, V121, P1986, DOI 10.1172/JCI43839
   Saito H, 2002, BLOOD, V99, P2207, DOI 10.1182/blood.V99.6.2207
   Sato Y, 1998, CRIT CARE MED, V26, P501, DOI 10.1097/00003246-199803000-00022
   Sharma AK, 2011, AM J RESP CRIT CARE, V183, P1539, DOI 10.1164/rccm.201007-1173OC
   Van Putte BP, 2005, CRIT CARE, V9, pR1, DOI 10.1186/cc2992
   Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877
   Wang Q, 2001, BLOOD, V97, P660, DOI 10.1182/blood.V97.3.660
   WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255
   Yiming MT, 2005, AM J RESP CELL MOL, V33, P549, DOI 10.1165/rcmb.2005-0133OC
   Yoshida K, 2006, AM J RESP CRIT CARE, V174, P689, DOI 10.1164/rccm.200502-276OC
NR 36
TC 10
Z9 10
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAY
PY 2012
VL 83
IS 3
BP 323
EP 331
DI 10.1016/j.mvr.2012.01.006
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 937VJ
UT WOS:000303690800009
PM 22342350
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Lin, CC
   Hsieh, NK
   Liou, HL
   Chen, HI
AF Lin, Chia-Chih
   Hsieh, Nan-Kuang
   Liou, Huey Ling
   Chen, Hsing I.
TI Niacinamide mitigated the acute lung injury induced by phorbol myristate
   acetate in isolated rat's lungs
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE phorbol myristate; niacinamide; ALI/ARDS; isolated perfused lungs; neutrophil-derived mediators; NO 
ID NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; NEUTROPHIL ELASTASE;
   POLY(ADP-RIBOSE) POLYMERASE-1; ORGAN DYSFUNCTION; PULMONARY-EDEMA;
   CONSCIOUS RATS; FAT-EMBOLISM; MURINE MODEL; ENDOTOXIN
AB Background: Phorbol myristate acetate (PMA) is a strong neutrophil activator and has been used to induce acute lung injury (ALI). Niacinamide (NAC) is a compound of B complex. It exerts protective effects on the ALI caused by various challenges. The purpose was to evaluate the protective effects of niacinamide (NAC) on the PMA-induced ALI and associated changes.
   Methods: The rat's lungs were isolated in situ and perfused with constant flow. A total of 60 isolated lungs were randomized into 6 groups to received Vehicle (DMSO 100 mu g/g), PMA 4 mu g/g (lung weight), cotreated with NAC 0, 100, 200 and 400 mg/g (lung weight). There were 10 isolated lungs in each group. We measured the lung weight and parameters related to ALI. The pulmonary arterial pressure and capillary filtration coefficient (K-fc) were determined in isolated lungs. ATP (adenotriphosphate) and PARP [ poly(adenosine diphophate-ribose) polymerase] contents in lung tissues were detected. Real-time PCR was employed to display the expression of inducible and endothelial NO synthases (iNOS and eNOS). The neutrophil-derived mediators in lung perfusate were determined.
   Results: PMA caused increases in lung weight parameters. This agent produced pulmonary hypertension and increased microvascular permeability. It resulted in decrease in ATP and increase in PARP. The expression of iNOS and eNOS was upregulated following PMA. PMA increased the neutrophil-derived mediators. Pathological examination revealed lung edema and hemorrhage with inflammatory cell infiltration. Immunohistochemical stain disclosed the presence of iNOS-positive cells in macrophages and endothelial cells. These pathophysiological and biochemical changes were diminished by NAC treatment. The NAC effects were dose-dependent.
   Conclusions: Our results suggest that neutrophil activation and release of neutrophil-derived mediators by PMA cause ALI and associated changes. NO production through the iNOS-producing cells plays a detrimental role in the PMA-induced lung injury. ATP is beneficial, while PARP plays a deteriorative effect on the PMA-induced ALI. NAC exerts protective effects on the inflammatory cascade leading to pulmonary injury. This B complex compound may be applied for clinical usage and therapeutic regimen.
C1 [Chen, Hsing I.] Tzu Chi Univ, Inst Physiol & Anat Med, Hualien, Taiwan.
C1 [Lin, Chia-Chih] Natl Dong Hwa Univ, Dept Phys Educ & Kinesiol, Hualien, Taiwan.
C1 [Hsieh, Nan-Kuang] Tao Yuan Gen Hosp, Dept Hlth, Dept Family Med, Tao Yuan, Taiwan.
C1 [Hsieh, Nan-Kuang] China Med Univ, Dept Pathol, Taichung, Taiwan.
C1 [Liou, Huey Ling] Taipei Vet Gen Hosp, Dept Nursing, Taipei, Taiwan.
C3 Tzu Chi University; National Dong Hwa University; China Medical
   University Taiwan; Taipei Veterans General Hospital
RP Chen, HI (corresponding author), Tzu Chi Univ, Inst Physiol & Anat Med, Hualien, Taiwan.
EM chenhi@mail.tcu.edu.tw
FU National Science Council, Taiwan [NSC-99-2320-B-320-010-MY3]
FX The present study was supported in part by a research grant
   (NSC-99-2320-B-320-010-MY3) from the National Science Council, Taiwan.
   The study protocol has been approved by the University Committee of
   Laboratory Animal Care and Use, and followed the guidelines of the
   National Animal Research Center. The authors are grateful to Prof.
   Yi-Ling Yang in Department of Biochemical Science and Technology,
   National Chia-Yi University for her excellent technical support on the
   RT-PCR and immunofluorescent staining. We also thank to Ms. A. Huang for
   the preparation of this manuscript.
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Bishop ML, 1996, FREE RADICALS CLIN C
   Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC
   Bowes J, 1998, BRIT J PHARMACOL, V124, P1760, DOI 10.1038/sj.bjp.0702009
   Burkart V, 1999, HORM METAB RES, V31, P641, DOI 10.1055/s-2007-978813
   Chen CF, 2001, J BIOMED SCI, V8, P446, DOI 10.1007/BF02256606
   Chen HI, 2006, CRIT CARE MED, V34, P758, DOI 10.1097/01.CCM.0000201902.37115.22
   Chen HI, 2003, J BIOMED SCI, V10, P588, DOI 10.1159/000073523
   Chen HI, 2008, CRIT CARE MED, V36, P1214, DOI 10.1097/CCM.0b013e31816a0607
   Chen HI, 2007, PATHOLOGY, V39, P339, DOI 10.1080/00313020701329740
   Chu SJ, 2001, CRIT CARE MED, V29, P819, DOI 10.1097/00003246-200104000-00028
   Chuang IC, 2007, PULM PHARMACOL THER, V20, P726, DOI 10.1016/j.pupt.2006.08.010
   Creamer KM, 2001, CHEST, V119, P1893, DOI 10.1378/chest.119.6.1893
   Cuzzocrea S, 1999, LIFE SCI, V65, P957, DOI 10.1016/S0024-3205(99)00325-2
   Ding R, 2011, INFLAMMATION
   Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x
   Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9
   Gale E A, 1996, Horm Res, V45 Suppl 1, P39
   HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607
   Hsu YH, 2008, PATHOLOGY, V40, P268, DOI 10.1080/00313020801911488
   Hur GM, 1999, BIOCHEM BIOPH RES CO, V261, P917, DOI 10.1006/bbrc.1999.1143
   Kan SH, 2010, INFLAMMATION, V33, P287, DOI 10.1007/s10753-010-9184-5
   Kao SJ, 2008, J TRAUMA, V64, P462, DOI 10.1097/TA.0b013e318058aa2e
   Kao SJ, 2007, J CARDIOVASC PHARM, V50, P333, DOI 10.1097/FJC.0b013e3180cbd18a
   Kao SJ, 2007, CLIN EXP PHARMACOL P, V34, P480, DOI 10.1111/j.1440-1681.2007.04598.x
   Kao SJ, 2006, CLIN EXP PHARMACOL P, V33, P33, DOI 10.1111/j.1440-1681.2006.04320.x
   Kao SJ, 2004, CLIN INFECT DIS, V38, P1784, DOI 10.1086/421021
   Kiefmann R, 2004, INTENS CARE MED, V30, P1421, DOI 10.1007/s00134-004-2301-x
   Kinoshita M, 2000, EUR SURG RES, V32, P337, DOI 10.1159/000052215
   Kristof AS, 1998, AM J RESP CRIT CARE, V158, P1883, DOI 10.1164/ajrccm.158.6.9802100
   Kuraki T, 2002, AM J RESP CRIT CARE, V166, P496, DOI 10.1164/rccm.2103118
   Lee RP, 2001, CLIN EXP PHARMACOL P, V28, P315, DOI 10.1046/j.1440-1681.2001.03446.x
   Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040
   Liaudet L, 2002, AM J RESP CRIT CARE, V165, P372, DOI 10.1164/ajrccm.165.3.2106050
   Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010
   Liu DD, 2008, CRIT CARE MED, V36, P565, DOI 10.1097/01.CCM.0000299737.24338.5C
   Murakami K, 2000, AM J RESP CRIT CARE, V161, P57, DOI 10.1164/ajrccm.161.1.9808142
   Muscara MN, 1996, J CHROMATOGR B, V686, P157, DOI 10.1016/S0378-4347(96)00229-0
   NAKAMURA K, 1991, NEPHRON, V58, P42, DOI 10.1159/000186376
   Numata M, 1998, J IMMUNOL, V160, P3031
   Pulido EJ, 1999, AM J PHYSIOL-LUNG C, V277, pL769, DOI 10.1152/ajplung.1999.277.4.L769
   Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC
   REMICK DG, 1994, ANN NY ACAD SCI, V723, P271, DOI 10.1111/j.1749-6632.1994.tb36733.x
   SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656
   Su CF, 2007, EUR RESPIR J, V30, P199, DOI 10.1183/09031936.00025107
   Su CF, 2007, CLIN EXP PHARMACOL P, V34, P339, DOI 10.1111/j.1440-1681.2007.04553.x
   Szabo C, 1999, SHOCK, V12, P1, DOI 10.1097/00024382-199907000-00001
   Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Wang D, 1999, J BIOMED SCI, V6, P28, DOI 10.1159/000025368
   WEITBERG AB, 1989, MUTAT RES, V216, P197, DOI 10.1016/0165-1161(89)90005-8
   Yang YL, 2008, J BIOMED SCI, V15, P499, DOI 10.1007/s11373-008-9238-y
NR 52
TC 5
Z9 9
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD MAR 1
PY 2012
VL 19
AR 27
DI 10.1186/1423-0127-19-27
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 916JW
UT WOS:000302099500001
PM 22375599
OA gold, Green Published
DA 2023-08-21
ER

PT J
AU Xing, JJ
   Yakubov, B
   Poroyko, V
   Birukova, AA
AF Xing, Junjie
   Yakubov, Bakhtiyor
   Poroyko, Valery
   Birukova, Anna A.
TI Opposite effects of ANP receptors in attenuation of LPS-induced
   endothelial permeability and lung injury
SO MICROVASCULAR RESEARCH
LA English
DT Article
ID ATRIAL-NATRIURETIC-PEPTIDE; ACTIVATED PROTEIN-KINASE; DIFFERENTIAL
   REGULATION; OXIDIZED PHOSPHOLIPIDS; PLASMA-LEVELS; INHIBITION;
   EXPRESSION; CLEARANCE; FAILURE; MOUSE
AB Atrial natriuretic peptide (ANP) has been recently identified as a modulator of acute lung injury (ALI) induced by pro-inflammatory agonists. While previous studies tested effects of exogenous ANP administration, the role of endogenous ANP in the course of ALI remains unexplored. This study examined regulation of ANP and its receptors NPR-A, NPR-B and NPR-C by LPS and involvement of ANP receptors in the modulation of LPS-induced lung injury. Primary cultures of human pulmonary endothelial cells (EC) were used in the in vitro tests. Expression of ANP and its receptors was determined by quantitative RT-PCR analysis. Agonist-induced cytoskeletal remodeling was evaluated by immunofluorescence staining, and EC barrier function was characterized by measurements of transendothelial electrical resistance. In the murine model of ALI, LPS-induced lung injury was assessed by measurements of protein concentration and cell count in bronchoalveolar lavage fluid (BAL). LPS stimulation significantly increased mRNA expression levels of ANP and NPR-A in pulmonary EC. Pharmacological inhibition of NPR-A augmented LPS-induced EC permeability and blocked barrier protective effects of exogenous ANP on LPS-induced intercellular gap formation. In contrast, pharmacological inhibition of ANP clearance receptor NPR-C significantly attenuated LPS-induced barrier disruptive effects. Administration of NPR-A inhibitor in vivo exacerbated LPS-induced lung injury, whereas inhibition of NPR-C suppressed LPS-induced increases in BAL cell count and protein content. These results demonstrate for the first time opposite effects of NPR-A and NPR-C in the modulation of ALI and suggest a compensatory protective mechanism of endogenous ANP in the maintenance of lung vascular permeability in ALI. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Xing, Junjie; Yakubov, Bakhtiyor; Poroyko, Valeriy; Birukova, Anna A.] Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukova, AA (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Med, Lung Injury Ctr, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
FU NHLBI [HL89257]; American Heart Association
FX Supported by NHLBI grant HL89257 and the American Heart Association
   Midwest Affiliate Grant-in-Aid.
CR Ahluwalia A, 2004, BASIC RES CARDIOL, V99, P83, DOI 10.1007/s00395-004-0459-6
   Anand-Srivastava MB, 2005, PEPTIDES, V26, P1044, DOI 10.1016/j.peptides.2004.09.023
   Baxter GF, 2004, BASIC RES CARDIOL, V99, P71, DOI 10.1007/s00395-004-0457-8
   Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06
   Birukova A. A., 2008, AM J RESP CELL MOL B
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Curry FRE, 2005, J CLIN INVEST, V115, P1458, DOI 10.1172/JCI25417
   DELPORTE C, 1992, EUR J PHARMACOL, V224, P183, DOI 10.1016/0014-2999(92)90803-C
   Doust JA, 2005, BRIT MED J, V330, P625, DOI 10.1136/bmj.330.7492.625
   EISON HB, 1988, CHEST, V94, P1040, DOI 10.1378/chest.94.5.1040
   Furst R, 2005, CIRC RES, V96, P43, DOI 10.1161/01.RES.0000151983.01148.06
   HOLLISTER AS, 1989, J CLIN INVEST, V83, P623, DOI 10.1172/JCI113926
   IMAMURA T, 1988, LIFE SCI, V42, P403, DOI 10.1016/0024-3205(88)90078-1
   Irwin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL849, DOI 10.1152/ajplung.00294.2004
   Karmpaliotis D, 2007, CHEST, V131, P964, DOI 10.1378/chest.06-1247
   Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3
   Klinger JR, 2006, EXP CELL RES, V312, P401, DOI 10.1016/j.yexcr.2005.11.001
   Louzier V, 2001, HUM GENE THER, V12, P503, DOI 10.1089/104303401300042401
   Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403
   Mitaka C, 1998, CHEST, V114, P223, DOI 10.1378/chest.114.1.223
   MITAKA C, 1992, AM REV RESPIR DIS, V146, P43, DOI 10.1164/ajrccm/146.1.43
   Moro C, 2004, J PHARMACOL EXP THER, V308, P984, DOI 10.1124/jpet.103.060913
   Onuoha GN, 2000, BURNS, V26, P449, DOI 10.1016/S0305-4179(99)00187-4
   Pandey KN, 2000, BIOCHEM BIOPH RES CO, V271, P374, DOI 10.1006/bbrc.2000.2627
   Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200
   Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014
   Potter LR, 2005, FRONT BIOSCI-LANDMRK, V10, P1205, DOI 10.2741/1613
   Rana R, 2006, CRIT CARE MED, V34, P1941, DOI 10.1097/01.CCM.0000220492.15645.47
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sakurai H, 2005, BURNS, V31, P737, DOI 10.1016/j.burns.2005.03.002
   Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Ueda S, 2006, SHOCK, V26, P134, DOI 10.1097/01.shk.0000226266.99960.d0
   VOLLMAR AM, 1995, J CLIN INVEST, V95, P2442, DOI 10.1172/JCI117944
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Xing JJ, 2011, J APPL PHYSIOL, V110, P213, DOI 10.1152/japplphysiol.00284.2010
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
NR 40
TC 7
Z9 10
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAR
PY 2012
VL 83
IS 2
BP 194
EP 199
DI 10.1016/j.mvr.2011.09.012
PG 6
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 899MA
UT WOS:000300818800015
PM 22001395
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Saffarzadeh, M
   Juenemann, C
   Queisser, MA
   Lochnit, G
   Barreto, G
   Galuska, SP
   Lohmeyer, J
   Preissner, KT
AF Saffarzadeh, Mona
   Juenemann, Christiane
   Queisser, Markus A.
   Lochnit, Guenter
   Barreto, Guillermo
   Galuska, Sebastian P.
   Lohmeyer, Juergen
   Preissner, Klaus T.
TI Neutrophil Extracellular Traps Directly Induce Epithelial and
   Endothelial Cell Death: A Predominant Role of Histones
SO PLOS ONE
LA English
DT Article
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; RECOMBINANT HUMAN DNASE; CYSTIC-FIBROSIS;
   NETTING NEUTROPHILS; MEDICAL PROGRESS; MYELOPEROXIDASE;
   LIPOPOLYSACCHARIDE; ENDOTOXIN
AB Neutrophils play an important role in innate immunity by defending the host organism against invading microorganisms. Antimicrobial activity of neutrophils is mediated by release of antimicrobial peptides, phagocytosis as well as formation of neutrophil extracellular traps (NET). These structures are composed of DNA, histones and granular proteins such as neutrophil elastase and myeloperoxidase. This study focused on the influence of NET on the host cell functions, particularly on human alveolar epithelial cells as the major cells responsible for gas exchange in the lung. Upon direct interaction with epithelial and endothelial cells, NET induced cytotoxic effects in a dose-dependent manner, and digestion of DNA in NET did not change NET-mediated cytotoxicity. Pre-incubation of NET with antibodies against histones, with polysialic acid or with myeloperoxidase inhibitor but not with elastase inhibitor reduced NET-mediated cytotoxicity, suggesting that histones and myeloperoxidase are responsible for NET-mediated cytotoxicity. Although activated protein C (APC) did decrease the histone-induced cytotoxicity in a purified system, it did not change NET-induced cytotoxicity, indicating that histone-dependent cytotoxicity of NET is protected against APC degradation. Moreover, in LPS-induced acute lung injury mouse model, NET formation was documented in the lung tissue as well as in the bronchoalveolar lavage fluid. These data reveal the important role of protein components in NET, particularly histones, which may lead to host cell cytotoxicity and may be involved in lung tissue destruction.
C1 [Saffarzadeh, Mona; Juenemann, Christiane; Queisser, Markus A.; Lochnit, Guenter; Galuska, Sebastian P.; Preissner, Klaus T.] Univ Giessen, Sch Med, Inst Biochem, Giessen, Germany.
C1 [Queisser, Markus A.] Northwestern Univ, Chicago, IL 60611, United States.
C1 [Barreto, Guillermo] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany.
C1 [Lohmeyer, Juergen] Univ Giessen, Dept Internal Med 2, Giessen, Germany.
C3 Justus Liebig University Giessen; Northwestern University; Max Planck
   Society; Justus Liebig University Giessen
RP Saffarzadeh, M (corresponding author), Univ Giessen, Sch Med, Inst Biochem, Giessen, Germany.
EM klaus.t.preissner@biochemie.med.uni-giessen.de
RI Queisser, Markus A/C-4426-2008; Barreto, Guillermo/U-5718-2017
OI Barreto, Guillermo/0000-0002-7777-4712; Galuska, Sebastian
   P./0000-0001-5565-0252
FU Bundesministerium fur Bildung und Forschung (Berlin, Germany); Clinical
   Research Group "Pneumonia" [01-KI-1004]; "Excellence Cluster
   Cardio-Pulmonary System" (ECCPS), Deutsche Forschungsgemeinschaft (Bonn,
   Germany)
FX This work was supported in part by the Bundesministerium fur Bildung und
   Forschung (Berlin, Germany), Clinical Research Group "Pneumonia"
   (01-KI-1004), and the "Excellence Cluster Cardio-Pulmonary System"
   (ECCPS), Deutsche Forschungsgemeinschaft (Bonn, Germany). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950
   Bergmann C, 2008, CLIN CANCER RES, V14, P3706, DOI 10.1158/1078-0432.CCR-07-5126
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606
   BOTHA AJ, 1995, J TRAUMA, V39, P411
   Bozinovski S, 2004, AM J PHYSIOL-LUNG C, V286, pL877, DOI 10.1152/ajplung.00275.2003
   BRANDT T, 1995, THORAX, V50, P880, DOI 10.1136/thx.50.8.880
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Cabanski M, 2009, AM J PHYSIOL-LUNG C, V297, pL608, DOI 10.1152/ajplung.90433.2008
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933
   Costa D, 2006, FREE RADICAL BIO MED, V40, P632, DOI 10.1016/j.freeradbiomed.2005.09.017
   DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1
   Douda DN, 2011, J IMMUNOL, V187, P1856, DOI 10.4049/jimmunol.1004201
   Faffe DS, 2000, EUR RESPIR J, V15, P85, DOI 10.1034/j.1399-3003.2000.15a16.x
   FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   FUJISHIMA S, 1995, INTENS CARE MED, V21, P277, DOI 10.1007/BF01701489
   Gong Q, 2008, INT IMMUNOPHARMACOL, V8, P792, DOI 10.1016/j.intimp.2008.01.026
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Gupta AK, 2005, HUM IMMUNOL, V66, P1146, DOI 10.1016/j.humimm.2005.11.003
   Gupta A, 2006, ANN NY ACAD SCI, V1075, P118, DOI 10.1196/annals.1368.015
   Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006
   Haegens A, 2008, EUR RESPIR J, V31, P252, DOI 10.1183/09031936.00029307
   Hakkim A, 2011, NAT CHEM BIOL, V7, P75, DOI [10.1038/nchembio.496, 10.1038/NCHEMBIO.496]
   Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107
   Hamutcu R, 2002, AM J RESP CRIT CARE, V165, P1172, DOI 10.1164/ajrccm.165.8.2104090
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Jones A, 2007, FASEB J, V21, P345, DOI 10.1096/fj.06-6675com
   Kanthack A. A., 1894, J PHYSL, V17, P80
   Kanthack AA, 1894, J PHYSL, V17, P81
   Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959
   Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383
   KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106
   Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180
   Lee JS, 2005, AM J PHYSIOL-LUNG C, V289, pL731, DOI 10.1152/ajplung.00196.2005
   Lim MB, 2011, J LEUKOC BIOL
   Liu M, 1997, INTENS CARE MED, V23, P718, DOI 10.1007/s001340050400
   Liu MY, 2005, AM J RESP CRIT CARE, V171, P298, DOI 10.1164/rccm.2412002
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Manzenreiter R, 2011, J CYST FIBROS
   Marcos V, 2010, NAT MED, V16, P1018, DOI 10.1038/nm.2209
   Massberg S, 2010, NAT MED, V16, P887, DOI 10.1038/nm.2184
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Medina E, 2009, J INNATE IMMUN, V1, P176, DOI 10.1159/000203699
   Mishra B, 2010, J NEUROSCI, V30, P12400, DOI 10.1523/JNEUROSCI.6407-09.2010
   Myzak MC, 2002, REDOX REP, V7, P47, DOI 10.1179/135100002125000181
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052
   Patel S, 2010, NITRIC OXIDE-BIOL CH, V22, P226, DOI 10.1016/j.niox.2010.01.001
   Perl M, 2008, MOL MED, V14, P465, DOI 10.2119/2008-00011.Perl
   RAPTIS L, 1980, J CLIN INVEST, V66, P1391, DOI 10.1172/JCI109992
   Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Rotta AT, 1998, CRIT CARE MED, V26, P1707, DOI 10.1097/00003246-199810000-00026
   Segel GB, 2011, J LEUKOCYTE BIOL, V89, P359, DOI 10.1189/jlb.0910538
   Steinmuller M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-30
   Szarka RJ, 1997, J IMMUNOL METHODS, V202, P49, DOI 10.1016/S0022-1759(96)00236-0
   Tasaka S, 2003, AM J RESP CELL MOL, V29, P252, DOI 10.1165/rcmb.2002-0132OC
   Thulke S, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-77
   Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223
   Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x
   Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639
   Valeva A, 2008, MED MICROBIOL IMMUN, V197, P285, DOI 10.1007/s00430-007-0061-2
   van der Vliet A, 2000, AM J PHYSIOL-LUNG C, V279, pL537, DOI 10.1152/ajplung.2000.279.3.L537
   Villanueva E, 2011, J IMMUNOL, V187, P538, DOI 10.4049/jimmunol.1100450
   Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Zhang D, 2001, J BIOL CHEM, V276, P3683, DOI 10.1074/jbc.M005390200
NR 73
TC 832
Z9 884
U1 6
U2 91
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2012
VL 7
IS 2
AR e32366
DI 10.1371/journal.pone.0032366
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 928RC
UT WOS:000302999600034
PM 22389696
OA Green Published, Green Submitted, gold
DA 2023-08-21
ER

PT J
AU Gorbunov, NV
   Atkins, JL
   Gurusamy, N
   Pitt, BR
AF Gorbunov, Nikolai V.
   Atkins, James L.
   Gurusamy, Narasimman
   Pitt, Bruce R.
TI Iron-induced remodeling in cultured rat pulmonary artery endothelial
   cells
SO BIOMETALS
LA English
DT Article
DE Iron complexes; ECs/HPMECs/HUVECs/MPVECs; Remodeling; Inflammation; Redox-stress 
ID TRANSFERRIN-BOUND IRON; LABILE PLASMA IRON; LEUKOCYTE DIAPEDESIS;
   OXIDATIVE STRESS; FOCAL ADHESION; OVERLOAD; INJURY; LUNG; PERMEABILITY;
   MICROVESSELS
AB Although iron is known to be a component of the pathogenesis and/or maintenance of acute lung injury (ALI) in experimental animals and human subjects, the majority of these studies have focused on disturbances in iron homeostasis in the airways resulting from exposure to noxious gases and particles. Considerably less is known about the effect of increased plasma levels of redox-reactive non-transferrin bound iron (NTBI) and its impact on pulmonary endothelium. Plasma levels of NTBI can increase under various pathophysiological conditions, including those associated with ALI, and multiple mechanisms are in place to affect the [Fe2+]/[Fe3+] redox steady state. It is well accepted, however, that intracellular transport of NTBI occurs after reduction of [Fe3+] to [Fe2+] (and is mediated by divalent metal transporters). Accordingly, as an experimental model to investigate mechanisms mediating vascular effects of redox reactive iron, rat pulmonary artery endothelial cells (RPAECs) were subjected to pulse treatment (10 min) with [Fe2+] nitriloacetate (30 mu M) in the presence of pyrithione, an iron ionophore, to acutely increase intracellular labile pool of iron. Cellular iron influx and cell shape profile were monitored with time-lapse imaging techniques. Exposure of RPAECs to [Fe2+] resulted in: (i) an increase in intracellular iron as detected by the iron sensitive fluorophore, PhenGreen; (ii) depletion of cell glutathione; and (iii) nuclear translocation of stress-response transcriptional factors Nrf2 and NFkB (p65). The resulting iron-induced cell alterations were characterized by cell polarization and formation of membrane cuplike and microvilli-like projections abundant with ICAM-1, caveolin-1, and F-actin. The iron-induced re-arrangements in cytoskeleton, alterations in focal cell-cell interactions, and cell buckling were accompanied by decrease in electrical resistance of RPAEC monolayer. These effects were partially eliminated in the presence of N,N'-bis (2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid, an iron chelator, and Y27632, a Rho-kinase inhibitor. Thus acute increases in labile iron in cultured pulmonary endothelium result in structural remodeling (and a proinflammatory phenotype) that occurs via post-transcriptional mechanisms regulated in a redox sensitive fashion.
C1 [Gorbunov, Nikolai V.] Henry Jackson Fdn Adv Mil Med Inc, Washington, DC, United States.
C1 [Gorbunov, Nikolai V.; Pitt, Bruce R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219, United States.
C1 [Gorbunov, Nikolai V.; Atkins, James L.] Walter Reed Army Inst Res, Silver Spring, MD 20910, United States.
C1 [Gurusamy, Narasimman] Univ Connecticut, Cardiovasc Res Ctr, Sch Med, Farmington, CT 06030, United States.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; United States Department of Defense; United States Army;
   Walter Reed Army Institute of Research (WRAIR); University of
   Connecticut
RP Gorbunov, NV (corresponding author), 8901 Wisconsin Ave, Bethesda, MD 20889 USA.
EM Nikolaiv.gorbunov@gmx.us
RI Gurusamy, Narasimman/ABU-6455-2022
OI Gurusamy, Narasimman/0000-0001-5579-1354
FU Department of the Army [PR033201]; US Army Medical Research; Materiel
   Command;  [R37 NIH HL65697]
FX The authors thank Dr. Yulia Y Tyurina, and Dr. Valerian E Kagan for
   their help with assessment of cell glutathione and Mr. Geoff Daniels
   (Leica Microsystems Inc.) for the confocal imaging consulting. This
   study was supported by the Department of the Army Peer Reviewed Medical
   Research Program (Grant No. PR033201 to J L A.), by the US Army Medical
   Research and Materiel Command and R37 NIH HL65697 (B R P.).
CR Adamson RH, 2002, J PHYSIOL-LONDON, V539, P295, DOI 10.1113/jphysiol.2001.013117
   ALREFAIE FN, 1992, BRIT J HAEMATOL, V82, P431, DOI 10.1111/j.1365-2141.1992.tb06441.x
   Atkins JL, 2011, BIOMETALS, V24, P279, DOI 10.1007/s10534-010-9394-1
   Atkins JL, 2006, J APPL PHYSIOL, V100, P1267, DOI 10.1152/japplphysiol.01059.2005
   Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Cabantchik ZI, 2005, BEST PRACT RES CL HA, V18, P277, DOI 10.1016/j.beha.2004.10.003
   Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129
   Chamaraux F, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/3/036009
   Dejana E, 2006, NAT CELL BIOL, V8, P105, DOI 10.1038/ncb0206-105
   Dresow B, 2008, BIOMETALS, V21, P273, DOI 10.1007/s10534-007-9116-5
   Dubick M, 2010, INFLAMM RES, V59, pS125
   Esposito BP, 2003, BLOOD, V102, P2670, DOI 10.1182/blood-2003-03-0807
   Feng D, 2002, MICROSC RES TECHNIQ, V57, P289, DOI 10.1002/jemt.10087
   Gorbunov NV, 2006, PROCEEDINGS OF THE XIII CONGRESS OF THE SOCIETY FOR FREE RADICAL RESEARCH INTERNATIONAL, P139
   Gorbunov NV, 2007, ANTIOXID REDOX SIGN, V9, P483, DOI 10.1089/ars.2006.1296
   Gorbunov NV, 2006, EXP MOL PATHOL, V80, P11, DOI 10.1016/j.yexmp.2005.06.007
   Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17
   Harada N, 2011, ARCH BIOCHEM BIOPHYS, V508, P101, DOI 10.1016/j.abb.2011.02.001
   HARRISON P, 1994, J CLIN PATHOL, V47, P350, DOI 10.1136/jcp.47.4.350
   Hod EA, 2010, BLOOD, V115, P4284, DOI 10.1182/blood-2009-10-245001
   Kartikasari AER, 2006, FASEB J, V20, P353, DOI 10.1096/fj.05-4700fje
   Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006
   Kress GJ, 2002, J NEUROSCI, V22, P5848
   Lagan AL, 2008, AM J PHYSIOL-LUNG C, V294, pL161, DOI 10.1152/ajplung.00169.2007
   Lane DJR, 2008, BIOFACTORS, V34, P191, DOI [10.1002/biof.5520340303, 10.3233/BIO-2009-1072]
   LOVSTAD RA, 1995, BIOMETALS, V8, P328
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356
   Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549
   Ozment CP, 2009, BBA-GEN SUBJECTS, V1790, P694, DOI 10.1016/j.bbagen.2008.09.010
   Porter JB, 1996, BLOOD, V88, P705, DOI 10.1182/blood.V88.2.705.bloodjournal882705
   Quadri SK, 2003, J BIOL CHEM, V278, P13342, DOI 10.1074/jbc.M209922200
   Richardson DR, 2010, P NATL ACAD SCI USA, V107, P10775, DOI 10.1073/pnas.0912925107
   Scheiber-Mojdehkar B, 2004, J AM SOC NEPHROL, V15, P1648, DOI 10.1097/01.ASN.0000130149.18412.56
   Shvartsman M, 2007, AM J PHYSIOL-CELL PH, V293, pC1383, DOI 10.1152/ajpcell.00054.2007
   Shvedova AA, 2000, J INVEST DERMATOL, V114, P354, DOI 10.1046/j.1523-1747.2000.00865.x
   Turi JL, 2004, FREE RADICAL BIO MED, V36, P850, DOI 10.1016/j.freeradbiomed.2003.12.008
   Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200
   van Buul JD, 2007, J CELL BIOL, V178, P1279, DOI 10.1083/jcb.200612053
   Zhang LM, 2006, EXP BIOL MED, V231, P1507, DOI 10.1177/153537020623100909
NR 41
TC 10
Z9 10
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0966-0844
J9 BIOMETALS
JI Biometals
PD FEB
PY 2012
VL 25
IS 1
BP 203
EP 217
DI 10.1007/s10534-011-9498-2
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 881LA
UT WOS:000299485000018
PM 22089858
DA 2023-08-21
ER

PT J
AU Wagner, MC
   Yeligar, SM
   Brown, LA
   Michael Hart, C
AF Wagner, Matthew C.
   Yeligar, Samantha M.
   Brown, Lou Ann
   Michael Hart, C.
TI PPAR gamma Ligands Regulate NADPH Oxidase, eNOS, and Barrier Function in
   the Lung Following Chronic Alcohol Ingestion
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Rosiglitazone; ALI/ARDS 
ID RESPIRATORY-DISTRESS-SYNDROME; ACTIVATED-RECEPTOR-GAMMA; PIOGLITAZONE
   CLINICAL-TRIAL; RANDOMIZED CONTROLLED-TRIAL; NITRIC-OXIDE; ETHANOL
   INGESTION; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; GLUTATHIONE HOMEOSTASIS;
   MYOCARDIAL-INFARCTION
AB Background: Chronic alcohol ingestion increases the incidence and severity of the acute respiratory distress syndrome (ARDS), where reactive species contribute to alveolar-capillary barrier dysfunction and noncardiogenic pulmonary edema. Previous studies demonstrated that chronic alcohol ingestion increased lung NADPH oxidase and endothelial nitric oxide synthase (eNOS) expression and that ligands for the peroxisome proliferator-activated receptor gamma (PPAR?) reduced NADPH oxidase expression. Therefore, we hypothesized that the PPAR? ligand, rosiglitazone, would attenuate alcohol-induced NADPH oxidase expression and pulmonary barrier dysfunction.
   Methods: C57Bl/6 mice were treated +/- alcohol in drinking water (20% w/v) for 12 weeks. During the final week of alcohol treatment, mice were gavaged with rosiglitazone (10 mg/kg/d) or vehicle. Selected animals were treated twice with lipopolysaccharide (LPS, 2 mg/kg IP) prior to sacrifice. Pulmonary barrier dysfunction was estimated from protein content of bronchoalveolar lavage (BAL) fluid.
   Results: LPS treatment increased BAL protein in alcohol-fed but not control mice, and rosiglitazone attenuated LPS and alcohol-induced pulmonary barrier dysfunction. Alcohol- and LPS-induced increases in lung eNOS, Nox1, and Nox4 expression were attenuated by rosiglitazone. In vitro, alcohol (0.10% w/v) increased H2O2 production, barrier dysfunction, eNOS, Nox1, and Nox4 expression in human umbilical vein endothelial cell (HUVEC) monolayers, effects also attenuated by rosiglitazone (10 mu M). Alcohol-induced HUVEC barrier dysfunction was attenuated by inhibition of NOS or addition of the eNOS cofactor, tetrahydrobiopterin.
   Conclusions: These results indicate that PPAR gamma activation reduced expression of eNOS, Nox1, Nox4, the production of reactive species, and barrier dysfunction caused by chronic alcohol ingestion and suggest that PPAR gamma represents a novel therapeutic target for strategies designed to reduce the risk of lung injury in patients with a history of chronic alcohol ingestion.
C1 [Michael Hart, C.] Atlanta VAMC, Dept Med, Decatur, GA 30033, United States.
C1 Emory Univ, Med Ctr, Decatur, GA 30033, United States.
C1 [Yeligar, Samantha M.; Brown, Lou Ann] Emory Univ, Dept Pediat, Div Neonatal Perinatal Med, Atlanta, GA 30322, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Health Care System; Emory University; Emory University
RP Michael Hart, C (corresponding author), Atlanta VAMC, Dept Med, 1670 Clairmont Rd,151-P, Decatur, GA 30033 USA.
EM michael.hart3@va.gov
FU NIAAA [5 T32AA013528-09]; Emory Alcohol and Lung Biology Center [5P50
   AA013 757-07]; Research Service of the Atlanta VA Medical Center
FX Funding for these studies was provided through an NIAAA T32 training
   grant (5 T32AA013528-09) and The Emory Alcohol and Lung Biology Center
   (5P50 AA013 757-07) and from the Research Service of the Atlanta VA
   Medical Center.
CR Asada K, 2004, AM J RESP CRIT CARE, V169, P195, DOI 10.1164/rccm.200207-740OC
   Bagi Z, 2004, AM J PHYSIOL-HEART C, V286, pH742, DOI 10.1152/ajpheart.00718.2003
   Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bendall JK, 2005, CIRC RES, V97, P864, DOI 10.1161/01.RES.0000187447.03525.72
   Brown LAS, 2007, AM J PHYSIOL-LUNG C, V292, pL824, DOI 10.1152/ajplung.00346.2006
   Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200
   Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325
   Calnek DS, 2003, ARTERIOSCL THROM VAS, V23, P52, DOI 10.1161/01.ATV.0000044461.01844.C9
   Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9
   Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347
   Erdmann E, 2007, J AM COLL CARDIOL, V49, P1772, DOI 10.1016/j.jacc.2006.12.048
   GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141
   Guidot DM, 2005, J INVEST MED, V53, P235, DOI 10.2310/6650.2005.53506
   Guidot DM, 2000, AM J PHYSIOL-LUNG C, V279, pL127, DOI 10.1152/ajplung.2000.279.1.L127
   Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956
   Holguin F, 1998, J CLIN INVEST, V101, P761, DOI 10.1172/JCI1396
   Home PD, 2007, NEW ENGL J MED, V357, P28, DOI 10.1056/NEJMoa073394
   Hwang J, 2007, VASC PHARMACOL, V46, P456, DOI 10.1016/j.vph.2007.01.007
   Hwang JN, 2005, AM J PHYSIOL-CELL PH, V288, pC899, DOI 10.1152/ajpcell.00474.2004
   Jerrells TR, 2007, ALCOHOL, V41, P357, DOI 10.1016/j.alcohol.2007.07.001
   Knepler JL, 2001, AM J PHYSIOL-CELL PH, V281, pC1064, DOI 10.1152/ajpcell.2001.281.3.C1064
   Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180
   LINKOLA J, 1979, ACTA PHYSIOL SCAND, V106, P75, DOI 10.1111/j.1748-1716.1979.tb06372.x
   Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719
   Martin GS, 2005, CRIT CARE, V9, pR74, DOI 10.1186/cc3025
   Meredith D, 2009, ARTERIOSCL THROM VAS, V29, P465, DOI 10.1161/ATVBAHA.109.184234
   Moss M, 2003, CRIT CARE MED, V31, P869, DOI 10.1097/01.CCM.0000055389.64497.11
   Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50
   Moss M, 2000, AM J RESP CRIT CARE, V161, P414, DOI 10.1164/ajrccm.161.2.9905002
   Nisbet RE, 2010, AM J RESP CELL MOL, V42, P482, DOI 10.1165/rcmb.2008-0132OC
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Polikandriotis JA, 2006, AM J RESP CELL MOL, V34, P314, DOI 10.1165/rcmb.2005-0320OC
   Polikandriotis JA, 2005, ALCOHOL CLIN EXP RES, V29, P1932, DOI 10.1097/01.alc.0000187597.62590.a4
   Polikandriotis JA, 2005, ARTERIOSCL THROM VAS, V25, P1810, DOI 10.1161/01.ATV.0000177805.65864.d4
   Polikandriotis JA, 2007, ALCOHOL, V41, P309, DOI 10.1016/j.alcohol.2007.03.012
   PUDDEY IB, 1987, LANCET, V1, P647
   Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0
   RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532
   Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004
   Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167
   Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x
   Song KJ, 2002, J LEUKOCYTE BIOL, V72, P1109
   Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wenz M, 1997, CHEST, V112, P478, DOI 10.1378/chest.112.2.478
   Wilcox R, 2007, STROKE, V38, P865, DOI 10.1161/01.STR.0000257974.06317.49
   WRIGHT JW, 1986, PHARMACOL BIOCHEM BE, V24, P813, DOI 10.1016/0091-3057(86)90416-8
   Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488
   Zingarelli B, 2003, J IMMUNOL, V171, P6827, DOI 10.4049/jimmunol.171.12.6827
NR 53
TC 31
Z9 31
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD FEB
PY 2012
VL 36
IS 2
BP 197
EP 206
DI 10.1111/j.1530-0277.2011.01599.x
PG 10
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse
GA 883DS
UT WOS:000299614700003
PM 21762184
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Konter, JM
   Parker, JL
   Baez, E
   Li, SZ
   Ranscht, B
   Denzel, M
   Little, FF
   Nakamura, K
   Ouchi, N
   Fine, A
   Walsh, K
   Summer, RS
AF Konter, Jason M.
   Parker, Jennifer L.
   Baez, Elizabeth
   Li, Stephanie Z.
   Ranscht, Barbara
   Denzel, Martin
   Little, Frederic F.
   Nakamura, Kazuto
   Ouchi, Noriyuki
   Fine, Alan
   Walsh, Kenneth
   Summer, Ross S.
TI Adiponectin Attenuates Lipopolysaccharide-Induced Acute Lung Injury
   through Suppression of Endothelial Cell Activation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; PLASMA ADIPONECTIN; INSULIN-RESISTANCE;
   LEPTIN RESISTANCE; CRITICALLY-ILL; ADIPOSE-TISSUE; OBESITY; MICE;
   INFLAMMATION; ASSOCIATION
AB Adiponectin (APN) is an adipose tissue-derived factor with anti-inflammatory and vascular protective properties whose levels paradoxically decrease with increasing body fat. In this study, APN's role in the early development of ALI to LPS was investigated. Intratracheal LPS elicited an exaggerated systemic inflammatory response in APN-deficient (APN(-/-)) mice compared with wildtype (wt) littermates. Increased lung injury and inflammation were observed in APN(-/-) mice as early as 4 h after delivery of LPS. Targeted gene expression profiling performed on immune and endothelial cells isolated from lung digests 4 h after LPS administration showed increased proinflammatory gene expression (e. g., IL-6) only in endothelial cells of APN(-/-) mice when compared with wt mice. Direct effects on lung endothelium were demonstrated by APN's ability to inhibit LPS-induced IL-6 production in primary human endothelial cells in culture. Furthermore, T-cadherin-deficient mice that have significantly reduced lung airspace APN but high serum APN levels had pulmonary inflammatory responses after intratracheal LPS that were similar to those of wt mice. These findings indicate the importance of serum APN in modulating LPS-induced ALI and suggest that conditions leading to hypoadiponectinemia (e. g., obesity) predispose to development of ALI through exaggerated inflammatory response in pulmonary vascular endothelium. The Journal of Immunology, 2012, 188: 854-863.
C1 [Konter, Jason M.; Baez, Elizabeth; Li, Stephanie Z.; Little, Frederic F.; Fine, Alan; Summer, Ross S.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118, United States.
C1 [Parker, Jennifer L.; Nakamura, Kazuto; Ouchi, Noriyuki; Walsh, Kenneth] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118, United States.
C1 [Ranscht, Barbara; Denzel, Martin] Sanford Burnham Med Res Inst, La Jolla, CA 92037, United States.
C3 Boston University; Boston University; Sanford Burnham Prebys Medical
   Discovery Institute
RP Summer, RS (corresponding author), Boston Univ, Sch Med, Ctr Pulm, 715 Albany St,R-304, Boston, MA 02118 USA.
EM rsummer@bu.edu
RI Denzel, Martin/C-9047-2014; OUCHI, Noriyuki/I-7306-2014
OI Denzel, Martin/0000-0002-5691-3349; Little,
   Frederic/0000-0003-4342-7007; Duffen, Jennifer/0000-0001-7797-037X;
   Fine, Alan/0000-0001-9351-3048
FU National Institutes of Health [K08 HL077138, AG15052, HL-59215,
   HL-105490]
FX This work was supported by National Institutes of Health Grants K08
   HL077138, AG15052, HL-59215, and HL-105490.
CR Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Anzueto A, 2011, THORAX, V66, P66, DOI 10.1136/thx.2010.145086
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Bellmeyer A, 2007, AM J RESP CRIT CARE, V175, P587, DOI 10.1164/rccm.200603-312OC
   Chen B, 2009, BRAIN RES, V1273, P129, DOI 10.1016/j.brainres.2009.04.002
   Denzel MS, 2010, J CLIN INVEST, V120, P4342, DOI 10.1172/JCI43464
   Durante-Mangoni E, 2006, ALIMENT PHARM THERAP, V24, P1349, DOI 10.1111/j.1365-2036.2006.03114.x
   Engeli S, 2003, DIABETES, V52, P942, DOI 10.2337/diabetes.52.4.942
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277
   Krakoff J, 2003, DIABETES CARE, V26, P1745, DOI 10.2337/diacare.26.6.1745
   Libby P, 2010, CIRC J, V74, P213, DOI 10.1253/circj.CJ-09-0706
   Matsumoto H, 2006, WORLD J GASTROENTERO, V12, P3352, DOI 10.3748/wjg.v12.i21.3352
   Medoff BD, 2009, AM J RESP CELL MOL, V41, P397, DOI 10.1165/rcmb.2008-0415OC
   Munzberg H, 2010, FORUM NUTR, V63, P123, DOI 10.1159/000264400
   Nakagawa Y, 2009, BIOCHEM BIOPH RES CO, V382, P183, DOI 10.1016/j.bbrc.2009.03.004
   Nakanishi K, 2011, AM J RESP CRIT CARE, V183, P1164, DOI 10.1164/rccm.201007-1091OC
   Ohashi K, 2009, MOL CELL BIOL, V29, P3487, DOI 10.1128/MCB.00126-09
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003
   Ouchi N, 2003, CIRCULATION, V107, P671, DOI 10.1161/01.CIR.0000055188.83694.B3
   Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295
   Sridulyakul P, 2003, CLIN HEMORHEOL MICRO, V29, P423
   Stapleton RD, 2010, CHEST, V138, P568, DOI 10.1378/chest.10-0014
   Stefan N, 2002, DIABETES, V51, P1884, DOI 10.2337/diabetes.51.6.1884
   Summer R, 2008, AM J PHYSIOL-LUNG C, V294, pL1035, DOI 10.1152/ajplung.00397.2007
   Summer R, 2009, AM J PHYSIOL-LUNG C, V297, pL432, DOI 10.1152/ajplung.90599.2008
   Takemura Yukihiro, 2007, Curr Atheroscler Rep, V9, P238, DOI 10.1007/s11883-007-0025-4
   Takemura Y, 2007, J CLIN INVEST, V117, P375, DOI 10.1172/JCI29709
   Tilg H, 2008, CLIN SCI, V114, P275, DOI 10.1042/CS20070196
   Towfigh S, 2009, J TRAUMA, V67, P1239, DOI 10.1097/TA.0b013e31818b1733
   Tsuchihashi H, 2006, J SURG RES, V134, P348, DOI 10.1016/j.jss.2006.01.001
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Uji Y, 2009, SURGERY, V145, P550, DOI 10.1016/j.surg.2009.01.010
   Walkey AJ, 2010, CRIT CARE MED, V38, P2329, DOI 10.1097/CCM.0b013e3181fa0561
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Wyder L, 2000, CANCER RES, V60, P4682
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Zhu M, 2010, AM J RESP CELL MOL, V43, P487, DOI 10.1165/rcmb.2009-0086OC
NR 43
TC 81
Z9 87
U1 1
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JAN 15
PY 2012
VL 188
IS 2
BP 854
EP 863
DI 10.4049/jimmunol.1100426
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 879IU
UT WOS:000299323700040
PM 22156343
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Chava, KR
   Tauseef, M
   Sharma, T
   Mehta, D
AF Chava, Koteswara Rao
   Tauseef, Mohammad
   Sharma, Tiffany
   Mehta, Dolly
TI Cyclic AMP response element-binding protein prevents endothelial
   permeability increase through transcriptional controlling p190RhoGAP
   expression
SO BLOOD
LA English
DT Article
ID THROMBIN-INDUCED INCREASE; NF-KAPPA-B; IN-VIVO; BARRIER DYSFUNCTION;
   VASCULAR LEAKAGE; RHOA ACTIVATION; P190 RHOGAP; CREB; ADENOSINE;
   MECHANISMS
AB Increased endothelial permeability contributes to the morbidity and mortality associated with chronic inflammatory diseases, including acute lung injury. Cyclic AMP response element-binding protein (CREB) transcriptional factor induces genes that regulate inflammation and vascular remodeling. However, the role of CREB in regulating endothelial barrier function is unknown. Here, we demonstrate that CREB maintains basal endothelial barrier function and suppresses endothelial permeability increase by diverse agonists such as thrombin, lipopolysaccharide, histamine, and VEGF. We show that CREB transcriptionally controls the expression of p190RhoGAP-A, a GTPase-activating protein that inhibits small GTPase RhoA. Impairing CREB function using small interfering RNA or dominant-negative (dn)-CREB mutant (dn-CREB) markedly suppressed p190RhoGAP-A expression, increased RhoA activity, induced actin stress fiber formation, and produced an amplified and protracted increase in endothelial permeability in response to thrombin. Rescuing p190RhoGAP-A expression restored the permeability defect in dn-CREB-transducing endothelial cells. These findings were recapitulated in vivo because dn-CREB expression in mice vasculature increased basal lung microvessel permeability and exaggerated permeability increase induced by thrombin and lipopolysaccharide. Inhibiting RhoA signaling restored endothelial barrier dysfunction in the dnCREB-expressing lung microvasculature. These results uncover a pivotal role of CREB in regulating endothelial barrier function by restricting RhoA signaling through controlling p190RhoGAP-A expression. (Blood. 2012; 119(1): 308-319)
C1 [Chava, Koteswara Rao; Tauseef, Mohammad; Sharma, Tiffany; Mehta, Dolly] Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612, United States.
C1 [Chava, Koteswara Rao; Tauseef, Mohammad; Sharma, Tiffany; Mehta, Dolly] Univ Illinois, Ctr Lung & Vasc Biol, Coll Med, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Mehta, D (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, 835 S Wolcott Ave, Chicago, IL 60612 USA.
EM dmehta@uic.edu
OI Tauseef, Mohammad/0000-0001-5317-4379
FU National Institutes of Health [HL71794, HL84153, PO1HL060678]
FX This work was supported by National Institutes of Health grants HL71794,
   HL84153, and PO1HL060678.
CR Abraham E, 2001, J IMMUNOL, V166, P522, DOI 10.4049/jimmunol.166.1.522
   Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115
   Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711
   Barlow C, 2006, AM J RESP CELL MOL, V34, P7, DOI 10.1165/rcmb.2005-0153OC
   Baumer Y, 2009, J CELL PHYSIOL, V220, P716, DOI 10.1002/jcp.21819
   Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011
   Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919-1925.2002
   Chava KR, 2009, ARTERIOSCL THROM VAS, V29, P809, DOI 10.1161/ATVBAHA.109.185777
   Chiappara G, 2007, ALLERGY, V62, P787, DOI 10.1111/j.1398-9995.2007.01417.x
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044
   Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Harrington EO, 2004, AM J PHYSIOL-LUNG C, V287, pL1091, DOI 10.1152/ajplung.00421.2003
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Ichiki T, 2006, ARTERIOSCL THROM VAS, V26, P449, DOI 10.1161/01.ATV.0000196747.79349.d1
   Ichiki T, 2003, HYPERTENSION, V42, P177, DOI 10.1161/01.HYP.0000079791.26014.04
   Klein IK, 2009, J BIOL CHEM, V284, P25953, DOI 10.1074/jbc.M109.035071
   Knezevic N, 2007, MOL CELL BIOL, V27, P6323, DOI 10.1128/MCB.00523-07
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112
   KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542
   Leonard MO, 2008, AM J RESP CRIT CARE, V178, P977, DOI 10.1164/rccm.200712-1890OC
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Matheson SF, 2006, DEV NEUROSCI-BASEL, V28, P538, DOI 10.1159/000095116
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D
   Minshall R. D., 2006, V176, P107
   Mroz RM, 2007, J PHYSIOL PHARMACOL, V58, P437
   Naoe H, 2010, MOL CELL BIOL, V30, P3994, DOI 10.1128/MCB.01358-09
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132
   Reusch JEB, 2003, CIRCULATION, V108, P1164, DOI 10.1161/01.CIR.0000084296.45158.50
   Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481
   Schlegel N, 2009, CRIT CARE MED, V37, P1735, DOI 10.1097/CCM.0b013e31819deb6a
   Settleman J, 2000, NAT CELL BIOL, V2, pE7, DOI 10.1038/71390
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shenkar R, 1997, AM J RESP CELL MOL, V16, P145, DOI 10.1165/ajrcmb.16.2.9032121
   Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X
   Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086
   TAKAI Y, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P338
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915
   Tullai JW, 2007, J BIOL CHEM, V282, P9482, DOI 10.1074/jbc.M700067200
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137
   Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046
NR 50
TC 31
Z9 33
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JAN 5
PY 2012
VL 119
IS 1
BP 308
EP 319
DI 10.1182/blood-2011-02-339473
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 875EE
UT WOS:000299012400037
PM 22049513
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Aso, H
   Ito, S
   Mori, A
   Morioka, M
   Suganuma, N
   Kondo, M
   Imaizumi, K
   Hasegawa, Y
AF Aso, Hiromichi
   Ito, Satoru
   Mori, Akemi
   Morioka, Masataka
   Suganuma, Nobukazu
   Kondo, Masashi
   Imaizumi, Kazuyoshi
   Hasegawa, Yoshinori
TI Prostaglandin E-2 enhances interleukin-8 production via EP4 receptor in
   human pulmonary microvascular endothelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; adenosine 3 ',5 '-cyclic monophosphate; chemokines; prostanoid EP receptor 
ID RESPIRATORY-DISTRESS-SYNDROME; SMOOTH-MUSCLE-CELLS; FACTOR-KAPPA-B;
   GENE-EXPRESSION; MECHANICAL STRETCH; LUNG INJURY; CA2+ INFLUX; MAP
   KINASE; IL-8; BARRIER
AB Aso H, Ito S, Mori A, Morioka M, Suganuma N, Kondo M, Imaizumi K, Hasegawa Y. Prostaglandin E-2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 302: L266-L273, 2012. First published November 11, 2011; doi:10.1152/ajplung.00248.2011.-Prostaglandin E-2 (PGE(2)) is a bioactive prostanoid implicated in the inflammatory processes of acute lung injury/acute respiratory distress syndrome. This study investigated whether PGE(2) can induce production of interleukin (IL)-8, the major chemokine for neutrophil activation, from human pulmonary microvascular endothelial cells (HPMVECs). PGE(2) significantly enhanced IL-8 protein production with increases in IL-8 mRNA expression and intracellular cAMP levels. HPMVECs expressed only EP4 receptor mRNA. The PGE(2) effects were mimicked by a selective EP4 receptor agonist, ONO-AE1-329, and inhibited by a selective EP4 receptor antagonist, ONO-AE3-208, or a protein kinase A inhibitor, Rp-adenosine 3',5'-cyclic monophosphorothioate triethylamine salt. The specific agonist for EP1, EP2, or EP3 receptor did not induce IL-8 production. PGE(2)-induced IL-8 production was accompanied by p38 phosphorylation and was significantly inhibited by a p38 inhibitor, SB-203580, but not by an ERK1/2 inhibitor, U-0126, or a JNK inhibitor, SP-600125. Additionally, PGE(2) increased cyclooxygenase-2 expression with no change in constitutive cyclooxygenase-1 expression, suggesting possible involvement of an autocrine or paracrine manner. In conclusion, PGE(2) enhances IL-8 production via EP4 receptor coupled to G(s) protein in HPMVECs. Activation of the cAMP/protein kinase A pathway, followed by p38 activation, is essential for these mechanisms. Because neutrophils play a critical role in the inflammation of acute lung injury/acute respiratory distress syndrome, IL-8 released from the pulmonary microvasculature in response to PGE(2) may contribute to pathophysiology of this disease.
C1 [Ito, Satoru] Nagoya Univ, Grad Sch Med, Dept Resp Med, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Ito, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Resp Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM itori@med.nagoya-u.ac.jp
RI Ito, Satoru/AAT-5219-2020; Kondo, Masashi/I-7378-2014; Hasegawa,
   Yoshinori/I-1277-2012
OI Ito, Satoru/0000-0001-7885-4653; 
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [22890837]
FX This work was supported by Grants-in-Aid for Scientific Research C no.
   22890837 from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (to S. Ito).
CR Aggarwal A, 2000, EUR RESPIR J, V15, P895, DOI 10.1034/j.1399-3003.2000.15e14.x
   Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje
   Alba-Loureiro TC, 2004, INFLAMM RES, V53, P658, DOI 10.1007/s00011-004-1308-7
   BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132
   Cheng M, 2007, BIORHEOLOGY, V44, P349
   DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Farmer PJ, 2001, AM J PHYSIOL-LUNG C, V280, pL732, DOI 10.1152/ajplung.2001.280.4.L732
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gloerich M, 2010, ANNU REV PHARMACOL, V50, P355, DOI 10.1146/annurev.pharmtox.010909.105714
   Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC
   Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593
   Grossini E, 2009, CELL PHYSIOL BIOCHEM, V23, P87, DOI 10.1159/000204097
   Harizi H, 2008, TRENDS MOL MED, V14, P461, DOI 10.1016/j.molmed.2008.08.005
   Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8
   Hashimoto S, 1999, EUR RESPIR J, V13, P1357, DOI 10.1034/j.1399-3003.1999.13f21.x
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847
   Ito S, 2008, AM J RESP CELL MOL, V38, P407, DOI 10.1165/rcmb.2007-0259OC
   Ito S, 2010, AM J RESP CELL MOL, V43, P26, DOI 10.1165/rcmb.2009-0073OC
   Iwaki M, 2009, BIOCHEM BIOPH RES CO, V389, P531, DOI 10.1016/j.bbrc.2009.09.020
   Iwata S, 2009, EUR J PHARMACOL, V605, P15, DOI 10.1016/j.ejphar.2008.12.045
   JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514
   Kaur M, 2008, AM J PHYSIOL-LUNG C, V295, pL505, DOI 10.1152/ajplung.00046.2008
   Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200
   Legler DF, 2010, INT J BIOCHEM CELL B, V42, P198, DOI 10.1016/j.biocel.2009.09.015
   Li LF, 2003, AM J PHYSIOL-LUNG C, V285, pL464, DOI 10.1152/ajplung.00031.2003
   MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578
   Maybin JA, 2011, AM J PATHOL, V178, P1245, DOI 10.1016/j.ajpath.2010.11.070
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mittal N, 2011, INFLAMMATION, V34, P92, DOI 10.1007/s10753-010-9211-6
   Mori A, 2011, EUR J PHARMACOL, V659, P72, DOI 10.1016/j.ejphar.2011.03.001
   Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193
   Ngiam N, 2010, AM J RESP CRIT CARE, V181, P947, DOI 10.1164/rccm.200908-1297OC
   Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766
   OZAKI T, 1987, J APPL PHYSIOL, V62, P219, DOI 10.1152/jappl.1987.62.1.219
   Park GY, 2006, AM J PHYSIOL-LUNG C, V290, pL797, DOI 10.1152/ajplung.00513.2005
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Park YS, 2007, ARTERIOSCL THROM VAS, V27, P1319, DOI 10.1161/ATVBAHA.106.132837
   PARSONS PE, 1985, AM REV RESPIR DIS, V132, P490
   Quesnel C, 2008, AM J PHYSIOL-LUNG C, V294, pL334, DOI 10.1152/ajplung.00096.2007
   Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200
   Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866
   Sayner SL, 2011, AM J PHYSIOL-LUNG C, V300, pL667, DOI 10.1152/ajplung.00433.2010
   STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200
   Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI13416
   Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001
NR 55
TC 28
Z9 29
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JAN
PY 2012
VL 302
IS 2
BP L266
EP L273
DI 10.1152/ajplung.00248.2011
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 875EP
UT WOS:000299013500009
PM 22080750
DA 2023-08-21
ER

PT J
AU Belvitch, P
   Dudek, SM
AF Belvitch, Patrick
   Dudek, Steven M.
TI Role of FAK in S1P-regulated endothelial permeability
SO MICROVASCULAR RESEARCH
LA English
DT Article
ID FOCAL ADHESION KINASE; MYOSIN LIGHT-CHAIN; CELL BARRIER ENHANCEMENT;
   ACUTE LUNG INJURY; SPHINGOSINE 1-PHOSPHATE; VE-CADHERIN; TYROSINE
   PHOSPHORYLATION; VASCULAR-PERMEABILITY; S1P(1) RECEPTOR; RHO-GTPASES
AB The vascular endothelium serves as a semi-selective barrier between the circulating contents of the blood and the tissues through which they flow. Disruption of this barrier results in significant organ dysfunction during devastating inflammatory syndromes such as sepsis and acute lung injury (ALI). Sphingosine 1-phosphate (S1P) is an endogenous lipid regulator of endothelial permeability that produces potent barrier enhancement via actin and junctional protein rearrangement and resultant cytoskeletal changes. A key effector protein in this S1P response is focal adhesion kinase (FAK), a highly conserved cytoplasmic tyrosine kinase involved in the engagement of integrins and assembly of focal adhesions (FA) through the catalysis of multiple downstream signals. After stimulation by S1P, endothelial FAK undergoes specific tyrosine phosphorylation that results in activation of the kinase and dynamic interactions with other effector molecules to improve the endothelial barrier. FAK participates in peripheral actin cytoskeletal rearrangement as well as cell-matrix (FA) and cell-cell (adherens junction) junctional complex strengthening that combine to decrease vascular permeability. This review summarizes the current knowledge of the role of FAK in mediating enhanced endothelial barrier function by S1P. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Belvitch, Patrick; Dudek, Steven M.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Inst Personalized Resp Med, Dept Med, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Dudek, SM (corresponding author), Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Inst Personalized Resp Med, Dept Med, COMRB 3143,MC 719,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM sdudek@uic.edu
FU National Heart Lung Blood Institute NIH [P01 HL 58064, R01 HL 88144]
FX This work was supported by grants from the National Heart Lung Blood
   Institute NIH grant P01 HL 58064 and R01 HL 88144. The authors thank
   Lichun Wang, Ph.D. for helpful discussions.
CR Alghisi GC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004449
   Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296
   Arce FT, 2008, BIOPHYS J, V95, P886, DOI 10.1529/biophysj.107.127167
   Argraves KM, 2008, J BIOL CHEM, V283, P25074, DOI 10.1074/jbc.M801214200
   Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829
   Bazzoni G, 2006, THROMB HAEMOSTASIS, V95, P36, DOI 10.1160/TH05-07-0488
   Birukova AA, 2007, MICROVASC RES, V73, P173, DOI 10.1016/j.mvr.2006.12.004
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Brown M, 2010, MICROVASC RES, V80, P75, DOI 10.1016/j.mvr.2009.12.010
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110
   Chang FM, 2007, MOL BIOL CELL, V18, P253, DOI 10.1091/mbc.E06-03-0207
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Dudek SM, 2007, CELL SIGNAL, V19, P1754, DOI 10.1016/j.cellsig.2007.03.011
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Golubovskaya VM, 2005, J BIOL CHEM, V280, P25008, DOI 10.1074/jbc.M414172200
   Guo MZ, 2005, MICROCIRCULATION, V12, P223, DOI 10.1080/10739680590905251
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hammad SM, 2010, J LIPID RES, V51, P3074, DOI 10.1194/jlr.D008532
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   ILLC D, 1995, NATURE, V377, P539
   Ito K, 2007, BIOCHEM BIOPH RES CO, V357, P212, DOI 10.1016/j.bbrc.2007.03.123
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833
   Lee JF, 2006, J BIOL CHEM, V281, P29190, DOI 10.1074/jbc.M604310200
   Lee JF, 2009, AM J PHYSIOL-HEART C, V296, pH33, DOI 10.1152/ajpheart.00097.2008
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087
   Young HL, 2007, AM J RESP CELL MOL, V37, P485, DOI 10.1165/rcmb.2006-0439OC
   Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031
   Liu ZJ, 2010, P NATL ACAD SCI USA, V107, P9944, DOI 10.1073/pnas.0914547107
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289
   Miura Y, 2000, J BIOCHEM-TOKYO, V127, P909, DOI 10.1093/oxfordjournals.jbchem.a022686
   Orr AW, 2004, FRONT BIOSCI-LANDMRK, V9, P1254, DOI 10.2741/1239
   Ossovskaya V, 2008, FEBS LETT, V582, P2402, DOI 10.1016/j.febslet.2008.06.004
   Owen KA, 2007, J CELL BIOL, V179, P1275, DOI 10.1083/jcb.200708093
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Playford MP, 2008, EXP CELL RES, V314, P3187, DOI 10.1016/j.yexcr.2008.08.010
   Quadri SK, 2007, AM J PHYSIOL-LUNG C, V292, pL334, DOI 10.1152/ajplung.00228.2006
   Quadri SK, 2003, J BIOL CHEM, V278, P13342, DOI 10.1074/jbc.M209922200
   Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db
   Rosen H, 2009, ANNU REV BIOCHEM, V78, P743, DOI 10.1146/annurev.biochem.78.072407.103733
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623
   SCHLAEPFER DD, 1994, NATURE, V372, P786
   Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626
   Shan YL, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000116
   Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com
   Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200
   Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367
   Strub GM, 2010, ADV EXP MED BIOL, V688, P141
   Sun XG, 2009, MICROVASC RES, V77, P304, DOI 10.1016/j.mvr.2008.12.004
   Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380
   Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006
   Troyanovsky B, 2008, AM J PHYSIOL-LUNG C, V294, pL266, DOI 10.1152/ajplung.00107.2007
   Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251
   Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   Wang L, 2011, EUR RESPIR J, V38, P78, DOI 10.1183/09031936.00047810
   Wang L, 2008, HISTOCHEM CELL BIOL, V129, P579, DOI 10.1007/s00418-008-0389-8
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Wu MH, 2005, J PHYSIOL-LONDON, V569, P359, DOI 10.1113/jphysiol.2005.096537
   Wu MH, 2003, J PHYSIOL-LONDON, V552, P691, DOI 10.1113/jphysiol.2003.048405
   Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200
   Xu M, 2007, AM J PHYSIOL-CELL PH, V293, pC1309, DOI 10.1152/ajpcell.00014.2007
   Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013
   YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193
   Yu JXA, 2009, MOL BIOL CELL, V20, P4706, DOI 10.1091/mbc.E09-07-0548
   Zhang GQ, 2010, AM J PHYSIOL-HEART C, V299, pH1494, DOI 10.1152/ajpheart.00462.2010
   Zhao J, 2009, CELL SIGNAL, V21, P1945, DOI 10.1016/j.cellsig.2009.09.002
   Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094
   Zhao YT, 2007, J BIOL CHEM, V282, P14165, DOI 10.1074/jbc.M701279200
NR 90
TC 42
Z9 46
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD JAN
PY 2012
VL 83
IS 1
SI SI
BP 22
EP 30
DI 10.1016/j.mvr.2011.08.012
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 875WY
UT WOS:000299067100004
PM 21925517
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Preira, P
   Leoni, T
   Valignat, MP
   Lellouch, A
   Robert, P
   Forel, JM
   Papazian, L
   Dumenil, G
   Bongrand, P
   Theodoly, O
AF Preira, Pascal
   Leoni, Thomas
   Valignat, Marie-Pierre
   Lellouch, Annemarie
   Robert, Philippe
   Forel, Jean-Marie
   Papazian, Laurent
   Dumenil, Guillaume
   Bongrand, Pierre
   Theodoly, Olivier
TI Microfluidic tools to investigate pathologies in the blood
   microcirculation
SO INTERNATIONAL JOURNAL OF NANOTECHNOLOGY
LA English
DT Article
DE microfluidics; microvasculature; cell mechanics; cell adhesion; cell migration; cell transmigration; respiratory distress syndrome; meningitis 
ID ACUTE RESPIRATORY-DISTRESS; REFLECTION MICROSCOPY; ADHESION; CELLS;
   FLOW; DEFORMATION; ENDOTHELIUM; NEUTROPHILS; CONTRAST; CHANNELS
AB We show how microfluidics technology can be used to fabricate simple and innovative biomimetic tools to shed new light on physiopathological events occurring in the blood microcirculation. Examples of applications are given in the context of the acute respiratory distress Syndrome (ARDS), an inflammatory disease of the lung triggered by a massive arrest of white blood cells in the lung microvasculature. The main challenge consists in building relevant micro-devices to reproduce key biological characteristics of blood capillaries. We present a series of tools that permit us to decouple the role of the multiple parameters involved in complex biological events. Straight narrow channels with non-adherent walls are used to characterise the passage of a cell in 4 mu m wide constrictions in the absence of adhesion, whereas channels covered by endothelial cells allow a quantitative measurement of cell adhesion in the absence of mechanical constraints. We show that incubation of white blood cells in sera of ARDS patients increases their stiffness, confirming the role of stiffness on the abnormal sequestration of white blood cells, whereas we could not bring to light a significant adhesion increase. The multiple branches and constrictions of the blood microvasculature network are mimicked here by series of interconnected crenelled constrictions with different symmetries. In symmetric crenels, cells adopt a stable deformed shape after a few constrictions and travel fast through successive constrictions with a constant orientation. In asymmetric channels, cell orientation and trajectory are perturbed between two constrictions. Unfavourable orientations upon entry can yield temporary or even definitive arrests with the stiffest cells. Finally, we present a new artificial micro-vessel with porous walls to mimic the porosity of real blood vessels. This new tool is useful to observe directly under a microscope the late stages of inflammation in the microvasculature such as immune cells transmigration, or the infection of a micro-vessel by pathogenic bacteria.
C1 [Preira, Pascal; Leoni, Thomas; Valignat, Marie-Pierre; Lellouch, Annemarie; Robert, Philippe; Bongrand, Pierre; Theodoly, Olivier] Univ Mediterranee, INSERM, U600, CNRS,UMR6212, F-13009 Marseille, France.
C1 [Forel, Jean-Marie; Papazian, Laurent] Univ Aix Marseille 2, CNRS, Hop Nord, URMITE,UMR6236, F-13015 Marseille 20, France.
C1 [Dumenil, Guillaume] Univ Paris 05, Fac Med Paris Descartes, F-75006 Paris, France.
C1 [Dumenil, Guillaume] INSERM, U970, PARCC, Ctr Rech Cardiovasc,HEGP, F-75015 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Aix-Marseille Universite; Centre National de la Recherche
   Scientifique (CNRS); Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille
   Universite; UDICE-French Research Universities; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen
   Georges-Pompidou - APHP
RP Theodoly, O (corresponding author), Univ Mediterranee, INSERM, U600, CNRS,UMR6212, Case 937,163 Ave Luminy, F-13009 Marseille, France.
EM pascal.preira@inserm.fr; thomas.leoni@inserm.fr;
   marie-pierre.valignat@inserm.fr; annemarie.lellouch@inserm.fr;
   philippe.robert@inserm.fr; jeanmarie.forel@ap-hm.fr;
   laurent.papazian@ap-hm.fr; guillaume.dumenil@inserm.fr;
   pierre.bongrand@inserm.fr; olivier.theodoly@inserm.fr
RI Lellouch, Annemarie C/E-9905-2014; theodoly, olivier/P-5402-2016;
   Robert, Philippe/P-9597-2016; Dumenil, Guillaume/F-7567-2015; Bongrand,
   Pierre/C-4456-2013; Dumenil, Guillaume/N-3377-2019; Valignat,
   Marie-Pierre/P-9558-2016
OI theodoly, olivier/0000-0001-8787-3709; Robert,
   Philippe/0000-0002-1343-994X; Dumenil, Guillaume/0000-0001-9174-9110;
   Bongrand, Pierre/0000-0001-6185-6572; Dumenil,
   Guillaume/0000-0001-9174-9110; Leoni, Thomas/0000-0002-0582-9534;
   valignat, marie-pierre/0000-0002-6031-3813
FU ANR; Region PACA; company CAPSUM-SAS; Association pour la Recherche sur
   le Cancer (ARC)
FX The authors thank Cyprien Gay for helpful discussions and acknowledge
   the Rhodia Company (LOF, Pessac, France) and CINAM (CNRS UPR 3118,
   Marseille, France) for technical support with microfabrication.
   Postdoctoral fellowship of TL was supported by ANR 'Bugs in Flow' and
   Doctoral fellowships of PP by both the Region PACA and the company
   CAPSUM-SAS. AL, MPV and OT acknowledge support from the Association pour
   la Recherche sur le Cancer (ARC).
CR Alon R, 2003, BLOOD, V101, P4437, DOI 10.1182/blood-2002-11-3427
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Ausserre D, 2006, NANO LETT, V6, P1384, DOI 10.1021/nl060353h
   AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141
   Balland M, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.021911
   Bathe M, 2002, BIOPHYS J, V83, P1917, DOI 10.1016/S0006-3495(02)73955-6
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Chaw KC, 2006, J PHYS CONF SER, V34, P747, DOI 10.1088/1742-6596/34/1/123
   Chaw KC, 2006, MICROVASC RES, V72, P153, DOI 10.1016/j.mvr.2006.06.003
   Chung S, 2009, LAB CHIP, V9, P269, DOI 10.1039/b807585a
   CURTIS ASG, 1964, J CELL BIOL, V20, P199, DOI 10.1083/jcb.20.2.199
   El-Ali J, 2006, NATURE, V442, P403, DOI 10.1038/nature05063
   Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0
   Gabriele S, 2010, LAB CHIP, V10, P1459, DOI 10.1039/c002257h
   Gabriele S, 2009, BIOPHYS J, V96, P4308, DOI 10.1016/j.bpj.2009.02.037
   GINGELL D, 1979, BIOPHYS J, V26, P507, DOI 10.1016/S0006-3495(79)85268-6
   Gross S, 2008, IMMUNOL LETT, V116, P7, DOI 10.1016/j.imlet.2007.11.012
   Harlan J.M., 1992, ADHESION ITS ROLE IN, P117
   Hawkins RJ, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.058103
   Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818
   HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Ibbotson GC, 2001, NAT MED, V7, P465, DOI 10.1038/86539
   Jacobelli J, 2010, NAT IMMUNOL, V11, P953, DOI 10.1038/ni.1936
   Khan OF, 2011, BIOMED MICRODEVICES, V13, P69, DOI 10.1007/s10544-010-9472-8
   Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651
   Lam WA, 2008, BRIT J HAEMATOL, V142, P497, DOI 10.1111/j.1365-2141.2008.07219.x
   LESSOR DL, 1979, J OPT SOC AM, V69, P357, DOI 10.1364/JOSA.69.000357
   Lewis SM, 2009, AM J RESP CELL MOL, V40, P724, DOI 10.1165/rcmb.2008-0252OC
   LIPOWSKY HH, 1978, CIRC RES, V43, P738, DOI 10.1161/01.RES.43.5.738
   Looney MR, 2011, NAT METHODS, V8, P91, DOI 10.1038/NMETH.1543
   Mairey E, 2006, J EXP MED, V203, P1939, DOI 10.1084/jem.20060482
   NEEDHAM D, 1990, J BIOMECH ENG-T ASME, V112, P269, DOI 10.1115/1.2891184
   Nishino M, 2005, J TRAUMA, V59, P1425, DOI 10.1097/01.ta.0000197356.83144.72
   Nomarski G., 1960, US Patent Office, Patent No. [2, 924, 142, 2924142, US2924142]
   RADLER J, 1993, J PHYS II, V3, P727
   Robert P., 2011, J IMMUNOL IN PRESS
   Rosenbluth MJ, 2008, LAB CHIP, V8, P1062, DOI 10.1039/b802931h
   Sabri S, 2000, J CELL SCI, V113, P1589
   Salieb-Beugelaar GB, 2010, ANAL CHEM, V82, P4848, DOI 10.1021/ac1009707
   Shao JB, 2009, LAB CHIP, V9, P3118, DOI 10.1039/b909312e
   Shelby JP, 2003, P NATL ACAD SCI USA, V100, P14618, DOI 10.1073/pnas.2433968100
   Skoutelis AT, 2000, CRIT CARE MED, V28, P2355, DOI 10.1097/00003246-200007000-00029
   Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756
   Song JW, 2005, ANAL CHEM, V77, P3993, DOI 10.1021/ac050131o
   Theodoly O, 2010, LANGMUIR, V26, P1940, DOI 10.1021/la902504y
   Tkachenko E, 2009, LAB CHIP, V9, P1085, DOI 10.1039/b812184b
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
   Valignat M.P., UNDERWATER NAN UNPUB
   van der Meer AD, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/823148
   van der Meer AD, 2010, BIOMICROFLUIDICS, V4, DOI 10.1063/1.3366720
   Velve-Casquillas G, 2010, NANO TODAY, V5, P28, DOI 10.1016/j.nantod.2009.12.001
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wong CW, 2002, AM J PATHOL, V161, P749, DOI 10.1016/S0002-9440(10)64233-2
   Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G
   Yap B, 2005, J APPL PHYSIOL, V98, P1930, DOI 10.1152/japplphysiol.01226.2004
   Yoshida K, 2006, AM J RESP CRIT CARE, V174, P689, DOI 10.1164/rccm.200502-276OC
   Young EWK, 2010, LAB CHIP, V10, P143, DOI 10.1039/b913390a
   Zernike F, 1942, PHYSICA, V9, P974, DOI 10.1016/S0031-8914(42)80079-8
NR 60
TC 7
Z9 7
U1 0
U2 51
PU INDERSCIENCE ENTERPRISES LTD
PI GENEVA
PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215
   GENEVA, SWITZERLAND
SN 1475-7435
EI 1741-8151
J9 INT J NANOTECHNOL
JI Int. J. Nanotechnol.
PY 2012
VL 9
IS 3-7
BP 529
EP 547
DI 10.1504/IJNT.2012.045340
PG 19
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA 894AX
UT WOS:000300400400025
OA Green Published
DA 2023-08-21
ER

PT J
AU Shah, NG
   Tulapurkar, ME
   Damarla, M
   Singh, IS
   Goldblum, SE
   Shapiro, P
   Hasday, JD
AF Shah, Nirav G.
   Tulapurkar, Mohan E.
   Damarla, Mahendra
   Singh, Ishwar S.
   Goldblum, Simeon E.
   Shapiro, Paul
   Hasday, Jeffrey D.
TI Febrile-range hyperthermia augments reversible TNF-alpha-induced
   hyperpermeability in human microvascular lung endothelial cells
SO INTERNATIONAL JOURNAL OF HYPERTHERMIA
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; hyperthermia; hyperpermeability; lung; MAPK 
ID RESPIRATORY-DISTRESS-SYNDROME; F-ACTIN DEPOLYMERIZATION;
   TUMOR-NECROSIS-FACTOR; BARRIER DYSFUNCTION; TYROSINE PHOSPHORYLATION;
   MONOLAYER PERMEABILITY; NEUTROPHIL RECRUITMENT; PARACELLULAR PATHWAY;
   PROTEIN INTERACTIONS; SIGNALING PATHWAYS
AB Fever commonly occurs in acute lung injury (ALI) and ALI occurs in 25% of victims of heat stroke. We have shown in mouse models of ALI that exposure to febrile-range hyperthermia (FRH), 39.5 degrees C, increases non-cardiogenic pulmonary oedema. In this study we studied the direct effects of FRH on endothelial barrier integrity using human microvascular endothelial cells (HMVEC-Ls). We analysed the effect of exposure to culture temperatures between 38.5 degrees and 41 degrees C with and without tumour necrosis factor-alpha (TNF-alpha) up to 250 U/mL for 6-24 h. We found that exposure to 2.5-250 U/mL TNF-alpha increased HMVEC-L permeability by 4.1-15.8-fold at 37 degrees C. Exposure to 39.5 degrees C alone caused variable, modest, lot-specific increases in HMVEC-L permeability, however raising culture temperature to 39.5 degrees C in the presence of TNF-alpha increased permeability an additional 1.6-4.5-fold compared with cells incubated with the same TNF-alpha concentration at 37 degrees C. Permeability occurred without measurable cytotoxicity and was reversible upon removal of TNF-alpha and reduction in temperature to 37 degrees C. Exposure to 39.5 degrees C or TNF-alpha each stimulated rapid activation of p38 and ERK but the effects were not additive. Treatment with inhibitors of ERK (U0126) or p38 (SB203580) each reduced TNF-alpha-induced permeability in 39.5 degrees C monolayers to levels in 37 degrees C cells, but did not alter TNF-alpha-induced permeability in the 37 degrees C cells. These results demonstrate that FRH directly increases paracellular pathway opening through a process that requires ERK and p38 MAPKs. A better understanding of this mechanism may provide new understanding about how fever may contribute to the pathogenesis of ALI and provide new therapeutic targets to improve clinical outcomes.
C1 [Shah, Nirav G.; Tulapurkar, Mohan E.; Singh, Ishwar S.; Hasday, Jeffrey D.] Univ Maryland, Sch Med, Div Pulm & Crit Care, Dept Med, Baltimore, MD 21201, United States.
C1 [Shah, Nirav G.; Tulapurkar, Mohan E.; Singh, Ishwar S.; Goldblum, Simeon E.; Hasday, Jeffrey D.] Univ Maryland, Mucosal Biol Res Ctr, Sch Med, Baltimore, MD 21201, United States.
C1 [Damarla, Mahendra] Johns Hopkins Med Inst, Dept Med, Div Pulm & Crit Care, Baltimore, MD 21205, United States.
C1 [Singh, Ishwar S.; Goldblum, Simeon E.; Hasday, Jeffrey D.] Baltimore VA Med Ctr, Res Serv, Baltimore, MD, United States.
C1 [Goldblum, Simeon E.] Univ Maryland, Div Infect Dis, Dept Med, Sch Med, Baltimore, MD 21201, United States.
C1 [Shapiro, Paul] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201, United States.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore; Johns
   Hopkins University; Johns Hopkins Medicine; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Baltimore VA Medical
   Center; University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Shah, NG (corresponding author), Univ Maryland, Sch Med, Div Pulm & Crit Care, Dept Med, 110 S Paca St,2nd Floor, Baltimore, MD 21201 USA.
EM nshah1@medicine.umaryland.edu
RI tulapurkar, mohan/F-1926-2015
OI tulapurkar, mohan/0000-0002-2476-5417
FU US National Institutes of Health [GM069431, GM066855, HL69057,
   HL085256]; US Veterans Association
FX This work was supported by US National Institutes of Health grants
   GM069431 (I. S. S.) and GM066855, HL69057 and HL085256 (J.D.H.), and by
   US Veterans Association Merit Review grants to J.D.H. and I. S. S. The
   authors alone are responsible for the content and writing of the paper.
CR Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.3.CO;2-D
   Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006
   Bannerman DD, 1997, AM J PHYSIOL-LUNG C, V273, pL217, DOI 10.1152/ajplung.1997.273.1.L217
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003
   Borbiev T, 2003, AM J PHYSIOL-LUNG C, V285, pL43, DOI 10.1152/ajplung.00460.2001
   Breslin JW, 2003, AM J PHYSIOL-HEART C, V284, pH92, DOI 10.1152/ajpheart.00330.2002
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cheuvront SN, 2010, J APPL PHYSIOL, V109, P1989, DOI 10.1152/japplphysiol.00367.2010
   Damarla M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004600
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dupuy DE, 2011, RADIOLOGY, V260, P633, DOI 10.1148/radiol.11091126
   Ellis GS, 2005, J APPL PHYSIOL, V98, P1799, DOI 10.1152/japplphysiol.01376.2004
   Friedl J, 2003, INT J ONCOL, V23, P611
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146
   GOLDBLUM SE, 1993, J CELL PHYSIOL, V157, P13, DOI 10.1002/jcp.1041570103
   GOLDBLUM SE, 1994, P NATL ACAD SCI USA, V91, P3448, DOI 10.1073/pnas.91.8.3448
   Goldblum SE, 1999, MOL BIOL CELL, V10, P1537, DOI 10.1091/mbc.10.5.1537
   GOLDBLUM SE, 1993, AM J PHYSIOL, V264, pC894, DOI 10.1152/ajpcell.1993.264.4.C894
   Hasday JD, 2003, AM J PATHOL, V162, P2005, DOI 10.1016/S0002-9440(10)64333-7
   Hasday JD, 2001, J APPL PHYSIOL, V90, P90, DOI 10.1152/jappl.2001.90.1.90
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200
   KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L
   Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21
   Konstantoulaki M, 2003, AM J PHYSIOL-LUNG C, V285, pL434, DOI 10.1152/ajplung.00075.2003
   Laupland KB, 2008, CRIT CARE MED, V36, P1531, DOI 10.1097/CCM.0b013e318170efd3
   Lipke AB, 2010, J IMMUNOL, V184, P3801, DOI 10.4049/jimmunol.0903191
   Liu T, 2009, J CELL PHYSIOL, V220, P600, DOI 10.1002/jcp.21773
   Lu Q, 2006, J APPL PHYSIOL, V101, P375, DOI 10.1152/japplphysiol.01515.2005
   Maity TK, 2011, CYTOKINE, V54, P61, DOI 10.1016/j.cyto.2010.12.017
   Niwa K, 2001, FREE RADICAL RES, V35, P519, DOI 10.1080/10715760100301531
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   POBER JS, 1988, AM J PATHOL, V133, P426
   Rice P, 2005, J IMMUNOL, V174, P3676, DOI 10.4049/jimmunol.174.6.3676
   RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Shah NG, 2009, AM J RESP CRIT CARE, V179
   SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657
   Singh IS, 2008, AM J RESP CELL MOL, V39, P235, DOI 10.1165/rcmb.2007-0294OC
   Sumagin R, 2011, AM J PHYSIOL-CELL PH, V301, pC804, DOI 10.1152/ajpcell.00135.2011
   Tulapurkar ME, 2012, AM J RESP CELL MOL, V46, P807, DOI 10.1165/rcmb.2011-0378OC
   Tulapurkar ME, 2011, INT J HYPERTHER, V27, P717, DOI 10.3109/02656736.2011.601528
   Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200
   Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025
   Varma S, 2002, MICROVASC RES, V63, P172, DOI 10.1006/mvre.2001.2381
   Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360
   Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wheeler AP, 2006, NEW ENGL J MED, V354, P2213
   Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X
NR 53
TC 12
Z9 14
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0265-6736
EI 1464-5157
J9 INT J HYPERTHER
JI Int. J. Hyperthermia
PY 2012
VL 28
IS 7
BP 627
EP 635
DI 10.3109/02656736.2012.690547
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 022EU
UT WOS:000309939200006
PM 22834633
OA Bronze
DA 2023-08-21
ER

PT J
AU Su, G
   Atakilit, A
   Li, JT
   Wu, NY
   Bhattacharya, M
   Zhu, JL
   Shieh, JE
   Li, E
   Chen, R
   Sun, S
   Su, CP
   Sheppard, D
AF Su, George
   Atakilit, Amha
   Li, John T.
   Wu, Nanyan
   Bhattacharya, Mallar
   Zhu, Jieling
   Shieh, Jennifer E.
   Li, Elizabeth
   Chen, Robert
   Sun, Stephen
   Su, Cynthia P.
   Sheppard, Dean
TI Absence of Integrin alpha v beta 3 Enhances Vascular Leak in Mice by
   Inhibiting Endothelial Cortical Actin Formation
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; sepsis; ALI/ARDS; integrins 
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; VINCULIN-BINDING-SITE;
   LIGHT-CHAIN KINASE; GROWTH-FACTOR; SPHINGOSINE 1-PHOSPHATE; BARRIER
   FUNCTION; RHO-KINASE; TALIN ROD; PERMEABILITY
AB Rationale: Sepsis and acute lung injury (ALI) have devastatingly high mortality rates. Both are associated with increased vascular leak, a process regulated by complex molecular mechanisms.
   Objectives: We hypothesized that integrin alpha v beta 3 could be an important determinant of vascular leak and endothelial permeability in sepsis and ALI.
   Methods: beta 3 subunit knockout mice were tested for lung vascular leak after endotracheal LPS, and systemic vascular leak and mortality after intraperitoneal LPS and cecal ligation and puncture. Possible contributory effects of beta 3 deficiency in platelets and other hematopoietic cells were excluded by bone marrow reconstitution experiments. Endothelial cells treated with alpha v beta 3 antibodies were evaluated for sphingosine-1 phosphate (S1P)-mediated alterations in barrier function, cytoskeletal arrangement, and integrin localization.
   Measurements and Main Results: beta 3 knockout mice had increased vascular leak and pulmonary edema formation after endotracheal LPS, and increased vascular leak and mortality after intraperitoneal LPS and cecal ligation and puncture. In endothelial cells, alpha v beta 3 antibodies inhibited barrier-enhancing and cortical actin responses to S1P. Furthermore, S1P induced translocation of alpha v beta 3 from discrete focal adhesions to cortically distributed sites through Gi- and Rac1-mediated pathways. Cortical alpha v beta 3 localization after S1P was decreased by alpha v beta 3 antibodies, suggesting that ligation of the alpha v beta 3 with its extracellular matrix ligands is required to stabilize cortical alpha v beta 3 focal adhesions.
   Conclusions: Our studies identify a novel mechanism by which alpha v beta 3 mitigates increased vascular leak, a pathophysiologic function central to sepsis and ALI. These studies suggest that drugs designed to block alpha v beta 3 may have the unexpected side effect of intensifying sepsis- and ALI-associated vascular endothelial leak.
C1 [Su, George; Atakilit, Amha; Li, John T.; Wu, Nanyan; Bhattacharya, Mallar; Zhu, Jieling; Shieh, Jennifer E.; Li, Elizabeth; Chen, Robert; Sun, Stephen; Su, Cynthia P.; Sheppard, Dean] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143, United States.
C3 University of California System; University of California San Francisco
RP Su, G (corresponding author), UCSF, Lung Biol Ctr, 1550 4th St,Room 545, San Francisco, CA 94121 USA.
EM george.su@ucsf.edu
FU NHLBI [HL083950, 1K08HL083097-01A1]
FX Supported by NHLBI HL083950 (D. S.) and 1K08HL083097-01A1 (G.S.).
CR Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Baluk P, 1999, BRIT J PHARMACOL, V126, P522, DOI 10.1038/sj.bjp.0702323
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004
   del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008
   Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759
   DENG XM, 1995, J APPL PHYSIOL, V78, P2052, DOI 10.1152/jappl.1995.78.6.2052
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989
   Gingras AR, 2009, J BIOL CHEM, V284, P8857, DOI 10.1074/jbc.M805937200
   Gingras AR, 2006, BIOCHEMISTRY-US, V45, P1805, DOI 10.1021/bi052136l
   Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2
   Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487
   Humphries JD, 2007, J CELL BIOL, V179, P1043, DOI 10.1083/jcb.200703036
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007-0167
   LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479
   Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552
   Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323
   LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223
   LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-#
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004
   Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200
   Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863
   QIAO RL, 1995, AM J PHYSIOL-CELL PH, V269, pC110, DOI 10.1152/ajpcell.1995.269.1.C110
   Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760
   Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Robinson SD, 2004, ARTERIOSCL THROM VAS, V24, P2108, DOI 10.1161/01.ATV.0000143857.27408.de
   Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B
   SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0
   SEPP NT, 1994, J INVEST DERMATOL, V103, P295, DOI 10.1111/1523-1747.ep12394617
   Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com
   Singh B, 2000, AM J PHYSIOL-LUNG C, V278, pL217, DOI 10.1152/ajplung.2000.278.1.L217
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   STUPACK DG, 2002, SCI STKE, pPE7
   Su G, 2007, AM J RESP CELL MOL, V36, P377, DOI 10.1165/rcmb.2006-0238OC
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WATANABE SI, 1995, INT IMMUNOL, V7, P1037, DOI 10.1093/intimm/7.7.1037
   Weis SM, 2007, BLOOD, V109, P1962, DOI 10.1182/blood-2005-10-038893
   Wu MH, 2001, J PHYSIOL-LONDON, V532, P785, DOI 10.1111/j.1469-7793.2001.0785e.x
   Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004
NR 56
TC 64
Z9 66
U1 0
U2 12
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JAN 1
PY 2012
VL 185
IS 1
BP 58
EP 66
DI 10.1164/rccm.201108-1381OC
PG 9
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA 872JV
UT WOS:000298806600015
PM 21980034
OA Green Published
DA 2023-08-21
ER

PT J
AU Zeng, H
   Pappas, C
   Belser, JA
   Houser, KV
   Zhong, WM
   Wadford, DA
   Stevens, T
   Balczon, R
   Katz, JM
   Tumpey, TM
AF Zeng, Hui
   Pappas, Claudia
   Belser, Jessica A.
   Houser, Katherine V.
   Zhong, Weiming
   Wadford, Debra A.
   Stevens, Troy
   Balczon, Ron
   Katz, Jacqueline M.
   Tumpey, Terrence M.
TI Human Pulmonary Microvascular Endothelial Cells Support Productive
   Replication of Highly Pathogenic Avian Influenza Viruses: Possible
   Involvement in the Pathogenesis of Human H5N1 Virus Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE LUNG INJURY; A SUBTYPE H5N1; MYCOBACTERIUM-TUBERCULOSIS;
   COMPARATIVE PATHOLOGY; RECEPTOR SPECIFICITY; RESPIRATORY-TRACT; H7
   VIRUSES; CLEAVAGE; HEMAGGLUTININ; EXPRESSION
AB Highly pathogenic avian influenza (HPAI) H5N1 viruses continue to cause sporadic human infections with a high fatality rate. Respiratory failure due to acute respiratory distress syndrome (ARDS) is a complication among hospitalized patients. Since progressive pulmonary endothelial damage is the hallmark of ARDS, we investigated host responses following HPAI virus infection of human pulmonary microvascular endothelial cells. Evaluation of these cells for the presence of receptors preferred by influenza virus demonstrated that avian-like (alpha 2-3-linked) receptors were more abundant than human-like (alpha 2-6-linked) receptors. To test the permissiveness of pulmonary endothelial cells to virus infection, we compared the replication of selected seasonal, pandemic (2009 H1N1 and 1918), and potentially pandemic (H5N1) influenza virus strains. We observed that these cells support productive replication only of HPAI H5N1 viruses, which preferentially enter through and are released from the apical surface of polarized human endothelial monolayers. Furthermore, A/Thailand/16/2004 and A/Vietnam/1203/2004 (VN/1203) H5N1 viruses, which exhibit heightened virulence in mammalian models, replicated to higher titers than less virulent H5N1 strains. VN/1203 infection caused a significant decrease in endothelial cell proliferation compared to other subtype viruses. VN/1203 virus was also found to be a potent inducer of cytokines and adhesion molecules known to regulate inflammation during acute lung injury. Deletion of the H5 hemagglutinin (HA) multibasic cleavage site did not affect virus infectivity but resulted in decreased virus replication in endothelial cells. Our results highlight remarkable tropism and infectivity of the H5N1 viruses for human pulmonary endothelial cells, resulting in the potent induction of host inflammatory responses.
C1 [Zeng, Hui; Pappas, Claudia; Belser, Jessica A.; Houser, Katherine V.; Zhong, Weiming; Wadford, Debra A.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333, United States.
C1 [Balczon, Ron] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688, United States.
C1 [Stevens, Troy] Univ S Alabama, Dept Pharmacol, Mobile, AL 36688, United States.
C1 [Stevens, Troy; Balczon, Ron] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688, United States.
C3 Centers for Disease Control & Prevention - USA; University of South
   Alabama; University of South Alabama; University of South Alabama
RP Tumpey, TM (corresponding author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM tft9@cdc.gov
OI Wadford, Debra/0000-0002-8630-427X
FU NIH [HL-60024, HL-66299]
FX This research was funded in part by NIH grants HL-60024 and HL-66299 to
   T.S.
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Alom-Ruiz SP, 2008, ANTIOXID REDOX SIGN, V10, P1089, DOI 10.1089/ars.2007.2007
   Azoulay E, 2002, CRIT CARE MED, V30, P781, DOI 10.1097/00003246-200204000-00010
   Baskin CR, 2009, P NATL ACAD SCI USA, V106, P3455, DOI 10.1073/pnas.0813234106
   Belser JA, 2008, P NATL ACAD SCI USA, V105, P7558, DOI 10.1073/pnas.0801259105
   Belser JA, 2011, J INFECT DIS, V203, P40, DOI 10.1093/infdis/jiq018
   Belser JA, 2009, J VIROL, V83, P7075, DOI 10.1128/JVI.00535-09
   Bertram S, 2010, REV MED VIROL, V20, P298, DOI 10.1002/rmv.657
   Birkness KA, 1999, INFECT IMMUN, V67, P653, DOI 10.1128/IAI.67.2.653-658.1999
   Bottcher-Friebertshauser E, 2010, J VIROL, V84, P5605, DOI 10.1128/JVI.00140-10
   Chan MCW, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-102
   Chosewood L.C., 2009, BIOSAFETY MICROBIOLO, Vfifth
   Chutinimitkul S, 2006, EMERG INFECT DIS, V12, P1041, DOI 10.3201/eid1206.060227
   Cotran R. S., 1999, ROBBINS PATHOLOGIC B
   de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Decha P, 2008, BIOPHYS J, V95, P128, DOI 10.1529/biophysj.107.127456
   Deng R, 2008, J PATHOL, V216, P328, DOI 10.1002/path.2417
   Gambotto A, 2008, LANCET, V371, P1464, DOI 10.1016/S0140-6736(08)60627-3
   Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3
   Guo XL, 2008, AMINO ACIDS, V35, P375, DOI 10.1007/s00726-007-0611-3
   Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419
   Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6
   Korteweg C, 2008, AM J PATHOL, V172, P1155, DOI 10.2353/ajpath.2008.070791
   Kuiken T, 2010, VET PATHOL, V47, P893, DOI 10.1177/0300985810378651
   Kusters S, 1997, EUR J IMMUNOL, V27, P2870, DOI 10.1002/eji.1830271119
   La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026
   Lamb RA, 1996, FIELDS VIROLOGY
   Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999
   Maines TR, 2005, J VIROL, V79, P11788, DOI 10.1128/JVI.79.18.11788-11800.2005
   Mehta PK, 2006, MICROB PATHOGENESIS, V41, P119, DOI 10.1016/j.micpath.2006.05.002
   Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625
   Ng WF, 2006, HUM PATHOL, V37, P381, DOI 10.1016/j.humpath.2006.01.015
   Nicholls JM, 2007, NAT MED, V13, P147, DOI 10.1038/nm1529
   Ocana-Macchi M, 2009, J VIROL, V83, P12947, DOI 10.1128/JVI.00468-09
   Park MS, 2006, P NATL ACAD SCI USA, V103, P8203, DOI 10.1073/pnas.0602566103
   Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5
   Perrone LA, 2010, J INFECT DIS, V202, P1161, DOI 10.1086/656365
   Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a
   Steinhauer DA, 1999, VIROLOGY, V258, P1, DOI 10.1006/viro.1999.9716
   Suzuki Y, 2000, J VIROL, V74, P11825, DOI 10.1128/JVI.74.24.11825-11831.2000
   To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N
   Tran TT, 2008, INT J BIOCHEM CELL B, V40, P2671, DOI 10.1016/j.biocel.2008.05.019
   Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392
   Uyeki TM, 2009, CLIN INFECT DIS, V49, P279, DOI 10.1086/600035
   van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548
   van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   WALLS HH, 1986, J CLIN MICROBIOL, V23, P240, DOI 10.1128/JCM.23.2.240-245.1986
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Yao L, 2008, FASEB J, V22, P733, DOI 10.1096/fj.06-7880com
   Yu HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002985
   Zeng H, 2007, J VIROL, V81, P12439, DOI 10.1128/JVI.01134-07
   Zeng H, 2011, J VIROL, V85, P686, DOI 10.1128/JVI.01568-10
   Zhang ZF, 2009, HUM PATHOL, V40, P735, DOI 10.1016/j.humpath.2008.08.015
NR 57
TC 73
Z9 83
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2012
VL 86
IS 2
BP 667
EP 678
DI 10.1128/JVI.06348-11
PG 12
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA 870MW
UT WOS:000298674600003
PM 22072765
OA Bronze, Green Published
DA 2023-08-21
ER

PT J
AU Zhang, LS
   Li, T
   Yu, DN
   Forman, BM
   Huang, WD
AF Zhang, Lisheng
   Li, Tao
   Yu, Donna
   Forman, Barry M.
   Huang, Wendong
TI FXR Protects Lung from Lipopolysaccharide-Induced Acute Injury
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID FARNESOID-X-RECEPTOR; BILE-ACID; ACTIVATION; EXPRESSION; CELLS;
   PROLIFERATION; RECRUITMENT; DISRUPTION; BLOCKING; ADHESION
AB Acute lung injury and its more severe form, acute respiratory distress syndrome, are characterized by an acute inflammatory response in the airspaces and lung parenchyma. The nuclear receptor farnesoid X receptor (FXR) is expressed in pulmonary artery endothelial cells. Here, we report a protective role of FXR in a lipopolysaccharide-induced mouse model of acute lung injury. Uponintratracheal injection of lipopolysaccharide, FXR-/- mice showed higher lung endothelial permeability, released more bronchoalveolar lavage cells to the alveoli, and developed acute pneumonia. Cell adhesion molecules were expressed at higher levels in FXR-/- mice as compared with control mice. Furthermore, lung regeneration was much slower in FXR-/- mice. In vitro experiments showed that FXR activation blocked TNF alpha-induced expression of P-selectin but stimulated proliferation of lung microvascular endothelial cells through up-regulation of Foxm1b. In addition, expression of a constitutively active FXR repressed the expression of proinflammatory genes and improved lung permeability and lung regeneration in FXR-/- mice. This study demonstrates a critical role of FXR in suppressing the inflammatory response in lung and promoting lung repair after injury. (Molecular Endocrinology 26: 27-36, 2012)
C1 [Zhang, Lisheng; Li, Tao; Yu, Donna; Forman, Barry M.; Huang, Wendong] City Hope Natl Med Ctr, Beckman Res Inst, Div Gene Regulat & Drug Discovery, Duarte, CA 91010, United States.
C3 City of Hope; Beckman Research Institute of City of Hope
RP Huang, WD (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Gene Regulat & Drug Discovery, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM whuang@coh.org
FU National Cancer Institute [1R01CA139158-01A2]
FX This work was supported by the National Cancer Institute Grant
   1R01CA139158-01A2 (to W.H.).
CR Bishop-Bailey D, 2004, P NATL ACAD SCI USA, V101, P3668, DOI 10.1073/pnas.0400046101
   Chen WD, 2010, HEPATOLOGY, V51, P953, DOI 10.1002/hep.23390
   Das A, 2009, ARTERIOSCL THROM VAS, V29, P562, DOI 10.1161/ATVBAHA.108.182725
   Gong HBA, 2009, J BIOL CHEM, V284, P30113, DOI 10.1074/jbc.M109.047753
   He FT, 2006, CIRC RES, V98, P192, DOI 10.1161/01.RES.0000200400.55539.85
   Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435
   Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200
   Kevil Christopher G., 2003, Pathophysiology, V9, P63, DOI 10.1016/S0928468002000834
   Kim I, 2007, CARCINOGENESIS, V28, P940, DOI 10.1093/carcin/bgl249
   Li YTY, 2007, ARTERIOSCL THROM VAS, V27, P2606, DOI 10.1161/ATVBAHA.107.152694
   Lucas R, 2009, BIOCHEM PHARMACOL, V77, P1763, DOI 10.1016/j.bcp.2009.01.014
   McMillan SJ, 2004, J IMMUNOL, V172, P2586, DOI 10.4049/jimmunol.172.4.2586
   Mencarelli A, 2009, J IMMUNOL, V183, P6657, DOI 10.4049/jimmunol.0901347
   Meng ZP, 2010, MOL ENDOCRINOL, V24, P886, DOI 10.1210/me.2009-0286
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029
   Piqueras L, 2009, J LEUKOCYTE BIOL, V86, P115, DOI [10.1189/jlb.0508284, 10.1189/JLB.0508284]
   Ramirez SH, 2008, J IMMUNOL, V180, P1854, DOI 10.4049/jimmunol.180.3.1854
   Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003
   Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3
   Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48
   SUBRAMANIAM M, 1995, J EXP MED, V181, P2277, DOI 10.1084/jem.181.6.2277
   Vavassori P, 2009, J IMMUNOL, V183, P6251, DOI 10.4049/jimmunol.0803978
   Wang YD, 2008, HEPATOLOGY, V48, P1632, DOI 10.1002/hep.22519
   Wang YD, 2008, MOL ENDOCRINOL, V22, P1622, DOI 10.1210/me.2007-0527
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zecca E, 2008, PEDIATRICS, V121, pE146, DOI 10.1542/peds.2007-1220
   Zhang LS, 2009, MOL ENDOCRINOL, V23, P137, DOI 10.1210/me.2008-0198
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 31
TC 28
Z9 36
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JAN
PY 2012
VL 26
IS 1
BP 27
EP 36
DI 10.1210/me.2011-0042
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 877RO
UT WOS:000299199800004
PM 22135065
OA Green Published, Bronze
DA 2023-08-21
ER

PT J
AU Zhang, SE
   Rahman, M
   Zhang, S
   Wang, YZ
   Herwald, H
   Jeppsson, B
   Thorlacius, H
AF Zhang, Songen
   Rahman, Milladur
   Zhang, Su
   Wang, Yongzhi
   Herwald, Heiko
   Jeppsson, Bengt
   Thorlacius, Henrik
TI p38 Mitogen-activated protein kinase signaling regulates streptococcal
   M1 protein-induced neutrophil activation and lung injury
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE CXC chemokines; MAPK; sepsis 
ID PULMONARY RECRUITMENT; PROCOAGULANT ACTIVITY; CHEMOKINE PRODUCTION;
   ESCHERICHIA-COLI; P-SELECTIN; RAT; INFECTIONS; INFLAMMATION; INHIBITION;
   MORTALITY
AB M1 serotype of Streptococcus pyogenes can cause STSS and acute lung damage. Herein, the purpose was to define the role of p38 MAPK signaling in M1 protein-induced pulmonary injury. Male C57BL/6 mice were treated with specific p38 MAPK inhibitors (SB 239063 and SKF 86002) prior to M1 protein challenge. Edema, neutrophil infiltration, and CXC chemokines were determined in the lung, 4 h after M1 protein administration. Flow cytometry was used to determine Mac-1 expression. Phosphorylation and activity of p38 MAPK were determined by immunoprecipitation and Western blot. IVM was used to analyze leukocyte-endothelium interactions in the pulmonary microcirculation. M1 protein challenge increased phosphorylation and activity of p38 MAPK in the lung, which was inhibited by SB 239063 and SKF 86002. Inhibition of p38 MAPK activity decreased M1 protein-induced infiltration of neutrophils, edema, and CXC chemokine formation in the lung, as well as Mac-1 up-regulation on neutrophils. IVM showed that p38 MAPK inhibition reduced leukocyte rolling and adhesion in the pulmonary microvasculature of M1 protein-treated mice. Our results indicate that p38 MAPK signaling regulates neutrophil infiltration in acute lung injury induced by streptococcal M1 protein. Moreover, p38 MAPK activity controls CXC chemokine formation in the lung, as well as neutrophil expression of Mac-1 and recruitment in the pulmonary microvasculature. In conclusion, these findings suggest that targeting the p38 MAPK signaling pathway may open new opportunities to protect against lung injury in streptococcal infections. J. Leukoc. Biol. 91: 137-145; 2012.
C1 [Zhang, Songen; Rahman, Milladur; Zhang, Su; Wang, Yongzhi; Jeppsson, Bengt; Thorlacius, Henrik] Lund Univ, Dept Clin Sci, Malmo Univ Hosp, Sect Surg, S-20502 Malmo, Sweden.
C1 [Herwald, Heiko] Lund Univ, Sect Clin & Expt Infect Med, S-20502 Malmo, Sweden.
C3 Lund University; Skane University Hospital; Lund University
RP Thorlacius, H (corresponding author), Lund Univ, Dept Surg, Malmo Univ Hosp, S-20502 Malmo, Sweden.
EM henrik.thorlacius@med.lu.se
RI Rahman, Milladur/ABF-9885-2021; Herwald, Heiko/AAN-3708-2021
OI Rahman, Milladur/0000-0002-8883-4848; Herwald, Heiko/0000-0002-8111-2842
FU Swedish Medical Research Council [2009-4872, 2008-7480]; Crafoordska
   stiftelsen; Einar och Inga Nilssons stiftelse; Harald och Greta
   Jaenssons stiftelse; Greta och Johan Kocks stiftelser; Froken Agnes
   Nilssons stiftelse; Franke och Margareta Bergqvists stiftelse for
   framjande av cancerfor-skning; Magnus Bergvalls stiftelse; Mossfelts
   stiftelse; Nanna Svartz stiftelse; Ruth och Richard Julins stiftelse;
   Svenska Lakaresallskapet; Allmana sjukhusets i Malmo stiftelse for
   bekampande av cancer; MAS fonder; Malmo University Hospital; Lund
   University
FX This work was supported by grants from the Swedish Medical Research
   Council (2009-4872 and 2008-7480), Crafoordska stiftelsen, Einar och
   Inga Nilssons stiftelse, Harald och Greta Jaenssons stiftelse, Greta och
   Johan Kocks stiftelser, Froken Agnes Nilssons stiftelse, Franke och
   Margareta Bergqvists stiftelse for framjande av cancerfor-skning, Magnus
   Bergvalls stiftelse, Mossfelts stiftelse, Nanna Svartz stiftelse, Ruth
   och Richard Julins stiftelse, Svenska Lakaresallskapet, Allmana
   sjukhusets i Malmo stiftelse for bekampande av cancer, MAS fonder, Malmo
   University Hospital, and Lund University.
CR Asaduzzaman M, 2008, SHOCK, V30, P254, DOI 10.1097/shk.0b013e318162c567
   Asaduzzaman M, 2008, CRIT CARE MED, V36, P482, DOI 10.1097/01.CCM.0B013E31816204FA
   Asaduzzaman M, 2009, BRIT J PHARMACOL, V156, P307, DOI 10.1111/j.1476-5381.2008.00021.x
   Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S
   Behr TM, 2001, CIRCULATION, V104, P1292, DOI 10.1161/hc3601.094275
   Borzone G, 2007, AM J PHYSIOL-REG I, V293, pR1342, DOI 10.1152/ajpregu.00343.2007
   Bryant AE, 2003, INFECT IMMUN, V71, P1903, DOI 10.1128/IAI.71.4.1903-1910.2003
   Chang CW, 2009, J BIOL CHEM, V284, P33195, DOI 10.1074/jbc.M109.020586
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Eliasson M, 2007, MICROB PATHOGENESIS, V43, P224, DOI 10.1016/j.micpath.2007.06.007
   Gao XP, 2001, J IMMUNOL, V167, P2895, DOI 10.4049/jimmunol.167.5.2895
   Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1
   Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310
   Khan MAS, 2004, IMMUNOLOGY, V112, P651, DOI 10.1111/j.1365-2567.2004.01923.x
   Klintman D, 2005, ANN SURG, V242, P830, DOI 10.1097/01.sla.0000189132.86878.f7
   Kuldo Joanna M., 2005, Current Vascular Pharmacology, V3, P11, DOI 10.2174/1570161052773898
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Luo Lihui, 2005, Eye Contact Lens, V31, P186, DOI 10.1097/01.ICL.0000162759.79740.46
   Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685
   Mehta S, 2006, CHEST, V130, P1679, DOI 10.1016/S0012-3692(15)50887-8
   Menezes GB, 2009, J IMMUNOL, V183, P7557, DOI 10.4049/jimmunol.0901786
   Mihaescu A, 2010, BRIT J SURG, V97, P226, DOI 10.1002/bjs.6811
   Mitsuoka H, 1999, CRIT CARE MED, V27, P1862, DOI 10.1097/00003246-199909000-00026
   Nilsson M, 2006, THROMB HAEMOSTASIS, V95, P982, DOI 10.1160/TH05-08-0572
   Olsnes C, 2011, SCAND J IMMUNOL, V74, P114, DOI 10.1111/j.1365-3083.2011.02555.x
   Pahlman LI, 2007, MICROBIOL-SGM, V153, P2458, DOI 10.1099/mic.0.2006/003285-0
   Pahlman LI, 2006, J IMMUNOL, V177, P1221, DOI 10.4049/jimmunol.177.2.1221
   Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456
   Schramm R, 2004, INFLAMM RES, V53, P644, DOI 10.1007/s00011-004-1307-8
   Shields Conor J, 2002, Curr Opin Crit Care, V8, P158, DOI 10.1097/00075198-200204000-00012
   Stambe C, 2003, J AM SOC NEPHROL, V14, P338, DOI 10.1097/01.ASN.0000048715.12315.FD
   Tekin D, 2001, AM J PHYSIOL-HEART C, V281, pH523, DOI 10.1152/ajpheart.2001.281.2.H523
   Tsai PJ, 2006, MICROBES INFECT, V8, P1440, DOI 10.1016/j.micinf.2006.01.002
   Veckman V, 2003, J LEUKOCYTE BIOL, V74, P395, DOI 10.1189/jlb.0402212
   Vikerfors A, 2009, SCAND J INFECT DIS, V41, P823, DOI 10.3109/00365540903179749
   Vuilleumier H, 2001, Swiss Surg, V7, P25, DOI 10.1024/1023-9332.7.1.25
   Wang SM, 2008, DIAGN MICR INFEC DIS, V61, P165, DOI 10.1016/j.diagmicrobio.2008.01.008
   Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200
   Zhang SG, 2011, AM J PHYSIOL-LUNG C, V300, pL930, DOI 10.1152/ajplung.00422.2010
   Zhang S, 2011, SHOCK, V35, P86, DOI 10.1097/SHK.0b013e3181ea4476
NR 40
TC 14
Z9 16
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JAN
PY 2012
VL 91
IS 1
BP 137
EP 145
DI 10.1189/jlb.0511268
PG 9
WC Cell Biology; Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Hematology; Immunology
GA 877HO
UT WOS:000299168600015
PM 21971519
DA 2023-08-21
ER

PT J
AU Hu, GD
   Chen, YH
   Zhang, L
   Tong, WC
   Cheng, YX
   Luo, YL
   Cai, SX
   Zhang, L
AF Hu Guo-dong
   Chen Ying-hua
   Zhang Lu
   Tong Wan-cheng
   Cheng Yuan-xiong
   Luo Ya-ling
   Cai Shao-xi
   Zhang Lin
TI The generation of the endothelial specific cdc42-deficient mice and the
   effect of cdc42 deletion on the angiogenesis and embryonic development
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE ECs/HPMECs/HUVECs/MPVECs; cdc42-deficient; cre/loxp; angiogenesis; embryonic development 
ID CAPILLARY LUMEN FORMATION; RHO PROTEINS; PERMEABILITY; GTPASES;
   ACTIVATION; MATRICES; NECROSIS; ACTIN; CELLS; RAC1
AB Background High microvascular permeability plays an essential role in pathological process of multiple diseases such as septic shock, acute lung injury and acute respiratory distress syndrome, and burns. Inhibiting hyperpermeability is significant for controlling these conditions. Cdc42, as a main member of the small Rho GTPase family, plays a critical role in controlling and regulating the endothelial junctional permeability. We aimed to generate and identify endothelial specific cdc42-deficient mice by the Cre/loxp recombination approach, for examination in an animal model of the contribution of the cdc42 gene in the microvascular barrier function.
   Methods We crossed cdc42(Flox/Flox) mice with mice expressing endothelial cell-specific Cre recombinase, and the offspring with the genotype cdc42(Flox/+)Tie2Cre(+/-) were back-crossed with the cdc42(Flox/Flox) mice. The cdc42(Flox/Flox)Tie2Cre(+/-) mice in the F2 generation were the target mice. If the cdc42 deficient mice did not survive, we would observe the cdc42 deficient mice embryos, and compare them with wild-type mice embryos.
   Results Cdc42(flox/+)Cre(+/-) mice were mated with the cdc42(Flox/Flox) mice and among the living offspring there were no cdc42(Flox/Flox)Cre(+/-) target mice. We found the endothelial special cdc42 deficient embryos at the E7.5-E16.5 stage. We observed that cdc42 deficient embryos were much smaller, had fewer vessels and were a little more swollen compared with the wild-type embryos.
   Conclusions Endothelial specific knockout of cdc42 caused embryonic lethality and the mice did not survive to birth. The target embryos were much smaller, had fewer vessels and were a little more swollen compared with the wild-type embryos. These results demonstrated that the cdc42 plays an important role in development of embryos and in development of microvessels as well as microvascular permeability. Chin Med J 2011;124(24):4155-4159
C1 [Hu Guo-dong; Tong Wan-cheng; Cheng Yuan-xiong; Luo Ya-ling; Cai Shao-xi] So Med Univ, Nanfang Hosp, Dept Resp Dis, Guangzhou 510515, Guangdong, China.
C1 [Chen Ying-hua; Zhang Lin] So Med Univ, Dept Histol & Embryol, Guangzhou 510515, Guangdong, China.
C1 So Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, China.
C3 Southern Medical University - China; Southern Medical University -
   China; Southern Medical University - China
RP Cai, SX (corresponding author), So Med Univ, Nanfang Hosp, Dept Resp Dis, Guangzhou 510515, Guangdong, Peoples R China.
EM zlilyzh@126.com; hxkcai@126.com; zlilyzh@126.com
RI chen, ying/HHS-8254-2022
FU National Natural Science Foundation of China [81171824]; Guangdong
   Natural Science Foundation [92510515010008]; Guangdong Province Science
   & Technology Program Project [2011B031800245]; Nanfang Hospital
   Superintendent Foundation [2010C002]
FX This study was supported by grants from National Natural Science
   Foundation of China (No. 81171824), Guangdong Natural Science Foundation
   (No. 92510515010008), Guangdong Province Science & Technology Program
   Project (No. 2011B031800245) and Nanfang Hospital Superintendent
   Foundation (No. 2010C002).
CR Bayless KJ, 2002, J CELL SCI, V115, P1123
   Broman MT, 2006, CIRC RES, V98, P73, DOI 10.1161/01.RES.0000198387.44395.e9
   Davis GE, 2003, MICROCIRCULATION, V10, P27, DOI 10.1038/sj.mn.7800175
   Fryer BH, 2005, CANCER LETT, V229, P13, DOI 10.1016/j.canlet.2004.12.009
   Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hippenstiel S, 2000, BLOOD, V95, P3044
   Kouklis P, 2004, CIRC RES, V94, P159, DOI 10.1161/01.RES.0000110418.38500.31
   Li Wen-Long, 2005, Acta Genetica Sinica, V32, P909
   Maillet M, 2009, J CLIN INVEST, V119, P3079, DOI 10.1172/JCI37694
   Merajver SD, 2005, J MAMMARY GLAND BIOL, V10, P291, DOI 10.1007/s10911-006-9002-8
   Mien VH, 2011, MICROVASC RES, V81, P34
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Xue Y, 2006, INT J CANCER, V118, P2965, DOI 10.1002/ijc.21763
   Yang L, 2007, P NATL ACAD SCI USA, V104, P5091, DOI 10.1073/pnas.0610819104
   Yuan HX, 2009, HEPATOLOGY, V49, P240, DOI 10.1002/hep.22610
NR 20
TC 15
Z9 16
U1 0
U2 10
PU CHINESE MEDICAL ASSOC
PI BEIJING
PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD DEC 20
PY 2011
VL 124
IS 24
BP 4155
EP 4159
DI 10.3760/cma.j.issn.0366-6999.2011.24.007
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 875UT
UT WOS:000299061400007
PM 22340378
DA 2023-08-21
ER

PT J
AU Itagaki, K
   Adibnia, Y
   Sun, SQ
   Zhao, C
   Sursal, T
   Chen, Y
   Junger, W
   Hauser, CJ
AF Itagaki, Kiyoshi
   Adibnia, Yasaman
   Sun, Shiqin
   Zhao, Cong
   Sursal, Tolga
   Chen, Yu
   Junger, Wolfgang
   Hauser, Carl J.
TI BACTERIAL DNA INDUCES PULMONARY DAMAGE VIA TLR-9 THROUGH CROSS-TALK WITH
   NEUTROPHILS
SO SHOCK
LA English
DT Article
DE Pathogen-associated molecular patterns (PAMPs); CpG DNA; bacterial DNA; ALI/ARDS; permeability; ECIS; adherence; qPCR 
ID TOLL-LIKE RECEPTORS; INFLAMMATION; CELLS
AB Bacterial DNA (bDNA) contains hypomethylated "CpG" repeats that can be recognized by Toll-like receptor 9 (TLR-9) as a pathogen-associated molecular pattern. The ability of bDNA to initiate lung injury via TLR-9 has been inferred on the basis of studies using artificial CpG DNA. But the role of authentic bDNA in lung injury is still unknown. Moreover, the mechanisms by which CpG DNA species can lead to pulmonary injury are unknown, although neutrophils (PMNs) are thought to play a key role in the genesis of septic acute lung injury. We evaluated the effects of bDNA on PMN-endothelial cell (EC) interactions thought critical for initiation of acute lung injury. Using a biocapacitance system to monitor real-time changes in endothelial permeability, we demonstrate here that bDNA causes EC permeability in a dose-dependent manner uniquely in the presence of PMNs. These permeability changes are inhibited by chloroquine, suggesting TLR-9 dependency. When PMNs were preincubated with bDNA and applied to ECs or when bDNA was applied to ECs without PMNs, no permeability changes were detected. To study the underlying mechanisms, we evaluated the effects of bDNA on PMN-EC adherence. Bacterial DNA significantly increased PMN adherence to ECs in association with upregulated adhesion molecules in both cell types. Taken together, our results strongly support the conclusion that bDNA can initiate lung injury by stimulating PMN-EC adhesive interactions predisposing to endothelial permeability. Bacterial DNA stimulation of TLR-9 appears to promote enhanced gene expression of adhesion molecules in both cell types. This leads to PMNEC cross-talk, which is required for injury to occur.
C1 [Itagaki, Kiyoshi; Zhao, Cong; Chen, Yu; Junger, Wolfgang; Hauser, Carl J.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215, United States.
C1 [Adibnia, Yasaman] Istanbul Med Sch, Istanbul, Turkey.
C1 [Sun, Shiqin] Harbin Med Univ, Coll Pharm, Daqing, China.
C1 [Sursal, Tolga] Eastern Virginia Med Sch, Norfolk, VA 23501, United States.
C3 Harvard University; Beth Israel Deaconess Medical Center; Istanbul
   University; Harbin Medical University; Eastern Virginia Medical School
RP Itagaki, K (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave,ST-8M10A, Boston, MA 02215 USA.
EM kitagaki@bidmc.harvard.edu
RI Hauser, Carl J./Y-1189-2019; Sursal, Tolga/AAN-8585-2021; Junger,
   Wolfgang G/I-1932-2013; Itagaki, Kiyoshi/M-5501-2015
OI Junger, Wolfgang G/0000-0003-3350-8452; Itagaki,
   Kiyoshi/0000-0002-6033-1122; Hauser, Carl/0000-0003-3167-1846
FU NIGMS/NIH [R01GM059179]; Department of Defense [DR080924]
FX Funding was received from NIGMS/NIH (R01GM059179) and from the
   Department of Defense (DR080924) to C.J.H.
CR Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6
   Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012
   EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   El Kebir D, 2009, J IMMUNOL, V182, P4386, DOI 10.4049/jimmunol.0803044
   FOMSGAARD A, 1989, SCAND J IMMUNOL, V29, P309, DOI 10.1111/j.1365-3083.1989.tb01129.x
   Garcia JGN, 2009, MICROVASC RES, V77, P1, DOI 10.1016/j.mvr.2009.01.001
   GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896
   Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063
   Itagaki K, 2011, J SURG RES, V169, P301, DOI 10.1016/j.jss.2009.10.016
   JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1
   Knuefermann P, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-72
   Lorne E, 2008, AM J PHYSIOL-CELL PH, V294, pC985, DOI 10.1152/ajpcell.00454.2007
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Sabroe I, 2002, CLIN EXP ALLERGY, V32, P984, DOI 10.1046/j.1365-2745.2002.01451.x
   SANCHEZCANTU L, 1989, ARCH SURG-CHICAGO, V124, P1432
   Tasaka S, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-84
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919
   Yamada H, 2004, CRIT CARE MED, V32, P2045, DOI 10.1097/01.CCM.0000142397.38134.EF
   Yamashiro S, 2001, J LEUKOCYTE BIOL, V69, P698
   Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 23
TC 29
Z9 31
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD DEC
PY 2011
VL 36
IS 6
BP 548
EP 552
DI 10.1097/SHK.0b013e3182369fb2
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 850OB
UT WOS:000297203800004
PM 21937948
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Lu, Q
   Sakhatskyy, P
   Grinnell, K
   Newton, J
   Ortiz, M
   Wang, YL
   Sanchez-Esteban, J
   Harrington, EO
   Rounds, S
AF Lu, Qing
   Sakhatskyy, Pavlo
   Grinnell, Katie
   Newton, Julie
   Ortiz, Melanie
   Wang, Yulian
   Sanchez-Esteban, Juan
   Harrington, Elizabeth O.
   Rounds, Sharon
TI Cigarette smoke causes lung vascular barrier dysfunction via oxidative
   stress-mediated inhibition of RhoA and focal adhesion kinase
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; permeability; lung edema; focal adhesion complexes; adhesion junction 
ID ENDOTHELIAL DYSFUNCTION; EPITHELIAL-CELLS; REDOX REGULATION;
   PULMONARY-EDEMA; SMALL GTPASES; EXPOSURE; ACTIVATION; PERMEABILITY;
   INJURY; INVOLVEMENT
AB Lu Q, Sakhatskyy P, Grinnell K, Newton J, Ortiz M, Wang Y, Sanchez-Esteban J, Harrington EO, Rounds S. Cigarette smoke causes lung vascular barrier dysfunction via oxidative stress-mediated inhibition of RhoA and focal adhesion kinase. Am J Physiol Lung Cell Mol Physiol 301: L847-L857, 2011. First published October 7, 2011; doi: 10.1152/ajplung. 00178.2011.-Cigarette smoke (CS) is a major cause of chronic lung and cardiovascular diseases. Recent studies indicate that tobacco use is also a risk factor for acute lung injury (ALI) associated with blunt trauma. Increased endothelial cell (EC) permeability is a hallmark of ALI. CS increases EC permeability in vitro and in vivo; however, the underlying mechanism is not well understood. In this study, we found that only 6 h of exposure to CS impaired endothelial barrier function in vivo, an effect associated with increased oxidative stress in the lungs and attenuated by the antioxidant N-acetylcysteine (NAC). CS also exacerbated lipopolysaccharide (LPS)-induced increase in vascular permeability in vivo. Similar additive effects were also seen in cultured lung EC exposed to cigarette smoke extract (CSE) and LPS. We further demonstrated that CSE caused disruption of focal adhesion complexes (FAC), F-actin fibers, and adherens junctions (AJ) and decreased activities of RhoA and focal adhesion kinase (FAK) in cultured lung EC. CSE-induced inhibition of RhoA and FAK, endothelial barrier dysfunction, and disassembly of FAC, F-actin, and AJ were prevented by NAC. In addition, the deleterious effects of CSE on FAC, F-actin fibers, and AJ were blunted by overexpression of constitutively active RhoA and of FAK. Our data indicate that CS causes endothelial barrier dysfunction via oxidative stress-mediated inhibition of RhoA and FAK.
C1 [Lu, Qing] Brown Univ, Providence VA Med Ctr, Alpert Med Sch, Vasc Res Lab,Dept Med,Res Serv, Providence, RI 02908, United States.
C1 [Wang, Yulian; Sanchez-Esteban, Juan] Brown Univ, Alpert Med Sch, Woman & Infants Hosp, Providence, RI 02908, United States.
C3 Brown University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Providence VA Medical Center; Brown University;
   Women & Infants Hospital Rhode Island
RP Lu, Q (corresponding author), Brown Univ, Providence VA Med Ctr, Alpert Med Sch, Vasc Res Lab,Dept Med,Res Serv, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM Qing_Lu@brown.edu
RI Rounds, Sharon/AAF-7380-2020
OI Harrington, Elizabeth/0000-0002-3207-5301
FU Providence VA Medical Center; VA Merit Review [HL64936, HL67795];
   American Thoracic Society/Pulmonary Hypertension Association;
   CardioPulmonary Research Training Program [T32 HL094300]
FX This study was supported with resources and the use of facilities at the
   Providence VA Medical Center and supported with VA Merit Review (S.
   Rounds), HL64936 (S. Rounds), HL67795 (E.O. Harrington), American
   Thoracic Society/Pulmonary Hypertension Association research award (Q.
   Lu). This study was also partially supported by T32 HL094300 Fellowship
   (CardioPulmonary Research Training Program) to P. Sakhatskyy and K.
   Grinnell.
CR Aghajanian A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008045
   BAZIN M, 1981, REV CAN BIOL EXPTL, V40, P263
   Bernhard D, 2005, FASEB J, V19, P1096, DOI 10.1096/fj.04-3192com
   Bhavsar TM, 2007, LUNG, V185, P227, DOI 10.1007/s00408-007-9013-2
   Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421
   BURNS AR, 1989, J APPL PHYSIOL, V66, P2109, DOI 10.1152/jappl.1989.66.5.2109
   Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC
   Conklin DJ, 2009, AM J PHYSIOL-HEART C, V296, pH1586, DOI 10.1152/ajpheart.00867.2008
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Facchinetti F, 2007, AM J RESP CELL MOL, V37, P617, DOI 10.1165/rcmb.2007-0130OC
   Ferrer E, 2011, EUR RESPIR J, V38, P617, DOI 10.1183/09031936.00105110
   Ferro TN, 2010, J TRAUMA, V69, P308, DOI 10.1097/TA.0b013e3181e1761e
   Fordjour AK, 2009, BBA-GEN SUBJECTS, V1790, P1179, DOI 10.1016/j.bbagen.2009.07.012
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Grinnell KL, 2011, MICROVASC RES   0422
   Guo MZ, 2005, MICROCIRCULATION, V12, P223, DOI 10.1080/10739680590905251
   Harrington EO, 2005, EXP CELL RES, V308, P407, DOI 10.1016/j.yexcr.2005.05.005
   HEFFNER JE, 1981, ANN INTERN MED, V95, P405, DOI 10.7326/0003-4819-95-4-405
   Henderson B, 2008, ATHEROSCLEROSIS, V201, P298, DOI 10.1016/j.atherosclerosis.2008.02.022
   Heo JY, 2006, BIOCHEMISTRY-US, V45, P14481, DOI 10.1021/bi0610101
   HOLDEN WE, 1989, J APPL PHYSIOL, V66, P443, DOI 10.1152/jappl.1989.66.1.443
   Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200
   Iizuka T, 2005, GENES CELLS, V10, P1113, DOI 10.1111/j.1365-2443.2005.00905.x
   Iribarren C, 2000, CHEST, V117, P163, DOI 10.1378/chest.117.1.163
   Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652
   Kosecik M, 2005, INT J CARDIOL, V100, P61, DOI 10.1016/j.ijcard.2004.05.069
   Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830
   Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367
   Lu Q, 2004, CIRC RES, V94, P306, DOI 10.1161/01.RES.0000113923.85084.C1
   Lu Q., 2011, MICROVASC RES   0519
   Lu Q, 2006, J APPL PHYSIOL, V101, P375, DOI 10.1152/japplphysiol.01515.2005
   Lu Q, 2010, AM J PHYSIOL-LUNG C, V298, pL755, DOI 10.1152/ajplung.00330.2009
   Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719
   MacNee William, 2005, Proc Am Thorac Soc, V2, P50, DOI 10.1513/pats.200411-056SF
   Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938
   Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006
   Ozaki K, 2010, J CARDIOL, V56, P307, DOI 10.1016/j.jjcc.2010.07.003
   Peinado VI, 2008, CHEST, V134, P808, DOI 10.1378/chest.08-0820
   Pierrou S, 2007, AM J RESP CRIT CARE, V175, P577, DOI 10.1164/rccm.200607-931OC
   Podowski M, 2009, AM J PATHOL, V175, P84, DOI 10.2353/ajpath.2009.080870
   Presson RG, 2011, AM J PATHOL, V179, P75, DOI 10.1016/j.ajpath.2011.03.048
   Qamar W, 2010, HUM EXP TOXICOL
   Quadri SK, 2007, AM J PHYSIOL-LUNG C, V292, pL334, DOI 10.1152/ajplung.00228.2006
   Rahman I, 2006, CURR DRUG TARGETS, V7, P707, DOI 10.2174/138945006777435254
   Rangasamy T, 2009, AM J PHYSIOL-LUNG C, V296, pL888, DOI 10.1152/ajplung.90369.2008
   Richens TR, 2009, AM J RESP CRIT CARE, V179, P1011, DOI 10.1164/rccm.200807-1148OC
   Sanchez-Esteban J, 2006, AM J PHYSIOL-LUNG C, V290, pL343, DOI 10.1152/ajplung.00189.2005
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Schlegel N, 2009, CRIT CARE MED, V37, P1735, DOI 10.1097/CCM.0b013e31819deb6a
   Schweitzer KS, 2011, AM J PHYSIOL-LUNG C, V301, pL836, DOI 10.1152/ajplung.00385.2010
   Sin DD, 2006, EUR RESPIR J, V28, P1245, DOI 10.1183/09031936.00133805
   Siu ER, 2009, P NATL ACAD SCI USA, V106, P9298, DOI 10.1073/pnas.0813113106
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Talukder MAH, 2011, AM J PHYSIOL-HEART C, V300, pH388, DOI 10.1152/ajpheart.00868.2010
   Taraseviciene-Stewart L, 2008, J CLIN INVEST, V118, P394, DOI 10.1172/JCI31811
   Tzima E, 2006, CIRC RES, V98, P176, DOI 10.1161/01.RES.0000200162.94463.d7
   Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200
   van der Vaart H, 2004, THORAX, V59, P713, DOI 10.1136/thx.2003.012468
   WITTEN ML, 1987, EXP LUNG RES, V13, P113, DOI 10.3109/01902148709064313
   Wright JL, 2008, J APPL PHYSIOL, V104, P1462, DOI 10.1152/japplphysiol.00520.2007
   Wu MH, 2005, J PHYSIOL-LONDON, V569, P359, DOI 10.1113/jphysiol.2005.096537
   Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179
   Yao HW, 2011, TOXICOL APPL PHARM, V254, P72, DOI 10.1016/j.taap.2009.10.022
   Yi J, 2008, NEOPLASIA, V10, P41, DOI 10.1593/neo.07754
   Yoshida T, 2010, NAT MED, V16, P767, DOI 10.1038/nm.2157
   Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094
NR 67
TC 53
Z9 56
U1 0
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD DEC
PY 2011
VL 301
IS 6
BP L847
EP L857
DI 10.1152/ajplung.00178.2011
PG 11
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 863JI
UT WOS:000298158200004
PM 21984567
OA Green Published
DA 2023-08-21
ER

PT J
AU O'Dea, KP
   Dokpesi, JO
   Tatham, KC
   Wilson, MR
   Takata, M
AF O'Dea, Kieran P.
   Dokpesi, Justina O.
   Tatham, Kate C.
   Wilson, Michael R.
   Takata, Masao
TI Regulation of monocyte subset proinflammatory responses within the lung
   microvasculature by the p38 MAPK/MK2 pathway
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE ALI/ARDS; endotoxemia; TNF/TNF-alpha/TNFR1; margination 
ID ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA
   STABILITY; NITRIC-OXIDE SYNTHASE; FLOW-CYTOMETRY; BONE-MARROW;
   FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY MONOCYTES; MARGINATED MONOCYTES
AB O'Dea KP, Dokpesi JO, Tatham KC, Wilson MR, Takata M. Regulation of monocyte subset proinflammatory responses within the lung microvasculature by the p38 MAPK/MK2 pathway. Am J Physiol Lung Cell Mol Physiol 301: L812-L821, 2011. First published August 26, 2011; doi:10.1152/ajplung.00092.2011.-Margination and activation of monocytes within the pulmonary microcirculation contribute substantially to the development of acute lung injury in mice. The enhanced LPS-induced TNF expression exhibited by Gr-1(high) compared with Gr-1(low) monocytes within the lung microvasculature suggests differential roles for these subsets. We investigated the mechanisms responsible for such heterogeneity of lung-marginated monocyte proinflammatory response using a combined in vitro and in vivo approach. The monocyte subset inflammatory response was studied in vitro in mouse peripheral blood mononuclear cell-lung endothelial cell coculture and in vivo in a two-hit model of intravenous LPS-induced monocyte margination and lung inflammation in mice, by flow cytometry-based quantification of proinflammatory genes and intracellular phospho-kinases. With LPS stimulation in vitro, TNF expression was consistently higher in Gr-1(high) than Gr-1(low) monocytes, markedly enhanced by coculture with endothelial cells, and abrogated by p38 MAPK inhibitors. Expression of IL-6, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) was only detectable under coculture conditions, was substantially higher in Gr-1(high) monocytes, and was attenuated by p38 inhibition. Consistent with these differential responses, phosphorylation of p38 and its substrate MAPK-activated protein kinase 2 (MK2) was significantly higher in the Gr-1(high) subset. In vivo, p38 inhibitor treatment significantly attenuated LPS-induced TNF expression in "lung-marginated" Gr-1(high) monocytes. LPS-induced p38/MK2 phosphorylation was higher in lung-marginated Gr-1(high) than Gr-1(low) monocytes and neutrophils, mirroring TNF expression. These results indicate that the p38/MK2 pathway is a critical determinant of elevated Gr-1(high) subset responsiveness within the lung microvasculature, producing a coordinated proinflammatory response that places Gr-1(high) monocytes as key orchestrators of pulmonary microvascular inflammation and injury.
C1 [O'Dea, Kieran P.; Dokpesi, Justina O.; Tatham, Kate C.; Wilson, Michael R.; Takata, Masao] Univ London Imperial Coll Sci Technol & Med, Sect Anaesthet Pain Med & Intens Care, Fac Med, Chelsea & Westminster Hosp, London SW10 9NH, England, United Kingdom.
C3 Imperial College London
RP Takata, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Anaesthet Pain Med & Intens Care, Fac Med, Chelsea & Westminster Hosp, London SW10 9NH, England.
EM m.takata@imperial.ac.uk
RI Tatham, Kate/AAB-5839-2020
OI Tatham, Kate/0000-0003-3080-8011
FU Biotechnology and Biological Sciences Research Council UK [BB/D01820X];
   Wellcome Trust [081208]; National Institute for Health Research
   [ACF-2008-21-008] Funding Source: researchfish
FX This study was supported by grants from Biotechnology and Biological
   Sciences Research Council UK (no. BB/D01820X) and Wellcome Trust (no.
   081208).
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Aoyagi T, 2011, INT IMMUNOL, V23, P97, DOI 10.1093/intimm/dxq460
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Asaduzzaman M, 2008, CRIT CARE MED, V36, P482, DOI 10.1097/01.CCM.0B013E31816204FA
   Badger AM, 1998, J IMMUNOL, V161, P467
   Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536
   Bertok S, 2011, AM J PHYSIOL-LUNG C, V300, pL781, DOI 10.1152/ajplung.00326.2010
   Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6
   Bueno C, 2002, J IMMUNOL METHODS, V264, P77, DOI 10.1016/S0022-1759(02)00083-2
   Burke B, 2008, IMMUNOL LETT, V118, P142, DOI 10.1016/j.imlet.2008.03.012
   Charavaryamath C, 2006, ANAT REC PART A, V288A, P1259, DOI 10.1002/ar.a.20401
   Chow S, 2001, CYTOMETRY, V46, P72, DOI 10.1002/cyto.1067
   Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012
   Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247
   Damarla M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004600
   DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264
   DOHERTY DE, 1994, J IMMUNOL, V153, P241
   Duraisamy S, 2008, EXPERT OPIN THER TAR, V12, P921, DOI [10.1517/14728222.12.8.921, 10.1517/14728222.12.8.921 ]
   FAN ST, 1993, J IMMUNOL, V150, P2972
   FLEMING TJ, 1993, J IMMUNOL, V151, P2399
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gill SS, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-69
   Hale MB, 2006, CURR OPIN MOL THER, V8, P215
   HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033
   Hatta M, 2010, FEMS IMMUNOL MED MIC, V58, P182, DOI 10.1111/j.1574-695X.2009.00616.x
   Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8
   Ilangumaran S, 2003, J IMMUNOL METHODS, V278, P221, DOI 10.1016/S0022-1759(03)00177-7
   Jia T, 2008, J IMMUNOL, V180, P6846, DOI 10.4049/jimmunol.180.10.6846
   Koll S, 1997, J LEUKOCYTE BIOL, V61, P679, DOI 10.1002/jlb.61.6.679
   Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061
   Krutzik PO, 2005, J IMMUNOL, V175, P2366, DOI 10.4049/jimmunol.175.4.2366
   Krutzik PO, 2005, J IMMUNOL, V175, P2357, DOI 10.4049/jimmunol.175.4.2357
   LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0
   Liu S, 2008, EUR J PHARMACOL, V584, P159, DOI 10.1016/j.ejphar.2008.02.009
   LO SK, 1995, J IMMUNOL, V154, P4768
   LUKACS NW, 1995, BLOOD, V86, P2767
   Mizuno K, 2005, CLIN EXP IMMUNOL, V142, P461, DOI 10.1111/j.1365-2005.02932.x
   Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200
   O'Dea KP, 2009, J IMMUNOL, V182, P1155, DOI 10.4049/jimmunol.182.2.1155
   O'Dea KP, 2005, AM J RESP CRIT CARE, V172, P1119, DOI 10.1164/rccm.200504-605OC
   Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361
   Perez OD, 2002, NAT BIOTECHNOL, V20, P155, DOI 10.1038/nbt0202-155
   Sachs UJH, 2011, BLOOD, V117, P669, DOI 10.1182/blood-2010-05-286146
   Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009
   Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
   Skrzeczynska-Moncznik J, 2008, SCAND J IMMUNOL, V67, P152, DOI 10.1111/j.1365-3083.2007.02051.x
   Smith JS, 2004, MOL THER, V9, P932, DOI 10.1016/j.ymthe.2004.03.010
   STAUB NC, 1982, ANN NY ACAD SCI, V384, P332, DOI 10.1111/j.1749-6632.1982.tb21382.x
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   Tudhope SJ, 2008, J PHARMACOL EXP THER, V324, P306, DOI 10.1124/jpet.107.127670
   van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wilson MR, 2009, AM J RESP CRIT CARE, V179, P914, DOI 10.1164/rccm.200806-877OC
   Zhao JY, 2008, IN VITRO CELL DEV-AN, V44, P145, DOI 10.1007/s11626-008-9088-y
   ZIEGLERHEITBROCK HWL, 1992, BLOOD, V79, P503
NR 60
TC 29
Z9 33
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD NOV
PY 2011
VL 301
IS 5
BP L812
EP L821
DI 10.1152/ajplung.00092.2011
PG 10
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 863JH
UT WOS:000298158100022
PM 21873449
OA Green Published
DA 2023-08-21
ER

PT J
AU Sachs, UJ
AF Sachs, Ulrich J. H.
TI Recent insights into the mechanism of transfusion-related acute lung
   injury
SO CURRENT OPINION IN HEMATOLOGY
LA English
DT Article
DE ALI/ARDS; neutrophils; transfusion; ALI/ARDS; transfusion 
ID RED-BLOOD-CELLS; ANIMAL-MODEL; CAUSE TRALI; RAT MODEL; ANTIBODY; PLASMA;
   LIPIDS; INFLAMMATION; ACTIVATION; COAGULOPATHY
AB Purpose of review
   This review summarizes the recent clinical and experimental literature on the pathogenesis of transfusion-related acute lung injury (TRALI), with a focus on mechanistic aspects.
   Recent findings
   Mechanisms by which leukocyte antibodies induce TRALI have been unraveled, including a multistep cascade for HLA class II-induced TRALI. Significant advances have also been made in the field of recipient-related factors that contribute to the development of TRALI, both in clinical and animal studies. In contrast, TRALI associated with the transfusion of blood components that do not contain antibodies is an emerging problem, especially because the relevance of mechanisms proposed earlier is questioned by the recent findings. New mechanisms need yet to be defined. The diversity of newly described factors contributing to TRALI demonstrates that a two-hit model falls too short to explain this complex syndrome and rather supports the previously proposed threshold model of TRALI.
   Summary
   Activated neutrophils are central in the pathophysiology of TRALI as their interaction with the lung endothelium causes capillary leak and pulmonary edema. Typically, numerous factors must act together in order to overcome a critical activation threshold of the neutrophil. At least one of these factors originates from a transfused blood component.
C1 Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany.
C3 Justus Liebig University Giessen
RP Sachs, UJ (corresponding author), Univ Giessen, Inst Clin Immunol & Transfus Med, Langhansstr 7, D-35392 Giessen, Germany.
EM ulrich.sachs@med.uni-giessen.de
RI Sachs, Ulrich/GSI-7824-2022
FU Deutsche Forschungsgemeinschaft (DFG) - Excellence Cluster
   Cardiopulmonary System (ECCPS) [SFB-TR 84]; University Medical Center
   Giessen and Marburg (UKGM) [10/2009]
FX Funding for research on which this article is based was received from
   the Deutsche Forschungsgemeinschaft (DFG) - Excellence Cluster
   Cardiopulmonary System (ECCPS) SFB-TR 84 and from the University Medical
   Center Giessen and Marburg (UKGM), research grant no. 10/2009.
CR Benson AB, 2011, LIVER TRANSPLANT, V17, P149, DOI 10.1002/lt.22212
   Benson AB, 2010, INTENS CARE MED, V36, P1710, DOI 10.1007/s00134-010-1954-x
   Blumberg N, 2010, TRANSFUSION, V50, P2738, DOI 10.1111/j.1537-2995.2010.02748.x
   Bux J, 2011, VOX SANG, V100, P122, DOI 10.1111/j.1423-0410.2010.01392.x
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Fung YL, 2010, BLOOD, V116, P3073, DOI 10.1182/blood-2010-05-284570
   Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC
   Gilliss BM, 2011, TRANSFUS MED REV, V25, P1, DOI 10.1016/j.tmrv.2010.08.002
   Hashimoto S, 2010, TRANSFUSION, V50, P2582, DOI 10.1111/j.1537-2995.2010.02779.x
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Keller-Stanislawski B, 2009, TRANSFUSION MED, V19, P340, DOI 10.1111/j.1365-3148.2009.00947.x
   Khan SY, 2010, BIOCHEM J, V432, P35, DOI 10.1042/BJ20091087
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Mangalmurti NS, 2009, BLOOD, V113, P1158, DOI 10.1182/blood-2008-07-166264
   Middelburg RA, 2011, VOX SANG, V100, P327, DOI 10.1111/j.1423-0410.2010.01420.x
   Middelburg RA, 2010, TRANSFUSION, V50, P2447, DOI 10.1111/j.1537-2995.2010.02715.x
   Nicholson SE, 2011, J TRAUMA, V70, P466, DOI 10.1097/TA.0b013e3182032584
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Sachs UJ, 2010, VOX SANG, V99, P456
   Sachs U J H, 2007, Intensive Care Med, V33 Suppl 1, pS3, DOI 10.1007/s00134-007-2873-3
   Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744
   Sachs UJH, 2011, BLOOD, V117, P669, DOI 10.1182/blood-2010-05-286146
   Saidenberg E, 2010, TRANSFUS MED REV, V24, P305, DOI 10.1016/j.tmrv.2010.05.005
   SEEGER W, 1990, BLOOD, V76, P1438
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   Smolenska-Sym G, 2010, VOX SANG, V99, P452
   Tuinman PR, 2011, CLIN EXP IMMUNOL, V165, P278, DOI 10.1111/j.1365-2249.2011.04422.x
   Tung JP, 2011, VOX SANG, V100, P219, DOI 10.1111/j.1423-0410.2010.01381.x
   Vamvakas EC, 2010, TRANSFUSION, V50, P600, DOI 10.1111/j.1537-2995.2009.02465.x
   Vlaar APJ, 2010, INTENS CARE MED, V36, P879, DOI 10.1007/s00134-010-1802-z
   Vlaar APJ, 2011, BLOOD, V117, P4218, DOI 10.1182/blood-2010-10-313973
   Vlaar APJ, 2010, BLOOD, V116, P1360, DOI 10.1182/blood-2009-10-248732
   Vlaar APJ, 2010, ANESTHESIOLOGY, V113, P92, DOI 10.1097/ALN.0b013e3181de6f25
   Vlaar APJ, 2010, CRIT CARE MED, V38, P771, DOI 10.1097/CCM.0b013e3181cc4d4b
   Vlaar AP, 2011, TRANSFUSION
   Wakamoto S, 2011, TRANSFUSION, V51, P993, DOI 10.1111/j.1537-2995.2010.02910.x
   Win N, 2008, TRANSFUSION MED, V18, P276, DOI 10.1111/j.1365-3148.2008.00885.x
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
NR 45
TC 36
Z9 38
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1065-6251
J9 CURR OPIN HEMATOL
JI Curr. Opin. Hematol.
PD NOV
PY 2011
VL 18
IS 6
BP 436
EP 442
DI 10.1097/MOH.0b013e32834bab01
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 836UW
UT WOS:000296140500009
PM 21912251
DA 2023-08-21
ER

PT J
AU Xiang, M
   Shi, XL
   Li, YH
   Xu, J
   Yin, LH
   Xiao, GZ
   Scott, MJ
   Billiar, TR
   Wilson, MA
   Fan, J
AF Xiang, Meng
   Shi, Xiaolian
   Li, Yuehua
   Xu, Jia
   Yin, Lianhua
   Xiao, Guozhi
   Scott, Melanie J.
   Billiar, Timothy R.
   Wilson, Mark A.
   Fan, Jie
TI Hemorrhagic Shock Activation of NLRP3 Inflammasome in Lung Endothelial
   Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MOBILITY GROUP BOX-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
   RESPIRATORY-DISTRESS-SYNDROME; NEUTROPHIL NADPH OXIDASE; MULTIPLE ORGAN
   FAILURE; SEVERE BLUNT TRAUMA; TLR2 UP-REGULATION; NAD(P)H OXIDASE;
   ISCHEMIA/REPERFUSION INJURY; ALVEOLAR MACROPHAGES
AB Hemorrhagic shock (HS) due to major trauma and surgery predisposes the host to the development of systemic inflammatory response syndrome (SIRS), including acute lung injury (ALI), through activating and exaggerating the innate immune response. IL-1 beta is a crucial proinflammatory cytokine that contributes to the development of SIRS and ALI. Lung endothelial cells (EC) are one important source of IL-1 beta, and the production of active IL-1 beta is controlled by the inflammasome. In this study, we addressed the mechanism underlying HS activation of the inflammasome in lung EC. We show that high mobility group box 1 acting through TLR4, and a synergistic collaboration with TLR2 and receptor for advanced glycation end products signaling, mediates HS-induced activation of EC NAD(P) H oxidase. In turn, reactive oxygen species derived from NAD(P) H oxidase promote the association of thioredoxin-interacting protein with the nucleotide-binding oligomerization domain-like receptor protein NLRP3 and subsequently induce inflammasome activation and IL-1 beta secretion from the EC. We also show that neutrophil-derived reactive oxygen species play a role in enhancing EC NAD(P) H oxidase activation and therefore an amplified inflammasome activation in response to HS. The present study explores a novel mechanism underlying HS activation of EC inflammasome and thus presents a potential therapeutic target for SIRS and ALI induced after HS. The Journal of Immunology, 2011, 187: 4809-4817.
C1 [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Pittsburgh, PA 15240, United States.
C1 [Xiang, Meng; Shi, Xiaolian; Li, Yuehua; Xu, Jia; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213, United States.
C1 [Xiang, Meng; Yin, Lianhua] Fudan Univ, Shanghai Med Coll, Dept Physiol & Pathophysiol, Shanghai 200032, China.
C1 [Shi, Xiaolian] Xi An Jiao Tong Univ, Coll Med, Dept Pharmacol, Xian 710061, China.
C1 [Xu, Jia] So Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, China.
C1 [Xiao, Guozhi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213, United States.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Fudan University;
   Xi'an Jiaotong University; Southern Medical University - China;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Fan, J (corresponding author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Bldg 1,Room 2W109 151L-U,Univ Dr C, Pittsburgh, PA 15240 USA.
EM jif7@pitt.edu
RI li, yueyue/IVH-9846-2023; LI, Yue/GRS-8071-2022; li, yue/HSF-7296-2023
FU National Institutes of Health [R01-HL-079669]; National Institutes of
   Health Center [P50-GM-53789]; Veterans Administration
FX This work was supported by National Institutes of Health Grant
   R01-HL-079669 (to J.F. and M.A.W.), National Institutes of Health Center
   Grant P50-GM-53789 (to T.R.B. and J.F.), and a Veterans Administration
   Merit Award (to J.F.).
CR Abraham E, 1999, INTENS CARE MED, V25, P556, DOI 10.1007/s001340050903
   Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950
   ABRAHAM E, 1988, CIRC SHOCK, V25, P33
   Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730
   Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565
   Assier E, 2004, J IMMUNOL, V172, P7661, DOI 10.4049/jimmunol.172.12.7661
   Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976
   Cotter MJ, 2001, AM J PATHOL, V159, P473, DOI 10.1016/S0002-9440(10)61719-1
   Czura CJ, 2003, CRIT CARE MED, V31, pS46, DOI 10.1097/00003246-200301001-00007
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Eckels P, 2008, SHOCK, V29, P17
   Fan J, 2006, AM J PHYSIOL-LUNG C, V290, pL738, DOI 10.1152/ajplung.00280.2005
   Fan J, 1998, J IMMUNOL, V161, P440
   Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696
   Fan J, 2007, SHOCK, V28, P213, DOI 10.1097/shk.0b013e318033ec9d
   Fan J, 2007, J IMMUNOL, V178, P6573, DOI 10.4049/jimmunol.178.10.6573
   FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836
   FISHER CJ, 1994, CIRC SHOCK, V44, P1
   FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593
   GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916
   HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752
   Huber TS, 2000, SHOCK, V13, P425, DOI 10.1097/00024382-200006000-00002
   Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919
   Huttunen HJ, 2002, CANCER RES, V62, P4805
   Impellizzeri D, 2011, BIOCHEM PHARMACOL, V81, P636, DOI 10.1016/j.bcp.2010.12.006
   Kaczorowski DJ, 2008, J LEUKOCYTE BIOL, V83, P546, DOI 10.1189/jlb.0607374
   Kim JY, 2005, AM J PHYSIOL-LUNG C, V288, pL958, DOI 10.1152/ajplung.00359.2004
   Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936
   Li YH, 2009, AM J PHYSIOL-REG I, V297, pR1670, DOI 10.1152/ajpregu.00445.2009
   Liu YJ, 2009, J IMMUNOL, V182, P572, DOI 10.4049/jimmunol.182.1.572
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010
   Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x
   Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Rao DA, 2007, J IMMUNOL, V179, P6536, DOI 10.4049/jimmunol.179.10.6536
   ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011
   ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372
   SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448
   SHENKAR R, 1993, LYMPHOKINE CYTOK RES, V12, P237
   Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tsung A, 2005, J IMMUNOL, V175, P7661, DOI 10.4049/jimmunol.175.11.7661
   Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117
   Xiang M, 2011, AM J RESP CELL MOL, V44, P333, DOI 10.1165/rcmb.2009-0408OC
   Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100
   Yang RK, 2006, MOL MED, V12, P105, DOI 10.2119/2006-00010.Yang
   Zanetti G, 1997, SCHWEIZ MED WSCHR, V127, P489
   Zeh HJ, 2005, J IMMUNOTHER, V28, P1, DOI 10.1097/00002371-200501000-00001
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
   ZHU XL, 1995, CYTOKINE, V7, P8, DOI 10.1006/cyto.1995.1002
NR 61
TC 122
Z9 137
U1 0
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2011
VL 187
IS 9
BP 4809
EP 4817
DI 10.4049/jimmunol.1102093
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 841ET
UT WOS:000296496000046
PM 21940680
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Xiao, B
   Xu, J
   Wang, GS
   Jiang, P
   Fang, F
   Huang, J
   Wang, JC
AF Xiao, Bo
   Xu, Jing
   Wang, Guansong
   Jiang, Peng
   Fang, Fang
   Huang, Jian
   Wang, Jianchun
TI Troglitazone-activated PPAR gamma inhibits LPS-induced lung alveolar
   type II epithelial cells injuries via TNF-alpha
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Alveolar type II epithelial cell; LPS; Peroxisome proliferator-activated receptor gamma; TNF/TNF-alpha/TNFR1 
ID RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA;
   RECEPTOR-GAMMA; ENDOTHELIAL-CELLS; APOPTOSIS; EXPRESSION;
   DIFFERENTIATION; PATHOPHYSIOLOGY; ROSIGLITAZONE
AB Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) are common syndromes characterized by diffuse, acute injury to the alveolar epithelium and pulmonary vascular endothelial cells, with high mortality rate for there are no effective pharmacological therapies. Peroxisome proliferators-activated receptor gamma (PPAR gamma), a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors, is ubiquitously expressed within the lung. Recent studies have indicated PPAR gamma can protect lung tissue and alleviate pulmonary inflammatory injury. But no studies examined whether PPAR gamma agonists can protect the alveolar epithelial cells cultured in vitro. We observed the protective effect of PPAR gamma in LPS-induced alveolar type II epithelial cells injury. The results showed troglitazone-activated PPAR gamma could inhibit the production of TNF-alpha, one of the most important inflammatory factors, and then increased the expression of surfactant-associated protein A (SP-A) and attenuate the apoptosis of alveolar type II epithelial cells. Our results suggest that PPAR gamma may have a potential therapeutic effect on ALI.
C1 [Xiao, Bo; Xu, Jing; Wang, Guansong; Jiang, Peng; Fang, Fang; Huang, Jian; Wang, Jianchun] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Affiliated Hosp 2, Chongqing, China.
C3 Army Medical University
RP Wang, JC (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Affiliated Hosp 2, Xinqiao St, Chongqing, Peoples R China.
EM wjc5577@126.com
FU National Natural Science Foundation of China [30570808]
FX Sources of Support: National Natural Science Foundation of China
   (30570808). We thank Fuyun Ji for her help in the experiment.
CR Arnold R, 2006, VIROLOGY, V346, P427, DOI 10.1016/j.virol.2005.11.009
   Basak S, 2008, CYTOKINE GROWTH F R, V19, P187, DOI 10.1016/j.cytogfr.2008.04.005
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Chaffer CL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-53
   Chen LX, 2010, MOL BIOL REP, V37, P3105, DOI 10.1007/s11033-009-9888-5
   Chen YS, 2010, MOL BIOL REP, V37, P2241, DOI 10.1007/s11033-009-9711-3
   Chima RS, 2008, CRIT CARE MED, V36, P2849, DOI 10.1097/CCM.0b013e318187810e
   Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573
   Cho DH, 2006, AM J PHYSIOL-CELL PH, V291, pC317, DOI 10.1152/ajpcell.00491.2005
   CIRELLI RA, 1995, J LEUKOCYTE BIOL, V57, P820, DOI 10.1002/jlb.57.6.820
   Ciura J, 2010, MOL BIOL REP, V37, P3729, DOI 10.1007/s11033-010-0026-1
   Cui JJ, 2010, MOL BIOL REP, V37, P1627, DOI 10.1007/s11033-009-9575-6
   Cuzzocrea S, 2004, EUR J PHARMACOL, V483, P79, DOI 10.1016/j.ejphar.2003.10.056
   Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037
   Dechert Ronald E, 2003, Respir Care Clin N Am, V9, P283, DOI 10.1016/S1078-5337(03)00031-5
   DOBBS LG, 1990, AM J PHYSIOL, V258, pL134, DOI 10.1152/ajplung.1990.258.4.L134
   Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36
   Frohlich E, 2005, ENDOCR-RELAT CANCER, V12, P291, DOI 10.1677/erc.1.00973
   Geiser T, 2003, SWISS MED WKLY, V133, P586
   Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117
   Griffiths MJD, 2005, LANCET, V366, P249, DOI 10.1016/S0140-6736(05)66916-4
   Hastings RH, 2000, J CLIN MONITOR COMP, V16, P385, DOI 10.1023/A:1011407820548
   Heikkinen S, 2007, BBA-MOL CELL BIOL L, V1771, P999, DOI 10.1016/j.bbalip.2007.03.006
   Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778
   Hong LZ, 2010, MOL BIOL REP, V37, P2285, DOI 10.1007/s11033-009-9721-1
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255
   Liu D, 2006, PHYSIOL RES, V55, P291, DOI 10.33549/physiolres.930822
   Liu D, 2005, CRIT CARE MED, V33, P2309, DOI 10.1097/01.CCM.0000183161.81503.7D
   Liu H, 2009, MOL BIOL REP, V36, P2099, DOI 10.1007/s11033-008-9422-1
   Lu Qing, 2005, Keio Journal of Medicine, V54, P184, DOI 10.2302/kjm.54.184
   Ma XH, 2010, MOL BIOL REP, V37, P3051, DOI 10.1007/s11033-009-9876-9
   Mason RJ, 2006, RESPIROLOGY, V11, pS12, DOI 10.1111/j.1440-1843.2006.00800.x
   Miakotina OL, 2002, AM J PHYSIOL-LUNG C, V283, pL418, DOI 10.1152/ajplung.00470.2001
   Micheal LF, 1997, ENDOCRINOLOGY, V138, P3695, DOI 10.1210/en.138.9.3695
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Patel HJ, 2003, J IMMUNOL, V170, P2663, DOI 10.4049/jimmunol.170.5.2663
   Posadas-Calleja JG, 2003, REV INVEST CLIN, V55, P465
   Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003
   Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614
   Standiford Theodore J, 2005, Proc Am Thorac Soc, V2, P226, DOI 10.1513/pats.200501-010AC
   Sugahara K, 2006, RESPIROLOGY, V11, pS28, DOI 10.1111/j.1440-1843.2006.00804.x
   Tao GH, 2009, MOL BIOL REP, V36, P2413, DOI 10.1007/s11033-009-9472-z
   WALKER SR, 1989, EXP LUNG RES, V15, P553, DOI 10.3109/01902148909069618
   Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P249
   White MK, 2001, EXP CELL RES, V263, P183, DOI 10.1006/excr.2000.5120
   XING Z, 1993, AM J PATHOL, V143, P1009
   Zhan J, 2011, MOL BIOL REP, V38, P1909, DOI 10.1007/s11033-010-0310-0
   Zhang C, 2011, MOL BIOL REP, V38, P601, DOI 10.1007/s11033-010-0146-7
   Zhang ZZ, 2010, MOL BIOL REP, V37, P2803, DOI 10.1007/s11033-009-9828-4
   Zhao YX, 2011, MOL BIOL REP, V38, P1115, DOI 10.1007/s11033-010-0208-x
   Zieleniak A, 2008, ARCH IMMUNOL THER EX, V56, P331, DOI 10.1007/s00005-008-0037-y
   Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015
NR 55
TC 10
Z9 14
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD NOV
PY 2011
VL 38
IS 8
BP 5009
EP 5015
DI 10.1007/s11033-010-0647-4
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 835DE
UT WOS:000296013600025
PM 21153920
DA 2023-08-21
ER

PT J
AU Pati, S
   Gerber, MH
   Menge, TD
   Wataha, KA
   Zhao, YH
   Baumgartner, JA
   Zhao, J
   Letourneau, PA
   Huby, MP
   Baer, LA
   Salsbury, JR
   Kozar, RA
   Wade, CE
   Walker, PA
   Dash, PK
   Cox, CS
   Doursout, MF
   Holcomb, JB
AF Pati, Shibani
   Gerber, Michael H.
   Menge, Tyler D.
   Wataha, Kathryn A.
   Zhao, Yuhai
   Baumgartner, John Adam
   Zhao, Jing
   Letourneau, Phillip A.
   Huby, Maria P.
   Baer, Lisa A.
   Salsbury, John R.
   Kozar, Rosemary A.
   Wade, Charles E.
   Walker, Peter A.
   Dash, Pramod K.
   Cox, Charles S., Jr.
   Doursout, Marie-Francoise
   Holcomb, John B.
TI Bone Marrow Derived Mesenchymal Stem Cells Inhibit Inflammation and
   Preserve Vascular Endothelial Integrity in the Lungs after Hemorrhagic
   Shock
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; STROMAL CELLS; ADHERENS JUNCTIONS;
   KAPOSIS-SARCOMA; GROWTH-FACTORS; VE-CADHERIN; INJURY; PERMEABILITY;
   DISEASE; SEPSIS
AB Hemorrhagic shock (HS) and trauma is currently the leading cause of death in young adults worldwide. Morbidity and mortality after HS and trauma is often the result of multi-organ failure such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), conditions with few therapeutic options. Bone marrow derived mesenchymal stem cells (MSCs) are a multipotent stem cell population that has shown therapeutic promise in numerous pre-clinical and clinical models of disease. In this paper, in vitro studies with pulmonary endothelial cells (PECs) reveal that conditioned media (CM) from MSCs and MSC-PEC co-cultures inhibits PEC permeability by preserving adherens junctions (VE-cadherin and beta-catenin). Leukocyte adhesion and adhesion molecule expression (VCAM-1 and ICAM-1) are inhibited in PECs treated with CM from MSC-PEC co-cultures. Further support for the modulatory effects of MSCs on pulmonary endothelial function and inflammation is demonstrated in our in vivo studies on HS in the rat. In a rat "fixed volume" model of mild HS, we show that MSCs administered IV potently inhibit systemic levels of inflammatory cytokines and chemokines in the serum of treated animals. In vivo MSCs also inhibit pulmonary endothelial permeability and lung edema with concurrent preservation of the vascular endothelial barrier proteins: VE-cadherin, Claudin-1, and Occludin-1. Leukocyte infiltrates (CD68 and MPO positive cells) are also decreased in lungs with MSC treatment. Taken together, these data suggest that MSCs, acting directly and through soluble factors, are potent stabilizers of the vascular endothelium and inflammation. These data are the first to demonstrate the therapeutic potential of MSCs in HS and have implications for the potential use of MSCs as a cellular therapy in HS-induced lung injury.
C1 [Pati, Shibani; Gerber, Michael H.; Menge, Tyler D.; Wataha, Kathryn A.; Zhao, Yuhai; Baumgartner, John Adam; Letourneau, Phillip A.; Huby, Maria P.; Baer, Lisa A.; Salsbury, John R.; Kozar, Rosemary A.; Wade, Charles E.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX, United States.
C1 [Pati, Shibani; Gerber, Michael H.; Menge, Tyler D.; Wataha, Kathryn A.; Zhao, Yuhai; Baumgartner, John Adam; Letourneau, Phillip A.; Huby, Maria P.; Baer, Lisa A.; Salsbury, John R.; Kozar, Rosemary A.; Wade, Charles E.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX, United States.
C1 [Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX, United States.
C1 [Zhao, Jing; Walker, Peter A.; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX, United States.
C1 [Doursout, Marie-Francoise] Univ Texas Hlth Sci Ctr Houston, Dept Anesthesiol, Houston, TX, United States.
C3 University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston; University of Texas System; University of Texas Health
   Science Center Houston; University of Texas System; University of Texas
   Health Science Center Houston; University of Texas System; University of
   Texas Health Science Center Houston
RP Pati, S (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX USA.
EM shibani.pati@uth.tmc.edu
RI Dash, Pramod Kumar/F-5832-2011
OI Dash, Pramod Kumar/0000-0001-6746-1002; holcomb,
   john/0000-0001-8312-9157; Salsbury, John/0000-0002-6536-6420
FU Mission Connect: The Institute for Rehabilitation and Research; National
   Institutes of Health [T32GM008792-11]
FX This work was supported by funding from Mission Connect: The Institute
   for Rehabilitation and Research and the National Institutes of Health
   T32GM008792-11. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Aird WC, 2003, CRIT CARE MED, V31, pS221, DOI 10.1097/01.CCM.0000057847.32590.C1
   Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Ball SG, 2007, J CELL MOL MED, V11, P1012, DOI 10.1111/j.1582-4934.2007.00120.x
   Ball SG, 2007, INT J BIOCHEM CELL B, V39, P379, DOI 10.1016/j.biocel.2006.09.005
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   Cinel I, 2007, CURR OPIN INFECT DIS, V20, P345, DOI 10.1097/QCO.0b013e32818be70a
   Crosby CV, 2005, BLOOD, V105, P2771, DOI 10.1182/blood-2004-06-2244
   Danchuk S, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt68
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   DIAZFLORES L, 1991, HISTOL HISTOPATHOL, V6, P269
   Fang XH, 2010, J BIOL CHEM, V285, P26211, DOI 10.1074/jbc.M110.119917
   Fein AM, 2000, CRIT CARE CLIN, V16, P289, DOI 10.1016/S0749-0704(05)70111-1
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   FLECK A, 1985, LANCET, V1, P781
   GROTZ MRW, 1995, SHOCK, V3, P362
   Guidot DM, 2006, AM J PHYSIOL-LUNG C, V291, pL301, DOI 10.1152/ajplung.00153.2006
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158
   Kamouchi M, 2010, CELL MOL NEUROBIOL
   Kerkar S, 2001, J TRAUMA, V51, P440, DOI 10.1097/00005373-200109000-00003
   Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921
   Lampugnani MG, 2007, THROMB RES, V120, pS1, DOI 10.1016/S0049-3848(07)70124-X
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Lee CC, 2005, SHOCK, V24, P177, DOI 10.1097/01.shk.0000171870.42900.15
   London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678
   Matthay MA, 2010, CHEST, V138, P965, DOI 10.1378/chest.10-0518
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001
   Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013
   Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4
   Pittenger Mark F., 2008, V449, P27, DOI 10.1007/978-1-60327-169-1_2
   Qian H, 2008, INT J MOL MED, V22, P325, DOI 10.3892/ijmm_00000026
   Rocco TR, 2001, ANN SURG, V233, P414, DOI 10.1097/00000658-200103000-00017
   SIMS DE, 1991, CAN J CARDIOL, V7, P431
   SINCLAIR DG, 1994, CHEST, V106, P535, DOI 10.1378/chest.106.2.535
   Sondeen JL, 2007, SHOCK, V28, P426, DOI 10.1097/shk.0b013e31804a5791
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Veevers-Lowe J, 2011, J CELL SCI, V124, P1288, DOI 10.1242/jcs.076935
   Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005
   Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weiss Daniel J, 2008, Proc Am Thorac Soc, V5, P637, DOI 10.1513/pats.200804-037DW
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
NR 47
TC 114
Z9 126
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2011
VL 6
IS 9
AR e25171
DI 10.1371/journal.pone.0025171
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834CT
UT WOS:000295936900029
PM 21980392
OA Green Published, gold, Green Submitted
DA 2023-08-21
ER

PT J
AU Krzyzaniak, MJ
   Peterson, CY
   Cheadle, G
   Loomis, W
   Wolf, P
   Kennedy, V
   Putnam, JG
   Bansal, V
   Eliceiri, B
   Baird, A
   Coimbra, R
AF Krzyzaniak, Michael J.
   Peterson, Carrie Y.
   Cheadle, Gerald
   Loomis, William
   Wolf, Paul
   Kennedy, Vince
   Putnam, James G.
   Bansal, Vishal
   Eliceiri, Brian
   Baird, Andrew
   Coimbra, Raul
TI Efferent vagal nerve stimulation attenuates acute lung injury following
   burn: The importance of the gut-lung axis
SO SURGERY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; FACTOR-KAPPA-B; SYSTEMIC INFLAMMATORY
   RESPONSE; THERMAL-INJURY; PHOSPHODIESTERASE INHIBITION; INTESTINAL
   INJURY; MESENTERIC LYMPH; BARRIER INJURY; PENTOXIFYLLINE; NEUTROPHILS
AB Background. The purpose of this study was to assess acute lung injury when protection to the gut mucosal barrier offered by vagus nerve stimulation is eliminated by an abdominal vagotomy.
   Methods. Male balb/c mice were subjected to 30% total body surface area steam burn With and without electrical stimulation to the right cervical vagus nerve. A cohort of animals were subjected to abdominal vagotomy. Lung histology, myeloperoxidase and ICAM-1 immune staining, myeloperoxidase enzymatic assay, and tissue KC levels were analyzed 24 hours after burn. Additionally, lung IkB-alpha, NF-kB immunoblots, and NF-kB-DNA binding measured by photon emission analysis Using NF-kB-luc transgenic mice Were performed.
   Results. Six hours post burn, phosphorylation of both NF-kB p65 and IkB-alpha were observed. Increased photon emission signal was seen in the lungs of NF-kB-luc transgenic animals. Vagal nerve stimulation blunted NF-kB activation similar to sham animals whereas abdominal vagotomy eliminated the anti-inflammatory effect. After burn, MPO positive cells and ICAM-1 expression in the lung endothelium was increased, and lung histology demonstrated significant injury at 24 hours. Vagal nerve stimulation markedly decreased neutrophil infiltration as demonstrated by MPO immune staining and enzyme activity. Vagal stimulation also markedly attenuated acute lung injury at 24 hours. The protective effects of vagal nerve stimulation were reversed by performing an abdominal vagotomy.
   Conclusion. Vagal nerve stimulation is an effective strategy to protect against acute lung injury following burn. Moreover, the protective effects of vagal nerve stimulation, in the prevention of acute lung injury are eliminated by performing an abdominal vagotomy. These results establish the importance of the gut-lung axis after burn in the genesis of acute lung injury. (Surgery 2011;150:379-89.)
C1 [Krzyzaniak, Michael J.; Peterson, Carrie Y.; Cheadle, Gerald; Loomis, William; Kennedy, Vince; Putnam, James G.; Bansal, Vishal; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, San Diego Sch Med, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103, United States.
C1 [Wolf, Paul] Univ Calif San Diego, San Diego Sch Med, Dept Pathol, San Diego, CA 92103, United States.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Coimbra, R (corresponding author), 200 W Arbor Dr 8896, San Diego, CA 92103 USA.
EM rcoimbra@ncsd.edu
RI Coimbra, Raul/AAP-3019-2020; COimbra, Raul/HJP-1207-2023; Peterson,
   Carrie/AAF-8586-2021
OI Coimbra, Raul/0000-0002-3759-6851; COimbra, Raul/0000-0002-3759-6851;
   Peterson, Carrie/0000-0002-8448-4633; Baird, Andrew/0000-0003-0027-9905;
   Eliceiri, Brian/0000-0003-1811-1916
FU NIGMS NIH HHS [P20 GM078421, P20 GM078421-05] Funding Source: Medline
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Berger F, 2008, EUR J NUCL MED MOL I, V35, P2275, DOI 10.1007/s00259-008-0870-6
   Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124
   Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Calkins CM, 2001, J SURG RES, V101, P232, DOI 10.1006/jsre.2001.6274
   CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009
   Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735
   Coimbra R, 2004, J TRAUMA, V57, P1157, DOI 10.1097/01.TA.0000151261.28640.F7
   Costantini TW, 2010, AM J PHYSIOL-GASTR L, V299, pG1308, DOI 10.1152/ajpgi.00156.2010
   Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0
   Costantini TW, 2009, J TRAUMA, V67, P1162, DOI 10.1097/TA.0b013e3181ba3577
   Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080
   Dancey DR, 1999, INTENS CARE MED, V25, P1231, DOI 10.1007/PL00003763
   Deitch E A, 2001, Curr Opin Crit Care, V7, P92, DOI 10.1097/00075198-200104000-00007
   DEMLING RH, 1984, SURGERY, V95, P136
   Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083
   Estenssoro E, 2002, CRIT CARE MED, V30, P2450, DOI 10.1097/00003246-200211000-00008
   HARMS BA, 1982, MICROVASC RES, V23, P77, DOI 10.1016/0026-2862(82)90032-2
   Ho TY, 2007, BIOMATERIALS, V28, P4370, DOI 10.1016/j.biomaterials.2007.07.005
   Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362
   Ipaktchi K, 2006, J IMMUNOL, V177, P8065, DOI 10.4049/jimmunol.177.11.8065
   Lpaktchi K, 2007, CRIT CARE MED, V35, P2139, DOI 10.1097/01.CCM.0000280568.61217.26
   Magnotti LJ, 1999, ARCH SURG-CHICAGO, V134, P1333, DOI 10.1001/archsurg.134.12.1333
   MAINOUS MR, 1995, SHOCK, V4, P193, DOI 10.1097/00024382-199509000-00007
   PRUITT BA, 1975, J TRAUMA, V15, P369
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143
   Song XM, 2010, BURNS, V36, P75, DOI 10.1016/j.burns.2009.02.002
   WALKER HL, 1968, J TRAUM, V8, P1049, DOI 10.1097/00005373-196811000-00006
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   WINDSOR ACJ, 1993, BRIT J SURG, V80, P10, DOI 10.1002/bjs.1800800106
   Zallen G, 1999, J SURG RES, V83, P83, DOI 10.1006/jsre.1999.5569
   Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134
NR 35
TC 40
Z9 44
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD SEP
PY 2011
VL 150
IS 3
BP 379
EP 389
DI 10.1016/j.surg.2011.06.008
PG 11
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 823FQ
UT WOS:000295108300003
PM 21783215
OA Green Accepted
DA 2023-08-21
ER

PT J
AU van der Heijden, M
   Amerongen, GPV
   van Bezu, J
   Paul, MA
   Groeneveld, ABJ
   van Hinsbergh, VWM
AF van der Heijden, Melanie
   Amerongen, Geerten P. van Nieuw
   van Bezu, Jan
   Paul, Marinus A.
   Groeneveld, A. B. Johan
   van Hinsbergh, Victor W. M.
TI Opposing Effects of the Angiopoietins on the Thrombin-Induced
   Permeability of Human Pulmonary Microvascular Endothelial Cells
SO PLOS ONE
LA English
DT Article
ID ACUTE LUNG INJURY; VASCULAR-PERMEABILITY; INDUCED INCREASE; BARRIER
   FUNCTION; GENE-THERAPY; VE-CADHERIN; IN-VIVO; TIE2; JUNCTIONS; KINASE
AB Background: Angiopoietin-2 (Ang-2) is associated with lung injury in ALI/ARDS. As endothelial activation by thrombin plays a role in the permeability of acute lung injury and Ang-2 may modulate the kinetics of thrombin-induced permeability by impairing the organization of vascular endothelial (VE-) cadherin, and affecting small Rho GTPases in human pulmonary microvascular endothelial cells (HPMVECs), we hypothesized that Ang-2 acts as a sensitizer of thrombin-induced hyperpermeability of HPMVECs, opposed by Ang-1.
   Methodology/Principal Findings: Permeability was assessed by measuring macromolecule passage and transendothelial electrical resistance (TEER). Angiopoietins did not affect basal permeability. Nevertheless, they had opposing effects on the thrombin-induced permeability, in particular in the initial phase. Ang-2 enhanced the initial permeability increase (passage, P = 0.010; TEER, P = 0.021) in parallel with impairment of VE-cadherin organization without affecting VE-cadherin Tyr685 phosphorylation or increasing RhoA activity. Ang-2 also increased intercellular gap formation. Ang-1 preincubation increased Rac1 activity, enforced the VE-cadherin organization, reduced the initial thrombin-induced permeability (TEER, P = 0.027), while Rac1 activity simultaneously normalized, and reduced RhoA activity at 15 min thrombin exposure (P = 0.039), but not at earlier time points. The simultaneous presence of Ang-2 largely prevented the effect of Ang-1 on TEER and macromolecule passage.
   Conclusions/Significance: Ang-1 attenuated thrombin-induced permeability, which involved initial Rac1 activation-enforced cell-cell junctions, and later RhoA inhibition. In addition to antagonizing Ang-1, Ang-2 had also a direct effect itself. Ang-2 sensitized the initial thrombin-induced permeability accompanied by destabilization of VE-cadherin junctions and increased gap formation, in the absence of increased RhoA activity.
C1 [van der Heijden, Melanie; Groeneveld, A. B. Johan] Vrije Univ Amsterdam, Med Ctr, Dept Intens Care, Inst Cardiovasc Res, Amsterdam, Netherlands.
C1 [van der Heijden, Melanie; Amerongen, Geerten P. van Nieuw; van Bezu, Jan; van Hinsbergh, Victor W. M.] Vrije Univ Amsterdam, Med Ctr, Dept Physiol, Inst Cardiovasc Res, Amsterdam, Netherlands.
C1 [Paul, Marinus A.] Vrije Univ Amsterdam, Med Ctr, Dept Cardiothorac Surg, Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije
   Universiteit Amsterdam
RP van der Heijden, M (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Intens Care, Inst Cardiovasc Res, Amsterdam, Netherlands.
EM nieuwamerongen@vumc.nl
FU Netherlands Heart Foundation [2003T032]; European Society of Intensive
   Care Medicine
FX GPvNA was supported by The Netherlands Heart Foundation (The Hague,
   grant 2003T032). MvdH was supported by the European Society of Intensive
   Care Medicine (ECCRN Levi Montalcini Biomedical Sciences Award 2007).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Amerongen GPV, 2000, CIRCULATION, V102, P2803
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005
   Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647
   Baumer Y, 2009, J CELL PHYSIOL, V220, P716, DOI 10.1002/jcp.21819
   Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298
   Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494
   Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324
   Cascone I, 2003, BLOOD, V102, P2482, DOI 10.1182/blood-2003-03-0670
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Findley CM, 2007, ARTERIOSCL THROM VAS, V27, P2619, DOI 10.1161/ATVBAHA.107.150482
   Finigan JH, 2009, MICROVASC RES, V77, P35, DOI 10.1016/j.mvr.2008.09.002
   Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714
   Fukuhara S, 2010, YAKUGAKU ZASSHI, V130, P1413, DOI 10.1248/yakushi.130.1413
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gorovoy M, 2007, CIRC RES, V101, P50, DOI 10.1161/CIRCRESAHA.106.145847
   Hoang MV, 2011, BLOOD, V117, P1751, DOI 10.1182/blood-2010-05-286831
   Huang YQ, 2008, CRIT CARE MED, V36, P262, DOI 10.1097/01.CCM.0000297955.02633.A4
   Jho D, 2005, CIRC RES, V96, P1282, DOI 10.1161/01.RES.0000171894.03801.03
   Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200
   Kim SR, 2008, EXP MOL MED, V40, P320, DOI 10.3858/emm.2008.40.3.320
   Kinney CM, 2008, AM J PHYSIOL-CELL PH, V294, pC241, DOI 10.1152/ajpcell.00187.2007
   Kipnis E, 2004, SHOCK, V21, P444, DOI 10.1097/00024382-200405000-00008
   LANGELER EG, 1988, THROMB HAEMOSTASIS, V60, P240
   LEEMREIS JR, 2006, CYTOM PART A, V69, P873
   Li XC, 2004, BLOOD, V104, P1716, DOI 10.1182/blood-2003-11-3744
   Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Marcus BC, 1998, ANN VASC SURG, V12, P384, DOI 10.1007/s100169900173
   Marron MB, 2007, J BIOL CHEM, V282, P30509, DOI 10.1074/jbc.M702535200
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493
   Oubaha M, 2009, BLOOD, V114, P3343, DOI 10.1182/blood-2008-12-196584
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Peters S, 2007, CYTOKINE, V40, P144, DOI 10.1016/j.cyto.2007.09.001
   Pizurki L, 2003, BRIT J PHARMACOL, V139, P329, DOI 10.1038/sj.bjp.0705259
   Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488
   Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Schubert SY, 2011, ARTERIOSCL THROM VAS, V31, P870, DOI 10.1161/ATVBAHA.110.218255
   Seegar TCM, 2010, MOL CELL, V37, P643, DOI 10.1016/j.molcel.2010.02.007
   Shelton JL, 2006, MICROVASC RES, V71, P40, DOI 10.1016/j.mvr.2005.11.003
   van der Heijden M, 2008, THORAX, V63, P903, DOI 10.1136/thx.2007.087387
   van der Heijden M, 2008, APOPTOSIS, V13, P404, DOI 10.1007/s10495-007-0173-6
   van der Heijden M, 2009, INTENS CARE MED, V35, P1567, DOI 10.1007/s00134-009-1560-y
   Wang YH, 2004, J CELL PHYSIOL, V198, P53, DOI 10.1002/jcp.10386
   Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159
   Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E
   WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
NR 58
TC 34
Z9 34
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2011
VL 6
IS 8
AR e23448
DI 10.1371/journal.pone.0023448
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 808CV
UT WOS:000293953700023
PM 21858121
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Losa, D
   Chanson, M
   Crespin, S
AF Losa, Davide
   Chanson, Marc
   Crespin, Sophie
TI Connexins as therapeutic targets in lung disease
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE connexins; gap junctions; Inflammation; lung disease 
ID GAP JUNCTIONAL COMMUNICATION; ALVEOLAR EPITHELIAL-CELLS; INTERCELLULAR
   COMMUNICATION; CYSTIC-FIBROSIS; MOUSE LUNG; MIMETIC PEPTIDES; AIRWAY
   CELLS; PULMONARY-HYPERTENSION; SURFACTANT SECRETION; EXTRACELLULAR ATP
AB Introduction: The lung is a mechanically active system exposed to the external environment and is particularly sensitive to injury and inflammation. Studies have identified intercellular communication pathways that promote proper lung function in response to injury and disease. These pathways involve connexins (Cxs) and gap junctional intercellular communication (GJIC).
   Areas covered in this review: The functional expression of Cxs in airway epithelium and vasculature, under normal and pathological conditions, is reviewed. Inhibition of GJIC and/or silencing of Cxs have been shown to modulate the course of disease development. Cx-based channels: i) coordinate ciliary beating and fluid transport to promote clearance of particulates, ii) regulate secretion of pulmonary surfactant, in response to deep inhalation by interconnecting type I and type II alveolar epithelial cells, and iii) are key mediators of pro-and anti-inflammatory signalling by the pulmonary endothelium, in order to modulate leukocyte recruitment from the circulation.
   Expert opinion: Cx-based channels play several central roles in promoting a regulated inflammatory response and facilitating lung repair, thus enabling the pulmonary epithelium and vasculature to behave as integrated systems. Several pathologies can disrupt the normal communication pathways required for proper lung function, including acute lung injury, asthma, cystic fibrosis, pulmonary fibrosis and cancer.
C1 [Losa, Davide] Univ Hosp Geneva, Fdn Med Res, Lab Clin Invest 3, CH-1211 Geneva, Switzerland.
C1 Univ Geneva, Fdn Med Res, Lab Clin Invest 3, CH-1211 Geneva, Switzerland.
C3 University of Geneva; University of Geneva
RP Chanson, M (corresponding author), Univ Hosp Geneva, Fdn Med Res, Lab Clin Invest 3, 64 Ave Roseraie, CH-1211 Geneva, Switzerland.
EM Marc.Chanson@hcuge.ch
RI Crespin, Sophie/FPW-7849-2022
OI Losa, Davide/0000-0001-5219-3244; Chanson, Marc/0000-0001-8104-2090
FU Swiss National Science Foundation; Vaincre la Mucoviscidose; Italian
   Cystic Fibrosis Research Foundation [19/2009]
FX The work done in the author's laboratory, part of which is reviewed in
   this paper, was supported by a grant from the Swiss National Science
   Foundation to M Chanson.; S Crespin is supported by Vaincre la
   Mucoviscidose and D Losa is supported by the Italian Cystic Fibrosis
   Research Foundation (grant FFC#19/2009, with the contribution of FFC
   delegation "La Bottega delle Donne").
CR Abraham V, 2001, AM J PHYSIOL-LUNG C, V280, pL1085, DOI 10.1152/ajplung.2001.280.6.L1085
   Albright CD, 2002, EXP MOL PATHOL, V72, P62, DOI 10.1006/exmp.2001.2411
   Ale-Agha N, 2009, BIOCHEM BIOPH RES CO, V390, P44, DOI 10.1016/j.bbrc.2009.09.057
   Andreeva AV, 2007, AM J PHYSIOL-LUNG C, V293, pL259, DOI 10.1152/ajplung.00112.2007
   Ashino Y, 2000, AM J PHYSIOL-LUNG C, V279, pL5, DOI 10.1152/ajplung.2000.279.1.L5
   Avanzo JL, 2006, LIFE SCI, V79, P2202, DOI 10.1016/j.lfs.2006.07.033
   Bara I, 2010, EUR RESPIR J, V36, P1174, DOI 10.1183/09031936.00019810
   Billaud M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-30
   Bodendiek SB, 2010, CURR MED CHEM, V17, P4191
   Boitano S, 2000, AM J PHYSIOL-LUNG C, V279, pL623, DOI 10.1152/ajplung.2000.279.4.L623
   BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526
   Boucher RC, 2007, TRENDS MOL MED, V13, P231, DOI 10.1016/j.molmed.2007.05.001
   Braet K, 2003, CELL CALCIUM, V33, P37, DOI 10.1016/S0143-4160(02)00180-X
   Bruzzone R, 2003, P NATL ACAD SCI USA, V100, P13644, DOI 10.1073/pnas.2233464100
   Carson JL, 1998, AM J RESP CELL MOL, V18, P111, DOI 10.1165/ajrcmb.18.1.2789
   Cesen-Cummings K, 1998, CARCINOGENESIS, V19, P61, DOI 10.1093/carcin/19.1.61
   Chadjichristos CE, 2010, CIRCULATION, V121, P123, DOI 10.1161/CIRCULATIONAHA.109.867176
   Chanson M, 2005, BBA-BIOMEMBRANES, V1711, P197, DOI 10.1016/j.bbamem.2004.10.005
   Chanson M, 1999, J CLIN INVEST, V103, P1677, DOI 10.1172/JCI5645
   Chanson M, 2001, AM J PATHOL, V158, P1775, DOI 10.1016/S0002-9440(10)64133-8
   Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P99, DOI 10.1111/j.1469-7793.1997.099bi.x
   Chaytor AT, 1998, J PHYSIOL-LONDON, V508, P561, DOI 10.1111/j.1469-7793.1998.561bq.x
   Chen Y, 2005, INT J CANCER, V113, P14, DOI 10.1002/ijc.20498
   Chen Y, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000549
   Chen Y, 2007, BIOCHEM BIOPH RES CO, V353, P559, DOI 10.1016/j.bbrc.2006.12.096
   COLOMBO BM, 1995, HUM GENE THER, V6, P763, DOI 10.1089/hum.1995.6.6-763
   Cronier L, 2009, ANTIOXID REDOX SIGN, V11, P323, DOI 10.1089/ars.2008.2153
   Cronin M, 2008, MOL CELL NEUROSCI, V39, P152, DOI 10.1016/j.mcn.2008.06.005
   DAHL G, 1994, BIOPHYS J, V67, P1816, DOI 10.1016/S0006-3495(94)80663-0
   Dahl G, 2007, CELL COMMUN ADHES, V14, P259, DOI 10.1080/15419060801891018
   de Souza N, 2011, NAT METHODS, V8, P43, DOI 10.1038/NMETH.F.328
   Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127
   Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70
   Eugenin EA, 2003, J IMMUNOL, V170, P1320, DOI 10.4049/jimmunol.170.3.1320
   Evans WH, 2007, CELL COMMUN ADHES, V14, P265, DOI 10.1080/15419060801891034
   Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061
   Girgis RE, 2010, EXPERT OPIN EMERG DR, V15, P71, DOI 10.1517/14728210903551271
   Gomes P, 2005, INVEST OPHTH VIS SCI, V46, P1208, DOI 10.1167/iovs.04-1181
   Harris A. L., 2009, CONNEXINS GUIDE
   Herve JC, 2005, CURR PHARM DESIGN, V11, P1941, DOI 10.2174/1381612054021060
   Herve JC, 2010, CURR PHARM DESIGN, V16, P3056
   Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349
   Huang S, 2003, CELL COMMUN ADHES, V10, P279, DOI 10.1080/714040440
   Huang S, 2003, J BIOL CHEM, V278, P8326, DOI 10.1074/jbc.M208264200
   Humbert M, 2004, NEW ENGL J MED, V351, P1425, DOI 10.1056/NEJMra040291
   Ichimura H, 2006, AM J PHYSIOL-LUNG C, V291, pL596, DOI 10.1152/ajplung.00036.2006
   Isakson BE, 2001, AM J PHYSIOL-LUNG C, V280, pL221, DOI 10.1152/ajplung.2001.280.2.L221
   Ito A, 2006, CANCER LETT, V234, P239, DOI 10.1016/j.canlet.2005.03.049
   Jacquot J, 2008, EXPERT REV MOL DIAGN, V8, P359, DOI 10.1586/14737159.8.4.359
   Jiang JX, 2005, BBA-BIOMEMBRANES, V1711, P208, DOI 10.1016/j.bbamem.2004.10.001
   Jinn Y, 1998, CANCER LETT, V127, P161, DOI 10.1016/S0304-3835(98)00032-9
   Johnson LN, 2009, ANTIOXID REDOX SIGN, V11, P355, DOI 10.1089/ars.2008.2183
   Kasper M, 1996, HISTOCHEM CELL BIOL, V106, P419
   King TJ, 2004, CANCER RES, V64, P7191, DOI 10.1158/0008-5472.CAN-04-0624
   King TJ, 2005, ONCOGENE, V24, P1718, DOI 10.1038/sj.onc.1208355
   Kolliputi N, 2010, J IMMUNOL, V184, P5819, DOI 10.4049/jimmunol.0902766
   Kreda SM, 2010, J PHYSIOL-LONDON, V588, P2255, DOI 10.1113/jphysiol.2009.186643
   Kuebler WM, 2002, AM J PHYSIOL-LUNG C, V282, pL917, DOI 10.1152/ajplung.00275.2001
   Kurdow R, 2002, ANN THORAC SURG, V73, P905, DOI 10.1016/S0003-4975(01)03413-0
   Kwak BR, 1999, J PHYSIOL-LONDON, V516, P679, DOI 10.1111/j.1469-7793.1999.0679u.x
   Lazarowski ER, 2009, CURR OPIN PHARMACOL, V9, P262, DOI 10.1016/j.coph.2009.02.004
   Lee YC, 1997, AM J PHYSIOL-LUNG C, V272, pL1105, DOI 10.1152/ajplung.1997.272.6.L1105
   Martin FJ, 2008, J IMMUNOL, V180, P4986, DOI 10.4049/jimmunol.180.7.4986
   Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667
   Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895
   Nakamura K, 1998, CELL TISSUE RES, V292, P487, DOI 10.1007/s004410051077
   Oviedo-Orta E, 2002, CELL BIOL INT, V26, P253, DOI 10.1006/cbir.2001.0840
   Park SJ, 2007, EXP MOL MED, V39, P629, DOI 10.1038/emm.2007.69
   Parthasarathi K, 2006, J CLIN INVEST, V116, P2193, DOI 10.1172/JCI26605
   Patel AS, 2005, AM J PHYSIOL-LUNG C, V289, pL489, DOI 10.1152/ajplung.00074.2005
   Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje
   Ram A, 2009, INT ARCH ALLERGY IMM, V149, P38, DOI 10.1159/000176305
   Ransford GA, 2009, AM J RESP CELL MOL, V41, P525, DOI 10.1165/rcmb.2008-0367OC
   Rignault S, 2007, SHOCK, V28, P78, DOI 10.1097/shk.0b013e3180310bd1
   Riteau N, 2010, AM J RESP CRIT CARE, V182, P774, DOI 10.1164/rccm.201003-0359OC
   Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003
   SANDERSON MJ, 1988, AM J PHYSIOL, V254, pC63, DOI 10.1152/ajpcell.1988.254.1.C63
   Sarieddine MZR, 2009, J CELL MOL MED, V13, P4560, DOI 10.1111/j.1582-4934.2008.00654.x
   Sato H, 2007, CANCER CHEMOTH PHARM, V60, P449, DOI 10.1007/s00280-006-0406-3
   Scemes E, 2007, NEURON GLIA BIOL, V3, P199, DOI 10.1017/S1740925X08000069
   Scerri I, 2006, CELL COMMUN ADHES, V13, P1, DOI 10.1080/15419060600631250
   Scheckenbach KEL, 2011, AM J RESP CELL MOL, V44, P74, DOI 10.1165/rcmb.2009-0361OC
   Seminario-Vidal L, 2009, J BIOL CHEM, V284, P20638, DOI 10.1074/jbc.M109.004762
   Sohl G, 2004, CARDIOVASC RES, V62, P228, DOI 10.1016/j.cardiores.2003.11.013
   Spray DC, 2006, GLIA, V54, P758, DOI 10.1002/glia.20429
   Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915
   Traub O, 1998, EUR J CELL BIOL, V77, P313, DOI 10.1016/S0171-9335(98)80090-3
   Trosko JE, 2002, CURR DRUG TARGETS, V3, P465, DOI 10.2174/1389450023347371
   Trovato-Salinaro A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-122
   Udaka N, 2007, CANCER LETT, V246, P224, DOI 10.1016/j.canlet.2006.02.020
   Van Dillen IJ, 2005, ANTICANCER RES, V25, P255
   Vliagoftis H, 1999, J ALLERGY CLIN IMMUN, V103, P656, DOI 10.1016/S0091-6749(99)70239-3
   Volmer JB, 2006, J IMMUNOL, V176, P4449, DOI 10.4049/jimmunol.176.7.4449
   von Maltzahn J, 2009, EUR J CELL BIOL, V88, P481, DOI 10.1016/j.ejcb.2009.04.004
   Wang JJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1112, DOI 10.1152/ajpcell.00097.2007
   Wang PM, 2002, AM J PHYSIOL-LUNG C, V282, pL912, DOI 10.1152/ajplung.00303.2001
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WARNER A, 1995, J PHYSIOL-LONDON, V488, P721, DOI 10.1113/jphysiol.1995.sp021003
   Wiszniewski L, 2007, DIFFERENTIATION, V75, P382, DOI 10.1111/j.1432-0436.2007.00157.x
   Wong CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441
   Yen CH, 2010, J CARDIOVASC PHARM, V55, P574, DOI 10.1097/FJC.0b013e3181d9f5f4
   Zahler S, 2003, J LEUKOCYTE BIOL, V73, P118, DOI 10.1189/jlb.0402184
   Zhang JZ, 2010, RESPIRATION, V80, P236, DOI 10.1159/000274384
   Zhang L, 2006, CANCER GENE THER, V13, P74, DOI 10.1038/sj.cgt.7700875
   Zhang ZQ, 2004, CARCINOGENESIS, V25, P473, DOI 10.1093/carcin/bgh036
NR 105
TC 31
Z9 32
U1 1
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD AUG
PY 2011
VL 15
IS 8
BP 989
EP 1002
DI 10.1517/14728222.2011.584875
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 790BX
UT WOS:000292564600007
PM 21585238
DA 2023-08-21
ER

PT J
AU Yang, Y
   Li, Q
   Deng, ZX
   Zhang, ZY
   Xu, JC
   Qian, GS
   Wang, GS
AF Yang, Yu
   Li, Qi
   Deng, Zhaoxia
   Zhang, Zhiyuan
   Xu, Jiancheng
   Qian, Guisheng
   Wang, Guansong
TI Protection from lipopolysaccharide-induced pulmonary microvascular
   endothelial cell injury by activation of hedgehog signaling pathway
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Hedgehog signal pathway; Sonic hedgehog; ECs/HPMECs/HUVECs/MPVECs; ALI/ARDS; LPS 
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; SONIC HEDGEHOG;
   IN-VITRO; INDUCED APOPTOSIS; CYTOKINE RELEASE; PROGENITOR CELLS;
   GROWTH-FACTORS; PROLIFERATION; DIFFERENTIATION
AB Pulmonary microvascular endothelial cells (PMVECs) are critically involved in the pathogenesis of acute lung injury. Hedgehog signaling pathway plays a fundamental role in embryonic development as well as adult morphogenesis and carcinogenesis. As the priming protein of hedgehog signaling pathway, sonic hedgehog (Shh) may recently be advantage for decreasing endothelial injury and promoting the repair of endothelial barrier function. To investigate the expression and role of hedgehog signal pathway in PMVECs injured by lipopolysaccharide (LPS), cells were divided into six groups: control group, LPS group, rhShh group, LPS + rhShh group, rhShh + cyclopamine group, and LPS + rhShh + cyclopamine group. Real time RT-PCR and Western blotting were used to detect the mRNA and protein expression of hedgehog signal molecules including Shh, Patched-1 (Ptc-1) and Gli1 in nucleus. The activity of PMVECs was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In this study, we found that Shh, Ptch1, and Gli1 were expressed in rat PMVECs and their expression decreased when cells were treated by LPS. In the other hand, LPS inhibited the activity of rat PMVECs and caused the cells injury. Activation of Hedgehog signaling pathway by Shh could elevate the activity of PMVECs with pretreatment by LPS. Therefore, hedgehog signaling pathway should play a protective role on injury PMVECs by LPS.
C1 [Yang, Yu; Li, Qi; Deng, Zhaoxia; Zhang, Zhiyuan; Xu, Jiancheng; Qian, Guisheng; Wang, Guansong] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing 400037, China.
C3 Army Medical University
RP Qian, GS (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing 400037, Peoples R China.
EM qiangs6@yahoo.com.cn; wanggs2003@gmail.com
FU National Natural Science Foundation of China [30770928, 30971309]; PLA
   [06G083, 08G093]; EPSCoR; Office Of The Director [1003970] Funding
   Source: National Science Foundation
FX This research was supported by the National Natural Science Foundation
   of China (30770928 and 30971309), the Key Program of "Eleventh Five-year
   Plan'' for Medical Sci & Tech Research of PLA (06G083 and 08G093).
CR Agouni A, 2007, FUND CLIN PHARMACOL, V21, P21
   Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796
   Aranguren XL, 2007, BLOOD, V109, P2634, DOI 10.1182/blood-2006-06-030411
   Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167
   Bijlsma MF, 2004, BIOESSAYS, V26, P387, DOI 10.1002/bies.20007
   Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3
   Byrd N, 2004, TRENDS CARDIOVAS MED, V14, P308, DOI 10.1016/j.tcm.2004.09.003
   Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437
   Chang Y, 2008, MOL BIOL REP, V35, P285, DOI 10.1007/s11033-007-9083-5
   Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603
   Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985
   Fu M, 2004, J CELL BIOL, V166, P673, DOI 10.1083/jcb.200401077
   Guazzi M, 2008, AM J PHYSIOL-HEART C, V294, pH1357, DOI 10.1152/ajpheart.00866.2007
   Guerrero I, 2003, SCIENCE, V301, P774, DOI 10.1126/science.1088625
   Hochman E, 2006, J BIOL CHEM, V281, P33860, DOI 10.1074/jbc.M605905200
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200
   Katoh Y, 2006, INT J MOL MED, V18, P1019
   Kim YI, 2011, MOL BIOL REP, V38, P3207, DOI 10.1007/s11033-010-9993-5
   Komarova Yulia A, 2007, Sci STKE, V2007, pre8
   Kusano KF, 2004, ARTERIOSCL THROM VAS, V24, P2102, DOI 10.1161/01.ATV.0000144813.44650.75
   Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983
   Lee SW, 2007, INT J MOL MED, V19, P445
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luh Shi-Ping, 2007, Journal of Zhejiang University-Science B, V8, P60, DOI 10.1631/jzus.2007.B0060
   Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020
   Ma XH, 2010, MOL BIOL REP, V37, P3051, DOI 10.1007/s11033-009-9876-9
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Olsen CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-43
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083
   Saqui-Salces M, 2010, BBA-MOL CELL RES, V1803, P786, DOI 10.1016/j.bbamcr.2010.03.008
   Tavella S, 2006, MATRIX BIOL, V25, P389, DOI 10.1016/j.matbio.2006.07.005
   Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405
   TOHRU M, 2006, J CLIN INVEST, V116, P2316, DOI DOI 10.1172/JCI29637
   Wang G, 2008, INT J BIOCHEM CELL B, V40, P461, DOI 10.1016/j.biocel.2007.08.008
   Wang GS, 2010, BBA-MOL CELL RES, V1803, P1359, DOI 10.1016/j.bbamcr.2010.09.002
   Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Warzecha J, 2006, J ORTHOP SCI, V11, P491, DOI 10.1007/s00776-006-1058-1
   Wojciak-Stothard B, 2007, J CELL SCI, V120, P929, DOI 10.1242/jcs.002212
   Wu Y, 2009, MOL BIOL REP, V36, P1113, DOI 10.1007/s11033-008-9286-4
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang KY, 2003, AM J RESP CRIT CARE, V167, P1567, DOI 10.1164/rccm.200207-664OC
   Zhang QJ, 2009, MOL BIOL REP, V36, P603, DOI 10.1007/s11033-008-9220-9
   Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154
NR 46
TC 20
Z9 25
U1 1
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2011
VL 38
IS 6
BP 3615
EP 3622
DI 10.1007/s11033-010-0473-8
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 777WW
UT WOS:000291656800003
PM 21110116
DA 2023-08-21
ER

PT J
AU Zhao, YT
   Gorshkova, IA
   Berdyshev, E
   He, DH
   Fu, PF
   Ma, WL
   Su, YL
   Usatyuk, PV
   Pendyala, S
   Oskouian, B
   Saba, JD
   Garcia, JGN
   Natarajan, V
AF Zhao, Yutong
   Gorshkova, Irina A.
   Berdyshev, Evgeny
   He, Donghong
   Fu, Panfeng
   Ma, Wenli
   Su, Yanlin
   Usatyuk, Peter V.
   Pendyala, Srikanth
   Oskouian, Babak
   Saba, Julie D.
   Garcia, Joe G. N.
   Natarajan, Viswanathan
TI Protection of LPS-Induced Murine Acute Lung Injury by
   Sphingosine-1-Phosphate Lyase Suppression
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE S1P/S1PR1/S1PR2/S1PR3; interleukin-6; transendothelial resistance; ALI/ARDS 
ID PROTEIN-COUPLED RECEPTORS; VEIN ENDOTHELIAL-CELLS; SPHINGOSINE
   1-PHOSPHATE; BARRIER INTEGRITY; KINASE; ENHANCEMENT; EXPRESSION;
   PHOSPHATE; PLASMA; FAMILY
AB A defining feature of acute lung injury (ALI) is the increased lung vascular permeability and alveolar flooding, which leads to associated morbidity and mortality. Specific therapies to alleviate the unremitting vascular leak in ALI are not currently clinically available; however, our prior studies indicate a protective role for sphingosine-1-phosphate (S1P) in animal models of ALI with reductions in lung edema. As S1P levels are tightly regulated by synthesis and degradation, we tested the hypothesis that inhibition of S1P lyase (S1PL), the enzyme that irreversibly degrades S1P via cleavage, could ameliorate ALI. Intratracheal instillation of LPS to mice enhanced S1PL expression, decreased S1P levels in lung tissue, and induced lung inflammation and injury. LPS challenge of wild-type mice receiving 2-acetyl-4(5)-[1(R),2(S),3(R),4-tetrahydroxybutyl]-imidazole to inhibit S1PL or S1PL(+/-) mice resulted in increased S1P levels in lung tissue and bronchoalveolar lavage fluids and reduced lung injury and inflammation. Moreover, down-regulation of S1PL expression by short interfering RNA (siRNA) in primary human lung microvascular endothelial cells increased S1P levels, and attenuated LPS-mediated phosphorylation of p38 mitogen-activated protein kinase and I-kappa B, IL-6 secretion, and endothelial barrier disruption via Rac1 activation. These results identify a novel role for intracellularly generated S1P in protection against ALI and suggest S1PL as a potential therapeutic target.
C1 [He, Donghong; Fu, Panfeng; Ma, Wenli; Usatyuk, Peter V.; Pendyala, Srikanth; Natarajan, Viswanathan] Univ Illinois, Dept Pharmacol, Chicago, IL 60612, United States.
C1 [Zhao, Yutong; Su, Yanlin] Univ Pittsburgh, Dept Med, Pittsburgh, PA, United States.
C1 [Gorshkova, Irina A.; Berdyshev, Evgeny; He, Donghong; Fu, Panfeng; Ma, Wenli; Usatyuk, Peter V.; Pendyala, Srikanth; Garcia, Joe G. N.; Natarajan, Viswanathan] Univ Illinois, Inst Personalized Resp Med, Chicago, IL 60612, United States.
C1 [Gorshkova, Irina A.; Berdyshev, Evgeny; Garcia, Joe G. N.; Natarajan, Viswanathan] Univ Illinois, Dept Med, Chicago, IL 60612, United States.
C1 [Oskouian, Babak; Saba, Julie D.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital; Children's
   Hospital Oakland Research Institute; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF
   Benioff Children's Hospital Oakland
RP Natarajan, V (corresponding author), Univ Illinois, Dept Pharmacol, E403 Med Sci Bldg,MC868,835 S Wolcott Ave, Chicago, IL 60612 USA.
EM visnatar@uic.edu
RI Garcia, Joe GN/E-8862-2010; Fu, Panfeng/F-7345-2015
OI Fu, Panfeng/0000-0001-8813-9258
FU National Institutes of Health [HL079396, HL091916, CA77528]
FX This work was supported by National Institutes of Health grants HL079396
   (V.N.), HL091916 (Y.Z.), and CA77528 (J.D.S.).
CR Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005
   Bandhuvula P, 2007, J LIPID RES, V48, P2769, DOI 10.1194/jlr.D700010-JLR200
   Bektas M, 2010, J BIOL CHEM, V285, P10880, DOI 10.1074/jbc.M109.081489
   Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281
   Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544
   Chen WSV, 2004, NAT GENET, V36, P304, DOI 10.1038/ng1306
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gorshkova I, 2008, J BIOL CHEM, V283, P11794, DOI 10.1074/jbc.M800250200
   Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D
   Haberberger RV, 2009, J ALLERGY CLIN IMMUN, V124, P933, DOI 10.1016/j.jaci.2009.06.034
   Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com
   Heringdorf DMZ, 2003, FEBS LETT, V554, P443, DOI 10.1016/S0014-5793(03)01219-5
   Hla T, 2000, ANN NY ACAD SCI, V905, P16
   Ikeda M, 2004, BIOCHEM BIOPH RES CO, V325, P338, DOI 10.1016/j.bbrc.2004.10.036
   Im DS, 2000, BIOCHEM BIOPH RES CO, V279, P139, DOI 10.1006/bbrc.2000.3933
   Ito K, 2007, BIOCHEM BIOPH RES CO, V357, P212, DOI 10.1016/j.bbrc.2007.03.123
   Kariya Y, 2005, GENES CELLS, V10, P605, DOI 10.1111/j.1365-2443.2005.00862.x
   Kato S, 2004, J AM SOC NEPHROL, V15, P1289
   Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x
   Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449
   Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200
   Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200
   Lai WQ, 2008, J IMMUNOL, V180, P4323, DOI 10.4049/jimmunol.180.6.4323
   Lin CI, 2006, J CELL BIOCHEM, V99, P1216, DOI 10.1002/jcb.20963
   Lin WN, 2007, CELL SIGNAL, V19, P1258, DOI 10.1016/j.cellsig.2007.01.009
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006
   Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103
   Nieuwenhuis B, 2009, J MOL MED, V87, P645, DOI 10.1007/s00109-009-0468-x
   Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007
   Oskouian B, 2005, J BIOL CHEM, V280, P18403, DOI 10.1074/jbc.M410928200
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103
   Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X
   Riccio A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3103pe1
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650
   Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   Schmahl J, 2007, NAT GENET, V39, P52, DOI 10.1038/ng1922
   Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640
   Sevransky JE, 2009, CRIT CARE, V13, DOI 10.1186/cc8048
   Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com
   Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244
   Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845
   Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112
   Wadgaonkar R, 2009, AM J PHYSIOL-LUNG C, V296, pL603, DOI 10.1152/ajplung.90357.2008
   Wang ZL, 2009, INFLAMM RES, V58, P649, DOI 10.1007/s00011-009-0030-x
   Yatomi Y, 1997, J BIOCHEM, V121, P969
   Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4
   Zhang YH, 2006, J PHYSIOL-LONDON, V575, P101, DOI 10.1113/jphysiol.2006.111575
   Zhao YT, 2007, J BIOL CHEM, V282, P14165, DOI 10.1074/jbc.M701279200
NR 55
TC 90
Z9 96
U1 1
U2 20
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD AUG
PY 2011
VL 45
IS 2
BP 426
EP 435
DI 10.1165/rcmb.2010-0422OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 808BQ
UT WOS:000293948900027
PM 21148740
OA Green Published
DA 2023-08-21
ER

PT J
AU Lindsay, CD
AF Lindsay, Christopher D.
TI Novel therapeutic strategies for acute lung injury induced by lung
   damaging agents: The potential role of growth factors as treatment
   options
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Review
DE inhalation; human toxicology; alternative methods; pathology 
ID RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR EPITHELIAL-CELLS;
   NECROSIS-FACTOR-ALPHA; ACID-INDUCED PROLIFERATION; PULMONARY-EDEMA
   FLUID; MESSENGER-RNA LEVELS; RETINOIC ACID; II PNEUMOCYTES; IN-VITRO;
   MECHANICAL VENTILATION
AB The increasing threat from terrorism has brought attention to the possible use of toxic industrial compounds (TICs) and other lung-damaging agents as weapons against civilian populations. The way in which these agents could be used favours the development of generic countermeasures. Improved medical countermeasures would increase survivability and improve the quality of recovery of lung damaged casualties. It is evident that there is a dearth of therapeutic regimes available to treat those forms of lung damage that currently require intensive care management. It is quite possible that mass casualties from a terrorist incident or major industrial accident involving the release of large quantities of inhaled TICs would place a severe burden on already scarce intensive care facilities. The development of effective pharmacological approaches to assist the recovery of casualties suffering from acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) may improve the prognosis of such patients (which is currently poor) and would ideally be used as a means of preventing subjects from developing the pulmonary oedema characteristic of ALI/ARDS. Many promising candidate pharmacological treatments have been evaluated for the treatment of ALI/ARDS, but their clinical value is often debatable. Thus, despite improvements in ventilation strategies, pharmacological intervention for ALI/ARDS remains problematical. A new approach is clearly required for the treatment of patients with severely compromised lungs. Whilst the pathology of ALI/ARDS associated with exposure to a variety of agents is complex, numerous experimental studies suggest that generic therapeutic intervention directed at approaches that aim to upregulate repair of the damaged alveolar blood/air barrier of the lung may be of value, particularly with respect to chemical-induced injury. To this end, keratinocyte growth factor (KGF), epithelial growth factor (EGF) and basic fibroblast growth factor (bFGF) are emerging as the most important candidates. Hepatocyte growth factor (HGF) does not have epithelial specificity for lung tissue. However, the enhanced effects of combinations of growth factors, such as the synergistic effect of HGF upon vascular endothelial growth factor (VEGF)mediated endothelial cell activity, and the combined effect of HGF and KGF in tissue repair should be investigated, particularly as the latter pair of growth factors are frequently implicated in processes associated with the repair of lung damage. Synergistic interactions also occur between trefoil factor family (TFF) peptides and growth factors such as EGF. TFF peptides are most likely to be of value as a short term therapeutic intervention strategy in stimulating epithelial spreading activities which allow damaged mucosal surfaces to be rapidly covered by epithelial cells.
C1 Def Sci & Technol Lab, Dept Biomed Sci, Salisbury SP4 0JQ, Wilts, England, United Kingdom.
C3 Defence Science & Technology Laboratory
RP Lindsay, CD (corresponding author), Def Sci & Technol Lab, Dept Biomed Sci, Salisbury SP4 0JQ, Wilts, England.
EM cdlindsay@dstl.gov.uk
FU Dstl for the Home Office Resilience Programme [18/05/173]
FX This document was produced by Dstl for the Home Office Resilience
   Programme under Contract reference 18/05/173.
CR Aarbiou J, 2002, J LEUKOCYTE BIOL, V72, P167
   ADAMSON IYR, 1990, AM J PATHOL, V137, P385
   ADAMSON IYR, 1992, ANAT EMBRYOL, V185, P275, DOI 10.1007/BF00211826
   Al-azzeh E, 2002, GUT, V51, P685, DOI 10.1136/gut.51.5.685
   Albertine KH, 1998, LUNG BIOL HEALTH DIS, V116, P37
   Aliotta JM, 2005, J CELL PHYSIOL, V204, P725, DOI 10.1002/jcp.20318
   Ambalavanan N, 2003, PEDIATR RES, V53, P240, DOI 10.1203/01.PDR.0000047656.17766.39
   *ARDSNET, 2000, NEW ENGL J MED, V324, P1301
   Bardales RH, 1996, AM J PATHOL, V149, P845
   Barkefors I, 2008, J BIOL CHEM, V283, P13905, DOI 10.1074/jbc.M704917200
   Bartelt-Hunt SL, 2006, ENVIRON SCI TECHNOL, V40, P4219, DOI 10.1021/es052400y
   Belloni PN, 2000, CHEST, V117, p235S, DOI 10.1378/chest.117.5_suppl_1.235S
   Berthiaume Y, 1999, THORAX, V54, P150, DOI 10.1136/thx.54.2.150
   BITTERMAN PB, 1994, CHEST, V105, pS118, DOI 10.1378/chest.105.3_Supplement.118S
   Blijlevens N, 2007, ANN ONCOL, V18, P817, DOI 10.1093/annonc/mdl332
   Blijlevens N, 2008, J CLIN ONCOL, V26, P1519, DOI 10.1200/JCO.2007.13.6028
   Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371
   Brake R, 2008, MOL CANCER RES, V6, P1337, DOI 10.1158/1541-7786.MCR-07-2131
   BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705
   Brower RG, 2001, CHEST, V120, P1347, DOI 10.1378/chest.120.4.1347
   BROWN R, 2008, 31118 DSTL
   Brown RFR, 1997, INT J EXP PATHOL, V78, P267, DOI 10.1046/j.1365-2613.1997.300363.x
   BROWN RFR, 2006, P AM THORACIC SOC, V3, pA136
   Buckley S, 1998, AM J PHYSIOL-LUNG C, V274, pL714, DOI 10.1152/ajplung.1998.274.5.L714
   Chandrasekher G, 2001, EXP EYE RES, V73, P191, DOI 10.1006/exer.2001.1026
   Chen J, 2005, DIABETES, V54, P2143, DOI 10.2337/diabetes.54.7.2143
   CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603
   COREY JG, 1992, TXB BIOCH CLIN CORRE, P557
   COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P253
   Danan C, 2002, AM J RESP CRIT CARE, V165, P1384, DOI 10.1164/rccm.200112-134BC
   Dasu MRK, 2003, BURNS, V29, P527, DOI 10.1016/S0305-4179(03)00154-2
   Desai TJ, 2001, RESPIR RES, V3, DOI 10.1186/rr169
   Dohi M, 2000, AM J RESP CRIT CARE, V162, P2302, DOI 10.1164/ajrccm.162.6.9908097
   Dorr W, 2005, INT J RADIAT BIOL, V81, P557, DOI 10.1080/09553000500196136
   Dossinger V, 2002, CELL PHYSIOL BIOCHEM, V12, P197, DOI 10.1159/000066279
   DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742
   Driscoll B, 2000, AM J PHYSIOL-LUNG C, V279, pL1191, DOI 10.1152/ajplung.2000.279.6.L1191
   EDELSON JD, 1994, BBA-MOL CELL RES, V1221, P159, DOI 10.1016/0167-4889(94)90008-6
   EVANS MJ, 1973, AM J PATHOL, V70, P175
   Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566
   Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327
   Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943
   Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001
   Fang KC, 2000, AM J RESP CELL MOL, V23, P142, DOI 10.1165/ajrcmb.23.2.f195
   Farrell JJ, 2002, J CLIN INVEST, V109, P193, DOI 10.1172/JCI200212529
   Fehrenbach H, 2000, HISTOCHEM CELL BIOL, V114, P49
   FINEGOLD SM, 1985, AM J MED, V79, P73, DOI 10.1016/0002-9343(85)90132-9
   FINKELSTEIN JN, 1990, TOXICOLOGY, V60, P41
   Finkelstein JN, 1997, ENVIRON HEALTH PERSP, V105, P1179, DOI 10.2307/3433529
   FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607
   FREEMAN W, 1975, ATLAS HISTOLOGY, P102
   Fu XB, 2000, WORLD J GASTROENTERO, V6, P353
   Geiser T, 2003, SWISS MED WKLY, V133, P586
   Geiser T, 2001, AM J RESP CRIT CARE, V163, P1384, DOI 10.1164/ajrccm.163.6.2006131
   Geiser T, 2000, AM J PHYSIOL-LUNG C, V279, pL1184, DOI 10.1152/ajplung.2000.279.6.L1184
   Gerritsen ME, 2005, CIRC RES, V96, P272, DOI 10.1161/01.RES.0000157575.66295.e0
   Gil L, 2007, INFECTION, V35, P421, DOI 10.1007/s15010-007-6350-2
   Gilbert M, 2008, DRUG FUTURE, V33, P515, DOI 10.1358/dof.2008.033.06.1221918
   Gillis P, 1999, J CELL SCI, V112, P2049
   Golpon HA, 2004, FASEB J, V18, P1716, DOI 10.1096/fj.04-1853fje
   GRANT MM, 1992, AM J PHYSIOL, V263, pL370, DOI 10.1152/ajplung.1992.263.3.L370
   GRIFFITHS GD, 1995, HUM EXP TOXICOL, V14, P155, DOI 10.1177/096032719501400201
   Griffiths GD, 1999, VACCINE, V17, P2562, DOI 10.1016/S0264-410X(99)00054-7
   GRIFFITHS GD, 1995, INHAL TOXICOL, V7, P269, DOI 10.3109/08958379509029098
   Griffiths MJD, 2005, LANCET, V366, P249, DOI 10.1016/S0140-6736(05)66916-4
   Guidot DM, 2002, CHEST, V122, p309S, DOI 10.1378/chest.122.6_suppl.309S
   GUYTON A, 1996, TXB MED PHYSL, P187
   Hammond MH, 2006, SENSOR ACTUAT B-CHEM, V116, P135, DOI 10.1016/j.snb.2005.12.065
   Haralson MA, 1997, J LAB CLIN MED, V130, P455, DOI 10.1016/S0022-2143(97)90120-7
   HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115
   Hastings RH, 2000, J CLIN MONITOR COMP, V16, P385, DOI 10.1023/A:1011407820548
   Heger RJ, 1999, J NUTR BIOCHEM, V10, P518, DOI 10.1016/S0955-2863(99)00038-8
   HENEMYREHARRIS CL, 2008, EPLASTY, V8, P136
   Hermans C, 1999, AM J RESP CRIT CARE, V159, P646, DOI 10.1164/ajrccm.159.2.9806064
   HINDS CJ, 1996, INTENSIVE CARE CONCI, P26
   Hoffmann W, 2005, CELL MOL LIFE SCI, V62, P2932, DOI 10.1007/s00018-005-5481-9
   Hoffmann W, 2004, PEPTIDES, V25, P727, DOI 10.1016/j.peptides.2004.03.019
   Hossain WA, 2008, J NEUROSCI RES, V86, P2376, DOI 10.1002/jnr.21685
   HUDSON LD, 1999, CHEST S1, V116, P74
   Jaffre S, 2002, AM J PHYSIOL-LUNG C, V282, pL310, DOI 10.1152/ajplung.00121.2001
   Jain R, 2006, MAYO CLIN PROC, V81, P205, DOI 10.4065/81.2.205
   Jansen A, 2004, INVEST OPHTH VIS SCI, V45, pU554
   Jardin F, 1999, INTENS CARE MED, V25, P936, DOI 10.1007/s001340050985
   JEFFERIES A, 1999, CRASH COURSE RESP SY, P203
   Jeffery PK, 1998, THORAX, V53, P129, DOI 10.1136/thx.53.2.129
   JIANG WG, 1993, BRIT J SURG, V80, P1368, DOI 10.1002/bjs.1800801104
   Jimenez PA, 1999, J SURG RES, V81, P238, DOI 10.1006/jsre.1998.5501
   Johnston CJ, 1996, RADIAT RES, V145, P762, DOI 10.2307/3579368
   Johnston CJ, 2002, RADIAT RES, V157, P256, DOI 10.1667/0033-7587(2002)157[0256:RIPFEO]2.0.CO;2
   KAISHI NK, 1998, J JPN RESP SOC, V36, P413
   Kakazu A, 2004, INVEST OPHTH VIS SCI, V45, P3485, DOI 10.1167/iovs.04-0372
   Kalabis J, 2006, J BIOL CHEM, V281, P6434, DOI 10.1074/jbc.M512905200
   Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779
   KAPANCI Y, 1969, LAB INVEST, V20, P101
   Khan A, 2007, CRIT CARE, V11, DOI 10.1186/cc6135
   Kim JC, 2005, INDIAN J BIOCHEM BIO, V42, P358
   Kotton DN, 2004, EXP HEMATOL, V32, P340, DOI 10.1016/j.exphem.2004.01.009
   Krein PM, 2002, CHEST, V122, p289S, DOI 10.1378/chest.122.6_suppl.289S
   KUHN C, 1991, CHEST, V99, pS11, DOI 10.1378/chest.99.3.11S
   KUMAR NM, 1995, EXP CELL RES, V221, P385, DOI 10.1006/excr.1995.1389
   KUMAR RK, 1995, PATHOLOGY, V27, P18, DOI 10.1080/00313029500169402
   Kumar VH, 2004, FRONT BIOSCI-LANDMRK, V9, P464, DOI 10.2741/1245
   Lassus P, 1999, AM J RESP CRIT CARE, V159, P1429, DOI 10.1164/ajrccm.159.5.9806073
   Lassus P, 2001, AM J RESP CRIT CARE, V164, P1981, DOI 10.1164/ajrccm.164.10.2012036
   Laufs U, 2004, CIRCULATION, V109, P220, DOI 10.1161/01.CIR.0000109141.48980.37
   Le Cras TD, 2004, AM J PHYSIOL-LUNG C, V287, pL134, DOI 10.1152/ajplung.00050.2004
   Lee J, 2006, AM J PHYSIOL-LUNG C, V290, pL685, DOI 10.1152/ajplung.00020.2005
   LEITCH AG, 1976, COMPANION MED STUDIE
   LESLIE CC, 1990, AM J RESP CELL MOL, V2, P99, DOI 10.1165/ajrcmb/2.1.99
   Lesur O, 1999, Can Respir J, V6, P71
   LESUR O, 1996, AM J PHYSIOL, V14, pL311
   LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218
   Li CM, 2000, AM J PHYSIOL-LUNG C, V279, pL1038, DOI 10.1152/ajplung.2000.279.6.L1038
   Lian XM, 2005, J IMMUNOL, V174, P7250, DOI 10.4049/jimmunol.174.11.7250
   Loncar MB, 2003, GUT, V52, P1297, DOI 10.1136/gut.52.9.1297
   Ludovini V, 2004, LUNG CANCER, V46, P77, DOI 10.1016/j.lungcan.2004.03.018
   LWEBUGAMUKASA JS, 1991, AM REV RESPIR DIS, V144, P452, DOI 10.1164/ajrccm/144.2.452
   Mallamaci F, 2008, J HYPERTENS, V26, P1875, DOI 10.1097/HJH.0b013e328307c3d2
   Markowicz P, 2000, AM J RESP CRIT CARE, V161, P1942, DOI 10.1164/ajrccm.161.6.9909122
   MARTIN J, 2008, BRIT NATL FORMULARY, P451
   Martinet Y, 1996, REV MAL RESPIR, V13, P123
   MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x
   MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250
   MAYER E, 1992, J THORAC CARDIOV SUR, V104, P180
   MCCORMACK FX, 1998, INTERSTITIAL LUNG DI, P165
   McGowan SE, 2002, CHEST, V121, p206S, DOI 10.1378/chest.121.5_suppl.206S
   Mendez JL, 2005, CURR OPIN CRIT CARE, V11, P29, DOI 10.1097/00075198-200502000-00005
   *MERCK, 2005, MERCK AC LUNG INJ AC
   METZLER DE, 1977, BIOCH CHEM REACTIONS, P958
   MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5
   MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306
   Nabeyrat E, 1998, AM J PHYSIOL-LUNG C, V275, pL71, DOI 10.1152/ajplung.1998.275.1.L71
   Nabeyrat E, 2000, AM J PHYSIOL-LUNG C, V278, pL42, DOI 10.1152/ajplung.2000.278.1.L42
   NALDINI L, 1991, ONCOGENE, V6, P501
   Nici L, 1996, AM J PHYSIOL-LUNG C, V270, pL242, DOI 10.1152/ajplung.1996.270.2.L242
   NIEMAN GF, 1981, J APPL PHYSIOL, V51, P895, DOI 10.1152/jappl.1981.51.4.895
   NOONE MR, 1983, BRIT MED J, V286, P341, DOI 10.1136/bmj.286.6362.341
   Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429
   Okada M, 2004, PEDIATR RES, V56, P336, DOI 10.1203/01.PDR.0000134255.58638.59
   PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250
   Panoskaltsis-Mortari A, 2000, AM J PHYSIOL-LUNG C, V278, pL988, DOI 10.1152/ajplung.2000.278.5.L988
   Parkhouse DA, 2003, CRIT CARE MED, V31, pA101
   Parkhouse DA, 2007, MIL MED, V172, P295, DOI 10.7205/MILMED.172.3.295
   Perkett Elizabeth Ann, 1995, Current Opinion in Pediatrics, V7, P242, DOI 10.1097/00008480-199506000-00002
   Piedboeuf B, 1996, AM J RESP CELL MOL, V15, P71, DOI 10.1165/ajrcmb.15.1.8679224
   PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0
   Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   PLOPPER CG, 1992, AM J PHYSIOL, V262, pL313, DOI 10.1152/ajplung.1992.262.3.L313
   POLLARD TD, 2002, CELL BIOL, P673
   Portnoy J, 2004, AM J RESP CELL MOL, V30, P901, DOI 10.1165/rcmb.2003-0406OC
   RAABERG L, 1992, AM J RESP CELL MOL, V6, P44, DOI 10.1165/ajrcmb/6.1.44
   Reynolds LJ, 1999, INT J BIOCHEM CELL B, V31, P951, DOI 10.1016/S1357-2725(99)00052-7
   Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com
   Roper JM, 2004, AM J PHYSIOL-LUNG C, V286, pL1045, DOI 10.1152/ajplung.00376.2003
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B
   RYAN RM, 1994, AM J PHYSIOL, V266, pL17, DOI 10.1152/ajplung.1994.266.1.L17
   Sadovski J, 2008, EUR RESPIR J, V31, P21, DOI 10.1183/09031936.00011707
   Savla U, 1998, AM J PHYSIOL-LUNG C, V274, pL883, DOI 10.1152/ajplung.1998.274.6.L883
   Schrey D, 2008, MONATSSCHR KINDERH, V156, P375, DOI 10.1007/s00112-008-1720-0
   SCHUSTER DP, 1995, INTENS CARE MED, V21, P101, DOI 10.1007/BF01726530
   Schwarze PE, 2000, TOXICOL LETT, V112, P165, DOI 10.1016/S0378-4274(99)00280-5
   Sessler CN, 1998, CRIT CARE CLIN, V14, P707, DOI 10.1016/S0749-0704(05)70027-0
   Shanker G, 1999, CELL BIOL INT, V23, P61, DOI 10.1006/cbir.1998.0325
   Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Siu D, 2004, MED HYPOTHESES, V63, P62, DOI 10.1016/j.mehy.2004.01.031
   Skibinski G, 2001, EUR J CANCER, V37, P1562, DOI 10.1016/S0959-8049(01)00164-2
   Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017
   Stern JB, 2003, REV MAL RESPIR, V20, P896
   Stevens TP, 1997, AM J PHYSIOL-LUNG C, V272, pL486, DOI 10.1152/ajplung.1997.272.3.L486
   STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0
   STRANDJORD TP, 1995, PEDIATR RES, V38, P851, DOI 10.1203/00006450-199512000-00005
   Sugahara K, 1998, INTENS CARE MED, V24, P434, DOI 10.1007/s001340050592
   Sugahara K, 1998, CELL TISSUE RES, V291, P295, DOI 10.1007/s004410050999
   Takeoka M, 1997, AM J PHYSIOL-LUNG C, V272, pL1174, DOI 10.1152/ajplung.1997.272.6.L1174
   Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763
   Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622
   Tsirigotis P, 2008, BONE MARROW TRANSPL, V42, P337, DOI 10.1038/bmt.2008.168
   Tuder RM, 2003, AM J RESP CELL MOL, V28, P551, DOI 10.1165/rcmb.F269
   Uhal BD, 1997, AM J PHYSIOL-LUNG C, V272, pL1031, DOI 10.1152/ajplung.1997.272.6.L1031
   ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086
   Ulrich K, 2005, AM J PHYSIOL-LUNG C, V288, pL1179, DOI 10.1152/ajplung.00450.2004
   VACCARO CA, 1981, J CELL BIOL, V91, P427, DOI 10.1083/jcb.91.2.427
   Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111
   Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005
   Warburton D, 2001, AM J RESP CRIT CARE, V164, pS59, DOI 10.1164/ajrccm.164.supplement_2.2106064
   Warburton D, 1998, BIOCHEM CELL BIOL, V76, P971, DOI 10.1139/bcb-76-6-971
   Ware LB, 2001, NATO SCI SER I LIFE, V336, P103
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Waters CM, 1999, J CELL PHYSIOL, V181, P424, DOI 10.1002/(SICI)1097-4652(199912)181:3<424::AID-JCP6>3.0.CO;2-Z
   WEIBEL ER, 1988, PULMONARY DIS DISORD, P11
   WHEATER PR, 1987, FUNCTIONAL HISTOLOGY, P187
   Whitsett JA, 1996, CLIN PERINATOL, V23, P753, DOI 10.1016/S0095-5108(18)30207-0
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Wilson SE, 1999, EXP EYE RES, V68, P377, DOI 10.1006/exer.1998.0603
   Wilson SE, 1999, INVEST OPHTH VIS SCI, V40, P2185
   WITSCHI H, 1991, CHEST, V99, pS22, DOI 10.1378/chest.99.3.22S
   WOLF HK, 1991, HEPATOLOGY, V14, P488, DOI 10.1002/hep.1840140314
   Wright TW, 1997, AM J RESP CELL MOL, V17, P491, DOI 10.1165/ajrcmb.17.4.2851
   WU KI, 1998, AM J PHYSIOL, V19, pL780
   Wu M, 2002, AM J RESP CRIT CARE, V166, P192, DOI 10.1164/rccm.200112-130OC
   Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277
   YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X
   YAO JL, 1995, CELL MOL BIOL RES, V41, P17
   Yi ES, 1996, AM J PATHOL, V149, P1963
   YOO J, 2002, FRONTIERS GASTROINTE, V25, P14
   Zahm JM, 2000, J CELL PHYSIOL, V185, P447, DOI 10.1002/1097-4652(200012)185:3<447::AID-JCP16>3.0.CO;2-D
   Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134
   Zgleszewski SE, 1999, J PEDIATR SURG, V34, P1187, DOI 10.1016/S0022-3468(99)90150-1
   Zilberberg MD, 2008, CRIT CARE MED, V36, P1451, DOI 10.1097/CCM.0b013e3181691a49
   2004, DRUGS R D, V5, P351
NR 214
TC 21
Z9 24
U1 0
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD JUL
PY 2011
VL 30
IS 7
BP 701
EP 724
DI 10.1177/0960327110376982
PG 24
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 780WV
UT WOS:000291891200020
PM 20621953
OA Bronze
DA 2023-08-21
ER

PT J
AU Makarova, AM
   Lebedeva, TV
   Nassar, T
   Higazi, AA
   Xue, J
   Carinato, ME
   Bdeir, K
   Cines, DB
   Stepanova, V
AF Makarova, Anastasia M.
   Lebedeva, Tatiana V.
   Nassar, Taher
   Higazi, Abd Al-Roof
   Xue, Jing
   Carinato, Maria E.
   Bdeir, Khalil
   Cines, Douglas B.
   Stepanova, Victoria
TI Urokinase-type Plasminogen Activator (uPA) Induces Pulmonary
   Microvascular Endothelial Permeability through Low Density Lipoprotein
   Receptor-related Protein (LRP)-dependent Activation of Endothelial
   Nitric-oxide Synthase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; KINASE-A PHOSPHORYLATION;
   BLOOD-BRAIN-BARRIER; ACUTE LUNG INJURY; FIBRIN DEPOSITION;
   ADENYLYL-CYCLASE; CELL BARRIER; VASCULAR-PERMEABILITY; MEDIATED
   ENDOCYTOSIS; ISCHEMIA-REPERFUSION
AB Urokinase plasminogen activator (uPA) and PA inhibitor type 1 (PAI-1) are elevated in acute lung injury, which is characterized by a loss of endothelial barrier function and the development of pulmonary edema. Two-chain uPA and uPA-PAI-1 complexes (1-20 nM) increased the permeability of monolayers of human pulmonary microvascular endothelial cells (PMVECs) in vitro and lung permeability in vivo. The effects of uPA-PAI-1 were abrogated by the nitric-oxide synthase (NOS) inhibitor L-NAME (N-D-nitro-L-arginine methyl ester). Two-chain uPA (1-20 nM) and uPA-PAI-1 induced phosphorylation of endothelial NOS-Ser(1177) in PMVECs, which was followed by generation of NO and the nitrosylation and dissociation of beta-catenin from VE-cadherin. uPA-induced phosphorylation of eNOS was decreased by anti-low density lipoprotein receptor-related protein-1 (LRP) antibody and an LRP antagonist, receptor-associated protein (RAP), and when binding to the uPA receptor was blocked by the isolated growth factor-like domain of uPA. uPA-induced phosphorylation of eNOS was also inhibited by the protein kinase A (PKA) inhibitor, myristoylated PKI, but was not dependent on PI3K-Akt signaling. LRP blockade and inhibition of PKA prevented uPA- and uPA-PAI-1-induced permeability of PMVEC monolayers in vitro and uPA-induced lung permeability in vivo. These studies identify a novel pathway involved in regulating PMVEC permeability and suggest the utility of uPA-based approaches that attenuate untoward permeability following acute lung injury while preserving its salutary effects on fibrinolysis and airway remodeling.
C1 [Makarova, Anastasia M.; Lebedeva, Tatiana V.; Higazi, Abd Al-Roof; Xue, Jing; Carinato, Maria E.; Bdeir, Khalil; Cines, Douglas B.; Stepanova, Victoria] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104, United States.
C1 [Nassar, Taher; Higazi, Abd Al-Roof] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Clin Biochem, IL-91120 Jerusalem, Israel.
C1 [Xue, Jing] Tianjin Huanhu Hosp, Dept Lab Med, Tianjin 300060, China.
C3 University of Pennsylvania; Hebrew University of Jerusalem; Hadassah
   University Medical Center
RP Stepanova, V (corresponding author), 512 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM vstepano@mail.med.upenn.edu
FU National Institutes of Health [HL-077760, 5T32 HL07971-07,
   NS053410-04S1, HD057355, HL076406, CA141228]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants HL-077760 (to A. A. H.), 5T32 HL07971-07, NS053410-04S1,
   HD057355, and HL076406 (to D. B. C.), and CA141228 (to V. S.).
CR Abraham E, 2003, J IMMUNOL, V170, P5644, DOI 10.4049/jimmunol.170.11.5644
   ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
   Armstead WM, 2008, J NEUROTRAUM, V25, P1375, DOI 10.1089/neu.2008.0666
   Armstead WM, 2005, STROKE, V36, P2265, DOI 10.1161/01.STR.0000181078.74698.b0
   Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Barazzone C, 1996, J CLIN INVEST, V98, P2666, DOI 10.1172/JCI119089
   BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Bdeir K, 2003, BLOOD, V102, P3600, DOI 10.1182/blood-2003-03-0949
   Bdeir K, 2010, AM J RESP CRIT CARE, V181, P935, DOI 10.1164/rccm.200907-1128OC
   Behzadian MA, 2003, FASEB J, V17, P752, DOI 10.1096/fj.02-0484fje
   Bindewald K, 2004, AM J PHYSIOL-CELL PH, V287, pC1246, DOI 10.1152/ajpcell.00132.2004
   Birukova AA, 2007, MICROVASC RES, V73, P173, DOI 10.1016/j.mvr.2006.12.004
   Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009
   Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977
   Bogatcheva NV, 2009, J CELL PHYSIOL, V221, P750, DOI 10.1002/jcp.21913
   BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2
   Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095
   Bucci M, 2005, P NATL ACAD SCI USA, V102, P904, DOI 10.1073/pnas.0408906102
   Cate JM, 2007, CURR DRUG TARGETS, V8, P971, DOI 10.2174/138945007781662337
   Chen HI, 2003, J BIOMED SCI, V10, P588, DOI 10.1159/000073523
   Cioffi DL, 2002, J CELL BIOL, V157, P1267, DOI 10.1083/jcb.200204022
   CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609
   Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467
   Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x
   Di Lorenzo A, 2009, P NATL ACAD SCI USA, V106, P14552, DOI 10.1073/pnas.0904073106
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139
   Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381
   Goretzki L, 1997, J CELL SCI, V110, P1395
   Hardaway RM, 2001, AM SURGEON, V67, P377
   Herz J, 2003, J CLIN INVEST, V112, P1483, DOI 10.1172/JCI200320337
   Hiroi YK, 2008, FASEB J, V22, P1450, DOI 10.1096/fj.07-9309com
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   IDELL S, 1989, J CLIN INVEST, V84, P695, DOI 10.1172/JCI114217
   Idell S, 1994, New Horiz, V2, P566
   IDELL S, 1991, AM REV RESPIR DIS, V144, P187, DOI 10.1164/ajrccm/144.1.187
   ISCHIROPOULOS H, 1994, AM J RESP CRIT CARE, V150, P337, DOI 10.1164/ajrccm.150.2.8049812
   Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672
   Kao SJ, 2003, J BIOMED SCI, V10, P58, DOI 10.1159/000068090
   KASAI S, 1985, J BIOL CHEM, V260, P2377
   Klein RC, 1999, NEUROSCI LETT, V273, P171, DOI 10.1016/S0304-3940(99)00649-7
   Kondrikov D, 2006, AM J PHYSIOL-LUNG C, V290, pL41, DOI 10.1152/ajplung.00444.2004
   KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611
   Kuramoto E, 2009, AM J PHYSIOL-LUNG C, V296, pL337, DOI 10.1152/ajplung.90434.2008
   Lardot CG, 1998, AM J RESP CRIT CARE, V157, P617, DOI 10.1164/ajrccm.157.2.9707052
   LASZLO F, 1995, EUR J PHARMACOL, V283, P47, DOI 10.1016/0014-2999(95)00281-O
   Lee NPY, 2003, ENDOCRINOLOGY, V144, P3114, DOI 10.1210/en.2002-0167
   LI H, 1994, J BIOL CHEM, V269, P8153
   Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001
   Loskutoff DJ, 2000, J CLIN INVEST, V106, P1441, DOI 10.1172/JCI11765
   MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647
   Martins-Green M, 2008, METHOD ENZYMOL, V443, P137, DOI 10.1016/S0076-6879(08)02008-9
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203
   Mundy AL, 2000, BRIT J ANAESTH, V85, P570, DOI 10.1093/bja/85.4.570
   Nagata K, 2003, CHEST, V124, P2293, DOI 10.1378/chest.124.6.2293
   Namiki A, 1992, JPN J PHARM S2, V58, p326P
   Nassar T, 2002, J BIOL CHEM, V277, P40499, DOI 10.1074/jbc.M207172200
   Nassar T, 2010, AM J RESP CELL MOL, V43, P703, DOI 10.1165/rcmb.2009-0257OC
   NEUHOF H, 1986, RESUSCITATION, V14, P23, DOI 10.1016/0300-9572(86)90004-3
   NYKJAER A, 1994, J BIOL CHEM, V269, P25668
   NYKJAER A, 1992, J BIOL CHEM, V267, P14543
   Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307
   PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006
   Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125
   Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946
   Rampersad SN, 2010, J BIOL CHEM, V285, P33614, DOI 10.1074/jbc.M110.140004
   Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147
   Samson AL, 2006, NEURON, V50, P673, DOI 10.1016/j.neuron.2006.04.013
   Sayner SL, 2006, CIRC RES, V98, P675, DOI 10.1161/01.RES.0000209516.84815.3e
   SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4
   SEEKAMP A, 1993, AM J PATHOL, V142, P1217
   Shetty S, 2008, AM J PHYSIOL-LUNG C, V295, pL967, DOI 10.1152/ajplung.90349.2008
   STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043
   Stepanova V, 2008, BLOOD, V112, P100, DOI 10.1182/blood-2007-07-104455
   Sugiura H, 1999, AM J RESP CRIT CARE, V160, P663, DOI 10.1164/ajrccm.160.2.9807160
   Symons JD, 2009, CIRC RES, V104, P1085, DOI 10.1161/CIRCRESAHA.108.189316
   Tarui T, 2006, THROMB HAEMOSTASIS, V95, P524, DOI 10.1160/TH05-06-0457
   Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013
   Thom SR, 2008, J BIOL CHEM, V283, P10822, DOI 10.1074/jbc.M709200200
   Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7
   Umapathy NS, 2010, J CELL PHYSIOL, V223, P215, DOI 10.1002/jcp.22029
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Waschke J, 2004, AM J PHYSIOL-HEART C, V287, pH2427, DOI 10.1152/ajpheart.00556.2004
   Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741
   WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035
   Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212
   Zhu B, 2010, AM J PHYSIOL-LUNG C, V299, pL493, DOI 10.1152/ajplung.00431.2009
NR 92
TC 16
Z9 18
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 1
PY 2011
VL 286
IS 26
BP 23044
EP 23053
DI 10.1074/jbc.M110.210195
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 782QP
UT WOS:000292025000039
PM 21540184
OA hybrid, Green Published
DA 2023-08-21
ER

PT J
AU Wang, L
   Chiang, ET
   Simmons, JT
   Garcia, JGN
   Dudek, SM
AF Wang, L.
   Chiang, Eddie T.
   Simmons, J. T.
   Garcia, Joe G. N.
   Dudek, Steven M.
TI FTY720-induced human pulmonary endothelial barrier enhancement is
   mediated by c-Abl
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
DE c-Abl; FTY720; junctional complexes; ECs/HPMECs/HUVECs/MPVECs; permeability 
ID RELAPSING MULTIPLE-SCLEROSIS; ADHERENS JUNCTION PROTEINS; FOCAL ADHESION
   KINASE; LIGHT-CHAIN KINASE; ACUTE LUNG INJURY; SPHINGOSINE 1-PHOSPHATE;
   TYROSINE KINASES; TIGHT JUNCTIONS; LYMPHOCYTIC-LEUKEMIA; VASCULAR
   HOMEOSTASIS
AB Strategies to improve pulmonary endothelial barrier function are needed to reverse the devastating effects of vascular leak in acute respiratory distress syndrome. FTY720 is a pharmaceutical analogue of the potent barrier-enhancing phospholipid sphingosine 1-phosphate (S1P). FTY720 decreases vascular permeability by an incompletely characterised mechanism that differs from S1P. Here, we describe its barrier-promoting effects on intracellular signalling and junctional assembly formation in human pulmonary endothelium.
   Permeability of cultured human pulmonary endothelial cells was assessed using transendothelial electrical resistance and dextran transwell assays. Junctional complex formation was assessed using membrane fractionation and immunofluorescence. Pharmacological inhibitors and small interfering (si) RNA were utilised to determine the effects of individual components on permeability.
   Unlike S1P, FTY720 failed to induce membrane translocation of adherens junction or tight junction proteins. beta-catenin, occludin, claudin-5 or zona occludens protein (ZO)-1/ZO-2 siRNAs did not alter FTY720-induced barrier enhancement. FTY720 induced focal adhesion kinase (FAK) phosphorylation and focal adhesion formation, with FAK siRNA partially attenuating the prolonged phase of barrier enhancement. Inhibition of Src, protein kinase (PK)A, PKG, PKC or protein phosphatase 2A failed to alter FTY720-induced barrier enhancement. FTY720 increased c-Abl tyrosine kinase activity and c-Abl siRNA attenuated peak barrier enhancement after FTY720.
   FTY720 enhances endothelial barrier function by a novel pathway involving c-Abl signalling.
C1 [Wang, L.; Chiang, E. T.; Simmons, J. T.; Garcia, J. G. N.; Dudek, S. M.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Coll Med, Inst Personalized Resp Med, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Dudek, SM (corresponding author), Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Coll Med, Inst Personalized Resp Med, COMRB 3143,MC 719,909 S Wolcott Ave, Chicago, IL 60612 USA.
EM sdudek@uic.edu
RI wang, lichun/D-3969-2013; Garcia, Joe GN/E-8862-2010
FU National Heart Lung Blood Institute (NIH) [P01 HL 58064, R01 HL 88144]
FX This work was supported by grants from the National Heart Lung Blood
   Institute (NIH grants P01 HL 58064 (J.G.N. Garcia) and R01 HL 88144 (S.
   M. Dudek)).
CR Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057
   Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859
   Braren R, 2006, J CELL BIOL, V172, P151, DOI 10.1083/jcb.200506184
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839
   Dudek SM, 2007, CELL SIGNAL, V19, P1754, DOI 10.1016/j.cellsig.2007.03.011
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876
   Farhadi A, 2006, J PHARMACOL EXP THER, V316, P1, DOI 10.1124/jpet.105.085449
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Garcia JGN, 2000, J APPL PHYSIOL, V89, P2333, DOI 10.1152/jappl.2000.89.6.2333
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Harrington EO, 2005, EXP CELL RES, V308, P407, DOI 10.1016/j.yexcr.2005.05.005
   HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327
   Huang XD, 2008, J CELL BIOL, V183, P711, DOI 10.1083/jcb.200801192
   Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494
   Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7
   Lee JF, 2006, J BIOL CHEM, V281, P29190, DOI 10.1074/jbc.M604310200
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Liu Q, 2008, BLOOD, V111, P275, DOI 10.1182/blood-2006-10-053884
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Matsubara T, 2006, J BONE MINER METAB, V24, P368, DOI 10.1007/s00774-006-0701-4
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Moldobaeva A, 2006, AM J PHYSIOL-LUNG C, V290, pL919, DOI 10.1152/ajplung.00434.2005
   Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185
   Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241
   Rentsendorj O, 2008, AM J PHYSIOL-LUNG C, V294, pL686, DOI 10.1152/ajplung.00417.2007
   Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sarai K, 2009, AM J PHYSIOL-CELL PH, V297, pC945, DOI 10.1152/ajpcell.00606.2008
   Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com
   Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200
   Sun XG, 2009, MICROVASC RES, V77, P304, DOI 10.1016/j.mvr.2008.12.004
   Tar K, 2006, J CELL BIOCHEM, V98, P931, DOI 10.1002/jcb.20829
   Troyanovsky B, 2008, AM J PHYSIOL-LUNG C, V294, pL266, DOI 10.1152/ajplung.00107.2007
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016
   VANITALLIE CM, 2004, P AM THORAC SOC, V1, P138
   Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003
   Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005
   Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434
   Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622
   Wu MH, 2005, J PHYSIOL-LONDON, V569, P359, DOI 10.1113/jphysiol.2005.096537
   Wu SW, 2005, CIRC RES, V96, P856, DOI 10.1161/01.RES.0000163632.67282.1f
   Xu M, 2007, AM J PHYSIOL-CELL PH, V293, pC1309, DOI 10.1152/ajpcell.00014.2007
   Zandy NL, 2007, P NATL ACAD SCI USA, V104, P17686, DOI 10.1073/pnas.0703077104
NR 54
TC 44
Z9 45
U1 0
U2 6
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUL
PY 2011
VL 38
IS 1
BP 78
EP 88
DI 10.1183/09031936.00047810
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA 785RW
UT WOS:000292247700013
PM 21071472
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Bertok, S
   Wilson, MR
   Dorr, AD
   Dokpesi, JO
   O'Dea, KP
   Marczin, N
   Takata, M
AF Bertok, Szabolcs
   Wilson, Michael R.
   Dorr, Anthony D.
   Dokpesi, Justina O.
   O'Dea, Kieran P.
   Marczin, Nandor
   Takata, Masao
TI Characterization of TNF receptor subtype expression and signaling on
   pulmonary endothelial cells in mice
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE cytokines; adhesion molecules; Inflammation; flow cytometry; LPS 
ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FACTOR-ALPHA; SEPTIC SHOCK;
   MONOCLONAL-ANTIBODY; DOUBLE-BLIND; INFLAMMATORY CYTOKINES; PERSISTENT
   ELEVATION; FUNCTIONAL-ANALYSIS; EDEMA REABSORPTION
AB Bertok S, Wilson MR, Dorr AD, Dokpesi JO, O'Dea KP, Marczin N, Takata M. Characterization of TNF receptor subtype expression and signaling on pulmonary endothelial cells in mice. Am J Physiol Lung Cell Mol Physiol 300: L781-L789, 2011. First published March 4, 2011; doi:10.1152/ajplung.00326.2010.-TNF plays a crucial role in the pathogenesis of acute lung injury. However, the expression profile of its two receptors, p55 and p75, on pulmonary endothelium and their influence on TNF signaling during lung microvascular inflammation remain uncertain. Using flow cytometry, we characterized the expression profile of TNF receptors on the surface of freshly harvested pulmonary endothelial cells (PECs) from mice and found expression of both receptors with dominance of p55. To investigate the impact of stimulating individual TNF receptors, we treated wild-type and TNF receptor knockout mice with intravenous TNF and determined surface expression of adhesion molecules (E-selectin, VCAM-1, ICAM-1) on PECs by flow cytometry. TNF-induced upregulation of all adhesion molecules was substantially attenuated by absence of p55, whereas lack of p75 had a similar but smaller effect that varied between adhesion molecules. Selective blockade of individual TNF receptors by specific antibodies in wild-type primary PEC culture confirmed that the in vivo findings were due to direct effects of TNF receptor inhibition on endothelium and not other cells (e. g., circulating leukocytes). Finally, we found that PEC surface expression of p55 dramatically decreased in the early stages of endotoxemia following intravenous LPS, while no change in p75 expression was detected. These data demonstrate a crucial in vivo role of p55 and an auxiliary role of p75 in TNF-mediated adhesion molecule upregulation on PECs. It is possible that the importance of the individual receptors varies at different stages of pulmonary microvascular inflammation following changes in their relative expression.
C1 [Bertok, Szabolcs; Wilson, Michael R.; Dorr, Anthony D.; Dokpesi, Justina O.; O'Dea, Kieran P.; Marczin, Nandor; Takata, Masao] Univ London Imperial Coll Sci Technol & Med, Sect Anaesthet Pain Med & Intens Care, Chelsea & Westminster Hosp, Fac Med, London SW10 9NH, England, United Kingdom.
C3 Imperial College London
RP Takata, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Anaesthet Pain Med & Intens Care, Chelsea & Westminster Hosp, Fac Med, 369 Fulham Rd, London SW10 9NH, England.
EM m.takata@imperial.ac.uk
FU Wellcome Trust [081208]; Biotechnology and Biological Sciences Research
   Council UK [D01820X]
FX This study was supported by grants from the Wellcome Trust (no. 081208)
   and Biotechnology and Biological Sciences Research Council UK (no.
   D01820X).
CR ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934
   Abraham E, 1998, LANCET, V351, P929
   Abraham E, 2001, CRIT CARE MED, V29, P503, DOI 10.1097/00003246-200103000-00006
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Al-Lamki RS, 2009, AM J TRANSPLANT, V9, P2679, DOI 10.1111/j.1600-6143.2009.02831.x
   Al-Lamki RS, 2005, FASEB J, V19, P1637, DOI 10.1096/fj.05-3841com
   Braun C, 2005, J IMMUNOL, V175, P3402, DOI 10.4049/jimmunol.175.5.3402
   Calkins CM, 2001, J SURG RES, V101, P232, DOI 10.1006/jsre.2001.6274
   Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935
   Chandrasekharan UM, 2007, BLOOD, V109, P1938, DOI 10.1182/blood-2006-05-020875
   Cohen J, 1996, CRIT CARE MED, V24, P1431, DOI 10.1097/00003246-199609000-00002
   Davidson BA, 1999, ANESTHESIOLOGY, V91, P486, DOI 10.1097/00000542-199908000-00024
   DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   Dri P, 1999, J IMMUNOL, V162, P460
   Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165
   Ebach DR, 2005, INFLAMM BOWEL DIS, V11, P533, DOI 10.1097/01.MIB.0000163698.34592.30
   Ebach DR, 2005, SHOCK, V23, P311, DOI 10.1097/01.shk.0000157301.87051.77
   Elia N, 2003, AM J RESP CRIT CARE, V168, P1043, DOI 10.1164/rccm.200206-618OC
   Ermert M, 2003, CYTOKINE, V22, P89, DOI 10.1016/S1043-4666(03)00117-0
   Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603
   Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002
   Fukuda N, 2001, AM J PHYSIOL-LUNG C, V280, pL1258, DOI 10.1152/ajplung.2001.280.6.L1258
   Gebb S, 2004, MICROVASC RES, V68, P1, DOI 10.1016/j.mvr.2004.02.002
   Gordon AC, 2004, GENES IMMUN, V5, P631, DOI 10.1038/sj.gene.6364136
   Grau GE, 1996, LAB INVEST, V74, P761
   Hart PH, 1996, J IMMUNOL, V157, P3672
   HIGUCHI M, 1994, J IMMUNOL, V152, P3550
   Higuchi Y, 2004, CIRCULATION, V109, P1892, DOI 10.1161/01.CIR.0000124227.00670.AB
   Joyce DA, 1997, IMMUNOL CELL BIOL, V75, P345, DOI 10.1038/icb.1997.53
   Jupp OJ, 2001, BIOCHEM J, V359, P525, DOI 10.1042/0264-6021:3590525
   King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006
   Krunkosky TM, 2005, AM J RESP CELL MOL, V33, P483, DOI 10.1165/rcmb.2005-0069OC
   Lacherade JC, 2001, AM J PHYSIOL-LUNG C, V281, pL134, DOI 10.1152/ajplung.2001.281.1.L134
   LEEUWENBERG JFM, 1995, CYTOKINE, V7, P457, DOI 10.1006/cyto.1995.0062
   MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5
   MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277
   Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200
   McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7
   MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Muller AM, 2002, EXP MOL PATHOL, V72, P221, DOI 10.1006/exmp.2002.2424
   Neumann B, 1996, J IMMUNOL, V156, P1587
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   O'Dea KP, 2005, AM J RESP CRIT CARE, V172, P1119, DOI 10.1164/rccm.200504-605OC
   PALEOLOG EM, 1994, BLOOD, V84, P2578
   Parsons PE, 2005, AM J PHYSIOL-LUNG C, V288, pL426, DOI 10.1152/ajplung.00302.2004
   PATEL BV, 2008, EUR RESPIR J, V32, pS280
   Peschon JJ, 1998, J IMMUNOL, V160, P943
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168
   PORTEU F, 1994, J BIOL CHEM, V269, P2834
   PORTEU F, 1991, J BIOL CHEM, V266, P18846
   PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599
   Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005
   Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608
   SCHLEIFFENBAUM B, 1990, J CLIN INVEST, V86, P184, DOI 10.1172/JCI114683
   SLOWIK MR, 1993, AM J PATHOL, V143, P1724
   THORP KM, 1992, CYTOKINE, V4, P313, DOI 10.1016/1043-4666(92)90072-Y
   vanderPoll T, 1997, J IMMUNOL, V158, P1490
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Wilson MR, 2007, AM J PHYSIOL-LUNG C, V293, pL60, DOI 10.1152/ajplung.00284.2006
   Wilson MR, 2005, AM J PHYSIOL-LUNG C, V288, pL599, DOI 10.1152/ajplung.00304.2004
   Wu SW, 2005, CIRC RES, V96, P856, DOI 10.1161/01.RES.0000163632.67282.1f
   Xanthoulea S, 2004, J EXP MED, V200, P367, DOI 10.1084/jem.20040435
   Zhou ZG, 2007, CELL SIGNAL, V19, P1238, DOI 10.1016/j.cellsig.2006.12.013
NR 67
TC 22
Z9 23
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2011
VL 300
IS 5
BP L781
EP L789
DI 10.1152/ajplung.00326.2010
PG 9
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 757MF
UT WOS:000290088800012
PM 21378027
OA Green Published, Green Submitted
DA 2023-08-21
ER

PT J
AU Ruchko, MV
   Gorodnya, OM
   Zuleta, A
   Pastukh, VM
   Gillespie, MN
AF Ruchko, Mykhaylo V.
   Gorodnya, Olena M.
   Zuleta, Andres
   Pastukh, Viktor M.
   Gillespie, Mark N.
TI The DNA glycosylase Ogg1 defends against oxidant-induced mtDNA damage
   and apoptosis in pulmonary artery endothelial cells
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE ROS; Mitochondrial DNA; Oxidative damage; Ogg1 depletion; DNA repair; apoptosis; Free radicals 
ID BASE EXCISION-REPAIR; INDUCED OXIDATIVE STRESS; MITOCHONDRIAL-DNA;
   MAMMALIAN-CELLS; DYSFUNCTION; POLYMORPHISMS; ASSOCIATION; PROTECTS;
   NUCLEAR; LESIONS
AB Emerging evidence suggests that mitochondrial (mt) DNA damage may be a trigger for apoptosis in oxidant-challenged pulmonary artery endothelial cells (PAECs). Understanding the rate-limiting determinants of mtDNA repair may point to new targets for intervention in acute lung injury. The base excision repair (BER) pathway is the only pathway for oxidative damage repair in mtDNA. One of the key BER enzymes is Ogg1, which excises the base oxidation product 8-oxoguanine. Previously we demonstrated that overexpression of mitochondrially targeted Ogg1 in PAECs attenuated apoptosis induced by xanthine oxidase (XO) treatment. To test the idea that Ogg1 is a potentially rate-limiting BER determinant protecting cells from oxidant-mediated death, PAECs transfected with siRNA to Ogg1 were challenged with XO and the extent of mitochondrial and nuclear DNA damage was determined along with indices of apoptosis. Transfected cells demonstrated significantly reduced Ogg1 activity, which was accompanied by delayed repair of XO-induced mtDNA damage and linked to increased XO-mediated apoptosis. The nuclear genome was undamaged by XO in either control PAECs or cells depleted of Ogg1. These observations suggest that Ogg1 plays a critical and possibly rate-limiting role in defending PAECs from oxidant-induced apoptosis by limiting the persistence of oxidative damage in the mitochondrial genome. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Gillespie, Mark N.] Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688, United States.
C1 Univ S Alabama, Coll Med, Ctr Lung Biol, Mobile, AL 36688, United States.
C3 University of South Alabama; University of South Alabama
RP Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA.
EM mgillesp@jaguar1.usouthal.edu
FU National Heart, Lung, and Blood Institute [PO1 HL66299, RO1 HL073244]
FX Dr. Glenn Wilson is acknowledged for his many helpful discussions
   concerning this work. We also appreciate the assistance of Ms. Gina
   Capley Bardwell. This study was supported by National Heart, Lung, and
   Blood Institute Grants PO1 HL66299 and RO1 HL073244.
CR Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392
   Chatterjee A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-235
   de Souza-Pinto NC, 2001, CANCER RES, V61, P5378
   Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001
   Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230
   Grishko V, 2001, FASEB J, V15, P1267, DOI 10.1096/fj.00-0755fje
   Grishko V, 2001, AM J PHYSIOL-LUNG C, V280, pL1300, DOI 10.1152/ajplung.2001.280.6.L1300
   Harrison JF, 2007, GLIA, V55, P1416, DOI 10.1002/glia.20556
   Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863
   Hollensworth SB, 2000, FREE RADICAL BIO MED, V28, P1161, DOI 10.1016/S0891-5849(00)00214-8
   Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529
   LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273
   Li WQ, 2009, CARCINOGENESIS, V30, P500, DOI 10.1093/carcin/bgp018
   Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002
   Meira LB, 2005, ADV EXP MED BIOL, V570, P125, DOI 10.1007/1-4020-3764-3_5
   Panduri V, 2009, FREE RADICAL BIO MED, V47, P750, DOI 10.1016/j.freeradbiomed.2009.06.010
   Paz-Elizur T, 2008, CANCER LETT, V266, P60, DOI 10.1016/j.canlet.2008.02.032
   Prachar J, 2010, GEN PHYSIOL BIOPHYS, V29, P160, DOI 10.4149/gpb_2010_02_160
   Rachek LI, 2006, DIABETES, V55, P1022, DOI 10.2337/diabetes.55.04.06.db05-0865
   Ricci C, 2008, AM J PHYSIOL-CELL PH, V294, pC413, DOI 10.1152/ajpcell.00362.2007
   Robertson AB, 2009, CELL MOL LIFE SCI, V66, P981, DOI 10.1007/s00018-009-8736-z
   Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004
   Shukla A, 2003, AM J PHYSIOL-LUNG C, V285, pL1018, DOI 10.1152/ajplung.00038.2003
   Stanczyk M, 2011, MOL BIOL REP, V38, P445, DOI 10.1007/s11033-010-0127-x
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Zharkov DO, 2008, CELL MOL LIFE SCI, V65, P1544, DOI 10.1007/s00018-008-7543-2
NR 27
TC 48
Z9 52
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAY 1
PY 2011
VL 50
IS 9
BP 1107
EP 1113
DI 10.1016/j.freeradbiomed.2010.10.692
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 752CA
UT WOS:000289664500010
PM 20969951
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Silva, PL
   Moraes, L
   Santos, RS
   Samary, C
   Ornellas, DS
   Maron-Gutierrez, T
   Morales, MM
   Saddy, F
   Capelozzi, VL
   Pelosi, P
   Marini, JJ
   de Abreu, MG
   Rocco, PRM
AF Silva, Pedro Leme
   Moraes, Lillian
   Santos, Raquel Souza
   Samary, Cynthia dos Santos
   Ornellas, Debora S.
   Maron-Gutierrez, Tatiana
   Morales, Marcelo Marcos
   Saddy, Felipe
   Capelozzi, Vera Luiza
   Pelosi, Paolo
   Marini, John J.
   de Abreu, Marcelo Gama
   Rocco, Patricia Rieken Macedo
TI Impact of pressure profile and duration of recruitment maneuvers on
   morphofunctional and biochemical variables in experimental lung injury
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE ALI/ARDS; sepsis; mechanical ventilation; electron microscopy; hyperinflation; Inflammation 
ID MECHANICAL VENTILATION; AIR-FLOW; PULMONARY; TOMOGRAPHY; INFLATION;
   STRATEGY; VOLUME; MODEL
AB Objective: To investigate the effects of the rate of airway pressure increase and duration of recruitment maneuvers on lung function and activation of inflammation, fibrogenesis, and apoptosis in experimental acute lung injury.
   Design: Prospective, randomized, controlled experimental study.
   Setting: University research laboratory.
   Subjects: Thirty-five Wistar rats submitted to acute lung injury induced by cecal ligation and puncture.
   Interventions: After 48 hrs, animals were randomly distributed into five groups (seven animals each): 1) nonrecruited (NR); 2) recruitment maneuvers (RMs) with continuous positive airway pressure (CPAP) for 15 secs (CPAP15); 3) RMs with CPAP for 30 secs (CPAP30); 4) RMs with stepwise increase in airway pressure (STEP) to targeted maximum within 15 secs (STEP15); and 5) RMs with STEP within 30 secs (STEP30). To perform STEP RMs, the ventilator was switched to a CPAP mode and positive end-expiratory pressure level was increased stepwise. At each step, airway pressure was held constant. RMs were targeted to 30 cm H2O. Animals were then ventilated for 1 hr with tidal volume of 6 mL/kg and positive end-expiratory pressure of 5 cm H2O.
   Measurements and Main Results: Blood gases, lung mechanics, histology (light and electronic microscopy), interleukin-6, caspase 3, and type 3 procollagen mRNA expressions in lung tissue. All RMs improved oxygenation and lung static elastance and reduced alveolar collapse compared to NR. STEP30 resulted in optimal performance, with: 1) improved lung static elastance vs. NR, CPAP15, and STEP15; 2) reduced alveolar-capillary membrane detachment and type 2 epithelial and endothelial cell injury scores vs. CPAP15 (p < .05); and 3) reduced gene expression of interleukin-6, type 3 procollagen, and caspase 3 in lung tissue vs. other RMs.
   Conclusions: Longer-duration RMs with slower airway pressure increase efficiently improved lung function, while minimizing the biological impact on lungs. (Crit Care Med 2011; 39:1074-1081)
C1 [Silva, Pedro L.; Moraes, Lillian; Santos, Raquel S.; Samary, Cynthia; Ornellas, Debora S.; Maron-Gutierrez, Tatiana; Saddy, Felipe; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Lab Pulm Invest, Rio De Janeiro, Brazil.
C1 [Maron-Gutierrez, Tatiana; Morales, Marcelo M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Cellular & Mol Physiol, Rio De Janeiro, Brazil.
C1 [Capelozzi, Vera L.] Univ Sao Paulo, Fac Med, Dept Pathol, Sao Paulo, Brazil.
C1 [Pelosi, Paolo] Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate, Genoa, Italy.
C1 [Marini, John J.] Univ Minnesota, Dept Pulm & Crit Care Med, Minneapolis, MN, United States.
C1 [de Abreu, Marcelo Gama] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Anesthesiol & Intens Care Therapy, Pulm Engn Grp, Dresden, Germany.
C3 Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de
   Janeiro; Universidade de Sao Paulo; University of Genoa; University of
   Minnesota System; University of Minnesota Twin Cities; Technische
   Universitat Dresden; Carl Gustav Carus University Hospital
RP Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Lab Pulm Invest, Rio De Janeiro, Brazil.
EM prmrocco@biof.ufrj.br
RI Maron-Gutierrez, Tatiana/F-2683-2013; Silva, Pedro Leme/AAD-8236-2019;
   Fisiologia, Ciencias Biologicas/C-2407-2012; Santos, Rosane S
   Sampaio/A-1597-2017; Capelozzi, Vera Luiza/C-6363-2013; ,
   Capelozzi/N-1737-2019; Rocco, Patricia/I-7460-2012
OI Silva, Pedro Leme/0000-0001-5838-4949; Santos, Rosane S
   Sampaio/0000-0001-6400-5706; , Capelozzi/0000-0001-9732-5853; Rocco,
   Patricia/0000-0003-1412-7136; Gama de Abreu,
   Marcelo/0000-0002-3554-883X; samary, cynthia/0000-0002-1860-4166;
   delmonte, samuel/0000-0002-3289-4577; Pelosi, Paolo/0000-0001-5055-3023;
   Maron-Gutierrez, Tatiana/0000-0002-6905-2007
FU Centers of Excellence Program [PRONEX-FAPERJ-E26/110.575/2010];
   Brazilian Council for Scientific and Technological Development
   [CNPq-573555/2008-7, 473274/2008-6]; Rio de Janeiro State Research
   Supporting Foundation [FAPERJ-E-26/102.910/2008, E26/110.550/2009,
   E26/110.292/2010, E-26/111.364/2010]; Sao Paulo State Research
   Supporting Foundation (FAPESP); Coordination for the Improvement of
   Higher Education Personnel [CAPES-Pos-Doc SUS 062/12/2009]; INCT-INOFAR
   [CNPq no 573.564/2008-6]
FX Supported, in part, by Centers of Excellence Program
   (PRONEX-FAPERJ-E26/110.575/2010), Brazilian Council for Scientific and
   Technological Development (CNPq-573555/2008-7 and 473274/2008-6), Rio de
   Janeiro State Research Supporting Foundation (FAPERJ-E-26/102.910/2008;
   E26/110.550/2009; E26/110.292/2010; and E-26/111.364/2010), Sao Paulo
   State Research Supporting Foundation (FAPESP), and Coordination for the
   Improvement of Higher Education Personnel ([CAPES-Pos-Doc SUS
   062/12/2009] and INCT-INOFAR [CNPq no 573.564/2008-6]).
CR Albert SP, 2009, J APPL PHYSIOL, V106, P757, DOI 10.1152/japplphysiol.90735.2008
   BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788
   Blanch Lluis, 2002, Respir Care Clin N Am, V8, P281, DOI 10.1016/S1078-5337(02)00009-6
   CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148
   D'Angelo E, 2004, J APPL PHYSIOL, V97, P260, DOI 10.1152/japplphysiol.01175.2003
   dos Santos CC, 2000, INTENS CARE MED, V26, P638, DOI 10.1007/s001340051217
   Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC
   Fanelli V, 2009, CRIT CARE MED, V37, P1046, DOI 10.1097/CCM.0b013e3181968e7e
   Gomes RFM, 2000, J APPL PHYSIOL, V89, P908, DOI 10.1152/jappl.2000.89.3.908
   Grasso S, 2009, AM J RESP CRIT CARE, V180, P415, DOI 10.1164/rccm.200901-0156OC
   Herrera MT, 2003, INTENS CARE MED, V29, P1345, DOI 10.1007/s00134-003-1756-5
   Hirai T, 1999, J APPL PHYSIOL, V86, P16, DOI 10.1152/jappl.1999.86.1.16
   Leite JHP, 2008, CRIT CARE MED, V36, P2621, DOI 10.1097/CCM.0b013e3181847b43
   Garcia CSNB, 2008, CRIT CARE MED, V36, P232, DOI 10.1097/01.CCM.0000295309.69123.AE
   Nucci G, 2003, J APPL PHYSIOL, V95, P348, DOI 10.1152/japplphysiol.01179.2001
   Odenstedt H, 2005, INTENS CARE MED, V31, P1706, DOI 10.1007/s00134-005-2799-6
   Oliveira GP, 2009, CRIT CARE, V13, DOI 10.1186/cc7888
   Passaro CP, 2009, CRIT CARE MED, V37, P1011, DOI 10.1097/CCM.0b013e3181962d85
   Riva DR, 2009, RESP PHYSIOL NEUROBI, V169, P62, DOI 10.1016/j.resp.2009.08.010
   Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
   Rocco PRM, 2001, AM J RESP CRIT CARE, V164, P1067, DOI 10.1164/ajrccm.164.6.2007062
   Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6
   Silva PL, 2010, CRIT CARE, V14, DOI 10.1186/cc9063
   Steimback PW, 2009, INTENS CARE MED, V35, P1120, DOI 10.1007/s00134-009-1439-y
   SUKI B, 1994, NATURE, V368, P615, DOI 10.1038/368615a0
   Takeuchi M, 2005, CRIT CARE MED, V33, P2010, DOI 10.1097/01.CCM.0000178174.53373.DA
   TENNEY SM, 1963, NATURE, V197, P54, DOI 10.1038/197054a0
NR 27
TC 31
Z9 32
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAY
PY 2011
VL 39
IS 5
BP 1074
EP 1081
DI 10.1097/CCM.0b013e318206d69a
PG 8
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 752CX
UT WOS:000289667000021
PM 21263326
DA 2023-08-21
ER

PT J
AU Wakamoto, S
   Fujihara, M
   Takahashi, D
   Niwa, K
   Sato, S
   Kato, T
   Azuma, H
   Ikeda, H
AF Wakamoto, Shinobu
   Fujihara, Mitsuhiro
   Takahashi, Daisuke
   Niwa, Koichi
   Sato, Shinichiro
   Kato, Toshiaki
   Azuma, Hiroshi
   Ikeda, Hisami
TI Enhancement of endothelial permeability by coculture with peripheral
   blood mononuclear cells in the presence of HLA Class II antibody that
   was associated with transfusion-related acute lung injury
SO TRANSFUSION
LA English
DT Article
ID PLATELET-ACTIVATING-FACTOR; TUMOR-NECROSIS-FACTOR; FACTOR PAF;
   HUMAN-MONOCYTES; TRALI; RELEASE; PATHOPHYSIOLOGY; ALLOANTIBODY;
   LEUKOTRIENES; PATHOGENESIS
AB BACKGROUND: HLA Class II antibody-initiated activation of monocytes possessing the corresponding antigen is thought to participate in the pathogenesis of transfusion-related acute lung injury (TRALI). Pulmonary edema, a hallmark of TRALI, is caused by increasing vascular permeability.
   STUDY DESIGN AND METHODS: To investigate the contribution of HLA Class II antibody and monocytes to the development of pulmonary edema in TRALI, we studied whether the permeability of human lung microvascular endothelial cells (HMVECs) could be enhanced by coculturing HMVECs with peripheral blood mononuclear cells (PBMNCs) in the presence of HLA Class II antibody-containing plasma, which was implicated in TRALI (anti-HLA-DR plasma). In addition, similar experiments were performed with human umbilical vein endothelial cells (HUVECs). The endothelial permeability to fluoresceinated dextran, which was added from the start of coculture, was measured.
   RESULTS: The coculture of HMVECs or HUVECs with PBMNCs in the presence of anti-HLA-DR plasma resulted in the increase of endothelial permeability in the corresponding antigen-antibody-dependent manner. CV-3988, a platelet-activating factor (PAF) receptor antagonist, almost completely suppressed the increase in endothelial permeability. Neutralizing antibodies to tumor necrosis factor (TNF)-alpha alone and simultaneous addition of the antibodies to TNF-alpha and interleukin (IL)-1 beta to the coculture partially suppressed the permeability increase of HMVECs and HUVECs, respectively.
   CONCLUSIONS: HLA Class II antibody and monocytes in the corresponding antigen-antibody combination caused the enhancement of endothelial permeability. PAF, TNF-alpha, and/or IL-1 beta might be involved in the endothelial permeability increase. HLA Class II antibody-initiated monocyte activation could lead to the development of pulmonary edema in TRALI.
C1 [Fujihara, Mitsuhiro] Hokkaido Red Cross Blood Ctr, Nishi Ku, Sapporo, Hokkaido 0630002, Japan.
C1 Tokyo Univ Agr, Fac Bioind, Dept Food Sci & Technol, Abashiri, Japan.
C3 Tokyo University of Agriculture
RP Fujihara, M (corresponding author), Hokkaido Red Cross Blood Ctr, Nishi Ku, Yamanote 2-2, Sapporo, Hokkaido 0630002, Japan.
EM fujihara@hokkaido.bc.jrc.or.jp
FU Northern Advancement Center for Science & Technology of Hokkaido Japan
FX This study was supported in part by Grants-in-Aid for Regional R&D
   Proposal-Based Program from Northern Advancement Center for Science &
   Technology of Hokkaido Japan.
CR Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Bossi F, 2004, J IMMUNOL, V173, P6921, DOI 10.4049/jimmunol.173.11.6921
   BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856
   BUSSOLINO F, 1995, EUR J BIOCHEM, V229, P327, DOI 10.1111/j.1432-1033.1995.tb20472.x
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Calvijo LC, 2001, J APPL PHYSIOL, V90, P261, DOI 10.1152/jappl.2001.90.1.261
   CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980
   Flesch BK, 2002, BRIT J HAEMATOL, V116, P673, DOI 10.1046/j.0007-1048.2001.03305.x
   Fujihara M, 2009, VASCULAR DIS PREVENT, V6, P170
   Fung YL, 2009, TRANSFUS MED REV, V23, P266, DOI 10.1016/j.tmrv.2009.06.001
   HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010
   IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x
   Kao GS, 2003, TRANSFUSION, V43, P185, DOI 10.1046/j.1537-2995.2003.00285.x
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Kopko PM, 2001, TRANSFUSION, V41, P1244, DOI 10.1046/j.1537-2995.2001.41101244.x
   Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846
   Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669
   Moses LA, 2000, TRANSFUSION, V40, P861, DOI 10.1046/j.1537-2995.2000.40070861.x
   Nicolle AL, 2004, TRANSFUSION MED, V14, P225, DOI 10.1111/j.0958-7578.2004.00504.x
   Nishimura M, 2007, VOX SANG, V93, P78, DOI 10.1111/j.1423-0410.2007.00925.x
   Nishimura M, 2007, TRANSFUSION MED, V17, P129, DOI 10.1111/j.1365-3148.2006.00721.x
   Nishimura M, 2001, TRANSFUSION, V41, P1268, DOI 10.1046/j.1537-2995.2001.41101268.x
   Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601
   POUBELLE PE, 1991, IMMUNOLOGY, V72, P181
   Sakagawa H, 2007, TRANSFUSION, V47, P154, DOI 10.1111/j.1537-2995.2007.01078.x
   SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614
   Seynhaeve ALB, 2006, CELL BIOCHEM BIOPHYS, V44, P157, DOI 10.1385/CBB:44:1:157
   SHIBATA Y, 1981, VOX SANG, V41, P25, DOI 10.1111/j.1423-0410.1981.tb01007.x
   Shigematsu A, 2004, TRANSFUSION MED, V50, P720
   Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929
   SISSON JH, 1987, J IMMUNOL, V138, P3918
   Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF
   TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8
   TERASHITA ZI, 1985, BIOCHEM PHARMACOL, V34, P1491, DOI 10.1016/0006-2952(85)90689-6
   VALONE FH, 1988, J IMMUNOL, V141, P3945
   VENABLE ME, 1993, J LIPID RES, V34, P691
   Wakamoto S, 2008, TRANSFUSION, V48, P2060, DOI 10.1111/j.1537-2995.2008.01809.x
   Wallis JP, 2003, TRANSFUSION, V43, P1053, DOI 10.1046/j.1537-2995.2003.00466.x
NR 39
TC 12
Z9 14
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD MAY
PY 2011
VL 51
IS 5
BP 993
EP 1001
DI 10.1111/j.1537-2995.2010.02910.x
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 759SC
UT WOS:000290267700016
PM 20977481
DA 2023-08-21
ER

PT J
AU Zhang, WF
   Zhu, XX
   Hu, DH
   Xu, CF
   Wang, YC
   Lv, GF
AF Zhang, Wan-Fu
   Zhu, Xiong-Xiang
   Hu, Dahai
   Xu, Cheng-Feng
   Wang, Yun-Chuan
   Lv, Gen-Fa
TI Intensive Insulin Treatment Attenuates Burn-Initiated Acute Lung Injury
   in Rats: Role of the Protective Endothelium
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID NITRIC-OXIDE; STRESS HYPERGLYCEMIA; GLUCOSE CONTROL; THERAPY; CELLS;
   APOPTOSIS; CYTOKINE; AKT
AB Nonmetabolic effects of intensive insulin therapy in critically ill patients have been reported, but the underlying mechanisms are unclear. This study was designed to test the hypothesis that intensive insulin treatment would attenuate burn-induced acute lung injury by protecting the pulmonary microvascular endothelium. The rat model of burn injury was achieved by exposure to 92 degrees C water for 18 seconds. The rats were randomly allocated into the sham, burn/normal saline (NS), and burn/intensive insulin treatment groups. Blood glucose level was maintained between 5 and 7 mmol/L in rats in the burn/intensive insulin treatment group. Pulmonary injury was assessed by hematoxylin and eosin staining, scanning electron microscopy, bronchoalveolar lavage fluid protein concentrations, the lung wet: dry weight ratio, and lung myeloperoxidase activity. Pulmonary microvascular endothelial cells were examined by transmission electron microscopy. Western blotting was used to determine the protein expression of caspase-3. Intensive insulin treatment markedly attenuated the acute lung injury, revealed by improvements in histological features and significant decreases in bronchoalveolar lavage fluid protein concentrations, pulmonary wet: dry weight ratio, and myeloperoxidase activity at 12 hours after injury (P < .05 or P < .01 vs burn/NS). Moreover, the injured pulmonary microvascular endothelial cells showed significant improvements, whereas caspase-3 was markedly downregulated in the burn/intensive insulin treatment group when compared with the burn/NS group. Overall, intensive insulin treatment efficiently attenuated pulmonary microvascular endothelial cell dysfunction, decreased cell apoptosis, and inhibited acute lung injury after a burn. These findings may be useful in preventing organ failure after burn injury. (J Burn Care Res 2011;32:e51-e58)
C1 [Zhang, Wan-Fu; Zhu, Xiong-Xiang; Hu, Da-Hai; Xu, Cheng-Feng; Wang, Yun-Chuan; Lv, Gen-Fa] Fourth Mil Med Univ, Dept Burns & Cutaneous Surg, Xijing Hosp, Xian 710032, Shaanxi, China.
C3 Air Force Military Medical University
RP Hu, DH (corresponding author), Fourth Mil Med Univ, Dept Burns & Cutaneous Surg, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
FU National Natural Science Foundation of China [30772249]
FX Supported by grant 30772249 from the National Natural Science Foundation
   of China.
CR Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07
   Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9
   Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194
   Chaudhuri A, 2004, CIRCULATION, V109, P849, DOI 10.1161/01.CIR.0000116762.77804.FC
   Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553
   Dandona P, 2001, J CLIN ENDOCR METAB, V86, P3257, DOI 10.1210/jc.86.7.3257
   Dandona P, 2005, J CLIN INVEST, V115, P2069, DOI 10.1172/JCI26045
   Deng HP, 2009, INT IMMUNOPHARMACOL, V9, P1251, DOI 10.1016/j.intimp.2009.07.009
   Dhainaut JF, 2002, PHYS REV LETT, V30, pS179u348
   Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE
   Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F
   Gauglitz GG, 2008, J BURN CARE RES, V29, P683, DOI 10.1097/BCR.0b013e31818481ce
   Gore DC, 2002, CRIT CARE MED, V30, P2438, DOI 10.1097/00003246-200211000-00006
   Hemmila MR, 2008, SURGERY, V144, P629, DOI 10.1016/j.surg.2008.07.001
   Huang YS, 1998, BURNS, V24, P706, DOI 10.1016/S0305-4179(98)00123-5
   Ishii H, 2000, Respirology, V5, P325, DOI 10.1046/j.1440-1843.2000.00271.x
   Jeschke MG, 2010, AM J RESP CRIT CARE, V182, P351, DOI 10.1164/rccm.201002-0190OC
   Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437
   Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253
   Krinsley JS, 2004, MAYO CLIN P, V79, P992
   Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385
   Li J, 2009, J MOL CELL CARDIOL, V47, P512, DOI 10.1016/j.yjmcc.2009.07.010
   Murphy JT, 2003, J TRAUMA, V54, P81, DOI 10.1097/00005373-200301000-00011
   Murphy JT, 2001, SHOCK, V16, P227, DOI 10.1097/00024382-200116030-00010
   Pidcoke HF, 2007, CRIT CARE MED, V35, pS524, DOI 10.1097/01.CCM.0000278065.72486.31
   Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256
   Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636
   Thorell A, 1999, Curr Opin Clin Nutr Metab Care, V2, P69, DOI 10.1097/00075197-199901000-00012
   Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506
   Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Whaley JG, 2009, J BURN CARE RES, V30, P1018, DOI 10.1097/BCR.0b013e3181bfb825
   Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22
   Zhang JP, 2008, J TRAUMA, V65, P401, DOI 10.1097/TA.0b013e31817cf732
NR 34
TC 11
Z9 13
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1559-047X
EI 1559-0488
J9 J BURN CARE RES
JI J. Burn Care Res.
PD MAY-JUN
PY 2011
VL 32
IS 3
BP E51
EP E58
DI 10.1097/BCR.0b013e318217f8ae
PG 8
WC Critical Care Medicine; Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Dermatology; Surgery
GA 760EZ
UT WOS:000290308500003
PM 21436719
DA 2023-08-21
ER

PT J
AU Jang, AS
   Concel, VJ
   Bein, K
   Brant, KA
   Liu, SN
   Pope-Varsalona, H
   Dopico, RA
   Di, YPP
   Knoell, DL
   Barchowsky, A
   Leikauf, GD
AF Jang, An Soo
   Concel, Vincent J.
   Bein, Kiflai
   Brant, Kelly A.
   Liu, Shannen
   Pope-Varsalona, Hannah
   Dopico, Richard A., Jr.
   Di, Y. P. Peter
   Knoell, Daren L.
   Barchowsky, Aaron
   Leikauf, George D.
TI Endothelial Dysfunction and Claudin 5 Regulation during Acrolein-Induced
   Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE ALI/ARDS; perivascular edema; permeability; smoke inhalation; carboxyl stress 
ID HAZARDOUS AIR-POLLUTANTS; QUANTITATIVE TRAIT ANALYSIS; FOXO
   TRANSCRIPTION FACTORS; INDUCED MUC5AC EXPRESSION; BLOOD-BRAIN-BARRIER;
   CIGARETTE-SMOKE; VE-CADHERIN; GENETIC SUSCEPTIBILITY; HUMAN HEALTH;
   INFLAMMATION
AB An integral membrane protein, Claudin 5 (CLDN5), is a critical component of endothelial tight junctions that control pericellular permeability. Breaching of endothelial barriers is a key event in the development of pulmonary edema during acute lung injury (ALI). A major irritant in smoke, acrolein can induce ALI possibly by altering CLDN5 expression. This study sought to determine the cell signaling mechanism controlling endothelial CLDN5 expression during ALI. To assess susceptibility, 12 mouse strains were exposed to acrolein (10 ppm, 24 h), and survival monitored. Histology, lavage protein, and CLDN5 transcripts were measured in the lung of the most sensitive and resistant strains. CLDN5 transcripts and phosphorylation status of forkhead box O1 (FOXO1) and catenin (cadherin-associated protein) beta 1 (CTNNB1) proteins were determined in control and acrolein-treated human endothelial cells. Mean survival time (MST) varied more than 2-fold among strains with the susceptible (BALB/cByJ) and resistant (129X1/SvJ) strains (MST, 17.3 +/- 1.9 h vs. 41.4 +/- 5.1 h, respectively). Histological analysis revealed earlier perivascular enlargement in the BALB/cByJ than in 129X1/SvJ mouse lung. Lung CLDN5 transcript and protein increased more in the resistant strain than in the susceptible strain. In human endothelial cells, 30 nM acrolein increased CLDN5 transcripts and increased p-FOXO1 protein levels. The phosphatidylinositol 3-kinase inhibitor LY294002 diminished the acrolein-induced increased CLDN5 transcript. Acrolein (300 nM) decreased CLDN5 transcripts, which were accompanied by increased FOXO1 and CTNNB1. The phosphorylation status of these transcription factors was consistent with the observed CLDN5 alteration. Preservation of endothelial CLDN5 may be a novel clinical approach for ALI therapy.
C1 [Jang, An Soo; Concel, Vincent J.; Bein, Kiflai; Brant, Kelly A.; Liu, Shannen; Pope-Varsalona, Hannah; Dopico, Richard A., Jr.; Di, Y. P. Peter; Barchowsky, Aaron; Leikauf, George D.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Grad Sch Publ Hlth, Pittsburgh, PA 15219, United States.
C1 [Jang, An Soo] Soon Chun Hyang Univ, Dept Internal Med, Puchon, South Korea.
C1 [Knoell, Daren L.] Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210, United States.
C1 [Knoell, Daren L.] Ohio State Univ, Dept Pharm, Columbus, OH 43210, United States.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Soonchunhyang University; University System of Ohio; Ohio
   State University; University System of Ohio; Ohio State University
RP Leikauf, GD (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Grad Sch Publ Hlth, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA.
EM gleikauf@pitt.edu
RI Di, Yuanpu Peter/H-4191-2016
OI Di, Yuanpu Peter/0000-0003-2028-2087; Leikauf,
   George/0000-0002-4514-7060; Bein, Kiflai/0000-0002-5206-0801
FU NIH [ES013781, ES015675, HL077763, HL085655, HL086981, HL091938]
FX This study was supported by NIH grants ES013781 (A.B.); ES015675,
   HL077763, and HL085655 (G.L.); HL086981 (D.L.), and HL091938 (P.D.).;
   D.K. has received a sponsored grant from the NIH (more than $100,000).
   G.L. has served on the advisory board for the NIH (less than $1,000).
   None of the other authors has a financial relationship with a commercial
   entity that has an interest in the subject of this manuscript.
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886
   Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106
   AYER HE, 1982, AM J PUBLIC HEALTH, V72, P1283, DOI 10.2105/AJPH.72.11.1283
   Barnes Kathleen C, 2005, Proc Am Thorac Soc, V2, P195, DOI 10.1513/pats.200502-013AC
   Bein K, 2009, AM J RESP CELL MOL, V41, P226, DOI 10.1165/rcmb.2008-0317OC
   Borchers MT, 1998, AM J PHYSIOL-LUNG C, V274, pL573, DOI 10.1152/ajplung.1998.274.4.L573
   Borchers MT, 1999, AM J PHYSIOL-LUNG C, V277, pL489, DOI 10.1152/ajplung.1999.277.3.L489
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   Chen H, 2008, J BIOL CHEM, V283, P29228, DOI 10.1074/jbc.M802906200
   COHEN SM, 1992, CANCER RES, V52, P3577
   Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815
   Coyne CB, 2003, AM J PHYSIOL-LUNG C, V285, pL1166, DOI 10.1152/ajplung.00182.2003
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Deshmukh HS, 2008, AM J RESP CELL MOL, V38, P446, DOI 10.1165/rcmb.2006-0339OC
   Deshmukh HS, 2009, AM J RESP CRIT CARE, V180, P834, DOI 10.1164/rccm.200903-0328OC
   Enkhbaatar P, 2004, CLIN SCI, V107, P137, DOI 10.1042/CS20040135
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Faroon O, 2008, TOXICOL IND HEALTH, V24, P447, DOI 10.1177/0748233708094188
   Faroon O, 2008, TOXICOL IND HEALTH, V24, P543, DOI 10.1177/0748233708098124
   FEIN A, 1980, CRIT CARE MED, V8, P94, DOI 10.1097/00003246-198002000-00008
   Feng ZH, 2006, P NATL ACAD SCI USA, V103, P15404, DOI 10.1073/pnas.0607031103
   Furuhata A, 2002, J BIOL CHEM, V277, P27919, DOI 10.1074/jbc.M202794200
   Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006
   Gao L, 2009, AM J PHYSIOL-LUNG C, V296, pL713, DOI 10.1152/ajplung.90269.2008
   Gavard J, 2008, NAT CELL BIOL, V10, P883, DOI 10.1038/ncb0808-883
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   HALES CA, 1992, J APPL PHYSIOL, V72, P555, DOI 10.1152/jappl.1992.72.2.555
   HALES CA, 1988, J APPL PHYSIOL, V64, P1121, DOI 10.1152/jappl.1988.64.3.1121
   Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j
   HOUEN G, 1994, ACTA CHEM SCAND, V48, P52, DOI 10.3891/acta.chem.scand.48-0052
   IZARD C, 1977, MUTAT RES, V47, P115
   JERMINI C, 1976, INT ARCH OCC ENV HEA, V36, P169, DOI 10.1007/BF00378272
   Kaarteenaho-Wiik R, 2009, J HISTOCHEM CYTOCHEM, V57, P187, DOI 10.1369/jhc.2008.951566
   Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779
   Kato S, 2008, J BIOL CHEM, V283, P35464, DOI 10.1074/jbc.M801011200
   KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202
   Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475
   Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620, DOI 10.1165/ajrcmb.22.5.3912
   Kosmidou I, 2008, J THROMB THROMBOLYS, V25, P259, DOI 10.1007/s11239-007-0062-4
   Koval M, 2010, AM J RESP CELL MOL, V42, P172, DOI 10.1165/rcmb.2008-0270OC
   Kunig AM, 2006, AM J PHYSIOL-LUNG C, V291, pL1068, DOI 10.1152/ajplung.00093.2006
   Lee Y, 1998, J BIOL CHEM, V273, P19490, DOI 10.1074/jbc.273.31.19490
   LEIKAUF GD, 1989, J APPL PHYSIOL, V66, P171, DOI 10.1152/jappl.1989.66.1.171
   Leikauf GD, 2002, ENVIRON HEALTH PERSP, V110, P505, DOI 10.1289/ehp.02110s4505
   Leikauf GD., 2009, ENV TOXICANTS HUMAN, V3rd ed., Lippmann M. Ed., P257
   Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7
   Mankertz J, 2007, CURR OPIN GASTROEN, V23, P379, DOI 10.1097/MOG.0b013e32816aa392
   Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890
   Nazaroff WW, 2004, J EXPO ANAL ENV EPID, V14, pS71, DOI 10.1038/sj.jea.7500361
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   O'Brien PJ, 2005, CRIT REV TOXICOL, V35, P609, DOI 10.1080/10408440591002183
   Park YS, 2008, ANN NY ACAD SCI, V1126, P185, DOI 10.1196/annals.1433.034
   Prows DR, 2008, AM J RESP CELL MOL, V38, P68, DOI 10.1165/rcmb.2006-0162OC
   Prows DR, 2007, PHYSIOL GENOMICS, V30, P262, DOI 10.1152/physiolgenomics.00232.2006
   Prows DR, 1997, NAT GENET, V17, P471, DOI 10.1038/ng1297-471
   Prows DR, 2001, AM J RESP CELL MOL, V24, P740, DOI 10.1165/ajrcmb.24.6.4303
   Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4
   Sakata K, 2003, BIOCHEM SOC T, V31, P371, DOI 10.1042/BST0310371
   Savov JD, 2004, AM J RESP CELL MOL, V31, P69, DOI 10.1165/rcmb.2003-0001OC
   Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033
   Shao BH, 2005, J BIOL CHEM, V280, P36386, DOI 10.1074/jbc.M508169200
   Soma T, 2004, EXP CELL RES, V300, P202, DOI 10.1016/j.yexcr.2004.07.012
   STEINHAGEN WH, 1984, TOXICOL APPL PHARM, V72, P495, DOI 10.1016/0041-008X(84)90126-1
   Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412
   TABOR CW, 1964, J BIOL CHEM, V239, P2194
   Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752
   Tam BN, 2004, J ENVIRON MANAGE, V73, P131, DOI 10.1016/j.jenvman.2004.06.012
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235
   Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058
   UHL M, 1994, RADIOLOGE, V34, P73
   Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464
   Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404
   Vasilyev N, 2005, CIRCULATION, V112, P2812, DOI 10.1161/CIRCULATIONAHA.105.542340
   Wang HT, 2009, CHEM RES TOXICOL, V22, P511, DOI 10.1021/tx800369y
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WEBER A, 1976, AM J PUBLIC HEALTH, V66, P672, DOI 10.2105/AJPH.66.7.672
   Wesselkamper SC, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-73
   Wesselkamper SC, 2000, AM J PHYSIOL-LUNG C, V279, pL575, DOI 10.1152/ajplung.2000.279.3.L575
   Wray C, 2009, AM J PHYSIOL-LUNG C, V297, pL219, DOI 10.1152/ajplung.00043.2009
NR 83
TC 49
Z9 52
U1 0
U2 13
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD APR
PY 2011
VL 44
IS 4
BP 483
EP 490
DI 10.1165/rcmb.2009-0391OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 753KX
UT WOS:000289773400007
PM 20525806
OA Green Published
DA 2023-08-21
ER

PT J
AU Li, HH
   Xu, J
   Wasserloos, KJ
   Li, J
   Tyurina, YY
   Kagan, VE
   Wang, XR
   Chen, AF
   Liu, ZQ
   Stoyanovsky, D
   Pitt, BR
   Zhang, LM
AF Li, Hui-Hua
   Xu, Jing
   Wasserloos, Karla J.
   Li, Jin
   Tyurina, Yulia Y.
   Kagan, Valerian E.
   Wang, Xiaorong
   Chen, Alex F.
   Liu, Zhao-Qian
   Stoyanovsky, Detcho
   Pitt, Bruce R.
   Zhang, Li-Ming
TI Cytoprotective effects of albumin, nitrosated or reduced, in cultured
   rat pulmonary vascular cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE S-nitrosoalbumin; reduced albumin; ECs/HPMECs/HUVECs/MPVECs; pulmonary smooth muscle; tert-butyl hydroperoxide; hydrogen sulfide 
ID TERT-BUTYL HYDROPEROXIDE; HUMAN SERUM-ALBUMIN; PROTEIN
   DISULFIDE-ISOMERASE; NITRIC-OXIDE SYNTHASE; HYDROGEN-SULFIDE;
   S-NITROSOALBUMIN; ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; ISCHEMIA/REPERFUSION
   INJURY; ERYTHROLEUKEMIA-CELLS
AB Li HH, Xu J, Wasserloos KJ, Li J, Tyurina YY, Kagan VE, Wang X, Chen AF, Liu ZQ, Stoyanovsky D, Pitt BR, Zhang LM. Cytoprotective effects of albumin, nitrosated or reduced, in cultured rat pulmonary vascular cells. Am J Physiol Lung Cell Mol Physiol 300: L526-L533, 2011. First published January 14, 2011; doi: 10.1152/ajplung.00282.2010.-S-nitrosoalbumin (SNO-Alb) has been shown to be an efficacious cytoprotective molecule in acute lung injury, as well as ischemia-reperfusion injury in heart and skeletal muscle. Nonetheless, limited information is available on the cellular mechanism of such protection. Accordingly, we investigated the protective effects of SNO-Alb [ and its denitrosated congener, reduced albumin (SH-Alb)] on tert-butyl hydroperoxide (tBH)-mediated cytotoxicity in cultured rat pulmonary microvascular endothelial cells (RPMEC), as well as hydrogen sulfide (H2S)-mediated cytotoxicity in rat pulmonary artery smooth muscle cells (RPASMC). We noted that tBH caused a concentration-dependent necrosis in RPMEC, and pretreatment of RPMEC with SNO-Alb dose-dependently decreased the sensitivity of these cells to tBH. A component of SNO-Alb cytoprotection was sensitive to N-G-nitro-L-arginine methyl ester and was associated with activation of endothelial nitric oxide synthase (eNOS), phenomena that could be reproduced with pretreatment with SH-Alb. Exogenous H2S caused concentration-dependent apoptosis in RPASMC due to activation of ERK1/2 and p38, as well as downregulation of Bcl-2. Pretreatment with SNO-Alb reduced H2S-mediated apoptosis in a concentration-dependent manner that was associated with SNO-Alb-mediated inhibition of activation of ERK1/2 and p38. Pretreatment with SNO-Alb reduced toxicity of 1 mM sodium hydrosulfide in an N-G-nitro-L-arginine methyl ester-sensitive fashion in RPASMC that expressed gp60 and neuronal NOS and was capable of transporting fluorescently labeled SH-Alb. Therefore, SNO-Alb is cytoprotective against models of oxidant-induced necrosis (tBH) and inhibitors of cellular respiration and apoptosis (H2S) in both pulmonary endothelium and smooth muscle, respectively, and a component of such protection can be attributed to a SH-Alb-mediated activation of constitutive NOS.
C1 [Zhang, Li-Ming] Univ Pittsburgh, Dept Anesthesiol, Med Ctr, Sch Med, Pittsburgh, PA 15213, United States.
C1 [Wasserloos, Karla J.; Li, Jin; Tyurina, Yulia Y.; Kagan, Valerian E.; Stoyanovsky, Detcho; Pitt, Bruce R.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Grad Sch Publ Hlth, Pittsburgh, PA 15213, United States.
C1 [Wang, Xiaorong; Chen, Alex F.] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213, United States.
C1 [Li, Hui-Hua; Liu, Zhao-Qian] Cent S Univ, Inst Clin Pharmacol, Changsha, Hunan, China.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Central South
   University
RP Zhang, LM (corresponding author), Univ Pittsburgh, Dept Anesthesiol, Med Ctr, Sch Med, 200 Lothrop St,MUH N463, Pittsburgh, PA 15213 USA.
EM ZhangL1@anes.upmc.edu
RI Li, Huihua/B-8795-2012
OI Liu, Zhaoqian/0000-0003-0428-3928; Tyurina, Yulia/0000-0003-0287-2091;
   Kagan, Valerian E./0000-0002-7245-1885; Li, Huihua/0009-0009-7725-407X;
   Stoyanovsky, Detcho/0000-0001-5591-4780
FU National Institutes of Health [K08 HL79456-01A1, NIH R37 HL65697, P50
   GM53789, HL-70755, HL-094488]
FX This work was supported by National Institutes of Health Grants K08
   HL79456-01A1 to L.M. Zhang, NIH R37 HL65697 and P50 GM53789 to B. R.
   Pitt, and HL-70755 and HL-094488 to V. E. Kagan.
CR Bauer C, 2004, SHOCK, V21, P165, DOI 10.1097/01.shk.0000107442.26299.fb
   Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3
   BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321
   Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581
   Cheong E, 2005, CELL CALCIUM, V37, P87, DOI 10.1016/j.ceca.2004.07.001
   de Franceschi L, 2006, AM J PHYSIOL-LUNG C, V291, pL457, DOI 10.1152/ajplung.00462.2005
   Du JB, 2004, HEART VESSELS, V19, P75, DOI 10.1007/s00380-003-0743-7
   FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207
   Gluckman TL, 2002, J ENDOTOXIN RES, V8, P17, DOI 10.1179/096805102125000047
   Gorbunov NV, 1997, J BIOL CHEM, V272, P12328, DOI 10.1074/jbc.272.19.12328
   Hallstrom S, 2002, CIRCULATION, V105, P3032, DOI 10.1161/01.CIR.0000018745.11739.9B
   Jakubowski A, 2009, N-S ARCH PHARMACOL, V379, P281, DOI 10.1007/s00210-008-0351-2
   Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727
   KHAN AA, 1990, TOXICOL APPL PHARM, V103, P482, DOI 10.1016/0041-008X(90)90321-K
   Li S, 2007, AM J PHYSIOL-CELL PH, V292, pC1263, DOI 10.1152/ajpcell.00382.2006
   Maniatis NA, 2006, CIRC RES, V99, P870, DOI 10.1161/01.RES.0000245187.08026.47
   MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7
   NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471
   Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998
   Semsroth S, 2005, J HEART LUNG TRANSPL, V24, P2226, DOI 10.1016/j.healun.2005.08.004
   Sengupta R, 2007, BIOCHEMISTRY-US, V46, P8472, DOI 10.1021/bi700449x
   Stamler JS, 2002, CURR OPIN CHEM BIOL, V6, P779, DOI 10.1016/S1367-5931(02)00383-6
   Stoyanovsky DA, 2005, J AM CHEM SOC, V127, P15815, DOI 10.1021/ja0529135
   Tang ZL, 2001, AM J PHYSIOL-LUNG C, V281, pL243, DOI 10.1152/ajplung.2001.281.1.L243
   Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250
   Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179
   Wagner F, 2009, CRIT CARE, V13, DOI 10.1186/cc7700
   Wang R, 2010, ANTIOXID REDOX SIGN, V12, P1061, DOI 10.1089/ars.2009.2938
   Yalowich JC, 1999, BIOCHEMISTRY-US, V38, P10691, DOI 10.1021/bi9829229
   Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje
   Zhang LM, 2006, EXP BIOL MED, V231, P1507, DOI 10.1177/153537020623100909
   Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008
   Zhu J, 2008, AM J PHYSIOL-CELL PH, V294, pC1012, DOI 10.1152/ajpcell.00411.2007
NR 33
TC 9
Z9 9
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD APR
PY 2011
VL 300
IS 4
BP L526
EP L533
DI 10.1152/ajplung.00282.2010
PG 8
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 742LC
UT WOS:000288943900004
PM 21239532
OA Green Published
DA 2023-08-21
ER

PT J
AU Eun, JC
   Moore, EE
   Banerjee, A
   Kelher, MR
   Khan, SY
   Elzi, DJ
   McLaughlin, NJD
   Silliman, CC
AF Eun, John C.
   Moore, Ernest E.
   Banerjee, Anirban
   Kelher, Marguerite R.
   Khan, Samina Y.
   Elzi, David J.
   McLaughlin, Nathan J. D.
   Silliman, Christopher C.
TI LEUKOTRIENE B-4 AND ITS METABOLITES PRIME THE NEUTROPHIL OXIDASE AND
   INDUCE PROINFLAMMATORY ACTIVATION OF HUMAN PULMONARY MICROVASCULAR
   ENDOTHELIAL CELLS
SO SHOCK
LA English
DT Article
DE Lipids; ICAM-1; LTB4 receptors; BLT1; BLT2 
ID MULTIPLE ORGAN FAILURE; ACUTE LUNG INJURY; ACUTE-INFLAMMATION;
   ARACHIDONIC-ACID; BIOSYNTHESIS; HYPERADHESIVENESS; PATHOGENESIS;
   LEUKOCYTES; LIPOXINS; RECEPTOR
AB Leukotrienes are proinflammatory lipid mediators, derived from arachidonic acid via 5-lipoxygenase (5-LO). Leukotriene B-4 (LTB4) is an effective polymorphonuclear neutrophil (PMN) chemoattractant, as well as being a major product of PMN priming. Leukotriene B-4 is rapidly metabolized into products that are thought to be inactive, and little is known about the effects of LTB4 on the pulmonary endothelium. We hypothesize that LTB4 and its metabolites are effective PMN priming agents and cause proinflammatory activation of pulmonary endothelial cells. Isolated PMNs were primed (5 min, 37 degrees C) with serial concentrations 10(-11) to 10(-5) M of LTB4 and its metabolites: 6-trans-LTB4, 20-OH-LTB4, and 20-COOH-LTB4, and then activated with fMLP. Primary human pulmonary microvascular endothelial cells (HMVECs) were incubated with these lipids (6 h, 37 degrees C, 5% CO2), and intercellular adhesion molecule 1 was measured by flow cytometry. Polymorphonuclear neutrophil adhesion was measured by myeloperoxidase assays, and to ensure that these reactions were specific to the LTB4 receptors, BLT1 and BLT2 were antagonized with CP105,696 (BLT1) or silenced with siRNA (BLT1 and BLT2). Leukotriene B-4 and its metabolites primed PMNs over a wide range of concentrations, depending on the specific metabolite. In addition, at high concentrations these lipids also caused increases in the surface expression of intercellular adhesion molecule 1 on HMVECs and induced HMVEC-mediated adhesion of PMNs. Silencing of BLT2 abrogated HMVEC activation, and blockade of BLT1 inhibited the observed PMN priming activity. We conclude that LTB4 and its omega-oxidation and nonenzymatic metabolites prime PMNs over a range of concentrations and activate HMVECs. These data have expanded the repertoire of causative agents in acute lung injury and postinjury multiple organ failure.
C1 [Silliman, Christopher C.] Bonfils Blood Ctr, Res Dept, Denver, CO 80230, United States.
C1 [Eun, John C.; Moore, Ernest E.] Denver Hlth Med Ctr, Dept Surg, Denver, CO, United States.
C1 [Eun, John C.; Moore, Ernest E.; Banerjee, Anirban; Kelher, Marguerite R.; Elzi, David J.; Silliman, Christopher C.] Univ Colorado, Sch Med, Dept Surg, Denver, CO, United States.
C1 [Khan, Samina Y.; McLaughlin, Nathan J. D.; Silliman, Christopher C.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO, United States.
C3 Denver Health Medical Center; University of Colorado System; University
   of Colorado Anschutz Medical Campus; University of Colorado Denver;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver
RP Silliman, CC (corresponding author), Bonfils Blood Ctr, Res Dept, 717 Yosemite St, Denver, CO 80230 USA.
EM christopher.silliman@ucdenver.edu
OI Elzi, David/0000-0002-6637-7607; Banerjee, Anirban/0000-0003-1690-2618
FU Bonfils Blood Center; National Institute of General Medical Sciences,
   National Institutes of Health [GM49222]
FX This work was supported by Bonfils Blood Center and grant GM49222 from
   National Institute of General Medical Sciences, National Institutes of
   Health.
CR BOKOCH GM, 1981, J BIOL CHEM, V256, P5317
   Crooks SW, 1998, INT J BIOCHEM CELL B, V30, P173, DOI 10.1016/S1357-2725(97)00123-4
   Cunha JM, 2003, BRIT J PHARMACOL, V139, P1135, DOI 10.1038/sj.bjp.0705346
   Gijon MA, 2007, J LIPID RES, V48, P716, DOI 10.1194/jlr.M600508-JLR200
   JACKSON RH, 1992, J PHARMACOL EXP THER, V262, P80
   Kavelaars A, 2003, J IMMUNOL, V171, P6128, DOI 10.4049/jimmunol.171.11.6128
   Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759
   Medoff BD, 2006, AM J PHYSIOL-LUNG C, V290, pL170, DOI 10.1152/ajplung.00212.2005
   MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4
   Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289
   OFLAHERTY JT, 1981, AM J PATHOL, V105, P264
   PALMBLAD J, 1994, J IMMUNOL, V152, P262
   PALMBLAD JEW, 1992, CLIN EXP IMMUNOL, V90, P300
   Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015
   Partrick DA, 2001, CRIT CARE MED, V29, P989, DOI 10.1097/00003246-200105000-00020
   PARTRICK DA, 1996, NEW HORIZ, V4, P194
   Sala A, 1998, BIOCHEMISTRY-MOSCOW+, V63, P84
   SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055
   SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335
   Silliman CC, 2006, CRIT CARE MED, V34, pS124, DOI 10.1097/01.CCM.0000214292.62276.8E
   Silliman CC, 2005, TRANSFUSION, V45, p109S, DOI 10.1111/j.1537-2995.2005.00531.x
   Tager AM, 2003, PROSTAG LEUKOTR ESS, V69, P123, DOI 10.1016/S0952-3278(03)00073-5
   TAKATA S, 1994, J CLIN INVEST, V93, P499, DOI 10.1172/JCI116999
   Trandafir CC, 2005, CLIN EXP PHARMACOL P, V32, P1027, DOI 10.1111/j.1440-1681.2005.04300.x
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
NR 25
TC 16
Z9 17
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD MAR
PY 2011
VL 35
IS 3
BP 240
EP 244
DI 10.1097/SHK.0b013e3181faceb3
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 727DT
UT WOS:000287778500004
PM 20926984
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Lam, CF
   Roan, JN
   Lee, CH
   Chang, PJ
   Huang, CC
   Liu, YC
   Jiang, MJ
   Tsai, YC
AF Lam, Chen-Fuh
   Roan, Jun-Neng
   Lee, Chou-Hwei
   Chang, Pei-Jung
   Huang, Chein-Chi
   Liu, Yen-Chin
   Jiang, Meei-Jyh
   Tsai, Yu-Chuan
TI Transplantation of Endothelial Progenitor Cells Improves Pulmonary
   Endothelial Function and Gas Exchange in Rabbits with Endotoxin-Induced
   Acute Lung Injury
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID ACUTE RESPIRATORY-DISTRESS; ACUTE MYOCARDIAL-INFARCTION;
   LIPOPOLYSACCHARIDE; EXPRESSION; NEUTROPHILS; APOPTOSIS; STRESS; NUMBER
AB BACKGROUND: Circulating endothelial progenitor cells (EPCs) have been therapeutically applied to aid vascular repair and myocardial regeneration. The number of circulating EPCs also provides invaluable outcome prediction for fatal diseases such as acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). However, evidence for the therapeutic potential of EPCs in subjects with ALI/ADRS is limited.
   METHODS: Circulating EPCs were obtained from rabbits using Ficoll centrifugation. One week after culturing EPCs in endothelial growth medium-2, ALI was induced in rabbits by intratracheal instillation of lipopolysaccharide (500 mu g/kg). Autologous EPCs or saline were administered IV after induction of ALI and animals were killed 2 days later. Pulmonary artery endothelial function and gas exchange were determined. Degrees of lung injury were assessed by alveolocapillary permeability, lung hemoglobin content, and myeloperoxidase activity.
   RESULTS: In comparison with controls, Po-2 in arterial blood was significantly elevated and pulmonary artery endothelium-dependent relaxation response was restored in rabbits receiving EPC transplantation. Lung water, Evan's blue, and bronchoalveolar lavage protein contents were significantly reduced in the EPC transplanted group, indicating a better preservation of the alveolocapillary membrane. Transplantation of EPCs decreased the lung hemoglobin level. Furthermore, expressions of CD11b and myeloperoxidase activity were also suppressed after administration of EPCs.
   CONCLUSIONS: Transplantation of EPCs restored pulmonary endothelial function, preserved integrity of the alveolocapillary barrier and suppressed the lung inflammatory response, thereby improving pulmonary gas exchange in rabbits with intratracheal lipopolysaccharide-induced ALI. Transplantation of EPCs can be a novel cell-based, endothelium-targeted therapeutic strategy for prevention and treatment of ALI/ARDS. (Anesth Analg 2011;112:620-7)
C1 [Lam, Chen-Fuh; Lee, Chou-Hwei; Chang, Pei-Jung; Huang, Chein-Chi; Liu, Yen-Chin; Tsai, Yu-Chuan] Natl Cheng Kung Univ, Dept Anesthesiol, Med Coll & Hosp, Tainan 70101, Taiwan.
C1 [Lee, Chou-Hwei; Jiang, Meei-Jyh] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Med Coll & Hosp, Tainan 70101, Taiwan.
C1 [Roan, Jun-Neng] Tainan Municipal Hosp, Div Cardiovasc Surg, Dept Surg, Tainan, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University
RP Tsai, YC (corresponding author), Natl Cheng Kung Univ, Dept Anesthesiol, Med Coll & Hosp, 138 Sheng Li Rd, Tainan 70101, Taiwan.
EM yctsai@mail.ncku.edu.tw
RI Liu, Yen-Chin/HOC-8913-2023; Roan, Jun-Neng/AFK-1022-2022
OI Liu, Yen-Chin/0000-0002-5247-1678; Roan, Jun-Neng/0000-0002-0312-0628
FU National Science Council of Taiwan [97-2314-B-006-023]
FX This study was supported by a research grant from the National Science
   Council of Taiwan (grant number 97-2314-B-006-023 to CFL).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948
   Alba-Loureiro TC, 2004, INFLAMM RES, V53, P658, DOI 10.1007/s00011-004-1308-7
   Asahara T, 2004, AM J PHYSIOL-CELL PH, V287, pC572, DOI 10.1152/ajpcell.00330.2003
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD
   Asti C, 2000, PULM PHARMACOL THER, V13, P61, DOI 10.1006/pupt.2000.0231
   Battistini B, 1998, PULM PHARMACOL THER, V11, P165, DOI 10.1006/pupt.1998.0133
   Burnham EL, 2005, AM J RESP CRIT CARE, V172, P854, DOI 10.1164/rccm.200410-1325OC
   d'Uscio LV, 2003, CIRC RES, V92, P88, DOI 10.1161/01.RES.0000049166.33035.62
   DALLAL MM, 1994, J APPL PHYSIOL, V77, P1030, DOI 10.1152/jappl.1994.77.2.1030
   FAGON JY, 2003, EUR RESPIR J, V42, P77
   Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087
   George J, 2003, ARTERIOSCL THROM VAS, V23, pE57, DOI 10.1161/01.ATV.0000107029.65274.db
   He TR, 2005, AM J PHYSIOL-HEART C, V289, pH968, DOI 10.1152/ajpheart.01166.2004
   He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f
   He TR, 2004, STROKE, V35, P2378, DOI 10.1161/01.STR.0000141893.33677.5d
   HENDERSON RF, 1984, ENVIRON HEALTH PERSP, V56, P115, DOI 10.2307/3429841
   Hingorani AD, 2000, ENDOTHEL CELL RES S, V7, P3
   Imamura S, 1997, PATHOL INT, V47, P16, DOI 10.1111/j.1440-1827.1997.tb04430.x
   Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035
   Kawamoto A, 2001, CIRCULATION, V103, P634
   Kitamura Y, 2001, AM J RESP CRIT CARE, V163, P762, DOI 10.1164/ajrccm.163.3.2003065
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Lam CF, 2008, ANESTHESIOLOGY, V108, P392, DOI 10.1097/ALN.0b013e318164ca64
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Oettgen P, 2006, CIRCULATION, V114, P353, DOI 10.1161/CIRCULATIONAHA.106.639385
   Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   Rezaiguia-Delclaux S, 2003, INTENS CARE MED, V29, P1151, DOI 10.1007/s00134-003-1809-9
   Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com
   Schachinger V, 2006, EUR HEART J, V27, P2775, DOI 10.1093/eurheartj/ehl388
   SOUKHOMOVSKAIA O, 2004, CIRCULATION, V110, P1209
   Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Tao J, 2007, J HUM HYPERTENS, V21, P353, DOI 10.1038/sj.jhh.1002147
   ULICH TR, 1994, INFLAMMATION, V18, P389, DOI 10.1007/BF01534436
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   Warburton David, 2008, Proc Am Thorac Soc, V5, P703, DOI 10.1513/pats.200801-012AW
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814
   Yamamoto T, 1998, J IMMUNOL, V161, P5704
   Yip HK, 2008, STROKE, V39, P69, DOI 10.1161/STROKEAHA.107.489401
NR 44
TC 37
Z9 43
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2011
VL 112
IS 3
BP 620
EP 627
DI 10.1213/ANE.0b013e3182075da4
PG 8
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA 726DG
UT WOS:000287698400026
PM 21233499
OA Bronze
DA 2023-08-21
ER

PT J
AU Wang, YL
   Malik, AB
   Sun, Y
   Hu, SY
   Reynolds, AB
   Minshall, RD
   Hu, GC
AF Wang, Yan-lei
   Malik, Asrar B.
   Sun, Yu
   Hu, Sanyuan
   Reynolds, Albert B.
   Minshall, Richard D.
   Hu, Guochang
TI Innate Immune Function of the Adherens Junction Protein p120-Catenin in
   Endothelial Response to Endotoxin
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERCELLULAR-ADHESION MOLECULE-1; KAPPA-B ACTIVATION; ACUTE LUNG
   INJURY; P120 CATENIN; NEUTROPHIL SEQUESTRATION; CADHERIN EXPRESSION;
   SIGNALING PATHWAYS; KINASE-ACTIVITY; MUTANT MICE; IRAK FAMILY
AB Sepsis-induced acute lung injury is a common clinical disorder in critically ill patients that is associated with high mortality. In this study, we investigated the role of p120-catenin (p120), a constituent of endothelial adherens junctions, in regulating the innate immune function of lungs. In mice in which acute lung injury was induced by i.p. administration of LPS, we observed a rapid decrease in the expression of p120 in lungs. The p120 protein expression was correlated inversely with severity of inflammation. Suppression of p120 expression in lung endothelial cells in mice using small interfering RNA resulted in high sensitivity to endotoxin and greatly increased the mortality compared with controls. Knockdown of p120 also increased the expression of ICAM-1, neutrophil recruitment, production of cytokines TNF-alpha and IL-6, pulmonary transvascular protein permeability, and lung water content in response to LPS. We demonstrated that endothelial p120 modulates lung innate immune function by interfering with the association of TLR4 with its adaptor MyD88 to block TLR4 signaling and NF-kappa B activation in endothelial cells. In conclusion, these studies have uncovered a novel innate immune function of endothelial p120 in downregulating the lung inflammatory response to endotoxin through the suppression of TLR4 signaling. The Journal of Immunology, 2011, 186: 3180-3187.
C1 [Wang, Yan-lei; Malik, Asrar B.; Sun, Yu; Minshall, Richard D.; Hu, Guochang] Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612, United States.
C1 [Wang, Yan-lei; Hu, Sanyuan] Shandong Univ, Dept Gen Surg, Qilu Hosp, Coll Med, Jinan 250012, China.
C1 [Malik, Asrar B.; Minshall, Richard D.] Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612, United States.
C1 [Sun, Yu] Shandong Univ, Inst Pharmacol, Coll Med, Jinan 250012, China.
C1 [Reynolds, Albert B.] Vanderbilt Univ, Dept Canc Biol, Med Ctr, Nashville, TN 37203, United States.
C1 [Minshall, Richard D.; Hu, Guochang] Univ Illinois, Dept Anesthesiol, Coll Med, Chicago, IL 60612, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Shandong University; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital; Shandong University; Vanderbilt University;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Hu, GC (corresponding author), Univ Illinois, Dept Pharmacol Mc 868, 835 S Wolcott Ave, Chicago, IL 60612 USA.
EM gchu@uic.edu
OI Malik, Asrar/0000-0002-8205-7128
FU American Heart Association [0730331N]; National Institutes of Health
   National Heart, Lung, and Blood Institute [HL104092, HL071626, P01
   HL060678]
FX This work was supported by American Heart Association Scientist
   Development Grant 0730331N (to G.H.) and National Institutes of Health
   National Heart, Lung, and Blood Institute Grants HL104092 (to G.H.),
   HL071626 (to R.D.M.), and P01 HL060678 (to R.D.M. and A.B.M.).
CR Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Alcaide P, 2008, BLOOD, V112, P2770, DOI 10.1182/blood-2008-03-147181
   Anastasiadis PZ, 2000, J CELL SCI, V113, P1319
   Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510
   Banerjee A, 2007, IMMUNOL CELL BIOL, V85, P420, DOI 10.1038/sj.icb.7100098
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110
   Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0
   Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004
   Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111
   Doerschuk CM, 1996, J IMMUNOL, V157, P4609
   Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853
   Gong P, 2008, J BIOL CHEM, V283, P13437, DOI 10.1074/jbc.M707986200
   Hirano S, 1996, AM J PHYSIOL-LUNG C, V270, pL836, DOI 10.1152/ajplung.1996.270.5.L836
   Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Hu GC, 2008, AM J PHYSIOL-LUNG C, V294, pL178, DOI 10.1152/ajplung.00263.2007
   Hu GC, 2010, CRIT CARE MED, V38, P194, DOI 10.1097/CCM.0b013e3181bc7c17
   Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115
   Iyer S, 2004, AM J PHYSIOL-LUNG C, V286, pL1143, DOI 10.1152/ajplung.00305.2003
   Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4
   Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315
   Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887
   Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325
   Kim TW, 2007, J EXP MED, V204, P1025, DOI 10.1084/jem.20061825
   Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679
   Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399
   Li XP, 2009, CARDIOVASC RES, V83, P72, DOI 10.1093/cvr/cvp100
   Lye E, 2004, J BIOL CHEM, V279, P40653, DOI 10.1074/jbc.M402666200
   Mamidipudi V, 2004, J BIOL CHEM, V279, P4161, DOI 10.1074/jbc.C300431200
   Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7
   Mo YY, 1996, CANCER RES, V56, P2633
   Moreland JG, 2002, AM J RESP CELL MOL, V27, P474, DOI 10.1165/rcmb.4694
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   Ohno H, 2007, BIOCHEM BIOPH RES CO, V353, P547, DOI 10.1016/j.bbrc.2006.12.061
   Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043
   Perez-Moreno M, 2008, P NATL ACAD SCI USA, V105, P15399, DOI 10.1073/pnas.0807301105
   Reynolds AB, 2007, BBA-MOL CELL RES, V1773, P2, DOI 10.1016/j.bbamcr.2006.09.019
   Sampson HW, 2007, J HISTOCHEM CYTOCHEM, V55, P845, DOI 10.1369/jhc.7A7184.2007
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   UHLIG S, 1995, AM J PATHOL, V146, P1235
   van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980
   Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001
   Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407
NR 49
TC 58
Z9 63
U1 0
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2011
VL 186
IS 5
BP 3180
EP 3187
DI 10.4049/jimmunol.1001252
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 721LT
UT WOS:000287356900057
PM 21278343
OA Green Accepted, Bronze
DA 2023-08-21
ER

PT J
AU Wolfson, RK
   Chiang, ET
   Garcia, JGN
AF Wolfson, Rachel K.
   Chiang, Eddie T.
   Garcia, Joe G. N.
TI HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and
   barrier disruption
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE HMGB1; RAGE; ALI/ARDS; ECs/HPMECs/HUVECs/MPVECs; MAPK; Hsp27 
ID GLYCATION END-PRODUCTS; GROUP BOX-1 PROTEIN;
   RESPIRATORY-DISTRESS-SYNDROME; TUMOR-NECROSIS-FACTOR; HEAT-SHOCK
   PROTEIN-27; P38 MAP KINASE; PERMEABILITY; RECEPTOR; DYSFUNCTION;
   ACTIVATION
AB Acute lung injury (ALI) results from loss of alveolar-capillary barrier integrity and the evolution of high-permeability pulmonary edema resulting in alveolar flooding and significant morbidity and mortality. HMGB1 is a late mediator of sepsis which uniquely participates in the evolution of sepsis and sepsis-induced ALI. The molecular events by which HMGB1 contributes to ALI remain poorly characterized. We characterized the role of HMGB1 in endothelial cell (EC) cytoskeletal rearrangement and vascular permeability, events essential to paracellular gap formation and barrier dysfunction characteristic of ALI. Initial experiments demonstrated HMGB1-mediated dose-dependent (5-20 mu g/ml) decreases in transendothelial cell electrical resistance (TER) in the human pulmonary artery EC, a reflection of loss of barrier integrity. Furthermore, HMGB1 produced dose-dependent increases in paracellular gap formation in concert with loss of peripheral organized actin fibers, dissociation of cell-cell junctional cadherins, and the development of central stress fibers, a phenotypic change associated with increased contractile activity and increased EC permeability. Using siRNA strategies directed against known HMGB1 receptors (RAGE, TLR2, TLR4), we systematically determined that the receptor for advanced glycation end products (RAGE) is the primary receptor signaling HMGB1-induced TER decreases and paracellular gap formation via p38 MAP kinase activation and phosphorylation of the actin-binding protein, Hsp27. These studies add to the understanding of HMGB1-induced inflammatory events and vascular barrier disruption and offer the potential for clinical intervention in sepsis-induced ALI. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Chiang, Eddie T.; Garcia, Joe G. N.] Univ Illinois, Inst Personalized Resp Med, Chicago, IL 60612, United States.
C1 [Wolfson, Rachel K.] Univ Chicago, Dept Pediat, Chicago, IL 60637, United States.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Chicago
RP Garcia, JGN (corresponding author), Univ Illinois, Inst Personalized Resp Med, 1737 W Polk St,305D AOB, Chicago, IL 60612 USA.
EM jggarcia@uic.edu
RI Garcia, Joe GN/E-8862-2010
FU National Institute of Child Health and Human Development [K12 HD043387];
   National Heart, Lung, and Blood Institute [K08 HL093359, HL 58064]
FX The authors gratefully acknowledge the expert technical assistance and
   contributions of Sara Camp and thank Lakshmi Natarajan for the continued
   maintenance and supply of high quality endothelial cell culture stocks.
   This work was supported by grants from the National Institute of Child
   Health and Human Development (K12 HD043387) and the National Heart,
   Lung, and Blood Institute (1(08 HL093359, HL 58064).
CR Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565
   ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004
   Birukova AA, 2009, NANOMED-NANOTECHNOL, V5, P30, DOI 10.1016/j.nano.2008.07.002
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300
   Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834
   Garcia JGN, 2002, FASEB J, V16, P1064, DOI 10.1096/fj.01-0895com
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Guo XH, 2006, APMIS, V114, P874, DOI 10.1111/j.1600-0463.2006.apm_372.x
   Hale KK, 1999, J IMMUNOL, V162, P4246
   Hirano S, 2004, CELL BIOL TOXICOL, V20, P1, DOI 10.1023/B:CBTO.0000021019.50889.aa
   Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383
   HYERS TM, 1991, AM REV RESPIR DIS, V144, P268, DOI 10.1164/ajrccm/144.2.268
   Kim JY, 2005, AM J PHYSIOL-LUNG C, V288, pL958, DOI 10.1152/ajplung.00359.2004
   Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune
   Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3
   Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061
   Landry J, 1999, BIOCHEM SOC SYMP, P79
   LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505
   Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704
   MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212
   MILLAR AB, 1989, LANCET, V2, P712, DOI 10.1016/S0140-6736(89)90772-1
   Mitola S, 2006, J IMMUNOL, V176, P12, DOI 10.4049/jimmunol.176.1.12
   Mounier N, 2002, CELL STRESS CHAPERON, V7, P167, DOI 10.1379/1466-1268(2002)007<0167:ACASHS>2.0.CO;2
   Otero K, 2001, BIOCHEM J, V359, P567, DOI 10.1042/0264-6021:3590567
   Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200
   Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002
   PHILLIPS PG, 1989, AM J PHYSIOL, V257, pC562, DOI 10.1152/ajpcell.1989.257.3.C562
   Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110
   Raman KG, 2006, AM J PHYSIOL-GASTR L, V291, pG556, DOI 10.1152/ajpgi.00055.2006
   Sappington PL, 2002, GASTROENTEROLOGY, V123, P790, DOI 10.1053/gast.2002.35391
   Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002
   Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9
   Sunden-Cullberg J, 2005, CRIT CARE MED, V33, P564, DOI 10.1097/01.ccm.0000155991.88802.4D
   SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016
   Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x
   Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
NR 46
TC 157
Z9 171
U1 2
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAR
PY 2011
VL 81
IS 2
BP 189
EP 197
DI 10.1016/j.mvr.2010.11.010
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 724ZS
UT WOS:000287615600006
PM 21146549
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Shaz, BH
   Stowell, SR
   Hillyer, CD
AF Shaz, Beth H.
   Stowell, Sean R.
   Hillyer, Christopher D.
TI Transfusion-related acute lung injury: from bedside to bench and back
SO BLOOD
LA English
DT Review
ID RED-BLOOD-CELLS; PULMONARY HYPERSENSITIVITY REACTION; RISK REDUCTION
   STRATEGY; UP-REGULATE CD11B; IN-VITRO MODEL; HUMAN NEUTROPHILS; ELASTASE
   RELEASE; CONCORDANT SUPEROXIDE; DONOR ANTIBODIES; ANIMAL-MODEL
AB Over the past 60 years, the transfusion medicine community has attained significant knowledge regarding transfusion-related acute lung injury (TRALI) through the bedside to bench and back to the bedside model. First, at the bedside, TRALI causes hypoxia and noncardiogenic pulmonary edema, typically within 6 hours of transfusion. Second, bedside studies showed a higher incidence in plasma and platelet products than in red blood cell products (the fatal TRALI incidence for plasma is 1:2-300 000 products; platelet, 1: 3-400 000; red blood cells, 1: 25 002 000), as well as an association with donor leukocyte antibodies (similar to 80% of cases). Third, at the bench, antibody-dependent and antibody-independent mechanisms have been described, requiring neutrophil and pulmonary endothelial cell activation. Antibodies, as well as alternate substances in blood products, result in neutrophil activation, which, in a susceptible patient, result in TRALI (2-hit hypothesis). Fourth, back to the bedside, policy changes based on results of these studies, such as minimizing use of plasma and platelet products from donors with leukocyte antibodies, have decreased the incidence of TRALI. Thus, steps to mitigate TRALI are in place, but a complete mechanistic understanding of the pathogenesis of TRALI and of which patients are at highest risk remains to be elucidated. (Blood. 2011; 117(5): 1463-1471)
C1 [Shaz, Beth H.; Hillyer, Christopher D.] New York Blood Ctr, New York, NY 10065, United States.
C1 [Shaz, Beth H.; Stowell, Sean R.] Emory Univ, Dept Pathol & Lab Med, Ctr Transfus & Cellular Therapies, Atlanta, GA 30322, United States.
C1 [Hillyer, Christopher D.] Weill Cornell Med Coll, Dept Med, Div Hematol Med Oncol, New York, NY, United States.
C3 New York Blood Center; Emory University; Cornell University; Weill
   Cornell Medicine
RP Shaz, BH (corresponding author), New York Blood Ctr, 310 E 67th St, New York, NY 10065 USA.
EM bshaz@nybloodcenter.org
OI Shaz, Beth/0000-0002-2270-4821
CR AABB, ASS B AABB
   Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   [Anonymous], NAT HEALTHC SAF NETW
   BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7
   Bierling P, 2009, VOX SANG, V96, P266, DOI 10.1111/j.1423-0410.2008.01144.x
   Blood Products Advisory Committee, 2007, TOP 2 TRANSF REL AC
   BRITTINGHAM TE, 1957, JAMA-J AM MED ASSOC, V165, P819, DOI 10.1001/jama.1957.02980250053013
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Danielson C, 2008, TRANSFUSION, V48, P2401, DOI 10.1111/j.1537-2995.2008.01879.x
   DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442
   Doan CA, 1926, J AMER MED ASSOC, V86, P1593, DOI 10.1001/jama.1926.02670470001001
   Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x
   Eder AF, 2010, TRANSFUSION, V50, P1732, DOI 10.1111/j.1537-2995.2010.02652.x
   Flesland O, 2007, Intensive Care Med, V33 Suppl 1, pS17, DOI 10.1007/s00134-007-2875-1
   GRIMMINGER F, 1991, CIRC RES, V68, P503, DOI 10.1161/01.RES.68.2.503
   HAMBURGER SA, 1990, BLOOD, V75, P550
   Jensen HM, 2010, VOX SANG, V98, P130, DOI 10.1111/j.1423-0410.2009.01235.x
   JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3
   Kao GS, 2003, TRANSFUSION, V43, P185, DOI 10.1046/j.1537-2995.2003.00285.x
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Keller-Stanislawski B, 2010, VOX SANG, V98, P70, DOI 10.1111/j.1423-0410.2009.01232.x
   KERNOFF PBA, 1972, BRIT J HAEMATOL, V23, P777, DOI 10.1111/j.1365-2141.1972.tb03492.x
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Kleinman S, 2010, TRANSFUSION, V50, P1312, DOI 10.1111/j.1537-2995.2010.02659.x
   Koch C, 2009, ANN THORAC SURG, V88, P1410, DOI 10.1016/j.athoracsur.2009.07.020
   Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Mangalmurti NS, 2009, BLOOD, V113, P1158, DOI 10.1182/blood-2008-07-166264
   Maslanka K, 2007, VOX SANG, V92, P247, DOI 10.1111/j.1423-0410.2007.00890.x
   Middelburg RA, 2008, TRANSFUSION, V48, P2167, DOI 10.1111/j.1537-2995.2008.01810.x
   MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661
   Murphy MF, 2009, TRANSFUSION, V49, P1779, DOI 10.1111/j.1537-2995.2009.02340.x
   Nakajima F, 2008, VOX SANG, V95, P318, DOI 10.1111/j.1423-0410.2008.01095.x
   Nakazawa H, 2009, TRANSFUSION, V49, P2434, DOI 10.1111/j.1537-2995.2009.02321.x
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Nishimura M, 2007, TRANSFUSION MED, V17, P129, DOI 10.1111/j.1365-3148.2006.00721.x
   Nishimura M, 2004, TRANSFUSION MED, V14, P359, DOI 10.1111/j.0958-7578.2004.00527.x
   Palfi M, 2001, TRANSFUSION, V41, P317, DOI 10.1046/j.1537-2995.2001.41030317.x
   Partrick DA, 1999, J SURG RES, V86, P42, DOI 10.1006/jsre.1999.5702
   Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015
   Partrick DA, 1998, J TRAUMA, V44, P592, DOI 10.1097/00005373-199804000-00006
   PHILIPPS E, 1966, DIS CHEST, V50, P619, DOI 10.1378/chest.50.6.619
   POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x
   Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533
   Ramachandran V, 2004, P NATL ACAD SCI USA, V101, P13519, DOI 10.1073/pnas.0403608101
   Rana R, 2006, CRIT CARE MED, V34, P1892, DOI 10.1097/01.CCM.0000220766.13623.FE
   Reichel CA, 2009, ARTERIOSCL THROM VAS, V29, P1787, DOI 10.1161/ATVBAHA.109.193268
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Sachs UJ, 2010, VOX SANG, V99, P456
   Sachs U J H, 2007, Intensive Care Med, V33 Suppl 1, pS3, DOI 10.1007/s00134-007-2873-3
   Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744
   Sachs UJH, 2005, TRANSFUSION, V45, P1628, DOI 10.1111/j.1537-2995.2005.00587.x
   SEEGER W, 1990, BLOOD, V76, P1438
   Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841
   Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   Silliman CC, 1996, TRANSFUSION, V36, P133, DOI 10.1046/j.1537-2995.1996.36296181925.x
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   Silliman CC, 2009, BLOOD REV, V23, P245, DOI 10.1016/j.blre.2009.07.005
   Sinnott P, 2004, EUR J IMMUNOGENET, V31, P271, DOI 10.1111/j.1365-2370.2004.00481.x
   Stainsby D, 2006, TRANSFUS MED REV, V20, P273, DOI 10.1016/j.tmrv.2006.05.002
   Stowell SR, 2007, BLOOD, V109, P219, DOI 10.1182/blood-2006-03-007153
   Stowell SR, 2009, MOL BIOL CELL, V20, P1408, DOI 10.1091/mbc.E08-07-0786
   Takahashi D, 2010, VOX SANG, V98, P560, DOI 10.1111/j.1423-0410.2010.01311.x
   TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548
   Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51
   Triulzi DJ, 2009, TRANSFUSION, V49, P1825, DOI 10.1111/j.1537-2995.2009.02206.x
   Triulzi DJ, 2009, ANESTH ANALG, V108, P770, DOI 10.1213/ane.0b013e31819029b2
   US Food and Drug Administration, 2010, FAT REP FDA FOLL BLO
   Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643
   VANBUREN NL, 1990, TRANSFUSION, V30, P42
   Vinten-Johansen J, 2004, CARDIOVASC RES, V61, P481, DOI 10.1016/j.cardiores.2003.10.011
   Vlaar APJ, 2010, ANESTHESIOLOGY, V113, P92, DOI 10.1097/ALN.0b013e3181de6f25
   Wakamoto S, 2008, TRANSFUSION, V48, P2060, DOI 10.1111/j.1537-2995.2008.01809.x
   WARD HN, 1968, ARCH INTERN MED, V122, P362, DOI 10.1001/archinte.122.4.362
   Welsby IJ, 2010, J THORAC CARDIOV SUR, V140, P1353, DOI 10.1016/j.jtcvs.2009.12.035
   Wilson M, 1997, J TRAUMA, V43, P302
   WOLF CFW, 1976, TRANSFUSION, V16, P135, DOI 10.1046/j.1537-2995.1976.16276155107.x
   Woodfin A, 2010, CURR OPIN HEMATOL, V17, P9, DOI 10.1097/MOH.0b013e3283333930
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
   YOMTOVIAN R, 1984, LANCET, V1, P244
   Zarbock A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502
   ZOON KC, 2001, TRANSFUSION RELATED
NR 86
TC 88
Z9 94
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD FEB 3
PY 2011
VL 117
IS 5
BP 1463
EP 1471
DI 10.1182/blood-2010-04-278135
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 715WV
UT WOS:000286925500011
PM 20944069
OA Bronze
DA 2023-08-21
ER

PT J
AU Jin, Y
   Lee, SJ
   Minshall, RD
   Choi, AMK
AF Jin, Yang
   Lee, Seon-Jin
   Minshall, Richard D.
   Choi, Augustine M. K.
TI Caveolin-1: a critical regulator of lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Review
DE apoptosis; Inflammation; caveolin-1 
ID NITRIC-OXIDE SYNTHASE; SIGNAL-TRANSDUCTION PATHWAYS; PULMONARY
   EPITHELIAL-CELLS; RECEPTOR TYROSINE KINASE; ANTIGEN-PRESENTING CELLS;
   ENDOTHELIAL-CELLS; IN-VIVO; HEME OXYGENASE-1; LIPID RAFTS; SCAFFOLDING
   DOMAIN
AB Jin Y, Lee SJ, Minshall RD, Choi AM. Caveolin-1: a critical regulator of lung injury. Am J Physiol Lung Cell Mol Physiol 300: L151-L160, 2011. First published November 19, 2010; doi:10.1152/ajplung.00170.2010.-Caveolin-1 (cav-1), a 22-kDa transmembrane scaffolding protein, is the principal structural component of caveolae. Cav-1 regulates critical cell functions including proliferation, apoptosis, cell differentiation, and transcytosis via diverse signaling pathways. Abundant in almost every cell type in the lung, including type I epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, macrophages, and neutrophils, cav-1 plays a crucial role in the pathogenesis of acute lung injury (ALI). ALI and its severe form, acute respiratory distress syndrome (ARDS), are responsible for significant morbidity and mortality in intensive care units, despite improvement in ventilation strategies. The pathogenesis of ARDS is still poorly understood, and therapeutic options remain limited. In this article, we summarize recent data regarding the regulation and function of cav-1 in lung biology and pathology, in particular as it relates to ALI. We further discuss the potential molecular and cellular mechanisms by which cav-1 expression contributes to ALI. Investigating the cellular functions of cav-1 may provide new insights for understanding the pathogenesis of ALI and provide novel targets for therapeutic interventions in the future.
C1 [Jin, Yang; Lee, Seon-Jin; Choi, Augustine M. K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med,Dept Med, Boston, MA 02115, United States.
C1 [Minshall, Richard D.] Univ Illinois, Ctr Lung & Vasc Biol, Dept Anesthesiol, Chicago, IL, United States.
C1 [Minshall, Richard D.] Univ Illinois, Ctr Lung & Vasc Biol, Dept Pharmacol, Chicago, IL, United States.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Jin, Y (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med,Dept Med, 75 Francis St, Boston, MA 02115 USA.
EM yjin@rics.bwh.harvard.edu
RI Lee, Seon-Jin/AAJ-8258-2020
OI Lee, Seon-Jin/0000-0001-7214-7536
FU NHLBI NIH HHS [K08 HL085601] Funding Source: Medline
CR Alonso MA, 2001, J CELL SCI, V114, P3957
   Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773
   Bento-Abreu A, 2009, J NEUROCHEM, V111, P49, DOI 10.1111/j.1471-4159.2009.06304.x
   Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693
   Buckley S, 1998, AM J PHYSIOL-LUNG C, V274, pL714, DOI 10.1152/ajplung.1998.274.5.L714
   Cai QC, 2003, ACTA PHARMACOL SIN, V24, P1051
   Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107
   Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200
   Cho WJ, 2007, J CELL MOL MED, V11, P1069, DOI 10.1111/j.1582-4934.2007.00113.x
   CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421
   Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429
   Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236
   Del Galdo F, 2008, CURR OPIN RHEUMATOL, V20, P713, DOI 10.1097/BOR.0b013e3283103d27
   Dong F, 2005, BRIT J PHARMACOL, V145, P323, DOI 10.1038/sj.bjp.0706193
   Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0
   Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448
   Fang PK, 2006, AM J PATHOL, V169, P2209, DOI 10.2353/ajpath.2006.060562
   Fernandez MA, 2006, SCIENCE, V313, P1628, DOI 10.1126/science.1130773
   Feron O, 1999, Curr Opin Clin Nutr Metab Care, V2, P291, DOI 10.1097/00075197-199907000-00007
   Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810
   Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5
   Franek WR, 2001, J BIOL CHEM, V276, P569, DOI 10.1074/jbc.M004716200
   Frank PG, 2004, CURR OPIN LIPIDOL, V15, P523, DOI 10.1097/00041433-200410000-00005
   Fujimoto T, 2000, J CELL SCI, V113, P3509
   Gadjeva M, 2010, J IMMUNOL, V184, P296, DOI 10.4049/jimmunol.0900604
   Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200
   Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633
   Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853
   GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517
   Goetz JG, 2008, J CELL BIOL, V180, P1261, DOI 10.1083/jcb.200709019
   Gumbleton M, 2000, PHARM RES-DORDR, V17, P1035, DOI 10.1023/A:1026464526074
   Han JM, 2002, MOL BIOL CELL, V13, P3976, DOI 10.1091/mbc.E02-02-0100
   Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005
   Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887
   Heikkila O, 2009, J GEN VIROL, V90, P197, DOI 10.1099/vir.0.004838-0
   Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042
   Hill WG, 2005, AM J PHYSIOL-CELL PH, V289, pC33, DOI 10.1152/ajpcell.00046.2005
   Hoetzel A, 2009, CRIT CARE MED, V37, P1708, DOI 10.1097/CCM.0b013e31819efa31
   Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486
   Hu GC, 2008, AM J PHYSIOL-LUNG C, V294, pL178, DOI 10.1152/ajplung.00263.2007
   Ingbar DH, 2000, CLIN CHEST MED, V21, P589, DOI 10.1016/S0272-5231(05)70168-4
   Ito J, 2006, J NEUROCHEM, V97, P1034, DOI 10.1111/j.1471-4159.2006.03805.x
   Jin Y, 2008, AM J RESP CELL MOL, V39, P171, DOI 10.1165/rcmb.2007-0323OC
   Jin Y, 2009, FASEB J, V23, P341, DOI 10.1096/fj.08-108423
   Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522
   Kasper M, 2009, CURR CANCER DRUG TAR, V9, P341, DOI 10.2174/156800909788166501
   Kogo H, 2004, J BIOL CHEM, V279, P25574, DOI 10.1074/jbc.M310807200
   Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327
   Le Saux CJ, 2008, J BIOL CHEM, V283, P5760, DOI 10.1074/jbc.M701572200
   Le Saux O, 2008, AM J PHYSIOL-LUNG C, V295, pL1007, DOI 10.1152/ajplung.90207.2008
   Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200
   Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375
   Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393
   Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184
   Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003
   Lim JS, 2010, AGING CELL, V9, P243, DOI 10.1111/j.1474-9726.2010.00554.x
   Linge A, 2007, INT J BIOCHEM CELL B, V39, P1964, DOI 10.1016/j.biocel.2007.05.018
   Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7
   Lohse MJ, 1996, BIOCHEM SOC T, V24, P975, DOI 10.1042/bst0240975
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Lv XJ, 2010, INFLAMM RES, V59, P531, DOI 10.1007/s00011-010-0157-9
   Maniatis NA, 2006, CIRC RES, V99, P870, DOI 10.1161/01.RES.0000245187.08026.47
   Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Medina FA, 2007, MICROBES INFECT, V9, P325, DOI 10.1016/j.micinf.2006.12.011
   Medina FA, 2006, INFECT IMMUN, V74, P6665, DOI 10.1128/IAI.00949-06
   Medina FA, 2006, CELL CYCLE, V5, P1865, DOI 10.4161/cc.5.16.3132
   Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4
   MEYRICK B, 1986, Critical Care Clinics, V2, P405
   Mirza MK, 2010, AM J PATHOL, V176, P2344, DOI 10.2353/ajpath.2010.091088
   MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0
   Mungunsukh O, 2010, AM J PHYSIOL-LUNG C, V298, pL696, DOI 10.1152/ajplung.00322.2009
   Odajima N, 2007, J HISTOCHEM CYTOCHEM, V55, P899, DOI 10.1369/jhc.7A7203.2007
   Ohnuma K, 2005, MOL CELL BIOL, V25, P7743, DOI 10.1128/MCB.25.17.7743-7757.2005
   Ohnuma K, 2004, P NATL ACAD SCI USA, V101, P14186, DOI 10.1073/pnas.0405266101
   Ohnuma K, 2007, J BIOL CHEM, V282, P10117, DOI 10.1074/jbc.M609157200
   Ohnuma K, 2009, BIOCHEM BIOPH RES CO, V386, P327, DOI 10.1016/j.bbrc.2009.06.027
   Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342
   Padhan K, 2007, J GEN VIROL, V88, P3067, DOI 10.1099/vir.0.82856-0
   PALADE GE, 1953, J APPL PHYS, V24, P1424
   Parat MO, 2004, SUB CELL BIOCHEM, V37, P425
   Ramirez MI, 2002, J HISTOCHEM CYTOCHEM, V50, P33, DOI 10.1177/002215540205000104
   Ravid D, 2008, EXP CELL RES, V314, P2762, DOI 10.1016/j.yexcr.2008.06.004
   Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200
   Razani B, 2001, J BIOL CHEM, V276, P38121
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z
   Saqr HE, 2006, J NEUROPATH EXP NEUR, V65, P152, DOI 10.1097/01.jnen.0000199574.86170.80
   SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395
   Schlott T, 2005, GYNECOL ONCOL, V98, P409, DOI 10.1016/j.ygyno.2005.04.034
   Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416
   SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759
   Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200
   Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200
   Schwab W, 1999, HISTOCHEM CELL BIOL, V112, P41, DOI 10.1007/s004180050390
   Shack S, 2003, MOL CELL BIOL, V23, P2407, DOI 10.1128/MCB.23.7.2407-2414.2003
   SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185
   Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100
   Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998
   Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673
   Sundivakkam PC, 2009, AM J PHYSIOL-CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008
   Thomas CM, 2008, J CELL MOL MED, V12, P796, DOI 10.1111/j.1582-4934.2008.00295.x
   Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200
   Tourkina E, 2008, AM J PHYSIOL-LUNG C, V294, pL843, DOI 10.1152/ajplung.00295.2007
   Tourkina E, 2010, ANN RHEUM DIS, V69, P1220, DOI 10.1136/ard.2009.117580
   van den Heuvel APJ, 2005, BIOCHEM J, V385, P795, DOI 10.1042/BJ20041449
   Vassilieva EV, 2009, BIOCHEM BIOPH RES CO, V379, P460, DOI 10.1016/j.bbrc.2008.12.118
   Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529
   Wallach-Dayan SB, 2006, AM J PHYSIOL-LUNG C, V290, pL790, DOI 10.1152/ajplung.00300.2004
   Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536
   Wang XQ, 2007, CANCER RES, V67, P9986, DOI 10.1158/0008-5472.CAN-07-1300
   Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC
   Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9
   Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200
   Xie ZH, 2003, CANCER RES, V63, P5370
   YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445
   Yang G, 2008, EXP MOL PATHOL, V84, P131, DOI 10.1016/j.yexmp.2007.08.004
   Yang GA, 2010, EXP MOL PATHOL, V89, P9, DOI 10.1016/j.yexmp.2010.03.009
   Zaas DW, 2009, J BIOL CHEM, V284, P9955, DOI 10.1074/jbc.M808629200
   Zaher TE, 2007, FREE RADICAL BIO MED, V42, P897, DOI 10.1016/j.freeradbiomed.2007.01.021
   Zhang M, 2009, AM J PHYSIOL-LUNG C, V297, pL945, DOI 10.1152/ajplung.00081.2009
   Zhao XX, 2009, BIOCHEM BIOPH RES CO, V378, P21, DOI 10.1016/j.bbrc.2008.10.123
   Zhao YY, 2009, TRENDS CARDIOVAS MED, V19, P238, DOI 10.1016/j.tcm.2010.02.003
   Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000
NR 124
TC 93
Z9 111
U1 3
U2 15
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD FEB
PY 2011
VL 300
IS 2
BP L151
EP L160
DI 10.1152/ajplung.00170.2010
PG 10
WC Physiology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Respiratory System
GA 714HW
UT WOS:000286800300001
PM 21097526
OA Green Published
DA 2023-08-21
ER

PT J
AU Perl, M
   Lomas-Neira, J
   Venet, F
   Chung, CS
   Ayala, A
AF Perl, Mario
   Lomas-Neira, Joanne L.
   Venet, Fabienne
   Chung, Chun-Shiang
   Ayala, Alfred
TI Pathogenesis of indirect (secondary) acute lung injury
SO EXPERT REVIEW OF RESPIRATORY MEDICINE
LA English
DT Review
DE apoptosis; ALI/ARDS; Fas; silencing; siRNA 
ID RESPIRATORY-DISTRESS-SYNDROME; EXTRACORPOREAL MEMBRANE-OXYGENATION;
   ANGIOTENSIN-CONVERTING ENZYME; EPITHELIAL BARRIER FUNCTION;
   COLONY-STIMULATING FACTOR; SOLUBLE FAS LIGAND; NEUTROPHIL APOPTOSIS;
   DENDRITIC CELLS; INTRAVASCULAR COAGULATION; VENTILATION STRATEGY
AB Expert Rev. Resp. Med. 5(1), 115-126(2011) At present, therapeutic interventions to treat acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) remain largely limited to lung-protective strategies, as no real molecular pathophysiologic-driven therapeutic intervention has yet become available. This is in part the result of the heterogeneous nature of the etiological processes that contribute to the state of ALI/ARDS. This article sets out to understand the development of ALI resulting from indirect pulmonary insults, such as extrapulmonary sepsis and trauma, shock, burn injury or mass transfusion, as opposed to direct pulmonary challenges, such as pneumonia, aspiration or lung contusion. Here, we consider not only the experimental and clinical data concerning the roles of various immune (neutrophil, macrophage, lymphocyte and dendritic) as well as nonimmune (epithelial and endothelial) cells in orchestrating the development of ALI resulting from indirect pulmonary stimuli, but also how these cell populations might be targeted therapeutically.
C1 [Lomas-Neira, Joanne; Chung, Chun-Shiang; Ayala, Alfred] Rhode Isl Hosp, Div Surg Res, Dept Surg, Providence, RI 02903, United States.
C1 [Perl, Mario] Univ Ulm, Sch Med, Dept Traumatol Hand & Reconstruct Surg, Ulm, Germany.
C1 [Lomas-Neira, Joanne; Chung, Chun-Shiang; Ayala, Alfred] Brown Univ, Providence, RI 02912, United States.
C1 [Venet, Fabienne] Hosp Civils Lyon, Hop E Herriot, Immunol Lab, Lyon, France.
C3 Lifespan Health Rhode Island; Rhode Island Hospital; Ulm University;
   Brown University; CHU Lyon
RP Ayala, A (corresponding author), Rhode Isl Hosp, Div Surg Res, Dept Surg, Aldrich 227,593 Eddy St, Providence, RI 02903 USA.
EM aayala@lifespan.org
OI Ayala, Alfred/0000-0002-5034-2995; Venet, Fabienne/0000-0003-0462-4235
FU  [NIH - RO1 HL73525];  [DFG-PE-908/2]
FX This work was supported in part by funds from the NIH - RO1 HL73525 to
   Alfred Ayala and DFG-PE-908/2 to Mario Perl. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137
   Aggarwal NR, 2010, PHYSIOL GENOMICS, V41, P109, DOI 10.1152/physiolgenomics.00131.2009
   Agre Peter, 2006, Proc Am Thorac Soc, V3, P5, DOI 10.1513/pats.200510-109JH
   Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0
   Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Atochina EN, 1997, AM J RESP CRIT CARE, V156, P1114, DOI 10.1164/ajrccm.156.4.96-12116
   Ayala A, 2002, AM J PATHOL, V161, P2283, DOI 10.1016/S0002-9440(10)64504-X
   Azoulay E, 2002, CRIT CARE MED, V30, P781, DOI 10.1097/00003246-200204000-00010
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589
   Baker CS, 1999, LANCET, V353, P1232, DOI 10.1016/S0140-6736(98)09449-5
   Bardales RH, 1996, AM J PATHOL, V149, P845
   Benjamim CF, 2005, BLOOD, V105, P3588, DOI 10.1182/blood-2004-08-3251
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6
   Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002
   Calfee CS, 2007, CRIT CARE MED, V35, P2243, DOI 10.1097/01.CCM.0000280434.33451.87
   Carney DE, 1999, CIRCULATION, V100, P400, DOI 10.1161/01.CIR.100.4.400
   CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690
   Clark SC, 2003, J THORAC CARDIOV SUR, V126, P2052, DOI 10.1016/S0022-5223(03)01187-5
   D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498
   de Heer HJ, 2005, SEMIN IMMUNOL, V17, P295, DOI 10.1016/j.smim.2005.05.002
   Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee
   Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151
   Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193
   DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596
   Dunican AL, 2000, SHOCK, V14, P284, DOI 10.1097/00024382-200014030-00007
   Dunican AL, 2000, SHOCK, V13, P244, DOI 10.1097/00024382-200003000-00012
   Endo Shigeatsu, 2006, Research Communications in Molecular Pathology and Pharmacology, V119, P53
   Ertel W, 1999, J TRAUMA, V46, P784, DOI 10.1097/00005373-199905000-00005
   Fialkow L, 2006, CRIT CARE, V10, DOI 10.1186/cc5090
   Fullerton DA, 1996, SURGERY, V120, P879, DOI 10.1016/S0039-6060(96)80098-5
   Gando S, 1997, J TRAUMA, V42, P1068, DOI 10.1097/00005373-199706000-00014
   Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031
   Goodman ER, 1999, ARCH SURG-CHICAGO, V134, P1049, DOI 10.1001/archsurg.134.10.1049
   Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D
   Guinee D, 1997, AM J PATHOL, V151, P999
   Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007
   Hayakawa M, 2010, SHOCK, V33, P14, DOI 10.1097/SHK.0b013e3181aa95c4
   HEFLIN AC, 1981, J CLIN INVEST, V68, P1253, DOI 10.1172/JCI110371
   Herridge MS, 2005, NEW ENGL J MED, V353, P1736, DOI 10.1056/NEJMe058205
   Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010
   INOUE S, 1995, ARCH SURG-CHICAGO, V130, P93
   Jimenez MF, 1997, ARCH SURG-CHICAGO, V132, P1263
   Kiener PA, 1997, J IMMUNOL, V159, P1594
   Kodama T, 2007, INTERNAL MED, V46, P699, DOI 10.2169/internalmedicine.46.6182
   Kotecha S, 2003, THORAX, V58, P961, DOI 10.1136/thorax.58.11.961
   LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047
   LAUFE MD, 1986, AM J MED, V80, P1022, DOI 10.1016/0002-9343(86)90659-5
   LAWRENCE MB, 1993, J IMMUNOL, V151, P6338
   Lee KS, 2008, RESP MED, V102, P464, DOI 10.1016/j.rmed.2007.10.001
   Lomas JL, 2003, SHOCK, V19, P358, DOI 10.1097/00024382-200304000-00011
   Lomas-Neira J, 2006, AM J PHYSIOL-LUNG C, V290, pL51, DOI 10.1152/ajplung.00028.2005
   Lomas-Neira JL, 2004, J LEUKOCYTE BIOL, V76, P58, DOI 10.1189/jlb.1103541
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007
   Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009
   Martin TR, 2002, J CLIN INVEST, V110, P1603, DOI 10.1172/JCI200217302
   Matsuno H, 2001, J RHEUMATOL, V28, P22
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250
   Matute-Bello G, 1999, J IMMUNOL, V163, P2217
   Matute-Bello G, 2001, INFECT IMMUN, V69, P5768, DOI 10.1128/IAI.69.9.5768-5776.2001
   Matute-Bello G, 2001, AM J PATHOL, V158, P153, DOI 10.1016/S0002-9440(10)63953-3
   MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004
   Modelska K, 1999, AM J RESP CRIT CARE, V160, P1450, DOI 10.1164/ajrccm.160.5.9901096
   Moloney ED, 2003, EUR RESPIR J, V21, P720, DOI 10.1183/09031936.03.00120102
   Monchi M, 1998, AM J RESP CRIT CARE, V158, P1076, DOI 10.1164/ajrccm.158.4.9802009
   Morris PE, 1997, INFLAMMATION, V21, P269, DOI 10.1023/A:1027393715300
   Nakajima T, 2010, J IMMUNOL, V184, P5835, DOI 10.4049/jimmunol.0903238
   Nakamura M, 2004, AM J PATHOL, V164, P1949, DOI 10.1016/S0002-9440(10)63755-8
   Nelson S, 1998, J INFECT DIS, V178, P1075, DOI 10.1086/515694
   Newman PJ, 1997, J CLIN INVEST, V100, pS25
   Novak N, 2008, J ALLERGY CLIN IMMUN, V121, pS370, DOI 10.1016/j.jaci.2007.06.001
   Nowak K, 2007, AM J PHYSIOL-LUNG C, V293, pL162, DOI 10.1152/ajplung.00001.2007
   OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904
   Peek GJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-163
   Pelosi P, 2003, EUR RESPIR J, V22, p48S, DOI 10.1183/09031936.03.00420803
   Pene F, 2008, J IMMUNOL, V181, P8513, DOI 10.4049/jimmunol.181.12.8513
   Perl M, 2005, AM J PATHOL, V167, P1545, DOI 10.1016/S0002-9440(10)61240-0
   Perl M, 2007, J AM COLL SURGEONS, V204, P840, DOI 10.1016/j.jamcollsurg.2007.02.023
   Perl M, 2007, AM J RESP CRIT CARE, V176, P591, DOI 10.1164/rccm.200611-1743OC
   Perl M, 2010, CRIT CARE MED, V38, P1179, DOI 10.1097/CCM.0b013e3181d4563f
   Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054
   Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X
   PRATT PC, 1979, AM J PATHOL, V95, P191
   Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006
   Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852
   Ricou B, 1996, AM J RESP CRIT CARE, V154, P346, DOI 10.1164/ajrccm.154.2.8756805
   RINALDO JE, 1985, AM REV RESPIR DIS, V131, P579, DOI 10.1164/arrd.1985.131.4.579
   Rocco PRM, 2005, CURR OPIN CRIT CARE, V11, P10, DOI 10.1097/00075198-200502000-00003
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   SABHARWAL AK, 1995, AM J RESP CRIT CARE, V151, P758
   SCARPATI EM, 1989, J BIOL CHEM, V264, P20705
   Seekamp A, 2001, SHOCK, V15, P254, DOI 10.1097/00024382-200115040-00002
   Seki H, 2010, INFLAMM RES, V59, P837, DOI 10.1007/s00011-010-0195-3
   Serrao KL, 2001, AM J PHYSIOL-LUNG C, V280, pL298, DOI 10.1152/ajplung.2001.280.2.L298
   Shijo H, 1998, INFLAMM RES, V47, P67, DOI 10.1007/s000110050278
   Skoutelis AT, 2000, CRIT CARE MED, V28, P2355, DOI 10.1097/00003246-200007000-00029
   STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736
   STEPHENS KE, 1988, AM REV RESPIR DIS, V138, P1300, DOI 10.1164/ajrccm/138.5.1300
   Suntharalingam G, 2001, CRIT CARE MED, V29, P562
   Suzuki T, 2005, AM J RESP CELL MOL, V33, P231, DOI 10.1165/rcmb.2005-0109OC
   Sznajder JI, 1999, AM J RESP CRIT CARE, V160, P1441
   Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659
   TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548
   Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9
   Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741
   van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311
   VANSTEENKISTE JF, 1989, BLUT, V58, P287, DOI 10.1007/BF00320168
   Venet F, 2010, AM J PATHOL, V176, P764, DOI 10.2353/ajpath.2010.090765
   Venet F, 2009, J IMMUNOL, V183, P3472, DOI 10.4049/jimmunol.0804119
   Vermaelen K, 2005, AM J RESP CRIT CARE, V172, P530, DOI 10.1164/rccm.200410-1384SO
   Vincent JL, 2006, CLIN CHEST MED, V27, P725, DOI 10.1016/j.ccm.2006.06.010
   WALKER DC, 1995, MICROVASC RES, V50, P397, DOI 10.1006/mvre.1995.1067
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7
   WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388
   Williams MA, 1999, J LEUKOCYTE BIOL, V65, P725, DOI 10.1002/jlb.65.6.725
   Wortinger MA, 2003, IMMUNOLOGY, V110, P225, DOI 10.1046/j.1365-2567.2003.01724.x
   Wunderink RG, 2001, CHEST, V119, P523, DOI 10.1378/chest.119.2.523
   Yang KY, 2003, AM J RESP CRIT CARE, V167, P1567, DOI 10.1164/rccm.200207-664OC
   Yilmaz M, 2007, CRIT CARE MED, V35, P2303, DOI 10.1097/01.CCM.0000284505.96481.24
   Zeiher BG, 2004, CRIT CARE MED, V32, P1695, DOI 10.1097/01.CCM.0000133332.48386.85
NR 130
TC 124
Z9 145
U1 2
U2 27
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-6348
EI 1747-6356
J9 EXPERT REV RESP MED
JI Expert Rev. Respir. Med.
PD FEB
PY 2011
VL 5
IS 1
BP 115
EP 126
DI 10.1586/ERS.10.92
PG 12
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA 056RD
UT WOS:000312507900018
PM 21348592
OA Green Accepted
DA 2023-08-21
ER

PT J
AU Sachs, UJH
   Wasel, W
   Bayat, B
   Bohle, RM
   Hattar, K
   Berghofer, H
   Reil, A
   Bux, J
   Bein, G
   Santoso, S
   Weissmann, N
AF Sachs, Ulrich J. H.
   Wasel, Wiebke
   Bayat, Behnaz
   Bohle, Rainer M.
   Hattar, Katja
   Berghoefer, Heike
   Reil, Angelika
   Bux, Juergen
   Bein, Gregor
   Santoso, Sentot
   Weissmann, Norbert
TI Mechanism of transfusion-related acute lung injury induced by HLA class
   II antibodies
SO BLOOD
LA English
DT Article
ID IN-VITRO MODEL; HUMAN NEUTROPHILS; DONOR ANTIBODIES; BLOOD-DONORS;
   TRALI; EXPRESSION; PATHOGENESIS; CELLS; VIVO; INTERLEUKIN-8
AB Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-associated mortality in the United States and other countries. In most TRALI cases, human leukocyte antigen (HLA) class II antibodies are detected in implicated donors. However, the corresponding antigens are not present on the cellular key players in TRALI: neutrophils and endothelium. In this study, we identify monocytes as a primary target in HLA class II-induced TRALI. Monocytes become activated when incubated with matched HLA class II antibodies and are capable of activating neutrophils, which, in turn, can induce disturbance of an endothelial barrier. In an ex vivo rodent model, HLA class II antibody-dependent monocyte activation leads to severe pulmonary edema in a relevant period of time, whenever neutrophils are present and the endothelium is preactivated. Our data suggest that in most TRALI cases, monocytes are cellular key players, because HLA class II antibodies induce TRALI by a reaction cascade initiated by monocyte activation. Furthermore, our data support the previous assumption that TRALI pathogenesis follows a threshold model. Having identified the biologic mechanism of HLA class II antibody-induced TRALI, strategies to avoid plasma from immunized donors, such as women with a history of pregnancy, appear to be justified preventive measures. (Blood. 2011;117(2):669-677)
C1 [Sachs, Ulrich J. H.; Wasel, Wiebke; Bayat, Behnaz; Berghoefer, Heike; Bein, Gregor; Santoso, Sentot] Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany.
C1 [Bohle, Rainer M.] Univ Saarland, Inst Pathol, D-6650 Homburg, Germany.
C1 [Hattar, Katja] Univ Giessen, Lung Ctr, Med Clin 5, D-35392 Giessen, Germany.
C1 [Reil, Angelika; Bux, Juergen] German Red Cross Blood Serv W, Hagen, Germany.
C1 [Weissmann, Norbert] Univ Giessen, Lung Ctr, ECCPS, D-35392 Giessen, Germany.
C3 Justus Liebig University Giessen; Saarland University; Justus Liebig
   University Giessen; Justus Liebig University Giessen
RP Sachs, UJH (corresponding author), Univ Giessen, Inst Clin Immunol & Transfus Med, Langhansstr 7, D-35392 Giessen, Germany.
EM ulrich.sachs@med.uni-giessen.de
RI Sachs, Ulrich/GSI-7824-2022; Hattar, Katja/HMW-1331-2023
OI Weissmann, Norbert/0000-0003-2675-3871; Hattar,
   Katja/0000-0001-6245-4663
FU Deutsche Forschungsgemeinschaft; University Medical Center Giessen and
   Marburg (UKGM) [10/2009GI]; Foundation for Hemotherapeutic Research,
   Bonn, Germany
FX This work was supported by the Deutsche Forschungsgemeinschaft
   (Excellence Cluster-Cardiopulmonary System; U.J.H.S. and N.W.), by the
   University Medical Center Giessen and Marburg (UKGM, research grant
   10/2009GI; S.S. and U.J.H.S.), and a fellowship from the Foundation for
   Hemotherapeutic Research, Bonn, Germany (U.J.H.S.).
CR ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668
   BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265
   BARNARD ML, 1992, J APPL PHYSIOL, V72, P1724, DOI 10.1152/jappl.1992.72.5.1724
   *BD BIOSC, 2008, TECHN B BD BIOSC, V413
   Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x
   Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x
   Crooks SW, 1998, INT J BIOCHEM CELL B, V30, P173, DOI 10.1016/S1357-2725(97)00123-4
   Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x
   Ermert L, 1998, J PHARMACOL EXP THER, V286, P1309
   Flesch BK, 2002, BRIT J HAEMATOL, V116, P673, DOI 10.1046/j.0007-1048.2001.03305.x
   Fung YL, 2009, TRANSFUS MED REV, V23, P266, DOI 10.1016/j.tmrv.2009.06.001
   Greinacher A, 2010, NAT MED, V16, P45, DOI 10.1038/nm.2070
   Hansch GM, 1999, KIDNEY INT, V55, P1811, DOI 10.1046/j.1523-1755.1999.00446.x
   HOLMAN RG, 1990, AM REV RESPIR DIS, V141, P134, DOI 10.1164/ajrccm/141.1.134
   JOHNSON A, 1989, AM J PHYSIOL, V256, pH1012, DOI 10.1152/ajpheart.1989.256.4.H1012
   Kao GS, 2003, TRANSFUSION, V43, P185, DOI 10.1046/j.1537-2995.2003.00285.x
   Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857
   Keller-Stanislawski B, 2010, VOX SANG, V98, P70, DOI 10.1111/j.1423-0410.2009.01232.x
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Koike J, 2000, FEBS LETT, V477, P84, DOI 10.1016/S0014-5793(00)01765-8
   Kopko PM, 2003, TRANSFUSION, V43, P177, DOI 10.1046/j.1537-2995.2003.00307.x
   Kopko PM, 2001, TRANSFUSION, V41, P1244, DOI 10.1046/j.1537-2995.2001.41101244.x
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Lydaki E, 2005, TRANSFUS APHER SCI, V33, P107, DOI 10.1016/j.transci.2004.12.001
   METZNER B, 1995, J INVEST DERMATOL, V104, P789, DOI 10.1111/1523-1747.ep12606993
   Middelburg RA, 2008, TRANSFUSION, V48, P2167, DOI 10.1111/j.1537-2995.2008.01810.x
   MUDZINSKI SP, 1995, BLOOD, V86, P2452, DOI 10.1182/blood.V86.6.2452a.bloodjournal8662452a
   Nishimura M, 2007, TRANSFUSION MED, V17, P129, DOI 10.1111/j.1365-3148.2006.00721.x
   POBER JS, 1986, TRANSPLANTATION, V41, P141, DOI 10.1097/00007890-198602000-00001
   Porretti L, 2004, EUR J HAEMATOL, V73, P295, DOI 10.1111/j.1600-0609.2004.00279.x
   Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x
   Reinisch W, 2003, CLIN EXP IMMUNOL, V133, P476, DOI 10.1046/j.1365-2249.2003.02245.x
   Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744
   Sachs UJH, 2004, BLOOD, V104, P727, DOI 10.1182/blood-2003-11-3809
   SEEGER W, 1995, MICROVASC RES, V50, P1, DOI 10.1006/mvre.1995.1033
   SEEGER W, 1990, BLOOD, V76, P1438
   SEEGER W, 1986, J APPL PHYSIOL, V61, P1781, DOI 10.1152/jappl.1986.61.5.1781
   SHASBY DM, 1985, BLOOD, V65, P605
   Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106
   Triulzi DJ, 2009, TRANSFUSION, V49, P1825, DOI 10.1111/j.1537-2995.2009.02206.x
   Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643
   Varela M, 2002, TRANSFUSION, V42, P1102, DOI 10.1046/j.1537-2995.2002.00225.x
   Vassallo RR, 2010, TRANSFUSION, V50, P1766, DOI 10.1111/j.1537-2995.2010.02626.x
   Wallis JP, 2003, TRANSFUSION, V43, P1053, DOI 10.1046/j.1537-2995.2003.00466.x
   Wallis JP, 2009, ROSSIS PRINCIPLES TR, V4, P870
   Win N, 2003, TRANSFUSION, V43, P545, DOI 10.1046/j.1537-2995.2003.00363.x
   Win N, 2007, HEMATOLOGY, V12, P461, DOI 10.1080/10245330701562345
   Wyman TH, 2002, AM J PHYSIOL-CELL PH, V283, pC1592, DOI 10.1152/ajpcell.00540.2001
NR 49
TC 65
Z9 72
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JAN 13
PY 2011
VL 117
IS 2
BP 669
EP 677
DI 10.1182/blood-2010-05-286146
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 705ZD
UT WOS:000286178700038
PM 21030555
OA Bronze
DA 2023-08-21
ER

PT J
AU Devaney, J
   Contreras, M
   Laffey, JG
AF Devaney, James
   Contreras, Maya
   Laffey, John G.
TI Clinical Review: Gene-based therapies for ALI/ARDS: where are we now?
SO CRITICAL CARE
LA English
DT Review
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; ADENOVIRUS-MEDIATED
   TRANSFER; PLACEBO-CONTROLLED TRIAL; AIRWAY EPITHELIAL-CELLS;
   FACTOR-KAPPA-B; CYSTIC-FIBROSIS; IN-VIVO; RECOMBINANT ADENOVIRUS; CECAL
   LIGATION
AB Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) confer substantial morbidity and mortality, and have no specific therapy. The accessibility of the distal lung epithelium via the airway route, and the relatively transient nature of ALI/ARDS, suggest that the disease may be amenable to gene-based therapies. Ongoing advances in our understanding of the pathophysiology of ALI/ARDS have revealed multiple therapeutic targets for gene-based approaches. Strategies to enhance or restore lung epithelial and/or endothelial cell function, to strengthen lung defense mechanisms against injury, to speed clearance of infection and to enhance the repair process following ALI/ARDS have all demonstrated promise in preclinical models. Despite three decades of gene therapy research, however, the clinical potential for gene-based approaches to lung diseases including ALI/ARDS remains to be realized. Multiple barriers to effective pulmonary gene therapy exist, including the pulmonary architecture, pulmonary defense mechanisms against inhaled particles, the immunogenicity of viral vectors and the poor transfection efficiency of nonviral delivery methods. Deficits remain in our knowledge regarding the optimal molecular targets for gene-based approaches. Encouragingly, recent progress in overcoming these barriers offers hope for the successful translation of gene-based approaches for ALI/ARDS to the clinical setting.
C1 [Contreras, Maya; Laffey, John G.] Galway Univ Hosp, Dept Anaesthesia & Intens Care Med, Galway, Ireland.
C1 [Devaney, James; Contreras, Maya; Laffey, John G.] Natl Univ Ireland, Lung Biol Grp, Regenerat Med Inst, Natl Ctr Biomed Engn Sci, Galway, Ireland.
C1 [Laffey, John G.] Natl Univ Ireland Galway, Inst Clin Sci, Sch Med, Galway, Ireland.
C3 Ollscoil na Gaillimhe-University of Galway; Ollscoil na
   Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of
   Galway
RP Laffey, JG (corresponding author), Galway Univ Hosp, Dept Anaesthesia & Intens Care Med, Newcastle Rd, Galway, Ireland.
EM john.laffey@nuigalway.ie
RI Laffey, John/G-4204-2010
OI Laffey, John/0000-0002-1246-9573; Devaney, James/0000-0002-7489-5463
FU Health Research Board, Dublin, Ireland [RP/2008/193]; European Research
   Council, Brussels, Belgium [ERC-2007-StG 207777]; Health Research Board
   (HRB) [RP-2008-193] Funding Source: Health Research Board (HRB)
FX The present work was supported by funding from the Health Research
   Board, Dublin, Ireland (Grant No. RP/2008/193), and by the European
   Research Council, Brussels, Belgium, under the Framework 7 Programme
   (Grant No. ERC-2007-StG 207777).
CR Adir Y, 2008, AM J PHYSIOL-LUNG C, V294, pL1233, DOI 10.1152/ajplung.00076.2007
   Aguilar S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008013
   Alton EWFW, 1999, LANCET, V353, P947, DOI 10.1016/S0140-6736(98)06532-5
   [Anonymous], 2000, NEW ENGL J MED
   Bromberg Z, 2008, CRIT CARE MED, V36, P246, DOI 10.1097/01.CCM.0000295473.56522.EF
   Buning H, 2008, J GENE MED, V10, P717, DOI 10.1002/jgm.1205
   Campbell AIM, 2001, CIRCULATION, V104, P2242, DOI 10.1161/hc4201.097838
   Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669
   Chen GH, 2000, J IMMUNOL, V165, P6496, DOI 10.4049/jimmunol.165.11.6496
   Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003
   Chtarto A, 2003, GENE THER, V10, P84, DOI 10.1038/sj.gt.3301838
   Crystal RG, 2002, HUM GENE THER, V13, P65, DOI 10.1089/10430340152712647
   Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487
   DUERR J, 2010, AM J RESP CELL MOL B, V178, P1245
   Dumasius V, 2002, CHEST, V121, p33S, DOI 10.1378/chest.121.3_suppl.33S
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Gao CJ, 2011, J TRAUMA, V70, P210, DOI 10.1097/TA.0b013e3181e7432d
   Gao HW, 2006, J IMMUNOL, V177, P612, DOI 10.4049/jimmunol.177.1.612
   Garbuzenko OB, 2010, P NATL ACAD SCI USA, V107, P10737, DOI 10.1073/pnas.1004604107
   GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547
   Griesenbach U, 2009, ADV DRUG DELIVER REV, V61, P128, DOI 10.1016/j.addr.2008.09.010
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700
   Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001
   Harvey BG, 1999, J CLIN INVEST, V104, P1245, DOI 10.1172/JCI7935
   HAY JG, 1995, HUM GENE THER, V6, P1487, DOI 10.1089/hum.1995.6.11-1487
   Hendrickson B, 2007, AM J RESP CELL MOL, V37, P414, DOI 10.1165/rcmb.2006-0276OC
   Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450
   Huang YQ, 2008, CRIT CARE MED, V36, P262, DOI 10.1097/01.CCM.0000297955.02633.A4
   Hyde SC, 2008, NAT BIOTECHNOL, V26, P549, DOI 10.1038/nbt1399
   Joseph PM, 2001, HUM GENE THER, V12, P1369, DOI 10.1089/104303401750298535
   Kabay B, 2007, WORLD J SURG, V31, P105, DOI 10.1007/s00268-006-0066-9
   KATKIN JP, 1995, HUM GENE THER, V6, P985, DOI 10.1089/hum.1995.6.8-985
   Kida H, 2008, AM J PATHOL, V172, P1542, DOI 10.2353/ajpath.2008.071052
   Koehler DR, 2000, PEDIATR RES, V48, P184, DOI 10.1203/00006450-200008000-00011
   Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H
   Lamartina S, 2003, MOL THER, V7, P271, DOI 10.1016/S1525-0016(02)00051-5
   Leung K, 2007, J GENE MED, V9, P10, DOI 10.1002/jgm.987
   Li TB, 2006, AM J PHYSIOL-LUNG C, V290, pL649, DOI 10.1152/ajplung.00205.2005
   Li YT, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-79
   Li Y, 2008, EUR J PHARMACOL, V590, P417, DOI 10.1016/j.ejphar.2008.06.047
   Liu H, 2007, AM J TRANSPLANT, V7, P2291, DOI 10.1111/j.1600-6143.2007.01942.x
   Liu XM, 2009, MOL THER, V17, P285, DOI 10.1038/mt.2008.248
   Lomas-Neira JL, 2005, J LEUKOCYTE BIOL, V77, P846, DOI 10.1189/jlb.1004617
   MacLoughlin RJ, 2009, J AEROSOL MED PULM D, V22, P323, DOI 10.1089/jamp.2008.0717
   Manning E, 2010, HUM GENE THER, V21, P713, DOI 10.1089/hum.2009.147
   Matsuda N, 2005, MOL PHARMACOL, V67, P1018, DOI 10.1124/mol.104.005926
   McAuliffe PF, 2006, GENE THER, V13, P276, DOI 10.1038/sj.gt.3302600
   McCarter SD, 2007, AM J RESP CRIT CARE, V175, P1014, DOI 10.1164/rccm.200609-1370OC
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Meng QH, 2004, J GENE MED, V6, P210, DOI 10.1002/jgm.483
   Moss RB, 2004, CHEST, V125, P509, DOI 10.1378/chest.125.2.509
   Moss RB, 2007, HUM GENE THER, V18, P726, DOI 10.1089/hum.2007.022
   Mustapa MFM, 2009, BIOCONJUGATE CHEM, V20, P518, DOI 10.1021/bc800450r
   Mutlu GM, 2007, AM J RESP CRIT CARE, V176, P582, DOI 10.1164/rccm.200608-1246OC
   Ostrowski LE, 2007, GENE THER, V14, P1492, DOI 10.1038/sj.gt.3302994
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Perabo L, 2008, COMB CHEM HIGH T SCR, V11, P118
   Perl M, 2005, AM J PATHOL, V167, P1545, DOI 10.1016/S0002-9440(10)61240-0
   Perricone MA, 2001, HUM GENE THER, V12, P1383, DOI 10.1089/104303401750298544
   Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B
   Saitoh H, 2002, EXP LUNG RES, V28, P219, DOI 10.1080/019021402753570518
   Scaria A, 1998, J VIROL, V72, P7302, DOI 10.1128/JVI.72.9.7302-7309.1998
   Shu Q, 2006, SHOCK, V26, P365, DOI 10.1097/01.shk.0000224722.65929.58
   Simpson AJ, 2001, J IMMUNOL, V167, P1778, DOI 10.4049/jimmunol.167.3.1778
   Sinn PL, 2003, J VIROL, V77, P5902, DOI 10.1128/JVI.77.10.5902-5910.2003
   Stern M, 2000, GENE THER, V7, P960, DOI 10.1038/sj.gt.3301193
   Strayer MS, 1998, AM J RESP CELL MOL, V18, P1
   Sud S, 2010, INTENS CARE MED, V36, P585, DOI 10.1007/s00134-009-1748-1
   Tagalakis AD, 2008, MOL THER, V16, P907, DOI 10.1038/mt.2008.38
   ter Horst Simone A J, 2006, BMC Pulm Med, V6, P8, DOI 10.1186/1471-2466-6-8
   Vandenberghe LH, 2009, GENE THER, V16, P311, DOI 10.1038/gt.2008.170
   Wagner JA, 1999, LARYNGOSCOPE, V109, P266, DOI 10.1097/00005537-199902000-00017
   Wang X, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-36
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Weiss Daniel J, 2008, Proc Am Thorac Soc, V5, P637, DOI 10.1513/pats.200804-037DW
   Weiss YG, 2001, ANESTHESIOLOGY, V95, P974, DOI 10.1097/00000542-200110000-00029
   Wheeler AP, 2006, NEW ENGL J MED, V354, P2213
   Writer M, 2006, J LIPOSOME RES, V16, P373, DOI 10.1080/08982100600992500
   Yan ZY, 2002, J VIROL, V76, P2043, DOI 10.1128/JVI.76.5.2043-2053.2002
   Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000
   Zamora MR, 2011, AM J RESP CRIT CARE, V183, P531, DOI 10.1164/rccm.201003-0422OC
   Zhang YX, 2010, J THORAC CARDIOV SUR, V139, P758, DOI 10.1016/j.jtcvs.2009.09.027
   Zhao YD, 2006, AM J RESP CELL MOL, V35, P182, DOI 10.1165/rcmb.2005-0115OC
   Zhou J, 2006, GENE THER, V13, P974, DOI 10.1038/sj.gt.3302746
   Zhou R, 2007, GENE THER, V14, P775, DOI 10.1038/sj.gt.3302936
   Zuckerman JB, 1999, HUM GENE THER, V10, P2973, DOI 10.1089/10430349950016384
NR 88
TC 33
Z9 42
U1 3
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
J9 CRIT CARE
JI Crit. Care
PY 2011
VL 15
IS 3
AR 224
DI 10.1186/cc10216
PG 12
WC Critical Care Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 832JB
UT WOS:000295799700059
PM 21699743
OA Green Published, gold
DA 2023-08-21
ER

PT J
AU Gurzu, S
   Jung, I
   Azamfirei, L
   Shin, BY
   Solomon, R
   Demian, D
   Kovacs, J
   Kim, HK
AF Gurzu, Simona
   Jung, Ioan
   Azamfirei, Leonard
   Shin, Bong Young
   Solomon, Raluca
   Demian, Daria
   Kovacs, Judith
   Kim, Han Kyeom
TI Vascular Endothelial Growth Factor Bioactivity and Its Receptors in
   Patients with Acute Respiratory Distress Syndrome
SO KOREAN JOURNAL OF PATHOLOGY
LA English
DT Article
DE respiratory distress syndrome, adult; VEGF/VEGFA; Pneumocytes; Hyaline membranes 
ID ACUTE LUNG INJURY; FACTOR VEGF; MECHANISMS; CELLS; MICE; ARDS; STRETCH;
   SURFACE; TISSUE
AB Background: Pathogenesis of acute respiratory distress syndrome (ARDS) is a controversial issue. Few studies have analyzed the possible role of vascular endothelial growth factor (VEGF) and its receptors in this lesion. Methods: We compared the immunohistochemical expression of VEGF, its receptors (VEGFR1, VEGFR2) and CD68, in normal lungs and lungs with ARDS. Fifty necropsy cases and 12 lung biopsies with ARDS were analyzed. In total, eight cases were in the early stage and 54 cases were in late stage of ARDS. In addition, the serum level of VEGF165 was also determined. Results: In normal lungs, all antibodies marked the endothelial cells (EC) and pneumocytes (PC), except for CD68, which was expressed in the alveolar macrophages. In early ARDS, the intensity of VEGF165 and VEGFR2 decreased in both EC and PC. VEGF121 was absent in PC but its expression increased in bronchial epithelium. VEGFR1 was expressed in the integral PC. In late ARDS, VEGF165 down-regulation was more significant in PC and EC but its intensity increased in hyaline membranes (HM). In some cases, HM were CD68 positive. The serum level of VEGF165 was up-regulated, while VEGF165 intensity in PC decreased and the HM appeared in alveolar spaces. Conclusions: Sporadic positivity of HM for CD68 and decreasing of VEGF165 expression in EC proved that VEGF165 is produced by PC, destroyed macrophages, and extravasated serum.
C1 [Gurzu, Simona; Jung, Ioan; Demian, Daria] Univ Med & Pharm Targu Mures, Dept Pathol, Targu Mures 540139, Romania.
C1 [Azamfirei, Leonard; Solomon, Raluca; Kovacs, Judith] Univ Med & Pharm Targu Mures, Dept Intens Care, Targu Mures 540139, Romania.
C1 [Shin, Bong Young; Kim, Han Kyeom] Korea Univ Coll Med, Korea Univ Guro Hosp, Dept Pathol, Seoul, South Korea.
C3 George Emil Palade University of Medicine, Pharmacy, Science, &
   Technology of Targu Mures; George Emil Palade University of Medicine,
   Pharmacy, Science, & Technology of Targu Mures; Korea University; Korea
   University Medicine (KU Medicine)
RP Gurzu, S (corresponding author), Univ Med & Pharm Targu Mures, Dept Pathol, 38 Ghe Marinescu St, Targu Mures 540139, Romania.
EM simonagurzu@yahoo.com
RI Azamfirei, Leonard/AAP-7975-2020; GURZU, SIMONA/AAD-2710-2019
OI Azamfirei, Leonard/0000-0003-3220-2267; gurzu,
   simona/0000-0003-3968-5118
FU Romanian National University Research Council (CNCSIS); Ministry of
   Education and Research [136/2008, 504/2010]; European Social Fund;
   Romanian Government [POSDRU/89/1.5/S/60782/2010]
FX This work was partially supported by the Romanian National University
   Research Council (CNCSIS), Ministry of Education and Research, projects
   frame: PNII-IDEI code 136/2008, PN II-PD, no. 504/2010 and by the
   Sectoral Operational Programme Human Resources Development, financed
   from the European Social Fund and by the Romanian Government under the
   contract number POSDRU/89/1.5/S/60782/2010.
CR Abadie Y, 2005, EUR RESPIR J, V25, P139, DOI 10.1183/09031936.04.00065504
   Azamfirei L, 2010, MINERVA ANESTESIOL, V76, P609
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Camera M, 1999, ARTERIOSCL THROM VAS, V19, P531, DOI 10.1161/01.ATV.19.3.531
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Epiphanio S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000916
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fong GH, 1999, DEVELOPMENT, V126, P3015
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Kaner RJ, 2001, MOL MED, V7, P240, DOI 10.1007/BF03401843
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Koh H, 2008, RESPIROLOGY, V13, P281, DOI 10.1111/j.1440-1843.2007.01193.x
   Kuhn H, 2010, RESPIROLOGY, V15, P343, DOI 10.1111/j.1440-1843.2009.01701.x
   Maitre B, 2001, EUR RESPIR J, V18, P100, DOI 10.1183/09031936.01.00074701
   Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   Medford ARL, 2009, J CRIT CARE, V24, P236, DOI 10.1016/j.jcrc.2008.04.003
   Medford ARL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-27
   Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004
   Ohwada A, 2003, THORAX, V58, P328, DOI 10.1136/thorax.58.4.328
   Perkins GD, 2005, THORAX, V60, P153, DOI 10.1136/thx.2004.027912
   Robinson CJ, 2001, J CELL SCI, V114, P853
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6
   Zheng W, 2001, AM J PHYSIOL-HEART C, V280, pH909, DOI 10.1152/ajpheart.2001.280.2.H909
NR 27
TC 1
Z9 1
U1 1
U2 8
PU KOREAN SOCIETY PATHOLOGISTS
PI SEOUL
PA ROOM 702 KOREAN MED ASSOC BLDG, 302-75 ICHON, 1 DONG, YOUNGSAN-GU,
   SEOUL, 140-721, SOUTH KOREA
SN 1738-1843
J9 KOREAN J PATHOL
JI Korean J. Pathol.
PY 2011
VL 45
IS 2
BP 139
EP 145
DI 10.4132/KoreanJPathol.2011.45.2.139
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 759IF
UT WOS:000290233300003
DA 2023-08-21
ER

PT J
AU Xing, JJ
   Moldobaeva, N
   Birukova, AA
AF Xing, Junjie
   Moldobaeva, Nurgul
   Birukova, Anna A.
TI Atrial natriuretic peptide protects against Staphylococcus
   aureus-induced lung injury and endothelial barrier dysfunction
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE cytoskeleton; ECs/HPMECs/HUVECs/MPVECs; Inflammation; vascular leakage 
ID PULMONARY GAS-EXCHANGE; P38 MAP KINASE; RHO-KINASE; LIPOTEICHOIC ACID;
   CYTOSKELETAL REORGANIZATION; DIFFERENTIAL REGULATION; ACTIVATION;
   PEPTIDOGLYCAN; THROMBIN; RAC
AB Xing J, Moldobaeva N, Birukova AA. Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. J Appl Physiol 110: 213-224, 2011. First published November 4, 2010; doi:10.1152/japplphysiol.00284.2010.-Lung inflammation and alterations in endothelial cell (EC) permeability are key events to development of acute lung injury (ALI). Protective effects of atrial natriuretic peptide (ANP) have been shown against inflammatory signaling and endothelial barrier dysfunction induced by gram-negative bacterial wall liposaccharide. We hypothesized that ANP may possess more general protective effects and attenuate lung inflammation and EC barrier dysfunction by suppressing inflammatory cascades and barrier-disruptive mechanisms shared by gram-negative and gram-positive pathogens. C57BL/6J wild-type or ANP knockout mice (Nppa-/-) were treated with gram-positive bacterial cell wall compounds, Staphylococcus aureus-derived peptidoglycan (PepG) and/or lipoteichoic acid (LTA) (intratracheal, 2.5 mg/kg each), with or without ANP (intravenous, 2 mu g/kg). In vitro, human pulmonary EC barrier properties were assessed by morphological analysis of gap formation and measurements of transendothelial electrical resistance. LTA and PepG markedly increased pulmonary EC permeability and activated p38 and ERK1/2 MAP kinases, NF-kappa B, and Rho/Rho kinase signaling. EC barrier dysfunction was further elevated upon combined LTA and PepG treatment, but abolished by ANP pretreatment. In vivo, LTA and PepG-induced accumulation of protein and cells in the bronchoalveolar lavage fluid, tissue neutrophil infiltration, and increased Evans blue extravasation in the lungs was significantly attenuated by intravenous injection of ANP. Accumulation of bronchoalveolar lavage markers of LTA/PepG-induced lung inflammation and barrier dysfunction was further augmented in ANP-/- mice and attenuated by exogenous ANP injection. These results strongly suggest a protective role of ANP in the in vitro and in vivo models of ALI associated with gram-positive infection. Thus ANP may have important implications in therapeutic strategies aimed at the treatment of sepsis and ALI-induced gram-positive bacterial pathogens.
C1 [Birukova, Anna A.] Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, Chicago, IL 60637, United States.
C3 University of Chicago
RP Birukova, AA (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, Off N613,5841 S Maryland Ave, Chicago, IL 60637 USA.
EM abirukov@medicine.bsd.uchicago.edu
FU National Heart, Lung, and Blood Institute [HL89257]; American Heart
   Association
FX This study was supported by National Heart, Lung, and Blood Institute
   grant HL89257 and the American Heart Association Midwest Affiliate
   Grant-in-Aid.
CR Aird WC, 2003, CRIT CARE MED, V31, pS221, DOI 10.1097/01.CCM.0000057847.32590.C1
   Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Baxter GF, 2004, BASIC RES CARDIOL, V99, P71, DOI 10.1007/s00395-004-0457-8
   Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725
   Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007
   Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431
   Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359
   Birukova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL593, DOI 10.1152/ajplung.90257.2008
   Birukova AA, 2008, J CELL PHYSIOL, V215, P715, DOI 10.1002/jcp.21354
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V292, pL924, DOI 10.1152/ajplung.00395.2006
   Birukova AA, 2009, AM J RESP CELL MOL, V40, P99, DOI 10.1165/rcmb.2008-0099OC
   Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9
   Chiu WT, 2009, CHEM-BIOL INTERACT, V181, P430, DOI 10.1016/j.cbi.2009.06.011
   Cioffi DL, 2009, ANTIOXID REDOX SIGN, V11, P765, DOI [10.1089/ars.2008.2221, 10.1089/ARS.2008.2221]
   Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359
   Dodd-O JM, 2008, AM J PHYSIOL-LUNG C, V294, pL714, DOI 10.1152/ajplung.00185.2007
   EISON HB, 1988, CHEST, V94, P1040, DOI 10.1378/chest.94.5.1040
   Fu P, 2009, EUR RESPIR J, V33, P612, DOI 10.1183/09031936.00014808
   Furst R, 2008, MOL PHARMACOL, V74, P1, DOI 10.1124/mol.108.045773
   Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0
   Furst R, 2005, CIRC RES, V96, P43, DOI 10.1161/01.RES.0000151983.01148.06
   Gacouin A, 2009, ANESTH ANALG, V109, P1584, DOI 10.1213/ANE.0b013e3181b6e9b6
   Hortal J, 2009, INTENS CARE MED, V35, P1518, DOI 10.1007/s00134-009-1523-3
   Houng AK, 2009, AM J PHYSIOL-HEART C, V296, pH655, DOI 10.1152/ajpheart.00684.2008
   IMAMURA T, 1988, LIFE SCI, V42, P403, DOI 10.1016/0024-3205(88)90078-1
   Irwin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL849, DOI 10.1152/ajplung.00294.2004
   Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183
   Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320
   Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428-7435.2005
   Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3
   Kim HS, 2006, J AM COLL CARDIOL, V47, p220A
   Klinger JR, 2006, EXP CELL RES, V312, P401, DOI 10.1016/j.yexcr.2005.11.001
   Leemans JC, 2002, AM J RESP CRIT CARE, V165, P1445, DOI 10.1164/rccm.2106045
   Liu S, 2008, EUR J PHARMACOL, V584, P159, DOI 10.1016/j.ejphar.2008.02.009
   LOFTON CE, 1991, J MOL CELL CARDIOL, V23, P919, DOI 10.1016/0022-2828(91)90134-8
   Lowe K, 2007, J SURG RES, V143, P70, DOI 10.1016/j.jss.2007.03.047
   Manukyan M, 2009, J IMMUNOL, V182, P3522, DOI 10.4049/jimmunol.0802280
   Matsuda N, 2008, BIOCHEM PHARMACOL, V75, P1065, DOI 10.1016/j.bcp.2007.10.036
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Melamed A, 2009, CRIT CARE, V13, DOI 10.1186/cc7733
   Mitaka C, 2002, CRIT CARE MED, V30, P1570, DOI 10.1097/00003246-200207000-00029
   Mitaka C, 1998, CHEST, V114, P223, DOI 10.1378/chest.114.1.223
   MITAKA C, 1992, AM REV RESPIR DIS, V146, P43, DOI 10.1164/ajrccm/146.1.43
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543
   NOBLE WH, 1975, J APPL PHYSIOL, V38, P681, DOI 10.1152/jappl.1975.38.4.681
   Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805
   Nwariaku FE, 2002, SHOCK, V18, P82, DOI 10.1097/00024382-200207000-00015
   Petrache I, 2003, BIOCHEM BIOPH RES CO, V306, P244, DOI 10.1016/S0006-291X(03)00945-8
   Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189
   Ruse M, 2006, IMMUNOL RES, V34, P33, DOI 10.1385/IR:34:1:33
   Sabrane K, 2005, J CLIN INVEST, V115, P1666, DOI 10.1172/JCI23360
   Slotta JE, 2006, INFLAMM RES, V55, P364, DOI 10.1007/s00011-006-6013-2
   Sun Hai-chen, 2005, Chin J Traumatol, V8, P67
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tanabe M, 1996, AM J RESP CRIT CARE, V154, P1351, DOI 10.1164/ajrccm.154.5.8912747
   Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC
   Teusch N, 2004, J IMMUNOL, V173, P507, DOI 10.4049/jimmunol.173.1.507
   Ueda S, 2006, SHOCK, V26, P134, DOI 10.1097/01.shk.0000226266.99960.d0
   Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200
   Vesely DL, 2009, J INVEST MED, V57, P29, DOI 10.2310/JIM.0b013e3181948b37
   Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639
   Wang HE, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-9
   Wang JE, 2003, SHOCK, V20, P402, DOI 10.1097/01.shk.0000092268.01859.0d
   Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004
   Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006
NR 70
TC 34
Z9 34
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD JAN
PY 2011
VL 110
IS 1
BP 213
EP 224
DI 10.1152/japplphysiol.00284.2010
PG 12
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Sport Sciences
GA 705MW
UT WOS:000286140900026
PM 21051573
OA Green Published
DA 2023-08-21
ER

EF